-DOCSTART- -X- O O

Clinical JJ N
description NN N
of IN N
encephalopathic JJ N
syndromes NNS N
and CC N
risk NN N
factors NNS N
for IN N
their PRP$ N
occurrence NN N
and CC N
outcome NN N
during IN N
melarsoprol NN 1_i
treatment NN N
of IN N
human JJ 1_p
African JJ 1_p
trypanosomiasis NN 1_p
. . 1_p

Encephalopathies NNS N
are VBP N
the DT N
most RBS N
feared JJ N
complications NNS N
of IN N
sleeping VBG N
sickness JJ N
treatment NN N
with IN N
melarsoprol NN 1_i
. . 1_i

To TO N
investigate VB N
the DT N
existence NN N
of IN N
risk NN N
factors NNS N
, , N
the DT N
incidence NN N
of IN N
encephalopathic JJ N
syndromes NNS N
and CC N
the DT N
relationship NN N
between IN N
the DT N
development NN N
of IN N
different JJ N
types NNS N
of IN N
encephalopathies NNS N
and CC N
the DT N
clinical JJ N
outcome NN N
was VBD N
studied VBN N
in IN N
a DT N
clinical JJ N
trial NN N
with IN N
588 CD 1_p
patients NNS 1_p
under IN 1_p
treatment NN 1_p
with IN 1_p
melarsoprol NN 1_i
. . 1_i

The DT N
38 CD 1_p
encephalopathy JJ 1_p
cases NNS 1_p
were VBD N
classified VBN N
into IN N
three CD N
types NNS N
according VBG N
to TO N
the DT N
leading VBG N
clinical JJ N
picture NN N
: : N
coma NN N
type NN N
, , N
convulsion NN N
type NN N
and CC N
psychotic JJ N
reactions NNS N
. . N

Nine JJ 1_p
patients NNS 1_p
were VBD 1_p
attributed VBN 1_p
to TO 1_p
the DT 1_p
convulsion NN 1_p
type NN 1_p
, , N
defined VBD N
as IN N
a DT N
transient JJ N
event NN N
of IN N
short JJ N
duration NN N
with IN N
convulsions NNS N
followed VBN N
by IN N
a DT N
post-ictal JJ N
phase NN N
, , N
without IN N
signs NNS N
of IN N
a DT N
generalized JJ N
disease NN N
. . N

None NN N
of IN N
these DT N
patients NNS N
died VBD N
from IN N
the DT N
reaction NN N
. . N

Febrile JJ 1_o
reactions NNS 1_o
in IN N
the DT N
48 CD N
h NN N
preceding VBG N
the DT N
reaction NN N
were VBD N
generally RB N
not RB N
observed VBN N
in IN N
this DT N
group NN N
. . N

Twenty-five JJ N
patients NNS N
were VBD N
attributed VBN N
to TO N
the DT N
coma NN N
type NN N
, , N
which WDT N
is VBZ N
a DT N
progredient JJ N
coma NN N
lasting VBG N
several JJ N
days NNS N
. . N

Those DT N
patients NNS N
often RB N
had VBD N
signs NNS N
of IN N
a DT N
generalized JJ N
disease NN N
such JJ N
as IN N
fever NN 1_o
( ( N
84 CD N
% NN N
) ) N
, , N
headache NN 1_o
( ( N
72 CD N
% NN N
) ) N
or CC N
bullous JJ 1_o
skin NN 1_o
( ( N
8 CD N
% NN N
) ) N
reactions NNS N
. . N

The DT N
risk NN 1_o
of IN 1_o
mortality NN 1_o
was VBD N
high JJ N
in IN N
this DT N
group NN N
( ( N
52 CD N
% NN N
) ) N
. . N

About IN N
14/16 CD N
patients NNS N
with IN N
encephalopathic JJ N
syndrome NN N
of IN N
the DT N
coma NN N
type NN N
were VBD N
infected VBN N
with IN N
malaria NNS N
. . N

Patients NNS N
with IN N
psychotic JJ N
reactions NNS N
or CC N
abnormal JJ N
psychiatric JJ N
behaviour NN N
( ( N
3/38 CD N
) ) N
and CC N
one CD N
patient NN N
who WP N
died VBD 1_o
after IN N
alcohol NN N
intake NN N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
. . N

The DT N
overall JJ 1_o
rate NN 1_o
of IN 1_o
encephalopathic JJ 1_o
syndromes NNS 1_o
in IN N
the DT N
cases NNS N
analysed VBD N
( ( N
n=34 NN N
) ) N
was VBD N
5.8 CD N
% NN N
, , N
of IN N
which WDT N
38.2 CD N
% NN N
died VBD N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
parameters NNS N
of IN N
predictive JJ N
value NN N
for IN N
the DT N
risk NN 1_o
of IN 1_o
developing VBG 1_o
an DT 1_o
encephalopathic JJ 1_o
syndrome NN 1_o
based VBN N
on IN N
the DT N
symptoms NNS N
and CC N
signs NNS N
before IN N
treatment NN N
initiation NN N
. . N

The DT N
appearance NN N
during IN N
treatment NN N
of IN N
febrile JJ 1_o
reactions NNS 1_o
( ( N
RR NNP N
11.5 CD N
) ) N
, , N
headache NN 1_o
( ( N
RR NNP N
2.5 CD N
) ) N
, , N
bullous JJ 1_o
eruptions NNS 1_o
( ( N
RR NNP N
4.5 CD N
) ) N
and CC N
systolic JJ 1_o
hypotension NN 1_o
( ( N
RR NNP N
2.6 CD N
) ) N
were VBD N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
for IN N
the DT N
occurrence NN N
of IN N
encephalopathic JJ N
syndromes NNS N
especially RB N
of IN N
the DT N
coma NN N
type NN N
. . N

-DOCSTART- -X- O O

The DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
fenfluramine NN 1_i
in IN N
autistic JJ 1_p
children NNS 1_p
: : 1_p
preliminary JJ N
analysis NN N
of IN N
a DT N
double-blind JJ N
study NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
comparison NN N
of IN N
transthoracic NN 1_i
and CC 1_i
transhiatal JJ 1_i
resection NN 1_i
for IN N
esophageal JJ 1_p
carcinoma NN 1_p
in IN 1_p
Asians NNPS 1_p
. . 1_p

BACKGROUND/AIMS NNP N
Transthoracic NNP 1_i
and CC 1_i
transhiatal JJ 1_i
esophagectomy NN 1_i
are VBP N
two CD N
common JJ N
procedures NNS N
for IN N
esophageal JJ N
cancer NN N
resection NN N
. . N

Prospective JJ N
studies NNS N
comparing VBG N
the DT N
two CD N
methods NNS N
in IN 1_p
Asian JJ 1_p
people NNS 1_p
are VBP N
few JJ N
. . N

In IN N
addition NN N
, , N
the DT N
data NNS N
comparing VBG N
their PRP$ N
effects NNS N
on IN N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
are VBP N
lacking VBG N
. . N

METHODOLOGY NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
from IN N
January NNP N
2003 CD N
. . N

Patients NNS 1_p
of IN 1_p
resectable JJ 1_p
esophageal JJ 1_p
cancer NN 1_p
of IN 1_p
comparable JJ 1_p
stage NN 1_p
were VBD N
allocated VBN N
to TO N
undergo VB N
the DT N
transthoracic NN 1_i
or CC 1_i
transhiatal JJ 1_i
procedure NN 1_i
in IN N
turn NN N
. . N

They PRP 1_i
were VBD 1_i
all DT 1_i
reconstructed VBN 1_i
with IN 1_i
stomach NN 1_i
interposition NN 1_i
through IN 1_i
the DT 1_i
retrosternal JJ 1_i
route NN 1_i
. . 1_i

Discharged VBN 1_i
patients NNS 1_i
were VBD 1_i
followed-up JJ 1_i
in IN 1_i
the DT 1_i
outpatient NN 1_i
clinic NN 1_i
. . 1_i

They PRP 1_i
were VBD 1_i
questioned VBN 1_i
on IN 1_i
the DT 1_i
topics NNS 1_i
of IN 1_i
( ( 1_o
i NN 1_o
) ) 1_o
severity NN 1_o
of IN 1_o
pain NN 1_o
, , 1_o
( ( 1_o
ii NN 1_o
) ) 1_o
ease NN 1_o
of IN 1_o
swallowing NN 1_o
, , 1_o
( ( 1_o
iii NN 1_o
) ) 1_o
satisfaction NN 1_o
of IN 1_o
daily JJ 1_o
activities NNS 1_o
, , 1_o
( ( 1_o
iv NN 1_o
) ) 1_o
dependence NN 1_o
on IN 1_o
medications NNS 1_o
, , 1_o
( ( 1_o
v NN 1_o
) ) 1_o
working VBG 1_o
ability NN 1_o
, , 1_o
( ( 1_o
vi NN 1_o
) ) 1_o
fatigue NN 1_o
, , 1_o
( ( 1_o
vii NN 1_o
) ) 1_o
appetite NN 1_o
, , 1_o
( ( 1_o
viii NN 1_o
) ) 1_o
sociality NN 1_o
, , 1_o
( ( 1_o
ix NN 1_o
) ) 1_o
happiness NN 1_o
and CC 1_o
( ( 1_o
x NNP 1_o
) ) 1_o
self NN 1_o
respect NN 1_o
, , 1_i
in IN 1_i
the DT 1_i
third JJ 1_i
, , 1_i
sixth JJ 1_i
and CC 1_i
twelfth JJ 1_i
month NN 1_i
. . 1_i

Also RB N
the DT N
demographic JJ 1_o
data NNS 1_o
, , 1_o
operative JJ 1_o
results NNS 1_o
and CC 1_o
survival NN 1_o
were VBD N
recorded VBN N
. . N

RESULTS VB N
Up IN 1_p
to TO 1_p
December NNP 1_p
2006 CD 1_p
, , 1_p
eighty-seven JJ 1_p
patients NNS 1_p
of IN 1_p
stage NN 1_p
II NNP 1_p
and CC 1_p
III NNP 1_p
, , 1_p
including VBG 1_p
71 CD 1_p
patients NNS 1_p
of IN 1_p
middle JJ 1_p
third JJ 1_p
lesions NNS 1_p
and CC 1_p
16 CD 1_p
lower JJR 1_p
third JJ 1_p
lesions NNS 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

The DT N
operation NN 1_o
time NN 1_o
was VBD N
significantly RB N
longer JJR N
, , N
and CC N
the DT N
leakage NN 1_o
rate NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
transthoracic NN N
group NN N
( ( N
Student NNP N
's POS N
t-test NN N
and CC N
Fischer NNP N
's POS N
exact JJ N
test NN N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
intraoperative JJ 1_o
blood NN 1_o
loss NN 1_o
and CC 1_o
postoperative JJ 1_o
hospital NN 1_o
stay NN 1_o
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
Student NNP N
t-test NN N
) ) N
. . N

Also RB N
, , N
the DT N
Kaplan-Meier NNP 1_o
survival NN 1_o
curves NNS 1_o
of IN N
these DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
by IN N
log-rank JJ N
test NN N
( ( N
p=0.286 NN N
) ) N
. . N

The DT N
score NN N
on IN N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
transhiatal JJ N
patients NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
transthoracic NN N
patients NNS N
in IN N
the DT N
third JJ N
, , N
sixth JJ N
and CC N
twelfth JJ N
month NN N
. . N

CONCLUSIONS NNP N
Transhiatal NNP 1_i
esophagectomy NN 1_i
is VBZ N
a DT N
safe JJ N
and CC N
fast JJ N
procedure NN N
. . N

The DT N
survival NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
transthoracic JJ N
approach NN N
. . N

Its PRP$ N
leakage NN 1_o
rate NN 1_o
was VBD N
lower JJR N
and CC N
quality NN N
of IN N
life NN N
was VBD N
better RBR N
. . N

-DOCSTART- -X- O O

Rituximab NNP 1_i
plus CC 1_i
concurrent JJ 1_i
infusional JJ 1_i
EPOCH NNP 1_i
chemotherapy NN 1_i
is VBZ N
highly RB N
effective JJ N
in IN 1_p
HIV-associated JJ 1_p
B-cell NNP 1_p
non-Hodgkin JJ 1_p
lymphoma NN 1_p
. . 1_p

Rituximab NNP N
plus CC N
intravenous JJ N
bolus NN N
chemotherapy NN N
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
immunocompetent JJ 1_p
patients NNS 1_p
with IN 1_p
B-cell NNP 1_p
non-Hodgkin JJ 1_p
lymphoma NN 1_p
( ( 1_p
NHL NNP 1_p
) ) 1_p
. . 1_p

Some DT N
studies NNS N
have VBP N
suggested VBN N
that IN N
rituximab NN N
is VBZ N
associated VBN N
with IN N
excessive JJ 1_o
toxicity NN 1_o
in IN N
HIV-associated NNP N
NHL NNP N
, , N
and CC N
that IN N
infusional JJ N
chemotherapy NN N
may MD N
be VB N
more RBR N
effective JJ N
. . N

We PRP N
performed VBD N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
of IN N
rituximab NN 1_i
( ( 1_i
375 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
) ) 1_i
given VBN 1_i
either CC 1_i
concurrently RB 1_i
before IN 1_i
each DT 1_i
infusional JJ 1_i
etoposide NN 1_i
, , 1_i
vincristine NN 1_i
, , 1_i
doxorubicin NN 1_i
, , 1_i
cyclophosphamide NN 1_i
, , 1_i
and CC 1_i
prednisone NN 1_i
( ( 1_i
EPOCH NNP 1_i
) ) 1_i
chemotherapy NN 1_i
cycle NN 1_i
or CC 1_i
sequentially RB 1_i
( ( 1_i
weekly JJ 1_i
for IN 1_i
6 CD 1_i
weeks NNS 1_i
) ) 1_i
after IN 1_i
completion NN 1_i
of IN 1_i
all DT 1_i
chemotherapy NN 1_i
in IN 1_i
HIV-associated NNP 1_i
NHL NNP 1_i
. . 1_i

EPOCH NNP 1_i
consisted VBD N
of IN N
a DT N
96-hour JJ N
intravenous JJ N
infusion NN N
of IN N
etoposide NN 1_i
, , 1_i
doxorubicin NN 1_i
, , 1_i
and CC 1_i
vincristine JJ 1_i
plus CC 1_i
oral JJ 1_i
prednisone NN 1_i
followed VBN N
by IN N
intravenous JJ N
bolus JJ N
cyclophosphamide NN 1_i
given VBN N
every DT N
21 CD N
days NNS N
for IN N
4 CD N
to TO N
6 CD N
cycles NNS N
. . N

In IN N
the DT N
concurrent NN N
arm NN N
, , N
35 CD N
of IN N
48 CD 1_p
evaluable JJ 1_p
patients NNS 1_p
( ( N
73 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
58 CD N
% NN N
-85 NNP N
% NN N
) ) N
had VBD N
a DT N
complete JJ 1_o
response NN 1_o
. . 1_o

In IN N
the DT N
sequential JJ N
arm NN N
, , N
29 CD N
of IN N
53 CD 1_p
evaluable JJ 1_p
patients NNS 1_p
( ( N
55 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
41 CD N
% NN N
-68 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
met VBN N
for IN N
the DT N
concurrent NN N
arm NN N
only RB N
. . N

Toxicity NNP 1_o
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
arms NNS N
, , N
although IN N
patients NNS N
with IN N
a DT N
baseline NN N
CD4 NNP 1_o
count NN N
less JJR N
than IN N
50/microL CD N
had VBD N
a DT N
high JJ N
infectious JJ 1_o
death NN 1_o
rate NN 1_o
in IN N
the DT N
concurrent NN N
arm NN N
. . N

We PRP N
conclude VBP N
that DT N
concurrent NN 1_i
rituximab NN 1_i
plus CC 1_i
infusional JJ 1_i
EPOCH NNP 1_i
is VBZ N
an DT N
effective JJ N
regimen NNS N
for IN N
HIV-associated JJ 1_p
lymphoma NN 1_p
. . 1_p

-DOCSTART- -X- O O

Effects NNS N
of IN N
weight JJ 1_i
reduction NN 1_i
interventions NNS 1_i
by IN N
community NN N
pharmacists NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
a DT N
meal JJ 1_i
replacement NN 1_i
( ( 1_i
MR NNP 1_i
) ) 1_i
program NN 1_i
with IN 1_i
a DT 1_i
conventional JJ 1_i
reduced-calorie JJ 1_i
diet NN 1_i
( ( 1_i
RCD NNP 1_i
) ) 1_i
for IN N
weight NN 1_o
management NN 1_o
using VBG N
the DT N
pharmacy NN 1_i
as IN 1_i
the DT 1_i
setting NN 1_i
and CC 1_i
the DT 1_i
pharmacist NN 1_i
as IN 1_i
the DT 1_i
point NN 1_i
of IN 1_i
contact NN 1_i
for IN 1_i
dietary JJ 1_i
advice NN 1_i
. . 1_i

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
, , N
open-label JJ N
trial NN N
. . N

SETTING NN N
Travis NNP 1_p
Pharmacy NNP 1_p
in IN 1_p
Shenandoah NNP 1_p
, , 1_p
Iowa NNP 1_p
. . 1_p

PATIENTS NNP N
Ninety-five JJ 1_p
patients NNS 1_p
from IN 1_p
southwestern JJ 1_p
iowa NN 1_p
and CC 1_p
southeastern JJ 1_p
Nebraska NNP 1_p
were VBD N
enrolled VBN N
, , N
of IN N
whom WP N
88 CD 1_p
were VBD 1_p
considered VBN 1_p
eligible JJ 1_p
for IN 1_p
comparison NN 1_p
( ( 1_p
by IN 1_p
continuing VBG 1_p
through IN 1_p
week NN 1_p
2 CD 1_p
of IN 1_p
the DT 1_p
study NN 1_p
) ) 1_p
. . 1_p

INTERVENTION JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
an DT N
MR NNP 1_i
plan NN N
or CC N
a DT N
traditional JJ N
RCD NNP 1_i
plan NN N
. . N

Patients NNS N
were VBD N
followed VBN N
for IN N
a DT N
3-month JJ N
period NN N
of IN N
active JJ N
weight JJ N
loss NN N
and CC N
a DT N
10-week JJ N
period NN N
of IN N
weight JJ N
maintenance NN N
. . N

Patients NNS N
returned VBD N
every DT N
3 CD N
weeks NNS N
for IN N
follow-up NN N
with IN N
the DT N
pharmacist NN N
, , N
for IN N
a DT N
total NN N
of IN N
13 CD N
visits NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
Weight NNP 1_o
changes NNS 1_o
. . 1_o

RESULTS NNP N
During IN N
the DT N
active JJ N
weight NN N
loss NN N
phase NN N
, , N
the DT N
MR NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
45 CD 1_p
) ) 1_p
and CC 1_p
RCD NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
43 CD 1_p
) ) 1_p
groups NNS N
lost VBD N
a DT N
significant JJ 1_o
amount NN 1_o
of IN 1_o
weight NN 1_o
, , N
although IN N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
groups NNS N
( ( N
mean JJ N
+/- JJ N
standard NN N
error NN N
= VBZ N
4.90 CD N
+/- JJ N
0.30 CD N
kg NN N
MR NNP N
versus NN N
4.30 CD N
+/- JJ N
0.30 CD N
kg NN N
RCD NNP N
; : N
P NNP N
= NNP N
.16 NNP N
) ) N
. . N

In IN N
the DT N
weight NN N
maintenance NN N
phase NN N
, , N
the DT N
MR NNP N
group NN N
lost VBD N
0.70 CD N
+/- JJ N
0.40 CD N
kg NN N
and CC N
the DT N
RCD NNP N
group NN N
lost VBD N
0.90 CD N
+/- JJ N
0.40 CD N
kg NN N
( ( N
P NNP N
= NNP N
.60 NNP N
) ) N
. . N

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
waist JJ 1_o
circumference NN 1_o
, , 1_o
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
triglyceride NN 1_o
levels NNS 1_o
. . 1_o

No DT N
significant JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
high-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
or CC 1_o
low-density NN 1_o
lipoprotein NNS 1_o
cholesterol NN 1_o
levels NNS 1_o
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
Successful NNP N
weight VBD 1_o
management NN 1_o
can MD N
be VB N
achieved VBN N
in IN N
a DT N
pharmacy NN N
setting NN N
. . N

Both DT N
MR NNP 1_i
and CC 1_i
RCD NNP 1_i
programs NNS N
were VBD N
effective JJ N
. . N

-DOCSTART- -X- O O

Overexpression NN N
of IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
and CC N
its PRP$ N
cellular JJ N
receptor NN N
KDR NNP N
( ( N
VEGFR-2 NNP N
) ) N
in IN N
the DT N
bone NN 1_p
marrow NN 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
. . 1_p

Vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
and CC N
its PRP$ N
cellular JJ N
receptor NN N
VEGFR-2 NNP N
have VBP N
been VBN N
implicated VBN N
as IN N
the DT N
main JJ N
endothelial JJ N
pathway NN N
required VBN N
for IN N
tumor NN N
neovascularization NN N
. . N

However RB N
, , N
the DT N
importance NN N
of IN N
the DT N
VEGF/VEGFR-2 NNP N
system NN N
for IN N
angiogenesis NN N
in IN N
hematologic JJ N
malignancies NNS N
such JJ N
as IN N
AML NNP N
remains VBZ N
to TO N
be VB N
elucidated VBN N
. . N

In IN 1_p
32 CD 1_p
patients NNS 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
untreated JJ 1_p
AML NNP 1_p
, , N
we PRP N
observed VBD N
by IN N
immunohistochemical JJ 1_i
analysis NN 1_i
of IN 1_i
bone NN 1_i
marrow NN 1_i
biopsies NNS 1_i
significantly RB N
higher JJR N
levels NNS N
of IN N
VEGF NNP N
and CC N
VEGFR-2 NNP N
expression NN N
than IN N
in IN N
10 CD 1_p
control NN 1_p
patients NNS 1_p
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
VEGFR-1 NNP N
staining NN N
levels NNS N
in IN N
AML NNP N
patients NNS N
were VBD N
in IN N
the DT N
same JJ N
range NN N
as IN N
in IN N
the DT N
controls NNS N
. . N

Expression NN 1_o
of IN 1_o
VEGF NNP 1_o
and CC 1_o
VEGFR-2 NNP 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
with IN N
a DT N
high JJ N
degree NN N
of IN N
microvessel NN N
density NN N
compared VBN N
to TO N
those DT N
with IN N
a DT N
low JJ N
degree NN N
( ( N
VEGF NNP N
: : N
P NNP N
=0.024 NNP N
; : N
VEGFR-2 JJ N
: : N
P NNP N
=0.040 NNP N
) ) N
and CC N
correlated VBN N
well RB N
with IN N
bone NN N
marrow NN N
microvessel NN N
density NN N
( ( N
r NN N
( ( N
s PRP N
) ) N
=0.566 NN N
and CC N
0.609 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Furthermore UH N
, , N
in IN N
patients NNS N
who WP N
achieved VBD N
a DT N
complete JJ N
remission NN 1_o
following VBG N
induction NN 1_i
chemotherapy VBD 1_i
VEGFR-2 NNP 1_o
staining NN 1_o
levels NNS 1_o
decreased VBN N
into IN N
the DT N
normal JJ N
range NN N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
results NNS N
provide VBP N
evidence NN N
for IN N
increased JJ N
expression NN N
of IN N
VEGF/VEGFR-2 NNP 1_o
of IN 1_o
leukemic JJ 1_o
blasts NNS 1_o
and CC N
correlation NN N
with IN N
angiogenesis NN N
in IN N
the DT N
bone NN N
marrow NN N
of IN N
AML NNP N
patients NNS N
. . N

Thus RB N
, , N
VEGF/VEGFR-2 NNP N
might MD N
constitute VB N
promising VBG N
targets NNS N
for IN N
antiangiogenic JJ 1_i
and CC N
antileukemic JJ 1_i
treatment NN 1_i
strategies NNS N
in IN N
AML NNP N
. . N

-DOCSTART- -X- O O

Low-dose JJ N
intravenous JJ N
midazolam NN 1_i
reduces NNS N
etomidate-induced JJ N
myoclonus NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
in IN N
patients NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
cardioversion NN 1_p
. . 1_p

BACKGROUND NNP N
Myoclonic NNP N
movements NNS N
are VBP N
a DT N
common JJ N
problem NN N
in IN N
unpremedicated JJ N
patients NNS 1_p
during IN 1_p
induction NN 1_p
of IN 1_p
anesthesia NN 1_p
with IN 1_p
etomidate NN 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
double-blind JJ N
fashion NN N
, , N
40 CD 1_p
patients NNS 1_p
( ( 1_p
ASA NNP 1_p
physical JJ 1_p
status NN 1_p
III-IV NNP 1_p
) ) 1_p
scheduled VBD 1_p
for IN 1_p
elective JJ 1_p
cardioversion NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
0.015 CD N
mg/kg NNS N
midazolam NN 1_i
or CC 1_i
placebo NN 1_i
90 CD N
s NN N
before IN N
the DT N
injection NN N
of IN N
0.3 CD N
mg/kg JJ N
etomidate NN 1_i
. . 1_i

Myoclonic JJ 1_o
movements NNS 1_o
and CC 1_o
sedation NN 1_o
were VBD N
recorded VBN N
on IN N
a DT N
scale NN N
between IN N
0 CD N
and CC N
3 CD N
. . N

Pulse NNP 1_o
oximetry NN 1_o
, , 1_o
noninvasive JJ 1_o
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
were VBD N
recorded VBN N
during IN N
the DT N
study NN N
period NN N
. . N

RESULTS NNP N
Two CD N
patients NNS N
( ( N
10 CD N
% NN N
) ) N
in IN N
the DT N
midazolam NN 1_i
group NN N
had VBD N
myoclonic JJ 1_o
movements NNS 1_o
after IN N
the DT N
administration NN N
of IN N
etomidate NN 1_i
, , N
whereas IN N
10 CD N
of IN N
the DT N
20 CD N
patients NNS N
( ( N
50 CD N
% NN N
) ) N
receiving VBG N
placebo NN 1_i
experienced VBD N
such JJ N
movements NNS N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

No UH N
other JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
; : N
in IN N
particular JJ N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
recovery NN N
5 CD N
min NN N
after IN N
the DT N
administration NN N
of IN N
etomidate NN N
. . N

CONCLUSIONS NNP N
IV NNP N
midazolam VBD 1_i
0.015 CD N
mg/kg NN N
administered VBD N
90 CD N
s NN N
before IN N
induction NN N
of IN N
anesthesia NN N
with IN N
etomidate NN N
is VBZ N
effective JJ N
in IN N
reducing VBG N
myoclonic JJ N
movements NNS N
and CC N
does VBZ N
not RB N
prolong JJ N
recovery NN N
in IN N
unpremedicated JJ N
patients NNS N
after IN N
short JJ N
procedures NNS N
. . N

-DOCSTART- -X- O O

A DT 1_p
double-blind JJ 1_p
crossover NN 1_p
comparison NN 1_p
of IN 1_p
pindolol NN 1_i
, , 1_i
metoprolol NN 1_i
, , 1_i
atenolol NN 1_i
and CC 1_p
labetalol NN 1_i
in IN 1_p
mild NN 1_p
to TO 1_p
moderate VB 1_p
hypertension NN 1_p
. . 1_p

1 CD N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
in IN N
a DT N
double-blind JJ N
randomized JJ N
crossover NN N
trial NN N
, , N
atenolol NN 1_i
, , 1_i
labetalol NN 1_i
, , 1_i
metoprolol NN 1_i
and CC 1_i
pindolol NN 1_i
. . 1_i

Considerable JJ N
differences NNS N
in IN N
dose NN 1_o
( ( 1_i
atenolol JJ 1_i
138 CD N
+/- JJ N
13 CD N
mg JJ N
daily RB N
; : N
labetalol VBZ 1_i
308 CD N
+/- JJ N
34 CD N
mg JJ N
daily RB N
; : N
metoprolol PRP 1_i
234 CD N
+/- JJ N
22 CD N
mg JJ N
daily RB N
; : N
and CC N
pindolol VB 1_i
24 CD N
+/-2 JJ N
mg NNS N
daily JJ N
were VBD N
required VBN N
to TO N
produce VB N
similar JJ N
antihypertensive JJ 1_o
effects NNS 1_o
. . 1_o

3 CD N
The DT 1_o
overall JJ 1_o
incidence NN 1_o
of IN 1_o
side-effects NNS 1_o
was VBD 1_o
similar JJ 1_o
with IN 1_o
atenolol NN 1_o
, , 1_o
metoprolol NN 1_o
and CC 1_o
pindolol NN 1_o
but CC 1_o
was VBD 1_o
slightly RB 1_o
less JJR 1_o
with IN 1_o
labetalol NN 1_o
. . 1_i

Sleep JJ 1_o
disturbances NNS 1_o
and CC 1_o
abnormal JJ 1_o
dreaming NN 1_o
patterns NNS 1_o
were VBD 1_o
most RBS 1_o
frequent JJ 1_o
with IN 1_o
pindolol NN 1_o
. . 1_i

4 CD N
There EX 1_o
was VBD 1_o
a DT 1_o
significantly RB 1_o
greater JJR 1_o
fall NN 1_o
in IN 1_o
pulse JJ 1_o
rate NN 1_o
during IN 1_o
atenolol NN 1_o
and CC 1_o
metoprolol NN 1_o
treatment NN 1_o
periods NNS 1_o
. . N

-DOCSTART- -X- O O

An DT N
evaluation NN N
of IN N
chemical JJ N
arthrodesis NN N
of IN N
the DT N
proximal JJ 1_p
interphalangeal NN 1_p
joint NN 1_p
in IN 1_p
the DT 1_p
horse NN 1_p
by IN N
using VBG N
monoiodoacetate NN 1_i
. . 1_i

The DT N
use NN N
of IN N
monoiodoacetate NN 1_i
( ( 1_i
MIA NNP 1_i
) ) 1_i
for IN N
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
( ( N
PIJ NNP N
) ) N
and CC N
the DT N
effect NN N
of IN N
exercise NN N
on IN N
the DT N
degree NN N
of IN N
fusion NN N
were VBD N
investigated VBN N
. . N

Eight JJ 1_p
horses NNS 1_p
received VBD N
3 CD N
injections NNS N
( ( N
Weeks NNP N
0 CD N
, , N
3 CD N
, , N
6 CD N
) ) N
of IN N
MIA NNP 1_i
( ( N
2 CD N
mL NN N
; : N
60 CD N
mg/mL NN N
) ) N
into IN N
the DT N
right NN N
or CC N
left VBD N
front JJ N
PIJ NNP N
. . N

Peri-operatively RB N
, , N
the DT N
horses NNS N
received VBD N
phenylbutazone NN 1_i
, , 1_i
butorphanol NN 1_i
, , 1_i
and CC 1_i
abaxial JJ 1_i
sesamoidean NN 1_i
nerve NN 1_i
blocks NNS 1_i
to TO N
relieve VB N
pain NN N
. . N

During IN N
the DT N
study NN N
, , N
the DT N
horses NNS N
were VBD N
monitored VBN N
for IN N
general JJ N
health NN N
, , N
lameness NN N
, , N
and CC N
swelling VBG N
around IN N
the DT N
injection NN N
area NN N
. . N

Radiographs NNP N
were VBD N
taken VBN N
biweekly RB N
to TO N
evaluate VB N
bony NN N
fusion NN N
. . N

Horses NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
non-exercised JJ 1_i
and CC N
exercised JJ 1_i
groups NNS N
. . N

Exercise NNP 1_i
consisted VBD N
of IN N
20 CD N
minutes NNS N
of IN N
trotting VBG N
on IN N
a DT N
treadmill NN N
( ( N
4 CD N
m/s NN N
) ) N
, , N
3 CD N
days NNS N
per IN N
week NN N
for IN N
13 CD N
weeks NNS N
. . N

The DT N
horses NNS N
were VBD N
euthanized VBN N
at IN N
24 CD N
weeks NNS N
. . N

Slab NNP N
sections NNS N
of IN N
the DT N
PIJ NNP N
were VBD N
evaluated VBN N
grossly RB N
and CC N
radiographically RB N
for IN N
bony NN N
fusion NN N
. . N

Histologic JJ N
examinations NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
articular JJ N
cartilage NN N
. . N

Three CD N
horses NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
after IN N
developing VBG N
soft JJ N
tissue NN N
necrosis NN N
around IN N
the DT N
injection NN N
site NN N
, , N
septic JJ N
arthritis NN N
, , N
and CC N
necrotic JJ N
tendinitis NN N
. . N

The DT N
remaining VBG N
horses NNS N
remained VBD N
healthy JJ N
, , N
developed VBD N
a DT N
grade NN N
1 CD N
to TO N
4 CD N
lameness NN N
with IN N
minimal JJ N
to TO N
severe VB N
swelling VBG N
in IN N
the DT N
PIJ NNP N
region NN N
. . N

All DT 1_o
5 CD 1_o
horses NNS 1_o
showed VBD 1_o
radiographic JJ 1_o
evidence NN 1_o
of IN 1_o
bony NN 1_o
fusion NN 1_o
, , 1_o
however RB 1_o
, , 1_o
no DT 1_o
fusion NN 1_o
was VBD 1_o
present JJ 1_o
when WRB 1_o
injected JJ 1_o
joints NNS 1_o
were VBD 1_o
examined VBN 1_o
on IN 1_o
postmortem NN 1_o
examination NN 1_o
. . 1_o

Histologic NNP 1_o
examination NN 1_o
revealed VBD 1_o
thinning NN 1_o
of IN 1_o
the DT 1_o
cartilage NN 1_o
, , 1_o
diffuse VBP 1_o
necrosis NN 1_o
of IN 1_o
chondrocytes NNS 1_o
, , 1_o
with IN 1_o
the DT 1_o
calcified JJ 1_o
zone NN 1_o
intact JJ 1_o
. . 1_o

Subjectively RB 1_o
, , 1_o
exercise NN 1_o
did VBD 1_o
not RB 1_o
influence VB 1_o
the DT 1_o
degree NN 1_o
of IN 1_o
cartilage NN 1_o
destruction NN 1_o
. . 1_o

Based VBN 1_o
on IN 1_o
this DT 1_o
study NN 1_o
, , 1_o
chemical JJ 1_o
arthrodesis NN 1_o
can MD 1_o
not RB 1_o
be VB 1_o
advocated VBN 1_o
in IN 1_o
clinical JJ 1_o
cases NNS 1_o
because IN 1_o
of IN 1_o
the DT 1_o
high JJ 1_o
complication NN 1_o
rate NN 1_o
and CC 1_o
lack NN 1_o
of IN 1_o
bony NN 1_o
fusion NN 1_o
. . 1_o

-DOCSTART- -X- O O

Direct JJ N
and CC N
indirect JJ N
effects NNS N
of IN N
interdental JJ 1_i
hygiene NN 1_i
in IN N
a DT N
clinical JJ N
trial NN N
. . N

Many JJ N
randomized VBD N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
in IN N
dental JJ N
research NN N
test NN N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
more JJR N
than IN N
one CD N
outcome NN N
variable NN N
. . N

Univariate NNP N
methods NNS N
, , N
such JJ N
as IN N
the DT N
t JJ N
test NN N
or CC N
analysis NN N
of IN N
covariance NN N
, , N
can MD N
not RB N
evaluate VB N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
multiple JJ N
outcomes NNS N
simultaneously RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
structural JJ 1_i
equation NN 1_i
modeling NN 1_i
( ( N
SEM NNP N
) ) N
to TO N
re-analyze VB N
a DT N
RCT NNP N
, , N
comparing VBG N
the DT N
effects NNS N
of IN N
pre-curved JJ 1_i
interdental JJ 1_i
brushes NNS 1_i
and CC 1_i
flossing VBG 1_i
on IN N
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
, , N
plaque JJ N
indices NNS N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
measured VBD N
at IN N
baseline NN N
, , N
intermediate NN N
, , N
and CC N
final JJ N
examinations NNS N
. . N

Results NNS N
of IN N
SEM NNP N
showed VBD N
that IN N
the DT N
observed JJ N
greater JJR 1_o
reduction NN 1_o
in IN 1_o
PPD NNP 1_o
and CC 1_o
BOP NNP 1_o
in IN N
persons NNS 1_p
using VBG 1_p
interdental JJ 1_p
brushing NN 1_p
than IN 1_p
in IN 1_p
those DT 1_p
flossing NN 1_p
is VBZ N
due JJ N
mainly RB N
to TO N
the DT N
greater JJR N
efficiency NN 1_o
in IN 1_o
plaque NN 1_o
removal NN 1_o
with IN N
the DT N
interdental JJ N
brushes NNS N
( ( N
indirect JJ N
effect NN N
) ) N
rather RB N
than IN N
to TO N
the DT N
compression NN N
of IN N
the DT N
interdental JJ N
papillae NN N
( ( N
direct JJ N
effect NN N
) ) N
. . N

In IN N
contrast NN N
, , N
smokers NNS 1_p
showed VBD N
less JJR N
BOP NNP 1_o
at IN N
baseline NN N
but CC N
also RB N
less RBR N
improvement NN N
in IN N
BOP NNP 1_o
through IN N
direct JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
antioxidants NNS 1_i
, , 1_i
zinc NN 1_i
, , 1_i
and CC 1_i
copper NN 1_i
on IN N
cognition NN 1_p
in IN 1_p
the DT 1_p
elderly JJ 1_p
: : 1_p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

Participants NNS 1_p
in IN 1_p
the DT 1_p
Age-Related JJ 1_p
Eye NNP 1_p
Disease NNP 1_p
Study NNP 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
daily JJ N
antioxidants NNS 1_i
( ( 1_i
vitamin JJ 1_i
C NNP 1_i
, , 1_i
500 CD 1_i
mg NN 1_i
; : 1_i
vitamin CC 1_i
E NNP 1_i
, , 1_i
400 CD 1_i
IU NNP 1_i
; : 1_i
beta NN 1_i
carotene NN 1_i
, , 1_i
15 CD 1_i
mg NN 1_i
) ) 1_i
, , 1_i
zinc NN 1_i
and CC 1_i
copper NN 1_i
( ( 1_i
zinc NN 1_i
, , 1_i
80 CD 1_i
mg NN 1_i
; : 1_i
cupric JJ 1_i
oxide NN 1_i
, , 1_i
2 CD 1_i
mg NN 1_i
) ) 1_i
, , 1_i
antioxidants NNS 1_i
plus CC 1_i
zinc NN 1_i
and CC 1_i
copper NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

A DT N
cognitive JJ N
battery NN N
was VBD N
administered VBN N
to TO N
2,166 CD 1_p
elderly JJ 1_p
persons NNS 1_p
after IN 1_p
a DT 1_p
median NN 1_p
of IN 1_p
6.9 CD 1_p
years NNS 1_p
of IN 1_p
treatment NN 1_p
. . 1_p

Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
any DT N
of IN N
the DT N
six CD 1_o
cognitive JJ 1_o
tests NNS 1_o
( ( N
p JJ N
> VBP N
0.05 CD N
for IN N
all DT N
) ) N
. . N

These DT N
results NNS N
do VBP N
not RB N
support VB N
a DT N
beneficial JJ 1_o
or CC 1_o
harmful JJ 1_o
effect NN 1_o
of IN 1_o
antioxidants NNS 1_o
or CC 1_o
zinc NN 1_o
and CC 1_o
copper NN 1_o
on IN N
cognition NN 1_o
in IN N
older JJR N
adults NNS N
. . N

-DOCSTART- -X- O O

Components NNS N
of IN N
working VBG N
memory NN N
and CC N
visual JJ N
selective JJ N
attention NN N
. . N

Load NNP N
theory NN N
( ( N
Lavie NNP N
, , N
N. NNP N
, , N
Hirst NNP N
, , N
A. NNP N
, , N
De NNP N
Fockert NNP N
, , N
J. NNP N
W. NNP N
, , N
& CC N
Viding NNP N
, , N
E. NNP N
[ NNP N
2004 CD N
] NNP N
. . N

Load NNP N
theory NN N
of IN N
selective JJ N
attention NN N
and CC N
cognitive JJ N
control NN N
. . N

Journal NNP N
of IN N
Experimental NNP N
Psychology NNP N
: : N
General NNP N
, , N
133 CD N
, , N
339-354 JJ N
. . N

) ) N
proposes VBZ N
that IN N
control NN 1_o
of IN 1_o
attention NN 1_o
depends VBZ N
on IN N
the DT N
amount NN 1_o
and CC 1_o
type NN 1_o
of IN 1_o
load NN 1_o
that WDT N
is VBZ N
imposed VBN N
by IN N
current JJ N
processing NN N
. . N

Specifically RB N
, , N
perceptual JJ N
load NN N
should MD N
lead VB N
to TO N
efficient JJ N
distractor NN N
rejection NN N
, , N
whereas IN N
working VBG N
memory NN N
load NN N
( ( N
dual-task JJ N
coordination NN N
) ) N
should MD N
hinder VB N
distractor NN 1_o
rejection NN 1_o
. . 1_o

Studies NNPS N
support VBP N
load NN N
theory NN N
's POS N
prediction NN N
that IN N
working VBG N
memory NN N
load NN N
will MD N
lead VB N
to TO N
larger JJR N
distractor NN 1_o
effects NNS 1_o
; : 1_o
however RB N
, , N
these DT N
studies NNS N
used VBD N
secondary JJ N
tasks NNS N
that WDT N
required VBD N
only RB N
verbal JJ N
working VBG N
memory NN N
and CC N
the DT N
central JJ N
executive NN N
. . N

The DT N
present JJ N
study NN N
examined VBD N
which WDT N
other JJ N
working VBG N
memory NN N
components NNS N
( ( N
visual JJ N
, , N
spatial JJ N
, , N
and CC N
phonological JJ N
) ) N
influence NN N
visual JJ 1_o
selective JJ 1_o
attention NN 1_o
. . 1_o

Subjects NNS 1_p
completed VBD 1_p
an DT 1_p
attentional JJ 1_o
capture NN 1_o
task NN 1_o
alone RB 1_i
( ( 1_i
single-task JJ 1_i
) ) 1_i
or CC 1_i
while IN 1_i
engaged VBN 1_i
in IN 1_i
a DT 1_i
working JJ 1_i
memory NN 1_i
task NN 1_i
( ( 1_i
dual-task JJ 1_i
) ) 1_i
. . 1_i

Results CC N
showed VBD N
that IN N
along IN N
with IN N
the DT N
central JJ N
executive NN N
, , N
visual JJ N
and CC N
spatial JJ N
working VBG N
memory NN N
influenced VBD N
selective JJ 1_o
attention NN 1_o
, , N
but CC N
phonological JJ N
working VBG N
memory NN N
did VBD N
not RB N
. . N

Specifically RB N
, , N
attentional JJ 1_o
capture NN 1_o
was VBD N
larger JJR N
when WRB N
visual JJ N
or CC N
spatial JJ N
working VBG N
memory NN N
was VBD N
loaded VBN N
, , N
but CC N
phonological JJ N
working VBG N
memory NN N
load NN N
did VBD N
not RB N
affect VB N
attentional JJ 1_o
capture NN 1_o
. . 1_o

The DT N
results NNS N
are VBP N
consistent JJ N
with IN N
load NN N
theory NN N
and CC N
suggest VBP N
specific JJ N
components NNS N
of IN N
working VBG N
memory NN N
influence NN N
visual JJ 1_o
selective JJ 1_o
attention NN 1_o
. . 1_o

-DOCSTART- -X- O O

Does NNP N
tetanus CC 1_i
immune VB 1_i
globulin NN 1_i
interfere RB N
with IN N
the DT N
immune JJ 1_o
response NN 1_o
to TO N
simultaneous JJ N
administration NN N
of IN N
tetanus-diphtheria JJ 1_i
vaccine NN 1_i
? . N
A DT N
comparative JJ N
clinical JJ N
trial NN 1_p
in IN 1_p
adults NNS 1_p
. . 1_p

In IN N
the DT N
management NN N
of IN N
wounds NNS N
, , N
sometimes RB N
it PRP N
is VBZ N
recommended VBN N
to TO N
give VB N
an DT N
adult-type JJ N
tetanus-diphtheria NN 1_i
( ( 1_i
Td NNP 1_i
) ) 1_i
vaccine NN 1_i
dose JJ N
plus CC N
tetanus JJ 1_i
immune JJ 1_i
globulin NN 1_i
( ( 1_i
TIG NNP 1_i
) ) 1_i
. . 1_i

Sixty NNP 1_p
and CC 1_p
59 CD 1_p
healthy JJ 1_p
young JJ 1_p
adults NNS 1_p
previously RB 1_p
immunized VBN 1_p
against IN 1_p
tetanus NN 1_p
( ( 1_p
T NNP 1_p
) ) 1_p
and CC 1_p
diphtheria NN 1_p
( ( 1_p
D NNP 1_p
) ) 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
receive VB 1_i
intramuscularly RB 1_i
either DT 1_i
Td NNP 1_i
vaccine NN 1_i
alone RB 1_i
( ( 1_i
group NN 1_i
1 CD 1_i
) ) 1_i
or CC 1_i
Td NNP 1_i
vaccine NN 1_i
plus CC 1_i
500 CD 1_i
IU NNP 1_i
of IN 1_i
TIG NNP 1_i
( ( 1_i
group NN 1_i
2 CD 1_i
) ) 1_i
simultaneously RB 1_i
. . 1_i

Antitoxin NNP 1_o
response NN 1_o
was VBD 1_i
assessed VBN 1_i
after IN 1_i
4 CD 1_i
weeks NNS 1_i
and CC 1_i
4 CD 1_i
months NNS 1_i
. . 1_i

Circulating VBG 1_o
antibodies NNS 1_o
were VBD 1_o
measured VBN 1_o
by IN 1_o
enzyme-linked JJ 1_o
immunosorbent NN 1_o
assay NN 1_o
( ( 1_o
ELISA NNP 1_o
) ) 1_o
. . 1_o

The DT N
cutoff NN N
of IN N
these DT N
tests NNS N
was VBD N
0.1 CD N
IU/mL NNP N
. . N

Titers NNS N
of IN N
0.1 CD N
IU/mL NNP N
or CC N
greater JJR N
were VBD N
considered VBN N
protective JJ N
. . N

For IN N
geometric JJ N
mean NN N
titers NNS N
( ( N
GMT NNP N
) ) N
, , N
antibody NN 1_o
titers NNS 1_o
below IN N
the DT N
cutoff NN N
of IN N
the DT N
assay NN N
were VBD N
given VBN N
, , N
arbitrarily RB N
, , N
0.05 CD N
IU/mL NNP N
. . N

At IN N
4 CD N
weeks NNS N
, , N
98 CD N
% NN N
or CC N
more JJR N
of IN N
the DT N
subjects NNS N
in IN N
group NN N
1 CD N
had VBD N
circulating NN 1_o
T NNP 1_o
and CC 1_o
D NNP 1_o
antitoxin NN 1_o
levels NNS 1_o
of IN N
0.1 CD N
IU/mL NNP N
or CC N
higher JJR N
; : N
in IN N
group NN N
2 CD N
, , N
95 CD N
% NN N
and CC N
90 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
titers NNS N
above IN N
this DT N
limit NN N
for IN N
T NNP N
and CC N
D NNP N
, , N
respectively RB N
. . N

At IN N
4 CD N
months NNS N
, , N
these DT N
percentages NNS N
were VBD N
98 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
T NNP 1_o
antitoxin NN 1_o
levels NNS 1_o
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
; : N
whereas CC N
96 CD N
% NN N
and CC N
88 CD N
% NN N
of IN N
the DT N
subjects NNS N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
had VBD N
D NNP 1_o
antitoxin NN 1_o
levels NNS 1_o
of IN N
0.1 CD N
IU/mL NNP N
or CC N
higher JJR N
, , N
respectively RB N
. . N

Significantly NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
higher JJR N
GMTs NNP N
were VBD N
seen VBN N
at IN N
the DT N
4-week JJ N
assessment NN N
( ( N
but CC N
not RB N
at IN N
4 CD N
months NNS N
) ) N
in IN N
group NN N
1 CD N
, , N
as IN N
compared VBN N
with IN N
group NN N
2 CD N
, , N
in IN N
both DT N
T NNP N
and CC N
D NNP N
antitoxin NN N
levels NNS N
( ( N
9.91 CD N
IU/mL NNP N
versus NN N
5.60 CD N
IU/mL NNP N
for IN N
T NNP N
antitoxin NN N
, , N
and CC N
2.86 CD N
IU/mL NNP N
versus NN N
1.45 CD N
IU/mL NNP N
for IN N
D NNP N
antitoxin NN N
) ) N
. . N

This DT N
finding NN N
resulted VBD N
from IN N
those DT N
participants NNS N
with IN N
low JJ N
( ( N
< JJ N
0.1 CD N
IU/mL NNP N
) ) N
prevaccination NN N
antibody NN N
titers NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Successful JJ N
new JJ N
method NN N
of IN N
extracorporeal JJ 1_i
percutaneous JJ 1_i
endoscopic NN 1_i
gastrostomy NN 1_i
( ( 1_i
E-PEG NNP 1_i
) ) 1_i
. . 1_i

BACKGROUND NNP N
Although IN N
percutaneous JJ 1_i
endoscopic NNS 1_i
gastrostomy NN 1_i
( ( 1_i
PEG NNP 1_i
) ) 1_i
has VBZ N
become VBN N
popular JJ N
for IN N
patients NNS 1_p
with IN 1_p
swallowing VBG 1_p
disorders NNS 1_p
as IN 1_p
a DT 1_p
nutrition NN 1_p
support NN 1_p
or CC 1_p
a DT 1_p
decompressant NN 1_p
of IN 1_p
gastrointestine NN 1_p
, , 1_p
perioperative JJ 1_p
complications NNS 1_p
associated VBN 1_p
with IN 1_p
PEG NNP 1_i
have VBP 1_p
not RB 1_p
decreased VBN 1_p
, , 1_p
especially RB 1_p
peristomal JJ 1_p
infections NNS 1_p
. . 1_p

To TO N
reduce VB N
peristomal JJ N
infections NNS N
, , N
we PRP N
designed VBD N
a DT N
new JJ N
method NN N
of IN N
gastrostomy NN N
by IN N
extracorporeal JJ N
approach NN N
under IN N
endoscopic JJ N
observation NN N
, , N
named VBN N
as IN N
extra-corporeal JJ 1_i
PEG NNP 1_i
( ( 1_i
E-PEG NNP 1_i
) ) 1_i
. . 1_i

METHODS NNP N
Experimental NNP N
studies NNS N
for IN N
E-PEG NNP 1_i
were VBD N
performed VBN N
repeatedly RB N
using VBG N
pigs NNS 1_p
under IN 1_p
general JJ 1_p
anesthesia NN 1_i
to TO N
confirm VB N
the DT N
safety NN N
of IN N
its PRP$ N
procedure NN N
for IN N
human JJ N
use NN N
. . N

After IN N
approval NN N
of IN N
institutional JJ N
ethics NNS N
review VBP N
board NN N
in IN N
our PRP$ N
university NN N
, , N
thirty JJ 1_p
patients NNS 1_p
with IN 1_p
prior JJ 1_p
consent NN 1_p
participated VBN N
in IN N
this DT N
study NN N
. . N

The DT N
operation NN 1_o
time NN 1_o
, , N
the DT N
incidence NN 1_o
rate NN 1_o
of IN 1_o
complications NNS 1_o
and CC 1_o
the DT 1_o
hospital NN 1_o
stay NN 1_o
were VBD N
compared VBN N
between IN N
E-PEG NNP 1_i
and CC 1_i
ordinary JJ 1_i
pull-method JJ 1_i
PEG NNP 1_i
groups NNS 1_i
. . N

RESULTS NNP N
Two CD N
patients NNS N
( ( N
6.7 CD N
% NN N
) ) N
in IN N
E-PEG NNP 1_i
group NN N
had VBD N
postoperative JJ 1_o
complications NNS 1_o
, , N
i.e. FW N
, , N
aspiration NN 1_o
pneumonia NN 1_o
and CC 1_o
surgical JJ 1_o
site NN 1_o
infection NN 1_o
. . 1_o

The DT N
operation NN 1_o
time NN 1_o
of IN N
E-PEG NNP 1_i
group NN N
was VBD N
5-16 JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
10.3 CD N
+/- JJ N
2.96 CD N
) ) N
min NN N
as IN N
compared VBN N
to TO N
14-37 JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
26.9 CD N
+/- JJ N
8.39 CD N
) ) N
min NN N
with IN N
pull-method JJ N
PEG NNP 1_i
. . 1_i

The DT N
postoperative JJ 1_o
hospital NN 1_o
day NN 1_o
of IN N
E-PEG NNP 1_i
was VBD N
within IN N
two CD N
days NNS N
except IN N
for IN N
the DT N
two CD N
complicated VBD N
cases NNS N
. . N

Significance NNP N
differences NNS N
of IN N
operation NN 1_o
time NN 1_o
, , 1_o
complication NN 1_o
rate NN 1_o
and CC 1_o
postoperative JJ 1_o
hospital NN 1_o
stay NN 1_o
between IN N
those DT N
groups NNS N
observed VBD N
statistically RB N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
E-PEG NNP 1_i
was VBD N
safe JJ 1_o
, , 1_o
tolerable JJ 1_o
and CC N
speedy NN N
when WRB N
compared VBN N
ordinary JJ N
pull-method JJ N
PEG NNP 1_i
. . 1_i

-DOCSTART- -X- O O

Phase NNP N
II NNP N
study NN N
of IN N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
bevacizumab NN 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
chemotherapy NN 1_i
or CC N
erlotinib NN 1_i
compared VBN N
with IN N
chemotherapy NN 1_i
alone RB 1_i
for IN N
treatment NN 1_p
of IN 1_p
recurrent NN 1_p
or CC 1_p
refractory NN 1_p
non JJ 1_p
small-cell JJ 1_p
lung NN 1_p
cancer NN 1_p
. . 1_p

PURPOSE NNP N
Bevacizumab NNP 1_i
, , N
a DT N
humanized JJ N
anti-vascular JJ N
endothelial JJ N
growth NN N
factor NN N
monoclonal JJ N
antibody NN N
, , N
and CC N
erlotinib RB 1_i
, , N
a DT N
reversible JJ N
, , N
orally RB N
available JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
tyrosine NN N
kinase NN N
inhibitor NN N
, , N
have VBP N
demonstrated VBN N
evidence NN N
of IN N
a DT N
survival JJ N
benefit NN N
in IN N
the DT N
treatment NN N
of IN N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
. . N

A DT N
single-arm JJ N
phase NN N
I PRP N
and CC N
II NNP N
study NN N
of IN N
bevacizumab NN 1_i
plus CC 1_i
erlotinib NN 1_i
demonstrated VBD N
encouraging JJ N
efficacy NN N
, , N
with IN N
a DT N
favorable JJ N
safety NN N
profile NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
phase NN N
II NNP N
trial NN N
evaluated VBD N
the DT N
safety NN N
of IN N
combining VBG 1_i
bevacizumab NN 1_i
with IN 1_i
either DT 1_i
chemotherapy NN 1_i
( ( 1_i
docetaxel NN 1_i
or CC 1_i
pemetrexed NN 1_i
) ) 1_i
or CC 1_i
erlotinib JJ 1_i
and CC N
preliminarily RB N
assessed VBN N
these DT N
combinations NNS N
versus VBP N
chemotherapy NN 1_i
alone RB N
, , N
as IN N
measured VBN N
by IN N
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
. . 1_o

All DT 1_p
patients NNS 1_p
had VBD 1_p
histologically RB 1_p
confirmed VBN 1_p
nonsquamous JJ 1_p
NSCLC NNP 1_p
that WDT 1_p
had VBD 1_p
progressed VBN 1_p
during IN 1_p
or CC 1_p
after IN 1_p
one CD 1_p
platinum-based JJ 1_p
regimen NNS 1_p
. . 1_p

RESULTS NNP N
One CD 1_p
hundred VBD 1_p
twenty NN 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
and CC N
treated VBN N
. . N

No DT N
unexpected JJ N
adverse JJ 1_o
events NNS 1_o
were VBD N
noted VBN N
. . N

Fewer JJR N
patients NNS N
( ( N
13 CD N
% NN N
) ) N
in IN N
the DT N
bevacizumab-erlotinib JJ 1_i
arm NN N
discontinued VBN N
treatment NN N
as IN N
a DT N
result NN 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
than IN N
in IN N
the DT N
chemotherapy NN 1_i
alone RB N
( ( N
24 CD N
% NN N
) ) N
or CC N
bevacizumab-chemotherapy NN 1_i
( ( N
28 CD N
% NN N
) ) N
arms NNS N
. . N

The DT N
incidence NN N
of IN N
grade NN 1_o
5 CD 1_o
hemorrhage NN 1_o
in IN N
patients NNS N
receiving VBG N
bevacizumab NN 1_i
was VBD N
5.1 CD N
% NN N
. . N

Although IN N
not RB N
statistically RB N
significant JJ N
, , N
relative JJ N
to TO N
chemotherapy VB N
alone RB N
, , N
the DT N
risk NN 1_o
of IN 1_o
disease NN 1_o
progression NN 1_o
or CC 1_o
death NN 1_o
was VBD N
0.66 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.38 CD N
to TO N
1.16 CD N
) ) N
among IN N
patients NNS N
treated VBN N
with IN N
bevacizumab-chemotherapy NN 1_i
and CC N
0.72 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.42 CD N
to TO N
1.23 CD N
) ) N
among IN N
patients NNS N
treated VBN N
with IN N
bevacizumab-erlotinib JJ 1_i
. . 1_i

One-year JJ 1_o
survival NN 1_o
rate NN 1_o
was VBD N
57.4 CD N
% NN N
for IN N
bevacizumab-erlotinib NN 1_i
and CC N
53.8 CD N
% NN N
for IN N
bevacizumab-chemotherapy NN 1_i
compared VBN N
with IN N
33.1 CD N
% NN N
for IN N
chemotherapy NN 1_i
alone RB N
. . N

CONCLUSION NNP N
Results NNP N
for IN N
PFS NNP 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
favor NN N
combination NN N
of IN N
bevacizumab NN 1_i
with IN N
either DT N
chemotherapy NN 1_i
or CC N
erlotinib NN N
over IN N
chemotherapy NN 1_i
alone RB N
in IN N
the DT N
second-line JJ N
setting NN N
. . N

No DT N
unexpected JJ N
safety NN 1_o
signals NNS 1_o
were VBD N
noted VBN N
. . N

The DT N
rate NN 1_o
of IN 1_o
fatal JJ 1_o
pulmonary JJ 1_o
hemorrhage NN 1_o
was VBD N
consistent JJ N
with IN N
previous JJ N
bevacizumab NN 1_i
trials NNS N
. . N

The DT N
toxicity NN 1_o
profile NN 1_o
of IN N
the DT N
bevacizumab-erlotinib JJ 1_i
combination NN 1_i
is VBZ N
favorable JJ N
compared VBN N
with IN N
either DT N
chemotherapy-containing JJ 1_i
group NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
low JJ N
and CC N
high JJ N
doses NNS N
of IN N
atorvastatin NN 1_i
on IN N
arterial JJ N
compliance NN N
. . N

At IN N
the DT N
beginning NN N
of IN N
atherosclerosis NN N
before IN N
evidence NN N
of IN N
morphological JJ 1_o
lesions NNS 1_o
or CC 1_o
plaques NNS 1_o
, , 1_o
vascular JJ 1_o
distensibility NN 1_o
or CC 1_o
arterial JJ 1_o
compliance NN 1_o
decreased VBN N
gradually RB N
. . N

This DT N
endothelial JJ N
dysfunction NN N
is VBZ N
regarded VBN N
as IN N
an DT N
early JJ N
feature NN N
of IN N
atherosclerosis NN N
. . N

In IN N
a DT 1_p
randomized JJ 1_p
, , 1_p
double-blind JJ 1_p
study NN 1_p
design NN 1_p
, , 1_p
group NN 1_p
1 CD 1_p
( ( 1_p
12 CD 1_p
patients NNS 1_p
; : 1_p
7 CD 1_p
males NNS 1_p
, , 1_p
5 CD 1_p
females NNS 1_p
) ) 1_p
with IN 1_p
serum JJ 1_o
LDL-C JJ 1_o
levels NNS 1_o
higher JJR 1_p
than IN 1_p
170 CD 1_p
mg/dL NN 1_p
and CC 1_p
without IN 1_p
any DT 1_p
other JJ 1_p
risk NN 1_p
factor NN 1_p
for IN 1_p
atherosclerosis NN 1_p
received VBD 1_p
three CD 1_p
months NNS 1_p
of IN 1_p
20 CD 1_p
mg/day JJ 1_p
atorvastatin FW 1_i
treatment NN 1_i
while IN 1_p
group NN 1_p
11 CD 1_p
( ( 1_p
8 CD 1_p
males NNS 1_p
, , 1_p
4 CD 1_p
females NNS 1_p
) ) 1_p
with IN 1_p
the DT 1_p
same JJ 1_p
characteristics NNS 1_p
received VBD 1_p
80 CD 1_p
mg/day NN 1_p
. . 1_p

Baseline NNP N
and CC N
posttreatment JJ N
serum NN 1_o
lipid JJ 1_o
fractions NNS 1_o
and CC 1_o
arterial JJ 1_o
compliance NN 1_o
were VBD N
measured VBN N
. . N

Arterial JJ 1_o
compliance NN 1_o
was VBD N
measured VBN N
noninvasively RB N
in IN N
the DT N
left JJ N
common JJ N
carotid NN N
artery NN N
with IN N
color NN N
Doppler NNP N
ultrasound NN N
. . N

Atorvastatin NNP 1_i
reduced VBD 1_o
total JJ 1_o
cholesterol NN 1_o
( ( 1_o
TC NNP 1_o
) ) 1_o
, , 1_o
LDL-C NNP 1_o
, , 1_o
and CC 1_o
triglyceride NN 1_o
levels NNS 1_o
by IN N
32 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
40.8 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
19 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
and CC N
increased VBD 1_o
HDL-C NNP 1_o
by IN N
6.9 CD N
% NN N
, , N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
in IN N
the DT N
first JJ N
group NN N
. . N

In IN N
the DT N
second JJ N
group NN N
these DT N
reductions NNS N
were VBD N
38.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
46.2 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
26.78 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
increase NN 1_o
in IN 1_o
HDL NNP 1_o
was VBD N
7.8 CD N
% NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

It PRP N
was VBD N
observed VBN N
that IN N
the DT N
decrease NN 1_o
in IN 1_o
serum NN 1_o
TC NNP 1_o
, , 1_o
LDL-C NNP 1_o
and CC 1_o
triglyceride NN 1_o
levels NNS 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
second JJ N
group NN N
than IN N
the DT N
first JJ N
group NN N
. . N

With IN N
atorvastatin NN 1_i
, , N
the DT N
distensibility NN 1_o
coefficient NN 1_o
( ( 1_o
DC NNP 1_o
) ) 1_o
and CC 1_o
compliance NN 1_o
coefficient NN 1_o
( ( 1_o
CC NNP 1_o
) ) 1_o
increased VBD 1_o
from IN N
18.7 CD N
+/- JJ N
3.4 CD N
to TO N
21.3 CD N
+/- JJ N
2.9 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.69 CD N
+/- JJ N
0.05 CD N
to TO N
0.77 CD N
+/- JJ N
0.03 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
the DT N
first JJ N
group NN N
while IN N
they PRP N
changed VBD N
from IN N
18.3 CD N
+/- JJ N
3.6 CD N
to TO N
21.9 CD N
+/- JJ N
3.0 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.70 CD N
+/- JJ N
0.04 CD N
to TO N
0.81 CD N
+/- JJ N
0.01 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
respectively RB N
, , N
in IN N
the DT N
second JJ N
group NN N
. . N

DC NNP 1_o
and CC 1_o
CC NNP 1_o
increased VBD 1_o
in IN N
both DT N
groups NNS N
, , N
but CC N
the DT N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
not RB N
significant JJ N
. . N

High JJ N
doses NNS N
of IN N
atorvastatin NN 1_i
reduce VB 1_o
blood NN 1_o
lipid NN 1_o
levels NNS 1_o
more RBR N
than IN N
conventional JJ N
doses NNS N
, , N
however RB N
, , N
the DT N
change NN N
in IN N
compliance NN N
is VBZ N
not RB N
dose-dependent JJ N
. . N

As IN N
endothelial JJ N
dysfunction NN N
is VBZ N
regarded VBN N
as IN N
an DT N
early JJ N
feature NN N
of IN N
atherosclerosis NN N
, , N
there EX N
would MD N
be VB N
no RB N
need NN N
to TO N
administer VB N
aggressive JJ N
doses NNS N
in IN N
a DT N
patient NN N
without IN N
any DT N
risk NN N
factors NNS N
other JJ N
than IN N
hyperlipidemia NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
cooking NN 1_i
plant NN 1_i
oils NNS 1_i
on IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE NNP N
One-third NNP N
of IN N
the DT N
total JJ N
population NN N
seems VBZ N
to TO N
develop VB N
minor JJ N
recurrent NN 1_p
aphthous JJ 1_p
stomatitis NN 1_p
( ( 1_p
RAS NNP 1_p
) ) 1_p
during IN N
their PRP$ N
lifetime NN N
. . N

However RB N
, , N
well-controlled JJ N
dietary JJ N
intervention NN N
studies NNS N
to TO N
prevent VB N
minor JJ N
RAS NNP N
are VBP N
very RB N
rare JJ N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
prevalence NN N
of IN N
RAS NNP N
decreased VBD N
with IN N
perilla NN 1_i
oil NN 1_i
( ( N
rich JJ N
in IN N
alpha-linolenic JJ N
acid NN N
) ) N
. . N

METHODS NNP N
Thirty NNP 1_p
subjects NNS 1_p
( ( 1_p
8 CD 1_p
men NNS 1_p
and CC 1_p
22 CD 1_p
women NNS 1_p
) ) 1_p
who WP 1_p
had VBD 1_p
minor JJ 1_p
RAS NNP 1_p
at IN 1_p
least JJS 1_p
once RB 1_p
a DT 1_p
month NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
soybean JJ 1_i
oil NN 1_i
group NN 1_i
or CC 1_i
a DT 1_i
perilla JJ 1_i
oil NN 1_i
group NN 1_i
in IN 1_i
a DT 1_i
double-blind JJ 1_i
manner NN 1_i
( ( 1_i
experimental JJ 1_i
phase NN 1_i
) ) 1_i
after IN 1_i
a DT 1_i
run-in JJ 1_i
phase NN 1_i
of IN 1_i
4 CD 1_i
mo NN 1_i
during IN 1_i
which WDT 1_i
subjects NNS 1_i
used VBD 1_i
a DT 1_i
reference NN 1_i
oil NN 1_i
, , 1_i
the DT 1_i
most RBS 1_i
popular JJ 1_i
cooking NN 1_i
oil NN 1_i
in IN 1_i
Japan NNP 1_i
, , 1_i
or CC 1_i
a DT 1_i
50/50 CD 1_i
mixture NN 1_i
of IN 1_i
soybean JJ 1_i
oil NN 1_i
and CC 1_i
rapeseed NN 1_i
oil NN 1_i
. . 1_i

During IN N
the DT N
experimental JJ N
phase NN N
, , N
subjects NNS N
were VBD N
asked VBN N
to TO N
use VB N
soybean JJ N
oil NN N
or CC N
perilla NN N
oil NN N
as IN N
the DT N
sole JJ N
cooking NN N
oil NN N
for IN N
8 CD N
mo NN N
. . N

Blood NN 1_o
samples NNS 1_o
were VBD N
collected VBN N
at IN N
the DT N
start NN N
and CC N
end NN N
of IN N
the DT N
experimental JJ N
phase NN N
for IN N
fatty JJ N
acid JJ N
analysis NN N
of IN N
total JJ N
plasma NN N
phospholipid JJ N
fraction NN N
. . N

Occurrence NN 1_o
and CC 1_o
needed VBN 1_o
days NNS 1_o
for IN 1_o
healing NN 1_o
of IN 1_o
minor JJ 1_o
RAS NNP 1_o
were VBD N
recorded VBN N
during IN N
the DT N
two CD N
phases NNS N
and CC N
compared VBN N
. . N

RESULTS NNP N
alpha-Linolenic JJ 1_o
acid JJ 1_o
concentrations NNS 1_o
in IN 1_o
the DT 1_o
plasma NN 1_o
phospholipid JJ 1_o
fraction NN 1_o
increased VBD 1_o
significantly RB N
in IN N
both DT N
groups NNS N
during IN N
the DT N
experimental JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

The DT N
prevalence NN N
of IN N
minor JJ 1_o
RAS NNP 1_o
in IN 1_o
the DT 1_o
experimental JJ 1_o
phase NN 1_o
decreased VBD 1_o
significantly RB 1_o
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
the DT N
run-in JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
, , N
without IN N
intergroup JJ N
differences NNS N
. . N

CONCLUSION NNP N
Perilla NNP N
oil NN N
, , N
which WDT N
is VBZ N
rich JJ N
in IN N
alpha-linolenic JJ N
acid NN N
, , N
was VBD N
not RB N
superior JJ N
to TO N
soybean VB N
oil NN N
in IN N
preventing VBG N
minor JJ N
RAS NNP N
. . N

There EX N
was VBD N
a DT N
possibility NN N
that IN N
avoiding VBG N
rapeseed VB N
oil NN N
might MD N
be VB N
beneficial JJ N
for IN N
prevention NN N
of IN N
minor JJ N
RAS NNP N
. . N

-DOCSTART- -X- O O

Theory-driven JJ 1_i
intervention NN 1_i
improves VBZ N
calcium JJ 1_o
intake NN 1_o
, , 1_o
osteoporosis NN 1_o
knowledge NN 1_o
, , 1_o
and CC 1_o
self-efficacy NN 1_o
in IN N
community-dwelling JJ 1_p
older JJR 1_p
Black NNP 1_p
adults NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN 1_o
of IN N
an DT N
osteoporosis JJ 1_i
education NN 1_i
program NN 1_i
to TO N
improve VB N
calcium NN 1_o
intake NN 1_o
, , 1_o
knowledge NN 1_o
, , 1_o
and CC 1_o
self-efficacy NN 1_o
in IN N
community-dwelling JJ 1_p
older JJR 1_p
Black NNP 1_p
adults NNS 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
repeated VBD N
measures NNS N
experimental JJ N
design NN N
. . N

SETTING NN N
Churches NNP 1_p
and CC 1_p
community-based JJ 1_p
organizations NNS 1_p
. . 1_p

PARTICIPANTS NNP N
Men NNP 1_p
and CC 1_p
women NNS 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
110 CD 1_p
) ) 1_p
50 CD 1_p
years NNS 1_p
old JJ 1_p
and CC 1_p
older JJR 1_p
from IN 1_p
3 CD 1_p
south JJ 1_p
Florida NNP 1_p
counties NNS 1_p
. . 1_p

INTERVENTION NNP N
Participants NNP N
randomly RB N
assigned VBD N
to TO N
either DT N
of IN N
2 CD N
groups NNS N
: : N
Group NNP N
1 CD N
( ( N
experimental JJ N
group NN N
) ) N
or CC N
Group NNP N
2 CD N
( ( 1_i
wait-list JJ 1_i
control NN 1_i
group NN 1_i
) ) 1_i
. . N

Group NNP N
1 CD N
participated VBD N
in IN N
6 CD 1_i
weekly JJ 1_i
education NN 1_i
program NN 1_i
sessions NNS 1_i
immediately RB N
following VBG N
baseline NN 1_i
assessment NN 1_i
, , N
and CC N
Group NNP N
2 CD N
started VBD N
the DT N
program NN N
following VBG N
Group NNP N
1 CD N
's POS N
program NN N
completion NN N
. . N

A DT N
tested JJ N
curriculum NN N
was VBD N
adapted VBN N
to TO N
meet VB N
the DT N
needs NNS N
of IN N
the DT N
target NN N
population NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Dietary NNP 1_o
calcium NN 1_o
intake NN 1_o
, , 1_o
osteoporosis NN 1_o
knowledge NN 1_o
, , 1_o
health NN 1_o
beliefs NNS 1_o
, , 1_o
and CC 1_o
self-efficacy NN 1_o
. . 1_o

ANALYSIS NNP N
Descriptive NNP N
and CC N
summary JJ N
statistics NNS N
, , N
repeated VBD N
measures NNS N
analysis NN N
of IN N
variance NN N
, , N
and CC N
regression NN N
analysis NN N
. . N

RESULTS NNP N
Of IN N
the DT N
total JJ N
participants NNS N
, , N
84.6 CD N
% NN N
completed VBD N
the DT N
study NN N
( ( N
mean JJ N
age NN N
= VBD N
70.2 CD N
years NNS N
) ) N
. . N

Overall UH N
, , N
an DT N
educational JJ 1_i
program NN 1_i
developed VBN N
with IN N
a DT N
theoretical JJ N
background NN N
was VBD N
associated VBN N
with IN N
improvement NN N
in IN N
calcium NN 1_o
intake NN 1_o
, , 1_o
knowledge NN 1_o
, , 1_o
and CC 1_o
self-efficacy NN 1_o
, , N
with IN N
no DT N
effect NN N
on IN N
most JJS N
health NN 1_o
belief NN 1_o
subscales NNS 1_o
. . 1_o

Assigned VBN N
group NN N
was VBD N
the DT N
major JJ N
predictor NN N
of IN N
change NN N
in IN N
calcium NN 1_o
intake NN 1_o
. . 1_o

CONCLUSIONS NNP N
AND NNP N
IMPLICATIONS NNP N
A NNP N
theory-driven JJ N
approach NN N
is VBZ N
valuable JJ N
in IN N
improving VBG N
behavior NN N
to TO N
promote VB N
bone NN N
health NN N
in IN N
this DT N
population NN N
. . N

Health NNP N
professionals NNS N
should MD N
consider VB N
using VBG N
more JJR N
theory-driven JJ N
approaches NNS N
in IN N
intervention NN N
studies NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
arzoxifene NN 1_i
( ( 1_i
LY353381 NNP 1_i
) ) 1_i
in IN N
hormone-sensitive JJ 1_p
advanced JJ 1_p
or CC 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
assessed VBD N
two CD N
doses NNS N
of IN N
the DT N
selective JJ 1_i
estrogen NN 1_i
receptor NN 1_i
modulator NN 1_i
arzoxifene NN 1_i
in IN N
women NNS 1_p
with IN 1_p
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

The DT N
primary JJ N
end NN N
point NN N
was VBD N
to TO N
choose VB N
the DT N
best JJS N
of IN N
two CD N
doses NNS N
of IN N
arzoxifene NN 1_i
based VBN N
on IN N
the DT N
response NN 1_o
rate NN 1_o
or CC 1_o
the DT 1_o
clinical JJ 1_o
benefit NN 1_o
rate NN 1_o
( ( 1_o
CBR NNP 1_o
) ) 1_o
. . 1_o

Pharmacokinetics NNPS 1_o
and CC 1_o
toxicities NNS 1_o
were VBD N
also RB N
assessed VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Ninety-two NNP 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
received VBD 1_i
arzoxifene JJ 1_i
20 CD 1_i
or CC 1_i
50 CD 1_i
mg/day NN 1_i
. . 1_i

Tumor NNP 1_o
response NN 1_o
was VBD 1_i
assessed VBN 1_i
using VBG 1_i
World NNP 1_i
Health NNP 1_i
Organization NNP 1_i
criteria NNS 1_i
. . 1_i

Toxicities NNS 1_o
were VBD 1_i
graded VBN 1_i
according VBG 1_i
to TO 1_i
the DT 1_i
National NNP 1_i
Cancer NNP 1_i
Institute NNP 1_i
Common NNP 1_i
Toxicity NNP 1_i
Criteria NNP 1_i
( ( 1_i
NCI-CTC NNP 1_i
) ) 1_i
system NN 1_i
. . 1_i

Pharmacokinetic JJ 1_o
data NNS 1_o
were VBD N
analyzed VBN N
using VBG N
the DT N
NONMEM NNP N
software NN N
program NN N
( ( N
GloboMax NNP N
, , N
Hanover NNP N
, , N
MD NNP N
, , N
USA NNP N
) ) N
. . N

RESULTS JJ N
Response JJ 1_o
rates NNS 1_o
in IN N
the DT N
20 CD N
mg NN N
arm NN N
were VBD N
numerically RB N
higher JJR N
than IN N
the DT N
50-mg JJ N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
40.5 CD N
% NN N
versus IN N
36.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
42.9 CD N
% NN N
versus IN N
27.3 CD N
% NN N
) ) N
. . N

CBR NNP 1_o
was VBD N
higher RBR N
in IN N
the DT N
20 CD N
mg NN N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
64.3 CD N
% NN N
versus IN N
61.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
59.5 CD N
% NN N
versus IN N
47.7 CD N
% NN N
) ) N
. . N

Arzoxifene NNP 1_i
was VBD N
well RB N
tolerated VBN N
. . N

There EX N
were VBD N
no DT N
study NN N
drug-related JJ 1_o
deaths NNS 1_o
. . 1_o

Mean NNP N
observed VBD N
steady-state JJ 1_o
plasma JJ 1_o
concentrations NNS 1_o
of IN N
arzoxifene NN 1_i
were VBD N
3.62 CD N
and CC N
7.48 CD N
ng/ml NN N
for IN N
the DT N
20 CD N
and CC N
50 CD N
mg NN N
doses NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN 1_o
or CC N
safety NN 1_o
between IN N
20 CD N
and CC N
50 CD N
mg NN N
of IN N
arzoxifene NN 1_i
. . 1_i

Accordingly RB N
, , N
arzoxifene VBZ 1_i
20 CD N
mg/day NN N
was VBD N
selected VBN N
for IN N
further JJ N
study NN N
in IN N
patients NNS N
with IN N
breast JJ N
cancer NN N
. . N

-DOCSTART- -X- O O

Split-face NNP N
comparison NN N
of IN N
the DT N
erbium NN 1_i
micropeel NN 1_i
with IN 1_i
intense JJ 1_i
pulsed JJ 1_i
light NN 1_i
. . 1_i

BACKGROUND VB N
A DT N
variety NN N
of IN N
photorejuvenative JJ N
techniques NNS N
have VBP N
been VBN N
utilized VBN N
to TO N
reverse VB N
the DT N
signs NNS N
of IN N
cutaneous JJ N
photoaging NN N
, , N
including VBG N
ablative JJ N
and CC N
nonablative JJ N
laser NN N
resurfacing NN N
as RB N
well RB N
as IN N
light-based JJ N
devices NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
split-face JJ N
randomized JJ N
prospective JJ N
open-label JJ N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
sequential JJ 1_i
erbium NN 1_i
: : 1_i
yttrium-aluminum-garnet NN 1_i
( ( 1_i
Er NNP 1_i
: : 1_i
YAG NN 1_i
) ) 1_i
laser NN 1_i
versus NN 1_i
intense JJ 1_i
pulsed VBN 1_i
light NN 1_i
( ( 1_i
IPL NNP 1_i
) ) 1_i
for IN N
the DT N
treatment NN N
of IN N
mild NN 1_p
to TO 1_p
moderate VB 1_p
facial JJ 1_p
photodamage NN 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
Ten NNP 1_p
subjects VBZ 1_p
( ( 1_p
ages IN 1_p
35-63 NNP 1_p
) ) 1_p
with IN 1_p
facial JJ 1_p
dyschromia NN 1_p
and CC 1_p
rhytides NNS 1_p
were VBD N
enrolled VBN N
. . N

Study NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
two CD N
treatment NN N
arms NNS N
, , N
Er NN 1_i
: : 1_i
YAG NNP 1_i
( ( N
3.8 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
, , N
30 CD N
% NN N
pattern JJ 1_i
overlap NN 1_i
, , N
0 CD N
% NN N
interpulse JJ 1_i
overlap NN 1_i
, , N
15 CD N
microm NN N
per IN N
pass NN N
with IN N
no DT N
coagulation NN N
) ) N
and CC N
IPL NNP 1_i
( ( N
560-nm JJ N
filter NN N
, , N
30 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
, , N
2.4/4.0-ms JJ N
pulse NN N
with IN N
10-ms JJ N
delay NN N
) ) N
, , N
each DT N
receiving VBG N
three CD N
sequential JJ N
treatments NNS N
spaced VBD N
1 CD N
month NN N
apart RB N
. . N

Subjective JJ N
and CC N
blinded VBD N
physician JJ N
evaluations NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
4 CD N
, , N
8 CD N
, , N
and CC N
20 CD N
weeks NNS N
posttreatment NN N
using VBG N
a DT N
nominal JJ N
scale NN N
from IN N
1 CD N
to TO N
4 CD N
. . N

Erythema NN N
and CC N
adverse JJ N
events NNS N
were VBD N
assessed VBN N
1 CD N
week NN N
following VBG N
each DT N
treatment NN N
. . N

RESULTS NNP N
Ten NNP 1_p
female JJ 1_p
subjects NNS 1_p
with IN 1_p
mild NN 1_p
to TO 1_p
moderate VB 1_p
facial JJ 1_p
photodamage NN 1_p
were VBD N
treated VBN N
with IN N
one CD N
pass NN N
of IN N
either DT N
IPL NNP N
or CC N
Er NNP N
: : N
YAG NN N
in IN N
a DT N
split-face JJ N
fashion NN N
. . N

Patients NNS N
received VBD N
three CD N
treatments NNS N
each DT N
spaced VBD N
1 CD N
month NN N
apart RB N
. . N

Nine NNP 1_p
of IN 1_p
10 CD 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
; : 1_p
1 CD N
withdrew VBD N
due JJ N
to TO N
pain VB 1_o
during IN N
the DT N
second JJ N
Er NNP N
: : N
YAG PRP$ N
treatment NN N
. . N

Baseline NNP N
subjective JJ N
and CC N
blinded VBD 1_o
physician JJ 1_o
dyschromia NN 1_o
and CC 1_o
rhytid NN 1_o
scores NNS 1_o
revealed VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
IPL NNP N
and CC N
Er NNP N
: : N
YAG NNP N
randomly RB N
assigned VBD N
sides NNS N
. . N

Up IN N
to TO N
three CD N
IPL NNP N
or CC N
Er NNP N
: : N
YAG NN N
treatments NNS N
did VBD N
not RB N
result VB N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
rhytid NN N
scores NNS N
. . N

Subjective NNP 1_o
and CC 1_o
blinded VBD 1_o
physician JJ 1_o
dyschromia NN 1_o
scores NNS 1_o
improved VBD 1_o
26 CD N
and CC N
38 CD N
% NN N
, , N
respectively RB N
, , N
3 CD N
months NNS N
after IN N
the DT N
final JJ N
IPL NNP N
treatment NN N
, , N
but CC N
only RB N
by IN N
7 CD N
and CC N
29 CD N
% NN N
, , N
respectively RB N
, , N
with IN N
Er NNP N
: : N
YAG NN N
. . N

Subjective JJ 1_o
global JJ 1_o
facial JJ 1_o
appearance NN 1_o
scores NNS 1_o
worsened VBN N
by IN N
5 CD N
% NN N
while IN N
blinded JJ N
physician JJ N
scores NNS N
improved VBN N
by IN N
16 CD N
% NN N
3 CD N
months NNS N
after IN N
3 CD N
Er NN N
: : N
YAG NN N
treatments NNS N
, , N
but CC N
by IN N
28 CD N
and CC N
20 CD N
% NN N
for IN N
IPL NNP N
, , N
respectively RB N
. . N

The DT N
overall JJ 1_o
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
and CC 1_o
subsequent JJ 1_o
downtime NN 1_o
was VBD N
increased VBN N
for IN N
Er NN N
: : N
YAG NNP N
( ( N
1/10 CD N
patients NNS N
experienced JJ N
hyperpigmentation NN 1_o
, , N
3/10 CD N
exfoliation NN 1_o
, , N
1/10 CD N
blistering NN 1_o
, , N
and CC N
5/10 CD N
discomfort NN 1_o
) ) 1_o
compared VBN N
to TO N
IPL NNP N
( ( N
1/10 CD N
exfoliation NN N
and CC N
1/10 CD N
discomfort NN N
) ) N
, , N
although IN N
no DT N
permanent JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
with IN N
either DT N
treatment NN N
arm NN N
. . N

CONCLUSIONS NNP N
While IN N
low-fluence JJ N
erbium NN N
resurfacing NN N
has VBZ N
a DT N
modest JJ N
effect NN N
on IN N
facial JJ 1_p
photodamage NN 1_p
, , N
patients NNS N
preferred VBD N
IPL NNP N
because IN N
it PRP N
resulted VBD N
in IN N
less JJR N
downtime NN N
. . N

The DT N
authors NNS N
have VBP N
indicated VBN N
no DT N
significant JJ N
interest NN N
with IN N
commercial JJ N
supporters NNS N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
venous JJ N
thromboembolism NN N
after IN N
knee NN 1_p
arthroplasty NN 1_p
. . 1_p

A DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
comparing VBG N
enoxaparin NN 1_i
with IN N
warfarin NN 1_i
. . 1_i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effectiveness NN 1_o
and CC 1_o
safety NN 1_o
of IN N
fixed-dose JJ 1_i
enoxaparin NN 1_i
and CC N
adjusted VBD 1_i
dose JJ 1_i
warfarin NN 1_i
in IN N
preventing VBG N
venous JJ N
thromboembolism NN N
after IN 1_p
knee NN 1_p
arthroplasty NN 1_p
. . 1_p

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
8 CD 1_p
university NN 1_p
hospitals NNS 1_p
. . 1_p

PATIENTS VB N
670 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
knee VBN 1_p
arthroplasty RB 1_p
. . 1_p

INTERVENTION NN N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
enoxaparin NN 1_i
( ( 1_i
30 CD 1_i
mg NN 1_i
subcutaneously RB 1_i
every DT 1_i
12 CD 1_i
hours NNS 1_i
) ) 1_i
or CC 1_i
adjusted-dose JJ 1_i
warfarin NN 1_i
( ( 1_i
international JJ 1_i
normalized VBN 1_i
ratio NN 1_i
, , 1_i
2.0 CD 1_i
to TO 1_i
3.0 CD 1_i
) ) 1_i
. . N

Both DT N
regimens NNS N
were VBD N
started VBN N
after IN N
surgery NN N
. . N

MEASUREMENTS PDT N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
incidence NN 1_o
of IN 1_o
deep JJ 1_o
venous JJ 1_o
thrombosis NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
adequate JJ 1_p
bilateral JJ 1_p
venograms NNS 1_p
; : 1_p
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
hemorrhage NN 1_o
. . 1_o

RESULTS NNP N
Among IN N
the DT N
417 CD 1_p
patients NNS 1_p
with IN 1_p
adequate JJ 1_p
venograms NNS 1_p
, , N
109 CD N
of IN N
211 CD N
warfarin NN 1_i
recipients NNS N
( ( N
51.7 CD N
% NN N
) ) N
had VBD N
deep JJ 1_o
venous JJ 1_o
thrombosis NN 1_o
compared VBN N
with IN N
76 CD N
of IN N
206 CD N
enoxaparin NN 1_i
recipients NNS N
( ( N
36.9 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
absolute NN 1_o
risk NN 1_o
difference NN 1_o
was VBD N
14.8 CD N
% NN N
in IN N
favor NN N
of IN N
enoxaparin NN 1_i
( ( N
95 CD N
% NN N
Cl NNP N
, , N
5.3 CD N
% NN N
to TO N
24.1 CD N
% NN N
) ) N
Twenty-two NNP N
warfarin NN 1_i
recipients NNS N
( ( N
10.4 CD N
% NN N
) ) N
and CC N
24 CD N
enoxaparin NN 1_i
recipients NNS N
( ( N
11.7 CD N
% NN N
) ) N
had VBD N
proximal JJ N
venous JJ N
thrombosis NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN 1_o
risk NN 1_o
difference NN 1_o
was VBD N
1.2 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN 1_i
( ( N
Cl NNP N
, , N
-7.2 NNP N
% NN N
to TO N
4.8 CD N
% NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
major JJ 1_o
bleeding NN 1_o
was VBD N
1.8 CD N
% NN N
( ( N
6 CD N
of IN N
334 CD N
patients NNS N
) ) N
in IN N
the DT N
warfarin NN N
group NN N
and CC N
2.1 CD N
% NN N
( ( N
7 CD N
of IN N
336 CD N
patients NNS N
) ) N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN 1_o
risk NN 1_o
difference NN 1_o
was VBD N
0.3 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN N
( ( N
Cl NNP N
, , N
-2.4 NNP N
% NN N
to TO N
1.8 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
A DT N
postoperative JJ N
, , N
fixed-dose JJ N
enoxaparin NN 1_i
regimen NNS N
is VBZ N
more RBR N
effective JJ N
than IN N
adjusted-dose JJ N
warfarin NN 1_i
in IN N
preventing VBG N
deep JJ N
venous JJ N
thrombosis NN N
after IN 1_p
knee NN 1_p
arthroplasty NN 1_p
. . 1_p

No DT N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
incidence NN N
of IN N
proximal JJ N
venous JJ N
thrombosis NN N
or CC N
clinically RB N
overt JJ N
hemorrhage NN N
. . N

-DOCSTART- -X- O O

Moclobemide NNP 1_i
, , 1_i
imipramine NN 1_i
and CC 1_i
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
major JJ 1_p
depression NN 1_o
. . 1_o

Moclobemide NNP 1_i
was VBD N
compared VBN N
with IN N
imipramine NN 1_i
and CC N
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
major JJ N
depressive JJ N
episodes NNS N
in IN N
75 CD 1_p
outpatients NNS 1_p
. . 1_p

The DT N
dosage NN N
of IN N
moclobemide NN 1_i
( ( 1_i
25 CD 1_i
patients NNS 1_i
) ) 1_i
was VBD 1_i
300 CD 1_i
mg JJ 1_i
daily RB 1_i
for IN 1_i
the DT 1_i
first JJ 1_i
5 CD 1_i
days NNS 1_i
, , 1_i
after IN 1_i
which WDT 1_i
it PRP 1_i
could MD 1_i
be VB 1_i
increased VBN 1_i
to TO 1_i
600 CD 1_i
mg. NNS 1_i
Imipramine NNP 1_i
( ( 1_i
25 CD 1_i
patients NNS 1_i
) ) 1_i
was VBD 1_i
given VBN 1_i
in IN 1_i
a DT 1_i
dosage NN 1_i
starting VBG 1_i
with IN 1_i
33 CD 1_i
mg NNS 1_i
and CC 1_i
gradually RB 1_i
increased VBD 1_i
to TO 1_i
100 CD 1_i
mg/day NN 1_i
in IN 1_i
the DT 1_i
first JJ 1_i
5 CD 1_i
days NNS 1_i
, , N
after IN N
which WDT N
it PRP N
could MD N
be VB N
further RB N
increased VBN N
; : N
25 CD 1_p
patients NNS 1_p
received VBD N
placebo NN 1_i
. . 1_i

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
as IN N
measured VBN N
by IN N
the DT N
Hamilton NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
for IN 1_o
Depression NNP 1_o
, , N
the DT N
overall JJ 1_o
assessment NN 1_o
of IN 1_o
efficacy NN 1_o
and CC N
the DT N
Zung NNP 1_o
Self-rating NNP 1_o
Scale NNP 1_o
, , N
and CC N
clearly RB N
superior JJ N
to TO N
placebo VB N
; : N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
active JJ N
drugs NNS N
. . N

Moclobemide NNP 1_i
was VBD N
better RBR 1_o
tolerated VBN 1_o
than IN N
imipramine NN 1_i
, , N
and CC N
was VBD N
almost RB N
comparable JJ N
to TO N
placebo VB N
in IN N
this DT N
respect NN N
. . N

-DOCSTART- -X- O O

Development NNP N
, , N
awareness NN N
and CC N
inductive JJ N
selectivity NN N
. . N

Two CD N
studies NNS N
examined VBD N
whether IN N
adults NNS 1_p
and CC 1_p
children NNS 1_p
could MD N
learn VB N
to TO N
make VB N
context-dependent JJ N
inferences NNS N
about IN N
novel JJ N
stimuli NNS N
and CC N
the DT N
role NN N
of IN N
awareness NN N
of IN N
context NN N
cues NNS N
in IN N
such JJ N
learning NN N
. . N

Participants NNS 1_p
were VBD N
trained VBN 1_i
to TO 1_i
match VB 1_i
probes NNS 1_i
to TO 1_i
targets NNS 1_i
on IN N
the DT N
basis NN N
of IN N
shape NN N
or CC N
color NN N
with IN N
the DT N
relevant JJ N
dimension NN N
shifting VBG N
according VBG N
to TO N
item NN N
context NN N
. . N

A DT N
selective JJ N
induction NN 1_i
test NN 1_i
then RB N
examined VBD N
context-dependent JJ N
responding NN N
in IN N
a DT N
more RBR N
complex JJ N
matching NN N
task NN N
. . N

Awareness NNP N
of IN N
the DT N
role NN N
of IN N
context NN N
was VBD N
assessed VBN N
using VBG N
a DT N
behavioral JJ 1_i
task NN 1_i
and CC N
explicit JJ 1_i
questions NNS 1_i
. . 1_i

Experiment JJ N
1 CD N
showed VBD N
that IN N
after IN N
training VBG 1_i
with IN N
the DT N
procedure NN N
described VBN N
by IN N
Sloutsky NNP N
and CC N
Fisher NNP N
( ( N
2008 CD N
) ) N
, , N
only RB N
a DT N
minority NN N
of IN N
adults NNS 1_p
showed VBD N
evidence NN N
of IN N
context-dependent JJ N
responding NN N
in IN N
the DT N
selective JJ N
induction NN N
test NN N
. . N

Experiment NN N
2 CD N
used VBD N
a DT N
modified JJ 1_i
training NN 1_i
protocol NN 1_i
that WDT N
promoted VBD N
attention NN N
to TO N
context VB N
cues NNS N
. . N

This DT N
led VBD N
to TO N
reliable VB N
selective JJ N
induction NN N
in IN N
a DT N
majority NN 1_p
of IN 1_p
adults NNS 1_p
and CC 1_p
a DT 1_p
sizeable JJ 1_p
proportion NN 1_p
of IN 1_p
4- JJ 1_p
to TO 1_p
6-year-olds NNS 1_p
. . 1_p

Crucially NNP N
, , N
in IN N
both DT 1_p
age NN 1_p
groups NNS 1_p
, , N
selective JJ 1_o
induction NN 1_o
was VBD N
dependent JJ N
on IN N
awareness NN N
of IN N
context NN N
. . N

Hence NNP N
, , N
children NNS 1_p
as RB 1_p
young JJ 1_p
as IN 1_p
4 CD 1_p
can MD N
learn VB N
to TO N
make VB N
selective JJ N
inferences NNS N
about IN N
novel JJ N
stimuli NNS N
, , N
but CC N
only RB N
when WRB N
they PRP N
are VBP N
aware JJ N
of IN N
the DT N
relevant JJ N
context NN N
cues NNS N
. . N

These DT N
results NNS N
challenge VBP N
previous JJ N
claims NNS N
that WDT N
selective JJ 1_o
induction NN 1_o
in IN N
children NNS 1_p
is VBZ N
the DT N
product NN N
of IN N
implicit JJ N
learning NN N
. . N

-DOCSTART- -X- O O

Enhancing VBG N
antiepileptic JJ 1_i
drug NN 1_i
adherence NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Suboptimal JJ N
adherence NN N
to TO N
antiepileptic JJ 1_i
drug NN 1_i
( ( 1_i
AED NNP 1_i
) ) 1_i
treatment NN 1_i
is VBZ N
commonplace NN N
, , N
and CC N
increases VBZ N
the DT N
risk NN N
of IN N
status NN N
epilepticus NN N
and CC N
sudden JJ N
unexplained JJ N
death NN N
in IN N
epilepsy NN N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
demonstrate VB N
whether IN N
an DT N
implementation NN 1_i
intention NN 1_i
intervention NN 1_i
involving VBG N
the DT N
completion NN N
of IN N
a DT N
simple JJ N
self-administered JJ 1_i
questionnaire NN 1_i
linking VBG N
the DT N
intention NN 1_i
of IN 1_i
taking VBG 1_i
medication NN 1_i
with IN 1_i
a DT 1_i
particular JJ 1_i
time NN 1_i
, , 1_i
place NN 1_i
, , 1_i
and CC 1_i
other JJ 1_i
activity NN 1_i
can MD N
improve VB N
AED NNP 1_i
treatment NN N
schedule NN N
adherence NN N
. . N

Of IN N
the DT N
81 CD 1_p
patients NNS 1_p
with IN 1_p
epilepsy NN 1_p
who WP N
were VBD N
randomized VBN N
, , N
69 CD 1_p
completed VBD 1_p
a DT 1_p
1-month JJ 1_p
monitoring NN 1_p
period NN 1_p
with IN N
an DT N
objective JJ N
measure NN N
of IN N
tablet NN N
taking NN N
( ( N
electronic JJ N
registration NN N
of IN N
pill NN N
bottle JJ N
openings NNS N
, , N
Medication NNP N
Event NNP N
Monitoring NNP N
System NNP N
[ NNP N
MEMS NNP N
] NNP N
) ) N
. . N

Intervention NN 1_i
participants NNS N
showed VBD N
improved JJ 1_o
adherence RB 1_o
relative JJ 1_o
to TO 1_o
controls VB 1_o
on IN N
all DT N
three CD N
outcomes NNS N
: : N
doses NNS 1_o
taken VBN 1_o
in IN 1_o
total JJ 1_o
( ( N
93.4 CD N
% NN N
vs. FW N
79.1 CD N
% NN N
) ) N
, , N
days NNS N
on IN N
which WDT N
correct VBP 1_o
dose NN 1_o
was VBD 1_o
taken VBN 1_o
( ( N
88.7 CD N
% NN N
vs. FW N
65.3 CD N
% NN N
) ) N
, , N
and CC N
doses VBZ 1_o
taken VBN 1_o
on IN 1_o
schedule NN 1_o
( ( N
78.8 CD N
% NN N
vs. FW N
55.3 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
implementation NN N
intention NN 1_i
intervention NN 1_i
may MD N
be VB N
an DT N
easy-to-administer JJ N
and CC N
effective JJ N
means NNS N
of IN N
promoting VBG N
AED NNP 1_i
adherence NN N
. . N

-DOCSTART- -X- O O

A DT N
study NN N
of IN N
postoperative JJ 1_i
cytostatic JJ 1_i
medication NN 1_i
in IN 1_p
patients NNS 1_p
with IN 1_p
operable JJ 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
lung NN 1_p
. . 1_p

-DOCSTART- -X- O O

Lack NN N
of IN N
antihistamine NN N
properties NNS N
of IN N
single JJ N
dose JJ N
cinnarizine NN 1_i
in IN N
man NN 1_p
. . 1_p

A DT N
simple JJ N
way NN N
to TO N
study VB N
a DT N
histamine JJ N
antagonist NN N
in IN N
man NN 1_p
is VBZ N
to TO N
observe VB N
the DT N
effect NN N
it PRP N
has VBZ N
on IN N
the DT N
magnitude NN N
of IN N
the DT N
skin JJ N
reaction NN N
to TO N
intradermal JJ N
histamine NN 1_i
. . 1_i

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
antihistamine JJ N
activity NN N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
75 CD N
mg NNS N
cinnarizine VBP 1_i
using VBG 1_i
75 CD N
mg JJ N
diphenhydramine NN 1_i
as IN 1_i
control NN 1_i
, , N
both DT N
being VBG N
compared VBN N
to TO N
placebo VB 1_i
. . 1_i

The DT N
study NN N
was VBD N
performed VBN N
with IN N
two CD 1_p
groups NNS 1_p
of IN 1_p
5 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
, , 1_p
each DT 1_p
group NN 1_p
receiving VBG 1_p
one CD 1_p
of IN 1_p
the DT 1_p
active JJ 1_p
treatments NNS 1_p
or CC 1_p
placebo NN 1_i
randomly RB 1_p
under IN 1_p
blind JJ 1_p
conditions NNS 1_p
. . 1_p

All DT N
subjects NNS N
received VBN N
intradermal JJ N
injections NNS N
on IN N
the DT N
forearm NN N
of IN N
a DT N
0.05 CD N
ml NN N
saline JJ 1_i
solution NN 1_i
containing VBG N
5 CD N
micrograms NNS N
of IN N
histamine NN 1_i
before IN N
and CC N
at IN N
different JJ N
times NNS N
after IN N
drug NN N
intake NN N
. . N

The DT N
histamine-induced JJ N
wheal JJ N
area NN N
was VBD N
measured VBN N
and CC N
, , N
after IN N
drug NN N
administration NN N
, , N
the DT N
percent NN N
decrease NN N
of IN N
the DT N
wheal JJ 1_o
area NN 1_o
was VBD N
calculated VBN N
. . N

Results NNS N
showed VBD N
that IN N
diphenhydramine NN 1_o
produced VBD 1_o
a DT 1_o
significant JJ 1_o
inhibition NN 1_o
of IN 1_o
the DT 1_o
histamine-induced JJ 1_o
wheal NN 1_o
size NN 1_o
at IN N
1.5 CD N
h NN N
which WDT N
lasted VBD N
up RB N
to TO N
4 CD N
h NNS N
after IN N
drug NN N
administration NN N
, , N
reaching VBG N
maximum JJ N
inhibition NN N
at IN N
2.5 CD N
h. NN N
After IN N
cinnarizine NN 1_i
treatment NN N
no DT 1_o
significant JJ 1_o
decrease NN 1_o
of IN 1_o
the DT 1_o
histamine-induced JJ 1_o
wheal JJ 1_o
area NN 1_o
was VBD 1_o
observed VBN 1_o
at IN 1_o
any DT 1_o
time NN 1_o
. . 1_o

-DOCSTART- -X- O O

An DT N
endovascular JJ 1_i
simulation NN 1_i
exercise NN 1_i
among IN N
radiology JJ 1_p
residents NNS 1_p
: : 1_p
comparison NN 1_o
of IN N
simulation NN 1_o
performance NN 1_o
with IN N
and CC N
without IN N
practice NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
compare VB 1_o
resident JJ N
endovascular JJ 1_o
simulator NN 1_o
performance NN 1_o
with IN N
and CC N
without IN N
prior JJ 1_i
simulation NN 1_i
. . 1_i

METHODS NNP N
Radiology NNP 1_p
residents NNS 1_p
were VBD N
guided VBN 1_i
through IN 1_i
a DT 1_i
practice NN 1_i
simulation NN 1_i
and CC 1_i
lectured VBN 1_i
on IN 1_i
endovascular JJ 1_i
therapy NN 1_i
, , 1_i
then RB 1_i
randomized VBD 1_i
to TO 1_i
simulate VB 1_i
femoral JJ 1_i
arterial JJ 1_i
intervention NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
prior JJ 1_i
iliac JJ 1_i
simulation NN 1_i
. . 1_i

Simulator NN 1_o
measurements NNS 1_o
, , 1_o
performance NN 1_o
grading NN 1_o
and CC 1_o
resident JJ 1_o
surveys NNS 1_o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Prior NNP 1_i
simulation NN 1_i
of IN 1_i
iliac JJ 1_i
intervention NN 1_i
significantly RB N
improved VBN N
resident JJ 1_o
performance NN 1_o
. . 1_o

In IN N
particular JJ N
, , N
it PRP N
resulted VBD N
in IN N
less RBR 1_o
catheter JJ 1_o
placement NN 1_o
without IN 1_o
a DT 1_o
wire NN 1_o
( ( N
P=.01 NNP N
) ) N
, , N
shorter JJR 1_o
time NN 1_o
to TO 1_o
proper VB 1_o
catheter NN 1_o
positioning NN 1_o
( ( N
P=.045 NNP N
) ) N
and CC N
use NN 1_o
of IN 1_o
oblique JJ 1_o
digital JJ 1_o
subtraction NN 1_o
angiography NN 1_o
( ( N
P=.035 NNP N
) ) N
. . N

Survey JJ N
respondents NNS N
valued VBD N
the DT N
experience NN N
. . N

CONCLUSION NNP N
Endovascular NNP 1_i
simulator NN 1_i
training VBG 1_i
improves NNS N
simulation NN 1_o
skills NNS 1_o
. . 1_o

Improvement NN N
of IN N
real-world JJ N
performance NN 1_o
and CC N
generalizability NN N
remain VBP N
to TO N
be VB N
shown VBN N
. . N

-DOCSTART- -X- O O

Randomized NNP N
clinical JJ N
study NN N
comparing VBG N
Compeed NNP 1_i
cold VBD 1_i
sore RB 1_i
patch NN 1_i
to TO N
acyclovir VB 1_i
cream RB 1_i
5 CD 1_i
% NN 1_i
in IN N
the DT N
treatment NN N
of IN N
herpes NNS 1_p
simplex JJ 1_p
labialis NN 1_p
. . 1_p

BACKGROUND NNP N
Hydrocolloid NNP N
technology NN N
has VBZ N
been VBN N
proven RB N
effective JJ N
in IN N
treating VBG N
dermal JJ N
wounds NNS N
. . N

A DT N
previous JJ N
study NN N
showed VBD N
that IN N
a DT N
newly RB N
developed VBN N
thin JJ 1_i
hydrocolloid NN 1_i
patch NN 1_i
[ NNP 1_i
Compeed NNP 1_i
cold VBD 1_i
sore RB 1_i
patch NN 1_i
( ( 1_i
CSP NNP 1_i
) ) 1_i
] NN 1_i
provided VBD N
multiple JJ N
wound-healing JJ N
benefits NNS N
across IN N
all DT N
stages NNS N
of IN N
a DT N
herpes NNS 1_p
simplex JJ 1_p
labialis NN 1_p
( ( 1_p
HSL NNP 1_p
) ) 1_p
outbreak NN N
. . N

METHODS NNP N
An DT N
assessment NN N
of IN N
CSP NNP N
efficacy NN N
and CC N
safety NN N
was VBD N
conducted VBN N
in IN N
an DT N
international JJ 1_p
, , 1_p
multicentre JJ 1_p
, , N
assessor-blinded JJ N
study NN N
, , N
which WDT N
enrolled VBD 1_p
728 CD 1_p
subjects NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
recurrent NN 1_p
HSL NNP 1_p
. . 1_p

Of IN N
these DT N
, , N
351 CD 1_p
experienced VBD N
an DT N
HSL NNP N
outbreak NN N
and CC N
were VBD N
randomized VBN N
to TO N
use VB N
CSP NNP N
( ( N
n JJ N
= NNP N
179 CD N
) ) N
or CC N
acyclovir JJ 1_i
cream NN 1_i
5 CD 1_i
% NN 1_i
( ( N
n JJ N
= NNP N
172 CD N
) ) N
at IN N
the DT N
onset NN N
of IN N
symptoms NNS N
until IN N
the DT N
lesion NN N
healed VBD N
, , N
for IN N
a DT N
maximum NN N
of IN N
10 CD N
days NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
subject NN 1_o
's POS 1_o
global JJ 1_o
assessment NN 1_o
of IN 1_o
therapy NN 1_o
( ( 1_o
SGAT NNP 1_o
; : 1_o
0-10 JJ 1_o
scale NN 1_o
; : 1_o
0 CD 1_o
= IN 1_o
no DT 1_o
response NN 1_o
, , 1_o
10 CD 1_o
= JJ 1_o
excellent JJ 1_o
response NN 1_o
) ) 1_o
. . 1_o

Multiple NNP N
secondary JJ N
end NN N
points NNS N
included VBD N
clinician-assessed JJ 1_o
healing NN 1_o
time NN 1_o
and CC 1_o
subject JJ 1_o
assessment NN 1_o
of IN 1_o
lesion NN 1_o
protection NN 1_o
, , 1_o
noticeability NN 1_o
and CC 1_o
social JJ 1_o
embarrassment NN 1_o
. . 1_o

RESULTS NNP N
CSP NNP 1_i
and CC 1_i
acyclovir NNS 1_i
were VBD N
highly RB N
effective JJ N
( ( N
mean JJ N
SGAT NNP N
= NNP N
7.89 CD N
and CC N
8.00 CD N
, , N
respectively RB N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
observed VBD N
( ( N
P NNP N
= NNP N
0.65 CD N
) ) N
. . N

The DT N
difference NN N
in IN N
healing VBG 1_o
times NNS 1_o
between IN 1_o
products NNS 1_o
was VBD N
not RB N
significant JJ N
( ( N
median JJ N
, , N
7.57 CD N
days NNS N
with IN N
CSP NNP N
vs. FW N
7.03 CD N
days NNS N
with IN N
acyclovir NN N
, , N
P NNP N
= NNP N
0.37 CD N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN 1_o
. . 1_o

CONCLUSION NNP N
CSP NNP 1_i
using VBG 1_i
hydrocolloid JJ 1_i
technology NN 1_i
provides VBZ N
an DT N
efficacious JJ 1_o
and CC 1_o
safe JJ 1_o
alternative NN N
to TO N
topical JJ N
antivirals NNS N
in IN N
treating VBG N
HSL NNP N
as IN N
a DT N
wound NN N
while IN N
affording VBG N
additional JJ N
immediate JJ N
benefits NNS N
of IN N
wound NN N
protection NN N
, , N
discretion NN N
and CC N
relief NN N
of IN N
social JJ N
embarrassment NN N
. . N

-DOCSTART- -X- O O

Parent NN 1_p
and CC 1_p
family NN 1_p
outcomes NNS 1_p
of IN 1_p
PEERS NNS 1_i
: : 1_i
a DT 1_p
social JJ 1_i
skills NNS 1_i
intervention NN 1_i
for IN 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

Raising VBG N
a DT N
child NN 1_p
with IN 1_p
an DT 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
is VBZ N
associated VBN N
with IN N
increased VBN N
family NN 1_p
chaos NN N
and CC N
parent NN 1_p
distress NN N
. . N

Successful JJ N
long-term JJ N
treatment NN N
outcomes NNS N
are VBP N
dependent JJ N
on IN N
healthy JJ N
systemic JJ N
functioning NN N
, , N
but CC N
the DT N
family NN 1_o
impact NN 1_o
of IN 1_o
treatment NN 1_o
is VBZ N
rarely RB N
evaluated VBN N
. . N

The DT 1_i
Program NNP 1_i
for IN 1_i
the DT 1_i
Education NNP 1_i
and CC 1_i
Enrichment NNP 1_i
of IN 1_i
Relational NNP 1_i
Skills NNP 1_i
( ( 1_i
PEERS NNP 1_i
) ) 1_i
is VBZ N
a DT N
social JJ N
skills NNS N
intervention NN N
designed VBN N
for IN N
adolescents NNS 1_p
with IN 1_p
high-functioning JJ 1_p
ASD NNP 1_p
. . 1_p

This DT N
study NN N
assessed VBD N
the DT N
impact NN N
of IN N
PEERS NNS 1_o
on IN N
family NN 1_o
chaos NN 1_o
, , 1_o
parenting VBG 1_o
stress NN 1_o
, , 1_o
and CC 1_o
parenting VBG 1_o
self-efficacy NN 1_o
via IN N
a DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Results NNP N
suggested VBD N
beneficial JJ N
effects NNS N
for IN N
the DT N
experimental JJ N
group NN N
in IN N
the DT N
domain NN N
of IN N
family NN 1_o
chaos NN 1_o
compared VBN N
to TO N
the DT N
waitlist NN N
control NN N
, , N
while IN N
parents NNS 1_p
in IN 1_p
the DT 1_p
PEERS NNP 1_i
experimental JJ 1_p
group NN 1_p
also RB N
demonstrated VBD N
increased JJ N
parenting VBG 1_o
self-efficacy NN 1_o
. . 1_o

These DT N
findings NNS N
highlight VBD N
adjunctive JJ N
family NN N
system NN N
benefits NNS N
of IN N
PEERS NNP 1_i
intervention NN 1_i
and CC N
suggest VBP N
the DT N
need NN N
for IN N
overall JJ N
better JJR N
understanding NN N
of IN N
parent NN N
and CC N
family NN N
outcomes NNS N
of IN N
ASD NNP N
interventions NNS N
. . N

-DOCSTART- -X- O O

Amphotericin NNP 1_i
B NNP 1_i
in IN 1_p
children NNS 1_p
with IN 1_p
malignant JJ 1_p
disease NN 1_p
: : 1_p
a DT N
comparison NN N
of IN N
the DT N
toxicities NNS N
and CC N
pharmacokinetics NNS N
of IN N
amphotericin NN 1_i
B NNP 1_i
administered VBN 1_i
in IN 1_i
dextrose JJ 1_i
versus NN 1_i
lipid JJ 1_i
emulsion NN 1_i
. . 1_i

In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
toxicity NN N
of IN N
1 CD N
mg NN N
of IN N
amphotericin NN 1_i
B NNP 1_i
( ( 1_i
AmB NNP 1_i
) ) 1_i
per IN N
kg NN N
of IN N
body NN N
weight JJ N
per IN N
day NN N
infused VBN N
in IN N
5 CD N
% NN N
dextrose NN 1_i
was VBD N
compared VBN N
with IN N
that DT N
of IN N
AmB NNP 1_i
infused VBD 1_i
in IN 1_i
lipid JJ 1_i
emulsion NN 1_i
in IN N
children NNS 1_p
with IN 1_p
malignant JJ 1_p
disease NN 1_p
. . 1_p

In IN N
an DT N
analysis NN N
of IN N
82 CD 1_p
children NNS 1_p
who WP 1_p
received VBD 1_p
a DT 1_p
full JJ 1_p
course NN 1_p
of IN 1_p
6 CD 1_p
days NNS 1_p
or CC 1_p
more JJR 1_p
of IN 1_p
AmB NNP 1_i
( ( 1_p
117 CD 1_p
courses NNS 1_p
) ) 1_p
, , N
it PRP N
was VBD N
shown VBN N
that IN N
there EX N
were VBD N
significant JJ N
increases NNS N
in IN N
plasma JJ N
urea JJ N
and CC N
creatinine JJ N
concentrations NNS N
and CC N
in IN N
potassium NN N
requirement NN N
after IN N
6 CD N
days NNS N
of IN N
therapy NN N
with IN N
both DT N
AmB NNP 1_i
infused VBN N
in IN N
dextrose NN 1_i
and CC N
AmB NNP 1_i
infused VBD N
in IN N
lipid JJ 1_i
emulsion NN 1_i
, , N
with IN N
there EX N
being VBG N
no DT N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
of IN N
AmB NNP 1_i
administration NN N
. . N

An DT N
intent-to-treat JJ N
comparison NN N
of IN N
the DT N
numbers NNS N
of IN N
courses NNS N
affected VBN N
by IN N
acute JJ N
toxicity NN N
( ( N
fever NN N
, , N
rigors NNS N
) ) N
and CC N
chronic JJ N
toxicity NN N
( ( N
nephrotoxicity NN N
) ) N
also RB N
indicated VBD N
that IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
AmB NNP 1_i
infused VBD 1_i
in IN 1_i
dextrose NN 1_i
( ( N
78 CD N
courses NNS N
) ) N
and CC N
AmB NNP 1_i
infused VBD 1_i
in IN 1_i
lipid JJ 1_i
emulsion NN 1_i
( ( N
84 CD N
courses NNS N
) ) N
. . N

The DT N
pharmacokinetics NNS 1_o
of IN 1_o
AmB NNP 1_o
were VBD N
investigated VBN N
in IN N
20 CD N
children NNS N
who WP N
received VBD N
AmB NNP 1_i
in IN 1_i
dextrose NN 1_i
and CC N
15 CD N
children NNS N
who WP N
received VBD N
AmB NNP 1_i
in IN 1_i
lipid JJ 1_i
emulsion NN 1_i
. . 1_i

Blood NN N
samples NNS N
were VBD N
collected VBN N
up RB N
to TO N
24 CD N
h NN N
after IN N
administration NN N
of IN N
the DT N
first JJ N
dose NN N
, , N
and CC N
the DT N
concentration NN 1_o
of IN 1_o
AmB NNP 1_o
in IN 1_o
plasma NN 1_o
was VBD N
analyzed VBN N
by IN N
a DT N
high-performance NN N
liquid NN N
chromatography NN N
assay NN N
. . N

The DT N
clearance NN 1_o
( ( 1_o
CL NNP 1_o
) ) 1_o
of IN 1_o
AmB NNP 1_o
in IN 1_o
dextrose NN 1_o
( ( N
0.039 CD N
+/- JJ N
0.016 CD N
liter NN N
. . N

h-1 NN N
. . N

kg-1 NN N
) ) N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
than IN N
the DT N
CL NNP N
of IN N
AmB NNP 1_i
in IN 1_i
lipid JJ 1_i
emulsion NN 1_i
( ( N
0.062 CD N
+/- JJ N
0 CD N
. . N

024 CD N
liter NN N
. . N

h-1 NN N
. . N

kg-1 NN N
) ) N
. . N

The DT N
steady-state JJ 1_o
volume NN 1_o
of IN 1_o
distribution NN 1_o
for IN 1_o
AmB NNP 1_o
in IN N
dextrose NN N
( ( N
0.83 CD N
+/- JJ N
0.33 CD N
liter NN N
. . N

kg-1 NN N
) ) N
was VBD N
also RB N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
than IN N
that DT N
for IN N
AmB NNP 1_i
in IN 1_i
lipid JJ 1_i
emulsion NN 1_i
( ( N
1.47 CD N
+/- JJ N
0.77 CD N
liter NN N
. . N

kg-1 NN N
) ) N
. . N

Although IN N
AmB NNP 1_o
in IN 1_o
lipid JJ 1_o
emulsion NN 1_o
is VBZ N
apparently RB N
cleared VBN N
faster RBR N
and CC N
distributes VBZ N
more RBR N
widely RB N
than IN N
AmB NNP 1_o
in IN 1_o
dextrose NN 1_o
, , N
this DT N
study NN N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
advantage NN N
with IN N
respect NN N
to TO N
safety NN 1_o
and CC 1_o
tolerance NN 1_o
in IN N
the DT N
administration NN N
of IN N
AmB NNP 1_i
in IN 1_i
lipid JJ 1_i
emulsion NN 1_i
compared VBN N
to TO N
its PRP$ N
administration NN N
in IN N
dextrose NN 1_i
in IN N
children NNS 1_p
with IN 1_p
malignant JJ 1_p
disease NN 1_p
. . 1_p

-DOCSTART- -X- O O

Reduction NN 1_o
of IN 1_o
oral JJ 1_o
mucositis NN 1_o
by IN N
filgrastim NN 1_i
( ( 1_i
r-metHuG-CSF JJ 1_i
) ) 1_i
in IN N
patients NNS 1_p
receiving VBG 1_p
chemotherapy NN 1_i
. . 1_i

Mucositis NNP 1_o
, , N
the DT N
inflammation NN N
and CC N
necrosis NN N
of IN N
mucosal NN N
membranes NNS N
, , N
is VBZ N
a DT N
serious JJ N
and CC N
debilitating VBG N
consequence NN N
of IN N
many JJ N
cancer NN N
therapies NNS N
. . N

We PRP N
were VBD N
interested JJ N
in IN N
the DT N
potential JJ N
role NN N
of IN N
filgrastim NN 1_i
( ( 1_i
recombinant JJ 1_i
methionyl NN 1_i
human JJ 1_i
granulocyte NN 1_i
colony-stimulating NN 1_i
factor NN 1_i
, , 1_i
r-metHuG-CSF NN 1_i
) ) 1_i
in IN N
the DT N
reduction NN 1_o
of IN 1_o
mucositis NN 1_o
. . 1_o

Patients NNS 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
small-cell NN 1_p
lung NN 1_p
cancer NN 1_p
( ( 1_p
SCLC NNP 1_p
) ) 1_p
were VBD N
treated VBN N
with IN N
CAE NNP 1_i
chemotherapy NN 1_i
( ( 1_i
cyclophosphamide NN 1_i
, , 1_i
doxorubicin NN 1_i
, , 1_i
and CC 1_i
etoposide RB 1_i
) ) 1_i
and CC 1_i
placebo NN 1_i
or CC 1_i
filgrastim NN 1_i
. . 1_i

If IN N
patients NNS N
had VBD N
an DT N
episode NN N
of IN N
febrile JJ N
neutropenia NNS N
, , N
they PRP N
received VBD N
unblinded JJ N
filgrastim NN N
in IN N
subsequent JJ N
CAE NNP N
cycles NNS N
. . N

Oral NNP 1_o
mucositis NN 1_o
was VBD N
considered VBN N
to TO N
have VB N
occurred VBN N
if IN N
a DT N
patient NN N
reported VBD N
any DT N
clinical JJ N
sign NN N
or CC N
symptom NN 1_o
of IN 1_o
oral JJ 1_o
mucositis NN 1_o
with IN 1_o
or CC 1_o
without IN 1_o
oral JJ 1_o
candidiasis NN 1_o
. . 1_o

Oral NNP 1_o
mucositis NN 1_o
was VBD N
analyzed VBN N
using VBG N
the DT N
unadjusted JJ N
chi-square JJ N
test NN N
, , N
and CC N
time NN 1_o
to TO 1_o
first JJ 1_o
episode NN 1_o
of IN 1_o
mucositis NN 1_o
was VBD N
analyzed VBN N
using VBG N
the DT N
stratified JJ N
log-rank JJ N
test NN N
as RB N
well RB N
as IN N
the DT N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
model NN N
. . N

During IN N
cycle NN N
1 CD N
, , N
placebo-treated JJ N
patients NNS N
had VBD N
more RBR N
episodes NNS N
of IN N
mucositis NN 1_o
( ( N
47 CD N
% NN N
) ) N
compared VBN N
with IN N
those DT N
patients NNS N
randomized VBN N
to TO N
filgrastim VB N
( ( N
28 CD N
% NN N
) ) N
. . N

Across IN N
all DT N
cycles NNS N
of IN N
treatment NN N
, , N
70 CD N
% NN N
of IN N
placebo-treated JJ N
patients NNS N
experienced VBD N
mucositis NN 1_o
, , N
compared VBN N
with IN N
53 CD N
% NN N
of IN N
patients NNS N
randomized VBN N
to TO N
filgrastim VB N
. . N

A DT N
significant JJ N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
chemotherapy-related JJ N
oral JJ 1_o
mucositis NN 1_o
occurred VBD N
across IN N
multiple JJ N
cycles NNS N
of IN N
treatment NN N
in IN N
patients NNS N
treated VBN N
with IN N
filgrastim NN N
. . N

-DOCSTART- -X- O O

Visual JJ 1_i
feedback NN 1_i
and CC 1_i
target NN 1_i
size NN 1_i
effects NNS 1_i
on IN 1_i
reach-to-grasp JJ 1_i
tasks NNS 1_i
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

This DT N
study NN N
explores VBZ N
the DT N
effects NNS N
of IN N
visual JJ N
condition NN N
and CC N
target NN N
size NN N
during IN N
four CD N
reach-to-grasp JJ 1_o
tasks NNS 1_o
between IN N
autistic JJ 1_p
children NNS 1_p
and CC 1_p
healthy JJ 1_p
controls NNS 1_p
. . 1_p

Twenty NNP 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
20 CD 1_p
healthy JJ 1_p
controls NNS 1_p
participated VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Qualisys NNP 1_o
motion NN 1_o
capture NN 1_o
system NN 1_o
and CC 1_o
kinematic JJ 1_o
measures NNS 1_o
were VBD 1_i
used VBN 1_i
to TO 1_i
record VB 1_i
movement NN 1_i
. . 1_i

Autistic NNP 1_p
group NN N
showed VBD N
significantly RB N
longer RBR 1_o
movement NN 1_o
time NN 1_o
, , 1_o
larger JJR 1_o
normalized VBN 1_o
jerk NN 1_o
score NN 1_o
, , 1_o
more RBR 1_o
movement NN 1_o
unit NN N
than IN N
controls NNS N
, , N
especially RB N
in IN N
non-visual JJ N
feedback NN N
and CC N
small JJ N
target NN N
blocks NNS N
. . N

Autistic NNP 1_p
group NN N
also RB N
showed VBD N
significantly RB N
larger JJR 1_o
maximal JJ 1_o
grip NN 1_o
aperture NN 1_o
and CC N
normalized JJ 1_o
maximal JJ 1_o
grip NN 1_o
aperture NN 1_o
in IN N
visual JJ N
feedback NN N
condition NN N
than IN N
controls NNS N
. . N

Autistic JJ 1_p
children NNS 1_p
demonstrate VBP N
motor NN 1_o
coordination NN 1_o
problems NNS 1_o
and CC N
also RB N
depend VBP N
on IN N
more JJR N
visual JJ 1_o
cuing NN 1_o
in IN N
high JJ N
accuracy NN N
tasks NNS N
. . N

Autistic JJ 1_p
children NNS 1_p
develop VB N
other JJ N
compensatory NN 1_o
skills NNS 1_o
while IN N
performing VBG N
tasks NNS N
. . N

-DOCSTART- -X- O O

New NNP 1_i
mini-extracorporeal JJ 1_i
circulation NN 1_i
system NN 1_i
( ( 1_i
ECC.O NNP 1_i
) ) 1_i
is VBZ N
a DT N
safe JJ N
technique NN N
in IN N
coronary JJ N
surgery NN N
. . N

OBJECTIVES NNP N
Cardiopulmonary NNP 1_i
bypass NN 1_i
( ( 1_i
CPB NNP 1_i
) ) 1_i
is VBZ N
known VBN N
to TO N
cause VB N
the DT N
systemic JJ N
inflammatory NN N
reaction NN N
after IN N
cardiac JJ N
surgery NN N
. . N

New NNP N
coated VBD N
and CC N
closed VBD N
loop NN N
circuit NN N
systems NNS N
may MD N
reduce VB N
this DT N
inflammation NN 1_o
response NN 1_o
and CC 1_o
improve VB 1_o
the DT 1_o
surgical JJ 1_o
outcome NN 1_o
. . 1_o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
mini-extracorporeal JJ 1_i
circulation NN 1_i
system NN 1_i
( ( 1_i
ECC.O NNP 1_i
) ) 1_i
in IN N
CABG NNP 1_p
patients NNS 1_p
. . 1_p

DESIGN NNP N
Forty NNP 1_p
patients NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
coronary JJ 1_p
surgery NN 1_p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
ECC.O NNP 1_i
group NN 1_i
and CC 1_i
the DT 1_i
standard JJ 1_i
CPB NNP 1_i
group NN 1_i
. . 1_i

Routine NNP N
hemodynamic JJ N
monitoring NN N
and CC N
biochemical JJ N
measurements NNS N
were VBD N
registered VBN N
according VBG N
to TO N
the DT N
hospital NN N
practice NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
outcome NN N
of IN N
the DT N
patients NNS N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
duration NN 1_o
of IN 1_o
intubation NN 1_o
following VBG 1_o
surgery NN 1_o
, , 1_o
the DT 1_o
length NN 1_o
of IN 1_o
intensive JJ 1_o
care NN 1_o
unit-stay JJ 1_o
or CC 1_o
the DT 1_o
total JJ 1_o
hospital NN 1_o
stay NN 1_o
. . 1_o

The DT N
haemoglobin JJ 1_o
level NN 1_o
was VBD N
significantly RB N
higher JJR N
( ( N
p=0.0069 NN N
) ) N
during IN N
and CC N
after IN N
the DT N
perfusion NN N
in IN N
the DT N
ECC.O NNP 1_i
group NN N
. . N

CONCLUSIONS VB N
The DT N
ECC.O NNP 1_i
system NN N
can MD N
be VB N
safely RB N
used VBN N
in IN N
CABG NNP 1_p
patients NNS 1_p
and CC N
it PRP N
maintains VBZ N
haemoglobin JJ N
level NN N
better RBR N
than IN N
conventional JJ N
CPB NNP 1_i
. . 1_i

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
Hanen NNP 1_i
's POS 1_i
'More JJR 1_i
Than NNP 1_i
Words NNP 1_i
' POS 1_i
in IN N
toddlers NNS 1_p
with IN 1_p
early JJ 1_p
autism NN 1_p
symptoms NNS 1_p
. . 1_p

BACKGROUND NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
compared VBN N
Hanen NNP 1_i
's POS 1_i
'More JJR 1_i
than IN 1_i
Words NNS 1_i
' POS 1_i
( ( 1_i
HMTW NNP 1_i
) ) 1_i
, , 1_i
a DT 1_i
parent-implemented JJ 1_i
intervention NN 1_i
, , N
to TO N
a DT N
'business NN 1_i
as IN 1_i
usual JJ 1_i
' POS 1_i
control NN 1_i
group NN N
. . N

METHODS NNP N
Sixty-two JJ 1_p
children NNS 1_p
( ( 1_p
51 CD 1_p
boys NNS 1_p
and CC 1_p
11 CD 1_p
girls NNS 1_p
; : 1_p
M NNP 1_p
age NN 1_p
= VBD 1_p
20 CD 1_p
months NNS 1_p
; : 1_p
SD NNP 1_p
= NNP 1_p
2.6 CD 1_p
) ) 1_p
who WP 1_p
met VBD 1_p
criteria NNS 1_p
for IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
and CC 1_p
their PRP$ 1_p
parents NNS 1_p
participated VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
HMTW NNP 1_i
intervention NN 1_i
was VBD N
provided VBN N
over IN N
3.5 CD N
months NNS N
. . N

There EX N
were VBD N
three CD N
measurement NN N
periods NNS N
: : N
prior RB 1_i
to TO 1_i
randomization NN 1_i
( ( 1_i
Time NNP 1_i
1 CD 1_i
) ) 1_i
and CC 1_i
at IN 1_i
5 CD 1_i
and CC 1_i
9 CD 1_i
months NNS 1_i
post VBN 1_i
enrollment NN 1_i
( ( 1_i
Times NNP 1_i
2 CD 1_i
and CC 1_i
3 CD 1_i
) ) 1_i
. . 1_i

Children NNP 1_o
's POS 1_o
communication NN 1_o
and CC 1_o
parental JJ 1_o
responsivity NN 1_o
were VBD 1_i
measured VBN 1_i
at IN 1_i
each DT 1_i
time NN 1_i
point NN 1_i
. . 1_i

Children NNP 1_o
's POS 1_o
object JJ 1_o
interest NN 1_o
, , 1_o
a DT 1_o
putative JJ 1_o
moderator NN 1_o
, , 1_i
was VBD 1_i
measured VBN 1_i
at IN 1_i
Time NNP 1_i
1 CD 1_i
. . 1_i

RESULTS VB N
There EX N
were VBD N
no DT N
main JJ N
effects NNS N
of IN N
the DT N
HMTW NNP 1_i
intervention NN N
on IN N
either DT N
parental JJ 1_o
responsivity NN 1_o
or CC N
children NNS 1_o
's POS 1_o
communication NN 1_o
. . 1_o

However RB N
, , N
the DT N
effects NNS N
on IN N
residualized JJ N
gains NNS N
in IN N
parental JJ 1_o
responsivity NN 1_o
from IN N
Time NNP N
1 CD N
to TO N
both DT N
Times NNP N
2 CD N
and CC N
3 CD N
yielded VBN N
noteworthy JJ N
effect NN N
sizes NNS N
( ( N
Glass NNP N
's POS N
? . N
= JJ N
.71 NN N
, , N
.50 NNP N
respectively RB N
) ) N
. . N

In IN N
contrast NN N
, , N
there EX N
were VBD N
treatment NN N
effects NNS N
on IN 1_o
child JJ 1_o
communication NN 1_o
gains NNS N
to TO N
Time VB N
3 CD N
that WDT N
were VBD N
moderated VBN N
by IN N
children NNS N
's POS N
Time NNP N
1 CD N
object JJ N
interest NN N
. . N

Children NNP N
with IN N
lower JJR N
levels NNS N
of IN N
Time NNP N
1 CD N
object JJ 1_o
interest NN 1_o
exhibited VBN N
facilitated JJ N
growth NN N
in IN 1_o
communication NN 1_o
; : 1_o
children NNS N
with IN N
higher JJR N
levels NNS N
of IN 1_o
object JJ 1_o
interest NN 1_o
exhibited VBD 1_o
growth NN 1_o
attenuation NN 1_o
. . 1_o

CONCLUSIONS VB N
The DT 1_i
HMTW NNP 1_i
intervention NN N
showed VBD N
differential JJ N
effects NNS N
on IN 1_o
child NN 1_o
communication NN 1_o
depending VBG N
on IN N
a DT N
baseline NN N
child NN N
factor NN N
. . N

HMTW NNP 1_i
facilitated VBD 1_o
communication NN 1_o
in IN N
children NNS N
with IN N
lower JJR N
levels NNS N
of IN N
Time NNP N
1 CD N
object JJ N
interest NN N
. . N

Parents NNS 1_p
of IN 1_p
children NNS 1_p
who WP 1_p
evidence NN 1_p
higher JJR 1_o
object JJ 1_o
interest NN 1_o
may MD N
require VB N
greater JJR N
support NN N
to TO N
implement VB N
the DT 1_i
HMTW NNP 1_i
strategies NNS N
, , N
or CC N
may MD N
require VB N
different JJ N
strategies NNS N
than IN N
those DT N
provided VBN N
by IN N
the DT 1_i
HMTW NNP 1_i
curriculum NN N
. . N

-DOCSTART- -X- O O

Study NNP N
of IN N
cytosine NN 1_i
arabinoside NN 1_i
( ( 1_i
NSC-63878 NNP 1_i
) ) 1_i
synchronization NN 1_i
plus CC 1_i
vincristine NN 1_i
( ( 1_i
NSC-67574 NNP 1_i
) ) 1_i
, , 1_i
prednisone NN 1_i
( ( 1_i
NSC-10023 NNP 1_i
) ) 1_i
, , 1_i
and CC 1_i
L-asparaginase NNP 1_i
( ( 1_i
NSC-109229 NNP 1_i
) ) 1_i
for IN N
remission NN N
induction NN N
in IN N
advanced JJ 1_p
acute NN 1_p
leukemia NN 1_p
in IN 1_p
children NNS 1_p
. . 1_p

Cytosine NNP 1_i
arabinoside NN 1_i
( ( 1_i
CA NNP 1_i
) ) 1_i
was VBD N
utilized VBN N
in IN N
efforts NNS N
to TO N
synchronize VB N
leukemic JJ N
cells NNS N
in IN N
DNA NNP N
synthesis NN N
for IN N
treatment NN N
with IN N
vincristine NN 1_i
, , 1_i
prednisone NN 1_i
, , 1_i
and CC 1_i
L-asparaginase NNP 1_i
in IN N
children NNS 1_p
with IN 1_p
acute JJ 1_p
leukemia NN 1_p
in IN 1_p
relapse NN 1_p
. . 1_p

The DT N
results NNS N
did VBD N
not RB N
indicate VB N
any DT N
therapeutic JJ 1_o
advantage NN 1_o
for IN N
patients NNS N
treated VBN N
with IN N
this DT N
combination NN N
compared VBN N
to TO N
those DT N
treated VBN N
without IN N
any DT N
attempt NN N
at IN N
CA NNP 1_i
synchronization NN 1_i
. . 1_i

-DOCSTART- -X- O O

Vitamin NNP 1_i
D NNP 1_i
supplementation NN 1_i
ameliorates VBZ N
hypoinsulinemia NN 1_o
and CC 1_o
hyperglycemia NN 1_o
in IN N
static JJ 1_p
magnetic JJ 1_p
field-exposed JJ 1_p
rat NN 1_p
. . 1_p

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
vitamin NN 1_i
D NNP 1_i
supplementation NN 1_i
on IN N
glucose NN 1_o
and CC 1_o
lipid JJ 1_o
metabolism NN 1_o
in IN N
static JJ 1_p
magnetic JJ 1_p
field NN 1_p
( ( 1_p
SMF NNP 1_p
) ) 1_p
-exposed VBD 1_p
rats NNS 1_p
. . 1_p

Rats NNS 1_p
exposed VBD N
to TO N
SMF NNP N
( ( N
128 CD N
mT NN N
; : N
1 CD N
h/day NN N
) ) N
during IN N
5 CD N
consecutive JJ N
days NNS N
showed VBD N
an DT N
increase NN N
in IN N
plasma JJ 1_o
glucose JJ 1_o
level NN 1_o
and CC 1_o
a DT 1_o
decrease NN 1_o
in IN 1_o
plasma JJ 1_o
insulin NN 1_o
concentration NN 1_o
. . 1_o

By IN N
contrast NN N
, , N
the DT N
same JJ N
treatment NN N
failed VBD N
to TO N
alter VB N
body NN 1_o
weight NN 1_o
and CC 1_o
plasmatic JJ 1_o
total NN 1_o
cholesterol NN 1_o
, , 1_o
high-density NN 1_o
lipoprotein NN 1_o
( ( 1_o
HDL NNP 1_o
) ) 1_o
-cholesterol NN 1_o
, , 1_o
low-density NN 1_o
lipoprotein NN 1_o
( ( 1_o
LDL NNP 1_o
) ) 1_o
-cholesterol NN 1_o
, , 1_o
and CC 1_o
triglyceride NN 1_o
levels NNS 1_o
. . 1_o

Interestingly RB N
, , N
supplementation NN N
with IN N
vitamin NN 1_i
D NNP 1_i
( ( N
1,600 CD N
IU/100 NNP N
g NN N
, , N
per IN N
os NN N
) ) N
corrected VBD N
and CC N
restored VBD N
glycemia NN 1_o
and CC 1_o
insulinemia NN 1_o
in IN N
SMF-exposed JJ 1_p
rats NNS 1_p
. . 1_p

The DT N
same JJ N
treatment NN N
had VBD N
no DT N
effects NNS N
on IN N
lipid JJ 1_o
metabolism NN 1_o
. . 1_o

-DOCSTART- -X- O O

Safety NN 1_o
, , 1_o
pharmacokinetics NNS 1_o
and CC 1_o
pharmocodynamics NNS 1_o
of IN N
recombinant JJ 1_i
human JJ 1_i
porphobilinogen NN 1_i
deaminase NN 1_i
in IN N
healthy JJ 1_p
subjects NNS 1_p
and CC 1_p
asymptomatic JJ 1_p
carriers NNS 1_p
of IN 1_p
the DT 1_p
acute JJ 1_p
intermittent NN 1_p
porphyria NNS 1_p
gene NN 1_p
who WP 1_p
have VBP 1_p
increased VBN 1_p
porphyrin NN 1_p
precursor NN 1_p
excretion NN 1_p
. . 1_p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Acute NNP N
intermittent NN N
porphyria NN N
is VBZ N
an DT N
autosomal JJ N
dominant JJ N
disorder NN N
caused VBN N
by IN N
deficient JJ N
activity NN N
of IN N
the DT N
third JJ N
enzyme NN N
in IN N
the DT N
haem NN N
biosynthetic JJ N
pathway NN N
, , N
porphobilinogen NN N
deaminase NN N
. . N

It PRP N
is VBZ N
characterised VBN N
by IN N
acute NN N
, , N
potentially RB N
life-threatening JJ N
neurological JJ N
attacks NNS N
that WDT N
are VBP N
precipitated VBN N
by IN N
various JJ N
drugs NNS N
, , N
reproductive JJ N
hormones NNS N
and CC N
other JJ N
factors NNS N
. . N

During IN N
acute JJ N
attacks NNS N
, , N
the DT N
porphyrin JJ N
precursors NNS N
5-aminolevulinic JJ N
acid NN N
and CC N
porphobilinogen NN N
accumulate NN N
and CC N
are VBP N
excreted VBN N
at IN N
high JJ N
concentrations NNS N
in IN N
the DT N
urine NN N
. . N

Current JJ N
treatment NN N
is VBZ N
based VBN N
on IN N
glucose JJ N
loading NN N
and CC N
parenteral JJ N
haem NN N
replenishment NN N
, , N
which WDT N
reduce VB N
the DT N
accumulation NN N
of IN N
5-aminolevulinic JJ 1_o
acid NN 1_o
and CC 1_o
porphobilinogen NN 1_o
. . 1_o

Recently RB N
, , N
a DT N
new JJ N
form NN N
of IN N
treatment NN N
based VBN N
on IN N
porphobilinogen NN 1_i
deaminase NN 1_i
enzyme JJ 1_i
replacement NN 1_i
therapy NN 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
an DT N
acute JJ N
intermittent NN N
porphyria NN N
mouse NN N
model NN N
which WDT N
, , N
during IN N
phenobarbital JJ N
( ( N
phenobarbitone NN N
) ) N
induction NN N
of IN N
haem JJ N
biosynthesis NN N
, , N
mimics VBZ N
the DT N
biochemical JJ N
pattern NN N
of IN N
acute JJ N
porphyric JJ N
attacks NNS N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
recombinant JJ 1_i
human JJ 1_i
porphobilinogen NN 1_i
deaminase NN 1_i
( ( 1_i
P NNP 1_i
9808 CD 1_i
) ) 1_i
, , N
administered VBN N
to TO N
healthy JJ 1_p
subjects NNS 1_p
and CC 1_p
asymptomatic JJ 1_p
porphobilinogen NN 1_p
deaminase-deficient JJ 1_p
subjects NNS 1_p
with IN 1_p
high JJ 1_p
concentrations NNS 1_p
of IN 1_p
porphobilinogen NN 1_p
, , 1_p
the DT 1_p
substrate NN 1_p
of IN 1_p
porphobilinogen NN 1_p
deaminase NN 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
Forty NNP 1_p
individuals NNS 1_p
participated VBD 1_p
in IN 1_p
this DT 1_p
two-part JJ 1_p
study NN 1_p
: : 1_p
20 CD 1_p
asymptomatic JJ 1_p
porphobilinogen NN 1_p
deaminase-deficient JJ 1_p
subjects NNS 1_p
( ( 1_p
both DT 1_p
male NN 1_p
and CC 1_p
female NN 1_p
) ) 1_p
with IN 1_p
> NN 1_p
or CC 1_p
=4 JJ 1_p
times NNS 1_p
the DT 1_p
upper JJ 1_p
reference NN 1_p
urinary JJ 1_p
porphobilinogen NN 1_p
level NN 1_p
, , 1_p
and CC 1_p
20 CD 1_p
healthy JJ 1_p
male JJ 1_p
subjects NNS 1_p
. . 1_p

Four CD N
different JJ N
doses NNS N
of IN N
recombinant JJ 1_i
human JJ 1_i
porphobilinogen NN 1_i
deaminase NN 1_i
were VBD N
studied VBN N
( ( N
0.5 CD N
, , N
1 CD N
, , N
2 CD N
and CC N
4 CD N
mg/kg NNS N
bodyweight VBN N
) ) N
. . N

Part VB 1_p
A NNP 1_p
included VBD 1_p
12 CD 1_p
asymptomatic JJ 1_p
porphobilinogen NN 1_p
deaminase-deficient JJ 1_p
subjects NNS 1_p
, , 1_p
and CC 1_p
the DT 1_p
enzyme NN 1_p
was VBD 1_p
administered VBN 1_p
in IN 1_p
an DT 1_p
open-label JJ 1_p
, , 1_p
single-dose JJ 1_p
design NN 1_p
. . 1_p

Part NN 1_p
B NNP 1_p
included VBD 1_p
20 CD 1_p
asymptomatic JJ 1_p
porphobilinogen NN 1_p
deaminase-deficient JJ 1_p
subjects NNS 1_p
and CC 1_p
20 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

The DT N
same JJ N
enzyme NN N
dosages NNS N
were VBD N
administered VBN N
as IN N
divided JJ N
doses NNS N
every DT N
12 CD N
hours NNS N
for IN N
4 CD N
consecutive JJ N
days NNS N
in IN N
a DT N
randomised JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
design NN N
. . N

The DT N
washout NN N
period NN N
between IN N
Parts NNS N
A NNP N
and CC N
B NNP N
was VBD N
2 CD N
weeks NNS N
. . N

METHODS NNP N
The DT N
concentrations NNS 1_o
of IN 1_o
recombinant JJ 1_o
human JJ 1_o
porphobilinogen NN 1_o
deaminase NN 1_o
and CC 1_o
titres NNS 1_o
of IN 1_o
antibodies NNS 1_o
against IN 1_o
recombinant JJ 1_o
human JJ 1_o
porphobilinogen NN 1_o
deaminase NN 1_o
were VBD N
analysed VBN N
by IN N
ELISA NNP N
. . N

Plasma NNP 1_o
porphobilinogen NN 1_o
and CC 1_o
5-aminolevulinic JJ 1_o
acid NN 1_o
concentrations NNS 1_o
were VBD N
analysed VBN N
using VBG N
a DT N
novel JJ N
liquid JJ N
chromatography-tandem JJ N
mass NN N
spectrometry NN N
method NN N
. . N

Urinary JJ 1_o
porphobilinogen NN 1_o
, , 1_o
5-aminolevulinic JJ 1_o
acid NN 1_o
and CC 1_o
porphyrin NN 1_o
concentrations NNS 1_o
, , N
as RB N
well RB N
as IN N
plasma NN 1_o
porphyrin NN 1_o
concentrations NNS 1_o
, , N
were VBD N
analysed VBN N
using VBG N
standard JJ N
methods NNS N
. . N

The DT N
pharmacodynamic JJ N
effect NN N
of IN N
the DT N
enzyme NN N
was VBD N
studied VBN N
through IN N
changes NNS N
in IN N
plasma NN N
porphobilinogen NN N
concentrations NNS N
. . N

RESULTS NNP N
No NNP N
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
observed VBN N
. . N

Seven JJ N
subjects NNS N
( ( N
four CD N
healthy JJ N
men NNS N
and CC N
three CD N
asymptomatic JJ N
porphobilinogen NN N
deaminase-deficient JJ N
subjects NNS N
) ) N
developed VBD N
antibodies NNS 1_o
against IN 1_o
recombinant JJ 1_o
human JJ 1_o
porphobilinogen NN 1_o
deaminase NN 1_o
but CC N
did VBD N
not RB N
experience VB N
allergic JJ 1_o
manifestations NNS 1_o
. . 1_o

The DT N
mean JJ 1_o
elimination NN 1_o
half-lives NNS 1_o
of IN 1_o
the DT 1_o
highest JJS 1_o
doses NNS 1_o
of IN 1_o
recombinant JJ 1_o
human JJ 1_o
porphobilinogen NN 1_o
deaminase NN 1_o
ranged VBD N
between IN N
1.7 CD N
and CC N
2.5 CD N
hours NNS N
for IN N
both DT N
healthy JJ N
men NNS N
and CC N
asymptomatic JJ N
porphobilinogen NN N
deaminase-deficient JJ N
subjects NNS N
. . N

The DT N
area NN 1_o
under IN 1_o
the DT 1_o
plasma JJ 1_o
concentration-time JJ 1_o
curve NN 1_o
was VBD N
proportional JJ N
to TO N
the DT N
respective JJ N
dose NN N
. . N

In IN N
asymptomatic JJ N
porphobilinogen NN N
deaminase-deficient JJ N
subjects NNS N
, , N
plasma NN 1_o
porphobilinogen NN 1_o
concentrations NNS 1_o
decreased VBD N
below IN N
measurable JJ N
levels NNS N
almost RB N
instantaneously RB N
after IN N
administration NN N
of IN N
any DT N
dose NN N
of IN N
the DT N
enzyme NN N
. . N

The DT N
effect NN N
lasted VBD N
for IN N
approximately RB N
2 CD N
hours NNS N
, , N
after IN N
which WDT N
the DT N
plasma NN 1_o
porphobilinogen NN 1_o
concentration NN 1_o
slowly RB N
increased VBD N
, , N
reaching VBG N
about IN N
70 CD N
% NN N
of IN N
the DT N
initial JJ N
values NNS N
12 CD N
hours NNS N
after IN N
administration NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
on IN N
plasma NN 1_o
5-aminolevulinic JJ 1_o
acid NN 1_o
concentrations NNS 1_o
, , N
and CC N
there RB N
was VBD N
a DT N
transitory JJ N
increment NN N
in IN N
porphyrin JJ 1_o
concentrations NNS 1_o
. . 1_o

The DT N
corresponding JJ 1_o
concentrations NNS 1_o
of IN 1_o
metabolites NNS 1_o
in IN 1_o
the DT 1_o
urine NN 1_o
reflected VBD N
the DT N
pattern NN N
observed VBN N
in IN N
the DT N
plasma NN N
. . N

CONCLUSIONS VB N
The DT N
recombinant JJ 1_i
human JJ 1_i
porphobilinogen NN 1_i
deaminase NN 1_i
enzyme JJ 1_i
preparation NN 1_i
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
to TO N
administer VB N
and CC N
effective JJ N
for IN N
removal NN N
of IN N
the DT N
accumulated JJ N
metabolite NN N
porphobilinogen NN N
from IN N
plasma NN N
and CC N
urine NN N
. . N

The DT N
pharmacokinetic JJ N
profile NN N
of IN N
recombinant JJ 1_i
human JJ 1_i
porphobilinogen NN 1_i
deaminase NN 1_i
showed VBD N
dose JJ N
proportionality NN N
, , N
and CC N
the DT N
elimination NN N
half-life NN N
was VBD N
about IN N
2.0 CD N
hours NNS N
for IN N
the DT N
two CD N
highest JJS N
doses NNS N
. . N

Thus RB N
, , N
clinical JJ N
grounds NNS N
were VBD N
established VBN N
for IN N
investigation NN N
of IN N
the DT N
therapeutic JJ 1_o
efficacy NN 1_o
of IN N
the DT N
enzyme NN N
during IN N
periods NNS N
of IN N
overt JJ N
disease NN N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
intermittent NN 1_p
porphyria NN 1_p
. . 1_p

-DOCSTART- -X- O O

Breast NNP 1_p
cancer NN 1_p
screening VBG 1_i
in IN N
Sweden NNP 1_p
. . 1_p

The DT N
single JJ N
modality NN N
approach NN N
. . N

Four CD 1_p
population-based JJ 1_p
breast NN 1_p
cancer NN 1_p
screening VBG 1_p
projects NNS 1_p
are VBP 1_p
in IN 1_p
progress NN 1_p
in IN 1_p
Sweden NNP 1_p
, , N
three CD N
of IN N
which WDT N
are VBP N
randomized VBN N
studies NNS N
. . N

Mammography NNP 1_i
is VBZ N
the DT N
only JJ N
screening NN N
method NN N
. . N

51 CD N
% NN N
of IN N
all DT N
carcinomas NN N
detected VBN N
at IN N
the DT N
first JJ N
screening NN N
were VBD N
either RB N
in IN N
situ NN N
or CC N
invasive JJ N
with IN N
a DT N
diameter NN N
of IN N
10 CD N
mm NN N
or CC N
less JJR N
. . N

Axillary JJ 1_o
metastases NNS 1_o
were VBD N
found VBN N
in IN N
16 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

Sensitivity NNP 1_o
was VBD N
over RB N
90 CD N
% NN N
in IN N
all DT N
projects NNS N
. . N

The DT 1_o
ultimate JJ 1_o
aim NN 1_o
of IN 1_o
the DT 1_o
randomized JJ 1_o
projects NNS 1_o
is VBZ 1_o
to TO 1_o
demonstrate VB 1_o
the DT 1_o
effect NN 1_o
of IN 1_o
screening VBG 1_o
on IN 1_o
breast NN 1_o
cancer NN 1_o
mortality NN 1_o
. . 1_o

It PRP N
is VBZ N
estimated VBN N
that IN N
mortality NN 1_o
statistics NNS 1_o
will MD N
reach VB N
significant JJ N
levels NNS N
in IN N
1983. CD N
, , N
-DOCSTART- -X- O O

[ JJ 1_i
Cred? NNP 1_i
's POS 1_i
prevention NN 1_i
method NN 1_i
has VBZ N
lost VBN N
its PRP$ 1_o
justification NN 1_o
today NN N
] NNP N
. . N

-DOCSTART- -X- O O

Using VBG N
a DT N
laryngeal JJ 1_i
tube NN 1_i
suction-device NN 1_i
( ( 1_i
LTS-D NNP 1_i
) ) 1_i
reduces VBZ N
the DT N
no DT 1_o
flow JJ 1_o
time NN 1_o
in IN N
a DT N
single JJ N
rescuer NN N
manikin NN N
study NN N
. . N

BACKGROUND NNP N
In IN N
2005 CD N
, , N
the DT N
European JJ N
Resuscitation NNP N
Council NNP N
and CC N
the DT N
American NNP N
Heart NNP N
Association NNP N
published VBD N
new JJ N
guidelines NNS N
for IN N
Advanced NNP N
Life NNP N
Support NNP N
. . N

One CD N
of IN N
the DT N
points NNS N
was VBD N
to TO N
reduce VB N
the DT N
time NN 1_o
without IN 1_o
chest JJS 1_o
compressions NNS 1_o
in IN N
the DT N
first JJ N
phase NN N
of IN N
cardiac JJ N
arrest NN N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
in IN N
a DT N
manikin JJ N
model NN N
whether IN N
using VBG N
the DT N
single-use JJ 1_i
laryngeal NN 1_i
tube NN 1_i
with IN 1_i
suction NN 1_i
option NN 1_i
( ( 1_i
LTS-D NNP 1_i
) ) 1_i
instead RB 1_i
of IN N
endotracheal JJ 1_i
intubation NN 1_i
( ( 1_i
ET NNP 1_i
) ) 1_i
and CC 1_i
bag-mask-valve JJ 1_i
ventilation NN 1_i
( ( 1_i
BMV NNP 1_i
) ) 1_i
for IN 1_i
emergency NN 1_i
airway NN 1_i
management NN 1_i
could MD 1_i
reduce VB N
the DT N
no-flow JJ 1_o
time NN 1_o
( ( 1_o
NFT NNP 1_o
) ) 1_o
. . N

The DT N
NFT NNP N
is VBZ N
defined VBN N
as IN N
the DT N
time NN N
during IN N
resuscitation NN N
when WRB N
no DT N
chest NN N
compressions NNS N
take VBP N
place NN N
. . N

METHODS CC N
A DT N
randomized JJ 1_p
, , 1_p
prospective JJ 1_p
study NN 1_p
was VBD 1_p
undertaken VBN 1_p
with IN 1_p
150 CD 1_p
volunteers NNS 1_p
who WP 1_p
performed VBD 1_p
management NN 1_p
of IN 1_p
a DT 1_p
standardized JJ 1_p
simulated JJ 1_p
cardiac NN 1_p
arrest NN 1_p
in IN 1_p
a DT 1_p
manikin NN 1_p
. . 1_p

Every DT N
participant NN N
was VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
different JJ N
airway RB N
management NN N
groups NNS N
( ( N
LTS-D JJ N
vs NN N
. . N

ET NNP N
vs. IN N
BMV NNP N
) ) N
. . N

RESULTS VB N
The DT N
LTS-D NNP 1_i
was VBD N
inserted VBN N
significantly RB N
faster RBR N
than IN N
the DT N
ET NNP N
tube NN N
( ( N
15 CD N
s NN N
vs. FW N
44 CD N
s NN N
, , N
respectively RB N
, , N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

During IN N
the DT N
cardiac JJ N
arrest NN N
simulation NN N
, , N
establishing VBG 1_o
and CC 1_o
performing VBG 1_o
ventilation NN 1_o
took VBD N
an DT N
average NN N
of IN N
57 CD N
s NN N
with IN N
the DT N
LTS-D NNP 1_i
compared VBN N
to TO N
116 CD N
s NN N
with IN N
ET NNP 1_i
and CC N
111 CD N
s NN N
with IN N
the DT N
BMV NNP 1_i
. . 1_i

Using VBG N
the DT N
LTS-D NNP 1_i
significantly RB N
reduced VBD N
NFT NNP 1_o
compared VBN N
to TO N
ET NNP 1_i
and CC N
the DT N
BMV NNP 1_i
( ( N
125 CD N
s NN N
vs. FW N
207 CD N
s NN N
vs. FW N
160 CD N
s NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

CONCLUSIONS NN N
In IN N
our PRP$ N
manikin NN N
study NN N
, , N
NFT NNP 1_o
was VBD N
reduced VBN N
significantly RB N
when WRB N
the DT N
LTS-D NNP 1_i
was VBD N
used VBN N
when WRB N
compared VBN N
to TO N
ET NNP 1_i
and CC 1_i
BMV NNP 1_i
. . 1_i

The DT N
results NNS N
of IN N
our PRP$ N
manikin NN N
study NN N
suggest VBP N
that IN N
for IN N
personnel NNS N
not RB N
experienced VBN N
in IN N
tracheal JJ N
intubation NN N
, , N
the DT N
LTS-D NNP 1_i
offers VBZ N
a DT N
good JJ N
alternative NN N
to TO N
ET NNP 1_i
and CC N
BMV NNP 1_i
to TO N
manage VB N
the DT N
airway NN N
during IN N
resuscitation NN N
, , N
and CC N
to TO N
avoid VB N
the DT N
failure NN N
to TO N
achieve VB N
tracheal JJ N
intubation NN N
with IN N
the DT N
ET NNP 1_i
, , N
and CC N
the DT N
failure NN N
to TO N
achieve VB N
adequate JJ N
ventilation NN N
with IN N
the DT N
BMV NNP 1_i
. . 1_i

-DOCSTART- -X- O O

[ JJ 1_i
Radiotherapy NNP 1_i
and/or NN 1_i
chemotherapy NN 1_i
in IN N
children NNS 1_p
with IN 1_p
primitive JJ 1_p
neuroectodermal JJ 1_p
tumor NN 1_p
( ( 1_p
PNET NNP 1_p
) ) 1_p
of IN 1_p
the DT 1_p
pineal JJ 1_p
region NN 1_p
] NN 1_p
. . N

-DOCSTART- -X- O O

Mindfulness-based JJ 1_i
therapy NN 1_i
in IN N
adults NNS 1_p
with IN 1_p
an DT 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Research NN N
shows VBZ N
that IN N
depression NN N
and CC N
anxiety NN N
disorders NNS N
are VBP N
the DT N
most RBS N
common JJ N
psychiatric JJ N
concern NN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

Mindfulness-based JJ 1_i
therapy NN 1_i
( ( 1_i
MBT NNP 1_i
) ) 1_i
has VBZ N
been VBN N
found VBN N
effective JJ N
in IN N
reducing VBG N
anxiety NN 1_o
and CC 1_o
depression NN 1_o
symptoms NNS 1_o
, , N
however RB N
research NN N
in IN N
autism NN N
is VBZ N
limited VBN N
. . N

Therefore RB N
, , N
we PRP N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
modified JJ 1_i
MBT NNP 1_i
protocol NN 1_i
( ( 1_i
MBT-AS NNP 1_i
) ) 1_i
in IN N
high-functioning NN 1_p
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

42 CD 1_p
participants NNS 1_p
were VBD N
randomized VBN N
into IN N
a DT N
9-week JJ N
MBT-AS JJ 1_i
training NN 1_i
or CC N
a DT N
wait-list JJ 1_i
control NN 1_i
group NN 1_i
. . 1_i

Results NNP N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
depression NN 1_o
, , 1_o
anxiety NN 1_o
and CC 1_o
rumination NN 1_o
in IN N
the DT N
intervention NN N
group NN N
, , N
as IN N
opposed VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Furthermore RB N
, , N
positive JJ 1_o
affect NN 1_o
increased VBN N
in IN N
the DT N
intervention NN N
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

Concluding NNP N
, , N
the DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
controlled VBN N
trial NN N
to TO N
demonstrate VB N
that IN N
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
can MD N
benefit VB N
from IN N
MBT-AS NNP 1_i
. . 1_i

-DOCSTART- -X- O O

[ IN N
The DT N
somatostatin NN 1_i
infusion NN 1_i
test NN 1_i
for IN N
the DT N
evaluation NN N
of IN N
glucose JJ 1_o
utilization NN 1_o
in IN N
bezafibrate JJ 1_i
medication NN 1_i
] NN 1_i
. . N

The DT N
utilisation NN N
of IN N
blood NN 1_o
glucose NN 1_o
may MD N
be VB N
used VBN N
for IN N
definition NN N
of IN N
insulin NN N
resistance NN N
in IN N
type NN 1_p
II NNP 1_p
diabetes VBZ 1_p
mellitus NN 1_p
. . 1_p

To TO N
evaluate VB N
this DT N
possibility NN N
we PRP N
adapted VBD N
an DT N
infusion NN 1_i
test NN 1_i
of IN 1_i
somatostatin NN 1_i
in IN 1_p
10 CD 1_p
normal JJ 1_p
persons NNS 1_p
( ( 1_p
age NN 1_p
26 CD 1_p
+/- JJ 1_p
3 CD 1_p
years NNS 1_p
, , 1_p
relative JJ 1_p
body NN 1_p
weight VBD 1_p
26 CD 1_p
+/- JJ 1_p
10 CD 1_p
% NN 1_p
according VBG 1_p
to TO 1_p
Broca NNP 1_p
) ) 1_p
in IN N
a DT N
randomized JJ N
cross-over NN N
therapy NN N
with IN N
bezafibrate NN 1_i
( ( N
3 CD N
X RB N
200 CD N
mg/die NN N
) ) N
. . N

As IN N
the DT N
coefficient NN N
of IN N
variation NN N
( ( N
VC NNP N
) ) N
of IN N
measured VBN N
blood NN 1_o
glucose NN 1_o
continuously RB N
increased VBD N
the DT N
best JJS N
time NN N
of IN N
a DT N
steady JJ N
state NN N
was VBD N
between IN N
90 CD N
and CC N
130 CD N
min NN N
after IN N
beginning VBG N
the DT N
infusion NN N
( ( N
mean JJ N
VC NNP N
8.9 CD N
% NN N
) ) N
. . N

While IN N
insulin NN 1_o
remained VBD N
nearly RB N
constant JJ N
( ( N
41 CD N
( ( N
45 CD N
; : N
38 CD N
) ) N
microU/ml NN N
) ) N
blood NN 1_o
glucose NN 1_o
dropped VBN N
by IN N
about IN N
14 CD N
% NN N
and CC N
reached VBD N
a DT N
steady JJ N
state NN N
of IN N
89 CD N
( ( N
134 CD N
; : N
45 CD N
) ) N
mg/dl NN N
. . N

During IN N
the DT N
therapy NN N
of IN N
bezafibrate NN 1_i
blood NN 1_o
glucose NN 1_o
was VBD N
significantly RB N
decreased VBN N
by IN N
36 CD N
% NN N
130 CD N
min NN N
after IN N
beginning VBG N
the DT N
infusion NN N
. . N

Although IN N
the DT N
effect NN N
was VBD N
not RB N
significant JJ N
during IN N
the DT N
whole JJ N
time NN N
of IN N
the DT N
steady JJ N
state NN N
it PRP N
became VBD N
evident JJ N
by IN N
a DT N
negative JJ N
correlation NN N
with IN N
lactate NN N
( ( N
r JJ N
= NNP N
-0.687 NNP N
) ) N
and CC N
pyruvate NN N
( ( N
r JJ N
= NNP N
-0.843 NNP N
) ) N
. . N

A DT N
correlation NN N
with IN N
a DT N
concomitant JJ N
decrease NN N
of IN N
triglyceride NN 1_o
and CC 1_o
cholesterol NN 1_o
also RB N
induced VBN N
by IN N
bezafibrate NN 1_i
could MD N
not RB N
be VB N
proven RB N
. . N

The DT N
results NNS N
show VBP N
that IN N
the DT N
infusion NN 1_i
test NN 1_i
of IN 1_i
somatostatin NN 1_i
is VBZ N
fitted VBN N
to TO N
measure VB N
a DT N
steady JJ N
state NN N
of IN N
blood NN 1_o
glucose NN 1_o
and CC 1_o
insulin NN 1_o
and CC N
that IN N
it PRP N
is VBZ N
possible JJ N
by IN N
this DT N
technique NN N
to TO N
quantify VB N
a DT N
changed JJ N
utilisation NN N
of IN N
blood NN N
glucose NN N
induced VBN N
by IN N
specific JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Potentials NNS N
of IN N
monocular NN 1_i
augmented VBN 1_i
reality NN 1_i
technology NN 1_i
in IN N
automobile NN N
production NN N
] NNP N
. . N

INTRODUCTION NNP N
Augmented NNP 1_i
reality NN 1_i
( ( 1_i
AR NNP 1_i
) ) 1_i
technologies NNS 1_i
can MD N
enrich VB N
the DT N
real JJ N
environment NN N
with IN N
visual JJ N
data NNS N
, , N
which WDT N
has VBZ N
potential JJ N
benefits NNS N
for IN N
optimising VBG N
the DT N
operator NN N
's POS N
working VBG N
process NN N
. . N

It PRP N
offers VBZ N
the DT N
possibility NN N
to TO N
provide VB N
context-sensitive JJ N
information NN N
independently RB N
of IN N
the DT N
user NN N
's POS N
location NN N
and CC N
position NN N
. . N

Data NNS N
are VBP N
presented VBN N
to TO N
the DT N
dominant JJ N
eye NN N
on IN N
a DT N
semi-transparent JJ N
mirror NN N
using VBG N
a DT N
head-mounted JJ N
display NN N
( ( N
HMD NNP N
) ) N
unit NN N
that WDT N
works VBZ N
with IN N
retinal JJ N
laser NN N
technology NN N
. . N

In IN N
this DT N
study NN N
the DT N
potential JJ N
benefits NNS N
and CC N
drawbacks NNS N
of IN N
this DT N
new JJ N
AR NNP 1_i
technology NN 1_i
were VBD N
evaluated VBN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
45 CD 1_p
participants NNS 1_p
without IN 1_p
any DT 1_p
visual JJ 1_p
impairment NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
3 CD N
groups NNS N
and CC N
completed VBD N
a DT N
variety NN N
of IN N
tasks NNS N
during IN N
a DT N
simulated JJ N
working JJ N
day NN N
. . N

Group NNP N
1 CD N
received VBD N
conventional JJ 1_i
working JJ 1_i
aids NNS 1_i
( ( 1_i
paper-based JJ 1_i
documents NNS 1_i
) ) 1_i
to TO 1_i
support VB 1_i
the DT 1_i
task NN 1_i
processing NN 1_i
. . 1_i

Group NNP N
2 CD N
additionally RB N
wore VBD N
an DT N
HMD NNP 1_i
unit NN 1_i
that WDT 1_i
was VBD 1_i
switched VBN 1_i
off RP 1_i
. . 1_i

Group NNP N
3 CD N
wore VBD N
a DT N
functioning NN N
HMD NNP 1_i
without IN 1_i
any DT 1_i
additional JJ 1_i
aids NNS 1_i
. . 1_i

Evaluation NN N
was VBD N
carried VBN N
out RP N
by IN N
means NNS N
of IN N
a DT N
standardised JJ N
questionnaire NN N
( ( N
BMS NNP N
) ) N
and CC N
a DT N
concentration NN N
test NN N
( ( N
d2 JJ N
Aufmerksamkeits-Belastungs-Test NNP N
) ) N
. . N

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
between IN N
the DT N
3 CD N
groups NNS N
were VBD N
found VBN N
in IN N
terms NNS N
of IN N
mental JJ 1_o
strain NN 1_o
, , 1_o
concentration-test JJ 1_o
performance NN 1_o
and CC 1_o
physical JJ 1_o
or CC 1_o
mental JJ 1_o
complaints NNS 1_o
reported VBN N
in IN N
a DT N
follow-up JJ N
interview NN N
. . N

Around IN N
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
noticed VBD N
a DT N
higher JJR 1_o
pressure NN 1_o
and CC 1_o
blurred JJ 1_o
vision NN 1_o
in IN 1_o
both DT 1_o
eyes NNS 1_o
as RB 1_o
well RB 1_o
as IN 1_o
headaches NNS 1_o
. . 1_o

Half NNP N
of IN N
the DT N
participants NNS N
complained VBD N
about IN N
deficiencies NNS N
concerning VBG N
the DT N
ergonomic JJ 1_o
hardware NN 1_o
design NN 1_o
of IN N
the DT N
AR NNP N
system NN N
. . N

DISCUSSION NNP N
Changes NNP N
in IN N
objective JJ N
ophthalmological JJ N
investigation NN N
parameters NNS N
were VBD N
not RB N
observed VBN N
. . N

Subjects NNS N
reported VBD N
reduced JJ N
acceptance NN N
of IN N
the DT N
HMD NNP N
based VBN N
on IN N
non-ophthalmological JJ N
reasons NNS N
, , N
for IN N
example NN N
, , N
the DT N
weight NN N
of IN N
the DT N
unit NN N
or CC N
the DT N
length NN N
of IN N
the DT N
cable NN N
. . N

However RB N
, , N
for IN N
some DT N
specific JJ N
working VBG N
tasks NNS N
, , N
advantages NNS N
in IN N
process NN N
optimisation NN N
and CC N
operator NN N
support NN N
were VBD N
observed VBN N
. . N

-DOCSTART- -X- O O

Palliative JJ 1_i
brachytherapy NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
primary JJ 1_i
stent JJ 1_i
placement NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
oesophageal JJ 1_p
cancer NN 1_p
, , N
a DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
whether IN N
a DT N
combination NN 1_i
of IN 1_i
self-expanding JJ 1_i
metal NN 1_i
stent NN 1_i
( ( 1_i
SEMS NNP 1_i
) ) 1_i
and CC 1_i
brachytherapy NN 1_i
provided VBD N
more RBR N
rapid JJ N
and CC N
prolonged JJ N
effect NN N
on IN N
dysphagia NN N
without IN N
increased VBN N
pain NN N
compared VBN N
to TO N
brachytherapy VB N
alone RB N
in IN N
patients NNS 1_p
with IN 1_p
incurable JJ 1_p
oesophageal JJ 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
41 CD 1_p
Patients NNPS 1_p
were VBD N
randomised VBN N
to TO N
SEMS NNP 1_i
followed VBN 1_i
by IN 1_i
brachytherapy NN 1_i
, , 1_i
8 CD 1_i
Gy?3 NNP 1_i
( ( 1_i
n=21 NN 1_i
) ) 1_i
or CC 1_i
brachytherapy VB 1_i
alone RB 1_i
, , 1_i
8 CD 1_i
Gy?3 NNP 1_i
( ( 1_i
n=20 NN 1_o
) ) 1_o
. . 1_o

Change NN 1_o
in IN 1_o
dysphagia NN 1_o
and CC 1_o
pain NN 1_o
three CD 1_o
and CC N
seven CD N
weeks NNS N
after IN N
randomisation NN N
( ( N
FU1 NNP N
and CC N
FU2 NNP N
) ) N
was VBD N
assessed VBN N
by IN N
patient-reported JJ N
outcome NN 1_o
. . 1_o

Dysphagia NNP 1_o
, , 1_o
other JJ N
symptoms NNS N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
were VBD N
assessed VBN N
every DT N
four CD N
weeks NNS N
thereafter RB N
. . N

The DT N
study NN N
was VBD N
closed VBN N
before IN N
the DT N
estimated VBN N
patient-number NN N
was VBD N
reached VBN N
due JJ N
to TO N
slow VB N
recruitment NN N
. . N

RESULTS JJ N
Patients NNPS N
receiving VBG 1_i
SEMS NNP 1_i
followed VBN 1_i
by IN 1_i
brachytherapy NN 1_i
had VBD 1_i
significantly RB N
improved VBN 1_o
dysphagia NN 1_o
at IN 1_o
FU1 NNP N
compared VBN N
to TO N
patients NNS N
receiving VBG 1_i
brachytherapy NN 1_i
alone RB 1_i
( ( 1_i
n=35 JJ N
) ) N
. . N

Difference NN N
in IN N
pain NN 1_o
was VBD 1_o
not RB N
observed VBN N
. . N

At IN N
FU2 NNP N
, , N
patients NNS N
in IN N
both DT N
arms NNS N
( ( N
n=21 NN N
) ) N
had VBD N
less JJR 1_o
dysphagia JJ 1_o
. . 1_o

Four CD N
patients NNS N
in IN N
the DT N
combined JJ N
treatment NN N
arm NN N
experienced VBD 1_o
manageable JJ 1_o
complications NNS 1_o
, , 1_o
no DT 1_o
complications NNS 1_o
occurred VBD 1_o
after IN N
brachytherapy NN N
alone RB N
. . N

CONCLUSION NNP N
For IN N
the DT N
relief NN N
of IN N
dysphagia NN 1_i
, , 1_i
SEMS NNP 1_i
followed VBN 1_i
by IN N
brachytherapy NN 1_i
is VBZ 1_i
preferable JJ N
and CC N
safe JJ N
for IN N
patients NNS N
in IN N
need NN N
of IN N
immediate JJ N
alleviation NN N
, , N
while IN 1_i
brachytherapy NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
preceding VBG 1_i
SEMS NNP 1_i
provides VBZ 1_i
relief NN N
within IN N
a DT N
few JJ N
weeks NNS N
after IN N
treatment NN N
. . N

-DOCSTART- -X- O O

High-intensity NNP 1_i
physical JJ 1_i
training NN 1_i
in IN N
adults NNS 1_p
with IN 1_p
asthma NN 1_p
. . 1_p

A DT N
comparison NN N
between IN N
training VBG 1_i
on IN 1_i
land NN 1_i
and CC 1_i
in IN 1_i
water NN 1_i
. . 1_i

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
inactive JJ 1_p
asthmatic JJ 1_p
patients NNS 1_p
could MD N
perform VB N
high-intensity JJ 1_i
physical JJ 1_i
training NN 1_i
equally RB N
well RB N
on IN 1_i
land NN 1_i
as IN 1_i
in IN 1_i
water NN 1_i
, , N
and CC N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
these DT N
training NN N
forms NNS N
. . N

Thirty-two JJ 1_p
adults NNS 1_p
with IN 1_p
asthma NN 1_p
, , N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
underwent VBD N
a DT N
10-week JJ 1_i
supervised JJ 1_i
rehabilitation NN 1_i
program NN 1_i
with IN 1_i
emphasis NN 1_i
on IN 1_i
physical JJ 1_i
training NN 1_i
. . 1_i

All DT N
patients NNS N
, , N
irrespective JJ N
of IN N
training VBG N
form NN N
, , N
were VBD N
able JJ N
to TO N
exercise VB N
to TO N
maximal VB N
intensity NN N
( ( N
80-90 CD N
% NN N
of IN N
estimated VBN N
maximal JJ N
heart NN N
rate NN N
) ) N
. . N

No UH N
asthmatic JJ 1_o
attacks NNS 1_o
occurred VBD N
in IN N
connection NN N
with IN N
the DT N
training NN N
sessions NNS N
. . N

Respiratory NNP 1_o
variables NNS 1_o
remained VBD N
almost RB N
unchanged JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
asthma NN 1_o
symptoms NNS 1_o
declined VBD 1_o
during IN N
the DT N
rehabilitation NN N
period NN N
, , N
and CC N
the DT N
subjects NNS N
needed VBN N
less JJR N
acute JJ N
asthma NN N
care NN N
after IN N
the DT N
rehabilitation NN N
. . N

The DT N
cardiovascular JJ 1_o
condition NN 1_o
improved VBN N
significantly RB N
and CC N
similarly RB N
in IN N
the DT N
two CD N
groups NNS N
. . N

Ten CD 1_p
patients NNS 1_p
, , 1_p
5 CD 1_p
in IN 1_p
each DT 1_p
group NN 1_p
, , N
had VBD N
exercise-induced JJ 1_o
asthma NN 1_o
at IN N
the DT N
start NN N
of IN N
the DT N
rehabilitation NN N
. . N

Only RB N
3 CD N
patients NNS N
, , N
2 CD N
from IN N
the DT N
water NN N
group NN N
and CC N
1 CD N
from IN N
the DT N
land NN N
group NN N
, , N
had VBD N
exercise-induced VBN 1_o
asthma NNS 1_o
after IN N
10 CD N
weeks NNS N
. . N

We PRP N
conclude VBP N
that IN N
indoor JJ N
training NN N
, , N
either CC N
on IN N
land NN N
or CC N
in IN N
water NN N
, , N
is VBZ N
beneficial JJ N
. . N

The DT N
effects NNS 1_o
of IN N
these DT N
two CD N
training NN N
forms NNS N
are VBP N
almost RB N
equivalent JJ N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
treatment NN N
of IN N
plantar NN 1_p
fasciitis NN 1_p
with IN N
an DT N
extracoporeal NN 1_i
shockwave NN 1_i
therapy NN 1_i
( ( 1_i
ESWT NNP 1_i
) ) 1_i
device NN 1_i
: : 1_i
a DT N
North JJ 1_p
American JJ 1_p
confirmatory NN 1_p
study NN 1_p
. . 1_p

Despite IN N
numerous JJ N
publications NNS N
and CC N
clinical JJ N
trials NNS N
, , N
the DT N
results NNS N
of IN N
treatment NN N
of IN N
recalcitrant JJ 1_p
chronic JJ 1_p
plantar NN 1_p
fasciitis NN 1_p
with IN N
extracorporeal JJ 1_i
shockwave JJ 1_i
therapy NN 1_i
( ( 1_i
ESWT NNP 1_i
) ) 1_i
still RB N
remain VBP N
equivocal JJ N
as IN N
to TO N
whether IN N
or CC N
not RB N
this DT N
treatment NN N
provides VBZ N
relief NN 1_o
from IN N
the DT 1_o
pain NN 1_o
associated VBN N
with IN N
this DT N
condition NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
extracorporeal NN N
shock NN N
wave VBP N
therapy NN N
can MD N
safely RB 1_o
and CC 1_o
effectively RB 1_o
relieve VB 1_o
the DT 1_o
pain NN 1_o
associated VBN N
with IN N
chronic JJ N
plantar NN N
fasciitis NN N
compared VBN N
to TO N
placebo VB N
treatment NN N
, , N
as IN N
demonstrated VBN N
by IN N
pain NN N
with IN N
walking NN N
in IN N
the DT N
morning NN N
. . N

This DT N
was VBD N
set VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
confirmatory JJ N
clinical JJ N
study NN N
undertaken VBN N
in IN N
four CD 1_p
outpatient NN 1_p
orthopedic NN 1_p
clinics NNS 1_p
. . 1_p

The DT 1_p
patients NNS 1_p
, , 1_p
114 CD 1_p
adult NN 1_p
subjects NNS 1_p
with IN 1_p
chronic JJ 1_p
plantar NN 1_p
fasciitis NN 1_p
, , 1_p
recalcitrant JJ 1_p
to TO 1_p
conservative JJ 1_p
therapies NNS 1_p
for IN 1_p
at IN 1_p
least JJS 1_p
6 CD 1_p
months NNS 1_p
, , N
were VBD N
randomized VBN N
to TO N
two CD N
groups NNS N
. . N

Treatment NNP N
consisted VBD N
of IN N
approximately RB N
3,800 CD 1_i
total JJ 1_i
shock NN 1_i
waves NNS 1_i
( ( N
+/-10 JJ N
) ) N
reaching VBG N
an DT N
approximated JJ N
total NN N
energy NN N
delivery NN N
of IN N
1,300 CD N
mJ/mm NN N
( ( N
2 CD N
) ) N
( ( N
ED+ NNP N
) ) N
in IN N
a DT N
single JJ N
session NN N
versus IN N
placebo NN 1_i
treatment NN 1_i
. . 1_i

This DT N
study NN N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
in IN N
the DT N
primary JJ N
efficacy NN N
outcome NN N
of IN N
pain NN 1_o
during IN N
the DT 1_o
first JJ 1_o
few JJ 1_o
minutes NNS 1_o
of IN 1_o
walking VBG 1_o
measured VBN N
by IN N
a DT N
visual JJ 1_o
analog NN 1_o
scale NN 1_o
. . 1_o

There EX N
was VBD N
also RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatments NNS N
in IN N
the DT N
number NN N
of IN N
participants NNS N
whose WP$ N
changes NNS N
in IN N
Visual NNP 1_o
Analog NNP 1_o
Scale NNP 1_o
scores VBZ 1_o
met VBD N
the DT N
study NN N
definition NN N
of IN N
success NN N
at IN N
both DT N
6 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
posttreatment NN N
; : N
and CC N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
posttreatment NN N
in IN N
the DT N
Roles NNP 1_o
and CC 1_o
Maudsley NNP 1_o
Score NNP 1_o
. . 1_o

The DT N
results NNS N
of IN N
this DT N
study NN N
confirm VBP N
that IN N
ESWT NNP 1_i
administered VBD N
with IN N
the DT N
Dornier NNP N
Epos NNP N
Ultra NNP N
is VBZ N
a DT N
safe JJ 1_o
and CC N
effective JJ 1_o
treatment NN N
for IN N
recalcitrant JJ N
plantar NN N
fasciitis NN N
. . N

-DOCSTART- -X- O O

Behavioral NNP 1_o
and CC 1_o
physiological JJ 1_o
effects NNS 1_o
of IN N
remifentanil NN 1_i
and CC 1_i
alfentanil NN 1_i
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

BACKGROUND IN N
The DT 1_o
subjective JJ 1_o
and CC 1_o
psychomotor JJ 1_o
effects NNS 1_o
of IN N
remifentanil NNS 1_i
have VBP N
not RB N
been VBN N
evaluated VBN N
. . N

Accordingly RB N
, , N
the DT N
authors NNS N
used VBD N
mood NN N
inventories NNS N
and CC N
psychomotor NN N
tests NNS N
to TO N
characterize VB N
the DT N
effects NNS N
of IN N
remifentanil NN 1_i
in IN N
healthy JJ 1_p
, , 1_p
non-drug-abusing JJ 1_p
volunteers NNS 1_p
. . 1_p

Alfentanil NNP N
was VBD N
used VBN N
as IN N
a DT N
comparator NN N
drug NN N
. . N

METHODS NNP N
Ten NNP 1_p
healthy JJ 1_p
volunteers NNS 1_p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ 1_i
, , N
crossover JJ N
trial NN N
in IN N
which WDT N
they PRP N
received VBD N
an DT N
infusion NN N
of IN N
saline NN 1_i
, , 1_i
remifentanil NN 1_i
, , 1_i
or CC 1_i
alfentanil NN 1_i
for IN 1_i
120 CD 1_i
min NN 1_i
. . 1_i

The DT N
age- JJ 1_i
and CC 1_i
weight-adjusted JJ 1_i
infusions NNS 1_i
( ( 1_i
determined VBN 1_i
with IN 1_i
STANPUMP NNP 1_i
, , 1_i
a DT 1_i
computer NN 1_i
modeling VBG 1_i
software NN 1_i
package NN 1_i
) ) 1_i
were VBD N
given VBN N
to TO N
achieve VB N
three CD N
predicted VBN N
constant JJ N
plasma NN N
levels NNS N
for IN N
40 CD 1_i
min NNS 1_i
each DT 1_i
of IN 1_i
remifentanil NN 1_i
( ( 1_i
0.75 CD 1_i
, , 1_i
1.5 CD 1_i
, , 1_i
and CC 1_i
3 CD 1_i
ng/ml NN 1_i
) ) 1_i
and CC 1_i
alfentanil NN 1_i
( ( 1_i
16 CD 1_i
, , 1_i
32 CD 1_i
, , 1_i
and CC 1_i
64 CD 1_i
ng/ml NN 1_i
) ) 1_i
. . 1_i

Mood NN N
forms NNS N
and CC N
psychomotor NN N
tests NNS N
were VBD N
completed VBN N
, , N
and CC N
miosis NN N
was VBD N
assessed VBN N
, , N
during IN N
and CC N
after IN N
the DT N
infusions NNS N
. . N

In IN N
addition NN N
, , N
analgesia NN N
was VBD N
tested VBN N
at IN N
each DT N
dose JJ N
level NN N
using VBG N
a DT N
cold-pressor JJ N
test NN N
. . N

RESULTS NNP N
Remifentanil NNP 1_i
had VBD N
prototypic VBN 1_o
micro-like JJ 1_o
opioid JJ 1_o
subjective JJ 1_o
effects NNS 1_o
, , 1_o
impaired JJ 1_o
psychomotor NN 1_o
performance NN 1_o
, , 1_o
and CC 1_o
produced VBD 1_o
analgesia NN 1_o
. . 1_o

Alfentanil NNP N
at IN N
the DT N
dose JJ N
range NN N
tested VBD N
had VBD N
more RBR N
mild JJ N
effects NNS N
on IN N
these DT N
measures NNS N
, , N
and CC N
the DT N
analgesia NN 1_o
data NNS N
indicated VBD N
that IN N
a DT N
40:1 CD N
potency NN N
ratio NN N
, , N
rather RB N
than IN N
the DT N
20:1 CD N
ratio NN N
we PRP N
used VBD N
, , N
may MD N
exist VB N
between IN N
remifentanil NN N
and CC N
alfentanil NN N
. . N

A DT N
psychomotor NN N
test NN N
administered VBD N
60 CD N
min NN N
after IN N
the DT N
remifentanil NN N
infusion NN N
was VBD N
discontinued VBN N
showed VBD N
that IN N
the DT N
volunteers NNS N
were VBD N
still RB N
impaired VBN N
, , N
although IN N
they PRP N
reported VBD N
feeling VBG N
no DT N
drug NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
notion NN N
that IN N
the DT N
pharmacodynamic JJ 1_o
effects NNS 1_o
of IN N
remifentanil NN 1_i
are VBP N
extremely RB N
short-lived JJ N
after IN N
the DT N
drug NN N
is VBZ N
no DT N
longer RB N
administered VBN N
must MD N
be VB N
questioned VBN N
given VBN N
our PRP$ N
findings NNS N
that IN N
psychomotor NN 1_o
effects NNS 1_o
were VBD N
still RB N
apparent JJ N
1 CD N
h NN N
after IN N
the DT N
infusion NN N
was VBD N
discontinued VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
leisure NN 1_i
programme NN 1_i
on IN N
quality NN 1_o
of IN 1_o
life NN 1_o
and CC 1_o
stress NN 1_o
of IN N
individuals NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

BACKGROUND NNP N
Even RB N
though IN N
there EX N
is VBZ N
research NN N
demonstrating VBG N
a DT N
positive JJ N
relationship NN N
between IN N
leisure NN N
participation NN N
and CC N
the DT N
two CD N
constructs NNS N
of IN N
quality NN 1_o
of IN 1_o
life NN 1_o
and CC 1_o
stress NN 1_o
reduction NN N
, , N
current JJ N
conceptualisation NN N
of IN N
leisure NN N
as IN N
a DT N
contributor NN N
to TO N
quality NN N
of IN N
life NN N
is VBZ N
limited VBN N
. . N

In IN N
addition NN N
, , N
in IN N
spite NN N
of IN N
improvements NNS N
in IN N
accurate JJ N
diagnosis NN N
of IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
at IN N
increasingly RB N
earlier JJR N
ages NNS N
and CC N
proliferation NN N
of IN N
interventions NNS N
, , N
research NN N
associated VBN N
with IN N
leisure NN N
and CC N
quality NN N
of IN N
life NN N
for IN N
people NNS 1_p
with IN 1_p
ASD NNP 1_p
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Therefore NNP N
, , N
a DT N
study NN N
using VBG N
a DT N
repeated JJ N
measures NNS N
design NN N
was VBD N
used VBN N
to TO N
measure VB N
effects NNS N
of IN N
a DT N
1-year JJ 1_i
group NN 1_i
leisure NN 1_i
programme NN 1_i
intended VBN N
to TO N
facilitate VB N
interaction NN 1_i
with IN 1_i
media NNS 1_i
, , 1_i
engagement NN 1_i
in IN 1_i
exercise NN 1_i
, , 1_i
playing VBG 1_i
games NNS 1_i
and CC 1_i
doing VBG 1_i
crafts NNS 1_i
, , 1_i
attending VBG 1_i
events NNS 1_i
, , 1_i
and CC 1_i
participating VBG 1_i
in IN 1_i
other JJ 1_i
recreation NN 1_i
activities NNS 1_i
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
37 CD 1_p
participants NNS 1_p
( ( 1_p
22 CD 1_p
male NN 1_p
, , 1_p
15 CD 1_p
female NN 1_p
) ) 1_p
, , 1_p
ages VBZ 1_p
17-39 JJ 1_p
( ( 1_p
M NNP 1_p
= NNP 1_p
31.49 CD 1_p
) ) 1_p
years NNS 1_p
at IN 1_p
the DT 1_p
beginning NN 1_p
of IN 1_p
the DT 1_p
programme NN 1_p
) ) 1_p
diagnosed VBD 1_p
with IN 1_p
an DT 1_p
ASD NNP 1_p
and CC 1_p
a DT 1_p
group NN 1_p
of IN 1_p
34 CD 1_p
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
as IN 1_p
control NN 1_i
group NN 1_i
( ( 1_i
waiting VBG 1_i
list NN 1_i
) ) 1_i
( ( 1_p
19 CD 1_p
male NN 1_p
, , 1_p
15 CD 1_p
female NN 1_p
) ) 1_p
, , 1_p
ages VBZ 1_p
24-38 JJ 1_p
( ( 1_p
M NNP 1_p
= VBZ 1_p
30 CD 1_p
at IN 1_p
programme JJ 1_p
initiation NN 1_p
) ) 1_p
years NNS 1_p
. . 1_p

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
overall JJ N
scores NNS N
of IN N
stress NN 1_o
levels NNS 1_o
for IN N
participants NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
and CC N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
four CD N
factors NNS N
of IN N
quality NN 1_o
of IN 1_o
life NN 1_o
that WDT N
were VBD N
measured VBN N
( ( 1_o
satisfaction NN 1_o
, , 1_o
independence NN 1_o
, , 1_o
competence NN 1_o
and CC 1_o
social JJ 1_o
interaction NN 1_o
) ) 1_o
as RB N
well RB N
as IN N
the DT N
total JJ 1_o
score NN 1_o
for IN 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
intervention NN N
12 CD N
months NNS N
later RB N
. . N

In IN N
contrast NN N
, , N
the DT N
control NN N
group NN N
demonstrated VBD N
no DT N
significant JJ N
improvements NNS N
related VBN N
to TO N
stress VB 1_o
or CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

Implications NNS N
of IN N
these DT N
findings NNS N
to TO N
leisure VB N
services NNS N
and CC N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
individuals NNS 1_p
with IN 1_p
ASD NNP 1_p
are VBP N
discussed VBN N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
the DT N
contention NN N
that WDT N
participation NN N
in IN N
recreation NN N
activities NNS N
positively RB N
influenced VBD N
the DT N
stress NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

-DOCSTART- -X- O O

[ IN N
The DT N
problems NNS N
of IN N
prophylactic JJ 1_i
chemotherapy NN 1_i
, , N
the DT N
second-look JJ N
operation NN N
and CC N
the DT N
maintenance NN N
of IN N
the DT N
remission NN N
in IN N
the DT N
treatment NN N
of IN N
ovarian JJ N
cancer NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

The DT N
results NNS N
of IN N
the DT N
treatment NN N
of IN N
1022 CD 1_p
ovarian JJ 1_p
cancers NNS 1_p
were VBD N
reviewed VBN N
and CC N
the DT N
problems NNS N
of IN N
prophylactic JJ 1_i
chemotherapy NN 1_i
, , N
a DT N
second JJ N
look NN N
operation NN N
and CC N
the DT N
maintenance NN N
of IN N
the DT N
remission NN N
were VBD N
studied VBN N
. . N

In IN N
ovarian JJ 1_p
cancers NNS 1_p
of IN 1_p
stage NN 1_p
1 CD 1_p
and CC 1_p
stage NN 1_p
2 CD 1_p
, , N
a DT N
post-operative JJ 1_i
prophylactic JJ 1_i
chemotherapy NN 1_i
is VBZ N
useful JJ N
only RB N
in IN N
cases NNS N
with IN N
tumor NN N
cells NNS N
in IN N
the DT N
secretions NNS N
of IN N
the DT N
pouch NN N
of IN N
Douglas NNP N
or CC N
in IN N
the DT N
ascites NNS N
and CC N
in IN N
cases NNS N
where WRB N
a DT N
sensitivity NN N
to TO N
the DT N
chemotherapy NN N
can MD N
be VB N
assumed VBN N
. . N

In IN N
about RB N
50 CD N
% NN N
of IN N
primarily RB 1_p
inoperable JJ 1_p
stage NN 1_p
3 CD 1_p
ovarian JJ 1_p
cancers NNS 1_p
, , N
the DT N
random NN N
treatment NN N
with IN N
cyclophosphamide NN 1_i
( ( 1_i
Endoxan NNP 1_i
) ) 1_i
results NNS N
in IN N
a DT N
clinical JJ 1_o
remission NN 1_o
. . 1_o

A DT N
significant JJ N
five CD 1_o
year NN 1_o
cure NN 1_o
rate NN 1_o
can MD N
only RB N
be VB N
obtained VBN N
if IN N
the DT N
uterus NN N
and CC N
the DT N
adnexa NN N
are VBP N
removed VBN N
. . N

Radical JJ N
operation NN N
during IN N
the DT N
remission NN N
appears VBZ N
to TO N
be VB N
very RB N
important JJ N
for IN N
survival NN 1_o
of IN N
the DT N
patient NN N
. . N

For IN N
the DT N
maintenance NN N
of IN N
the DT N
remission NN N
continuous JJ N
chemotherapy NN 1_i
for IN N
at IN N
least JJS N
2 CD N
years NNS N
following VBG N
treatment NN N
by IN N
operation NN N
and CC N
radiotherapy NN 1_i
is VBZ N
necessary JJ N
. . N

-DOCSTART- -X- O O

Double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
study NN N
of IN N
metronidazole NN 1_i
as IN 1_p
a DT 1_p
disease NN 1_p
modifying VBG 1_p
agent NN 1_p
in IN 1_p
the DT 1_p
treatment NN 1_p
of IN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
. . 1_p

Anecdotal JJ N
reports NNS N
suggest VBP N
that IN N
metronidazole NN N
may MD N
have VB N
disease NN N
modifying VBG N
activity NN N
in IN N
the DT N
treatment NN 1_p
of IN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
. . 1_p

To TO N
assess VB N
possible JJ N
beneficial JJ 1_o
effects NNS 1_o
a DT N
double JJ N
blind NN N
, , N
comparative JJ N
trial NN N
of IN 1_i
metronidazole NN 1_i
and CC 1_i
placebo NN 1_i
was VBD N
performed VBN N
. . N

Fifty JJ 1_p
patients NNS 1_p
with IN 1_p
active JJ 1_p
rheumatoid NN 1_p
arthritis NN 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
to TO 1_p
receive VB 1_p
active JJ 1_i
drug NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
24 CD 1_p
) ) 1_p
or CC 1_i
placebo NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
26 CD 1_p
) ) 1_p
and CC 1_p
reviewed VBN 1_p
at IN 1_p
weeks NNS 1_p
0 CD 1_p
, , 1_p
1 CD 1_p
, , 1_p
4 CD 1_p
, , 1_p
8 CD 1_p
, , 1_p
12 CD 1_p
, , 1_p
16 CD 1_p
, , 1_p
and CC 1_p
24 CD 1_p
. . 1_p

Detailed JJ 1_o
assessment NN 1_o
of IN N
drug NN 1_o
safety NN 1_o
, , 1_o
biochemical JJ 1_o
and CC 1_o
haematological JJ 1_o
parameters NNS 1_o
, , N
and CC N
efficacy NN 1_o
was VBD N
made VBN N
at IN N
these DT N
dates NNS N
. . N

Dose NNP N
regimen NNS N
was VBD N
400 CD N
mg JJ N
twice RB N
daily RB N
from IN N
weeks NNS N
0 CD N
to TO N
eight CD N
, , N
increasing VBG N
to TO N
400 CD N
mg NNS N
three CD N
times NNS N
a DT N
day NN N
from IN N
weeks NNS N
nine CD N
to TO N
24 CD N
provided VBD N
that IN N
no DT N
adverse JJ N
effects NNS N
were VBD N
recorded VBN N
. . N

Most JJS N
patients NNS N
were VBD N
unable JJ N
to TO N
tolerate VB 1_o
metronidazole NN 1_o
because IN N
of IN N
side NN 1_o
effects NNS 1_o
or CC N
lack NN 1_o
of IN 1_o
efficacy NN 1_o
, , N
with IN N
only RB N
five CD N
( ( N
21 CD N
% NN N
) ) N
continuing VBG N
to TO N
take VB N
the DT N
drug NN N
at IN N
24 CD N
weeks NNS N
. . N

For IN N
those DT N
patients NNS N
attaining VBG N
12 CD N
weeks NNS N
of IN N
treatment NN N
an DT N
overall JJ 1_o
improvement NN 1_o
in IN 1_o
articular JJ 1_o
index NN 1_o
and CC 1_o
morning NN 1_o
stiffness NN 1_o
was VBD N
found VBN N
. . N

No DT N
improvement NN 1_o
in IN N
laboratory JJ 1_o
indices NNS 1_o
of IN 1_o
disease NN 1_o
activity NN 1_o
was VBD N
seen VBN N
, , N
however RB N
. . N

In IN N
this DT N
study NN N
metronidazole NN N
did VBD N
not RB N
have VB N
disease NN 1_o
modifying VBG 1_o
properties NNS 1_o
and CC N
was VBD N
unacceptably RB 1_o
toxic JJ 1_o
. . 1_o

-DOCSTART- -X- O O

Efficacy NN 1_o
of IN N
dose-intensified JJ N
MEC NNP 1_i
( ( 1_i
methotrexate NN 1_i
, , 1_i
epirubicin NN 1_i
and CC 1_i
cisplatin NN 1_i
) ) 1_i
chemotherapy NN N
for IN N
advanced JJ 1_p
urothelial JJ 1_p
carcinoma NN 1_p
: : 1_p
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
MEC NNP 1_i
and CC N
M-VAC NNP 1_i
( ( 1_i
methotrexate NN 1_i
, , 1_i
vinblastine NN 1_i
, , 1_i
doxorubicin NN 1_i
and CC 1_i
cisplatin NN 1_i
) ) 1_i
. . N

Japanese JJ 1_p
Urothelial JJ 1_p
Cancer NNP 1_p
Research NNP 1_p
Group NNP 1_p
. . 1_p

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
antitumor NN 1_o
activity NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
T3b NNP 1_p
, , 1_p
T4 NNP 1_p
or CC 1_p
metastatic JJ 1_p
urothelial JJ 1_p
carcinoma NN 1_p
treated VBN 1_p
with IN 1_p
MEC NNP 1_i
or CC 1_p
M-VAC NNP 1_i
chemotherapy NN 1_p
, , N
by IN N
performing VBG N
a DT N
multi-center JJ N
randomized JJ N
prospective JJ N
study NN N
. . N

METHODS NNP N
From IN 1_p
1991 CD 1_p
to TO 1_p
1995 CD 1_p
, , 1_p
89 CD 1_p
patients NNS 1_p
with IN 1_p
T3b NNP 1_p
, , 1_p
T4 NNP 1_p
or CC 1_p
metastatic JJ 1_p
urothelial JJ 1_p
carcinoma NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
methotrexate NN 1_i
, , 1_i
epirubicin NN 1_i
and CC 1_i
cisplatin NN 1_i
chemotherapy NN 1_i
group NN 1_i
( ( 1_i
arm JJ 1_i
1 CD 1_i
: : 1_i
S-MEC JJ 1_i
therapy NN 1_i
; : 1_i
n CC 1_i
= VB 1_i
29 CD 1_i
) ) 1_i
, , 1_i
a DT 1_i
dose-intensified JJ 1_i
MEC NNP 1_i
therapy NN 1_i
combined VBN 1_i
with IN 1_i
G-CSF NNP 1_i
group NN 1_i
( ( 1_i
arm JJ 1_i
2 CD 1_i
: : 1_i
I-MEC JJ 1_i
therapy NN 1_i
; : 1_i
n CC 1_i
= VB 1_i
30 CD 1_i
) ) 1_i
or CC 1_i
a DT 1_i
methotrexate NN 1_i
, , 1_i
vinblastine NN 1_i
, , 1_i
doxorubicin NN 1_i
and CC 1_i
cisplatin NN 1_i
chemotherapy NN 1_i
( ( 1_i
arm JJ 1_i
3 CD 1_i
: : 1_i
M-VAC JJ 1_i
therapy NN 1_i
; : 1_i
n CC 1_i
= VB 1_i
30 CD 1_i
) ) 1_i
. . 1_i

At IN N
the DT N
registration NN N
center NN N
, , N
the DT N
patients NNS N
were VBD N
stratified VBN N
into IN N
previously RB N
untreated JJ N
patients NNS N
and CC N
patients NNS N
with IN N
recurrence NN N
after IN N
radical JJ N
operation NN N
and CC N
then RB N
randomly RB N
allocated VBN N
to TO N
the DT N
treatment NN N
groups NNS N
. . N

In IN N
each DT N
arm NN N
, , N
two CD N
or CC N
more JJR N
courses NNS N
of IN N
chemotherapy NN N
( ( N
4-week JJ N
cycles NNS N
) ) N
were VBD N
performed VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
88 CD N
eligible JJ N
patients NNS N
, , N
four CD N
treated VBN N
with IN N
S-MEC NNP 1_i
therapy NN 1_i
and CC N
two CD N
treated VBN N
with IN N
I-MEC NNP 1_i
therapy NN N
showed VBD N
CR NNP N
. . N

The DT N
response NN 1_o
rates NNS 1_o
( ( 1_o
CR NNP 1_o
+ NNP 1_o
PR NNP 1_o
) ) 1_o
were VBD N
52 CD N
% NN N
( ( N
15/29 CD N
) ) N
with IN N
S-MEC NNP 1_i
therapy NN 1_i
, , N
76 CD N
% NN N
( ( N
22/29 CD N
) ) N
with IN N
I-MEC NNP 1_i
therapy NN N
and CC N
47 CD N
% NN N
( ( N
14/30 CD N
) ) N
with IN N
M-VAC NNP 1_i
therapy NN N
. . N

The DT N
response NN 1_o
rate NN 1_o
with IN 1_o
I-MEC NNP 1_o
therapy NN 1_o
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
with IN N
M-VAC NNP 1_i
therapy NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Although IN N
the DT N
incidence NN N
of IN N
leukopenia NN N
was VBD N
low JJ N
with IN N
I-MEC NNP 1_o
therapy NN 1_o
, , N
the DT N
incidence NN N
of IN N
thrombocytopenia NN 1_o
was VBD N
high JJ N
with IN N
this DT N
therapy NN N
. . N

CONCLUSION NNP N
MEC NNP 1_i
therapy NN 1_i
used VBN N
in IN N
this DT N
study NN N
is VBZ N
promising VBG N
in IN N
terms NNS N
of IN N
the DT N
antitumor NN 1_o
effects NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Improving VBG N
peer NN 1_o
engagement NN 1_o
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
on IN 1_p
the DT 1_p
school NN 1_p
playground NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
test VB N
the DT N
effects NNS N
of IN N
a DT N
psychosocial JJ 1_i
intervention NN 1_i
, , 1_i
Remaking VBG 1_i
Recess NNP 1_i
, , N
on IN N
peer NN N
engagement NN N
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

Using VBG N
a DT N
randomized VBN N
, , N
wait-list-controlled JJ N
design NN N
, , N
the DT N
intervention NN N
was VBD N
implemented VBN N
during IN N
recess NN N
at IN N
four CD 1_p
elementary JJ 1_p
schools NNS 1_p
. . 1_p

The DT N
immediate JJ 1_i
treatment NN 1_i
( ( 1_i
IT NNP 1_i
) ) 1_i
group NN 1_p
consisted VBD 1_p
of IN 1_p
13 CD 1_p
( ( 1_p
2 CD 1_p
female NN 1_p
) ) 1_p
elementary JJ 1_p
school NN 1_p
students NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
the DT 1_p
wait-list NN 1_i
( ( 1_i
WL NNP 1_i
) ) 1_i
group NN 1_i
contained VBD 1_p
11 CD 1_p
( ( 1_p
4 CD 1_p
female NN 1_p
) ) 1_p
students NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

All DT 1_p
of IN 1_p
the DT 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
were VBD N
fully RB N
included VBN N
in IN N
the DT N
general JJ N
education NN N
program NN N
. . N

Analyses VBZ N
revealed VBD N
that IN N
time NN 1_o
spent VBN 1_o
engaged VBN 1_o
with IN 1_o
peers NNS 1_o
was VBD 1_o
significantly RB 1_o
increased VBN 1_o
for IN N
the DT N
IT NNP N
group NN N
and CC N
maintained VBD N
over IN N
the DT N
follow-up JJ N
. . N

School NNP N
playground JJ N
staff NN N
in IN N
the DT N
IT NNP N
group NN N
showed VBD 1_o
increased JJ 1_o
behaviors NNS 1_o
aimed VBN 1_o
at IN 1_o
improving VBG 1_o
peer NN 1_o
engagement NN 1_o
for IN 1_o
children NNS 1_o
with IN 1_p
ASD NNP 1_p
compared VBN N
to TO N
playground VB N
staff NN N
at IN N
the DT N
WL NNP N
sites NNS N
. . N

These DT N
improvements NNS 1_o
did VBD 1_o
not RB 1_o
maintain VB 1_o
to TO N
follow-up JJ N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
low JJ N
dose NN N
, , N
brief JJ N
intervention NN N
can MD N
be VB N
beneficial JJ N
in IN N
increasing VBG N
peer NN 1_o
engagement NN 1_o
for IN 1_o
children NNS 1_o
with IN 1_o
autism NN 1_o
in IN N
inclusive JJ N
settings NNS N
, , N
but CC N
continued VBD N
support NN N
of IN N
playground JJ N
staff NN N
is VBZ N
likely JJ N
needed VBN N
. . N

-DOCSTART- -X- O O

Thermal JJ 1_i
welding VBG 1_i
versus NN 1_i
bipolar JJ 1_i
tonsillectomy NN 1_i
: : 1_i
a DT N
comparative JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
thermal JJ 1_i
welding VBG 1_i
tonsillectomy NN 1_i
( ( 1_i
TWT NNP 1_i
) ) 1_i
with IN 1_i
bipolar JJ 1_i
electrocautery NN 1_i
tonsillectomy NN 1_i
( ( 1_i
BET NNP 1_i
) ) 1_i
procedure NN 1_i
. . 1_i

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
on IN N
150 CD 1_p
consecutive JJ 1_p
adult NN 1_p
patients NNS 1_p
undergoing VBG 1_p
tonsillectomy NN 1_i
. . 1_i

Indications NNS 1_p
included VBD 1_p
chronic JJ 1_p
tonsillitis NN 1_p
and CC 1_p
obstructive JJ 1_p
sleep NN 1_p
apnea NN 1_p
syndrome NN 1_p
. . 1_p

Exclusion NN 1_p
criteria NNS 1_p
included VBD 1_p
peritonsillar JJ 1_p
abscess NN 1_p
history NN 1_p
, , 1_p
bleeding VBG 1_p
disorders NNS 1_p
, , 1_p
and CC 1_p
any DT 1_p
other JJ 1_p
procedure NN 1_p
together RB 1_p
with IN 1_p
tonsillectomy NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
TWT NNP 1_i
or CC N
BET NNP 1_i
groups NNS N
. . N

Intraoperative JJ 1_o
bleeding NN 1_o
, , 1_o
operative JJ 1_o
time NN 1_o
, , 1_o
postoperative JJ 1_o
pain NN 1_o
, , 1_o
complication NN 1_o
rates NNS 1_o
, , 1_o
and CC 1_o
return VB 1_o
to TO 1_o
normal JJ 1_o
diet JJ 1_o
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
In IN N
the DT N
TWT NNP 1_i
group NN N
there EX N
was VBD N
no DT N
measurable JJ N
intraoperative JJ 1_o
bleeding NN 1_o
, , N
while IN N
mean JJ 1_o
bleeding NN 1_o
for IN N
BET NNP 1_i
group NN N
was VBD N
16 CD N
mL NN N
. . N

No DT N
significant JJ N
difference NN N
regarding VBG N
mean JJ 1_o
operative JJ 1_o
time NN 1_o
was VBD N
noticed VBN N
. . N

Mean NNP 1_o
postoperative JJ 1_o
pain NN 1_o
score NN 1_o
and CC 1_o
mean JJ 1_o
time NN 1_o
for IN 1_o
return NN 1_o
to TO 1_o
normal JJ 1_o
diet JJ 1_o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TWT NNP 1_i
group NN N
. . N

Primary JJ 1_o
hemorrhage NN 1_o
occurred VBD N
in IN N
1 CD N
subject NN N
of IN N
the DT N
BET NNP 1_i
group NN N
. . N

Secondary JJ 1_o
postoperative JJ 1_o
hemorrhage NN 1_o
was VBD N
noticed VBN N
in IN N
1 CD N
subject NN N
of IN N
the DT N
TWT NNP 1_i
group NN N
and CC N
3 CD N
subjects NNS N
of IN N
the DT N
BET NNP 1_i
group NN N
. . N

CONCLUSION NNP N
Thermal NNP 1_i
welding VBG 1_i
tonsillectomy JJ 1_i
procedure NN 1_i
provides VBZ N
sufficient JJ N
hemostasis NN 1_o
, , N
lower JJR N
postoperative NN 1_o
pain NN 1_o
, , N
and CC N
quick JJ 1_o
return NN 1_o
to TO 1_o
normal JJ 1_o
diet JJ 1_o
. . 1_o

EBM JJ N
RATING NNP N
A-1b NNP N
. . N

-DOCSTART- -X- O O

Effects NNS 1_o
of IN N
telmisartan NN 1_i
and CC 1_i
enalapril NN 1_i
on IN N
renoprotection NN N
in IN N
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
chronic JJ 1_p
kidney NN 1_p
disease NN 1_p
. . 1_p

BACKGROUND NNP N
Blocking VBG N
the DT N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
angiotensin NN N
receptor NN N
blockers NNS N
or CC N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
protects VBZ N
against IN N
renal JJ N
injury NN N
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
kidney NN 1_p
disease NN 1_p
( ( 1_p
CKD NNP 1_p
) ) 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
chronic JJ N
effects NNS N
of IN N
telmisartan NN 1_i
and CC N
enalapril NN 1_i
on IN N
proteinuria NN N
, , N
urinary JJ 1_o
liver-type JJ 1_o
fatty JJ 1_o
acid-binding JJ 1_o
protein NN 1_o
( ( 1_o
L-FABP NNP 1_o
) ) 1_o
and CC N
endothelin $ 1_o
( ( 1_o
ET NNP 1_o
) ) 1_o
-1 NN 1_o
levels NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
mild JJ 1_p
CKD NNP 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty NNP 1_p
CKD NNP 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
renal JJ 1_p
insufficiency NN 1_p
( ( 1_p
20 CD 1_p
men NNS 1_p
and CC 1_p
10 CD 1_p
women NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
37 CD 1_p
years NNS 1_p
; : 1_p
estimated VBN 1_o
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
( ( 1_o
eGFR NN 1_o
) ) 1_o
> VBZ 1_p
60 CD 1_p
mL NN 1_p
min NN 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
and CC 1_p
blood NN 1_p
pressure NN 1_p
> VBZ 1_p
130/85 CD 1_p
mmHg NN 1_p
) ) 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
telmisartan NN 1_i
at IN 1_i
80 CD 1_i
mg NNS 1_i
day NN 1_i
( ( 1_i
-1 NN 1_i
) ) 1_i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
enalapril VBN 1_i
at IN 1_i
10 CD 1_i
mg NNS 1_i
day NN 1_i
( ( 1_i
-1 NN 1_i
) ) 1_i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

We PRP N
measured VBD N
blood NN 1_o
pressure NN 1_o
, , 1_o
serum JJ 1_o
creatinine NN 1_o
, , 1_o
eGFR NN 1_o
, , 1_o
urinary JJ 1_o
protein NN 1_o
, , 1_o
L-FABP NNP 1_o
and CC 1_o
ET-1 NNP 1_o
before IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
start NN N
of IN N
treatment NN N
. . N

RESULTS VB N
The DT N
blood NN 1_o
pressure NN 1_o
reduction NN 1_o
rate NN 1_o
was VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Urinary JJ 1_o
protein NN 1_o
, , 1_o
L-FABP NNP 1_o
and CC 1_o
ET-1 NNP 1_o
levels NNS 1_o
were VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
after IN N
treatment NN N
, , N
but CC N
the DT N
reduction NN 1_o
rates NNS 1_o
were VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
telmisartan NN 1_i
than IN N
in IN N
those DT N
receiving VBG N
enalapril NN 1_i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Estimated VBN N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
was VBD N
increased VBN N
similarly RB N
in IN N
both DT N
groups NNS N
at IN N
12 CD N
months NNS N
. . N

CONCLUSIONS NNP N
The DT N
study NN N
results NNS N
suggest VBP N
that IN N
telmisartan JJ 1_i
results NNS N
in IN N
a DT N
greater JJR N
reduction NN N
of IN N
urinary JJ 1_o
markers NNS 1_o
than IN N
does VBZ N
enalapril VB 1_i
and CC N
that IN N
this DT N
effect NN N
occurs VBZ N
by IN N
a DT N
mechanism NN N
independent JJ N
of IN N
blood NN N
pressure NN N
reduction NN N
. . N

It PRP N
would MD N
be VB N
needed VBN N
to TO N
investigate VB N
whether IN N
the DT N
differences NNS N
may MD N
be VB N
distinct JJ N
or CC N
not RB N
the DT N
same JJ N
when WRB N
other JJ N
dosages NNS N
are VBP N
used VBN N
. . N

-DOCSTART- -X- O O

Science NN N
to TO N
practice NN N
in IN N
underserved JJ N
communities NNS N
: : N
the DT N
effectiveness NN 1_o
of IN N
school NN 1_i
mental JJ 1_i
health NN 1_i
programming NN 1_i
. . 1_i

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
treatment NN 1_i
program NN 1_i
comprised VBN 1_i
of IN 1_i
several JJ 1_i
components NNS 1_i
based VBN 1_i
on IN 1_i
evidence-based JJ 1_i
treatments NNS 1_i
( ( 1_i
EBTs NNP 1_i
) ) 1_i
for IN 1_i
disruptive JJ 1_i
behavior NN 1_i
problems NNS 1_i
delivered VBN N
to TO N
youth VB 1_p
participating VBG 1_p
in IN 1_p
a DT 1_p
school NN 1_p
mental JJ 1_p
health NN 1_p
program NN 1_p
in IN 1_p
an DT 1_p
underserved JJ 1_p
community NN 1_p
in IN 1_p
the DT 1_p
Appalachian JJ 1_p
region NN 1_p
. . 1_p

Participants NNS N
were VBD N
117 CD 1_p
children NNS 1_p
in IN 1_p
kindergarten VBN 1_p
through IN 1_p
6th CD 1_p
grade NN 1_p
including VBG 1_p
91 CD 1_p
children NNS 1_p
( ( 1_p
78 CD 1_p
% NN 1_p
male NN 1_p
) ) 1_p
from IN 1_p
5 CD 1_p
schools NNS 1_p
who WP 1_p
were VBD 1_p
consecutively RB 1_p
referred VBN 1_p
to TO 1_p
the DT 1_p
intervention NN 1_i
program NN 1_i
and CC 1_p
26 CD 1_p
children NNS 1_p
( ( 1_p
73 CD 1_p
% NN 1_p
male NN 1_p
) ) 1_p
from IN 1_p
3 CD 1_p
schools NNS 1_p
in IN 1_p
which WDT 1_p
program NN 1_p
implementation NN 1_p
was VBD 1_p
delayed VBN 1_p
for IN 1_p
1 CD 1_p
year NN 1_p
. . 1_p

Treatment NNP N
outcome NN N
was VBD N
measured VBN N
via IN N
parent NN 1_o
and CC 1_o
teacher JJ 1_o
ratings NNS 1_o
of IN 1_o
child NN 1_o
symptoms NNS 1_o
and CC 1_o
functioning VBG 1_o
. . 1_o

The DT N
treatment NN N
condition NN N
resulted VBD N
in IN N
significant JJ N
reduction NN N
in IN N
hyperactivity/impulsivity NN 1_o
and CC 1_o
early JJ 1_o
aggressive JJ 1_o
and CC 1_o
delinquent JJ 1_o
behavior NN 1_o
, , 1_o
as RB 1_o
well RB 1_o
as IN 1_o
significant JJ 1_o
improvement NN 1_o
in IN 1_o
several JJ 1_o
other JJ 1_o
functional JJ 1_o
domains NNS 1_o
. . 1_o

Results VB N
suggest JJS N
that IN N
EBTs NNP 1_i
can MD N
retain VB N
their PRP$ N
effectiveness NN 1_o
when WRB N
transported VBN N
to TO N
a DT N
community NN N
context NN N
. . N

-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
of IN N
early JJ 1_i
discharge NN 1_i
after IN 1_p
uncomplicated JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

Out IN N
of IN N
383 CD 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( 1_p
MI NNP 1_p
) ) 1_p
patients NNS 1_p
aged VBN 1_p
below IN 1_p
70 CD 1_p
years NNS 1_p
, , 1_p
252 CD 1_p
( ( 1_p
66 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
judged VBN 1_p
after IN 1_p
the DT 1_p
third JJ 1_p
day NN 1_p
in IN 1_p
hospital NN 1_p
to TO 1_p
have VB 1_p
had VBN 1_p
uncomplicated VBN 1_p
infarctions NNS 1_p
. . 1_p

These DT N
patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
two CD N
groups NNS N
, , N
one CD 1_i
of IN 1_i
which WDT 1_i
was VBD 1_i
given VBN 1_i
treatment NN 1_i
for IN 1_i
8 CD 1_i
days NNS 1_i
and CC 1_i
the DT 1_i
other JJ 1_i
for IN 1_i
15 CD 1_i
days NNS 1_i
. . 1_i

No DT N
significant JJ N
differences NNS 1_o
in IN 1_o
mortality NN 1_o
, , 1_o
morbidity NN 1_o
or CC 1_o
incapacity NN 1_o
for IN 1_o
work NN 1_o
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
. . N

The DT N
findings NNS N
thus RB N
support VBP N
previous JJ N
conclusions NNS N
that WDT N
early RB 1_i
discharge VBP 1_i
from IN N
hospital NN N
after IN N
uncomplicated JJ N
MI NNP N
is VBZ N
not RB N
associated VBN N
with IN N
greater JJR N
risk NN N
for IN N
the DT N
patient NN N
than IN N
later RB N
discharge NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
chlorhexidine JJ 1_i
varnish NN 1_i
on IN N
the DT N
gingival NN 1_o
status NN 1_o
of IN 1_p
adolescents NNS 1_p
. . 1_p

The DT N
purpose NN N
of IN N
this DT N
blind NN N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
a DT N
two-stage JJ N
chlorhexidine NN 1_i
varnish NN 1_i
, , N
after IN N
three CD N
months NNS N
, , N
on IN N
the DT N
gingival NN 1_p
status NN 1_p
of IN 1_p
11- JJ 1_p
to TO 1_p
15-year-old JJ 1_p
children NNS 1_p
attending VBG 1_p
a DT 1_p
school NN 1_p
in IN 1_p
Rio NNP 1_p
de IN 1_p
Janeiro NNP 1_p
, , 1_p
Brazil NNP 1_p
. . 1_p

Subjects NNS N
participating VBG N
in IN N
the DT N
study NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
control VB 1_p
( ( 1_p
C NNP 1_p
) ) 1_p
and CC 1_p
treatment NN 1_p
( ( 1_p
T NNP 1_p
) ) 1_p
groups NNS 1_p
, , 1_p
n JJ 1_p
= NN 1_p
53 CD 1_p
and CC 1_p
n JJ 1_p
= NN 1_p
57 CD 1_p
, , N
respectively RB N
. . N

All DT N
subjects NNS 1_p
were VBD N
matched VBN 1_p
at IN 1_p
baseline NN 1_p
on IN 1_p
age NN 1_p
, , 1_p
salivary JJ 1_p
levels NNS 1_p
of IN 1_p
mutans NNS 1_p
streptococci VBP 1_p
, , 1_p
and CC 1_p
caries NNS 1_p
scores NNS 1_p
. . 1_p

After IN N
elimination NN N
of IN N
carious JJ N
lesions NNS N
, , N
a DT N
prophylaxis NN 1_i
was VBD N
given VBN N
to TO N
both DT N
groups NNS N
. . N

The DT N
chlorhexidine NN 1_i
varnish NN 1_i
was VBD N
then RB N
painted VBN N
on IN N
the DT N
entire JJ N
dentition NN N
of IN N
Group NNP N
T NNP N
subjects VBZ N
only RB N
. . N

Prior NNP N
to TO N
caries NNS N
elimination NN N
, , N
and CC N
again RB N
after IN N
three CD N
months NNS N
, , N
the DT N
gingival NN N
index NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
gingival NN 1_o
status NN 1_o
of IN N
study NN N
subjects NNS N
. . N

An DT N
average NN N
of IN N
106.6 CD N
+/- JJ N
8.9 CD N
and CC N
107.7 CD N
+/- JJ N
6.2 CD N
gingival NN N
sites NNS N
per IN N
subject NN N
( ( N
four CD N
sites NNS N
per IN N
tooth NN N
) ) N
in IN N
Groups NNP N
C NNP N
and CC N
T NNP N
, , N
respectively RB N
, , N
were VBD N
examined VBN N
by IN N
the DT N
same JJ N
calibrated JJ N
examiner NN N
on IN N
two CD N
occasions NNS N
. . N

For IN N
statistical JJ N
purposes NNS N
, , N
data NNS N
were VBD N
dichotomized VBN N
[ NNP N
( ( N
0,1 CD N
) ) N
( ( N
2,3 CD N
) ) N
] NN N
for IN N
the DT N
gingival JJ N
index NN N
. . N

Independent NNP N
t-tests NNS N
and CC N
paired VBN N
t-tests NNS N
were VBD N
used VBN N
to TO N
analyze VB N
the DT N
data NN N
. . N

The DT N
percentage NN 1_o
of IN 1_o
sites NNS 1_o
per IN 1_o
subject NN 1_o
with IN 1_o
scores NNS 1_o
of IN 1_o
two CD 1_o
or CC 1_o
three CD 1_o
at IN N
the DT N
baseline NN N
were VBD N
balanced VBN N
between IN N
study NN N
groups NNS N
( ( N
3.7 CD N
+/- JJ N
7.1 CD N
for IN N
T NNP N
; : N
1.8 CD N
+/- JJ N
3.2 CD N
for IN N
C NNP N
; : N
p VBZ N
= $ N
0.08 CD N
) ) N
. . N

After IN N
three CD N
months NNS N
, , N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
the DT N
average JJ N
percentage NN 1_o
of IN 1_o
sites NNS 1_o
with IN 1_o
scores NNS 1_o
of IN 1_o
two CD 1_o
or CC 1_o
three CD 1_o
was VBD N
demonstrated VBN N
in IN N
the DT N
T NNP N
group NN N
( ( N
0.7 CD N
+/- JJ N
2.4 CD N
, , N
T NNP N
, , N
p NN N
< VBD N
0.0001 CD N
; : N
1.3 CD N
+/- JJ N
3.0 CD N
, , N
C NNP N
, , N
p NN N
< NNP N
0.25 CD N
) ) N
. . N

The DT N
authors NNS N
concluded VBD N
that IN N
the DT N
application NN N
of IN N
a DT N
chlorhexidine NN 1_i
varnish NN 1_i
significantly RB N
improved VBD N
the DT N
gingival JJ 1_o
health NN 1_o
of IN N
T NNP N
subjects NNS N
for IN N
up IN N
to TO N
three CD N
months NNS N
. . N

A DT N
significant JJ N
improvement NN N
in IN N
the DT N
gingival NN 1_o
health NN 1_o
could MD N
not RB N
be VB N
demonstrated VBN N
in IN N
the DT N
C NNP N
group NN N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
sentinel NN N
lymph NN N
node JJ N
tumor NN N
burden NN N
on IN N
survival NN N
in IN N
melanoma NN 1_p
. . 1_p

BACKGROUND NNP N
Completion NNP 1_i
lymph NN 1_i
node NN 1_i
dissection NN 1_i
( ( 1_i
CLND NNP 1_i
) ) 1_i
is VBZ N
the DT N
standard JJ N
procedure NN N
for IN N
patients NNS 1_p
with IN 1_p
positive JJ 1_p
sentinel NNS 1_p
lymph NN 1_p
nodes NNS 1_p
( ( 1_p
SLN NNP 1_p
) ) 1_p
. . 1_p

With IN N
extensive JJ N
pathological JJ N
workup NN N
, , N
increased VBD N
numbers NNS N
of IN N
small JJ N
metastatic JJ N
deposits NNS N
are VBP N
detected VBN N
in IN N
SLN NNP N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
prognostic JJ N
significance NN N
of IN N
SLN NNP N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
= VBP N
0.2 CD N
mm NNS N
in IN N
patients NNS 1_p
treated VBN 1_p
in IN 1_p
a DT 1_p
referral JJ 1_p
cancer NN 1_p
center NN 1_p
in IN 1_p
Brazil NNP 1_p
. . 1_p

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
stage NN 1_p
I/II NNP 1_p
melanoma NN 1_p
, , 1_p
consecutively RB 1_p
submitted VBN 1_p
to TO 1_p
a DT 1_p
SLN NNP 1_i
procedure NN 1_i
by IN 1_p
the DT 1_p
same JJ 1_p
surgeon NN 1_p
from IN 1_p
2000 CD 1_p
to TO 1_p
2006 CD 1_p
, , 1_p
were VBD 1_p
evaluated VBN 1_p
. . 1_p

All DT N
positive JJ N
SLN NNP N
and CC N
randomly RB N
selected VBN N
negative JJ N
cases NNS N
were VBD N
reviewed VBN N
by IN N
two CD N
pathologists NNS N
. . N

Different NNP N
prognostic JJ N
factors NNS N
and CC N
SLN NNP N
tumor NN N
burden NN N
were VBD N
recorded VBN N
. . N

Additional JJ N
positive JJ N
non-SLN NN N
after IN N
CLND NNP N
, , N
and CC N
disease VB N
outcome NN N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Of IN N
381 CD 1_p
patients NNS 1_p
who WP 1_p
underwent VBP 1_p
SLN NNP 1_p
biopsy NN 1_p
, , 1_p
103 CD 1_p
( ( 1_p
27 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
positive JJ 1_p
. . 1_p

The DT N
mean/median JJ N
Breslow NNP N
tumor NN 1_o
thickness NN 1_o
in IN N
the DT N
overall JJ N
group NN N
was VBD N
3.4/2.0 CD N
mm NN N
and CC N
in IN N
the DT N
SLN NNP N
positive JJ N
patients NNS N
was VBD N
5.72/4.0 CD N
mm NN N
. . N

Among IN N
these DT N
patients NNS N
, , N
48 CD N
( ( N
47 CD N
% NN N
) ) N
had VBD N
metastatic JJ N
deposits NNS N
> VBP N
2 CD N
mm NN N
( ( N
macrometastasis NN N
) ) N
, , N
49 CD N
( ( N
47 CD N
% NN N
) ) N
had VBD N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
=2 VBP N
mm NNS N
but CC N
> $ N
0.2 CD N
mm NN N
( ( N
micrometastasis NN N
) ) N
, , N
and CC N
6 CD N
( ( N
6 CD N
% NN N
) ) N
had VBD N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
=0.2 VBP N
mm NNS N
( ( N
submicrometastasis NN N
) ) N
. . N

Additional JJ N
positive JJ N
non-SLN NNS N
were VBD N
detected VBN N
in IN N
29 CD N
% NN N
of IN N
patients NNS N
with IN N
macrometastasis NN N
, , N
in IN N
25 CD N
% NN N
of IN N
patients NNS N
with IN N
micrometastasis NN N
, , N
and CC N
in IN N
0 CD N
% NN N
of IN N
patients NNS N
with IN N
submicrometastases NNS N
. . N

At IN N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
the DT N
estimated VBN N
3-year JJ N
overall JJ N
survival NN N
was VBD N
92 CD N
% NN N
for IN N
negative JJ N
SLN NNP N
, , N
64 CD N
% NN N
for IN N
micrometastases NNS N
, , N
53 CD N
% NN N
for IN N
macrometastases NNS N
, , N
and CC N
100 CD N
% NN N
for IN N
submicrometastases NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
the DT N
present JJ N
study NN N
, , N
patients NNS N
with IN N
SLN NNP N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
=0.2 VBP N
mm NNS N
had VBD N
no DT N
additional JJ N
positive JJ N
non-SLNs NN N
, , N
and CC N
no DT N
recurrences NNS N
or CC N
deaths NNS N
were VBD N
recorded VBN N
, , N
suggesting VBG N
that IN N
their PRP$ N
prognosis NN N
is VBZ N
equivalent JJ N
to TO N
that DT N
of IN N
patients NNS N
with IN N
negative JJ N
SLN NNP N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
angiotensin JJ 1_i
II-receptor NNP 1_i
blocker NN 1_i
vs. FW N
dihydropiridine NN 1_i
calcium NN 1_i
channel NN 1_i
blocker NN 1_i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
with IN 1_p
hypertension NN 1_p
( ( N
J-RHYTHM NNP N
II NNP N
study NN N
) ) N
. . N

AIMS NNP N
Atrial NNP N
fibrillation NN N
( ( N
AF NNP N
) ) N
is VBZ N
a DT N
common JJ N
arrhythmia NN N
frequently RB N
associated VBN N
with IN N
hypertension NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
lowering VBG N
blood NN N
pressure NN N
by IN N
angiotensin JJ 1_i
II-receptor NNP 1_i
blockers NNS 1_i
( ( 1_i
ARB NNP 1_i
) ) 1_i
has VBZ N
more JJR N
beneficial JJ N
effects NNS N
than IN N
by IN N
conventional JJ 1_i
calcium NN 1_i
channel NN 1_i
blockers NNS 1_i
( ( 1_i
CCB NNP 1_i
) ) 1_i
on IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
with IN N
hypertension NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
Japanese JJ 1_p
Rhythm NNP 1_p
Management NNP 1_p
Trial NNP 1_p
II NNP 1_p
for IN 1_p
Atrial NNP 1_p
Fibrillation NNP 1_p
( ( 1_p
J-RHYTHM NNP 1_p
II NNP 1_p
study NN 1_p
) ) 1_p
is VBZ N
an DT N
open-label JJ N
randomized JJ N
comparison NN N
between IN N
an DT N
ARB NNP 1_i
( ( 1_i
candesartan NN 1_i
) ) 1_i
and CC N
a DT N
CCB NNP 1_i
( ( 1_i
amlodipine NN 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ N
AF NNP N
associated VBN N
with IN N
hypertension NN N
. . N

Using VBG N
daily JJ N
transtelephonic JJ 1_i
monitoring NN 1_i
, , N
we PRP N
examined VBD N
asymptomatic JJ N
and CC N
symptomatic JJ N
paroxysmal NN 1_o
AF NNP 1_o
episodes VBZ N
during IN N
a DT N
maximum JJ N
1 CD N
year NN N
treatment NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
difference NN 1_o
in IN 1_o
AF NNP 1_o
frequency NN 1_o
between IN N
the DT N
pre-treatment JJ N
period NN N
and CC N
the DT N
final JJ N
month NN N
of IN N
the DT N
follow-up NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
included VBD N
cardiovascular JJ 1_o
events NNS 1_o
, , 1_o
development NN 1_o
of IN 1_o
persistent JJ 1_o
AF NNP 1_o
, , 1_o
left VBD 1_o
atrial JJ 1_o
dimension NN 1_o
, , 1_o
and CC 1_o
quality-of-life NN 1_o
( ( 1_o
QOL NNP 1_o
) ) 1_o
. . 1_o

The DT 1_p
study NN 1_p
enrolled VBD 1_p
318 CD 1_p
patients NNS 1_p
( ( 1_p
66 CD 1_p
years NNS 1_p
, , 1_p
male/female JJ 1_p
219/99 CD 1_p
, , 1_p
158 CD 1_p
in IN 1_p
the DT 1_p
ARB NNP 1_i
group NN 1_p
and CC 1_p
160 CD 1_p
in IN 1_p
the DT 1_p
CCB NNP 1_i
group NN 1_p
) ) 1_p
treated VBD 1_p
at IN 1_p
48 CD 1_p
sites NNS 1_p
throughout IN 1_p
Japan NNP 1_p
. . 1_p

At IN 1_p
baseline NN 1_p
, , 1_p
the DT 1_p
frequency NN 1_o
of IN 1_o
AF NNP 1_o
episodes NNS 1_o
( ( 1_p
days/month NN 1_p
) ) 1_p
was VBD 1_p
3.8 CD 1_p
? . 1_p
5.0 CD 1_p
in IN 1_p
the DT 1_p
ARB NNP 1_p
group NN 1_p
vs. FW 1_p
4.8 CD 1_p
? . 1_p
6.3 CD 1_p
in IN 1_p
the DT 1_p
CCB NNP 1_p
group NN 1_p
( ( 1_p
not RB N
significant JJ N
) ) N
. . N

During IN N
the DT N
follow-up JJ 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
was VBD 1_o
significantly RB N
lower JJR N
in IN N
the DT N
CCB NNP N
group NN N
than IN N
in IN N
the DT N
ARB NNP N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT 1_o
AF NNP 1_o
frequency NN 1_o
decreased VBD 1_o
similarly RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
endpoint NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT 1_o
development NN 1_o
of IN 1_o
persistent JJ 1_o
AF NNP 1_o
, , 1_o
changes NNS 1_o
in IN 1_o
left JJ 1_o
atrial JJ 1_o
dimension NN 1_o
, , 1_o
occurrence NN 1_o
of IN 1_o
cardiovascular JJ 1_o
events NNS 1_o
, , 1_o
or CC 1_o
changes NNS 1_o
in IN 1_o
QOL NNP 1_o
. . 1_o

CONCLUSIONS NNP N
In IN N
patients NNS 1_p
with IN 1_p
paroxysmal JJ 1_p
AF NNP 1_p
and CC 1_p
hypertension NN 1_p
, , 1_p
treatment NN N
of IN N
hypertension NN N
by IN N
candesartan NN 1_i
did VBD 1_i
not RB N
have VB N
an DT N
advantage NN N
over RP 1_i
amlodipine NN 1_i
in IN 1_i
the DT N
reduction NN N
in IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
( ( N
umin JJ N
CTR NNP N
C000000427 NNP N
) ) N
. . N

-DOCSTART- -X- O O

p16 NN 1_o
( ( 1_o
INK4a NNP 1_o
) ) 1_o
Expression NN 1_o
does VBZ N
not RB N
predict VB N
the DT N
outcome NN N
of IN N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grade VBD N
2 CD N
. . N

Spontaneous JJ N
regression NN N
of IN N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grade VBD N
2 CD N
( ( N
CIN2 NNP N
) ) N
lesions NNS N
has VBZ N
been VBN N
recognized VBN N
since IN N
1955 CD N
, , N
but CC N
predictors NNS N
of IN N
this DT N
are VBP N
poorly RB N
understood JJ N
. . N

Among IN N
the DT N
predictive JJ N
markers NNS N
studied VBN N
, , N
p16 FW 1_i
( ( 1_i
INK4a NNP 1_i
) ) 1_i
has VBZ N
been VBN N
suggested VBN N
to TO N
be VB N
of IN N
some DT N
value NN N
in IN N
monitoring VBG N
the DT N
diagnosis NN N
of IN N
CIN2 NNP N
. . N

In IN N
this DT N
clinical JJ N
trial NN N
, , N
90 CD 1_p
Brazilian JJ 1_p
women NNS 1_p
, , 1_p
diagnosed VBD 1_p
to TO 1_p
CIN2 NNP 1_p
and CC 1_p
high-risk JJ 1_p
human JJ 1_p
papillomavirus NN 1_p
infection NN 1_p
, , 1_p
were VBD 1_p
randomized VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
of IN 1_p
equal JJ 1_p
size NN 1_p
: : 1_p
45 CD 1_p
women NNS 1_p
whose WP$ 1_p
lesions NNS 1_i
were VBD 1_i
excised VBN 1_i
and CC 1_p
45 CD 1_p
women NNS 1_p
subjected VBN 1_p
to TO 1_p
prospective JJ 1_i
follow-up NN 1_i
at IN 1_p
3-month JJ 1_p
intervals NNS 1_p
at IN 1_p
least JJS 1_p
for IN 1_p
1 CD 1_p
year NN 1_p
( ( 1_p
mean JJ 1_p
6.8 CD 1_p
months NNS 1_p
) ) 1_p
. . 1_p

p16 NN 1_o
( ( 1_o
INK4a NNP 1_o
) ) 1_o
expression NN 1_o
was VBD N
analyzed VBN N
in IN N
paraffin-embedded JJ N
sections NNS N
using VBG N
immunohistochemical JJ 1_i
staining NN 1_i
. . 1_i

Among IN N
the DT N
45 CD 1_p
women NNS 1_p
in IN N
the DT N
follow-up JJ N
group NN N
, , N
42 CD N
% NN N
experienced VBD N
spontaneous JJ N
regression NN N
, , N
11 CD N
% NN N
showed VBD N
persistence NN N
, , N
22 CD N
% NN N
progressed VBN N
to TO N
CIN3 NNP N
, , N
and CC N
20 CD N
% NN N
had VBD N
partial JJ N
regression NN N
to TO N
CIN1 NNP N
or CC N
ASCUS NNP N
( ( N
atypical JJ N
squamous JJ N
cell NN N
undetermined JJ N
signifiance NN N
) ) N
. . N

p16 NN 1_o
( ( 1_o
INK4a NNP 1_o
) ) 1_o
expression NN 1_o
was VBD N
detected VBN N
in IN N
68.9 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

In IN N
univariate JJ 1_o
survival NN 1_o
( ( 1_o
Cox NNP 1_o
) ) 1_o
analysis NN 1_o
, , N
no DT N
significant JJ N
difference NN N
in IN N
regression NN N
was VBD N
obtained VBN N
between IN N
p16 NN 1_i
( ( 1_i
INK4a NNP 1_i
) ) 1_i
-negative NN 1_i
and CC 1_i
-positive JJ 1_i
CIN2 NNP N
lesions NNS N
( ( N
adjusted VBN N
HR NNP N
= NNP N
1.1 CD N
; : N
95 CD N
% NN N
CI NNP N
0.6-2.0 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
p16 NN 1_o
( ( 1_o
INK4a NNP 1_o
) ) 1_o
expression NN 1_o
could MD N
be VB N
useful JJ N
in IN N
the DT N
diagnosis NN 1_o
of IN 1_o
CIN2 NNP 1_o
. . 1_o

However RB N
, , N
it PRP N
failed VBD N
to TO N
predict VB N
the DT N
outcome NN N
of IN N
CIN2 NNP 1_o
. . 1_o

Because IN N
of IN N
its PRP$ N
high JJ N
spontaneous JJ N
regression NN N
rate NN N
, , N
follow-up NN N
could MD N
be VB N
considered VBN N
as IN N
a DT N
management NN N
option NN N
of IN N
CIN2 NNP N
in IN N
young JJ N
and CC N
compliant JJ N
women NNS N
. . N

-DOCSTART- -X- O O

Erythema JJ 1_p
migrans NNS 1_p
: : 1_p
comparison NN N
of IN N
treatment NN N
with IN N
azithromycin NN 1_i
, , 1_i
doxycycline NN 1_i
and CC 1_i
phenoxymethylpenicillin NN 1_i
. . 1_i

Azithromycin NNP 1_i
, , 1_i
doxycycline NN 1_i
and CC 1_i
phenoxymethylpenicillin NN 1_i
were VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
study NN N
of IN N
64 CD 1_p
patients NNS 1_p
with IN 1_p
typical JJ 1_p
erythema NN 1_p
migrans NNS 1_p
. . 1_p

Twenty CD N
patients NNS N
were VBD N
treated VBN N
with IN N
oral JJ 1_i
azithromycin NN 1_i
, , N
250 CD N
mg NN N
bd NN N
for IN N
two CD N
days NNS N
followed VBN N
by IN N
250 CD N
mg NNS N
od NN N
for IN N
eight CD N
days NNS N
, , N
21 CD N
patients NNS N
were VBD N
given VBN N
phenoxymethylpenicillin $ 1_i
1 CD N
million CD N
IU NNP N
tds NN N
for IN N
14 CD N
days NNS N
and CC N
23 CD N
patients NNS N
received JJ N
doxycycline NN 1_i
, , N
100 CD N
mg NN N
bd NN N
for IN N
14 CD N
days NNS N
. . N

All DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
24 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
persistence NN N
of IN N
cutaneous JJ 1_o
lesions NNS 1_o
after IN N
starting VBG N
treatment NN N
; : N
the DT N
mean JJ 1_o
durations NNS 1_o
were VBD N
10.5 CD N
days NNS N
in IN N
the DT N
penicillin NN 1_i
group NN N
, , N
8.8 CD N
days NNS N
in IN N
the DT N
doxycycline NN 1_i
group NN N
and CC N
8.6 CD N
days NNS N
in IN N
the DT N
azithromycin NN 1_i
group NN N
. . N

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
the DT N
resolution NN 1_o
of IN 1_o
associated JJ 1_o
local JJ 1_o
and/or NN 1_o
systemic NN 1_o
symptoms NNS 1_o
. . 1_o

The DT N
response NN 1_o
time NN 1_o
was VBD N
shortest VBN N
in IN N
patients NNS N
treated VBN N
with IN N
azithromycin NN 1_i
. . 1_i

Two CD N
patients NNS N
who WP N
received VBD N
phenoxymethylpenicillin NN 1_i
and CC N
two CD N
given VBN N
doxycycline VBP 1_i
subsequently RB N
developed VBN N
major JJ N
manifestations NNS N
of IN N
Lyme NNP 1_o
borreliosis NN 1_o
; : 1_o
these DT N
did VBD N
not RB N
occur VB N
in IN N
patients NNS N
receiving VBG N
azithromycin RB 1_i
. . 1_i

Although IN N
azithromycin NN 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
erythema NN N
migrans NNS N
, , N
further JJ N
studies NNS N
will MD N
be VB N
needed VBN N
to TO N
determine VB N
the DT N
optimal JJ N
dosage NN N
and CC N
duration NN N
of IN N
therapy NN N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
study NN N
on IN N
the DT N
activity NN N
of IN N
plafibride NN 1_i
in IN N
the DT N
treatment NN N
of IN N
type NN 1_p
IV NNP 1_p
hyperlipoproteinemia NN 1_p
. . 1_p

The DT N
effects NNS N
of IN N
a DT N
new JJ N
drug NN N
, , N
N-2- NNP 1_i
( ( 1_i
p-chlorophenoxy JJ 1_i
) ) 1_i
-isobutyryl-N'-morpholinomethylurea NN 1_i
( ( 1_i
plafibride NN 1_i
, , 1_i
ITA NNP 1_i
104 CD 1_i
) ) 1_i
, , N
were VBD N
studied VBN N
in IN N
a DT N
double JJ N
blind NN N
study NN N
lasting VBG N
four CD N
months NNS N
on IN N
a DT N
group NN 1_p
of IN 1_p
30 CD 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
type NN 1_p
IV NNP 1_p
hyperlipoproteinemia NN 1_p
. . 1_p

In IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
active JJ N
drug NN N
significant JJ N
reductions NNS N
in IN N
blood NN 1_o
triglycerides NNS 1_o
were VBD N
obtained VBN N
, , N
with IN N
a DT N
trend NN N
to TO N
normal JJ N
. . N

Reduction NN N
in IN N
blood NN 1_o
cholesterol NN 1_o
was VBD N
inconsistent JJ N
and CC N
not RB N
significant JJ N
. . N

As IN N
for IN N
the DT N
lipoproteinogram NN N
, , N
a DT N
tendency NN N
towards IN N
a DT N
decrease NN N
in IN N
the DT N
pre-beta-lipoprotein JJ 1_o
fraction NN 1_o
was VBD N
observed VBN N
and CC N
so RB N
was VBD N
a DT N
non-significant JJ N
tendency NN N
towards IN N
an DT N
increase NN N
in IN N
the DT N
alpha- JJ N
and CC N
beta-lipoprotein JJ N
fractions NNS N
. . N

Studies NNS N
on IN N
the DT N
platelet NN N
functioning NN N
showed VBD N
an DT N
obvious JJ N
decrease NN N
in IN N
platelet NN 1_o
aggregation NN 1_o
in IN N
those DT N
patients NNS N
treated VBN N
with IN N
the DT N
active JJ N
drug NN N
. . N

This DT N
was VBD N
very RB N
evident JJ N
for IN N
the DT N
ADP NNP N
and CC N
adrenaline JJ N
inductors NNS N
and CC N
rather RB N
less RBR N
significant JJ N
for IN N
collagen NN N
. . N

Neither CC N
platelet NN 1_o
adhesiveness NN 1_o
nor CC 1_o
aggregation NN 1_o
rate NN 1_o
changed VBN N
. . N

Tolerance NN 1_o
of IN N
the DT N
drug NN N
was VBD N
generally RB N
excellent JJ N
. . N

In IN N
one CD N
patient NN N
a DT N
decrease NN N
in IN N
some DT N
palpebral JJ 1_o
xanthelasmas NN 1_o
was VBD N
observed VBN N
after IN N
two CD N
months NNS N
of IN N
treatment NN N
with IN N
the DT N
active JJ N
drug NN N
. . N

In IN N
only RB N
one CD N
case NN N
there EX N
was VBD N
heartburn NN 1_o
and CC N
this DT N
was VBD N
corrected VBN N
with IN N
alkalines NNS N
. . N

In IN N
one CD N
other JJ N
case NN N
an DT N
urticarial JJ 1_o
rash NN 1_o
appeared VBD N
, , N
but CC N
disappeared VBD N
spontaneously RB N
when WRB N
the DT N
drug NN N
was VBD N
temporarily RB N
stopped VBN N
and CC N
did VBD N
not RB N
reappear VB N
when WRB N
it PRP N
was VBD N
administered VBN N
again RB N
. . N

During IN N
the DT N
trial NN N
no DT N
evidence NN N
of IN N
renal JJ 1_o
, , 1_o
hepatic JJ 1_o
or CC 1_o
hematological JJ 1_o
malfunctions NNS 1_o
were VBD N
observed VBN N
. . N

However RB N
, , N
a DT N
slight JJ N
tendency NN N
towards IN N
an DT N
increase NN N
in IN N
the DT N
GOT NNP 1_o
, , 1_o
GPT NNP 1_o
and CC 1_o
LDH NNP 1_o
was VBD N
observed VBN N
, , N
which WDT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

The DT N
drug NN N
tested VBD N
may MD N
be VB N
very RB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
type NN 1_o
IV NNP 1_o
hyperlipoproteinemia NN 1_o
, , N
especially RB N
in IN N
those DT N
forms NNS N
in IN N
which WDT N
an DT N
increase NN N
in IN N
thromboembolic JJ 1_o
risk NN 1_o
is VBZ N
suspected VBN N
, , N
either RB N
associated VBN N
with IN N
, , N
or CC N
secondary JJ N
to TO N
, , N
the DT N
actual JJ N
atherosclerotic JJ N
disease NN N
. . N

-DOCSTART- -X- O O

Utility NN N
of IN N
the DT N
bladder NN 1_i
flap NN 1_i
at IN N
cesarean JJ 1_i
delivery NN 1_i
: : 1_i
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
omission NN N
of IN N
the DT N
bladder NN 1_i
flap NN 1_i
in IN N
primary JJ 1_p
and CC 1_p
repeat JJ 1_p
cesarean JJ 1_i
deliveries NNS 1_i
shortens VBZ N
operating VBG N
time NN N
without IN N
increasing VBG N
intraoperative JJ N
and CC N
postoperative JJ N
complications NNS N
. . N

METHODS NNP N
We PRP N
randomized VBD N
258 CD 1_p
women NNS 1_p
undergoing VBG 1_p
primary JJ 1_i
and CC 1_i
repeat JJ 1_i
cesarean JJ 1_i
deliveries NNS 1_i
at IN 1_p
32 CD 1_p
weeks NNS 1_p
of IN 1_p
gestation NN 1_p
or CC 1_p
more JJR 1_p
to TO 1_p
creation NN 1_i
( ( 1_p
n=131 JJ 1_p
) ) 1_p
or CC 1_p
omission NN 1_i
( ( 1_p
n=127 JJ 1_p
) ) 1_p
of IN 1_p
the DT 1_p
bladder NN 1_p
flap NN 1_p
. . 1_p

Emergency NNP N
cesarean JJ N
deliveries NNS N
, , N
planned VBD N
vertical JJ N
uterine NN N
incisions NNS N
, , N
and CC N
previous JJ N
abdominal JJ 1_i
surgeries NNS 1_i
besides IN N
cesarean JJ 1_i
deliveries NNS 1_i
were VBD N
excluded VBN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
total JJ 1_o
operating NN 1_o
time NN 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
were VBD N
bladder JJ 1_o
injury NN 1_o
, , 1_o
incision-to-delivery JJ 1_o
time NN 1_o
, , 1_o
incision-to-fascial JJ 1_o
closure NN 1_o
time NN 1_o
, , 1_o
estimated VBN 1_o
blood NN 1_o
loss NN 1_o
, , 1_o
postoperative JJ 1_o
microhematuria NN 1_o
, , 1_o
postoperative JJ 1_o
pain NN 1_o
, , 1_o
hospital NN 1_o
days NNS 1_o
, , 1_o
endometritis NN 1_o
, , 1_o
and CC 1_o
urinary JJ 1_o
tract NN 1_o
infection NN 1_o
. . 1_o

Analysis NN N
followed VBD N
the DT N
intention-to-treat JJ N
principle NN N
. . N

RESULTS VB N
The DT N
median JJ 1_o
skin NN 1_o
incision NN 1_o
to TO 1_o
delivery NN 1_o
interval NN 1_o
was VBD N
shorter JJR N
with IN N
omission NN 1_i
of IN 1_i
the DT 1_i
bladder NN 1_i
flap NN 1_i
( ( N
9 CD N
[ NN N
range NN N
1-43 JJ N
] NNS N
compared VBN N
with IN N
10 CD N
[ JJ N
range NN N
2-70 JJ N
] NNP N
minutes NNS N
; : N
P=.04 NNP N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
total JJ 1_o
operating NN 1_o
time NN 1_o
( ( N
51 CD N
[ NN N
range NN N
18-124 JJ N
] NNP N
minutes NNS N
compared VBN N
with IN N
51 CD N
[ JJ N
range NN N
16-178 JJ N
] NN N
; : N
P=.10 NNP N
) ) N
. . N

No DT N
bladder NN 1_o
injuries NNS 1_o
occurred VBD N
in IN N
either DT N
group NN N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
estimated VBN 1_o
blood NN 1_o
loss NN 1_o
, , 1_o
change NN 1_o
in IN 1_o
hemoglobin JJ 1_o
level NN 1_o
, , 1_o
postoperative JJ 1_o
microhematuria NN 1_o
, , 1_o
postoperative JJ 1_o
pain NN 1_o
, , 1_o
hospital NN 1_o
days NNS 1_o
, , 1_o
endometritis NN 1_o
, , 1_o
or CC 1_o
urinary JJ 1_o
tract NN 1_o
infection NN 1_o
. . 1_o

CONCLUSION NNP N
Omission NNP N
of IN N
the DT N
bladder NN N
flap NN N
at IN N
primary JJ N
and CC N
repeat JJ N
cesarean JJ N
deliveries NNS N
does VBZ N
not RB N
increase VB N
intraoperative JJ N
or CC N
postoperative JJ N
complications NNS N
. . N

Incision-to-delivery JJ N
time NN N
is VBZ N
shortened VBN N
but CC N
total JJ N
operating NN N
time NN N
appears VBZ N
unchanged JJ N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
, , N
www.ClinicalTrials.gov NN N
, , N
NCT00918996 NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
I PRP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
direct JJ 1_i
current JJ 1_i
pulse NN 1_i
stimulating VBG 1_i
acupoints NNS 1_i
of IN 1_i
JiaJi NNP 1_i
( ( N
T10-13 NNP N
) ) N
and CC N
Ciliao NNP N
( ( N
BL NNP N
32 CD N
) ) N
with IN N
Han NNP 1_i
's POS 1_i
Acupoint NNP 1_i
Nerve NNP 1_i
Stimulator NNP 1_i
on IN N
labour NN 1_o
pain NN 1_o
in IN 1_p
women NNS 1_p
: : 1_p
a DT N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
clinical JJ N
effect NN N
and CC N
safety NN N
of IN N
direct JJ 1_i
current JJ 1_i
( ( 1_i
DC NNP 1_i
) ) 1_i
pulse NN 1_i
produced VBN 1_i
by IN 1_i
Han NNP 1_i
's POS 1_i
Acupoint NNP 1_i
Nerve NNP 1_i
Stimulator NNP 1_i
in IN N
reduction NN N
( ( N
HANS NNP N
) ) N
of IN N
labor NN 1_o
pain NN 1_o
. . 1_o

METHODS NNP N
Totally RB N
120 CD 1_p
participants NNS 1_p
were VBD N
enrolled VBN N
in IN N
this DT N
clinical JJ N
trial NN N
, , N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
including VBG N
: : N
HANS NNP 1_i
group NN 1_i
, , 1_i
patient NN 1_i
controlled VBD 1_i
intravenous JJ 1_i
analgesia NN 1_i
( ( 1_i
PCIA NNP 1_i
) ) 1_i
group NN 1_i
, , 1_i
patient-controlled JJ 1_i
epidural JJ 1_i
analgesia NN 1_i
( ( 1_i
PCEA NNP 1_i
) ) 1_i
group NN N
and CC N
control NN N
group NN N
. . N

The DT N
HANS NNP 1_i
group NN N
was VBD N
treated VBN N
by IN N
stimulating VBG N
the DT N
acupoints NNS 1_i
of IN 1_i
JiaJi NNP 1_i
( ( N
T10-L3 NNP N
) ) N
and CC N
Ciliao NNP 1_i
( ( N
BL NNP N
32 CD N
) ) N
with IN N
DC NNP 1_i
pulse NN 1_i
of IN N
100 CD N
Hz NNP N
and CC N
15-30 JJ N
mA NN N
produced VBN N
by IN N
a DT N
portable JJ 1_i
battery-powered JJ 1_i
Han NNP 1_i
's POS 1_i
Acupoint NNP 1_i
Nerve NNP 1_i
Stimulator NNP 1_i
for IN N
30 CD N
min NN N
. . N

The DT N
PCIA NNP 1_i
group NN N
was VBD N
intravenously RB N
infused VBN N
Ondansetron NNP 1_i
( ( N
8 CD N
mg NN N
) ) N
for IN N
5 CD N
min NNS N
, , N
then RB N
tramadol VB 1_i
injection NN 1_i
( ( N
1.5 CD N
mg/kg NN N
) ) N
was VBD N
slowly RB N
dripped VBN N
by IN N
using VBG N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
with IN N
50 CD N
mL NNS N
tramadol NN 1_i
( ( N
0.70 CD N
% NN N
) ) N
+ NN N
ondansetron NN 1_i
( ( N
8 CD N
mg NN N
) ) N
, , N
background JJ N
infusion NN N
2 CD N
mL/h NN N
, , N
PCA NNP N
dose NN N
of IN N
2 CD N
mL NNS N
, , N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
. . N

In IN N
PCEA NNP 1_i
group NN N
, , N
women NNS N
received VBD N
intrathecal JJ N
injection NN 1_i
ropivacaine NN 1_i
( ( N
3 CD N
mg NN N
) ) N
in IN N
L2-3 NNP N
, , N
and CC N
epidural JJ N
catheter NN N
was VBD N
connected VBN N
to TO N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
, , N
with IN N
100 CD N
mL NNS N
Ropivacaine NNP 1_i
( ( N
0.1 CD N
% NN N
) ) N
and CC N
Sufentanil NNP 1_i
( ( N
50 CD N
ug NN N
) ) N
, , N
background JJ N
infusion NN N
5 CD N
mL NN N
, , N
Patient NNP 1_i
controlled VBD 1_i
analgesia NN 1_i
( ( 1_i
PCA NNP 1_i
) ) 1_i
dose NN N
of IN N
5 CD N
mL NNS N
, , N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
. . N

The DT N
control NN N
group NN N
was VBD N
not RB N
received VBN N
analgesia NN N
. . N

The DT 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
, , 1_o
stage NN 1_o
and CC 1_o
manner NN 1_o
of IN 1_o
labor NN 1_o
, , 1_o
Apgar NNP 1_o
score NN 1_o
of IN 1_o
newborn JJ 1_o
, , 1_o
neonatal JJ 1_o
weights NNS 1_o
, , 1_o
oxytocin JJ 1_o
dosage NN 1_o
, , 1_o
postpartum NN 1_o
hemorrhage NN 1_o
and CC 1_o
side NN 1_o
effects NNS 1_o
were VBD N
monitored VBN N
in IN N
all DT N
groups NNS N
. . N

RESULTS VB N
The DT N
vital JJ N
signs NNS N
were VBD N
all DT N
stable JJ N
in IN N
the DT N
four CD N
analgesic JJ N
groups NNS N
. . N

After IN N
analgesia NN N
, , N
there EX N
was VBD N
statistical JJ N
difference NN N
in IN N
VAS NNP 1_o
score NN 1_o
between IN N
HANS NNP 1_i
group NN N
and CC N
control NN 1_i
group NN N
, , N
between IN N
PCEA NNP 1_i
group NN N
and CC N
the DT N
control NN 1_i
group NN N
, , N
between IN N
PCIA NNP 1_i
group NN N
and CC N
control NN 1_i
group NN N
. . N

The DT N
analgesic JJ 1_o
effect NN 1_o
in IN N
the DT N
PCEA NNP 1_i
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
that DT N
of IN N
other JJ N
two CD N
groups NNS N
. . N

The DT N
second JJ N
stage NN N
of IN N
labor NN N
in IN N
the DT N
PCEA NNP 1_i
group NN N
was VBD N
longer JJR N
than IN N
the DT N
other JJ N
three CD N
groups NNS N
, , N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
. . N

The DT N
Apgar NNP N
score NN N
of IN N
newborn JJ N
1 CD N
min NN N
after IN N
birth NN N
in IN N
the DT N
PCIA NNP 1_i
group NN N
was VBD N
slightly RB N
lower JJR N
than IN N
that DT N
of IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
. . N

The DT N
neonatal JJ 1_o
weights NNS 1_o
between IN N
four CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
rate NN 1_o
of IN 1_o
cesarean JJ 1_o
section NN 1_o
in IN N
the DT N
control NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
the DT N
labor NN N
analgesia NN N
group NN N
, , N
there EX N
was VBD N
statistically RB N
difference NN N
in IN N
four CD N
groups NNS N
. . N

The DT N
number NN N
of IN N
PCIA NNP 1_i
group NN N
that WDT N
used VBD 1_o
oxytocin NN 1_o
was VBD N
lower JJR N
than IN N
that DT N
of IN N
other JJ N
three CD N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
postpartum JJ 1_o
hemorrhage NN 1_o
between IN N
four CD N
groups NNS N
. . N

The DT N
side NN N
effects NNS N
of IN N
the DT N
PCEA NNP 1_i
group NN N
were VBD N
itching VBG 1_o
, , 1_o
uroschesis NN 1_o
and CC 1_o
neonatal JJ 1_o
asphyxia NN 1_o
and CC N
PCIA NNP 1_i
group NN N
were VBD N
nausea RB 1_o
and CC 1_o
vomiting VBG 1_o
and CC 1_o
neonatal JJ 1_o
asphyxia NN 1_o
. . 1_o

However RB N
, , N
fewer JJR N
side-effects NNS 1_o
were VBD N
observed VBN N
in IN N
the DT N
HANS NNP 1_i
group NN N
. . N

CONCLUSION NNP N
The DT N
DC NNP N
pulse NN N
produced VBN N
by IN N
HANS NNP 1_i
may MD N
be VB N
a DT N
non-pharmacological JJ N
alternative NN N
to TO N
labor NN N
pain NN N
with IN N
fewer JJR N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

Secondary JJ N
caries NNS N
formation NN N
in IN N
vitro NN N
around IN N
glass NN 1_p
ionomer-lined JJ 1_p
amalgam NN 1_p
and CC 1_p
composite JJ 1_p
restorations NNS 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
in IN N
vitro JJ N
secondary JJ N
caries NNS N
study NN N
was VBD N
to TO N
examine VB N
the DT N
glass-ionomer JJ 1_i
liner NN 1_i
's POS 1_i
effect NN N
on IN N
wall-lesion NN N
inhibition NN N
when WRB N
a DT N
conventional JJ N
and CC N
a DT N
light-cured JJ N
glass NN 1_i
ionomer NN 1_i
liner NN 1_i
was VBD N
placed VBN N
under IN N
amalgam NN 1_i
and CC N
composite JJ 1_i
resin NN 1_i
restorations NNS N
. . N

Class NNP N
V NNP N
preparations NNS N
in IN N
extracted JJ 1_p
upper JJ 1_p
premolars NNS 1_p
were VBD 1_p
used VBN 1_p
and CC 1_p
ten JJ 1_p
restorations NNS 1_p
were VBD 1_p
used VBN 1_p
for IN 1_p
each DT 1_p
of IN 1_p
the DT 1_p
following JJ 1_p
groups NNS 1_p
: : 1_p
( ( 1_i
i NN 1_i
) ) 1_i
two CD 1_i
layers NNS 1_i
of IN 1_i
copal JJ 1_i
varnish JJ 1_i
and CC 1_i
amalgam NN 1_i
; : 1_i
( ( 1_i
ii NN 1_i
) ) 1_i
conventional JJ 1_i
glass-ionomer JJ 1_i
and CC 1_i
amalgam NN 1_i
; : 1_i
( ( 1_i
iii NN 1_i
) ) 1_i
light-cured JJ 1_i
glass-ionomer NN 1_i
and CC 1_i
amalgam NN 1_i
; : 1_i
( ( 1_i
iv NN 1_i
) ) 1_i
bonding NN 1_i
agent NN 1_i
and CC 1_i
light-cured JJ 1_i
composite JJ 1_i
resin NN 1_i
; : 1_i
( ( 1_i
v NN 1_i
) ) 1_i
conventional JJ 1_i
glass-ionomer JJ 1_i
, , 1_i
bonding JJ 1_i
agent NN 1_i
and CC 1_i
light-cured JJ 1_i
composite JJ 1_i
resin NN 1_i
; : 1_i
( ( 1_i
vi NN 1_i
) ) 1_i
light-cured JJ 1_i
glass-ionomer NN 1_i
, , 1_i
extended VBD 1_i
0.3 CD 1_i
mm NN 1_i
short NN 1_i
of IN 1_i
the DT 1_i
enamel JJ 1_i
margin NN 1_i
bonding VBG 1_i
agent NN 1_i
and CC 1_i
light-cured JJ 1_i
composite JJ 1_i
resin NN 1_i
; : 1_i
and CC 1_i
( ( 1_i
vii NN 1_i
) ) 1_i
light-cured JJ 1_i
glass-ionomer NN 1_i
, , 1_i
extended VBD 1_i
1 CD 1_i
mm NN 1_i
short NN 1_i
of IN 1_i
the DT 1_i
enamel NN 1_i
margin NN 1_i
, , 1_i
bonding VBG 1_i
agent NN 1_i
and CC 1_i
light-cured JJ 1_i
composite JJ 1_i
resin NN 1_i
. . 1_i

The DT N
teeth NNS 1_p
were VBD N
thermocycled VBN N
and CC N
artificial JJ 1_i
caries NNS 1_i
were VBD N
created VBN N
using VBG N
an DT N
acid-gel NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
showed VBD N
that IN N
artificial JJ 1_o
recurrent NN 1_o
caries NNS 1_o
can MD N
be VB N
reduced VBN 1_o
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
a DT N
glass-ionomer JJ 1_i
liner NN 1_i
under IN 1_i
amalgam JJ 1_i
restorations NNS 1_i
. . 1_i

The DT N
results NNS N
also RB N
showed VBD N
that IN N
when WRB N
the DT N
light-cured JJ N
glass-ionomer JJ 1_i
liner NN N
was VBD N
placed VBN N
0.3 CD N
mm NN N
from IN N
the DT N
cavosurface NN N
margin NN N
under IN N
composite JJ N
resin NN N
restoration NN N
, , N
the DT N
artificial JJ 1_o
recurrent NN 1_o
caries NNS 1_o
reduced VBN 1_o
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

-DOCSTART- -X- O O

Veterans NNS 1_p
Affairs VBP 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
antiarrhythmic JJ N
trial NN N
. . N

CHF NNP N
STAT NNP N
Investigators NNP N
. . N

This DT N
is VBZ N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
antiarrhythmic JJ N
drug NN N
therapy NN N
on IN N
mortality NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
and CC 1_p
ventricular JJ 1_p
arrhythmia NN 1_p
. . 1_p

Patients NNS N
will MD N
be VB N
assigned VBN N
to TO N
receive VB N
either CC N
amiodarone VB 1_i
or CC 1_i
placebo VB 1_i
. . 1_i

Eligible JJ 1_p
patients NNS 1_p
include VBP 1_p
those DT 1_p
with IN 1_p
ischemic JJ 1_p
and CC 1_p
nonischemic JJ 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
and CC 1_p
with IN 1_p
> NNP 1_p
or CC 1_p
= $ 1_p
10 CD 1_p
ventricular JJ 1_p
premature NN 1_p
beats NNS 1_p
per IN 1_p
hour NN 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
must MD 1_p
have VB 1_p
shortness NN 1_p
of IN 1_p
breath NN 1_p
with IN 1_p
minimal JJ 1_p
exertion NN 1_p
or CC 1_p
paroxysmal JJ 1_p
nocturnal JJ 1_p
dyspnea NN 1_p
, , 1_p
a DT 1_p
left JJ 1_p
ventricular JJ 1_p
internal JJ 1_p
dimension NN 1_p
( ( 1_p
LVIDd NNP 1_p
) ) 1_p
by IN 1_p
echocardiogram NN 1_p
of IN 1_p
> NN 1_p
or CC 1_p
= $ 1_p
55 CD 1_p
mm NN 1_p
or CC 1_p
a DT 1_p
cardiothoracic JJ 1_p
ratio NN 1_p
of IN 1_p
> $ 1_p
0.5 CD 1_p
and CC 1_p
an DT 1_p
ejection NN 1_p
fraction NN 1_p
of IN 1_p
< NN 1_p
or CC 1_p
= VB 1_p
40 CD 1_p
% NN 1_p
. . 1_p

All DT N
patients NNS N
will MD N
receive VB N
vasodilator NN N
therapy NN N
, , N
unless IN N
they PRP N
find VBP N
it PRP N
intolerable JJ N
. . N

Patients NNS 1_p
will MD 1_p
be VB 1_p
entered VBN 1_p
into IN 1_p
the DT 1_p
study NN 1_p
for IN 1_p
2.5 CD 1_p
years NNS 1_p
and CC 1_p
followed VBD 1_p
for IN 1_p
an DT 1_p
additional JJ 1_p
2 CD 1_p
years NNS 1_p
. . 1_p

Drug NNP N
therapy NN N
will MD N
be VB N
continued VBN N
for IN N
all DT N
patients NNS N
throughout IN N
the DT N
entire JJ N
study NN N
unless IN N
adverse JJ N
reactions NNS N
occur VBP N
that IN N
necessitate JJ N
individualized JJ N
treatment NN N
. . N

The DT N
expectation NN N
is VBZ N
that IN N
674 CD 1_p
patients NNS 1_p
will MD 1_p
be VB 1_p
entered VBN 1_p
into IN 1_p
the DT 1_p
study NN 1_p
from IN 1_p
25 CD 1_p
participating VBG 1_p
centers NNS 1_p
. . 1_p

This DT N
sample JJ N
size NN N
will MD N
allow VB N
for IN N
the DT N
detection NN N
of IN N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
2-year JJ 1_o
mortality NN 1_o
( ( N
20 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
patients NNS N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
a DT N
power NN N
of IN N
0.90 CD N
and CC N
a DT N
2-sided JJ N
alpha JJ N
level NN N
of IN N
0.05 CD N
. . N

Intermittent JJ N
Holter NNP N
monitoring NN N
, , N
radionuclide JJ N
ventriculograms NN N
, , N
pulmonary JJ N
function NN N
tests NNS N
, , N
echocardiograms NNS N
, , N
and CC N
blood NN N
tests NNS N
, , N
including VBG N
arterial JJ N
blood NN N
gases NNS N
, , N
will MD N
be VB N
required VBN N
for IN N
each DT N
patient NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Atrial NNP 1_o
remodeling NN 1_o
after IN N
mitral JJ 1_i
valve NN 1_i
surgery NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
permanent JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
. . 1_p

BACKGROUND NNP N
Mitral NNP N
valve NNP N
pathology NN N
is VBZ N
frequently RB N
associated VBN N
with IN N
auricular JJ N
dilatation NN N
and CC N
atrial JJ N
fibrillation NN N
. . N

Mitral JJ 1_i
surgery NN 1_i
allows VBZ N
an DT N
immediate JJ N
surgical JJ N
auricular NN N
remodeling NN N
and CC N
besides NNS N
in IN N
those DT N
cases NNS N
in IN N
which WDT N
sinus NN N
rhythm NN N
is VBZ N
reached VBN N
, , N
it PRP N
is VBZ N
followed VBN N
by IN N
a DT N
late JJ N
remodeling NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
process NN N
of IN N
postoperative JJ N
auricular JJ N
remodeling VBG N
in IN N
patients NNS 1_p
with IN 1_p
permanent JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
undergoing VBG 1_p
mitral JJ 1_i
surgery NN 1_i
. . 1_i

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
, , N
50 CD 1_p
patients NNS 1_p
with IN 1_p
permanent JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
and CC 1_p
dilated VBD 1_p
left JJ 1_p
atrium NN 1_p
, , 1_p
submitted VBN 1_p
to TO 1_p
surgical JJ 1_p
mitral JJ 1_p
repair NN 1_p
, , N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Group NNP 1_i
I PRP 1_i
contained VBD 1_i
25 CD 1_i
patients NNS 1_i
with IN 1_i
left JJ 1_i
auricular JJ 1_i
reduction NN 1_i
and CC 1_i
mitral JJ 1_i
surgery NN 1_i
, , 1_i
and CC 1_i
Group NNP 1_i
II NNP 1_i
contained VBD 1_i
25 CD 1_i
patients NNS 1_i
with IN 1_i
isolated JJ 1_i
valve NN 1_i
surgery NN 1_i
. . 1_i

Both DT N
groups NNS N
were VBD N
considered VBN N
homogeneous JJ N
in IN N
the DT N
preoperative JJ N
assessment NN N
. . N

RESULTS NNP N
After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
31 CD N
months NNS N
, , N
46 CD N
% NN N
of IN N
patients NNS N
included VBN N
in IN N
Group NNP N
I PRP N
versus VBP N
18 CD N
% NN N
of IN N
patients NNS N
included VBN N
in IN N
Group NNP N
II NNP N
restarted VBD N
sinus JJ 1_o
rhythm NN 1_o
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

An DT N
auricular JJ 1_o
remodeling NN 1_o
with IN 1_o
size NN 1_o
regression NN 1_o
occurred VBD N
in IN N
those DT N
patients NNS N
who WP N
recovered VBD N
from IN N
sinus NN N
rhythm NN N
, , N
worthy NN N
of IN N
remark NN N
in IN N
Group NNP N
II NNP N
( ( N
-10.8 CD N
% NN N
of IN N
left JJ N
auricular JJ N
volume NN N
reduction NN N
in IN N
Group NNP N
I PRP N
compared VBN N
to TO N
-21.5 VB N
% NN N
in IN N
Group NNP N
II NNP N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

A DT N
new JJ 1_o
atrial JJ 1_o
enlargement NN 1_o
took VBD N
place NN N
in IN N
those DT N
patients NNS N
who WP N
remained VBD N
with IN N
atrial JJ N
fibrillation NN N
( ( N
+16.8 CD N
% NN N
left VBD N
auricular JJ N
volume NN N
in IN N
Group NNP N
I PRP N
vs. VBP N
+8.4 CD N
% NN N
in IN N
Group NNP N
II NNP N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mitral NNP N
surgery NN N
produces VBZ N
an DT N
atrial JJ N
postoperative NN N
volume NN N
that IN N
decrease NN N
especially RB N
when WRB N
reduction NN N
techniques NNS N
are VBP N
employed VBN N
. . N

Late JJ N
left VBD N
atrial JJ N
remodeling VBG N
depended VBN N
on IN N
the DT N
type NN N
of IN N
atrial JJ 1_o
rhythm NN 1_o
and CC N
postoperative JJ 1_o
surgical JJ 1_o
volume NN 1_o
. . 1_o

-DOCSTART- -X- O O

Pazopanib NNP 1_i
in IN N
locally RB 1_p
advanced JJ 1_p
or CC 1_p
metastatic JJ 1_p
renal NN 1_p
cell NN 1_p
carcinoma NN 1_p
: : 1_p
results NNS N
of IN N
a DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
Pazopanib NNP 1_i
is VBZ N
an DT N
oral JJ 1_i
angiogenesis NN 1_i
inhibitor NN 1_i
targeting VBG N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor NN N
, , N
platelet-derived JJ N
growth NN N
factor NN N
receptor NN N
, , N
and CC N
c-Kit NN N
. . N

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
phase NN N
III NNP N
study NN N
evaluated VBD N
efficacy NN N
and CC N
safety NN N
of IN N
pazopanib JJ 1_i
monotherapy NN 1_i
in IN N
treatment-naive JJ 1_p
and CC 1_p
cytokine-pretreated JJ 1_i
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
renal JJ 1_p
cell NN 1_p
carcinoma NN 1_p
( ( 1_p
RCC NNP 1_p
) ) 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Adult NNP 1_p
patients NNS 1_p
with IN 1_p
measurable JJ 1_p
, , 1_p
locally RB 1_p
advanced JJ 1_p
, , 1_p
and/or JJ 1_p
metastatic JJ 1_p
RCC NNP 1_p
were VBD N
randomly RB N
assigned VBN N
2:1 CD N
to TO N
receive VB 1_i
oral JJ 1_i
pazopanib NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
. . 1_o

Secondary JJ N
end NN N
points NNS N
included VBD N
overall JJ 1_o
survival NN 1_o
, , 1_o
tumor NN 1_o
response NN 1_o
rate NN 1_o
( ( 1_o
Response NNP 1_o
Evaluation NNP 1_o
Criteria NNP 1_o
in IN 1_o
Solid NNP 1_o
Tumors NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
safety NN 1_o
. . 1_o

Radiographic JJ N
assessments NNS N
of IN N
tumors NNS N
were VBD N
independently RB N
reviewed VBN N
. . N

Results NNS N
Of IN 1_p
435 CD 1_p
patients NNS 1_p
enrolled VBD 1_p
, , 1_p
233 CD 1_p
were VBD 1_p
treatment NN 1_p
naive JJ 1_p
( ( 1_p
54 CD 1_p
% NN 1_p
) ) 1_p
and CC 1_p
202 CD 1_p
were VBD 1_p
cytokine NN 1_p
pretreated VBN 1_p
( ( 1_p
46 CD 1_p
% NN 1_p
) ) 1_p
. . 1_p

PFS NNP 1_o
was VBD N
significantly RB N
prolonged VBN N
with IN N
pazopanib NNS 1_i
compared VBN N
with IN N
placebo NN 1_i
in IN N
the DT N
overall JJ N
study NN N
population NN N
( ( N
median JJ N
, , N
PFS NNP N
9.2 CD N
v NN N
4.2 CD N
months NNS N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.34 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
the DT N
treatment-naive JJ 1_i
subpopulation NN N
( ( N
median JJ N
PFS NNP N
11.1 CD N
v NN N
2.8 CD N
months NNS N
; : N
HR NNP N
, , N
0.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.60 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
and CC N
the DT N
cytokine-pretreated JJ N
subpopulation NN N
( ( N
median JJ N
PFS NNP N
, , N
7.4 CD N
v NN N
4.2 CD N
months NNS N
; : N
HR NNP N
, , N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.35 CD N
to TO N
0.84 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
objective JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
30 CD N
% NN N
with IN N
pazopanib NN 1_i
compared VBN N
with IN N
3 CD N
% NN N
with IN N
placebo NN 1_i
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
median JJ 1_o
duration NN 1_o
of IN 1_o
response NN 1_o
was VBD N
longer JJR N
than IN N
1 CD N
year NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
diarrhea RB 1_o
, , 1_o
hypertension NN 1_o
, , 1_o
hair NN 1_o
color NN 1_o
changes NNS 1_o
, , 1_o
nausea NN 1_o
, , 1_o
anorexia NN 1_o
, , 1_o
and CC 1_o
vomiting VBG 1_o
. . 1_o

There EX N
was VBD N
no DT N
evidence NN N
of IN N
clinically RB N
important JJ N
differences NNS N
in IN N
quality NN N
of IN N
life NN N
for IN N
pazopanib JJ 1_i
versus NN 1_i
placebo NN 1_i
. . 1_i

CONCLUSION NNP N
Pazopanib NNP 1_i
demonstrated VBD N
significant JJ N
improvement NN N
in IN N
PFS NNP N
and CC N
tumor NN N
response NN N
compared VBN N
with IN N
placebo NN 1_i
in IN N
treatment-naive JJ 1_p
and CC 1_p
cytokine-pretreated JJ 1_i
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
and/or NNS 1_p
metastatic JJ 1_p
RCC NNP 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
efficiency NN N
of IN N
cytokines NNS 1_i
in IN N
prophylactics NNS N
and CC N
treatment NN N
of IN N
infectious JJ 1_p
and CC 1_p
inflammatory JJ 1_p
complications NNS 1_p
after IN 1_p
oral JJ 1_p
surgery NN 1_p
procedures NNS 1_p
] VBP 1_p
. . N

The DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
prevention NN 1_p
and CC 1_p
treatment NN 1_p
of IN 1_p
infectious JJ 1_p
and CC 1_p
inflammatory JJ 1_p
complications NNS 1_p
after IN 1_p
oral JJ 1_p
surgery NN 1_p
procedures NNS 1_p
. . 1_p

Combined VBN 1_i
therapy NN 1_i
with IN 1_i
antibiotics NNS 1_i
and CC 1_i
superlimf NN 1_i
promotes VBZ N
a DT N
more RBR N
rapid JJ N
reduction NN 1_o
in IN N
the DT N
duration NN 1_o
of IN 1_o
clinical JJ 1_o
symptoms NNS 1_o
and CC 1_o
duration NN 1_o
of IN 1_o
treatment NN 1_o
than IN N
monotherapy NN 1_i
with IN 1_i
antibiotics NNS 1_i
. . 1_i

Results NNS N
of IN N
the DT N
study NN N
substantiate VBP N
the DT N
feasibility NN N
of IN N
using VBG N
superlimf NN 1_i
in IN N
outpatient JJ 1_p
oral JJ N
surgical JJ N
procedures NNS N
for IN N
infectious JJ N
and CC N
inflammatory JJ N
complications NNS N
treatment NN N
. . N

-DOCSTART- -X- O O

Tissue NN N
microarray NN N
in IN N
a DT N
subset NN N
of IN N
South JJ 1_p
African JJ 1_p
patients NNS 1_p
with IN 1_p
DLBCL NNP 1_p
. . 1_p

Tissue NN N
samples NNS N
from IN N
93 CD 1_p
de NNS 1_p
novo FW 1_p
diffuse RB 1_p
large JJ 1_p
B-cell NNP 1_p
lymphoma NN 1_p
patients NNS 1_p
seen VBN 1_p
between IN 1_p
1995 CD 1_p
and CC 1_p
2009 CD 1_p
randomly NN 1_p
receiving VBG 1_p
either CC 1_p
standard JJ 1_i
combination NN 1_i
chemotherapy NN 1_i
( ( 1_i
CHOP NNP 1_i
, , 1_p
n=48 NN 1_p
) ) 1_p
or CC 1_i
the DT 1_i
identical JJ 1_i
program NN 1_i
with IN 1_i
rituximab NN 1_i
( ( 1_p
n=45 JJ 1_p
) ) 1_p
were VBD N
subtyped VBN N
using VBG N
an DT N
investigational JJ N
immunohistochemical NN N
( ( N
IHC NNP N
) ) N
based VBN N
tissue NN N
microarray NN N
( ( N
TMA NNP N
) ) N
and CC N
contrasted VBN N
to TO N
the DT N
approximately RB N
corresponding JJ N
categories NNS N
as IN N
defined VBN N
either CC N
by IN N
Hans NNPS N
and CC N
associates NNS N
using VBG N
a DT N
three CD N
marker NN N
panel NN N
into IN N
germinal JJ N
or CC N
non-germinal JJ N
centre NN N
subtypes NNS N
or CC N
by IN N
Choi NNP N
and CC N
colleagues NNS N
with IN N
two CD N
additional JJ N
antibodies NNS N
into IN N
germinal JJ N
centre NN N
( ( N
GCB NNP N
) ) N
or CC N
activated VBN N
B-cells NNP N
( ( N
ABC NNP N
) ) N
. . N

Each DT N
of IN N
these DT N
primary JJ N
subdivisions NNS N
was VBD N
further RBR N
evaluated VBN 1_o
for IN 1_o
expression NN 1_o
of IN 1_o
BCL2 NNP 1_o
and CC 1_o
LMO2 NNP 1_o
both DT N
of IN N
which WDT N
are VBP N
recognised VBN N
to TO N
predicate VB N
response NN N
. . N

The DT N
addition NN N
of IN N
rituximab NN N
to TO N
the DT N
uniform JJ N
drug NN N
regimen NNS N
did VBD N
not RB N
show VB N
any DT N
significant JJ N
improvement NN N
in IN N
5 CD N
years NNS N
overall JJ 1_o
( ( N
63 CD N
% NN N
versus IN N
59 CD N
% NN N
, , N
p RB N
0.68 CD N
) ) N
or CC 1_o
event-free JJ 1_o
survival NN 1_o
( ( N
42 CD N
% NN N
versus IN N
39 CD N
% NN N
, , N
p RB N
0.94 CD N
) ) N
, , N
for IN N
CHOP NNP N
versus NN N
R-CHOP NNP N
comparisons NNS N
. . N

Similarly RB N
no DT N
differences NNS N
were VBD N
evident JJ N
in IN N
subtype JJ N
analysis NN N
. . N

Interestingly RB N
however RB N
, , N
when WRB N
segregated VBN N
on IN N
the DT N
Choi NNP N
criteria NNS N
, , N
cytotoxic NN N
drugs NNS N
alone RB N
showed VBD N
a DT N
non-significant JJ N
trend NN N
in IN N
improved JJ N
survival NN N
( ( N
74 CD N
% NN N
versus IN N
55 CD N
% NN N
, , N
p RB N
0.32 CD N
) ) N
as RB N
well RB N
as IN N
event-free JJ N
survival NN N
( ( N
44 CD N
% NN N
versus IN N
40 CD N
% NN N
, , N
p RB N
0.42 CD N
) ) N
for IN N
the DT N
germinal JJ N
centre NN N
as IN N
opposed VBN N
to TO N
the DT N
activated VBN N
B-cell NNP N
subtype NN N
. . N

Nevertheless NNP N
not RB N
even RB N
a DT N
small JJ N
difference NN N
could MD N
be VB N
demonstrated VBN N
in IN N
the DT N
presence NN N
of IN N
the DT N
anti JJ N
CD NN N
20 CD N
monoclonal JJ N
antibody NN N
. . N

According VBG N
to TO N
Choi NNP N
, , N
both DT N
regimens NNS N
( ( N
chemotherapy NN N
or CC N
immunotherapy VB N
antibody NN N
) ) N
revealed VBD N
similar JJ N
results NNS N
to TO N
the DT N
Hans NNPS N
algorithm VBP N
on IN N
5 CD N
years NNS N
OS NNP N
as RB N
well RB N
as IN N
3 CD N
year NN N
EFS NNP N
when WRB N
comparing VBG N
GCB NNP N
versus NN N
ABC NNP N
or CC N
non-GCB JJ N
subgroups NNS N
. . N

BCL2 NNP N
and CC N
LMO2 NNP N
marker NNP N
expression NN N
of IN N
the DT N
respective JJ N
immunohistochemical JJ N
( ( N
IHC NNP N
) ) N
subtype NN N
, , N
despite IN N
small JJ N
sample NN N
size NN N
, , N
revealed VBD N
the DT N
following NN N
. . N

Analysis NN N
by IN N
Choi NNP N
criteria NNS N
on IN N
survival NN N
for IN N
BCL2 NNP N
, , N
no DT N
matter NN N
for IN N
which WDT N
subsets NNS N
( ( N
GCB NNP N
or CC N
ABC NNP N
) ) N
or CC N
treatment NN N
modality NN N
( ( N
chemotherapy NN N
with IN N
or CC N
without IN N
the DT N
addition NN N
of IN N
rituximab NN N
) ) N
showed VBD N
no DT N
difference NN N
in IN N
5 CD N
years NNS N
OS NNP N
or CC N
EFS NNP N
. . N

In IN N
contrast NN N
, , N
a DT N
significant JJ N
difference NN N
for IN N
better JJR N
EFS NNP N
( ( N
p=0.0015 NN N
) ) N
in IN N
the DT N
BCL2 NNP N
positive JJ N
group NN N
of IN N
the DT N
ABC NNP N
subgroups NNS N
subtypes NNS N
treated VBN N
with IN N
rituximab NN N
containing VBG N
chemotherapy NN N
. . N

For IN N
LMO2 NNP N
similar JJ N
results NNS N
on IN N
survival JJ N
outcome NN N
were VBD N
seen VBN N
thus RB N
showing VBG N
no DT N
difference NN N
in IN N
5 CD 1_o
years NNS 1_o
OS NNP 1_o
or CC 1_o
EFS NNP 1_o
- : N
regardless NN N
of IN N
subtype NN N
or CC N
treatment NN N
modality NN N
. . N

Also RB N
here RB N
, , N
this DT N
was VBD N
contrasted VBN N
by IN N
better JJR N
EFS NNP N
( ( N
p=0.039 NN N
) ) N
in IN N
the DT N
LMO2 NNP N
positive JJ N
group NN N
of IN N
ABC NNP N
subtypes NNS N
when WRB N
treated VBN N
with IN N
the DT N
rituximab NN N
containing VBG N
regimen NNS N
. . N

The DT N
use NN N
of IN N
the DT N
IHC NNP N
based VBN N
TMA NNP N
methodology NN N
has VBZ N
shown VBN N
to TO N
be VB N
a DT N
simple JJ 1_o
, , 1_o
cost NN 1_o
effective JJ 1_o
and CC 1_o
a DT 1_o
robust JJ 1_o
alternative NN 1_o
to TO 1_o
gene NN 1_o
expression NN 1_o
profiling VBG 1_o
( ( 1_o
GEP NNP 1_o
) ) 1_o
which WDT N
is VBZ N
currently RB N
regarded VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
classification NN N
in IN N
lymphomas NN N
. . N

It PRP N
provides VBZ N
a DT N
useful JJ N
prognostic JJ N
tool NN N
in IN N
stratifying VBG N
DLBCL NNP N
or CC N
other JJ N
entities NNS N
in IN N
future JJ N
, , N
even RB N
when WRB N
frozen JJ N
tissue NN N
samples NNS N
are VBP N
not RB N
available JJ N
for IN N
GEP NNP N
analysis NN N
. . N

With IN N
the DT N
current JJ N
budgetary JJ N
limitations NNS N
in IN N
South JJ 1_p
African JJ 1_p
public JJ 1_p
hospitals NNS 1_p
chemotherapy VBP N
protocols NNS N
for IN N
lymphoproliferative JJ N
disorders NNS N
exclude VBP N
agents NNS N
such JJ N
as IN N
rituximab NN N
. . N

Local JJ N
therapeutic JJ N
drug NN N
committees NNS N
consider VBP N
the DT N
approximately RB N
15 CD N
% NN N
overall JJ N
survival NN 1_o
benefit NN 1_o
seen VBN N
at IN N
5 CD N
years NNS N
for IN N
DLBCL NNP N
when WRB N
rituximab NN N
is VBZ N
added VBN N
to TO N
combination VB N
chemotherapy NN N
as IN N
too RB N
marginal JJ N
for IN N
justifying VBG N
the DT N
arising VBG N
additional JJ N
expenses NNS N
. . N

Accordingly RB N
, , N
demonstration NN N
that IN N
a DT N
specific JJ N
molecular JJ N
subtype NN N
accounts NNS N
for IN N
superior JJ N
outcome NN N
, , N
when WRB N
using VBG N
these DT N
regimens NNS N
, , N
is VBZ N
needed VBN N
. . N

Such JJ N
an DT N
option NN N
would MD N
provide VB N
convincing VBG N
evidence NN N
for IN N
the DT N
use NN N
of IN N
immunochemotherapy NN N
in IN N
a DT N
resource NN N
constrained VBD N
setting NN N
. . N

-DOCSTART- -X- O O

Utilization NN N
patterns NNS N
of IN N
conventional JJ 1_i
and CC 1_i
complementary/alternative JJ 1_i
treatments NNS 1_i
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
and CC 1_p
developmental JJ 1_p
disabilities NNS 1_p
in IN 1_p
a DT 1_p
population-based JJ 1_p
study NN 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
utilization NN N
of IN N
conventional JJ 1_i
treatments NNS 1_i
and CC 1_i
utilization NN 1_i
of IN 1_i
complementary JJ 1_i
and CC 1_i
alternative JJ 1_i
medicine NN 1_i
in IN N
preschoolers NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
and CC 1_p
other JJ 1_p
developmental JJ 1_p
disabilities NNS 1_p
( ( 1_p
DD NNP 1_p
) ) 1_p
. . 1_p

METHODS JJ N
Participants NNS 1_p
were VBD 1_p
578 CD 1_p
children NNS 1_p
who WP 1_p
were VBD 1_p
part NN 1_p
of IN 1_p
an DT 1_p
ongoing JJ 1_p
population-based JJ 1_p
, , 1_p
case-control JJ 1_p
study NN 1_p
of IN 1_p
2- JJ 1_p
to TO 1_p
5-year JJ 1_p
olds NNS 1_p
with IN 1_p
ASD NNP 1_p
, , 1_p
DD NNP 1_p
, , 1_p
and CC 1_p
the DT 1_p
general JJ 1_p
population NN 1_p
. . 1_p

Parents NNS N
completed VBD N
an DT N
interview NN N
on IN N
past JJ N
and CC N
current JJ N
services NNS N
. . N

RESULTS NNP N
Four CD 1_p
hundred VBD 1_p
fifty-three JJ 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
125 CD 1_p
DD NNP 1_p
children NNS 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

ASD NNP N
families NNS N
received VBD N
more RBR N
hours NNS N
of IN N
conventional JJ 1_o
services NNS 1_o
compared VBN N
with IN N
DD NNP N
families NNS N
( ( N
17.8 CD N
vs RB N
11 CD N
; : N
p NN N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
use NN N
of IN N
psychotropic NN N
medications NNS N
was VBD N
low JJ N
in IN N
both DT N
groups NNS N
( ( N
approximately RB N
3 CD N
% NN N
) ) N
. . N

Overall JJ N
, , N
complementary JJ 1_o
and CC 1_o
alternative JJ 1_o
medicine NN 1_o
( ( 1_o
CAM NNP 1_o
) ) 1_o
use NN N
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
ASD NNP N
( ( N
39 CD N
% NN N
) ) N
versus NN N
DD NNP N
( ( N
30 CD N
% NN N
) ) N
. . N

Hispanic JJ 1_p
families NNS 1_p
in IN N
both DT N
groups NNS N
used VBD N
CAM NNP 1_o
less RBR N
often RB N
than IN N
non-Hispanic JJ 1_p
families NNS 1_p
. . 1_p

Variables NNS N
such JJ N
as IN N
level NN 1_o
of IN 1_o
function NN 1_o
, , 1_o
immunization NN 1_o
status NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
presence NN 1_o
of IN 1_o
an DT 1_o
identified VBN 1_o
neurogenetic JJ 1_o
disorder NN 1_o
were VBD N
not RB N
predictive JJ N
of IN N
CAM NNP 1_i
use NN N
. . N

A DT N
higher JJR N
level NN 1_o
of IN 1_o
parental JJ 1_o
education NN 1_o
was VBD N
associated VBN N
with IN N
an DT N
increased VBN N
CAM NNP 1_o
use NN N
in IN N
ASD NNP N
and CC N
DD NNP N
. . N

Families NNS 1_p
who WP N
used VBD N
> $ N
20 CD N
hours NNS N
per IN N
week NN N
of IN N
conventional JJ 1_i
services NNS 1_i
were VBD N
more RBR N
likely JJ N
to TO N
use VB N
CAM NNP 1_i
, , N
including VBG N
potentially RB N
unsafe JJ N
or CC N
disproven JJ N
CAM NNP 1_i
. . 1_i

Underimmunized VBN 1_p
children NNS 1_p
were VBD N
marginally RB N
more RBR N
likely JJ N
to TO N
use VB N
CAM NNP 1_i
but CC N
not RB N
more RBR N
likely JJ N
to TO N
have VB N
received VBN N
potentially RB N
unsafe JJ N
or CC N
disproven JJ N
CAM NNP 1_i
. . 1_i

CONCLUSION NNP N
Use NNP N
of IN N
CAM NNP 1_i
is VBZ N
common JJ N
in IN N
families NNS 1_p
of IN 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
neurodevelopmental JJ 1_p
disorders NNS 1_p
, , N
and CC N
it PRP N
is VBZ N
predicted VBN N
by IN N
higher JJR N
parental JJ N
education NN N
and CC N
non-Hispanic JJ N
ethnicity NN N
but CC N
not RB N
developmental JJ N
characteristics NNS N
. . N

Further NNP N
research NN N
should MD N
address VB N
how WRB N
health NN N
care NN N
providers NNS N
can MD N
support VB N
families NNS N
in IN N
making VBG N
decisions NNS N
about IN N
CAM NNP 1_i
use NN N
. . N

-DOCSTART- -X- O O

Perioperative JJ 1_i
blood NN 1_i
transfusions NNS 1_i
, , 1_i
with IN 1_i
or CC 1_i
without IN 1_i
allogeneic JJ 1_i
leucocytes NNS 1_i
, , N
relate NN N
to TO N
survival VB 1_o
, , N
not RB N
to TO N
cancer NN 1_o
recurrence NN 1_o
. . 1_o

BACKGROUND NNP N
Perioperative NNP 1_i
blood NN 1_i
transfusions NNS 1_i
are VBP N
reported VBN N
to TO N
be VB N
related VBN N
to TO N
cancer NN 1_o
recurrence NN 1_o
and CC N
reduced JJ 1_o
survival NN 1_o
. . 1_o

Different NNP N
underlying VBG N
mechanisms NNS N
have VBP N
been VBN N
proposed VBN N
, , N
and CC N
allogeneic JJ N
leucocytes NNS N
in IN N
transfused JJ N
blood NN N
have VBP N
been VBN N
suggested VBN N
to TO N
contribute VB N
to TO N
this DT N
phenomenon NN N
. . N

METHODS NNP N
Packed VBD 1_i
red JJ 1_i
cells NNS 1_i
without IN 1_i
buffy NN 1_i
coat NN 1_i
( ( 1_i
PC NNP 1_i
group NN 1_i
) ) 1_i
were VBD 1_i
compared VBN 1_i
with IN 1_i
filtered JJ 1_i
, , 1_i
leucoreduced VBD 1_i
, , 1_i
red JJ 1_i
cells NNS 1_i
( ( 1_i
LD NNP 1_i
group NN 1_i
) ) 1_i
in IN N
a DT N
randomized JJ N
trial NN 1_p
of IN 1_p
697 CD 1_p
patients NNS 1_p
with IN 1_p
colorectal JJ 1_p
carcinoma NN 1_p
. . 1_p

Five-year JJ 1_o
survival NN 1_o
and CC 1_o
cancer NN 1_o
recurrence NN 1_o
rates NNS 1_o
were VBD N
determined VBN N
, , N
with IN N
special JJ N
emphasis NN N
on IN N
the DT N
location NN 1_o
of IN 1_o
recurrence NN 1_o
. . 1_o

RESULTS VB N
The DT N
intention-to-treat JJ N
analysis NN N
showed VBD N
a DT N
survival JJ 1_o
rate NN 1_o
of IN N
63.6 CD N
per IN N
cent NN N
in IN N
the DT N
PC NN N
group NN N
and CC N
65.3 CD N
per IN N
cent NN N
in IN N
the DT N
LD NNP N
group NN N
( ( N
P NNP N
= NNP N
0.69 CD N
) ) N
, , N
with IN N
recurrence NN 1_o
rates NNS 1_o
of IN N
27.8 CD N
and CC N
27.9 CD N
per IN N
cent NN N
respectively RB N
. . N

The DT N
observational JJ N
analysis NN N
showed VBD N
a DT N
significant JJ N
difference NN 1_o
in IN 1_o
survival NN 1_o
between IN N
transfused VBN N
and CC N
non-transfused JJ N
patients NNS N
( ( N
59.6 CD N
versus NN N
72.9 CD N
per IN N
cent NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
difference NN 1_o
in IN 1_o
cancer NN 1_o
recurrence NN 1_o
rate NN 1_o
between IN N
transfused VBN N
and CC N
non-transfused JJ N
patients NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
29.8 CD N
versus NN N
24.3 CD N
per IN N
cent NN N
; : N
P NNP N
= NNP N
0.13 CD N
) ) N
. . N

Local JJ 1_o
recurrences NNS 1_o
were VBD N
more RBR N
frequent JJ N
in IN N
transfused JJ N
than IN N
non-transfused JJ N
patients NNS N
( ( N
11.9 CD N
versus NN N
7.6 CD N
per IN N
cent NN N
; : N
P NNP N
= NNP N
0.09 CD N
) ) N
. . N

CONCLUSION NNP N
Leucocyte NNP N
depletion NN N
of IN N
perioperative NN 1_i
transfused VBN 1_i
blood NN 1_i
has VBZ N
no DT N
effect NN N
on IN N
long-term JJ 1_o
survival NN 1_o
and/or NN 1_o
cancer NN 1_o
recurrence NN 1_o
. . 1_o

Perioperative JJ N
blood NN N
transfusions NNS N
are VBP N
associated VBN N
with IN N
impaired JJ N
survival NN N
, , N
but CC N
not RB N
with IN N
cancer NN N
recurrence NN N
. . N

The DT N
slight JJ N
increase NN N
in IN N
local JJ N
recurrence NN 1_o
rate NN 1_o
in IN N
transfused JJ 1_p
patients NNS 1_p
appears VBZ N
to TO N
be VB N
related VBN N
to TO N
complicated VBN N
, , N
in IN N
particular JJ N
rectal NN N
, , N
surgery NN N
. . N

-DOCSTART- -X- O O

Aripiprazole NNP 1_i
in IN N
the DT N
treatment NN N
of IN N
irritability NN 1_o
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
short-term JJ 1_o
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
aripiprazole NN 1_i
in IN N
the DT N
treatment NN N
of IN N
irritability NN 1_o
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
who WP 1_p
were VBD 1_p
manifesting VBG 1_p
behaviors NNS 1_p
such JJ 1_p
as IN 1_p
tantrums NNS 1_p
, , 1_p
aggression NN 1_p
, , 1_p
self-injurious JJ 1_p
behavior NN 1_p
, , 1_p
or CC 1_p
a DT 1_p
combination NN 1_p
of IN 1_p
these DT 1_p
. . 1_p

METHODS NN N
This DT N
8-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
of IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
( ( 1_p
aged VBN 1_p
6-17 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

Patients NNS 1_i
were VBD 1_i
randomly RB 1_i
assigned VBN 1_i
( ( 1_i
1:1 CD 1_i
) ) 1_i
to TO 1_i
flexibly RB 1_i
dosed JJ 1_i
aripiprazole NN 1_i
( ( 1_i
target NN 1_i
dosage NN 1_i
: : 1_i
5 CD 1_i
, , 1_i
10 CD 1_i
, , 1_i
or CC 1_i
15 CD 1_i
mg/day NN 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

Efficacy NNP N
outcome JJ N
measures NNS N
included VBD N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
irritability NN 1_o
subscale NN 1_o
and CC 1_o
the DT 1_o
Clinical JJ 1_o
Global NNP 1_o
Impression-Improvement NN 1_o
score NN 1_o
( ( 1_o
CGI-I NNP 1_o
) ) 1_o
. . 1_o

Safety NN 1_o
and CC 1_o
tolerability NN 1_o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS JJ N
Ninety-eight JJ 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
placebo NN 1_i
( ( N
n JJ N
= NNP N
51 CD N
) ) N
or CC N
aripiprazole JJ N
( ( N
n JJ N
= NNP N
47 CD N
) ) N
. . N

Mean JJ N
improvement NN N
in IN N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
irritability NN 1_o
subscale NN 1_o
score NN 1_o
was VBD N
significantly RB N
greater JJR N
with IN N
aripiprazole NN 1_i
than IN N
with IN N
placebo NN 1_i
from IN N
week NN N
1 CD N
through IN N
week NN N
8 CD N
. . N

Aripiprazole NNP N
demonstrated VBD N
significantly RB N
greater JJR N
global JJ N
improvements NNS N
than IN N
placebo NN N
, , N
as IN N
assessed VBN N
by IN N
the DT N
mean JJ N
CGI-I NNP 1_o
score NN 1_o
from IN N
week NN N
1 CD N
through IN N
week NN N
8 CD N
; : N
however RB N
, , N
clinically RB N
significant JJ N
residual JJ 1_o
symptoms NNS 1_o
may MD N
still RB N
persist VB N
for IN N
some DT N
patients NNS N
. . N

Discontinuation NNP 1_o
rates NNS 1_o
as IN N
a DT N
result NN N
of IN N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
10.6 CD N
% NN N
for IN N
aripiprazole NN 1_i
and CC N
5.9 CD N
% NN N
for IN N
placebo NN 1_i
. . 1_i

Extrapyramidal NNP 1_o
symptom-related JJ 1_o
AE NNP 1_o
rates NNS 1_o
were VBD N
14.9 CD N
% NN N
for IN N
aripiprazole NN 1_i
and CC N
8.0 CD N
% NN N
for IN N
placebo NN 1_i
. . 1_i

No DT N
serious JJ N
AEs NNP N
were VBD N
reported VBN N
. . N

Mean NNP N
weight VBD 1_o
gain NN 1_o
was VBD N
2.0 CD N
kg NN N
on IN N
aripiprazole NN N
and CC N
0.8 CD N
kg NN N
on IN N
placebo NN N
at IN N
week NN N
8 CD N
. . N

CONCLUSIONS NNP N
Aripiprazole NNP 1_i
was VBD N
efficacious JJ N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
irritability NN 1_p
associated VBN 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
and CC N
was VBD N
generally RB N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
Positive NNP 1_i
Action NNP 1_i
on IN N
the DT N
emotional JJ N
health NN N
of IN N
urban JJ 1_p
youth NN 1_p
: : 1_p
a DT N
cluster-randomized JJ N
trial NN N
. . N

PURPOSE NNP N
We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
Positive JJ 1_i
Action NNP 1_i
( ( 1_i
PA NNP 1_i
) ) 1_i
, , N
a DT N
school-based JJ 1_i
social-emotional JJ 1_i
learning NN 1_i
and CC 1_i
health NN 1_i
promotion NN 1_i
program NN 1_i
, , N
on IN N
the DT N
emotional JJ N
health NN N
of IN N
predominately RB 1_p
low-income JJ 1_p
and CC 1_p
ethnic JJ 1_p
minority NN 1_p
urban JJ 1_p
youth NN 1_p
. . 1_p

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
matched-pair JJ N
, , N
cluster-randomized JJ N
controlled VBN N
trial NN N
involving VBG N
14 CD 1_p
Chicago NNP 1_p
public JJ 1_p
schools NNS 1_p
. . 1_p

Outcomes NNS N
were VBD N
assessed VBN N
over IN N
a DT N
6-year JJ 1_p
period NN 1_p
of IN 1_p
program NN 1_p
implementation NN 1_p
for IN 1_p
a DT 1_p
cohort NN 1_p
of IN 1_p
youth NN 1_p
in IN 1_p
each DT 1_p
school NN 1_p
, , 1_p
followed VBD 1_p
from IN 1_p
grades NNS 1_p
3 CD 1_p
to TO 1_p
8 CD 1_p
. . 1_p

Youth NN N
reported VBD N
on IN N
their PRP$ N
emotional JJ N
health NN N
( ( N
positive JJ N
affect NN N
, , N
life NN N
satisfaction NN N
, , N
depression NN N
, , N
anxiety NN N
) ) N
and CC N
social-emotional JJ N
and CC N
character NN N
development NN N
. . N

Growth-curve NNP N
and CC N
structural-equation NN N
modeling NN N
analyses NNS N
assessed VBD N
overall JJ N
program NN N
effects NNS N
on IN N
the DT N
emotional JJ N
health NN N
outcomes NNS N
as RB N
well RB N
as IN N
mediation NN N
of IN N
these DT N
effects NNS N
via IN N
the DT N
program NN N
's POS N
impact NN N
on IN N
youths NNS N
' POS N
social-emotional JJ N
and CC N
character NN N
development NN N
. . N

RESULTS JJ N
Students NNS N
in IN N
PA NNP 1_i
schools NNS N
, , N
compared VBN N
with IN N
those DT N
in IN N
control NN 1_i
schools NNS N
, , N
had VBD N
more RBR N
favorable JJ N
change NN N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
in IN N
positive JJ N
affect NN N
( ( N
standardized JJ N
mean NN N
difference NN N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
.17 NNP N
) ) N
and CC 1_o
life NN 1_o
satisfaction NN 1_o
( ( N
ES NNP N
= NNP N
.13 NNP N
) ) N
as RB N
well RB N
as IN N
significantly RB N
lower JJR 1_o
depression NN 1_o
( ( 1_o
ES NNP N
= NNP N
-.14 NNP N
) ) N
and CC N
anxiety NN 1_o
( ( 1_o
ES NNP 1_o
= NNP N
-.26 NNP N
) ) N
at IN N
study JJ N
end NN N
point NN N
. . N

Program NNP N
effects NNS 1_o
for IN 1_o
positive JJ 1_o
affect NN 1_o
, , 1_o
depression NN 1_o
, , 1_o
and CC 1_o
anxiety NN 1_o
were VBD 1_o
mediated VBN N
by IN N
more RBR N
favorable JJ N
change NN N
over IN N
time NN N
in IN N
social-emotional JJ N
and CC N
character NN N
development NN N
for IN N
students NNS N
in IN N
PA NNP N
schools NNS N
. . N

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
that IN N
universal JJ 1_i
, , 1_i
school-based JJ 1_i
programs NNS 1_i
can MD 1_i
benefit VB 1_i
the DT N
emotional JJ N
health NN N
of IN 1_p
youth NN 1_p
in IN 1_p
low-income JJ 1_p
, , 1_p
urban JJ 1_p
settings NNS 1_p
. . 1_p

The DT 1_p
modest JJ N
magnitude NN N
of IN N
effects NNS N
over IN N
an DT N
extended JJ N
period NN N
of IN N
program NN N
implementation NN N
, , N
however RB N
, , N
reflects VBZ N
the DT N
challenges NNS N
of IN N
both DT N
mounting VBG N
interventions NNS N
and CC N
offsetting VBG N
formidable JJ N
risks NNS N
for IN N
mental JJ N
health NN N
problems NNS N
in IN N
such JJ N
environments NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
alfentanil NN 1_i
, , 1_i
fentanyl NN 1_i
and CC N
sufentanil NN 1_i
for IN N
total JJ N
intravenous JJ N
anaesthesia NN N
with IN N
propofol NN 1_i
in IN N
patients NNS 1_p
undergoing VBG 1_p
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
surgery NN 1_p
. . 1_p

We PRP N
have VBP N
studied VBN N
the DT N
pharmacokinetics NNS 1_o
and CC 1_o
pharmacodynamics NNS 1_o
of IN N
alfentanil NN 1_i
, , 1_i
fentanyl NN 1_i
and CC N
sufentanil VB 1_i
together RB N
with IN N
propofol NN 1_i
in IN N
patients NNS 1_p
undergoing VBG 1_p
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
graft NN 1_p
surgery NN 1_p
( ( 1_p
CABG NNP 1_p
) ) 1_p
. . 1_p

Sixty JJ 1_p
patients NNS 1_p
( ( 1_p
age NN 1_p
40-73 CD 1_p
yr NN 1_p
, , 1_p
56 CD 1_p
male NN 1_p
) ) 1_p
were VBD 1_p
assigned VBN 1_p
randomly RB 1_p
to TO 1_p
receive VB 1_p
alfentanil NN 1_i
, , 1_i
fentanyl NN 1_i
or CC 1_i
sufentanil NN 1_i
and CC 1_i
propofol NN 1_i
. . 1_i

Plasma NNP 1_o
concentrations NNS 1_o
of IN N
these DT N
drugs NNS N
and CC N
times NNS 1_o
for IN 1_o
the DT 1_o
plasma NN 1_o
concentration NN 1_o
to TO 1_o
decrease VB 1_o
by IN 1_o
50 CD 1_o
% NN 1_o
( ( N
t50 NN N
) ) N
and CC N
80 CD N
% NN N
( ( N
t80 NN N
) ) N
after IN N
cessation NN N
of IN N
the DT N
infusion NN N
were VBD N
determined VBN N
. . N

Times NNS 1_o
were VBD N
recorded VBN N
to TO N
awakening VBG N
and CC N
tracheal JJ N
extubation NN N
. . N

Total JJ 1_o
dose NN 1_o
and CC 1_o
plasma JJ 1_o
concentrations NNS 1_o
of IN N
propofol NN N
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

Mean NNP 1_o
total JJ 1_o
doses NNS 1_o
of IN N
alfentanil NN 1_i
, , 1_i
fentanyl NN 1_i
and CC 1_i
sufentanil NN 1_i
were VBD N
443 CD N
, , N
45 CD N
and CC N
4.4 CD N
micrograms NNS N
kg-1 JJ N
, , N
respectively RB N
. . N

Time NN 1_o
to TO 1_o
awakening VBG 1_o
did VBD N
not RB N
differ VB N
significantly RB N
. . N

In IN N
patients NNS N
receiving VBG N
fentanyl NN 1_i
, , N
the DT N
trachea NN 1_o
was VBD N
extubated VBN 1_o
on IN N
average JJ N
2 CD N
h NN N
later RB N
than IN N
in IN N
those DT N
receiving VBG N
sufentanil NN 1_i
and CC N
3 CD N
h NN N
later RB N
than IN N
in IN N
those DT N
receiving VBG N
alfentanil NN 1_i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
t80 NN 1_o
of IN N
fentanyl NN 1_i
was VBD N
longer JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
that DT N
of IN N
alfentanil NN 1_i
or CC N
sufentanil NN 1_i
, , N
and CC N
there RB N
was VBD N
a DT N
linear JJ N
correlation NN N
between IN N
the DT N
t80 NN 1_o
of IN N
the DT N
opioid NN N
and CC N
the DT N
time NN 1_o
to TO 1_o
tracheal VB 1_o
extubation NN 1_o
( ( N
r JJ N
= VBZ N
0.51 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

However RB N
, , N
the DT N
t50 NN 1_o
values NNS 1_o
for IN N
these DT N
opioids NNS N
were VBD N
similar JJ N
and CC N
did VBD N
not RB N
correlate VB N
with IN N
recovery NN 1_o
time NN 1_o
. . 1_o

In IN N
conclusion NN N
, , N
patients NNS 1_p
undergoing VBG 1_p
CABG NNP 1_p
and CC N
who WP N
were VBD N
anaesthetized VBN N
with IN N
fentanyl NN 1_i
and CC N
propofol NN 1_i
needed VBN N
mechanical JJ 1_o
ventilatory NN 1_o
support NN 1_o
for IN N
a DT N
significantly RB N
longer JJR N
time NN N
than IN N
those DT N
receiving VBG N
alfentanil NN 1_i
or CC N
sufentanil NN 1_i
and CC N
propofol NN 1_i
. . 1_i

On IN N
the DT N
basis NN N
of IN N
the DT N
interindividual JJ N
variation NN N
observed VBD N
, , N
the DT N
time NN 1_o
to TO 1_o
tracheal VB 1_o
extubation NN 1_o
was VBD N
most RBS N
predictable JJ N
in IN N
patients NNS N
receiving VBG N
alfentanil NN 1_i
and CC N
most RBS N
variable JJ N
in IN N
patients NNS N
receiving VBG N
fentanyl NN 1_i
, , N
a DT N
finding NN N
which WDT N
may MD N
be VB N
important JJ N
if IN N
the DT N
patients NNS N
are VBP N
transferred VBN N
to TO N
a DT N
step-down JJ N
unit NN N
on IN N
the DT N
evening NN N
of IN N
the DT N
operation NN N
. . N

-DOCSTART- -X- O O

Large-dose JJ N
intravenous JJ N
ferric NNS 1_i
carboxymaltose VBP 1_i
injection NN 1_i
for IN N
iron NN 1_p
deficiency NN 1_p
anemia NN 1_p
in IN 1_p
heavy JJ 1_p
uterine JJ 1_p
bleeding NN 1_p
: : 1_p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
objective NN N
was VBD N
to TO N
evaluate VB N
efficacy NN N
and CC N
safety NN N
of IN N
rapid JJ N
, , N
large-dose JJ 1_i
intravenous JJ 1_i
( ( 1_i
IV NNP 1_i
) ) 1_i
administration NN 1_i
of IN 1_i
ferric JJ 1_i
carboxymaltose NN 1_i
compared VBN N
to TO N
oral JJ 1_i
iron NN 1_i
in IN N
correcting VBG N
iron NN N
deficiency NN N
anemia NN N
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
, , N
477 CD 1_p
women NNS 1_p
with IN 1_p
anemia NN 1_p
, , 1_p
iron NN 1_p
deficiency NN 1_p
, , 1_p
and CC 1_p
heavy JJ 1_p
uterine JJ 1_p
bleeding NN 1_p
were VBD 1_p
assigned VBN 1_p
to TO N
receive VB N
either DT N
IV NNP 1_i
ferric NN 1_i
carboxymaltose NN 1_i
( ( N
< JJ N
or=1000 NN N
mg NN N
over IN N
15 CD N
min NNS N
, , N
repeated VBD N
weekly JJ N
to TO N
achieve VB N
a DT N
total JJ N
calculated JJ N
replacement NN N
dose NN N
) ) N
or CC N
325 CD N
mg NN N
of IN 1_i
ferrous JJ 1_i
sulfate NN 1_i
( ( N
65 CD N
mg NN N
elemental JJ N
iron NN N
) ) N
prescribed VBD N
orally RB N
thrice JJ N
daily RB N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
Compared VBD N
to TO N
those DT N
assigned VBN N
to TO N
ferrous JJ 1_i
sulfate NN 1_i
, , N
more JJR N
patients NNS N
assigned VBD N
to TO N
ferric VB 1_i
carboxymaltose NN 1_i
responded VBN N
with IN N
a DT N
hemoglobin NN 1_o
( ( 1_o
Hb NNP 1_o
) ) 1_o
increase NN N
of IN N
2.0 CD N
g/dL NN N
or CC N
more JJR N
( ( N
82 CD N
% NN N
vs. FW N
62 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
treatment NN N
difference NN N
12.2-28.3 CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
, , N
more JJR N
achieved VBD N
a DT N
3.0 CD N
g/dL NN N
or CC N
more JJR N
increase NN N
( ( N
53 CD N
% NN N
vs. FW N
36 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
more JJR N
achieved JJ N
correction NN 1_o
( ( N
Hb NNP N
> NNP N
or= VBD N
12 CD N
g/dL NN N
) ) N
of IN N
anemia NN N
( ( N
73 CD N
% NN N
vs. FW N
50 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Patients NNS N
treated VBD N
with IN N
ferric JJ 1_i
carboxymaltose NN 1_i
compared VBN N
to TO N
those DT N
prescribed VBN N
ferrous JJ 1_i
sulfate NN 1_i
reported VBD N
greater JJR N
gains NNS N
in IN N
vitality NN 1_o
and CC 1_o
physical JJ 1_o
function NN 1_o
and CC 1_o
experienced JJ 1_o
greater JJR 1_o
improvement NN 1_o
in IN 1_o
symptoms NNS 1_o
of IN 1_o
fatigue NN 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ 1_o
adverse JJ 1_o
drug NN 1_o
events NNS 1_o
. . 1_o

CONCLUSIONS NNP N
In IN N
patients NNS 1_p
with IN 1_p
iron NN 1_p
deficiency NN 1_p
anemia NN 1_p
due JJ 1_p
to TO 1_p
heavy JJ 1_p
uterine JJ 1_p
bleeding NN 1_p
, , N
rapid JJ N
IV NNP N
administration NN N
of IN N
large JJ N
doses NNS N
of IN N
a DT N
new JJ 1_i
iron NN 1_i
agent NN 1_i
, , 1_i
ferric JJ 1_i
carboxymaltose NN 1_i
, , N
is VBZ N
more RBR N
effective JJ N
than IN N
oral JJ 1_i
iron NN 1_i
therapy NN 1_i
in IN N
correcting VBG 1_o
anemia NN 1_o
, , 1_o
replenishing VBG 1_o
iron NN 1_o
stores NNS 1_o
, , 1_o
and CC 1_o
improving VBG 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

-DOCSTART- -X- O O

Using VBG N
the DT N
virtual JJ 1_i
reality-cognitive JJ 1_i
rehabilitation NN 1_i
approach NN N
to TO N
improve VB N
contextual JJ 1_o
processing NN 1_o
in IN 1_o
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

BACKGROUND NNP N
This DT N
pilot NN N
study NN N
investigated VBD N
the DT N
efficacy NN N
of IN N
a DT N
novel JJ 1_i
virtual JJ 1_i
reality-cognitive JJ 1_i
rehabilitation NN 1_i
( ( 1_i
VR-CR NNP 1_i
) ) 1_i
intervention NN 1_i
to TO N
improve VB N
contextual JJ 1_o
processing NN 1_o
of IN N
objects NNS N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Previous JJ N
research NN N
supports VBZ N
that IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
show NN N
deficits NNS N
in IN N
contextual JJ 1_o
processing NN 1_o
, , N
as RB N
well RB N
as IN N
deficits NNS N
in IN N
its PRP$ N
elementary JJ N
components NNS N
: : N
abstraction NN 1_o
and CC 1_o
cognitive JJ 1_o
flexibility NN 1_o
. . 1_o

METHODS NNP N
Four CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
participated VBN N
in IN N
a DT N
multiple-baseline JJ N
, , N
single-subject JJ N
study NN N
. . N

The DT N
children NNS 1_p
were VBD N
taught JJ N
how WRB N
to TO N
see VB N
objects NNS N
in IN N
context NN N
by IN N
reinforcing VBG N
attention NN N
to TO N
pivotal JJ N
contextual JJ N
information NN N
. . N

RESULTS NNP N
All NNP N
children NNS 1_p
demonstrated VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
contextual JJ 1_o
processing NN 1_o
and CC 1_o
cognitive JJ 1_o
flexibility NN 1_o
. . 1_o

Mixed JJ N
results NNS N
were VBD N
found VBN N
on IN N
the DT N
control NN N
test NN N
and CC N
changes NNS N
in IN N
context-related JJ 1_o
behaviours NNS 1_o
. . 1_o

CONCLUSIONS NNP N
Larger-scale JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
and CC N
usability NN N
in IN N
comprehensive JJ N
educational JJ N
programs NNS N
. . N

-DOCSTART- -X- O O

Skin NNP 1_o
manifestations NNS 1_o
of IN 1_o
inhaled JJ 1_o
corticosteroids NNS 1_o
in IN N
COPD NNP 1_p
patients NNS 1_p
: : 1_p
results NNS N
from IN N
Lung NNP N
Health NNP N
Study NNP N
II NNP N
. . N

OBJECTIVE NNP N
To TO N
define VB N
the DT N
relationship NN N
between IN N
skin NN 1_o
bruising NN 1_o
( ( 1_o
as RB 1_o
well RB 1_o
as IN 1_o
other JJ 1_o
cutaneous JJ 1_o
manifestations NNS 1_o
) ) 1_o
and CC N
inhaled VBN N
corticosteroid NN 1_i
( ( 1_i
ICS NNP 1_i
) ) 1_i
therapy NN N
vs NN N
placebo NN N
in IN N
subjects NNS 1_p
with IN 1_p
COPD NNP 1_p
who WP N
were VBD N
participating VBG N
in IN N
a DT N
clinical JJ N
trial NN N
. . N

To TO N
explore VB N
the DT N
relationship NN N
between IN N
easy JJ 1_o
skin NN 1_o
bruising NN 1_o
and CC 1_o
other JJ 1_o
systemic JJ 1_o
effects NNS 1_o
of IN 1_o
ICS NNP 1_o
therapy NN 1_o
, , N
including VBG N
adrenal JJ 1_o
suppression NN 1_o
and CC 1_o
loss NN 1_o
of IN 1_o
bone JJ 1_o
mineral JJ 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
. . 1_o

DESIGN NNP N
Double-blind NNP N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
triamcinolone NN 1_i
acetonide NN 1_i
( ( N
1200 CD N
microg FW N
daily RB N
) ) N
vs NN N
placebo NN 1_i
in IN N
participants NNS 1_p
with IN 1_p
mild-to-moderate JJ 1_p
COPD NNP 1_p
. . 1_p

SETTING NNP N
Lung NNP N
Health NNP N
Study NNP N
II NNP N
, , N
a DT N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
ICS NNP 1_i
compared VBN N
to TO N
placebo VB 1_i
in IN N
1,116 CD 1_p
participants NNS 1_p
in IN 1_p
10 CD 1_p
centers NNS 1_p
over IN 1_p
> $ 1_p
3.5 CD 1_p
to TO 1_p
4.5 CD 1_p
years NNS 1_p
. . 1_p

PARTICIPANTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
1,116 CD 1_p
smokers NNS 1_p
or CC 1_p
recent JJ 1_p
ex-smokers NNS 1_p
with IN 1_p
mild-to-moderate JJ 1_p
COPD NNP 1_p
( ( 1_p
age NN 1_p
range NN 1_p
, , 1_p
40 CD 1_p
to TO 1_p
69 CD 1_p
years NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
56.3 CD 1_p
years NNS 1_p
; : 1_p
37.2 CD 1_p
% NN 1_p
female NN 1_p
) ) 1_p
. . 1_p

MEASUREMENTS NNP N
AND CC N
RESULTS NNP N
Every NNP N
6 CD N
months NNS N
, , N
a DT N
structured JJ N
questionnaire NN N
was VBD N
administered VBN N
to TO N
elicit VB N
reports NNS N
of IN N
any DT N
bruising NN 1_o
and/or NN 1_o
skin NN 1_o
rashes NNS 1_o
, , 1_o
slow JJ 1_o
healing NN 1_o
of IN 1_o
cuts NNS 1_o
or CC 1_o
sores NNS 1_o
, , 1_o
or CC 1_o
other JJ 1_o
skin JJ 1_o
changes NNS 1_o
. . 1_o

Compliance NN N
with IN N
inhaler NN N
use NN N
was VBD N
assessed VBN N
by IN N
canister NN N
weighing VBG N
. . N

A DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
ICS NNP 1_i
than IN N
placebo NN 1_i
participants NNS N
who WP N
complied VBD N
with IN N
using VBG N
their PRP$ N
inhaler NN N
reported VBD N
easy JJ 1_o
bruising NN 1_o
( ( N
11.2 CD N
% NN N
vs JJ N
3.5 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
the DT N
slow JJ 1_o
healing NN 1_o
of IN 1_o
skin NN 1_o
cuts NNS 1_o
or CC 1_o
sores NNS 1_o
( ( N
2.4 CD N
% NN N
vs JJ N
0.5 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Older JJR 1_p
men NNS 1_p
in IN N
the DT N
ICS NNP 1_i
group NN N
with IN N
good JJ N
inhaler NN N
compliance NN N
appeared VBD N
to TO N
be VB N
at IN N
the DT N
greatest JJS N
risk NN 1_o
of IN 1_o
bruising VBG 1_o
. . 1_o

In IN N
those DT N
participants NNS N
undergoing VBG N
serial JJ N
measurements NNS N
of IN N
adrenal JJ N
function NN N
and CC N
BMD NNP N
, , N
no DT N
association NN N
was VBD N
noted VBN N
between IN N
skin JJ 1_o
bruising NN 1_o
and CC N
either CC N
the DT N
suppression NN 1_o
of IN 1_o
adrenal JJ 1_o
function NN 1_o
or CC 1_o
the DT 1_o
loss NN 1_o
of IN 1_o
BMD NNP 1_o
as IN N
systemic JJ N
complications NNS N
of IN N
ICS NNP N
use NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
moderate-to-high JJ N
doses NNS N
of IN N
ICSs NNP N
result NN N
in IN N
an DT N
increased JJ N
incidence NN N
of IN N
easy JJ 1_o
bruising NN 1_o
and CC 1_o
impairment NN 1_o
in IN 1_o
skin NN 1_o
healing NN 1_o
in IN N
middle-aged JJ 1_p
to TO 1_p
elderly JJ 1_p
persons NNS 1_p
with IN 1_p
COPD NNP 1_p
. . 1_p

No DT N
association NN N
was VBD N
noted VBN N
between IN N
skin JJ 1_o
bruising NN 1_o
and CC N
other JJ N
markers NNS N
of IN N
systemic JJ 1_o
toxicity NN 1_o
from IN N
the DT N
use NN N
of IN N
ICSs NNP 1_i
. . N

-DOCSTART- -X- O O

Continuous JJ 1_i
event NN 1_i
recorders NNS 1_i
did VBD N
not RB N
affect VB N
anxiety NN 1_o
or CC N
quality NN 1_o
of IN 1_o
life NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
palpitations NNS 1_p
. . 1_p

OBJECTIVES NNP N
Palpitations NNPS N
can MD N
generate VB N
feelings NNS N
of IN N
anxiety NN 1_o
and CC N
decrease NN N
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QoL NNP 1_o
) ) 1_o
due JJ N
to TO N
fear VB N
of IN N
a DT N
cardiac JJ N
abnormality NN N
. . N

Continuous JJ 1_i
event NN 1_i
recorders NNS 1_i
( ( 1_i
CERs NNP 1_i
) ) 1_i
have VBP N
proven VBN N
to TO N
be VB N
successful JJ N
in IN N
diagnosing VBG N
causes NNS N
of IN N
palpitations NNS N
but CC N
may MD N
affect VB N
patient NN N
QoL NNP 1_o
and CC N
anxiety NN 1_o
. . 1_o

The DT N
aim NN N
is VBZ N
to TO N
determine VB N
anxiety NN 1_o
and CC N
health-related JJ 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
-QoL NN 1_o
and CC N
evaluate VB N
the DT N
burden NN N
of IN N
carrying VBG N
a DT N
CER NNP 1_i
in IN N
general JJ N
practice NN N
populations NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
Patients NNP 1_p
( ( 1_p
n=244 JJ 1_p
) ) 1_p
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

One CD N
group NN N
( ( N
n=127 RB N
) ) N
carried VBD N
a DT N
CER NNP 1_i
during IN N
4 CD N
weeks NNS N
. . N

One CD 1_p
hundred CD 1_p
and CC 1_p
seventeen JJ 1_p
patients NNS 1_p
formed VBD N
the DT N
usual JJ 1_i
care NN 1_i
( ( 1_i
UC NNP 1_i
) ) 1_i
group NN N
. . N

State-Trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
( ( 1_o
STAI NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
Short NNP 1_o
Form-36 NNP 1_o
( ( 1_o
SF-36 NNP 1_o
) ) 1_o
were VBD N
administered VBN N
at IN N
study NN N
inclusion NN N
, , N
after IN N
1 CD N
, , N
6 CD N
months NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
patients NNS N
reported VBD N
greater JJR N
anxiety NN 1_o
and CC N
lower JJR 1_o
QoL NNP 1_o
than IN N
healthy JJ N
populations NNS N
. . N

The DT N
CER NNP 1_i
group NN N
had VBD N
three CD N
times NNS N
more RBR N
cardiac JJ 1_o
diagnoses NNS 1_o
than IN N
the DT N
UC NNP 1_i
group NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
CER NNP 1_i
group NN N
and CC N
UC NNP 1_i
group NN N
at IN N
6 CD N
weeks NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
UC NNP 1_i
group NN N
showed VBD N
QoL NNP 1_o
improvement NN 1_o
and CC N
less JJR N
anxiety NN 1_o
compared VBN N
to TO N
the DT N
CER NNP 1_i
group NN N
. . N

Type NN 1_o
of IN 1_o
diagnosis NN 1_o
had VBD N
influence NN N
, , N
but CC N
did VBD N
not RB N
fully RB N
explain VB N
these DT N
differences NNS N
. . N

CONCLUSION VB N
A DT N
CER NNP 1_i
does VBZ N
not RB N
negatively RB N
influence JJ N
anxiety NN 1_o
or CC N
QoL NNP 1_o
. . 1_o

Better NNP N
outcomes VBZ N
in IN N
the DT N
UC NNP 1_i
group NN N
might MD N
be VB N
attributed VBN N
to TO N
less JJR N
cardiac JJ 1_o
diagnosis NN 1_o
and CC N
more JJR N
emphasis NN N
on IN N
psychological JJ 1_o
well-being NN 1_o
. . 1_o

-DOCSTART- -X- O O

Whole-body JJ 1_i
CT NNP 1_i
screening NN 1_i
: : 1_i
scan JJ 1_i
delay NN 1_i
and CC 1_i
contrast NN 1_i
injection NN 1_i
duration NN N
for IN N
optimal JJ 1_o
enhancement NN 1_o
of IN 1_o
abdominal JJ 1_o
organs NNS 1_o
and CC 1_o
deep JJ 1_o
vessels NNS 1_o
. . 1_o

PURPOSE NNP N
To TO N
assess VB N
the DT N
optimal JJ N
scan JJ N
delays NNS N
and CC N
contrast NN N
injection NN N
durations NNS N
for IN N
contrast-enhanced JJ 1_i
whole-body NN 1_i
computed VBN 1_i
tomography NN 1_i
( ( 1_i
CT NNP 1_i
) ) 1_i
. . 1_i

MATERIALS NNP N
AND CC N
METHODS NNP N
One CD 1_p
hundred VBD 1_p
forty-two JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
: : N
protocol NN 1_i
A-scan JJ 1_i
delay NN 1_i
of IN 1_i
65 CD 1_i
s NNS 1_i
after IN 1_i
starting VBG 1_i
contrast NN 1_i
injection NN 1_i
over IN 1_i
30 CD 1_i
s NNS 1_i
; : 1_i
protocol CC 1_i
B-105 NNP 1_i
and CC 1_i
70 CD 1_i
s NN 1_i
; : 1_i
and CC 1_i
protocol VB 1_i
C-145 NNP 1_i
and CC 1_i
110 CD 1_i
s NN 1_i
, , N
respectively RB N
. . N

Contrast NNP 1_o
enhancement NN 1_o
and CC 1_o
diagnostic JJ 1_o
acceptability NN 1_o
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Qualitative JJ 1_o
assessment NN 1_o
was VBD N
subtle JJ N
among IN N
the DT N
three CD N
protocols NNS N
. . N

Homogenous JJ 1_o
enhancement NN 1_o
of IN 1_o
deep JJ 1_o
veins NNS 1_o
was VBD N
more RBR N
assuredly RB N
achieved VBN N
with IN N
protocol NN N
C. NNP N
CONCLUSION NNP N
With IN N
protocol NN 1_i
C NNP 1_i
, , N
qualitatively RB N
acceptable JJ N
enhancement NN N
can MD N
be VB N
obtained VBN N
in IN N
whole-body JJ 1_i
CT NNP 1_i
. . 1_i

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
transient JJ 1_i
ulnar JJ 1_i
artery NN 1_i
compression NN 1_i
to TO N
recanalize VB N
acute JJ N
radial JJ N
artery NN N
occlusion NN N
after IN N
transradial JJ N
catheterization NN N
. . N

Radial JJ N
artery NN N
occlusion NN N
( ( N
RAO NNP N
) ) N
can MD N
result VB N
from IN N
transradial JJ N
catheterization NN N
. . N

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
RAO NNP N
with IN N
2 CD N
heparin JJ N
dosage NN N
regimens NNS N
after IN N
transradial JJ N
coronary JJ N
angiography NN N
, , N
and CC N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
achieve VB N
acute JJ N
radial JJ N
artery NN N
recanalization NN N
. . N

Patients NNS 1_p
referred VBD 1_p
for IN 1_p
coronary JJ 1_p
angiography NN 1_p
were VBD N
randomized VBN N
to TO N
very-low-dose JJ 1_i
heparin NN 1_i
( ( N
2,000 CD N
IU NNP N
) ) N
or CC N
low-dose JJ 1_i
heparin NN 1_i
( ( N
5,000 CD N
IU NNP N
) ) N
. . N

On IN N
sheath NN N
removal NN N
, , N
hemostasis NN N
was VBD N
obtained VBN N
using VBG N
the DT N
TR NNP N
band NN N
with IN N
a DT N
plethysmography-guided JJ N
patent NN N
hemostasis NN N
technique NN N
. . N

In IN N
the DT N
case NN N
of IN N
RAO NNP N
as IN N
assessed VBN N
by IN N
duplex JJ N
ultrasonography NN N
3 CD N
to TO N
4 CD N
hours NNS N
after IN N
hemostasis NN N
, , N
immediate JJ N
1-hour JJ N
ulnar JJ N
artery NN N
compression NN N
was VBD N
applied VBN N
. . N

Hematomas NNP N
> VBD N
15 CD N
cm NN N
( ( N
2 CD N
) ) N
were VBD N
also RB N
assessed VBN N
. . N

We PRP N
randomized VBD N
465 CD 1_p
patients NNS 1_p
, , N
222 CD N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
243 CD N
in IN N
the DT N
5,000-IU JJ N
group NN N
. . N

The DT N
baseline NN N
and CC N
procedural JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
incidence NN 1_o
of IN 1_o
initial JJ 1_o
RAO NNP 1_o
was VBD N
5.9 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
with IN N
a DT N
compression NN N
time NN N
of IN N
2.10 CD N
? . N
0.78 CD N
hours NNS N
and CC N
2.25 CD N
? . N
0.82 CD N
hours NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

After IN 1_i
ulnar JJ 1_i
artery NN 1_i
compression NN 1_i
, , 1_i
the DT 1_o
final JJ 1_o
incidence NN 1_o
of IN 1_o
RAO NNP 1_o
was VBD 1_o
4.1 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
0.8 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

The DT 1_o
incidence NN 1_o
of IN 1_o
local JJ 1_o
hematoma NN 1_o
was VBD 1_o
2.3 CD N
% NN N
and CC N
3.7 CD N
% NN N
in IN N
the DT N
2,000- JJ N
and CC N
5,000-IU JJ N
groups NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.42 CD N
) ) N
. . N

In IN N
conclusion NN 1_o
, , 1_o
acute JJ 1_o
RAO NNP 1_o
after IN 1_o
transradial JJ 1_o
catheterization NN 1_o
can MD 1_o
be VB N
recanalized VBN N
by IN N
early JJ N
1-hour JJ 1_i
homolateral JJ 1_i
ulnar JJ 1_i
artery NN 1_i
compression NN 1_i
. . 1_i

This DT N
simple JJ N
nonpharmacologic JJ N
method NN N
was VBD 1_o
effective JJ 1_o
and CC 1_o
safe JJ 1_o
in IN 1_o
patients NNS 1_p
with IN 1_p
very-low- JJ 1_p
and CC 1_p
low-dose JJ 1_p
heparin NN 1_p
. . 1_p

Nevertheless NNP N
, , N
the DT N
incidence NN N
of IN N
final JJ N
RAO NNP N
remained VBD 1_o
significantly RB 1_o
lower JJR 1_o
after IN 1_o
a DT N
higher JJR N
anticoagulation NN N
level NN N
. . N

-DOCSTART- -X- O O

Topiramate NNP 1_i
improves VBZ N
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
when WRB N
used VBN N
to TO N
prevent VB N
migraine NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
assess VB N
changes NNS N
in IN N
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
HRQoL NNP 1_o
) ) 1_o
measures VBZ 1_o
among IN N
patients NNS 1_p
receiving VBG 1_p
topiramate NN 1_i
( ( 1_i
TPM NNP 1_i
) ) 1_i
100 CD 1_p
mg/d NN 1_p
in IN 1_p
two CD 1_p
divided JJ 1_p
doses NNS 1_p
for IN 1_p
migraine JJ 1_p
prevention NN 1_p
in IN N
three CD N
randomized NNS N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
26-week JJ N
trials NNS N
with IN N
similar JJ 1_p
protocols NNS 1_p
and CC 1_p
study NN 1_p
populations NNS 1_p
. . 1_p

BACKGROUND NNP N
Migraine NNP N
substantially RB N
impairs VBZ N
HRQoL NNP 1_o
and CC N
work NN 1_o
productivity NN 1_o
before IN N
, , N
during IN N
, , N
and CC N
after IN N
attacks NNS N
. . N

Approximately RB N
50 CD N
% NN N
of IN N
patients NNS N
with IN N
migraine NN N
could MD N
be VB N
recommended VBN N
for IN N
preventive JJ N
therapies NNS N
, , N
yet RB N
only RB N
3 CD N
% NN N
to TO N
5 CD N
% NN N
of IN N
patients NNS N
receive VBP N
them PRP N
. . N

TPM NNP 1_i
is VBZ N
an DT N
effective JJ 1_o
and CC 1_o
generally RB 1_o
well-tolerated JJ 1_o
migraine NN N
prophylactic NN N
( ( N
preventive JJ N
) ) N
therapy NN N
for IN N
adults NNS N
, , N
as IN N
demonstrated VBN N
in IN N
several JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trials NNS N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
in IN N
double-blind NN N
, , N
placebo-controlled JJ N
studies NNS N
of IN N
TPM NNP 1_i
in IN N
migraine JJ N
prevention NN N
are VBP N
paresthesia NN 1_o
, , 1_o
fatigue NN 1_o
, , 1_o
anorexia NN 1_o
, , 1_o
nausea NN 1_o
, , 1_o
taste NN 1_o
alteration NN 1_o
, , 1_o
and CC 1_o
diarrhea NN 1_o
. . 1_o

DESIGN NNP N
AND CC N
METHODS NNP N
The DT N
Migraine-Specific NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
MSQ NNP 1_o
, , N
version NN N
2.1 CD N
) ) N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
TPM NNP 1_i
100 CD N
mg/d NN N
on IN N
the DT N
functionality NN N
and CC N
HRQoL NNP N
of IN N
randomized VBN N
intent-to-treat NN 1_p
( ( 1_p
ITT NNP 1_p
) ) 1_p
and CC 1_p
study-completer JJ 1_p
populations NNS 1_p
pooled VBD N
from IN N
three CD N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trials NNS N
. . N

MSQ NNP 1_o
scores NNS 1_o
( ( N
0 CD N
to TO N
100 CD N
, , N
higher JJR N
score NN N
indicates VBZ N
better RBR N
functioning VBG N
) ) N
were VBD N
assessed VBN N
for IN N
the DT N
following JJ N
three CD N
domains NNS N
: : N
role NN N
restriction NN N
( ( N
examines VBZ N
the DT N
degree NN N
to TO N
which WDT N
performance NN N
of IN N
daily JJ N
activities NNS N
is VBZ N
limited VBN N
by IN N
migraine NN N
) ) N
, , N
role NN N
prevention NN N
( ( N
examines VBZ N
the DT N
degree NN N
to TO N
which WDT N
performance NN N
of IN N
daily JJ N
activities NNS N
is VBZ N
interrupted VBN N
by IN N
migraine NN N
) ) N
, , N
and CC N
emotional JJ 1_o
function NN 1_o
( ( N
examines JJ N
feelings NNS N
of IN N
frustration NN N
and CC N
helplessness NN N
due JJ N
to TO N
migraine VB N
) ) N
. . N

Between-group JJ N
differences NNS N
from IN N
baseline NN N
in IN N
mean JJ 1_o
MSQ NNP 1_o
domain NN 1_o
scores NNS 1_o
for IN N
TPM NNP 1_i
100 CD N
mg/d NN N
and CC N
placebo NN 1_i
were VBD N
compared VBN N
using VBG N
a DT N
mixed-effects NNS N
model NN N
with IN N
piecewise NN N
linear JJ N
regression NN N
. . N

Effect JJ N
sizes NNS N
were VBD N
calculated VBN N
to TO N
estimate VB N
the DT N
magnitude NN N
of IN N
change NN N
in IN N
HRQoL NNP N
that WDT N
can MD N
be VB N
associated VBN N
with IN N
TPM NNP 1_i
therapy NN 1_i
. . 1_i

RESULTS NNP N
TPM NNP 1_i
100 CD N
mg/d NN N
significantly RB N
improved VBN N
all DT 1_o
three CD 1_o
MSQ NNP 1_o
domains NNS 1_o
compared VBN N
with IN N
placebo NN 1_i
for IN N
both DT N
the DT N
ITT NNP N
( ( 1_i
TPM NNP 1_i
, , N
n JJ N
= VBP N
372 CD N
; : N
placebo NN 1_i
, , N
n JJ N
= NNP N
362 CD N
) ) N
and CC N
study-completer NN N
( ( N
TPM NNP N
, , N
n JJ N
= VBP N
220 CD N
; : N
placebo NN N
, , N
n JJ N
= NNP N
216 CD N
) ) N
populations NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
for IN N
all DT N
three CD N
domains NNS N
, , N
both DT N
populations NNS N
) ) N
. . N

Effect JJ N
sizes NN N
for IN N
TPM NNP 1_i
100 CD N
mg/d NN N
varied VBD N
from IN N
0.40 CD N
to TO N
0.78 CD N
, , N
indicating VBG N
that IN N
the DT N
changes NNS N
in IN N
MSQ NNP 1_o
scores NNS 1_o
for IN N
TPM NNP 1_i
100 CD N
mg/d NN N
were VBD N
moderate JJ N
and CC N
may MD N
be VB N
clinically RB N
significant JJ N
. . N

CONCLUSION NNP N
TPM NNP 1_i
100 CD N
mg/d NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
prevention NN N
of IN N
migraine NN 1_o
headache NN 1_o
in IN 1_p
adults NNS 1_p
. . 1_p

As IN N
the DT N
MSQ NNP N
results NNS N
from IN N
the DT N
three CD N
randomized VBN N
, , N
placebo-controlled JJ N
trials NNS N
indicate VBP N
, , N
HRQoL NNP 1_o
is VBZ N
significantly RB N
improved VBN N
for IN N
up RB N
to TO N
6 CD N
months NNS N
following VBG N
initiation NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Randomised VBN N
placebo-controlled JJ 1_i
trial NN N
of IN N
rhesus-human JJ 1_i
reassortant JJ 1_i
rotavirus NN 1_i
vaccine NN 1_i
for IN N
prevention NN N
of IN N
severe JJ 1_o
rotavirus NN 1_o
gastroenteritis NN 1_o
. . 1_o

BACKGROUND NNP N
Rotavirus NNP N
is VBZ N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
acute JJ N
childhood NN N
gastroenteritis NN N
. . N

Vaccination NN N
with IN N
live JJ N
oral JJ N
heterologous JJ N
rotavirus NN N
vaccines NNS N
may MD N
prevent VB N
rotavirus NN N
gastroenteritis NN N
. . N

We PRP N
assessed VBD N
the DT N
efficacy NN 1_o
of IN N
rhesus-human JJ 1_i
reassortant JJ 1_i
rotavirus NN 1_i
tetravalent NN 1_i
vaccine NN 1_i
( ( 1_i
RRV-TV NNP 1_i
) ) 1_i
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
Finnish JJ 1_p
children NNS 1_p
in IN N
a DT N
randomised JJ N
placebo-controlled JJ 1_i
double-blind JJ N
trial NN N
. . N

METHODS NNP N
Placebo NNP 1_i
or CC 1_i
RRV-TV NNP 1_i
( ( N
titre JJ N
4x10 CD N
( ( N
5 CD N
) ) N
plaque-forming JJ N
units NNS N
) ) N
was VBD N
given VBN N
to TO N
infants NNS 1_p
at IN 1_p
ages NNS 1_p
2 CD 1_p
, , 1_p
3 CD 1_p
, , 1_p
and CC 1_p
5 CD 1_p
months NNS 1_p
. . 1_p

The DT N
children NNS N
were VBD N
followed VBN N
up RP N
for IN N
one CD N
or CC N
two CD N
rotavirus JJ N
epidemic JJ N
seasons NNS N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
protection NN 1_o
against IN 1_o
severe JJ 1_o
rotavirus NN 1_o
gastroenteritis NN 1_o
( ( N
score JJ N
> NN N
or CC N
=11 NN N
on IN N
a DT N
20-point JJ N
severity NN N
scale NN N
) ) N
. . N

2398 CD 1_p
children NNS 1_p
were VBD 1_p
enrolled VBN 1_p
and CC N
received VBN N
at IN N
least JJS N
one CD N
dose NN N
of IN N
RRV-TV NNP N
( ( N
n=1191 NN N
) ) N
or CC N
placebo NN 1_i
( ( N
n=1207 JJ N
) ) N
. . N

The DT N
primary JJ N
efficacy NN N
analysis NN N
was VBD N
based VBN N
on IN N
children NNS N
who WP N
received VBD N
three CD N
doses NNS N
of IN N
RRV-TV NNP N
( ( N
n=1128 NN N
) ) N
or CC N
placebo NN N
( ( N
n=1145 JJ N
) ) N
. . N

FINDINGS $ N
256 CD N
episodes NNS N
of IN N
rotavirus NN N
gastroenteritis NN N
occurred VBD N
at IN N
any DT N
time NN N
during IN N
the DT N
study NN N
; : N
65 CD N
were VBD N
among IN N
1191 CD N
RRV-TV JJ 1_i
recipients NNS N
, , N
and CC N
191 CD N
among IN N
1207 CD N
placebo NN 1_i
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
66 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
55-74 JJ N
] NN N
; : N
intention-to-treat JJ N
analysis NN N
) ) N
. . N

226 CD N
episodes NNS N
were VBD N
included VBN N
in IN N
the DT N
primary JJ N
efficacy NN 1_o
analysis NN N
of IN N
fully RB N
vaccinated VBN N
children NNS N
( ( N
54 CD N
among IN N
1128 CD N
RRV-TV JJ N
recipients NNS N
, , N
172 CD N
among IN N
1145 CD N
placebo NN N
recipients NNS N
; : N
vaccine VB N
efficacy NN N
68 CD N
% NN N
[ JJ N
57-76 JJ N
] NN N
) ) N
. . N

100 CD N
episodes NNS N
were VBD N
severe JJ N
, , N
eight CD N
in IN N
RRV-TV NNP 1_i
recipients NNS N
and CC N
92 CD N
in IN N
placebo NN N
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
91 CD N
% NN N
[ JJ N
82-96 JJ N
] NN N
) ) N
. . N

INTERPRETATION NNP N
RRV-TV NNP 1_i
vaccine NN 1_i
was VBD N
highly RB N
effective JJ N
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
young JJ 1_p
children NNS 1_p
. . 1_p

Incorporation NN N
of IN N
this DT N
vaccine NN N
into IN N
routine JJ N
immunisation NN N
schedules NNS N
of IN N
infants NNS N
could MD N
reduce VB N
severe JJ 1_o
rotavirus NN 1_o
gastroenteritis NN 1_o
by IN N
90 CD N
% NN N
and CC N
severe JJ 1_o
gastroenteritis NN 1_o
of IN N
all DT N
causes NNS N
in IN N
young JJ N
children NNS N
by IN N
60 CD N
% NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
dietary JJ N
supplementation NN N
with IN N
n-3 JJ N
fatty JJ N
acids NNS N
on IN N
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
graft NN 1_p
patency NN 1_p
. . 1_p

Epidemiologic NNP N
and CC N
experimental JJ N
data NNS N
suggest VBP N
that IN N
a DT N
high JJ N
dietary JJ N
intake NN N
of IN N
long-chain JJ N
polyunsaturated JJ N
n-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
may MD N
reduce VB N
the DT N
risk NN N
of IN N
atherothrombotic JJ N
disease NN N
. . N

In IN N
a DT N
randomized NN N
, , N
controlled VBD N
study NN N
, , N
610 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
grafting VBG 1_p
were VBD N
assigned VBN N
either RB N
to TO N
a DT N
fish JJ 1_i
oil NN 1_i
group NN 1_i
, , 1_i
receiving VBG 1_i
4 CD 1_i
g/day NN 1_i
of IN 1_i
fish JJ 1_i
oil NN 1_i
concentrate NN 1_i
, , 1_i
or CC 1_i
to TO 1_i
a DT 1_i
control NN 1_i
group NN 1_i
. . 1_i

All DT 1_p
patients NNS 1_p
received VBD 1_p
antithrombotic JJ 1_i
treatment NN 1_i
, , 1_i
either CC 1_i
aspirin NN 1_i
or CC 1_i
warfarin NN 1_i
. . 1_i

Their PRP$ N
diet JJ N
and CC N
serum JJ N
phospholipid JJ N
fatty JJ N
acid NN N
profiles NNS N
were VBD N
monitored VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
1-year JJ N
graft NN 1_o
patency NN 1_o
, , N
which WDT N
was VBD N
assessed VBN N
by IN N
angiography NN N
in IN N
95 CD N
% NN N
of IN N
patients NNS N
. . N

Vein NNP 1_o
graft JJ 1_o
occlusion NN 1_o
rates NNS 1_o
per IN 1_o
distal JJ 1_o
anastomoses NNS 1_o
were VBD N
27 CD N
% NN N
in IN N
the DT N
fish JJ 1_i
oil NN 1_i
group NN N
and CC N
33 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
0.77 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.60 CD N
to TO N
0.99 CD N
, , N
p NN N
= NNP N
0.034 CD N
) ) N
. . N

In IN N
the DT N
fish JJ 1_i
oil NN 1_i
group NN N
, , N
43 CD N
% NN N
of IN N
the DT N
patients NNS N
had VBD N
> VBN 1_o
or CC 1_o
= $ 1_o
1 CD 1_o
occluded VBN 1_o
vein NN 1_o
graft NN 1_o
( ( 1_o
s PRP 1_o
) ) 1_o
compared VBN N
with IN N
51 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
0.72 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.51 CD N
to TO N
1.01 CD N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
. . N

Moreover RB N
, , N
in IN N
the DT N
entire JJ N
patient NN N
group NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
trend NN N
to TO N
fewer JJR N
patients NNS N
with IN N
vein JJ N
graft NN N
occlusions NNS N
with IN N
increasing VBG N
relative JJ N
change NN N
in IN N
serum JJ 1_o
phospholipid JJ 1_o
n-3 JJ 1_o
fatty JJ 1_o
acids NNS 1_o
during IN N
the DT N
study NN N
period NN N
( ( N
p NN N
for IN N
linear JJ N
trend NN N
= VBZ N
0.0037 CD N
) ) N
. . N

Thus RB N
, , N
in IN N
patients NNS 1_p
undergoing VBG 1_p
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
grafting NN 1_p
, , N
dietary JJ N
supplementation NN N
with IN N
n-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
reduced VBD N
the DT N
incidence NN N
of IN N
vein NN N
graft NN N
occlusion NN N
, , N
and CC N
an DT N
inverse JJ N
relation NN N
between IN N
relative JJ N
change NN N
in IN N
serum JJ 1_o
phospholipid JJ 1_o
n-3 JJ 1_o
fatty JJ 1_o
acids NNS 1_o
and CC 1_o
vein NN 1_o
graft NN 1_o
occlusions NNS 1_o
was VBD N
observed VBN N
. . N

-DOCSTART- -X- O O

Object JJ 1_o
interest NN 1_o
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
a DT N
treatment NN N
comparison NN N
. . N

A DT N
randomized JJ N
control NN N
trial NN N
comparing VBG N
two CD N
social JJ 1_i
communication NN 1_i
treatments NNS 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
examined VBD N
the DT N
effect NN N
of IN N
treatment NN N
on IN N
object JJ N
interest NN N
. . N

Thirty-two JJ 1_p
children NNS 1_p
, , 1_p
18-60 JJ 1_p
months NNS 1_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Picture NNP 1_i
Exchange NNP 1_i
Communication NNP 1_i
System NNP 1_i
( ( 1_i
PECS NNP 1_i
) ) 1_i
or CC 1_i
Responsive JJ 1_i
Education NN 1_i
and CC 1_i
Prelinguistic NNP 1_i
Milieu NNP 1_i
Teaching NNP 1_i
( ( 1_i
RPMT NNP 1_i
) ) 1_i
condition NN 1_i
. . 1_i

Assessment NN N
of IN N
object JJ 1_o
interest NN 1_o
was VBD N
conducted VBN N
in IN N
an DT N
unstructured JJ N
play NN N
session NN N
with IN N
different JJ N
toys NNS N
, , N
activities NNS N
, , N
adult NN N
, , N
and CC N
location NN N
than IN N
experienced VBN N
in IN N
treatment NN N
. . N

Results NNS N
indicated VBD N
children NNS N
in IN N
the DT N
RPMT NNP 1_i
condition NN N
showed VBD N
greater JJR N
increases NNS N
in IN N
object JJ 1_o
interest NN 1_o
as IN N
compared VBN N
to TO N
children NNS N
in IN N
the DT N
PECS NNP 1_i
condition NN N
. . N

Because IN N
child JJ N
characteristics NNS N
such JJ N
as IN N
interest NN N
in IN N
objects NNS N
may MD N
influence VB N
response NN N
to TO N
interventions NNS N
using VBG N
object JJ N
play NN N
as IN N
contexts NN N
for IN N
treatment NN N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
improve VB N
our PRP$ N
understanding NN N
of IN N
whether IN N
intervention NN N
can MD N
affect VB N
object JJ N
interest NN N
. . N

-DOCSTART- -X- O O

Examining VBG N
the DT N
Relationship NNP N
Between NNP N
Parental NNP N
Anxiety NNP N
and CC N
Treatment NNP N
Response NNP N
in IN N
Children NNP 1_p
and CC 1_p
Adolescents NNP 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorder NNP 1_p
and CC 1_p
Anxiety NNP 1_p
. . 1_p

In IN N
response NN N
to TO N
the DT N
high JJ N
co-occurrence NN N
of IN N
anxiety NN N
symptoms NNS N
in IN N
youth NN 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
, , N
several JJ N
interventions NNS N
have VBP N
been VBN N
developed VBN N
for IN N
this DT N
population NN N
. . N

In IN N
spite NN N
of IN N
promising JJ N
findings NNS N
, , N
some DT N
youth NN 1_p
with IN 1_p
ASD NNP 1_p
respond NN N
only RB N
minimally RB N
to TO N
such JJ N
interventions NNS N
. . N

To TO N
understand VB N
potential JJ N
factors NNS N
that WDT N
may MD N
impact VB N
treatment NN N
response NN N
, , N
the DT N
current JJ N
study NN N
explores VBZ N
the DT N
role NN N
of IN N
parental JJ N
anxiety NN N
in IN N
youth NN N
treatment NN N
outcome NN N
. . N

Thirty-one CD 1_p
youth NN 1_p
with IN 1_p
ASD NNP 1_p
, , 1_p
ages VBZ 1_p
7-18 CD 1_p
, , 1_p
and CC 1_p
their PRP$ 1_p
parents NNS 1_p
participated VBN N
in IN N
the DT N
study NN N
. . N

Parents NNS 1_i
completed VBD 1_i
the DT 1_i
State/Trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
pre- JJ 1_i
and CC 1_i
post-treatment JJ 1_i
. . 1_i

Contrary NNP N
to TO N
previous JJ N
research NN N
, , N
there EX N
was VBD N
no DT N
correlation NN N
between IN N
parental JJ 1_o
anxiety NN 1_o
and CC 1_o
youth NN 1_o
anxiety NN 1_o
at IN N
baseline NN N
or CC N
post-treatment NN N
. . N

However RB N
, , N
parental JJ 1_o
trait NN 1_o
anxiety NN 1_o
significantly RB N
decreased VBN N
from IN N
pre- JJ N
to TO N
post-treatment NN N
for IN N
parents NNS N
of IN N
treatment NN N
responders NNS N
. . N

The DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
and CC N
suggest VB N
a DT N
youth-to-parent JJ N
influence NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observations NNS N
on IN N
the DT N
treatment NN N
of IN N
hookworm NN 1_p
, , 1_p
Ascaris NNP 1_p
and CC 1_p
Trichuris NNP 1_p
infection NN 1_p
with IN N
oxibendazole JJ 1_i
] NN 1_i
. . N

340 CD 1_p
cases NNS 1_p
of IN 1_p
hookworm NN 1_p
infection NN 1_p
, , 1_p
196 CD 1_p
cases NNS 1_p
of IN 1_p
ascariasis NN 1_p
and CC 1_p
178 CD 1_p
cases NNS 1_p
of IN 1_p
trichuriasis NN 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
an DT 1_i
anthelmintic JJ 1_i
, , 1_i
oxibendazole JJ 1_i
, , 1_i
15mg/kg.d CD 1_i
x JJ 1_i
3d CD 1_i
; : 1_i
102 CD 1_i
, , 1_i
70 CD 1_i
and CC 1_i
66 CD 1_i
cases NNS 1_i
of IN 1_i
respective JJ 1_i
infections NNS 1_i
were VBD 1_i
treated VBN 1_i
with IN 1_i
pyrantel NN 1_i
10mg/kg.d CD 1_i
x NN 1_i
3d CD 1_i
and CC 1_i
108 CD 1_i
, , 1_i
74 CD 1_i
and CC 1_i
63 CD 1_i
cases NNS 1_i
took VBD 1_i
placebo NN 1_i
for IN 1_i
comparison NN 1_i
and CC 1_i
as IN 1_i
control NN 1_i
under IN 1_i
double-blind JJ 1_i
observations NNS 1_i
. . 1_i

Re-examinations NNS N
of IN N
the DT N
stool NN N
were VBD N
performed VBN N
after IN N
the DT N
treatment NN N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
oxibendazole NN N
, , N
the DT N
egg NN 1_o
negative JJ 1_o
conversion NN 1_o
rates NNS 1_o
of IN 1_o
hookworm NN 1_o
, , 1_o
Ascaris NNP 1_o
and CC 1_o
Trichuris NNP 1_o
were VBD N
70.3-80.6 CD N
% NN N
, , N
92.5-97.8 CD N
and CC N
67.0-71.0 CD N
% NN N
respectively RB N
. . N

The DT N
egg NN 1_o
reduction NN 1_o
rates NNS 1_o
of IN 1_o
hookworm NN 1_o
were VBD N
98.1-98.6 CD N
% NN N
. . N

The DT N
larval JJ 1_o
negative JJ 1_o
conversion NN 1_o
rates NNS 1_o
of IN 1_o
Ancylostoma NNP 1_o
duodenale NN 1_o
and CC 1_o
Necator NNP 1_o
americanus VBP 1_o
were VBD N
77.7 CD N
and CC N
83.2 CD N
% NN N
respectively RB N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
pyrantel NN N
, , N
the DT N
egg NN 1_o
negative JJ 1_o
conversion NN 1_o
rates NNS 1_o
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
73.5 CD N
, , N
90.0 CD N
and CC N
28.8 CD N
% NN N
respectively RB N
. . N

The DT N
egg NN 1_o
reduction NN 1_o
rate NN 1_o
of IN 1_o
hookworm NN 1_o
was VBD N
98.8 CD N
% NN N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
placebo NN N
, , N
the DT N
egg NN 1_o
negative JJ 1_o
conversion NN 1_o
rates NNS 1_o
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
6.5 CD N
, , N
29.7 CD N
and CC N
7.9 CD N
% NN N
. . N

No CC N
marked JJ N
adverse JJ N
reactions NNS N
were VBD N
observed VBN N
by IN N
clinical JJ N
and CC N
laboratory JJ N
examinations NNS N
. . N

-DOCSTART- -X- O O

Anti-angiogenic JJ 1_o
effects NNS 1_o
of IN N
epigallocatechin-3-gallate NN 1_i
in IN N
human JJ N
skin NN N
. . N

Epigallocatechin-3-gallate NNP 1_i
( ( 1_i
EGCG NNP 1_i
) ) 1_i
is VBZ N
the DT N
main JJ N
polyphenol JJ N
component NN N
of IN N
green JJ N
tea NN N
. . N

This DT N
compound NN N
exhibits VBZ N
antioxidant JJ 1_o
, , 1_o
immunomodulatory JJ 1_o
, , 1_o
photoprotective JJ 1_o
, , 1_o
anti-angiogenic JJ 1_o
, , 1_o
and CC 1_o
anti-inflammatory JJ 1_o
properties NNS 1_o
. . 1_o

We PRP N
conducted VBD N
a DT N
small JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
split VBD N
face NN N
trial NN N
using VBG N
a DT N
cream NN 1_i
containing VBG 1_i
2.5 CD 1_i
% NN 1_i
w/w NN 1_i
of IN 1_i
EGCG NNP 1_i
. . 1_i

Four CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
with IN 1_p
significant JJ 1_p
erythema NN 1_p
and CC 1_p
telangiectasia NN 1_p
on IN 1_p
the DT 1_p
face NN 1_p
applied VBD N
EGCG NNP 1_i
cream NN 1_i
to TO N
one CD N
side NN N
of IN N
the DT N
face NN N
, , N
and CC N
vehicle NN 1_i
control NN 1_i
cream NN 1_i
to TO N
the DT N
other JJ N
, , N
twice JJ N
daily RB N
for IN N
six CD N
weeks NNS N
. . N

After IN N
six CD N
weeks NNS N
, , N
biopsies NNS 1_o
were VBD N
taken VBN N
from IN N
EGCG NNP 1_i
and CC N
vehicle NN 1_i
treated VBN 1_i
sites NNS N
. . N

Immunohistochemistry NN 1_o
was VBD N
used VBN N
to TO N
measure VB N
VEGF NNP 1_o
and CC 1_o
HIF-1 NNP 1_o
?. NNP 1_o
HIF-1 NNP 1_o
? . 1_o
expression NN 1_o
was VBD 1_o
decreased VBN N
in IN N
EGCG NNP 1_i
treated VBD 1_i
sites NNS N
, , N
such JJ N
that IN N
28.4 CD N
% NN N
of IN N
the DT N
epidermis NN N
showed VBD 1_o
positive JJ 1_o
staining NN 1_o
in IN 1_o
vehicle NN N
treated VBD N
vs. FW N
13.8 CD N
% NN N
in IN N
EGCG NNP 1_i
treated VBD 1_i
sites NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
similar JJ N
decrease NN N
in IN N
VEGF NNP 1_o
expression NN 1_o
was VBD 1_o
found VBN N
( ( N
6.7 CD N
% NN N
in IN N
EGCG NNP 1_i
vs. FW 1_i
11.0 CD N
% NN N
in IN N
in IN N
vehicle-treated JJ 1_i
skin NN 1_i
( ( N
p JJ N
< NNP 1_i
0.005 CD 1_i
) ) 1_i
. . 1_i

EGCG NNP 1_i
topical JJ 1_i
treatments NNS N
influence VB 1_o
HIF-1 NNP 1_o
? . 1_o
induction NN 1_o
and CC 1_o
VEGF NNP 1_o
expression NN 1_o
and CC 1_o
may MD N
serve VB N
as IN N
a DT N
potential JJ N
agent NN N
in IN N
the DT N
prevention NN 1_o
of IN 1_o
telangiectasias NN 1_o
. . 1_o

-DOCSTART- -X- O O

Clinical JJ N
trial NN N
: : N
marine NN 1_i
lipid JJ 1_i
suppositories NNS 1_i
as IN N
laxatives NNS N
. . N

UNLABELLED JJ N
Cod-liver JJ N
oil NN N
and CC N
other JJ N
marine NN N
products NNS N
containing VBG N
polyunsaturated JJ N
fatty JJ N
acids NNS N
have VBP N
anti-inflammatory JJ N
, , N
anti-bacterial JJ N
and CC N
anti-viral JJ N
effects NNS N
and CC N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
various JJ N
inflammatory NN N
and CC N
infectious JJ N
diseases NNS N
. . N

We PRP N
developed VBD N
suppositories NNS 1_i
and CC 1_i
ointment NN 1_i
with IN 1_i
30 CD 1_i
% NN 1_i
free JJ 1_i
fatty JJ 1_i
acid NN 1_i
( ( 1_i
FFA NNP 1_i
) ) 1_i
extract NN 1_i
from IN 1_i
omega-3 JJ 1_i
fish JJ 1_i
oil NN 1_i
. . 1_i

Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN 1_o
of IN N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
and CC N
to TO N
explore VB N
the DT N
laxative JJ 1_o
effect NN 1_o
of IN N
the DT N
suppositories NNS N
. . N

Thirty NNP 1_p
healthy JJ 1_p
volunteers NNS 1_p
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
study NN N
group NN N
administrating VBG N
30 CD N
% NN N
FFA NNP 1_i
suppositories NNS 1_i
and CC N
applying VBG N
30 CD N
% NN N
FFA NNP 1_i
ointment NN 1_i
to TO N
the DT N
perianal JJ N
region NN N
twice RB N
per IN N
day NN N
for IN N
two CD N
weeks NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
using VBG N
placebo NN 1_i
suppositories NNS 1_i
and CC N
ointment NN N
in IN N
a DT N
double JJ N
blinded JJ N
manner NN N
. . N

RESULTS NNP N
No NNP N
serious JJ 1_o
toxic NN 1_o
effects NNS 1_o
or CC 1_o
irritation NN 1_o
were VBD N
observed VBN N
. . N

In IN N
the DT N
study NN N
group NN N
93 CD N
% NN N
felt VBD N
the DT N
urge NN 1_o
to TO 1_o
defecate VB 1_o
after IN N
administration NN N
of IN N
the DT N
suppositories NNS N
as IN N
compared VBN N
to TO N
37 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Subsequently RB N
90 CD N
% NN N
in IN N
the DT N
study NN N
group NN N
defecated VBD 1_o
, , N
compared VBN N
to TO N
33 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
were VBD N
well RB N
tolerated VBN N
with IN N
no DT N
significant JJ N
toxic JJ 1_o
side NN 1_o
effects NNS 1_o
observed VBD N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
suppositories NNS N
have VBP N
a DT N
distinct JJ N
laxative JJ 1_o
effect NN 1_o
and CC N
we PRP N
aim VBP N
to TO N
explore VB N
this DT N
effect NN N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
endoscopic NN 1_i
fundoplication NN 1_i
and CC 1_i
proton NN 1_i
pump NN 1_i
inhibitors NNS 1_i
on IN N
baseline NN 1_o
impedance NN 1_o
and CC 1_o
heartburn NN N
severity NN 1_o
in IN N
GERD NNP 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Antireflux NNP N
therapy NN N
may MD N
lead VB N
to TO N
recovery NN N
of IN N
impaired JJ N
mucosal NN N
integrity NN N
in IN N
gastro-esophageal JJ 1_p
reflux NN 1_p
disease NN 1_p
( ( 1_p
GERD NNP 1_p
) ) 1_p
patients NNS 1_p
as IN N
reflected VBN N
by IN N
an DT N
increase NN 1_o
in IN 1_o
baseline JJ 1_o
impedance NN 1_o
. . 1_o

The DT N
study NN N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
endoscopic NN 1_i
fundoplication NN 1_i
and CC 1_i
proton NN 1_i
pump NN 1_i
inhibitor NN 1_i
( ( 1_i
PPI NNP 1_i
) ) 1_i
PPI NNP 1_i
therapy NN 1_i
on IN N
baseline NN 1_o
impedance NN 1_o
and CC 1_o
heartburn NN 1_o
severity NN 1_o
in IN N
GERD NNP 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
Forty-seven JJ 1_p
GERD NNP 1_p
patients NNS 1_p
randomized VBD 1_p
to TO 1_p
endoscopic VB 1_i
fundoplication NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
32 CD 1_p
) ) 1_p
or CC 1_p
PPI NNP 1_i
therapy NN 1_i
( ( 1_i
n JJ 1_p
= NNP 1_p
15 CD 1_p
) ) 1_p
, , 1_p
and CC 1_p
29 CD 1_p
healthy JJ 1_p
controls NNS 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

Before IN 1_p
randomization NN N
and CC N
6 CD N
months NNS N
after IN N
treatment NN 1_o
, , 1_o
baseline NN 1_o
impedance NN 1_o
was VBD 1_o
obtained VBN 1_i
during IN 1_i
24-h JJ 1_i
pH-impedance NN 1_i
monitoring NN 1_o
. . 1_o

Heartburn NNP 1_o
severity NN 1_o
was VBD 1_o
evaluated VBN 1_o
using VBG 1_o
the DT 1_o
GERD-HRQL NNP 1_o
questionnaire NN 1_o
. . 1_o

KEY NNP 1_o
RESULTS NNP N
Before IN N
treatment NN 1_o
, , 1_o
baseline NN 1_o
impedance NN 1_o
in IN 1_o
GERD NNP 1_o
patients NNS 1_p
was VBD 1_p
lower JJR N
than IN N
in IN 1_p
healthy JJ 1_p
controls NNS 1_p
( ( 1_p
p VB 1_p
< RB 1_p
0.001 CD N
) ) N
. . N

Antireflux NNP N
therapy NN N
increased VBD 1_o
baseline JJ 1_o
impedance NN 1_o
( ( 1_o
from IN 1_o
1498 CD N
[ JJ N
IQR NNP N
951-2472 CD N
] NN N
to TO N
2393 CD N
[ NNP N
IQR NNP N
1353-3027 JJ N
] NN N
? . N
, , N
p VBZ N
= NNP N
0.001 CD N
) ) N
, , N
however RB N
it PRP N
only RB N
led VBD N
to TO 1_o
a DT 1_o
partial JJ 1_o
recovery NN 1_o
when WRB N
compared VBN N
to TO N
healthy JJ N
controls NNS N
( ( N
2393 CD N
[ NNP N
IQR NNP N
1353-3027 JJ N
] NNP N
vs NN N
2983 CD N
[ NNP N
2335-3810 JJ N
] NN N
? . N
, , N
p VBZ N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
effect NN N
of IN N
both DT N
treatment NN N
options NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
despite IN N
the DT N
increased JJ N
number NN 1_o
of IN 1_o
non-acid JJ 1_o
reflux NN 1_o
events NNS 1_o
in IN 1_i
the DT 1_i
PPI NNP 1_i
group NN 1_i
. . N

No DT 1_o
correlation NN 1_o
was VBD N
found VBN N
between IN 1_o
baseline NN 1_o
impedance NN 1_o
and CC 1_o
GERD NNP 1_o
symptoms NNS 1_o
before IN N
or CC N
after IN N
treatment NN N
. . N

CONCLUSIONS NNP N
& CC N
INFERENCES NNP N
Reduction NNP N
in IN N
acid NN N
reflux NN N
by IN N
endoscopic JJ 1_i
fundoplication NN 1_i
or CC 1_i
PPI NNP 1_i
therapy VBP 1_i
leads VBZ N
to TO N
an DT N
increase NN N
in IN N
baseline JJ 1_o
impedance NN 1_o
in IN 1_o
GERD NNP 1_o
patients NNS 1_p
, , 1_p
likely RB N
to TO N
reflect VB N
recovery NN N
of IN N
mucosal NN N
integrity NN N
. . N

The DT N
impact NN N
of IN N
non-acid JJ N
reflux NN N
events NNS N
on IN N
esophageal NN N
mucosal NN N
integrity NN N
may MD N
be VB N
limited VBN N
as IN N
no DT N
difference NN N
in IN N
the DT N
increase NN N
in IN N
baseline JJ 1_o
impedance NN 1_o
was VBD 1_o
observed VBN N
after IN N
both DT N
treatment NN N
options NNS N
. . N

The DT N
lack NN N
of IN N
association NN N
between IN 1_o
impedance NN 1_o
baseline NN 1_o
and CC 1_o
heartburn NN 1_o
severity NN 1_o
indicates VBZ 1_o
that IN N
other JJ N
factors NNS N
may MD N
contribute VB N
to TO N
heartburn VB N
perception NN N
in IN N
GERD NNP N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
Interceed NNP 1_i
( ( 1_i
TC7 NNP 1_i
) ) 1_i
absorbable JJ 1_i
adhesion NN 1_i
barrier NN 1_i
to TO N
reduce VB N
postoperative JJ 1_o
adhesion NN 1_o
reformation NN 1_o
in IN N
infertility NN 1_p
and CC 1_p
endometriosis NN 1_p
surgery NN 1_p
. . 1_p

The DT N
Obstetrics NNPS N
and CC N
Gynecology NNP N
Adhesion NNP N
Prevention NNP N
Committee NNP N
. . N

Interceed NNP 1_i
( ( 1_i
TC7 NNP 1_i
) ) 1_i
is VBZ N
a DT N
fabric NN N
composed VBN N
of IN N
oxidized JJ N
, , N
regenerated VBD N
cellulose NN N
that WDT N
was VBD N
designed VBN N
to TO N
reduce VB N
the DT N
formation NN N
of IN N
postsurgical JJ N
adhesions NNS N
. . N

We PRP N
evaluated VBD N
Interceed NNP 1_i
( ( 1_i
TC7 NNP 1_i
) ) 1_i
in IN N
a DT N
randomized JJ N
, , N
multicenter RB N
clinical JJ N
study NN N
. . N

Sixty-three JJ 1_p
infertility NN 1_p
patients NNS 1_p
had VBD N
bilateral JJ N
pelvic JJ N
sidewall NN N
adhesions NNS N
removed VBD N
at IN N
laparotomy NN N
. . N

One CD N
pelvic NN N
sidewall NN N
was VBD N
covered VBN N
by IN N
Interceed NNP 1_i
( ( 1_i
TC7 NNP 1_i
) ) 1_i
and CC N
the DT N
other JJ 1_i
was VBD 1_i
left VBN 1_i
uncovered JJ 1_i
. . 1_i

The DT N
deperitonealized JJ N
areas NNS N
( ( N
N NNP N
= NNP N
205 CD N
) ) N
of IN N
all DT N
sidewalls NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
less JJR N
than IN N
100 CD N
mm2 NN N
, , N
N NNP N
= NNP N
72 CD N
; : N
100-1000 CD N
mm2 NN N
, , N
N NNP N
= NNP N
95 CD N
; : N
and CC N
more JJR N
than IN N
1000 CD N
mm2 NN N
, , N
N NNP N
= VBZ N
38 CD N
. . N

The DT N
effectiveness NN 1_o
of IN 1_o
Interceed NNP 1_o
( ( 1_o
TC7 NNP 1_o
) ) 1_o
was VBD N
evaluated VBN N
at IN N
laparoscopy JJ N
10-98 JJ N
days NNS N
after IN N
laparotomy NN 1_i
. . 1_i

Significantly RB N
more JJR N
adhesions NNS 1_o
were VBD N
observed VBN N
at IN N
laparoscopy NN N
on IN N
the DT N
control NN N
pelvic JJ N
sidewalls NNS N
( ( N
48 CD N
of IN N
63 CD N
, , N
76 CD N
% NN N
) ) N
than IN N
on IN N
the DT N
treated VBN N
sides NNS N
( ( N
26 CD N
of IN N
63 CD N
, , N
41 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
.0001 NN N
) ) N
. . N

The DT N
Interceed NNP 1_o
( ( 1_o
TC7 NNP 1_o
) ) 1_o
-treated VBD 1_o
sidewalls NNS N
also RB N
had VBD N
significantly RB N
less RBR N
area NN 1_o
involved VBN 1_o
with IN 1_o
adhesions NNS 1_o
at IN N
laparoscopy NN N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
, , N
P NNP N
less JJR N
than IN N
.001 NN N
, , N
and CC N
P NNP N
less JJR N
than IN N
.001 NN N
in IN N
the DT N
three CD N
groups NNS N
, , N
respectively RB N
) ) N
. . N

Twenty-eight JJ N
women NNS N
with IN N
severe JJ N
endometriosis NN N
also RB N
had VBD N
significantly RB N
more JJR N
adhesions NNS 1_o
on IN N
the DT N
control NN N
side NN N
( ( N
23 CD N
of IN N
28 CD N
, , N
82 CD N
% NN N
) ) N
than IN N
on IN N
the DT N
treated JJ N
side NN N
( ( N
14 CD N
of IN N
28 CD N
, , N
50 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
Interceed NNP 1_i
( ( 1_i
TC7 NNP 1_i
) ) 1_i
effectively RB N
reduced VBD N
the DT N
incidence NN N
and CC N
extent NN N
of IN N
postoperative JJ 1_o
adhesions NNS 1_o
, , N
even RB N
in IN N
patients NNS N
with IN N
severe JJ N
endometriosis NN N
. . N

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
a DT N
psychological JJ 1_i
intervention NN 1_i
on IN N
quality NN 1_o
of IN 1_o
life NN 1_o
in IN N
non-metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
psychological JJ 1_i
intervention NN 1_i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
and CC 1_o
behaviour NN 1_o
of IN N
women NNS 1_p
diagnosed VBN 1_p
with IN 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

36 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
with IN 1_p
non-metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
assigned VBD 1_p
to TO 1_p
surgery VB 1_p
and CC 1_p
systemic VB 1_p
chemotherapy NN 1_p
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
psychological JJ 1_i
intervention NN 1_i
( ( 1_i
weekly JJ 1_i
cognitive VBP 1_i
individual JJ 1_i
psychotherapy NN 1_i
and CC 1_i
bimonthly JJ 1_i
family NN 1_i
counselling VBG 1_i
) ) 1_i
or CC N
standard JJ 1_i
follow-up NN 1_i
. . 1_i

Personality NNP 1_o
( ( 1_o
16-PF JJ 1_o
and CC 1_o
IIQ NNP 1_o
) ) 1_o
, , 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
FLIC NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
depression NN 1_o
( ( 1_o
BDI NNP 1_o
) ) 1_o
scores NNS 1_o
were VBD N
the DT N
endpoints NNS N
for IN N
this DT N
study NN N
, , N
and CC N
the DT N
questionnaires NNS N
were VBD N
completed VBN N
by IN N
the DT N
patients NNS N
at IN N
diagnosis NN N
, , N
and CC N
up RB N
to TO N
9 CD N
months NNS N
after IN N
diagnosis NN N
. . N

Cognitive JJ N
psychotherapy NN N
and CC N
family NN N
counselling NN N
improved VBD N
both DT N
depression NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
indexes NNS 1_o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Better NNP N
emotional JJ 1_o
coping NN 1_o
behaviours NNS 1_o
were VBD N
also RB N
revealed VBN N
by IN N
some DT N
changes NNS N
in IN N
personality NN N
traits NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

-DOCSTART- -X- O O

Long-term JJ 1_o
functional JJ 1_o
outcomes NNS 1_o
and CC 1_o
predictors NNS 1_o
of IN 1_o
shunt-dependent JJ 1_o
hydrocephalus NN 1_o
after IN 1_p
treatment NN 1_p
of IN 1_p
ruptured JJ 1_p
intracranial JJ 1_p
aneurysms NN 1_p
in IN N
the DT N
BRAT NNP N
trial NN N
: : N
revisiting VBG N
the DT N
clip NN N
vs NN N
coil NN N
debate NN N
. . N

BACKGROUND NNP N
Acute NNP 1_p
hydrocephalus NN 1_p
is VBZ N
a DT N
well-known JJ N
sequela NN N
of IN N
aneurysmal JJ N
subarachnoid JJ N
hemorrhage NN N
( ( N
SAH NNP N
) ) N
. . N

Controversy NNP N
exists VBZ N
about IN N
whether IN N
open JJ N
microsurgical JJ N
methods NNS N
serve VBP N
to TO N
reduce VB N
shunt NN 1_o
dependency NN 1_o
compared VBN N
with IN N
endovascular JJ N
techniques NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
predictors NNS N
of IN N
shunt-dependent JJ 1_o
hydrocephalus NN 1_o
and CC 1_o
functional JJ 1_o
outcomes NNS 1_o
after IN N
aneurysmal JJ N
SAH NNP N
. . N

METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
471 CD 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
part NN 1_p
of IN 1_p
a DT 1_p
prospective JJ 1_p
, , 1_p
randomized VBN 1_p
, , 1_p
controlled VBN 1_p
trial NN 1_p
from IN 1_p
2003 CD 1_p
to TO 1_p
2007 CD 1_p
were VBD 1_p
retrospectively RB 1_p
reviewed VBN 1_p
. . 1_p

All DT N
variables NNS N
including VBG N
demographic JJ 1_o
data NNS 1_o
, , 1_o
medical JJ 1_o
history NN 1_o
, , 1_o
treatment NN 1_o
, , 1_o
imaging NN 1_o
, , 1_o
and CC 1_o
functional JJ 1_o
outcomes NNS 1_o
were VBD N
included VBN N
as IN N
part NN N
of IN N
the DT N
trial NN N
. . N

No DT N
additional JJ N
variables NNS N
were VBD N
retrospectively RB N
collected VBN N
. . N

RESULTS NNP N
Ultimately RB N
, , N
147 CD N
patients NNS N
( ( N
31.2 CD N
% NN N
) ) N
required VBD N
a DT N
ventriculoperitoneal JJ N
shunt NN N
( ( N
VPS NNP N
) ) N
in IN N
our PRP$ N
series NN N
. . N

Age NNP N
, , N
dissecting VBG N
aneurysm NN N
type NN N
, , N
ruptured VBD N
vertebrobasilar JJ N
aneurysm NN N
, , N
Fisher NNP N
grade NN N
, , N
Hunt NNP N
and CC N
Hess NNP N
grade NN N
, , N
admission NN N
intraventricular JJ N
hemorrhage NN N
, , N
admission NN N
intraparenchymal JJ N
hemorrhage NN N
, , N
blood NN N
in IN N
the DT N
fourth JJ N
ventricle NN N
on IN N
admission NN N
, , N
perioperative JJ N
ventriculostomy NN N
, , N
and CC N
hemicraniectomy NN N
were VBD N
significant JJ N
risk NN N
factors NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
associated VBN N
with IN N
shunt-dependent JJ 1_o
hydrocephalus NN 1_o
on IN N
univariate JJ N
analysis NN N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
intraventricular JJ 1_o
hemorrhage NN 1_o
and CC 1_o
intraparenchymal JJ 1_o
hemorrhage NN 1_o
were VBD N
independent JJ N
risk NN N
factors NNS N
for IN N
shunt NN 1_o
dependency NN 1_o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Clipping VBG 1_i
vs JJ N
coiling VBG 1_i
treatment NN N
was VBD N
not RB N
statistically RB N
associated VBN N
with IN N
VPS NNP N
after IN N
SAH NNP N
on IN N
both DT N
univariate JJ N
and CC N
multivariate JJ N
analyses NNS N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
receive VB N
a DT N
VPS NNP N
at IN N
discharge NN N
had VBD N
higher JJR N
Glasgow NNP 1_o
Outcome NNP 1_o
Scale NNP 1_o
and CC 1_o
Barthel NNP 1_o
Index NNP 1_o
scores NNS 1_o
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
functionally RB N
independent JJ N
and CC N
to TO N
return VB N
to TO N
work VB N
72 CD N
months NNS N
after IN N
surgery NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
no DT N
difference NN N
in IN N
shunt NN 1_o
dependency NN 1_o
after IN N
SAH NNP N
among IN N
patients NNS 1_p
treated VBN 1_p
by IN 1_p
endovascular JJ 1_p
or CC 1_p
microsurgical JJ 1_p
means NNS 1_p
. . 1_p

Patients NNS N
in IN N
whom WP N
shunt-dependent JJ 1_o
hydrocephalus NN 1_o
does VBZ N
not RB N
develop VB N
after IN N
SAH NNP N
tend VBP N
to TO N
have VB N
improved VBN N
long-term JJ N
functional JJ N
outcomes NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Structural NNP N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
induced VBN N
by IN N
topical JJ N
glaucoma NN N
medication NN N
] NNP N
. . N

PURPOSE VB N
The DT N
topical JJ 1_i
medication NN 1_i
represents VBZ N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
the DT N
primary JJ N
open JJ N
angle NN N
glaucoma NN N
. . N

The DT N
study NN N
is VBZ N
aimed VBN N
at IN N
assessing VBG N
the DT N
structural JJ N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
induced VBN N
by IN N
topical JJ 1_i
glaucoma NN 1_i
medication NN 1_i
. . 1_i

METHODS NNP N
For IN N
this DT N
purpose NN N
, , N
we PRP N
carried VBD N
out RP N
a DT N
40 CD N
weeks NNS N
, , N
prospective JJ N
, , N
experimental JJ N
, , N
epidemiological-operational JJ N
and CC N
randomized JJ N
study NN N
enrolling VBG N
18 CD 1_p
patients NNS 1_p
( ( 1_p
36 CD 1_p
eyes NNS 1_p
) ) 1_p
with IN 1_p
recently RB 1_p
primary JJ 1_p
open JJ 1_p
angle NN 1_p
glaucoma NN 1_p
. . 1_p

The DT N
eyes NNS N
were VBD N
divided VBN N
into IN N
treatment NN N
( ( 1_i
non-selective JJ 1_i
beta NN 1_i
blockers NNS 1_i
or CC 1_i
selective JJ 1_i
, , 1_i
prostaglandin JJ 1_i
analogues NNS 1_i
, , 1_i
topical JJ 1_i
carbonic JJ 1_i
anhydrase NN 1_i
inhibitors NNS 1_i
) ) 1_i
in IN N
four CD N
groups NNS N
. . N

The DT N
assessment NN N
was VBD N
performed VBN N
by IN N
comparison NN N
with IN N
control NN 1_i
group NN 1_p
( ( 1_p
4 CD 1_p
patients NNS 1_p
) ) 1_p
who WP 1_p
was VBD 1_p
instilled VBN 1_p
with IN 1_p
natural JJ 1_i
tears NNS 1_i
( ( 1_p
with IN 1_p
different JJ 1_p
preservative NN 1_p
) ) 1_p
. . 1_p

Both CC N
the DT N
cytology NN N
and CC N
the DT N
conjunctival NN N
biopsy NN N
specimens NNS N
were VBD N
investigated VBN N
by IN N
histological JJ N
exams NNS N
and CC N
immunohistochemistry NN N
using VBG N
different JJ N
monoclonal JJ N
antibodies NNS N
. . N

The DT N
study NN N
was VBD N
performed VBN N
by IN N
collaboration NN N
with IN N
The DT N
National NNP N
Institute NNP N
of IN N
Research NNP N
and CC N
Development NNP N
in IN N
Pathology NNP N
and CC N
Biomedical NNP N
Sciences- NNP N
V. NNP N
Babes NNP N
-Bucharest NNP N
. . N

RESULTS VB N
The DT N
morphometric JJ N
analysis NN N
of IN N
histological JJ N
sections NNS N
of IN N
conjunctiva NN N
showed VBD N
the DT N
following JJ N
changes NNS N
: : N
squamous JJ 1_o
metaplasia NN 1_o
( ( N
significant JJ N
increases NNS N
in IN N
the DT N
thickness NN 1_o
and CC 1_o
number NN 1_o
of IN 1_o
epithelial JJ 1_o
cell NN 1_o
layers NNS 1_o
) ) 1_o
, , 1_o
inflammation NN 1_o
( ( N
increase VB N
the DT N
number NN 1_o
of IN 1_o
lymphocytes NNS 1_o
, , 1_o
macrophages NNS 1_o
and CC 1_o
fibroblasts NNS 1_o
) ) 1_o
and CC 1_o
subconjunctival JJ 1_o
fibrosis NN 1_o
. . 1_o

According VBG N
to TO N
the DT N
type NN N
of IN N
medication NN N
, , N
we PRP N
observed VBD N
the DT N
significant JJ N
increase NN N
of IN N
subepithelial JJ 1_o
collagen NN 1_o
density NN 1_o
and CC 1_o
degenerative JJ 1_o
changes NNS 1_o
of IN 1_o
fibrocytes NNS 1_o
, , 1_o
the DT 1_o
reduction NN 1_o
of IN 1_o
extracellular JJ 1_o
matrix NN 1_o
and CC 1_o
also RB 1_o
the DT 1_o
up-regulation NN 1_o
of IN 1_o
antibodies NNS 1_o
against IN 1_o
matrix JJ 1_o
metalloproteinase NN 1_o
and CC 1_o
allergic JJ 1_o
changes NNS 1_o
. . 1_o

According VBG N
to TO N
structural JJ N
changes NNS N
, , N
the DT N
immunohistochemistry NN N
confirmed VBD N
the DT N
tendency NN N
of IN N
chronic JJ 1_o
inflammation NN 1_o
. . 1_o

CONCLUSIONS VB N
This DT N
study NN N
revealed VBD N
important JJ N
structural JJ N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN 1_o
after IN N
topical JJ 1_i
glaucoma NN 1_i
medication NN 1_i
. . 1_i

The DT N
category NN N
and CC N
the DT N
intensity NN N
of IN N
these DT N
changes NNS N
are VBP N
dependent JJ N
on IN N
the DT N
sort NN N
of IN N
therapy NN N
and CC N
the DT N
topical JJ N
treatment NN N
period NN N
. . N

The DT N
findings NNS N
showed VBD N
that IN N
benzalkonium NN 1_i
chloride NN 1_i
( ( 1_i
the DT 1_i
most RBS 1_i
common JJ 1_i
preservative NN 1_i
of IN 1_i
antiglaucoma NN 1_i
drugs NNS 1_i
) ) 1_i
is VBZ N
a DT N
major JJ N
factor NN N
for IN N
conjunctival NN N
metaplasia NN N
. . N

-DOCSTART- -X- O O

Prospective JJ N
evaluation NN N
of IN N
the DT N
macrolide NN 1_i
antibiotic JJ 1_i
dirithromycin NN 1_i
for IN N
the DT N
treatment NN N
of IN N
Helicobacter NNP 1_p
pylori NN 1_p
. . 1_p

BACKGROUND NNP N
Macrolide NNP 1_i
antibiotics NNS 1_i
are VBP N
active JJ N
in IN N
vitro NN N
and CC N
in IN N
vivo NN N
against IN N
Helicobacter NNP 1_p
pylori NN 1_p
. . 1_p

We PRP N
assessed VBD N
a DT N
newer JJR N
macrolide NN 1_i
, , 1_i
dirithromycin NN 1_i
, , N
for IN N
the DT N
treatment NN N
of IN N
H. NNP N
pylori FW N
in IN N
two CD N
separate JJ N
studies NNS N
. . N

METHODS NNP N
Volunteers NNPS 1_p
with IN 1_p
H. NNP 1_p
pylori FW 1_p
infection NN 1_p
( ( 1_p
by IN 1_p
13C-urea JJ 1_p
breath NN 1_p
test NN 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
2-week JJ N
treatment NN N
regimens NNS N
. . N

Study NNP N
1 CD N
: : N
dirithromycin NN 1_i
500 CD 1_i
mg NN 1_i
q.d.s. NN 1_i
, , N
dirithromycin VBZ 1_i
500 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
omeprazole JJ 1_i
40 CD 1_i
mg JJ 1_i
q.d.s. NN 1_i
, , N
or CC 1_i
dirithromycin VB 1_i
500 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
metronidazole JJ 1_i
500 CD 1_i
mg NN 1_i
t.d.s NN 1_i
. . 1_i

Study CC N
2 CD N
: : N
dirithromycin NN 1_i
500 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
omeprazole JJ 1_i
20 CD 1_i
mg NN 1_i
b.d. NN 1_i
, , N
dirithromycin NN 1_i
1000 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
omeprazole JJ 1_i
20 CD 1_i
mg NN 1_i
b.d. NN 1_i
, , N
or CC 1_i
amoxycillin RB 1_i
500 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
omepirazole JJ 1_i
20 CD 1_i
mg NN 1_i
b.d NN 1_i
. . 1_i

Four CD N
weeks NNS N
after IN N
the DT N
completion NN N
of IN N
therapy NN N
a DT N
repeat NN N
13C-urea JJ N
breath NN N
test NN N
was VBD N
done VBN N
to TO N
assess VB N
for IN N
cure NN N
. . N

RESULTS NNP N
No NNP N
patient NN N
taking VBG N
dirithromycin JJ 1_i
alone RB 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
6 CD 1_p
) ) 1_p
or CC N
in IN N
combination NN N
with IN N
omeprazole JJ 1_i
( ( N
n JJ N
= NNP N
26 CD N
) ) N
achieved VBD N
cure NN 1_o
of IN 1_o
their PRP$ 1_o
infection NN 1_o
. . 1_o

Eradication NN 1_o
of IN 1_o
H. NNP 1_o
pylori NN 1_o
was VBD N
seen VBN N
in IN N
one CD N
of IN N
seven CD N
patients NNS N
taking VBG N
dirithromycin JJ 1_i
plus CC N
metronidazole JJ 1_i
. . 1_i

Five CD N
of IN N
10 CD N
patients NNS N
taking VBG N
omeprazole-amoxycillin JJ 1_i
dual JJ N
therapy NN N
had VBD N
their PRP$ N
H. NNP 1_o
pylori NN 1_o
infection NN 1_o
cured VBD 1_o
( ( N
P NNP N
= VBZ N
0.0007 CD N
vs. NN N
patients NNS N
taking VBG N
dirithromycin JJ 1_i
plus CC N
omeprazole JJ 1_i
) ) 1_i
. . N

Eleven NNP N
( ( N
47 CD N
% NN N
) ) N
of IN N
32 CD N
patients NNS N
taking VBG N
dirithromycin JJ 1_i
alone RB N
or CC N
combined VBN N
with IN N
omeprazole JJ 1_i
reported VBD 1_o
side-effects NNS 1_o
, , N
but CC N
only RB N
two CD N
( ( N
6 CD N
% NN N
) ) N
stopped VBD N
therapy NN N
prematurely RB N
as IN N
a DT N
result NN N
of IN N
side-effects NNS 1_o
. . 1_o

CONCLUSION NNP N
No NNP N
subject JJ N
taking VBG N
dirithromycin NN 1_i
alone RB N
or CC N
in IN N
combination NN N
with IN N
omeprazole NN 1_i
had VBD N
their PRP$ N
H. NNP N
pylori NN N
infection NN N
cured VBD 1_o
. . 1_o

Dirithromycin NNP 1_i
, , N
in IN N
the DT N
regimen NNS N
used VBN N
, , N
shows VBZ N
little JJ N
promise NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
H. NNP 1_p
pylori JJ 1_p
infection NN 1_p
. . 1_p

-DOCSTART- -X- O O

Magnesium NN 1_i
sulphate NN 1_i
only RB N
slightly RB N
reduces VBZ N
the DT N
shivering VBG 1_o
threshold NN 1_o
in IN 1_p
humans NNS 1_p
. . 1_p

BACKGROUND NNP N
Hypothermia NNP 1_i
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
stroke NN N
or CC N
acute JJ N
myocardial JJ N
infarction NN N
; : N
however RB N
, , N
it PRP N
provokes VBZ N
vigorous JJ N
shivering NN N
, , N
which WDT N
causes VBZ N
potentially RB N
dangerous JJ N
haemodynamic JJ N
responses NNS N
and CC N
prevents NNS N
further RBR N
hypothermia NN N
. . N

Magnesium NNP 1_i
is VBZ N
an DT N
attractive JJ N
anti-shivering NN N
agent NN N
because IN N
it PRP N
is VBZ N
used VBN N
for IN N
treatment NN N
of IN N
postoperative JJ N
shivering NN N
and CC N
provides VBZ N
protection NN N
against IN N
ischaemic JJ N
injury NN N
in IN N
animal JJ N
models NNS N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
magnesium NN 1_i
reduces VBZ N
the DT N
threshold NN N
( ( N
triggering VBG N
core RB N
temperature NN N
) ) N
and CC N
gain NN N
of IN N
shivering VBG 1_o
without IN N
substantial JJ N
sedation NN 1_o
or CC N
muscle NN N
weakness NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
nine CD 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
( ( 1_p
18-40 JJ 1_p
yr NN 1_p
) ) 1_p
on IN 1_p
two CD 1_p
randomly NNS 1_p
assigned VBN 1_p
treatment NN 1_p
days NNS 1_p
: : 1_p
( ( N
1 CD N
) ) N
control NN 1_i
and CC N
( ( N
2 CD N
) ) N
magnesium NN 1_i
( ( N
80 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
followed VBN N
by IN N
infusion NN N
at IN N
2 CD N
g NN N
h NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

Lactated VBN 1_i
Ringer NNP 1_i
's POS 1_i
solution NN 1_i
( ( N
4 CD N
degrees NNS N
C NNP N
) ) N
was VBD N
infused VBN N
via IN N
a DT N
central JJ N
venous JJ N
catheter NN N
over IN N
a DT N
period NN N
of IN N
approximately RB N
2 CD N
h NN N
to TO N
decrease VB N
tympanic JJ 1_o
membrane NN 1_o
temperature NN 1_o
by IN N
approximately RB N
1.5 CD N
degrees NNS N
C NNP N
h NN N
( ( N
-1 NNP N
) ) N
. . N

A DT N
significant JJ N
and CC N
persistent JJ N
increase NN N
in IN N
oxygen JJ 1_o
consumption NN N
identified VBD N
the DT N
threshold NN N
. . N

The DT N
gain NN 1_o
of IN 1_o
shivering NN 1_o
was VBD N
determined VBN N
by IN N
the DT N
slope NN N
of IN N
oxygen NN N
consumption NN N
vs NN N
core NN 1_o
temperature NN 1_o
regression NN N
. . N

Sedation NN 1_o
was VBD N
evaluated VBN N
using VBG N
a DT N
verbal JJ 1_o
rating NN 1_o
score NN 1_o
( ( 1_o
VRS NNP 1_o
) ) 1_o
from IN N
0 CD N
to TO N
10 CD N
and CC N
bispectral JJ 1_o
index NN 1_o
( ( 1_o
BIS NNP 1_o
) ) 1_o
of IN 1_o
the DT 1_o
EEG NNP 1_o
. . 1_o

Peripheral NNP 1_o
muscle NN 1_o
strength NN 1_o
was VBD N
evaluated VBN N
using VBG N
dynamometry NN N
and CC N
spirometry NN N
. . N

Data NNS N
were VBD N
analysed VBN N
using VBG N
repeated JJ N
measures NNS N
anova VBP N
; : N
P NNP N
< VBD N
0.05 CD N
was VBD N
statistically RB N
significant JJ N
. . N

RESULTS NNP N
Magnesium NNP 1_i
reduced VBD N
the DT N
shivering NN 1_o
threshold NN 1_o
( ( N
36.3 CD N
[ NNP N
SD NNP N
0.4 CD N
] NNP N
degrees NNS N
C NNP N
vs VBD N
36.6 CD N
[ JJ N
0.3 CD N
] NN N
degrees NNS N
C NNP N
, , N
P NNP N
= NNP N
0.040 CD N
) ) N
. . N

It PRP N
did VBD N
not RB N
affect VB N
the DT N
gain NN 1_o
of IN 1_o
shivering VBG 1_o
( ( N
control NN N
, , N
437 CD N
[ NN N
289 CD N
] NN N
ml NN N
min NN N
( ( N
-1 NNP N
) ) N
degrees VBZ N
C NNP N
( ( N
-1 NNP N
) ) N
; : N
magnesium NN N
, , N
573 CD N
[ NN N
370 CD N
] NN N
ml NN N
min NN N
( ( N
-1 NNP N
) ) N
degrees VBZ N
C NNP N
( ( N
-1 NNP N
) ) N
; : N
P=0.344 NNP N
) ) N
. . N

The DT N
magnesium NN 1_i
bolus NN N
did VBD N
not RB N
produce VB N
significant JJ N
sedation NN 1_o
or CC N
appreciably RB N
reduce VB N
muscle NN 1_o
strength NN 1_o
. . 1_o

CONCLUSIONS NNP N
Magnesium NNP 1_i
significantly RB N
reduced VBD N
the DT N
shivering NN 1_o
threshold NN 1_o
. . 1_o

However RB N
, , N
in IN N
view NN N
of IN N
the DT N
modest JJ N
absolute NN N
reduction NN N
, , N
this DT N
finding NN N
is VBZ N
considered VBN N
to TO N
be VB N
clinically RB N
unimportant JJ N
for IN N
induction NN N
of IN N
therapeutic JJ N
hypothermia NN N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
oral JJ N
misoprostol NN 1_i
and CC N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ 1_p
stage NN 1_p
of IN 1_p
labor NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ N
misoprostol NN N
400 CD N
mug NN N
with IN N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ N
stage NN N
of IN N
labor NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
conducted VBN N
in IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

Three CD 1_p
hundred VBD 1_p
and CC 1_p
fifty-five JJ 1_p
women NNS 1_p
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ 1_i
misoprostol NN 1_i
400 CD 1_i
mug NN 1_i
or CC 1_i
intramuscular JJ 1_i
syntometrine NN 1_i
in IN N
the DT N
third JJ 1_p
stage NN 1_p
of IN 1_p
labor NN 1_p
were VBD N
studied VBN N
. . N

The DT N
change NN N
in IN N
hemoglobin JJ 1_o
level NN 1_o
from IN N
before IN N
to TO N
48 CD N
h NN N
after IN N
delivery NN N
, , N
use NN N
of IN N
additional JJ N
oxytocics NNS N
and CC N
treatment NN N
related JJ N
side NN N
effects NNS N
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
the DT N
change NN N
in IN N
hemoglobin JJ 1_o
level NN 1_o
and CC 1_o
mean JJ 1_o
blood NN 1_o
loss NN 1_o
. . 1_o

The DT N
incidence NN N
of IN N
shivering NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
misoprostol NN 1_i
group NN N
whilst VBD N
that IN N
of IN N
vomiting NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
syntometrine NN 1_i
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN 1_o
, , 1_o
headache NN 1_o
, , 1_o
diarrhea NN 1_o
and CC 1_o
pyrexia NN 1_o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Orally RB N
administered VBD N
misoprostol NN 1_i
at IN N
a DT N
dose NN N
of IN N
400 CD N
mug NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
in IN N
preventing VBG N
post-partum JJ N
blood NN 1_o
loss NN 1_o
, , N
as IN N
measured VBN N
by IN N
the DT N
peri-partum JJ N
change NN N
in IN N
hemoglobin JJ 1_o
level NN 1_o
and CC N
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

Competitive JJ 1_i
memory NN 1_i
training NN 1_i
( ( 1_i
COMET NNP 1_i
) ) 1_i
for IN N
treating VBG N
low JJ 1_o
self-esteem NNS 1_o
in IN 1_p
patients NNS 1_p
with IN 1_p
depressive JJ 1_p
disorders NNS 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Self-esteem NNP N
is VBZ N
a DT N
major JJ N
concern NN N
in IN N
mood NN N
disorders NNS N
. . N

Low JJ 1_o
self-esteem NN 1_o
is VBZ N
a DT N
symptom NN N
of IN N
depressive JJ N
disorders NNS N
and CC N
is VBZ N
considered VBN N
by IN N
some DT N
to TO N
be VB N
a DT N
predictor NN N
for IN N
relapse NN N
, , N
whereas JJ N
high JJ N
self-esteem NN N
seems VBZ N
to TO N
buffer VB N
against IN N
depression NN N
. . N

Recently RB N
, , N
Competitive NNP 1_o
Memory NNP 1_o
Training NNP 1_o
( ( 1_o
COMET NNP 1_o
) ) 1_o
has VBZ N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
the DT N
enhancement NN N
of IN N
self-esteem NN N
in IN N
several JJ N
psychopathological JJ N
conditions NNS N
. . N

The DT N
current JJ N
study NN N
assesses VBZ N
whether IN N
COMET NNP 1_i
is VBZ N
also RB N
an DT N
effective JJ N
intervention NN N
for IN N
patients NNS N
with IN N
depressive JJ N
disorders NNS N
. . N

METHODS NNP N
Sixty-one JJ 1_p
patients NNS 1_p
with IN 1_p
depressive JJ 1_p
disorders NNS 1_p
who WP 1_p
were VBD 1_p
already RB 1_p
in IN 1_p
therapy NN 1_p
in IN 1_p
an DT 1_p
outpatient JJ 1_p
mental JJ 1_p
health NN 1_p
institution NN 1_p
were VBD N
randomly RB N
assigned VBN 1_p
to TO N
either DT N
eight CD N
group NN N
sessions NNS N
of IN N
COMET NNP 1_i
in IN 1_i
addition NN 1_i
to TO 1_i
their PRP$ 1_i
regular JJ 1_i
therapy NN 1_i
( ( 1_i
COMET NNP 1_i
+ NNP 1_i
therapy NN 1_i
as IN 1_i
usual JJ 1_i
[ NNP 1_i
TAU NNP 1_i
] NN 1_i
: : 1_i
the DT N
experimental JJ N
group NN N
) ) N
or CC N
to TO N
8 CD N
weeks NNS N
of IN 1_i
ongoing VBG 1_i
regular JJ 1_i
therapy NN 1_i
( ( 1_i
TAU NNP 1_i
only RB 1_i
: : 1_i
the DT N
control NN N
group NN N
) ) N
. . N

These DT N
latter JJ N
( ( N
control NN N
) ) N
patients NNS N
received VBD N
COMET NNP 1_i
after IN N
their PRP$ N
TAU NNP 1_i
only RB N
period NN N
. . N

All DT N
patients NNS N
in IN N
both DT N
groups NNS N
that WDT N
completed VBD N
COMET NNP 1_i
were VBD N
contacted VBN N
3 CD N
and CC N
6 CD N
months NNS N
later RB N
to TO N
assess VB N
whether IN N
the DT N
effects NNS 1_o
of IN 1_o
COMET NNP 1_o
had VBD N
remained VBN N
stable JJ N
. . N

RESULTS NNP N
Compared VBD N
to TO N
the DT N
patients NNS N
who WP N
received VBD N
TAU NNP 1_i
only RB N
, , N
patients NNS N
in IN N
the DT N
COMET NNP 1_i
+ NNP 1_i
TAU NNP 1_i
condition NN N
showed VBD N
significant JJ 1_o
improvement NN 1_o
with IN N
large JJ 1_o
effect NN 1_o
sizes VBZ 1_o
on IN 1_o
indices NNS 1_o
of IN 1_o
self-esteem JJ 1_o
, , 1_o
depression NN 1_o
, , 1_o
and CC 1_o
depressive JJ 1_o
rumination NN 1_o
. . 1_o

The DT N
therapeutic JJ 1_o
effects NNS 1_o
of IN N
COMET NNP 1_i
+ NNP 1_i
TAU NNP 1_i
remained VBD N
stable JJ 1_o
after IN N
3 CD N
and CC N
6 CD N
months NNS N
on IN N
all DT N
outcome NN N
measures NNS N
or CC N
improved VBN N
even RB N
further RBR N
. . N

CONCLUSION NNP N
COMET NNP 1_i
for IN N
low JJ N
self-esteem JJ N
seems VBZ N
to TO N
be VB N
an DT N
efficacious JJ N
trans-diagnostic JJ N
intervention NN N
that WDT N
can MD N
relatively RB N
easily RB N
be VB N
added VBN N
to TO N
the DT N
regular JJ N
treatment NN N
of IN N
patients NNS N
with IN N
depressive JJ N
disorders NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
remifentanil NN 1_i
with IN N
fentanyl NN 1_i
for IN N
deep JJ 1_o
sedation NN 1_o
in IN N
oral JJ N
surgery NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
recovery NN N
for IN N
oral JJ 1_p
surgery NN 1_p
patients NNS 1_p
given VBN N
a DT N
deep JJ N
sedation NN N
regimen NNS N
of IN N
midazolam NN 1_i
, , 1_i
propofol NN 1_i
, , N
and CC N
remifentanil NN 1_i
with IN N
a DT N
standard JJ N
control NN N
of IN N
fentanyl NN N
in IN N
place NN N
of IN N
remifentanil NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized NN N
, , N
prospective JJ N
, , N
single-blinded JJ N
controlled VBD N
study NN N
. . N

Group NNP N
1 CD N
, , N
the DT N
control NN N
, , N
received VBD N
midazolam JJ 1_i
0.03 CD 1_i
mg/kg NN 1_i
, , 1_i
fentanyl VBP 1_i
1 CD 1_i
microg/kg NN 1_i
, , 1_i
and CC 1_i
propofol VB 1_i
initially RB 1_i
at IN 1_i
140 CD 1_i
microg/kg/min NN 1_i
. . 1_i

Group NNP N
2 CD N
received VBD N
midazolam RB 1_i
0.03 CD 1_i
mg/kg NN 1_i
, , 1_i
remifentanil NN 1_i
: : 1_i
propofol NN 1_i
( ( 1_i
1:500 CD 1_i
) ) 1_i
given VBN 1_i
at IN 1_i
an DT 1_i
initial JJ 1_i
propofol JJ 1_i
infusion NN 1_i
rate NN 1_i
of IN 1_i
40 CD 1_i
microg/kg/min NN 1_i
. . 1_i

Outcome NNP N
measures NNS N
included VBD N
time NN 1_o
to TO 1_o
response NN 1_o
to TO 1_o
verbal JJ 1_o
command NN 1_o
, , 1_o
Aldrete NNP 1_o
score VBD 1_o
= JJ 1_o
9 CD 1_o
, , 1_o
Postanesthesia NNP 1_o
Discharge NNP 1_o
Scoring NNP 1_o
System NNP 1_o
= VBD 1_o
7 CD 1_o
, , 1_o
and CC 1_o
assessment NN 1_o
by IN 1_o
the DT 1_o
Digit NNP 1_o
Symbol NNP 1_o
Substitution NNP 1_o
Test NNP 1_o
. . 1_o

RESULTS NNP N
Forty-seven JJ 1_p
subjects NNS 1_p
were VBD 1_p
entered VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Baseline NNP N
findings NNS N
were VBD N
homogenous JJ N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Subjects NNS N
in IN N
group NN N
2 CD N
recovered VBN N
earlier JJR N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
and CC N
required VBN N
less JJR N
propofol NN 1_i
for IN N
both DT N
the DT N
induction NN 1_o
( ( N
0.8 CD N
+/- JJ N
0.4 CD N
versus NN N
1.2 CD N
+/- JJ N
0.6 CD N
mg/kg NN N
; : N
mean JJ N
+/- JJ N
SD NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
maintenance NN 1_o
of IN 1_o
deep JJ 1_o
sedation NN 1_o
( ( N
46 CD N
+/- JJ N
9 CD N
versus NN N
131 CD N
+/- JJ N
17 CD N
microg/kg/min NN N
; : N
P NNP N
< NNP N
.005 NNP N
) ) N
. . N

There EX N
were VBD N
minor JJ N
differences NNS N
in IN N
vital JJ N
signs NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
demonstrated VBD N
that IN N
this DT N
remifentanil JJ N
regimen NNS N
provided VBD N
significantly RB N
more RBR N
rapid JJ 1_o
recovery NN 1_o
and CC N
used VBD N
significantly RB N
less JJR N
propofol JJ 1_i
compared VBN N
with IN N
the DT N
fentanyl JJ 1_i
regimen NNS N
. . N

-DOCSTART- -X- O O

Directed VBN 1_i
forgetting NN 1_i
in IN N
high-functioning JJ 1_p
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

Rehearsal NNP N
strategies NNS N
of IN N
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASDs NNP 1_p
) ) 1_p
and CC 1_p
demographically RB 1_p
matched VBN 1_p
typically RB 1_p
developed VBN 1_p
( ( 1_p
TD NNP 1_p
) ) 1_p
adults NNS 1_p
were VBD N
strategically RB N
manipulated VBN N
by IN N
cueing VBG N
participants NNS N
to TO N
either DT N
learn NN 1_i
, , N
or CC N
forget VB 1_i
each DT N
list NN N
word NN N
prior RB N
to TO N
a DT N
recognition NN 1_i
task NN 1_i
. . 1_i

Participants NNS N
were VBD N
also RB N
asked VBN N
to TO N
distinguish VB N
between IN N
autonoetic JJ N
and CC N
noetic JJ N
states NNS N
of IN N
awareness NN N
using VBG N
the DT N
Remember/Know NNP N
paradigm NN N
. . N

The DT N
ASD NNP 1_p
group NN 1_p
recognised VBD N
a DT N
similar JJ N
number NN N
of IN N
to-be-forgotten JJ 1_o
words NNS 1_o
as IN N
the DT N
TD NNP N
group NN N
, , N
but CC N
significantly RB N
fewer JJR N
to-be-learned JJ 1_o
words NNS 1_o
. . 1_o

This DT N
deficit NN 1_o
was VBD N
only RB N
evident JJ 1_o
in IN 1_o
Remember NNP 1_o
responses NNS 1_o
that WDT N
reflect VBP N
autonoetic JJ 1_o
awareness NN 1_o
, , 1_o
or CC 1_o
episodic JJ 1_o
memory NN 1_o
, , 1_o
and CC 1_o
not RB 1_o
Know NNP 1_o
responses VBZ 1_o
. . 1_o

These DT N
findings NNS 1_o
support VBP 1_o
the DT N
elaborative JJ N
encoding NN N
deficit NN N
hypothesis NN N
and CC N
provide VB N
a DT N
link NN 1_o
between IN 1_o
the DT 1_o
previously RB 1_o
established VBN 1_o
mild JJ 1_o
episodic JJ 1_o
memory NN 1_o
impairments NNS 1_o
in IN 1_o
adults NNS 1_o
with IN 1_o
high JJ 1_o
functioning VBG 1_o
autism NN 1_o
and CC 1_o
the DT 1_o
encoding NN 1_o
strategies NNS 1_o
employed VBN N
. . N

-DOCSTART- -X- O O

EEG NNP N
mapping NN N
and CC N
psychopharmacological JJ N
studies NNS N
with IN N
denbufylline NN 1_i
in IN N
SDAT NNP 1_p
and CC 1_p
MID NNP 1_p
. . 1_p

Computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
, , N
electroencephalograms FW N
( ( N
EEG NNP N
) ) N
, , N
clinical JJ N
and CC N
psychometric JJ N
data NNS N
were VBD N
obtained VBN N
in IN N
96 CD 1_p
mildly RB 1_p
to TO 1_p
moderately RB 1_p
demented JJ 1_p
patients NNS 1_p
( ( 1_p
72 CD 1_p
women NNS 1_p
, , 1_p
24 CD 1_p
men NNS 1_p
) ) 1_p
, , 1_p
aged VBN 1_p
61-96 CD 1_p
years NNS 1_p
( ( 1_p
mean VB 1_p
82 CD 1_p
) ) 1_p
, , 1_p
diagnosed VBD 1_p
according VBG 1_p
to TO 1_p
DSM-III NNP 1_p
criteria NNS 1_p
. . 1_p

Patients NNS 1_p
were VBD 1_p
off RP 1_p
drugs NNS 1_p
for IN 1_p
at IN 1_p
least JJS 1_p
2 CD 1_p
weeks NNS 1_p
and CC 1_p
subdiagnosed VBD 1_p
according VBG 1_p
to TO 1_p
the DT 1_p
modified VBN 1_p
Marshall-Hachinski NNP 1_p
ischemic JJ 1_p
score NN 1_p
and CC 1_p
CT NNP 1_p
in IN 1_p
45 CD 1_p
senile JJ 1_p
dementia NN 1_p
of IN 1_p
the DT 1_p
Alzheimer NNP 1_p
type NN 1_p
( ( 1_p
SDAT NNP 1_p
) ) 1_p
and CC 1_p
51 CD 1_p
multiinfarct NN 1_p
dementia NN 1_p
( ( 1_p
MID NNP 1_p
) ) 1_p
patients NNS 1_p
. . 1_p

Evaluations NNS N
were VBD N
carried VBN N
out RP N
before IN N
and CC N
12 CD N
weeks NNS N
after IN N
treatment NN N
with IN N
either DT N
100 CD N
mg NNS N
denbufylline JJ 1_i
BID NNP N
or CC N
placebo NN 1_i
and CC N
included VBD N
EEG NNP N
mapping NN N
, , N
the DT N
Sandoz NNP N
Clinical NNP N
Assessment NNP N
Geriatric NNP N
( ( N
SCAG NNP N
) ) N
score/factors NNS N
, , N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
, , N
the DT N
Digit NNP N
Symbol NNP N
Substitution NNP N
Test NNP N
( ( N
DSST NNP N
) ) N
, , N
the DT N
Trail-Making JJ N
Test NNP N
( ( N
TMT NNP N
) ) N
and CC N
the DT N
Digit NNP N
Span NNP N
Test NNP N
( ( N
DS NNP N
) ) N
. . N

Descriptive NNP N
data NNS N
analysis NN N
including VBG N
confirmatory JJ N
statements NNS N
found VBN N
delta/theta JJ 1_o
activity NN 1_o
enhanced VBD N
, , N
alpha NN 1_o
and CC 1_o
beta NN 1_o
activity NN 1_o
reduced VBN N
, , N
total JJ 1_o
power NN 1_o
augmented VBN N
, , N
and CC N
the DT N
centroid NN 1_o
slowed VBD N
down RB N
over RB N
various JJ N
brain NN N
regions NNS N
in IN N
patients NNS N
as IN N
compared VBN N
with IN N
controls NNS N
. . N

The DT N
two CD N
subtypes NNS N
of IN N
dementia NN N
could MD N
be VB N
differentiated VBN N
in IN N
some DT N
conventional JJ N
EEG NNP N
variables NNS N
but CC N
mostly RB N
by IN N
means NNS N
of IN N
power NN N
asymmetry NN N
indices NNS N
. . N

Denbufylline NNP 1_i
induced VBD N
a DT N
statistically RB N
significant JJ N
and CC N
clinically RB N
relevant JJ N
improvement NN 1_o
in IN 1_o
both DT 1_o
SDAT NNP 1_o
and CC 1_o
MID NNP 1_o
patients NNS N
, , N
whereas NNS N
after IN N
placebo NN 1_i
this DT N
was VBD N
not RB N
the DT N
case NN N
in IN N
CGI NNP N
, , N
the DT N
TMT NNP N
, , N
and CC N
the DT N
DS NNP N
, , N
with IN N
interdrug JJ N
differences NNS N
being VBG N
significant JJ N
in IN N
all DT N
primary JJ N
target NN N
variables NNS N
such JJ N
as IN N
the DT N
CGI NNP 1_o
, , 1_o
MMS NNP 1_o
, , 1_o
SCAG NNP 1_o
, , 1_o
and CC 1_o
DSST NNP 1_o
. . 1_o

Thus RB N
, , N
both DT N
the DT N
degenerative NN N
and CC N
vascular JJ N
type NN N
of IN N
dementia NN N
exhibited VBD N
a DT N
therapeutic JJ N
benefit NN N
that WDT N
could MD N
be VB N
objectified VBN N
at IN N
the DT N
neurophysiological JJ N
level NN N
by IN N
EEG NNP N
mapping NN N
in IN N
an DT N
improvement NN N
of IN N
vigilance NN N
. . N

-DOCSTART- -X- O O

High-dose JJ 1_i
pyridoxine NN 1_i
and CC 1_i
magnesium NN 1_i
administration NN 1_i
in IN N
children NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
: : 1_p
an DT N
absence NN N
of IN N
salutary JJ N
effects NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Several JJ N
reports NNS N
have VBP N
described VBN N
salutary JJ N
effects NNS N
such JJ N
as IN N
decreased JJ N
physical JJ N
aggression NN N
and CC N
improved VBN N
social JJ N
responsiveness NN N
being VBG N
associated VBN N
with IN N
the DT N
administration NN N
of IN N
high JJ N
doses NNS N
of IN N
pyridoxine NN 1_i
and CC 1_i
magnesium NN 1_i
( ( 1_i
HDPM NNP 1_i
) ) 1_i
in IN N
open-labeled JJ N
and CC N
controlled JJ N
studies NNS N
of IN N
patients NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Despite IN N
this DT N
fact NN N
, , N
this DT N
intervention NN N
remains VBZ N
controversial JJ N
. . N

A DT N
10-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
examine VB N
both DT N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
HDPM NNP 1_i
in IN N
autism NN N
. . N

Twelve CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
and CC 1_p
10 CD 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
6 CD 1_p
years NNS 1_p
3 CD 1_p
months NNS 1_p
) ) 1_p
were VBD 1_p
able JJ 1_p
to TO 1_p
complete VB 1_p
the DT 1_p
study NN 1_p
. . 1_p

HDPM NNP 1_i
at IN N
an DT N
average JJ N
dose NN N
of IN N
638.9 CD N
mg NN N
of IN N
pyridoxine NN 1_i
and CC N
216.3 CD N
mg NN N
of IN N
magnesium NN 1_i
oxide NN 1_i
was VBD N
ineffective JJ N
in IN N
ameliorating VBG 1_o
autistic JJ 1_o
behaviors NNS 1_o
as IN N
assessed VBN N
by IN N
the DT N
Children NNP 1_o
's POS 1_o
Psychiatric NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
( ( 1_o
CPRS NNP 1_o
) ) 1_o
, , 1_o
the DT 1_o
Clinical NNP 1_o
Global NNP 1_o
Impression NNP 1_o
Scale NNP 1_o
, , 1_o
and CC 1_o
the DT 1_o
NIMH NNP 1_o
Global NNP 1_o
Obsessive NNP 1_o
Compulsive NNP 1_o
Scale NNP 1_o
. . 1_o

Furthermore NNP N
, , N
no DT N
clinically RB N
significant JJ N
side NN N
effects NNS N
were VBD N
noted VBN N
during IN N
HDPM NNP 1_i
administration NN N
. . N

A DT N
trend NN N
for IN N
a DT N
transient JJ N
change NN N
on IN N
the DT N
CPRS NNP N
was VBD N
found VBN N
that IN N
was VBD N
possibly RB N
due JJ N
to TO N
a DT N
placebo NN N
response NN N
. . N

This DT N
study NN N
raises VBZ N
doubts NNS N
about IN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
HDPM NNP 1_i
in IN N
autistic JJ N
disorder NN N
. . N

-DOCSTART- -X- O O

Feasibility NNP N
study NN N
of IN N
the DT N
effects NNS 1_o
of IN N
art NN N
as IN N
a DT N
creative JJ N
engagement NN N
intervention NN N
during IN N
stroke NN N
rehabilitation NN N
on IN N
improvement NN N
of IN N
psychosocial JJ 1_o
outcomes NNS 1_o
: : 1_o
study NN N
protocol NN N
for IN N
a DT N
single JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
: : N
the DT N
ACES NNP N
study NN N
. . N

BACKGROUND NNP N
Benefits NNP N
of IN N
art NN N
participation NN N
after IN N
stroke NN N
are VBP N
becoming VBG N
increasingly RB N
recognized VBN N
. . N

Qualitative JJ N
studies NNS N
suggest VBP N
that IN N
participation NN N
in IN N
visual JJ N
arts NNS N
creative JJ N
engagement JJ N
interventions NNS N
( ( N
CEIs NNP N
) ) N
during IN N
rehabilitation NN N
after IN N
stroke NN N
may MD N
improve VB N
mood NN 1_o
, , 1_o
self-esteem JJ 1_o
, , 1_o
hope NN 1_o
and CC N
some DT N
aspects NNS N
of IN N
physical JJ N
recovery NN N
. . N

This DT N
study NN N
examines VBZ N
the DT N
feasibility NN N
of IN N
undertaking VBG N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
CEI NNP N
delivered VBN N
by IN N
artists NNS N
within IN N
in-patient JJ N
stroke NN N
rehabilitation NN N
to TO N
test VB N
effectiveness NN N
. . N

METHODS/DESIGN NNP N
This DT N
trial NN N
is VBZ N
a DT N
two CD N
arm NN N
, , N
single-blind NN N
, , N
randomized VBN N
controlled VBN N
feasibility NN N
trial NN N
within IN N
in-patient JJ N
stroke NN N
rehabilitation NN N
. . N

We PRP N
will MD N
recruit VB N
80 CD 1_p
patients NNS 1_p
receiving VBG 1_i
stroke NN 1_i
rehabilitation NN 1_i
in IN 1_i
two CD 1_i
stroke VBD 1_i
units NNS 1_i
in IN 1_i
a DT 1_i
health NN 1_i
board NN 1_i
area NN 1_i
of IN 1_i
Scotland NNP 1_i
( ( 1_i
40 CD 1_i
patients NNS 1_i
in IN 1_i
each DT 1_i
arm NN 1_i
) ) 1_i
. . 1_i

Intervention NNP 1_i
arm NN 1_i
participants NNS 1_i
will MD 1_i
receive VB 1_i
a DT 1_i
visual-arts NNS 1_i
based VBN 1_i
CEI NNP 1_i
facilitated VBN 1_i
by IN 1_i
experienced JJ 1_i
artists NNS 1_i
. . 1_i

Artists NNS 1_i
will MD 1_i
follow VB 1_i
an DT 1_i
intervention NN 1_i
protocol NN 1_i
with IN 1_i
specific JJ 1_i
components NNS 1_i
that WDT 1_i
enable VBP 1_i
participants NNS 1_i
to TO 1_i
set VB 1_i
, , 1_i
achieve VB 1_i
and CC 1_i
review VB 1_i
artistic JJ 1_i
goals NNS 1_i
. . 1_i

Participants NNS 1_i
will MD 1_i
receive VB 1_i
up RP 1_i
to TO 1_i
eight CD 1_i
intervention NN 1_i
sessions NNS 1_i
, , 1_i
four CD 1_i
within IN 1_i
a DT 1_i
group NN 1_i
and CC 1_i
four CD 1_i
one-to-one NN 1_i
with IN 1_i
the DT 1_i
artist NN 1_i
. . 1_i

Control NNP N
group NN N
participants NNS N
will MD N
receive VB N
usual JJ N
care NN N
only.Data JJ N
collection NN N
will MD N
occur VB N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
three-month JJ N
follow-up NN N
. . N

Stroke-related JJ 1_o
health NN 1_o
status NN 1_o
is VBZ N
the DT N
primary JJ N
outcome NN N
; : N
mood NN 1_o
, , 1_o
self-esteem JJ 1_o
, , 1_o
self-efficacy JJ 1_o
, , 1_o
perceived JJ 1_o
recovery NN 1_o
control NN 1_o
and CC 1_o
hope NN 1_o
are VBP 1_o
secondary JJ 1_o
outcomes NNS N
. . N

Semi-structured JJ N
interviews NNS N
will MD N
be VB N
conducted VBN N
with IN N
purposively RB N
selected VBN N
patients NNS N
, , N
artists NNS N
and CC N
healthcare JJ N
staff NN N
to TO N
elicit VB 1_o
views NNS 1_o
and CC 1_o
experiences NNS 1_o
of IN N
the DT N
intervention NN N
and CC N
feasibility NN 1_o
and CC 1_o
acceptability NN 1_o
of IN N
trial NN N
processes NNS N
. . N

Recruitment JJ 1_o
rates NNS 1_o
, , 1_o
retention NN 1_o
rates NNS 1_o
and CC 1_o
patient JJ 1_o
preference NN 1_o
for IN 1_o
art JJ 1_o
participation NN 1_o
will MD N
also RB N
be VB N
collected VBN N
. . N

Data NNP N
will MD N
indicate VB N
, , N
with IN N
confidence NN N
intervals NNS N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
choosing VBG N
or CC N
refusing VBG N
participation NN N
in IN N
the DT N
CEI NNP N
and CC N
will MD N
allow VB N
calculation NN N
of IN N
recruitment NN 1_o
rates NNS 1_o
for IN N
a DT N
future JJ N
definitive JJ N
trial NN N
. . N

Summary NNP N
data NNS N
will MD N
indicate VB N
potential JJ N
variability NN N
, , N
magnitude NN N
and CC N
direction NN N
of IN N
difference NN N
between IN N
groups NNS N
. . N

Findings NNS N
will MD N
inform VB N
sample JJ N
size NN N
calculations NNS N
for IN N
a DT N
definitive JJ N
trial NN N
. . N

Thematic JJ N
analysis NN N
of IN N
qualitative JJ N
data NNS N
will MD N
be VB N
managed VBN N
using VBG N
the DT N
Framework NNP N
Approach NNP N
. . N

Framework NNP N
is VBZ N
an DT N
analytical JJ N
approach NN N
for IN N
qualitative JJ N
data NNS N
, , N
commonly RB N
used VBN N
in IN N
policy NN N
and CC N
medical JJ N
research NN N
. . N

DISCUSSION NNP N
If IN N
shown VBN N
to TO N
demonstrate VB N
effects NNS N
, , N
this DT N
intervention NN N
has VBZ N
the DT N
potential JJ N
to TO N
address VB N
aspects NNS N
of IN N
stroke NN N
recovery NN N
previously RB N
. . N

Not RB N
routinely RB N
addressed VBN N
in IN N
rehabilitation NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Registered NNP N
with IN N
Clinical NNP N
Trials.Gov NNP N
: : N
NCT02085226 NN N
on IN N
6th CD N
March NNP N
2014 CD N
. . N

-DOCSTART- -X- O O

Right RB N
ventricular JJ N
function NN N
during IN N
high-frequency JJ 1_i
oscillatory JJ 1_i
ventilation NN 1_i
in IN N
adults NNS 1_p
with IN 1_p
acute JJ 1_p
respiratory NN 1_p
distress NN 1_p
syndrome NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
mean JJ N
airway JJ N
pressure NN N
under IN N
high-frequency NN 1_i
oscillatory NN 1_i
ventilation NN 1_i
on IN N
right JJ N
ventricular JJ N
function NN N
. . N

DESIGN NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Intensive NNP N
care NN N
unit NN N
of IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

PATIENTS NNP N
Sixteen NNP 1_p
consecutive JJ 1_p
patients NNS 1_p
within IN 1_p
the DT 1_p
first JJ 1_p
48 CD 1_p
hrs NN 1_p
of IN 1_p
mainly RB 1_p
pulmonary JJ 1_p
acute NN 1_p
respiratory NN 1_p
distress JJ 1_p
syndrome NN 1_p
. . 1_p

INTERVENTIONS NNP N
After IN N
a DT N
6-hr-period JJ N
of IN N
protective JJ 1_i
conventional JJ 1_i
mechanical JJ 1_i
ventilation NN 1_i
, , N
patients NNS N
were VBD N
submitted VBN N
to TO N
three CD 1_i
1-hr JJ 1_i
periods NNS 1_i
of IN 1_i
high-frequency NN 1_i
oscillatory NN 1_i
ventilation NN 1_i
( ( N
+5 JJ N
, , N
+10 NNP N
, , N
+15 NNP N
) ) N
in IN N
a DT N
randomized JJ N
order NN N
, , N
with IN N
a DT N
mean JJ N
airway NN N
pressure NN N
level NN N
determined VBN N
by IN N
adding VBG N
5 CD 1_i
, , 1_i
10 CD 1_i
, , 1_i
or CC 1_i
15 CD 1_i
cm NNS 1_i
H2O NNP 1_i
to TO N
the DT N
mean JJ N
airway NN N
pressure NN N
recorded VBN N
during IN N
conventional JJ N
mechanical JJ N
ventilation NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Mean NNP 1_o
airway JJ 1_o
pressure NN 1_o
was VBD N
18?3 CD N
cm JJ N
H2O NNP N
during IN 1_i
conventional JJ 1_i
mechanical JJ 1_i
ventilation NN 1_i
and CC N
was VBD N
increased VBN N
until IN N
33?3 CD N
cm NNS N
H2O NNP N
at IN N
high-frequency NN 1_i
oscillatory NN 1_i
ventilation+15 NN 1_o
. . 1_o

Right NNP 1_o
ventricular JJ 1_o
function NN 1_o
was VBD 1_o
assessed VBN N
using VBG 1_o
transesophageal JJ 1_o
echocardiography NN 1_o
. . 1_o

During IN 1_i
conventional JJ 1_i
mechanical JJ 1_i
ventilation NN 1_i
, , 1_i
nine CD N
patients NNS N
presented VBD N
a DT N
right JJ 1_o
ventricular NN 1_o
dysfunction NN 1_o
( ( 1_o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
ratio NN N
> NNP N
0.6 CD N
) ) N
of IN N
whom WP N
four CD N
patients NNS N
had VBD N
a DT N
right JJ 1_o
ventricular NN 1_o
failure NN 1_o
( ( 1_o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
ratio NN 1_i
> NNP 1_i
0.9 CD 1_i
) ) 1_i
. . 1_i

High-frequency NNP 1_i
oscillatory JJ 1_i
ventilation+10 NN 1_i
and CC 1_i
+15 VB N
further RB 1_o
worsened VBN 1_o
right JJ 1_o
ventricular NN 1_o
function NN 1_o
, , 1_o
resulting VBG N
in IN N
about IN N
a DT N
40 CD N
% NN N
increase NN N
in IN N
right JJ 1_o
ventricular JJ 1_o
end-diastolic JJ 1_o
area/left NN 1_o
ventricular JJ 1_o
end-diastolic JJ 1_o
area NN 1_o
ratio NN 1_o
and CC 1_o
a DT N
30 CD N
% NN N
increase NN N
in IN N
end-diastolic JJ 1_o
eccentricity NN 1_o
index NN 1_o
when WRB 1_o
compared VBN N
with IN 1_i
conventional JJ 1_i
mechanical JJ 1_i
ventilation NN 1_i
or CC 1_i
high-frequency NN 1_i
oscillatory NN 1_i
ventilation+5 NN 1_i
periods NNS 1_i
. . N

At IN N
high-frequency JJ N
oscillatory NN N
ventilation+15 NN N
, , N
15 CD N
patients NNS N
had VBD 1_o
right JJ 1_o
ventricular JJ 1_o
dysfunction NN 1_o
and CC 1_o
nine CD N
had VBD 1_o
right JJ 1_o
ventricular JJ 1_o
failure NN 1_o
. . 1_o

High-frequency NNP N
oscillatory JJ N
ventilation NN N
did VBD N
not RB 1_o
improve VB 1_o
oxygenation NN 1_o
whatever IN 1_o
the DT N
mean JJ N
airway NN N
pressure NN N
level NN N
. . N

A DT N
significant JJ N
redistribution NN N
of IN N
tidal JJ N
variation NN N
to TO N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lung NN N
was VBD N
observed VBN N
on IN N
electrical JJ N
impedance NN N
tomography NN N
measurements NNS N
when WRB 1_o
increasing VBG 1_o
mean VB 1_o
airway JJ 1_o
pressure NN 1_o
. . 1_o

However RB N
, , N
this DT N
redistribution NN N
was VBD N
not RB N
observed VBN N
in IN N
patients NNS N
who WP N
presented VBD N
a DT N
worsening NN 1_o
of IN 1_o
right JJ 1_o
ventricular JJ 1_o
function NN 1_o
( ( 1_o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
increase NN N
> VBD N
40 CD N
% NN N
) ) N
at IN N
high-frequency NN 1_i
oscillatory NN 1_i
ventilation+15 NN 1_i
. . 1_i

CONCLUSIONS NNP N
In IN N
patients NNS 1_p
with IN 1_p
mainly RB 1_p
pulmonary JJ 1_p
acute NN 1_p
respiratory NN 1_p
distress NN 1_p
syndrome NN 1_p
, , 1_p
using VBG N
high JJ N
mean JJ N
airway NN N
pressure NN N
under IN 1_i
high-frequency NN 1_i
oscillatory JJ 1_i
ventilation NN 1_i
can MD 1_o
worsen VB 1_o
right JJ 1_o
ventricular NN 1_o
function NN 1_o
when WRB 1_o
compared VBN N
with IN 1_i
protective JJ 1_i
conventional JJ 1_i
mechanical JJ 1_i
ventilation NN 1_i
, , 1_i
notably RB N
in IN N
patients NNS N
in IN N
whom WP N
high-frequency NN N
oscillatory NN N
ventilation NN N
produced VBD N
less JJR N
alveolar JJ N
recruitment NN N
of IN N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lungs NNS N
. . N

This DT N
study NN N
highlights VBZ N
the DT N
interest NN N
of IN N
monitoring VBG N
right JJ N
ventricular JJ N
function NN N
during IN 1_i
high-frequency JJ 1_i
oscillatory JJ 1_i
ventilation NN 1_i
. . 1_i

-DOCSTART- -X- O O

Management NN N
of IN N
large JJ N
bowel NN N
obstruction NN N
with IN N
self-expanding JJ 1_i
metal NN 1_i
stents NNS 1_i
. . 1_i

A DT N
multicentre JJ N
retrospective NN N
study NN N
of IN N
factors NNS N
determining VBG N
outcome NN N
. . N

AIM NNP N
UK NNP N
cancer NN N
guidelines NNS N
recommend VBP N
patients NNS 1_p
with IN 1_p
colonic JJ 1_p
obstruction NN 1_p
due JJ 1_p
to TO 1_p
suspected JJ 1_p
malignancy NN 1_p
be VB N
considered VBN N
for IN N
stenting VBG 1_i
with IN 1_i
a DT 1_i
self-expanding JJ 1_i
metal NN 1_i
stent NN 1_i
( ( 1_i
SEMS NNP 1_i
) ) 1_i
. . 1_i

Considerable JJ N
variation NN N
in IN N
practice NN N
exists NNS N
due JJ N
to TO N
a DT N
lack NN N
of IN N
expertise NN N
, , N
technical JJ N
difficulties NNS N
and CC N
other JJ N
, , N
as IN N
yet RB N
ill-defined JJ N
features NNS N
. . N

This DT N
retrospective JJ N
multi-centre NN N
study NN N
aims VBZ N
to TO N
determine VB N
the DT N
outcome NN N
following VBG N
colonic JJ N
stenting VBG N
for IN N
large JJ N
bowel NN N
obstruction NN N
and CC N
identify VB N
factors NNS N
associated VBN N
with IN N
successful JJ N
intervention NN N
. . N

METHOD NNP N
A NNP N
regional JJ N
programme NN N
of IN N
colonic JJ N
stenting VBG N
for IN N
large JJ N
bowel NN N
obstruction NN N
, , N
in IN 1_p
five CD 1_p
UK NNP 1_p
centres NNS 1_p
from IN 1_p
2005 CD 1_p
to TO 1_p
2010 CD 1_p
was VBD N
evaluated VBN N
for IN N
outcome NN N
including VBG N
technical JJ 1_o
and CC 1_o
clinical JJ 1_o
success NN 1_o
, , 1_o
survival NN 1_o
, , 1_o
complications NNS 1_o
and CC 1_o
reoperation NN 1_o
. . 1_o

RESULTS VB N
A DT 1_p
SEMS NNP 1_i
was VBD 1_p
inserted VBN 1_p
in IN 1_p
334 CD 1_p
patients NNS 1_p
, , 1_p
including VBG 1_p
264 CD 1_p
( ( 1_p
79.0 CD 1_p
% NN 1_p
) ) 1_p
for IN 1_p
palliation NN 1_p
and CC 1_p
52 CD 1_p
( ( 1_p
15.6 CD 1_p
% NN 1_p
) ) 1_p
as IN 1_p
a DT 1_p
bridge NN 1_p
to TO 1_p
surgery NN 1_p
. . 1_p

Technical NNP 1_o
success NN 1_o
was VBD N
achieved VBN N
in IN N
292 CD N
( ( N
87.4 CD N
% NN N
) ) N
patients NNS N
, , N
with IN N
46 CD N
( ( N
13.8 CD N
% NN N
) ) N
experiencing VBG N
a DT N
complication NN N
or CC N
technical JJ N
failure NN N
. . N

Reoperation NN 1_o
was VBD N
required VBN N
in IN N
39 CD N
( ( N
14.8 CD N
% NN N
) ) N
patients NNS N
stented VBN N
for IN N
palliation NN N
of IN N
colorectal JJ 1_p
cancer NN 1_p
of IN N
whom WP N
16 CD N
( ( N
6.1 CD N
% NN N
) ) N
subsequently RB N
required VBN N
a DT N
colostomy NN 1_p
. . 1_p

A DT N
one-stage JJ 1_o
primary JJ 1_o
anastomosis NN 1_o
was VBD N
achieved VBN N
in IN N
35 CD N
( ( N
67.3 CD N
% NN N
) ) N
of IN N
the DT N
52 CD 1_p
patients NNS 1_p
undergoing VBG 1_p
stenting VBG 1_p
as IN 1_p
a DT 1_p
bridge NN 1_p
to TO 1_p
resection NN 1_p
. . 1_p

Technical JJ 1_o
success NN 1_o
did VBD N
not RB N
vary JJ N
by IN N
indication NN 1_o
or CC 1_o
site NN 1_o
of IN 1_o
obstruction NN 1_o
( ( N
P NNP N
= NNP N
0.60 CD N
) ) N
but CC N
was VBD N
higher JJR N
for IN N
operators NNS N
who WP N
had VBD N
performed VBN N
more JJR N
than IN N
10 CD N
procedures NNS N
( ( N
OR NNP N
3.34 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

ASA NNP N
grade VBD N
?3 NNP N
predicted VBD N
a DT N
worse JJ 1_o
clinical JJ 1_o
outcome NN 1_o
( ( 1_o
OR CC N
0.43 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT 1_o
through-the-scope NN 1_o
( ( 1_o
TTS NNP 1_o
) ) 1_o
endoscopy NN 1_o
technique NN 1_o
was VBD 1_o
more RBR 1_o
successful JJ 1_o
than IN 1_o
radiological JJ N
placement NN N
alone RB N
( ( N
90.3 CD N
% NN N
vs JJ N
74.8 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Experienced VBD N
operators NNS N
using VBG N
a DT N
TTS NNP 1_p
technique NN 1_p
achieved VBD 1_p
a DT N
better JJR N
outcome NN N
for IN N
the DT N
emergency NN N
management NN N
of IN N
large JJ N
bowel NN N
obstruction NN 1_p
. . 1_p

Older JJR 1_p
, , 1_p
sicker NN 1_p
patients NNS 1_p
and CC 1_p
those DT 1_p
with IN 1_p
extracolonic JJ 1_p
and CC 1_p
benign JJ 1_p
strictures NNS 1_p
fared VBD 1_p
less JJR N
well RB N
. . N

-DOCSTART- -X- O O

Clinical JJ N
benefit NN N
with IN N
docetaxel JJ 1_i
plus CC 1_i
fluorouracil JJ 1_i
and CC 1_i
cisplatin NNS 1_i
compared VBN N
with IN N
cisplatin NN 1_i
and CC 1_i
fluorouracil NN 1_i
in IN N
a DT N
phase NN N
III NNP N
trial NN N
of IN N
advanced JJ 1_p
gastric NN 1_p
or CC 1_p
gastroesophageal NN 1_p
cancer NN 1_p
adenocarcinoma NN 1_p
: : 1_p
the DT N
V-325 NNP N
Study NNP N
Group NNP N
. . N

PURPOSE NNP N
For IN 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
gastric NN 1_p
or CC 1_p
gastroesophageal NN 1_p
cancer NN 1_p
( ( 1_p
AGGEC NNP 1_p
) ) 1_p
providing VBG N
clinical JJ N
benefit NN N
with IN N
improved JJ N
palliation NN N
is VBZ N
highly RB N
desirable JJ N
. . N

However RB N
, , N
a DT N
prospective JJ N
evaluation NN N
of IN N
clinical JJ N
benefit NN N
in IN N
AGGEC NNP N
patients NNS N
has VBZ N
never RB N
before RB N
been VBN N
reported VBN N
in IN N
a DT N
phase NN N
III NNP N
setting NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN 1_p
a DT 1_p
multinational JJ 1_p
trial NN 1_p
( ( 1_p
V325 NNP 1_p
) ) 1_p
, , 1_p
445 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
and CC 1_p
treated VBN 1_p
with IN N
either DT N
docetaxel JJ 1_i
plus CC 1_i
cisplatin JJ 1_i
and CC 1_i
fluorouracil NN 1_i
( ( 1_i
DCF NNP 1_i
) ) 1_i
or CC N
cisplatin NN 1_i
and CC 1_i
fluorouracil NN 1_i
( ( 1_i
CF NNP 1_i
) ) 1_i
. . 1_i

Clinical JJ N
benefit NN N
was VBD N
prospectively RB N
evaluated VBN N
in IN N
this DT N
trial NN N
as IN N
a DT N
secondary JJ N
end NN N
point NN N
. . N

The DT N
primary JJ N
measure NN N
for IN N
clinical JJ N
benefit NN N
analysis NN N
was VBD N
time NN 1_o
to TO 1_o
definitive VB 1_o
worsening NN 1_o
by IN N
one CD N
or CC N
more JJR N
categories NNS N
of IN N
Karnofsky NNP 1_o
performance NN 1_o
status NN 1_o
( ( N
KPS NNP N
) ) N
. . N

Secondary JJ N
clinical JJ N
benefit NN N
end NN N
points NNS N
included VBD N
time NN 1_o
to TO 1_o
5 CD 1_o
% NN 1_o
definitive JJ 1_o
weight NN 1_o
loss NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
definitive JJ 1_o
worsening NN 1_o
of IN 1_o
appetite NN 1_o
by IN 1_o
one CD 1_o
grade NN 1_o
, , 1_o
pain-free JJ 1_o
survival NN 1_o
( ( 1_o
defined VBN 1_o
as IN 1_o
time NN 1_o
to TO 1_o
first JJ 1_o
appearance NN 1_o
of IN 1_o
pain NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
time NN 1_o
to TO 1_o
first JJ 1_o
cancer NN 1_o
pain-related JJ 1_o
opioid JJ 1_o
intake NN 1_o
. . 1_o

Clinical JJ N
benefit NN N
assessments NNS N
were VBD N
recorded VBN N
at IN N
each DT N
clinic JJ N
visit NN N
. . N

RESULTS NNP N
Clinical JJ N
benefit NN N
assessments NNS N
were VBD N
performed VBN N
in IN N
more JJR N
than IN N
75 CD N
% NN N
of IN N
patients NNS N
throughout IN N
V325 NNP N
. . N

DCF NNP N
significantly RB N
prolonged VBD N
time NN 1_o
to TO 1_o
definitive JJ 1_o
worsening NN 1_o
of IN 1_o
KPS NNP 1_o
compared VBN N
with IN N
CF NNP 1_i
( ( N
median JJ N
, , N
6.1 CD N
v NN N
4.8 CD N
months NNS N
; : N
hazard RB N
ratio NN N
, , N
1.38 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.08 CD N
to TO N
1.76 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
.009 NNP N
) ) N
. . N

Although IN N
time NN 1_o
to TO 1_o
definitive JJ 1_o
weight NN 1_o
loss NN 1_o
and CC 1_o
time NN 1_o
to TO 1_o
definitive JJ 1_o
worsening NN 1_o
of IN 1_o
appetite NN 1_o
favored VBN N
DCF NNP 1_i
, , N
the DT N
results NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Pain-free JJ 1_o
survival NN 1_o
and CC 1_o
time NN 1_o
to TO 1_o
first JJ 1_o
cancer NN 1_o
pain-related JJ 1_o
opioid JJ 1_o
intake NN 1_o
were VBD N
comparable JJ N
. . N

CONCLUSION NN N
To TO N
our PRP$ N
knowledge NN N
, , N
V325 NNP N
is VBZ N
the DT N
first JJ N
phase NN N
III NNP N
trial NN N
to TO N
report VB N
clinical JJ N
benefit NN N
in IN N
AGGEC NNP N
patients NNS N
. . N

Clinical JJ N
benefit NN N
was VBD N
assessed VBN N
beyond IN N
protocol-specific JJ 1_i
chemotherapy NN 1_i
. . 1_i

The DT N
addition NN N
of IN N
D NNP 1_i
to TO N
CF NNP 1_i
not RB N
only RB N
significantly RB N
improved VBN N
clinical JJ N
benefit NN N
but CC N
also RB N
improved JJ N
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
progression NN 1_o
, , 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
compared VBN N
with IN N
CF NNP 1_i
. . 1_i

-DOCSTART- -X- O O

Short-term JJ N
effects NNS N
of IN N
prednisolone NN 1_i
and CC 1_i
dexamethasone NN 1_i
on IN N
circulating VBG 1_o
concentrations NNS 1_o
of IN 1_o
leptin NN 1_o
and CC 1_o
sex NN 1_o
hormone-binding JJ 1_o
globulin NN 1_o
in IN N
children NNS 1_p
being VBG 1_p
treated VBN 1_p
for IN 1_p
acute JJ 1_p
lymphoblastic JJ 1_p
leukaemia NN 1_p
. . 1_p

OBJECTIVE NNP N
Disturbances NNPS N
in IN N
body NN N
weight JJ N
regulation NN N
are VBP N
often RB N
encountered VBN N
during IN N
glucocorticoid JJ 1_i
treatment NN 1_i
and CC N
are VBP N
associated VBN N
with IN N
increased JJ N
insulin NN N
resistance NN N
and CC N
truncal JJ N
fat NN N
accumulation NN N
. . N

Children NNP 1_p
were VBD 1_p
investigated VBN 1_p
who WP 1_p
were VBD 1_p
receiving VBG 1_p
glucocorticoid JJ 1_i
treatment NN 1_i
for IN 1_p
acute JJ 1_p
lymphoblastic JJ 1_p
leukaemia NN 1_p
( ( 1_p
ALL DT 1_p
) ) 1_p
. . 1_p

They PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
prednisolone VB 1_i
or CC 1_i
dexamethasone VB 1_i
as IN N
part NN N
of IN N
induction NN N
of IN N
remission NN N
. . N

This DT N
randomization NN N
process NN N
provided VBD N
a DT N
suitable JJ N
opportunity NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
these DT N
two CD N
administered VBD N
steroid NN N
on IN N
surrogate JJ N
markers NNS N
of IN N
adipocyte NN N
activity NN N
( ( N
leptin NN N
) ) N
and CC N
hyperinsulinaemia/insulin JJ N
resistance NN N
( ( N
SHBG NNP N
) ) N
. . N

DESIGN NNP N
AND CC N
PATIENTS NNP N
Prospective NNP N
study NN N
over IN N
16 CD N
weeks NNS N
of IN N
children NNS 1_p
randomized VBN N
to TO N
receive VB N
prednisolone NN 1_i
( ( 1_i
40 CD 1_i
mg/m2 NN 1_i
) ) 1_i
or CC 1_i
dexamethasone NN 1_i
( ( 1_i
6.5 CD 1_i
mg/m2 NN 1_i
) ) 1_i
as IN 1_i
part NN 1_i
of IN 1_i
the DT 1_i
MRC-ALL97/99 NNP 1_i
induction NN 1_i
chemotherapy NN 1_i
for IN 1_i
ALL NNP 1_i
. . 1_i

Nineteen NNP 1_p
children NNS 1_p
( ( 1_p
8 CD 1_p
male NN 1_p
, , 1_p
11 CD 1_p
female NN 1_p
) ) 1_p
with IN 1_p
a DT 1_p
median JJ 1_p
age NN 1_p
5.9 CD 1_p
years NNS 1_p
( ( 1_p
range VB 1_p
2.6-13 CD 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
recruited VBN 1_p
into IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Main NNP N
outcome JJ N
measures NNS N
were VBD N
body JJ 1_o
mass NN 1_o
index NN 1_o
( ( 1_o
BMI NNP 1_o
) ) 1_o
, , 1_o
serum JJ 1_o
leptin NN 1_o
and CC 1_o
sex NN 1_o
hormone NN 1_o
binding VBG 1_o
globulin NN 1_o
( ( 1_o
SHBG NNP 1_o
) ) 1_o
. . 1_o

RESULTS NNP N
Glucocorticoid NNP N
administration NN N
for IN N
5 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
increases NNS N
in IN N
BMI NNP 1_o
, , 1_o
leptin NN 1_o
( ( 1_o
corrected VBN 1_o
for IN 1_o
BMI NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
leptin NN 1_o
: : 1_o
SHBG NNP 1_o
ratio NN 1_o
and CC 1_o
lowering NN 1_o
of IN 1_o
SHBG NNP 1_o
. . 1_o

Dose NNP N
for IN N
dose NN N
, , N
dexamethasone NN 1_i
was VBD N
significantly RB N
more RBR N
potent JJ N
than IN N
prednisolone NN 1_i
in IN N
altering VBG N
these DT N
parameters NNS N
. . N

CONCLUSIONS NNP N
Short-term JJ N
glucocorticoid NN N
treatment NN N
has VBZ N
significant JJ N
effects NNS N
on IN N
BMI NNP N
, , N
leptin NN N
and CC N
SHBG NNP N
. . N

The DT N
leptin NN N
: : N
SHBG NNP N
ratio NN N
increase NN N
indicates VBZ N
that IN N
this DT N
may MD N
be VB N
a DT N
novel JJ N
and CC N
sensitive JJ N
biochemical JJ N
marker NN N
of IN N
metabolic JJ N
change NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
glucocorticoid JJ 1_i
treatment NN 1_i
regimens NNS 1_i
should MD N
be VB N
kept VBN N
as RB N
short JJ N
as IN N
possible JJ N
to TO N
avoid VB N
possible JJ N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
increased JJ N
adiposity NN N
and CC N
insulin NN N
resistance NN N
. . N

-DOCSTART- -X- O O

Recommending VBG N
self-paced JJ 1_i
exercise NN 1_i
among IN N
overweight JJ 1_p
and CC 1_p
obese JJ 1_p
adults NNS 1_p
: : 1_p
a DT N
randomized JJ N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
National NNP N
guidelines NNS N
call NN N
for IN N
exercise NN N
of IN N
at IN N
least JJS N
moderate JJ N
intensity NN N
; : N
however RB N
, , N
recommending VBG N
self-paced JJ 1_i
exercise NN 1_i
may MD N
lead VB N
to TO N
better JJR N
adherence NN 1_o
, , N
particularly RB N
among IN N
overweight JJ 1_p
and CC 1_p
obese JJ 1_p
adults NNS 1_p
. . 1_p

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
proof-of-concept NN N
for IN N
recommending VBG N
self-paced JJ N
exercise NN N
among IN N
overweight JJ N
adults NNS N
. . N

METHODS NNP N
Fifty-nine NNP 1_p
healthy JJ 1_p
, , 1_p
low-active JJ 1_p
( ( 1_p
exercise NN 1_p
< VBZ 1_p
60 CD 1_p
min/week NN 1_p
) ) 1_p
, , 1_p
overweight JJ 1_p
( ( 1_p
body JJ 1_p
mass NN 1_p
index NN 1_p
25.0-39.9 JJ 1_p
) ) 1_p
adults NNS 1_p
( ( 1_p
18-65 JJ 1_p
) ) 1_p
received VBD N
a DT N
6-month JJ 1_i
print-based JJ 1_i
exercise NN 1_i
promotion NN 1_i
program NN 1_i
with IN 1_i
the DT 1_i
goal NN 1_i
of IN 1_i
walking VBG 1_i
30-60 JJ 1_i
min/day NN 1_i
. . 1_i

Participants NNS N
were VBD N
surreptitiously RB N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
recommendation NN 1_i
for IN 1_i
either DT 1_i
self-paced JJ 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
30 CD 1_i
) ) 1_i
or CC 1_i
moderate JJ 1_i
( ( 1_i
64-76 JJ 1_i
% NN N
maximum JJ N
heart NN N
rate NN N
; : N
n CC N
= VB N
29 CD N
) ) N
intensity NN 1_i
exercise NN 1_i
. . 1_i

All DT 1_p
participants NNS 1_p
used VBN 1_p
electronic JJ 1_p
diaries NNS 1_p
and CC 1_p
heart NN 1_p
rate NN 1_p
monitors NNS 1_p
to TO 1_p
track VB 1_o
exercise NN 1_o
frequency NN 1_o
, , 1_o
duration NN 1_o
, , 1_o
and CC 1_o
intensity NN 1_o
. . 1_o

RESULTS VB N
The DT N
self-paced JJ N
condition NN N
reported VBD N
more RBR 1_o
minutes/week NNS 1_o
of IN 1_o
walking NN 1_o
( ( N
f JJ N
( ( N
2 CD N
) ) N
= NN N
0.17 CD N
, , N
p NN N
= NNP N
0.045 CD N
) ) N
and CC N
a DT N
trend NN N
toward IN N
greater JJR 1_o
exercise-related JJ 1_o
energy NN 1_o
expenditure/week NN 1_o
( ( 1_o
f JJ N
( ( N
2 CD N
) ) N
= NN N
0.12 CD N
, , N
p NN N
= NNP N
0.243 CD N
) ) N
, , N
corresponding VBG N
to TO N
approximately RB N
26 CD N
additional JJ N
minutes/week NN N
and CC N
83 CD N
additional JJ N
kilocalories/week NN N
over IN N
6 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Explicit NNP N
recommendation NN N
for IN N
self-paced JJ 1_i
exercise NN 1_i
may MD 1_i
improve VB 1_o
adherence NN 1_o
to TO 1_o
exercise VB 1_o
programs NNS 1_o
among IN 1_o
overweight JJ 1_p
and CC 1_p
obese JJ 1_p
adults NNS 1_p
. . N

-DOCSTART- -X- O O

Marginal NNP N
biotin NN N
deficiency NN N
during IN N
normal JJ 1_p
pregnancy NN 1_p
. . 1_p

BACKGROUND NNP N
Biotin NNP N
deficiency NN N
is VBZ N
teratogenic JJ N
in IN N
several JJ 1_p
mammalian JJ 1_p
species NNS 1_p
. . 1_p

Approximately RB N
50 CD N
% NN N
of IN N
pregnant JJ 1_p
women NNS 1_p
have VBP N
an DT N
abnormally RB N
increased JJ N
urinary JJ N
excretion NN N
of IN N
3-hydroxyisovaleric JJ 1_o
acid NN 1_o
( ( 1_o
3-HIA JJ 1_o
) ) 1_o
, , N
which WDT N
probably RB N
reflects VBZ N
decreased JJ N
activity NN N
of IN N
the DT N
biotin-dependent JJ N
enzyme JJ N
methylcrotonyl-CoA JJ N
carboxylase NN N
. . N

However RB N
, , N
increased VBD N
3-HIA JJ N
excretion NN N
could MD N
result VB N
from IN N
pregnancy NN N
per IN N
se NN N
( ( N
eg JJ N
, , N
from IN N
an DT N
effect NN N
of IN N
pregnancy NN N
on IN N
renal JJ N
handling NN N
of IN N
organic JJ N
acids NNS N
) ) N
. . N

OBJECTIVE IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
biotin VBZ N
supplementation NN N
significantly RB N
decreases VBZ N
3-HIA JJ N
excretion NN N
in IN N
pregnant JJ 1_p
women NNS 1_p
with IN 1_p
abnormally RB 1_p
increased VBN 1_p
3-HIA JJ 1_p
excretion NN 1_p
. . 1_p

DESIGN NNP N
Twenty-six NNP 1_p
pregnant JJ 1_p
women NNS 1_p
with IN 1_p
increased JJ 1_p
3-HIA JJ 1_p
excretion NN 1_p
were VBD 1_p
studied VBN 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
, , 1_p
placebo-controlled JJ 1_i
trial NN 1_p
; : 1_p
10 CD N
women NNS N
were VBD N
studied VBN N
during IN N
early JJ N
pregnancy NN N
( ( N
6-17 JJ N
wk NN N
gestation NN N
) ) N
and CC N
16 CD N
women NNS N
during IN N
late JJ N
pregnancy NN N
( ( N
21-37 JJ N
wk NN N
gestation NN N
) ) N
. . N

Urine JJ 1_o
samples NNS 1_o
were VBD N
collected VBN N
before IN N
and CC N
after IN N
14 CD N
d NN N
of IN N
supplementation NN N
with IN N
300 CD 1_i
microg NNS 1_i
( ( 1_i
1.2 CD 1_i
micromol NN 1_i
) ) 1_i
biotin/d NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

RESULTS NNP N
In IN N
the DT N
early-pregnancy NN N
group NN N
, , N
3-HIA JJ 1_o
excretion NN 1_o
decreased VBN N
( ( N
P NNP N
< NNP N
0.006 CD N
) ) N
by IN N
11.7 CD N
+/- JJ N
3.6 CD N
mmol/mol NN N
creatinine NN N
( ( N
mean JJ N
+/- NNP N
SEM NNP N
) ) N
in IN N
the DT N
5 CD N
women NNS N
who WP N
received VBD N
biotin NN N
supplements NNS N
, , N
whereas IN N
3-HIA JJ 1_o
excretion NN 1_o
increased VBN N
by IN N
1.6 CD N
+/- JJ N
0.6 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
5 CD N
women NNS N
who WP N
received VBD N
placebo NN N
. . N

In IN N
the DT N
late-pregnancy NN N
group NN N
, , N
3-HIA JJ 1_o
excretion NN 1_o
decreased VBN N
( ( N
P NNP N
< NNP N
0.002 CD N
) ) N
by IN N
7.1 CD N
+/- JJ N
1.2 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
8 CD N
women NNS N
who WP N
received VBD N
biotin NN N
supplements NNS N
, , N
whereas IN N
3-HIA JJ 1_o
excretion NN 1_o
increased VBN N
by IN N
0.9 CD N
+/- JJ N
1.8 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
8 CD N
women NNS N
who WP N
received VBD N
placebo NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
evidence NN N
that IN N
the DT N
increased JJ N
excretion NN 1_o
of IN 1_o
3-HIA JJ 1_o
seen VBN N
frequently RB N
in IN N
normal JJ 1_p
pregnancy NN 1_p
reflects VBZ N
reduced VBN N
biotin JJ 1_o
status NN 1_o
. . 1_o

The DT N
conclusion NN N
that IN N
marginal JJ N
biotin NN N
deficiency NN N
occurs VBZ N
frequently RB N
in IN N
the DT N
first JJ N
trimester NN N
further RBR N
raises NNS N
concern NN N
about IN N
potential JJ N
human JJ N
teratogenicity NN N
. . N

-DOCSTART- -X- O O

Isoniazid NNP 1_i
prophylaxis NN N
for IN N
tuberculosis NN 1_p
in IN 1_p
HIV NNP 1_p
infection NN 1_p
: : 1_p
a DT N
meta-analysis NN N
of IN N
randomized VBN N
controlled JJ N
trials NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
isoniazid NN 1_i
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN N
in IN N
tuberculin JJ 1_p
skin JJ 1_p
test-positive JJ 1_p
and CC 1_p
negative JJ 1_p
individuals NNS 1_p
with IN 1_p
HIV NNP 1_p
infection NN 1_p
. . 1_p

DESIGN NNP N
Meta-analysis NN N
of IN N
randomized VBN N
controlled JJ N
trials NNS N
. . N

SETTING NNP N
Seven NNP 1_p
trials NNS 1_p
from IN 1_p
Mexico NNP 1_p
, , 1_p
Haiti NNP 1_p
, , 1_p
the DT 1_p
United NNP 1_p
States NNPS 1_p
, , 1_p
Zambia NNP 1_p
, , 1_p
Uganda NNP 1_p
and CC 1_p
Kenya NNP 1_p
. . 1_p

PATIENTS NNP N
Individuals NNP 1_p
free JJ 1_p
from IN 1_p
tuberculosis NN 1_p
, , 1_p
2367 CD 1_p
persons NNS 1_p
in IN 1_p
the DT 1_p
intervention NN 1_p
and CC 1_p
2162 CD 1_p
in IN 1_p
the DT 1_p
control NN 1_p
groups NNS 1_p
. . 1_p

INTERVENTION NNP N
Comparison NNP 1_o
of IN 1_o
isoniazid NN 1_o
with IN 1_o
placebo NN 1_o
or CC 1_o
no DT 1_o
prophylaxis NN 1_o
. . 1_o

METHODS NNP N
A NNP N
systematic JJ N
search NN N
of IN N
the DT N
literature NN N
was VBD N
carried VBN N
out IN N
from IN N
1985 CD N
to TO N
October NNP N
1997 CD N
for IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
isoniazid JJ 1_i
prophylaxis NN 1_p
in IN 1_p
HIV-infected JJ 1_p
persons NNS 1_p
. . 1_p

Two CD N
reviewers NNS N
evaluated VBD N
the DT N
relevance NN N
of IN N
each DT N
candidate NN N
study NN N
and CC N
the DT N
validity NN N
of IN N
eligible JJ N
trials NNS N
. . N

Studies NNS N
were VBD N
pooled VBN N
using VBG N
a DT N
random JJ N
effect NN N
model NN N
, , N
conducting VBG N
secondary JJ N
analyses NNS N
for IN N
tuberculin JJ N
skin JJ N
test-positive JJ N
and CC N
negative JJ N
persons NNS N
. . N

RESULTS JJ N
Mean JJ N
follow-up NN N
in IN N
trials NNS N
varied VBD N
between IN N
0.4 CD N
and CC N
3.2 CD N
years NNS N
. . N

Pooling VBG N
all DT N
seven CD N
trials NNS N
, , N
a DT N
risk NN 1_o
ratio NN 1_o
was VBD N
found VBN N
for IN N
persons NNS N
treated VBN N
with IN N
isoniazid NN 1_i
for IN N
developing VBG N
tuberculosis NN N
of IN N
0.58 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
0.43-0.80 JJ N
] NN N
and CC N
0.94 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.83-1.07 NNP N
) ) N
for IN N
death NN 1_o
. . 1_o

In IN N
groups NNS N
of IN N
tuberculin JJ N
skin JJ N
test-positive JJ N
and CC N
negative JJ N
persons NNS N
, , N
the DT N
risk NN 1_o
ratio NN 1_o
of IN 1_o
tuberculosis NN 1_o
was VBD N
0.40 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.24-0.65 NNP N
) ) N
and CC N
0.84 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.54-1.30 NNP N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
difference NN 1_o
in IN 1_o
the DT 1_o
effectiveness NN 1_o
of IN N
isoniazid JJ 1_i
versus NN N
placebo NN 1_i
between IN N
these DT N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.03 CD N
, , N
for IN N
the DT N
difference NN N
of IN N
summary JJ N
estimates NNS N
) ) N
. . N

Consistency NN N
of IN N
results NNS N
was VBD N
found VBN N
across IN N
trials NNS N
( ( N
P NNP N
> NNP N
0.10 CD N
, , N
heterogeneity NN N
value NN N
) ) N
for IN N
all DT N
comparisons NNS N
. . N

CONCLUSIONS NNP N
Prophylaxis NNP N
with IN N
isoniazid JJ 1_i
reduces NNS N
the DT N
risk NN N
of IN N
tuberculosis NN N
in IN N
persons NNS 1_p
with IN 1_p
HIV NNP 1_p
infection NN 1_p
. . 1_p

The DT N
effect NN N
is VBZ N
restricted VBN 1_p
to TO 1_p
tuberculin VB 1_p
skin JJ 1_p
test-positive JJ 1_p
persons NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Position NN N
of IN N
anterior JJ N
capsulorhexis NN N
and CC N
posterior JJ N
capsule NN N
opacification NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
whether IN N
the DT N
position NN N
of IN N
the DT N
anterior JJ N
continuous JJ N
curvilinear NN N
capsulorhexis NN N
influences VBZ N
the DT N
rate NN 1_o
of IN 1_o
posterior JJ 1_o
capsule NN 1_o
opacification NN 1_o
( ( 1_o
PCO NNP 1_o
) ) 1_o
. . 1_o

METHODS CC N
A DT 1_p
total NN 1_p
of IN 1_p
119 CD 1_p
patients NNS 1_p
, , 1_p
aged VBN 1_p
61-86 CD 1_p
years NNS 1_p
, , 1_p
underwent JJ 1_p
cataract NN 1_p
surgery NN 1_p
with IN 1_p
phacoemulsification NN 1_p
performed VBN 1_p
by IN 1_p
a DT 1_p
single JJ 1_p
surgeon NN 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
implantation NN N
with IN N
either CC N
a DT N
silicone NN 1_i
intraocular NN 1_i
lens NNS 1_i
( ( 1_i
IOL NNP 1_i
) ) 1_i
( ( 1_i
SI40NB NNP 1_i
, , 1_i
Allergan NNP 1_i
) ) 1_i
or CC 1_i
an DT 1_i
AcrySof NNP 1_i
IOL NNP 1_i
( ( N
MA60BM NNP N
, , N
Alcon NNP N
) ) N
. . N

Three CD N
years NNS N
after IN N
surgery NN N
, , N
the DT N
rate NN 1_o
of IN 1_o
PCO NNP 1_o
was VBD N
analysed VBN N
using VBG N
the DT N
evaluation NN N
of IN N
posterior JJ N
capsule NN N
opacification NN N
computer NN N
software NN N
( ( N
EPCO NNP N
) ) N
. . N

The DT N
results NNS N
were VBD N
related VBN N
to TO N
the DT N
capsulorhexis NN N
position NN N
, , N
which WDT N
was VBD N
assessed VBN N
with IN N
a DT N
retroillumination NN N
photograph NN N
. . N

RESULTS VB N
If IN N
the DT N
capsulorhexis NN 1_o
was VBD N
located VBN N
partially RB N
or CC N
completely RB N
off IN N
the DT N
optics NNS 1_o
of IN 1_o
the DT 1_o
IOL NNP 1_o
, , N
compared VBN N
to TO N
totally RB 1_o
on IN 1_o
the DT 1_o
IOL NNP 1_o
, , N
significantly RB N
more JJR N
PCO NNP 1_o
was VBD N
found VBN N
( ( N
p JJ N
= NNP N
0.0014 CD N
) ) N
. . N

When WRB N
comparing VBG N
within IN N
each DT N
IOL NNP N
type NN N
, , N
patients NNS N
with IN N
AcrySof NNP N
IOLs NNP N
were VBD N
found VBN N
to TO N
have VB N
significantly RB N
less JJR N
PCO NNP 1_o
when WRB N
the DT N
capsulorhexis NN N
was VBD N
totally RB N
on IN N
the DT N
optic JJ N
( ( N
p JJ N
= NNP N
0.0048 CD N
) ) N
. . N

This DT N
difference NN N
was VBD N
also RB N
significant JJ N
in IN N
the DT N
silicone NN N
group NN N
( ( N
p JJ N
= NNP N
0.041 CD N
) ) N
. . N

CONCLUSION VB N
A NNP N
relatively RB N
small JJ N
and CC N
central JJ N
capsulorhexis NN N
allowing VBG N
for IN N
the DT N
complete JJ N
covering NN N
of IN N
the DT N
IOL NNP 1_i
optics NNS 1_i
by IN N
the DT N
rhexis NN N
edges VBZ N
seems VBZ N
to TO N
protect VB N
against IN N
PCO NNP 1_o
in IN N
cataract NN N
surgery NN N
, , N
with IN N
both DT N
round-edged JJ N
silicone NN N
IOLs NNP N
and CC N
sharp-edged JJ N
hydrophobic JJ N
acrylic JJ 1_i
IOLs NNP 1_i
. . 1_i

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
effect NN N
of IN N
acetazolamide NN 1_i
on IN N
cystoid NN 1_p
macular NN 1_p
oedema NN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
Behcet NNP 1_p
's POS 1_p
disease NN 1_p
. . 1_p

AIM NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
acetazolamide NN 1_i
on IN N
cystoid NN N
macular NN N
oedema NN N
( ( N
CMO NNP N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
Behcet NNP 1_p
's POS 1_p
disease NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
67 CD 1_p
eyes NNS 1_p
of IN 1_p
35 CD 1_p
Behcet NNP 1_p
's POS 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
, , 1_p
but CC 1_p
well-controlled JJ 1_p
uveitis NN 1_p
, , 1_p
and CC 1_p
CMO NNP 1_p
were VBD N
randomised VBN N
into IN N
a DT N
double-masked JJ N
, , N
crossover JJ N
trial NN N
comparing VBG N
the DT N
effect NN N
of IN N
acetazolamide NN 1_i
vs NN 1_i
placebo NN 1_i
. . 1_i

The DT N
patients NNS N
received VBD N
an DT N
initial JJ N
4-week JJ N
course NN N
of IN N
either CC N
250 CD N
mg NN N
acetazolamide JJ 1_i
twice RB N
daily RB N
( ( N
b.i.d NN N
. . N

) ) N
or CC N
placebo NN 1_i
, , N
followed VBN N
by IN N
a DT N
4-week JJ N
washout NN N
period NN N
. . N

They PRP N
then RB N
received VBD N
a DT N
4-week JJ N
course NN N
of IN N
the DT N
reverse NN N
study NN N
medication NN N
. . N

An DT N
improvement NN N
in IN N
visual JJ 1_o
acuity NN 1_o
and CC 1_o
fundus NN 1_o
fluorescein VBP 1_o
angiographic JJ 1_o
findings NNS 1_o
was VBD N
assessed VBN N
. . N

RESULTS NNP N
In IN N
total JJ N
, , N
29 CD 1_p
patients NNS 1_p
( ( 1_p
55 CD 1_p
eyes NNS 1_p
) ) 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
and CC 1_p
were VBD 1_p
available JJ 1_p
for IN 1_p
analysis NN 1_p
. . 1_p

Of IN 1_p
the DT 1_p
29 CD 1_p
, , 1_p
16 CD 1_p
men NNS 1_p
and CC 1_p
13 CD 1_p
were VBD 1_p
women NNS 1_p
. . 1_p

The DT 1_p
age NN 1_p
range NN 1_p
was VBD 1_p
13-50 JJ 1_p
years NNS 1_p
( ( 1_p
mean JJ 1_p
33.6 CD 1_p
years NNS 1_p
) ) 1_p
. . 1_p

Patients NNS N
on IN N
acetazolamide NN 1_i
showed VBD N
a DT N
slightly RB N
better RBR N
improvement NN N
of IN N
angiographic JJ 1_o
signs NNS 1_o
( ( N
at IN N
least JJS N
by IN N
one CD N
grade NN N
improvement NN N
) ) N
over IN N
that DT N
of IN N
placebo NN 1_i
( ( N
12 CD N
vs NN N
five CD N
eyes NNS N
) ) N
. . N

They PRP N
also RB N
had VBD N
less JJR N
deterioration NN 1_o
of IN 1_o
angiographic JJ 1_o
signs NNS 1_o
over IN N
that DT N
of IN N
placebo NN 1_i
( ( N
three CD N
vs NN N
seven CD N
eyes NNS N
) ) N
. . N

However RB N
, , N
these DT N
findings NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P=0.99 NNP N
) ) N
. . N

Acetazolamide NNP 1_i
had VBD N
no DT N
statistically RB N
significant JJ N
effect NN N
( ( N
P=0.53 NNP N
) ) N
on IN N
the DT N
improvement NN N
of IN N
visual JJ 1_o
acuity NN 1_o
of IN N
patients NNS N
over IN N
that DT N
of IN N
placebo NN 1_i
( ( N
13 CD N
vs NN N
eight CD N
eyes NNS N
) ) N
, , N
nor CC N
on IN N
the DT N
deterioration NN N
of IN N
visual JJ 1_o
acuity NN 1_o
( ( N
three CD N
vs NN N
11 CD N
eyes NNS N
) ) N
. . N

CONCLUSION NNP N
Despite IN N
seemingly RB N
favourable JJ N
results NNS N
, , N
the DT N
4-week JJ N
course NN N
of IN N
acetazolamide NN 1_i
( ( N
250 CD N
mg NN N
b.i.d NN N
. . N

) ) N
has VBZ N
no DT N
statistically RB N
significant JJ N
effect NN N
on IN N
the DT N
improvement NN N
of IN N
the DT N
visual JJ 1_o
acuity NN 1_o
and CC N
the DT N
fluorescein NN 1_o
angiographic JJ 1_o
findings NNS 1_o
in IN N
Behcet NNP 1_p
's POS 1_p
patients NNS 1_p
with IN 1_p
CMO NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Cardiovascular JJ 1_o
safety NN 1_o
and CC 1_o
gastrointestinal JJ 1_o
tolerability NN 1_o
of IN N
etoricoxib JJ 1_i
vs NN 1_i
diclofenac NN 1_i
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
( ( N
The DT N
MEDAL NNP N
study NN N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
cardiovascular JJ 1_o
( ( 1_o
CV NNP 1_o
) ) 1_o
and CC 1_o
other JJ 1_o
safety NN 1_o
and CC 1_o
efficacy NN 1_o
parameters NNS 1_o
of IN N
etoricoxib JJ 1_i
60 CD N
and CC N
90 CD N
mg NN N
, , N
and CC N
diclofenac VBZ 1_i
150 CD N
mg. NN N
METHODS NNP N
This DT N
double-blind NN N
study NN N
randomized VBD N
OA NNP 1_p
patients NNS 1_p
to TO N
etoricoxib VB 1_i
90 CD N
mg NN N
, , N
then RB N
to TO N
60 CD N
mg NNS N
once RB N
daily JJ N
vs NNS N
diclofenac VBP 1_i
75 CD N
mg JJ N
twice RB N
daily RB N
; : N
RA NNP 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
etoricoxib VB 1_i
90 CD N
mg NNS N
once RB N
daily JJ N
or CC N
diclofenac JJ 1_i
75 CD N
mg JJ N
twice RB N
daily RB N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
non-inferiority NN N
of IN N
etoricoxib JJ 1_i
vs NN N
diclofenac NN 1_i
for IN N
thrombotic JJ N
CV NNP N
events NNS N
( ( N
95 CD N
% NN N
CI NNP N
upper JJ N
bound NN N
of IN N
hazard NN N
ratio NN N
< NNP N
1.30 CD N
) ) N
. . N

Other JJ 1_o
safety NN 1_o
and CC 1_o
efficacy NN 1_o
parameters NNS 1_o
were VBD N
evaluated VBN N
in IN N
cohorts NNS N
of IN N
patients NNS N
based VBN N
on IN N
etoricoxib NN 1_i
dose NN N
and CC N
disease NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
23 CD 1_p
504 CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
with IN N
mean JJ N
treatment NN N
duration NN N
from IN N
19.4 CD N
to TO N
20.8 CD N
months NNS N
. . N

The DT N
thrombotic JJ 1_o
CV NNP 1_o
risk NN 1_o
hazard NN 1_o
ratio NN 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
( ( 1_i
etoricoxib UH 1_i
to TO N
diclofenac VB N
) ) N
was VBD N
0.96 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.81 CD N
, , N
1.15 CD N
) ) N
, , N
consistent JJ N
with IN N
non-inferiority NN N
of IN N
etoricoxib NN 1_i
to TO N
diclofenac VB 1_i
. . 1_i

The DT N
cumulative JJ 1_o
gastrointestinal NN 1_o
( ( 1_o
GI NNP 1_o
) ) 1_o
/liver VBP 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
AEs NNP 1_o
) ) 1_o
discontinuation NN 1_o
rate NN 1_o
was VBD N
significantly RB N
lower JJR N
for IN N
etoricoxib JJR 1_i
than IN N
diclofenac NN 1_i
in IN N
each DT N
patient NN N
cohort NN N
; : N
HR NNP N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
of IN N
0.46 CD N
( ( N
0.39 CD N
, , N
0.54 CD N
) ) N
, , N
0.52 CD N
( ( N
0.42 CD N
, , N
0.63 CD N
) ) N
and CC N
0.49 CD N
( ( N
0.39 CD N
, , N
0.62 CD N
) ) N
for IN N
the DT N
60 CD N
mg NN N
OA NNP N
, , N
90 CD N
mg NN N
OA NNP N
and CC N
RA NNP N
cohorts NNS N
. . N

The DT N
maximum JJ 1_o
average JJ 1_o
change NN 1_o
in IN 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
with IN N
etoricoxib NN 1_i
was VBD N
3.4-3.6 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
1.0-1.5 JJ N
mmHg NN N
) ) N
, , N
while IN N
diclofenac NN N
produced VBD N
a DT N
maximum JJ N
average JJ N
change NN N
of IN N
0.9-1.9 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
0.0-0.5 JJ N
mmHg NN N
) ) N
. . N

Both DT N
agents NNS N
resulted VBD N
in IN N
similar JJ N
efficacy NN 1_o
regardless NN N
of IN N
etoricoxib NN N
dose NN N
. . N

CONCLUSION NNP N
Long-term NNP N
etoricoxib NN 1_i
use NN N
is VBZ N
associated VBN N
with IN N
a DT N
risk NN 1_o
of IN 1_o
thrombotic JJ 1_o
CV NNP 1_o
events NNS 1_o
comparable JJ N
with IN N
that DT N
of IN N
diclofenac NN 1_i
. . 1_i

Compared VBN N
with IN N
diclofenac NN 1_i
, , 1_i
etoricoxib RB 1_i
demonstrated VBD N
a DT N
greater JJR N
risk NN 1_o
of IN 1_o
renovascular JJ 1_o
AEs NNP 1_o
, , N
but CC N
a DT N
more RBR N
favourable JJ N
GI/liver NNP 1_o
tolerability NN 1_o
profile NN 1_o
. . 1_o

-DOCSTART- -X- O O

Randomized VBN N
controlled JJ N
trial NN N
for IN N
early JJ 1_i
intervention NN 1_i
for IN N
autism NN N
: : N
a DT N
pilot NN N
study NN N
of IN N
the DT N
Autism NNP 1_i
1-2-3 JJ 1_i
Project NNP 1_i
. . 1_i

We PRP N
piloted VBD N
a DT N
2-week JJ N
Autism-1-2-3 NNP 1_i
early JJ 1_i
intervention NN 1_i
for IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
their PRP$ 1_p
parents NNS 1_p
immediately RB N
after IN N
diagnosis NN N
that WDT N
targeted VBD N
at IN N
( ( 1_i
1 CD 1_i
) ) 1_i
eye NN 1_i
contact NN 1_i
, , 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
gesture NN 1_i
and CC 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
vocalization/words NNS 1_i
. . 1_i

Seventeen JJ 1_p
children NNS 1_p
were VBD 1_p
randomized VBN 1_p
into IN 1_p
the DT 1_p
Intervention NNP 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
9 CD 1_p
) ) 1_p
and CC 1_p
Control NNP 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
8 CD 1_p
) ) 1_p
groups NNS 1_p
. . 1_p

Outcome NNP N
measures NNS N
included VBD N
the DT N
Autism NNP 1_o
Diagnostic NNP 1_o
Observation NNP 1_o
Schedule NNP 1_o
, , 1_o
Ritvo-Freeman NNP 1_o
Real NNP 1_o
Life NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
, , 1_o
Symbolic NNP 1_o
Play NNP 1_o
Test NNP 1_o
, , 1_o
and CC 1_o
Parenting NNP 1_o
Stress NNP 1_o
Index NNP 1_o
. . 1_o

Children NNP 1_p
with IN 1_p
autism NN 1_p
improved VBN N
in IN N
language/communication NN 1_o
, , 1_o
reciprocal JJ 1_o
social JJ 1_o
interaction NN 1_o
, , 1_o
and CC 1_o
symbolic JJ 1_o
play NN 1_o
. . 1_o

Parents NNS N
perceived VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
children NNS 1_o
's POS 1_o
language NN 1_o
, , 1_o
social JJ 1_o
interaction NN 1_o
, , 1_o
and CC 1_o
their PRP$ 1_o
own JJ 1_o
stress NN 1_o
level NN 1_o
. . 1_o

This DT N
intervention NN N
can MD N
serve VB N
as IN N
short-term JJ N
training NN 1_i
on IN 1_i
communication NN 1_i
and CC 1_i
social JJ 1_i
interaction NN 1_i
for IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
reduce VB N
the DT N
stress NN N
of IN N
their PRP$ N
parents NNS N
during IN N
the DT N
long JJ N
waiting NN N
time NN N
for IN N
public JJ N
health NN N
services NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
propranolol NN 1_i
on IN N
word NN N
fluency NN N
in IN N
autism NN 1_p
. . 1_p

OBJECTIVE NNP N
AND CC N
BACKGROUND NNP N
Autism NNP N
is VBZ N
characterized VBN N
by IN N
repetitive JJ N
behaviors NNS N
and CC N
impaired JJ N
socialization NN N
and CC N
communication NN N
. . N

Preliminary JJ N
evidence NN N
showed VBD N
possible JJ N
language NN N
benefits NNS N
in IN N
autism NN N
from IN N
the DT N
?-adrenergic JJ 1_i
antagonist NN 1_i
propranolol NN 1_i
. . 1_i

Earlier JJR N
studies NNS N
in IN N
other JJ N
populations NNS N
suggested VBD 1_i
propranolol NN 1_i
might MD N
benefit VB N
performance NN N
on IN N
tasks NNS N
involving VBG N
a DT N
search NN N
of IN N
semantic JJ N
and CC N
associative JJ N
networks NNS N
under IN N
certain JJ N
conditions NNS N
. . N

Therefore RB N
, , N
we PRP N
wished VBD N
to TO N
determine VB N
whether IN N
this DT N
benefit NN N
of IN 1_i
propranolol NN 1_i
includes VBZ N
an DT N
effect NN N
on IN N
semantic JJ N
fluency NN N
in IN N
autism NN N
. . N

METHODS NNP 1_p
A NNP 1_p
sample NN 1_p
of IN 1_p
14 CD 1_p
high-functioning JJ 1_p
adolescent NN 1_p
and CC 1_p
adult NN 1_p
participants NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
14 CD 1_p
matched VBN 1_p
controls NNS 1_p
were VBD N
given VBN N
letter NN N
and CC N
category NN N
word NN N
fluency NN N
tasks NNS N
on IN N
2 CD N
separate JJ N
testing NN N
sessions NNS N
; : N
1 CD N
test NN N
was VBD N
given VBN N
60 CD N
minutes NNS N
after IN N
the DT N
administration NN N
of IN N
40 CD N
mg NNS 1_i
propranolol JJ 1_i
orally RB N
, , N
and CC N
1 CD N
test NN N
was VBD N
given VBN N
after IN 1_i
placebo NN 1_i
, , 1_i
administered VBN N
in IN N
a DT N
double-blinded JJ N
, , N
counterbalanced JJ N
manner NN N
. . N

RESULTS JJ 1_p
Participants NNS 1_p
with IN 1_p
autism NN 1_p
were VBD N
significantly RB N
impaired VBN N
compared VBN N
with IN N
controls NNS N
on IN N
both DT 1_o
fluency NN 1_o
tasks NNS 1_o
. . 1_o

Propranolol NNP 1_i
significantly RB N
improved VBD 1_o
performance NN 1_o
on IN 1_o
category NN 1_o
fluency NN 1_o
, , 1_o
but CC N
not RB 1_o
letter NN 1_o
fluency NN 1_o
among IN N
autism NN 1_p
participants NNS 1_p
. . 1_p

No DT 1_o
drug NN 1_o
effect NN 1_o
was VBD N
observed VBN N
among IN N
controls NNS N
. . N

Expected VBN N
drug NN N
effects NNS N
on IN 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
were VBD N
observed VBN N
in IN N
both CC N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Results NNP N
are VBP N
consistent JJ N
with IN N
a DT N
selective JJ N
beneficial JJ N
effect NN N
of IN 1_i
propranolol NN 1_i
on IN N
flexibility NN N
of IN N
access NN N
to TO N
semantic JJ N
and CC N
associative JJ N
networks NNS N
in IN N
autism NN N
, , N
with IN N
no DT N
observed JJ N
effect NN N
on IN N
phonological JJ N
networks NNS N
. . N

Further NNP N
study NN N
will MD N
be VB N
necessary JJ N
to TO N
understand VB N
potential JJ N
clinical JJ N
implications NNS N
of IN N
this DT N
finding NN N
. . N

-DOCSTART- -X- O O

Early JJ N
withdrawal NN N
of IN N
calcineurin NN 1_i
inhibitors NNS 1_i
and CC 1_i
everolimus JJ 1_i
monotherapy NN 1_i
in IN N
de FW 1_p
novo FW 1_p
liver NN 1_p
transplant NN 1_p
recipients VBZ 1_p
preserves VBZ N
renal JJ N
function NN N
. . N

We PRP N
designed VBD N
a DT N
randomized JJ N
trial NN N
to TO N
assess VB N
whether IN N
the DT N
early JJ 1_i
withdrawal NN 1_i
of IN 1_i
cyclosporine NN 1_i
( ( 1_i
CsA NNP 1_i
) ) 1_i
followed VBN 1_i
by IN 1_i
the DT 1_i
initiation NN 1_i
of IN 1_i
everolimus NN 1_i
( ( 1_i
Evr NNP 1_i
) ) 1_i
monotherapy NN 1_i
in IN N
de FW 1_p
novo FW 1_p
liver FW 1_p
transplantation NN 1_p
( ( 1_p
LT NNP 1_p
) ) 1_p
patients NNS 1_p
would MD N
result VB N
in IN N
superior JJ N
renal JJ N
function NN N
compared VBN N
to TO N
a DT N
CsA-based JJ N
immunosuppression NN N
protocol NN N
. . N

All DT N
patients NNS N
were VBD N
treated VBN N
with IN N
CsA NNP 1_i
for IN N
the DT N
first JJ N
10 CD N
days NNS N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
Evr NNP 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
CsA NNP 1_i
up RB N
to TO N
day NN N
30 CD N
, , N
then RB N
either DT N
continued VBN N
on IN N
Evr NNP 1_i
monotherapy NN 1_i
( ( 1_i
Evr NNP 1_i
group NN 1_i
) ) 1_i
or CC N
maintained VBN N
on IN N
CsA NNP 1_i
with/without NN 1_i
mycophenolate NN 1_i
mofetil NN 1_i
( ( 1_i
CsA NNP 1_i
group NN 1_i
) ) 1_i
in IN N
case NN N
of IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
. . N

Seventy-eight JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
( ( 1_i
Evr NNP 1_i
n RB N
= VBZ N
52 CD N
; : N
CsA NNP 1_i
n VBD N
= NNP N
26 CD N
) ) N
. . N

The DT N
1-year JJ 1_o
freedom NN 1_o
from IN 1_o
efficacy NN 1_o
failure NN 1_o
in IN N
Evr NNP 1_i
group NN N
was VBD N
75 CD N
% NN N
versus IN N
69.2 CD N
% NN N
in IN N
CsA NNP 1_i
group NN N
, , N
p VBP N
= JJ N
0.36 CD N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
patient JJ 1_o
survival NN 1_o
between IN N
the DT N
two CD N
groups NNS N
. . N

Mean NNP 1_o
modification NN 1_o
of IN 1_o
diet NN 1_o
in IN 1_o
renal JJ 1_o
disease NN 1_o
( ( 1_o
MDRD NNP 1_o
) ) 1_o
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
Evr NNP 1_i
group NN N
at IN N
12 CD N
months NNS N
( ( N
87.7 CD N
? . N
26.1 CD N
vs. IN N
59.9 CD N
? . N
12.6 CD N
mL/min NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

The DT 1_o
incidence NN 1_o
of IN 1_o
CKD NNP 1_o
stage NN 1_o
? . 1_o
3 CD 1_o
( ( 1_o
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
< $ N
60 CD N
mL/min NN N
) ) N
was VBD N
higher RBR N
in IN N
the DT N
CsA NNP 1_i
group NN N
at IN N
1 CD N
year NN N
( ( N
52.2 CD N
% NN N
vs. FW N
15.4 CD N
% NN N
, , N
p NN N
= NNP N
0.005 CD N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
early JJ N
withdrawal NN 1_i
of IN 1_i
CsA NNP 1_i
followed VBN 1_i
by IN 1_i
Evr NNP 1_i
monotherapy NN 1_i
in IN 1_i
de FW 1_p
novo FW 1_p
LT NNP 1_p
patients NNS 1_p
is VBZ 1_p
associated VBN N
with IN N
an DT N
improvement NN N
in IN N
renal JJ N
function NN N
, , N
with IN N
a DT N
similar JJ N
incidence NN N
of IN N
rejection NN N
and CC N
major JJ N
complications NNS N
. . N

-DOCSTART- -X- O O

PSK NNP 1_i
may MD N
suppress VB N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
to TO N
improve VB N
survival NN N
of IN N
advanced JJ 1_p
gastric JJ 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
A NNP N
recent JJ N
report NN N
showed VBD N
that IN N
oral JJ 1_i
adjuvant JJ 1_i
immunochemotherapy NN 1_i
with IN 1_i
protein-bound JJ 1_i
polysaccharide NN 1_i
K NNP 1_i
( ( 1_i
PSK NNP 1_i
) ) 1_i
and CC 1_i
tegafur/uracil NN 1_i
( ( 1_i
UFT NNP 1_i
) ) 1_i
for IN N
stage NN N
II NNP N
and CC N
III NNP N
colorectal JJ N
cancer NN N
improves VBZ N
overall JJ N
survival NN N
compared VBN N
with IN N
UFT NNP 1_i
alone RB 1_i
. . 1_i

PSK NNP 1_i
has VBZ N
been VBN N
supposed VBN N
to TO N
improve VB N
survival NN N
through IN N
immunological JJ N
mechanisms NNS N
such JJ N
as IN N
induction NN N
of IN N
cytokines NNS N
, , N
regulation NN N
of IN N
Th1/Th2 NNP N
balance NN N
, , N
and CC N
inhibition NN N
of IN N
immunosuppressive JJ N
molecules NNS N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
mechanisms NNS N
by IN N
which WDT N
PSK NNP 1_i
influences VBZ N
immunological JJ 1_o
parameters NNS 1_o
such JJ N
as IN N
Th1 NNP 1_o
cells NNS 1_o
( ( 1_o
IFN-gamma-positive JJ 1_o
CD4 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
) ) 1_o
, , 1_o
Th2 NNP 1_o
cells NNS 1_o
( ( 1_o
IL-4-positive JJ 1_o
CD4 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
) ) 1_o
, , 1_o
Th1/Th2 NNP 1_o
ratio NN 1_o
, , 1_o
NKT NNP 1_o
cells NNS 1_o
( ( 1_o
CD56 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
and CC 1_o
CD57 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
) ) 1_o
, , 1_o
NK NNP 1_o
cells NNS 1_o
, , 1_o
and CC 1_o
CD25 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
CD4 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
in IN N
stage NN 1_p
III NNP 1_p
gastric JJ 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
3 CD N
g NN N
PSK NNP 1_i
plus CC 1_i
300 CD 1_i
mg NN 1_i
UFT NNP 1_i
( ( 1_i
PSK NNP 1_i
group NN 1_i
) ) 1_i
or CC N
300 CD N
mg JJ N
UFT NNP 1_i
alone RB 1_i
( ( N
control NN N
) ) N
orally RB N
each DT N
day NN N
for IN N
at IN N
least JJS N
1 CD N
year NN N
following VBG N
their PRP$ N
operation NN N
. . N

RESULTS NNP N
Twenty-one CD 1_p
registered VBD 1_p
patients NNS 1_p
with IN 1_p
stage NN 1_p
III NNP 1_p
gastric JJ 1_p
cancer NN 1_p
were VBD N
analyzed VBN N
. . N

The DT N
3-year JJ 1_o
overall JJ 1_o
survival NN 1_o
was VBD N
62.2 CD N
% NN N
in IN N
the DT N
PSK NNP 1_i
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
12.5 CD N
% NN N
in IN N
the DT N
control NN 1_i
group NN 1_i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

Before IN N
operation NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
proportions NNS N
of IN N
Th1 NNP 1_o
cells NNS 1_o
, , 1_o
Th2 NNP 1_o
cells NNS 1_o
, , 1_o
Th1/Th2 NNP 1_o
ratio NN 1_o
, , 1_o
CD56 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
, , 1_o
CD57 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
, , 1_o
NK NNP 1_o
cells NNS 1_o
, , 1_o
and CC 1_o
CD4 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
CD25 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
between IN N
PSK NNP N
and CC N
control NN N
groups NNS N
. . N

However RB N
, , N
after IN N
operation NN N
, , N
CD57 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
T NNP 1_o
cells NNS 1_o
decreased VBD N
significantly RB N
in IN N
the DT N
PSK NNP 1_i
group NN N
compared VBN N
to TO N
the DT N
control NN N
( ( N
P NNP N
= NNP N
0.0486 CD N
) ) N
. . N

When WRB N
all DT N
patients NNS N
were VBD N
analyzed VBN N
, , N
patients NNS N
with IN N
increased JJ N
proportion NN N
( ( N
> JJ N
18 CD N
% NN N
) ) N
of IN N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
showed VBD N
worse JJR N
survival NN N
than IN N
those DT N
with IN N
lower JJR N
( ( N
< CD N
or CC N
= VB N
18 CD N
% NN N
) ) N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
( ( N
3-year JJ N
survival NN N
, , N
25.0 CD N
and CC N
45.7 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.046 CD N
) ) N
, , N
consistent JJ N
with IN N
our PRP$ N
previous JJ N
report NN N
that WDT N
high JJ N
CD57 NNP N
( ( N
+ NNP N
) ) N
is VBZ N
an DT N
indicator NN N
of IN N
poor JJ N
prognosis NN N
in IN N
patients NNS N
with IN N
advanced JJ N
gastric JJ N
cancer NN N
. . N

However RB N
, , N
in IN N
the DT N
group NN N
treated VBD N
with IN N
PSK NNP 1_i
+ NNP 1_i
UFT NNP 1_i
, , N
3-year JJ 1_o
survival NN 1_o
of IN N
CD57-high JJ N
patients NNS N
was VBD N
as RB N
great JJ N
as IN N
that DT N
of IN N
CD57-low JJ N
patients NNS N
( ( N
66.7 CD N
and CC N
51.4 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.67 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
PSK NNP 1_i
improves VBZ N
overall JJ N
survival NN N
of IN N
stage NN 1_p
III NNP 1_p
gastric JJ 1_p
cancer NN 1_p
patients NNS 1_p
partly RB N
by IN N
inhibiting VBG N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
, , N
a DT N
proven JJ N
poor JJ N
prognostic JJ N
factor NN N
in IN N
advanced JJ N
gastric JJ N
cancer NN N
. . N

-DOCSTART- -X- O O

Bronchial JJ 1_p
carcinoma NN 1_p
. . 1_p

II NNP N
. . N

Quantitative JJ N
measurements NNS N
of IN N
the DT N
quality NN 1_o
of IN 1_o
survival NN 1_o
. . 1_o

A DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
the DT N
result NN N
of IN N
therapy NN N
in IN N
inoperable JJ 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
disease NN 1_p
. . 1_p

Forty-eight JJ 1_p
bronchial JJ 1_p
carcinoma NN 1_p
patients NNS 1_p
in IN 1_p
clinicoanatomical JJ 1_p
stage NN 1_p
4 CD 1_p
of IN 1_p
the DT 1_p
disease NN 1_p
( ( 1_p
advanced JJ 1_p
disease NN 1_p
) ) 1_p
were VBD N
randomly RB 1_p
assigned VBN 1_p
to TO N
groups NNS 1_p
for IN N
radiotherapy NN 1_i
, , 1_i
chemotherapy NN 1_i
( ( 1_i
cyclophosphamide NN 1_i
) ) 1_i
and CC 1_i
placebo JJ 1_i
treatment NN 1_i
, , N
respectively RB N
. . N

The DT N
results NNS N
were VBD N
assessed VBN N
by IN N
the DT N
survival JJ 1_o
time NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
survival NN 1_o
. . 1_o

The DT N
median JJ 1_o
survival NN 1_o
time NN 1_o
was VBD N
4.7 CD N
months NNS N
for IN N
radiotherapy NN 1_i
, , N
4.7 CD N
months NNS N
for IN N
cyclophosphamide NN 1_i
and CC N
1.7 CD N
months NNS N
for IN N
placebo NN 1_i
. . 1_i

The DT N
median JJ 1_o
total JJ 1_o
sum NN 1_o
of IN 1_o
vitagram NN 1_o
points NNS 1_o
was VBD N
28.1 CD N
for IN N
radiotherapy NN 1_i
, , N
20.7 CD N
for IN N
cyclophosphamide NN 1_i
and CC N
6.8 CD N
for IN N
placebo NN 1_i
. . 1_i

When WRB N
calculated JJ N
per IN N
month NN N
, , N
the DT N
median JJ 1_o
sum NN 1_o
of IN 1_o
vitagram NN 1_o
points NNS 1_o
was VBD N
5.9 CD N
for IN N
radiotherapy NN 1_i
, , N
5.7 CD N
for IN N
cyclophosphamide NN 1_i
and CC N
4.8 CD N
for IN N
placebo NN 1_i
. . 1_i

Statistically RB N
the DT N
results NNS N
give VBP N
no DT N
reason NN N
to TO N
believe VB N
that IN N
placebo NN 1_i
is VBZ N
better JJR N
than IN N
radiotherapy NN 1_i
, , N
but CC N
it PRP N
can MD N
not RB N
be VB N
excluded VBN N
that IN N
radiotherapy NN 1_i
patients NNS N
could MD N
have VB N
a DT N
much RB N
longer JJR N
survival NN 1_o
. . 1_o

As IN N
for IN N
cyclophosphamide NN 1_i
versus NN N
radiotherapy NN 1_i
, , N
the DT N
differences NNS N
are VBP N
to TO N
uncertain VB N
for IN N
any DT N
conclusion NN N
to TO N
be VB N
drawn VBN N
. . N

-DOCSTART- -X- O O

Conservative JJ 1_i
treatment NN 1_i
of IN N
plantar NN 1_p
fasciitis NN 1_p
. . 1_p

A DT N
prospective JJ N
study NN N
. . N

A DT N
randomized JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
individual JJ 1_o
effectiveness NN 1_o
of IN N
three CD N
types NNS N
of IN N
conservative JJ 1_i
therapy NN 1_i
in IN N
the DT N
treatment NN N
of IN N
plantar NN N
fasciitis NN N
. . N

One CD 1_p
hundred VBD 1_p
three CD 1_p
subjects NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
one CD 1_p
of IN 1_p
three CD 1_p
treatment NN 1_p
categories NNS 1_p
: : 1_p
anti-inflammatory NN 1_i
, , 1_i
accommodative JJ 1_i
, , 1_i
or CC 1_i
mechanical JJ 1_i
. . 1_i

Subjects NNS 1_p
were VBD N
treated VBN N
for IN N
3 CD N
months NNS N
, , N
with IN N
follow-up JJ N
visits NNS N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
weeks NNS N
. . N

For IN N
the DT N
85 CD 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
, , N
a DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
groups NNS N
, , N
with IN N
mechanical JJ 1_i
treatment NN 1_i
with IN 1_i
taping VBG 1_i
and CC 1_i
orthoses NNS 1_i
proving VBG N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
anti-inflammatory JJ 1_i
or CC N
accommodative JJ 1_i
modalities NNS 1_i
. . 1_i

-DOCSTART- -X- O O

[ VB N
A DT N
randomized JJ N
comparative NN N
study NN N
of IN N
surgical JJ 1_i
adjuvant NN 1_i
chemotherapy NN 1_i
using VBG 1_i
5-fluorouracil JJ 1_i
and CC 1_i
dl-leucovorin JJ 1_i
with IN 1_i
CDDP NNP 1_i
5-FU JJ 1_i
and CC 1_i
dl-leucovorin JJ 1_i
for IN N
colorectal JJ 1_p
cancer NN 1_p
] NNP 1_p
. . N

A NNP N
randomized JJ N
comparative NN N
study NN N
of IN N
surgical JJ 1_i
adjuvant NN 1_i
chemotherapy NN 1_i
using VBG N
dl-leucovorin JJ 1_i
( ( 1_i
dl-LV JJ 1_i
) ) 1_i
and CC 1_i
5-fluorouracil JJ 1_i
( ( 1_i
5-FU JJ 1_i
) ) 1_i
( ( 1_i
FL-therapy NNP 1_i
) ) 1_i
with IN 1_i
CDDP NNP 1_i
, , 1_i
5-FU JJ 1_i
, , 1_i
and CC 1_i
dl-LV JJ 1_i
( ( 1_i
PFL-therapy NNP 1_i
) ) 1_i
was VBD N
conducted VBN N
. . N

The DT N
following VBG N
were VBD N
the DT N
administration NN N
schedules NNS N
: : N
Arm VB N
A DT N
was VBD N
13 CD N
mg/m2 NN N
of IN N
CDDP NNP 1_i
, , N
300 CD N
mg/m2 NN N
of IN N
5-FU JJ 1_i
, , N
and CC N
30 CD N
mg/body NN N
of IN N
dl-LV NN 1_i
for IN N
5 CD N
consecutive JJ N
days NNS N
and CC N
arm NN N
B NNP N
was VBD N
300 CD N
mg/m2 NN N
of IN N
5-FU JJ 1_i
and CC N
30 CD N
mg/body NN N
of IN N
dl-LV NN 1_i
for IN N
5 CD N
consecutive JJ N
days NNS N
. . N

Both DT N
regimens NNS N
were VBD N
followed VBN N
by IN N
biweekly JJ N
administration NN N
of IN N
the DT N
same JJ N
dose NN N
of IN N
dl-LV JJ 1_i
and CC N
5-FU JJ 1_i
in IN N
outpatients NNS N
. . N

Arm VB N
A DT N
was VBD N
started VBN N
at IN N
the DT N
26th CD N
postoperative JJ N
day NN N
and CC N
arm NN N
B NNP N
at IN N
the DT N
21st CD N
day NN N
on IN N
average NN N
. . N

Some DT N
26 CD 1_p
cases NNS 1_p
composed VBN 1_p
of IN 1_p
11 CD 1_p
cases NNS 1_p
of IN 1_p
arm NN 1_p
A NNP 1_p
and CC 1_p
15 CD 1_p
cases NNS 1_p
of IN 1_p
arm NN 1_p
B NNP 1_p
completed VBD N
the DT N
administration NN N
schedules NNS N
. . N

Only RB N
one CD N
case NN N
in IN N
arm NN N
A NN N
was VBD N
complicated VBN N
by IN N
local JJ 1_o
recurrence NN 1_o
around IN N
35 CD N
months NNS N
after IN N
operation NN N
. . N

Major JJ N
toxicities NNS 1_o
were VBD N
anorexia JJ 1_o
and CC 1_o
neutropenia NN 1_o
. . 1_o

Both CC N
toxicities NNS 1_o
were VBD N
seen VBN N
more RBR N
in IN N
arm NN N
A NN N
than IN N
in IN N
arm NN N
B NNP N
, , N
showing VBG N
complete JJ N
recovery NN 1_o
in IN N
all DT N
cases NNS N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
PFL-therapy NNP 1_i
and CC N
FL-therapy NNP 1_i
seem VBP N
to TO N
be VB N
possible JJ N
and CC N
promising JJ N
surgical JJ 1_i
adjuvant NN 1_i
therapies NNS 1_i
for IN N
advanced JJ 1_o
colorectal JJ 1_o
carcinoma NN 1_o
. . 1_o

-DOCSTART- -X- O O

Analgesic JJ N
efficacy NN N
of IN N
low-dose JJ N
diclofenac NN 1_i
versus NN 1_i
paracetamol NN 1_i
and CC 1_i
placebo NN 1_i
in IN N
postoperative JJ 1_p
dental NN 1_p
pain NN 1_p
. . 1_p

AIMS NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
diclofenac-K NN 1_i
( ( N
12.5 CD N
mg NN N
) ) N
vs NN N
paracetamol NN 1_i
( ( N
500 CD N
mg NN N
) ) N
and CC N
placebo VB 1_i
given VBN N
in IN N
a DT N
flexible JJ N
dosage NN N
regimen NNS N
to TO N
treat VB N
pain NN 1_p
resulting VBG 1_p
from IN 1_p
extraction NN 1_p
of IN 1_p
impacted JJ 1_p
third JJ 1_p
molar JJ 1_p
teeth NN 1_p
. . 1_p

METHODS NNP N
This DT N
was VBD N
a DT N
2-day JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ 1_i
study NN N
of IN N
diclofenac-K NN 1_i
( ( 1_i
12.5 CD 1_i
mg NN 1_i
) ) 1_i
tablets VBZ 1_i
vs JJ 1_i
paracetamol NN 1_i
( ( N
500 CD N
mg NN N
) ) N
tablets NNS N
and CC N
placebo NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
or CC 1_p
severe JJ 1_p
pain NN 1_p
within IN 1_p
8 CD 1_p
hours NNS 1_p
of IN 1_p
extraction NN 1_p
of IN 1_p
impacted JJ 1_p
third JJ 1_p
molars NNS 1_p
. . 1_p

RESULTS NNP N
After IN N
the DT N
first JJ N
2-tablet JJ N
dose NN N
, , N
patients NNS N
took VBD N
on IN N
average JJ N
2.5 CD N
additional JJ N
tablets NNS N
of IN N
diclofenac-K NN 1_i
or CC N
2.4 CD N
tablets NNS N
of IN N
paracetamol NN 1_i
, , N
almost RB N
all DT N
as IN N
1-tablet JJ N
doses NNS N
. . N

Most JJS N
placebo JJ 1_i
patients NNS N
discontinued VBN N
by IN N
taking VBG N
rescue JJ 1_o
medication NN 1_o
( ( N
ibuprofen JJ N
200 CD N
mg NN N
) ) N
on IN N
the DT N
first JJ N
day NN N
. . N

Pain NNP 1_o
relief NN 1_o
after IN N
the DT N
initial JJ N
dose NN N
of IN N
diclofenac-K NN 1_i
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
was VBD N
superior JJ N
to TO N
placebo VB 1_i
( ( N
P NNP N
< NNP N
.01 NNP N
for IN N
all DT N
efficacy NN N
outcomes NNS N
) ) N
and CC N
comparable JJ N
to TO N
paracetamol VB 1_i
( ( N
2 CD N
x RB N
500 CD N
mg NN N
) ) N
. . N

About IN N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
took VBD N
rescue NN 1_o
medication NN 1_o
during IN N
the DT N
study NN N
, , N
compared VBN N
to TO N
78 CD N
% NN N
on IN N
placebo NN 1_i
. . 1_i

About IN N
70 CD N
% NN N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
considered VBD N
the DT N
overall JJ 1_o
pain NN 1_o
relief NN 1_o
to TO N
be VB N
some DT N
, , N
a DT N
lot NN N
, , N
or CC N
complete JJ N
compared VBN N
to TO N
only RB N
15 CD N
% NN N
on IN N
placebo NN 1_i
. . 1_i

The DT N
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
in IN N
each DT N
active JJ N
treatment NN N
group NN N
was VBD N
low JJ N
and CC N
comparable JJ N
between IN N
the DT N
treatments NNS N
. . N

CONCLUSION NNP N
An DT N
initial JJ N
double-dose NN N
of IN N
diclofenac-K NN 1_i
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
or CC N
paracetamol NN 1_i
( ( N
2 CD N
x RB N
500 CD N
mg NNS N
) ) N
adequately RB N
relieved VBD N
the DT N
most RBS N
intense JJ N
postoperative NN 1_o
pain NN 1_o
, , N
and CC N
the DT N
flexible JJ N
multiple NN N
dose JJ N
regimen NNS N
( ( N
1 CD N
or CC N
2 CD N
tablets NNS N
) ) N
maintained VBD N
adequate JJ N
pain NN 1_o
relief NN 1_o
thereafter RB N
. . N

Most JJS N
patients NNS N
needed VBN N
only RB N
1-tablet JJ N
doses NNS N
following VBG N
the DT N
initial JJ N
2-tablet JJ N
dose NN N
. . N

-DOCSTART- -X- O O

Prediction NN N
of IN N
gestational JJ N
diabetes NNS N
mellitus VBP N
in IN N
the DT N
first JJ 1_p
trimester NN 1_p
, , N
comparison NN N
of IN N
fasting VBG N
plasma NN N
glucose NN N
, , N
two-step JJ N
and CC N
one-step JJ N
methods NNS N
: : N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
the DT N
diagnostic JJ 1_o
performance NN 1_o
of IN N
three CD N
methods NNS N
commonly RB N
used VBD N
for IN N
GDM NNP N
screening NN N
: : N
fasting NN 1_i
plasma NN 1_i
glucose NN 1_i
( ( 1_i
FPG NNP 1_i
) ) 1_i
, , N
two-step JJ N
50 CD N
g NN N
glucose JJ 1_i
challenge NN 1_i
test NN 1_i
( ( 1_i
GCT NNP 1_i
) ) 1_i
, , N
and CC N
75 CD 1_i
g NN 1_i
glucose JJ 1_i
tolerance NN 1_i
test NN 1_i
( ( 1_i
GTT NNP 1_i
) ) 1_i
in IN N
a DT N
randomized JJ N
study NN N
design NN N
to TO N
predict VB N
GDM NNP N
in IN N
the DT N
first JJ 1_p
trimester NN 1_p
and CC N
determine VB N
the DT N
best JJS N
approach NN N
in IN N
predicting VBG N
GDM NNP N
. . N

In IN N
a DT N
non-blind JJ N
, , N
parallel-group JJ N
prospective JJ N
randomized VBN N
controlled VBN N
study NN N
; : N
736 CD 1_p
singleton NN 1_p
pregnant JJ 1_p
women NNS 1_p
underwent JJ N
FPG NNP N
testing NN N
in IN N
the DT N
first JJ N
trimester NN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
; : N
two-step JJ 1_i
50 CD 1_i
g NN 1_i
GCT NNP 1_i
and CC 1_i
75 CD 1_i
g NN 1_i
GTT NNP 1_i
. . 1_i

GDM NNP N
diagnosis NN N
was VBD N
made VBN N
according VBG N
to TO N
Carpenter-Coustan NNP N
or CC N
ADA NNP N
( ( N
American NNP N
Diabetes NNP N
Association NNP N
) ) N
criteria NNS N
in IN N
two-step JJ N
50 CD N
g NN N
GCT NNP N
and CC N
75 CD N
g NN N
GTT NNP N
groups NNS N
, , N
respectively RB N
. . N

Subsequent JJ N
testing NN N
was VBD N
performed VBN N
by IN N
two-step JJ N
50 CD N
g NN N
GCT NNP N
at IN N
24-28 JJ N
weeks NNS N
for IN N
screen JJ N
negatives NNS N
. . N

After IN 1_p
excluding VBG 1_p
the DT 1_p
women NNS 1_p
who WP 1_p
were VBD 1_p
lost VBN 1_p
to TO 1_p
follow-up NN 1_p
or CC 1_p
withdrawn NN 1_p
as IN 1_p
a DT 1_p
result NN 1_p
of IN 1_p
pregnancy NN 1_p
loss NN 1_p
, , 1_p
486 CD 1_p
pregnant JJ 1_p
women NNS 1_p
were VBD 1_p
recruited VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
FPG NNP N
, , N
two-step JJ N
GCT NNP N
, , N
and CC N
one-step JJ N
GTT NNP N
methods NNS N
identified VBD N
GDM NNP 1_o
in IN N
25/486 CD N
( ( N
5.1 CD N
% NN N
) ) N
, , N
15/248 CD N
( ( N
6.0 CD N
% NN N
) ) N
, , N
and CC N
27/238 CD N
( ( N
11.3 CD N
% NN N
) ) N
women NNS 1_p
, , N
respectively RB N
. . N

Area NNP 1_o
under IN 1_o
ROC NNP 1_o
curves NNS 1_o
were VBD N
0.623 CD N
, , N
0.708 CD N
, , N
and CC N
0.792 CD N
, , N
respectively RB N
. . N

Sensitivities NNS 1_o
were VBD N
47.17 CD N
, , N
68.18 CD N
, , N
and CC N
87.1 CD N
% NN N
, , N
respectively RB N
. . N

Specificities NNS 1_o
were VBD N
77.37 CD N
, , N
100 CD N
, , N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

Positive JJ 1_o
predictive JJ 1_o
values NNS 1_o
were VBD N
20.33 CD N
, , N
100 CD N
, , N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

Negative JJ 1_o
predictive JJ 1_o
values NNS 1_o
were VBD N
92.29 CD N
, , N
97 CD N
, , N
and CC N
98.1 CD N
% NN N
, , N
respectively RB N
. . N

Until IN N
superior JJ N
screening VBG N
alternatives NNS N
become VBP N
available JJ N
, , N
the DT N
75 CD N
g NNS N
GTT NNP N
may MD N
be VB N
preferred VBN N
for IN N
GDM NNP N
screening NN N
in IN N
the DT N
first JJ 1_p
trimester NN 1_p
. . 1_p

-DOCSTART- -X- O O

Corticosteroids NNP 1_i
plus CC 1_i
pulse JJ 1_i
cyclophosphamide NN 1_i
and CC 1_i
plasma NN 1_i
exchanges NNS 1_i
versus VBP N
corticosteroids NNS 1_i
plus CC 1_i
pulse JJ 1_i
cyclophosphamide NN 1_i
alone RB 1_i
in IN N
the DT N
treatment NN N
of IN N
polyarteritis NN 1_p
nodosa NN 1_p
and CC 1_p
Churg-Strauss NNP 1_p
syndrome NN 1_p
patients NNS 1_p
with IN 1_p
factors NNS 1_p
predicting VBG 1_p
poor JJ 1_p
prognosis NN 1_p
. . 1_p

A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
in IN N
sixty-two JJ 1_p
patients NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
define VB N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
severe JJ 1_p
polyarteritis NN 1_p
nodosa NN 1_p
( ( 1_p
PAN NNP 1_p
) ) 1_p
and CC 1_p
Churg-Strauss JJ 1_p
syndrome NN 1_p
( ( 1_p
CSS NNP 1_p
) ) 1_p
and CC N
to TO N
investigate VB N
the DT N
indication NN N
for IN N
plasma JJ N
exchange NN N
treatment NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
in IN N
which WDT N
62 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
receive VB 1_p
either DT 1_p
prednisone NN 1_i
plus CC 1_i
cyclophosphamide NN 1_i
( ( 1_i
intravenous JJ 1_i
bolus NN 1_i
) ) 1_i
( ( 1_i
group NN 1_i
A NNP 1_i
; : 1_i
n JJ 1_i
= NNP 1_i
28 CD 1_i
) ) 1_i
or CC 1_i
prednisone JJ 1_i
plus CC 1_i
cyclophosphamide JJ 1_i
( ( 1_i
intravenous JJ 1_i
bolus NN 1_i
) ) 1_i
plus CC 1_i
plasma JJ 1_i
exchanges NNS 1_i
( ( 1_p
group NN 1_p
B NNP 1_p
; : 1_p
n CC 1_p
= VB 1_p
34 CD 1_p
) ) 1_p
as IN 1_p
first-line JJ 1_p
treatment NN 1_p
for IN 1_p
severe JJ 1_p
PAN NNP 1_p
or CC 1_p
CSS NNP 1_p
. . 1_p

Factors NNS N
predicting VBG N
poor JJ N
prognosis NN N
were VBD N
renal JJ N
symptoms NNS N
, , N
gastrointestinal JJ N
tract NN N
involvement NN N
, , N
cardiomyopathy NN N
, , N
central JJ N
nervous JJ N
system NN N
involvement NN N
, , N
weight JJ N
loss NN N
> VBZ N
10 CD N
% NN N
of IN N
body NN N
weight NN N
, , N
and CC N
age NN N
> VBP N
50 CD N
years NNS N
old JJ N
. . N

Patients NNS N
with IN N
hepatitis NN N
B NNP N
virus-related JJ N
PAN NNP N
were VBD N
not RB N
included VBN N
in IN N
this DT N
study NN N
. . N

The DT N
end NN N
point NN N
of IN N
the DT N
study NN N
was VBD N
control NN N
of IN N
the DT N
disease NN N
( ( N
recovery NN N
or CC N
remission NN N
) ) N
or CC N
death NN N
. . N

RESULTS NNP N
Clinical NNP N
symptoms NNS N
and CC N
laboratory JJ N
findings NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Initial NNP N
control NN N
of IN N
the DT N
disease NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Relapse NNP 1_o
after IN N
initial JJ N
control NN N
of IN N
the DT N
disease NN N
was VBD N
observed VBN N
in IN N
7 CD N
patients NNS N
( ( N
4 CD N
in IN N
group NN N
A NNP N
and CC N
3 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

The DT N
mean JJ 1_o
+/- JJ 1_o
SD NNP 1_o
followup NN 1_o
period NN N
was VBD N
31.1 CD N
+/- JJ N
20 CD N
months NNS N
for IN N
group NN N
A NNP N
and CC N
35.9 CD N
+/- JJ N
16.8 CD N
months NNS N
for IN N
group NN N
B NNP N
. . N

At IN N
5 CD N
years NNS N
of IN N
followup NN N
, , N
38 CD N
patients NNS N
( ( N
61.3 CD N
% NN N
) ) N
were VBD N
cured VBN 1_o
( ( N
16 CD N
in IN N
group NN N
A NNP N
and CC N
22 CD N
in IN N
group NN N
B NNP N
) ) N
, , N
and CC N
5 CD N
( ( N
8.1 CD N
% NN N
) ) N
were VBD N
in IN N
remission NN N
without IN N
treatment NN N
but CC N
had VBD N
not RB N
yet RB N
completed VBN N
the DT N
cure-defining JJ N
period NN N
of IN N
18 CD N
months NNS N
( ( N
3 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

Eight NNP N
( ( N
12.9 CD N
% NN N
) ) N
( ( N
2 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
were VBD N
considered VBN N
to TO N
be VB N
in IN N
clinical JJ 1_o
remission NN 1_o
and CC N
required VBD N
a DT N
maintenance NN 1_o
regimen NN 1_o
of IN 1_o
low-dose JJ 1_o
corticosteroids NNS 1_o
. . 1_o

Eleven JJ N
patients NNS N
died VBD 1_o
during IN N
the DT N
study NN N
period NN N
( ( N
7 CD N
in IN N
group NN N
A NNP N
[ RB N
25 CD N
% NN N
] NN N
, , N
4 CD N
in IN N
group NN N
B NNP N
[ VBZ N
11.8 CD N
% NN N
] NN N
) ) N
. . N

Uncontrolled VBN N
vasculitis NN N
was VBD N
responsible JJ N
for IN N
4 CD N
deaths NNS 1_o
( ( N
2 CD N
in IN N
each DT N
group NN N
) ) N
, , N
and CC N
treatment NN 1_o
side NN 1_o
effects NNS 1_o
caused VBD N
the DT N
death NN 1_o
of IN N
1 CD N
patient NN N
in IN N
group NN N
A NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
5-year JJ 1_o
cumulative JJ 1_o
survival NN 1_o
rates NNS 1_o
of IN N
the DT N
2 CD N
groups NNS N
( ( N
75 CD N
% NN N
and CC N
88 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
our PRP$ N
data NNS N
, , N
combined VBN N
treatment NN N
with IN N
prednisone NN 1_i
, , 1_i
cyclophosphamide NN 1_i
, , N
and CC N
plasma NN 1_i
exchanges NNS 1_i
is VBZ N
not RB N
superior JJ N
to TO N
treatment NN N
with IN N
prednisone NN 1_i
and CC N
cyclophosphamide VB 1_i
alone RB N
, , N
and CC N
plasma JJ N
exchanges NNS N
should MD N
not RB N
be VB N
systematically RB N
proposed VBN N
for IN N
initial JJ N
treatment NN N
of IN N
severe JJ N
PAN NNP N
or CC N
CSS NNP N
. . N

-DOCSTART- -X- O O

Comparison NNP 1_o
of IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
with IN N
sequential JJ N
chemotherapy NN N
for IN N
intermediate-grade JJ 1_p
and CC 1_p
high-grade JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
in IN 1_p
first JJ 1_p
complete JJ 1_o
remission NN 1_o
: : 1_o
a DT 1_p
study NN 1_p
of IN 1_p
464 CD 1_p
patients NNS 1_p
. . 1_p

Groupe NNP N
d'Etude NN N
des NNS N
Lymphomes NNP N
de IN N
l'Adulte FW N
. . N

PURPOSE NNP N
Intensive NNP N
chemotherapy NN N
followed VBN N
by IN N
autotransplantation NN N
has VBZ N
given VBN N
promising VBG N
results NNS N
in IN N
partially RB N
responding VBG N
or CC N
sensitive JJ N
relapsed JJ N
patients NNS 1_p
with IN 1_p
aggressive JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
. . 1_p

In IN N
1987 CD N
, , N
we PRP N
designed VBD N
a DT N
randomized VBN N
study NN N
to TO N
evaluate VB N
the DT N
potential JJ N
benefit NN 1_o
of IN N
a DT N
high-dose JJ 1_i
regimen NN 1_i
containing VBG 1_i
cyclophosphamide NN 1_i
, , 1_i
carmustine NN 1_i
, , 1_i
and CC 1_i
etoposide RB 1_i
( ( 1_i
CBV NNP 1_i
) ) 1_i
followed VBN 1_i
by IN 1_i
autotransplantation NN 1_i
over IN 1_i
a DT 1_i
consolidative JJ 1_i
sequential JJ 1_i
chemotherapy NN 1_i
( ( 1_i
ifosfamide JJ 1_i
, , 1_i
etoposide RB 1_i
, , 1_i
asparaginase NN 1_i
, , 1_i
and CC 1_i
cytarabine NN 1_i
) ) 1_i
in IN N
patients NNS N
in IN N
first JJ N
complete JJ N
remission NN N
with IN N
intermediate- JJ 1_p
and CC 1_p
high-grade JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS 1_p
were VBD 1_p
younger JJR 1_p
than IN 1_p
55 CD 1_p
years NNS 1_p
and CC 1_p
had VBD 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
adverse JJ 1_p
prognostic JJ 1_p
factor NN 1_p
. . 1_p

Induction NNP N
treatment NN N
was VBD N
that IN N
of IN N
the DT N
LNH84 NNP N
protocol NN N
with IN N
an DT N
open JJ N
randomization NN N
on IN N
the DT N
anthracycline NN 1_i
. . 1_i

Patients NNS N
in IN N
complete JJ 1_o
remission NN 1_o
were VBD N
further JJ N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
consolidation NN N
procedure NN N
. . N

RESULTS NNP N
After IN N
induction NN N
treatment NN N
, , N
464 CD 1_p
patients NNS 1_p
were VBD N
assessable JJ N
for IN N
the DT N
consolidation NN N
phase NN N
. . N

With IN N
a DT N
median JJ N
follow-up JJ N
duration NN N
of IN N
28 CD N
months NNS N
, , N
the DT N
3-year JJ 1_o
disease-free JJ 1_o
survival NN 1_o
rate NN 1_o
was VBD N
52 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
45 CD N
% NN N
to TO N
59 CD N
% NN N
) ) N
in IN N
the DT N
sequential JJ N
chemotherapy NN N
arm NN N
and CC N
59 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
52 CD N
% NN N
to TO N
66 CD N
% NN N
) ) N
in IN N
the DT N
autologous JJ N
transplant NN N
arm NN N
( ( N
P NNP N
= NNP N
.46 NNP N
, , N
relative JJ N
risk NN N
= NNP N
0.90 CD N
) ) N
. . N

The DT N
3-year JJ 1_o
survival NN 1_o
rate NN 1_o
did VBD N
not RB N
differ VB N
between IN N
sequential JJ N
chemotherapy NN N
and CC N
autotransplantation NN N
, , N
at IN N
71 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
64 CD N
% NN N
to TO N
78 CD N
% NN N
) ) N
and CC N
69 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
62 CD N
% NN N
to TO N
76 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.60 NNP N
, , N
relative JJ N
risk NN N
= NNP N
1.11 CD N
) ) N
. . N

CONCLUSION NNP N
For IN N
such JJ N
a DT N
subset NN N
of IN N
patients NNS N
, , N
consolidation NN N
with IN N
the DT N
CBV NNP N
regimen NNS N
followed VBN N
by IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
is VBZ N
not RB N
superior JJ 1_o
to TO N
sequential JJ N
chemotherapy NN N
. . N

-DOCSTART- -X- O O

Role NNP N
of IN N
diltiazem NN 1_i
in IN N
the DT N
treatment NN N
of IN N
silent JJ N
myocardial JJ N
ischemia NN N
. . N

Silent JJ N
myocardial JJ N
ischemia NN N
is VBZ N
a DT N
frequent JJ N
finding NN N
when WRB N
Holter NNP N
monitoring NN N
is VBZ N
done VBN N
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
coronary JJ 1_p
disease NN 1_p
. . 1_p

Silent JJ N
ischemia NN N
is VBZ N
associated VBN N
with IN N
a DT N
worse JJR N
prognosis NN N
in IN N
patients NNS N
with IN N
stable JJ N
or CC N
unstable JJ N
angina NN N
, , N
survivors NNS N
of IN N
myocardial JJ N
infarction NN N
, , N
and CC N
populations NNS N
at IN N
risk NN N
for IN N
coronary JJ N
disease NN N
. . N

Whether NNP N
medical JJ N
therapy NN N
for IN N
silent JJ N
ischemia NN N
improves VBZ N
prognosis NN N
is VBZ N
not RB N
known VBN N
. . N

In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
, , N
multicenter JJ N
trial NN N
of IN N
60 CD 1_p
patients NNS 1_p
with IN 1_p
documented JJ 1_p
coronary JJ 1_p
disease NN 1_p
, , 1_p
positive JJ 1_p
exercise NN 1_p
tests NNS 1_p
, , 1_p
and CC 1_p
ischemic JJ 1_p
episodes NNS 1_p
on IN 1_p
Holter NNP 1_p
monitoring NN 1_p
, , N
long-acting JJ N
diltiazem NN 1_i
reduced VBD N
ischemic JJ 1_o
episodes NNS 1_o
by IN N
50 CD N
% NN N
compared VBN N
to TO N
placebo VB 1_i
, , N
from IN N
a DT N
mean NN N
of IN N
5.6 CD N
to TO N
2.8 CD N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

Efficacy NN 1_o
was VBD N
maintained VBN N
over IN N
24 CD N
h NNS N
and CC N
diltiazem NN 1_i
also RB N
significantly RB N
improved VBN N
exercise NN 1_o
test NN 1_o
parameters NNS 1_o
. . 1_o

Three CD N
smaller JJR N
studies NNS N
also RB N
demonstrated VBD N
that IN N
diltiazem NN 1_i
effectively RB N
reduces VBZ N
ambulatory JJ 1_o
ischemia NN 1_o
; : 1_o
however RB N
, , N
results NNS N
with IN N
nifedipine JJ N
are VBP N
conflicting VBG N
, , N
with IN N
several JJ N
studies NNS N
showing VBG N
no DT N
benefit NN N
. . N

In IN N
contrast NN N
, , N
beta-blockers NNS N
reliably RB N
reduce VB N
ischemic JJ 1_o
episodes NNS 1_o
. . 1_o

The DT N
role NN N
of IN N
medical JJ N
therapy NN N
for IN N
silent JJ N
ischemia NN N
will MD N
be VB N
clarified VBN N
only RB N
when WRB N
its PRP$ N
effect NN N
upon IN N
morbidity NN N
and CC N
mortality NN N
are VBP N
determined VBN N
. . N

-DOCSTART- -X- O O

Inhibition NN N
of IN N
epidural JJ 1_o
morphine-induced JJ 1_o
pruritus NN 1_o
by IN N
intravenous JJ N
droperidol NN 1_i
. . 1_i

The DT N
effect NN N
of IN N
increasing VBG N
the DT N
doses NNS N
of IN N
morphine NN 1_i
and CC N
of IN N
droperidol NN 1_i
. . 1_i

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Because IN N
the DT N
mechanism NN N
of IN N
inhibition NN N
of IN N
epidural JJ N
morphine-induced JJ N
pruritus NN N
by IN N
droperidol NN N
is VBZ N
not RB N
clear JJ N
, , N
this DT N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
larger JJR N
doses NNS N
of IN N
droperidol NN 1_i
or CC 1_i
morphine NN 1_i
, , N
or CC N
both DT N
. . N

METHODS VB N
A DT N
double-blind NN N
study NN N
was VBD N
performed VBN N
in IN N
210 CD 1_p
ASA NNP 1_p
I PRP 1_p
or CC 1_p
II NNP 1_p
patients NNS 1_p
undergoing VBG 1_p
cesarean JJ 1_p
delivery NN 1_p
, , 1_p
who WP 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
six CD 1_p
groups NNS 1_p
. . 1_p

All DT N
patients NNS N
received VBD N
epidural JJ 1_i
anesthesia NN 1_i
with IN 1_i
0.5 CD 1_i
% NN 1_i
bupivacaine NN 1_i
containing VBG 1_i
1:200,000 CD 1_i
epinephrine NN 1_i
, , 1_i
to TO 1_i
which WDT 1_i
2 CD 1_i
mg NN 1_i
( ( N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
or CC N
4 CD N
mg NN N
( ( N
groups NNS N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
) ) N
morphine NN 1_i
sulfate NN 1_i
was VBD N
added VBN N
. . N

Just RB N
after IN N
delivery NN N
, , N
2.5 CD N
mg NN N
droperidol NN 1_i
was VBD N
given VBN N
intravenously RB N
to TO N
groups NNS N
2 CD N
and CC N
5 CD N
, , N
and CC N
5 CD N
mg NN N
was VBD N
given VBN N
to TO N
groups NNS N
3 CD N
and CC N
6 CD N
. . N

During IN N
the DT N
postoperative JJ N
period NN N
, , N
the DT N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
occurrence NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
pruritus NN 1_o
( ( N
classified VBN N
as IN N
absent NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
) ) N
or CC N
other JJ 1_o
untoward JJ 1_o
symptoms NNS 1_o
. . 1_o

The DT N
groups NNS N
were VBD N
compared VBN N
for IN N
the DT N
incidence NN 1_o
of IN 1_o
pruritus NN 1_o
by IN N
the DT N
Mann-Whitney NNP N
nonparametric JJ N
test NN N
. . N

RESULTS VB N
The DT N
incidence NN 1_o
of IN 1_o
pruritus NN 1_o
was VBD N
significantly RB N
reduced VBN N
only RB N
when WRB N
the DT N
control NN N
group NN N
. . N

( ( N
no DT N
droperidol NN 1_i
) ) 1_i
was VBD N
compared VBN N
with IN N
the DT N
group NN N
that WDT N
received VBD N
2.5 CD N
mg NN N
droperidol NN 1_i
, , N
both DT N
when WRB N
2 CD N
mg NN N
and CC N
when WRB N
4 CD N
mg NN N
morphine NN 1_i
was VBD N
used VBN N
. . N

A DT N
5-mg JJ N
dose NN N
of IN N
droperidol NN N
had VBD N
no DT N
inhibitory JJ 1_o
effect NN 1_o
. . 1_o

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
incidence NN 1_o
of IN 1_o
pruritus NN 1_o
between IN N
use NN N
of IN N
2 CD N
mg NNS N
and CC N
4 CD N
mg NN N
morphine NN 1_i
. . 1_i

Other JJ N
untoward JJ 1_o
effects NNS 1_o
of IN N
morphine NN 1_i
either DT N
could MD N
not RB N
be VB N
observed VBN N
or CC N
occurred VBN N
with IN N
an DT N
incidence NN N
unaffected VBN N
by IN N
either DT N
dose NN N
of IN N
droperidol NN 1_i
. . 1_i

CONCLUSION NNP N
Pruritus NNP 1_o
caused VBN N
by IN N
epidural JJ N
use NN N
of IN N
2 CD N
or CC N
4 CD N
mg NN N
of IN N
morphine NN 1_i
is VBZ N
inhibited VBN N
by IN N
the DT N
intravenous JJ N
use NN N
of IN N
2.5 CD N
mg NNS N
droperidol RB 1_i
but CC N
not RB N
by IN N
a DT N
larger JJR N
dose NN N
. . N

-DOCSTART- -X- O O

Multicenter NNP N
trial NN N
of IN N
cryotherapy NN 1_i
for IN N
retinopathy NN 1_p
of IN 1_p
prematurity NN 1_p
: : 1_p
preliminary JJ N
results NNS N
. . N

Cryotherapy NNP 1_i
for IN N
Retinopathy NNP N
of IN N
Prematurity NNP N
Cooperative NNP N
Group NNP N
. . N

We PRP N
report VBP N
the DT N
preliminary JJ N
3-month JJ N
outcome NN N
of IN N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
cryotherapy NN 1_i
for IN 1_i
treatment NN 1_i
of IN 1_i
retinopathy NN 1_i
of IN 1_i
prematurity NN 1_i
( ( N
ROP NNP N
) ) N
. . N

Transscleral JJ 1_i
cryotherapy NN 1_i
to TO N
the DT N
avascular JJ N
retina NN N
was VBD N
applied VBN N
to TO N
one CD 1_p
randomly NN 1_p
selected VBN 1_p
eye NN 1_p
when WRB N
there EX N
was VBD N
threshold JJ N
disease NN N
( ( N
defined VBN N
as IN N
five CD N
or CC N
more JJR N
contiguous JJ N
or CC N
eight CD N
cumulative JJ N
30 CD N
degree JJ N
sectors NNS N
[ VBP N
clock NN N
hours NNS N
] CD N
of IN N
stage NN N
3 CD N
ROP NNP N
in IN N
zone CD N
1 CD N
or CC N
2 CD N
in IN N
the DT N
presence NN N
of IN N
plus JJ N
disease NN N
) ) N
. . N

An DT N
unfavorable JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
posterior JJ 1_o
retinal JJ 1_o
detachment NN 1_o
, , 1_o
retinal JJ 1_o
fold NN 1_o
involving VBG 1_o
the DT 1_o
macula NN 1_o
, , 1_o
or CC 1_o
retrolental JJ 1_o
tissue NN 1_o
. . 1_o

At IN N
this DT N
writing NN N
, , N
172 CD 1_p
infants NNS 1_p
had VBD 1_p
been VBN 1_p
examined VBN 1_p
3 CD 1_p
months NNS 1_p
after IN 1_p
randomization NN 1_p
. . 1_p

An DT N
unfavorable JJ 1_o
outcome NN 1_o
was VBD N
significantly RB N
less JJR N
frequent JJ N
in IN N
the DT N
eyes NNS N
undergoing VBG N
cryotherapy NN 1_i
( ( N
21.8 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
untreated JJ N
eyes NNS N
( ( N
43 CD N
% NN N
) ) N
. . N

While IN N
the DT N
surgery NN N
was VBD N
stressful JJ N
, , N
no DT N
unexpected JJ 1_o
complications NNS 1_o
occurred VBD N
during IN N
or CC N
following VBG N
treatment NN N
. . N

These DT N
data NNS N
support NN N
the DT N
efficacy NN 1_o
of IN N
cryotherapy NN 1_i
in IN N
reducing VBG N
by IN N
approximately RB N
one CD N
half PDT N
the DT N
risk NN N
of IN N
unfavorable JJ N
retinal JJ N
outcome NN N
from IN N
threshold JJ N
ROP NNP N
. . N

-DOCSTART- -X- O O

Teaching VBG N
young JJ 1_p
nonverbal JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
useful JJ N
speech NN N
: : N
a DT N
pilot NN N
study NN N
of IN N
the DT N
Denver NNP 1_i
Model NNP 1_i
and CC 1_i
PROMPT NNP 1_i
interventions NNS 1_i
. . 1_i

This DT N
single JJ N
subject NN N
design NN N
study NN N
examined VBD N
two CD N
models NNS N
of IN N
intervention NN N
: : N
Denver NNP 1_i
Model NNP 1_i
( ( 1_i
which WDT 1_i
merges VBZ 1_i
behavioral JJ 1_i
, , 1_i
developmental JJ 1_i
, , 1_i
and CC 1_i
relationship-oriented JJ 1_i
intervention NN 1_i
) ) 1_i
, , 1_i
and CC 1_i
PROMPT NNP 1_i
( ( 1_i
a DT 1_i
neuro-developmental JJ 1_i
approach NN 1_i
for IN 1_i
speech JJ 1_i
production NN 1_i
disorders NNS 1_i
) ) 1_i
. . 1_i

Ten CD 1_p
young JJ 1_p
, , 1_p
nonverbal JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
were VBD N
matched VBN N
in IN N
pairs NNS N
and CC N
randomized VBN N
to TO N
treatment NN N
. . N

They PRP N
received VBD N
12 CD N
1-h JJ N
weekly JJ N
sessions NNS N
of IN N
therapy NN N
and CC N
daily JJ N
1-h JJ N
home NN N
intervention NN N
delivered VBN N
by IN N
parents NNS N
. . N

Fidelity NNP N
criteria NNS N
were VBD N
maintained VBN N
throughout IN N
. . N

Eight NNP N
of IN N
the DT N
ten JJ N
children NNS N
used VBN N
five CD N
or CC N
more JJR N
novel JJ N
, , N
functional JJ 1_o
words NNS N
spontaneously RB N
and CC N
spoke VBD N
multiple JJ 1_o
times NNS 1_o
per IN 1_o
hour NN 1_o
by IN N
the DT N
conclusion NN N
of IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
acquired VBN 1_o
language NN 1_o
skills NNS 1_o
by IN N
intervention NN N
group NN N
. . N

Initial JJ N
characteristics NNS N
of IN N
the DT N
best JJS N
responders NNS N
were VBD N
mild JJ 1_p
to TO 1_p
moderate VB 1_p
symptoms NNS 1_p
of IN 1_p
autism NN 1_p
, , 1_p
better JJR 1_p
motor NN 1_o
imitation NN 1_o
skills NNS 1_o
, , 1_o
and CC 1_o
emerging VBG 1_o
joint JJ 1_o
attention NN 1_o
skills NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Smoking VBG 1_o
cessation NN 1_o
with IN N
smokeless JJ 1_i
tobacco NN 1_i
and CC N
group NN 1_i
therapy NN 1_i
: : 1_i
an DT N
open JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Smokeless NNP 1_i
tobacco NN 1_i
might MD N
be VB N
effective JJ N
as IN N
an DT N
adjunct NN N
for IN N
smoking VBG 1_o
cessation NN 1_o
. . 1_o

We PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
smokeless NN 1_i
tobacco NN 1_i
and CC N
group NN 1_i
support NN 1_i
for IN N
smoking VBG 1_o
cessation NN 1_o
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
that WDT N
compared VBN N
smokeless NN 1_i
tobacco NN 1_i
plus CC 1_i
group NN 1_i
support NN 1_i
versus NN 1_i
group NN 1_i
support NN 1_i
only RB 1_i
. . 1_i

The DT N
study NN 1_p
enrolled VBD 1_p
263 CD 1_p
healthy JJ 1_p
smokers NNS 1_p
( ( 1_p
M NNP 1_p
( ( 1_p
age NN 1_p
) ) 1_p
= VBZ 1_p
49 CD 1_p
years NNS 1_p
) ) 1_p
who WP 1_p
smoked VBD 1_p
a DT 1_p
mean NN 1_p
of IN 1_p
24 CD 1_p
cigarettes/day NN 1_p
, , 1_p
with IN 1_p
a DT 1_p
mean NN 1_p
of IN 1_p
31 CD 1_p
pack-years NNS 1_p
. . 1_p

Smokeless NNP 1_i
tobacco NN 1_i
was VBD N
provided VBN N
for IN N
7 CD N
weeks NNS N
( ( N
or CC N
up RB N
to TO N
12 CD N
) ) N
, , N
combined VBN N
with IN N
eight CD N
group NN 1_i
support NN 1_i
visits NNS 1_i
provided VBN 1_i
by IN 1_i
nurses NNS 1_i
. . 1_i

The DT N
control NN 1_i
group NN 1_i
received VBD N
group NN 1_i
support NN 1_i
only RB 1_i
. . 1_i

Smoking VBG 1_o
cessation NN 1_o
rates NNS 1_o
were VBD N
statistically RB N
significantly RB N
better RBR N
in IN N
the DT N
smokeless NN N
tobacco NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
during IN N
the DT N
first JJ N
7 CD N
weeks NNS N
. . N

Point-prevalence NN 1_o
abstinence NN 1_o
rates NNS 1_o
at IN N
7 CD N
weeks NNS N
were VBD N
36.4 CD N
% NN N
versus IN N
20.8 CD N
% NN N
( ( N
OR NNP N
= VBZ N
2.52 CD N
, , N
p NN N
= NNP N
.001 NNP N
) ) N
, , N
respectively RB N
; : N
and CC N
continuous JJ 1_o
abstinence NN 1_o
rates NNS 1_o
from IN N
weeks NNS N
4 CD N
to TO N
7 CD N
were VBD N
31.5 CD N
% NN N
versus IN N
19.2 CD N
% NN N
( ( N
OR NNP N
= VBZ N
1.94 CD N
, , N
p NN N
= NNP N
.023 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
primary JJ N
outcomes NNS N
( ( N
i.e. JJ N
, , N
6-month JJ 1_o
point NN 1_o
prevalence NN 1_o
) ) 1_o
were VBD N
23.1 CD N
% NN N
versus IN N
20.8 CD N
% NN N
, , N
respectively RB N
( ( N
OR NNP N
= VBZ N
1.31 CD N
, , N
ns NN N
) ) N
. . N

Smokeless NNP 1_i
tobacco NN 1_i
was VBD N
relatively RB N
well RB N
tolerated VBN 1_o
, , N
although IN N
15 CD N
subjects NNS N
( ( N
11.2 CD N
% NN N
) ) N
stopped VBD N
use NN N
due JJ N
to TO N
adverse JJ 1_o
events NNS 1_o
. . 1_o

A DT N
total NN N
of IN N
25 CD N
subjects NNS N
( ( N
17.5 CD N
% NN N
) ) N
were VBD N
still RB N
using VBG N
smokeless JJ N
tobacco NN N
after IN N
6 CD N
months NNS N
. . N

This DT N
trial NN N
demonstrated VBD N
short-term JJ 1_o
efficacy NN 1_o
of IN 1_o
smokeless JJ 1_o
tobacco NN 1_o
in IN N
combination NN N
with IN N
group NN N
support NN N
for IN N
smoking VBG N
cessation NN N
but CC N
no DT N
long-term JJ 1_o
efficacy NN 1_o
. . 1_o

-DOCSTART- -X- O O

A DT N
pharmacy NN 1_i
discharge NN 1_i
plan NN 1_i
for IN N
hospitalized JJ 1_p
elderly JJ 1_p
patients NNS 1_p
-- : 1_p
a DT 1_p
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVES UH N
to TO N
investigate VB N
the DT N
effectiveness NN 1_o
of IN 1_o
a DT 1_o
pharmacy NN 1_o
discharge NN 1_o
plan NN 1_o
in IN N
elderly JJ 1_p
hospitalized JJ 1_p
patients NNS 1_p
. . 1_p

DESIGN NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SUBJECTS NNP N
AND CC N
SETTINGS NNP N
we PRP N
randomized VBD N
patients NNS 1_p
aged VBN 1_p
75 CD 1_p
years NNS 1_p
and CC 1_p
older JJR 1_p
on IN 1_p
four CD 1_p
or CC 1_p
more JJR 1_p
medicines NNS 1_p
who WP 1_p
had VBD 1_p
been VBN 1_p
discharged VBN 1_p
from IN 1_p
three CD 1_p
acute JJ 1_p
general JJ 1_p
and CC 1_p
one CD 1_p
long-stay JJ 1_p
hospital NN 1_p
to TO 1_p
a DT 1_p
pharmacy NN 1_p
intervention NN 1_p
or CC 1_p
usual JJ 1_p
care NN 1_p
. . 1_p

INTERVENTIONS VBZ N
the DT N
hospital NN 1_i
pharmacist NN 1_i
developed VBD 1_i
discharge NN 1_i
plans NNS 1_i
which WDT N
gave VBD N
details NNS N
of IN N
medication NN N
and CC N
support NN N
required VBN N
by IN N
the DT N
patient NN N
. . N

A DT N
copy NN N
was VBD N
given VBN N
to TO N
the DT N
patient NN N
and CC N
to TO N
all DT N
relevant JJ N
professionals NNS N
and CC N
carers NNS N
. . N

This DT N
was VBD N
followed VBN N
by IN N
a DT N
domiciliary JJ N
assessment NN N
by IN N
a DT N
community NN N
pharmacist NN N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
patients NNS N
were VBD N
discharged VBN 1_i
from IN 1_i
hospital NN 1_i
following VBG 1_i
standard JJ 1_i
procedures NNS 1_i
that WDT N
included VBD N
a DT N
discharge NN N
letter NN N
to TO N
the DT N
general JJ N
practitioner NN N
listing VBG N
current JJ N
medications NNS N
. . N

OUTCOMES IN N
the DT N
primary JJ N
outcome NN N
was VBD N
re-admission NN 1_o
to TO 1_o
hospital VB 1_o
within IN 1_o
6 CD 1_o
months NNS 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
included VBD N
the DT N
number NN 1_o
of IN 1_o
deaths NNS 1_o
, , 1_o
attendance NN 1_o
at IN 1_o
hospital JJ 1_o
outpatient NN 1_o
clinics NNS 1_o
and CC 1_o
general JJ 1_o
practice NN 1_o
and CC 1_o
proportion NN 1_o
of IN 1_o
days NNS 1_o
in IN 1_o
hospital NN 1_o
over IN 1_o
the DT 1_o
follow-up JJ 1_o
period NN 1_o
, , 1_o
together RB 1_o
with IN 1_o
patients NNS 1_o
' POS 1_o
general JJ 1_o
well-being NN 1_o
, , 1_o
satisfaction NN 1_o
with IN 1_o
the DT 1_o
service NN 1_o
and CC 1_o
knowledge NN 1_o
of IN 1_o
and CC 1_o
adherence NN 1_o
to TO 1_o
prescribed VB 1_o
medication NN 1_o
. . 1_o

RESULTS NNP N
we PRP 1_p
recruited VBD 1_p
362 CD 1_p
patients NNS 1_p
, , 1_p
of IN 1_p
whom WP 1_p
181 CD 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
each DT 1_p
group NN 1_p
. . 1_p

We PRP 1_p
collected VBD 1_p
hospital NN 1_p
and CC 1_p
general JJ 1_p
practice NN 1_p
data NNS 1_p
on IN 1_p
at IN 1_p
least JJS 1_p
91 CD 1_p
and CC 1_p
72 CD 1_p
% NN 1_p
of IN 1_p
patients NNS 1_p
respectively RB 1_p
at IN 1_p
each DT 1_p
follow-up JJ 1_p
point NN 1_p
and CC 1_p
interviewed VBD 1_p
between IN 1_p
43 CD 1_p
and CC 1_p
90 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
study NN 1_p
subjects NNS 1_p
. . 1_p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
re-admitted JJ 1_o
to TO 1_o
hospital VB 1_o
between IN N
baseline NN N
and CC N
3 CD N
months NNS N
or CC N
3 CD N
and CC N
6 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
the DT N
secondary JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
we PRP N
found VBD N
no DT N
evidence NN N
to TO N
suggest VB N
that IN N
the DT N
co-ordinated JJ N
hospital NN N
and CC N
community NN 1_i
pharmacy NN 1_i
care NN 1_i
discharge NN 1_i
plans NNS 1_i
in IN N
elderly JJ N
patients NNS N
in IN N
this DT N
study NN N
influence NN N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Do NNP N
cognitive JJ N
measures NNS N
and CC N
brain NN N
circuitry NN N
predict VBP N
outcomes NNS N
of IN N
exercise NN N
in IN N
Parkinson NNP 1_p
Disease NNP 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
emerging VBG N
research NN N
detailing VBG N
the DT N
relationship NN N
between IN N
balance/gait/falls NNS N
and CC N
cognition NN N
. . N

Imaging VBG N
studies NNS N
also RB N
suggest VBP N
a DT N
link NN N
between IN N
structural JJ N
and CC N
functional JJ N
changes NNS N
in IN N
the DT N
frontal JJ N
lobe NN N
( ( N
a DT N
region NN N
commonly RB N
associated VBN N
with IN N
cognitive JJ N
function NN N
) ) N
and CC N
mobility NN N
. . N

People NNS 1_p
with IN 1_p
Parkinson NNP 1_p
's POS 1_p
disease NN 1_p
have VBP N
important JJ N
changes NNS N
in IN N
cognitive JJ N
function NN N
that WDT N
may MD N
impact VB N
rehabilitation NN N
efficacy NN N
. . N

Our PRP$ N
underlying JJ N
hypothesis NN N
is VBZ N
that IN N
cognitive JJ N
function NN N
and CC N
frontal JJ N
lobe NN N
connections NNS N
with IN N
the DT N
basal NN N
ganglia NN N
and CC N
brainstem NN N
posture/locomotor NN N
centers NNS N
are VBP N
responsible JJ N
for IN N
postural JJ N
deficits NNS N
in IN N
people NNS 1_p
with IN 1_p
Parkinson NNP 1_p
's POS 1_p
disease NN 1_p
and CC N
play VB N
a DT N
role NN N
in IN N
rehabilitation NN N
efficacy NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
1 CD N
) ) N
determine NN N
if IN N
people NNS 1_p
with IN 1_p
Parkinson NNP 1_p
's POS 1_p
disease NN 1_p
can MD N
improve VB N
mobility NN N
and/or IN N
cognition NN N
after IN N
partaking VBG N
in IN N
a DT N
cognitively RB 1_i
challenging JJ 1_i
mobility NN 1_i
exercise NN 1_i
program NN 1_i
and CC N
2 CD N
) ) N
determine NN N
if IN N
cognition NN N
and CC N
brain NN N
circuitry NN N
deficits NNS N
predict VBP N
responsiveness NN N
to TO N
exercise VB 1_i
rehabilitation NN 1_i
. . 1_i

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
cross-over NN N
controlled VBN N
intervention NN N
to TO N
take VB N
place NN N
at IN N
a DT N
University NNP 1_p
Balance NNP 1_p
Disorders NNP 1_p
Laboratory NNP 1_p
. . 1_p

The DT N
study NN 1_p
participants NNS 1_p
will MD 1_p
be VB 1_p
people NNS 1_p
with IN 1_p
Parkinson NNP 1_p
's POS 1_p
disease NN 1_p
who WP 1_p
meet VBZ 1_p
inclusion NN 1_p
criteria NNS 1_p
for IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
intervention NN N
will MD N
be VB N
6 CD 1_i
weeks NNS 1_i
of IN 1_i
group NN 1_i
exercise NN 1_i
( ( 1_i
case NN 1_i
) ) 1_i
and CC 1_i
6 CD 1_i
weeks NNS 1_i
of IN 1_i
group NN 1_i
education NN 1_i
( ( 1_i
control NN 1_i
) ) 1_i
. . 1_i

The DT N
exercise NN N
is VBZ N
a DT N
cognitively JJ 1_i
challenging VBG 1_i
program NN 1_i
based VBN 1_i
on IN 1_i
the DT 1_i
Agility NNP 1_i
Boot NNP 1_i
Camp NNP 1_i
for IN N
people NNS N
with IN N
PD NNP N
. . N

The DT 1_i
education NN 1_i
program NN 1_i
is VBZ N
a DT N
6-week JJ N
program NN N
to TO N
teach VB 1_i
people NNS 1_i
how WRB 1_i
to TO 1_i
better RBR 1_i
live JJ 1_i
with IN 1_i
a DT 1_i
chronic JJ 1_i
disease NN 1_i
. . 1_i

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
the DT N
MiniBESTest NNP 1_o
and CC N
the DT N
secondary JJ N
outcomes NNS N
are VBP N
measures NNS N
of IN N
mobility NN 1_o
, , 1_o
cognition NN 1_o
and CC 1_o
neural JJ 1_o
imaging NN 1_o
. . 1_o

DISCUSSION NNP N
The DT N
results NNS N
from IN N
this DT N
study NN N
will MD N
further VB N
our PRP$ N
understanding NN N
of IN N
the DT N
relationship NN N
between IN N
cognition NN N
and CC N
mobility NN N
with IN N
a DT N
focus NN N
on IN N
brain NN N
circuitry NN N
as IN N
it PRP N
relates VBZ N
to TO N
rehabilitation VB N
potential JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
clinical JJ N
trials.gov NN N
( ( N
NCT02231073 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Children NNP 1_p
with IN 1_p
autistic JJ 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

II NN N
: : N
parents NNS 1_p
are VBP N
unable JJ N
to TO N
distinguish VB N
secretin NN N
from IN N
placebo NN N
under IN N
double-blind JJ N
conditions NNS N
. . N

BACKGROUND NNP N
Standardised VBD 1_o
measures NNS 1_o
of IN 1_o
behaviour NNS 1_o
have VBP N
failed VBN N
to TO N
detect VB N
short JJ 1_o
term NN 1_o
improvement NN 1_o
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
following VBG N
treatment NN N
with IN N
secretin NN 1_i
. . 1_i

However RB N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
standardised JJ N
measures NNS N
are VBP N
insensitive JJ N
to TO N
dimensions NNS N
of IN N
child NN N
behaviour NN N
that WDT N
are VBP N
nonetheless RB N
detectable JJ N
by IN N
parents NNS N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
ability NN 1_o
of IN 1_o
parents NNS 1_o
of IN 1_o
children NNS 1_o
with IN 1_o
autism NN 1_o
to TO N
guess VB N
, , N
under IN N
double JJ N
blind NN N
conditions NNS N
, , N
whether IN N
their PRP$ N
child NN N
had VBD N
received VBN N
secretin NN 1_i
or CC N
placebo NN 1_i
. . 1_i

METHODS NNP N
2x2 CD N
crossover NN N
randomised VBD N
blinded VBN N
study NN N
, , N
comparing VBG N
the DT N
effect NN N
of IN N
synthetic JJ 1_i
human JJ 1_i
secretin NN 1_i
2 CD N
U/kg NNP N
to TO N
placebo VB 1_i
( ( 1_i
saline NN 1_i
) ) 1_i
. . 1_i

Sixty CD 1_p
two CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
( ( 1_p
aged VBN 1_p
43-103 CD 1_p
months NNS 1_p
) ) 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
placebo NN 1_i
, , 1_i
followed VBD 1_i
six CD 1_i
weeks NNS 1_i
later RB 1_i
by IN 1_i
secretin NN 1_i
, , N
and CC N
group NN N
2 CD N
received VBD N
secretin NN 1_i
followed VBN 1_i
by IN 1_i
placebo NN 1_i
. . 1_i

At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN N
, , N
parents NNS 1_p
were VBD N
asked VBN N
to TO N
guess VB N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
. . N

RESULTS NNP N
Twenty NNP 1_p
seven CD 1_p
families NNS 1_p
guessed VBD N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
correctly RB N
and CC N
27 CD 1_p
guessed VBN 1_p
incorrectly RB 1_p
. . 1_p

In IN N
48 CD N
instances NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
improvement NN 1_o
; : 1_o
in IN N
six CD N
cases NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
deterioration NN 1_o
. . 1_o

Six NNP 1_p
families NNS 1_p
saw VBD N
no DT N
difference NN N
after IN N
either DT N
infusion NN N
, , N
and CC N
offered VBD N
no DT N
guess NN N
. . N

One CD N
family NN N
dropped VBD N
out RP N
after IN N
the DT N
first JJ N
infusion NN N
, , N
and CC N
one CD N
family NN N
was VBD N
lost VBN N
to TO N
follow VB N
up RP N
after IN N
the DT N
second JJ N
infusion NN N
. . N

CONCLUSION NNP N
In IN N
a DT N
controlled JJ N
setting NN N
, , N
parents NNS 1_p
of IN 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
are VBP N
unable JJ N
to TO N
distinguish VB N
the DT N
short JJ 1_o
term NN 1_o
behavioural JJ 1_o
effects NNS 1_o
of IN N
secretin NN 1_i
from IN N
placebo NN 1_i
. . 1_i

-DOCSTART- -X- O O

[ JJ N
Safety NNP N
of IN N
adjuvant JJ 1_i
dose-dense JJ 1_i
chemotherapy NN 1_i
with IN 1_i
paclitaxel NN 1_i
and CC 1_i
epirubicin NN 1_i
for IN N
high-risk JJ 1_p
breast NN 1_p
cancer NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
safety NN 1_o
and CC 1_o
tolerance NN 1_o
of IN N
adjuvant JJ 1_i
dose-dense JJ 1_i
chemotherapy NN 1_i
with IN 1_i
paclitaxel NN 1_i
and CC 1_i
epirubicin NN 1_i
for IN N
high-risk JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
From IN N
January NNP N
2004 CD N
to TO N
December NNP N
2006 CD N
, , N
101 CD 1_p
patients NNS 1_p
with IN 1_p
high-risk JJ 1_p
breast NN 1_p
cancer NN 1_p
after IN 1_p
surgical JJ 1_p
resection NN 1_p
were VBD N
enrolled VBN N
into IN N
this DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
dose-dense NN N
and CC N
regular JJ N
groups NNS N
. . N

Each DT N
patient NN N
received VBD N
6 CD 1_i
cycles NNS 1_i
of IN 1_i
chemotherapy NN 1_i
with IN 1_i
intravenous JJ 1_i
administration NN 1_i
of IN 1_i
paclitaxel NN 1_i
( ( 1_i
175 CD 1_i
mg/m2 NN 1_i
, , 1_i
on IN 1_i
D3 NNP 1_i
) ) 1_i
and CC 1_i
epirubicin $ 1_i
( ( 1_i
60 CD 1_i
mg/m2 NN 1_i
, , 1_i
on IN 1_i
Dl NNP 1_i
and CC 1_i
D2 NNP 1_i
) ) 1_i
. . 1_i

The DT N
dose-dense JJ 1_i
group NN 1_i
had VBD 1_i
repeated VBN 1_i
treatment NN 1_i
every DT 1_i
two CD 1_i
weeks NNS 1_i
, , N
while IN N
the DT N
regular JJ 1_i
group NN 1_i
repeated VBD 1_i
it PRP 1_i
every DT 1_i
three CD 1_i
weeks NNS 1_i
. . 1_i

G-CSF NNP 1_i
was VBD 1_i
used VBN 1_i
in IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
3 CD 1_i
microg/kg NNS 1_i
on IN 1_i
D5-D9 NNP 1_i
during IN N
each DT N
cycle NN N
in IN N
the DT N
dose-dense JJ N
group NN N
. . N

While IN N
in IN N
the DT N
regular JJ N
group NN N
, , N
it PRP N
was VBD N
used VBN N
only RB N
under IN N
the DT N
condition NN N
that IN N
grade VBD N
II NNP N
neutropenia NN N
occurred VBD N
. . N

RESULTS VB N
The DT N
toxicity NN 1_o
could MD N
be VB N
evaluated VBN N
in IN N
101 CD 1_p
patients NNS 1_p
. . 1_p

Major JJ 1_o
grade JJ 1_o
II-IV NNP 1_o
toxicities NNS 1_o
included VBD 1_o
: : 1_o
neutropenia NN 1_o
, , 1_o
nausea NN 1_o
, , 1_o
vomiting VBG 1_o
and CC 1_o
alopecia NN 1_o
. . 1_o

The DT N
incidence NN N
of IN N
grade JJ 1_o
III-IV NNP 1_o
neutropenia NN 1_o
was VBD N
16.0 CD N
% NN N
in IN N
the DT N
dose-dense JJ N
group NN N
versus VBD N
54.9 CD N
% NN N
in IN N
the DT N
regular JJ N
group NN N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
; : N
postponing VBG N
of IN N
chemotherapy NN N
was VBD N
2.4 CD N
% NN N
versus IN N
6.0 CD N
% NN N
( ( N
P NNP N
= NNP N
0.027 CD N
) ) N
. . N

Ninety-eight JJ 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
chemotherapy NN 1_p
as IN 1_p
planed VBN 1_p
. . 1_p

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
24 CD N
months NNS N
, , N
the DT N
median JJ 1_o
DFS NNP 1_o
and CC 1_o
OS NNP 1_o
were VBD N
not RB N
reached VBN N
. . N

The DT N
relapse-free JJ 1_o
rate NN 1_o
and CC 1_o
survival NN 1_o
rate NN 1_o
were VBD N
89.8 CD N
% NN N
and CC N
100 CD N
% NN N
in IN N
the DT N
dose-dense JJ N
group NN N
, , N
which WDT N
were VBD N
87.8 CD N
% NN N
and CC N
93.9 CD N
% NN N
in IN N
the DT N
regular JJ N
group NN N
. . N

The DT N
relapse-free JJ 1_o
rate NN 1_o
of IN 1_o
the DT 1_o
high-risk JJ 1_o
patients NNS 1_o
in IN N
the DT N
dose-dense JJ N
group NN N
was VBD N
86.8 CD N
% NN N
versus IN N
81.3 CD N
% NN N
in IN N
the DT N
regular JJ N
group NN N
, , N
and CC N
the DT N
corresponding JJ N
survival NN N
rate NN N
was VBD N
100 CD N
% NN N
versus IN N
90.6 CD N
% NN N
. . N

CONCLUSION NNP N
Adjuvant NNP 1_i
dose-dense JJ 1_i
chemotherapy NN 1_i
with IN 1_i
paclitaxel NN 1_i
and CC 1_i
epirubicin NN 1_i
is VBZ N
safe JJ N
, , N
tolerable JJ N
and CC N
promising VBG N
for IN N
high-risk JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
crossover NN N
study NN N
of IN N
Cappra? NNP 1_i
for IN N
the DT N
treatment NN N
of IN 1_p
mild NN 1_p
or CC 1_p
mild NN 1_p
to TO 1_p
moderate VB 1_p
erectile JJ 1_p
dysfunction NN 1_p
in IN 1_p
Thai NNP 1_p
male NN 1_p
. . 1_p

Erectile JJ N
dysfunction NN N
( ( N
ED NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
major JJ N
health NN N
concerns NNS N
affects VBZ N
the DT N
quality NN N
of IN N
life NN N
among IN 1_p
Thai NNP 1_p
male NN 1_p
. . 1_p

The DT N
treatment NN N
of IN N
ED NNP N
by IN N
the DT N
first-line JJ N
drugs NNS N
is VBZ N
limited VBN N
to TO N
a DT N
certain JJ N
group NN N
of IN N
patients NNS N
due JJ N
to TO N
their PRP$ N
side NN N
effects NNS N
and CC N
costs NNS N
. . N

Alternative JJ N
medicine NN N
can MD N
be VB N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
ED NNP N
. . N

This DT N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , 1_i
crossover NN N
study NN N
aimed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN 1_i
Cappra NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
, , 1_i
a DT N
traditional JJ N
herbal NN N
medicine NN N
which WDT N
was VBD N
used VBN N
in IN N
Thailand NNP N
for IN N
decades NNS N
, , N
for IN N
the DT N
treatment NN N
of IN N
mild NN 1_p
and CC 1_p
mild NN 1_p
to TO 1_p
moderate VB 1_p
ED NNP 1_p
in IN 1_p
Thai NNP 1_p
patients NNS 1_p
. . 1_p

A DT N
total NN N
of IN N
63 CD 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
or CC 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
ED NNP 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
receive VB 1_i
Cappra NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
for IN 1_i
two CD N
weeks NNS N
in IN N
the DT N
first JJ N
period NN N
, , N
followed VBN N
by IN N
one CD N
week NN N
washout NN N
period NN N
. . N

The DT N
patients NNS N
were VBD N
switched VBN N
to TO N
the DT N
alternative JJ N
treatment NN N
in IN N
the DT N
second JJ N
period NN N
. . N

The DT N
efficacy NN 1_o
was VBD 1_o
assessed VBN N
by IN N
the DT N
International NNP 1_o
Index NNP 1_o
of IN 1_o
Erectile NNP 1_o
Function NNP 1_o
( ( 1_o
IIEF NNP 1_o
) ) 1_o
questionnaire NN 1_o
and CC 1_o
adverse JJ 1_o
events NNS 1_o
. . 1_o

Sixty NNP 1_o
one CD N
patients NNS N
completed VBD N
the DT N
study NN N
. . N

There EX N
was VBD N
an DT N
improvement NN N
of IN N
IIEF NNP 1_o
score NN 1_o
for IN 1_o
all DT N
domains NNS N
in IN N
Cappra NNP N
( ( N
? . N
) ) N
group NN N
compared VBN N
with IN N
placebo NN N
group NN N
. . N

The DT N
mean JJ 1_o
change NN 1_o
of IN 1_o
IIEF NNP 1_o
score NN 1_o
from IN 1_o
baseline NN N
for IN N
erectile JJ N
function NN N
domain NN N
of IN N
Cappra NNP N
( ( N
? . N
) ) N
was VBD N
significantly RB N
higher JJR N
than IN N
placebo NN N
( ( N
4.87 CD N
vs NN N
3.44 CD N
, , N
p NN N
= NNP N
0.032 CD N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
dizziness NN 1_o
( ( 1_o
13.3 CD 1_o
% NN N
Cappra NNP N
( ( N
? . N
) ) N
, , N
9.6 CD N
% NN N
placebo NN 1_o
) ) 1_o
, , 1_o
face NN 1_o
numbness NN 1_o
( ( 1_o
1.6 CD 1_o
% NN 1_o
Cappra NNP N
( ( N
? . N
) ) N
, , N
0 CD N
% NN N
placebo NN N
) ) 1_o
, , 1_o
and CC 1_o
tachycardia NN 1_o
( ( 1_o
1.6 CD 1_o
% NN 1_o
Cappra NNP N
( ( N
? . N
) ) N
, , N
0 CD N
% NN N
placebo NN N
) ) N
. . N

The DT N
results NNS N
from IN N
this DT N
study NN N
demonstrated VBD N
that IN N
Cappra NNP N
( ( N
? . N
) ) N
is VBZ N
effective JJ N
and CC N
well-tolerated JJ N
and CC N
can MD N
be VB N
used VBN N
as IN N
alternative JJ N
therapy NN N
for IN N
mild NN N
and CC N
mild NN N
to TO N
moderate VB N
ED NNP N
. . N

-DOCSTART- -X- O O

Suppression NN N
of IN N
immediate JJ N
and CC N
late JJ N
anti-IgE-induced JJ 1_o
skin NN 1_o
reactions NNS 1_o
by IN N
topically RB N
applied VBN N
alcohol/onion NN 1_i
extract NN 1_i
. . 1_i

In IN N
a DT N
double JJ N
blind NN N
study NN N
, , N
alcohol/onion NN 1_i
extract NN 1_i
( ( 1_i
5 CD 1_i
% NN 1_i
ethanol NN 1_i
) ) 1_i
was VBD N
injected VBN N
simultaneously RB N
with IN N
20 CD 1_i
IU NNP 1_i
and CC 1_i
200 CD 1_i
IU NNP 1_i
rabbit NN 1_i
anti-human-IgE JJ 1_i
intradermally RB 1_i
in IN N
12 CD 1_p
adult NN 1_p
volunteers NNS 1_p
( ( 1_p
6 CD 1_p
atopics NNS 1_p
, , 1_p
6 CD 1_p
non-atopics NNS 1_p
) ) 1_p
. . 1_p

Diameters NNS N
of IN N
wheals NNS N
and CC N
flares NNS N
were VBD N
measured VBN N
10 CD N
min NN N
after IN N
and CC N
compared VBN N
with IN N
control NN N
sites NNS N
challenged VBD N
with IN N
20 CD N
IU NNP N
and CC N
200 CD N
IU NNP N
anti-IgE NN 1_i
in IN 1_i
a DT 1_i
5 CD 1_i
% NN 1_i
ethanol JJ 1_i
solution NN N
. . N

The DT N
skin NN N
sites NNS N
were VBD N
then RB N
treated VBN N
epidermally RB N
with IN N
45 CD 1_i
% NN 1_i
alcohol/onion NN 1_i
extract NN 1_i
and CC N
45 CD 1_i
% NN 1_i
ethanol NN 1_i
under IN N
occlusion NN N
. . N

Diameters NNS N
of IN N
late JJ N
cutaneous JJ N
reactions NNS N
were VBD N
measured VBN N
hourly RB N
. . N

Oedema NNP N
formation NN N
was VBD N
clinically RB N
estimated VBN N
according VBG N
to TO N
an DT N
arbitrary JJ N
scale NN N
and CC N
skin NN N
thickness NN N
measured VBN N
with IN N
a DT N
calliper NN N
. . N

In IN N
the DT N
onion-treated JJ 1_i
skin NN N
sites VBZ N
the DT N
wheal JJ 1_o
areas NNS 1_o
were VBD N
significantly RB 1_o
reduced VBN 1_o
( ( N
20 CD N
IU NNP N
: : N
control NN N
: : N
108 CD N
+/- JJ N
53 CD N
mm2 NN N
; : N
onion NN N
69 CD N
+/- JJ N
42 CD N
mm2 NN N
, , N
P NNP N
less JJR N
than IN N
0.05 CD N
; : N
200 CD N
IU NNP N
anti-IgE JJ N
: : N
control NN N
: : N
152 CD N
+/- JJ N
25 CD N
mm2 NN N
, , N
onion NN N
: : N
138 CD N
+/- JJ N
26 CD N
mm2 NN N
, , N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

The DT N
oedema JJ 1_o
formation NN 1_o
during IN N
the DT N
late JJ N
phase NN N
skin JJ N
reaction NN N
was VBD N
markedly RB N
depressed JJ N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
at IN N
2 CD N
h NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
at IN N
4 CD N
and CC N
6 CD N
h NN N
, , N
P NNP N
less JJR N
than IN N
0.02 CD N
at IN N
8 CD N
h NN N
) ) N
. . N

The DT N
extent NN N
of IN N
late JJ N
skin NN 1_o
reactions NNS 1_o
was VBD N
slightly RB N
, , N
but CC N
not RB N
significantly RB N
reduced VBN N
. . N

Obviously RB N
, , N
onions NNS 1_i
contain VBP N
pharmacologically RB N
active JJ N
substances NNS N
with IN N
anti-inflammatory JJ N
and/or NN N
allergic NN N
properties NNS N
. . N

-DOCSTART- -X- O O

Measurement NN N
of IN N
peptidase NN 1_o
activity NN 1_o
and CC N
evaluation NN N
of IN N
effectiveness NN N
of IN N
administration NN N
of IN N
minocycline NN 1_i
for IN N
treatment NN N
of IN N
dogs NNS 1_p
with IN 1_p
periodontitis NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
determine VB N
clinical JJ 1_o
, , 1_o
enzymatic JJ 1_o
, , 1_o
and CC 1_o
microbiologic JJ 1_o
effects NNS 1_o
of IN N
controlled-release NN N
localized JJ N
administration NN N
of IN N
minocycline NN 1_i
on IN N
dogs NNS 1_p
with IN 1_p
periodontitis NN 1_p
. . 1_p

ANIMALS NNP N
Five CD 1_p
adult NN 1_p
Beagles NNS 1_p
with IN 1_p
periodontitis NN 1_p
. . 1_p

PROCEDURE NNP N
After IN N
tooth CC N
scaling VBG N
and CC N
root NN N
planing NN N
, , N
2 CD N
treatment NN N
, , N
1 CD N
placebo NN N
, , N
and CC N
1 CD N
control NN N
site NN N
were VBD N
selected VBN N
for IN N
each DT N
dog NN N
. . N

Treatment NN N
sites NNS N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
received VBD N
a DT N
periodontal JJ 1_i
formulation NN 1_i
of IN 1_i
minocycline NN 1_i
hydrochloride NN 1_i
, , 1_i
placebo NN 1_i
sites NNS N
( ( N
5 CD N
) ) N
received VBD 1_i
ointment JJ 1_i
without IN 1_i
minocycline NN 1_i
, , 1_i
and CC 1_i
control VB 1_i
sites NNS 1_i
( ( 1_i
5 CD 1_i
) ) 1_i
did VBD 1_i
not RB 1_i
receive VB 1_i
ointment NN 1_i
. . 1_i

Treatments NNS N
were VBD N
administered VBN N
4 CD N
times NNS N
at IN N
weekly JJ N
intervals NNS N
. . N

Peptidase NNP 1_o
activity NN 1_o
and CC 1_o
clinical JJ 1_o
and CC 1_o
microbiologic JJ 1_o
effects NNS 1_o
were VBD N
evaluated VBN N
and CC N
compared VBN N
among IN N
sites NNS N
for IN N
17 CD N
weeks NNS N
. . N

RESULTS NNP N
Bleeding NNP 1_o
of IN 1_o
the DT 1_o
gums NNS 1_o
on IN 1_o
probing VBG 1_o
( ( 1_o
BOP NNP 1_o
) ) 1_o
and CC 1_o
pocket NN 1_o
depth NN 1_o
( ( 1_o
PD NNP 1_o
) ) 1_o
improved VBD 1_o
at IN N
the DT N
treatment NN N
site NN N
and CC N
were VBD N
maintained VBN N
for IN N
13 CD N
weeks NNS N
after IN N
treatment NN N
. . N

However RB N
, , N
BOP NNP 1_o
and CC 1_o
PD NNP 1_o
in IN N
placebo NN N
and CC N
control VB N
sites NNS N
increased VBN N
from IN N
weeks NNS N
9 CD N
to TO N
17 CD N
Peptidase NNP 1_o
activity NN 1_o
in IN N
the DT N
periodontal JJ N
pocket NN N
decreased VBD N
noticeably RB N
from IN N
week NN N
1 CD N
to TO N
17 CD N
, , N
compared VBN N
with IN N
baseline NN N
values NNS N
for IN N
the DT N
treatment NN N
site NN N
. . N

However RB N
, , N
peptidase NN 1_o
activity NN 1_o
for IN N
placebo NN N
and CC N
control VB N
sites NNS N
increased VBN N
and CC N
were VBD N
above RB N
baseline JJ N
values NNS N
on IN N
week NN N
9 CD N
and CC N
week NN N
13 CD N
, , N
respectively RB N
. . N

Total JJ 1_o
bacterial JJ 1_o
counts NNS 1_o
decreased VBN N
by IN N
90 CD N
% NN N
for IN N
treatment NN N
sites NNS N
and CC N
remained VBD N
at IN N
that DT N
value NN N
for IN N
13 CD N
weeks NNS N
. . N

However RB N
, , N
for IN N
placebo NN N
and CC N
control NN N
sites NNS N
, , N
bacterial JJ 1_o
counts NNS 1_o
increased VBD N
and CC N
reached VBD N
the DT N
baseline NN N
value NN N
on IN N
week NN N
17 CD N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
Increased VBD 1_o
peptidase NN 1_o
activity NN 1_o
is VBZ N
correlated VBN N
with IN N
the DT N
progression NN N
of IN N
periodontitis NN 1_p
in IN 1_p
dogs NNS 1_p
. . 1_p

Treatment NN N
with IN N
minocycline NN 1_i
, , N
using VBG N
a DT N
localized VBN N
delivery NN N
system NN N
, , N
was VBD N
effective JJ N
in IN N
dogs NNS N
for IN N
at IN N
least JJS N
13 CD N
weeks NNS N
after IN N
cessation NN N
of IN N
drug NN N
administration NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
eltanolone NN 1_i
and CC N
thiopental NN 1_i
in IN N
anaesthesia NN 1_o
for IN N
termination NN 1_p
of IN 1_p
pregnancy NN 1_p
. . 1_p

Eltanolone NNP 1_i
, , N
a DT N
new JJ N
steroid JJ N
hypnotic NN N
, , N
was VBD N
compared VBN N
to TO N
thiopental VB N
in IN N
short JJ N
anaesthesia NN N
. . N

Sixty NNP 1_p
unpremedicated VBD 1_p
, , 1_p
Asa NNP 1_p
1-2 JJ 1_p
women NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
eltanolone NN 1_i
0.6 CD 1_i
( ( N
group NN N
E1 NNP N
) ) N
or CC N
0.8 CD N
mg.kg-1 JJ N
( ( N
group NN N
E2 NNP N
) ) N
or CC N
thiopental JJ 1_i
4 CD N
mg.kg-1 NN N
( ( N
group NN N
T NNP N
) ) N
for IN N
induction NN N
of IN N
anaesthesia NN N
. . N

One CD N
minute NN N
before IN N
induction NN N
glycopyrrolate NN 1_i
0.2 CD 1_i
mg NN 1_i
and CC 1_i
alfentanil JJ 1_i
15 CD 1_i
micrograms.kg-1 JJ 1_i
i.v NN N
. . N

were VBD N
administered VBN N
. . N

If IN N
induction NN N
failed VBD N
, , N
additional JJ N
boluses NNS N
of IN N
the DT N
test NN N
drug NN N
were VBD N
given VBN N
. . N

Anaesthesia NNP N
was VBD N
maintained VBN N
with IN N
67 CD N
% NN N
nitrous JJ 1_i
oxide NN 1_i
in IN 1_i
oxygen NN 1_i
, , N
and CC N
additional JJ N
bolus NN N
doses NNS N
of IN N
the DT N
test NN N
drug NN N
were VBD N
given VBN N
in IN N
a DT N
standardized JJ N
fashion NN N
, , N
if IN N
needed VBN N
. . N

Recovery NN 1_o
was VBD N
assessed VBN N
by IN N
a DT N
research NN N
nurse NN N
blinded VBD N
to TO N
the DT N
agent NN N
used VBN N
. . N

Mean JJ 1_o
+/- JJ 1_o
s.d NN 1_o
. . 1_o

induction NN 1_o
doss NN 1_o
were VBD N
0.7 CD N
+/- JJ N
0.1 CD N
mg.kg-1 NN N
( ( N
group NN N
E1 NNP N
) ) N
, , N
0.8 CD N
+/- JJ N
0.1 CD N
mg.kg-1 NN N
( ( N
group NN N
E2 NNP N
) ) N
and CC N
4.0 CD N
+/- JJ N
0.0 CD N
mg.kg-1 NN N
( ( N
group NN N
T NNP N
) ) N
. . N

Induction NN 1_o
time NN 1_o
was VBD N
prolonged VBN N
in IN N
the DT N
group NN N
E1 NNP N
compared VBN N
to TO N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Side JJ 1_o
effects NNS 1_o
were VBD N
few JJ N
in IN N
all DT N
groups NNS N
, , N
but CC N
involuntary JJ 1_o
muscle NN 1_o
movements NNS 1_o
or CC 1_o
hypertonus NN 1_o
occurred VBD N
in IN N
23 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
eltanolone NN N
and CC N
in IN N
3 CD N
% NN N
in IN N
the DT N
thiopental JJ N
groups NNS N
( ( N
n.s NN N
) ) N
. . N

Early JJ 1_o
recovery NN 1_o
( ( 1_o
eye NN 1_o
opening NN 1_o
, , 1_o
orientation NN 1_o
and CC 1_o
sitting VBG 1_o
) ) 1_o
was VBD N
slower VBN N
in IN N
both DT N
eltanolone NN N
groups NNS N
compared VBN N
to TO N
the DT N
thiopental JJ N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
found VBN N
in IN N
toleration NN N
of IN N
oral JJ N
fluids NNS N
, , N
walking VBG N
, , N
voiding VBG N
, , N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Comparative JJ N
evaluation NN N
of IN N
percutaneous JJ 1_i
laser NN 1_i
and CC N
radiofrequency NN 1_i
ablation NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
HCC NNP 1_p
smaller JJR 1_p
than IN 1_p
4 CD 1_p
cm NN 1_p
. . 1_p

OBJECTIVE CC N
This DT N
study NN N
was VBD N
done VBN N
to TO N
compare VB N
percutaneous JJ 1_i
laser NN 1_i
ablation NN 1_i
( ( 1_i
PLA NNP 1_i
) ) 1_i
and CC N
radiofrequency NN 1_i
thermoablation NN 1_i
( ( 1_i
RFA NNP 1_i
) ) 1_i
for IN N
the DT N
treatment NN N
of IN N
hepatocellular JJ 1_p
carcinoma NN 1_p
( ( 1_p
HCC NNP 1_p
) ) 1_p
? . 1_p
4 CD 1_p
cm NN 1_p
, , 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
liver JJ 1_p
cirrhosis NN 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP 1_p
Thirty NNP 1_p
patients NNS 1_p
with IN 1_p
single JJ 1_p
HCC NNP 1_p
? . 1_p
4 CD 1_p
cm NN 1_p
in IN 1_p
diameter NN 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
one CD 1_p
of IN 1_p
two CD 1_p
treatments NNS 1_p
: : 1_p
15 CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
PLA NNP 1_i
, , N
using VBG 1_i
a DT 1_i
multifibre NN 1_i
system NN 1_i
connected VBN 1_i
to TO 1_i
a DT 1_i
neodymium JJ 1_i
yttrium-aluminium-garnet NN 1_i
laser NN 1_i
source NN 1_i
; : 1_i
15 CD 1_i
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
RFA NNP 1_i
, , 1_i
using VBG 1_i
an DT 1_i
expandable JJ 1_i
needle JJ 1_i
electrode NN 1_i
. . 1_i

Patients NNS 1_i
were VBD N
followed VBN N
up RP N
for IN N
up RB N
to TO N
12 CD N
months NNS N
. . N

RESULTS VB N
A NNP N
complete JJ N
response NN N
was VBD N
obtained VBN N
in IN N
87 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
PLA NNP N
and CC N
in IN N
93 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
RFA NNP N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
. . N

The DT N
overall JJ 1_o
local JJ 1_o
recurrence-free JJ 1_o
survival NN 1_o
rates NNS 1_o
at IN 1_o
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
comparable JJ N
. . N

However RB N
, , N
a DT N
higher JJR 1_o
rate NN 1_o
of IN 1_o
recurrence NN 1_o
was VBD 1_o
observed VBN N
in IN N
the DT N
PLA NNP N
group NN N
for IN N
lesions NNS N
? . N
21 CD N
mm NN N
( ( N
p JJ N
= NNP N
0.0081 CD N
) ) 1_o
. . 1_o

A DT 1_o
postablation NN 1_o
syndrome NN 1_o
was VBD 1_o
documented VBN 1_o
in IN 1_p
13 CD 1_p
patients NNS 1_p
( ( 1_p
1 CD 1_p
PLA NNP 1_p
; : N
12 CD N
RFA NNP N
) ) N
. . N

Tumour JJ 1_o
necrosis NN 1_o
factor-? NN 1_o
was VBD 1_o
significantly RB 1_o
higher JJR N
in IN N
the DT N
RFA NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
RFA NNP N
is VBZ N
more RBR N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
HCC NNP N
compared VBN 1_i
to TO 1_i
PLA NNP 1_i
for IN N
lesions NNS N
? . N
21 CD N
mm NN N
. . N

However RB N
, , N
PLA NNP N
should MD N
be VB N
considered VBN N
a DT N
viable JJ N
treatment NN N
option NN N
for IN N
HCC NNP N
? . N
20 CD N
mm NN N
, , N
in IN N
view NN N
of IN N
the DT N
lower JJR N
incidence NN N
of IN N
complications NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
motor NN 1_i
training NN 1_i
involving VBG N
the DT N
less-affected JJ N
side NN N
( ( N
MTLA NNP N
) ) N
in IN N
post-stroke JJ 1_p
subjects NNS 1_p
: : 1_p
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

INTRODUCTION NNP N
Poststroke NNP N
, , N
less-severe JJ N
motor NN N
impairment NN N
occurs VBZ N
on IN N
the DT N
ipsilesional JJ N
side NN N
of IN N
body NN N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
the DT N
motor NN 1_i
training NN 1_i
involving VBG N
the DT N
less-affected JJ N
side NN N
( ( N
MTLA NNP N
) ) N
in IN N
stroke NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
double-blinded JJ N
pilot NN N
study NN N
conducted VBN 1_p
in IN 1_p
the DT 1_p
occupational JJ 1_p
therapy NN 1_p
unit NN 1_p
of IN 1_p
a DT 1_p
rehabilitation NN 1_p
Institute NNP 1_p
. . 1_p

A DT 1_p
convenience NN 1_p
sample NN 1_p
of IN 1_p
35 CD 1_p
stroke NN 1_p
subjects NNS 1_p
( ( 1_p
mean JJ 1_p
poststroke NN 1_p
duration NN 1_p
, , 1_p
28.76 CD 1_p
weeks NNS 1_p
) ) 1_p
was VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
( ( N
the DT N
experimental NN N
group NN N
: : N
17 CD N
and CC N
control VB N
group NN N
: : N
18 CD N
) ) N
. . N

Thirty-two JJ 1_p
participants NNS 1_p
completed VBD 1_p
the DT 1_p
entire JJ 1_p
study NN 1_p
protocol NN 1_p
. . 1_p

The DT N
experimental JJ N
group NN N
and CC N
control NN N
group NN N
were VBD N
provided VBN N
MTLA NNP 1_i
and CC 1_i
neurophysiological-based JJ 1_i
conventional JJ 1_i
therapy NN 1_i
respectively RB 1_i
. . 1_i

Both CC N
the DT N
groups NNS N
received VBD N
24 CD N
treatment NN N
sessions NNS N
( ( N
60 CD N
minutes NNS N
each DT N
) ) N
over IN N
the DT N
period NN N
of IN N
two CD N
months NNS N
. . N

The DT N
Affected JJ N
side NN N
was VBD N
assessed VBN N
using VBG N
Brunnstrom NNP 1_o
recovery NN 1_o
stage NN 1_o
( ( 1_o
BRS NNP 1_o
) ) 1_o
and CC 1_o
Fugl-Meyer NNP 1_o
assessment NN 1_o
( ( 1_o
FMA NNP 1_o
) ) 1_o
whereas VBD N
the DT N
less-affected JJ N
side NN N
was VBD N
evaluated VBN N
by IN N
Minnesota NNP 1_o
manual JJ 1_o
dexterity NN 1_o
test NN 1_o
( ( 1_o
MMDT NNP 1_o
) ) 1_o
, , 1_o
Purdue NNP 1_o
peg NNP 1_o
board NN 1_o
test NN 1_o
( ( 1_o
PPBT NNP 1_o
) ) 1_o
and CC 1_o
Manual JJ 1_o
Muscle NNP 1_o
Testing NNP 1_o
( ( 1_o
MMT NNP 1_o
) ) 1_o
. . 1_o

RESULTS NNP N
Postintervention NNP N
, , N
the DT N
less-affected JJ N
side NN N
of IN N
experimental JJ N
group NN N
demonstrated VBD N
significant JJ N
improvement NN 1_o
for IN 1_o
MMDT NNP 1_o
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
, , N
PPBT NNP 1_o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
and CC N
MMT NNP 1_o
( ( N
P NNP N
< VBZ N
0.001 CD N
to TO N
0.043 CD N
) ) N
in IN N
comparison NN N
to TO N
the DT N
control NN N
group NN N
. . N

Further RB N
, , N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
the DT N
experimental JJ N
group NN N
exhibited VBD N
positive JJ N
significant JJ N
change NN N
for IN N
the DT N
measure NN 1_o
of IN 1_o
affected JJ 1_o
side NN 1_o
[ NNP 1_o
BRS NNP 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC 1_o
FMA NNP 1_o
( ( 1_o
P NNP N
< VBZ N
0.001 CD N
to TO N
0.03 CD N
) ) N
] NN N
at IN N
post NN N
assessment NN N
. . N

CONCLUSION NNP 1_o
MTLA NNP 1_o
enhanced VBD 1_o
the DT N
muscle NN N
strength NN N
, , N
dexterity NN N
and CC N
coordination NN N
of IN N
the DT N
less-affected JJ N
side NN N
as RB N
well RB N
as IN N
the DT N
motor NN N
recovery NN N
of IN N
the DT N
affected JJ N
side NN N
in IN N
poststroke NN 1_p
hemiparetic JJ 1_p
subjects NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Concurrent NNP N
alcohol NN 1_i
dependence NN 1_i
among IN N
methadone-maintained JJ 1_p
cocaine NN 1_p
abusers NNS 1_p
is VBZ N
associated VBN N
with IN N
greater JJR N
abstinence NN 1_o
. . 1_o

Concurrent NNP 1_i
alcohol NN 1_i
dependence NN 1_i
( ( 1_i
AD NNP 1_i
) ) 1_i
among IN N
polysubstance NN N
abusers NNS N
has VBZ N
been VBN N
associated VBN N
with IN N
negative JJ N
consequences NNS N
, , N
although IN N
it PRP N
may MD N
not RB N
necessarily RB N
lead VB N
to TO N
poor JJ N
treatment NN N
outcomes NNS N
. . N

One CD N
of IN N
the DT N
most RBS N
efficacious JJ N
treatments NNS N
for IN N
cocaine NN N
abuse NN N
is VBZ N
contingency JJ 1_i
management NN 1_i
( ( 1_i
CM NNP 1_i
) ) 1_i
, , N
but CC N
little JJ N
research NN N
has VBZ N
explored VBN N
the DT N
impact NN N
of IN N
AD NNP 1_i
on IN N
abstinence NN 1_o
outcomes NNS 1_o
, , N
particularly RB N
among IN N
patients NNS 1_p
in IN 1_p
methadone JJ 1_p
maintenance NN 1_p
. . 1_p

Using VBG N
data NNS N
from IN N
three CD N
trials NNS N
of IN N
CM NNP N
for IN N
cocaine NN N
use NN N
, , N
we PRP N
compared VBN N
baseline JJ 1_o
characteristics NNS 1_o
and CC 1_o
posttreatment NN 1_o
and CC 1_o
follow-up JJ 1_o
cocaine NN 1_o
outcomes NNS 1_o
between IN N
methadone-maintained JJ 1_i
, , 1_i
cocaine-dependent JJ 1_i
patients NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
193 CD 1_p
) ) 1_p
with IN 1_i
and CC 1_i
without IN 1_i
concurrent JJ 1_i
AD NNP 1_i
, , 1_i
randomized VBN 1_i
to TO 1_i
standard VB 1_i
care NN 1_i
( ( 1_i
SC NNP 1_i
) ) 1_i
with IN 1_i
or CC 1_i
without IN 1_i
CM NNP 1_i
. . 1_i

Patients NNS 1_p
with IN 1_i
and CC 1_i
without IN 1_i
concurrent JJ 1_i
AD NNP 1_i
had VBD N
similar JJ N
baseline NN N
characteristics NNS N
, , N
with IN N
the DT N
exception NN N
that WDT N
AD NNP 1_i
patients NNS N
reported VBD N
more RBR N
alcohol NN N
use NN N
. . N

AD NN 1_i
patients NNS N
achieved VBN N
longer JJR N
durations NNS 1_o
of IN 1_o
cocaine NN 1_o
abstinence NN 1_o
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
submit VB N
a DT N
cocaine-negative JJ 1_o
sample NN 1_o
at IN N
follow-up JJ N
than IN N
non-AD JJ 1_i
patients NNS N
. . N

Patients NNS N
randomized VBD N
to TO N
CM NNP 1_i
achieved VBD N
better RBR N
outcomes NNS 1_o
than IN N
those DT N
randomized VBN N
to TO N
SC NNP 1_i
, , N
but CC N
there EX N
was VBD N
no DT N
interaction NN N
between IN N
treatment NN N
condition NN N
and CC N
AD NNP 1_i
status NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
cocaine-using JJ 1_p
methadone NN 1_p
patients NNS 1_p
with IN N
AD NNP 1_i
achieve VBP N
greater JJR N
cocaine NN 1_o
abstinence NN 1_o
than IN N
their PRP$ N
non-AD JJ 1_i
counterparts NNS N
and CC N
should MD N
not RB N
necessarily RB N
be VB N
viewed VBN N
as IN N
more RBR N
difficult JJ N
to TO N
treat VB N
. . N

-DOCSTART- -X- O O

Comparison NNP N
between IN N
obtained VBN N
mydriasis NN 1_p
in IN 1_p
type NN 1_p
2 CD 1_p
diabetics NNS 1_p
and CC 1_p
non-diabetic JJ 1_p
patients NNS 1_p
. . 1_p

BACKGROUND/AIMS NNP N
To TO N
evaluate VB N
and CC N
compare VB N
obtained VBN N
mydriasis NN N
with IN N
phenylephrine JJ 1_i
10 CD N
% NN N
associated VBN N
with IN N
tropicamide JJ 1_i
1 CD N
% NN N
in IN N
type NN 1_p
2 CD 1_p
diabetics NNS 1_p
and CC 1_p
non-diabetic JJ 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
50 CD 1_p
patients NNS 1_p
( ( 1_p
100 CD 1_p
eyes NNS 1_p
) ) 1_p
scheduled VBD 1_p
for IN 1_p
fundoscopy NN 1_p
were VBD 1_p
dilated VBN 1_p
with IN 1_p
phenylephrine JJ 1_i
10 CD 1_i
% NN 1_i
and CC 1_i
yropicamide RB 1_i
1 CD 1_i
% NN 1_i
( ( N
group NN N
0 CD N
: : N
n JJ N
= $ N
20 CD N
type NN N
2 CD N
diabetic JJ N
patients NNS N
, , N
40 CD N
eyes NNS N
, , N
and CC N
group NN N
1 CD N
: : N
n JJ N
= $ N
30 CD N
non-diabetic JJ N
patients NNS N
, , N
60 CD N
eyes NNS N
) ) N
. . N

Only RB N
one CD N
drop NN N
per IN N
eye NN N
of IN N
each DT N
drug NN N
was VBD N
administered VBN N
. . N

In IN N
both DT N
groups NNS N
, , N
pupil VBP 1_o
diameter NN 1_o
was VBD N
measured VBN N
after IN N
40 CD N
minutes NNS N
of IN N
eye NN N
drops NNS N
instillation NN N
. . N

RESULTS NNP N
Both DT N
groups NNS N
were VBD N
similar JJ N
regarding VBG N
age NN N
( ( N
p JJ N
= NN N
0.06 CD N
, , N
Mann-Whitney NNP N
test NN N
) ) N
. . N

Mean NNP 1_o
pupil NN 1_o
diameter NN 1_o
in IN N
group NN N
0 CD N
was VBD N
8.57 CD N
and CC N
8.73 CD N
in IN N
group NN N
1 CD N
. . N

There EX N
was VBD N
no DT N
statistic JJ 1_o
difference NN 1_o
between IN N
both DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.44 CD N
) ) N
. . N

Pupil NNP 1_o
diameter NN 1_o
was VBD N
greater JJR N
than IN N
7 CD N
mm NNS N
in IN N
all DT N
patients NNS N
( ( N
100 CD N
% NN N
) ) N
. . N

CONCLUSION NN N
When WRB N
an DT N
appropriate JJ N
drug NN N
combination NN N
is VBZ N
used VBN N
, , N
diabetic JJ N
patients NNS N
can MD N
achieve VB N
mydriasis NN 1_o
as RB N
satisfactory JJ N
as IN N
non-diabetic JJ N
patients NNS N
, , N
allowing VBG N
adequate JJ N
fundus NN N
examination NN N
and/or IN N
retinopathy JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Desmopressin NNP 1_i
in IN N
the DT N
treatment NN N
of IN N
nocturia NNS 1_p
: : 1_p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
investigate VB N
efficacy NN 1_o
, , 1_o
safety NN 1_o
, , N
and CC N
impact NN N
on IN N
quality NN 1_o
of IN 1_o
sleep NN 1_o
of IN N
desmopressin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
nocturia NNS N
. . N

METHODS NNP N
Adults NNP 1_p
aged VBD 1_p
> NNP 1_p
or CC 1_p
=18 NNP 1_p
yr NN 1_p
with IN 1_p
nocturia NNS 1_p
( ( 1_p
> CD 1_p
or CC 1_p
=2 VB 1_p
voids/night NN 1_p
) ) 1_p
received VBD N
desmopressin JJ 1_i
tablets NNS N
( ( N
0.1 CD N
, , N
0.2 CD N
, , N
or CC N
0.4 CD N
mg NN N
) ) N
during IN N
a DT N
3-wk JJ N
dose-titration NN N
period NN N
. . N

Patients NNS N
should MD N
show VB N
sufficient JJ N
response NN N
during IN N
the DT N
dose-titration JJ N
period NN N
( ( N
> CD N
or CC N
=20 CD N
% NN N
reduction NN N
in IN N
nocturnal JJ N
diuresis NN N
) ) N
and CC N
a DT N
return NN N
of IN N
nocturnal JJ N
diuresis NN N
to TO N
> VB N
or CC N
=80 VB N
% NN N
of IN N
baseline NN N
levels NNS N
during IN N
washout NN N
. . N

Eligible JJ N
patients NNS N
then RB N
entered VBD N
a DT N
3-wk JJ N
double-blind JJ N
treatment NN N
period NN N
and CC N
received VBD N
either CC N
desmopressin NN 1_i
or CC N
placebo NN 1_i
. . 1_i

RESULTS CC N
127 CD 1_p
patients NNS 1_p
were VBD 1_p
randomised VBN 1_p
to TO N
either DT N
desmopressin NN 1_i
( ( N
n=61 JJ N
) ) N
or CC N
placebo NN 1_i
( ( N
n=66 JJ N
) ) N
. . N

Twenty NNP N
( ( N
33 CD N
% NN N
) ) N
desmopressin-treated JJ 1_i
patients NNS N
compared VBN N
with IN N
seven CD N
( ( N
11 CD N
% NN N
) ) N
placebo-treated JJ 1_i
patients NNS N
showed VBD N
a DT N
clinical JJ N
response NN N
, , N
defined VBD N
as IN N
a DT N
> NN N
or CC N
=50 CD N
% NN N
reduction NN N
in IN N
the DT N
number NN 1_o
of IN 1_o
nocturnal JJ 1_o
voids NNS 1_o
compared VBN N
with IN N
baseline NN N
( ( N
p=0.0014 NN N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
desmopressin NN 1_i
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
mean JJ 1_o
number NN 1_o
of IN 1_o
nocturnal JJ 1_o
voids NNS 1_o
( ( N
39 CD N
% NN N
reduction NN N
with IN N
desmopressin NN 1_i
vs. FW N
15 CD N
% NN N
with IN N
placebo NN 1_i
; : 1_i
absolute JJ N
difference NN N
-0.84 NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
duration NN 1_o
of IN 1_o
the DT 1_o
first JJ 1_o
sleep JJ 1_o
period NN 1_o
( ( N
prolonged VBN N
by IN N
108 CD N
min NNS N
with IN N
desmopressin NN 1_i
vs. FW N
41 CD N
min NN N
with IN N
placebo NN 1_i
; : 1_i
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Quality NN 1_o
of IN 1_o
sleep NN 1_o
was VBD N
also RB N
improved VBN N
with IN N
desmopressin NN 1_i
versus NN N
placebo NN 1_i
( ( N
statistically RB N
significant JJ N
for IN N
one CD N
of IN N
the DT N
two CD N
parameters NNS N
evaluated VBD N
) ) N
. . N

Adverse JJ 1_o
events NNS 1_o
were VBD N
mainly RB N
mild JJ N
. . N

CONCLUSIONS NNP N
Oral NNP N
desmopressin NN 1_i
tablets NNS N
provide VBP N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN 1_o
for IN N
nocturia NN N
. . N

Compared VBN N
with IN N
placebo NN 1_i
, , N
nocturnal JJ 1_o
voiding NN 1_o
frequency NN 1_o
is VBZ N
reduced VBN N
, , N
duration NN N
of IN N
the DT N
first JJ N
sleep JJ N
period NN N
is VBZ N
increased VBN N
, , N
and CC N
sleep JJ 1_o
quality NN 1_o
may MD N
be VB N
improved VBN N
. . N

-DOCSTART- -X- O O

Heparin NNP 1_i
therapy NN 1_i
in IN N
venous JJ 1_p
thromboembolism NN 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
pulmonary JJ 1_p
embolism NN 1_p
or CC 1_p
deep JJ 1_p
venous JJ 1_p
thrombosis NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
intermittent NN 1_i
or CC 1_i
continuous JJ 1_i
intravenous JJ 1_i
heparin NN 1_i
therapy NN 1_i
. . 1_i

In IN N
patients NNS 1_p
with IN 1_p
an DT 1_p
enhanced JJ 1_p
risk NN 1_p
of IN 1_p
bleeding NN 1_o
, , N
major JJ N
bleeding NN N
was VBD N
significantly RB N
more JJR N
common JJ N
during IN N
the DT N
intermittent NN N
use NN N
of IN N
heparin NN N
; : N
in IN N
patients NNS 1_p
without IN 1_p
these DT 1_p
risk NN 1_p
factors NNS 1_p
, , N
hemorrhage NN 1_o
occurred VBD N
with IN N
equal JJ N
frequency NN N
during IN N
intermittent NN N
and CC N
continuous JJ 1_i
heparin NN 1_i
therapy NN 1_i
. . 1_i

Recurrent JJ 1_o
thromboembolism NN 1_o
was VBD N
seen VBN N
significantly RB N
more RBR N
often RB N
in IN N
patients NNS 1_p
receiving VBG 1_p
continuous JJ 1_p
heparin NN 1_p
therapy NN 1_p
. . 1_p

Controlling VBG N
the DT N
dose NN N
of IN N
heparin NN N
with IN N
coagulation NN N
tests NNS N
resulted VBD N
in IN N
the DT N
administration NN N
of IN N
significantly RB N
larger JJR N
daily JJ N
doses NNS N
of IN N
heparin NN N
with IN N
intermittent JJ N
injections NNS N
than IN N
with IN N
continuous JJ N
infusion NN N
. . N

Therefore RB N
, , N
the DT N
bleeding VBG N
complications NNS N
of IN N
intermittent JJ N
heparin NN N
therapy NN N
could MD N
have VB N
been VBN N
due JJ N
to TO N
the DT N
higher JJR N
dose NN N
, , N
and CC N
the DT N
recurrences NNS N
associated VBN N
with IN N
continuous JJ N
heparin NNS N
therapy NN N
may MD N
have VB N
resulted VBN N
from IN N
lower JJR N
doses NNS N
rather RB N
than IN N
from IN N
differences NNS N
in IN N
the DT N
method NN N
of IN N
administration NN N
. . N

In IN N
a DT N
small JJ N
trial NN N
, , N
arbitrary JJ N
lower JJR N
doses NNS N
of IN N
heparin NN N
given VBN N
intermittently RB N
similar JJ N
to TO N
the DT N
doses NNS N
of IN N
heparin NN N
given VBN N
continuously RB N
resulted VBN N
in IN N
fewer JJR N
bleeding NN 1_o
complications NNS 1_o
and CC N
more JJR N
recurrences NNS 1_o
. . 1_o

In IN N
patients NNS 1_p
without IN 1_p
risk NN 1_p
factors NNS 1_p
for IN 1_p
bleeding NN 1_p
, , N
the DT N
intermittent JJ N
administration NN 1_i
of IN 1_i
heparin NN 1_i
in IN N
the DT N
higher JJR N
dose NN N
is VBZ N
preferable JJ N
because IN N
of IN N
fewer JJR N
recurrences NNS N
and CC N
no DT N
increase NN N
in IN N
hemorrhagic JJ 1_o
complications NNS 1_o
. . 1_o

In IN N
patients NNS 1_p
with IN 1_p
a DT 1_p
high JJ 1_p
risk NN 1_p
of IN 1_p
bleeding NN 1_p
, , N
conventional JJ 1_i
doses NNS 1_i
of IN 1_i
heparin NN 1_i
given VBN N
continuously RB N
can MD N
reduce VB N
the DT N
rate NN 1_o
of IN 1_o
hemorrhagic JJ 1_o
complications NNS 1_o
but CC N
will MD N
result VB N
in IN N
more JJR N
recurrences NNS N
. . N

-DOCSTART- -X- O O

Altered NNP N
growth NN 1_o
hormone NN 1_o
response NN 1_o
after IN N
growth NN 1_i
hormone NN 1_i
releasing VBG 1_i
hormone CD 1_i
administration NN 1_i
in IN N
chronic JJ N
renal JJ N
failure NN N
. . N

Eleven NNP 1_p
chronic JJ 1_p
renal JJ 1_p
failure NN 1_p
patients NNS 1_p
and CC 1_p
11 CD 1_p
matched JJ 1_p
controls NNS 1_p
, , N
received VBD N
growth NN 1_i
hormone NN 1_i
GHRH NNP 1_i
( ( 1_i
1 CD 1_i
microgram/kg RB 1_i
iv NN 1_i
) ) 1_i
or CC 1_i
TRH NNP 1_i
( ( 1_i
400 CD 1_i
microgram RB 1_i
iv NN 1_i
) ) 1_i
on IN N
separate JJ N
occasions NNS N
, , N
immediately RB N
before IN N
undergoing JJ N
hemodialysis NN N
. . N

GHRH-induced JJ 1_i
GH NNP N
peak NN N
in IN N
uremics NNS N
( ( N
22.7 CD N
+/- JJ N
5.2 CD N
micrograms/l NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
that DT N
obtained VBN N
in IN N
control NN N
subjects NNS N
( ( N
16.0 CD N
+/- JJ N
4.3 CD N
micrograms/l NN N
) ) N
. . N

However RB N
, , N
the DT 1_p
uremic JJ 1_p
patients NNS 1_p
did VBD N
not RB N
show VB N
the DT N
habitual JJ N
post-peak JJ N
fall NN N
, , N
remaining VBG N
GH NNP 1_o
levels NNS 1_o
over IN N
10 CD N
micrograms/l NNS N
till IN N
the DT N
end NN N
of IN N
the DT N
test NN N
. . N

Differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Uremic JJ 1_p
patients NNS 1_p
showed VBD N
PRL NNP 1_o
values VBZ 1_o
higher JJR N
than IN N
in IN N
controls NNS N
, , N
however RB N
their PRP$ N
TRH-induced JJ 1_o
PRL NNP 1_o
peak NN 1_o
( ( N
20.6 CD N
+/- JJ N
6.6 CD N
micrograms/l NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
that DT N
of IN N
controls NNS N
( ( N
26.5 CD N
+/- JJ N
3.0 CD N
micrograms/l NN N
) ) N
. . N

Again NNP N
chronic JJ 1_p
renal JJ 1_p
failure NN 1_p
patients NNS 1_p
showed VBD N
PRL NNP 1_o
plasma NN 1_o
values NNS 1_o
abnormally RB N
elevated VBD N
till IN N
the DT N
end NN N
of IN N
the DT N
test NN N
. . N

Differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Administration NN N
of IN N
placebo NN 1_i
to TO N
a DT N
different JJ 1_p
group NN 1_p
of IN 1_p
seven CD 1_p
uremic JJ 1_p
patients NNS 1_p
did VBD N
not RB N
alter VB N
GH NNP 1_o
and CC 1_o
PRL NNP 1_o
plasma NN 1_o
levels NNS 1_o
. . 1_o

This DT N
sustained JJ N
secretion NN N
of IN N
both DT N
GH NNP 1_o
and CC 1_o
PRL NNP 1_o
in IN N
uremia NN N
could MD N
be VB N
attributed VBN N
to TO N
reduced VB N
kidney NN N
clearance NN N
. . N

However RB N
, , N
when WRB N
subjects NNS N
were VBD N
examined VBN N
individually RB N
both DT N
the DT N
GHRH- NNP 1_o
and CC 1_o
the DT 1_o
TRH-induced NNP 1_o
hormonal JJ 1_o
peaks NNS 1_o
and CC 1_o
the DT 1_o
subsequent JJ 1_o
fall NN 1_o
were VBD N
not RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

Unlike IN N
with IN N
controls NNS N
, , N
in IN N
uremic JJ 1_p
patients NNS 1_p
GHRH-stimulated JJ 1_i
GH NNP N
and CC N
TRH-stimulated NNP 1_i
PRL/GH NNP 1_o
peaks NNS 1_o
were VBD N
dispersed VBN N
throughout IN N
the DT N
120 CD N
min JJ N
period NN N
. . N

In IN N
controls NNS N
GH NNP 1_o
and CC 1_o
PRL NNP 1_o
peaks NNS N
clustered VBD N
around IN N
15-30 JJ N
min NN N
. . N

The DT N
peak JJ N
dispersion NN N
created VBD N
a DT N
false JJ N
impression NN N
of IN N
flattened JJ N
curves NNS N
or CC N
sustained VBN N
hypersecretion NN N
in IN N
uremia NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Results NNS N
of IN N
the DT N
EICESS-92 NNP N
Study NNP N
: : N
two CD N
randomized JJ N
trials NNS N
of IN N
Ewing NNP N
's POS N
sarcoma NN N
treatment NN 1_i
-- : 1_i
cyclophosphamide NN 1_i
compared VBN N
with IN N
ifosfamide NN 1_i
in IN N
standard-risk JJ 1_p
patients NNS 1_p
and CC N
assessment NN N
of IN N
benefit NN N
of IN N
etoposide NN 1_i
added VBD N
to TO N
standard VB N
treatment NN N
in IN N
high-risk JJ 1_p
patients NNS 1_p
. . 1_p

PURPOSE VB N
The DT N
European NNP N
Intergroup NNP N
Cooperative NNP N
Ewing NNP N
's POS N
Sarcoma NNP N
Study NNP N
investigated VBD N
whether IN N
cyclophosphamide NN 1_i
has VBZ N
a DT N
similar JJ N
efficacy NN N
as IN N
ifosfamide NN 1_i
in IN N
standard-risk JJ 1_p
( ( 1_p
SR NNP 1_p
) ) 1_p
patients NNS 1_p
and CC N
whether IN N
the DT N
addition NN N
of IN N
etoposide JJ 1_i
improves NNS N
survival VBP 1_o
in IN N
high-risk NN 1_p
( ( 1_p
HR NNP 1_p
) ) 1_p
patients NNS 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
SR NNP 1_p
patients NNS 1_p
( ( 1_p
localized JJ 1_p
tumors NNS 1_p
, , 1_p
volume NN 1_p
< VBD 1_p
100 CD 1_p
mL NN 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
four CD N
courses NNS N
of IN N
vincristine NN 1_i
, , 1_i
dactinomycin NN 1_i
, , 1_i
ifosfamide NN 1_i
, , 1_i
and CC 1_i
doxorubicin NN 1_i
( ( 1_i
VAIA NNP 1_i
) ) 1_i
induction NN 1_i
therapy NN 1_i
followed VBN N
by IN N
10 CD N
courses NNS N
of IN N
either DT N
VAIA NNP 1_i
or CC 1_i
vincristine NN 1_i
, , 1_i
dactinomycin NN 1_i
, , 1_i
cyclophosphamide NN 1_i
, , 1_i
and CC 1_i
doxorubicin NN 1_i
( ( 1_i
VACA NNP 1_i
; : 1_i
cyclophosphamide NN 1_i
replacing VBG 1_i
ifosfamide NN 1_i
) ) 1_i
. . N

HR $ 1_p
patients NNS 1_p
( ( 1_p
volume NN 1_p
> NNP 1_p
or=100 VBZ 1_p
mL NN 1_p
or CC 1_p
metastases NNS 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
14 CD N
courses NNS N
of IN N
either DT N
VAIA NNP 1_i
or CC N
VAIA NNP 1_i
plus CC 1_i
etoposide NN 1_i
( ( 1_i
EVAIA NNP 1_i
) ) 1_i
. . N

Outcome JJ N
measures NNS N
were VBD N
event-free JJ 1_o
survival NN 1_o
( ( 1_o
EFS NNP 1_o
; : 1_o
defined VBD N
as IN N
the DT N
time NN N
to TO N
first JJ N
recurrence NN N
, , N
progression NN N
, , N
second JJ N
malignancy NN N
, , N
or CC N
death NN N
) ) N
and CC N
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
. . 1_o

RESULTS VB N
A DT N
total NN 1_p
of IN 1_p
647 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
: : 1_p
79 CD 1_p
SR NNP 1_p
patients NNS 1_p
were VBD 1_p
assigned VBN 1_p
to TO 1_p
VAIA NNP 1_i
, , 1_p
76 CD 1_p
SR NN 1_p
patients NNS 1_p
were VBD 1_p
assigned VBN 1_p
to TO 1_p
VACA NNP 1_i
, , 1_p
240 CD 1_p
HR NNP 1_p
were VBD 1_p
assigned VBN 1_p
to TO 1_p
VAIA NNP 1_i
, , 1_p
and CC 1_p
252 CD 1_p
HR NNP 1_p
patients NNS 1_p
were VBD 1_p
assigned VBN 1_p
to TO 1_p
EVAIA NNP 1_i
. . 1_i

The DT N
median JJ N
follow-up NN N
was VBD N
8.5 CD N
years NNS N
. . N

In IN N
the DT N
SR NNP 1_p
group NN 1_p
, , N
the DT N
hazard NN 1_o
ratios NNS 1_o
( ( N
VACA NNP N
v NNP N
VAIA NNP N
) ) N
for IN N
EFS NNP N
and CC N
OS NNP N
were VBD N
0.91 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.55 CD N
to TO N
1.53 CD N
) ) N
and CC N
1.08 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.58 CD N
to TO N
2.03 CD N
) ) N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
higher JJR N
incidence NN N
of IN N
hematologic JJ 1_o
toxicities NNS 1_o
in IN N
the DT N
VACA NNP N
arm NN N
. . N

In IN N
the DT N
HR NNP 1_p
group NN 1_p
, , N
the DT N
EFS NNP 1_o
and CC 1_o
OS NNP 1_o
hazard NN 1_o
ratios NNS 1_o
( ( N
EVAIA NNP N
v NNP N
VAIA NNP N
) ) N
indicated VBD N
a DT N
17 CD N
% NN N
reduction NN N
in IN N
the DT N
risk NN N
of IN N
an DT N
event NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-35 NNP N
% NN N
to TO N
5 CD N
% NN N
; : N
P NNP N
= NNP N
.12 NNP N
) ) N
and CC N
15 CD N
% NN N
reduction NN N
in IN N
dying VBG N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-34 NNP N
% NN N
to TO N
10 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

The DT N
effect NN N
seemed VBD N
greater JJR N
among IN N
patients NNS N
without IN N
metastases NNS N
( ( N
hazard NN N
ratio NN N
= VBZ N
0.79 CD N
; : N
P NNP N
= NNP N
.16 NNP N
) ) N
than IN N
among IN N
those DT N
with IN N
metastases NNS N
( ( N
hazard NN N
ratio NN N
= VBZ N
0.96 CD N
; : N
P NNP N
= NNP N
.84 NNP N
) ) N
. . N

CONCLUSION NNP N
Cyclophosphamide NNP N
seemed VBD N
to TO N
have VB N
a DT N
similar JJ N
effect NN N
on IN N
EFS NNP 1_o
and CC 1_o
OS NNP 1_o
as IN N
ifosfamide NN N
in IN N
SR NNP 1_p
patients NNS 1_p
but CC N
was VBD N
associated VBN N
with IN N
increased JJ N
toxicity NN 1_o
. . 1_o

In IN N
HR NNP 1_p
patients NNS 1_p
, , N
the DT N
addition NN N
of IN N
etoposide NN N
seemed VBD N
to TO N
be VB N
beneficial JJ N
. . N

-DOCSTART- -X- O O

Intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
on IN N
infection NN N
rate NN N
, , N
days NNS N
in IN N
NICU NNP N
, , N
in-hospital JJ 1_o
mortality NN 1_o
and CC 1_o
neurological JJ 1_o
outcome NN 1_o
in IN N
severe JJ 1_p
traumatic JJ 1_p
brain NN 1_p
injury NN 1_p
patients NNS 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVES NNP N
Evaluate NNP N
the DT N
impact NN N
of IN N
an DT N
intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
and CC N
conventional JJ 1_i
glucose NN 1_i
control NN 1_i
protocol NN 1_i
during IN N
staying VBG N
in IN N
neurological JJ N
intensive JJ N
care NN N
unit NN N
( ( N
NICU NNP N
) ) N
on IN N
infection NN 1_o
rate NN 1_o
, , 1_o
days NNS 1_o
in IN 1_o
NICU NNP 1_o
, , 1_o
in-hospital JJ 1_o
mortality NN 1_o
and CC 1_o
long-term JJ 1_o
neurological JJ 1_o
outcome NN 1_o
in IN N
severe JJ 1_p
traumatic JJ 1_p
brain NN 1_p
injury NN 1_p
( ( 1_p
TBI NNP 1_p
) ) 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
A NNP N
total NN N
of IN N
240 CD 1_p
patients NNS 1_p
with IN 1_p
severe JJ 1_p
TBI NNP 1_p
( ( 1_p
GCS NNP 1_p
score RB 1_p
3-8 JJ 1_p
) ) 1_p
admitted VBD 1_p
to TO 1_p
NICU NNP 1_p
were VBD N
prospectively RB N
enrolled VBN N
and CC N
randomly RB N
assigned VBD N
either DT N
to TO N
conventional JJ 1_i
insulin NN 1_i
therapy NN 1_i
or CC N
to TO N
intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
. . 1_i

Patients NNS N
in IN N
intensive JJ 1_i
glucose NNS 1_i
control NN 1_i
group NN 1_i
( ( N
n=121 NN N
) ) N
received VBD N
continuous JJ 1_i
insulin NN 1_i
infusion NN 1_i
to TO N
maintain VB N
glucose JJ N
levels NNS N
between IN N
4.4 CD N
m NNS N
mol/l NN N
( ( N
80 CD N
mg/dl NN N
) ) N
and CC N
6.1 CD N
m NN N
mol/l NN N
( ( N
110 CD N
mg/dl NN N
) ) N
. . N

Patients NNS N
in IN N
the DT N
conventional JJ 1_i
treatment NN 1_i
group NN 1_i
( ( N
n=119 RB N
) ) N
were VBD N
not RB N
given VBN N
insulin NN 1_i
unless IN N
glucose JJ 1_o
levels NNS 1_o
were VBD N
greater JJR N
than IN N
11.1 CD N
m JJ N
mol/l NN N
( ( N
200mg/dl CD N
) ) N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
with IN N
insulin JJ 1_i
infusion NN N
to TO N
maintain VB N
normoglycemia RB N
after IN N
leaving VBG N
NICU NNP N
. . N

Comparison NNP N
was VBD N
made VBN N
against IN N
conventional JJ 1_i
insulin NN 1_i
therapy NN 1_i
using VBG N
a DT N
randomized JJ N
trial NN N
design NN N
. . N

The DT N
primary JJ N
outcomes NNS N
is VBZ N
the DT N
mortality NN 1_o
rate NN 1_o
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

The DT N
second JJ N
outcomes NNS N
including VBG N
ICU NNP 1_o
infection NN 1_o
rate NN 1_o
, , 1_o
duration NN 1_o
of IN 1_o
ICU NNP 1_o
stay NN 1_o
, , 1_o
in-hospital JJ 1_o
mortality NN 1_o
rate NN 1_o
and CC 1_o
neurologic JJ 1_o
outcome NN 1_o
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
gender NN 1_p
( ( 1_p
66 CD 1_p
% NN 1_p
vs. FW 1_p
67 CD 1_p
% NN 1_p
male NN 1_p
) ) 1_p
, , 1_p
age NN 1_p
( ( 1_p
46+/-11 CD 1_p
years NNS 1_p
vs. IN 1_p
45+/-10 CD 1_p
years NNS 1_p
) ) 1_p
, , 1_p
APACHE NNP 1_p
II NNP 1_p
score NN 1_p
( ( 1_p
30 CD 1_p
vs. FW 1_p
29 CD 1_p
) ) 1_p
, , 1_p
TISS-28 NNP 1_o
score NN 1_o
( ( 1_p
47 CD 1_p
vs. FW 1_p
46 CD 1_p
) ) 1_p
, , 1_p
and CC 1_p
Glasgow NNP 1_o
Coma NNP 1_o
Score NNP 1_o
( ( 1_p
GCS NNP 1_p
, , 1_p
5.3 CD 1_p
vs. FW 1_p
5.3 CD 1_p
) ) 1_p
between IN N
the DT N
two CD N
groups NNS N
. . N

Overall JJ 1_o
mortality NN 1_o
rates NNS 1_o
at IN N
6 CD N
months NNS N
follow-up JJ N
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
61 CD N
of IN N
117 CD N
, , N
52.1 CD N
% NN N
vs. FW N
62 CD N
of IN N
116 CD N
, , N
53.4 CD N
% NN N
; : N
P=0.8 NNP N
) ) N
. . N

The DT N
infection NN 1_o
rate NN 1_o
during IN N
the DT N
study NN N
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
who WP N
received VBD N
conventional JJ 1_i
insulin NN 1_i
therapy NN 1_i
than IN N
that DT N
in IN N
patients NNS N
who WP N
received VBD N
intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
( ( N
46.2 CD N
% NN N
vs. FW N
31.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
days NNS 1_o
stay VBP 1_o
in IN 1_o
NICU NNP 1_o
was VBD N
shorter RBR N
in IN N
intensive JJ 1_i
insulin NN 1_i
control NN 1_i
group NN 1_i
than IN N
that DT N
in IN N
conventional JJ 1_i
therapy NN 1_i
group NN 1_i
[ VBD N
4.2 CD N
days NNS N
vs. FW N
5.6 CD N
days NNS N
( ( N
medians NNS N
) ) N
P NNP N
< $ N
0.05 CD N
] NNP N
. . N

The DT N
in-hospital JJ 1_o
mortality NN 1_o
during IN N
the DT N
study NN N
was VBD N
similar JJ N
in IN N
conventional JJ 1_i
and CC 1_i
intensive JJ 1_i
therapy NN 1_i
groups NNS 1_i
( ( N
34 CD N
of IN N
119 CD N
, , N
28.6 CD N
% NN N
vs. FW N
35 CD N
of IN N
121 CD N
, , N
28.9 CD N
% NN N
in IN N
the DT N
conventional JJ 1_i
and CC 1_i
intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
groups NNS N
; : N
P=0.85 NNP N
) ) N
. . N

The DT N
neurologic JJ 1_o
outcome NN 1_o
according VBG N
to TO N
Glasgow NNP 1_o
Outcome NNP 1_o
Score NNP 1_o
( ( 1_o
GOS NNP 1_o
) ) 1_o
at IN N
6 CD N
months NNS N
( ( N
GOS NNP N
5 CD N
and CC N
4 CD N
) ) N
was VBD N
better RBR N
in IN N
the DT N
intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
group NN N
( ( N
34 CD N
of IN N
117 CD N
, , N
29.1 CD N
% NN N
) ) N
than IN N
that DT N
in IN N
the DT N
conventional JJ 1_i
therapy NN 1_i
group NN N
( ( N
26 CD N
of IN N
116 CD N
, , N
22.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mortality NNP 1_o
rates NNS 1_o
at IN N
6 CD N
months NNS N
follow-up NNS N
are VBP N
not RB N
affected VBN N
by IN N
intensive JJ N
glucose NNS N
control NN N
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
TBI NNP 1_p
. . 1_p

Intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
decreases VBZ N
infection NN 1_o
rate NN 1_o
and CC 1_o
days NNS 1_o
in IN 1_o
NICU NNP 1_o
and CC N
improves VBZ 1_o
the DT 1_o
neurological JJ 1_o
outcome NN 1_o
at IN N
6 CD N
months NNS N
follow-up RB N
, , N
while IN N
has VBZ N
no DT N
obvious JJ N
influence NN N
on IN N
in-hospital JJ 1_o
mortality NN 1_o
of IN N
severe JJ 1_p
TBI NNP 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Comparative JJ N
evaluation NN N
of IN N
calcium NN 1_i
hydroxide NN 1_i
and CC 1_i
zinc NN 1_i
oxide RB 1_i
eugenol RB 1_i
as IN N
root JJ 1_o
canal JJ 1_o
filling NN 1_o
materials NNS 1_o
for IN 1_p
primary JJ 1_p
molars NNS 1_p
: : 1_p
a DT N
clinical JJ N
and CC N
radiographic JJ N
study NN N
. . N

Calcium NNP 1_i
hydroxide NN 1_i
, , N
a DT N
material NN N
widely RB N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
permanent JJ N
teeth NN N
has VBZ N
not RB N
been VBN N
used VBN N
frequently RB N
for IN N
pulpectomy NN N
in IN N
primary JJ N
teeth NNS N
. . N

A DT N
comparative JJ N
evaluation NN N
of IN N
calcium NN 1_i
hydroxide NN 1_i
and CC 1_i
zinc NN 1_i
oxide NN 1_i
eugenol NN 1_i
used VBN 1_i
as IN 1_i
root JJ 1_o
canal JJ 1_o
filling NN 1_o
materials NNS 1_o
in IN N
primary JJ 1_p
molars NNS 1_p
is VBZ N
presented VBN N
. . N

-DOCSTART- -X- O O

A DT N
sensory JJ 1_i
integration NN 1_i
therapy NN 1_i
program NN 1_i
on IN N
sensory JJ 1_p
problems NNS 1_p
for IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

The DT N
study NN N
was VBD N
planned VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
sensory JJ 1_i
integration NN 1_i
therapy NN 1_i
program NN 1_i
on IN N
sensory JJ 1_o
problems NNS 1_o
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

This DT N
study NN N
was VBD N
conducted VBN N
at IN N
the DT N
Trakya NNP 1_p
University NNP 1_p
Training NNP 1_p
and CC 1_p
Research NNP 1_p
Center NNP 1_p
for IN 1_p
Mentally NNP 1_p
and CC 1_p
Physically NNP 1_p
Handicapped NNP 1_p
Children NNP 1_p
in IN 1_p
Turkey NNP 1_p
. . 1_p

The DT N
children NNS N
were VBD N
separated VBN N
into IN N
two CD N
groups NNS N
, , N
each DT N
comprising VBG 1_p
15 CD 1_p
children NNS 1_p
between IN 1_p
7 CD 1_p
and CC 1_p
11 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
autism NN 1_p
, , 1_p
according VBG 1_p
to TO 1_p
DSM-IV NNP 1_p
criteria NNS 1_p
. . 1_p

The DT N
children NNS N
in IN N
each DT N
group NN N
were VBD N
assessed VBN N
initially RB N
on IN N
a DT N
checklist NN N
, , N
Sensory NNP N
Evaluation NNP N
Form NNP N
for IN N
Children NNP N
with IN N
Autism NNP N
, , N
developed VBD N
to TO N
evaluate VB N
sensory JJ 1_o
characteristics NNS 1_o
of IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
participants NNS N
were VBD N
assessed VBN N
again RB N
on IN N
the DT N
checklist NN N
. . N

Statistically NNP N
significant JJ N
differences NNS N
between IN N
groups NNS N
indicated VBD N
that IN N
the DT N
sensory JJ 1_i
integration NN 1_i
therapy NN 1_i
program NN 1_i
positively RB N
affected VBD N
treated JJ N
children NNS N
. . N

-DOCSTART- -X- O O

[ NNS N
Are VBP N
there EX N
indications NNS N
for IN N
adjuvant JJ 1_i
chemotherapy NN 1_i
after IN 1_i
excision NN 1_p
of IN 1_p
colorectal JJ 1_p
cancer NN 1_p
? . N
] UH N
. . N

-DOCSTART- -X- O O

Service NNP N
variation NN N
in IN N
baseline NN N
variables NNS N
and CC N
prediction NN N
of IN N
risk NN N
in IN N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
psychological JJ 1_i
treatment NN 1_i
in IN N
repeated JJ N
parasuicide NN N
: : N
the DT N
POPMACT NNP N
Study NNP N
. . N

The DT N
treatment NN N
protocol NN N
and CC N
baseline NN N
characteristics NNS N
of IN N
480 CD 1_p
subjects NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
repeated VBN 1_p
parasuicide NN 1_p
recruited VBN N
in IN N
five CD N
centres NNS N
to TO N
a DT N
randomised VBN N
therapeutic JJ N
trial NN N
of IN N
manual JJ 1_i
assisted VBN 1_i
cognitive-behaviour JJ 1_i
therapy NN 1_i
( ( 1_i
MACT NNP 1_i
) ) 1_i
and CC 1_i
treatment NN 1_i
as IN 1_i
usual JJ 1_i
( ( 1_i
TAU NNP 1_i
) ) 1_i
are VBP N
described VBN N
. . N

Most JJS 1_p
patients NNS 1_p
had VBD 1_p
significant JJ 1_p
anxiety NN 1_o
and CC 1_o
depressive JJ 1_o
disturbance NN 1_o
with IN 1_p
42 CD 1_p
% NN 1_p
having VBG 1_p
a DT 1_p
personality NN 1_p
disorder NN 1_p
. . 1_p

Variation NNP N
in IN N
service NN N
policies NNS N
influenced VBD N
recruitment NN N
, , N
with IN N
earlier RBR N
assessment JJ N
centres NNS N
seeing VBG N
people NNS N
with IN N
more RBR N
frequent JJ N
episodes NNS 1_o
of IN 1_o
self-harm NN 1_o
and CC N
greater JJR N
parasuicide NN 1_o
risk NN 1_o
than IN N
later JJR N
ones NNS N
. . N

Parasuicide NNP 1_o
risk NN 1_o
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
those DT N
with IN N
their PRP$ N
first JJ N
parasuicide NN N
episode NN N
at IN N
an DT N
earlier JJR N
age NN N
and CC N
in IN N
those DT N
with IN N
a DT N
more RBR N
recent JJ N
latest JJS N
episode NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
venlafaxine NN 1_i
on IN N
ongoing VBG N
and CC N
experimentally RB N
induced JJ N
pain NN N
in IN N
neuropathic JJ 1_p
pain NN 1_p
patients NNS 1_p
: : 1_p
a DT N
double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIM NNP N
The DT N
aim NN N
of IN N
this DT N
randomized VBN N
double JJ N
blind NN N
placebo NN 1_i
controlled VBD N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effectiveness NN N
and CC N
the DT N
safety NN N
of IN N
venlafaxine JJ 1_i
XR NNP 1_i
75 CD 1_i
and CC 1_i
150 CD 1_i
mg NN 1_i
on IN N
ongoing VBG N
pain NN N
and CC N
on IN N
quantitative JJ N
sensory NN N
tests NNS N
in IN N
60 CD 1_p
patients NNS 1_p
with IN 1_p
neuropathic JJ 1_p
pain NN 1_p
for IN 1_p
8 CD 1_p
weeks NNS 1_p
. . 1_p

METHODS NNP N
Evaluation NNP N
parameters NNS N
consisted VBD N
of IN N
ongoing VBG N
pain NN N
intensity NN N
( ( N
VAS NNP N
) ) N
, , N
patient JJ N
satisfaction NN N
, , N
side NN N
effects NNS N
, , N
global JJ N
efficacy NN N
and CC N
tolerance NN N
. . N

Quantitative JJ N
sensory NN N
measurements NNS N
taken VBN N
from IN N
the DT N
affected JJ N
area NN N
before IN N
and CC N
after IN N
the DT N
drug NN N
treatment NN N
included VBD N
pin-prick JJ N
hyperalgesia NN N
, , N
allodynia NN N
, , N
detection NN N
and CC N
pain NN N
thresholds NNS N
to TO N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
, , N
temporal JJ N
summation NN N
of IN N
repetitive JJ N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
. . N

RESULTS VB 1_p
A DT 1_p
total NN 1_p
of IN 1_p
55 CD 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

VAS NNP 1_o
scores NNS 1_o
decreased VBD N
significantly RB N
compared VBN N
to TO N
the DT N
baseline NN N
measurements NNS N
in IN N
all DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS 1_p
regarding VBG 1_p
pain NN 1_o
intensity NN 1_o
and CC 1_o
escape NN 1_o
medication NN 1_o
. . 1_o

The DT N
areas NNS 1_o
of IN 1_o
allodynia NN 1_o
and CC 1_o
pin-prick JJ 1_o
hyperalgesia NN 1_o
decreased VBN N
significantly RB N
in IN N
venlafaxine NN N
groups NNS N
compared VBN N
to TO N
the DT N
placebo NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
regarding VBG N
the DT N
detection NN N
thresholds NNS N
( ( N
electrical JJ N
and CC N
heat NN N
) ) N
. . N

The DT N
pain NN 1_o
threshold NN 1_o
and CC 1_o
the DT 1_o
summation NN 1_o
threshold NN 1_o
to TO 1_o
electrical JJ 1_o
stimuli NNS 1_o
and CC 1_o
the DT 1_o
summation NN 1_o
threshold NN 1_o
to TO 1_o
heat VB 1_o
stimuli NNS 1_o
increased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine JJ 1_i
groups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
degree NN 1_o
of IN 1_o
the DT 1_o
temporal JJ 1_o
summation NN 1_o
to TO 1_o
electrical JJ 1_o
and CC 1_o
heat NN 1_o
stimuli NNS 1_o
decreased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine NN 1_i
groups NNS N
compared VBN N
to TO N
the DT N
placebo NN N
. . N

CONCLUSION VB N
The DT N
study NN N
showed VBD N
significant JJ N
effect NN N
of IN N
venlafaxine NN 1_i
in IN N
the DT N
manifestations NNS N
of IN N
hyperalgesia NN N
and CC N
temporal JJ N
summation NN N
, , N
but CC N
not RB N
on IN N
the DT N
ongoing JJ N
pain NN N
intensity NN N
. . N

Furthermore RB N
, , N
the DT N
quantitative JJ N
sensory NN N
tests NNS N
provided VBD N
complementing VBG N
information NN N
to TO N
the DT N
clinical JJ N
measures NNS N
. . N

-DOCSTART- -X- O O

Cognitive JJ 1_i
behavioral JJ 1_i
therapy NN 1_i
for IN N
early JJ 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
and CC 1_p
clinical JJ 1_p
anxiety NN 1_p
: : 1_p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

Clinically RB N
elevated JJ N
anxiety NN N
is VBZ N
a DT N
common JJ N
, , N
impairing JJ N
feature NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

A DT N
modular JJ N
CBT NNP 1_i
program NN N
designed VBN N
for IN N
preteens NNS 1_p
with IN 1_p
ASD NNP 1_p
, , N
Behavioral NNP 1_i
Interventions NNP 1_i
for IN N
Anxiety NNP N
in IN N
Children NNP N
with IN N
Autism NNP N
( ( N
BIACA NNP N
; : N
Wood NNP N
et FW N
al. NN N
, , N
2009 CD N
) ) N
was VBD N
enhanced VBN N
and CC N
modified VBN N
to TO N
address VB N
the DT N
developmental JJ N
needs NNS N
of IN N
early JJ 1_p
adolescents NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
clinical JJ 1_p
anxiety NN 1_p
. . 1_p

Thirty-three JJ 1_p
adolescents NNS 1_p
( ( 1_p
11-15 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP 1_i
or CC N
an DT N
equivalent JJ 1_i
waitlist NN 1_i
period NN 1_i
. . 1_i

The DT N
CBT NNP 1_i
model NN N
emphasized VBD N
exposure NN 1_i
, , 1_i
challenging VBG 1_i
irrational JJ 1_i
beliefs NNS 1_i
, , N
and CC N
behavioral JJ 1_i
supports NNS 1_i
provided VBN N
by IN N
caregivers NNS N
, , N
as RB N
well RB N
as IN N
numerous JJ N
ASD-specific JJ N
treatment NN N
elements NNS N
. . N

Independent JJ N
evaluators NNS N
, , N
parents NNS N
, , N
and CC N
adolescents NNS N
rated VBN N
symptom JJ 1_o
severity NN 1_o
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
. . N

In IN N
intent-to-treat JJ N
analyses NNS N
, , N
the DT N
CBT NNP 1_i
group NN N
outperformed VBD N
the DT N
waitlist NN N
group NN N
on IN N
independent JJ N
evaluators NNS N
' POS N
ratings NNS 1_o
of IN 1_o
anxiety NN 1_o
severity NN 1_o
on IN 1_o
the DT 1_o
Pediatric NNP 1_o
Anxiety NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
( ( 1_o
PARS NNP 1_o
) ) 1_o
and CC N
79 CD N
% NN N
of IN N
the DT N
CBT NNP N
group NN N
met VBD N
Clinical JJ 1_o
Global NNP 1_o
Impressions-Improvement NNP 1_o
scale NN 1_o
criteria NNS N
for IN N
positive JJ N
treatment NN N
response NN N
at IN N
posttreatment NN N
, , N
as IN N
compared VBN N
to TO N
only RB N
28.6 CD N
% NN N
of IN N
the DT N
waitlist NN N
group NN N
. . N

Group NNP N
differences NNS N
were VBD N
not RB N
found VBN N
for IN N
diagnostic JJ 1_o
remission NN 1_o
or CC 1_o
questionnaire NN 1_o
measures NNS 1_o
of IN 1_o
anxiety NN 1_o
. . 1_o

However RB N
, , N
parent-report JJ 1_o
data NNS 1_o
indicated VBD N
that IN N
there EX N
was VBD N
a DT N
positive JJ 1_o
treatment NN 1_o
effect NN 1_o
of IN 1_o
CBT NNP 1_o
on IN 1_o
autism NN 1_o
symptom JJ 1_o
severity NN 1_o
. . 1_o

The DT N
CBT NNP 1_i
manual JJ N
under IN N
investigation NN N
, , N
enhanced VBD N
for IN N
early JJ N
adolescents NNS N
with IN N
ASD NNP N
, , N
yielded VBD N
meaningful JJ N
treatment NN N
effects NNS N
on IN N
the DT N
primary JJ N
outcome NN N
measure NN N
( ( N
PARS NNP N
) ) N
, , N
although IN N
additional JJ N
developmental JJ N
modifications NNS N
to TO N
the DT N
manual NN N
are VBP N
likely JJ N
warranted VBN N
. . N

Future JJ N
studies NNS N
examining VBG N
this DT N
protocol NN N
relative NN N
to TO N
an DT N
active JJ N
control NN N
are VBP N
needed VBN N
. . N

-DOCSTART- -X- O O

Failure NN N
of IN N
lithium NN 1_i
to TO N
reduce VB N
period NN N
of IN N
neutropenia NN N
during IN N
induction NN 1_i
therapy NN 1_i
of IN N
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
. . 1_p

Fifty-four CD 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
daunorubicin NN 1_i
, , 1_i
cytosine JJ 1_i
arabinoside NN 1_i
and CC 1_i
thioquanine NN 1_i
for IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ 1_i
lithium NN 1_i
carbonate NN 1_i
1200 CD 1_i
mg JJ 1_i
daily JJ 1_i
or CC 1_i
no DT 1_i
lithium NN 1_i
. . 1_i

The DT N
duration NN 1_o
of IN 1_o
neutropenia NN 1_o
( ( N
less JJR N
than IN N
0.5 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
was VBD N
similar JJ N
between IN N
controls NNS N
( ( N
median JJ N
22.5 CD N
days NNS N
) ) N
and CC N
patients NNS N
treated VBN N
with IN N
lithium NN 1_i
( ( N
median JJ N
24 CD N
days NNS N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
remissions NNS 1_o
, , 1_o
relapse-free JJ 1_o
survival NN 1_o
and CC 1_o
survival NN 1_o
were VBD N
similar JJ 1_o
for IN N
the DT N
lithium NN 1_i
treated VBD N
and CC N
control VB N
groups NNS N
of IN N
patients NNS N
. . N

There EX N
was VBD N
no DT N
apparent JJ N
clinical JJ 1_o
efficacy NN 1_o
in IN N
the DT N
use NN N
of IN N
lithium NN 1_i
to TO N
reduce VB N
the DT N
period NN N
of IN N
neutropenia NN N
in IN N
patients NNS 1_p
undergoing JJ 1_p
remission NN 1_p
induction NN 1_i
therapy NN 1_i
for IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
. . 1_p

-DOCSTART- -X- O O

A DT N
randomised JJ N
trial NN N
evaluating VBG N
pain NN 1_o
and CC 1_o
bleeding NN 1_o
after IN 1_p
a DT 1_p
first JJ 1_p
trimester NN 1_p
miscarriage NN 1_p
treated VBD 1_p
surgically RB 1_p
or CC 1_p
medically RB 1_p
. . 1_p

Miscarriage NN N
treated VBD N
surgically RB 1_i
and CC 1_i
medically RB 1_i
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
evaluating VBG N
pain NN 1_o
and CC 1_o
bleeding NN 1_o
. . 1_o

Surgery NN N
is VBZ N
associated VBN N
with IN N
less JJR 1_o
pain NN 1_o
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
and CC N
vaginal JJ 1_o
bleeding NN 1_o
( ( N
duration NN N
and CC N
severity NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
than IN N
medical JJ N
treatment NN N
, , N
fewer JJR 1_o
daily JJ 1_o
hospital NN 1_o
attendances NNS 1_o
( ( N
2.5 CD N
compared VBN N
with IN N
three CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
but CC N
a DT N
greater JJR N
drop NN N
in IN N
haemoglobin JJ N
concentration NN N
( ( N
difference NN N
, , N
1 CD N
g/dl NN N
; : N
CI95 NNP N
% NN N
= NNP N
0.3-1.6 NN N
) ) N
. . N

-DOCSTART- -X- O O

The DT N
development NN N
and CC N
feasibility NN N
of IN N
a DT N
composite JJ N
score NN N
of IN N
echocardiographic JJ N
indices NNS N
that WDT N
may MD N
stratify VB N
outcome NN N
in IN N
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
mellitus NNS 1_p
. . 1_p

BACKGROUND NNP N
Early JJ N
detection NN N
of IN N
changes NNS N
in IN N
cardiac JJ N
structure NN N
and CC N
function NN N
associated VBN N
with IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
( ( 1_p
T2DM NNP 1_p
) ) 1_p
is VBZ N
important JJ N
. . N

However RB N
when WRB N
multiple JJ N
abnormalities NNS N
are VBP N
present JJ N
, , N
combining VBG N
individual JJ N
measurements NNS N
can MD N
be VB N
subjective JJ N
. . N

This DT N
study NN N
sought VBD N
to TO N
create VB N
a DT N
simple JJ N
echo NN 1_o
score NN 1_o
that WDT N
summarises VBZ N
measurements NNS N
that WDT N
may MD N
detect VB N
early JJ N
and CC N
prognostically RB N
important JJ N
changes NNS N
in IN N
cardiac JJ N
function NN N
. . N

METHODS NNP N
Standard NNP 1_i
echocardiography NN 1_i
was VBD 1_p
performed VBN 1_p
on IN 1_p
849 CD 1_p
people NNS 1_p
with IN 1_p
T2DM NNP 1_p
( ( 1_p
median JJ 1_p
age NN 1_p
65years CD 1_p
, , 1_p
40 CD 1_p
% NN 1_p
female NN 1_p
, , 1_p
median JJ 1_p
duration NN 1_p
of IN 1_p
diabetes NNS 1_p
5.5years CD 1_p
) ) 1_p
. . 1_p

Principal JJ N
components NNS N
analysis NN N
was VBD N
performed VBN N
on IN N
measurements NNS N
of IN N
LV NNP 1_o
mass NN 1_o
, , 1_o
LA NNP 1_o
volume NN 1_o
, , 1_o
E NN 1_o
: : 1_o
e NN 1_o
' '' 1_o
, , N
and CC N
s NN 1_o
' '' 1_o
, , N
to TO N
create VB N
an DT N
objective JJ 1_o
summary NN 1_o
score NN 1_o
. . 1_o

The DT N
score NN N
was VBD N
included VBN N
in IN N
two CD N
Cox NNP N
proportional JJ N
hazard NN N
models NNS N
adjusted VBN N
for IN N
CV NNP N
risk NN N
factors NNS N
: : N
one CD N
estimated VBD N
the DT N
development NN N
of IN N
heart NN 1_o
failure NN 1_o
( ( 1_o
HF NNP 1_o
) ) 1_o
and CC N
the DT N
second JJ N
estimated VBN N
any DT 1_o
CV NNP 1_o
event NN 1_o
. . 1_o

RESULTS VB N
The DT N
first JJ N
two CD N
principal JJ N
components NNS N
represented VBD N
75 CD N
% NN N
of IN N
the DT N
variation NN N
between IN N
the DT N
four CD N
echo NN N
measurements NNS N
. . N

A DT N
continuous JJ N
score NN N
that WDT N
represents VBZ N
the DT N
residual JJ N
difference NN N
between IN N
these DT N
two CD N
components NNS N
was VBD N
derived VBN N
that IN N
only RB N
requires VBZ N
measurement NN N
of IN N
medial JJ N
E NN N
: : N
e NN N
' '' N
and CC N
s VB N
' '' N
. . N

The DT N
score NN N
was VBD N
significantly RB N
associated VBN N
with IN N
the DT N
development NN 1_o
of IN 1_o
HF NNP 1_o
within IN N
four CD N
years NNS N
( ( N
hazard RB N
ratio VBZ N
1.34 CD N
; : N
95 CD N
% NN N
CI NNP N
1.15 CD N
, , N
1.56 CD N
) ) N
. . N

CONCLUSIONS NNP N
We PRP N
have VBP N
developed VBN N
a DT N
simple NN N
, , N
objective JJ N
score NN 1_o
that WDT N
enhances VBZ N
the DT N
use NN N
of IN N
echocardiography NN 1_i
in IN N
the DT N
detection NN N
of IN N
sub-clinical JJ N
cardiac JJ N
disease NN N
in IN N
people NNS 1_p
with IN 1_p
T2DM NNP 1_p
. . 1_p

Initial JJ N
findings NNS N
suggest VBP N
that IN N
it PRP N
may MD N
help VB N
identify VB N
those DT N
at IN N
increased VBN N
risk NN N
of IN N
developing VBG N
HF NNP N
within IN N
four CD N
years NNS N
. . N

-DOCSTART- -X- O O

Counselling NN 1_i
of IN N
postnatal JJ N
depression NN N
: : N
a DT N
controlled VBN N
study NN N
on IN N
a DT N
population NN 1_p
based VBN 1_p
Swedish JJ 1_p
sample NN 1_p
. . 1_p

In IN N
a DT N
two-stage JJ N
screening NN N
procedure NN N
using VBG N
the DT N
Edinburgh NNP 1_o
Postnatal NNP 1_o
Depression NNP 1_o
Scale NNP 1_o
( ( 1_o
EPDS NNP 1_o
) ) 1_o
at IN N
8 CD N
and CC N
12 CD N
weeks NNS N
postpartum NN 1_p
and CC N
the DT N
Montgomery-Asberg NNP 1_o
Depression NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
( ( 1_o
MADRS NNP 1_o
) ) 1_o
and CC N
DSM-III-R NNP 1_o
at IN N
about RB N
13 CD N
weeks NNS N
postpartum NN N
, , N
41 CD 1_p
women NNS 1_p
identified VBN 1_p
as IN 1_p
depressed JJ 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
study NN N
and CC N
a DT N
control NN N
group NN N
. . N

The DT N
women NNS N
in IN N
the DT N
study NN N
group NN N
received VBD N
6 CD 1_i
weekly JJ 1_i
, , 1_i
counselling VBG 1_i
visits NNS 1_i
by IN 1_i
the DT 1_i
Child NNP 1_i
Health NNP 1_i
Clinic NNP 1_i
nurse NN 1_i
and CC 1_i
the DT 1_i
control NN 1_i
group NN 1_i
received VBD 1_i
routine JJ 1_i
primary NN 1_i
care NN 1_i
. . 1_i

Twelve NNP N
( ( N
80 CD N
% NN N
) ) N
of IN N
15 CD N
women NNS N
with IN N
major JJ N
depression NN N
in IN N
the DT N
study NN N
group NN N
were VBD N
fully RB 1_o
recovered VBN 1_o
after IN N
the DT N
intervention NN N
compared VBN N
to TO N
4 CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
16 CD N
in IN N
the DT N
control NN N
group NN N
. . N

Counselling VBG 1_i
by IN N
health NN N
nurses NNS N
is VBZ N
helpful JJ N
in IN N
managing VBG N
postnatal JJ N
depression NN N
and CC N
seems VBZ N
to TO N
work VB N
well RB N
within IN N
the DT N
Swedish JJ N
Primary NNP N
Health NNP N
Care NNP N
system NN N
. . N

-DOCSTART- -X- O O

Hemostasis NN N
by IN N
bipolar JJ 1_i
coagulation NN 1_i
versus NN N
suture NN 1_i
after IN N
surgical JJ 1_i
stripping NN 1_i
of IN N
bilateral JJ N
ovarian JJ N
endometriomas NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
estimate VB N
whether IN N
the DT N
suture NN 1_i
of IN 1_i
the DT 1_i
ovary JJ 1_i
is VBZ N
superior JJ N
to TO N
bipolar JJ 1_i
coagulation NN 1_i
in IN N
preserving VBG N
ovarian JJ N
reserve NN N
in IN N
infertile JJ 1_p
women NNS 1_p
undergoing VBG 1_p
laparoscopic JJ 1_i
stripping NN 1_i
of IN 1_i
bilateral JJ 1_i
endometriomas NN 1_i
. . 1_i

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING NN N
University NNP 1_p
teaching NN 1_p
hospital NN 1_p
. . 1_p

PATIENTS CC N
100 CD 1_p
patients NNS 1_p
with IN 1_p
bilateral JJ 1_p
endometriomas NN 1_p
. . 1_p

INTERVENTIONS NNP N
Patients NNPS N
underwent JJ N
stripping NN 1_i
of IN 1_i
bilateral JJ 1_i
endometriomas NNS 1_i
and CC N
were VBD N
randomized VBN N
to TO N
undergo VB N
hemostasis NN N
by IN N
use NN N
of IN N
either DT N
laparoscopic NN 1_i
suturing NN 1_i
( ( 1_i
LS NNP 1_i
group NN 1_i
) ) 1_i
or CC 1_i
bipolar JJ 1_i
coagulation NN 1_i
( ( 1_i
BC NNP 1_i
group NN N
) ) N
. . N

Changes NNS 1_o
in IN 1_o
ovarian JJ 1_o
reserve NN 1_o
were VBD N
investigated VBN N
by IN N
measuring VBG N
the DT N
levels NNS N
of IN N
anti-Mullerian JJ 1_o
hormone NN 1_o
( ( 1_o
AMH NNP 1_o
) ) 1_o
and CC 1_o
basal JJ 1_o
follicle-stimulating JJ 1_o
hormone NN 1_o
( ( 1_o
FSH NNP 1_o
) ) 1_o
before IN N
surgery NN N
and CC N
at IN N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
from IN N
surgery NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
At IN N
3-month JJ N
, , N
6-month JJ N
, , N
and CC N
12-month JJ N
follow-up NN N
, , N
in IN N
both DT N
study NN N
groups NNS N
, , N
postsurgical JJ 1_o
AMH NNP 1_o
levels NNS 1_o
were VBD N
significantly RB N
lower JJR N
and CC N
basal VB 1_o
FSH NNP 1_o
levels NNS 1_o
were VBD N
significantly RB N
higher JJR N
than IN N
before RB N
surgery NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
mean JJ N
percentage NN N
decrease NN N
of IN N
AMH NNP 1_o
levels NNS 1_o
in IN N
the DT N
BC NNP 1_i
group NN N
and CC N
LS NNP 1_i
group NN N
at IN N
3- JJ N
, , N
6- JJ N
, , N
and CC N
12-month JJ N
follow-up NN N
. . N

The DT N
mean JJ N
percentage NN N
increase NN N
in IN N
basal JJ 1_o
FSH NNP 1_o
was VBD N
higher RBR N
in IN N
the DT N
BC NNP 1_i
group NN N
than IN N
in IN N
the DT N
LS NNP 1_i
group NN N
at IN N
both DT N
3-month JJ N
( ( N
p JJ N
= NNP N
.023 NNP N
) ) N
and CC N
6-month JJ N
follow-up NN N
( ( N
p JJ N
= NNP N
.029 NNP N
) ) N
, , N
but CC N
not RB N
at IN N
12-month JJ N
follow-up NN N
. . N

Pregnancy NNP 1_o
rate NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
conception NN 1_o
, , 1_o
and CC 1_o
rate NN 1_o
of IN 1_o
endometrioma NN 1_o
recurrence NN 1_o
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
study NN N
groups NNS N
. . N

CONCLUSION NNP N
Laparoscopic NNP 1_i
stripping NN 1_i
of IN 1_i
ovarian JJ 1_i
endometriotic JJ 1_i
cyst NN 1_i
significantly RB N
decreases VBZ N
serum JJ 1_o
AMH NNP 1_o
levels NNS 1_o
and CC N
increases VBZ N
basal JJ 1_o
FSH NNP 1_o
levels NNS 1_o
independent JJ N
from IN N
the DT N
method NN N
used VBN N
to TO N
obtain VB N
hemostasis NN N
on IN N
the DT N
ovarian JJ N
tissue NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
yoga NNP 1_i
versus NN 1_i
stretching VBG 1_i
for IN N
chronic JJ 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
: : 1_o
protocol NN N
for IN N
the DT N
Yoga NNP N
Exercise NNP N
Self-care NNP N
( ( N
YES NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Back NNP 1_o
pain NN 1_o
, , N
one CD N
of IN N
the DT N
most RBS N
prevalent JJ N
conditions NNS N
afflicting VBG N
American JJ N
adults NNS N
, , N
is VBZ N
the DT N
leading VBG N
reason NN N
for IN N
using VBG N
complementary JJ 1_i
and CC 1_i
alternative JJ 1_i
medicine NN 1_i
( ( 1_i
CAM NNP 1_i
) ) 1_i
therapies NNS 1_i
. . 1_i

Yoga NNP 1_i
is VBZ N
an DT N
increasingly RB N
popular JJ N
mind-body NN N
CAM NNP N
therapy NN N
often RB N
used VBN N
for IN N
relieving VBG 1_o
back RB 1_o
pain NN 1_o
and CC N
several JJ N
small JJ N
studies NNS N
have VBP N
found VBN N
yoga RB N
effective JJ N
for IN N
this DT N
condition NN N
. . N

This DT N
study NN N
will MD N
assess VB N
whether IN N
yoga NN 1_i
is VBZ N
effective JJ N
for IN N
treating VBG N
chronic JJ 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
compared VBN N
with IN N
self PRP 1_i
care NN 1_i
and CC 1_i
exercise NN 1_i
and CC N
will MD N
explore VB N
the DT N
mechanisms NNS N
responsible JJ N
for IN N
any DT N
observed JJ N
benefits NNS N
. . N

METHODS/DESIGN NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
210 CD 1_p
participants NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
lasting NN 1_p
at IN 1_p
least JJS 1_p
3 CD 1_p
months NNS 1_p
will MD 1_p
be VB 1_p
recruited VBN 1_p
from IN 1_p
primary JJ 1_p
care NN 1_p
clinics NNS 1_p
of IN 1_p
a DT 1_p
large JJ 1_p
healthcare NN 1_p
system NN 1_p
based VBN 1_p
in IN 1_p
Seattle NNP 1_p
. . 1_p

They PRP N
will MD N
be VB N
randomized VBN N
in IN N
a DT N
2:2:1 CD N
ratio NN N
to TO N
receive VB N
12 CD 1_i
weekly JJ 1_i
yoga NN 1_i
classes NNS 1_i
, , 1_i
12 CD 1_i
weekly JJ 1_i
conventional JJ 1_i
therapeutic JJ 1_i
exercise NN 1_i
classes NNS 1_i
of IN 1_i
comparable JJ 1_i
physical JJ 1_i
exertion NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
self-care JJ 1_i
book NN 1_i
. . 1_i

Interviewers NNS N
masked VBD N
to TO N
participants NNS N
' POS N
treatment NN N
group NN N
will MD N
assess VB N
outcomes NNS N
at IN N
baseline NN N
and CC N
6 CD N
, , N
12 CD N
and CC N
26 CD N
weeks NNS N
after IN N
randomization NN N
. . N

Primary JJ N
outcomes NNS N
will MD N
be VB N
back-related JJ 1_o
dysfunction NN 1_o
and CC 1_o
symptom NN 1_o
bothersomeness NN 1_o
. . 1_o

In IN N
addition NN N
, , N
data NNS N
will MD N
be VB N
collected VBN N
on IN N
physical JJ 1_o
measurements NNS 1_o
( ( 1_o
e.g. NN 1_o
, , N
flexion NN 1_o
) ) 1_o
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
and CC N
saliva NN N
samples NNS N
will MD N
be VB N
obtained VBN N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
weeks NNS N
. . N

Information NN N
will MD N
be VB N
collected VBN N
on IN N
specific JJ N
physical JJ N
, , N
psychological JJ N
, , N
and CC N
physiological JJ N
factors NNS N
to TO N
allow VB N
exploration NN N
of IN N
possible JJ N
mechanisms NNS N
of IN N
action NN N
through IN N
which WDT N
yoga NN 1_i
could MD N
relieve VB 1_o
back RB 1_o
pain NN 1_o
and CC 1_o
dysfunction NN 1_o
. . 1_o

The DT N
effectiveness NN N
of IN N
yoga NN 1_i
will MD N
be VB N
assessed VBN N
using VBG N
analysis NN N
of IN N
covariance NN N
( ( N
using VBG N
general JJ N
estimating VBG N
equations NNS N
- : N
GEE NNP N
) ) N
within IN N
an DT N
intention-to-treat JJ N
context NN N
. . N

If IN N
yoga NN 1_i
is VBZ N
found VBN N
effective JJ N
, , N
further JJ N
analyses NNS N
will MD N
explore VB N
whether IN N
yoga NN N
's POS N
benefits NNS N
are VBP N
attributable JJ N
to TO N
physical JJ N
, , N
psychological JJ N
and/or NN N
physiological JJ N
factors NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
will MD N
provide VB N
the DT N
clearest JJS N
evidence NN N
to TO N
date NN N
about IN N
the DT N
value NN N
of IN N
yoga NN 1_i
as IN N
a DT N
therapeutic JJ N
option NN N
for IN N
treating VBG N
chronic JJ 1_o
back RB 1_o
pain NN 1_o
, , N
and CC N
if IN N
the DT N
results NNS N
are VBP N
positive JJ N
, , N
will MD N
help VB N
focus VB N
future JJ N
, , N
more RBR N
in-depth JJ N
, , N
research NN N
on IN N
the DT N
most RBS N
promising JJ N
potential JJ N
mechanisms NN N
of IN N
action NN N
identified VBN N
by IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

Wavefront-guided JJ 1_i
versus NN 1_i
standard NN 1_i
LASIK NNP 1_i
enhancement NN 1_i
for IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
efficacy NN 1_o
, , 1_o
safety NN 1_o
, , 1_o
predictability NN 1_o
, , 1_o
stability NN 1_o
, , 1_o
and CC 1_o
changes NNS 1_o
in IN 1_o
higher-order NN 1_o
aberrations NNS 1_o
( ( 1_o
HOAs NNP 1_o
) ) 1_o
and CC N
contrast JJ 1_o
sensitivity NN 1_o
( ( 1_o
CS NNP 1_o
) ) 1_o
after IN N
wavefront-guided JJ 1_i
and CC 1_i
standard JJ 1_i
LASIK NNP 1_i
enhancement NN 1_i
for IN N
the DT N
correction NN N
of IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
comparative JJ N
clinical JJ N
study NN N
. . N

PARTICIPANTS NNP N
Twenty NNP 1_p
eyes NNS 1_p
of IN 1_p
20 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
( ( 1_p
spherical JJ 1_p
equivalent NN 1_p
[ NNP 1_p
SE NNP 1_p
] NNP 1_p
, , 1_p
-2.01+/-1.36 NNP 1_p
diopters NNS 1_p
[ NNP 1_p
D NNP 1_p
] NNP 1_p
) ) 1_p
treated VBD 1_p
with IN 1_p
wavefront-guided JJ 1_i
Zyoptix NNP 1_i
Ablation NNP 1_i
Refinement NNP 1_i
software NN 1_i
( ( 1_i
ZAR NNP 1_i
) ) 1_i
LASIK NNP 1_i
and CC 1_p
20 CD 1_p
eyes NNS 1_p
of IN 1_p
20 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
( ( 1_p
SE NNP 1_p
, , 1_p
-1.81+/-1.21 NNP 1_p
D NNP 1_p
) ) 1_p
treated VBD 1_p
with IN 1_p
standard JJ 1_i
Planoscan NNP 1_i
LASIK NNP 1_i
, , 1_p
both DT 1_p
for IN 1_p
residual JJ 1_p
refractive JJ 1_p
error NN 1_p
enhancement NN 1_p
. . 1_p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP 1_o
, , 1_o
safety NN 1_o
, , 1_o
predictability NN 1_o
, , 1_o
stability NN 1_o
, , 1_o
HOAs NNP 1_o
, , 1_o
and CC 1_o
CS NNP 1_o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
enhancement NN N
at IN N
6 CD N
months NNS N
' POS N
follow-up NN N
. . N

METHODS NNP N
Uncorrected VBD 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
UCVA NNP 1_o
) ) 1_o
, , 1_o
best-corrected JJ 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
BCVA NNP 1_o
) ) 1_o
, , 1_o
manifest JJS 1_o
refraction NN 1_o
, , 1_o
CS NNP 1_o
by IN 1_o
means NNS 1_o
of IN 1_o
the DT 1_o
Functional NNP 1_o
Acuity NNP 1_o
Contrast NNP 1_o
Test NNP 1_o
, , 1_o
and CC 1_o
HOAs NNP 1_o
by IN 1_o
means NNS 1_o
of IN 1_o
Zywave NNP 1_o
aberrometry NN 1_o
were VBD N
evaluated VBN N
preoperatively RB N
and CC N
6 CD N
months NNS N
after IN N
retreatment NN N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
postoperatively RB N
, , N
UCVA NNP 1_o
was VBD N
20/25 CD N
or CC N
better JJR N
in IN N
100 CD N
% NN N
of IN N
the DT N
eyes NNS N
. . N

Efficacy NN 1_o
indexes NNS 1_o
were VBD N
1.09 CD N
for IN N
ZAR NNP 1_i
patients NNS N
and CC N
0.95 CD N
for IN N
Planoscan JJ 1_i
patients NNS N
. . N

No DT 1_o
eyes NNS 1_o
lost VBN 1_o
> CD N
or CC N
=1 JJ N
line NN N
of IN N
BCVA NNP 1_o
; : 1_o
in IN N
the DT N
ZAR NNP 1_i
group NN N
, , N
2 CD N
eyes NNS N
gained VBD 1_o
1 CD N
line NN N
and CC N
6 CD N
eyes NNS N
gained VBN 1_o
> CD N
or CC N
=2 JJ N
lines NNS N
; : N
in IN N
the DT N
Planoscan NNP 1_i
group NN N
, , N
3 CD N
eyes NNS N
gained VBD N
1 CD N
line NN N
. . N

The DT N
ZAR NNP 1_i
group NN N
showed VBD N
a DT N
percentage NN N
of IN N
eyes NNS N
( ( N
94.4 CD N
% NN N
) ) N
within IN N
the DT N
0.5-D JJ N
range NN N
in IN N
SE NNP N
higher JJR N
than IN N
that DT N
shown VBN N
by IN N
the DT N
Planoscan NNP 1_i
group NN N
( ( N
88.8 CD N
% NN N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
HOA NNP 1_o
root NN 1_o
mean NN 1_o
square NN 1_o
( ( 1_o
RMS NNP 1_o
) ) 1_o
increased VBD N
on IN N
average NN N
by IN N
a DT N
factor NN N
of IN N
1.44 CD N
for IN N
the DT N
Planoscan NNP 1_i
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

No UH N
change NN N
or CC N
reduction NN 1_o
in IN 1_o
HOA NNP 1_o
RMS NNP 1_o
was VBD N
found VBN N
in IN N
the DT N
ZAR NNP 1_i
group NN N
( ( N
factor NN N
of IN N
0.96 CD N
; : N
P NNP N
> NNP N
0.01 CD N
) ) N
. . N

Contrast NNP 1_o
sensitivity NN 1_o
was VBD N
reduced VBN N
in IN N
the DT N
Planoscan NNP 1_i
group NN N
only RB N
at IN N
the DT N
highest JJS N
spatial JJ N
frequency NN N
( ( N
18 CD N
cycles NNS N
per IN N
degree NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN 1_o
of IN 1_o
CS NNP 1_o
as IN 1_o
a DT 1_o
function NN 1_o
of IN 1_o
HOA NNP 1_o
increase NN 1_o
for IN N
the DT N
Planoscan NNP 1_i
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
for IN N
the DT N
ZAR NNP 1_i
group NN N
at IN N
any DT N
spatial JJ 1_o
frequency NN 1_o
( ( N
1.5-18 JJ N
cycles NNS N
per IN N
degree NN N
; : N
P NNP N
> NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Wavefront-guided JJ 1_i
LASIK NNP 1_i
using VBG N
the DT N
ZAR NNP N
algorithm NN N
is VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
procedure NN N
for IN N
treatment NN N
of IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

Wavefront-guided JJ 1_i
LASIK NNP 1_i
does VBZ N
not RB N
increase VB N
HOAs NNP N
and CC N
does VBZ N
not RB N
modify VB N
CS NNP N
compared VBN N
with IN N
preoperative JJ N
values NNS N
. . N

Wavefront-guided JJ 1_i
LASIK NNP 1_i
seems VBZ N
to TO N
be VB N
better JJR N
than IN N
standard JJ N
LASIK NNP 1_i
for IN N
retreatments NNS N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
sleep JJ N
quality NN N
, , N
but CC N
not RB N
hormones VB N
predict JJ N
time NN N
to TO N
postpartum VB N
depression NN N
recurrence NN N
. . N

BACKGROUND NNP N
Poor NNP N
sleep JJ N
quality NN N
, , N
dysregulation NN N
of IN N
hormones NNS N
and CC N
increased VBD N
inflammatory JJ N
cytokines NNS N
are VBP N
all DT N
associated VBN N
with IN N
the DT N
risk NN N
for IN N
postpartum NN N
major JJ N
depression NN N
( ( N
PPMD NNP N
) ) N
. . N

We PRP N
evaluated VBD N
change NN N
over IN N
time NN N
in IN N
sleep JJ 1_o
quality NN 1_o
and CC N
hormones NNS 1_o
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum RB N
, , N
as RB N
well RB N
as IN N
a DT N
single JJ N
cytokine NN N
measure NN N
, , N
and CC N
their PRP$ N
association NN N
with IN N
PPMD NNP N
recurrence NN N
. . N

METHODS JJ N
Participants NNS 1_p
were VBD 1_p
pregnant JJ 1_p
women NNS 1_p
( ( 1_p
N=56 NNP 1_p
) ) 1_p
, , 1_p
with IN 1_p
past JJ 1_p
histories NNS 1_p
of IN 1_p
MDD/PPMD NNP 1_p
but CC 1_p
not RB 1_p
depressed VBN 1_p
in IN 1_p
their PRP$ 1_p
current JJ 1_p
pregnancy NN 1_p
. . 1_p

The DT N
Pittsburgh NNP 1_o
Sleep NNP 1_o
Quality NNP 1_o
Index NNP 1_o
( ( 1_i
PSQI NNP 1_i
) ) 1_i
and CC N
blood NN 1_i
samples NNS 1_i
were VBD 1_i
collected VBN 1_i
8 CD N
times NNS N
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum NN N
. . N

Estradiol NNP 1_o
, , 1_o
prolactin NN 1_o
and CC 1_o
cortisol NN 1_o
, , 1_o
and CC 1_o
a DT 1_o
single JJ 1_o
measure NN 1_o
of IN 1_o
IL-6 NNP 1_o
were VBD N
assayed VBN N
. . N

Recurrence NN N
was VBD N
determined VBN N
by IN N
two CD N
consecutive JJ N
21-item JJ 1_o
Hamilton NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
for IN 1_o
Depression NNP 1_o
( ( 1_o
HRSD NNP 1_o
) ) 1_o
scores?15 NN 1_o
and CC 1_o
clinician JJ 1_o
interview NN 1_o
. . 1_o

RESULTS NNP N
In IN N
the DT N
analyses NNS N
of IN N
time NN N
to TO N
PPMD NNP 1_o
recurrence NN 1_o
, , 1_o
poor JJ 1_o
sleep JJ 1_o
quality NN 1_o
, , 1_o
but CC N
none NN N
of IN N
the DT N
hormones NNS N
, , N
was VBD N
associated VBN N
with IN 1_o
PPMD NNP 1_o
recurrence NN 1_o
( ( 1_o
p JJ N
< NNP N
.05 NNP N
) ) N
after IN N
controlling VBG N
for IN N
medication NN N
assignment NN N
. . N

With IN N
every DT N
one CD N
point NN N
increase NN N
in IN N
PSQI NNP N
scores NNS N
across IN N
time NN N
, , N
a DT N
woman NN N
's POS N
risk NN N
for IN N
recurrence NN N
increased VBN N
by IN N
approximately RB N
25 CD N
% NN N
There EX N
was VBD N
no DT N
significant JJ N
association NN N
between IN 1_o
PSQI NNP 1_o
scores NNS 1_o
and CC 1_o
IL-6 NNP 1_o
concentrations NNS 1_o
in IN N
early JJ N
postpartum NN N
( ( N
? . N
( ( N
2 CD N
) ) N
=0.98 NN N
, , N
p=.32 NN N
) ) N
. . N

CONCLUSIONS NNP N
Poor NNP N
sleep VBP N
quality NN N
across IN N
the DT N
first JJ N
17 CD N
weeks NNS N
post-delivery JJ N
increases NNS N
the DT N
risk NN N
for IN N
recurrent JJ N
PPMD NNP N
among IN 1_p
women NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
MDD NNP 1_p
. . 1_p

Changes NNS 1_p
in IN N
the DT N
hormonal JJ N
milieu NN N
were VBD N
not RB N
associated VBN N
with IN N
recurrence NN N
. . N

Further JJ N
exploration NN N
of IN N
the DT N
degree NN N
to TO N
which WDT N
poor JJ N
sleep NN N
contributes NNS N
to TO N
hormonal JJ N
and CC N
cytokine JJ N
dysregulation NN N
and CC N
how WRB N
they PRP N
are VBP N
involved VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
PPMD NNP N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Absolute NNP N
bioavailability NN N
of IN N
a DT N
new JJ N
high JJ N
dose NN N
methylprednisolone NN 1_i
tablet NN N
formulation NN N
. . N

This DT N
was VBD N
a DT N
single-blind JJ N
, , N
single-dose JJ N
, , N
randomized VBN N
crossover NN N
study NN N
to TO N
determine VB N
the DT N
absolute JJ 1_o
bioavailability NN 1_o
of IN N
Medrol NNP 1_i
, , N
a DT N
new JJ N
high JJ N
dose NN N
( ( N
100 CD N
mg NN N
) ) N
methylprednisolone NN 1_i
tablet NN N
product NN N
, , N
by IN N
comparing VBG N
it PRP N
with IN N
100 CD N
mg NNS N
methylprednisolone NN 1_i
from IN N
an DT N
intravenous JJ N
formulation NN N
, , N
Solu-Medrol NNP 1_i
. . 1_i

Fourteen NNP 1_p
healthy JJ 1_p
, , 1_p
non-smoking JJ 1_p
, , 1_p
Caucasian JJ 1_p
male NN 1_p
volunteers NNS 1_p
took VBD N
part NN N
. . N

On IN N
treatment NN N
days NNS N
volunteers NNS N
remained VBD N
recumbent NN N
for IN N
4 CD N
hours NNS N
after IN N
drug NN N
administration NN N
, , N
with IN N
food NN N
and CC N
fluid NN N
intake VBP N
standardized VBN N
over IN N
this DT N
period NN N
. . N

Serial JJ N
blood NN N
samples NNS N
were VBD N
drawn VBN N
over IN N
a DT N
14-hour JJ N
period NN N
after IN N
drug NN N
administration NN N
. . N

Plasma NNP 1_o
methylprednisolone NN 1_o
concentrations NNS 1_o
were VBD N
determined VBN N
by IN N
high JJ N
performance NN N
liquid NN N
chromatography NN N
. . N

The DT N
geometric JJ N
means NNS N
of IN N
AUCi.v NNP 1_o
. . 1_o

and CC 1_o
AUCtablet NNP 1_o
were VBD N
4,049 CD N
and CC N
3,334 CD N
ng.h/ml NN N
, , N
respectively RB N
. . N

The DT N
absolute JJ 1_o
bioavailability NN 1_o
of IN N
the DT N
tablet NN N
product NN N
was VBD N
82 CD N
% NN N
, , N
which WDT N
is VBZ N
in IN N
agreement NN N
with IN N
published VBN N
data NNS N
for IN N
other JJ N
oral JJ N
dosage NN N
forms NNS N
of IN N
methylprednisolone NN 1_i
. . 1_i

Volunteers NNS N
displayed VBD N
the DT N
expected VBN N
rise NN N
in IN N
peripheral JJ 1_o
blood NN 1_o
neutrophil NN 1_o
count NN 1_o
, , N
but CC N
no DT N
other JJ N
clinically RB 1_o
relevant JJ 1_o
changes NNS 1_o
in IN 1_o
hematology NN 1_o
or CC 1_o
clinical JJ 1_o
chemistry NN 1_o
were VBD N
observed VBN N
. . N

No DT N
adverse JJ 1_o
drug NN 1_o
reactions NNS 1_o
were VBD N
recorded VBN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
tablet NN N
product NN N
can MD N
be VB N
used VBN N
as IN N
a DT N
substitute NN N
for IN N
parenteral JJ N
methylprednisolone NN 1_i
in IN N
situations NNS N
requiring VBG N
high-dose JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

[ IN N
The DT N
effects NNS N
of IN N
early JJ 1_i
enteral JJ 1_i
nutrition NN 1_i
with IN 1_i
addition NN 1_i
of IN 1_i
probiotics NNS 1_i
on IN N
the DT N
prognosis NN N
of IN N
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
severe JJ 1_p
acute NN 1_p
pancreatitis NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
curative JJ N
effect NN N
of IN N
early JJ 1_i
enteral JJ 1_i
nutrition NN 1_i
( ( 1_i
EN NNP 1_i
) ) 1_i
supplemented VBD 1_i
with IN 1_i
probiotics NNS 1_i
( ( 1_i
bifidobacterium NN 1_i
) ) 1_i
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
acute NN 1_p
pancreatitis NN 1_p
( ( 1_p
ASP NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Seventy NNP 1_p
SAP NNP 1_p
cases NNS 1_p
admitted VBD 1_p
from IN 1_p
January NNP 1_p
2005 CD 1_p
to TO 1_p
October NNP 1_p
2012 CD 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
into IN N
parenteral JJ 1_i
nutrition NN 1_i
( ( 1_i
PN NNP 1_i
) ) 1_i
group NN 1_p
( ( 1_p
n=22 NN 1_p
) ) 1_p
, , 1_p
EN NNP 1_i
group NN 1_p
( ( 1_p
n=25 CC 1_p
) ) 1_p
and CC 1_p
bifidobacterium NN 1_i
added VBD 1_i
EN NNP 1_i
( ( 1_i
P+EN NNP 1_i
) ) 1_i
group NN 1_p
( ( 1_p
n=23 RB 1_p
) ) 1_p
. . 1_p

In IN N
P+EN NNP 1_i
group NN N
, , N
patients NNS N
were VBD N
given VBN N
their PRP$ N
nutrition NN N
the DT N
same JJ N
as IN N
that DT N
of IN N
EN NNP 1_i
, , N
and CC N
also RB N
probiotics NNS 1_i
( ( 1_i
bifidobacterium NN 1_i
, , N
4 CD N
capsules NNS N
every DT N
12 CD N
hours NNS N
, , N
given VBN N
through IN N
nasal JJ N
gastric JJ N
tube NN N
, , N
each DT N
capsule NN N
weighing VBG N
210 CD N
mg NN N
) ) N
. . N

The DT N
routine JJ N
treatment NN N
including VBG N
anti-infection NN 1_i
and CC 1_i
anti-acid JJ 1_i
agents NNS 1_i
, , N
and CC N
that IN N
of IN N
inhibition NN N
of IN N
pancreatic JJ N
secretion NN N
were VBD N
given VBN N
, , N
except IN N
for IN N
the DT N
different JJ N
nutritional JJ N
interventions NNS N
in IN N
all DT N
groups NNS N
. . N

The DT N
blood NN N
samples NNS N
were VBD N
collected VBN N
for IN N
e NN N
same JJ N
measurements NNS N
of IN N
interleukin-8 JJ 1_o
( ( 1_o
IL-8 NNP 1_o
) ) 1_o
and CC 1_o
tumor JJ 1_o
necrosis NN 1_o
factor NN 1_o
( ( 1_o
TNF-? NNP 1_o
) ) 1_o
by IN N
enzyme NN N
linked VBN N
immunosorbent JJ N
assay NN N
( ( N
ELISA NNP N
) ) N
, , N
and CC N
for IN N
the DT 1_o
C-reactive JJ 1_o
protein NN 1_o
( ( 1_o
CRP NNP 1_o
) ) 1_o
, , 1_o
lactic JJ 1_o
acid NN 1_o
dehydrogenase NN 1_o
( ( 1_o
LDH NNP 1_o
) ) 1_o
, , 1_o
white JJ 1_o
blood NN 1_o
cell NN 1_o
( ( 1_o
WBC NNP 1_o
) ) 1_o
count NN 1_o
, , 1_o
amylase NN 1_o
and CC 1_o
lipase NN 1_o
by IN N
biochemistry NN N
assay VBP N
1 CD N
day NN N
before IN N
intervention NN N
of IN N
nutrition NN N
, , N
and CC N
7 CD N
days NNS N
and CC N
14 CD N
days NNS N
after IN N
intervention NN N
. . N

Changes NNS N
in IN N
organ JJ N
function NN N
and CC N
outcome NN N
were VBD N
also RB N
recorded VBN N
at IN N
the DT N
same JJ N
time NN N
points NNS N
. . N

RESULTS VB N
The DT 1_o
plasma JJ 1_o
levels NNS 1_o
of IN 1_o
IL-8 NNP 1_o
, , 1_o
TNF-? NNP 1_o
, , 1_o
CRP NNP 1_o
, , 1_o
LDH NNP 1_o
, , 1_o
WBC NNP 1_o
count NN 1_o
, , 1_o
amylase NN 1_o
and CC 1_o
lipase NN 1_o
were VBD 1_o
significantly RB N
reduced VBN N
after IN N
nutritional JJ N
intervention NN N
compared VBN N
with IN N
their PRP$ N
levels NNS N
on IN N
day NN N
1 CD N
before IN N
intervention NN N
in IN N
all DT N
three CD N
groups NNS N
. . N

The DT 1_o
plasma JJ 1_o
IL-8 NNP 1_o
, , 1_o
TNF-? NNP 1_o
, , 1_o
CRP NNP 1_o
, , 1_o
lipase NN 1_o
, , 1_o
LDH NNP 1_o
at IN 1_o
14 CD N
days NNS N
after IN N
intervention NN N
of IN N
nutrition NN N
in IN N
P+EN NNP 1_i
group NN 1_i
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
PN NNP 1_i
group NN N
and CC N
EN NNP 1_i
group NN N
( ( N
IL-8 NNP N
: : N
21.00 CD N
? . N
7.07 CD N
?g/L NN N
vs. FW N
48.00 CD N
? . N
10.32 CD N
?g/L NN N
, , N
32.00 CD N
? . N
9.30 CD N
?g/L NN N
; : N
TNF-? JJ N
: : N
44.3 CD N
? . N
10.9 CD N
ng/L JJ N
vs. FW N
132.1 CD N
? . N
34.1 CD N
ng/L NN N
, , N
67.8 CD N
? . N
22.3 CD N
ng/L NN N
; : N
CRP NNP N
: : N
35.0 CD N
? . N
12.4 CD N
mg/L NN N
vs. FW N
103.2 CD N
? . N
49.2 CD N
mg/L NN N
, , N
63.0 CD N
? . N
29.2 CD N
mg/L NN N
; : N
lipase NN N
: : N
269 CD N
? . N
79 CD N
U/L NNP N
vs. FW N
670 CD N
? . N
145 CD N
U/L NNP N
, , N
310 CD N
? . N
78 CD N
U/L NNP N
; : N
LDH NNP N
: : N
21.8 CD N
? . N
10.3 CD N
U/L NNP N
vs. FW N
78.1 CD N
? . N
37.4 CD N
U/L NNP N
, , N
37.9 CD N
? . N
25.1 CD N
U/L NNP N
, , N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
WBC NNP 1_o
count NN 1_o
in IN 1_o
P+EN NNP 1_o
group NN N
was VBD N
significantly RB N
lower JJR N
than IN 1_i
that DT 1_i
in IN 1_i
PN NNP 1_i
group NN N
( ( N
5.9 CD N
? . N
3.0 CD N
? . N
10?/L CD N
, , N
6.3 CD N
? . N
3.2 CD N
? . N
10?/L CD N
vs. IN N
9.6 CD N
? . N
3.0 CD N
?10?/L NN N
, , N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN 1_o
in IN 1_o
amylase NN 1_o
between IN 1_i
P+EN NNP 1_i
group NN 1_i
and CC 1_i
PN NNP 1_i
group NN N
( ( N
211 CD N
? . N
49 CD N
U/L NNP N
, , N
236 CD N
? . N
52 CD N
U/L NNP N
vs. FW N
298 CD N
? . N
71 CD N
U/L NNP N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT 1_o
gastrointestinal JJ 1_o
dysfunction NN 1_o
score NN 1_o
in IN 1_o
P+EN NNP 1_i
, , 1_i
EN NNP 1_i
, , 1_i
PN NNP 1_i
groups NNS 1_i
14 CD N
days NNS N
after IN N
nutritional JJ N
intervention NN N
was VBD N
0.28 CD N
? . N
0.05 CD N
, , N
0.43 CD N
? . N
0.09 CD N
, , N
0.71 CD N
? . N
0.11 CD N
, , N
respectively RB N
, , N
with IN N
statistically RB N
significant JJ N
differences NNS N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Compared VBN N
with IN N
PN NNP 1_i
and CC 1_i
EN NNP 1_i
groups NNS 1_i
, , N
the DT 1_o
incidence NN 1_o
of IN 1_o
upper JJ 1_o
gastrointestinal JJ 1_o
bleeding NN 1_o
( ( 1_o
1 CD 1_o
vs. FW 1_o
9 CD N
, , 1_o
2 CD 1_o
) ) 1_o
, , 1_o
infection NN 1_o
and CC 1_o
abscess NN 1_o
( ( 1_o
2 CD 1_o
vs. FW N
12 CD N
, , N
5 CD N
) ) N
was VBD N
lower JJR N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
hospital JJ N
day NN N
was VBD N
significantly RB N
shortened VBN N
in IN N
P+EN NNP N
group NN N
( ( N
10.4 CD N
? . N
3.9 CD N
days NNS N
vs. FW N
25.8 CD N
? . N
6.4 CD N
days NNS N
, , N
13.4 CD N
? . N
5.2 CD N
days NNS N
, , N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT 1_o
significant JJ 1_o
statistical JJ 1_o
difference NN 1_o
in IN 1_o
mortality NN 1_o
rate NN 1_o
among IN 1_o
three CD N
groups NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN 1_i
early JJ 1_i
EN NNP 1_i
with IN 1_i
addition NN 1_i
of IN 1_i
probiotics NNS 1_i
( ( 1_i
bifidobacterium NN 1_i
) ) 1_i
resulted VBD 1_i
in IN N
significant JJ N
lowering NN 1_o
of IN 1_o
the DT 1_o
level NN 1_o
of IN 1_o
pro-inflammatory JJ 1_o
cytokines NNS 1_o
, , N
earlier JJR 1_o
restoration NN 1_o
of IN 1_o
gastrointestinal JJ 1_o
function NN 1_o
, , 1_o
decrease NN 1_o
of IN 1_o
complications NNS 1_o
such JJ 1_o
as IN 1_o
infection NN 1_o
, , 1_o
and CC 1_o
shortening NN 1_o
of IN 1_o
hospital JJ 1_o
day NN 1_o
in IN N
patients NNS N
with IN N
SAP NNP N
. . N

-DOCSTART- -X- O O

Azimilide NNP 1_i
decreases VBZ N
recurrent JJ 1_o
ventricular JJ 1_o
tachyarrhythmias NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
implantable JJ 1_p
cardioverter NN 1_p
defibrillators NNS 1_p
. . 1_p

OBJECTIVES VB N
This DT N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
azimilide JJ 1_i
dihydrochloride NN 1_i
( ( 1_i
AZ NNP 1_i
) ) 1_i
on IN N
anti-tachycardia JJ 1_o
pacing NN 1_o
( ( 1_o
ATP NNP 1_o
) ) 1_o
and CC N
shock-terminated JJ 1_o
events NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
implantable JJ 1_p
cardioverter NN 1_p
defibrillators NNS 1_p
( ( 1_p
ICDs NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND NNP N
Animal NNP N
studies NNS N
have VBP N
shown VBN N
the DT N
effectiveness NN N
of IN N
AZ NNP N
for IN N
therapy NN N
of IN N
supraventricular JJ N
and CC N
ventricular JJ N
tachycardia NN N
( ( N
VT NNP N
) ) N
. . N

Azimilide NNP 1_i
dihydrochloride NN 1_i
was VBD N
investigated VBN N
as IN N
adjunctive JJ N
treatment NN N
for IN N
reducing VBG N
the DT N
frequency NN N
of IN N
VT NNP N
and CC N
, , N
thus RB N
, , N
the DT N
need NN N
for IN N
ICD NNP N
therapies NNS N
, , N
including VBG N
ATP NNP N
and CC N
cardioversion/defibrillation NN N
( ( N
ICD NNP N
shocks NNS N
) ) N
in IN N
patients NNS N
with IN N
inducible JJ N
monomorphic JJ N
VT. NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
172 CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
daily VB N
treatment NN N
with IN N
placebo NN 1_i
, , N
35 CD N
mg NN N
, , N
75 CD N
mg NN N
, , N
or CC N
125 CD N
mg NN N
of IN N
oral JJ 1_i
AZ NNP 1_i
in IN N
this DT N
dose-ranging JJ N
pilot NN N
study NN N
of IN N
patients NNS 1_p
with IN 1_p
ICDs NNP 1_p
. . 1_p

The DT 1_p
majority NN 1_p
of IN 1_p
patients NNS 1_p
had VBD 1_p
a DT 1_p
history NN 1_p
of IN 1_p
documented JJ 1_p
remote JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
and CC 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
New NNP 1_p
York NNP 1_p
Heart NNP 1_p
Association NNP 1_p
class NN 1_p
II NNP 1_p
or CC 1_p
III NNP 1_p
. . 1_p

RESULTS VB N
The DT N
frequency NN 1_o
of IN 1_o
appropriate JJ 1_o
shocks NNS 1_o
and CC 1_o
ATP NNP 1_o
were VBD N
significantly RB N
decreased VBN N
among IN N
AZ-treated JJ N
patients NNS N
compared VBN N
with IN N
placebo NN N
patients NNS N
. . N

The DT N
incidence NN 1_o
of IN 1_o
ICD NNP 1_o
therapies NNS 1_o
per IN 1_o
patient-year NN 1_o
among IN N
the DT N
placebo NN N
group NN N
was VBD N
36 CD N
, , N
and CC N
it PRP N
was VBD N
10 CD N
, , N
12 CD N
, , N
and CC N
9 CD N
among IN N
35 CD N
mg NNS N
, , N
75 CD N
mg NN N
, , N
and CC N
125 CD N
mg NNS N
AZ NNP N
patients NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
= VBD N
0.31 CD N
, , N
p NN N
= NNP N
0.0001 CD N
) ) N
. . N

Azimilide NNP N
dihydrochloride NN N
was VBD N
generally RB N
well RB 1_o
tolerated VBN 1_o
and CC N
did VBD N
not RB N
affect VB 1_o
left VBD 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
or CC 1_o
minimal JJ 1_o
energy NN 1_o
requirements NNS 1_o
for IN 1_o
defibrillation NN 1_o
or CC 1_o
pacing NN 1_o
. . 1_o

CONCLUSIONS NNP N
Azimilide NNP 1_i
dihydrochloride NN 1_i
may MD N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
drug NN N
for IN N
reducing VBG N
the DT N
frequency NN 1_o
of IN 1_o
VT NNP 1_o
and CC 1_o
ventricular JJ 1_o
fibrillation NN 1_o
in IN N
patients NNS N
with IN N
implanted JJ N
ICDs NNP N
. . N

-DOCSTART- -X- O O

A DT N
controlled VBN N
trial NN N
with IN N
diclofensine NN 1_i
, , N
a DT N
new JJ N
psychoactive JJ N
drug NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
depression NN N
. . N

Diclofensine NNP 1_i
inhibits VBZ N
the DT N
uptake NN N
of IN N
serotonin NN N
, , N
noradrenaline NN N
and CC N
dopamine NN N
. . N

In IN N
a DT N
controlled JJ N
study NN N
, , N
out-patients NNS 1_p
suffering VBG 1_p
from IN 1_p
moderate JJ 1_p
to TO 1_p
severe JJ 1_p
depression NN 1_p
were VBD N
treated VBN N
with IN N
the DT N
objective NN N
of IN N
assessing VBG N
the DT N
new JJ N
drug NN N
's POS N
therapeutically RB N
effective JJ N
dose NN N
range NN N
. . N

Maprotiline NNP 1_i
was VBD N
used VBN N
as IN N
a DT N
reference NN N
drug NN N
: : N
fourteen JJ 1_p
patients NNS 1_p
were VBD 1_p
assigned VBN 1_p
to TO 1_p
receive VB 1_p
diclofensine NN 1_i
and CC 1_p
thirteen NN 1_p
to TO 1_p
receive VB 1_p
maprotiline NN 1_i
in IN 1_p
a DT 1_p
double-blind JJ 1_p
design NN 1_p
. . 1_p

Depending VBG N
on IN N
tolerance NN N
and CC N
efficacy NN N
, , N
they PRP N
were VBD N
treated VBN N
for IN N
periods NNS N
ranging VBG N
from IN N
5 CD N
to TO N
150 CD N
days NNS N
. . N

Doses NNS N
were VBD N
titrated VBN N
to TO N
the DT N
optimum NN N
. . N

Findings NNS N
suggest VBP N
that IN N
a DT N
50 CD N
mg JJ N
daily JJ N
dose NN N
of IN N
diclofensine NN 1_i
would MD N
be VB N
sufficient JJ N
for IN N
the DT N
majority NN N
of IN N
the DT N
patients NNS N
. . N

The DT N
dosage NN N
can MD N
be VB N
safely RB N
increased VBN N
up RP N
to TO N
150 CD N
mg NNS N
daily RB N
but CC N
this DT N
offers VBZ N
few JJ N
therapeutic JJ N
advantages NNS N
. . N

While IN N
the DT N
efficacy NN 1_o
index NN 1_o
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
similar JJ N
( ( N
approximately RB N
60 CD N
% NN N
) ) N
, , N
they PRP N
differed VBD N
greatly RB N
in IN N
their PRP$ N
profile NN 1_o
of IN 1_o
side-effects NNS 1_o
. . 1_o

No DT 1_o
signs NNS 1_o
of IN 1_o
abrupt JJ 1_o
dissipation NN 1_o
of IN 1_o
the DT 1_o
achieved JJ 1_o
clinical JJ 1_o
effects NNS 1_o
were VBD N
observed VBN N
during IN N
continued JJ N
treatment NN N
, , N
and CC N
no DT 1_o
withdrawal NN 1_o
reactions NNS 1_o
were VBD N
observed VBN N
when WRB N
the DT N
treatment NN N
was VBD N
stopped VBN N
. . N

The DT N
new JJ N
drug NN N
may MD N
be VB N
more RBR N
effective JJ 1_o
in IN N
treating VBG N
patients NNS 1_p
in IN 1_p
whom WP 1_p
a DT 1_p
psycho-energizing NN 1_p
and CC 1_p
mood NN 1_p
alleviating VBG 1_p
effect NN 1_p
is VBZ 1_p
desired VBN 1_p
. . 1_p

-DOCSTART- -X- O O

Long-term JJ 1_i
oral JJ 1_i
branched-chain NN 1_i
amino NN 1_i
acid NN 1_i
treatment NN 1_i
in IN N
chronic JJ 1_p
hepatic JJ 1_p
encephalopathy NN 1_p
. . 1_p

A DT N
randomized JJ N
double-blind JJ N
casein-controlled JJ N
trial NN N
. . N

The DT 1_p
Italian JJ 1_p
Multicenter NNP 1_p
Study NNP 1_p
Group NNP 1_p
. . 1_p

In IN N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
, , N
branched-chain JJ 1_i
amino NN 1_i
acids NNS 1_i
and CC N
placebo NN 1_i
( ( 1_i
casein NN 1_i
) ) 1_i
were VBD N
compared VBN N
as IN N
a DT N
treatment NN N
for IN N
chronic JJ 1_p
hepatic JJ 1_p
encephalopathy NN 1_p
in IN 1_p
cirrhosis NN 1_p
. . 1_p

After IN N
a DT N
15-day JJ N
run-in JJ N
period NN N
with IN N
controlled JJ N
diet JJ N
( ( N
45-65 JJ N
g NN N
protein NN N
) ) N
, , N
the DT N
patients NNS 1_p
were VBD 1_p
administered VBN 1_p
, , 1_p
in IN 1_p
addition NN 1_p
to TO 1_p
their PRP$ 1_p
diet JJ 1_p
, , 1_p
branched-chain JJ 1_i
amino NN 1_i
acids NNS 1_i
( ( 1_p
0.24 CD 1_p
g/kg NN 1_p
, , 1_p
30 CD 1_p
patients NNS 1_p
) ) 1_p
or CC 1_p
an DT 1_p
equinitrogenous JJ 1_i
amount NN 1_i
of IN 1_i
casein NN 1_i
( ( 1_p
34 CD 1_p
patients NNS 1_p
) ) 1_p
. . 1_p

One CD N
patient NN N
on IN N
branched-chain NN N
amino NN N
acids NNS N
and CC N
two CD N
on IN N
casein NNS N
were VBD N
lost VBN N
to TO N
the DT N
study NN N
. . N

After IN N
3 CD N
months NNS N
, , N
the DT N
index NN 1_o
of IN 1_o
portal-systemic JJ 1_o
encephalopathy NN 1_o
significantly RB N
improved VBN N
in IN N
patients NNS N
on IN N
active JJ 1_i
treatment NN 1_i
( ( N
from IN N
40 CD N
[ JJ N
S.D NNP N
. . N

14 CD N
] CD N
% NN N
to TO N
21 CD N
[ NNS N
17 CD N
] NN N
) ) N
, , N
but CC N
was VBD N
not RB N
in IN N
subjects NNS N
receiving VBG N
casein NN 1_i
( ( N
from IN N
37 CD N
[ $ N
13 CD N
] NNP N
% NN N
to TO N
36 CD N
[ NNS N
12 CD N
] NN N
) ) N
. . N

Two CD N
or CC N
more JJR N
parameters NNS N
of IN N
the DT N
index NN N
improved VBD N
in IN N
24 CD N
patients NNS N
treated VBN N
with IN N
amino JJ 1_i
acids NNS 1_i
( ( N
80 CD N
% NN N
; : N
confidence NN N
limits NNS N
, , N
61-92 CD N
% NN N
) ) N
, , N
and CC N
only RB N
in IN N
12 CD N
receiving VBG N
casein NN 1_i
( ( N
35 CD N
% NN N
; : N
confidence NN N
limits NNS N
, , N
20-54 JJ N
% NN N
; : N
p CC N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
improve VB N
were VBD N
given VBN N
an DT N
alternative JJ 1_i
treatment NN 1_i
for IN N
3 CD N
more JJR N
months NNS N
. . N

Casein-treated JJ 1_o
patients NNS 1_o
given VBN 1_o
branched-chain JJ 1_o
amino NN 1_o
acids NNS 1_o
rapidly RB N
improved VBN 1_o
. . 1_o

The DT N
changes NNS N
in IN N
neuropsychologic JJ N
function NN N
were VBD N
associated VBN N
with IN N
an DT N
improvement NN N
in IN N
semiquantitative JJ 1_o
nitrogen NN 1_o
balance NN 1_o
, , N
which WDT N
became VBD N
consistently RB N
positive JJ N
in IN N
amino JJ 1_i
acid-treated JJ 1_i
subjects NNS N
; : N
there EX N
was VBD N
also RB N
a DT N
mild JJ N
improvement NN N
in IN N
nutritional JJ 1_o
parameters NNS 1_o
and CC N
in IN N
liver JJ 1_o
function NN 1_o
tests NNS N
. . N

The DT N
supplementation NN N
of IN N
oral JJ 1_i
branched-chain NN 1_i
amino NN 1_i
acids NNS 1_i
to TO N
the DT N
diet NN N
is VBZ N
superior JJ N
to TO N
casein VB 1_i
as IN N
a DT N
treatment NN N
for IN N
providing VBG N
adequate JJ N
nitrogen JJ 1_o
supply NN 1_o
and CC N
improving VBG N
the DT N
mental JJ 1_o
state NN 1_o
of IN N
cirrhotic JJ 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
encephalopathy NN 1_p
. . 1_p

-DOCSTART- -X- O O

Effect NN N
of IN N
n-3 JJ 1_i
polyunsaturated JJ 1_i
fatty JJ 1_i
acid NNS 1_i
intake VBP 1_i
on IN N
phospholipid JJ N
fatty JJ N
acid JJ N
composition NN N
in IN N
plasma NN N
and CC N
erythrocytes NNS N
. . N

To TO N
characterize VB N
the DT N
time NN N
course NN N
of IN N
plasma NN N
and CC N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
changes NNS N
after IN N
n-3 JJ 1_i
polyunsaturated JJ 1_i
fatty JJ 1_i
acid NN 1_i
( ( 1_i
PUFA NNP 1_i
) ) 1_i
supplementation NN 1_i
, , N
20 CD 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
receive VB N
either DT N
four CD 1_i
1-g JJ 1_i
capsules NNS 1_i
of IN 1_i
n-3 JJ 1_i
PUFA NNP 1_i
ethyl NN 1_i
esters NNS 1_i
or CC 1_i
four CD 1_i
1-g JJ 1_i
capsules NNS 1_i
of IN 1_i
olive JJ 1_i
oil NN 1_i
( ( 1_i
as IN 1_i
placebo NN 1_i
) ) 1_i
for IN N
a DT N
period NN N
of IN N
4 CD N
mo NN N
, , N
followed VBN N
by IN N
a DT N
3-mo JJ N
washout NN N
period NN N
. . N

Fatty NNP 1_o
acids NNS 1_o
of IN 1_o
plasma NN 1_o
and CC 1_o
RBC NNP 1_o
phospholipid JJ 1_o
fractions NNS 1_o
were VBD N
analyzed VBN N
at IN N
0 CD N
, , N
2 CD N
, , N
and CC N
4 CD N
mo NN N
of IN N
treatment NN N
and CC N
at IN N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
mo NN N
of IN N
washout NN N
. . N

During IN N
n-3 JJ 1_i
PUFA NNP 1_i
supplementation NN 1_i
, , N
accumulations NNS N
of IN N
eicosapentaenoic NN 1_o
( ( 1_o
EPA NNP 1_o
) ) 1_o
, , 1_o
docosapentaenoic FW 1_o
( ( 1_o
DPA NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
docosahexaenoic NN 1_o
( ( 1_o
DHA NNP 1_o
) ) 1_o
acids NNS 1_o
were VBD N
marked VBN N
after IN N
2 CD N
mo NN N
with IN N
differences NNS N
among IN N
different JJ N
fractions NNS N
of IN N
plasma NN N
and CC N
RBCs NNP N
in IN N
further JJ N
accumulation NN N
up RB N
to TO N
4 CD N
mo NN N
. . N

During IN N
the DT N
first JJ N
and CC N
second JJ N
months NNS N
of IN N
the DT N
washout NN N
, , N
slight JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
changes NNS 1_o
of IN 1_o
various JJ 1_o
fatty JJ 1_o
acids NNS 1_o
among IN 1_o
different JJ 1_o
phospholipid JJ 1_o
fractions NNS 1_o
, , N
but CC N
after IN N
3 CD N
mo NN N
of IN N
washout NN N
, , N
only RB N
minor JJ N
alterations NNS N
were VBD N
still RB N
detectable JJ N
with IN N
respect NN N
to TO N
pretreatment VB N
values NNS N
. . N

These DT N
data NNS N
confirm VBP N
the DT N
complex JJ N
relations NNS N
among IN N
different JJ 1_o
fatty JJ 1_o
acid NN 1_o
pools NNS 1_o
after IN N
n-3 JJ 1_i
PUFA NNP 1_i
supplementation NN 1_i
. . 1_i

-DOCSTART- -X- O O

Relationships NNS N
of IN N
PROP NNP N
Taste NNP N
Phenotype NNP N
, , N
Taste NNP N
Receptor NNP N
Genotype NNP N
, , N
and CC N
Oral NNP N
Nicotine NNP N
Replacement NNP N
Use NNP N
. . N

INTRODUCTION NNP N
Recommended VBD N
dosage NN N
of IN N
oral JJ N
nicotine JJ N
replacement NN N
therapy NN N
( ( N
NRT NNP N
) ) N
product NN N
is VBZ N
often RB N
not RB N
achieved VBN N
in IN N
smoking VBG N
cessation NN N
attempts NNS N
. . N

n-6-propylthiouracil NN N
( ( N
PROP NNP N
) ) N
bitter NN N
taste NN N
phenotype NN N
may MD N
be VB N
a DT N
potential JJ N
risk NN N
factor NN N
for IN N
non-adherence NN N
to TO N
oral JJ N
NRT NNP N
products NNS N
due JJ N
to TO N
their PRP$ N
bitter JJ N
taste NN N
. . N

There EX N
is VBZ N
limited JJ N
literature NN N
on IN N
this DT N
phenotype NN N
in IN N
the DT N
context NN N
of IN N
smoking NN N
and CC N
none NN N
in IN N
relation NN N
to TO N
oral JJ N
NRT NNP N
pharmacotherapy NN N
. . N

METHODS NNP N
The DT N
association NN N
of IN N
PROP NNP N
taste NN N
phenotype NN N
with IN N
NRT NNP N
usage NN N
and CC N
sensory JJ N
response NN N
to TO N
products NNS N
was VBD N
examined VBN N
. . N

In IN N
a DT N
cross-over JJ N
experimental JJ N
design NN N
, , N
120 CD 1_p
participants NNS 1_p
received VBD 1_p
a DT 1_p
1 CD 1_i
week NN 1_i
supply NN 1_i
of IN 1_i
nicotine JJ 1_i
inhalers NNS 1_i
and CC 1_i
1 CD 1_i
week NN 1_i
of IN 1_i
nicotine JJ 1_i
lozenges NNS 1_i
with IN N
random JJ N
assignment NN N
to TO N
order NN N
. . N

Mixed JJ N
effects NNS N
linear JJ N
model NN N
analyses NNS N
were VBD N
conducted VBN N
. . N

RESULTS NNP N
PROP NNP N
taste NN N
phenotype NN N
and CC N
taste NN N
receptor NN N
genotype NN N
were VBD N
not RB N
associated VBN N
with IN N
NRT NNP N
usage NN N
or CC N
sensory JJ N
response NN N
to TO N
NRT NNP N
, , N
after IN N
adjusting VBG N
for IN N
other JJ N
factors NNS N
. . N

However RB N
, , N
PROP NNP N
non-tasters NNS N
used VBD N
a DT N
higher JJR N
number NN 1_o
of IN 1_o
lozenges NNS 1_o
per IN 1_o
day NN 1_o
( ( N
continuous JJ N
exposure NN N
) ) N
than IN N
nicotine JJ N
cartridges NNS N
( ( N
intermittent JJ N
exposure NN N
) ) N
. . N

Unexpectedly RB N
, , N
half NN N
of IN N
baseline JJ N
PROP NNP N
non-tasters NNS N
shifted VBD N
to TO N
taster VB N
phenotype JJ N
2 CD N
weeks NNS N
after IN N
smoking VBG N
cessation NN N
or CC N
reduction NN N
. . N

Menthol NNP 1_p
cigarette NN 1_p
smokers NNS 1_p
identified VBD N
higher JJR 1_o
NRT NNP 1_o
strength NN 1_o
of IN 1_o
sensation NN 1_o
scores NNS 1_o
than IN N
nonmenthol JJ 1_p
smokers NNS 1_p
. . 1_p

Taste NNP N
receptor NN N
genotype NN N
was VBD N
related VBN N
to TO N
PROP NNP N
taste NN N
phenotype NN N
( ( N
Kendall NNP N
? . N
= NNP N
.591 NNP N
, , N
p NN N
= NNP N
.0001 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
nonsignificant JJ N
relationship NN N
of IN N
PROP NNP N
phenotype NN N
and CC N
NRT NNP N
usage NN N
may MD N
be VB N
associated VBN N
with IN N
NRT NNP N
under-dosing JJ N
and CC N
limited JJ N
variance NN N
in IN N
the DT N
outcome NN N
variable NN N
. . N

PROP NNP N
non-tasters NNS N
' POS N
greater JJR N
use NN N
of IN N
lozenges NNS N
is VBZ N
consistent JJ N
with IN N
nicotine JJ N
exposure NN N
being VBG N
less RBR N
aversive JJ N
to TO N
non-tasters NNS N
. . N

Further NNP N
research NN N
of IN N
this DT N
and CC N
other JJ N
factors NNS N
impacting VBG N
NRT NNP N
usage NN N
are VBP N
warranted VBN N
to TO N
effectively RB N
inform VB N
smoking VBG N
cessation NN N
pharmacotherapy NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
heat NN 1_i
and CC 1_i
cold NN 1_i
on IN N
the DT N
perineum NN N
after IN N
episiotomy/laceration NN 1_p
. . 1_p

The DT N
Redness NNP 1_o
Edema NNP 1_o
Ecchymosis NNP 1_o
Discharge NNP 1_o
Approximation NNP 1_o
( ( 1_o
REEDA NNP 1_o
) ) 1_o
tool NN 1_o
, , N
devised VBN N
to TO N
evaluate VB N
postpartum NN N
healing NN N
of IN N
the DT N
perineum NN N
following VBG N
an DT N
episiotomy/laceration NN 1_i
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
heat NN 1_i
and CC 1_i
cold NN 1_i
on IN N
the DT N
perineum NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
delivery NN N
. . N

Ninety NN 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
one CD 1_p
of IN 1_p
three CD 1_p
treatment NN 1_p
groups NNS 1_p
. . 1_p

Treatment NNP N
consisted VBD N
of IN N
30 CD 1_p
subjects NNS 1_p
applying VBG 1_p
a DT 1_p
warm JJ 1_i
perineal NN 1_i
pack NN 1_i
, , 1_p
30 CD 1_p
applying VBG 1_p
a DT 1_p
cold JJ 1_i
perineal NN 1_i
pack NN 1_i
, , 1_p
and CC 1_p
30 CD 1_p
taking VBG 1_p
a DT 1_p
warm JJ 1_i
sitz NN 1_i
bath NN 1_i
. . 1_i

Analysis NN N
of IN N
variance NN N
indicated VBD N
no DT N
difference NN N
in IN N
the DT N
REEDA NNP 1_o
score NN 1_o
before IN N
or CC N
two CD N
hours NNS N
after IN N
treatment NN N
. . N

A DT N
Pearson NNP N
r NN N
correlation NN N
indicated VBD N
the DT N
REEDA NNP N
score NN N
was VBD N
associated VBN N
with IN N
a DT N
laceration NN 1_o
and CC 1_o
not RB 1_o
with IN 1_o
infant JJ 1_o
weight NN 1_o
. . 1_o

Although IN N
these DT N
findings NNS N
do VBP N
not RB N
support VB N
assumptions NNS N
from IN N
the DT N
literature NN N
, , N
this DT N
study NN N
provides VBZ N
baseline JJ N
data NNS N
and CC N
trends NNS N
for IN N
future JJ N
study NN N
. . N

-DOCSTART- -X- O O

Twenty-four CD N
vs. IN N
forty-eight JJ N
weeks NNS N
of IN N
re-therapy NN N
with IN N
interferon NN 1_i
alpha NN 1_i
2b CD 1_i
and CC 1_i
ribavirin VB 1_i
in IN N
interferon NN 1_p
alpha NN 1_p
monotherapy NN 1_p
relapsers NNS 1_p
with IN 1_p
chronic JJ 1_p
hepatitis NN 1_p
C. NNP 1_p
BACKGROUND/AIM NNP N
Roughly NNP N
50 CD N
% NN N
of IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
, , N
who WP N
relapsed VBD N
after IN N
a DT N
previous JJ N
monotherapy NN N
with IN N
interferon NN N
alpha NN N
, , N
will MD N
respond VB N
in IN N
a DT N
sustained JJ N
fashion NN N
to TO N
24 CD N
weeks NNS N
of IN N
re-therapy NN N
with IN N
the DT N
combination NN 1_i
of IN 1_i
interferon NN 1_i
alpha NN 1_i
plus CC 1_i
ribavirin NN 1_i
. . 1_i

Whether CC N
prolonging VBG N
treatment NN N
duration NN N
to TO N
48 CD N
weeks NNS N
will MD N
further RB N
increase VB N
sustained JJ N
response NN N
rates NNS N
remains VBZ N
ill JJ N
defined VBN N
. . N

In IN N
this DT N
randomised VBN N
controlled VBD N
pilot JJ N
trial NN N
we PRP N
compared VBN N
the DT N
efficacy NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
a DT N
24 CD N
week NN N
with IN N
that DT N
of IN N
a DT N
48 CD N
week NN N
course NN N
of IN N
combination NN N
therapy NN N
with IN N
interferon NN N
alpha NN N
and CC N
ribavirin NN N
in IN N
interferon NN 1_p
monotherapy NN 1_p
relapsers NNS 1_p
with IN 1_p
chronic JJ 1_p
hepatitis NN 1_p
C. NNP 1_p
METHODS NNP N
Interferon NNP 1_p
alpha NN 1_p
monotherapy NN 1_p
relapsers NNS 1_p
with IN 1_p
chronic JJ 1_p
hepatitis NN 1_p
C NNP 1_p
were VBD N
randomised VBN N
to TO N
receive VB N
interferon NN 1_i
alpha NN 1_i
2b CD 1_i
( ( N
3 CD N
x RB N
3 CD N
MIU NNP N
sc JJ N
weekly RB N
) ) N
and CC N
oral JJ 1_i
ribavirin NN 1_i
( ( N
1000/1200 CD N
mg NNS N
po JJ N
daily RB N
) ) N
for IN N
either DT N
24 CD N
weeks NNS N
or CC N
48 CD N
weeks NNS N
. . N

Virological JJ N
response NN N
was VBD N
evaluated VBN N
by IN N
HCV NNP N
RNA NNP N
PCR NNP N
at IN N
week NN N
10 CD N
( ( N
initial JJ N
response NN N
) ) N
, , N
at IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
end JJ N
of- JJ N
treatment NN N
response NN N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
24 CD N
weeks NNS N
follow-up JJ N
( ( N
sustained JJ N
response NN N
) ) N
. . N

Only JJ 1_p
patients NNS 1_p
with IN 1_p
negative JJ 1_p
HCV NNP 1_p
RNA NNP 1_p
at IN 1_p
week NN 1_p
10 CD 1_p
continued VBD 1_p
treatment NN 1_p
. . 1_p

Adverse JJ 1_o
events NNS 1_o
were VBD N
recorded VBN N
at IN N
regular JJ N
intervals NNS N
. . N

RESULTS NNP N
Thirty-seven JJ 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
19 CD 1_p
( ( 1_p
6 CD 1_p
females NNS 1_p
, , 1_p
median JJ 1_p
age NN 1_p
43 CD 1_p
) ) 1_p
in IN 1_p
the DT 1_p
24 CD 1_p
week NN 1_p
and CC 1_p
18 CD 1_p
( ( 1_p
5 CD 1_p
females NNS 1_p
, , 1_p
median JJ 1_p
age NN 1_p
40 CD 1_p
) ) 1_p
in IN 1_p
the DT 1_p
48 CD 1_p
week NN 1_p
treatment NN 1_p
arm NN 1_p
. . 1_p

Baseline JJ 1_p
characteristics NNS 1_p
were VBD 1_p
similar JJ 1_p
in IN 1_p
both DT 1_p
groups NNS 1_p
. . 1_p

At IN N
treatment NN N
week NN N
10 CD N
, , N
12/19 CD N
( ( N
63 CD N
% NN N
) ) N
in IN N
the DT N
24 CD N
week NN N
group NN N
and CC N
14/18 CD N
( ( N
78 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
48 CD N
week NN N
group NN N
had VBD N
lost VBN 1_o
HCV NNP 1_o
RNA NNP 1_o
in IN 1_o
serum NN 1_o
( ( N
p JJ N
= NNP N
0.33 CD N
) ) N
. . N

All DT N
initial JJ N
responders NNS N
remained VBD N
HCV NNP 1_o
RNA NNP 1_o
negative JJ 1_o
throughout IN N
the DT N
treatment NN N
period NN N
. . N

Sustained VBN 1_o
response NN 1_o
rates NNS 1_o
were VBD N
10/19 CD N
( ( N
53 CD N
% NN N
) ) N
in IN N
the DT N
24 CD N
week NN N
group NN N
and CC N
13/18 CD N
( ( N
72 CD N
% NN N
) ) N
in IN N
the DT N
48 CD N
week NN N
group NN N
( ( N
p JJ N
= NNP N
0.31 CD N
) ) N
. . N

Three CD 1_p
patients NNS 1_p
discontinued VBN 1_p
treatment NN 1_p
early JJ 1_p
( ( 1_p
two CD 1_p
due JJ 1_p
to TO 1_p
moderate VB 1_o
adverse JJ 1_o
events NNS 1_o
, , 1_p
one CD 1_p
due JJ 1_p
to TO 1_p
non-compliance NN 1_p
) ) 1_p
. . 1_p

Dose JJ N
modifications NNS N
were VBD N
necessary JJ N
in IN N
9 CD N
patients NNS N
, , N
4 CD N
in IN N
the DT N
24 CD N
week NN N
and CC N
5 CD N
in IN N
the DT N
48 CD N
week NN N
group NN N
for IN N
anaemia NN 1_o
, , 1_o
neutropenia NN 1_o
, , 1_o
nausea NN 1_o
and CC 1_o
depression NN 1_o
, , N
respectively RB N
. . N

CONCLUSION NNP N
Prolonging NNP N
interferon NN N
/ NNP N
ribavirin NN N
combination NN N
therapy NN N
in IN N
interferon NN N
alpha NN N
monotherapy NN N
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
from IN N
24 CD N
to TO N
48 CD N
weeks NNS N
may MD N
increase VB N
sustained JJ 1_o
response NN 1_o
rates NNS 1_o
. . 1_o

Larger NNP N
controlled VBD N
trials NNS N
using VBG N
pegylated JJ N
interferon NN N
alpha NN N
and CC N
ribavirin NN N
in IN N
relapsers NNS 1_p
with IN 1_p
chronic JJ 1_p
hepatitis NN 1_p
C NNP 1_p
seem VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

The DT N
cumulative JJ N
dose NN N
response NN N
effect NN N
of IN N
eicosapentaenoic NN 1_i
and CC N
docosahexaenoic JJ 1_i
acid NN 1_i
on IN N
blood NN 1_o
pressure NN 1_o
, , 1_o
plasma NN 1_o
lipid JJ 1_o
profile NN 1_o
and CC 1_o
diet JJ 1_o
pattern NN 1_o
in IN N
mild NN 1_p
to TO 1_p
moderate VB 1_p
essential JJ 1_p
hypertensive JJ 1_p
black JJ 1_p
patients NNS 1_p
. . 1_p

In IN N
this DT N
study NN N
eicosapentaenoic VBZ 1_i
acid NNS 1_i
( ( 1_i
EPA NNP 1_i
) ) 1_i
and CC 1_i
docosahexaenoic JJ 1_i
acid NN 1_i
( ( 1_i
DHA NNP 1_i
) ) 1_i
were VBD N
given VBN N
in IN N
a DT N
cumulative JJ N
manner NN N
, , N
every DT N
6 CD N
weeks NNS N
, , N
starting VBG N
with IN N
10 CD N
mg NNS N
, , N
then RB N
100 CD N
mg NNS N
, , N
1000 CD N
mg NN N
and CC N
10,000 CD N
mg NNS N
EPA NNP 1_i
daily RB N
to TO N
mild VB 1_p
to TO 1_p
moderate VB 1_p
essential JJ 1_p
hypertensive JJ 1_p
black JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
corresponding JJ N
DHA NNP 1_i
doses NNS N
were VBD N
3 CD N
, , N
33 CD N
, , N
333 CD N
and CC N
3333 CD N
mg. NN N
A NNP N
control NN N
group NN N
was VBD N
given VBN N
olive JJ 1_i
oil NN 1_i
as IN 1_i
placebo NN 1_i
for IN N
the DT N
entire JJ N
24 CD N
weeks NNS N
. . N

The DT N
placebo NN 1_i
group NN N
had VBD N
lower JJR 1_o
diastolic NN 1_o
and CC 1_o
systolic JJ 1_o
blood NN 1_o
pressures NNS 1_o
after IN N
24 CD N
weeks NNS N
than IN N
the DT N
EPA NNP 1_i
and CC N
DHA NNP 1_i
group NN N
. . N

No DT N
effect NN 1_o
was VBD N
seen VBN N
on IN N
plasma NN 1_o
triglycerides NNS 1_o
, , 1_o
cholesterol NN 1_o
, , 1_o
HDL-cholesterol NNP 1_o
and CC 1_o
gamma-glutamyltranspeptidase NN 1_o
at IN N
any DT N
stage NN N
of IN N
the DT N
trial NN N
. . N

In IN N
the DT N
EPA NNP 1_i
group NN N
plasma VBD 1_o
free-EPA NN 1_o
increased VBN 1_o
significantly RB 1_o
from IN N
1000 CD N
mg NN N
onwards NNS N
and CC N
plasma JJ 1_o
free-arachidonic JJ 1_o
acid NN 1_o
( ( 1_o
AA NNP 1_o
) ) 1_o
decreased VBD 1_o
after IN N
1000 CD N
mg NN N
EPA NNP 1_i
. . 1_i

No DT N
other JJ N
plasma NN 1_o
free JJ 1_o
essential JJ 1_o
fatty NN 1_o
acid RB 1_o
changed VBD 1_o
during IN N
the DT N
trial NN N
, , N
although IN N
the DT N
HDL NNP 1_o
: : 1_o
cholesterol NN 1_o
increased VBD 1_o
slightly RB 1_o
but CC N
non-significantly RB 1_o
with IN N
an DT N
increase NN 1_o
in IN N
EPA NNP 1_o
and CC 1_o
DHA NNP 1_o
. . 1_o

No NNP N
significant JJ 1_o
changes NNS 1_o
in IN N
diet JJ 1_o
pattern NN 1_o
or CC 1_o
body NN 1_o
mass NN 1_o
was VBD N
observed VBN 1_o
. . 1_o

It PRP N
is VBZ N
therefore RB N
concluded JJ N
that IN N
EPA NNP 1_i
and CC N
DHA NNP 1_i
supplementation NN 1_i
had VBD N
no DT N
beneficial JJ N
effects NNS N
in IN N
mild NN 1_p
to TO 1_p
moderate VB 1_p
essential JJ 1_p
hypertensive JJ 1_p
black JJ 1_p
patients NNS 1_p
except IN N
for IN N
a DT N
lowering NN 1_o
of IN 1_o
plasma NN 1_o
AA NNP 1_o
. . 1_o

-DOCSTART- -X- O O

Stroke NNP N
team NN N
remote NN N
evaluation NN N
using VBG N
a DT N
digital JJ N
observation NN N
camera NN N
in IN N
Arizona NNP 1_p
: : 1_p
the DT N
initial JJ N
mayo NN N
clinic JJ N
experience NN N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Telemedicine NNP N
techniques NNS N
can MD N
be VB N
used VBN N
to TO N
address VB N
the DT N
rural-metropolitan JJ 1_p
disparity NN N
in IN N
acute JJ N
stroke NN N
care NN N
. . N

The DT N
Stroke NNP N
Team NNP N
Remote NNP N
Evaluation NNP N
Using VBG N
a DT N
Digital NNP N
Observation NNP N
Camera NNP N
( ( N
STRokE NNP N
DOC NNP N
) ) N
trial NN N
reported VBD N
more RBR N
accurate JJ N
decision NN N
making NN N
for IN N
telemedicine JJ 1_i
consultations NNS N
compared VBN N
with IN N
telephone-only JJ 1_i
and CC N
that IN N
the DT N
California-based JJ N
research NN N
network NN N
facilitated VBD N
a DT N
high JJ N
rate NN N
of IN N
thrombolysis NN N
use NN N
, , N
improved VBN N
data NNS N
collection NN N
, , N
low JJ N
risk NN N
of IN N
complications NNS N
, , N
low JJ N
technical JJ N
complications NNS N
, , N
and CC N
favorable JJ N
assessment NN N
times NNS N
. . N

The DT N
main JJ N
objective NN N
of IN N
the DT N
STRokE NNP N
DOC NNP N
Arizona NNP N
TIME NNP N
( ( N
The DT N
Initial NNP N
Mayo NNP N
Clinic NNP N
Experience NNP N
) ) N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
feasibility NN N
of IN N
establishing VBG N
, , N
de FW N
novo FW N
, , N
a DT N
single-hub JJ N
, , N
multirural JJ N
spoke VBD N
hospital JJ N
telestroke NN N
research NN N
network NN N
across IN N
a DT N
large JJ N
geographical JJ N
area NN N
in IN N
Arizona NNP N
by IN N
replicating VBG N
the DT N
STRokE NNP N
DOC NNP N
protocol NN N
. . N

METHODS NNP N
Methods NNP N
included VBD N
prospective JJ N
, , N
single-hub JJ N
, , N
2-spoke JJ N
, , N
randomized VBN N
, , N
blinded VBD N
, , N
controlled VBD N
trial NN N
of IN N
a DT N
2-way JJ N
, , N
site-independent JJ N
, , N
audiovisual JJ 1_i
telemedicine NN 1_i
system NN 1_i
designed VBN 1_i
for IN 1_i
remote JJ 1_i
examination NN 1_i
of IN N
adult NN 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
stroke NN 1_p
versus IN 1_p
telephone NN 1_i
consultation NN 1_i
to TO 1_i
assess VB 1_i
eligibility NN 1_i
for IN 1_i
treatment NN 1_i
with IN 1_p
intravenous JJ 1_i
thrombolysis NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
whether IN N
the DT N
decision NN 1_o
to TO 1_o
give VB 1_o
thrombolysis NN 1_o
was VBD 1_o
correct JJ 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
were VBD N
rate NN 1_o
of IN 1_o
thrombolytic JJ 1_o
use NN 1_o
, , 1_o
90-day JJ 1_o
functional JJ 1_o
outcomes NNS 1_o
, , 1_o
incidence NN 1_o
of IN 1_o
intracerebral JJ 1_o
hemorrhages NNS 1_o
, , 1_o
and CC 1_o
technical JJ 1_o
observations NNS 1_o
. . 1_o

RESULTS NN N
From IN 1_p
December NNP 1_p
2007 CD 1_p
to TO 1_p
October NNP 1_p
2008 CD 1_p
, , 1_p
54 CD 1_p
patients NNS 1_p
were VBD 1_p
assessed VBN 1_p
, , N
27 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
each DT N
arm NN N
. . N

Mean JJ N
National NNP N
Institutes NNPS N
of IN N
Health NNP N
Stroke NNP N
Scale NNP N
score NN N
at IN N
presentation NN N
was VBD N
7.3 CD N
( ( N
SD NNP N
6.2 CD N
) ) N
points NNS N
. . N

No DT N
consultations NNS N
were VBD N
aborted VBN N
; : N
however RB N
, , N
technical JJ 1_o
problems NNS 1_o
( ( N
74 CD N
% NN N
) ) N
were VBD N
prevalent JJ N
in IN N
the DT N
telemedicine NN N
arm NN N
. . N

Overall JJ N
, , N
the DT N
correct JJ N
treatment NN 1_o
decision NN 1_o
was VBD N
established VBN N
in IN N
87 CD N
% NN N
of IN N
the DT N
consultations NNS N
. . N

Both DT N
modalities NNS N
, , N
telephone NN N
( ( N
89 CD N
% NN N
correct NN N
) ) N
and CC N
telemedicine NN N
( ( N
85 CD N
% NN N
correct NN N
) ) N
, , N
performed VBN N
well RB N
. . N

Intravenous JJ N
thrombolytic JJ 1_i
treatment NN 1_i
was VBD N
used VBN N
in IN N
30 CD N
% NN N
of IN N
the DT N
telemedicine NN N
and CC N
telephone NN N
consultations NNS N
. . N

Good JJ N
functional JJ 1_o
outcomes NNS 1_o
at IN N
90 CD N
days NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
mortality NN 1_o
( ( N
4 CD N
% NN N
in IN N
telemedicine NN N
and CC N
11 CD N
% NN N
in IN N
telephone NN N
) ) N
or CC N
rates NNS 1_o
of IN 1_o
intracerebral JJ 1_o
hemorrhage NN 1_o
( ( N
4 CD N
% NN N
in IN N
telemedicine NN N
and CC N
0 CD N
% NN N
in IN N
telephone NN N
) ) N
. . N

CONCLUSIONS VB N
It PRP N
is VBZ N
feasible JJ N
to TO N
extend VB N
the DT N
original JJ N
STRokE NNP N
DOC NNP N
trial NN N
protocol NN N
to TO N
a DT N
new JJ N
state NN N
and CC N
establish VB N
an DT N
operational JJ N
single-hub NN N
, , N
multispoke VBD N
rural JJ N
hospital NN N
telestroke VBD N
research NN N
network NN N
in IN N
Arizona NNP N
. . N

The DT N
trial NN N
was VBD N
not RB N
designed VBN N
to TO N
have VB N
sufficient JJ N
power NN N
to TO N
detect VB N
a DT N
difference NN N
between IN N
the DT N
2 CD N
consultative JJ N
modes NNS N
: : N
telemedicine NN N
and CC N
telephone-only RB N
. . N

Whether CC N
by IN N
telemedicine NN N
or CC N
telephone NN N
consultative JJ N
modalities NNS N
, , N
there EX N
were VBD N
appropriate JJ N
treatment NN 1_o
decisions NNS 1_o
, , N
high JJ N
rates NNS N
of IN N
thrombolysis NN 1_o
use NN 1_o
, , N
improved VBN N
data NNS 1_o
collection NN 1_o
, , N
low JJ N
rates NNS 1_o
of IN 1_o
intracerebral JJ 1_o
hemorrhage NN 1_o
, , N
and CC N
equally RB N
favorable JJ N
time NN 1_o
requirements NNS 1_o
. . 1_o

The DT N
learning VBG N
curve NN N
was VBD N
steep JJ N
for IN N
the DT N
hub NN N
and CC N
spoke VBD N
personnel NNS N
of IN N
the DT N
new JJ N
telestroke NN N
network NN N
, , N
as IN N
reflected VBN N
by IN N
frequent JJ N
technical JJ N
problems NNS N
. . N

Overall NNP N
, , N
the DT N
results NNS N
support VBD N
the DT N
effectiveness NN N
of IN N
highly RB N
organized VBN N
and CC N
structured VBN N
stroke NN N
telemedicine NN N
networks NNS N
for IN N
extending VBG N
expert JJ N
stroke NN N
care NN N
into IN N
rural JJ 1_p
remote JJ 1_p
communities NNS 1_p
lacking VBG 1_p
sufficient JJ 1_p
neurological JJ 1_p
expertise NN 1_p
. . 1_p

-DOCSTART- -X- O O

Effects NNS N
of IN N
diet JJ 1_i
and CC 1_i
Aspergillus NNP 1_i
oryzae VBP 1_i
extract NN 1_i
or CC 1_i
Saccharomyces NNS 1_i
cervisiae VBP 1_i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
of IN N
lambs NNS 1_p
and CC 1_p
steers NNS 1_p
fed VBP 1_p
to TO 1_p
meet VB 1_p
requirements NNS 1_p
of IN 1_p
natural JJ 1_p
markets NNS 1_p
. . 1_p

Two CD N
studies NNS N
were VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
diet JJ 1_i
and CC 1_i
feed JJ 1_i
additive NN 1_i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
of IN N
lambs NNS 1_p
and CC 1_p
cattle NNS 1_p
destined VBD 1_p
for IN 1_p
all DT 1_p
natural JJ 1_p
markets NNS 1_p
. . 1_p

In IN N
Exp NNP N
. . N

1 CD 1_p
, , 1_p
48 CD 1_p
Dorset NNP 1_p
? . 1_p
Hampshire NNP 1_p
lambs NN 1_p
( ( 1_p
initial JJ 1_p
BW NNP 1_p
29.4 CD 1_p
? . 1_p
0.1 CD 1_p
kg NN 1_p
) ) 1_p
were VBD 1_p
used VBN N
in IN N
a DT N
randomized JJ N
complete JJ N
block NN N
experiment NN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
Aspergillus NNP 1_i
oryzae NNP 1_i
extract NN 1_i
, , 1_i
Amaferm NNP 1_i
( ( 1_i
AMF NNP 1_i
) ) 1_i
supplementation NN 1_i
( ( 1_i
1 CD N
g/d NN N
) ) N
in IN N
an DT N
85 CD N
% NN 1_i
concentrate NN 1_i
diet NN 1_i
on IN 1_i
growth NN N
and CC N
carcass NN N
characteristics NNS 1_p
. . 1_p

Lambs NNP 1_p
were VBD 1_p
allotted VBN 1_p
to TO 1_p
12 CD 1_p
pens NNS 1_p
( ( 1_p
4 CD 1_p
lambs NNS 1_p
per IN 1_p
pen NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
blocked VBN 1_p
by IN 1_p
sex NN 1_p
and CC 1_p
BW NNP 1_p
. . 1_p

Lambs NNP N
were VBD N
fed VBN N
until IN N
the DT N
average JJ N
BW NNP N
of IN N
each DT N
pen NN N
reached VBD N
a DT N
target NN N
BW NNP N
( ( N
55.4 CD N
kg NN N
for IN N
wethers NNS N
and CC N
50.0 CD N
kg NN N
for IN N
ewes NN N
) ) N
, , N
at IN N
which WDT N
time NN N
the DT N
entire JJ N
pen NN N
of IN N
lambs NN N
was VBD N
slaughtered VBN N
. . N

Amaferm NNP N
resulted VBD N
in IN N
a DT N
greater JJR N
( ( N
P=0.07 NNP 1_o
) ) 1_o
G NNP 1_o
: : 1_o
F. NNP 1_o
In IN N
Exp NNP 1_p
. . 1_p

2 CD 1_p
, , N
168 CD 1_p
crossbred VBD 1_p
steers NNS 1_p
( ( 1_p
initial JJ 1_p
BW NNP 1_p
300 CD 1_p
? . 1_p
0.7 CD 1_p
kg NN 1_p
) ) 1_p
were VBD 1_p
used VBN N
in IN N
a DT N
trial NN N
with IN N
a DT N
3 CD N
? . N
2 CD N
factorial JJ N
arrangement NN N
of IN N
treatments NNS N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
0.5 CD N
g/d NN N
of IN 1_i
Saccaromyces NNP 1_i
cervisiae NN 1_i
boulardii NN 1_i
CNCM NNP 1_i
1079-Levucell CD 1_i
SB NNP 1_i
( ( 1_i
LEV NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
3 CD N
g/d NN N
of IN 1_i
AMF NNP 1_i
with IN N
2 CD N
corn NN N
sources NNS 1_i
, , 1_i
dry JJ 1_i
whole-shelled JJ 1_i
corn NN 1_i
or CC 1_i
high JJ 1_i
moisture NN 1_i
corn NN 1_i
, , 1_i
on IN 1_i
growth NN N
and CC N
carcass NN N
characteristics NNS 1_o
. . 1_o

Neither CC 1_o
LEV NNP 1_o
nor CC 1_o
AMF NNP 1_o
improved VBD 1_o
( ( 1_o
P NNP 1_o
> NNP 1_o
0.10 CD 1_o
) ) 1_o
carcass NN 1_o
characteristics NNS 1_o
compared VBN 1_o
with IN 1_o
control NN 1_o
or CC 1_o
non-feed-supplemented JJ 1_o
steers NNS 1_o
. . 1_o

Addition NN 1_o
of IN 1_i
LEV NNP 1_i
to TO N
high-concentrate NN N
, , N
corn-based JJ N
diets NNS 1_o
did VBD 1_o
not RB 1_o
improve VB 1_o
( ( 1_o
P NNP 1_o
> NNP 1_o
0.10 CD 1_o
) ) 1_o
growth NN 1_o
performance NN 1_o
of IN 1_o
feedlot NN 1_o
steers NNS 1_o
. . 1_o

However RB 1_o
, , N
addition NN 1_i
of IN 1_i
AMF NNP 1_i
to TO N
a DT N
diet JJ N
composed VBN N
of IN N
dry JJ N
whole-shelled JJ N
corn NN N
resulted VBD N
in IN N
an DT 1_o
improvement NN 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
0.05 CD 1_o
) ) 1_o
in IN 1_o
G NNP 1_o
: : 1_o
F NNP 1_o
( ( N
0.208 CD N
vs. FW N
0.194 CD N
) ) N
. . N

Results VB N
indicate JJ N
that WDT N
at IN N
the DT N
amounts NNS N
fed VBN N
, , N
AMF NNP 1_i
may MD N
improve VB 1_o
G NNP 1_o
: : 1_o
F NNP 1_o
for IN N
lambs NN 1_p
and CC 1_p
steers NNS 1_p
fed VBP 1_p
dry JJ N
corn-based JJ N
finishing VBG N
diets NNS N
. . N

-DOCSTART- -X- O O

Using VBG N
personalized VBN 1_i
feedback NN 1_i
to TO N
reduce VB N
alcohol NN N
use NN N
among IN N
hazardous JJ 1_p
drinking VBG 1_p
college NN 1_p
students NNS 1_p
: : 1_p
the DT N
moderating VBG N
effect NN N
of IN N
alcohol-related JJ N
negative JJ N
consequences NNS N
. . N

UNLABELLED JJ N
Web-based JJ 1_i
screening NN 1_i
and CC 1_i
brief JJ 1_i
interventions NNS 1_i
that WDT N
include VBP N
personalized VBN N
feedback NN N
about IN N
their PRP$ N
alcohol NN N
use NN N
have VBP N
proven VBN N
to TO N
be VB N
particularly RB N
promising VBG N
for IN N
reducing VBG N
hazardous JJ 1_p
drinking NN 1_p
among IN 1_p
university JJ 1_p
students NNS 1_p
. . 1_p

Despite IN N
the DT N
increasing VBG N
use NN N
of IN N
these DT N
approaches NNS N
, , N
there EX N
is VBZ N
still RB N
relatively RB N
little JJ N
known VBN N
about IN N
how WRB N
the DT N
content NN N
of IN N
these DT N
interventions NNS N
may MD N
influence VB N
outcomes NNS N
and CC N
who WP N
may MD N
benefit VB N
most JJS N
from IN N
these DT N
approaches NNS N
. . N

The DT N
current JJ N
study NN N
sought VBD N
to TO N
address VB N
these DT N
issues NNS N
by IN N
examining VBG N
how WRB N
individual JJ N
differences NNS N
in IN N
alcohol NN N
consequences NNS N
influence NN N
outcomes NNS N
of IN N
a DT N
laboratory-based JJ 1_i
computerized JJ 1_i
intervention NN 1_i
. . 1_i

METHODS NNP N
One-hundred JJ 1_p
and CC 1_p
nineteen JJ 1_p
introductory NN 1_p
psychology NN 1_p
students NNS 1_p
who WP 1_p
either DT 1_p
had VBD 1_p
two CD 1_p
episodes NNS 1_p
of IN 1_p
heavy JJ 1_p
episodic JJ 1_p
drinking NN 1_p
in IN 1_p
the DT 1_p
past JJ 1_p
month NN 1_p
or CC 1_p
scored VBN 1_p
?8 NNS 1_p
on IN 1_p
the DT 1_p
AUDIT NNP 1_p
participated VBD 1_p
in IN 1_p
this DT 1_p
randomized VBN 1_p
controlled VBD 1_p
trial NN 1_p
for IN 1_p
course NN 1_p
credit NN 1_p
. . 1_p

Participants NNS N
were VBD N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
in IN N
this DT N
2 CD N
Intervention NNP 1_i
( ( 1_i
Alcohol NNP 1_i
Feedback NNP 1_i
vs. IN 1_i
Control NNP 1_i
) ) 1_i
?2 FW 1_i
Assessment NNP 1_i
( ( 1_i
Motivational NNP 1_i
Assessment NNP 1_i
vs. IN 1_i
No NNP 1_i
Motivational NNP 1_i
Assessment NNP 1_i
) ) 1_i
between-subjects NNS 1_i
design NN 1_o
. . 1_o

Quantity NN 1_o
of IN 1_o
alcohol NN 1_o
consumed VBN 1_o
per IN 1_o
week NN 1_o
and CC 1_o
heavy JJ 1_o
episodic JJ 1_o
drinking VBG 1_o
one CD 1_o
month NN 1_o
later RBR 1_o
were VBD 1_o
the DT N
primary JJ N
dependent JJ N
variables NNS N
. . N

RESULTS NNP N
Controlling VBG N
for IN N
corresponding VBG N
baseline NN 1_o
alcohol NN 1_o
measures NNS 1_o
, , 1_o
hierarchical JJ 1_o
linear JJ N
regression NN N
analyses NNS N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
intervention NN N
condition NN N
and CC N
baseline VB N
alcohol-related JJ N
consequences NNS N
. . N

For IN N
those DT N
who WP N
reported VBD N
more JJR N
alcohol NN N
consequences NNS N
at IN N
baseline NN N
, , N
the DT N
alcohol NN N
intervention NN N
resulted VBD N
in IN N
significantly RB N
less JJR 1_o
alcohol NN 1_o
use NN 1_o
and CC 1_o
fewer JJR 1_o
heavy JJ 1_o
drinking NN 1_o
episodes NNS 1_o
at IN 1_o
follow-up JJ N
, , N
while IN N
no DT N
difference NN N
was VBD N
observed VBN N
between IN N
intervention NN N
conditions NNS N
for IN N
those DT N
with IN N
few JJ N
baseline NN N
consequences NNS N
. . N

Assessment NN N
did VBD N
not RB N
moderate VB N
intervention NN N
effects NNS N
. . N

DISCUSSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN 1_i
a DT 1_i
feedback-based JJ 1_i
computerized JJ 1_i
intervention NN 1_i
that WDT 1_i
includes VBZ N
normative JJ N
information NN N
about IN 1_o
alcohol NN 1_o
use NN 1_o
and CC 1_o
consequences NNS N
may MD N
be VB N
more RBR N
effective JJ N
for IN N
hazardous JJ 1_p
drinking NN 1_p
students NNS 1_p
who WP 1_p
are VBP 1_p
experiencing VBG 1_p
higher JJR 1_p
levels NNS 1_p
of IN 1_p
alcohol-related JJ 1_p
consequences NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Greater NNP N
knowledge NN 1_o
gain NN 1_o
with IN N
structured VBN 1_i
than IN N
student-directed JJ 1_i
learning NN 1_i
in IN N
Child NNP 1_p
Health NNP 1_p
: : 1_p
cluster NN N
randomized VBD N
trial NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
detect VB N
a DT N
difference NN N
in IN N
knowledge NN 1_o
gain NN 1_o
between IN N
students NNS 1_p
receiving VBG 1_p
structured JJ 1_i
versus NN 1_i
student-directed JJ 1_i
learning NN 1_i
for IN 1_p
the DT 1_p
two-week JJ 1_p
Child NNP 1_p
Health NNP 1_p
outpatient NN 1_p
module NN 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
138 CD 1_p
phase NN 1_p
3 CD 1_p
( ( 1_p
year NN 1_p
4 CD 1_p
) ) 1_p
medical JJ 1_p
students NNS 1_p
in IN 1_p
10 CD 1_p
two-week JJ 1_p
paediatric JJ 1_p
outpatient NN 1_p
blocks NNS 1_p
at IN 1_p
the DT 1_p
Department NNP 1_p
of IN 1_p
Child NNP 1_p
Health NNP 1_p
, , 1_p
University NNP 1_p
of IN 1_p
Dundee NNP 1_p
, , 1_p
Scotland NNP 1_p
, , N
were VBD N
randomized VBN N
to TO N
student-directed JJ 1_i
or CC 1_i
structured VBN 1_i
learning NN 1_i
between IN N
January NNP N
and CC N
December NNP N
2002 CD N
. . N

Pre- JJ 1_o
and CC 1_o
post-course JJ 1_o
tests NNS 1_o
were VBD N
administered VBN N
at IN N
the DT N
start NN N
and CC N
the DT N
end NN N
of IN N
the DT N
attachment NN N
; : N
129 CD 1_p
students NNS 1_p
sat VBD 1_p
both DT 1_p
tests NNS 1_p
. . 1_p

Results NNS N
are VBP N
presented VBN N
as IN N
mean JJ N
scores NNS N
with IN N
standard JJ N
deviations NNS N
or CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
in IN N
parentheses NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
gain NN 1_o
in IN 1_o
knowledge NN 1_o
of IN N
the DT N
Child NNP N
Health NNP N
core NN N
curriculum NN N
that WDT N
is VBZ N
covered VBN N
in IN N
the DT N
outpatient NN N
setting VBG N
. . N

Although IN N
pre-course JJ 1_o
scores NNS 1_o
were VBD N
similar JJ N
( ( N
student-directed JJ N
25.3 CD N
( ( N
7.3 CD N
) ) N
; : N
structured VBN N
24.8 CD N
( ( N
7.5 CD N
) ) N
) ) N
the DT N
structured JJ N
approach NN N
resulted VBD N
in IN N
higher JJR N
post-course NN 1_o
scores NNS 1_o
in IN N
comparison NN N
with IN N
the DT N
student-directed JJ N
approach NN N
( ( N
student-directed JJ N
41.8 CD N
( ( N
9.4 CD N
) ) N
; : N
structured VBN N
53.8 CD N
( ( N
8.8 CD N
) ) N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

Knowledge NNP 1_o
gain NN 1_o
showed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
learning NN N
approaches NNS N
( ( N
student-directed JJ N
16.5 CD N
( ( N
3.7 CD N
) ) N
; : N
structured VBN N
29.1 CD N
( ( N
3.8 CD N
) ) N
, , N
difference NN N
= VBD N
12.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.3 CD N
to TO N
13.9 CD N
) ) N
) ) N
. . N

Low JJ N
pre-course JJ 1_o
scores NNS 1_o
or CC N
gender VB N
did VBD N
not RB N
affect VB N
knowledge NN 1_o
gain NN 1_o
. . 1_o

In IN N
the DT N
Child NNP N
Health NNP N
outpatient NN N
setting NN N
, , N
the DT N
'traditional NNP N
' POS N
structured JJ N
approach NN N
led VBD N
to TO N
significantly RB N
greater JJR N
knowledge NN 1_o
gain NN 1_o
in IN N
comparison NN N
with IN N
the DT N
'novel NNP N
' POS N
student-directed JJ N
approach NN N
. . N

The DT N
findings NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
careful JJ N
evaluation NN N
of IN N
novel JJ N
medical JJ N
education NN N
strategies NNS N
before IN N
their PRP$ N
implementation NN N
in IN N
medical JJ N
schools NNS N
, , N
and CC N
the DT N
need NN N
for IN N
further JJ N
research NN N
to TO N
define VB N
the DT N
effective JJ N
methods NNS N
for IN N
delivering VBG N
medical JJ N
education NN N
in IN N
Child NNP N
Health NNP N
. . N

-DOCSTART- -X- O O

Repeated VBN N
doses NNS N
of IN N
porcine NN 1_i
secretin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
autism NN 1_p
: : 1_p
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Anecdotal NNP N
reports NNS N
on IN N
the DT N
efficacy NN N
of IN N
secretin NN 1_i
in IN N
autism NN N
raised VBN N
great JJ N
hopes NNS N
for IN N
the DT N
treatment NN N
of IN N
children NNS 1_p
with IN N
this DT N
disorder NN N
. . N

Initial JJ N
single-dose JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trials NNS N
failed VBD N
to TO N
demonstrate VB N
any DT N
therapeutic JJ N
effects NNS N
of IN N
secretin NN 1_i
. . 1_i

The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
test VB N
the DT N
outcome NN N
of IN N
repeated VBN N
doses NNS N
and CC N
to TO N
examine VB N
whether IN N
there EX N
is VBZ N
a DT N
subgroup NN N
of IN N
children NNS N
who WP N
are VBP N
more RBR N
likely JJ N
to TO N
achieve VB N
positive JJ N
effects NNS N
. . N

METHOD NNP N
Sixty-four JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
( ( 1_p
ages VBZ 1_p
2-7 CD 1_p
years NNS 1_p
; : 1_p
55 CD 1_p
boys NNS 1_p
and CC 1_p
9 CD 1_p
girls NNS 1_p
) ) 1_p
with IN 1_p
a DT 1_p
range NN 1_p
of IN 1_p
intelligence NN 1_p
quotient NN 1_p
and CC 1_p
verbal JJ 1_p
ability NN 1_p
were VBD N
randomly RB N
assigned VBN N
, , N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
to TO N
secretin VB 1_i
or CC 1_i
placebo VB 1_i
groups NNS N
. . N

Children NNP N
received VBD N
2 CD N
doses NNS N
of IN N
placebo NN 1_i
or CC 1_i
porcine NN 1_i
secretin NN 1_i
, , N
6 CD N
weeks NNS N
apart RB N
. . N

Assessments NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
3 CD N
weeks NNS N
after IN N
each DT N
injection NN N
using VBG N
several JJ N
outcome JJ N
measures NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
group NN N
differences VBZ N
on IN N
formal JJ 1_o
measures NNS 1_o
of IN 1_o
language NN 1_o
, , 1_o
cognition NN 1_o
, , 1_o
or CC 1_o
autistic JJ 1_o
symptomatology NN 1_o
. . 1_o

Subgroupings NNS N
based VBN N
on IN N
cognitive JJ 1_o
level NN 1_o
, , 1_o
the DT 1_o
presence NN 1_o
or CC 1_o
absence NN 1_o
of IN 1_o
diarrhea NN 1_o
, , N
or CC N
a DT N
history NN N
of IN N
regression NN 1_o
failed VBD N
to TO N
show VB N
any DT N
significant JJ N
therapeutic JJ N
effects NNS N
of IN N
secretin NN 1_i
. . 1_i

CONCLUSION NNP N
No DT N
evidence NN N
is VBZ N
provided VBN N
for IN N
the DT N
efficacy NN 1_o
of IN N
repeated JJ N
doses NNS N
of IN N
porcine NN 1_i
secretin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

The DT N
possible JJ N
relationship NN N
between IN N
relief NN N
of IN N
biological JJ 1_o
symptoms NNS 1_o
and CC N
enhanced VBD N
skill JJ 1_o
performance NN 1_o
is VBZ N
discussed VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
10 CD N
Hz NNP N
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
rTMS NN 1_i
) ) 1_i
on IN N
clinical JJ N
global JJ N
impression NN N
in IN N
chronic JJ 1_p
schizophrenia NN 1_p
. . 1_p

UNLABELLED IN N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
sham-controlled JJ N
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
rTMS NN 1_i
) ) 1_i
study NN N
in IN N
chronic JJ 1_p
schizophrenia NN 1_p
in-patients NNS 1_p
( ( 1_p
n=35 NN 1_p
) ) 1_p
to TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
10 CD 1_i
Hz NNP 1_i
stimulation NN N
. . N

Patients NNS 1_p
, , N
who WP N
were VBD N
on IN N
stable JJ 1_p
antipsychotic JJ 1_p
treatment NN 1_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
active JJ N
or CC N
sham JJ N
condition NN N
. . N

In IN N
the DT N
active JJ N
rTMS NN 1_i
group NN N
, , N
ten JJ N
sessions NNS N
with IN N
a DT N
total NN N
of IN N
10,000 CD N
stimuli NNS N
were VBD N
applied VBN N
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
at IN N
110 CD N
% NN N
of IN N
motor NN N
threshold NN N
. . N

The DT N
sham NN 1_i
group NN N
received VBD N
corresponding VBG N
sham JJ 1_i
stimulation NN 1_i
. . 1_i

Clinical JJ N
improvement NN N
was VBD N
measured VBN N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
scale NN N
( ( N
primary JJ N
outcome NN N
measure NN N
) ) N
, , N
the DT N
Global NNP N
Assessment NNP N
of IN N
Functioning NNP N
Scale NNP N
( ( N
GAF NNP N
) ) N
and CC N
the DT N
Positive NNP N
and CC N
Negative NNP N
Symptom NNP N
Scale NNP N
( ( N
PANSS NNP N
; : N
secondary JJ N
outcome NN N
measures NNS N
) ) N
. . N

Between-group JJ 1_o
comparisons NNS 1_o
revealed VBD 1_o
no DT 1_o
significant JJ 1_o
differences NNS 1_o
in IN 1_o
clinical JJ 1_o
outcome NN 1_o
variables NNS 1_o
. . 1_o

Only RB 1_o
a DT 1_o
subgroup NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
pronounced JJ 1_o
negative JJ 1_o
symptoms NNS 1_o
developed VBD 1_o
some DT 1_o
clinical JJ 1_o
improvement NN 1_o
as IN 1_o
indicated VBN 1_o
by IN 1_o
significant JJ 1_o
changes NNS 1_o
in IN 1_o
the DT 1_o
GAF-scale NNP 1_o
. . 1_o

Besides IN N
there EX 1_o
is VBZ 1_o
some DT 1_o
evidence NN 1_o
for IN 1_o
a DT 1_o
more RBR 1_o
favourable JJ 1_o
clinical JJ 1_o
outcome NN 1_o
within IN 1_o
this DT 1_o
subgroup NN 1_o
after IN 1_o
rTMS NN 1_o
in IN 1_o
the DT 1_o
CGI-S NNP 1_o
and CC 1_o
PANSS NNP 1_o
negative JJ 1_o
scale NN 1_o
, , 1_o
too RB 1_o
. . 1_o

In IN N
line NN N
with IN N
earlier JJR N
investigations NNS N
, , N
our PRP$ N
results NNS 1_o
suggest VBP 1_o
a DT 1_o
moderate JJ 1_o
- : 1_o
potentially RB 1_o
clinically RB 1_o
relevant JJ 1_o
- : 1_o
treatment NN 1_o
effect NN 1_o
of IN 1_o
prefrontal JJ 1_o
10 CD 1_o
Hz NNP 1_o
rTMS NN 1_o
stimulation NN 1_o
in IN 1_o
chronic JJ 1_o
patients NNS 1_o
. . 1_o

However RB N
, , N
in IN N
our PRP$ N
study NN N
this DT N
beneficial JJ N
effect NN N
was VBD N
restricted VBN N
to TO N
subjects NNS N
with IN N
pronounced JJ N
negative JJ N
symptoms NNS N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
INFORMATION NNP N
ClinicalTrial.gov NNP N
Identifier NNP N
: : N
NCT00169689 NNP N
, , N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
body NN 1_o
weight NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
: : 1_o
paradoxical JJ N
outcome NN N
events NNS N
in IN N
overweight NN 1_p
and CC 1_p
obese JJ 1_p
subjects NNS 1_p
with IN 1_p
cardiovascular JJ 1_p
disease NN 1_p
. . 1_p

BACKGROUND/OBJECTIVES IN N
The DT N
Sibutramine NNP N
Cardiovascular NNP N
OUTcomes NNP N
( ( N
SCOUT NNP N
) ) N
trial NN N
showed VBD N
a DT N
significantly RB N
increased VBN N
relative JJ N
risk NN N
of IN N
nonfatal JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
, , N
but CC N
not RB N
mortality NN 1_o
, , N
in IN N
overweight JJ 1_p
and CC 1_p
obese JJ 1_p
subjects NNS 1_p
receiving VBG 1_p
long-term JJ 1_i
sibutramine NN 1_i
treatment NN 1_i
with IN 1_i
diet JJ 1_i
and CC 1_i
exercise NN 1_i
. . 1_i

We PRP N
examined VBD N
the DT N
relationship NN N
between IN N
early JJ N
changes NNS N
( ( N
both DT N
increases NNS N
and CC N
decreases NNS N
) ) N
in IN N
body NN 1_o
weight NN 1_o
and CC N
blood NN 1_o
pressure NN 1_o
, , N
and CC N
the DT N
impact NN N
of IN N
these DT N
changes NNS N
on IN N
subsequent JJ N
cardiovascular JJ 1_o
outcome NN 1_o
events NNS 1_o
. . 1_o

SUBJECTS/METHODS VB N
A DT 1_p
total NN 1_p
of IN 1_p
9804 CD 1_p
male NN 1_p
and CC 1_p
female JJ 1_p
subjects NNS 1_p
, , 1_p
aged VBD 1_p
55 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
, , 1_p
with IN 1_p
a DT 1_p
body NN 1_p
mass NN 1_p
index NN 1_p
of IN 1_p
27-45 JJ 1_p
kg NNS 1_p
m NN 1_p
( ( 1_p
-2 NN 1_p
) ) 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
this DT 1_p
current JJ 1_p
subanalysis NN 1_p
of IN 1_p
the DT N
SCOUT NNP N
trial NN N
. . N

Subjects NNS N
were VBD N
required VBN 1_p
to TO 1_p
have VB 1_p
a DT 1_p
history NN 1_p
of IN 1_p
cardiovascular JJ 1_p
disease NN 1_p
and/or VBD 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
mellitus VBP 1_p
with IN 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
cardiovascular NN 1_p
risk NN 1_p
factor NN 1_p
( ( 1_p
hypertension NN 1_p
, , 1_p
dyslipidemia NN 1_p
, , 1_p
current JJ 1_p
smoking NN 1_p
or CC 1_p
diabetic JJ 1_p
nephropathy NN 1_p
) ) 1_p
to TO 1_p
assess VB N
cardiovascular JJ N
outcomes NNS N
. . N

Post NNP N
hoc NN N
subgroup NN N
analyses NNS 1_o
of IN 1_o
weight NN 1_o
change NN 1_o
( ( 1_o
categories NNS 1_o
) ) N
and CC N
blood NN 1_o
pressure NN 1_o
were VBD 1_o
performed VBN N
overall JJ N
and CC N
by IN N
treatment NN N
group NN N
( ( N
6-week JJ 1_i
sibutramine NN 1_i
followed VBN 1_i
by IN N
randomized JJ 1_i
placebo NN 1_i
or CC 1_i
continued JJ 1_i
sibutramine NN 1_i
) ) 1_i
. . 1_i

The DT 1_i
primary JJ 1_o
outcome NN 1_o
event NN 1_o
( ( 1_o
POE NNP 1_o
) ) 1_o
was VBD 1_o
a DT 1_o
composite NN 1_o
of IN 1_o
nonfatal JJ 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
nonfatal JJ 1_o
stroke NN 1_o
, , 1_o
resuscitated VBD 1_o
cardiac JJ 1_o
arrest NN 1_o
or CC 1_o
cardiovascular JJ 1_o
death NN 1_o
. . 1_o

Time-to-event JJ 1_o
analyses NNS N
of IN N
the DT N
POE NNP N
were VBD N
performed VBN N
using VBG N
Cox NNP N
regression NN N
models NNS N
with IN N
factors NNS N
for IN N
treatment NN N
, , N
subgroups NNS N
and CC N
interactions NNS N
. . N

RESULTS NNP N
During IN N
the DT N
initial JJ N
6-week JJ 1_i
sibutramine NN 1_i
treatment NN 1_i
period NN 1_o
, , 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
decreased VBD 1_o
progressively RB N
with IN N
increasing VBG 1_o
weight JJ 1_o
loss NN 1_o
in IN 1_o
hypertensive JJ N
subjects NNS N
( ( N
-8.1?10.5 JJ N
mm NN N
Hg NNP N
with IN N
< NNP N
5 CD N
kg NN N
weight NN N
loss NN N
to TO N
-10.8?11.0 VB N
mm JJ N
Hg NNP N
with IN N
?5 NNP N
kg FW N
weight JJ N
loss NN N
) ) N
. . N

The DT N
highest JJS 1_o
POE JJ 1_o
incidence NN 1_o
occurred VBD 1_o
mainly RB N
in IN N
groups NNS N
with IN N
increases NNS N
in IN N
both DT 1_o
weight NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
. . 1_o

However RB N
, , N
with IN N
long-term JJ 1_i
sibutramine NN 1_i
treatment NN 1_i
, , N
a DT N
markedly RB 1_o
lower JJR 1_o
blood NN 1_o
pressure NN 1_o
tended VBD 1_o
to TO N
increase VB 1_o
POEs NNP 1_o
. . 1_o

CONCLUSION NNP 1_o
Modest NNP 1_o
weight VBD 1_o
loss NN 1_o
and CC N
modest JJ N
lower JJR 1_o
blood NN 1_o
pressure NN 1_o
each DT 1_o
reduced VBD N
the DT N
incidence NN N
of IN N
cardiovascular JJ N
events NNS N
, , N
as IN N
expected VBN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
early JJ N
marked JJ 1_o
weight NN 1_o
loss NN 1_o
and CC N
rapid JJ 1_o
blood NN 1_o
pressure NN 1_o
reduction NN 1_o
seems VBZ N
to TO N
be VB N
harmful JJ N
in IN N
this DT 1_p
obese JJ 1_p
elderly JJ 1_p
cardiovascular NN 1_p
diseased VBD 1_p
population NN 1_p
. . N

-DOCSTART- -X- O O

Scintigraphic JJ N
evaluation NN N
of IN N
a DT N
new JJ 1_i
capsule-type JJ 1_i
colon NN 1_i
specific JJ 1_i
drug NN 1_i
delivery NN 1_i
system NN 1_i
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

Colonic JJ 1_i
drug NN 1_i
delivery NN 1_i
is VBZ N
intended VBN N
for IN N
local JJ N
or CC N
systemic JJ N
therapies NNS N
. . N

The DT N
lack NN N
of IN N
predictive NN N
in IN N
vitro NN N
or CC N
animal JJ N
model NN N
leads VBZ N
to TO N
considerable JJ N
time NN N
delays NNS N
in IN N
colonic JJ N
product NN N
development NN N
. . N

The DT N
objective NN N
of IN N
this DT N
scintigraphic JJ N
study NN N
was VBD N
to TO N
provide VB N
proof NN N
of IN N
concept NN N
for IN N
a DT N
novel JJ 1_i
capsule-type JJ 1_i
colonic NN 1_i
delivery NN 1_i
system NN 1_i
( ( 1_i
Colon-Targeted JJ 1_i
Delivery NNP 1_i
Capsule NNP 1_i
) ) 1_i
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

The DT N
human JJ N
data NN N
validates VBZ N
the DT N
design NN N
concept NN N
behind IN N
the DT N
release NN N
mechanism NN N
, , N
in IN N
that DT N
capsule NN N
disintegration NN N
, , N
and CC N
hence RB N
drug NN 1_o
release NN 1_o
, , N
did VBD N
not RB N
start VB N
until IN N
5 CD N
h NNS N
after IN N
gastric JJ N
emptying NN N
, , N
irrespective NN N
of IN N
whether IN N
the DT N
product NN N
was VBD N
administered VBN N
to TO N
fasted VBN N
or CC N
fed VBN N
subjects NNS N
. . N

However RB N
, , N
the DT N
potential NN N
for IN N
prolonged JJ N
gastric JJ N
residence NN N
for IN N
large JJ N
enteric JJ N
coated VBN N
products NNS N
intended VBN N
for IN N
intestinal JJ N
targeting NN N
was VBD N
also RB N
observed VBN N
; : N
overall JJ N
, , N
the DT N
study NN N
provides VBZ N
a DT N
focus NN N
for IN N
subsequent JJ N
product NN N
development NN N
and CC N
highlights NNS N
the DT N
role NN N
of IN N
scintigraphy NN N
in IN N
dynamically RB N
visualizing VBG N
the DT N
drug NN N
delivery NN N
process NN N
. . N

-DOCSTART- -X- O O

Absorption NN 1_o
of IN 1_o
intramuscular JJ 1_o
phenobarbitone NN 1_o
in IN N
children NNS 1_p
with IN 1_p
severe JJ 1_p
falciparum NN 1_p
malaria NN 1_p
. . 1_p

The DT N
absorption NN 1_o
of IN 1_o
intramuscular JJ 1_o
phenobarbitone NN 1_o
7 CD 1_i
mg.kg-1 NN 1_i
was VBD N
studied VBN N
in IN N
11 CD 1_p
Karen NNP 1_p
children NNS 1_p
aged VBD 1_p
between IN 1_p
1.7 CD 1_p
and CC 1_p
11 CD 1_p
y NN 1_p
with IN 1_p
severe JJ 1_p
falciparum NN 1_p
malaria NN 1_p
. . 1_p

Eight CD 1_p
of IN 1_p
the DT 1_p
children NNS 1_p
were VBD 1_p
comatose JJ 1_p
. . 1_p

Clinical JJ N
findings NNS N
were VBD N
compared VBN N
with IN N
those DT N
in IN N
9 CD 1_p
further JJ 1_p
children NNS 1_p
with IN 1_p
severe JJ 1_p
malaria NNS 1_p
of IN 1_p
similar JJ 1_p
age NN 1_p
range NN 1_p
( ( 1_p
four CD 1_p
of IN 1_p
whom WP 1_p
were VBD 1_p
unconscious JJ 1_p
) ) 1_p
, , N
who WP N
received VBD N
an DT N
identical JJ 1_i
placebo NN 1_i
. . 1_i

One CD N
child NN N
, , N
who WP N
had VBD N
received VBN N
placebo NN N
, , N
had VBD N
repeated VBN 1_o
convulsions NNS 1_o
and CC N
died VBD N
1 CD N
h NN N
after IN N
admission NN N
to TO N
hospital NN N
. . N

The DT N
remainder NN N
made VBD N
an DT N
uncomplicated JJ 1_o
recovery NN 1_o
. . 1_o

There EX N
were VBD N
no DT N
convulsions NNS 1_o
subsequent VBP N
to TO N
treatment NN N
, , N
although IN N
the DT N
study NN N
was VBD N
too RB N
small JJ N
to TO N
assess VB N
anticonvulsant JJ N
efficacy NN N
. . N

There EX N
was VBD N
no DT N
observable JJ N
toxicity NN 1_o
, , N
but CC N
phenobarbitone NN N
recipients NNS N
had VBD N
a DT N
significant JJ N
tendency NN N
to TO N
deepen VB N
in IN N
their PRP$ N
level NN 1_o
of IN 1_o
coma NN 1_o
or CC N
to TO N
become VB 1_o
sleepy NN 1_o
within IN N
the DT N
4 CD N
h NN N
after IN N
drug NN N
administration NN N
. . N

Phenobarbitone NNP N
was VBD N
rapidly RB N
absorbed VBN N
, , N
reaching VBG N
a DT N
mean NN N
( ( N
range NN N
) ) N
peak NN N
concentration NN N
of IN N
34.2 CD N
[ JJ N
29.3-42.6 JJ N
] JJ N
mumol.l-1 NN N
in IN N
a DT N
median NN N
( ( N
range NN N
) ) N
of IN N
4 CD N
( ( N
2.5-12 CD N
) ) N
h. NN N
These DT N
values NNS N
are VBP N
comparable JJ N
to TO N
those DT N
previously RB N
reported VBN N
in IN N
healthy JJ N
children NNS N
and CC N
in IN N
children NNS N
with IN N
febrile JJ 1_o
convulsions NNS 1_o
. . 1_o

Intramuscular NNP N
phenobarbitone NN N
is VBZ N
well RB N
absorbed VBN N
in IN N
children NNS 1_p
with IN 1_p
severe JJ 1_p
malaria NNS 1_p
; : 1_p
the DT N
optimum JJ N
prophylactic JJ N
anticonvulsant NN N
dose NN N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

-DOCSTART- -X- O O

Middle NNP 1_o
cerebral JJ 1_o
arterial JJ 1_o
blood NN 1_o
flow NN 1_o
velocity NN 1_o
and CC 1_o
hemodynamics NNS 1_o
in IN N
heart NN N
surgery NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
propofol NN 1_i
, , 1_i
isoflurane NN 1_i
, , 1_i
and CC 1_i
sevoflurane NN 1_i
on IN N
middle JJ 1_o
cerebral JJ 1_o
arterial JJ 1_o
blood NN 1_o
flow NN 1_o
velocity NN 1_o
during IN N
open JJ 1_p
heart NN 1_p
surgery NN 1_p
, , N
and CC N
the DT N
relationship NN N
between IN N
these DT N
effects NNS N
and CC N
hemodynamic JJ N
parameters NNS N
. . N

Fifty-two JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
on IN 1_p
cardiopulmonary JJ 1_p
bypass NN 1_p
were VBD N
divided VBN N
randomly RB N
into IN N
3 CD N
groups NNS N
: : N
the DT N
first JJ N
group NN 1_i
received VBD 1_i
100 CD 1_i
microg NNS 1_i
x JJ 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
x VBP 1_i
min NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
propofol NN 1_i
, , 1_i
the DT 1_i
other JJ 1_i
groups NNS 1_i
received VBD 1_i
one CD 1_i
minimum NN 1_i
alveolar JJ 1_i
concentration NN 1_i
of IN 1_i
sevoflurane NN 1_i
or CC 1_i
isoflurane NN 1_i
for IN 1_i
anesthesia JJ 1_i
maintenance NN 1_i
. . 1_i

Middle NNP 1_o
cerebral JJ 1_o
arterial JJ 1_o
blood NN 1_o
flow NN 1_o
velocities NNS 1_o
were VBD N
measured VBN N
by IN N
transcranial JJ N
Doppler NNP N
, , N
and CC N
hemodynamics NNS 1_o
were VBD N
measured VBN N
by IN N
the DT N
thermodilution NN N
technique NN N
. . N

Middle NNP 1_o
cerebral JJ 1_o
arterial JJ 1_o
blood NN 1_o
flow NN 1_o
velocities NNS 1_o
decreased VBN N
significantly RB N
after IN N
administration NN N
of IN N
isoflurane NN N
and CC N
propofol NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
. . N

After IN N
weaning VBG N
from IN N
cardiopulmonary JJ N
bypass NN N
, , N
cerebral JJ 1_o
blood NN 1_o
flow NN 1_o
increased VBD 1_o
and CC N
came VBD N
close RB N
to TO N
the DT N
value NN N
after IN N
induction NN N
in IN N
all DT N
groups NNS N
. . N

The DT N
pulsatility NN 1_o
index NN 1_o
and CC 1_o
resistivity NN 1_o
index NN 1_o
increased VBD N
significantly RB N
only RB N
after IN N
the DT N
propofol NN N
infusion NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Parenteral NNP 1_i
amino NN 1_i
acid NN 1_i
and CC N
metabolic JJ N
acidosis NN N
in IN N
premature JJ 1_p
infants NNS 1_p
. . 1_p

BACKGROUND NNP N
Aggressive NNP 1_i
parenteral JJ 1_i
nutrition NN 1_i
( ( 1_i
PN NNP 1_i
) ) 1_i
including VBG 1_i
amino JJ 1_i
acids NNS 1_i
is VBZ N
recommended VBN N
for IN N
low-birth-weight JJ 1_p
infants NNS 1_p
to TO N
prevent VB N
energy NN N
and CC N
protein NN N
deficit NN N
. . N

Their PRP$ N
impact NN N
on IN N
acid-base JJ N
homeostasis NN N
has VBZ N
not RB N
been VBN N
examined VBN N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
impact NN N
of IN N
dose NN N
and CC N
duration NN N
of IN N
parenteral JJ 1_i
amino NN 1_i
acids NNS 1_i
, , 1_i
with IN 1_i
cysteine NN 1_i
, , N
on IN N
acid-base JJ N
parameters NNS N
in IN N
122 CD 1_p
low-birth-weight JJ 1_p
infants NNS 1_p
. . 1_p

Premature NN 1_p
infants NNS 1_p
< VBP 1_p
or=32 JJ 1_p
weeks NNS 1_p
, , 1_p
< NNP 1_p
or=1850 MD 1_p
g VB 1_p
, , 1_p
and CC 1_p
receiving VBG 1_p
parenteral JJ 1_i
amino NN 1_i
acids NNS 1_i
at IN 1_p
1.5 CD 1_p
g/kg/d NN 1_p
for IN 1_p
an DT 1_p
extended JJ 1_p
period NN 1_p
( ( 1_p
> JJ 1_p
24 CD 1_p
hours NNS 1_p
) ) 1_p
, , 1_p
or CC 1_p
3 CD 1_p
g/kg/d NN 1_p
for IN 1_p
a DT 1_p
short JJ 1_p
( ( 1_p
5 CD 1_p
hour NN 1_p
) ) 1_p
, , 1_p
extended VBD 1_p
( ( 1_p
24 CD 1_p
hour NN 1_p
) ) 1_p
, , 1_p
or CC 1_p
prolonged VBN 1_p
( ( 1_p
3-5 JJ 1_p
days NNS 1_p
) ) 1_p
duration NN 1_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Data NNS N
were VBD N
obtained VBN N
at IN N
age NN N
0-3 JJ N
days NNS N
( ( N
n JJ N
= NNP N
43 CD N
) ) N
or CC N
, , N
when WRB N
clinically RB N
stable JJ N
, , N
age NN N
3-5 JJ N
days NNS N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

Data NNS N
from IN N
30 CD 1_p
infants NNS 1_p
, , 1_p
matched VBN 1_p
for IN 1_p
birth NN 1_p
weight NN 1_p
and CC 1_p
gestational JJ 1_p
age NN 1_p
, , 1_p
receiving VBG 1_p
PN NNP 1_i
during IN 1_p
the DT 1_p
first JJ 1_p
5 CD 1_p
days NNS 1_p
after IN 1_p
birth NN 1_p
were VBD N
also RB N
obtained VBN N
. . N

Acidosis NNP N
was VBD N
defined VBN N
as IN N
pH NN N
< $ N
7.25 CD N
. . N

RESULTS JJ N
Acidosis NNP 1_o
was VBD N
evident JJ N
in IN N
all DT N
infants NNS N
between IN N
2 CD N
and CC N
5 CD N
days NNS N
after IN N
birth NN N
. . N

Infants NNS 1_p
with IN 1_p
large JJ 1_p
patent NN 1_p
ductus NN 1_p
arteriosus NN 1_p
( ( 1_p
PDA NNP 1_p
) ) 1_p
exhibited VBD N
significantly RB N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
lower JJR 1_o
pH NN 1_o
early RB N
, , N
had VBD N
higher JJR N
blood NN 1_o
urea JJ 1_o
nitrogen NN 1_o
levels NNS 1_o
( ( N
26 CD N
+/- JJ N
9 CD N
vs NN N
18 CD N
+ NN N
8 CD N
mg/dL NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
, , N
and CC N
had VBD N
greater JJR 1_o
weight JJ 1_o
loss NN 1_o
( ( N
approximately RB N
17 CD N
% NN N
of IN N
birth NN N
weight NN N
) ) N
when WRB N
compared VBN N
with IN N
infants NNS N
without IN N
PDA NNP N
. . N

Gestational NNP 1_o
age NN 1_o
, , 1_o
weight JJ 1_o
loss NN 1_o
, , 1_o
and CC 1_o
patent NN 1_o
ductus NN 1_o
arteriosus NN 1_o
accounted VBD N
for IN N
65 CD N
% NN N
of IN N
variance NN N
in IN N
acidosis NN N
. . N

CONCLUSIONS NNP N
Low-birth-weight JJ 1_p
infants NNS 1_p
develop VB N
metabolic JJ N
acidosis NN N
between IN N
2 CD N
and CC N
5 CD N
days NNS N
after IN N
birth NN N
, , N
irrespective NN N
of IN N
dose NN N
and CC N
duration NN N
of IN N
parenteral JJ 1_i
amino NN 1_i
acid JJ 1_i
administration NN 1_i
. . 1_i

Careful JJ N
management NN N
of IN N
parenteral JJ 1_i
fluids NNS 1_i
and CC N
comorbidities NNS N
may MD N
lower VB N
the DT N
incidence NN N
of IN N
acidosis NN N
and CC N
promote NN N
protein NN N
accretion NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
surgical JJ 1_i
staging NN 1_i
in IN N
evaluating VBG N
the DT N
radiotherapeutic JJ N
outcome NN N
in IN N
RTOG NNP N
# # N
77-06 NNP N
, , N
a DT N
phase NN N
III NNP N
study NN N
for IN N
T1BN0M0 NNP N
( ( N
A2 NNP N
) ) N
and CC N
T2N0M0 NNP N
( ( N
B NNP N
) ) N
prostate NN N
carcinoma NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
survival NN N
and CC N
time NN N
to TO N
metastatic JJ N
disease NN N
in IN N
patients NNS 1_p
treated VBN 1_p
for IN 1_p
localized JJ 1_p
prostatic JJ 1_p
carcinoma NN 1_p
in IN 1_p
a DT 1_p
Phase NNP 1_i
III NNP 1_i
radiotherapy NN 1_i
( ( 1_p
RT NNP 1_p
) ) 1_p
protocol NN 1_p
, , 1_p
Radiation NNP 1_i
Therapy NNP 1_i
Oncology NNP 1_i
Group NNP 1_i
( ( 1_p
RTOG NNP 1_p
) ) 1_p
77-06 NN 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
T18N0M0 NNP 1_p
( ( 1_p
A2 NNP 1_p
) ) 1_p
or CC 1_p
T2N0M0 NNP 1_p
( ( 1_p
B NNP 1_p
) ) 1_p
disease NN 1_p
after IN 1_p
lymphangiogram NN 1_p
( ( 1_p
LAG NNP 1_p
) ) 1_p
or CC 1_p
staging VBG 1_p
laparotomy NN 1_p
( ( 1_p
SL NNP 1_p
) ) 1_p
were VBD 1_p
randomized VBN 1_p
between IN 1_p
prophylactic JJ 1_p
radiation NN 1_p
to TO 1_p
the DT 1_p
pelvic JJ 1_p
lymph NN 1_p
nodes NNS 1_p
and CC 1_p
prostatic JJ 1_p
bed NN 1_p
vs. FW 1_p
prostatic JJ 1_p
bed NN 1_p
alone RB 1_p
. . 1_p

The DT N
outcome NN N
of IN N
both DT N
treatment NN N
arms NNS N
, , N
as RB N
well RB N
as IN N
a DT N
comparison NN N
of IN N
the DT N
LAG NNP N
group NN N
, , N
to TO N
that DT N
of IN N
the DT N
SL NNP N
group NN N
, , N
are VBP N
updated VBN N
. . N

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
449 CD 1_p
eligible JJ 1_p
males NNS 1_p
were VBD 1_p
entered VBN 1_p
into IN 1_p
RTOG NNP 1_p
protocol NN 1_p
7706 CD 1_p
between IN 1_p
1978 CD 1_p
and CC 1_p
1983 CD 1_p
. . 1_p

Lymph NNP N
node IN N
staging VBG N
was VBD N
mandatory JJ N
but CC N
at IN N
the DT N
physician NN N
's POS N
discretion NN N
; : N
117 CD 1_p
( ( 1_p
26 CD 1_p
% NN 1_p
) ) 1_p
patients NNS 1_p
had VBD 1_p
SL NNP 1_p
, , 1_p
while IN 1_p
332 CD 1_p
( ( 1_p
74 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
LAG NNP 1_p
. . 1_p

Follow-up NNP N
was VBD N
a DT N
median NN N
of IN N
12 CD N
years NNS N
and CC N
a DT N
maximum NN N
of IN N
16 CD N
years NNS N
. . N

For IN N
those DT N
randomized VBN N
to TO N
receive VB N
prophylactic JJ N
pelvic NNS N
lymph VBP N
nodal JJ N
irradiation NN N
, , N
45 CD N
Gy NNP N
of IN N
megavoltage NN N
RT NNP N
was VBD N
delivered VBN N
via IN N
multiple JJ N
portals NNS N
in IN N
4.5-5 JJ N
weeks NNS N
, , N
while IN N
all DT N
patients NNS N
received VBD N
65 CD N
Gy NNP N
in IN N
6.5-8 JJ N
weeks NNS N
to TO N
the DT N
prostatic JJ N
bed NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
survival JJ 1_o
whether IN N
treatment NN N
was VBD N
administered VBN N
to TO N
the DT N
prostate NN N
or CC N
prostate NN N
and CC N
pelvic JJ N
lymph NN N
nodes NNS N
. . N

The DT N
SL NNP N
group NN N
had VBD N
greater JJR N
12-year JJ 1_o
survival NN 1_o
than IN N
the DT N
LAG NNP N
group NN N
( ( N
48 CD N
% NN N
vs. FW N
38 CD N
% NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

Disease-free JJ 1_o
survival NN 1_o
was VBD N
statistically RB N
significant JJ N
, , N
with IN N
38 CD N
% NN N
for IN N
the DT N
SL NNP N
group NN N
vs. FW N
26 CD N
% NN N
for IN N
the DT N
LAG NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Bone NNP 1_o
metastasis NN 1_o
was VBD N
less JJR N
common JJ N
in IN N
the DT N
SL NNP N
group NN N
( ( N
14 CD N
% NN N
) ) N
than IN N
the DT N
LAG NNP N
group NN N
( ( N
27 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSION NN N
At IN N
12-year JJ N
median JJ N
follow-up NN N
, , N
there EX N
still RB N
was VBD N
no DT N
survival JJ N
difference NN N
in IN N
those DT N
patients NNS N
treated VBD N
prophylactically RB N
to TO N
the DT N
pelvic JJ N
nodes NNS N
and CC N
prostatic JJ N
bed NN N
vs. IN N
the DT N
prostatic JJ N
bed NN N
alone RB N
. . N

Those DT N
patients NNS N
not RB N
surgically RB N
staged VBN N
with IN N
only RB N
LAG NNP N
for IN N
lymph JJ N
node JJ N
evaluation NN N
were VBD N
less RBR N
accurately RB N
staged VBN N
, , N
as IN N
reflected VBN N
by IN N
a DT N
statistically RB N
significant JJ N
reduced VBN N
survival NN N
and CC N
earlier JJR N
metastases NNS N
. . N

-DOCSTART- -X- O O

The DT N
double-blind JJ N
sham-controlled JJ N
study NN N
of IN N
high-frequency NN 1_i
rTMS NN 1_i
( ( N
20 CD N
Hz NNP N
) ) N
for IN N
negative JJ N
symptoms NNS N
in IN N
schizophrenia NN 1_p
: : 1_p
negative JJ N
results NNS N
. . N

The DT N
high-frequency NN 1_i
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
HF-rTMS NNP 1_i
) ) 1_i
over IN N
the DT N
prefrontal JJ N
cortex NN N
is VBZ N
a DT N
promising JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN 1_p
. . 1_p

Using VBG N
double-blind JJ N
sham-controlled JJ N
parallel NN N
design NN N
, , N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
HF-rTMS NNP 1_i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
on IN N
negative JJ N
symptoms NNS N
in IN N
patients NNS 1_p
with IN 1_p
schizophrenia NN 1_p
. . 1_p

Sixteen NNP 1_p
schizophrenia NN 1_p
patients NNS 1_p
with IN 1_p
predominantly RB 1_p
negative JJ 1_p
symptoms NNS 1_p
on IN 1_p
stable JJ 1_p
antipsychotic JJ 1_p
medication NN 1_p
were VBD N
treated VBN N
with IN N
20 CD 1_i
Hz NNP 1_i
rTMS NN 1_i
( ( N
90 CD N
% NN N
of IN N
motor NN N
threshold NN N
, , N
2000 CD N
stimuli NN N
per IN N
session NN N
) ) N
over IN N
ten JJ N
days NNS N
within IN N
2 CD N
weeks NNS N
with IN N
six CD N
weeks NNS N
follow-up RB N
. . N

The DT N
effect NN N
was VBD N
assessed VBN N
using VBG N
PANSS NNP 1_o
, , 1_o
CGI NNP 1_o
, , 1_o
MADRS NNP 1_o
and CC 1_o
neuropsychological JJ 1_o
tests NNS 1_o
. . 1_o

We PRP N
failed VBD N
to TO N
find VB N
any DT N
significant JJ N
effect NN N
of IN N
active JJ 1_o
rTMS NN 1_o
. . 1_o

Sham NNP 1_o
rTMS NN 1_o
showed VBD N
a DT N
trend NN N
for IN N
improvement NN 1_o
over IN 1_o
time NN 1_o
on IN N
positive JJ 1_o
and CC 1_o
negative JJ 1_o
subscales NNS 1_o
of IN 1_o
PANSS NNP 1_o
and CC 1_o
MADRS NNP 1_o
. . 1_o

Between-group NNP N
comparisons NNS N
failed VBD N
to TO N
reveal VB N
any DT N
significant JJ N
differences NNS N
on IN N
any DT N
rating NN 1_o
scales NNS 1_o
except IN N
a DT N
positive JJ 1_o
subscale NN 1_o
of IN 1_o
PANSS NNP 1_o
after IN N
8 CD N
weeks NNS N
. . N

Results NNS N
from IN N
our PRP$ N
study NN N
did VBD N
not RB N
confirm VB N
that IN N
HF-rTMS NNP 1_o
over IN N
the DT N
left JJ N
DLPCF NNP 1_o
affects VBZ 1_o
the DT 1_o
negative JJ 1_o
symptoms NNS 1_o
of IN 1_o
schizophrenia NN 1_o
and CC N
alternative JJ N
rTMS NN N
approaches NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Hepatorenal JJ N
syndrome NN N
. . N

Studies NNS N
of IN N
the DT N
effect NN N
of IN N
vascular JJ N
volume NN N
and CC N
intraperitoneal JJ N
pressure NN N
on IN N
renal JJ 1_o
and CC 1_o
hepatic JJ 1_o
function NN 1_o
. . 1_o

Eleven JJ 1_p
patients NNS 1_p
with IN 1_p
well-documented JJ 1_p
hepatorenal JJ 1_p
syndrome NN 1_p
were VBD N
studied VBN N
by IN N
measurement NN N
of IN N
blood NN 1_o
volume NN 1_o
, , 1_o
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
, , 1_o
renal JJ 1_o
plasma NN 1_o
flow NN 1_o
, , 1_o
plasma VBP 1_o
aldosterone JJ 1_o
concentration NN 1_o
, , 1_o
renin JJ 1_o
substrate NN 1_o
concentration NN 1_o
, , 1_o
and CC 1_o
plasma JJ 1_o
renin NN 1_o
activity NN 1_o
. . 1_o

They PRP N
were VBD N
then RB N
given VBN N
750 CD 1_i
ml NN 1_i
of IN 1_i
stored JJ 1_i
plasma NN 1_i
, , 1_i
750 CD 1_i
ml NN 1_i
of IN 1_i
fresh JJ 1_i
frozen JJ 1_i
plasma NN 1_i
, , 1_i
and CC 1_i
then RB 1_i
an DT 1_i
infusion NN 1_i
of IN 1_i
angiotensin NN 1_i
II NNP 1_i
, , N
in IN N
random JJ N
order NN N
on IN N
successive JJ N
days NNS N
. . N

Infusion NN 1_i
of IN 1_i
fresh JJ 1_i
frozen JJ 1_i
plasma NN 1_i
improved VBD N
function NN N
more RBR N
than IN N
did VBD N
stored VBN N
plasma NN N
and CC N
in IN N
addition NN N
returned VBD N
a DT N
very RB N
low JJ N
filtration NN N
fraction NN N
toward IN N
normal JJ N
. . N

Angiotensin NNP 1_i
II NNP 1_i
infusion NN 1_i
increased VBD N
filtration NN 1_o
fraction NN 1_o
, , N
but CC N
decreased VBD N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
, , 1_o
renal JJ 1_o
plasma NN 1_o
flow NN 1_o
, , 1_o
and CC 1_o
urine JJ 1_o
flow NN 1_o
sharply RB N
. . N

Patients NNS N
were VBD N
then RB N
given VBN N
a DT N
daily JJ N
infusion NN N
of IN N
1,000 CD 1_i
ml NNS 1_i
of IN 1_i
fresh JJ 1_i
frozen JJ 1_i
plasma NN 1_i
for IN N
seven CD N
to TO N
18 CD N
days NNS N
to TO N
expand VB N
the DT N
blood NN N
volume NN N
to TO N
supranormal JJ N
levels NNS N
as IN N
assayed VBN N
by IN N
serial JJ N
measurement NN N
of IN N
blood NN N
volume NN N
. . N

Plasma NNP 1_o
aldosterone NN 1_o
levels NNS 1_o
decreased VBN N
to TO N
a DT N
normal JJ N
range NN N
, , N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
and CC 1_o
renal JJ 1_o
plasma NN 1_o
flow NN 1_o
both DT N
increased VBN N
, , N
and CC N
urinary JJ 1_o
excretion NN 1_o
of IN 1_o
sodium NN 1_o
and CC 1_o
potassium NN 1_o
both DT N
returned VBN N
toward IN N
normal JJ N
. . N

The DT N
effect NN N
of IN N
intraperitoneal JJ 1_o
pressure NN 1_o
was VBD N
then RB N
studied VBN N
by IN N
measuring VBG N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
, , 1_o
renal JJ 1_o
plasma NN 1_o
flow NN 1_o
, , 1_o
pressure NN 1_o
in IN 1_o
the DT 1_o
vena NN 1_o
cava NN 1_o
, , 1_o
hepatic JJ 1_o
vein NN 1_o
free JJ 1_o
flow NN 1_o
, , 1_o
and CC 1_o
hepatic JJ 1_o
vein NNS 1_o
wedged VBD 1_o
pressure NN 1_o
before IN N
, , N
during IN N
, , N
and CC N
after IN N
paracentesis NN N
to TO N
reduce VB N
the DT N
intraperitoneal JJ N
pressure NN N
from IN N
30 CD N
to TO N
40 CD N
cm NNS N
H2O NNP N
to TO N
12 CD N
to TO N
17 CD N
cm NN N
H2O NNP N
. . N

Venous JJ 1_o
pressures NNS 1_o
moved VBD N
parallel RB N
to TO N
ascitic JJ 1_o
fluid NN 1_o
pressures NNS 1_o
, , N
and CC N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
, , 1_o
renal JJ 1_o
plasma NN 1_o
flow NN 1_o
, , 1_o
and CC 1_o
urine JJ 1_o
flow NN 1_o
all DT N
improved VBD N
sharply RB N
; : N
then RB N
, , N
as IN N
ascitic JJ N
fluid NN N
continued VBD N
to TO N
form VB N
, , N
reducing VBG N
vascular JJ 1_o
volume NN 1_o
, , 1_o
urine JJ 1_o
flow NN 1_o
, , 1_o
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
renal JJ 1_o
plasma NN 1_o
flow NN 1_o
all DT N
decreased VBD N
slowly RB N
. . N

Six CD N
patients NNS N
then RB N
underwent JJ N
placement NN N
of IN N
a DT N
LeVeen NNP N
shunt NN N
. . N

Improvement NN N
in IN N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
and CC 1_o
renal JJ 1_o
plasma NN 1_o
flow NN 1_o
and CC 1_o
clinical JJ 1_o
condition NN 1_o
was VBD N
dramatic JJ N
. . N

During IN N
postoperative JJ N
observation NN N
of IN N
up IN N
to TO N
two CD N
years NNS N
, , N
progressive JJ N
improvement NN N
in IN N
hepatic JJ 1_o
function NN 1_o
has VBZ N
occurred VBN N
. . N

-DOCSTART- -X- O O

REVIVE JJ N
Trial NN N
: : N
Retrograde JJ N
Delivery NNP N
of IN N
Autologous NNP N
Bone NNP N
Marrow NNP N
in IN N
Patients NNP 1_p
With IN 1_p
Heart NNP 1_p
Failure NNP 1_p
. . 1_p

UNLABELLED NNP N
Cell NNP 1_i
therapy NN 1_i
is VBZ N
an DT N
evolving VBG N
option NN N
for IN N
patients NNS 1_p
with IN 1_p
end-stage JJ 1_p
heart NN 1_p
failure NN 1_p
and CC 1_p
ongoing NN 1_p
symptoms NNS 1_p
despite IN 1_p
optimal JJ 1_p
medical JJ 1_p
therapy NN 1_p
. . 1_p

Our PRP$ N
goal NN N
was VBD N
to TO N
evaluate VB N
retrograde VB N
bone NN N
marrow NN N
cell NN N
delivery NN N
in IN N
patients NNS 1_p
with IN 1_p
either DT 1_p
ischemic JJ 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
IHF NNP 1_p
) ) 1_p
or CC 1_p
nonischemic JJ 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
NIHF NNP 1_p
) ) 1_p
. . 1_p

This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
, , N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
the DT N
safety NN N
and CC N
feasibility NN N
of IN N
bone NN 1_i
marrow NN 1_i
aspirate NN 1_i
concentrate NN 1_i
( ( N
BMAC NNP N
) ) N
infused VBD N
retrograde NN 1_i
into IN N
the DT N
coronary JJ N
sinus NN N
. . N

Sixty JJ 1_p
patients NNS 1_p
were VBD 1_p
stratified VBN 1_p
by IN 1_p
IHF NNP 1_p
and CC 1_p
NIHF NNP 1_p
and CC N
randomized VBN N
to TO N
receive VB N
either DT N
BMAC NNP 1_i
infusion NN 1_i
or CC N
control NN 1_i
( ( N
standard JJ N
heart NN N
failure NN N
care NN N
) ) N
in IN N
a DT N
4:1 CD N
ratio NN N
. . N

Accordingly RB N
, , N
24 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
ischemic JJ N
BMAC NNP N
group NN N
and CC N
6 CD N
to TO N
the DT N
ischemic JJ N
control NN N
group NN N
. . N

Similarly RB N
, , N
24 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
nonischemic JJ N
BMAC NNP N
group NN N
and CC N
6 CD N
to TO N
the DT N
nonischemic JJ N
control NN N
group NN N
. . N

All DT 1_p
60 CD 1_p
patients NNS 1_p
were VBD 1_p
successfully RB 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
treatment NN N
groups NNS N
received VBD N
BMAC NNP 1_i
infusion NN 1_i
without IN N
complications NNS N
. . N

The DT N
left JJ 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
in IN N
the DT N
patients NNS N
receiving VBG N
BMAC NNP N
demonstrated VBD N
significant JJ 1_o
improvement NN 1_o
compared VBN N
with IN N
baseline NN N
, , N
from IN N
25.1 CD N
% NN N
at IN N
screening VBG N
to TO N
31.1 CD N
% NN N
at IN N
12 CD N
months NNS N
( ( N
p=.007 NN N
) ) N
in IN N
the DT N
NIHF NNP N
group NN N
and CC N
from IN N
26.3 CD N
% NN N
to TO N
31.1 CD N
% NN N
in IN N
the DT N
IHF NNP N
group NN N
( ( N
p=.035 NN N
) ) N
. . N

The DT N
end-systolic JJ 1_o
diameter NN 1_o
decreased VBN 1_o
significantly RB 1_o
in IN N
the DT N
nonischemic JJ N
BMAC NNP 1_i
group NN N
from IN N
55.6 CD N
to TO N
50.9 CD N
mm NN N
( ( N
p=.020 NN N
) ) N
. . N

Retrograde NNP N
BMAC NNP N
delivery NN 1_o
is VBZ 1_o
safe JJ 1_o
. . 1_o

All DT N
patients NNS N
receiving VBG N
BMAC NNP N
experienced VBD 1_o
improvements NNS 1_o
in IN N
left JJ 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
, , N
but CC N
only RB N
those DT N
with IN N
NIHF NNP N
showed VBD N
improvements NNS 1_o
in IN N
left JJ 1_o
ventricular JJ 1_o
end-systolic JJ 1_o
diameter NN 1_o
and CC 1_o
B-type NNP 1_o
natriuretic JJ 1_o
peptide NN 1_o
. . 1_o

These DT N
results NNS N
provide VBP N
the DT N
basis NN N
for IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
in IN N
HF NNP N
patients NNS N
. . N

SIGNIFICANCE VB N
This DT N
work NN N
is VBZ N
the DT N
first JJ N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
using VBG N
high-dose JJ N
cell NN N
therapy NN N
delivered VBN N
via IN N
a DT N
retrograde JJ N
coronary JJ N
sinus NN N
infusion NN N
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

This DT N
was VBD N
a DT N
multinational JJ N
, , N
multicenter NN N
study NN N
, , N
and CC N
it PRP N
is VBZ N
novel JJ N
, , N
translatable JJ N
, , N
and CC N
scalable JJ N
. . N

On IN N
the DT N
basis NN N
of IN N
this DT N
trial NN N
and CC N
the DT N
safety NN N
of IN N
retrograde JJ N
coronary JJ N
sinus NN N
infusion NN N
, , N
there EX N
are VBP N
three CD N
other JJ N
trials NNS N
under IN N
way NN N
using VBG N
this DT N
route NN N
of IN N
delivery NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
continuous JJ N
subcutaneous JJ N
insulin NN 1_i
infusion NN N
and CC N
intensive JJ N
injection NN N
therapy NN N
in IN N
type NN 1_p
1 CD 1_p
diabetes NNS 1_p
for IN 1_p
patients NNS 1_p
with IN 1_p
long-standing JJ 1_p
poor JJ 1_p
glycemic JJ 1_p
control NN 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
assess VB N
in IN N
a DT N
randomized JJ N
crossover NN N
trial NN N
the DT N
efficacy NN N
of IN N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
in IN N
improving VBG N
glycemic JJ 1_o
control NN 1_o
and CC 1_o
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
in IN N
type JJ 1_p
1 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
long-standing JJ 1_p
poor JJ 1_p
glycemic JJ 1_p
control NN 1_p
. . 1_p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
79 CD 1_p
patients NNS 1_p
in IN 1_p
11 CD 1_p
Dutch NN 1_p
centers NNS 1_p
were VBD N
randomized VBN N
to TO N
16 CD N
weeks NNS N
of IN N
continuous JJ 1_i
subcutaneous JJ 1_i
insulin NN 1_i
infusion NN 1_i
followed VBN 1_i
by IN 1_i
16 CD 1_i
weeks NNS 1_i
intensive JJ 1_i
injection NN 1_i
therapy NN 1_i
or CC 1_i
the DT 1_i
reverse JJ 1_i
order NN 1_i
. . 1_i

Glycemic NNP N
control NN N
was VBD N
assessed VBN N
by IN N
HbA NNP N
( ( N
1c CD N
) ) N
, , N
self-reported JJ N
hypoglycemic JJ N
events NNS N
, , N
and CC N
blood NN N
glucose JJ N
memory NN N
meter NN N
read VBD N
outs NNS N
. . N

Changes NNS N
in IN N
quality NN 1_o
of IN 1_o
life NN 1_o
were VBD N
assessed VBN N
by IN N
self-report JJ N
questionnaires NNS N
administered VBN N
at IN N
baseline NN N
and CC N
16 CD N
weeks NNS N
. . N

RESULTS NNP N
As IN N
the DT N
drop-out NN N
rate NN N
after IN N
crossover NN N
was VBD N
high JJ N
( ( N
17 CD N
of IN N
79 CD N
patients NNS N
[ JJ N
22 CD N
% NN N
] NN N
) ) N
, , N
we PRP N
analyzed VBD N
the DT N
trial NN N
as IN N
a DT N
parallel JJ N
clinical JJ N
trial NN N
, , N
using VBG N
data NNS N
of IN N
the DT N
first JJ N
half NN N
of IN N
the DT N
crossover NN N
phase NN N
only RB N
. . N

At IN N
16 CD N
weeks NNS N
, , N
mean JJ 1_o
HbA NNP 1_o
( ( 1_o
1c CD 1_o
) ) 1_o
was VBD N
0.84 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.31 NNP N
to TO N
-0.36 VB N
) ) N
lower JJR N
in IN N
the DT N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
group NN N
compared VBN N
with IN N
the DT N
insulin NN 1_i
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Stability NN 1_o
of IN 1_o
blood NN 1_o
glucose JJ 1_o
self-measurement JJ 1_o
values NNS 1_o
, , N
expressed VBD N
as IN N
SD NNP N
of IN N
the DT N
nine-point JJ N
blood NN N
glucose NN N
profiles NNS N
, , N
improved VBN N
in IN N
the DT N
insulin NN N
pump NN N
group NN N
by IN N
29.3 CD N
+/- JJ N
41.1 CD N
vs. FW N
8.2 CD N
+/- JJ N
36.5 CD N
% NN N
in IN N
the DT N
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
mild JJ 1_o
hypoglycemic JJ 1_o
episodes NNS 1_o
per IN N
patient-week NN N
was VBD N
0.99 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.11-1.87 NN N
) ) N
higher JJR N
in IN N
the DT N
insulin NN N
pump NN N
group NN N
( ( N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

Weight NNP 1_o
gain NN 1_o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Scores NNS 1_o
on IN 1_o
the DT 1_o
Short-Form JJ 1_o
36-Item JJ 1_o
subscales NNS 1_o
'general POS 1_o
health NN 1_o
' '' 1_o
and CC 1_o
'mental JJ 1_o
health NN 1_o
' '' 1_o
improved VBN N
in IN N
the DT N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
group NN N
, , N
compared VBN N
with IN N
stable JJ N
values NNS N
in IN N
the DT N
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.048 CD N
and CC N
0.050 CD N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Continuous NNP N
subcutaneous JJ N
insulin NN 1_i
infusion NN N
improves VBZ N
glycemic JJ N
control NN N
and CC N
some DT N
aspects NNS N
of IN N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
long-term JJ 1_p
poor JJ 1_p
glycemic JJ 1_p
control NN 1_p
. . 1_p

-DOCSTART- -X- O O

Prediction NN N
of IN N
metabolic JJ N
and CC N
cardiopulmonary JJ N
responses NNS N
to TO N
maximum JJ 1_i
cycle NN 1_i
ergometry NN 1_i
: : 1_i
a DT N
randomised JJ N
study NN N
. . N

All DT N
of IN N
the DT N
most RBS N
widely-cited JJ N
studies NNS N
for IN N
the DT N
prediction NN N
of IN N
maximum JJ 1_o
exercise NN 1_o
responses NNS 1_o
have VBP N
utilized VBN N
either CC 1_p
volunteers NNS 1_p
or CC 1_p
referred JJ 1_p
subjects NNS 1_p
. . 1_p

Therefore RB N
, , N
selection NN N
bias NN N
, , N
with IN N
overestimation NN N
of IN N
the DT N
reference NN N
values NNS N
, , N
is VBZ N
a DT N
likely JJ N
consequence NN N
. . N

In IN N
order NN N
to TO N
establish VB N
a DT N
set NN N
of IN N
predictive JJ N
equations NNS N
for IN N
the DT N
gas NN 1_o
exchange NN 1_o
, , 1_o
ventilatory NN 1_o
and CC 1_o
cardiovascular JJ 1_o
responses NNS 1_o
to TO N
maximum VB 1_i
ramp-incremental JJ 1_i
cycle NN 1_i
ergometry NN 1_i
, , N
this DT 1_p
study NN 1_p
prospectively RB 1_p
evaluated VBD 1_p
120 CD 1_p
sedentary JJ 1_p
individuals NNS 1_p
( ( 1_p
60 CD 1_p
males NNS 1_p
, , 1_p
60 CD 1_p
females NNS 1_p
, , 1_p
aged VBD 1_p
20-80 CD 1_p
) ) 1_p
, , 1_p
randomly-selected JJ 1_p
from IN 1_p
> JJ 1_p
8,000 CD 1_p
subjects NNS 1_p
. . 1_p

Regular JJ N
physical JJ 1_o
activity NN 1_o
pattern NN 1_o
by IN 1_o
questionnaire NN 1_o
, , 1_o
body NN 1_o
composition NN 1_o
by IN 1_o
anthropometry NN 1_o
and CC 1_o
dual JJ 1_o
energy NN 1_o
X-ray JJ 1_o
absorptiometry NN 1_o
( ( 1_o
n JJ 1_o
= NNP 1_o
75 CD 1_o
) ) 1_o
and CC 1_o
knee JJ 1_o
strength NN 1_o
by IN 1_o
isokinetic JJ 1_o
dynamometry NN 1_o
were VBD N
also RB N
assessed VBN N
. . N

Previously RB N
reported VBD N
equations NNS N
typically RB N
overestimated VBD N
the DT N
subjects NNS N
' POS N
peak NN 1_o
oxygen NN 1_o
uptake NN 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Prediction NN N
linear JJ N
equations NNS N
for IN N
the DT N
main JJ N
variables NNS N
of IN N
clinical JJ N
interest NN N
were VBD N
established VBN N
by IN N
backward NN N
stepwise NN N
regression NN N
analysis NN N
including VBG N
: : N
sex NN N
, , N
age NN N
, , N
knee NN N
extensor NN N
peak NN N
torque NN N
, , N
bone-free JJ N
lean JJ N
leg NN N
mass NN N
, , N
total JJ N
and CC N
lean JJ N
body NN N
mass NN N
, , N
height NN N
, , N
and CC N
physical JJ N
activity NN N
scores NNS N
. . N

Reference NN 1_o
intervals NNS 1_o
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
) ) N
were VBD N
calculated VBN N
: : N
some DT N
of IN N
these DT N
values NNS N
differed VBD N
markedly RB N
from IN N
those DT N
formerly RB N
recommended VBN N
. . N

The DT N
results NNS N
therefore RB N
might MD N
provide VB N
a DT N
more RBR N
appropriate JJ N
frame NN N
of IN N
reference NN N
for IN N
interpretation NN N
of IN N
the DT N
responses NNS 1_o
to TO 1_o
symptom-limited JJ 1_o
ramp JJ 1_o
incremental JJ 1_o
cycle NN 1_o
ergometry NN 1_o
in IN N
sedentary JJ 1_p
subjects NNS 1_p
; : 1_p
i.e NN N
. . N

those DT N
usually RB N
referred VBN N
for IN N
clinical JJ N
cardiopulmonary JJ N
exercise NN N
tests NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
perioperative JJ N
parecoxib NN 1_i
on IN N
postoperative JJ 1_o
pain NN 1_o
and CC 1_o
local JJ 1_o
inflammation NN 1_o
factors NNS N
PGE2 NNP N
and CC N
IL-6 NNP N
for IN N
total JJ N
knee NN N
arthroplasty NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
. . N

To TO N
assess VB N
the DT N
efficacy NN 1_o
of IN N
postoperative JJ N
pain NN N
management NN N
and CC N
the DT N
concentration NN N
change NN N
of IN N
PGE-2 NNP N
and CC N
IL-6 NNP N
of IN N
joint JJ N
fluid NN N
with IN N
parecoxib NN 1_i
after IN N
postoperative JJ N
total JJ N
knee NN N
arthroplasty NN N
. . N

In IN N
the DT N
study NN N
, , N
100 CD 1_p
patients NNS 1_p
experiencing VBG 1_p
primary JJ 1_p
TKA NNP 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
study NN N
group NN N
, , N
receiving VBG N
parecoxib NN 1_i
sodium NN 1_i
( ( N
40 CD N
mg NN N
) ) N
intravenously RB N
( ( N
IV NNP N
) ) N
at IN N
the DT N
completion NN N
of IN N
surgery NN N
and CC N
once RB N
every DT N
12 CD N
h NN N
for IN N
totally RB N
6 CD N
times NNS N
postoperatively RB N
, , N
and CC 1_i
placebo NN 1_i
group NN 1_i
, , N
receiving VBG 1_i
normal JJ 1_i
saline JJ 1_i
2 CD 1_i
mL NN N
IV NNP N
at IN N
the DT N
same JJ N
time NN N
points NNS 1_o
. . 1_o

Efficacy NN 1_o
was VBD 1_o
assessed VBN N
by IN N
total JJ 1_o
amount NN 1_o
of IN 1_o
morphine NN 1_o
consumed VBN 1_o
, , 1_o
pain VBP 1_o
intensity NN 1_o
, , 1_o
range NN 1_o
of IN 1_o
motion NN 1_o
( ( 1_o
ROM NNP 1_o
) ) 1_o
, , 1_o
the DT 1_o
concentration NN 1_o
change NN 1_o
of IN 1_o
PGE-2 NNP 1_o
and CC 1_o
IL-6 NNP 1_o
of IN 1_o
joint JJ 1_o
fluid NN 1_o
, , 1_o
and CC 1_o
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
( ( 1_o
PONV NNP 1_o
) ) 1_o
postoperatively RB 1_o
. . N

Patients NNS N
in IN N
study NN N
group NN N
consumed VBD N
significantly RB N
less JJR 1_o
morphine NN 1_o
, , 1_o
experienced VBD 1_o
significant JJ N
less JJR 1_o
pain NN 1_o
scores NNS 1_o
, , 1_o
and CC 1_o
obtained VBD N
significantly RB N
more RBR 1_o
ROM NNP 1_o
( ( 1_o
P NNP 1_o
< NNP N
0.01 CD N
) ) N
compared VBN N
with IN N
that DT N
in IN N
placebo NN N
group NN N
during IN N
3 CD N
days NNS N
postoperatively RB 1_o
. . 1_o

The DT 1_o
concentration NN 1_o
of IN 1_o
PGE-2 NNP 1_o
and CC 1_o
IL-6 NNP 1_o
of IN 1_o
joint JJ 1_o
fluid NN 1_o
in IN N
study NN N
group NN N
are VBP N
significantly RB N
lower JJR N
than IN N
that DT N
in IN 1_i
placebo NN 1_i
group NN 1_i
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
during IN N
24 CD N
h NNS N
postoperatively RB 1_o
. . 1_o

The DT 1_o
overall JJ 1_o
incidence NN 1_o
of IN 1_o
PONV NNP 1_o
was VBD N
low JJ N
and CC N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
the DT N
perioperative JJ N
administration NN 1_i
of IN 1_i
parecoxib NN 1_i
after IN 1_i
primary JJ 1_i
TKA NNP N
resulted VBD N
in IN N
significantly RB N
improved VBN N
postoperative JJ 1_o
analgesic JJ 1_o
management NN 1_o
as IN 1_o
defined VBN 1_o
by IN N
reduction NN N
in IN N
opioid JJ N
requirement NN 1_o
, , 1_o
lower JJR 1_o
pain NN 1_o
scores NNS 1_o
and CC 1_o
ROM NNP 1_o
, , 1_o
and CC N
significantly RB 1_o
lowered VBD 1_o
local JJ 1_o
inflammation NN 1_o
factors NNS 1_o
PGE2 NNP 1_o
and CC 1_o
IL-6 NNP 1_o
. . N

-DOCSTART- -X- O O

[ RB N
Comparative NNP N
study NN N
of IN N
cinoxacin NN 1_i
( ( 1_i
Cinobac NNP 1_i
) ) 1_i
, , 1_i
nitrofurantoin FW 1_i
( ( 1_i
Furadantine NNP 1_i
MC NNP 1_i
) ) 1_i
and CC 1_i
oxolinic JJ 1_i
acid NN 1_i
( ( 1_i
Uritrate NNP 1_i
) ) 1_i
in IN N
urinary JJ N
tract NN N
infections NNS N
. . N

Results NNS N
of IN N
a DT N
random NN N
study NN N
of IN N
three CD 1_p
groups NNS 1_p
of IN 1_p
30 CD 1_p
patients NNS 1_p
with IN 1_p
uncomplicated JJ 1_p
urinary JJ 1_p
infections NNS 1_p
] VBP 1_p
. . 1_p

-DOCSTART- -X- O O

Controlled-release NNP N
melatonin NN 1_i
, , 1_i
singly RB 1_i
and CC 1_i
combined VBN 1_i
with IN 1_i
cognitive JJ 1_i
behavioural JJ 1_i
therapy NN 1_i
, , N
for IN N
persistent JJ 1_p
insomnia NN 1_o
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
. . N

Although IN N
melatonin NN 1_i
and CC 1_i
cognitive-behavioural JJ 1_i
therapy NN 1_i
have VBP N
shown VBN N
efficacy NN N
in IN N
treating VBG N
sleep JJ 1_p
disorders NNS 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
, , N
little JJ N
is VBZ N
known VBN N
about IN N
their PRP$ N
relative NN N
or CC N
combined VBN N
efficacy NN N
. . N

One CD 1_p
hundred CD 1_p
and CC 1_p
sixty JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
, , 1_p
aged VBN 1_p
4-10 CD 1_p
years NNS 1_p
, , 1_p
suffering VBG 1_p
from IN 1_p
sleep JJ 1_p
onset NN 1_p
insomnia NN 1_p
and CC 1_p
impaired JJ 1_p
sleep JJ 1_p
maintenance NN 1_p
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
either DT N
( ( N
1 CD N
) ) N
combination NN 1_i
of IN 1_i
controlled-release JJ 1_i
melatonin NN 1_i
and CC 1_i
cognitive-behavioural JJ 1_i
therapy NN 1_i
; : 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
controlled-release NN 1_i
melatonin NN 1_i
; : 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
four CD 1_i
sessions NNS 1_i
of IN 1_i
cognitive-behavioural JJ 1_i
therapy NN 1_i
; : 1_i
or CC 1_i
( ( 1_i
4 CD 1_i
) ) 1_i
placebo FW 1_i
drug NN 1_i
treatment NN 1_i
condition NN 1_i
for IN N
12 CD N
weeks NNS N
in IN N
a DT N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
ratio NN N
. . N

Children NNP N
were VBD N
studied VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Treatment NNP N
response NN N
was VBD N
assessed VBN N
with IN N
1-week JJ N
actigraphic JJ N
monitoring NN N
, , N
sleep JJ N
diary NN N
and CC N
sleep JJ N
questionnaire NN N
. . N

Main NNP N
outcome NN N
measures NNS N
, , N
derived VBN N
actigraphically RB N
, , N
were VBD N
sleep JJ 1_o
latency NN 1_o
, , 1_o
total JJ 1_o
sleep JJ 1_o
time NN 1_o
, , 1_o
wake VBP 1_o
after IN 1_o
sleep JJ 1_o
onset NN 1_o
and CC 1_o
number NN 1_o
of IN 1_o
awakenings NNS 1_o
. . 1_o

The DT N
active JJ N
treatment NN N
groups NNS N
all DT N
resulted VBD N
in IN N
improvements NNS N
across IN N
all DT N
outcome NN N
measures NNS N
, , N
with IN N
moderate-to-large JJ N
effect NN N
sizes VBZ N
from IN N
baseline NN N
to TO N
a DT N
12-week JJ N
assessment NN N
. . N

Melatonin NNP 1_i
treatment NN N
was VBD N
mainly RB N
effective JJ N
in IN N
reducing VBG N
insomnia NN 1_o
symptoms NNS 1_o
, , N
while IN N
cognitive-behavioural JJ 1_i
therapy NN 1_i
had VBD N
a DT N
light JJ N
positive JJ N
impact NN N
mainly RB N
on IN N
sleep JJ 1_o
latency NN 1_o
, , N
suggesting VBG N
that IN N
some DT N
behavioural JJ N
aspects NNS N
might MD N
play VB N
a DT N
role NN N
in IN N
determining VBG N
initial JJ 1_o
insomnia NN 1_o
. . 1_o

The DT N
combination NN N
treatment NN N
group NN N
showed VBD N
a DT N
trend NN N
to TO N
outperform VB N
other JJ N
active JJ N
treatment NN N
groups NNS N
, , N
with IN N
fewer JJR N
dropouts NNS N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
treatment NN N
responders NNS N
achieving VBG N
clinically RB N
significant JJ N
changes NNS N
( ( N
63.38 CD N
% NN N
normative JJ N
sleep JJ N
efficiency NN N
criterion NN N
of IN N
> $ N
85 CD N
% NN N
and CC N
84.62 CD N
% NN N
, , N
sleep JJ N
onset NN N
latency NN N
< VBD N
30 CD N
min NN N
) ) N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
adding VBG N
behavioural JJ 1_i
intervention NN 1_i
to TO N
melatonin VB 1_i
treatment NN N
seems VBZ N
to TO N
result VB N
in IN N
a DT N
better JJR N
treatment NN N
response NN N
, , N
at IN N
least JJS N
in IN N
the DT N
short JJ N
term NN N
. . N

-DOCSTART- -X- O O

Interferential JJ 1_i
therapy NN 1_i
electrode NN 1_i
placement NN 1_i
technique NN 1_i
in IN N
acute NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
: : 1_p
a DT N
preliminary JJ N
investigation NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
interferential JJ 1_i
therapy NN 1_i
( ( 1_i
IFT NNP 1_i
) ) 1_i
electrode VBP 1_i
placement NN 1_i
technique NN 1_i
compared VBN N
with IN N
a DT N
control NN 1_i
treatment NN 1_i
in IN N
subjects NNS 1_p
with IN 1_p
acute NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
( ( 1_p
LBP NNP 1_p
) ) 1_p
. . 1_p

DESIGN NNP N
Single-blind NNP N
, , N
randomized VBD N
, , N
controlled VBD N
trial NN N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

SETTING NN N
Outpatient NNP 1_p
physiotherapy NN 1_p
departments NNS 1_p
in IN 1_p
hospital NN 1_p
and CC 1_p
university NN 1_p
settings NNS 1_p
. . 1_p

PATIENTS VB N
A DT N
random JJ N
sample NN N
of IN N
60 CD 1_p
eligible JJ 1_p
patients NNS 1_p
with IN 1_p
back JJ 1_p
pain NN 1_p
( ( 1_p
28 CD 1_p
men NNS 1_p
, , 1_p
32 CD 1_p
women NNS 1_p
) ) 1_p
were VBD 1_p
recruited VBN 1_p
by IN 1_p
general JJ 1_p
practitioners NNS 1_p
and CC 1_p
self-referral JJ 1_p
for IN N
physiotherapy NN N
treatment NN N
and CC N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

INTERVENTIONS NNP N
( ( N
1 CD N
) ) N
IFT NNP 1_i
painful JJ 1_i
area NN 1_i
and CC 1_i
The DT 1_i
Back NNP 1_i
Book NNP 1_i
, , N
( ( N
2 CD N
) ) N
IFT NNP 1_i
spinal JJ 1_i
nerve NN 1_i
and CC 1_i
The DT 1_i
Back NNP 1_i
Book NNP 1_i
, , N
and CC N
( ( N
3 CD N
) ) N
Control NN 1_i
, , 1_i
The DT 1_i
Back NNP 1_i
Book NNP 1_i
only RB N
. . N

Standardized VBN N
IFT NNP 1_i
stimulation NN N
parameters NNS N
were VBD N
used VBN N
: : N
carrier NN N
frequency NN N
3.85 CD N
kHz NN N
; : N
140 CD N
Hz NNP N
constant NN N
; : N
pulse JJ N
duration NN N
130 CD N
micros NN N
; : N
30 CD N
minutes NNS N
' POS N
duration NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Pain NNP 1_o
Rating NNP 1_o
Index NNP 1_o
, , 1_o
Roland-Morris NNP 1_o
Disability NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
RMDQ NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
EuroQol NNP 1_o
were VBD N
completed VBN N
by IN N
subjects NNS N
pretreatment JJ N
, , N
at IN N
discharge NN N
, , N
and CC N
3-month JJ N
follow-up NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
had VBD N
significant JJ N
improvements NNS N
in IN N
all DT N
outcomes NNS N
at IN N
follow-up NN N
. . N

Subjects NNS N
managed VBN N
by IN N
IFT NNP N
spinal JJ N
nerve NN N
and CC N
The DT N
Back NNP N
Book NNP N
displayed VBD N
both DT N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
.030 NNP N
) ) N
and CC N
clinically RB N
meaningful JJ N
reduction NN 1_o
in IN 1_o
functional JJ 1_o
disability NN 1_o
( ( 1_o
RMDQ NNP 1_o
) ) 1_o
, , N
compared VBN N
with IN N
management NN N
via IN N
IFT NNP N
painful JJ N
area NN N
and CC N
The DT N
Back NNP N
Book NNP N
combined VBD N
or CC N
The DT N
Back JJ N
Book NNP N
alone RB N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
showed VBD N
that IN N
IFT NNP 1_i
electrode FW 1_i
placement NN 1_i
technique NN 1_i
affects VBZ N
LBP-specific JJ N
functional JJ N
disability NN N
, , N
providing VBG N
preliminary JJ N
implications NNS N
for IN N
future JJ N
clinical JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

Plasma NNP N
pH NN N
does VBZ N
not RB N
influence VB N
the DT N
cerebral JJ 1_p
metabolic JJ 1_p
ratio NN 1_p
during IN 1_p
maximal JJ 1_p
whole JJ 1_p
body NN 1_p
exercise NN 1_p
. . 1_p

Exercise NN N
lowers VBZ N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
of IN N
O2 NNP N
to TO N
carbohydrate VB N
( ( N
glucose+1/2 JJ N
lactate NN N
) ) N
and CC N
metabolic JJ N
acidosis NN N
appears VBZ N
to TO N
promote VB 1_o
cerebral JJ 1_o
lactate JJ 1_o
uptake NN 1_o
. . 1_o

However RB N
, , N
the DT N
influence NN N
of IN N
pH NN N
on IN N
cerebral JJ N
lactate JJ N
uptake NN N
and CC N
, , N
in IN N
turn NN N
, , N
on IN N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
during IN N
exercise NN N
is VBZ N
not RB N
known VBN N
. . N

Sodium NN 1_i
bicarbonate NN 1_i
( ( 1_i
Bicarb NNP 1_i
, , 1_i
1 CD 1_i
M NNP 1_i
; : 1_i
350-500 CD 1_i
ml NN 1_i
) ) 1_i
or CC 1_i
an DT 1_i
equal JJ 1_i
volume NN 1_i
of IN 1_i
normal JJ 1_i
saline NN 1_i
( ( 1_i
Sal NNP 1_i
) ) 1_i
was VBD 1_i
infused VBN 1_i
intravenously RB 1_i
at IN 1_i
a DT 1_i
constant JJ 1_i
rate NN 1_i
during IN 1_i
a DT 1_i
'2000 CD 1_i
m NN 1_i
' '' 1_i
maximal JJ 1_i
ergometer NN 1_i
row NN 1_i
in IN N
six CD 1_p
male JJ 1_p
oarsmen NNS 1_p
( ( 1_p
23?2 CD 1_p
years NNS 1_p
; : 1_p
mean?S.D. NN 1_p
) ) 1_p
. . 1_p

During IN N
the DT N
Sal NNP N
trial NN 1_o
, , 1_o
pH NN 1_o
decreased VBD 1_o
from IN N
7.41?0.01 CD N
at IN N
rest NN N
to TO N
7.02?0.02 CD N
but CC N
only RB N
to TO N
7.36?0.02 CD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
during IN N
the DT N
Bicarb NNP N
trial NN N
. . 1_o

Arterial JJ 1_o
lactate NN 1_o
increased VBD 1_o
to TO N
21.4?0.8 CD N
and CC N
32.7?2.3 CD N
mM NN N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
the DT 1_o
arterial-jugular JJ 1_o
venous JJ 1_o
lactate NN 1_o
difference NN 1_o
increased VBD N
from-0.03?0.01 JJ N
mM NN N
at IN N
rest NN N
to TO N
3.2?0.9 CD N
mM NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
3.4?1.4 CD N
mM NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
following VBG N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
, , N
respectively RB N
. . N

Accordingly RB 1_o
, , 1_o
the DT 1_o
cerebral JJ 1_o
metabolic NN 1_o
ratio NN 1_o
decreased VBD 1_o
equally RB N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
: : N
from IN N
5.8?0.6 CD N
at IN N
rest NN N
to TO N
1.7?0.1 CD N
and CC N
1.8?0.2 CD N
, , N
respectively RB N
. . N

The DT 1_o
enlarged JJ 1_o
blood-buffering NN 1_o
capacity NN 1_o
after IN 1_o
infusion NN 1_i
of IN 1_i
Bicarb NNP 1_i
eliminated VBD 1_o
metabolic JJ 1_o
acidosis NN 1_o
during IN 1_o
maximal JJ N
exercise NN N
but CC N
that DT N
did VBD N
not RB N
affect VB N
the DT 1_o
cerebral JJ 1_o
lactate NN 1_o
uptake NN 1_o
and CC 1_o
, , 1_o
therefore RB N
, , N
the DT N
decrease NN N
in IN N
the DT 1_o
cerebral JJ 1_o
metabolic NN 1_o
ratio NN 1_o
. . 1_o

-DOCSTART- -X- O O

Longterm NNP 1_o
safety NN 1_o
, , 1_o
efficacy NN 1_o
, , 1_o
and CC 1_o
radiographic JJ 1_o
outcome NN 1_o
with IN N
etanercept JJ 1_i
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
early JJ 1_p
rheumatoid NN 1_p
arthritis NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
safety NN 1_o
, , 1_o
efficacy NN 1_o
, , 1_o
and CC 1_o
radiographic JJ 1_o
progression NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
early JJ 1_p
rheumatoid NN 1_p
arthritis NN 1_p
( ( 1_p
RA NNP 1_p
) ) 1_p
undergoing VBG 1_p
longterm JJ 1_p
treatment NN 1_p
with IN 1_p
etanercept NN 1_i
. . 1_i

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
early JJ 1_p
RA NNP 1_p
( ( 1_p
disease JJ 1_p
duration NN 1_p
of IN 1_p
3 CD 1_p
years NNS 1_p
or CC 1_p
less JJR 1_p
) ) 1_p
who WP 1_p
had VBD 1_p
completed VBN 1_p
a DT 1_p
2-year JJ 1_p
efficacy NN 1_p
study NN 1_p
comparing VBG 1_p
etanercept NNS 1_i
and CC 1_i
methotrexate NN 1_i
( ( 1_i
MTX NNP 1_i
) ) 1_i
were VBD 1_p
followed VBN 1_p
in IN 1_p
an DT 1_p
extension NN 1_p
where WRB N
they PRP N
received VBD N
25 CD N
mg NNS N
etanercept JJ 1_i
twice RB N
weekly RB N
. . N

Safety NNP 1_o
was VBD N
summarized VBN N
descriptively RB N
and CC N
compared VBN N
with IN N
data NNS N
from IN N
the DT N
efficacy NN N
study NN N
. . N

Efficacy NNP 1_o
and CC 1_o
radiographic JJ 1_o
progression NN 1_o
were VBD N
assessed VBN N
using VBG N
American JJ 1_o
College NNP 1_o
of IN 1_o
Rheumatology NNP 1_o
response NN 1_o
criteria NNS 1_o
, , 1_o
disease NN 1_o
activity NN 1_o
scores VBZ 1_o
, , N
and CC N
Total NNP 1_o
Sharp NNP 1_o
Score NNP 1_o
( ( 1_o
TSS NNP 1_o
) ) 1_o
. . N

RESULTS JJ N
Rates NNS 1_o
of IN 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
and CC 1_o
serious JJ 1_o
infections NNS 1_o
did VBD N
not RB N
increase VB N
with IN N
longterm JJ N
exposure NN N
to TO N
etanercept VB N
, , N
and CC N
were VBD N
similar JJ N
to TO N
rates NNS N
reported VBN N
for IN N
the DT N
blinded JJ N
portion NN N
of IN N
the DT N
efficacy NN N
study NN N
. . N

Efficacy NNP 1_o
was VBD N
sustained VBN N
in IN N
patients NNS 1_p
who WP 1_p
completed VBD 1_p
5 CD 1_p
years NNS 1_p
of IN 1_p
etanercept JJ 1_i
treatment NN 1_p
at IN N
the DT N
time NN N
of IN N
this DT N
report NN N
( ( N
N NNP N
= NNP N
201 CD N
) ) N
, , N
even RB N
in IN N
those DT N
who WP N
decreased VBD N
or CC N
discontinued VBN N
use NN N
of IN N
MTX NNP N
or CC N
corticosteroids NNS N
. . N

No DT N
radiographic JJ 1_o
progression NN 1_o
( ( N
change NN N
in IN N
TSS NNP N
< NNP N
or CC N
= VB N
0 CD N
) ) N
was VBD N
seen VBN N
in IN N
55 CD N
% NN N
of IN N
patients NNS N
with IN N
5-year JJ N
radiographs NN N
; : N
negative JJ N
change NN N
( ( N
TSS NNP N
< NNP N
0 CD N
) ) N
was VBD N
seen VBN N
in IN N
11 CD N
% NN N
. . N

CONCLUSION NNP N
Etanercept NNP 1_i
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
early JJ 1_p
RA NNP 1_p
was VBD N
generally RB N
well RB N
tolerated VBN N
for IN N
up RB N
to TO N
5 CD N
years NNS N
. . N

The DT N
results NNS N
indicate VBP N
sustained VBN N
efficacy NN 1_o
and CC 1_o
decreased JJ 1_o
rate NN 1_o
of IN 1_o
radiographic JJ 1_o
progression NN 1_o
. . 1_o

The DT N
rate NN 1_o
of IN 1_o
radiographic JJ 1_o
progression NN 1_o
was VBD N
low JJ N
compared VBN N
with IN N
other JJ N
studies NNS N
, , N
emphasizing VBG N
the DT N
benefit NN N
gained VBN N
in IN N
patients NNS 1_p
with IN 1_p
early JJ 1_p
aggressive JJ 1_p
RA NNP 1_p
who WP N
undergo VBP N
longterm JJ N
treatment NN N
with IN N
etanercept NN 1_i
. . 1_i

-DOCSTART- -X- O O

Human NNP 1_i
papillomavirus NN 1_i
and CC N
Papanicolaou NNP 1_i
tests NNS 1_i
to TO N
screen VB N
for IN N
cervical JJ N
cancer NN N
. . N

BACKGROUND NNP N
Screening NNP N
for IN N
cervical JJ N
cancer NN N
based VBN N
on IN N
testing VBG N
for IN N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
increases VBZ N
the DT N
sensitivity NN N
of IN N
detection NN N
of IN N
high-grade NN N
( ( N
grade JJ N
2 CD N
or CC N
3 CD N
) ) N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
, , N
but CC N
whether IN N
this DT N
gain NN N
represents VBZ N
overdiagnosis NN N
or CC N
protection NN N
against IN N
future JJ N
high-grade JJ N
cervical JJ N
epithelial JJ N
neoplasia NN N
or CC N
cervical JJ N
cancer NN N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
In IN 1_p
a DT 1_p
population-based JJ 1_p
screening NN 1_p
program NN 1_p
in IN 1_p
Sweden NNP 1_p
, , 1_p
12,527 CD 1_p
women NNS 1_p
32 CD 1_p
to TO 1_p
38 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
at IN N
a DT N
1:1 CD N
ratio NN N
to TO N
have VB N
an DT N
HPV NNP 1_i
test NN 1_i
plus CC 1_i
a DT 1_i
Papanicolaou NNP 1_i
( ( 1_i
Pap NNP 1_i
) ) 1_i
test NN 1_i
( ( 1_i
intervention NN 1_i
group NN 1_i
) ) 1_i
or CC N
a DT 1_i
Pap JJ 1_i
test NN 1_i
alone RB 1_i
( ( 1_i
control VB 1_i
group NN 1_i
) ) 1_i
. . 1_i

Women NNS N
with IN N
a DT N
positive JJ N
HPV NNP 1_i
test NN 1_i
and CC N
a DT N
normal JJ N
Pap NNP 1_i
test NN 1_i
result NN N
were VBD N
offered VBN N
a DT N
second JJ N
HPV NNP 1_i
test NN 1_i
at IN N
least JJS N
1 CD N
year NN N
later RB N
, , N
and CC N
those DT N
who WP N
were VBD N
found VBN N
to TO N
be VB N
persistently RB N
infected VBN N
with IN N
the DT N
same JJ N
high-risk JJ N
type NN N
of IN N
HPV NNP N
were VBD N
then RB N
offered VBN N
colposcopy NN N
with IN N
cervical JJ N
biopsy NN N
. . N

A DT N
similar JJ N
number NN N
of IN N
double-blinded JJ 1_o
Pap NNP 1_o
smears NNS 1_o
and CC 1_o
colposcopies NNS 1_o
with IN 1_o
biopsy NN 1_o
were VBD N
performed VBN N
in IN N
randomly RB N
selected VBN N
women NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Comprehensive JJ N
registry NN N
data NNS N
were VBD N
used VBN N
to TO N
follow VB N
the DT N
women NNS N
for IN N
a DT N
mean NN N
of IN N
4.1 CD N
years NNS N
. . N

The DT N
relative JJ N
rates NNS 1_o
of IN 1_o
grade JJ 1_o
2 CD 1_o
or CC 1_o
3 CD 1_o
cervical JJ 1_o
intraepithelial JJ 1_o
neoplasia NN 1_o
or CC 1_o
cancer NN 1_o
detected VBN 1_o
at IN N
enrollment NN N
and CC N
at IN N
subsequent JJ N
screening VBG N
examinations NNS N
were VBD N
calculated VBN N
. . N

RESULTS NNP N
At IN N
enrollment NN N
, , N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
intervention NN 1_i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
lesions NNS 1_o
of IN 1_o
grade NN 1_o
2 CD 1_o
or CC 1_o
3 CD 1_o
cervical JJ 1_o
intraepithelial JJ 1_o
neoplasia NN 1_o
or CC 1_o
cancer NN 1_o
was VBD N
51 CD N
% NN N
greater JJR N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
13 CD N
to TO N
102 CD N
) ) N
than IN N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
control NN 1_i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
such JJ N
lesions NNS N
. . N

At IN N
subsequent JJ N
screening VBG N
examinations NNS N
, , N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
intervention NN 1_i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
grade VBN N
2 CD 1_o
or CC 1_o
3 CD 1_o
lesions NNS 1_o
or CC 1_o
cancer NN 1_o
was VBD N
42 CD N
% NN N
less JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
4 CD N
to TO N
64 CD N
) ) N
and CC N
the DT N
proportion NN N
with IN N
grade JJ N
3 CD N
lesions NNS N
or CC N
cancer NN N
was VBD N
47 CD N
% NN N
less JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
2 CD N
to TO N
71 CD N
) ) N
than IN N
the DT N
proportions NNS N
of IN N
control NN 1_i
women NNS N
who WP N
were VBD N
found VBN N
to TO N
have VB N
such JJ N
lesions NNS N
. . N

Women NNS N
with IN N
persistent JJ N
HPV NNP N
infection NN N
remained VBD N
at IN N
high JJ N
risk NN N
for IN N
grade JJ N
2 CD N
or CC N
3 CD N
lesions NNS N
or CC N
cancer NN N
after IN N
referral JJ N
for IN N
colposcopy NN N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
an DT N
HPV NNP 1_i
test NN 1_i
to TO N
the DT N
Pap NNP 1_i
test NN 1_i
to TO N
screen JJ N
women NNS 1_p
in IN 1_p
their PRP$ 1_p
mid-30s NN 1_p
for IN N
cervical JJ N
cancer NN N
reduces VBZ N
the DT N
incidence NN N
of IN N
grade NN N
2 CD N
or CC N
3 CD N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
or CC N
cancer NN N
detected VBN N
by IN N
subsequent JJ N
screening NN N
examinations NNS N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00479375 NNP N
[ NNP N
ClinicalTrials.gov NNP N
] NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
piracetam NN 1_i
on IN N
regional JJ N
cerebral JJ 1_o
blood NN 1_o
flow NN 1_o
and CC 1_o
mental JJ 1_o
functions NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
organic JJ 1_p
dementia NN 1_p
. . 1_p

The DT N
effects NNS N
of IN N
piracetam NN 1_i
( ( N
Nootropil NNP N
, , N
UCB6215 NNP N
) ) N
on IN N
mental JJ 1_o
functions NNS 1_o
and CC 1_o
on IN 1_o
regional JJ 1_o
cerebral JJ 1_o
blood NN 1_o
flow NN 1_o
( ( 1_o
rCBF NN 1_o
) ) 1_o
were VBD N
investigated VBN N
in IN N
eight CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
presenile JJ 1_p
age NN 1_p
who WP 1_p
displayed VBD 1_p
symptoms NNS 1_p
of IN 1_p
moderate JJ 1_p
dementia NN 1_p
. . 1_p

The DT N
double-blind JJ N
crossover NN N
design NN N
included VBD N
nine CD N
measurement NN N
occasions NNS N
, , N
each DT N
involving VBG N
rCBF NN 1_o
measurement NN 1_o
by IN N
the DT N
133-Xe JJ 1_i
inhalation NN 1_i
method NN 1_i
, , N
ratings NNS N
of IN N
symptoms NNS N
of IN N
dementia NN N
, , N
personality NN N
changes NNS N
, , N
and CC N
side NN N
effects NNS N
, , N
and CC N
a DT N
psychometric JJ N
investigation NN N
. . N

Three CD N
investigations NNS N
were VBD N
included VBN N
in IN N
each DT N
of IN N
three CD N
treatment NN N
periods NNS N
. . N

The DT N
first JJ N
investigation NN N
in IN N
a DT N
period NN N
was VBD N
made VBN N
without IN N
medication NN N
. . N

Then RB N
either DT N
placebo NN 1_i
or CC 1_i
piracetam VB 1_i
4.8 CD N
g/day NN N
or CC N
9.6 CD N
g/day NN N
was VBD N
given VBN N
during IN N
four CD N
weeks NNS N
with IN N
measurements NNS N
after IN N
2 CD N
weekks NN N
and CC N
4 CD N
weeks NNS N
. . N

There EX N
were VBD N
intervals NNS N
of IN N
4 CD N
weeks NNS N
without IN N
medication NN N
between IN N
the DT N
treatment NN N
periods NNS N
. . N

Piracetam NNP 1_i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
either CC N
mental JJ 1_o
functions NNS 1_o
or CC 1_o
rCBF NN 1_o
. . 1_o

-DOCSTART- -X- O O

Recombinant JJ 1_i
human JJ 1_i
granulocyte NN 1_i
and CC 1_i
granulocyte-macrophage JJ 1_i
colony-stimulating JJ 1_i
factor NN 1_i
( ( 1_i
G-CSF NNP 1_i
and CC 1_i
GM-CSF NNP 1_i
) ) 1_i
administered VBD N
following VBG N
cytotoxic NN 1_i
chemotherapy NNS 1_i
have VBP N
a DT N
similar JJ N
ability NN N
to TO N
mobilize VB N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
. . N

The DT N
availability NN N
of IN N
hematopoietic JJ N
growth NN N
factors NNS N
has VBZ N
greatly RB N
facilitated VBN N
the DT N
mobilization NN 1_o
and CC 1_o
collection NN 1_o
of IN 1_o
peripheral JJ 1_o
blood NN 1_o
stem NN 1_o
cells NNS 1_o
( ( 1_o
PBSC NNP 1_o
) ) 1_o
. . 1_o

It PRP N
was VBD N
the DT N
aim NN N
of IN N
this DT N
double-blind NN N
study NN N
to TO N
compare VB N
the DT N
PBSC-mobilizing NNP N
efficacy NN N
of IN N
recombinant JJ 1_i
human JJ 1_i
G-CSF NNP 1_i
and CC N
GM-CSF NNP 1_i
when WRB N
administered VBN N
post-chemotherapy NN 1_i
. . 1_i

Twenty-six JJ 1_p
patients NNS 1_p
with IN 1_p
relapsed JJ 1_p
Hodgkin NNP 1_p
's POS 1_p
disease NN 1_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Their PRP$ 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
31 CD 1_p
years NNS 1_p
( ( 1_p
range NN 1_p
, , 1_p
22-59 JJ 1_p
) ) 1_p
and CC 1_p
14 CD 1_p
patients NNS 1_p
were VBD 1_p
males NNS 1_p
and CC 1_p
12 CD 1_p
were VBD 1_p
females NNS 1_p
. . 1_p

Patients NNS 1_p
were VBD 1_p
pretreated VBN 1_p
with IN 1_p
a DT 1_p
median NN 1_p
of IN 1_p
eight CD 1_p
cycles NNS 1_p
of IN 1_p
cytotoxic NN 1_i
chemotherapy NN 1_i
, , 1_p
while IN 1_p
18 CD 1_p
patients NNS 1_p
had VBD 1_p
undergone JJ 1_p
extended JJ 1_p
field NN 1_p
irradiation NN 1_p
. . 1_p

The DT N
patients NNS N
received VBD N
dexamethasone RB 1_i
24 CD 1_i
mg JJ 1_i
days NNS 1_i
1-7 CD 1_i
, , 1_i
melphalan FW 1_i
30 CD 1_i
mg/m2 NNS 1_i
day NN 1_i
3 CD 1_i
, , 1_i
BCNU NNP 1_i
60 CD 1_i
mg/m2 NN 1_i
day NN 1_i
3 CD 1_i
, , 1_i
etoposide RB 1_i
75 CD 1_i
mg/m2 JJ 1_i
days NNS 1_i
4-7 CD 1_i
, , 1_i
Ara-C NNP 1_i
100 CD 1_i
mg/m2 NN 1_i
twice RB 1_i
daily JJ 1_i
days NNS 1_i
4-7 JJ 1_i
( ( 1_i
Dexa-BEAM NNP 1_i
) ) 1_i
. . N

Twelve CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB 1_i
5/microg/kg/day CD 1_i
G-CSF NNP 1_i
and CC N
14 CD N
patients NNS N
to TO N
receive VB N
5 CD 1_i
microg/kg/day JJ 1_i
GM-CSF NNP 1_i
, , N
both DT N
administered VBN N
subcutaneously RB N
starting VBG N
on IN N
day NN N
1 CD N
after IN N
the DT N
end NN N
of IN N
Dexa-BEAM NNP 1_i
. . 1_i

Primary JJ N
endpoints NNS N
of IN N
the DT N
study NN N
were VBD N
the DT N
number NN 1_o
of IN 1_o
CD34+ NNP 1_o
cells NNS 1_o
harvested VBD 1_o
per IN 1_o
kg NN 1_o
body NN 1_o
weight VBD 1_o
on IN 1_o
the DT 1_o
occasion NN 1_o
of IN 1_o
six CD 1_o
consecutive JJ 1_o
leukaphereses NNS 1_o
and CC N
the DT N
time NN 1_o
needed VBN 1_o
for IN 1_o
hematological JJ 1_o
reconstitution NN 1_o
following VBG 1_o
autografting VBG 1_o
. . 1_o

Twenty-one CD N
patients NNS N
completed VBN N
PBSC NNP N
collection NN N
, , N
and CC N
six CD N
patients NNS N
of IN N
the DT N
G-CSF NNP N
group NN N
and CC N
nine CD N
of IN N
the DT N
GM-CSF NNP N
group NN N
were VBD N
autografted VBN N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
with IN N
respect NN N
to TO N
the DT N
median JJ 1_o
yield NN 1_o
of IN 1_o
CFU-GM NNP 1_o
and CC 1_o
CD34+ NNP 1_o
cells NNS 1_o
: : 1_o
32.5 CD N
x $ N
10 CD N
( ( N
4 CD N
) ) N
/kg NN N
vs $ N
31.3 CD N
x $ N
10 CD N
( ( N
4 CD N
) ) N
/kg CD N
CFU-GM NNP N
, , N
and CC N
7.6 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
vs $ N
5.6 CD N
x $ N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
CD34+ NNP N
cells NNS N
, , N
for IN N
G-CSF NNP 1_o
and CC 1_o
GM-CSF NNP 1_o
, , N
respectively RB N
( ( N
U NNP N
test NN N
, , N
P= NNP N
0.837 CD N
and CC N
0.696 CD N
) ) N
. . N

High-dose JJ N
chemotherapy NN N
consisted VBN N
of IN N
cyclophosphamide NN 1_i
1.7 CD N
g/m2 JJ N
days NNS N
1-4 CD N
, , N
BCNU NNP 1_i
150 CD N
mg/m2 NN N
days NNS N
1-4 CD N
, , N
etoposide RB 1_i
400 CD N
mg/m2 JJ N
days NNS N
1-4 JJ N
. . N

All DT N
patients NNS N
transplanted VBN N
with IN N
more JJR N
than IN N
5 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
CD34+ NNP N
cells/kg NN N
had VBD N
a DT N
rapid JJ N
platelet NN 1_o
recovery NN 1_o
( ( N
20 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
between IN N
6 CD N
and CC N
11 CD N
days NNS N
and CC N
neutrophil JJ 1_o
recovery NN 1_o
( ( N
0.5 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
/1 NN N
) ) N
between IN N
9 CD N
and CC N
16 CD N
days NNS N
, , N
while IN N
patients NNS N
transplanted VBN N
with IN N
less JJR N
than IN N
5 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
had VBD N
a DT N
delayed VBN 1_o
reconstitution NN 1_o
, , N
regardless RB N
of IN N
the DT N
kind NN N
of IN N
growth NN N
factor NN N
used VBN N
for IN N
PBSC NNP N
mobilization NN N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
data NNS N
indicate VBP N
that IN N
in IN N
patients NNS 1_p
with IN 1_p
Hodgkin NNP 1_p
's POS 1_p
disease NN 1_p
G-CSF NNP N
and CC N
GM-CSF NNP N
given VBN N
after IN N
salvage NN N
chemotherapy NN N
appear VBP N
to TO N
be VB N
not RB N
different JJ N
in IN N
their PRP$ N
ability NN 1_o
to TO 1_o
mobilize VB 1_o
PBSC NNP 1_o
resulting VBG N
in IN N
a DT N
similar JJ N
time NN 1_o
needed VBN 1_o
for IN 1_o
hematological JJ 1_o
reconstitution NN 1_o
when WRB N
autografted VBD N
following VBG N
high-dose JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
preoperative JJ N
skull NN N
block NN N
on IN N
pediatric JJ 1_p
moyamoya NN 1_p
disease NN 1_p
. . 1_p

OBJECT NNP N
Stable JJ N
hemodynamics NNS N
, , N
normocapnia NN N
, , N
and CC N
adequate JJ N
pain NN N
relief NN N
are VBP N
considered VBN N
important JJ N
factors NNS N
in IN N
the DT N
reduction NN N
of IN N
neurological JJ N
complications NNS N
in IN N
pediatric JJ 1_p
patients NNS 1_p
undergoing JJ 1_p
encephaloduroarteriomyosynangiosis NN 1_i
( ( 1_i
EDAMS NNP 1_i
) ) 1_i
operations NNS 1_p
for IN 1_p
the DT 1_p
treatment NN 1_p
of IN 1_p
moyamoya JJ 1_p
disease NN 1_p
. . 1_p

A DT N
preoperative JJ N
skull NN N
block NN N
may MD N
reduce VB N
hemodynamic JJ 1_o
fluctuations NNS 1_o
and CC 1_o
hypo- NN 1_o
or CC 1_o
hyperventilation NN 1_o
due JJ N
to TO N
emergence VB N
delirium NN N
or CC N
oversedation NN N
and CC N
provide VB N
adequate JJ N
pain NN N
relief NN N
, , N
thereby RB N
reducing VBG N
postoperative JJ 1_o
morbidity NN 1_o
. . 1_o

METHODS NNP N
Pediatric NNP 1_p
patients NNS 1_p
( ( 1_p
age NN 1_p
3-13 CD 1_p
years NNS 1_p
) ) 1_p
undergoing VBG 1_p
EDAMS NNP 1_i
surgery NN 1_i
for IN 1_p
moyamoya JJ 1_p
disease NN 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
a DT 1_p
nerve NN 1_p
block NN 1_p
( ( 1_p
NB NNP 1_p
) ) 1_p
group NN 1_p
( ( 1_p
18 CD 1_p
cases NNS 1_p
) ) 1_p
or CC 1_p
control VB 1_p
group NN 1_p
( ( 1_p
21 CD 1_p
cases NNS 1_p
) ) 1_p
. . N

The DT N
treatment NN N
group NN N
patients NNS N
received VBD N
a DT N
preoperative JJ N
NB NNP 1_i
( ( N
0.25 CD N
% NN N
5-8 JJ N
ml NN N
bupivacaine NN 1_i
mixed JJ N
with IN N
20-40 JJ N
mg NNS N
methylprednisolone NN 1_i
) ) 1_i
targeting VBG N
the DT N
supraorbital NN N
, , N
supratrochlear JJ N
, , N
auriculotemporal JJ N
, , N
and CC N
posterior JJ N
auricular JJ N
nerves NNS N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
NB NNP N
. . N

General NNP N
anesthesia NN N
with IN N
sevoflurane NN 1_i
was VBD N
induced VBN N
in IN N
both DT N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
NB NNP N
group NN N
, , N
stable JJ 1_o
hemodynamic JJ 1_o
parameters NNS 1_o
were VBD N
obtained VBN N
with IN N
a DT N
lower JJR N
sevoflurane NN N
concentration NN N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

For IN N
delirious JJ 1_o
awakening NN 1_o
, , N
the DT N
odds NNS N
ratio NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
4.9 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

Pain NNP 1_o
and CC 1_o
analgesic JJ 1_o
requirement NN 1_o
were VBD N
higher JJR N
in IN N
the DT N
control NN N
patients NNS N
than IN N
in IN N
the DT N
NB-treated JJ N
patients NNS N
during IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
stay NN N
. . N

However RB N
, , N
the DT N
arterial JJ 1_o
CO NNP 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
tension NN 1_o
in IN 1_o
the DT 1_o
postanesthesia NN 1_o
care NN 1_o
unit NN 1_o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
odds NNS 1_o
ratio NN 1_o
in IN N
the DT N
control NN N
group NN N
for IN N
the DT N
rate NN 1_o
of IN 1_o
morbidity NN 1_o
( ( 1_o
cerebral JJ 1_o
infarction NN 1_o
and CC 1_o
reversible JJ 1_o
ischemic JJ 1_o
neurological JJ 1_o
deficits NNS 1_o
) ) 1_o
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
following VBG N
the DT N
operation NN N
was VBD N
3.2 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
skull JJ N
block NN N
during IN N
EDAMS NNP N
surgery NN N
provided VBD N
easy JJ N
hemodynamic JJ 1_o
control NN 1_o
, , 1_o
calm JJ 1_o
awakening NN 1_o
, , 1_o
and CC 1_o
better JJR 1_o
pain NN 1_o
relief NN 1_o
and CC N
may MD N
be VB N
related VBN N
to TO N
the DT N
reduced VBN N
postoperative JJ 1_o
morbidity NN 1_o
. . 1_o

-DOCSTART- -X- O O

Comparative NNP N
in IN N
vitro JJ N
dissolution NN N
and CC N
in IN N
vivo JJ N
bioavailability NN N
of IN N
diflunisal/naproxen JJ N
fixed-dose JJ N
combination NN N
tablets NNS N
and CC N
concomitant JJ N
administration NN N
of IN N
diflunisal NN N
and CC N
naproxen NN N
in IN N
healthy JJ 1_p
adult NN 1_p
subjects NNS 1_p
. . 1_p

A DT N
simple JJ N
validated JJ N
high-performance NN N
liquid NN N
chromatography NN N
( ( N
HPLC NNP N
) ) N
assay NN N
was VBD N
developed VBN N
for IN N
determination NN N
of IN N
diflunisal NN N
and CC N
naproxen NN N
in IN N
human JJ N
plasma NN N
samples NNS N
. . N

This DT N
is VBZ N
to TO N
compare VB N
the DT N
bioavailability NN 1_o
of IN 1_o
diflunisal-naproxen JJ 1_o
fixed-dose JJ 1_o
combination NN 1_o
( ( 1_o
FDC NNP 1_o
) ) 1_o
with IN N
their PRP$ N
separate JJ N
dosage NN N
forms NNS N
. . N

The DT N
in IN N
vitro JJ N
dissolution NN N
study NN N
was VBD N
adopted VBN N
to TO N
compare VB N
the DT N
dissolution NN 1_o
behavior NN 1_o
of IN 1_o
FDC NNP 1_o
with IN N
respect NN N
to TO N
separate VB N
marketed VBN N
tablets NNS N
. . N

In IN N
vivo NN N
study NN N
was VBD N
conducted VBN N
according VBG N
to TO N
a DT N
single-center NN N
, , N
randomized VBN N
, , N
single-dose JJ N
, , N
laboratory-blinded JJ N
, , N
2 CD N
Way NNP N
, , N
Cross-Over NNP N
Study NNP N
with IN N
a DT N
washout JJ N
period NN N
of IN N
10 CD N
days NNS N
. . N

Under IN 1_p
fasting VBG 1_p
conditions NNS 1_p
, , 1_p
24 CD 1_p
healthy JJ 1_p
Egyptian JJ 1_p
male NN 1_p
volunteers NNS 1_p
were VBD N
randomly RB 1_i
allocated VBN 1_i
to TO 1_i
receive VB 1_i
a DT 1_i
single JJ 1_i
oral JJ 1_i
dose NN 1_i
of IN 1_i
either DT 1_i
one CD 1_i
FDC NNP 1_i
tablet NN 1_i
or CC 1_i
co-administration NN 1_i
of IN 1_i
two CD 1_i
separate JJ 1_i
diflunisal NN 1_i
and CC 1_i
naproxen RB 1_i
marketed VBN 1_i
tablets NNS 1_i
. . 1_i

Plasma NNP 1_i
samples NNS 1_i
were VBD 1_i
obtained VBN 1_i
over IN 1_i
a DT 1_i
72-h JJ 1_i
interval NN 1_i
and CC 1_i
analyzed VBN 1_i
for IN 1_i
diflunisal NN 1_o
and CC 1_o
naproxen NN 1_o
by IN 1_i
reversed JJ 1_i
phase NN 1_i
liquid NN 1_i
chromatography NN 1_i
with IN 1_i
UV NNP 1_i
detection NN 1_i
. . 1_i

The DT N
pharmacokinetic JJ N
parameters NNS N
Cmax NNP 1_o
, , 1_o
AUC0-t NNP 1_o
, , 1_o
AUC0-? NNP 1_o
, , 1_o
tmax NN 1_o
, , 1_o
and CC 1_o
t1/2 NNS 1_o
were VBD 1_o
determined VBN 1_o
from IN N
plasma JJ N
concentration-time JJ N
profiles NNS N
. . N

The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN N
of IN N
log NN N
transformed VBN N
values NNS N
of IN N
Cmax NNP 1_o
, , 1_o
AUC0-t NNP 1_o
, , 1_o
and CC 1_o
AUCt-? NNP 1_o
of IN 1_o
the DT N
2 CD N
treatments NNS N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.8-1.25 JJ N
) ) N
for IN N
bioequivalence NN N
. . N

From IN N
pharmacokinetic JJ N
and CC N
in IN N
vitro JJ N
studies NNS N
perspectives NNS N
, , N
1 CD N
FDC NNP N
tablet NN N
demonstrated VBD N
similar JJ N
relative JJ N
bioavailability NN N
with IN N
the DT N
2 CD N
individual JJ N
-reference NN N
tablets NNS N
. . N

-DOCSTART- -X- O O

Exhaled JJ N
NO NNP N
during IN N
graded VBN N
changes NNS N
in IN N
inhaled JJ N
oxygen NN N
in IN N
man NN 1_p
. . 1_p

BACKGROUND NNP N
Nitric NNP 1_i
oxide NN 1_i
( ( N
NO NNP N
) ) N
is VBZ N
present JJ N
in IN N
the DT N
exhaled JJ N
air NN N
of IN N
animals NNS N
and CC N
humans NNS N
. . N

In IN N
isolated JJ N
animal JJ N
lungs NNS N
the DT N
amount NN N
of IN N
exhaled JJ N
NO NNP N
is VBZ N
decreased VBN N
during IN N
hypoxia NN N
. . N

A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
whether IN N
changes NNS N
in IN N
arterial JJ N
oxygen NN N
tension NN N
affect NN N
levels NNS N
of IN N
exhaled JJ N
NO NNP N
in IN N
humans NNS 1_p
. . 1_p

METHODS NNP N
Sixteen NNP 1_p
healthy JJ 1_p
subjects NNS 1_p
were VBD N
randomised VBN N
to TO N
inhale VB 1_i
different JJ 1_i
gas NN 1_i
mixtures NNS 1_i
of IN 1_i
oxygen NN 1_i
and CC 1_i
nitrogen NN 1_i
in IN N
a DT N
double JJ N
blind NN N
crossover NN N
study NN N
. . N

Eight NNP N
gas NN 1_i
mixtures NNS 1_i
of IN 1_i
oxygen NN 1_i
and CC 1_i
nitrogen NN 1_i
( ( N
fractional JJ N
inspired VBN N
oxygen NN N
concentration NN N
( ( N
FiO2 NNP N
) ) N
0.1 CD N
to TO N
1.0 CD N
) ) N
were VBD N
administered VBN N
. . N

Exhaled VBD 1_o
NO DT 1_o
was VBD N
measured VBN N
with IN N
a DT N
chemiluminescence NN N
detector NN N
from IN N
end NN N
expiratory NN N
single JJ N
breath NN N
exhalation NN N
. . N

RESULTS VB N
A DT N
dose-dependent JJ N
change NN N
in IN N
exhaled JJ 1_o
NO NNP 1_o
during IN N
graded VBN 1_o
oxygen NN 1_o
breathing NN 1_o
was VBD N
observed VBN N
( ( N
p JJ N
= NNP N
0.0012 CD N
) ) N
. . N

The DT N
mean NN 1_o
( ( 1_o
SE NNP 1_o
) ) 1_o
exhaled VBD 1_o
NO DT 1_o
concentration NN 1_o
was VBD N
31 CD N
( ( N
3 CD N
) ) N
ppb NN N
at IN N
baseline NN N
, , N
39 CD N
( ( N
4 CD N
) ) N
ppb NN N
at IN N
an DT N
FiO2 NNP N
of IN N
1.0 CD N
, , N
and CC N
26 CD N
( ( N
3 CD N
) ) N
ppb NN N
at IN N
an DT N
FiO2 NNP N
of IN N
0.1 CD N
. . N

CONCLUSIONS VB N
The DT N
NO NNP 1_o
concentration NN 1_o
in IN N
exhaled JJ N
air NN N
in IN N
healthy JJ 1_p
humans NNS 1_p
is VBZ N
dependent JJ N
on IN N
oxygen NN N
tension NN N
. . N

Hyperoxia NNP N
increases VBZ N
the DT N
level NN N
of IN N
exhaled JJ N
NO NNP N
, , N
which WDT N
indicates VBZ N
increased VBD N
NO DT N
production NN N
. . N

The DT N
mechanism NN N
behind IN N
this DT N
phenomenon NN N
remains VBZ N
to TO N
be VB N
elucidated VBN N
. . N

-DOCSTART- -X- O O

Pegfilgrastim NN 1_i
for IN N
peripheral JJ N
CD34+ NNP N
mobilization NN N
in IN N
patients NNS 1_p
with IN 1_p
solid JJ 1_o
tumours NNS 1_o
. . 1_o

The DT N
efficacy NN 1_o
of IN N
pegfilgrastim+/-chemotherapy NN 1_i
for IN N
mobilizing VBG N
stem NN N
cells NNS N
in IN N
patients NNS 1_p
with IN 1_p
solid JJ 1_o
tumours NN 1_o
was VBD N
assessed VBN N
. . N

In IN N
cycle NN N
0 CD N
, , N
a DT N
14-day JJ N
prechemotherapy NN N
cycle NN N
, , N
patients NNS 1_p
( ( 1_p
N=61 NNP 1_p
) ) 1_p
were VBD N
randomized VBN N
open-label NN N
to TO N
single JJ N
doses NNS N
of IN N
pegfilgrastim NN 1_i
( ( N
6 CD N
, , N
12 CD N
or CC N
18 CD N
mg NN N
) ) N
on IN N
day NN N
1 CD N
, , N
or CC N
daily RB N
filgrastim NNS 1_i
( ( N
10 CD N
microg/kg NN N
) ) N
for IN N
< NN N
or CC N
=7 JJ N
days NNS N
. . N

Mean JJ 1_o
peak JJ 1_o
peripheral JJ 1_o
CD34+ NNP 1_o
cell NN 1_o
counts NNS 1_o
increased VBD 1_o
with IN N
pegfilgrastim NN 1_i
dose NN N
, , N
but CC N
were VBD N
significantly RB 1_o
higher JJR 1_o
than IN N
filgrastim JJR 1_i
only RB N
at IN N
the DT N
18 CD N
mg NN N
dose NN N
( ( N
10.17 CD N
vs RB N
4.96 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.014 NNP N
) ) N
. . N

In IN N
the DT N
clinically NN N
relevant JJ N
period NN N
of IN N
days NNS N
3-7 CD N
, , N
both DT N
12 CD N
and CC N
18 CD N
mg NN N
pegfilgrastim NN 1_i
doses NNS N
produced VBD N
significantly RB 1_o
higher JJR 1_o
peak NN 1_o
CD34+ NNP 1_o
counts VBZ 1_o
( ( N
8.18 CD N
and CC N
9.96 CD N
vs NN N
4.51 CD N
x NN N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
for IN N
filgrastim NN 1_i
; : 1_i
P=0.034 NNP N
and CC N
0.006 CD N
) ) N
. . N

In IN N
cycle NN N
1 CD N
, , N
patients NNS N
received VBD N
carboplatin/paclitaxel NNS 1_i
on IN N
day NN N
1 CD N
, , N
followed VBD N
from IN N
day NN N
2 CD N
by IN N
pegfilgrastim JJ 1_i
6-18 JJ N
mg NN N
or CC N
daily JJ N
filgrastim NN 1_i
( ( N
5 CD N
microg/kg/day NN N
for IN N
< NN N
or CC N
=14 NNP N
days NNS N
) ) N
as IN N
per IN N
randomization NN N
in IN N
cycle NN N
0 CD N
. . N

There EX N
were VBD N
no DT 1_o
significant JJ 1_o
differences NNS 1_o
in IN N
mean JJ 1_o
peak NN 1_o
CD34+ NNP 1_o
count NN 1_o
between IN N
pegfilgrastim NN 1_i
and CC N
filgrastim NN 1_i
, , N
but CC N
there EX N
was VBD N
an DT N
advantage NN N
for IN N
pegfilgrastim NN 1_i
18 CD N
mg NN N
in IN N
the DT N
relevant JJ N
period NN N
of IN N
days NNS N
7-12 NNP N
( ( N
3.14 CD N
vs RB N
1.19 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.043 NNP N
) ) N
. . N

A DT N
single JJ N
pegfilgrastim NN 1_i
dose NN N
( ( N
> CD N
or CC N
=6 VB N
mg NN N
) ) N
could MD N
be VB N
substituted VBN N
for IN N
daily JJ N
filgrastim NN 1_i
in IN N
cytokine-only JJ 1_o
peripheral JJ 1_o
CD34+ NNP 1_o
cell NN 1_o
mobilization NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
SNRI NNP 1_i
venlafaxine NN 1_i
improves VBZ N
emotional JJ 1_o
unawareness NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
post-stroke JJ 1_p
depression NN 1_p
. . 1_p

OBJECTIVE CC N
Patients NNPS 1_p
with IN 1_p
stroke NNS 1_p
have VBP N
a DT N
high JJ N
prevalence NN N
of IN N
depression NN N
and CC N
unawareness NN N
of IN N
emotions NNS N
or CC N
alexithymia NN 1_o
. . 1_o

Here RB N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
the DT N
serotoninergic NN 1_i
and CC 1_i
noradrenergic JJ 1_i
reuptake NN 1_i
inhibitor NN 1_i
( ( 1_i
SNRI NNP 1_i
) ) 1_i
venlafaxine NN 1_i
in IN N
comparison NN N
with IN N
the DT N
SSRI NNP 1_i
fluoxetine NN 1_i
on IN N
alexithymia NN 1_o
severity NN N
in IN N
patients NNS 1_p
with IN 1_p
DSM-IV NNP 1_p
post-stroke JJ 1_p
major JJ 1_p
depressive-like JJ 1_p
episode NN 1_p
( ( 1_p
PSD NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Fifty NNP 1_p
inpatients NNS 1_p
with IN 1_p
first-ever JJ 1_p
stroke NN 1_p
and CC 1_p
PSD NNP 1_p
were VBD 1_p
consecutively RB 1_p
enrolled VBN 1_p
in IN N
this DT N
randomized JJ N
open-label NN N
study NN N
. . N

Twenty-five JJ N
were VBD N
treated VBN N
with IN N
the DT N
SNRI NNP 1_i
venlafaxine NN 1_i
SR NNP N
( ( N
75-150 JJ N
mg/die NN N
) ) N
, , N
and CC N
25 CD N
with IN N
the DT N
SSRI NNP 1_i
fluoxetine NN 1_i
( ( N
20-40 JJ N
mg/die NN N
) ) N
. . N

All DT N
patients NNS N
were VBD N
assessed VBN N
at IN N
day NN N
0 CD N
, , N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
8 CD N
weeks NNS N
, , N
using VBG N
the DT N
Mini-Mental JJ 1_o
State NNP 1_o
Examination NNP 1_o
, , 1_o
the DT 1_o
Hamilton NNP 1_o
Depression NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
, , 1_o
and CC 1_o
the DT 1_o
Toronto NNP 1_o
Alexithymia NNP 1_o
Scale NNP 1_o
( ( N
TAS-20 NNP N
) ) N
. . N

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
fluoxetine NN N
and CC N
those DT N
treated VBN N
with IN N
venlafaxine NN N
showed VBD N
similar JJ N
improvement NN N
in IN N
depressive JJ 1_o
symptoms NNS 1_o
. . 1_o

However RB N
, , N
patients NNS N
treated VBD N
with IN N
venlafaxine NN N
had VBD N
a DT N
greater JJR N
improvement NN N
on IN N
alexithymia NN 1_o
severity NN 1_o
than IN N
those DT N
treated VBN N
with IN N
fluoxetine NN N
. . N

The DT N
effect NN N
of IN N
venlafaxine NN N
on IN N
unawareness NN 1_o
of IN 1_o
emotions NNS 1_o
was VBD N
evident JJ N
in IN N
patients NNS N
with IN N
alexithymia NN N
( ( N
TAS-20 NNP N
> NNP N
or= IN N
61 CD N
) ) N
at IN N
the DT N
baseline NN N
and CC N
in IN N
those DT N
without IN N
alexithymia NN N
( ( N
TAS-20 NNP N
< NNP N
61 CD N
) ) N
. . N

CONCLUSIONS JJ N
Antidepressants NNPS N
acting VBG N
on IN N
both CC N
the DT N
serotoninergic NN N
and CC N
noradrenergic JJ N
systems NNS N
might MD N
represent VB N
a DT N
valid JJ N
resource NN N
not RB N
only RB N
for IN N
the DT N
treatment NN N
of IN N
depression NN N
but CC N
also RB N
for IN N
improving VBG N
emotional JJ 1_o
unawareness NN 1_o
in IN N
stroke NN 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
phase JJ N
III NNP N
, , N
controlled VBD N
trial NN N
comparing VBG N
levobupivacaine JJ 1_i
0.25 CD N
% NN N
, , N
ropivacaine VB 1_i
0.25 CD N
% NN N
and CC N
bupivacaine VB 1_i
0.25 CD N
% NN N
by IN N
the DT N
caudal JJ 1_p
route NN 1_p
in IN 1_p
children NNS 1_p
. . 1_p

BACKGROUND IN N
The DT N
rationale NN N
for IN N
replacing VBG N
racemic JJ 1_i
bupivacaine NN 1_i
with IN N
the DT N
s-enantiomers NNS 1_i
levobupivacaine NN 1_i
and CC N
ropivacaine NN 1_i
is VBZ N
to TO N
provide VB N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
with IN N
the DT N
same JJ N
analgesic JJ 1_o
efficacy NN 1_o
and CC N
less RBR N
postoperative JJ 1_o
motor NN 1_o
block NN 1_o
. . 1_o

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase JJ N
III NNP N
, , N
controlled VBD N
trial NN N
we PRP N
compared VBN N
the DT N
caudal JJ N
administration NN N
of IN N
levobupivacaine JJ 1_i
0.25 CD N
% NN N
and CC N
ropivacaine VB 1_i
0.25 CD N
% NN N
with IN N
bupivacaine JJ 1_i
0.25 CD N
% NN N
in IN N
children NNS 1_p
. . 1_p

METHODS NNP N
Ninety-nine JJ 1_p
ASA NNP 1_p
I-II NNP 1_p
children NNS 1_p
less JJR 1_p
than IN 1_p
10 CD 1_p
yr JJ 1_p
old JJ 1_p
scheduled VBN 1_p
for IN 1_p
elective JJ 1_p
sub-umbilical JJ 1_p
surgery NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
caudal JJ N
block NN N
with IN N
bupivacaine JJ 1_i
0.25 CD N
% NN N
, , N
ropivacaine VB 1_i
0.25 CD N
% NN N
or CC N
levobupivacaine VB 1_i
0.25 CD N
% NN N
. . N

The DT N
primary JJ N
outcome NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
clinical JJ 1_o
efficacy NN 1_o
of IN 1_o
the DT 1_o
caudal JJ 1_o
block NN 1_o
during IN 1_o
the DT 1_o
operation NN 1_o
. . 1_o

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
analgesic JJ 1_o
onset JJ 1_o
time NN 1_o
, , 1_o
pain NN 1_o
relief NN 1_o
after IN 1_o
the DT 1_o
operation NN 1_o
and CC 1_o
residual JJ 1_o
motor NN 1_o
blockade NN 1_o
. . 1_o

RESULTS VB N
The DT N
proportion NN N
of IN N
children NNS N
with IN N
effective JJ N
analgesia NN N
during IN N
the DT N
operation NN N
was VBD N
similar JJ N
among IN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
analgesic JJ N
onset NN N
time NN N
of IN N
the DT N
caudal NN N
block NN N
. . N

Bupivacaine NNP N
produced VBD N
a DT N
significant JJ N
incidence NN N
of IN N
residual JJ 1_o
motor NN 1_o
block NN 1_o
compared VBN N
with IN N
levobupivacaine NN N
or CC N
ropivacaine NN N
at IN N
wake-up NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
receiving VBG N
rescue NN N
analgesia NN N
after IN N
surgery NN N
. . N

However RB N
, , N
analgesic JJ N
block NN N
lasted VBD N
significantly RB N
longer RBR N
in IN N
patients NNS N
receiving VBG N
bupivacaine NN N
( ( N
P=0.03 NNP N
) ) N
. . N

CONCLUSION NNP N
During IN N
sub-umbilical JJ N
surgery NN N
, , N
caudal JJ N
levobupivacaine NN N
, , N
ropivacaine NN N
and CC N
bupivacaine NN N
provided VBN N
comparable JJ N
analgesic JJ 1_o
efficacy NN 1_o
. . 1_o

Bupivacaine NNP N
produced VBD N
a DT N
higher JJR N
incidence NN 1_o
of IN 1_o
residual JJ 1_o
motor NN 1_o
blockade NN 1_o
and CC N
a DT N
longer RBR N
analgesic JJ 1_o
block NN 1_o
than IN N
ropivacaine NN N
and CC N
levobupivacaine NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
zoledronic JJ 1_i
acid NN 1_i
on IN N
disseminated JJ N
tumour NN N
cells NNS N
in IN N
women NNS 1_p
with IN 1_p
locally RB 1_p
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
: : 1_p
an DT N
open JJ N
label NN N
, , N
randomised VBN N
, , N
phase VB N
2 CD N
trial NN N
. . N

BACKGROUND NNP N
Treatment NNP N
with IN N
bisphosphonates NNS 1_i
decreases NNS N
bone VBP N
loss NN N
and CC N
can MD N
increase VB N
disease-free JJ N
survival NN N
in IN N
patients NNS 1_p
with IN 1_p
breast JJ 1_p
cancer NN 1_p
. . 1_p

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
zoledronic JJ 1_i
acid NN 1_i
on IN N
clearance NN N
of IN N
disseminated JJ 1_o
tumour NN 1_o
cells NNS 1_o
( ( 1_o
DTCs NNP 1_o
) ) 1_o
from IN N
the DT N
bone NN N
marrow NN N
in IN N
women NNS 1_p
undergoing VBG 1_p
neoadjuvant JJ 1_p
chemotherapy NN 1_p
for IN 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
Patients NNPS N
were VBD N
recruited VBN N
for IN N
this DT N
open-label JJ 1_p
, , 1_p
phase VB 1_p
2 CD 1_p
randomised JJ 1_p
trial NN 1_p
between IN 1_p
March NNP 1_p
17 CD 1_p
, , 1_p
2003 CD 1_p
, , 1_p
and CC 1_p
May NNP 1_p
19 CD 1_p
, , 1_p
2006 CD 1_p
, , 1_p
at IN 1_p
a DT 1_p
single JJ 1_p
centre NN 1_p
. . 1_p

Eligible JJ 1_p
patients NNS 1_p
had VBD 1_p
clinical JJ 1_p
stage NN 1_p
II-III NNP 1_p
( ( 1_p
> CD 1_p
or CC 1_p
= VB 1_p
T2 NNP 1_p
and/or JJ 1_p
> NN 1_p
or CC 1_p
= VB 1_p
N1 NNP 1_p
) ) 1_p
newly RB 1_p
diagnosed VBN 1_p
breast NN 1_p
cancer NN 1_p
, , 1_p
Eastern NNP 1_p
Cooperative NNP 1_p
Oncology NNP 1_p
Group NNP 1_p
performance NN 1_p
status NN 1_p
of IN 1_p
0 CD 1_p
or CC 1_p
1 CD 1_p
, , 1_p
and CC 1_p
normal JJ 1_p
cardiac NN 1_p
, , 1_p
renal JJ 1_p
, , 1_p
and CC 1_p
liver JJ 1_p
function NN 1_p
. . 1_p

120 CD 1_p
women NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
, , N
using VBG N
allocation NN N
concealment NN N
, , N
to TO N
receive VB N
4 CD 1_i
mg NN 1_i
zoledronic JJ 1_i
acid NN 1_i
intravenously RB 1_i
every DT 1_i
3 CD N
weeks NNS N
( ( N
n=60 NN N
) ) N
, , N
or CC N
no DT 1_i
zoledronic JJ 1_i
acid NN 1_i
( ( N
n=60 JJ N
) ) N
, , N
for IN N
1 CD N
year NN N
concomitant NN N
with IN N
four CD 1_i
cycles NNS 1_i
of IN 1_i
neoadjuvant JJ 1_i
epirubicin NN 1_i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC 1_i
docetaxel JJ 1_i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
and CC 1_i
two CD 1_i
cycles NNS 1_i
of IN 1_i
adjuvant JJ 1_i
epirubicin JJ 1_i
plus CC 1_i
docetaxel JJ 1_i
. . 1_i

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
number NN N
of IN N
patients NNS N
with IN N
detectable JJ 1_o
DTCs NNP 1_o
at IN N
3 CD N
months NNS N
. . N

Final NNP N
analysis NN N
was VBD N
done VBN N
1 CD N
year NN N
after IN N
the DT N
last JJ N
patient NN N
was VBD N
enrolled VBN N
. . N

Analyses NNS N
were VBD N
done VBN N
for IN N
all DT N
patients NNS N
with IN N
available JJ N
data NNS N
at IN N
3 CD N
months NNS N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00242203 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT N
120 CD 1_p
patients NNS 1_p
initially RB 1_p
enrolled VBD 1_p
, , 1_p
one CD 1_p
withdrew NN 1_p
after IN 1_p
signing VBG 1_p
consent NN 1_p
and CC 1_p
one CD 1_p
patient NN 1_p
's POS 1_p
baseline NN 1_p
bone NN 1_p
marrow NN 1_p
was VBD 1_p
not RB 1_p
available JJ 1_p
. . 1_p

Both DT N
of IN N
these DT N
patients NNS N
were VBD N
in IN N
the DT N
control NN N
group NN N
. . N

At IN N
3 CD N
months NNS N
, , N
109 CD 1_p
bone-marrow NN 1_p
samples NNS 1_p
were VBD 1_p
available JJ 1_p
for IN N
analysis NN N
. . N

In IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
, , N
bone NN N
marrow NN N
was VBD N
not RB N
collected VBN N
from IN N
one CD N
patient NN N
because IN N
of IN N
disease NN N
progression NN N
, , N
one CD N
patient NN N
was VBD N
taken VBN N
off RP N
study NN N
because IN N
of IN N
severe JJ N
diarrhoea NN N
, , N
and CC N
two CD N
patients NNS N
had VBD N
not RB N
consented VBN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
bone NN N
marrow NN N
was VBD N
not RB N
collected VBN N
from IN N
two CD N
patients NNS N
because IN N
of IN N
disease NN N
progression NN N
, , N
one CD N
patient NN N
withdrew VBD N
consent NN N
, , N
and CC N
three CD N
patients NNS N
were VBD N
not RB N
consented VBN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

At IN N
baseline NN N
, , N
DTCs NNP N
were VBD N
detected VBN N
in IN N
26 CD N
of IN N
60 CD N
patients NNS N
in IN N
the DT N
zoledronic JJ 1_i
acid NN 1_i
group NN N
and CC N
28 CD N
of IN N
58 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

At IN N
3 CD N
months NNS N
, , N
17 CD N
of IN N
56 CD N
patients NNS N
receiving VBG N
zoledronic JJ N
acid NN N
versus IN N
25 CD N
of IN N
53 CD N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
zoledronic JJ N
acid NN N
had VBD N
detectable JJ N
DTCs NNP N
( ( N
p=0.054 NN N
) ) N
. . N

The DT N
most RBS N
common JJ N
grade NN N
3-4 JJ N
toxicities NNS N
were VBD N
infection NN N
( ( N
five CD N
of IN N
60 CD N
patients NNS N
in IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
and CC N
six CD N
of IN N
59 CD N
in IN N
the DT N
control NN N
group NN N
) ) N
and CC N
thrombosis NN N
( ( N
five CD N
of IN N
60 CD N
in IN N
the DT N
zoledronic JJ N
acid NN N
and CC N
two CD N
of IN N
59 CD N
in IN N
the DT N
control NN N
group NN N
) ) N
. . N

There EX N
was VBD N
one CD N
documented JJ N
case NN N
of IN N
osteonecrosis NN 1_o
in IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
. . N

INTERPRETATION NNP N
Zoledronic NNP 1_i
acid NN 1_i
administered VBD N
with IN N
chemotherapy NN N
resulted VBN N
in IN N
a DT N
decreased JJ N
proportion NN N
of IN N
patients NNS N
with IN N
DTCs NNP N
detected VBD N
in IN N
the DT N
bone NN N
marrow NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

Our PRP$ N
study NN N
supports VBZ N
the DT N
hypothesis NN N
that IN N
the DT N
antimetastatic JJ N
effects NNS N
of IN N
zoledronic JJ 1_i
acid NN 1_i
may MD N
be VB N
through IN N
effects NNS N
on IN N
DTCs NNP N
. . N

FUNDING NN N
Novartis NN N
Pharmaceuticals NNP N
and CC N
Pfizer NNP N
Inc NNP N
. . N

-DOCSTART- -X- O O

A DT N
Double-Blind JJ N
Placebo-Controlled JJ 1_i
Study NNP N
of IN N
the DT N
Effects NNS N
of IN N
Olprinone NNP 1_i
, , N
a DT N
Specific JJ 1_i
Phosphodiesterase NNP 1_i
III NNP 1_i
Inhibitor NNP 1_i
, , N
for IN N
Preventing VBG N
Postoperative NNP N
Atrial NNP N
Fibrillation NNP N
in IN N
Patients NNP 1_p
Undergoing NNP 1_p
Pulmonary NNP 1_p
Resection NNP 1_p
for IN 1_p
Lung NNP 1_p
Cancer NNP 1_p
. . 1_p

BACKGROUND NNP N
We PRP N
previously RB N
reported VBD N
that IN N
patients NNS N
with IN N
elevated JJ 1_p
preoperative JJ 1_p
B-type NNP 1_p
natriuretic JJ 1_p
peptide NN 1_p
( ( 1_p
BNP NNP 1_p
) ) 1_p
levels NNS 1_p
have VBP N
an DT N
increased VBN N
risk NN N
for IN N
postoperative JJ N
atrial JJ N
fibrillation NN N
following VBG N
lung NN N
cancer NN N
surgery NN N
. . N

The DT N
present JJ N
study NN N
evaluated VBD N
whether IN N
the DT N
specific JJ 1_i
phosphodiesterase NN 1_i
III NNP 1_i
inhibitor NN 1_i
olprinone NN 1_i
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
postoperative JJ N
atrial JJ N
fibrillation NN N
in IN N
patients NNS N
with IN N
elevated JJ N
BNP NNP N
levels NNS N
undergoing VBG N
pulmonary JJ N
resection NN N
for IN N
lung NN N
cancer NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
with IN N
40 CD 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
elevated VBN 1_p
preoperative JJ 1_p
BNP NNP 1_p
levels NNS 1_p
( ( 1_p
? . 1_p
30 CD 1_p
pg/mL NN 1_p
) ) 1_p
and CC 1_p
underwent JJ 1_p
scheduled VBN 1_p
lung NN 1_p
cancer NN 1_p
surgery NN 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
were VBD 1_p
in IN 1_p
sinus JJ 1_p
rhythm NN 1_p
at IN 1_p
surgery NN 1_i
. . 1_i

Low-dose JJ 1_i
olprinone NN 1_i
or CC 1_i
placebo NN 1_i
was VBD 1_i
continuously RB N
infused VBN N
for IN N
24 CD N
h NN N
and CC N
started VBD N
just RB N
before RB N
anesthesia JJ N
induction NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT 1_o
incidence NN 1_o
of IN 1_o
postoperative JJ 1_o
atrial JJ 1_o
fibrillation NN 1_o
. . 1_o

The DT N
secondary JJ N
end NN N
points NNS N
were VBD 1_o
perioperative JJ 1_o
hemodynamics NNS 1_o
and CC 1_o
levels NNS 1_o
of IN 1_o
BNP NNP 1_o
, , 1_o
WBC NNP 1_o
counts VBZ 1_o
, , 1_o
and CC 1_o
C-reactive JJ 1_o
protein NN 1_o
. . 1_o

RESULTS VB N
The DT 1_o
incidence NN 1_o
of IN 1_o
postoperative JJ 1_o
atrial JJ 1_o
fibrillation NN 1_o
was VBD 1_o
significantly RB N
lower JJR N
in IN N
the DT 1_i
olprinone NN 1_i
group NN 1_i
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
10 CD N
% NN N
vs JJ N
60 CD N
% NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT 1_i
olprinone NN 1_i
group NN 1_i
showed VBD N
significantly RB 1_o
lower JJR 1_o
BNP NNP 1_o
, , 1_o
WBC NNP 1_o
counts VBZ 1_o
, , 1_o
and CC 1_o
C-reactive JJ 1_o
protein NN 1_o
levels NNS 1_o
after IN 1_o
surgery NN N
. . N

CONCLUSIONS NNP N
Continuous NNP N
infusion NN N
of IN N
olprinone NN N
during IN N
lung NN N
cancer NN N
surgery NN N
was VBD 1_o
safe JJ 1_o
and CC 1_o
reduced VBD N
the DT 1_o
incidence NN 1_o
of IN 1_o
postoperative JJ 1_o
atrial JJ 1_o
fibrillation NN 1_o
following VBG 1_o
pulmonary JJ N
resection NN N
in IN N
patients NNS N
with IN N
elevated JJ N
preoperative JJ N
BNP NNP N
levels NNS N
. . N

TRIAL NNP N
REGISTRY NNP N
Japan NNP N
Primary NNP N
Registries NNP N
Network NNP N
; : N
No NNP N
. . N

: : N
JPRN-UMIN2404 JJ N
; : N
URL NNP N
: : N
http NN N
: : N
//www.umin.ac.jp/ctr/ NN N
. . N

-DOCSTART- -X- O O

Endurance NNP 1_i
physical JJ 1_i
activity NN 1_i
, , 1_i
diet JJ 1_i
and CC N
fibrinolysis NN N
. . N

The DT N
impact NN N
of IN N
long-term JJ 1_i
, , 1_i
heavy JJ 1_i
exercise NN 1_i
on IN N
recently RB N
established VBN N
cardiovascular/thromboembolic JJ N
risk NN N
factors NNS N
of IN N
the DT N
fibrinolytic JJ N
system NN N
, , N
tissue NN N
plasminogen NN N
activator NN N
( ( N
tPA NN N
) ) N
and CC N
plasminogen NN N
activator NN N
inhibitor NN N
( ( N
PAI-1 NNP N
) ) N
in IN N
relation NN N
to TO N
food NN N
composition NN N
was VBD N
studied VBN N
. . N

Twenty NNP 1_p
healthy JJ 1_p
men NNS 1_p
, , 1_p
aged VBN 1_p
18-55 CD 1_p
years NNS 1_p
participated VBN N
in IN N
a DT N
14-day JJ 1_i
skiing NN 1_i
tour NN 1_i
through IN 1_i
the DT 1_i
Swedish JJ 1_i
mountains NNS 1_i
, , 1_i
carrying VBG 1_i
a DT 1_i
pack NN 1_i
load NN 1_i
of IN 1_i
30 CD 1_i
kg NNS 1_i
, , 1_i
and CC 1_i
spending VBG 1_i
each DT 1_i
night NN 1_i
in IN 1_i
self-dug JJ 1_i
igloos NN 1_i
( ( 1_i
ambient JJ 1_i
temp NN 1_i
-10 NN 1_i
degrees NNS 1_i
to TO 1_i
-25 VB 1_i
degrees NNS 1_i
C NNP 1_i
) ) 1_i
, , 1_i
and CC 1_i
were VBD 1_i
randomized VBN 1_i
to TO 1_i
2 CD 1_i
food NN 1_i
regimens NNS 1_i
having VBG 1_i
30 CD 1_i
or CC 1_i
40 CD 1_i
energy NN 1_i
percent NN 1_i
of IN 1_i
fat NN 1_i
. . 1_i

Individual JJ 1_i
records NNS 1_i
were VBD 1_i
kept VBN 1_i
of IN 1_i
all DT 1_i
consumed VBN 1_i
food NN 1_i
. . 1_i

Citrated VBD 1_o
plasma NN 1_o
was VBD 1_i
obtained VBN 1_i
before IN 1_i
and CC 1_i
after IN 1_i
1 CD 1_i
and CC 1_i
2 CD 1_i
weeks NNS 1_i
of IN 1_i
exercise NN 1_i
: : 1_i
tPA NN 1_o
release NN 1_o
was VBD 1_i
assessed VBN 1_i
by IN 1_i
a DT 1_i
10 CD 1_i
min NN 1_i
venous JJ 1_i
occlusion NN 1_i
( ( 1_i
VO NNP 1_i
) ) 1_i
test NN 1_i
. . 1_i

At IN N
baseline NN N
, , N
daily JJ 1_o
dietary JJ 1_o
fiber NN 1_o
intake NN 1_o
correlated VBD N
negatively RB N
with IN N
PAI-1 NNP N
activity NN N
. . N

Already RB N
after IN N
the DT N
first JJ N
week NN N
of IN N
the DT N
skiing VBG N
tour NN N
there EX N
were VBD N
significant JJ N
drops NNS N
in IN N
PAI-1 NNP 1_o
activities NNS 1_o
, , 1_o
cholesterol NN 1_o
and CC 1_o
triglycerides NNS 1_o
. . 1_o

The DT N
tPA JJ 1_o
mass NN 1_o
concentrations NNS 1_o
also RB N
dropped VBD N
, , N
both DT N
before IN N
and CC N
after IN N
VO NNP N
, , N
but CC N
tPA JJ 1_o
activities NNS 1_o
were VBD N
unchanged JJ N
, , N
as IN N
were VBD N
von JJ 1_o
Willebrand NNP 1_o
factor NN 1_o
( ( 1_o
vWF NN 1_o
) ) 1_o
levels NNS 1_o
. . 1_o

These DT N
changes NNS N
were VBD N
related VBN N
mainly RB N
to TO N
the DT N
expenditure NN N
of IN N
energy NN N
, , N
calculated VBN N
from IN N
the DT N
food NN N
consumption NN N
, , N
and CC N
appeared VBD N
to TO N
be VB N
mediated VBN N
through IN N
changed VBN N
insulin NN N
sensitivity NN N
and CC N
decreased VBD N
body NN N
fat JJ N
mass NN N
. . N

The DT N
energy NN N
percent NN N
of IN N
fat NN N
in IN N
the DT N
food NN N
had VBD N
no DT N
differential JJ N
impact NN N
. . N

The DT N
effects NNS N
receded VBD N
a DT N
few JJ N
weeks NNS N
after IN N
cessation NN N
of IN N
the DT N
endurance NN N
exercise NN N
. . N

Thus RB N
, , N
endurance JJ 1_i
physical JJ 1_i
activity NN 1_i
improves VBZ N
the DT N
fibrinolytic JJ N
risk NN N
factor NN N
profile NN N
by IN N
reducing VBG N
PAI-1 NNP N
while IN N
leaving VBG N
tPA JJ 1_o
activity NN N
unaffected VBD N
, , N
independently RB N
of IN N
food NN N
composition NN N
. . N

A DT N
low JJ N
dietary JJ N
fiber NN N
intake NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
higher JJR N
PAI-1 NN 1_o
activities NNS 1_o
at IN N
baseline NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
Sandostatin NNP 1_i
prophylaxis NN 1_i
for IN 1_p
preservation NN 1_o
injury NN 1_o
after IN 1_p
pancreas JJ 1_p
transplantation NN 1_p
. . 1_p

-DOCSTART- -X- O O

Zinc NNP 1_i
supplementation NN 1_i
in IN N
alcoholic JJ 1_p
cirrhosis NN 1_p
. . 1_p

A DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

A DT N
double-blind JJ N
clinical JJ N
trial NN N
with IN N
zinc NN 1_i
sulfate NN 1_i
, , N
0.2 CD N
g NN N
three CD N
times NNS N
daily RB N
, , N
and CC 1_i
a DT 1_i
placebo NN 1_i
was VBD N
performed VBN N
in IN N
30 CD 1_p
patients NNS 1_p
with IN 1_p
biopsy-proven JJ 1_p
alcoholic JJ 1_p
liver NN 1_p
cirrhosis NN 1_p
. . 1_p

The DT N
disease NN N
was VBD N
in IN N
a DT N
stable JJ N
phase NN N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
showed VBD N
evidence NN N
of IN N
a DT N
decompensated VBN N
liver NN N
function NN N
. . N

Parameters NNS 1_o
of IN 1_o
liver NN 1_o
function NN 1_o
, , 1_o
taste NN 1_o
acuity NN 1_o
, , 1_o
dark JJ 1_o
adaptation NN 1_o
and CC 1_o
of IN 1_o
zinc NN 1_o
and CC 1_o
vitamin VB 1_o
A DT 1_o
metabolism NN 1_o
were VBD N
followed VBN N
for IN N
six CD N
weeks NNS N
. . N

In IN N
the DT N
zinc-treated JJ N
group NN N
of IN N
16 CD N
patients NNS N
, , N
serum JJ 1_o
zinc NN 1_o
rose VBD N
from IN N
a DT N
normal JJ N
mean JJ N
value NN N
of IN N
13.3 CD N
to TO N
17.4 CD N
mumol/l NNS N
, , N
whereas IN N
the DT N
mean JJ 1_o
serum NN 1_o
vitamin VBZ 1_o
A DT 1_o
level NN 1_o
remained VBD N
practically RB N
unaltered JJ N
within IN N
the DT N
normal JJ N
range NN N
, , N
1.89 CD N
at IN N
the DT N
entry NN N
and CC N
1.83 CD N
mumol/l NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Plasma NNP 1_o
prothrombin NN 1_o
and CC 1_o
serum JJ 1_o
alkaline JJ 1_o
phosphatase NN 1_o
levels NNS 1_o
of IN N
the DT N
zinc NNP N
group NN N
increased VBD N
and CC N
serum JJ 1_o
bilirubin NN 1_o
and CC 1_o
serum JJ 1_o
carotene NN 1_o
decreased VBN N
significantly RB N
. . N

The DT N
dark JJ 1_o
adaptation NN 1_o
did VBD N
not RB N
change NN N
, , N
but CC N
the DT N
taste NN 1_o
function NN 1_o
was VBD N
significantly RB N
improved VBN N
during IN N
zinc NN N
treatment NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
zinc NN 1_i
supplementation NN 1_i
causes VBZ N
alleviation NN N
of IN N
certain JJ N
abnormalities NNS N
of IN N
cirrhotics NNS 1_p
, , N
which WDT N
deserves VBZ N
further JJ N
attention NN N
. . N

-DOCSTART- -X- O O

Learning VBG N
the DT N
'traceback NN 1_i
' POS 1_i
approach NN 1_i
for IN N
interscalene JJ 1_p
block NN 1_p
. . 1_p

-DOCSTART- -X- O O

Oxytocin NNP 1_i
increases VBZ N
retention NN 1_o
of IN 1_o
social JJ 1_o
cognition NN 1_o
in IN N
autism NN N
. . N

BACKGROUND NNP N
Oxytocin NNP 1_i
dysfunction NN N
might MD N
contribute VB N
to TO N
the DT N
development NN N
of IN N
social JJ N
deficits NNS N
in IN N
autism NN N
, , N
a DT N
core NN N
symptom NN N
domain NN N
and CC N
potential JJ N
target NN N
for IN N
intervention NN N
. . N

This DT N
study NN N
explored VBD N
the DT N
effect NN N
of IN N
intravenous JJ N
oxytocin JJ 1_i
administration NN N
on IN N
the DT N
retention NN N
of IN N
social JJ N
information NN N
in IN N
autism NN N
. . N

METHODS NNP N
Oxytocin NNP 1_i
and CC 1_i
placebo NN 1_i
challenges NNS N
were VBD N
administered VBN N
to TO N
15 CD 1_p
adult NN 1_p
subjects NNS 1_p
diagnosed VBN 1_p
with IN 1_p
autism NN 1_p
or CC 1_p
Asperger NNP 1_p
's POS 1_p
disorder NN 1_p
, , 1_p
and CC 1_p
comprehension NN 1_p
of IN 1_p
affective JJ 1_p
speech NN 1_p
( ( 1_p
happy JJ 1_p
, , 1_p
indifferent JJ 1_p
, , 1_p
angry JJ 1_p
, , 1_p
and CC 1_p
sad NN 1_p
) ) 1_p
in IN N
neutral JJ N
content NN N
sentences NNS N
was VBD N
tested VBN N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
showed VBD N
improvements NNS N
in IN N
affective JJ 1_o
speech NN 1_o
comprehension NN 1_o
from IN N
pre- JJ N
to TO N
post-infusion NN N
; : N
however RB N
, , N
whereas NNS N
those DT N
who WP N
received VBD N
placebo NN 1_i
first RB N
tended VBD N
to TO N
revert VB N
to TO N
baseline VB N
after IN N
a DT N
delay NN N
, , N
those DT N
who WP N
received VBD N
oxytocin PRP N
first RB N
retained VBD N
the DT N
ability NN N
to TO N
accurately RB N
assign VB 1_o
emotional JJ 1_o
significance NN 1_o
to TO 1_o
speech VB 1_o
intonation NN 1_o
on IN N
the DT N
speech NN N
comprehension NN N
task NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
are VBP N
consistent JJ N
with IN N
studies NNS N
linking VBG N
oxytocin NN 1_i
to TO N
social JJ 1_o
recognition NN 1_o
in IN N
rodents NNS N
as RB N
well RB N
as IN N
studies NNS N
linking VBG N
oxytocin NN N
to TO N
prosocial JJ 1_o
behavior NN 1_o
in IN N
humans NNS N
and CC N
suggest VBP N
that IN N
oxytocin NN N
might MD N
facilitate VB N
social JJ N
information NN N
processing NN N
in IN N
those DT N
with IN N
autism NN N
. . N

These DT N
findings NNS N
also RB N
provide VBP N
preliminary JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
oxytocin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
autism NN N
. . N

-DOCSTART- -X- O O

Placebo-controlled JJ N
pilot NN N
trial NN N
of IN N
mecamylamine NN 1_i
for IN N
treatment NN N
of IN N
autism NN 1_o
spectrum NN 1_o
disorders NNS 1_o
. . 1_o

OBJECTIVE NNP N
To TO N
explore VB N
possible JJ N
benefits NNS N
of IN N
a DT N
nicotinic JJ 1_i
acetylcholine NN 1_i
receptor NN 1_i
( ( 1_i
nAChR JJ 1_i
) ) 1_i
agent NN 1_i
for IN N
autistic JJ 1_o
symptoms NNS 1_o
based VBN N
on IN N
postmortem NN N
observation NN N
of IN N
nAChR JJ N
abnormalities NNS N
( ( N
deficient JJ N
?4?2 NN N
nAChRs NN N
, , N
excess JJ N
?7 NNP N
nAChRs NN N
) ) N
in IN N
brains NNS 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

METHOD NNP 1_i
Mecamylamine NNP 1_i
, , 1_i
because IN 1_i
of IN N
its PRP$ N
safety NN N
record NN N
in IN N
children NNS N
with IN N
other JJ N
disorders NNS N
, , N
was VBD N
chosen VBN N
for IN N
this DT N
first JJ N
exploration NN 1_p
. . 1_p

Twenty NNP 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
age NN 1_p
4-12 CD 1_p
years NNS 1_p
were VBD 1_p
randomly RB N
assigned VBN N
for IN N
14 CD N
weeks NNS N
to TO N
placebo VB 1_i
( ( 1_i
n=8 NN 1_i
) ) N
or CC N
mecamylamine NN 1_i
( ( 1_i
n=12 JJ 1_i
) ) N
in IN N
ascending VBG N
fixed JJ N
doses NNS N
: : N
0.5 CD N
mg/day NN N
for IN N
6 CD N
weeks NNS N
, , N
2.5 CD N
mg NN N
for IN N
2 CD N
weeks NNS N
, , N
then RB N
5 CD N
mg/day NN N
for IN N
6 CD N
weeks NNS N
. . N

Improvement NNP N
was VBD N
rated VBN N
by IN N
a DT N
blinded JJ N
independent JJ N
evaluator NN N
. . N

Because IN N
of IN N
small JJ N
sample NN N
, , N
data NNS N
analysis NN N
was VBD N
descriptive JJ N
. . N

RESULTS NNP 1_p
Eighteen JJ 1_p
participants NNS 1_p
( ( 1_p
10 CD 1_p
mecamylamine NN 1_i
, , 1_i
8 CD 1_i
placebo NN 1_i
) ) 1_i
completed VBD 1_i
the DT 1_p
study NN 1_p
. . 1_p

All DT 1_p
doses NNS N
were VBD N
well RB 1_o
tolerated VBN 1_o
; : 1_o
the DT 1_o
only JJ N
side NN N
effect NN N
of IN N
note NN N
was VBD N
constipation NN 1_o
( ( 1_o
50 CD 1_o
% NN N
compared VBN N
with IN N
25 CD N
% NN N
of IN N
placebo NN 1_i
group NN 1_i
) ) N
. . N

Three CD N
children NNS N
had VBD N
clinically RB 1_o
nonsignificant JJ 1_o
electrocardiographic JJ 1_o
QT NNP 1_o
prolongation NN 1_o
. . 1_o

Both DT 1_o
groups NNS N
showed VBD N
modest JJ N
to TO N
moderate VB N
improvement NN N
, , N
but CC N
differences NNS N
between IN N
groups NNS N
were VBD N
negligible JJ N
. . N

On IN N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
the DT N
Ohio NNP 1_o
Autism NNP 1_o
Clinical NNP 1_o
Impressions NNP 1_o
Scale NNP 1_o
, , 1_o
90 CD 1_o
% NN N
of IN N
the DT N
active JJ N
treatment NN N
group NN N
showed VBD N
improvement NN N
at IN N
some DT N
point NN N
( ( N
but CC N
only RB N
40 CD N
% NN N
sustained VBD N
it PRP N
) ) N
, , N
compared VBN N
with IN N
62 CD N
% NN N
on IN N
placebo NN 1_i
. . 1_i

Of IN 1_i
the DT N
four CD N
in IN N
active JJ N
treatment NN N
that WDT N
sustained VBD N
improvement NN N
, , N
three CD N
had VBD N
a DT N
maximum JJ N
dose NN N
of IN N
0.13-0.15 JJ N
mg/kg/day NN N
, , N
while IN N
those DT N
who WP N
regressed VBD N
had VBD N
doses NNS N
?0.18 JJ N
mg/kg/day NN N
. . N

Graphed VBN N
means NNS N
suggested VBD N
better RBR N
outcome NN N
with IN N
lower JJR N
mg/kg NN N
and CC N
longer JJR N
medication NN N
duration NN N
. . N

Four CD N
parents NNS N
spontaneously RB N
reported VBD N
reduced JJ 1_o
hyperactivity NN 1_o
and CC 1_o
irritability NN 1_o
and CC 1_o
better JJR 1_o
verbalization NN 1_o
and CC 1_o
continued JJ 1_i
mecamylamine NN 1_i
at IN 1_i
their PRP$ 1_i
own JJ N
expense NN N
. . N

CONCLUSION NNP 1_i
Mecamylamine NNP 1_i
appeared VBD 1_i
to TO N
be VB N
safe JJ N
, , N
but CC N
not RB N
very RB N
effective JJ 1_o
in IN 1_o
autism NN 1_o
. . 1_o

The DT 1_o
suggestion NN N
of IN N
better JJR N
results NNS N
at IN N
lower JJR N
doses NNS N
and CC N
longer JJR N
exposure NN N
warrants NNS N
consideration NN N
for IN N
future JJ N
trials NNS N
. . N

The DT N
next JJ N
step NN N
would MD N
be VB N
exploration NN N
of IN N
a DT N
more RBR N
specific JJ 1_i
?4?2 NNP 1_i
nAChR JJ 1_i
agonist NN 1_i
, , 1_i
such JJ 1_i
as IN 1_i
varenicline NN 1_i
. . 1_i

-DOCSTART- -X- O O

Predictive JJ N
and CC N
prognostic JJ N
roles NNS N
of IN N
BRAF NNP 1_p
mutation NN 1_p
in IN 1_p
stage NN 1_p
III NNP 1_p
colon NN 1_p
cancer NN 1_p
: : 1_p
results NNS N
from IN N
intergroup JJ N
trial NN N
CALGB NNP N
89803 CD N
. . N

PURPOSE NNP N
Alterations NNPS N
in IN N
the DT N
RAS-RAF-MAP2K NNP N
( ( N
MEK NNP N
) ) N
-MAPK VBP N
signaling VBG N
pathway NN N
are VBP N
major JJ N
drivers NNS N
in IN N
colorectal JJ 1_p
carcinogenesis NN 1_p
. . 1_p

In IN N
colorectal JJ N
cancer NN N
, , N
BRAF NNP N
mutation NN N
is VBZ N
associated VBN N
with IN N
microsatellite JJ N
instability NN N
( ( N
MSI NNP N
) ) N
, , N
and CC N
typically RB N
predicts VBZ N
inferior JJ N
prognosis NN N
. . N

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
BRAF NNP N
mutation NN N
on IN N
survival NN N
and CC N
treatment NN N
efficacy NN N
in IN N
patients NNS 1_p
with IN 1_p
stage NN 1_p
III NNP 1_p
colon NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
We PRP N
assessed VBD N
status NN 1_i
of IN 1_i
BRAF NNP 1_i
c.1799T NN 1_i
> VBZ 1_i
A NNP 1_i
( ( 1_i
p.V600E NN 1_i
) ) 1_i
mutation NN 1_i
and CC 1_i
MSI NNP 1_i
in IN N
506 CD 1_p
stage NN 1_p
III NNP 1_p
colon NN 1_p
cancer NN 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
adjuvant NN 1_p
chemotherapy NN 1_i
trial NN 1_i
[ NNP 1_i
5-fluorouracil CD 1_i
and CC 1_i
leucovorin NN 1_i
( ( 1_i
FU/LV NNP 1_i
) ) 1_i
vs. FW 1_i
irinotecan JJ 1_i
( ( 1_i
CPT11 NNP 1_i
) ) 1_i
, , 1_i
FU NNP 1_i
and CC 1_i
LV NNP 1_i
( ( 1_i
IFL NNP 1_i
) ) 1_i
; : 1_i
CALGB $ N
89803 CD N
] NNP N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
model NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
prognostic JJ N
role NN N
of IN N
BRAF NNP N
mutation NN N
, , N
adjusting VBG N
for IN N
clinical JJ N
features NNS N
, , N
adjuvant JJ N
chemotherapy NN 1_i
arm NN N
, , N
and CC N
MSI NNP N
status NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
431 CD N
BRAF NNP N
wild-type JJ N
patients NNS N
, , N
75 CD 1_p
BRAF-mutated JJ 1_p
patients NNS 1_p
experienced VBD N
significantly RB N
worse JJR N
overall JJ 1_o
survival NN 1_o
[ NNP 1_o
OS NNP 1_o
; : 1_o
log-rank JJ N
P NNP N
= NNP N
0.015 CD N
; : N
multivariate NN N
HR NNP N
= NNP N
1.66 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.05-2.63 JJ N
] NN N
. . N

By IN N
assessing VBG N
combined JJ N
status NN N
of IN N
BRAF NNP N
and CC N
MSI NNP N
, , N
it PRP N
seemed VBD N
that IN N
BRAF-mutated NNP N
MSS NNP N
( ( N
microsatellite JJ N
stable NN N
) ) N
tumor NN N
was VBD N
an DT N
unfavorable JJ N
subtype NN N
, , N
whereas JJ N
BRAF NNP N
wild-type JJ N
MSI-high NNP N
tumor NN N
was VBD N
a DT N
favorable JJ N
subtype NN N
, , N
and CC N
BRAF-mutated JJ N
MSI-high JJ N
tumor NN N
and CC N
BRAF NNP N
wild-type JJ N
MSS NNP N
tumor NN N
were VBD N
intermediate JJ N
subtypes NNS N
. . N

Among IN N
patients NNS N
with IN N
BRAF-mutated JJ N
tumors NNS N
, , N
a DT N
nonsignificant JJ N
trend NN N
toward IN N
improved JJ N
OS NNP 1_o
was VBD N
observed VBN N
for IN N
IFL NNP 1_i
versus NN N
FU/LV NNP 1_i
arm NN N
( ( N
multivariate JJ N
HR NNP N
= NNP N
0.52 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.25-1.10 NN N
) ) N
. . N

Among IN N
patients NNS N
with IN N
BRAF NNP N
wild-type JJ N
cancer NN N
, , N
IFL NNP 1_i
conferred VBD N
no DT N
suggestion NN N
of IN N
benefit NN N
beyond IN N
FU/LV NNP 1_i
alone RB N
( ( N
multivariate JJ N
HR NNP N
= NNP N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.72-1.46 NN N
) ) N
. . N

CONCLUSIONS NNP N
BRAF NNP N
mutation NN N
is VBZ N
associated VBN N
with IN N
inferior JJ N
survival NN 1_o
in IN N
stage NN 1_p
III NNP 1_p
colon NN 1_p
cancer NN 1_p
. . 1_p

Additional JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
whether IN N
there EX N
is VBZ N
any DT N
predictive JJ N
role NN N
of IN N
BRAF NNP N
mutation NN N
for IN N
irinotecan-based JJ 1_i
therapy NN 1_i
. . 1_i

-DOCSTART- -X- O O

Cytokine NN 1_o
levels NNS 1_o
and CC 1_o
systemic JJ 1_o
toxicity NN 1_o
in IN N
patients NNS 1_p
undergoing VBG 1_p
isolated JJ 1_i
limb NN 1_i
perfusion NN 1_i
with IN 1_i
high-dose JJ 1_i
tumor NN 1_i
necrosis NN 1_i
factor NN 1_i
, , 1_i
interferon NN 1_i
gamma NN 1_i
, , 1_i
and CC 1_i
melphalan NN 1_i
. . 1_i

PURPOSE NNP N
Isolated NNP 1_i
limb NN 1_i
perfusion NN 1_i
( ( 1_i
ILP NNP 1_i
) ) 1_i
with IN 1_i
tumor NN 1_i
necrosis NN 1_i
factor NN 1_i
( ( 1_i
TNF NNP 1_i
) ) 1_i
, , 1_i
interferon JJ 1_i
gamma NN 1_i
, , 1_i
and CC 1_i
melphalan NN 1_i
( ( 1_i
M NNP 1_i
) ) 1_i
has VBZ N
been VBN N
reported VBN N
to TO N
result VB N
in IN N
high JJ N
response NN 1_o
rates NNS 1_o
for IN N
extremity NN N
melanoma NN N
and CC N
sarcoma NN N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
relationship NN N
of IN N
systemic JJ N
TNF NNP N
exposure NN N
to TO N
induction NN N
of IN N
several JJ N
secondary JJ 1_o
mediators NNS 1_o
and CC N
incidence NN N
of IN N
systemic JJ 1_o
toxicity NN 1_o
. . 1_o

PATIENTS NNP N
AND CC N
METHODS NNP N
Nineteen NNP 1_p
patients NNS 1_p
with IN 1_p
extremity NN 1_p
melanoma NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
16 CD 1_p
) ) 1_p
or CC 1_p
sarcoma NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
3 CD 1_p
) ) 1_p
, , N
underwent JJ N
90-minute JJ N
ILP NNP 1_i
with IN 1_i
TNF-alpha NNP 1_i
, , 1_i
interferon NN 1_i
gamma NN 1_i
( ( N
0.2 CD N
mg NN N
) ) N
, , N
and CC 1_i
M NNP 1_i
( ( N
10 CD N
to TO N
13 CD N
mg/L NN N
of IN N
limb NN N
volume NN N
) ) N
( ( 1_i
TNF/IFN/M NNP 1_i
) ) 1_i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
or CC 1_i
M NNP 1_i
alone RB 1_i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
. . N

Continuous JJ N
intraoperative JJ N
monitoring NN N
( ( N
CIM NNP N
) ) N
for IN N
systemic JJ N
leak NN N
from IN N
the DT N
perfusion NN N
circuit NN N
was VBD N
performed VBN N
using VBG N
radioactive JJ N
iodine-131 JJ 1_i
albumin NN 1_i
. . 1_i

Cytokine NN N
levels NNS N
in IN N
the DT N
perfusate NN N
and CC N
systemic JJ N
circulation NN N
during IN N
and CC N
after IN N
ILP NNP N
were VBD N
measured VBN N
by IN N
enzyme-linked JJ 1_i
immunosorbent NN 1_i
assay NN 1_i
. . 1_i

RESULTS NNP N
Systemic NNP 1_o
leaks VBZ 1_o
> CD 1_o
or CC 1_o
= VB 1_o
1 CD 1_o
% NN 1_o
from IN N
the DT N
perfusion NN 1_o
circuit NN 1_o
occurred VBD N
in IN N
six CD N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
and CC N
in IN N
four CD N
who WP N
received VBD N
M NNP N
alone RB N
. . N

Hypotension NNP 1_o
that IN 1_o
required VBD 1_o
vasopressor NN 1_o
support NN 1_o
occurred VBD N
in IN N
six CD N
of IN N
six CD N
patients NNS N
with IN N
evidence NN N
of IN N
a DT N
leak NN N
( ( N
> CD N
or CC N
= VB N
1 CD N
% NN N
) ) N
and CC N
zero CD N
of IN N
six CD N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
< JJ N
1 CD N
% NN N
) ) N
. . N

These DT N
six CD N
patients NNS N
had VBD N
significantly RB N
higher JJR N
peak JJ 1_o
systemic JJ 1_o
TNF NNP 1_o
levels NNS 1_o
during IN N
and CC N
after IN N
perfusion NN N
than IN N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
2.8 CD N
and CC N
8.2 CD N
ng/mL JJ N
v NN N
0.7 CD N
and CC N
2.0 CD N
ng/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

All PDT N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
had VBD N
significantly RB N
greater JJR N
increases NNS N
in IN N
systemic JJ 1_o
interleukin-6 JJ 1_o
( ( 1_o
IL-6 NNP 1_o
) ) 1_o
levels NNS 1_o
than IN N
in IN N
patients NNS N
with IN N
M NNP N
alone RB N
( ( N
12,395 CD N
+/- JJ N
10,374 CD N
pg/mL NN N
v NN N
79.4 CD N
+/- JJ N
7.2 CD N
pg/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Intracellular JJ 1_o
adhesion NN 1_o
molecule NN 1_o
( ( 1_o
ICAM NNP 1_o
) ) 1_o
, , 1_o
IL-8 NNP 1_o
, , 1_o
and CC 1_o
TNF-R JJ 1_o
levels NNS 1_o
were VBD N
also RB N
increased VBN N
after IN N
ILP NNP N
with IN N
TNF/IFN/M NNP N
. . N

CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
. . N

Patients NNS N
with IN N
a DT N
measured JJ N
leak NN N
of IN N
> NN N
or CC N
= VB N
1 CD N
% NN N
develop NN N
mild NN N
and CC N
transient JJ N
postoperative JJ N
hypotension NN N
with IN N
significantly RB N
higher JJR N
systemic JJ N
TNF NNP N
levels NNS N
and CC N
lower JJR N
perfusate NN N
TNF NNP N
levels NNS N
than IN N
in IN N
patients NNS N
without IN N
leaks NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
statins NNS 1_i
on IN N
progression NN N
of IN N
subclinical JJ 1_o
brain NN 1_o
infarct NN 1_o
. . 1_o

BACKGROUND NNP N
Subclinical NNP 1_o
brain NN 1_o
infarct NN 1_o
( ( 1_o
SBI NNP 1_o
) ) 1_o
is VBZ N
associated VBN N
with IN N
subsequent JJ N
stroke NN N
and CC N
cognitive JJ N
decline NN N
. . N

A DT N
longitudinal JJ N
epidemiological JJ N
study NN N
suggests VBZ N
that IN N
statins NNS 1_i
may MD N
prevent VB N
development NN N
of IN N
SBI NNP 1_o
. . 1_o

We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
statins NNS 1_i
upon IN N
development NN 1_o
of IN 1_o
brain NN 1_o
infarct NN 1_o
by IN N
performing VBG N
a DT N
post-hoc JJ N
analysis NN N
of IN N
the DT N
Regression NNP N
of IN N
Cerebral NNP N
Artery NNP N
Stenosis NNP N
( ( N
ROCAS NNP N
) ) N
study NN N
. . N

METHODS NNP N
The DT N
ROCAS NNP N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
simvastatin NN 1_i
20 CD N
mg JJ N
daily JJ N
upon IN N
progression NN N
of IN N
asymptomatic JJ N
middle JJ N
cerebral JJ N
artery NN N
stenosis NN N
among IN N
stroke-free JJ 1_p
individuals NNS 1_p
over IN 1_p
2 CD 1_p
years NNS 1_p
. . 1_p

A DT N
total NN 1_p
of IN 1_p
227 CD 1_p
subjects NNS 1_p
were VBD N
randomized VBN N
to TO N
either DT N
placebo NN 1_i
( ( N
n JJ N
= NNP N
114 CD N
) ) N
or CC N
simvastatin $ 1_i
20 CD N
mg JJ N
daily JJ N
( ( N
n JJ N
= NNP N
113 CD N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
brain NN 1_o
infarcts NNS 1_o
as IN N
detected VBN N
by IN N
MRI NNP N
was VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
number NN 1_o
of IN 1_o
new JJ 1_o
brain NN 1_o
infarcts NNS 1_o
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS NNP N
Among IN N
the DT N
227 CD 1_p
randomized JJ 1_p
subjects NNS 1_p
, , 1_p
33 CD 1_p
( ( 1_p
14.5 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
SBI VBN 1_p
at IN 1_p
baseline NN 1_p
. . 1_p

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
significantly RB N
fewer JJR N
subjects NNS N
in IN N
the DT N
active JJ N
group NN N
( ( N
n JJ N
= NNP N
1 CD N
) ) N
had VBD N
new JJ 1_o
brain NN 1_o
infarcts NNS 1_o
compared VBN N
with IN N
the DT N
placebo NN 1_i
group NN N
( ( N
n JJ N
= VBZ N
8 CD N
; : N
p NN N
= VBZ N
0.018 CD N
) ) N
. . N

The DT N
new JJ N
brain NN 1_o
infarcts NNS 1_o
of IN N
subjects NNS N
in IN N
the DT N
active JJ N
group NN N
were VBD N
subclinical JJ N
. . N

Among IN N
the DT N
placebo NN 1_i
group NN N
, , N
the DT N
new JJ N
brain NN 1_o
infarcts NNS 1_o
of IN N
3 CD N
subjects NNS N
were VBD N
symptomatic JJ N
while IN N
those DT N
of IN N
the DT N
remaining VBG N
5 CD N
subjects NNS N
were VBD N
subclinical JJ N
. . N

Among IN N
putative JJ N
variables NNS N
, , N
multivariate JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
only RB N
the DT N
baseline NN N
number NN N
of IN N
SBIs NNP 1_o
( ( N
OR NNP N
= VBZ N
6.27 CD N
, , N
95 CD N
% NN N
CI NNP N
2.4-16.5 CD N
) ) N
and CC N
simvastatin JJ 1_i
treatment NN N
( ( N
OR NNP N
= VBZ N
0.09 CD N
, , N
95 CD N
% NN N
CI NNP N
0.01-0.82 NN N
) ) N
independently RB N
predicted VBD N
the DT N
development NN N
of IN N
new JJ N
brain NN N
infarcts NNS N
. . N

CONCLUSIONS NNP N
Consistent NNP N
with IN N
findings NNS N
of IN N
the DT N
epidemiological JJ N
study NN N
, , N
our PRP$ N
study NN N
suggests VBZ N
that IN N
statins NNS N
may MD N
prevent VB N
the DT N
development NN N
of IN N
a DT N
new JJ N
brain NN 1_o
infarct NN 1_o
. . 1_o

-DOCSTART- -X- O O

Effect NN N
of IN N
beta-blocking NN N
drugs NNS N
on IN N
beta-cell NN N
function NN N
and CC N
insulin NN N
sensitivity NN N
in IN N
hypertensive JJ 1_p
non-diabetic JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
effects NNS N
of IN N
two CD N
beta-blocking JJ N
drugs NNS N
on IN N
endogenous JJ N
insulin NN N
secretion NN N
and CC N
insulin NN N
sensitivity NN N
were VBD N
investigated VBN N
in IN N
a DT N
double-blind JJ N
cross-over NN N
study NN N
in IN N
13 CD 1_p
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
each DT N
of IN N
three CD N
2-week JJ N
treatment NN N
periods NNS N
with IN N
propranolol JJ 1_i
80 CD 1_i
mg NN 1_i
b.i.d. NN 1_i
, , N
atenolol RB 1_i
50 CD 1_i
mg NN 1_i
b.i.d NN 1_i
. . 1_i

and CC 1_i
placebo JJ 1_i
b.i.d NN 1_i
. . 1_i

Endogenous JJ N
insulin NN N
secretion NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
serum JJ N
insulin NN N
and CC N
C-peptide NNP N
before IN N
and CC N
6 CD N
min NN N
after IN N
iv JJ N
administration NN N
of IN N
glucagon NN N
; : N
insulin JJ N
sensitivity NN N
was VBD N
determined VBN N
by IN N
measuring VBG N
insulin NN N
binding VBG N
to TO N
erythrocytes NNS N
, , N
and CC N
as IN N
the DT N
glucose JJ N
disappearance NN N
rate NN N
( ( N
KITT NNP N
) ) N
after IN N
i.v NN N
. . N

insulin NN N
. . N

Fasting VBG N
concentrations NNS N
of IN N
serum JJ N
free JJ N
fatty NN N
acids NNS N
( ( N
S-FFA NNP N
) ) N
and CC N
plasma JJ N
gastric JJ N
inhibitory NN N
polypeptide NN N
( ( N
P-GIP NNP N
) ) N
were VBD N
also RB N
recorded VBN N
during IN N
the DT N
three CD N
study NN N
periods NNS N
. . N

Both DT N
propranolol NN 1_i
and CC N
atenolol NN 1_i
reduced VBD N
blood NN 1_o
pressure NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
S-FFA NNP 1_o
concentrations NNS 1_o
compared VBN N
to TO N
placebo VB 1_i
, , N
and CC N
all DT N
patients NNS N
showed VBD N
measurable JJ N
plasma JJ N
concentrations NNS N
of IN N
propranolol NN N
and CC N
atenolol NN N
. . N

The DT N
results NNS N
can MD N
be VB N
considered VBN N
representative JJ N
, , N
therefore RB N
, , N
of IN N
clinical JJ 1_o
beta-blockade NN 1_o
. . 1_o

The DT N
two CD N
drugs NNS N
did VBD N
not RB N
significantly RB N
influence VB N
the DT N
fasting NN 1_o
blood NN 1_o
glucose JJ 1_o
level NN 1_o
. . 1_o

There EX N
was VBD N
an DT N
increase NN N
in IN N
fasting VBG 1_o
and CC 1_o
glucagon-stimulated JJ 1_o
serum NN 1_o
C-peptide NNP 1_o
concentration NN 1_o
during IN N
propranolol JJ N
therapy NN N
compared VBN N
with IN N
placebo NN N
( ( N
p JJ N
= NN N
0.037 CD N
and CC N
p VB N
= JJ N
0.030 CD N
, , N
respectively RB N
) ) N
, , N
although IN N
this DT N
was VBD N
not RB N
reflected VBN N
by IN N
a DT N
significant JJ N
change NN N
in IN N
serum JJ 1_o
insulin NN 1_o
. . 1_o

Propranolol NNP 1_i
and CC N
atenolol RB N
did VBD N
not RB N
significantly RB N
influence JJ N
insulin NN 1_o
binding NN 1_o
to TO 1_o
erythrocytes NNS 1_o
, , N
but CC N
they PRP N
clearly RB N
reduced VBD N
the DT N
glucose JJ 1_o
disappearance NN 1_o
rate NN 1_o
KITT NNP 1_o
was VBD N
compared VBN N
to TO N
placebo VB N
( ( N
p JJ N
= NN N
0.0036 CD N
and CC N
p VB N
= NNP N
0.0003 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

The DT N
findings NNS N
support VBP N
the DT N
view NN N
that IN N
beta-blocking JJ N
drugs NNS N
can MD N
influence VB N
glucose JJ 1_o
metabolism NN 1_o
by IN N
mechanisms NNS N
other JJ N
than IN N
inhibition NN N
of IN N
endogenous JJ 1_o
insulin NN 1_o
secretion NN 1_o
. . 1_o

-DOCSTART- -X- O O

Safety NN 1_o
of IN N
ferumoxytol NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
anemia NN 1_p
and CC 1_p
CKD NNP 1_p
. . 1_p

BACKGROUND NNP N
Iron NNP N
deficiency NN N
anemia NN N
is VBZ N
a DT N
common JJ N
complication NN N
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
kidney NN 1_p
disease NN 1_p
( ( 1_p
CKD NNP 1_p
) ) 1_p
. . 1_p

Currently NNP N
available JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
iron NN 1_i
replacement NN 1_i
therapies NNS 1_i
have VBP N
either DT N
inconvenient JJ N
regimens NNS N
of IN N
administration NN N
or CC N
adverse JJ N
event NN N
profiles NNS N
that WDT N
limit VBP N
their PRP$ N
utility NN N
in IN N
the DT N
outpatient NN 1_p
setting NN N
. . N

Ferumoxytol NNP 1_i
is VBZ N
a DT N
novel NN N
, , N
semisynthetic JJ N
, , N
carbohydrate-coated JJ N
, , N
superparamagnetic JJ N
iron NN N
oxide NN N
nanoparticle NN N
that WDT N
is VBZ N
administered VBN N
IV NNP N
as IN N
an DT N
injection NN N
. . N

The DT N
main JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
safety NN 1_o
of IN N
ferumoxytol NN 1_i
for IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
CKD NNP 1_p
stages VBZ 1_p
1 CD 1_p
to TO 1_p
5 CD 1_p
and CC 1_p
5D CD 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
Phase NNP N
3 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
crossover NN N
, , N
multicenter NN N
study NN N
of IN N
a DT N
single JJ N
510-mg JJ N
dose NN N
of IN N
ferumoxytol JJ 1_i
versus NN 1_i
saline NN 1_i
as IN 1_i
placebo NN 1_i
. . 1_i

SETTING NNP N
& CC N
PARTICIPANTS NNP N
750 CD 1_p
patients NNS 1_p
with IN 1_p
CKD NNP 1_p
stages VBZ 1_p
1 CD 1_p
to TO 1_p
5 CD 1_p
and CC 1_p
5D CD 1_p
. . 1_p

INTERVENTION NNP N
An DT N
IV NNP 1_i
injection NN 1_i
of IN N
either CC N
17 CD N
mL NN N
of IN N
ferumoxytol NN 1_i
or CC 1_i
saline NN 1_i
placebo NN 1_i
over IN N
17 CD N
seconds NNS N
on IN N
day NN N
0 CD N
and CC N
the DT N
alternate NN N
agent NN N
on IN N
day NN N
7 CD N
. . N

OUTCOMES NNP N
& CC N
MEASUREMENTS NNP N
Descriptive NNP N
comparison NN N
of IN N
adverse JJ 1_o
events NNS 1_o
, , 1_o
laboratory NN 1_o
tests NNS 1_o
, , 1_o
and CC 1_o
vital JJ 1_o
signs NNS 1_o
. . 1_o

RESULTS NNP N
Of IN N
750 CD 1_p
randomly NNS 1_p
assigned VBD 1_p
patients NNS 1_p
with IN 1_p
CKD NNP 1_p
, , 1_p
60 CD 1_p
% NN 1_p
were VBD 1_p
not RB 1_p
on IN 1_p
dialysis NN 1_i
therapy NN 1_i
. . 1_i

713 CD 1_p
patients NNS 1_p
received VBD 1_p
ferumoxytol JJ 1_i
, , 1_p
and CC 1_p
711 CD 1_p
received VBD 1_p
placebo NN 1_i
. . 1_i

There EX N
were VBD N
420 CD 1_p
adverse JJ 1_o
events NNS 1_o
reported VBD 1_p
; : 1_p
242 CD 1_p
in IN 1_p
152 CD 1_p
patients NNS 1_p
( ( 1_p
21.3 CD 1_p
% NN 1_p
) ) 1_p
with IN 1_p
ferumoxytol NN 1_p
and CC 1_p
178 CD 1_p
in IN 1_p
119 CD 1_p
patients NNS 1_p
( ( 1_p
16.7 CD 1_p
% NN 1_p
) ) 1_p
with IN 1_p
placebo NN 1_i
. . 1_i

The DT N
incidence NN 1_o
of IN 1_o
related JJ 1_o
adverse JJ 1_o
events NNS 1_o
was VBD N
5.2 CD N
% NN N
with IN N
ferumoxytol NN 1_i
and CC N
4.5 CD N
% NN N
with IN N
placebo NN 1_i
. . 1_i

The DT N
most RBS N
common JJ N
related JJ N
adverse JJ 1_o
events NNS 1_o
after IN N
each DT N
treatment NN N
included VBD N
symptoms NNS 1_o
related VBN N
to TO N
the DT N
injection/infusion NN 1_o
site NN 1_o
, , 1_o
dizziness NN 1_o
, , 1_o
pruritus NN 1_o
, , 1_o
headache NN 1_o
, , 1_o
fatigue NN 1_o
, , 1_o
and CC 1_o
nausea NN 1_o
. . 1_o

Serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
occurred VBD N
in IN N
21 CD N
patients NNS N
( ( N
2.9 CD N
% NN N
) ) N
after IN N
ferumoxytol NN 1_i
and CC N
13 CD N
patients NNS N
( ( N
1.8 CD N
% NN N
) ) N
after IN N
placebo NN 1_i
. . 1_i

Serious JJ 1_o
related JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
observed VBN N
in IN N
1 CD N
patient NN N
( ( N
0.1 CD N
% NN N
) ) N
after IN N
each DT N
treatment NN N
. . N

There EX N
was VBD N
no DT N
meaningful JJ N
decrease NN N
in IN N
blood NN 1_o
pressure NN 1_o
after IN N
administration NN N
of IN N
ferumoxytol NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

LIMITATIONS NNP N
Follow-up NNP N
was VBD N
7 CD N
days NNS N
after IN N
each DT N
study NN N
treatment NN N
. . N

CONCLUSIONS NNP N
Ferumoxytol NNP 1_i
is VBZ N
well RB N
tolerated VBN 1_o
and CC N
has VBZ N
a DT N
safety NN 1_o
profile NN 1_o
similar JJ N
to TO N
placebo VB 1_i
in IN N
anemic JJ 1_p
patients NNS 1_p
with IN 1_p
CKD NNP 1_p
stages VBZ 1_p
1 CD 1_p
to TO 1_p
5 CD 1_p
and CC 1_p
5D CD 1_p
. . 1_p

-DOCSTART- -X- O O

Avatar NNP N
assistant NN N
: : N
improving VBG N
social JJ 1_o
skills NNS 1_o
in IN N
students NNS 1_p
with IN 1_p
an DT 1_p
ASD NNP 1_p
through IN N
a DT N
computer-based JJ 1_i
intervention NN 1_i
. . 1_i

This DT N
study NN N
assessed VBD N
the DT N
efficacy NN 1_o
of IN N
FaceSay NNP 1_i
, , 1_i
a DT 1_i
computer-based JJ 1_i
social JJ 1_o
skills NNS 1_o
training VBG 1_i
program NN 1_i
for IN N
children NNS 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorders NNP 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

This DT N
randomized VBD N
controlled VBN N
study NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
49 CD 1_p
) ) 1_p
indicates VBZ 1_p
that IN N
providing VBG 1_p
children NNS 1_p
with IN 1_p
low-functioning JJ 1_p
autism NN 1_p
( ( 1_p
LFA NNP 1_p
) ) 1_p
and CC 1_p
high JJ 1_p
functioning NN 1_p
autism NN 1_p
( ( 1_p
HFA NNP 1_p
) ) 1_p
opportunities VBZ 1_p
to TO N
practice NN N
attending VBG N
to TO N
eye NN N
gaze NN N
, , N
discriminating VBG N
facial JJ N
expressions NNS N
and CC N
recognizing VBG N
faces VBZ N
and CC N
emotions NNS N
in IN N
FaceSay NNP N
's POS N
structured JJ N
environment NN N
with IN N
interactive JJ N
, , N
realistic JJ N
avatar NN N
assistants NNS N
improved VBD N
their PRP$ 1_o
social JJ 1_o
skills NNS 1_o
abilities NNS 1_o
. . 1_o

The DT N
children NNS N
with IN N
LFA NNP N
demonstrated VBD N
improvements NNS N
in IN N
two CD N
areas NNS N
of IN N
the DT N
intervention NN 1_o
: : 1_o
emotion NN 1_o
recognition NN 1_o
and CC 1_o
social JJ 1_o
interactions NNS 1_o
. . 1_o

The DT N
children NNS N
with IN N
HFA NNP N
demonstrated VBD N
improvements NNS N
in IN N
all DT N
three CD N
areas NNS 1_o
: : 1_o
facial JJ 1_o
recognition NN 1_o
, , 1_o
emotion NN 1_o
recognition NN 1_o
, , 1_o
and CC 1_o
social JJ 1_o
interactions NNS 1_o
. . 1_o

These DT N
findings NNS N
, , N
particularly RB N
the DT N
measured JJ N
improvements NNS N
to TO N
social JJ 1_o
interactions NNS 1_o
in IN 1_o
a DT N
natural JJ N
environment NN N
, , N
are VBP N
encouraging VBG N
. . N

-DOCSTART- -X- O O

Thrombolysis NN N
is VBZ N
superior JJ N
to TO N
heparin VB N
for IN N
non-obstructive JJ 1_p
mitral JJ 1_p
mechanical JJ 1_p
valve NN 1_p
thrombosis NN 1_p
. . 1_p

BACKGROUND NNP N
AND NNP N
AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
Non-obstructive NNP 1_p
prosthetic JJ 1_p
valve NN 1_p
thrombosis NN 1_p
( ( 1_p
PVT NNP 1_p
) ) 1_p
is VBZ N
a DT N
unique JJ N
subset NN N
that WDT N
features VBZ N
clinical JJ N
presentation NN N
without IN N
heart NN N
failure NN N
, , N
and CC N
may MD N
be VB N
asymptomatic JJ N
. . N

Thrombolysis NN N
has VBZ N
been VBN N
accepted VBN N
for IN N
obstructive JJ N
PVT NNP N
, , N
but CC N
treatment NN N
strategies NNS N
of IN N
non-obstructive JJ N
PVT NNP N
are VBP N
controversial JJ N
. . N

This DT N
study NN N
compared VBN N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
thrombolysis NN N
and CC N
heparin NN N
treatment NN N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
Between NNP N
1993 CD N
and CC N
1998 CD N
, , N
20 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
were VBD 1_p
found VBN 1_p
by IN 1_p
multiplane NN 1_p
transesophageal NN 1_i
echocardiography NN 1_i
( ( 1_p
TEE NNP 1_p
) ) 1_p
to TO 1_p
have VB 1_p
non-obstructive JJ 1_p
PVT NNP 1_p
. . 1_p

TEE NNP N
was VBD N
performed VBN N
for IN N
peripheral JJ N
embolism NN N
in IN N
two CD N
patients NNS N
, , N
stroke VBD N
or CC N
transient JJ N
ischemic JJ N
attack NN N
in IN N
six CD N
, , N
stroke NN N
and CC N
fever NN N
in IN N
two CD N
, , N
fever RB N
in IN N
one CD N
patient NN N
, , N
as IN N
a DT N
routine JJ N
postoperative JJ N
examination NN N
in IN N
two CD N
patients NNS N
, , N
and CC N
for IN N
other JJ N
reasons NNS N
in IN N
seven CD N
. . N

Patients NNS N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
group NN N
I PRP N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
received VBD N
streptokinase-mediated JJ 1_i
fibrinolysis NN 1_i
; : 1_i
group NN N
II NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
received VBD N
intravenous JJ 1_i
heparin NNS 1_i
by IN 1_i
infusion NN 1_i
. . 1_i

Treatment NN N
was VBD N
monitored VBN N
using VBG N
TEE NNP N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
patient JJ N
groups NNS N
with IN N
regard NN N
to TO N
sex NN N
, , N
age NN N
, , N
type NN N
of IN N
prosthesis NN N
and CC N
time NN N
since IN N
operation NN N
, , N
though IN N
anticoagulant JJ N
status NN N
was VBD N
more RBR N
often RB N
inadequate JJ N
in IN N
group NN N
II NNP N
. . N

By IN N
TEE NNP N
, , N
valve FW 1_o
motion NN 1_o
was VBD N
normal JJ N
in IN N
all DT N
patients NNS N
. . N

In IN N
group NN N
I PRP N
, , N
all DT N
thrombi NNS 1_o
were VBD N
mobile JJ 1_o
and CC N
5-13 JJ N
mm NN N
in IN N
diameter NN N
; : N
in IN N
group NN N
II NNP N
, , N
all DT N
thrombi NNS N
but CC N
three CD N
were VBD N
mobile JJ 1_o
and CC N
3-18 JJ N
mm NN N
in IN N
diameter NN N
. . N

In IN N
group NN N
I PRP N
, , N
thrombolysis NN N
was VBD N
successful JJ N
in IN N
all DT N
patients NNS N
, , N
without IN N
complications NNS 1_o
, , N
within IN N
6-72 JJ N
h. NN N
In IN N
group NN N
II NNP N
, , N
heparin NN 1_i
treatment NN N
was VBD N
successful JJ N
in IN N
six CD N
patients NNS N
in IN N
3-32 JJ N
days NNS N
. . N

In IN N
one CD N
patient NN N
, , N
seven CD N
days NNS N
' CD N
of IN N
unsuccessful JJ N
heparin NN N
was VBD N
followed VBN N
by IN N
two CD N
months NNS N
' POS N
successful JJ N
coumarin NN N
therapy NN N
. . N

Among IN N
five CD N
unsuccessful JJ N
cases NNS N
, , N
the DT N
thrombus JJ 1_o
size NN 1_o
increased VBD N
in IN N
four CD N
( ( N
three CD N
became VBD N
obstructive JJ N
in IN N
7-35 JJ N
days NNS N
) ) N
; : N
all DT N
four CD N
patients NNS N
were VBD N
switched VBN N
to TO N
fibrinolysis NN N
, , N
which WDT N
was VBD N
successful JJ N
without IN N
complications NNS N
in IN N
12-60 JJ N
h. NN N
The DT N
fifth JJ N
patient NN N
developed VBD N
a DT N
stroke NN 1_o
after IN N
nine CD N
days NNS N
of IN N
heparin JJ N
treatment NN N
and CC N
was VBD N
subsequently RB N
operated VBN N
on IN N
. . N

CONCLUSIONS NNP N
Non-obstructive JJ N
PVT NNP N
may MD N
be VB N
asymptomatic JJ N
in IN N
one-third NN N
of IN N
patients NNS N
. . N

Thrombolysis NNP N
is VBZ N
an DT N
efficient JJ 1_o
and CC 1_o
safe JJ 1_o
treatment NN N
, , N
and CC N
may MD N
be VB N
first-line JJ N
therapy NN N
if IN N
there EX N
is VBZ N
no DT N
contraindication NN N
. . N

Heparin NNP 1_i
treatment NN N
was VBD N
successful JJ N
in IN N
about IN N
one-half NN N
of IN N
our PRP$ N
cases NNS N
in IN N
the DT N
presence NN N
of IN N
sessile NN N
or CC N
small JJ N
thrombi NN N
and CC N
inadequate JJ N
anticoagulant NN N
status NN N
. . N

In IN N
unsuccessful JJ N
cases NNS N
, , N
thrombi NN N
became VBD N
obstructive JJ N
or CC N
caused JJ N
stroke NN 1_o
during IN N
heparin JJ N
therapy NN N
, , N
the DT N
adequate JJ N
duration NN N
of IN N
which WDT N
remains VBZ N
unclear JJ N
. . N

-DOCSTART- -X- O O

[ JJ 1_i
Prognostic NNP 1_i
experiences NNS 1_i
in IN N
the DT N
long-term JJ 1_i
differential JJ 1_i
therapy NN 1_i
of IN N
chronic JJ 1_p
aggressive JJ 1_p
hepatitides NNS 1_p
] VBP 1_p
. . N

-DOCSTART- -X- O O

Subcutaneous JJ N
low-molecular-weight JJ 1_i
heparin NN 1_i
compared VBN N
with IN N
continuous JJ N
intravenous JJ N
unfractionated JJ 1_i
heparin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
proximal JJ 1_p
deep JJ 1_p
vein NN 1_p
thrombosis NN 1_p
. . 1_p

BACKGROUND VB N
A DT N
low-molecular-weight JJ 1_i
heparin NN 1_i
, , 1_i
enoxaparin JJ 1_i
sodium NN 1_i
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
in IN N
preventing VBG N
deep JJ 1_p
vein NN 1_p
thrombosis NN 1_p
both DT 1_p
in IN 1_p
general JJ 1_p
surgery NN 1_p
and CC 1_p
in IN 1_p
high-risk JJ 1_p
orthopedic JJ 1_p
surgery NN 1_p
. . 1_p

We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
randomized VBN N
trial NN N
with IN N
enoxaparin NN N
in IN N
the DT N
treatment NN N
of IN N
established VBN N
deep JJ N
vein NN N
thrombosis NN N
. . N

METHODS NNP N
In IN N
a DT N
multicenter NN N
trial NN N
, , N
we PRP N
compared VBN N
fixed-dose RB N
subcutaneous JJ N
enoxaparin NN 1_i
, , N
given VBN N
twice RB N
daily RB N
, , N
with IN N
adjusted-dose JJ N
intravenous JJ N
unfractionated JJ 1_i
heparin NN 1_i
( ( 1_i
UFH NNP 1_i
) ) 1_i
given VBN N
by IN N
continuous JJ N
intravenous JJ N
infusion NN N
for IN N
the DT N
initial JJ N
10 CD N
days NNS N
of IN N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
proximal JJ 1_p
vein NN 1_p
thrombosis NN 1_p
. . 1_p

The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
the DT N
change NN 1_o
of IN 1_o
the DT 1_o
size NN 1_o
of IN 1_o
the DT 1_o
thrombus NN 1_o
assessed VBN N
by IN N
repeated JJ N
venograms NNS N
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
safety NN N
was VBD N
based VBN N
on IN N
the DT N
incidence NN 1_o
of IN 1_o
major JJ 1_o
bleeding VBG 1_o
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
. . N

RESULTS CC N
There EX 1_p
were VBD 1_p
67 CD 1_p
patients NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

Venographic NNP N
assessment NN N
of IN N
clot NN 1_o
size NN 1_o
evolution NN 1_o
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
showed VBD N
a DT N
statistically RB N
significant JJ N
superiority NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
of IN N
enoxaparin NN 1_i
over IN N
the DT N
reference NN N
treatment NN N
with IN N
UFH NNP 1_i
. . 1_i

Moreover RB N
, , N
the DT N
incidence NN 1_o
of IN 1_o
overall JJ 1_o
recurrent JJ 1_o
thromboembolic JJ 1_o
events NNS 1_o
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
in IN N
the DT N
UFH NNP 1_i
group NN N
( ( N
seven CD N
of IN N
67 CD N
) ) N
than IN N
in IN N
the DT N
enoxaparin NN 1_i
group NN N
( ( N
one CD N
of IN N
67 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ 1_o
bleeding VBG 1_o
complications NNS 1_o
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
Enoxaparin NNP 1_i
is VBZ N
at IN N
least JJS N
as IN N
effective JJ N
and CC N
safe JJ N
as IN N
UFH NNP 1_i
under IN N
the DT N
conditions NNS N
of IN N
this DT N
study NN N
. . N

Moreover RB N
, , N
it PRP N
is VBZ N
more RBR N
comfortable JJ N
for IN N
patients NNS N
and CC N
less JJR N
time-consuming NN N
for IN N
nurses NNS N
and CC N
laboratories NNS N
. . N

Thus RB N
, , N
our PRP$ N
study NN N
confirmed VBD N
, , N
with IN N
the DT N
use NN N
of IN N
enoxaparin NN 1_i
, , N
other JJ N
observations NNS N
that IN N
low-molecular-weight JJ 1_i
heparin NN 1_i
provides VBZ N
a DT N
real JJ N
therapeutic JJ N
advance NN N
in IN N
the DT N
treatment NN N
of IN N
deep JJ 1_p
vein NN 1_p
thrombosis NN 1_p
. . 1_p

-DOCSTART- -X- O O

Severe JJ 1_o
complications NNS 1_o
of IN N
5-fluorouracil JJ 1_i
and CC 1_i
cisplatin NN 1_i
with IN 1_i
concomitant JJ 1_i
radiotherapy NN 1_i
in IN N
inoperable JJ 1_p
non-metastatic JJ 1_p
squamous JJ 1_p
cell NN 1_p
oesophageal NN 1_p
cancer NN 1_p
after IN N
intubation NN N
-- : N
early JJ N
termination NN N
of IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
. . N

-DOCSTART- -X- O O

Recombinant JJ 1_i
human JJ 1_i
erythropoietin NN 1_i
. . 1_i

-DOCSTART- -X- O O

Marginal NNP N
zone NN N
B NNP N
cell NN N
lymphoma NN N
of IN N
the DT N
parotid JJ N
glands NNS N
: : N
results NNS N
of IN N
a DT N
randomised JJ N
trial NN N
comparing VBG N
radiotherapy NN 1_i
to TO N
combined VBN 1_i
therapy NN 1_i
. . 1_i

39 CD 1_p
patients NNS 1_p
with IN 1_p
marginal JJ 1_p
zone NN 1_p
B NNP 1_p
cell NN 1_p
lymphoma NN 1_p
( ( 1_p
MZBCL NNP 1_p
) ) 1_p
of IN 1_p
the DT 1_p
parotid NN 1_p
glands NNS 1_p
( ( 1_p
stages NNS 1_p
I PRP 1_p
or CC 1_p
II NNP 1_p
) ) 1_p
were VBD 1_p
studied VBN 1_p
. . 1_p

They PRP N
were VBD N
randomized VBN N
to TO N
be VB N
treated VBN N
with IN N
either DT N
radiotherapy NN 1_i
alone RB 1_i
( ( N
extended JJ N
fields NNS N
, , N
4500 CD N
cGy NN N
) ) N
or CC N
radiotherapy NN 1_i
( ( 1_i
the DT 1_i
same JJ 1_i
schedule NN 1_i
) ) 1_i
plus CC 1_i
adjuvant JJ 1_i
chemotherapy NN 1_i
( ( 1_i
cyclophosphamide NN 1_i
, , 1_i
vincristine NN 1_i
and CC 1_i
prednisone NN 1_i
) ) 1_i
. . 1_i

The DT N
end NN 1_o
points NNS 1_o
were VBD N
survival JJ 1_o
and CC 1_o
time NN 1_o
to TO 1_o
treatment NN 1_o
failure NN 1_o
( ( 1_o
TTF NNP 1_o
) ) 1_o
. . 1_o

Patients NNPS N
who WP N
received VBD N
radiotherapy VB 1_i
alone RB N
had VBD N
a DT N
complete JJ 1_o
remission NN 1_o
rate NN 1_o
of IN N
100 CD N
% NN N
, , N
the DT N
TTF NNP 1_o
was VBD N
90 CD N
% NN N
at IN N
5 CD N
years NNS N
and CC N
overall JJ 1_o
survival NN 1_o
at IN N
5 CD N
years NNS N
was VBD N
90 CD N
% NN N
with IN N
no DT N
statistical JJ N
difference NN N
when WRB N
compared VBN N
with IN N
patients NNS N
who WP N
received VBD N
combined JJ 1_i
therapy NN 1_i
[ NN N
100 CD N
, , N
80 CD N
and CC N
95 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.5 CD N
) ) N
] NN N
. . N

Although IN N
adjuvant JJ 1_i
chemotherapy NN 1_i
was VBD N
well RB N
tolerated VBN 1_o
, , N
the DT N
use NN N
of IN N
this DT N
therapeutic JJ N
approach NN N
in IN N
patients NNS N
with IN N
early JJ N
stage NN N
MZBCL NNP N
did VBD N
not RB N
offer VB N
any DT N
advantage NN N
over IN N
radiotherapy NN N
alone RB N
as IN N
the DT N
initial JJ N
treatment NN N
. . N

Until IN N
now RB N
, , N
radiotherapy NN 1_i
was VBD N
considered VBN N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
this DT N
clinical JJ N
setting NN N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O

[ NNS N
Randomized NNP N
clinical JJ N
trial NN N
between IN N
nutritional JJ 1_i
counselling NN 1_i
and CC N
commercial JJ N
hypocaloric NN 1_i
diet NN 1_i
in IN N
weight JJ N
loss NN N
in IN N
obese JJ 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
arthropathy JJ 1_p
] NN 1_p
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
The DT N
aim NN N
of IN N
our PRP$ N
work NN N
was VBD N
to TO N
evaluate VB N
in IN N
obese JJ 1_p
patients NNS 1_p
with IN 1_p
an DT 1_p
indication NN 1_p
of IN 1_p
replacement NN 1_p
surgery NN 1_p
for IN 1_p
degenerative JJ 1_p
osteoarthritis NN 1_p
, , N
the DT N
utility NN N
of IN N
a DT N
hypocaloric JJ N
diet NN N
with IN N
Optisource NNP 1_i
vs FW N
nutritional JJ N
counseling NN N
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
Thirty NNP 1_p
six CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
in IN N
both DT N
branches NNS N
: : N
diet JJ 1_i
I PRP 1_i
with IN 1_i
lunch NN 1_i
and CC 1_i
dinner NN 1_i
substituted VBN 1_i
by IN 1_i
two CD 1_i
Optisource NNP 1_i
( ( N
1109,3 CD N
kcal/day NN N
, , N
166,4g CD N
of IN N
carbohydrates NNS N
( ( N
60 CD N
% NN N
) ) N
, , N
63g CD N
of IN N
proteins NNS N
( ( N
23 CD N
% NN N
) ) N
, , N
21,3g CD N
of IN N
lipids NNS N
17 CD N
% NN N
) ) N
and CC N
diet JJ N
II NNP 1_i
with IN 1_i
nutritional JJ 1_i
counselling VBG 1_i
with IN 1_i
a DT 1_i
decrease NN 1_i
of IN 1_i
500 CD 1_i
cal/day NN 1_i
from IN 1_i
the DT 1_i
previous JJ 1_i
dietary JJ 1_i
intake NN 1_i
. . 1_i

Before IN N
and CC N
3 CD N
months NNS N
after IN N
treatment NN N
, , N
a DT N
nutritional JJ N
and CC N
biochemical JJ N
study NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
Nineteen JJ N
patients NNS N
were VBD N
randomized VBN N
in IN N
group NN N
I PRP N
and CC N
17 CD N
patients NNS N
in IN N
group NN N
II NNP N
. . N

19 CD N
patients NNS N
finished VBD N
the DT N
study NN N
in IN N
group NN N
I PRP N
and CC N
14 CD N
in IN N
group NN N
II NNP N
. . N

Weight NNP 1_o
loss NN 1_o
was VBD N
higher RBR N
in IN N
group NN N
I PRP N
than IN N
II NNP N
( ( N
7,7 CD N
[ RB N
4,7 CD N
] JJ N
vs NN N
3,92 CD N
[ NN N
3,32 CD N
] NNP N
kg NN N
; : N
P=.05 NNP N
) ) N
, , N
with IN N
a DT N
significant JJ N
decrease NN N
of IN N
HOMA NNP 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
in IN N
group NN N
I. NNP N
Decreases NNP N
of IN N
body NN 1_o
mass NN 1_o
index NN 1_o
( ( N
-2,9 NNP N
[ VBZ N
1,8 CD N
] NN N
vs NN N
-1,4 NNP N
[ VBZ N
0,9 CD N
] NN N
; : N
P=.05 NNP N
) ) N
, , N
fat JJ 1_o
mass NN 1_o
( ( N
-3,8 JJ N
[ $ N
3,4 CD N
] NNP N
vs NN N
-2,3 NNP N
[ VBZ N
1,7 CD N
] NN N
kg NN N
; : N
P=.0,05 NNP N
) ) N
and CC N
HOMA NNP 1_o
( ( N
-2,0 NNP N
[ VBZ N
2,2 CD N
] NN N
vs NN N
-0,4 NNP N
[ VBZ N
1,82 CD N
] NN N
; : N
P=.05 NNP N
) ) N
were VBD N
higher JJR N
in IN N
group NN N
I PRP N
than IN N
II NNP N
. . N

CONCLUSIONS NNP N
Obese JJ 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
osteoarthritis NN 1_p
treated VBN N
with IN N
a DT N
mixed JJ N
diet NN N
supplemented VBN N
with IN N
a DT N
commercial JJ 1_i
hypocaloric NN 1_i
formula NN 1_i
improved VBD N
weight NN 1_o
, , 1_o
fat JJ 1_o
mass NN 1_o
and CC 1_o
HOMA NNP 1_o
in IN N
a DT N
better JJR N
way NN N
than IN N
patients NNS N
treated VBN N
with IN N
a DT N
dietary JJ 1_i
counselling NN 1_i
alone RB N
. . N

-DOCSTART- -X- O O

An DT N
intervention NN N
to TO N
decrease VB N
stigma NN 1_o
in IN N
young JJ 1_p
adults NNS 1_p
with IN 1_p
sickle NN 1_p
cell NN 1_p
disease NN 1_p
. . 1_p

Young NNP 1_p
adults NNS 1_p
with IN 1_p
sickle NN 1_p
cell NN 1_p
disease NN 1_p
( ( 1_p
SCD NNP 1_p
) ) 1_p
are VBP N
often RB N
stigmatized VBN N
when WRB N
they PRP N
seek VBP N
care NN N
for IN N
pain NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
an DT N
intervention NN N
to TO N
decrease VB N
health-related JJ 1_o
stigma NN 1_o
during IN N
care-seeking NN N
. . N

Young NNP 1_p
adults NNS 1_p
with IN 1_p
SCD NNP 1_p
ages VBZ 1_p
18 CD 1_p
to TO 1_p
35 CD 1_p
years NNS 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
90 CD 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
either VB 1_i
the DT 1_i
care-seeking JJ 1_i
intervention NN 1_i
( ( 1_i
CSI NNP 1_i
) ) 1_i
or CC 1_i
an DT 1_i
attention NN 1_i
control NN 1_i
group NN 1_i
that WDT 1_i
participated VBD 1_i
in IN 1_i
life NN 1_i
review NN 1_i
interviews NNS 1_i
. . 1_i

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
by IN N
t NN N
tests NNS N
and CC N
longitudinal JJ N
data NNS N
analyses NNS N
on IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
the DT N
last JJ N
time NN N
point NN N
in IN N
total JJ 1_o
health-related JJ 1_o
stigma NN 1_o
and CC N
health-related JJ 1_o
stigma NN 1_o
by IN 1_o
doctors NNS 1_o
. . 1_o

Findings NNS N
suggest VBP N
that IN N
the DT N
CSI NNP 1_i
was VBD N
associated VBN N
with IN N
significant JJ N
increased JJ N
awareness NN 1_o
of IN 1_o
perceived JJ 1_o
total JJ 1_o
stigma NN 1_o
and CC N
stigma NN 1_o
by IN 1_o
doctors NNS 1_o
compared VBN N
with IN N
the DT N
attention NN N
control NN N
group NN N
. . N

These DT N
findings NNS N
are VBP N
promising VBG N
in IN N
terms NNS N
of IN N
lessons NNS N
learned VBN N
from IN N
a DT N
pilot NN N
intervention NN N
that WDT N
focused VBD N
on IN N
the DT N
role NN N
communication NN N
skills NNS N
play VBP N
in IN N
decreasing VBG N
health-related JJ N
stigma NN N
in IN N
young JJ 1_p
adults NNS 1_p
with IN 1_p
SCD NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Gemcitabine NNP 1_i
and CC N
split-dose JJ N
paclitaxel NN 1_i
or CC N
docetaxel NN 1_i
in IN N
metastatic JJ N
breast NN N
cancer NN N
: : N
a DT N
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
activity NN 1_o
and CC 1_o
toxicity NN 1_o
of IN N
split-dose JJ 1_i
paclitaxel NN 1_i
or CC 1_i
docetaxel NN 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
gemcitabine NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
( ( 1_p
MBC NNP 1_p
) ) 1_p
who WP 1_p
had VBD 1_p
previously RB 1_p
received VBN 1_p
anthracyclines NNS 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
total NN 1_p
of IN 1_p
210 CD 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
gemcitabine NN 1_i
1,250 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
Days VBZ 1_i
1 CD 1_i
and CC 1_i
8 CD 1_i
and CC 1_i
paclitaxel VB 1_i
175 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
as IN 1_i
a DT 1_i
3-h JJ 1_i
infusion NN 1_i
on IN 1_i
Day NNP 1_i
1 CD 1_i
( ( 1_i
GP1 NNP 1_i
) ) 1_i
; : 1_i
gemcitabine $ 1_i
1,000 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
Days VBZ 1_i
1 CD 1_i
and CC 1_i
8 CD 1_i
and CC 1_i
paclitaxel VB 1_i
100 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
as IN 1_i
a DT 1_i
1-h JJ 1_i
infusion NN 1_i
on IN 1_i
Days NNP 1_i
1 CD 1_i
and CC 1_i
8 CD 1_i
( ( 1_i
GP2 NNP 1_i
) ) 1_i
; : 1_i
gemcitabine $ 1_i
1,000 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
Days VBZ 1_i
1 CD 1_i
and CC 1_i
8 CD 1_i
and CC 1_i
docetaxel VB 1_i
40 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
as IN 1_i
a DT 1_i
1-h JJ 1_i
infusion NN 1_i
on IN 1_i
Days NNP 1_i
1 CD 1_i
and CC 1_i
8 CD 1_i
( ( 1_i
GD NNP 1_i
) ) 1_i
. . N

Cycles NNS N
were VBD N
repeated VBN N
every DT N
3 CD N
weeks NNS N
. . N

RESULTS NNP N
For IN N
the DT N
204 CD 1_p
patients NNS 1_p
evaluable JJ 1_p
for IN 1_p
response NN 1_p
assessment NN 1_p
, , 1_p
the DT 1_p
response NN 1_o
rates NNS 1_o
were VBD 1_p
48.6 CD 1_p
% NN 1_p
for IN 1_p
GP1 NNP 1_p
, , 1_p
52.2 CD 1_p
% NN 1_p
for IN 1_p
GP2 NNP 1_p
, , 1_p
and CC 1_p
52.3 CD 1_p
% NN 1_p
for IN 1_p
GD NNP 1_p
. . 1_p

Median JJ 1_o
response NN 1_o
duration NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
treatment NN 1_o
failure NN 1_o
, , 1_o
and CC 1_o
time NN 1_o
to TO 1_o
progression NN 1_o
( ( 1_o
TTP NNP 1_o
) ) 1_o
were VBD N
similar JJ N
in IN N
each DT N
arm NN N
. . N

Median JJ 1_o
TTP NNP 1_o
for IN N
GP1 NNP N
, , N
GP2 NNP N
and CC N
GD NNP N
was VBD N
7.5 CD N
, , N
7.0 CD N
and CC N
7.4 CD N
months NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
208 CD 1_p
patients NNS 1_p
evaluable JJ 1_p
for IN 1_p
safety NN 1_o
, , N
the DT N
most RBS N
common JJ N
grade NN N
3/4 CD N
toxicity NN 1_o
for IN N
each DT N
regimen NN N
was VBD N
neutropaenia RB 1_o
, , N
with IN N
64 CD N
% NN N
, , N
57 CD N
% NN N
, , N
and CC N
68 CD N
% NN N
for IN N
GP1 NNP N
, , N
GP2 NNP N
, , N
and CC N
GD NNP N
, , N
respectively RB N
. . N

Grade VB N
4 CD N
neutropaenia NN 1_o
, , N
grade VBD N
3/4 CD N
anaemia NN 1_o
, , 1_o
febrile JJ 1_o
neutropaenia NN 1_o
, , 1_o
and CC 1_o
diarrhoea NNS 1_o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
docetaxel NN N
arm NN N
, , N
as IN N
was VBD N
the DT N
use NN N
of IN N
intravenous JJ N
antibiotics NNS N
and CC N
blood NN N
transfusions NNS N
. . N

CONCLUSION VB N
The DT N
study NN N
confirmed VBD N
the DT N
high JJ N
activity NN N
of IN N
gemcitabine-taxane JJ 1_i
combinations NNS 1_i
in IN N
MBC NNP N
. . N

Split-dose JJ N
paclitaxel NN 1_i
had VBD N
similar JJ N
activity NN 1_o
and CC N
toxicity NN 1_o
to TO N
the DT N
3-weekly JJ N
administration NN N
. . N

The DT N
split-dose JJ N
docetaxel NN 1_i
regimen NNS N
had VBD N
similar JJ N
activity NN 1_o
to TO N
the DT N
paclitaxel NN 1_i
combinations NNS 1_i
though IN N
associated VBN N
with IN N
higher JJR N
toxicity NN 1_o
. . 1_o

-DOCSTART- -X- O O

Memory NN 1_o
monitoring NN N
by IN N
animals NNS 1_p
and CC 1_p
humans NNS 1_p
. . 1_p

The DT N
authors NNS N
asked VBD N
whether IN N
animals NNS 1_p
and CC 1_p
humans NNS 1_p
would MD N
use VB N
similarly RB N
an DT N
uncertain JJ N
response NN 1_o
to TO N
escape VB N
indeterminate JJ N
memories NNS N
. . N

Monkeys NNS 1_p
and CC 1_p
humans NNS 1_p
performed VBD 1_p
serial JJ 1_i
probe NN 1_i
recognition NN 1_i
tasks NNS 1_i
that WDT N
produced VBD N
differential JJ N
memory NN N
difficulty NN N
across IN N
serial JJ N
positions NNS N
( ( N
e.g. NN N
, , N
primacy NN N
and CC N
recency NN N
effects NNS N
) ) N
. . N

Participants NNS 1_p
were VBD N
given VBN N
an DT N
escape NN N
option NN N
that WDT N
let VBD N
them PRP N
avoid VB N
any DT N
trials NNS N
they PRP N
wished VBD N
and CC N
receive VB N
a DT N
hint NN N
to TO N
the DT N
trial NN N
's POS N
answer NN N
. . N

Across IN N
species NNS N
, , N
across IN N
tasks NNS N
, , N
and CC N
even RB N
across IN N
conspecifics NNS N
with IN N
sharper NN N
or CC N
duller NN N
memories NNS N
, , N
monkeys NNS 1_p
and CC 1_p
humans NNS 1_p
used VBD 1_o
the DT 1_o
escape NN 1_o
option NN 1_o
selectively RB N
when WRB N
more RBR N
indeterminate JJ N
memory NN N
traces NNS N
were VBD N
probed VBN N
. . N

Their PRP$ N
pattern NN N
of IN N
escaping VBG N
always RB N
mirrored VBN N
the DT N
pattern NN N
of IN N
their PRP$ N
primary JJ N
memory NN N
performance NN N
across IN N
serial JJ N
positions NNS N
. . N

Signal-detection NN 1_o
analyses NNS 1_o
confirm VBP N
the DT N
similarity NN N
of IN N
the DT N
animals NNS N
' POS N
and CC N
humans NNS N
' POS N
performances NNS N
. . N

Optimality NNP 1_o
analyses VBZ 1_o
assess VB N
their PRP$ N
efficiency NN 1_o
. . 1_o

Several JJ N
aspects NNS N
of IN N
monkeys NNS N
' POS N
performance NN N
suggest VBP N
the DT N
cognitive JJ N
sophistication NN N
of IN N
their PRP$ N
decisions NNS N
to TO N
escape VB N
. . N

-DOCSTART- -X- O O

Computer NNP 1_i
Decision NNP 1_i
Support NNP 1_i
Changes NNP N
Physician NNP 1_p
Practice NNP 1_o
But CC N
Not RB N
Knowledge NNP 1_o
Regarding VBG N
Autism NNP 1_p
Spectrum NNP 1_p
Disorders NNP 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
examine VB N
whether IN N
adding VBG N
an DT N
autism NN N
module NN N
promoting VBG N
adherence NN N
to TO N
clinical JJ N
guidelines NNS N
to TO N
an DT N
existing VBG N
computer NN 1_i
decision NN 1_i
support NN 1_i
system NN 1_i
( ( N
CDSS NNP N
) ) N
changed VBD N
physician JJ N
knowledge NN N
and CC N
self-reported JJ N
clinical JJ N
practice NN N
. . N

METHODS NNP N
The DT 1_p
CHICA NNP 1_i
( ( 1_i
Child NNP 1_i
Health NNP 1_i
Improvement NNP 1_i
through IN 1_i
Computer NNP 1_i
Automation NNP 1_i
) ) 1_i
system NN 1_i
, , 1_p
a DT 1_p
CDSS NNP 1_i
, , 1_p
was VBD 1_p
enhanced VBN 1_p
with IN 1_p
a DT 1_p
module NN 1_p
to TO 1_p
improve VB 1_p
management NN 1_o
of IN 1_o
autism NN 1_o
in IN 1_p
2 CD 1_p
of IN 1_p
the DT 1_p
4 CD 1_p
community NN 1_p
pediatric JJ 1_p
clinics NNS 1_p
using VBG 1_p
the DT 1_p
system NN 1_p
. . 1_p

We PRP N
examined VBD N
the DT N
knowledge NN N
and CC N
beliefs NN N
of IN N
pediatric JJ 1_p
users NNS 1_p
using VBG N
cross-sectional JJ 1_p
surveys NNS 1_p
administered VBN N
at IN N
3 CD N
time NN N
points NNS N
( ( N
baseline NN N
, , N
12 CD N
months NNS N
and CC N
24 CD N
months NNS N
post-implementation NN N
) ) N
between IN 1_p
November NNP 1_p
2010 CD 1_p
and CC 1_p
January NNP 1_p
2013 CD 1_p
. . 1_p

Surveys NNS 1_o
measured VBD N
knowledge NN 1_o
, , 1_o
beliefs NNS 1_o
and CC 1_o
self-reported JJ 1_o
practice NN 1_o
patterns NNS 1_o
related VBN 1_o
to TO 1_o
autism NN 1_o
. . 1_o

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
45 CD 1_p
, , 1_p
39 CD 1_p
, , 1_p
and CC 1_p
42 CD 1_p
pediatricians NNS 1_p
responded VBD 1_p
at IN 1_p
each DT 1_p
time NN 1_p
point NN 1_p
, , 1_p
respectively RB 1_p
, , 1_p
a DT 1_p
95-100 CD 1_p
% NN 1_p
response NN 1_p
rate NN 1_p
. . 1_p

Respondents NNS N
' POS N
knowledge NN 1_o
of IN 1_o
autism NN 1_o
and CC 1_o
perception NN 1_o
of IN 1_o
role NN 1_o
for IN 1_o
diagnosis NN 1_o
did VBD N
not RB N
vary JJ N
between IN N
control NN N
and CC N
intervention NN N
groups NNS N
either CC N
at IN N
baseline NN N
or CC N
any DT N
of IN N
the DT N
two CD N
post-intervention NN N
time NN N
points NNS N
. . N

At IN N
baseline NN N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
these DT N
groups NNS N
in IN N
rates NNS 1_o
in IN 1_o
the DT 1_o
routine JJ 1_o
use NN 1_o
of IN 1_o
parent-rated JJ 1_o
screening NN 1_o
instruments NNS 1_o
for IN N
autism NN N
. . N

However RB N
, , N
by IN N
12 CD N
and CC N
24 CD N
months NNS N
post-implementation NN N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
intervention NN N
and CC N
control NN N
clinics NNS N
in IN N
terms NNS N
of IN N
the DT N
intervention NN N
clinics NNS N
consistently RB N
screening VBG N
eligible JJ N
patients NNS N
with IN N
a DT N
validated JJ N
autism NN N
tool NN N
. . N

Physicians NNS N
at IN N
all DT N
clinics NNS N
reported VBD N
ongoing JJ N
challenges NNS N
to TO N
community NN N
resources NNS N
for IN N
further JJ N
work-up NN N
and CC N
treatment NN N
related VBN N
to TO N
autism NN N
. . N

CONCLUSIONS VB N
A DT N
CDSS NNP 1_i
module NN N
to TO N
improve VB N
primary JJ N
care NN N
management NN N
of IN N
ASD NNP N
in IN N
pediatric JJ N
practice NN N
led VBD N
to TO N
significant JJ N
improvements NNS N
in IN N
physician-reported JJ 1_o
use NN 1_o
of IN 1_o
validated JJ 1_o
screening NN 1_o
tools NNS 1_o
to TO N
screen VB N
for IN N
ASDs NNP N
. . N

However RB N
it PRP N
did VBD N
not RB N
lead VB N
to TO N
corresponding VBG N
changes NNS N
in IN N
physician JJ 1_o
knowledge NN 1_o
or CC 1_o
attitudes NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Determination NN N
of IN N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
DIG NNP N
trial NN N
. . N

The DT N
Digitalis NNP N
Investigation NNP N
Group NNP N
( ( N
DIG NNP N
) ) N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo-controlled JJ 1_i
trial NN N
whose WP$ N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
digoxin NN 1_i
had VBD N
beneficial JJ N
, , N
harmful JJ N
, , N
or CC N
no DT N
effect NN N
on IN N
total JJ N
mortality NN N
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
who WP 1_p
were VBD 1_p
in IN 1_p
sinus NN 1_p
rhythm NN 1_p
and CC 1_p
whose WP$ 1_p
ejection NN 1_p
fraction NN 1_p
was VBD 1_p
< JJ 1_p
/=0.45 NNP 1_p
. . 1_p

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
large JJ N
simple JJ N
trial NN N
with IN N
a DT 1_p
large JJ 1_p
number NN 1_p
of IN 1_p
centers NNS 1_p
( ( 1_p
302 CD 1_p
) ) 1_p
in IN 1_p
the DT 1_p
United NNP 1_p
States NNPS 1_p
and CC 1_p
Canada NNP 1_p
, , 1_p
many JJ 1_p
of IN 1_p
which WDT 1_p
were VBD 1_p
inexperienced VBN 1_p
in IN 1_p
research NN 1_p
. . 1_p

To TO N
ensure VB N
that IN N
the DT N
results NNS N
of IN N
the DT N
trial NN N
would MD N
be VB N
reported VBN N
accurately RB N
without IN N
possible JJ N
bias NN N
due JJ N
to TO N
missing VBG N
data NNS N
, , N
the DT N
study NN N
leadership NN N
decided VBD N
that IN N
no DT N
outcome NN N
results NNS N
would MD N
be VB N
reported VBN N
until IN N
the DT N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
known VBN N
for IN N
at IN N
least JJS N
97 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
. . N

Planning VBG N
for IN N
closeout NN N
of IN N
the DT N
study NN N
began VBD N
a DT N
year NN N
prior RB N
to TO N
the DT N
common JJ N
end NN N
date NN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
and CC N
included VBD N
plans NNS N
for IN N
obtaining VBG N
vital JJ N
status NN N
on IN N
December NNP N
31 CD N
, , N
1995 CD N
. . N

Participants NNS N
were VBD N
given VBN 1_i
postcards NNS 1_i
at IN 1_i
their PRP$ 1_i
final JJ 1_i
study NN 1_i
visit NN 1_i
to TO 1_i
be VB 1_i
completed VBN 1_i
and CC 1_i
mailed VBN 1_i
on IN 1_i
or CC 1_i
after IN 1_i
January NNP 1_i
1 CD 1_i
, , 1_i
1996 CD 1_i
. . 1_i

Of IN 1_p
5602 CD 1_p
postcards NNS 1_p
distributed VBN 1_p
, , 1_p
5070 CD 1_p
( ( 1_p
90.5 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
completed VBN 1_p
and CC 1_p
returned VBN 1_p
. . 1_p

A DT N
contract NN N
search NN N
agency NN N
was VBD N
hired VBN N
to TO N
locate VB N
the DT N
remaining VBG N
participants NNS N
. . N

Of IN 1_p
the DT 1_p
total JJ 1_p
7788 CD 1_p
participants NNS 1_p
entered VBD 1_p
into IN 1_p
the DT 1_p
DIG NNP 1_p
trial NN 1_p
, , 1_p
only RB 1_p
97 CD 1_p
participants NNS 1_p
( ( 1_p
1.2 CD 1_p
% NN 1_p
) ) 1_p
could MD 1_p
not RB 1_p
have VB 1_p
their PRP$ 1_p
vital JJ 1_o
status NN 1_o
as IN 1_p
of IN 1_p
December NNP 1_p
31 CD 1_p
, , 1_p
1995 CD 1_p
determined VBD 1_p
. . 1_p

It PRP N
is VBZ N
recommended VBN N
that IN N
investigators NNS N
having VBG N
an DT N
outcome NN N
measure NN N
with IN N
a DT N
common JJ N
end NN N
date NN N
include VBP N
plans NNS N
in IN N
their PRP$ N
protocols NNS N
for IN N
obtaining VBG N
their PRP$ N
measures NNS N
and CC N
activate VBP N
those DT N
plans NNS N
as RB N
early RB N
as IN N
possible JJ N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

LNH-84 JJ N
regimen NNS N
: : N
a DT N
multicenter NN N
study NN N
of IN N
intensive JJ N
chemotherapy NN N
in IN N
737 CD 1_p
patients NNS 1_p
with IN 1_p
aggressive JJ 1_p
malignant JJ 1_p
lymphoma NN 1_p
. . 1_p

From IN 1_p
July NNP 1_p
1984 CD 1_p
to TO 1_p
September NNP 1_p
1987 CD 1_p
, , 1_p
737 CD 1_p
patients NNS 1_p
with IN 1_p
aggressive JJ 1_p
malignant JJ 1_p
lymphoma NN 1_p
( ( 1_p
ML NNP 1_p
) ) 1_p
were VBD N
treated VBN N
by IN N
an DT N
intensive JJ 1_i
regimen NNS 1_i
( ( 1_i
LNH-84 NNP 1_i
) ) 1_i
comprising VBG N
three CD 1_i
or CC 1_i
four CD 1_i
courses NNS 1_i
of IN 1_i
doxorubicin NN 1_i
, , 1_i
75 CD 1_i
mg/m2 NN 1_i
; : 1_i
cyclophosphamide NN 1_i
, , 1_i
1,200 CD 1_i
mg/m2 NN 1_i
; : 1_i
vindesine NN 1_i
, , 1_i
2 CD 1_i
mg/m2 NN 1_i
x NN 1_i
2 CD 1_i
; : 1_i
bleomycin NN 1_i
, , 1_i
10 CD 1_i
mg NN 1_i
x NN 1_i
2 CD 1_i
; : 1_i
and CC 1_i
prednisolone NN 1_i
, , 1_i
60 CD 1_i
mg/m2 NN 1_i
x NN 1_i
5 CD 1_i
( ( 1_i
ACVB NNP 1_i
) ) 1_i
, , 1_i
consolidation NN 1_i
with IN 1_i
high-dose JJ 1_i
methotrexate NN 1_i
, , 1_i
ifosfamide NN 1_i
, , 1_i
etoposide RB 1_i
, , 1_i
asparaginase NN 1_i
, , 1_i
and CC 1_i
cytarabine NN 1_i
, , 1_i
and CC 1_i
a DT 1_i
randomized VBN 1_i
late JJ 1_i
intensification NN 1_i
with IN 1_i
two CD 1_i
courses NNS 1_i
of IN 1_i
cytarabine NN 1_i
, , 1_i
cyclophosphamide NN 1_i
, , 1_i
teniposide NN 1_i
, , 1_i
bleomycin NN 1_i
, , 1_i
and CC 1_i
prednisone NN 1_i
( ( 1_i
AraCVmB NNP 1_i
) ) 1_i
. . 1_i

Four CD 1_p
hundred VBD 1_p
forty-two JJ 1_p
patients NNS 1_p
had VBD N
intermediate-grade JJ N
ML NNP N
, , N
221 CD N
highgrade NN N
ML NNP N
, , N
and CC N
74 CD N
unclassified JJ N
ML NNP N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
had VBD N
advanced JJ N
disease NN N
: : N
stage NN N
IIE NNP N
( ( N
23 CD N
% NN N
) ) N
, , N
III NNP N
( ( N
13 CD N
% NN N
) ) N
, , N
or CC N
IV NNP N
( ( N
47 CD N
% NN N
) ) N
; : N
38 CD N
% NN N
disseminated JJ N
nodes NNS N
; : N
38 CD N
% NN N
two CD N
or CC N
more JJR N
extranodal JJ N
sites NNS N
; : N
and CC N
41 CD N
% NN N
a DT N
tumoral JJ N
mass NN N
greater JJR N
than IN N
10 CD N
cm NN N
. . N

Five CD N
hundred VBD N
fifty-three JJ N
patients NNS N
( ( N
75 CD N
% NN N
) ) N
went VBD N
into IN N
complete JJ 1_o
remission NN 1_o
( ( 1_o
CR NNP 1_o
) ) 1_o
, , N
63 CD N
( ( N
9 CD N
% NN N
) ) N
into IN N
partial JJ 1_o
remission NN 1_o
, , N
62 CD N
( ( N
8 CD N
% NN N
) ) N
failed VBD 1_o
to TO 1_o
respond VB 1_o
, , N
and CC N
59 CD N
( ( N
8 CD N
% NN N
) ) N
died VBD 1_o
during IN N
ACVB NNP N
courses NNS N
, , N
17 CD N
of IN N
them PRP N
from IN N
progression NN N
of IN N
the DT N
disease NN N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
23 CD N
months NNS N
, , N
the DT N
estimated VBN N
2-year JJ N
overall JJ 1_o
survival NN 1_o
time NN 1_o
to TO 1_o
failure NN 1_o
( ( 1_o
TTF NNP 1_o
) ) 1_o
, , N
and CC N
time NN 1_o
to TO 1_o
relapse VB 1_o
( ( 1_o
TTR NNP 1_o
) ) 1_o
survival NN 1_o
are VBP N
67 CD N
% NN N
, , N
56 CD N
% NN N
, , N
and CC N
67 CD N
% NN N
, , N
respectively RB N
. . N

Patients NNS N
receiving VBG N
a DT N
late JJ N
intensification NN N
had VBD N
the DT N
same JJ N
relapse NN 1_o
rate NN 1_o
as IN N
the DT N
other JJ N
patients NNS N
. . N

A DT N
persistent JJ 1_o
fibronecrotic JJ 1_o
mass NN 1_o
was VBD N
found VBN N
in IN N
150 CD N
patients NNS N
( ( N
20 CD N
% NN N
) ) N
and CC N
did VBD N
not RB N
influence VB N
the DT N
relapse NN 1_o
rate NN 1_o
. . 1_o

Toxicity NNP 1_o
was VBD N
mainly RB N
neutropenia JJ 1_o
and CC N
infection NN 1_o
during IN N
the DT N
ACVB NNP N
courses NNS N
, , N
with IN N
40 CD N
patients NNS N
( ( N
5 CD N
% NN N
) ) N
dying VBG 1_o
from IN 1_o
septic JJ 1_o
complications NNS 1_o
while IN N
responding VBG N
to TO N
treatment NN N
. . N

Fifty-three JJ N
percent NN N
of IN N
the DT N
patients NNS N
had VBD N
a DT N
neutropenia NN 1_o
less JJR N
than IN N
0.500 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
, , N
58 CD N
% NN N
fever NN N
( ( N
6 CD N
% NN N
grade JJ N
4 CD N
) ) N
, , N
and CC N
49 CD N
% NN N
a DT N
documented JJ 1_o
infection NN 1_o
( ( N
8 CD N
% NN N
grade JJ N
4 CD N
) ) N
. . N

These DT N
results NNS N
obtained VBD N
with IN N
the DT N
LNH-84 JJ N
regimen NNS N
demonstrate VBP N
that IN N
this DT N
therapeutic JJ N
scheme NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
aggressive JJ N
ML NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
computer-assisted JJ 1_i
practice NN 1_i
on IN N
reading NN 1_o
and CC 1_o
spelling NN 1_o
in IN N
children NNS 1_p
with IN 1_p
learning VBG 1_p
disabilities NNS 1_p
] NNP 1_p
. . N

The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
effects NNS N
of IN N
computer-assisted JJ 1_i
practice NN 1_i
on IN 1_i
reading NN 1_i
and CC 1_i
spelling NN 1_i
in IN 1_i
children NNS 1_p
with IN 1_p
learning VBG 1_p
disabilities NNS 1_p
( ( 1_p
LD NNP 1_p
) ) 1_p
. . 1_p

We PRP N
compared VBN N
three CD N
practice NN N
conditions NNS N
, , N
one CD N
with IN N
reading NN 1_i
and CC N
two CD N
with IN N
spelling NN 1_i
, , N
in IN N
order NN N
to TO N
test VB N
whether IN N
computer-based JJ 1_i
reading NN 1_i
and CC 1_i
spelling NN 1_i
practice NN 1_i
has VBZ N
an DT N
influence NN N
on IN N
the DT N
development NN N
of IN N
reading NN N
and CC N
spelling VBG N
ability NN N
in IN N
children NNS 1_p
with IN 1_p
LD NNP 1_p
. . 1_p

A NNP N
sample NN N
was VBD N
selected VBN N
of IN N
85 CD 1_p
children NNS 1_p
with IN 1_p
LD NNP 1_p
, , 1_p
with IN 1_p
age NN 1_p
range NN 1_p
between IN 1_p
8 CD 1_p
years NNS 1_p
and CC 1_p
10 CD 1_p
years NNS 1_p
( ( 1_p
age NN 1_p
, , 1_p
M=111.02 NNP 1_p
, , 1_p
SD=9.6 NNP 1_p
) ) 1_p
, , 1_p
whose WP$ 1_p
spelling VBG 1_p
performance NN 1_p
was VBD 1_p
two CD 1_p
years NNS 1_p
below IN 1_p
grade JJ 1_p
level NN 1_p
. . 1_p

The DT N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
groups NNS N
: : N
1 CD 1_i
) ) 1_i
Copy NNPS 1_i
the DT 1_i
target NN 1_i
word NN 1_i
from IN 1_i
the DT 1_i
computer NN 1_i
screen NN 1_i
( ( 1_i
n=22 NN 1_i
) ) 1_i
, , 1_i
2 CD 1_i
) ) 1_i
Memorize VB 1_i
the DT 1_i
target NN 1_i
word NN 1_i
and CC 1_i
write VB 1_i
it PRP 1_i
from IN 1_i
memory NN 1_i
( ( 1_i
n=21 JJ 1_i
) ) 1_i
, , 1_i
3 CD 1_i
) ) 1_i
Word NNP 1_i
reading NN 1_i
( ( 1_i
n=21 JJ 1_i
) ) 1_i
, , 1_i
and CC 1_i
4 CD 1_i
) ) 1_i
the DT 1_i
untrained JJ 1_i
control NN 1_i
group NN 1_i
( ( N
n=21 RB N
) ) N
. . N

We PRP N
administered VBD N
measures NNS N
of IN N
pseudoword NN 1_o
reading NN 1_o
, , 1_o
phonological JJ 1_o
awareness NN 1_o
, , 1_o
phonological JJ 1_o
word NN 1_o
decoding NN 1_o
and CC 1_o
orthographical JJ 1_o
word NN 1_o
decoding VBG 1_o
tasks NNS 1_o
. . 1_o

We PRP N
examined VBD N
the DT N
learning NN 1_o
effects NNS 1_o
and CC 1_o
transfer NN 1_o
effects NNS 1_o
on IN 1_o
words NNS 1_o
classified VBN 1_o
as IN 1_o
a DT 1_o
function NN 1_o
of IN 1_o
length NN 1_o
, , 1_o
consistency NN 1_o
, , 1_o
and CC 1_o
complexity NN 1_o
of IN 1_o
syllable JJ 1_o
structure NN 1_o
. . 1_o

Overall JJ N
, , N
the DT N
results NNS N
showed VBD N
that IN N
reading VBG N
training VBG N
did VBD N
not RB N
improve VB N
spelling NN N
; : N
however RB N
, , N
the DT N
children NNS N
who WP N
participated VBD N
in IN N
the DT N
copy NN N
training NN N
condition NN N
improved VBD N
their PRP$ N
spelling NN N
skills NNS N
. . N

-DOCSTART- -X- O O

Outcome NN N
of IN N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
in IN N
disseminated JJ 1_p
small JJ 1_p
noncleaved-cell JJ 1_p
lymphoma NN 1_p
and CC 1_p
B-cell NNP 1_p
leukemia NN 1_p
: : 1_p
a DT N
Children NNP 1_p
's POS 1_p
Cancer NNP 1_p
Group NNP 1_p
study NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
initial JJ N
CNS NNP N
involvement NN N
on IN N
outcome NN N
and CC N
patterns NNS N
of IN N
failure NN N
in IN N
patients NNS 1_p
with IN 1_p
disseminated JJ 1_p
small JJ 1_p
noncleaved-cell JJ 1_p
lymphoma NN 1_p
and CC 1_p
B-cell NNP 1_p
leukemia NN 1_p
who WP 1_p
were VBD 1_p
treated VBN 1_p
in IN 1_p
four CD 1_i
successive JJ 1_i
Children NNP 1_i
's POS 1_i
Cancer NNP 1_i
Group NNP 1_i
trials NNS 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
Of IN N
462 CD 1_p
patients NNS 1_p
with IN 1_p
disseminated JJ 1_p
disease NN 1_p
, , 1_p
49 CD 1_p
( ( 1_p
10.6 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
CNS NNP 1_p
disease NN 1_p
at IN 1_p
diagnosis NN 1_p
( ( 1_p
CNS+ NNP 1_p
) ) 1_p
. . 1_p

CNS NNP N
disease NN N
included VBD N
meningeal JJ N
disease NN N
or CC N
CNS NNP N
parenchymal JJ N
masses NNS N
with IN N
or CC N
without IN N
cranial JJ N
neuropathies NNS N
( ( N
CSF+/Mass NNP N
; : N
CNPs NNP N
) ) N
in IN N
36 CD N
patients NNS N
and CC N
isolated JJ N
CNPs NNP N
in IN N
13 CD N
. . N

Of IN 1_p
the DT 1_p
CNS+ NNP 1_p
patients NNS 1_p
, , 1_p
28 CD 1_p
had VBD 1_p
M2 NNP 1_p
( ( 1_p
5 CD 1_p
% NN 1_p
to TO 1_p
25 CD 1_p
% NN 1_p
blasts NNS 1_p
) ) 1_p
or CC 1_p
M3 NNP 1_p
( ( 1_p
> VB 1_p
25 CD 1_p
% NN 1_p
blasts NNS 1_p
) ) 1_p
bone NN 1_p
marrow JJ 1_p
involvement NN 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
received VBD 1_p
protocol-based JJ 1_i
systemic JJ 1_i
and CC 1_i
intrathecal JJ 1_i
chemotherapy NN 1_i
. . 1_i

Thirty-six JJ N
patients NNS N
also RB N
received VBD N
CNS NNP 1_i
irradiation NN 1_i
. . 1_i

RESULTS NNP N
Relapses NNPS 1_o
occurred VBD N
in IN N
21 CD N
( ( N
43 CD N
% NN N
) ) N
of IN N
49 CD N
patients NNS N
, , N
predominantly RB N
in IN N
the DT N
CNS NNP N
( ( N
71 CD N
% NN N
) ) N
and CC N
bone NN N
marrow NN N
( ( N
52 CD N
% NN N
) ) N
. . N

The DT N
3-year JJ 1_o
event-free JJ 1_o
survival NN 1_o
+/- JJ N
SE NNP N
for IN N
all DT N
patients NNS N
with IN N
CNS+ NNP N
disease NN N
was VBD N
45 CD N
% NN N
+/- JJ N
7 CD N
% NN N
. . N

Patients NNS N
with IN N
CSF+/Mass NNP N
had VBD N
a DT N
nominally RB N
higher JJR 1_o
treatment NN 1_o
failure NN 1_o
rate NN 1_o
compared VBN N
with IN N
patients NNS N
with IN N
CNS- NNP N
after IN N
adjusting VBG N
for IN N
marrow NN N
status NN N
and CC N
lactate VB N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
diagnosis NN N
, , N
with IN N
a DT N
relative JJ 1_o
failure NN 1_o
rate NN 1_o
( ( 1_o
RFR NNP 1_o
) ) 1_o
of IN N
1.52 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.88 CD N
to TO N
2.6 CD N
; : N
P NNP N
=.15 NNP N
) ) N
. . N

In IN N
comparison NN N
, , N
the DT N
RFRs NNP 1_o
for IN N
patients NNS N
with IN N
M2 NNP N
or CC N
M3 NNP N
marrow NN N
and CC N
for IN N
those DT N
with IN N
LDH NNP N
levels NNS N
greater JJR N
than IN N
500 CD N
IU/L NNP N
after IN N
adjusting VBG N
for IN N
CNS NNP 1_o
disease NN 1_o
were VBD N
1.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
2.0 CD N
; : N
P NNP N
=.029 NNP N
) ) N
and CC N
2.2 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.5 CD N
to TO N
3.0 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
RFR NNP 1_o
for IN N
patients NNS N
with IN N
isolated JJ 1_o
CNPs NNP 1_o
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.36 CD N
to TO N
2.1 CD N
; : N
P NNP N
=.76 NNP N
) ) N
. . N

CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
, , N
with IN N
the DT N
treatments NNS N
used VBN N
during IN N
the DT N
period NN N
covered VBN N
by IN N
these DT N
studies NNS N
, , N
the DT N
presence NN N
of IN N
CSF+/Mass NNP N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
was VBD N
associated VBN N
with IN N
a DT N
nominally RB 1_o
worse JJR 1_o
outcome JJ 1_o
independent JJ N
of IN N
initial JJ N
bone NN N
marrow NN N
status NN N
and CC N
LDH NNP N
level NN N
, , N
but CC N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -X- O O

Pain NN 1_o
and CC 1_o
fatigue JJ 1_o
management NN 1_o
: : 1_o
results NNS N
of IN N
a DT N
nursing NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

PURPOSE/OBJECTIVES NNP N
Through IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
to TO N
compare VB N
patients NNS 1_p
undergoing VBG 1_p
an DT 1_p
initial JJ 1_p
course NN 1_p
of IN 1_p
chemotherapy NN 1_i
who WP 1_p
report VBP 1_p
pain NN 1_o
and CC 1_o
fatigue NN 1_o
at IN 1_p
baseline NN 1_p
and CC 1_p
who WP 1_p
are VBP 1_p
receiving VBG 1_p
conventional JJ 1_i
care NN 1_i
alone RB 1_i
with IN 1_p
those DT 1_p
receiving VBG 1_p
conventional JJ 1_i
care NN 1_i
plus CC 1_i
a DT 1_i
nursing NN 1_i
intervention NN 1_i
on IN N
outcomes NNS N
reported VBN N
at IN N
20 CD N
weeks NNS N
. . N

SETTING NN N
Chemotherapy NNP 1_p
clinics NNS 1_p
of IN 1_p
two CD 1_p
comprehensive JJ 1_p
and CC 1_p
two CD 1_p
community NN 1_p
cancer NN 1_p
centers NNS 1_p
. . 1_p

METHODS NNP N
Interviews NNP N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
10 CD N
and CC N
20 CD N
weeks NNS N
. . N

An DT N
18-week JJ N
, , N
10-contact JJ N
nursing NN 1_i
intervention NN 1_i
utilizing VBG 1_i
problem-solving JJ 1_i
approaches NNS 1_i
to TO 1_i
symptom VB 1_i
management NN 1_i
and CC 1_i
improving VBG 1_i
physical JJ 1_o
functioning NN 1_o
and CC 1_o
emotional JJ 1_o
health NN 1_o
was VBD N
implemented VBN N
. . N

SAMPLE VB N
The DT N
sample NN N
consisted VBD N
of IN N
53 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
experimental JJ 1_p
arm NN 1_p
and CC 1_p
60 CD 1_p
in IN 1_p
the DT 1_p
control NN 1_p
arm NN 1_p
who WP 1_p
reported VBD 1_p
pain NN 1_o
and CC 1_o
fatigue NN 1_o
at IN 1_p
baseline NN 1_p
. . 1_p

VARIABLES NNP N
Pain NNP 1_o
and CC 1_o
fatigue NN 1_o
, , 1_o
numbers NNS 1_o
of IN 1_o
other JJ 1_o
symptoms NNS 1_o
, , 1_o
and CC 1_o
physical JJ 1_o
role NN 1_o
impact NN 1_o
and CC 1_o
social-functioning JJ 1_o
subscales NNS 1_o
from IN N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
36 CD N
Short NNP N
Form NNP N
. . N

FINDINGS NNP N
Patients NNPS N
who WP N
received VBD N
the DT N
intervention NN 1_i
reported VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN 1_o
of IN 1_o
symptoms NNS 1_o
experienced VBN 1_o
and CC N
improved VBN N
physical JJ 1_o
and CC 1_o
social JJ 1_o
functioning NN 1_o
. . 1_o

Fewer JJR N
patients NNS N
in IN N
the DT N
experimental JJ N
arm NN N
reported VBD N
both DT N
pain NN 1_o
and CC 1_o
fatigue NN 1_o
at IN N
20 CD N
weeks NNS N
. . N

CONCLUSIONS NNP N
Behavioral NNP 1_i
interventions NNS 1_i
targeted VBD N
to TO N
patients NNS N
with IN N
pain NN 1_o
and CC 1_o
fatigue NN 1_o
can MD N
reduce VB N
symptom JJ 1_o
burden NN 1_o
, , N
improve VB N
the DT N
quality NN 1_o
of IN 1_o
the DT 1_o
daily JJ 1_o
life NN 1_o
of IN N
patients NNS N
, , N
and CC N
demonstrate VB N
the DT N
value-added JJ N
role NN N
of IN N
nursing VBG 1_i
care NN 1_i
for IN N
patients NNS N
undergoing JJ N
chemotherapy NN N
. . N

IMPLICATIONS NNP N
FOR IN N
NURSING NNP N
These DT N
data NNS N
support VBD N
the DT N
value-added JJ N
role NN N
of IN N
nursing NN 1_i
interventions NNS 1_i
for IN N
symptom JJ N
management NN N
and CC N
improved JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
during IN N
the DT N
course NN N
of IN N
cancer NN N
treatment NN N
. . N

-DOCSTART- -X- O O

Kata NNP 1_i
techniques NNS 1_i
training VBG 1_i
consistently RB N
decreases VBZ N
stereotypy NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

The DT N
effects NNS N
of IN N
14 CD N
weeks NNS N
of IN N
Kata NNP 1_i
techniques NNS 1_i
training VBG 1_i
on IN N
stereotypic JJ N
behaviors NNS N
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
were VBD N
investigated VBN N
. . N

The DT N
study NN N
included VBD N
30 CD 1_p
eligible JJ 1_p
( ( 1_p
diagnosed JJ 1_p
ASD NNP 1_p
, , 1_p
school NN 1_p
age NN 1_p
) ) 1_p
children NNS 1_p
with IN 1_p
ages NNS 1_p
ranging VBG 1_p
from IN 1_p
5 CD 1_p
to TO 1_p
16 CD 1_p
years NNS 1_p
whom WP N
they PRP N
assigned VBD N
to TO N
an DT N
exercise NN N
( ( N
n=15 JJ N
) ) N
or CC N
a DT N
no-exercise JJ 1_i
control NN 1_i
group NN 1_i
( ( N
n=15 RB N
) ) N
. . N

Participants NNS N
of IN N
the DT N
exercise NN N
group NN N
received VBD N
Kata NNP 1_i
techniques NNS 1_i
instruction VBP 1_i
four CD N
times NNS N
per IN N
week NN N
for IN N
14 CD N
weeks NNS N
( ( N
56 CD N
sessions NNS N
) ) N
. . N

Stereotypy NNP 1_i
was VBD N
assessed VBN N
at IN N
baseline NN N
( ( N
pre-intervention NN N
) ) N
, , N
week NN N
14 CD N
( ( N
post-intervention NN N
) ) N
, , N
and CC N
at IN N
one CD N
month NN N
follow VB N
up RP N
in IN N
both DT N
groups NNS N
. . N

Results NNS N
showed VBD N
that IN N
Kata NNP N
techniques NNS N
training VBG N
significantly RB N
reduced VBN 1_o
stereotypy NN 1_o
in IN 1_o
the DT 1_o
exercise NN 1_o
group NN 1_o
. . 1_o

Following VBG N
participation NN N
in IN N
Kata NNP N
techniques NNS N
training NN N
, , N
stereotypy NN 1_o
decreased VBN 1_o
from IN 1_o
baseline NN 1_o
levels NNS 1_o
by IN N
a DT N
M NNP N
of IN N
42.54 CD N
% NN N
across IN N
participants NNS N
. . N

Interestingly NNP N
, , N
after IN N
30 CD N
days NNS N
of IN N
no DT N
practice NN N
, , N
stereotypy NN 1_o
in IN 1_o
the DT 1_o
exercise NN 1_o
group NN 1_o
remained VBD 1_o
significantly RB 1_o
decreased VBN 1_o
compared VBN N
to TO N
pre-intervention NN N
time NN N
. . N

The DT N
participants NNS N
of IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
in IN N
the DT N
stereotypy NN 1_o
. . 1_o

Teaching VBG N
martial JJ N
arts NNS N
techniques NNS N
to TO N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
for IN N
a DT N
long JJ N
period NN N
of IN N
time NN N
consistently RB N
decreased VBN N
their PRP$ N
stereotypic NN N
behaviors NNS N
. . N

-DOCSTART- -X- O O

How WRB N
well RB N
do VB N
blood NN 1_o
folate VB 1_o
concentrations NNS 1_o
predict VBP N
dietary JJ 1_i
folate NN 1_i
intakes NNS 1_i
in IN N
a DT N
sample NN N
of IN N
Canadian JJ 1_p
lactating VBG 1_p
women NNS 1_p
exposed VBN 1_p
to TO 1_p
high JJ 1_p
levels NNS 1_p
of IN 1_p
folate NN 1_p
? . N
An DT N
observational JJ N
study NN N
. . N

BACKGROUND NNP N
In IN N
1998 CD N
, , N
mandatory JJ N
folic JJ N
acid JJ N
fortification NN N
of IN N
white JJ 1_i
flour NN 1_i
and CC 1_i
select JJ 1_i
cereal NN 1_i
grain NN 1_i
products NNS 1_i
was VBD N
implemented VBN N
in IN N
Canada NNP 1_p
with IN N
the DT N
intention NN N
to TO N
increase VB N
dietary JJ 1_i
folate JJ 1_i
intakes NNS 1_i
of IN N
reproducing VBG 1_p
women NNS 1_p
. . 1_p

Folic NNP N
acid JJ N
fortification NN N
has VBZ N
produced VBN N
a DT N
dramatic JJ N
increase NN N
in IN N
blood NN N
folate JJ N
concentrations NNS N
among IN N
reproductive JJ N
age NN N
women NNS N
, , N
and CC N
a DT N
reduction NN N
in IN N
neural JJ N
tube NN N
defect NN N
( ( N
NTD NNP N
) ) N
-affected VBD N
pregnancies NNS N
. . N

In IN N
response NN N
to TO N
improved VBN N
blood NN N
folate NN N
concentrations NNS N
, , N
many JJ N
health NN N
care NN N
professionals NNS N
are VBP N
asking VBG N
whether IN N
a DT N
folic JJ 1_i
acid NN 1_i
supplement NN 1_i
is VBZ N
necessary JJ N
for IN N
NTD NNP N
prevention NN N
among IN N
women NNS 1_p
with IN 1_p
high JJ 1_p
blood NN 1_p
folate NN 1_p
values NNS 1_p
, , N
and CC N
how WRB N
reliably RB N
high JJ N
RBC NNP N
folate NN N
concentrations NNS N
predict VBP N
folate JJ N
intakes NNS N
shown VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
to TO N
be VB N
protective JJ N
against IN N
NTDs NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
how WRB N
predictive JJ N
blood NN 1_o
folate NN 1_o
concentrations NNS 1_o
and CC 1_o
folate NN 1_o
intakes NNS 1_o
are VBP N
of IN N
each DT N
other JJ N
in IN N
a DT N
sample NN N
of IN N
well-educated JJ 1_p
lactating VBG 1_p
Canadian JJ 1_p
women NNS 1_p
exposed VBN 1_p
to TO 1_p
high JJ 1_p
levels NNS 1_p
of IN 1_p
synthetic JJ 1_p
folate NN 1_p
. . 1_p

METHODS NNP N
The DT N
relationship NN N
between IN N
blood NN 1_o
folate NN 1_o
concentrations NNS 1_o
and CC N
dietary JJ 1_o
folate NN 1_o
intakes NNS 1_o
, , N
determined VBN N
by IN N
weighed VBN 1_i
food NN 1_i
records NNS 1_i
, , N
were VBD N
assessed VBN N
in IN N
a DT N
sample NN 1_p
of IN 1_p
predominantly RB 1_p
university-educated JJ 1_p
lactating VBG 1_p
women NNS 1_p
( ( 1_p
32 CD 1_p
+/- JJ 1_p
4 CD 1_p
yr NN 1_p
) ) 1_p
at IN 1_p
4- JJ 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
53 CD 1_p
) ) 1_p
and CC 1_p
16-wk JJ 1_p
postpartum NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
55 CD 1_p
) ) 1_p
. . 1_p

RESULTS NNP N
Median JJ N
blood NN 1_o
folate NN 1_o
concentrations NNS 1_o
of IN N
all DT N
participants NNS N
were VBD N
well RB N
above IN N
plasma NN N
and CC N
RBC NNP N
folate VBP N
cut-off NN N
levels NNS N
indicative CD N
of IN N
deficiency NN N
( ( N
6.7 CD N
and CC N
317 CD N
nmol/L NN N
, , N
respectively RB N
) ) N
and CC N
all DT N
, , N
except IN N
for IN N
2 CD N
subjects NNS N
, , N
were VBD N
above IN N
the DT N
cut-off NN N
for IN N
NTD-risk NNP N
reduction NN N
( ( N
> $ N
906 CD N
nmol/L NN N
) ) N
. . N

Only RB N
modest JJ N
associations NNS N
existed VBD N
between IN N
total JJ 1_o
folate NN 1_o
intakes NNS 1_o
and CC N
plasma NN 1_o
( ( N
r JJ N
= NN N
0.46 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
RBC NNP N
( ( N
r VB N
= RB N
0.36 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
folate NN 1_o
concentrations NNS 1_o
at IN N
16-wk JJ N
postpartum NN N
. . N

Plasma NNP 1_o
and CC 1_o
RBC NNP 1_o
folate VBP 1_o
values NNS 1_o
at IN N
16-wk JJ N
postpartum NN N
correctly RB N
identified VBD N
the DT N
quartile NN N
of IN N
folate JJ N
intake NN N
of IN N
only RB N
26 CD N
of IN N
55 CD N
( ( N
47 CD N
% NN N
) ) N
and CC N
18 CD N
of IN N
55 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
subjects NNS N
, , N
respectively RB N
. . N

The DT N
mean JJ N
RBC NNP 1_o
folate NN 1_o
concentration NN 1_o
of IN N
women NNS N
consuming VBG N
151-410 JJ N
microg/d NN N
of IN N
synthetic JJ N
folate NN N
( ( N
2nd CD N
quartile NN N
of IN N
intake NN N
) ) N
did VBD N
not RB N
differ VB N
from IN N
that DT N
of IN N
women NNS N
consuming VBG N
> JJ N
410 CD N
microg/d NN N
( ( N
3rd CD N
and CC N
4th CD N
quartile NN N
) ) N
. . N

CONCLUSION NNP N
Folate NNP 1_o
intakes NNS 1_o
, , N
estimated VBN N
by IN N
food NN N
composition NN N
tables NNS N
, , N
and CC N
blood NN 1_o
folate NN 1_o
concentrations NNS 1_o
are VBP N
not RB N
predictive JJ N
of IN N
each DT N
other JJ N
in IN N
Canadian JJ N
lactating VBG N
women NNS N
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
folate NN 1_o
. . 1_o

Synthetic JJ N
intakes NNS N
> VBP N
151-410 JJ N
microg/d NN N
in IN N
these DT N
women NNS N
produced VBD N
little JJ N
additional JJ N
benefit NN N
in IN N
terms NNS N
of IN N
maximizing VBG N
RBC NNP N
content NN N
. . N

More JJR N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
blood NN 1_o
folate NN 1_o
concentration NN 1_o
and CC N
NTD NNP N
risk NN N
. . N

Until IN N
data NNS N
from IN N
such JJ N
studies NNS N
are VBP N
available JJ N
, , N
women NNS N
planning VBG N
a DT N
pregnancy NN N
should MD N
continue VB N
to TO N
consume VB N
a DT N
daily JJ N
folic JJ 1_i
acid JJ 1_i
supplement NN 1_i
of IN N
400 CD N
microg NN N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
infusion NN 1_p
time NN 1_p
on IN N
the DT N
acute JJ 1_o
toxicity NN 1_o
of IN 1_o
amphotericin NN 1_o
B NNP 1_o
: : 1_o
results NNS N
of IN N
a DT N
randomized JJ N
double-blind NN N
study NN N
. . N

-DOCSTART- -X- O O

Alternating VBG 1_i
chemotherapy NN 1_i
in IN N
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
. . 1_p

Based VBN N
on IN N
the DT N
hypothesis NN N
of IN N
Goldie NNP N
and CC N
Coldman NNP N
, , N
rapid JJ 1_i
cyclic JJ 1_i
alternating VBG 1_i
chemotherapy NN 1_i
has VBZ N
been VBN N
supposed VBN N
to TO N
be VB N
a DT N
favorable JJ N
treatment NN N
modality NN N
in IN N
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
. . 1_p

This DT N
approach NN N
has VBZ N
been VBN N
tested VBN N
in IN N
a DT N
large JJ N
series NN N
of IN N
trials NNS N
since IN N
the DT N
late JJ N
70 CD N
's POS N
. . N

A NNP N
few JJ N
trials NNS N
performed VBD N
randomization NN N
between IN N
alternating VBG N
and CC N
continuous JJ N
treatment NN N
after IN N
a DT N
period NN N
of IN N
initial JJ 1_i
common JJ 1_i
continuous JJ 1_i
therapy NN 1_i
. . 1_i

The DT N
results NNS N
of IN N
these DT N
studies NNS N
are VBP N
controversial JJ N
and CC N
their PRP$ N
interpretation NN N
is VBZ N
complicated VBN N
by IN N
the DT N
effects NNS N
of IN N
the DT N
continuous JJ N
pretreatment NN N
. . N

Recently RB N
, , N
most JJS N
trials NNS N
were VBD N
designed VBN N
as IN N
2-arm JJ N
approaches NNS N
with IN N
a DT N
comparison NN N
of IN N
continuous JJ 1_i
standard NN 1_i
therapy NN 1_i
based VBN 1_i
on IN 1_i
the DT 1_i
CAV- NNP 1_i
or CC 1_i
CMC-protocol NNP 1_i
with IN 1_i
an DT 1_i
alternating VBG 1_i
schedule NN 1_i
often RB 1_i
consisting VBG 1_i
of IN 1_i
the DT 1_i
CAV- NNP 1_i
or CC 1_i
CMC-derived JJ 1_i
combinations NNS 1_i
and CC 1_i
a DT 1_i
second JJ 1_i
regimen NN 1_i
including VBG 1_i
cisplatinum NN 1_i
and/or NN 1_i
etoposide NN 1_i
. . 1_i

In IN N
these DT N
trials NNS N
the DT N
addition NN N
of IN N
the DT N
second JJ N
regimen NNS N
in IN N
the DT N
alternating NN N
treatment NN N
arms NNS N
has VBZ N
improved VBN N
the DT N
treatment NN N
results NNS N
. . N

However RB N
, , N
these DT N
trials NNS N
could MD N
not RB N
clarify VB N
whether IN N
this DT N
advantage NN N
was VBD N
due JJ N
to TO N
the DT N
concept NN N
of IN N
alternating VBG N
treatment NN N
or CC N
to TO N
the DT N
high JJ N
activity NN N
of IN N
new JJ N
drugs NNS N
given VBN N
early RB N
in IN N
the DT N
course NN N
of IN N
therapy NN N
in IN N
the DT N
alternating NN N
treatment NN N
arms NNS N
. . N

To TO N
ameliorate VB N
this DT N
weakness NN N
, , N
3 CD N
studies NNS N
were VBD N
designed VBN N
as IN N
3-arms JJ N
approaches NNS N
using VBG N
both DT N
alternating VBG N
protocols NNS N
as IN N
continuous JJ N
control NN N
arms NNS N
. . N

Whereas IN N
one CD N
investigation NN N
noticed VBD N
an DT N
advantage NN N
of IN N
the DT N
alternating NN N
schedule NN N
, , N
the DT N
two CD N
others NNS N
observed VBD N
no DT N
difference NN N
. . N

These DT N
studies NNS N
did VBD N
not RB N
report VB N
their PRP$ N
criteria NNS N
for IN N
shifting VBG N
non-responding JJ N
patients NNS N
from IN N
continuous JJ N
treatment NN N
to TO N
second JJ N
line NN N
therapy NN N
. . N

The DT N
longer JJR N
these DT N
patients NNS N
stayed VBD N
on IN N
the DT N
continuous JJ N
protocol NN N
the DT N
more JJR N
the DT N
study NN N
design NN N
favoured VBD N
the DT N
alternating VBG N
therapy NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

The DT N
development NN N
of IN N
a DT N
web- JJ 1_i
and CC 1_i
a DT 1_i
print-based JJ 1_i
decision NN 1_i
aid NN 1_i
for IN N
prostate NN 1_o
cancer NN 1_o
screening VBG 1_o
. . 1_o

BACKGROUND NNP N
Whether NNP N
early JJ N
detection NN N
and CC N
treatment NN N
of IN N
prostate NN N
cancer NN N
( ( N
PCa NNP N
) ) N
will MD N
reduce VB N
disease-related JJ 1_o
mortality NN 1_o
remains VBZ N
uncertain JJ N
. . N

As IN N
a DT N
result NN N
, , N
tools NNS N
are VBP N
needed VBN N
to TO N
facilitate VB N
informed JJ N
decision NN 1_o
making NN 1_o
. . 1_o

While IN N
there EX N
have VBP N
been VBN N
several JJ N
decision NN N
aids NNS N
( ( N
DAs NNP N
) ) N
developed VBD N
and CC N
tested VBD N
, , N
very RB N
few JJ N
have VBP N
included VBN N
an DT N
exercise NN N
to TO N
help VB N
men NNS N
clarify VB N
their PRP$ N
values NNS 1_o
and CC 1_o
preferences NNS 1_o
about IN N
PCa NNP N
screening NN N
. . N

Further NNP N
, , N
only RB N
one CD N
DA NNP N
has VBZ N
utilized VBN N
an DT N
interactive JJ N
web-based JJ N
format NN N
, , N
which WDT N
allows VBZ N
for IN N
an DT N
expansion NN N
and CC N
customization NN N
of IN N
the DT N
material NN N
. . N

We PRP N
describe VBP N
the DT N
development NN N
of IN N
two CD N
DAs NNP N
, , N
a DT N
booklet NN 1_i
and CC N
an DT N
interactive JJ 1_i
website NN 1_i
, , N
each DT N
with IN N
a DT N
values NNS N
clarification NN N
component NN N
and CC N
designed VBN N
for IN N
use NN N
in IN N
diverse JJ N
settings NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
two CD N
feasibility NN N
studies NNS N
to TO N
assess VB N
men NNS 1_p
's POS 1_p
( ( 1_p
45-70 CD 1_p
years NNS 1_p
) ) 1_p
Internet NNP 1_p
access NN 1_p
and CC 1_p
their PRP$ 1_p
willingness NN 1_p
to TO 1_p
use VB 1_p
a DT 1_p
web- JJ 1_i
vs. FW 1_i
a DT 1_i
print-based JJ 1_i
tool NN 1_i
. . 1_i

The DT N
booklet NN N
was VBD N
adapted VBN N
from IN N
two CD N
previous JJ N
versions NNS N
evaluated VBN N
in IN N
randomized VBN 1_i
controlled JJ 1_i
trials NNS 1_i
( ( 1_i
RCTs NNP 1_i
) ) 1_i
and CC N
the DT N
website NN 1_i
was VBD N
created VBN N
to TO N
closely RB N
match VB N
the DT N
content NN N
of IN N
the DT N
revised JJ N
booklet NN N
. . N

Usability NNP 1_o
testing NN 1_o
was VBD N
conducted VBN N
to TO N
obtain VB N
feedback NN N
regarding VBG N
draft JJ N
versions NNS N
of IN N
the DT N
materials NNS N
. . N

The DT N
tools NNS N
were VBD N
also RB N
reviewed VBN N
by IN N
a DT N
plain NN N
language NN N
expert NN N
and CC N
the DT N
interdisciplinary JJ N
research NN N
team NN N
. . N

Feedback NN N
on IN N
the DT N
content NN N
and CC N
presentation NN N
led VBD N
to TO N
iterative JJ N
modifications NNS N
of IN N
the DT N
tools NNS N
. . N

RESULTS VB N
The DT N
feasibility NN N
studies NNS N
confirmed VBD N
that IN N
the DT N
Internet NNP 1_o
was VBD N
a DT N
viable JJ N
medium NN N
, , N
as IN N
the DT N
majority NN N
of IN N
men NNS N
used VBN 1_o
a DT 1_o
computer NN 1_o
, , N
had VBD N
access NN 1_o
to TO 1_o
the DT 1_o
Internet NNP 1_o
, , N
and CC N
Internet NNP 1_o
use NN 1_o
increased VBD N
over IN N
time NN N
. . N

Feedback NN N
from IN N
the DT N
usability NN N
testing VBG N
on IN N
the DT N
length NN 1_o
, , 1_o
presentation NN 1_o
, , 1_o
and CC 1_o
content NN 1_o
of IN 1_o
the DT 1_o
materials NNS 1_o
was VBD N
incorporated VBN N
into IN N
the DT N
final JJ N
versions NNS N
of IN N
the DT N
booklet NN N
and CC N
website NN N
. . N

Both CC N
the DT N
feasibility NN 1_o
studies NNS 1_o
and CC 1_o
the DT 1_o
usability NN 1_o
testing VBG 1_o
highlighted VBD N
the DT N
need NN N
to TO N
address VB N
men NNS 1_p
's POS 1_p
informed VBN 1_p
decision NN 1_p
making VBG 1_p
regarding VBG N
screening NN N
. . N

CONCLUSIONS NNP N
Informed NNP N
decision NN N
making VBG N
for IN N
PCa NNP N
screening NN N
is VBZ N
crucial JJ N
at IN N
present JJ N
and CC N
may MD N
be VB N
important JJ N
for IN N
some DT N
time NN N
, , N
particularly RB N
if IN N
a DT N
definitive JJ N
recommendation NN N
either DT N
for IN N
or CC N
against IN N
screening VBG N
does VBZ N
not RB N
emerge VB N
from IN N
ongoing VBG N
prostate NN N
cancer NN N
screening VBG N
trials NNS N
. . N

We PRP N
have VBP N
detailed VBN N
our PRP$ N
efforts NNS N
at IN N
developing VBG N
print- JJ N
and CC N
web-based JJ N
DAs NNP N
to TO N
assist VB N
men NNS N
in IN N
determining VBG N
how WRB N
to TO N
best VB N
meet VB N
their PRP$ N
PCa NNP N
screening NN N
preferences NNS N
. . N

Following VBG N
completion NN N
of IN N
our PRP$ N
ongoing JJ N
RCT NNP N
designed VBN N
to TO N
test VB N
these DT N
materials NNS N
, , N
our PRP$ N
goal NN N
will MD N
be VB N
to TO N
develop VB N
a DT N
dissemination NN 1_o
project NN 1_o
for IN N
the DT N
more RBR N
effective JJ N
tool NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00623090 NNP N
. . N

-DOCSTART- -X- O O

Compliance NN N
with IN N
depot NN 1_i
medroxyprogesterone NN 1_i
acetate NN 1_i
: : 1_i
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
of IN N
intensive JJ N
reminders NNS N
. . N

We PRP N
enrolled VBD N
women NNS 1_p
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
to TO N
determine VB N
whether IN N
an DT N
intensive JJ N
reminder NN N
system NN N
would MD N
improve VB N
compliance NN N
in IN N
women NNS 1_p
receiving VBG 1_p
depot NN 1_i
medroxyprogesterone NN 1_i
injections NNS 1_p
. . 1_p

Women NNP N
selecting VBG N
this DT N
treatment NN N
were VBD N
assigned VBN N
to TO N
a DT N
group NN N
that WDT N
received VBD N
both DT N
mail NN 1_i
and CC 1_i
telephone NN 1_i
reminders NNS 1_i
or CC N
to TO N
a DT N
second JJ N
group NN N
that WDT N
received VBD N
only RB 1_i
a DT 1_i
scheduled JJ 1_i
appointment NN 1_i
at IN 1_i
the DT 1_i
time NN 1_i
of IN 1_i
the DT 1_i
previous JJ 1_i
injection NN 1_i
. . 1_i

The DT N
rate NN 1_o
of IN 1_o
continuation NN 1_o
and CC N
the DT N
rate NN 1_o
of IN 1_o
on-time JJ 1_o
injections NNS 1_o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Women NNS N
who WP N
had VBD N
prolonged VBN 1_o
bleeding NN 1_o
were VBD N
more RBR N
likely JJ N
to TO N
discontinue VB N
depot VB N
medroxyprogesterone JJ N
injections NNS N
. . N

-DOCSTART- -X- O O

Albendazole JJ 1_i
trial NN N
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day NN N
for IN N
subarachnoid NN 1_p
and CC 1_p
intraventricular JJ 1_p
cysticercosis NN 1_p
. . 1_p

Thirty-six JJ 1_p
patients NNS 1_p
with IN 1_p
subarachnoid JJ 1_p
and CC 1_p
intraventricular JJ 1_p
cysticercosis NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
albendazole NN 1_i
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day JJ N
plus CC N
dexamethasone NN 1_i
for IN N
8 CD N
days NNS N
. . N

Results NNS N
favored VBD N
a DT N
higher JJR N
dose NN N
, , N
with IN N
larger JJR 1_o
cyst NN 1_o
reduction NN 1_o
on IN N
MRI NNP N
at IN N
90 CD N
and CC N
180 CD N
days NNS N
and CC N
higher JJR N
albendazole JJ 1_o
sulfoxide NN 1_o
levels NNS 1_o
in IN 1_o
plasma NN 1_o
. . 1_o

An DT N
albendazole JJ 1_i
course NN N
at IN N
30 CD N
mg/kg/day NN N
combined VBN N
with IN N
corticosteroids NNS 1_i
is VBZ N
safe JJ 1_o
and CC 1_o
more RBR 1_o
effective JJ 1_o
than IN N
the DT N
usual JJ N
dose NN N
. . N

A DT N
single JJ N
treatment NN N
was VBD N
insufficient JJ 1_o
in IN N
intraventricular JJ N
and CC N
giant JJ N
cysts NNS N
. . N

-DOCSTART- -X- O O

Moisture-vapour-permeable JJ 1_i
film NN 1_i
as IN N
an DT N
outpatient JJ 1_p
burn NN 1_p
dressing VBG 1_p
. . 1_p

This DT N
study NN N
compares VBZ N
a DT N
moisture-vapour-permeable JJ 1_i
film NN 1_i
( ( 1_i
MVPF NNP 1_i
) ) 1_i
with IN N
silver NN 1_i
sulphadiazine NN 1_i
in IN N
a DT N
randomized JJ N
prospective JJ N
manner NN N
for IN N
the DT N
treatment NN N
of IN N
outpatient NN 1_p
burns NNS 1_p
. . 1_p

The DT N
two CD 1_p
treatment NN 1_p
groups NNS 1_p
were VBD 1_p
closely RB 1_p
matched VBN 1_p
in IN 1_p
age NN 1_p
, , 1_p
sex NN 1_p
, , 1_p
per IN 1_p
cent NN 1_p
of IN 1_p
BSA NNP 1_p
burned VBD 1_p
, , 1_p
and CC 1_p
in IN 1_p
burn JJ 1_p
severity NN 1_p
and CC 1_p
locations NNS 1_p
. . 1_p

The DT N
MVPF NNP 1_i
group NN N
demonstrated VBD N
a DT N
39.0 CD N
per IN N
cent NN N
greater JJR N
reduction NN N
in IN N
pain NN 1_o
after IN N
application NN N
of IN N
the DT N
dressing NN N
over IN N
the DT N
silver JJ 1_i
sulphadiazine NN 1_i
group NN N
. . N

Patients NNS N
in IN N
the DT N
MVPF NNP 1_i
film NN N
group NN N
also RB N
reported VBD N
significantly RB N
less JJR N
difficulty NN 1_o
in IN 1_o
wound NN 1_o
care NN 1_o
and CC N
in IN N
dressing VBG 1_o
interference NN 1_o
with IN 1_o
their PRP$ 1_o
daily JJ 1_o
functions NNS 1_o
. . 1_o

The DT N
clinical JJ 1_o
infection NN 1_o
rate NN 1_o
and CC 1_o
time NN 1_o
to TO 1_o
healing VBG 1_o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
management NN 1_o
of IN N
outpatient NN 1_p
burns NNS 1_p
, , N
MVPF NNP 1_i
was VBD N
found VBN N
to TO N
be VB N
superior JJ N
to TO N
silver VB 1_i
sulphadiazine NN 1_i
. . 1_i

-DOCSTART- -X- O O

Short- JJ 1_o
and CC 1_o
long-term JJ 1_o
effects NNS 1_o
of IN N
tactile JJ 1_i
massage NN 1_i
on IN N
salivary JJ 1_o
cortisol NN 1_o
concentrations NNS 1_o
in IN N
Parkinson NNP 1_p
's POS 1_p
disease NN 1_p
: : 1_p
a DT N
randomised JJ N
controlled VBN N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Parkinson NNP N
's POS N
disease NN N
( ( N
PD NNP N
) ) N
is VBZ N
a DT N
chronic JJ N
neurodegenerative JJ N
disorder NN N
with IN N
limited JJ N
knowledge NN N
about IN N
the DT N
normal JJ N
function NN N
and CC N
effects NNS N
of IN N
non-pharmacological JJ 1_i
therapies NNS 1_i
on IN N
the DT N
hypothalamic-pituitary-adrenal JJ 1_o
( ( 1_o
HPA NNP 1_o
) ) 1_o
axis NN 1_o
. . 1_o

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
basal NN 1_o
diurnal JJ 1_o
and CC 1_o
total JJ 1_o
secretion NN 1_o
of IN 1_o
salivary JJ 1_o
cortisol NN 1_o
in IN N
short- JJ N
and CC N
long-term JJ N
aspects NNS N
of IN N
tactile JJ 1_i
massage NN 1_i
( ( 1_i
TM NNP 1_i
) ) 1_i
. . 1_i

METHODS NNP N
DESIGN NNP N
Prospective NNP N
, , N
Controlled NNP N
and CC N
Randomised VBD N
Multicentre NNP N
Trial NNP N
. . N

SETTING NN N
AND JJ N
INTERVENTIONS NNP N
Forty-five NNP 1_p
women NNS 1_p
and CC 1_p
men NNS 1_p
, , 1_p
aged VBN 1_p
50-79 CD 1_p
years NNS 1_p
, , 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

Twenty-nine NN 1_p
of IN 1_p
them PRP 1_p
were VBD 1_p
blindly RB 1_p
randomised VBN 1_p
to TO 1_p
tactile VB 1_i
massage NN 1_i
( ( 1_i
TM NNP 1_i
) ) 1_i
and CC 1_p
16 CD 1_p
of IN 1_p
them PRP 1_p
to TO 1_p
the DT 1_p
control NN 1_i
group NN 1_p
, , 1_p
rest NN 1_i
to TO 1_i
music NN 1_i
( ( 1_i
RTM NNP 1_i
) ) 1_i
. . 1_i

Ten CD N
interventions NNS N
were VBD N
given VBN N
during IN N
8 CD N
weeks NNS N
followed VBN N
by IN N
a DT N
26 CD N
weeks NNS N
of IN N
follow JJ N
up RB N
. . N

Salivary JJ 1_o
cortisol NN 1_o
was VBD N
collected VBN N
at IN N
8 CD N
am VBP N
, , N
1 CD N
pm NN N
, , N
8 CD N
pm NN N
, , N
and CC N
8 CD N
am VBP N
the DT N
next JJ N
day NN N
, , N
on IN N
five CD N
occasions NNS N
. . N

With IN N
the DT N
first JJ N
and CC N
eighth JJ N
interventions NNS N
, , N
it PRP N
was VBD N
collected VBN N
immediately RB N
before IN N
and CC N
after IN N
intervention NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
aim NN N
was VBD N
to TO N
assess VB 1_o
and CC 1_o
compare VB 1_o
cortisol JJ 1_o
concentrations NNS 1_o
before IN N
and CC N
immediately RB N
after IN N
intervention NN N
and CC N
also RB N
during IN N
the DT N
follow-up JJ N
period NN N
. . N

The DT N
secondary JJ N
aim NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN 1_o
of IN 1_o
age NN 1_o
, , 1_o
gender NN 1_o
, , 1_o
body NN 1_o
mass NN 1_o
index NN 1_o
( ( 1_o
BMI NNP 1_o
) ) 1_o
, , 1_o
duration NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
PD NNP 1_o
, , 1_o
effects NNS 1_o
of IN 1_o
interventional JJ 1_o
time-point NN 1_o
of IN 1_o
the DT 1_o
day NN 1_o
, , 1_o
and CC 1_o
levodopa JJ 1_o
doses NNS 1_o
on IN 1_o
cortisol JJ 1_o
concentration NN 1_o
. . 1_o

RESULTS VB N
The DT N
median JJ 1_o
cortisol NN 1_o
concentrations NNS 1_o
for IN N
all DT N
participants NNS N
were VBD N
16.0 CD N
, , N
5.8 CD N
, , N
2.8 CD N
, , N
and CC N
14.0 CD N
nmol/L NN N
at IN N
baseline NN N
, , N
later RB N
reproduced VBD N
four CD N
times NNS N
without IN N
significant JJ N
differences NNS N
. . N

Cortisol NNP 1_o
concentrations NNS 1_o
decreased VBD N
significantly RB N
after IN N
TM NNP 1_i
intervention NN N
but CC N
no DT N
change NN N
in IN N
diurnal JJ N
salivary JJ N
cortisol NN N
pattern NN N
was VBD N
found VBN N
. . N

The DT N
findings NNS N
of IN N
reduced JJ N
salivary JJ 1_o
cortisol NN 1_o
concentrations NNS 1_o
immediately RB N
after IN N
the DT N
interventions NNS N
are VBP N
in IN N
agreement NN N
with IN N
previous JJ N
studies NNS N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
TM NNP 1_i
and CC N
control NN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
correlations NNS N
between IN N
cortisol JJ 1_o
concentrations NNS 1_o
and CC N
age NN 1_o
, , 1_o
gender NN 1_o
, , 1_o
BMI NNP 1_o
, , 1_o
time-point NN 1_o
for IN 1_o
intervention NN 1_o
, , 1_o
time NN 1_o
interval NN 1_o
between IN 1_o
anti-parkinson JJ 1_o
pharmacy NN 1_o
intake NN 1_o
and CC 1_o
sampling NN 1_o
, , 1_o
levodopa NN 1_o
doses NNS 1_o
, , 1_o
duration NN 1_o
, , 1_o
or CC 1_o
severity NN 1_o
of IN 1_o
PD NNP 1_o
. . 1_o

CONCLUSIONS NNP N
Diurnal NNP 1_o
salivary JJ 1_o
cortisol NN 1_o
rhythm NN 1_o
was VBD N
normal JJ N
. . N

Salivary JJ 1_o
cortisol NN 1_o
concentrations NNS 1_o
were VBD N
significantly RB N
reduced VBN N
after IN N
the DT N
TM NNP 1_i
intervention NN N
and CC N
after IN N
RTM NNP 1_i
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
and CC N
no DT N
sustained JJ N
long-term JJ N
effect NN N
. . N

No CC N
associations NNS N
were VBD N
seen VBN N
between IN N
salivary JJ 1_o
cortisol NN 1_o
concentration NN 1_o
and CC N
clinical JJ N
and/or NN N
pharmacological JJ N
characteristics NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
, , N
NCT01734876 NNP N
and CC N
FoU NNP N
Sweden NNP N
108881 CD N
. . N

-DOCSTART- -X- O O

[ JJ 1_o
Hepatoprotective NNP 1_o
activity NN 1_o
of IN N
remaxol NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
hepatic JJ 1_p
disorders NNS 1_p
] VBP 1_p
. . N

This DT N
milticentre NN N
randomized VBD N
clinical JJ N
study NN N
of IN N
the DT N
efficiency NN 1_o
of IN N
remaxol JJ 1_i
infusion NN 1_i
solution NN 1_i
( ( N
hepatoprotective JJ N
medicine NN N
for IN N
chronic JJ N
liver NN N
dysfunction NN N
) ) N
included VBD N
494 CD 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
hepatitis NN 1_p
B NNP 1_p
and CC 1_p
C. NNP 1_p
294 CD N
of IN N
them PRP N
staying VBG 1_p
in IN 1_p
7 CD 1_p
clinics NNS 1_p
were VBD N
given VBN N
remaxol NNS 1_i
and CC N
200 CD N
ones NNS N
received VBD N
placebo NN 1_i
. . 1_i

Randomization NN N
was VBD N
achieved VBN N
by IN N
the DT N
envelope NN N
method NN N
. . N

A DT N
detailed JJ N
description NN N
of IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
of IN N
the DT N
diseases NNS N
is VBZ N
presented VBN N
. . N

Effects NNS N
of IN N
remaxol NN 1_i
vs NN 1_i
placebo NN 1_i
on IN N
the DT N
functional JJ 1_o
activity NN 1_o
of IN N
affected VBN N
liver NN N
are VBP N
discussed VBN N
. . N

Results NNS N
of IN N
laboratory NN N
and CC N
clinical JJ N
analysis NN N
indicate VBP N
that IN N
mechanism NN N
of IN N
remaxol JJ 1_i
action NN N
is VBZ N
based VBN N
on IN N
hepatoprotective JJ 1_o
, , 1_o
antioxidative JJ 1_o
, , 1_o
and CC 1_o
anticholestatic JJ 1_o
activities NNS 1_o
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -X- O O

Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
cancer NN N
: : N
current JJ N
status NN N
of IN N
the DT N
Austrain NNP 1_p
Czech JJ 1_p
German NNP 1_p
gastric NN 1_p
cancer NN 1_p
prevention NN N
trial NN N
( ( N
PRISMA NNP N
Study NNP N
) ) N
. . N

AIM UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
Helicobacter NNP N
pylori VBZ N
eradication NN N
alone RB N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
gastric JJ 1_o
cancer NN 1_o
in IN N
a DT N
subgroup NN 1_p
of IN 1_p
individuals NNS 1_p
with IN 1_p
an DT 1_p
increased VBN 1_p
risk NN 1_p
for IN 1_p
this DT 1_p
fatal JJ 1_p
disease NN 1_p
. . 1_p

METHODS NNP N
It PRP N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
multinational JJ N
multicenter NN N
trial NN N
. . N

Men NN 1_p
between IN 1_p
55 CD 1_p
and CC 1_p
65 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
a DT 1_p
gastric JJ 1_p
cancer NN 1_p
phenotype NN 1_p
of IN 1_p
Helicobacter NNP 1_p
pylori FW 1_p
gastritis NN 1_p
are VBP 1_p
randomized VBN 1_p
to TO N
receive VB N
a DT N
7 CD N
day NN N
course NN N
of IN N
omeprazole JJ 1_i
2 CD 1_i
X NN 1_i
20mg CD 1_i
, , 1_i
clarithromycin VBD 1_i
2 CD 1_i
X NNP 1_i
500mg CD 1_i
, , 1_i
and CC 1_i
amoxicillin RB 1_i
2 CD 1_i
X NNS 1_i
1g CD 1_i
for IN 1_i
7 CD 1_i
days NNS 1_i
, , 1_i
or CC 1_i
omeprazole JJ 1_i
2 CD 1_i
X NN 1_i
20mg CD 1_i
plus CC 1_i
placebo NN 1_i
. . 1_i

Follow-up JJ N
endoscopy NN N
is VBZ N
scheduled VBN N
3 CD N
months NNS N
after IN N
therapy NN N
, , N
and CC N
thereafter RB N
in IN N
one-year JJ N
intervals NNS N
. . N

Predefined VBN N
study NN N
endpoints NNS N
are VBP N
gastric JJ 1_o
cancer NN 1_o
, , 1_o
precancerous JJ 1_o
lesions NNS 1_o
( ( 1_o
dysplasia NN 1_o
, , 1_o
adenoma NN 1_o
) ) 1_o
, , 1_o
other JJ 1_o
cancers NNS 1_o
, , 1_o
and CC 1_o
death NN 1_o
. . 1_o

RESULTS NNP N
Since IN 1_p
March NNP 1_p
1998 CD 1_p
, , 1_p
1524 CD 1_p
target NN 1_p
patients NNS 1_p
have VBP 1_p
been VBN 1_p
screened VBN 1_p
, , 1_p
279 CD 1_p
patients NNS 1_p
( ( 1_p
18.3 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
a DT 1_p
corpus NN 1_p
dominant JJ 1_p
type NN 1_p
of IN 1_p
H. NNP 1_p
pylori FW 1_p
gastritis NN 1_p
, , 1_p
and CC 1_p
167 CD 1_p
of IN 1_p
those DT 1_p
were VBD 1_p
randomized VBN 1_p
( ( N
58.8 CD N
% NN N
) ) N
. . N

In IN N
the DT N
active JJ N
treatment NN N
group NN N
( ( N
r NN N
= RB N
86 CD N
) ) N
, , N
H. NNP N
pylori VBZ N
infection NN N
infection NN N
was VBD N
cured VBN 1_o
in IN N
88.9 CD N
% NN N
of IN N
patients NNS N
. . N

Currently RB N
, , N
the DT N
cumulative JJ N
follow-up JJ N
time NN N
is VBZ N
3046 CD N
months NNS N
( ( N
253.38 CD N
patient NN N
years NNS N
, , N
median NN N
follow VBP N
up RB N
16 CD N
months NNS N
) ) N
. . N

So RB N
far RB N
, , N
none NN N
of IN N
the DT N
patients NNS N
developed VBD N
gastric JJ 1_o
cancer NN 1_o
or CC 1_o
any DT 1_o
precancerous JJ 1_o
lesion NN 1_o
. . 1_o

Three NNP N
( ( N
1.8 CD N
% NN N
) ) N
patients NNS N
reached VBD N
study NN 1_o
endpoints NNS 1_o
other JJ 1_o
than IN 1_o
gastric JJ 1_o
cancer NN 1_o
. . 1_o

CONCLUSION NNP N
Among IN N
men NNS N
between IN N
55 CD N
and CC N
65 CD N
years NNS N
of IN N
age NN N
, , N
the DT N
gastric JJ N
cancer NN N
phenotype NN N
of IN N
H. NNP N
pylori FW N
gastritis NN N
appears VBZ N
to TO N
be VB N
more JJR N
common JJ N
than IN N
expected VBN N
. . N

Further RBR N
follow VB N
up RB N
and CC N
continuing VBG N
recruitment NN N
are VBP N
necessary JJ N
to TO N
fulfil VB N
the DT N
main JJ N
aim NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Maintenance NN N
of IN N
response NN N
following VBG N
stabilization NN N
of IN N
mixed JJ N
index NN N
episodes NNS N
with IN N
olanzapine JJ 1_i
monotherapy NN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
of IN N
bipolar JJ 1_p
1 CD 1_p
disorder NN 1_p
. . 1_p

BACKGROUND NNP N
In IN N
a DT N
population NN N
of IN N
patients NNS 1_p
with IN 1_p
manic JJ 1_p
and CC 1_p
mixed JJ 1_p
mood NN 1_p
episodes NNS 1_p
, , N
olanzapine NN 1_i
has VBZ N
proven VBN N
effective JJ N
in IN N
maintaining VBG N
response NN N
, , N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

Whether IN N
this DT N
is VBZ N
true JJ N
for IN N
the DT N
subpopulation NN N
of IN N
patients NNS N
with IN N
a DT N
mixed JJ N
index NN N
episode NN N
is VBZ N
not RB N
known VBN N
. . N

METHODS NNP N
Post-hoc JJ N
analyses NNS N
were VBD N
conducted VBN N
on IN N
data NNS N
from IN N
patients NNS 1_p
presenting VBG 1_p
with IN 1_p
a DT 1_p
mixed JJ 1_p
index NN 1_p
episode NN 1_p
who WP 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
larger JJR 1_p
double-blind NN 1_p
, , 1_p
placebo-controlled JJ 1_i
trial NN 1_p
. . 1_p

Patients NNS 1_p
who WP 1_p
met VBD 1_p
remission NN 1_p
criteria NNS 1_p
at IN 1_p
2 CD 1_p
consecutive JJ 1_p
weekly JJ 1_p
visits NNS 1_p
during IN 1_p
6 CD 1_p
to TO 1_p
12 CD 1_p
weeks NNS 1_p
of IN 1_p
open-label JJ 1_p
olanzapine JJ 1_i
treatment NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
olanzapine VB 1_i
or CC N
placebo VB 1_i
treatment NN N
for IN N
48 CD N
weeks NNS N
. . N

The DT N
incidence NN N
of IN N
and CC N
time NN N
to TO N
symptomatic JJ 1_o
relapse NN 1_o
were VBD N
calculated VBN N
for IN N
any DT N
mood NN N
episode NN N
, , N
and CC N
for IN N
depressive JJ N
, , N
manic JJ N
, , N
hypo-manic JJ N
, , N
and CC N
mixed JJ N
mood NN N
episodes NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
121 CD 1_p
of IN 1_p
304 CD 1_p
patients NNS 1_p
( ( N
39.8 CD N
% NN N
) ) N
met VBD N
criteria NNS N
for IN N
symptomatic JJ 1_o
remission NN 1_o
in IN N
the DT N
open-label JJ N
treatment NN N
phase NN N
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
olanzapine VB 1_i
( ( N
n=76 NN N
) ) N
or CC N
placebo NN N
( ( N
n=45 JJ N
) ) N
. . N

Compared VBN N
to TO N
the DT N
placebo NN 1_i
group NN N
, , N
the DT N
olanzapine NN 1_i
group NN N
had VBD N
a DT N
lower JJR N
incidence NN N
of IN N
( ( N
59.2 CD N
% NN N
versus IN N
91.1 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
longer JJR N
time NN N
to TO N
( ( N
46 CD N
versus NN N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
symptomatic JJ 1_o
relapse NN 1_o
of IN N
any DT N
kind NN N
. . N

Olanzapine-treated JJ 1_i
patients NNS N
also RB N
experienced VBD N
longer JJR N
time NN 1_o
to TO 1_o
depressive VB 1_o
symptomatic JJ 1_o
relapse NN 1_o
( ( N
85 CD N
versus NN N
22 CD N
days NNS N
, , N
p=0.001 NN N
) ) N
and CC N
manic JJ 1_o
symptomatic JJ 1_o
relapse NN 1_o
( ( N
too RB N
few JJ N
relapses NNS N
to TO N
calculate VB N
versus NN N
42 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
than IN N
did VBD N
placebo-treated JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
placebo NN 1_i
, , 1_i
olanzapine JJ 1_i
treatment NN N
was VBD N
associated VBN N
with IN N
longer JJR N
maintenance NN 1_o
of IN 1_o
response NN 1_o
in IN N
patients NNS 1_p
presenting VBG 1_p
with IN 1_p
a DT 1_p
mixed JJ 1_p
index NN 1_p
episode NN 1_p
of IN 1_p
bipolar NN 1_p
I PRP 1_p
disorder VBP 1_p
. . 1_p

-DOCSTART- -X- O O

Switching VBG N
patients NNS 1_p
with IN 1_p
asthma NN 1_p
from IN N
chlorofluorocarbon NN N
( ( N
CFC NNP N
) ) N
albuterol NN N
to TO N
hydrofluoroalkane-134a NN 1_i
( ( 1_i
HFA NNP 1_i
) ) 1_i
albuterol NN 1_i
. . 1_i

Chlorofluorocarbon NNP N
( ( N
CFC NNP N
) ) N
propellants VBZ N
deplete JJ N
stratospheric JJ N
ozone NN N
. . N

Production NN N
and CC N
use NN N
of IN N
CFCs NNS N
, , N
except IN N
for IN N
certain JJ N
critical JJ N
exemptions NNS N
, , N
has VBZ N
been VBN N
prohibited VBN N
by IN N
the DT N
Montreal NNP N
Protocol NNP N
. . N

Use NNP N
of IN N
CFCs NNPS N
as IN N
propellants NNS N
in IN N
metered-dose JJ N
inhalers NNS N
( ( N
MDIs NNP N
) ) N
is VBZ N
still RB N
allowed VBN N
, , N
but CC N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
is VBZ N
planning VBG N
the DT N
transition NN N
to TO N
alternative JJ N
propellants NNS N
for IN N
use NN N
in IN N
MDIs NNP N
. . N

Hydrofluoroalkane-134a NNP 1_i
( ( 1_i
HFA NNP 1_i
) ) 1_i
, , N
a DT N
non-ozone-depleting JJ N
propellant NN N
, , N
has VBZ N
been VBN N
used VBN N
to TO N
reformulate VB N
albuterol NN N
( ( N
HFA NNP N
albuterol NN N
) ) N
. . N

This DT N
study NN N
evaluates VBZ N
whether IN N
comparable JJ N
safety NN N
and CC N
efficacy NN N
continues VBZ N
for IN N
12 CD N
weeks NNS N
after IN N
patients NNS 1_p
with IN 1_p
asthma NNS 1_p
are VBP N
switched VBN 1_i
from IN 1_i
CFC NNP 1_i
albuterol NN 1_i
to TO 1_i
HFA NNP 1_i
albuterol NN 1_i
. . 1_i

Patients NNS 1_p
with IN 1_p
asthma JJ 1_p
stabilized VBN 1_p
on IN 1_p
CFC NNP 1_p
albuterol NN 1_p
during IN N
a DT N
12-week JJ N
safety NN N
and CC N
efficacy NN N
trial NN N
were VBD N
randomized VBN N
to TO N
either DT 1_i
continue NN 1_i
receiving VBG 1_i
CFC NNP 1_i
albuterol NN 1_i
or CC 1_i
to TO 1_i
be VB 1_i
switched VBN 1_i
to TO 1_i
receive VB 1_i
HFA NNP 1_i
albuterol NN 1_i
in IN 1_i
a DT 1_i
yearlong JJ 1_i
safety NN 1_i
and CC 1_i
efficacy NN 1_i
trial NN 1_i
. . 1_i

Safety NN 1_o
and CC 1_o
efficacy NN 1_o
were VBD N
compared VBN N
over IN N
the DT N
first JJ N
12 CD N
weeks NNS N
of IN N
the DT N
yearlong JJ N
trial NN N
between IN N
patients NNS N
who WP N
had VBD N
remained VBN N
on IN N
CFC NNP N
albuterol NN N
and CC N
those DT N
who WP N
had VBD N
been VBN N
switched VBN N
to TO N
HFA NNP N
albuterol NN N
. . N

Bronchodilator NNP 1_o
efficacy NN 1_o
was VBD N
evaluated VBN N
by IN N
serial JJ 1_o
spirometry NN 1_o
for IN N
6 CD N
hr NN N
after IN N
the DT N
patients NNS N
self-administered VBD N
the DT N
study NN N
drug NN N
in IN N
the DT N
clinic NN N
. . N

Safety NNP 1_o
was VBD N
assessed VBN N
by IN N
measuring VBG N
changes NNS 1_o
in IN 1_o
pulse JJ 1_o
rate NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
electrocardiogram NN 1_o
( ( 1_o
ECG NNP 1_o
) ) 1_o
intervals NNS 1_o
after IN N
dosing VBG N
with IN N
study JJ N
drug NN N
, , N
monitoring VBG 1_o
adverse JJ 1_o
events NNS 1_o
, , N
and CC N
performing VBG N
prestudy NN N
and CC N
poststudy NN N
laboratory NN 1_o
testing NN 1_o
and CC 1_o
physical JJ 1_o
examinations NNS 1_o
. . 1_o

No DT N
significant JJ N
differences NNS N
in IN N
bronchodilator NN 1_o
efficacy NN 1_o
between IN N
the DT N
patients NNS N
continuing VBG N
to TO N
receive VB N
CFC NNP N
albuterol NN N
and CC N
those DT N
switched VBN N
to TO N
HFA NNP 1_i
albuterol NN 1_i
were VBD N
found VBN N
in IN N
the DT N
12 CD N
weeks NNS N
after IN N
the DT N
switch NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
two CD N
products NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
pulse JJ 1_o
rate NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
ECG NNP 1_o
intervals NNS 1_o
. . 1_o

Adverse JJ 1_o
event NN 1_o
profiles NNS 1_o
were VBD N
similar JJ N
for IN N
the DT N
two CD N
products NNS N
, , N
except IN N
the DT N
patients NNS N
remaining VBG N
on IN N
CFC NNP N
albuterol NN N
reported VBD N
increased JJ N
asthma NN N
symptoms NNS N
and CC N
rhinitis VB N
significantly RB N
more RBR N
often RB N
than IN N
the DT N
patients NNS N
switched VBD N
to TO N
HFA NNP N
albuterol NN N
. . N

No DT N
clinically RB N
meaningful JJ N
changes NNS 1_o
in IN N
laboratory NN N
tests NNS N
or CC N
physical JJ N
examinations NNS N
were VBD N
found VBN N
in IN N
either DT N
treatment NN N
group NN N
. . N

Patients NNS 1_p
with IN 1_p
asthma JJ 1_p
switched VBN N
from IN N
CFC NNP N
albuterol NN N
to TO N
HFA NNP 1_i
albuterol NN 1_i
receive VBP N
comparable JJ N
bronchodilation NN N
with IN N
a DT N
similar JJ N
safety NN N
profile NN N
as IN N
those DT N
continuing VBG N
to TO N
receive VB N
CFC NNP N
albuterol NN N
. . N

-DOCSTART- -X- O O

Endobronchial JJ N
ultrasonography-guided JJ N
transbronchial JJ 1_i
needle JJ 1_i
aspiration NN 1_i
increases VBZ N
the DT N
diagnostic JJ 1_o
yield NN 1_o
of IN N
peripheral JJ 1_p
pulmonary JJ 1_p
lesions NNS 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
diagnostic JJ 1_o
yield NN 1_o
of IN N
endobronchial JJ 1_i
ultrasonography NN 1_i
( ( 1_i
EBUS NNP 1_i
) ) 1_i
-guided VBD 1_i
transbronchial JJ 1_i
needle JJ 1_i
aspiration NN 1_i
( ( 1_i
TBNA NNP 1_i
) ) 1_i
for IN N
peripheral JJ N
pulmonary JJ N
lesions NNS N
( ( N
PPLs NNP N
) ) N
has VBZ N
not RB N
been VBN N
evaluated VBN N
. . N

The DT N
diagnostic JJ N
impact NN N
of IN N
TBNA NNP N
when WRB N
the DT N
EBUS NNP N
probe NN N
is VBZ N
adjacent JJ N
to TO N
lesions NNS N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

DESIGN VB N
A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
. . N

METHODS NNP N
Two CD 1_p
hundred VBD 1_p
two CD 1_p
patients NNS 1_p
with IN 1_p
PPLs NNP 1_p
and CC 1_p
positive JJ 1_p
EBUS NNP 1_p
findings NNS 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

They PRP N
were VBD N
randomly RB N
classified VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
the DT N
EBUS NNP N
conventional JJ N
diagnostic JJ N
procedures NNS N
( ( N
CDPs NNP N
) ) N
group NN N
( ( N
103 CD N
patients NNS N
) ) N
, , N
both DT N
transbronchial JJ 1_i
biopsy NN 1_i
( ( N
TBB NNP N
) ) N
and CC N
bronchial JJ N
washing NN N
( ( N
BW NNP N
) ) N
were VBD N
performed VBN N
. . N

In IN N
the DT N
EBUS-TBNA JJ N
plus CC N
CDPs NNP N
group NN N
( ( N
99 CD N
patients NNS N
) ) N
, , N
TBNA NNP N
, , N
TBB NNP N
, , N
and CC N
BW NNP N
were VBD N
performed VBN N
. . N

The DT N
diagnostic JJ 1_o
yield NN 1_o
in IN N
each DT N
group NN N
was VBD N
compared VBN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
182 CD 1_p
patients NNS 1_p
( ( 1_p
94 CD 1_p
in IN 1_p
the DT 1_p
EBUS NNP 1_p
CDPs NNP 1_p
group NN 1_p
and CC 1_p
88 CD 1_p
in IN 1_p
the DT 1_p
EBUS-TBNA JJ 1_p
plus CC 1_p
CDPs NNP 1_p
group NN 1_p
) ) 1_p
were VBD 1_p
analyzed VBN 1_p
. . 1_p

The DT N
yield NN 1_o
in IN 1_o
the DT 1_o
EBUS-TBNA JJ 1_o
plus CC N
CDPs NNP N
group NN N
( ( N
78.4 CD N
% NN N
) ) N
was VBD N
significantly RB N
higher JJR N
than IN N
the DT N
EBUS NNP N
CDPs NNP N
group NN N
( ( N
60.6 CD N
% NN N
, , N
p NN N
= NNP N
0.015 CD N
) ) N
. . N

Cases NNS N
in IN N
which WDT N
the DT N
EBUS NNP N
probe NN N
was VBD N
located VBN N
within IN N
the DT N
lesions NNS N
had VBD N
a DT N
significantly RB N
higher RBR 1_o
diagnostic JJ 1_o
yield NN 1_o
( ( N
78.3 CD N
% NN N
) ) N
than IN N
when WRB N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
them PRP N
( ( N
47.2 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Concerning VBG N
the DT N
three CD N
different JJ N
techniques NNS N
, , N
TBNA NNP N
showed VBD N
the DT N
highest JJS 1_o
diagnostic JJ 1_o
yield NN 1_o
( ( N
62.5 CD N
% NN N
) ) N
in IN N
comparison NN N
to TO N
TBB NNP N
( ( N
48.9 CD N
% NN N
) ) N
and CC N
to TO N
BW NNP N
( ( N
19.8 CD N
% NN N
) ) N
. . N

The DT N
diagnostic JJ 1_o
yield NN 1_o
of IN 1_o
TBNA NNP 1_o
remained VBD N
unchanged JJ N
even RB N
when WRB N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
the DT N
lesions NNS N
( ( N
p JJ N
= NNP N
0.89 CD N
) ) N
. . N

No DT N
additional JJ N
adverse JJ 1_o
effects NNS 1_o
were VBD N
observed VBN N
in IN N
the DT N
EBUS-TBNA JJ N
plus CC N
CDPs NNP N
group NN N
. . N

CONCLUSIONS NNP N
Applying NNP N
TBNA NNP N
to TO N
EBUS-guided NNP N
CDPs NNP N
further RBR N
increased VBD N
the DT N
diagnostic JJ 1_o
yield NN 1_o
of IN N
PPLs NNP N
without IN N
additional JJ N
risk NN N
. . N

The DT N
diagnostic JJ 1_o
advantage NN 1_o
of IN N
TBNA NNP N
became VBD N
more RBR N
obvious JJ N
if IN N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
the DT N
lesions NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
Identifier NNP N
: : N
NCT00626587 NN N
. . N

-DOCSTART- -X- O O

Minimal NNP 1_i
clinically RB 1_i
important JJ 1_i
change NN 1_i
for IN N
pain NN 1_o
intensity NN 1_o
, , 1_o
functional JJ 1_o
status NN 1_o
, , N
and CC N
general JJ N
health NN 1_o
status NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
nonspecific JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
Cohort NNP N
study NN N
. . N

OBJECTIVES NNP N
To TO N
estimate VB N
the DT N
Minimal NNP 1_o
Clinically NNP 1_o
Important NNP 1_o
Change NNP 1_o
( ( 1_o
MCIC NNP 1_o
) ) 1_o
of IN N
the DT N
pain NN 1_o
intensity NN 1_o
numerical JJ 1_o
rating NN 1_o
scale NN 1_o
( ( 1_o
PI-NRS NNP 1_o
) ) 1_o
, , N
the DT N
Quebec NNP 1_o
Back NNP 1_o
Pain NNP 1_o
Disability NNP 1_o
Scale NNP 1_o
( ( 1_o
QBPDS NNP 1_o
) ) 1_o
, , N
and CC N
the DT N
Euroqol NNP 1_o
( ( 1_o
EQ NNP 1_o
) ) 1_o
in IN N
patients NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
MCIC NNP N
can MD N
provide VB N
valuable JJ N
information NN N
for IN N
researchers NNS N
, , N
healthcare NN N
providers NNS N
, , N
and CC N
policymakers NNS N
. . N

METHODS NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
with IN N
442 CD 1_p
patients NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
were VBD 1_p
used VBN 1_p
. . 1_p

The DT N
MCIC NNP 1_i
was VBD N
estimated VBN N
over IN N
a DT N
12-week JJ N
period NN N
, , N
and CC N
three CD N
different JJ N
methods NNS N
were VBD N
used VBN N
: : N
1 CD N
) ) N
mean NN N
change NN N
scores NNS N
, , N
2 CD N
) ) N
minimal NN N
detectable JJ N
change NN N
, , N
and CC N
3 CD N
) ) N
optimal VBD N
cutoff NN N
point NN N
in IN N
receiver NN N
operant JJ N
curves NNS N
. . N

The DT N
global JJ N
perceived JJ N
effect NN N
scale NN N
( ( N
GPE NNP N
) ) N
was VBD N
used VBN N
as IN N
an DT N
external JJ N
criterion NN N
. . N

The DT N
effect NN N
of IN N
initial JJ N
scores NNS N
on IN N
the DT N
MCIC NNP 1_i
was VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
The DT N
MCIC NNP 1_o
of IN N
the DT N
PI-NRS NNP N
ranged VBD N
from IN N
3.5 CD N
to TO N
4.7 CD N
points NNS N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
2.5 CD N
to TO N
4.5 CD N
points NNS N
in IN N
chronic JJ N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
. . N

The DT N
MCIC NNP 1_o
of IN 1_o
the DT 1_o
QBPDS NNP 1_o
was VBD N
estimated VBN N
between IN N
17.5 CD N
to TO N
32.9 CD N
points NNS N
and CC N
8.5 CD N
to TO N
24.6 CD N
points NNS N
for IN N
( ( 1_p
sub NN 1_p
) ) 1_p
acute NN 1_p
and CC 1_p
chronic JJ 1_p
patients NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

The DT N
MCIC NNP 1_o
for IN 1_o
the DT 1_o
EQ NNP 1_o
ranged VBD N
from IN N
0.07 CD N
to TO N
0.58 CD N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
0.09 CD N
to TO N
0.28 CD N
in IN N
patients NNS N
with IN N
chronic JJ N
low JJ N
back RB N
pain NN N
. . N

CONCLUSION NNP N
Reporting VBG N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
have VBP N
made VBN N
a DT N
MCIC NNP 1_i
adds VBZ N
to TO N
the DT N
interpretability NN N
of IN N
study NN N
results NNS N
. . N

We PRP N
present VBD N
a DT N
range NN N
of IN N
MCIC NNP 1_i
values NNS N
and CC N
advocate VB N
the DT N
choice NN N
of IN N
a DT N
single JJ N
MCIC NNP 1_i
value NN N
according VBG N
to TO N
the DT N
specific JJ N
context NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
modified VBN 1_i
eggs NNS 1_i
and CC 1_i
an DT 1_i
egg-yolk NN 1_i
based VBN 1_i
beverage NN 1_i
on IN 1_p
serum NN 1_o
lutein NN 1_o
and CC 1_o
zeaxanthin JJ 1_o
concentrations NNS 1_o
and CC N
macular JJ N
pigment NN N
optical JJ N
density NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

UNLABELLED CC N
Increasing VBG N
evidence NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
lutein NN N
and CC N
zeaxanthin NN N
on IN N
the DT N
progression NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
lutein NN 1_i
or CC 1_i
zeaxanthin NN 1_i
enriched VBN 1_i
eggs NNS 1_i
or CC 1_i
a DT 1_i
lutein JJ 1_i
enriched VBN 1_i
egg-yolk NN 1_i
based VBN 1_i
buttermilk NN 1_i
beverage NN 1_i
on IN N
serum NN 1_o
lutein NN 1_o
and CC 1_o
zeaxanthin JJ 1_o
concentrations NNS 1_o
and CC N
macular JJ N
pigment NN N
levels NNS N
. . N

Naturally RB 1_i
enriched VBN 1_i
eggs NNS 1_i
were VBD N
made VBN N
by IN N
increasing VBG N
the DT N
levels NNS N
of IN N
the DT N
xanthophylls NNP N
lutein NN N
and CC N
zeaxanthin NN 1_i
in IN N
the DT N
feed NN N
given VBN N
to TO N
laying VBG N
hens NNS N
. . N

One CD 1_p
hundred VBD 1_p
healthy JJ 1_p
volunteers NNS 1_p
were VBD 1_p
recruited VBN 1_p
and CC 1_p
randomized VBN 1_p
into IN 1_p
5 CD 1_p
groups NNS 1_p
for IN 1_p
90 CD 1_p
days NNS 1_p
. . 1_p

Group NNP N
one CD N
added VBD N
one CD 1_i
normal JJ 1_i
egg NN 1_i
to TO 1_i
their PRP$ 1_i
daily JJ 1_i
diet NNS 1_i
and CC N
group NN 1_i
two CD 1_i
received VBD 1_i
a DT 1_i
lutein NN 1_i
enriched VBD 1_i
egg-yolk NN 1_i
based VBN 1_i
beverage NN 1_i
. . 1_i

Group NNP N
three CD N
added VBD N
one CD 1_i
lutein NN 1_i
enriched VBD 1_i
egg NN 1_i
and CC N
group NN 1_i
four CD 1_i
one CD 1_i
zeaxanthin NN 1_i
enriched VBD 1_i
egg NN 1_i
to TO 1_i
their PRP$ 1_i
diet JJ 1_i
. . 1_i

Group NNP N
five CD N
was VBD N
the DT N
control NN 1_i
group NN 1_i
and CC 1_i
individuals NNS 1_i
in IN 1_i
this DT 1_i
group NN 1_i
did VBD 1_i
not RB 1_i
modify VB 1_i
their PRP$ 1_i
daily JJ 1_i
diet NN 1_i
. . 1_i

Serum NNP 1_o
lutein NN 1_o
and CC 1_o
zeaxanthin JJ 1_o
concentrations NNS 1_o
and CC N
macular JJ 1_o
pigment NN 1_o
densities NNS 1_o
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
day NN N
45 CD N
and CC N
day NN N
90 CD N
. . N

Macular JJ 1_o
pigment NN 1_o
density NN 1_o
was VBD N
measured VBN N
by IN N
heterochromatic JJ N
flicker NN N
photometry NN N
. . N

Serum NNP 1_o
lutein JJ 1_o
concentration NN 1_o
in IN N
the DT N
lutein NN N
enriched VBD N
egg NN N
and CC N
egg NN N
yolk-based JJ N
beverage NN N
groups NNS N
increased VBD N
significantly RB N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
76 CD N
% NN N
and CC N
77 CD N
% NN N
) ) N
. . N

A DT N
strong JJ N
increase NN N
in IN N
the DT N
serum NN 1_o
zeaxanthin NN 1_o
concentration NN 1_o
was VBD N
observed VBN N
in IN N
individuals NNS N
receiving VBG N
zeaxanthin NN 1_i
enriched VBN 1_i
eggs NNS 1_i
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
430 CD N
% NN N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
in IN N
macular JJ 1_o
pigment NN 1_o
density NN 1_o
in IN N
the DT N
various JJ N
groups NNS N
tested VBN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
daily JJ N
consumption NN N
of IN N
lutein NN 1_i
or CC 1_i
zeaxanthin NN 1_i
enriched VBN 1_i
egg NN 1_i
yolks NNS 1_i
as RB N
well RB N
as IN N
an DT N
egg NN 1_i
yolk-based JJ 1_i
beverage NN 1_i
show NN N
increases VBZ N
in IN N
serum NN 1_o
lutein NN 1_o
and CC 1_o
zeaxanthin NN 1_o
levels NNS 1_o
that WDT N
are VBP N
comparable JJ N
with IN N
a DT N
daily JJ N
use NN N
of IN N
5 CD N
mg NN N
supplements NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00527553 NNP N
. . N

-DOCSTART- -X- O O

A DT N
web-based JJ N
computer-tailored JJ N
smoking NN 1_i
prevention NN 1_i
programme NN 1_i
for IN N
primary JJ 1_p
school NN 1_p
children NNS 1_p
: : 1_p
intervention NN N
design NN N
and CC N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Although IN N
the DT N
number NN N
of IN N
smokers NNS N
has VBZ N
declined VBN N
in IN N
the DT N
last JJ N
decade NN N
, , N
smoking NN N
is VBZ N
still RB N
a DT N
major JJ N
health NN N
problem NN N
among IN N
youngsters NNS 1_p
and CC 1_p
adolescents NNS 1_p
. . 1_p

For IN N
this DT N
reason NN N
, , N
there EX N
is VBZ N
a DT N
need NN N
for IN N
effective JJ N
smoking NN N
prevention NN N
programmes VBZ N
targeting VBG N
primary JJ 1_p
school NN 1_p
children NNS 1_p
. . 1_p

A DT N
web-based JJ N
computer-tailored JJ N
feedback NN 1_i
programme NN 1_i
may MD N
be VB N
an DT N
effective JJ N
intervention NN N
to TO N
stimulate VB N
youngsters NNS N
not RB N
to TO N
start VB N
smoking NN N
, , N
and CC N
increase VB N
their PRP$ N
knowledge NN 1_o
about IN 1_o
the DT 1_o
adverse JJ 1_o
effects NNS 1_o
of IN 1_o
smoking NN 1_o
and CC N
their PRP$ N
attitudes NNS N
and CC N
self-efficacy NN N
regarding VBG N
non-smoking JJ N
. . N

METHODS NNP N
& CC N
DESIGN NNP N
This DT N
paper NN N
describes VBZ N
the DT N
development NN N
and CC N
evaluation NN N
protocol NN N
of IN N
a DT N
web-based JJ 1_i
out-of-school JJ 1_i
smoking NN 1_i
prevention NN 1_i
programme NN 1_i
for IN N
primary JJ 1_p
school NN 1_p
children NNS 1_p
( ( 1_p
age NN 1_p
10-13 CD 1_p
years NNS 1_p
) ) 1_p
entitled VBD 1_p
'Fun CD 1_p
without IN 1_p
Smokes NNP 1_p
' POS 1_p
. . N

It PRP N
is VBZ N
a DT N
transformation NN N
of IN N
a DT N
postal JJ N
mailed VBN N
intervention NN N
to TO N
a DT N
web-based JJ N
intervention NN N
. . N

Besides IN N
this DT N
transformation NN N
the DT N
effects NNS N
of IN N
prompts NNS N
will MD N
be VB N
examined VBN N
. . N

This DT N
web-based JJ N
intervention NN N
will MD N
be VB N
evaluated VBN N
in IN N
a DT N
2-year JJ N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
( ( N
c-RCT JJ N
) ) N
with IN N
three CD N
study NN N
arms NNS N
. . N

An DT N
intervention NN N
and CC N
intervention NN N
+ NNP N
prompt JJ N
condition NN N
will MD N
be VB N
evaluated VBN N
for IN N
effects NNS N
on IN N
smoking VBG 1_o
behaviour NN 1_o
, , N
compared VBN N
with IN N
a DT N
no DT N
information NN N
control NN N
condition NN N
. . N

Information NN N
about IN N
pupils NNS 1_o
' POS 1_o
smoking NN 1_o
status NN 1_o
and CC N
other JJ N
factors NNS N
related VBN N
to TO N
smoking NN N
will MD N
be VB N
obtained VBN N
using VBG N
a DT N
web-based JJ N
questionnaire NN N
. . N

After IN N
completing VBG N
the DT N
questionnaire NN N
pupils VBZ N
in IN N
both DT N
intervention NN N
conditions NNS N
will MD N
receive VB N
three CD N
computer-tailored JJ N
feedback NN N
letters NNS N
in IN N
their PRP$ N
personal JJ N
e-mail NN N
box NN N
. . N

Attitudes NNS 1_o
, , 1_o
social JJ 1_o
influences NNS 1_o
and CC 1_o
self-efficacy JJ 1_o
expectations NNS 1_o
will MD N
be VB N
the DT N
content NN N
of IN N
these DT N
personalised VBN N
feedback NN N
letters NNS N
. . N

Pupils NNS N
in IN N
the DT N
intervention NN N
+ NNP N
prompt JJ N
condition NN N
will MD N
- : N
in IN N
addition NN N
to TO N
the DT N
personalised VBN N
feedback NN N
letters NNS N
- : N
receive JJ N
e-mail NN N
and CC N
SMS NNP N
messages NNS N
prompting VBG N
them PRP N
to TO N
revisit VB N
the DT N
'Fun CD N
without IN N
Smokes NNP N
' POS N
website NN N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
will MD N
be VB N
ever RB 1_o
smoking VBG 1_o
and CC 1_o
the DT 1_o
utilisation NN 1_o
of IN 1_o
the DT 1_o
'Fun NN 1_o
without IN 1_o
Smokes NNP 1_o
' POS 1_o
website NN 1_o
. . 1_o

Measurements NNS N
will MD N
be VB N
carried VBN N
out RP N
at IN N
baseline NN N
, , N
12 CD N
months NNS N
and CC N
24 CD N
months NNS N
of IN N
follow-up JJ N
. . N

DISCUSSION VB N
The DT N
present JJ N
study NN N
protocol NN N
describes VBZ N
the DT N
purpose NN N
, , N
intervention NN N
design NN N
and CC N
study NN N
protocol NN N
of IN N
'Fun CD N
without IN N
Smokes NNP N
' POS N
. . N

Expectations NNS N
are VBP N
that IN N
pupils NNS N
receiving VBG N
tailored JJ N
advice NN N
will MD N
be VB N
less RBR N
likely JJ N
to TO N
smoke VB N
after IN N
24 CD N
months NNS N
in IN N
contrast NN N
to TO N
pupils VB N
in IN N
the DT N
control NN N
condition NN N
. . N

Furthermore NNP N
, , N
tailored VBD N
feedback NN N
letters NNS N
and CC N
prompting NN N
is VBZ N
expected VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
providing VBG N
tailored JJ N
feedback NN N
letters NNS N
only RB N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
NTR3116 NNP N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
premature JJ N
labor NN N
by IN N
17 CD 1_i
alpha-hydroxyprogesterone JJ 1_i
caproate NN 1_i
. . 1_i

Eighty NNP 1_p
pregnant JJ 1_p
women NNS 1_p
at IN 1_p
high JJ 1_p
risk NN 1_p
of IN 1_p
giving VBG 1_p
birth NN 1_p
prematurely RB 1_p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

Treatment NN N
with IN N
either DT N
17 CD 1_i
alpha-hydroxyprogesterone NN 1_i
caproate NN 1_i
, , 1_i
250 CD 1_i
mg NN 1_i
by IN 1_i
intramuscular JJ 1_i
injection NN 1_i
once RB 1_i
a DT 1_i
week NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
placebo NN 1_i
was VBD N
given VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

Imminent JJ N
premature NN N
labor NN N
occurred VBD N
in IN N
29.0 CD N
% NN N
of IN N
the DT N
treated VBN N
group NN N
and CC N
in IN N
59.4 CD N
% NN N
of IN N
the DT N
control NN 1_i
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.025 CD N
) ) N
. . N

The DT N
rate NN 1_o
of IN 1_o
premature NN 1_o
deliveries NNS 1_o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
treated JJ N
group NN N
( ( N
16.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
37.82 CD N
% NN N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
cases NNS N
of IN N
perinatal JJ 1_o
death NN 1_o
or CC 1_o
fetal JJ 1_o
malformations NNS 1_o
in IN N
either DT N
group NN N
. . N

The DT N
mean JJ 1_o
birth NN 1_o
weight NN 1_o
of IN N
all DT N
infants NNS N
of IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
those DT N
of IN N
the DT N
control NN N
group NN N
( ( N
3111.9 CD N
+/- JJ N
905 CD N
gm NN N
versus NN N
2680 CD N
+/- JJ N
813.4 CD N
gm NN N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
results NNS N
support VB N
treatment NN N
with IN N
progesterone NN 1_i
caproate NN 1_i
for IN N
the DT N
prevention NN N
of IN N
premature JJ N
labor NN N
. . N

-DOCSTART- -X- O O

Multicenter NNP N
randomized VBD N
phase NN N
2 CD N
clinical JJ N
trial NN N
of IN N
a DT N
recombinant JJ 1_i
human JJ 1_i
endostatin NN 1_i
adenovirus NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
carcinoma NN 1_p
. . 1_p

A DT N
randomized JJ N
, , N
open-label JJ N
, , N
phase JJ N
2 CD N
, , N
multicenter RB N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
the DT N
addition NN N
of IN N
a DT N
recombinant JJ 1_i
human JJ 1_i
endostatin NN 1_i
adenovirus NN 1_i
( ( 1_i
E10A NNP 1_i
) ) 1_i
to TO 1_i
cisplatin VB 1_i
and CC 1_i
paclitaxel VB 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
or CC 1_p
nasopharyngeal JJ 1_p
carcinoma NN 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
locally RB 1_p
advanced JJ 1_p
or CC 1_p
metastatic JJ 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
or CC 1_p
nasopharyngeal JJ 1_p
carcinoma NN 1_p
not RB 1_p
suitable JJ 1_p
for IN 1_p
operation NN 1_p
or CC 1_p
radiotherapy NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
E10A NNP 1_i
plus CC 1_i
chemotherapy NN 1_i
every DT N
3 CD N
weeks NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
cycles NNS N
or CC N
to TO N
receive VB N
chemotherapy NN 1_i
only RB 1_i
. . 1_i

One CD 1_p
hundred CD 1_p
and CC 1_p
thirty-six JJ 1_p
eligible JJ 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
. . 1_p

The DT N
addition NN N
of IN N
E10A NNP N
did VBD N
not RB N
significantly RB N
improve VB N
the DT N
objective JJ 1_o
response NN 1_o
rate NN 1_o
( ( N
29.9 CD N
versus RB N
39.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.154 CD N
) ) N
. . N

However RB N
, , N
patients NNS N
who WP N
received VBD N
endostatin NN N
had VBD N
longer RBR N
progression-free JJ 1_o
survival NN 1_o
( ( N
7.03 CD N
versus NN N
3.60 CD N
months NNS N
, , N
P NNP N
= NNP N
0.006 CD N
; : N
hazard VBN N
ratio NN N
: : N
0.55 CD N
) ) N
. . N

The DT N
combination NN N
of IN N
E10A NNP N
with IN N
chemotherapy NN N
benefited VBN N
prior JJ N
chemotherapy-treated JJ N
patients NNS N
and CC N
those DT N
who WP N
received VBD N
three CD N
to TO N
four CD N
treatment NN N
cycles NNS N
( ( N
6.50 CD N
versus NN N
3.43 CD N
months NNS N
, , N
P NNP N
= NNP N
0.003 CD N
; : N
8.27 CD N
versus IN N
4.27 CD N
months NNS N
, , N
P NNP N
= NNP N
0.018 CD N
; : N
respectively RB N
) ) N
. . N

The DT N
overall JJ 1_o
disease NN 1_o
control NN 1_o
rate NN 1_o
significantly RB N
increased VBD N
from IN N
80.6 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
to TO N
92.6 CD N
% NN N
in IN N
the DT N
test NN N
group NN N
( ( N
P NNP N
= NNP N
0.034 CD N
) ) N
. . N

Except IN N
for IN N
fever NN 1_o
, , 1_o
no DT 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
associated VBN N
with IN N
the DT N
E10A NNP N
treatment NN N
. . N

In IN N
summary JJ N
, , N
E10A NNP N
plus CC N
chemotherapy NN N
is VBZ N
a DT N
safe JJ 1_o
and CC 1_o
effective JJ 1_o
therapeutic JJ 1_o
approach NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
or CC 1_p
nasopharyngeal JJ 1_p
carcinoma NN 1_p
. . 1_p

-DOCSTART- -X- O O

Oral JJ N
desensitization NN N
in IN N
papular JJ 1_p
urticaria NN 1_p
in IN 1_p
children NNS 1_p
. . 1_p

Papular JJ 1_p
urticaria NN 1_p
( ( 1_p
PU NNP 1_p
) ) 1_p
is VBZ N
among IN N
the DT N
commonest JJS N
skin NN N
ailments NNS N
in IN N
children NNS N
. . N

Induced NNP N
specific JJ N
desensitization NN N
to TO N
insect VB N
bites NNS N
is VBZ N
theoretically RB N
an DT N
effective JJ N
means NNS N
of IN N
prevention NN N
of IN N
PU NNP N
. . N

In IN N
this DT N
double JJ N
blind NN N
placebo NN 1_i
controlled VBD N
study NN N
, , N
an DT N
oral JJ 1_i
vaccine NN 1_i
prepared VBN 1_i
from IN 1_i
insect JJ 1_i
saliva NN 1_i
was VBD N
compared VBN N
with IN N
placebo NN 1_i
( ( 1_i
stable JJ 1_i
vaccine NN 1_i
solvent NN 1_i
) ) 1_i
. . 1_i

Vaccine NNP 1_i
and CC 1_i
placebo NN 1_i
effectiveness NN N
were VBD N
tested VBN N
by IN N
counting VBG 1_o
active JJ 1_o
PU NNP 1_o
lesions NNS 1_o
, , 1_o
serum NN 1_o
eosinophils NNS 1_o
, , 1_o
and CC 1_o
IgE NNP 1_o
, , N
before IN N
and CC N
after IN N
4 CD N
months NNS N
of IN N
treatment NN N
. . N

Statistically NNP N
significant JJ N
differences NNS N
between IN N
oral JJ N
vaccine NN N
and CC N
placebo NN N
were VBD N
not RB N
found VBN N
in IN N
the DT N
clinical JJ N
or CC N
the DT N
immunological JJ N
variables NNS N
tested VBN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
although IN N
a DT N
lack NN N
of IN N
oral JJ N
vaccine NN N
efficacy NN N
was VBD N
suspected VBN N
, , N
larger JJR N
study NN N
samples NNS N
are VBP N
needed VBN N
to TO N
strengthen VB N
our PRP$ N
conclusion NN N
. . N

-DOCSTART- -X- O O

A DT N
crossover NN N
study NN N
of IN N
risperidone NN 1_i
in IN N
children NNS 1_p
, , 1_p
adolescents NNS 1_p
and CC 1_p
adults NNS 1_p
with IN 1_p
mental JJ 1_p
retardation NN 1_p
. . 1_p

Risperidone NN 1_i
has VBZ N
shown VBN N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
for IN N
aggressive JJ N
and CC N
destructive JJ 1_p
behaviors NNS N
in IN N
short-term JJ N
studies NNS N
. . N

This DT N
longer-duration NN N
study NN N
includes VBZ N
a DT N
broad JJ N
sample NN N
. . N

Forty NNP 1_p
subjects NNS 1_p
, , 1_p
aged VBN 1_p
8-56 CD 1_p
years NNS 1_p
( ( 1_p
mean=22 NN 1_p
) ) 1_p
, , 1_p
all DT 1_p
with IN 1_p
mental JJ 1_p
retardation NN 1_p
and CC 1_p
36 CD 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
participated VBD 1_p
in IN N
this DT N
22-week JJ N
crossover NN N
study NN N
, , N
with IN N
24 CD N
weeks NNS N
of IN N
open JJ N
maintenance NN N
thereafter RB N
. . N

Of IN N
40 CD N
subjects NNS N
, , N
23 CD N
( ( N
57.5 CD N
% NN N
) ) N
responded VBD N
fully RB N
( ( N
50 CD N
% NN N
decrease NN 1_o
in IN 1_o
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist-Community NNP 1_o
Irritability NNP 1_o
subscale NNP 1_o
score NN 1_o
) ) 1_o
, , N
while IN N
35 CD N
subjects NNS N
( ( N
87.5 CD N
% NN N
) ) N
showed VBD N
a DT N
25 CD N
% NN N
decrease NN 1_o
. . 1_o

Gender NNP N
, , N
mood NN N
disorder NN N
, , N
and CC N
antiseizure NN N
medications NNS N
did VBD N
not RB N
alter VB N
response NN N
. . N

Increased VBN 1_o
appetite NN 1_o
and CC 1_o
weight JJ 1_o
gain NN 1_o
were VBD N
common JJ N
. . N

Low JJ N
dose JJ N
risperidone NN N
was VBD N
effective JJ 1_o
for IN 1_o
aggressive JJ 1_o
behavior NN 1_o
in IN N
persons NNS N
with IN N
MR. NNP N
More NNP N
long-term JJ N
studies NNS N
are VBP N
needed VBN N
, , N
incorporating VBG N
weight NN N
control NN N
interventions NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
enoxaparin NN 1_i
and CC 1_i
standard JJ 1_i
heparin NN 1_i
in IN N
gynaecologic JJ 1_p
oncologic JJ 1_p
surgery NN 1_p
: : 1_p
a DT N
randomised JJ N
prospective JJ N
double-blind NN N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
haemorrhagic JJ N
complications NNS N
and CC N
efficacy NN N
of IN N
enoxaparin NN 1_i
, , N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMWH NNP N
) ) N
, , N
and CC N
conventional JJ N
standard NN 1_i
heparin NN 1_i
( ( 1_i
SH NNP 1_i
) ) 1_i
in IN N
gynaecological JJ 1_p
oncologic NN 1_p
surgery NN 1_p
. . 1_p

MATERIALS NNP N
METHODS NNP N
A NNP N
double JJ N
blind NN N
, , N
randomised VBD N
trial NN N
was VBD N
performed VBN N
on IN N
102 CD 1_p
consecutive JJ 1_p
women NNS 1_p
undergoing VBG 1_p
gynaecologic JJ 1_p
cancer NN 1_p
surgery NN 1_p
with IN 1_p
pelvic NN 1_p
and CC 1_p
paraaortic JJ 1_p
lymphadenectomy NN 1_p
. . 1_p

The DT N
women NNS N
were VBD N
separated VBN N
into IN N
those DT N
who WP N
were VBD N
given VBN N
2,500 CD 1_i
IU NNP 1_i
enoxaparin NN 1_i
once RB 1_i
daily JJ 1_i
and CC 1_i
SH NNP 1_i
in IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
5,000 CD 1_i
IU NNP 1_i
three CD 1_i
times NNS 1_i
daily RB 1_i
. . 1_i

The DT N
groups NNS N
were VBD N
analysed VBN N
for IN N
intraoperative JJ N
blood NN N
loss NN N
, , N
drainage NN N
, , N
transfusion NN N
requirements NNS N
, , N
perioperative JJ N
haemoglobin NN N
decrease NN N
, , N
wound NN N
haematoma NN N
, , N
and CC N
clinical JJ N
deep NN N
venous JJ N
thrombosis NN N
. . N

RESULTS VB N
The DT 1_p
two CD 1_p
groups NNS 1_p
were VBD 1_p
well RB 1_p
matched VBN 1_p
for IN 1_p
age NN 1_p
, , 1_p
weight NN 1_p
, , 1_p
and CC 1_p
other JJ 1_p
factors NNS 1_p
, , N
which WDT N
could MD N
predispose VB N
to TO N
the DT N
development NN 1_o
of IN 1_o
deep JJ 1_o
venous JJ 1_o
thrombosis NN 1_o
( ( 1_o
DVT NNP 1_o
) ) 1_o
and CC 1_o
haemorrhage NN 1_o
. . 1_o

No DT N
patient NN N
developed VBD N
clinical JJ 1_o
significant JJ 1_o
DVT NNP 1_o
, , 1_o
wound NN 1_o
haematoma NN 1_o
or CC 1_o
intra-abdominal JJ 1_o
bleeding NN 1_o
. . 1_o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
bleeding VBG 1_o
complications NNS 1_o
between IN N
the DT N
two CD N
regimens NNS N
. . N

The DT N
antiFXa JJ 1_o
level NN 1_o
in IN N
the DT N
plasma NN N
was VBD N
correlated VBN N
strongly RB N
with IN N
patient JJ N
weight NN N
. . N

CONCLUSIONS VB N
A NNP N
dose NN N
of IN N
2,500 CD N
IU NNP N
enoxaparin/day NN 1_i
does VBZ N
not RB N
cause VB N
more RBR N
bleeding JJ N
complications NNS N
than IN N
SH NNP N
5,000 CD N
IU NNP N
three CD N
times NNS N
daily RB N
when WRB N
used VBN N
to TO N
prevent VB N
thrombosis NN N
. . N

However RB N
, , N
the DT N
dose NN N
of IN N
enoxaparin NN N
must MD N
be VB N
adjusted VBN N
to TO N
the DT N
patient NN N
's POS N
weight NN N
. . N

-DOCSTART- -X- O O

Antibiotic JJ N
elimination NN N
of IN N
group-B JJ N
streptococci NN N
in IN N
urine NN N
in IN N
prevention NN N
of IN N
preterm JJ 1_o
labour NN 1_o
. . 1_o

The DT N
presence NN N
of IN N
group-B JJ N
streptococci NN N
in IN N
the DT N
urine NN N
of IN N
pregnant JJ 1_p
women NNS 1_p
seems VBZ N
to TO N
be VB N
associated VBN N
with IN N
preterm JJ N
labour NN N
. . N

Urine JJ N
samples NNS N
from IN N
4122 CD 1_p
women NNS 1_p
at IN 1_p
27-31 JJ 1_p
weeks NNS 1_p
' POS 1_p
gestation NN 1_p
were VBD N
examined VBN N
for IN N
bacteria NNS N
. . N

Group-B JJ N
streptococci NN N
were VBD N
found VBN N
in IN N
the DT N
urine NN N
of IN N
69 CD 1_p
women NNS 1_p
. . 1_p

In IN N
a DT N
double-blind NN N
, , N
controlled VBD N
study NN N
these DT N
patients NNS N
were VBD N
given VBN N
either CC N
penicillin NN 1_i
( ( N
10 CD N
( ( N
6 CD N
) ) N
IU NNP N
three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
; : N
37 CD N
patients NNS N
) ) N
or CC N
placebo NN 1_i
( ( N
32 CD N
patients NNS N
) ) N
. . N

The DT N
rates NNS N
of IN N
primary JJ 1_o
rupture NN 1_o
of IN 1_o
the DT 1_o
membranes NNS 1_o
( ( N
11 CD N
% NN N
v JJ N
53 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
preterm VB 1_o
labour NN 1_o
( ( N
5.4 CD N
% NN N
v JJ N
38 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.002 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
penicillin NN 1_i
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
treatment NN N
and CC N
follow-up NN N
to TO N
prevent VB N
recolonisation NN N
in IN N
pregnant JJ 1_p
women NNS 1_p
with IN 1_p
group-B JJ 1_p
streptococci NN 1_p
in IN 1_p
the DT 1_p
urine NN 1_p
may MD N
reduce VB N
the DT N
frequency NN 1_o
of IN 1_o
preterm JJ 1_o
labour NN 1_o
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Post NNP N
hoc NN N
analysis NN N
of IN N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ 1_i
acid NNS 1_i
versus VBP N
daily JJ N
oral JJ N
risedronate NN 1_i
on IN N
lumbar NN N
spine NN N
bone NN N
mineral JJ N
density NN N
in IN N
different JJ N
subgroups NNS 1_p
with IN 1_p
glucocorticoid-induced JJ 1_p
osteoporosis NN 1_p
. . 1_p

This DT N
study NN N
summarizes VBZ N
the DT N
treatment NN N
effect NN N
of IN N
zoledronic JJ 1_i
acid JJ 1_i
infusion NN N
on IN N
lumbar NN 1_o
spine NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
in IN N
different JJ 1_p
subgroups NNS 1_p
with IN 1_p
glucocorticoid-induced JJ 1_p
osteoporosis NN 1_p
. . 1_p

Zoledronic JJ 1_i
acid NN 1_i
is VBZ N
significantly RB N
more RBR N
effective JJ N
than IN N
risedronate NN 1_i
in IN N
increasing VBG N
lumbar NN 1_o
spine NN 1_o
( ( 1_o
LS NNP 1_o
) ) 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
in IN N
both DT N
prevention NN N
and CC N
treatment NN N
of IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

Introduction NN N
In IN N
patients NNS 1_p
on IN 1_p
glucocorticoids NNS 1_i
, , N
a DT N
single JJ N
zoledronic NN 1_i
acid NN 1_i
infusion NN N
significantly RB N
increased VBD N
BMD NNP 1_o
versus IN N
daily JJ N
oral JJ N
risedronate NN 1_i
. . 1_i

We PRP N
assessed VBD N
treatment NN N
effect NN N
on IN N
LS NNP 1_o
BMD NNP 1_o
in IN N
different JJ 1_p
patient NN 1_p
subgroups NNS 1_p
at IN N
month NN N
12 CD N
that WDT N
contributed VBD N
to TO N
the DT N
risk NN N
of IN N
osteoporosis NN N
in IN N
addition NN N
to TO N
glucocorticoids NNS N
. . N

Methods NNS N
Patients NNPS 1_p
randomized VBN N
to TO N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ 1_i
acid NN 1_i
5 CD N
mg NN N
or CC N
risedronate NN 1_i
( ( N
5 CD N
mg/day NN N
) ) N
and CC N
stratified VBN N
based VBN N
on IN N
glucocorticoids NNS 1_i
duration NN N
[ FW N
treatment NN N
( ( N
> JJ N
3 CD N
months NNS N
) ) N
and CC N
prevention NN N
( ( N
? . N
3 CD N
months NNS N
) ) N
subpopulations NNS 1_p
] VBP 1_p
were VBD 1_p
subgrouped VBN 1_p
by IN 1_p
age NN 1_p
; : 1_p
gender NN 1_p
; : 1_p
menopausal NN 1_p
status NN 1_p
in IN 1_p
women NNS 1_p
; : 1_p
dose VB 1_p
and CC 1_p
duration NN 1_p
of IN 1_p
prednisone NN 1_i
during IN 1_i
the DT 1_p
trial NN 1_p
; : 1_p
and CC 1_p
baseline VB 1_p
serum JJ 1_p
25-OH JJ 1_p
vitamin NN 1_p
D NNP 1_p
, , 1_p
LS NNP 1_p
BMD NNP 1_p
T-score NNP 1_p
, , 1_p
creatinine JJ 1_p
clearance NN 1_p
, , 1_p
and CC 1_p
concomitant JJ 1_p
medication NN 1_p
use NN 1_p
. . 1_p

Results NNS N
At IN N
month NN N
12 CD N
, , 1_i
zoledronic JJ 1_i
acid NN 1_i
significantly RB 1_i
increased VBD 1_o
LS NNP 1_o
BMD NNP 1_o
versus NN 1_o
risedronate NN 1_i
in IN 1_i
patients NNS N
? . N
74 CD N
years NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
treatment NN N
and CC N
65-74 JJ N
years NNS N
( ( N
P NNP N
= NNP N
0.0008 CD N
) ) N
in IN N
the DT N
prevention NN N
subpopulation NN N
. . N

At IN N
month NN N
12 CD N
, , N
zoledronic JJ 1_i
acid NN 1_i
significantly RB 1_i
increased VBD 1_o
LS NNP 1_o
BMD NNP 1_o
versus NN 1_i
risedronate NN 1_i
in IN 1_i
both DT N
subpopulations NNS N
irrespective VBP N
of IN N
gender NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
cumulative JJ N
prednisone NN N
dose NN N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
postmenopausal NN N
status NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
premenopausal JJ N
women NNS N
, , N
in IN N
both DT N
subpopulations NNS 1_i
, , 1_i
zoledronic JJ 1_i
acid NN 1_i
significantly RB 1_i
increased VBD 1_o
total JJ 1_o
hip NN 1_o
BMD NNP 1_o
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
versus NN 1_i
risedronate NN 1_i
at IN 1_i
month NN N
12 CD N
but CC N
not RB N
LS NNP 1_o
BMD NNP 1_o
. . N

Osteoporotic JJ 1_p
patients NNS 1_p
in IN 1_p
the DT N
prevention NN N
( ( N
P=0.0189 NNP N
) ) N
and CC N
osteopenic JJ N
patients NNS N
in IN N
the DT N
treatment NN N
subpopulation NN N
( ( N
P=0.0305 NNP N
) ) N
showed VBD N
significant JJ 1_o
LS NNP 1_o
BMD NNP 1_o
increases VBZ N
with IN N
zoledronic JJ 1_i
acid NNS 1_i
versus NN 1_i
risedronate NN 1_i
at IN 1_i
month NN N
12 CD N
. . N

Conclusions NNS N
This DT N
post NN N
hoc NN N
analysis NN N
suggests VBZ N
that IN N
zoledronic JJ 1_i
acid NN 1_i
is VBZ 1_i
significantly RB N
more RBR N
effective JJ N
than IN N
risedronate NN 1_i
in IN 1_i
increasing VBG 1_o
LS NNP 1_o
BMD NNP 1_o
in IN N
prevention NN N
and CC N
treatment NN N
of IN N
glucocorticoid-induced JJ N
osteoporosis NN N
across IN N
a DT N
wide JJ N
range NN N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O

Multimodal NNP N
therapy NN N
for IN N
the DT N
management NN N
of IN N
primary JJ 1_p
, , 1_p
nonmetastatic JJ 1_p
Ewing NNP 1_p
's POS 1_p
sarcoma NN 1_p
of IN 1_p
bone NN 1_p
: : 1_p
an DT N
Intergroup NNP N
Study NNP N
. . N

A NNP N
randomized JJ N
study NN N
of IN N
264 CD 1_p
children NNS 1_p
and CC 1_p
adults NNS 1_p
with IN 1_p
previously RB 1_p
untreated VBN 1_p
localized JJ 1_p
Ewing NNP 1_p
's POS 1_p
sarcoma NN 1_p
of IN 1_p
bone NN 1_p
was VBD N
undertaken VBN N
between IN 1_p
1973 CD 1_p
and CC 1_p
1978 CD 1_p
by IN 1_p
83 CD 1_p
institutions NNS 1_p
of IN 1_p
three CD 1_p
national JJ 1_p
study NN 1_p
groups NNS 1_p
: : 1_p
Children NNP 1_p
's POS 1_p
Cancer NNP 1_p
Study NNP 1_p
Group NNP 1_p
, , 1_p
Southwest NNP 1_p
Oncology NNP 1_p
Group NNP 1_p
, , 1_p
and CC 1_p
Cancer NNP 1_p
and CC 1_p
Leukemia NNP 1_p
Group NNP 1_p
B NNP 1_p
. . 1_p

The DT N
Intergroup NNP N
Study NNP N
was VBD N
designed VBN N
to TO N
determine VB N
if IN N
the DT N
addition NN 1_i
of IN 1_i
adriamycin NN 1_i
( ( 1_i
ADR NNP 1_i
) ) 1_i
or CC 1_i
bilateral JJ 1_i
pulmonary JJ 1_i
radiotherapy NN 1_i
( ( 1_i
RT NNP 1_i
) ) 1_i
to TO 1_i
vincristine VB 1_i
, , 1_i
dactinomycin NN 1_i
, , 1_i
and CC 1_i
cyclophosphamide NN 1_i
( ( 1_i
VAC NNP 1_i
therapy NN 1_i
) ) 1_i
would MD N
improve VB 1_o
survival NN 1_o
and CC 1_o
reduce VB 1_o
local JJ 1_o
recurrences NNS 1_o
and CC 1_o
metastases NNS 1_o
. . N

All DT N
patients NNS N
received VBD N
RT NNP 1_i
to TO N
the DT N
primary JJ N
lesion NN N
, , N
and CC N
the DT N
survival NN 1_o
rate NN 1_o
after IN N
3 CD N
years NNS N
was VBD N
65 CD N
% NN N
. . N

The DT N
most RBS N
effective JJ N
treatment NN N
regimen NNS N
was VBD N
VAC NNP N
plus CC N
ADR NNP N
; : N
74 CD N
% NN N
of IN N
the DT N
patients NNS N
were VBD N
free JJ N
of IN N
disease NN N
at IN N
2 CD N
years NNS N
. . N

The DT N
lengths NNS 1_o
of IN 1_o
disease-free JJ 1_o
status NN 1_o
and CC 1_o
survival NN 1_o
of IN 1_o
patients NNS 1_o
treated VBN N
with IN N
VAC NNP N
plus CC N
ADR NNP N
or CC N
VAC NNP N
plus CC N
RT NNP N
did VBD N
not RB N
differ VB N
. . N

However RB N
, , N
both DT N
regimens NNS N
were VBD N
significantly RB N
superior JJ N
to TO N
treatment NN N
with IN N
VAC NNP N
alone RB N
. . N

The DT N
addition NN N
of IN N
ADR NNP 1_i
or CC N
bilateral JJ N
pulmonary JJ N
RT NNP N
to TO N
VAC NNP 1_i
was VBD N
highly RB 1_o
advantageous JJ 1_o
to TO N
patients NNS N
with IN N
nonpelvic JJ N
primaries NNS N
. . N

Bone NN N
and CC N
lung NN N
were VBD N
the DT N
major JJ N
sites NNS N
of IN N
distant JJ N
relapse NN N
, , N
but CC N
the DT N
addition NN N
of IN N
bilateral JJ N
pulmonary JJ N
RT NNP N
showed VBD N
no DT 1_o
advantage NN 1_o
over IN N
that DT N
of IN N
ADR NNP N
in IN N
reducing VBG N
the DT N
occurrence NN 1_o
of IN 1_o
lung NN 1_o
metastases NNS 1_o
. . 1_o

These DT N
recent JJ N
results NNS N
should MD N
eliminate VB N
some DT N
of IN N
the DT N
pessimism NN N
that WDT N
has VBZ N
accompanied VBN N
a DT N
diagnosis NN N
of IN N
Ewing NNP N
's POS N
sarcoma NN N
, , N
although IN N
distant JJ N
metastases NNS N
continued VBD N
to TO N
be VB N
a DT N
major JJ N
reason NN N
for IN N
failure NN N
in IN N
the DT N
control NN N
of IN N
this DT N
tumor NN N
. . N

Survival NN N
of IN N
these DT N
patients NNS N
can MD N
be VB N
improved VBN N
through IN N
well-controlled JJ N
clinical JJ N
trials NNS N
designed VBN N
to TO N
determine VB N
optimal JJ N
adjuvant JJ N
chemotherapy NN N
and CC N
treatment NN N
of IN N
the DT N
primary JJ N
lesion NN N
. . N

-DOCSTART- -X- O O

1999 CD N
WHO/ISH NNP N
Guidelines NNP N
applied VBD N
to TO N
a DT N
1999 CD 1_p
MONICA NNP 1_p
sample NN 1_p
from IN 1_p
northern JJ 1_p
Sweden NNP 1_p
. . 1_p

BACKGROUND NNP N
Treating NNP N
hypertension NN N
with IN N
drugs NNS N
is VBZ N
so RB N
far RB N
the DT N
most RBS N
cost-effective JJ N
way NN N
to TO N
reduce VB N
this DT N
important JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

It PRP N
is VBZ N
, , N
however RB N
, , N
important JJ N
to TO N
determine VB N
absolute NN N
risk NN N
, , N
and CC N
thereby RB N
estimate VB N
indication NN N
for IN N
drug NN N
treatment NN N
, , N
in IN N
order NN N
to TO N
maintain VB N
a DT N
cost-effective JJ N
drug NN N
treatment NN N
. . N

WHO/ISH NNP N
Hypertension NNP N
Guidelines NNP N
from IN N
1999 CD N
propose NN N
a DT N
risk NN N
stratification NN N
for IN N
estimating VBG N
absolute NN N
risk NN N
for IN N
CVD NNP N
based VBN N
on IN N
blood NN N
pressure NN N
and CC N
additional JJ N
risk NN N
factors NNS N
, , N
target NN N
organ JJ N
damage NN N
( ( N
TOD NNP N
) ) N
and CC N
CVD NNP N
. . N

OBJECTIVES NNP N
We PRP N
studied VBD N
the DT N
consequences NNS N
of IN N
applying VBG N
the DT N
recent JJ N
WHO/ISH NNP 1_i
risk NN 1_i
stratification NN 1_i
scheme NN 1_i
to TO N
a DT N
MONICA NNP 1_p
sample NN 1_p
of IN 1_p
6000 CD 1_p
subjects NNS 1_p
from IN 1_p
a DT 1_p
geographically RB 1_p
defined VBN 1_p
population NN 1_p
in IN 1_p
northern JJ 1_p
Sweden NNP 1_p
, , 1_p
regarding VBG 1_p
indications NNS 1_p
for IN 1_p
treatment NN 1_p
, , 1_p
target VB 1_p
blood NN 1_p
pressure NN 1_p
and CC 1_p
risk NN 1_p
distribution NN 1_p
. . 1_p

METHODS NNP N
We PRP N
have VBP N
risk-classified JJ N
each DT N
of IN N
these DT N
patients NNS N
using VBG N
a DT N
computer NN 1_i
program NN 1_i
, , N
according VBG N
to TO N
the DT N
WHO/ISH NNP N
scheme NN N
. . N

Data NNP N
on IN N
TOD NNP N
were VBD N
not RB N
available JJ N
. . N

RESULTS NNP N
In IN N
all DT N
, , N
917 CD N
( ( N
15 CD N
% NN N
) ) N
had VBD N
drug-treated JJ 1_p
hypertension NN 1_p
. . 1_p

Three-quarters NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
were VBD N
inadequately RB N
treated VBN N
, , N
with IN N
blood NN 1_o
pressure NN 1_o
levels NNS 1_o
at IN N
or CC N
above VB N
140 CD N
or CC N
90 CD N
mmHg NN N
. . N

1773 CD N
( ( N
30 CD N
% NN N
of IN N
5997 CD N
) ) N
untreated JJ 1_p
subjects NNS 1_p
had VBD N
a DT N
blood NN N
pressure NN N
of IN N
140/90 CD N
or CC N
above RB N
; : N
16 CD N
% NN N
in IN N
the DT N
low- JJ 1_p
, , N
62 CD N
% NN N
in IN N
the DT N
medium- NN 1_p
, , N
8 CD N
% NN N
in IN N
the DT N
high- NN 1_p
, , N
and CC N
14 CD N
% NN N
in IN N
the DT N
very-high-risk JJ 1_p
group NN 1_p
. . 1_p

The DT N
corresponding JJ N
risk-group JJ N
pattern NN N
for IN N
the DT N
inadequately RB N
treated JJ N
hypertensives NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
was VBD N
5.5 CD N
, , N
48.3 CD N
, , N
11.1 CD N
and CC N
35.2 CD N
% NN N
, , N
respectively RB N
. . N

If IN N
we PRP N
shifted VBD N
the DT N
target NN N
blood NN N
pressure NN N
from IN N
below IN N
140/90 CD N
to TO N
below VB N
130/85 CD N
for IN N
drug-treated JJ N
subjects NNS N
under IN N
60 CD N
( ( N
n JJ N
= NNP N
278 CD N
) ) N
the DT N
number NN 1_o
of IN 1_o
inadequately RB 1_o
treated JJ 1_o
subjects NNS 1_o
increased VBN N
by IN N
34 CD N
( ( N
12.2 CD N
% NN N
of IN N
278 CD N
) ) N
; : N
14 CD N
in IN N
the DT N
low-risk JJ N
group NN N
, , N
15 CD N
in IN N
the DT N
medium-risk JJ N
group NN N
, , N
and CC N
only RB N
five CD N
in IN N
the DT N
high- JJ N
or CC N
very-high-risk JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Only RB N
one-fifth NN N
of IN N
the DT N
drug-treated JJ N
hypertensives NNS N
were VBD N
well RB N
controlled VBN N
. . N

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
newly RB 1_o
detected VBN 1_o
blood NN 1_o
pressure NN 1_o
elevation NN 1_o
was VBD N
high JJ N
. . N

The DT N
majority NN N
of IN N
younger JJR N
subjects NNS N
with IN N
high JJ N
blood NN N
pressure NN N
had VBD N
low JJ N
risk NN N
, , N
but CC N
in IN N
those DT 1_p
aged VBN 1_p
45-54 CD 1_p
this DT N
had VBD N
already RB N
risen VBN N
to TO N
a DT N
medium NN N
risk NN N
. . N

Changing VBG N
the DT N
target NN N
blood NN N
pressure NN N
to TO N
below IN N
130/85 CD N
, , N
for IN N
subjects NNS 1_p
aged VBN 1_p
below IN 1_p
60 CD 1_p
, , N
as IN N
recommended VBN N
by IN N
WHO/ISH NNP N
, , N
affects VBZ N
predominantly RB N
low- JJ N
and CC N
medium-risk JJ N
groups NNS N
. . N

-DOCSTART- -X- O O

Application NN N
of IN N
the DT N
Itch NNP N
Severity NNP N
Score NNP N
in IN N
patients NNS 1_p
with IN 1_p
moderate-to-severe JJ 1_p
plaque JJ 1_p
psoriasis NN 1_p
: : 1_p
Clinically NNP N
important JJ N
difference NN N
and CC N
responder NN N
analyses NNS N
. . N

The DT N
Itch NNP N
Severity NNP N
Score NNP N
( ( N
ISS NNP N
) ) N
, , N
a DT N
0-10 JJ N
numeric JJ N
rating NN N
scale NN N
, , N
was VBD N
used VBN N
to TO N
assess VB N
pruritus NN N
due JJ N
to TO N
psoriasis VB N
in IN N
a DT N
Phase NNP N
2 CD N
b NN N
trial NN N
of IN N
tofacitinib NN N
, , N
a DT N
novel JJ N
oral JJ N
Janus NNP N
kinase NN N
inhibitor NN 1_p
. . 1_p

197 CD 1_p
patients NNS 1_p
with IN 1_p
moderate-to-severe JJ 1_p
plaque NN 1_p
psoriasis NN 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
tofacitinib VB 1_i
2 CD 1_i
, , 1_i
5 CD 1_i
or CC 1_i
15 CD 1_i
mg JJ 1_i
twice RB 1_i
daily RB 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

The DT 1_i
ISS NNP N
was VBD N
recorded VBN N
daily RB N
from IN N
baseline NN N
to TO N
week NN N
2 CD N
and CC N
at IN N
study NN N
visits NNS N
. . N

Following VBG N
good JJ N
and CC N
recommended VBD N
research NN N
practice NN N
, , N
we PRP N
performed VBD N
analyses NNS N
to TO N
examine VB N
the DT N
clinically RB N
important JJ N
differences NNS N
( ( N
CID NNP N
) ) N
( ( N
between-group JJ N
difference NN N
or CC N
within-group JJ N
difference NN N
) ) N
and CC N
clinically RB N
important JJ N
responders NNS N
( ( N
CIR NNP N
) ) N
( ( N
within-patient JJ N
change NN N
) ) N
for IN N
the DT N
ISS NNP N
. . N

The DT N
CID NNP N
and CC N
CIR NNP N
were VBD N
defined VBN N
using VBG 1_o
Patient NNP 1_o
Global NNP 1_o
Assessment NNP 1_o
of IN 1_o
psoriasis NN 1_o
as IN 1_o
an DT N
anchor NN N
and CC N
were VBD N
estimated VBN N
with IN N
a DT N
longitudinal JJ N
model NN N
. . N

A DT N
CID NNP N
on IN N
the DT N
ISS NNP N
was VBD N
1.64 CD N
and CC N
, , N
by IN N
day NN N
10 CD N
, , N
the DT N
mean JJ N
changes NNS N
from IN N
baseline NN 1_o
in IN 1_o
ISS NNP 1_o
values NNS 1_o
for IN 1_o
the DT N
tofacitinib NN 1_i
doses NNS 1_i
( ( N
placebo-adjusted JJ N
) ) N
exceeded VBD N
CID NNP N
. . N

A NNP N
CIR NNP N
on IN N
the DT N
ISS NNP N
was VBD N
a DT N
30 CD N
% NN N
improvement NN N
from IN N
baseline NN N
and CC N
, , N
at IN N
week NN N
12 CD N
, , N
87.2 CD N
% NN N
to TO N
100 CD N
% NN N
of IN N
patients NNS N
receiving VBG 1_i
tofacitinib NN 1_i
reached VBD 1_i
?30 CD N
% NN N
improvement NN N
versus IN N
29.4 CD N
% NN N
of IN N
patients NNS N
receiving VBG 1_i
placebo NN 1_i
( ( 1_i
p JJ 1_i
< NNP 1_i
0.0001 CD N
) ) N
. . N

Overall UH N
, , N
the DT N
CID NNP N
and CC N
CIR NNP N
analyses NNS N
play VBP N
vital JJ N
roles NNS N
in IN N
the DT N
interpretation NN N
of IN N
the DT N
treatment NN N
effects NNS N
measured VBN N
by IN N
ISS NNP N
. . N

-DOCSTART- -X- O O

Single-dose JJ 1_i
and CC 1_i
multi-dose JJ 1_i
clindamycin NN 1_i
therapy NN 1_i
fails VBZ N
to TO N
demonstrate VB N
efficacy NN N
in IN N
preventing VBG N
infectious JJ N
and CC N
inflammatory JJ N
complications NNS N
in IN N
third JJ 1_p
molar JJ 1_p
surgery NN 1_p
. . 1_p

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
single- JJ 1_i
and CC 1_i
multi-dose JJ 1_i
( ( 1_i
5-day JJ 1_i
) ) 1_i
clindamycin NN 1_i
therapy NN 1_i
for IN N
the DT N
prevention NN N
of IN N
inflammatory JJ N
complications NNS N
in IN N
patients NNS 1_p
undergoing VBG 1_p
lower JJR 1_p
third JJ 1_p
molar JJ 1_p
surgical JJ 1_p
extraction NN 1_p
with IN 1_p
bone NN 1_p
removal NN 1_p
. . 1_p

Patients NNS 1_p
who WP N
qualified VBD N
for IN N
the DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
were VBD N
randomly RB N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
single JJ 1_i
dose NN 1_i
of IN 1_i
oral JJ 1_i
clindamycin NN 1_i
administered VBN 1_i
preoperatively RB 1_i
( ( N
single-dose JJ N
group NN N
) ) N
; : N
( ( N
2 CD N
) ) N
clindamycin NN 1_i
administered VBD 1_i
preoperatively RB 1_i
with IN 1_i
continued JJ 1_i
therapy NN 1_i
for IN 1_i
5 CD 1_i
days NNS 1_i
( ( N
5-day JJ N
group NN N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
a DT N
placebo NN 1_i
group NN N
. . N

The DT N
following JJ N
parameters NNS N
were VBD N
evaluated VBN N
on IN N
the DT N
first JJ N
, , N
second JJ N
and CC N
seventh JJ N
days NNS N
postsurgery NN N
: : N
trismus NN 1_o
, , 1_o
facial JJ 1_o
swelling NN 1_o
, , 1_o
body NN 1_o
temperature NN 1_o
, , 1_o
lymphadenopathy JJ 1_o
, , 1_o
alveolar JJ 1_o
osteitis NN 1_o
and CC 1_o
subjective JJ 1_o
pain NN 1_o
sensations NNS 1_o
. . 1_o

There EX 1_p
were VBD 1_p
86 CD 1_p
patients NNS 1_p
( ( 1_p
31 CD 1_p
in IN 1_p
the DT 1_p
single-dose JJ 1_p
group NN 1_p
, , 1_p
28 CD 1_p
in IN 1_p
the DT 1_p
5-day JJ 1_p
group NN 1_p
and CC 1_p
27 CD 1_p
in IN 1_p
the DT 1_p
placebo NN 1_i
group NN 1_p
) ) 1_p
enrolled VBD 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
postoperative JJ 1_o
inflammatory JJ 1_o
complications NNS 1_o
in IN N
patients NNS N
during IN N
the DT N
first JJ N
and CC N
second JJ N
days NNS N
postsurgery NN N
. . N

A DT N
statistically RB N
significant JJ N
variation NN 1_o
in IN N
body NN 1_o
temperature NN 1_o
was VBD N
reported VBN N
on IN N
the DT N
seventh JJ N
day NN N
. . N

Analysis NN N
of IN N
the DT N
postoperative JJ 1_o
analgesic JJ 1_o
intake NN 1_o
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
examined VBN N
groups NNS N
. . N

Clindamycin NNP 1_i
applied VBD N
in IN N
a DT N
single JJ N
preoperative NN N
dose NN N
of IN N
600 CD N
mg NN N
with IN N
or CC N
without IN N
subsequent JJ N
5-day JJ N
therapy NN N
does VBZ N
not RB N
demonstrate VB N
efficacy NN 1_o
in IN N
prophylaxis NN N
for IN N
postoperative JJ N
inflammatory NN N
complications NNS N
after IN N
third JJ N
molar JJ N
surgery NN N
. . N

-DOCSTART- -X- O O

Working VBG N
memory NN N
and CC N
cognitive JJ N
flexibility-training NN N
for IN N
children NNS 1_p
with IN 1_p
an DT 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
People NNPS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASDs NNP 1_p
) ) 1_p
experience NN N
executive NN N
function NN N
( ( N
EF NNP N
) ) N
deficits NNS N
. . N

There EX N
is VBZ N
an DT N
urgent JJ N
need NN N
for IN N
effective JJ N
interventions NNS N
, , N
but CC N
in IN N
spite NN N
of IN N
the DT N
increasing VBG N
research NN N
focus NN N
on IN N
computerized JJ N
cognitive JJ N
training NN N
, , N
this DT N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
ASD NNP N
. . N

Hence NNP N
, , N
we PRP N
investigated VBD N
two CD N
EF NNP 1_i
training NN 1_i
conditions NNS 1_i
in IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
121 CD 1_p
, , 1_p
8-12 CD 1_p
years NNS 1_p
, , 1_p
IQ NNP 1_p
> NNP 1_p
80 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT 1_i
adaptive JJ 1_i
working JJ 1_i
memory NN 1_i
( ( 1_i
WM NNP 1_i
) ) 1_i
training NN 1_i
, , 1_i
an DT 1_i
adaptive JJ 1_i
cognitive JJ 1_i
flexibility-training NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
non-adaptive JJ 1_i
control NN 1_i
training NN 1_i
( ( 1_i
mock-training JJ 1_i
) ) 1_i
. . 1_i

Braingame NNP 1_i
Brian NNP 1_i
, , 1_i
a DT 1_i
computerized JJ 1_i
EF-training NN 1_i
with IN 1_i
game-elements NNS 1_i
, , N
was VBD N
used VBN N
. . N

Outcome JJ N
measures NNS N
( ( N
pretraining VBG N
, , N
post-training NN N
, , N
and CC N
6-week-follow-up JJ N
) ) N
were VBD N
near-transfer JJ 1_o
to TO 1_o
trained JJ 1_o
EFs NNP 1_o
, , 1_o
far-transfer NN 1_o
to TO 1_o
other JJ 1_o
EFs NNP 1_o
( ( 1_o
sustained VBN 1_o
attention NN 1_o
and CC 1_o
inhibition NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
parent NN 1_o
's POS 1_o
ratings NNS 1_o
of IN 1_o
daily JJ 1_o
life NN 1_o
EFs NNP 1_o
, , 1_o
social JJ 1_o
behavior NN 1_o
, , 1_o
attention NN 1_o
deficit NN 1_o
hyperactivity NN 1_o
disorder NN 1_o
( ( 1_o
ADHD NNP 1_o
) ) 1_o
-behavior NN 1_o
, , 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

RESULTS NNP N
Attrition-rate NNP 1_o
was VBD N
26 CD N
% NN N
. . N

Children NNP N
in IN N
all DT N
conditions NNS N
who WP N
completed VBD N
the DT N
training NN N
improved VBN N
in IN N
WM NNP 1_o
, , 1_o
cognitive JJ 1_o
flexibility NN 1_o
, , 1_o
attention NN 1_o
, , 1_o
and CC 1_o
on IN 1_o
parent NN 1_o
's POS 1_o
ratings NNS 1_o
, , 1_o
but CC 1_o
not RB 1_o
in IN 1_o
inhibition NN 1_o
. . 1_o

There EX N
were VBD N
no DT N
significant JJ N
differential JJ N
intervention NN N
effects NNS N
, , N
although IN N
children NNS N
in IN N
the DT N
WM NNP N
condition NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
on IN N
near-transfer JJ 1_o
WM NNP 1_o
and CC 1_o
ADHD-behavior NNP 1_o
, , N
and CC N
children NNS N
in IN N
the DT N
cognitive JJ N
flexibility NN N
condition NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
on IN N
near-transfer JJ 1_o
flexibility NN 1_o
. . 1_o

CONCLUSION NNP N
Although IN N
children NNS N
in IN N
the DT N
WM NNP N
condition NN N
tended VBD N
to TO N
improve VB N
more RBR N
in IN N
WM NNP 1_o
and CC 1_o
ADHD-behavior NNP 1_o
, , N
the DT N
lack NN N
of IN N
differential JJ N
improvement NN N
on IN N
most JJS N
outcome JJ N
measures NNS N
, , N
the DT N
absence NN N
of IN N
a DT N
clear JJ N
effect NN N
of IN N
the DT N
adaptive JJ N
training NN N
compared VBN N
to TO N
the DT N
mock-training NN N
, , N
and CC N
the DT N
high JJ N
attrition NN N
rate NN N
suggest VBP N
that IN N
the DT N
training NN N
in IN N
its PRP$ N
present JJ N
form NN N
is VBZ N
probably RB N
not RB N
suitable JJ N
for IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Does VBZ N
3-day JJ N
course NN N
of IN N
oral JJ 1_i
amoxycillin NN 1_i
benefit NN N
children NNS 1_p
of IN 1_p
non-severe JJ 1_p
pneumonia NN 1_p
with IN 1_p
wheeze NN 1_p
: : 1_p
a DT N
multicentric NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
WHO-defined JJ N
pneumonias NN N
, , N
treated VBN N
with IN N
antibiotics NNS N
, , N
are VBP N
responsible JJ N
for IN N
a DT N
significant JJ N
proportion NN N
of IN N
childhood NN N
morbidity NN N
and CC N
mortality NN N
in IN N
the DT N
developing NN 1_p
countries NNS 1_p
. . 1_p

Since IN N
substantial JJ N
proportion NN N
pneumonias NNS N
have VBP N
a DT N
viral JJ N
etiology NN N
, , N
where WRB N
children NNS N
are VBP N
more RBR N
likely JJ N
to TO N
present VB N
with IN N
wheeze NN N
, , N
there EX N
is VBZ N
a DT N
concern NN N
that WDT N
currently RB N
antibiotics NNS N
are VBP N
being VBG N
over-prescribed JJ N
for IN N
it PRP N
. . N

Hence VB N
the DT N
current JJ N
trial NN N
was VBD N
conducted VBN N
with IN N
the DT N
objective NN N
to TO N
show VB N
the DT N
therapeutic JJ N
equivalence NN N
of IN N
two CD N
treatments NNS N
( ( 1_i
placebo NN 1_i
and CC N
amoxycillin NN 1_i
) ) 1_i
for IN N
children NNS 1_p
presenting VBG 1_p
with IN 1_p
non-severe JJ 1_p
pneumonia NN 1_p
with IN 1_p
wheeze NN 1_p
, , 1_p
who WP 1_p
have VBP 1_p
persistent VBN 1_p
fast RB 1_p
breathing NN 1_p
after IN 1_p
nebulisation NN 1_p
with IN 1_p
salbutamol NN 1_p
, , 1_p
and CC 1_p
have VBP 1_p
normal JJ 1_p
chest NN 1_p
radiograph NN 1_p
. . 1_p

METHODOLOGY NNP N
This DT N
multi-centric JJ N
, , N
randomised VBD N
placebo NN 1_i
controlled VBN N
double JJ N
blind NN N
clinical JJ N
trial NN N
intended VBN N
to TO N
investigate VB N
equivalent JJ N
efficacy NN N
of IN N
placebo NN 1_i
and CC N
amoxicillin NN 1_i
and CC N
was VBD N
conducted VBN N
in IN N
ambulatory NN N
care NN N
settings NNS N
in IN N
eight CD 1_p
government NN 1_p
hospitals NNS 1_p
in IN 1_p
India NNP 1_p
. . 1_p

Participants NNS 1_p
were VBD 1_p
children NNS 1_p
aged VBN 1_p
2-59 JJ 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
, , N
who WP N
received VBD N
either DT N
oral JJ N
amoxycillin NN 1_i
( ( N
31-54 JJ N
mg/Kg/day NN N
, , N
in IN N
three CD N
divided JJ N
doses NNS N
for IN N
three CD N
days NNS N
) ) N
or CC N
placebo NN N
, , N
and CC N
standard JJ 1_i
bronchodilator NN 1_i
therapy NN 1_i
. . 1_i

Primary JJ N
outcome NN N
was VBD N
clinical JJ 1_o
failure NN 1_o
on IN 1_o
or CC 1_o
before IN 1_o
day- JJ 1_o
4 CD 1_o
. . 1_o

PRINCIPAL JJ N
FINDINGS NNP N
We PRP N
randomized VBD N
836 CD 1_p
cases NNS 1_p
in IN 1_p
placebo NN 1_p
and CC 1_p
835 CD 1_p
in IN 1_p
amoxycillin NN 1_p
group NN 1_p
. . 1_p

Clinical JJ 1_o
failures NNS 1_o
occurred VBD N
in IN N
201 CD N
( ( N
24.0 CD N
% NN N
) ) N
on IN N
placebo NN N
and CC N
166 CD N
( ( N
19.9 CD N
% NN N
) ) N
on IN N
amoxycillin NN 1_i
( ( N
risk NN N
difference NN N
4.2 CD N
% NN N
in IN N
favour NN N
of IN N
antibiotic JJ N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.2 CD N
to TO N
8.1 CD N
) ) N
. . N

Adherence NN 1_o
for IN N
both DT N
placebo NN N
and CC N
amoxycillin NN 1_i
was VBD N
> JJ N
96 CD N
% NN N
and CC N
98.9 CD N
% NN N
subjects NNS N
were VBD N
followed VBN N
up RP N
on IN N
day- JJ N
4 CD N
. . N

Clinical JJ 1_o
failure NN 1_o
was VBD N
associated VBN N
with IN N
( ( N
i NN N
) ) N
placebo NN 1_o
treatment NN 1_o
( ( N
adjusted VBN N
OR NNP N
= $ N
1.28 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01 CD N
to1.62 NN N
) ) N
, , N
( ( N
ii NN N
) ) N
excess JJ 1_o
respiratory JJ 1_o
rate NN 1_o
of IN 1_o
> $ 1_o
10 CD 1_o
breaths NNS 1_o
per IN 1_o
minute NN 1_o
( ( N
adjusted VBN N
OR NNP N
= $ N
1.51 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.19 CD N
, , N
1.92 CD N
) ) N
, , N
( ( N
iii NN N
) ) N
vomiting VBG 1_o
at IN 1_o
enrolment NN 1_o
( ( N
adjusted VBN N
OR NNP N
= $ N
1.49 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.13 CD N
, , N
1.96 CD N
) ) N
, , N
( ( N
iv NN N
) ) N
history NN 1_o
of IN 1_o
use NN 1_o
of IN 1_o
broncho-dilators NNS 1_o
( ( N
adjusted VBN N
OR NNP N
= $ N
1.71 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.30 CD N
, , N
2.24 CD N
) ) N
and CC N
( ( N
v NN N
) ) N
non-adherence NN 1_o
( ( N
adjusted VBN N
OR NNP N
= $ N
8.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
4.36 CD N
, , N
14.92 CD N
) ) N
. . N

CONCLUSIONS NNP N
Treating NNP N
children NNS 1_p
with IN 1_p
non-severe JJ 1_p
pneumonia NN 1_p
and CC 1_p
wheeze NN 1_p
with IN N
a DT N
placebo NN N
is VBZ N
not RB N
equivalent JJ N
to TO N
treatment NN N
with IN N
oral JJ N
amoxycillin NN 1_i
. . 1_i

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00407394 NNP N
. . N

-DOCSTART- -X- O O

Risk NN N
of IN N
infection NN N
after IN N
penetrating VBG N
abdominal JJ N
trauma NN N
. . N

To TO N
identify VB N
the DT N
risk NN N
factors NNS N
for IN N
the DT N
development NN N
of IN N
postoperative JJ N
septic JJ N
complications NNS N
in IN N
patients NNS 1_p
with IN 1_p
intestinal JJ 1_p
perforation NN 1_p
after IN 1_p
abdominal JJ 1_p
trauma NN 1_p
, , N
and CC N
to TO N
compare VB N
the DT N
efficacies NNS N
of IN N
single-drug JJ 1_i
and CC 1_i
dual-drug JJ 1_i
prophylactic JJ 1_i
antibiotic JJ 1_i
therapy NN 1_i
, , N
we PRP N
studied VBD N
145 CD 1_p
patients NNS 1_p
who WP 1_p
presented VBD 1_p
with IN 1_p
abdominal JJ 1_p
trauma NN 1_p
and CC 1_p
intestinal JJ 1_p
perforation NN 1_p
at IN 1_p
two CD 1_p
hospitals NNS 1_p
between IN 1_p
July NNP 1_p
1979 CD 1_p
and CC 1_p
June NNP 1_p
1982 CD 1_p
. . 1_p

Logistic-regression NN N
analysis NN N
showed VBD N
that IN N
a DT N
higher JJR N
risk NN N
of IN N
infection NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
was VBD N
associated VBN N
with IN N
increased JJ N
age NN N
, , N
injury NN N
to TO N
the DT N
left NN N
colon NN N
necessitating VBG N
colostomy NN N
, , N
a DT N
larger JJR N
number NN N
of IN N
units NNS N
of IN N
blood NN N
or CC N
blood NN N
products NNS N
administered VBN N
at IN N
surgery NN N
, , N
and CC N
a DT N
larger JJR N
number NN N
of IN N
injured JJ N
organs NNS N
. . N

The DT N
presence NN N
of IN N
shock NN N
on IN N
arrival NN N
, , N
which WDT N
was VBD N
found VBN N
to TO N
increase VB N
the DT N
risk NN 1_o
of IN 1_o
infection NN 1_o
when WRB N
this DT N
factor NN N
was VBD N
analyzed VBN N
individually RB N
, , N
did VBD N
not RB N
add VB N
predictive JJ N
power NN N
. . N

Patients NNS 1_p
with IN 1_p
postoperative JJ 1_p
sepsis NN 1_p
were VBD N
hospitalized VBN 1_o
significantly RB 1_o
longer RBR N
than IN N
were VBD N
patients NNS N
without IN N
infection NN N
( ( N
13.8 CD N
vs. FW N
7.7 CD N
days NNS N
, , N
P NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

Both DT N
treatment NN N
regimens VBZ 1_i
-- : 1_i
cefoxitin VB 1_i
given VBN 1_i
alone RB 1_i
and CC 1_i
clindamycin JJ 1_i
and CC 1_i
gentamicin JJ 1_i
given VBN 1_i
together RB 1_i
-- : 1_i
resulted VBD 1_i
in IN N
similar JJ N
infection NN 1_o
rates NNS 1_o
, , 1_o
drug NN 1_o
toxicity NN 1_o
, , 1_o
duration NN 1_o
of IN 1_o
hospitalization NN 1_o
, , 1_o
and CC 1_o
costs NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Treatment NN N
of IN N
stable JJ 1_p
angina NN 1_p
of IN 1_p
effort NN 1_p
with IN N
verapamil NN 1_i
: : 1_i
a DT N
double-blind NN N
, , N
placebo-controlled JJ 1_i
randomized VBN N
crossover NN N
study NN N
. . N

The DT N
effects NNS N
of IN N
verapamil NN 1_i
were VBD N
assessed VBN N
in IN N
26 CD 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
exertional JJ 1_p
angina NN 1_p
pectoris NN 1_p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
crossover NN N
protocol NN N
using VBG N
serial JJ N
treadmill NN N
tests NNS N
. . N

Verapamil NNP 1_i
, , N
480 CD N
mg/day NN N
, , N
reduced VBD N
anginal JJ 1_o
frequency NN 1_o
from IN N
5.6 CD N
+/- JJ N
7.3 CD N
to TO N
2.2 CD N
+/- JJ N
3.9 CD N
attacks NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
nitroglycerin JJ 1_o
consumption NN 1_o
from IN N
3.4 CD N
+/- JJ N
4.9 CD N
to TO N
1.2 CD N
+/- JJ N
2.5 CD N
tablets NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN 1_i
. . 1_i

Treadmill NNP 1_o
time NN 1_o
increased VBD N
from IN N
6.4 CD N
+/- JJ N
2.1 CD N
minutes NNS N
during IN N
the DT N
placebo NN 1_i
phase NN N
to TO N
7.5 CD N
+/- JJ N
1.8 CD N
minutes NNS N
during IN N
the DT N
verapamil JJ 1_i
phase NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP 1_i
's POS 1_i
beneficial JJ N
effect NN N
appeared VBD N
to TO N
be VB N
related VBN N
, , N
in IN N
part NN N
, , N
to TO N
a DT N
10 CD N
% NN N
reduction NN N
of IN N
the DT N
rate-pressure JJ 1_o
product NN 1_o
at IN N
rest NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
a DT N
12 CD N
% NN N
reduction NN N
during IN N
submaximal JJ N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP 1_i
also RB N
caused VBD N
less JJR N
marked JJ N
ST-segment JJ 1_o
depressions NNS 1_o
at IN 1_o
peak NN 1_o
exercise NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
at IN N
a DT N
similar JJ N
rate-pressure NN N
product NN N
, , N
suggesting VBG N
a DT N
favorable JJ N
redistribution NN N
of IN N
coronary JJ 1_o
blood NN 1_o
flow NN 1_o
to TO N
the DT N
ischemic JJ N
zone NN N
. . N

Side JJ N
effects NNS N
from IN N
verapamil NN 1_i
were VBD N
minimal JJ N
, , N
consisting VBG N
mainly RB N
of IN N
constipation NN 1_o
( ( N
six CD N
patients NNS N
) ) N
. . N

Verapamil NNP 1_i
appears VBZ N
to TO N
be VB N
a DT N
safe JJ 1_o
and CC 1_o
effective JJ 1_o
drug NN N
for IN N
treating VBG N
angina NN 1_p
of IN N
effort NN N
. . N

-DOCSTART- -X- O O

Assessment NN N
of IN N
response NN N
to TO N
induction NN N
therapy NN N
and CC N
its PRP$ N
influence NN N
on IN N
5-year JJ 1_o
failure-free JJ 1_o
survival NN 1_o
in IN 1_p
group NN 1_p
III NNP 1_p
rhabdomyosarcoma NN 1_p
: : 1_p
the DT N
Intergroup NNP N
Rhabdomyosarcoma NNP N
Study-IV NNP N
experience NN N
-- : N
a DT N
report NN N
from IN N
the DT N
Soft NNP N
Tissue NNP N
Sarcoma NNP N
Committee NNP N
of IN N
the DT N
Children NNP N
's POS N
Oncology NNP N
Group NNP N
. . N

PURPOSE NNP N
Initial NNP N
response NN N
to TO N
induction NN 1_i
chemotherapy NN 1_i
predicts VBZ N
failure-free JJ 1_o
survival NN 1_o
( ( 1_o
FFS NNP 1_o
) ) 1_o
in IN N
osteosarcoma NN 1_p
and CC 1_p
Ewing NNP 1_p
's POS 1_p
sarcoma NN 1_p
. . 1_p

For IN N
Intergroup NNP N
Rhabdomyosarcoma NNP N
Study NNP N
( ( N
IRS NNP N
) ) N
IV VBZ N
patients NNS 1_p
with IN 1_p
group NN 1_p
III NNP 1_p
rhabdomyosarcoma NN 1_p
, , N
we PRP N
assessed VBD N
whether IN N
reported VBN N
response NN N
assessed VBN N
by IN N
anatomic JJ N
imaging NN N
at IN N
week NN N
8 CD N
predicted VBD N
FFS NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
studied VBD N
444 CD 1_p
group NN 1_p
III NNP 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
induction NN 1_i
therapy NN 1_i
, , 1_p
had VBD 1_p
response NN 1_p
assessed VBN 1_p
at IN 1_p
week NN 1_p
8 CD 1_p
by IN 1_p
anatomic JJ 1_i
imaging NN 1_i
, , 1_i
and CC 1_i
continued VBD 1_i
with IN 1_i
protocol NN 1_i
therapy NN 1_i
. . 1_i

Induction NNP 1_i
chemotherapy NN 1_i
was VBD N
generally RB N
followed VBN N
by IN N
radiation NN 1_i
therapy NN 1_i
( ( 1_i
RT NNP 1_i
) ) 1_i
starting VBG N
after IN N
week NN N
9 CD N
. . N

Response NN 1_o
to TO N
induction NN N
therapy NN N
was VBD N
determined VBN N
at IN N
weeks NNS N
0 CD N
and CC N
8 CD N
. . N

Local JJ N
institutions NNS N
coded VBD N
response NN N
. . N

RESULTS JJ N
Response JJ 1_o
rate NN 1_o
for IN N
the DT N
entire JJ N
cohort NN N
at IN N
week NN N
8 CD N
was VBD N
77 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
73 CD N
% NN N
to TO N
81 CD N
% NN N
; : N
complete JJ 1_o
response NN 1_o
[ NNP 1_o
CR NNP 1_o
] NNP 1_o
, , N
21 CD N
% NN N
; : N
partial JJ 1_o
response NN 1_o
[ NNP 1_o
PR NNP 1_o
] NNP 1_o
, , N
56 CD N
% NN N
) ) N
but CC N
response NN N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP 1_o
( ( N
P NNP N
= NNP N
.57 NNP N
) ) N
. . N

Two CD N
hundred VBD N
seventy-two JJ N
patients NNS N
received VBD N
standard-timing JJ N
RT NNP N
at IN N
week NN N
9 CD N
and CC N
thus RB N
only RB N
chemotherapy NN N
during IN N
induction NN N
. . N

Response NNP 1_o
rate NN 1_o
was VBD N
81 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP 1_o
, , N
76 CD N
% NN N
to TO N
86 CD N
% NN N
; : N
CR NNP 1_o
, , N
22 CD N
% NN N
; : N
PR NNP 1_o
, , N
59 CD N
% NN N
) ) N
. . N

In IN N
these DT N
patients NNS N
, , N
response NN N
did VBD 1_o
not RB 1_o
influence VB 1_o
FFS NNP 1_o
except IN N
for IN N
those DT N
with IN N
alveolar JJ N
histology NN N
. . N

One CD N
hundred VBD N
thirty-two NN N
other JJ N
patients NNS N
received VBN N
chemotherapy NN N
and CC N
RT NNP N
during IN N
induction NN N
( ( N
up-front JJ N
RT NNP N
) ) N
. . N

Response JJ 1_o
rate NN 1_o
was VBD N
65 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP 1_o
, , N
57 CD N
% NN N
to TO N
73 CD N
% NN N
; : N
CR NNP 1_o
, , N
12 CD N
% NN N
; : N
PR NNP 1_o
, , N
53 CD N
% NN N
) ) N
, , N
but CC N
response NN N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP 1_o
( ( N
P NNP N
= NNP N
.69 NNP N
) ) N
. . N

Forty JJ N
patients NNS N
received VBD N
no DT N
RT NNP N
at IN N
all DT N
( ( N
protocol JJ N
violation NN N
) ) N
and CC N
response NN N
to TO N
induction NN N
therapy NN N
had VBD N
no DT 1_o
effect NN 1_o
on IN N
FFS NNP 1_o
. . 1_o

CONCLUSION NNP N
In IN N
IRS-IV NNP N
, , N
response NN 1_o
rate NN 1_o
to TO N
induction NN N
therapy NN N
was VBD N
77 CD N
% NN N
in IN N
group NN 1_p
III NNP 1_p
patients NNS 1_p
, , N
was VBD N
independent JJ N
of IN N
histology NN N
, , N
and CC N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP 1_o
overall JJ N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
videotape NN 1_i
information NN 1_i
intervention NN 1_i
at IN N
discharge NN N
on IN N
diet JJ N
and CC N
exercise NN N
compliance NN N
after IN N
coronary JJ N
bypass NN N
surgery NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
evaluated VBD N
the DT N
relative JJ N
effects NNS N
on IN N
compliance NN N
with IN N
recommended JJ N
lifestyle JJ N
changes NNS N
of IN N
two CD N
experimental JJ 1_i
videotapes NNS 1_i
that WDT N
involved VBD N
different JJ N
approaches NNS N
for IN N
preparing VBG N
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
graft NN 1_p
( ( 1_p
CABG NNP 1_p
) ) 1_p
patients NNS 1_p
for IN N
the DT N
posthospital JJ N
recovery NN N
period NN N
. . N

The DT N
tapes NNS N
differed VBN N
in IN N
the DT N
extent NN N
to TO N
which WDT N
they PRP N
portrayed VBD N
the DT N
recovery NN N
period NN N
as IN N
a DT N
steady JJ N
, , N
forward JJ N
progression NN N
versus IN N
a DT N
series NN N
of IN N
ups NNS N
and CC N
downs NNS N
. . N

METHODS NNP N
Two CD 1_p
hundred VBD 1_p
sixteen JJ 1_p
male NN 1_p
and CC 1_p
female JJ 1_p
CABG NNP 1_p
patients NNS 1_p
were VBD N
assigned VBN N
randomly RB N
either DT N
to TO N
view VB N
one CD 1_i
of IN 1_i
the DT 1_i
two CD 1_i
videotapes NNS 1_i
before IN 1_i
discharge NN 1_i
from IN 1_i
the DT 1_i
hospital NN 1_i
or CC 1_i
to TO 1_i
receive VB 1_i
only RB 1_i
the DT 1_i
standard JJ 1_i
discharge NN 1_i
preparation NN 1_i
provided VBN N
by IN N
the DT N
hospital NN N
. . N

All DT N
patients NNS N
completed VBN N
measures NNS 1_o
of IN 1_o
anxiety NN 1_o
and CC 1_o
self-efficacy NN 1_o
at IN N
discharge NN N
, , N
1 CD N
month NN N
and CC N
3 CD N
months NNS N
after IN N
discharge NN N
from IN N
the DT N
hospital NN N
. . N

Patients NNS N
also RB N
completed VBD N
measures NNS N
of IN N
dietary JJ 1_o
fat JJ 1_o
consumption NN 1_o
and CC N
activity NN 1_o
level NN 1_o
1 CD 1_o
and CC 1_o
3 CD 1_o
months NNS N
after IN N
discharge NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
controls NNS N
, , N
patients NNS N
who WP N
viewed VBD N
either DT N
of IN N
the DT N
videotapes NNS 1_i
before IN N
hospital NN N
release NN N
reported VBD N
higher JJR N
self-efficacy NN 1_o
for IN 1_o
adhering VBG 1_o
to TO 1_o
the DT 1_o
recommended VBN 1_o
low-fat NN 1_o
diet JJ 1_o
both DT N
at IN N
discharge NN N
and CC N
1 CD N
month NN N
after IN N
surgery NN N
. . N

Viewing VBG N
either DT N
of IN N
the DT N
videotapes NNS N
also RB N
resulted VBD N
in IN N
significantly RB 1_o
less JJR 1_o
dietary JJ 1_o
fat NN 1_o
intake NN 1_o
1 CD 1_o
month NN 1_o
after IN 1_o
hospital NN 1_o
release NN 1_o
compared VBN N
with IN N
controls NNS N
. . N

Patients NNS N
who WP N
viewed VBD N
the DT N
tape NN N
that WDT N
portrayed VBD N
the DT N
recovery NN N
period NN N
as IN N
consisting NN N
of IN N
ups NNS N
and CC N
downs NNS N
also RB N
reported VBD N
significantly RB N
more RBR N
frequent JJ N
moderate JJ 1_o
exercise NN 1_o
at IN 1_o
1 CD 1_o
month NN 1_o
and CC N
more RBR N
frequent JJ N
strenuous JJ 1_o
exercise NN 1_o
3 CD N
months NNS N
after IN N
discharge NN N
. . N

CONCLUSIONS VB N
The DT N
experimental JJ N
videotapes NNS 1_i
proved VBD N
to TO N
be VB N
an DT N
effective JJ N
method NN N
for IN N
increasing VBG N
dietary JJ 1_o
and CC 1_o
exercise NN 1_o
compliance NN 1_o
during IN N
the DT N
first JJ N
3 CD N
months NNS N
after IN N
CABG NNP N
. . N

-DOCSTART- -X- O O

Non-verbal JJ 1_i
communication NN 1_i
of IN 1_i
compassion NN 1_i
: : 1_i
measuring NN N
psychophysiologic JJ N
effects NNS N
. . N

BACKGROUND NNP N
Calm NNP N
, , N
compassionate NN N
clinicians NNS N
comfort VBP N
others NNS N
. . N

To TO N
evaluate VB N
the DT N
direct JJ N
psychophysiologic JJ N
benefits NNS N
of IN N
non-verbal JJ 1_i
communication NN 1_i
of IN 1_i
compassion NN 1_i
( ( 1_i
NVCC NNP 1_i
) ) 1_i
, , N
it PRP N
is VBZ N
important JJ N
to TO N
minimize VB N
the DT N
effect NN N
of IN N
subjects NNS N
' POS N
expectation NN N
. . N

This DT N
preliminary JJ N
study NN N
was VBD N
designed VBN N
to TO N
a DT N
) ) N
test NN N
the DT N
feasibility NN N
of IN N
two CD N
strategies NNS N
for IN N
maintaining VBG N
subject JJ N
blinding VBG N
to TO N
non-verbal JJ 1_i
communication NN 1_i
of IN 1_i
compassion NN 1_i
( ( 1_i
NVCC NNP 1_i
) ) 1_i
, , N
and CC N
b NN N
) ) N
determine NN N
whether IN N
blinded JJ N
subjects NNS N
would MD N
experience VB N
psychophysiologic JJ N
effects NNS N
from IN N
NVCC NNP N
. . N

METHODS NNP N
Subjects NNPS 1_p
were VBD 1_p
healthy JJ 1_p
volunteers NNS 1_p
who WP 1_p
were VBD 1_p
told VBN 1_p
the DT 1_p
study NN 1_p
was VBD 1_p
evaluating VBG 1_p
the DT 1_p
effect NN 1_p
of IN 1_p
time NN 1_p
and CC 1_p
touch NN 1_p
on IN 1_p
the DT 1_p
autonomic JJ 1_p
nervous JJ 1_p
system NN 1_p
. . 1_p

The DT 1_p
practitioner NN 1_p
had VBD 1_p
more JJR 1_p
than IN 1_p
10 CD 1_p
years NNS 1_p
' POS 1_p
experience NN 1_p
with IN 1_p
loving-kindness JJ 1_i
meditation NN 1_i
( ( 1_p
LKM NNP 1_p
) ) 1_p
, , 1_p
a DT 1_p
form NN 1_p
of IN 1_p
NVCC NNP 1_i
. . 1_i

Subjects NNS N
completed VBD N
10-point JJ 1_o
visual JJ 1_o
analog NN 1_o
scales NNS 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
for IN 1_o
stress NN 1_o
, , 1_o
relaxation NN 1_o
, , 1_o
and CC 1_o
peacefulness NN 1_o
before IN N
and CC N
after IN N
LKM NNP N
. . N

To TO N
assess VB N
physiologic JJ 1_o
effects NNS 1_o
, , N
practitioners NNS N
and CC N
subjects NNS N
wore VBP N
cardiorespiratory JJ 1_o
monitors NNS 1_o
to TO 1_o
assess VB 1_o
respiratory JJ 1_o
rate NN 1_o
( ( 1_o
RR NNP 1_o
) ) 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
variability NN 1_o
( ( 1_o
HRV NNP 1_o
) ) 1_o
throughout IN N
the DT N
4 CD N
10-minute JJ N
study NN N
periods NNS N
: : N
Baseline NNP N
( ( N
both DT N
practitioner NN 1_i
and CC 1_i
subjects NNS 1_i
read VBP 1_i
neutral JJ 1_i
material NN 1_i
) ) 1_i
; : 1_i
non-tactile-LKM JJ N
( ( 1_i
subjects NNS 1_i
read VBP 1_i
while IN 1_i
the DT 1_i
practitioner NN 1_i
practiced VBD 1_i
LKM NNP 1_i
while IN 1_i
pretending VBG 1_i
to TO 1_i
read VB 1_i
) ) 1_i
; : 1_i
tactile-LKM JJ N
( ( 1_i
subjects NNS 1_i
rested VBN 1_i
while IN 1_i
the DT 1_i
practitioner NN 1_i
practiced VBD 1_i
LKM NNP 1_i
while IN 1_i
lightly RB 1_i
touching VBG 1_i
the DT 1_i
subject NN 1_i
on IN 1_i
arms NNS 1_i
, , 1_i
shoulders NNS 1_i
, , 1_i
hands NNS 1_i
, , 1_i
feet NNS 1_i
, , 1_i
and CC 1_i
legs NNS 1_i
) ) 1_i
; : 1_i
Post-Intervention JJ N
Rest NNP N
( ( 1_i
subjects NNS 1_i
rested VBN 1_i
; : 1_i
the DT 1_i
practitioner NN 1_i
read NN 1_i
) ) 1_i
. . N

To TO N
assess VB N
blinding NN N
, , N
subjects NNS N
were VBD N
asked VBN N
after IN N
the DT N
interventions NNS N
what WP N
the DT N
practitioner NN N
was VBD N
doing VBG N
during IN N
each DT N
period NN N
( ( N
reading NN N
, , N
touch NN N
, , N
or CC N
something NN N
else RB N
) ) N
. . N

RESULTS JJ N
Subjects NNPS 1_p
' POS 1_p
mean JJ 1_p
age NN 1_p
was VBD 1_p
43.6 CD 1_p
years NNS 1_p
; : 1_p
all DT 1_p
were VBD 1_p
women NNS 1_p
. . 1_p

Blinding NNP N
was VBD N
maintained VBN N
and CC N
the DT N
practitioner NN N
was VBD N
able JJ N
to TO N
maintain VB N
meditation NN 1_o
for IN N
both DT N
tactile JJ N
and CC N
non-tactile JJ N
LKM NNP N
interventions NNS N
as IN N
reflected VBN N
in IN N
significantly RB N
reduced VBN N
RR NNP 1_o
. . 1_o

Despite IN N
blinding NN N
, , N
subjects NNS N
' POS N
VAS NNP 1_o
scores NNS 1_o
improved VBN N
from IN N
baseline NN N
to TO N
post-intervention NN N
for IN N
stress NN 1_o
( ( N
5.5 CD N
vs. FW N
2.2 CD N
) ) N
, , N
relaxation NN 1_o
( ( N
3.8 CD N
vs. FW N
8.8 CD N
) ) N
and CC N
peacefulness NN 1_o
( ( N
3.8 CD N
vs. FW N
9.0 CD N
, , N
P NNP N
< VBZ N
0.05 CD N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

Subjects NNS N
also RB N
had VBD N
significant JJ N
reductions NNS N
in IN N
RR NNP 1_o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
improved VBN 1_o
HRV NNP 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
both DT N
tactile JJ N
and CC N
non-tactile JJ N
LKM NNP N
. . N

CONCLUSION NNP N
It PRP N
is VBZ N
possible JJ N
to TO N
test VB N
the DT N
effects NNS N
of IN N
LKM NNP N
with IN N
tactile JJ N
and CC N
non-tactile JJ N
blinding NN N
strategies NNS N
; : N
even RB N
with IN N
blinding VBG N
in IN N
this DT N
small JJ N
preliminary JJ N
study NN N
, , N
subjects NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
well-being NN N
which WDT N
were VBD N
reflected VBN N
in IN N
objective JJ N
physiologic JJ N
measures NNS N
of IN N
autonomic JJ N
activity NN N
. . N

Extending VBG N
compassion NN N
is VBZ N
not RB N
only RB N
good JJ N
care NN N
; : N
it PRP N
may MD N
also RB N
be VB N
good JJ N
medicine NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
US NNP N
National NNP N
ClinicalTrials.gov NNP N
registration NN N
number NN N
, , N
NCT01428674 NNP N
. . N

-DOCSTART- -X- O O

Medication NN N
and CC N
parent NN N
training NN N
in IN N
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
and CC 1_p
serious JJ 1_p
behavior NN 1_p
problems NNS 1_p
: : 1_p
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Many JJ N
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
( ( 1_p
PDDs NNP 1_p
) ) 1_p
have VBP 1_p
serious JJ 1_o
, , 1_o
functionally RB 1_o
impairing VBG 1_o
behavioral JJ 1_o
problems NNS 1_o
. . 1_o

We PRP N
tested VBD N
whether IN N
combined VBN 1_i
treatment NN 1_i
( ( 1_i
COMB NNP 1_i
) ) 1_i
with IN 1_i
risperidone NN 1_i
and CC 1_i
parent NN 1_i
training NN 1_i
( ( 1_i
PT NNP 1_i
) ) 1_i
in IN N
behavior JJ N
management NN N
is VBZ N
superior JJ N
to TO N
medication VB N
alone RB N
( ( N
MED NNP N
) ) N
in IN N
improving VBG N
severe JJ 1_o
behavioral JJ 1_o
problems NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
PDDs NNP 1_p
. . 1_p

METHOD NNP N
This DT N
24-week JJ N
, , N
three-site JJ N
, , N
randomized VBN N
, , N
parallel-groups JJ N
clinical JJ N
trial NN N
enrolled VBD N
124 CD 1_p
children NNS 1_p
, , 1_p
aged VBD 1_p
4 CD 1_p
through IN 1_p
13 CD 1_p
years NNS 1_p
, , 1_p
with IN 1_p
PDDs NNP 1_p
, , 1_p
accompanied VBN 1_p
by IN 1_p
frequent JJ 1_p
tantrums NNS 1_p
, , 1_p
self-injury NN 1_p
, , 1_p
and CC 1_p
aggression NN 1_p
. . 1_p

The DT N
children NNS N
were VBD N
randomized VBN N
3:2 CD N
to TO N
COMB NNP N
( ( N
n JJ N
= NNP N
75 CD N
) ) N
or CC N
MED NNP N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

The DT N
participants NNS N
received VBD N
risperidone JJ 1_i
monotherapy NN 1_i
from IN N
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
( ( N
with IN N
switch NN N
to TO N
aripiprazole VB 1_i
if IN N
risperidone NN 1_i
was VBD N
ineffective JJ N
) ) N
. . N

Parents NNS N
in IN N
the DT N
COMB NNP N
group NN N
( ( N
n JJ N
= VBZ N
75 CD N
; : N
60.5 CD N
% NN N
) ) N
received VBD N
a DT N
mean NN N
of IN N
10.9 CD N
PT NNP N
sessions NNS N
. . N

The DT N
primary JJ N
measure NN N
of IN N
compliance NN N
was VBD N
the DT N
Home NNP 1_o
Situations NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
HSQ NNP 1_o
) ) 1_o
score NN 1_o
. . 1_o

RESULTS NNP N
Primary JJ N
: : N
intent-to-treat JJ N
random NN N
effects NNS N
regression NN N
showed VBD N
that IN N
COMB NNP 1_i
was VBD N
superior JJ N
to TO N
MED NNP N
on IN N
HSQ NNP 1_o
( ( N
p JJ N
= NNP N
.006 NNP N
) ) N
[ VBP N
effect NN N
size NN N
at IN N
week NN N
24 CD N
( ( N
d NN N
) ) N
= VBZ N
0.34 CD N
] NN N
. . N

The DT N
HSQ NNP 1_o
score NN 1_o
declined VBD N
from IN N
4.31 CD N
( ( N
? . N
1.67 CD N
) ) N
to TO N
1.23 CD N
( ( N
? . N
1.36 CD N
) ) N
for IN N
COMB NNP N
compared VBN N
with IN N
4.16 CD N
( ( N
? . N
1.47 CD N
) ) N
to TO N
1.68 CD N
( ( N
? . N
1.36 CD N
) ) N
for IN N
MED NNP N
. . N

Secondary JJ N
: : N
groups NNS N
did VBD N
not RB N
differ VB 1_o
on IN 1_o
Clinical JJ 1_o
Global NNP 1_o
Impressions-Improvement NN 1_o
scores NNS 1_o
at IN 1_o
endpoint NN N
; : N
compared VBN N
with IN N
MED NNP N
, , N
COMB NNP N
showed VBD N
significant JJ N
reductions NNS 1_o
on IN 1_o
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
Irritability NNP 1_o
( ( 1_o
d JJ 1_o
= VBZ N
0.48 CD N
; : N
p NN N
= NNP N
.01 NNP N
) ) N
, , 1_o
Stereotypic NNP 1_o
Behavior NNP 1_o
( ( 1_o
d JJ 1_o
= VBZ N
0.23 CD N
; : N
p NN N
= NNP N
.04 NNP N
) ) N
, , N
and CC N
Hyperactivity/Noncompliance NNP 1_o
subscales NNS 1_o
( ( 1_o
d VB 1_o
= RB N
0.55 CD N
; : N
p NN N
= NNP N
.04 NNP N
) ) N
. . N

Final NNP 1_i
risperidone NN 1_o
mean NN 1_o
dose NN 1_o
for IN 1_o
MED NNP N
was VBD N
2.26 CD N
mg/day NN N
( ( N
0.071 CD N
mg/kg NN N
) ) N
, , N
compared VBN N
with IN N
1.98 CD N
mg/day NN N
for IN N
COMB NNP N
( ( N
0.066 CD N
mg/kg NN N
) ) N
( ( N
p JJ N
= NNP N
.04 NNP N
) ) N
. . N

CONCLUSIONS NNP 1_i
Medication NNP 1_i
plus CC 1_i
PT NNP 1_i
resulted VBD N
in IN N
greater JJR 1_o
reduction NN 1_o
of IN 1_o
serious JJ 1_o
maladaptive JJ 1_o
behavior NN 1_o
than IN 1_o
MED NNP N
in IN 1_p
children NNS 1_p
with IN 1_p
PDDs NNP 1_p
, , 1_p
with IN 1_p
a DT N
lower JJR N
risperidone NN N
dose NN N
. . N

-DOCSTART- -X- O O

The DT N
NORwegian JJ N
study NN N
on IN N
DIstrict NNP N
treatment NN N
of IN N
ST-elevation NNP 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( N
NORDISTEMI NNP N
) ) N
. . N

OBJECTIVES NNP N
Thrombolysis NNP N
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
patients NNS 1_p
with IN 1_p
ST-elevation NNP 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( 1_p
STEMI NNP 1_p
) ) 1_p
living NN 1_p
in IN 1_p
rural JJ 1_p
areas NNS 1_p
with IN 1_p
long JJ 1_p
transfer NN 1_p
delays NNS 1_p
to TO 1_p
percutaneous JJ 1_p
coronary JJ 1_p
intervention NN 1_p
( ( 1_p
PCI NNP 1_p
) ) 1_p
. . 1_p

This DT N
trial NN N
compares VBZ N
two CD N
different JJ N
strategies NNS N
following VBG N
thrombolysis NN N
: : N
to TO N
transfer VB N
all DT N
patients NNS N
for IN N
immediate JJ N
coronary JJ N
angiography NN N
and CC N
intervention NN N
, , N
or CC N
to TO N
manage VB N
the DT N
patients NNS N
more RBR N
conservatively RB N
. . N

DESIGN VB N
The DT 1_p
NORwegian JJ 1_p
study NN 1_p
on IN 1_p
DIstrict NNP 1_p
treatment NN 1_p
of IN 1_p
STEMI NNP 1_p
( ( 1_p
NORDISTEMI NNP 1_p
) ) 1_p
is VBZ N
an DT N
open JJ N
, , N
prospective JJ N
, , N
randomized VBD 1_i
controlled VBN 1_i
trial NN 1_i
in IN 1_i
patients NNS 1_i
with IN 1_i
STEMI NNP 1_i
of IN 1_i
less JJR 1_i
than IN 1_i
6 CD 1_i
hours NNS 1_i
of IN 1_i
duration NN 1_i
and CC 1_i
more JJR 1_i
than IN 1_i
90 CD 1_i
minutes NNS 1_i
expected VBD 1_i
time NN 1_i
delay NN 1_i
to TO 1_i
PCI NNP 1_i
. . 1_i

A NNP 1_p
total NN 1_p
of IN 1_p
266 CD 1_p
patients NNS 1_p
will MD N
receive VB 1_i
full-dose JJ 1_i
thrombolysis NN 1_i
, , 1_i
preferably RB 1_i
pre-hospital JJ 1_i
, , 1_i
and CC 1_i
then RB 1_i
be VB 1_i
randomized VBN 1_i
to TO 1_i
either DT 1_i
strategy NN 1_i
. . 1_i

Our PRP$ N
primary JJ N
endpoint NN N
is VBZ N
the DT N
one CD N
year NN N
combined VBN 1_o
incidence NN 1_o
of IN 1_o
death NN 1_o
, , 1_o
reinfarction NN 1_o
, , 1_o
stroke VBD 1_o
or CC 1_o
new JJ 1_o
myocardial JJ 1_o
ischaemia NN 1_o
. . 1_o

The DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00161005 NNP N
. . N

RESULTS VBN N
By IN N
April NNP 1_p
2006 CD 1_p
, , 1_p
109 CD 1_p
patients NNS 1_p
have VBP N
been VBN N
randomized VBN N
. . N

Thrombolysis NN N
has VBZ N
been VBN N
given VBN N
pre-hospital JJ N
to TO N
52 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
median JJ N
transport NN N
distance NN N
from IN N
first JJ N
medical JJ N
contact NN N
to TO N
catheterization NN N
laboratory NN N
was VBD N
155 CD N
km NN N
( ( N
range JJ N
90-396 CD N
km NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
study NN N
are VBP N
expected VBN N
in IN N
2008 CD N
. . N

-DOCSTART- -X- O O

Relief NN N
of IN N
periorbital JJ N
pain NN N
after IN N
acute JJ N
angle JJ N
closure NN N
glaucoma NN N
attack NN N
by IN N
botulinum NN 1_i
toxin NN 1_i
type NN 1_i
A NNP 1_i
. . 1_i

PURPOSE NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
botulinum NN 1_i
toxin NN 1_i
type NN 1_i
A NNP 1_i
( ( 1_i
BoNT-A NNP 1_i
) ) 1_i
injection NN N
in IN N
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
intractable JJ 1_p
periorbital NN 1_p
pain NN 1_p
after IN 1_p
acute JJ 1_p
angle JJ 1_p
closure NN 1_p
glaucoma NN 1_p
( ( 1_p
AACG NNP 1_p
) ) 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
prospective JJ N
randomized VBN N
intervention NN N
study NN N
, , N
19 CD 1_p
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
periorbital JJ 1_p
pain NN 1_p
after IN 1_p
an DT 1_p
AACG NNP 1_p
attack NN 1_p
were VBD N
injected VBN 1_i
with IN 1_i
BoNT-A NNP 1_i
or CC 1_i
placebo NN 1_i
for IN N
pain NN N
relief NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
on IN N
days NNS N
1 CD N
, , N
2 CD N
, , N
7 CD N
, , N
14 CD N
, , N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
. . N

The DT N
main JJ N
outcomes NNS N
were VBD N
mean JJ N
change NN N
of IN N
visual JJ N
analog NN N
rating NN N
scale NN N
( ( N
VARS NNP N
) ) N
and CC N
index NN N
scores NNS N
measured VBN N
through IN N
a DT N
quality-of-life JJ N
questionnaire NN N
( ( N
EQ-5D NNP N
) ) N
, , N
and CC N
changes NNS N
in IN N
the DT N
visual JJ 1_o
analog NN 1_o
scale NN 1_o
( ( N
VAS NNP N
) ) N
, , N
all DT N
of IN N
which WDT N
were VBD N
assessed VBN N
at IN N
each DT N
visit NN N
. . N

A DT N
secondary JJ N
outcome NN N
was VBD N
the DT N
frequency NN N
and CC N
nature NN N
of IN N
adverse JJ N
events NNS N
and CC N
the DT N
number NN N
of IN N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
study NN N
as IN N
a DT N
result NN N
. . N

RESULTS NN N
In IN N
the DT N
treatment NN N
group NN N
( ( N
n=10 NN N
) ) N
, , N
the DT N
mean JJ 1_o
index NN 1_o
score NN 1_o
of IN 1_o
EQ-5D NNP 1_o
and CC 1_o
VAS NNP 1_o
changed VBD N
significantly RB N
from IN N
the DT N
placebo NN 1_i
group NN N
( ( N
by IN N
0.299 CD N
and CC N
2.61 CD N
, , N
respectively RB N
) ) N
from IN N
day NN N
2 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
VARS NNP 1_o
of IN 1_o
EQ-5D NNP 1_o
also RB N
disclosed VBD N
significant JJ N
changes NNS N
from IN N
day NN N
2 CD N
( ( N
17 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
addition NN N
, , N
efficacy NN 1_o
was VBD N
maintained VBN N
mainly RB N
between IN N
days NNS N
2 CD N
and CC N
60 CD N
but CC N
declined VBD N
slightly RB N
by IN N
day NN N
90 CD N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
treatment-related JJ N
adverse JJ N
events NNS N
in IN N
the DT N
treatment NN N
and CC N
placebo NN N
groups NNS N
were VBD N
local JJ 1_o
tenderness NN 1_o
( ( N
21 CD N
% NN N
) ) N
, , N
subcutaneous JJ 1_o
hemorrhage NN 1_o
( ( N
10.5 CD N
% NN N
) ) N
, , N
and CC N
conjunctivitis NN 1_o
( ( N
10.5 CD N
% NN N
) ) N
. . N

No UH N
severe JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
reported VBN N
during IN N
the DT N
study NN N
or CC N
follow-up JJ N
period NN N
. . N

CONCLUSIONS NNP N
BoNT-A NNP 1_i
is VBZ N
effective JJ N
and CC N
well RB N
tolerated VBN N
for IN N
the DT N
treatment NN N
of IN N
periorbital JJ N
pain NN N
after IN N
an DT N
AACG NNP N
attack NN N
. . N

Its PRP$ N
effects NNS N
may MD N
be VB N
maintained VBN N
for IN N
3 CD N
months NNS N
. . N

-DOCSTART- -X- O O

Efficacy NN 1_o
of IN N
patient JJ 1_i
education NN 1_i
and CC 1_i
supervised VBD 1_i
exercise NN 1_i
vs NN N
patient JJ 1_i
education NN 1_i
alone RB 1_i
in IN N
patients NNS 1_p
with IN 1_p
hip JJ 1_p
osteoarthritis NN 1_p
: : 1_p
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
patient JJ 1_i
education NN 1_i
and CC 1_i
supervised VBD 1_i
exercise NN 1_i
with IN N
that DT N
of IN N
patient JJ 1_i
education NN 1_i
alone RB 1_i
for IN N
the DT N
management NN 1_o
of IN 1_o
pain NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
hip NN 1_p
osteoarthritis NN 1_p
( ( 1_p
OA NNP 1_p
) ) 1_p
. . 1_p

DESIGN NNP N
Single NNP N
blind IN N
randomized JJ N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Recruitment NNP N
of IN N
patients NNS 1_p
from IN 1_p
hospitals NNS 1_p
, , 1_p
primary JJ 1_p
health NN 1_p
care NN 1_p
and CC 1_p
advertisement NN 1_p
, , 1_p
Oslo NNP 1_p
, , 1_p
Norway NNP 1_p
. . 1_p

PARTICIPANTS NNP N
109 CD 1_p
patients NNS 1_p
with IN 1_p
radiographic JJ 1_p
and CC 1_p
symptomatic JJ 1_p
hip NN 1_p
OA NNP 1_p
with IN 1_p
mild NN 1_p
to TO 1_p
moderate VB 1_p
symptoms NNS 1_p
. . 1_p

INTERVENTIONS NNP N
Patient NNP 1_i
education NN 1_i
( ( 1_i
PE NNP 1_i
) ) 1_i
. . 1_i

Patient JJ 1_i
education NN 1_i
and CC 1_i
supervised VBN 1_i
exercise NN 1_i
( ( 1_i
PE+SE NNP 1_i
) ) 1_i
. . 1_i

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
pain NN 1_o
subscale NN 1_o
of IN 1_o
the DT 1_o
Western NNP 1_o
Ontario NNP 1_o
and CC 1_o
McMaster NNP 1_o
Universities NNP 1_o
Osteoarthritis NNP 1_o
Index NNP 1_o
( ( 1_o
WOMAC NNP 1_o
pain NN 1_o
) ) 1_o
. . 1_o

RESULTS NNP N
No NNP N
significant JJ N
between IN N
group NN N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP 1_o
pain NN 1_o
over IN N
the DT N
16-month JJ N
follow-up NN N
. . N

Significant JJ N
improvements NNS N
were VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcome NN N
WOMAC NNP 1_o
physical JJ 1_o
function NN 1_o
( ( N
P=0.011 NNP N
) ) N
in IN N
the DT N
group NN N
receiving VBG N
PE+SE NNP 1_i
compared VBN N
to TO N
the DT N
group NN N
receiving VBG N
PE NNP 1_i
only RB N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP 1_o
stiffness NN 1_o
, , N
the DT N
SF-36 JJ N
subscales NNS N
or CC N
the DT N
activity NN N
scale NN N
. . N

The DT N
effect NN N
sizes VBZ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
for IN N
WOMAC NNP 1_o
pain NN 1_o
were VBD N
-0.26 NNP N
( ( N
0.11 CD N
, , N
-0.64 NN N
) ) N
, , N
-0.35 NNP N
( ( N
0.07 CD N
, , N
-0.77 NN N
) ) N
, , N
and CC N
-0.30 NNP N
( ( N
0.15 CD N
, , N
-0.75 NN N
) ) N
, , N
and CC N
for IN N
WOMAC NNP 1_o
physical JJ 1_o
function NN 1_o
-0.29 NNP N
( ( N
0.09 CD N
, , N
-0.67 NN N
) ) N
, , N
-0.48 NNP N
( ( N
-0.06 NNP N
, , N
-0.91 NNP N
) ) N
, , N
and CC N
-0.47 NNP N
( ( N
-0.02 NNP N
, , N
-0.93 NNP N
) ) N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
, , N
respectively RB N
, , N
in IN N
favor NN N
of IN N
the DT N
group NN N
receiving VBG N
both DT N
PE NNP 1_i
and CC 1_i
SE NNP 1_i
. . 1_i

All DT N
patients NNS N
attended VBD N
the DT N
three-session JJ N
PE NNP 1_i
program NN 1_i
, , N
and CC N
75 CD N
% NN N
performed VBN N
?16 JJ N
sessions NNS N
of IN N
the DT N
12-week JJ 1_i
SE NNP 1_i
program NN 1_i
. . N

CONCLUSION NNP N
The DT N
study NN N
could MD N
not RB N
demonstrate VB N
a DT N
significant JJ N
difference NN N
in IN N
pain NN 1_o
reduction NN 1_o
over IN 1_o
time NN N
between IN 1_i
PE+SE NNP 1_i
vs NNP 1_i
PE NNP 1_i
alone RB 1_i
. . 1_i

Adding VBG 1_i
SE NNP 1_i
to TO 1_i
PE NNP 1_i
may MD 1_i
improve VB 1_o
physical JJ 1_o
function NN 1_o
, , 1_o
but CC N
the DT N
magnitude NN N
of IN N
possible JJ N
benefit NN N
is VBZ N
unknown JJ N
as IN N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
around IN N
the DT N
mean JJ N
difference NN N
were VBD N
wide JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials NNP N
NCT00319423 NNP N
. . N

-DOCSTART- -X- O O

The DT N
additive JJ N
analgesic JJ N
efficacy NN N
of IN N
acetaminophen NN 1_i
, , N
1000 CD N
mg NN N
, , N
and CC N
codeine NN 1_i
, , N
60 CD N
mg NN N
, , N
in IN N
dental JJ 1_p
pain NN 1_p
. . 1_p

In IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
single-dose JJ N
trial NN N
the DT N
analgesic JJ N
contribution NN N
of IN N
acetaminophen NN 1_i
, , 1_i
1000 CD 1_i
mg NN 1_i
, , 1_i
and CC 1_i
codeine NN 1_i
, , 1_i
60 CD 1_i
mg NN 1_i
, , N
was VBD N
determined VBN N
. . N

The DT N
study NN N
was VBD N
a DT N
2 CD N
X NN N
2 CD N
factorial JJ N
experiment NN N
in IN N
which WDT N
120 CD 1_p
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
pain NN 1_p
as IN 1_p
a DT 1_p
result NN 1_p
of IN 1_p
oral JJ 1_p
surgery NN 1_p
rated VBD N
their PRP$ N
pain NN 1_o
intensity NN 1_o
and CC 1_o
pain NN 1_o
relief NN 1_o
for IN N
up IN N
to TO N
5 CD N
hours NNS N
after IN N
a DT N
single JJ N
dose NN N
of IN N
one CD N
of IN N
: : N
1000 CD N
mg NN N
acetaminophen NN 1_i
, , N
60 CD N
mg NN N
codeine NN 1_i
, , N
1000 CD N
mg NN N
acetaminophen NN 1_i
plus CC 1_i
60 CD 1_i
mg NN 1_i
codeine NN 1_i
, , N
or CC N
placebo NN 1_i
. . 1_i

The DT N
factorial JJ N
analysis NN N
showed VBD N
that IN N
both DT N
1000 CD N
mg NN N
acetaminophen NN 1_i
and CC N
60 CD N
mg NN N
codeine NN 1_i
made VBD N
a DT N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
contribution NN N
to TO N
the DT N
analgesic JJ 1_o
effectiveness NN 1_o
of IN 1_o
the DT 1_o
combination NN 1_o
on IN 1_o
all DT 1_o
measures NNS 1_o
of IN 1_o
efficacy NN 1_o
( ( 1_o
sum NN 1_o
of IN 1_o
pain NN 1_o
intensity NN 1_o
differences NNS 1_o
, , 1_o
largest JJS 1_o
pain NN 1_o
intensity NN 1_o
difference NN 1_o
, , 1_o
total JJ 1_o
pain NN 1_o
relief NN 1_o
, , 1_o
largest JJS 1_o
pain NN 1_o
relief NN 1_o
, , 1_o
and CC 1_o
time NN 1_o
to TO 1_o
remedication NN 1_o
) ) 1_o
. . 1_o

The DT N
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
effects NNS 1_o
did VBD N
not RB N
appear VB N
to TO N
differ VB N
among IN N
the DT N
treatments NNS N
, , N
including VBG N
placebo NN 1_i
. . 1_i

-DOCSTART- -X- O O

Trials NNS 1_o
and CC N
tribulations NNS 1_o
in IN N
speech NN 1_i
therapy NN 1_i
. . 1_i

-DOCSTART- -X- O O

Fine NNP 1_i
needle JJ 1_i
aspiration NN 1_i
coupled VBN 1_i
with IN 1_i
real-time JJ 1_i
PCR NNP 1_i
: : 1_i
a DT N
painless JJ N
methodology NN N
to TO N
study VB N
adaptive JJ N
functional JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
In IN N
this DT N
study NN N
we PRP N
developed VBD N
a DT N
new JJ N
methodology NN 1_i
for IN N
obtaining VBG N
human JJ N
skeletal JJ N
muscle NN N
samples NNS N
to TO N
evaluate VB N
gene NN N
expression NN N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
a DT N
fine JJ 1_i
needle JJ 1_i
aspiration NN 1_i
technique NN 1_i
, , N
which WDT N
allows VBZ N
us PRP N
to TO N
extract VB N
a DT N
small JJ N
tissue NN N
sample NN N
in IN N
a DT N
significantly RB N
less RBR N
invasive JJ N
manner NN N
than IN N
with IN N
classic JJ N
biopsy NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Multiplex NNP 1_i
tandem VBD 1_i
RT-PCR NNP 1_i
was VBD N
used VBN N
to TO N
determine VB N
the DT N
mRNA NN N
levels NNS N
of IN N
genes NNS N
involved VBN N
in IN N
ATP NNP N
production NN N
and CC N
mitochondrial JJ N
biogenesis NN N
in IN N
muscle NN N
tissue NN N
. . N

Samples NNS 1_o
of IN 1_o
vastus NN 1_o
lateralis NNS 1_o
muscle NN 1_o
were VBD N
obtained VBN N
from IN N
21 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
with IN 1_p
different JJ 1_p
fitness NN 1_p
levels NNS 1_p
. . 1_p

The DT N
principal JJ N
findings NNS N
in IN N
our PRP$ N
study NN N
show VB N
a DT N
strong JJ N
correlation NN N
between IN N
PGC-1alpha NNP 1_o
and CC 1_o
COX5B NNP 1_o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
between IN N
PGC-1alpha NNP 1_o
and CC 1_o
MT-CO2 NNP 1_o
( ( N
p=0.017 NN N
) ) N
expression NN N
. . N

Furthermore NNP N
, , N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
mtDNA NN N
content NN N
and CC N
the DT N
percentage NN N
of IN N
MHCI NNP N
present NN N
in IN N
the DT N
aspired JJ N
samples NNS N
were VBD N
found VBN N
( ( N
p=0.028 NN N
) ) N
. . N

These DT N
data NNS N
are VBP N
in IN N
agreement NN N
with IN N
current JJ N
knowledge NN N
on IN N
skeletal JJ N
muscle NN N
physiology NN N
and CC N
show VB N
the DT N
reliability NN N
of IN N
the DT N
proposed VBN N
method NN N
. . N

CONCLUSION VB N
This DT N
painless JJ 1_i
methodology NN 1_i
can MD N
be VB N
used VBN N
to TO N
investigate VB N
, , N
in IN N
vivo NN N
, , N
human JJ N
muscle NN N
RNA NNP N
and CC N
DNA NNP N
adaptations NNS N
in IN N
response NN N
to TO N
either DT N
physiological JJ N
and/or NN N
pharmacological JJ N
stimuli NN N
. . N

This DT N
method NN N
has VBZ N
major JJ N
clinical JJ N
relevance NN N
, , N
such JJ N
as IN N
its PRP$ N
application NN N
in IN N
clarifying VBG N
the DT N
mechanisms NN N
underling VBG N
metabolic JJ N
and CC N
systemic JJ N
disorders NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
human JJ N
papillomavirus NN N
testing NN N
of IN N
clinician-collected JJ 1_i
and CC 1_i
self-collected JJ 1_i
samples NNS 1_i
during IN N
follow-up JJ N
after IN N
screen-and-treat NN N
. . N

Screen-and-treat JJ N
cervical JJ N
cancer NN N
prevention NN N
programs NNS N
based VBN N
on IN N
high-risk JJ N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
testing NN N
and CC N
cryotherapy NN N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
resource-limited JJ N
settings NNS N
. . N

However RB N
, , N
because IN N
cryotherapy NN N
is VBZ N
not RB N
100 CD N
% NN N
effective JJ N
, , N
follow-up JJ N
is VBZ N
needed VBN N
after IN N
treatment NN N
to TO N
detect VB N
post-treatment JJ N
failures NNS N
. . N

We PRP N
compared VBN N
the DT N
test NN N
performances NNS N
of IN N
high-risk JJ N
HPV NNP N
testing NN N
( ( N
Hybrid JJ N
Capture NNP N
2 CD N
) ) N
using VBG N
self-collected JJ 1_i
and CC 1_i
clinician-collected JJ 1_i
samples NNS 1_i
as RB N
well RB N
as IN N
cervical JJ 1_i
cytology NN 1_i
for IN N
identifying VBG N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grades NNS N
2 CD N
or CC N
3 CD N
or CC N
invasive JJ N
cervical JJ N
cancer NN N
( ( N
CIN2+ NNP N
) ) N
among IN 1_p
women NNS 1_p
who WP 1_p
did VBD 1_p
( ( 1_p
n=812 NN 1_p
) ) 1_p
and CC 1_p
did VBD 1_p
not RB 1_p
( ( 1_p
n=1858 JJ 1_p
) ) 1_p
undergo VBP 1_p
cryotherapy NN 1_p
in IN 1_p
a DT 1_p
South JJ 1_p
African JJ 1_p
screen-and-treat JJ 1_p
trial NN 1_p
. . 1_p

At IN N
6 CD N
months NNS N
after IN N
enrolment NN N
( ( N
and CC N
after IN N
cryotherapy NN 1_i
, , N
if IN N
performed VBN N
) ) N
, , N
women NNS N
were VBD N
tested VBN N
using VBG N
all DT N
three CD N
screening VBG N
methods NNS N
and CC N
then RB N
underwent JJ N
colposcopy/biopsy NN 1_i
. . N

A DT N
predefined JJ N
subset NN N
of IN N
women NNS N
( ( N
n=1,455 NN N
) ) N
had VBD N
extended VBN N
follow-up NN N
with IN N
colposcopy/biopsy NN 1_i
at IN N
12 CD N
months NNS N
. . N

A DT N
total NN N
of IN N
33 CD N
and CC N
91 CD N
cases NNS N
of IN N
CIN2+ NNP N
were VBD N
detected VBN N
among IN N
treated JJ N
and CC N
untreated JJ N
women NNS N
, , N
respectively RB N
. . N

The DT N
sensitivity NN 1_o
of IN 1_o
HPV NNP 1_o
testing VBG 1_o
using VBG N
clinician-collected JJ 1_i
samples NNS 1_i
and CC N
cervical JJ N
cytology NN N
did VBD N
not RB N
differ VB N
by IN N
treatment NN N
status NN N
. . N

HPV NNP N
testing VBG N
of IN N
clinician-collected JJ 1_i
samples NNS 1_i
detected VBN N
the DT N
most RBS N
cases NNS N
of IN N
CIN2+ NNP 1_o
among IN N
both DT N
treated VBN N
( ( N
85 CD N
% NN N
) ) N
and CC N
untreated JJ N
( ( N
91 CD N
% NN N
) ) N
women NNS N
( ( N
p=0.31 NN N
) ) N
. . N

Cytology NNP 1_o
( ( N
at IN N
a DT N
cutoff NN N
of IN N
atypical JJ N
squamous JJ N
cells NNS N
of IN N
undetermined JJ N
significance NN N
or CC N
greater JJR N
) ) N
detected VBD N
76 CD N
% NN N
of IN N
cases NNS N
among IN N
both DT N
treated VBN N
and CC N
untreated JJ N
women NNS N
. . N

However RB N
, , N
the DT N
sensitivity NN 1_o
of IN 1_o
HPV NNP 1_o
testing VBG 1_o
using VBG N
self-collected JJ 1_i
samples NNS 1_i
was VBD N
significantly RB N
lower JJR N
among IN N
treated JJ N
versus NN N
untreated JJ N
women NNS N
( ( N
55 CD N
% NN N
vs. FW N
78 CD N
% NN N
, , N
p=0.01 NN N
) ) N
. . N

HPV NNP N
testing VBG N
using VBG N
self-collected JJ 1_i
vaginal JJ 1_i
specimens NNS 1_i
may MD N
be VB N
useful JJ N
in IN N
primary JJ N
screening NN N
but CC N
performs NNS N
poorly RB N
for IN N
detecting VBG N
post-treatment JJ 1_o
failures NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Dopamine NNP 1_i
transporter NN 1_i
gene NN 1_i
moderates VBZ N
response NN N
to TO N
behavioral JJ 1_p
parent NN 1_p
training NN 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
ADHD NNP 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

There EX N
is VBZ N
great JJ N
variability NN N
in IN N
the DT N
degree NN N
to TO N
which WDT N
children NNS 1_p
with IN 1_p
attention NN 1_p
deficit/hyperactivity NN 1_p
disorder NN 1_p
( ( 1_p
ADHD NNP 1_p
) ) 1_p
improve VBP N
through IN N
behavioral JJ N
treatments NNS N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
influence NN N
of IN N
the DT N
dopamine NN 1_i
transporter NN 1_i
gene NN 1_i
( ( 1_i
SCL6A3/DAT1 NNP 1_i
) ) 1_i
on IN N
outcome NN N
of IN N
behavioral JJ 1_i
parent NN 1_i
training NN 1_i
( ( 1_i
BPT NNP 1_i
) ) 1_i
. . 1_i

Study NNP 1_p
subjects NNS 1_p
were VBD 1_p
a DT 1_p
subsample NN 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
50 CD 1_p
, , 1_p
for IN 1_p
whom WP 1_p
DAT1 NNP 1_p
genotypes NNS 1_p
were VBD 1_p
available JJ 1_p
) ) 1_p
of IN 1_p
a DT 1_p
randomized VBN 1_p
controlled VBN 1_p
BPT NNP 1_p
effectiveness NN 1_p
study NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
94 CD 1_p
) ) 1_p
comparing VBG 1_p
BPT NNP 1_i
plus CC 1_i
ongoing JJ 1_i
routine JJ 1_i
clinical JJ 1_i
care NN 1_i
( ( 1_i
RCC NNP 1_i
) ) 1_i
versus NN 1_i
RCC NNP 1_i
alone RB 1_i
in IN 1_i
referred JJ 1_p
children NNS 1_p
( ( 1_p
4-12 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
with IN 1_p
ADHD NNP 1_p
. . 1_p

Treatment NNP N
outcome NN N
was VBD N
based VBN N
on IN N
parent-reported JJ N
ADHD NNP N
symptoms NNS N
and CC N
behavioral JJ N
problems NNS N
. . N

Presence NNP N
of IN N
2 CD N
versus NN N
no DT N
or CC N
1 CD N
DAT1 NNP N
10-repeat JJ N
allele NN N
served VBD N
as IN N
moderator NN N
variable NN N
. . N

Time NNP N
? . N
Treatment NNP N
? . N
Genotype NNP N
effect NN N
was VBD N
analyzed VBN N
with IN N
repeated-measures JJ N
analysis NN N
of IN N
variance NN N
, , N
controlling VBG N
for IN N
baseline JJ N
medication NN N
status NN N
. . N

Results VB N
indicate JJ N
that IN 1_o
DAT1 NNP 1_o
moderated VBD 1_o
treatment NN 1_o
response NN 1_o
( ( 1_o
p JJ N
= NNP N
.009 NNP 1_o
) ) 1_o
. . 1_o

In IN 1_o
children NNS 1_o
with IN 1_o
no DT 1_o
or CC 1_o
1 CD 1_o
DAT1 NNP 1_o
10-repeat JJ 1_o
allele NN 1_o
, , 1_o
superior JJ 1_o
treatment NN 1_o
effects NNS 1_o
of IN 1_o
BPT NNP 1_o
+ NNP 1_o
RCC NNP 1_o
compared VBN 1_o
with IN 1_o
RCC NNP 1_o
alone RB 1_o
were VBD 1_o
present JJ 1_o
( ( 1_o
p JJ 1_o
= NNP 1_o
.005 NNP 1_o
) ) 1_o
, , 1_o
which WDT 1_o
was VBD 1_o
not RB 1_o
the DT 1_o
case NN 1_o
in IN 1_o
children NNS 1_o
with IN 1_o
2 CD 1_o
DAT1 NNP 1_o
10-repeat JJ 1_o
alleles NNS 1_o
( ( 1_o
p JJ 1_o
= NNP 1_o
.57 NNP 1_o
) ) 1_o
. . 1_o

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
genetic JJ N
differences NNS N
in IN N
DAT1 NNP 1_o
in IN 1_o
children NNS N
with IN N
ADHD NNP N
influence VBP N
their PRP$ N
susceptibility NN N
to TO N
a DT N
behavioral JJ 1_o
intervention NN 1_o
directed VBD 1_o
at IN N
shaping VBG N
their PRP$ N
environment NN N
through IN N
their PRP$ N
parents NNS N
. . N

The DT N
role NN N
of IN N
the DT 1_i
dopamine NN 1_i
system NN 1_i
in IN 1_i
motivation NN N
and CC N
learning NN N
and CC N
in IN N
the DT N
aberrant JJ N
sensitivity NN N
to TO N
reinforcement VB N
in IN N
children NNS N
with IN N
ADHD NNP N
may MD N
explain VB N
this DT N
moderating NN N
effect NN N
, , N
given VBN N
that IN N
the DT N
management NN N
of IN N
contingencies NNS N
is VBZ N
typically RB N
addressed VBN N
in IN N
BPT NNP 1_i
. . 1_i

-DOCSTART- -X- O O

International NNP 1_p
Czech NNP 1_i
and CC 1_i
Slovak NNP 1_i
cooperation NN 1_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
differentiated JJ 1_p
thyroid NN 1_p
cancer NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
paper NN N
is VBZ N
to TO N
present VB N
our PRP$ N
experience NN N
concerning VBG N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
Slovak NNP 1_p
patients NNS 1_p
with IN 1_p
differentiated JJ 1_p
thyroid NN 1_p
cancer NN 1_p
in IN 1_p
Slovak NNP 1_p
and CC 1_p
Czech NNP 1_p
hospitals NNS 1_p
. . 1_p

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
demonstrate VB N
the DT N
means NNS 1_o
of IN 1_o
this DT 1_o
cooperation NN 1_o
and CC N
the DT N
results NNS 1_o
of IN N
therapy NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
From NNP 1_p
September NNP 1_p
1991 CD 1_p
to TO 1_p
October NNP 1_p
2005 CD 1_p
in IN 1_p
the DT 1_p
Department NNP 1_p
of IN 1_p
Nuclear NNP 1_p
Medicine NNP 1_p
in IN 1_p
Ostrava NNP 1_p
357 CD 1_p
patients NNS 1_p
from IN 1_p
the DT 1_p
Slovak NNP 1_p
Republic NNP 1_p
with IN 1_p
differentiated VBN 1_p
thyroid NN 1_p
cancers NNS 1_p
( ( 1_p
follicular JJ 1_p
and CC 1_p
papillary JJ 1_p
) ) 1_p
underwent NN 1_p
complex JJ 1_i
therapy NN 1_i
. . 1_i

They PRP 1_p
were VBD 1_p
diagnosed VBN 1_p
and CC 1_p
operated VBN 1_p
due JJ 1_p
to TO 1_p
the DT 1_p
cancer NN 1_p
( ( 1_p
near-total JJ 1_p
thyroidectomy NN 1_p
and CC 1_p
removal NN 1_p
of IN 1_p
lymph JJ 1_p
node JJ 1_p
metastases NNS 1_p
) ) 1_p
in IN 1_p
Slovak NNP 1_p
hospitals NNS 1_p
. . 1_p

Then RB 1_p
they PRP 1_p
were VBD 1_p
sent VBN 1_p
to TO 1_p
the DT 1_p
Department NNP 1_p
of IN 1_p
Nuclear NNP 1_p
Medicine NNP 1_p
in IN 1_p
Ostrava NNP 1_p
in IN 1_p
the DT 1_p
Czech NNP 1_p
Republic NNP 1_p
. . 1_p

In IN N
this DT N
department NN N
a DT N
radioiodine JJ 1_i
ablation NN N
of IN N
thyroid JJ N
remnants NNS N
, , N
by IN N
means NNS N
of IN N
the DT N
treatment NN 1_i
amount NN N
of IN N
radioiodine NN 1_i
of IN N
a DT N
standard JJ N
activity NN N
of IN N
3.7 CD N
GBq NNP N
, , N
was VBD N
performed VBN N
, , N
and CC N
then RB N
a DT N
suppression NN N
and CC N
substitution NN 1_i
therapy NN 1_i
of IN N
thyroid JJ N
hormones NNS N
was VBD N
started VBN N
. . N

After IN N
3-6 JJ N
months NNS N
some DT N
patients NNS N
were VBD N
examined VBN N
by IN N
means NNS N
of IN N
diagnostic JJ 1_o
whole JJ 1_o
body NN 1_o
scintigraphy NN 1_o
after IN N
application NN N
of IN N
300 CD N
MBq NNP N
131I CD N
. . N

Some DT N
patients NNS N
were VBD N
treated VBN N
by IN N
means NNS N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
7.4 CD N
GBq NNP N
131I CD N
and CC N
after IN N
5 CD N
days NNS N
whole JJ N
body NN N
scintigraphy NN N
( ( N
WBS NNP N
) ) N
was VBD N
performed VBN N
. . N

In IN N
both DT N
of IN N
these DT N
groups NNS N
of IN N
patients NNS N
the DT N
diagnostic JJ N
or CC N
therapeutic JJ N
radioiodine NN 1_i
application NN N
was VBD N
done VBN N
after IN N
withdrawal NN N
of IN N
thyroid JJ N
hormone NN N
treatment NN N
. . N

If IN N
thyroglobulin JJ 1_o
levels NNS 1_o
were VBD N
low JJ N
and CC N
WBSs NNP 1_o
were VBD N
negative JJ N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Martin NNP N
. . N

Patients NNS N
with IN N
radioiodine NN N
accumulated VBN N
metastases NNS N
were VBD N
again RB N
treated VBN N
with IN N
radioiodine NN 1_i
in IN N
Ostrava NNP N
. . N

If IN N
indicated VBN N
, , N
external JJ N
radiation NN 1_i
therapy NN 1_i
targeted VBN N
on IN N
the DT N
neck NN N
and CC N
upper JJ N
mediastinum NN N
was VBD N
performed VBN N
in IN N
the DT N
Slovak NNP 1_p
Republic NNP 1_p
, , 1_p
in IN 1_p
the DT 1_p
University NNP 1_p
Hospital NNP 1_p
in IN 1_p
Martin NNP 1_p
. . 1_p

Newly RB N
formed VBN N
lymph JJ N
node NN N
metastases NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
Slovakia NNP N
, , N
too RB N
. . N

Generally RB N
we PRP N
have VBP N
very RB N
good JJ 1_o
treatment NN 1_o
results NNS 1_o
. . 1_o

Also RB N
, , N
economically RB N
our PRP$ N
partnership NN N
is VBZ N
cost VBN 1_o
effective JJ 1_o
. . 1_o

Our PRP$ N
collaboration NN N
also RB N
successfully RB N
continues VBZ N
after IN N
entrance NN N
of IN N
the DT N
Slovak NNP N
Republic NNP N
and CC N
the DT N
Czech NNP N
Republic NNP N
to TO N
the DT N
European NNP N
Union NNP N
in IN N
2004 CD N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
multi-centre JJ N
study NN N
show NN N
that IN N
international JJ N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN 1_i
in IN N
the DT N
complex JJ N
therapy NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancers NNS N
is VBZ N
successful JJ N
, , N
with IN N
high JJ N
efficacy NN N
. . N

The DT N
treatment NN N
results NNS N
were VBD N
very RB N
similar JJ N
to TO N
therapeutic JJ N
results NNS N
in IN N
our PRP$ N
patients NNS N
from IN N
the DT N
Czech NNP N
Republic NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Prevention NNP N
of IN N
migraine NN 1_o
with IN N
flunarizine NN 1_i
and CC N
acetylsalicylic JJ 1_i
acid NN 1_i
. . 1_i

A DT N
double-blind JJ N
study NN N
] NNP N
. . N

UNLABELLED CC N
30 CD 1_p
children NNS 1_p
between IN 1_p
7 CD 1_p
and CC 1_p
17 CD 1_p
years NNS 1_p
suffering VBG 1_p
from IN 1_p
at IN 1_p
least JJS 1_p
2 CD 1_p
attacks/month NN 1_p
of IN 1_p
common JJ 1_p
or CC 1_p
classical JJ 1_p
migraine NN 1_p
since IN 1_p
more JJR 1_p
than IN 1_p
1 CD 1_p
year NN 1_p
were VBD N
studied VBN N
. . N

After IN N
clinical JJ N
exclusion NN N
of IN N
symptomatic JJ N
headache NN N
4 CD N
weeks NNS N
were VBD N
documented VBN N
by IN N
means NNS N
of IN N
a DT N
migraine NN N
diary NN N
. . N

Prophylaxis NNP N
with IN N
Calcium NNP N
entry NN N
blocker NN 1_i
Flunarizine NNP 1_i
( ( 1_i
Sibelium NNP 1_i
) ) 1_i
or CC N
Thromboxane VB N
A DT N
inhibitor NN N
Acetylsalicylic NNP 1_i
acid NN 1_i
( ( 1_i
ASS NNP 1_i
) ) 1_i
was VBD N
carried VBN N
out RP N
in IN N
a DT N
double JJ N
blind NN N
design NN N
for IN N
3 CD N
months NNS N
. . N

Medication NNP N
was VBD N
given VBN N
as IN N
one CD N
dosage NN N
in IN N
the DT N
evening NN N
: : N
2-5 JJ N
mg/kg NN N
KG NNP N
ASS NNP 1_i
or CC N
5-10 JJ N
mg NN N
Flunarizine NNP 1_i
. . 1_i

Documented NNP N
attack NN 1_o
frequency NN 1_o
and CC 1_o
duration NN 1_o
were VBD N
controlled VBN N
at IN N
monthly JJ N
physical JJ N
examinations NNS N
. . N

Final JJ N
results NNS N
showed VBD N
no DT N
differences NNS N
in IN N
significant JJ N
reduction NN 1_o
of IN 1_o
attack NN 1_o
frequency NN 1_o
or CC 1_o
symptoms NNS 1_o
between IN N
both DT N
different JJ N
therapeutic JJ N
principals NNS N
. . N

72.4 CD N
% NN N
( ( N
ASS NNP N
73.3 CD N
% NN N
; : N
Flunarizine NNP 1_i
71.4 CD N
% NN N
) ) N
of IN N
patients NNS N
were VBD N
attack-free JJ N
or CC N
had VBD N
at IN N
least JJS N
a DT N
50 CD N
% NN N
reduction NN N
. . N

Migraine NNP 1_o
frequency NN 1_o
of IN N
initially RB N
7-8 NNP N
was VBD N
reduced VBN N
to TO N
1-2 JJ N
attacks/month NN N
. . N

Duration NN 1_o
remained VBD N
constant JJ N
in IN N
both DT N
groups NNS N
( ( N
1-3 JJ N
h NN N
) ) N
. . N

Side JJ N
effects NNS N
were VBD N
slight JJ 1_o
body NN 1_o
weight VBD 1_o
gain NN 1_o
or CC N
abdominal JJ 1_o
pain NN 1_o
after IN N
intake NN N
, , N
prophylaxis NN N
had VBD N
not RB N
to TO N
be VB N
interrupted VBN N
therefore RB N
. . N

Longtime JJ N
prognosis NN N
is VBZ N
not RB N
yet RB N
possible JJ N
because IN N
the DT N
time NN N
of IN N
observation NN N
is VBZ N
too RB N
short JJ N
so RB N
far RB N
. . N

CONCLUSION NNP N
Both NNP N
substances NNS N
are VBP N
definitely RB N
useful JJ N
and CC N
have VBP N
few JJ N
side NN N
effects NNS N
in IN N
childhood NN 1_p
migraine NN 1_p
. . 1_p

If IN N
the DT N
response NN N
to TO N
one CD N
is VBZ N
insufficient JJ N
the DT N
other JJ N
substance NN N
should MD N
be VB N
tried VBN N
. . N

-DOCSTART- -X- O O

Increased VBN 1_o
growth NN 1_o
hormone NN 1_o
response NN N
to TO N
sumatriptan VB 1_i
challenge NN N
in IN N
adult NN 1_p
autistic JJ 1_p
disorders NNS 1_p
. . 1_p

Serotonergic NNP N
( ( N
5-HT JJ N
) ) N
abnormalities NNS N
have VBP N
been VBN N
documented VBN N
in IN N
autism NN N
. . N

To TO N
assess JJ N
sensitivity NN N
of IN N
the DT N
5-HT1d JJ N
receptor NN N
, , N
growth NN 1_o
hormone NN 1_o
response NN 1_o
to TO N
the DT N
5-HT1d JJ 1_i
receptor NN 1_i
agonist NN 1_i
sumatriptan NN 1_i
was VBD N
studied VBN N
in IN N
adult NN 1_p
autistic JJ 1_p
patients NNS 1_p
and CC 1_p
matched VBD 1_p
normal JJ 1_p
controls NNS 1_p
. . 1_p

In IN N
this DT N
study NN N
, , N
11 CD 1_p
adult NN 1_p
patients NNS 1_p
with IN 1_p
autism NN 1_p
or CC 1_p
Asperger NNP 1_p
's POS 1_p
disorder NN 1_p
were VBD 1_p
compared VBN 1_p
with IN 1_p
nine CD 1_p
matched JJ 1_p
controls NNS 1_p
. . 1_p

All DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
single JJ 1_i
dose JJ 1_i
sumatriptan NN 1_i
( ( 1_i
6 CD 1_i
mg RB 1_i
SQ NNP 1_i
) ) 1_i
and CC 1_i
placebo NN 1_i
challenges NNS 1_i
, , 1_i
separated VBN 1_i
by IN 1_i
a DT 1_i
1-week JJ 1_i
interval NN 1_i
, , 1_i
and CC 1_i
growth NN 1_o
hormone NN 1_o
was VBD 1_i
measured VBN 1_i
before IN 1_i
and CC 1_i
during IN 1_i
the DT 1_i
challenges NNS 1_i
. . 1_i

The DT N
results NNS N
showed VBD N
a DT N
highly RB N
significant JJ N
diagnosisxdrugxtime JJ 1_o
interaction NN 1_o
on IN N
repeated JJ N
measure NN N
analysis NN N
covaried VBD N
for IN N
baseline NN N
. . N

This DT N
suggests VBZ N
that IN N
autistic JJ 1_p
patients NNS 1_p
had VBD N
significantly RB N
greater JJR N
growth NN 1_o
hormone NN 1_o
response NN 1_o
to TO N
sumatriptan VB 1_i
than IN N
normal JJ N
controls NNS N
, , N
independent JJ N
of IN N
placebo JJ N
effects NNS N
. . N

Therefore RB N
, , N
abnormalities NNS N
in IN N
5-HT JJ N
regulation NN N
in IN N
autism NN N
may MD N
be VB N
related VBN N
to TO N
increased VBN N
sensitivity NN N
of IN N
the DT N
5-HT1d JJ N
inhibitory NN N
receptor NN N
in IN N
autism NN N
. . N

-DOCSTART- -X- O O

[ NN N
Study NNP N
on IN N
treatment NN N
of IN N
iron-deficiency NN N
anemia NN N
by IN N
shengxuening VBG 1_i
] NNP 1_i
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
shengxuening VBG 1_i
( ( 1_i
SXN NNP 1_i
) ) 1_i
in IN N
treating VBG N
iron-deficiency NN 1_p
anemia NN 1_p
( ( 1_p
IDA NNP 1_p
) ) 1_p
and CC N
to TO N
explore VB N
its PRP$ N
molecular JJ N
mechanism NN N
on IN N
iron NN N
metabolism NN N
balance NN N
regulation NN N
. . N

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
IDA NNP 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
the DT 1_p
treated VBN 1_p
group NN 1_p
and CC 1_p
the DT 1_p
control NN 1_i
group NN 1_p
, , 1_p
50 CD 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

They PRP N
were VBD N
treated VBN N
with IN N
SXN NNP 1_i
( ( 1_i
0.1 CD 1_i
g NN 1_i
, , 1_i
three CD 1_i
times NNS 1_i
per IN 1_i
day NN 1_i
) ) 1_i
and CC 1_i
ferrous JJ 1_i
gluconate NN 1_i
( ( 1_i
0.1 CD 1_i
g NN 1_i
, , 1_i
three CD 1_i
times NNS 1_i
per IN 1_i
day NN 1_i
) ) 1_i
respectively RB 1_i
, , 1_i
for IN 1_i
30 CD 1_i
days NNS 1_i
. . 1_i

Levels NNS 1_o
of IN 1_o
serum NN 1_o
iron NN 1_o
( ( 1_o
Fe NNP 1_o
) ) 1_o
, , 1_o
total JJ 1_o
iron NN 1_o
binding NN 1_o
capacity NN 1_o
( ( 1_o
TIBC NNP 1_o
) ) 1_o
, , 1_o
transferrin JJ 1_o
saturation NN 1_o
( ( 1_o
TS NNP 1_o
) ) 1_o
, , 1_o
serum JJ 1_o
ferritin NN 1_o
( ( 1_o
SF NNP 1_o
) ) 1_o
, , 1_o
transferrin NN 1_o
( ( 1_o
Tf NNP 1_o
) ) 1_o
, , 1_o
soluble JJ 1_o
transferrin NN 1_o
receptor NN 1_o
( ( 1_o
sTfR NN 1_o
) ) 1_o
and CC 1_o
blood NN 1_o
routine JJ 1_o
test NN 1_o
, , 1_o
as RB 1_o
well RB 1_o
as IN 1_o
scoring NN 1_o
of IN 1_o
TCM NNP 1_o
qi-blood JJ 1_o
deficiency NN 1_o
Syndrome NNP 1_o
were VBD N
conducted VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
in IN N
the DT N
treated JJ N
group NN N
reached VBD N
92 CD N
% NN N
, , N
it PRP N
was VBD N
shown VBN N
that IN N
SXN NNP N
could MD N
improve VB N
the DT N
iron NN 1_o
metabolism NN 1_o
, , 1_o
increase NN 1_o
levels NNS 1_o
of IN 1_o
Fe NNP 1_o
, , 1_o
TS NNP 1_o
, , 1_o
SF NNP 1_o
and CC 1_o
reduce VB 1_o
levels NNS 1_o
of IN 1_o
TIBC NNP 1_o
, , 1_o
Tf NNP 1_o
, , 1_o
sTfR NN 1_o
, , N
it PRP N
has VBZ N
obvious JJ N
effect NN N
in IN N
promoting VBG N
erythrocyte JJ N
generation NN N
and CC N
could MD N
promote VB N
formation NN N
of IN N
leucocytes NNS N
and CC N
platelets NNS N
. . N

The DT N
total JJ 1_o
effective JJ 1_o
rate NN 1_o
in IN N
the DT N
control NN N
group NN N
was VBD N
32 CD N
% NN N
, , N
which WDT N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
treated JJ N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
effect NN N
of IN N
SXN NNP 1_i
in IN N
treating VBG N
IDA NNP N
and CC N
qi-blood JJ N
deficiency NN N
Syndrome NNP N
is VBZ N
evident JJ N
, , N
it PRP N
could MD N
improve VB N
the DT N
iron NN N
metabolism NN N
, , N
increase NN N
levels NNS N
of IN N
Fe NNP N
, , N
TS NNP N
, , N
SF NNP N
and CC N
lower JJR N
levels NNS N
of IN N
TIBC NNP N
, , N
Tf NNP N
, , N
sTfR NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
platelet NN 1_i
suppressant NN 1_i
, , 1_i
anticoagulant JJ 1_i
and CC 1_i
fibrinolytic JJ 1_i
therapy NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
recurrent JJ 1_p
venous JJ 1_p
thrombosis NN 1_p
. . 1_p

-DOCSTART- -X- O O

Quantifying VBG N
oral JJ 1_i
analgesic JJ 1_i
consumption NN N
using VBG N
a DT N
novel JJ N
method NN N
and CC N
comparison NN N
with IN N
patient-controlled JJ 1_p
intravenous JJ 1_p
analgesic JJ 1_i
consumption NN 1_p
. . 1_p

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
vaginal JJ 1_i
tablets NNS 1_i
containing VBG N
lactobacilli JJ 1_i
versus NN N
pH NN 1_i
tablets NNS 1_i
on IN N
vaginal JJ 1_o
health NN 1_o
and CC 1_o
inflammatory JJ 1_o
cytokines NNS 1_o
: : 1_o
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
lactobacilli NN 1_i
on IN N
vaginal JJ 1_o
health NN 1_o
and CC 1_o
proinflammatory NN 1_o
cytokines NNS 1_o
. . 1_o

Sixty-seven JJ 1_p
patients NNS 1_p
with IN 1_p
bacterial JJ 1_p
vaginosis NN 1_p
( ( 1_p
BV NNP 1_p
) ) 1_p
, , 1_p
50 CD 1_p
with IN 1_p
intermediate JJ 1_p
flora NNS 1_p
and CC 1_p
42 CD 1_p
with IN 1_p
normal JJ 1_p
vaginal JJ 1_p
flora NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN N
this DT N
double-blind NN N
study NN N
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB 1_i
probiotic JJ 1_i
lactobacilli JJ 1_i
vaginal JJ 1_i
tablets NNS 1_i
( ( 1_i
L. NNP 1_i
brevis NN 1_i
CD2 NNP 1_i
, , 1_i
L. NNP 1_i
salivarius NN 1_i
subsp NN 1_i
. . 1_i

salicinius NN 1_i
, , 1_i
L. NNP 1_i
plantarum NN 1_i
) ) 1_i
or CC 1_i
the DT 1_i
vaginal JJ 1_i
pH NN 1_i
tablet NN 1_i
( ( 1_i
active JJ 1_i
comparator NN 1_i
) ) 1_i
. . 1_i

Cervico-vaginal JJ N
lavage NN N
was VBD N
collected VBN N
to TO N
measure VB N
the DT N
concentrations NNS N
of IN N
IL-1? NNP N
, , N
TNF? NNP N
and CC N
IL-6 NNP N
by IN N
ELISA NNP N
. . N

Neutral JJ N
sphingomyelinase NN N
activity NN N
was VBD N
also RB N
quantified VBN N
in IN N
both DT N
arms NNS N
before IN N
and CC N
after IN N
treatment NN N
. . N

The DT N
probiotic JJ N
vaginal JJ N
tablet NN N
was VBD N
well RB 1_o
tolerated VBN 1_o
and CC 1_o
no DT N
side NN 1_o
effects NNS 1_o
were VBD 1_o
reported VBN N
. . N

The DT N
study NN N
demonstrated VBD N
a DT N
cure NN 1_o
rate NN 1_o
of IN N
nearly RB N
80 CD N
% NN N
; : N
i.e. NN N
, , N
32 CD N
% NN N
of IN N
the DT N
women NNS N
could MD N
restore VB N
normal JJ N
vaginal JJ N
flora NNS N
and CC N
47 CD N
% NN N
had VBD 1_o
improved VBN 1_o
Nugent NNP 1_o
score NN 1_o
, , 1_o
whereas RB 1_o
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
did VBD N
not RB N
clear JJ N
BV NNP N
in IN N
the DT N
first JJ N
follow-up NN N
( ( N
after IN N
8 CD N
days NNS N
treatment NN N
) ) N
. . N

The DT N
pH JJ N
tablet NN N
containing VBG N
pH NN N
lowering VBG N
compounds NNS N
induced JJ N
resolution NN 1_o
of IN 1_o
BV NNP 1_o
and CC 1_o
restoration NN 1_o
of IN 1_o
normal JJ 1_o
vaginal JJ 1_o
flora NN 1_o
in IN N
74 CD N
% NN N
and CC N
26 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
lactobacilli JJ N
tablet NN N
was VBD N
found VBN N
to TO N
be VB N
better JJR N
than IN N
the DT N
pH JJ N
tablet NN N
in IN N
preventing VBG 1_o
BV NNP 1_o
in IN 1_o
healthy JJ 1_o
subjects NNS N
. . N

A DT N
significant JJ N
reduction NN 1_o
in IN 1_o
IL-1? NNP 1_o
and CC 1_o
IL-6 NNP 1_o
vaginal JJ 1_o
cytokines NNS 1_o
was VBD 1_o
observed VBN 1_o
after IN N
treatment NN N
with IN N
lactobacilli NN N
, , N
while IN N
the DT N
active JJ N
comparator NN N
did VBD N
not RB N
have VB N
any DT N
effect NN N
on IN N
local JJ N
proinflammatory NN N
cytokines NNS N
. . 1_o

Vaginal JJ 1_o
neutral JJ 1_o
sphingomyelinase NN 1_o
activity NN 1_o
was VBD N
not RB N
modified VBN N
in IN N
either DT N
group NN N
. . N

Vaginal NNP N
tablets NNS N
containing VBG N
lactobacilli NN N
can MD N
cure VB N
BV NNP 1_o
and CC 1_o
reduce VB 1_o
vaginal JJ 1_o
inflammatory NN 1_o
response NN 1_o
. . N

-DOCSTART- -X- O O

Hepatic JJ N
cytoprotective JJ N
effect NN N
of IN N
ischemic JJ 1_i
and CC 1_i
anesthetic JJ 1_i
preconditioning NN 1_i
before IN N
liver JJ N
resection NN N
when WRB N
using VBG N
intermittent JJ N
vascular JJ N
inflow JJ N
occlusion NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Ischemic NNP 1_i
preconditioning NN 1_i
( ( 1_i
IPC NNP 1_i
) ) 1_i
and CC N
anesthetic JJ 1_i
preconditioning NN 1_i
( ( 1_i
APC NNP 1_i
) ) 1_i
have VBP N
been VBN N
reported VBN N
to TO N
attenuate VB N
ischemia-reperfusion NN N
( ( N
IR NNP N
) ) N
injury NN N
after IN N
liver JJ N
resection NN N
under IN N
continuous JJ N
inflow JJ N
occlusion NN N
. . N

This DT N
study NN N
evaluates VBZ N
whether IN N
these DT N
strategies NNS N
enhance VBP N
hepatic JJ N
protection NN N
of IN N
remnant JJ N
liver NN N
against IN N
IR NNP N
after IN N
liver JJ 1_p
resection NN 1_p
with IN 1_p
intermittent JJ 1_i
clamping NN 1_i
( ( 1_i
INT NNP 1_i
) ) 1_i
. . 1_i

METHODS CC N
A DT 1_p
total NN 1_p
of IN 1_p
106 CD 1_p
patients NNS 1_p
without IN 1_p
underlying VBG 1_p
liver NN 1_p
disease NN 1_p
and CC 1_p
submitted VBN 1_p
to TO 1_p
liver VB 1_p
resection NN 1_p
using VBG 1_p
INT NNP 1_p
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
: : N
IPC NNP 1_i
( ( 1_i
10 CD 1_i
minutes NNS 1_i
of IN 1_i
inflow JJ 1_i
occlusion NN 1_i
followed VBN 1_i
by IN 1_i
10 CD 1_i
minutes NNS 1_i
of IN 1_i
reperfusion NN 1_i
before IN 1_i
liver JJ 1_i
transection NN 1_i
) ) 1_i
, , 1_i
APC NNP 1_i
( ( 1_i
sevoflurane JJ 1_i
administration NN 1_i
for IN 1_i
20 CD 1_i
minutes NNS 1_i
before IN 1_i
liver JJ 1_i
transection NN 1_i
) ) 1_i
, , 1_i
and CC 1_i
INT NNP 1_i
( ( 1_i
no DT 1_i
preconditioning NN 1_i
) ) 1_i
. . 1_i

Patients NNS N
were VBD N
also RB N
stratified VBN N
according VBG N
to TO N
the DT N
extent NN N
of IN N
the DT N
hepatectomy NN N
. . N

Cytoprotection NN 1_o
was VBD N
evaluated VBN N
by IN N
comparing VBG 1_o
hepatocyte NN 1_o
and CC 1_o
endothelial JJ 1_o
dysfunction NN 1_o
markers NNS 1_o
, , 1_o
apoptosis NN 1_o
, , 1_o
histologic JJ 1_o
lesions NNS 1_o
, , 1_o
and CC 1_o
postoperative JJ 1_o
outcome NN 1_o
. . 1_o

RESULTS NNP N
No NNP N
differences NNS N
were VBD N
observed VBN N
in IN N
preoperative JJ 1_o
chemotherapy NN 1_o
and CC 1_o
steatosis NN 1_o
, , 1_o
total JJ 1_o
warm JJ 1_o
ischemia NN 1_o
time NN 1_o
, , 1_o
operative JJ 1_o
time NN 1_o
, , 1_o
or CC 1_o
blood NN 1_o
loss NN 1_o
. . 1_o

Kinetics NNS 1_o
of IN 1_o
transaminases NNS 1_o
( ( N
aspartate JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.137 NNP N
; : N
alanine JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.616 NNP N
) ) N
, , N
bilirubin FW 1_o
( ( N
P NNP N
= NNP N
.980 NNP N
) ) N
, , N
and CC N
hyaluronic JJ 1_o
acid NN 1_o
increase NN N
( ( N
P NNP N
= NNP N
.514 NNP N
) ) N
revealed VBD N
no DT N
differences NNS N
. . N

Significant JJ 1_o
apoptosis NN 1_o
was VBD N
present JJ N
in IN N
40 CD N
% NN N
of IN N
patients NNS N
, , N
mild-to-moderate JJ 1_o
leukocyte NN 1_o
infiltration NN 1_o
and CC 1_o
steatosis NN 1_o
in IN N
45 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
mild VB 1_o
sinusoidal JJ 1_o
congestion NN 1_o
in IN N
65 CD N
% NN N
, , N
with IN N
a DT N
similar JJ N
distribution NN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

When WRB N
patients NNS N
were VBD N
stratified VBN N
by IN N
major JJ N
versus NN N
minor JJ N
resections NNS N
, , N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
variables NNS N
studied VBN N
. . N

Postoperative JJ N
clinical JJ N
outcomes NNS N
were VBD N
also RB N
similar JJ N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
these DT N
protocols NNS 1_i
of IN 1_i
IPC NNP 1_i
and CC 1_i
APC NNP 1_i
used VBD N
in IN N
this DT N
study NN N
do VBP N
not RB N
provide VB N
better JJR N
cytoprotection NN N
from IN N
IR NNP N
when WRB N
INT NNP 1_i
is VBZ N
used VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
coronary JJ N
sinus NN N
occlusion NN N
on IN N
myocardial JJ N
ischaemia NN N
in IN N
humans NNS N
: : N
role NN N
of IN N
coronary JJ N
collateral NN N
function NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
intermittent VBP N
coronary JJ N
sinus NN N
occlusion NN N
( ( N
iCSO NN N
) ) N
reduces VBZ N
myocardial JJ 1_o
ischaemia NN 1_o
, , N
and CC N
that IN N
the DT N
amount NN N
of IN N
ischaemia NN 1_o
reduction NN N
is VBZ N
related VBN N
to TO N
coronary JJ N
collateral NN N
function NN N
. . N

DESIGN NNP N
Prospective JJ N
case-control NN N
study NN N
with IN N
intraindividual JJ N
comparison NN N
of IN N
myocardial JJ N
ischaemia NN N
during IN N
two CD N
2-min JJ N
coronary JJ N
artery NN N
balloon NN N
occlusions NNS N
with IN N
and CC N
without IN N
simultaneous JJ N
iCSO NN N
by IN N
a DT N
balloon-tipped JJ N
catheter NN N
. . N

SETTING NNP N
University NNP 1_p
Hospital NNP 1_p
. . 1_p

PATIENTS VB N
35 CD 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
stable JJ 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
. . 1_p

INTERVENTION NNP N
2-min JJ 1_i
iCSO NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Myocardial NNP 1_o
ischaemia NN 1_o
as IN N
assessed VBN N
by IN N
intracoronary JJ 1_o
( ( 1_o
i.c JJ 1_o
. . 1_o

) ) 1_o
ECG NNP 1_o
ST NNP 1_o
shift NN 1_o
at IN 1_i
2 CD 1_i
min NN 1_i
of IN 1_i
coronary JJ 1_i
artery NN 1_i
balloon NN 1_i
occlusion NN 1_i
. . 1_i

Collateral NNP 1_o
flow JJ 1_o
index NN 1_o
( ( 1_o
CFI NNP 1_o
) ) 1_o
without IN 1_o
iCSO NN 1_o
, , 1_o
that WDT 1_o
is VBZ N
, , N
the DT N
ratio NN N
between IN N
mean JJ N
distal JJ N
coronary JJ N
occlusive NN N
( ( N
Poccl NNP N
) ) N
and CC N
mean JJ N
aortic JJ N
pressure NN N
( ( N
Pao NNP N
) ) N
both DT N
minus JJ N
central JJ N
venous JJ N
pressure NN N
. . N

RESULTS NNP N
I.c NNP N
. . N

ECG NNP 1_o
ST NNP 1_o
segment NN 1_o
shift NN 1_o
( ( N
elevation NN N
in IN N
all DT N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
with IN N
iCSO JJ N
versus NN N
without IN N
iCSO NN N
was VBD N
1.33?1.25 CD N
mV JJ N
versus NN N
1.85?1.45 CD N
mV NN N
, , N
p NN N
< VBD N
0.0001 CD N
. . N

Regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
degree NN N
of IN N
i.c NN 1_o
. . 1_o

ECG NNP 1_o
ST NNP 1_o
shift NN 1_o
reduction NN 1_o
during IN 1_o
iCSO NN N
was VBD N
related VBN N
to TO N
CFI NNP N
, , N
best RB N
fitting VBG N
a DT N
Lorentzian JJ N
function NN N
( ( N
r NN N
( ( 1_o
2 CD 1_o
) ) 1_o
=0.61 NN 1_o
) ) 1_o
. . 1_o

Ischaemia NNP 1_o
reduction NN 1_o
with IN 1_o
iCSO NN 1_o
was VBD 1_o
greatest VBN 1_o
at IN N
a DT N
CFI NNP N
of IN N
0.05-0.20 NNP N
, , N
whereas NN N
in IN N
the DT N
low JJ N
and CC N
high JJ N
CFI NNP N
range VBP N
the DT N
effect NN N
of IN N
iCSO NN N
was VBD N
absent JJ N
. . N

CONCLUSIONS NNP N
ICSO NNP N
reduces VBZ N
myocardial JJ N
ischaemia NN N
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
. . 1_p

Ischaemia NNP N
reduction NN N
by IN N
iCSO JJ N
depends NNS N
on IN N
coronary JJ N
collateral NN N
function NN N
. . N

A DT N
minimal JJ N
degree NN N
of IN N
collateral NN 1_o
function NN 1_o
is VBZ 1_o
necessary JJ N
to TO N
render VB N
iCSO JJ N
effective JJ N
. . N

ICSO NNP N
can MD N
not RB N
manifest VB N
an DT N
effect NN N
when WRB N
collateral NN N
function NN N
prevents NNS N
ischaemia NN N
in IN N
the DT N
first JJ N
place NN N
. . N

-DOCSTART- -X- O O

A DT N
study NN N
of IN N
noninvasive JJ 1_i
positive-pressure JJ 1_i
mechanical JJ 1_i
ventilation NN 1_i
in IN N
the DT N
treatment NN N
of IN N
acute NN 1_p
lung NN 1_p
injury NN 1_p
with IN 1_p
a DT 1_p
complex JJ 1_p
critical JJ 1_p
care NN 1_p
ventilator NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
there EX N
would MD N
be VB N
better RB N
clinical JJ N
outcomes NNS N
following VBG N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
lung NN 1_p
injury NN 1_p
( ( 1_p
ALI NNP 1_p
) ) 1_p
using VBG N
noninvasive JJ 1_i
positive-pressure JJ 1_i
mechanical JJ 1_i
ventilation NN 1_i
( ( 1_i
NIPPV NNP 1_i
) ) 1_i
delivered VBD 1_i
via IN 1_i
a DT 1_i
complex JJ 1_i
critical JJ 1_i
care NN 1_i
ventilator NN 1_i
compared VBN 1_i
with IN 1_i
a DT 1_i
conventional JJ 1_i
mini-ventilator NN 1_i
. . 1_i

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
ALI NNP 1_p
who WP 1_p
required VBD 1_p
NIPPV NNP 1_p
were VBD 1_p
prospectively RB 1_p
enrolled VBN 1_p
and CC N
randomly RB N
divided VBD N
between IN N
three CD N
intervention NN N
groups NNS N
: : N
group NN N
A DT N
was VBD N
ventilated VBN N
using VBG N
a DT N
mini-ventilator NN 1_i
; : 1_i
groups NNS N
B NNP N
and CC N
C NNP N
were VBD N
ventilated VBN N
using VBG N
a DT N
complex JJ 1_i
critical JJ 1_i
care NN 1_i
ventilator NN 1_i
using VBG 1_i
different JJ 1_i
settings NNS 1_i
. . 1_i

Clinical JJ 1_o
parameters NNS 1_o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
8 CD N
h NN N
of IN N
mechanical JJ N
ventilation NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
51 CD 1_p
patients NNS 1_p
with IN 1_p
ALI NNP 1_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

Clinical JJ N
parameters NNS N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
underwent JJ N
greater JJR N
improvements NNS N
than IN N
those DT N
in IN N
group NN N
A NNP N
. . N

Group NNP N
C NNP N
demonstrated VBD N
the DT N
lowest JJS N
treatment NN 1_o
failure NN 1_o
rate NN 1_o
( ( N
23.5 CD N
% NN N
) ) N
. . N

Failure NN 1_o
rates NNS 1_o
were VBD N
highest JJS N
in IN N
group NN N
A NNP N
( ( N
58.8 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
findings NNS N
of IN N
this DT N
present JJ N
study NN N
suggest VBP N
that IN N
there EX N
were VBD N
more JJR N
satisfactory JJ N
clinical JJ 1_o
outcomes NNS 1_o
following VBG N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
ALI NNP 1_p
when WRB N
NIPPV NNP N
was VBD N
delivered VBN N
using VBG N
a DT N
complex JJ N
critical JJ N
care NN N
ventilator NN N
compared VBN N
with IN N
a DT N
conventional JJ N
mini-ventilator NN N
. . N

-DOCSTART- -X- O O

Prospective JJ N
trial NN N
of IN N
intraoperative JJ 1_i
mitomycin NN 1_i
C NNP 1_i
in IN N
the DT N
treatment NN N
of IN N
primary JJ 1_p
pterygium NN 1_p
. . 1_p

AIMS VB N
A NNP N
prospective JJ N
, , N
randomised VBD N
, , N
double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
study NN N
of IN N
intraoperative JJ 1_i
mitomycin NN 1_i
C NNP 1_i
as IN N
adjunctive JJ N
treatment NN N
of IN N
primary JJ 1_p
pterygium NN 1_p
was VBD N
conducted VBN N
. . N

METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
66 CD 1_p
eyes NNS 1_p
of IN 1_p
54 CD 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
pterygium NN 1_p
were VBD N
treated VBN N
with IN N
excision NN 1_i
, , 1_i
with IN 1_i
or CC 1_i
without IN 1_i
a DT 1_i
single JJ 1_i
intraoperative JJ 1_i
application NN 1_i
of IN 1_i
mitomycin NN 1_i
C NNP 1_i
( ( N
0.1 CD N
mg/ml NN N
for IN N
5 CD N
minutes NNS N
) ) N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC 1_o
toxicity NN 1_o
of IN N
this DT N
adjunctive JJ N
treatment NN N
. . N

The DT N
mean NN N
follow VBP N
up RB N
was VBD N
14.1 CD N
months NNS N
( ( N
range VB N
12-23 JJ N
months NNS N
) ) N
. . N

RESULTS NNP N
Of IN N
the DT N
36 CD N
eyes NNS N
that WDT N
underwent JJ N
simple JJ N
excision NN N
, , N
14 CD N
( ( N
38.8 CD N
% NN N
) ) N
exhibited VBD N
recurrences NNS 1_o
whereas IN N
only RB N
one CD N
of IN N
30 CD N
eyes NNS N
( ( N
3.33 CD N
% NN N
) ) N
treated VBD N
with IN N
excision NN N
and CC N
intraoperative JJ N
application NN N
of IN N
mitomycin NN 1_i
C NNP 1_i
had VBD N
recurrence NN 1_o
( ( N
p JJ N
= NNP N
0.0006 CD N
) ) N
. . N

Neither CC N
serious JJ N
ocular JJ 1_o
complications NNS 1_o
nor CC 1_o
systemic JJ 1_o
toxicity NN 1_o
were VBD N
noted VBN N
in IN N
the DT N
mitomycin NN 1_i
C NNP 1_i
treated VBD N
group NN N
. . N

CONCLUSION NNP N
Intraoperative NNP N
mitomycin NN 1_i
C NNP 1_i
appears VBZ N
to TO N
be VB N
an DT N
effective JJ N
and CC N
safe JJ N
adjunctive JJ N
treatment NN N
of IN N
primary JJ 1_p
pterygium NN 1_p
. . 1_p

-DOCSTART- -X- O O

Braced NNP N
for IN N
impact NN N
: : N
reducing VBG N
military JJ 1_p
paratroopers NNS 1_p
' POS 1_p
ankle NN N
sprains NNS N
using VBG N
outside-the-boot JJ 1_i
braces NNS 1_i
. . 1_i

BACKGROUND NNP N
Ankle NNP N
injuries VBZ N
account NN N
for IN N
30 CD N
to TO N
60 CD N
% NN N
of IN N
all DT N
parachuting VBG N
injuries NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
if IN N
outside-the-boot JJ N
ankle NN N
braces NNS N
could MD N
reduce VB N
ankle JJ N
sprains NNS N
during IN N
Army NNP 1_p
paratrooper IN 1_p
training NN 1_p
. . 1_p

METHODS NNP N
The DT N
randomized JJ N
trial NN N
involved VBD N
777 CD 1_p
volunteers NNS 1_p
from IN 1_p
the DT 1_p
U.S. NNP 1_p
Army NNP 1_p
Airborne NNP 1_p
School NNP 1_p
, , 1_p
Fort NNP 1_p
Benning NNP 1_p
, , 1_p
Ga. NNP 1_p
Of IN N
this DT N
group NN N
, , N
745 CD 1_p
completed VBD 1_p
all DT 1_p
study NN 1_p
requirements NNS 1_p
( ( 1_p
369 CD 1_p
brace-wearers NNS 1_i
and CC 1_p
376 CD 1_p
non-brace-wearers NNS 1_i
) ) 1_i
. . 1_p

Each DT N
volunteer NN N
made VBD N
five CD N
parachute NN N
jumps NNS N
, , N
for IN N
a DT N
total NN N
of IN N
3,674 CD N
jumps NNS N
. . N

RESULTS VB N
The DT N
incidence NN 1_o
of IN 1_o
inversion NN 1_o
ankle NN 1_o
sprains NNS 1_o
was VBD N
1.9 CD N
% NN N
in IN N
non-brace-wearers NNS N
and CC N
0.3 CD N
% NN N
in IN N
brace-wearers NNS N
( ( N
risk NN N
ratio NN N
, , N
6.9 CD N
; : N
p NN N
= VBZ N
0.04 CD N
) ) N
. . N

Other JJ N
injuries NNS N
appeared VBD N
unaffected JJ N
by IN N
the DT N
brace NN N
. . N

Overall NNP N
, , N
5.3 CD N
% NN N
of IN N
the DT N
non-brace JJ N
group NN N
and CC N
4.6 CD N
% NN N
of IN N
the DT N
brace NN N
group NN N
experienced VBD N
at IN N
least JJS N
one CD N
injury NN N
. . N

The DT N
risk NN 1_o
ratio NN 1_o
for IN 1_o
injured JJ 1_o
individuals NNS 1_o
was VBD N
1.2:1 CD N
( ( N
non-brace NN N
to TO N
brace VB N
groups NNS N
; : N
p CC N
= VB N
0.65 CD N
) ) N
. . N

CONCLUSION NNP N
Inversion NNP 1_o
ankle NN 1_o
sprains NNS 1_o
during IN 1_p
parachute JJ 1_p
training NN 1_p
can MD N
be VB N
significantly RB N
reduced VBN N
by IN N
using VBG N
an DT N
outside-the-boot JJ N
ankle NN N
brace NN N
, , N
with IN N
no DT N
increase NN N
in IN N
risk NN N
for IN N
other JJ N
injuries NNS N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
of IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
supplemental JJ N
arginine NN 1_i
to TO N
enhance VB N
immune JJ N
function NN N
in IN N
persons NNS 1_p
with IN 1_p
HIV/AIDS NNP 1_p
. . 1_p

OBJECTIVE NNP N
We PRP N
collected VBD N
preliminary JJ N
data NNS N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
supplemental JJ N
arginine NN 1_i
to TO N
improve VB N
natural JJ N
killer NN N
cell NN N
cytotoxicity NN N
in IN N
a DT N
sample NN N
of IN N
persons NNS 1_p
with IN 1_p
human JJ 1_p
immunodeficiency NN 1_p
virus NN 1_p
( ( 1_p
HIV NNP 1_p
) ) 1_p
and CC 1_p
acquired VBD 1_p
immunodeficiency NN 1_p
syndrome NN 1_p
( ( 1_p
AIDS NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
pilot NN N
study NN N
in IN N
an DT N
academic JJ N
medical JJ N
center-based JJ N
infectious JJ N
disease NN N
clinic NN N
, , N
11 CD 1_p
clinically RB 1_p
stable JJ 1_p
, , 1_p
HIV-infected JJ 1_p
adults NNS 1_p
had VBD 1_p
been VBN 1_p
treated VBN 1_p
with IN 1_p
highly RB 1_p
active JJ 1_p
, , 1_p
antiretroviral JJ 1_i
therapy NN 1_i
and CC 1_p
had VBD 1_p
HIV NNP 1_p
plasma NN 1_p
RNA NNP 1_p
levels NNS 1_p
of IN 1_p
less JJR 1_p
than IN 1_p
10 CD 1_p
000 CD 1_p
copies/mL NN 1_p
. . 1_p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
19.6 CD 1_i
g NN 1_i
of IN 1_i
arginine/d NN 1_i
( ( N
n JJ N
= NNP N
6 CD N
) ) N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
5 CD N
) ) N
for IN N
14 CD N
d. NN N
Plasma NNP 1_o
HIV NNP 1_o
RNA NNP 1_o
levels NNS 1_o
, , 1_o
neuropsychologic RB 1_o
functioning NN 1_o
, , 1_o
and CC 1_o
self-reported JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
analyzed VBN N
for IN N
safety NN N
of IN N
treatment NN N
. . N

Efficacy NN 1_o
was VBD N
measured VBN N
by IN N
natural JJ N
killer NN N
cell NN N
cytotoxicity NN N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
participants NNS N
experienced VBD N
any DT N
adverse JJ 1_o
clinical NN 1_o
, , 1_o
virologic NN 1_o
, , 1_o
or CC 1_o
neuropsychologic JJ 1_o
events NNS 1_o
that WDT N
necessitated VBD N
withdrawal NN N
from IN N
the DT N
study NN N
. . N

The DT N
arginine-supplemented JJ 1_i
group NN N
showed VBD N
a DT N
mean JJ 1_o
natural JJ 1_o
killer NN 1_o
cell NN 1_o
cytotoxicity NN 1_o
increase NN N
of IN N
18.9 CD N
lytic JJ N
units NNS N
, , N
whereas IN N
the DT N
placebo NN N
group NN N
showed VBD N
an DT N
increase NN N
of IN N
0.3 CD N
lytic JJ N
units NNS N
. . N

This DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.79 CD N
) ) N
. . N

CONCLUSIONS NNP N
Short-term JJ N
arginine NN 1_i
supplementation NN N
is VBZ N
safe JJ N
for IN N
persons NNS 1_p
with IN 1_p
HIV/AIDS NNP 1_p
. . 1_p

Additional NNP N
studies NNS N
with IN N
larger JJR N
samples NNS N
and CC N
longer JJR N
periods NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
arginine JJ N
supplementation NN N
on IN N
other JJ N
indices NNS N
of IN N
immune JJ N
function NN N
and CC N
on IN N
clinical JJ N
outcomes NNS N
such JJ N
as IN N
intercurrent JJ N
illnesses NNS N
. . N

-DOCSTART- -X- O O

Teaching VBG 1_i
children NNS 1_i
with IN 1_i
autism NN 1_i
to TO 1_i
seek VB 1_i
information NN 1_i
: : 1_i
acquisition NN N
of IN N
novel JJ N
information NN N
and CC N
generalization NN N
of IN N
responding VBG N
. . N

A DT 1_i
time NN 1_i
delay NN 1_i
procedure NN 1_i
was VBD 1_i
used VBN 1_i
to TO 1_i
teach VB 1_i
3 CD 1_i
children NNS 1_i
with IN 1_i
autism NN 1_i
to TO 1_i
ask VB 1_i
the DT 1_i
question NN 1_i
What WP 1_i
's VBZ 1_i
that DT 1_i
? . 1_i
when WRB 1_i
novel JJ 1_i
stimuli NNS 1_i
were VBD 1_i
presented VBN 1_i
during IN 1_i
an DT 1_i
instructional JJ 1_i
task NN 1_i
. . 1_i

Once IN N
the DT N
ability NN N
to TO N
ask VB N
the DT N
question NN N
was VBD N
acquired VBN N
, , N
the DT N
children NNS N
's POS N
ability NN N
to TO N
learn VB N
novel JJ N
information NN N
by IN N
asking VBG N
the DT N
question NN N
was VBD N
assessed VBN N
. . N

The DT N
children NNS N
were VBD N
then RB N
taught VBN N
to TO N
ask VB N
the DT N
question NN N
within IN N
a DT N
less RBR N
structured JJ N
context NN N
. . N

All DT N
three CD N
studies NNS N
used VBD N
a DT N
multiple JJ N
baseline NN N
across IN N
participants NNS N
. . N

Generalization NN N
was VBD N
assessed VBN N
in IN N
a DT N
different JJ N
room NN N
, , N
to TO N
a DT N
new JJ N
person NN N
, , N
and CC N
to TO N
novel VB N
stimuli NNS N
. . N

All DT N
of IN N
the DT N
children NNS 1_p
learned VBD N
to TO N
ask VB N
the DT N
question NN N
within IN N
the DT N
instructional JJ N
context NN N
, , N
while IN N
on IN N
a DT N
walk NN N
in IN N
the DT N
school NN N
building NN N
, , N
and CC N
to TO N
request VB N
information NN N
about IN N
three-dimensional JJ N
objects NNS N
. . N

The DT N
acquisition NN 1_o
of IN 1_o
novel JJ 1_o
information NN 1_o
was VBD N
consistent JJ N
for IN N
receptive JJ N
and CC N
expressive JJ N
tests NNS N
for IN N
2 CD N
of IN N
the DT N
children NNS N
, , N
with IN N
varied JJ N
results NNS N
for IN N
the DT N
3rd CD N
. . N

These DT N
studies NNS N
indicate VBP N
that IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
can MD N
be VB N
taught VBN N
to TO N
ask VB N
questions NNS N
that WDT N
lead VBP N
to TO N
the DT N
acquisition NN N
of IN N
new JJ N
information NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
primaquine NN 1_i
regimens NNS 1_i
for IN N
primaquine-resistant JJ N
Plasmodium NNP N
vivax NN N
malaria NN N
in IN N
Thailand NNP 1_p
. . 1_p

To TO N
define VB N
the DT N
current JJ N
efficacy NN N
of IN N
Fansidar NNP 1_i
( ( 1_i
F. NNP 1_i
Hoffmann-La NNP 1_i
Roche NNP 1_i
Ltd. NNP 1_i
, , N
Basel NNP 1_i
Switzerland NNP 1_i
) ) 1_i
( ( 1_i
pyrimethamine NN 1_i
and CC 1_i
sulfadoxine NN 1_i
) ) 1_i
, , 1_i
primaquine NN 1_i
in IN N
a DT N
high JJ N
dose NN N
, , N
and CC N
artesunate NN 1_i
for IN N
treating VBG N
acute JJ N
Plasmodium NNP N
vivax NN N
malaria NN N
, , N
we PRP N
conducted VBD N
a DT N
comparative JJ N
clinical JJ N
trial NN N
of IN N
these DT N
3 CD N
drugs NNS N
in IN N
an DT N
open-label JJ N
study NN N
. . N

Patients NNS 1_p
( ( 1_p
15-65 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
were VBD 1_p
assigned VBN 1_p
to TO 1_p
1 CD 1_p
of IN 1_p
4 CD 1_p
treatments NNS 1_p
regimens VBZ 1_p
in IN 1_p
a DT 1_p
serial JJ 1_p
order NN 1_p
. . 1_p

Ninety NNP 1_p
percent NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
were VBD 1_p
infected VBN 1_p
at IN 1_p
Thailand-Myanmar NNP 1_p
border NN 1_p
. . 1_p

Patients NNS N
in IN N
group NN N
I PRP N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
received VBN N
Fansidar NNP 1_i
( ( N
3 CD N
tablets NNS N
, , N
75 CD N
mg NN N
of IN N
pyrimethamine NN 1_i
and CC 1_i
1,500 CD 1_i
mg NN 1_i
of IN 1_i
sulfadoxine NN 1_i
, , N
a DT N
single JJ N
dose NN N
on IN N
the DT N
first JJ N
day NN N
) ) N
, , N
group NN N
II NNP N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
received VBN N
Fansidar NNP 1_i
( ( 1_i
3 CD 1_i
tablets NNS 1_i
, , 1_i
75 CD 1_i
mg NN 1_i
of IN 1_i
pyrimethamine NN 1_i
and CC 1_i
1,500 CD 1_i
mg NN 1_i
of IN 1_i
sulfadoxine NN 1_i
, , N
a DT N
single JJ N
dose NN N
on IN N
the DT N
first JJ N
day NN N
) ) N
and CC N
then RB N
received VBD N
primaquine NN 1_i
( ( 1_i
30 CD 1_i
mg NN 1_i
a DT 1_i
day NN 1_i
for IN 1_i
14 CD 1_i
days NNS 1_i
) ) 1_i
, , N
group NN N
III NNP N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
received VBN 1_i
primaquine NN 1_i
( ( 1_i
30 CD 1_i
mg NN 1_i
a DT 1_i
day NN 1_i
for IN 1_i
14 CD 1_i
days NNS 1_i
) ) 1_i
, , N
and CC N
group NN N
IV NNP N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
received VBN 1_i
artesunate NN 1_i
( ( N
200 CD N
mg NN N
once RB N
a DT N
day NN N
for IN N
3 CD N
days NNS N
) ) N
and CC N
then RB N
primaquine VB 1_i
( ( N
30 CD N
mg NN N
a DT N
day NN N
for IN N
14 CD N
days NNS N
) ) N
. . N

Cure NN 1_o
rates NNS 1_o
on IN N
day NN N
28 CD N
of IN N
follow-up NN N
were VBD N
40 CD N
% NN N
, , N
100 CD N
% NN N
, , N
100 CD N
% NN N
, , N
and CC N
100 CD N
% NN N
in IN N
groups NNS N
I PRP N
, , N
II NNP N
, , N
II NNP N
, , N
and CC N
IV NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
4 CD N
and CC N
5 CD N
patients NNS N
in IN N
group NN N
I PRP N
showing VBG N
post-treatment JJ 1_o
reappearance NN 1_o
of IN 1_o
parasitemia NN 1_o
at IN N
< NNP N
or CC N
= VB N
16 CD N
days NNS N
and CC N
between IN N
17 CD N
and CC N
28 CD N
days NNS N
, , N
respectively RB N
. . N

Patients NNS N
in IN N
the DT N
other JJ N
3 CD N
groups NNS N
showed VBD N
negative JJ 1_o
parasitemias NN 1_o
within IN N
7 CD N
days NNS N
after IN N
treatment NN N
. . N

Artesunate NNP N
plus CC N
primaquine NN N
( ( N
group NN N
IV NNP N
) ) N
cleared VBD N
parasitemia NN 1_o
faster RBR N
than IN N
the DT N
other JJ N
3 CD N
regimens NNS N
. . N

There EX N
is VBZ N
a DT N
high JJ N
proportion NN N
of IN N
ineffectiveness NN 1_o
of IN N
Fansidar NNP N
for IN N
treatment NN N
of IN N
P. NNP N
vivax FW N
malaria NN N
and CC N
it PRP N
should MD N
be VB N
no RB N
longer RBR N
used VBN N
for IN N
treatment NN N
of IN N
P. NNP N
vivax FW N
malaria NN N
acquired VBD N
at IN N
the DT N
Thailand-Myanmar NNP N
border NN N
. . N

A DT N
high JJ N
dose NN N
of IN N
primaquine NN N
is VBZ N
safe JJ 1_o
and CC 1_o
effective JJ 1_o
in IN N
the DT N
treatment NN N
of IN N
P. NNP N
vivax FW N
malaria NN N
during IN N
the DT N
28-day JJ N
follow-up JJ N
period NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
prethrombolytic JJ 1_i
cyclosporine-A JJ 1_i
injection NN 1_i
on IN N
clinical JJ N
outcome NN N
of IN N
acute JJ 1_p
anterior JJ 1_p
ST-elevation NNP 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

INTRODUCTION NNP N
Reperfusion NNP N
injury NN N
reduces VBZ N
the DT N
benefits NNS N
of IN N
early JJ N
reperfusion NN N
therapies NNS N
after IN N
acute JJ N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
. . N

Cyclosporine-A NNP 1_i
( ( 1_i
CsA NNP 1_i
) ) 1_i
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
opening NN N
of IN N
the DT N
mitochondrial JJ N
permeability NN N
transition NN N
pore NN N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
play VB N
a DT N
key JJ N
role NN N
in IN N
myocardial JJ N
reperfusion NN N
injury NN N
. . N

The DT N
impact NN N
of IN N
this DT N
treatment NN N
on IN N
clinical JJ N
outcomes NNS N
of IN N
acute JJ N
STEMI NNP N
remains VBZ N
unknown JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
investigate VB N
the DT N
clinical JJ N
outcomes NNS N
of IN N
using VBG N
this DT N
drug NN N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
anterior JJ 1_p
STEMI NNP 1_p
receiving VBG 1_p
thrombolytic JJ 1_p
treatment NN 1_p
( ( 1_p
TLT NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
In IN N
this DT N
double-blinded JJ N
randomized JJ N
clinical JJ N
trial NN N
, , N
101 CD 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
anterior JJ 1_p
STEMI NNP 1_p
who WP 1_p
were VBD 1_p
candidate NN 1_p
for IN 1_p
TLT NNP 1_p
, , N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
into IN N
treatment NN N
or CC N
control NN N
groups NNS N
. . N

Patients NNS 1_i
in IN 1_i
the DT 1_i
treatment NN 1_i
group NN 1_i
received VBD 1_i
an DT 1_i
intravenous JJ 1_i
bolus NN 1_i
injection NN 1_i
of IN 1_i
2.5 CD 1_i
mg/kg NN 1_i
of IN 1_i
CsA NNP 1_i
immediately RB 1_i
before IN 1_i
TLT NNP 1_i
. . 1_i

The DT 1_i
patients NNS 1_i
in IN 1_i
the DT 1_i
control NN 1_i
group NN 1_i
received VBD 1_i
an DT 1_i
equivalent JJ 1_i
volume NN 1_i
of IN 1_i
normal JJ 1_i
saline NN 1_i
. . 1_i

Infarct NNP 1_o
size NN 1_o
, , 1_o
occurrence NN 1_o
of IN 1_o
major JJ 1_o
arrhythmias NNS 1_o
, , 1_o
heart NN 1_o
failure NN 1_o
, , 1_o
left VBD 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
( ( 1_o
LVEF NNP 1_o
) ) 1_o
, , 1_o
TLT-related JJ 1_o
complications NNS 1_o
, , 1_o
in-hospital JJ 1_o
and CC 1_o
6-month JJ 1_o
mortality NN 1_o
rates NNS 1_o
were VBD N
investigated VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
the DT N
demographics NNS 1_o
, , 1_o
myocardial JJ 1_o
enzyme NN 1_o
release NN 1_o
, , 1_o
occurrence NN 1_o
of IN 1_o
major JJ 1_o
arrhythmias NNS 1_o
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
12 CD N
( ( N
23.5 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.80 CD N
] NN N
, , N
heart NN 1_o
failure NN 1_o
[ VBZ N
18 CD N
( ( N
36 CD N
% NN N
) ) N
vs. FW N
19 CD N
( ( N
38.3 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.83 CD N
] NN N
, , N
LVEF NNP 1_o
at IN 1_o
first JJ 1_o
day NN 1_o
[ VB N
34.7 CD N
? . N
9.9 CD N
% NN N
vs. FW N
33.5 CD N
? . N
8.1 CD N
% NN N
, , N
P NNP N
= VBZ N
0.50 CD N
] NN N
or CC N
at IN N
discharge NN 1_o
[ $ 1_o
37.7 CD N
? . N
10 CD N
% NN N
vs. FW N
36.1 CD N
? . N
8.2 CD N
% NN N
, , N
P NNP N
= VBZ N
0.43 CD N
] NN N
, , N
and CC N
in-hospital JJ 1_o
[ NN 1_o
4 CD 1_o
( ( N
8 CD N
% NN N
) ) N
vs. FW N
6 CD N
( ( N
11.8 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.74 CD N
] NN 1_o
or CC 1_o
6-month JJ 1_o
mortality NN 1_o
rates NNS 1_o
[ VBP 1_o
9 CD 1_o
( ( N
18 CD N
% NN N
) ) N
vs. FW N
10 CD N
( ( N
19.6 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.99 CD N
] NN N
between IN N
the DT N
CsA NNP N
vs. IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
the DT N
prethrombolytic JJ N
administration NN N
of IN N
CsA NNP N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
infarct JJ 1_o
size NN 1_o
or CC 1_o
any DT N
improvement NN N
in IN N
clinical JJ N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Dihydroergocryptine NN 1_i
in IN N
the DT N
management NN N
of IN N
senile JJ 1_p
psycho-organic JJ 1_p
syndrome NN 1_p
. . 1_p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
randomized JJ N
study NN N
is VBZ N
described VBN N
of IN N
an DT N
assessment NN N
of IN N
the DT N
efficacy NN 1_o
and CC 1_o
relative JJ 1_o
safety NN 1_o
of IN N
the DT N
ergot NN N
alkaloid NN N
, , N
dihydroergocryptine NN 1_i
, , N
on IN N
52 CD 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
organic JJ 1_p
brain NN 1_p
syndrome NN 1_p
over IN 1_p
a DT 1_p
period NN 1_p
of IN 1_p
three CD 1_p
months NNS 1_p
using VBG 1_p
a DT 1_p
series NN 1_p
of IN 1_p
neurophysiological JJ 1_o
tests NNS 1_o
. . 1_o

The DT N
results NNS N
indicated VBD N
that IN N
short-term JJ N
treatment NN N
with IN N
the DT N
alkaloid NN N
improved VBD N
memory NN 1_o
impairment NN 1_o
. . 1_o

The DT N
side-effects NNS 1_o
were VBD N
mild JJ N
and CC N
transient NN N
in IN N
both CC N
the DT N
dihydroergocryptine NN 1_i
and CC N
placebo NN N
groups NNS N
and CC N
there EX N
were VBD N
no DT N
alterations NNS 1_o
in IN 1_o
blood NN 1_o
chemistry NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
pain-free JJ 1_i
treadmill NN 1_i
training VBG 1_i
on IN N
fibrinogen NN N
, , N
haematocrit NN N
, , N
and CC N
lipid JJ N
profile NN N
in IN N
patients NNS 1_p
with IN 1_p
claudication NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effect NN N
of IN N
pain-free JJ 1_i
treadmill NN 1_i
training VBG 1_i
on IN N
changes NNS N
of IN N
plasma NN 1_o
fibrinogen NN 1_o
, , 1_o
haematocrit NN 1_o
, , 1_o
lipid JJ 1_o
profile NN 1_o
, , 1_o
and CC 1_o
walking VBG 1_o
ability NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
claudication NN 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
control NN N
trial NN N
. . N

METHODS NNP N
Sixty-eight JJ 1_p
patients NNS 1_p
with IN 1_p
peripheral JJ 1_p
obstructive JJ 1_p
arterial JJ 1_p
disease NN 1_p
and CC 1_p
intermittent JJ 1_p
claudication NN 1_p
( ( 1_p
Fontaine NNP 1_p
stage NN 1_p
II NNP 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
into IN N
the DT N
treadmill NN 1_i
training NN 1_i
( ( N
repetitive JJ N
intervals NNS N
to TO N
onset VB N
of IN N
claudication NN N
pain NN N
, , N
three CD N
times NNS N
a DT N
week NN N
) ) N
or CC N
a DT N
control NN 1_i
group NN 1_i
( ( 1_i
no DT 1_i
change NN 1_i
in IN 1_i
physical JJ 1_i
activity NN 1_i
) ) 1_i
over IN N
3 CD N
months NNS N
. . N

Both DT N
groups NNS N
performed VBD N
treadmill JJ 1_i
test NN N
to TO N
assess VB N
pain-free JJ 1_o
walking NN 1_o
time NN 1_o
( ( 1_o
PFWT NNP 1_o
) ) 1_o
and CC 1_o
maximal JJ 1_o
walking NN 1_o
time NN 1_o
( ( 1_o
MWT NNP 1_o
) ) 1_o
and CC 1_o
had VBD 1_o
blood NN 1_o
analyses NNS 1_o
[ VBP 1_o
for IN 1_o
haematocrit NN 1_o
, , 1_o
fibrinogen NN 1_o
, , 1_o
triglycerides NNS 1_o
, , 1_o
and CC 1_o
cholesterol NN 1_o
: : 1_o
total JJ 1_o
, , 1_o
high-density JJ 1_o
lipoprotein NN 1_o
( ( 1_o
HDL NNP 1_o
) ) 1_o
and CC 1_o
low-density JJ 1_o
lipoprotein NN 1_o
( ( 1_o
LDL NNP 1_o
) ) 1_o
] VBD 1_o
done VBN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
and CC N
12 CD N
weeks NNS N
of IN N
the DT N
study NN N
. . N

RESULTS NNP N
Total NNP 1_o
and CC 1_o
LDL NNP 1_o
cholesterol NN 1_o
levels NNS 1_o
in IN 1_o
the DT 1_o
training NN 1_o
group NN 1_o
decreased VBD 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
14.8 CD N
% NN N
and CC N
20,5 CD N
% NN N
, , N
respectively RB N
. . N

Significant NNP N
( ( N
p JJ N
< NNP N
0.05 CD 1_o
) ) 1_o
HDL NNP 1_o
cholesterol NN 1_o
increased VBD 1_o
( ( 1_o
14.6 CD 1_o
% NN 1_o
) ) 1_o
and CC 1_o
triglycerides NNS 1_o
decreased VBN 1_o
( ( 1_o
19 CD 1_o
% NN 1_o
) ) 1_o
in IN 1_o
the DT N
training NN N
group NN N
but CC N
changes NNS N
of IN N
all PDT N
these DT N
lipids NNS N
were VBD N
insignificant JJ N
in IN N
the DT N
control NN N
group NN N
over IN N
the DT N
3 CD N
months NNS N
. . N

Haematocrit NNP 1_o
and CC 1_o
fibrinogen NN 1_o
changes NNS 1_o
were VBD N
insignificant JJ N
in IN N
both DT N
groups NNS N
. . N

PFWT NNP 1_o
was VBD 1_o
prolonged VBN N
by IN N
109 CD N
% NN N
and CC N
MWT NNP 1_o
increased VBN N
by IN N
54 CD N
% NN N
in IN N
the DT N
training NN N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
The DT N
improvement NN N
in IN N
walking VBG N
time NN N
over IN N
3 CD N
months NNS N
of IN N
pain-free JJ 1_i
treadmill NN 1_i
training NN 1_i
parallels NNS 1_i
with IN N
progressive JJ N
normalization NN N
of IN N
lipid JJ N
profiles NNS N
in IN N
patients NNS 1_p
with IN 1_p
claudication NN 1_p
. . 1_p

-DOCSTART- -X- O O

Controlled VBN N
prospective JJ N
trial NN N
of IN N
prednisolone NN 1_i
and CC 1_i
cytotoxics NNS 1_i
in IN N
progressive JJ 1_p
IgA NNP 1_p
nephropathy NN 1_p
. . 1_p

In IN N
a DT N
single-center JJ N
, , N
multiple-referral JJ N
source NN N
study NN N
, , N
38 CD 1_p
patients NNS 1_p
with IN 1_p
progressive JJ 1_p
IgA NNP 1_p
nephropathy NN 1_p
and CC 1_p
controlled VBN 1_p
hypertension NN 1_p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
prednisolone NN 1_i
and CC 1_i
cytotoxic NN 1_i
agents NNS 1_i
, , N
to TO N
therapy VB N
with IN N
low-dose JJ 1_i
cyclophosphamide NN 1_i
then RB 1_i
azathioprine VB 1_i
, , 1_i
and CC 1_i
to TO 1_i
control VB 1_i
groups NNS 1_i
. . 1_i

The DT N
follow-up JJ N
period NN N
lasted VBD N
2 CD N
to TO N
6 CD N
yr. JJ N
Renal NNP N
survival NN N
, , N
as IN N
assessed VBN N
by IN N
Kaplan-Meier NNP N
analysis NN N
annually RB N
to TO N
5 CD N
yr NN N
, , N
showed VBD N
significant JJ N
preservation NN N
of IN N
function NN N
from IN N
3 CD N
yr NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
82 CD N
, , N
82 CD N
, , N
72 CD N
, , N
and CC N
72 CD N
% NN N
for IN N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
and CC N
5 CD N
yr NN N
, , N
respectively RB N
, , N
compared VBN N
with IN N
68 CD N
, , N
47 CD N
, , N
26 CD N
, , N
and CC N
6 CD N
% NN N
in IN N
controls NNS N
. . N

Rate NNP N
of IN N
loss NN 1_o
of IN 1_o
renal JJ 1_o
function NN 1_o
, , N
evaluated VBN N
objectively RB N
by IN N
least-squares JJ 1_o
analyses NNS 1_o
of IN 1_o
reciprocal JJ 1_o
serum NN 1_o
creatinine NN 1_o
, , N
was VBD N
reduced-and NN N
in IN N
one-third NN N
of IN N
the DT N
patients NNS N
, , N
arrested-during JJ N
immunosuppressive JJ N
treatment NN N
. . N

Proteinuria NNP 1_o
, , 1_p
present NN 1_p
in IN 1_p
all DT 1_p
patients NNS 1_p
at IN 1_p
the DT 1_p
time NN 1_p
of IN 1_p
entry NN 1_p
into IN 1_p
the DT 1_p
trial NN 1_p
, , N
was VBD N
reduced VBN N
by IN N
treatment NN N
from IN N
12 CD N
mo NN N
, , N
compared VBN N
with IN N
pretreatment NN 1_o
levels NNS 1_o
or CC 1_o
controls NNS 1_o
; : 1_o
erythrocyturia NN 1_o
was VBD N
reduced VBN N
from IN N
6 CD N
mo NN N
. . N

Histologic NNP 1_o
activity NN 1_o
and CC 1_o
chronicity NN 1_o
indexes NNS 1_o
were VBD N
determined VBN N
in IN N
renal JJ N
biopsies NNS N
performed VBN N
at IN N
trial NN N
entry NN N
. . N

Multivariate NNP 1_o
analysis NN 1_o
demonstrated VBD N
that IN N
mesangial JJ 1_o
cell NN 1_o
proliferation NN 1_o
and CC 1_o
matrix NN 1_o
scores NNS 1_o
were VBD N
highest JJS N
in IN N
those DT N
patients NNS N
with IN N
more RBR N
rapidly RB N
progressive JJ N
disease NN N
. . N

No DT N
morphologic JJ 1_o
variable NN 1_o
or CC 1_o
residual JJ 1_o
renal JJ 1_o
function NN 1_o
predicted VBD N
response NN N
to TO N
immunosuppressive JJ N
therapy NN N
at IN N
entry NN N
. . N

Mean NNP 1_o
arterial JJ 1_o
pressures NNS 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
treatment NN N
and CC N
control NN N
groups NNS N
. . N

There EX N
was VBD N
thus RB N
no DT N
explanation NN N
other JJ N
than IN N
treatment NN N
for IN N
the DT N
improved JJ N
outcome NN N
in IN N
patients NNS N
who WP N
received VBD N
immunosuppressive JJ N
therapy NN N
. . N

Morbidity NNP 1_o
attributable JJ N
to TO N
treatment NN N
or CC N
to TO N
renal JJ 1_o
failure NN 1_o
occurred VBD N
in IN N
both DT N
groups NNS N
; : N
an DT N
audit NN N
showed VBD N
that IN N
benefits NNS 1_o
of IN 1_o
therapy NN 1_o
outweighed VBN N
expected VBD N
or CC N
minor JJ N
side NN N
effects NNS N
of IN N
drugs NNS N
in IN N
this DT N
population NN N
at IN N
risk NN N
of IN N
end-stage JJ N
renal JJ N
failure NN N
. . N

Patients NNS 1_p
selected VBN 1_p
for IN 1_p
moderately RB 1_p
progressive JJ 1_o
IgA NNP 1_o
nephropathy JJ 1_o
benefit NN N
from IN N
treatment NN N
with IN N
prednisolone NN 1_i
and CC N
cytotoxic NN 1_i
agents NNS 1_i
; : 1_i
results NNS N
are VBP N
consistent JJ N
with IN N
modulation NN 1_o
of IN 1_o
systemic JJ 1_o
immune JJ 1_o
response NN 1_o
or CC 1_o
nephritic JJ 1_o
injury NN 1_o
, , N
thus RB N
explaining VBG N
improved VBN N
outcome NN N
, , N
and CC N
indicate VBP N
that IN N
this DT N
therapy NN N
has VBZ N
an DT N
acceptably RB N
low JJ N
risk NN N
of IN N
side NN 1_o
effects NNS 1_o
. . 1_o

-DOCSTART- -X- O O

There EX N
is VBZ N
no DT N
sweet JJ N
escape NN N
from IN N
social JJ N
pain NN N
: : N
glucose NN N
does VBZ N
not RB N
attenuate VB N
the DT N
effects NNS 1_p
of IN 1_p
ostracism NN 1_p
. . 1_p

Ostracism NN N
causes VBZ N
social JJ N
pain NN N
and CC N
is VBZ N
known VBN N
to TO N
activate VB N
regions NNS N
of IN N
the DT N
brain NN N
that WDT N
are VBP N
involved VBN N
in IN N
the DT N
representation NN N
of IN N
physical JJ N
pain NN N
. . N

Previous JJ N
research NN N
has VBZ N
observed VBN N
that IN N
acetominophen NN 1_i
( ( N
a DT N
common JJ N
pain NN N
reliever NN N
) ) N
can MD N
reduce VB N
the DT N
pain NN N
of IN N
exclusion NN N
. . N

The DT N
taste NN N
and CC N
consumption NN N
of IN N
glucose NN N
can MD N
also RB N
relieve VB N
physical JJ N
pain NN N
, , N
and CC N
the DT N
purpose NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
examine VB N
whether IN N
it PRP N
might MD N
also RB N
reduce VB N
the DT N
negative JJ 1_o
emotional JJ 1_o
effects NNS 1_o
of IN 1_o
ostracism NN 1_o
. . 1_o

In IN N
an DT N
appropriately RB N
powered JJ N
experiment NN N
, , N
participants NNS 1_p
were VBD 1_p
given VBN 1_p
25g CD 1_i
of IN 1_i
glucose NN 1_i
or CC 1_i
a DT 1_i
sucralose JJ 1_i
placebo NN 1_i
before IN 1_p
being VBG 1_p
ostracized VBN 1_p
while IN 1_p
playing VBG 1_p
Cyberball NNP 1_p
. . 1_p

Strong NNP N
effects NNS N
of IN N
ostracism NN N
were VBD N
observed VBN N
, , N
however RB N
, , N
there EX N
was VBD N
no DT N
effect NN N
of IN N
glucose NN 1_o
on IN N
immediate JJ 1_o
or CC 1_o
delayed VBN 1_o
self-reported JJ 1_o
needs NNS 1_o
or CC 1_o
mood NN 1_o
. . 1_o

These DT N
results NNS N
are VBP N
discussed VBN N
in IN N
reference NN N
to TO N
the DT N
possibility NN N
that IN N
social JJ N
pain NN N
is VBZ N
unlike IN N
physical JJ N
pain NN N
since IN N
the DT N
latter NN N
is VBZ N
affected VBN N
by IN N
glucose NN N
, , N
which WDT N
is VBZ N
believed VBN N
to TO N
lessen VB N
pain NN N
by IN N
increasing VBG N
endogenous JJ N
opioid NN N
activity NN N
. . N

-DOCSTART- -X- O O

Double NNP N
hearing NN N
protection NN N
and CC N
speech NN N
intelligibility-room NN N
for IN N
improvement NN N
. . N

INTRODUCTION NNP N
Double NNP N
hearing NN N
protection NN N
is VBZ N
used VBN N
in IN N
many JJ N
air NN N
forces NNS N
around IN N
the DT N
world NN N
for IN N
protection NN N
in IN N
noisy NN N
aircraft NN N
environments NNS N
, , N
particularly RB N
in IN N
helicopters NNS N
. . N

The DT N
usual JJ N
combination NN N
is VBZ N
foam JJ N
ear JJ N
plugs NNS N
under IN N
headset NN N
or CC N
helmet JJ N
muffs NNS N
. . N

Much RB N
of IN N
the DT N
research NN N
that WDT N
spurred VBD N
the DT N
introduction NN N
of IN N
foam NN N
earplugs NNS N
indicated VBD N
little JJ N
change NN N
in IN N
speech NN N
intelligibility NN N
in IN N
persons NNS N
with IN N
normal JJ N
hearing NN N
. . N

However RB N
, , N
aircrew VBD N
often RB N
complain VBP N
about IN N
having VBG N
to TO N
maximize VB N
intercom JJ N
volume NN N
for IN N
speech NN N
understanding NN N
, , N
causing VBG N
a DT N
situation NN N
with IN N
no DT N
reserve NN N
volume NN N
and CC N
bad JJ N
sound NN N
quality NN N
. . N

In IN N
recent JJ N
years NNS N
, , N
further JJ N
developments NNS N
have VBP N
included VBN N
so-called JJ N
hi-fi JJ N
plugs NNS N
and CC N
custom NN N
made VBD N
ear NN N
plugs NNS N
which WDT N
are VBP N
claimed VBN N
to TO N
improve VB N
speech NN N
communication NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
project NN N
was VBD N
to TO N
investigate VB N
different JJ N
types NNS N
of IN N
ear NN N
plugs NNS N
and CC N
their PRP$ N
effect NN N
on IN N
speech NN N
intelligibility NN N
in IN N
helicopter NN N
noise NN N
. . N

METHODS NNP N
Each DT 1_p
of IN 1_p
nine CD 1_p
normal-hearing JJ 1_p
pilot NN 1_p
subjects NNS 1_p
were VBD 1_p
placed VBN 1_p
in IN N
an DT 1_i
environment NN 1_i
of IN 1_i
recorded VBN 1_i
helicopter NN 1_i
noise NN 1_i
from IN 1_i
a DT 1_i
BO-105 JJ 1_i
helicopter NN 1_i
. . 1_i

Speech NNP 1_i
audiometry NN 1_i
was VBD 1_i
performed VBN 1_i
under IN 1_i
four CD 1_i
different JJ 1_i
conditions NNS 1_i
: : 1_i
headset NN 1_i
only RB 1_i
, , 1_i
and CC 1_i
three CD 1_i
different JJ 1_i
ear NN 1_i
plugs NNS 1_i
worn VBN 1_i
under IN 1_i
the DT 1_i
headset NN 1_i
. . 1_i

Fitting NN 1_i
of IN 1_i
the DT 1_i
ear JJ 1_i
plugs NN 1_i
was VBD 1_i
performed VBN 1_i
by IN 1_i
an DT 1_i
ear NN 1_i
, , 1_i
nose JJ 1_i
and CC 1_i
throat JJ 1_i
specialist NN 1_i
to TO 1_i
ensure VB 1_i
similar JJ 1_i
conditions NNS 1_i
. . 1_i

The DT N
sequence NN N
of IN N
test NN N
conditions NNS N
was VBD N
randomized VBN N
and CC N
double-blind JJ N
. . N

In IN N
addition NN N
, , N
a DT N
subjective JJ 1_o
rating NN 1_o
scale NN 1_o
was VBD N
used VBN N
. . N

RESULTS NNP N
Wearing NNP N
foam JJ N
ear NN N
plugs NNS N
under IN N
the DT N
headset NN N
decreased VBD N
speech JJ 1_o
intelligibility NN 1_o
dramatically RB N
. . N

The DT N
hi-fi JJ N
plug NN N
was VBD N
somewhat RB N
better JJR N
than IN N
foam NN N
plugs NNS N
, , N
and CC N
the DT N
custom NN N
made VBD N
ear JJ N
plug NN N
provided VBD N
a DT N
speech NN 1_o
intelligibility NN 1_o
close RB N
to TO N
the DT N
headset-only JJ N
situation NN N
. . N

Subjective JJ 1_o
rating NN 1_o
scores NNS 1_o
coincided VBD N
with IN N
these DT N
findings NNS N
. . N

DISCUSSION NNP N
In IN N
helicopter NN N
noise NN N
, , N
custom NN N
made VBD N
ear JJ N
plugs NNS N
may MD N
provide VB N
a DT N
much RB N
improved VBN N
speech JJ 1_o
intelligibility NN 1_o
over IN N
conventional JJ N
plugs NNS N
when WRB N
worn VBN N
under IN N
a DT N
headset NN N
, , N
while IN N
maintaining VBG N
improved JJ N
noise NN 1_o
protection NN 1_o
over IN N
the DT N
headset-alone JJ N
situation NN N
. . N

Custom NNP N
made VBD N
ear JJ N
plugs NNS N
might MD N
therefore RB N
be VB N
a DT N
good JJ N
alternative NN N
to TO N
other JJ N
forms NNS N
of IN N
enhanced JJ 1_o
noise NN 1_o
protection NN 1_o
in IN N
helicopters NNS N
. . N

-DOCSTART- -X- O O

Effect NNP N
of IN N
four CD 1_i
intermediate JJ 1_i
layer NN 1_i
treatments NNS 1_i
on IN N
microleakage NN 1_p
of IN 1_p
Class NNP 1_p
II NNP 1_p
composite JJ 1_p
restorations NNS 1_p
. . 1_p

This DT N
in IN N
vitro NN N
study NN N
examines VBZ N
the DT N
marginal JJ N
sealing NN N
ability NN N
of IN N
four CD 1_i
different JJ 1_i
intermediate JJ 1_i
materials NNS 1_i
applied VBN N
before IN N
placement NN N
of IN N
a DT N
condensable JJ 1_i
composite NN 1_i
. . 1_i

Class NNP 1_p
II NNP 1_p
preparations NNS 1_p
were VBD N
made VBN N
with IN N
gingival JJ N
margins NNS N
placed VBD N
1.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
cementoenamel JJ N
junction NN N
of IN N
60 CD 1_p
extracted JJ 1_p
teeth NNS 1_p
, , N
randomly RB N
assigned VBN N
to TO N
five CD 1_p
groups NNS 1_p
of IN 1_p
12 CD 1_p
. . 1_p

Following VBG N
restoration NN N
, , N
teeth EX N
were VBD N
thermocycled VBN N
, , N
soaked VBN N
in IN N
0.5 CD N
% NN N
basic JJ N
fuchsin NN 1_i
, , N
and CC N
sectioned VBD N
longitudinally RB N
. . N

The DT N
resin-modified JJ 1_i
glass NN 1_i
ionomer NN 1_i
cement NN 1_i
demonstrated VBD N
significantly RB N
less JJR 1_o
microleakage NN 1_o
than IN N
the DT N
use NN N
of IN N
a DT N
dentin NN 1_i
bonding NN 1_i
agent NN 1_i
alone RB 1_i
or CC N
in IN N
combination NN 1_i
with IN 1_i
flowable JJ 1_i
composite JJ 1_i
, , N
flowable JJ N
compomer NN N
, , N
or CC N
autoploymerizing VBG N
composite JJ N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
Dunn NNP N
's POS N
test NN N
) ) N
. . N

This DT N
study NN N
supports VBZ N
the DT N
use NN N
of IN N
the DT N
glass NN 1_i
ionomer NN 1_i
open JJ 1_i
sandwich NN 1_i
technique NN 1_i
in IN N
deep JJ 1_p
Class NNP 1_p
II NNP 1_p
direct JJ 1_p
composite JJ 1_p
restorations NNS 1_p
. . 1_p

-DOCSTART- -X- O O

The DT N
relative JJ N
contributions NNS N
of IN N
medication NN 1_i
adherence NN 1_i
and CC 1_i
AA NNP 1_i
meeting NN 1_i
attendance NN 1_i
to TO N
abstinent VB N
outcome NN N
for IN N
chronic JJ 1_p
alcoholics NNS 1_p
. . 1_p

Our PRP$ N
preliminary JJ N
studies NNS N
of IN N
the DT N
efficacy NN N
of IN N
lithium NN 1_i
carbonate NN 1_i
therapy NN 1_i
for IN N
alcoholism NN N
under IN N
double-blind NN N
, , N
placebo-controlled JJ N
conditions NNS N
demonstrated VBD N
that IN N
alcoholics NNS 1_p
who WP 1_p
took VBD 1_p
their PRP$ 1_p
assigned JJ 1_p
medication NN 1_p
( ( 1_i
lithium NN 1_i
or CC 1_i
placebo NN 1_i
) ) 1_i
for IN 1_p
the DT 1_p
first JJ 1_p
6 CD 1_p
months NNS 1_p
after IN 1_p
discharge NN 1_p
from IN 1_p
an DT 1_p
inpatient JJ 1_p
rehabilitation NN 1_p
program NN 1_p
were VBD N
more RBR N
likely JJ N
to TO N
abstain VB N
from IN N
any DT N
alcohol NN N
use NN N
for IN N
18 CD N
months NNS N
following VBG N
discharge NN N
than IN N
were VBD N
alcoholics NNS 1_p
who WP 1_p
took VBD 1_p
their PRP$ 1_p
medication NN 1_p
erratically RB 1_p
or CC 1_p
not RB 1_p
at IN 1_p
all DT 1_p
. . 1_p

Attendance NN 1_p
at IN 1_p
Alcoholics NNP 1_p
Anonymous NNP 1_p
( ( 1_p
AA NNP 1_p
) ) 1_p
meetings NNS 1_p
was VBD N
also RB N
associated VBN N
with IN N
medication NN N
adherence NN N
. . N

We PRP N
applied VBD N
a DT N
structural JJ N
equation NN N
model NN N
to TO N
data NNS N
on IN N
the DT N
relationships NNS N
between IN N
medication NN N
adherence NN N
, , N
AA NNP N
meeting NN N
attendance NN N
and CC N
abstinent JJ 1_o
outcome NN 1_o
to TO N
clarify VB N
whether IN N
medication NN N
adherence NN N
or CC N
AA NNP N
meeting NN N
attendance NN N
better RBR N
explains VBZ N
the DT N
positive-outcome JJ N
adherence NN 1_o
effect NN N
we PRP N
observed VBD N
. . N

Both DT N
medication NN N
adherence NN N
and CC N
AA NNP N
meeting NN N
attendance NN N
evidenced VBD N
direct JJ N
and CC N
independent JJ N
influences NNS N
on IN N
abstinent JJ N
outcome NN N
: : N
medication NN N
adherence NN N
showed VBD N
a DT N
small JJ N
direct JJ N
influence NN N
, , N
and CC N
AA NNP N
meeting NN N
attendance NN N
showed VBD N
a DT N
much RB N
larger JJR N
, , N
independent JJ N
influence NN N
. . N

-DOCSTART- -X- O O

Different NNP N
therapeutic JJ N
modalities NNS N
for IN N
treatment NN N
of IN N
melasma NN 1_o
. . 1_o

BACKGROUND NNP N
Chemical NNP 1_i
peels NNS 1_i
and CC N
topical JJ 1_i
depigmenting NN 1_i
agents NNS 1_i
have VBP N
become VBN N
a DT N
popular JJ N
modality NN N
in IN N
the DT N
treatment NN N
of IN N
melasma NN 1_o
. . 1_o

AIMS NNP N
To TO N
compare VB N
the DT N
clinical JJ 1_o
efficacy NN 1_o
of IN N
trichloroacetic JJ 1_i
acid NN 1_i
peel VB 1_i
20 CD 1_i
% NN 1_i
vs NN 1_i
. . N

Jessner NNP 1_i
's POS 1_i
solution NN 1_i
peel NN 1_i
vs. IN 1_i
the DT 1_i
topical JJ 1_i
mixture NN 1_i
of IN 1_i
hydroquinone NN 1_i
2 CD 1_i
% NN 1_i
and CC 1_i
kojic NN 1_i
acid NN 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty NNP 1_p
five CD 1_p
patients NNS 1_p
with IN 1_p
melasma NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
into IN 1_p
three CD 1_p
groups NNS 1_p
of IN 1_p
fifteen JJ 1_p
patients NNS 1_p
each DT 1_p
. . 1_p

Group NNP N
A NNP N
received VBD N
Jessner NNP 1_i
's POS 1_i
solution NN 1_i
peel NN 1_i
, , N
group NN N
B NNP N
received VBD N
trichloroacetic JJ 1_i
acid NN 1_i
peel VB 1_i
20 CD 1_i
% NN 1_i
, , N
and CC N
group NN N
C NNP N
received VBD N
topical JJ 1_i
hydroquinone NN 1_i
2 CD 1_i
% NN 1_i
and CC 1_i
kojic NN 1_i
acid NN 1_i
. . 1_i

All DT N
patients NNS N
were VBD N
seen VBN N
in IN N
follow-up JJ N
period NN N
after IN N
16 CD N
weeks NNS N
; : N
clinical JJ N
evaluation NN N
using VBG N
Melasma NNP 1_o
Area NNP 1_o
and CC 1_o
Severity NNP 1_o
Index NNP 1_o
( ( 1_o
MASI NNP 1_o
) ) 1_o
score NN 1_o
and CC 1_o
photography NN 1_o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
treatment NN N
and CC N
after IN N
16 CD N
weeks NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
decrease NN N
in IN N
MASI NNP 1_o
score NN 1_o
in IN N
all DT N
three CD N
groups NNS N
after IN N
treatment NN N
and CC N
after IN N
follow-up JJ N
period NN N
but CC N
after IN N
treatment NN N
MASI NNP 1_o
score NN 1_o
was VBD N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
it PRP N
was VBD N
also RB N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

After IN N
the DT N
follow-up JJ N
period NN N
, , N
MASI NNP 1_o
score NN 1_o
was VBD N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
A NNP N
( ( N
P NNP N
= NNP N
0.035 CD N
) ) N
. . N

The DT N
statistical JJ N
analysis NN N
was VBD N
done VBN N
through IN N
one-way JJ N
anova NN N
followed VBN N
by IN N
least JJS N
significant JJ N
difference NN N
( ( N
LSD NNP N
) ) N
. . N

CONCLUSION NNP N
Trichloroacetic NNP 1_i
acid VBD 1_i
20 CD 1_i
% NN 1_i
showed VBD N
better JJR N
results NNS N
than IN N
Jessner NNP 1_i
's POS 1_i
solution NN 1_i
as IN N
peeling NN N
agent NN N
and CC N
hydroquinone VB 1_i
2 CD 1_i
% NN 1_i
with IN 1_i
kojic JJ 1_i
acid NN 1_i
as IN N
a DT N
topical JJ N
agent NN N
in IN N
the DT N
treatment NN 1_o
of IN 1_o
melasma NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
effect NN 1_o
of IN N
posture NN 1_i
on IN N
Cheyne-Stokes NNP N
respirations NNS N
and CC N
hemodynamics NNS N
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

STUDY NNP N
OBJECTIVES NNP N
Cheyne-Stokes NNP N
respirations NNS N
occur VBP N
in IN N
40 CD N
% NN N
of IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

Orthopnea NNP N
is VBZ N
a DT N
cardinal JJ N
symptom NN N
of IN N
heart NN N
failure NN N
and CC N
may MD N
affect VB N
the DT N
patient NN N
's POS N
sleeping VBG N
angle NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB 1_o
the DT 1_o
respiratory NN 1_o
and CC 1_o
hemodynamic JJ 1_o
response NN 1_o
to TO N
sleeping VBG 1_i
angle NN 1_i
in IN N
a DT N
group NN 1_p
of IN 1_p
subjects NNS 1_p
with IN 1_p
stable JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

DESIGN NNP N
Twenty-five JJ 1_p
patients NNS 1_p
underwent JJ N
overnight JJ N
polysomnography NN N
with IN N
simultaneous JJ N
and CC N
continuous JJ N
impedance NN N
cardiographic JJ N
monitoring NN N
. . N

Sleeping VBG 1_o
polysomnographic JJ 1_o
and CC 1_o
impedance JJ 1_o
cardiographic JJ 1_o
data NNS 1_o
were VBD N
recorded VBN N
. . N

SETTING VBG N
The DT N
study NN N
was VBD N
conducted VBN N
in IN N
a DT N
sleep JJ N
center NN N
. . N

PATIENTS VB N
All DT 1_p
25 CD 1_p
patients NNS 1_p
had VBD 1_p
clinically RB 1_p
stable JJ 1_p
heart NN 1_p
failure NN 1_p
and CC 1_p
left VBD 1_p
ventricular JJ 1_p
ejection NN 1_p
fractions NNS 1_p
< VBP 1_p
40 CD 1_p
% NN 1_p
. . 1_p

INTERVENTIONS NNP N
The DT N
patients NNS N
slept VBD 1_i
at IN 1_i
0 CD 1_i
degrees NNS 1_i
, , 1_i
15 CD 1_i
degrees NNS 1_i
, , 1_i
30 CD 1_i
degrees NNS 1_i
, , 1_i
and CC 1_i
45 CD 1_i
degrees NNS 1_i
in IN 1_i
random JJ 1_i
order NN 1_i
. . 1_i

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Seventeen NNP N
patients NNS N
had VBD N
Cheyne-Stokes NNP 1_o
apneas NNS 1_o
( ( N
index NN N
> RB N
5/h CD N
) ) N
and CC N
23 CD N
patients NNS N
had VBD N
hypopneas NNS 1_o
( ( N
index NN N
> RB N
5/h CD N
) ) N
. . N

The DT N
hypopnea NN 1_o
index NN 1_o
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG N
angle NN N
. . N

The DT N
Cheyne-Stokes NNP 1_o
apnea NN 1_o
index NN 1_o
decreased VBD N
with IN N
increasing VBG N
sleeping VBG N
angle NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

This DT N
effect NN N
was VBD N
seen VBN N
only RB N
during IN N
supine JJ N
sleep NN N
and CC N
non-rapid JJ N
eye NN N
movement NN N
sleep NN N
and CC N
was VBD N
absent VBN N
in IN N
non-supine JJ N
sleep NN N
, , N
rapid JJ N
eye NN N
movement NN N
sleep NN N
, , N
and CC N
during IN N
periods NNS N
of IN N
wakefulness NN N
. . N

Thoracic NNP 1_o
fluid NN 1_o
content NN 1_o
index NN 1_o
and CC 1_o
left VBD 1_o
ventricular JJ 1_o
hemodynamics NNS 1_o
measured VBN N
by IN N
impedance NN N
cardiography NN N
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG N
angle NN N
. . N

CONCLUSIONS NNP N
Changing VBG N
the DT N
heart NN N
failure NN N
patient NN N
's POS N
sleeping VBG N
angle NN N
from IN N
0 CD N
degrees NNS N
to TO N
45 CD N
degrees NNS N
results NNS N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
Cheyne-Stokes NNP N
apneas NN N
. . N

This DT N
decrease NN N
occurs VBZ N
on IN N
a DT N
constant JJ N
base NN N
of IN N
hypopneas NNS N
. . N

The DT N
changes NNS N
in IN N
Cheyne-Stokes NNP N
apneas NNS N
are VBP N
not RB N
related VBN N
to TO N
changes NNS N
in IN N
lung NN N
congestion NN N
and CC N
left VBD N
ventricular JJ N
hemodynamics NNS N
. . N

-DOCSTART- -X- O O

Auditory NNP 1_i
integration NN 1_i
training NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_o
: : 1_o
no DT N
behavioral JJ N
benefits NNS N
detected VBN N
. . N

Auditory NNP 1_i
integration NN 1_i
training NN 1_i
and CC 1_i
a DT 1_i
control NN 1_i
treatment NN 1_i
were VBD N
provided VBN N
for IN N
16 CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_o
in IN N
a DT N
crossover NN N
experimental JJ N
design NN N
. . N

Measures NNS N
, , N
blind NN N
to TO N
treatment NN N
order NN N
, , N
included VBD N
parent NN 1_o
and CC 1_o
teacher JJ 1_o
ratings NNS 1_o
of IN 1_o
behavior NN 1_o
, , 1_o
direct JJ 1_o
observational JJ 1_o
recordings NNS 1_o
, , 1_o
IQ NNP 1_o
, , 1_o
language NN 1_o
, , 1_o
and CC 1_o
social/adaptive JJ 1_o
tests NNS 1_o
. . 1_o

Significant JJ 1_o
differences NNS 1_o
tended VBD N
to TO N
show VB N
that IN N
the DT N
control NN N
condition NN N
was VBD N
superior JJ 1_o
on IN 1_o
parent-rated JJ 1_o
measures NNS 1_o
of IN 1_o
hyperactivity NN 1_o
and CC 1_o
on IN 1_o
direct JJ 1_o
observational JJ 1_o
measures NNS 1_o
of IN 1_o
ear-occlusion NN 1_o
. . 1_o

No DT 1_o
differences NNS 1_o
were VBD N
detected VBN N
on IN N
teacher-rated JJ 1_o
measures NNS 1_o
. . 1_o

Children NNP 1_o
's POS 1_o
IQs NNP 1_o
and CC 1_o
language NN 1_o
comprehension NN 1_o
did VBD 1_o
not RB 1_o
increase VB 1_o
, , N
but CC N
adaptive/social JJ 1_o
behavior NN 1_o
scores NNS 1_o
and CC 1_o
expressive JJ 1_o
language NN 1_o
quotients NNS 1_o
decreased VBN 1_o
. . 1_o

The DT N
majority NN N
of IN N
parents NNS 1_p
( ( N
56 CD N
% NN N
) ) N
were VBD N
unable JJ 1_o
to TO 1_o
report VB 1_o
in IN 1_o
retrospect NN 1_o
when WRB N
their PRP$ N
child NN N
had VBD N
received VBN N
auditory JJ 1_i
integration NN 1_i
training NN 1_i
. . 1_i

No DT 1_o
individual JJ N
child NN 1_p
was VBD N
identified VBN N
as IN N
benefiting VBG 1_o
clinically RB 1_o
or CC 1_o
educationally RB 1_o
from IN N
the DT N
treatment NN N
. . N

-DOCSTART- -X- O O

[ JJ 1_i
Radiotherapy NNP 1_i
for IN N
choroidal JJ N
neovascularization NN N
in IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

A DT N
pilot NN N
study NN N
using VBG N
low- JJ 1_i
versus NN 1_i
high-dose JJ 1_i
photon NN 1_i
bean NN 1_i
radiation NN 1_i
] NN 1_i
. . N

PURPOSE NNP N
Several JJ N
pilot NN N
studies NNS N
have VBP N
indicated VBN N
that IN N
low-dose JJ 1_i
radiation NN 1_i
therapy NN 1_i
might MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
course NN N
of IN N
choroidal JJ N
neovascularization NN N
( ( N
CNV NNP N
) ) N
in IN N
age-related JJ 1_p
macular JJ 1_p
degeneration NN 1_p
( ( 1_p
AMD NNP 1_p
) ) 1_p
. . 1_p

This DT N
study NN N
aimed VBD N
to TO N
ascertain VB N
whether IN N
such JJ N
treatment NN N
might MD N
halt VB N
the DT N
progression NN N
of IN N
neovascular JJ N
AMD NNP N
and CC N
whether IN N
a DT N
low JJ N
or CC N
a DT N
high JJ N
radiation NN N
dose NN N
should MD N
be VB N
applied VBN N
. . N

PATIENTS VB N
The DT N
patients NNS 1_p
comprised VBD 1_p
some DT 1_p
randomized VBN 1_p
to TO 1_p
0 CD 1_i
vs NNS 1_i
10 CD 1_i
vs NNS 1_i
36 CD 1_i
Gy NNP 1_i
of IN 1_i
radiation NN 1_i
and CC 1_p
( ( 1_p
after IN 1_p
a DT 1_p
change NN 1_p
of IN 1_p
the DT 1_p
study NN 1_p
protocol NN 1_p
became VBD 1_p
necessary JJ 1_p
) ) 1_p
others NNS 1_p
who WP 1_p
participated VBD 1_p
in IN 1_p
a DT 1_p
prospective JJ 1_p
, , 1_p
controlled VBD 1_p
non-randomized JJ 1_p
pilot NN 1_p
study NN 1_p
. . 1_p

Enclosed VBN N
were VBD N
eyes NNS 1_p
with IN 1_p
visual JJ 1_p
acuity NN 1_p
of IN 1_p
> NN 1_p
or CC 1_p
= VB 1_p
0.1 CD 1_p
and CC 1_p
< NNP 1_p
or CC 1_p
= $ 1_p
0.6 CD 1_p
revealing VBG 1_p
a DT 1_p
juxta-subfoveal JJ 1_p
CNV NNP 1_p
either NN 1_p
of IN 1_p
the DT 1_p
occult NN 1_p
type NN 1_p
( ( 1_p
type JJ 1_p
1 CD 1_p
) ) 1_p
or CC 1_p
the DT 1_p
classic JJ 1_p
type NN 1_p
( ( 1_p
isolated JJ 1_p
or CC 1_p
as IN 1_p
part NN 1_p
of IN 1_p
a DT 1_p
predominantly RB 1_p
occult JJ 1_p
lesion NN 1_p
) ) 1_p
. . 1_p

RESULTS NNP N
Eyes NNP N
treated VBD N
with IN N
10 CD 1_i
Gy NNP 1_i
for IN N
occult NN N
CNV NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
were VBD N
subject JJ N
to TO N
severe JJ 1_o
visual JJ 1_o
loss NN 1_o
in IN N
41.6 CD N
% NN N
of IN N
the DT N
cases NNS N
compared VBN N
to TO N
38.5 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
at IN N
12 CD N
months NNS N
of IN N
follow-up NN N
. . N

For IN N
eyes NNS N
treated VBN N
with IN N
10 CD 1_i
Gy NNP 1_i
because IN N
of IN N
classic JJ N
CNV NNP N
, , N
the DT N
corresponding JJ N
figures NNS N
were VBD N
33 CD N
% NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
and CC N
57 CD N
% NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
respectively RB N
. . N

At IN N
18 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT N
percentages NNS N
were VBD N
63 CD N
% NN N
and CC N
75 CD N
% NN N
respectively RB N
. . N

Fluorescein NNP 1_o
angiographic JJ 1_o
growth NN 1_o
of IN 1_o
classic JJ 1_o
and CC 1_o
occult NN 1_o
CNV NNP 1_o
could MD N
not RB N
be VB N
halted VBN N
by IN N
10 CD N
Gy NNP N
, , N
while IN N
a DT N
temporary JJ 1_o
growth NN 1_o
retardation NN 1_o
was VBD N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD 1_i
Gy NNP 1_i
. . 1_i

CONCLUSION NNP N
In IN N
the DT N
study NN N
presented VBD N
, , N
the DT N
natural JJ N
course NN N
of IN N
occult NN N
CNV NNP N
could MD N
not RB N
be VB N
improved VBN N
by IN N
irradiation NN N
with IN N
10 CD 1_i
or CC 1_i
36 CD 1_i
Gy NNP 1_i
. . 1_i

In IN N
cases NNS N
of IN N
classic JJ N
CNV NNP N
, , N
low-dose JJ N
irradiation NN N
with IN N
10 CD 1_i
Gy NNP 1_i
postponed VBD N
severe JJ 1_o
visual JJ 1_o
loss NN 1_o
by IN N
a DT N
maximum NN N
of IN N
18 CD N
months NNS N
. . N

A DT N
positive JJ N
treatment NN N
effect NN N
was VBD N
also RB N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD 1_i
Gy NNP 1_i
; : 1_i
however RB N
, , N
a DT N
25 CD N
% NN N
incidence NN N
of IN N
radiation NN N
retinopathy NN N
seems VBZ N
unacceptable JJ N
. . N

-DOCSTART- -X- O O

Recombinant JJ 1_i
human JJ 1_i
erythropoietin NN 1_i
therapy NN 1_i
for IN N
anemic JJ 1_p
cancer NN 1_p
patients NNS 1_p
on IN 1_p
combination NN 1_p
chemotherapy NN 1_p
. . 1_p

BACKGROUND NNP N
Patients NNPS 1_p
with IN 1_p
advanced JJ 1_p
cancer NN 1_p
frequently RB 1_p
experience VBZ 1_p
clinically RB 1_o
significant JJ 1_o
anemia NN 1_o
, , N
which WDT N
is VBZ N
often RB N
exacerbated VBN N
by IN N
myelosuppressive JJ N
chemotherapy NN N
. . N

Consistent JJ N
with IN N
the DT N
anemia NN N
of IN N
chronic JJ N
disease NN N
, , N
studies NNS N
have VBP N
documented VBN N
serum JJ N
erythropoietin NN N
levels NNS N
that WDT N
are VBP N
inappropriately RB N
low JJ N
for IN N
the DT N
degree NN N
of IN N
anemia NN N
in IN N
cancer NN 1_p
patients NNS 1_p
. . 1_p

Myelosuppressive JJ N
chemotherapy NN N
impairs NNS N
erythropoiesis NN N
, , N
which WDT N
may MD N
not RB N
fully RB N
recover VB N
between IN N
treatment NN N
cycles NNS N
. . N

Recombinant NNP 1_i
human JJ 1_i
erythropoietin NN 1_i
( ( 1_i
rHuEPO NN 1_i
) ) 1_i
has VBZ N
been VBN N
used VBN N
safely RB N
and CC N
effectively RB N
to TO N
treat VB N
anemia NN N
in IN N
AIDS NNP N
patients NNS N
receiving VBG N
zidovudine NN N
( ( N
AZT NNP N
) ) N
and CC N
in IN N
patients NNS N
with IN N
chronic JJ N
renal JJ N
failure NN N
. . N

PURPOSE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
role NN N
of IN N
rHuEPO NN N
in IN N
reducing VBG N
symptomatic JJ 1_o
anemia NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
cancer NN 1_p
who WP 1_p
were VBD 1_p
receiving VBG 1_p
myelosuppressive JJ 1_p
chemotherapy NN 1_p
( ( 1_p
excluding VBG 1_p
cisplatin NN 1_p
) ) 1_p
. . 1_p

METHODS NNP N
We PRP N
studied VBD N
153 CD 1_p
anemic JJ 1_p
cancer NN 1_p
patients NNS 1_p
receiving VBG 1_p
cyclic JJ 1_i
combination NN 1_i
chemotherapy NN 1_i
in IN N
a DT N
prospective JJ N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

The DT N
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
rHuEPO NN 1_i
( ( N
150 CD N
U/kg NNP N
) ) N
or CC N
placebo NN 1_i
subcutaneously RB N
three CD N
times NNS N
a DT N
week NN N
for IN N
a DT N
maximum NN N
of IN N
12 CD N
weeks NNS N
or CC N
until IN N
the DT N
hematocrit JJ 1_o
level NN 1_o
increased VBD N
to TO N
38 CD N
% NN N
-40 JJ N
% NN N
. . N

If IN N
the DT N
hematocrit NN 1_o
reached VBD N
this DT N
target NN N
level NN N
before IN N
12 CD N
weeks NNS N
, , N
the DT N
rHuEPO NN 1_i
dose NN N
could MD N
be VB N
reduced VBN N
to TO N
maintain VB N
the DT N
hematocrit NN N
at IN N
that DT N
level NN N
for IN N
the DT N
duration NN N
of IN N
the DT N
study NN N
. . N

Response NNP N
to TO N
rHuEPO VB 1_i
therapy NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
changes NNS 1_o
in IN 1_o
hematocrit NN 1_o
level NN 1_o
, , 1_o
transfusion NN 1_o
requirements NNS 1_o
, , 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

Quality-of-life JJ 1_o
assessment NN N
was VBD N
based VBN N
on IN N
patients NNS N
' POS N
responses NNS N
to TO N
questionnaires NNS N
before IN N
and CC N
after IN N
the DT N
courses NNS N
of IN N
therapy NN N
. . N

RESULTS VB N
The DT N
increase NN 1_o
in IN 1_o
hematocrit NN 1_o
in IN N
the DT N
rHuEPO-treated JJ 1_i
group NN 1_p
compared VBN N
with IN N
hematocrit NN 1_o
in IN N
the DT N
placebo-treated JJ 1_i
group NN 1_p
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
as IN N
measured VBN N
by IN N
percentage NN N
point NN N
of IN N
change NN N
from IN N
baseline NN N
to TO N
final JJ N
evaluation NN N
, , N
by IN N
an DT N
increase NN N
in IN N
hematocrit JJ 1_o
level NN N
of IN N
six CD N
percentage NN N
points NNS N
or CC N
more JJR N
unrelated JJ N
to TO N
transfusion NN N
, , N
and CC N
by IN N
a DT N
rise NN N
in IN N
hematocrit NN 1_o
level NN 1_o
to TO N
38 CD N
% NN N
or CC N
more JJR N
unrelated JJ N
to TO N
transfusion NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
the DT N
reduction NN N
in IN N
mean JJ 1_o
units NNS 1_o
of IN 1_o
blood NN 1_o
transfused VBN 1_o
per IN 1_o
patient NN 1_o
during IN N
months NNS N
2 CD N
and CC N
3 CD N
of IN N
therapy NN N
combined VBN N
in IN N
rHuEPO-treated JJ 1_i
patients NNS 1_p
compared VBN N
with IN N
placebo-treated JJ 1_p
patients NNS 1_p
( ( N
0.91 CD N
U NNP N
versus NN N
1.65 CD N
U NNP N
; : N
P NNP N
= NNP N
.056 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
rHuEPO-treated JJ 1_i
patients NNS 1_p
experienced VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
energy NN 1_o
level NN 1_o
and CC 1_o
ability NN 1_o
to TO 1_o
perform VB 1_o
daily JJ 1_o
activities NNS 1_o
( ( N
P NNP N
< NNP N
or CC N
= NNP N
.05 NNP N
) ) N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
showed VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
toxic JJ 1_o
effects NNS 1_o
except IN N
for IN N
increased JJ N
incidence NN N
of IN N
diaphoresis NN 1_o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
diarrhea NN 1_o
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
in IN N
the DT N
rHuEPO-treated JJ 1_p
group NN 1_p
. . 1_p

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that DT N
rHuEPO NN 1_i
is VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
reversing VBG N
anemia RB 1_o
related VBN N
to TO N
advanced JJ N
cancer NN N
or CC N
to TO N
chemotherapy VB N
for IN N
cancer NN N
. . N

-DOCSTART- -X- O O

Comparison NNP 1_p
of IN 1_p
synemol JJ 1_i
cream NN 1_i
and CC 1_p
other JJ 1_i
topical JJ 1_i
corticosteroid NN 1_i
creams NNS 1_i
using VBG 1_p
the DT 1_p
vasoconstrictor NN 1_p
bioassay NN 1_p
. . 1_p

The DT N
human JJ 1_p
vasoconstrictor NN 1_p
bioassay NN 1_p
was VBD N
used VBN N
to TO N
assess VB N
the DT N
potency NN N
of IN N
open JJ 1_p
applications NNS 1_p
of IN 1_p
Synemol NNP 1_i
cream NN 1_i
( ( 1_p
0.025 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
Diprosone NNP 1_i
cream NN 1_i
( ( 1_i
0.05 CD 1_i
% NN 1_i
) ) 1_i
, , 1_i
Aristocort-A NNP 1_i
cream NN 1_i
( ( 1_p
0.5 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
Valisone NNP 1_i
cream NN 1_i
( ( 1_i
0.1 CD 1_i
% NN 1_i
) ) 1_i
. . 1_p

Intensity NN N
of IN N
vasoconstriction NN 1_p
was VBD N
determined VBN N
eight CD N
, , N
twenty-four NN N
, , N
and CC N
thirty-two JJ N
hours NNS N
after IN N
application NN N
. . N

Results NNS N
obtained VBD N
from IN N
the DT N
average JJ N
intensity NN 1_o
scores NNS 1_o
of IN N
the DT N
three CD N
determinations NNS N
indicated VBD N
that IN N
Synemol NNP 1_i
cream NN 1_i
( ( N
0.025 CD N
% NN N
) ) N
is VBZ N
actually RB N
a DT N
more RBR N
active JJ N
compound NN N
than IN N
are VBP N
Diprosone NNP 1_i
cream NN 1_i
( ( N
0.05 CD N
% NN N
) ) N
, , N
Aristocort-A NNP 1_i
cream NN 1_i
( ( N
0.5 CD N
% NN N
) ) N
, , N
and CC N
Valisone NNP 1_i
cream NN 1_i
( ( N
0.1 CD N
% NN N
) ) N
, , N
and CC N
that IN N
its PRP$ N
activity NN N
is VBZ N
longer RBR N
acting VBG N
. . N

-DOCSTART- -X- O O

BCG NNP 1_i
( ( 1_i
RIVM NNP 1_i
) ) 1_i
versus NN N
mitomycin JJ 1_i
intravesical JJ 1_i
therapy NN 1_i
in IN N
superficial JJ 1_p
bladder NN 1_p
cancer NN 1_p
. . 1_p

First JJ N
results NNS N
of IN N
randomized JJ N
prospective JJ N
trial NN N
. . N

This DT N
study NN N
presents VBZ N
the DT N
preliminary JJ N
results NNS N
of IN N
a DT N
randomized JJ N
prospective JJ N
two-arm NN N
study NN N
in IN N
which WDT N
bacillus JJ 1_i
Calmette-Gu?rin NNP 1_i
( ( 1_i
BCG NNP 1_i
) ) 1_i
RIVM NNP 1_i
, , 1_i
a DT 1_i
Dutch JJ 1_i
BCG NNP 1_i
preparation NN N
, , N
is VBZ N
compared VBN N
with IN 1_i
mitomycin JJ 1_i
C NNP 1_i
( ( N
MMC NNP N
) ) N
in IN 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
or CC 1_p
recurrent JJ 1_p
superficial JJ 1_p
bladder NN 1_p
tumors NNS 1_p
, , 1_p
including VBG 1_p
carcinoma NN 1_p
in IN 1_p
situ NN 1_p
( ( 1_p
CIS NNP 1_p
) ) 1_p
. . 1_p

Therapeutic JJ N
regimens NNS N
were VBD N
as IN N
follows VBZ N
: : N
after IN N
complete JJ N
transurethral JJ N
resection NN N
of IN N
all DT N
visible JJ N
tumors NNS N
, , N
BCG NNP 1_i
RIVM NNP 1_i
( ( N
1 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
bacilli NN N
in IN N
50 CD N
mL NNS N
saline NN N
) ) N
was VBD N
instilled VBN N
once RB N
a DT N
week NN N
for IN N
six CD N
consecutive JJ N
weeks NNS N
, , N
and CC 1_i
mitomycin VB 1_i
C NNP 1_i
( ( N
30 CD N
mg NN N
in IN N
50 CD N
mL NNS N
saline NN N
) ) N
was VBD N
administered VBN N
once RB N
a DT N
week NN N
for IN N
one CD N
month NN N
( ( N
weeks NNS N
1 CD N
to TO N
4 CD N
) ) N
and CC N
thereafter RB N
once RB N
a DT N
month NN N
for IN N
a DT N
total NN N
of IN N
six CD N
months NNS N
. . N

Reported VBN 1_o
are VBP 1_o
the DT 1_o
incidence NN 1_o
of IN 1_o
side NN 1_o
effects NNS 1_o
in IN 1_p
165 CD 1_p
patients NNS 1_p
and CC 1_p
the DT 1_o
recurrence NN 1_o
rate NN 1_o
of IN 1_o
tumors NNS 1_o
in IN 1_p
308 CD 1_p
patients NNS 1_p
after IN 1_p
a DT 1_p
follow-up JJ 1_p
period NN 1_p
of IN 1_p
twelve JJ 1_p
months NNS 1_p
. . 1_p

Drug-induced NNP 1_o
, , 1_o
or CC 1_o
chemical NN 1_o
cystitis NN 1_o
was VBD N
observed VBN N
in IN N
13 CD N
( ( N
16.7 CD N
% NN N
) ) N
of IN N
78 CD N
BCG-treated JJ N
patients NNS N
and CC N
in IN N
12 CD N
( ( N
13.8 CD N
% NN N
) ) N
of IN N
87 CD N
MMC-treated JJ N
patients NNS N
. . N

In IN N
the DT N
same JJ N
groups NNS 1_o
bacterial JJ 1_o
cystitis NN 1_o
occurred VBD N
in IN N
17 CD N
( ( N
21.8 CD N
% NN N
) ) N
patients NNS N
and CC N
in IN N
16 CD N
( ( N
18.4 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
BCG-treated JJ N
group NN N
( ( N
N NNP N
= NNP N
148 CD N
) ) N
, , N
44 CD N
( ( N
29.8 CD N
% NN N
) ) N
had VBD 1_o
recurrent JJ 1_o
tumors NNS 1_o
, , 1_o
while IN N
in IN N
the DT N
MMC-treated JJ N
group NN N
( ( N
N NNP N
= NNP N
160 CD N
) ) N
, , N
40 CD N
( ( N
25.0 CD N
% NN N
) ) N
had VBD N
a DT N
recurrence NN 1_o
. . 1_o

The DT 1_o
recurrence NN 1_o
rate NN 1_o
for IN 1_i
BCG-treated JJ 1_i
patients NNS N
was VBD N
0.33 CD N
; : N
the DT N
recurrence NN N
rate NN N
for IN 1_i
MMC-treated JJ 1_i
patients NNS N
was VBD N
0.29 CD N
( ( N
P NNP N
= NNP N
0.560 CD N
, , N
not RB N
significant JJ N
) ) N
. . N

These DT N
preliminary JJ N
data NNS N
demonstrated VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
arms NNS N
with IN N
regard NN N
to TO 1_o
toxicity NN 1_o
and CC 1_o
recurrence NN 1_o
of IN 1_o
tumors NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Perceptual JJ 1_o
wind-up NN 1_o
in IN N
the DT N
human JJ 1_p
oesophagus NN 1_p
is VBZ N
enhanced VBN N
by IN N
central JJ N
sensitisation NN N
. . N

BACKGROUND NNP N
Oesophageal NNP N
acid JJ N
infusion NN N
induces NNS N
enhanced VBD N
pain NN N
hypersensitivity NN N
in IN N
non-acid JJ N
exposed JJ N
upper JJ N
oesophagus NN N
( ( N
secondary JJ N
hyperalgesia NN N
) ) N
in IN N
patients NNS N
with IN N
non-cardiac JJ N
chest NN N
pain NN N
, , N
thus RB N
suggesting VBG N
central JJ N
sensitisation NN N
contributes NNS N
to TO N
visceral JJ N
pain NN N
hypersensitivity NN N
in IN N
functional JJ N
gut NN N
disorders NNS N
( ( N
FGD NNP N
) ) N
. . N

Perceptual JJ N
wind-up JJ N
( ( N
increased JJ N
pain NN N
perception NN N
to TO N
constant JJ N
intensity NN N
sensory NN N
stimuli NN N
at IN N
frequencies NNS N
> VBP N
or=0.3 JJ N
Hz NNP N
) ) N
is VBZ N
used VBN N
as IN N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
to TO N
investigate VB N
pain NN N
syndromes NNS N
where WRB N
pain NN N
hypersensitivity NN N
is VBZ N
important JJ N
( ( N
for IN N
example NN N
, , N
fibromyalgia NN N
) ) N
. . N

AIMS $ N
Wind-up JJ N
in IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
has VBZ N
not RB N
been VBN N
explored VBN N
. . N

We PRP N
hypothesised VBD N
that IN N
if IN N
wind-up NN N
is VBZ N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
, , N
then RB N
oesophageal JJ N
wind-up NN N
should MD N
be VB N
enhanced VBN N
by IN N
secondary JJ N
hyperalgesia NN N
. . N

METHODS NNP N
In IN N
eight CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
( ( 1_p
seven CD 1_p
males NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
32 CD 1_p
years NNS 1_p
) ) 1_p
, , N
perception NN N
at IN N
pain NN N
threshold NN N
to TO N
a DT N
train NN N
of IN N
20 CD N
electrical JJ 1_i
stimuli NNS 1_i
applied VBN N
to TO N
the DT N
hand NN N
and CC N
upper JJ N
oesophagus NN N
( ( N
UO NNP N
) ) N
at IN N
either DT N
0.1 CD 1_i
Hz NNP 1_i
( ( N
control NN N
) ) N
or CC N
2 CD 1_i
Hz NNP 1_i
was VBD N
determined VBN N
before IN N
and CC N
one CD N
hour NN N
after IN N
a DT N
30 CD N
minute NN N
lower JJR N
oesophageal NN N
acid JJ N
infusion NN N
. . N

RESULTS NNP N
Wind-up JJ 1_o
occurred VBD N
only RB N
with IN N
the DT N
2 CD 1_i
Hz NNP 1_i
train NN N
in IN N
the DT N
UO NNP N
and CC N
hand NN N
( ( N
both DT N
p=0.01 NN N
) ) N
. . N

Following VBG N
acid JJ N
infusion NN N
, , N
pain VBP 1_o
threshold JJ 1_o
decreased VBN 1_o
( ( N
17 CD N
( ( N
4 CD N
) ) N
% NN N
; : N
p=0.01 NN N
) ) N
in IN N
the DT N
UO NNP N
, , N
suggesting VBG N
the DT N
presence NN N
of IN N
secondary JJ N
hyperalgesia NN N
. . N

Wind-up UH 1_o
to TO 1_o
the DT 1_o
2 CD 1_o
Hz NNP 1_o
train NN 1_o
increased VBD N
in IN N
the DT N
UO NNP 1_o
( ( N
wind-up JJ N
ratio NN N
1.4 CD N
( ( N
0.1 CD N
) ) N
to TO N
1.6 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.03 NN N
) ) N
but CC N
not RB N
in IN N
the DT N
hand NN N
( ( N
wind-up JJ N
ratio NN N
1.3 CD N
( ( N
0.1 CD N
) ) N
and CC N
1.3 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.3 NN N
) ) N
CONCLUSION NNP N
Enhanced NNP N
wind-up NN N
after IN N
secondary JJ N
oesophageal NN N
hyperalgesia NN N
suggests VBZ N
that IN N
visceral JJ N
pain NN N
hypersensitivity NN N
induced VBN N
by IN N
central JJ N
sensitisation NN N
results NNS N
from IN N
increased JJ N
central JJ N
neuronal JJ N
excitability NN N
. . N

Wind-up JJ N
may MD N
offer VB N
new JJ N
opportunities NNS N
to TO N
investigate VB N
the DT N
contribution NN N
of IN N
central JJ N
neuronal JJ N
changes NNS N
to TO N
symptoms NNS N
in IN N
FGD NNP N
. . N

-DOCSTART- -X- O O

Pre-operative JJ 1_i
radiochemotherapy NN 1_i
for IN N
rectal JJ 1_p
cancer NN 1_p
. . 1_p

A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
pre-operative JJ 1_i
vs. FW 1_i
postoperative JJ 1_i
radiochemotherapy NN 1_i
in IN N
rectal JJ 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
find VB N
out RP N
whether IN N
pre-operative JJ 1_i
radiochemotherapy NN 1_i
had VBD N
any DT N
survival JJ 1_o
advantage NN 1_o
over IN N
postoperative JJ 1_i
radiochemotherapy NN 1_i
for IN N
rectal JJ 1_p
carcinoma NN 1_p
patients NNS 1_p
without IN 1_p
distant JJ 1_p
metastasis NN 1_p
or CC 1_p
peritoneal JJ 1_p
carcinomatosis NN 1_p
. . 1_p

MATERIAL NNP N
AND CC N
METHODS NNP N
Between NNP 1_p
January NNP 1_p
1998 CD 1_p
and CC 1_p
December NNP 1_p
2003 CD 1_p
, , 1_p
51 CD 1_p
rectal JJ 1_p
carcinoma NN 1_p
patients NNS 1_p
without IN 1_p
distant JJ 1_p
metastasis NN 1_p
or CC 1_p
peritoneal JJ 1_p
carcinomatosis NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
pre-operative JJ 1_i
( ( 1_i
PRE NNP 1_i
) ) 1_i
and CC N
postoperative JJ 1_i
( ( 1_i
POST NNP 1_i
) ) 1_i
radiochemotherapy NN 1_i
groups NNS N
. . N

Twenty-six CD N
were VBD N
assigned VBN N
to TO N
the DT N
PRE NNP N
group NN N
and CC N
were VBD N
operated VBN N
on IN N
5 CD N
to TO N
8 CD N
weeks NNS N
after IN N
the DT N
completion NN N
of IN N
radiotherapy NN 1_i
. . 1_i

The DT N
other JJ N
25 CD N
patients NNS N
were VBD N
operated VBN N
on IN N
immediately RB N
and CC N
received VBD N
radiotherapy NN N
postoperatively RB N
2 CD N
to TO N
4 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
between IN N
4 CD N
to TO N
51 CD N
months NNS N
. . N

RESULTS NNP N
In IN N
the DT N
PRE NNP N
group NN N
the DT N
rates NNS 1_o
of IN 1_o
disease-free JJ 1_o
survival NN 1_o
were VBD N
92 CD N
% NN N
, , N
70 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
56 CD N
% NN N
at IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
POST NNP N
group NN N
those DT N
percentages NNS N
were VBD N
83 CD N
% NN N
, , N
68 CD N
% NN N
, , N
51 CD N
% NN N
and CC N
51 CD N
% NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.707 CD N
) ) N
. . N

One-year JJ 1_o
and CC 1_o
4-year JJ 1_o
overall JJ 1_o
survival NN 1_o
rates NNS 1_o
in IN N
the DT N
PRE NNP N
group NN N
were VBD N
100 CD N
% NN N
and CC N
86 CD N
% NN N
respectively RB N
and CC N
100 CD N
% NN N
and CC N
60 CD N
% NN N
in IN N
the DT N
POST NNP N
group NN N
( ( N
p JJ N
= NNP N
0.520 CD N
) ) N
. . N

CONCLUSION NNP N
No NNP N
statistical JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
survival JJ 1_o
rates NNS 1_o
of IN N
the DT N
rectal JJ 1_p
carcinoma NN 1_p
patients NNS 1_p
receiving VBG N
radiotherapy NN N
either CC N
pre-operatively RB N
or CC N
postoperatively RB N
. . N

However RB N
, , N
the DT N
disease-free JJ 1_o
survival NN 1_o
rates NNS 1_o
of IN N
the DT N
PRE NNP 1_i
group NN N
were VBD N
higher JJR N
than IN N
the DT N
POST NNP 1_i
group NN N
's POS N
during IN N
each DT N
year NN N
and CC N
overall JJ 1_o
survival NN 1_o
rates NNS 1_o
were VBD N
higher JJR N
after IN N
the DT N
third JJ N
and CC N
fourth JJ N
years NNS N
. . N

We PRP N
conclude VBP N
that IN N
pre-operative JJ 1_i
radiotherapy NN 1_i
is VBZ N
at IN 1_o
least JJS 1_o
as RB 1_o
effective JJ 1_o
as IN 1_o
postoperative JJ 1_i
radiotherapy NN 1_i
. . 1_i

-DOCSTART- -X- O O

Is VBZ N
psychotherapy VBN 1_i
more RBR N
effective JJ N
when WRB N
therapists NNS 1_p
disclose VB N
information NN N
about IN N
themselves PRP N
? . N
Theorists NNS N
have VBP N
long RB N
debated VBN N
the DT N
wisdom NN N
of IN N
therapists NNS 1_p
disclosing VBG 1_o
personal JJ 1_o
information NN 1_o
during IN 1_p
psychotherapy NN 1_i
. . 1_i

Some DT N
observers NNS N
have VBP N
argued VBN N
that IN N
such JJ N
therapist JJ N
self-disclosure NN N
impedes NNS N
treatment NN N
, , N
whereas IN N
others NNS N
have VBP N
suggested VBN N
that IN N
it PRP N
enhances VBZ N
the DT N
effectiveness NN 1_o
of IN 1_o
therapy NN 1_o
. . 1_o

To TO N
test VB N
these DT N
competing VBG N
positions NNS N
, , N
therapists NNS 1_p
at IN 1_p
a DT 1_p
university NN 1_p
counseling NN 1_p
center NN 1_p
were VBD N
instructed VBN N
to TO N
increase VB 1_i
the DT 1_i
number NN 1_i
of IN 1_i
self-disclosures NNS 1_i
they PRP N
made VBD N
during IN N
treatment NN 1_i
of IN N
one CD 1_p
client NN 1_p
and CC N
refrain NN 1_i
from IN 1_i
making VBG 1_i
self-disclosures NNS 1_i
during IN 1_i
treatment NN 1_i
of IN N
another DT 1_p
client NN 1_p
. . 1_p

Analyses NNS N
revealed VBD N
that IN N
clients NNS N
receiving VBG N
psychotherapy NN 1_i
under IN N
conditions NNS N
of IN N
heightened VBN N
therapist NN 1_i
disclosure NN 1_i
not RB N
only RB N
reported VBD N
lower JJR 1_o
levels NNS 1_o
of IN 1_o
symptom NN 1_o
distress NN 1_o
but CC N
also RB N
liked VBD 1_o
their PRP$ 1_o
therapist NN 1_o
more RBR 1_o
. . 1_o

Such JJ N
findings NNS N
suggest VBP N
that IN N
self-disclosure NN N
by IN N
the DT N
therapist NN N
may MD N
improve VB N
both PDT N
the DT N
quality NN 1_o
of IN 1_o
the DT 1_o
therapeutic JJ 1_o
relationship NN 1_o
and CC 1_o
the DT 1_o
outcome NN 1_o
of IN 1_o
treatment NN 1_o
. . 1_o

-DOCSTART- -X- O O

Lamotrigine NNP 1_i
therapy NN 1_i
for IN N
autistic JJ 1_p
disorder NN 1_p
: : 1_p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

In IN N
autism NN N
, , N
glutamate NN N
may MD N
be VB N
increased VBN N
or CC N
its PRP$ N
receptors NNS N
up-regulated JJ N
as IN N
part NN N
of IN N
an DT N
excitotoxic JJ N
process NN N
that WDT N
damages NNS N
neural JJ N
networks NNS N
and CC N
subsequently RB N
contributes VBZ N
to TO N
behavioral VB N
and CC N
cognitive VB N
deficits NNS N
seen VBN N
in IN N
the DT N
disorder NN N
. . N

This DT N
was VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
of IN N
lamotrigine NN 1_i
, , N
an DT N
agent NN N
that WDT N
modulates VBZ N
glutamate JJ N
release NN N
. . N

Twenty-eight JJ 1_p
children NNS 1_p
( ( 1_p
27 CD 1_p
boys NNS 1_p
) ) 1_p
ages VBZ 1_p
3 CD 1_p
to TO 1_p
11 CD 1_p
years NNS 1_p
( ( 1_p
M NNP 1_p
= NNP 1_p
5.8 CD 1_p
) ) 1_p
with IN 1_p
a DT 1_p
primary JJ 1_p
diagnosis NN 1_p
of IN 1_p
autistic JJ 1_p
disorder NN 1_p
received VBD 1_i
either CC 1_i
placebo NN 1_i
or CC 1_i
lamotrigine JJ 1_i
twice JJ 1_i
daily RB 1_i
. . 1_i

In IN N
children NNS N
on IN N
lamotrigine NN 1_i
, , 1_i
the DT 1_i
drug NN 1_i
was VBD 1_i
titrated VBN 1_i
upward RB 1_i
over IN 1_i
8 CD 1_i
weeks NNS 1_i
to TO 1_i
reach VB 1_i
a DT 1_i
mean JJ 1_i
maintenance NN 1_i
dose NN 1_i
of IN 1_i
5.0 CD 1_i
mg/kg NNS 1_i
per IN 1_i
day NN 1_i
. . 1_i

This DT 1_i
dose NN 1_i
was VBD 1_i
then RB 1_i
maintained VBN 1_i
for IN 1_i
4 CD 1_i
weeks NNS 1_i
. . 1_i

Following VBG 1_i
maintenance NN 1_i
evaluations NNS 1_i
, , 1_i
the DT 1_i
drug NN 1_i
was VBD 1_i
tapered VBN 1_i
down RB 1_i
over RB 1_i
2 CD 1_i
weeks NNS 1_i
. . 1_i

The DT 1_i
trial NN 1_i
ended VBD 1_i
with IN 1_i
a DT 1_i
4-week JJ 1_i
drug-free JJ 1_i
period NN 1_i
. . 1_i

Outcome NNP N
measures VBZ N
included VBD N
improvements NNS 1_o
in IN 1_o
severity NN 1_o
and CC 1_o
behavioral JJ 1_o
features NNS 1_o
of IN 1_o
autistic JJ 1_o
disorder NN 1_o
( ( 1_o
stereotypies NNS 1_o
, , 1_o
lethargy NN 1_o
, , 1_o
irritability NN 1_o
, , 1_o
hyperactivity NN 1_o
, , 1_o
emotional JJ 1_o
reciprocity NN 1_o
, , 1_o
sharing VBG 1_o
pleasures NNS 1_o
) ) 1_o
and CC 1_o
improvements NNS 1_o
in IN 1_o
language NN 1_o
and CC 1_o
communication NN 1_o
, , 1_o
socialization NN 1_o
, , 1_o
and CC 1_o
daily RB 1_o
living VBG 1_o
skills NNS 1_o
noted VBD N
after IN N
12 CD N
weeks NNS N
( ( N
the DT N
end NN N
of IN N
a DT N
4-week JJ N
maintenance NN N
phase NN N
) ) N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
significant JJ N
differences NNS N
in IN N
improvements NNS N
between IN N
lamotrigine NN 1_i
or CC 1_i
placebo NN 1_i
groups NNS N
on IN N
the DT N
Autism NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
, , 1_o
the DT 1_o
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
, , 1_o
the DT 1_o
Vineland NNP 1_o
Adaptive NNP 1_o
Behavior NNP 1_o
scales NNS 1_o
, , 1_o
the DT 1_o
PL-ADOS NNP 1_o
, , 1_o
or CC 1_o
the DT 1_o
CARS NNPS 1_o
. . 1_o

Parent NN 1_o
rating NN 1_o
scales NNS 1_o
showed VBD N
marked JJ N
improvements NNS N
, , N
presumably RB N
due JJ N
to TO N
expectations NNS N
of IN N
benefits NNS N
. . N

-DOCSTART- -X- O O

Evolution NN N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
during IN N
intensive JJ N
vincristine/corticosteroid NNS 1_i
chemotherapy NN 1_i
for IN N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

Neuropathy NNP N
and CC N
myopathy NN N
are VBP N
common JJ N
sequelae NN N
of IN N
intensive JJ 1_i
chemotherapy NN 1_i
protocols NNS 1_i
that WDT 1_i
contain VBP 1_i
vincristine JJ 1_i
and CC 1_i
corticosteroids NNS 1_i
. . 1_i

The DT N
authors NNS N
prospectively RB N
monitored VBD N
the DT N
evolution NN N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
during IN N
an DT N
intensive JJ N
12-week JJ N
chemotherapy NN 1_i
program NN N
for IN N
patients NNS 1_p
with IN 1_p
intermediate JJ 1_p
and CC 1_p
high-grade JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
. . 1_p

In IN N
this DT N
study NN N
, , N
vincristine NN 1_i
was VBD N
administered VBN N
by IN N
bolus NN 1_i
injection NN N
followed VBN N
by IN N
a DT N
3-day JJ N
continuous JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
infusion NN N
( ( N
total JJ N
dose NN N
of IN N
2.0 CD N
mg/m2 NNS N
every DT N
other JJ N
week NN N
) ) N
; : N
the DT N
maximum JJ N
dose NN N
of IN N
vincristine NN 1_i
was VBD N
not RB N
arbitrarily RB N
limited VBN N
. . N

Cronassial NNP 1_i
, , 1_i
a DT 1_i
mixture NN 1_i
of IN 1_i
four CD 1_i
naturally RB 1_i
occurring VBG 1_i
gangliosides NNS 1_i
, , N
was VBD N
administered VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
test NN N
to TO N
evaluate VB N
whether IN N
this DT N
agent NN N
could MD N
prevent VB N
vincristine-induced JJ 1_i
neuropathy NN N
. . N

High JJ N
doses NNS N
of IN N
dexamethasone NN 1_i
( ( N
50 CD N
mg/d NN N
for IN N
3 CD N
days NNS N
weekly RB N
or CC N
every DT N
other JJ N
week NN N
) ) N
were VBD N
also RB N
prescribed VBN N
. . N

Patients NNS N
were VBD N
monitored VBN N
every DT N
4 CD N
weeks NNS N
with IN N
comprehensive JJ N
physical JJ N
and CC N
neurologic JJ N
examinations NNS N
and CC N
electrophysiologic JJ N
studies NNS N
of IN N
peripheral JJ N
nerve NN N
function NN N
. . N

Twenty-seven JJ 1_p
patients NNS 1_p
were VBD 1_p
fully RB 1_p
evaluable JJ 1_p
. . 1_p

Weakness NNP 1_o
was VBD N
a DT N
prominent JJ N
adverse JJ N
reaction NN N
in IN N
this DT N
study NN N
, , N
and CC N
all DT N
patients NNS N
had VBD N
moderate JJ 1_o
to TO 1_o
severe VB 1_o
signs NNS 1_o
and CC 1_o
symptoms NNS 1_o
of IN 1_o
neuropathy JJ 1_o
and CC 1_o
myopathy JJ 1_o
. . 1_o

Cronassial NNP 1_i
( ( N
100 CD N
mg NN N
) ) N
administered VBN N
by IN N
intramuscular NN N
( ( N
IM NNP N
) ) N
injection NN N
daily RB N
provided VBD N
no DT N
protection NN N
against IN N
the DT N
development NN 1_o
of IN 1_o
neuropathic JJ 1_o
symptoms NNS 1_o
. . 1_o

Vincristine NNP 1_i
typically RB N
impaired VBD N
fine-motor JJ 1_o
coordination NN 1_o
initially RB N
, , N
whereas JJ N
corticosteroids NNS 1_i
were VBD N
associated VBN N
with IN N
delayed JJ N
development NN 1_o
of IN 1_o
proximal JJ 1_o
muscle NN 1_o
weakness NN 1_o
. . 1_o

Results NNS N
of IN N
electrodiagnostic JJ N
studies NNS N
did VBD N
not RB N
add VB N
to TO N
the DT N
clinical JJ N
examination NN N
results NNS N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
symptomatic JJ 1_o
weakness NN 1_o
due JJ N
to TO N
neuropathy JJ N
or CC N
myopathy JJ N
appears VBZ N
in IN N
a DT N
predictable JJ N
manner NN N
during IN N
intensive JJ N
vincristine/corticosteroid-based JJ 1_i
treatment NN 1_i
protocols NNS N
. . N

Simple JJ N
clinical JJ N
tests NNS N
can MD N
be VB N
used VBN N
to TO N
rapidly RB N
distinguish VB N
between IN N
toxic JJ N
effects NNS N
due JJ N
either RB N
to TO N
vincristine VB 1_i
or CC 1_i
corticosteroids NNS 1_i
, , N
and CC N
routine JJ N
implementation NN N
of IN N
these DT N
tests NNS N
can MD N
prevent VB N
inappropriate JJ N
dose JJ N
attenuation NN N
of IN N
these DT N
agents NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Case-controll NNP N
study NN N
on IN N
the DT N
synergistic JJ 1_o
effects NNS 1_o
of IN N
electroacupuncture NN 1_i
on IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ 1_i
debridement NN 1_i
] NN 1_i
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
synergistic JJ 1_o
effects NNS 1_o
of IN N
electroacupuncture NN 1_i
on IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ 1_i
debridement NN 1_i
. . 1_i

METHODS NNP N
From NNP N
May NNP 1_p
2008 CD 1_p
to TO 1_p
July NNP 1_p
2010 CD 1_p
, , 1_p
78 CD 1_p
patients NNS 1_p
with IN 1_p
knee JJ 1_p
osteoarthritis NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

There EX N
were VBD N
42 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
experimental JJ 1_p
group NN 1_p
, , 1_p
including VBG 1_p
16 CD 1_p
males NNS 1_p
and CC 1_p
26 CD 1_p
females NNS 1_p
, , 1_p
ranging VBG 1_p
in IN 1_p
age NN 1_p
from IN 1_p
41 CD 1_p
to TO 1_p
63 CD 1_p
years NNS 1_p
, , 1_p
with IN 1_p
an DT 1_p
average NN 1_p
of IN 1_p
( ( 1_p
53.62 CD 1_p
+/- JJ 1_p
6.53 CD 1_p
) ) 1_p
years NNS 1_p
; : 1_p
the DT 1_p
disease NN 1_p
course NN 1_p
ranged VBD 1_p
from IN 1_p
8 CD 1_p
to TO 1_p
24 CD 1_p
months NNS 1_p
, , 1_p
with IN 1_p
an DT 1_p
average NN 1_p
of IN 1_p
( ( 1_p
10.35 CD 1_p
+/- JJ 1_p
6.42 CD 1_p
) ) 1_p
months NNS 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
treated VBN N
with IN N
arthroscopic JJ 1_i
debridement NN 1_i
combined VBN 1_i
with IN 1_i
electroacupuncture NN 1_i
after IN 1_i
operation NN 1_i
. . 1_i

There EX N
were VBD N
36 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
control NN 1_p
group NN 1_p
, , 1_p
including VBG 1_p
14 CD 1_p
males NNS 1_p
and CC 1_p
22 CD 1_p
females NNS 1_p
, , 1_p
ranging VBG 1_p
in IN 1_p
age NN 1_p
from IN 1_p
40 CD 1_p
to TO 1_p
62 CD 1_p
years NNS 1_p
, , 1_p
with IN 1_p
an DT 1_p
average NN 1_p
of IN 1_p
( ( 1_p
54.34 CD 1_p
+/- JJ 1_p
7.67 CD 1_p
) ) 1_p
years NNS 1_p
; : 1_p
the DT 1_p
disease NN 1_o
course NN 1_o
ranged VBD 1_p
from IN 1_p
6 CD 1_p
to TO 1_p
25 CD 1_p
months NNS 1_p
, , 1_p
with IN 1_p
an DT 1_p
average NN 1_p
of IN 1_p
( ( 1_p
11.94 CD 1_p
+/- JJ 1_p
5.13 CD 1_p
) ) 1_p
months NNS 1_p
. . 1_p

Those DT N
patients NNS N
were VBD N
treated VBN N
only RB N
with IN N
arthroscopic JJ 1_i
debridment NN 1_i
. . 1_i

All PDT N
the DT N
patients NNS N
performed VBD N
isometric JJ 1_i
quadriceps NNS 1_i
femoris JJ 1_i
contraction NN 1_i
exercise NN 1_i
and CC 1_i
knee NN 1_i
flexion NN 1_i
and CC 1_i
extension NN 1_i
activities NNS 1_i
after IN 1_i
operation NN 1_i
. . 1_i

The DT N
visual JJ 1_o
analog NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
score NN 1_o
and CC 1_o
Lysholm NNP 1_o
knee VBD 1_o
score NN 1_o
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
therapeutic JJ N
effects NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
patients NNS N
were VBD N
followed VBN N
up RP N
, , N
and CC N
the DT N
duration NN N
ranged VBD N
from IN N
12 CD N
to TO N
30 CD N
months NNS N
, , N
with IN N
an DT N
average NN N
of IN N
15.6 CD N
months NNS N
. . N

At IN N
the DT N
final JJ N
follow-up NN N
, , N
VAS NNP 1_o
score NN 1_o
was VBD N
significantly RB N
decreased VBN N
, , N
and CC N
the DT N
Lysholm NNP 1_o
score NN 1_o
, , N
except IN N
for IN N
the DT N
item NN N
demanding VBG N
for IN N
support NN N
, , N
significantly RB N
increased VBN N
, , N
compared VBN N
with IN N
those DT N
before IN N
surgery NN N
respectively RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
significant JJ N
difference NN N
in IN N
VAS NNP 1_o
score NN 1_o
between IN N
two CD N
groups NNS N
after IN N
treatment NN N
. . N

As IN N
to TO N
Lysholm NNP 1_o
score NN 1_o
, , N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
limp NN 1_o
, , 1_o
pain NN 1_o
, , 1_o
swelling VBG 1_o
, , 1_o
stair NN 1_o
activity NN 1_o
and CC 1_o
squat NN 1_o
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
items NNS N
of IN N
interlocking VBG 1_o
and CC 1_o
instability NN 1_o
between IN N
two CD N
groups NNS N
after IN N
treatment NN N
. . N

CONCLUSION NNP N
Electroacupuncture NNP N
can MD N
effectively RB N
improve VB N
the DT N
clinical JJ 1_o
symptoms NNS 1_o
and CC N
knee VB N
joint NN N
's POS N
motor NN 1_o
function NN 1_o
of IN 1_o
knee NN 1_o
joints NNS 1_o
in IN N
patients NNS N
with IN 1_p
knee JJ 1_p
osteoarthritis NN 1_p
, , N
as RB N
well RB N
as IN N
the DT N
synergistic JJ N
effects NNS N
on IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ N
debridement NN N
, , N
leading VBG N
to TO N
a DT N
much RB N
better JJR N
long-term JJ N
therapeutic JJ N
effect NN N
with IN N
respect NN N
of IN N
improving VBG N
the DT N
function NN N
of IN N
knee NN N
joint NN N
. . N

This DT N
therapy NN N
, , N
combined VBN N
with IN N
traditional JJ N
Chinese JJ N
medicine NN N
and CC N
Western JJ N
Medicine NNP N
, , N
is VBZ N
worth IN N
of IN N
clinical JJ N
application NN N
in IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
. . N

-DOCSTART- -X- O O

Injection NNP 1_i
sclerotherapy NN 1_i
versus NN 1_i
electrocoagulation NN 1_i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ 1_p
haemorrhoids NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
study VB N
the DT N
symptomatology NN N
of IN N
early JJ 1_p
hemorrhoids NNS 1_p
and CC N
to TO N
compare VB N
injection NN 1_i
sclerotherapy NN 1_i
( ( 1_i
IS NNP 1_i
) ) 1_i
with IN 1_i
electrocoagulation NN 1_i
( ( 1_i
EC NNP 1_i
) ) 1_i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ N
haemorrhoids NNS N
with IN N
respect NN N
to TO N
pain VB 1_o
during IN 1_o
the DT 1_o
procedure NN 1_o
, , 1_o
reduction NN 1_o
in IN 1_o
bleeding VBG 1_o
per IN 1_o
rectum NN 1_o
, , N
and CC N
overall JJ 1_o
patient NN 1_o
satisfaction NN 1_o
score NN 1_o
. . 1_o

METHODS NNP N
A NNP N
total NN N
of IN N
102 CD 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
in IN N
this DT N
experimental JJ N
study NN N
at IN 1_p
the DT 1_p
POF NNP 1_p
Hospital NNP 1_p
, , 1_p
Wah NNP 1_p
Cantt NNP 1_p
from IN 1_p
October NNP 1_p
2004 CD 1_p
to TO 1_p
June NNP 1_p
2005 CD 1_p
. . 1_p

A DT N
detailed JJ N
history NN N
was VBD N
taken VBN N
and CC N
proctoscopic JJ N
examination NN N
was VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
then RB N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
Lottery NNP N
method NN N
) ) N
. . N

One CD N
group NN N
was VBD N
subjected VBN N
to TO N
EC NNP N
and CC N
the DT N
other JJ N
to TO N
IS NNP N
. . N

In IN N
the DT N
EC NNP N
, , N
using VBG N
the DT N
EC NNP N
machine NN N
( ( N
Wieda NNP N
, , N
China NNP N
) ) N
, , N
direct JJ N
current JJ N
of IN N
10-20 JJ N
mA NN N
was VBD N
applied VBN N
in IN N
the DT N
submucosal JJ N
plane NN N
of IN N
each DT N
pile NN N
core NN N
for IN N
5-7 JJ N
minutes NNS N
. . N

In IN N
the DT N
IS NNP N
1-2 JJ N
ml NN N
of IN N
5 CD N
% NN N
phenol NN 1_i
in IN 1_i
almond NN 1_i
oil NN 1_i
was VBD N
injected VBN N
in IN N
the DT N
same JJ N
plane NN N
in IN N
each DT N
pile NN N
core NN N
. . N

Pain NN 1_o
during IN 1_o
the DT 1_o
procedure NN 1_o
, , 1_o
reduction NN 1_o
in IN 1_o
bleeding VBG 1_o
per IN 1_o
rectum NN 1_o
and CC 1_o
overall JJ 1_o
patient NN 1_o
satisfaction NN 1_o
, , N
were VBD N
studied VBN N
as IN N
outcome JJ N
measures NNS N
. . N

RESULTS VB N
The DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
was VBD 1_p
44 CD 1_p
years NNS 1_p
, , 1_p
86 CD 1_p
were VBD 1_p
males NNS 1_p
and CC 1_p
16 CD 1_p
were VBD 1_p
females NNS 1_p
. . 1_p

Two CD N
thirds NNS N
of IN N
the DT N
patients NNS N
were VBD N
having VBG N
symptoms NNS N
for IN N
more JJR N
than IN N
6 CD N
months NNS N
. . N

A DT N
third JJ N
of IN N
patients NNS N
had VBD N
associated VBN N
local JJ 1_o
pain NN 1_o
while IN N
another DT N
third JJ N
had VBD N
associated VBN N
mucous JJ 1_o
discharge NN 1_o
. . 1_o

Chronic JJ 1_o
constipation NN 1_o
was VBD N
present JJ N
in IN N
81 CD N
% NN N
patients NNS N
. . N

Only RB N
24.5 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
had VBD 1_p
a DT 1_p
positive JJ 1_p
family NN 1_p
history NN 1_p
of IN 1_p
haemorrhoids NNS 1_p
. . 1_p

Patients NNS N
in IN N
the DT N
electrocoagulation NN N
( ( N
EC NNP N
) ) N
group NN N
experienced VBD N
more JJR N
pain NN 1_o
during IN 1_o
the DT 1_o
procedure NN 1_o
than IN N
the DT N
injection NN N
sclerotherapy NN 1_i
( ( 1_i
IS NNP 1_i
) ) 1_i
group NN N
( ( N
P NNP N
< NNP N
0.000 CD N
) ) N
, , N
but CC N
EC NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
IS NNP N
in IN N
terms NNS N
of IN N
reducing VBG N
the DT N
bleeding NN 1_o
per IN 1_o
rectum NN 1_o
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
and CC N
also RB N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
were VBD N
fully RB 1_o
satisfied VBN 1_o
with IN N
EC NNP N
than IN N
with IN N
IS NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

CONCLUSION NNP N
EC NNP N
, , N
although IN N
more RBR N
painful JJ 1_o
, , N
is VBZ N
a DT N
safe JJ 1_o
, , N
more RBR N
effective JJ 1_o
and CC N
a DT N
highly RB 1_o
satisfying JJ 1_o
procedure NN N
for IN N
treating VBG N
early JJ N
hemorrhoids NNS N
. . N

-DOCSTART- -X- O O

Gene NNP N
variants NNS N
in IN N
CYP2C19 NNP N
are VBP N
associated VBN N
with IN N
altered VBN N
in IN N
vivo JJ N
bupropion NN 1_i
pharmacokinetics NNS N
but CC N
not RB N
bupropion-assisted JJ N
smoking VBG 1_p
cessation NN 1_p
outcomes NNS N
. . N

Bupropion NNP 1_i
is VBZ N
used VBN N
clinically RB N
to TO N
treat VB N
depression NN N
and CC N
to TO N
promote VB N
smoking VBG N
cessation NN N
. . N

It PRP N
is VBZ N
metabolized VBN N
by IN N
CYP2B6 NNP N
to TO N
its PRP$ N
active JJ N
metabolite JJ N
hydroxybupropion NN N
, , N
yet CC N
alterations NNS N
in IN N
CYP2B6 NNP N
activity NN N
have VBP N
little JJ N
impact NN N
on IN N
bupropion NN 1_o
plasma NN 1_o
levels NNS 1_o
. . 1_o

Furthermore RB N
, , N
less JJR N
than IN N
10 CD N
% NN N
of IN N
a DT N
bupropion NN 1_i
dose NN N
is VBZ N
excreted VBN N
as IN N
urinary JJ N
bupropion NN 1_i
and CC N
its PRP$ N
characterized JJ N
metabolites NNS N
hydroxybupropion NN N
, , N
threohydrobupropion NN N
, , N
and CC N
erythrohydrobupropion NN N
, , N
suggesting VBG N
that IN N
alternative JJ N
metabolic JJ N
pathways NNS N
may MD N
exist VB N
. . N

In IN N
vitro JJ N
data NNS N
suggested VBD N
CYP2C19 NNP N
could MD N
metabolize VB N
bupropion NN 1_i
. . 1_i

The DT N
current JJ N
study NN N
investigated VBD N
the DT N
impact NN N
of IN N
functional JJ N
CYP2C19 NNP N
genetic JJ N
variants NNS N
on IN N
bupropion NN N
pharmacokinetics NNS N
and CC N
treatment NN N
outcomes NNS N
. . N

In IN N
42 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
, , N
CYP2C19*2 NNP N
( ( N
a DT N
reduced VBN N
activity NN N
allele NN N
) ) N
was VBD N
associated VBN N
with IN N
higher JJR N
bupropion NN 1_i
area NN N
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
, , N
but CC N
similar JJ N
hydroxybupropion NN N
AUC NNP N
. . N

The DT N
mean JJ 1_o
bupropion NN 1_o
AUC NNP 1_o
was VBD N
771 CD N
versus NN N
670 CD N
hours?ng/ml NN N
in IN N
individuals NNS N
with IN N
and CC N
without IN N
CYP2C19*2 NNP N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CYP2C19*2 NNP N
was VBD N
also RB N
associated VBN N
with IN N
higher JJR 1_o
threohydrobupropion NN 1_o
and CC 1_o
erythrohydrobupropion NN 1_o
AUC NNP 1_o
( ( 1_o
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

Adjusting VBG N
for IN N
CYP2B6 NNP N
genotype NN N
did VBD N
not RB N
alter VB N
these DT N
associations NNS N
, , N
and CC N
CYP2C19 NNP N
variants NNS N
did VBD N
not RB N
alter VB N
the DT N
utility NN N
of IN N
the DT 1_o
hydroxybupropion/bupropion NN 1_o
ratio NN 1_o
as IN 1_o
a DT N
measure NN N
of IN N
CYP2B6 NNP N
activity NN N
. . N

Finally RB N
, , N
in IN N
a DT N
clinical JJ N
trial NN N
of IN N
540 CD 1_p
smokers NNS 1_p
, , 1_p
CYP2C19 NNP N
genotype NN N
was VBD N
not RB N
associated VBN N
with IN N
smoking VBG 1_o
cessation NN 1_o
outcomes NNS 1_o
, , 1_o
supporting VBG N
the DT N
hypothesis NN N
that WDT 1_i
bupropion NN 1_i
response NN 1_i
is VBZ N
mediated VBN N
by IN N
hydroxybupropion NN 1_o
, , 1_o
which WDT N
is VBZ N
not RB N
altered VBN N
by IN N
CYP2C19 NNP N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
study NN N
reports VBZ N
the DT N
first JJ N
in IN N
vivo JJ N
evidence NN N
that IN N
reduced VBD 1_o
CYP2C19 NNP 1_o
activity NN 1_o
significantly RB 1_o
increases VBZ N
the DT 1_o
steady-state JJ 1_o
exposure NN 1_o
to TO 1_o
bupropion NN 1_o
and CC 1_o
its PRP$ 1_o
reductive JJ 1_o
metabolites NNS 1_o
threohydrobupropion NN 1_o
and CC 1_o
erythrohydrobupropion NN 1_o
. . 1_o

These DT N
pharmacokinetic JJ N
changes NNS N
were VBD N
not RB N
associated VBN N
with IN N
differences NNS N
in IN N
bupropion NN N
's POS N
ability NN N
to TO N
promote VB N
smoking VBG N
cessation NN N
in IN N
smokers NNS 1_p
, , 1_p
but CC N
may MD N
influence VB N
the DT 1_o
side NN 1_o
effects NNS 1_o
and CC 1_o
toxicity NN 1_o
associated VBN 1_o
with IN 1_i
bupropion NN 1_i
. . 1_i

-DOCSTART- -X- O O

Visit-to-visit NNP N
blood NN 1_o
pressure NN 1_o
variability NN 1_o
in IN N
the DT N
European NNP N
Lacidipine NNP N
Study NNP N
on IN N
Atherosclerosis NNP N
: : N
methodological JJ N
aspects NNS N
and CC N
effects NNS N
of IN N
antihypertensive JJ 1_i
treatment NN 1_i
. . 1_i

BACKGROUND NNP N
Recent NNP N
studies NNS N
have VBP N
reported VBN N
that IN N
in IN N
patients NNS 1_p
under IN 1_p
antihypertensive JJ 1_p
treatment NN 1_p
visit-to-visit NN 1_p
( ( 1_p
or CC 1_p
long-term JJ 1_p
) ) 1_p
variability NN 1_o
of IN 1_o
clinic JJ 1_o
BP NNP 1_o
within IN N
a DT N
given VBN N
patient NN N
has VBZ N
an DT N
independent JJ N
prognostic JJ N
significance NN N
. . N

Partly RB N
based VBN N
on IN N
between-patient JJ N
dispersion NN N
of IN N
BP NNP N
values NNS N
during IN N
treatment NN N
( ( N
interindividual JJ N
variability NN N
) ) N
it PRP N
has VBZ N
also RB N
been VBN N
reported VBN N
that IN N
long-term JJ 1_o
clinic JJ 1_o
BP NNP 1_o
variability NN 1_o
is VBZ N
greater JJR N
for IN N
?-blocker JJR 1_i
than IN N
for IN 1_i
calcium NN 1_i
antagonist NN 1_i
and CC N
other JJ N
types NNS N
of IN N
treatment NN N
. . N

GOALS NNP N
To TO N
measure VB 1_o
visit-to-visit JJ 1_o
intraindividual JJ 1_o
variations NNS 1_o
of IN N
both DT N
clinic JJ N
and CC N
24-h JJ N
mean NN N
BP NNP N
in IN N
the DT 1_p
hypertensive JJ 1_p
patients NNS 1_p
of IN 1_p
the DT 1_p
European NNP 1_p
Lacidipine NNP 1_p
Study NNP 1_p
on IN 1_p
Atherosclerosis NNP 1_p
( ( 1_p
ELSA NNP 1_p
) ) 1_p
trial NN 1_p
treated VBD 1_p
for IN 1_p
4 CD 1_p
years NNS 1_p
with IN 1_p
either DT 1_i
atenolol NN 1_i
or CC 1_i
lacidipine NN 1_i
, , 1_i
and CC N
to TO N
check VB N
whether IN N
interindividual JJ N
clinic NN N
and CC N
24-h JJ 1_o
BP NNP 1_o
variabilities NNS 1_o
during IN N
treatment NN N
can MD N
really RB N
be VB N
considered VBN N
a DT N
surrogate NN N
of IN N
intraindividual JJ N
variabilities NNS N
in IN N
exploring VBG N
differences NNS N
between IN 1_i
?-blocker NN 1_i
and CC 1_i
calcium NN 1_i
antagonist NN 1_i
treatments NNS 1_i
. . 1_i

METHODS NNP 1_o
Long-term JJ 1_o
intraindividual JJ 1_o
BP NNP 1_o
variability NN 1_o
was VBD 1_o
defined VBN N
as IN N
the DT 1_o
coefficient NN 1_o
of IN 1_o
variation NN 1_o
of IN 1_o
the DT 1_o
average JJ 1_o
systolic JJ 1_o
or CC 1_o
diastolic JJ 1_o
values NNS 1_o
of IN 1_o
clinic JJ 1_o
and CC 1_o
24-h JJ 1_o
BP NNP 1_o
measured VBD 1_o
at IN N
each DT N
visit NN N
throughout IN N
the DT N
treatment NN N
period NN 1_p
. . 1_p

Patients NNS 1_p
in IN 1_p
whom WP 1_p
at IN 1_p
least JJS 1_p
seven CD 1_p
clinic JJ 1_p
( ( 1_p
6-month JJ 1_p
intervals NNS 1_p
) ) 1_p
or CC 1_p
at IN 1_p
least JJS 1_p
three CD 1_p
( ( 1_p
yearly JJ 1_p
intervals NNS 1_p
) ) 1_p
24-h JJ 1_p
values NNS 1_p
were VBD 1_p
available JJ 1_p
from IN 1_p
the DT 1_p
end NN 1_p
of IN 1_p
the DT 1_p
drug NN 1_p
titration NN 1_p
phase NN 1_p
to TO 1_p
the DT 1_p
end NN 1_p
of IN 1_p
the DT 1_p
study NN 1_p
were VBD 1_p
considered VBN 1_p
. . 1_p

RESULTS JJ 1_o
Visit-to-visit JJ 1_o
24-h JJ 1_o
SBP/DBP NNP 1_o
variabilities NNS 1_o
were VBD 1_o
20-25 CD N
% NN N
smaller JJR N
than IN N
, , N
and CC N
loosely RB N
correlated VBN N
with IN 1_o
clinic JJ 1_o
BP NNP 1_o
variability NN 1_o
( ( 1_o
r NN N
( ( N
2 CD N
) ) N
< FW N
0.022 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
very RB N
limited JJ N
relationship NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
< FW 1_o
0.026 CD 1_o
) ) 1_o
between IN 1_o
visit-to-visit NN 1_o
and CC 1_o
within IN 1_o
24-h JJ 1_o
ambulatory NN 1_o
BP NNP 1_o
variabilities NNS 1_o
, , 1_o
the DT 1_o
latter JJ 1_o
being VBG N
two CD N
to TO N
three CD N
times NNS N
greater JJR N
than IN N
the DT N
former JJ N
. . 1_o

Visit-to-visit JJ 1_o
intraindividual JJ 1_o
clinic NN 1_o
SBP NNP 1_o
variability NN 1_o
was VBD 1_o
only RB 1_o
slightly RB N
lower JJR N
on IN N
calcium NN N
antagonist NN N
than IN N
on IN N
?-blocker JJ N
treatment NN N
but CC N
little JJ N
or CC N
no DT N
between-treatment JJ N
difference NN N
was VBD N
found VBN N
for IN 1_o
visit-to-visit NN 1_o
clinic NN 1_o
DBP NNP 1_o
and CC 1_o
ambulatory JJ 1_o
SBP/DBP NNP 1_o
particularly RB 1_o
in IN N
patients NNS N
under IN N
monotherapy NN N
throughout IN N
the DT N
study NN N
. . N

Interindividual NNP 1_o
BP NNP 1_o
variability NN 1_o
was VBD 1_o
markedly RB 1_o
greater JJR N
than IN N
the DT N
intra-individiual JJ N
one CD N
of IN N
which WDT N
it PRP N
did VBD N
not RB N
precisely RB N
reflect VB N
the DT N
treatment-induced JJ N
changes NNS N
. . N

CONCLUSION NN N
In IN 1_p
mild-to-moderate JJ 1_p
hypertensive JJ 1_o
patients NNS 1_o
, , 1_o
visit-to-visit JJ 1_o
BP NNP 1_o
variability NN 1_o
does VBZ 1_o
not RB 1_o
differ VB 1_o
substantially RB 1_i
between IN 1_i
?-blocker NN 1_i
and CC 1_i
calcium NN 1_i
antagonist NN 1_i
treatment NN 1_i
. . 1_i

Major JJ N
discrepancies NNS N
exist VBP N
between IN N
visit-to-visit NN N
BP NNP N
variability NN N
as IN N
quantified VBN N
by IN N
24-h JJ N
vs. FW N
clinic JJ N
BP NNP N
, , N
making VBG N
investigation NN N
of IN N
which WDT N
of IN N
these DT N
indices NNS N
is VBZ N
clinically RB N
more RBR N
relevant JJ N
important JJ N
. . N

Interindividual JJ 1_o
BP NNP 1_o
variability NN 1_o
during IN N
treatment NN N
shows NNS N
marked VBD N
quantitative JJ N
differences NNS N
with IN N
intraindividual JJ N
BP NNP N
variability NN N
questioning VBG N
whether IN N
its PRP$ N
use NN N
can MD N
accurately RB N
reflect VB N
individual JJ N
BP NNP N
variations NNS N
from IN N
one CD N
visit NN N
to TO N
another DT N
. . N

-DOCSTART- -X- O O

Neurophysiological JJ 1_o
responses NNS 1_o
to TO 1_o
faces VBZ 1_o
and CC 1_o
gaze JJ 1_o
direction NN 1_o
differentiate NN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
, , 1_p
ADHD NNP 1_p
and CC 1_p
ASD+ADHD NNP 1_p
. . 1_p

Children NNP 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
and CC 1_p
attention NN 1_p
deficit NN 1_p
hyperactivity NN 1_p
disorder NN 1_p
( ( 1_p
ADHD NNP 1_p
) ) 1_p
demonstrate VBP N
face NN 1_o
processing NN 1_o
abnormalities NNS 1_o
that WDT N
may MD N
underlie VB N
social JJ N
impairment NN N
. . N

Despite IN N
substantial JJ N
overlap NN N
between IN N
ASD NNP N
and CC N
ADHD NNP N
, , N
ERP NNP 1_o
markers NNS 1_o
of IN 1_o
face NN 1_o
and CC 1_o
gaze NN 1_o
processing NN 1_o
have VBP N
not RB N
been VBN N
directly RB N
compared VBN N
across IN N
pure NN N
and CC N
comorbid NN N
cases NNS N
. . N

Children NNP 1_p
with IN 1_p
ASD NNP 1_p
( ( 1_p
n=19 NN 1_p
) ) 1_p
, , 1_p
ADHD NNP 1_p
( ( 1_p
n=18 NN 1_p
) ) 1_p
, , 1_p
comorbid JJ 1_p
ASD+ADHD NNP 1_p
( ( 1_p
n=29 NN 1_p
) ) 1_p
and CC 1_p
typically RB 1_p
developing VBG 1_p
( ( 1_p
TD NNP 1_p
) ) 1_p
controls NNS 1_p
( ( 1_p
n=26 NN 1_p
) ) 1_p
were VBD N
presented VBN N
with IN N
upright/inverted JJ 1_i
faces VBZ 1_i
with IN 1_i
direct/averted VBN 1_i
gaze NN 1_i
, , N
with IN N
concurrent JJ N
recording NN N
of IN N
the DT N
P1 NNP N
and CC N
N170 NNP N
components NNS N
. . N

While IN N
the DT N
N170 NNP N
was VBD N
predominant VBN N
in IN N
the DT N
right NN N
hemisphere NN N
in IN N
TD NNP N
and CC N
ADHD NNP N
, , N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
( ( 1_p
ASD/ASD+ADHD NNP 1_p
) ) 1_p
showed VBD N
a DT N
bilateral JJ N
distribution NN N
. . N

In IN N
addition NN N
, , N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
demonstrated VBD N
altered JJ N
response NN 1_o
to TO 1_o
gaze VB 1_o
direction NN 1_o
on IN N
P1 NNP N
latency NN N
and CC N
no DT N
sensitivity NN 1_o
to TO 1_o
gaze VB 1_o
direction NN 1_o
on IN N
midline-N170 JJ N
amplitude NN N
compared VBN N
to TO N
TD NNP N
and CC N
ADHD NNP N
. . N

In IN N
contrast NN N
, , N
children NNS 1_p
with IN 1_p
ADHD NNP 1_p
( ( 1_p
ADHD/ASD+ADHD NNP 1_p
) ) 1_p
exhibited VBD N
a DT N
reduced JJ N
face NN 1_o
inversion NN 1_o
effect NN 1_o
on IN N
P1 NNP N
latency NN N
compared VBN N
to TO N
TD NNP N
and CC N
ASD NNP N
. . N

These DT N
findings NNS N
suggest VBP N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
have VBP N
specific JJ N
abnormalities NNS 1_o
in IN 1_o
gaze NN 1_o
processing NN 1_o
and CC 1_o
altered JJ 1_o
neural JJ 1_o
specialisation NN 1_o
, , N
whereas JJ N
children NNS 1_p
with IN 1_p
ADHD NNP 1_p
show NN N
abnormalities NNS 1_o
at IN N
early JJ N
visual JJ N
attention NN N
stages NNS N
. . N

Children NNP 1_p
with IN 1_p
ASD+ADHD NNP 1_p
are VBP N
an DT N
additive JJ N
co-occurrence NN N
with IN N
deficits NNS N
of IN N
both DT N
disorders NNS N
. . N

Elucidating VBG N
the DT N
neural JJ N
basis NN N
of IN N
the DT N
overlap NN N
between IN N
ASD NNP N
and CC N
ADHD NNP N
is VBZ N
likely JJ N
to TO N
inform VB N
aetiological JJ N
investigation NN N
and CC N
clinical JJ N
assessment NN N
. . N

-DOCSTART- -X- O O

Oesophageal JJ 1_p
intubation NN 1_p
can MD N
be VB N
undetected VBN N
by IN N
auscultation NN 1_i
of IN N
the DT N
chest NN N
. . N

Prompt NNP N
detection NN N
of IN N
oesophageal JJ 1_i
intubation NN 1_i
is VBZ N
a DT N
primary JJ N
concern NN N
in IN N
anaesthetic JJ N
practice NN N
. . N

This DT N
blind NN N
, , N
randomised VBD N
study NN N
evaluates NNS N
three CD N
widely RB N
used JJ N
tests NNS N
of IN N
intubation NN 1_i
. . 1_i

Forty NNP 1_p
patients NNS 1_p
had VBD 1_p
both DT 1_p
their PRP$ 1_p
trachea NN 1_p
and CC 1_p
oesophagus NN 1_p
intubated VBN 1_i
, , N
each DT N
patient NN N
was VBD N
studied VBN N
twice RB N
. . N

Auscultation NN 1_o
of IN 1_o
the DT 1_o
epigastrium NN 1_o
, , N
right NN N
and CC N
left VBD N
axilla NN N
is VBZ N
more RBR N
reliable JJ N
than IN N
auscultation NN N
of IN N
the DT N
chest NN N
, , N
and CC N
the DT N
anaesthetist NN 1_p
's POS 1_p
feeling NN 1_p
when WRB 1_p
he PRP 1_p
squeezes VBZ 1_p
the DT 1_p
bag NN 1_p
. . 1_p

P NNP N
= VBD N
0.001 CD N
and CC N
P NNP N
= NNP N
0.048 CD N
, , N
respectively RB N
. . N

The DT N
tests NNS N
were VBD N
carried VBN N
out RP N
after IN N
gastric JJ N
distension NN N
with IN N
gas NN N
had VBD N
occurred VBN N
. . N

We PRP N
conclude VBP N
that DT N
auscultation NN N
of IN N
epigastrium NN N
, , N
right NN N
and CC N
left VBD N
axilla NN N
, , N
are VBP N
recommended VBN N
. . N

-DOCSTART- -X- O O

A DT N
brief JJ 1_i
adherence NN 1_i
intervention NN 1_i
that WDT N
improved VBD N
glycemic JJ 1_o
control NN 1_o
: : 1_o
mediation NN N
by IN N
patterns NNS N
of IN N
adherence NN N
. . N

This DT N
study NN N
examined VBD N
whether IN N
longitudinal JJ N
adherence NN N
profiles NNS N
mediated VBD N
the DT N
relationship NN N
between IN N
a DT 1_p
brief JJ 1_p
adherence NN 1_i
intervention NN 1_i
and CC 1_p
glycemic JJ 1_p
control NN 1_p
among IN 1_p
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
. . 1_p

Adherence NNP 1_i
was VBD N
assessed VBN N
using VBG N
the DT N
Medication NNP N
Event NNP N
Monitoring NNP N
System NNP N
. . N

Longitudinal JJ N
analysis NN N
via IN N
growth NN N
curve VBP N
mixture NN N
modeling NN N
was VBD N
carried VBN N
out IN N
to TO N
classify VB N
patients NNS N
according VBG N
to TO N
patterns NNS N
of IN N
adherence NN 1_i
to TO 1_i
oral JJ 1_i
hypoglycemic JJ 1_i
agents NNS 1_i
. . 1_i

Hemoglobin NNP N
A1c NNP N
assays NNS N
were VBD N
used VBN N
to TO N
measure VB N
glycemic JJ 1_o
control NN 1_o
as IN N
the DT N
clinical JJ N
outcome NN N
. . N

Across IN N
the DT N
whole JJ N
sample NN N
, , N
longitudinal JJ N
adherence NN N
profiles NNS N
mediated VBD N
35.2 CD N
% NN N
( ( N
13.2 CD N
, , N
81.0 CD N
% NN N
) ) N
of IN N
the DT N
effect NN N
of IN N
a DT N
brief JJ N
adherence NN 1_i
intervention NN 1_i
on IN N
glycemic JJ 1_o
control NN 1_o
[ NN N
from IN N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
= VBZ N
8.48 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
( ( N
3.24 CD N
, , N
22.2 CD N
) ) N
to TO N
4.00 CD N
, , N
95 CD N
% NN N
CI NNP N
( ( N
1.34 CD N
, , N
11.93 CD N
) ) N
] NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
patients NNS N
in IN N
the DT N
intervention NN N
had VBD N
better JJR N
glycemic JJ 1_o
control NN 1_o
largely RB N
due JJ N
to TO N
their PRP$ N
greater JJR N
likelihood NN N
of IN N
adherence NN N
to TO N
oral JJ N
hypoglycemic JJ N
agents NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
the DT N
efficacy NN N
of IN N
heparinized VBN 1_i
and CC 1_i
nonheparinized JJ 1_i
solutions NNS 1_i
for IN N
maintenance NN 1_o
of IN 1_o
perioperative JJ 1_o
radial JJ 1_o
arterial JJ 1_o
catheter NN 1_o
patency NN 1_o
and CC 1_o
subsequent JJ 1_o
occlusion NN 1_o
. . 1_o

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled VBD N
study NN N
, , N
we PRP N
compared VBN N
heparinized VBN 1_i
and CC 1_i
nonheparinized VBN 1_i
infusions NNS 1_i
for IN N
the DT N
maintenance NN 1_o
of IN 1_o
perioperative JJ 1_o
arterial JJ 1_o
catheter NN 1_o
patency NN 1_o
and CC 1_o
the DT 1_o
incidence NN 1_o
of IN 1_o
subsequent JJ 1_o
radial JJ 1_o
arterial JJ 1_o
occlusion NN 1_o
. . 1_o

Two-hundred JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN N
into IN N
2 CD 1_i
groups NNS 1_i
to TO 1_i
receive VB 1_i
heparinized VBN 1_i
( ( 1_i
group NN 1_i
H NNP 1_i
, , 1_i
n JJ 1_i
= NNP 1_i
100 CD 1_i
) ) 1_i
or CC 1_i
nonheparinized VBN 1_i
( ( 1_i
group NN 1_i
S NNP 1_i
, , 1_i
n JJ 1_i
= NNP 1_i
100 CD 1_i
) ) 1_i
flush NN 1_i
solutions NNS 1_i
. . 1_i

Radial NNP 1_o
and CC 1_o
ulnar JJ 1_o
blood NN 1_o
flows NNS 1_o
were VBD 1_i
assessed VBN 1_i
using VBG 1_i
Doppler NNP 1_o
probe NN 1_o
and CC 1_o
pulse JJ 1_o
oximetry NN 1_o
before IN 1_i
, , 1_i
just RB 1_i
after IN 1_i
, , 1_i
and CC 1_i
24 CD 1_i
h NN 1_i
after IN 1_i
decannulation NN 1_o
by IN 1_i
the DT 1_i
same JJ 1_i
investigator NN 1_i
. . 1_i

The DT 1_o
cannulation NN 1_o
site NN 1_o
was VBD N
examined VBN N
for IN N
complications NNS 1_o
such JJ 1_o
as IN 1_o
hematoma NN 1_o
, , 1_o
nerve JJ 1_o
injury NN 1_o
, , 1_o
and CC 1_o
infection NN 1_o
. . 1_o

The DT N
mean JJ N
duration NN N
of IN N
cannulations NNS 1_o
was VBD N
378 CD N
+/- JJ N
159.0 CD N
min NN N
in IN N
group NN N
H NNP N
and CC N
332 CD N
+/- JJ N
154.6 CD N
min NN N
in IN N
group NN N
S. NNP N
The DT N
mean JJ N
number NN N
of IN N
corrective JJ N
interventions NNS N
caused VBN N
by IN N
dampening VBG N
of IN N
the DT N
pressure NN N
wave NN N
( ( N
mean JJ N
number NN N
of IN N
positional JJ N
changes NNS N
[ VBP N
group NN N
S NNP N
, , N
1.5 CD N
+/- JJ N
2.0 CD N
; : N
group NN N
H NNP N
, , N
1.4 CD N
+/- JJ N
3.8 CD N
] NN N
and CC N
mean JJ N
number NN N
of IN N
manual JJ 1_o
flushes NNS 1_o
[ VBP N
group NN N
S NNP N
, , N
1.3 CD N
+/- JJ N
1.7 CD N
; : N
group NN N
H NNP N
, , N
1.2 CD N
+/- JJ N
1.2 CD N
] NN N
) ) N
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

After IN N
decannulation NN N
, , N
partial JJ 1_o
or CC 1_o
total JJ 1_o
occlusion NN 1_o
developed VBD N
in IN N
20 CD N
group NN N
H NNP N
patients NNS N
and CC N
16 CD N
group NN N
S NNP N
patients NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

The DT N
incidence NN N
of IN N
occlusion NN 1_o
was VBD N
correlated VBN N
to TO N
the DT N
presence NN 1_p
of IN 1_p
hematoma NN 1_o
at IN 1_p
the DT 1_p
puncture NN 1_p
site NN 1_p
after IN 1_p
decannulation NN 1_p
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
, , N
long JJ 1_o
duration NN 1_o
of IN 1_o
cannulation NN 1_o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
age NN 1_p
< VBP 1_p
65 CD 1_p
yr NN 1_p
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
there EX N
is VBZ N
no DT N
significant JJ N
difference NN N
between IN N
heparinized VBN 1_i
and CC 1_i
nonheparinized VBN 1_i
flush JJ 1_i
solutions NNS 1_i
for IN N
the DT N
maintenance NN 1_o
of IN 1_o
perioperative JJ 1_o
radial JJ 1_o
artery NN 1_o
catheter NN 1_o
patency NN 1_o
. . 1_o

-DOCSTART- -X- O O

Effects NNS N
of IN N
iron NN 1_i
supplements NNS 1_i
and CC N
perinatal JJ N
factors NNS N
on IN N
fetal JJ N
hemoglobin NN N
disappearance NN N
in IN N
LBW NNP 1_p
infants NNS 1_p
. . 1_p

BACKGROUND IN N
The DT N
homeostatic JJ N
mechanisms NN N
of IN N
iron NN N
metabolism NN N
and CC N
erythropoiesis NN N
in IN N
infants NNS N
are VBP N
unclear JJ N
. . N

Infants NNS N
synthesize VB N
both DT N
fetal JJ N
hemoglobin NN N
( ( N
HbF NNP N
) ) N
and CC N
adult NN N
hemoglobin NN N
( ( N
HbA NNP N
) ) N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
how WRB N
the DT N
hemoglobin NN N
switch NN N
is VBZ N
regulated VBN N
. . N

We PRP N
hypothesized VBD N
that IN N
iron NN N
supplements NNS N
to TO N
infants NNS N
affect VB N
the DT N
disappearance NN N
of IN N
HbF NNP N
. . N

METHODS NNP N
We PRP N
randomized VBD N
285 CD 1_p
low-birth-weight JJ 1_p
infants NNS 1_p
( ( 1_p
2,000-2,500 JJ 1_p
g NN 1_p
) ) 1_p
into IN 1_p
three CD N
intervention NN N
groups NNS 1_i
receiving VBG 1_i
0 CD 1_i
, , 1_i
1 CD 1_i
, , 1_i
or CC 1_i
2 CD 1_i
mg/kg/d NN 1_i
of IN 1_i
iron NN 1_i
supplements NNS 1_i
from IN 1_i
6 CD 1_i
wk NN 1_i
to TO 1_i
6 CD 1_i
mo NN 1_i
of IN 1_i
age NN 1_i
. . 1_i

In IN N
the DT N
present JJ N
secondary JJ N
analysis NN 1_i
, , 1_i
we PRP 1_i
analyzed VBD 1_o
iron NN 1_o
status NN 1_o
, , 1_o
total JJ 1_o
hemoglobin NN 1_o
( ( 1_o
Hb NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
HbF NNP 1_o
fraction NN 1_o
at IN 1_i
6 CD 1_i
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
at IN N
6 CD N
mo NN N
and CC N
calculated VBD N
absolute JJ N
levels NNS N
of IN N
HbF NNP N
. . N

RESULTS NNP N
We PRP N
observed VBD N
dose-dependent JJ N
increased JJ N
levels NNS N
of IN N
Hb NNP 1_o
in IN 1_o
iron-supplemented JJ N
groups NNS N
at IN N
6 CD N
mo NN N
of IN N
age NN N
. . N

However RB N
, , N
for IN 1_o
absolute JJ 1_o
HbF NNP 1_o
concentration NN 1_o
, , 1_o
there EX 1_o
was VBD 1_o
no DT N
similar JJ N
effect NN N
of IN N
intervention NN 1_o
. . 1_o

Mean NNP 1_o
( ( 1_o
SD NNP 1_o
) ) 1_o
HbF NNP 1_o
was VBD N
81.2 CD N
( ( N
16.8 CD N
) ) N
, , N
37.0 CD N
( ( N
13.8 CD N
) ) N
, , N
and CC N
8.1 CD N
( ( N
5.6 CD N
) ) N
g/l NN N
at IN N
6 CD N
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
6 CD N
mo NN N
, , N
respectively RB N
, , N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

In IN N
linear JJ N
regression NN N
analyses NNS N
, , N
postconceptional JJ N
age NN N
turned VBD N
out RP N
as IN N
the DT N
major JJ N
predictor NN N
of IN N
HbF NNP N
, , N
independent JJ N
of IN N
gestational JJ N
age NN N
at IN N
birth NN N
. . N

CONCLUSION NNP N
Our PRP$ N
hypothesis NN N
was VBD N
rejected VBN N
. . N

Instead RB N
, , N
we PRP N
confirmed VBD N
a DT N
close JJ N
correlation NN N
to TO N
postconceptional JJ N
age NN N
, , N
supporting VBG N
a DT N
genetically RB N
programmed VBN N
switch NN N
, , N
insensitive JJ N
to TO N
most JJS N
environmental JJ N
factors NNS N
including VBG N
birth NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
a DT N
behavioral JJ 1_i
intervention NN 1_i
for IN N
black JJ 1_p
MSM NNP 1_p
: : 1_p
the DT N
DiSH NNP N
study NN N
. . N

OBJECTIVE NNP N
To TO N
test VB N
a DT N
new JJ N
behavioral JJ N
intervention NN N
for IN N
black JJ 1_p
MSM NNP 1_p
in IN N
reducing VBG N
sexual JJ N
risk NN N
and CC N
increasing VBG N
social JJ N
support NN N
and CC N
intentions NNS N
to TO N
use VB N
condoms NNS N
. . N

DESIGN VB N
A DT N
single-site JJ N
, , N
unblinded JJ N
randomized VBN N
trial NN N
in IN N
New NNP 1_p
York NNP 1_p
City NNP 1_p
with IN N
3-month JJ N
follow-up NN N
. . N

METHODS NNP N
Participants NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
283 CD 1_p
) ) 1_p
reporting NN 1_p
at IN 1_p
least JJS 1_p
two CD 1_p
sexual JJ 1_p
partners NNS 1_p
and CC 1_p
unprotected JJ 1_p
anal JJ 1_p
intercourse NN 1_p
with IN 1_p
a DT 1_p
man NN 1_p
in IN 1_p
the DT 1_p
past JJ 1_p
3 CD 1_p
months NNS 1_p
were VBD N
enrolled VBN N
and CC N
randomized VBN N
to TO N
a DT N
social-cognitive JJ 1_i
theory-based JJ 1_i
intervention NN 1_i
or CC 1_i
control NN 1_i
comparison NN 1_i
. . 1_i

Men NN N
in IN N
the DT N
intervention NN N
group NN N
participated VBD N
in IN N
five CD N
2-h JJ N
group NN N
sessions NNS N
focused VBD N
on IN N
creating VBG N
a DT N
group NN N
environment NN N
with IN N
sexual JJ N
risk-reduction NN N
information NN N
and CC N
exercises VBZ N
woven VBN N
into IN N
joint JJ N
meal JJ N
preparation NN N
and CC N
sharing NN N
activities NNS N
, , N
while IN N
exploring VBG N
self-efficacy JJ N
perceptions NNS N
and CC N
outcome JJ N
expectancies NNS N
. . N

Intervention NNP N
( ( N
n JJ N
= NNP N
142 CD N
) ) N
and CC N
control NN N
( ( N
n JJ N
= NNP N
141 CD N
) ) N
groups NNS N
received VBD N
standard JJ N
HIV NNP N
counseling NN N
and CC N
testing VBG N
at IN N
baseline NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
study NN N
arms NNS N
at IN N
3 CD N
months NNS N
in IN N
number NN 1_o
of IN 1_o
male JJ 1_o
partners NNS 1_o
, , 1_o
number NN 1_o
of IN 1_o
unprotected JJ 1_o
anal JJ 1_o
intercourse NN 1_o
partners NNS 1_o
, , 1_o
proportion NN 1_o
reporting NN 1_o
unprotected JJ 1_o
sex NN 1_o
, , 1_o
number NN 1_o
of IN 1_o
acts NNS 1_o
protected VBN 1_o
by IN 1_o
condoms NNS 1_o
, , 1_o
self-efficacy NN 1_o
, , 1_o
condom NN 1_o
attitudes NNS 1_o
, , 1_o
condom NN 1_o
intentions NNS 1_o
, , 1_o
social JJ 1_o
isolation NN 1_o
and CC 1_o
psychological JJ 1_o
distress NN 1_o
. . 1_o

In IN N
both DT N
arms NNS N
combined VBN N
, , N
declines NNS N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
were VBD N
observed VBN N
in IN N
sexual JJ 1_o
risk NN 1_o
behaviors NNS 1_o
, , 1_o
social JJ 1_o
isolation NN 1_o
and CC 1_o
psychological JJ 1_o
distress NN 1_o
, , N
whereas IN N
self-efficacy NN 1_o
, , 1_o
condom NN 1_o
attitudes NNS 1_o
and CC 1_o
condom NN 1_o
intentions NNS N
improved VBN N
. . N

CONCLUSION NNP N
As IN N
the DT N
HIV NNP N
epidemic JJ N
continues VBZ N
to TO N
have VB N
a DT N
dramatic JJ N
impact NN N
on IN N
black JJ 1_p
MSM NNP 1_p
in IN 1_p
the DT 1_p
USA NNP 1_p
, , N
the DT N
urgency NN N
to TO N
design VB N
innovative JJ N
interventions NNS N
continues VBZ N
. . N

-DOCSTART- -X- O O

Pilot NNP N
study NN N
of IN N
the DT N
effectiveness NN N
of IN N
weighted JJ 1_i
vests NNS 1_i
. . 1_i

OBJECTIVE NN N
In IN N
this DT N
pilot NN N
study NN N
, , N
we PRP N
determined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
weighted JJ 1_i
vest NN 1_i
on IN N
attention NN N
to TO N
task VB N
for IN N
second-grade JJ 1_p
general JJ 1_p
education NN 1_p
students NNS 1_p
with IN 1_p
difficulty NN 1_p
attending VBG 1_p
. . 1_p

METHOD NNP N
We PRP N
used VBD N
an DT N
intervention NN 1_i
and CC N
a DT N
control NN 1_i
group NN N
and CC N
an DT N
ABA NNP N
design NN N
to TO N
compare VB N
participants NNS N
' POS N
percentage NN N
of IN N
time NN N
on IN N
task NN N
with IN 1_i
and CC 1_i
without IN 1_i
a DT 1_i
vest NN 1_i
. . 1_i

Ten CD 1_p
participants NNS 1_p
from IN 1_p
nine CD 1_p
elementary JJ 1_p
schools NNS 1_p
in IN 1_p
a DT 1_p
suburban JJ 1_p
Texas NNP 1_p
school NN 1_p
district NN 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
an DT N
intervention NN 1_i
or CC N
a DT N
control NN 1_i
group NN N
. . N

Control NNP N
group NN N
participants NNS N
wore VBD N
a DT N
nonweighted JJ 1_i
vest NN 1_i
. . 1_i

Participants NNS N
, , N
classroom NN N
teachers NNS N
, , N
and CC N
research NN N
assistants NNS N
who WP N
coded VBD N
the DT N
data NNS N
were VBD N
blind RB N
as IN N
to TO N
the DT N
group NN N
to TO N
which WDT N
the DT N
participants NNS N
were VBD N
assigned VBN N
. . N

RESULTS VB N
A NNP N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
indicated VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
or CC N
between IN N
baseline NN N
, , N
intervention NN N
, , N
and CC N
withdrawal NN N
conditions NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN N
the DT N
weighted JJ 1_i
vests NNS 1_i
were VBD N
not RB N
effective JJ N
in IN N
increasing VBG N
time NN 1_o
on IN 1_o
task NN 1_o
. . 1_o

These DT N
results NNS N
should MD N
be VB N
generalized VBN N
cautiously RB N
owing VBG N
to TO N
the DT N
small JJ N
sample NN N
size NN N
and CC N
participant JJ N
selection NN N
process NN N
. . N

-DOCSTART- -X- O O

Further JJ N
validation NN N
of IN N
the DT N
alcohol NN N
dependence NN N
scale NN N
as IN N
an DT N
index NN N
of IN N
severity NN N
. . N

OBJECTIVE CC N
The DT N
Alcohol NNP 1_i
Dependence NNP 1_i
Scale NNP 1_i
( ( N
ADS NNP N
) ) N
yields VBZ N
continuous JJ N
scores NNS N
purported VBN N
to TO N
reflect VB N
the DT N
severity NN N
of IN N
the DT N
dependence NN N
syndrome NN N
. . N

We PRP N
evaluated VBD N
the DT N
concurrent JJ 1_o
validity NN 1_o
of IN 1_o
the DT 1_o
ADS NNP 1_o
as IN 1_o
a DT 1_o
general JJ 1_o
measure NN 1_o
of IN 1_o
severity NN 1_o
and CC 1_o
the DT 1_o
screening VBG 1_o
accuracy NN 1_o
of IN N
the DT N
total JJ N
score NN N
and CC N
subscales NNS N
to TO N
detect VB N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
( ( N
DSM-IV NNP N
) ) N
, , N
physiological JJ N
dependence NN N
. . N

METHOD NNP N
Treatment-seeking JJ 1_p
, , 1_p
alcohol-dependent JJ 1_p
individuals NNS 1_p
entering VBG 1_p
the DT 1_p
Combining NNP 1_p
Pharmacotherapies NNPS 1_p
and CC 1_p
Behavioral NNP 1_p
Interventions NNP 1_p
for IN 1_p
Alcohol NNP 1_p
Dependence NNP 1_p
( ( 1_p
COMBINE NNP 1_p
) ) 1_p
Study NNP 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
1,372 CD 1_p
; : 1_p
69 CD 1_p
% NN 1_p
men NNS 1_p
) ) 1_p
completed VBD N
the DT N
ADS NNP N
, , N
diagnostic JJ N
interviews NNS N
, , N
and CC N
other JJ N
measures NNS N
before IN N
randomization NN N
. . N

Analyses NNS 1_o
of IN 1_o
variance NN 1_o
tested VBN 1_o
differences NNS 1_o
between IN 1_o
ADS NNP 1_o
quartiles NNS 1_o
on IN 1_o
alcohol- JJ 1_o
related JJ 1_o
measures NNS 1_o
. . 1_o

Areas NNP N
under IN N
the DT N
receiver NN N
operating VBG N
characteristic JJ N
( ( N
AUROC NNP N
) ) N
curve NN N
assessed VBD N
screening VBG N
accuracy NN N
for IN N
DSM-IV NNP N
physiological JJ N
dependence NN N
( ( N
tolerance NN N
or CC N
withdrawal NN N
) ) N
or CC N
withdrawal VB N
alone RB N
. . N

RESULTS NNP N
ADS NNP N
quartiles VBZ N
differed VBN N
on IN N
age NN N
, , N
other JJ N
demographics NNS N
, , N
and CC N
prior RB N
treatment NN N
episodes NNS N
. . N

Linear JJ N
correlation NN N
showed VBD N
moderate JJ N
to TO N
large JJ N
magnitude NN N
associations NNS N
with IN N
alcohol-related JJ N
self-report JJ N
measures NNS N
and CC N
most JJS N
indices NNS N
of IN N
consumption NN N
. . N

ADS NNP N
quartiles NNS N
differed VBD N
significantly RB N
on IN N
proportion NN 1_o
with IN 1_o
DSM-IV NNP 1_o
physiological JJ 1_o
dependence NN 1_o
, , N
but CC N
AUROC NNP N
curves NNS N
indicated VBD N
that IN N
the DT N
ADS NNP N
had VBD N
limited VBN N
accuracy NN 1_o
as IN N
a DT N
continuous JJ N
measure NN N
to TO N
detect VB N
DSMIV NNP 1_o
physiological JJ 1_o
dependence NN 1_o
( ( N
AUROC NNP N
= NNP N
.75 NNP N
[ VBD N
95 CD N
% NN N
confidence NN N
interval NN N
{ ( N
CI NNP N
} ) N
: : N
.70-.79 JJ N
] NN N
and CC N
.67 NNP N
[ VBP N
95 CD N
% NN N
CI NNP N
: : N
.60-.74 JJ N
] NN N
for IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
; : N
p CC N
= NNP N
.08 NNP N
) ) N
or CC N
withdrawal VB N
alone RB N
( ( N
AUROC NNP N
= NNP N
.77 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
: : N
.74-.80 JJ N
] NN N
and CC N
.74 NNP N
[ VBP N
95 CD N
% NN N
CI NNP N
: : N
.69-.79 JJ N
] NN N
for IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
; : N
p CC N
= NNP N
.30 NNP N
) ) N
. . N

Screening VBG 1_o
accuracy NN 1_o
was VBD N
comparably RB N
limited VBN N
based VBN N
on IN N
ADS NNP N
subscales NNS N
reflecting VBG N
psychoperceptual JJ N
or CC N
psychophysical JJ N
withdrawal NN N
. . N

CONCLUSIONS VB N
The DT N
ADS NNP N
reflected VBD N
variation NN N
in IN N
symptom JJ N
severity NN N
but CC N
did VBD N
not RB N
adequately RB N
identify VB N
physiological JJ N
dependence NN N
or CC N
withdrawal NN N
in IN N
treatment-seeking JJ 1_p
individuals NNS 1_p
with IN 1_p
DSM-IV NNP 1_p
alcohol NN 1_p
dependence NN 1_p
. . 1_p

-DOCSTART- -X- O O

Risperidone NN 1_i
in IN N
the DT N
treatment NN N
of IN N
disruptive JJ N
behavioral NN N
symptoms NNS N
in IN N
children NNS 1_p
with IN 1_p
autistic JJ 1_p
and CC 1_p
other JJ 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
risperidone NN 1_i
for IN N
the DT N
treatment NN N
of IN N
disruptive JJ N
behavioral NN N
symptoms NNS N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
other JJ 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
( ( 1_p
PDD NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
In IN N
this DT N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
, , N
risperidone/placebo JJ 1_i
solution NN 1_i
( ( N
0.01-0.06 JJ N
mg/kg/day NN N
) ) N
was VBD N
administered VBN N
to TO N
79 CD 1_p
children NNS 1_p
who WP 1_p
were VBD 1_p
aged VBN 1_p
5 CD 1_p
to TO 1_p
12 CD 1_p
years NNS 1_p
and CC 1_p
had VBD 1_p
PDD NNP 1_p
. . 1_p

Behavioral NNP N
symptoms NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
( ( 1_o
ABC NNP 1_o
) ) 1_o
, , N
Nisonger NNP N
Child NNP N
Behavior NNP N
Rating NNP N
Form NNP N
, , N
and CC N
Clinical JJ N
Global NNP N
Impression-Change NNP N
. . N

Safety NNP N
assessments NNS N
included VBD N
vital JJ N
signs NNS N
, , N
electrocardiogram NN N
, , N
extrapyramidal NN N
symptoms NNS N
, , N
adverse JJ N
events NNS N
, , N
and CC N
laboratory NN N
tests NNS N
. . N

RESULTS NNP N
Subjects NNPS N
who WP N
were VBD N
taking VBG N
risperidone NN 1_i
( ( N
mean JJ N
dosage NN N
: : N
0.04 CD N
mg/kg/day NN N
; : N
1.17 CD N
mg/day NN N
) ) N
experienced VBD N
a DT N
significantly RB N
greater JJR N
mean JJ 1_o
decrease NN 1_o
on IN 1_o
the DT 1_o
irritability NN 1_o
subscale NN 1_o
of IN 1_o
the DT 1_o
ABC NNP 1_o
( ( N
primary JJ N
endpoint NN N
) ) N
compared VBN N
with IN N
those DT N
who WP N
were VBD N
taking VBG N
placebo NN N
. . N

By IN N
study NN N
endpoint NN N
, , N
risperidone-treated JJ 1_i
subjects NNS N
exhibited VBD N
a DT N
64 CD N
% NN N
improvement NN N
over IN N
baseline NN N
in IN N
the DT N
irritability NN 1_o
score NN 1_o
almost RB N
double JJ N
that IN N
of IN N
placebo-treated JJ 1_i
subjects NNS N
( ( N
31 CD N
% NN N
) ) N
. . N

Risperidone-treated JJ 1_i
subjects NNS N
also RB N
exhibited VBD N
significantly RB N
greater JJR N
decreases NNS N
on IN N
the DT N
other JJ N
4 CD 1_o
subscales NNS 1_o
of IN 1_o
the DT 1_o
ABC NNP 1_o
; : 1_o
on IN N
the DT N
conduct NN 1_o
problem NN 1_o
, , 1_o
insecure/anxious JJ 1_o
, , 1_o
hyperactive JJ 1_o
, , 1_o
and CC 1_o
overly RB 1_o
sensitive JJ 1_o
subscales NNS 1_o
of IN 1_o
the DT 1_o
Nisonger NNP 1_o
Child NNP 1_o
Behavior NNP 1_o
Rating NNP 1_o
Form NNP 1_o
( ( 1_o
parent JJ 1_o
version NN 1_o
) ) 1_o
; : 1_o
and CC 1_o
on IN 1_o
the DT 1_o
Visual NNP 1_o
Analog NNP 1_o
Scale NNP 1_o
of IN N
the DT N
most RBS N
troublesome JJ N
symptom NN N
. . N

More JJR N
risperidone-treated JJ 1_i
subjects NNS N
( ( N
87 CD N
% NN N
) ) N
showed VBD N
global JJ N
improvement NN N
in IN N
their PRP$ N
condition NN N
compared VBN N
with IN N
the DT N
placebo NN 1_i
group NN N
( ( N
40 CD N
% NN N
) ) N
. . N

Somnolence NN 1_o
, , N
the DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
event NN N
, , N
was VBD N
noted VBN N
in IN N
72.5 CD N
% NN N
versus IN N
7.7 CD N
% NN N
of IN N
subjects NNS N
( ( 1_i
risperidone NN 1_i
vs NN 1_i
placebo NN 1_i
) ) 1_i
and CC N
seemed VBD N
manageable JJ N
with IN N
dose/dose-schedule JJ N
modification NN N
. . N

Risperidone-treated JJ 1_i
subjects NNS N
experienced VBD N
statistically RB N
significantly RB N
greater JJR N
increases NNS N
in IN N
weight NN 1_o
( ( N
2.7 CD N
vs RB N
1.0 CD N
kg NN N
) ) N
, , N
pulse JJ 1_o
rate NN 1_o
, , 1_o
and CC 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
. . 1_o

Extrapyramidal NNP N
symptoms JJ N
scores NNS N
were VBD N
comparable JJ N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Risperidone NNP 1_i
was VBD N
well RB N
tolerated VBN N
and CC N
efficacious JJ N
in IN N
treating VBG N
behavioral JJ N
symptoms NNS N
associated VBN N
with IN N
PDD NNP 1_p
in IN 1_p
children NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Computer-assisted JJ 1_i
instruction NN 1_i
: : 1_i
an DT N
effective JJ N
instructional JJ N
method NN N
for IN N
HIV NNP 1_o
prevention NN 1_o
education NN N
? . N
PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
of IN N
a DT N
computer-assisted JJ 1_i
instruction NN 1_i
( ( 1_i
CAI NNP 1_i
) ) 1_i
-based VBD 1_i
intervention NN 1_i
to TO N
a DT N
more RBR N
traditional JJ 1_i
lecture-based JJ 1_i
intervention NN 1_i
for IN N
influencing VBG N
psychosocial JJ N
correlates NNS N
of IN N
human JJ 1_p
immunodeficiency NN 1_p
virus NN 1_p
( ( 1_p
HIV NNP 1_p
) ) 1_p
preventive JJ N
behaviors NNS N
. . N

METHODS NNP N
Students NNPS 1_p
enrolled VBD 1_p
in IN 1_p
a DT 1_p
Human NNP 1_p
Sexuality NNP 1_p
course NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
152 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
CAI NNP 1_i
, , 1_i
Lecture NNP 1_i
, , 1_i
or CC 1_i
No DT 1_i
Intervention NNP 1_i
group NN 1_i
. . 1_i

Participants NNS N
in IN N
the DT N
CAI NNP N
group NN N
reviewed VBD N
a DT N
1-hour JJ N
long JJ N
CAI NNP 1_i
program NN 1_i
, , N
participants NNS N
in IN N
the DT N
Lecture NNP N
group NN N
were VBD N
presented VBN N
with IN N
a DT N
1-hour JJ N
long JJ N
lecture NN N
, , N
and CC N
participants NNS N
in IN N
the DT N
No NNP N
Intervention NNP N
group NN N
received VBD N
no DT N
intervention NN N
. . N

After IN N
completing VBG N
the DT N
respective JJ N
interventions NNS N
, , N
all DT N
participants NNS N
completed VBD N
the DT N
HIV NNP 1_o
questionnaire NN 1_o
, , N
which WDT N
measured VBD N
selected VBN N
Social NNP 1_o
Cognitive NNP 1_o
Theory NNP 1_o
constructs NNS N
associated VBN N
with IN N
HIV NNP 1_o
preventive JJ 1_o
behaviors NNS 1_o
. . 1_o

MANCOVA NNP N
, , N
ANCOVA NNP N
and CC N
Post NNP N
Hoc NNP N
analyses NNS N
were VBD N
utilized JJ N
to TO N
test VB N
for IN N
significant JJ N
differences NNS N
among IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS VB N
The DT N
analyses NNS N
disclosed VBD N
that IN N
, , N
compared VBN N
to TO N
participants NNS N
in IN N
the DT N
Lecture NNP N
group NN N
, , N
participants NNS N
in IN N
the DT N
CAI NNP N
group NN N
scored VBD N
significantly RB N
higher JJR N
on IN N
the DT N
scales NNS 1_o
measuring VBG 1_o
autoimmune JJ 1_o
deficiency NN 1_o
syndrome NN 1_o
( ( 1_o
AIDS NNP 1_o
) ) 1_o
knowledge NN 1_o
, , 1_o
self-evaluative JJ 1_o
outcome NN 1_o
motivation NN 1_o
, , 1_o
and CC 1_o
intention NN 1_o
to TO 1_o
practice NN 1_o
HIV NNP 1_o
preventive JJ 1_o
behaviors NNS 1_o
with IN N
current JJ N
partner NN N
. . N

In IN N
addition NN N
, , N
compared VBN N
to TO N
the DT N
No NNP N
Intervention NNP N
group NN N
, , N
the DT N
CAI NNP N
group NN N
scored VBD N
significantly RB N
higher JJR N
on IN N
the DT N
scales NNS 1_o
measuring VBG 1_o
physical JJ 1_o
outcome NN 1_o
motivation NN 1_o
and CC 1_o
social JJ 1_o
outcome NN 1_o
motivation NN 1_o
. . 1_o

CONCLUSIONS NNP N
CAI-based JJ N
programs NNS N
can MD N
be VB N
effective JJ N
for IN N
delivering VBG N
instruction NN N
on IN N
HIV NNP 1_o
prevention NN 1_o
. . 1_o

However RB N
, , N
because IN N
of IN N
certain JJ N
limitations NNS N
, , N
this DT N
type NN N
of IN N
program NN N
is VBZ N
best RB N
utilized VBN N
as IN N
part NN N
of IN N
a DT N
more RBR N
comprehensive JJ N
intervention NN N
that WDT N
uses VBZ N
several JJ N
different JJ N
delivery NN N
systems NNS N
. . N

-DOCSTART- -X- O O

Single NNP N
and CC N
combined VBN N
effects NNS N
of IN N
atropine NN 1_i
and CC 1_i
metoclopramide NN 1_i
on IN N
the DT N
lower JJR 1_p
oesophageal JJ 1_p
sphincter NN 1_p
pressure NN 1_p
. . 1_p

The DT N
effects NNS N
of IN N
atropine NN 1_i
and CC 1_i
metoclopramide NN 1_i
on IN N
the DT N
lower JJR 1_o
oesophageal JJ 1_o
sphincter NN 1_o
pressure NN 1_o
( ( 1_o
LOSP NNP 1_o
) ) 1_o
were VBD N
studied VBN N
in IN N
12 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
using VBG 1_p
oesophageal JJ 1_p
pressure NN 1_p
transducers NNS 1_p
. . 1_p

Atropine NNP 1_i
decreased VBD N
LOSP NNP 1_o
significantly RB N
at IN N
5 CD N
min NN N
after IN N
i.v NN N
. . N

injection NN N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
) ) N
and CC N
this DT N
change NN N
was VBD N
sustained VBN N
for IN N
60 CD N
min NN N
. . N

Metoclopramide NNP 1_i
increased VBD N
LOSP NNP 1_o
significantly RB N
at IN N
3 CD N
min NN N
after IN N
administration NN N
i.v NN N
. . N

( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
this DT N
change NN N
was VBD N
sustained VBN N
for IN N
40 CD N
min NNS N
. . N

Following VBG N
consecutive JJ N
administration NN N
of IN N
the DT N
drugs NNS N
the DT N
effects NNS N
of IN N
atropine NN 1_i
predominated VBN N
. . N

-DOCSTART- -X- O O

A DT N
first-in-man JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
study NN N
to TO N
evaluate VB N
the DT N
safety NN 1_o
and CC 1_o
feasibility NN 1_o
of IN N
autologous JJ 1_i
delipidated VBN 1_i
high-density NN 1_i
lipoprotein NN 1_i
plasma NN 1_i
infusions NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
coronary JJ 1_p
syndrome NN 1_p
. . 1_p

OBJECTIVES CC N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
whether IN N
serial JJ 1_i
autologous JJ 1_i
infusions NNS 1_i
of IN 1_i
selective JJ 1_i
high-density NN 1_i
lipoprotein NN 1_i
( ( 1_i
HDL NNP 1_i
) ) 1_i
delipidated VBD 1_i
plasma NN 1_i
are VBP N
feasible JJ 1_o
and CC N
well RB N
tolerated VBN 1_o
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
coronary JJ 1_p
syndrome NN 1_p
( ( 1_p
ACS NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND NNP N
Low NNP N
HDL NNP N
is VBZ N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

Plasma NNP N
selective JJ N
delipidation NN N
converts NNS N
alphaHDL VBP N
to TO N
prebeta-like JJ N
HDL NNP N
, , N
the DT N
most RBS N
effective JJ N
form NN N
of IN N
HDL NNP N
for IN N
lipid JJ N
removal NN N
from IN N
arterial JJ N
plaques NNS N
. . N

METHODS NNP N
ACS NNP 1_p
patients NNS 1_p
undergoing VBG 1_p
cardiac JJ 1_p
catheterization NN 1_p
with IN 1_p
> NNP 1_p
or=1 VBP 1_p
nonobstructive JJ 1_p
native JJ 1_p
coronary JJ 1_p
artery NN 1_p
atheroma NN 1_p
were VBD N
randomized VBN N
to TO N
either DT N
7 CD N
weekly JJ N
HDL NNP 1_i
selective NN 1_i
delipidated VBD 1_i
or CC 1_i
control VB 1_i
plasma JJ 1_i
apheresis/reinfusions NNS 1_i
. . 1_i

Patients NNS N
underwent JJ N
intravascular JJ 1_o
ultrasound NN 1_o
( ( 1_o
IVUS NNP 1_o
) ) 1_o
evaluation NN 1_o
of IN N
the DT N
target NN N
vessel NN N
during IN N
the DT N
catheterization NN N
for IN N
ACS NNP N
and CC N
up RB N
to TO N
14 CD N
days NNS N
following VBG N
the DT N
final JJ N
apheresis/reinfusion NN 1_i
session NN N
. . N

2-D JJ N
gel JJ N
electrophoresis NN N
of IN N
delipidated JJ N
plasmas NN N
established VBN N
successful JJ N
conversion NN N
of IN N
alphaHDL NN N
to TO N
prebeta-like JJ N
HDL NNP N
. . N

The DT N
trial NN N
was VBD N
complete JJ N
with IN N
28 CD 1_p
patients NNS 1_p
randomized VBN N
. . N

RESULTS NNP N
All DT N
reinfusion NN N
sessions NNS N
were VBD N
tolerated VBN 1_o
well RB N
by IN N
all DT N
patients NNS N
. . N

The DT N
levels NNS 1_o
of IN 1_o
prebeta-like JJ 1_o
HDL NNP 1_o
and CC 1_o
alphaHDL NN 1_o
in IN N
the DT N
delipidated JJ N
plasma NN N
converted VBD N
from IN N
5.6 CD N
% NN N
to TO N
79.1 CD N
% NN N
and CC N
92.8 CD N
% NN N
to TO N
20.9 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
IVUS NNP N
data NNS N
demonstrated VBD N
a DT N
numeric JJ N
trend NN N
toward IN N
regression NN N
in IN N
the DT N
total JJ N
atheroma NN 1_o
volume NN 1_o
of IN N
-12.18 JJ N
+/- JJ N
36.75 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
delipidated JJ N
group NN N
versus VBD N
an DT N
increase NN N
of IN N
total JJ 1_o
atheroma JJ 1_o
volume NN 1_o
of IN N
2.80 CD N
+/- JJ N
21.25 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.268 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN 1_p
ACS NNP 1_p
patients NNS 1_p
, , N
serial JJ N
autologous JJ N
infusions NNS N
of IN N
selective JJ 1_i
HDL NNP 1_i
delipidated VBD 1_i
plasma NNS 1_i
are VBP N
clinically RB 1_o
feasible JJ 1_o
and CC N
well RB N
tolerated VBN 1_o
. . 1_o

This DT N
therapy NN N
may MD N
offer VB N
a DT N
novel JJ N
adjunct JJ N
treatment NN N
for IN N
patients NNS 1_p
presenting VBG 1_p
with IN 1_p
ACS NNP 1_p
. . 1_p

Further NNP N
study NN N
will MD N
be VB N
needed VBN N
to TO N
determine VB N
its PRP$ N
ability NN N
to TO N
reduce VB N
clinical JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Efficacy NN 1_o
of IN N
topical JJ N
azithromycin NN 1_i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
in IN N
the DT N
treatment NN N
of IN N
posterior JJ 1_p
blepharitis NN 1_p
. . 1_p

INTRODUCTION NNP N
Azithromycin NNP 1_i
, , N
a DT N
broad-spectrum JJ N
antibiotic JJ N
with IN N
potent JJ N
anti-inflammatory JJ N
activities NNS N
, , N
has VBZ N
the DT N
potential JJ N
to TO N
effectively RB N
treat VB N
blepharitis NN 1_o
, , 1_p
an DT 1_p
inflammatory JJ 1_p
disease NN 1_p
of IN 1_p
the DT 1_p
eyelid JJ 1_p
with IN 1_p
abnormal JJ 1_p
eyelid JJ 1_p
flora NN 1_p
as IN 1_p
an DT 1_p
etiologic JJ 1_p
determinant NN 1_p
. . 1_p

The DT N
present JJ N
study NN N
compared VBN N
the DT N
efficacy NN 1_o
of IN N
topical JJ N
azithromycin NN 1_i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
( ( N
AzaSite NNP N
; : N
Inspire NNP N
Pharmaceuticals NNP N
, , N
Inc NNP N
, , N
NC NNP N
, , N
USA NNP N
) ) N
combined VBD N
with IN N
warm JJ N
compresses NNS N
( ( N
azithromycin JJ N
group NN N
) ) N
to TO N
warm JJ N
compresses NNS N
alone RB N
( ( N
compress JJ N
group NN N
) ) N
in IN N
patients NNS N
with IN N
posterior JJ N
blepharitis NN N
. . N

METHODS NNP N
Twenty-one CD 1_p
patients NNS 1_p
diagnosed VBN 1_p
with IN 1_p
posterior JJ 1_p
blepharitis NN 1_p
were VBD N
randomized VBN N
in IN N
an DT N
open-label JJ N
study NN N
to TO N
receive VB N
either DT N
azithromycin NN 1_i
plus CC 1_i
warm JJ 1_i
compresses NNS 1_i
( ( N
10 CD N
patients NNS N
) ) N
, , N
or CC N
compresses VBZ N
alone RB N
( ( N
11 CD N
patients NNS N
) ) N
. . N

All DT N
patients NNS N
were VBD N
instructed VBN N
to TO N
apply VB N
compresses NNS N
to TO N
each DT N
eye NN N
for IN N
5-10 JJ N
minutes NNS N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Each DT N
eye NN N
in IN N
the DT N
azithromycin NN 1_i
group NN N
also RB N
received VBD N
azithromycin JJ N
solution NN N
( ( N
1 CD N
drop NN N
) ) N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
2 CD N
days NNS N
followed VBN N
by IN N
once RB N
daily JJ N
for IN N
the DT N
next JJ N
12 CD N
days NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
at IN N
study NN N
initiation NN N
( ( N
visit IN N
1 CD N
) ) N
and CC N
at IN N
end NN N
of IN N
treatment NN N
( ( N
visit IN N
2 CD N
) ) N
for IN N
the DT N
severity NN N
of IN N
five CD N
clinical JJ N
signs NNS N
: : N
eyelid JJ 1_o
debris NN 1_o
, , 1_o
eyelid JJ 1_o
redness NN 1_o
, , 1_o
eyelid JJ 1_o
swelling NN 1_o
, , 1_o
meibomian JJ 1_o
gland NN 1_o
( ( 1_o
MG NNP 1_o
) ) 1_o
plugging NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
quality NN 1_o
of IN 1_o
MG NNP 1_o
secretion NN 1_o
. . 1_o

At IN N
visit NN N
2 CD N
, , N
patients NNS N
also RB N
rated VBD N
their PRP$ N
degree NN N
of IN N
overall JJ 1_o
symptomatic JJ 1_o
relief NN 1_o
. . 1_o

RESULTS NNP N
Twenty NNP 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

At IN N
visit NN N
2 CD N
, , N
patients NNS N
in IN N
the DT N
azithromycin NN 1_i
group NN N
demonstrated VBD N
significant JJ 1_o
improvements NNS 1_o
in IN N
MG NNP 1_o
plugging NN 1_o
, , 1_o
MG NNP 1_o
secretions NNS 1_o
, , 1_o
and CC 1_o
eyelid JJ 1_o
redness NN 1_o
as IN N
compared VBN N
with IN N
the DT N
compress NN N
group NN N
. . N

In IN N
the DT N
azithromycin NN 1_i
group NN N
, , N
MG NNP 1_o
plugging VBG 1_o
resolved VBN N
completely RB N
in IN N
three CD N
patients NNS N
and CC N
MG NNP 1_o
secretion NN 1_o
returned VBD 1_o
to TO 1_o
normal JJ 1_o
in IN N
two CD N
patients NNS N
; : N
no DT N
such JJ N
results NNS N
were VBD N
seen VBN N
in IN N
the DT N
compress NN N
group NN N
. . N

Furthermore RB N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
azithromycin NN N
group NN N
rated VBD N
overall JJ 1_o
symptomatic JJ 1_o
relief NN 1_o
as IN N
excellent NN N
or CC N
good JJ N
. . N

Visual JJ 1_o
acuity NN 1_o
measurements NNS 1_o
and CC 1_o
biomicroscopic JJ 1_o
evaluation NN 1_o
revealed VBD N
no DT 1_o
ocular JJ 1_o
safety NN 1_o
issues NNS 1_o
. . 1_o

CONCLUSION NNP N
Azithromycin NNP 1_i
ophthalmic JJ N
solution NN N
in IN N
combination NN N
with IN N
warm JJ N
compresses NNS N
provided VBD N
a DT N
significantly RB 1_o
greater JJR 1_o
clinical JJ 1_o
benefit NN 1_o
than IN N
warm JJ N
compresses NNS N
alone RB N
in IN N
treating VBG N
the DT N
signs NNS 1_o
and CC 1_o
symptoms NNS 1_o
of IN 1_o
posterior JJ 1_o
blepharitis NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
bromazepam NN 1_i
over IN 1_p
the DT 1_p
central JJ 1_p
and CC 1_p
frontal JJ 1_p
areas NNS 1_p
during IN 1_p
a DT 1_p
motor NN 1_p
task NN 1_p
: : 1_p
an DT N
EEG NNP N
study NN N
. . N

The DT N
present JJ N
study NN N
investigates VBZ N
the DT N
influence NN N
of IN N
bromazepam NN 1_i
while IN 1_p
executing VBG 1_p
a DT 1_p
motor NN 1_p
task NN 1_p
. . 1_p

Specifically RB N
, , N
we PRP N
intend VBP N
to TO N
analyze VB N
the DT N
changes NNS N
in IN N
alpha NN 1_o
absolute JJ 1_o
power NN 1_o
under IN N
two CD N
experimental JJ N
conditions NNS N
, , N
bromazepam NN 1_i
and CC 1_i
placebo NN 1_i
. . 1_i

We PRP N
also RB N
included VBD N
analyses NNS N
of IN N
theta NN N
and CC N
beta NN N
frequencies NNS N
. . N

We PRP 1_p
collected VBD 1_p
electroencephalographic JJ 1_i
data NNS 1_i
before IN 1_i
, , 1_i
during IN 1_i
, , 1_i
and CC 1_i
after IN 1_i
motor NN 1_i
task NN 1_i
execution NN 1_i
. . 1_i

We PRP N
used VBD N
a DT N
Two CD 1_i
Way NNP 1_i
ANOVA NNP 1_i
to TO 1_i
investigate VB 1_i
the DT 1_i
condition NN 1_i
( ( 1_i
PL NNP 1_i
? . 1_i
Br6 NNP 1_i
mg NN 1_i
) ) 1_i
and CC 1_i
moment NN 1_i
( ( 1_i
pre NN 1_i
and CC 1_i
post NN 1_i
) ) 1_i
variables NNS 1_i
for IN 1_i
the DT 1_i
following JJ 1_i
electrodes NNS 1_i
: : 1_i
Fp1 NNP 1_i
, , 1_i
Fp2 NNP 1_i
, , 1_i
F7 NNP 1_i
, , 1_i
F3 NNP 1_i
, , 1_i
Fz NNP 1_i
, , 1_i
F4 NNP 1_i
, , 1_i
F8 NNP 1_i
, , 1_i
C3 NNP 1_i
, , 1_i
CZ NNP 1_i
and CC 1_i
C4 NNP 1_i
. . 1_i

We PRP N
found VBD N
a DT N
main JJ N
effect NN N
for IN N
condition NN N
on IN N
the DT N
electrodes NNS N
FP1 NNP N
, , N
F7 NNP N
, , N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
, , N
C3 NNP N
and CC N
CZ NNP N
, , N
for IN N
alpha NN N
and CC N
beta NN N
bands NNS N
. . N

For IN N
beta NN N
band NN N
we PRP N
also RB N
found VBD N
a DT N
main JJ N
effect NN N
for IN N
condition NN N
on IN N
the DT N
electrodes NNS N
Fp2 NNP N
, , N
F8 NNP N
and CC N
C4 NNP N
; : N
for IN N
theta NN N
band NN N
we PRP N
identified VBD N
a DT N
main JJ N
effect NN N
for IN N
condition NN N
on IN N
C3 NNP N
, , N
Cz NNP N
and CC N
C4 NNP N
electrodes NNS N
. . N

This DT N
finding NN N
suggests VBZ N
that IN N
the DT N
motor NN N
task NN N
did VBD N
not RB N
have VB N
any DT N
influence NN N
on IN N
the DT 1_o
electrocortical JJ 1_o
activity NN 1_o
in IN N
alpha NN N
, , N
and CC N
that IN N
the DT N
existing VBG N
modifications NNS N
were VBD N
a DT N
consequence NN N
due JJ N
merely RB N
to TO N
the DT N
drug NN N
use NN N
. . N

Despite IN N
its PRP$ N
anxiolytic JJ N
and CC N
sedative JJ N
action NN N
, , N
bromazepam NN 1_i
did VBD N
not RB N
show VB N
any DT N
significant JJ N
changes NNS N
when WRB 1_p
the DT 1_p
individuals NNS 1_p
executed VBD 1_p
a DT 1_p
finger NN 1_p
extension NN 1_p
motor NN 1_p
task NN 1_p
. . 1_p

-DOCSTART- -X- O O

Strength NN N
of IN N
vital JJ N
force NN N
in IN N
classical JJ N
homeopathy NN N
: : N
bio-psycho-social-spiritual JJ N
correlates NNS N
within IN N
a DT N
complex JJ N
systems NNS N
context NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
associations NNS N
between IN N
a DT N
global JJ N
rating NN N
for IN N
the DT N
classical JJ N
homeopathic JJ N
construct NN N
of IN N
vital JJ N
force NN N
and CC N
clinician JJ N
and CC N
patient JJ N
ratings NNS N
on IN N
previously RB N
validated VBN N
bio-psycho-social-spiritual JJ N
questionnaires NNS N
. . N

METHODS NNP N
Sixty-two NNP 1_p
( ( 1_p
62 CD 1_p
) ) 1_p
community-recruited JJ 1_p
patients NNS 1_p
with IN 1_p
fibromyalgia NN 1_p
( ( 1_p
FM NNP 1_p
) ) 1_p
were VBD N
assessed VBN N
at IN N
baseline NN N
prior RB N
to TO N
a DT N
clinical JJ N
trial NN N
of IN N
individualized JJ N
homeopathy NN N
. . N

Two CD 1_p
homeopaths NNS 1_p
jointly RB 1_p
performed VBD 1_p
case-taking JJ 1_i
interviews NNS 1_i
. . 1_i

A DT 1_p
conventional JJ 1_p
medical JJ 1_p
provider NN 1_p
independently RB 1_p
evaluated VBD 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
standardized JJ 1_p
history NN 1_p
and CC 1_p
physical JJ 1_p
examination NN 1_p
. . 1_p

Homeopaths NNP N
rated VBD N
each DT N
patient NN N
's POS N
vital JJ N
force NN N
( ( N
five-point JJ N
Likert NNP N
scale NN N
, , N
with IN N
1 CD N
= JJ N
very RB N
weak JJ N
to TO N
5 CD N
= NNS N
very RB N
strong JJ N
) ) N
. . N

Homeopaths NNP N
and CC N
the DT N
conventional JJ N
medical JJ N
provider NN N
rated VBN N
their PRP$ N
Clinical JJ 1_o
Global NNP 1_o
Impression NNP 1_o
( ( 1_o
CGI NNP 1_o
) ) 1_o
of IN 1_o
the DT 1_o
severity NN 1_o
of IN 1_o
illness NN 1_o
( ( N
1 CD N
= NNP N
normal JJ N
; : N
7 CD N
= NN N
among IN N
the DT N
most RBS N
extremely RB N
ill JJ N
) ) N
. . N

Patients NNS N
completed VBD N
self-rating JJ 1_o
scales NNS 1_o
on IN 1_o
pain NN 1_o
, , 1_o
global JJ 1_o
health NN 1_o
, , 1_o
mood NN 1_o
, , 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
coping VBG 1_o
style NN 1_o
, , 1_o
health NN 1_o
locus NN 1_o
of IN 1_o
control NN 1_o
, , 1_o
multidimensional JJ 1_o
well-being NN 1_o
, , 1_o
spirituality NN 1_o
, , 1_o
sense NN 1_o
of IN 1_o
coherence NN 1_o
, , 1_o
positive JJ 1_o
states NNS 1_o
of IN 1_o
mind NN 1_o
, , 1_o
and CC 1_o
social JJ 1_o
desirability NN 1_o
. . 1_o

RESULTS NNP N
Greater NNP N
vital JJ 1_o
force NN 1_o
ratings NNS 1_o
( ( N
mean VB N
2.9 CD N
standard JJ N
deviation NN N
[ NNP N
SD NNP N
] NNP N
0.6 CD N
) ) N
correlated VBN N
moderately RB N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.005 CD N
) ) N
with IN N
less JJR N
severe JJ N
CGI NNP 1_o
illness NN 1_o
ratings NNS N
by IN N
the DT N
homeopaths NNS N
( ( N
r VB N
=-0.59 NN N
) ) N
, , N
decreased VBD N
patient-rated JJ 1_o
mental JJ 1_o
confusion NN 1_o
( ( N
r VB N
=-0.43 NN N
) ) N
, , N
higher JJR N
vigor NN 1_o
( ( N
r JJ N
= NNP N
0.38 CD N
) ) N
, , N
and CC N
greater JJR N
positive JJ 1_o
states NNS 1_o
of IN 1_o
mind NN 1_o
( ( N
r JJ N
= NNP N
0.36 CD N
) ) N
. . N

Vital NNP N
force NN N
also RB N
showed VBD N
correlations NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
lower JJR N
CGI NNP 1_o
ratings NNS 1_o
by IN N
the DT N
conventional JJ N
medical JJ N
provider NN N
( ( N
r VB N
=-0.32 NN N
) ) N
, , N
better RB N
selfrated VBN N
quality NN 1_o
of IN 1_o
life NN 1_o
( ( N
r JJ N
= NNP N
0.33 CD N
) ) N
, , N
lesser JJR N
fatigue NN 1_o
( ( N
r VB N
=-0.31 NN N
) ) N
, , N
better JJR 1_o
global JJ 1_o
health NN 1_o
( ( N
r VB N
= RB N
0.29 CD N
) ) N
, , N
greater JJR 1_o
sense NN 1_o
of IN 1_o
coherence NN 1_o
( ( N
r JJ N
= NNP N
0.28 CD N
) ) N
, , N
powerful-others JJ 1_o
health NN 1_o
locus NN 1_o
of IN 1_o
control NN 1_o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
increased VBD 1_o
emotional JJ 1_o
well-being NN 1_o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
and CC N
higher JJR 1_o
social JJ 1_o
desirability NN 1_o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
but CC N
not RB N
with IN N
age NN N
, , N
pain NN N
, , N
or CC N
illness JJ N
duration NN N
. . N

CONCLUSION NNP N
Homeopathic NNP N
vital JJ N
force NN N
ratings NNS N
reflect VBP N
better JJR N
perceived VBN N
mental JJ N
function NN N
, , N
energy NN N
, , N
and CC N
positive JJ N
dimensions NNS N
of IN N
the DT N
individual NN N
, , N
beyond IN N
absence NN N
of IN N
disease NN N
. . N

-DOCSTART- -X- O O

Physical JJ N
activity NN N
for IN N
patients NNS 1_p
undergoing VBG 1_p
an DT 1_p
allogeneic JJ 1_p
hematopoietic JJ 1_p
stem NN 1_p
cell NN 1_p
transplantation NN 1_p
: : 1_p
benefits NNS N
of IN N
a DT N
moderate JJ 1_i
exercise NN 1_i
intervention NN 1_i
. . 1_i

UNLABELLED IN N
An DT N
allogeneic JJ 1_i
hematopoietic JJ 1_i
stem NN 1_i
cell NN 1_i
transplantation NN 1_i
( ( N
HSCT NNP N
) ) N
can MD N
have VB N
profound VBN N
and CC N
lasting JJ N
adverse JJ N
effects NNS N
on IN N
a DT N
patient NN N
's POS N
physical JJ N
and CC N
psychological JJ N
well-being NN N
. . N

So RB N
far RB N
, , N
only RB N
few JJ N
studies NNS N
have VBP N
investigated VBN N
the DT N
effectiveness NN 1_o
of IN N
physical JJ N
activity NN N
over IN N
the DT N
entire JJ N
inpatient NN N
phase NN N
of IN N
an DT N
allogeneic JJ N
HSCT NNP N
. . N

PURPOSE NNP N
We PRP N
performed VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
to TO N
examine VB N
the DT N
influence NN N
of IN N
a DT N
controlled JJ N
moderate JJ 1_i
exercise NN 1_i
program NN 1_i
starting VBG N
parallel JJ N
to TO N
chemotherapeutic JJ N
conditioning NN N
and CC N
total JJ N
body NN N
irradiation NN N
on IN N
the DT N
patient NN N
's POS N
physical JJ N
and CC N
psychological JJ N
constitution NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty-seven NNP 1_p
patients NNS 1_p
undergoing VBG 1_p
an DT 1_p
allogeneic JJ 1_p
HSCT NNP 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
exercise NN 1_i
group NN 1_i
( ( 1_i
EG NNP 1_i
) ) 1_i
or CC N
a DT N
control NN 1_i
group NN 1_i
( ( 1_i
CG NNP 1_i
) ) 1_i
. . N

While IN N
the DT N
EG NNP N
took VBD N
part NN N
in IN N
an DT N
endurance NN N
and CC N
activity NN N
of IN N
daily JJ N
living-training JJ N
twice NN N
a DT N
day NN N
, , N
the DT N
CG NNP N
received VBD N
the DT N
clinic NN N
's POS N
standard JJ N
physiotherapy NN N
program NN N
once RB N
a DT N
day NN N
. . N

RESULTS NNP N
Significant NNP 1_o
differences VBZ 1_o
and/or JJ N
trends NNS N
in IN N
favor NN N
of IN N
the DT N
EG NNP N
were VBD N
observed VBN N
regarding VBG N
the DT N
primary JJ N
endpoint NN N
endurance NN 1_o
performance NN 1_o
( ( N
P=0.002 NNP N
) ) N
, , N
muscular JJ 1_o
strength NN 1_o
( ( N
P=0.022 NNP N
) ) N
, , N
fatigue NN 1_o
( ( N
P=0.046 NNP N
) ) N
, , N
and CC N
emotional JJ 1_o
state NN 1_o
( ( N
P=0.028 NNP N
) ) N
without IN N
posing VBG N
an DT N
additional JJ N
risk NN N
for IN N
the DT N
individual NN N
. . N

CONCLUSION VB N
The DT N
results NNS N
show VBP N
that IN N
the DT N
training NN N
program NN N
is VBZ N
feasible JJ N
and CC N
seems VBZ N
to TO N
have VB N
positive JJ N
influences NNS N
on IN N
physical JJ 1_o
performance NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
in IN N
patients NNS 1_p
undergoing VBG 1_p
an DT 1_p
allogeneic JJ 1_p
HSCT NNP 1_p
. . 1_p

However RB N
, , N
further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
confirm VB N
these DT N
results NNS N
. . N

-DOCSTART- -X- O O

TENS NNP 1_i
for IN N
the DT N
treatment NN N
of IN N
writer NN 1_p
's POS 1_p
cramp NN 1_p
dystonia NN 1_p
: : 1_p
a DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
study NN N
. . N

Manipulation NNP N
of IN N
afferent NN N
inputs NNS N
may MD N
temporarily RB N
modulate VB N
dystonic JJ N
spasms NNS N
. . N

Ten CD 1_p
patients NNS 1_p
with IN 1_p
writer NN 1_p
's POS 1_p
cramp NN 1_p
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
in IN N
which WDT N
the DT N
effects NNS N
of IN N
transcutaneous JJ 1_i
electrical JJ 1_i
stimulation NN 1_i
( ( 1_i
TENS NNP 1_i
) ) 1_i
and CC 1_i
placebo JJ 1_i
treatment NN N
were VBD N
compared VBN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
using VBG N
four CD N
measures NNS 1_o
of IN 1_o
dystonic JJ 1_o
impairment NN 1_o
. . 1_o

The DT N
TENS NNP 1_i
group NN N
showed VBD N
a DT N
significant JJ 1_o
improvement NN 1_o
that WDT N
persisted VBD N
for IN N
3 CD N
weeks NNS N
in IN N
three CD N
of IN N
the DT N
four CD N
measures NNS N
. . N

-DOCSTART- -X- O O

Real-Time JJ N
Assessment NNP N
of IN N
the DT N
Effect NNP 1_o
of IN 1_o
Biofeedback NNP 1_o
Therapy NNP 1_o
with IN N
Migraine NNP N
: : N
A DT N
Pilot NNP N
Study NNP N
. . N

BACKGROUND NNP N
Biofeedback NNP 1_i
therapy NN 1_i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
migraine NN N
. . N

However RB N
, , N
previous JJ N
studies NNS N
have VBP N
assessed VBN N
its PRP$ N
effectiveness NN N
using VBG N
paper-and-pencil JJ N
diaries NNS N
, , N
which WDT N
are VBP N
not RB N
very RB N
reliable JJ N
. . N

PURPOSE VB N
The DT N
objective NN N
of IN N
the DT N
present JJ N
pilot NN N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
feasibility NN N
of IN N
using VBG N
computerized JJ N
ecological JJ N
momentary JJ N
assessment NN N
( ( N
EMA NNP N
) ) N
for IN N
evaluating VBG 1_o
the DT 1_o
efficacy NN 1_o
of IN 1_o
BF NNP 1_o
treatment NN 1_o
for IN N
migraine NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHOD NNP N
The DT N
subjects NNS N
comprised VBD N
one CD 1_p
male NN 1_p
and CC 1_p
26 CD 1_p
female JJ 1_p
patients NNS 1_p
with IN 1_p
migraine NN 1_p
. . 1_p

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
biofeedback NN 1_i
or CC N
wait-list JJ 1_i
control NN 1_i
groups NNS 1_i
. . 1_i

Patients NNS N
were VBD N
asked VBN N
to TO N
carry VB N
a DT N
palmtop-type JJ N
computer NN N
to TO N
record VB N
momentary NN N
symptoms NNS N
for IN N
4 CD N
weeks NNS N
before IN N
and CC N
after IN N
biofeedback NN 1_i
treatment NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
headache JJ 1_o
intensity NN 1_o
. . 1_o

The DT N
secondary JJ N
outcome NN N
measures NNS N
included VBD N
psychological JJ 1_o
stress NN 1_o
, , 1_o
anxiety NN 1_o
, , 1_o
irritation NN 1_o
, , 1_o
headache-related JJ 1_o
disability NN 1_o
and CC 1_o
the DT 1_o
frequency NN 1_o
( ( 1_o
number NN 1_o
of IN 1_o
days NNS 1_o
per IN 1_o
month NN 1_o
) ) 1_o
of IN 1_o
migraine NN 1_o
attack NN 1_o
and CC 1_o
of IN 1_o
headache NN 1_o
of IN 1_o
at IN 1_o
least JJS 1_o
moderate JJ 1_o
intensity NN 1_o
( ( N
pain NN N
rating NN N
?50 NN N
) ) N
. . N

RESULTS NNP 1_o
Headache NNP 1_o
intensity NN 1_o
showed VBD 1_o
significant JJ N
main JJ N
effects NNS N
of IN N
period NN N
( ( N
before IN N
vs. NN N
after IN N
therapy NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
and CC N
group NN N
( ( N
biofeedback IN N
vs. FW N
control NN N
groups NNS N
, , N
p VBP N
= RB N
0.42 CD N
) ) N
and CC N
a DT N
significant JJ N
period NN N
? . N
group NN N
interaction NN N
( ( N
p JJ N
< NNP 1_o
0.001 CD 1_o
) ) 1_o
. . 1_o

Biofeedback NNP 1_o
reduced VBD 1_o
the DT 1_o
duration NN 1_o
of IN 1_o
headaches NNS 1_o
by IN 1_o
1.9 CD 1_o
days NNS N
, , N
and CC N
the DT 1_o
frequency NN 1_o
of IN 1_o
days NNS 1_o
when WRB 1_o
headache NN 1_o
intensity NN 1_o
was VBD 1_o
?50 VBN 1_o
by IN N
2.4 CD N
times NNS N
. . N

In IN N
addition NN 1_o
, , 1_o
headache-related JJ 1_o
disability NN 1_o
, , 1_o
psychological JJ 1_o
stress NN 1_o
, , 1_o
depression NN 1_o
, , 1_o
anxiety NN 1_o
, , 1_o
and CC 1_o
irritation NN 1_o
were VBD 1_o
significantly RB N
improved VBN N
. . N

CONCLUSION VB N
The DT N
present JJ N
study NN N
used VBN N
computerized VBN N
EMA NNP N
to TO N
show VB 1_i
that DT 1_i
biofeedback NN 1_i
could MD 1_i
improve VB 1_o
the DT 1_o
symptoms NNS 1_o
of IN 1_o
migraine NN 1_o
, , 1_o
including VBG 1_o
psychological JJ 1_o
stress NN 1_o
and CC 1_o
headache-related JJ 1_o
disability NN 1_o
. . 1_o

-DOCSTART- -X- O O

Placebo-controlled JJ 1_i
trial NN N
evaluating VBG N
safety NN N
with IN N
12-months JJ N
continuous JJ N
use NN N
of IN N
6 CD 1_i
% NN 1_i
hydrogen NN 1_i
peroxide IN 1_i
whitening VBG 1_i
strips NNS 1_i
. . 1_i

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
6 CD 1_i
% NN 1_i
hydrogen NN 1_i
peroxide IN 1_i
whitening VBG 1_i
strips NNS 1_i
over IN N
12 CD N
months NNS N
. . N

METHODS NNP N
80 CD 1_p
adults NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
equally RB N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
6 CD 1_i
% NN 1_i
hydrogen NN 1_i
peroxide JJ 1_i
strips NNS 1_i
or CC 1_i
placebo VB 1_i
strips NNS 1_i
. . 1_i

Strips NNS N
were VBD N
worn JJ N
5 CD N
min JJ N
daily RB N
for IN N
12 CD N
months NNS N
. . N

Safety NNP N
and CC N
tolerability NN N
were VBD N
assessed VBN N
via IN N
oral JJ N
status NN N
interviews NNS N
and CC N
oral JJ N
examinations NNS N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
of IN N
use NN N
. . N

RESULTS NNP N
Tooth NNP N
sensitivity NN N
and CC N
oral JJ N
irritation NN N
were VBD N
the DT N
two CD N
most JJS N
common JJ N
adverse JJ N
events NNS N
. . N

After IN N
12 CD N
months NNS N
use RB N
, , N
tooth DT N
sensitivity NN N
was VBD N
reported VBN N
by IN N
10 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
6 CD 1_i
% NN 1_i
strip NN 1_i
group NN N
with IN N
a DT N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
( ( N
2.8 CD N
% NN N
, , N
23.7 CD N
% NN N
) ) N
and CC N
5 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.6 CD N
% NN N
, , N
16.9 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
reported VBN N
oral JJ N
irritation NN N
was VBD N
0 CD N
% NN N
in IN N
the DT N
6 CD 1_i
% NN 1_i
strip NN 1_i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0 CD N
% NN N
, , N
8.8 CD N
% NN N
) ) N
and CC N
2.5 CD N
% NN N
in IN N
the DT N
placebo NN 1_i
strip NN 1_i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.1 CD N
% NN N
, , N
13.2 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
observed JJ N
oral JJ N
irritation NN N
was VBD N
also RB N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.67 CD N
) ) N
for IN N
the DT N
percent NN N
of IN N
subjects NNS N
with IN N
each DT N
type NN N
of IN N
adverse JJ N
event NN N
. . N

In IN N
the DT N
6 CD 1_i
% NN 1_i
strip NN 1_i
group NN N
, , N
two CD N
subjects NNS N
discontinued VBN N
product NN N
use NN N
due JJ N
to TO N
an DT N
adverse JJ N
event NN N
( ( N
tooth JJ N
sensitivity NN N
) ) N
compared VBN N
to TO N
no DT N
subjects NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

Groups NNP N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.49 CD N
) ) N
with IN N
respect NN N
to TO N
this DT N
outcome NN N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
6 CD 1_i
% NN 1_i
hydrogen NN 1_i
peroxide IN 1_i
whitening VBG 1_i
strips NNS 1_i
over IN N
12 CD N
months NNS N
resulted VBN N
in IN N
a DT N
safety NN N
profile NN N
similar JJ N
to TO N
that DT N
seen VBN N
with IN N
placebo JJ 1_i
strips NNS 1_i
. . 1_i

-DOCSTART- -X- O O

Tailored NNP 1_i
, , 1_i
iterative JJ 1_i
, , 1_i
printed JJ 1_i
dietary JJ 1_i
feedback NN 1_i
is VBZ N
as RB N
effective JJ N
as IN N
group NN N
education NN N
in IN N
improving VBG N
dietary JJ N
behaviours NNS N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
control NN N
trial NN N
in IN N
middle-aged JJ 1_p
adults NNS 1_p
with IN 1_p
cardiovascular JJ 1_p
risk NN 1_p
factors NNS 1_p
. . 1_p

BACKGROUND NNP N
Tailored NNP N
nutrition NN N
interventions NNS N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
non-tailored JJ N
materials NNS N
in IN N
changing VBG N
dietary JJ N
behaviours NNS N
, , N
particularly RB N
fat JJ N
intake NN N
and CC N
fruit NN N
and CC N
vegetable JJ N
intake NN N
. . N

But CC N
further JJ N
research NN N
examining VBG N
efficacy NN N
of IN N
tailored JJ N
nutrition NN N
education NN N
in IN N
comparison NN N
to TO N
other JJ N
nutrition JJ N
education NN N
methods NNS N
and CC N
across IN N
a DT N
wider NN N
range NN N
of IN N
dietary JJ N
behaviours NNS N
is VBZ N
needed VBN N
. . N

The DT 1_p
Stages NNPS 1_p
to TO 1_p
Healthy NNP 1_p
Eating NNP 1_p
Patterns NNP 1_p
Study NNP 1_p
( ( 1_p
STEPs NNP 1_p
) ) 1_p
was VBD N
an DT N
intervention NN N
study NN N
, , N
in IN N
middle-aged JJ 1_p
adults NNS 1_p
with IN 1_p
cardiovascular JJ 1_p
risk NN 1_p
factors NNS 1_p
, , N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
delivered VBN N
by IN N
mail NN N
in IN N
improving VBG N
short-term JJ N
dietary JJ N
behaviour NN N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat NN N
, , N
fruit NN N
, , N
vegetable JJ N
and CC N
grain NN N
and CC N
cereal NN N
intake NN N
. . N

METHODS NNP N
STEPs NNP N
was VBD N
a DT N
3-month JJ N
randomised VBN N
controlled VBN N
trial NN N
with IN N
a DT N
pre NN N
and CC N
post-test JJ N
design NN N
. . N

There EX N
were VBD N
three CD N
experimental JJ N
conditions NNS N
: : N
1 CD N
) ) N
tailored VBN 1_i
, , 1_i
iterative JJ 1_i
, , 1_i
printed JJ 1_i
dietary JJ 1_i
feedback NN 1_i
( ( 1_i
TF NNP 1_i
) ) 1_i
with IN N
three CD N
instalments NNS N
mail-delivered JJ N
over IN N
a DT N
3-month JJ N
period NN N
that WDT N
were VBD N
re-tailored VBN N
to TO N
most RBS N
recent JJ N
assessment NN N
of IN N
dietary JJ N
intake NN N
, , N
intention NN N
to TO N
change VB N
and CC N
assessment NN N
of IN N
self-adequacy NN N
of IN N
dietary JJ N
intake NN N
. . N

Tailoring VBG N
for IN N
dietary JJ N
intake NN N
was VBD N
performed VBN N
on IN N
data NNS N
from IN N
a DT N
validated JJ N
63-item JJ N
combination NN N
FFQ NNP N
designed VBN N
for IN N
the DT N
purpose JJ N
2 CD N
) ) N
small JJ N
group NN N
nutrition NN 1_i
education NN 1_i
sessions NNS 1_i
( ( N
GE NNP N
) ) N
: : N
consisting NN N
of IN N
two CD N
90-minute JJ N
dietitian-led JJ N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
and CC N
3 CD N
) ) N
and CC N
a DT N
wait-listed JJ N
control NN N
( ( N
C NNP N
) ) N
group NN N
who WP N
completed VBD N
the DT N
dietary JJ 1_i
measures NNS 1_i
and CC 1_i
socio-demographic JJ 1_i
questionnaires NNS 1_i
at IN N
baseline NN N
and CC N
3-months JJ N
later NN N
. . N

Dietary NNP N
outcome NN N
measures NNS N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ 1_o
fat JJ 1_o
intake NN 1_o
( ( 1_o
g NN 1_o
) ) 1_o
, , N
and CC N
the DT N
intake NN 1_o
of IN 1_o
fruit NN 1_o
( ( 1_o
serves NNS 1_o
) ) 1_o
, , 1_o
vegetables NNS 1_o
( ( 1_o
serves NNS 1_o
) ) 1_o
, , 1_o
grain NN 1_o
and CC 1_o
cereals NNS 1_o
as IN N
total JJ 1_o
and CC 1_o
wholegrain NN 1_o
( ( 1_o
serves NNS 1_o
) ) 1_o
were VBD N
collected VBN N
using VBG N
7-day JJ N
estimated VBN N
dietary JJ N
records NNS N
. . N

Descriptive JJ N
statistics NNS N
, , N
paired VBD N
t-tests NNS N
and CC N
general JJ N
linear JJ N
models NNS N
adjusted VBN N
for IN N
baseline NN N
dietary JJ N
intake NN N
, , N
age NN N
and CC N
gender NN N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
different JJ N
nutrition NN N
interventions NNS N
. . N

RESULTS VB N
The DT N
TF NNP 1_i
group NN N
reported VBD N
a DT N
significantly RB N
greater JJR N
increase NN N
in IN N
fruit JJ 1_o
intake NN 1_o
( ( N
0.3 CD N
serves/d NN N
P NNP N
= NNP N
0.031 CD N
) ) N
in IN N
comparison NN N
to TO N
GE NNP N
and CC N
the DT N
C NNP N
group NN N
. . N

All DT N
three CD N
intervention NN N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
total JJ 1_o
saturated JJ 1_o
fat JJ 1_o
intake NN 1_o
. . 1_o

GE NNP N
also RB N
had VBD N
a DT N
within-group JJ N
increase NN N
in IN N
mean JJ 1_o
vegetable JJ 1_o
intake NN 1_o
after IN N
3 CD N
months NNS N
, , N
but CC N
this DT N
increase NN N
was VBD N
not RB N
different JJ N
from IN N
changes NNS N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
was VBD N
more RBR N
effective JJ N
than IN N
small JJ N
group NN N
nutrition NN N
education NN N
in IN N
improving VBG N
the DT N
short-term JJ N
fruit NN N
intake VB N
behaviour NN N
, , N
and CC N
as IN N
effective JJ N
in IN N
improving VBG N
saturated VBN N
fat JJ N
intake NN N
of IN N
middle-aged JJ 1_p
adults NNS 1_p
with IN 1_p
cardiovascular JJ 1_p
risk NN 1_p
factors NNS 1_p
. . 1_p

This DT N
showed VBD N
that IN N
a DT N
low-level JJ N
dietary JJ N
intervention NN N
could MD N
achieve VB N
modest JJ N
dietary JJ N
behaviour NN N
changes NNS N
that WDT N
are VBP N
of IN N
public JJ N
health NN N
significance NN N
. . N

-DOCSTART- -X- O O

Cognitive JJ N
effects NNS N
of IN N
lithium NN 1_i
carbonate NN 1_i
and CC 1_i
haloperidol NN 1_i
in IN N
treatment-resistant JJ 1_p
aggressive JJ 1_p
children NNS 1_p
. . 1_p

The DT N
effects NNS N
of IN N
lithium NN 1_i
carbonate NN 1_i
and CC 1_i
haloperidol NN 1_i
on IN N
cognition NN N
were VBD N
examined VBN N
in IN N
a DT N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
study NN N
of IN N
61 CD 1_p
treatment-resistant JJ 1_p
, , 1_p
hospitalized VBN 1_p
school-aged JJ 1_p
children NNS 1_p
. . 1_p

They PRP N
all DT N
had VBD N
a DT N
DSM-III JJ N
diagnosis NN N
of IN N
conduct NN N
disorder NN N
-- : N
undersocialized JJ 1_p
, , 1_p
aggressive JJ 1_p
, , 1_p
with IN 1_p
a DT 1_p
profile NN 1_p
of IN 1_p
highly RB 1_p
explosive JJ 1_p
and CC 1_p
aggressive JJ 1_p
behavior NN 1_p
. . 1_p

Children NNP 1_p
were VBD 1_p
assessed VBN 1_p
at IN 1_p
the DT 1_p
end NN 1_p
of IN 1_p
a DT 1_p
two-week JJ 1_p
placebo-baseline JJ 1_i
period NN 1_p
and CC 1_p
again RB 1_p
after IN 1_p
four CD 1_p
weeks NNS 1_p
of IN 1_p
treatment NN 1_p
. . 1_p

Drug NNP N
effects NNS N
on IN N
cognition NN N
were VBD N
mild JJ N
. . N

Haloperidol NNP 1_i
( ( N
mean JJ N
dose NN N
, , N
2.95 CD N
mg/day NN N
) ) N
caused VBD N
significant JJ N
decreases NNS N
in IN N
Porteus NNP 1_o
Maze NNP 1_o
test NN 1_o
quotient NN 1_o
scores NNS 1_o
and CC N
a DT N
slowing NN 1_o
of IN 1_o
reaction NN 1_o
time NN 1_o
( ( 1_o
RT NNP 1_o
) ) 1_o
on IN N
a DT N
simple JJ N
RT NNP N
task NN N
. . N

Lithium JJ 1_i
carbonate NN 1_i
( ( N
mean JJ N
dose NN N
, , N
1,166 CD N
mg/day NN N
) ) N
adversely RB N
affected JJ N
qualitative JJ 1_o
scores NNS 1_o
on IN 1_o
the DT 1_o
Porteus NNP 1_o
Maze NNP 1_o
test NN 1_o
. . 1_o

No DT N
significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
the DT N
Matching NNP 1_o
Familiar NNP 1_o
Figures NNP 1_o
Test NNP 1_o
, , 1_o
short-term JJ 1_o
recognition NN 1_o
memory NN 1_o
and CC 1_o
concept NN 1_o
attainment NN 1_o
tasks NNS 1_o
, , 1_o
or CC 1_o
the DT 1_o
Stroop NNP 1_o
Test NNP 1_o
. . 1_o

-DOCSTART- -X- O O

Correlations NNS N
between IN N
the DT N
clinical JJ 1_o
, , 1_o
histological JJ 1_o
and CC 1_o
neurophysiological JJ 1_o
examinations NNS 1_o
in IN N
patients NNS 1_p
before IN 1_p
and CC 1_p
after IN 1_p
parotid JJ 1_i
gland NN 1_i
tumor NN 1_i
surgery NN 1_i
: : 1_i
verification NN N
of IN N
facial JJ N
nerve NN N
transmission NN N
. . N

Parotid NNP N
gland NN N
tumor NN N
surgery NN N
sometimes RB N
leads VBZ N
to TO N
facial JJ N
nerve NN N
paralysis NN N
. . N

Malignant NNP N
more JJR N
than IN N
benign JJ N
tumors NNS N
determine VBP N
nerve NN N
function NN N
preoperatively RB N
, , N
while IN N
postoperative JJ N
observations NNS N
based VBN N
on IN N
clinical JJ N
, , N
histological JJ N
and CC N
neurophysiological JJ N
studies NNS N
have VBP N
not RB N
been VBN N
reported VBN N
in IN N
detail NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
evaluation NN N
and CC N
correlations NNS N
of IN N
histological JJ 1_o
properties NNS 1_o
of IN 1_o
tumor NN 1_o
( ( 1_o
its PRP$ 1_o
size NN 1_o
and CC 1_o
location NN 1_o
) ) 1_o
and CC N
clinical JJ 1_o
and CC 1_o
neurophysiological JJ 1_o
assessment NN 1_o
of IN 1_o
facial JJ 1_o
nerve NN 1_o
function NN 1_o
pre- NN 1_o
and CC 1_o
post-operatively RB 1_o
( ( N
1 CD N
and CC N
6 CD N
months NNS N
) ) N
. . N

Comparative JJ N
studies NNS N
included VBD N
17 CD 1_p
patients NNS 1_p
with IN 1_p
benign JJ 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
13 CD 1_p
) ) 1_p
and CC 1_p
malignant JJ 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
4 CD 1_p
) ) 1_p
tumors NNS 1_p
. . 1_p

Clinical JJ 1_o
assessment NN 1_o
was VBD N
based VBN N
on IN N
House-Brackmann NNP 1_o
scale NN 1_o
( ( 1_o
H-B NNP 1_o
) ) 1_o
, , 1_o
neurophysiological JJ 1_o
diagnostics NNS 1_o
included VBD 1_o
facial JJ 1_o
electroneurography NN 1_o
[ NNP 1_o
ENG NNP 1_o
, , 1_o
compound NN 1_o
muscle NN 1_o
action NN 1_o
potential NN 1_o
( ( 1_o
CMAP NNP 1_o
) ) 1_o
] NN 1_o
, , 1_o
mimetic JJ 1_o
muscle NN 1_o
electromyography NN 1_o
( ( 1_o
EMG NNP 1_o
) ) 1_o
and CC 1_o
blink-reflex JJ 1_o
examinations NNS 1_o
( ( 1_o
BR NNP 1_o
) ) 1_o
. . 1_o

Mainly RB N
grade VBD N
I PRP N
of IN N
H-B NNP 1_o
was VBD N
recorded VBN N
both DT N
pre- JJ N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
and CC N
post-operatively RB N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
small JJ 1_p
( ( 1_p
1.5-2.4 JJ 1_p
cm NN 1_p
) ) 1_p
benign NN 1_p
tumors NNS 1_p
located VBN 1_p
in IN 1_p
superficial JJ 1_p
lobes NNS 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
medium NN 1_p
size NN 1_p
( ( 1_p
2.5-3.4 JJ 1_p
cm NN 1_p
) ) 1_p
malignant NN 1_p
tumors NNS 1_p
in IN 1_p
both DT 1_p
lobes NNS 1_p
were VBD N
scored VBN N
at IN N
grade NN N
I PRP N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
and CC N
III NNP N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
pre- NN N
and CC N
mainly RB N
VI NNP N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
post-operatively RB N
. . N

CMAP NNP 1_o
amplitudes NNS 1_o
after IN N
stimulation NN N
of IN N
mandibular JJ N
marginal JJ N
branch NN N
were VBD N
reduced VBN N
at IN N
about RB N
25 CD N
% NN N
in IN N
patients NNS 1_p
with IN 1_p
benign JJ 1_p
tumors NNS 1_p
after IN N
surgery NN N
. . N

In IN N
the DT N
cases NNS N
of IN N
malignant JJ N
tumors NNS N
CMAPs NNP 1_o
were VBD N
not RB N
recorded VBN N
following VBG N
stimulation NN N
of IN N
any DT N
branch NN N
. . N

A DT N
similar JJ N
trend NN N
was VBD N
found VBN N
for IN N
BR NNP 1_o
results NNS 1_o
. . 1_o

H-B NNP 1_o
and CC 1_o
ENG NNP 1_o
results NNS N
revealed VBD N
positive JJ N
correlations NNS N
between IN N
the DT N
type NN N
of IN N
tumor NN N
and CC N
surgery NN N
with IN N
facial JJ N
nerve NN N
function NN N
. . N

Neurophysiological JJ N
studies NNS N
detected VBN N
clinically RB 1_o
silent JJ 1_o
facial JJ 1_o
nerve NN 1_o
neuropathy NN 1_o
of IN 1_o
mandibular JJ 1_o
marginal JJ 1_o
branch NN 1_o
in IN N
postoperative JJ N
period NN N
. . N

Needle NNP 1_o
EMG NNP 1_o
, , 1_o
ENG NNP 1_o
and CC 1_o
BR NNP 1_o
examinations NNS 1_o
allow VBP N
for IN N
the DT N
evaluation NN N
of IN N
face NN 1_o
muscles NNS 1_o
reinnervation NN 1_o
and CC 1_o
facial JJ 1_o
nerve NN 1_o
regeneration NN 1_o
. . 1_o

-DOCSTART- -X- O O

[ JJ N
Comparison NNP N
of IN N
fracture NN 1_o
resistance NN 1_o
of IN N
pulpless NN 1_i
teeth NNS 1_i
restored VBD 1_i
with IN 1_i
fiber NN 1_i
reinforced VBN 1_i
composite JJ 1_i
posts NNS 1_i
and CC N
three CD 1_i
kinds NNS 1_i
of IN 1_i
resin NN 1_i
core NN 1_i
material NN 1_i
] NNP 1_i
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
fracture NN 1_o
resistances NNS 1_o
of IN N
pulpless NN N
teeth NNS N
restored VBD N
with IN N
FRC NNP 1_i
( ( 1_i
Fiber NNP 1_i
Reinforced NNP 1_i
Composite NNP 1_i
) ) 1_i
posts NNS 1_i
and CC N
three CD 1_i
kinds NNS 1_i
of IN 1_i
resin NN 1_i
core NN 1_i
material NN 1_i
. . 1_i

METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
42 CD 1_p
recently RB 1_p
extracted VBN 1_p
upper JJ 1_p
incisors NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
3 CD 1_p
groups NNS 1_p
. . 1_p

Group NNP N
A NNP N
was VBD N
restored VBN N
with IN N
prefabricated JJ 1_i
glass-fiber JJ 1_i
posts NNS 1_i
and CC 1_i
Artglass NNP 1_i
polymer NN 1_i
core NN 1_i
; : 1_i
group NN N
B NNP N
with IN N
prefabricated JJ 1_i
glass-fiber JJ 1_i
posts NNS 1_i
and CC 1_i
Charisma NNP 1_i
composite JJ 1_i
resin NN 1_i
core NN 1_i
; : 1_i
and CC N
group NN N
C NNP N
with IN N
prefabricated JJ 1_i
glass-fiber JJ 1_i
posts NNS 1_i
and CC 1_i
AB NNP 1_i
composite JJ 1_i
resin NN 1_i
core NN 1_i
. . 1_i

In IN N
every DT N
group NN N
, , N
the DT N
core NN N
material NN N
was VBD N
processed VBN N
by IN N
hot-press NN N
and CC N
non JJ N
hot-press NN N
respectively RB N
. . N

The DT N
posts NNS N
size NN N
and CC N
shape NN N
were VBD N
identical JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

All DT 1_p
teeth NNS 1_p
were VBD 1_p
fully RB 1_p
covered VBN 1_p
with IN 1_p
polycarbonate JJ 1_p
resin NN 1_p
crowns NNS 1_p
. . 1_p

Fracture NN 1_o
resistance NN 1_o
was VBD N
measured VBN N
by IN N
applying VBG N
point NN N
force NN N
at IN N
130 CD N
degrees NNS N
to TO N
the DT N
long JJ N
axis NN N
of IN N
the DT N
teeth NN N
on IN N
an DT N
universal JJ N
testing NN N
machine NN N
. . N

RESULTS JJ N
Mean JJ 1_o
fracture NN 1_o
threshold NN 1_o
was VBD N
505.4 CD N
N NNP N
+/- JJ N
42.0 CD N
N NNP N
and CC N
564.1 CD N
N NNP N
+/- JJ N
41.7 CD N
N NNP N
in IN N
group NN N
A NNP N
, , N
411.3 CD N
N NNP N
+/- JJ N
23.3 CD N
N NNP N
and CC N
315.3 CD N
N NNP N
+/- JJ N
19.1 CD N
N NNP N
in IN N
group NN N
B NNP N
and CC N
358.4 CD N
N NNP N
+/- JJ N
36.1 CD N
N NNP N
and CC N
423.4 CD N
N NNP N
+/- JJ N
47.5 CD N
N NNP N
in IN N
group NN N
C. NNP N
In IN N
all DT N
groups NNS N
, , N
there EX N
was VBD N
no DT 1_o
posts NNS 1_o
fracture NN 1_o
and CC 1_o
polycarbonate NN 1_o
resin NN 1_o
crowns NNS 1_o
fragmentation NN 1_o
. . 1_o

CONCLUSION VB N
The DT N
composite JJ N
restoration NN N
of IN N
FRC NNP 1_i
posts NNS 1_i
combined VBD 1_i
with IN 1_i
resin NN 1_i
core NN 1_i
and CC 1_i
resin VB 1_i
crown NN 1_i
can MD N
improve VB N
the DT N
fracture NN 1_o
resistance NN 1_o
of IN N
the DT N
pulpless JJ N
roots NNS N
. . N

The DT N
strength NN N
of IN N
resin NN N
core NN N
material NN N
can MD N
be VB N
increased VBN N
by IN N
hot-press JJ 1_i
methods NNS 1_i
. . 1_i

-DOCSTART- -X- O O

Outcomes NNS N
of IN N
Japanese JJ 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
treated VBN N
with IN N
pre-operative JJ 1_i
and CC 1_i
post-operative JJ 1_i
anastrozole NN 1_i
or CC 1_i
tamoxifen NN 1_i
. . 1_i

The DT N
present JJ N
study NN N
examined VBD N
long-term JJ N
efficacy NN 1_o
outcomes NNS 1_o
in IN N
a DT N
subgroup NN 1_p
of IN 1_p
postmenopausal NN 1_p
, , 1_p
estrogen VBP 1_p
receptor-positive JJ 1_p
Japanese JJ 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
from IN 1_p
the DT 1_p
Pre-Operative JJ 1_i
Arimidex NNP 1_i
Compared NNP 1_p
with IN 1_p
Tamoxifen NNP 1_i
trial NN 1_p
, , N
following VBG 1_i
pre-operative JJ 1_i
( ( 1_i
3 CD 1_i
months NNS 1_i
) ) 1_i
and CC 1_i
post-operative JJ 1_i
( ( 1_i
5 CD 1_i
years NNS 1_i
) ) 1_i
adjuvant VBP 1_i
treatment NN 1_i
with IN 1_i
either DT 1_i
anastrozole NN 1_i
or CC 1_i
tamoxifen NN 1_i
. . 1_i

Patients NNS 1_p
with IN 1_p
large JJ 1_p
, , 1_p
potentially RB 1_p
operable JJ 1_p
, , 1_p
locally-advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB 1_i
anastrozole NN 1_i
( ( 1_i
1 CD 1_i
mg/day NN 1_i
) ) 1_i
plus CC 1_i
tamoxifen JJ 1_i
placebo NN 1_i
or CC 1_i
tamoxifen NN 1_i
( ( 1_i
20 CD 1_i
mg/day NN 1_i
) ) 1_i
plus CC 1_i
anastrozole JJ 1_i
placebo NN 1_i
pre-operatively RB 1_i
. . 1_i

After IN N
surgery NN N
at IN N
3 CD N
months NNS N
, , N
patients NNS 1_i
continued VBD 1_i
on IN 1_i
the DT 1_i
same JJ 1_i
study NN 1_i
medication NN 1_i
as IN 1_i
adjuvant JJ 1_i
therapy NN 1_i
for IN 1_i
up IN 1_i
to TO 1_i
5 CD 1_i
years NNS 1_i
or CC 1_i
until IN 1_i
recurrence NN 1_i
, , 1_i
intolerable JJ 1_i
toxicity NN 1_i
or CC 1_i
withdrawal NN 1_i
of IN 1_i
patient JJ 1_i
consent NN 1_i
. . 1_i

Recurrence-free JJ 1_o
survival NN 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
were VBD N
measured VBN N
from IN N
the DT N
date NN N
of IN N
randomization NN N
to TO N
the DT N
date NN N
of IN N
recurrence NN N
or CC N
death NN N
, , N
whichever WDT N
occurred VBD N
first RB N
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ 1_o
events NNS 1_o
throughout IN N
the DT N
study NN N
period NN N
and CC N
up RB N
to TO N
30 CD N
days NNS N
following VBG N
administration NN N
of IN N
the DT N
last JJ N
study NN N
medication NN N
. . N

During IN N
post-operative JJ N
adjuvant JJ N
therapy NN N
, , N
4/48 CD N
( ( N
8 CD N
% NN N
) ) N
anastrozole NN 1_i
and CC N
25/49 CD N
( ( N
51 CD N
% NN N
) ) N
tamoxifen NN 1_i
patients NNS N
experienced VBD N
recurrence NN 1_o
. . 1_o

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
recurrence-free JJ 1_o
survival NN 1_o
between IN N
the DT N
two CD N
groups NNS N
( ( N
hazard JJ N
ratio NN N
0.14 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
0.05-0.41 NN N
; : N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
overall JJ 1_o
survival NN 1_o
with IN N
anastrozole NN 1_i
( ( N
0.21 CD N
; : N
0.05-0.96 CD N
; : N
P NNP N
= NNP N
0.0436 CD N
) ) N
and CC N
there EX N
were VBD N
2/48 CD N
( ( N
4 CD N
% NN N
) ) N
and CC N
10/49 CD N
( ( N
20 CD N
% NN N
) ) N
deaths NNS 1_o
with IN N
anastrozole JJ 1_i
and CC 1_i
tamoxifen NN 1_i
, , N
respectively RB N
. . N

Most JJS N
patients NNS N
responding VBG N
to TO N
pre-operative JJ N
therapy NN N
remained VBD N
recurrence-free JJ 1_o
. . 1_o

Sequential JJ N
pre-operative/post-operative JJ N
treatment NN N
with IN N
anastrozole JJ 1_i
resulted VBN N
in IN N
lower JJR N
recurrence NN 1_o
and CC N
death NN 1_o
rates NNS 1_o
, , N
compared VBN N
with IN N
tamoxifen NN 1_i
. . 1_i

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
magnesium NN 1_i
added VBN N
to TO N
levobupivacaine VB 1_i
for IN N
femoral JJ N
nerve NN N
block NN N
on IN N
postoperative JJ N
analgesia NN N
in IN N
patients NNS 1_p
undergoing VBG 1_p
ACL NNP 1_p
reconstruction NN 1_p
. . 1_p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomised VBD N
double-blind NN N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
magnesium NN 1_i
added VBN N
to TO N
local JJ N
anaesthetics NNS N
on IN N
postoperative JJ N
VAS NNP N
scores NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
time NN N
to TO N
first JJ N
mobilisation NN N
, , N
patient JJ N
satisfaction NN N
and CC N
rescue NN N
analgesic JJ N
requirements NNS N
in IN N
arthroscopic JJ N
ACL NNP N
reconstruction NN N
surgery NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
107 CD 1_p
American JJ 1_p
Society NNP 1_p
of IN 1_p
Anaesthesiologists NNP 1_p
physical JJ 1_p
status NN 1_p
grade NN 1_p
I PRP 1_p
and CC 1_p
II NNP 1_p
patients NNS 1_p
between IN 1_p
18 CD 1_p
and CC 1_p
65 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
who WP 1_p
were VBD 1_p
scheduled VBN 1_p
to TO 1_p
undergo VB 1_p
elective JJ 1_p
anterior JJ 1_p
crucial JJ 1_p
ligament NN 1_p
( ( 1_p
ACL NNP 1_p
) ) 1_p
reconstruction NN 1_p
with IN 1_p
hamstring VBG 1_p
autografts NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
Groups NNP N
L NNP N
( ( N
n JJ N
= NNP N
51 CD N
) ) N
and CC N
LM NNP N
( ( N
n JJ N
= NNP N
56 CD N
) ) N
using VBG N
the DT N
closed-envelope NN N
method NN N
. . N

Group NNP N
LM NNP N
was VBD N
administered VBN N
19 CD N
ml NN N
of IN N
0.25 CD 1_i
% NN 1_i
levobupivacaine NN 1_i
and CC 1_i
1 CD 1_i
ml NN 1_i
of IN 1_i
15 CD 1_i
% NN 1_i
magnesium NN 1_i
sulphate NN 1_i
, , N
while IN N
Group NNP 1_i
L NNP 1_i
was VBD 1_i
administered VBN 1_i
20 CD 1_i
ml NN 1_i
of IN 1_i
0.25 CD 1_i
% NN 1_i
levobupivacaine NN 1_i
for IN N
femoral JJ N
blockade NN N
. . N

General NNP N
anaesthesia NN N
was VBD N
administered VBN N
using VBG N
laryngeal JJ N
airway RB N
masks NNS N
following VBG N
neural JJ N
blockade NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
heart NN 1_o
rate NN 1_o
and CC 1_o
mean VB 1_o
arterial JJ 1_o
pressure NN 1_o
, , 1_o
oxygen NN 1_o
saturation NN 1_o
, , 1_o
visual JJ 1_o
analogue NN 1_o
score NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
, , 1_o
verbal JJ 1_o
rating NN 1_o
scale NN 1_o
( ( 1_o
VRS NNP 1_o
) ) 1_o
, , 1_o
rescue NN 1_o
analgesic JJ 1_o
requirements NNS 1_o
, , 1_o
total JJ 1_o
opioid JJ 1_o
consumption NN 1_o
, , N
side NN N
effects NNS N
and CC N
time NN N
to TO N
first JJ N
mobilisation NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
4th CD N
, , N
6th CD N
, , N
12th CD N
and CC N
24th CD N
hours NNS N
postoperatively RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
demographic JJ 1_o
data NNS 1_o
, , 1_o
mean JJ 1_o
arterial JJ 1_o
pressure NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
or CC 1_o
oxygen NN 1_o
saturation NN 1_o
between IN N
groups NNS N
. . N

The DT N
area NN 1_o
under IN 1_o
the DT 1_o
curve NN 1_o
VAS NNP 1_o
and CC 1_o
VRS NNP 1_o
scores NNS 1_o
were VBD N
lower JJR N
at IN N
4 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NN N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.001 CD N
, , N
p NN N
= VBD N
0.016 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
rescue NN 1_o
analgesic JJ 1_o
requirement NN 1_o
and CC 1_o
the DT 1_o
total JJ 1_o
opioid JJ 1_o
consumption NN 1_o
were VBD N
significantly RB N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.015 CD N
, , N
p NN N
= VBD N
0.019 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
time NN 1_o
to TO 1_o
first JJ 1_o
mobilisation NN 1_o
and CC 1_o
the DT 1_o
Likert NNP 1_o
score NN 1_o
( ( N
completely RB N
comfortable JJ N
; : N
quite RB N
comfortable JJ N
; : N
slight JJ N
discomfort NN N
; : N
painful JJ N
; : N
very RB N
painful JJ N
) ) N
were VBD N
higher JJR N
, , N
and CC N
the DT N
block NN 1_o
onset VBD 1_o
time NN 1_o
was VBD N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.014 CD N
and CC N
p VB N
= JJ N
0.012 CD N
, , N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
terms NNS N
of IN N
side NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
magnesium NN 1_i
to TO N
levobupivacaine VB N
prolongs NNS N
the DT N
sensory NN N
and CC N
motor NN N
block NN N
duration NN N
without IN N
increasing VBG N
side NN N
effects NNS N
, , N
enhances VBZ N
the DT N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
and CC N
increases VBZ N
patient JJ N
satisfaction NN N
; : N
however RB N
, , N
the DT N
addition NN N
of IN N
magnesium NN N
delays VBZ N
the DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
decreases VBZ N
rescue NN N
analgesic JJ N
requirements NNS N
. . N

-DOCSTART- -X- O O

Helping VBG N
women NNS N
make VBP N
choices NNS N
about IN N
mammography NN N
screening NN N
: : N
an DT N
online NN N
randomized VBN N
trial NN N
of IN N
a DT N
decision NN N
aid NN N
for IN N
40-year-old JJ 1_p
women NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
decision NN 1_i
aid NN 1_i
( ( 1_i
DA NNP 1_i
) ) 1_i
on IN N
women NNS N
's POS N
knowledge NN N
of IN N
the DT N
benefits NNS N
and CC N
harms NNS N
of IN N
screening VBG N
and CC N
on IN N
their PRP$ N
ability NN N
to TO N
make VB N
an DT N
informed JJ N
decision NN N
. . N

METHODS NNP N
An DT N
online NN N
randomized VBN N
controlled VBN N
trial NN N
among IN N
321 CD 1_p
women NNS 1_p
aged VBN 1_p
38-45 CD 1_p
years NNS 1_p
was VBD 1_p
conducted VBN 1_p
. . 1_p

Participants NNS N
were VBD N
randomized VBN N
to TO N
either DT N
immediate JJ 1_i
or CC 1_i
delayed JJ 1_i
access NN 1_i
to TO 1_i
the DT 1_i
online NN 1_i
DA NNP 1_i
which WDT N
( ( N
i NN N
) ) N
explained VBD N
the DT N
benefits NNS N
and CC N
harms NNS N
, , N
( ( N
ii NN N
) ) N
included VBD N
a DT N
values NNS N
clarification NN N
exercise NN N
and CC N
a DT N
worksheet NN N
to TO N
support VB N
decision NN N
making NN N
. . N

The DT N
primary JJ N
outcome NN N
, , N
knowledge NN 1_o
of IN 1_o
benefits NNS 1_o
and CC 1_o
harms NNS 1_o
of IN 1_o
screening NN 1_o
, , 1_o
and CC 1_o
secondary JJ 1_o
outcomes NNS 1_o
, , 1_o
informed VBN 1_o
choice NN 1_o
( ( 1_o
composite JJ 1_o
of IN 1_o
knowledge NN 1_o
, , 1_o
values NNS 1_o
and CC 1_o
intention NN 1_o
) ) 1_o
, , 1_o
anxiety NN 1_o
and CC 1_o
acceptability NN 1_o
of IN 1_o
the DT 1_o
DA NNP 1_o
were VBD N
measured VBN N
using VBG N
online JJ N
questionnaires NNS N
. . N

RESULTS NNP N
Women NNP 1_p
in IN 1_p
the DT 1_p
intervention NN 1_p
group NN 1_p
were VBD N
more RBR N
knowledgeable JJ 1_o
( ( N
mean VB N
score NN N
out IN N
of IN N
10 CD N
, , N
7.35 CD N
vs NN N
6.27 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
made VBN 1_o
a DT 1_o
decision NN 1_o
( ( N
82 CD N
% NN N
vs JJ N
61 CD N
% NN N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Of IN N
those DT N
who WP N
made VBD N
a DT N
decision NN N
, , N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
were VBD N
less RBR N
likely JJ N
to TO N
start VB 1_o
screening VBG 1_o
now RB 1_o
( ( N
52 CD N
% NN N
vs JJ N
65 CD N
% NN N
p=0.05 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
proportion NN 1_o
of IN 1_o
women NNS 1_o
who WP 1_o
made VBD 1_o
an DT 1_o
informed JJ 1_o
choice NN 1_o
( ( N
71 CD N
% NN N
intervention NN N
group NN N
vs VBD N
64 CD N
% NN N
control NN 1_i
group NN N
, , N
p=0.24 NN N
) ) N
. . N

The DT N
DA NNP N
was VBD N
helpful JJ N
, , N
balanced JJ N
and CC N
clear JJ N
, , N
and CC N
did VBD N
not RB N
make VB N
women NNS N
anxious JJ 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
DA NNP N
increased VBD N
knowledge NN 1_o
and CC N
reduced JJ N
indecision NN 1_o
, , N
without IN N
increasing VBG N
feelings NNS 1_o
of IN 1_o
anxiety NN 1_o
. . 1_o

PRACTICE NNP N
IMPLICATIONS NNP N
This DT N
decision NN N
aid NN N
is VBZ N
easy JJ N
to TO N
access NN N
online NN N
and CC N
could MD N
be VB N
an DT N
inexpensive JJ N
way NN N
of IN N
supporting VBG N
women NNS N
aged VBN N
40 CD N
who WP N
are VBP N
considering VBG N
whether IN N
to TO N
start VB N
screening VBG N
now RB N
, , N
or CC N
wait VBP N
until IN N
they PRP N
are VBP N
50 CD N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
demonstrate VB N
the DT N
potential NN N
of IN N
DAs NNP N
to TO N
help VB N
inform VB N
women NNS N
about IN N
both DT N
the DT N
benefits NNS N
and CC N
risks NNS N
of IN N
screening VBG N
at IN N
this DT N
age NN N
and CC N
to TO N
support VB N
women NNS N
and CC N
clinicians NNS N
in IN N
this DT N
decision NN N
making VBG N
process NN N
. . N

-DOCSTART- -X- O O

Syncope NNP 1_p
Evaluation NNP N
in IN N
the DT N
Emergency NNP N
Department NNP N
Study NNP N
( ( N
SEEDS NNP N
) ) N
: : N
a DT N
multidisciplinary JJ N
approach NN N
to TO N
syncope VB 1_p
management NN N
. . N

BACKGROUND VB N
The DT N
primary JJ N
aim NN N
and CC N
central JJ N
hypothesis NN N
of IN N
the DT N
study NN N
are VBP N
that IN N
a DT N
designated VBN N
syncope NN N
unit NN N
in IN N
the DT N
emergency NN N
department NN N
improves VBZ N
diagnostic JJ N
yield NN N
and CC N
reduces NNS N
hospital JJ N
admission NN N
for IN N
patients NNS 1_p
with IN 1_p
syncope NN 1_p
who WP 1_p
are VBP 1_p
at IN 1_p
intermediate JJ 1_p
risk NN 1_p
for IN 1_p
an DT 1_p
adverse JJ 1_p
cardiovascular JJ 1_p
outcome NN 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
single-center JJ 1_p
study NN 1_p
, , 1_p
patients NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
2 CD N
treatment NN N
arms NNS N
: : N
syncope NN 1_i
unit NN 1_i
evaluation NN 1_i
and CC 1_i
standard NN 1_i
care NN 1_i
. . 1_i

The DT N
2 CD N
groups NNS N
were VBD N
compared VBN N
with IN N
chi2 JJ N
test NN N
for IN N
independence NN N
of IN N
categorical JJ N
variables NNS N
. . N

Wilcoxon NNP N
rank VBD N
sum JJ N
test NN N
was VBD N
used VBN N
for IN N
continuous JJ N
variables NNS N
. . N

Survival NNP 1_o
was VBD N
estimated VBN N
with IN N
the DT N
Kaplan-Meier NNP N
method NN N
. . N

One CD 1_p
hundred VBD 1_p
three CD 1_p
consecutive JJ 1_p
patients NNS 1_p
( ( 1_p
53 CD 1_p
women NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
64+/-17 CD 1_p
years NNS 1_p
) ) 1_p
entered VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

Fifty-one CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
syncope NN N
unit NN N
. . N

For IN N
the DT N
syncope NN N
unit NN N
and CC N
standard JJ N
care NN N
patients NNS N
, , N
the DT N
presumptive JJ 1_o
diagnosis NN 1_o
was VBD N
established VBN N
in IN N
34 CD N
( ( N
67 CD N
% NN N
) ) N
and CC N
5 CD N
( ( N
10 CD N
% NN N
) ) N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
hospital JJ 1_o
admission NN 1_o
was VBD N
required VBN N
for IN N
22 CD N
( ( N
43 CD N
% NN N
) ) N
and CC N
51 CD N
( ( N
98 CD N
% NN N
) ) N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
total JJ 1_o
patient-hospital JJ 1_o
days NNS 1_o
were VBD N
reduced VBN N
from IN N
140 CD N
to TO N
64 CD N
. . N

Actuarial JJ 1_o
survival NN 1_o
was VBD N
97 CD N
% NN N
and CC N
90 CD N
% NN N
( ( N
P=0.30 NNP N
) ) N
, , N
and CC N
survival JJ 1_o
free JJ 1_o
from IN 1_o
recurrent JJ 1_o
syncope NN 1_o
was VBD N
88 CD N
% NN N
and CC N
89 CD N
% NN N
( ( N
P=0.72 NNP N
) ) N
at IN N
2 CD N
years NNS N
for IN N
the DT N
syncope NN N
unit NN N
and CC N
standard JJ N
care NN N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
novel JJ N
syncope NN N
unit NN N
designed VBN N
for IN N
this DT N
study NN N
significantly RB N
improved VBN N
diagnostic JJ 1_o
yield NN 1_o
in IN N
the DT N
emergency NN N
department NN N
and CC N
reduced JJ N
hospital NN 1_o
admission NN 1_o
and CC N
total JJ 1_o
length NN 1_o
of IN 1_o
hospital NN 1_o
stay NN 1_o
without IN N
affecting VBG N
recurrent NN N
syncope NN N
and CC N
all-cause JJ N
mortality NN 1_o
among IN N
intermediate-risk JJ 1_p
patients NNS 1_p
. . 1_p

Observations NNS N
from IN N
the DT N
present JJ N
study NN N
provide VBP N
benchmark NN N
data NNS N
for IN N
improving VBG N
patient NN N
care NN N
and CC N
effectively RB N
utilizing JJ N
healthcare JJ N
resources NNS N
. . N

-DOCSTART- -X- O O

Teriparatide NNP N
improves VBZ N
early JJ 1_o
callus NN 1_o
formation NN 1_o
in IN N
distal JJ 1_p
radial JJ 1_p
fractures NNS 1_p
. . 1_p

BACKGROUND NNP N
Teriparatide NNP N
( ( N
parathyreoid JJ N
hormone NN N
; : N
PTH NNP N
1-34 CD N
) ) N
increases VBZ N
skeletal JJ N
mass NN N
in IN N
humans NNS N
and CC N
improves VBZ N
fracture NN N
healing VBG N
in IN N
animals NNS N
. . N

A DT N
recent JJ N
randomized JJ N
multicenter NN N
trial NN N
of IN N
nonoperated JJ 1_p
distal JJ 1_p
radial NN 1_p
fractures NNS 1_p
showed VBD N
a DT N
moderate JJ N
shortening NN N
of IN N
the DT N
time NN N
to TO N
restoration NN N
of IN N
cortical JJ N
continuity NN N
by IN N
treatment NN N
with IN N
20 CD 1_i
microg NNS 1_i
( ( 1_i
low-dose JJ 1_i
) ) 1_i
teriparatide NN 1_i
per IN 1_i
day NN 1_i
, , 1_i
but CC 1_i
not RB 1_i
with IN 1_i
40 CD 1_i
microg NNS 1_i
( ( 1_i
high-dose JJ 1_i
) ) 1_i
. . N

As IN N
radiographic JJ N
cortical JJ N
continuity NN N
appears VBZ N
late RB N
in IN N
the DT N
healing NN N
process NN N
, , N
perhaps RB N
too RB N
late JJ N
for IN N
clinical JJ N
relevance NN N
, , N
we PRP N
studied VBD N
the DT N
qualitative JJ N
appearance NN N
of IN N
the DT N
callus JJ N
5 CD N
weeks NNS N
after IN N
fracture NN N
. . N

METHODS NNP N
One CD 1_p
third NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
of IN 1_p
the DT 1_p
international JJ 1_p
trial NN 1_p
were VBD 1_p
treated VBN 1_p
at IN 1_p
Link?ping NNP 1_p
University NNP 1_p
Hospital NNP 1_p
. . 1_p

The DT N
multicenter NN N
trial NN N
did VBD N
not RB N
evaluate VB N
early JJ N
callus NN N
formation NN N
. . N

We PRP N
therefore RB N
made VBD N
a DT N
blinded JJ N
qualitative JJ N
scoring NN N
of IN N
the DT N
callus NN N
at IN N
5 CD N
weeks NNS N
in IN N
our PRP$ 1_p
27 CD 1_p
patients NNS 1_p
. . 1_p

Callus NNP N
formation NN N
was VBD N
arbitrarily RB N
classified VBN N
as IN N
rich JJ N
, , N
intermediate JJ N
, , N
or CC N
poor JJ N
. . N

RESULTS NNP N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN 1_o
rich JJ 1_o
( ( N
none NN N
had VBD N
received VBN N
placebo RB N
, , N
3 CD N
low-dose JJ N
teriparatide NN N
, , N
and CC N
6 CD N
high-dose JJ N
teriparatide NN N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN 1_o
intermediate NN 1_o
( ( N
1 CD N
had VBD N
received VBN N
placebo RB N
, , N
5 CD N
low-dose JJ N
, , N
and CC N
3 CD N
high-dose JJ N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN 1_o
poor JJ 1_o
( ( N
7 CD N
had VBD N
received VBN N
placebo RB N
, , N
1 CD N
low-dose JJ N
, , N
and CC N
1 CD N
high-dose NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

INTERPRETATION NN N
This DT N
is VBZ N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
of IN N
an DT N
outcome NN N
variable NN N
, , N
which WDT N
was VBD N
not RB N
in IN N
the DT N
official JJ N
protocol NN N
. . N

The DT N
results NNS N
must MD N
therefore RB N
be VB N
interpreted VBN N
with IN N
caution NN N
. . N

However RB N
, , N
in IN N
combination NN N
with IN N
the DT N
results NNS N
of IN N
the DT N
larger JJR N
trial NN N
, , N
the DT N
data NN N
suggest NN N
that IN N
radiographic JJ N
quality NN N
at IN N
an DT N
early JJ N
time NN N
point NN N
might MD N
be VB N
a DT N
sensitive JJ N
variable NN N
, , N
perhaps RB N
better JJR N
than IN N
time NN N
to TO N
cortical JJ N
continuity NN N
. . N

Moreover RB N
, , N
teriparatide RB 1_i
appeared VBD N
to TO N
improve VB 1_o
early JJ 1_o
callus NN 1_o
formation NN 1_o
in IN 1_p
distal JJ 1_p
radial JJ 1_p
fractures NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Face NNP 1_i
composite JJ 1_i
effects NNS N
reveal VBP N
abnormal JJ N
face NN N
processing NN N
in IN N
Autism NNP 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

Although IN N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
individuals NNS 1_p
with IN 1_p
an DT 1_p
Autism NNP 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
process NN N
faces VBZ N
less RBR N
holistically RB N
than IN N
typically RB N
developing VBG N
controls NNS N
, , N
there EX N
are VBP N
few JJ N
direct JJ N
investigations NNS N
of IN N
this DT N
hypothesis NN N
. . N

This DT N
question NN N
was VBD N
addressed VBN N
before IN N
using VBG N
the DT N
composite JJ N
paradigm NN N
( ( N
Teunisse NNP N
, , N
J. NNP N
P. NNP N
, , N
& CC N
de FW N
Gelder NNP N
, , N
B NNP N
. . N

( ( N
2003 CD N
) ) N
. . N

Face NN N
processing NN N
in IN N
adolescents NNS N
with IN N
autistic JJ N
disorder NN N
: : N
The DT N
inversion NN N
and CC N
composite JJ N
effects NNS N
. . N

Brain NNP N
Cognition NNP N
, , N
52 CD N
( ( N
3 CD N
) ) N
, , N
285-294. JJ N
) ) N
. . N

The DT N
results NNS N
had VBD N
revealed VBN N
that IN N
adolescents NNS 1_p
with IN 1_p
ASDs NNP 1_p
were VBD N
less RBR N
sensitive JJ N
than IN N
controls NNS N
to TO N
the DT N
misalignment NN N
of IN N
face NN N
parts NNS N
and CC N
it PRP N
was VBD N
concluded VBN N
their PRP$ N
face NN N
processing NN N
was VBD N
less RBR N
holistic JJ N
. . N

However RB N
, , N
because IN N
of IN N
shortcomings NNS N
of IN N
the DT N
design NN N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
distinguish VB N
whether IN N
individuals NNS 1_p
with IN 1_p
Autism NNP 1_p
processed VBD N
both DT N
aligned VBN N
and CC N
misaligned VBN N
composites NNS N
in IN N
a DT N
part-based JJ N
fashion NN N
, , N
or CC N
both DT N
in IN N
a DT N
holistic JJ N
fashion NN N
. . N

We PRP N
compared VBN N
adolescents NNS 1_i
with IN 1_i
ASDs NNP 1_i
to TO 1_p
controls VB 1_i
matched VBN 1_p
on IN 1_p
sex NN 1_p
, , 1_p
age NN 1_p
and CC 1_p
IQ NNP 1_p
on IN N
a DT N
more RBR N
complete JJ N
version NN N
of IN N
the DT N
composite JJ 1_i
paradigm NN 1_i
. . 1_i

The DT 1_o
results NNS 1_o
indicate VBP 1_o
that IN 1_o
individuals NNS 1_o
with IN 1_o
ASDs NNP 1_o
, , 1_o
like IN 1_o
controls NNS 1_o
, , 1_o
experience NN 1_o
interference NN 1_o
from IN 1_o
facial JJ 1_o
features NNS 1_o
that IN 1_o
they PRP 1_o
are VBP 1_o
told VBN 1_o
to TO 1_o
ignore VB 1_o
. . 1_o

However RB 1_o
, , 1_o
while IN 1_o
such JJ 1_o
interference NN 1_o
is VBZ 1_o
released VBN 1_o
for IN 1_o
controls NNS 1_o
if IN 1_o
parts NNS 1_o
of IN 1_o
face NN 1_o
composites NNS 1_o
are VBP 1_o
misaligned VBN 1_o
, , 1_o
individuals NNS 1_o
with IN 1_o
ASDs NNP 1_o
show VBP 1_o
comparable JJ 1_o
interference NN 1_o
from IN 1_o
irrelevant JJ 1_o
parts NNS 1_o
regardless RB 1_o
of IN 1_o
alignment NN 1_o
. . 1_o

Two CD 1_o
different JJ 1_o
interpretations NNS 1_o
are VBP 1_o
discussed VBN 1_o
, , 1_o
both DT 1_o
compatible JJ 1_o
with IN 1_o
the DT 1_o
idea NN 1_o
that WDT 1_o
perceptual JJ 1_o
and CC 1_o
or CC 1_o
attentional JJ 1_o
abnormalities NNS 1_o
in IN 1_o
ASDs NNP 1_o
result NN 1_o
in IN 1_o
a DT 1_o
diminished JJ 1_o
level NN 1_o
of IN 1_o
expertise NN 1_o
for IN 1_o
faces VBZ 1_o
. . 1_o

-DOCSTART- -X- O O

Traumatic JJ 1_p
brain NN 1_p
injury-related JJ 1_p
attention NN 1_o
deficits NNS 1_o
: : 1_o
treatment NN N
outcomes NNS 1_o
with IN N
lisdexamfetamine JJ 1_i
dimesylate NN 1_i
( ( 1_i
Vyvanse NNP 1_i
) ) 1_i
. . 1_i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Attention NNP N
deficits NNS N
are VBP N
often RB N
among IN N
the DT N
most RBS N
persistent JJ N
and CC N
debilitating VBG N
impairments NNS N
resulting VBG N
from IN N
traumatic JJ N
brain NN N
injury NN N
( ( N
TBI NNP N
) ) N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
lisdexamfetamine JJ 1_i
dimesylate NN 1_i
( ( 1_i
Vyvanse NNP 1_i
) ) 1_i
in IN N
treating VBG N
attention NN 1_o
deficits NNS 1_o
due JJ 1_p
to TO 1_p
moderate-to-severe JJ 1_p
TBI NNP 1_p
. . 1_p

It PRP N
was VBD N
the DT N
first JJ N
study NN N
of IN N
lisdexamfetamine JJ 1_i
dimesylate NN 1_i
with IN N
this DT 1_p
population NN 1_p
and CC N
, , N
in IN N
fact NN N
, , N
was VBD N
the DT N
first JJ N
controlled VBN N
trial NN N
in IN N
this DT N
area NN N
examining VBG N
a DT N
stimulant JJ N
medication NN N
option NN N
other JJ N
than IN N
methylphenidate NN 1_i
. . 1_i

METHODS NNP N
This DT N
was VBD N
a DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
cross-over JJ N
trial NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
22 CD 1_p
rigorously RB 1_p
selected VBN 1_p
cases NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
13 CD 1_p
of IN 1_p
whom WP 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
. . 1_p

They PRP 1_p
were VBD 1_p
16-42 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC 1_p
had VBD 1_p
newly RB 1_p
acquired VBN 1_p
attention NN 1_o
deficits NNS 1_o
persisting VBG 1_p
for IN 1_p
6-34 JJ 1_p
months NNS 1_p
post-injury NN 1_p
. . 1_p

They PRP 1_p
were VBD N
assessed VBN N
on IN N
a DT N
broad JJ N
range NN N
of IN N
neuropsychological JJ 1_o
and CC 1_o
behavioural JJ 1_o
measures NNS 1_o
at IN N
baseline NN N
, , N
6-weeks JJ N
and CC N
at IN N
12-weeks JJ N
. . N

RESULTS NNP N
AND CC N
CONCLUSIONS NNP N
Positive NNP N
treatment NN N
effects NNS N
were VBD N
found VBN N
involving VBG N
selective JJ N
measures NNS N
of IN N
sustained JJ 1_o
attention NN 1_o
, , 1_o
working VBG 1_o
memory NN 1_o
, , 1_o
response NN 1_o
speed NN 1_o
stability NN 1_o
and CC 1_o
endurance NN 1_o
and CC 1_o
in IN 1_o
aspects NNS 1_o
of IN 1_o
executive NN 1_o
functioning NN 1_o
. . 1_o

No DT N
major JJ N
problems NNS N
with IN N
safety NN 1_o
or CC 1_o
tolerability NN 1_o
were VBD N
observed VBN N
. . N

Some DT N
moderating VBG N
treatment NN N
effects NNS N
were VBD N
found VBN N
from IN N
a DT N
broad JJ N
range NN N
of IN N
pre-treatment JJ N
subject JJ N
characteristics NNS N
and CC N
injury NN N
variables NNS N
examined VBN N
. . N

Avenues NNS N
for IN N
further JJ N
research NN N
and CC N
treatment NN N
applications NNS N
in IN N
this DT N
area NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Hexetidine NNP 1_i
( ( 1_i
'Oraldene NNP 1_i
' POS 1_i
) ) 1_i
: : 1_i
a DT N
report NN N
on IN N
its PRP$ N
antibacterial JJ 1_o
and CC 1_o
antifungal JJ 1_o
properties NNS 1_o
on IN N
the DT N
oral JJ N
flora NNS N
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

A DT N
randomized JJ N
, , N
double-blind JJ N
crossover NN N
trial NN N
, , N
in IN N
10 CD 1_p
adult NN 1_p
healthy JJ 1_p
subjects NNS 1_p
, , N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
the DT N
antibacterial JJ 1_o
and CC 1_o
antifungal JJ 1_o
activity NN 1_o
of IN N
a DT N
0.1 CD 1_i
% NN 1_i
solution NN 1_i
of IN 1_i
hexetidine NN 1_i
with IN 1_i
that DT 1_i
of IN 1_i
placebo NN 1_i
. . 1_i

The DT N
pre-dosing JJ N
oral JJ N
flora NN N
of IN N
the DT N
subjects NNS N
was VBD N
assessed VBN N
from IN N
saliva NN 1_o
samples NNS 1_o
cultured VBD N
for IN N
aerobic JJ 1_o
and CC 1_o
anaerobic JJ 1_o
bacteria NNS 1_o
, , N
as RB N
well RB N
as IN N
Candida NNP 1_o
albicans NNS 1_o
. . 1_o

Subjects NNS N
then RB N
rinsed VBD N
their PRP$ N
mouths NNS N
for IN N
1 CD N
minute JJ N
3-times NNS N
a DT N
day NN N
with IN N
15 CD N
ml NNS N
0.1 CD N
% NN N
hexetidine NN 1_i
or CC 1_i
placebo NN 1_i
, , N
saliva NN N
samples NNS N
being VBG N
collected VBN N
at IN N
2 CD N
minutes NNS N
, , N
30 CD N
minutes NNS N
, , N
1 CD N
hour NN N
, , N
3 CD N
hours NNS N
and CC N
5 CD N
hours NNS N
post-dosing JJ N
. . N

Dosing NN N
was VBD N
continued VBN N
for IN N
8 CD N
consecutive JJ N
days NNS N
on IN N
each DT N
treatment NN N
with IN N
an DT N
intervening VBG N
wash-out JJ N
period NN N
of IN N
1 CD N
week NN N
. . N

Hexetidine NNP 1_i
reduced VBD N
aerobic JJ 1_o
bacterial JJ 1_o
counts NNS 1_o
on IN N
Day NNP N
1 CD N
and CC N
Day NNP N
8 CD N
by IN N
a DT N
maximum NN N
of IN N
83 CD N
% NN N
and CC N
86 CD N
% NN N
, , N
respectively RB N
, , N
at IN N
2 CD N
minutes NNS N
post-dosing JJ N
. . N

The DT N
reductions NNS N
were VBD N
statistically RB N
significantly RB N
lower JJR N
than IN N
placebo VB 1_i
up IN N
to TO N
1 CD N
hour NN N
post-dose JJ N
on IN N
Day NNP N
1 CD N
and CC N
up RB N
to TO N
3 CD N
hours NNS N
post-dose JJ N
on IN N
Day NNP N
8 CD N
. . N

Similarly RB N
for IN N
anaerobic JJ 1_o
bacterial JJ 1_o
counts NNS 1_o
, , N
92 CD N
% NN N
and CC N
88 CD N
% NN N
maximum JJ N
reductions NNS N
were VBD N
recorded VBN N
on IN N
Day NNP N
1 CD N
and CC N
Day NNP N
8 CD N
, , N
which WDT N
again RB N
were VBD N
significantly RB N
lower JJR N
than IN N
placebo NN N
for IN N
up IN N
to TO N
3 CD N
hours NNS N
post-dose JJ N
. . N

For IN N
Candida NNP 1_o
albicans NNS 1_o
, , N
however RB N
, , N
the DT N
maximum JJ N
reduction NN N
was VBD N
91 CD N
% NN N
on IN N
the DT N
first JJ N
day NN N
and CC N
67 CD N
% NN N
on IN N
Day NNP N
8 CD N
, , N
maintained VBD N
for IN N
30 CD N
minutes NNS N
post-dosing JJ N
. . N

Although IN N
not RB N
eradicating VBG 1_o
completely RB 1_o
aerobic JJ 1_o
and CC 1_o
anaerobic JJ 1_o
bacteria NNS 1_o
, , N
it PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
substantial JJ N
reduction NN 1_o
in IN N
their PRP$ N
numbers NNS N
should MD N
prove VB N
clinically RB N
useful JJ N
. . N

-DOCSTART- -X- O O

Pathology NN N
parameters NNS N
and CC N
adjuvant JJ 1_o
tamoxifen NN 1_o
response NN 1_o
in IN N
a DT N
randomised JJ N
premenopausal NN 1_p
breast NN 1_p
cancer NN 1_p
trial NN N
. . N

BACKGROUND NNP N
Subgroups NNP N
of IN N
breast NN N
cancer NN N
that WDT N
have VBP N
an DT N
impaired JJ N
response NN N
to TO N
endocrine VB N
treatment NN N
, , N
despite IN N
hormone NN N
receptor NN N
positivity NN N
, , N
are VBP N
still RB N
poorly RB N
defined VBN N
. . N

Breast NNP N
cancer NN N
can MD N
be VB N
subdivided VBN N
according VBG N
to TO N
standard JJ N
pathological JJ N
parameters NNS N
including VBG N
histological JJ N
type NN N
, , N
grade NN N
, , N
and CC N
assessment NN N
of IN N
proliferation NN N
. . N

These DT N
parameters NNS N
are VBP N
the DT N
net JJ N
result NN N
of IN N
combinations NNS N
of IN N
genetic JJ N
alterations NNS N
effecting VBG N
tumour JJ N
behaviour NN N
and CC N
could MD N
potentially RB N
reflect VB N
subtypes NNS N
that IN N
respond NN N
differently RB N
to TO N
endocrine VB N
treatment NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
usefulness NN N
of IN N
these DT N
parameters NNS N
as IN N
predictors NNS N
of IN N
the DT N
response NN N
to TO N
tamoxifen VB 1_i
in IN N
premenopausal JJ 1_p
women NNS 1_p
with IN 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

MATERIALS/METHODS NNP N
Clinically NNP N
established VBD N
pathological JJ N
parameters NNS N
were VBD N
assessed VBN N
and CC N
related VBN N
to TO N
the DT N
tamoxifen NN 1_i
response NN N
in IN N
500 CD 1_p
available JJ 1_p
tumour NN 1_p
specimens NNS 1_p
from IN 1_p
564 CD 1_p
premenopausal NN 1_p
patients NNS 1_p
with IN 1_p
breast JJ 1_p
cancer NN 1_p
randomised VBD N
to TO N
either DT N
two CD N
years NNS N
of IN N
tamoxifen NN 1_i
or CC N
no DT 1_i
treatment NN 1_i
with IN N
14 CD N
years NNS N
of IN N
follow NN N
up RB N
. . N

Proliferation NN N
was VBD N
further RB N
evaluated VBN N
by IN N
immunohistochemical JJ N
Ki-67 NNP N
expression NN N
. . N

RESULTS NNP N
Oestrogen NNP 1_o
receptor NN 1_o
positive JJ 1_o
ductal JJ 1_o
carcinomas NN 1_o
responded VBD N
as IN N
expected VBN N
to TO N
tamoxifen VB 1_i
, , N
whereas IN N
the DT N
difference NN N
in IN N
recurrence NN 1_o
free JJ 1_o
survival NN 1_o
between IN N
control NN 1_i
and CC N
tamoxifen NN 1_i
treated VBD N
patients NNS N
was VBD N
less RBR N
apparent JJ N
in IN N
the DT N
relatively RB N
few JJ N
lobular JJ N
carcinomas NN N
. . N

For IN N
histological JJ N
grade NN N
, , N
there EX N
was VBD N
no DT N
obvious JJ N
difference NN N
in IN N
treatment NN N
response NN N
between IN N
the DT N
groups NNS N
. . N

The DT N
relation NN N
between IN N
proliferation NN N
and CC N
tamoxifen NN 1_i
response NN N
seemed VBD N
to TO N
be VB N
more RBR 1_o
complex JJ 1_o
, , 1_o
with IN 1_o
a DT 1_o
clear JJ 1_o
response NN 1_o
in IN 1_o
tumours NN 1_o
with IN 1_o
high JJ 1_o
and CC 1_o
low JJ 1_o
proliferation NN 1_o
, , N
whereas JJ N
tumours NN N
with IN N
intermediate JJ N
proliferation NN N
defined VBN N
by IN N
Ki-67 NNP N
responded VBD N
more RBR N
poorly RB 1_o
. . 1_o

CONCLUSIONS NNP N
Clinically NNP N
established VBD N
pathology NN N
parameters NNS N
seem VBP N
to TO N
mirror VB N
the DT N
endocrine NN N
treatment NN N
response NN N
and CC N
could MD N
potentially RB N
be VB N
valuable JJ N
in IN N
future JJ N
treatment NN N
decisions NNS N
for IN N
patients NNS 1_p
with IN 1_p
breast JJ 1_p
cancer NN 1_p
. . 1_p

-DOCSTART- -X- O O

Reactive JJ N
balance NN N
adjustments NNS N
to TO N
unexpected JJ 1_i
perturbations NNS 1_i
during IN 1_p
human JJ 1_p
walking NN 1_p
. . 1_p

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
unexpected JJ 1_i
forward NN 1_i
perturbations NNS 1_i
( ( 1_i
FP NNP 1_i
) ) 1_i
during IN N
gait NN N
on IN N
lower JJR 1_o
extremity NN 1_o
joint NN 1_o
mechanics NNS 1_o
and CC 1_o
muscle NN 1_o
Electromyographic NNP 1_o
( ( 1_o
EMG NNP 1_o
) ) 1_o
patterns VBZ 1_o
in IN N
healthy JJ 1_p
adults NNS 1_p
. . 1_p

The DT N
muscles NNS N
surrounding VBG N
the DT N
hip NN N
were VBD N
found VBN N
to TO N
be VB N
most RBS N
important JJ N
in IN N
maintaining VBG 1_o
control NN 1_o
of IN 1_o
the DT 1_o
trunk NN 1_o
and CC 1_o
preventing VBG 1_o
collapse NN 1_o
in IN N
response NN N
to TO N
the DT N
FP NNP N
. . N

Distinct NNP 1_o
lower JJR 1_o
extremity NN 1_o
joint JJ 1_o
moment NN 1_o
and CC 1_o
power NN 1_o
patterns NNS 1_o
were VBD N
observed VBN N
in IN N
response NN N
to TO N
the DT N
FP NNP 1_i
but CC N
an DT N
overall JJ N
positive JJ N
moment NN 1_o
of IN 1_o
support NN 1_o
( ( 1_o
M NNP 1_o
( ( 1_o
s PRP 1_o
) ) 1_o
) ) 1_o
was VBD N
maintained VBN N
. . N

Therefore RB N
, , N
reactive JJ 1_o
balance NN 1_o
control NN 1_o
was VBD N
a DT N
synchronized JJ N
effort NN N
of IN N
the DT N
lower JJR N
extremity NN N
joints NNS N
to TO N
prevent VB N
collapse NN N
during IN N
the DT N
FP NNP 1_i
. . 1_i

-DOCSTART- -X- O O

Clinical JJ N
application NN 1_i
of IN 1_i
C-reactive JJ 1_i
protein NN 1_i
across IN N
the DT 1_p
spectrum NN 1_p
of IN 1_p
acute JJ 1_p
coronary JJ 1_p
syndromes NNS 1_p
. . 1_p

BACKGROUND NNP N
High-sensitivity NNP 1_i
C-reactive JJ 1_i
protein NN 1_i
( ( 1_i
hsCRP NN 1_i
) ) 1_i
is VBZ N
associated VBN N
with IN N
adverse JJ N
cardiovascular JJ N
outcomes NNS N
in IN N
acute JJ 1_p
coronary JJ 1_p
syndromes NNS 1_p
( ( 1_p
ACS NNP 1_p
) ) 1_p
. . 1_p

The DT N
ability NN N
to TO N
formulate VB N
recommendations NNS N
regarding VBG N
clinical JJ N
use NN N
of IN N
hsCRP NN 1_i
is VBZ N
limited VBN N
by IN N
a DT N
paucity NN N
of IN N
data NNS N
regarding VBG N
several JJ N
key JJ N
issues NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
hsCRP NN 1_i
across IN N
the DT N
spectrum NN N
of IN N
ACS NNP N
. . N

METHODS NNP N
hsCRP NN 1_o
was VBD N
measured VBN N
on IN N
admission NN N
in IN N
3225 CD 1_p
patients NNS 1_p
with IN 1_p
ACS NNP 1_p
. . 1_p

hsCRP NN 1_o
concentrations NNS 1_o
were VBD N
compared VBN N
in IN N
patients NNS N
who WP N
suffered VBD N
an DT N
adverse JJ N
cardiac NN N
outcome NN N
within IN N
10 CD N
months NNS N
of IN N
study NN N
entry NN N
and CC N
in IN N
patients NNS N
who WP N
had VBD N
no DT N
adverse JJ N
event NN N
. . N

Because IN N
of IN N
heterogeneity NN N
in IN N
the DT N
relationship NN N
between IN N
hsCRP NN 1_i
and CC N
clinical JJ N
outcomes NNS N
, , N
evaluation NN N
was VBD N
limited VBN N
to TO N
patients NNS N
from IN N
whom WP N
samples NNS N
were VBD N
collected VBN N
within IN N
48 CD N
h NN N
of IN N
symptom JJ N
onset NN N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
highest JJS N
quartile NN N
of IN N
hsCRP NN 1_i
compared VBN N
to TO N
those DT N
in IN N
the DT N
lowest JJS N
quartile NN N
were VBD N
at IN N
increased VBN N
risk NN 1_o
of IN 1_o
death NN 1_o
at IN N
30 CD N
days NNS N
[ RB N
adjusted VBN N
hazard NN N
ratio NN N
( ( N
adjHR NN N
) ) N
4.6 CD N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
and CC N
10 CD N
months NNS N
( ( N
adjHR JJ N
3.9 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
unstable JJ N
angina/non-ST-elevation JJ N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
, , N
hsCRP JJ 1_i
> FW N
3 CD N
mg/L NN N
was VBD N
associated VBN N
with IN N
increased JJ 1_o
10-month JJ 1_o
mortality NN 1_o
( ( N
adjHR JJ N
2.3 CD N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
whereas RB N
in IN N
STEMI NNP N
a DT N
relationship NN N
with IN N
mortality NN N
was VBD N
seen VBN N
at IN N
hsCRP JJ N
> $ N
10 CD N
mg/L NN N
( ( N
adjHR JJ N
3.0 CD N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

Increased VBN N
concentrations NNS N
of IN N
hsCRP NN 1_o
were VBD N
strongly RB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
heart NN 1_o
failure NN 1_o
at IN N
30 CD N
days NNS N
( ( N
adjHR JJ N
8.2 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
10 CD N
months NNS N
( ( N
adjHR JJ N
2.6 CD N
, , N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

CONCLUSION NNP N
Increased VBD N
baseline JJ 1_o
concentrations NNS 1_o
of IN 1_o
hsCRP NN 1_o
are VBP N
strongly RB N
associated VBN N
with IN N
mortality NN 1_o
and CC 1_o
heart NN 1_o
failure NN 1_o
across IN N
the DT N
ACS NNP N
spectrum NN N
. . N

hsCRP JJ 1_i
measurement NN N
should MD N
be VB N
performed VBN N
early RB N
after IN N
presentation NN N
and CC N
index NN N
diagnosis-specific JJ N
cutpoints NNS N
should MD N
be VB N
used VBN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
comparison NN N
of IN N
the DT N
Endeavor NNP 1_i
zotarolimus-eluting JJ 1_i
stent NN 1_i
versus IN 1_i
the DT 1_i
TAXUS NNP 1_i
paclitaxel-eluting JJ 1_i
stent NN 1_i
in IN N
de FW N
novo FW N
native JJ N
coronary JJ N
lesions NNS N
12-month JJ N
outcomes NNS N
from IN N
the DT N
ENDEAVOR NNP N
IV NNP N
trial NN N
. . N

OBJECTIVES CC N
The DT N
ENDEAVOR NNP N
IV NNP N
( ( N
Randomized NNP N
Comparison NNP N
of IN N
Zotarolimus-Eluting NNP 1_i
and CC N
Paclitaxel-Eluting NNP 1_i
Stents NNP 1_i
in IN N
Patients NNP N
with IN N
Coronary NNP N
Artery NNP N
Disease NNP N
) ) N
trial NN N
evaluated VBD N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
the DT N
zotarolimus-eluting JJ 1_i
stent NN 1_i
( ( 1_i
ZES NNP 1_i
) ) 1_i
compared VBN 1_i
with IN 1_i
the DT 1_i
paclitaxel-eluting JJ 1_i
stent NN 1_i
( ( 1_i
PES NNP 1_i
) ) 1_i
. . N

BACKGROUND NNP N
First-generation NNP N
drug-eluting NN N
stents NNS N
have VBP N
reduced VBN N
angiographic JJ N
and CC N
clinical JJ N
restenosis NN N
, , N
but CC N
long-term JJ N
safety NN N
remains VBZ N
controversial JJ N
. . N

A DT N
second-generation JJ 1_i
drug-eluting JJ 1_i
stent NN 1_i
, , N
which WDT N
delivers VBZ N
zotarolimus NN 1_i
, , N
a DT N
potent JJ N
antiproliferative JJ N
agent NN N
, , N
via IN N
a DT N
biocompatible JJ N
phosphorylcholine NN N
polymer NN N
on IN N
a DT N
cobalt JJ N
alloy NN N
thin-strut JJ N
stent NN N
has VBZ N
shown VBN N
promising JJ N
experimental JJ N
and CC N
early JJ N
clinical JJ N
results NNS N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
( ( N
1:1 CD N
) ) N
, , N
single-blind JJ N
, , N
controlled JJ N
trial NN N
comparing VBG N
outcomes NNS N
of IN N
patients NNS 1_p
with IN 1_p
single JJ 1_p
de FW 1_p
novo FW 1_p
coronary JJ 1_p
lesions NNS 1_p
treated VBN 1_p
with IN 1_p
ZES NNP 1_p
or CC 1_p
PES NNP 1_p
. . 1_p

The DT N
primary JJ 1_o
end NN 1_o
point NN 1_o
was VBD 1_o
noninferiority NN 1_o
of IN 1_o
9-month JJ 1_o
target NN 1_o
vessel JJ 1_o
failure NN 1_o
defined VBD 1_o
as IN 1_o
cardiac JJ 1_o
death NN 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
or CC 1_o
target VB 1_o
vessel JJ 1_o
revascularization NN 1_o
. . 1_o

RESULTS NNP N
Among IN N
a DT N
total NN N
of IN N
1,548 CD 1_p
patients NNS 1_p
assigned VBN 1_p
to TO 1_p
ZES NNP 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
773 CD 1_p
) ) 1_p
or CC 1_p
PES NNP 1_p
( ( N
n JJ N
= NNP N
775 CD N
) ) N
, , N
at IN N
9 CD N
months NNS N
, , N
ZES NNP N
was VBD N
noninferior JJ N
to TO N
PES VB N
with IN N
rates NNS N
of IN N
target NN 1_o
vessel JJ 1_o
failure NN 1_o
6.6 CD N
% NN N
versus IN N
7.1 CD N
% NN N
, , N
respectively RB N
( ( N
p NN N
( ( N
noninferiority NN N
) ) N
< NN N
or CC N
= VB N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
periprocedural JJ 1_o
myocardial JJ 1_o
infarctions NNS 1_o
with IN N
ZES NNP 1_i
( ( N
0.5 CD N
% NN N
vs. FW N
2.2 CD N
% NN N
; : N
p CC N
= VB N
0.007 CD N
) ) N
, , N
whereas VBP N
at IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
rates NNS N
of IN N
cardiac JJ 1_o
death NN 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
target NN 1_o
vessel NN 1_o
revascularization NN 1_o
, , 1_o
or CC 1_o
stent JJ 1_o
thrombosis NN 1_o
. . 1_o

Although IN N
incidence NN N
of IN N
8-month JJ N
binary JJ 1_o
angiographic JJ 1_o
in-segment JJ 1_o
restenosis NN 1_o
was VBD N
higher RBR N
in IN N
patients NNS N
treated VBN N
with IN N
ZES NNP 1_i
versus NN N
PES NNP N
( ( N
15.3 CD N
% NN N
vs. FW N
10.4 CD N
% NN N
; : N
p CC N
= VB N
0.284 CD N
) ) N
, , N
rates NNS N
of IN N
12-month JJ N
target NN 1_o
lesion NN 1_o
revascularization NN 1_o
were VBD N
similar JJ N
( ( N
4.5 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.228 CD N
) ) N
, , N
especially RB N
in IN N
patients NNS N
without IN N
planned JJ N
angiographic JJ N
follow-up NN N
( ( N
3.6 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.756 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
demonstrate VBP N
that IN N
ZES NNP 1_i
has VBZ N
similar JJ N
clinical JJ N
safety NN N
and CC N
efficacy NN N
compared VBN N
with IN N
PES NNP 1_i
in IN N
simple JJ N
and CC N
medium JJ N
complexity NN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

( ( N
ENDEAVOR NNP N
IV NNP N
Clinical NNP N
Trial NNP N
; : N
NCT00217269 NNP N
) ) N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
case NN 1_i
management NN 1_i
on IN N
the DT N
costs NNS 1_o
of IN 1_o
health NN 1_o
care NN 1_o
for IN N
enrollees NNS N
in IN N
Medicare NNP N
Plus NNP N
Choice NNP N
plans VBZ N
: : N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
measure VB N
the DT N
effects NNS N
of IN N
case NN N
management NN N
on IN N
an DT N
older JJR 1_p
population NN 1_p
's POS 1_p
costs NNS 1_o
of IN 1_o
health NN 1_o
care NN 1_o
. . 1_o

DESIGN VB N
A DT N
1-year JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

SETTING NN N
Multiple NNP 1_p
sites NNS 1_p
of IN 1_p
care NN 1_p
in IN 1_p
San NNP 1_p
Francisco NNP 1_p
, , 1_p
California NNP 1_p
. . 1_p

PARTICIPANTS NN N
Patients NNPS 1_p
aged VBD 1_p
65 CD 1_p
or CC 1_p
older JJR 1_p
of IN 1_p
primary JJ 1_p
care NN 1_p
physicians NNS 1_p
in IN 1_p
a DT 1_p
large JJ 1_p
provider NN 1_p
organization NN 1_p
bearing VBG 1_p
financial JJ 1_p
risk NN 1_p
for IN 1_p
their PRP$ 1_p
care NN 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
6409 CD 1_p
) ) 1_p
. . 1_p

INTERVENTION NNP N
Screening VBG 1_i
for IN 1_i
high JJ 1_i
risk NN 1_i
and CC 1_i
provision NN 1_i
of IN 1_i
social JJ 1_i
work-based JJ 1_i
case NN 1_i
management NN 1_i
. . 1_i

OUTCOME NNP N
MEASURES NNP N
Volume NN 1_o
and CC 1_o
cost NN 1_o
of IN 1_o
hospital NN 1_o
, , 1_o
physician NN 1_o
, , 1_o
case NN 1_o
management NN 1_o
, , 1_o
and CC 1_o
other JJ 1_o
health-related JJ 1_o
services NNS 1_o
. . 1_o

RESULTS VB N
The DT N
experimental JJ N
group NN N
used VBD N
more JJR N
case NN 1_o
management NN 1_o
services NNS 1_o
than IN N
the DT N
control NN N
group NN N
( ( N
0.09 CD N
vs. FW N
0.02 CD N
months NNS N
per IN N
person NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
experimental JJ N
group NN N
's POS N
average JJ N
total JJ 1_o
payments NNS 1_o
for IN 1_o
health NN 1_o
care NN 1_o
were VBD N
slightly RB N
lower JJR N
( ( N
$ $ N
3148 CD N
vs IN N
$ $ N
3277 CD N
, , N
P NNP N
= NNP N
.40 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
no DT N
statistically RB N
significant JJ N
evidence NN N
that IN N
social JJ N
work-oriented JJ N
case NN N
management NN N
reduces VBZ N
the DT N
use NN N
or CC N
the DT N
cost NN 1_o
of IN 1_o
health NN 1_o
care NN 1_o
for IN N
high-risk JJ N
older JJR N
people NNS N
. . N

Other JJ N
potentially RB N
favorable JJ N
effects NNS N
of IN N
this DT N
type NN N
of IN N
case NN N
management NN N
need NN N
to TO N
be VB N
evaluated VBN N
, , N
as IN N
do VBP N
the DT N
effects NNS N
of IN N
other JJ N
types NNS N
of IN N
case NN N
management NN N
. . N

-DOCSTART- -X- O O

Sublingual JJ N
administration NN N
of IN N
micronized JJ 1_i
estradiol NN 1_i
and CC 1_i
progesterone NN 1_i
, , N
with IN N
and CC N
without IN N
micronized VBN 1_i
testosterone NN 1_i
: : 1_i
effect NN N
on IN N
biochemical JJ 1_p
markers NNS 1_p
of IN 1_p
bone NN 1_o
metabolism NN 1_p
and CC 1_o
bone JJ 1_o
mineral JJ 1_o
density NN 1_o
. . 1_o

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
the DT N
relative JJ N
efficacy NN N
of IN N
the DT N
sublingual JJ N
administration NN N
of IN N
micronized JJ 1_i
estradiol NN 1_i
( ( 1_i
E2 NNP 1_i
) ) 1_i
, , 1_i
progesterone NN 1_i
( ( 1_i
P4 NNP 1_i
) ) 1_i
, , 1_i
and CC 1_i
testosterone NN 1_i
( ( 1_i
T NNP 1_i
) ) 1_i
on IN N
bone NN 1_p
mineral JJ 1_p
density NN 1_p
and CC 1_p
biochemical JJ 1_p
markers NNS 1_p
of IN 1_p
bone NN 1_p
metabolism NN 1_p
. . 1_p

DESIGN NN N
In IN N
this DT N
double-blind NN N
, , N
prospective JJ N
study NN N
, , N
postmenopausal JJ 1_p
women NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD 1_p
treatment NN 1_p
groups NNS 1_p
: : 1_p
hysterectomized VBN 1_p
women NNS 1_p
were VBD N
assigned VBN N
to TO N
either DT N
1 CD N
) ) N
micronized VBN 1_i
E2 NNP 1_i
( ( N
0.5 CD N
mg NN N
) ) N
or CC N
2 CD N
) ) N
micronized VBN 1_i
E2 NNP 1_i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN 1_i
T NNP 1_i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

Women NNS 1_p
with IN 1_p
intact JJ 1_p
uteri NNS 1_p
were VBD N
assigned VBN N
to TO N
either DT N
3 CD N
) ) N
micronized VBN 1_i
E2 NNP 1_i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN 1_i
P4 NNP 1_i
( ( N
100 CD N
mg NN N
) ) N
or CC N
4 CD N
) ) N
micronized VBN 1_i
E2 NNP 1_i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ 1_i
micronized VBN 1_i
P4 NNP 1_i
( ( N
100 CD N
mcg NN N
) ) N
+ VBZ 1_i
micronized VBN 1_i
T NNP 1_i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

For IN N
the DT N
purpose NN N
of IN N
this DT N
study NN N
, , N
the DT N
four CD N
treatment NN N
groups NNS N
were VBD N
combined VBN N
into IN N
two CD N
groups NNS N
for IN N
all DT N
comparisons NNS N
. . N

The DT N
E2 NNP 1_i
and CC N
E2+P4 NNP 1_i
groups NNS N
were VBD N
combined VBN N
into IN N
the DT N
HRT NNP 1_p
alone RB 1_p
group NN 1_p
( ( 1_p
n=30 NN 1_p
) ) 1_p
, , N
and CC N
the DT N
E2+T NNP 1_i
and CC N
E2+P4+T NNP 1_i
groups NNS N
were VBD N
combined VBN N
into IN N
the DT N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
group NN 1_p
( ( 1_p
n=27 RB 1_p
) ) 1_p
. . 1_p

Hormones NNPS N
were VBD N
administered VBN N
sublingually RB N
as IN N
a DT N
single JJ N
tablet NN N
twice RB N
a DT N
day NN N
for IN N
12 CD N
months NNS N
. . N

Bone NNP 1_o
mineral JJ 1_o
density NN 1_o
was VBD N
measured VBN N
in IN N
the DT N
anterior-posterior JJ N
lumbar NN N
spine NN N
and CC N
total JJ N
left JJ N
hip NN N
via IN N
dual JJ N
energy NN N
x-ray JJ N
absorptiometry NN N
. . N

Bone NNP 1_o
metabolism NN 1_o
was VBD N
assessed VBN N
via IN N
serum JJ N
bone-specific JJ N
alkaline NN N
phosphatase NN N
and CC N
urinary JJ N
deoxypyridinoline NN N
and CC N
cross-linked JJ N
N-telopeptide NNP N
of IN N
type NN N
I PRP N
collagen VBP N
, , N
both DT N
normalized VBN N
to TO N
creatinine VB N
. . N

Data NNP N
were VBD N
analyzed VBN N
via IN N
a DT N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
and CC N
a DT N
Student NN N
's POS N
t JJ N
test NN N
( ( N
alpha=0.05 NN N
) ) N
. . N

RESULTS VB N
The DT 1_p
subjects NNS 1_p
were VBD 1_p
of IN 1_p
similar JJ 1_p
age NN 1_p
( ( 1_p
54.0 CD 1_p
+/- JJ 1_p
0.8 CD 1_p
years NNS 1_p
) ) 1_p
, , 1_p
height VBD 1_p
( ( 1_p
64.0 CD 1_p
+/- JJ 1_p
0.3 CD 1_p
in IN 1_p
) ) 1_p
, , 1_p
weight VBD 1_p
( ( 1_p
157.6 CD 1_p
+/- JJ 1_p
4.2 CD 1_p
lb NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
had VBD 1_p
similar JJ 1_p
baseline NN 1_p
follicle-stimulating NN 1_p
hormone NN 1_p
( ( 1_p
66.4 CD 1_p
+/- JJ 1_p
3.2 CD 1_p
mIU/L NN 1_p
) ) 1_p
, , 1_p
E2 NNP 1_p
( ( 1_p
26.4 CD 1_p
+/- JJ 1_p
1.5 CD 1_p
pg/ml NN 1_p
) ) 1_p
, , 1_p
P4 NNP 1_p
( ( 1_p
0.3 CD 1_p
+/- JJ 1_p
0.1 CD 1_p
ng/ml NN 1_p
) ) 1_p
, , 1_p
total JJ 1_p
T NNP 1_p
( ( 1_p
19.0 CD 1_p
+/- JJ 1_p
1.5 CD 1_p
ng/dL NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
bioavailable JJ 1_p
T NNP 1_p
( ( 1_p
3.7 CD 1_p
+/- JJ 1_p
0.3 CD 1_p
ng/dL NN 1_p
) ) 1_p
levels NNS 1_p
. . 1_p

During IN N
therapy NN N
, , N
serum NN N
levels NNS N
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
each DT N
hormone NN N
. . N

Bone NNP 1_o
mineral JJ 1_o
density NN 1_o
and CC 1_o
bone NN 1_o
markers NNS 1_o
at IN N
baseline NN N
were VBD N
similar JJ N
for IN N
each DT N
treatment NN N
group NN N
. . N

Bone-specific JJ 1_o
alkaline JJ 1_o
phosphatase NN 1_o
decreased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
-14.3 JJ N
+/- JJ N
4.1 CD N
% NN N
in IN N
the DT N
HRT NNP 1_i
alone RB N
group NN N
and CC N
by IN N
-8.2 NNP N
+/- JJ N
4.6 CD N
% NN N
in IN N
the DT N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
group NN N
. . N

Deoxypyridinoline NNP N
levels NNS 1_o
decreased VBN N
significantly RB N
in IN N
the DT N
HRT NNP 1_i
alone RB 1_i
and CC N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
groups NNS N
, , N
- : N
14.4 CD N
+/- JJ N
6.8 CD N
% NN N
and CC N
-26.9 JJ N
+/- JJ N
7.6 CD N
% NN N
, , N
respectively RB N
. . N

Significant JJ N
reductions NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
cross-linked JJ 1_o
N-telopeptide NNP 1_o
of IN 1_o
type NN 1_o
I PRP 1_o
collagen VBP 1_o
were VBD N
also RB N
observed VBN N
in IN N
both DT N
groups NNS N
, , N
-24.4 VBD N
+/- JJ N
6.5 CD N
% NN N
and CC N
-39.5 JJ N
+/- JJ N
8.6 CD N
% NN N
, , N
respectively RB N
. . N

Bone NNP 1_o
mineral JJ 1_o
density NN 1_o
in IN 1_o
the DT 1_o
lumbar NN 1_o
spine NN 1_o
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
+2.2 JJ N
+/- JJ N
0.5 CD N
% NN N
the DT N
HRT NNP 1_i
alone RB 1_i
group NN N
and CC N
by IN N
+ JJ N
1.8 CD N
+/- JJ N
0.6 CD N
% NN N
in IN N
the DT N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
group NN N
. . N

Total JJ 1_o
hip NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
was VBD N
maintained VBN N
in IN N
the DT N
HRT NNP 1_i
alone RB 1_i
group NN N
( ( N
+0.4 JJ N
+/- JJ N
0.4 CD N
% NN N
) ) N
and CC N
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
group NN N
( ( N
+ JJ N
1.8 CD N
+/- JJ N
0.5 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Sublingual NNP N
micronized VBD N
HRT NNP 1_i
favorably RB N
decreases VBZ N
serum NN 1_o
and CC 1_o
urine JJ 1_o
markers NNS 1_o
of IN 1_o
bone NN 1_o
metabolism NN 1_o
, , N
prevents VBZ N
bone JJ 1_o
loss NN 1_o
, , N
and CC N
results NNS N
in IN N
a DT N
slight JJ N
increase NN N
in IN N
spine NN 1_o
and CC 1_o
hip NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
. . 1_o

Although IN N
the DT N
addition NN N
of IN N
testosterone NN N
to TO N
HRT NNP 1_i
for IN N
1 CD N
year NN N
did VBD N
not RB N
result VB N
in IN N
added JJ N
benefit NN N
to TO N
the DT N
spine NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
, , N
it PRP N
did VBD N
result VB N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
hip NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
. . 1_o

Longer JJR N
duration NN N
of IN N
therapy NN N
may MD N
have VB N
further JJR N
improved VBN N
these DT N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Clinical JJ 1_o
efficacy NN 1_o
of IN N
antazoline NN 1_i
in IN N
rapid JJ 1_o
cardioversion NN 1_o
of IN 1_o
paroxysmal JJ 1_o
atrial JJ 1_o
fibrillation NN 1_o
-- : 1_o
a DT 1_o
protocol NN N
of IN N
a DT N
single JJ N
center NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
( ( N
the DT N
AnPAF NNP N
Study NNP N
) ) N
. . N

BACKGROUND NNP N
Rapid NNP 1_o
conversion NN 1_o
of IN 1_o
atrial JJ 1_o
fibrillation NN 1_o
( ( 1_o
AF NNP 1_o
) ) 1_o
to TO 1_o
sinus VB 1_o
rhythm NN 1_o
may MD N
be VB N
achieved VBN N
by IN N
the DT N
administration NN N
of IN N
class NN 1_i
IA NNP 1_i
, , 1_i
IC NNP 1_i
and CC 1_i
III NNP 1_i
antiarrhythmic JJ 1_i
drugs NNS 1_i
or CC 1_i
vernakalant JJ 1_i
hydrochloride NN 1_i
. . 1_i

However RB N
, , N
that IN N
treatment NN N
may MD N
be VB N
related VBN N
to TO N
potential JJ N
pro-arrhythmia NN N
, , N
lack NN N
of IN N
efficacy NN N
or CC N
the DT N
exceptionally RB N
high JJ N
cost NN N
of IN N
a DT N
compound NN N
used VBN N
. . N

Antazoline NNP 1_i
is VBZ N
a DT N
first JJ N
generation NN N
antihistaminic JJ N
agent NN N
with IN N
chinidin-like JJ N
properties NNS N
. . N

When WRB N
administered VBN N
intravenously RB N
, , N
antazoline JJ 1_i
exerts VBZ N
a DT N
strong JJ 1_o
antiarrhythmic JJ 1_o
effect NN 1_o
on IN N
supraventricular JJ 1_o
arrhythmia NN 1_o
, , N
especially RB N
on IN N
AF NNP 1_o
, , N
facilitating VBG N
rapid JJ 1_o
conversion NN 1_o
to TO 1_o
sinus VB 1_o
rhythm NN 1_o
. . 1_o

Despite IN N
a DT N
relative JJ N
lack NN N
of IN N
published VBN N
data NNS N
antazoline NN N
has VBZ N
been VBN N
marketed VBN N
in IN N
Poland NNP N
and CC N
widely RB N
used VBN N
in IN N
cardiology NN N
wards NNS N
and CC N
emergency NN N
rooms NNS N
for IN N
many JJ N
years NNS N
due JJ N
to TO N
its PRP$ N
efficacy NN N
, , N
safety NN N
and CC N
rapid JJ N
onset NN N
of IN N
action NN N
within IN N
minutes NNS N
of IN N
administration NN N
. . N

METHODS/DESIGN CC N
A DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ 1_i
, , N
superiority JJ N
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
assess VB N
clinical JJ 1_o
efficacy NN 1_o
of IN N
antazoline NN 1_i
in IN N
rapid JJ N
conversion NN N
of IN N
AF NNP N
to TO N
sinus VB N
rhythm NN N
. . N

Eligible JJ 1_p
patients NNS 1_p
will MD 1_p
present VB 1_p
AF NNP 1_p
lasting VBG 1_p
less JJR 1_p
than IN 1_p
43 CD 1_p
hours NNS 1_p
, , 1_p
will MD 1_p
be VB 1_p
in IN 1_p
stable JJ 1_p
cardio-pulmonary JJ 1_p
condition NN 1_p
and CC 1_p
will MD 1_p
have VB 1_p
no DT 1_p
prior JJ 1_p
history NN 1_p
of IN 1_p
advanced JJ 1_p
heart NN 1_p
failure NN 1_p
or CC 1_p
significant JJ 1_p
valvular JJ 1_p
disease NN 1_p
. . 1_p

Long-term JJ N
antiarrhythmic JJ N
therapy NN N
is VBZ N
not RB N
considered VBN N
an DT N
exclusion NN N
criterion NN N
. . N

Subjects NNS N
who WP N
fulfill VBP N
selection NN N
criteria NNS N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
receive VB N
intravenously RB N
either DT N
antazoline NN 1_i
or CC N
placebo NN 1_i
in IN N
divided JJ N
doses NNS N
and CC N
observed VBD N
for IN N
1.5 CD N
hours NNS N
after IN N
conversion NN N
to TO N
sinus VB N
rhythm NN N
or CC N
after IN N
the DT N
last JJ N
i.v NN N
. . N

bolus NN N
. . N

Primary JJ N
end NN N
point NN N
will MD N
be VB N
the DT N
conversion NN 1_o
of IN 1_o
AF NNP 1_o
to TO 1_o
sinus VB 1_o
rhythm NN 1_o
confirmed VBN 1_o
in IN 1_o
an DT 1_o
electrocardiogram NN 1_o
( ( 1_o
ECG NNP 1_o
) ) 1_o
during IN N
the DT N
observation NN N
period NN N
. . N

Secondary JJ N
end NN N
points NNS N
will MD N
be VB N
comprised VBN 1_o
of IN 1_o
time NN 1_o
to TO 1_o
conversion NN 1_o
and CC 1_o
return NN 1_o
of IN 1_o
AF NNP 1_o
during IN N
the DT N
observation NN N
period NN N
. . N

Special JJ N
consideration NN N
will MD N
be VB N
given VBN N
to TO N
the DT N
observation NN N
of IN N
any DT N
adverse JJ 1_o
events NNS 1_o
. . 1_o

A DT N
sample JJ 1_p
size NN 1_p
of IN 1_p
80 CD 1_p
patients NNS 1_p
was VBD 1_p
calculated VBN 1_p
based VBN N
on IN N
the DT N
following JJ N
assumptions NNS N
: : N
two-tailed JJ N
test NN N
, , N
a DT N
type NN N
I PRP N
error VBP N
of IN N
0.01 CD N
, , N
a DT N
power NN N
of IN N
90 CD N
% NN N
, , N
efficacy NN 1_o
of IN N
placebo JJ 1_i
5 CD N
% NN N
, , N
efficacy NN N
of IN N
antazoline JJ 1_i
50 CD N
% NN N
and CC N
20 CD N
% NN N
drop-out JJ N
rate NN N
to TO N
fulfill VB N
the DT N
criteria NNS N
of IN N
intention-to-treat JJ N
analysis NN N
. . N

Due NNP N
to TO N
the DT N
presumed JJ N
lack NN N
of IN N
statistical JJ N
power NN N
, , N
the DT N
secondary JJ N
end NN N
points NNS N
and CC N
safety NN N
endpoints NNS N
will MD N
be VB N
considered VBN N
exploratory JJ N
. . N

CLINICAL JJ N
TRIALS NNP N
REGISTRY NNP N
ClinicalTrials.gov NNP N
, , N
NCT01527279 NNP N
. . N

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
amalgam JJ 1_i
dental JJ 1_i
fillings NNS 1_i
on IN N
the DT N
frequency NN 1_o
of IN 1_o
Helicobacter NNP 1_o
pylori POS 1_o
infection NN 1_o
and CC 1_o
H. NNP 1_o
pylori JJ 1_o
eradication NN 1_o
rates NNS 1_o
in IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
concomitant NN 1_i
, , 1_i
quadruple NN 1_i
, , 1_i
and CC 1_i
levofloxacin-based JJ 1_i
therapies NNS 1_i
. . 1_i

BACKGROUND NNP N
AND NNP N
AIM NNP N
Mercury NNP N
exposure NN N
is VBZ N
encountered VBN N
most RBS N
commonly RB N
in IN N
individuals NNS 1_p
with IN 1_p
amalgam JJ 1_i
fillings NNS 1_i
. . 1_i

The DT N
toxic NN N
, , N
bactericidal NN N
, , N
and CC N
immunosuppressive JJ N
effects NNS N
of IN N
mercury NN N
are VBP N
well RB N
known VBN N
. . N

Furthermore NN N
, , N
multiple JJ N
antibiotic JJ N
resistance NN N
can MD N
be VB N
transferred VBN N
, , N
together RB N
with IN N
mercury NN N
resistance NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
frequency NN 1_o
of IN 1_o
Helicobacter NNP 1_o
pylori FW 1_o
infection NN 1_o
in IN N
dyspeptic JJ 1_p
patients NNS 1_p
with IN 1_p
amalgam JJ 1_p
fillings NNS 1_p
and CC 1_p
the DT 1_p
effect NN 1_p
of IN 1_p
the DT 1_p
amalgam JJ 1_p
fillings NNS 1_p
on IN 1_p
H. NNP 1_o
pylori JJ 1_o
eradication NN 1_o
rates NNS 1_o
in IN 1_p
these DT 1_p
patients NNS 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Four NNP 1_p
hundred VBD 1_p
and CC 1_p
seventy-five JJ 1_p
patients NNS 1_p
who WP 1_p
presented VBD 1_p
with IN 1_p
dyspeptic JJ 1_p
complaints NNS 1_p
and CC 1_p
underwent JJ 1_p
upper JJ 1_p
gastrointestinal JJ 1_p
endoscopy NN 1_p
and CC 1_p
gastric JJ 1_p
biopsy NN 1_p
were VBD 1_p
included VBN 1_p
in IN N
this DT N
study NN N
. . N

One CD N
hundred CD N
and CC N
sixty-nine JJ N
( ( N
35.6 CD N
% NN N
) ) N
patients NNS N
were VBD N
negative JJ N
and CC N
306 CD N
( ( N
64.4 CD N
% NN N
) ) N
patients NNS N
were VBD N
positive JJ N
for IN N
H. NNP N
pylori NN N
. . N

All DT N
of IN N
the DT N
participants NNS N
underwent JJ N
dental JJ N
examinations NNS N
in IN N
a DT N
blinded JJ N
manner NN N
. . N

The DT N
participants NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
on IN N
the DT N
basis NN N
of IN N
the DT N
presence NN N
of IN N
amalgam JJ N
fillings NNS N
. . N

The DT N
H. NNP N
pylori-positive JJ N
patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
three CD N
subgroups NNS N
: : N
patients NNS N
who WP N
received VBD N
concomitant JJ 1_i
therapy NN 1_i
( ( 1_i
CT NNP 1_i
) ) 1_i
( ( 1_i
rabeprazole-amoxicillin-clarithromycin-metronidazole JJ 1_i
for IN N
14 CD N
days NNS N
; : N
n=122 CC N
) ) N
; : N
patients NNS N
who WP N
received VBD N
quadruple JJ 1_i
therapy NN 1_i
( ( 1_i
QT NNP 1_i
) ) 1_i
( ( 1_i
rabeprazole-tetracycline-metronidazole-colloidal JJ 1_i
bismuth NN 1_i
subcitrate NN 1_i
for IN N
10 CD N
days NNS N
; : N
n=97 CC N
) ) N
; : N
and CC N
patients NNS N
who WP N
received VBD N
levofloxacin-based JJ 1_i
therapy NN 1_i
( ( 1_i
LT NNP 1_i
) ) 1_i
( ( 1_i
rabeprazole-amoxicillin-levofloxacin JJ 1_i
for IN N
10 CD N
days NNS N
; : N
n=87 CC N
) ) N
. . N

Eradication NNP 1_o
success NN 1_o
was VBD N
detected VBN N
by IN N
a DT N
urea JJ N
breath NN N
test NN N
6 CD N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

RESULTS VB N
The DT N
frequency NN 1_o
of IN N
H. NNP 1_o
pylori FW 1_o
infection NN 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
filling NN 1_i
group NN 1_p
compared VBN N
with IN N
the DT N
nonfilling VBG 1_p
group NN 1_p
( ( N
53.7 CD N
and CC N
78.8 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
eradication NN 1_o
rates NNS 1_o
in IN N
the DT N
CT NNP 1_i
, , 1_i
QT NNP 1_i
, , 1_i
and CC 1_i
LT NNP 1_i
groups NNS N
were VBD N
65.5 CD N
, , N
67.0 CD N
, , N
and CC N
58.6 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
intention-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
and CC N
69.6 CD N
, , N
70.7 CD N
, , N
and CC N
62.2 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
per-protocol NN N
( ( N
PP NNP N
) ) N
analysis NN N
. . N

In IN N
all DT N
of IN N
the DT N
H. NNP 1_p
pylori-positive JJ 1_p
patients NNS 1_p
and CC N
separately RB N
in IN N
the DT N
CT NNP 1_i
and CC N
LT NNP 1_i
groups NNS N
, , N
the DT N
eradication NN 1_o
rates NNS 1_o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
filling NN 1_i
group NN N
compared VBN N
with IN N
the DT N
nonfilling VBG 1_i
group NN N
. . N

However RB N
, , N
in IN N
the DT N
QT NNP 1_i
group NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
patients NNS N
with IN N
and CC N
without IN N
fillings NNS N
( ( N
P=0.001 NNP N
, , N
0.003 CD N
, , N
0.012 CD N
, , N
0.14 CD N
, , N
respectively RB N
) ) N
. . N

Logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
absence NN N
of IN N
amalgam NN N
filling VBG N
exerts NNS N
independent JJ N
effects NNS N
on IN N
the DT N
increased JJ N
frequency NN 1_o
of IN 1_o
H. NNP 1_o
pylori FW 1_o
infection NN 1_o
and CC N
increased JJ 1_o
rate NN 1_o
of IN 1_o
H. NNP 1_o
pylori FW 1_o
eradication NN 1_o
. . 1_o

CONCLUSION NNP N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
show VB N
a DT N
lower JJR N
frequency NN 1_o
of IN 1_o
H. NNP 1_o
pylori FW 1_o
colonization NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
amalgam JJ 1_i
fillings NNS 1_i
than IN N
without IN N
and CC N
that IN N
H. NNP 1_o
pylori FW 1_o
eradication NN 1_o
rates NNS 1_o
are VBP N
lower JJR N
in IN N
patients NNS 1_p
with IN 1_p
amalgam JJ 1_i
fillings NNS 1_i
compared VBN N
to TO N
those DT N
without IN N
. . N

-DOCSTART- -X- O O

Contribution NN N
of IN N
endogenous JJ N
bradykinin NN N
to TO N
fibrinolysis NN 1_o
, , 1_o
inflammation NN 1_o
, , 1_o
and CC 1_o
blood NN 1_o
product NN 1_o
transfusion NN 1_o
following VBG 1_p
cardiac JJ 1_p
surgery NN 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Bradykinin NNP N
increases VBZ N
during IN N
cardiopulmonary JJ 1_p
bypass NN 1_p
( ( 1_p
CPB NNP 1_p
) ) 1_p
and CC N
stimulates VBZ N
the DT N
release NN 1_o
of IN 1_o
nitric JJ 1_o
oxide NN 1_o
, , 1_o
inflammatory JJ 1_o
cytokines NNS 1_o
, , 1_o
and CC 1_o
tissue-type JJ 1_o
plasminogen NN 1_o
activator NN 1_o
( ( 1_o
t-PA JJ 1_o
) ) 1_o
, , N
acting VBG N
through IN N
its PRP$ N
B2 NNP N
receptor NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
endogenous JJ N
bradykinin NN N
contributes NNS N
to TO N
the DT N
fibrinolytic JJ 1_o
and CC 1_o
inflammatory JJ 1_o
response NN 1_o
to TO 1_o
CPB NNP 1_o
and CC 1_o
that IN 1_o
bradykinin NN 1_o
B2 NNP 1_o
receptor NN 1_o
antagonism NN 1_o
reduces VBZ 1_o
fibrinolysis NN 1_o
, , 1_o
inflammation NN 1_o
, , 1_o
and CC 1_o
subsequent JJ 1_o
transfusion NN 1_o
requirements NNS 1_o
. . 1_o

Patients NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
115 CD 1_p
) ) 1_p
were VBD N
prospectively RB N
randomized VBN N
to TO N
placebo VB 1_i
, , 1_i
?-aminocaproic JJ 1_i
acid NN 1_i
( ( 1_i
EACA NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
HOE NNP 1_i
140 CD 1_i
, , 1_i
a DT N
bradykinin NN N
B2 NNP N
receptor NN N
antagonist NN N
. . N

Bradykinin NNP N
B2 NNP N
receptor NN N
antagonism NN N
decreased VBD 1_o
intraoperative JJ 1_o
fibrinolytic JJ 1_o
capacity NN 1_o
as RB N
much RB N
as IN 1_i
EACA NNP 1_i
, , 1_i
but CC N
only RB 1_i
EACA NNP 1_i
decreased VBD 1_o
D-dimer NNP 1_o
formation NN 1_o
and CC N
tended VBD N
to TO N
decrease VB 1_o
postoperative JJ 1_o
bleeding NN 1_o
. . 1_o

Although IN 1_i
EACA NNP 1_i
and CC 1_i
HOE NNP 1_i
140 CD 1_i
decreased VBD 1_o
fibrinolysis NN 1_o
and CC 1_o
EACA NNP 1_o
attenuated VBD 1_o
blood NN 1_o
loss NN 1_o
, , 1_o
these DT N
treatments NNS N
did VBD N
not RB N
reduce VB N
the DT N
proportion NN N
of IN N
patients NNS N
transfused VBN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
endogenous JJ N
bradykinin NN N
contributes NNS N
to TO 1_o
t-PA JJ 1_o
generation NN 1_o
in IN 1_p
patients NNS 1_p
undergoing VBG 1_p
CPB NNP 1_p
, , 1_p
but CC N
that IN N
additional JJ N
effects NNS N
on IN 1_o
plasmin NN 1_o
generation NN 1_o
contribute NN N
to TO 1_o
decreased VBN 1_o
D-dimer NNP 1_o
concentrations NNS 1_o
during IN 1_i
EACA NNP 1_i
treatment NN N
. . N

-DOCSTART- -X- O O

Are NNP N
PRO NNP 1_i
discharge NN 1_i
screens NNS 1_i
associated VBN N
with IN N
postdischarge NN N
adverse JJ N
outcomes NNS N
? . N
OBJECTIVE IN N
We PRP N
evaluate VBP N
whether IN N
patient JJ N
outcomes NNS N
may MD N
be VB N
affected VBN N
by IN N
possible JJ N
errors NNS N
in IN N
care NN N
at IN N
discharge NN N
as IN N
assessed VBN N
by IN N
Peer NNP N
Review NNP N
Organizations NNP N
( ( N
PROs NNP N
) ) N
. . N

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
The DT 1_p
three CD 1_p
data NNS 1_p
sources NNS 1_p
for IN 1_p
the DT 1_p
study NN 1_p
were VBD 1_p
( ( 1_p
1 CD 1_p
) ) 1_p
the DT 1_p
generic JJ 1_i
screen NN 1_i
results NNS 1_i
of IN 1_p
a DT 1_p
3 CD 1_p
percent NN 1_p
random JJ 1_p
sample NN 1_p
of IN 1_p
Medicare NNP 1_p
beneficiaries NNS 1_p
age NN 1_p
65 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
who WP 1_p
were VBD 1_p
admitted VBN 1_p
to TO 1_p
California NNP 1_p
hospitals NNS 1_p
between IN 1_p
1 CD 1_p
July NNP 1_p
1987 CD 1_p
and CC 1_p
30 CD 1_p
June NNP 1_p
1988 CD 1_p
( ( 1_p
n JJ 1_p
= $ 1_p
20,136 CD 1_p
patients NNS 1_p
) ) 1_p
; : 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
the DT 1_p
1987 CD 1_p
and CC 1_p
1988 CD 1_p
California NNP 1_p
Medicare NNP 1_p
Provided VBD 1_p
Analysis NNP 1_i
and CC 1_i
Review NNP 1_i
( ( 1_i
MEDPAR NNP 1_i
) ) 1_i
data NN 1_i
files NNS 1_i
; : 1_i
and CC 1_p
( ( 1_p
3 CD 1_p
) ) 1_p
the DT 1_p
American NNP 1_i
Hospital NNP 1_i
Association NNP 1_i
( ( 1_i
AHA NNP 1_i
) ) 1_i
1988 CD 1_i
Annual NNP 1_i
Survey NNP 1_i
of IN 1_i
Hospitals NNP 1_i
. . 1_i

STUDY NNP N
DESIGN NNP N
Multivariate NNP 1_i
logistic JJ 1_i
regression NN 1_i
analysis NN 1_i
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
association NN N
between IN N
the DT N
results NNS N
of IN N
generic JJ N
discharge NN N
administered VBN N
by IN N
the DT N
PROs NNP N
and CC N
two CD N
patient JJ N
outcomes NNS N
: : N
mortality NN N
and CC N
readmission NN N
within IN N
30 CD N
days NNS N
. . N

The DT N
analysis NN N
was VBD N
adjusted VBN N
for IN N
other JJ N
patient JJ N
characteristics NNS N
recorded VBN N
on IN N
the DT N
uniform JJ N
discharge NN N
abstract NN N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Four NNP N
discharge NN N
screens NNS N
indicated VBD N
an DT N
increased VBN N
risk NN 1_o
of IN 1_o
an DT 1_o
adverse JJ 1_o
outcome-absence NN 1_o
of IN 1_o
documentation NN 1_o
of IN 1_o
discharge NN 1_o
planning NN 1_o
, , 1_o
elevated JJ 1_o
temperature NN 1_o
, , 1_o
abnormal JJ 1_o
pulse NN 1_o
, , 1_o
and CC 1_o
unaddressed JJ 1_o
abnormal JJ 1_o
test NN 1_o
results NNS 1_o
at IN N
discharge NN N
. . N

The DT N
other JJ N
three CD N
discharge NN N
screens NNS N
examined-abnormal JJ 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
IV NNP 1_o
fluids NNS 1_o
or CC 1_o
drugs NNS 1_o
, , 1_o
and CC 1_o
wound JJ 1_o
drainage NN 1_o
before IN N
discharge-were JJ N
unrelated JJ N
to TO N
postdischarge VB N
adverse JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
Generic NNP 1_i
discharge NN 1_i
screens NNS 1_i
based VBN N
on IN N
inadequate JJ N
discharge NN N
planning NN N
, , N
abnormal JJ 1_o
pulse NN 1_o
, , 1_o
increased JJ 1_o
temperature NN 1_o
, , N
or CC N
unaddressed JJ 1_o
abnormal JJ 1_o
tests NNS 1_o
may MD N
be VB N
important JJ N
indicators NNS N
of IN N
substandard NN N
care NN N
. . N

Other JJ N
discharge NN N
screens NNS N
apparently RB N
do VBP N
not RB N
detect VB N
errors NNS N
in IN N
care NN N
associated VBN N
with IN N
major JJ N
consequences NNS N
for IN N
patients NNS N
. . N

-DOCSTART- -X- O O

Long-term JJ N
effects NNS N
of IN N
risperidone NN 1_i
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
a DT N
placebo NN 1_i
discontinuation NN N
study NN N
. . N

OBJECTIVE IN N
The DT N
short-term JJ N
benefit NN N
of IN N
risperidone NN 1_i
in IN N
ameliorating VBG N
severe JJ 1_o
disruptive JJ 1_o
behavior NN 1_o
in IN N
pediatric JJ 1_p
patients NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
is VBZ N
well RB N
established VBN N
; : N
however RB N
, , N
only RB N
one CD N
placebo-controlled JJ 1_i
, , N
long-term JJ N
study NN N
of IN N
efficacy NN N
is VBZ N
available JJ N
. . N

METHOD NNP N
Thirty-six JJ 1_p
children NNS 1_p
with IN 1_p
an DT 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
5-17 JJ 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
accompanied VBN 1_p
by IN 1_p
severe JJ 1_p
tantrums NNS 1_p
, , 1_p
aggression NN 1_p
, , 1_p
or CC 1_p
self-injurious JJ 1_p
behavior NN 1_p
, , N
started VBD N
8-week JJ N
open-label JJ N
treatment NN N
with IN N
risperidone NN 1_i
. . 1_i

Responders NNP N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
continued VBD N
treatment NN N
for IN N
another DT N
16 CD N
weeks NNS N
, , N
followed VBN N
by IN N
a DT N
double-blind JJ N
discontinuation NN N
( ( N
n JJ N
= VBZ N
24 CD N
; : N
two CD N
patients NNS N
discontinued VBN N
treatment NN N
because IN N
of IN N
weight JJ N
gain NN N
) ) N
consisting NN N
of IN N
either CC N
3 CD N
weeks NNS N
of IN N
taper NN N
and CC N
5 CD N
weeks NNS N
of IN N
placebo NN 1_i
only RB N
or CC N
continuing VBG N
use NN N
of IN N
risperidone NN 1_i
. . 1_i

Relapse NNP N
was VBD N
defined VBN N
as IN N
a DT N
significant JJ N
deterioration NN N
of IN N
symptoms NNS N
based VBN N
on IN N
clinical JJ N
judgment NN N
and CC N
a DT N
parent NN N
questionnaire NN N
. . N

RESULTS NNP N
Risperidone NNP 1_i
was VBD N
superior JJ N
to TO N
placebo VB 1_i
in IN N
preventing VBG N
relapse NN 1_o
: : 1_o
this DT N
occurred VBD N
in IN N
3 CD N
of IN N
12 CD N
patients NNS N
continuing VBG N
on IN N
risperidone NN N
versus NN N
8 CD N
of IN N
12 CD N
who WP N
switched VBD N
to TO N
placebo VB N
( ( N
p JJ N
= NNP N
.049 NNP N
) ) N
. . N

Weight NNP 1_o
gain NN 1_o
, , 1_o
increased VBD 1_o
appetite RB 1_o
, , 1_o
anxiety NN 1_o
, , 1_o
and CC 1_o
fatigue NN 1_o
were VBD N
the DT N
most RBS N
frequently RB N
reported VBN N
side NN N
effects NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicates VBZ N
the DT N
effectiveness NN N
of IN N
risperidone NN N
during IN N
a DT N
period NN N
of IN N
several JJ N
months NNS N
, , N
reducing VBG N
disruptive JJ 1_o
behavior NN 1_o
in IN N
about IN N
half NN N
of IN N
the DT N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

The DT N
results NNS N
provide VBP N
a DT N
rationale NN N
for IN N
the DT N
continuing VBG N
use NN N
of IN N
risperidone NN 1_i
beyond IN N
6 CD N
months NNS N
, , N
although IN N
considerable JJ N
weight JJ 1_o
gain NN 1_o
can MD N
limit VB N
the DT N
use NN N
of IN N
this DT N
agent NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
intervention NN N
to TO N
improve VB N
ongoing VBG 1_o
participation NN 1_o
in IN 1_o
mammography NN 1_o
. . 1_o

OBJECTIVE UH N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
interventions NNS 1_i
intended VBN 1_i
to TO N
increase VB N
rates NNS 1_o
of IN 1_o
regular JJ 1_o
breast NN 1_o
cancer NN 1_o
screening NN 1_o
, , N
according VBG N
to TO N
recommended VBN N
guidelines NNS N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
2 CD N
outreach NN 1_i
interventions NNS 1_i
( ( 1_i
a DT 1_i
mail NN 1_i
reminder NN 1_i
and CC 1_i
a DT 1_i
telephone NN 1_i
reminder NN 1_i
plus CC 1_i
appointment JJ 1_i
scheduling NN 1_i
) ) 1_i
compared VBN N
with IN N
a DT N
routine JJ 1_i
publicity NN 1_i
campaign NN 1_i
to TO N
encourage VB N
continued JJ 1_o
participation NN 1_o
in IN 1_o
mammography NN 1_o
screening NN 1_o
. . 1_o

PARTICIPANTS NNP N
AND CC N
METHODS NNP N
Participants NNS 1_p
were VBD 1_p
1908 CD 1_p
women NNS 1_p
aged VBD 1_p
50 CD 1_p
to TO 1_p
75 CD 1_p
years NNS 1_p
continuously RB 1_p
enrolled VBD 1_p
in IN 1_p
a DT 1_p
large JJ 1_p
group-model JJ 1_p
HMO NNP 1_p
during IN 1_p
the DT 1_p
study NN 1_p
who WP 1_p
underwent VBD 1_p
a DT 1_p
bilateral JJ 1_p
mammogram NN 1_p
during IN 1_p
the DT 1_p
first JJ 1_p
quarter NN 1_p
of IN 1_p
1994 CD 1_p
and CC 1_p
no DT 1_p
subsequent JJ 1_p
mammogram NN 1_p
during IN 1_p
the DT 1_p
next JJ 1_p
18 CD 1_p
to TO 1_p
21 CD 1_p
months NNS 1_p
. . 1_p

Data NNS N
were VBD N
obtained VBN N
from IN N
health NN N
plan NN N
administrative JJ N
data NNS N
files NNS N
supplemented VBN N
by IN N
medical JJ N
chart NN N
review NN N
. . N

Women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
( ( N
1 CD N
) ) N
a DT 1_i
mail NN 1_i
reminder NN 1_i
, , 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
a DT 1_i
telephone NN 1_i
reminder NN 1_i
, , 1_i
or CC 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
routine JJ 1_i
publicity NN 1_i
on IN 1_i
mammography NN 1_i
for IN 1_i
all DT 1_i
women NNS 1_i
. . 1_i

The DT N
outcome NN N
measure NN N
was VBD N
a DT N
mammogram NN 1_o
received VBN 1_o
after IN 1_o
the DT 1_o
intervention NN 1_o
period NN 1_o
and CC 1_o
within IN 1_o
2 CD 1_o
years NNS 1_o
of IN 1_o
the DT 1_o
initial JJ 1_o
mammogram NN 1_o
date NN 1_o
. . 1_o

RESULTS NNP N
Bivariate NNP N
and CC N
multivariate VB N
statistical JJ N
analyses NNS N
showed VBD N
that IN N
participation NN N
was VBD N
significantly RB N
higher JJR N
for IN N
women NNS N
contacted VBN N
by IN N
telephone NN N
than IN N
through IN N
routine JJ N
publicity NN N
. . N

Mail NN N
reminders NNS N
were VBD N
no DT N
more RBR N
effective JJ N
than IN N
a DT N
routine JJ 1_i
publicity NN 1_i
campaign NN 1_i
. . 1_i

Primary NNP N
care NN N
physician NN N
and CC N
gynecologist JJ N
visits NNS N
increased VBD N
the DT N
likelihood NN N
of IN N
a DT N
subsequent JJ 1_o
mammogram NN 1_o
for IN N
women NNS N
in IN N
all DT N
intervention NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Telephone NNP 1_i
contact NN 1_i
by IN N
regular JJ N
health NN N
plan NN N
staff NN N
was VBD N
more RBR N
successful JJ N
than IN N
publicity NN N
in IN N
encouraging VBG N
continued JJ N
participation NN 1_o
in IN N
mammography NN 1_o
screening NN 1_o
in IN N
women NNS N
enrolled VBN N
in IN N
a DT N
group-model JJ N
managed NN N
health NN N
care NN N
plan NN N
. . N

Because IN N
mailings NNS N
did VBD N
not RB N
influence VB N
participation NN N
in IN N
mammography NN 1_o
screening NN 1_o
, , N
health NN N
plans NNS N
should MD N
be VB N
cautious JJ N
about IN N
investing VBG N
in IN N
member NN N
mailings NNS N
without IN N
first JJ N
evaluating VBG N
their PRP$ N
effectiveness NN N
in IN N
the DT N
context NN N
of IN N
existing VBG N
outreach NN N
efforts NNS N
. . N

-DOCSTART- -X- O O

Partial-area JJ 1_p
method NN 1_p
in IN 1_p
bioequivalence NN 1_p
assessment NN N
: : N
naproxen NN 1_i
. . 1_i

Regulatory NNP N
authorities NNS N
require VBP N
demonstration NN N
of IN N
bioequivalence NN 1_p
through IN N
comparisons NNS N
of IN N
different JJ N
pharmacokinetic JJ N
parameters NNS N
, , N
the DT N
area NN 1_o
under IN 1_o
the DT 1_o
plasma JJ 1_o
concentration-time JJ 1_o
curve NN 1_o
( ( 1_o
AUC NNP 1_o
) ) 1_o
, , 1_o
the DT 1_o
maximum JJ 1_o
plasma JJ 1_o
concentration NN 1_o
( ( 1_o
Cmax NNP 1_o
) ) 1_o
, , N
and CC N
the DT 1_o
time NN 1_o
to TO 1_o
reach VB 1_o
peak JJ 1_o
concentration NN 1_o
( ( 1_o
Tmax NNP 1_o
) ) 1_o
. . 1_o

The DT N
applicability NN N
and CC N
validity NN N
of IN N
regulatory JJ N
requirements NNS N
have VBP N
been VBN N
widely RB N
criticized VBN N
on IN N
statistical JJ N
and CC N
clinical JJ N
relevance NN N
grounds NNS N
. . N

For IN N
most JJS N
noncomplicated JJ N
absorption NN N
models NNS N
, , N
the DT N
AUC NNP 1_o
correlates VBZ N
well RB N
with IN N
the DT N
extent NN N
of IN N
absorption NN N
. . N

However RB N
, , N
in IN N
nonlinear JJ N
models NNS N
of IN N
absorption NN N
, , N
in IN N
mechanisms NN N
involving VBG N
recycling NN N
of IN N
drugs NNS N
, , N
and CC N
for IN N
drugs NNS N
with IN N
long JJ N
half-life NN N
, , N
the DT N
use NN N
of IN N
total JJ N
AUC NNP 1_o
( ( N
from IN N
zero CD N
to TO N
infinity NN N
) ) N
can MD N
give VB N
erroneous JJ N
and CC N
clinically RB N
irrelevant JJ N
results NNS N
since IN N
the DT N
area NN N
is VBZ N
mostly RB N
determined VBN N
by IN N
elimination NN N
phase NN N
or CC N
by IN N
recycling VBG N
. . N

The DT N
calculation NN N
of IN N
total JJ N
AUC NNP 1_o
also RB N
involves VBZ N
prolonged JJ N
sampling NN N
, , N
adding VBG N
to TO N
the DT N
cost NN N
and CC N
risks NNS N
associated VBN N
with IN N
bioequivalence NN N
studies NNS N
. . N

The DT N
use NN N
of IN N
Cmax NNP 1_o
or CC 1_o
Tmax NNP 1_o
as IN N
a DT N
measure NN N
of IN N
rate NN N
of IN N
absorption NN N
, , N
to TO N
correlate VB N
with IN N
clinical JJ N
relevance NN N
, , N
is VBZ N
widely RB N
criticized VBN N
on IN N
logical JJ N
, , N
technical JJ N
, , N
and CC N
statistical JJ N
grounds NNS N
. . N

For IN N
drugs NNS N
used VBN N
on IN N
a DT N
multiple-dose JJ N
basis NN N
, , N
Cmax NNP 1_o
and CC N
Tmax NNP 1_o
evaluations NNS N
become VBP N
redundant JJ N
since IN N
the DT N
average JJ N
plateau NN 1_o
concentration NN 1_o
is VBZ N
not RB N
affected VBN N
by IN N
these DT N
parameters NNS N
. . N

To TO N
resolve VB N
the DT N
drawbacks NNS N
in IN N
the DT N
traditional JJ N
methodology NN N
of IN N
bioequivalence NN N
evaluation NN N
, , N
the DT N
use NN N
of IN N
partial JJ N
areas NNS N
in IN N
lieu NN N
of IN N
total JJ N
AUC NNP 1_o
, , 1_o
Tmax NNP 1_o
, , 1_o
and CC 1_o
Cmax NNP 1_o
is VBZ N
suggested VBN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
logic NN N
and CC N
robustness NN N
of IN N
the DT N
partial-area JJ 1_p
method NN 1_p
in IN 1_p
establishing VBG 1_p
bioequivalence NN 1_p
. . 1_p

We PRP N
conclude VBP N
that IN N
the DT N
5h CD 1_o
AUC NNP 1_o
is VBZ N
a DT N
more RBR N
relevant JJ N
parameter NN N
to TO N
establish VB N
naproxen NNS 1_i
bioequivalence NN N
than IN N
AUCinf NNP 1_o
. . 1_o

We PRP N
recommend VBP N
against IN N
using VBG N
symmetrical JJ N
confidence NN N
intervals NNS N
and CC N
report NN N
excellent JJ N
agreement NN N
among IN N
several JJ N
methods NNS N
of IN N
calculating VBG N
confidence NN 1_o
intervals NNS 1_o
, , 1_o
probability NN 1_o
values NNS 1_o
, , 1_o
and CC 1_o
nonparametric JJ 1_o
tests NNS 1_o
. . 1_o

We PRP N
suggest VBP N
that IN N
a DT N
single-point JJ 1_o
short-term JJ 1_o
AUC NNP 1_o
is VBZ N
a DT N
better JJR N
indicator NN N
of IN N
the DT N
bioequivalence NN N
of IN N
generic JJ N
products NNS N
than IN N
the DT N
total JJ N
AUC NNP 1_o
, , 1_o
Cmax NNP 1_o
, , 1_o
and CC 1_o
Tmax NNP 1_o
as IN N
required VBN N
currently RB N
by IN N
the DT N
regulatory JJ N
authorities NNS N
. . N

-DOCSTART- -X- O O

Preparation NN N
and CC N
immune JJ N
activity NN N
analysis NN N
of IN N
H5N1 NNP 1_p
subtype NN 1_p
avian JJ 1_p
influenza NN 1_p
virus NN 1_p
recombinant JJ 1_p
protein-based JJ 1_p
vaccine NN 1_p
. . 1_p

Avian JJ N
influenza NN N
is VBZ N
a DT N
severe JJ N
disease NN N
among IN N
farmed JJ 1_p
poultry NN 1_p
and CC 1_p
free-living JJ 1_p
birds NNS 1_p
and CC N
a DT N
constant JJ N
threat NN N
to TO N
the DT N
commercial JJ 1_p
chicken NN 1_p
industry NN 1_p
around IN N
the DT N
world NN N
. . N

Hemagglutinin NNP N
( ( N
HA NNP N
) ) N
is VBZ N
the DT N
major JJ N
immunogen NN N
on IN N
the DT N
envelope NN N
of IN N
influenza NN N
A NNP N
virus NN N
and CC N
is VBZ N
the DT N
predominant JJ N
inducer NN N
of IN N
neutralizing VBG N
antibody NN N
. . N

To TO N
obtain VB N
the DT N
bioactive JJ N
antigen NN N
proteins NNS N
in IN N
large JJ N
quantities NNS N
, , N
a DT N
new JJ N
protein NN N
expression NN N
vector NN N
pBCX NN N
was VBD N
constructed VBN N
, , N
which WDT N
is VBZ N
based VBN N
on IN N
the DT N
pET32a NN N
vector NN N
. . N

The DT N
HA NNP N
gene NN N
of IN N
the DT N
H5N1 NNP N
subtype NN N
of IN N
avian JJ N
influenza NN N
virus NN N
( ( N
AIV NNP N
) ) N
was VBD N
inserted VBN N
into IN N
the DT N
pBCX NN 1_p
vector NN 1_p
and CC N
expressed VBD N
efficiently RB N
in IN N
Escherichia NNP N
coli NN N
BL21 NNP N
( ( N
DE3 NNP N
) ) N
. . N

Fused VBN N
expression NN N
of IN N
the DT N
exogenous JJ N
gene NN N
and CC N
msyB NN N
produced VBD N
a DT N
97-kDa JJ N
msyB-HA JJ N
fusion NN N
protein NN N
. . N

Sodium NNP 1_i
dodecyl VBZ 1_i
sulfate-PAGE NN 1_i
combined VBN 1_i
with IN 1_i
scanning VBG 1_i
analysis NN 1_i
demonstrated VBD N
that IN N
the DT N
msyB-HA JJ N
fusion NN N
protein NN N
accounted VBD N
for IN N
29.5 CD N
% NN N
of IN N
the DT N
total JJ N
bacterial JJ N
protein NN N
, , N
90.5 CD N
% NN N
being VBG N
soluble JJ N
. . N

The DT N
msyB-HA JJ N
fusion NN N
protein NN N
was VBD N
purified VBN N
with IN N
nondenaturing VBG N
50 CD N
% NN N
Ni-NTA JJ N
column NN N
chromatography NN N
, , N
and CC N
the DT N
result NN N
showed VBD N
that IN N
24 CD N
mg NN N
of IN N
purified JJ N
msyB-HA JJ N
fusion NN N
protein NN N
could MD N
be VB N
obtained VBN N
from IN N
1 CD N
L NNP N
of IN N
induced JJ N
expression NN N
bacterial JJ N
culture NN N
medium NN N
. . N

The DT N
comparative JJ N
results NNS N
in IN N
the DT N
present JJ N
study NN N
showed VBD N
that IN N
pBCX NN N
was VBD N
superior JJ N
to TO N
pET32a VB N
as IN N
a DT N
protein NN N
expression NN N
vector NN N
. . N

Western JJ N
blotting NN N
showed VBD N
the DT N
recombinant JJ N
msyB-HA NN N
( ( N
rHA NN N
) ) N
to TO N
have VB N
better JJR N
antigenic JJ 1_o
activity NN 1_o
, , N
which WDT N
may MD N
be VB N
the DT N
result NN N
from IN N
the DT N
better JJR N
posttranslation NN N
protein NN N
modification NN N
and CC N
folding NN N
in IN N
the DT N
pBCX NN N
expression NN N
system NN N
. . N

With IN N
the DT N
rHA NN N
fusion NN N
protein NN N
as IN N
antigen NN N
, , N
we PRP N
successfully RB N
prepared VBD N
and CC N
screened VBD N
specific JJ N
monoclonal JJ N
antibodys NN N
against IN N
the DT N
H5N1 NNP N
subtype NN N
AIV NNP N
, , N
which WDT N
indicated VBD N
that IN N
the DT N
rHA NN N
had VBD N
antigen VBN N
epitopes NNS N
and CC N
biofunctions NNS N
. . N

The DT N
immune JJ N
test NN N
confirmed VBD N
that IN N
the DT N
rHA NN N
protein NN N
vaccine NN N
could MD N
also RB N
induce VB N
high JJ N
neutralizing NN N
antibodies NNS N
, , N
and CC N
the DT N
AIV NNP N
challenge NN N
test NN N
proved VBD N
that IN N
the DT N
rHA JJ N
protein-based JJ N
vaccine NN N
could MD N
prevent VB N
the DT N
corresponding JJ N
infection NN N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
the DT N
recombinant JJ N
HA NNP N
protein NN N
produced VBN N
by IN N
the DT N
pBCX NN N
expression NN N
system NN N
could MD N
be VB N
used VBN N
as IN N
a DT N
recombinant JJ N
protein-based JJ N
vaccine NN N
and CC N
has VBZ N
potential NN N
for IN N
further JJ N
development NN N
for IN N
diagnosis NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Validity NNP N
of IN N
cardiotocography NN 1_i
in IN N
the DT N
detection NN N
of IN N
umbilical JJ 1_o
cord NN 1_o
complications NNS 1_o
] VBP 1_o
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
validity NN N
of IN N
cardiotocography NN 1_i
for IN N
the DT N
detection NN N
of IN N
cord NN 1_o
complications NNS 1_o
. . 1_o

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP 1_p
low-risk JJ 1_p
population NN 1_p
of IN 1_p
4196 CD 1_p
cases NNS 1_p
was VBD 1_p
selected VBN 1_p
in IN 1_p
which WDT 1_p
cord NN 1_p
complications NNS 1_p
have VBP 1_p
been VBN 1_p
recognized VBN 1_p
in IN 1_p
34.3 CD 1_p
% NN 1_p
. . 1_p

Cases VBZ 1_p
with IN 1_p
cord NN 1_p
complications NNS 1_p
and CC 1_p
controls NNS 1_p
were VBD 1_p
paired VBN 1_p
by IN N
parity NN N
, , N
gestational JJ N
age NN N
, , N
maternal JJ N
age NN N
and CC N
mode NN N
of IN N
delivery NN N
. . N

25 CD 1_p
pairs NNS 1_p
were VBD 1_p
randomly RB 1_p
selected VBN 1_p
. . 1_p

50 CD N
tracings NNS N
were VBD N
presented VBN N
twice RB N
to TO N
4 CD N
obstetricians NNS N
in IN N
a DT N
double-blind JJ N
manner NN N
. . N

As IN N
parameters NNS N
for IN N
the DT N
determination NN N
of IN N
the DT N
validity NN N
of IN N
fetal JJ N
monitoring VBG N
the DT N
reliability NN N
, , N
positive JJ N
( ( N
ppv NN N
) ) N
and CC N
negative JJ N
predictive JJ N
value NN N
( ( N
npv JJ N
) ) N
, , N
sensitivity NN N
and CC N
specificity NN N
were VBD N
used VBN N
. . N

Inter- JJ N
and CC N
intra-observer JJ N
variability NN N
were VBD N
also RB N
examined VBN N
. . N

RESULTS NNP N
Reliability NNP 1_o
52 CD N
% NN N
, , N
ppv RB 1_o
52 CD N
% NN N
, , N
npv RB 1_o
52 CD N
% NN N
, , N
sensitivity NN 1_o
46 CD N
% NN N
, , N
specificity NN 1_o
58 CD N
% NN N
. . N

Interobserver NNP N
variability NN N
: : N
All DT N
4 CD N
obstetricians NNS N
agreed VBD N
in IN N
47 CD N
of IN N
100 CD N
evaluations NNS N
. . N

The DT N
level NN 1_o
of IN 1_o
agreement NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
controls NNS N
( ( N
63 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
cord NN N
complication NN N
group NN N
( ( N
56 CD N
% NN N
) ) N
. . N

The DT N
intraobserver NN 1_o
variability NN 1_o
was VBD N
25 CD N
% NN N
. . N

CONCLUSIONS NNP N
Cardiotocography NNP 1_i
is VBZ N
not RB N
useful JJ N
for IN N
the DT N
detection NN 1_o
of IN 1_o
cord NN 1_o
complications NNS 1_o
. . 1_o

The DT N
range NN N
of IN N
possibilities NNS N
has VBZ N
not RB N
been VBN N
exploited VBN N
yet RB N
, , N
even RB N
for IN N
the DT N
evaluation NN N
of IN N
the DT N
fetal JJ N
state NN N
. . N

-DOCSTART- -X- O O

Modest NNP N
antihypertensive JJ N
effect NN N
of IN N
epanolol NN 1_i
, , N
a DT N
beta NN N
1-selective JJ N
receptor NN N
blocker NN N
with IN N
beta NN N
1 CD N
agonist NN N
activity NN N
: : N
an DT N
acute NN N
and CC N
long-term JJ N
hemodynamic NN N
study NN N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
and CC N
double JJ N
crossover NN N
comparison NN N
with IN N
atenolol NN N
on IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

Beta-blockers NNS N
with IN N
less JJR N
cardiodepressive JJ N
effect NN N
than IN N
traditional JJ N
nonselective JJ N
beta NN N
( ( N
1+2 CD N
) ) N
-blocking VBG N
agents NNS N
could MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
, , N
provided VBD N
the DT N
reduction NN N
in IN N
blood NN N
pressure NN N
was VBD N
satisfactory JJ N
. . N

Epanolol NNP 1_i
, , N
a DT N
selective JJ N
beta NN N
1-receptor JJ N
blocker NN N
with IN N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
, , N
induced VBD N
a DT N
fall NN N
in IN N
intraarterial JJ 1_o
pressure NN 1_o
of IN N
8 CD N
% NN N
at IN N
rest NN N
sitting VBG N
and CC N
11 CD N
% NN N
during IN N
100 CD N
W NNP N
bicycle NN N
exercise NN N
after IN N
the DT N
first JJ N
dose NN N
of IN N
200 CD N
mg NNS N
in IN N
12 CD 1_p
patients NNS 1_p
with IN 1_p
essential JJ 1_p
hypertension NN 1_p
. . 1_p

Heart NNP 1_o
rate NN 1_o
, , 1_o
stroke VBD 1_o
index NN 1_o
, , 1_o
and CC 1_o
cardiac JJ 1_o
index NN 1_o
initially RB N
fell VBD N
by IN N
14 CD N
% NN N
, , N
11 CD N
% NN N
, , N
and CC N
23 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
total JJ 1_o
peripheral JJ 1_o
resistance NN 1_o
index NN 1_o
increased VBD N
by IN N
21 CD N
% NN N
after IN N
2 CD N
hours NNS N
, , N
and CC N
then RB N
reverted VBD N
towards IN N
the DT N
pretreatment NN N
level NN N
. . N

After IN N
10 CD N
months NNS N
of IN N
epanolol JJ 1_i
treatment NN N
( ( N
mean JJ N
300 CD N
mg/day NN N
) ) N
, , N
the DT N
reduction NN 1_o
in IN N
arterial JJ 1_o
pressure NN 1_o
was VBD N
5 CD N
% NN N
at IN N
rest NN N
and CC N
10 CD N
% NN N
during IN N
exercise NN N
. . N

Cardiac NNP 1_o
index NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
were VBD N
still RB N
reduced VBN N
14-21 CD N
% NN N
, , N
while IN N
total JJ 1_o
peripheral JJ 1_o
resistance NN 1_o
was VBD N
unchanged JJ N
or CC N
slightly RB N
increased VBN N
( ( N
2-10 CD N
% NN N
) ) N
. . N

Twenty-four JJ 1_o
hour NN 1_o
ambulatory NN 1_o
blood NN 1_o
pressure NN 1_o
was VBD N
higher JJR N
on IN N
epanolol NN 1_i
( ( N
300 CD N
mg/day NN N
) ) N
than IN N
on IN N
atenolol NN 1_i
( ( N
150 CD N
mg/day NN N
) ) N
treatment NN N
( ( N
137/97 CD N
vs. FW N
128/91 CD N
mmHg NN N
) ) N
. . N

Thus RB N
, , N
the DT N
achieved VBN 1_o
blood NN 1_o
pressure NN 1_o
reduction NN 1_o
induced VBN N
by IN N
epanolol NN 1_i
was VBD N
moderate JJ N
, , N
while IN N
other JJ N
characteristics NNS N
of IN N
beta-receptor NN N
blockade NN N
, , N
in IN N
particular JJ N
, , N
the DT N
reduction NN 1_o
of IN 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
cardiac JJ 1_o
output NN 1_o
, , N
were VBD N
maintained VBN N
. . N

This DT N
suggests VBZ N
that IN N
the DT N
compound NN N
may MD N
be VB N
useful JJ N
for IN N
other JJ N
cardiovascular JJ 1_p
disorders NNS 1_p
, , N
e.g. NN N
, , N
angina JJ 1_p
pectoris NN 1_p
in IN 1_p
patients NNS 1_p
without IN 1_p
hypertension NN 1_p
or CC 1_p
cardiac JJ 1_p
arrhythmia NN 1_p
. . 1_p

-DOCSTART- -X- O O

Hypotensive JJ N
effects NNS N
and CC N
influence NN N
on IN N
serum NN 1_o
lipids NNS 1_o
of IN N
SQ29,852 NNP 1_i
, , 1_i
a DT 1_i
new JJ 1_i
angiotensin NN 1_i
converting VBG 1_i
enzyme JJ 1_i
inhibitor NN 1_i
, , N
in IN N
patients NNS 1_p
with IN 1_p
essential JJ 1_p
hypertension NN 1_p
: : 1_p
a DT N
comparison NN N
with IN N
atenolol NN 1_i
. . 1_i

The DT N
effects NNS N
of IN N
SQ29,852 NNP 1_i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
, , N
a DT N
new JJ N
angiotensin NN 1_i
converting VBG 1_i
enzyme JJ 1_i
inhibitor NN 1_i
, , N
and CC N
atenolol NN 1_i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
, , N
monotherapies NNS N
were VBD N
compared VBN N
in IN N
46 CD 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
essential JJ 1_p
hypertension NN 1_p
. . 1_p

Both DT N
SQ29,852 NNP 1_i
( ( N
mean VBP N
dose RB N
15.0 CD N
+/- JJ N
5.1 CD N
mg/day NN N
) ) N
and CC N
atenolol $ 1_i
( ( N
mean VB N
dose RB N
37.5 CD N
+/- JJ N
18.5 CD N
mg/day NN N
) ) N
significantly RB N
decreased VBN N
both DT N
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressures NNS 1_o
. . 1_o

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
serum NN 1_o
lipids NNS 1_o
, , 1_o
apolipoproteins NNS 1_o
, , 1_o
lipoproteins VBZ 1_o
or CC 1_o
atherosclerotic JJ 1_o
indices NNS 1_o
after IN N
both DT N
SQ29,852 NNP 1_i
and CC N
atenolol RB 1_i
. . 1_i

There EX N
were VBD N
also RB N
no DT 1_o
significant JJ 1_o
inter-group JJ 1_o
differences NNS 1_o
. . 1_o

There EX N
were VBD N
no DT N
serious JJ 1_o
side NN 1_o
effects NNS 1_o
or CC 1_o
abnormal JJ 1_o
laboratory NN 1_o
tests NNS 1_o
in IN N
both DT N
treatment NN N
groups NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
SQ29,852 NNP 1_i
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
drug NN N
without IN N
adverse JJ 1_o
effect NN 1_o
on IN N
lipid JJ N
metabolism NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
vitamin NN 1_i
D NNP 1_i
supplementation NN 1_i
on IN N
inflammatory JJ 1_o
markers NNS 1_o
in IN N
African JJ 1_p
Americans NNPS 1_p
: : 1_p
results NNS N
of IN N
a DT N
four-arm JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
. . N

African JJ 1_p
Americans NNPS 1_p
have VBP 1_p
a DT 1_p
disproportionate JJ 1_p
burden NN 1_p
of IN 1_p
inflammation-associated JJ 1_p
chronic JJ 1_p
diseases NNS 1_p
such JJ N
as IN N
cancer NN N
and CC N
lower JJR N
circulating NN N
levels NNS N
of IN N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
. . N

The DT N
effect NN N
of IN N
vitamin NN 1_i
D3 NNP 1_i
( ( 1_i
cholecalciferol NN 1_i
) ) 1_i
supplementation NN 1_i
on IN N
inflammatory JJ 1_o
markers NNS 1_o
is VBZ N
uncertain JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
supplemental JJ 1_i
oral JJ 1_i
vitamin NN 1_i
D NNP 1_i
( ( 1_i
placebo NN 1_i
, , N
1,000 CD N
, , N
2,000 CD N
, , N
or CC N
4,000 CD N
IU/day NN N
of IN N
vitamin NN N
D3 NNP N
orally RB N
for IN N
3 CD N
months NNS N
) ) N
in IN N
328 CD 1_p
African JJ 1_p
Americans NNPS 1_p
( ( 1_p
median JJ 1_p
age NN 1_p
, , 1_p
51 CD 1_p
years NNS 1_p
) ) 1_p
of IN 1_p
public JJ 1_p
housing NN 1_p
communities NNS 1_p
in IN 1_p
Boston NNP 1_p
, , 1_p
MA NNP 1_p
, , 1_p
who WP 1_p
were VBD 1_p
enrolled VBN 1_p
over RP 1_p
three CD 1_p
consecutive JJ 1_p
winter NN 1_p
periods NNS 1_p
( ( 1_p
2007-2010 JJ 1_p
) ) 1_p
. . 1_p

Change NN N
from IN N
0 CD N
to TO N
3 CD N
months NNS N
of IN N
plasma NN 1_o
levels NNS 1_o
of IN 1_o
25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
D NNP 1_o
, , 1_o
high-sensitivity JJ 1_o
C-reactive JJ 1_o
protein NN 1_o
( ( 1_o
CRP NNP 1_o
) ) 1_o
, , 1_o
interleukin FW 1_o
( ( 1_o
IL NNP 1_o
) ) 1_o
-6 NN 1_o
, , 1_o
IL-10 NNP 1_o
, , 1_o
and CC 1_o
soluble JJ 1_o
TNF-? NNP 1_o
receptor NN 1_o
type NN 1_o
2 CD 1_o
( ( 1_o
sTNF-R2 NN 1_o
) ) 1_o
in IN N
292 CD N
( ( N
89 CD N
% NN N
) ) N
participants NNS N
were VBD N
measured VBN N
. . N

Overall NNP N
, , N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN 1_o
CRP NNP 1_o
, , 1_o
IL-6 NNP 1_o
, , 1_o
IL-10 NNP 1_o
, , 1_o
and CC 1_o
sTNF-R2 NNS 1_o
were VBD N
observed VBN N
after IN N
the DT N
vitamin NN N
D NNP N
supplementation NN N
period NN N
. . N

Baseline NNP 1_o
CRP NNP 1_o
was VBD N
significantly RB N
inversely RB N
associated VBN N
with IN N
the DT 1_o
baseline NN 1_o
25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
D NNP 1_o
level NN 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
unadjusted JJ N
and CC N
adjusted JJ N
models NNS N
. . N

An DT N
interaction NN N
between IN N
baseline NN 1_o
25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
D NNP 1_o
and CC 1_o
vitamin NNP 1_o
D NNP 1_o
supplementation NN 1_o
was VBD N
observed VBN N
for IN N
outcome JJ N
change NN N
in IN 1_o
log NN 1_o
CRP NNP 1_o
( ( N
month NN N
3-month RB N
0 CD N
; : N
P NNP N
for IN N
interaction NN N
= NNP N
0.04 CD N
) ) N
. . N

Within IN N
an DT N
unselected JJ N
population NN N
of IN N
African JJ N
Americans NNPS N
, , N
short-term JJ 1_i
exposure NN 1_i
to TO 1_i
vitamin VB 1_i
D NNP 1_i
supplementation NN 1_i
produced VBD N
no DT N
change NN N
in IN 1_o
circulating VBG 1_o
inflammatory JJ 1_o
markers NNS 1_o
. . 1_o

This DT N
study NN N
confirms VBZ N
the DT N
strong JJ N
independent JJ N
association NN N
of IN 1_o
CRP NNP 1_o
with IN 1_o
25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
D NNP 1_o
status NN N
even RB N
after IN N
adjusting VBG N
for IN N
body NN N
mass NN N
index NN N
. . N

Future JJ N
studies NNS N
of IN N
longer JJR N
supplemental JJ N
vitamin NN N
D3 NNP N
duration NN N
are VBP N
necessary JJ N
to TO N
examine VB N
the DT N
complex JJ N
influence NN N
of IN N
vitamin NN N
D3 NNP N
on IN N
CRP NNP N
and CC N
other JJ N
chronic JJ N
inflammatory NN N
cytokines NNS N
for IN N
possible JJ N
reduction NN N
of IN 1_p
cancer NN 1_p
health NN 1_p
disparities NNS 1_p
in IN 1_p
African JJ 1_p
Americans NNPS 1_p
. . 1_p

-DOCSTART- -X- O O

Treatment NN N
of IN N
duodenal JJ 1_p
ulcer NN 1_p
with IN N
low-dose JJ 1_i
antacids NNS 1_i
. . 1_i

The DT N
aim NN N
of IN N
the DT N
present JJ N
investigation NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
a DT N
low-dose JJ 1_i
antacid NN 1_i
( ( 1_i
Maalox NNP 1_i
70 CD 1_i
, , N
280 CD N
mmol/day NN N
) ) N
with IN N
that DT N
of IN N
the DT N
H2-receptor NNP 1_i
antagonist NN 1_i
cimetidine NN 1_i
( ( 1_i
Tagamet NNP 1_i
, , N
200 CD N
mg NN N
three CD N
times NNS N
daily RB N
and CC N
400 CD N
mg/day NN N
) ) N
after IN N
14 CD N
and CC N
28 CD N
days NNS N
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ 1_p
ulcer NN 1_p
. . 1_p

The DT N
prospective JJ N
multicentre NN N
study NN N
included VBD N
171 CD 1_p
patients NNS 1_p
with IN 1_p
endoscopically RB 1_p
confirmed VBN 1_p
duodenal JJ 1_p
ulcers NNS 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
groups NNS N
with IN N
antacid JJ 1_i
containing VBG 1_i
Mg NNP 1_i
and CC 1_i
Al NNP 1_i
hydroxide NN 1_i
( ( 1_i
M NNP 1_i
) ) 1_i
( ( 1_i
4 CD 1_i
X RB N
70 CD N
mmol/day NN N
; : N
n CC N
= VB N
86 CD N
) ) N
or CC N
to TO N
the DT N
group NN N
receiving VBG N
cimetidine NN 1_i
( ( N
T NNP N
) ) N
( ( N
1000 CD N
mg/day NN N
; : N
n CC N
= VB N
85 CD N
) ) N
. . N

The DT N
two CD 1_p
treatment NN 1_p
groups NNS 1_p
were VBD N
matched VBN N
for IN N
age NN N
, , N
sex NN N
, , N
drinking NN N
and CC N
smoking NN N
habits NNS N
, , N
and CC N
drug NN N
use NN N
. . N

Endoscopic JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
14 CD N
days NNS N
later RB N
. . N

If IN N
the DT N
ulcer NN N
was VBD N
still RB N
present JJ N
at IN N
this DT N
time NN N
, , N
the DT N
second JJ N
endoscopic NN N
examination NN N
was VBD N
done VBN N
after IN N
a DT N
further JJ N
14 CD N
days NNS N
. . N

Endoscopically RB N
, , N
the DT N
ulcer NN N
had VBD N
healed VBN 1_o
at IN N
14 CD N
days NNS N
in IN N
38.8 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
in IN N
34.9 CD N
% NN N
( ( N
T NNP N
) ) N
and CC N
at IN N
28 CD N
days NNS N
in IN N
80.0 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
74.7 CD N
% NN N
( ( N
T NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
healing VBG 1_o
rate NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Complaints NNS 1_o
, , N
measured VBN N
as IN N
percentage NN N
of IN N
days NNS N
per IN N
week NN N
with IN N
upper JJ 1_o
abdominal JJ 1_o
pain NN 1_o
, , N
were VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
pain VB 1_o
relief NN 1_o
or CC 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

Treatment NN N
had VBD N
to TO N
be VB N
abandoned VBN N
in IN N
one CD N
patient NN N
receiving VBG N
antacid NN N
because IN N
of IN N
diarrhoea NN N
and CC N
in IN N
one CD N
patient NN N
receiving VBG N
cimetidine NN N
because IN N
of IN N
the DT N
absence NN N
of IN N
any DT N
response NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Recruitment NN 1_o
and CC 1_o
Reasons NNP 1_o
for IN 1_o
Non-Participation NNP 1_o
in IN N
a DT N
Family-Coping-Orientated JJ 1_i
Palliative NNP 1_i
Home NNP 1_i
Care NNP 1_i
Trial NNP N
( ( N
FamCope NNP N
) ) N
. . N

Cancer NN 1_p
patients NNS 1_p
and CC 1_p
their PRP$ 1_p
family NN 1_p
caregivers NNS 1_p
need VBP N
support NN N
to TO N
cope VB N
with IN N
physical JJ N
, , N
psychosocial JJ N
, , N
and CC N
existential JJ N
problems NNS N
early RB N
in IN N
the DT N
palliative JJ N
care NN N
trajectory NN N
. . N

Many JJ N
interventions NNS N
target VBP N
patient JJ N
symptomatology NN N
, , N
with IN N
health NN N
care NN N
professionals NNS N
acting VBG N
as IN N
problem-solvers NNS N
. . N

Family RB N
coping VBG N
, , N
however RB N
, , N
is VBZ N
a DT N
new JJ N
research NN N
area NN N
within IN N
palliative JJ N
care NN N
. . N

The DT N
FamCope NNP 1_i
intervention NN 1_i
was VBD N
developed VBN N
to TO N
test VB N
if IN N
a DT N
nurse-led JJ 1_i
family-coping-orientated JJ 1_i
palliative NN 1_i
home NN 1_i
care NN 1_i
intervention NN 1_i
would MD N
help VB N
families NNS N
cope VB N
with IN N
physical JJ N
and CC N
psychosocial JJ N
problems NNS N
at IN N
home NN N
-- : N
together RB N
as IN N
a DT N
family NN N
and CC N
in IN N
interaction NN N
with IN N
health NN N
care NN N
professionals NNS N
. . N

However RB N
, , N
an DT N
unexpectedly RB N
high JJ N
number NN N
of IN N
families NNS N
declined VBD N
participation NN 1_o
in IN N
the DT N
trial NN N
. . N

We PRP N
describe VBP N
and CC N
discuss VBP N
the DT N
recruitment NN 1_o
strategy NN 1_o
and CC N
patient NN 1_o
reported VBD 1_o
reasons NNS 1_o
for IN N
non-participation NN 1_o
to TO N
add VB N
to TO N
the DT N
knowledge NN N
about IN N
what WP N
impedes JJ N
recruitment NN N
and CC N
to TO N
identify VB N
the DT N
factors NNS N
that WDT N
influence NN N
willingness NN N
to TO N
participate VB N
in IN N
research NN N
aimed VBN N
at IN N
family NN N
coping VBG N
early RB N
in IN N
the DT N
palliative JJ N
care NN N
trajectory NN N
. . N

Patients NNS 1_p
with IN 1_p
advanced JJ 1_p
cancer NN 1_p
and CC 1_p
their PRP$ 1_p
closest JJS 1_p
relative NN 1_p
were VBD 1_p
recruited VBN 1_p
from IN 1_p
medical JJ 1_p
, , 1_p
surgical JJ 1_p
, , 1_p
and CC 1_p
oncological JJ 1_p
departments NNS 1_p
. . 1_p

Reasons NNS N
for IN N
non-participation NN 1_o
were VBD N
registered VBN N
and CC N
characteristics NNS N
of IN N
participants NNS N
and CC N
non-participants NNS N
were VBD N
compared VBN N
to TO N
evaluate VB N
differences NNS N
between IN N
subgroups NNS N
of IN N
non-participants NNS N
based VBN N
on IN N
reasons NNS N
not RB N
to TO N
participate VB N
and CC N
reasons NNS N
to TO N
participate VB N
in IN N
the DT N
trial NN N
. . N

A DT N
total NN N
of IN N
65.9 CD N
% NN N
of IN N
the DT N
families NNS N
declined VBD N
participation NN 1_o
. . 1_o

Two CD N
main JJ N
categories NNS N
for IN N
declining VBG N
participation NN 1_o
emerged VBD N
: : N
first RB N
, , N
that IN N
the DT N
burden NN N
of IN N
illness NN N
is VBZ N
too RB N
great JJ N
and CC N
, , N
second JJ N
, , N
that IN N
it PRP N
was VBD N
too RB N
soon RB N
to TO N
receive VB N
this DT N
kind NN N
of IN N
support NN N
. . N

Men NN 1_p
were VBD N
more RBR N
likely JJ N
to TO N
participate VB 1_o
than IN N
women NNS 1_p
. . 1_p

Patients NNS N
in IN N
the DT N
too RB N
soon RB N
group NN N
had VBD N
similar JJ N
characteristics NNS N
to TO N
participants NNS N
in IN N
the DT N
trial NN N
. . N

Timing NN N
of IN N
interventions NNS N
and CC N
readiness NN N
of IN N
patients NNS N
and CC N
their PRP$ N
relatives NNS N
seems VBZ N
to TO N
affect VB N
willingness NN 1_o
to TO 1_o
receive VB 1_o
a DT 1_o
family-coping-orientated JJ 1_o
care NN 1_o
approach NN 1_o
and CC N
impeded JJ N
recruitment NN N
to TO N
this DT N
trial NN N
. . N

Our PRP$ N
findings NNS N
can MD N
be VB N
used VBN N
in IN N
further JJ N
research NN N
and CC N
in IN N
clinical JJ N
practice NN N
in IN N
order NN N
to TO N
construct VB N
interventions NNS N
and CC N
target NN N
relevant JJ N
populations NNS N
for IN N
early JJ N
family-coping-orientated JJ N
palliative NN 1_i
care NN 1_i
. . 1_i

-DOCSTART- -X- O O

Lack NN N
of IN N
interaction NN N
between IN N
pantoprazole NN 1_i
and CC 1_i
digoxin NN 1_i
at IN N
therapeutic JJ N
doses NNS N
in IN 1_p
man NN 1_p
. . 1_p

Substituted JJ 1_i
benzimidazole JJ 1_i
inhibitors NNS 1_i
of IN N
the DT N
gastric JJ N
H+/K+ATPase NNP N
may MD N
interact VB N
with IN N
the DT N
cytochrome NN N
P450 NNP N
enzyme NN N
system NN N
and CC N
alter VB N
the DT N
pharmacokinetics NNS N
of IN N
coadministered JJ N
drugs NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
changes NNS N
in IN N
intragastric JJ N
pH NN N
might MD N
alter VB N
the DT N
absorption NN N
of IN N
other JJ N
drugs NNS N
. . N

The DT N
primary JJ N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
pantoprazole JJ 1_i
modifies NNS N
the DT N
steady-state JJ N
serum NN N
concentrations NNS N
of IN N
orally RB N
administered VBN N
digoxin NN 1_i
. . 1_i

Secondary JJ N
aims NNS N
were VBD N
the DT N
influence NN N
of IN N
digoxin NN 1_i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
pantoprazole NN 1_i
as RB N
well RB N
as IN N
safety NN N
and CC N
tolerability NN N
. . N

Eighteen NNP 1_p
healthy JJ 1_p
volunteers NNS 1_p
received VBD N
a DT N
single JJ N
oral JJ 1_i
dose NN 1_i
of IN 1_i
pantoprazole NN 1_i
( ( 1_i
40 CD 1_i
mg NN 1_i
) ) 1_i
and CC 1_i
serum JJ 1_i
concentrations NNS 1_i
were VBD N
determined VBN N
. . N

Three CD N
to TO N
10 CD N
days NNS N
later RB N
, , N
subjects NNS N
received VBD N
in IN N
a DT N
single-blind NN N
, , N
randomized VBN N
, , N
crossover JJ N
fashion NN N
oral JJ N
beta-acetyldigoxin NN 1_i
( ( N
0.2 CD N
mg NN N
) ) N
twice RB N
daily RB N
and CC N
concomitant JJ 1_i
oral JJ 1_i
pantoprazole NN 1_i
( ( N
40 CD N
mg NN N
) ) N
or CC N
placebo JJ 1_i
once RB N
daily JJ N
for IN N
5 CD N
days NNS N
. . N

Serum NNP N
concentrations NNS N
of IN N
pantoprazole NN 1_i
and CC 1_i
digoxin NN 1_i
were VBD N
determined VBN N
on IN N
day NN N
5 CD N
. . N

Primary JJ N
characteristics NNS N
for IN N
confirmative JJ N
assessment NN N
of IN N
no DT N
interaction NN N
were VBD N
AUC NNP 1_o
and CC 1_o
Cmax NNP 1_o
of IN 1_o
digoxin NN 1_o
. . 1_o

Lack NNP N
of IN N
interaction NN N
in IN N
the DT N
sense NN N
of IN N
equivalence NN N
was VBD N
concluded VBN N
for IN N
both DT N
digoxin NN N
( ( N
with IN N
and CC N
without IN N
pantoprazole NN 1_i
) ) 1_i
and CC N
pantoprazole JJ 1_i
( ( 1_i
with IN 1_i
and CC 1_i
without IN 1_i
digoxin NN 1_i
) ) 1_i
as IN N
the DT N
90 CD N
% NN N
-confidence NN N
intervals NNS N
of IN N
the DT N
respective JJ N
AUC- NNP 1_o
and CC 1_o
Cmax-ratios NNP 1_o
were VBD N
within IN N
the DT N
equivalence NN N
range NN N
of IN N
0.8-1.25 NNP N
. . N

Pantoprazole NNP 1_i
did VBD N
not RB N
influence VB N
the DT N
characteristic JJ N
ECG NNP N
modifications NNS N
( ( N
T-wave NNP N
) ) N
caused VBN N
by IN N
digoxin NN N
. . N

Both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN 1_o
and CC N
no DT N
adverse JJ 1_o
events NNS 1_o
or CC N
clinically RB N
relevant JJ N
alterations NNS N
in IN N
vital JJ N
signs NNS N
or CC N
clinical JJ N
laboratory NN N
parameters NNS N
were VBD N
observed VBN N
during IN N
treatment NN N
. . N

In IN N
conclusion NN N
, , N
pantoprazole NN 1_i
and CC 1_i
digoxin NN 1_i
may MD N
be VB N
administered VBN N
concomitantly RB N
without IN N
the DT N
need NN N
for IN N
dose JJ N
adjustment NN N
. . N

-DOCSTART- -X- O O

Association NNP N
between IN N
platelet NN N
activation NN N
and CC N
fibrinolysis NN N
in IN N
acute JJ 1_p
stroke NN 1_p
patients NNS 1_p
. . 1_p

We PRP N
aimed VBD N
to TO N
evaluate VB N
platelet NN N
activation NN N
and CC N
fibrinolyis NN N
in IN N
acute JJ 1_p
atherosclerotic JJ 1_p
ischemic JJ 1_p
stroke NN 1_p
patients NNS 1_p
to TO N
clarify VB N
the DT N
relationship NN N
between IN N
them PRP N
. . N

Plasma VB 1_o
P-selectin NNP 1_o
antigen NN 1_o
, , 1_o
tissue NN 1_o
plasminogen NN 1_o
activator NN 1_o
( ( 1_o
tPA NN 1_o
) ) 1_o
antigen NN 1_o
and CC 1_o
activity NN 1_o
, , 1_o
and CC 1_o
plasminogen NN 1_o
activator NN 1_o
inhibitor-1 JJ 1_o
( ( 1_o
PAI-1 NNP 1_o
) ) 1_o
activity NN 1_o
were VBD N
determined VBN N
in IN N
60 CD 1_p
acute JJ 1_p
atherosclerotic JJ 1_p
stroke NN 1_p
patients NNS 1_p
and CC 1_p
matched VBN 1_p
control NN 1_p
subjects NNS 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
were VBD 1_p
examined VBN 1_p
within IN 1_p
72 CD 1_p
h NN 1_p
after IN 1_p
stroke NN 1_p
onset NN 1_p
. . 1_p

The DT N
levels NNS 1_o
of IN 1_o
P-selectin NNP 1_o
, , 1_o
tPA NN 1_o
antigen NN 1_o
, , 1_o
and CC 1_o
PAI-1 JJ 1_o
activity NN 1_o
were VBD N
all DT N
significantly RB 1_o
higher JJR 1_o
in IN N
stroke NN N
patients NNS N
compared VBN N
with IN N
controls NNS N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
; : N
the DT N
level NN 1_o
of IN 1_o
tPA JJ 1_o
activity NN 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
patients NNS N
than IN N
that DT N
in IN N
controls NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
. . N

These DT N
markers NNS N
did VBD N
not RB N
change VB N
much RB N
at IN N
different JJ N
time NN N
points NNS N
within IN N
72 CD N
h. NN N
In IN N
stroke NN N
group NN N
, , N
P-selectin NNP 1_o
concentration NN 1_o
was VBD N
highly RB N
correlated VBN N
to TO N
PAI-1 NNP 1_o
activity NN 1_o
( ( N
r NN N
= VBZ N
0.8433 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
to TO N
tPA VB 1_o
antigen NN 1_o
( ( N
r JJ N
= NNP N
-0.1752 NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
and CC N
tPA NN 1_o
activity NN 1_o
( ( N
r NN N
= VBZ N
0.2465 CD N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
which WDT N
was VBD N
further RBR N
confirmed VBN N
in IN N
the DT N
multiple JJ N
linear JJ N
regression NN N
analysis NN N
( ( N
F NNP N
= NNP N
47.052 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Our PRP$ N
results NNS N
indicate VBP N
increased JJ 1_o
platelet NN 1_o
activation NN 1_o
and CC N
decreased JJ 1_o
fibrinolysis NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
atherosclerotic JJ 1_p
ischemic JJ 1_p
stroke NN 1_p
. . 1_p

Increased VBN N
platelet NN 1_o
activation NN 1_o
may MD N
be VB N
correlated VBN N
with IN N
decreased JJ N
fibrinolysis NN N
. . N

-DOCSTART- -X- O O

Treatment NN 1_o
of IN 1_o
human JJ 1_o
tungiasis NN 1_o
with IN N
niridazole JJ 1_i
( ( 1_i
Ambilhar NNP 1_i
) ) 1_i
a DT N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
Selaginella NNP 1_i
combined VBD N
with IN N
radiotherapy NN 1_i
on IN N
nasopharyngeal JJ 1_p
carcinoma NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
Chinese JJ N
herbal JJ N
medicine NN N
Selaginella-induced NNP N
radiosensitization NN N
of IN N
terminal JJ 1_p
nasopharyngeal JJ 1_p
carcinoma NN 1_p
( ( 1_p
NPC NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Totally RB N
180 CD 1_p
patients NNS 1_p
with IN 1_p
NPC NNP 1_p
were VBD N
divided VBN N
equally RB N
into IN N
3 CD N
groups NNS N
with IN N
the DT N
same JJ N
radiotherapeutic JJ N
protocols NNS N
. . N

The DT N
patients NNS N
in IN N
group NN 1_i
A NNP 1_i
received VBD 1_i
radiotherapy NN 1_i
alone RB 1_i
, , 1_i
those DT 1_i
in IN 1_i
group NN 1_i
B NNP 1_i
were VBD 1_i
given VBN 1_i
daily JJ 1_i
Selaginella NNP 1_i
( ( 1_i
30 CD 1_i
g NN 1_i
) ) 1_i
prepared VBD 1_i
into IN 1_i
50 CD 1_i
ml JJ 1_i
decoction NN 1_i
during IN 1_i
the DT 1_i
entire JJ 1_i
course NN 1_i
of IN 1_i
radiotherapy NN 1_i
, , N
and CC N
those DT N
in IN N
group NN 1_i
C NNP 1_i
had VBD 1_i
Selaginella NNP 1_i
30 CD 1_i
g JJ 1_i
daily RB 1_i
in IN 1_i
the DT 1_i
late JJ 1_i
course NN 1_i
of IN 1_i
radiotherapy NN 1_i
. . 1_i

RESULTS VB N
The DT N
complete JJ 1_o
remission NN 1_o
rate NN 1_o
of IN 1_o
nasopharyngeal JJ 1_o
primary JJ 1_o
lesions NNS 1_o
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
group NN N
A NNP N
, , N
with IN N
also RB N
significantly RB N
higher JJR N
complete JJ N
remission NN 1_o
rates NNS 1_o
of IN 1_o
the DT 1_o
cervical JJ 1_o
lymph NN 1_o
nodes NNS 1_o
. . 1_o

The DT N
acute JJ 1_o
toxicity NN 1_o
of IN 1_o
the DT 1_o
skin NN 1_o
and CC 1_o
mucous JJ 1_o
membrane NN 1_o
was VBD N
milder RBR N
in IN N
the DT N
latter JJ N
two CD N
groups NNS N
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Selaginella NNP 1_i
may MD N
induce VB N
radiosensitization NN N
for IN N
terminal JJ 1_p
NPC NNP 1_p
and CC N
does VBZ N
not RB N
increase VB N
the DT N
acute JJ N
toxicity NN N
of IN N
radiotherapy NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
fluoxetine NN 1_i
and CC 1_i
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
obesity NN 1_o
. . 1_o

Our PRP$ N
study NN N
aims VBZ N
at IN N
assessing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
fluoxetine NN 1_i
as IN N
compared VBN N
with IN N
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
obesity NN 1_p
using VBG N
a DT N
double-blind JJ N
crossover NN N
design NN N
. . N

We PRP N
studied VBD N
42 CD 1_p
obese JJ 1_p
women NNS 1_p
( ( 1_p
body NN 1_p
mass NN 1_p
index NN 1_p
35.9 CD 1_p
+/- JJ 1_p
5.3 CD 1_p
kg/m2 NN 1_p
) ) 1_p
. . 1_p

The DT N
obese JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
start VB N
treatment NN N
with IN N
fluoxetine NN 1_i
( ( N
group NN N
A NNP N
) ) N
or CC N
placebo NN 1_i
( ( N
group NN N
B NNP N
) ) N
for IN N
3 CD N
months NNS N
( ( N
period NN N
1 CD N
) ) N
. . N

After IN N
a DT N
1-month JJ N
washout NN N
period NN N
, , N
treatment NN N
was VBD N
crossed VBN N
for IN N
the DT N
following JJ N
3 CD N
months NNS N
( ( N
period NN N
2 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
weight JJ 1_o
loss NN 1_o
when WRB N
the DT N
patients NNS N
were VBD N
treated VBN N
with IN N
fluoxetine NN 1_i
( ( N
group NN N
A NNP N
period NN N
1 CD N
and CC N
group NN N
B NNP N
period NN N
2 CD N
) ) N
as IN N
compared VBN N
with IN N
patients NNS N
treated VBN N
with IN N
placebo NN 1_i
( ( N
group NN N
B NNP N
period NN N
1 CD N
and CC N
group NN N
A NNP N
period NN N
2 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
monthly JJ 1_o
weight NN 1_o
reduction NN 1_o
during IN N
both DT N
treatments NNS N
. . N

In IN N
conclusion NN N
, , N
we PRP N
demonstrated VBD N
that IN N
serotoninergic JJ 1_i
drugs NNS 1_i
such JJ N
as IN N
fluoxetine JJ 1_i
need VBP N
further JJ N
investigation NN N
before IN N
being VBG N
used VBN N
indiscriminately RB N
in IN N
obese JJ 1_p
subjects NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Are NNP N
oral JJ N
cathartics NNS N
of IN N
value NN N
in IN N
optimizing VBG N
the DT N
gallium NN N
scan JJ N
? . N
Concise NNP N
communication NN N
. . N

The DT N
normal JJ N
intestinal JJ N
secretion NN N
of IN N
9-15 CD N
% NN N
of IN N
an DT N
administered VBN N
dose NN N
of IN N
gallium-67 NN 1_i
may MD N
prevent VB N
early JJ N
detection NN N
of IN N
intra-abdominal JJ N
disease NN N
. . N

We PRP 1_p
randomized VBD 1_p
50 CD 1_p
patients NNS 1_p
to TO N
receive VB N
either DT N
no DT 1_i
bowel NN 1_i
preparation NN 1_i
or CC 1_i
30 CD 1_i
cc NN 1_i
of IN 1_i
milk NN 1_i
of IN 1_i
magnesia JJ 1_i
plus CC 1_i
5 CD 1_i
cc NN 1_i
of IN 1_i
cascara NN 1_i
. . 1_i

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN 1_o
with IN 1_o
which WDT 1_o
gallium NN 1_o
interfered VBD 1_o
with IN 1_o
readings NNS 1_o
or CC 1_o
time NN 1_o
to TO 1_o
complete VB 1_o
the DT 1_o
study NN 1_o
. . 1_o

-DOCSTART- -X- O O

Prophylactic JJ 1_i
training NN 1_i
for IN N
the DT N
prevention NN N
of IN N
radiotherapy-induced JJ N
trismus NN N
- : N
a DT N
randomised JJ N
study NN N
. . N

BACKGROUND NNP N
Radiotherapy-induced JJ N
trismus NN N
( ( N
RTIT NNP N
) ) N
is VBZ N
a DT N
debilitating VBG N
condition NN N
without IN N
any DT N
proven JJ N
effective JJ N
treatment NN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
effectiveness NN 1_o
of IN N
prophylactic JJ 1_i
training NN 1_i
to TO N
prevent VB N
RTIT NNP N
during IN N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN 1_p
RT NNP 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
( ( 1_p
HNC NNP 1_p
) ) 1_p
, , N
also RB N
investigating VBG N
the DT N
incidence NN N
of IN N
RTIT NNP N
. . N

METHODS NNP N
Sixty-six JJ 1_p
consecutive JJ 1_p
patients NNS 1_p
from IN 1_p
two CD 1_p
RT NNP 1_p
clinics NNS 1_p
in IN 1_p
Sweden NNP 1_p
were VBD N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
: : N
training NN 1_i
with IN 1_i
TheraBite NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
Jaw NNPS 1_i
Motion NNP 1_i
Rehabilitation NNP 1_i
System NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
or CC 1_i
a DT 1_i
control NN 1_i
group NN 1_o
. . 1_o

Maximum NNP 1_o
interincisal JJ 1_o
openings NNS 1_o
( ( 1_o
MIO NNP 1_o
) ) 1_o
were VBD 1_o
recorded VBN 1_o
at IN N
baseline NN N
and CC N
once RB N
a DT N
week NN N
during IN N
treatment NN N
, , N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

Training NNP N
frequency NN N
was VBD N
recorded VBN N
by IN N
patients NNS N
in IN N
a DT N
log NN N
book NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
MIO NNP 1_o
between IN 1_o
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
at IN N
any DT N
of IN N
the DT N
measurement NN N
points NNS N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
maintained VBD N
their PRP$ N
normal JJ N
variation NN N
in IN N
MIO NNP 1_o
at IN 1_o
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

A NNP N
small JJ N
group NN N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
had VBD N
a DT N
17 CD N
% NN N
mean JJ N
decrease NN N
in IN N
MIO NNP 1_o
by IN 1_o
week NN N
6 CD N
compared VBN N
to TO N
baseline VB N
and CC N
improved VB N
their PRP$ 1_o
MIO NNP 1_o
by IN 1_o
using VBG N
the DT N
training NN N
programme NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
mean JJ N
difference NN N
in IN N
MIO NNP 1_o
from IN 1_o
baseline NN N
to TO N
week NN N
6 CD N
( ( N
3 CD N
mm NN N
, , N
p NN N
= NNP N
0.018 CD N
) ) N
, , N
and CC N
month NN N
6 CD N
( ( N
2.7 CD N
mm NN N
, , N
p NN N
= NNP N
0.040 CD N
) ) N
, , N
for IN N
patients NNS N
receiving VBG N
3D CD N
conformal JJ N
radiotherapy NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
MIO NNP 1_o
between IN 1_o
patients NNS N
treated VBN N
with IN N
RT NNP N
and CC N
concurrent JJ N
chemotherapy NN N
compared VBN N
to TO N
patients NNS N
with IN N
RT NNP N
only RB N
at IN N
12 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.033 CD N
) ) N
. . N

CONCLUSIONS JJ 1_p
Patients NNS 1_p
with IN 1_p
HNC NNP 1_p
undergoing VBG 1_p
high JJ 1_p
dose NN 1_p
RT NNP 1_p
do VBP N
not RB N
need VB N
to TO N
be VB N
burdened VBN N
with IN N
an DT N
intense JJ N
prophylactic JJ N
training NN N
programme NN N
during IN N
RT NNP N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

MIO NNP 1_o
measurements NNS 1_o
during IN N
RT NNP N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
are VBP N
recommended VBN N
to TO N
identify VB N
a DT N
small JJ N
risk NN N
group NN N
who WP N
are VBP N
an DT N
exception NN N
and CC N
may MD N
need VB 1_i
a DT 1_i
training NN 1_i
programme NN 1_i
. . 1_i

-DOCSTART- -X- O O

Supplementation NN N
with IN N
a DT 1_i
blend NN 1_i
of IN 1_i
krill NN 1_i
and CC 1_i
salmon JJ 1_i
oil NN 1_i
is VBZ N
associated VBN N
with IN N
increased VBN N
metabolic NN N
risk NN N
in IN N
overweight JJ 1_p
men NNS 1_p
. . 1_p

BACKGROUND NNP N
Krill NNP 1_i
is VBZ N
an DT N
increasingly RB N
popular JJ N
source NN N
of IN N
marine JJ N
n-3 JJ N
( ( N
?-3 JJ N
) ) N
PUFA NNP N
that WDT N
is VBZ N
seen VBN N
as IN N
a DT N
premium JJ N
product NN N
. . N

However RB N
, , N
to TO N
our PRP$ N
knowledge NN N
, , N
the DT N
effect NN N
of IN 1_i
krill-oil JJ 1_i
supplementation NN 1_i
on IN N
insulin NN N
sensitivity NN N
in IN N
humans NNS N
has VBZ N
not RB N
been VBN N
reported VBN N
. . N

OBJECTIVE IN N
We PRP N
assessed VBD N
whether IN 1_i
supplementation NN 1_i
with IN 1_i
a DT 1_i
blend NN 1_i
of IN 1_i
krill NN 1_i
and CC 1_i
salmon NN 1_i
( ( 1_i
KS NNP 1_i
) ) 1_i
oil NN 1_i
[ NN N
which WDT N
is VBZ N
rich JJ N
in IN N
eicosapentaenoic JJ N
acid NN N
( ( N
EPA NNP N
) ) N
and CC N
docosahexaenoic JJ N
acid NN N
( ( N
DHA NNP N
) ) N
] VBZ N
affects NNS N
insulin JJ N
sensitivity NN N
in IN 1_p
overweight JJ 1_p
men NNS 1_p
. . 1_p

DESIGN VB N
The DT N
design NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled VBD N
crossover RB N
trial NN N
. . N

A DT N
total NN 1_p
of IN 1_p
47 CD 1_p
men NNS 1_p
with IN 1_p
a DT 1_p
mean NN 1_p
? . 1_p
SD NNP 1_p
age NN 1_p
of IN 1_p
46.5 CD 1_p
? . 1_p
5.1 CD 1_p
y NN 1_p
, , 1_p
who WP 1_p
were VBD 1_p
overweight JJ 1_p
[ NNP 1_p
body NN 1_p
mass NN 1_p
index NN 1_p
( ( 1_p
in IN 1_p
kg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
) ) 1_p
from IN 1_p
25 CD 1_p
to TO 1_p
30 CD 1_p
] NNS 1_p
but CC 1_p
otherwise RB 1_p
healthy JJ 1_p
, , 1_p
received VBD 1_p
5 CD N
1-g JJ N
capsules NNS N
of IN N
KS NNP 1_i
oil NN 1_i
or CC 1_i
a DT 1_i
control NN 1_i
( ( 1_i
canola JJ 1_i
oil NN 1_i
) ) 1_i
for IN 1_i
8 CD N
wk NN N
and CC N
crossed VBD N
over IN N
to TO N
another DT N
treatment NN N
after IN N
an DT N
8-wk JJ N
washout NN N
period NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
insulin JJ 1_o
sensitivity NN 1_o
assessed VBN 1_o
by IN 1_o
using VBG 1_o
the DT 1_o
Matsuda NNP 1_o
method NN 1_o
from IN 1_o
an DT 1_o
oral-glucose-tolerance JJ 1_o
test NN 1_o
. . 1_o

Secondary JJ 1_o
outcomes NNS N
included VBD 1_o
lipid JJ 1_o
profiles NNS 1_o
, , 1_o
inflammatory JJ 1_o
markers NNS 1_o
, , 1_o
24-h JJ 1_o
ambulatory NN 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
carotid JJ 1_o
artery NN 1_o
intimamedia NN 1_o
thickness NN 1_o
. . 1_o

RESULTS NNP 1_o
Unexpectedly RB 1_o
, , 1_o
insulin JJ 1_o
sensitivity NN 1_o
( ( 1_o
per IN 1_o
the DT N
Matsuda NNP N
index NN N
) ) N
was VBD N
14 CD N
% NN N
lower JJR N
with IN N
the DT N
KS NNP 1_i
oil NN 1_i
than IN 1_i
with IN N
the DT N
control NN N
oil NN N
( ( N
P NNP N
= NNP N
0.049 CD N
) ) N
. . N

A DT N
mediation NN N
analysis NN N
showed VBD N
that IN N
, , N
after IN N
controlling VBG N
for IN N
the DT N
likely JJ N
positive JJ N
effects NNS N
of IN N
blood NN 1_o
EPA NNP 1_o
and CC 1_o
DHA NNP 1_o
( ( 1_o
i.e. FW 1_o
, , N
the DT N
omega-3 JJ N
index NN N
) ) N
, , N
the DT N
reduction NN N
in IN N
insulin NN 1_o
sensitivity NN 1_o
after IN 1_o
KS-oil NNP 1_i
supplementation NN 1_i
was VBD 1_i
more RBR N
marked JJ N
[ JJ N
27 CD N
% NN N
lower JJR N
than IN N
with IN N
the DT N
control NN N
oil NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
] NN N
. . N

CONCLUSIONS NNP 1_i
Supplementation NNP 1_i
with IN 1_i
a DT 1_i
blend NN 1_i
of IN 1_i
KS NNP 1_i
oil NN 1_i
is VBZ 1_i
associated VBN N
with IN N
decreased JJ 1_o
insulin NN 1_o
sensitivity NN 1_o
. . 1_o

Thus RB 1_o
, , 1_i
krill-oil JJ 1_i
supplementation NN 1_i
in IN 1_i
overweight JJ 1_p
adults NNS 1_p
could MD 1_p
exacerbate VB 1_o
risk NN 1_o
of IN 1_o
diabetes NNS 1_o
and CC 1_o
cardiovascular JJ N
disease NN N
. . N

This DT N
trial NN N
was VBD N
prospectively RB N
registered VBN N
at IN N
the DT N
Australian JJ 1_p
New NNP 1_p
Zealand NNP 1_p
Clinical NNP 1_p
Trials NNP N
Registry NNP N
as IN N
ACTRN12611000602921 NNP N
. . N

-DOCSTART- -X- O O

Exemestane NN 1_i
for IN N
breast-cancer JJ 1_p
prevention NN 1_p
in IN 1_p
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

BACKGROUND NNP N
Tamoxifen NNP N
and CC N
raloxifene NN N
have VBP N
limited VBN N
patient JJ N
acceptance NN N
for IN N
primary JJ N
prevention NN N
of IN N
breast NN N
cancer NN N
. . N

Aromatase NNP N
inhibitors NNS N
prevent VBP N
more JJR N
contralateral JJ N
breast NN N
cancers NNS N
and CC N
cause NN N
fewer JJR N
side NN N
effects NNS N
than IN N
tamoxifen NN N
in IN N
patients NNS 1_p
with IN 1_p
early-stage JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
trial NN N
of IN N
exemestane NN 1_i
designed VBN N
to TO N
detect VB N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN N
in IN N
invasive JJ N
breast NN N
cancer NN N
, , N
eligible JJ 1_p
postmenopausal NN 1_p
women NNS 1_p
35 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
or CC 1_p
older JJR 1_p
had VBD 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
of IN 1_p
the DT 1_p
following JJ 1_p
risk NN 1_p
factors NNS 1_p
: : 1_p
60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
or CC 1_p
older JJR 1_p
; : 1_p
Gail NNP 1_p
5-year JJ 1_p
risk NN 1_p
score NN 1_p
greater JJR 1_p
than IN 1_p
1.66 CD 1_p
% NN 1_p
( ( 1_p
chances NNS 1_p
in IN 1_p
100 CD 1_p
of IN 1_p
invasive JJ 1_p
breast NN 1_p
cancer NN 1_p
developing VBG 1_p
within IN 1_p
5 CD 1_p
years NNS 1_p
) ) 1_p
; : 1_p
prior JJ 1_p
atypical JJ 1_p
ductal NN 1_p
or CC 1_p
lobular JJ 1_p
hyperplasia NN 1_p
or CC 1_p
lobular JJ 1_p
carcinoma NN 1_p
in IN 1_p
situ NN 1_p
; : 1_p
or CC 1_p
ductal JJ 1_p
carcinoma NN 1_p
in IN 1_p
situ NN 1_p
with IN 1_p
mastectomy NN 1_p
. . 1_p

Toxic NNP 1_o
effects NNS 1_o
and CC 1_o
health-related JJ 1_o
and CC 1_o
menopause-specific JJ 1_o
qualities NNS 1_o
of IN 1_o
life NN 1_o
were VBD N
measured VBN N
. . N

RESULTS VB N
A DT N
total NN 1_p
of IN 1_p
4560 CD 1_p
women NNS 1_p
for IN 1_p
whom WP 1_p
the DT 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
62.5 CD 1_p
years NNS 1_p
and CC 1_p
the DT 1_p
median JJ 1_o
Gail NNP 1_o
risk NN 1_o
score NN 1_o
was VBD 1_p
2.3 CD 1_p
% NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
exemestane NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

At IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
11 CD N
invasive JJ N
breast NN N
cancers NNS N
were VBD N
detected VBN N
in IN N
those DT N
given VBN N
exemestane NN 1_i
and CC N
in IN N
32 CD N
of IN N
those DT N
given VBN N
placebo NNS 1_i
, , N
with IN N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN 1_o
in IN 1_o
the DT 1_o
annual JJ 1_o
incidence NN 1_o
of IN 1_o
invasive JJ 1_o
breast NN 1_o
cancer NN 1_o
( ( N
0.19 CD N
% NN N
vs. FW N
0.55 CD N
% NN N
; : N
hazard CC N
ratio NN N
, , N
0.35 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.18 CD N
to TO N
0.70 CD N
; : N
P=0.002 NNP N
) ) N
. . N

The DT N
annual JJ 1_o
incidence NN 1_o
of IN 1_o
invasive JJ 1_o
plus CC 1_o
noninvasive JJ 1_o
( ( 1_o
ductal JJ 1_o
carcinoma NN 1_o
in IN 1_o
situ NN 1_o
) ) 1_o
breast NN 1_o
cancers NNS 1_o
was VBD N
0.35 CD N
% NN N
on IN N
exemestane NN N
and CC N
0.77 CD N
% NN N
on IN N
placebo NN 1_i
( ( N
hazard JJ N
ratio NN N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.79 CD N
; : N
P=0.004 NNP N
) ) N
. . N

Adverse JJ 1_o
events NNS 1_o
occurred VBD N
in IN N
88 CD N
% NN N
of IN N
the DT N
exemestane NN N
group NN N
and CC N
85 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
P=0.003 NNP N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
skeletal JJ 1_o
fractures NNS 1_o
, , 1_o
cardiovascular JJ 1_o
events NNS 1_o
, , 1_o
other JJ 1_o
cancers NNS 1_o
, , 1_o
or CC 1_o
treatment-related JJ 1_o
deaths NNS 1_o
. . 1_o

Minimal JJ N
quality-of-life JJ 1_o
differences NNS N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Exemestane NNP 1_i
significantly RB N
reduced VBD N
invasive JJ 1_p
breast NN 1_p
cancers NNS 1_p
in IN 1_p
postmenopausal JJ 1_p
women NNS 1_p
who WP 1_p
were VBD 1_p
at IN 1_p
moderately RB 1_p
increased VBN 1_p
risk NN 1_p
for IN 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

During IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
3 CD N
years NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
no DT N
serious JJ N
toxic NN N
effects NNS N
and CC N
only RB N
minimal JJ N
changes NNS N
in IN N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

( ( N
Funded VBN N
by IN N
Pfizer NNP N
and CC N
others NNS N
; : N
NCIC NNP N
CTG NNP N
MAP.3 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00083174 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
a DT N
CBT NNP 1_i
intervention NN 1_i
for IN N
anxiety NN 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
Asperger NNP 1_o
syndrome NN 1_o
. . 1_o

BACKGROUND IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
brief JJ 1_i
CBT NNP 1_i
intervention NN 1_i
for IN 1_i
anxiety NN 1_i
with IN N
children NNS 1_p
diagnosed VBN 1_p
with IN 1_p
Asperger NNP 1_p
syndrome NN 1_p
( ( 1_p
AS IN 1_p
) ) 1_p
. . 1_p

A DT N
second JJ N
interest NN N
was VBD N
to TO N
evaluate VB N
whether IN N
more RBR N
intensive JJ N
parent NN N
involvement NN N
would MD N
increase VB N
the DT N
child NN N
's POS N
ability NN N
to TO N
manage VB N
anxiety NN N
outside IN N
of IN N
the DT N
clinic JJ N
setting NN N
. . N

METHODS NNP N
Seventy-one JJ 1_p
children NNS 1_p
aged VBN 1_p
ten NNS 1_p
to TO 1_p
twelve VB 1_p
years NNS 1_p
were VBD 1_p
recruited VBN 1_p
to TO N
participate VB N
in IN N
the DT N
anxiety NN N
programme NN N
. . N

All DT 1_p
children NNS 1_p
were VBD 1_p
diagnosed VBN 1_p
with IN 1_p
AS NNP 1_p
and CC 1_p
the DT 1_p
presence NN 1_p
of IN 1_p
anxiety NN 1_p
symptoms NNS 1_p
was VBD N
accepted VBN N
on IN N
parent NN N
report NN N
via IN N
brief JJ N
interview NN N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
intervention NN 1_i
for IN 1_i
child NN 1_i
only RB 1_i
, , 1_i
intervention NN 1_i
for IN 1_i
child NN 1_i
and CC 1_i
parent NN 1_i
, , 1_i
wait-list JJ 1_i
control NN 1_i
. . 1_i

RESULTS VB N
The DT N
two CD N
intervention NN N
groups NNS N
demonstrated VBD N
significant JJ N
decreases NNS N
in IN N
parent-reported JJ 1_o
anxiety NN 1_o
symptoms NNS 1_o
at IN N
follow-up JJ N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
child NN N
's POS N
ability NN N
to TO N
generate VB N
positive JJ N
strategies NNS N
in IN N
an DT N
anxiety-provoking JJ N
situation NN N
. . N

There EX N
were VBD N
a DT N
number NN N
of IN N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
interventions NNS N
to TO N
suggest VB N
parent NN N
involvement NN N
as IN N
beneficial JJ N
. . N

CONCLUSIONS VB N
The DT N
sample NN N
of IN N
children NNS N
with IN N
AS NNP N
in IN N
this DT N
study NN N
presented VBD N
with IN N
a DT N
profile NN N
of IN N
anxiety NN N
similar JJ N
to TO N
a DT N
sample NN N
of IN N
clinically RB N
diagnosed VBN N
anxious JJ N
children NNS N
. . N

The DT N
intervention NN N
was VBD N
endorsed VBN N
by IN N
parents NNS N
as IN N
a DT N
useful JJ N
programme NN N
for IN N
children NNS 1_p
diagnosed VBN 1_p
with IN 1_p
Asperger NNP 1_p
syndrome NN 1_p
and CC 1_p
exhibiting VBG 1_p
anxiety NN 1_p
symptoms NNS 1_p
, , N
and CC N
active JJ N
parent NN N
involvement NN N
enhanced VBD N
the DT N
usefulness NN N
of IN N
the DT N
programme NN N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
and CC N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
resistive JJ 1_i
exercise NN 1_i
on IN N
skeletal JJ N
muscle NN N
in IN N
marrow NN 1_p
transplant NN 1_p
recipients NNS 1_p
receiving VBG 1_p
total JJ 1_p
parenteral JJ 1_p
nutrition NN 1_p
. . 1_p

Skeletal JJ 1_o
muscle NN 1_o
protein NN 1_o
loss NN 1_o
occurs VBZ N
during IN N
marrow JJ N
transplantation NN N
despite IN N
total JJ N
parenteral JJ N
nutrition NN N
. . N

To TO N
determine VB N
if IN N
muscle NN 1_o
atrophy NN 1_o
could MD N
be VB N
minimized VBN N
with IN N
exercise NN 1_i
therapy NN 1_i
, , N
30 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
marrow JJ 1_p
transplantation NN 1_p
for IN 1_p
acute NN 1_p
leukemia NN 1_p
completed VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
receive VB N
: : N
( ( N
1 CD N
) ) N
no DT 1_i
therapy NN 1_i
( ( 1_i
controls NNS 1_i
) ) 1_i
, , 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
physical JJ 1_i
therapy NN 1_i
thrice NN 1_i
weekly RB 1_i
( ( 1_i
PT3 NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
physical JJ 1_i
therapy NN 1_i
five CD 1_i
times NNS 1_i
weekly JJ 1_i
( ( N
PT5 NNP N
) ) N
. . N

Patients NNS N
were VBD N
studied VBN N
through IN N
35 CD N
days NNS N
posttransplant NN N
. . N

Muscle NNP 1_o
protein NN 1_o
status NN 1_o
and CC 1_o
turnover NN 1_o
was VBD N
assessed VBN N
by IN N
weekly JJ 1_o
nitrogen NN 1_o
balance NN 1_o
, , 1_o
and CC 1_o
creatinine NN 1_o
and CC 1_o
3-methylhistidine JJ 1_o
excretion NN 1_o
. . 1_o

Results NNS N
favored VBD N
a DT N
muscle NN N
protein-sparing JJ N
effect NN N
of IN N
exercise NN 1_i
, , N
as IN N
a DT N
significant JJ N
decrease NN N
in IN N
creatinine JJ 1_o
excretion NN 1_o
in IN N
controls NNS N
only RB N
suggested VBD N
muscle NN 1_o
protein NN 1_o
loss NN 1_o
associated VBN N
with IN N
inactivity NN N
. . N

Changes NNS N
in IN N
arm NN 1_o
muscle NN 1_o
area NN 1_o
correlated VBN N
with IN N
energy NN N
, , N
but CC N
not RB N
protein JJ N
intake NN N
. . N

Large JJ N
individual JJ N
variation NN N
, , N
inadequate JJ N
nutritional JJ N
support NN N
and CC N
differences NNS N
in IN N
admission NN N
arm NN N
muscle NN N
area NN N
may MD N
have VB N
clouded VBN N
these DT N
results NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
digoxin NN 1_i
on IN N
muscle NN N
reflexes NNS N
in IN N
normal JJ 1_p
humans NNS 1_p
. . 1_p

Blockade NNP N
of IN N
the DT N
skeletal JJ N
muscle NN N
Na NNP N
( ( N
+ NNP N
) ) N
-K NN N
( ( N
+ NNP N
) ) N
-ATPase NN N
pump NN N
by IN N
digoxin NN 1_i
could MD N
result VB N
in IN N
a DT N
more RBR N
marked JJ N
hyperkaliema NN N
during IN N
a DT N
forearm JJ N
exercise NN N
, , N
which WDT N
in IN N
turn NN N
could MD N
stimulate VB N
the DT N
mechano- NN N
and CC N
metaboreceptors NNS N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
, , N
and CC N
cross-over-design NN N
study NN N
, , N
we PRP N
measured VBD N
mean JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
MBP NNP 1_o
) ) 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
, , 1_o
ventilation NN 1_o
( ( 1_o
V NNP 1_o
( ( 1_o
E NNP 1_o
) ) 1_o
) ) 1_o
, , 1_o
oxygen JJ 1_o
saturation NN 1_o
( ( 1_o
SpO NNP 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
) ) 1_o
, , 1_o
muscle FW 1_o
sympathetic JJ 1_o
nerve NN 1_o
activity NN 1_o
( ( 1_o
MSNA NNP 1_o
) ) 1_o
, , 1_o
venous JJ 1_o
plasma NN 1_o
potassium NN 1_o
and CC 1_o
lactic JJ 1_o
acid NN 1_o
during IN 1_o
dynamic JJ 1_o
handgrip NN 1_o
exercises NNS 1_o
, , 1_o
and CC 1_o
local JJ 1_o
circulatory NN 1_o
arrest NN 1_o
in IN N
11 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

Digoxin NNP 1_i
enhanced VBD N
MBP NNP 1_o
during IN N
exercise NN N
but CC N
not RB N
during IN N
the DT N
post-handgrip JJ N
ischemia NN N
and CC N
had VBD N
no DT N
effect NN N
on IN N
HR NNP 1_o
, , 1_o
V NNP 1_o
( ( 1_o
E NNP 1_o
) ) 1_o
, , 1_o
SpO NNP 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
, , 1_o
and CC 1_o
MSNA NNP 1_o
. . 1_o

Venous NNP 1_o
plasma JJ 1_o
potassium NN 1_o
and CC 1_o
lactic JJ 1_o
acid NN 1_o
were VBD N
also RB N
not RB N
affected VBN N
by IN N
digoxin-induced JJ 1_i
skeletal JJ N
muscle NN N
Na NNP N
( ( N
+ NNP N
) ) N
-K NN N
( ( N
+ NNP N
) ) N
-ATPase NN N
blockade NN N
. . N

We PRP N
conclude VBP N
that IN N
digoxin NN 1_i
increased VBD N
MBP NNP N
during IN N
dynamic JJ N
exercise NN N
in IN N
healthy JJ 1_p
humans NNS 1_p
, , N
independently RB N
of IN N
changes NNS N
in IN N
potassium NN N
and CC N
lactic JJ N
acid NN N
. . N

A DT N
modest JJ N
direct JJ N
sensitization NN N
of IN N
the DT N
muscle NN N
mechanoreceptors NNS N
is VBZ N
unlikely JJ N
and CC N
other JJ N
mechanisms NNS N
, , N
independent JJ N
of IN N
muscle NN N
reflexes NNS N
and CC N
related VBN N
to TO N
the DT N
inotropic JJ N
effects NNS N
of IN N
digoxin NN 1_i
, , N
might MD N
be VB N
implicated VBN N
. . N

-DOCSTART- -X- O O

A DT N
cognitive-behavioral JJ 1_i
intervention NN 1_i
for IN N
emotion NN N
regulation NN N
in IN N
adults NNS 1_p
with IN 1_p
high-functioning JJ 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Adults NNP 1_p
with IN 1_p
high-functioning JJ 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
have VBP 1_p
difficulties NNS 1_p
in IN 1_p
social JJ 1_p
communication NN 1_p
; : 1_p
thus RB N
, , N
these DT N
individuals NNS N
have VBP N
trouble NN N
understanding VBG N
the DT N
mental JJ N
states NNS N
of IN N
others NNS N
. . N

Recent JJ N
research NN N
also RB N
suggests VBZ N
that IN N
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
are VBP N
unable JJ N
to TO N
understand VB N
their PRP$ N
own JJ N
mental JJ N
states NNS N
, , N
which WDT N
could MD N
lead VB N
to TO N
difficulties NNS N
in IN N
emotion-regulation NN N
. . N

Some DT N
studies NNS N
have VBP N
reported VBN N
the DT N
efficacy NN N
of IN N
cognitive-behavioral JJ 1_i
therapy NN 1_i
( ( 1_i
CBT NNP 1_i
) ) 1_i
in IN N
improving VBG N
emotion-regulation NN N
among IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

The DT N
current JJ N
study NN N
will MD N
investigate VB N
the DT N
efficacy NN N
of IN N
group-based JJ N
CBT NNP N
for IN N
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

METHODS/DESIGN NNP N
The DT N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
waitlist NN N
controlled VBD N
, , N
single-blinded JJ N
trial NN N
. . N

The DT 1_p
participants NNS 1_p
will MD 1_p
be VB 1_p
60 CD 1_p
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
; : 1_p
30 CD 1_p
will MD 1_p
be VB 1_p
assigned VBN 1_p
to TO 1_p
a DT 1_p
CBT NNP 1_i
group NN 1_p
and CC 1_p
30 CD 1_p
to TO 1_p
a DT 1_p
waitlist NN 1_i
control NN 1_i
group NN 1_i
. . 1_i

Primary NNP N
outcome JJ N
measures NNS N
are VBP N
the DT N
20-item JJ 1_o
Toronto NNP 1_o
Alexithymia NNP 1_o
Scale NNP 1_o
, , 1_o
the DT 1_o
Coping NNP 1_o
Inventory NNP 1_o
for IN 1_o
Stressful NNP 1_o
Situations NNP 1_o
, , 1_o
the DT 1_o
Motion NNP 1_o
Picture NNP 1_o
Mind-Reading NNP 1_o
task NN 1_o
, , 1_o
and CC 1_o
an DT 1_o
ASD NNP 1_o
questionnaire NN 1_o
. . 1_o

The DT N
secondary JJ N
outcome NN N
measures NNS N
are VBP N
the DT N
Center NNP 1_o
for IN 1_o
Epidemiological NNP 1_o
Studies NNPS 1_o
Depression NNP 1_o
Scale NNP 1_o
, , 1_o
the DT 1_o
World NNP 1_o
Health NNP 1_o
Organization NNP 1_o
Quality NNP 1_o
of IN 1_o
Life NNP 1_o
Scale NNP 1_o
26-item JJ 1_o
version NN 1_o
, , 1_o
the DT 1_o
Global NNP 1_o
Assessment NNP 1_o
of IN 1_o
Functioning NNP 1_o
, , 1_o
State-trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
, , 1_o
Social NNP 1_o
Phobia NNP 1_o
and CC 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
, , 1_o
and CC 1_o
Liebowitz NNP 1_o
Social NNP 1_o
Anxiety NNP 1_o
Scale NNP 1_o
. . 1_o

All DT N
will MD N
be VB N
administered VBN N
during IN N
the DT N
pre- JJ N
and CC N
post-intervention NN N
, , N
and CC N
12 CD N
week NN N
follow-up JJ N
periods NNS N
. . N

The DT N
CBT NNP N
group NN N
will MD N
receive VB N
group NN N
therapy NN N
over IN N
an DT N
8 CD N
week NN N
period NN N
( ( N
one CD N
session NN N
per IN N
week NN N
) ) N
with IN N
each DT N
session NN N
lasting VBG N
approximately RB N
100 CD N
minutes NNS N
. . N

Group NNP N
therapy NN N
will MD N
consist VB N
of IN N
four CD N
or CC N
five CD N
adults NNS N
with IN N
ASD NNP N
and CC N
two CD N
psychologists NNS N
. . N

We PRP N
will MD N
be VB N
using VBG N
visual JJ N
materials NNS N
for IN N
this DT N
program NN N
, , N
mainly RB N
the DT N
Cognitive NNP N
Affective NNP N
Training NNP N
kit NN N
. . N

DISCUSSION NNP N
This DT N
trial NN N
will MD N
hopefully RB N
indicate VB N
the DT N
efficacy NN N
of IN N
group-based JJ N
CBT NNP N
for IN N
adults NNS N
with IN N
high- JJ N
functioning NN N
ASD NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
This DT N
trial NN N
was VBD N
registered VBN N
in IN N
The DT N
University NNP N
Hospital NNP N
Medical NNP N
Information NNP N
Network NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
No NNP N
. . N

UMIN000006236 NNP N
. . N

-DOCSTART- -X- O O

No DT N
gains NNS N
in IN N
efficacy NN 1_o
observed VBN N
by IN N
adding VBG N
gemcitabine NN 1_i
to TO 1_i
adjuvant VB 1_i
therapy NN 1_i
for IN N
lymph JJ 1_p
node-positive JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ 1_i
enzyme NN 1_i
inhibitor NN 1_i
imidapril NN 1_i
on IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

This DT N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
early JJ N
treatment NN N
with IN N
angiotensin-converting JJ 1_i
enzyme NN 1_i
( ( 1_i
ACE NNP 1_i
) ) 1_i
inhibitors NNS 1_i
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
is VBZ N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ 1_o
function NN 1_o
, , N
as RB N
well RB N
as IN N
left VBN 1_o
ventricular JJ 1_o
function NN 1_o
. . 1_o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS N
of IN N
plasma NN 1_o
plasminogen NN 1_o
activator NN 1_o
inhibitor NN 1_o
( ( 1_o
PAI NNP 1_o
) ) 1_o
activity NN 1_o
and CC N
serum JJ 1_o
ACE NNP 1_o
activity NN 1_o
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD 1_p
patients NNS 1_p
with IN 1_p
AMI NNP 1_p
within IN 1_p
12 CD 1_p
hours NNS 1_p
after IN 1_p
the DT 1_p
onset NN 1_p
of IN 1_p
the DT 1_p
symptom NN 1_p
and CC 1_p
who WP 1_p
randomly VBP 1_p
received VBN 1_p
early JJ 1_p
treatment NN 1_p
with IN 1_p
either CC 1_p
the DT 1_p
ACE NNP 1_i
inhibitor NN 1_i
imidapril NN 1_i
or CC 1_i
a DT 1_i
placebo NN 1_i
( ( 1_p
20 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
imidapril NN 1_p
group NN 1_p
and CC 1_p
20 CD 1_p
in IN 1_p
the DT 1_p
placebo NN 1_p
group NN 1_p
) ) 1_p
. . 1_p

The DT N
levels NNS 1_o
of IN 1_o
serum JJ 1_o
ACE NNP 1_o
activity NN 1_o
in IN N
the DT N
imidapril NN 1_i
group NN N
decreased VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
8 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN 1_i
, , N
and CC N
the DT N
levels NNS N
24 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
3.6 CD N
+/- JJ N
0.6 CD N
IU/L NNP N
vs VBD N
7.4 CD N
+/- JJ N
0.8 CD N
IU/L NNP N
; : N
p VBZ N
< $ N
0.001 CD N
) ) N
. . N

The DT N
plasma JJ 1_o
PAI NNP 1_o
activity NN 1_o
increased VBD N
gradually RB N
to TO N
peak VB N
levels NNS N
16 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN N
and CC N
placebo NN N
. . N

The DT N
levels NNS N
in IN N
the DT N
placebo NN N
group NN N
decreased VBD N
gradually RB N
but CC N
remained VBD N
high JJ N
during IN N
the DT N
study NN N
period NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS 1_o
of IN 1_o
PAI NNP 1_o
activity NN 1_o
in IN N
the DT N
imidapril NN 1_i
group NN N
decreased VBD N
rapidly RB N
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
. . N

The DT N
levels NNS 1_o
of IN 1_o
left JJ 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN N
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
imidapril NN 1_i
, , N
an DT N
ACE NNP N
inhibitor NN N
, , N
might MD N
be VB N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ 1_o
function NN 1_o
and CC N
left VBD 1_o
ventricular JJ 1_o
function NN 1_o
in IN N
the DT N
acute JJ N
phase NN N
of IN N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O

Immune NNP 1_o
status NN 1_o
of IN 1_p
infants NNS 1_p
fed VBN 1_p
soy-based JJ 1_i
formulas NNS 1_i
with IN 1_p
or CC 1_p
without IN 1_p
added JJ 1_i
nucleotides NNS 1_i
for IN 1_p
1 CD 1_p
year NN 1_p
: : 1_p
part NN N
2 CD N
: : N
immune NN N
cell NN N
populations NNS N
. . N

BACKGROUND NNP N
Infants NNPS 1_p
fed VBD 1_p
a DT 1_p
soy JJ 1_i
protein NN 1_i
isolate-based JJ 1_i
formula NN 1_i
have VBP N
immunization NN 1_o
responses NNS 1_o
similar JJ N
to TO N
breast-fed JJ N
infants NNS N
. . N

However RB N
, , N
cellular JJ 1_o
aspects NNS 1_o
of IN 1_o
the DT 1_o
immunologic JJ 1_o
development NN 1_o
of IN N
soy-fed JJ 1_p
infants NNS 1_p
have VBP N
not RB N
been VBN N
studied VBN N
extensively RB N
. . N

Nucleotides NNP 1_i
added VBD N
to TO N
milk-based JJ N
formula NN N
benefit NN N
infant NN N
immune NN N
status NN N
, , N
but CC N
reports NNS N
of IN N
the DT N
immunologic JJ 1_o
effects NNS 1_o
of IN N
adding VBG N
nucleotides NNS 1_i
to TO N
soy-based JJ 1_i
formula NN 1_i
are VBP N
not RB N
available JJ N
. . N

This DT N
study NN N
examines VBZ N
immune RB 1_o
cell JJ 1_o
populations NNS 1_o
of IN N
infants NNS 1_p
fed VBN 1_p
soy JJ 1_i
protein NN 1_i
isolate NN 1_i
formulas NNS 1_i
with IN 1_p
and CC 1_p
without IN 1_p
added VBN 1_p
nucleotides NNS 1_i
for IN 1_p
1 CD 1_p
year NN 1_p
. . 1_p

METHODS NNP N
Newborn NNP 1_p
, , 1_p
term NN 1_p
infants NNS 1_p
studied VBN 1_p
in IN 1_p
a DT 1_p
masked JJ 1_p
12-month JJ 1_p
feeding VBG 1_p
trial NN 1_p
were VBD N
assigned VBN 1_i
randomly RB 1_i
to TO 1_i
soy VB 1_i
formula NN 1_i
groups NNS 1_i
with IN 1_i
and CC 1_i
without IN 1_i
added VBN 1_i
nucleotides NNS 1_i
( ( 1_i
n JJ 1_i
= NN 1_i
94 CD 1_i
, , 1_i
n RB 1_i
= VBZ 1_i
92 CD 1_i
) ) 1_i
. . 1_i

A DT N
nonrandomized JJ 1_p
human JJ 1_i
milk/formula-fed JJ 1_i
cohort NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
81 CD 1_i
) ) 1_i
, , 1_i
was VBD 1_i
concurrently RB N
enrolled VBN N
. . N

Blood NN 1_i
samples NNS 1_i
were VBD 1_i
collected VBN 1_i
at IN 1_i
6 CD 1_i
, , 1_i
7 CD 1_i
, , 1_i
and CC 1_i
12 CD 1_i
months NNS 1_i
. . 1_i

Thirty-two NNP 1_o
immune NN 1_o
cell NN 1_o
populations NNS 1_o
were VBD N
characterized VBN N
using VBG N
three-color JJ N
flow JJ N
cytometry NN N
. . N

Cellular JJ N
markers NNS N
were VBD N
chosen VBN N
to TO N
assess VB N
general JJ 1_o
pediatric JJ 1_o
immune NN 1_o
status NN 1_o
, , 1_o
emphasizing VBG 1_o
maturation NN 1_o
and CC 1_o
activation NN 1_o
of IN 1_o
B NNP 1_o
, , 1_o
T NNP 1_o
, , 1_o
and CC 1_o
NK NNP 1_o
lymphocytes NNS 1_o
. . 1_o

RESULTS NNP N
All NNP N
cell VBP N
populations NNS N
, , N
number NN N
and CC N
percentages NNS N
, , N
were VBD N
within IN N
age-related JJ N
normal JJ N
ranges NNS N
. . N

The DT N
only JJ N
significant JJ N
difference NN N
found VBD N
between IN N
soy JJ 1_i
formula NN 1_i
and CC 1_p
human JJ 1_i
milk/formula-fed JJ 1_i
infants NNS 1_p
was VBD N
the DT N
percentage NN 1_o
of IN 1_o
CD57 NNP 1_o
+ NNP 1_o
NK NNP 1_o
T NNP 1_o
cells NNS 1_o
at IN N
12 CD N
months NNS N
( ( N
human JJ N
milk/formula NN N
> NNP N
soy NN N
formula NN N
, , N
P NNP N
= NNP N
0.034 CD N
) ) N
. . N

There EX N
were VBD N
significant JJ N
differences NNS N
at IN N
some DT N
time NN N
points NNS N
between IN N
human JJ N
milk/formula-fed JJ N
and CC N
nucleotide-supplemented JJ 1_i
soy NN N
formula-fed JJ N
infants NNS N
in IN N
populations NNS 1_o
of IN 1_o
lymphocytes NNS 1_o
, , 1_o
eosinophils NNS 1_o
, , 1_o
total JJ 1_o
T NNP 1_o
, , 1_o
helper NN 1_o
T NNP 1_o
, , 1_o
naive JJ 1_o
helper NN 1_o
, , 1_o
memory/effector NN 1_o
helper NN 1_o
, , 1_o
CD57 NNP 1_o
- : 1_o
T NN 1_o
, , 1_o
and CC 1_o
CD11b NNP 1_o
+ NNP 1_o
CD8 NNP 1_o
+ NNP 1_o
NK NNP 1_o
cells NNS 1_o
. . 1_o

None NN N
of IN N
the DT N
cell NN 1_o
populations NNS 1_o
differed VBD N
between IN N
infants NNS 1_p
fed VBN 1_p
soy JJ 1_p
formula NN 1_p
versus NN N
soy NN N
plus CC N
nucleotides NNS 1_i
. . 1_i

CONCLUSIONS NNP N
Infants NNPS 1_p
fed VBD 1_p
this DT 1_p
commercial JJ 1_p
soy NN 1_p
formula NN 1_p
demonstrated VBD N
immune JJ 1_o
cell NN 1_o
status NN 1_o
similar JJ N
to TO N
human JJ 1_p
milk/formula-fed JJ 1_p
infants NNS 1_p
, , N
consistent JJ N
with IN N
normal JJ N
immune JJ 1_o
system NN 1_o
development NN 1_o
. . 1_o

The DT N
addition NN N
of IN N
nucleotides NNS 1_i
to TO N
soy VB N
formula NN N
did VBD N
not RB N
significantly RB N
change VBP N
specific JJ N
individual JJ N
immune NN 1_o
cell NN 1_o
populations NNS 1_o
but CC N
tended VBD N
to TO N
increase VB N
numbers NNS 1_o
and CC 1_o
percentages NNS 1_o
of IN 1_o
T NNP 1_o
cells NNS 1_o
and CC N
decreased JJ N
numbers NNS 1_o
and CC 1_o
percentages NNS 1_o
of IN 1_o
NK NNP 1_o
cells NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Multifaceted VBN 1_i
support NN 1_i
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
diabetes NNS N
care NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
in IN N
general JJ N
practice NN N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
multifaceted VBN 1_i
intervention NN 1_i
to TO N
improve VB N
the DT N
clinical JJ N
decision NN N
making NN N
of IN N
general JJ 1_p
practitioners NNS 1_p
( ( 1_p
GPs NNP 1_p
) ) 1_p
for IN 1_p
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
. . 1_p

To TO N
identify VB N
practice NN N
characteristics NNS N
which WDT N
predict VBP N
success NN N
. . N

METHODS NNP N
Cluster NNP 1_p
randomized VBD 1_p
controlled VBN 1_p
trial NN 1_p
with IN 1_p
124 CD 1_p
practices NNS 1_p
and CC 1_p
185 CD 1_p
GPs NNP 1_p
in IN 1_p
The DT 1_p
Netherlands NNP 1_p
. . 1_p

The DT 1_i
intervention NN 1_i
group NN 1_i
received VBD 1_i
feedback JJ 1_i
reports NNS 1_i
and CC 1_i
support NN 1_i
from IN 1_i
a DT 1_i
facilitator NN 1_i
; : 1_i
the DT 1_i
control NN 1_i
group NN 1_i
received VBD 1_i
no DT 1_i
special JJ 1_i
attention NN 1_i
. . 1_i

Outcome JJ 1_i
measures NNS 1_i
were VBD 1_i
the DT 1_i
compliance NN 1_o
rates NNS 1_o
with IN 1_o
evidence-based JJ 1_o
recommendations NNS 1_o
pertaining VBG 1_o
to TO 1_o
discussion NN 1_o
of IN 1_o
body NN 1_o
weight NN 1_o
control NN 1_o
, , 1_o
discussion NN 1_o
of IN 1_o
problems NNS 1_o
with IN 1_o
medication NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
measurement NN 1_o
, , 1_o
foot NN 1_o
examination NN 1_o
, , 1_o
eye NN 1_o
examination NN 1_o
, , 1_o
initiating VBG 1_o
anti-diabetic JJ 1_o
medication NN 1_o
or CC 1_o
increasing VBG 1_o
the DT 1_o
dosage NN 1_o
in IN 1_o
cases NNS 1_o
of IN 1_o
uncontrolled JJ 1_o
blood NN 1_o
glucose NN 1_o
, , 1_o
and CC 1_o
scheduling VBG 1_o
a DT 1_o
follow-up JJ 1_o
appointment NN 1_o
. . 1_o

RESULTS VB N
The DT N
GPs NNP N
reported VBD N
on IN N
their PRP$ N
clinical JJ N
decision NN N
making NN N
in IN N
1410 CD 1_p
consultations NNS 1_p
with IN 1_p
Type NNP 1_p
2 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
at IN 1_p
baseline NN 1_p
and CC 1_p
1449 CD 1_p
consultations NNS 1_p
after IN N
the DT N
intervention NN N
period NN N
. . N

The DT N
intervention NN N
resulted VBD N
in IN N
statistically RB N
significant JJ N
improvement NN N
for IN N
two CD N
of IN N
the DT N
seven CD N
outcome JJ N
measures NNS N
: : N
foot NN 1_o
examination NN 1_o
( ( N
odds NNS N
ratio VBP N
1.68 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
1.19-2.39 JJ N
) ) N
and CC N
eye NN N
examination NN 1_o
( ( N
1.52 CD N
; : N
1.07-2.16 JJ N
) ) N
. . N

Discussion NN 1_o
of IN 1_o
problems NNS 1_o
with IN 1_o
medication NN 1_o
showed VBD N
a DT N
near JJ N
significant JJ N
trend NN N
towards NNS N
increased VBD N
benefit NN N
for IN N
the DT N
intervention NN N
group NN N
( ( N
1.52 CD N
; : N
0.99-2.32 JJ N
) ) N
. . N

Practice NNP 1_o
characteristics NNS 1_o
were VBD N
not RB N
found VBN N
to TO N
be VB N
related VBN N
to TO N
the DT N
success NN N
of IN N
the DT N
intervention NN N
. . N

CONCLUSIONS NNP N
Feedback NNP N
reports NNS N
with IN N
support NN N
from IN N
facilitators NNS N
appear VBP N
to TO N
increase VB N
rates NNS N
of IN N
foot NN 1_o
examination NN 1_o
and CC 1_o
eye NN 1_o
examination NN 1_o
in IN N
general JJ N
practice NN N
. . N

Alternative JJ N
interventions NNS N
should MD N
be VB N
explored VBN N
to TO N
improve VB N
the DT N
pursuit NN N
of IN N
metabolic JJ N
control NN N
by IN N
GPs NNP N
. . N

-DOCSTART- -X- O O

Ascorbic NNP 1_i
acid NN 1_i
and CC N
performance NN 1_o
in IN N
man NN N
. . N

Effects NNS N
on IN N
performance NN 1_o
of IN N
1 CD N
, , N
2 CD N
and CC N
4 CD N
g NN N
ascorbic JJ 1_i
acid NN 1_i
were VBD N
studied VBN N
from IN N
0.5-5.5 JJ N
h NN N
after IN N
ingestion NN N
in IN N
six CD 1_p
healthy JJ 1_p
females NNS 1_p
. . 1_p

Diazepam NNP 1_i
( ( 1_i
5 CD 1_i
mg NN 1_i
) ) 1_i
was VBD 1_i
included VBN 1_i
as IN 1_i
an DT 1_i
active JJ 1_i
control NN 1_i
, , N
and CC N
it PRP N
impaired VBD N
digit JJ 1_o
symbol NN 1_o
substitution NN 1_o
, , 1_o
visuomotor NN 1_o
coordination NN 1_o
and CC 1_o
complex JJ 1_o
reaction NN 1_o
time NN 1_o
. . 1_o

There EX N
were VBD N
no DT N
effects NNS N
of IN N
any DT N
dose NN N
of IN N
ascorbic JJ 1_i
acid NN 1_i
on IN N
performance NN 1_o
. . 1_o

-DOCSTART- -X- O O

Laser NNP 1_i
conization NN 1_i
versus NN N
cold JJ 1_i
knife NN 1_i
conization NN 1_i
. . 1_i

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
compares VBZ N
, , N
for IN N
the DT N
first JJ N
time NN N
, , N
measured VBN N
blood NN N
loss NN N
at IN N
conization NN N
and CC N
within IN N
24 CD N
hours NNS N
after IN N
using VBG N
either CC N
the DT N
cold JJ 1_i
knife NN 1_i
technique NN 1_i
or CC 1_i
the DT 1_i
carbon NN 1_i
dioxide NN 1_i
laser NN 1_i
scalpel NN 1_i
. . 1_i

One CD 1_p
hundred CD 1_p
and CC 1_p
ten VB 1_p
consecutive JJ 1_p
patients NNS 1_p
were VBD 1_p
evaluated VBN 1_p
. . 1_p

The DT N
median JJ 1_o
blood NN 1_o
loss NN 1_o
in IN N
the DT N
laser NN N
group NN N
of IN N
55 CD N
patients NNS N
was VBD N
4.6 CD N
milliliters NNS N
at IN N
, , N
and CC N
within IN N
, , N
24 CD N
hours NNS N
after IN N
operation NN N
compared VBN N
with IN N
30.1 CD N
milliliters NNS N
in IN N
the DT N
cold JJ 1_i
knife NN 1_i
group NN N
of IN N
55 CD N
patients NNS N
. . N

More RBR N
important JJ N
, , N
however RB N
, , N
is VBZ N
that IN N
the DT N
corresponding JJ N
figures NNS N
for IN N
the DT N
range NN 1_o
of IN 1_o
bleeding VBG 1_o
were VBD N
0.4 CD N
to TO N
155.4 CD N
milliliters NNS N
and CC N
5.6 CD N
to TO N
1,570.9 CD N
milliliters NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN 1_o
rate NN 1_o
for IN 1_o
bleeding VBG 1_o
complications NNS 1_o
requiring VBG 1_o
surgical JJ 1_o
intervention NN 1_o
was VBD N
1.8 CD N
per IN N
cet NN N
for IN N
the DT N
laser NN N
group NN N
and CC N
14.6 CD N
per IN N
cent NN N
for IN N
the DT N
cold JJ 1_i
knife NN 1_i
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
, , N
p RB N
less JJR N
than IN N
0.015 CD N
-- : N
Fischer NNP N
's POS N
exact JJ N
test NN N
. . N

Conization NN N
for IN N
treatment NN N
of IN N
premalignant JJ 1_p
changes NNS 1_p
of IN 1_p
the DT 1_p
cervix NN 1_p
uteri NN 1_p
will MD N
probably RB N
remain VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
some DT N
time NN N
to TO N
come VB N
. . N

It PRP N
is VBZ N
our PRP$ N
opinion NN N
that IN N
, , N
in IN N
the DT N
future NN N
, , N
laser JJR 1_i
conization NN N
will MD N
replace VB N
cold JJ 1_i
knife NN 1_i
conization NN N
. . N

-DOCSTART- -X- O O

A DT N
Randomized NNP N
Controlled NNP N
Trial NNP N
to TO N
Improve VB N
Social NNP N
Skills NNP N
in IN N
Young NNP 1_p
Adults NNP 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorder NNP 1_p
: : 1_p
The DT N
UCLA NNP 1_i
PEERS NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
Program NNP 1_i
. . 1_i

Research NNP N
suggests VBZ N
that IN N
impaired JJ N
social JJ N
skills NNS N
are VBP N
often RB N
the DT N
most RBS N
significant JJ N
challenge NN N
for IN N
those DT N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
yet RB N
few JJ N
evidence-based JJ 1_o
social JJ 1_o
skills NNS 1_o
interventions NNS N
exist VBP N
for IN 1_p
adults NNS 1_p
on IN 1_p
the DT 1_p
spectrum NN 1_p
. . 1_p

This DT N
replication NN N
trial NN N
tested VBD N
the DT 1_o
effectiveness NN 1_o
of IN 1_i
PEERS NNP 1_i
, , 1_i
a DT 1_i
caregiver-assisted JJ 1_i
social JJ 1_i
skills NNS 1_i
program NN 1_i
for IN 1_p
high-functioning JJ 1_p
young JJ 1_p
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Using VBG N
a DT N
randomized VBN 1_p
controlled JJ 1_p
design NN 1_p
, , 1_p
22 CD 1_p
young JJ 1_p
adults NNS 1_p
18-24 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
a DT N
treatment NN 1_i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC 1_i
delayed VBN 1_i
treatment NN 1_i
control NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
group NN N
. . N

Results NNP N
revealed VBD N
that IN N
the DT N
treatment NN N
group NN N
improved VBD N
significantly RB N
in IN 1_o
overall JJ 1_o
social JJ 1_o
skills NNS 1_o
, , 1_o
frequency NN 1_o
of IN 1_o
social JJ 1_o
engagement NN 1_o
, , 1_o
and CC 1_o
social JJ 1_o
skills NNS 1_o
knowledge NN 1_o
, , 1_o
and CC N
significantly RB N
reduced VBN 1_o
ASD NNP 1_o
symptoms NNS 1_o
related VBN 1_o
to TO 1_o
social JJ 1_o
responsiveness NN 1_o
following VBG 1_o
PEERS NNP 1_o
. . 1_o

Most JJS N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
a DT N
16-week JJ N
follow-up JJ N
assessment NN N
with IN N
new JJ N
improvements NNS N
observed VBN N
. . N

-DOCSTART- -X- O O

Partial JJ N
depletion NN 1_o
of IN 1_o
tissue NN 1_o
factor NN 1_o
pathway NN 1_o
inhibitor NN 1_o
during IN N
subcutaneous JJ N
administration NN N
of IN N
unfractionated JJ N
heparin NN 1_i
, , N
but CC N
not RB N
with IN N
two CD N
low JJ N
molecular JJ N
weight NN N
heparins NNS N
. . N

Tissue NNP N
factor NN N
pathway NN N
inhibitor NN N
( ( N
TFPI NNP N
) ) N
is VBZ N
released VBN N
to TO N
circulating VBG N
blood NN N
after IN N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
and CC N
subcutaneous JJ N
( ( N
s.c. NN N
) ) N
injections NNS N
of IN N
heparins NNS N
, , N
and CC N
may MD N
thus RB N
contribute VB N
to TO N
the DT N
antithrombotic JJ N
effect NN N
of IN N
heparins NNS N
. . N

We PRP N
have VBP N
recently RB N
shown VBN N
that IN N
total JJ N
TFPI NNP 1_o
activity NN 1_o
, , 1_o
plasma VBP 1_o
free JJ 1_o
TFPI NNP 1_o
antigen NN 1_o
, , N
and CC N
heparin NN 1_o
releasable JJ 1_o
TFPI NNP 1_o
were VBD N
partially RB N
depleted VBN N
during IN N
repeated VBN N
and CC N
continuous JJ N
i.v NN N
. . N

infusion NN N
of IN N
unfractionated JJ 1_i
heparin NN 1_i
( ( N
UFH NNP N
) ) N
, , N
but CC N
not RB N
during IN N
s.c. JJ N
treatment NN N
with IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMWH NNP N
) ) N
. . N

The DT N
difference NN N
may MD N
be VB N
attributed VBN N
to TO N
a DT N
different JJ N
mode NN N
of IN N
action NN N
or CC N
the DT N
different JJ N
mode NN N
of IN N
administration NN N
. . N

In IN N
the DT N
present JJ N
randomized VBN N
cross-over NN N
study NN N
, , N
s.c. JJ N
administration NN N
of IN N
therapeutic JJ N
doses NNS N
of IN N
UFH NNP 1_i
was VBD N
compared VBN N
with IN N
s.c. JJ N
administration NN 1_i
of IN 1_i
two CD 1_i
LMWHs NNP 1_i
. . 1_i

12 CD 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
were VBD N
treated VBN N
for IN N
3 CD N
d NN N
with IN N
UFH NNP 1_i
, , N
250 CD N
U/kg NNP N
twice RB N
daily RB N
, , N
dalteparin NN 1_i
, , 1_i
200 CD 1_i
U/kg NNP 1_i
once RB 1_i
daily RB 1_i
, , 1_i
and CC 1_i
enoxaparin RB 1_i
, , N
1.5 CD N
mg/kg NN N
once RB N
daily JJ N
. . N

Six CD 1_p
participants NNS 1_p
were VBD N
also RB N
treated VBN N
with IN N
UFH NNP 1_i
, , N
300 CD N
U/kg NNP N
once RB N
daily RB N
. . N

On IN N
day NN N
5 CD N
a DT N
single JJ N
dose NN N
of IN N
either DT N
drug NN N
was VBD N
given VBN N
. . N

Peak NNP 1_o
levels NNS 1_o
of IN 1_o
total JJ 1_o
TFPI NNP 1_o
activity NN 1_o
and CC 1_o
free JJ 1_o
TFPI NNP 1_o
antigen NN 1_o
were VBD N
detected VBN N
1 CD N
h NN N
after IN N
injection NN N
, , N
whereas IN N
maximal JJ 1_o
prolongation NN 1_o
of IN 1_o
activated VBN 1_o
partial JJ 1_o
thromboplastin NN 1_o
time NN 1_o
( ( 1_o
APTT NNP 1_o
) ) 1_o
and CC 1_o
peak JJ 1_o
levels NNS 1_o
of IN 1_o
anti-factor JJ 1_o
Xa NNP 1_o
activity NN 1_o
and CC 1_o
anti-factor NN 1_o
IIa NNP 1_o
activity NN 1_o
were VBD N
detected VBN N
after IN N
4 CD N
h. NN N
On IN N
UFH NNP 1_i
administered VBD N
twice RB N
daily RB N
, , N
free JJ 1_o
TFPI NNP 1_o
antigen NN 1_o
decreased VBN N
by IN N
44 CD N
% NN N
from IN N
baseline JJ N
level NN N
before IN N
the DT N
first JJ N
injection NN N
on IN N
day NN N
1 CD N
to TO N
pre-injection NN N
level NN N
on IN N
day NN N
5 CD N
. . N

On IN N
UFH NNP 1_i
administered VBD N
once RB N
daily JJ N
, , N
basal JJ 1_o
free JJ 1_o
TFPI NNP 1_o
antigen NN 1_o
decreased VBN N
by IN N
50 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
27 CD N
% NN N
on IN N
day NN N
2 CD N
, , N
3 CD N
and CC N
5 CD N
respectively RB N
, , N
compared VBN N
with IN N
day NN N
1 CD N
. . N

Minimal JJ 1_o
depletion NN 1_o
of IN 1_o
TFPI NNP 1_o
was VBD N
detected VBN N
during IN N
treatment NN N
with IN N
LMWHs NNP N
. . N

The DT N
study NN N
demonstrates VBZ N
the DT N
different JJ N
modes NNS N
of IN N
action NN N
of IN N
LMWHs NNP 1_i
and CC N
UFH NNP 1_i
and CC N
may MD N
help VB N
to TO N
explain VB N
the DT N
superior JJ N
antithrombotic JJ N
efficacy NN N
of IN N
LMWHs NNP N
. . N

-DOCSTART- -X- O O

Oxygen NNP N
saturation NN N
targets NNS N
in IN N
infants NNS 1_p
with IN 1_p
bronchiolitis NN 1_p
( ( 1_p
BIDS NNP 1_p
) ) 1_p
: : 1_p
a DT N
double-blind NN N
, , N
randomised VBN N
, , N
equivalence JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
American JJ N
Academy NNP N
of IN N
Pediatrics NNP N
recommends VBZ N
a DT N
permissive JJ N
hypoxaemic JJ N
target NN N
for IN N
an DT N
oxygen NN 1_o
saturation NN 1_o
of IN N
90 CD N
% NN N
for IN N
children NNS N
with IN N
bronchiolitis NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
WHO NNP N
recommendations NNS N
for IN N
targets NNS N
in IN N
children NNS 1_p
with IN 1_p
lower JJR 1_p
respiratory NN 1_p
tract JJ 1_p
infections NNS 1_p
. . 1_p

No DT N
evidence NN N
exists VBZ N
to TO N
support VB N
this DT N
threshold NN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
whether IN N
the DT N
90 CD N
% NN N
or CC N
higher JJR N
target NN N
for IN N
management NN N
of IN N
oxygen NN 1_i
supplementation NN 1_i
was VBD N
equivalent JJ N
to TO N
a DT N
normoxic JJ N
94 CD N
% NN N
or CC N
higher JJR N
target NN N
for IN N
infants NNS N
admitted VBN N
to TO N
hospital VB N
with IN N
viral JJ N
bronchiolitis NN N
. . N

METHODS NNP N
We PRP N
did VBD N
a DT N
parallel-group NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
equivalence NN N
trial NN N
of IN N
infants NNS 1_p
aged VBN 1_p
6 CD 1_p
weeks NNS 1_p
to TO 1_p
12 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
physician-diagnosed JJ 1_p
bronchiolitis NN 1_p
newly RB 1_p
admitted VBN 1_p
into IN 1_p
eight CD 1_p
paediatric JJ 1_p
hospital NN 1_p
units NNS 1_p
in IN 1_p
the DT 1_p
UK NNP 1_p
( ( 1_p
the DT 1_p
Bronchiolitis NNP 1_p
of IN 1_p
Infancy NNP 1_p
Discharge NNP 1_p
Study NNP 1_p
[ NNP 1_p
BIDS NNP 1_p
] NNP 1_p
) ) 1_p
. . 1_p

A DT N
central JJ N
computer NN N
randomly RB N
allocated VBD N
( ( N
1:1 CD N
) ) N
infants NNS N
, , N
in IN N
varying VBG N
length NN N
blocks NNS N
of IN N
four CD N
and CC N
six CD N
and CC N
without IN N
stratification NN N
, , N
to TO N
be VB N
clipped VBN N
to TO N
standard VB 1_i
oximeters NNS 1_i
( ( N
patients NNS N
treated VBN N
with IN N
oxygen NN N
if IN N
pulse JJ N
oxygen NN N
saturation NN N
[ NNP N
SpO2 NNP N
] NNP N
< VBD N
94 CD N
% NN N
) ) N
or CC N
modified VBN 1_i
oximeters NNS 1_i
( ( N
displayed VB N
a DT N
measured JJ N
value NN N
of IN N
90 CD N
% NN N
as IN N
94 CD N
% NN N
, , N
therefore RB N
oxygen IN N
not RB N
given VBN N
until IN N
SpO2 NNP N
< VBD N
90 CD N
% NN N
) ) N
. . N

All DT N
parents NNS N
, , N
clinical JJ N
staff NN N
, , N
and CC N
outcome JJ N
assessors NNS N
were VBD N
masked VBN N
to TO N
allocation NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
time NN 1_o
to TO 1_o
resolution NN 1_o
of IN 1_o
cough NN 1_o
( ( N
prespecified JJ N
equivalence NN N
limits NNS N
of IN N
plus CC N
or CC N
minus CC N
2 CD N
days NNS N
) ) N
in IN N
the DT N
intention-to-treat JJ N
population NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ISRCTN NNP N
, , N
number NN N
ISRCTN28405428 NNP N
. . N

FINDINGS NNP N
Between NNP N
Oct NNP N
3 CD N
, , N
and CC N
March NNP N
30 CD N
, , N
2012 CD N
, , N
and CC N
Oct NNP N
1 CD N
, , N
and CC N
March NNP N
29 CD N
, , N
2013 CD N
, , N
we PRP N
randomly VBP N
assigned VBD N
308 CD 1_p
infants NNS 1_p
to TO N
standard VB N
oximeters NNS N
and CC N
307 CD N
infants NNS N
to TO N
modified JJ N
oximeters NNS N
. . N

Cough NNP 1_o
resolved VBN N
by IN N
15?0 CD N
days NNS N
( ( N
median JJ N
) ) N
in IN N
both DT N
groups NNS N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
-1 NN N
to TO N
2 CD N
) ) N
and CC N
so RB N
oxygen JJ N
thresholds NNS N
were VBD N
equivalent JJ N
. . N

We PRP N
recorded VBD N
35 CD 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
in IN N
32 CD N
infants NNS N
in IN N
the DT N
standard NN N
care NN N
group NN N
and CC N
25 CD 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
in IN N
24 CD N
infants NNS N
in IN N
the DT N
modified NNP N
care NN N
group NN N
. . N

In IN N
the DT N
standard NN N
care NN N
group NN N
, , N
eight CD N
infants NNS 1_o
transferred VBN 1_o
to TO 1_o
a DT 1_o
high-dependency NN 1_o
unit NN 1_o
, , 1_o
23 CD N
were VBD 1_o
readmitted VBN 1_o
, , 1_o
and CC N
one CD N
had VBD N
a DT N
prolonged JJ 1_o
hospital NN 1_o
stay NN 1_o
. . 1_o

In IN N
the DT N
modified NNP N
care NN N
group NN N
, , N
12 CD N
infants NNS N
were VBD N
transferred VBN N
to TO N
a DT N
high-dependency NN 1_o
unit NN 1_o
and CC N
12 CD N
were VBD 1_o
readmitted VBN 1_o
to TO 1_o
hospital NN 1_o
. . 1_o

Recorded VBN N
adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

INTERPRETATION NNP N
Management NNP N
of IN 1_p
infants NNS 1_p
with IN 1_p
bronchiolitis NN 1_p
to TO N
an DT N
oxygen NN N
saturation NN N
target NN N
of IN N
90 CD N
% NN N
or CC N
higher JJR N
is VBZ N
as IN N
safe JJ N
and CC N
clinically RB N
effective JJ N
as IN N
one CD N
of IN N
94 CD N
% NN N
or CC N
higher JJR N
. . N

Future JJ N
research NN N
should MD N
assess VB N
the DT N
benefits NNS N
and CC N
risks NNS N
of IN N
different JJ N
oxygen NN N
saturation NN N
targets NNS N
in IN N
acute JJ N
respiratory NN N
infection NN N
in IN N
older JJR N
children NNS N
, , N
particularly RB N
in IN N
developing VBG N
nations NNS N
where WRB N
resources NNS N
are VBP N
scarce JJ N
. . N

FUNDING NNP N
National NNP N
Institute NNP N
for IN N
Health NNP N
Research NNP N
, , N
Health NNP N
Technology NNP N
Assessment NNP N
programme NN N
. . N

-DOCSTART- -X- O O

Neridronate NNP 1_i
prevents NNS N
bone NN 1_o
loss NN 1_o
in IN N
patients NNS 1_p
receiving VBG 1_p
androgen JJ 1_i
deprivation NN 1_i
therapy NN 1_i
for IN 1_p
prostate NN 1_p
cancer NN 1_p
. . 1_p

UNLABELLED VBN N
Today NN N
, , N
androgen NN 1_i
deprivation NN 1_i
therapy NN 1_i
is VBZ N
a DT N
cornerstone NN N
of IN N
treatment NN N
for IN N
advanced JJ 1_p
prostate NN 1_p
cancer NN 1_p
, , N
although IN N
it PRP N
presents VBZ N
important JJ N
complications NNS N
such JJ N
as IN N
osteoporosis NN 1_o
. . 1_o

Neridronate NNP 1_i
, , 1_i
a DT 1_i
relatively RB 1_i
new JJ 1_i
bisphosphonate NN 1_i
, , N
is VBZ N
able JJ N
to TO N
prevent VB N
bone NN 1_o
loss NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
prostate JJ 1_p
cancer NN 1_p
during IN 1_p
androgen JJ 1_p
ablation NN 1_p
. . 1_p

INTRODUCTION NNP N
Androgen-deprivation NNP N
therapy NN N
( ( N
ADT NNP N
) ) N
is VBZ N
a DT N
cornerstone NN N
of IN N
treatment NN N
for IN N
advanced JJ 1_p
prostate NN 1_p
cancer NN 1_p
. . 1_p

This DT N
therapy NN N
has VBZ N
iatrogenic JJ N
complications NNS N
, , N
such JJ N
as IN N
osteoporosis NN N
. . N

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
of IN N
neridronate NN N
, , N
a DT N
relatively RB N
new JJ N
bisphosphonate NN N
, , N
to TO N
prevent VB N
bone JJ N
loss NN N
during IN N
androgen JJ N
ablation NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Forty-eight NNP 1_p
osteoporotic JJ 1_p
patients NNS 1_p
with IN 1_p
prostate JJ 1_p
cancer NN 1_p
, , 1_p
treated VBN 1_p
with IN 1_p
3-month JJ 1_p
depot NN 1_p
triptorelina NN 1_i
, , N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
different JJ N
treatment NN N
groups NNS N
: : N
group NN N
A NNP N
( ( 1_p
n JJ 1_p
= NNP 1_p
24 CD 1_p
) ) 1_p
was VBD N
treated VBN N
with IN N
a DT N
daily JJ 1_i
calcium NN 1_i
and CC 1_i
cholecalciferol NN 1_i
supplement NN 1_i
( ( N
500 CD N
mg NN N
of IN N
elemental JJ N
calcium NN N
and CC N
400 CD N
IU NNP N
cholecalciferol NN N
) ) N
, , N
and CC N
group NN N
B NNP N
( ( 1_p
n JJ 1_p
= NNP 1_p
24 CD 1_p
) ) 1_p
received VBN N
in IN N
addition NN N
to TO N
the DT N
same JJ N
daily JJ 1_i
calcium NN 1_i
and CC 1_i
cholecalciferol NN 1_i
supplement NN 1_i
, , N
25 CD N
mg NN N
of IN N
neridronate JJ 1_i
given VBN N
intramuscularly RB N
every DT N
month NN N
. . N

All DT N
patients NNS N
also RB N
received VBD N
bicalutamide RB 1_i
for IN N
4 CD N
weeks NNS N
. . N

Lumbar NNP 1_o
and CC 1_o
femoral JJ 1_o
BMD NNP 1_o
was VBD N
evaluated VBN N
by IN N
DXA NNP N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
year NN N
of IN N
therapy NN N
; : N
moreover CC N
, , N
deoxypyridinoline NN 1_o
( ( 1_o
DPD NNP 1_o
) ) 1_o
and CC 1_o
bone $ 1_o
alkaline JJ 1_o
phosphatase NN 1_o
( ( 1_o
BALP NNP 1_o
) ) 1_o
were VBD N
determined VBN N
at IN N
the DT N
beginning NN N
, , N
midway RB N
through IN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS NNP N
After IN N
6 CD N
and CC N
12 CD N
months NNS N
, , N
whereas JJ N
patients NNS N
treated VBD N
only RB N
with IN N
calcium NN N
and CC N
cholecalciferol NN N
( ( N
group NN N
A NNP N
) ) N
showed VBD N
a DT N
marked JJ 1_o
bone NN 1_o
loss NN 1_o
, , N
with IN N
increased JJ 1_o
levels NNS 1_o
of IN 1_o
DPD NNP 1_o
and CC 1_o
BALP NNP 1_o
compared VBN N
with IN N
baseline NN N
values NNS N
, , N
patients NNS N
treated VBD N
also RB N
with IN N
neridronate NN N
( ( N
group NN N
B NNP N
) ) N
had VBD N
substantially RB N
unchanged JJ N
levels NNS N
of IN N
these DT N
markers NNS N
. . N

After IN N
1 CD N
year NN N
of IN N
treatment NN N
, , N
lumbar NN 1_o
and CC 1_o
total JJ 1_o
hip NN 1_o
BMD NNP 1_o
decreased VBD 1_o
significantly RB 1_o
in IN N
patients NNS N
treated VBN N
only RB N
with IN N
calcium NN N
and CC N
cholecalciferol NN N
( ( N
group NN N
A NNP N
) ) N
, , N
whereas IN N
it PRP N
did VBD N
not RB N
change VB 1_o
significantly RB 1_o
at IN N
any DT N
skeletal JJ N
site NN N
in IN N
patients NNS N
treated VBN N
also RB N
with IN N
neridronate NN N
( ( N
group NN N
B NNP N
) ) N
. . N

No DT N
relevant JJ 1_o
side NN 1_o
effects NNS 1_o
were VBD N
recorded VBN N
during IN N
our PRP$ N
study NN N
. . N

CONCLUSIONS NNP N
Neridronate NNP 1_i
is VBZ N
an DT N
effective JJ N
treatment NN N
in IN N
preventing VBG N
bone NN 1_o
loss NN 1_o
in IN N
the DT N
hip NN N
and CC N
lumbar NN N
spine NN N
in IN N
men NNS 1_p
receiving VBG 1_p
ADT NNP 1_p
for IN 1_p
prostate NN 1_p
cancer NN 1_p
. . 1_p

-DOCSTART- -X- O O

One CD 1_i
quadrant JJ 1_i
sub-Tenon NN 1_i
's POS 1_i
capsule NN 1_i
anesthesia NN 1_i
in IN N
anterior JJ 1_p
segment NN 1_p
surgery NN 1_p
. . 1_p

Reports NNS N
of IN N
complications NNS N
associated VBN N
with IN N
local JJ 1_p
anesthesia NN 1_p
in IN 1_p
ophthalmic JJ 1_p
surgery NN 1_p
have VBP N
increased VBN N
conspicuously RB N
in IN N
recent JJ N
years NNS N
. . N

Sub-Tenon NNP 1_i
's POS 1_i
capsule NN 1_i
anesthesia NN 1_i
for IN N
anterior JJ N
segment NN N
surgery NN N
avoids IN N
the DT N
risks NNS N
of IN N
retrobulbar NN 1_i
and CC N
peribulbar NN N
injections NNS N
. . N

This DT N
study NN N
compared VBN N
sub-Tenon NN 1_i
's POS 1_i
and CC N
retrobulbar NN 1_i
anesthesia NN 1_i
. . 1_i

Patients NNS 1_p
undergoing VBG 1_p
various JJ 1_p
anterior JJ 1_p
segment NN 1_p
surgery NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
sub-Tenon NN 1_i
's POS 1_i
or CC 1_i
retrobulbar NN 1_i
anesthesia NN 1_i
; : 1_i
300 CD 1_p
were VBD 1_p
operated VBN 1_p
with IN 1_p
1-quadrant JJ 1_i
sub-Tenon NN 1_i
's POS 1_i
anesthesia NN 1_i
( ( 1_i
1-QST JJ 1_i
) ) 1_i
and CC 1_p
the DT 1_p
results NNS 1_p
were VBD 1_p
compared VBN 1_p
with IN 1_p
270 CD 1_p
patients NNS 1_p
operated VBN 1_p
with IN 1_p
retrobulbar NN 1_i
anesthesia NN 1_i
. . 1_i

Retrobulbar NNP 1_i
anesthesia NN 1_i
consisted VBD N
of IN N
a DT N
2.5 CD N
ml NN N
injection NN N
of IN N
a DT N
1:1 CD N
mixture NN N
of IN N
2 CD N
% NN N
lidocaine NN 1_i
without IN 1_i
epinephrine NN 1_i
and CC 1_i
0.5 CD 1_i
% NN 1_i
bupivacaine NN 1_i
. . 1_i

Sub-Tenon NNP 1_i
's POS 1_i
anesthesia NN 1_i
involved VBN N
direct JJ N
transconjunctival JJ N
infiltration NN N
of IN N
the DT N
same JJ N
local JJ N
anesthetic JJ N
directly RB N
into IN N
the DT N
sub-Tenon NN N
's POS N
space NN N
, , N
in IN N
the DT N
inferior-nasal JJ N
quadrant NN N
, , N
using VBG N
a DT N
blunt NN N
23-gauge JJ N
cannula NN N
. . N

Patients NNS 1_p
undergoing VBG 1_p
various JJ 1_p
anterior JJ 1_p
segment NN 1_p
surgery NN 1_p
procedures NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1-QST CD 1_i
or CC N
retrobulbar VB 1_i
anesthesia NN 1_i
; : 1_i
300 CD N
patients NNS N
were VBD N
operated VBN N
with IN N
1-QST JJ N
and CC N
the DT N
results NNS N
were VBD N
compared VBN N
with IN N
270 CD N
patients NNS N
operated VBN N
with IN N
retrobulbar NN N
anesthesia NN N
. . N

Preinjection NN 1_o
mean NN 1_o
( ( 1_o
+/- JJ 1_o
SD NNP 1_o
) ) 1_o
IOP NNP 1_o
wer $ N
12.9 CD N
+/- JJ N
3.7 CD N
mmHg NN N
in IN N
the DT N
retrobulbar NN 1_i
and CC N
13.4 CD N
+/- JJ N
3.2 CD N
mmHg NN N
in IN N
the DT N
1-QST JJ 1_i
patients NNS N
. . N

Preoperative JJ 1_o
intraocular JJ 1_o
pressures NNS 1_o
were VBD N
8.7 CD N
+/- JJ N
3.0 CD N
mmHg NN N
in IN N
the DT N
retrobulbar NN 1_i
and CC N
9.2 CD N
+/- JJ N
3.2 CD N
mmHg NN N
in IN N
1-QST JJ 1_i
patients NNS N
. . N

Pre- NNP 1_o
and CC 1_o
postinjection NN 1_o
IOP NNP 1_o
for IN N
retrobulbar NN 1_i
and CC N
1-QST JJ 1_i
patients NNS N
were VBD N
similar JJ N
. . N

Pain NN 1_o
scores NNS 1_o
for IN 1_o
delivery NN 1_o
of IN 1_o
the DT 1_o
anesthetic JJ 1_o
, , N
using VBG N
a DT N
numerical JJ 1_o
rating NN 1_o
scale NN 1_o
, , N
produced VBD N
a DT N
median JJ N
score NN N
of IN N
1 CD N
for IN N
1-QST JJ N
and CC N
2 CD N
for IN N
the DT N
retrobulbar NN 1_i
technique NN N
. . N

For IN N
the DT N
subsequent JJ N
operative JJ N
procedure NN N
, , N
the DT N
median JJ N
score NN N
was VBD N
1 CD N
for IN N
1-QST JJ 1_i
and CC N
2 CD N
for IN N
the DT N
retrobulbar NN N
patients NNS N
. . N

Complete JJ 1_o
akinesia NN 1_o
was VBD N
achieved VBN N
in IN N
41 CD N
% NN N
with IN N
1-QST JJ 1_i
and CC N
in IN N
69 CD N
% NN N
of IN N
retrobulbar NN N
patients NNS N
. . N

1-QST JJ 1_i
patients NNS N
with IN N
incomplete JJ 1_o
akinesia NN 1_o
most RBS N
often RB N
had VBD N
lateral JJ 1_o
muscle NN 1_o
function NN 1_o
which WDT N
did VBD N
not RB N
interfere VB N
with IN N
the DT N
operation NN N
. . N

We PRP N
found VBD N
the DT N
use NN N
of IN N
a DT N
blunt NN N
cannula NN N
to TO N
deliver VB N
anesthetic JJ N
into IN N
the DT N
sub-Tenon NN N
's POS N
space NN N
as IN N
a DT N
simple NN N
, , N
safe JJ N
and CC N
effective JJ N
alternative JJ N
approach NN N
to TO N
traditional JJ N
retrobulbar NN 1_i
anesthesia NN 1_i
in IN N
anterior JJ N
segment NN N
surgery NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomized NN N
study NN N
concerning VBG N
the DT N
point NN N
A NNP N
dose NN N
in IN N
high-dose JJ 1_i
rate NN 1_i
intracavitary JJ 1_i
therapy NN 1_i
for IN N
carcinoma NN 1_p
of IN 1_p
the DT 1_p
uterine JJ 1_p
cervix NN 1_p
. . 1_p

The DT N
final JJ N
results NNS N
. . N

PURPOSE NNP N
High-dose JJ 1_i
rate NN 1_i
( ( 1_i
HDR NNP 1_i
) ) 1_i
remote VBP 1_i
afterloading VBG 1_i
intracavitary JJ 1_i
therapy NN 1_i
has VBZ N
been VBN N
recognized VBN N
as IN N
an DT N
effective JJ N
and CC N
safe JJ N
treatment NN N
modality NN N
for IN N
carcinoma NN 1_p
of IN 1_p
the DT 1_p
uterine JJ 1_p
cervix NN 1_p
. . 1_p

Since IN N
1983 CD N
, , N
a DT N
prospective JJ N
randomized NN N
study NN N
was VBD N
started VBN N
in IN N
order NN N
to TO N
investigate VB N
the DT N
more RBR N
advantageous JJ N
treatment NN N
schedule NN N
with IN N
keeping VBG N
the DT N
local JJ N
control NN N
rate NN N
. . N

This DT N
paper NN N
reports VBZ N
the DT N
final JJ N
results NNS N
in IN N
terms NNS N
of IN N
survival NN N
, , N
local JJ N
control NN N
and CC N
complications NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP 1_p
January NNP 1_p
1983 CD 1_p
and CC 1_p
February NNP 1_p
1989 CD 1_p
, , 1_p
a DT 1_p
total NN 1_p
of IN 1_p
165 CD 1_p
patients NNS 1_p
with IN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
uterine JJ 1_p
cervix NN 1_p
was VBD 1_p
entered VBN 1_p
in IN 1_p
a DT 1_p
prospective JJ 1_p
randomized NN 1_p
study NN 1_p
concerning VBG 1_p
the DT 1_p
point NN 1_p
A NNP 1_p
dose NN 1_i
of IN 1_i
HDR NNP 1_i
therapy NN 1_i
( ( 1_i
6 CD 1_i
Gy/fraction NNP 1_i
vs FW 1_i
7.5 CD 1_i
Gy/fraction NNP 1_i
) ) 1_i
and CC 1_i
external JJ 1_i
irradiation NN 1_i
dose NN 1_i
at IN 1_i
Department NNP 1_i
of IN 1_i
Radiation NNP 1_i
Therapy NNP 1_i
, , 1_p
The DT 1_p
Center NNP 1_p
for IN 1_p
Adult NNP 1_p
Diseases NNP 1_p
, , 1_p
Osaka NNP 1_p
. . 1_p

UICC NNP 1_p
[ VBD 1_p
20 CD 1_p
] JJ 1_p
stage NN 1_p
distribution NN 1_p
of IN 1_p
patients NNS 1_p
was VBD 1_p
as IN 1_p
follows VBZ 1_p
: : 1_p
stage NN 1_p
IA NNP 1_p
= NNP 1_p
4 CD 1_p
, , 1_p
stage NN 1_p
IB NNP 1_p
= NNP 1_p
33 CD 1_p
, , 1_p
stage NN 1_p
IIA NNP 1_p
= NNP 1_p
18 CD 1_p
, , 1_p
stage NN 1_p
IIB NNP 1_p
= NNP 1_p
38 CD 1_p
, , 1_p
stage NN 1_p
III NNP 1_p
= NNP 1_p
57 CD 1_p
, , 1_p
stage NN 1_p
IV NNP 1_p
= VBZ 1_p
15 CD 1_p
. . 1_p

RESULTS VB N
Overall JJ N
5-year JJ 1_o
cause NN 1_o
specific JJ 1_o
survivals NNS 1_o
were VBD N
as IN N
follows VBZ N
: : N
stage NN N
IA NNP N
= VBZ N
100 CD N
% NN N
, , N
stage NN N
IB NNP N
= VBZ N
96 CD N
% NN N
, , N
stage NN N
IIA NNP N
= VBZ N
92 CD N
% NN N
, , N
stage NN N
IIB NNP N
= VBZ N
79 CD N
% NN N
, , N
stage NN N
III NNP N
= VBZ N
57 CD N
% NN N
, , N
stage NN N
IV NNP N
= VBZ N
27 CD N
% NN N
. . N

In IN N
each DT N
stage NN N
, , N
5-year JJ 1_o
survival NN 1_o
rates NNS 1_o
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
were VBD N
100 CD N
% NN N
, , N
93 CD N
% NN N
in IN N
stage NN N
I PRP N
, , N
82 CD N
% NN N
and CC N
85 CD N
% NN N
in IN N
stage NN N
II NNP N
, , N
62 CD N
% NN N
and CC N
52 CD N
% NN N
in IN N
stage NN N
II NNP N
and CC N
22 CD N
% NN N
and CC N
31 CD N
% NN N
in IN N
stage NN N
IV NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
among IN N
these DT N
survival JJ N
curves NNS N
in IN N
each DT N
stage NN N
. . N

Five-year JJ 1_o
local JJ 1_o
failure NN 1_o
rates NNS 1_o
were VBD N
16 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
16 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.9096 CD N
) ) N
, , N
and CC N
corresponding VBG N
distant JJ N
failure NN N
rates NNS N
were VBD N
23 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
19 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.2955 CD N
) ) N
. . N

Moderate-to-severe JJ 1_o
complications NNS 1_o
requiring VBG N
treatment NN N
( ( N
Kottmeier NNP N
's POS N
grade NN N
2 CD N
or CC N
more JJR N
) ) N
were VBD N
noted VBN N
in IN N
6 CD N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
and CC N
6 CD N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
group NN N
B NNP N
. . N

All DT N
of IN N
the DT N
bladder NN 1_o
and CC 1_o
rectal JJ 1_o
complications NNS 1_o
needed VBD N
medical JJ N
treatment NN N
( ( N
Kottmeier NNP N
's POS N
grade NN N
2 CD N
) ) N
. . N

Severe JJ 1_o
complications NNS 1_o
receiving VBG N
surgery NN N
were VBD N
noted VBN N
in IN N
4 CD N
patients NNS N
( ( N
A DT N
: : N
1 CD N
; : N
B NNP N
: : N
3 CD N
) ) N
, , N
i.e. FW N
, , N
small JJ N
intestine NN N
3 CD N
and CC N
sigmoid JJ N
colon NN N
1 CD N
patient NN N
. . N

Another DT N
1 CD N
patient NN N
( ( N
A DT N
) ) N
was VBD N
dead JJ 1_o
of IN N
ileus NN N
. . N

CONCLUSIONS NNP N
There EX N
were VBD N
no DT N
statistically RB 1_o
significant JJ 1_o
differences NNS 1_o
between IN 1_o
2 CD 1_o
treatment NN 1_o
schedules NNS 1_o
in IN 1_o
survival NN 1_o
rates NNS 1_o
, , 1_o
failure NN 1_o
patterns NNS 1_o
and CC 1_o
complications NNS 1_o
rates NNS 1_o
. . 1_o

This DT N
fact NN N
suggests VBZ N
that IN N
small JJ N
number NN N
of IN N
fractions NNS N
( ( N
7.5 CD N
Gy/fraction NNP N
) ) N
may MD N
be VB N
advantageous JJ N
because IN N
of IN N
short JJ N
duration NN N
and CC N
a DT N
low JJ N
load NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
VX-770 NNP 1_i
in IN N
persons NNS 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
and CC 1_p
the DT 1_p
G551D-CFTR NNP 1_p
mutation NN 1_p
. . 1_p

BACKGROUND VB N
A DT N
new JJ N
approach NN N
in IN N
the DT N
treatment NN N
of IN N
cystic JJ N
fibrosis NN N
involves VBZ N
improving VBG N
the DT N
function NN N
of IN N
mutant JJ N
cystic JJ N
fibrosis NN N
transmembrane NN N
conductance NN N
regulator NN N
( ( N
CFTR NNP N
) ) N
. . N

VX-770 NNP N
, , N
a DT N
CFTR NNP N
potentiator NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
increase VB N
the DT N
activity NN N
of IN N
wild-type NN N
and CC N
defective JJ N
cell-surface NN N
CFTR NNP N
in IN N
vitro NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
39 CD 1_p
adults NNS 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
and CC 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
G551D-CFTR JJ 1_p
allele NN 1_p
to TO N
receive VB N
oral JJ 1_i
VX-770 NNP 1_i
every DT N
12 CD N
hours NNS N
at IN N
a DT N
dose NN N
of IN N
25 CD N
, , N
75 CD N
, , N
or CC N
150 CD N
mg NN N
or CC N
placebo NN 1_i
for IN N
14 CD N
days NNS N
( ( N
in IN N
part NN N
1 CD N
of IN N
the DT N
study NN N
) ) N
or CC N
VX-770 JJ 1_i
every DT N
12 CD N
hours NNS N
at IN N
a DT N
dose NN N
of IN N
150 CD N
or CC N
250 CD N
mg NN N
or CC N
placebo NN 1_i
for IN N
28 CD N
days NNS N
( ( N
in IN N
part NN N
2 CD N
of IN N
the DT N
study NN N
) ) N
. . N

RESULTS VBN N
At IN N
day NN N
28 CD N
, , N
in IN N
the DT N
group NN N
of IN N
subjects NNS N
who WP N
received VBD N
150 CD N
mg NNS N
of IN N
VX-770 NNP N
, , N
the DT N
median JJ N
change NN N
in IN N
the DT N
nasal JJ 1_o
potential JJ 1_o
difference NN 1_o
( ( N
in IN N
response NN N
to TO N
the DT N
administration NN N
of IN N
a DT N
chloride-free JJ N
isoproterenol JJ N
solution NN N
) ) N
from IN N
baseline NN N
was VBD N
-3.5 JJ N
mV NN N
( ( N
range NN N
, , N
-8.3 NNP N
to TO N
0.5 CD N
; : N
P=0.02 NNP N
for IN N
the DT N
within-subject JJ N
comparison NN N
, , N
P=0.13 NNP N
vs. FW N
placebo NN N
) ) N
, , N
and CC N
the DT N
median JJ N
change NN N
in IN N
the DT N
level NN 1_o
of IN 1_o
sweat NN 1_o
chloride NN 1_o
was VBD N
-59.5 JJ N
mmol NN N
per IN N
liter NN N
( ( N
range NN N
, , N
-66.0 NN N
to TO N
-19.0 VB N
; : N
P=0.008 NNP N
within-subject NN N
, , N
P=0.02 NNP N
vs. FW N
placebo NN N
) ) N
. . N

The DT N
median JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
percent NN N
of IN N
predicted VBN N
forced JJ 1_o
expiratory NN 1_o
volume NN 1_o
in IN N
1 CD N
second NN N
was VBD N
8.7 CD N
% NN N
( ( N
range NN N
, , N
2.3 CD N
to TO N
31.3 CD N
; : N
P=0.008 NNP N
for IN N
the DT N
within-subject JJ N
comparison NN N
, , N
P=0.56 NNP N
vs. FW N
placebo NN N
) ) N
. . N

None NN N
of IN N
the DT N
subjects NNS N
withdrew VBD N
from IN N
the DT N
study NN N
. . N

Six NNP N
severe JJ 1_o
adverse JJ 1_o
events NNS 1_o
occurred VBD N
in IN N
two CD N
subjects NNS N
( ( 1_o
diffuse IN 1_o
macular NN 1_o
rash NN 1_o
in IN N
one CD N
subject NN N
and CC N
five CD N
incidents NNS N
of IN N
elevated VBN 1_o
blood NN 1_o
and CC 1_o
urine JJ 1_o
glucose NN 1_o
levels NNS 1_o
in IN N
one CD N
subject NN N
with IN N
diabetes NNS 1_o
) ) 1_o
. . N

All DT N
severe JJ N
adverse JJ N
events NNS N
resolved VBN N
without IN N
the DT N
discontinuation NN N
of IN N
VX-770 NNP N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN 1_o
and CC 1_o
adverse-event JJ 1_o
profile NN 1_o
of IN N
VX-770 NNP N
showed VBD N
that IN N
VX-770 NNP N
was VBD N
associated VBN N
with IN N
within-subject JJ N
improvements NNS N
in IN N
CFTR NNP 1_o
and CC 1_o
lung NN 1_o
function NN 1_o
. . 1_o

These DT N
findings NNS N
provide VBP N
support NN N
for IN N
further JJ N
studies NNS N
of IN N
pharmacologic JJ N
potentiation NN N
of IN N
CFTR NNP N
as IN N
a DT N
means NN N
to TO N
treat VB 1_p
cystic JJ 1_p
fibrosis NN 1_p
. . 1_p

( ( N
Funded VBN N
by IN N
Vertex NNP N
Pharmaceuticals NNP N
and CC N
others NNS N
; : N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00457821 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

Administration NN N
of IN N
subcutaneous JJ N
buffered VBN N
lidocaine JJ 1_i
prior RB N
to TO N
breast VB 1_p
lymphoscintigraphy NN 1_p
reduces NNS N
pain VBP 1_o
without IN N
decreasing VBG N
lymph NN N
node DT N
visualization NN N
. . N

UNLABELLED NNP N
Breast NNP N
lymphoscintigraphy NN N
using VBG N
( ( N
99m CD N
) ) N
Tc-sulfur CD N
colloid NN N
( ( N
( ( N
99m CD N
) ) N
Tc-SC NN N
) ) N
is VBZ N
well RB N
established VBN N
in IN N
clinical JJ N
practice NN N
for IN N
staging VBG N
patients NNS 1_p
with IN 1_p
breast JJ 1_p
carcinoma NN 1_p
. . 1_p

Nearly RB N
all DT N
patients NNS N
report VBP N
having VBG N
pain NN 1_o
during IN N
the DT N
procedure NN N
. . N

However RB N
, , N
techniques NNS N
used VBN N
to TO N
minimize VB N
pain NN 1_o
during IN N
breast NN 1_p
lymphoscintigraphy NN 1_i
are VBP N
highly RB N
variable JJ N
across IN N
institutions NNS N
. . N

Our PRP$ N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
anesthetizing VBG N
the DT N
skin NN N
with IN N
sodium JJ 1_i
bicarbonatehether-buffered JJ 1_i
lidocaine NN 1_i
before IN N
performing VBG N
breast NN N
lymphoscintigraphy NN N
reduced VBD N
the DT N
pain NN 1_o
experienced VBN N
by IN N
the DT N
patients NNS N
. . N

The DT N
second JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
anesthetizing VBG N
the DT N
skin NN N
with IN N
buffered JJ N
lidocaine NN N
changed VBN N
visualization NN 1_o
of IN 1_o
lymph NN 1_o
nodes NNS 1_o
. . 1_o

METHODS NNP N
This DT N
prospective JJ N
, , N
patient-masked JJ N
and CC N
randomized JJ N
study NN N
involved VBN N
performing VBG N
breast NN 1_i
lymphoscintigraphy NN 1_i
in IN N
a DT N
control NN 1_p
group NN 1_p
and CC 1_p
experimental JJ 1_p
group NN 1_p
of IN 1_p
female JJ 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

The DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
skin NN N
anesthetic JJ N
before IN N
( ( N
99m CD N
) ) N
Tc-SC CD N
injections NNS N
, , N
whereas IN N
the DT N
experimental JJ N
group NN N
first JJ N
underwent JJ N
skin NN N
anesthesia NN N
with IN N
an DT N
injection NN N
of IN N
2 CD 1_i
% NN 1_i
sodium JJ 1_i
bicarbonate-buffered JJ 1_i
lidocaine NN 1_i
. . 1_i

All DT N
patients NNS N
were VBD N
asked VBN N
to TO N
rate NN 1_o
their PRP$ 1_o
pain NN 1_o
levels NNS 1_o
, , 1_o
using VBG 1_o
the DT 1_o
National NNP 1_o
Institutes NNPS 1_o
of IN 1_o
Health NNP 1_o
pain NN 1_o
scale NN 1_o
, , N
before IN N
the DT N
procedure NN N
and CC N
immediately RB N
after IN N
the DT N
injections NNS N
. . N

The DT N
change NN 1_o
in IN 1_o
pain NN 1_o
from IN 1_o
baseline NN 1_o
was VBD N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

After IN N
the DT N
injections NNS N
, , N
scintigraphic JJ N
imaging NN N
of IN N
the DT N
axilla NN N
was VBD N
performed VBN N
, , N
and CC N
the DT N
number NN 1_o
of IN 1_o
axillary JJ 1_o
lymph NN 1_o
nodes NNS 1_o
visualized VBN 1_o
was VBD N
recorded VBN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
preprocedural JJ N
baseline NN 1_o
pain NN 1_o
from IN N
the DT N
control NN N
group NN N
, , N
compared VBN N
with IN N
the DT N
experimental JJ N
group NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
increase NN 1_o
in IN 1_o
pain NN 1_o
experienced VBD N
during IN N
the DT N
procedure NN N
between IN N
the DT N
control NN N
group NN N
and CC N
the DT N
experimental JJ N
group NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
detection NN 1_o
of IN 1_o
lymph NN 1_o
nodes NNS 1_o
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.56 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
from IN N
our PRP$ N
study NN N
indicate VBP N
that IN N
injecting VBG N
subcutaneous JJ N
buffered VBN N
lidocaine NN 1_i
before IN N
intradermal JJ N
injection NN N
of IN N
( ( N
99m CD N
) ) N
Tc-SC NN N
for IN N
breast NN N
lymphoscintigraphy NN N
significantly RB N
decreases VBZ N
patient JJ 1_o
pain NN 1_o
without IN N
interfering VBG N
with IN N
lymph JJ 1_o
node JJ 1_o
visualization NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
effectiveness NN N
of IN N
omeprazole NN 1_i
, , 1_i
clarithromycin NN 1_i
and CC N
tinidazole NN 1_i
in IN N
eradicating VBG 1_o
Helicobacter NNP 1_o
pylori NN 1_o
in IN N
a DT N
community NN N
screen NN N
and CC N
treat NN N
programme NN N
. . N

Leeds NNP N
Help NNP N
Study NNP N
Group NNP N
. . N

INTRODUCTION NNP N
Helicobacter NNP N
pylori NN N
screening NN N
and CC N
treatment NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
cost-effective JJ N
method NN N
of IN N
preventing VBG N
gastric JJ N
cancer NN N
. . N

AIM NNP N
To TO N
assess VB N
, , N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
the DT N
efficacy NN N
of IN N
therapy NN N
in IN N
eradicating VBG N
H. NNP N
pylori NN N
as IN N
part NN N
of IN N
a DT N
screening NN N
programme NN N
, , N
and CC N
to TO N
report VB N
the DT N
adverse JJ N
events NNS N
associated VBN N
with IN N
this DT N
strategy NN N
. . N

METHODS NNP N
Subjects NNPS 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
40-49 JJ 1_p
years NNS 1_p
were VBD 1_p
randomly RB 1_p
selected VBN 1_p
from IN 1_p
the DT 1_p
lists NNS 1_p
of IN 1_p
36 CD 1_p
primary JJ 1_p
care NN 1_p
centres NNS 1_p
. . 1_p

Participants NNS N
attended VBD N
their PRP$ N
local JJ N
practice NN N
and CC N
H. NNP N
pylori VBP N
status NN N
was VBD N
determined VBN N
by IN N
13C-urea JJ N
breath NN N
test NN N
. . N

Infected VBN N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
omeprazole JJ 1_i
20 CD 1_i
mg NN 1_i
b.d. NN 1_i
, , N
clarithromycin VBP 1_i
250 CD 1_i
mg NN 1_i
b.d NN 1_i
. . 1_i

and CC 1_i
tinidazole JJ 1_i
500 CD 1_i
mg NN 1_i
b.d NN 1_i
. . 1_i

for IN N
7 CD N
days NNS N
( ( N
OCT NNP N
) ) N
or CC N
identical JJ N
placebos NN 1_i
. . 1_i

Eradication NN 1_o
was VBD N
determined VBN N
by IN N
a DT N
13C-urea JJ N
breath NN N
test NN N
6 CD N
months NNS N
and CC N
2 CD N
years NNS N
after IN N
the DT N
first JJ N
visit NN N
. . N

Successful JJ 1_o
eradication NN 1_o
was VBD N
defined VBN N
as IN N
two CD N
negative JJ 1_o
13C-urea JJ 1_o
breath NN 1_o
tests NNS 1_o
or CC 1_o
one CD 1_o
negative JJ 1_o
and CC 1_o
one CD 1_o
missing VBG 1_o
test NN 1_o
. . 1_o

Adverse JJ 1_o
events NNS 1_o
and CC 1_o
compliance NN 1_o
were VBD N
assessed VBN N
at IN N
the DT N
6-month JJ N
visit NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
32 CD 1_p
929 CD 1_p
subjects NNS 1_p
were VBD 1_p
invited VBN 1_p
to TO 1_p
attend VB 1_p
, , 1_p
8407 CD 1_p
were VBD 1_p
evaluable JJ 1_p
, , 1_p
and CC 1_p
2329 CD 1_p
( ( 1_p
28 CD 1_p
% NN 1_p
) ) 1_p
of IN 1_p
these DT 1_p
were VBD 1_p
H. NNP 1_o
pylori-positive JJ 1_o
. . 1_o

A DT 1_p
total NN 1_p
of IN 1_p
1161 CD 1_p
subjects NNS 1_p
were VBD N
randomized VBN N
to TO N
OCT NNP N
and CC N
1163 CD N
to TO N
placebo VB N
; : N
over IN N
80 CD N
% NN N
returned VBN N
for IN N
a DT N
repeat NN N
13C-urea JJ N
breath NN N
test NN N
on IN N
at IN N
least JJS N
one CD N
occasion NN N
. . N

The DT N
eradication NN 1_o
rates NNS 1_o
in IN N
those DT N
allocated VBN N
to TO N
OCT NNP N
were VBD N
as IN N
follows VBZ N
: : N
intention-to-treat NN N
, , N
710 CD N
out IN N
of IN N
1161 CD N
( ( N
61 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
58-64 JJ N
% NN N
) ) N
; : N
evaluable JJ N
710 CD N
out IN N
of IN N
967 CD N
( ( N
73 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
: : N
71-76 CD N
% NN N
) ) N
; : N
took VBD N
all DT N
medication NN N
645 CD N
out IN N
of IN N
769 CD N
( ( N
84 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
: : N
81-87 CD N
% NN N
) ) N
. . N

Adverse JJ 1_o
events NNS 1_o
occurred VBD N
in IN N
45 CD N
% NN N
of IN N
the DT N
treatment NN N
group NN N
and CC N
in IN N
18 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
relative JJ N
risk NN N
2.5 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
2.1-2.9 JJ N
) ) N
. . N

Compliance NN N
, , N
male JJ N
gender NN N
, , N
no DT N
antibiotic JJ N
prescription NN N
in IN N
the DT N
subsequent JJ N
2 CD N
years NNS N
and CC N
experiencing VBG 1_o
a DT 1_o
bitter JJ 1_o
taste NN 1_o
with IN N
the DT N
medication NN N
were VBD N
independently RB N
associated VBN N
with IN N
treatment NN N
success NN N
. . N

CONCLUSIONS VB N
The DT N
OCT NNP N
regimen NN N
has VBZ N
an DT N
eradication NN 1_o
rate NN 1_o
of IN N
61 CD N
% NN N
in IN N
intention-to-treat JJ N
analysis NN N
and CC N
is VBZ N
therefore RB N
less RBR N
successful JJ N
in IN N
treating VBG N
H. NNP N
pylori NN N
as IN N
part NN N
of IN N
a DT N
screening NN N
programme NN N
compared VBN N
with IN N
hospital JJ N
studies NNS N
in IN N
dyspeptic JJ 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Short-term JJ 1_o
metabolic NN 1_o
and CC 1_o
cardiovascular JJ 1_o
effects NNS 1_o
of IN N
metformin NN 1_i
in IN N
markedly RB 1_p
obese JJ 1_p
adolescents NNS 1_p
with IN 1_p
normal JJ 1_p
glucose JJ 1_p
tolerance NN 1_p
. . 1_p

OBJECTIVE CC N
Although IN N
metformin NN 1_i
( ( N
MET NNP N
) ) N
is VBZ N
an DT N
insulin JJ N
sensitizer NN N
currently RB N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
the DT N
treatment NN N
of IN N
some DT N
of IN N
the DT N
complications NNS N
of IN N
childhood NN N
obesity NN N
besides IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
, , N
few JJ N
studies NNS N
have VBP N
comprehensively RB N
examined VBN N
its PRP$ N
metabolic NN N
and CC N
clinical JJ N
effects NNS N
in IN N
obese JJ N
children NNS N
with IN N
normal JJ N
glucose JJ N
tolerance NN N
( ( N
NGT NNP N
) ) N
. . N

METHODS NNP N
We PRP N
therefore RB N
conducted VBD N
a DT N
4-month JJ N
double-blind JJ N
clinical JJ N
trial NN N
in IN N
28 CD 1_p
obese JJ 1_p
[ JJ 1_p
mean NN 1_p
body NN 1_o
mass NN 1_o
index NN 1_o
( ( 1_o
BMI NNP 1_o
) ) 1_o
: : 1_o
40.3 CD 1_p
+/- JJ 1_p
5.7 CD 1_p
kg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
] NN 1_p
, , 1_p
insulin-resistant JJ 1_p
[ JJ 1_p
homeostasis NN 1_p
model NN 1_p
assessment JJ 1_p
- : 1_p
insulin NN 1_p
resistance NN 1_p
: : 1_p
7.6 CD 1_p
+/- JJ 1_p
2.8 CD 1_p
and CC 1_p
whole JJ 1_p
body NN 1_p
insulin JJ 1_p
sensitivity NN 1_p
index NN 1_p
( ( 1_p
WBISI NNP 1_p
) ) 1_p
: : 1_p
1.5 CD 1_p
+/- JJ 1_p
0.7 CD 1_p
] JJ 1_p
adolescents NNS 1_p
( ( 1_p
age NN 1_p
15.0 CD 1_p
+/- JJ 1_p
1.3 CD 1_p
yr NN 1_p
) ) 1_p
randomized VBD 1_p
to TO 1_p
MET NNP 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
15 CD 1_p
, , 1_p
dose JJ 1_p
1500 CD 1_p
mg JJ 1_p
daily JJ 1_p
) ) 1_p
or CC 1_p
placebo NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
13 CD 1_p
) ) 1_p
. . 1_p

RESULTS VB N
The DT N
treatment NN N
with IN N
MET NNP N
was VBD N
well RB N
tolerated VBN N
. . N

MET NNP N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
BMI NNP 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
as RB N
well RB N
as IN N
with IN N
a DT N
reduction NN N
in IN N
subcutaneous JJ 1_o
fat NN 1_o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
, , N
particularly RB N
the DT N
deep JJ 1_o
subcutaneous JJ 1_o
fat NN 1_o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
as IN N
assessed VBN N
by IN N
magnetic JJ N
resonance NN N
imaging NN N
. . N

Postintervention NN N
, , N
the DT N
MET NNP N
group NN N
had VBD N
a DT N
35 CD N
% NN N
improvement NN N
in IN N
insulin NN 1_o
sensitivity NN 1_o
( ( 1_o
WBISI NNP 1_o
) ) 1_o
compared VBN N
with IN N
the DT N
placebo NN 1_i
group NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

However RB N
, , N
significance NN N
was VBD N
lost VBN N
with IN N
adjustments NNS N
for IN N
differences NNS N
in IN N
baseline JJ N
insulin NN 1_o
sensitivity NN 1_o
( ( N
p JJ N
= NNP N
0.09 CD N
) ) N
. . N

While IN N
there EX N
was VBD N
no DT N
change NN N
in IN N
inflammatory JJ 1_o
cytokines NNS 1_o
or CC 1_o
lipid JJ 1_o
parameters NNS 1_o
, , 1_o
cardiovascular JJ 1_o
function NN 1_o
as IN N
assessed VBN N
by IN N
heart NN 1_o
rate NN 1_o
recovery NN 1_o
after IN N
exercise NN N
improved VBN N
with IN N
MET NNP N
and CC N
worsened VBN N
in IN N
placebo NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Short-term NNP N
use NN N
of IN N
MET NNP N
is VBZ N
well RB N
tolerated VBN 1_o
by IN N
obese JJ 1_p
children NNS 1_p
with IN 1_p
NGT NNP 1_p
and CC N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
BMI NNP N
and CC N
autonomic JJ N
control NN N
of IN N
the DT N
heart NN N
as RB N
well RB N
as IN N
a DT N
trend NN N
toward IN N
improved JJ N
insulin NN 1_o
sensitivity NN 1_o
. . 1_o

Thus RB N
, , N
long-term JJ N
treatment NN N
with IN N
MET NNP N
may MD N
provide VB N
a DT N
means NN N
to TO N
ameliorate VB N
the DT N
cardio-metabolic JJ 1_o
consequences NNS 1_o
of IN 1_o
adolescent JJ 1_o
obesity NN 1_o
. . 1_o

-DOCSTART- -X- O O

Effect NN N
of IN N
daily JJ N
etidronate NN 1_i
on IN N
the DT N
osteolysis NN N
of IN N
multiple JJ N
myeloma NN N
. . N

Progressive NNP N
bone NN N
disease NN N
in IN N
multiple JJ N
myeloma NN N
frequently RB N
leads VBZ N
to TO N
osteolysis VB N
, , N
bone NN N
resorption NN N
, , N
pathologic JJ N
fractures NNS N
, , N
vertebral JJ N
compression NN N
, , N
and CC N
hypercalcemia NN N
. . N

We PRP N
conducted VBD N
a DT N
double-blind NN N
study NN N
in IN N
173 CD 1_p
newly RB 1_p
diagnosed VBN 1_p
multiple JJ 1_p
myeloma NN 1_p
patients NNS 1_p
of IN 1_p
etidronate JJ 1_p
disodium NN 1_p
( ( 1_p
EHDP NNP 1_p
) ) 1_p
, , 1_p
a DT 1_p
diphosphonate NN 1_p
compound NN 1_p
that WDT 1_p
reduces VBZ 1_p
bone NN 1_p
resorption NN 1_p
by IN 1_p
inhibiting VBG 1_p
osteoclastic JJ 1_p
activity NN 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ 1_i
EHDP NNP 1_i
5 CD 1_i
mg/kg/d NN 1_i
or CC 1_i
placebo NN 1_i
until IN N
death NN N
or CC N
discontinuation NN N
due JJ N
to TO N
intolerance VB N
or CC N
refusal VB N
. . N

The DT N
extent NN N
of IN N
vertebral JJ N
deformity NN N
was VBD N
measured VBN N
by IN N
a DT N
vertebral JJ N
index NN N
as RB N
well RB N
as IN N
height NN N
. . N

The DT N
frequency NN 1_o
of IN 1_o
pathologic JJ 1_o
fractures NNS 1_o
, , 1_o
hypercalcemia NN 1_o
, , 1_o
and CC 1_o
bone NN 1_o
pain NN 1_o
was VBD N
regularly RB N
assessed VBN N
, , N
as RB N
well RB N
as IN N
size NN N
and CC N
number NN N
of IN N
osteolytic JJ N
lesions NNS N
. . N

All DT N
patients NNS N
received VBD N
melphalan JJ 1_i
and CC N
prednisone JJ 1_i
daily JJ N
for IN N
4 CD N
days NNS N
every DT N
4 CD N
weeks NNS N
as IN N
the DT N
primary JJ N
chemotherapy NN N
for IN N
their PRP$ N
disease NN N
. . N

Although IN N
the DT N
repeated JJ N
measures NNS N
analysis NN N
showed VBD N
a DT N
significant JJ N
height JJ 1_o
loss NN 1_o
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
treatment NN N
arms NNS N
( ( N
P NNP N
= NNP N
.98 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
bone NN 1_o
pain NN 1_o
, , 1_o
episodes NNS 1_o
of IN 1_o
hypercalcemia NN 1_o
, , 1_o
or CC 1_o
development NN 1_o
of IN 1_o
pathologic JJ 1_o
fractures NNS 1_o
. . 1_o

Patients NNS 1_p
on IN 1_p
EHDP NNP 1_i
showed VBD N
less JJR N
deterioration NN 1_o
in IN 1_o
their PRP$ 1_o
vertebral JJ 1_o
index NN 1_o
, , N
but CC N
this DT N
difference NN N
only RB N
approached VBD N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
.07 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
EHDP NNP 1_i
therapy NN N
used VBN N
in IN N
this DT N
dosage NN N
schedule NN N
does VBZ N
not RB N
have VB N
a DT N
clinically RB N
significant JJ N
impact NN N
in IN N
multiple JJ N
myeloma NN N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
study NN N
of IN N
administration NN N
methods NNS N
of IN N
granisetron NN 1_i
injection NN 1_i
used VBN N
to TO N
treat VB N
nausea/vomiting VBG N
induced VBN N
by IN N
cancer NN N
chemotherapy NN N
without IN N
cisplatin NN N
in IN N
tumors NNS 1_p
of IN 1_p
hematopoietic JJ 1_p
organs NNS 1_p
. . 1_p

Keihanshin NNP N
Study NNP N
Group NNP N
of IN N
Hematological NNP N
Malignancies NNP N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effect NN N
of IN N
granisetron NN 1_i
injection NN 1_i
at IN N
a DT N
dose NN N
of IN N
40 CD N
microg/kg NNS N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
nausea/vomiting VBG N
induced VBN N
by IN N
multidrug NN 1_i
combined VBN 1_i
cancer NN 1_i
chemotherapy NN 1_i
excluding VBG 1_i
cisplatin NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
tumors NNS 1_p
of IN 1_p
hematopoietic JJ 1_p
organs NNS 1_p
was VBD N
evaluated VBN N
by IN N
comparing VBG N
a DT N
30-min JJ N
infusion NN N
and CC N
a DT N
slow JJ N
intravenous JJ N
injection NN N
given VBN N
over IN N
30 CD N
s. JJ N
METHODS NNP N
A DT N
two-group JJ N
random-allocation NN N
comparative NN N
study NN N
was VBD N
performed VBN N
with IN N
the DT N
cooperation NN N
of IN N
multiple JJ 1_p
institutions NNS 1_p
using VBG 1_p
a DT 1_p
central JJ 1_p
registration NN 1_p
system NN 1_p
. . 1_p

RESULTS NNP N
In IN N
the DT N
treatment NN N
of IN N
acute JJ N
clinical JJ N
symptoms NNS N
, , N
appetite NN 1_o
was VBD N
described VBN N
as IN N
similar JJ N
to TO N
that IN N
during IN N
good JJ N
health NN N
by IN N
61.1 CD N
% NN N
of IN N
patients NNS N
( ( 1_p
55/93 CD 1_p
) ) 1_p
in IN N
the DT N
instillation NN N
group NN N
and CC N
by IN N
47.3 CD N
% NN N
( ( 1_p
44/93 CD 1_p
) ) 1_p
in IN N
the DT N
slow JJ N
injection NN N
group NN N
, , N
a DT N
significant JJ N
advantage NN N
in IN N
the DT N
infusion NN N
group NN N
. . N

However RB N
, , N
no DT 1_o
significant JJ 1_o
differences NNS 1_o
in IN N
the DT N
number NN 1_o
of IN 1_o
episodes NNS 1_o
of IN 1_o
vomiting NN 1_o
, , 1_o
the DT 1_o
severity NN 1_o
of IN 1_o
nausea NN 1_o
or CC 1_o
clinical JJ 1_o
efficacy NN 1_o
were VBD N
found VBN N
. . N

In IN N
the DT N
final JJ N
clinical JJ N
evaluation NN N
and CC N
assessment NN N
of IN N
usefulness NN N
based VBN N
on IN N
the DT N
subjective JJ N
judgement NN N
of IN N
physicians NNS N
throughout IN N
the DT N
entire JJ N
therapeutic JJ N
period NN N
, , N
no DT N
differences NNS N
were VBD N
discernible JJ N
. . N

No DT N
side NN N
effects NNS N
were VBD N
reported VBN N
for IN N
either DT N
method NN N
and CC N
there EX N
was VBD N
no DT N
indication NN N
of IN N
a DT N
sex NN N
difference NN N
concerning VBG N
efficacy NN N
. . N

However RB N
, , N
the DT N
efficacy NN 1_o
in IN 1_o
patients NNS 1_o
with IN N
an DT N
anemic JJ N
tendency NN N
was VBD N
slightly RB 1_o
inferior JJ 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
maintenance NN N
of IN N
appetite NN N
during IN N
the DT N
administration NN N
of IN N
anticancer NN N
drugs NNS N
is VBZ N
very RB N
important JJ N
to TO N
maintain VB N
patients NNS N
' POS N
daily JJ N
activities NNS N
and CC N
quality NN N
of IN N
life NN N
. . N

The DT N
present JJ N
results NNS N
support VB N
the DT N
usefulness NN N
of IN N
infusion NN N
of IN N
granisetron NN 1_i
as IN N
an DT N
administration NN N
method NN N
during IN N
chemotherapy NN N
for IN N
malignant JJ N
hemopathy NN N
. . N

-DOCSTART- -X- O O

Pain NN N
relief NN N
can MD N
reduce VB N
hypoxemia NN 1_o
in IN N
distressed JJ 1_p
neonates NNS 1_p
during IN N
routine JJ N
treatment NN N
procedures NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
opioids NNS 1_i
could MD N
reduce VB N
the DT N
hypoxemia NN 1_o
and CC 1_o
hemodynamic JJ 1_o
instability NN 1_o
associated VBN N
with IN N
routine JJ N
intensive JJ N
care NN N
procedures NNS N
in IN N
neonates NNS 1_p
with IN 1_p
respiratory JJ 1_p
distress NN 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
and CC N
placebo-controlled JJ 1_i
study NN N
. . N

METHODS NNP N
Physiological NNP N
, , N
plasma JJ N
beta-endorphin NN N
, , N
cortisol NN N
, , N
and CC N
glucose JJ N
responses NNS N
to TO N
routine VB N
treatment NN N
procedures NNS N
were VBD N
studied VBN N
in IN N
84 CD 1_p
mechanically RB 1_p
ventilated VBN 1_p
distressed JJ 1_p
neonates NNS 1_p
randomized VBN N
into IN N
groups NNS N
receiving VBG N
1 CD 1_i
mg/kg JJ 1_i
meperidine NN 1_i
or CC 1_i
0.9 CD 1_i
% NN 1_i
saline NN 1_i
15 CD N
minutes NNS N
before IN N
tracheal JJ 1_i
suction NN 1_i
or CC 1_i
routine JJ 1_i
nursing NN 1_i
care NN 1_i
. . 1_i

RESULTS VB N
The DT N
duration NN 1_o
of IN 1_o
hypoxemia NN 1_o
( ( 1_o
transcutaneous JJ 1_o
partial JJ 1_o
pressure NN 1_o
of IN 1_o
O2 NNP 1_o
< NNP N
6.6 CD N
kPa NN N
( ( N
< JJ N
50 CD N
mm NN N
Hg NNP N
) ) N
and/or VBP N
arterial JJ 1_o
blood NN 1_o
oxygen NN 1_o
saturation NN 1_o
< VBD N
80 CD N
% NN N
) ) N
during IN N
treatment NN N
procedures NNS N
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
saline NN N
group NN N
( ( N
mean JJ N
82 CD N
vs NN N
36 CD N
seconds NNS N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
and CC N
distress JJ N
quantified VBN N
by IN N
a DT N
novel JJ N
behavioral JJ N
scoring VBG N
method NN N
was VBD N
much RB N
higher JJR N
. . N

Changes NNS N
in IN N
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
or CC 1_o
plasma VB 1_o
beta-endorphin JJ 1_o
, , 1_o
cortisol NN 1_o
, , 1_o
and CC 1_o
glucose JJ 1_o
concentration NN 1_o
did VBD N
not RB N
show VB N
any DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
Newborns NNP 1_p
with IN 1_p
respiratory JJ 1_p
difficulties NNS 1_p
often RB N
suffer VBP N
from IN N
hypoxemia NN N
during IN N
essential JJ N
treatment NN N
procedures NNS N
. . N

The DT N
use NN N
of IN N
opioid JJ 1_i
analgesia NN 1_i
may MD N
reduce VB N
the DT N
duration NN 1_o
of IN 1_o
hypoxemia NN 1_o
and CC N
the DT N
associated JJ N
distress NN 1_o
and CC N
, , N
therefore RB N
, , N
may MD N
improve VB N
the DT N
long-term JJ N
results NNS N
of IN N
neonatal JJ N
intensive JJ N
care NN N
. . N

-DOCSTART- -X- O O

A DT N
phase NN N
III NNP N
study NN N
of IN N
belatacept-based JJ 1_i
immunosuppression NN 1_i
regimens NNS 1_i
versus VBP 1_i
cyclosporine NN 1_i
in IN N
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
( ( N
BENEFIT NNP N
study NN N
) ) N
. . N

Belatacept NNP 1_i
, , N
a DT N
costimulation NN N
blocker NN N
, , N
may MD N
preserve VB N
renal JJ 1_o
function NN 1_o
and CC N
improve VB N
long-term JJ 1_o
outcomes NNS 1_o
versus IN N
calcineurin JJ 1_i
inhibitors NNS 1_i
in IN N
kidney NN N
transplantation NN N
. . N

This DT N
Phase NNP N
III NNP N
study NN N
( ( N
Belatacept NNP N
Evaluation NNP N
of IN N
Nephroprotection NNP N
and CC N
Efficacy NNP N
as IN N
First-line NNP N
Immunosuppression NNP N
Trial NNP N
) ) N
assessed VBD N
a DT N
more RBR N
intensive JJ N
( ( N
MI NNP N
) ) N
or CC N
less RBR N
intensive JJ N
( ( N
LI NNP N
) ) N
regimen NNS N
of IN N
belatacept JJ 1_i
versus NN 1_i
cyclosporine NN 1_i
in IN N
adults NNS 1_p
receiving VBG 1_p
a DT 1_p
kidney NN 1_p
transplant NN 1_p
from IN 1_p
living NN 1_p
or CC 1_p
standard JJ 1_p
criteria NNS 1_p
deceased VBN 1_p
donors NNS 1_p
. . 1_p

The DT N
co-primary JJ N
endpoints NNS N
at IN N
12 CD N
months NNS N
were VBD N
patient/graft JJ 1_o
survival NN 1_o
, , N
a DT N
composite JJ 1_o
renal JJ 1_o
impairment NN 1_o
endpoint NN 1_o
( ( N
percent NN N
with IN N
a DT N
measured JJ N
glomerular JJ N
filtration NN N
rate NN N
( ( N
mGFR NN N
) ) N
< VBZ N
60 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
at IN N
Month NNP N
12 CD N
or CC N
a DT N
decrease NN N
in IN N
mGFR JJ N
> NN N
or CC N
=10 VB N
mL/min/1.73 JJ N
m NN N
( ( N
2 CD N
) ) N
Month NNP N
3-Month JJ N
12 CD N
) ) N
and CC N
the DT N
incidence NN 1_o
of IN 1_o
acute JJ 1_o
rejection NN 1_o
. . 1_o

At IN N
Month NNP N
12 CD N
, , N
both DT N
belatacept IN 1_i
regimens NNS N
had VBD N
similar JJ N
patient/graft NN 1_o
survival NN 1_o
versus NN N
cyclosporine NN N
( ( N
MI NNP N
: : N
95 CD N
% NN N
, , N
LI NNP N
: : N
97 CD N
% NN N
and CC N
cyclosporine NN 1_i
: : 1_i
93 CD N
% NN N
) ) N
, , N
and CC N
were VBD N
associated VBN N
with IN N
superior JJ 1_o
renal JJ 1_o
function NN 1_o
as IN N
measured VBN N
by IN N
the DT N
composite JJ 1_o
renal JJ 1_o
impairment NN 1_o
endpoint NN 1_o
( ( N
MI NNP N
: : N
55 CD N
% NN N
; : N
LI NNP N
: : N
54 CD N
% NN N
and CC N
cyclosporine NN 1_i
: : 1_i
78 CD N
% NN N
; : N
p CC N
< CD N
or CC N
= VB N
0.001 CD N
MI NNP N
or CC N
LI NNP N
versus IN N
cyclosporine NN 1_i
) ) 1_i
and CC N
by IN N
the DT N
mGFR NN 1_o
( ( N
65 CD N
, , N
63 CD N
and CC N
50 CD N
mL/min NN N
for IN N
MI NNP N
, , N
LI NNP N
and CC N
cyclosporine NN 1_i
; : 1_i
p CC N
< CD N
or CC N
= VB N
0.001 CD N
MI NNP N
or CC N
LI NNP N
versus IN N
cyclosporine NN 1_i
) ) 1_i
. . N

Belatacept IN N
patients NNS N
experienced VBD N
a DT N
higher JJR N
incidence NN 1_o
( ( N
MI NNP N
: : N
22 CD N
% NN N
, , N
LI NNP N
: : N
17 CD N
% NN N
and CC N
cyclosporine NN 1_i
: : 1_i
7 CD N
% NN N
) ) N
and CC N
grade NN 1_o
of IN 1_o
acute JJ 1_o
rejection NN 1_o
episodes NNS 1_o
. . 1_o

Safety NN 1_o
was VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
, , N
but CC N
posttransplant JJ 1_o
lymphoproliferative JJ 1_o
disorder NN 1_o
was VBD N
more RBR N
common JJ N
in IN N
the DT N
belatacept NN 1_i
groups NNS N
. . N

Belatacept NNP 1_i
was VBD N
associated VBN N
with IN N
superior JJ N
renal JJ 1_o
function NN 1_o
and CC N
similar JJ N
patient/graft NN 1_o
survival NN 1_o
versus NN N
cyclosporine NN 1_i
at IN N
1 CD N
year NN N
posttransplant NN N
, , N
despite IN N
a DT N
higher JJR N
rate NN 1_o
of IN 1_o
early JJ 1_o
acute JJ 1_o
rejection NN 1_o
. . 1_o

-DOCSTART- -X- O O

[ NN N
Study NNP N
on IN N
safety NN N
and CC N
immunogenicity NN N
of IN N
oral JJ 1_i
poliomyelitis NN 1_i
attenuated VBD 1_i
live JJ 1_i
vaccine NN 1_i
( ( N
human JJ N
diploid NN N
cell NN N
) ) N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN 1_o
and CC N
Immunogenicity NNP 1_o
of IN N
the DT N
Poliomyelitis NNP 1_i
vaccine NN 1_i
( ( N
Human NNP N
Diploid NNP N
Cell NNP N
) ) N
in IN N
> NN N
or CC N
=2 VB 1_p
month-old JJ 1_p
children NNS 1_p
. . 1_p

METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD 1_p
healthy JJ 1_p
children NNS 1_p
of IN 1_p
2-5 JJ 1_p
months NNS 1_p
old JJ 1_p
in IN 1_p
Jiangsu NNP 1_p
province NN 1_p
were VBD 1_p
administered VBN 1_p
OPV NNP 1_i
( ( 1_i
HDC NNP 1_i
) ) 1_i
vaccine NN 1_i
and CC 1_i
control NN 1_i
vaccines NNS 1_i
. . 1_i

The DT N
antibody NN N
was VBD N
tested VBN N
by IN N
neutralization NN N
test NN N
. . N

RESULTS NNP N
After IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP 1_i
( ( 1_i
HDC NNP 1_i
) ) 1_i
vaccine NN 1_i
, , N
the DT N
systemic JJ 1_o
reactions NNS 1_o
were VBD N
mild JJ N
. . N

After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP 1_i
( ( 1_i
HDC NNP 1_i
) ) 1_i
vaccine NN 1_i
, , N
the DT N
immune JJ 1_o
success NN 1_o
rates NNS 1_o
of IN 1_o
I PRP 1_o
, , 1_o
II NNP 1_o
, , 1_o
III NNP 1_o
type NN 1_o
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP 1_o
of IN 1_o
I PRP 1_o
, , 1_o
II NNP 1_o
, , 1_o
III NNP 1_o
type NN 1_o
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
OPV NNP 1_i
( ( 1_i
HDC NNP 1_i
) ) 1_i
vaccine NN 1_i
was VBD N
safe JJ N
and CC N
immunogenicity NN N
for IN N
the DT 1_p
children NNS 1_p
> VBP 1_p
or CC 1_p
=2 JJ 1_p
months NNS 1_p
old JJ 1_p
. . 1_p

-DOCSTART- -X- O O

[ NN 1_p
Evaluating VBG 1_p
an DT 1_p
interactive JJ 1_i
, , 1_i
multi-media JJ 1_i
learning NN 1_i
system NN 1_i
for IN 1_p
the DT 1_p
study NN 1_p
of IN 1_p
primary JJ 1_p
open JJ 1_p
angle NN 1_p
glaucoma NN 1_p
] NNP 1_p
. . N

Using VBG N
the DT N
interactive JJ 1_i
multimedia NN 1_i
learning NN 1_i
system NN 1_i
for IN N
studying VBG N
open-angle JJ 1_p
glaucoma NN 1_p
[ $ N
3 CD N
] CC N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
case-controlled JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
value NN N
of IN N
this DT N
new JJ N
form NN N
of IN N
learning VBG N
in IN N
terms NNS N
of IN N
acceptance NN 1_o
and CC 1_o
the DT 1_o
imparting NN 1_o
of IN 1_o
knowledge NN 1_o
. . 1_o

This DT N
article NN N
describes VBZ N
details NNS N
of IN N
the DT N
study NN N
and CC N
presents NNS N
their PRP$ N
results NNS N
. . N

Results NNS N
were VBD N
established VBN N
on IN N
the DT N
basis NN N
of IN N
targeted JJ N
questions NNS N
asked VBD N
prior JJ N
to TO N
and CC N
after IN N
the DT N
learning NN N
phase NN N
, , N
followed VBN N
by IN N
an DT N
analysis NN N
of IN N
frequencies NNS N
and CC N
significance NN N
testing NN N
by IN N
the DT N
Chi NNP N
squared VBD N
method NN N
. . N

It PRP N
was VBD N
shown VBN N
that IN N
the DT N
imparting NN 1_o
of IN 1_o
knowledge NN 1_o
is VBZ N
significantly RB N
improved VBN N
when WRB N
this DT N
learning NN 1_i
system NN 1_i
is VBZ N
employed VBN N
. . N

In IN N
addition NN N
, , N
after IN N
its PRP$ N
first JJ N
use NN N
, , N
acceptance NN 1_o
of IN 1_o
this DT 1_o
new JJ 1_o
medium NN 1_o
rose VBD N
dramatically RB N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
between IN N
the DT N
effect NN N
of IN N
oxytocin NN 1_i
only RB 1_i
and CC N
oxytocin JJ 1_i
plus CC 1_i
propranolol NN 1_i
on IN N
the DT N
labor NN 1_o
( ( N
a DT N
double NN N
blind NN N
randomized VBN N
trial NN N
) ) N
. . N

OBJECTIVE CC N
The DT N
comparison NN N
between IN N
the DT N
effect NN N
of IN N
oxytocin NN 1_i
alone RB 1_i
or CC N
in IN 1_i
combination NN 1_i
with IN 1_i
propranolol NN 1_i
on IN N
labor NN 1_o
. . 1_o

METHODS NNP N
A NNP N
double JJ N
blind NN N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
performed VBN N
on IN N
150 CD 1_p
nulliparas NNS 1_p
with IN 1_p
a DT 1_p
gestational JJ 1_p
age NN 1_p
of IN 1_p
39-41 JJ 1_p
weeks NNS 1_p
of IN 1_p
pregnancy NN 1_p
and CC 1_p
a DT 1_p
Bishop NNP 1_p
score NN 1_p
of IN 1_p
< NN 1_p
or CC 1_p
=5 NN 1_p
. . 1_p

In IN N
the DT N
first JJ N
group NN N
( ( 1_i
oxytocin JJ 1_i
group NN N
= NNP N
75 CD N
) ) N
, , N
oxytocin FW 1_i
alone RB 1_i
was VBD N
used VBN N
for IN N
induction NN 1_o
of IN 1_o
labor NN 1_o
. . 1_o

In IN N
the DT N
second JJ N
group NN N
( ( 1_i
propranolol JJ 1_i
group NN N
= VBD N
75 CD N
cases NNS N
) ) N
, , N
before IN N
the DT N
beginning NN N
of IN N
oxytocin NN 1_i
, , N
2 CD N
mg NN N
propranolol NN 1_i
was VBD N
slowly RB N
injected VBN N
intravenously RB N
then RB N
the DT N
oxytocin NN 1_i
was VBD N
initiated VBN N
. . N

RESULTS VB N
The DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
delivered VBD 1_o
in IN 1_o
the DT 1_o
first JJ 1_o
day NN 1_o
showed VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
mean JJ N
duration NN 1_o
for IN 1_o
obtaining VBG 1_o
good JJ 1_o
contractions NNS 1_o
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN 1_i
group NN N
in IN N
both CC N
the DT N
first JJ N
and CC N
second JJ N
day NN N
of IN N
induction NN N
The DT N
mean JJ N
interval NN N
between IN N
the DT N
beginning NN N
of IN N
induction NN N
until IN N
the DT N
beginning NN N
of IN N
active JJ N
phase NN N
at IN N
the DT N
first JJ N
day NN N
of IN N
induction NN N
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN 1_i
group NN N
. . N

The DT N
mean JJ 1_o
interval NN 1_o
between IN 1_o
the DT 1_o
beginning NN 1_o
of IN 1_o
induction NN 1_o
until IN 1_o
delivery NN 1_o
at IN 1_o
the DT 1_o
first JJ 1_o
day NN 1_o
of IN 1_o
induction NN 1_o
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN 1_i
group NN N
. . N

The DT N
amount NN 1_o
of IN 1_o
necessary JJ 1_o
oxytocin NN 1_o
for IN N
the DT N
first JJ N
day NN N
of IN N
induction NN N
was VBD N
less RBR N
in IN N
the DT N
propranolol NN 1_i
group NN N
. . N

CONCLUSION NNP N
Propranolol NNP 1_i
may MD N
shorten VB N
the DT N
induction NN 1_o
duration NN 1_o
and CC 1_o
labor NN 1_o
and CC N
reduce VB N
the DT N
amount NN N
of IN N
necessary JJ N
oxytocin NN 1_i
. . 1_i

-DOCSTART- -X- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
or CC 1_p
atrial JJ 1_p
flutter NN 1_p
. . 1_p

BACKGROUND NNP N
Diltiazem NNP 1_i
, , N
a DT N
calcium NN N
channel NN N
blocker NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
in IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
and/or IN 1_p
atrial JJ 1_p
flutter NN 1_p
. . 1_p

However RB N
, , N
there EX N
have VBP N
been VBN N
no DT N
pharmacokinetic/pharmacodynamic JJ N
studies NNS N
of IN N
diltiazem NN N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ 1_i
diltiazem NNS 1_i
were VBD N
determined VBN N
in IN N
32 CD 1_p
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
or CC 1_p
atrial JJ 1_p
flutter NN 1_p
( ( 1_p
mean JJ 1_p
+/- NN 1_p
SD NNP 1_p
age NN 1_p
, , 1_p
66 CD 1_p
+/- JJ 1_p
7 CD 1_p
years NNS 1_p
; : 1_p
mean VB 1_p
baseline JJ 1_p
heart NN 1_p
rate NN 1_p
, , 1_p
131 CD 1_p
+/- JJ 1_p
10 CD 1_p
beats NNS 1_p
per IN 1_p
minute NN 1_p
) ) 1_p
after IN 1_p
20 CD 1_p
mg NN 1_p
or CC 1_p
20 CD 1_p
mg NN 1_p
followed VBN 1_p
by IN 1_p
25-mg JJ 1_p
bolus NN 1_p
doses NNS 1_p
and CC 1_p
a DT 1_p
10 CD 1_p
and CC 1_p
15 CD 1_p
mg/hr NN 1_p
infusion NN 1_p
for IN 1_p
24 CD 1_p
hours NNS 1_p
. . N

After IN N
the DT N
10 CD N
and CC N
15 CD N
mg/hr JJ N
infusions NNS N
of IN N
diltiazem NN 1_i
, , N
mean JJ N
+/- JJ N
SD NNP N
elimination NN N
half-life NN N
was VBD N
6.8 CD N
+/- JJ N
1.8 CD N
and CC N
6.9 CD N
+/- JJ N
1.5 CD N
hours NNS N
, , N
volume NN N
of IN N
distribution NN N
was VBD N
411 CD N
+/- JJ N
151.8 CD N
and CC N
299 CD N
+/- JJ N
70.8 CD N
I PRP N
, , N
and CC N
systemic JJ N
clearance NN N
was VBD N
42 CD N
+/- JJ N
12.4 CD N
and CC N
31 CD N
+/- JJ N
8.3 CD N
l/hr NN N
, , N
respectively RB N
. . N

Percentages NNS 1_o
of IN 1_o
the DT 1_o
plasma JJ 1_o
concentrations NNS 1_o
of IN 1_o
the DT 1_o
principal JJ 1_o
metabolites NNS 1_o
desacetyldiltiazem NNS 1_o
and CC 1_o
N-desmethyldiltiazem NNP 1_o
to TO 1_o
diltiazem VB 1_o
were VBD N
< JJ N
15 CD N
% NN N
and CC N
< $ N
10 CD N
% NN N
, , N
respectively RB N
. . N

Thirty NNP 1_p
of IN 1_p
32 CD 1_p
patients NNS 1_p
maintained VBD N
response NN N
throughout IN N
the DT N
24-hour JJ N
infusion NN N
of IN N
diltiazem NN N
. . N

Using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
pharmacodynamic JJ N
model NN N
, , N
a DT N
strong JJ N
relation NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
0.78 CD N
+/- JJ N
0.2 CD N
) ) N
was VBD N
observed VBN N
between IN N
plasma NN 1_o
diltiazem NN 1_o
concentration NN 1_o
and CC 1_o
percent JJ 1_o
heart NN 1_o
rate NN 1_o
reduction NN 1_o
. . 1_o

Mean JJ 1_o
+/- JJ 1_o
SD NNP 1_o
Emax NNP 1_o
( ( N
maximum JJ N
percent NN N
reduction NN N
in IN N
heart NN N
rate NN N
from IN N
baseline NN N
) ) N
and CC N
EC50 NNP 1_o
( ( N
plasma JJ N
diltiazem NN N
concentration NN N
that WDT N
achieves VBZ N
half DT N
Emax NNP N
) ) N
were VBD N
52 CD N
+/- JJ N
17 CD N
% NN N
and CC N
110 CD N
+/- JJ N
84 CD N
ng/ml NN N
, , N
respectively RB N
. . N

The DT N
model NN N
predicts VBZ N
that IN N
mean JJ N
plasma NN 1_o
diltiazem NN 1_o
concentration NN 1_o
of IN N
79 CD N
, , N
172 CD N
, , N
and CC N
294 CD N
ng/ml NNS N
are VBP N
required VBN N
to TO N
produce VB N
a DT N
20 CD N
% NN N
, , N
30 CD N
% NN N
, , N
and CC N
40 CD N
% NN N
reduction NN N
in IN N
heart NN 1_o
rate NN 1_o
, , N
respectively RB N
. . N

A DT N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent NN N
change NN N
in IN N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
SBP NNP 1_o
) ) 1_o
or CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
DBP NNP 1_o
) ) 1_o
from IN N
baseline NN N
was VBD N
not RB N
observed VBN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
SBP/DBP NNP N
: : N
0.35 CD N
+/- JJ N
0.24/0.36 CD N
+/- JJ N
0.2 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
untoward JJ N
side NN N
effects NNS N
observed VBN N
. . N

CONCLUSIONS NNP N
First NNP N
, , N
the DT N
pharmacokinetics NNS N
of IN N
diltiazem NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
or CC 1_p
atrial JJ 1_p
flutter NN 1_p
is VBZ N
nonlinear JJ N
with IN N
an DT N
apparent JJ N
dose-dependent JJ N
decrease NN N
in IN N
systemic JJ N
clearance NN N
with IN N
increasing VBG N
infusion NN N
rate NN N
. . N

Second NNP N
, , N
using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
model NN N
, , N
there EX N
is VBZ N
a DT N
strong JJ N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent JJ N
heart NN N
rate NN N
reduction NN N
. . N

Third NNP N
, , N
the DT N
plasma JJ N
concentrations NNS N
of IN N
the DT N
principal JJ N
metabolites NNS N
desacetyldiltiazem NNS N
and CC N
N-desmethyldiltiazem NNP N
are VBP N
low JJ N
and CC N
are VBP N
not RB N
expected VBN N
to TO N
contribute VB N
significantly RB N
to TO N
the DT N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

[ RB N
Clinical NNP N
study NN N
of IN N
feiyanqing VBG 1_i
rectum NN 1_i
condensed VBD 1_i
liquid NN 1_i
in IN N
treating VBG N
36 CD N
cases NNS N
of IN N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanism NN N
of IN N
Feiyangqin NNP 1_i
Rectum NNP 1_i
Condensed VBD 1_i
Liquid NNP 1_i
( ( 1_i
FRCL NNP 1_i
) ) 1_i
in IN N
treating VBG N
children NNS 1_p
syncytial JJ 1_p
viral JJ 1_p
pneumonia NN 1_p
. . 1_p

Methods NNS N
Seventy-two JJ 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
, , 1_p
the DT 1_p
36 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
treated JJ 1_p
group NN 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
FRCL NNP 1_i
, , 1_p
and CC 1_p
the DT 1_p
other JJ 1_p
36 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
control NN 1_p
group NN 1_p
simply RB 1_p
treated VBD 1_p
with IN 1_p
Western JJ 1_i
medicine NN 1_i
. . 1_i

Efficacy NN 1_o
of IN N
treatment NN N
on IN N
clinical JJ N
condition NN N
and CC N
some DT N
immune JJ 1_o
function NN 1_o
( ( 1_o
IgA NNP 1_o
, , 1_o
IgG NNP 1_o
, , 1_o
CD3 NNP 1_o
, , 1_o
CD4 NNP 1_o
) ) 1_o
were VBD N
observed VBN N
. . N

RESULTS NNP N
In IN N
the DT N
treated JJ N
group NN N
, , N
28 CD N
patients NNS N
were VBD N
cured VBN 1_o
( ( N
77.8 CD N
% NN N
) ) N
, , N
treatment NN N
was VBD N
markedly RB N
effective JJ N
in IN N
4 CD N
patients NNS N
( ( N
11.1 CD N
% NN N
) ) N
, , N
effective JJ N
in IN N
2 CD N
( ( N
5.5 CD N
% NN N
) ) N
and CC N
ineffective JJ N
in IN N
2 CD N
( ( N
5.6 CD N
% NN N
) ) N
, , N
with IN N
the DT N
total JJ 1_o
effective JJ 1_o
rate NN 1_o
of IN N
94.4 CD N
% NN N
. . N

The DT N
corresponding JJ N
number NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
20 CD N
( ( N
55.6 CD N
% NN N
) ) N
, , N
7 CD N
( ( N
19.4 CD N
% NN N
) ) N
, , N
6 CD N
( ( N
16.7 CD N
% NN N
) ) N
, , N
3 CD N
( ( N
8.3 CD N
% NN N
) ) N
and CC N
91.7 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
cure NN 1_o
rate NN 1_o
in IN N
the DT N
treated JJ N
group NN N
was VBD N
obviously RB N
superior JJ N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

FRCL NNP 1_i
could MD N
improve VB N
serum NN 1_o
IgA NNP 1_o
, , 1_o
IgG NNP 1_o
, , 1_o
CD3 NNP 1_o
, , 1_o
CD4 NNP 1_o
, , 1_o
and CC 1_o
CD4/CD8 NNP 1_o
, , 1_o
lower JJR 1_o
serum NN 1_o
IgE NNP 1_o
, , N
these DT N
indexes NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
significantly RB N
different JJ N
to TO N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
FRCL NNP 1_i
had VBD N
the DT N
action NN N
in IN N
treating VBG N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
without IN N
any DT N
adverse JJ N
reaction NN N
, , N
one CD N
of IN N
its PRP$ N
mechanisms NN N
might MD N
be VB N
related VBN N
to TO N
its PRP$ N
regulation NN N
on IN N
immune JJ N
function NN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
of IN N
oral JJ 1_i
erythromycin FW 1_i
versus FW 1_i
oral JJ 1_i
tetracycline NN 1_i
in IN N
the DT N
treatment NN N
of IN N
acne JJ 1_o
vulgaris NN 1_o
. . 1_o

A DT N
double-blind JJ N
study NN N
. . N

The DT N
efficacy NN 1_o
of IN N
erythromycin JJ 1_o
base NN 1_o
( ( 1_o
E-Mycin JJ 1_o
tablets NNS 1_o
, , 1_o
333 CD 1_o
mg NN 1_o
) ) 1_o
and CC N
the DT N
efficacy NN 1_o
of IN N
tetracycline JJ 1_o
hydrochloride NN 1_o
( ( N
Panmycin NNP N
tablets NNS N
) ) N
were VBD N
compared VBN N
in IN N
this DT N
double-blind NN N
, , N
randomized VBN N
study NN N
. . N

Two CD 1_p
hundred VBD 1_p
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
moderately RB 1_p
severe JJ 1_p
acne NNS 1_p
vulgaris NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
study NN N
. . N

One CD N
hundred VBD N
patients NNS N
received VBD N
1 CD 1_i
gm NN 1_i
of IN 1_i
erythromycin JJ 1_i
base NN 1_i
by IN N
mouth JJ N
per IN N
day NN N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
333 CD N
mg/day NN N
for IN N
8 CD N
weeks NNS N
, , N
plus CC N
placebo NN 1_i
for IN 1_i
tetracycline NN 1_i
. . 1_i

The DT N
second JJ N
group NN N
of IN N
patients NNS N
received VBD N
1 CD N
gm NN N
of IN N
tetracycline NN 1_i
by IN N
mouth JJ N
per IN N
day NN N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
500 CD N
mg/day NN N
for IN N
8 CD N
weeks NNS N
, , N
plus CC N
placebo NN 1_i
for IN 1_i
erythromycin NN 1_i
. . 1_i

Both DT N
drugs NNS N
reduced VBD N
acne JJ 1_o
severity NN 1_o
to TO N
the DT N
same JJ N
extent NN N
. . N

Pustules NNP 1_o
, , 1_o
papules NNS 1_o
, , 1_o
and CC 1_o
open JJ 1_o
comedo NN 1_o
counts NNS 1_o
decreased VBN N
significantly RB N
over IN N
the DT N
12-week JJ N
period NN N
. . N

Seventy-seven JJ N
percent NN N
of IN N
the DT N
erythromycin-treated JJ N
patients NNS N
and CC N
89 CD N
% NN N
of IN N
the DT N
tetracycline-treated JJ N
patients NNS N
stated VBD N
that IN N
their PRP$ N
acne NN 1_o
was VBD N
markedly RB N
improved VBN N
or CC N
improved VBN N
by IN N
week NN N
12 CD N
. . N

Most JJS N
of IN N
the DT N
side NN N
effects NNS N
in IN N
patients NNS N
treated VBN N
with IN N
erythromycin NNS N
were VBD N
gastrointestinal JJ 1_o
symptoms NNS 1_o
. . 1_o

Among IN N
the DT N
side NN N
effects NNS N
in IN N
patients NNS N
treated VBN N
with IN N
tetracycline NN N
were VBD N
Candida NNP 1_o
vaginitis NN 1_o
in IN N
one CD N
patient NN N
and CC N
pseudotumor NN 1_o
cerebri NN 1_o
in IN N
one CD N
patient NN N
. . N

-DOCSTART- -X- O O

Extra JJ 1_i
prompts NNS 1_i
versus IN N
no DT 1_i
extra JJ 1_i
prompts NNS 1_i
in IN N
self-care JJ N
training NN N
of IN N
autistic JJ 1_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
. . 1_p

A DT N
color-coded JJ 1_i
extra JJ 1_i
prompt JJ 1_i
procedure NN 1_i
was VBD 1_i
compared VBN 1_i
to TO 1_i
a DT 1_i
no DT 1_i
extra JJ 1_i
prompt JJ 1_i
procedure NN 1_i
in IN N
teaching VBG N
autistic JJ 1_p
children NNS 1_p
and CC 1_p
adolescents VBZ 1_p
how WRB N
to TO N
lace VB N
shoes NNS N
. . N

One CD N
randomly NN N
assigned VBN N
group NN N
of IN N
10 CD 1_p
autistic JJ 1_p
subjects NNS 1_p
first RB N
learned VBD 1_i
to TO 1_i
lace VB 1_i
shoes NNS 1_i
whose WP$ 1_i
laces NNS 1_i
and CC 1_i
eyelets NNS 1_i
were VBD 1_i
color-coded JJ 1_i
red JJ 1_i
and CC 1_i
white JJ 1_i
, , 1_i
and CC 1_i
then RB 1_i
encountered VBD 1_i
the DT 1_i
no DT 1_i
extra JJ 1_i
prompt JJ 1_i
condition NN 1_i
in IN 1_i
which WDT 1_i
color NN 1_i
codes NNS 1_i
could MD 1_i
no RB 1_i
longer RB 1_i
be VB 1_i
depended VBN 1_i
upon IN 1_i
to TO 1_i
solve VB 1_i
the DT 1_i
position NN 1_i
discriminations NNS 1_i
required VBN 1_i
to TO 1_i
lace VB 1_i
properly RB 1_i
. . 1_i

In IN N
a DT N
counterbalanced JJ N
fashion NN N
, , N
the DT N
other JJ N
group NN N
of IN N
10 CD 1_p
autistic JJ 1_p
subjects NNS 1_p
reached VBN N
criterion NN N
on IN N
the DT N
non-color-coded JJ N
, , N
naturalistic JJ N
shoe NN N
before IN N
experiencing VBG N
the DT N
extra JJ N
prompt JJ N
condition NN N
. . N

Analysis NN N
of IN N
variance NN N
and CC N
post-hoc JJ N
analyses NNS N
suggest VBP N
that IN N
subjects NNS N
who WP N
first RB N
learned VBN N
under IN N
the DT N
color-coded JJ N
, , N
extra JJ N
prompt JJ N
condition NN N
encountered VBD N
significant JJ N
difficulty NN N
in IN N
transferring VBG N
their PRP$ N
newly RB N
acquired VBN N
skill NN N
to TO N
the DT N
naturalistic JJ N
, , N
non-color-coded JJ N
condition NN N
, , N
whereas JJ N
subjects NNS N
who WP N
learned VBD N
initially RB N
without IN N
the DT N
extra JJ N
prompts NNS N
had VBD N
little JJ N
difficulty NN N
with IN N
the DT N
subsequent JJ N
color-coded JJ N
condition NN N
. . N

A DT N
follow-up JJ N
procedure NN N
requiring VBG N
all DT N
subjects NNS N
to TO N
choose VB N
between IN N
the DT N
color NN N
prompt NN N
and CC N
the DT N
position NN N
cue NN N
revealed VBD N
that IN N
11 CD N
of IN N
20 CD 1_p
subjects NNS 1_p
consistently RB N
chose VBD N
the DT N
color NN N
cue NN N
, , N
even RB N
though IN N
it PRP N
resulted VBD N
in IN N
improper JJ N
lacing NN N
. . N

It PRP N
is VBZ N
recommended VBN N
that IN N
clinicians NNS N
avoid VBP N
the DT N
use NN N
of IN N
highly RB N
salient JJ N
, , N
non-criterion-related JJ N
prompts NNS N
in IN N
teaching VBG N
certain JJ N
types NNS N
of IN N
adaptive JJ N
skills NNS N
to TO N
autistic JJ 1_p
children NNS 1_p
. . 1_p

-DOCSTART- -X- O O

[ RB N
Clinical JJ N
benefits NNS N
of IN N
normothermic JJ 1_i
cardiopulmonary JJ 1_i
bypass NN 1_i
on IN N
postoperative JJ N
systemic JJ N
metabolism NN N
] NNP N
. . N

To TO N
evaluate VB N
the DT N
influence NN N
of IN N
body NN N
temperature NN N
during IN N
cardiopulmonary JJ 1_i
bypass NN 1_i
( ( 1_i
CPB NNP 1_i
) ) 1_i
on IN N
postoperative JJ 1_o
systemic JJ 1_o
metabolism NN 1_o
, , N
32 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
elective JJ 1_p
cardiac NN 1_p
surgery NN 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
either DT 1_p
hypothermia NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
16 CD 1_p
) ) 1_p
or CC 1_p
normothermia NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
16 CD 1_p
) ) 1_p
. . 1_p

Serial JJ N
hemodynamic JJ N
parameters NNS N
and CC N
blood NN N
samples NNS N
were VBD N
obtained VBN N
after IN N
surgery NN N
. . N

CPB NNP 1_o
and CC 1_o
operation NN 1_o
times NNS 1_o
were VBD N
significantly RB N
shorter JJR N
and CC N
the DT N
platelet NN 1_o
reduction NN 1_o
ratio NN 1_o
during IN N
CPB NNP 1_i
[ NNP N
= NNP N
( ( N
platelets NNS N
before IN N
CPB-platelets NNS N
after IN N
CPB NNP N
) ) N
/platelets VBZ N
before IN N
CPB NNP N
] NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
normothermic JJ N
patients NNS N
than IN N
in IN N
hypothermic JJ N
patients NNS N
. . N

The DT N
platelet NN 1_o
reduction NN 1_o
ratio NN 1_o
was VBD N
dependent JJ N
on IN N
the DT N
minimum JJ N
rectal JJ N
temperature NN N
during IN N
CPB NNP 1_o
, , 1_o
the DT 1_o
operation NN 1_o
time NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
CPB NNP 1_o
time NN 1_o
. . 1_o

In IN N
the DT N
early JJ N
postoperative JJ N
period NN N
, , N
hypothermic JJ N
patients NNS N
had VBD N
abnormally RB N
high JJ 1_o
systemic JJ 1_o
vascular NN 1_o
resistance NN 1_o
and CC 1_o
a DT 1_o
reduced JJ 1_o
cardiac JJ 1_o
index NN 1_o
compared VBN 1_o
with IN 1_o
the DT 1_o
normothermic JJ 1_o
patients NNS 1_o
. . 1_o

There EX N
were VBD N
no DT N
differences NNS N
between IN N
2 CD N
groups NNS N
in IN N
postoperative JJ 1_o
hepatic JJ 1_o
and CC 1_o
renal JJ 1_o
functions NNS 1_o
, , 1_o
changes NNS 1_o
in IN 1_o
oxygen NN 1_o
consumption NN 1_o
, , 1_o
arterial-venous JJ 1_o
PCO2 NNP 1_o
or CC 1_o
arterial-venous JJ 1_o
pH JJ 1_o
gradient NN 1_o
. . 1_o

This DT N
study NN N
suggested VBD N
a DT N
beneficial JJ N
influence NN N
of IN N
normothermic JJ 1_i
CPB NNP 1_i
on IN N
postoperative JJ 1_o
hemodynamics NNS 1_o
. . 1_o

Normothermic NNP 1_i
CPB NNP 1_i
was VBD N
not RB N
associated VBN N
with IN N
adverse JJ 1_o
effects NNS 1_o
on IN N
postoperative JJ 1_o
metabolic JJ 1_o
recovery NN 1_o
. . 1_o

-DOCSTART- -X- O O

Oral NNP 1_i
sucrose VBD 1_i
as IN N
an DT N
analgesic JJ N
drug NN N
for IN N
procedural JJ N
pain NN N
in IN N
newborn JJ 1_p
infants NNS 1_p
: : 1_p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Many JJ N
infants NNS 1_p
admitted VBN 1_p
to TO 1_p
hospital VB 1_p
undergo RB N
repeated VBN N
invasive JJ N
procedures NNS N
. . N

Oral NNP 1_i
sucrose NN 1_i
is VBZ N
frequently RB N
given VBN N
to TO N
relieve VB N
procedural JJ N
pain NN N
in IN N
neonates NNS 1_p
on IN N
the DT N
basis NN N
of IN N
its PRP$ N
effect NN N
on IN N
behavioural JJ N
and CC N
physiological JJ N
pain NN N
scores NNS N
. . N

We PRP N
assessed VBD N
whether IN N
sucrose JJ 1_i
administration NN N
reduces NNS N
pain-specific JJ 1_o
brain NN 1_o
and CC 1_o
spinal JJ 1_o
cord NN 1_o
activity NN 1_o
after IN N
an DT N
acute JJ 1_p
noxious JJ 1_p
procedure NN 1_p
in IN N
newborn JJ 1_p
infants NNS 1_p
. . 1_p

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
, , N
59 CD 1_p
newborn JJ 1_p
infants NNS 1_p
at IN 1_p
University NNP 1_p
College NNP 1_p
Hospital NNP 1_p
( ( 1_p
London NNP 1_p
, , 1_p
UK NNP 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
0?5 CD N
mL JJ N
24 CD 1_i
% NN 1_i
sucrose JJ 1_i
solution NN 1_i
or CC N
0?5 CD N
mL NNS N
sterile JJ 1_i
water NN 1_i
2 CD 1_i
min NN N
before IN N
undergoing VBG N
a DT N
clinically RB N
required VBN N
heel NN N
lance NN N
. . N

Randomisation NN N
was VBD N
by IN N
a DT N
computer-generated JJ N
randomisation NN N
code NN N
, , N
and CC N
researchers NNS N
, , N
clinicians NNS N
, , N
participants NNS N
, , N
and CC N
parents NNS N
were VBD N
masked VBN N
to TO N
the DT N
identity NN N
of IN N
the DT N
solutions NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD 1_o
pain-specific JJ 1_o
brain NN 1_o
activity NN 1_o
evoked VBN 1_o
by IN 1_o
one CD N
time-locked JJ N
heel NN N
lance NN 1_o
, , 1_o
recorded VBN 1_o
with IN 1_o
electroencephalography NN 1_o
and CC 1_o
identified VBN 1_o
by IN 1_o
principal JJ 1_o
component NN 1_o
analysis NN 1_o
. . 1_o

Secondary JJ N
measures NNS N
were VBD 1_o
baseline JJ 1_o
behavioural JJ 1_o
and CC 1_o
physiological JJ 1_o
measures NNS 1_o
, , 1_o
observational JJ 1_o
pain NN 1_o
scores NNS 1_o
( ( 1_o
PIPP NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
spinal JJ 1_o
nociceptive JJ 1_o
reflex NN 1_o
withdrawal NN 1_o
activity NN 1_o
. . 1_o

Data NNS N
were VBD N
analysed VBN N
per IN N
protocol NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
, , N
number NN N
ISRCTN78390996 NNP N
. . N

FINDINGS NNP N
29 CD N
infants NNS 1_p
were VBD 1_p
assigned VBN N
to TO N
receive VB 1_i
sucrose NN 1_i
and CC 1_i
30 CD N
to TO N
sterilised JJ 1_i
water NN 1_i
; : 1_i
20 CD 1_i
and CC N
24 CD N
infants NNS N
, , N
respectively RB N
, , N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
of IN N
the DT N
primary JJ N
outcome JJ N
measure NN 1_o
. . 1_o

Nociceptive JJ 1_o
brain NN 1_o
activity NN 1_o
after IN 1_o
the DT 1_o
noxious JJ 1_o
heel NN 1_o
lance NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
infants NNS N
who WP N
received VBD 1_i
sucrose JJ 1_i
and CC 1_i
those DT N
who WP N
received VBD 1_i
sterile JJ 1_i
water NN 1_i
( ( 1_i
sucrose JJ 1_i
: : 1_i
mean JJ 1_i
0?10 CD N
, , N
95 CD N
% NN N
CI NNP N
0?04-0?16 CD 1_i
; : 1_i
sterile JJ 1_i
water NN 1_i
: : 1_i
mean NN 1_i
0?08 CD N
, , N
0?04-0?12 CD N
; : N
p=0?46 NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
recorded VBN N
between IN N
the DT 1_i
sucrose NN 1_i
and CC 1_i
sterile JJ 1_i
water NN 1_i
groups NNS 1_i
in IN N
the DT N
magnitude NN N
or CC 1_o
latency NN 1_o
of IN 1_o
the DT 1_o
spinal JJ 1_o
nociceptive JJ 1_o
reflex NN 1_o
withdrawal NN 1_o
recorded VBN 1_o
from IN N
the DT N
biceps NNS N
femoris NN N
of IN N
the DT N
stimulated JJ N
leg NN N
. . N

The DT N
PIPP NNP 1_o
score NN 1_o
was VBD 1_o
significantly RB N
lower JJR N
in IN N
infants NNS N
given VBN 1_i
sucrose JJR 1_i
than IN N
in IN N
those DT N
given VBN 1_i
sterile JJ 1_i
water NN 1_i
( ( 1_i
mean JJ 1_i
5?8 CD N
, , N
95 CD N
% NN N
CI NNP N
3?7-7?8 CD N
vs NN N
8?5 CD N
, , N
7?3-9?8 CD N
; : N
p=0?02 NN N
) ) N
and CC N
significantly RB N
more JJR 1_p
infants NNS 1_p
had VBD 1_p
no DT N
change NN N
in IN N
facial JJ N
expression NN N
after IN N
sucrose JJ 1_i
administration NN 1_i
( ( N
seven CD N
of IN N
20 CD N
[ JJ N
35 CD N
% NN N
] JJ N
vs NN N
none NN N
of IN N
24 CD N
; : N
p NN N
< VBZ N
0?0001 CD N
) ) N
. . N

INTERPRETATION NNP N
Our PRP$ N
data NNS N
suggest VBP N
that IN N
oral JJ N
sucrose NN 1_i
does VBZ 1_i
not RB N
significantly RB N
affect JJ N
activity NN N
in IN 1_p
neonatal JJ 1_p
brain NN 1_p
or CC N
spinal JJ N
cord NN N
nociceptive JJ N
circuits NNS N
, , N
and CC N
therefore RB N
might MD N
not RB N
be VB N
an DT N
effective JJ N
analgesic JJ N
drug NN N
. . N

The DT N
ability NN N
of IN 1_i
sucrose NN 1_i
to TO 1_i
reduce VB 1_i
clinical JJ N
observational JJ N
scores NNS N
after IN N
noxious JJ N
events NNS N
in IN N
newborn JJ 1_p
infants NNS 1_p
should MD N
not RB N
be VB N
interpreted VBN N
as IN N
pain NN N
relief NN N
. . N

FUNDING NNP N
Medical NNP N
Research NNP N
Council NNP N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
World NNP 1_i
Wide NNP 1_i
Web-based JJ 1_i
directories NNS 1_i
for IN N
tracing VBG 1_p
subjects NNS 1_p
in IN 1_p
epidemiologic JJ 1_p
studies NNS 1_p
. . 1_p

The DT N
recent JJ N
availability NN N
of IN N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
has VBZ N
opened VBN N
up RP N
a DT N
new JJ N
approach NN N
for IN N
tracing VBG 1_p
subjects NNS 1_p
in IN 1_p
epidemiologic JJ 1_p
studies NNS 1_p
. . 1_p

The DT N
completeness NN N
of IN N
two CD 1_p
World NNP 1_i
Wide NNP 1_i
Web-based JJ 1_i
directories NNS 1_i
( ( 1_i
Canada411 NNP 1_i
and CC 1_i
InfoSpace NNP 1_i
Canada NNP 1_i
) ) 1_i
for IN N
subject JJ N
tracing NN N
was VBD N
evaluated VBN N
by IN N
using VBG N
a DT N
randomized VBN N
crossover NN N
design NN N
for IN N
346 CD 1_p
adults NNS 1_p
randomly RB 1_p
selected VBN 1_p
from IN 1_p
respondents NNS 1_p
in IN 1_p
an DT 1_p
ongoing JJ 1_p
cohort NN 1_p
study NN 1_p
. . 1_p

About IN N
half NN N
( ( N
56.4 CD N
% NN N
) ) N
of IN N
the DT N
subjects NNS N
were VBD N
successfully RB N
located VBN N
by IN N
using VBG N
either CC N
Canada411 NNP 1_i
or CC 1_i
InfoSpace NNP 1_i
. . 1_i

Of IN N
the DT N
43.6 CD N
% NN N
of IN N
the DT N
subjects NNS N
who WP N
could MD N
not RB N
be VB N
located VBN N
using VBG N
either CC N
directory NN N
, , N
the DT N
majority NN N
( ( N
73.5 CD N
% NN N
) ) N
were VBD N
female JJ N
. . N

Overall JJ N
, , N
there EX N
was VBD N
no DT N
clear JJ N
advantage NN 1_o
of IN N
one CD N
directory NN N
over IN N
the DT N
other JJ N
. . N

Although IN N
Canada411 NNP N
could MD N
find VB 1_o
significantly RB 1_o
more RBR 1_o
subjects NNS 1_o
than IN N
InfoSpace NNP N
, , N
the DT N
number NN 1_o
of IN 1_o
potential JJ 1_o
matches NNS 1_o
returned VBN N
by IN N
Canada411 NNP N
was VBD N
also RB N
higher JJR N
, , N
which WDT N
meant VBD N
that IN N
a DT N
longer RBR N
list NN N
of IN N
potential JJ N
matches NNS N
had VBD N
to TO N
be VB N
examined VBN N
before IN N
a DT N
true JJ N
match NN N
could MD N
be VB N
found VBN N
. . N

One CD N
strategy NN N
to TO N
minimize VB N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
per IN N
true JJ N
match NN N
is VBZ N
to TO N
first JJ N
search NN N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
then RB N
by IN N
Canada411 NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
and CC N
finally RB N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
initial JJ N
. . N

Internet-based JJ N
searches NNS N
represent VBP N
a DT N
potentially RB N
useful JJ N
approach NN N
to TO N
tracing VBG N
subjects NNS 1_p
in IN 1_p
epidemiologic JJ 1_p
studies NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Placebo-controlled JJ 1_i
acute JJ N
dosage NN N
naltrexone NN 1_i
study NN N
in IN N
young JJ 1_p
autistic JJ 1_p
children NNS 1_p
. . 1_p

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
crossover NN N
trial NN N
23 CD 1_p
autistic JJ 1_p
children NNS 1_p
were VBD N
treated VBN N
with IN N
a DT N
single JJ N
40-mg JJ N
dose NN N
of IN N
the DT N
opiate JJ N
antagonist NN N
naltrexone NN 1_i
. . 1_i

Drug JJ N
effects NNS 1_o
were VBD N
monitored VBN N
by IN N
detailed JJ N
playroom NN N
observations NNS N
, , N
actometers NNS N
, , N
and CC N
parents NNS N
' POS N
checklist NN N
ratings NNS N
( ( 1_o
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
, , 1_o
social JJ 1_o
items NNS 1_o
and CC 1_o
target NN 1_o
behaviors NNS 1_o
) ) 1_o
. . 1_o

Naltrexone CD 1_i
treatment NN N
failed VBD N
to TO N
produce VB N
significant JJ 1_o
changes NNS 1_o
in IN N
social JJ 1_o
behavior NN 1_o
, , N
but CC N
it PRP N
did VBD N
reduce VB 1_o
irritability NN 1_o
and CC 1_o
target NN 1_o
scores NNS 1_o
on IN 1_o
behavior JJ 1_o
checklists NNS 1_o
. . 1_o

The DT N
playroom NN N
data NNS N
indicated VBD N
that IN N
naltrexone NN 1_i
significantly RB 1_o
affected VBD 1_o
indices NNS N
of IN N
activity NN 1_o
and CC 1_o
attention NN 1_o
. . 1_o

-DOCSTART- -X- O O

Lead-time NN N
in IN N
the DT N
European NNP N
Randomised VBD N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP 1_p
Cancer NNP 1_p
. . 1_p

BACKGROUND NNP N
Lead-time NNP N
is VBZ N
defined VBN N
as IN N
the DT N
time NN N
by IN N
which WDT N
screening VBG N
advances VBZ N
the DT N
diagnosis NN N
compared VBN N
with IN N
absence NN N
of IN N
screening VBG N
. . N

A DT N
sufficiently RB N
long JJ N
lead-time JJ N
needs NNS N
to TO N
be VB N
achieved VBN N
so RB N
that IN N
cancer NN N
can MD N
be VB N
detected VBN N
while IN N
still RB N
curable JJ N
. . N

A DT N
very RB N
short JJ N
lead-time NN N
may MD N
indicate VB N
poor JJ N
sensitivity NN N
of IN N
the DT N
screening JJ N
test NN N
, , N
while IN N
a DT N
very RB N
long JJ N
lead-time JJ N
suggests NNS N
overdiagnosis NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
, , N
a DT 1_p
total NN 1_p
of IN 1_p
56,294 CD 1_p
men NNS 1_p
aged VBN 1_p
55-74 CD 1_p
years NNS 1_p
were VBD 1_p
screened VBN 1_p
with IN 1_p
serum NN 1_i
prostate NN 1_i
specific JJ 1_i
antigen NN 1_i
( ( 1_i
PSA NNP 1_i
) ) 1_i
in IN 1_p
five CD 1_p
countries NNS 1_p
of IN 1_p
the DT 1_p
European NNP 1_p
Randomised VBD 1_p
Study NNP 1_p
of IN 1_p
Screening NNP 1_p
for IN 1_p
Prostate NNP 1_p
Cancer NNP 1_p
( ( 1_p
ERSPC NNP 1_p
) ) 1_p
with IN 1_p
an DT 1_p
overall JJ 1_p
detection NN 1_p
rate NN 1_p
( ( 1_p
prevalence NN 1_p
) ) 1_p
of IN 1_p
2.8 CD 1_p
% NN 1_p
( ( 1_p
1972 CD 1_p
prostate NN 1_p
cancers NNS 1_p
) ) 1_p
. . 1_p

Prostate NNP 1_p
cancer NN 1_p
incidence NN 1_p
among IN 1_p
92,142 CD 1_p
men NNS 1_p
randomly RB 1_p
allocated VBN 1_p
to TO 1_p
the DT 1_p
control NN 1_p
arm NN 1_p
of IN 1_p
the DT 1_p
trial NN 1_p
was VBD 1_p
also RB 1_p
assessed VBN 1_p
. . 1_p

Lead-time NNP 1_o
was VBD N
estimated VBN N
as IN N
the DT N
time NN N
required VBN N
to TO N
accumulate VB N
a DT N
similar JJ N
cumulative JJ N
risk NN N
of IN N
prostate NN N
cancer NN N
in IN N
the DT N
control NN N
arm NN N
to TO N
the DT N
detection NN N
rate NN N
in IN N
the DT N
intervention NN N
arm NN N
, , N
i.e NN N
. . N

from IN N
the DT N
ratio NN N
of IN N
detection NN N
rate NN N
( ( N
prevalence NN N
of IN N
screen-detected JJ N
cases NNS N
) ) N
and CC N
expected VBN N
incidence NN N
( ( N
cumulative JJ N
risk NN N
) ) N
. . N

RESULTS NNP N
Using VBG N
a DT N
serum JJ N
PSA NNP N
cut-off NN N
of IN N
4 CD N
ng/ml NNS N
, , N
the DT N
mean JJ 1_o
lead-time NN 1_o
in IN N
the DT N
whole NN N
study NN N
population NN N
was VBD N
estimated VBN N
as IN N
6.8 CD N
years NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
7.9-8.4 NN N
) ) N
. . N

It PRP N
was VBD N
8 CD N
years NNS N
in IN N
The DT N
Netherlands NNP 1_p
, , N
6 CD N
in IN N
Sweden NNP 1_p
and CC 1_p
Finland NNP 1_p
, , N
5 CD N
in IN N
Italy NNP 1_p
and CC N
4 CD N
in IN N
Belgium NNP 1_p
. . 1_p

The DT N
mean JJ 1_o
lead-time NN 1_o
was VBD N
similar JJ N
, , N
6-7 JJ N
years NNS N
, , N
at IN N
ages NNS N
50-64 CD N
years NNS N
, , N
but CC N
close RB N
to TO N
8 CD N
years NNS N
among IN N
men NNS N
aged VBN N
65-74 CD N
years NNS N
. . N

A DT N
lower JJR N
PSA NNP 1_o
cut-off JJ 1_o
level NN 1_o
of IN N
3 CD N
ng/ml NNS N
used VBN N
in IN N
Sweden NNP N
and CC N
The DT N
Netherlands NNP N
prolonged VBD N
the DT N
mean JJ N
lead-time JJ N
by IN N
approximately RB N
1 CD N
year NN N
. . N

Lead-time NNP 1_o
based VBN 1_o
on IN 1_o
advanced JJ 1_o
prostate NN 1_o
cancer NN 1_o
only RB N
was VBD N
slightly RB N
shorter JJR N
, , N
mean JJ N
5.3 CD N
years NNS N
( ( N
95 CD N
% NN N
CI NNP N
4.6-6.0 CD N
) ) N
. . N

The DT N
lead-time NN 1_o
for IN 1_o
the DT 1_o
second JJ 1_o
screening NN 1_o
round NN 1_o
was VBD N
slightly RB N
shorter JJR N
than IN N
that DT N
for IN N
the DT N
first JJ N
( ( N
5.9 CD N
, , N
95 CD N
% NN N
CI NNP N
5.4-6.4 CD N
) ) N
, , N
reflecting VBG N
a DT N
similar JJ N
relation NN N
between IN N
detection NN N
rate NN N
and CC N
control NN N
group NN N
incidence NN N
. . N

CONCLUSION VB N
The DT N
lead-time NN N
for IN N
prostate NN N
cancer NN N
found VBD N
in IN N
ERSPC NNP N
substantially RB N
exceeded VBD N
that IN N
found NN N
for IN N
breast NN N
, , N
cervical JJ N
and CC N
colorectal JJ N
cancer NN N
screening NN N
. . N

One CD N
round NN N
of IN N
prostate NN N
cancer NN N
screening VBG N
can MD N
advance VB N
clinical JJ N
diagnosis NN N
by IN N
4-8 JJ N
years NNS N
. . N

Overdiagnosis NN N
or CC N
detection NN N
of IN N
non-progressive JJ N
tumours NNS N
may MD N
contribute VB N
substantially RB N
to TO N
the DT N
lead-time NN 1_o
. . 1_o

-DOCSTART- -X- O O

Safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
oral JJ N
DMSA NNP 1_i
therapy NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
Part VB N
A DT N
-- : N
medical JJ N
results NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
oral JJ 1_i
dimercapto NN 1_i
succinic JJ 1_i
acid NN 1_i
( ( 1_i
DMSA NNP 1_i
) ) 1_i
therapy NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
ages VBZ 1_p
3-8 CD 1_p
years NNS 1_p
. . 1_p

METHODS NNP N
Phase NNP 1_p
1 CD 1_p
involved VBD 1_p
65 CD 1_p
children NNS 1_p
who WP 1_p
received VBD 1_p
one CD 1_p
round NN 1_p
of IN 1_p
DMSA NNP 1_i
( ( 1_p
3 CD 1_p
days NNS 1_p
) ) 1_p
. . 1_p

Participants NNS 1_p
who WP 1_p
had VBD 1_p
high JJ 1_p
urinary JJ 1_p
excretion NN 1_p
of IN 1_p
toxic JJ 1_p
metals NNS 1_p
were VBD N
selected VBN N
to TO N
continue VB N
on IN N
to TO N
phase VB N
2 CD N
. . N

In IN N
phase NN 1_p
2 CD 1_p
, , 1_p
49 CD 1_p
participants NNS 1_p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
double-blind JJ N
design NN N
to TO N
receive VB N
an DT N
additional JJ N
6 CD N
rounds NNS N
of IN N
either DT N
DMSA NNP 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

RESULTS NNP N
DMSA NNP N
greatly RB N
increased VBD N
the DT N
excretion NN 1_o
of IN 1_o
lead NN 1_o
, , N
substantially RB N
increased VBN N
excretion NN 1_o
of IN 1_o
tin NN 1_o
and CC 1_o
bismuth NN 1_o
, , N
and CC N
somewhat RB N
increased VBD N
the DT N
excretion NN 1_o
of IN 1_o
thallium NN 1_o
, , 1_o
mercury NN 1_o
, , 1_o
antimony NN 1_o
, , 1_o
and CC 1_o
tungsten RB 1_o
. . 1_o

There EX N
was VBD N
some DT N
increase NN N
in IN N
urinary JJ 1_o
excretion NN 1_o
of IN 1_o
essential JJ 1_o
minerals NNS 1_o
, , N
especially RB N
potassium JJ N
and CC N
chromium NN N
. . N

The DT N
Phase NNP N
1 CD N
single JJ N
round NN N
of IN N
DMSA NNP 1_i
led VBD N
to TO N
a DT N
dramatic JJ N
normalization NN 1_o
of IN 1_o
RBC NNP 1_o
glutathione NN 1_o
in IN N
almost RB N
all DT N
cases NNS N
, , N
and CC N
greatly RB N
improved VBN N
abnormal JJ 1_o
platelet NN 1_o
counts NNS 1_o
, , N
suggesting VBG N
a DT N
significant JJ N
decrease NN N
in IN N
inflammation NN 1_o
. . 1_o

CONCLUSION NNP N
Overall NNP N
, , N
DMSA NNP 1_i
therapy NN N
seems VBZ N
to TO N
be VB N
reasonably RB N
safe JJ 1_o
, , 1_o
effective JJ 1_o
in IN N
removing VBG N
several JJ N
toxic JJ 1_o
metals NNS 1_o
( ( N
especially RB N
lead VBP N
) ) N
, , N
dramatically RB N
effective JJ N
in IN N
normalizing VBG 1_o
RBC NNP 1_o
glutathione NN 1_o
, , N
and CC N
effective JJ N
in IN N
normalizing VBG 1_o
platelet NN 1_o
counts NNS 1_o
. . 1_o

Only RB N
1 CD N
round NN N
( ( N
3 CD N
days NNS N
) ) N
was VBD N
sufficient JJ N
to TO N
improve VB N
glutathione NN 1_o
and CC 1_o
platelets NNS 1_o
. . 1_o

Additional JJ N
rounds NNS N
increased VBD N
excretion NN 1_o
of IN 1_o
toxic JJ 1_o
metals NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Local JJ 1_o
contextual JJ 1_o
processing NN 1_o
in IN N
major JJ N
depressive JJ N
disorder NN N
. . N

OBJECTIVE CC N
The DT N
study NN N
investigated VBD N
local JJ 1_o
contextual JJ 1_o
processing NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
major JJ 1_p
depressive JJ 1_p
disorder NN 1_p
( ( 1_p
MDD NNP 1_p
) ) 1_p
. . 1_p

This DT N
was VBD N
defined VBN N
as IN N
the DT N
ability NN N
to TO N
utilize VB N
predictive JJ N
contextual JJ N
information NN N
to TO N
facilitate VB N
detection NN N
of IN N
predictable JJ N
versus NN N
random JJ N
targets NNS N
. . N

METHOD NNP N
We PRP N
recorded VBD N
EEG NNP 1_i
in IN N
15 CD 1_p
MDD NNP 1_p
patients NNS 1_p
and CC 1_p
14 CD 1_p
age-matched JJ 1_p
controls NNS 1_p
. . 1_p

Recording VBG 1_i
blocks NNS 1_i
consisted VBN 1_i
of IN 1_i
targets NNS 1_i
preceded VBN 1_i
by IN 1_i
randomized JJ 1_i
sequences NNS 1_i
of IN 1_i
standards NNS 1_i
and CC 1_i
by IN 1_i
sequences NNS 1_i
of IN 1_i
standards NNS 1_i
that WDT 1_i
included VBD 1_i
a DT 1_i
predictive JJ 1_i
sequence NN 1_i
signaling VBG 1_i
the DT 1_i
occurrence NN 1_i
of IN 1_i
a DT 1_i
subsequent JJ 1_i
target NN 1_i
event NN 1_i
. . 1_i

RESULTS NNP N
Both NNP N
MDD NNP 1_p
patients NNS 1_p
and CC 1_p
age-matched JJ 1_p
controls NNS 1_p
demonstrated VBD N
a DT N
significant JJ 1_o
reaction NN 1_o
time NN 1_o
( ( 1_o
RT NNP 1_o
) ) 1_o
and CC 1_o
P3b NNP 1_o
latency NN 1_o
differences NNS 1_o
between IN N
predicted VBN N
and CC N
random JJ N
targets NNS N
. . N

However RB N
, , N
patients NNS N
demonstrated VBD N
a DT N
specific JJ 1_o
prolongation NN 1_o
of IN N
these DT N
measures NNS N
during IN N
processing NN N
of IN N
predicted JJ N
targets NNS N
, , N
as RB N
well RB N
as IN N
an DT N
attenuation NN 1_o
of IN 1_o
P3b NNP 1_o
amplitudes NNS 1_o
for IN N
the DT N
predictive JJ N
sequence NN N
. . N

In IN N
addition NN N
, , N
patients NNS N
target VBP N
N1 NNP 1_o
amplitudes NNS 1_o
were VBD 1_o
attenuated VBN 1_o
compared VBN N
with IN N
controls NNS 1_i
. . 1_i

CONCLUSION NNP N
MDD NNP 1_p
patients NNS 1_p
were VBD N
able JJ N
to TO N
utilize VB 1_o
predictive JJ 1_o
context NN 1_o
in IN N
order NN N
to TO N
facilitate VB N
processing NN N
of IN N
deterministic JJ N
targets NNS N
, , N
however RB N
, , N
this DT N
ability NN 1_o
was VBD 1_o
limited VBN 1_o
compared VBN N
to TO N
controls NNS N
, , N
as IN N
demonstrated VBN N
by IN N
context-dependent JJ N
P3b NNP N
deficits NNS N
. . N

SIGNIFICANCE NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
patients NNS N
with IN N
major JJ N
depression NN N
have VBP N
altered VBN 1_o
processing NN 1_o
of IN 1_o
local JJ 1_o
contextual JJ 1_o
processing NN 1_o
. . 1_o

-DOCSTART- -X- O O

Peripheral NNP N
intravenous JJ 1_o
line NN 1_o
survival NN 1_o
and CC N
phlebitis NN 1_o
prevention NN N
in IN N
patients NNS 1_p
receiving VBG 1_p
intravenous JJ 1_p
antibiotics NNS 1_i
: : 1_i
heparin/hydrocortisone NN N
versus IN N
in-line JJ N
filters NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
use NN N
of IN N
in-line JJ N
filtration NN N
with IN N
the DT N
addition NN N
of IN N
heparin/hydrocortisone NN 1_i
( ( N
hep/hc NN N
) ) N
to TO N
the DT N
infusate NN N
for IN N
both DT N
phlebitis NN N
prevention NN N
and CC N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
line NN N
survival NN N
in IN N
peripheral JJ N
i.v NN N
. . N

catheters NNS N
. . N

This DT N
study NN N
was VBD N
specific JJ 1_p
for IN 1_p
a DT 1_p
patient NN 1_p
group NN 1_p
receiving VBG 1_p
prolonged JJ 1_p
courses NNS 1_p
of IN 1_p
i.v NN 1_p
. . 1_p

antibiotics NNS 1_p
. . 1_p

Analysis NN N
of IN N
the DT N
two CD N
endpoints NNS N
for IN N
conventional JJ N
short JJ N
i.v NN 1_i
. . 1_i

catheters NNS 1_i
( ( N
short JJ N
lines NNS N
) ) N
versus NN N
long RB N
( ( N
30 CD N
cm NN N
) ) N
i.v NN N
. . N

catheters NNS N
( ( N
long JJ N
lines NNS N
) ) N
was VBD N
also RB N
performed VBN N
. . N

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
receiving VBG 1_p
intermittent JJ 1_p
i.v NN 1_p
. . 1_p

antibiotics NNS 1_i
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
their PRP$ N
drugs NNS N
either CC N
through IN N
an DT N
in-line JJ N
filter NN N
using VBG N
a DT N
drug-free JJ N
infusate NN N
or CC N
with IN N
no DT N
filter NN N
and CC N
an DT N
infusate NN N
containing VBG N
heparin JJ 1_i
500 CD N
units NNS N
and CC N
hydrocortisone NN 1_i
10 CD N
mg/L NN N
. . N

Infusion NN N
sites NNS N
were VBD N
assessed VBN N
daily RB N
. . N

RESULTS NNP N
Both NNP N
the DT N
hep/hc NN N
and CC N
filter NN N
groups NNS N
were VBD N
similar JJ N
in IN N
terms NNS N
of IN N
phlebitis NN 1_o
incidence NN 1_o
and CC 1_o
i.v NN 1_o
. . 1_o

line NN 1_o
survival NN 1_o
when WRB N
analyzed VBN N
separately RB N
for IN N
both DT N
short JJ N
and CC N
long JJ N
lines NNS N
. . N

Long NNP N
lines NNS N
displayed VBD N
markedly RB N
prolonged JJ N
survival NN 1_o
times NNS 1_o
and CC N
reduced JJ N
phlebitis NN 1_o
compared VBN N
with IN N
short JJ N
lines NNS N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
of IN N
i.v NN N
. . N

filters NNS N
in IN N
excluding VBG N
the DT N
large JJ N
particle NN N
load NN N
introduced VBN N
by IN N
i.v NN N
. . N

antibiotics NNS N
and CC N
hence NN N
in IN N
reducing VBG N
the DT N
subsequent JJ N
phlebitis NN N
makes VBZ N
them PRP N
a DT N
useful JJ N
alternative NN N
to TO N
the DT N
use NN N
of IN N
hep/hc NN N
. . N

The DT N
use NN N
of IN N
filters NNS N
in IN N
this DT N
patient JJ N
group NN N
may MD N
offer VB N
advantages NNS N
in IN N
terms NNS N
of IN N
ease NN N
of IN N
use NN N
and CC N
a DT N
possible JJ N
decrease NN N
in IN N
hep/hc-related JJ 1_o
problems NNS 1_o
. . N

Long JJ N
lines NNS N
offer VBP N
practical JJ N
advantages NNS N
over IN N
short JJ N
lines NNS N
for IN N
patients NNS 1_p
requiring VBG 1_p
longer JJR 1_p
term NN 1_p
i.v NN 1_p
. . 1_p

access NN 1_p
. . 1_p

-DOCSTART- -X- O O

The DT N
reliability NN N
of IN N
catheter-tip JJ 1_i
transducers NNS 1_i
for IN N
the DT N
measurement NN N
of IN N
intrauterine JJ 1_o
pressure NN 1_o
in IN N
the DT N
third JJ 1_p
stage NN 1_p
of IN 1_p
labour NN 1_p
. . 1_p

In IN N
order NN N
to TO N
assess VB N
the DT N
reliability NN N
of IN N
intrauterine JJ 1_o
pressure NN 1_o
measurements NNS N
in IN N
the DT N
third JJ N
stage NN N
of IN N
labour NN N
, , N
catheter-tip JJ 1_i
transducers NNS 1_i
were VBD N
used VBN N
in IN N
20 CD 1_p
women NNS 1_p
randomly RB 1_p
allocated VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
of IN 1_p
10 CD 1_p
. . 1_p

In IN N
each DT N
case NN N
in IN N
the DT N
first JJ N
group NN N
two CD N
catheters NNS 1_i
were VBD N
tied VBN N
together RB N
and CC N
introduced VBN N
transcervically RB N
into IN N
the DT N
uterine JJ N
cavity NN N
after IN N
delivery NN N
of IN N
the DT N
placenta NN N
. . N

In IN N
each DT N
case NN N
in IN N
the DT N
second JJ N
group NN N
two CD N
catheters NNS N
were VBD N
inserted VBN N
independently RB N
into IN N
the DT N
same JJ N
uterine JJ N
cavity NN N
. . N

The DT N
active JJ 1_o
and CC 1_o
cumulative JJ 1_o
active JJ 1_o
pressures NNS 1_o
recorded VBN N
from IN N
the DT N
pairs NNS N
of IN N
catheters NNS 1_i
within IN N
each DT N
uterine JJ N
cavity NN N
were VBD N
compared VBN N
. . N

Comparison NNP N
of IN N
individual JJ 1_o
active JJ 1_o
pressure NN 1_o
readings NNS N
from IN N
separate JJ N
transducers NNS N
revealed VBD N
good JJ N
agreement NN N
whether IN N
the DT N
catheters NNS 1_i
were VBD N
tied VBN N
together RB N
or CC N
were VBD N
separate JJ N
. . N

Cumulative JJ 1_o
active JJ 1_o
pressure NN 1_o
was VBD N
very RB N
similar JJ N
when WRB N
assessed VBN N
by IN N
each DT N
catheter NN 1_i
in IN N
the DT N
same JJ N
uterus NN N
. . N

Intrauterine NNP 1_i
catheter-tip JJ 1_i
transducers NNS 1_i
can MD N
be VB N
used VBN N
reliably RB N
to TO N
measure VB N
uterine JJ 1_o
activity NN 1_o
in IN N
the DT N
third JJ 1_p
stage NN 1_p
of IN 1_p
labour JJ 1_p
although IN N
there EX N
may MD N
be VB N
minor JJ N
contraction NN N
by IN N
contraction NN N
differences NNS N
in IN N
recordings NNS N
of IN N
individual JJ 1_o
active JJ 1_o
pressures NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Tinzaparin NNP 1_i
versus NN 1_i
dalteparin NN 1_i
for IN N
periprocedure NN N
prophylaxis NN N
of IN N
thromboembolic JJ N
events NNS N
in IN N
hemodialysis NN 1_p
patients NNS 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Low-molecular-weight JJ 1_i
heparin NN 1_i
( ( 1_i
LMWH NNP 1_i
) ) 1_i
is VBZ N
cleared VBN N
predominantly RB N
by IN N
the DT N
kidneys NNS N
and CC N
hence NN N
there EX N
is VBZ N
uncertainty NN N
about IN N
the DT N
safety NN N
of IN N
its PRP$ N
use NN N
in IN N
hemodialysis NN 1_p
( ( 1_p
HD NNP 1_p
) ) 1_p
patients NNS 1_p
. . 1_p

Our PRP$ N
primary JJ N
objective NN N
was VBD N
to TO N
compare VB N
whether IN N
tinzaparin NN 1_i
and CC N
dalteparin VB 1_i
differentially RB N
accumulate JJ N
in IN N
HD NNP 1_p
patients NNS 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
Open-label NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
HD NNP 1_p
patients NNS 1_p
undergoing JJ 1_p
periprocedure NN 1_p
bridging VBG 1_p
anticoagulation NN 1_p
. . 1_p

INTERVENTION NN N
After IN N
warfarin JJ 1_i
therapy NN 1_i
was VBD N
discontinued VBN N
, , N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
3 CD 1_i
daily JJ 1_i
doses NNS 1_i
of IN 1_i
tinzaparin NN 1_i
( ( 1_i
175 CD 1_i
IU/kg NNP 1_i
) ) 1_i
or CC 1_i
dalteparin NN 1_i
( ( N
200 CD N
IU/kg NNP N
) ) N
, , N
with IN N
2 CD N
intervening VBG N
HD NNP N
treatments NNS N
between IN N
the DT N
first JJ N
dose NN N
of IN N
study JJ N
drug NN N
and CC N
their PRP$ N
procedure NN N
. . N

OUTCOMES CC N
The DT N
primary JJ N
outcome NN N
was VBD N
predialysis JJ 1_o
anti-Xa JJ 1_o
levels NNS 1_o
20 CD 1_o
to TO 1_o
24 CD 1_o
hours NNS 1_o
after IN 1_o
the DT 1_o
third JJ 1_o
LMWH NNP 1_o
dose NN 1_o
( ( N
therapeutic JJ N
target NN N
, , N
< JJ N
0.2 CD N
IU/mL NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
thromboembolic JJ 1_o
events NNS 1_o
and CC 1_o
major JJ 1_o
bleeding NN 1_o
. . 1_o

RESULTS NNP N
Of IN N
29 CD 1_p
eligible JJ 1_p
and CC 1_p
consenting VBG 1_p
patients NNS 1_p
, , N
17 CD N
patients NNS N
received VBN N
tinzaparin JJ 1_i
and CC N
12 CD N
patients NNS N
received VBD N
dalteparin JJ 1_i
. . 1_i

Mean JJ 1_o
predialysis NN 1_o
anti-Xa JJ 1_o
level NN 1_o
20-24 JJ 1_o
hours NNS 1_o
after IN N
the DT N
third JJ N
LMWH NNP N
dose NN N
was VBD N
0.37 CD N
? . N
0.23 CD N
( ( N
SD NNP N
) ) N
IU/mL NNP N
for IN 1_i
tinzaparin NN 1_i
and CC N
0.62 CD N
? . N
0.41 CD N
IU/mL NNP N
for IN 1_i
dalteparin NN 1_i
( ( 1_i
P NNP N
= NNP N
0.1 CD N
) ) N
, , N
indicating VBG N
clinically RB N
important JJ N
accumulation NN N
for IN N
both DT N
drugs NNS N
. . N

No DT N
invasive JJ 1_o
procedures NNS 1_o
were VBD 1_o
canceled VBN N
due JJ N
to TO N
study VB N
drug NN N
accumulation NN N
. . N

4 CD N
patients NNS N
experienced VBD 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
1 CD N
major JJ N
bleed NN N
after IN N
traumatic JJ N
arteriovenous JJ N
fistula NN N
puncture NN N
in IN N
the DT 1_i
tinzaparin NN 1_i
arm NN 1_i
, , N
2 CD N
non-ST-elevation JJ N
myocardial JJ N
infarctions NNS N
[ VBP N
1 CD N
in IN N
each DT N
group NN N
] NNP N
, , N
and CC N
1 CD N
upper-extremity JJ N
deep RB N
venous JJ N
thrombosis NN 1_i
[ NNP 1_i
dalteparin NN 1_i
group NN 1_i
] NNP N
) ) N
. . N

LIMITATIONS NNP N
Small NNP N
sample NN N
size NN N
. . N

CONCLUSIONS NNP 1_i
Dalteparin NNP 1_i
and CC 1_i
tinzaparin VB 1_i
significantly RB 1_i
accumulate VB N
in IN N
HD NNP 1_p
patients NNS 1_p
at IN 1_p
therapeutic JJ N
doses NNS N
. . N

Bridging VBG N
therapy NN N
with IN N
LMWHs NNP N
at IN N
therapeutic JJ N
doses NNS N
in IN N
HD NNP N
patients NNS N
who WP N
require VBP N
temporary JJ N
interruption NN N
of IN N
warfarin NN 1_i
therapy NN 1_i
has VBZ 1_i
the DT N
potential NN N
for IN N
complications NNS N
and CC N
is VBZ N
of IN N
uncertain JJ N
benefit NN N
. . N

Other JJ N
anticoagulation NN N
strategies NNS N
, , N
including VBG N
no DT N
bridging NN N
therapy NN N
or CC N
intravenous JJ 1_i
heparin NN 1_i
, , 1_i
need VBP N
comparative JJ N
evaluation NN N
in IN N
this DT N
unique JJ N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O

Community-based JJ 1_i
treatment NN 1_i
for IN N
opioid JJ 1_p
dependent JJ 1_p
offenders NNS 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Primary NNP 1_i
care NN 1_i
opioid JJ 1_i
substitution NN 1_i
treatment NN 1_i
( ( 1_i
OST NNP 1_i
) ) 1_i
has VBZ N
not RB N
been VBN N
compared VBN N
to TO N
program-based JJ N
OST NNP 1_i
for IN N
community-supervised JJ 1_p
offenders NNS 1_p
. . 1_p

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
project NN N
was VBD N
to TO N
compare VB N
primary JJ N
care NN N
to TO N
specialist VB N
supervised JJ N
OST NNP N
for IN N
opioid JJ N
dependent JJ N
offenders NNS N
in IN N
terms NNS N
of IN N
substance NN 1_o
use NN 1_o
and CC N
HIV NNP 1_o
risk NN 1_o
outcomes NNS 1_o
. . 1_o

METHODS NNP N
This DT N
project NN N
randomly RB N
assigned VBD N
15 CD 1_p
jail NN 1_p
diversion NN 1_p
participants NNS 1_p
to TO N
either DT N
: : N
( ( N
i NN N
) ) N
primary NN 1_i
care NN 1_i
buprenorphine NN 1_i
OST NNP 1_i
, , 1_i
( ( 1_i
ii NN 1_i
) ) 1_i
specialist NN 1_i
facility NN 1_i
buprenorphine NN 1_i
OST NNP 1_i
, , 1_i
or CC 1_i
( ( 1_i
iii JJ 1_i
) ) 1_i
specialist NN 1_i
facility NN 1_i
methadone NN 1_i
OST NNP 1_i
. . 1_i

Participation NNP N
lasted VBD N
13.5 CD N
months NNS N
( ( N
12-month JJ N
active JJ N
treatment NN N
plus CC N
a DT N
post-participation JJ N
visit NN N
) ) N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
endorsed VBN N
0 CD N
days NNS N
of IN N
opioid JJ N
use NN N
in IN N
the DT N
previous JJ N
14 CD N
at IN N
follow-up NN N
. . N

Specialty NNP N
care NN N
reduced VBD N
HIV NNP 1_o
risk NN 1_o
( ( 1_o
Risk NNP 1_o
Assessment NNP 1_o
Battery NNP 1_o
composite JJ 1_o
score NN 1_o
) ) 1_o
over IN N
6 CD N
months NNS N
( ( N
-.24 VB N
? . N
.17 NN N
) ) N
compared VBN N
to TO N
primary VB N
care NN N
( ( N
.02 VB N
? . N
.14 NN N
; : N
p CC N
= NNP N
.032 NNP N
) ) N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
primary NN N
care NN 1_i
OST NNP 1_i
feasibility NN 1_i
for IN N
a DT N
community-supervised JJ N
offender NN N
sample NN N
. . N

Specialist NNP N
care NN N
may MD N
facilitate VB N
improvements NNS N
in IN N
secondary JJ N
outcomes NNS N
, , N
such JJ N
as IN N
HIV NNP 1_o
risk NN 1_o
behaviors NNS 1_o
. . 1_o

SCIENTIFIC NNP 1_o
SIGNIFICANCE NNP N
Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
( ( N
i NN N
) ) N
the DT N
role NN N
of IN N
primary JJ N
care NN N
in IN N
addicted VBN N
offender NN N
management NN N
, , N
and CC N
( ( N
ii NN N
) ) N
the DT N
matching NN N
of IN N
offenders NNS N
, , N
based VBN N
upon IN N
history NN N
and CC N
co-morbidity NN N
, , N
to TO N
care VB N
coordination NN N
conditions NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
m-chlorophenylpiperazine NN 1_i
on IN N
plasma NN 1_o
homovanillic JJ 1_o
acid NN 1_o
concentrations NNS 1_o
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

In IN N
view NN N
of IN N
the DT N
abundant JJ N
anatomical JJ N
and CC N
functional JJ N
interactions NNS N
between IN N
serotonin NN N
and CC N
dopamine NN N
systems NNS N
, , N
this DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
the DT N
serotonin JJ N
agonist NN N
, , N
m-chlorophenylpiperazine NN 1_i
( ( 1_i
mCPP NN 1_i
) ) 1_i
on IN N
plasma NN 1_o
concentrations NNS 1_o
of IN 1_o
the DT 1_o
dopamine NN 1_o
metabolite NN 1_o
, , 1_o
homovanillic JJ 1_o
acid NN 1_o
. . 1_o

Plasma NNP N
prolactin NN N
levels NNS N
, , N
body NN N
temperature NN N
, , N
and CC N
mCPP RB 1_o
blood NN N
level NN N
were VBD N
also RB N
measured VBN N
. . N

mCPP NN 1_i
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
placebo $ 1_i
were VBD N
administered VBN N
orally RB N
to TO N
10 CD 1_p
healthy JJ 1_p
men NNS 1_p
in IN N
a DT N
randomized JJ N
double-blind NN N
design NN N
. . N

Variables NNS N
were VBD N
measured VBN N
for IN N
210 CD N
min NNS N
after IN N
administration NN N
of IN N
capsules NNS N
. . N

mCPP NNS 1_o
raised VBD 1_o
prolactin NN 1_o
and CC 1_o
temperature NN 1_o
as IN 1_o
compared VBN 1_o
to TO 1_o
placebo VB 1_o
, , N
but CC N
did VBD N
not RB N
affect VB N
plasma NN 1_o
homovanillic JJ 1_o
acid JJ 1_o
concentrations NNS 1_o
. . 1_o

Results VB N
suggest JJS N
that IN N
mCPP NN 1_o
does VBZ 1_o
not RB 1_o
alter VB 1_o
dopamine NN 1_o
function NN 1_o
. . 1_o

-DOCSTART- -X- O O

Ambulatory JJ 1_o
activity NN 1_o
of IN N
children NNS 1_p
with IN 1_p
cerebral JJ 1_p
palsy NN 1_p
: : 1_p
which WDT N
characteristics NNS N
are VBP N
important JJ N
? . N
AIM NNP N
To TO N
assess VB N
ambulatory JJ 1_o
activity NN 1_o
of IN N
children NNS 1_p
with IN 1_p
cerebral JJ 1_p
palsy NN 1_p
( ( 1_p
CP NNP 1_p
) ) 1_p
, , 1_p
aged VBD 1_p
7 CD 1_p
to TO 1_p
13 CD 1_p
years NNS 1_p
, , 1_p
and CC N
identify VB N
associated VBN N
characteristics NNS N
. . N

METHOD NNP 1_p
Sixty-two JJ 1_p
children NNS 1_p
with IN 1_p
spastic JJ 1_p
CP NNP 1_p
( ( 1_p
39 CD 1_p
males NNS 1_p
, , 1_p
23 CD 1_p
females NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
10y CD 1_p
1mo CD 1_p
, , 1_p
SD NNP 1_p
1y CD 1_p
8mo CD 1_p
; : 1_p
age NN 1_p
range NN 1_p
7-13y NNP 1_p
) ) 1_p
, , 1_p
classified VBD 1_p
as IN 1_p
Gross NNP 1_p
Motor NNP 1_p
Function NNP 1_p
Classification NNP 1_p
System NNP 1_p
( ( 1_p
GMFCS NNP 1_p
) ) 1_p
levels NNS 1_p
I PRP 1_p
to TO 1_p
III NNP 1_p
, , 1_p
participated VBD 1_o
. . 1_o

Ambulatory NNP 1_o
activity NN 1_o
was VBD 1_o
measured VBN N
during IN N
1 CD N
week NN N
with IN N
a DT N
StepWatch NNP N
activity NN N
monitor NN N
as IN N
steps NNS N
per IN N
day NN N
, , N
and CC N
time NN N
spent VBN N
at IN N
medium NN N
and CC N
high JJ N
step NN N
rates NNS N
. . N

Multiple JJ N
linear JJ N
regression NN N
analyses NNS N
were VBD N
performed VBN N
following VBG N
a DT N
backward JJ N
selection NN N
procedure NN N
until IN N
only RB N
independent JJ N
variables NNS N
with IN N
p JJ N
< $ N
0.05 CD N
remained VBN N
in IN N
the DT N
model NN 1_i
. . 1_i

Ambulatory JJ 1_i
activity NN 1_i
outcome NN 1_i
parameters NNS N
served VBD N
as IN N
dependent JJ N
variables NNS N
, , N
and CC N
disease NN N
, , N
personal JJ N
, , N
and CC N
environmental JJ N
characteristics NNS N
as IN N
independent JJ N
variables NNS 1_o
. . 1_o

Ambulatory NNP 1_o
activity NN 1_o
was VBD 1_o
corrected VBN N
for IN N
body NN N
height NN N
. . N

RESULTS NNP N
Children NNP N
took VBD N
more RBR N
steps NNS N
during IN N
school NN N
days NNS N
( ( N
5169 CD N
steps NNS N
, , N
SD NNP N
1641 CD N
) ) N
than IN N
during IN N
weekend NN N
days NNS N
( ( N
4158 CD N
steps NNS N
, , N
SD NNP N
2048 CD N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

Higher JJR N
GMFCS NNP N
level NN N
, , N
bilateral JJ N
CP NNP N
, , N
and CC N
higher JJR N
age NN N
were VBD N
associated VBN N
with IN N
lower JJR 1_o
ambulatory NN 1_o
activity NN 1_o
on IN 1_o
school NN 1_o
days NNS 1_o
( ( 1_o
R NNP 1_o
( ( 1_o
2 CD N
) ) N
ranged VBD N
from IN N
43-53 CD N
% NN N
) ) N
, , N
whereas JJ N
bilateral JJ N
CP NNP N
, , N
higher JJR N
age NN N
, , N
and CC N
no DT N
sport NN N
club NN N
participation NN N
were VBD N
associated VBN N
with IN N
lower JJR 1_o
ambulatory NN 1_o
activity NN 1_o
in IN 1_o
the DT 1_o
weekend NN 1_o
( ( 1_o
R NNP 1_o
( ( 1_o
2 CD N
) ) N
ranged VBD N
from IN N
21-42 CD 1_o
% NN 1_o
) ) 1_o
. . 1_o

Correcting VBG 1_o
for IN 1_o
body NN 1_o
height NN 1_o
decreased VBD 1_o
the DT N
association NN N
with IN N
age NN N
. . N

INTERPRETATION NNP N
Interventions NNP N
should MD N
focus VB N
at IN N
increasing VBG 1_o
physical JJ 1_o
activity NN 1_o
at IN 1_o
the DT N
weekend NN N
for IN N
children NNS 1_p
with IN 1_p
bilateral JJ 1_p
spastic JJ 1_p
CP NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Benefit NN N
of IN N
FSH NNP 1_i
priming NN 1_i
of IN N
women NNS 1_p
with IN 1_p
PCOS NNP 1_p
to TO N
the DT N
in IN N
vitro JJ N
maturation NN N
procedure NN N
and CC N
the DT N
outcome NN N
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
rates NNS 1_o
of IN 1_o
in IN 1_o
vitro JJ 1_o
oocyte JJ 1_o
maturation NN 1_o
, , 1_o
fertilization NN 1_o
and CC 1_o
cleavage NN 1_o
, , N
as RB N
well RB N
as IN N
implantation NN 1_o
rate NN 1_o
and CC 1_o
pregnancy NN 1_o
rate NN 1_o
, , N
could MD N
be VB N
improved VBN N
by IN N
low-dose JJ N
priming NN N
with IN N
FSH NNP 1_i
in IN N
vivo NN N
before IN N
retrieval NN N
of IN N
immature NN N
oocytes NNS N
in IN N
patients NNS 1_p
with IN 1_p
polycystic JJ 1_p
ovary JJ 1_p
syndrome NN 1_p
( ( 1_p
PCOS NNP 1_p
) ) 1_p
. . 1_p

From IN 1_p
March NNP 1_p
1998 CD 1_p
to TO 1_p
June NNP 1_p
2000 CD 1_p
, , 1_p
a DT 1_p
total NN 1_p
of IN 1_p
28 CD 1_p
women NNS 1_p
underwent JJ 1_p
36 CD 1_p
completed VBN 1_p
treatment NN 1_p
cycles NNS 1_p
, , N
randomized VBN N
sequentially RB N
in IN N
one CD N
of IN N
two CD N
groups NNS N
. . N

Women NNP N
in IN N
group NN N
1 CD N
( ( N
n JJ N
= $ N
12 CD N
cycles NNS N
) ) N
received VBD N
no DT 1_i
stimulation NN 1_i
and CC N
women NNS N
in IN N
group NN N
2 CD N
( ( N
n JJ N
= $ N
24 CD N
cycles NNS N
) ) N
received VBD N
150 CD N
iu NN N
recombinant JJ 1_i
FSH NNP 1_i
day NN N
( ( N
-1 NNP N
) ) N
for IN N
3 CD N
days NNS N
, , N
initiated VBN N
on IN N
day NN N
3 CD N
after IN N
menstruation NN N
. . N

Aspiration NN N
was VBD N
performed VBN N
transvaginally RB N
between IN N
day NN N
9 CD N
and CC N
day NN N
17 CD N
in IN N
the DT N
unstimulated JJ N
group NN N
and CC N
on IN N
day NN N
8 CD N
or CC N
day NN N
9 CD N
in IN N
the DT N
FSH-primed NNP N
group NN N
after IN N
FSH NNP N
deprivation NN N
for IN N
2 CD N
or CC N
3 CD N
days NNS N
. . N

All DT N
cumulus-enclosed JJ N
oocytes NNS N
of IN N
healthy JJ N
appearance NN N
were VBD N
matured VBN N
in IN N
culture NN N
medium NN N
( ( N
TCM-199 NNP N
) ) N
in IN N
vitro NN N
for IN N
28-36 JJ N
h NN N
before IN N
intracytoplasmic JJ N
sperm NN N
injection NN N
( ( N
ICSI NNP N
) ) N
. . N

After IN N
oocyte JJ N
retrieval NN N
the DT N
women NNS N
were VBD N
given VBN N
oestradiol NNS N
( ( N
6 CD N
mg NNS N
day NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
progesterone JJ N
administration NN N
( ( N
300 CD N
mg NNS N
day NN N
( ( N
-1 NNP N
) ) N
) ) N
was VBD N
initiated VBN N
2 CD N
days NNS N
later RB N
. . N

Suitable JJ N
embryos NN N
( ( N
maximum JJ N
two CD N
embryos NN N
) ) N
were VBD N
transferred VBN N
on IN N
day NN N
3 CD N
after IN N
ICSI NNP N
. . N

The DT N
percentage NN 1_o
of IN 1_o
oocytes NNS 1_o
reaching VBG 1_o
metaphase NN 1_o
II NNP 1_o
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
FSH-primed NNP N
group NN N
( ( N
59 CD N
% NN N
, , N
92/156 CD N
) ) N
compared VBN N
with IN N
the DT N
non-primed JJ N
group NN N
( ( N
44 CD N
% NN N
, , N
36/81 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
rates NNS 1_o
of IN 1_o
oocyte JJ 1_o
fertilization NN 1_o
and CC 1_o
cleavage NN 1_o
between IN N
these DT N
groups NNS N
. . N

No DT N
pregnancies NNS 1_o
were VBD N
obtained VBN N
in IN N
group NN N
1 CD N
( ( N
0 CD N
% NN N
, , N
0/12 CD N
) ) N
, , N
whereas JJ N
seven CD N
clinical JJ 1_o
pregnancies NNS 1_o
were VBD N
obtained VBN N
in IN N
group NN N
2 CD N
( ( N
29 CD N
% NN N
, , N
7/24 CD N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
group NN N
2 CD N
, , N
37 CD N
embryo NN N
transfers NNS N
resulted VBD N
in IN N
eight CD N
implantations NNS 1_o
( ( N
21.6 CD N
% NN N
) ) N
. . N

Three CD N
healthy JJ 1_o
singleton NN 1_o
children NNS 1_o
have VBP N
been VBN N
born VBN 1_o
at IN N
term NN N
; : N
the DT N
remaining VBG N
pregnancies NNS N
ended VBN N
with IN N
spontaneous JJ 1_o
abortions NNS 1_o
in IN N
the DT N
first JJ N
trimester NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
priming VBG N
with IN N
recombinant JJ N
FSH NNP N
before IN N
harvesting NN N
of IN N
immature NN N
oocytes NNS N
from IN N
patients NNS 1_p
with IN 1_p
PCOS NNP 1_p
may MD N
improve VB N
the DT N
maturational JJ 1_o
potential NN 1_o
of IN 1_o
the DT 1_o
oocytes NNS 1_o
and CC 1_o
the DT 1_o
implantation NN 1_o
rate NN 1_o
of IN 1_o
the DT 1_o
cleaved JJ 1_o
embryos NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
11-beta-hydroxysteroid JJ N
dehydrogenase NN N
type NN N
1 CD N
inhibitor NN N
INCB13739 NNP 1_i
improves VBZ N
hyperglycemia NN 1_o
in IN 1_p
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
inadequately RB 1_p
controlled VBN 1_p
by IN 1_p
metformin NN 1_p
monotherapy NN 1_p
. . 1_p

OBJECTIVE CC N
11-Beta-hydroxysteroid JJ N
dehydrogenase NN N
type NN N
1 CD N
( ( N
11betaHSD1 CD N
) ) N
converts NNS N
inactive JJ N
cortisone NN N
into IN N
active JJ N
cortisol NN N
, , N
thereby RB N
amplifying VBG N
intracellular JJ N
glucocorticoid JJ N
action NN N
. . N

The DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
the DT N
11betaHSD1 CD N
inhibitor NN N
INCB13739 NNP N
were VBD N
assessed VBN N
when WRB N
added VBN N
to TO N
ongoing VBG N
metformin NN N
monotherapy NN N
in IN N
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
exhibiting VBG 1_p
inadequate JJ 1_p
glycemic NNS 1_p
control NN 1_p
( ( 1_p
A1C NNP 1_p
7-11 CD 1_p
% NN 1_p
) ) 1_p
. . 1_p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
This DT N
double-blind JJ N
placebo-controlled JJ 1_i
paralleled VBN N
study NN N
randomized VBD N
302 CD 1_p
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
( ( 1_p
mean JJ 1_p
A1C NNP 1_p
8.3 CD 1_p
% NN 1_p
) ) 1_p
on IN 1_p
metformin NN 1_i
monotherapy NN 1_i
( ( 1_p
mean JJ 1_p
1.5 CD 1_p
g/day NN 1_p
) ) 1_p
to TO N
receive VB N
one CD N
of IN N
five CD N
INCB13739 NNP 1_i
doses NNS 1_i
or CC 1_i
placebo NN 1_i
once RB N
daily JJ N
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
change NN 1_o
in IN 1_o
A1C NNP 1_o
at IN 1_o
study JJ 1_o
end NN 1_o
. . 1_o

Other JJ N
end NN N
points NNS N
included VBD N
changes NNS 1_o
in IN 1_o
fasting VBG 1_o
glucose NN 1_o
, , 1_o
lipids NNS 1_o
, , 1_o
weight NN 1_o
, , 1_o
adverse JJ 1_o
events NNS 1_o
, , 1_o
and CC 1_o
safety NN 1_o
. . 1_o

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
, , N
200 CD N
mg NN N
of IN N
INCB13739 NNP N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
A1C NNP 1_o
( ( N
-0.6 NNP N
% NN N
) ) N
, , N
fasting VBG 1_o
plasma NN 1_o
glucose NN 1_o
( ( N
-24 NNP N
mg/dl NN N
) ) N
, , N
and CC N
homeostasis NN 1_o
model NN 1_o
assessment-insulin JJ 1_o
resistance NN 1_o
( ( N
HOMA-IR NNP N
) ) N
( ( N
-24 CD N
% NN N
) ) N
compared VBN N
with IN N
placebo NN N
. . N

Total JJ 1_o
cholesterol NN 1_o
, , 1_o
LDL NNP 1_o
cholesterol NN 1_o
, , 1_o
and CC 1_o
triglycerides NNS 1_o
were VBD N
all DT N
significantly RB N
decreased VBN N
in IN N
hyperlipidemic JJ N
patients NNS N
. . N

Body NNP 1_o
weight VBD 1_o
decreased JJ N
relative NN N
to TO N
placebo VB N
after IN N
INCB13739 NNP N
therapy NN N
. . N

A DT N
reversible JJ N
dose-dependent JJ N
elevation NN N
in IN N
adrenocorticotrophic JJ 1_o
hormone NN 1_o
, , N
generally RB N
within IN N
the DT N
normal JJ N
reference NN N
range NN N
, , N
was VBD N
observed VBN N
. . N

Basal NNP 1_o
cortisol JJ 1_o
homeostasis NN 1_o
, , 1_o
testosterone NN 1_o
in IN 1_o
men NNS 1_o
, , 1_o
and CC 1_o
free JJ 1_o
androgen NN 1_o
index NN 1_o
in IN 1_o
women NNS 1_o
were VBD N
unchanged JJ N
by IN N
INCB13739 NNP N
. . N

Adverse JJ N
events NNS N
were VBD N
similar JJ N
across IN N
all DT N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
INCB13739 NNP N
added VBD N
to TO N
ongoing VBG N
metformin NN N
therapy NN N
was VBD N
efficacious JJ 1_o
and CC N
well RB N
tolerated VBN 1_o
in IN N
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
who WP 1_p
had VBD 1_p
inadequate JJ 1_p
glycemic NNS 1_p
control NN 1_p
with IN 1_p
metformin NN 1_p
alone RB 1_p
. . 1_p

11BetaHSD1 CD N
inhibition NN N
offers NNS N
a DT N
new JJ N
potential JJ N
approach NN N
to TO N
control VB N
glucose JJ 1_o
and CC 1_o
cardiovascular JJ 1_o
risk NN 1_o
factors NNS 1_o
in IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
. . 1_p

-DOCSTART- -X- O O

[ VB N
The DT N
effect NN N
of IN N
indobufen NN 1_i
on IN N
aortocoronary JJ 1_p
bypass NN 1_p
patency NN 1_p
after IN N
1 CD N
week NN N
and CC N
after IN N
1 CD N
year NN N
] NN N
. . N

A DT N
randomized JJ N
clinical JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effect NN N
of IN N
conventional JJ 1_i
antiaggregation NN 1_i
therapy NN 1_i
( ( 1_i
ASA NNP 1_i
plus CC 1_i
dipyridamole NN 1_i
) ) 1_i
versus NN N
indobufen NN 1_i
in IN N
patients NNS 1_p
after IN 1_p
aortocoronary JJ 1_p
bypass NN 1_p
( ( 1_p
ACB NNP 1_p
) ) 1_p
surgery NN 1_p
. . 1_p

The DT N
patency NN N
of IN N
venous JJ N
ACB NNP N
using VBG N
coronary JJ N
DSA NNP N
one CD N
week NN N
and CC N
one CD N
year NN N
after IN N
surgery NN N
was VBD N
evaluated VBN N
in IN N
52 CD 1_p
patients NNS 1_p
divided VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
study NN N
included VBD N
only RB N
ACB NNP 1_p
's POS 1_p
with IN 1_p
intraoperative JJ 1_p
blood NN 1_p
flow NN 1_p
rates NNS 1_p
< VBP N
or CC N
= VBP N
40 CD N
ml/min NN N
as IN N
it PRP N
is VBZ N
just RB N
these DT N
ACB NNP N
's POS N
which WDT N
are VBP N
at IN N
the DT N
highest JJS N
risk NN N
of IN N
early JJ N
and CC N
late JJ N
occlusions NNS N
. . N

While IN N
, , N
in IN N
the DT N
ASA NNP 1_i
plus CC 1_i
dipyridamole-treated JJ 1_i
group NN N
, , N
occlusions NNS 1_o
were VBD N
found VBN N
in IN N
11 CD N
of IN N
the DT N
39 CD N
reconstructions NNS N
( ( N
28.2 CD N
% NN N
) ) N
, , N
the DT N
proportion NN N
was VBD N
nine CD N
out IN N
of IN N
37 CD N
procedures NNS N
( ( N
24.3 CD N
% NN N
) ) N
in IN N
the DT N
indobufen NN 1_i
group NN N
. . N

One CD N
year NN N
after IN N
surgery NN N
, , N
occlusion NN 1_o
was VBD N
found VBN N
in IN N
14 CD N
out IN N
of IN N
32 CD N
ACB NNP N
's POS N
( ( N
43.7 CD N
% NN N
) ) N
in IN N
the DT N
ASA NNP N
plus CC N
dipyridamole JJ 1_i
group NN N
compared VBN N
to TO N
14 CD N
occlusions NNS N
in IN N
31 CD N
ACB NNP N
's POS N
( ( N
45.2 CD N
% NN N
) ) N
in IN N
the DT N
indobufen NN 1_i
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
number NN 1_o
of IN 1_o
occlusions NNS 1_o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Because IN N
of IN N
some DT N
benefits NNS N
of IN N
indobufen NN N
compared VBN N
to TO N
ASA NNP N
( ( 1_o
shorter JJR 1_o
time NN 1_o
of IN 1_o
effect NN 1_o
, , 1_o
superior JJ 1_o
tolerance NN 1_o
in IN 1_o
patients NNS 1_o
with IN 1_o
ulceration NN 1_o
) ) 1_o
, , N
the DT N
former JJ N
drug NN N
can MD N
be VB N
recommended VBN N
for IN N
use NN N
in IN N
some DT N
indicated JJ N
cases NNS N
. . N

-DOCSTART- -X- O O

Reducing VBG N
blood NN 1_o
loss NN 1_o
in IN N
simultaneous JJ 1_p
bilateral JJ 1_p
total NN 1_p
knee NN 1_p
arthroplasty NN 1_p
: : 1_p
combined VBN N
intravenous-intra-articular JJ N
tranexamic JJ 1_i
acid NN 1_i
administration NN N
. . N

A DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
We PRP N
asked VBD N
whether IN N
tranexamic JJ 1_i
acid NN 1_i
( ( 1_i
TXA NNP 1_i
) ) 1_i
administration NN N
could MD N
reduce VB N
blood NN 1_o
loss NN 1_o
and CC 1_o
blood NN 1_o
transfusion NN 1_o
requirements NNS 1_o
after IN 1_p
simultaneous JJ 1_p
bilateral JJ 1_p
total NN 1_p
knee NN 1_p
arthroplasty NN 1_p
( ( 1_p
TKA NNP 1_p
) ) 1_p
. . 1_p

This DT N
study NN N
examined VBD N
the DT N
role NN N
of IN N
a DT N
novel JJ N
method NN N
of IN N
TXA NNP N
administration NN N
in IN N
TKA NNP N
. . N

METHODS NNP N
TXA NNP 1_i
was VBD 1_i
administered VBN 1_i
as IN 1_i
a DT 1_i
bolus NN 1_i
dose NN 1_i
of IN 1_i
15 CD 1_i
mg/kg NNS 1_i
10 CD 1_i
min NN 1_i
before IN 1_i
the DT 1_i
inflation NN 1_i
of IN 1_i
the DT 1_i
tourniquet NN 1_i
on IN 1_i
the DT 1_i
first JJ 1_i
side NN 1_i
. . 1_i

This DT 1_i
was VBD 1_i
followed VBN 1_i
by IN 1_i
intra-articular JJ 1_i
administration NN 1_i
of IN 1_i
3 CD 1_i
grams NNS 1_i
at IN 1_i
10 CD 1_i
min NN 1_i
before IN 1_i
the DT 1_i
deflation NN 1_i
of IN 1_i
the DT 1_i
tourniquet NN 1_i
. . 1_i

IV NNP 1_i
infusion NN 1_i
of IN 1_i
10 CD 1_i
mg/kg/h NN 1_i
was VBD 1_i
continued VBN 1_i
for IN 1_i
3h CD 1_i
following VBG 1_i
completion NN 1_i
on IN 1_i
the DT 1_i
second JJ 1_i
side NN 1_i
. . 1_i

We PRP N
measured VBD N
volume NN 1_o
of IN 1_o
drained JJ 1_o
blood NN 1_o
48 CD 1_o
h NN 1_o
postoperatively RB 1_o
, , 1_o
decrease NN 1_o
in IN 1_o
hemoglobin NN 1_o
levels NNS 1_o
12h CD 1_o
postoperatively RB 1_o
, , 1_o
amount NN 1_o
of IN 1_o
blood NN 1_o
transfused VBN 1_o
( ( 1_o
BT NNP 1_o
) ) 1_o
, , N
and CC N
number NN 1_o
of IN 1_o
patients NNS 1_o
requiring VBG 1_o
allogenic JJ 1_o
BT NNP 1_o
. . 1_o

RESULTS NNP N
Median JJ N
postoperative JJ N
volume NN 1_o
of IN 1_o
drained JJ 1_o
blood NN 1_o
was VBD N
lower JJR N
in IN N
the DT N
group NN N
receiving VBG N
TXA NNP 1_i
( ( N
500.00 CD N
mL NN N
) ) N
than IN N
in IN N
control NN N
subjects NNS N
( ( N
900.00 CD N
mL NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
[ VBD N
95 CD N
% NN N
CI NNP N
( ( N
-525.00 NNP N
) ) N
to TO N
( ( N
-300.00 NNP N
) ) N
] NN N
. . N

The DT N
median JJ 1_o
hemoglobin NN 1_o
decrease NN 1_o
12 CD 1_o
h NN 1_o
postoperatively RB 1_o
was VBD N
lower JJR N
in IN N
patients NNS 1_p
receiving VBG N
TXA NNP N
( ( N
2.10 CD N
g/dL NN N
) ) N
than IN N
in IN N
control NN N
subjects NNS N
( ( N
3.10 CD N
g/dL NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
[ VBD N
95 CD N
% NN N
CI NNP N
( ( N
-1.60 NNP N
) ) N
to TO N
( ( N
-0.60 NNP N
) ) N
] NN N
. . N

The DT N
amount NN 1_o
of IN 1_o
BT NNP 1_o
and CC 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
requiring VBG 1_o
BT NNP 1_o
were VBD N
lower JJR N
in IN N
patients NNS N
receiving VBG N
TXA NNP N
than IN N
in IN N
control NN N
subjects NNS N
. . N

Nevertheless RB N
, , N
the DT N
number NN N
of IN N
allogeneic JJ N
units NNS N
of IN N
packed JJ 1_o
red JJ 1_o
blood NN 1_o
cells NNS 1_o
transfused VBN 1_o
in IN N
the DT N
postoperative JJ N
period NN N
was VBD N
not RB N
significantly RB N
higher RBR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
TXA NNP N
group NN N
( ( N
p=0.109 NN N
) ) N
[ VBZ N
95 CD N
% NN N
CI NNP N
( ( N
0.101 CD N
) ) N
to TO N
( ( N
0.117 CD N
) ) N
] NN N
. . N

CONCLUSIONS VB N
This DT N
prospective JJ N
randomized NN N
study NN N
showed VBD N
that IN N
during IN N
simultaneous JJ N
bilateral JJ N
TKA NNP N
, , N
TXA NNP 1_i
reduced VBD N
blood NN 1_o
loss NN 1_o
with IN N
negligible JJ N
side NN 1_o
effects NNS 1_o
. . 1_o

-DOCSTART- -X- O O

A DT N
workplace NN 1_i
intervention NN 1_i
for IN N
increasing VBG N
outdoor JJ 1_p
workers NNS 1_p
' POS 1_p
use NN N
of IN N
solar JJ N
protection NN N
. . N

OBJECTIVES NNP N
Outdoor NNP 1_p
workers NNS 1_p
are VBP N
at IN N
high JJ N
risk NN N
of IN N
developing VBG N
skin JJ N
cancer NN N
. . N

Primary JJ N
prevention NN N
in IN N
this DT N
group NN N
can MD N
potentially RB N
reduce VB N
the DT N
incidence NN N
of IN N
skin NN N
cancer NN N
, , N
and CC N
also RB N
potentiates VBZ N
the DT N
spontaneous JJ N
remission NN N
of IN N
existing VBG N
solar JJ N
keratoses NNS N
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
a DT N
solar JJ 1_i
protection NN 1_i
intervention NN 1_i
targeting VBG N
outdoor JJ 1_p
workers NNS 1_p
. . 1_p

METHODS NNP N
Outdoor NNP 1_p
workers NNS 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
to TO 1_p
an DT 1_p
intervention NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
65 CD 1_p
) ) 1_p
or CC 1_i
control VB 1_i
group NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
77 CD 1_p
) ) 1_p
. . 1_p

The DT N
intervention NN N
group NN N
received VBD N
individual JJ 1_i
skin NN 1_i
screening NN 1_i
by IN 1_i
a DT 1_i
dermatologist NN 1_i
and CC 1_i
participated VBD 1_i
in IN 1_i
an DT 1_i
education NN 1_i
session NN 1_i
. . 1_i

Pre- NNP N
and CC N
posttest JJS N
outcome NN N
measures NNS N
included VBD N
solar JJ 1_o
protection NN 1_o
behavior NN 1_o
( ( N
assessed VBN N
using VBG N
a DT N
validated JJ N
diary NN N
) ) N
, , N
knowledge NN 1_o
, , N
and CC N
attitudes NNS 1_o
. . 1_o

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ 1_o
increase NN 1_o
( ( N
16 CD N
% NN N
) ) N
in IN N
the DT N
percentage NN N
of IN N
outdoor JJ N
workers NNS N
who WP N
were VBD N
using VBG N
a DT N
high JJ 1_o
level NN 1_o
of IN 1_o
solar JJ 1_o
protection NN 1_o
at IN N
posttest NN N
compared VBN N
to TO N
pretest VB N
in IN N
the DT N
intervention NN N
group NN N
, , N
but CC N
there EX N
was VBD N
no DT 1_o
change NN 1_o
in IN N
the DT N
control NN N
group NN N
. . N

Although IN N
both DT N
groups NNS N
improved VBN 1_o
in IN N
their PRP$ N
knowledge NN 1_o
score NN 1_o
, , N
the DT N
intervention NN 1_o
group NN 1_o
showed VBD 1_o
a DT 1_o
significantly RB 1_o
greater JJR 1_o
improvement NN 1_o
at IN N
posttest JJS N
. . N

No DT 1_o
changes NNS 1_o
in IN 1_o
attitudes NNS 1_o
were VBD N
detected VBN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
suggest VBP N
that IN N
changes NNS N
in IN N
solar JJ 1_o
protection NN 1_o
are VBP N
achievable JJ N
with IN N
outdoor JJ 1_p
workers NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Neuromuscular JJ N
excitability NN N
changes NNS N
in IN N
the DT N
vastus NN N
medialis NN N
following VBG N
anterior JJ 1_i
cruciate JJ 1_i
ligament NN 1_i
reconstruction NN 1_i
. . 1_i

PURPOSE NNP N
Quadriceps NNP N
weakness NN N
following VBG N
anterior JJ 1_p
cruciate JJ 1_i
ligament NN 1_i
reconstruction NN 1_i
( ( 1_i
ACLR NNP 1_i
) ) 1_i
is VBZ N
prevalent JJ N
despite IN N
intensive JJ N
rehabilitation NN N
. . N

Diminished NNP N
neuromuscular JJ N
excitability NN N
is VBZ N
one CD N
potential JJ N
factor NN N
that WDT N
may MD N
limit VB N
muscular JJ N
recovery NN N
following VBG N
injury NN N
or CC N
surgery NN N
. . N

The DT N
H-reflex NNP 1_o
provides VBZ N
a DT N
measure NN N
of IN N
alpha NN N
motorneuron NN N
( ( N
neuromuscular JJ N
) ) N
excitability NN N
in IN N
the DT N
sensory-motor JJ N
pathway NN N
of IN N
the DT N
respective JJ N
muscle NN N
and CC N
nerve NN N
. . N

To TO N
date NN N
the DT N
vastus NN N
medialis NN N
( ( N
VM NNP N
) ) N
and CC N
soleus NN N
( ( N
SOL NNP N
) ) N
H-reflexes NNP N
have VBP N
been VBN N
examined VBN N
primarily RB N
in IN N
control NN N
subjects NNS 1_p
with IN 1_p
induced JJ 1_p
knee NNS 1_p
joint JJ 1_p
effusion NN 1_p
. . 1_p

This DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
evaluated VBD N
the DT N
affect NN N
of IN N
ACLR NNP 1_i
, , N
utilizing VBG N
hamsting NN 1_o
( ( 1_o
HS NNP 1_o
) ) 1_o
or CC 1_o
bone-patellar JJ 1_o
tendon-bone NN 1_o
( ( 1_o
BTB NNP 1_o
) ) 1_o
autograft NN 1_o
, , 1_o
on IN 1_o
VM NNP 1_o
and CC 1_o
SOL NNP 1_o
H-reflex NNP 1_o
latency NN 1_o
and CC 1_o
amplitude NN 1_o
in IN N
twenty JJ 1_p
subjects NNS 1_p
. . 1_p

METHODS NNP N
Preoperatively RB N
bilateral JJ N
VM NNP N
and CC N
SOL NNP N
H-reflex NNP N
tests NNS N
were VBD N
conducted VBN N
. . N

VM NNP 1_o
and CC 1_o
SOL NNP 1_o
H-reflexes NNP 1_o
were VBD N
subsequently RB N
conducted VBN N
on IN N
the DT N
involved VBN N
lower JJR N
extremity NN N
at IN N
1 CD N
and CC N
3 CD N
months NNS N
post VBN N
surgery NN N
. . N

At IN N
each DT N
test NN N
session NN N
subjects NNS 1_p
completed VBN N
visual JJ 1_o
analog NN 1_o
scales NNS 1_o
and CC 1_o
knee VB 1_o
girth NN 1_o
was VBD N
measured VBN N
. . N

RESULTS VB N
The DT N
VM NNP 1_o
H-reflex NNP 1_o
amplitude NN 1_o
increased VBD N
in IN N
the DT N
HS NNP N
group NN N
at IN N
3 CD N
months NNS N
compared VBN N
to TO N
1-month JJ N
post NN N
surgery NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

Significant JJ N
changes NNS N
over IN N
time NN N
were VBD N
also RB N
noted VBN N
in IN N
the DT N
visual JJ 1_o
analog NN 1_o
pain NN 1_o
and CC 1_o
functional JJ 1_o
scales NNS 1_o
and CC 1_o
the DT 1_o
mid-patella JJ 1_o
girth NN 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
increased JJ N
VM NNP 1_o
H-reflex NNP 1_o
amplitude NN 1_o
at IN N
3 CD N
months NNS N
following VBG N
HS NNP N
autograft NN N
ACLR NNP 1_i
demonstrates VBZ N
an DT N
increase NN N
in IN N
VM NNP 1_o
neuromuscular JJ 1_o
excitability NN 1_o
. . 1_o

Increased VBN N
VM NNP 1_o
neuromuscular JJ 1_o
excitability NN 1_o
was VBD N
not RB N
evident JJ N
in IN N
patients NNS N
following VBG N
BTB NNP N
reconstruction NN N
. . N

The DT N
increased JJ N
neuromuscular JJ 1_o
excitability NN 1_o
, , N
observed VBD N
only RB N
in IN N
the DT N
HS NNP N
group NN N
, , N
warrants NNS N
consideration NN N
when WRB N
selecting VBG N
graft NN N
type NN N
for IN N
patients NNS 1_p
with IN 1_p
extensive JJ 1_p
preoperative JJ 1_p
quadriceps NNS 1_p
dysfunction NN 1_p
. . 1_p

-DOCSTART- -X- O O

Bioequivalence NNP N
evaluation NN N
of IN N
a DT N
fixed VBN 1_i
dose JJ 1_i
combination NN 1_i
lamivudine NN 1_i
+ NNP 1_i
stavudine NN 1_i
tablet NN N
with IN N
concurrent JJ N
administration NN N
of IN N
lamivudine JJ 1_i
tablet NN N
and CC N
stavudine NN 1_i
capsule NN N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

The DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
rate NN 1_o
and CC 1_o
extent NN 1_o
of IN 1_o
absorption NN 1_o
of IN N
a DT N
fixed VBN N
dose JJ N
combination NN N
tablet NN N
of IN N
lamivudine NN 1_i
( ( 1_i
CAS NNP 1_i
134678-17-4 CD 1_i
) ) 1_i
and CC 1_i
stavudine NN 1_i
( ( 1_i
CAS NNP 1_i
3056-17-5 CD 1_i
) ) 1_i
with IN N
the DT N
concurrent JJ N
administration NN N
of IN N
lamivudine JJ 1_i
tablet NN 1_i
and CC 1_i
stavudine NN 1_i
capsule NN 1_i
in IN N
24 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
under IN 1_p
fasting VBG 1_p
conditions NNS 1_p
. . 1_p

The DT N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
test NN N
or CC N
reference NN N
treatment NN N
, , N
with IN N
the DT N
two CD N
treatment NN N
periods NNS N
separated VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
7 CD N
days NNS N
. . N

Plasma NNP 1_o
samples NNS 1_o
were VBD N
analyzed VBN N
for IN N
both DT N
analytes NNS N
lamivudine VBP 1_i
and CC N
stavudine VBP 1_i
by IN N
a DT N
validated JJ N
analytical JJ N
method NN N
. . N

Since IN N
the DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
test/reference NN 1_o
mean JJ N
ratio NN N
of IN N
the DT N
In-transformed NNP N
pharmacokinetic JJ N
variables NNS N
C NNP 1_o
( ( 1_o
max NN 1_o
) ) 1_o
AUC NNP 1_o
( ( 1_o
0-t JJ 1_o
) ) 1_o
and CC 1_o
AUC NNP 1_o
( ( 1_o
0-infinity NN 1_o
) ) 1_o
were VBD N
clearly RB N
within IN N
the DT N
conventional JJ N
bioequivalence NN N
range NN N
of IN N
80 CD N
% NN N
to TO N
125 CD N
% NN N
, , N
the DT N
two CD N
treatments NNS N
were VBD N
considered VBN N
bioequivalent NN N
. . N

The DT N
safety NN 1_o
profiles NNS 1_o
of IN N
both DT N
the DT N
test NN N
and CC N
reference NN N
formulations NNS N
were VBD N
comparable JJ N
. . N

-DOCSTART- -X- O O

Safety NNP N
assessment NN N
of IN N
docosahexaenoic NN 1_i
acid NN 1_i
in IN N
X-linked JJ 1_p
retinitis NN 1_p
pigmentosa NN 1_p
: : 1_p
the DT N
4-year JJ N
DHAX NNP N
trial NN N
. . N

PURPOSE NNP N
Docosahexaenoic NNP N
acid NN N
( ( N
DHA NNP N
) ) N
continues VBZ N
to TO N
be VB N
evaluated VBN N
and CC N
recommended VBN N
as IN N
treatment NN N
and CC N
prophylaxis NN N
for IN N
various JJ N
diseases NNS N
. . N

We PRP N
recently RB N
assessed VBD N
efficacy NN N
of IN N
high-dose JJ N
DHA NNP N
supplementation NN N
to TO N
slow VB N
vision NN 1_o
loss NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
X-linked JJ 1_p
retinitis NN 1_p
pigmentosa NN 1_p
( ( 1_p
XLRP NNP 1_p
) ) 1_p
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Because IN N
DHA NNP N
is VBZ N
a DT N
highly RB N
unsaturated JJ N
fatty JJ N
acid NN N
, , N
it PRP N
could MD N
serve VB N
as IN N
a DT N
target NN N
for IN N
free-radical JJ N
induced JJ N
oxidation NN N
, , N
resulting VBG N
in IN N
increased VBN N
oxidative JJ N
stress NN N
. . N

Biosafety NNP 1_o
was VBD N
monitored VBN N
during IN N
the DT N
4-year JJ N
trial NN N
to TO N
determine VB N
whether IN N
DHA NNP N
supplementation NN N
was VBD N
associated VBN N
with IN N
identifiable JJ N
risks NNS N
. . N

METHODS NNP N
Males NNP 1_p
( ( 1_p
n JJ 1_p
= VBZ 1_p
78 CD 1_p
; : 1_p
7-31 CD 1_p
years NNS 1_p
) ) 1_p
meeting NN 1_p
entry NN 1_p
criteria NNS 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

The DT N
modified JJ N
intent-to-treat JJ N
cohort NN N
( ( N
DHA NNP N
= NNP N
33 CD N
; : N
placebo NN 1_i
= VBZ N
27 CD N
) ) N
adhered VBD N
to TO N
the DT N
protocol NN N
? . N
1 CD N
year NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
to TO N
an DT N
oral JJ N
dose NN N
of IN N
30 CD 1_i
mg/kg/d NNS 1_i
DHA NNP 1_i
or CC 1_i
placebo VB 1_i
plus CC 1_i
a DT N
daily JJ N
multivitamin NN N
. . N

Comprehensive NNP N
metabolic JJ N
analyses NNS N
were VBD N
assessed VBN N
for IN N
group NN N
differences NNS N
. . N

Treatment-emergent JJ 1_o
adverse JJ 1_o
events NNS 1_o
including VBG 1_o
blood NN 1_o
chemistry NN 1_o
metabolites NNS 1_o
were VBD 1_o
recorded VBN N
. . N

RESULTS VBN N
By IN N
year NN N
4 CD N
, , N
supplementation NN 1_o
elevated VBD 1_o
plasma NN 1_o
and CC 1_o
red JJ 1_o
blood NN 1_o
cell-DHA JJ 1_o
4.4- JJ 1_o
and CC 1_o
3.6-fold JJ N
, , N
respectively RB N
, , N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.00001 CD N
) ) N
. . N

Over IN N
the DT N
trial NN N
duration NN N
, , N
no DT N
significant JJ N
differences NNS N
between IN N
DHA NNP N
and CC N
placebo NN N
groups NNS N
were VBD N
found VBN N
for IN 1_o
vitamin NN 1_o
A NNP 1_o
, , 1_o
vitamin NN 1_o
E NNP 1_o
, , 1_o
platelet NN 1_o
aggregation NN 1_o
, , 1_o
antioxidant JJ 1_o
activity NN 1_o
, , 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
, , 1_o
or CC 1_o
oxidized VBN 1_o
LDL NNP 1_o
levels NNS 1_o
( ( 1_o
all DT N
P NNP N
> NNP N
0.14 CD 1_o
) ) 1_o
. . 1_o

Adverse JJ 1_o
events NNS 1_o
were VBD 1_o
transient JJ N
and CC 1_o
not RB 1_o
considered VBN 1_o
severe JJ 1_o
( ( 1_o
e.g. JJ N
, , N
gastrointestinal JJ 1_o
[ NN 1_o
GI NNP 1_o
] NNP 1_o
irritability NN 1_o
, , 1_o
blood NN 1_o
chemistry NN 1_o
alterations NNS 1_o
) ) 1_o
. . 1_o

One CD N
participant NN N
was VBD N
unable JJ N
to TO N
tolerate VB 1_o
persistent JJ 1_o
GI NNP 1_o
discomfort NN 1_o
. . 1_o

CONCLUSIONS NNP N
Long-term NNP N
, , N
high-dose JJ N
DHA NNP N
supplementation NN N
to TO N
patients NNS 1_p
with IN 1_p
XLRP NNP 1_p
was VBD 1_p
associated VBN N
with IN 1_o
limited JJ 1_o
safety NN 1_o
risks NNS 1_o
in IN 1_o
this DT N
4-year JJ N
trial NN N
. . N

Nevertheless NNP 1_o
, , 1_o
GI NNP 1_o
symptoms NNS 1_o
should MD 1_o
be VB N
monitored VBN N
in IN N
all DT N
patients NNS N
taking VBG N
high JJ N
dose JJ N
DHA NNP N
especially RB N
those DT N
with IN N
personal JJ N
or CC N
family NN N
history NN N
of IN N
GI NNP N
disturbances NNS N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00100230 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

Disc NNP 1_i
coablation NN 1_i
and CC 1_i
epidural JJ 1_i
injection NN 1_i
of IN 1_i
steroids NNS 1_i
: : 1_i
a DT N
comparison NN N
of IN N
strategies NNS N
in IN N
the DT N
treatment NN N
of IN N
mechanical JJ 1_p
spinal JJ 1_p
discogenic NN 1_p
pain NN 1_p
. . 1_p

In IN N
this DT N
study NN N
two CD N
strategies NNS N
in IN N
the DT N
treatment NN N
of IN N
Mechanical NNP N
Spinal NNP N
Discogenic NNP N
Pain NNP N
have VBP N
been VBN N
compared VBN N
: : N
Disc NNP 1_i
Coablation NNP 1_i
and CC 1_i
Epidural NNP 1_i
Injection NNP 1_i
of IN 1_i
Steroids NNP 1_i
. . 1_i

In IN 1_p
2003 CD 1_p
50 CD 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
one CD 1_i
or CC 1_i
two CD 1_i
epidural JJ 1_i
injections NNS 1_i
have VBP 1_p
been VBN 1_p
selected VBN 1_p
ad NN 1_p
random NN 1_p
and CC 1_p
50 CD 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
disc JJ 1_i
coablation NN 1_i
. . 1_i

Comparison NNP N
of IN N
the DT N
data NNS N
indicated VBD N
an DT N
improvement NN N
of IN N
average JJ 1_o
VAS NNP 1_o
when WRB N
relaxed NN N
for IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
while IN N
after IN N
slight-moderate JJ N
strain NN N
, , N
this DT N
value NN N
was VBD N
significant JJ N
only RB N
after IN N
coablation NN 1_i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Finally RB N
, , N
average JJ 1_o
VAS NNP 1_o
was VBD N
clearly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
after IN N
coablation NN N
as IN N
compared VBN N
to TO N
epidural JJ 1_i
injections NNS 1_i
. . N

-DOCSTART- -X- O O

Examination NN 1_o
of IN N
aggression NN 1_o
and CC N
self-injury NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
and CC 1_p
serious JJ 1_p
behavioral JJ 1_p
problems NNS 1_p
. . 1_p

This DT N
study NN N
identified VBD N
subtypes NNS N
of IN N
aggression NN N
in IN N
a DT N
sample NN N
of IN N
206 CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
who WP 1_p
participated VBD 1_p
in IN 1_p
2 CD 1_i
risperidone NN 1_i
trials NNS 1_i
. . 1_i

The DT N
narratives NNS N
were VBD N
derived VBN N
from IN N
a DT N
parent NN N
interview NN N
about IN N
each DT N
child NN N
's POS N
2 CD N
most RBS N
pressing JJ N
problems NNS N
. . N

Five CD N
subtypes NNS N
of IN N
aggression NN N
emerged VBN N
: : N
hot JJ 1_o
aggression NN 1_o
only RB 1_o
, , 1_o
cold JJ 1_o
aggression NN 1_o
only RB 1_o
, , 1_o
self-injurious JJ 1_o
behavior NN 1_o
( ( 1_o
SIB NNP 1_o
) ) 1_o
only RB 1_o
, , 1_o
aggression NN 1_o
and CC 1_o
SIB NNP 1_o
, , N
and CC N
nonaggressive JJ 1_o
. . 1_o

All DT N
groups NNS N
showed VBD N
a DT N
high JJ N
rate NN N
of IN N
positive JJ 1_o
response NN 1_o
to TO N
risperidone VB N
with IN N
no DT N
differences NNS N
across IN N
subtypes NNS N
. . N

These DT N
study NN N
findings NNS N
extend VBP N
understanding NN N
of IN N
aggression NN N
in IN N
ASD NNP N
and CC N
may MD N
be VB N
useful JJ N
to TO N
guide VB N
further RB N
study NN N
on IN N
biological JJ N
mechanisms NNS N
and CC N
individualized JJ N
treatment NN N
in IN N
ASD NNP N
. . N

-DOCSTART- -X- O O

Cost-effectiveness NN 1_o
of IN N
cognitive-behavioral JJ 1_i
group NN 1_i
therapy NN 1_i
for IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
in IN N
cancer NN 1_p
patients NNS 1_p
. . 1_p

Anxiety NNP 1_o
and CC 1_o
fear NN 1_o
are VBP N
often RB N
associated VBN N
with IN N
chronic JJ N
conditions NNS N
such JJ N
as IN N
cancer NN N
. . N

This DT N
paper NN N
targets VBZ N
the DT N
cost-effectiveness JJ 1_o
analysis NN 1_o
of IN N
a DT N
cognitive-behavioral JJ 1_i
group NN 1_i
therapy NN 1_i
( ( 1_i
CBT NNP 1_i
) ) 1_i
in IN N
comparison NN N
to TO N
a DT N
client-centered JJ 1_i
, , 1_i
supportive-experiential JJ 1_i
group NN 1_i
therapy NN 1_i
( ( 1_i
SET NNP 1_i
) ) 1_i
in IN N
cancer NN 1_p
patients NNS 1_p
with IN 1_p
dysfunctional JJ 1_p
fear NN 1_p
of IN 1_p
progression NN 1_p
. . 1_p

An DT N
incremental JJ N
cost-effectiveness JJ 1_o
analysis NN 1_o
was VBD N
performed VBN N
using VBG N
data NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
among IN N
cancer NN 1_p
patients NNS 1_p
receiving VBG 1_p
inpatient JJ 1_p
rehabilitation NN 1_p
. . 1_p

The DT N
means NNPS 1_o
, , 1_o
95 CD 1_o
% NN 1_o
confidence NN 1_o
intervals NNS 1_o
[ VBP 1_o
95 CD 1_o
% NN 1_o
CI NNP 1_o
] NNP 1_o
, , 1_o
incremental JJ 1_o
cost-effectiveness JJ 1_o
graphic NN 1_o
and CC 1_o
acceptability NN 1_o
curve NN 1_o
were VBD N
obtained VBN N
from IN N
1,000 CD N
bootstrap NN N
replications NNS N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
174 CD 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
economic JJ 1_p
evaluation NN 1_p
. . 1_p

The DT N
estimated JJ 1_o
means VBZ 1_o
[ JJ N
95 CD N
% NN N
CI NNP N
] NNP N
of IN 1_o
direct JJ 1_o
costs NNS 1_o
and CC 1_o
reduction NN 1_o
of IN 1_o
fear NN 1_o
of IN 1_o
progression NN 1_o
were VBD N
< JJ N
euro JJ N
> NN N
9,045.03 CD N
[ JJ N
6,359.07 CD N
; : N
12,091.87 CD N
] NN N
and CC N
1.41 CD N
[ JJ N
0.93 CD N
; : N
1.92 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
SET NNP N
and CC N
< NNP N
euro VBP N
> $ N
6,682.78 CD N
[ JJ N
4,998.09 CD N
; : N
8,440.95 CD N
] NN N
and CC N
1.44 CD N
[ JJ N
1.02 CD N
; : N
1.09 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
CBT NNP 1_i
. . 1_i

The DT N
incremental JJ 1_o
cost-effectiveness JJ 1_o
ratio NN 1_o
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
amounts NNS N
to TO N
minus NNS N
< NNP N
euro VBP N
> $ N
78,741.66 CD N
[ NNP N
-154,987.20 NNP N
; : N
110,486.32 CD N
] NN N
for IN N
an DT N
additional JJ N
unit NN N
of IN N
effect NN N
. . N

Given VBN N
the DT N
acceptability NN 1_o
curve NN 1_o
, , N
there EX N
is VBZ N
a DT N
92.4 CD N
% NN N
chance NN N
that IN N
the DT N
CBT NNP 1_i
, , N
compared VBN N
with IN N
the DT N
SET NNP 1_i
, , N
is VBZ N
cost-effective JJ 1_o
without IN N
the DT N
need NN N
of IN N
additional JJ N
costs NNS N
to TO N
payers NNS N
. . N

Our PRP$ N
main JJ N
result NN N
is VBZ N
the DT N
superior JJ N
cost-effectiveness NN 1_o
of IN N
the DT N
cognitive-behavioral JJ 1_i
intervention NN 1_i
program NN N
in IN N
comparison NN N
to TO N
the DT N
non-directive JJ N
encounter NN N
group NN N
for IN N
our PRP$ N
sample NN N
of IN N
cancer NN 1_p
patients NNS 1_p
with IN 1_p
high JJ 1_p
levels NNS 1_p
of IN 1_p
anxiety NN 1_o
. . 1_o

-DOCSTART- -X- O O

Eye NNP N
movements NNS N
affirm NN N
: : N
automatic JJ 1_o
overt NN 1_o
gaze NN 1_o
and CC 1_o
arrow NN 1_o
cueing NN 1_o
for IN N
typical JJ 1_p
adults NNS 1_p
and CC 1_p
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

People NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
show NN N
reduced VBN N
interest NN 1_o
towards NNS N
social JJ 1_o
aspects NNS 1_o
of IN 1_o
the DT 1_o
environment NN 1_o
and CC N
a DT N
lesser JJR N
tendency NN 1_o
to TO N
follow VB 1_o
other JJ 1_o
people NNS 1_o
's POS 1_o
gaze NN 1_o
in IN N
the DT N
real JJ N
world NN N
. . N

However RB N
, , N
most JJS N
studies NNS N
have VBP N
shown VBN N
that IN N
people NNS 1_p
with IN 1_p
ASD NNP 1_p
do VBP N
respond VB N
to TO N
eye-gaze JJ N
cues NNS N
in IN N
experimental JJ N
paradigms NN N
, , N
though IN N
it PRP N
is VBZ N
possible JJ N
that IN N
this DT N
behaviour NN N
is VBZ N
based VBN N
on IN N
an DT N
atypical JJ N
strategy NN N
. . N

We PRP N
tested VBD N
this DT N
possibility NN N
in IN N
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
using VBG N
a DT N
cueing NN 1_i
task NN 1_i
combined VBN 1_i
with IN 1_i
eye-movement JJ 1_i
recording NN 1_i
. . 1_i

Both DT N
eye NN N
gaze NN N
and CC N
arrow VB N
pointing VBG N
distractors NNS N
resulted VBD N
in IN N
overt JJ 1_o
cueing NN 1_o
effects NNS 1_o
, , N
both DT N
in IN N
terms NNS N
of IN N
increased VBN 1_o
saccadic JJ 1_o
reaction NN 1_o
times NNS 1_o
, , N
and CC N
in IN N
proportions NNS 1_o
of IN 1_o
saccades NNS 1_o
executed VBN 1_o
to TO 1_o
the DT 1_o
cued VBN 1_o
direction NN 1_o
instead RB 1_o
of IN 1_o
to TO 1_o
the DT 1_o
target NN 1_o
, , N
for IN N
both DT N
participant JJ N
groups NNS N
. . N

Our PRP$ N
results NNS N
confirm VBP N
previous JJ N
reports NNS N
that IN N
eye NN N
gaze NN N
cues NNS N
as RB N
well RB N
as IN N
arrow NN N
cues NNS N
result VBP N
in IN N
automatic JJ 1_o
orienting NN 1_o
of IN 1_o
overt JJ 1_o
attention NN 1_o
. . 1_o

Moreover RB N
, , N
since IN N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
between IN N
arrow NN N
and CC N
eye NN N
gaze NN N
cues NNS N
, , N
we PRP N
conclude VBP N
that IN N
overt JJ 1_o
attentional JJ 1_o
orienting NN 1_o
in IN N
ASD NNP N
, , N
at IN N
least JJS N
in IN N
response NN N
to TO N
centrally RB N
presented VBN N
schematic JJ N
directional JJ N
distractors NNS N
, , N
is VBZ N
typical JJ N
. . N

-DOCSTART- -X- O O

The DT N
response NN N
of IN N
neuropathic JJ 1_o
pain NN 1_o
and CC 1_o
pain NN 1_o
in IN 1_o
complex JJ 1_o
regional JJ 1_o
pain NN 1_o
syndrome NN 1_o
I PRP 1_p
to TO N
carbamazepine VB 1_i
and CC N
sustained-release JJ 1_i
morphine NN 1_i
in IN N
patients NNS 1_p
pretreated VBN 1_p
with IN 1_p
spinal JJ 1_i
cord NN 1_i
stimulation NN 1_i
: : 1_i
a DT N
double-blinded JJ N
randomized NN N
study NN N
. . N

Forty-three JJ 1_p
patients NNS 1_p
with IN 1_p
peripheral JJ 1_p
neuropathic JJ 1_p
pain NN 1_p
, , 1_p
exclusively RB 1_p
pain NN 1_p
reduced VBN 1_p
by IN 1_p
spinal JJ 1_i
cord NN 1_i
stimulation NN 1_i
( ( 1_i
SCS NNP 1_i
) ) 1_i
, , 1_p
were VBD 1_p
switched VBN 1_p
into IN 1_p
a DT 1_p
painful JJ 1_p
state NN 1_p
after IN 1_p
SCS NNP 1_i
inactivation NN 1_p
. . 1_p

This DT N
mode NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
pain-relieving JJ N
effect NN N
of IN N
carbamazepine NN 1_i
( ( 1_i
CMZ NNP 1_i
) ) 1_i
and CC N
opioids NNS 1_i
in IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

In IN N
Phase NNP N
1 CD N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
CMZ NNP 1_i
( ( 1_i
600 CD 1_i
mg/d NN 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
during IN N
an DT N
SCS-free JJ N
period NN N
of IN N
8 CD N
days NNS N
. . N

In IN N
Phase NNP N
2 CD N
, , N
after IN N
a DT N
CMZ NNP 1_i
elimination NN N
interval NN N
of IN N
7 CD N
days NNS N
, , N
38 CD N
patients NNS N
received VBD N
either RB N
sustained-release JJ 1_i
morphine NN 1_i
( ( 1_i
90 CD 1_i
mg/d NN 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
for IN N
8 CD N
days NNS N
. . N

In IN N
cases NNS N
of IN N
intolerable JJ 1_o
pain NN 1_o
, , N
the DT N
patients NNS N
were VBD N
authorized VBN N
to TO N
reactivate VB N
their PRP$ N
SCS NNP 1_i
. . 1_i

The DT N
pain NN 1_o
intensity NN 1_o
was VBD N
rated VBN N
on IN N
a DT N
numeric JJ 1_o
analog NN 1_o
scale NN 1_o
. . 1_o

In IN N
38 CD N
patients NNS N
who WP N
completed VBD N
Phase NNP N
1 CD N
, , N
significant JJ N
delay NN 1_o
in IN 1_o
pain JJ 1_o
increase NN 1_o
was VBD N
observed VBN N
in IN N
the DT N
CMZ NNP 1_i
group NN N
as IN N
compared VBN N
with IN N
placebo NN 1_i
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

In IN N
Phase NNP N
2 CD N
, , N
the DT N
trend NN N
observed VBD N
with IN N
morphine NN 1_i
was VBD N
insignificant JJ N
( ( N
P NNP N
= NNP N
0.41 CD N
) ) N
. . N

Two CD N
CMZ JJ 1_i
patients NNS N
and CC N
one CD N
morphine NN 1_i
patient NN N
showed VBD N
complete JJ 1_o
pain NN 1_o
relief NN 1_o
and CC N
preferred VBN N
to TO N
continue VB N
the DT N
medication NN N
. . N

Thirty-five JJ N
patients NNS N
returned VBN N
to TO N
SCS NNP 1_i
. . 1_i

We PRP N
conclude VBP N
that DT N
CMZ NNP 1_i
is VBZ N
effective JJ N
in IN N
peripheral JJ N
neuropathic JJ 1_o
pain NN 1_o
. . 1_o

Morphine NNP 1_i
obviously RB N
requires VBZ N
larger JJR N
individually RB N
titrated VBD N
dosages NNS N
than IN N
those DT N
used VBN N
in IN N
this DT N
study NN N
for IN N
results NNS N
to TO N
be VB N
adequately RB N
interpreted VBN N
. . N

-DOCSTART- -X- O O

Effectiveness NN 1_o
of IN N
once-daily JJ 1_i
monotherapy NN 1_i
with IN N
a DT N
new JJ N
nifedipine NN N
sustained VBN N
release NN N
calcium NN N
antagonist NN N
. . N

Data NNS N
from IN N
2 CD 1_p
separate JJ 1_p
multicenter NN 1_p
, , N
double-blind JJ N
clinical JJ N
studies NNS N
following VBG N
the DT N
same JJ N
protocol NN N
, , N
except IN N
for IN N
the DT N
selection NN N
of IN N
doses NNS N
, , N
were VBD N
pooled VBN N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
fixed JJ N
doses NNS N
of IN N
a DT N
new JJ 1_i
sustained-release NN 1_i
( ( 1_i
SR NNP 1_i
) ) 1_i
formulation NN 1_i
of IN 1_i
nifedipine JJ 1_i
compared VBN N
with IN N
placebo NN 1_i
in IN N
388 CD 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
uncomplicated JJ 1_p
essential JJ 1_p
hypertension NN 1_p
. . 1_p

After IN N
a DT N
3-6 JJ N
week NN N
placebo NN N
washout IN N
period NN N
, , N
the DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
placebo NN 1_i
or CC 1_i
nifedipine JJ 1_i
SR-20 JJ N
mg NN N
( ( N
study NN N
I PRP N
only RB N
) ) N
, , N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
, , N
or CC N
150 CD N
mg NN N
( ( N
study VB N
II NNP N
only RB N
) ) N
. . N

Among IN N
the DT N
278 CD N
patients NNS N
who WP N
completed VBD N
6 CD N
weeks NNS N
of IN N
active JJ N
therapy NN N
, , N
mean JJ 1_o
supine VBP 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
reductions NNS 1_o
from IN N
pretreatment JJ N
baseline NN N
were VBD N
5.9 CD N
, , N
9.3 CD N
, , N
9.2 CD N
, , N
11.1 CD N
, , N
and CC N
13.2 CD N
mm NN N
Hg NNP N
in IN N
the DT N
placebo NN N
, , N
20- JJ N
, , N
50- JJ N
, , N
100- JJ N
, , N
and CC N
150-mg JJ N
groups NNS N
, , N
respectively RB N
. . N

The DT N
reductions NNS N
achieved VBN N
in IN N
each DT N
of IN N
the DT N
nifedipine JJ 1_i
SR NNP N
groups NNS N
were VBD N
statistically RB N
significant JJ N
versus NN N
baseline NN N
values NNS N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

All DT N
nifedipine-SR JJ N
doses NNS N
reduced VBN 1_o
supine JJ 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
significantly RB N
more RBR N
than IN N
placebo NN 1_i
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
linear JJ N
relationship NN N
between IN N
the DT N
log NN 1_o
of IN 1_o
the DT 1_o
dose NN 1_o
and CC N
the DT N
blood NN 1_o
pressure NN 1_o
reduction NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Automated VBN 1_o
ambulatory JJ 1_o
blood NN 1_o
pressure NN 1_o
recordings NNS 1_o
performed VBN N
in IN N
221 CD N
of IN N
the DT N
patients NNS N
showed VBD N
that IN N
the DT N
blood NN 1_o
pressure NN 1_o
was VBD 1_o
lowered VBN 1_o
evenly RB N
through IN N
the DT N
entire JJ N
24-hour JJ N
dosing NN N
period NN N
. . N

The DT N
doses NNS N
that WDT N
were VBD N
effective JJ N
and CC N
associated VBN N
with IN N
the DT N
fewest JJS N
adverse JJ N
reactions NNS N
were VBD N
20 CD N
mg NNS N
and CC N
50 CD N
mg NN N
once RB N
daily RB N
. . N

-DOCSTART- -X- O O

Assessment NN N
from IN N
Functional JJ N
Perspectives NNS N
: : N
Using NNP N
Sensorimotor NNP 1_i
Control NNP 1_i
in IN 1_i
the DT 1_i
Hand NNP 1_i
as IN N
an DT N
Outcome NNP N
Indicator NNP N
in IN N
the DT N
Surgical NNP N
Treatment NNP N
of IN N
Carpal NNP 1_p
Tunnel NNP 1_p
Syndrome NNP 1_p
. . 1_p

To TO N
investigate VB N
whether IN N
sensorimotor NN 1_o
control NN 1_o
of IN 1_o
the DT 1_o
hand NN 1_o
could MD N
be VB N
an DT N
outcome NN 1_o
indicator NN 1_o
after IN N
carpal JJ N
tunnel NN N
release NN N
( ( N
CTR NNP N
) ) N
, , N
this DT N
work NN N
examined VBD N
changes NNS N
in IN N
the DT N
results NNS N
of IN N
patients NNS N
' POS N
manual JJ 1_i
tactile NN 1_i
test NN 1_i
( ( N
MTT NNP N
) ) N
, , N
pinch-holding-up JJ 1_i
activity NN 1_i
( ( N
PHUA NNP N
) ) N
, , N
two-point JJ 1_i
discrimination NN 1_i
( ( N
2PD CD N
) ) N
and CC N
Semmes-Weinstein JJ 1_i
monofilament NN 1_i
( ( N
SWM NNP N
) ) N
tests NNS N
. . N

Participants NNS N
included VBD N
30 CD 1_p
predominantly RB 1_p
sensory JJ 1_p
neuropathy JJ 1_p
CTS NNP 1_p
patients NNS 1_p
, , 1_p
as IN 1_p
confirmed VBN 1_p
by IN 1_p
a DT 1_p
nerve NN 1_p
conduction NN 1_p
study NN 1_p
. . 1_p

The DT N
MTT NNP 1_o
, , 1_o
precision NN 1_o
pinch NN 1_o
performance NN 1_o
in IN 1_o
PHUA NNP 1_o
and CC 1_i
traditional JJ 1_o
sensibility NN 1_o
( ( 1_o
2PD CD 1_o
and CC 1_o
SWM NNP 1_o
) ) 1_o
tests NNS 1_o
were VBD N
used VBN N
to TO N
examine VB N
different JJ N
aspects NNS N
of IN N
sensory JJ 1_o
status NN 1_o
at IN N
the DT N
time-points NNS N
of IN N
two CD N
weeks NNS N
before IN N
operation NN N
and CC N
one CD N
month NN N
post-operation NN N
, , N
with IN N
a DT N
single-blind JJ N
design NN N
. . N

The DT N
results NNS N
showed VBD N
significant JJ N
improvements NNS N
in IN N
the DT N
sensory JJ 1_o
function NN 1_o
as IN N
detected VBN N
by IN N
the DT N
2PD CD 1_i
and CC N
SWM NNP 1_i
tests NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
sensorimotor JJ 1_o
function NN 1_o
as IN N
detected VBN N
by IN N
the DT N
MTT NNP 1_i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
PHUA NNP 1_i
test NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
patients NNS N
receiving VBG N
CTR NNP N
. . N

The DT N
responsiveness NN N
of IN N
the DT N
SWM NNP 1_i
, , 1_i
MTT NNP 1_i
and CC 1_i
PHUA NNP 1_i
tests NNS 1_i
( ( N
effect NN N
size NN N
> NN N
0.5 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
are VBP N
better JJR N
than IN N
that DT N
of IN N
two-point JJ N
discrimination NN N
test NN N
( ( N
effect NN N
size NN N
< NN N
0.5 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
pinch JJ 1_o
strength NN 1_o
saw VBD N
a DT N
decline NN N
compared VBN N
to TO N
baseline VB N
with IN N
a DT N
moderate JJ N
effect NN N
sizes NNS N
( ( N
effect NN N
size NN N
= NN N
0.7 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

This DT N
cohort NN N
study NN N
found VBD N
that IN N
the DT N
MTT NNP 1_i
and CC N
PHUA NNP 1_i
test NN N
can MD N
both VB N
meet VB N
all PDT N
the DT N
statistical JJ N
criteria NNS N
with IN N
regard NN N
to TO N
assessing VBG N
treatment NN N
outcomes NNS N
for IN N
patients NNS 1_p
with IN 1_p
CTS NNP 1_p
. . 1_p

In IN N
addition NN N
, , N
the DT N
results NNS N
of IN N
this DT N
work NN N
provide RB N
clinicians VBZ N
with IN N
the DT N
information NN N
that IN N
the DT N
sensorimotor NN 1_o
functions NNS 1_o
of IN N
the DT N
hands NNS N
, , N
as IN N
assessed VBN N
by IN N
MTT NNP 1_i
and CC 1_i
PHUA NNP 1_i
, , N
are VBP N
responsive JJ N
to TO N
clinical JJ N
changes NNS N
due JJ N
to TO N
CTR NNP N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
prostaglandin NN N
inhibition NN N
by IN N
indomethacin NN 1_i
on IN N
blood NN 1_o
pressure NN 1_o
and CC N
renal JJ 1_o
function NN 1_o
in IN N
hypertensive JJ 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
cilazapril NN 1_i
. . 1_i

1 CD N
. . N

In IN N
a DT N
placebo-controlled JJ 1_i
double-blind JJ N
cross-over NN N
study NN N
lasting VBG N
6 CD N
weeks NNS N
, , N
twenty JJ 1_p
patients NNS 1_p
with IN 1_p
essential JJ 1_p
hypertension NN 1_p
were VBD N
treated VBN N
with IN N
placebo NN 1_i
for IN N
2 CD N
weeks NNS N
followed VBN N
by IN N
oral JJ 1_i
cilazapril NN 1_i
2.5 CD N
mg NN N
once RB N
a DT N
day NN N
or CC N
oral JJ 1_i
indomethacin NN 1_i
50 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

Afterwards NNS N
they PRP N
received VBD N
the DT N
combination NN N
of IN N
both DT N
drugs NNS N
for IN N
a DT N
further JJ N
2 CD N
weeks NNS N
. . N

2 CD N
. . N

Cilazapril NNP 1_i
significantly RB N
lowered VBD N
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
for IN N
a DT N
period NN N
of IN N
24 CD N
h NNS N
post JJ N
administration NN N
. . N

3 CD N
. . N

Indomethacin NNP 1_i
significantly RB N
attenuated VBD N
the DT N
antihypertensive JJ 1_o
activity NN 1_o
of IN N
cilazapril NN 1_i
. . 1_i

This DT N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
who WP N
were VBD N
treated VBN N
for IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
with IN N
indomethacin JJ 1_i
plus CC 1_i
placebo NN 1_i
( ( N
and CC N
subsequently RB N
with IN N
cilazapril NN 1_i
in IN N
addition NN N
) ) N
than IN N
in IN N
the DT N
subjects NNS N
who WP N
first RB N
received VBD N
cilazapril JJ 1_i
plus CC 1_i
placebo NN 1_i
and CC N
then RB N
the DT N
combination NN N
. . N

4 CD N
. . N

Correspondingly VB N
the DT N
decrease NN N
of IN N
plasma JJ 1_o
renin NN 1_o
activity NN 1_o
( ( 1_o
PRA NNP 1_o
) ) 1_o
and CC 1_o
urinary JJ 1_o
prostaglandin NN 1_o
excretion NN 1_o
( ( 1_o
PGE2 NNP 1_o
) ) 1_o
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
treated VBD N
initially RB N
with IN N
indomethacin NN 1_i
. . 1_i

5 CD N
. . N

The DT N
effect NN N
of IN N
indomethacin NN 1_i
on IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
cilazapril NN 1_i
appears VBZ N
to TO N
depend VB N
upon IN N
the DT N
sequence NN N
of IN N
drug NN N
administration NN N
. . N

-DOCSTART- -X- O O

A DT N
placebo-controlled JJ 1_i
, , N
randomized JJ N
clinical JJ N
trial NN N
using VBG N
testosterone NN 1_i
undecanoate NN 1_i
with IN 1_i
injectable JJ 1_i
norethisterone JJ 1_i
enanthate NN 1_i
: : 1_i
effect NN N
on IN N
anthropometric NN 1_p
, , 1_p
metabolic JJ 1_p
and CC 1_p
biochemical JJ 1_p
parameters NNS 1_p
. . 1_p

Testosterone CD N
administered VBD N
alone RB N
or CC N
in IN N
combination NN N
with IN N
progestogens NNS N
in IN N
male JJ N
contraception NN N
induces NNS N
reversible JJ N
oligo-azoospermia JJ N
, , N
but CC N
its PRP$ N
effects NNS N
on IN N
body NN N
composition NN N
and CC N
metabolism NN N
are VBP N
less RBR N
known JJ N
. . N

We PRP N
analysed VBD 1_p
anthropometric JJ 1_p
and CC 1_p
metabolic JJ 1_p
parameters NNS 1_p
in IN 1_p
five CD 1_p
groups NNS 1_p
of IN 1_p
10 CD 1_p
males NNS 1_p
: : 1_p
four CD 1_p
receiving VBG 1_p
testosterone NN 1_i
undecanoate NN 1_i
( ( N
TU NNP N
: : N
1000 CD N
mg NN N
) ) N
plus CC 1_i
norethisterone JJ 1_i
enanthate NN 1_i
( ( N
NETE NNP N
: : N
200 CD N
mg NN N
) ) N
at IN N
different JJ N
intervals NNS N
( ( N
every DT N
8 CD N
weeks NNS N
: : N
NETE-8 JJ N
; : N
every DT N
12 CD N
weeks NNS N
: : N
NETE-12 NN N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12 JJ N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
TU NNP 1_i
plus CC 1_i
placebo JJ 1_i
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12/0 NNP N
) ) N
and CC N
one CD N
placebo NN 1_i
( ( N
NETE-0/0 NNP N
) ) N
for IN N
a DT N
total NN N
of IN N
48 CD N
weeks NNS N
. . N

Body NNP 1_o
mass NN 1_o
index NN 1_o
( ( 1_o
BMI NNP 1_o
) ) 1_o
and CC 1_o
waist JJ 1_o
circumference NN 1_o
did VBD 1_o
not RB 1_o
change VB 1_o
in IN N
any DT N
groups NNS N
except IN N
for IN N
the DT N
NETE-8 NNP N
in IN N
which WDT N
BMI NNP 1_o
increased VBD 1_o
significantly RB 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
. . N

Lean JJ 1_o
body NN 1_o
mass NN 1_o
( ( 1_o
MAMC NNP 1_o
or CC 1_o
AMA NNP 1_o
) ) 1_o
increased VBD 1_o
significantly RB 1_o
in IN N
the DT N
highest JJS N
hormonal JJ N
dose NN N
groups NNS N
( ( N
p JJ N
= NN N
0.04 CD N
, , N
NETE-6/12 NNP N
; : N
p VBZ N
= $ N
0.004 CD N
, , N
NETE-8 NNP N
) ) N
. . N

No UH N
differences NNS N
were VBD N
observed VBN N
in IN N
glucose JJ 1_o
levels NNS 1_o
, , 1_o
insulin NN 1_o
sensitivity NN 1_o
index NN 1_o
and CC 1_o
lipid JJ 1_o
profile NN 1_o
as RB N
well RB N
as IN N
in IN N
biochemical JJ 1_o
and CC 1_o
cell NN 1_o
count NN 1_o
parameters NNS 1_o
in IN N
any DT N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
NETE NNP N
and CC N
TU NNP N
for IN N
48 CD N
weeks NNS N
were VBD N
not RB N
accompanied VBN N
by IN N
any DT N
metabolic JJ 1_o
changes NNS 1_o
and CC 1_o
any DT 1_o
adverse JJ 1_o
effects NNS 1_o
. . 1_o

The DT N
weight JJ 1_o
gain NN 1_o
of IN N
the DT N
highest JJS N
NETE JJ N
plus CC N
TU JJ N
dosage NN N
was VBD N
mainly RB N
because IN N
of IN N
gain NN N
in IN N
muscle NN N
mass NN N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
a DT N
DNAemia NNP 1_i
cut-off NN 1_i
for IN N
monitoring VBG N
human JJ N
cytomegalovirus NN N
infection NN N
reduces VBZ N
the DT N
number NN 1_o
of IN 1_o
preemptively RB 1_o
treated VBN 1_o
children NNS 1_o
and CC 1_p
young JJ 1_p
adults NNS 1_p
receiving VBG 1_p
hematopoietic JJ 1_p
stem-cell JJ 1_p
transplantation NN 1_p
compared VBN N
with IN N
qualitative JJ 1_i
pp65 NN 1_i
antigenemia NN 1_i
. . 1_i

We PRP N
performed VBD N
a DT N
randomized JJ N
trial NN N
comparing VBG N
the DT N
use NN N
of IN N
quantitative JJ 1_i
DNAemia NNP 1_i
versus NN 1_i
positive JJ 1_i
antigenemia NN 1_i
for IN N
starting VBG N
preemptive JJ N
antihuman NN N
cytomegalovirus NN N
( ( N
HCMV NNP N
) ) N
therapy NN N
in IN N
hematopoietic JJ 1_p
stem-cell JJ 1_p
transplantation NN 1_p
( ( 1_p
HSCT NNP 1_p
) ) 1_p
recipients NNS 1_p
. . 1_p

In IN N
the DT N
DNAemia NNP 1_i
arm NN N
, , N
antiviral JJ 1_i
therapy NN 1_i
was VBD N
initiated VBN N
on IN N
reaching VBG N
a DT N
DNAemia NNP 1_i
cut-off NN 1_i
of IN N
10 CD N
000 CD N
DNA NNP N
copies/mL NN N
of IN N
whole JJ N
blood NN N
, , N
whereas NNS N
in IN N
the DT N
antigenemia NN N
arm NN N
, , N
therapy NN N
was VBD N
started VBN N
in IN N
the DT N
presence NN N
of IN N
a DT N
positive JJ 1_i
antigenemia NN 1_i
. . 1_i

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
number NN N
of IN N
patients NNS N
treated VBN N
in IN N
the DT N
2 CD N
arms NNS N
. . N

On IN N
the DT N
whole NN N
, , N
178 CD 1_p
patients NNS 1_p
( ( 1_p
89 CD 1_p
in IN 1_p
each DT 1_p
arm NN 1_p
) ) 1_p
, , 1_p
receiving VBG 1_p
unmanipulated JJ 1_i
HSCT NNP 1_i
from IN 1_p
either CC 1_p
a DT 1_p
relative NN 1_p
or CC 1_p
an DT 1_p
unrelated JJ 1_p
donor NN 1_p
, , N
completed VBD N
the DT N
study NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
HCMV NNP 1_o
infection NN 1_o
was VBD N
comparable JJ N
in IN N
DNAemia NNP N
and CC N
antigenemia NN N
arms NNS N
( ( N
34 CD N
% NN N
vs JJ N
42 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
.259 NNP N
) ) N
, , N
the DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
treated VBN 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
DNAemia NNP 1_i
arm NN N
( ( N
18 CD N
% NN N
vs JJ N
31 CD N
% NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

No DT N
patient NN N
developed VBD N
HCMV NNP 1_o
disease NN 1_o
. . 1_o

The DT N
use NN N
of IN N
a DT N
DNAemia NNP 1_i
cut-off NN 1_i
avoids NNS N
unnecessary JJ N
antiviral JJ 1_i
treatment NN 1_i
. . 1_i

-DOCSTART- -X- O O

Compliance NN N
with IN N
continuous JJ 1_i
passive JJ 1_i
movement NN 1_i
is VBZ N
low JJ N
after IN N
surgical JJ N
treatment NN N
of IN N
idiopathic JJ 1_p
club JJ 1_p
foot NN 1_p
in IN 1_p
infants NNS 1_p
: : 1_p
a DT N
prospective JJ N
, , N
double-blinded JJ N
clinical JJ N
study NN N
. . N

Treatment NN N
by IN N
continuous JJ 1_i
passive JJ 1_i
movement NN 1_i
at IN 1_i
home NN 1_i
is VBZ N
an DT N
alternative JJ N
to TO N
immobilisation NN N
in IN N
a DT N
cast NN N
after IN 1_p
surgery NN 1_p
for IN 1_p
club JJ 1_p
foot NN 1_p
. . 1_p

Compliance NN N
with IN N
the DT N
recommended JJ N
treatment NN N
, , N
of IN N
at IN N
least JJS N
four CD N
hours NNS N
daily RB N
, , N
is VBZ N
unknown JJ N
. . N

The DT N
duration NN N
of IN N
treatment NN N
was VBD N
measured VBN N
in IN N
24 CD 1_p
of IN 1_p
27 CD 1_p
consecutive JJ 1_p
children NNS 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
24 CD 1_p
months NNS 1_p
( ( 1_p
5 CD 1_p
to TO 1_p
75 CD 1_p
) ) 1_p
following VBG 1_p
posteromedial JJ 1_p
release NN 1_p
for IN 1_p
idiopathic JJ 1_p
club JJ 1_p
foot NN 1_p
. . 1_p

Only RB N
21 CD N
% NN N
( ( N
5 CD N
) ) N
of IN N
the DT N
children NNS N
used VBD N
the DT N
continuous JJ 1_i
passive JJ 1_i
movement NN 1_i
machine NN N
as IN N
recommended JJ N
. . N

The DT N
mean JJ N
duration NN N
of IN N
treatment NN N
at IN N
home NN N
each DT N
day NN N
was VBD N
126 CD N
minutes NNS N
( ( N
11 CD N
to TO N
496 CD N
) ) N
. . N

The DT N
mean JJ 1_o
range NN 1_o
of IN 1_o
movement NN 1_o
for IN 1_o
plantar NN 1_o
flexion NN 1_o
improved VBD 1_o
from IN 1_o
15.2 CD 1_o
degrees NNS 1_o
( ( 1_o
10.0 CD 1_o
degrees NNS 1_o
to TO 1_o
20.6 CD 1_o
degrees NNS 1_o
) ) 1_o
to TO 1_o
18.7 CD 1_o
degrees NNS 1_o
( ( 1_o
10.0 CD 1_o
degrees NNS 1_o
to TO 1_o
33.0 CD 1_o
degrees NNS 1_o
) ) 1_o
and CC 1_o
for IN 1_o
dorsiflexion NN 1_o
from IN 1_o
12.3 CD 1_o
degrees NNS 1_o
( ( 1_o
7.4 CD 1_o
degrees NNS 1_o
to TO 1_o
19.4 CD 1_o
degrees NNS 1_o
) ) 1_o
to TO 1_o
18.9 CD 1_o
degrees NNS 1_o
( ( 1_o
10.0 CD 1_o
degrees NNS 1_o
to TO 1_o
24.1 CD 1_o
degrees NNS 1_o
) ) 1_o
( ( 1_o
both DT 1_o
, , 1_o
p NN 1_o
= NNP 1_o
0.0001 CD 1_o
) ) 1_o
when WRB 1_o
the DT 1_o
first JJ 1_o
third NN 1_o
of IN 1_o
therapy NN 1_o
was VBD 1_o
compared VBN 1_o
with IN 1_o
the DT 1_o
last JJ 1_o
third JJ 1_o
. . 1_o

A DT N
low JJ N
level NN N
of IN N
patient JJ N
compliance NN N
must MD N
be VB N
considered VBN N
when WRB N
the DT N
outcome NN N
after IN N
treatment NN N
at IN N
home NN N
is VBZ N
interpreted VBN N
. . N

-DOCSTART- -X- O O

Active NNP 1_i
specific JJ 1_i
immunotherapy NN 1_i
for IN N
stage NN 1_p
II NNP 1_p
and CC 1_p
stage NN 1_p
III NNP 1_p
human JJ 1_p
colon NN 1_p
cancer NN 1_p
: : 1_p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Colon NNP N
cancer NN N
is VBZ N
curable JJ N
by IN N
surgery NN N
, , N
but CC N
cure NN N
rate NN N
depends VBZ N
on IN N
the DT N
extent NN N
of IN N
disease NN N
. . N

We PRP N
investigated VBD N
whether IN N
adjuvant JJ N
active JJ 1_i
specific JJ 1_i
immunotherapy NN 1_i
( ( N
ASI NNP N
) ) N
with IN N
an DT N
autologous JJ N
tumour JJ N
cell-BCG JJ N
vaccine NN N
with IN N
surgical JJ N
resection NN N
was VBD N
more RBR N
beneficial JJ N
than IN N
resection NN N
alone RB N
in IN N
stage NN N
II NNP N
and CC N
III NNP N
colon NN N
cancer NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
, , N
254 CD 1_p
patients NNS 1_p
with IN 1_p
colon NN 1_p
cancer NN 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
postoperative JJ 1_i
ASI NNP 1_i
or CC 1_i
no DT 1_i
adjuvant JJ 1_i
treatment NN 1_i
. . 1_i

ASI NNP N
was VBD N
three CD N
weekly JJ N
vaccinations NNS N
starting VBG N
4 CD N
weeks NNS N
after IN N
surgery NN N
, , N
with IN N
a DT N
booster NN N
vaccination NN N
at IN N
6 CD N
months NNS N
with IN N
10 CD N
( ( N
7 CD N
) ) N
irradiated VBN N
autologous JJ 1_i
tumour NN 1_i
cells NNS 1_i
. . 1_i

The DT N
first JJ N
vaccinations NNS N
contained VBN N
10 CD N
( ( N
7 CD N
) ) N
BCG NNP N
organisms UH N
. . N

We PRP N
followed VBD N
up RP N
patients NNS N
for IN N
time NN N
to TO N
recurrence VB N
, , N
and CC N
recurrence-free JJ N
and CC N
overall JJ N
survival NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
The DT N
5.3 CD N
year NN N
median JJ N
follow-up NN N
( ( N
range VB N
8 CD N
months NNS N
to TO N
8 CD N
years NNS N
11 CD N
months NNS N
) ) N
showed VBD N
44 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
7-66 CD N
) ) N
risk NN N
reduction NN N
for IN N
recurrence NN N
in IN N
the DT N
recurrence-free JJ N
period NN N
in IN N
all DT N
patients NNS N
receiving VBG N
ASI NNP 1_i
( ( N
p=0.023 NN N
) ) N
. . N

Overall JJ N
, , N
there EX N
were VBD N
40 CD N
recurrences NNS N
in IN N
the DT N
control NN N
group NN N
and CC N
25 CD N
in IN N
the DT N
ASI NNP N
group NN N
. . N

Analysis NN N
by IN N
stage NN N
showed VBD N
no DT N
significant JJ N
benefit NN N
of IN N
ASI NNP 1_o
in IN N
stage NN N
III NNP N
disease NN N
. . N

The DT N
major JJ N
impact NN N
of IN N
ASI NNP N
was VBD N
seen VBN N
in IN N
patients NNS 1_p
with IN 1_p
stage NN 1_p
II NNP 1_p
disease NN 1_p
, , N
with IN N
a DT N
significantly RB N
longer RBR N
recurrence-free JJ 1_o
period NN 1_o
( ( N
p=0.011 NN N
) ) N
and CC N
61 CD N
% NN N
( ( N
18-81 JJ N
) ) N
risk NN 1_o
reduction NN 1_o
for IN 1_o
recurrences NNS 1_o
. . 1_o

Recurrence-free JJ 1_o
survival NN 1_o
was VBD N
significantly RB N
longer RBR N
with IN N
ASI NNP N
( ( N
42 CD N
% NN N
risk NN N
reduction NN N
for IN N
recurrence NN N
or CC N
death NN N
[ JJ N
0-68 JJ N
] NN N
, , N
p=0.032 NN N
) ) N
and CC N
there EX N
was VBD N
a DT N
trend NN N
towards VBZ N
improved VBN N
overall JJ 1_o
survival NN 1_o
. . 1_o

INTERPRETATION NNP N
ASI NNP N
gave VBD N
significant JJ N
clinical JJ N
benefit NN N
in IN N
surgically RB N
resected VBN N
patients NNS N
with IN N
stage NN 1_p
II NNP 1_p
colon NN 1_p
cancer NN 1_p
. . 1_p

ASI NNP N
has VBZ N
minimal JJ N
adverse JJ N
reactions NNS N
and CC N
should MD N
be VB N
considered VBN N
in IN N
the DT N
management NN N
of IN N
stage NN N
II NNP N
colon NN N
cancer NN N
. . N

-DOCSTART- -X- O O

Most JJS N
functional JJ N
outcomes NNS N
are VBP N
similar JJ N
for IN N
men NNS 1_p
and CC 1_p
women NNS 1_p
after IN 1_p
hip JJ 1_p
fracture NN 1_p
: : 1_p
a DT N
secondary JJ N
analysis NN N
of IN N
the DT N
enhancing VBG N
mobility NN N
after IN N
hip NN N
fracture NN N
trial NN N
. . N

BACKGROUND VB N
The DT N
impact NN N
of IN N
gender NN N
on IN N
functional JJ N
outcomes NNS N
after IN N
hip NN N
fracture NN N
is VBZ N
not RB N
known VBN N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
gender NN N
influenced VBD N
functional JJ 1_o
outcome NN 1_o
and CC 1_o
response NN 1_o
to TO 1_o
exercise VB 1_o
in IN N
older JJR 1_p
people NNS 1_p
after IN 1_p
hip JJ 1_p
fracture NN 1_p
, , N
and CC N
to TO N
determine VB N
if IN N
any DT N
differences NNS N
persisted VBN N
after IN N
adjusting VBG N
for IN N
cognition NN N
, , N
weight NN N
and CC N
age NN N
. . N

METHOD NNP N
Secondary JJ 1_p
analysis NN 1_i
of IN 1_i
data NNS 1_i
from IN 1_i
the DT 1_i
Enhancing NNP 1_i
Mobility NNP 1_i
After IN 1_i
Hip NNP 1_i
Fracture NNP 1_i
trial NN 1_i
in IN 1_p
which WDT 1_p
older JJR 1_p
people NNS 1_p
after IN 1_p
hip JJ 1_p
fracture NN 1_p
received VBD N
either CC N
a DT N
lower JJR 1_i
or CC 1_i
higher JJR 1_i
intensity NN 1_i
exercise NN 1_i
program NN 1_i
. . 1_i

Functional NNP 1_o
outcomes NNS 1_o
included VBD N
physical JJ 1_o
performance NN 1_o
and CC 1_o
self-reported JJ 1_o
measures NNS 1_o
. . 1_o

Regression NNP N
models NNS N
were VBD N
used VBN N
to TO N
compare VB N
genders NNS N
at IN N
baseline NN N
, , N
week NN N
4 CD N
and CC N
week NN N
16 CD N
, , N
with IN N
adjustment NN N
for IN N
baseline NN N
values NNS N
, , N
cognition NN N
, , N
weight NN N
and CC N
age NN N
. . N

Interaction NN N
terms NNS N
were VBD N
used VBN N
to TO N
assess VB N
a DT N
differential JJ N
impact NN N
of IN N
the DT N
intervention NN N
by IN N
gender NN N
. . N

RESULTS NNP N
Outcome NNP N
data NNS N
were VBD N
available JJ N
for IN N
160 CD 1_p
participants NNS 1_p
, , 1_p
30 CD 1_p
men NNS 1_p
( ( 1_p
19 CD 1_p
% NN 1_p
) ) 1_p
and CC 1_p
130 CD 1_p
women NNS 1_p
( ( 1_p
81 CD 1_p
% NN 1_p
) ) 1_p
at IN N
baseline NN N
, , N
with IN N
the DT N
withdrawal NN N
of IN N
4 CD N
men NNS N
( ( N
13 CD N
% NN N
) ) N
and CC N
6 CD N
women NNS N
( ( N
5 CD N
% NN N
) ) N
at IN N
week NN N
16 CD N
. . N

There EX N
were VBD N
no DT 1_o
gender NN 1_o
differences NNS 1_o
for IN N
any DT N
baseline JJ 1_o
measures NNS 1_o
or CC N
for IN N
most JJS N
of IN N
the DT N
19 CD N
functional JJ 1_o
outcome NN 1_o
measures NNS 1_o
at IN N
weeks NNS N
4 CD N
and CC N
16 CD N
. . N

At IN N
week NN N
4 CD N
men NNS N
performed VBD N
better RBR N
in IN N
knee NN 1_o
extensor NN 1_o
strength NN 1_o
( ( N
2.1 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
0.6 CD N
to TO N
3.7 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

This DT N
difference NN 1_o
did VBD 1_o
not RB 1_o
persist VB 1_o
after IN N
adjustment NN N
for IN N
body NN 1_o
weight NN 1_o
, , N
however RB N
persisted VBN N
after IN N
adjusting VBG N
for IN N
baseline NN 1_o
, , 1_o
cognition NN 1_o
, , 1_o
and CC 1_o
age NN 1_o
( ( N
p JJ N
= NNP N
0.038 CD N
) ) N
. . N

At IN N
week NN N
4 CD N
, , N
men NNS N
performed VBD N
better RBR N
in IN N
coordinated JJ 1_o
stability NN 1_o
( ( N
-10.0 JJ N
error NN N
score NN N
, , N
95 CD N
% NN N
CI NNP N
-17.6 NNP N
to TO N
-2.4 VB N
, , N
p=0.010 NN N
) ) N
and CC N
this DT N
persisted VBN 1_o
after IN N
adjusting VBG N
for IN N
baseline NN 1_o
values NNS 1_o
only RB N
but CC N
not RB N
for IN N
cognition NN 1_o
and CC 1_o
age NN 1_o
( ( N
p JJ N
= NNP N
0.073 CD N
) ) N
. . N

At IN N
week NN N
16 CD N
, , N
men NNS N
performed VBD N
better RBR N
in IN N
coordinated JJ 1_o
stability NN 1_o
( ( N
-10.2 JJ N
error NN N
score NN N
, , N
95 CD N
% NN N
CI NNP N
-18.4 NNP N
to TO N
-1.9 VB N
, , N
p=0.016 NN N
) ) N
and CC N
this DT N
persisted VBN 1_o
after IN N
adjusting VBG N
only RB N
for IN N
cognitive JJ 1_o
impairment NN 1_o
( ( N
p JJ N
= NNP N
0.029 CD N
) ) N
but CC N
not RB N
for IN N
age NN 1_o
and CC 1_o
baseline NN 1_o
( ( N
p JJ N
= NNP N
0.135 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
indication NN N
of IN N
a DT N
differential JJ 1_o
impact NN 1_o
of IN 1_o
intervention NN 1_o
type NN 1_o
on IN N
the DT N
basis NN N
of IN N
gender NN N
. . N

CONCLUSIONS VB N
A DT N
few JJ N
between IN N
gender NN N
differences NNS N
were VBD N
observed VBN N
in IN N
strength NN 1_o
and CC 1_o
balance NN 1_o
, , N
however RB N
these DT N
appeared VBD N
to TO N
be VB N
confounded VBN N
by IN N
body NN 1_o
weight NN 1_o
, , 1_o
age NN 1_o
and/or JJ 1_o
cognition NN 1_o
. . 1_o

-DOCSTART- -X- O O

A DT N
randomized JJ N
cross-over NN N
study NN N
of IN N
inhalation NN N
of IN N
diesel NN N
exhaust NN N
, , N
hematological JJ N
indices NNS N
, , N
and CC N
endothelial JJ N
markers NNS N
in IN N
humans NNS N
. . N

BACKGROUND NNP N
Exposure NNP N
to TO N
traffic-related JJ N
air NN N
pollution NN N
( ( N
TRAP NNP N
) ) N
is VBZ N
considered VBN N
a DT N
trigger NN N
for IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Diesel NNP N
Exhaust NNP N
( ( N
DE NNP N
) ) N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
TRAP NNP N
in IN N
the DT N
world NN N
. . N

We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
DE NNP N
inhalation NN N
on IN N
circulating VBG N
blood NN N
cell NN N
populations NNS N
, , N
hematological JJ N
indices NNS N
, , N
and CC N
systemic JJ N
inflammatory NN N
cytokines NNS N
in IN N
humans NNS N
using VBG N
a DT N
specialized JJ N
facility NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
balanced VBD N
to TO N
order NN N
, , N
17 CD 1_p
metabolic JJ 1_p
syndrome NN 1_p
( ( 1_p
MetS NNP 1_p
) ) 1_p
and CC 1_p
15 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
inhaled VBN 1_i
filtered JJ 1_i
air NN 1_i
( ( 1_i
FA NNP 1_i
) ) 1_i
or CC 1_i
DE NNP 1_i
exposure NN 1_i
in IN 1_p
two-hour JJ 1_p
sessions NNS 1_p
on IN 1_p
different JJ 1_p
days NNS 1_p
with IN 1_p
a DT 1_p
minimum JJ 1_p
2-week JJ 1_p
washout NN 1_p
period NN 1_p
. . 1_p

We PRP N
collected VBD N
blood NN N
pre-exposure NN N
, , N
7 CD N
, , N
and CC N
22 CD N
hours NNS N
after IN N
exposure NN N
initiation NN N
and CC N
measured VBD N
the DT N
complete JJ N
blood NN 1_o
count NN 1_o
and CC 1_o
differential JJ 1_o
. . 1_o

We PRP N
performed VBD N
multiplex JJ N
cytokine NN N
assay NN N
to TO N
measure VB N
the DT N
changes NNS N
in IN N
the DT N
systemic JJ N
inflammatory NN N
cytokines NNS N
, , N
and CC N
endothelial JJ N
adhesion NN N
molecules NNS N
( ( N
n=15 NN N
) ) N
. . N

A DT N
paired JJ N
analysis NN N
compared VBN N
the DT N
effect NN N
of IN N
DE NNP N
and CC N
FA NNP N
exposures NNS N
for IN N
the DT N
change NN N
from IN N
pre-exposure NN N
to TO N
the DT N
subsequent JJ N
time NN N
points NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
increase NN 1_o
in IN 1_o
the DT 1_o
hematocrit NN 1_o
was VBD N
noted VBN N
7 CD N
hrs NNS N
after IN N
DE NNP N
[ FW N
1.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.9 CD N
to TO N
1.9 CD N
% NN N
) ) N
] NN N
compared VBN N
to TO N
FA NNP N
exposure NN N
[ VBZ N
0.5 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-0.09 NN N
to TO N
1.0 CD N
% NN N
) ) N
; : N
p=0.008 NN N
. . N

The DT N
hemoglobin NN 1_o
levels NNS 1_o
increased VBD 1_o
non-significantly RB N
at IN N
7 CD N
hrs JJ N
post NN N
DE NNP N
[ NNP N
0.3 CD N
gm/dL NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.2 CD N
to TO N
0.5 CD N
gm/dL NN N
) ) N
] VBZ N
versus JJ N
FA NNP N
exposure NN N
[ VBZ N
0.2 CD N
gm/dL NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0 CD N
to TO N
0.3 CD N
gm/dL NN N
) ) N
] NN N
; : N
p=0.06 NN N
. . N

Furthermore RB N
, , N
the DT N
platelet NN 1_o
count NN 1_o
increased VBD 1_o
22 CD N
hrs NN N
after IN N
DE NNP N
exposure NN N
in IN N
healthy JJ N
, , N
but CC N
not RB N
in IN N
MetS NNP N
subjects NNS N
[ FW N
DE NNP N
: : N
16.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
10.2 CD N
to TO N
23 CD N
) ) N
thousand CD N
platelets/mL JJ N
versus NN N
[ NN N
FA NNP N
: : N
3.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-9.5 NN N
to TO N
16.3 CD N
) ) N
thousand CD N
platelets/mL NN N
) ) N
] NN N
; : N
p=0.04 NN N
. . N

No DT N
DE NNP 1_o
effect NN 1_o
was VBD N
observed VBN N
for IN N
WBC NNP 1_o
, , 1_o
neutrophils RB 1_o
, , 1_o
lymphocytes VBZ 1_o
or CC N
erythrocytes VBZ 1_o
. . 1_o

Using VBG N
the DT N
multiplex JJ N
assay NN N
, , N
small JJ N
borderline NN N
significant JJ N
increases NNS 1_o
in IN 1_o
matrix JJ 1_o
metalloproteinase-9 NN 1_o
, , 1_o
interleukins NNS 1_o
( ( 1_o
IL NNP 1_o
) ) 1_o
-1 NNP 1_o
beta NN 1_o
, , 1_o
6 CD 1_o
and CC 1_o
10 CD 1_o
occurred VBD N
7 CD N
hrs NN N
post NN N
exposure NN N
initiation NN N
, , N
whereas IN N
E-selectin NNP 1_o
, , 1_o
intercellular JJ 1_o
adhesion NN 1_o
molecule-1 NN 1_o
, , N
and CC N
vascular JJ 1_o
cell NN 1_o
adhesion NN 1_o
molecule NN 1_o
-1 NNP 1_o
, , N
and CC N
myeloperoxidase VB 1_o
22 CD 1_o
hrs NN N
post NN N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
short-term JJ N
DE NNP N
exposure NN N
results NNS N
in IN N
hemoconcentration NN 1_o
and CC 1_o
thrombocytosis NN 1_o
, , N
which WDT N
are VBP N
important JJ N
determinants NNS N
of IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Multiplex NNP N
assay VBP N
showed VBD N
a DT N
non-significant JJ N
increase NN N
in IN N
IL-1? NNP N
and CC N
IL-6 NNP N
immediately RB N
post NN N
exposure NN N
followed VBN N
by IN N
myeloperoxidase NN N
and CC N
endothelial JJ N
activation NN N
molecules NNS N
. . N

Further NNP N
specific JJ N
assays NNS N
in IN N
a DT N
larger JJR N
population NN N
will MD N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
systemic JJ N
inflammatory JJ N
mechanisms NNS N
following VBG N
acute NN N
exposure NN N
to TO N
TRAP NNP N
. . N

-DOCSTART- -X- O O

Chlorthalidone NN 1_i
does VBZ N
not RB N
increase VB N
the DT N
hypotensive JJ 1_o
effect NN 1_o
of IN N
nifedipine NN 1_i
in IN N
essential JJ N
hypertensives NNS N
: : N
a DT N
crossover NN 1_p
multicentre NN 1_p
study NN 1_p
. . 1_p

To TO N
determine VB N
whether IN N
the DT N
combination NN N
of IN N
nifedipine JJ 1_i
+ NNP 1_i
chlorthalidone NN 1_i
exerts VBZ N
an DT N
additive JJ 1_o
antihypertensive JJ 1_o
effect NN 1_o
when WRB N
compared VBN N
with IN N
single-drug JJ N
treatment NN N
, , N
we PRP N
studied VBD N
66 CD 1_p
uncomplicated JJ 1_p
essential JJ 1_p
hypertensives NNS 1_p
, , 1_p
with IN 1_p
diastolic JJ 1_p
blood NN 1_p
pressure NN 1_p
of IN 1_p
greater JJR 1_p
than IN 1_p
100 CD 1_p
and CC 1_p
less JJR 1_p
than IN 1_p
115 CD 1_p
mmHg NN 1_p
. . 1_p

At IN N
the DT N
end NN N
of IN N
a DT N
1-month JJ N
washout NN N
placebo NN 1_i
period NN N
, , N
using VBG N
a DT N
double-blind JJ N
crossover NN N
design NN N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
nifedipine VB 1_i
( ( N
20 CD N
mg NN N
twice RB N
a DT N
day NN N
) ) N
, , N
chlorthalidone NN 1_i
( ( N
25 CD N
mg NN N
once RB N
a DT N
day NN N
) ) N
, , N
the DT N
two CD N
drugs NNS N
combined VBN N
at IN N
the DT N
same JJ N
doses NNS N
and CC N
the DT N
corresponding JJ N
placebo NN 1_i
. . 1_i

Compared VBN N
with IN N
the DT N
randomly NN N
allocated VBD N
placebo NN N
, , N
the DT N
three CD N
active JJ N
treatments NNS N
significantly RB N
reduced VBD N
blood NN 1_o
pressure NN 1_o
without IN N
changing VBG N
the DT N
heart NN 1_o
rate NN 1_o
or CC 1_o
body NN 1_o
weight NN 1_o
. . 1_o

Both CC N
the DT N
absolute NN 1_o
and CC N
percentage NN 1_o
decreases NNS 1_o
in IN N
mean JJ 1_o
blood NN 1_o
pressure NN 1_o
induced VBN N
by IN N
nifedipine NN 1_i
and CC N
the DT N
combination NN N
compared VBN N
with IN N
placebo NN 1_i
were VBD N
similar JJ N
and CC N
significantly RB N
greater JJR N
than IN N
those DT N
induced VBN N
by IN N
chlorthalidone NN 1_i
. . 1_i

Taken VB N
together RB N
, , N
these DT N
data NNS N
show VBP N
that IN N
the DT N
combination NN N
of IN N
nifedipine JJ 1_i
+ FW 1_i
chlorthalidone NN 1_i
does VBZ N
not RB N
exert VB N
any DT N
additive JJ 1_o
antihypertensive JJ 1_o
effect NN 1_o
compared VBN N
with IN N
nifedipine JJ 1_i
alone RB N
. . N

This DT N
finding NN N
indicates VBZ N
that IN N
the DT N
combination NN N
of IN N
a DT N
dihydropyridine JJ 1_i
calcium NN 1_i
antagonist NN 1_i
+ VBD 1_i
a DT 1_i
thiazide JJ 1_i
diuretic NN 1_i
is VBZ N
probably RB N
devoid JJ N
of IN N
any DT N
particular JJ N
clinical JJ 1_o
significance NN 1_o
in IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ 1_p
essential JJ 1_p
hypertensives NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Antihistamines NNS 1_i
do VBP N
not RB N
inhibit VB N
the DT N
wheal NN N
induced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
autologous JJ N
serum NN N
in IN N
resistant JJ N
chronic JJ N
idiopathic JJ N
urticaria NN N
. . N

Some DT N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
idiopathic JJ 1_p
urticaria NN 1_p
( ( 1_p
CIU NNP 1_p
) ) 1_p
are VBP N
resistant JJ N
to TO N
conventional JJ N
doses NNS N
of IN N
antihistamines NNS 1_i
( ( 1_i
AHs NNP 1_i
) ) 1_i
. . 1_i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
check VB N
whether IN N
the DT N
skin JJ 1_o
wheal NN 1_o
and CC 1_o
flare JJ 1_o
reaction NN 1_o
produced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
autologous JJ 1_i
serum NN 1_i
( ( 1_i
AS IN 1_i
) ) 1_i
and CC N
by IN N
histamine NN 1_i
differs NNS N
in IN N
AH-resistant NNP 1_p
and CC 1_p
AH NNP 1_p
responder VBP 1_p
CIU NNP 1_p
patients NNS 1_p
. . 1_p

CIU NNP 1_p
patients NNS 1_p
with IN 1_p
treatment NN 1_p
failure NN 1_p
under IN 1_p
fexofenadine NN 1_i
at IN 1_p
180 CD 1_p
mg NN 1_p
q.d NN 1_p
. . 1_p

increased VBD 1_i
their PRP$ 1_i
daily JJ 1_i
dose NN 1_i
of IN N
AH NNP N
to TO N
4 CD N
tablets NNS N
daily RB N
. . N

Those DT 1_p
with IN 1_p
significant JJ 1_p
improvement NN 1_p
of IN 1_p
urticaria JJ 1_p
activity NN 1_p
score NN 1_p
under IN 1_p
fexofenadine NN 1_i
at IN 1_p
180 CD 1_p
mg NNS 1_p
were VBD N
included VBN N
in IN N
the DT N
CIU NNP N
group NN N
. . N

Subjects VBZ N
with IN N
treatment NN N
failure NN N
despite IN N
a DT N
full JJ N
8-week JJ N
fourfold JJ N
fexofenadine NN 1_i
treatment NN N
were VBD N
included VBN N
in IN N
the DT N
resistant JJ N
CIU NNP N
( ( N
R-CIU NNP N
group NN N
) ) N
. . N

The DT 1_p
control NN 1_p
group NN 1_p
consisted VBD 1_p
of IN 1_p
sex- JJ 1_p
and CC 1_p
age-matched JJ 1_p
patents NNS 1_p
with IN 1_p
allergic JJ 1_p
rhinitis NN 1_p
. . 1_p

The DT N
AS NNP N
skin JJ N
test NN N
and CC N
intradermal JJ N
histamine-induced JJ 1_i
wheal NN N
and CC N
flare JJ N
reaction NN N
were VBD N
performed VBN N
at IN N
baseline NN N
( ( N
without IN N
AH NNP N
) ) N
, , N
after IN N
8 CD N
and CC N
16 CD N
weeks NNS N
( ( N
under IN N
AH NNP N
treatment NN N
) ) N
. . N

Forty-six JJ 1_p
subjects NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
CIU NNP 1_p
group NN 1_p
, , 1_p
21 CD 1_p
were VBD 1_p
in IN 1_p
the DT 1_p
R-CIU NNP 1_p
group NN 1_p
, , 1_p
and CC 1_p
44 CD 1_p
were VBD 1_p
in IN 1_p
the DT 1_p
control NN 1_p
group NN 1_p
. . 1_p

Under IN N
AH NNP N
therapy NN N
, , N
the DT N
skin JJ 1_o
reaction NN 1_o
to TO 1_o
intradermal VB 1_o
histamine JJ 1_o
injection NN 1_o
was VBD N
significantly RB N
diminished VBN N
in IN N
all DT N
study NN N
groups NNS N
. . N

In IN N
the DT N
R-CIU NNP N
group NN N
, , N
fexofenadine NN 1_i
at IN N
180 CD N
mg NNS N
did VBD N
not RB N
suppress VB N
AS-induced NNP 1_o
wheal JJ 1_o
reaction NN 1_o
( ( N
5.96 CD N
? . N
2.25 CD N
mm NN N
; : N
p CC N
= VB N
0.85 CD N
) ) N
, , N
and CC N
with IN N
a DT N
fourfold JJ 1_i
AH NNP 1_i
dose VB N
some DT 1_o
reduction NN 1_o
of IN 1_o
AS-induced NNP 1_o
wheal NN 1_o
( ( N
3.79 CD N
? . N
1.74 CD N
mm NN N
; : N
p CC N
= VB N
0.008 CD N
) ) N
was VBD N
observed VBN N
but CC N
remained VBD N
larger JJR N
than IN N
in IN N
the DT N
CIU NNP N
( ( N
2.31 CD N
? . N
1.12 CD N
; : N
p NN N
= VBZ N
0.006 CD N
) ) N
and CC N
control NN N
groups NNS N
( ( N
2.52 CD N
? . N
1.36 CD N
; : N
p NN N
= VBZ N
0.037 CD 1_i
) ) 1_i
. . 1_i

AHs NNP 1_i
do VBP N
not RB N
inhibit VB N
the DT N
wheal NN N
induced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
AS NNP N
in IN N
R-CIU NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
explicit JJ 1_i
instruction NN 1_i
on IN 1_i
Japanese JJ 1_i
Verbal NNP 1_i
Learning NNP 1_i
Test NNP 1_i
in IN N
schizophrenia NN 1_p
patients NNS 1_p
. . 1_p

After IN N
random JJ N
assignment NN N
of IN N
20 CD 1_p
schizophrenia NN 1_p
patients NNS 1_p
to TO N
either DT N
an DT N
explicit NN 1_i
or CC 1_i
normal JJ 1_i
instruction NN 1_i
group NN N
, , N
the DT N
Japanese JJ 1_i
Verbal NNP 1_i
Learning NNP 1_i
Test NNP 1_i
was VBD N
administered VBN N
to TO N
them PRP N
. . N

Results VB N
reveal NN N
that IN N
explicit JJ N
instruction NN N
group NN N
patients NNS N
demonstrated VBD N
more RBR N
improved JJ 1_o
memory NN 1_o
performance NN 1_o
using VBG N
semantic JJ N
clustering NN N
, , N
suggesting VBG N
that IN N
explicit NN N
and CC N
direct JJ N
teaching NN N
facilitates VBZ N
patients NNS N
' POS N
learning NN N
of IN N
information NN N
. . N

-DOCSTART- -X- O O

Continual JJ 1_i
feeding NN 1_i
of IN N
two CD N
types NNS N
of IN N
microalgal JJ 1_i
biomass NN 1_i
affected VBD N
protein JJ N
digestion NN N
and CC N
metabolism NN N
in IN N
laying VBG 1_p
hens NNS 1_p
. . 1_p

A DT N
14-wk JJ N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
nutritional JJ N
efficacy NN 1_o
and CC 1_o
ssmetabolic JJ 1_o
impact NN 1_o
of IN N
2 CD N
types NNS N
of IN N
microalgal JJ 1_i
biomass NN 1_i
as IN N
alternative JJ N
protein NN N
sources NNS N
in IN N
laying VBG 1_p
hen JJ 1_p
diets NNS N
. . N

Shaver NNP 1_p
hens VBZ 1_p
( ( 1_p
total JJ 1_p
= NN 1_p
150 CD 1_p
and CC 1_p
26 CD 1_p
wk NNS 1_p
old JJ 1_p
) ) 1_p
were VBD N
fed VBN N
1 CD N
of IN N
5 CD N
diets NNS N
: : N
a DT 1_i
control NN 1_i
or CC 1_i
a DT 1_i
defatted JJ 1_i
green JJ 1_i
microalgal NN 1_i
biomass NN 1_i
( ( 1_i
DG NNP 1_i
; : 1_i
Desmodesmus NNP 1_i
spp NN 1_i
. . 1_i

) ) 1_i
at IN N
25 CD N
% NN N
and CC N
a DT 1_i
full-fatted JJ 1_i
diatom NN 1_i
biomass NN 1_i
( ( 1_i
FD NNP 1_i
; : 1_i
Staurosira NNP 1_i
spp NN 1_i
. . 1_i

) ) 1_i
at IN N
11.7 CD N
% NN N
inclusion NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
protease NN 1_i
. . 1_i

This DT N
experiment NN N
consisted VBD N
of IN N
5 CD N
replicates NNS N
per IN N
treatment NN N
and CC N
each DT N
replicate NN N
contained VBD N
6 CD N
hens NNS N
individually RB N
reared VBN N
in IN N
cages NNS N
( ( N
1 CD N
hen NN N
for IN N
biochemical JJ N
data/replicate NN N
) ) N
. . N

Despite IN N
decreased JJ N
ADFI NNP N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
hens VBZ N
fed JJ N
DG NNP N
or CC N
FD NNP N
had VBD N
final JJ N
BW NNP N
, , N
overall JJ N
hen-day JJ N
egg NN N
production NN N
, , N
and CC N
egg NN N
quality NN N
similar JJ N
to TO N
the DT N
controls NNS N
. . N

Feeding VBG N
DG NNP N
or CC N
FD NNP N
did VBD N
not RB N
alter VB 1_o
plasma JJ 1_o
concentrations NNS 1_o
of IN 1_o
insulin NN 1_o
, , 1_o
glutamine NN 1_o
, , 1_o
and CC 1_o
uric JJ 1_o
acid NN 1_o
or CC 1_o
alkaline JJ 1_o
phosphatase NN 1_o
activity NN 1_o
at IN N
wk $ N
8 CD N
or CC N
14 CD N
but CC N
decreased VBD N
plasma JJ 1_o
3-methyhistine JJ 1_o
concentrations NNS 1_o
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
and CC N
tartrate-resistant JJ 1_o
acid NN 1_o
phosphatase NN 1_o
( ( 1_o
TRAP NNP 1_o
) ) 1_o
activities NNS 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
at IN N
wk $ N
14 CD N
and CC N
improved VBN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
ileal NN N
total JJ N
AA NNP N
digestibility NN N
. . N

Although IN N
DG NNP N
or CC N
FD NNP N
exhibited VBD N
moderate JJ 1_o
effects NNS 1_o
on IN N
intestinal JJ 1_o
brush NN 1_o
border NN 1_o
protease NN 1_o
activities NNS 1_o
and CC 1_o
mRNA NN 1_o
levels NNS 1_o
of IN 1_o
duodenal JJ 1_o
transporters NNS 1_o
Pept1 NNP 1_o
, , 1_o
Lat1 NNP 1_o
, , 1_o
and CC 1_o
Cat1 NNP 1_o
, , N
both DT N
substantially RB N
enhanced VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
phosphorylation NN 1_o
of IN 1_o
hepatic JJ 1_o
protein NN 1_o
synthesis NN 1_o
key JJ 1_o
regulator NN 1_o
S6 NNP 1_o
ribosomal NN 1_o
protein NN 1_o
( ( N
S6 NNP N
) ) N
and CC N
the DT N
ratio NN N
of IN N
phospho-S6 NN N
to TO N
S6 NNP N
in IN N
the DT N
liver NN N
of IN N
hens NNS N
. . N

However RB N
, , N
DG NNP N
and CC N
FD NNP N
manifested VBD N
with IN N
different JJ N
impacts NNS N
on IN N
weights NNS 1_o
of IN 1_o
egg NN 1_o
and CC 1_o
egg NN 1_o
albumen NNS 1_o
, , 1_o
proteolytic JJ 1_o
activity NN 1_o
of IN 1_o
jejunal JJ 1_o
digesta NN 1_o
, , 1_o
plasma JJ 1_o
TRAP NNP 1_o
activity NN 1_o
, , 1_o
ileal JJ 1_o
total JJ 1_o
AA NNP 1_o
digestibility NN 1_o
, , 1_o
and CC 1_o
several JJ 1_o
intestinal JJ 1_o
genes NNS 1_o
and CC 1_o
hepatic JJ 1_o
proteins NNS 1_o
. . 1_o

Supplemental JJ N
protease NN N
in IN N
the DT N
DG NNP N
and CC N
FD NNP N
diets NNS N
produced VBD N
mixed JJ 1_o
effects NNS 1_o
on IN N
a DT N
number NN 1_o
of IN 1_o
measures NNS 1_o
. . 1_o

In IN N
conclusion NN N
, , N
our PRP$ N
findings NNS N
revealed VBD N
the DT N
feasibility NN N
of IN N
including VBG N
greater JJR N
levels NNS N
of IN N
microalgal JJ 1_i
biomass NN 1_i
as IN N
a DT N
source NN N
of IN N
feed NN N
protein NN N
for IN N
laying VBG 1_p
hens NNS 1_p
and CC N
a DT N
novel JJ N
potential NN N
of IN N
the DT N
biomass NN N
in IN N
improving VBG N
dietary JJ N
protein NN N
digestion NN N
and CC N
body NN N
protein VBP N
metabolism NN N
than IN N
previously RB N
perceived VBN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
umbilical JJ 1_i
cord NN 1_i
serum NN 1_i
therapy NN 1_i
for IN N
persistent JJ 1_p
corneal JJ 1_p
epithelial JJ 1_p
defects NNS 1_p
. . 1_p

AIMS NNP N
To TO N
evaluate VB N
umbilical JJ 1_i
cord NN 1_i
serum NN 1_i
therapy NN 1_i
as IN N
a DT N
means NN N
of IN N
promoting VBG N
the DT N
healing NN N
of IN N
persistent JJ 1_o
corneal JJ 1_o
epithelial JJ 1_o
defects NNS 1_o
. . 1_o

METHODS NNP N
Umbilical NNP 1_i
cord NN 1_i
serum NN 1_i
or CC 1_i
autologous JJ 1_i
serum NN 1_i
drops NNS 1_i
were VBD N
used VBN N
to TO N
promote VB N
the DT N
healing NN N
of IN N
persistent JJ 1_o
epithelial JJ 1_o
defects NNS 1_o
. . 1_o

The DT N
study NN N
design NN N
was VBD N
a DT N
prospective JJ N
randomised VBN N
controlled VBD N
clinical JJ N
trial NN N
. . N

60 CD 1_p
eyes NNS 1_p
of IN 1_p
59 CD 1_p
patients NNS 1_p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
31 CD N
in IN N
the DT N
cord NN 1_i
serum NN 1_i
group NN N
and CC N
29 CD N
in IN N
the DT N
autologous JJ 1_i
serum NN 1_i
control NN 1_i
group NN 1_i
. . 1_i

Epithelial JJ N
defects NNS N
measuring VBG N
at IN N
least JJS N
2 CD N
mm NN N
in IN N
linear JJ N
dimension NN N
resistant NN N
to TO N
conventional JJ N
medical JJ N
management NN N
were VBD N
included VBN N
. . N

Serial JJ N
measurements NNS N
of IN N
the DT N
size NN N
of IN N
the DT N
epithelial JJ N
defects-namely RB N
, , N
two CD N
maximum JJ N
linear JJ N
dimensions NNS N
perpendicular VBP N
to TO N
each DT N
other JJ N
, , N
and CC N
the DT N
area NN N
and CC N
perimeter NN N
was VBD N
done VBN N
at IN N
start NN N
of IN N
therapy NN N
and CC N
follow VB N
up RP N
days NNS N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
. . N

Rate NN 1_o
of IN 1_o
healing NN 1_o
of IN 1_o
the DT 1_o
epithelial JJ 1_o
defects NNS 1_o
were VBD N
measured VBN N
as IN N
percentage NN N
decrease NN N
from IN N
the DT N
baseline NN N
parameter NN N
at IN N
each DT N
subsequent NN N
follow VBP N
up RB N
. . N

The DT N
data NNS N
were VBD N
analysed VBN N
by IN N
the DT N
non-parametric JJ N
Wilcoxon NNP N
rank NN N
sum NN N
test NN N
using VBG N
STATA NNP N
7.0 CD N
. . N

RESULTS VB N
The DT N
median JJ N
percentage NN N
decrease NN 1_o
in IN 1_o
the DT 1_o
size NN 1_o
of IN 1_o
the DT 1_o
epithelial JJ 1_o
defect NN 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
cord NN 1_i
serum NN 1_i
group NN N
at IN N
days NNS N
7 CD N
, , N
14 CD N
and CC N
21 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
when WRB N
measured VBN N
in IN N
terms NNS N
of IN N
the DT N
area NN N
and CC N
perimeter NN N
. . N

A DT N
greater JJR N
number NN N
of IN N
patients NNS N
showed VBD N
complete JJ 1_o
re-epithelialisation NN 1_o
with IN N
umbilical JJ N
cord NN 1_i
serum NN 1_i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
than IN N
with IN N
autologous JJ N
serum NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
( ( N
Pearson NNP N
chi VBZ N
= NNP N
0.19 CD N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
reported VBD N
any DT N
side NN N
effects NNS N
or CC N
discomfort NN N
with IN N
either DT N
treatment NN N
. . N

CONCLUSIONS NNP N
Umbilical NNP 1_i
cord NN 1_i
serum NN 1_i
leads VBZ N
to TO N
faster RBR 1_o
healing NN 1_o
of IN 1_o
the DT 1_o
persistent JJ 1_o
corneal NN 1_o
epithelial JJ 1_o
defects NNS 1_o
refractory NN N
to TO N
all DT N
medical JJ N
management NN N
compared VBN N
to TO N
autologous JJ 1_i
serum NN 1_i
. . 1_i

-DOCSTART- -X- O O

Mexiletine NNP 1_i
for IN N
treatment NN N
of IN N
chronic JJ N
painful JJ N
diabetic JJ N
neuropathy NN N
. . N

Sixteen NNP 1_p
of IN 1_p
nineteen JJ 1_p
patients NNS 1_p
completed VBD 1_p
a DT 1_p
randomised JJ 1_p
double-blind NN 1_p
crossover NN 1_p
trial NN 1_p
to TO 1_p
assess VB 1_p
the DT 1_p
effect NN 1_p
of IN 1_p
oral JJ 1_i
mexiletine NN 1_i
( ( 1_i
10 CD 1_i
mg/kg NNS 1_i
bodyweight JJ 1_i
daily RB 1_i
) ) 1_i
on IN 1_i
the DT 1_i
symptoms NNS 1_i
and CC 1_i
signs NNS 1_i
of IN 1_i
chronic JJ 1_i
painful JJ 1_i
diabetic JJ 1_i
neuropathy NN 1_i
. . 1_i

The DT 1_p
median JJ 1_p
age NN 1_p
of IN 1_p
the DT 1_p
sixteen JJ 1_p
patients NNS 1_p
was VBD 1_p
50 CD 1_p
years NNS 1_p
( ( 1_p
range VB 1_p
30-64 NNP 1_p
) ) 1_p
. . 1_p

Assessment NN N
with IN N
a DT N
five-item JJ 1_o
clinical JJ 1_o
symptom NN 1_o
scale NN 1_o
showed VBD N
significant JJ N
improvement NN N
during IN N
the DT N
mexiletine NN N
phase NN N
compared VBN N
with IN N
the DT N
placebo NN 1_i
phase NN N
. . N

Pain NN 1_o
was VBD N
reduced VBN N
during IN N
mexiletine NN 1_i
but CC N
not RB N
during IN N
placebo NN 1_i
, , N
as IN N
assessed VBN N
by IN N
a DT N
visual JJ N
analogue NN N
rating NN N
scale NN N
. . N

Mexiletine NNP 1_i
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
tendon NN 1_o
reflexes NNS 1_o
, , 1_o
vibration NN 1_o
threshold NN 1_o
levels NNS 1_o
, , 1_o
beat-to-beat JJ 1_o
variation NN 1_o
in IN 1_o
heart NN 1_o
rate NN 1_o
during IN 1_o
deep JJ 1_o
breathing NN 1_o
, , 1_o
and CC 1_o
postural JJ 1_o
blood NN 1_o
pressure NN 1_o
response NN 1_o
. . 1_o

Mild JJ 1_o
side-effects NNS 1_o
were VBD N
seen VBN N
in IN N
three CD N
of IN N
the DT N
sixteen JJ N
patients NNS N
during IN N
mexiletine JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

The DT N
effectiveness NN 1_o
and CC N
cost NN 1_o
of IN N
passive JJ 1_o
warming NN 1_o
in IN N
adult NN 1_p
ambulatory NN 1_p
surgery NN 1_p
patients NNS 1_p
. . 1_p

Hypothermia NNP N
is VBZ N
a DT N
common JJ N
problem NN N
for IN N
surgical JJ 1_p
patients NNS 1_p
and CC N
can MD N
result VB N
in IN N
many JJ N
complications NNS N
. . N

Because IN N
few JJ N
studies NNS N
compare VBP N
methods NNS N
of IN N
passive JJ N
warming NN N
, , N
we PRP N
used VBD N
an DT N
unblinded JJ N
, , N
prospective JJ N
, , N
experimental JJ N
, , N
randomized JJ N
design NN N
to TO N
compare VB N
the DT N
effectiveness NN 1_o
of IN N
two CD N
passive JJ N
methods NNS N
of IN N
normothermia JJ N
management NN N
in IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
( ( N
PACU NNP N
) ) N
. . N

We PRP N
assigned VBD N
a DT N
total NN N
of IN N
578 CD 1_p
adult NN 1_p
ambulatory NN 1_p
surgery NN 1_p
patients NNS 1_p
to TO N
either VB N
a DT N
control NN 1_i
group NN 1_i
that WDT N
was VBD N
given VBN N
two CD 1_i
folded JJ 1_i
, , 1_i
warmed JJ 1_i
cotton NN 1_i
blankets NNS 1_i
or CC 1_i
a DT 1_i
treatment NN 1_i
group NN 1_i
that WDT 1_i
was VBD 1_i
given VBN 1_i
a DT 1_i
warmed NN 1_i
, , 1_i
unfolded JJ 1_i
cotton NN 1_i
sheet NN 1_i
and CC 1_i
cotton NN 1_i
blanket NN 1_i
. . 1_i

We PRP N
recorded VBD N
patients NNS 1_o
' POS 1_o
temperatures NNS 1_o
on IN 1_o
their PRP$ 1_o
arrival NN 1_o
in IN 1_o
the DT 1_o
PACU NNP 1_o
and CC 1_o
at IN 1_o
30 CD 1_o
minutes NNS 1_o
after IN 1_o
arrival NN 1_o
. . 1_o

The DT N
treatment NN N
group NN N
had VBD N
temperatures NNS 1_o
that WDT N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
control NN N
group NN N
30 CD N
minutes NNS N
after IN N
arrival NN N
in IN N
the DT N
PACU NNP N
, , N
and CC N
the DT N
treatment NN N
group NN N
experienced VBD N
a DT N
greater JJR N
change NN 1_o
in IN 1_o
temperature NN 1_o
from IN N
baseline NN N
measurements NNS N
to TO N
those DT N
taken VBN N
at IN N
30 CD N
minutes NNS N
. . N

The DT N
treatment NN N
group NN N
also RB N
used VBD N
fewer JJR N
warmed JJ N
blankets NNS N
, , N
resulting VBG N
in IN N
cost NN N
savings NNS N
for IN N
the DT N
PACU NNP N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
colchicine NN 1_i
versus NN N
placebo NN 1_i
for IN N
the DT N
treatment NN N
of IN N
pericardial JJ 1_p
effusion NN 1_p
after IN 1_p
open-heart JJ 1_p
surgery NN 1_p
: : 1_p
A DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Pericardial NNP 1_o
effusion NN 1_o
( ( 1_o
PE NNP 1_o
) ) 1_o
, , N
a DT N
common JJ N
complication NN N
after IN N
open-heart JJ N
surgery NN N
, , N
accounts NNS N
for IN N
50 CD N
% NN N
to TO N
85 CD N
% NN N
of IN N
patients NNS N
. . N

Although IN N
reversible JJ N
in IN N
most JJS N
of IN N
the DT N
cases NNS N
, , N
it PRP N
could MD N
be VB N
life NN N
threatening VBG N
in IN N
the DT N
occurrence NN N
of IN N
tamponade NN N
in IN N
large JJ N
effusions NNS N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
colchicine NN N
on IN N
PE NNP 1_o
after IN 1_p
open-heart JJ 1_p
surgery NN 1_p
. . 1_p

METHODS NNP N
The DT N
study NN N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
triple-blind JJ N
, , N
placebo-controlled JJ 1_i
single-center JJ 1_p
trial NN 1_p
at IN 1_p
Tehran NNP 1_p
Heart NNP 1_p
Center NNP 1_p
. . 1_p

A NNP 1_p
total NN 1_p
of IN 1_p
149 CD 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
or CC 1_p
moderate JJ 1_p
PE NNP 1_p
in IN 1_p
transthoracic NN 1_p
echocardiography NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB 1_i
1 CD 1_i
mg/d NNS 1_i
colchicine NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
74 CD 1_i
) ) 1_i
or CC 1_i
1 CD 1_i
tablet NN 1_i
of IN 1_i
placebo NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
75 CD 1_i
) ) 1_i
for IN 1_i
2 CD 1_i
weeks NNS 1_i
and CC 1_i
then RB 1_i
underwent JJ 1_i
follow-up JJ 1_i
echocardiography NN 1_i
. . 1_i

RESULTS NNP N
Baseline NNP N
and CC N
clinical JJ N
characteristics NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
study NN N
groups NNS N
except IN N
for IN N
age NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
graft JJ N
numbers NNS N
( ( N
P NNP N
= NNP N
.005 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pretreatment NN N
and CC N
posttreatment NN N
PE NNP 1_o
sizes VBZ 1_o
between IN N
the DT N
2 CD N
study NN N
groups NNS N
( ( N
P NNP N
= NNP N
.440 NNP N
and CC N
.844 NNP N
, , N
respectively RB N
) ) N
. . N

Median JJ N
( ( N
25th-75th JJ N
percentiles NNS N
) ) N
of IN N
effusion NN 1_o
changes NNS 1_o
was VBD N
5 CD N
mm NN N
( ( N
1-7.6 JJ N
mm NN N
) ) N
in IN N
the DT N
colchicine NN 1_i
group NN N
and CC N
5 CD N
mm NN N
( ( N
1-6.6 JJ N
mm NN N
) ) N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
P NNP N
= NNP N
.932 NNP N
) ) N
. . N

Intervention NNP N
had VBD N
no DT N
significant JJ N
impact NN N
on IN N
pretreatment NN N
and CC N
posttreatment JJ 1_o
effusion NN 1_o
values NNS 1_o
and CC 1_o
changes NNS 1_o
in IN N
isolated JJ 1_o
coronary JJ 1_o
artery NN 1_o
bypass NN 1_o
graft NN 1_o
surgery NN 1_o
patients NNS 1_o
( ( N
P NNP N
= NNP N
.607 NNP N
, , N
.539 NNP N
, , N
and CC N
.628 NNP N
, , N
respectively RB N
) ) N
. . N

After IN N
adjustment NN N
for IN N
possible JJ N
confounders NNS N
, , N
there EX N
was VBD N
still RB N
no DT N
significant JJ N
difference NN N
in IN N
postoperative JJ N
PE NNP 1_o
between IN N
the DT N
2 CD N
study NN N
groups NNS N
( ( N
t JJ N
= NNP N
-0.285 NNP N
, , N
P NNP N
= NNP N
.776 NNP N
) ) N
. . N

CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
prescription NN N
of IN N
colchicine NN 1_i
does VBZ N
not RB N
seem VB N
to TO N
be VB N
effective JJ N
in IN N
treatment NN N
of IN N
asymptomatic JJ 1_o
postoperative JJ 1_o
PE NNP 1_o
. . 1_o

This DT N
could MD N
be VB N
justified VBN N
in IN N
case NN N
that IN N
the DT N
etiology NN N
of IN N
most JJS N
of IN N
the DT N
PEs NNP 1_p
might MD N
be VB N
contribution NN N
of IN N
noninflammatory JJ N
factors NNS N
which WDT N
are VBP N
better JJR N
to TO N
be VB N
dealt VBN N
with IN N
observational JJ N
approaches NNS N
. . N

-DOCSTART- -X- O O

Anti-inflammatory JJ 1_o
effects NNS 1_o
of IN N
inhaled JJ 1_i
carbon NN 1_i
monoxide NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
COPD NNP 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

In IN N
vitro NN N
and CC N
in IN N
vivo JJ N
studies NNS N
have VBP N
shown VBN N
that IN N
carbon NN 1_i
monoxide NN 1_i
( ( N
CO NNP N
) ) N
has VBZ N
both DT N
anti-inflammatory JJ N
and CC N
anti-oxidant JJ N
capacities NNS N
. . N

Since IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
is VBZ N
characterised VBN N
by IN N
inflammation NN N
and CC N
oxidative JJ N
stress NN N
, , N
low-dose JJ 1_i
CO NNP 1_i
could MD N
be VB N
of IN N
therapeutic JJ N
use NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
feasibility NN 1_o
and CC 1_o
anti-inflammatory JJ 1_o
effects NNS 1_o
of IN N
100-125 JJ N
ppm NN N
CO NNP 1_i
inhalation NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
stable JJ 1_p
COPD NNP 1_p
. . 1_p

In IN N
total JJ N
, , N
20 CD 1_p
ex-smoking JJ 1_p
COPD NNP 1_p
patients NNS 1_p
with IN 1_p
post-bronchodilator NN 1_p
forced JJ 1_p
expiratory NN 1_p
volume NN 1_p
in IN 1_p
one CD 1_p
second NN 1_p
( ( 1_p
FEV NNP 1_p
( ( 1_p
1 CD 1_p
) ) 1_p
) ) 1_p
> $ 1_p
1.20 CD 1_p
L NNP 1_p
and CC 1_p
FEV NNP 1_p
( ( 1_p
1 CD 1_p
) ) 1_p
/forced VBD 1_p
vital JJ 1_p
capacity NN 1_p
< VBP 1_p
70 CD 1_p
% NN 1_p
were VBD N
enrolled VBN N
in IN N
a DT N
randomised JJ N
, , N
placebo-controlled JJ 1_i
, , N
crossover NN N
study NN N
. . N

Effects NNS 1_o
on IN 1_o
inflammation NN 1_o
were VBD N
measured VBN N
in IN N
induced JJ 1_o
sputum NN 1_o
and CC 1_o
blood NN 1_o
. . 1_o

CO NNP 1_o
inhalation NN 1_o
was VBD N
feasible JJ 1_o
and CC N
patients NNS 1_o
' POS 1_o
vital JJ 1_o
signs NNS 1_o
were VBD N
unaffected VBN N
; : N
2 CD N
h.day NN N
( ( N
-1 NNP N
) ) N
inhalation NN N
of IN N
low-dose JJ N
CO NNP N
on IN N
4 CD N
consecutive JJ N
days NNS N
led VBD N
to TO N
a DT N
maximal JJ N
individual JJ N
carboxyhaemoglobin NN 1_o
level NN 1_o
of IN N
4.5 CD N
% NN N
. . N

Two CD N
exacerbations NNS 1_o
occurred VBD N
in IN N
the DT N
CO NNP N
period NN N
. . N

CO NNP N
inhalation NN N
led VBD N
to TO N
trends NNS N
in IN N
reduced JJ 1_o
sputum NN 1_o
eosinophils NNS 1_o
( ( N
median JJ N
reduction NN N
0.25 CD N
% NN N
point NN N
) ) N
and CC N
improved JJ 1_o
responsiveness NN 1_o
to TO 1_o
methacholine VB 1_o
( ( N
median JJ N
provocative NN N
concentration NN N
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV NNP N
( ( N
1 CD N
) ) N
0.85 CD N
versus $ N
0.63 CD N
mg.mL NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

Inhalation NN N
of IN N
100-125 JJ N
ppm NN N
carbon NN 1_i
monoxide NN 1_i
by IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
in IN 1_p
a DT 1_p
stable JJ 1_p
phase NN 1_p
was VBD N
feasible JJ N
and CC N
led VBD N
to TO N
trends NNS N
in IN N
reduction NN N
of IN N
sputum NN N
eosinophils NNS N
and CC N
improvement NN 1_o
of IN 1_o
responsiveness NN 1_o
to TO 1_o
methacholine VB 1_o
. . 1_o

Further NNP N
studies NNS N
need VBP N
to TO N
confirm VB N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
in IN N
inflammatory JJ 1_p
lung NN 1_p
diseases NNS 1_p
. . 1_p

-DOCSTART- -X- O O

To TO N
share NN N
or CC N
not RB N
to TO N
share NN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
consent NN 1_o
for IN 1_o
data NNS 1_o
sharing VBG 1_o
in IN 1_p
genome JJ 1_p
research NN 1_p
. . 1_p

PURPOSE NNP N
Despite IN N
growing VBG N
concerns NNS N
toward IN N
maintaining VBG N
participants NNS N
' POS N
privacy NN N
, , N
individual JJ N
investigators NNS N
collecting VBG N
tissue NN N
and CC N
other JJ N
biological JJ N
specimens NNS N
for IN N
genomic JJ N
analysis NN N
are VBP N
encouraged VBN N
to TO N
obtain VB N
informed JJ 1_i
consent NN 1_i
for IN N
broad JJ N
data NNS N
sharing VBG N
. . N

Our PRP$ N
purpose NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
on IN N
research NN N
enrollment NN N
and CC N
data NNS N
sharing VBG N
decisions NNS N
of IN N
three CD N
different JJ N
consent NN N
types NNS N
( ( N
traditional JJ N
, , N
binary JJ N
, , N
or CC N
tiered VBN N
) ) N
with IN N
varying VBG N
levels NNS N
of IN N
control NN N
and CC N
choices NNS N
regarding VBG N
data NNS N
sharing VBG N
. . N

METHODS VB N
A DT N
single-blinded JJ N
, , N
randomized VBN N
controlled VBD 1_i
trial NN N
was VBD N
conducted VBN N
with IN N
323 CD 1_p
eligible JJ 1_p
adult NN 1_p
participants NNS 1_p
being VBG 1_p
recruited VBN 1_p
into IN 1_p
one CD 1_p
of IN 1_p
six CD 1_p
genome JJ 1_p
studies NNS 1_p
at IN 1_p
Baylor NNP 1_p
College NNP 1_p
of IN 1_p
Medicine NNP 1_p
in IN 1_p
Houston NNP 1_p
, , 1_p
Texas NNP 1_p
, , 1_p
between IN 1_p
January NNP 1_p
2008 CD 1_p
and CC 1_p
August NNP 1_p
2009 CD 1_p
. . 1_p

Participants NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
one CD 1_p
of IN 1_p
three CD 1_p
experimental JJ 1_i
consent NN 1_i
documents NNS 1_i
( ( 1_p
traditional JJ 1_p
, , 1_p
n JJ 1_p
= VBP 1_p
110 CD 1_p
; : 1_p
binary JJ 1_p
, , 1_p
n JJ 1_p
= VBP 1_p
103 CD 1_p
; : 1_p
and CC 1_p
tiered VBD 1_p
, , 1_p
n JJ 1_p
= NNP 1_p
110 CD 1_p
) ) 1_p
. . 1_p

Debriefing VBG N
in IN N
follow-up JJ N
visits NNS N
provided VBD N
participants NNS N
a DT N
detailed JJ N
review NN N
of IN N
all DT N
consent NN N
types NNS N
and CC N
the DT N
chance NN N
to TO N
change VB N
data NNS N
sharing VBG N
choices NNS N
or CC N
decline VB N
genome NN N
study NN N
participation NN N
. . N

RESULTS NNP N
Before IN N
debriefing VBG N
, , N
83.9 CD N
% NN N
of IN N
participants NNS N
chose JJ N
public JJ N
data NNS N
release NN N
. . N

After IN N
debriefing VBG N
, , N
53.1 CD N
% NN N
chose JJ N
public JJ 1_o
data NNS 1_o
release NN 1_o
, , N
33.1 CD N
% NN N
chose NN N
restricted VBN 1_o
( ( 1_o
controlled JJ 1_o
access NN 1_o
database NN 1_o
) ) 1_o
release NN 1_o
, , N
and CC N
13.7 CD N
% NN N
opted VBN 1_o
out IN 1_o
of IN 1_o
data NNS 1_o
sharing VBG 1_o
. . 1_o

Only RB N
one CD N
participant NN N
declined VBD N
genome JJ N
study NN N
participation NN N
due JJ N
to TO N
data VB 1_o
sharing NN 1_o
concerns NNS 1_o
. . 1_o

CONCLUSION NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
most JJS N
participants NNS N
are VBP N
willing JJ N
to TO N
publicly RB 1_o
release VB 1_o
their PRP$ N
genomic JJ N
data NNS N
; : N
however RB N
, , N
a DT N
significant JJ N
portion NN N
prefers NNS N
restricted VBD 1_o
release NN 1_o
. . 1_o

These DT N
results NNS N
suggest VBP N
discordance NN N
between IN N
existing VBG N
data NNS N
sharing VBG N
policies NNS N
and CC N
participants NNS N
' POS N
judgments NNS N
and CC N
desires NNS N
. . N

-DOCSTART- -X- O O

Safety NN N
of IN N
injectable JJ 1_i
opioid JJ 1_i
maintenance NN 1_i
treatment NN 1_i
for IN N
heroin NN 1_p
dependence NN 1_p
. . 1_p

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
growing VBG N
debate NN N
about IN N
injectable JJ 1_i
opioid JJ 1_i
treatment NN 1_i
programs NNS 1_i
in IN N
many JJ N
Western JJ 1_p
countries NNS 1_p
. . 1_p

This DT N
is VBZ N
the DT N
first JJ N
placebo-controlled JJ 1_i
study NN N
of IN N
the DT N
safety NN N
of IN N
injectable JJ 1_i
opioids NNS 1_i
in IN N
a DT N
controlled JJ N
treatment NN N
setting NN N
. . N

METHODS NNP N
Twenty-five JJ 1_p
opioid-dependent JJ 1_p
patients NNS 1_p
on IN 1_p
intravenous JJ 1_i
( ( 1_i
IV NNP 1_i
) ) 1_i
heroin NN 1_i
or CC 1_i
IV NNP 1_i
methadone CD 1_i
maintenance NN 1_i
treatment NN 1_i
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
their PRP$ N
individual JJ 1_i
prescribed VBN 1_i
IV NNP 1_i
maintenance NN 1_i
dose NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

Acute JJ 1_o
drug NN 1_o
effects NNS 1_o
were VBD N
recorded VBN N
, , N
focusing VBG N
on IN N
electrocardiography NN 1_o
, , 1_o
respiratory NN 1_o
movements NNS 1_o
, , 1_o
arterial JJ 1_o
blood NN 1_o
oxygen NN 1_o
saturation NN 1_o
, , 1_o
and CC 1_o
electroencephalography NN 1_o
( ( 1_o
EEG NNP 1_o
) ) 1_o
. . 1_o

RESULTS NNP N
After IN N
heroin JJ 1_i
injection NN 1_i
, , N
marked VBD N
respiratory JJ 1_o
depression NN 1_o
progressing VBG N
to TO N
a DT N
Cheyne-Stokes NNP 1_o
pattern NN 1_o
occurred VBD N
. . N

Peripheral NNP 1_o
arterial JJ 1_o
blood NN 1_o
oxygenation NN 1_o
decreased VBD N
to TO N
78.9 CD N
+/- JJ N
8.7 CD N
% NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
ranging VBG N
from IN N
52 CD N
% NN N
-90 CD N
% NN N
. . N

During IN N
hypoxia NN 1_o
, , N
7 CD N
of IN N
the DT N
16 CD 1_p
subjects NNS 1_p
experienced JJ N
intermittent NN N
and CC N
somewhat RB N
severe JJ N
bradycardia NN 1_o
. . 1_o

Five CD N
subjects NNS N
exhibited VBN N
paroxysmal JJ 1_o
EEG NNP 1_o
patterns NNS 1_o
. . 1_o

After IN N
methadone NN 1_i
injection NN 1_i
, , N
respiratory JJ 1_o
depression NN 1_o
was VBD N
less RBR N
pronounced JJ N
than IN N
after IN N
heroin JJ 1_i
injection NN 1_i
. . 1_i

No DT N
relevant JJ N
bradycardia NN 1_o
was VBD N
noted VBN N
. . N

CONCLUSIONS NNP N
Opioid NNP 1_i
doses VBZ N
commonly RB N
prescribed VBN N
in IN N
IV NNP 1_i
opioid FW 1_i
treatment NN 1_i
induce NN N
marked VBD N
respiratory NN 1_o
and CC 1_o
circulatory NN 1_o
depression NN 1_o
, , N
as RB N
well RB N
as IN N
occasionally RB N
irregular JJ 1_o
paroxysmal JJ 1_o
EEG NNP 1_o
activity NN 1_o
. . 1_o

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
optimize VB N
the DT N
clinical JJ N
practice NN N
of IN N
IV NNP 1_i
opioid FW 1_i
treatment NN 1_i
to TO N
prevent VB N
serious JJ N
complications NNS N
. . N

Moreover RB N
, , N
the DT N
extent NN N
of IN N
the DT N
observed JJ N
effects NNS N
raises VBZ N
questions NNS N
about IN N
the DT N
appropriateness NN N
of IN N
IV NNP 1_i
opioid FW 1_i
treatment NN 1_i
in IN N
the DT N
present JJ N
form NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ 1_i
study NN N
of IN N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
diethylpropion NN 1_i
in IN N
the DT N
treatment NN N
of IN N
obese JJ 1_p
subjects NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
diethylpropion NN 1_i
on IN N
a DT N
long-term JJ N
basis NN N
, , N
with IN N
emphasis NN N
in IN N
cardiovascular JJ N
and CC N
psychiatric JJ N
safety NN N
aspects NNS N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
. . N

MEASUREMENTS NNP N
Following VBG N
a DT N
2-week JJ N
screening NN N
period NN N
, , N
69 CD 1_p
obese JJ 1_p
healthy JJ 1_p
adults NNS 1_p
received VBD 1_p
a DT 1_p
hypocaloric JJ 1_i
diet NN 1_i
and CC N
were VBD N
randomized VBN N
to TO N
diethylpropion VB 1_i
50 CD 1_i
mg NNS 1_i
BID NNP 1_i
( ( N
n=37 NN N
) ) N
or CC N
placebo NN 1_i
( ( N
n=32 JJ N
) ) N
for IN N
6 CD N
months NNS N
. . N

After IN N
this DT N
period NN N
, , N
all DT N
participants NNS N
received VBN N
diethylpropion NN 1_i
in IN N
an DT N
open-label JJ N
extension NN N
for IN N
an DT N
additional JJ N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
percentage NN 1_o
change NN 1_o
in IN 1_o
body NN 1_o
weight NN 1_o
. . 1_o

Electrocardiogram NNP 1_o
( ( 1_o
ECG NNP 1_o
) ) 1_o
, , 1_o
echocardiography NN 1_o
and CC 1_o
clinical JJ 1_o
chemistry NN 1_o
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
every DT N
6 CD N
months NNS N
. . N

Psychiatric NNP 1_o
evaluation NN 1_o
and CC 1_o
application NN 1_o
of IN 1_o
Hamilton NNP 1_o
rating NN 1_o
scales NNS 1_o
for IN 1_o
depression NN 1_o
and CC 1_o
anxiety NN 1_o
were VBD N
also RB N
performed VBN N
by IN N
experienced JJ N
psychiatrists NNS N
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
. . N

RESULTS NNP N
After IN N
6 CD N
months NNS N
, , N
the DT N
diethylpropion NN N
group NN N
lost VBD N
an DT N
average NN N
of IN N
9.8 CD N
% NN N
( ( N
s.d NN N
. . N

6.9 CD N
% NN N
) ) N
of IN N
initial JJ N
body NN 1_o
weight VBD 1_o
vs RB N
3.2 CD N
% NN N
( ( N
3.7 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

From IN N
baseline NN N
to TO N
month NN N
12 CD N
, , N
the DT N
mean JJ 1_o
weight NN 1_o
loss NN 1_o
produced VBN N
by IN N
diethylpropion NN N
was VBD N
10.6 CD N
% NN N
( ( N
8.3 CD N
% NN N
) ) N
. . N

Participants NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
who WP N
were VBD N
switched VBN N
to TO N
diethylpropion NN 1_i
after IN N
6 CD N
months NNS N
lost VBN N
an DT N
average NN N
of IN N
7.0 CD N
% NN N
( ( N
7.7 CD N
% NN N
) ) N
of IN N
initial JJ 1_o
body NN 1_o
weight NN 1_o
. . 1_o

The DT N
difference NN N
between IN N
groups NNS N
at IN N
month NN N
12 CD N
was VBD N
not RB N
significant JJ N
( ( N
P=0.07 NNP N
) ) N
. . N

No DT N
differences NNS N
in IN N
blood NN 1_o
pressure NN 1_o
, , 1_o
pulse JJ 1_o
rate NN 1_o
, , 1_o
ECG NNP 1_o
and CC 1_o
psychiatric JJ 1_o
evaluation NN 1_o
were VBD N
observed VBN N
. . N

Dry NNP 1_o
mouth NN 1_o
and CC 1_o
insomnia NN 1_o
were VBD N
the DT N
most RBS N
frequent JJ N
adverse JJ N
events NNS N
. . N

CONCLUSION NNP N
Diethylpropion NNP 1_i
plus CC N
diet JJ N
produced VBN N
sustained VBN N
and CC N
clinically RB N
significant JJ N
weight JJ 1_o
loss NN 1_o
over IN N
1 CD N
year NN N
. . N

It PRP N
seems VBZ N
to TO N
be VB N
safe JJ N
in IN N
relation NN N
to TO N
cardiovascular VB N
and CC N
psychiatric JJ N
aspects NNS N
in IN N
a DT N
well-selected JJ 1_p
population NN 1_p
. . 1_p

-DOCSTART- -X- O O

[ NN 1_i
Mitoxantrone NNP 1_i
( ( 1_i
MTX NNP 1_i
) ) 1_i
versus NN 1_i
mitomycin NN 1_i
C NNP 1_i
( ( 1_i
MMC NNP 1_i
) ) 1_i
in IN N
the DT N
ablative JJ N
treatment NN N
of IN 1_p
Ta NNP 1_p
, , 1_p
T1 NNP 1_p
superficial JJ 1_p
bladder NN 1_p
tumors NNS 1_p
. . 1_p

Phase NNP N
III NNP N
, , N
randomized VBD N
prospective JJ N
study NN N
] NNP N
. . N

A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
ablation NN 1_o
capacity NN 1_o
of IN N
mitoxantrone NN 1_i
in IN N
Ta-T1 NNP N
superficial JJ N
bladder NN N
tumors NNS N
versus VBP N
mitomycin JJ 1_i
C NNP 1_i
, , N
a DT N
drug NN N
whose WP$ N
intravesical JJ N
ablation NN N
properties NNS N
are VBP N
well-known JJ N
. . N

Fifty-seven JJ 1_p
patients NNS 1_p
comprised VBD N
the DT N
study NN N
. . N

The DT N
tumor NN N
was VBD N
not RB N
completely RB N
resected VBN N
when WRB N
the DT N
patient NN N
underwent JJ N
TUR NNP N
. . N

This DT N
residual JJ N
tumor NN N
was VBD N
used VBN N
as IN N
control NN N
. . N

The DT N
patients NNS N
were VBD N
treated VBN N
with IN N
either DT N
20 CD N
mg NN N
Mitoxantrone NNP 1_i
or CC N
40 CD N
mg NNS N
mitomycin JJ 1_i
C NNP 1_i
weekly NN N
for IN N
8 CD N
weeks NNS N
and CC N
two CD N
other JJ N
instillations NNS N
every DT N
15 CD N
days NNS N
in IN N
50 CD N
ml NNS N
saline JJ N
solution NN N
. . N

Response NNP 1_o
to TO 1_o
therapy NN 1_o
was VBD N
evaluated VBN N
between IN N
the DT N
4th CD N
and CC N
8th CD N
week NN N
and CC N
classified VBD N
as IN N
complete JJ 1_o
response NN 1_o
( ( 1_o
CR NNP 1_o
) ) 1_o
, , N
defined VBD N
as IN N
no DT N
gross JJ 1_o
and CC 1_o
microscopic JJ 1_o
evidence NN 1_o
of IN 1_o
residual JJ 1_o
tumor NN 1_o
, , N
or CC N
no DT 1_o
response NN 1_o
( ( 1_o
NR NNP 1_o
) ) 1_o
or CC 1_o
therapeutic JJ 1_o
failure NN 1_o
. . 1_o

CR NNP N
was VBD N
observed VBN N
in IN N
77.7 CD N
% NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
mitomycin JJ 1_i
C NNP 1_i
and CC N
in IN N
50 CD N
% NN N
in IN N
those DT N
that WDT N
had VBD N
been VBN N
treated VBN N
with IN N
Mitoxantrone NNP 1_i
. . 1_i

Treatment NNP N
was VBD N
discontinued VBN N
because IN N
of IN N
side NN 1_o
effects NNS 1_o
in IN N
15 CD N
% NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
mitomycin JJ 1_i
C NNP 1_i
and CC N
in IN N
63.4 CD N
% NN N
of IN N
those DT N
who WP N
received VBD N
Mitoxantrone NNP 1_i
. . 1_i

We PRP N
can MD N
conclude VB N
from IN N
the DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
that IN N
Mitoxantrone NNP 1_i
is VBZ N
a DT N
useful JJ N
agent NN N
for IN N
ablation NN N
therapy NN N
of IN N
superficial JJ 1_p
bladder NN 1_p
tumors NNS 1_p
, , N
although IN N
the DT N
high JJ N
incidence NN N
of IN N
severe JJ N
side NN 1_o
effects NNS 1_o
warrants NNS N
its PRP$ N
limited JJ N
use NN N
and CC N
at IN N
high JJ N
dilutions NNS N
. . N

-DOCSTART- -X- O O

Phase NN N
I PRP N
pharmacokinetic JJ N
, , N
food NN N
effect NN N
, , N
and CC N
pharmacogenetic JJ N
study NN N
of IN N
oral JJ N
irinotecan JJ 1_i
given VBN N
as IN N
semisolid JJ N
matrix NN N
capsules NNS N
in IN N
patients NNS 1_p
with IN 1_p
solid JJ 1_p
tumors NNS 1_p
. . 1_p

PURPOSE NNP N
To TO N
characterize VB N
the DT N
maximum-tolerated JJ N
dose NN N
, , N
recommended VBD N
dose NN N
, , N
dose-limiting JJ N
toxicities NNS N
( ( N
DLT NNP N
) ) N
, , N
pharmacokinetic JJ N
profile NN N
, , N
and CC N
food NN N
effect NN N
of IN N
orally RB N
administered VBN N
irinotecan JJ 1_i
formulated VBN N
as IN N
new JJ N
semisolid JJ N
matrix NN N
capsules NNS N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
Irinotecan NNP 1_i
was VBD N
given VBN N
orally RB N
in IN N
fasted JJ 1_p
patients NNS 1_p
once RB N
daily JJ N
for IN N
5 CD N
consecutive JJ N
days NNS N
and CC N
repeated VBD N
every DT N
3 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
take VB N
the DT N
drug NN N
along IN N
with IN N
a DT N
high-fat JJ 1_i
, , 1_i
high-calorie JJ 1_i
breakfast NN 1_i
for IN N
the DT N
administration NN N
at IN N
day NN N
1 CD N
of IN N
the DT N
first JJ N
or CC N
second JJ N
cycle NN N
. . N

Dosages NNS N
tested VBN N
were VBD N
70 CD N
and CC N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
. . N

RESULTS NNP N
Twenty-five JJ 1_p
patients NNS 1_p
received VBD N
101 CD N
cycles NNS N
of IN N
therapy NN N
( ( N
median JJ N
two CD N
cycles NNS N
, , N
range VB N
1-15 JJ N
) ) N
. . N

During IN N
the DT N
first JJ N
cycle NN N
, , N
grade VBD 1_o
3 CD 1_o
delayed VBN 1_o
diarrhea NN 1_o
and CC 1_o
grade VBD 1_o
3 CD 1_o
fever NN 1_o
were VBD N
the DT N
DLTs NNP N
at IN N
the DT N
dosage NN N
of IN N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
in IN N
three CD N
out IN N
of IN N
five CD N
patients NNS N
. . N

Hematologic NNP 1_o
and CC 1_o
nonhematologic JJ 1_o
toxicities NNS 1_o
were VBD N
mild JJ N
to TO N
moderate VB N
. . N

Exposure NN 1_o
to TO 1_o
the DT 1_o
active JJ 1_o
metabolite JJ 1_o
SN-38 NN 1_o
was VBD N
relatively RB N
high JJ N
compared VBN N
with IN N
i.v NN N
. . N

infusion NN N
, , N
but CC N
no DT N
relevant JJ N
accumulation NN N
was VBD N
observed VBN N
. . N

Food NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
irinotecan JJ 1_i
pharmacokinetics NNS N
. . N

One CD N
confirmed VBD N
partial JJ 1_o
remission NN 1_o
and CC N
10 CD N
disease NN 1_o
stabilizations NNS 1_o
were VBD N
observed VBN N
in IN N
previously RB N
treated VBN N
patients NNS N
. . N

No DT N
association NN N
was VBD N
found VBN N
between IN N
the DT N
UGT1A1*28 NNP N
genotype NN N
and CC N
the DT N
risk NN N
of IN N
severe JJ 1_o
irinotecan-induced JJ 1_o
toxicity NN 1_o
. . 1_o

CONCLUSIONS NNP N
For IN N
oral JJ N
irinotecan JJ 1_i
, , N
a DT N
dose NN N
of IN N
70 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
3 CD N
weeks NNS N
is VBZ N
recommended VBN N
for IN N
further JJ N
studies NNS N
. . N

Delayed NNP N
diarrhea NN N
was VBD N
the DT N
main JJ N
DLT NNP N
, , N
similar JJ N
to TO N
that DT N
observed VBN N
with IN N
intravenously RB N
administered VBN N
irinotecan JJ N
. . N

This DT N
study NN N
confirms VBZ N
that IN N
oral JJ N
administration NN N
of IN N
irinotecan JJ 1_i
is VBZ N
feasible JJ N
and CC N
may MD N
have VB N
favorable JJ N
pharmacokinetic JJ N
characteristics NNS N
. . N

-DOCSTART- -X- O O

A DT N
controlled JJ N
trial NN N
of IN N
intravenous JJ N
immune JJ 1_i
globulin NN 1_i
to TO N
reduce VB N
nosocomial JJ 1_o
infections NNS 1_o
in IN N
very-low-birth-weight JJ 1_p
infants NNS 1_p
. . 1_p

National NNP N
Institute NNP N
of IN N
Child NNP N
Health NNP N
and CC N
Human NNP N
Development NNP N
Neonatal NNP N
Research NNP N
Network NNP N
. . N

BACKGROUND NNP N
Nosocomial NNP 1_o
infections NNS 1_o
are VBP N
a DT N
major JJ N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
in IN N
premature JJ 1_p
infants NNS 1_p
. . 1_p

As IN N
a DT N
rule NN N
, , N
their PRP$ N
low JJ N
serum NN N
gamma NN N
globulin NN N
levels NNS N
at IN N
birth NN N
subsequently RB N
decline VBZ N
to TO N
hypogammaglobulinemic VB N
values NNS N
; : N
hence NN N
, , N
prophylactic JJ N
administration NN N
of IN N
intravenous JJ N
immune NNS 1_i
globulin NN 1_i
may MD N
reduce VB N
the DT N
rate NN N
of IN N
hospital-acquired JJ N
infections NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
multicenter NN N
, , N
two-phase NN N
controlled VBD N
trial NN N
, , N
2416 CD 1_p
infants NNS 1_p
were VBD 1_p
stratified VBN 1_p
according VBG 1_p
to TO 1_p
birth NN 1_p
weight NN 1_p
( ( 1_p
501 CD 1_p
to TO 1_p
1000 CD 1_p
g NN 1_p
and CC 1_p
1001 CD 1_p
to TO 1_p
1500 CD 1_p
g NN 1_p
) ) 1_p
and CC N
randomly RB N
assigned VBN N
to TO N
an DT N
intravenous JJ 1_i
immune JJ 1_i
globulin NN 1_i
group NN 1_i
( ( N
n IN N
= NNP N
1204 CD N
) ) N
or CC N
a DT N
control NN 1_i
group NN 1_i
( ( N
n IN N
= NNP N
1212 CD N
) ) N
. . N

Control NN 1_p
infants NNS 1_p
were VBD N
given VBN N
placebo JJ N
infusions NNS N
during IN N
phase NN N
1 CD N
of IN N
the DT N
study NN N
( ( N
n JJ N
= NNP N
623 CD N
) ) N
but CC N
were VBD N
not RB N
given VBN N
any DT N
infusions NNS N
during IN N
phase NN N
2 CD N
( ( N
n JJ N
= NNP N
589 CD N
) ) N
. . N

Infants NNS 1_p
weighing VBG 1_p
501 CD 1_p
to TO 1_p
1000 CD 1_p
g NN 1_p
at IN 1_p
birth NN 1_p
were VBD N
given VBN N
900 CD N
mg NN N
of IN N
immune JJ 1_i
globulin NN 1_i
per IN N
kilogram NN N
of IN N
body NN N
weight NN N
, , N
and CC N
infants NNS N
weighing VBG N
1001 CD N
to TO N
1500 CD N
g NN N
at IN N
birth NN N
were VBD N
given VBN N
a DT N
dose NN N
of IN N
700 CD N
mg NNS N
per IN N
kilogram NN N
. . N

The DT N
immune JJ 1_i
globulin NN 1_i
infusions NNS N
were VBD N
repeated VBN N
every DT N
14 CD N
days NNS N
until IN N
the DT N
infants NNS N
weighed VBD N
1800 CD N
g NN N
, , N
were VBD N
transferred VBN N
to TO N
another DT N
center NN N
, , N
died VBD N
, , N
or CC N
were VBD N
sent VBN N
home NN N
from IN N
the DT N
hospital NN N
. . N

RESULTS NNP N
Nosocomial JJ 1_o
infections NNS 1_o
of IN 1_o
the DT 1_o
blood NN 1_o
, , 1_o
meninges NNS 1_o
, , 1_o
or CC 1_o
urinary JJ 1_o
tract NN 1_o
occurred VBD N
in IN N
439 CD N
of IN N
the DT N
2416 CD N
infants NNS N
( ( N
18.2 CD N
percent NN N
) ) N
: : N
208 CD N
( ( N
17.3 CD N
percent NN N
) ) N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
231 CD N
( ( N
19.1 CD N
percent NN N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
relative JJ N
risk NN N
, , N
0.91 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.77 CD N
to TO N
1.08 CD N
) ) N
. . N

Septicemia NNP 1_o
occurred VBD N
in IN N
15.5 CD N
percent NN N
of IN N
the DT N
immune JJ N
globulin NN N
recipients NNS N
and CC N
17.2 CD N
percent NN N
of IN N
the DT N
controls NNS N
. . N

During IN N
phase NN N
1 CD N
the DT N
rate NN N
of IN N
nosocomial JJ 1_o
infections NNS 1_o
was VBD N
13.4 CD N
percent NN N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
17.8 CD N
percent NN N
in IN N
the DT N
control NN N
group NN N
; : N
the DT N
respective JJ N
rates NNS N
during IN N
phase NN N
2 CD N
were VBD N
21.0 CD N
percent NN N
and CC N
20.4 CD N
percent NN N
. . N

The DT N
predominant JJ N
organisms NNS N
included VBD N
gram-positive JJ N
cocci NN N
( ( N
53.0 CD N
percent NN N
) ) N
, , N
gram-negative JJ N
bacilli NN N
( ( N
22.4 CD N
percent NN N
) ) N
, , N
and CC N
candida NN N
species NNS N
( ( N
16.0 CD N
percent NN N
) ) N
. . N

Adverse JJ 1_o
reactions NNS 1_o
were VBD N
rarely RB N
observed VBN N
during IN N
the DT N
infusions NNS N
. . N

Immune NNP N
globulin NN N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
respiratory NN 1_o
distress NN 1_o
syndrome NN 1_o
, , 1_o
bronchopulmonary JJ 1_o
dysplasia NN 1_o
, , 1_o
intracranial JJ 1_o
hemorrhage NN 1_o
, , 1_o
the DT 1_o
duration NN 1_o
of IN 1_o
hospitalization NN 1_o
, , 1_o
or CC 1_o
mortality NN 1_o
. . 1_o

The DT N
incidence NN N
of IN N
necrotizing VBG 1_o
enterocolitis NN 1_o
was VBD N
12.0 CD N
percent NN N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
9.5 CD N
percent NN N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
Prophylactic NNP N
use NN N
of IN N
intravenous JJ N
immune JJ N
globulin NN N
failed VBD N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
hospital-acquired JJ 1_o
infections NNS 1_o
in IN N
very-low-birth-weight JJ 1_p
infants NNS 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
small JJ 1_i
needle-knife JJ 1_i
comprehensive JJ 1_i
therapy NN 1_i
on IN N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ 1_p
nonspecific NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
patient NN 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effect NN N
of IN N
small JJ 1_i
needle-knife JJ 1_i
comprehensive JJ 1_i
therapy NN 1_i
on IN N
pain NN 1_o
and CC 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
in IN N
the DT N
chronic JJ 1_p
nonspecific NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
patient NN 1_p
. . 1_p

METHODS NNP N
Three CD 1_p
hundred VBD 1_p
and CC 1_p
five CD 1_p
cases NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
needle-knife JJ 1_i
group NN 1_i
of IN N
153 CD N
cases NNS N
and CC N
a DT N
physiotherapy NN 1_i
group NN 1_i
of IN N
152 CD N
cases NNS N
. . N

The DT N
needle-knife JJ 1_i
group NN N
were VBD N
treated VBN N
with IN N
small JJ 1_i
needle-knife JJ 1_i
releasing NN 1_i
therapy NN 1_i
, , 1_i
blocking VBG 1_i
and CC 1_i
functional JJ 1_i
training NN 1_i
. . 1_i

The DT N
physiotherapy NN 1_i
group NN N
were VBD N
treated VBN N
with IN N
ultra-short JJ 1_i
wave NN 1_i
, , 1_i
modulated VBD 1_i
medium NN 1_i
frequency NN 1_i
current JJ 1_i
, , 1_i
massage NN 1_i
and CC 1_i
functional JJ 1_i
training NN 1_i
. . 1_i

Pain NN 1_o
was VBD N
assessed VBN N
by IN N
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
was VBD N
determined VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
pain NN 1_o
and CC 1_o
the DT 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
were VBD N
significantly RB N
improved VBN N
in IN N
the DT N
two CD N
groups NNS N
; : N
and CC N
after IN N
treatment NN N
, , N
the DT N
VAS NNP 1_o
score NN 1_o
and CC 1_o
the DT 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
were VBD N
( ( N
1.60 CD N
+/- JJ N
0.38 CD N
) ) N
points NNS N
and CC N
( ( N
65.76 CD N
+/- JJ N
15.11 CD N
) ) N
cm NN N
in IN N
the DT N
needle-knife JJ 1_i
group NN N
and CC N
( ( N
4.59 CD N
+/- JJ N
1.09 CD N
) ) N
points NNS N
and CC N
( ( N
53.74 CD N
+/- JJ N
15.13 CD N
) ) N
cm NN N
in IN N
the DT N
physiotherapy NN N
group NN N
, , N
respectively RB N
, , N
the DT N
needle-knife JJ 1_i
group NN N
being VBG N
significantly RB N
better JJR N
than IN N
the DT N
physiotherapy NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Follow-up NNP N
survey NN N
of IN N
6-36 JJ N
months NNS N
showed VBD N
that IN N
the DT N
VAS NNP 1_o
score NN 1_o
and CC 1_o
the DT 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
in IN N
the DT N
needle-knife JJ 1_i
group NN N
were VBD N
superior JJ N
to TO N
those DT N
in IN N
the DT N
physiotherapy NN 1_i
group NN N
. . N

CONCLUSION NNP N
Small NNP 1_i
needle-knife JJ 1_i
comprehensive JJ 1_i
therapy NN 1_i
can MD N
significantly RB N
improve VB N
pain NN 1_o
and CC 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
in IN N
the DT N
chronic JJ 1_p
nonspecific NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
patient NN 1_p
, , N
with IN N
a DT N
stable JJ N
long-term JJ N
therapeutic JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Quantitative JJ N
monitoring NN N
of IN N
serum NN 1_o
hepatitis NN 1_o
B NNP 1_o
virus NN 1_o
DNA NNP 1_o
and CC N
blood NN 1_o
lymphocyte JJ 1_o
subsets NNS 1_o
during IN N
combined JJ 1_i
prednisolone NN 1_i
and CC 1_i
interferon-alpha JJ 1_i
therapy NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
hepatitis NN 1_p
B NNP 1_p
. . 1_p

Several JJ N
investigators NNS N
have VBP N
reported VBN N
a DT N
significantly RB N
reduced VBN N
CD4/CD8 NNP 1_o
ratio NN 1_o
, , N
as IN N
defined VBN N
by IN N
monoclonal JJ N
antibodies NNS N
, , N
in IN N
the DT N
peripheral JJ N
blood NN N
of IN N
Caucasian JJ 1_p
patients NNS 1_p
with IN N
chronic JJ 1_p
active JJ 1_p
hepatitis NN 1_p
B NNP 1_p
( ( 1_p
CAHB NNP 1_p
) ) 1_p
. . N

In IN N
Asian JJ 1_p
patients NNS 1_p
with IN N
chronic JJ N
hepatitis NN N
B NNP N
, , N
quantitative JJ N
analyses NNS N
of IN N
subpopulations NNS N
of IN N
peripheral JJ N
blood NN N
lymphocytes NNS N
have VBP N
not RB N
been VBN N
able JJ N
to TO N
confirm VB N
these DT N
findings NNS N
. . N

In IN N
this DT N
work NN N
, , N
we PRP N
analysed VBD N
the DT N
frequency NN N
of IN N
peripheral JJ N
blood NN N
lymphocyte NN N
subsets NNS N
in IN N
10 CD 1_p
Chinese JJ 1_p
patients NNS 1_p
with IN 1_p
histologically RB 1_p
proven VBN 1_p
CAHB NNP 1_p
and CC 1_p
seven CD 1_p
healthy JJ 1_p
Chinese JJ 1_p
individuals NNS 1_p
. . 1_p

Four CD N
of IN N
the DT N
10 CD N
CAHB NNP N
patients NNS N
received VBD N
combined JJ 1_i
prednisolone/interferon-alpha2b JJ 1_i
( ( 1_i
IFN-alpha2b NNP 1_i
) ) 1_i
therapy NN 1_i
. . 1_i

Peripheral NNP 1_o
blood NN 1_o
samples NNS 1_o
were VBD N
consecutively RB N
collected VBN N
for IN N
analysis NN N
of IN N
lymphocyte JJ N
subpopulations NNS N
using VBG N
an DT N
indirect JJ N
immunofluorescence NN N
( ( N
IF NNP N
) ) N
method NN N
, , N
and CC N
hepatitis NN N
B NNP N
virus NN N
( ( N
HBV NNP N
) ) N
DNA NN N
was VBD N
quantified VBN N
by IN N
a DT N
chemiluminescent NN N
, , N
molecular-hybridization NN N
assay NN N
. . N

Peripheral NNP 1_o
blood NN 1_o
mononuclear NN 1_o
cells NNS 1_o
from IN N
seven CD N
Chinese JJ N
control NN N
individuals NNS N
comprised VBD N
63 CD N
+/- JJ N
3 CD N
% NN N
CD3+ NNP N
cells NNS N
, , N
of IN N
which WDT N
41 CD N
+/- JJ N
4 CD N
% NN N
were VBD N
of IN N
CD4+ NNP N
and CC N
23 CD N
+/- JJ N
2 CD N
% NN N
of IN N
CD8+ NNP N
subsets NNS N
. . N

The DT N
mean JJ 1_o
CD4/CD8 NNP 1_o
ratio NN 1_o
in IN N
the DT N
healthy JJ N
controls NNS N
was VBD N
1.9 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
= NNP N
1.1-2.7 NN N
) ) N
. . N

The DT N
CD4/CD8 NNP 1_o
ratios NNS 1_o
were VBD N
significantly RB N
reduced VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
the DT N
10 CD N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
B NNP N
, , N
compared VBN N
with IN N
those DT N
of IN N
the DT N
controls NNS N
, , N
owing VBG N
to TO N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
number NN 1_o
of IN 1_o
CD8+ NNP 1_o
cells NNS 1_o
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

During IN N
the DT N
treatment NN N
with IN N
prednisolone NN 1_i
, , N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
CD4/CD8 NNP 1_o
ratio NN 1_o
was VBD N
observed VBN N
in IN N
all DT N
treated JJ N
patients NNS N
. . N

This DT N
increase NN N
was VBD N
mainly RB N
caused VBN N
by IN N
a DT N
decrease NN N
in IN N
the DT N
number NN 1_o
of IN 1_o
CD8+ NNP 1_o
cells NNS 1_o
and CC N
was VBD N
accompanied VBN N
by IN N
an DT N
increase NN 1_o
in IN 1_o
serum JJ 1_o
HBV NNP 1_o
DNA NNP 1_o
levels NNS 1_o
, , N
which WDT N
peaked VBD N
during IN N
the DT N
latter JJ N
part NN N
of IN N
the DT N
prednisolone NN N
cycle NN N
. . N

During IN N
the DT N
treatment NN N
with IN N
IFN-alpha2b NNP 1_i
, , N
a DT N
second JJ N
increase NN N
in IN N
the DT N
CD4/CD8 NNP 1_o
ratio NN 1_o
was VBD N
observed VBN N
, , N
which WDT N
was VBD N
caused VBN N
by IN N
an DT N
increase NN N
in IN N
CD4+ NNP 1_o
cells NNS 1_o
. . 1_o

A DT N
marked JJ N
decrease NN N
in IN N
viral JJ 1_o
load NN 1_o
was VBD N
observed VBN N
, , N
during IN N
treatment NN N
with IN N
IFN-alpha2b NNP 1_i
, , N
in IN N
patients NNS N
with IN N
HBV NNP N
DNA NNP N
levels NNS N
below IN N
10 CD N
000 CD N
pg JJ N
ml-1 NN N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
CD4/CD8 NNP 1_o
ratios NNS 1_o
in IN N
Chinese JJ 1_p
CAHB NNP 1_p
patients NNS 1_p
do VBP N
not RB N
differ VB N
from IN N
those DT N
of IN N
Caucasian JJ 1_p
patients NNS 1_p
with IN 1_p
CAHB NNP 1_p
, , N
when WRB N
analysed VBN N
using VBG N
similar JJ N
methods NNS N
for IN N
the DT N
enumeration NN N
of IN N
lymphocyte JJ N
subsets NNS N
. . N

Profound NNP N
effects NNS N
on IN N
cellular JJ 1_o
distribution NN 1_o
and CC 1_o
viral JJ 1_o
replication NN 1_o
were VBD N
noted VBN N
during IN N
the DT N
combined JJ N
prednisolone/IFN-alpha2b JJ N
therapy NN N
. . N

Additional JJ N
studies NNS N
of IN N
the DT N
modulatory JJ 1_o
effect NN 1_o
of IN N
the DT N
combined JJ N
therapy NN N
on IN N
the DT N
distribution NN N
of IN N
lymphocyte JJ N
subsets NNS N
and CC N
cytokine NN N
profiles NNS N
in IN N
relation NN N
to TO N
the DT N
therapeutic JJ N
outcome NN N
of IN N
HBV NNP N
infection NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
placebo- JJ 1_i
and CC N
active-controlled JJ N
study NN N
of IN N
paliperidone NN 1_i
extended-release NN N
as IN N
maintenance NN N
treatment NN N
in IN 1_p
patients NNS 1_p
with IN 1_p
bipolar JJ 1_p
I PRP 1_p
disorder VBP 1_p
after IN 1_p
an DT 1_p
acute JJ 1_p
manic NN 1_p
or CC 1_p
mixed JJ 1_p
episode NN 1_p
. . 1_p

BACKGROUND NNP N
Paliperidone NNP 1_i
ER NNP 1_i
monotherapy NN 1_i
was VBD N
efficacious JJ N
in IN N
treating VBG N
acute NN N
mania NN N
in IN N
two CD N
3-week JJ N
studies NNS N
in IN 1_p
patients NNS 1_p
with IN 1_p
bipolar JJ 1_p
I PRP 1_p
disorder VBP 1_p
. . 1_p

We PRP N
assessed VBD N
its PRP$ N
efficacy NN N
in IN N
a DT N
study NN N
investigating VBG N
maintenance NN N
treatment NN N
of IN N
clinically RB 1_p
stable JJ 1_p
patients NNS 1_p
with IN 1_p
this DT 1_p
disorder NN 1_p
. . 1_p

METHODS NNP N
Patients NNPS 1_p
( ( 1_p
n=766 JJ 1_p
) ) 1_p
, , 1_p
aged VBD 1_p
18 CD 1_p
to TO 1_p
65 CD 1_p
years NNS 1_p
inclusive JJ 1_p
, , 1_p
with IN 1_p
current JJ 1_p
manic NN 1_p
or CC 1_p
mixed JJ 1_p
episodes NNS 1_p
were VBD 1_p
initially RB 1_p
randomized VBN 1_p
( ( N
4:1 CD N
) ) N
to TO N
flexibly-dosed JJ N
paliperidone NN 1_i
ER NNP 1_i
( ( N
3-12 JJ N
mg/day NN N
) ) N
or CC N
olanzapine JJ 1_i
( ( N
5-20 JJ N
mg/day NN N
; : N
3-week JJ N
acute NN N
treatment NN N
phase NN N
) ) N
; : N
responders NNS N
continued VBD N
the DT N
same JJ N
treatment NN N
( ( N
12-week JJ N
continuation NN N
phase NN N
) ) N
. . N

Patients NNS 1_p
on IN 1_p
paliperidone NN 1_i
ER NNP 1_i
who WP 1_p
achieved VBD 1_p
remission NN 1_p
during IN N
this DT N
phase NN N
were VBD N
randomized VBN N
( ( N
1:1 CD N
) ) N
to TO N
fixed-dose JJ N
paliperidone NN 1_i
ER NNP 1_i
( ( N
n=152 NN N
) ) N
or CC N
placebo NN 1_i
( ( N
n=148 JJ N
) ) N
; : N
those DT N
on IN N
olanzapine JJ 1_i
continued VBN N
to TO N
receive VB N
that DT N
at IN N
fixed VBN N
dose NN N
( ( N
n=83 JJ N
) ) N
( ( N
maintenance NN N
phase NN N
) ) N
. . N

RESULTS NNP N
Median JJ 1_o
time NN 1_o
to TO 1_o
recurrence VB 1_o
of IN 1_o
any DT 1_o
mood NN 1_o
symptoms NNS 1_o
( ( 1_o
primary JJ 1_o
endpoint NN 1_o
) ) 1_o
was VBD N
: : N
558 CD N
days NNS N
( ( 1_i
paliperidone JJ 1_i
ER NNP 1_i
) ) 1_i
, , N
283 CD N
days NNS N
( ( 1_i
placebo NN 1_i
) ) 1_i
and CC N
not RB N
observed VBN N
with IN N
olanzapine NN 1_i
( ( N
< JJ N
50 CD N
% NN N
of IN N
patients NNS N
experienced JJ N
recurrence NN N
) ) N
. . N

Time NN 1_o
to TO 1_o
recurrence VB 1_o
of IN 1_o
any DT 1_o
mood NN 1_o
symptoms NNS 1_o
was VBD N
significantly RB N
longer RBR N
with IN N
paliperidone NN 1_i
ER NNP 1_i
than IN N
placebo NN N
( ( N
p=0.017 NN N
; : N
based VBN N
on IN N
weighted JJ N
Z-test NNP N
at IN N
0.0198 CD N
significance NN N
level NN N
; : N
hazard CC N
ratio VB N
[ JJ N
placebo NN N
: : N
paliperidone NN N
ER NNP N
; : N
unweighted VBD N
95 CD N
% NN N
confidence NN N
interval JJ N
] NN N
: : N
1.43 CD N
[ $ N
1.03 CD N
; : N
1.98 CD N
] NN N
) ) N
; : N
the DT N
difference NN N
was VBD N
significant JJ N
for IN N
preventing VBG N
recurrence NN 1_o
of IN 1_o
manic NN 1_o
, , N
but CC N
not RB N
depressive JJ N
, , N
symptoms NNS N
. . N

Treatment-emergent JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
maintenance NN 1_o
phase NN 1_o
) ) 1_o
occurred VBD N
more RBR N
often RB N
in IN N
olanzapine JJ 1_i
group NN N
( ( N
64 CD N
% NN N
) ) N
than IN N
placebo NN 1_i
( ( N
59 CD N
% NN N
) ) N
or CC N
paliperidone NN 1_i
ER NNP 1_i
groups NNS N
( ( N
55 CD N
% NN N
) ) N
. . N

LIMITATIONS JJ N
Responder-enriched JJ N
design NN N
prevents NNS N
extrapolation NN N
of IN N
data NNS N
to TO 1_p
patients NNS 1_p
not RB 1_p
previously RB 1_p
stabilized VBN 1_p
on IN 1_p
paliperidone NN 1_i
ER NNP 1_i
. . 1_i

CONCLUSIONS NNP N
Paliperidone NNP 1_i
ER NNP 1_i
significantly RB N
delayed VBD N
the DT N
time NN N
to TO N
recurrence VB N
of IN N
any DT N
mood NN N
symptoms NNS N
, , N
versus NN N
placebo NN 1_i
, , N
in IN 1_p
patients NNS 1_p
with IN 1_p
bipolar JJ 1_p
I PRP 1_p
disorder VBP 1_p
. . 1_p

No DT N
new JJ N
safety NN N
concerns NNS N
emerged VBD N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
inhaled JJ N
heparin NN 1_i
on IN N
adenosine-induced JJ 1_p
bronchial JJ 1_p
hyperreactivity NN 1_p
. . 1_p

Glycosaminoglycan JJ 1_i
heparin NN 1_i
possesses VBZ N
multiple JJ N
noncoagulant JJ N
properties NNS N
including VBG N
antiinflammatory JJ N
actions NNS N
. . N

We PRP N
have VBP N
previously RB N
shown VBN N
that IN N
heparin NN 1_i
attenuates VBZ N
the DT N
methacholine-induced JJ N
bronchoconstriction NN N
in IN N
humans NNS 1_p
. . 1_p

In IN N
contrast NN N
to TO N
methacholine VB N
, , N
a DT N
stimulus NN N
that WDT N
induces VBZ N
airway RP N
constriction NN N
mainly RB N
by IN N
direct JJ N
stimulation NN N
of IN N
airway JJ N
smooth JJ N
muscle NN N
cells NNS N
, , N
adenosine JJ N
airway RB N
responsiveness JJ N
reflects VBZ N
indirectly RB N
induced VBN N
airway RP N
narrowing VBG N
via IN N
inflammatory JJ N
mediators NNS N
or CC N
neural JJ N
reflex JJ N
mechanisms NNS N
. . N

Whether NNP N
heparin NN 1_i
modulates VBZ N
bronchial JJ N
hyperreactivity NN N
induced VBN N
by IN N
adenosine NN N
, , N
is VBZ N
not RB N
well RB N
known VBN N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
inhaled JJ 1_i
heparin NN 1_i
on IN N
adenosine-induced JJ N
bronchoconstriction NN N
and CC N
compared VBN N
the DT N
inhibitory JJ N
role NN N
of IN N
heparin NN 1_i
on IN N
the DT N
adenosine NN N
challenge NN N
test NN N
with IN N
that DT N
on IN N
the DT N
methacholine NN N
challenge NN N
test NN N
. . N

Fifteen JJ 1_p
subjects NNS 1_p
( ( 1_p
7 CD 1_p
males NNS 1_p
, , 1_p
8 CD 1_p
females NNS 1_p
) ) 1_p
with IN 1_p
mild JJ 1_p
asthma NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Bronchial JJ N
provocation NN N
tests NNS N
were VBD N
performed VBN N
in IN N
a DT N
single-blind NN N
, , N
crossover NN N
, , N
randomized VBN N
order NN N
, , N
and CC N
repeated VBD N
45 CD N
minutes NNS N
after IN N
placebo NN 1_i
or CC N
aerosolized VBN 1_i
heparin JJ 1_i
inhalation NN 1_i
( ( N
1,000 CD N
U/kg NNP N
) ) N
. . N

The DT N
heparin NN 1_i
increased VBD N
the DT N
geometric JJ 1_o
mean NN 1_o
log NN 1_o
methacholine NN 1_o
PD20 NNP 1_o
value NN 1_o
from IN N
0.47 CD N
+/- JJ N
0.16 CD N
( ( N
2.95 CD N
mg/ml NN N
) ) N
to TO N
0.96 CD N
+/- JJ N
0.10 CD N
( ( N
8.91 CD N
mg/ml NN N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.0009 CD N
) ) N
in IN N
15 CD N
patients NNS N
and CC N
the DT N
geometric JJ 1_o
mean NN 1_o
log NN 1_o
adenosine NN 1_o
PD20 NNP 1_o
values VBZ 1_o
from IN N
1.59 CD N
+/- JJ N
0.23 CD N
( ( N
38.9 CD N
mg/ml NN N
) ) N
to TO N
1.98 CD N
+/- JJ N
0.14 CD N
( ( N
97.7 CD N
mg/ml NN N
) ) N
( ( N
NS NNP N
) ) N
in IN N
7 CD N
patients NNS N
whose WP$ N
baseline JJ N
adenosine NN N
PD20 NNP N
levels NNS N
were VBD N
less JJR N
than IN N
200 CD N
mg/ml NN N
. . N

The DT N
degree NN 1_o
of IN 1_o
protection NN 1_o
by IN N
heparin NN 1_i
against IN N
adenosine-induced JJ N
bronchoconstriction NN N
was VBD N
not RB N
correlated VBN N
with IN N
that DT N
against IN N
methacholine-induced JJ N
bronchoconstriction NN N
( ( N
r JJ N
= NN N
0.60 CD N
, , N
NS NNP N
) ) N
. . N

The DT N
data NN N
suggest NN N
that WDT N
inhaled VBD N
heparin NN 1_i
may MD N
have VB N
an DT N
inhibitory JJ N
effect NN N
on IN N
the DT N
methacholine NN N
bronchial JJ N
challenge NN N
, , N
and CC N
thus RB N
, , N
most JJS N
likely JJ N
directs VBZ N
its PRP$ N
effect NN N
against IN N
smooth JJ N
muscle NN N
. . N

Heparin NNP 1_i
caused VBD N
less JJR N
attenuation NN N
of IN N
a DT N
challenge NN N
with IN N
adenosine NN N
and CC N
probably RB N
does VBZ N
not RB N
affect VB N
mast NN N
cell NN N
degranulation NN N
. . N

-DOCSTART- -X- O O

Pentoxifylline NNP 1_i
therapy NN N
in IN N
HIV NNP 1_p
seropositive JJ 1_p
subjects NNS 1_p
with IN 1_p
elevated JJ 1_p
TNF NNP 1_p
. . 1_p

Tumor NNP N
necrosis IN N
factor-alpha JJ N
( ( N
TNF-alpha NNP N
) ) N
is VBZ N
thought VBN N
to TO N
induce VB N
cachexia NN N
in IN N
subjects NNS N
infected VBN N
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
HIV-seropositive JJ 1_p
patients NNS 1_p
would MD N
benefit VB N
from IN N
treatment NN N
with IN N
pentoxifylline NN 1_i
, , N
a DT N
known VBN N
suppressor NN N
of IN N
TNF-alpha NNP N
production NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
how WRB N
pentoxifylline NN 1_i
at IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
800 CD 1_i
mg JJ 1_i
thrice JJ 1_i
daily RB 1_i
would MD N
influence VB N
the DT N
cellular JJ 1_o
immune NN 1_o
system NN 1_o
in IN N
HIV-seropositive JJ N
persons NNS 1_p
with IN 1_p
elevated JJ 1_p
TNF-alpha NNP 1_p
. . 1_p

Six NNP 1_p
HIV-seropositive JJ 1_p
subjects NNS 1_p
with IN 1_p
elevated JJ 1_p
amounts NNS 1_p
of IN 1_p
TNF-alpha NNP 1_p
in IN 1_p
plasma NN 1_p
at IN 1_p
least JJS 1_p
at IN 1_p
two CD 1_p
occasions NNS 1_p
were VBD N
included VBN N
in IN N
an DT N
open JJ N
, , N
controlled VBN N
, , N
randomized VBN N
, , N
cross-over JJ N
study NN N
consisting VBG N
of IN N
a DT N
6 CD 1_i
week NN 1_i
treatment NN 1_i
period NN 1_i
and CC 1_i
a DT 1_i
6 CD 1_i
week NN 1_i
control NN 1_i
period NN 1_i
. . 1_i

Blood NN N
samples NNS N
were VBD N
collected VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
. . N

Pentoxifylline NNP N
treatment NN N
did VBD N
not RB N
influence VB N
the DT N
concentration NN 1_o
of IN 1_o
plasma-TNF-alpha NN 1_o
, , 1_o
subpopulations NNS 1_o
of IN 1_o
blood NN 1_o
mononuclear NN 1_o
cells NNS 1_o
, , 1_o
the DT 1_o
proliferative JJ 1_o
responses NNS 1_o
nor CC 1_o
the DT 1_o
natural JJ 1_o
killer NN 1_o
( ( 1_o
NK NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
lymphokine NN 1_o
activated VBN 1_o
killer NN 1_o
( ( 1_o
LAK NNP 1_o
) ) 1_o
cell NN 1_o
activities NNS 1_o
. . 1_o

Furthermore RB N
, , N
pentoxifylline JJ N
treatment NN N
did VBD N
not RB N
influence VB N
the DT N
weight NN 1_o
, , 1_o
temperature NN 1_o
, , 1_o
well RB 1_o
being VBG 1_o
, , 1_o
or CC 1_o
tiredness NN 1_o
of IN 1_o
the DT 1_o
subjects NNS 1_o
. . 1_o

However RB N
, , N
the DT N
patients NNS N
frequently RB N
reported VBD N
gastrointestinal JJ 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

In IN N
vitro NN N
, , N
however RB N
, , N
pentoxifylline NN N
at IN N
suprapharmacological JJ N
concentrations NNS N
inhibited VBD N
the DT N
blood NN 1_o
mononuclear NN 1_o
cell NN 1_o
( ( 1_o
BMNC NNP 1_o
) ) 1_o
proliferative NN 1_o
responses NNS 1_o
, , 1_o
NK NNP 1_o
, , N
and CC N
LAK NNP 1_o
cell NN 1_o
activities NNS 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
addition NN N
of IN N
amifostine NN 1_i
to TO 1_i
carboplatin VB 1_i
and CC 1_i
paclitaxel VB 1_i
based VBN 1_i
chemoradiation NN 1_i
in IN N
locally RB 1_p
advanced JJ 1_p
non-small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
: : 1_p
long-term JJ N
follow-up NN N
of IN N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
( ( N
RTOG NNP N
) ) N
randomized VBD N
trial NN N
9801 CD N
. . N

INTRODUCTION NNP N
We PRP N
report VBP N
the DT N
long-term JJ N
results NNS N
of IN N
RTOG NNP N
9801 CD N
, , N
a DT N
randomized JJ N
trial NN N
investigating VBG N
the DT N
ability NN N
of IN N
amifostine NN 1_i
, , N
a DT N
radioprotector NN N
, , N
to TO N
reduce VB N
chemoradiation-induced JJ N
esophagitis NN N
. . N

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
stages NNS 1_p
II NNP 1_p
and CC 1_p
IIIA/B NNP 1_p
non-small-cell JJ 1_p
lung NN 1_p
cancer NN 1_p
received VBD N
induction NN N
paclitaxel NN 1_i
225 CD N
mg/m2 NN N
intravenously RB N
( ( N
IV NNP N
) ) N
and CC N
carboplatin JJ 1_i
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
6 CD N
both DT N
days NNS N
1 CD N
and CC N
22 CD N
, , N
followed VBN N
by IN N
concurrent JJ N
weekly JJ N
paclitaxel NN 1_i
( ( N
50 CD N
mg/m2 NN N
) ) N
and CC N
carboplatin NN 1_i
( ( N
AUC NNP N
2 CD N
) ) N
, , N
with IN N
hyperfractionated VBN 1_i
radiation NN 1_i
therapy NN 1_i
( ( N
69.6 CD N
Gy NNP N
at IN N
1.2 CD N
Gy NNP N
BID NNP N
) ) N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
amifostine VB 1_i
( ( N
AM NNP N
) ) N
500 CD N
mg JJ N
IV NNP N
four CD N
times NNS N
per IN N
week NN N
or CC N
no-AM JJ N
during IN N
chemoradiotherapy NN N
. . N

Stratification NN N
factors NNS N
included VBD N
age NN N
( ( N
< JJ N
70 CD N
vs. FW N
?70 CD N
years NNS N
) ) N
, , N
stage NN N
and CC N
performance NN N
status NN N
. . N

RESULTS VB 1_p
243 CD 1_p
patients NNS 1_p
( ( 1_p
pts NNS 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
; : 1_p
120 CD 1_p
received VBD 1_p
AM NNP 1_p
, , 1_p
123 CD 1_p
received VBD 1_p
no-AM JJ 1_p
. . 1_p

Two CD 1_p
pts NNS 1_p
on IN 1_p
each DT 1_p
arm NN 1_p
were VBD 1_p
found VBN 1_p
ineligible JJ 1_p
. . 1_p

Overall JJ 1_p
, , 1_p
85 CD 1_p
% NN 1_p
of IN 1_p
patients NNS 1_p
were VBD 1_p
?70 JJ 1_p
years NNS 1_p
; : 1_p
75 CD 1_p
% NN 1_p
had VBD 1_p
a DT 1_p
KPS NNP 1_p
?90 NNP 1_p
. . 1_p

34 CD 1_p
% NN 1_p
had VBD 1_o
squamous JJ 1_o
histology NN 1_o
. . 1_o

With IN 1_o
median JJ N
follow-up NN N
of IN N
96.3 CD N
months NNS N
( ( N
for IN N
patients NNS N
still RB N
alive JJ N
) ) N
, , 1_o
overall JJ 1_o
survival NN 1_o
was VBD 1_o
identical JJ 1_o
( ( N
hazard JJ N
ratio NN N
1.03 CD N
( ( N
0.79-1.34 NN N
) ) N
, , N
NS NNP N
) ) N
: : N
five-year JJ 1_o
survival JJ 1_o
17 CD 1_o
% NN 1_o
in IN 1_o
both DT N
arms NNS N
. . N

The DT 1_o
incidence NN 1_o
of IN 1_o
late JJ 1_o
grade NN 1_o
3-5 JJ 1_o
toxicities NNS 1_o
was VBD 1_o
16 CD 1_o
% NN N
in IN N
the DT N
AM NNP N
arm NN N
and CC N
19 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
( ( N
hazard JJ N
ratio NN N
1.24 CD N
( ( N
0.66-2.32 NN N
) ) N
, , N
NS NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
arms NNS N
regarding VBG 1_o
overall JJ 1_o
survival NN 1_o
, , 1_o
disease-free JJ 1_o
survival NN 1_o
or CC 1_o
long-term JJ 1_o
toxicity NN 1_o
. . 1_o

CONCLUSION VB 1_o
The DT N
chemoradiation NN N
regimen NNS 1_i
of IN 1_i
carboplatin NN 1_i
and CC 1_i
paclitaxel NN 1_i
produced VBN 1_i
long-term JJ N
results NNS N
in IN N
the DT N
multi-institutional JJ N
setting NN N
comparable JJ N
to TO N
other JJ N
regimens NNS 1_i
. . 1_i

Amifostine NNP 1_i
did VBD 1_i
not RB 1_i
appear VB N
to TO N
compromise VB 1_o
survival NN 1_o
. . 1_o

As IN 1_o
done VBN 1_o
in IN N
RTOG NNP N
9801 CD N
, , N
more RBR N
consistent JJ N
reporting NN N
of IN N
long JJ N
term NN 1_o
toxicity NN 1_o
is VBZ 1_o
needed VBN 1_o
for IN N
comparison NN N
of IN N
different JJ N
chemoradiation NN N
regimens NNS N
. . N

-DOCSTART- -X- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
tamoxifen JJ N
plus CC N
sequential JJ N
CMF NNP N
chemotherapy NN N
versus NN N
tamoxifen NN N
alone RB N
in IN N
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

Eighty-eight JJ 1_p
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
, , 1_p
in IN 1_p
whom WP 1_p
estrogen NN 1_p
receptors NNS 1_p
( ( 1_p
ER NNP 1_p
) ) 1_p
were VBD 1_p
positive JJ 1_p
or CC 1_p
unknown JJ 1_p
, , N
were VBD N
treated VBN N
on IN N
a DT N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN 1_o
of IN N
tamoxifen NN 1_i
and CC 1_i
to TO 1_i
assess VB 1_i
the DT 1_i
therapeutic JJ 1_o
advantage NN 1_o
of IN 1_i
sequentially RB 1_i
adding VBG 1_i
low-dose JJ 1_i
cyclophosphamide-methotrexate-5-fluorouracil NN 1_i
( ( 1_i
CMF NNP 1_i
) ) 1_i
chemotherapy NN 1_i
in IN 1_i
tamoxifen JJ 1_i
responders NNS 1_i
. . 1_i

Patients NNS 1_p
with IN 1_p
known JJ 1_p
ER NNP 1_p
negative JJ 1_p
status NN 1_p
were VBD 1_p
not RB 1_p
studied VBN 1_p
. . 1_p

After IN N
the DT N
initial JJ N
12-week JJ N
treatment NN N
with IN N
tamoxifen NN 1_i
alone RB 1_i
, , N
60 CD N
% NN N
of IN N
ER NNP N
positive JJ N
patients NNS N
achieved VBD N
complete JJ 1_o
or CC 1_o
partial JJ 1_o
response NN 1_o
as IN N
did VBD N
35 CD N
% NN N
in IN N
whom WP N
ER NNP N
were VBD N
unknown JJ N
. . N

Response VB 1_o
status NN 1_o
further RB N
improved VBN N
in IN N
18 CD N
% NN N
randomized VBN N
to TO N
continue VB N
tamoxifen VB N
alone RB N
vs JJ N
31 CD N
% NN N
in IN N
whom WP N
CMF NNP N
was VBD N
added VBN N
to TO N
tamoxifen VB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
time NN N
to TO N
the DT N
development NN 1_o
of IN 1_o
progressive JJ 1_o
disease NN 1_o
or CC 1_o
survival NN 1_o
between IN N
the DT N
ER NNP N
positive JJ N
and CC N
ER NNP N
unknown JJ N
patients NNS N
or CC N
between IN N
the DT N
tamoxifen NN N
and CC N
tamoxifen JJ N
plus CC N
CMF JJ N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
inability NN N
to TO N
determine VB N
ER NNP N
status NN N
should MD N
not RB N
prejudice VB N
against IN N
the DT N
use NN N
of IN N
tamoxifen NN N
in IN N
postmenopausal NN 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

No DT N
benefit NN N
has VBZ N
been VBN N
demonstrated VBN N
from IN N
the DT N
addition NN N
of IN N
CMF NNP N
chemotherapy NN N
in IN N
tamoxifen JJ N
responders NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ 1_i
nutrition NN 1_i
on IN N
postoperative JJ 1_o
ileus NN 1_o
and CC 1_o
anastomotic JJ 1_o
leakage NN 1_o
following VBG N
colorectal JJ N
surgery NN N
( ( N
SANICS NNP N
II NNP N
trial NN N
) ) N
: : N
a DT N
study NN N
protocol NN N
for IN N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Postoperative NNP N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
are VBP N
important JJ N
complications NNS N
following VBG N
colorectal JJ N
surgery NN N
associated VBN N
with IN N
short-term JJ N
morbidity NN N
and CC N
mortality NN N
. . N

Previous JJ N
experimental JJ N
and CC N
preclinical JJ N
studies NNS N
have VBP N
shown VBN N
that IN N
a DT N
short JJ N
intervention NN N
with IN N
enriched JJ N
enteral JJ N
nutrition NN N
dampens VBZ N
inflammation NN N
via IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
and CC N
thereby RB N
reduces NNS N
postoperative JJ N
ileus NN N
. . N

Furthermore RB N
, , N
early JJ N
administration NN N
of IN N
enteral JJ N
nutrition NN N
reduced VBD N
anastomotic JJ 1_o
leakage NN 1_o
. . 1_o

This DT N
study NN N
will MD N
investigate VB N
the DT N
effect NN N
of IN N
nutritional JJ N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
just RB N
before RB N
, , N
during IN N
and CC N
early RB N
after IN N
colorectal JJ N
surgery NN N
on IN N
inflammation NN N
, , N
postoperative JJ N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
. . N

METHODS/DESIGN NNP N
This DT N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
will MD N
include VB N
280 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
colorectal JJ 1_p
surgery NN 1_p
. . 1_p

All DT N
patients NNS 1_p
will MD N
receive VB N
a DT N
selfmigrating JJ 1_i
nasojejunal JJ 1_i
tube NN 1_i
that WDT N
will MD N
be VB N
connected VBN N
to TO N
a DT N
specially RB N
designed VBN N
blinded VBN N
tubing NN N
system NN N
. . N

Patients NNS 1_p
will MD N
be VB N
allocated VBN N
either DT N
to TO N
the DT N
intervention NN N
group NN N
, , N
receiving VBG 1_i
perioperative JJ 1_i
nutrition NN 1_i
, , N
or CC N
to TO N
the DT N
control NN N
group NN N
, , N
receiving VBG 1_i
no DT 1_i
nutrition NN 1_i
. . 1_i

The DT N
primary JJ N
endpoint NN N
is VBZ N
postoperative JJ 1_o
ileus NN 1_o
. . 1_o

Secondary JJ N
endpoints NNS N
include VBP N
anastomotic JJ 1_o
leakage NN 1_o
, , 1_o
local JJ 1_o
and CC 1_o
systemic JJ 1_o
inflammation NN 1_o
, , 1_o
( ( 1_o
aspiration NN 1_o
) ) 1_o
pneumonia NN 1_o
, , 1_o
surgical JJ 1_o
complications NNS 1_o
classified VBD 1_o
according VBG 1_o
to TO 1_o
Clavien-Dindo NNP 1_o
, , 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
gut FW 1_o
barrier JJR 1_o
integrity NN 1_o
and CC 1_o
time NN 1_o
until IN 1_o
functional JJ 1_o
recovery NN 1_o
. . 1_o

Furthermore NNP N
, , N
a DT N
cost-effectiveness JJ N
analysis NN N
will MD N
be VB N
performed VBN N
. . N

DISCUSSION NNP N
Activation NNP N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ N
enteral JJ N
feeding NN N
is VBZ N
expected VBN N
to TO N
dampen VB N
the DT N
local JJ 1_o
and CC 1_o
systemic JJ 1_o
inflammatory NN 1_o
response NN 1_o
. . 1_o

Consequently RB N
, , N
postoperative JJ 1_o
ileus NN 1_o
will MD N
be VB N
reduced VBN N
as RB N
well RB N
as IN N
anastomotic JJ 1_o
leakage NN 1_o
. . 1_o

The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
enriched JJ N
nutrition NN N
given VBN N
shortly RB N
before RB N
, , N
during IN N
and CC N
after IN N
surgery NN N
in IN N
a DT N
clinical JJ N
setting NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT02175979 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
25 CD N
June NNP N
2014 CD N
. . N

Dutch VB N
Trial JJ N
Registry NN N
: : N
NTR4670 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
1 CD N
August NNP N
2014 CD N
. . N

-DOCSTART- -X- O O

Testing VBG N
three CD N
different JJ N
cancer NN N
genetics NNS N
registry VBP N
recruitment JJ N
methods NNS N
with IN N
Hispanic JJ 1_p
cancer NN 1_p
patients NNS 1_p
and CC 1_p
their PRP$ 1_p
family NN 1_p
members NNS 1_p
previously RB 1_p
registered VBN 1_p
in IN 1_p
local JJ 1_p
cancer NN 1_p
registries NNS 1_p
in IN 1_p
Texas NNP 1_p
. . 1_p

OBJECTIVE NN N
To TO N
increase VB N
accrual JJ N
among IN N
Hispanics NNPS 1_p
to TO 1_p
the DT 1_p
Cancer NNP 1_p
Genetics NNP 1_p
Network NNP 1_p
national JJ 1_p
cancer NN 1_p
genetics NNS 1_p
registry NN 1_p
. . 1_p

METHODS NNP N
Drawing VBG N
from IN N
South NNP 1_p
Texas NNP 1_p
cancer NN 1_p
registries NNS 1_p
, , 1_p
444 CD 1_p
Hispanic JJ 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
one CD N
of IN N
three CD N
experimental JJ N
conditions NNS N
: : N
standard JJ 1_i
direct-mailed JJ 1_i
procedures NNS 1_i
( ( 1_i
X1 NNP 1_i
) ) 1_i
, , 1_i
X1 NNP 1_i
plus CC 1_i
culturally RB 1_i
tailored JJ 1_i
materials NNS 1_i
( ( 1_i
X2 NNP 1_i
) ) 1_i
, , N
and CC N
X2 NNP 1_i
plus CC 1_i
interpersonal JJ 1_i
phone NN 1_i
contact NN 1_i
( ( 1_i
X3 NNP 1_i
) ) 1_i
. . N

Participants NNS N
were VBD N
also RB N
surveyed VBN N
about IN N
the DT N
effectiveness NN N
of IN N
the DT N
education NN N
materials NNS N
and CC N
the DT N
phone NN N
contact NN N
. . N

A DT N
refusal NN N
survey NN N
was VBD N
provided VBN N
for IN N
those DT N
who WP N
declined VBD N
to TO N
join VB N
the DT N
study NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
154 CD 1_p
individuals NNS 1_p
joined VBD 1_p
the DT 1_p
Cancer NNP 1_p
Genetics NNP 1_p
Network NNP 1_p
. . 1_p

The DT N
X3 JJ 1_o
condition NN 1_o
yielded VBD 1_o
the DT 1_o
greatest JJS 1_o
accrual JJ 1_o
( ( N
43.2 CD N
% NN N
) ) N
compared VBN N
to TO N
X1 NNP N
( ( N
30.9 CD N
% NN N
) ) N
and CC N
X2 NNP N
( ( N
29.9 CD N
% NN N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

Tailored VBN N
materials NNS N
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
but CC N
were VBD N
highly RB N
regarded VBN N
. . N

The DT N
main JJ N
reasons NNS N
for IN N
not RB N
participating VBG N
were VBD N
a DT N
lack NN 1_o
of IN 1_o
interest NN 1_o
and CC 1_o
time NN 1_o
requirements NNS 1_o
. . 1_o

CONCLUSION NNP N
Interpersonal NNP 1_i
communication NN 1_i
can MD N
have VB N
a DT N
powerful JJ N
effect NN N
on IN N
recruitment NN N
. . N

However RB N
, , N
more JJR N
research NN N
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
cost-efficacy NN N
of IN N
more JJR N
labor-intensive JJ N
approaches NNS N
to TO N
registry VB N
accrual JJ N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
adjuvant JJ N
buspirone NN 1_i
for IN N
irritability NN 1_o
in IN 1_p
autism NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
brain NN N
serotonin NN N
level NN N
is VBZ N
decreased VBN N
in IN N
individuals NNS N
with IN N
autism NN N
. . N

Buspirone NNP N
is VBZ N
a DT N
5-HT JJ N
( ( N
1A CD N
) ) N
receptor NN N
agonist NN N
with IN N
antiaggressive JJ N
effects NNS N
increasing VBG N
prosocial JJ N
behaviors NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
an DT N
8-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ 1_i
clinical JJ N
trial NN N
. . N

Participants NNS 1_p
included VBD 1_p
40 CD 1_p
outpatient JJ 1_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

The DT N
patients NNS N
took VBD N
buspirone NN 1_i
plus CC 1_i
risperidone NN 1_i
or CC 1_i
risperidone NN 1_i
plus CC 1_i
placebo NN 1_i
during IN N
8 CD N
weeks NNS N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
week NN N
4 CD N
, , N
and CC N
week NN N
8 CD N
using VBG N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
Rating NNP N
Scale NNP N
. . N

RESULTS NNP N
Eighteen JJ 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
placebo NN 1_p
group NN 1_p
and CC N
16 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
buspirone NN 1_p
group NN 1_p
completed VBD N
this DT N
trial NN N
. . N

The DT N
mean JJ N
dose NN N
of IN N
buspirone NN N
was VBD N
6.7 CD N
( ( N
SD NNP N
2.7 CD N
) ) N
mg/day NN N
. . N

Irritability NNP 1_o
subscale JJ 1_o
score NN 1_o
significantly RB N
decreased VBD N
during IN N
this DT N
trial NN N
in IN N
both DT N
groups NNS N
( ( N
buspirone NN N
group NN N
: : N
declined VBD N
from IN N
25.7 CD N
[ NNS N
SD NNP N
5.7 CD N
] NN N
to TO N
16.3 CD N
[ NNS N
SD NNP N
8.5 CD N
] NNP N
; : N
placebo CC N
group NN N
: : N
declined VBD N
from IN N
24.7 CD N
[ NNS N
SD NNP N
7.6 CD N
] NN N
to TO N
18.2 CD N
[ NNS N
SD NNP N
7.7 CD N
] NN N
) ) N
. . N

The DT N
Cohen NNP N
d NN N
effect NN N
size NN N
was VBD N
.45 NNP N
. . N

Thirteen NNP N
( ( N
81.2 CD N
% NN N
) ) N
of IN N
16 CD N
patients NNS N
in IN N
the DT N
buspirone NN N
group NN N
and CC N
7 CD N
( ( N
38.9 CD N
% NN N
) ) N
of IN N
18 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
showed VBD N
a DT N
?30 NN N
% NN N
decline NN N
in IN N
irritability NN 1_o
score NN 1_o
. . 1_o

The DT 1_o
relative JJ 1_o
risk NN 1_o
for IN 1_o
treatment NN N
was VBD N
2.1 CD N
. . N

There EX N
were VBD N
no DT N
serious JJ 1_o
adverse JJ 1_o
effects NNS 1_o
. . 1_o

The DT N
most RBS N
common JJ N
adverse JJ N
effects NNS N
in IN N
the DT 1_i
buspirone NN 1_i
group NN 1_i
were VBD 1_o
increased VBN 1_o
appetite RB 1_o
, , 1_o
drowsiness NN 1_o
, , 1_o
and CC 1_o
fatigue NN 1_o
. . 1_o

CONCLUSION VB N
This DT N
clinical JJ N
trial NN N
supports NNS N
that IN N
low JJ N
dose VB N
buspirone NN N
plus CC N
risperidone NN N
is VBZ N
more RBR N
effective JJ N
than IN N
risperidone NN N
plus CC N
placebo NN N
for IN N
treating VBG 1_o
irritability NN 1_o
in IN 1_o
individuals NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ 1_i
Therapy NNP 1_i
of IN N
metastatic JJ 1_p
endocrine NN 1_p
tumors NNS 1_p
of IN 1_p
the DT 1_p
gastrointestinal JJ 1_p
tract NN 1_p
] NN 1_p
. . 1_p

-DOCSTART- -X- O O

Types NNS N
of IN N
parent NN 1_i
verbal JJ 1_i
responsiveness NN 1_i
that WDT N
predict VBP N
language NN N
in IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

PURPOSE VB N
This DT N
study NN N
examined VBD N
short-term JJ N
predictive JJ N
associations NNS N
between IN N
5 CD N
different JJ N
types NNS N
of IN N
parent NN 1_i
verbal JJ 1_i
responsiveness NN 1_i
and CC N
later RB N
spoken JJ N
vocabulary NN N
for IN N
32 CD 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
a DT 1_p
confirmed JJ 1_p
diagnosis NN 1_p
of IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

METHOD NNP N
Parent NNP 1_i
verbal JJ 1_i
utterances NNS 1_i
were VBD N
coded VBN N
from IN N
videotapes NNS 1_i
of IN 1_i
naturalistic JJ 1_i
parent-child JJ 1_i
play NN 1_i
sessions NNS 1_i
using VBG N
interval JJ 1_i
and CC N
event-based JJ 1_i
coding NN 1_i
. . 1_i

A DT N
vocabulary JJ 1_o
difference NN 1_o
score NN 1_o
, , N
calculated VBD N
using VBG N
the DT N
MacArthur NNP N
Communicative NNP N
Development NNP N
Inventories NNP N
( ( N
L. NNP N
Fenson NNP N
et FW N
al. NN N
, , N
1993 CD N
) ) N
, , N
was VBD N
used VBN N
as IN N
the DT N
outcome NN N
measure NN N
of IN N
spoken JJ N
vocabulary JJ N
6 CD N
months NNS N
later RB N
. . N

RESULTS VB N
Parent JJ N
follow-in JJ N
comments NNS N
and CC N
follow-in JJ N
directives NNS N
predicted VBD N
spoken JJ N
vocabulary JJ N
after IN N
controlling VBG N
for IN N
child JJ N
engagement NN N
. . N

Parent NNP 1_o
expansions NNS 1_o
of IN 1_o
child NN 1_o
verbal JJ 1_o
utterances NNS 1_o
predicted VBD N
spoken JJ 1_o
vocabulary JJ 1_o
after IN N
controlling VBG N
for IN N
child NN N
talkativeness NN N
. . N

When WRB N
entered VBN N
together RB N
into IN N
a DT N
regression NN N
analysis NN N
, , N
metrics NNS N
that IN N
represented VBD N
( ( N
a DT N
) ) N
the DT 1_o
number NN 1_o
of IN 1_o
parent NN 1_o
utterances NNS 1_o
following VBG 1_o
into IN 1_o
the DT 1_o
child NN 1_o
's POS 1_o
focus NN 1_o
of IN 1_o
attention NN 1_o
and CC N
( ( N
b NN N
) ) N
the DT 1_o
number NN 1_o
of IN 1_o
parent NN 1_o
utterances NNS 1_o
responding VBG 1_o
to TO 1_o
child VB 1_o
verbal JJ 1_o
communication NN 1_o
acts NNS N
both DT N
accounted VBD N
for IN N
unique JJ N
variance NN N
in IN N
predicting VBG N
change NN N
in IN N
spoken JJ 1_o
vocabulary NN 1_o
from IN N
Time NNP N
1 CD N
to TO N
Time NNP N
2 CD N
. . N

CONCLUSION NNP N
Parent NNP 1_i
verbal JJ 1_i
utterances NNS 1_i
that WDT N
follow VBP N
into IN N
the DT N
child NN N
's POS N
current JJ N
focus NN N
of IN N
attention NN N
or CC N
respond NN N
to TO N
child VB N
verbal JJ N
communication NN N
acts NNS N
may MD N
facilitate VB N
the DT N
process NN N
of IN N
early JJ N
vocabulary JJ N
acquisition NN N
by IN N
mitigating VBG N
the DT N
need NN N
for IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
to TO N
use VB N
attention-following JJ N
as IN N
a DT N
word-learning JJ N
strategy NN N
. . N

-DOCSTART- -X- O O

Noradrenergic NNP N
moderation NN 1_o
of IN N
working VBG N
memory NN N
impairments NNS N
in IN N
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

In IN N
addition NN N
to TO N
having VBG N
difficulties NNS N
with IN N
social JJ N
communications NNS N
, , N
individuals NNS 1_p
with IN 1_p
an DT 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
often RB N
also RB N
experience JJ N
impairment NN 1_o
in IN 1_o
higher-order NN 1_o
, , 1_o
executive NN 1_o
skills NNS 1_o
. . 1_o

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
pharmacological JJ N
modulation NN N
of IN N
the DT N
norepinephrine NN N
system NN N
on IN N
the DT N
severity NN N
of IN N
such JJ N
impairments NNS N
. . N

A DT N
sample NN N
of IN N
14 CD 1_p
high-functioning JJ 1_p
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
a DT 1_p
demographically-matched JJ 1_p
comparison NN 1_p
group NN 1_p
of IN 1_p
13 CD 1_p
typically RB 1_p
developing VBG 1_p
individuals NNS 1_p
participated VBN 1_p
. . 1_p

An DT N
AX NNP 1_o
continuous JJ 1_o
performance NN 1_o
test NN 1_o
( ( 1_o
AX-CPT NNP 1_o
) ) 1_o
was VBD N
used VBN N
to TO N
evaluate VB N
working VBG N
memory NN N
and CC N
inhibitory NN N
control NN N
. . N

AX-CPT JJ 1_o
performance NN 1_o
was VBD N
assessed VBN N
following VBG N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
propranolol NN 1_i
( ( 1_i
a DT 1_i
beta NN 1_i
adrenergic JJ 1_i
antagonist NN 1_i
) ) 1_i
and CC 1_i
following VBG 1_i
placebo NN 1_i
( ( N
sugar NN N
pill NN N
) ) N
administration NN N
. . N

Individuals NNS 1_p
with IN 1_p
ASD NNP 1_p
performed VBD 1_o
more RBR N
poorly RB N
than IN N
non-ASD JJ N
individuals NNS N
in IN N
the DT N
working JJ N
memory NN N
condition NN N
( ( N
BX NNP N
trials NNS N
) ) N
. . N

Importantly RB N
, , N
administration NN N
of IN N
propranolol NN 1_i
attenuated VBN 1_o
this DT 1_o
impairment NN 1_o
, , N
with IN N
the DT N
ASD NNP N
group NN N
performing VBG 1_o
significantly RB N
better RBR N
in IN N
the DT N
propranolol NN N
condition NN N
than IN N
the DT N
placebo JJ N
condition NN N
. . N

Working VBG 1_o
memory NN 1_o
performance NN 1_o
of IN N
the DT N
non-ASD JJ N
group NN N
was VBD N
unaffected VBN N
by IN N
propranolol/placebo JJ N
administration NN N
. . N

No DT N
group NN N
or CC N
medication NN N
effects NNS 1_o
were VBD N
observed VBN N
for IN N
the DT N
inhibition NN 1_o
condition NN 1_o
( ( N
AY NNP N
trials NNS N
) ) N
. . N

The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
norepinephrine NN N
may MD N
play VB N
a DT N
role NN N
in IN N
some DT N
, , N
but CC N
not RB N
necessarily RB N
all RB N
, , N
cognitive JJ 1_o
impairments NNS 1_o
associated VBN N
with IN N
ASD NNP N
. . N

Additional NNP N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
understand VB N
whether IN N
this DT N
role NN N
is VBZ N
primarily RB N
causal JJ N
or CC N
compensatory NN N
in IN N
nature NN N
. . N

-DOCSTART- -X- O O

Butorphanol NNP 1_i
and CC 1_i
meperidine NN 1_i
compared VBN N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
ureteral JJ 1_p
colic NN 1_p
. . 1_p

Pain NNP N
relief NN N
was VBD N
evaluated VBN N
in IN N
81 CD 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
ureteral JJ 1_p
colic NN 1_p
and CC 1_p
the DT 1_p
confirmed JJ 1_p
presence NN 1_p
of IN 1_p
a DT 1_p
calculus NN 1_p
. . 1_p

A DT N
randomized JJ 1_p
double-blind JJ 1_p
comparison NN 1_p
of IN 1_p
intramuscular JJ 1_p
2 CD 1_p
and CC 1_p
4 CD 1_p
mg. NN 1_p
butorphanol NN 1_i
and CC 1_i
80 CD 1_p
mg. NNS 1_p
meperidine NN 1_i
was VBD 1_p
used VBN 1_p
. . 1_p

Pain NNP 1_o
intensity NN 1_o
and CC N
pain NN 1_o
relief NN 1_o
were VBD N
evaluated VBN N
at IN N
half JJ N
hour NN N
and CC N
hourly JJ N
intervals NNS N
for IN N
4 CD N
hours NNS N
. . N

A DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN 1_i
was VBD N
found VBN N
to TO N
be VB N
analgesically RB N
equivalent JJ N
to TO N
80 CD N
mg. NNS N
meperidine NN 1_i
, , N
while IN N
a DT N
4 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN 1_i
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
80 CD N
mg. JJ N
meperidine NN 1_i
and CC N
2 CD N
mg. NN N
butorphanol NN 1_i
. . 1_i

Each DT N
patient NN N
received VBD N
up RB N
to TO N
2 CD N
doses NNS N
of IN N
analgesic JJ N
medication NN N
when WRB N
necessary JJ N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN 1_o
of IN 1_o
side JJ 1_o
effects NNS 1_o
among IN N
treatments NNS N
. . N

One CD N
patient NN N
had VBD N
visual JJ 1_o
hallucinations NNS 1_o
after IN N
a DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN 1_i
, , N
possibly RB N
owing VBG N
to TO N
its PRP$ N
antagonistic JJ N
activity NN N
to TO N
significant JJ N
narcotic JJ N
experience NN N
given VBN N
previously RB N
at IN N
another DT N
hospital NN N
. . N

There EX N
was VBD N
no DT N
other JJ N
evidence NN N
of IN N
toxicity NN 1_o
with IN N
butorphanol NN 1_i
. . 1_i

It PRP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ 1_o
, , 1_o
effective JJ 1_o
and CC 1_o
wall RB 1_o
tolerated JJ 1_o
drug NN N
for IN N
the DT N
treatment NN N
of IN N
ureteral JJ N
colic NN N
and CC N
is VBZ N
recommended VBN N
in IN N
place NN N
of IN N
narcotics NNS N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
topical JJ N
hemostatic JJ N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
TISSEEL NNP 1_i
VH NNP 1_i
S/D NNP 1_i
fibrin NN 1_i
sealant NN 1_i
compared VBN N
with IN N
currently RB 1_i
licensed VBN 1_i
TISSEEL NNP 1_i
VH NNP 1_i
in IN N
patients NNS 1_p
undergoing JJ 1_p
cardiac JJ 1_p
surgery NN 1_p
: : 1_p
a DT N
phase NN N
3 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
clinical JJ N
study NN N
. . N

AIM NNP N
TISSEEL NNP N
VH NNP N
is VBZ N
the DT N
only JJ N
commercially RB N
available JJ N
fibrin NN N
sealant NN N
indicated VBD N
as IN N
an DT N
adjunct NN N
to TO N
conventional JJ N
methods NNS N
of IN N
hemostasis NN N
during IN N
cardiac JJ N
surgery NN N
. . N

A DT N
next JJ N
generation NN N
fibrin NN 1_i
sealant NN 1_i
( ( 1_i
TISSEEL NNP 1_i
VH NNP 1_i
S/D NNP 1_i
) ) 1_i
has VBZ N
been VBN N
developed VBN N
in IN N
frozen JJ N
, , N
ready-to-use JJ N
form NN N
with IN N
an DT N
added JJ N
virus NN N
inactivation NN N
step NN N
( ( N
solvent/detergent JJ N
[ NNP N
S/D NNP N
] NNP N
treatment NN N
) ) N
to TO N
provide VB N
added JJ N
safety NN N
and CC N
convenience NN N
to TO N
the DT N
currently RB N
licensed VBN N
product NN N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
compare VB N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
the DT N
two CD N
products NNS N
. . N

METHODS NNP N
Phase NNP N
3 CD N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter NN N
study NN N
to TO N
compare VB N
TISSEEL NNP 1_i
VH NNP 1_i
S/D NNP 1_i
to TO 1_i
TISSEEL NNP 1_i
VH NNP 1_i
during IN N
cardiac JJ N
surgery NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
achieved VBD 1_o
hemostasis NN 1_o
at IN 1_p
the DT 1_p
primary JJ 1_p
treatment NN 1_p
site NN 1_p
within IN 1_p
5 CD 1_p
min NN 1_p
, , 1_p
and CC 1_p
maintained VBD 1_p
hemostasis NN 1_p
until IN 1_p
surgical JJ 1_p
closure NN 1_p
. . 1_p

RESULTS VB N
The DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
achieved VBD 1_o
hemostasis NN 1_o
at IN N
the DT N
primary JJ N
treatment NN N
site NN N
within IN N
5 CD N
min NN N
, , N
and CC N
maintained VBD 1_o
hemostasis NN 1_o
until IN N
surgical JJ N
closure NN N
was VBD N
88.2 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
and CC N
89.6 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
in IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

The DT N
difference NN N
in IN N
proportions NNS N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
minus CC N
TISSEEL NNP N
VH NNP N
, , N
was VBD N
1.4 CD N
% NN N
with IN N
a DT N
standard JJ N
error NN N
of IN N
3.70 CD N
% NN N
. . N

The DT N
lower JJR N
97.5 CD N
% NN N
confidence NN N
bound NN N
of IN N
this DT N
difference NN N
was VBD N
8.6 CD N
% NN N
, , N
which WDT N
is VBZ N
above IN N
the DT N
predefined JJ N
noninferiority NN N
margin NN N
of IN N
15 CD N
% NN N
. . N

Therefore RB N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
at IN N
least JJS N
as RB N
efficacious JJ N
as IN N
TISSEEL NNP N
VH NNP N
. . N

The DT N
safety NN N
profile NN N
of IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
was VBD N
very RB N
similar JJ N
to TO N
that DT N
of IN N
currently RB N
licensed VBN N
TISSEEL NNP N
VH NNP N
as IN N
assessed VBN N
by IN N
the DT N
safety NN N
endpoints NNS N
. . N

CONCLUSION NNP N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
safe JJ 1_o
and CC N
effective JJ 1_o
for IN N
use NN N
as IN N
an DT N
adjunct NN N
to TO N
hemostasis VB N
in IN N
patients NNS 1_p
undergoing JJ 1_p
cardiac JJ 1_p
surgery NN 1_p
. . 1_p

-DOCSTART- -X- O O

Less NNP N
tachycardia NN 1_o
in IN N
adults NNS 1_p
when WRB N
using VBG N
atropine VBP 1_i
0.9 CD N
mg NNS N
compared VBN N
with IN N
1.2 CD N
mg NNS N
plus CC N
neostigmine JJ 1_i
2.5 CD N
mg NN N
. . N

OBJECTIVE CC N
Compare NNP N
the DT N
increase NN N
in IN N
heart NN 1_o
rate NN 1_o
in IN 1_p
adults NNS 1_p
after IN N
0.9 CD N
vs. FW N
1.2 CD N
mg NN N
of IN N
atropine JJ 1_i
plus CC 1_i
neostigmine JJ 1_i
2.5 CD N
mg NN N
as IN N
the DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
reversal NN N
agent NN N
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
randomized NN N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
trial NN N
on IN N
46 CD 1_p
adults NNS 1_p
ASA NNP 1_p
I-II NNP 1_p
, , 1_p
undergoing VBG 1_p
elective JJ 1_p
gynecological NN 1_p
or CC 1_p
general JJ 1_p
surgery NN 1_p
with IN 1_p
balanced JJ 1_p
general JJ 1_p
anesthesia NN 1_p
was VBD N
performed VBN N
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
After IN N
surgery NN N
, , N
the DT N
study NN N
group NN N
received VBD N
0.9 CD 1_i
mg NN 1_i
of IN 1_i
atropine NN 1_i
, , N
while IN N
the DT N
control NN 1_i
group NN N
received VBD N
1.2 CD 1_i
mg NN 1_i
of IN 1_i
atropine NN 1_i
. . 1_i

Both DT N
groups NNS N
received VBD N
2.5 CD 1_i
mg NN 1_i
of IN 1_i
neostigmine JJ 1_i
simultaneously RB 1_i
. . 1_i

RESULTS VB N
The DT N
heart NN 1_o
rate NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
were VBD N
taken VBN N
at IN N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
, , N
9 CD N
, , N
10 CD N
, , N
15 CD N
, , N
20 CD N
, , N
25 CD N
, , N
and CC N
30 CD N
min NN N
after IN N
the DT N
injection NN N
. . N

The DT N
increase NN 1_o
in IN 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
between IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

The DT N
heart NN 1_o
rate NN 1_o
( ( N
at IN N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
min NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
study NN N
group NN N
increased VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
blood NN 1_o
pressure NN 1_o
between IN N
groups NNS N
and CC N
no DT N
side NN N
effects NNS N
occurred VBD N
. . N

CONCLUSION VB N
The DT N
authors NNS N
conclude VBP N
that IN N
0.9 CD N
mg NN N
of IN N
atropine NN 1_i
with IN N
2.5 CD N
mg NNS N
neostigmine JJ 1_i
can MD N
be VB N
safely RB N
used VBN N
as IN N
the DT N
reversal NN N
agent NN N
for IN N
a DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
, , N
particularly RB N
in IN N
patients NNS N
for IN N
whom WP N
any DT N
increase NN N
in IN N
heart NN 1_o
rate NN 1_o
would MD N
be VB N
harmful JJ N
. . N

-DOCSTART- -X- O O

Is VBZ N
the DT N
effect NN N
of IN N
mobile JJ 1_i
phone NN 1_i
radiofrequency NN 1_i
waves NNS 1_i
on IN N
human JJ N
skin JJ N
perfusion NN N
non-thermal JJ N
? . N
OBJECTIVE UH N
To TO N
establish VB N
whether IN N
SkBF NNP 1_o
can MD N
be VB N
modified VBN N
by IN N
exposure NN N
to TO N
the DT N
radiofrequency NN 1_i
waves NNS 1_i
emitted VBN 1_i
by IN 1_i
a DT 1_i
mobile JJ 1_i
phone NN 1_i
when WRB N
the DT N
latter NN N
is VBZ N
held VBN N
against IN N
the DT N
jaw NN N
and CC N
ear NN N
. . N

METHODS NNP N
Variations NNP 1_o
in IN 1_o
SkBF NNP 1_o
and CC N
Tsk NNP N
in IN N
adult NN 1_p
volunteers NNS 1_p
were VBD N
simultaneously RB N
recorded VBN 1_i
with IN 1_i
a DT 1_i
thermostatic JJ 1_i
laser NN 1_i
Doppler NNP 1_i
system NN 1_i
during IN 1_i
a DT 1_i
20-minute JJ 1_i
radiofrequency NN 1_i
exposure NN 1_i
session NN 1_i
and CC 1_i
a DT 1_i
20-minute JJ 1_i
sham NN 1_i
session NN 1_i
. . 1_i

The DT N
skin JJ N
microvessels NNS N
' POS N
vasodilatory NN N
reserve NN N
was VBD N
assessed VBN N
with IN N
a DT N
heat NN N
challenge NN N
at IN N
the DT N
end NN N
of IN N
the DT N
protocol NN N
. . N

RESULTS NNP N
During IN N
the DT N
radiofrequency NN 1_i
exposure NN 1_i
session NN 1_i
, , N
SkBF NNP 1_o
increased VBD N
( ( N
vs. FW N
baseline NN N
) ) N
more JJR N
than IN N
during IN N
the DT N
sham JJ 1_i
exposure NN 1_i
session NN 1_i
. . 1_i

The DT N
sessions NNS N
did VBD N
not RB N
differ VB N
significant JJ N
in IN N
terms NNS N
of IN N
the DT N
Tsk NNP 1_o
time-course JJ 1_o
response NN 1_o
. . 1_o

The DT N
skin JJ 1_o
microvessels NNS 1_o
' POS 1_o
vasodilatory NN 1_o
ability NN 1_o
was VBD N
found VBN N
to TO N
be VB N
greater JJR N
during IN N
radiofrequency NN N
exposure NN N
than IN N
during IN N
sham JJ N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
reveal VBP N
the DT N
existence NN N
of IN N
a DT N
specific JJ N
vasodilatory JJ 1_o
effect NN N
of IN N
mobile JJ 1_i
phone NN 1_i
radiofrequency NN 1_i
emission NN 1_i
on IN N
skin JJ N
perfusion NN N
. . N

-DOCSTART- -X- O O

Quantitative JJ N
angiographic JJ N
methods NNS N
for IN N
appropriate JJ N
end-point JJ 1_o
analysis NN 1_o
, , 1_o
edge-effect JJ 1_o
evaluation NN 1_o
, , N
and CC N
prediction NN 1_o
of IN 1_o
recurrent NN 1_o
restenosis NN 1_o
after IN N
coronary JJ 1_i
brachytherapy NN 1_i
with IN 1_p
gamma JJ 1_p
irradiation NN 1_p
. . 1_p

OBJECTIVES CC N
The DT N
study NN N
was VBD N
done VBN N
to TO N
investigate VB N
the DT N
relationship NN N
between IN N
clinical JJ N
restenosis NN N
and CC N
the DT N
relative JJ N
angiographic JJ N
location NN N
of IN N
the DT N
recurrent NN N
restenotic JJ N
lesion NN N
, , N
after IN N
treatment NN N
of IN N
in-stent JJ 1_p
restenosis NN 1_p
with IN N
vascular JJ 1_i
brachytherapy NN 1_i
in IN N
the DT N
Washington NNP 1_p
Radiation NNP 1_p
for IN 1_p
In-Stent NNP 1_p
Restenosis NNP 1_p
Trial NNP 1_p
( ( 1_p
WRIST NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND NNP N
Intracoronary NNP 1_i
radiation NN 1_i
therapy NN 1_i
reduces VBZ N
recurrence NN N
of IN N
in-stent JJ N
restenosis NN N
. . N

We PRP N
investigated VBD N
the DT N
above JJ N
objective NN N
in IN N
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
WRIST NNP 1_p
. . 1_p

METHODS NNP N
The DT N
WRIST NNP N
study NN N
randomized VBD 1_p
130 CD 1_p
patients NNS 1_p
to TO 1_p
double-blinded JJ 1_i
therapy NN 1_i
with IN 1_i
gamma JJ 1_i
irradiation NN 1_i
( ( 1_i
iridium-192 JJ 1_i
[ NNP 1_i
( ( 1_i
192 CD 1_i
) ) 1_i
Ir NNP 1_i
] NNP 1_i
) ) 1_i
versus NN 1_i
placebo NN 1_i
after IN 1_p
interventional JJ 1_i
treatment NN 1_i
of IN 1_i
diffuse NN 1_i
in-stent JJ 1_i
restenosis NN 1_i
. . 1_i

After IN N
the DT N
intervention NN N
and CC N
at IN N
follow-up NN N
, , N
three CD N
vessel NN N
segments NNS N
were VBD N
individually RB N
analyzed VBN N
with IN N
quantitative JJ N
coronary JJ N
angiography NN N
: : N
1 CD N
) ) N
the DT N
stent NN N
, , N
2 CD N
) ) N
the DT N
radiation NN N
ribbon NN N
, , N
and CC N
3 CD N
) ) N
the DT N
ribbon+margin NN N
segment NN N
( ( N
including VBG N
5 CD N
mm NN N
on IN N
either DT N
end NN N
of IN N
the DT N
injured JJ N
or CC N
radiation-ribbon JJ N
segment NN N
) ) N
. . N

Receiver NNP N
operator NN N
curves NNS N
( ( N
ROC NNP N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
follow-up JJ N
percent NN N
diameter NN N
stenosis NN N
( ( N
DS NNP N
) ) N
for IN N
each DT N
of IN N
the DT N
three CD N
analyzed VBD N
segments NNS N
in IN N
predicting VBG N
target NN N
vessel NN N
revascularization NN N
( ( N
TVR NNP N
) ) N
. . N

RESULTS NNP N
( ( N
192 CD N
) ) N
Ir NNP N
reduced VBD N
recurrent JJ 1_o
restenosis NN 1_o
( ( N
23.7 CD N
% NN N
vs. FW N
60.7 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
length NN 1_o
of IN 1_o
recurrent JJ 1_o
restenosis NN 1_o
( ( N
8.99 CD N
+/- JJ N
4.34 CD N
mm NN N
vs. FW N
17.54 CD N
+/- JJ N
10.48 CD N
mm NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
at IN N
follow-up JJ N
compared VBN N
to TO N
placebo VB N
. . N

Isolated NNP 1_o
stent NN 1_o
edge NN 1_o
( ( N
3.4 CD N
% NN N
) ) N
and CC N
ribbon NN 1_o
edge NN 1_o
( ( N
1.7 CD N
% NN N
) ) N
restenoses VBZ 1_o
were VBD N
infrequent NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
best JJS N
angiographic JJ N
surrogate NN N
of IN N
TVR NNP N
was VBD N
the DT N
50 CD N
% NN N
follow-up JJ N
DS NNP N
obtained VBD N
from IN N
the DT N
ribbon+margin NN N
analysis NN N
( ( N
ROC NNP N
area NN N
0.806 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
WRIST NNP N
, , N
not RB N
only RB N
was VBD N
( ( 1_i
192 CD 1_i
) ) 1_i
Ir NNP 1_i
therapy NN 1_i
effective JJ N
in IN N
reducing VBG N
restenosis NN N
, , N
but CC N
it PRP N
also RB N
reduced VBD N
the DT N
lesion NN N
length NN N
of IN N
treatment NN N
failures NNS N
by IN N
50 CD N
% NN N
, , N
and CC N
it PRP N
was VBD N
not RB N
associated VBN N
with IN N
edge NN N
proliferation NN N
. . N

The DT N
restenosis NN N
rate NN N
obtained VBN N
from IN N
the DT N
vessel NN N
segment NN N
inclusive NN N
of IN N
the DT N
dose JJ N
fall-off JJ N
zones NNS N
was VBD N
the DT N
best JJS N
correlate NN N
of IN N
TVR NNP N
and CC N
should MD N
become VB N
a DT N
standard JJ N
analysis NN N
site NN N
in IN N
all DT N
vascular JJ N
brachytherapy NN N
trials NNS N
. . N

-DOCSTART- -X- O O

Potential JJ N
effect NN N
of IN N
the DT N
risk NN N
of IN N
ovarian JJ 1_i
cancer NN 1_i
algorithm NN 1_i
( ( 1_i
ROCA NNP 1_i
) ) 1_i
on IN N
the DT N
mortality NN 1_o
outcome NN 1_o
of IN N
the DT N
Prostate NNP N
, , N
Lung NNP N
, , N
Colorectal NNP N
and CC N
Ovarian NNP N
( ( N
PLCO NNP N
) ) N
trial NN N
. . N

Recently RB N
, , N
the DT N
Prostate NNP 1_p
, , 1_p
Lung NNP 1_p
, , 1_p
Colorectal NNP 1_p
and CC 1_p
Ovarian NNP 1_p
( ( 1_p
PLCO NNP 1_p
) ) 1_p
Trial NNP 1_p
reported VBD N
no DT N
mortality NN N
benefit NN N
for IN N
annual JJ N
screening NN 1_i
with IN 1_i
CA-125 NNP 1_i
and CC 1_i
transvaginal JJ 1_i
ultrasound NN 1_i
( ( 1_i
TVU NNP 1_i
) ) 1_i
. . 1_i

Currently NNP N
ongoing VBG N
is VBZ N
the DT N
UK NNP N
Collaborative NNP N
Trial NNP N
of IN N
Ovarian JJ N
Cancer NNP N
Screening NNP N
( ( N
UKCTOCS NNP N
) ) N
, , N
which WDT N
utilizes VBZ N
the DT N
risk NN N
of IN N
ovarian JJ 1_i
cancer NN 1_i
algorithm NN 1_i
( ( 1_i
ROCA NNP 1_i
) ) 1_i
, , N
a DT N
statistical JJ N
tool NN N
that IN N
considers NNS N
current JJ N
and CC N
past JJ N
CA125 NNP N
values NNS N
to TO N
determine VB N
ovarian JJ N
cancer NN N
risk NN N
. . N

In IN N
contrast NN N
, , N
PLCO NNP N
used VBD N
a DT N
single JJ N
cutoff NN N
for IN N
CA125 NNP N
, , N
based VBN N
on IN N
current JJ N
levels NNS N
alone RB N
. . N

We PRP N
investigated VBD N
whether IN N
having VBG N
had VBD N
used VBN N
ROCA NNP 1_i
in IN 1_i
PLCO NNP 1_i
could MD N
have VB N
, , N
under IN N
optimal JJ N
assumptions NNS N
, , N
resulted VBD N
in IN N
a DT N
significant JJ 1_o
mortality NN 1_o
benefit NN 1_o
by IN N
applying VBG N
ROCA NNP N
to TO N
PLCO NNP N
CA125 NNP N
screening VBG N
values NNS N
. . N

A DT N
best-case JJ N
scenario NN N
assumed VBD N
that IN N
all DT 1_p
cancers NNS 1_p
showing VBG 1_p
a DT 1_p
positive JJ 1_p
screen NN 1_p
result NN 1_p
earlier RBR 1_p
with IN 1_p
ROCA NNP 1_p
than IN 1_p
under IN 1_p
the DT 1_p
PLCO NNP 1_p
protocol NN N
would MD N
have VB N
avoided VBN N
mortality NN 1_o
; : 1_o
under IN N
a DT N
stage-shift JJ N
scenario NN N
, , N
such JJ 1_p
women NNS 1_p
were VBD N
assigned VBN N
survival JJ N
equivalent NN N
to TO N
Stage VB N
I/II NNP N
screen-detected JJ N
cases NNS N
. . N

Updated VBN N
PLCO NNP N
data NNS N
show VBP N
132 CD 1_p
intervention NN 1_p
arm NN 1_p
ovarian JJ 1_p
cancer NN 1_p
deaths NNS 1_p
versus VBP 1_p
119 CD 1_p
in IN 1_p
usual JJ 1_p
care NN 1_p
( ( N
relative JJ N
risk NN N
, , N
RR NNP N
= NNP N
1.11 CD N
) ) N
. . N

Forty-three JJ N
ovarian JJ N
cancer NN N
cases NNS N
, , N
25 CD N
fatal NN N
, , N
would MD N
have VB N
been VBN N
detected VBN N
earlier RBR N
with IN N
ROCA NNP 1_i
, , N
with IN N
a DT N
median JJ N
( ( N
minimum JJ N
) ) N
advance NN N
time NN N
for IN N
fatal JJ 1_o
cases NNS 1_o
of IN N
344 CD N
( ( N
147 CD N
) ) N
days NNS N
. . N

Best-case JJ N
and CC N
stage-shift JJ N
scenarios NNS N
gave VBD N
25 CD N
and CC N
19 CD N
deaths NNS 1_o
prevented VBN N
with IN N
ROCA NNP 1_i
, , N
for IN N
RRs NNP N
of IN N
0.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.69-1.17 NN N
) ) N
and CC N
0.95 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.74-1.23 NN N
) ) N
, , N
respectively RB N
. . N

Having VBG N
utilized JJ N
ROCA NNP 1_i
in IN N
PLCO NNP N
would MD N
not RB N
have VB N
led VBN N
to TO N
a DT N
significant JJ N
mortality NN 1_o
benefit NN 1_o
of IN N
screening VBG N
. . N

However RB N
, , N
ROCA NNP 1_i
could MD N
still RB N
show VB N
a DT N
significant JJ N
effect NN N
in IN N
other JJ N
screening NN N
trials NNS N
, , N
including VBG N
UKCTOCS NNP N
. . N

-DOCSTART- -X- O O

No DT N
pain NN 1_o
relief NN 1_o
with IN N
the DT N
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
. . 1_i

The DT N
sense NN N
of IN N
body NN N
ownership NN N
can MD N
be VB N
easily RB N
disrupted VBN N
during IN N
illusions NNS N
and CC N
the DT N
most RBS N
common JJ N
illusion NN N
is VBZ N
the DT N
rubber JJ 1_i
hand NN 1_i
illusion NN 1_i
. . 1_i

An DT N
idea NN N
that WDT N
is VBZ N
rapidly RB N
gaining VBG N
popularity NN N
in IN N
clinical JJ N
pain NN N
medicine NN N
is VBZ N
that IN N
body NN 1_i
ownership NN 1_i
illusions NNS 1_i
can MD N
be VB N
used VBN N
to TO N
modify VB N
pathological JJ N
pain NN N
sensations NNS N
and CC N
induce VB N
analgesia NN N
. . N

However RB N
, , N
this DT N
idea NN N
has VBZ N
not RB N
been VBN N
empirically RB N
evaluated VBN N
. . N

Two CD N
separate JJ N
research NN N
laboratories NNS N
undertook VBP N
independent JJ N
randomized VBN N
repeated JJ N
measures NNS N
experiments NNS N
, , N
both DT N
designed VBN N
to TO N
detect VB N
an DT N
effect NN N
of IN N
the DT N
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
on IN N
experimentally RB N
induced JJ N
hand NN 1_o
pain NN 1_o
. . 1_o

In IN N
Experiment JJ N
1 CD N
, , N
16 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
rated VBD N
the DT N
pain NN 1_o
evoked VBN N
by IN N
noxious JJ 1_i
heat NN 1_i
stimuli NNS 1_i
( ( N
5 CD N
s NN N
duration NN N
; : N
interstimulus CC N
interval JJ N
25 CD N
s NN N
) ) N
of IN N
set NN N
temperatures NNS N
( ( N
47? CD N
, , N
48? CD N
and CC N
49?C CD N
) ) N
during IN N
the DT N
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
or CC 1_i
during IN 1_i
a DT 1_i
control JJ 1_i
condition NN 1_i
. . 1_i

There EX 1_i
was VBD N
a DT N
main JJ N
effect NN N
of IN N
stimulus JJ 1_o
temperature NN 1_o
on IN 1_o
pain NN 1_o
ratings NNS 1_o
, , 1_o
but CC 1_o
no DT N
main JJ 1_o
effect NN 1_o
of IN 1_o
condition NN 1_o
( ( 1_o
p JJ 1_o
= NNP N
0.32 CD N
) ) N
, , N
nor CC N
a DT 1_o
condition NN 1_o
x JJ 1_o
temperature NN 1_o
interaction NN 1_o
( ( 1_o
p JJ 1_o
= NNP N
0.31 CD 1_p
) ) 1_p
. . 1_p

In IN 1_p
Experiment JJ 1_p
2 CD 1_p
, , 1_p
20 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
underwent JJ 1_p
quantitative JJ N
sensory NN N
testing VBG N
to TO N
determine VB 1_o
heat NN 1_o
and CC 1_o
cold JJ 1_o
pain NN 1_o
thresholds NNS 1_o
during IN 1_o
the DT N
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
or CC 1_i
during IN N
a DT N
control JJ N
condition NN N
. . N

Secondary JJ N
analyses NNS N
involved VBN 1_o
heat NN 1_o
and CC 1_o
cold JJ 1_o
detection NN 1_o
thresholds NNS 1_o
and CC 1_o
paradoxical JJ 1_o
heat NN 1_o
sensations NNS 1_o
. . 1_o

Again NNP 1_o
, , N
there EX N
was VBD N
no DT N
main JJ 1_o
effect NN 1_o
of IN 1_o
condition NN 1_o
on IN 1_o
heat NN 1_o
pain NN 1_o
threshold NN 1_o
( ( 1_o
p JJ 1_o
= NNP N
0.17 CD N
) ) N
, , N
nor CC N
on IN N
cold JJ 1_o
pain NN 1_o
threshold NN 1_o
( ( 1_o
p JJ 1_o
= NNP N
0.65 CD N
) ) N
, , N
nor CC N
on IN N
any DT N
of IN N
the DT N
secondary JJ 1_o
measures NNS 1_o
( ( 1_o
p VB 1_o
< $ N
0.56 CD N
for IN N
all DT N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
does VBZ 1_i
not RB N
induce VB 1_o
analgesia NN 1_o
. . 1_o

-DOCSTART- -X- O O

Pharmacodynamic JJ N
effects NNS N
on IN N
biochemical JJ 1_o
markers NNS 1_o
of IN 1_o
bone NN 1_o
turnover NN 1_o
and CC 1_o
pharmacokinetics NNS 1_o
of IN N
the DT N
cathepsin NN 1_i
K NNP 1_i
inhibitor NN 1_i
, , 1_i
ONO-5334 NNP 1_i
, , N
in IN N
an DT N
ascending VBG N
multiple-dose NN N
, , N
phase NN N
1 CD N
study NN N
. . N

Selective JJ N
inhibitors NNS N
of IN N
cathepsin NN N
K NNP N
, , N
which WDT N
has VBZ N
a DT N
major JJ N
role NN N
in IN N
the DT N
degradation NN N
of IN N
bone NN N
collagen NN N
, , N
are VBP N
potential JJ N
new JJ N
treatments NNS N
for IN N
osteoporosis NN N
. . N

The DT N
pharmacokinetics NNS 1_o
and CC 1_o
the DT 1_o
pharmacodynamic JJ 1_o
effects NNS 1_o
on IN 1_o
biochemical JJ 1_o
markers NNS 1_o
of IN 1_o
bone NN 1_o
turnover NN 1_o
of IN N
the DT N
new JJ N
cathepsin NN 1_i
K NNP 1_i
inhibitor NN 1_i
, , 1_i
ONO-5334 NNP 1_i
, , N
were VBD N
investigated VBN N
in IN N
a DT N
multiple JJ N
ascending NN N
dose NN N
, , N
phase NN N
1 CD N
study NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
120 CD 1_p
healthy JJ 1_p
postmenopausal NN 1_p
women NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
and CC 1_p
doses NNS 1_i
of IN 1_i
10 CD 1_i
to TO 1_i
600 CD 1_i
mg NNS 1_i
once RB 1_i
daily JJ 1_i
and CC 1_i
50 CD 1_i
and CC 1_i
300 CD 1_i
mg NN 1_i
twice RB 1_i
daily RB 1_i
were VBD 1_i
evaluated VBN 1_i
in IN 1_i
15- JJ 1_i
and CC 1_i
28-day JJ 1_i
multiple-dosing JJ 1_i
cohorts NNS 1_i
. . 1_i

Plasma NNP N
ONO-5334 NNP N
concentration NN N
reached VBD N
steady JJ N
state NN N
within IN N
2 CD N
days NNS N
. . N

Twenty-four CD N
hours NNS N
after IN N
the DT N
last JJ N
dose NN N
in IN N
the DT N
15-day JJ N
multiple-dose JJ N
cohort NN N
, , N
100 CD N
, , N
300 CD N
, , N
and CC N
600 CD N
mg NN N
once RB N
daily RB N
reduced VBN N
urinary JJ 1_o
C-terminal JJ 1_o
telopeptide NN 1_o
of IN 1_o
type NN 1_o
I PRP 1_o
collagen VBP 1_o
by IN N
a DT N
mean NN N
( ( N
? . N
standard JJ N
deviation NN N
) ) N
44.9 CD N
% NN N
? . N
13.6 CD N
% NN N
, , N
84.5 CD N
% NN N
? . N
4.4 CD N
% NN N
, , N
and CC N
92.5 CD N
% NN N
? . N
1.3 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
28-day JJ N
cohort NN N
showed VBD N
similar JJ N
effects NNS N
. . N

There EX N
were VBD N
far RB N
smaller JJR N
effects NNS 1_o
on IN 1_o
bone-specific JJ 1_o
alkaline JJ 1_o
phosphatase NN 1_o
( ( 1_o
B-ALP NNP 1_o
) ) 1_o
, , 1_o
tartrate-resistant JJ 1_o
acid NN 1_o
phosphatase NN 1_o
5b CD 1_o
( ( 1_o
TRAP5b NNP 1_o
) ) 1_o
, , 1_o
or CC 1_o
osteocalcin NN 1_o
( ( 1_o
OC NNP 1_o
) ) 1_o
( ( 1_o
measured VBN 1_o
after IN N
28 CD N
days NNS N
) ) 1_i
. . 1_i

ONO-5334 NN 1_i
was VBD 1_i
well RB N
tolerated VBN N
up RP N
to TO N
600 CD N
mg/d NNS N
and CC N
for IN N
up RB N
to TO N
28 CD N
days NNS N
of IN N
multiple JJ N
dosing NN N
. . N

Multiple JJ N
dosing VBG N
with IN N
ONO-5334 NNP 1_i
100 CD 1_i
mg NN N
resulted VBD N
in IN N
considerable JJ N
suppression NN 1_o
of IN 1_o
bone NN 1_o
resorption NN 1_o
markers NNS 1_o
with IN 1_o
no DT N
appreciable JJ N
effects NNS 1_o
on IN 1_o
bone NN 1_o
formation NN 1_o
markers NNS 1_o
( ( 1_o
B-ALP NNP 1_o
, , 1_o
OC NNP 1_o
) ) 1_o
or CC 1_o
osteoclast JJ 1_o
number NN 1_o
( ( 1_o
TRAP5b NNP 1_o
) ) 1_o
. . 1_o

-DOCSTART- -X- O O

Closure NN N
of IN N
the DT N
femoral JJ N
artery NN N
after IN 1_p
cardiac JJ 1_p
catheterization NN 1_p
: : 1_p
a DT N
comparison NN N
of IN N
Angio-Seal NNP N
, , N
StarClose NNP N
, , N
and CC N
manual JJ N
compression NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
Angio-Seal NNP 1_i
( ( 1_i
AS NNP 1_i
) ) 1_i
and CC 1_i
StarClose NNP 1_i
( ( 1_i
SC NNP 1_i
) ) 1_i
and CC 1_i
manual JJ 1_i
compression NN 1_i
( ( 1_i
MC NNP 1_i
) ) 1_i
on IN N
efficacy NN 1_o
of IN 1_o
hemostasis NN 1_o
, , 1_o
complication NN 1_o
rate NN 1_o
, , 1_o
safety NN 1_o
of IN 1_o
early JJ 1_o
mobilization NN 1_o
, , 1_o
and CC 1_o
patient JJ 1_o
comfort NN 1_o
. . 1_o

BACKGROUND NNP N
Closure NNP N
of IN N
the DT N
femoral JJ N
artery NN N
after IN N
cardiac JJ N
catheterization NN N
can MD N
be VB N
obtained VBN N
through IN N
different JJ N
methods NNS N
. . N

Today NN N
, , N
physicians NNS N
can MD N
choose VB N
from IN N
a DT N
number NN N
of IN N
different JJ N
devices NNS N
to TO N
achieve VB N
arterial JJ N
closure NN N
. . N

METHODS NNP N
In IN 1_i
a DT 1_i
prospective JJ 1_i
trial NN 1_i
450 CD 1_p
patients NNS 1_p
were VBD 1_i
randomized VBN 1_i
to TO 1_i
AS NNP 1_i
, , 1_i
SC NNP 1_i
, , 1_i
or CC 1_i
MC NNP 1_i
. . 1_i

Patients NNS 1_i
were VBD 1_i
mobilized VBN 1_i
1 CD 1_i
to TO 1_i
2 CD 1_i
hr NN 1_i
after IN 1_i
device NN 1_i
placement NN 1_i
, , 1_i
and CC 1_i
6 CD 1_i
hr NN 1_i
after IN 1_i
MC NNP 1_i
. . 1_i

Data NNP N
were VBD N
collected VBN N
during IN N
hospital JJ N
admission NN N
and CC N
by IN N
telephone NN N
at IN N
one CD N
month NN N
after IN N
hospital JJ N
discharge NN N
. . N

RESULTS JJ N
Devices NNPS N
were VBD N
used VBN N
in IN N
138/150 CD N
allocated JJ N
to TO N
AS NNP N
and CC N
124/150 CD N
allocated VBN N
to TO N
SC NNP N
patients NNS N
( ( N
92 CD N
% NN N
vs. FW N
83 CD N
% NN N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
Patients NNS N
with IN N
MC NNP N
experienced VBD N
more JJR N
pain NN 1_o
during IN 1_o
sheath NN 1_o
removal NN 1_o
than IN N
patients NNS N
receiving VBG N
a DT N
device NN N
, , N
and CC N
rated VBD N
their PRP$ N
period NN 1_o
of IN 1_o
bed NN 1_o
rest NN 1_o
as IN N
less RBR N
comfortable JJ N
. . N

Oozing VBG 1_o
and CC 1_o
need VB 1_o
for IN 1_o
pressure NN 1_o
bandage NN 1_o
at IN 1_o
the DT 1_o
puncture NN 1_o
site NN 1_o
were VBD N
observed VBN N
in IN N
37 CD N
AS IN N
patients NNS N
and CC N
57 CD N
SC NNP N
patients NNS N
( ( N
25 CD N
% NN N
vs. FW N
38 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Hematoma NNP 1_o
occurred VBD N
in IN N
15 CD N
AS IN N
patients NNS N
, , N
in IN N
17 CD N
SC NNP N
patients NNS N
, , N
and CC N
in IN N
14 CD N
MC NNP N
patients NNS N
( ( N
11 CD N
vs. FW N
14 CD N
vs. FW N
9 CD N
% NN N
, , N
ns NN N
) ) N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
no DT N
difference NN N
in IN N
safety NN 1_o
between IN N
the DT N
three CD N
methods NNS N
of IN N
arterial JJ N
closure NN N
. . N

SC NNP N
was VBD N
more RBR N
often RB N
not RB N
used VBN N
or CC N
successfully RB N
deployed VBN N
. . N

SC JJ N
patients NNS N
more RBR N
often RB N
had VBD N
continuing VBG N
oozing VBG 1_o
. . 1_o

On IN N
patient JJ 1_o
comfort NN 1_o
, , N
closure NN N
devices NNS N
performed VBD N
better JJR N
than IN N
MC NNP N
. . N

Early JJ N
ambulation NN N
in IN N
patients NNS N
with IN N
a DT N
closure NN N
device NN N
is VBZ N
safe JJ N
. . N

AS NNP N
is VBZ N
the DT N
preferred JJ N
method NN N
of IN N
arterial JJ N
closure NN N
after IN N
cardiac JJ N
catheterization NN N
. . N

-DOCSTART- -X- O O

A DT N
single JJ N
infusion NN N
of IN N
intravenous JJ N
ketamine NN 1_i
improves VBZ N
pain VBP N
relief NN N
in IN N
patients NNS 1_p
with IN 1_p
critical JJ 1_p
limb NN 1_p
ischaemia NN 1_p
: : 1_p
results NNS N
of IN N
a DT N
double JJ N
blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

We PRP N
report VBP N
the DT N
first JJ N
double JJ N
blind NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
regular JJ N
opioids NNS 1_i
and CC N
an DT N
infusion NN N
of IN N
low JJ N
dose NN N
( ( N
0.6 CD N
mg/kg NN N
) ) N
intravenous JJ N
ketamine NN 1_i
compared VBN N
with IN N
opioids NNS 1_i
and CC N
placebo NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
allodynia NN 1_p
, , 1_p
hyperalgesia NN 1_p
and CC 1_p
hyperpathia NN 1_p
secondary JJ 1_p
to TO 1_p
critical JJ 1_p
limb NN 1_p
ischaemia NN 1_p
. . 1_p

Thirty-five JJ 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
, , 1_p
18 CD 1_p
received VBD N
regular JJ N
opioids NNS 1_i
plus CC 1_i
ketamine NN 1_i
, , N
while IN N
17 CD 1_p
received VBD N
regular JJ 1_i
opioids NNS 1_i
plus CC 1_i
placebo NN 1_i
. . 1_i

Using VBG N
the DT N
Brief NNP 1_o
Pain NNP 1_o
Inventory NNP 1_o
, , 1_o
the DT 1_o
% NN 1_o
pain NN 1_o
relief NN 1_o
that IN N
the DT N
patients NNS N
in IN N
the DT N
ketamine NN N
group NN N
attributed VBD N
to TO N
their PRP$ N
medication NN N
improved VBN N
significantly RB N
from IN N
50 CD N
% NN N
immediately RB N
pre-infusion NN N
to TO N
65 CD N
% NN N
24 CD N
h JJ N
post-infusion NN N
and CC N
69 CD N
% NN N
5 CD N
days NNS N
post VBN N
infusion NN N
. . N

Over IN N
the DT N
same JJ N
period NN N
, , N
the DT N
pain NN 1_o
relief NN 1_o
achieved VBN 1_o
by IN N
the DT N
placebo NN N
group NN N
rose VBD N
from IN N
58 CD N
% NN N
pre-infusion NN N
to TO N
56 CD N
% NN N
24 CD N
h NN N
post NN N
infusion NN N
and CC N
then RB N
50 CD N
% NN N
relief NN N
5 CD N
days NNS N
later RB N
. . N

This DT N
was VBD N
statistically RB 1_o
significant JJ 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
using VBG N
both DT N
the DT N
t-test NN 1_o
and CC 1_o
the DT 1_o
Wilcoxon NNP 1_o
Rank NNP 1_o
Sum NNP 1_o
test NN 1_o
. . 1_o

The DT N
ketamine NN N
group NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
24 CD N
h NN N
post NN N
infusion NN N
of IN N
the DT N
effect NN N
of IN N
pain NN 1_o
on IN N
their PRP$ N
general JJ N
activity NN N
( ( N
P=0.03 NNP N
) ) N
and CC N
on IN N
their PRP$ N
enjoyment NN N
of IN N
life NN N
( ( N
P=0.004 NNP N
) ) N
. . N

This DT N
study NN N
shows VBZ N
that IN N
combining VBG N
a DT N
single JJ N
infusion NN N
of IN N
low JJ N
dose JJ N
ketamine NN N
with IN N
regular JJ N
opioid JJ 1_i
analgesia NN 1_i
can MD N
result VB N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
pain NN 1_o
relief NN 1_o
for IN N
this DT N
patient NN N
group NN N
. . N

-DOCSTART- -X- O O

Body NN N
size NN N
indexes NNS N
for IN N
optimizing VBG N
iodine NN 1_i
dose NN N
for IN N
aortic JJ 1_p
and CC 1_p
hepatic JJ 1_p
enhancement NN 1_p
at IN 1_p
multidetector NN 1_p
CT NNP 1_p
: : 1_p
comparison NN N
of IN N
total JJ N
body NN N
weight NN N
, , N
lean JJ N
body NN N
weight NN N
, , N
and CC N
blood NN N
volume NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
and CC N
compare VB N
total JJ 1_o
body NN 1_o
weight NN 1_o
( ( 1_o
TBW NNP 1_o
) ) 1_o
, , 1_o
lean JJ 1_o
body NN 1_o
weight NN 1_o
( ( 1_o
LBW NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
estimated VBD 1_o
blood NN 1_o
volume NN 1_o
( ( 1_o
BV NNP 1_o
) ) 1_o
for IN N
the DT N
adjustment NN N
of IN N
the DT N
iodine NN 1_i
dose NN 1_i
required VBN N
for IN N
contrast NN N
material-enhanced JJ N
multidetector NN N
computed VBD N
tomography NN N
( ( N
CT NNP N
) ) N
of IN N
the DT N
aorta NN N
and CC N
liver NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Institutional NNP N
review NN N
committee NN N
approval NN N
and CC N
written VBN N
informed JJ N
consent NN N
were VBD N
obtained VBN N
. . N

One CD 1_p
hundred VBD 1_p
twenty NN 1_p
patients NNS 1_p
( ( 1_p
54 CD 1_p
men NNS 1_p
, , 1_p
66 CD 1_p
women NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
64.1 CD 1_p
years NNS 1_p
; : 1_p
range NN 1_p
, , 1_p
19-88 CD 1_p
years NNS 1_p
) ) 1_p
who WP 1_p
underwent JJ 1_p
multidetector NN 1_i
CT NNP 1_i
of IN 1_p
the DT 1_p
upper JJ 1_p
abdomen NNS 1_p
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
of IN N
40 CD N
patients NNS N
each DT N
: : N
( ( N
a DT N
) ) N
TBW NNP N
group NN N
( ( N
0.6 CD N
g NN N
of IN N
iodine NN 1_i
per IN N
kilogram NN N
of IN N
TBW NNP N
) ) N
, , N
( ( N
b NN N
) ) N
LBW NNP N
group NN N
( ( N
0.821 CD N
g NN N
of IN N
iodine NN 1_i
per IN N
kilogram NN N
of IN N
LBW NNP N
) ) N
, , N
and CC N
( ( N
c NN N
) ) N
BV NNP N
group NN N
( ( N
men NNS N
, , N
8.6 CD N
g NN N
of IN N
iodine NN 1_i
per IN N
liter NN N
of IN N
BV NNP N
; : N
women NNS N
, , N
9.9 CD N
g NN N
of IN N
iodine NN N
per IN N
liter NN N
of IN N
BV NNP N
) ) N
. . N

Change NN N
in IN N
CT NNP N
number NN N
between IN N
unenhanced JJ N
and CC N
contrast-enhanced JJ N
images NNS N
per IN N
gram NN N
of IN N
iodine NN N
and CC N
maximum JJ N
hepatic JJ N
enhancement NN N
( ( N
MHE NNP N
) ) N
adjusted VBD N
for IN N
iodine NN 1_i
dose NN N
were VBD N
examined VBN N
for IN N
correlation NN N
with IN N
TBW NNP N
, , N
LBW NNP N
, , N
and CC N
BV NNP N
by IN N
using VBG N
linear JJ N
regression NN N
analysis NN N
. . N

RESULTS NNP N
In IN N
the DT N
portal JJ N
venous JJ N
phase NN N
, , N
correlation NN 1_o
coefficients NNS 1_o
for IN N
the DT N
correlation NN 1_o
of IN 1_o
change NN 1_o
in IN 1_o
CT NNP 1_o
number NN 1_o
per IN 1_o
gram NN 1_o
of IN N
iodine NN 1_i
with IN N
TBW NNP 1_o
for IN N
the DT N
aorta NN N
and CC N
liver NN N
were VBD N
-0.71 NNP N
and CC N
-0.79 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
TBW NNP N
group NN N
; : N
-0.80 CC N
and CC N
-0.86 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
LBW NNP N
group NN N
; : N
and CC N
-0.68 VB N
and CC N
-0.66 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
BV NNP N
group NN N
. . N

In IN N
the DT N
liver NN N
, , N
they PRP N
were VBD N
marginally RB N
higher JJR N
in IN N
the DT N
LBW NNP N
group NN N
than IN N
in IN N
the DT N
BV NNP N
group NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Adjusted VBN 1_o
MHE NNP 1_o
remained VBD N
constant JJ N
at IN N
77.9 CD N
HU NNP N
+/- JJ N
10.2 CD N
( ( N
standard JJ N
deviation NN N
) ) N
in IN N
the DT N
LBW NNP 1_o
group NN N
with IN N
respect NN N
to TO N
TBW NNP 1_o
, , N
but CC N
it PRP N
increased VBD N
in IN N
the DT N
TBW NNP 1_o
( ( N
r VB N
= RB N
0.80 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
BV NNP 1_o
( ( N
r VB N
= RB N
0.70 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
groups NNS N
as IN N
TBW NNP 1_o
increased VBD N
. . N

CONCLUSION NN N
When WRB 1_o
LBW NNP 1_o
, , 1_o
rather RB 1_o
than IN 1_o
TBW NNP 1_o
or CC 1_o
BV NNP 1_o
, , 1_o
is VBZ 1_o
used VBN 1_o
, , N
the DT N
iodine NN 1_i
dose NN N
required VBN N
to TO N
achieve VB N
consistent JJ N
hepatic JJ N
enhancement NN N
may MD N
be VB N
estimated VBN N
more RBR N
precisely RB N
and CC N
with IN N
reduced JJ N
patient-to-patient JJ N
variability NN N
. . N

-DOCSTART- -X- O O

A DT N
randomised JJ N
double-blind NN N
control NN N
study NN N
of IN N
early JJ N
intracoronary JJ 1_i
autologous JJ 1_i
bone NN 1_i
marrow NN 1_i
cell NN 1_i
infusion NN 1_i
in IN N
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( N
REGENERATE-AMI NNP N
) ) N
. . N

INTRODUCTION NNP N
Acute NNP N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
remains VBZ N
a DT N
major JJ N
cause NN N
of IN N
mortality NN N
and CC N
morbidity NN N
worldwide VBP N
despite IN N
the DT N
latest JJS N
therapeutic JJ N
advances NNS N
designed VBN N
to TO N
decrease VB N
myocardial JJ N
injury NN N
. . N

Preclinical NNP N
and CC N
emerging VBG N
clinical JJ N
evidence NN N
show NN N
that IN N
the DT N
intracoronary JJ N
injection NN N
of IN N
autologous JJ 1_i
bone NN 1_i
marrow NN 1_i
mononuclear JJ 1_i
cells NNS 1_i
( ( N
BMCs NNP N
) ) N
following VBG N
AMI NNP N
leads VBZ N
to TO N
improvement NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
function NN N
( ( N
LVEF NNP N
) ) N
. . N

In IN N
this DT N
clinical JJ N
trial NN N
we PRP N
will MD N
for IN N
the DT N
first JJ N
time NN N
assess VB N
the DT N
effect NN 1_o
of IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
infusion NN N
of IN N
autologous JJ N
BMCs NNP N
following VBG N
AMI NNP N
on IN N
cardiac JJ N
function NN N
. . N

METHODS NNP N
AND CC N
ANALYSIS NNP N
REGENERATE-AMI NNP N
is VBZ N
a DT N
double-blind JJ N
, , N
randomised VBN N
, , N
multicentre FW 1_p
, , N
placebo-controlled JJ 1_i
trial NN N
to TO N
determine VB N
whether IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
intracoronary JJ N
infusion NN N
of IN N
BMCs NNP N
improves NNS N
LVEF NNP N
after IN N
AMI NNP N
. . N

The DT N
study NN N
will MD N
enrol VB 1_p
100 CD 1_p
patients NNS 1_p
presenting VBG 1_p
with IN 1_p
an DT 1_p
anterior JJ 1_p
AMI NNP 1_p
demonstrating VBG 1_p
anterior JJ 1_p
regional JJ 1_p
wall NN 1_p
motion NN 1_p
abnormality NN 1_p
. . 1_p

Patients NNS N
will MD N
be VB N
randomised VBN N
to TO N
receive VB N
intracoronary JJ 1_i
infusion NN 1_i
of IN 1_i
BMCs NNP 1_i
or CC N
placebo NN 1_i
( ( N
0.9 CD N
% NN N
saline NN 1_i
) ) 1_i
. . N

Primary JJ N
endpoint NN N
will MD N
be VB N
change NN 1_o
in IN 1_o
LVEF NNP 1_o
at IN 1_o
1 CD 1_o
year NN 1_o
compared VBN 1_o
to TO 1_o
baseline VB 1_o
, , 1_o
measured VBN 1_o
by IN 1_o
cardiac JJ 1_o
MRI NNP 1_o
. . 1_o

Secondary JJ N
endpoints NNS N
at IN N
6 CD N
months NNS N
include VBP N
the DT N
change NN 1_o
in IN 1_o
global JJ 1_o
LVEF NNP 1_o
relative NN 1_o
to TO 1_o
baseline VB 1_o
measured VBN 1_o
by IN 1_o
quantitative JJ 1_o
left NN 1_o
ventriculography NN 1_o
and CC 1_o
echocardiography NN 1_o
, , 1_o
as RB 1_o
well RB 1_o
as IN 1_o
major JJ 1_o
adverse JJ 1_o
cardiac NN 1_o
events NNS 1_o
which WDT N
is VBZ N
also RB N
measured VBN N
at IN N
1 CD N
year NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
The DT N
study NN N
will MD N
be VB N
performed VBN N
in IN N
agreement NN N
with IN N
the DT N
Declaration NNP N
of IN N
Helsinki NNP N
and CC N
is VBZ N
approved VBN N
by IN N
local JJ N
ethics NNS N
committee NN N
( ( N
NRES NNP N
Committee NNP N
London NNP N
West NNP N
London NNP N
: : N
07/Q0603/76 CD N
) ) N
. . N

TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//clincialtrials.gov NN N
( ( N
NCT00765453 NNP N
) ) N
. . N

The DT N
results NNS N
of IN N
the DT N
trial NN N
will MD N
be VB N
published VBN N
according VBG N
to TO N
the DT N
CONSORT NNP N
statement NN N
and CC N
will MD N
be VB N
presented VBN N
at IN N
conferences NNS N
and CC N
reported VBD N
in IN N
peer-reviewed JJ N
journals NNS N
. . N

-DOCSTART- -X- O O

Iloprost NN 1_i
in IN N
cardiopulmonary JJ N
bypass NN N
procedures NNS N
. . N

The DT N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
during IN N
cardiopulmonary JJ 1_p
bypass NN 1_p
and CC N
effects NNS N
on IN N
post-operative JJ 1_p
placebo-controlled JJ 1_i
study NN 1_p
of IN 1_p
145 CD 1_p
patients NNS 1_p
. . 1_p

Significant JJ N
preservation NN N
of IN N
platelet NN N
numbers NNS N
and CC N
function NN N
were VBD N
shown VBN N
without IN N
significant JJ N
haemodynamic JJ N
problems NNS N
, , N
but CC N
no DT N
effect NN N
on IN N
cerebral JJ N
deficits NNS N
could MD N
be VB N
found VBN N
. . N

The DT N
use NN N
of IN N
iloprost NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
thrombocytopenia NN 1_p
seems VBZ N
justified JJ N
, , N
but CC N
the DT N
clinical JJ N
benefits NNS N
from IN N
its PRP$ N
use NN N
in IN N
routine JJ N
cardiopulmonary JJ N
bypass NN N
remain NN N
to TO N
be VB N
shown VBN N
. . N

-DOCSTART- -X- O O

Can MD N
analysis NN N
of IN N
the DT N
bispectral JJ N
index NN N
prove VB N
helpful JJ N
when WRB N
monitoring VBG N
titration NN N
of IN N
doses NNS N
of IN N
midazolam NN 1_i
and CC N
ketamine NN 1_i
for IN N
sedation NN N
during IN N
paediatric JJ 1_o
cardiac JJ 1_o
catheterization NN 1_o
. . 1_o

OBJECTIVE IN N
We PRP N
investigated VBD N
the DT N
use NN N
of IN N
the DT N
bispectral JJ 1_i
index NN 1_i
for IN N
monitoring VBG N
sedation NN 1_i
during IN N
cardiac JJ 1_o
catheterization NN 1_o
. . 1_o

The DT N
scores NNS N
for IN N
the DT N
bispectral JJ N
index NN N
may MD N
not RB N
reflect VB N
correct JJ N
values NNS N
in IN N
children NNS N
, , N
but CC N
may MD N
be VB N
helpful JJ N
during IN N
titration NN N
of IN N
sedatives NNS N
such JJ N
as IN N
midazolam NN 1_i
and CC 1_i
ketamine NN 1_i
. . 1_i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
in IN N
126 CD 1_p
patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
cardiac JJ 1_p
catheterization NN 1_p
in IN 1_p
a DT 1_p
teaching JJ 1_p
hospital NN 1_p
. . 1_p

They PRP 1_p
ranged VBD 1_p
in IN 1_p
age NN 1_p
from IN 1_p
4 CD 1_p
months NNS 1_p
to TO 1_p
15 CD 1_p
years NNS 1_p
. . 1_p

In IN N
66 CD N
patients NNS N
, , N
sedation NN 1_i
was VBD N
performed VBN N
without IN 1_i
use NN 1_i
of IN 1_i
the DT 1_i
bispectral JJ 1_i
index NN 1_i
, , 1_i
while IN 1_i
the DT 1_i
index NN 1_i
was VBD 1_i
used VBN 1_i
in IN 1_i
the DT 1_i
other JJ 1_i
60 CD N
patients NNS N
. . N

The DT N
data NN N
collected VBD N
included JJ N
heart NN N
rate NN N
, , N
mean VBP N
arterial JJ N
pressure NN N
, , N
respiratory NN N
rate NN N
, , N
saturation NN N
of IN N
oxygen NN N
, , N
amount NN N
of IN N
sedatives NNS N
, , N
awakening VBG N
time NN N
and CC N
adverse JJ N
effects NNS N
. . N

We PRP N
subdivided VBD N
the DT N
patients NNS N
into IN N
age-related JJ N
groups NNS N
for IN N
each DT N
parameter NN N
. . N

RESULTS VB N
The DT N
demographic JJ N
data NNS N
were VBD N
not RB N
statistically RB N
different JJ N
. . N

Monitoring VBG N
with IN N
the DT N
bispectral JJ N
index NN N
in IN N
those DT N
aged VBN N
from IN N
1 CD N
to TO N
3 CD N
years NNS N
revealed VBD N
use NN N
of IN N
lower JJR N
doses NNS N
of IN N
midazolam NN N
, , N
at IN N
2.09 CD N
mg NNS N
per IN N
kg NN N
per IN N
hr NN N
, , N
with IN N
standard JJ N
deviation NN N
of IN N
0.36 CD N
, , N
and CC N
similarly RB N
lowers NNS N
doses NNS N
of IN N
ketamine NN N
, , N
at IN N
2.07 CD N
mg NNS N
per IN N
kg NN N
per IN N
hr NN N
, , N
with IN N
standard JJ N
deviation NN N
of IN N
0.22 CD N
, , N
the DT N
values NNS N
in IN N
those DT N
not RB N
monitored VBN N
being VBG N
2.93 CD N
, , N
with IN N
standard JJ N
deviation NN N
of IN N
0.45 CD N
, , N
and CC N
2.96 CD N
with IN N
standard JJ N
deviation NN N
of IN N
0.51 CD N
respectively RB N
, , N
these DT N
difference NN N
being VBG N
statistically RB N
significant JJ N
( ( N
p JJ N
= NN N
0.001 CD N
and CC N
p VB N
= JJ N
0.04 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
those DT N
aged VBN 1_p
from IN 1_p
3 CD 1_p
to TO 1_p
6 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
dosage NN N
of IN N
midazolam NN N
was VBD N
2.09 CD N
, , N
with IN N
deviation NN N
of IN N
0.36 CD N
, , N
and CC N
of IN N
ketamine NN N
1.78 CD N
, , N
with IN N
deviation NN N
of IN N
0.27 CD N
, , N
following VBG N
use NN N
of IN N
the DT N
bispectral JJ N
index NN N
, , N
compared VBN N
to TO N
2.89 CD N
with IN N
deviation NN N
of IN N
0.28 CD N
, , N
and CC N
2.62 CD N
with IN N
deviation NN N
of IN N
0.69 CD N
respectively RB N
, , N
when WRB N
the DT N
bispectral JJ N
index NN N
was VBD N
not RB N
used VBN N
, , N
these DT N
again RB N
being VBG N
significant JJ N
differences NNS N
( ( N
p JJ N
= NN N
0.033 CD N
and CC N
p VB N
= NNP N
0.04 CD N
) ) N
. . N

The DT 1_o
requirements NNS 1_o
for IN 1_o
respiratory JJ 1_o
support NN 1_o
and CC 1_o
adverse JJ 1_o
effects NNS 1_o
were VBD N
also RB N
significantly RB N
lower JJR N
when WRB N
using VBG N
the DT N
bispectral JJ N
index NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
regarding VBG N
dosages NNS N
at IN N
the DT N
ages NNS N
of IN N
4 CD N
months NNS N
to TO N
1 CD N
year NN N
, , N
and CC N
6 CD N
to TO N
15 CD N
years NNS N
. . N

The DT 1_o
awakening JJ 1_o
time NN 1_o
, , N
however RB N
, , N
was VBD N
shorter NN N
with IN N
use NN N
of IN N
the DT N
index NN N
in IN N
those DT N
aged VBN N
from IN N
1 CD N
to TO N
6 CD N
years NNS N
. . N

CONCLUSIONS NN N
When WRB N
using VBG N
the DT N
bispectral JJ N
index NN N
for IN N
monitoring VBG N
sedation NN N
during IN N
catheterization NN N
in IN N
children NNS 1_p
, , N
we PRP N
noted VBD N
decreased JJ 1_o
need NN 1_o
for IN 1_o
doses NNS 1_o
of IN 1_o
midazolam NN 1_o
and CC 1_o
ketamine NN 1_o
, , N
a DT N
lower JJR 1_o
need NN 1_o
for IN 1_o
respiratory JJ 1_o
support NN 1_o
and CC 1_o
less JJR 1_o
adverse JJ 1_o
effects NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Carboplatin NNP 1_i
and CC 1_i
pegylated VBN 1_i
liposomal JJ 1_i
doxorubicin NN 1_i
versus NN N
carboplatin NN 1_i
and CC 1_i
paclitaxel NN 1_i
in IN N
very RB 1_p
platinum-sensitive JJ 1_p
ovarian JJ 1_p
cancer NN 1_p
patients NNS 1_p
: : 1_p
results NNS N
from IN N
a DT N
subset JJ 1_p
analysis NN 1_p
of IN 1_p
the DT 1_p
CALYPSO NNP 1_p
phase NN 1_p
III NNP 1_p
trial NN 1_p
. . 1_p

AIM NNP N
To TO N
perform VB N
a DT N
subset JJ N
analysis NN N
of IN N
patients NNS 1_p
with IN 1_p
very RB 1_p
platinum-sensitive JJ 1_p
recurrent NN 1_p
ovarian JJ 1_p
cancer NN 1_p
( ( 1_p
ROC NNP 1_p
) ) 1_p
enrolled VBD 1_p
in IN 1_p
the DT 1_p
phase NN 1_p
III NNP 1_p
CALYPSO NNP 1_p
trial NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT 1_p
international JJ 1_p
non-inferiority JJ 1_p
trial NN 1_p
enrolled VBD 1_p
women NNS 1_p
with IN 1_p
ROC NNP 1_p
that WDT 1_p
relapsed VBD 1_p
> $ 1_p
6 CD 1_p
months NNS 1_p
following VBG 1_p
first- JJ 1_p
or CC 1_p
second-line JJ 1_p
platinum- JJ 1_i
and CC 1_i
paclitaxel-based JJ 1_i
therapies NNS 1_i
. . 1_i

Patients NNS N
were VBD N
randomised VBN N
to TO N
CD VB 1_i
[ JJ 1_i
carboplatin-pegylated JJ 1_i
liposomal JJ 1_i
doxorubicin NN 1_i
( ( 1_i
PLD NNP 1_i
) ) 1_i
] VBD 1_i
or CC 1_i
CP NNP 1_i
( ( 1_i
carboplatin-paclitaxel NN 1_i
) ) 1_i
and CC N
stratified VBN N
by IN N
treatment-free JJ N
interval NN N
( ( N
TFI NNP N
) ) N
. . N

In IN N
this DT N
analysis NN N
, , N
patients NNS 1_p
with IN 1_p
a DT 1_p
TFI NNP 1_p
> NNP 1_p
24 CD 1_p
months NNS 1_p
were VBD N
analysed VBN N
separately RB N
for IN N
progression NN N
free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
the DT N
primary JJ N
endpoint NN N
of IN N
CALYPSO NNP N
, , N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
and CC N
safety NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
259 CD 1_p
very RB 1_p
platinum-sensitive JJ 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
( ( 1_p
n=131 UH 1_p
, , 1_p
CD NNP 1_p
; : 1_p
n=128 RB 1_p
, , 1_p
CP NNP 1_p
) ) 1_p
. . 1_p

Median JJ 1_o
PFS NNP 1_o
was VBD N
12.0 CD N
months NNS N
for IN N
the DT N
CD NN 1_i
arm NN N
and CC N
12.3 CD N
months NNS N
for IN N
CP NNP 1_i
[ NNP N
HR=1.05 NNP N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.79-1.40 NNP N
) ) N
; : N
P=0.73 NNP N
for IN N
superiority NN N
] NNP N
and CC N
median JJ 1_o
OS NNP 1_o
was VBD N
40.2 CD N
months NNS N
for IN N
CD NN N
and CC N
43.9 CD N
for IN N
CP NNP N
[ NNP N
HR=1.18 NNP N
( ( N
95 CD N
% NN N
CI NNP N
0.85-1.63 NN N
) ) N
; : N
P=0.33 NNP N
for IN N
superiority NN N
] NNP N
. . N

Overall JJ N
response NN 1_o
rates NNS 1_o
were VBD N
42 CD N
% NN N
and CC N
38 CD N
% NN N
, , N
respectively RB N
( ( N
P=0.46 NNP N
) ) N
. . N

Toxicities NNPS 1_o
were VBD N
more RBR N
common JJ N
with IN N
CP NNP 1_i
versus NN N
CD NN 1_i
, , N
including VBG N
grade NN 1_o
3/4 CD 1_o
neutropenia NN 1_o
( ( N
40.8 CD N
% NN N
versus IN N
27.5 CD N
% NN N
; : N
P=0.025 NNP N
) ) N
, , N
nausea NN 1_o
( ( N
4.8 CD N
% NN N
versus IN N
3.1 CD N
% NN N
; : N
P=0.47 NNP N
) ) N
, , N
allergic JJ 1_o
reaction NN 1_o
( ( N
8 CD N
% NN N
versus IN N
3.1 CD N
% NN N
; : N
P=0.082 NNP N
) ) N
sensory NN 1_o
neuropathy JJ 1_o
( ( N
4.8 CD N
% NN N
versus IN N
2.3 CD N
% NN N
; : N
P=0.27 NNP N
) ) N
and CC N
grade $ 1_o
2 CD 1_o
alopecia NN 1_o
( ( N
88 CD N
% NN N
versus IN N
9.2 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Grade $ 1_o
3/4 CD 1_o
thrombocytopenia NN 1_o
( ( N
12.2 CD N
% NN N
versus IN N
3.2 CD N
% NN N
; : N
P=0.007 NNP N
) ) N
and CC N
mucositis NN 1_o
( ( N
2.3 CD N
% NN N
versus IN N
0 CD N
% NN N
; : N
P=0.089 NNP N
) ) N
were VBD N
more RBR N
common JJ N
with IN N
CD NNP 1_i
. . 1_i

Grade VB 1_o
3/4 CD 1_o
hand-foot JJ 1_o
syndrome NN 1_o
occurred VBD N
rarely RB N
with IN N
CD NNP 1_i
( ( N
3 CD N
patients NNS N
versus JJ N
0 CD N
in IN N
CP NNP N
arm NN N
; : N
P=0.089 NNP N
) ) N
. . N

CONCLUSION NNP N
CP NNP N
and CC N
CD NNP N
were VBD N
equally RB N
effective JJ N
treatment NN N
regimens NNS N
for IN N
patients NNS 1_p
with IN 1_p
very RB 1_p
platinum-sensitive JJ 1_p
ROC NNP 1_p
. . 1_p

The DT N
favourable JJ N
risk-benefit JJ N
profile NN N
suggests VBZ N
carboplatin-PLD NN 1_i
as IN N
treatment NN N
of IN N
choice NN N
for IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Perception NN N
of IN N
social JJ 1_o
interactions NNS 1_o
in IN N
depressed JJ 1_p
psychiatric JJ 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Effect NN N
of IN N
marine NN 1_i
oils NNS 1_i
supplementation NN 1_i
on IN N
coagulation NN N
and CC N
cellular JJ N
activation NN N
in IN N
whole JJ N
blood NN N
. . N

A DT N
study NN N
was VBD N
performed VBN N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
supplemental JJ N
intake NN N
of IN N
various JJ N
marine NN N
oils NNS N
known VBN N
to TO N
be VB N
part NN N
of IN N
the DT N
Eskimo NNP 1_p
diet NN 1_p
. . 1_p

Healthy JJ 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
( ( 1_p
134 CD 1_p
) ) 1_p
were VBD N
randomly RB N
selected VBN N
to TO N
consume VB N
15 CD N
mL/d NN N
of IN N
oil NN 1_i
from IN 1_i
blubber NN 1_i
of IN 1_i
seal NN 1_i
, , 1_i
cod NN 1_i
liver NN 1_i
, , 1_i
seal/cod NN 1_i
liver NN 1_i
, , 1_i
blubber NN 1_i
of IN 1_i
Minke NNP 1_i
whale NN 1_i
, , 1_i
or CC 1_i
no DT 1_i
oil NN 1_i
for IN N
ten JJ N
weeks NNS N
. . N

Total JJ 1_o
cholesterol NN 1_o
was VBD N
unchanged JJ N
in IN N
the DT N
oil NN N
groups NNS N
, , N
whereas RB N
high JJ 1_o
density NN 1_o
lipoprotein VBP 1_o
cholesterol NN 1_o
increased VBD N
7 CD N
% NN N
in IN N
the DT N
seal/cod NN 1_i
liver NN 1_i
oil NN 1_i
( ( N
CLO NNP N
) ) N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
11 CD N
% NN N
in IN N
the DT N
whale JJ 1_i
oil NN 1_i
group NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

Triacylglycerol NNP 1_o
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
CLO NNP N
group NN N
only RB N
. . N

The DT N
concentration NN 1_o
of IN 1_o
prothrombin JJ 1_o
fragment JJ 1_o
1 CD 1_o
+ JJ 1_o
2 CD 1_o
was VBD N
reduced VBN N
25 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
after IN N
whale JJ N
oil NN N
supplementation NN N
. . N

No DT N
change NN N
in IN N
fibrinogen NN 1_o
or CC 1_o
factor NN 1_o
VIIc NNP 1_o
was VBD N
detected VBN N
. . N

Tumor NNP 1_o
necrosis NN 1_o
factor NN 1_o
generation NN 1_o
in IN 1_o
lipopolysaccharide NN 1_o
( ( 1_o
LPS NNP 1_o
) ) 1_o
-stimulated VBD 1_o
blood NN 1_o
was VBD N
30 CD N
% NN N
reduced VBN N
after IN N
whale JJ N
oil NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
was VBD N
unaffected VBN N
by IN N
intake NN N
of IN N
seal NN N
or CC N
CLO NNP N
. . N

The DT N
LPS-induced JJ 1_o
tissue NN 1_o
factor NN 1_o
activity NN 1_o
in IN 1_o
monocytes NNS 1_o
was VBD N
reduced VBN N
to TO N
a DT N
significant JJ N
degree NN N
only RB N
in IN N
the DT N
seal/CLO NN N
group NN N
( ( N
34 CD N
% NN N
) ) N
and CC N
whale JJ N
oil NN N
group NN N
( ( N
35 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
most RBS N
dramatic JJ N
change NN N
in IN N
thromboxane NN 1_o
B2 NNP 1_o
in IN N
LPS-stimulated NNP N
blood NN N
was VBD N
seen VBN N
after IN N
whale JJ N
oil NN N
intake NN N
with IN N
44 CD N
% NN N
reduction NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Supplementation NN N
of IN N
a DT N
regular JJ N
diet NN N
with IN N
a DT N
combination NN N
of IN N
seal JJ N
oil NN N
and CC N
CLO NNP N
and CC N
especially RB N
with IN N
whale JJ N
oil NN N
seems VBZ N
to TO N
have VB N
beneficial JJ N
effects NNS N
on IN N
several JJ N
products NNS N
thought VBN N
to TO N
be VB N
associated VBN N
with IN N
cardiovascular JJ N
and CC N
thrombotic JJ N
diseases NNS N
. . N

-DOCSTART- -X- O O

Noradrenergic NNP 1_p
mechanisms NNS 1_p
in IN 1_p
akathisia NN 1_p
: : 1_p
treatment NN 1_p
with IN 1_p
propranolol NN 1_i
and CC 1_i
clonidine NN 1_i
. . 1_i

-DOCSTART- -X- O O

Laryngeal JJ N
preservation NN N
with IN N
induction NN 1_i
chemotherapy NN 1_i
for IN N
hypopharyngeal NN 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
: : 1_p
10-year JJ N
results NNS N
of IN N
EORTC NNP N
trial NN N
24891 CD N
. . N

BACKGROUND NNP N
We PRP N
report VBP N
the DT N
10-year JJ N
results NNS N
of IN N
the DT N
EORTC NNP N
trial NN N
24891 CD N
comparing VBG N
a DT N
larynx-preservation JJ 1_i
approach NN 1_i
to TO 1_p
immediate VB 1_i
surgery NN 1_i
in IN 1_p
hypopharynx NN 1_p
and CC 1_p
lateral JJ 1_p
epilarynx NN 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
. . 1_p

MATERIAL NNP N
AND CC N
METHODS NNP N
Two CD 1_p
hundred CD 1_p
and CC 1_p
two CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
surgical JJ N
approach NN N
( ( 1_i
total JJ 1_i
laryngectomy NN 1_i
with IN 1_i
partial JJ 1_i
pharyngectomy NN 1_i
and CC 1_i
neck NN 1_i
dissection NN 1_i
, , 1_i
followed VBN 1_i
by IN 1_i
irradiation NN 1_i
) ) 1_i
or CC 1_i
to TO 1_i
the DT 1_i
chemotherapy NN 1_i
arm NN 1_i
up IN 1_i
to TO 1_i
three CD 1_i
cycles NNS 1_i
of IN 1_i
induction NN 1_i
chemotherapy NN 1_i
( ( 1_i
cisplatin JJ 1_i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
+ CD N
5-FU JJ N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1-5 JJ N
) ) N
followed VBD N
for IN N
complete JJ N
responders NNS N
by IN N
irradiation NN 1_i
and CC N
otherwise RB N
by IN N
conventional JJ 1_i
treatment NN 1_i
. . 1_i

The DT N
end NN N
points NNS N
were VBD N
overall JJ 1_o
survival JJ 1_o
[ NN N
OS NNP N
, , N
noninferiority NN N
: : N
hazard NN N
ratio NN N
( ( N
preservation/surgery NN N
) ) N
? . N
1.428 CD N
, , N
one-sided JJ N
? . N
= $ N
0.05 CD 1_o
] NNP 1_o
, , 1_o
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
and CC 1_o
survival JJ 1_o
with IN 1_o
a DT 1_o
functional JJ 1_o
larynx NN 1_o
( ( 1_o
SFL NNP 1_o
) ) 1_o
. . 1_o

RESULTS NNP 1_o
At IN N
a DT N
median JJ N
follow-up NN N
of IN N
10.5 CD N
years NNS N
on IN N
194 CD 1_p
eligible JJ 1_p
patients NNS 1_o
, , 1_o
disease JJ 1_o
evolution NN 1_o
was VBD 1_o
seen VBN N
in IN N
54 CD N
and CC N
49 CD N
patients NNS N
in IN N
the DT N
surgery NN N
and CC N
chemotherapy NN N
arm NN N
, , N
respectively RB N
, , N
and CC N
81 CD N
and CC N
83 CD N
patients NNS N
had VBD N
died VBN N
. . N

The DT N
10-year JJ 1_o
OS NNP 1_o
rate NN 1_o
was VBD 1_o
13.8 CD N
% NN N
in IN N
the DT N
surgery NN N
arm NN N
and CC N
13.1 CD N
% NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
. . N

The DT N
10-year JJ 1_o
PFS NNP 1_o
rates NNS 1_o
were VBD 1_o
8.5 CD N
% NN N
and CC N
10.8 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
the DT N
chemotherapy NN N
arm NN N
, , N
the DT N
10-year JJ 1_o
SFL NNP 1_o
rate NN 1_o
was VBD 1_o
8.7 CD N
% NN N
. . N

CONCLUSION NNP N
This DT N
strategy NN N
did VBD N
not RB N
compromise VB 1_o
disease NN 1_o
control NN 1_o
or CC 1_o
survival NN 1_o
( ( 1_o
that IN 1_o
remained VBD N
poor JJ N
) ) N
and CC N
allowed VBD N
more JJR N
than IN N
half NN N
of IN N
the DT N
survivors NNS N
to TO N
retain VB N
their PRP$ N
larynx NN N
. . N

-DOCSTART- -X- O O

Flow-cytometric JJ N
studies NNS N
with IN N
eleutherococcus JJ 1_i
senticosus NN 1_i
extract NN 1_i
as IN N
an DT N
immunomodulatory NN N
agent NN N
. . N

A DT N
placebo-controlled JJ 1_i
study NN N
of IN N
the DT N
effect NN N
of IN N
an DT N
Eleutherococcus NNP 1_i
senticosus NN 1_i
extract NN 1_i
( ( 1_i
Eleukokk NNP 1_i
) ) 1_i
on IN N
the DT N
immune NN 1_p
system NN 1_p
was VBD N
performed VBN N
with IN N
36 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
utilising VBG 1_p
quantitative JJ 1_p
multi-parameter NN 1_p
flow NN 1_p
cytometry NN 1_p
with IN 1_p
monoclonal JJ 1_p
antibodies NNS 1_p
directed VBN 1_p
against IN 1_p
specific JJ 1_p
surface NN 1_p
markers NNS 1_p
of IN 1_p
human JJ 1_p
lymphocyte JJ 1_p
subsets NNS 1_p
. . 1_p

Volunteers NNS N
in IN N
the DT N
verum NN N
group NN N
received VBD N
10 CD N
ml NN N
of IN N
an DT N
ethanolic JJ 1_i
( ( 1_i
vincamine JJ 1_i
free JJ 1_i
) ) 1_i
eleutherococcus VBP 1_i
senticosus JJ 1_i
preparation NN 1_i
, , N
3 CD N
times NNS N
daily RB N
for IN N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
placebo NN 1_i
, , 1_i
the DT 1_i
eleutherococcus NN 1_i
extract NN 1_i
was VBD 1_i
substituted VBN 1_i
by IN 1_i
additional JJ 1_i
wine NN 1_i
, , 1_i
resulting VBG 1_i
in IN 1_i
identical JJ 1_i
final JJ 1_i
concentrations NNS 1_i
of IN 1_i
ethanol NN 1_i
in IN 1_i
both DT 1_i
preparations NNS 1_i
. . 1_i

The DT N
purpose NN N
of IN N
the DT N
double-blind NN N
study NN N
was VBD N
the DT N
demonstration NN N
of IN N
possible JJ N
effects NNS N
on IN N
the DT N
cellular JJ 1_o
immune NN 1_o
status NN 1_o
, , N
as IN N
determined VBN N
by IN N
quantitative JJ 1_o
flow NN 1_o
cytometry NN 1_o
. . 1_o

The DT N
most RBS N
salient JJ N
feature NN N
in IN N
the DT N
verum NN N
group NN N
was VBD N
a DT N
drastic JJ N
increase NN N
in IN N
the DT N
absolute JJ 1_o
number NN 1_o
of IN 1_o
immunocompetent JJ 1_o
cells NNS 1_o
, , N
with IN N
an DT N
especially RB N
pronounced JJ N
effect NN N
on IN N
T NNP 1_o
lymphocytes NNS 1_o
, , N
predominantly RB N
of IN N
the DT N
helper/inducer NN 1_o
type NN 1_o
, , N
but CC N
also RB N
on IN N
cytotoxic NN 1_o
and CC 1_o
natural JJ 1_o
killer NN 1_o
cells NNS 1_o
. . 1_o

In IN N
addition NN N
, , N
a DT N
general JJ N
enhancement NN N
of IN N
the DT N
activation NN 1_o
state NN 1_o
of IN 1_o
T NNP 1_o
lymphocytes NNS 1_o
was VBD N
observed VBN N
. . N

No DT N
side NN 1_o
effects NNS 1_o
were VBD N
observed VBN N
during IN N
the DT N
trial NN N
or CC N
afterwards NNS N
( ( N
observation NN N
period NN N
6 CD N
months NNS N
) ) N
. . N

-DOCSTART- -X- O O

Buccal JJ 1_i
misoprostol NN 1_i
to TO N
decrease VB N
blood NN 1_o
loss NN 1_o
after IN 1_p
vaginal JJ 1_p
delivery NN 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
buccal JJ 1_i
misoprostol NN 1_i
to TO N
decrease VB N
bleeding NN 1_o
after IN 1_p
vaginal JJ 1_p
delivery NN 1_p
. . 1_p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS 1_p
between IN 1_p
22 CD 1_p
weeks NNS 1_p
and CC 1_p
42 CD 1_p
weeks NNS 1_p
of IN 1_p
gestation NN 1_p
with IN 1_p
anticipated JJ 1_p
vaginal JJ 1_p
delivery NN 1_p
. . 1_p

Patients NNS N
were VBD N
given VBN N
either CC N
a DT N
200-mug JJ 1_i
misoprostol NN 1_i
tablet NN 1_i
or CC 1_i
placebo NN 1_i
in IN N
the DT N
buccal JJ N
space NN N
at IN N
the DT N
time NN N
of IN N
cord NN N
clamping NN N
. . N

A DT N
continuous JJ N
dilute NN N
intravenous JJ N
oxytocin JJ 1_i
infusion NN N
was VBD N
given VBN N
to TO N
all DT N
patients NNS N
at IN N
delivery NN N
of IN N
the DT N
placenta NN N
. . N

Postpartum NNP 1_o
hemorrhage NN 1_o
was VBD N
defined VBN N
as IN N
blood NN 1_o
loss NN 1_o
exceeding VBG N
500 CD N
mL NN N
. . N

Sample NNP N
size NN N
calculations NNS N
based VBN N
on IN N
previous JJ N
studies NNS N
assumed VBD N
a DT N
13 CD N
% NN N
incidence NN N
of IN N
postpartum NN N
hemorrhage NN N
in IN N
the DT N
control NN N
group NN N
. . N

To TO N
show VB N
a DT N
statistically RB N
significant JJ N
reduction NN N
of IN N
postpartum NN N
hemorrhage NN N
a DT 1_p
total NN 1_p
of IN 1_p
1,604 CD 1_p
patients NNS 1_p
would MD 1_p
be VB 1_p
required VBN 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
848 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
and CC 1_p
756 CD 1_p
randomly RB 1_p
assigned VBN 1_p
, , 1_p
377 CD 1_p
in IN 1_p
the DT 1_p
misoprostol NN 1_i
group NN 1_p
and CC 1_p
379 CD 1_p
in IN 1_p
the DT 1_p
placebo NN 1_i
group NN 1_p
. . 1_p

Demographic NNP 1_p
, , 1_p
antepartum NN 1_p
, , 1_p
and CC 1_p
intrapartum NN 1_p
characteristics NNS 1_p
were VBD 1_p
similar JJ 1_p
between IN 1_p
the DT 1_p
groups NNS 1_p
. . 1_p

The DT N
incidence NN 1_o
of IN 1_o
postpartum NN 1_o
hemorrhage NN 1_o
, , N
3 CD N
% NN N
compared VBN N
with IN N
5 CD N
% NN N
, , N
( ( N
relative JJ N
risk NN N
0.65 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
0.33-1.29 JJ N
, , N
P NNP N
= NNP N
.22 NNP N
) ) N
, , N
mean JJ 1_o
estimated VBN 1_o
blood NN 1_o
loss NN 1_o
, , N
322 CD N
compared VBN N
with IN N
329 CD N
mL NNS N
, , N
( ( N
P NNP N
= NNP N
.45 NNP N
) ) N
, , N
and CC N
mean JJ 1_o
minutes NNS 1_o
of IN 1_o
the DT 1_o
third JJ 1_o
stage NN 1_o
of IN 1_o
labor NN 1_o
, , N
6.7 CD N
compared VBN N
with IN N
6.9 CD N
( ( N
P NNP N
= NNP N
.52 NNP N
) ) N
were VBD N
similar JJ N
between IN N
the DT N
groups NNS N
, , N
misoprostol NN 1_i
and CC N
placebo NN 1_i
, , N
respectively RB N
. . N

Hemoglobin NNP 1_o
difference NN 1_o
before IN 1_o
and CC 1_o
after IN 1_o
delivery NN 1_o
, , 1_o
need NN 1_o
for IN 1_o
second JJ 1_o
or CC 1_o
third JJ 1_o
uterotonic JJ 1_o
agent NN 1_o
, , 1_o
and CC 1_o
all DT 1_o
measured VBN 1_o
neonatal JJ 1_o
variables NNS 1_o
including VBG 1_o
birth NN 1_o
weights NNS 1_o
, , 1_o
and CC 1_o
umbilical JJ 1_o
cord NN 1_o
pH NN 1_o
were VBD N
similar JJ N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
Buccal NNP 1_i
misoprostol NN 1_i
at IN N
cord NN N
clamping NN N
is VBZ N
no DT N
more RBR N
effective JJ N
than IN N
placebo NN 1_i
in IN N
reducing VBG N
postpartum JJ 1_o
hemorrhage NN 1_o
. . 1_o

-DOCSTART- -X- O O

Levamisole NNP 1_i
versus NN 1_i
placebo NN 1_i
as IN N
an DT N
adjunct NN N
to TO N
primary JJ N
therapy NN N
of IN N
laryngopharyngeal JJ 1_p
epidermoid JJ 1_p
carcinoma NN 1_p
. . 1_p

Evaluation NN N
of IN N
the DT N
immune JJ N
status NN N
. . N

Twenty-four CD 1_p
patients NNS 1_p
, , 1_p
with IN 1_p
a DT 1_p
biopsy-proven JJ 1_p
laryngeal NN 1_p
or CC 1_p
hypopharyngeal NN 1_p
carcinoma NN 1_p
, , N
received VBD N
as IN N
an DT N
adjunct NN N
to TO N
their PRP$ N
primary JJ N
treatment NN N
( ( N
surgery JJ N
and/or RB N
radiotherapy NN N
) ) N
, , N
levamisole JJ 1_i
( ( 1_i
150 CD 1_i
mg NNS 1_i
daily RB 1_i
during IN 1_i
three CD 1_i
consecutive JJ 1_i
days NNS 1_i
, , 1_i
every DT 1_i
fortnight NN 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
, , N
following VBG N
a DT N
single-blind JJ N
, , N
but CC N
randomized VBD N
method NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
follow-up NN N
, , N
an DT N
investigation NN N
of IN N
the DT N
immune NN 1_o
status NN N
was VBD N
done VBN N
, , N
and CC N
compared VBN N
with IN N
that DT N
of IN N
a DT N
healthy JJ 1_p
control-group NN 1_p
. . 1_p

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
immunity NN 1_o
is VBZ N
disturbed VBN N
in IN N
patients NNS 1_p
with IN 1_p
laryngo-pharyngeal JJ 1_p
cancer NN 1_p
, , N
but CC N
that IN N
this DT N
disturbance NN N
does VBZ N
not RB N
clearly RB N
correlate NN N
with IN N
the DT N
clinical JJ N
state NN N
of IN N
the DT N
disease NN N
. . N

Also RB N
, , N
the DT N
immunological JJ N
measures NNS N
did VBD N
not RB N
appear VB N
relevant JJ N
to TO N
the DT N
significantly RB N
favourable JJ N
effect NN N
of IN N
levamisole NN N
on IN N
the DT N
prognosis NN N
. . N

-DOCSTART- -X- O O

Sequential JJ 1_i
therapy NN 1_i
versus IN 1_i
standard JJ 1_i
triple-drug JJ 1_i
therapy NN 1_i
for IN N
Helicobacter NNP N
pylori JJ N
eradication NN N
: : N
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Antimicrobial NNP N
resistance NN N
has VBZ N
decreased VBN N
eradication NN N
rates NNS N
for IN N
Helicobacter NNP 1_p
pylori JJ 1_p
infection NN 1_p
worldwide NN N
. . N

A DT N
sequential JJ N
treatment NN N
schedule NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
, , N
but CC N
studies NNS N
published VBN N
to TO N
date NN N
were VBD N
performed VBN N
in IN N
Italy NNP N
. . N

We PRP N
undertook VBD N
this DT N
study NN N
to TO N
determine VB N
whether IN N
these DT N
results NNS N
could MD N
be VB N
replicated VBN N
in IN 1_p
India NNP 1_p
. . 1_p

METHODS NNP N
A NNP N
randomized JJ N
, , N
open-labeled JJ N
, , N
prospective JJ N
controlled VBN N
trial NN N
comparing VBG N
sequential JJ 1_i
vs. FW 1_i
standard JJ 1_i
triple-drug JJ 1_i
therapy NN 1_i
was VBD N
carried VBN N
out RP N
at IN 1_p
Lokmanya NNP 1_p
Tilak NNP 1_p
Municipal NNP 1_p
General NNP 1_p
Hospital NNP 1_p
, , 1_p
Mumbai NNP 1_p
. . 1_p

Two CD 1_p
hundred CD 1_p
and CC 1_p
thirty-one JJ 1_p
patients NNS 1_p
with IN 1_p
dyspepsia NNS 1_p
were VBD N
randomized VBN N
to TO N
a DT N
10-day JJ 1_i
sequential JJ 1_i
regimen NNS 1_i
( ( 1_i
40 CD 1_i
mg NN 1_i
of IN 1_i
pantoprazole NN 1_i
, , 1_i
1 CD 1_i
g NN 1_i
of IN 1_i
amoxicillin NN 1_i
, , 1_i
each DT 1_i
administered VBN 1_i
twice RB 1_i
daily RB 1_i
for IN 1_i
the DT 1_i
first JJ 1_i
5 CD 1_i
days NNS 1_i
, , 1_i
followed VBN 1_i
by IN 1_i
40 CD 1_i
mg NNS 1_i
of IN 1_i
pantoprazole NN 1_i
, , 1_i
500 CD 1_i
mg NN 1_i
of IN 1_i
clarithromycin NN 1_i
, , 1_i
and CC 1_i
500 CD 1_i
mg NN 1_i
of IN 1_i
tinidazole NN 1_i
, , 1_i
each DT 1_i
administered VBN 1_i
twice RB 1_i
daily RB 1_i
for IN 1_i
the DT 1_i
remaining VBG 1_i
5 CD 1_i
days NNS 1_i
) ) 1_i
or CC 1_i
to TO 1_i
standard VB 1_i
14-day JJ 1_i
therapy NN 1_i
( ( 1_i
40 CD 1_i
mg NN 1_i
of IN 1_i
pantoprazole NN 1_i
, , 1_i
500 CD 1_i
mg NN 1_i
of IN 1_i
clarithromycin NN 1_i
, , 1_i
and CC 1_i
1 CD 1_i
g NN 1_i
of IN 1_i
amoxicillin NN 1_i
, , 1_i
each DT 1_i
administered VBN 1_i
twice RB 1_i
daily RB 1_i
) ) 1_i
. . 1_i

RESULTS VB N
The DT N
eradication NN 1_o
rate NN 1_o
achieved VBN N
with IN N
the DT N
sequential JJ 1_i
regimen NN 1_i
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
obtained VBN N
with IN N
the DT N
triple JJ 1_i
therapy NN 1_i
. . 1_i

Per-protocol JJ 1_o
eradication NN 1_o
rate NN 1_o
of IN N
sequential JJ 1_i
therapy NN 1_i
was VBD N
92.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
85.8-96.1 CD N
% NN N
) ) N
vs. FW N
81.8 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
73.9-87.8 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.027 CD N
) ) N
for IN N
standard JJ 1_i
drug NN 1_i
therapy NN 1_o
. . 1_o

Intention-to-treat JJ 1_o
eradication NN 1_o
rates NNS 1_o
were VBD 1_o
88.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
80.9-93.0 CD N
% NN N
) ) N
vs. FW N
79.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
71.1-85.4 CD N
% NN N
) ) N
, , N
p JJ N
= NN N
0.029 CD N
, , N
respectively RB 1_o
. . 1_o

The DT 1_o
incidence NN 1_o
of IN 1_o
major JJ 1_o
and CC 1_o
minor JJ 1_o
side NN 1_o
effects NNS 1_o
between IN N
therapy NN N
groups NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
14.6 CD N
% NN N
in IN N
the DT N
triple JJ N
therapy NN N
group NN N
vs. FW N
23.5 CD N
% NN N
in IN N
sequential JJ N
group NN N
, , N
p VBP N
= RB N
0.12 CD N
) ) N
. . N

Follow NNP N
up RP N
was VBD N
incomplete JJ N
in IN N
3.3 CD N
% NN N
and CC N
4.7 CD N
% NN N
patients NNS N
in IN N
standard JJ 1_i
and CC 1_i
sequential JJ 1_i
therapy NN 1_i
groups NNS 1_i
, , N
respectively RB N
. . 1_i

Sequential JJ 1_i
therapy NN 1_i
includes VBZ 1_i
one CD N
additional JJ N
antibiotic NN N
( ( N
tinidazole NN 1_i
) ) N
that WDT N
is VBZ N
not RB N
contained VBN N
in IN N
standard JJ 1_i
therapy NN 1_i
. . 1_i

CONCLUSIONS NNP 1_i
Sequential NNP 1_i
therapy NN 1_i
was VBD 1_i
significantly RB N
better JJR N
than IN N
standard JJ 1_i
therapy NN 1_i
for IN 1_i
eradicating VBG 1_o
H. NNP 1_o
pylori JJ 1_o
infection NN 1_o
. . 1_o

-DOCSTART- -X- O O

Hemolytic JJ 1_i
streptococcus NN 1_i
preparation NN 1_i
OK-432 NNP 1_i
; : 1_i
beneficial JJ N
adjuvant NN N
therapy NN N
in IN N
recurrent NN 1_p
gastric JJ 1_p
carcinoma NN 1_p
. . 1_p

The DT N
administration NN N
of IN N
a DT N
hemolytic JJ 1_i
streptococcus NN 1_i
preparation NN 1_i
, , N
OK-432 NNP N
, , N
is VBZ N
thought VBN N
to TO N
be VB N
of IN N
therapeutic JJ N
value NN N
in IN N
the DT N
treatment NN N
of IN N
cancer NN 1_p
patients NNS 1_p
through IN N
a DT N
stimulatory JJ N
effect NN N
on IN N
the DT N
immune NN N
system NN N
. . N

In IN N
order NN N
to TO N
evaluate VB N
any DT N
beneficial JJ N
effect NN N
of IN N
such JJ N
an DT N
administration NN N
, , N
a DT 1_p
group NN 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
recurrent JJ 1_p
gastric JJ 1_p
cancer NN 1_p
was VBD N
studied VBN N
. . N

This DT N
group NN N
was VBD N
randomly RB N
subdivided VBN N
into IN N
3 CD 1_i
groups NNS 1_i
: : 1_i
1 CD 1_i
) ) 1_i
Intradermal NNP 1_i
group NN 1_i
( ( 1_i
ID NNP 1_i
Group NNP 1_i
) ) 1_i
, , 1_i
42 CD 1_i
patients NNS 1_i
given VBN 1_i
an DT 1_i
intradermal JJ 1_i
injections NNS 1_i
of IN 1_i
OK-432 NNP 1_i
. . 1_i

2 CD 1_i
) ) 1_i
Intramuscular NNP 1_i
group NN 1_i
( ( 1_i
IM NNP 1_i
Group NNP 1_i
) ) 1_i
, , 1_i
40 CD 1_i
patients NNS 1_i
given VBN 1_i
an DT 1_i
intramuscular JJ 1_i
injections NNS 1_i
of IN 1_i
OK-432 NNP 1_i
. . 1_i

3 CD 1_i
) ) 1_i
Control NNP 1_i
group NN 1_i
( ( 1_i
C NNP 1_i
Group NNP 1_i
) ) 1_i
, , 1_i
39 CD 1_i
patients NNS 1_i
not RB 1_i
given VBN 1_i
injections NNS 1_i
. . 1_i

Each DT N
group NN N
was VBD N
studied VBN N
in IN N
regards NNS N
to TO N
the DT N
length NN 1_o
of IN 1_o
survival NN 1_o
, , N
the DT N
host NN 1_o
immune JJ 1_o
response NN 1_o
and CC 1_o
the DT 1_o
incidence NN 1_o
of IN 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

When WRB N
compared VBN N
to TO N
the DT N
IM NNP N
and CC N
C NNP N
Groups NNP N
, , N
the DT N
ID NNP N
Group NNP N
showed VBD N
improved JJ N
survival NN 1_o
. . 1_o

Accompanying VBG N
this DT N
improved JJ N
survival NN N
, , N
the DT N
ID NNP N
Group NNP N
also RB N
had VBD N
greater JJR N
white JJ 1_o
cell NN 1_o
and CC 1_o
lymphocyte NN 1_o
counts NNS 1_o
, , N
a DT N
greater JJR N
number NN N
of IN N
T NNP 1_o
cells NNS 1_o
, , N
and CC N
a DT N
more RBR N
dramatic JJ 1_o
skin NN 1_o
reaction NN 1_o
to TO N
the DT N
extracted VBN N
cell NN N
wall NN N
polysaccharide NN N
of IN N
hemolytic JJ N
streptococcus NN N
Su-strain NNP N
( ( N
Su-PS NNP N
) ) N
. . N

The DT N
ID NNP N
Group NNP N
, , N
following VBG N
OK-432 JJ N
injection NN N
, , N
had VBD N
a DT N
4.8 CD N
% NN N
incidence NN N
of IN N
fever NN 1_o
and CC N
a DT N
52.4 CD N
% NN N
incidence NN N
of IN N
local JJ 1_o
abscess NN 1_o
formation NN 1_o
at IN N
the DT N
injection NN N
site NN N
. . N

90 CD N
% NN N
of IN N
the DT N
IM NNP N
Group NNP N
developed VBD N
fever RB 1_o
but CC N
abscess JJ 1_o
formation NN 1_o
was VBD N
absent VBN N
in IN N
all DT N
patients NNS N
. . N

From IN N
these DT N
results NNS N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
in IN N
the DT N
patients NNS N
tested VBN N
, , N
intradermal JJ N
injection NN N
of IN N
OK-432 NNP N
appears VBZ N
to TO N
be VB N
clinically RB N
superior JJ N
to TO N
intramuscular JJ N
injection NN N
. . N

-DOCSTART- -X- O O

Divalproex NNP 1_i
versus NN 1_i
placebo NN 1_i
for IN N
the DT N
prevention NN N
of IN N
irritability NN 1_o
associated VBN N
with IN N
fluoxetine JJ 1_i
treatment NN N
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

-DOCSTART- -X- O O

Dose-response JJ 1_o
effect NN 1_o
of IN N
flecainide NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
symptomatic JJ 1_p
paroxysmal JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
and/or NN 1_p
flutter NN 1_p
monitored VBD 1_p
with IN 1_p
trans-telephonic JJ 1_p
electrocardiography NN 1_p
: : 1_p
a DT N
multicenter NN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

BACKGROUND VB N
A DT N
double-blind NN N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS 1_p
with IN 1_p
paroxysmal JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
or CC 1_p
flutter NN 1_p
( ( 1_p
PAF/PAFL NNP 1_p
) ) 1_p
experiencing VBG 1_p
2 CD 1_p
or CC 1_p
more JJR 1_p
episodes NNS 1_p
of IN 1_p
symptomatic JJ 1_p
PAF/PAFL NNP 1_p
during IN 1_p
a DT 1_p
28-day JJ 1_p
observation NN 1_p
period NN 1_p
to TO 1_p
determine VB 1_p
the DT 1_p
dose-response JJ 1_p
effect NN 1_o
and CC 1_o
safety NN 1_o
of IN 1_p
flecainide NN 1_i
. . 1_i

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
143 CD 1_p
patients NNS 1_p
at IN 1_p
30 CD 1_p
centers NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
25 CD N
, , N
50 CD N
, , N
or CC N
100 CD N
mg NN N
of IN N
flecainide NN 1_i
or CC 1_i
placebo VB 1_i
twice JJ N
daily JJ N
( ( N
BID NNP N
) ) N
. . N

In IN N
123 CD 1_p
patients NNS 1_p
( ( N
per IN N
protocol NN N
set NN N
) ) N
, , N
those DT N
remaining VBG N
free JJ N
from IN N
PAF/PAFL NNP 1_o
after IN N
the DT N
treatment NN N
were VBD N
3.1 CD N
% NN N
on IN N
placebo NN 1_i
, , N
7.7 CD N
% NN N
on IN N
25 CD N
mg/BID NN N
, , N
9.4 CD N
% NN N
on IN N
50 CD N
mg/BID NN N
, , N
and CC N
39.4 CD N
% NN N
on IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN 1_i
. . 1_i

As IN N
a DT N
whole JJ N
group NN N
, , N
a DT N
significant JJ 1_o
linear JJ 1_o
dose-response NN 1_o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
was VBD N
observed VBN N
and CC N
a DT N
significant JJ N
difference NN N
between IN N
placebo NN N
and CC N
100 CD N
mg/BID NN N
was VBD N
observed VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
similar JJ N
dose-response NN 1_o
between IN N
the DT N
present JJ N
study NN N
and CC N
Caucasian NNP N
study NN N
was VBD N
demonstrated VBN N
. . N

Although IN N
there EX N
were VBD N
5 CD N
patients NNS N
who WP N
needed VBD N
cardioversion NN 1_o
or CC 1_o
ablation NN 1_o
because IN N
of IN N
frequent JJ N
episodes NNS N
of IN N
PAF/PAFL NNP N
( ( N
2 CD N
in IN N
25 CD N
mg/BID NN N
, , N
1 CD N
in IN N
50 CD N
mg/BID NN N
, , N
and CC N
2 CD N
in IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN 1_i
) ) 1_i
, , N
neither CC N
death NN 1_o
nor CC 1_o
ventricular JJ 1_o
proarrhythmic JJ 1_o
event NN 1_o
was VBD N
reported VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicated VBD N
that IN N
flecainide NN 1_i
exerted VBD N
a DT N
significant JJ N
dose-dependent JJ N
effect NN N
on IN N
the DT N
prevention NN N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
recurrence NN N
and CC N
showed VBD N
that IN N
there EX N
was VBD N
no DT N
inter-ethnic JJ N
difference NN N
in IN N
the DT N
clinical JJ N
effect NN N
of IN N
flecainide NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
PAF/PAFL NNP 1_p
. . 1_p

-DOCSTART- -X- O O

[ IN N
The DT N
effects NNS N
of IN N
tirofiban NN 1_i
on IN N
acute JJ N
non-ST JJ N
segment NN N
elevation NN N
myocardial JJ 1_o
infarction NN 1_o
patients NNS 1_p
not RB 1_p
receiving VBG 1_p
early JJ 1_p
reperfusion NN 1_p
intervention NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
tirofiban NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
non-ST- JJ 1_p
segment NN 1_p
elevation NN 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( 1_p
NSTEMI NNP 1_p
) ) 1_p
without IN 1_p
early JJ 1_p
reperfusion NN 1_p
intervention NN 1_p
. . 1_p

METHODS NNP N
A NNP N
total NN 1_p
of IN 1_p
151 CD 1_p
NSTEMI NNP 1_p
patients NNS 1_p
without IN 1_p
early JJ 1_p
reperfusion NN 1_p
intervention NN 1_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
randomized VBN N
to TO N
the DT N
tirofiban NN 1_i
group NN N
( ( N
n JJ N
= NNP N
76 CD N
) ) N
and CC N
the DT N
control NN 1_i
group NN 1_i
( ( 1_i
n JJ 1_i
= NNP N
75 CD N
) ) N
. . N

Coronary JJ 1_i
angiography NN 1_i
was VBD N
performed VBN N
at IN N
day NN N
3 CD N
and CC N
day NN N
7 CD N
, , N
while IN N
percutaneous JJ N
coronary JJ N
intervention NN 1_i
( ( N
PCI NNP N
) ) N
was VBD N
performed VBN N
when WRB N
necessary JJ N
. . N

Parameters NNS N
including VBG N
thrombolysis NN 1_o
in IN 1_o
myocardial JJ 1_o
infarction NN 1_o
( ( 1_o
TIMI NNP 1_o
) ) 1_o
flow NN 1_o
, , 1_o
bleeding VBG 1_o
complications NNS 1_o
and CC 1_o
clinic JJ 1_o
events NNS 1_o
within IN N
30 CD N
days NNS N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Before IN N
PCI NNP N
, , N
no DT N
increase NN N
in IN N
the DT N
percentage NN 1_o
of IN 1_o
patient NN 1_o
with IN 1_o
TIMI NNP 1_o
flow VBP 1_o
better JJR N
than IN N
TIMI-2 NNP N
was VBD N
observed VBN N
by IN N
the DT N
treatment NN N
of IN N
tirofiban NN 1_i
( ( N
69.3 CD N
% NN N
vs JJ N
78.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

While IN N
after IN N
PCI NNP N
, , N
significant JJ N
increase NN N
in IN N
the DT N
percentage NN 1_o
of IN 1_o
patient NN 1_o
with IN 1_o
TIMI NNP 1_o
flow VBP 1_o
better JJR N
than IN N
TIMI-2 NNP N
was VBD N
manifested VBN N
in IN N
the DT N
tirofiban NN 1_i
group NN N
( ( N
96.0 CD N
% NN N
vs JJ N
100.0 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Tirofiban NNP N
treatment NN N
also RB N
significantly RB N
decreased VBD 1_o
the DT 1_o
rate NN 1_o
of IN 1_o
poor JJ 1_o
myocardial JJ 1_o
perfusion NN 1_o
after IN N
PCI NNP N
( ( N
19.7 CD N
% NN N
vs JJ N
34.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
were VBD N
0 CD N
and CC N
4 CD N
major JJ 1_o
adverse JJ 1_o
cardiovascular NN 1_o
events NNS 1_o
( ( 1_o
MACE NNP 1_o
) ) 1_o
within IN N
30 CD N
days NNS N
observed VBN N
in IN N
the DT N
tirofiban NN 1_i
group NN N
and CC N
the DT N
control NN N
group NN N
( ( N
0.0 CD N
% NN N
vs JJ N
5.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

No DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
found VBN N
in IN N
the DT N
bleeding NN 1_o
complications NNS 1_o
within IN N
30 CD N
days NNS N
including VBG N
the DT N
mild JJ 1_o
hemorrhage NN 1_o
( ( N
5 CD N
vs RB N
4 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.75 CD N
) ) N
, , N
severe JJ 1_o
hemorrhage NN 1_o
( ( N
2 CD N
vs RB N
1 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.56 CD N
) ) N
or CC N
severe JJ 1_o
thrombocytopenia NN 1_o
( ( N
2 CD N
vs RB N
0 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.49 CD N
) ) N
. . N

CONCLUSIONS NNP N
Tirofiban NNP N
treatment NN N
does VBZ N
not RB N
increase VB N
the DT N
bleeding JJ 1_o
complications NNS 1_o
in IN N
NSTEMI NNP 1_p
patients NNS 1_p
without IN 1_p
early JJ 1_p
PCI NNP 1_p
. . 1_p

Tirofiban NN N
can MD N
improve VB N
the DT N
TIMI NNP N
flow NN N
and CC N
the DT N
myocardial JJ N
perfusion NN N
after IN N
PCI NNP N
with IN N
less JJR N
MACE NNP N
within IN N
30 CD N
days NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
early JJ N
phase NN N
II NNP N
study NN N
of IN N
bicalutamide NN 1_i
( ( 1_i
Casodex NNP 1_i
) ) 1_i
in IN N
patients NNS 1_p
with IN 1_p
prostatic JJ 1_p
cancer NN 1_p
] NN 1_p
. . N

To TO N
investigate VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
bicalutamide NN 1_i
( ( N
Casodex NNP N
) ) N
with IN N
its PRP$ N
clinically NN N
recommended VBD N
dose NN N
, , N
the DT N
randomized VBN N
early JJ N
phase NN N
II NNP N
study NN N
was VBD N
performed VBN N
in IN N
124 CD 1_p
patients NNS 1_p
with IN 1_p
prostatic JJ 1_p
cancer NN 1_p
( ( 1_p
stage NN 1_p
C NNP 1_p
, , 1_p
D NNP 1_p
) ) 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
given VBN N
50 CD 1_i
, , 1_i
80 CD 1_i
or CC 1_i
100 CD 1_i
mg NN 1_i
of IN 1_i
bicalutamide NN 1_i
orally RB N
once RB N
a DT N
day NN N
in IN N
fixed JJ N
doses NNS N
for IN N
12 CD N
weeks NNS N
; : N
122 CD N
patients NNS N
were VBD N
eligible JJ N
for IN N
evaluation NN N
. . N

The DT N
overall JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
50.0 CD N
% NN N
( ( N
20/40 CD N
) ) N
, , N
61.0 CD N
% NN N
( ( N
25/41 CD N
) ) N
and CC N
53.7 CD N
% NN N
( ( N
22/41 CD N
) ) N
in IN N
the DT N
50 CD N
mg NN N
, , N
80 CD N
mg NN N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
response NN 1_o
rate NN 1_o
in IN 1_o
prostate NN 1_o
lesion NN 1_o
, , 1_o
bone NN 1_o
and CC 1_o
lymph NN 1_o
node NN 1_o
metastases NNS 1_o
was VBD N
slightly RB N
higher JJR N
in IN N
the DT N
80 CD N
mg NN N
group NN N
than IN N
in IN N
the DT N
50 CD N
mg NN N
and CC N
100 CD N
mg NN N
groups NNS N
. . N

The DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
showing VBG 1_o
a DT 1_o
response NN 1_o
with IN 1_o
regard NN 1_o
to TO 1_o
serum VB 1_o
PSA NNP 1_o
( ( 1_o
CR NNP 1_o
and CC 1_o
PR NNP 1_o
) ) 1_o
was VBD N
84.2 CD N
, , N
92.7 CD N
and CC N
97.6 CD N
% NN N
in IN N
the DT N
50 CD N
, , N
80 CD N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
reactions NNS 1_o
was VBD N
65.0 CD N
, , N
61.0 CD N
and CC N
61.0 CD N
% NN N
in IN N
the DT N
50 CD N
, , N
80 CD N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT 1_o
significant JJ 1_o
difference NN 1_o
in IN N
overall JJ 1_o
safety NN 1_o
rating NN 1_o
in IN N
the DT N
three CD N
groups NNS N
. . N

Frequent JJ 1_o
adverse JJ 1_o
reactions NNS 1_o
were VBD N
gynecomastia JJ 1_o
and CC 1_o
breast NN 1_o
pain NN 1_o
. . 1_o

Only RB N
one CD N
patient NN N
in IN N
the DT N
80 CD N
mg NN N
group NN N
was VBD N
withdrawn VBN 1_o
due JJ 1_o
to TO 1_o
shortness VB 1_o
of IN 1_o
breath NN 1_o
. . 1_o

Serum NNP 1_o
concentrations NNS 1_o
of IN 1_o
LH NNP 1_o
, , 1_o
testosterone NN 1_o
and CC 1_o
estradiol NN 1_o
increased VBD 1_o
significantly RB 1_o
after IN N
treatment NN N
. . N

Bicalutamide NNP 1_i
was VBD N
concluded VBN N
to TO N
be VB N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
patients NNS 1_p
with IN 1_p
prostatic JJ 1_p
cancer NN 1_p
, , N
and CC N
its PRP$ N
recommended VBD N
dose NN N
was VBD N
80 CD N
mg NN N
once RB N
daily RB N
. . N

-DOCSTART- -X- O O

Single-dose JJ N
pharmacokinetics NNS N
of IN N
delavirdine NN 1_i
mesylate NN 1_i
and CC 1_i
didanosine NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
human JJ 1_o
immunodeficiency NN 1_o
virus NN 1_o
infection NN 1_o
. . 1_o

Delavirdine NNP N
is VBZ N
a DT N
nonnucleoside JJ N
reverse NN N
transcriptase NN N
inhibitor NN N
with IN N
in IN N
vitro JJ N
activity NN N
against IN N
human JJ 1_o
immunodeficiency NN 1_o
virus NN 1_o
type NN 1_o
1 CD 1_o
( ( 1_p
HIV-1 NNP 1_p
) ) 1_p
that WDT N
is VBZ N
currently RB N
being VBG N
evaluated VBN N
in IN N
combination NN N
regimens NNS N
with IN N
various JJ N
nucleoside JJ N
analogs NNS N
, , N
including VBG N
didanosine NN N
. . N

Due NNP N
to TO N
the DT N
pH-dependent JJ N
solubility NN N
of IN N
delavirdine NN N
, , N
the DT N
buffering NN N
agents NNS N
in IN N
didanosine JJ N
formulations NNS N
may MD N
reduce VB N
delavirdine NN N
absorption NN N
. . N

To TO N
evaluate VB N
the DT N
potential JJ N
interaction NN N
between IN N
these DT N
agents NNS N
, , N
12 CD 1_p
HIV-infected JJ 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
[ NNP 1_p
+/- JJ 1_p
standard NN 1_p
deviation NN 1_p
] NNP 1_p
CD4+ NNP 1_p
cell NN 1_p
count NN 1_p
, , 1_p
304 CD 1_p
+/- JJ 1_p
213/mm3 CD 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
in IN N
a DT N
three-way JJ N
crossover NN N
single-dose JJ N
study NN N
. . N

Didanosine NNP 1_i
( ( N
125 CD N
to TO N
200 CD N
mg NNS N
given VBN N
as IN N
buffered JJ N
tablets NNS N
) ) N
and CC N
delavirdine JJ 1_i
mesylate NN 1_i
( ( N
400 CD N
mg NN N
) ) N
pharmacokinetics NNS N
were VBD N
evaluated VBN N
when WRB N
each DT N
drug NN N
was VBD N
given VBN N
alone RB N
( ( N
treatments NNS N
A DT N
and CC N
B NNP N
, , N
respectively RB N
) ) N
, , N
when WRB N
the DT N
two CD N
drugs NNS N
were VBD N
given VBN N
concurrently RB N
( ( N
treatment NN N
C NNP N
) ) N
, , N
and CC N
when WRB N
didanosine NN 1_i
was VBD N
given VBN N
1 CD N
h NN N
after IN N
delavirdine NN 1_i
( ( N
treatment NN N
D NNP N
) ) N
. . N

Delavirdine NNP 1_o
exposure NN 1_o
was VBD N
reduced VBN N
by IN N
concurrent JJ N
administration NN N
of IN N
didanosine NN 1_i
. . 1_i

The DT N
maximum JJ 1_o
drug NN 1_o
concentration NN 1_o
in IN 1_o
serum NN 1_o
( ( 1_o
Cmax NNP 1_o
) ) 1_o
was VBD N
reduced VBN N
from IN N
7.22 CD N
+/- JJ N
4.0 CD N
to TO N
3.51 CD N
+/- JJ N
1.9 CD N
microM NN N
, , N
and CC N
the DT N
area NN 1_o
under IN 1_o
the DT 1_o
concentration-time JJ 1_o
curve NN 1_o
from IN N
0 CD N
h NN N
to TO N
infinity NN N
( ( N
AUC0 NNP N
-- : N
> JJ N
infinity NN N
) ) N
was VBD N
reduced VBN N
from IN N
22.5 CD N
+/- JJ N
14 CD N
to TO N
14 CD N
+/- JJ N
5.7 CD N
microM.h NN N
. . N

The DT N
extent NN 1_o
of IN 1_o
N-dealkylation NNP 1_o
, , N
as IN N
indicated VBN N
by IN N
the DT N
ratio NN 1_o
of IN 1_o
the DT 1_o
N-dealkylated JJ 1_o
delavirdine NN 1_o
AUC0 NNP 1_o
-- : 1_o
> JJ 1_o
infinity NN 1_o
to TO N
the DT N
delavirdine NN 1_o
AUC0 NNP 1_o
-- : 1_o
> JJ 1_o
infinity NN 1_o
, , N
was VBD N
unchanged JJ N
across IN N
study NN N
treatments NNS N
( ( N
P NNP N
= NNP N
0.708 CD N
) ) N
. . N

Reductions NNPS N
in IN N
didanosine NN 1_o
exposure NN 1_o
were VBD N
observed VBN N
during IN N
concurrent JJ N
administration NN N
with IN N
delavirdine NN N
with IN N
a DT N
Cmax NNP 1_o
reduction NN N
from IN N
4.65 CD N
+/- JJ N
2.0 CD N
to TO N
3.22 CD N
+/- JJ N
0.59 CD N
microM NN N
and CC N
an DT N
AUC0 NNP N
-- : N
> JJ N
infinity NN N
reduction NN N
from IN N
7.93 CD N
+/- JJ N
3.9 CD N
to TO N
6.54 CD N
+/- JJ N
2.3 CD N
microM.h NN N
. . N

Thus RB N
, , N
concurrent JJ N
administration NN N
of IN N
delavirdine NN N
and CC N
didanosine NN N
may MD N
reduce VB N
the DT N
AUC0 NNP 1_o
-- : 1_o
> JJ 1_o
infinity NN 1_o
of IN N
both DT N
drugs NNS N
, , N
although IN N
the DT N
clinical JJ N
significance NN N
of IN N
this DT N
reduction NN N
is VBZ N
unknown JJ N
. . N

Administration NN N
of IN N
delavirdine JJ 1_i
1 CD N
h NN N
before IN N
didanosine NN 1_i
avoided VBD N
the DT N
interaction NN N
. . N

Due NNP N
to TO N
the DT N
single-dose JJ N
nature NN N
of IN N
this DT N
study NN N
, , N
these DT N
findings NNS N
require VBP N
further JJ N
evaluation NN N
at IN N
steady JJ N
state NN N
. . N

-DOCSTART- -X- O O

Deliberate NNP N
mild RBS 1_i
intraoperative JJ 1_i
hypothermia NN 1_i
for IN N
craniotomy NN 1_p
. . 1_p

BACKGROUND NNP N
Despite IN N
enthusiasm NN N
for IN N
the DT N
use NN N
of IN N
mild JJ 1_i
hypothermia NN 1_i
during IN N
neurosurgical JJ N
procedures NNS N
, , N
this DT N
therapy NN N
has VBZ N
not RB N
been VBN N
evaluated VBN N
systematically RB N
. . N

This DT N
study NN N
examined VBD N
the DT N
feasibility NN N
and CC N
safety NN N
of IN N
deliberate JJ N
mild JJ N
hypothermia NN N
and CC N
rewarming NN N
. . N

METHODS NNP N
Thirty NNP 1_p
patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
craniotomy NN 1_p
were VBD 1_p
assigned VBN 1_p
to TO 1_p
either VB 1_p
a DT 1_p
normothermic JJ 1_i
or CC 1_i
mildly RB 1_i
hypothermic JJ 1_i
group NN 1_p
. . 1_p

Tympanic NNP N
membrane NN N
temperature NN N
was VBD N
monitored VBN N
at IN N
anesthetic JJ N
induction NN N
, , N
throughout IN N
the DT N
isoflurane-fentanyl-N2O-O2 JJ 1_i
anesthetic JJ 1_i
, , N
and CC N
for IN N
18 CD N
h NN N
postoperatively RB N
. . N

Normothermic JJ N
patients NNS N
were VBD N
warmed VBN N
to TO N
36.5-37.0 JJ N
degrees NNS N
C NNP N
after IN N
an DT N
initial JJ N
temperature NN N
decrease NN N
, , N
and CC N
hypothermic JJ N
patients NNS N
were VBD N
cooled VBN N
to TO N
35 CD N
degrees NNS N
C. NNP N
In IN N
the DT N
hypothermic JJ N
group NN N
temperatures NNS N
were VBD N
allowed VBN N
to TO N
drift VB N
to TO N
34.5 CD N
degrees NNS N
C NNP N
before IN N
rewarming VBG N
was VBD N
initiated VBN N
. . N

Water NNP N
blankets NNS N
and CC N
convective JJ N
heating NN N
devices NNS N
were VBD N
used VBN N
to TO N
cool VB N
and CC N
rewarm VB N
. . N

RESULTS VB N
The DT N
minimum JJ 1_o
temperature NN 1_o
achieved VBN N
by IN N
the DT N
hypothermic JJ N
group NN N
was VBD N
34.3 CD N
+/- JJ N
0.4 CD N
degrees NNS N
C. NNP N
Cooling NNP 1_o
occurred VBD N
at IN N
a DT N
rate NN N
of IN N
1.0 CD N
+/- JJ N
0.4 CD N
degrees NNS N
C/h NNP N
. . N

Rewarming VBG 1_o
took VBD N
place NN N
at IN N
a DT N
rate NN N
of IN N
0.7 CD N
+/- JJ N
0.6 CD N
degrees NNS N
C/h NNP N
( ( N
range VB N
0.1-1.8 NN N
) ) N
in IN N
the DT N
hypothermic JJ N
group NN N
. . N

Hypothermia NNP 1_o
did VBD N
not RB N
delay VB N
emergence NN N
from IN N
anesthesia NN 1_o
( ( N
20 CD N
+/- JJ N
15 CD N
min NN N
) ) N
compared VBN N
with IN N
normothermia NN N
( ( N
15 CD N
+/- JJ N
15 CD N
min NN N
, , N
P NNP N
= NNP N
.45 NNP N
) ) N
. . N

Mean JJ 1_o
temperature NN 1_o
upon IN 1_o
intensive JJ 1_o
care NN 1_o
unit NN 1_o
admission NN 1_o
was VBD N
35.8 CD N
+/- JJ N
1.0 CD N
degrees NNS N
C NNP N
for IN N
the DT N
hypothermic JJ N
group NN N
and CC N
37.1 CD N
+/- JJ N
0.5 CD N
degrees NNS N
C NNP N
for IN N
the DT N
normothermic JJ N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
hypothermic JJ N
patients NNS N
had VBD N
more RBR N
postoperative JJ 1_o
shivering NN 1_o
. . 1_o

From IN N
8 CD N
to TO N
18 CD N
h NN N
postoperatively RB N
the DT N
temperatures NNS 1_o
of IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
except IN N
for IN N
a DT N
slightly RB N
greater JJR N
temperature NN 1_o
in IN N
the DT N
hypothermic JJ N
patients NNS N
at IN N
12 CD N
h NN N
( ( N
37.6 CD N
+/- JJ N
0.5 CD N
vs. FW N
37.3 CD N
+/- JJ N
0.4 CD N
degrees NNS N
C NNP N
, , N
P NNP N
= NNP N
.029 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
deliberate NN N
mild JJ N
hypothermia NN N
is VBZ N
easily RB N
achieved VBN N
intraoperatively RB N
, , N
complete JJ N
rewarming NN N
may MD N
be VB N
difficult JJ N
to TO N
attain VB N
during IN N
craniotomy NN 1_p
with IN N
current JJ N
methods NNS N
. . N

In IN N
addition NN N
to TO N
the DT N
need NN N
for IN N
determining VBG N
whether IN N
deliberate NN N
mild NNS N
hypothermia VBP N
confers NNS N
cerebral JJ N
protection NN N
in IN N
humans NNS N
, , N
the DT N
potential JJ N
risks NNS N
of IN N
the DT N
therapy NN N
need NN N
to TO N
be VB N
further JJ N
characterized VBN N
. . N

-DOCSTART- -X- O O

Epirubicin NNP 1_i
and CC 1_i
cyclophosphamide VB 1_i
versus NN N
epirubicin NN 1_i
and CC 1_i
docetaxel NN 1_i
as IN N
first-line JJ N
therapy NN N
for IN N
women NNS 1_p
with IN 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
: : 1_p
final JJ N
results NNS N
of IN N
a DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
. . N

BACKGROUND VB N
This DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
epirubicin NN 1_i
and CC 1_i
cyclophosphamide NN 1_i
( ( 1_i
EC NNP 1_i
) ) 1_i
with IN 1_i
epirubicin NN 1_i
and CC 1_i
docetaxel NN 1_i
( ( 1_i
Taxotere NNP 1_i
) ) 1_i
( ( 1_i
ED NNP 1_i
) ) 1_i
as IN N
first-line JJ N
chemotherapy NN N
for IN N
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
240 CD 1_p
) ) 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
receive VB N
either DT N
ED NNP 1_i
( ( 1_i
epirubicin JJ 1_i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC 1_i
docetaxel $ 1_i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
or CC N
EC NNP 1_i
( ( 1_i
epirubicin VBP 1_i
90 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC N
cyclophosphamide $ 1_i
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
objective JJ 1_o
response NN 1_o
rate NN 1_o
( ( 1_o
ORR NNP 1_o
) ) 1_o
. . 1_o

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
, , 1_o
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
safety NN 1_o
. . 1_o

RESULTS NNP N
ORR NNP 1_o
for IN N
patients NNS N
randomly RB N
assigned VBN N
to TO N
receive VB N
EC NNP 1_i
and CC N
ED NNP 1_i
were VBD N
42 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.63 CD N
) ) N
. . N

Median JJ 1_o
PFS NNP 1_o
[ NNP N
10.1 CD N
versus NN N
10.3 CD N
months NNS N
; : N
hazard VBN N
ratio NN N
( ( N
HR NNP N
) ) N
0.98 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.38 CD N
] NN N
and CC N
OS NNP 1_o
( ( N
19.9 CD N
versus NN N
30.0 CD N
months NNS N
; : N
HR NNP N
0.663 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.21 CD N
) ) N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
. . N

Although IN N
grade JJ 1_o
3/4 CD 1_o
leucopenia NN 1_o
occurred VBD N
more RBR N
frequently RB N
with IN N
ED NNP 1_i
( ( N
81 CD N
% NN N
versus IN N
73 CD N
% NN N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
febrile JJ 1_o
neutropenia NN 1_o
and CC 1_o
grade VBD 1_o
3/4 CD 1_o
infections NNS 1_o
. . 1_o

Grade VB 1_o
3/4 CD 1_o
non-haematologic JJ 1_o
toxicity NN 1_o
was VBD N
infrequent JJ N
in IN N
both DT N
arms NNS N
. . N

Congestive JJ 1_o
heart NN 1_o
failure NN 1_o
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
in IN N
each DT N
arm NN N
. . N

CONCLUSION NN N
In IN N
this DT N
randomised JJ N
trial NN N
, , N
no DT N
differences NNS N
in IN N
the DT N
efficacy NN N
study VBD N
end JJ N
points NNS N
were VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

-DOCSTART- -X- O O

Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
within IN N
travenous JJ N
dexketoprofen NN 1_i
improves VBZ N
postoperative JJ N
analgesia NN N
in IN N
abdominal JJ 1_p
hysterectomies NNS 1_p
. . 1_p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
In IN N
this DT N
study NN N
, , N
our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
intravenous JJ N
dexketoprofen NNS 1_i
trometamol VBP 1_i
with IN N
ilioinguinal JJ N
and CC N
iliohypogastric JJ N
nerve NN N
block NN N
on IN N
analgesic JJ N
quality NN N
and CC N
morphine NN N
consumption NN N
after IN N
total JJ 1_p
abdominal JJ 1_p
hysterectomy NN 1_p
operations NNS 1_p
. . 1_p

METHODS NNP N
We PRP 1_p
conducted VBD 1_p
this DT 1_p
randomized VBN 1_p
controlled VBD 1_p
clinical JJ 1_p
study NN 1_p
on IN 1_p
61 CD 1_p
patients NNS 1_p
. . 1_p

The DT 1_p
study NN 1_p
was VBD 1_p
conducted VBN 1_p
in IN 1_p
the DT 1_p
operation NN 1_p
room NN 1_p
, , 1_p
post-anesthesia JJ 1_p
care NN 1_p
unit NN 1_p
, , 1_p
and CC 1_p
inpatient JJ 1_p
clinic NN 1_p
. . 1_p

We PRP N
randomly RB N
grouped VBD N
the DT N
61 CD 1_p
patients NNS 1_p
into IN 1_p
control NN 1_i
group NN 1_i
( ( 1_p
group NN 1_p
C NNP 1_p
) ) 1_p
, , 1_p
block NN 1_i
group NN 1_i
( ( 1_p
group NN 1_p
B NNP 1_p
) ) 1_p
and CC 1_p
dexketoprofen-block JJ 1_i
group NN 1_i
( ( 1_p
group NN 1_p
DB NNP 1_p
) ) 1_p
. . N

Before IN N
the DT N
skin NN N
incision NN N
performed VBD N
after IN N
anesthesia JJ N
induction NN N
, , N
we PRP N
performed VBD N
ilioinguinal JJ 1_i
iliohypogastric JJ 1_i
block NN 1_i
( ( N
group NN N
C NNP N
given VBN N
saline NN 1_i
and CC N
group NN N
P NNP N
and CC N
DB NNP 1_i
given VBN N
levobupivacaine NN 1_i
) ) 1_i
. . N

In IN N
contrast NN N
to TO N
group NN N
C NNP N
and CC N
B NNP N
, , N
group NN N
DB NNP N
was VBD N
given VBN N
dexketoprofen RB 1_i
. . 1_i

We PRP N
administered VBD N
morphine JJ 1_i
analgesia NN 1_i
to TO N
all DT N
patients NNS N
by IN N
patient-controlled JJ N
analgesia NN N
( ( N
PCA NNP N
) ) N
during IN N
the DT N
postoperative JJ N
24 CD N
hours NNS N
. . N

We PRP N
recorded VBD N
Visual NNP 1_o
Analogue NNP 1_o
Scale NNP 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
, , 1_o
satisfaction NN 1_o
scores NNS 1_o
, , 1_o
morphine NN 1_o
consumption NN 1_o
and CC 1_o
side NN 1_o
effects NNS 1_o
during IN N
postoperative JJ N
24 CD N
hours NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
the DT N
DB NNP N
group?s NN 1_o
VAS NNP 1_o
scores VBZ 1_o
to TO 1_o
be VB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
and CC N
block NN N
group?s NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
values NNS N
at IN N
postoperative JJ N
1st CD N
, , N
2nd CD N
, , N
6th CD N
and CC N
12th CD N
hours NNS 1_o
. . 1_o

VAS NNP 1_o
scores NNS 1_o
of IN 1_o
group NN N
C NNP N
were VBD N
higher JJR N
than IN N
of IN N
group NN N
B NNP N
at IN N
postoperative JJ N
fi NN N
rst VBD N
2 CD N
hours NNS N
. . N

Time NNP N
to TO N
fi VB N
rst JJ N
PCA NNP N
demand NN N
was VBD N
longer RBR 1_o
, , 1_o
morphine JJ 1_o
consumption NN 1_o
values NNS 1_o
were VBD 1_o
lower JJR N
and CC N
satisfaction NN 1_o
scores NNS 1_o
were VBD 1_o
higher JJR N
in IN N
group NN N
DB NNP N
than IN N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
with IN N
IV NNP 1_i
dexketoprofen NN 1_i
increases NNS 1_i
patient JJ N
satisfaction NN N
by IN N
decreasing VBG N
opioid JJ N
consumption NN N
, , N
increasing VBG N
patient JJ N
satisfaction NN N
, , N
which WDT N
suggests VBZ N
that IN N
dexketoprofen NN N
trometamol NN N
is VBZ N
an DT N
effective JJ N
non-steroidal JJ N
anti-inflammatory JJ N
analgesic NN N
in IN N
postoperative JJ N
analgesia NN N
. . N

-DOCSTART- -X- O O

Ciprofloxacin/dexamethasone NNP 1_i
drops VBZ N
decrease VB N
the DT N
incidence NN N
of IN N
physician JJ N
and CC N
patient JJ N
outcomes NNS N
of IN N
otorrhea NN 1_o
after IN N
tube JJ N
placement NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
ciprofloxacin JJ 1_i
0.3 CD 1_i
% NN 1_i
/dexamethasone CD 1_i
0.1 CD N
% NN N
( ( N
CIPRODEX NNP N
, , N
Alcon NNP N
, , N
Ft. NNP N
Worth NNP N
, , N
TX NNP N
) ) N
for IN N
the DT N
prevention NN N
of IN N
early JJ N
post-operative JJ N
otorrhea NN N
following VBG N
TT NNP N
placement NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-center JJ N
, , N
randomized VBN N
, , N
evaluator-blinded JJ N
, , N
parallel-group JJ N
study NN N
. . N

Two CD 1_p
hundred VBD 1_p
children NNS 1_p
undergoing VBG 1_p
bilateral JJ 1_p
TT NNP 1_p
placement NN 1_p
were VBD 1_p
categorized VBN 1_p
as IN 1_p
having VBG 1_p
unilateral JJ 1_p
( ( 1_p
wet/dry JJ 1_p
) ) 1_p
, , 1_p
bilateral JJ 1_p
( ( 1_p
wet/wet NN 1_p
) ) 1_p
, , 1_p
or CC 1_p
no DT 1_p
( ( 1_p
dry/dry NN 1_p
) ) 1_p
effusion NN 1_p
at IN 1_p
the DT 1_p
time NN 1_p
of IN 1_p
surgery NN 1_p
. . 1_p

All DT N
patients NNS N
received VBD N
Ciprodex NNP 1_i
or CC 1_i
no DT 1_i
treatment NN 1_i
for IN 1_i
5 CD 1_i
days NNS 1_i
post-operatively RB 1_i
and CC N
returned VBN N
at IN N
2 CD N
weeks NNS N
. . N

RESULTS NNP N
Physician-observed JJ 1_o
otorrhea NN 1_o
was VBD N
reported VBN N
in IN N
5 CD N
( ( N
4.95 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
Ciprodex NNP N
and CC N
39 CD N
( ( N
39.39 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
no DT N
treatment NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Treatment NN N
decreased VBD N
otorrhea NNS 1_o
in IN N
all DT N
groups NNS N
, , N
while IN N
the DT N
greatest JJS N
benefit NN N
was VBD N
observed VBN N
in IN N
patients NNS N
with IN N
bilateral JJ N
effusion NN N
( ( N
93 CD N
% NN N
reduction NN N
) ) N
. . N

Ciprodex NNP N
treatment NN N
also RB N
decreased VBD N
the DT N
rate NN 1_o
of IN 1_o
clinically RB 1_o
diagnosed VBN 1_o
otitis NN 1_o
media NNS 1_o
( ( 1_o
OM NNP 1_o
) ) 1_o
and CC 1_o
effusion NN 1_o
following VBG N
TT NNP N
placement NN N
( ( N
p JJ N
< NN N
or CC N
=0.0006 NN N
) ) N
. . N

CONCLUSION NNP N
Ciprodex NNP N
reduced VBD N
early JJ 1_o
post-operative JJ 1_o
otorrhea NN 1_o
, , 1_o
clinically RB 1_o
diagnosed VBN 1_o
OM NNP 1_o
and CC N
effusion NN 1_o
following VBG N
TT NNP N
insertion NN N
. . N

The DT N
greatest JJS N
reduction NN N
in IN N
otorrhea NN 1_o
was VBD N
observed VBN N
in IN N
patients NNS 1_p
with IN 1_p
bilateral JJ 1_p
effusion NN 1_p
at IN 1_p
the DT 1_p
time NN 1_p
of IN 1_p
surgery NN 1_p
. . 1_p

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
to TO N
improve VB N
venipuncture NN 1_o
compliance NN 1_o
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

OBJECTIVE NNP N
Medical NNP N
procedures NNS N
, , N
particularly RB N
venipuncture NN N
( ( N
the DT N
puncture NN N
of IN N
a DT N
vein NN N
especially RB N
for IN N
the DT N
withdrawal NN N
of IN N
blood NN N
) ) N
, , N
can MD N
cause VB N
serious JJ 1_o
distress NN 1_o
and CC N
behavior JJ 1_o
disturbance NN 1_o
for IN N
many JJ N
children NNS N
. . N

Noncompliance NN N
to TO N
blood VB N
draws NNS N
can MD N
have VB N
significant JJ N
ramifications NNS N
in IN N
both DT N
research NN N
and CC N
clinical JJ N
settings NNS N
. . N

The DT N
negative JJ 1_o
reactions NNS 1_o
may MD N
be VB N
exacerbated VBN N
in IN N
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Even RB N
so RB N
, , N
there EX N
has VBZ N
been VBN N
little JJ N
research NN N
into IN N
the DT N
prevalence NN N
of IN N
the DT N
problem NN N
or CC N
effective JJ N
intervention NN N
procedures NNS N
. . N

In IN N
response NN N
to TO N
these DT N
concerns NNS N
, , N
we PRP N
developed VBD N
and CC N
evaluated VBD N
the DT N
Blood NNP 1_i
Draw NNP 1_i
Intervention NNP 1_i
Program NNP 1_i
. . 1_i

The DT N
program NN N
was VBD N
designed VBN N
to TO N
be VB N
easy JJ N
to TO N
use VB N
, , N
require VB N
little JJ N
provider NN N
or CC N
family NN N
time NN N
, , N
effectively RB N
reduce VB N
negative JJ 1_o
behaviors NNS 1_o
, , N
and CC N
increase VB 1_o
blood NN 1_o
draw JJ 1_o
compliance NN 1_o
. . 1_o

METHOD NNP N
In IN N
a DT N
quasi-randomized JJ N
trial NN N
over IN N
the DT N
course NN N
of IN N
? . N
18 CD N
months NNS 1_p
, , 1_p
58 CD 1_p
of IN 1_p
210 CD 1_p
families NNS 1_p
with IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
participating VBG 1_p
in IN 1_p
a DT 1_p
larger JJR 1_p
study NN 1_p
of IN 1_p
phenotypic NN 1_p
and CC 1_p
genotypic NN 1_p
factors NNS 1_p
reported VBD 1_p
significant JJ 1_p
concerns NNS 1_p
about IN 1_p
blood NN 1_p
draws NNS 1_p
and CC 1_p
elected VBN 1_p
to TO 1_p
use VB 1_p
the DT 1_p
Blood NNP 1_p
Draw NNP 1_p
Intervention NNP 1_p
Program NNP 1_p
. . 1_p

RESULTS NNP N
Completion NNP N
of IN N
the DT N
program NN N
increased VBD 1_o
blood NN 1_o
draw NN 1_o
compliance NN 1_o
rates NNS 1_o
from IN 1_o
85.4 CD N
% NN N
to TO N
96.6 CD N
% NN N
( ( N
odds NNS N
ratio VBP N
= JJ N
4.80 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
= VBD N
1.12 CD N
, , N
20.59 CD N
; : N
p NN N
= NNP N
.03 NNP N
) ) N
. . N

CONCLUSION NNP N
Results NNP N
indicate VBP N
the DT N
efficacy NN N
of IN N
the DT N
program NN N
in IN N
a DT N
research NN N
setting NN N
and CC N
suggest VB N
a DT N
potential JJ N
clinical JJ N
application NN N
. . N

The DT N
current JJ N
intervention NN N
, , N
unlike IN N
many JJ N
others NNS N
for IN N
the DT N
same JJ N
or CC N
similar JJ N
difficulties NNS N
proposed VBN N
in IN N
the DT N
past NN N
, , N
was VBD N
successful JJ N
without IN N
requiring VBG N
extensive JJ N
time NN N
, , N
training NN N
, , N
or CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
providers NNS N
and CC N
parents NNS N
or CC N
their PRP$ N
children NNS N
, , N
nor CC N
did VBD N
it PRP N
require VB N
large-scale JJ N
institutional JJ N
changes NNS N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
of IN N
intravenous JJ N
ibutilide JJ 1_i
versus NN N
procainamide NN 1_i
for IN N
enhancing VBG N
termination NN N
of IN N
atrial JJ N
flutter NN N
by IN N
atrial JJ N
overdrive JJ N
pacing NN N
. . N

This DT N
study NN N
compares VBZ N
the DT N
influence NN N
of IN N
intravenous JJ N
ibutilide NN 1_i
, , N
a DT N
class NN N
III NNP N
antiarrhythmic JJ N
agent NN N
, , N
with IN N
procainamide NN 1_i
, , N
a DT N
class NN N
IA NNP N
antiarrhythmic JJ N
agent NN N
, , N
and CC N
with IN N
placebo NN 1_i
on IN N
its PRP$ N
ability NN N
to TO N
terminate VB N
atrial JJ N
flutter NN N
using VBG N
rapid JJ N
atrial JJ N
pacing NN N
. . N

Fifty-nine NNP 1_p
episodes NNS 1_p
of IN 1_p
atrial JJ 1_p
flutter NN 1_p
in IN 1_p
54 CD 1_p
patients NNS 1_p
who WP 1_p
failed VBD 1_p
to TO 1_p
terminate VB 1_p
with IN 1_p
an DT 1_p
intravenous JJ 1_p
infusion NN 1_p
of IN 1_p
ibutilide NN 1_i
, , 1_i
procainamide NN 1_i
, , 1_i
or CC 1_i
placebo VB 1_i
alone JJ 1_p
underwent JJ 1_p
attempts NNS 1_p
at IN 1_p
pacing VBG 1_p
termination NN 1_p
using VBG 1_p
a DT 1_p
standard JJ 1_p
protocol NN 1_p
of IN 1_p
burst JJ 1_p
atrial JJ 1_p
overdrive JJ 1_p
pacing NN 1_p
. . 1_p

Atrial JJ N
flutter NN N
cycle NN N
length NN N
and CC N
atrial JJ N
monophasic JJ N
action NN N
potential JJ N
duration NN N
recorded VBN N
from IN N
the DT N
right JJ N
atrium NN N
during IN N
atrial JJ N
flutter NN N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
following VBG N
infusion NN N
of IN N
ibutilide NN 1_i
, , 1_i
procainamide NN 1_i
, , N
or CC N
placebo NN 1_i
. . 1_i

Both DT N
ibutilide JJ 1_i
and CC N
procainamide JJ 1_i
significantly RB N
enhanced VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
pacing-induced JJ 1_o
termination NN 1_o
of IN 1_o
atrial JJ 1_o
flutter NN 1_o
compared VBN N
with IN N
placebo NN 1_i
. . 1_i

Pacing VBG N
converted VBD N
2 CD N
of IN N
11 CD N
patients NNS N
( ( N
18 CD N
% NN N
) ) N
who WP N
received VBD N
placebo NN 1_i
, , N
13 CD N
of IN N
15 CD N
patients NNS N
( ( N
87 CD N
% NN N
) ) N
who WP N
received VBD N
ibutilide RB 1_i
, , N
and CC N
29 CD N
of IN N
33 CD N
patients NNS N
( ( N
88 CD N
% NN N
) ) N
who WP N
received VBD N
procainamide RB 1_i
to TO N
sinus VB 1_o
rhythm NN 1_o
. . 1_o

Ibutilide NNP 1_i
and CC N
procainamide RB 1_i
compared VBN N
with IN N
placebo NN 1_i
markedly RB N
reduced VBD N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
the DT N
incidence NN 1_o
of IN 1_o
pacing-induced JJ 1_o
atrial JJ 1_o
fibrillation NN 1_o
. . 1_o

The DT 1_o
atrial JJ 1_o
flutter NN 1_o
cycle NN 1_o
length NN 1_o
was VBD N
prolonged VBN N
significantly RB N
less RBR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
atrial JJ 1_o
monophasic JJ 1_o
action NN 1_o
potential JJ 1_o
duration NN 1_o
was VBD N
increased VBN N
significantly RB N
more RBR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
by IN N
ibutilide NN 1_i
than IN N
by IN N
procainamide NN 1_i
. . 1_i

Although IN N
the DT N
electrophysiologic JJ N
changes NNS N
induced VBN N
by IN N
these DT N
antiarrhythmic JJ N
agents NNS N
contributed VBD N
to TO N
facilitating VBG N
pacing-induced JJ N
termination NN N
, , N
neither CC N
tachycardia JJ 1_o
cycle NN 1_o
length NN 1_o
nor CC 1_o
action NN 1_o
potential JJ 1_o
duration NN 1_o
were VBD N
useful JJ N
predictors NNS N
of IN N
the DT N
ability NN N
of IN N
pacing VBG N
to TO N
terminate VB N
atrial JJ N
flutter NN N
. . N

In IN N
conclusion NN N
, , N
despite IN N
differing VBG N
electrophysiologic JJ N
effects NNS N
, , N
the DT N
use NN N
of IN N
intravenous JJ N
ibutilide NN 1_i
or CC N
procainamide NN 1_i
enhances VBZ N
the DT N
termination NN 1_o
of IN 1_o
atrial JJ 1_o
flutter NN 1_o
by IN 1_o
atrial JJ 1_o
overdrive JJ 1_o
pacing NN 1_o
. . 1_o

-DOCSTART- -X- O O

Gabapentin NNP 1_i
for IN N
the DT N
prevention NN N
of IN N
postoperative JJ 1_o
pain NN 1_o
after IN 1_p
vaginal JJ 1_p
hysterectomy NN 1_p
. . 1_p

Gabapentin NNP 1_i
alleviates VBZ N
and/or JJ N
prevents NNS N
acute JJ 1_o
nociceptive JJ 1_o
and CC 1_o
inflammatory JJ 1_o
pain NN 1_o
both DT N
in IN N
animals NNS 1_p
and CC 1_p
volunteers NNS 1_p
, , N
especially RB N
when WRB N
given VBN N
before IN N
trauma NN N
. . N

Gabapentin NNP 1_i
might MD N
also RB N
reduce VB N
postoperative JJ 1_o
pain NN 1_o
. . 1_o

To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
gabapentin NN 1_i
reduces VBZ N
the DT N
postoperative JJ 1_o
need NN 1_o
for IN 1_o
additional JJ 1_o
pain NN 1_o
treatment NN 1_o
( ( N
postoperative JJ N
opioid NN N
sparing VBG N
effect NN N
of IN N
gabapentin NN 1_i
in IN N
humans NNS 1_p
) ) 1_p
, , N
we PRP N
gave VBD N
1200 CD N
mg NN N
of IN N
gabapentin NN 1_i
or CC N
15 CD N
mg NN N
of IN N
oxazepam NN 1_i
( ( 1_i
active JJ 1_i
placebo NN 1_i
) ) 1_i
2.5 CD N
h NN N
prior RB N
to TO N
induction NN N
of IN N
anaesthesia NN N
to TO N
patients NNS 1_p
undergoing VBG 1_p
elective JJ 1_i
vaginal JJ 1_i
hysterectomy NN 1_i
in IN N
an DT N
active JJ N
placebo-controlled JJ N
, , N
double JJ N
blind NN N
, , N
randomised VBD N
study NN N
. . N

Gabapentin NNP 1_i
reduced VBD N
the DT N
need NN N
for IN N
additional JJ N
postoperative JJ 1_o
pain NN 1_o
treatment NN 1_o
( ( N
PCA NNP N
boluses NNS N
of IN N
50 CD N
microg NN N
of IN N
fentanyl NN N
) ) N
by IN N
40 CD N
% NN N
during IN N
the DT N
first JJ N
20 CD N
postoperative JJ N
hours NNS N
. . N

During IN N
the DT N
first JJ N
2 CD N
postoperative JJ N
hours NNS N
pain VBP 1_o
scores NNS 1_o
at IN 1_o
rest NN 1_o
and CC 1_o
worst JJS 1_o
pain NN 1_o
score NN 1_o
( ( N
VAS NNP N
0-100 NNP N
mm NN N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
active JJ N
placebo NN 1_i
group NN N
compared VBN N
to TO N
the DT N
gabapentin-treated JJ 1_i
patients NNS N
. . N

Additionally RB N
, , N
pretreatment NN N
with IN N
gabapentin NN 1_i
reduced VBD N
the DT N
degree NN 1_o
of IN 1_o
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
incidence NN 1_o
of IN 1_o
vomiting/retching VBG 1_o
possibly RB N
either RB N
due JJ N
to TO N
the DT N
diminished JJ N
need NN N
for IN N
postoperative JJ 1_o
pain NN 1_o
treatment NN N
with IN N
opioids NNS N
or CC N
because IN N
of IN N
an DT N
anti-emetic JJ N
effect NN N
of IN N
gabapentin NN 1_i
itself PRP N
. . N

No DT N
preoperative JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
encountered VBN N
with IN N
respect NN N
to TO N
the DT N
side NN N
effects NNS N
of IN N
the DT N
premedication NN N
. . N

However RB N
, , N
15 CD N
mg NN N
oxazepam NN 1_i
was VBD N
more RBR N
effective JJ 1_o
in IN N
relieving VBG N
preoperative JJ 1_o
anxiety NN 1_o
than IN N
1200 CD N
mg NN N
gabapentin NN 1_i
. . 1_i

-DOCSTART- -X- O O

Parecoxib NNP 1_i
for IN N
analgesia NN 1_p
after IN 1_p
craniotomy NN 1_p
. . 1_p

BACKGROUND NNP N
Pain NNP 1_o
after IN N
craniotomy NN N
is VBZ N
often RB N
under-treated JJ N
. . N

Opiates VBZ N
carry VBP N
distinct JJ N
disadvantages NNS N
. . N

Non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
have VBP N
an DT N
anti-platelet JJ N
action NN N
and CC N
carry VBP N
a DT N
bleeding NN N
risk NN N
. . N

Cyclo-oxygenase JJ N
2 CD N
inhibitors NNS N
such JJ N
as IN N
parecoxib NNS N
are VBP N
not RB N
associated VBN N
with IN N
a DT N
bleeding NN N
risk NN N
and CC N
would MD N
be VB N
welcome JJ N
analgesics NNS N
if IN N
shown VBN N
to TO N
be VB N
effective JJ N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
study NN N
, , N
we PRP N
investigated VBD N
the DT N
analgesic JJ N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
parecoxib NN 1_i
40 CD 1_i
mg NN 1_i
given VBN N
at IN N
dural JJ N
closure NN N
in IN N
82 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
elective JJ 1_p
craniotomies NNS 1_p
. . 1_p

Remifentanil NNP 1_i
was VBD N
used VBN N
intraoperatively RB N
, , N
and CC N
i.v NN 1_i
. . 1_i

morphine NN 1_i
was VBD N
titrated VBN N
to TO N
the DT N
requirement NN N
in IN N
the DT N
post-anaesthetic JJ N
unit NN N
. . N

On IN N
the DT N
ward NN N
, , N
i.m NN 1_i
. . 1_i

morphine VB 1_i
5 CD 1_i
mg NNS 1_i
as IN N
required VBN N
and CC N
regular JJ N
acetaminophen NN 1_i
was VBD N
prescribed VBN N
. . N

Morphine NNP 1_i
use NN N
and CC N
visual JJ 1_o
analogue NN 1_o
pain NN 1_o
scores NNS 1_o
were VBD N
recorded VBN N
at IN N
1 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS NNP N
Parecoxib NNP N
reduced VBD 1_o
pain NN 1_o
scores NNS 1_o
at IN N
6 CD N
h NN N
and CC N
morphine NN N
use NN N
at IN N
6 CD N
and CC N
12 CD N
h NN N
after IN N
operation NN N
. . N

However RB N
, , N
overall JJ N
, , N
it PRP N
had VBD N
only RB N
minimal JJ N
impact NN N
on IN N
postoperative JJ 1_o
analgesia NN 1_o
. . 1_o

We PRP N
found VBD N
a DT N
wide JJ N
variability NN N
in IN N
analgesic JJ N
requirements NNS N
where WRB N
11 CD N
% NN N
of IN N
patients NNS N
required VBN N
no DT N
opioids NNS N
and CC N
16 CD N
% NN N
required VBN N
more JJR N
than IN N
15 CD N
mg JJ N
i.v NN N
. . N

morphine VB N
1 CD N
h NN N
after IN N
the DT N
surgery NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
only RB N
limited JJ N
evidence NN N
to TO N
support VB N
parecoxib NN N
as IN N
an DT N
analgesic JJ N
after IN N
craniotomy NN N
. . N

-DOCSTART- -X- O O

Pilot NNP N
study NN N
of IN N
imiquimod JJ 1_i
5 CD 1_i
% NN 1_i
cream NN 1_i
as IN N
adjunctive JJ 1_i
therapy NN 1_i
to TO N
curettage VB 1_i
and CC N
electrodesiccation NN 1_i
for IN N
nodular JJ 1_p
basal NN 1_p
cell NN 1_p
carcinoma NN 1_p
. . 1_p

BACKGROUND NNP N
Curettage NNP 1_i
and CC 1_i
electrodesiccation NN 1_i
( ( 1_i
C NNP 1_i
& CC 1_i
D NNP 1_i
) ) 1_i
is VBZ N
a DT N
widely RB N
used VBN N
method NN N
to TO N
treat VB N
nodular JJ 1_p
basal NN 1_p
cell NN 1_p
carcinoma NN 1_p
( ( 1_p
BCC NNP 1_p
) ) 1_p
. . 1_p

However RB N
, , N
residual JJ N
tumor NN N
is VBZ N
present JJ N
immediately RB N
after IN N
the DT N
procedure NN N
in IN N
approximately RB N
20 CD N
to TO N
40 CD N
% NN N
of IN N
cases NNS N
. . N

Imiquimod NNP N
, , N
a DT N
topical JJ N
immune NN N
response NN N
modifier NN N
that WDT N
targets VBZ N
Toll-like NNP N
receptor NN N
7 CD N
, , N
is VBZ N
currently RB N
approved VBN N
for IN N
superficial JJ N
BCC NNP N
. . N

OBJECTIVE NNP N
In IN N
a DT N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
, , N
the DT N
administration NN N
of IN N
imiquimod NN 1_i
after IN N
C NNP N
& CC N
D NNP N
was VBD N
investigated VBN N
to TO N
determine VB N
if IN N
the DT N
combination NN N
regimen NNS N
would MD N
reduce VB N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
compared VBN N
with IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
alone RB N
in IN N
patients NNS 1_p
with IN 1_p
nodular JJ 1_p
BCC NNP 1_p
. . 1_p

METHODS NNP N
Twenty NNP 1_p
patients NNS 1_p
received VBD N
three CD N
cycles NNS N
of IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
followed VBN N
by IN N
imiquimod JJ 1_i
5 CD 1_i
% NN 1_i
or CC 1_i
vehicle NN 1_i
cream NN 1_i
once RB 1_i
daily JJ 1_i
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ 1_i
therapy NN 1_i
. . 1_i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
. . N

The DT N
secondary JJ N
end NN N
points NNS N
included VBD N
the DT N
time NN N
to TO N
heal VB N
and CC N
cosmetic JJ N
appearance NN N
. . N

RESULTS NNP N
Twenty NNP 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
the DT N
imiquimod NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
10 CD 1_p
) ) 1_p
or CC N
vehicle NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
10 CD 1_p
) ) 1_p
treatment NN N
group NN N
. . N

At IN N
8 CD N
weeks NNS N
, , N
the DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
residual JJ 1_o
tumor NN 1_o
was VBD N
substantially RB N
decreased VBN N
with IN N
imiquimod JJ 1_i
therapy NN N
( ( N
10 CD N
% NN N
) ) N
compared VBN N
with IN N
vehicle NN 1_i
( ( N
40 CD N
% NN N
) ) N
. . N

Wounds VBZ N
in IN N
the DT N
vehicle NN N
group NN N
healed VBD 1_o
more RBR N
quickly RB N
than IN N
those DT N
in IN N
the DT N
imiquimod NN N
group NN N
, , N
although IN N
by IN N
8 CD N
weeks NNS N
, , N
all DT N
excision NN N
sites NNS N
were VBD N
healed VBN N
. . N

The DT N
majority NN N
of IN N
scars NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
atrophic JJ N
and CC N
hypopigmented VBD N
, , N
whereas IN N
most JJS N
scars NNS N
in IN N
the DT N
imiquimod NN 1_i
group NN N
were VBD N
flat JJ N
and CC N
slightly RB N
pink VBP N
. . N

CONCLUSION NNP N
Imiquimod NNP 1_i
5 CD N
% NN N
cream NN N
once RB N
daily JJ N
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ N
therapy NN N
after IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
substantially RB N
reduced VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
and CC N
improved VBD N
the DT N
cosmetic JJ N
appearance NN N
compared VBN N
with IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
alone RB N
. . N

These DT N
preliminary JJ N
results NNS N
suggest VBP N
that IN N
further JJ N
studies NNS N
to TO N
investigate VB N
imiquimod JJ 1_i
adjunctive JJ 1_i
therapy NN 1_i
are VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

Time NN N
to TO N
onset VB N
of IN N
clinically RB N
meaningful JJ N
improvement NN N
with IN N
tadalafil JJ 1_i
5 CD N
mg NN N
once RB N
daily JJ N
for IN N
lower JJR 1_p
urinary JJ 1_p
tract NN 1_p
symptoms NNS 1_p
secondary JJ 1_p
to TO 1_p
benign VB 1_p
prostatic JJ 1_p
hyperplasia NN 1_p
: : 1_p
analysis NN N
of IN N
data NNS N
pooled VBN N
from IN N
4 CD N
pivotal JJ N
, , N
double-blind JJ N
, , N
placebo NN 1_i
controlled VBD N
studies NNS N
. . N

PURPOSE NNP N
Tadalafil NNP 1_i
once RB N
daily RB N
for IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
secondary JJ N
to TO N
benign VB N
prostatic JJ N
hyperplasia NN N
consistently RB N
shows VBZ N
statistically RB N
significant JJ N
I-PSS JJ N
improvements NNS N
. . N

However RB N
, , N
physicians NNS N
and CC N
patients NNS N
wish JJ N
to TO N
know VB 1_o
whether IN N
tadalafil JJ 1_i
provides VBZ N
rapid JJ N
, , N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
. . N

In IN N
this DT N
post NN N
hoc NN N
analysis NN N
we PRP N
integrated VBD N
results NNS N
from IN N
4 CD N
placebo NN 1_i
controlled VBN N
studies NNS N
to TO N
determine VB N
the DT N
duration NN N
of IN N
tadalafil NN 1_i
once RB N
daily RB N
required VBN N
to TO N
achieve VB N
clinically RB N
meaningful JJ N
improvement NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
performed VBD N
post NN N
hoc NN N
analysis NN N
of IN N
data NNS N
integrated VBN N
from IN N
4 CD N
double-blind JJ N
studies NNS N
of IN N
tadalafil NN 1_i
5 CD N
mg NN N
and CC 1_i
placebo NN 1_i
once RB N
daily RB N
in IN N
742 CD 1_p
and CC 1_p
735 CD 1_p
men NNS 1_p
, , 1_p
respectively RB 1_p
, , 1_p
45 CD 1_p
years NNS 1_p
old JJ 1_p
or CC 1_p
older JJR 1_p
with IN 1_p
total JJ 1_p
I-PSS JJ 1_p
13 CD 1_p
or CC 1_p
greater JJR 1_p
. . 1_p

Two CD N
clinically RB N
meaningful JJ N
improvement NN N
categories NNS N
were VBD N
assessed VBN N
, , N
including VBG N
1 CD 1_o
) ) 1_o
3-point CD 1_o
or CC 1_o
greater JJR 1_o
baseline NN 1_o
to TO 1_o
end VB 1_o
point NN 1_o
total JJ 1_o
I-PSS JJ 1_o
improvement NN 1_o
and CC 1_o
2 CD 1_o
) ) 1_o
25 CD 1_o
% NN 1_o
or CC 1_o
greater JJR 1_o
baseline NN 1_o
to TO 1_o
end VB 1_o
point NN 1_o
total JJ 1_o
I-PSS JJ 1_o
improvement NN 1_o
. . 1_o

I-PSS NNP 1_o
was VBD N
assessed VBN N
at IN N
weeks NNS N
4 CD N
, , N
8 CD N
and CC N
12 CD N
in IN N
all DT N
studies NNS N
, , N
week NN N
1 CD N
in IN N
2 CD N
and CC N
week NN N
2 CD N
in IN N
1 CD N
. . N

Results NNS N
in IN N
men NNS N
treated VBN N
with IN N
tadalafil NN 1_i
who WP N
showed VBD N
clinically RB N
meaningful JJ N
improvement NN N
( ( N
responders NNS N
) ) N
were VBD N
further RB N
examined VBN N
to TO N
determine VB N
the DT N
earliest JJS 1_o
time NN 1_o
to TO 1_o
clinically RB 1_o
meaningful JJ 1_o
improvement NN 1_o
. . 1_o

RESULTS NNP N
Of IN N
742 CD N
tadalafil NNS 1_i
treated VBD N
patients NNS N
513 CD N
( ( N
69.1 CD N
% NN N
) ) N
and CC N
444 CD N
( ( N
59.8 CD N
% NN N
) ) N
demonstrated VBD N
category JJ N
1 CD N
and CC N
2 CD N
clinically RB 1_o
meaningful JJ 1_o
improvement NN 1_o
, , N
respectively RB N
, , N
at IN N
the DT N
study NN N
end NN N
point NN N
. . N

Of IN N
234 CD N
category NN N
1 CD N
responders NNS N
with IN N
week NN N
1 CD N
assessments NNS N
140 CD N
( ( N
59.8 CD N
% NN N
) ) N
achieved VBD N
clinically RB 1_o
meaningful JJ 1_o
improvement NN 1_o
by IN N
week NN N
1 CD N
and CC N
407 CD N
of IN N
the DT N
total NN N
of IN N
513 CD N
category NN N
1 CD N
responders NNS N
( ( N
79.3 CD N
% NN N
) ) N
showed VBD N
it PRP N
by IN N
week NN N
4 CD N
. . N

Of IN N
the DT N
205 CD N
category NN N
2 CD N
responders NNS N
with IN N
week NN N
1 CD N
assessments NNS N
103 CD N
( ( N
50.2 CD N
% NN N
) ) N
achieved VBD N
clinically RB 1_o
meaningful JJ 1_o
improvement NN 1_o
by IN N
week NN N
1 CD N
while IN N
322 CD N
of IN N
the DT N
444 CD N
category NN N
2 CD N
responders NNS N
( ( N
72.5 CD N
% NN N
) ) N
did VBD N
so RB N
by IN N
week NN N
4 CD N
. . N

CONCLUSIONS NNP N
Tadalafil NNP 1_i
5 CD N
mg NN N
once RB N
daily RB N
led VBN N
to TO N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
approximately RB N
two-thirds NNS N
of IN N
men NNS N
with IN N
lower JJR 1_p
urinary JJ 1_p
tract NN 1_p
symptoms NNS 1_p
secondary JJ N
to TO N
benign VB N
prostatic JJ N
hyperplasia NN N
. . N

More JJR N
than IN N
half NN N
of IN N
this DT N
group NN N
of IN N
tadalafil NN 1_i
treated VBN N
responders NNS N
achieved VBD N
clinically RB N
meaningful JJ N
improvement NN N
after IN N
1 CD N
week NN N
of IN N
therapy NN N
and CC N
more JJR N
than IN N
70 CD N
% NN N
did VBD N
so RB N
within IN N
4 CD N
weeks NNS N
. . N

-DOCSTART- -X- O O

A DT N
community-based JJ 1_p
randomized JJ N
trial NN N
of IN N
praziquantel NN 1_i
to TO N
control VB N
schistosomiasis NN N
morbidity NN N
in IN N
schoolchildren NN 1_p
in IN 1_p
Zambia NNP 1_p
. . 1_p

A DT N
community-based JJ 1_p
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
of IN N
praziquantel NN 1_i
was VBD N
carried VBN N
out RP N
in IN N
an DT 1_p
area NN 1_p
of IN 1_p
Zambia NNP 1_p
endemic FW 1_p
for IN 1_p
schistosomiasis NN 1_p
. . 1_p

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
treatment NN N
on IN N
Schistosoma NNP 1_p
mansoni NNP 1_p
morbidity NN N
. . N

A DT N
total NN N
of IN N
377 CD 1_p
infected JJ 1_p
children NNS 1_p
, , 1_p
aged VBD 1_p
seven CD 1_p
to TO 1_p
19 CD 1_p
years NNS 1_p
, , N
was VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
of IN N
190 CD N
( ( N
group NN N
A NNP N
) ) N
and CC N
one CD N
of IN N
187 CD N
( ( N
group NN N
B NNP N
) ) N
. . N

All DT 1_p
children NNS 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
40 CD 1_p
mg NNS 1_p
praziquantel/kg NN 1_i
at IN 1_p
the DT 1_p
start NN 1_p
of IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Six CD N
months NNS N
later RB N
, , N
the DT N
children NNS 1_p
in IN N
group NN N
A NNP N
were VBD N
re-treated JJ N
with IN N
the DT N
same JJ N
dose NN N
of IN N
praziquantel NN 1_i
, , N
while IN N
the DT N
children NNS 1_p
in IN N
group NN N
B NNP N
were VBD N
given VBN N
placebos NNS 1_i
. . 1_i

All DT N
children NNS 1_p
were VBD N
followed VBN N
up RP N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
initial JJ N
treatment NN N
, , N
morbidity NN 1_o
being VBG N
clinically RB N
evaluated VBN N
at IN N
the DT N
six- JJ N
and CC N
12-month JJ N
follow-ups NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
, , N
in IN N
both DT N
groups NNS N
of IN N
children NNS 1_p
, , N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
splenomegaly NN 1_o
, , 1_o
hepatomegaly NN 1_o
, , 1_o
and CC 1_o
subjective JJ 1_o
symptoms NNS 1_o
of IN 1_o
morbidity NN 1_o
six CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
treatment NN N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
, , N
between IN N
the DT N
two CD N
groups NNS N
, , N
in IN N
the DT N
prevalences NNS N
of IN N
these DT N
symptoms NNS N
of IN N
morbidity NN 1_o
. . 1_o

It PRP N
therefore RB N
appears VBZ N
that IN N
once-yearly JJ N
treatment NN N
of IN N
children NNS 1_p
, , 1_p
in IN 1_p
this DT 1_p
and CC 1_p
similar JJ 1_p
endemic JJ 1_p
areas NNS 1_p
, , N
is VBZ N
sufficient JJ N
to TO N
reduce VB N
schistosomiasis NN N
morbidity NN N
to TO N
, , N
and CC N
maintain VB N
it PRP N
at IN N
, , N
a DT N
tolerable JJ N
level NN N
. . N

-DOCSTART- -X- O O

Removal NN 1_i
of IN 1_i
hypertrophied JJ 1_i
anal JJ 1_i
papillae NN 1_i
and CC 1_i
fibrous JJ 1_i
anal JJ 1_i
polyps NN 1_i
increases NNS N
patient JJ 1_o
satisfaction NN 1_o
after IN 1_p
anal JJ 1_p
fissure NN 1_p
surgery NN 1_p
. . 1_p

BACKGROUND NNP N
Hypertrophied NNP N
anal JJ N
papillae NN N
and CC N
fibrous JJ N
anal JJ N
polyps NNS N
are VBP N
frequently RB N
found VBN N
in IN N
association NN N
with IN N
chronic JJ N
fissure NN N
in IN N
ano NN N
. . N

Usually RB N
, , N
no DT N
specific JJ N
attention NN N
is VBZ N
given VBN N
to TO N
them PRP N
and CC N
they PRP N
are VBP N
considered VBN N
normal JJ N
findings NNS N
. . N

The DT N
present JJ N
prospective JJ N
study NN N
was VBD N
aimed VBN N
at IN N
determining VBG N
whether IN N
removal NN 1_i
of IN 1_i
hypertrophied JJ 1_i
anal JJ 1_i
papillae NN 1_i
and CC 1_i
fibrous JJ 1_i
anal JJ 1_i
polyps NNS 1_i
while IN N
dealing VBG N
with IN N
chronic JJ N
fissure NN N
in IN N
ano JJ N
confers NNS N
long-term JJ 1_o
benefit NN 1_o
to TO N
patients NNS 1_p
. . 1_p

METHODS NNP N
Between NNP 1_p
July NNP 1_p
1999 CD 1_p
and CC 1_p
December NNP 1_p
2000 CD 1_p
, , 1_p
140 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
anal JJ 1_p
sphincterotomy NN 1_p
were VBD N
randomized VBN 1_i
into IN 1_i
two CD 1_i
groups NNS 1_i
to TO 1_i
have VB 1_i
their PRP$ 1_i
fibrous JJ 1_i
polyps NNS 1_i
and CC 1_i
hypertrophied VBD 1_i
anal JJ 1_i
papillae NN 1_i
either DT 1_i
removed VBN 1_i
by IN 1_i
radiofrequency NN 1_i
surgery NN 1_i
or CC 1_i
left VBN 1_i
intact JJ 1_i
. . 1_i

After IN N
two CD N
years NNS N
, , N
they PRP N
underwent VBP N
a DT N
detailed JJ N
interview NN 1_o
by IN 1_o
an DT 1_o
independent JJ 1_o
, , 1_o
masked JJ 1_o
investigator NN 1_o
. . 1_o

RESULTS NNP N
Overall JJ N
84 CD N
% NN N
of IN N
patients NNS 1_p
who WP 1_p
had VBD 1_p
polyp NN 1_p
and CC 1_p
papilla NN 1_p
removal NN 1_p
rated VBD N
the DT N
outcome NN 1_o
of IN 1_o
their PRP$ 1_o
surgery NN 1_o
as IN N
excellent NN N
or CC N
good JJ N
in IN N
comparison NN N
to TO N
58 CD N
% NN N
of IN N
controls NNS N
. . N

The DT N
mean JJ N
satisfaction NN N
grading NN N
was VBD N
9.2 CD N
on IN N
a DT N
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
8.1 CD N
in IN N
controls NNS N
( ( N
p=0.004 NN N
) ) N
. . N

CONCLUSION NNP N
Removal NNP 1_i
of IN 1_i
hypertrophied JJ 1_i
anal JJ 1_i
papillae NN 1_i
and CC 1_i
fibrous JJ 1_i
anal JJ 1_i
polyps NNS 1_i
should MD N
be VB N
an DT N
essential JJ N
part NN N
of IN N
treatment NN N
of IN N
chronic JJ N
fissure NN N
in IN N
ano NN N
. . N

Persistence NN N
of IN N
these DT N
structures NNS N
leaves VBZ N
behind IN N
a DT N
sense NN N
of IN N
incomplete JJ N
treatment NN N
, , N
reducing VBG N
the DT N
overall JJ 1_o
satisfaction NN 1_o
on IN N
the DT N
part NN N
of IN N
the DT N
patient NN N
. . N

Radiofrequency NNP 1_i
procedure NN 1_i
is VBZ N
useful JJ N
in IN N
eradication NN N
of IN N
these DT N
concomitant JJ N
pathologies NNS N
. . N

-DOCSTART- -X- O O

Pilot NNP N
randomized VBD N
controlled VBN N
trial NN N
of IN N
Reciprocal NNP 1_i
Imitation NNP 1_i
Training NNP 1_i
for IN N
teaching VBG N
elicited VBN N
and CC N
spontaneous JJ 1_o
imitation NN 1_o
to TO N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Children NNP 1_p
with IN 1_p
autism NN 1_p
exhibit NN N
significant JJ N
deficits NNS N
in IN N
imitation NN 1_o
skills NNS 1_o
. . 1_o

Reciprocal JJ 1_i
Imitation NNP 1_i
Training NNP 1_i
( ( 1_i
RIT NNP 1_i
) ) 1_i
, , N
a DT N
naturalistic JJ N
imitation NN N
intervention NN N
, , N
was VBD N
developed VBN N
to TO N
teach VB N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
to TO N
imitate VB N
during IN N
play NN N
. . N

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
of IN N
RIT NNP N
on IN N
elicited VBN N
and CC N
spontaneous JJ N
imitation NN 1_o
skills NNS 1_o
in IN N
21 CD 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Results NNP N
found VBD N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB 1_o
more RBR 1_o
gains NNS 1_o
in IN N
elicited JJ 1_o
and CC 1_o
spontaneous JJ 1_o
imitation NN 1_o
, , N
replicating VBG N
previous JJ N
single-subject JJ N
design NN N
studies NNS N
. . N

Number NNP 1_o
of IN 1_o
spontaneous JJ 1_o
play NN 1_o
acts NNS 1_o
at IN N
pre-treatment NN N
was VBD N
related VBN N
to TO N
improvements NNS N
in IN N
imitation NN 1_o
during IN N
the DT N
intervention NN N
, , N
suggesting VBG N
that IN N
children NNS N
with IN N
a DT N
greater JJR N
play NN N
repertoire NN N
make VBP N
greater JJR N
gains NNS N
during IN N
RIT NNP N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
an DT N
Asha NNP 1_i
intervention NN 1_i
on IN N
depressive JJ 1_o
symptoms NNS 1_o
among IN N
rural JJ 1_p
women NNS 1_p
living VBG 1_p
with IN 1_p
AIDS NNP 1_p
in IN 1_p
India NNP 1_p
: : 1_p
comparison NN N
of IN N
the DT N
Asha-Life NNP 1_i
and CC 1_i
Usual NNP 1_i
Care NNP 1_i
program NN 1_i
. . 1_i

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
pilot NN N
study NN N
is VBZ N
to TO N
conduct VB N
an DT N
intervention NN N
with IN N
68 CD 1_p
rural JJ 1_p
women NNS 1_p
living VBG 1_p
with IN 1_p
AIDS NNP 1_p
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
two CD N
different JJ N
programs NNS N
on IN N
depressive JJ N
symptoms NNS N
. . N

The DT N
trial NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
Asha-Life NNP 1_i
intervention NN 1_i
engaging VBG N
with IN N
an DT N
HIV-trained JJ N
village NN N
woman NN N
, , N
Asha NNP 1_i
( ( 1_i
Accredited NNP 1_i
Social NNP 1_i
Health NNP 1_i
Activist NNP 1_i
) ) 1_i
, , N
to TO N
participate VB N
in IN N
the DT N
care NN N
of IN N
women NNS N
living VBG N
with IN N
AIDS NNP N
( ( N
WLA NNP N
) ) N
, , N
along IN N
with IN N
other JJ N
health NN N
care NN N
providers NNS N
compared VBN N
to TO N
a DT N
Usual NNP 1_i
Care NNP 1_i
group NN 1_i
. . 1_i

Two CD 1_p
high JJ 1_p
prevalence NN 1_p
HIV/AIDS NNP 1_p
villages NNS 1_p
in IN 1_p
rural JJ 1_p
Andhra NNP 1_p
Pradesh NNP 1_p
, , 1_p
which WDT 1_p
were VBD 1_p
demographically RB 1_p
alike JJ 1_p
and CC 1_p
served VBN 1_p
by IN 1_p
distinct JJ 1_p
Public NNP 1_p
Health NNP 1_p
Centers NNP 1_p
, , 1_p
were VBD 1_p
selected VBN 1_p
randomly RB 1_p
from IN 1_p
a DT 1_p
total NN 1_p
of IN 1_p
16 CD 1_p
villages NNS 1_p
. . 1_p

The DT N
findings NNS N
of IN N
this DT N
study NN N
demonstrated VBD N
that IN N
the DT N
Asha-Life JJ 1_i
participants NNS N
significantly RB 1_o
reduced VBD 1_o
their PRP$ N
depressive JJ 1_o
symptom NN 1_o
scores NNS 1_o
compared VBN N
to TO N
the DT N
Usual NNP N
Care NNP N
participants NNS N
. . N

Moreover RB N
, , N
women NNS 1_p
living VBG 1_p
with IN 1_p
AIDS NNP 1_p
who WP N
demonstrated VBD N
higher JJR N
depressive JJ 1_o
symptom NN 1_o
scores NNS 1_o
at IN N
baseline NN N
had VBD N
greater JJR N
reduction NN N
in IN N
their PRP$ N
depressive NN 1_o
symptoms NNS 1_o
than IN N
women NNS N
with IN N
lower JJR N
scores NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
fluoride NN 1_i
and CC 1_i
chlorhexidine NN 1_i
on IN N
the DT N
microflora NN 1_o
of IN 1_o
dental JJ 1_o
root NN 1_o
surfaces NNS 1_o
and CC N
progression NN N
of IN N
root-surface NN N
caries NNS N
. . N

The DT N
effects NNS N
of IN N
fluoride NN 1_i
and CC 1_i
chlorhexidine NN 1_i
varnishes NNS N
on IN N
the DT N
microflora NN N
of IN N
dental JJ N
root NN N
surfaces NNS N
and CC N
on IN N
the DT N
progression NN N
of IN N
root-surface NN N
caries NNS N
were VBD N
studied VBN N
. . N

Forty-four CD 1_p
patients NNS 1_p
, , 1_p
surgically RB 1_p
treated VBN 1_p
for IN 1_p
advanced JJ 1_p
periodontal JJ 1_p
disease NN 1_p
, , N
were VBD N
distributed VBN N
at IN N
random NN N
among IN N
three CD N
groups NNS N
. . N

All DT N
patients NNS N
received VBD N
a DT N
standardized JJ N
preventive JJ N
treatment NN N
. . N

Furthermore RB N
, , N
the DT N
dentition NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
two CD N
experimental JJ N
groups NNS N
was VBD N
treated VBN N
, , N
at IN N
three-month JJ N
intervals NNS N
, , N
with IN N
chlorhexidine NN 1_i
and CC 1_i
fluoride JJ 1_i
varnish NN 1_i
, , N
respectively RB N
. . N

Patients NNS N
in IN N
the DT N
control NN 1_i
group NN 1_i
received VBD N
no DT N
additional JJ N
treatment NN N
. . N

In IN N
the DT N
experimental JJ N
groups NNS N
, , N
plaque NN N
samples NNS N
were VBD N
collected VBN N
from IN N
selected VBN N
sound NN N
and CC N
carious JJ N
root NN N
surfaces NNS N
at IN N
baseline NN N
and CC N
at IN N
three CD N
, , N
six CD N
, , N
and CC N
nine CD N
months NNS N
after IN N
the DT N
onset NN N
of IN N
the DT N
study NN N
. . N

The DT N
presence NN N
of IN N
root-surface NN N
caries NNS N
was VBD N
scored VBN N
at IN N
baseline NN N
and CC N
after IN N
one CD N
year NN N
. . N

In IN N
addition NN N
, , N
the DT N
texture NN N
, , N
depth NN N
, , N
and CC N
color NN N
of IN N
the DT N
root-surface JJ N
lesions NNS N
were VBD N
monitored VBN N
. . N

Mutans NNPS 1_o
streptococci VBP 1_o
on IN 1_o
root NN 1_o
surfaces NNS 1_o
were VBD 1_o
suppressed VBN 1_o
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
during IN N
the DT N
whole JJ N
experimental JJ N
period NN N
in IN N
the DT N
chlorhexidine NN 1_i
varnish JJ N
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
fluoride JJ 1_i
varnish JJ N
group NN N
. . N

A DT N
non-significant JJ N
increase NN 1_o
in IN 1_o
the DT 1_o
number NN 1_o
of IN 1_o
Actinomyces NNP 1_o
viscosus/naeslundii NN 1_o
was VBD N
noted VBN N
after IN N
treatment NN N
with IN N
chlorhexidine NN 1_i
and CC N
fluoride JJ 1_i
varnish NN N
. . N

The DT N
increase NN 1_o
in IN 1_o
the DT 1_o
number NN 1_o
of IN 1_o
decayed JJ 1_o
and CC 1_o
filled JJ 1_o
root NN 1_o
surfaces NNS 1_o
after IN N
one CD N
year NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

After IN N
treatment NN N
with IN N
chlorhexidine JJ 1_i
varnish NN N
, , N
significantly RB N
more RBR N
initial JJ 1_o
root-surface JJ 1_o
lesions NNS 1_o
had VBD 1_o
hardened VBN 1_o
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

-DOCSTART- -X- O O

The DT N
individual JJ N
responsiveness NN N
to TO N
growth NN 1_i
hormone NN 1_i
( ( 1_i
GH NNP 1_i
) ) 1_i
treatment NN 1_i
in IN N
GH-deficient NNP 1_p
adults NNS 1_p
is VBZ N
dependent JJ N
on IN N
the DT N
level NN N
of IN N
GH-binding NNP N
protein NN N
, , N
body NN 1_o
mass NN 1_o
index NN 1_o
, , N
age NN N
, , N
and CC N
gender NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
study VB N
the DT N
individual JJ N
responsiveness NN N
to TO N
GH NNP 1_i
treatment NN 1_i
in IN N
terms NNS N
of IN N
body NN N
composition NN N
and CC N
to TO N
search VB N
for IN N
possible JJ N
predictors NNS N
of IN N
the DT N
response NN N
in IN N
GH-deficient NNP N
adults NNS N
. . N

Sixty-eight JJ 1_p
patients NNS 1_p
( ( 1_p
44 CD 1_p
men NNS 1_p
and CC 1_p
24 CD 1_p
women NNS 1_p
) ) 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
44.3 CD 1_p
( ( 1_p
1.2 CD 1_p
) ) 1_p
yr NN 1_p
and CC 1_p
verified VBD 1_p
GH NNP 1_p
deficiency NN 1_p
participated VBD 1_p
in IN 1_p
a DT 1_p
2-phase JJ 1_p
treatment NN 1_p
trial NN 1_p
with IN N
an DT N
initial JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ 1_i
, , N
6-month JJ N
period NN N
, , N
followed VBN N
by IN N
an DT N
open JJ N
treatment NN N
period NN N
, , N
thereby RB N
ensuring VBG N
all DT N
patients NNS 1_p
12 CD 1_p
months NNS 1_p
of IN 1_p
GH NNP 1_p
treatment NN 1_p
. . 1_p

Recombinant JJ 1_i
human JJ 1_i
GH NNP 1_i
was VBD N
administered VBN N
sc JJ N
daily RB N
at IN N
bedtime NN N
, , N
with IN N
a DT N
target NN N
dose NN N
of IN N
12 CD N
micrograms/kg NNS N
x JJ N
day NN N
. . N

GHBP NNP N
was VBD N
measured VBN N
by IN N
ligand-mediated JJ N
immunofunctional JJ N
assay NN N
, , N
and CC N
serum JJ N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
was VBD N
determined VBN N
by IN N
RIA NNP N
after IN N
acid-ethanol JJ N
extraction NN N
, , N
using VBG N
a DT N
truncated JJ N
IGF-I JJ N
analog NN N
as IN N
the DT N
radioligand NN N
. . N

Lean JJ 1_o
body NN 1_o
mass NN 1_o
( ( 1_o
LBM NNP 1_o
) ) 1_o
and CC 1_o
body NN 1_o
fat NN 1_o
( ( 1_o
BF NNP 1_o
) ) 1_o
were VBD N
determined VBN N
by IN N
dual JJ N
energy NN N
x-ray JJ N
absorptiometry NN N
, , N
and CC N
total JJ N
body NN N
water NN N
( ( N
TBW NNP N
) ) N
was VBD N
determined VBN N
by IN N
bioelectrical JJ N
impedance NN N
. . N

During IN N
the DT N
placebo NN N
control NN N
period NN N
, , N
serum JJ 1_o
IGF-I NNP 1_o
, , 1_o
LBM NNP 1_o
, , 1_o
and CC 1_o
TBW NNP 1_o
increased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
BF NNP 1_o
decreased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
serum JJ 1_o
GHBP NNP 1_o
was VBD N
unchanged JJ N
in IN N
the DT N
group NN N
treated VBD N
with IN N
GH NNP N
compared VBN N
with IN N
the DT N
patients NNS N
treated VBN N
with IN N
placebo NN N
. . N

After IN N
12 CD N
months NNS N
of IN N
GH NNP N
treatment NN N
, , N
the DT N
individual JJ N
changes NNS N
in IN N
BF NNP 1_o
ranged VBD N
from IN N
-12.5 NN N
to TO N
4.3 CD N
kg NNS N
and CC N
from IN N
-4.5 NNP N
to TO N
10.1 CD N
kg NNS N
in IN N
LBM NNP N
. . N

Age NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
baseline JJ 1_o
GHBP NNP 1_o
level NN 1_o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
increase NN N
in IN N
LBM NNP N
. . N

The DT N
GH-induced JJ 1_o
increment NN 1_o
in IN 1_o
IGF-I NNP 1_o
and CC 1_o
TBW NNP 1_o
was VBD N
greater JJR N
in IN N
men NNS N
than IN N
in IN N
women NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas IN N
the DT N
decreases NNS N
in IN N
BF NNP 1_o
were VBD N
similar JJ N
in IN N
men NNS N
and CC N
women NNS N
. . N

This DT N
trial NN N
demonstrates VBZ N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
GH NNP 1_i
administration NN N
in IN N
GH-deficient NNP N
adults NNS N
. . N

The DT N
best JJS N
response NN N
to TO N
GH NNP N
was VBD N
obtained VBN N
in IN N
younger JJR N
patients NNS N
with IN N
low JJ N
GHBP NNP N
levels NNS N
. . N

Furthermore RB N
, , N
men NNS N
responded VBD N
better RBR N
than IN N
women NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Diphtheria NNP N
antitoxin NN N
level NN N
2 CD N
years NNS N
after IN N
booster NN 1_i
vaccination NN 1_i
] NNP 1_i
. . N

In IN N
a DT N
prospective JJ N
, , N
controlled VBN N
, , N
randomized VBN N
, , N
multicenter RBR N
study VBP N
the DT N
immunogenicity NN N
of IN N
a DT N
single JJ N
( ( N
day NN N
0 CD N
) ) N
and CC N
two CD N
( ( N
day NN N
0 CD N
, , N
28 CD N
) ) N
booster NN 1_i
vaccination NN 1_i
against IN 1_i
diphtheria NN 1_i
were VBD N
compared VBN N
in IN N
subjects NNS 1_p
who WP 1_p
had VBD 1_p
received VBN 1_p
their PRP$ 1_p
last JJ 1_p
diphtheria NN 1_i
vaccination NN 1_i
more JJR 1_p
than IN 1_p
10 CD 1_p
years NNS 1_p
ago RB 1_p
. . 1_p

Both DT N
short-term JJ N
and CC N
long-term JJ N
immunogenicity NN N
was VBD N
assessed VBN N
by IN N
determining VBG N
diphtheria NN 1_o
antitoxin NN 1_o
levels NNS 1_o
four CD N
weeks NNS N
after IN N
vaccination NN 1_i
and CC N
after IN N
one CD N
and CC N
two CD N
years NNS N
. . N

102 CD 1_p
subjects NNS 1_p
received VBD 1_p
the DT 1_p
first JJ 1_i
booster NN 1_i
vaccination NN 1_i
, , 1_i
and CC 1_i
83 CD 1_i
were VBD 1_i
vaccinated VBN 1_i
twice RB 1_i
. . 1_i

Prior NNP N
to TO N
the DT N
first JJ N
vaccination NN N
27 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
subjects NNS 1_p
had VBD N
a DT N
diphtheria NN 1_o
antitoxin NN 1_o
level NN 1_o
below IN N
0.01 CD N
I.U./ml NNP N
; : N
after IN N
the DT N
first JJ N
booster NN N
only RB N
5 CD N
% NN N
were VBD N
unprotected VBN N
. . N

The DT N
second JJ N
booster NN 1_i
did VBD N
not RB N
show VB N
a DT N
significant JJ N
effect NN N
, , N
however RB N
, , N
in IN N
1 CD N
of IN N
the DT N
5 CD N
subjects NNS N
who WP N
were VBD N
still RB N
unprotected VBN N
after IN N
the DT N
first JJ N
booster NN N
the DT N
second JJ N
elicited VBD N
an DT N
antitoxin JJ 1_o
level NN 1_o
of IN N
more JJR N
than IN N
0.01 CD N
I.U./ml NNP N
. . N

After IN N
one CD N
and CC N
two CD N
years NNS N
7 CD 1_p
% NN 1_p
and CC 1_p
8 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
subjects NNS 1_p
had VBD N
diphtheria VBN 1_o
antitoxin JJ 1_o
level NN 1_o
below IN N
0.01 CD N
I.U./ml NNP N
. . N

A NNP N
serological JJ N
effect NN N
of IN N
a DT N
second JJ N
booster NN 1_i
vaccination NN 1_i
four CD N
weeks NNS N
after IN N
the DT N
first JJ N
one NN N
could MD N
not RB N
be VB N
demonstrated VBN N
neither RB N
after IN N
one CD N
nor CC N
after IN N
two CD N
years NNS N
. . N

-DOCSTART- -X- O O

Intranasal NNP 1_i
recombinant JJ 1_i
alfa-2b JJ 1_i
interferon NN 1_i
treatment NN 1_o
of IN N
naturally RB 1_o
occurring VBG 1_o
common JJ 1_o
colds NNS 1_o
. . 1_o

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
patients NNS 1_p
with IN 1_p
naturally RB 1_p
occurring VBG 1_p
common JJ 1_p
colds NNS 1_p
of IN 1_p
less JJR 1_p
than IN 1_p
or CC 1_p
equal JJ 1_p
to TO 1_p
48 CD 1_p
h NNS 1_p
duration NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
nasal JJ N
sprays NNS N
of IN N
recombinant JJ 1_i
alfa-2b JJ 1_i
interferon NN 1_i
at IN N
10 CD N
or CC N
20 CD N
MU/day NNPS N
or CC N
placebo VB 1_i
four CD N
times NNS N
per IN N
day NN N
for IN N
5 CD N
days NNS N
. . N

The DT N
10-MU JJ 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
74 CD 1_p
) ) 1_p
, , 1_p
20-MU JJ 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
74 CD 1_p
) ) 1_p
, , 1_p
and CC 1_p
placebo NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
72 CD 1_p
) ) 1_p
groups NNS 1_p
had VBD N
comparable JJ N
frequencies NNS N
of IN N
documented JJ N
rhinovirus NN N
colds NNS N
( ( N
50 CD N
to TO N
65 CD N
% NN N
) ) N
and CC N
mean JJ 1_o
durations NNS 1_o
of IN 1_o
pretreatment NN 1_o
symptoms NNS 1_o
( ( N
26 CD N
to TO N
27 CD N
h NN N
) ) N
. . N

The DT N
median JJ 1_o
duration NN 1_o
of IN 1_o
colds NNS 1_o
tended VBD N
to TO N
be VB N
longer RBR N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
10 CD N
days NNS N
) ) N
than IN N
the DT N
10-MU JJ N
group NN N
( ( N
8 CD N
days NNS N
) ) N
or CC N
placebo VBN 1_i
group NN N
( ( N
8 CD N
days NNS N
) ) N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
. . N

In IN N
those DT N
with IN N
proven JJ N
rhinovirus NN N
colds NNS N
treated VBD N
within IN N
24 CD N
h NN N
, , N
the DT N
median JJ 1_o
duration NN 1_o
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
9 CD N
days NNS N
) ) N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
6 CD N
days NNS N
) ) N
. . N

No DT N
differences NNS N
favoring VBG N
interferon NN N
treatment NN N
were VBD N
found VBN N
in IN N
respiratory JJ 1_o
symptom JJ 1_o
scores NNS 1_o
or CC 1_o
resolution NN 1_o
of IN 1_o
specific JJ 1_o
symptoms NNS 1_o
. . 1_o

On IN N
days NNS N
5 CD N
and CC N
7 CD N
, , N
nasal JJ 1_i
washings NNS 1_i
from IN N
compliant JJ N
subjects NNS N
with IN N
proven JJ N
rhinovirus NN N
colds NNS N
yielded VBD N
rhinoviruses NNS N
more RBR N
often RB N
in IN N
placebo NN 1_i
( ( N
47 CD N
and CC N
48 CD N
% NN N
, , N
respectively RB N
) ) N
than IN N
in IN N
interferon NN 1_i
( ( N
15 CD N
and CC N
16 CD N
% NN N
, , N
respectively RB N
) ) N
recipients NNS N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
no DT N
differences NNS N
in IN N
new JJ N
respiratory NN 1_o
illness JJ 1_o
occurrence NN 1_o
were VBD N
observed VBN N
in IN N
household NN N
contacts NNS N
. . N

Interferon NNP 1_i
recipients NNS N
had VBD N
significantly RB N
higher JJR N
frequencies NNS N
of IN N
blood NN 1_o
in IN 1_o
nasal JJ 1_o
mucus NN 1_o
( ( N
16 CD N
to TO N
18 CD N
% NN N
) ) N
than IN N
did VBD N
placebo VB 1_i
recipients NNS N
( ( N
4 CD N
% NN N
) ) N
during IN N
treatment NN N
. . N

Antibiotics NNS 1_o
for IN N
presumed JJ N
secondary JJ N
infections NNS N
were VBD N
given VBN N
more RBR N
often RB N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
11 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
0 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Nasal NNP N
sprays NNS N
of IN N
recombinant JJ 1_i
alfa-2b JJ 1_i
interferon NN 1_i
were VBD N
not RB N
an DT N
effective JJ 1_o
treatment NN 1_o
for IN 1_o
natural JJ 1_o
colds NNS 1_o
and CC N
were VBD N
associated VBN N
with IN N
toxicity NN 1_o
. . 1_o

-DOCSTART- -X- O O

Timing VBG N
for IN N
delivering VBG N
individualized JJ 1_i
patient JJ 1_i
education NN 1_i
intervention NN 1_i
to TO N
Coronary NNP 1_p
Artery NNP 1_p
Bypass NNP 1_p
Graft NNP 1_p
patients NNS 1_p
: : 1_p
An DT N
RCT NNP N
. . N

BACKGROUND NNP N
The DT N
primary JJ N
focus NN N
of IN N
this DT N
study NN N
is VBZ N
on IN N
the DT N
timing NN N
of IN N
the DT N
delivery NN N
of IN N
education NN N
to TO N
patients NNS 1_p
who WP 1_p
had VBD 1_p
CABG NNP 1_i
surgery NN 1_i
. . 1_i

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
an DT N
individualized JJ 1_i
telephone NN 1_i
patient JJ 1_i
education NN 1_i
intervention NN 1_i
, , N
delivered VBN N
at IN N
two CD N
different JJ N
points NNS N
in IN N
time NN N
( ( N
1-2 JJ N
days NNS N
pre-discharge JJ N
versus JJ N
1-2 JJ N
days NNS N
post-discharge NN N
) ) N
in IN N
enhancing VBG N
the DT N
CABG NNP 1_p
patient NN 1_p
's POS 1_p
knowledge NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
performance NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
and CC N
symptom JJ N
frequency NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
clinical JJ N
trial NN N
that WDT N
included VBD N
a DT N
convenience NN 1_p
sample NN 1_p
of IN 1_p
first JJ 1_p
time NN 1_p
CABG NNP 1_p
patients NNS 1_p
. . 1_p

Individuals NNS N
who WP N
received VBD N
education NN 1_i
pre-discharge NN 1_i
were VBD N
compared VBN N
to TO N
individuals NNS 1_p
who WP 1_p
received VBD 1_p
education NN 1_p
post-discharge NN 1_p
on IN 1_p
the DT 1_p
outcomes NNS 1_p
. . 1_p

RESULTS NNP N
Results NNP N
indicated VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
outcomes NNS 1_o
between IN 1_o
the DT 1_o
two CD 1_o
time NN 1_o
points NNS 1_o
. . 1_o

As NNP N
well RB N
, , N
anxiety NN 1_o
levels NNS 1_o
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
pre-discharge NN N
group NN N
than IN N
the DT N
post-discharge JJ N
group NN N
. . N

CONCLUSIONS VB N
The DT N
individualized JJ N
nature NN N
of IN N
the DT N
educational JJ 1_i
intervention NN 1_i
may MD N
have VB N
accounted VBN N
for IN N
non-significant JJ N
findings NNS N
reported VBN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
Nurses NNP N
may MD N
consider VB N
assessing VBG N
anxiety NN 1_o
levels NNS 1_o
prior RB N
to TO N
delivery NN N
of IN N
educational JJ N
interventions NNS N
, , N
implement JJ N
interventions NNS N
aimed VBN N
at IN N
reducing VBG N
anxiety NN N
levels NNS N
, , N
and CC N
provide VB N
individualized JJ N
teaching NN N
. . N

-DOCSTART- -X- O O

Two CD N
different JJ N
methods NNS N
for IN N
donor JJ 1_p
hepatic JJ 1_p
transection NN 1_p
: : 1_p
cavitron NN 1_i
ultrasonic JJ 1_i
surgical JJ 1_i
aspirator NN 1_i
with IN 1_i
bipolar JJ 1_i
cautery NN 1_i
versus NN N
cavitron NN 1_i
ultrasonic JJ 1_i
surgical JJ 1_i
aspirator NN 1_i
with IN 1_i
radiofrequency NN 1_i
coagulator-A JJ 1_i
randomized VBN N
controlled JJ N
trial NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
Cavitron NNP 1_i
ultrasonic JJ 1_i
surgical JJ 1_i
aspirator NN 1_i
( ( 1_i
CUSA NNP 1_i
) ) 1_i
with IN 1_i
bipolar JJ 1_i
cautery NN 1_i
( ( 1_i
BP NNP 1_i
) ) 1_i
to TO 1_i
CUSA NNP 1_i
with IN 1_i
a DT 1_i
radiofrequency NN 1_i
coagulator NN 1_i
[ NN N
TissueLink NNP N
( ( N
TL NNP N
) ) N
] VBP N
in IN N
terms NNS N
of IN N
efficacy NN N
and CC N
safety NN N
for IN N
hepatic JJ N
transection NN N
in IN N
living VBG N
donor NN N
liver JJ N
transplantation NN N
. . N

Twenty-four CD 1_p
living NN 1_p
liver NN 1_p
donors NNS 1_p
( ( 1_p
n JJ 1_p
= VBP 1_p
12 CD 1_p
for IN 1_p
each DT 1_p
group NN 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
undergo VB N
hepatic JJ N
transection NN N
using VBG N
CUSA NNP 1_i
with IN 1_i
BP NNP 1_i
or CC N
CUSA NNP 1_i
with IN 1_i
TL NNP 1_i
. . 1_i

Blood NNP 1_o
loss NN 1_o
during IN 1_o
parenchymal JJ 1_o
transection NN 1_o
and CC 1_o
speed NN 1_o
of IN 1_o
transection NN 1_o
were VBD N
the DT N
primary JJ N
endpoints NNS N
, , N
whereas IN N
the DT N
degree NN 1_o
of IN 1_o
postoperative JJ 1_o
liver JJ 1_o
injury NN 1_o
and CC 1_o
morbidity NN 1_o
were VBD N
secondary JJ N
endpoints NNS N
. . N

Median JJ 1_o
blood NN 1_o
loss NN 1_o
during IN 1_o
liver JJ 1_o
transection NN 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
195.2 CD N
+/- JJ N
84.5 CD N
versus NN N
343.3 CD N
+/- JJ N
198.4 CD N
mL NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
, , N
and CC N
liver JJS 1_o
transection NN 1_o
was VBD N
significantly RB N
faster RBR N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
0.7 CD N
+/- JJ N
0.2 CD N
versus NN N
0.5 CD N
+/- JJ N
0.2 CD N
cm NN N
( ( N
2 CD N
) ) N
/minute NN N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

Significantly RB N
fewer JJR 1_o
ties NNS 1_o
were VBD N
required VBN N
during IN N
liver JJ N
transection NN N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
15.8 CD N
+/- JJ N
4.8 CD N
versus NN N
22.8 CD N
+/- JJ N
7.9 CD N
ties NNS N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

The DT N
morbidity NN 1_o
rates NNS 1_o
were VBD N
similar JJ N
for IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
CUSA NNP N
with IN N
TL NNP N
is VBZ N
superior JJ N
to TO N
CUSA NNP N
with IN N
BP NNP N
for IN N
donor JJ N
hepatectomy NN N
in IN N
terms NNS N
of IN N
blood NN 1_o
loss NN 1_o
and CC 1_o
speed NN 1_o
of IN 1_o
transection NN 1_o
with IN 1_o
no DT 1_o
increase NN 1_o
in IN 1_o
morbidity NN 1_o
. . 1_o

-DOCSTART- -X- O O

Phase NNP N
III NNP N
trial NN N
of IN N
satraplatin NN 1_i
, , N
an DT N
oral JJ N
platinum NN 1_i
plus CC 1_i
prednisone NN 1_i
vs. FW 1_i
prednisone NN 1_i
alone RB 1_i
in IN N
patients NNS 1_p
with IN 1_p
hormone-refractory JJ 1_p
prostate NN 1_p
cancer NN 1_p
. . 1_p

Satraplatin NNP 1_i
is VBZ N
a DT N
novel JJ N
oral JJ N
platinum NN 1_i
( ( N
IV NNP N
) ) N
complex VBP N
that DT N
shows VBZ N
activity NN N
against IN N
hormone-refractory JJ 1_p
prostate NN 1_p
cancer NN 1_p
( ( 1_p
HRPC NNP 1_p
) ) 1_p
in IN N
cisplatin-resistant JJ 1_i
human JJ N
tumor NN N
lines NNS N
in IN N
phase NN N
I PRP N
and CC N
phase VB N
II NNP N
trials NNS N
. . N

A DT N
randomized JJ N
multicenter NN N
phase NN N
III NNP N
trial NN N
with IN N
a DT N
target NN N
sample JJ N
size NN N
of IN N
380 CD 1_p
patients NNS 1_p
was VBD 1_p
initiated VBN 1_p
in IN 1_p
men NNS 1_p
with IN 1_p
HRPC NNP 1_p
. . 1_p

After IN N
50 CD 1_p
randomized JJ 1_p
patients NNS 1_p
, , N
the DT N
trial NN N
was VBD N
closed VBN N
to TO N
further RBR N
accrual JJ N
by IN N
the DT N
sponsoring VBG N
company NN N
. . N

An DT N
ad NN N
hoc NN N
analysis NN N
of IN N
all DT N
available JJ N
data NNS N
is VBZ N
reported VBN N
here RB N
. . N

Eligibility NNP N
criteria NNS N
included VBD N
pathological JJ N
proof NN N
of IN N
prostate NN 1_p
cancer NN 1_p
, , N
documented VBN N
progression NN N
despite IN N
prior JJ N
hormonal JJ N
manipulation NN N
, , N
WHO WP N
PS NNP N
0-2 NN N
, , N
and CC N
no DT N
daily JJ N
intake NN N
of IN N
narcotic JJ 1_i
analgesics NNS 1_i
. . 1_i

Patients NNS N
were VBD N
randomized VBN N
between IN N
satraplatin NN 1_i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
for IN N
5 CD N
days NNS N
plus CC N
prednisone JJ 1_i
10 CD N
mg NNS N
orally RB N
BID NNP N
or CC N
prednisone VB 1_i
alone RB N
. . N

Compliance NN N
was VBD N
excellent JJ N
. . N

48/50 CD N
patients NNS N
have VBP N
progressed VBN 1_o
and CC N
42 CD N
have VBP N
died VBN 1_o
, , N
mostly RB N
due JJ N
to TO N
prostate VB N
cancer NN N
. . N

Median JJ 1_o
overall JJ 1_o
survival NN 1_o
was VBD N
14.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
13.7-28.4 JJ N
) ) N
on IN N
the DT N
satraplatin NN 1_i
plus CC N
prednisone NN 1_i
arm NN N
and CC N
11.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
8.4-23.1 JJ N
) ) N
on IN N
prednisone NN 1_i
alone RB N
( ( N
hazard JJ N
ratio NN N
, , N
HR NNP N
= NNP N
0.84 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.46-1.55 NN N
) ) N
. . N

A DT N
> JJ N
50 CD N
% NN N
decrease NN N
in IN N
prostrate NN 1_o
specific JJ 1_o
antigen NN 1_o
( ( N
PSA NNP N
) ) N
was VBD N
seen VBN N
in IN N
9/27 CD N
( ( N
33.3 CD N
% NN N
) ) N
in IN N
the DT N
satraplatin NN 1_i
plus CC 1_i
prednisone NN 1_i
arm NN N
vs. FW N
2/23 CD N
( ( N
8.7 CD N
% NN N
) ) N
on IN N
the DT N
prednisone NN 1_i
alone RB N
arm NN N
. . N

Progression-free JJ 1_o
survival NN 1_o
was VBD N
5.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.8-13.7 JJ N
) ) N
on IN N
the DT N
satraplatin NN 1_i
plus CC N
prednisone NN 1_i
arm NN N
as IN N
compared VBN N
to TO N
2.5 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.1- JJ N
4.7 CD N
) ) N
on IN N
the DT N
prednisone NN 1_i
alone RB N
arm NN N
( ( N
HR NNP N
= NNP N
0.50 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.28-0.92 NN N
) ) N
. . N

This DT N
difference NN N
is VBZ N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.023 CD N
) ) N
. . N

Toxicity NN 1_o
was VBD N
generally RB N
minimal JJ N
in IN N
both DT N
arms NNS N
. . N

This DT N
randomized JJ N
comparison NN N
of IN N
a DT N
combination NN N
of IN N
satraplatin NN 1_i
and CC 1_i
prednisone NN 1_i
versus NN N
prednisone NN N
alone RB N
supports VBZ N
the DT N
antitumor NN N
activity NN N
of IN N
the DT N
combination NN N
. . N

Its PRP$ N
role NN N
in IN N
the DT N
treatment NN N
of IN N
HPRC NNP N
remains VBZ N
to TO N
be VB N
elucidated VBN N
in IN N
an DT N
appropriate JJ N
phase NN N
III NNP N
setting NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
controlled VBN N
, , N
parallel-group JJ N
trial NN N
of IN N
routine JJ 1_i
prophylaxis NN 1_i
vs. IN 1_i
on-demand JJ 1_i
treatment NN 1_i
with IN 1_i
sucrose-formulated JJ 1_i
recombinant JJ 1_i
factor NN 1_i
VIII NNP 1_i
in IN 1_p
adults NNS 1_p
with IN 1_p
severe JJ 1_p
hemophilia NN 1_p
A NNP 1_p
( ( 1_p
SPINART NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND IN N
The DT N
benefits NNS N
of IN N
routine JJ 1_i
prophylaxis NN 1_i
vs. IN 1_i
on-demand JJ 1_i
treatment NN 1_i
with IN 1_i
factor NN 1_i
VIII NNP 1_i
products NNS 1_i
have VBP 1_i
not RB N
been VBN N
evaluated VBN N
in IN N
controlled JJ N
clinical JJ N
trials NNS N
in IN N
older JJR 1_p
patients NNS 1_p
with IN 1_p
hemophilia PDT 1_p
A NNP 1_p
. . N

OBJECTIVES NNP N
To TO N
report VB N
results NNS N
from IN N
a DT N
preplanned JJ N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
first JJ N
year NN N
of IN N
the DT N
3-year JJ N
SPINART NNP N
study NN N
, , N
which WDT N
compares VBZ N
routine JJ N
prophylaxis NN N
with IN N
on-demand JJ N
treatment NN N
with IN 1_i
sucrose-formulated JJ 1_i
recombinant JJ 1_i
FVIII NNP 1_i
( ( 1_i
rFVIII-FS NN 1_i
) ) 1_i
. . 1_i

PATIENTS/METHODS NNP N
SPINART NNP N
is VBZ N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
parallel-group NN N
, , N
multinational JJ N
trial NN 1_p
. . 1_p

Males NNS 1_p
aged VBN 1_p
12-50 CD 1_p
years NNS 1_p
with IN 1_p
severe JJ 1_p
hemophilia NN 1_p
A NNP 1_p
, , 1_p
? . 1_p
150 CD 1_p
days NNS 1_p
of IN 1_p
exposure NN 1_p
to TO 1_p
FVIII NNP 1_p
, , 1_p
no DT 1_p
FVIII NNP 1_p
inhibitors NNS 1_p
, , 1_p
no DT 1_p
prophylaxis NN 1_p
for IN 1_p
> $ 1_p
12 CD 1_p
consecutive JJ 1_p
months NNS 1_p
in IN 1_p
the DT 1_p
past JJ 1_p
5 CD 1_p
years NNS 1_p
and CC 1_p
6-24 JJ 1_p
bleeding NN 1_p
episodes NNS 1_p
in IN 1_p
the DT 1_p
preceding VBG 1_p
6 CD 1_p
months NNS 1_p
were VBD 1_p
randomized VBN N
1 CD N
: : N
1 CD N
to TO N
rFVIII-FS JJ 1_i
prophylaxis NN 1_i
( ( 1_i
25 CD 1_i
IU NNP 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
, , 1_i
three CD 1_i
times NNS 1_i
weekly JJ 1_i
) ) 1_i
or CC 1_i
on-demand JJ 1_i
treatment NN 1_i
. . 1_i

The DT 1_i
primary JJ N
efficacy NN N
endpoint NN 1_o
, , 1_o
number NN 1_o
of IN 1_o
total JJ 1_o
bleeding VBG 1_o
episodes NNS 1_o
in IN 1_o
the DT N
intent-to-treat JJ N
population NN N
, , N
was VBD N
analyzed VBN N
after IN N
the DT N
last JJ N
patient NN N
had VBD N
completed VBN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

A DT N
negative JJ N
binomial JJ N
model NN N
was VBD N
used VBN N
for IN N
the DT N
primary JJ N
endpoint NN N
analysis NN N
; : N
analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
for IN N
confirmatory JJ N
analysis NN N
of IN N
annualized JJ N
bleeding NN N
rates NNS N
. . N

RESULTS NNP 1_p
Eighty-four JJ 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
and CC 1_p
analyzed VBN 1_p
( ( 1_p
n JJ 1_p
= $ 1_p
42 CD 1_p
per IN 1_p
group NN 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
30.6 CD 1_p
years NNS 1_p
; : 1_p
median JJ 1_p
treatment NN 1_p
duration NN 1_p
, , 1_p
1.7 CD 1_p
years NNS 1_p
) ) 1_p
. . 1_p

The DT 1_p
median JJ N
number NN N
of IN N
total JJ 1_o
bleeding NN 1_o
episodes NNS 1_o
and CC 1_o
total JJ 1_o
bleeding NN 1_o
episodes NNS 1_o
per IN N
year NN N
were VBD N
significantly RB N
lower JJR N
with IN N
prophylaxis NN N
than IN N
with IN N
on-demand JJ N
treatment NN N
( ( N
total JJ N
, , N
0 CD N
vs. FW N
54.5 CD N
; : N
total JJ N
per IN N
year NN N
, , N
0 CD N
vs. FW N
27.9 CD N
; : N
both DT N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

No DT N
treatment-related JJ N
adverse JJ N
events NNS N
occurred VBD N
, , N
and CC N
no DT N
patients NNS N
developed VBD N
FVIII NNP N
inhibitors NNS N
. . N

CONCLUSIONS NNP N
Routine NNP N
prophylaxis NN N
with IN N
rFVIII-FS JJ 1_i
leads NNS 1_i
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
bleeding VBG N
as IN N
compared VBN N
with IN N
on-demand JJ N
treatment NN N
. . N

Adverse JJ N
events NNS N
were VBD N
consistent JJ N
with IN N
the DT N
established VBN 1_i
rFVIII-FS NN 1_i
safety NN 1_i
profile NN N
. . N

-DOCSTART- -X- O O

Reliable JJ N
LC-MS/MS JJ 1_i
assay NN 1_i
for IN N
the DT N
estimation NN 1_o
of IN 1_o
rilpivirine NN 1_o
in IN 1_p
human JJ 1_p
plasma NN 1_p
: : 1_p
application NN N
to TO N
a DT N
bioequivalence NN N
study NN N
and CC N
incurred JJ N
sample NN N
reanalysis NN N
. . N

A DT N
simple JJ N
, , N
precise JJ N
, , N
and CC N
rapid JJ N
stable JJ N
isotope NN N
dilution NN N
liquid VBD N
chromatography-tandem JJ N
mass NN N
spectrometry NN N
method NN N
has VBZ N
been VBN N
developed VBN N
and CC N
validated VBN N
for IN N
the DT N
quantification NN N
of IN N
rilpivirine NN 1_p
, , N
a DT N
non-nucleoside JJ N
reverse NN N
transcriptase NN N
inhibitor NN N
in IN N
human JJ 1_p
plasma NN 1_p
. . 1_p

Rilpivirine NNP N
and CC N
its PRP$ N
deuterated JJ N
analogue NN N
, , N
rilpivirine-d6 NN 1_i
, , N
used VBD N
as IN N
an DT N
internal JJ N
standard NN N
( ( N
IS NNP N
) ) N
were VBD N
quantitatively RB N
extracted VBN N
by IN N
liquid-liquid JJ N
extraction NN N
with IN N
methyl-tert-butyl JJ N
ether NN N
and CC N
diethyl NN N
ether RB N
solvent JJ N
mixture NN N
from IN N
50 CD N
?L JJ N
plasma NN N
. . N

The DT N
chromatography NN N
was VBD N
achieved VBN N
on IN N
Gemini NNP N
C18 NNP N
( ( N
150 CD N
? . N
4.6 CD N
mm NN N
, , N
5 CD N
?m NN N
) ) N
analytical JJ N
column NN N
in IN N
a DT N
run JJ N
time NN N
of IN N
2.2 CD N
min NN N
. . N

The DT N
precursor NN N
? . N
product NN N
ion NN N
transitions NNS N
for IN N
rilpivirine NN N
( ( N
m/z $ N
367.1 CD N
? . N
128.0 CD N
) ) N
and CC N
IS NNP N
( ( N
m/z $ N
373.2 CD N
? . N
134.2 CD N
) ) N
were VBD N
monitored VBN N
on IN N
a DT N
triple JJ N
quadrupole JJ N
mass NN N
spectrometer NN N
in IN N
the DT N
positive JJ N
ionization NN N
mode NN N
. . N

The DT N
linearity NN N
of IN N
the DT N
method NN N
was VBD N
established VBN N
in IN N
the DT N
concentration NN N
range NN N
of IN N
0.5-200 JJ N
ng/mL NN N
. . N

The DT 1_o
mean JJ 1_o
extraction NN 1_o
recovery NN 1_o
for IN N
rilpivirine NN N
( ( N
94.9 CD N
% NN N
) ) N
and CC N
IS NNP N
( ( N
99.9 CD N
% NN N
) ) N
from IN N
spiked VBN N
plasma NN N
samples NNS N
was VBD N
consistent JJ N
and CC N
reproducible JJ 1_o
. . 1_o

The DT 1_o
IS-normalized JJ 1_o
matrix NN 1_o
factors NNS 1_o
for IN 1_o
rilpivirine NN 1_o
ranged VBN N
from IN N
0.98 CD N
to TO N
1.02 CD N
across IN N
three CD N
quality NN N
controls NNS 1_o
. . 1_o

Bench NNP 1_o
top JJ 1_o
, , 1_o
freeze-thaw JJ 1_o
, , 1_o
wet JJ 1_o
extract NN 1_o
, , 1_o
and CC 1_o
long-term JJ 1_o
stability NN 1_o
of IN N
rilpivirine NN N
was VBD N
examined VBN N
in IN N
spiked JJ N
plasma NN N
samples NNS N
. . N

The DT N
application NN N
of IN N
the DT N
method NN N
was VBD N
demonstrated VBN N
by IN N
a DT N
bioequivalence NN N
study NN N
with IN N
25 CD 1_i
mg NNS 1_i
rilpivirine JJ 1_i
tablet NN 1_i
formulation NN 1_p
in IN 1_p
40 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

The DT N
assay JJ N
reproducibility NN N
was VBD N
shown VBN N
by IN N
reanalysis NN N
of IN 1_p
200 CD 1_p
study NN 1_p
samples NNS 1_p
and CC 1_p
the DT N
% NN N
change NN N
in IN N
the DT N
concentration NN N
of IN N
repeat NN N
values NNS N
from IN N
the DT N
original JJ N
values NNS N
was VBD N
within IN N
?15 NNP N
% NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
metformin NN 1_i
and CC 1_i
insulin NN 1_i
on IN N
sympathetic JJ N
nerve NN N
activity NN N
, , N
norepinephrine JJ N
spillover NN N
and CC N
blood NN N
pressure NN N
in IN N
obese JJ 1_p
, , 1_p
insulin JJ 1_p
resistant NN 1_p
, , 1_p
normoglycemic JJ 1_p
, , 1_p
hypertensive JJ 1_p
men NNS 1_p
. . 1_p

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
metformin NN 1_i
on IN N
insulin NN N
sensitivity NN N
and CC N
to TO N
further RBR N
examine VB N
the DT N
relationship NN N
between IN N
insulin NN N
resistance NN N
, , N
sympathetic JJ N
nerve NN N
activity NN N
and CC N
blood NN N
pressure NN N
, , N
6 CD 1_p
obese JJ 1_p
insulin NN 1_p
resistant NN 1_p
, , 1_p
normoglycemic JJ 1_p
hypertensive JJ 1_p
men NNS 1_p
were VBD 1_p
investigated VBN 1_p
( ( 1_p
age NN 1_p
49 CD 1_p
+/- JJ 1_p
2 CD 1_p
years NNS 1_p
, , 1_p
BMI NNP 1_p
27.6 CD 1_p
+/- JJ 1_p
1.2 CD 1_p
, , 1_p
mean JJ 1_p
+/- JJ 1_p
SEM NNP 1_p
) ) 1_p
. . 1_p

The DT N
study NN N
had VBD N
a DT N
placebo NN 1_i
controlled VBN N
, , N
double JJ N
blind NN N
, , N
cross NN N
over IN N
design NN N
with IN N
6 CD N
weeks NNS N
' POS N
metformin NN 1_i
treatment NN 1_i
( ( 1_i
850 CD 1_i
mg RB 1_i
b.i.d NN 1_i
) ) 1_i
vs NN 1_i
placebo NN 1_i
. . 1_i

Blood NNP 1_o
pressure NN 1_o
was VBD N
measured VBN N
weekly RB N
. . N

At IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
, , N
glucose JJ 1_o
infusion NN 1_o
rate NN 1_o
( ( 1_o
GIR NNP 1_o
) ) 1_o
, , 1_o
muscle FW 1_o
sympathetic JJ 1_o
nerve NN 1_o
activity NN 1_o
( ( 1_o
MSA NNP 1_o
) ) 1_o
and CC 1_o
renal JJ 1_o
and CC 1_o
total JJ 1_o
body NN 1_o
norepinephrine NN 1_o
( ( 1_o
NE NNP 1_o
) ) 1_o
kinetics NNS 1_o
( ( 1_o
radioisotope VB 1_o
dilution NN 1_o
) ) 1_o
were VBD N
examined VBN N
during IN N
euglycemic JJ N
hyperinsulinemic JJ N
clamp NN N
. . N

Fasting VBG 1_o
insulin NN 1_o
was VBD N
13 CD N
+/- JJ N
3 CD N
and CC N
10 CD N
+/- JJ N
2 CD N
mU/l NN N
and CC N
fasting VBG N
glucose JJ N
5.3 CD N
+/- JJ N
0.2 CD N
and CC N
5.1 CD N
+/- JJ N
0.1 CD N
mmol/l NN N
after IN N
placebo NN N
and CC N
metformin NN N
treatment NN N
, , N
respectively RB N
( ( N
ns JJ N
) ) N
. . N

GIR NNP N
during IN N
the DT N
last JJ N
hour NN N
of IN N
the DT N
insulin NN N
clamp NN N
was VBD N
3.7 CD N
+/- JJ N
0.6 CD N
vs JJ N
3.6 CD N
+/- JJ N
0.6 CD N
mg/kg NN N
x NN N
min NN N
( ( N
ns JJ N
) ) N
. . N

Resting VBG 1_o
MSA NNP 1_o
, , 1_o
total JJ 1_o
body NN 1_o
and CC 1_o
right JJ 1_o
renal NN 1_o
NE NNP 1_o
spillover NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
after IN N
placebo NN 1_i
and CC N
metformin NN 1_i
treatment NN N
. . N

Systolic NNP 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressures NNS 1_o
were VBD N
151 CD N
+/- JJ N
10/95 CD N
+/- JJ N
5 CD N
mmHg NN N
after IN N
placebo NN N
and CC N
146 CD N
+/- JJ N
5/94 CD N
+/- JJ N
5 CD N
mmHg NN N
after IN N
metformin NN N
treatment NN N
( ( N
ns JJ N
) ) N
. . N

Thus NNP N
metformin NN 1_i
treatment NN N
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
insulin NN N
sensitivity NN N
, , N
blood NN 1_o
pressure NN 1_o
or CC 1_o
sympathetic JJ 1_o
activity NN 1_o
in IN N
this DT N
small JJ N
group NN N
of IN N
patients NNS N
. . N

Renal JJ N
plasma NN N
flow NN N
and CC N
MSA NNP N
increased VBD N
significantly RB N
during IN N
the DT N
insulin NN N
clamp NN N
, , N
whereas JJ N
renal JJ N
NE NNP N
and CC N
total JJ N
body NN N
NE NNP N
spillover NN N
remained VBD N
unchanged JJ N
, , N
suggesting VBG N
nonuniform JJ N
regional JJ N
sympathetic JJ N
nerve NN N
responses NNS N
to TO N
acute VB N
hyperinsulinemia NN N
. . N

-DOCSTART- -X- O O

Controlled VBN N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
evaluation NN N
of IN N
partial JJ 1_i
ceramic JJ 1_i
crowns NNS 1_i
inserted VBN N
with IN N
RelyX NNP 1_i
Unicem NNP 1_i
with IN 1_i
or CC 1_i
without IN 1_i
selective JJ 1_i
enamel NN 1_i
etching VBG 1_i
. . 1_i

1-year JJ N
results NNS N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
performance NN N
of IN N
partial JJ 1_o
ceramic JJ 1_o
crowns NNS 1_o
( ( 1_o
PCCs NNP 1_o
) ) 1_o
inserted VBD 1_i
with IN 1_i
RelyX NNP 1_i
Unicem NNP 1_i
( ( 1_i
RXU NNP 1_i
) ) 1_i
either CC 1_i
with IN 1_i
( ( 1_i
RXU+E NNP 1_i
) ) 1_i
or CC 1_i
without IN 1_i
( ( 1_i
RXU NNP 1_i
) ) 1_i
selective VBP 1_i
enamel JJ 1_i
etching NN 1_i
. . 1_i

METHODS NNP N
34 CD 1_p
patients NNS 1_p
( ( 1_p
15 CD 1_p
male NN 1_p
, , 1_p
19 CD 1_p
female NN 1_p
) ) 1_p
participated VBD 1_p
in IN 1_p
the DT 1_p
investigation NN 1_p
, , 1_p
with IN 1_p
a DT 1_p
total NN 1_p
of IN 1_p
68 CD 1_p
PCC NNP 1_p
restorations NNS 1_p
. . 1_p

In IN N
each DT N
patient NN N
, , N
one CD N
PCC NNP 1_i
was VBD N
randomly RB N
assigned VBN N
to TO N
insertion NN N
with IN N
RXU NNP 1_i
, , N
the DT N
second JJ N
PCC NNP 1_i
was VBD N
assigned VBN N
to TO N
insertion NN N
with IN N
RXU+E NNP 1_i
. . 1_i

The DT N
PCCs NNPS N
were VBD N
CAD/CAM NNP N
fabricated VBD N
using VBG N
the DT N
Cerec NNP 1_i
3 CD 1_i
system NN 1_i
. . 1_i

RXU NN 1_i
: : 1_i
25 CD N
PCCs NNP N
were VBD N
placed VBN N
in IN N
molars NNS N
, , N
nine CD N
in IN N
premolars NNS N
. . N

RXU+E NN 1_i
: : 1_i
26 CD N
PCCs NNP N
were VBD N
placed VBN N
in IN N
molars NNS N
, , N
eight CD N
in IN N
premolars NNS N
. . N

The DT N
restorations NNS N
were VBD N
clinically RB N
rated VBN N
using VBG N
modified VBN N
United NNP N
States NNPS N
Public NNP N
Health NNP N
Service NNP N
( ( N
USPHS NNP N
) ) N
criteria NNS N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
months NNS N
after IN N
placement NN N
. . N

The DT N
median JJ 1_p
patient NN 1_p
age NN 1_p
was VBD 1_p
41 CD 1_p
years NNS 1_p
( ( 1_p
24-59 CD 1_p
years NNS 1_p
) ) 1_p
. . 1_p

The DT N
median JJ N
( ( N
25-75 CD N
% NN N
) ) N
PBI NNP N
was VBD N
6 CD N
% NN N
( ( N
3-9 CD N
% NN N
) ) N
. . N

RESULTS NNP N
All DT 1_p
patients NNS 1_p
were VBD 1_p
available JJ 1_p
for IN 1_p
the DT 1_p
three CD 1_p
recall NN 1_p
appointments NNS 1_p
. . 1_p

One CD N
PCC NNP N
( ( 1_i
RXU NNP 1_i
) ) 1_i
debonded VBD 1_o
after IN N
11 CD N
months NNS N
in IN N
situ NN N
, , N
one CD N
PCC NNP N
( ( 1_i
RXU+E NNP 1_i
) ) 1_i
fractured VBD 1_o
after IN N
12 CD N
months NNS N
in IN N
situ NN N
. . N

Both DT N
restorations NNS 1_o
had VBD N
to TO N
be VB N
replaced VBN 1_o
. . 1_o

At IN N
the DT N
12 CD N
months NNS N
recall RB N
, , N
66 CD N
of IN N
68 CD N
controlled JJ N
restorations NNS N
were VBD N
functional JJ 1_o
without IN N
need NN N
of IN N
replacement NN N
. . N

The DT N
evaluation NN N
using VBG N
USHPS NNP N
criteria NNS N
revealed VBD N
a DT N
significant JJ N
decrease NN N
of IN N
alfa JJ 1_o
ratings NNS 1_o
over IN 1_o
time NN 1_o
with IN 1_o
respect NN 1_o
to TO 1_o
criteria VB 1_o
marginal JJ 1_o
adaptation NN 1_o
and CC 1_o
marginal JJ 1_o
discoloration NN 1_o
. . 1_o

No DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
luting VBG N
techniques NNS N
, , N
RXU NNP 1_i
and CC 1_i
RXU+E NNP 1_i
, , N
we PRP N
reobserved VBD N
during IN N
the DT N
observation NN N
period NN N
of IN N
1 CD N
year NN N
. . N

Within IN N
the DT N
limitations NNS N
of IN N
the DT N
present JJ N
study NN N
, , N
adhesive JJ N
luting NN N
with IN N
RXU NNP 1_i
with IN N
or CC N
without IN N
selective JJ N
enamel NN N
etching NN N
can MD N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O

[ JJ N
Long-term JJ N
effects NNS N
of IN N
7-year JJ N
growth NN 1_i
hormone CD 1_i
substitution NN 1_i
on IN N
bone NN 1_o
metabolism NN 1_o
, , 1_o
bone NN 1_o
density NN 1_o
, , 1_o
and CC 1_o
bone NN 1_o
quality NN 1_o
in IN N
growth NN 1_p
hormone-deficient JJ 1_p
adults NNS 1_p
] FW 1_p
. . 1_p

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Subnormal NNP 1_o
bone NN 1_o
mineral NN 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
and CC 1_o
increased JJ 1_o
fracture NN 1_o
risk NN 1_o
are VBP N
described VBN N
in IN N
patients NNS 1_p
with IN 1_p
growth NN 1_p
hormone NN 1_p
deficiency NN 1_p
( ( 1_p
GHD NNP 1_p
) ) 1_p
. . 1_p

Growth NNP 1_i
hormone NN 1_i
( ( 1_i
GH NNP 1_i
) ) 1_i
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
beneficial JJ N
effects NNS 1_o
on IN 1_o
bone NN 1_o
in IN N
GHD NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
long-term JJ N
effects NNS N
of IN N
GH NNP 1_i
replacement NN 1_i
therapy NN 1_i
on IN N
bone NN 1_o
metabolism NN 1_o
, , 1_o
BMD NNP 1_o
, , 1_o
and CC 1_o
bone NN 1_o
quality NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
GHD NNP 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
20 CD 1_p
adult NN 1_p
patients NNS 1_p
with IN 1_p
GHD NNP 1_i
( ( 1_p
eleven JJ 1_p
male NN 1_p
, , 1_p
nine CD 1_p
female NN 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
42.5 CD 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
and CC N
randomized VBN N
to TO N
either DT N
GH NNP 1_i
or CC 1_i
placebo NN 1_i
in IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
0.25 CD 1_i
U/kg NNP 1_i
body NN N
weight/week NN N
. . N

After IN N
6 CD N
months NNS N
all DT N
patients NNS N
received VBD N
GH NNP 1_i
. . 1_i

After IN N
a DT N
1-year JJ N
double-blind NN N
, , N
placebo-controlled JJ 1_i
study NN N
the DT N
patients NNS N
were VBD N
followed VBN N
for IN N
another DT N
72 CD N
months NNS N
in IN N
an DT N
open JJ N
study NN N
. . N

The DT N
patients NNS N
were VBD N
compared VBN N
to TO N
20 CD N
age- JJ N
und JJ N
sex-matched JJ N
healthy JJ N
controls NNS N
. . N

Bone NNP 1_o
turnover NN 1_o
was VBD N
determined VBN N
by IN N
ICTP NNP N
( ( N
type NN N
I PRP N
collagen VBP N
carboxyterminal JJ N
cross-linked JJ N
telopeptide NN N
) ) N
as IN N
parameter NN N
of IN N
bone NN N
resorption NN N
and CC N
PICP NNP N
( ( N
carboxyterminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
) ) N
as IN N
marker NN N
of IN N
bone NN N
formation NN N
. . N

BMD NNP 1_o
was VBD N
measured VBN N
at IN N
the DT N
lumbar NN N
spine NN N
by IN N
dual-photon JJ N
absorptiometry NN N
( ( N
DPA NNP N
) ) N
and CC N
at IN N
the DT N
forearm NN N
by IN N
single-photon JJ N
absorptiometry NN N
( ( N
SPA NNP N
) ) N
. . N

Apparent JJ 1_o
phalangeal NN 1_o
ultrasound JJ 1_o
transmission NN 1_o
velocity NN 1_o
( ( 1_o
APU NNP 1_o
) ) 1_o
was VBD N
assessed VBN N
as IN N
parameter NN N
of IN N
bone NN N
quality NN N
independent JJ N
of IN N
BMD NNP N
. . N

RESULTS NNP N
At IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
BMD NNP 1_o
at IN N
both DT N
measuring VBG N
sites NNS N
was VBD N
lower JJR N
in IN N
patients NNS N
with IN N
GHD NNP 1_i
than IN N
in IN N
healthy JJ N
controls NNS N
. . N

During IN N
the DT N
1st CD N
year NN N
of IN N
GH NNP N
replacement NN N
therapy NN N
BMD NNP 1_o
decreased VBD N
, , N
followed VBN N
by IN N
a DT N
continuous JJ N
increase NN N
in IN N
BMD NNP 1_o
( ( N
about IN N
12 CD N
% NN N
) ) N
up RB N
to TO N
60 CD N
months NNS N
which WDT N
remained VBD N
unchanged JJ N
thereafter RB N
, , N
building VBG N
up RP N
a DT N
plateau NN N
. . N

After IN N
72 CD N
months NNS N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
patients NNS N
and CC N
the DT N
healthy JJ N
controls NNS N
could MD N
be VB N
detected VBN N
. . N

Concerning VBG N
parameters NNS N
of IN N
bone NN 1_o
turnover NN 1_o
, , 1_o
first RB 1_o
ICTP NNP 1_o
as IN N
marker NN 1_o
of IN 1_o
bone NN 1_o
resorption NN 1_o
showed VBD N
a DT N
significant JJ N
increase NN N
, , N
later RB N
on IN N
the DT N
marker NN 1_o
of IN 1_o
bone NN 1_o
formation NN 1_o
increased VBD N
as RB N
well RB N
. . N

APU NNP 1_o
decreased VBD N
during IN N
the DT N
first JJ N
6 CD N
months NNS N
of IN N
treatment NN N
, , N
but CC N
had VBD N
returned VBN N
to TO N
its PRP$ N
baseline NN N
value NN N
after IN N
24 CD N
months NNS N
and CC N
remained VBD N
unchanged JJ N
throughout IN N
the DT N
rest NN N
of IN N
the DT N
study NN N
. . N

CONCLUSION NNP N
BMD NNP 1_o
is VBZ N
subnormal JJ N
in IN N
adults NNS N
with IN N
GHD NNP 1_i
. . 1_i

GH NNP 1_i
replacement NN N
therapy NN N
stimulates VBZ N
bone CD 1_o
turnover NN 1_o
in IN N
patients NNS N
with IN N
GHD NNP N
and CC N
in IN N
the DT N
long JJ N
term NN N
such JJ N
stimulation NN N
results NNS N
in IN N
an DT N
increased JJ N
BMD NNP 1_o
. . 1_o

Thereby NNP N
, , N
GH NNP 1_i
shows VBZ N
a DT N
triphasic JJ N
action NN N
on IN N
BMD NNP 1_o
: : 1_o
an DT N
initial JJ N
decrease NN N
in IN N
BMD NNP 1_o
during IN N
the DT N
1st CD N
year NN N
, , N
followed VBN N
by IN N
a DT N
continuous JJ N
increase NN N
in IN N
BMD NNP 1_o
with IN N
buildup NN N
of IN N
a DT N
stable JJ N
plateau NN N
after IN N
60 CD N
months NNS N
. . N

The DT N
newly RB N
formed VBN N
bone NN N
seems VBZ N
to TO N
have VB N
normal JJ 1_o
bone NN 1_o
elasticity NN 1_o
. . 1_o

-DOCSTART- -X- O O

Asthma NNP N
and CC N
the DT N
home NN N
environment NN N
of IN N
low-income JJ 1_p
urban JJ 1_p
children NNS 1_p
: : 1_p
preliminary JJ N
findings NNS N
from IN N
the DT N
Seattle-King NNP N
County NNP N
healthy JJ N
homes NNS N
project NN N
. . N

OBJECTIVES NNP N
Childhood NNP N
asthma NN N
is VBZ N
a DT N
growing VBG N
public JJ N
health NN N
concern NN N
in IN N
low-income JJ N
urban JJ N
communities NNS N
. . N

Indoor NNP N
exposure NN N
to TO N
asthma VB N
triggers NNS N
has VBZ N
emerged VBN N
as IN N
an DT N
important JJ N
cause NN N
of IN N
asthma JJ N
exacerbations NNS N
. . N

We PRP N
describe VBP N
indoor JJ N
environmental JJ N
conditions NNS N
related VBN N
to TO N
asthma JJ N
triggers NNS N
among IN N
a DT N
low-income JJ 1_p
urban JJ 1_p
population NN 1_p
in IN 1_p
Seattle/King NNP 1_p
County NNP 1_p
, , 1_p
Washington NNP 1_p
, , 1_p
as RB 1_p
well RB 1_p
as IN 1_p
caregiver NN 1_p
knowledge NN 1_p
and CC N
resources NNS N
related VBN N
to TO N
control VB N
of IN N
these DT N
triggers NNS N
. . N

METHODS NNP N
Data NNP N
are VBP N
obtained VBN N
from IN N
in-person JJ N
, , N
structured JJ N
, , N
closed-end JJ N
interviews NNS N
with IN N
the DT N
caretakers NNS 1_p
of IN 1_p
children NNS 1_p
aged VBN 1_p
4-12 CD 1_p
years NNS 1_p
with IN 1_p
persistent JJ 1_p
asthma NN 1_p
living NN 1_p
in IN 1_p
households NNS 1_p
with IN 1_p
incomes NNS 1_p
less JJR 1_p
than IN 1_p
200 CD 1_p
% NN 1_p
of IN 1_p
poverty NN 1_p
. . 1_p

Additional JJ N
information NN N
is VBZ N
collected VBN N
during IN N
a DT N
home NN N
inspection NN N
. . N

The DT N
children NNS 1_p
and CC 1_p
their PRP$ 1_p
caregivers NNS 1_p
are VBP 1_p
participants NNS 1_p
in IN 1_p
the DT 1_p
ongoing JJ 1_p
Seattle-King JJ 1_p
County NNP 1_p
Healthy NNP 1_p
Homes NNP 1_p
Project NNP 1_p
, , 1_p
a DT 1_p
randomized VBN 1_p
controlled JJ 1_p
trial NN 1_p
of IN 1_p
an DT 1_p
intervention NN 1_i
to TO 1_p
empower VB 1_p
low-income JJ 1_p
families NNS 1_p
to TO 1_p
reduce VB 1_p
exposure NN 1_p
to TO 1_p
indoor VB 1_p
asthma JJ 1_p
triggers NNS 1_p
. . 1_p

We PRP N
report VBP N
findings NNS N
on IN N
the DT N
conditions NNS N
of IN N
the DT N
homes NNS N
prior RB N
to TO N
this DT N
intervention NN N
among IN N
the DT 1_p
first JJ 1_p
112 CD 1_p
enrolled JJ 1_p
households NNS 1_p
. . 1_p

RESULTS VB N
A DT N
smoker NN N
was VBD N
present JJ N
in IN N
37.5 CD N
% NN N
of IN N
homes NNS N
. . N

Mold NNP 1_o
was VBD 1_o
visible JJ 1_o
in IN N
26.8 CD N
% NN N
of IN N
homes NNS N
, , N
water NN 1_o
damage NN 1_o
was VBD N
present JJ N
in IN N
18.6 CD N
% NN N
of IN N
homes NNS N
, , N
and CC N
damp JJ 1_o
conditions NNS 1_o
occurred VBD N
in IN N
64.8 CD N
% NN N
of IN N
households NNS N
, , N
while IN N
39.6 CD N
% NN N
of IN N
caregivers NNS N
were VBD N
aware JJ N
that IN N
excessive JJ N
moisture NN N
can MD N
increase VB N
exposures NNS N
to TO N
allergens NNS N
. . N

Dust-trapping JJ 1_o
reservoirs NNS 1_o
were VBD N
common JJ N
; : N
76.8 CD N
% NN N
of IN N
children NNS N
's POS N
bedrooms NNS N
had VBD N
carpeting NN N
. . N

Cockroach NNP 1_o
infestation NN 1_o
in IN 1_o
the DT 1_o
past JJ 1_o
3 CD 1_o
months NNS 1_o
was VBD N
reported VBN N
by IN N
23.4 CD N
% NN N
of IN N
caregivers NNS N
, , N
while IN N
57.1 CD N
% NN N
were VBD N
unaware JJ N
of IN N
the DT N
association NN 1_o
of IN 1_o
roaches NNS 1_o
and CC 1_o
asthma NN 1_o
. . 1_o

Only RB N
19.8 CD N
% NN N
of IN N
the DT N
children NNS N
had VBD N
allergy-control JJ 1_o
mattress NN 1_o
covers NNS 1_o
. . 1_o

CONCLUSIONS NNP N
Many JJ N
low-income JJ 1_p
urban JJ 1_p
children NNS 1_p
with IN 1_p
asthma NN 1_p
in IN N
King NNP N
County NNP N
live VBP N
in IN N
indoor JJ N
environments NNS N
that WDT N
place VBP N
them PRP N
at IN N
substantial JJ N
risk NN N
of IN N
ongoing VBG N
exposure NN N
to TO N
asthma VB N
triggers NNS N
. . N

Substandard NNP N
housing NN N
and CC N
lack NN N
of IN N
resources NNS N
often RB N
underlie VBP N
these DT N
exposures NNS N
. . N

Initiatives VBZ N
involving VBG N
health NN N
educators NNS N
, , N
outreach NN N
workers NNS N
, , N
medical JJ N
providers NNS N
, , N
health NN N
care NN N
insurers NNS N
, , N
housing NN N
agencies NNS N
, , N
and CC N
elected VBN N
officials NNS N
are VBP N
needed VBN N
to TO N
reduce VB N
these DT N
exposures NNS N
. . N

-DOCSTART- -X- O O

Patients NNS N
appreciation NN N
for IN N
information NN N
on IN N
anesthesia NN 1_i
and CC N
anxiolysis NN 1_i
in IN N
dentistry NN N
. . N

AIM NNP N
The DT N
research NN N
regards VBZ N
information NN N
on IN N
anesthesia NN 1_i
to TO N
patients NNS 1_p
undergoing VBG 1_p
oral JJ 1_p
surgery NN 1_p
. . 1_p

Every DT N
patient NN N
evaluated VBD N
the DT N
information NN N
received VBD N
at IN N
the DT N
end NN N
of IN N
the DT N
preoperative JJ N
visit NN N
and CC N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

METHODS NNP N
One CD 1_p
hundred-fifty JJ 1_p
dental JJ 1_p
patients NNS 1_p
were VBD N
asked VBN N
about IN N
the DT N
most RBS N
appreciated JJ N
information NN N
received VBN N
in IN N
the DT N
preoperative JJ N
visit NN N
on IN N
the DT N
anxiolytic JJ 1_i
technique NN 1_i
, , N
local JJ N
anesthesia NN N
and CC N
treatment NN N
of IN N
the DT N
perioperative JJ N
pain NN N
. . N

Afterwards IN N
the DT N
patients NNS N
had VBD N
to TO N
report VB N
on IN N
their PRP$ N
reaction NN N
to TO N
the DT N
content NN N
of IN N
the DT N
preoperative JJ N
visit NN N
and CC N
information NN N
quality NN N
. . N

On IN N
a DT N
phone NN N
interview NN N
they PRP N
had VBD N
to TO N
evaluate VB N
their PRP$ N
appreciation NN N
of IN N
the DT N
anxiolytic JJ N
technique NN N
, , N
their PRP$ N
perception NN N
during IN N
loco-regional JJ 1_i
anesthesia NN 1_i
and CC N
incidence NN N
of IN N
pain NN N
and CC N
edema NN N
. . N

RESULTS VB N
The DT N
most RBS N
appreciated JJ N
details NNS N
were VBD N
those DT N
on IN N
the DT N
intervention NN N
, , N
pharmacologic JJ N
treatment NN N
, , N
postoperative JJ N
complicances NNS N
, , N
postoperative JJ N
pain NN N
and CC N
operative JJ N
competence NN N
; : N
less CC N
appreciated JJ N
were VBD N
those DT N
on IN N
loco-regional JJ N
anesthesia NN N
, , N
duration NN N
of IN N
the DT N
intervention NN N
, , N
anxiolytic JJ N
techniques NNS N
, , N
hospital JJ N
reception NN N
and CC N
permanence NN N
in IN N
the DT N
hospital NN N
. . N

Ninety-eight JJ N
percent NN N
of IN N
the DT N
patients NNS N
considered VBN N
to TO N
have VB N
been VBN N
adequately RB N
informed VBN N
on IN N
a DT N
context NN N
judged VBN N
to TO N
be VB N
extraordinary JJ N
( ( N
99.3 CD N
% NN N
) ) N
, , N
96.6 CD N
% NN N
indicated VBD N
the DT N
information NN N
as IN N
necessary JJ N
, , N
98.6 CD N
% NN N
appreciated VBD N
the DT N
treatment NN 1_o
of IN N
the DT N
intraoperative JJ N
and CC N
postoperative JJ N
( ( N
99.3 CD N
% NN N
) ) N
pain NN N
and CC N
99.3 CD N
% NN N
the DT N
anxiolytic JJ N
treatment NN N
. . N

On IN N
the DT N
telephone NN N
interview NN N
, , N
100 CD N
% NN N
of IN N
patients NNS N
expressed VBN N
satisfaction NN N
for IN N
the DT N
experienced JJ N
intraoperative JJ 1_o
tranquillity NN 1_o
, , N
91.3 CD N
% NN N
complained VBD N
for IN N
not RB N
having VBG N
received VBN N
in IN N
the DT N
past NN N
a DT N
similar JJ N
preoperative JJ N
visit NN N
, , N
99.3 CD N
% NN N
wished VBD N
a DT N
diffused JJ 1_o
application NN 1_o
of IN N
the DT N
information NN N
. . N

The DT N
loco-regional JJ N
anesthesia NN N
was VBD N
associated VBN N
to TO N
psychological JJ N
detachment NN N
in IN N
84 CD N
% NN N
of IN N
the DT N
cases NNS N
and CC N
the DT N
incidence NN N
of IN N
postoperative JJ 1_o
pain NN 1_o
was VBD N
of IN N
36 CD N
% NN N
. . N

CONCLUSION NNP N
The DT N
information NN N
on IN N
the DT N
anxiolytic JJ 1_i
techniques NNS 1_i
, , 1_i
loco-regional JJ 1_i
anesthesia NN 1_i
, , 1_i
treatment NN 1_i
of IN 1_i
perioperative JJ 1_i
pain NN 1_i
and CC N
postoperative JJ N
distress NN N
was VBD N
enthusiastically RB N
accepted VBN N
and CC N
albeit VBN N
initially RB N
induced JJ N
feelings NNS N
of IN N
astonishment NN N
resulted VBD N
to TO N
be VB N
appreciated VBN 1_o
and CC N
preferred VBN 1_o
in IN N
the DT N
whole NN N
of IN N
the DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Comparative JJ 1_o
effectiveness NN 1_o
of IN N
exercise NN N
electrocardiography NN N
with IN N
or CC N
without IN N
myocardial JJ N
perfusion NN N
single JJ N
photon NN N
emission NN N
computed VBD N
tomography NN N
in IN N
women NNS 1_p
with IN 1_p
suspected JJ 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
: : 1_p
results NNS N
from IN N
the DT N
What WP N
Is VBZ N
the DT N
Optimal NNP N
Method NNP N
for IN N
Ischemia NNP N
Evaluation NNP N
in IN N
Women NNP N
( ( N
WOMEN NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
paucity NN N
of IN N
randomized JJ N
trials NNS N
regarding VBG N
diagnostic JJ N
testing NN N
in IN N
women NNS 1_p
with IN 1_p
suspected JJ 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
( ( 1_p
CAD NNP 1_p
) ) 1_p
. . 1_p

It PRP N
remains VBZ N
unclear JJ N
whether IN N
the DT N
addition NN N
of IN N
myocardial JJ N
perfusion NN N
imaging NN N
( ( N
MPI NNP N
) ) N
to TO N
the DT N
standard JJ N
ECG NNP N
exercise NN N
treadmill NN N
test NN N
( ( N
ETT NNP N
) ) N
provides VBZ N
incremental JJ N
information NN N
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
women NNS 1_p
with IN 1_p
suspected JJ 1_p
CAD NNP 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
randomized VBD N
symptomatic JJ 1_p
women NNS 1_p
with IN 1_p
suspected JJ 1_p
CAD NNP 1_p
, , 1_p
an DT 1_i
interpretable JJ 1_i
ECG NNP 1_i
, , 1_i
and CC 1_i
?5 NNP 1_i
metabolic JJ 1_i
equivalents NNS 1_i
on IN 1_i
the DT 1_p
Duke NNP 1_p
Activity NNP 1_p
Status NNP 1_p
Index NNP 1_p
to TO 1_p
1 CD N
of IN N
2 CD N
diagnostic JJ N
strategies NNS 1_i
: : 1_i
ETT NNP 1_i
or CC 1_i
exercise NN 1_i
MPI NNP 1_i
. . 1_i

The DT N
primary JJ N
end NN N
point NN N
was VBD 1_o
2-year JJ 1_o
incidence NN 1_o
of IN 1_o
major JJ 1_o
adverse JJ 1_o
cardiac NN 1_o
events NNS 1_o
, , 1_o
defined VBN 1_o
as IN 1_o
CAD NNP 1_o
death NN 1_o
or CC 1_o
hospitalization NN 1_o
for IN 1_o
an DT 1_o
acute JJ 1_o
coronary JJ 1_o
syndrome NN 1_o
or CC 1_o
heart NN 1_o
failure NN 1_o
. . 1_o

A DT N
total NN 1_p
of IN 1_p
824 CD 1_p
women NNS 1_p
were VBD 1_p
randomized VBN N
to TO N
ETT NNP 1_i
or CC 1_i
exercise NN 1_i
MPI NNP 1_i
. . 1_i

For IN N
women NNS N
randomized VBN N
to TO N
ETT NNP 1_o
, , 1_o
ECG NNP 1_o
results NNS 1_o
were VBD N
normal JJ N
in IN N
64 CD N
% NN N
, , N
indeterminate NN N
in IN N
16 CD N
% NN N
, , N
and CC N
abnormal JJ N
in IN N
20 CD N
% NN N
. . N

By IN N
comparison NN N
, , N
the DT 1_o
exercise NN 1_o
MPI NNP 1_o
results NNS 1_o
were VBD 1_o
normal JJ N
in IN N
91 CD N
% NN N
, , N
mildly RB N
abnormal JJ N
in IN N
3 CD N
% NN N
, , N
and CC N
moderate VB N
to TO N
severely RB N
abnormal JJ N
in IN N
6 CD N
% NN N
. . N

At IN N
2 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
major JJ 1_o
adverse JJ 1_o
cardiac NN 1_o
events NNS 1_o
( ( 1_o
98.0 CD N
% NN N
for IN N
ETT NNP N
and CC N
97.7 CD N
% NN N
for IN N
MPI NNP N
; : N
P=0.59 NNP N
) ) N
. . N

Compared VBN N
with IN N
ETT NNP 1_o
, , 1_o
index NN 1_o
testing VBG 1_o
costs NNS 1_o
were VBD 1_o
higher JJR N
for IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
downstream NN N
procedural NN N
costs NNS N
were VBD N
slightly RB N
lower JJR N
( ( N
P=0.0008 NNP N
) ) N
. . N

Overall UH N
, , N
the DT 1_o
cumulative JJ 1_o
diagnostic JJ 1_o
cost NN 1_o
savings NNS 1_o
was VBD 1_o
48 CD N
% NN N
for IN N
ETT NNP N
compared VBN N
with IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
low-risk JJ N
, , N
exercising VBG N
women NNS N
, , N
a DT N
diagnostic JJ N
strategy NN N
that WDT N
uses VBZ N
ETT NNP N
versus NN N
exercise NN N
MPI NNP N
yields NNS N
similar JJ N
2-year JJ N
posttest NN N
outcomes NNS N
while IN N
providing VBG N
significant JJ N
diagnostic JJ N
cost NN N
savings NNS N
. . N

The DT N
ETT NNP N
with IN N
selective JJ N
follow-up JJ N
testing NN N
should MD N
be VB N
considered VBN N
as IN N
the DT N
initial JJ N
diagnostic JJ N
strategy NN N
in IN N
symptomatic JJ 1_p
women NNS 1_p
with IN 1_p
suspected JJ 1_p
CAD NNP 1_p
. . 1_p

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00282711 NNP N
. . N

-DOCSTART- -X- O O

Transcutaneous JJ 1_i
electrical JJ 1_i
nerve NN 1_i
stimulation NN 1_i
following VBG 1_p
appendicectomy NN 1_p
: : 1_p
the DT N
placebo NN N
effect NN N
. . N

A DT N
controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
transcutaneous JJ 1_i
electrical JJ 1_i
nerve NN 1_i
stimulation NN 1_i
( ( 1_i
TENS NNP 1_i
) ) 1_i
with IN 1_i
standard JJ 1_i
intramuscular JJ 1_i
opiate NN 1_i
analgesia NN 1_i
in IN N
the DT N
management NN N
of IN N
postoperative JJ N
pain NN N
following VBG 1_p
appendicectomy NN 1_p
. . 1_p

Consecutive JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
emergency NN 1_i
appendicectomy NN 1_i
were VBD N
randomised VBN N
into IN N
control NN N
, , N
sham NN 1_i
TENS NNP 1_i
and CC 1_i
active JJ 1_i
TENS NNP 1_i
groups NNS 1_i
. . 1_i

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN 1_o
severity NN 1_o
and CC 1_o
analgesic JJ 1_o
intake NN 1_o
in IN N
both DT N
active JJ 1_i
and CC 1_i
sham JJ 1_i
TENS NNP 1_i
groups NNS N
when WRB N
compared VBN N
with IN N
the DT N
control NN 1_i
group NN 1_i
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

No DT N
difference NN N
was VBD N
demonstrated VBN N
in IN N
pain NN 1_o
severity NN 1_o
between IN N
active JJ 1_i
and CC 1_i
sham JJ 1_i
TENS NNP 1_i
groups NNS N
but CC N
the DT N
active JJ 1_i
TENS NNP 1_i
group NN N
required VBD N
slightly RB N
less JJR N
analgesia NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
major JJ N
benefit NN N
of IN N
TENS NNP 1_i
in IN N
the DT N
postappendicectomy NN 1_p
patient NN 1_p
is VBZ N
due JJ N
to TO N
its PRP$ N
'placebo JJ N
effect NN N
' POS N
and CC N
its PRP$ N
use NN N
in IN N
this DT N
situation NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Dissociation NN N
between IN N
cortical JJ N
activation NN N
and CC N
cognitive JJ N
performance NN N
under IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
in IN N
chronic JJ N
hypotension NN N
. . N

The DT N
present JJ N
study NN N
explored VBD N
the DT N
impact NN N
of IN N
pharmacological JJ 1_i
blood NN 1_i
pressure NN 1_i
elevation NN 1_i
on IN N
cortical JJ N
activation NN N
and CC N
reaction NN N
time NN N
in IN N
chronic JJ 1_p
hypotension NN 1_p
. . 1_p

Effects NNS N
of IN N
the DT N
sympathomimetic JJ 1_i
etilefrine NN 1_i
were VBD N
investigated VBN N
in IN N
50 CD 1_p
hypotensive JJ 1_p
persons NNS 1_p
based VBN N
on IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ 1_i
double JJ N
blind NN N
design NN N
. . N

As IN N
an DT N
indicator NN N
of IN N
cortical JJ N
excitability NN N
, , N
the DT N
contingent NN N
negative JJ N
variation NN N
( ( N
CNV NNP N
) ) N
, , N
induced VBN N
by IN N
a DT N
constant JJ N
foreperiod NN N
reaction NN N
time NN N
task NN N
, , N
was VBD N
assessed VBN N
at IN N
frontal JJ N
( ( N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
Cz NNP N
, , N
C4 NNP N
) ) N
scalp NN N
sites NNS N
. . N

Etilefrine NNP 1_i
provoked VBD N
a DT N
decrease NN N
in IN N
the DT N
frontal NN 1_o
and CC 1_o
central JJ 1_o
CNV NNP 1_o
. . 1_o

In IN N
contrast NN N
, , N
shorter JJR N
reaction NN 1_o
times NNS 1_o
were VBD N
observed JJ N
following JJ N
drug NN N
administration NN N
. . N

The DT N
degree NN 1_o
of IN N
pharmacologically RB N
induced VBN 1_o
blood NN 1_o
pressure NN 1_o
elevation NN 1_o
was VBD N
correlated VBN N
to TO N
CNV NNP N
attrition NN N
as RB N
well RB N
as IN N
to TO N
performance NN N
enhancement NN N
. . N

Inhibitory JJ N
effects NNS N
of IN N
baroreceptor NN N
activation NN N
on IN N
cortical JJ N
excitability NN N
and CC N
enhanced VBD N
cerebral JJ N
blood NN N
flow NN N
are VBP N
considered VBN N
to TO N
be VB N
involved VBN N
in IN N
mediating VBG N
the DT N
effects NNS N
of IN N
blood NN 1_o
pressure NN 1_o
elevation NN 1_o
on IN N
cerebral JJ N
functioning NN N
. . N

Implications NNS N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ 1_o
hypotension NN 1_o
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Intratunnel NNP 1_i
versus NN 1_i
extratunnel RB 1_i
autologous JJ 1_i
hamstring VBG 1_i
double-bundle JJ 1_i
graft NN 1_i
for IN N
anterior JJ 1_p
cruciate NN 1_p
ligament JJ 1_p
reconstruction NN 1_p
: : 1_p
a DT N
comparison NN N
of IN N
2 CD N
femoral JJ N
fixation NN N
procedures NNS N
. . N

BACKGROUND NNP N
Anatomic NNP N
double-bundle JJ N
anterior JJ 1_p
cruciate NN 1_p
ligament NN 1_p
( ( 1_p
ACL NNP 1_p
) ) 1_p
reconstruction NN N
provides VBZ N
excellent JJ N
results NNS N
for IN N
restoring VBG 1_o
normal JJ 1_o
kinematics NNS 1_o
to TO 1_o
the DT 1_o
knee NN 1_o
. . 1_o

Nevertheless RB N
, , N
strong JJ N
evidence NN N
supporting VBG N
an DT N
ideal NN N
method NN N
for IN N
fixation NN N
of IN N
the DT N
ACL NNP N
graft NN N
is VBZ N
lacking VBG N
. . N

HYPOTHESIS NNP N
Intratunnel NNP 1_i
femoral JJ 1_i
fixation NN 1_i
of IN 1_i
the DT 1_i
ACL NNP 1_i
graft NN 1_i
via IN 1_i
a DT 1_i
cross-pin JJ 1_i
fixation NN 1_i
technique NN 1_i
would MD N
provide VB N
better JJR N
clinical JJ N
and CC N
objective JJ N
results NNS N
than IN N
the DT N
extratunnel JJ 1_i
femoral JJ 1_i
fixation NN 1_i
with IN 1_i
cortical JJ 1_i
buttons NNS 1_i
. . 1_i

STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
; : N
Level NNP N
of IN N
evidence NN N
, , N
2 CD N
. . N

METHODS NNP N
Seventy NNP 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
unilateral JJ 1_p
ACL-deficient JJ 1_p
knee NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
femoral JJ N
fixation NN N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
35 CD N
patients NNS N
) ) N
was VBD N
fixed VBN 1_i
with IN 1_i
2 CD 1_i
bioabsorbable JJ 1_i
Rigidfix NNP 1_i
pins NNS 1_i
, , 1_i
1 CD 1_i
cross-pin NN 1_i
per IN 1_i
bundle NN 1_i
, , 1_i
while IN 1_i
group NN 1_i
B NNP 1_i
( ( 1_i
35 CD 1_i
patients NNS 1_i
) ) 1_i
was VBD 1_i
secured VBN 1_i
with IN 1_i
1 CD 1_i
EndoButton NNP 1_i
cortical JJ 1_i
button NN 1_i
per IN 1_i
bundle NN 1_i
. . 1_i

All DT N
femoral JJ N
tunnels NNS N
were VBD N
created VBN N
via IN N
an DT N
anteromedial JJ N
portal NN N
, , N
and CC N
a DT N
bioabsorbable JJ N
Biointrafix NNP N
interference NN N
screw NN N
was VBD N
used VBN N
for IN N
tibial JJ N
fixation NN N
for IN N
both DT N
groups NNS N
. . N

The DT N
evaluation NN N
of IN N
the DT N
patients NNS N
was VBD N
performed VBN N
by IN N
history NN N
details NNS N
, , N
clinical JJ N
examination NN N
findings NNS N
, , N
measurement NN N
of IN N
the DT N
joint JJ N
laxity NN N
by IN N
KT-1000 NNP 1_i
arthrometer NN 1_i
, , N
and CC N
use NN N
of IN N
validated JJ N
patient JJ N
outcome NN N
questionnaires NNS N
. . N

Statistical JJ N
analysis NN N
was VBD N
carried VBN N
out RP N
with IN N
Fisher NNP N
exact JJ N
and CC N
Mann-Whitney NNP N
U NNP N
tests NNS N
, , N
with IN N
P NNP N
< NNP N
.05 NNP N
considered VBD N
the DT N
cutoff NN N
level NN N
of IN N
significance NN N
. . N

RESULTS NNP N
At IN N
a DT N
mean JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
34 CD 1_p
and CC 1_p
32 CD 1_p
patients NNS 1_p
of IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
, , N
were VBD N
available JJ N
for IN N
evaluation NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
regarding VBG N
the DT N
subjective NN N
and CC N
objective JJ N
outcomes NNS N
, , N
except IN N
for IN N
KT-1000 NNP N
arthrometer NN N
values NNS N
. . N

The DT N
median JJ 1_o
KT-1000 NNP 1_o
value NN 1_o
of IN N
patients NNS N
in IN N
the DT N
cross-pin JJ N
fixation NN N
group NN N
was VBD N
1.30 CD N
mm NNS N
, , N
while IN N
the DT N
median JJ N
value NN N
in IN N
the DT N
cortical JJ 1_i
button NN 1_i
fixation NN 1_i
group NN N
was VBD N
1.95 CD N
mm NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Four CD N
patients NNS N
with IN N
ACL NNP N
grafts NNS N
that WDT N
were VBD N
fixed VBN N
with IN N
cortical JJ 1_i
buttons NNS 1_i
demonstrated VBD N
failure NN N
of IN N
stability NN 1_o
via IN 1_o
the DT 1_o
instrumented JJ 1_o
knee NN 1_o
laxity NN 1_o
testing NN 1_o
, , N
while IN N
patients NNS N
from IN N
the DT N
other JJ N
group NN N
had VBD N
no DT N
failures NNS N
. . N

CONCLUSION NNP N
Intratunnel NNP 1_i
femoral JJ 1_i
fixation NN 1_i
of IN 1_i
the DT 1_i
double-bundle JJ 1_i
ACL NNP 1_i
graft NN 1_i
from IN N
the DT N
cross-pin JJ N
fixation NN N
technique NN N
provided VBD N
better RBR N
instrumented JJ N
knee NN 1_o
laxity NN 1_o
results NNS N
than IN N
did VBD N
the DT N
extratunnel NN 1_i
femoral JJ 1_i
fixation NN 1_i
with IN 1_i
cortical JJ 1_i
buttons NNS 1_i
. . 1_i

Future NNP N
larger JJR N
studies NNS N
comparing VBG N
these DT N
2 CD N
techniques NNS N
should MD N
be VB N
conducted VBN N
to TO N
ensure VB N
the DT N
availability NN N
of IN N
stronger JJR N
evidence NN N
supporting VBG N
the DT N
findings NNS N
of IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

New NNP 1_i
drug NN 1_i
trials NNS 1_i
in IN N
attention NN 1_p
deficit NN 1_p
disorder NN 1_p
. . 1_p

-DOCSTART- -X- O O

Correlation NN N
between IN N
in IN N
vivo JJ N
humoral JJ N
and CC N
in IN N
vitro JJ N
cellular JJ N
immune NN N
responses NNS N
following VBG N
immunization NN N
with IN N
hepatitis NN 1_i
B NNP 1_i
surface NN 1_i
antigen NN 1_i
( ( 1_i
HBsAg NNP 1_i
) ) 1_i
vaccines NNS 1_i
. . 1_i

To TO N
study VB N
the DT N
regulation NN N
of IN N
the DT N
human JJ 1_p
immune NN 1_p
response NN 1_p
to TO 1_p
hepatitis VB 1_i
B NNP 1_i
surface NN 1_i
antigen NN 1_i
( ( 1_i
HBsAg NNP 1_i
) ) 1_i
we PRP N
have VBP N
carefully RB N
monitored VBN N
the DT N
in IN N
vivo JJ N
humoral JJ N
and CC N
in IN N
vitro JJ N
cellular JJ N
immune NN N
responses NNS N
to TO N
HBsAg NNP N
in IN N
50 CD 1_p
subjects NNS 1_p
receiving VBG 1_p
four CD 1_p
doses NNS 1_p
of IN 1_p
hepatitis NN 1_i
B NNP 1_i
vaccine NN 1_i
according VBG 1_p
to TO 1_p
a DT 1_p
0 CD 1_p
, , 1_p
1 CD 1_p
, , 1_p
2 CD 1_p
, , 1_p
12 CD 1_p
month NN 1_p
vaccination NN 1_p
scheme NN 1_p
. . 1_p

Twenty-three JJ 1_p
subjects NNS 1_p
were VBD 1_p
given VBN 1_p
a DT 1_p
plasma-derived JJ 1_i
vaccine NN 1_i
( ( 1_i
Hevac NNP 1_i
B NNP 1_i
) ) 1_i
and CC 1_p
27 CD 1_p
received VBD 1_p
a DT 1_p
recombinant JJ 1_i
HBsAg NNP 1_i
vaccine NN 1_i
( ( 1_i
yeast-derived JJ 1_i
; : 1_i
Engerix-B NNP 1_i
) ) 1_i
. . 1_i

The DT N
humoral JJ N
and CC N
cellular JJ N
immune NN N
responses NNS N
were VBD N
measured VBN N
before IN N
vaccination NN N
( ( N
day NN N
0 CD N
) ) N
; : N
6 CD N
days NNS N
after IN N
the DT N
second JJ N
dose NN N
( ( N
day NN N
36 CD N
) ) N
; : N
6 CD N
days NNS N
( ( N
day NN N
66 CD N
) ) N
, , N
2 CD N
months NNS N
( ( N
day NN N
120 CD N
) ) N
and CC N
10 CD N
months NNS N
( ( N
day NN N
365 CD N
) ) N
after IN N
the DT N
third JJ N
dose NN N
and CC N
1 CD N
month NN N
after IN N
the DT N
fourth JJ N
dose NN N
( ( N
day NN N
395 CD N
) ) N
. . N

Based VBN N
on IN N
the DT N
kinetics NNS N
of IN N
the DT N
humoral JJ N
immune NN N
responses NNS N
, , N
the DT N
vaccinees NNS N
could MD N
be VB N
classified VBN N
into IN N
fast NN N
, , N
intermediate JJ N
and CC N
slow/non-responders NNS N
. . N

Based VBN N
on IN N
the DT N
magnitude NN N
of IN N
the DT N
immune JJ N
response NN N
( ( N
anti-HBs JJ N
titre NN N
) ) N
on IN N
day NN N
395 CD N
, , N
the DT N
vaccinees NNS N
could MD N
be VB N
divided VBN N
into IN N
high JJ N
( ( N
> FW N
or CC N
= VB N
2000 CD N
U NNP N
l-1 NN N
) ) N
and CC N
low JJ N
( ( N
< CD N
or CC N
= VB N
2000 CD N
U NNP N
l-1 NN N
) ) N
responders NNS N
. . N

A DT N
close JJ N
correlation NN N
between IN N
the DT N
kinetics NNS N
and CC N
the DT N
magnitude NN N
of IN N
the DT N
humoral JJ 1_o
immune NN 1_o
response NN 1_o
was VBD N
observed VBN N
. . N

The DT N
in IN 1_o
vivo JJ 1_o
anti-HBs JJ 1_o
response NN 1_o
was VBD N
measured VBN N
using VBG N
commercially RB N
available JJ N
immunoradiometric JJ N
assays NNS N
. . N

The DT N
in IN 1_o
vitro NN 1_o
cellular JJ 1_o
immune JJ 1_o
response NN 1_o
was VBD N
measured VBN N
using VBG N
an DT N
HBsAg-specific JJ N
lymphoproliferation NN N
assay NN N
. . N

Because IN N
of IN N
interassay JJ N
variability NN N
the DT N
results NNS N
were VBD N
considered VBN N
as IN N
dichotomous JJ 1_o
variables NNS 1_o
( ( N
proliferation NN N
versus IN N
non-proliferation NN N
) ) N
for IN N
further JJ N
data NNS N
analysis NN N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
was VBD N
observed VBN N
between IN N
the DT N
kinetics NNS N
and CC N
magnitude NN N
of IN N
the DT N
humoral JJ N
immune JJ N
response NN N
on IN N
the DT N
one CD N
hand NN N
and CC N
the DT N
in IN N
vitro JJ N
anti-HBs JJ N
response NN N
on IN N
the DT N
other JJ N
hand NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Sex NN 1_o
risk NN 1_o
behavior NN 1_o
among IN N
adolescent JJ 1_p
and CC 1_p
young JJ 1_p
adult NN 1_p
children NNS 1_p
of IN 1_p
opiate JJ 1_p
addicts NNS 1_p
: : 1_p
outcomes NNS N
from IN N
the DT N
focus NN N
on IN N
families NNS N
prevention VBP N
trial NN N
and CC N
an DT N
examination NN N
of IN N
childhood NN N
and CC N
concurrent JJ N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
. . N

This DT N
study NN N
reports VBZ N
on IN N
rates NNS 1_o
and CC 1_o
predictors NNS 1_o
of IN 1_o
sex NN 1_o
risk NN 1_o
behavior NN 1_o
among IN N
a DT N
sample NN N
of IN N
adolescent NN 1_p
and CC 1_p
young JJ 1_p
adult NN 1_p
children NNS 1_p
of IN 1_p
parents NNS 1_p
enrolled VBN 1_p
in IN 1_p
methadone NN 1_i
treatment NN 1_p
for IN 1_p
opiate JJ 1_p
addiction NN 1_p
. . 1_p

Data NNS 1_p
are VBP 1_p
from IN 1_p
151 CD 1_p
participants NNS 1_p
( ( 1_p
80 CD 1_p
males NNS 1_p
, , 1_p
71 CD 1_p
females NNS 1_p
) ) 1_p
in IN 1_p
the DT 1_p
Focus NNP 1_p
on IN 1_p
Families NNP 1_p
( ( 1_p
FOF NNP 1_p
) ) 1_p
project NN 1_p
, , 1_p
a DT 1_p
randomized JJ 1_p
trial NN 1_p
of IN 1_p
a DT 1_p
family NN 1_i
intervention NN 1_i
and CC 1_p
a DT 1_p
study NN 1_p
of IN 1_p
the DT 1_p
development NN 1_p
of IN 1_p
at-risk JJ 1_p
children NNS 1_p
. . 1_p

The DT 1_p
study NN 1_p
participants NNS 1_p
are VBP 1_p
children NNS 1_p
of IN 1_p
parents NNS 1_p
enrolled VBN 1_p
in IN 1_p
methadone NN 1_i
treatment NN 1_i
between IN 1_p
1990 CD 1_p
and CC 1_p
1993 CD 1_p
. . 1_p

Participants NNS 1_p
were VBD 1_p
interviewed VBN 1_p
in IN 1_p
2005 CD 1_p
when WRB 1_p
they PRP 1_p
ranged VBD 1_p
in IN 1_p
age NN 1_p
from IN 1_p
15 CD 1_p
to TO 1_p
29 CD 1_p
years NNS 1_p
. . 1_p

In IN N
the DT N
year NN N
prior RB N
to TO N
the DT N
follow-up NN N
, , N
79 CD N
% NN N
of IN N
the DT N
males NNS N
and CC N
83 CD N
% NN N
of IN N
females NNS N
were VBD N
sexually RB N
active JJ N
, , N
26 CD N
% NN N
of IN N
males NNS N
and CC N
10 CD N
% NN N
of IN N
females NNS N
had VBD N
more JJR N
than IN N
one CD N
partner NN N
in IN N
the DT N
prior JJ N
year NN N
, , N
and CC N
34 CD N
% NN N
of IN N
males NNS N
and CC N
24 CD N
% NN N
of IN N
females NNS N
reported VBN N
having VBG N
sex NN N
outside IN N
of IN N
a DT N
committed JJ N
relationship NN N
. . N

Twenty-four CD N
percent NN N
of IN N
males NNS N
and CC N
17 CD N
% NN N
of IN N
females NNS N
met VBD N
criteria NNS N
for IN N
high-risk JJ 1_o
sexual JJ 1_o
behavior NN 1_o
, , N
reporting VBG N
casual JJ N
or CC N
multiple JJ N
partners NNS N
in IN N
the DT N
prior JJ N
year NN N
and CC N
inconsistent NN N
condom NN N
use NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN 1_i
and CC N
control NN 1_i
conditions NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
any DT N
measure NN N
of IN N
sex NN 1_o
risk NN 1_o
behavior NN 1_o
examined VBN N
. . N

None NN N
of IN N
the DT N
measures NNS N
of IN N
parent NN N
behavior NN N
and CC N
family NN N
processes NNS N
derived VBN N
from IN N
data NNS N
at IN N
baseline NN N
of IN N
the DT N
FOF NNP N
study NN N
predicted VBD N
whether IN N
participants NNS N
engaged VBN N
in IN N
high-risk JJ 1_o
sex NN 1_o
. . 1_o

Among IN N
measures NNS N
derived VBN N
from IN N
data NNS N
collected VBN N
at IN N
long-term JJ N
follow-up NN N
, , N
however RB N
, , N
having VBG N
ever RB N
met VBN N
criteria NNS N
for IN N
substance NN N
abuse NN N
or CC N
dependence NN N
predicted VBN N
greater JJR N
likelihood NN N
of IN N
high-risk JJ 1_o
sexual JJ 1_o
behavior NN 1_o
, , N
and CC N
being VBG N
married VBD N
or CC N
being VBG N
in IN N
a DT N
romantic JJ N
relationship NN N
was VBD N
associated VBN N
with IN N
lower JJR N
likelihood NN N
of IN N
high-risk JJ 1_o
sexual JJ 1_o
behavior NN 1_o
. . 1_o

The DT N
findings NNS N
point NN N
to TO N
the DT N
important JJ N
role NN N
of IN N
committed JJ N
relationships NNS N
in IN N
regulating VBG N
sex NN 1_o
risk NN 1_o
behavior NN 1_o
among IN N
this DT N
population NN N
, , N
as RB N
well RB N
as IN N
heightened VBN N
levels NNS N
of IN N
sex NN 1_o
risk NN 1_o
behavior NN 1_o
associated VBN N
with IN N
substance NN N
abuse NN N
or CC N
dependence NN N
. . N

-DOCSTART- -X- O O

Population NNP N
pharmacokinetic/pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
DPP-4 NNP 1_i
inhibitor NN 1_i
linagliptin NN 1_i
in IN N
Japanese JJ 1_p
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
mellitus RB 1_p
. . 1_p

OBJECTIVES NNP N
Linagliptin NNP 1_i
is VBZ N
a DT N
novel JJ N
, , N
highly RB N
selective JJ N
and CC N
long JJ N
acting VBG N
DPP-4 NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
type NN N
2 CD N
diabetes NNS N
mellitus FW N
( ( N
T2DM NNP N
) ) N
. . N

Linagliptin JJ 1_i
exhibits VBZ N
non-linear JJ N
pharmacokinetics NNS N
( ( N
PK NNP N
) ) N
due JJ N
to TO N
saturable JJ N
binding NN N
to TO N
plasma VB N
and CC N
tissue VB N
DPP-4 NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
characterize VB N
the DT N
PK NNP N
and CC N
PK/DPP-4 NNP N
inhibition NN N
relationship NN N
of IN N
linagliptin NN 1_i
in IN N
Japanese JJ 1_p
patients NNS 1_p
with IN 1_p
T2DM NNP 1_p
using VBG N
a DT N
population NN N
PK/DPP-4 NNP N
model NN N
and CC N
to TO N
support VB N
the DT N
rationale NN N
for IN N
the DT N
therapeutic JJ N
dose NN N
in IN N
Japanese JJ N
patients NNS N
by IN N
simulation NN N
. . N

METHODS NNP N
Linagliptin NNP 1_i
plasma NN N
concentration NN N
and CC N
DPP-4 NNP N
inhibition NN N
measurements NNS N
from IN N
a DT N
placebo-controlled JJ 1_i
, , N
parallel JJ N
group NN N
multiple NN N
( ( N
28 CD N
days NNS N
) ) N
dose VBP N
trial NN N
that WDT N
included VBD N
36 CD 1_p
T2DM NNP 1_p
patients NNS 1_p
( ( 1_p
18 CD 1_p
patients NNS 1_p
each DT 1_p
in IN 1_p
2.5 CD 1_p
mg NN 1_p
and CC 1_p
10 CD 1_p
mg NNS 1_p
dose JJ 1_p
group NN 1_p
) ) 1_p
were VBD N
used VBN N
for IN N
analysis NN N
. . N

Modeling NNP N
was VBD N
performed VBN N
using VBG N
FOCE NNP N
INTERACTION NNP N
estimation NN N
method NN N
implemented VBN N
in IN N
NONMEM NNP N
V. NNP N
The DT N
linagliptin JJ N
plasma JJ N
concentration- NN N
and CC N
DPP-4 NNP N
inhibition- JJ N
time NN N
profiles NNS N
were VBD N
simulated VBN N
for IN N
Japanese JJ N
patients NNS N
receiving VBG N
5 CD N
mg JJ N
linagliptin NN 1_i
once RB N
daily JJ N
by IN N
the DT N
model NN N
established VBN N
. . N

RESULTS NNP N
Nonlinear NNP N
PK NNP N
of IN N
linagliptin NN N
in IN N
T2DM NNP N
patients NNS N
were VBD N
well RB N
described VBN N
by IN N
a DT N
2-compartment JJ N
model NN N
assuming VBG N
concentration-dependent JJ N
binding NN N
to TO N
DPP-4 NNP N
in IN N
the DT N
central JJ N
and CC N
peripheral JJ N
compartment NN N
. . N

Plasma NNP 1_o
DPP-4 NNP 1_o
inhibition NN 1_o
was VBD N
integrated VBN N
in IN N
the DT N
model NN N
by IN N
relating VBG N
the DT N
model-predicted JJ N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin JJ 1_i
linearly JJ N
to TO N
DPP-4 JJ N
inhibition NN N
. . N

The DT N
simulation NN N
predicted VBD N
that IN N
for IN N
the DT N
5 CD N
mg NN N
dose NN N
group NN N
the DT N
trough JJ N
DPP-4 JJ 1_o
inhibition NN 1_o
at IN N
steady-state NN N
was VBD N
84.2 CD N
% NN N
, , N
which WDT N
is VBZ N
higher JJR N
than IN N
the DT N
target NN N
inhibition NN N
( ( N
?80 CD N
% NN N
) ) N
for IN N
an DT N
effective JJ N
dose NN N
of IN N
DPP-4 NNP N
inhibitor NN N
. . N

In IN N
2.5 CD N
mg NNS N
dose JJ N
group NN 1_o
, , 1_o
steady-state JJ 1_o
DPP-4 NNP 1_o
inhibition NN 1_o
of IN 1_o
> $ N
80 CD N
% NN N
was VBD N
not RB N
maintained VBN N
over IN N
24 CD N
hours NNS N
( ( N
observed VBN N
and CC N
simulated VBN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
nonlinear JJ N
PK NNP N
of IN N
linagliptin NN 1_i
and CC 1_i
its PRP$ N
plasma JJ N
DPP-4 JJ N
inhibition NN N
in IN N
patients NNS N
were VBD N
well RB N
characterized VBN N
by IN N
a DT N
target-mediated JJ N
drug NN N
disposition NN N
model NN N
relating VBG N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin NN N
to TO N
DPP-4 NNP N
inhibition NN N
. . N

Simulations NNS N
of IN N
plasma JJ N
DPP-4 NNP N
inhibition NN N
suggest VBP N
that IN N
5 CD N
mg NNS N
linagliptin JJ 1_i
once RB 1_i
daily JJ N
is VBZ N
an DT N
appropriate JJ N
therapeutic JJ N
dose NN N
for IN N
Japanese JJ N
patients NNS N
with IN N
T2DM NNP N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
0.25 CD N
% NN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine VBP N
with IN N
0.25 CD N
% NN N
RS-bupivacaine NNP N
for IN N
epidural JJ N
analgesia NN 1_o
in IN 1_p
labour NN 1_p
. . 1_p

We PRP N
have VBP N
compared VBN N
the DT N
efficacy NN N
of IN N
0.25 CD N
% NN N
S NNP 1_i
( ( 1_i
- : 1_i
) ) 1_i
-bupivacaine VBP 1_i
with IN N
0.25 CD N
% NN N
RS-bupivacaine NNP 1_i
in IN N
providing VBG N
epidural JJ 1_o
analgesia NN 1_o
for IN N
labour NN N
in IN N
a DT N
randomized JJ N
, , N
multicentre JJ N
, , N
double-blind JJ N
study NN N
. . N

Analgesia NNP 1_i
was VBD 1_i
initiated VBN 1_i
with IN 1_i
10 CD 1_i
ml NN 1_i
of IN 1_i
the DT 1_i
study NN 1_i
solution NN 1_i
and CC 1_i
maintained VBN 1_i
with IN 1_i
10-ml JJ 1_i
top-ups NNS 1_i
. . 1_i

We PRP N
studied VBD N
137 CD 1_p
women NNS 1_p
and CC N
treatments NNS N
were VBD N
found VBN N
to TO N
be VB N
equivalent JJ N
for IN N
onset NN N
, , N
duration NN N
and CC N
quality NN N
of IN N
block NN N
. . N

Median JJ 1_o
onset NN 1_o
of IN 1_o
pain NN 1_o
relief NN 1_o
was VBD N
12 CD N
min NN N
for IN N
both DT N
drugs NNS N
and CC N
median JJ N
duration NN N
was VBD N
49 CD N
( ( N
range VB N
3-129 NNP N
) ) N
min NN N
and CC N
51 CD N
( ( N
7-157 CD N
) ) N
min NN N
for IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
RS NNP N
bupivacaine NN N
, , N
respectively RB N
. . N

The DT N
estimated JJ N
treatment NN N
difference NN N
for IN N
duration NN 1_o
of IN 1_o
pain NN 1_o
relief NN 1_o
was VBD N
-4 NNP N
( ( N
90 CD N
% NN N
CI NNP N
-13 NNP N
, , N
6 CD N
) ) N
min NN N
. . N

Thirty NNP N
patients NNS N
failed VBD N
to TO N
achieve VB 1_o
pain NN 1_o
relief NN 1_o
after IN N
the DT N
first JJ N
injection NN N
( ( N
20 CD N
patients NNS N
after IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
10 CD N
after IN N
RS-bupivacaine NNP N
; : N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

However RB N
, , N
median JJ 1_o
duration NN 1_o
of IN 1_o
pain NN 1_o
relief NN 1_o
from IN N
the DT N
first JJ N
top-up NN N
was VBD N
82 CD N
( ( N
range VB N
3-164 NNP N
) ) N
min NN N
for IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
76 CD N
( ( N
22-221 JJ N
) ) N
min NN N
for IN N
RS-bupivacaine NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
quality NN 1_o
of IN 1_o
analgesia NN 1_o
, , N
as IN N
assessed VBN N
by IN N
the DT N
investigators NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
extent NN N
of IN N
sensory JJ 1_o
block NN 1_o
, , 1_o
percentage NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
motor NN 1_o
block NN 1_o
or CC 1_o
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Migration NN 1_p
of IN 1_p
the DT 1_p
acetabular JJ 1_p
component NN 1_p
: : 1_p
effect NN 1_o
of IN 1_o
cement NN 1_o
pressurization NN 1_o
and CC 1_o
significance NN 1_o
of IN 1_o
early JJ 1_o
radiolucency NN 1_o
: : 1_o
a DT N
randomized JJ N
5-year JJ N
study NN N
using VBG N
radiostereometry NN 1_i
. . 1_i

BACKGROUND NNP N
Cementing NNP N
technique NN N
is VBZ N
a DT N
crucial JJ N
factor NN N
in IN N
prosthesis NN 1_p
fixation NN 1_p
. . 1_p

No DT N
randomized JJ N
studies NNS N
have VBP N
been VBN N
published VBN N
, , N
however RB N
, , N
comparing VBG N
the DT N
outcome NN N
of IN N
conventional JJ N
fingerpacking NN N
with IN N
the DT N
outcome NN N
of IN N
pressurization NN N
of IN N
the DT N
cement NN N
prior RB N
to TO N
cup VB N
insertion NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
randomized VBD N
50 CD 1_p
THAs NNP 1_i
to TO 1_i
either VB 1_i
fingerpacking NN 1_i
or CC 1_i
sequential JJ 1_i
pressurization NN 1_i
( ( 1_i
including VBG 1_i
individual JJ 1_i
pressurization NN 1_i
of IN 1_i
each DT 1_i
anchorage NN 1_i
hole NN 1_i
) ) 1_i
and CC 1_p
followed VBD 1_p
the DT 1_p
patients NNS 1_p
with IN 1_p
RSA NNP 1_i
for IN 1_p
5 CD 1_p
years NNS 1_p
. . 1_p

The DT N
penetration NN N
of IN N
cement NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
measured VBN N
on IN N
digital JJ N
radiographs NN N
. . N

Postoperative JJ N
radiolucent NN 1_o
lines NNS 1_o
around IN 1_o
the DT 1_o
cup NN 1_o
were VBD 1_o
correlated VBN 1_o
to TO 1_o
later RBR 1_o
RSA NNP 1_o
results NNS 1_o
. . 1_o

For IN N
clinical JJ N
evaluation NN N
, , N
we PRP N
used VBD N
SF-36 NNP N
and CC N
HHS NNP N
. . N

RESULTS VB N
The DT N
pressurized JJ N
group NN N
of IN N
THAs NNP N
was VBD N
more RBR N
stable JJ N
regarding VBG N
changes NNS N
in IN N
inclination NN N
. . N

We PRP N
found VBD N
no DT N
other JJ N
difference NN N
in IN N
the DT N
migratory NN N
behavior NN N
. . N

The DT N
cement NN N
penetration NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
deeper RBR N
with IN N
the DT N
pressurization NN N
technique NN N
than IN N
with IN N
fingerpacking NN N
. . N

For IN N
the DT N
whole JJ N
group NN N
taken VBN N
together RB N
, , N
there EX N
was VBD N
a DT N
strong JJ N
relation NN N
between IN N
the DT N
presence NN N
of IN N
radiolucent NN N
lines NNS N
as IN N
measured VBN N
on IN N
the DT N
postoperative JJ N
radiograph NN N
and CC N
later JJ N
migration NN N
observed VBN N
by IN N
RSA NNP N
at IN N
2 CD N
and CC N
5 CD N
years NNS N
. . N

INTERPRETATION NNP N
Pressurization NNP N
of IN N
the DT N
cement NN N
produced VBD N
better JJR N
cement NN N
penetration NN N
and CC N
increased VBD N
the DT N
cup NN N
stability NN N
in IN N
terms NNS N
of IN N
changes NNS N
in IN N
inclination NN N
. . N

Early JJ N
findings NNS N
of IN N
radiolucent NN N
lines NNS N
can MD N
predict VB N
later RB N
unfavorable JJ N
cup NN N
migration NN N
. . N

-DOCSTART- -X- O O

Long-term JJ N
results NNS N
regarding VBG N
the DT N
use NN N
of IN N
recombinant JJ 1_i
interferon NN 1_i
alpha-2b NN 1_i
in IN N
the DT N
treatment NN N
of IN N
II NNP 1_p
type NN 1_p
mixed JJ 1_p
essential JJ 1_p
cryoglobulinemia NN 1_p
. . 1_p

Thirty-three JJ 1_p
patients NNS 1_p
with IN 1_p
II NNP 1_p
type NN 1_p
mixed JJ 1_p
essential JJ 1_p
cryoglobulinemia NN 1_p
( ( 1_p
MEC NNP 1_p
) ) 1_p
were VBD 1_p
randomized VBN 1_p
into IN N
two CD N
groups NNS N
: : N
one CD N
to TO N
receive VB N
combined JJ 1_i
therapy NN 1_i
including VBG 1_i
prednisone NN 1_i
plus CC 1_i
interferon NN 1_i
, , 1_i
the DT 1_i
other JJ 1_i
to TO 1_i
receive VB 1_i
prednisone NN 1_i
therapy NN 1_i
. . 1_i

Interferon NNP 1_i
was VBD N
administered VBN N
as IN N
induction NN N
treatment NN N
( ( N
3 CD N
Mu/day NNP N
) ) N
and CC N
then RB N
as IN N
maintenance NN N
therapy NN N
( ( N
3 CD N
Mu NNP N
three CD N
times NNS N
a DT N
week NN N
) ) N
. . N

83 CD N
% NN N
of IN N
the DT N
combined JJ N
therapy NN N
patients NNS N
responded VBD N
as IN N
opposed VBN N
to TO N
27 CD N
% NN N
of IN N
the DT N
prednisone NN N
treated VBD N
patients NNS N
. . N

Among IN N
the DT N
patients NNS N
that WDT N
responded VBD N
to TO N
combined VBN N
therapy NN N
, , N
nine CD N
of IN N
them PRP N
had VBD N
a DT N
complete JJ N
response NN N
, , N
four CD N
a DT N
partial JJ N
response NN N
, , N
and CC N
two CD N
a DT N
minor JJ N
response NN N
. . N

None NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
prednisone NN 1_i
therapy NN N
responded VBD N
completely RB N
but CC N
only RB N
two CD N
had VBD N
a DT N
partial JJ N
and CC N
two CD N
a DT N
minor JJ N
response NN N
. . N

Four CD N
patients NNS N
( ( N
three CD N
of IN N
combined VBN 1_i
therapy NN 1_i
and CC N
one CD N
of IN N
prednisone NN 1_i
therapy NN N
) ) N
showed VBD N
proteinuria NN 1_o
before IN N
the DT N
treatment NN N
which WDT N
improved VBD N
at IN N
the DT N
end NN N
of IN N
the DT N
induction NN N
therapy NN N
. . N

Ten CD N
patients NNS N
showed VBD N
anti-HCV JJ 1_o
positivity NN 1_o
which WDT N
remained VBD N
unchanged JJ N
after IN N
the DT N
treatment NN N
. . N

Three CD N
patients NNS N
showed VBD N
liver JJ 1_o
involvement NN 1_o
secondary JJ N
to TO N
cryoglobulinemia VB 1_o
and CC N
an DT N
improvement NN N
of IN N
histological JJ 1_o
pattern NN 1_o
after IN N
the DT N
induction NN N
with IN N
combined JJ N
therapy NN N
. . N

One CD N
patient NN N
showed VBD N
an DT N
improvement NN N
of IN N
peripheral JJ 1_o
neuropathy NNS 1_o
after IN N
induction NN N
with IN N
the DT N
combined JJ 1_i
therapy NN 1_i
. . 1_i

These DT N
data NNS N
suggest VBP N
the DT N
effectiveness NN N
of IN N
interferon NN 1_i
given VBN N
as IN N
induction NN N
and CC N
as IN N
maintenance NN N
treatment NN N
in IN N
the DT N
therapy NN N
of IN N
II NNP 1_p
type NN 1_p
mixed JJ 1_p
essential JJ 1_p
cryoglobulinemia NN 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ 1_o
Therapeutic NNP 1_o
efficacy NN 1_o
of IN N
youdujing VBG 1_i
preparation NN 1_i
in IN N
treating VBG N
cervical JJ 1_p
high-risk JJ 1_p
human JJ 1_p
papilloma NN 1_p
virus NN 1_p
infection NN 1_p
patients NNS 1_p
] VBP 1_p
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanisms NN N
of IN N
Youdujing NNP 1_i
( ( 1_i
YDJ NNP 1_i
) ) 1_i
preparation NN 1_i
in IN N
treating VBG N
the DT N
cervical JJ 1_p
high-risk JJ 1_p
human JJ 1_p
papilloma NN 1_p
virus NN 1_p
( ( 1_p
HR-HPV NNP 1_p
) ) 1_p
infection NN 1_p
. . 1_p

METHODS NNP N
Totally RB 1_p
HR-HPV NNP 1_p
infection NN 1_p
70 CD 1_p
patients NNS 1_p
were VBD N
assigned VBN N
to TO N
the DT N
treatment NN 1_i
group NN N
and CC N
the DT N
control NN 1_i
group NN N
using VBG N
random JJ N
single JJ N
blind NN N
method NN N
, , N
35 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

YDJ NNP 1_i
external JJ 1_i
lotion NN 1_i
and CC 1_i
YDJ NNP 1_i
cream NN 1_i
were VBD N
applied VBN N
to TO N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
, , N
while IN N
normal JJ 1_i
saline NN 1_i
was VBD N
applied VBN N
for IN N
those DT N
in IN N
the DT N
control NN 1_i
group NN N
. . N

HR-HPV NNP 1_o
DNA NNP 1_o
detection NN 1_o
was VBD N
performed VBN N
by IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
menstruation NN N
after IN N
3 CD N
menstrual JJ N
cycles NNS N
. . N

The DT N
cervical JJ N
biopsy NN N
and CC N
cervical JJ N
smear NN N
were VBD N
performed VBN N
using VBG N
vaginoscope NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

The DT N
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
human JJ 1_o
telomerase NN 1_o
reverse NN 1_o
transcriptase NN 1_o
( ( 1_o
hTERT NN 1_o
) ) 1_o
was VBD N
detected VBN N
from IN N
fresh JJ N
tissues NNS N
of IN N
the DT N
cervical JJ N
lesion NN N
. . N

RESULTS VB N
The DT N
total JJ 1_o
effective JJ 1_o
rate NN 1_o
was VBD N
96.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
higher JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
70.00 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Before IN N
treatment NN N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
pathological JJ 1_o
results NNS 1_o
of IN 1_o
the DT 1_o
cervix NN 1_o
and CC N
the DT N
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
hTERT NN 1_o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
hTERT NN 1_o
decreased VBN N
in IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Better JJR N
effects NNS N
on IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN 1_o
and CC N
the DT N
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
hTERT NN 1_o
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
YDJ NNP 1_i
played VBD N
a DT N
role NN N
in IN N
clearing VBG N
HR-HPV NNP 1_o
infection NN 1_o
and CC N
reversing VBG N
the DT N
cervical JJ 1_o
precancerous JJ 1_o
changes NNS 1_o
possibly RB N
through IN N
down-regulating NN N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
and CC N
lowering VBG N
the DT N
telomerase NN N
activation NN N
. . N

-DOCSTART- -X- O O

Cholesterol-lowering JJ N
effect NN N
of IN N
stanol NN 1_i
ester NN 1_i
in IN N
a DT N
US NNP 1_p
population NN 1_p
of IN 1_p
mildly RB 1_p
hypercholesterolemic JJ 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
stanol NN 1_i
esters NNS 1_i
in IN N
lowering VBG N
cholesterol NN N
in IN N
a DT N
US NNP 1_p
population NN 1_p
. . 1_p

SUBJECTS NNP N
AND NNP N
METHODS NNP N
After IN N
a DT N
run-in JJ N
phase NN N
, , N
318 CD 1_p
subjects NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
margarine-like JJ N
spreads NNS N
containing VBG N
stanol JJ 1_i
ester NN 1_i
or CC 1_i
placebo NN 1_i
for IN N
8 CD N
weeks NNS N
: : N
EU NNP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN 1_i
( ( 1_i
ester JJ 1_i
form NN 1_i
) ) 1_i
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
European JJ N
formula NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN 1_i
( ( 1_i
ester JJ 1_i
form NN 1_i
) ) 1_i
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
2 CD N
G NNP N
: : N
0.67 CD N
g NN N
of IN N
stanol NN 1_i
( ( N
ester JJ N
form NN N
) ) N
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
or CC N
placebo VB 1_i
spread NN N
. . N

RESULTS JJ N
Mean JJ 1_o
+/- JJ 1_o
SD NNP 1_o
baseline NN 1_o
total NN 1_o
cholesterol NN 1_o
( ( 1_o
TC NNP 1_o
) ) 1_o
and CC 1_o
low-density JJ 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
( ( 1_o
LDL-C NNP 1_o
) ) 1_o
levels NNS 1_o
were VBD N
233+/-20 JJ N
and CC N
153+21 CD N
mg+/-dL NN N
, , N
respectively RB N
. . N

In IN N
the DT N
US NNP N
3 CD N
G NNP N
group NN N
, , N
3 CD N
g JJ N
daily NN N
of IN N
stanol JJ 1_i
esters NNS 1_i
lowered VBD N
TC NNP 1_o
and CC 1_o
LDL-C NNP 1_o
levels NNS 1_o
by IN N
6.4 CD N
% NN N
and CC N
10.1 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
response NN N
compared VBN N
with IN N
2 CD N
g NNS N
daily RB N
( ( N
US PRP N
2 CD N
G NNP N
) ) N
. . N

Triglyceride NNP 1_o
and CC 1_o
high-density NN 1_o
lipoprotein NNS 1_o
cholesterol NN 1_o
levels NNS 1_o
were VBD N
unchanged JJ N
. . N

The DT N
incidence NN N
of IN N
adverse JJ 1_o
effects NNS 1_o
was VBD N
not RB N
different JJ N
from IN N
placebo NN 1_i
. . 1_i

Serum NNP 1_o
vitamin VBD 1_o
A DT 1_o
and CC 1_o
25-hydroxyvitamin JJ 1_o
D NNP 1_o
levels NNS 1_o
were VBD N
not RB N
affected VBN N
. . N

CONCLUSIONS NNP N
Stanol NNP 1_i
esters NNS 1_i
lowered VBD N
TC NNP 1_o
and CC 1_o
LDL-C NNP 1_o
levels NNS 1_o
in IN N
a DT N
mildly RB 1_p
hypercholesterolemic JJ 1_p
US NNP 1_p
population NN 1_p
without IN N
evidence NN N
of IN N
adverse JJ N
effects NNS N
. . N

It PRP N
may MD N
be VB N
a DT N
useful JJ N
dietary JJ N
adjunct NN N
to TO N
lower VB N
cholesterol NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
evaluation NN N
of IN N
the DT N
WOMAC NNP N
3.0 CD N
OA NNP N
Index NNP N
in IN N
numeric JJ N
rating NN N
scale NN N
format NN N
using VBG N
a DT N
computerized JJ 1_i
touch NN 1_i
screen NN 1_i
version NN 1_i
. . 1_i

BACKGROUND IN N
The DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
( ( N
WOMAC NNP N
) ) N
Osteoarthritis NNP N
Index NNP N
is VBZ N
a DT N
previously RB N
described VBN N
self-administered JJ N
questionnaire NN N
covering VBG N
three CD N
domains NNS N
: : N
pain NN 1_o
, , 1_o
stiffness NN 1_o
and CC 1_o
function NN 1_o
. . 1_o

It PRP N
has VBZ N
been VBN N
validated VBN N
in IN N
patients NNS N
with IN N
osteoarthritis NN 1_p
( ( 1_p
OA NNP 1_p
) ) 1_p
of IN 1_p
the DT 1_p
hip NN 1_p
or CC 1_p
knee NN 1_p
in IN N
a DT N
paper-based JJ N
format NN N
. . N

AIM NNP N
To TO N
validate VB N
the DT N
WOMAC NNP N
3.0 CD N
using VBG N
a DT N
numerical JJ N
rating NN N
scale NN N
in IN N
a DT N
computerized JJ N
touch NN N
screen NN N
format NN N
allowing VBG N
immediate JJ N
evaluation NN N
of IN N
the DT N
questionnaire NN N
. . N

In IN N
the DT N
computed JJ N
version NN N
cartoons NNS N
, , N
written VBN N
and CC N
audio JJ N
instruments NNS N
were VBD N
included VBN N
in IN N
order NN N
facilitate NN N
application NN N
. . N

METHODS NNP N
Fifty NNP 1_p
patients NNS 1_p
, , 1_p
demographically RB 1_p
balanced VBN 1_p
, , 1_p
with IN 1_p
radiographically RB 1_p
proven JJ 1_p
primary JJ 1_p
hip NN 1_p
or CC 1_p
knee NN 1_p
OA NNP 1_p
completed VBD 1_p
the DT 1_p
classical JJ 1_i
paper NN 1_i
and CC 1_i
the DT 1_i
new JJ 1_i
computerized JJ 1_i
WOMAC NNP 1_i
version NN 1_i
. . 1_i

Subjects NNS N
were VBD N
randomized VBN N
either RB N
to TO N
paper NN N
format NN N
or CC N
computerized JJ N
format NN N
first RB N
to TO N
balance VB N
possible JJ N
order NN N
effects NNS N
. . N

RESULTS VB N
The DT N
intra-class JJ N
correlation NN N
coefficients NNS N
for IN N
pain NN 1_o
, , 1_o
stiffness NN 1_o
and CC 1_o
function NN 1_o
values NNS 1_o
were VBD N
0.915 CD N
, , N
0.745 CD N
and CC N
0.940 CD N
, , N
respectively RB N
. . N

The DT N
Spearman NNP N
correlation NN N
coefficients NNS N
for IN N
pain NN 1_o
, , 1_o
stiffness NN 1_o
and CC 1_o
function NN 1_o
were VBD N
0.88 CD N
, , N
0.77 CD N
and CC N
0.87 CD N
, , N
respectively RB N
. . N

CONCLUSION NNP N
These DT N
data NNS N
indicate VBP N
that IN N
the DT N
computerized JJ N
WOMAC NNP N
OA NNP N
index NN N
3.0 CD N
is VBZ N
comparable JJ N
to TO N
the DT N
paper NN N
WOMAC NNP N
in IN N
all DT N
three CD N
dimensions NNS N
. . N

The DT 1_i
computerized JJ 1_i
version NN 1_i
would MD N
allow VB N
physicians NNS N
to TO N
get VB N
an DT N
immediate JJ N
result NN N
and CC N
if IN N
present JJ N
a DT N
direct JJ N
comparison NN N
with IN N
a DT N
previous JJ N
exam NN N
. . N

-DOCSTART- -X- O O

Safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
a DT N
new JJ 1_i
3.3 CD 1_i
g NN 1_i
b.i.d NN 1_i
. . 1_i

tablet NN 1_i
formulation NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
mild-to-moderately-active JJ 1_p
ulcerative JJ 1_p
colitis NN 1_p
: : 1_p
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
a DT N
new JJ N
twice-daily JJ N
balsalazide NN 1_i
disodium NN 1_i
1.1 CD 1_i
g NN 1_i
tablet NN 1_i
dosing VBG N
regimen NNS N
( ( N
6.6 CD N
g/day NN N
, , N
three CD N
tablets NNS N
twice RB N
daily RB N
) ) N
for IN N
the DT N
treatment NN N
of IN N
mild-to-moderately-active JJ N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
, , N
multicenter NN 1_p
study NN 1_p
patients NNS 1_p
with IN 1_p
symptoms NNS 1_p
of IN 1_p
acute JJ 1_p
UC NNP 1_p
and CC 1_p
a DT 1_p
baseline NN 1_p
Modified NNP 1_p
Mayo NNP 1_p
Disease NNP 1_p
Activity NNP 1_p
Index NNP 1_p
( ( 1_p
MMDAI NNP 1_p
) ) 1_p
score NN 1_p
between IN 1_p
6 CD 1_p
and CC 1_p
10 CD 1_p
, , 1_p
inclusive JJ 1_p
, , 1_p
with IN 1_p
a DT 1_p
subscale JJ 1_p
rating NN 1_p
of IN 1_p
> NNP 1_p
or CC 1_p
=2 NN 1_p
for IN 1_p
both DT 1_p
rectal JJ 1_p
bleeding NN 1_p
and CC 1_p
mucosal JJ 1_p
appearance NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
3.3 CD N
g NN N
of IN N
balsalazide NN 1_i
or CC 1_i
placebo NN 1_i
tablets NNS N
twice RB N
daily RB N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
achieving VBG N
clinical JJ N
improvement NN N
( ( N
> CD N
or CC N
=3 VB N
point NN N
improvement NN N
in IN N
MMDAI NNP N
) ) N
and CC N
improvement NN N
in IN N
rectal JJ N
bleeding NN N
( ( N
> CD N
or CC N
=1 VB N
point NN N
improvement NN N
) ) N
at IN N
8 CD N
weeks NNS N
. . N

Safety NN N
assessments NNS N
were VBD N
conducted VBN N
from IN N
baseline NN N
through IN N
2-weeks JJ N
post-treatment JJ N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
249 CD 1_p
patients NNS 1_p
( ( 1_p
166 CD 1_p
balsalazide NN 1_i
, , 1_p
83 CD 1_p
placebo NN 1_i
) ) 1_i
received VBD N
at IN N
least JJS N
1 CD N
dose NN N
of IN N
study NN N
medication NN N
. . N

The DT N
mean JJ 1_o
MMDAI NNP 1_o
score NN 1_o
at IN N
baseline NN N
was VBD N
7.9 CD N
; : N
62 CD N
% NN N
of IN N
patients NNS N
had VBD N
a DT N
score NN N
> NN N
or CC N
=8.0 NN N
( ( N
moderate JJ N
disease NN N
) ) N
. . N

A DT N
significantly RB N
larger JJR N
proportion NN N
of IN N
patients NNS N
achieved VBN 1_o
clinical JJ 1_o
improvement NN 1_o
and CC 1_o
improvement NN 1_o
in IN 1_o
rectal JJ 1_o
bleeding NN 1_o
in IN N
the DT N
balsalazide NN 1_i
group NN N
vs. FW N
the DT N
placebo NN 1_i
group NN N
( ( N
55 CD N
vs. FW N
40 CD N
% NN N
, , N
P=0.02 NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
reported VBN N
were VBD N
worsening VBG 1_o
of IN 1_o
UC NNP 1_o
and CC 1_o
headache NN 1_o
; : 1_o
both DT N
were VBD N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

CONCLUSIONS NNP N
Balsalazide NNP 1_i
disodium NN 1_i
1.1 CD N
g NN N
tablets NNS N
administered VBD N
as IN N
3.3 CD N
g JJ N
twice RB N
daily RB N
are VBP N
effective JJ 1_o
, , 1_o
well RB 1_o
tolerated VBN 1_o
and CC 1_o
significantly RB 1_o
better JJR 1_o
than IN N
placebo NN 1_i
for IN N
improving VBG 1_o
signs NNS 1_o
and CC 1_o
symptoms NNS 1_o
of IN 1_o
mild-to-moderately-active JJ 1_o
UC NNP 1_o
. . 1_o

This DT N
new JJ N
formulation NN N
with IN N
a DT N
reduced VBN N
pill NN N
and CC N
dosing VBG N
burden NN N
offers VBZ N
the DT N
potential NN N
to TO N
improve VB N
convenience NN 1_o
and CC 1_o
compliance NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
active JJ 1_p
UC NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Plasmakinetic JJ 1_i
prostate NN 1_i
resection NN 1_i
in IN N
the DT N
treatment NN N
of IN N
benign JJ N
prostate JJ N
hyperplasia NN N
: : N
results NNS N
of IN N
1-year JJ N
follow VBP N
up RP N
. . N

AIM NNP N
In IN N
our PRP$ N
randomized JJ N
prospective JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficiency NN N
of IN N
plasmakinetic JJ 1_i
resection NN 1_i
of IN 1_i
prostate NN 1_i
( ( 1_i
PKRP NNP 1_i
) ) 1_i
by IN N
comparing VBG N
the DT N
preoperative NN N
and CC N
postoperative JJ N
results NNS N
of IN N
the DT N
transurethral JJ 1_i
resection NN 1_i
of IN 1_i
prostate NN 1_i
( ( N
TURP NNP N
) ) N
and CC N
PKRP NNP N
techniques NNS N
which WDT N
we PRP N
administered VBD N
in IN N
patients NNS 1_p
with IN 1_p
benign JJ 1_p
prostate NN 1_p
hyperplasia NN 1_p
( ( 1_p
BPH NNP 1_p
) ) 1_p
in IN 1_p
our PRP$ 1_p
clinic NN 1_p
. . 1_p

METHODS NNP N
Of IN N
57 CD 1_p
patients NNS 1_p
for IN 1_p
whom WP 1_p
we PRP 1_p
thought VBD 1_p
an DT 1_p
operative JJ 1_p
intervention NN 1_p
was VBD 1_p
necessary JJ 1_p
, , N
30 CD N
cases NNS N
in IN N
the DT N
first JJ N
group NN N
had VBD N
a DT N
TURP NNP 1_i
and CC N
24 CD N
cases NNS N
in IN N
the DT N
second JJ N
group NN N
had VBD N
a DT N
PKRP NNP 1_i
. . 1_i

International NNP 1_o
prostate JJ 1_o
symptom NN 1_o
scores NNS 1_o
( ( 1_o
I-PSS NNP 1_o
) ) 1_o
, , 1_o
uroflowmetry UH 1_o
, , 1_o
measurement NN 1_o
of IN 1_o
residual JJ 1_o
urine JJ 1_o
amount NN 1_o
and CC 1_o
ultrasonography NN 1_o
were VBD N
performed VBN N
for IN N
each DT N
patient NN N
both DT N
preoperatively RB N
and CC N
postoperatively RB N
( ( N
first JJ N
month NN N
and CC N
first JJ N
year NN N
) ) N
. . N

Operation NNP 1_o
times NNS 1_o
, , 1_o
urethral JJ 1_o
catheterization NN 1_o
times NNS 1_o
, , 1_o
preoperative JJ 1_o
and CC 1_o
postoperative JJ 1_o
Hb NNP 1_o
, , 1_o
Htc NNP 1_o
and CC 1_o
serum VB 1_o
Na NNP 1_o
values NNS 1_o
of IN N
the DT N
patients NNS N
were VBD N
compared VBN N
and CC N
the DT N
complications NNS N
of IN N
the DT N
groups NNS N
were VBD N
also RB N
compared VBN N
. . N

RESULTS VB N
On IN N
first JJ N
month NN N
and CC N
first JJ N
year NN N
follow VBP N
up RP N
between IN N
the DT N
groups NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
statistical JJ 1_o
difference NN 1_o
in IN N
I-PSS NNP 1_o
, , 1_o
maximum JJ 1_o
flow NN 1_o
rate NN 1_o
, , 1_o
average NN 1_o
flow NN 1_o
, , 1_o
residual JJ 1_o
urine NN 1_o
and CC 1_o
size NN 1_o
of IN 1_o
the DT 1_o
prostate NN 1_o
. . 1_o

The DT N
decrease NN N
in IN N
serum NN 1_o
Na NNP 1_o
level NN 1_o
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
TURP NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
operation NN 1_o
times NNS 1_o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

While IN N
the DT N
postoperative JJ 1_o
catheterization NN 1_o
time NN 1_o
was VBD N
75.7 CD N
h NN N
in IN N
TURP NNP N
group NN N
, , N
it PRP N
was VBD N
found VBN N
to TO N
be VB N
42 CD N
h NN N
in IN N
PKRP NNP N
group NN N
and CC N
it PRP N
was VBD N
clear JJ N
that IN N
catheterization NN 1_o
time NN 1_o
was VBD N
significantly RB N
shorter JJR N
( ( N
P NNP N
< NNP N
0001 CD N
) ) N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
obvious JJ N
that IN N
PKRP NNP 1_i
is VBZ N
as RB N
efficient JJ N
as IN N
TURP NNP N
and CC N
it PRP N
has VBZ N
a DT N
similar JJ N
morbidity NN N
. . N

In IN N
our PRP$ N
opinion NN N
, , N
PKRP NNP 1_i
makes VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
BPH NNP N
with IN N
its PRP$ N
advantages NNS N
, , N
such JJ N
as IN N
early JJ N
removal NN N
of IN N
postoperative JJ N
urethral JJ N
catheter NN N
, , N
a DT N
shorter JJR N
hospital NN N
stay NN N
and CC N
the DT N
absence NN N
of IN N
TUR NNP N
syndrome NN N
risk NN N
. . N

-DOCSTART- -X- O O

[ JJ 1_i
Gluten-free NNP 1_i
diet NN 1_i
in IN N
infantile JJ 1_p
autism NN 1_p
. . 1_p

A NNP N
therapeutic JJ N
trial NN N
] NN N
. . N

It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
there EX N
may MD N
be VB N
a DT N
connection NN N
between IN N
wheat-gluten/milk-casein NN N
and CC N
mental JJ N
disorders NNS N
such JJ N
as IN N
schizophrenia NN N
, , N
hyperactivity NN N
and CC N
autism NN N
. . N

In IN N
this DT N
study NN N
seven CD 1_p
patients NNS 1_p
with IN 1_p
infantile JJ 1_p
autism NN 1_p
, , 1_p
three CD 1_p
before IN 1_p
puberty NN 1_p
and CC 1_p
four CD 1_p
after IN 1_p
puberty NN 1_p
, , N
were VBD N
given VBN N
a DT N
gluten-free JJ 1_i
diet NN 1_i
. . 1_i

Three CD N
children NNS N
were VBD N
provoked VBN N
with IN N
gluten/placebo NN 1_i
in IN N
a DT N
double-blind NN N
study NN N
. . N

Four CD N
young JJ N
patients NNS N
participated VBN N
in IN N
an DT N
open JJ N
study NN N
and CC N
were VBD N
given VBN N
a DT N
gluten-free JJ 1_i
diet NN 1_i
in IN 1_i
six CD 1_i
months NNS 1_i
. . 1_i

Behaviour NNP 1_o
was VBD N
registered VBN N
before RB N
, , N
during IN N
and CC N
after IN N
the DT N
period NN N
with IN N
a DT N
gluten-free JJ 1_i
diet NN 1_i
. . 1_i

Visual NNP 1_o
Analogue NNP 1_o
Scale NNP 1_o
and CC 1_o
Real NNP 1_o
Life NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
were VBD N
used VBN N
to TO N
register VB N
changes NNS N
in IN N
behaviour NN N
. . N

No DT N
connection NN N
was VBD N
observed VBN N
between IN N
gluten NNS 1_o
and CC 1_o
behaviour VB 1_o
typical JJ N
for IN N
these DT N
patients NNS N
. . N

On IN N
the DT N
contrary JJ N
, , N
the DT N
gluten-free JJ 1_i
diet NN 1_i
seemed VBD N
to TO N
be VB N
another DT N
negative JJ N
factor NN N
leading VBG N
to TO N
further JJ N
social JJ 1_o
isolation NN 1_o
in IN N
this DT N
group NN N
of IN N
highly RB 1_p
socially RB 1_p
handicapped JJ 1_p
patients NNS 1_p
and CC N
families NNS N
. . N

-DOCSTART- -X- O O

Cobedding NN 1_i
of IN 1_i
twin JJ 1_i
premature NN 1_i
infants NNS 1_i
: : 1_i
calming VBG N
effects NNS 1_o
on IN N
pain NN 1_o
responses NNS 1_o
. . 1_o

BACKGROUND IN N
The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
whether IN N
cobedding VBG 1_i
of IN 1_i
preterm NN 1_i
twins NNS 1_i
has VBZ N
analgesic JJ 1_o
effects NNS 1_o
during IN N
heel NN N
lancing VBG N
or CC N
not RB N
. . N

METHODS NNP N
One CD 1_p
hundred VBD 1_p
premature NN 1_p
twins NNS 1_p
( ( 1_p
50 CD 1_p
sets NNS 1_p
) ) 1_p
born VBP 1_p
between IN 1_p
26 CD 1_p
weeks NNS 1_p
' POS 1_p
and CC 1_p
34 CD 1_p
weeks NNS 1_p
' POS 1_p
gestation NN 1_p
undergoing VBG 1_p
heel NN 1_p
blood NN 1_p
sampling VBG 1_p
were VBD N
randomly RB N
assigned VBN N
into IN N
two CD N
groups NNS N
: : N
the DT N
cobedding VBG 1_i
group NN 1_i
( ( 1_i
receiving VBG 1_i
care NN 1_i
in IN 1_i
the DT 1_i
same JJ 1_i
incubator NN 1_i
) ) 1_i
and CC N
the DT N
standard JJ 1_i
care NN 1_i
group NN 1_i
( ( 1_i
receiving VBG 1_i
care NN 1_i
in IN 1_i
separate JJ 1_i
incubators NNS 1_i
) ) 1_i
. . 1_i

Pain NN 1_o
was VBD 1_o
assessed VBN 1_o
using VBG 1_o
the DT 1_o
premature NN 1_o
infant NN 1_o
pain NN 1_o
profile IN 1_o
score NN 1_o
. . 1_o

Duration NN 1_o
of IN 1_o
crying NN 1_o
was VBD N
measured VBN N
after IN N
heel NN N
blood NN N
sampling NN N
, , N
and CC N
salivary JJ 1_o
cortisol NN 1_o
was VBD N
measured VBN N
prior RB N
to TO N
and CC N
after IN N
heel NN N
blood NN N
sampling VBG N
. . N

RESULTS JJ N
Infants NNS N
in IN N
the DT N
standard NN 1_i
care NN 1_i
group NN N
cried VBD 1_o
for IN 1_o
a DT 1_o
longer JJR 1_o
time NN 1_o
during IN N
heel NN N
lancing VBG N
than IN N
those DT N
in IN N
the DT N
cobedding NN 1_i
group NN N
( ( N
42.6 CD N
? . N
19.8 CD N
seconds NNS N
vs. FW N
36.4 CD N
? . N
21.7 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

The DT 1_o
mean JJ 1_o
premature NN 1_o
infant NN 1_o
pain NN 1_o
profile IN 1_o
score NN 1_o
after IN 1_o
heel NN N
lancing NN N
was VBD 1_o
significantly RB 1_o
higher JJR 1_o
in IN 1_o
the DT 1_i
standard NN 1_i
care NN 1_i
group NN 1_i
( ( N
9.8 CD N
? . N
2.6 CD N
vs. IN N
8.06 CD N
? . N
2.8 CD N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
. . N

The DT N
mean JJ 1_o
salivary JJ 1_o
cortisol NN 1_o
after IN 1_o
heel NN N
lancing NN N
was VBD N
also RB N
significantly RB 1_o
higher RBR 1_o
in IN 1_o
the DT N
standard NN 1_i
care NN 1_i
group NN 1_i
( ( N
24.3 CD N
? . N
7.4 CD N
nmol/L JJ N
vs. FW N
20.8 CD N
? . N
7.4 CD N
nmol/L NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

No DT 1_o
significant JJ 1_o
adverse JJ 1_o
effects NNS 1_o
were VBD 1_o
seen VBN N
with IN 1_i
cobedding VBG 1_i
. . 1_i

CONCLUSION NNP 1_i
Cobedding NNP 1_i
is VBZ 1_i
a DT 1_i
comforting JJ N
measure NN 1_p
for IN 1_p
twin JJ 1_p
premature NN 1_p
infants NNS 1_p
during IN 1_p
heel NN N
lancing NN N
, , N
which WDT N
can MD N
be VB N
performed VBN N
without IN N
any DT N
significant JJ 1_o
adverse JJ 1_o
effects NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Survey NNP 1_i
response NN N
inducements NNS N
for IN N
registered JJ 1_p
nurses NNS 1_p
. . 1_p

The DT N
past JJ N
20 CD N
years NNS N
have VBP N
seen VBN N
an DT N
overall JJ N
decline NN N
in IN N
survey NN N
response NN N
rates NNS N
and CC N
an DT N
even RB N
more RBR N
pronounced JJ N
decline NN N
in IN N
samples NNS N
of IN N
health NN 1_p
care NN 1_p
professionals NNS 1_p
. . 1_p

The DT N
authors NNS N
tested VBD N
the DT N
use NN N
of IN N
a DT N
thank NN 1_i
you PRP 1_i
or CC 1_i
reminder VB 1_i
postcard NN 1_i
as IN N
a DT N
method NN N
by IN N
which WDT N
to TO N
stem VB N
the DT N
tide NN N
of IN N
declining VBG N
response NN N
rates NNS N
. . N

The DT N
authors NNS N
conducted VBD N
a DT N
mail NN 1_i
and CC 1_i
telephone NN 1_i
survey NN 1_i
of IN 1_p
49,605 CD 1_p
registered JJ 1_p
nurses NNS 1_p
for IN 1_p
the DT 1_p
2000 CD 1_p
National NNP 1_p
Sample NNP 1_p
Survey NNP 1_p
of IN 1_p
Registered NNP 1_p
Nurses NNP 1_p
and CC N
sent VBD N
an DT N
extra JJ N
mailing NN N
to TO N
a DT N
random JJ N
subsample NN N
( ( N
n JJ N
= NNP N
4,968 CD N
) ) N
. . N

They PRP N
then RB N
compared VBN N
response NN 1_o
rates NNS N
for IN N
both DT N
groups NNS N
. . N

Contrary NNP N
to TO N
prior VB N
research NN N
, , N
this DT N
study NN N
found VBD N
that IN N
reminder NN N
postcards NNS N
did VBD N
not RB N
improve VB N
response NN 1_o
rates NNS 1_o
or CC 1_o
rates NNS 1_o
of IN 1_o
return NN 1_o
. . 1_o

There EX N
may MD N
be VB N
several JJ N
reasons NNS N
for IN N
this DT N
finding NN N
, , N
including VBG N
the DT N
general JJ N
familiarity NN N
with IN N
, , N
and CC N
high JJ N
saliency NN N
of IN N
, , N
this DT N
research NN N
project NN N
for IN N
the DT N
nursing NN N
community NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
even RB N
widely RB N
accepted VBN N
best JJS N
practices NNS N
for IN N
survey NN N
methods NNS N
deserve VBP N
scrutiny NN N
when WRB N
applied VBN N
to TO N
special JJ N
subpopulations NNS N
. . N

-DOCSTART- -X- O O

Fadrozole NNP 1_i
HCL NNP 1_i
( ( 1_i
CGS-16949A NNP 1_i
) ) 1_i
versus NN N
megestrol NN 1_i
acetate VBP 1_i
treatment NN N
of IN N
postmenopausal NN 1_p
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
breast NN 1_p
carcinoma NN 1_p
: : 1_p
results NNS N
of IN N
two CD N
randomized JJ N
double JJ N
blind NN N
controlled VBD N
multiinstitutional JJ N
trials NNS N
. . N

BACKGROUND NNP N
Breast NNP 1_p
cancer NN 1_p
patients NNS 1_p
with IN 1_p
prior JJ 1_p
response NN 1_p
to TO 1_p
endocrine VB 1_p
therapy NN 1_p
achieve VB N
subsequent JJ N
benefit NN N
from IN N
additional JJ N
endocrine NN N
therapies NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
an DT N
aromatase NN N
inhibitor NN N
, , N
fadrozole JJ 1_i
HCL NNP 1_i
, , N
were VBD N
compared VBN N
with IN N
megestrol NN N
acetate NN N
in IN N
post NN 1_p
menopausal NN 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
disease NN 1_p
progression NN 1_p
after IN 1_p
receiving VBG 1_p
antiestrogen NN 1_p
therapy NN 1_p
either DT 1_p
for IN 1_p
metastatic JJ 1_p
disease NN 1_p
or CC 1_p
as IN 1_p
adjuvant JJ 1_p
therapy NN 1_p
. . 1_p

METHODS NNP N
In IN 1_p
2 CD 1_p
multiinstitutional JJ 1_p
prospective JJ 1_p
trials NNS 1_p
, , 1_p
683 CD 1_p
postmenopausal NN 1_p
patients NNS 1_p
were VBD N
randomized VBN 1_i
to TO 1_i
receive VB 1_i
either DT 1_i
fadrozole JJ 1_i
HCL NNP 1_i
, , 1_i
1 CD 1_i
mg NN 1_i
twice RB 1_i
daily RB 1_i
, , 1_i
or CC 1_i
megestrol NN 1_i
acetate NN 1_i
, , 1_i
40 CD 1_i
mg NN 1_i
4 CD 1_i
times NNS 1_i
daily RB 1_i
, , 1_i
in IN 1_i
a DT 1_i
double JJ 1_i
blind NN 1_i
fashion NN 1_i
after IN 1_i
progression NN 1_i
on IN 1_i
first-line JJ 1_i
hormonal JJ 1_i
therapy NN 1_i
. . 1_i

Objective JJ 1_o
response NN 1_o
rates NNS 1_o
, , 1_o
time NN 1_o
to TO 1_o
progression NN 1_o
, , 1_o
survival NN 1_o
and CC 1_o
safety NN 1_o
of IN N
the DT N
two CD N
regimens NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Results NNP N
of IN N
intent-to-treat JJ N
analyses NNS N
are VBP N
presented VBN N
in IN N
this DT N
study NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
detected VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
time NN 1_o
to TO 1_o
progression NN 1_o
, , 1_o
objective JJ 1_o
response NN 1_o
rates NNS 1_o
, , 1_o
duration NN 1_o
of IN 1_o
response NN 1_o
, , 1_o
and CC 1_o
survival NN 1_o
in IN N
either DT N
trial NN N
. . N

There EX N
were VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ 1_o
experiences NNS 1_o
, , N
except IN N
that DT N
weight NN 1_o
gain NN 1_o
, , 1_o
fluid JJ 1_o
retention NN 1_o
, , 1_o
and CC 1_o
dyspnea NN 1_o
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
megestrol NN N
acetate NN N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
fadrozole JJ N
HCL NNP N
, , N
whereas JJ N
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
fadrozole JJ N
HCL NNP N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
megestrol NN N
acetate NN N
. . N

CONCLUSIONS NNP N
Fadrozole NNP 1_i
HCL NNP 1_i
was VBD N
as RB N
efficacious JJ 1_o
as IN N
megestrol NN N
acetate NN N
in IN N
postmenopausal NN 1_p
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
breast NN 1_p
carcinoma NN 1_p
after IN N
one CD N
hormonal JJ N
therapy NN N
. . N

Adverse JJ N
experiences NNS N
were VBD N
mild JJ N
with IN N
both DT N
therapies NNS N
, , N
but CC N
megestrol NN N
acetate NN N
was VBD N
associated VBN N
wiht PDT N
a DT N
higher JJR N
frequency NN N
of IN N
weight NN 1_o
gain NN 1_o
, , 1_o
fluid JJ 1_o
retention NN 1_o
and CC 1_o
dyspnea NN 1_o
, , N
whereas JJ N
fadrozole NN 1_i
HCL NNP 1_i
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
frequency NN N
of IN N
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
. . 1_o

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
a DT N
spiritually RB 1_i
based VBN 1_i
and CC 1_i
non-spiritually RB 1_i
based VBN 1_i
educational JJ 1_i
intervention NN 1_i
for IN N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN N
church-attending JJ 1_p
African-American JJ 1_p
men NNS 1_p
. . 1_p

INTRODUCTION NNP N
Health NNP 1_i
communication NN 1_i
interventions NNS 1_i
have VBP N
been VBN N
modestly RB N
effective JJ N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN 1_p
African-American JJ 1_p
men NNS 1_p
; : 1_p
however RB N
, , N
knowledge NN N
and CC N
informed JJ N
decision NN N
making NN N
is VBZ N
still RB N
questionable JJ N
even RB N
with IN N
screening VBG N
. . N

Church-based JJ N
programs NNS N
may MD N
be VB N
more RBR N
effective JJ N
if IN N
they PRP N
are VBP N
spiritually RB N
based VBN N
in IN N
nature NN N
. . N

OBJECTIVE CC N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
to TO N
implement VB N
and CC N
provide VB N
an DT N
initial JJ N
evaluation NN N
of IN N
a DT N
spiritually RB N
based VBN N
prostate NN N
cancer NN N
screening VBG N
informed JJ N
decision NN N
making VBG N
intervention NN N
for IN N
African-American JJ 1_p
men NNS 1_p
who WP 1_p
attend VBP 1_p
church NN 1_p
, , N
and CC N
determine VB N
its PRP$ N
efficacy NN N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
. . N

DESIGN NNP N
AND CC N
METHOD NNP N
Churches NNP 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
the DT N
spiritually RB 1_i
based VBN 1_i
or CC 1_i
the DT 1_i
non-spiritual JJ 1_i
intervention NN 1_i
. . 1_i

Trained NNP N
community NN N
health NN N
advisors NNS N
, , N
who WP N
were VBD N
African-American JJ N
male JJ N
church NN N
members NNS N
, , N
led VBD N
an DT N
educational JJ 1_i
session NN 1_i
and CC N
distributed VBD 1_i
educational JJ 1_i
print NN 1_i
materials NNS 1_i
. . 1_i

Participants NNS N
completed VBD N
baseline NN N
and CC N
immediate JJ N
follow-up JJ N
surveys NNS N
to TO N
assess VB N
the DT N
intervention NN N
impact NN N
on IN N
study NN N
outcomes NNS N
. . N

RESULTS VB N
The DT N
spiritually RB N
based VBN N
intervention NN N
appeared VBD N
to TO N
be VB N
more RBR N
effective JJ N
in IN N
areas NNS N
such JJ N
as IN N
knowledge NN N
, , N
and CC N
men NNS N
read VBP N
more JJR N
of IN N
their PRP$ N
materials NNS 1_o
in IN N
the DT N
spiritually RB N
based VBN N
group NN N
than IN N
in IN N
the DT N
non-spiritual JJ N
group NN N
. . N

CONCLUSIONS NNP N
Further NNP N
examination NN N
of IN N
the DT N
efficacy NN 1_o
of IN N
the DT N
spiritually RB N
based VBN N
approach NN N
to TO N
health NN N
communication NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Pimecrolimus NNP 1_i
cream VBZ 1_i
1 CD N
% NN N
vs. FW N
betamethasone CD 1_i
17-valerate JJ 1_i
0.1 CD N
% NN N
cream NN N
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

A DT N
randomized JJ N
open-label JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Seborrhoeic NNP N
dermatitis NN N
is VBZ N
a DT N
chronic JJ N
inflammatory NN N
disease NN N
with IN N
remissions NNS N
and CC N
exacerbations NNS N
, , N
characterized VBN N
by IN N
erythema NN N
, , N
scaling VBG N
and CC N
pruritus JJ N
primarily RB N
on IN N
the DT N
face NN N
, , N
scalp NN N
and CC N
chest NN N
. . N

Corticosteroids NNP N
and CC N
antifungals NNS N
are VBP N
the DT N
mainstay NN N
of IN N
therapy NN N
. . N

However RB N
, , N
chronic JJ N
use NN N
of IN N
corticosteroids NNS N
is VBZ N
associated VBN N
with IN N
side-effects NNS N
such JJ N
as IN N
skin JJ N
atrophy NN N
and CC N
telangiectasia NN N
. . N

Pimecrolimus NNP 1_i
, , N
an DT N
inhibitor NN N
of IN N
calcineurin NN N
, , N
has VBZ N
been VBN N
used VBN N
successfully RB N
in IN N
one CD N
patient NN N
with IN N
seborrhoeic JJ N
dermatitis NN N
. . N

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
randomized VBN N
open-label JJ N
clinical JJ N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
pimecrolimus NN 1_i
in IN N
comparison NN N
with IN N
a DT N
potent NN N
corticosteroid NN 1_i
( ( 1_i
betamethasone CD 1_i
17-valerate NN 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

METHODS NNP N
Twenty NNP 1_p
patients NNS 1_p
with IN 1_p
seborrhoeic JJ 1_p
dermatitis NN 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
this DT 1_p
study NN 1_p
, , 1_p
11 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
pimecrolimus JJ 1_i
1 CD 1_i
% NN 1_i
cream NN 1_i
group NN 1_i
and CC 1_p
nine CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
betamethasone NN 1_i
17-valerate JJ 1_i
0.1 CD 1_i
% NN 1_i
cream NN 1_i
group NN 1_i
. . 1_i

Patients NNS N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
thin JJ N
layer NN N
of IN N
the DT N
study NN N
products NNS N
twice RB N
daily RB N
at IN N
the DT N
lesional JJ N
area NN N
and CC N
to TO N
discontinue VB N
treatment NN N
as RB N
soon RB N
as IN N
symptoms NNS N
were VBD N
absent JJ N
. . N

Clinical JJ N
measures NNS N
assessed VBN N
were VBD N
erythema RB 1_o
, , 1_o
scaling VBG 1_o
and CC 1_o
pruritus NN 1_o
which WDT N
were VBD N
evaluated VBN N
using VBG N
a DT N
four-point JJ N
scale NN N
( ( N
0-3 JJ N
) ) N
. . N

RESULTS NNP N
Both NNP N
pimecrolimus FW 1_i
and CC N
betamethasone NN 1_i
were VBD N
highly RB N
effective JJ 1_o
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

Betamethasone NNP 1_i
reduced VBD N
all DT N
three CD N
parameters NNS N
, , N
erythema NN 1_o
, , 1_o
scaling VBG 1_o
and CC 1_o
pruritus NN 1_o
, , N
faster JJR N
than IN N
pimecrolimus NN 1_i
, , N
but CC N
the DT N
differences NNS N
in IN N
reduction NN N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Relapses NNS 1_o
were VBD N
observed VBN N
more RBR N
frequently RB N
and CC N
were VBD N
more JJR N
severe JJ N
with IN N
betamethasone NN 1_i
than IN N
with IN N
pimecrolimus NN 1_i
. . 1_i

Moreover RB N
, , N
pruritus NN 1_o
was VBD N
not RB N
observed VBN N
after IN N
discontinuation NN N
of IN N
treatment NN N
from IN N
day NN N
15 CD N
and CC N
beyond IN N
in IN N
the DT N
pimecrolimus NN 1_i
group NN N
, , N
whereas IN N
it PRP N
was VBD N
reported VBN N
in IN N
most JJS N
patients NNS N
of IN N
the DT N
betamethasone NN 1_i
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

CONCLUSIONS VB N
It PRP N
appears VBZ N
that IN N
pimecrolimus NN 1_i
, , N
a DT N
nonsteroidal JJ N
topical JJ N
treatment NN N
, , N
may MD N
be VB N
an DT N
excellent JJ N
alternative JJ N
therapeutic JJ N
modality NN N
for IN N
treating VBG N
seborrhoeic JJ N
dermatitis NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Isometric NNP N
hip NN N
muscle NN N
strength NN N
in IN N
posttraumatic JJ N
below-knee NN 1_p
amputees NNS 1_p
] VBP 1_p
. . N

BACKGROUND/AIM NNP N
Traumas NNP N
and CC N
war NN N
injuries NNS N
, , N
next JJ N
to TO N
chronic JJ N
occlusive JJ N
artery NN N
disease NN N
and CC N
diabetes VBZ N
mellitus-derived JJ N
complications NNS N
, , N
are VBP N
the DT N
most RBS N
frequent JJ N
cause NN N
of IN N
the DT N
lower JJR N
limbs JJ N
amputation NN N
. . N

They PRP N
affect VBP N
mostly RB N
younger JJR 1_p
population NN 1_p
that WDT N
need VBP N
a DT N
higher JJR N
level NN N
of IN N
activities NNS N
as IN N
compared VBN N
with IN N
the DT N
elderly JJ N
. . N

Medical JJ 1_i
rehabilitation NN 1_i
is VBZ N
very RB N
significant JJ N
for IN N
the DT N
muscle NN N
performance NN N
improvement NN N
in IN N
this DT N
population NN N
providing VBG N
their PRP$ N
social JJ N
reintegration NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
below-knee JJ N
amputation NN N
on IN N
the DT N
hip NN N
isometric JJ N
muscle NN N
strength NN N
and CC N
effect NN N
of IN N
rehabilitation NN N
on IN N
improvement NN N
of IN N
hip NN N
muscle NN N
strength NN N
in IN N
below-knee NN 1_p
amputees NNS 1_p
, , 1_p
secondary JJ 1_p
to TO 1_p
war NN 1_p
wounding VBG 1_p
. . 1_p

METHODS NNP N
Forty NNP 1_p
below-knee NN 1_p
amputees NNS 1_p
( ( 1_p
after IN 1_p
war NN 1_p
wounding NN 1_p
) ) 1_p
, , 1_p
average JJ 1_p
age NN 1_p
35.6 CD 1_p
+/- JJ 1_p
10.6 CD 1_p
years NNS 1_p
, , 1_p
that WDT 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
primary JJ 1_i
rehabilitation NN 1_i
program NN 1_i
with IN 1_i
prosthetics NNS 1_i
, , 1_p
were VBD 1_p
examined VBN 1_p
. . 1_p

Objective JJ N
parameters NNS N
were VBD N
used VBN N
to TO N
evaluate VB N
therapeutical JJ N
effects NNS N
. . N

Isometric NNP 1_o
muscle NN 1_o
strength NN 1_o
of IN 1_o
hip NN 1_o
flexors NNS 1_o
, , 1_o
extensors NNS 1_o
, , 1_o
abductors NNS 1_o
and CC 1_o
adductors NNS 1_o
was VBD 1_o
measured VBN 1_o
by IN 1_o
dynamometer NN 1_o
and CC 1_o
expressed VBN 1_o
in IN 1_o
Newton NNP 1_o
( ( 1_o
N NNP 1_o
) ) 1_o
at IN 1_o
admission NN 1_o
, , 1_o
control NN 1_o
and CC 1_o
discharge NN 1_o
for IN 1_i
each DT 1_i
patient NN 1_i
. . 1_i

Average JJ N
length NN N
of IN N
the DT N
treatment NN N
was VBD N
51 CD N
+/- JJ N
34.1 CD N
days NNS N
. . N

RESULTS NNP N
For IN N
isometric JJ N
hip NN N
flexors NNS N
( ( N
t JJ N
= NNP N
-1.99346 NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
extensors NNS N
( ( N
t JJ N
= NNP N
-4.629073 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
abductors NNS N
( ( N
t JJ N
= NNP N
-4.9408 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
adductors NNS N
( ( N
t JJ N
= NNP N
-2.00228 NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
muscle NN 1_o
strength NN 1_o
was VBD N
significantly RB N
less JJR N
on IN N
the DT N
amputated VBN N
than IN N
on IN N
nonamputated JJ N
side NN N
. . N

The DT N
highest JJS N
differences NNS N
in IN N
muscle NN 1_o
strength NN 1_o
between IN N
amputated VBN N
and CC N
nonamputated VBN N
limbs NNS N
were VBD N
noted VBN N
for IN N
hip NN N
abductors NNS N
( ( N
26.6 CD N
% NN N
) ) N
and CC N
extensors NNS N
( ( N
23.3 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
significant JJ N
improvement NN N
of IN N
mean JJ 1_o
values NNS 1_o
of IN 1_o
strength NN 1_o
for IN N
all DT N
examined VBN N
hip NN N
muscles NNS N
after IN N
rehabilitation NN N
and CC N
prosthetics NNS N
for IN N
both DT N
legs NNS N
in IN N
comparison NN N
to TO N
beginning NN N
of IN N
the DT N
therapy NN N
. . N

The DT N
hip NN N
abductor NN N
on IN N
the DT N
amputated JJ N
side NN N
was VBD N
for IN N
19.4 CD N
% NN N
weaker NN N
after IN N
rehabilitation NN N
in IN N
comparison NN N
to TO N
the DT N
non-amputated JJ N
limb NN N
. . N

CONCLUSION NNP N
Decreases NNP N
of IN N
isometric JJ N
muscle NN N
strength NN N
in IN N
all DT N
examined JJ N
hip NN N
muscles NNS N
were VBD N
observed VBN N
, , N
more RBR N
in IN N
the DT N
amputated JJ N
limb NN N
. . N

Rehabilitation NN N
with IN N
prosthetics NNS N
is VBZ N
a DT N
successful JJ N
method NN N
for IN N
improving VBG N
isometric JJ N
hip NN N
muscle NN N
strength NN N
on IN N
the DT N
both DT N
, , N
amputated VBN 1_p
and CC 1_p
non-amputated JJ 1_p
limbs NNS 1_p
in IN 1_p
war NN 1_p
wounded VBD 1_p
below-knee JJ 1_p
amputees NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Heparin NNP 1_i
plus CC 1_i
dipyridamole NN 1_i
in IN N
childhood NN 1_p
hemolytic-uremic JJ 1_p
syndrome NN 1_p
: : 1_p
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

From IN N
1976 CD 1_p
to TO 1_p
1985 CD 1_p
, , 1_p
a DT 1_p
total NN 1_p
of IN 1_p
58 CD 1_p
infants NNS 1_p
and CC 1_p
children NNS 1_p
with IN 1_p
the DT 1_p
hemolytic-uremic JJ 1_p
syndrome NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
either RB N
with IN N
heparin NN 1_i
and CC 1_i
dipyridamole NN 1_i
or CC 1_i
with IN 1_i
supportive JJ 1_i
management NN 1_i
only RB 1_i
. . 1_i

In IN N
the DT N
treatment NN N
group NN N
, , N
two CD N
patients NNS N
died VBD N
in IN N
the DT N
early JJ N
weeks NNS N
of IN N
the DT N
disease NN N
. . N

Analysis NN N
of IN N
clinical JJ N
and CC N
laboratory NN N
data NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
group NN N
of IN N
patients NNS N
as IN N
to TO N
the DT N
evolution NN N
of IN N
their PRP$ N
illness NN N
except IN N
for IN N
a DT N
significantly RB N
higher JJR N
incidence NN 1_o
of IN 1_o
anuria NNS 1_o
and CC N
a DT N
significantly RB N
faster RBR 1_o
recovery NN 1_o
from IN 1_o
hypertension NN 1_o
in IN N
the DT N
treated JJ N
group NN N
. . N

Renal NNP N
biopsy NN N
studies NNS N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
incidence NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
the DT 1_o
histologic JJ 1_o
lesions NNS 1_o
. . 1_o

The DT N
long-term JJ N
data NNS N
on IN N
blood NN 1_o
pressure NN 1_o
and CC 1_o
creatinine JJ 1_o
clearance NN 1_o
values NNS 1_o
in IN N
the DT N
survivors NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

This DT N
study NN N
indicates VBZ N
that IN N
treatment NN 1_i
with IN 1_i
heparin NN 1_o
and CC 1_o
dipyridamole NN 1_o
has VBZ N
no DT N
benefit NN 1_o
over IN 1_o
symptomatic JJ 1_o
therapy NN 1_o
alone RB N
in IN N
the DT N
typical JJ N
form NN N
of IN N
childhood NN 1_p
hemolytic-uremic JJ 1_p
syndrome NN 1_p
. . 1_p

-DOCSTART- -X- O O

Autism NNP N
Spectrum NNP N
Social NNP N
Stories NNP N
In IN N
Schools NNP N
Trial NNP N
( ( N
ASSSIST NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
feasibility NN N
randomised VBN N
controlled VBN N
trial NN N
analysing VBG N
clinical JJ 1_o
and CC 1_o
cost-effectiveness NN 1_o
of IN 1_o
Social NNP 1_o
Stories NNP 1_o
in IN N
mainstream JJ N
schools NNS N
. . N

INTRODUCTION NNP N
Current NNP N
evidence NN N
suggests VBZ N
that IN N
Social NNP 1_i
Stories NNPS 1_i
can MD N
be VB N
effective JJ N
in IN N
tackling VBG N
problem NN 1_o
behaviours NNS 1_o
exhibited VBN N
by IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

Exploring VBG N
the DT N
meaning NN N
of IN N
behaviour NN N
from IN N
a DT N
child NN N
's POS N
perspective JJ N
allows NNS N
stories NNS N
to TO N
provide VB N
social JJ N
information NN N
that WDT N
is VBZ N
tailored VBN N
to TO N
their PRP$ N
needs NNS N
. . N

Case NNP N
reports VBZ N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
have VBP N
suggested VBN N
that IN N
these DT N
stories NNS N
can MD N
lead VB N
to TO N
a DT N
number NN N
of IN N
benefits NNS N
including VBG N
improvements NNS N
in IN N
social JJ 1_o
interactions NNS 1_o
and CC 1_o
choice NN 1_o
making NN 1_o
in IN N
educational JJ N
settings NNS N
. . N

METHODS NNP N
AND CC N
ANALYSIS NNP N
The DT N
feasibility NN 1_o
of IN 1_o
clinical JJ 1_o
and CC 1_o
cost-effectiveness NN 1_o
of IN N
a DT N
Social NNP 1_i
Stories NNP 1_i
toolkit NN N
will MD N
be VB N
assessed VBN N
using VBG N
a DT N
randomised VBN N
control NN N
framework NN N
. . N

Participants NNS 1_p
( ( 1_p
n=50 NN 1_p
) ) 1_p
will MD 1_p
be VB 1_p
randomised VBN 1_p
to TO 1_p
either CC 1_p
the DT 1_p
Social NNP 1_i
Stories NNPS 1_i
intervention NN 1_i
or CC 1_i
a DT 1_i
comparator NN 1_i
group NN 1_i
where WRB 1_p
they PRP 1_p
will MD 1_p
be VB 1_p
read VBN 1_p
standard JJ 1_p
stories NNS 1_p
for IN 1_p
an DT 1_p
equivalent JJ 1_p
amount NN 1_p
of IN 1_p
time NN 1_p
. . 1_p

Statistics NNS N
will MD N
be VB N
calculated VBN N
for IN N
recruitment NN 1_o
rates NNS 1_o
, , 1_o
follow-up JJ 1_o
rates NNS 1_o
and CC 1_o
attrition NN 1_o
. . 1_o

Economic JJ N
analysis NN N
will MD N
determine VB N
appropriate JJ N
measures NNS 1_o
of IN 1_o
generic JJ 1_o
health NN 1_o
and CC 1_o
resource NN 1_o
use NN 1_o
categories NNS 1_o
for IN 1_o
cost-effectiveness JJ 1_o
analysis NN 1_o
. . 1_o

Qualitative JJ N
analysis NN N
will MD N
ascertain VB N
information NN N
on IN N
perceptions NNS N
about IN N
the DT N
feasibility NN 1_o
and CC 1_o
acceptability NN 1_o
of IN N
the DT N
intervention NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
National NNP N
Health NNP N
Service NNP N
Ethics NNP N
Approval NNP N
( ( N
NHS NNP N
; : N
ref VBZ N
11/YH/0340 CD N
) ) N
for IN N
the DT N
trial NN N
protocol NN N
has VBZ N
been VBN N
obtained VBN N
along IN N
with IN N
NHS NNP N
Research NNP N
and CC N
Development NNP N
permission NN N
from IN N
Leeds NNP N
and CC N
York NNP N
Partnership NNP N
NHS NNP N
Foundation NNP N
Trust NNP N
. . N

All DT N
adverse JJ 1_o
events NNS 1_o
will MD N
be VB N
closely RB N
monitored VBN N
, , N
documented VBN N
and CC N
reported VBN N
to TO N
the DT N
study NN N
Data NNP N
Monitoring NNP N
Ethics NNP N
Committee NNP N
. . N

At IN N
least JJS N
one CD N
article NN N
in IN N
a DT N
peer NN N
reviewed VBN N
journal NN N
will MD N
be VB N
published VBN N
and CC N
research NN N
findings NNS N
presented VBN N
at IN N
relevant JJ N
conferences NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN96286707 NNP N
. . N

-DOCSTART- -X- O O

Educational JJ 1_i
intervention NN 1_i
for IN N
altering VBG N
water-sanitation NN N
behavior NN N
to TO N
reduce VB N
childhood NN 1_p
diarrhea NN 1_o
in IN 1_p
urban JJ 1_p
Bangladesh NNP 1_p
: : 1_p
impact NN N
on IN N
nutritional JJ N
status NN N
. . N

We PRP N
evaluated VBD N
whether IN N
an DT N
educational JJ 1_i
intervention NN 1_i
that WDT N
was VBD N
effective JJ N
in IN N
reducing VBG N
childhood NN 1_p
diarrhea NN 1_o
also RB N
improved VBD N
childhood JJ 1_o
nutritional JJ 1_o
status NN 1_o
. . 1_o

Fifty-one CD 1_p
communities NNS 1_p
of IN 1_p
38 CD 1_p
families NNS 1_p
each DT 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
intervention NN 1_i
or CC 1_i
no DT 1_i
intervention NN 1_i
. . 1_i

During IN N
1 CD N
y NNS N
of IN N
follow-up JJ N
the DT N
rate NN 1_o
of IN 1_o
diarrhea NN 1_o
( ( N
per IN N
100 CD N
wk NN N
) ) N
in IN N
children NNS 1_p
less JJR 1_p
than IN 1_p
6 CD 1_p
y NN 1_p
in IN N
the DT N
intervention NN N
group NN N
was VBD N
5.89 CD N
episodes NNS N
whereas VBP N
that IN N
in IN N
the DT N
nonintervention NN N
group NN N
was VBD N
7.55 CD N
episodes NNS N
( ( N
protective JJ N
efficacy NN N
22 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

During IN N
the DT N
same JJ N
follow-up JJ N
period NN N
children NNS N
in IN N
both DT N
groups NNS N
exhibited VBD N
comparable JJ N
patterns NNS N
of IN N
weight JJ 1_o
gain NN 1_o
; : 1_o
1 CD N
y NN N
after IN N
the DT N
intervention NN N
the DT N
mean JJ 1_o
weight NN 1_o
for IN 1_o
age NN 1_o
of IN N
children NNS N
in IN N
both DT N
groups NNS N
was VBD N
76 CD N
% NN N
of IN N
the DT N
NCHS NNP N
standard NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
that WDT N
experienced VBD N
a DT N
major JJ 1_o
deterioration NN 1_o
or CC 1_o
improvement NN 1_o
of IN 1_o
nutritional JJ 1_o
status NN 1_o
. . 1_o

We PRP N
conclude VBP N
that IN N
an DT N
intervention NN N
that WDT N
reduces VBZ N
rates NNS N
of IN N
childhood NN 1_o
diarrhea NN 1_o
may MD N
not RB N
necessarily RB N
also RB N
improve VB N
nutritional JJ 1_o
status NN 1_o
. . 1_o

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
a DT N
theory-based JJ 1_i
intervention NN 1_i
to TO N
increase VB N
colorectal JJ 1_o
cancer NN 1_o
screening VBG 1_o
among IN 1_p
Iranian JJ 1_p
health NN 1_p
club NN 1_p
members NNS 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

Colorectal JJ N
cancer NN N
is VBZ N
the DT N
third JJ N
most RBS N
commonly RB N
diagnosed JJ N
cancer NN N
and CC N
the DT N
fourth JJ N
leading VBG N
cause NN N
of IN N
death NN N
in IN N
the DT N
world NN N
. . N

There EX N
are VBP N
few JJ N
published VBN N
studies NNS N
that WDT N
have VBP N
used VBN N
theory-based JJ 1_i
interventions NNS 1_i
designed VBN N
to TO N
increase VB N
colorectal JJ N
cancer NN N
screening VBG N
in IN N
community NN N
lay VBP N
health NN N
organizations NNS N
. . N

The DT N
present JJ N
study NN N
was VBD N
guided VBN N
by IN N
the DT N
theoretical JJ N
concepts NNS N
of IN N
the DT N
preventive JJ N
health NN N
model NN N
. . N

Twelve NNP 1_p
health NN 1_p
clubs NNS 1_p
of IN 1_p
a DT 1_p
municipal JJ 1_p
district NN 1_p
in IN 1_p
Tehran NNP 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
two CD N
study NN N
groups NNS N
with IN N
equal JJ N
ratio NN N
. . N

The DT N
control NN N
group NN N
received VBD 1_i
usual JJ 1_i
services NNS 1_i
throughout IN 1_i
the DT 1_i
study NN 1_i
while IN N
the DT N
intervention NN N
group NN N
also RB N
received VBD 1_i
a DT 1_i
theory-based JJ 1_i
educational JJ 1_i
program NN 1_i
on IN 1_i
colorectal JJ 1_i
cancer NN 1_i
screening VBG 1_i
plus CC 1_i
a DT 1_i
reminder NN 1_i
call NN 1_i
. . 1_i

Screening VBG 1_o
behavior NN 1_o
, , N
the DT N
main JJ N
outcome NN N
, , N
was VBD N
assessed VBN N
4 CD N
months NNS N
after IN N
randomization NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
360 CD 1_p
members NNS 1_p
aged VBN 1_p
50 CD 1_p
and CC 1_p
older JJR 1_p
from IN 1_p
12 CD 1_p
health NN 1_p
clubs NNS 1_p
completed VBD 1_p
a DT 1_p
baseline NN 1_p
survey NN 1_p
. . 1_p

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD N
increased JJ 1_o
knowledge NN 1_o
of IN 1_o
colorectal JJ 1_o
cancer NN 1_o
and CC 1_o
screening NN 1_o
tests NNS 1_o
at IN N
4 CD N
months NNS N
follow-up JJ N
( ( N
p NN N
's POS N
< NNP N
.001 NNP N
) ) N
. . N

Moreover RB N
, , N
exposure NN N
to TO N
the DT N
theory-based JJ 1_i
intervention NN 1_i
significantly RB N
improved VBN 1_o
self-efficacy NN 1_o
, , 1_o
perceived VBN 1_o
susceptibility NN 1_o
, , 1_o
efficacy NN 1_o
of IN 1_o
screening NN 1_o
, , 1_o
social JJ 1_o
support NN 1_o
, , 1_o
and CC 1_o
intention NN 1_o
to TO 1_o
be VB 1_o
screened VBN 1_o
for IN 1_o
colorectal JJ 1_o
cancer NN 1_o
, , N
from IN N
baseline NN N
to TO N
4 CD N
months NNS N
follow-up JJ N
( ( N
p NN N
's POS N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
screening NN 1_o
rate NN 1_o
for IN 1_o
colorectal JJ 1_o
cancer NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
= JJ N
15.93 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
5.57 CD N
, , N
45.53 CD N
) ) N
. . N

Our PRP$ N
theory-based JJ N
intervention NN N
was VBD N
found VBN N
to TO N
have VB N
a DT N
significant JJ N
effect NN N
on IN N
colorectal JJ 1_o
cancer NN 1_o
screening VBG 1_o
use NN N
as IN N
measured VBN N
by IN N
self-report NN N
. . N

The DT N
findings NNS N
could MD N
have VB N
implications NNS N
for IN N
colorectal JJ N
cancer NN N
screening VBG N
program NN N
development NN N
and CC N
implementation NN N
in IN N
primary JJ N
health NN N
care NN N
settings NNS N
and CC N
through IN N
other JJ N
community NN N
organizations NNS N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
ketorolac NN 1_i
is VBZ N
associated VBN N
with IN N
decreased VBN N
pneumonia NN N
following VBG N
rib NN 1_p
fractures NNS 1_p
. . 1_p

BACKGROUND IN N
The DT N
effectiveness NN N
of IN N
the DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
ketorolac NN 1_i
in IN N
reducing VBG N
pulmonary JJ 1_p
morbidity NN 1_p
after IN 1_p
rib NN 1_p
fractures NNS 1_p
remains VBZ N
largely RB N
unknown JJ N
. . N

METHODS VB N
A DT N
retrospective JJ N
cohort NN N
study NN N
was VBD N
conducted VBN N
spanning VBG N
January NNP N
2003 CD N
to TO N
June NNP N
2011 CD N
assessing VBG N
pneumonia NN N
within IN N
30 CD N
days NNS N
and CC N
potential JJ N
adverse JJ N
effects NNS N
of IN N
ketorolac NN 1_i
among IN N
all DT 1_p
patients NNS 1_p
with IN 1_p
rib JJ 1_p
fractures NNS 1_p
who WP 1_p
received VBD 1_p
ketorolac NN 1_p
< $ 1_p
4 CD 1_p
days NNS 1_p
after IN 1_p
injury NN 1_p
compared VBN 1_p
with IN 1_p
a DT 1_p
random JJ 1_p
sample NN 1_p
of IN 1_p
those DT 1_p
who WP 1_p
did VBD 1_p
not RB 1_p
. . 1_p

RESULTS NNP N
Among IN N
202 CD 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
ketorolac NN 1_i
and CC 1_p
417 CD 1_p
who WP 1_p
did VBD 1_p
not RB 1_p
, , N
ketorolac NN N
use NN N
was VBD N
associated VBN N
with IN N
decreased VBN N
pneumonia NN 1_o
( ( N
odds NNS N
ratio NN N
, , N
.14 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
.04 '' N
to TO N
.46 VB N
) ) N
and CC N
increased VBD N
ventilator-free JJ 1_o
days NNS 1_o
( ( N
difference NN N
, , N
1.8 CD N
days NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.1 CD N
to TO N
2.5 CD N
) ) N
and CC N
intensive JJ 1_o
care NN 1_o
unit-free JJ 1_o
days NNS 1_o
( ( N
difference NN N
, , N
2.1 CD N
days NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.3 CD N
to TO N
3.0 CD N
) ) N
within IN N
30 CD N
days NNS N
. . N

The DT N
rates NNS 1_o
of IN 1_o
acute JJ 1_o
kidney NN 1_o
injury NN 1_o
, , 1_o
gastrointestinal JJ 1_o
hemorrhage NN 1_o
, , 1_o
and CC 1_o
fracture NN 1_o
nonunion NN 1_o
were VBD N
not RB N
different JJ N
. . N

CONCLUSIONS NNP N
Early JJ N
administration NN N
of IN N
ketorolac NNS 1_i
to TO N
patients NNS 1_p
with IN 1_p
rib JJ 1_p
fractures NNS 1_p
is VBZ N
associated VBN N
with IN N
a DT N
decreased JJ N
likelihood NN N
of IN N
pneumonia NN 1_o
, , N
without IN N
apparent JJ N
risks NNS N
. . N

-DOCSTART- -X- O O

Cognitive-behavioural JJ 1_i
stress NN 1_i
management NN 1_i
with IN N
HIV-positive JJ 1_p
homosexual JJ 1_p
men NNS 1_p
: : 1_p
mechanisms NNS N
of IN N
sustained JJ N
reductions NNS 1_o
in IN 1_o
depressive JJ 1_o
symptoms NNS 1_o
. . 1_o

BACKGROUND IN N
We PRP N
examined VBD N
the DT N
sustained JJ N
efficacy NN N
of IN N
a DT N
group-based JJ 1_i
cognitive-behavioural JJ 1_i
stress NN 1_i
management NN 1_i
( ( 1_i
CBSM NNP 1_i
) ) 1_i
intervention NN 1_i
in IN N
comparison NN N
to TO N
a DT N
modified VBN N
wait-list NN 1_i
control NN 1_i
condition NN 1_i
on IN N
measures NNS N
of IN N
mood NN 1_o
, , 1_o
coping VBG 1_o
and CC 1_o
social JJ 1_o
support NN 1_o
in IN N
mildly RB 1_p
symptomatic JJ 1_p
HIV-positive JJ 1_p
homosexual JJ 1_p
and CC 1_p
bisexual JJ 1_p
men NNS 1_p
. . 1_p

Participants NNS 1_p
were VBD 1_p
recruited VBN 1_p
largely RB 1_p
during IN 1_p
the DT 1_p
era NN 1_p
prior RB 1_p
to TO 1_p
highly RB 1_p
active JJ 1_p
antiretroviral JJ 1_p
therapy NN 1_p
( ( 1_p
HAART NNP 1_p
; : 1_p
1992-1997 JJ 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Men NNPS 1_p
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
10-week JJ N
, , N
group-based JJ N
CBSM NNP 1_i
intervention NN 1_i
( ( N
n JJ N
= NNP N
83 CD N
) ) N
or CC N
a DT 1_p
psychoeducational JJ 1_i
seminar NN 1_i
group NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
46 CD 1_p
) ) 1_p
. . 1_p

All DT N
participants NNS N
completed VBD N
a DT N
battery NN 1_i
of IN 1_i
psychosocial JJ 1_o
questionnaires NNS 1_o
administered VBN 1_i
by IN 1_i
a DT 1_i
research NN 1_i
assistant NN 1_i
at IN 1_i
baseline NN 1_i
, , 1_i
immediately RB 1_i
following VBG 1_i
the DT 1_i
10-week JJ 1_i
CBSM NNP 1_i
intervention NN 1_i
period NN 1_i
, , 1_i
and CC 1_i
at IN 1_i
a DT 1_i
6-month JJ 1_i
follow-up NN 1_i
. . 1_i

RESULTS NNP N
Men NNP 1_p
in IN 1_p
the DT 1_p
CBSM NNP 1_p
group NN 1_p
maintained VBD N
previously RB N
observed VBN N
effects NNS N
on IN N
depressive NN 1_o
symptoms NNS 1_o
and CC 1_o
perceived VBD 1_o
social JJ 1_o
support NN 1_o
. . 1_o

These DT N
sustained JJ N
effects NNS N
of IN N
CBSM NNP N
on IN N
depressive JJ N
symptoms NNS N
were VBD N
mediated VBN N
by IN N
10-week JJ 1_o
increases NNS 1_o
in IN 1_o
cognitive JJ 1_o
coping NN 1_o
( ( N
i.e JJ N
. . N

positive JJ N
reframing NN N
) ) N
. . N

DISCUSSION NNP N
CBSM NNP N
appears VBZ N
to TO N
be VB N
a DT N
potentially RB N
efficacious JJ N
treatment NN N
that WDT N
reduces VBZ N
and CC N
maintains NNS N
lower JJR N
levels NNS N
of IN N
depressive NN N
symptoms NNS N
and CC N
enhances VBZ N
social JJ N
support NN N
in IN N
HIV-positive JJ 1_p
homosexual JJ 1_p
and CC 1_p
bisexual JJ 1_p
men NNS 1_p
. . 1_p

In IN N
particular JJ N
, , N
changes NNS 1_o
in IN 1_o
positive JJ 1_o
reframing NN 1_o
during IN N
the DT N
10-week JJ N
intervention NN N
period NN N
remain VBP N
a DT N
crucial JJ N
factor NN N
contributing VBG N
to TO N
sustained VBN N
reductions NNS 1_o
in IN 1_o
depressive JJ 1_o
symptoms NNS 1_o
. . N

-DOCSTART- -X- O O

Exploring VBG N
the DT N
social JJ 1_o
impact NN 1_o
of IN N
being VBG N
a DT N
typical JJ 1_i
peer NN 1_i
model NN 1_i
for IN N
included JJ N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

This DT N
study NN N
examined VBD N
the DT N
social JJ 1_o
impact NN 1_o
of IN N
being VBG N
a DT N
typical JJ N
peer NN N
model NN N
as IN N
part NN N
of IN N
a DT N
social JJ 1_i
skills NNS 1_i
intervention NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

Participants NNS N
were VBD N
drawn VBN N
from IN N
a DT N
randomized-controlled-treatment JJ N
trial NN N
that WDT N
examined VBD N
the DT N
effects NNS N
of IN N
targeted JJ N
interventions NNS 1_i
on IN N
the DT N
social JJ 1_o
networks NNS 1_o
of IN N
60 CD 1_p
elementary-aged JJ 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Results NNP N
demonstrated VBD N
that DT N
typical JJ N
peer NN N
models NNS N
had VBD N
higher RBR 1_o
social JJ 1_o
network NN 1_o
centrality NN 1_o
, , 1_o
received VBN 1_o
friendships NNS 1_o
, , 1_o
friendship JJ 1_o
quality NN 1_o
, , 1_o
and CC 1_o
less JJR 1_o
loneliness JJR 1_o
than IN N
non-peer JJ N
models NNS N
. . N

Peer NNP 1_i
models NNS 1_i
were VBD N
also RB N
more RBR 1_o
likely JJ 1_o
to TO N
be VB N
connected VBN N
with IN N
children NNS N
with IN N
ASD NNP N
than IN N
non-peer JJ N
models NNS N
at IN N
baseline NN N
and CC N
exit NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
typical JJ N
peers NNS N
can MD N
be VB N
socially RB N
connected VBN N
to TO N
children NNS N
with IN N
ASD NNP N
, , N
as RB N
well RB N
as IN N
other JJ N
classmates NNS N
, , N
and CC N
maintain VB N
a DT N
strong JJ 1_o
and CC 1_o
positive JJ 1_o
role NN 1_o
within IN N
the DT N
classroom NN N
. . N

-DOCSTART- -X- O O

Multicomponent NNP N
interdisciplinary JJ N
group NN N
intervention NN N
for IN N
self-management NN N
of IN N
fibromyalgia NN 1_p
: : 1_p
a DT N
mixed-methods NNS N
randomized VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND VB N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
the DT N
PASSAGE NNP 1_i
Program NNP 1_i
, , N
a DT N
structured JJ N
multicomponent NN 1_i
interdisciplinary JJ 1_i
group NN 1_i
intervention NN 1_i
for IN N
the DT N
self-management NN N
of IN N
FMS NNP 1_p
. . 1_p

METHODS NNP N
A DT N
mixed-methods NNS N
randomized VBN N
controlled VBN N
trial NN N
( ( 1_i
intervention NN 1_i
( ( 1_i
INT NNP 1_i
) ) 1_i
vs. FW 1_i
waitlist NN 1_i
( ( 1_i
WL NNP 1_i
) ) 1_i
) ) 1_i
was VBD N
conducted VBN N
with IN N
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
FMS NNP 1_p
. . 1_p

Data NNP N
were VBD N
collected VBN N
at IN N
baseline NN N
( ( N
T0 NNP N
) ) N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
( ( N
T1 NNP N
) ) N
, , N
and CC N
3 CD N
months NNS N
later RB N
( ( N
T2 NNP N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
change NN N
in IN N
pain NN 1_o
intensity NN 1_o
( ( N
0-10 JJ N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
fibromyalgia JJ 1_o
severity NN 1_o
, , 1_o
pain NN 1_o
interference NN 1_o
, , 1_o
sleep JJ 1_o
quality NN 1_o
, , 1_o
pain VBP 1_o
coping VBG 1_o
strategies NNS 1_o
, , 1_o
depression NN 1_o
, , 1_o
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
patient JJ 1_o
global JJ 1_o
impression NN 1_o
of IN 1_o
change NN 1_o
( ( 1_o
PGIC NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
perceived VBD 1_o
pain NN 1_o
relief NN 1_o
. . 1_o

Qualitative JJ N
group NN N
interviews NNS N
with IN N
a DT N
subset NN N
of IN N
patients NNS N
were VBD N
also RB N
conducted VBN N
. . N

Complete NNP N
data NN N
from IN N
T0 NNP N
to TO N
T2 NNP N
were VBD N
available JJ N
for IN N
43 CD 1_p
patients NNS 1_p
. . 1_p

RESULTS VB N
The DT N
intervention NN N
had VBD N
a DT N
statistically RB N
significant JJ N
impact NN N
on IN N
the DT N
three CD N
PGIC NNP N
measures NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
PASSAGE NNP N
Program NNP N
, , N
the DT N
percentages NNS N
of IN N
patients NNS N
who WP N
perceived VBD N
overall JJ N
improvement NN N
in IN N
their PRP$ N
pain NN 1_o
levels NNS 1_o
, , 1_o
functioning NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
INT NNP N
Group NNP N
( ( N
73 CD N
% NN N
, , N
55 CD N
% NN N
, , N
77 CD N
% NN N
respectively RB N
) ) N
than IN N
in IN N
the DT N
WL NNP N
Group NNP N
( ( N
8 CD N
% NN N
, , N
12 CD N
% NN N
, , N
20 CD N
% NN N
) ) N
. . N

The DT N
same JJ N
differences NNS N
were VBD N
observed JJ N
3 CD N
months NNS N
post-intervention NN N
( ( N
Intervention NNP N
group NN N
: : N
62 CD N
% NN N
, , N
43 CD N
% NN N
, , N
38 CD N
% NN N
vs JJ N
Waitlist NNP N
Group NNP N
: : N
13 CD N
% NN N
, , N
13 CD N
% NN N
, , N
9 CD N
% NN N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
who WP N
reported VBD N
? . 1_o
50 CD 1_o
% NN 1_o
pain NN 1_o
relief NN 1_o
was VBD 1_o
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
INT NNP N
Group NNP N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
( ( N
36 CD N
% NN N
vs JJ N
12 CD N
% NN N
) ) N
and CC N
3 CD N
months NNS N
post-intervention NN N
( ( N
33 CD N
% NN N
vs JJ N
4 CD N
% NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
qualitative JJ N
analysis NN N
were VBD N
in IN N
line NN N
with IN N
the DT N
quantitative JJ N
findings NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
the DT N
intervention NN N
. . N

The DT N
improvement NN N
, , N
however RB N
, , N
was VBD N
not RB N
reflected VBN N
in IN N
the DT N
primary JJ N
outcome NN N
and CC N
other JJ N
secondary JJ N
outcome NN N
measures NNS N
. . N

CONCLUSION NNP N
The DT N
PASSAGE NNP N
Program NNP N
was VBD N
effective JJ N
in IN N
helping VBG 1_p
FMS NNP 1_p
patients NNS 1_p
gain VBP 1_p
a DT N
sense NN N
of IN N
control NN N
over IN N
their PRP$ N
symptoms NNS N
. . N

We PRP N
suggest VBP N
including VBG N
PGIC NNP N
in IN N
future JJ N
clinical JJ N
trials NNS N
on IN N
FMS NNP 1_p
as IN 1_p
they PRP N
appear VBP N
to TO N
capture VB N
important JJ N
aspects NNS N
of IN N
the DT N
patients NNS N
' POS N
experience NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
International NNP N
Standard NNP N
Randomized NNP N
Controlled NNP N
Trial NNP N
Number NNP N
Register NNP N
ISRCTN14526380 NNP N
. . N

-DOCSTART- -X- O O

Duration NN N
of IN N
untreated JJ N
negative JJ N
and CC N
positive JJ N
symptoms NNS N
of IN N
psychosis NN 1_p
and CC N
cognitive JJ N
impairment NN N
in IN N
first JJ 1_p
episode NN 1_p
psychosis NN 1_p
. . 1_p

BACKGROUND NNP N
Duration NNP N
of IN N
untreated JJ 1_p
psychosis NN 1_p
( ( 1_p
DUP NNP 1_p
) ) 1_p
has VBZ N
been VBN N
significantly RB N
associated VBN N
with IN N
poor JJ 1_o
clinical JJ 1_o
and CC 1_o
social JJ 1_o
outcomes NNS 1_o
in IN N
First NNP 1_p
Episode NNP 1_p
Psychosis NNP 1_p
( ( 1_p
FEP NNP 1_p
) ) 1_p
patients NNS 1_p
, , N
but CC N
an DT N
association NN N
with IN N
cognitive JJ N
outcomes NNS N
has VBZ N
not RB N
been VBN N
clearly RB N
established VBN N
. . N

METHOD NNP N
Seventy-seven NNP 1_p
consecutively RB 1_p
admitted VBD 1_p
, , 1_p
drug-na?ve JJ 1_p
patients NNS 1_p
with IN 1_p
FEP NNP 1_p
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
at IN N
1month CD N
and CC N
6months CD N
. . N

Underlying VBG N
dimensions NNS N
of IN N
DUP NNP N
( ( N
general JJ N
prodrome NN N
and CC N
positive JJ N
, , N
negative JJ N
and CC N
disorganisation NN N
symptoms NNS N
) ) N
were VBD N
assessed VBN N
using VBG N
the DT 1_o
Symptom NNP 1_o
Onset NNP 1_o
in IN 1_o
Schizophrenia NNP 1_o
( ( 1_o
SOS NNP 1_o
) ) 1_o
inventory NN 1_o
( ( N
Perkins NNP N
et FW N
al. NN N
, , N
2000 CD N
) ) N
. . N

To TO N
assess VB N
the DT N
effect NN N
of IN N
DUP NNP N
on IN N
the DT 1_o
neuropsychological JJ 1_o
status NN 1_o
of IN N
the DT N
patients NNS N
, , N
a DT N
linear JJ N
mixed-effect JJ N
model NN N
was VBD N
fitted VBN N
to TO N
each DT N
neuropsychological JJ N
dimension NN N
. . N

These DT N
models NNS N
included VBD N
a DT N
dichotomised JJ N
version NN N
of IN N
DUP NNP N
( ( N
short JJ N
versus NN N
long JJ N
duration NN N
) ) N
as IN N
a DT N
fixed JJ N
effect NN N
, , N
several JJ N
adjusting VBG N
variables NNS N
to TO N
account VB N
for IN N
patient NN N
differences NNS N
, , N
and CC N
a DT N
random JJ N
effect NN N
to TO N
incorporate VB N
the DT N
longitudinal JJ N
structure NN N
of IN N
the DT N
data NNS N
. . N

RESULTS JJ N
Patients NNPS N
with IN N
a DT N
short JJ N
duration NN N
of IN 1_p
untreated JJ 1_p
negative JJ 1_p
symptoms NNS 1_p
( ( 1_p
DUNS NNP 1_p
) ) 1_p
or CC 1_p
a DT 1_p
short JJ 1_p
duration NN 1_p
of IN 1_p
untreated JJ 1_p
positive JJ 1_p
symptoms NNS 1_p
( ( 1_p
DUPS NNP 1_o
) ) 1_o
outperformed VBD N
patients NNS N
with IN N
a DT N
long JJ N
duration NN N
of IN N
untreated JJ N
symptoms NNS N
on IN 1_o
memory NN 1_o
tasks NNS 1_o
and CC 1_o
a DT 1_o
pre-attentional JJ 1_o
visual JJ 1_o
task NN 1_o
but CC N
not RB N
on IN 1_o
measures NNS 1_o
of IN 1_o
verbal JJ 1_o
fluency NN 1_o
, , 1_o
attention NN 1_o
, , 1_o
reaction NN 1_o
time NN 1_o
, , 1_o
visual JJ 1_o
processing NN 1_o
and CC 1_o
executive NN 1_o
functions NNS 1_o
. . 1_o

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
additional JJ N
support NN N
for IN N
an DT N
early JJ N
intervention NN N
to TO N
shorten VB N
DUP NNP N
to TO N
facilitate VB N
a DT N
better JJR 1_o
outcome NN 1_o
in IN 1_o
memory NN 1_o
and CC 1_o
attentional JJ 1_o
domains NNS 1_o
of IN 1_p
FEP NNP 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Prospective JJ N
comparison NN N
of IN N
nasal JJ 1_i
versus IN 1_i
oral JJ 1_i
insertion NN 1_i
of IN 1_i
a DT 1_i
thin JJ 1_i
video NN 1_i
endoscope NN 1_i
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
Attempts NNP N
have VBP N
been VBN N
made VBN N
to TO N
improve VB N
patient NN N
's POS N
tolerance NN N
of IN N
upper JJ 1_i
gastrointestinal JJ 1_i
endoscopy NN 1_i
and CC N
to TO N
decrease VB N
the DT N
need NN N
for IN N
sedation NN N
, , N
using VBG N
thinner NN N
endoscopes NNS N
and CC N
a DT N
nasal JJ N
introduction NN N
route NN N
. . N

We PRP N
prospectively RB N
compared VBN N
the DT N
oral JJ 1_i
and CC 1_i
nasal JJ 1_i
routes NNS 1_i
in IN N
volunteers NNS N
, , N
using VBG N
a DT N
thin JJ 1_i
prototype NN 1_i
video NN 1_i
endoscope NN 1_i
. . 1_i

METHODS NNP N
Ten NNP 1_p
healthy JJ 1_p
volunteers NNS 1_p
underwent JJ 1_p
two CD 1_i
upper JJ 1_i
gastrointestinal JJ 1_i
endoscopies NNS 1_i
in IN 1_p
a DT 1_p
random JJ 1_p
order NN 1_p
on IN 1_p
two CD 1_p
different JJ 1_p
days NNS 1_p
, , 1_p
with IN 1_p
the DT 1_p
procedure NN 1_p
being VBG 1_p
carried VBN 1_p
out RP 1_p
by IN 1_p
a DT 1_p
single JJ 1_p
experienced JJ 1_p
endoscopist NN 1_p
. . 1_p

Parameters NNS N
assessed VBD N
were VBD N
the DT N
tolerance NN 1_o
of IN 1_o
scope NN 1_o
insertion NN 1_o
and CC 1_o
the DT 1_o
assessment NN 1_o
of IN 1_o
the DT 1_o
entire JJ 1_o
procedure NN 1_o
( ( N
0-10 JJ N
scale NN N
) ) N
, , N
the DT N
method NN 1_o
of IN 1_o
insertion NN 1_o
preferred VBN 1_o
by IN 1_o
the DT 1_o
volunteers NNS 1_o
, , 1_o
the DT 1_o
completeness NN 1_o
of IN 1_o
the DT 1_o
examination NN 1_o
( ( N
assessed VBN N
by IN N
an DT N
independent JJ N
endoscopist NN N
) ) N
, , N
and CC N
the DT N
time NN 1_o
required VBN 1_o
for IN 1_o
the DT 1_o
procedure NN 1_o
. . 1_o

RESULTS NNP N
In IN N
one CD N
patient NN N
, , N
nasal JJ 1_o
insertion NN 1_o
failed VBD N
, , N
and CC N
she PRP N
was VBD N
excluded VBN N
from IN N
further JJ N
analysis NN N
. . N

The DT N
insertion NN 1_o
of IN 1_o
the DT 1_o
scope NN 1_o
was VBD N
easier JJR N
via IN N
the DT N
oral JJ N
route NN N
, , N
as IN N
reflected VBN N
in IN N
a DT N
shorter JJR N
examination NN 1_o
time NN 1_o
( ( N
mean JJ N
165 CD N
vs. FW N
210 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.017 CD N
) ) N
and CC N
patients NNS 1_o
' POS 1_o
tolerance NN 1_o
for IN 1_o
the DT 1_o
scope NN 1_o
insertion NN 1_o
( ( N
mean JJ N
score NN N
: : N
8 CD N
for IN N
oral JJ N
vs. FW N
4 CD N
for IN N
nasal JJ N
route NN N
; : N
p CC N
= VB N
0.03 CD N
) ) N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
gagging VBG 1_o
occurred VBD N
more RBR N
frequently RB N
during IN N
oral JJ 1_i
endoscopy NN 1_i
( ( N
6/9 CD N
vs NN N
1/9 CD N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
. . N

Three CD N
of IN N
the DT N
volunteers NNS N
in IN N
each DT N
case NN N
preferred VBD 1_o
the DT N
oral JJ N
or CC N
the DT N
nasal JJ N
route NN N
, , N
and CC N
three CD N
were VBD N
not RB N
decided VBN N
, , N
in IN N
case NN N
of IN N
a DT N
repeated JJ N
endoscopy NN N
. . N

Similarly RB N
, , N
the DT N
overall JJ 1_o
tolerance NN 1_o
for IN 1_o
the DT 1_o
procedure NN 1_o
did VBD N
not RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Thin-diameter NNP 1_i
gastroscopes NNS 1_i
seem VBP N
to TO N
improve VB N
patient NN 1_o
's POS 1_o
tolerance NN 1_o
. . 1_o

In IN N
this DT N
small JJ N
study NN N
in IN N
volunteers NNS N
, , N
nasal JJ N
introduction NN N
showed VBD N
no DT N
overall JJ N
benefit NN N
over IN N
oral JJ N
introduction NN N
. . N

Modifications NNS N
of IN N
the DT N
scope NN N
to TO N
achieve VB N
better JJR N
nasal NN N
passage NN N
are VBP N
necessary JJ N
. . N

-DOCSTART- -X- O O

ACE NNP 1_i
inhibitors NNS 1_i
or CC 1_i
AT-1 JJ 1_i
antagonists NNS 1_i
- : N
which WDT N
is VBZ N
OPTIMAAL NNP N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
? . N
OPTIMAAL NNP N
( ( N
Optimal NNP N
Trial NNP N
in IN N
Myocardial NNP N
Infarction NNP N
with IN N
the DT N
Angiotensin NNP N
II NNP N
Antagonist NNP N
Losartan NNP N
) ) N
is VBZ N
the DT N
first JJ N
major JJ N
study NN N
to TO N
compare VB N
an DT N
angiotensin NN 1_i
II NNP 1_i
Type NNP 1_i
1 CD 1_i
antagonist NN 1_i
losartan NN 1_i
( ( N
Cozaar NNP N
trade NN N
mark NN N
, , N
Merck NNP N
) ) N
with IN N
an DT N
ACE NNP N
inhibitor NN N
captonpril NN 1_i
( ( N
Capoten NNP N
trade NN N
mark NN N
, , N
Elan NNP N
) ) N
after IN 1_p
myocardial JJ 1_p
infarction NN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
left JJ 1_p
ventricular JJ 1_p
dysfunction NN 1_p
. . 1_p

Patients NNS 1_p
were VBD N
assigned VBN N
to TO N
a DT N
target NN N
dose NN N
of IN N
losartan JJ 1_i
50 CD N
mg/day NN N
and CC N
captopril NN 1_i
50 CD N
mg NN N
t.i.d. NN N
, , N
as IN N
tolerated VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
all-cause JJ 1_o
mortality NN 1_o
and CC N
there EX N
were VBD N
499 CD N
( ( N
18 CD N
% NN N
) ) N
and CC N
447 CD N
( ( N
16 CD N
% NN N
) ) N
deaths NNS 1_o
in IN N
the DT N
losartan NN 1_i
and CC 1_i
captopril NN 1_i
group NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
significantly RB N
more JJR N
cardiovascular JJ 1_o
deaths NNS 1_o
with IN N
losartan NN N
( ( N
420 CD N
, , N
15 CD N
% NN N
) ) N
than IN N
with IN N
captopril NN 1_i
( ( N
363 CD N
, , N
13 CD N
% NN N
; : N
p CC N
= VB N
0.03 CD N
) ) N
. . N

Losartan NNP 1_i
was VBD N
better RBR N
tolerated VBN 1_o
than IN N
captopril NN 1_i
with IN N
fewer JJR N
patients NNS 1_o
discontinuing VBG 1_o
medication NN 1_o
( ( N
17 CD N
versus RB N
23 CD N
% NN N
for IN N
losartan NN 1_i
and CC N
captopril NN 1_i
, , N
respectively RB N
) ) N
. . N

In IN N
conclusion NN N
, , N
if IN N
tolerated VBN N
, , N
captopril NN 1_i
should MD N
remain VB N
the DT N
preferred JJ N
treatment NN N
for IN N
patients NNS 1_p
after IN N
complicated VBN N
acute JJ 1_o
myocardial JJ 1_o
infarction NN 1_o
. . 1_o

-DOCSTART- -X- O O

Amisulpride NNP 1_i
versus NN N
bromocriptine NN 1_i
in IN N
infantile JJ 1_p
autism NN 1_p
: : 1_p
a DT N
controlled VBN N
crossover NN N
comparative NN N
study NN N
of IN N
two CD N
drugs NNS N
with IN N
opposite JJ N
effects NNS N
on IN N
dopaminergic JJ N
function NN N
. . N

An DT N
alteration NN N
of IN N
dopaminergic NN 1_o
( ( 1_o
DA NNP 1_o
) ) 1_o
function NN 1_o
much RB N
more RBR N
complex JJ N
than IN N
simple JJ N
hyperactivity NN N
has VBZ N
been VBN N
evoked VBN N
in IN N
infantile JJ 1_p
autism NN 1_p
. . 1_p

We PRP N
therefore RB N
compared VBN N
the DT N
clinical JJ 1_o
efficacy NN 1_o
of IN N
a DT N
DA NNP 1_i
antagonist NN 1_i
( ( 1_i
amisulpride IN 1_i
) ) 1_i
and CC N
a DT N
DA NNP 1_i
agonist NN 1_i
( ( 1_i
bromocriptine NN 1_i
) ) 1_i
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
trial NN N
in IN N
9 CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
, , 1_p
likely RB 1_p
severely RB 1_p
mentally RB 1_p
retarded JJ 1_p
. . 1_p

Amisulpride NNP 1_i
acts VBZ N
preferentially RB N
on IN N
specific JJ N
autistic JJ N
symptoms NNS N
whereas VBP N
bromocriptine JJ 1_i
acts NNS N
more RBR N
on IN N
motor NN 1_o
hyperactivity NN 1_o
and CC 1_o
attention NN 1_o
symptoms NNS 1_o
. . 1_o

These DT N
findings NNS N
raise VBP N
the DT N
specificity NN N
of IN N
these DT N
two CD N
drugs NNS N
which WDT N
appear VBP N
to TO N
act VB N
preferentially RB N
on IN N
some DT N
target NN N
symptoms NNS N
and CC N
are VBP N
consistent JJ N
with IN N
some DT N
clinical JJ N
and CC N
pharmacological JJ N
observations NNS N
showing VBG N
a DT N
sedative JJ 1_o
effect NN 1_o
with IN N
low JJ N
doses NNS N
of IN N
DA NNP 1_i
agonists NNS 1_i
and CC N
a DT N
stimulant JJ 1_o
effect NN 1_o
with IN N
low JJ N
doses NNS N
of IN N
DA NNP 1_i
antagonists NNS 1_i
such JJ N
as IN N
the DT N
benzamides NNS 1_i
. . 1_i

-DOCSTART- -X- O O

Pruritus NN N
in IN N
HIV-1 NNP N
disease NN N
: : N
therapy NN N
with IN N
drugs NNS N
which WDT N
may MD N
modulate VB N
the DT N
pattern NN N
of IN N
immune JJ 1_o
dysregulation NN 1_o
. . 1_o

BACKGROUND NNP N
Pruritus NNP 1_p
in IN 1_p
HIV-1+ NNP 1_p
patients NNS 1_p
is VBZ N
common JJ N
and CC N
increases VBZ N
with IN N
disease NN N
progression NN N
. . N

The DT N
causes NNS N
of IN N
pruritus NN N
are VBP N
numerous JJ N
including VBG N
xerosis NN N
, , N
drug NN N
and CC N
photoeruptions NNS N
, , N
follicular JJ N
and CC N
papular JJ N
eruptions NNS N
as RB N
well RB N
as IN N
infestations NNS N
and CC N
infections NNS N
by IN N
a DT N
wide JJ N
range NN N
of IN N
organisms NNS N
. . N

One CD N
other JJ N
possible JJ N
factor NN N
contributing VBG N
to TO N
pruritus VB N
is VBZ N
the DT N
pattern NN N
of IN N
immune JJ N
dysregulation NN N
. . N

With IN N
advancing VBG N
HIV-1 JJ N
disease NN N
there EX N
is VBZ N
Th1 NNP N
to TO N
Th2 NNP N
cytokine NN N
switching VBG N
. . N

METHODS NNP N
After IN N
some DT N
positive JJ N
results NNS N
with IN N
prostaglandin JJ N
inhibitors NNS N
, , N
we PRP N
undertook VBP N
a DT N
study NN N
in IN N
which WDT N
we PRP N
randomly VBP N
placed VBN N
patients NNS 1_p
on IN 1_p
four CD 1_p
different JJ 1_p
forms NNS 1_p
of IN 1_p
therapy NN 1_p
for IN 1_p
their PRP$ 1_p
pruritus NN 1_p
. . 1_p

The DT N
therapies NNS N
included VBD N
hydroxyzine NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
doxepin NN 1_i
at IN 1_i
night NN 1_i
, , 1_i
pentoxifylline NN 1_i
, , 1_i
indomethacin NN 1_i
and CC 1_i
topical JJ 1_i
moisturization NN 1_i
with IN 1_i
medium-strength JJ 1_i
topical JJ 1_i
steroids NNS 1_i
. . 1_i

All DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
both DT N
subjective JJ 1_o
relief NN 1_o
as RB N
well RB N
as IN N
side NN 1_o
effects NNS 1_o
. . 1_o

RESULTS NNP N
Patients NNPS N
placed VBD N
on IN N
indomethacin NN N
obtained VBN N
relief NN 1_o
more RBR N
consistently RB N
and CC N
more RBR N
completely RB N
. . N

Patients NNS 1_p
on IN 1_p
pentoxifylline NN 1_p
had VBD N
the DT N
fewest JJS N
side NN 1_o
effects NNS 1_o
of IN N
all DT N
oral JJ N
therapies NNS N
. . N

Patients NNS N
on IN N
antihistamines NNS N
with IN N
or CC N
without IN N
doxepin NN N
had VBD N
the DT N
highest JJS N
incidence NN 1_o
of IN 1_o
side NN 1_o
effects NNS 1_o
, , N
although IN N
more JJR N
of IN N
these DT N
patients NNS N
reported VBD N
a DT N
greater JJR N
degree NN 1_o
of IN 1_o
relief NN 1_o
than IN N
patients NNS N
on IN N
pentoxifylline NN N
. . N

All DT N
patients NNS N
on IN N
oral JJ N
therapy NN N
overall NN N
had VBD N
greater JJR 1_o
relief NN 1_o
than IN N
patients NNS N
using VBG N
topical JJ N
steroids NNS N
. . N

CONCLUSION VB N
The DT N
systemic JJ N
therapies NNS N
which WDT N
may MD N
modulate VB N
the DT N
pattern NN N
of IN N
immune JJ 1_o
dysregulation NN 1_o
seen VBN N
in IN N
HIV-1 NNP N
disease NN N
may MD N
be VB N
beneficial JJ 1_o
in IN N
the DT N
pruritus NN N
seen VBN N
in IN N
late-stage JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Are NNP N
brand-name JJ N
and CC N
generic JJ 1_i
warfarin NN 1_i
interchangeable JJ N
? . N
Multiple JJ N
n-of-1 JJ N
randomized NN N
, , N
crossover NN N
trials NNS N
. . N

BACKGROUND NNP N
Warfarin NNP 1_i
is VBZ N
a DT N
commonly RB N
used VBN N
anticoagulant NN N
in IN N
North NNP N
America NNP N
. . N

Several JJ N
generic JJ N
formulations NNS N
have VBP N
been VBN N
approved VBN N
, , N
raising VBG N
concern NN N
over IN N
the DT N
safety NN 1_o
and CC N
efficacy NN 1_o
of IN N
these DT N
products NNS N
compared VBN N
with IN N
brand-name JJ N
Coumadin NNP 1_i
. . 1_i

OBJECTIVE NNP N
To TO N
ensure VB N
that IN N
generic JJ N
warfarin NN N
products NNS N
can MD N
be VB N
safely RB N
interchanged VBN N
with IN N
Coumadin NNP N
. . N

METHODS NNP N
Multiple NNP N
n-of-1 JJ N
randomized NN N
, , N
double-blind NN N
, , N
crossover NN N
trials NNS N
switched VBD N
outpatients NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
7 CD 1_p
) ) 1_p
between IN N
a DT N
generic JJ 1_i
warfarin NN 1_i
formulation NN 1_i
( ( 1_i
Apo-warfarin NNP 1_i
) ) 1_i
and CC 1_i
Coumadin NNP 1_i
over IN 1_i
30 CD 1_i
weeks NNS 1_i
. . 1_i

Study NNP 1_p
patients NNS 1_p
took VBD 1_p
each DT 1_p
drug NN 1_p
for IN 1_p
five CD 1_p
3-week JJ 1_p
periods NNS 1_p
, , 1_p
with IN 1_p
international JJ 1_o
normalized VBN 1_o
ratio NN 1_o
( ( 1_o
INR NNP 1_o
) ) 1_o
measurements VBZ 1_p
taken VBN 1_p
twice RB 1_p
per IN 1_p
period NN 1_p
. . 1_p

Inter- JJ N
and CC N
intrapatient JJ N
differences NNS N
between IN N
generic JJ N
warfarin NN 1_i
and CC N
Coumadin NNP 1_i
were VBD N
compared VBN N
, , N
and CC N
overall JJ N
study NN N
patient NN N
results NNS N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
a DT N
Coumadin NNP N
control NN N
group NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
warfarin NN N
products NNS N
in IN N
terms NNS N
of IN N
mean JJ 1_o
INR NNP 1_o
results NNS 1_o
or CC N
number NN 1_o
of IN 1_o
dosage JJ 1_o
adjustments NNS 1_o
required VBN 1_o
. . 1_o

There EX N
also RB N
was VBD N
no DT N
difference NN N
in IN N
INR NNP 1_o
variation NN 1_o
based VBN N
on IN N
warfarin JJ N
formulation NN N
( ( N
p JJ N
> NNP N
0.69 CD N
) ) N
, , N
nor CC N
was VBD N
a DT N
patient NN N
and CC N
warfarin JJ N
interaction NN N
found VBD N
( ( N
p JJ N
> NNP N
0.81 CD N
) ) N
. . N

The DT N
INR NNP 1_o
results NNS 1_o
were VBD N
not RB N
influenced VBN N
by IN N
whether IN N
patients NNS N
were VBD N
maintained VBN N
on IN N
Coumadin NNP N
only RB N
( ( N
control VB N
group NN N
) ) N
or CC N
interchanged VBN N
between IN N
Coumadin NNP 1_i
and CC N
generic JJ 1_i
warfarin NN 1_i
( ( N
p JJ N
= NNP N
0.98 CD N
) ) N
. . N

CONCLUSIONS VB N
It PRP N
appears VBZ N
that IN N
patients NNS N
can MD N
safely RB 1_o
and CC 1_o
effectively RB 1_o
switch VB 1_o
between IN N
generic JJ N
warfarin NN 1_i
and CC N
Coumadin NNP 1_i
. . 1_i

-DOCSTART- -X- O O

Behavioral JJ 1_o
changes NNS 1_o
in IN N
autistic JJ 1_p
individuals NNS 1_p
as IN N
a DT N
result NN N
of IN N
wearing VBG N
ambient JJ 1_i
transitional JJ 1_i
prism NN 1_i
lenses NNS 1_i
. . 1_i

A DT N
double-blind JJ N
crossover NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
wearing VBG 1_i
ambient JJ 1_i
lenses NNS 1_i
to TO N
reduce VB N
the DT N
behavioral JJ N
symptoms NNS N
of IN N
autism NN N
. . N

Eighteen NNP 1_p
autistic JJ 1_p
individuals NNS 1_p
, , 1_p
ranging VBG 1_p
in IN 1_p
age NN 1_p
from IN 1_p
7 CD 1_p
to TO 1_p
18 CD 1_p
years NNS 1_p
, , N
participated VBD N
in IN N
the DT N
study NN N
. . N

Behavior NNP 1_o
, , 1_o
attention NN 1_o
, , 1_o
and CC 1_o
orientation NN 1_o
were VBD N
evaluated VBN N
at IN N
1 CD N
1/2 CD N
months NNS N
, , N
2 CD N
months NNS N
, , N
3 CD N
months NNS N
, , N
and CC N
4 CD N
months NNS N
. . N

Compared VBN N
to TO N
the DT N
placebo NN 1_i
condition NN N
, , N
the DT N
results NNS N
showed VBD N
a DT N
decrease NN N
in IN N
behavior JJ 1_o
problems NNS 1_o
at IN N
the DT N
1 CD N
1/2 CD N
and CC N
2 CD N
month NN N
assessment NN N
periods NNS N
and CC N
a DT N
slight JJ N
loss NN N
of IN N
these DT N
benefits NNS N
at IN N
the DT N
3 CD N
and CC N
4 CD N
month NN N
assessment NN N
periods NNS N
. . N

These DT N
findings NNS N
support VBP N
the DT N
prediction NN N
that WDT N
ambient JJ 1_i
lenses NNS 1_i
, , N
worn VBN N
without IN N
engaging VBG N
in IN N
visual-motor NN N
exercises NNS N
, , N
have VBP N
positive JJ N
effects NNS N
on IN N
autistic JJ 1_p
individuals NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Abdominoperineal NNP 1_i
resection NN 1_i
and CC N
anterior JJ 1_i
resection NN 1_i
in IN N
the DT N
treatment NN N
of IN N
rectal JJ 1_p
cancer NN 1_p
: : 1_p
results NNS N
in IN N
relation NN N
to TO N
adjuvant VB 1_i
preoperative JJ 1_i
radiotherapy NN 1_i
. . 1_i

The DT N
outcome NN N
of IN N
patients NNS 1_p
with IN 1_p
rectal JJ 1_p
cancer NN 1_p
treated VBN 1_p
by IN 1_p
abdominoperineal NN 1_i
or CC 1_i
anterior JJ 1_i
resection NN 1_i
, , 1_i
with IN 1_i
or CC 1_i
without IN 1_i
preoperative JJ 1_i
radiotherapy NN 1_i
, , N
was VBD N
assessed VBN N
to TO N
detect VB N
any DT N
differences NNS N
attributable JJ N
to TO N
the DT N
operative JJ N
method NN N
and CC N
interactions NNS N
between IN N
radiotherapy NN N
and CC N
type NN N
of IN N
surgery NN N
. . N

The DT N
study NN N
was VBD N
based VBN N
on IN N
1292 CD 1_p
patients NNS 1_p
included VBN 1_p
in IN 1_p
two CD 1_p
consecutive JJ 1_p
controlled VBN 1_p
randomized JJ 1_p
trials NNS 1_p
of IN 1_p
preoperative JJ 1_i
radiotherapy NN 1_i
in IN 1_p
operable JJ 1_p
rectal JJ 1_p
carcinoma NN 1_p
. . 1_p

The DT N
outcome NN N
was VBD N
not RB N
related VBN N
to TO N
surgical JJ N
method NN N
. . N

Radiotherapy NNP N
increased VBD N
postoperative JJ 1_o
mortality NN 1_o
and CC 1_o
complications NNS 1_o
and CC N
reduced JJ N
local JJ 1_o
and CC 1_o
distant JJ 1_o
recurrence NN 1_o
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
overall JJ 1_o
survival NN 1_o
. . 1_o

Effects NNS N
of IN N
radiotherapy NN 1_i
were VBD N
similar JJ N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
surgery NN N
, , N
except IN N
that IN N
the DT N
increase NN N
in IN N
postoperative JJ 1_o
mortality NN 1_o
in IN N
irradiated JJ N
patients NNS N
was VBD N
greater JJR N
in IN N
those DT N
treated VBN N
with IN N
abdominoperineal JJ N
resection NN N
. . N

Sphincter-saving JJ 1_i
procedures NNS 1_i
appear VBP N
to TO N
have VB N
no DT N
adverse JJ N
effects NNS N
on IN N
outcome NN N
of IN N
rectal JJ 1_p
cancer NN 1_p
, , N
but CC N
the DT N
optimum JJ N
use NN N
of IN N
radiotherapy NN N
is VBZ N
still RB N
to TO N
be VB N
defined VBN N
. . N

-DOCSTART- -X- O O

A DT N
randomised VBN N
, , N
controlled VBD N
study NN N
of IN N
dietary JJ 1_i
intervention NN 1_i
in IN N
autistic JJ 1_p
syndromes NNS 1_p
. . 1_p

Impaired NNP N
social JJ N
interaction NN N
, , N
communication NN N
and CC N
imaginative JJ N
skills NNS N
characterize VBP N
autistic JJ N
syndromes NNS N
. . N

In IN N
these DT N
syndromes NNS N
urinary JJ N
peptide NN N
abnormalities NNS N
, , N
derived VBN N
from IN N
gluten NN N
, , N
gliadin NN N
, , N
and CC N
casein NN N
, , N
are VBP N
reported VBN N
. . N

They PRP N
reflect VBP N
processes NNS N
with IN N
opioid JJ N
effect NN N
. . N

The DT N
aim NN N
of IN N
this DT N
single JJ N
blind NN N
study NN N
was VBD N
to TO N
evaluate VB N
effect NN N
of IN N
gluten NN 1_i
and CC 1_i
casein-free JJ 1_i
diet NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autistic JJ 1_p
syndromes NNS 1_p
and CC 1_p
urinary JJ 1_p
peptide NN 1_p
abnormalities NNS 1_p
. . 1_p

A DT N
randomly RB N
selected VBN N
diet JJ 1_p
and CC 1_p
control NN 1_p
group NN 1_p
with IN 1_p
10 CD 1_p
children NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
participated VBD 1_p
. . 1_p

Observations NNS 1_o
and CC 1_o
tests NNS 1_o
were VBD N
done VBN N
before RB N
and CC N
after IN N
a DT N
period NN N
of IN N
1 CD N
year NN N
. . N

The DT N
development NN 1_o
for IN N
the DT N
group NN N
of IN N
children NNS N
on IN N
diet NN N
was VBD N
significantly RB N
better JJR N
than IN N
for IN N
the DT N
controls NNS 1_i
. . 1_i

-DOCSTART- -X- O O

Vascular JJ N
pedicle NN N
width NN N
in IN N
acute JJ 1_p
lung JJ 1_p
injury NN 1_p
: : 1_p
correlation NN N
with IN N
intravascular JJ N
pressures NNS N
and CC N
ability NN N
to TO N
discriminate VB N
fluid NN N
status NN N
. . N

INTRODUCTION NNP N
Conservative NNP 1_i
fluid NN 1_i
management NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
lung NN 1_p
injury NN 1_p
( ( 1_p
ALI NNP 1_p
) ) 1_p
increases VBZ N
time NN N
alive JJ N
and CC N
free JJ N
from IN N
mechanical JJ 1_i
ventilation NN 1_i
. . 1_i

Vascular JJ 1_o
pedicle NN 1_o
width NN 1_o
( ( 1_o
VPW NNP 1_o
) ) 1_o
is VBZ N
a DT N
non-invasive JJ N
measurement NN N
of IN N
intravascular JJ N
volume NN N
status NN N
. . N

The DT N
VPW NNP N
was VBD N
studied VBN N
in IN N
ALI NNP 1_p
patients NNS 1_p
to TO N
determine VB N
the DT N
correlation NN N
between IN N
VPW NNP N
and CC N
intravascular JJ N
pressure NN N
measurements NNS N
and CC N
whether IN N
VPW NNP N
could MD N
predict VB N
fluid JJ N
status NN N
. . N

METHODS NNP N
This DT N
retrospective JJ N
cohort NN N
study NN N
involved VBD N
152 CD 1_p
patients NNS 1_p
with IN 1_p
ALI NNP 1_p
enrolled VBD 1_p
in IN 1_p
the DT 1_p
Fluid NNP 1_p
and CC 1_p
Catheter NNP 1_p
Treatment NNP 1_p
Trial NNP 1_p
( ( 1_p
FACTT NNP 1_p
) ) 1_p
from IN 1_p
five CD 1_p
NHLBI NNP 1_p
ARDS NNP 1_p
( ( 1_p
Acute NNP 1_p
Respiratory NNP 1_p
Distress NNP 1_p
Syndrome NNP 1_p
) ) 1_p
Network NNP 1_p
sites NNS 1_p
. . 1_p

VPW NNP 1_o
and CC 1_o
central JJ 1_o
venous JJ 1_o
pressure NN 1_o
( ( 1_o
CVP NNP 1_o
) ) 1_o
or CC 1_o
pulmonary JJ 1_o
artery NN 1_o
occlusion NN 1_o
pressure NN 1_o
( ( 1_o
PAOP NNP 1_o
) ) 1_o
from IN N
the DT N
first JJ N
four CD N
study NN N
days NNS N
were VBD N
correlated VBN N
. . N

The DT N
relationships NNS 1_o
between IN 1_o
VPW NNP 1_o
, , 1_o
positive JJ 1_o
end-expiratory JJ 1_o
pressure NN 1_o
( ( 1_o
PEEP NNP 1_o
) ) 1_o
, , 1_o
cumulative JJ 1_o
fluid NN 1_o
balance NN 1_o
, , 1_o
and CC 1_o
PAOP NNP 1_o
were VBD N
also RB N
evaluated VBN N
. . N

Receiver NNP N
operator NN N
characteristic NN N
( ( N
ROC NNP N
) ) N
curves NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
ability NN N
of IN N
VPW NNP 1_o
to TO N
detect VB N
PAOP NNP N
< NNP N
8 CD N
mmHg NN N
and CC N
PAOP NNP N
? . N
18 CD N
mm NN N
Hg NNP N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
71 CD 1_p
and CC 1_p
152 CD 1_p
patients NNS 1_p
provided VBD 1_p
118 CD N
and CC N
276 CD N
paired VBN N
VPW/PAOP NNP N
and CC N
VPW/CVP NNP N
measurements NNS N
, , N
respectively RB N
. . N

VPW NNP N
correlated VBD N
with IN N
PAOP NNP N
( ( N
r VB N
= RB N
0.41 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
less RBR N
well RB N
with IN N
CVP NNP N
( ( N
r VB N
= RB N
0.21 CD N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
linear JJ N
regression NN N
, , N
VPW NNP N
correlated VBD N
with IN 1_o
PAOP NNP 1_o
1.5-fold JJ 1_o
better JJR N
than IN N
cumulative JJ N
fluid NN N
balance NN N
and CC N
2.5-fold JJ N
better JJR N
than IN N
PEEP NNP N
. . N

VPW NNP N
discriminated VBD N
achievement NN N
of IN N
PAOP NNP 1_o
< NNP 1_o
8 CD N
mm NN N
Hg NNP N
( ( N
AUC NNP N
= NNP N
0.73 CD N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
with IN 1_o
VPW NNP 1_o
?67 NNP 1_o
mm VBD N
demonstrating VBG N
71 CD N
% NN N
sensitivity NN N
( ( N
95 CD N
% NN N
CI NNP N
30 CD N
to TO N
95 CD N
% NN N
) ) N
and CC N
68 CD N
% NN N
specificity NN N
( ( N
95 CD N
% NN N
CI NNP N
59 CD N
to TO N
75 CD N
% NN N
) ) N
. . N

For IN N
discriminating VBG N
a DT N
hydrostatic JJ N
component NN N
of IN N
the DT N
edema NN N
( ( N
that WDT N
is VBZ N
, , N
PAOP NNP N
? . N
18 CD N
mm NN N
Hg NNP N
) ) N
, , 1_o
VPW NNP 1_o
? . N
72 CD N
mm NN N
demonstrated VBD N
61.4 CD N
% NN N
sensitivity NN N
( ( N
95 CD N
% NN N
CI NNP N
47 CD N
to TO N
74 CD N
% NN N
) ) N
and CC N
61 CD N
% NN N
specificity NN N
( ( N
49 CD N
to TO N
71 CD N
% NN N
) ) N
( ( N
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
0.69 CD N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
VPW NNP N
correlates VBZ N
with IN N
PAOP NNP N
better JJR N
than IN N
CVP NNP N
in IN 1_p
patients NNS 1_p
with IN 1_p
ALI NNP 1_p
. . 1_p

Due NNP 1_p
to TO N
its PRP$ N
only JJ N
moderate JJ N
sensitivity NN N
and CC N
specificity NN N
, , N
the DT N
ability NN N
of IN N
VPW NNP N
to TO N
discriminate VB N
fluid NN N
status NN N
in IN 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
lung NN 1_p
injury NN 1_p
is VBZ N
limited JJ N
and CC N
should MD N
only RB N
be VB N
considered VBN N
when WRB N
intravascular JJ N
pressures NNS N
are VBP N
unavailable JJ N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
17 CD 1_i
beta-oestradiol JJ 1_i
and CC N
progesterone NN 1_i
on IN N
finger NN 1_o
skin JJ 1_o
circulation NN 1_o
in IN N
healthy JJ 1_p
women NNS 1_p
and CC 1_p
in IN 1_p
women NNS 1_p
with IN 1_p
primary JJ 1_p
Raynaud NNP 1_p
's POS 1_p
phenomenon NN 1_p
. . 1_p

The DT N
effects NNS N
of IN N
sex NN N
, , N
the DT N
menstrual JJ N
cycle NN N
, , N
oral JJ N
contraceptives NNS N
, , N
pregnancy NN N
, , N
and CC N
the DT N
menopause NN N
on IN N
skin JJ N
perfusion NN N
in IN N
healthy JJ 1_p
women NNS 1_p
and CC N
in IN N
patients NNS 1_p
with IN 1_p
Raynaud NNP 1_p
's POS 1_p
phenomenon NN 1_p
suggest VBP N
a DT N
role NN N
of IN N
female JJ N
sex NN N
hormones NNS N
. . N

However RB N
, , N
no DT N
clear JJ N
relation NN N
between IN N
skin JJ 1_o
blood NN 1_o
flow NN 1_o
and CC N
circulating VBG N
concentrations NNS N
of IN N
oestrogens NNS N
or CC N
progestogens NNS N
has VBZ N
yet RB N
been VBN N
found VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
orally RB N
administered VBN N
17 CD 1_i
beta-oestradiol JJ 1_i
and CC 1_i
progesterone NN 1_i
on IN N
finger NN 1_o
skin NN 1_o
blood NN 1_o
flow NN 1_o
before IN N
and CC N
during IN N
heat NN N
and CC N
cold JJ N
challenge NN N
in IN N
17 CD 1_p
healthy JJ 1_p
normotensive JJ 1_p
women NNS 1_p
and CC 1_p
in IN 1_p
12 CD 1_p
women NNS 1_p
with IN 1_p
Raynaud NNP 1_p
's POS 1_p
phenomenon NN 1_p
. . 1_p

In IN N
each DT N
subject NN N
standardized VBN N
finger NN N
heating NN N
( ( N
45 CD N
degrees NNS N
C NNP N
water NN N
bath NN N
, , N
10 CD N
min NN N
) ) N
and CC N
cooling VBG N
tests NNS N
( ( N
15 CD N
degrees NNS N
C NNP N
water NN N
bath NN N
, , N
5 CD N
min NN N
and CC N
20 CD N
min JJ N
recovery NN N
) ) N
were VBD N
performed VBN N
twice RB N
on IN N
the DT N
second JJ N
( ( N
or CC N
third JJ N
) ) N
day NN N
of IN N
two CD N
consecutive JJ N
menstrual JJ N
cycles NNS N
. . N

17 CD 1_i
beta-Oestradiol JJ 1_i
( ( N
9 CD N
mg NN N
) ) N
or CC N
progesterone NN 1_i
( ( N
300 CD N
mg NN N
) ) N
were VBD N
given VBN N
before IN N
the DT N
second JJ N
test NN N
, , N
after IN N
a DT N
first JJ N
test NN N
with IN N
placebo NN 1_i
. . 1_i

Both DT N
hormonal JJ N
doses NNS N
resulted VBN N
in IN N
( ( N
high JJ N
) ) N
physiological JJ 1_o
concentrations NNS 1_o
. . 1_o

Fingertip NNP 1_o
skin JJ 1_o
temperature NN 1_o
and CC 1_o
laser NN 1_o
Doppler NNP 1_o
flux NN 1_o
were VBD N
measured VBN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
test NN 1_o
results NNS 1_o
after IN N
placebo NN N
and CC N
after IN N
progesterone NN N
. . N

Although IN N
values NNS N
of IN N
fingertip NN N
skin NN N
temperature NN N
and CC N
laser NN N
Doppler NNP N
flux NN N
after IN N
17 CD N
beta-oestradiol NN N
tended VBD N
to TO N
be VB N
higher JJR N
only RB N
the DT N
precooling NN N
values NNS N
in IN N
the DT N
healthy JJ N
subjects NNS N
reached VBD N
significance NN N
: : N
fingertip NN N
skin NN N
temperature NN N
respectively RB N
with IN N
placebo NN N
and CC N
with IN N
oestradiol NN N
( ( N
mean JJ N
( ( N
SD NNP N
) ) N
) ) N
: : N
32.7 CD N
( ( N
1.0 CD N
) ) N
and CC N
33.1 CD N
( ( N
0.8 CD N
) ) N
degrees NNS N
C NNP N
; : N
laser JJR N
Doppler NNP N
flux NN N
with IN N
placebo NN N
and CC N
with IN N
oestradiol NN N
: : N
33.6 CD N
( ( N
11.7 CD N
) ) N
and CC N
42.2 CD N
( ( N
9.5 CD N
) ) N
perfusion NN N
units NNS N
; : N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Etanercept NNP 1_i
treatment NN N
in IN N
adults NNS 1_p
with IN 1_p
established VBN 1_p
rheumatoid NN 1_p
arthritis NN 1_p
: : 1_p
7 CD N
years NNS N
of IN N
clinical JJ N
experience NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
longterm JJ N
etanercept FW 1_i
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
disease NN 1_p
modifying VBG 1_p
antirheumatic JJ 1_p
drug NN 1_p
( ( 1_p
DMARD NNP 1_p
) ) 1_p
refractory NN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
( ( 1_p
RA NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Safety NNP N
results NNS N
are VBP N
reported VBN N
for IN N
714 CD 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
etanercept RB 1_i
in IN 1_p
one CD 1_p
of IN 1_p
7 CD 1_p
initial JJ 1_p
trials NNS 1_p
or CC 1_p
a DT 1_p
longterm JJ 1_p
extension NN 1_p
. . 1_p

Efficacy NN N
results NNS N
are VBP N
reported VBN N
for IN N
581 CD 1_p
patients NNS 1_p
who WP 1_p
enrolled VBD 1_p
in IN 1_p
the DT 1_p
extension NN 1_p
. . 1_p

RESULTS NNP N
Of IN N
the DT N
714 CD 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
initial JJ 1_p
trials NNS 1_p
, , 1_p
581 CD 1_p
( ( 1_p
81 CD 1_p
% NN 1_p
) ) 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
extension NN 1_p
, , 1_p
and CC 1_p
388 CD 1_p
( ( 1_p
54 CD 1_p
% NN 1_p
) ) 1_p
patients NNS 1_p
are VBP 1_p
continuing VBG 1_p
to TO 1_p
receive VB 1_p
etanercept JJ 1_i
therapy NN 1_i
. . 1_i

The DT N
longest JJS N
individual JJ N
treatment NN N
was VBD N
8.2 CD N
years NNS N
, , N
with IN N
3139 CD N
total JJ N
patient-years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

Rates NNS 1_o
of IN 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( N
overall JJ N
rate=14.8 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
serious JJ 1_o
infections NNS 1_o
( ( N
overall JJ N
rate=4.2 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
cancer NN 1_o
( ( N
overall JJ N
rate=1.0 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
and CC 1_o
deaths NNS 1_o
( ( N
overall JJ N
rate=0.7 NN N
events/100 IN N
patient-yrs NN N
) ) N
were VBD N
stable JJ N
each DT N
year NN N
, , N
through IN N
8 CD N
years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

For IN N
356 CD 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
6 CD 1_p
years NNS 1_p
of IN 1_p
etanercept JJ 1_p
treatment NN 1_p
, , N
response NN 1_o
rates NNS 1_o
were VBD N
ACR20=73 NNP N
% NN N
, , N
ACR50=52 NNP N
% NN N
, , N
ACR70=27 NNP N
% NN N
, , N
DAS28 NNP N
CRP NNP N
good JJ N
response=52 NN N
% NN N
, , N
and CC N
DAS28 NNP N
CRP NNP N
remission=37 VBZ N
% NN N
of IN N
patients NNS N
. . N

Similar JJ N
responses NNS N
occurred VBD N
in IN N
167 CD 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
Year NNP 1_p
7 CD 1_p
. . 1_p

Doses NNS 1_o
of IN N
concomitant JJ N
methotrexate NN N
or CC N
corticosteroids NNS N
were VBD N
reduced VBN N
in IN N
many JJ N
patients NNS N
who WP N
maintained VBD N
clinical JJ N
responses NNS N
. . N

CONCLUSION VB N
The DT N
safety NN 1_o
profile NN 1_o
of IN N
etanercept NN 1_i
was VBD N
consistent JJ N
over IN N
time NN N
, , N
with IN N
rates NNS 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
similar JJ N
to TO N
those DT N
reported VBN N
for IN N
patients NNS 1_p
with IN 1_p
RA NNP 1_p
in IN 1_p
general JJ 1_p
. . 1_p

Durable JJ N
clinical JJ N
responses NNS N
were VBD N
observed VBN N
in IN N
some DT N
patients NNS N
for IN N
7 CD N
years NNS N
or CC N
more JJR N
. . N

The DT N
benefit-to-risk JJ N
ratio NN N
for IN N
longterm JJ N
etanercept JJ 1_i
treatment NN N
remains VBZ N
highly RB N
favorable JJ N
. . N

-DOCSTART- -X- O O

5-Fluorouracil JJ 1_i
, , 1_i
adriamycin JJ 1_i
, , 1_i
cyclophosphamide NN 1_i
( ( 1_i
FAC NNP 1_i
) ) 1_i
vs. FW N
5-fluorouracil JJ 1_i
, , 1_i
epirubicin JJ 1_i
, , 1_i
cyclophosphamide NN 1_i
( ( 1_i
FEC NNP 1_i
) ) 1_i
in IN N
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

94 CD 1_p
evaluable JJ 1_p
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
5-fluorouracil JJ 1_i
, , 1_i
adriamycin JJ 1_i
, , 1_i
and CC 1_i
cyclophosphamide NN 1_i
( ( 1_i
FAC NNP 1_i
) ) 1_i
or CC 1_i
5-fluorouracil JJ 1_i
, , 1_i
epirubicin JJ 1_i
, , 1_i
and CC 1_i
cyclophosphamide NN 1_i
( ( 1_i
FEC NNP 1_i
) ) 1_i
, , N
with IN N
cycles NNS N
repeated VBN N
every DT N
3 CD N
weeks NNS N
. . N

The DT N
objective JJ 1_o
response NN 1_o
rate NN 1_o
to TO N
FAC NNP 1_i
was VBD N
46 CD N
% NN N
versus IN N
44 CD N
% NN N
to TO N
FEC NNP 1_i
. . 1_i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
median JJ 1_o
duration NN 1_o
of IN 1_o
response NN 1_o
and CC 1_o
median JJ 1_o
survival NN 1_o
for IN N
the DT N
two CD N
regimens NNS N
. . N

Toxicity NN 1_o
was VBD N
more RBR N
frequent JJ N
and CC N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
FAC NNP 1_i
. . 1_i

Results NNP N
indicate JJ N
therapeutic JJ N
equivalence NN N
of IN N
the DT N
two CD N
regimens NNS N
and CC N
reduced JJ N
toxicity NN N
of IN N
the DT N
epirubicin JJ N
arm NN N
. . N

-DOCSTART- -X- O O

Stapled VBN 1_i
hemorrhoidopexy NN 1_i
vs. FW 1_i
Harmonic NNP 1_i
Scalpel NNP 1_i
hemorrhoidectomy NN 1_i
: : 1_i
a DT N
randomized JJ N
trial NN N
. . N

PURPOSE VB N
A NNP N
randomized JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
and CC N
compare VB N
stapled VBN 1_i
hemorrhoidopexy NN 1_i
with IN 1_i
excisional JJ 1_i
hemorrhoidectomy NN 1_i
in IN N
which WDT N
the DT N
Harmonic NNP N
Scalpel NNP N
was VBD N
used VBN N
. . N

METHODS JJ N
Patients NNS 1_p
with IN 1_p
Grade NNP 1_p
III NNP 1_p
hemorrhoids NNS 1_p
who WP 1_p
were VBD 1_p
employed VBN 1_p
during IN 1_p
the DT 1_p
trial NN 1_p
period NN 1_p
were VBD N
recruited VBN N
and CC N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
Harmonic NNP 1_i
Scalpel NNP 1_i
hemorrhoidectomy NN 1_i
, , 1_i
and CC 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
stapled VBD 1_i
hemorrhoidopexy NN 1_i
. . 1_i

All DT N
operations NNS N
were VBD N
performed VBN N
by IN N
a DT N
single JJ N
surgeon NN N
. . N

In IN N
the DT N
stapled JJ N
group NN N
, , N
the DT N
doughnut NN N
obtained VBN N
was VBD N
sent VBN N
for IN N
histopathologic JJ N
examination NN N
to TO N
determine VB N
whether IN N
smooth JJ N
muscles NNS N
were VBD N
included VBN N
in IN N
the DT N
specimen NNS N
. . N

Operative NNP N
data NN N
and CC N
complications NNS N
were VBD N
recorded VBN N
, , N
and CC N
patients NNS N
were VBD N
followed VBN N
up RP N
through IN N
a DT N
structured JJ N
pro JJ N
forma NN N
protocol NN N
. . N

An DT N
independent JJ N
assessor NN N
was VBD N
assigned VBN N
to TO N
obtain VB N
postoperative JJ N
pain NN 1_o
scores NNS 1_o
and CC 1_o
satisfaction NN 1_o
scores NNS 1_o
at IN N
six-month JJ N
follow-up JJ N
. . N

Patients NNS N
were VBD N
also RB N
administered VBN N
a DT N
simple JJ 1_o
questionnaire NN 1_o
at IN N
follow-up JJ N
to TO N
assess VB N
continence NN N
functions NNS N
. . N

RESULTS NNP N
Over IN 1_p
a DT 1_p
20-month JJ 1_p
period NN 1_p
, , 1_p
88 CD 1_p
patients NNS 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

The DT N
two CD N
groups NNS N
were VBD N
matched VBN N
for IN N
age NN N
and CC N
gender NN N
distribution NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
identified VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
operation NN 1_o
time NN 1_o
, , 1_o
blood NN 1_o
loss NN 1_o
, , 1_o
day NN 1_o
of IN 1_o
first JJ 1_o
bowel NN 1_o
movement NN 1_o
after IN 1_o
surgery NN 1_o
, , 1_o
and CC 1_o
complication NN 1_o
rates NNS 1_o
. . 1_o

Despite IN N
a DT N
similar JJ N
parenteral NN N
and CC N
oral JJ N
analgesic JJ N
requirement NN N
, , N
the DT N
stapled VBN N
group NN N
had VBD N
a DT N
significantly RB N
better RBR N
pain NN 1_o
score NN 1_o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
; : N
these DT N
patients NNS N
also RB N
had VBD N
a DT N
significantly RB N
shorter JJR N
length NN 1_o
of IN 1_o
stay NN 1_o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
on IN N
average NN N
resumed VBN N
work NN N
nine CD N
days NNS N
earlier RBR N
than IN N
the DT N
group NN N
treated VBD N
with IN N
the DT N
Harmonic NNP N
Scalpel NNP N
( ( N
6.7 CD N
vs. FW N
15.6 CD N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Although IN N
88 CD N
percent NN N
of IN N
doughnuts NNS N
obtained VBN N
in IN N
the DT N
stapled JJ N
group NN N
contained VBD N
some DT N
smooth JJ 1_o
muscle NN 1_o
fibers NNS 1_o
, , N
no DT N
association NN N
was VBD N
found VBN N
between IN N
smooth JJ 1_o
muscle NN 1_o
incorporation NN 1_o
and CC N
postoperative JJ 1_o
continence NN 1_o
function NN 1_o
, , N
and CC N
as IN N
a DT N
whole JJ N
the DT N
continence NN N
outcomes NNS N
of IN N
the DT N
stapled VBN N
group NN N
were VBD N
similar JJ N
to TO N
those DT N
after IN N
Harmonic NNP N
Scalpel NNP N
hemorrhoidectomy NN N
. . N

Finally RB N
, , N
at IN N
six-month JJ N
follow-up JJ N
, , N
patients NNS N
who WP N
underwent VBP N
the DT N
stapled JJ 1_i
procedure NN N
had VBD N
significantly RB N
better JJR N
satisfaction NN 1_o
scores NNS 1_o
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Stapled NNP 1_i
hemorrhoidopexy NN 1_i
is VBZ N
a DT N
safe JJ 1_o
and CC 1_o
effective JJ 1_o
procedure NN N
for IN N
Grade NNP N
III NNP N
hemorrhoidal JJ N
disease NN N
. . N

Patients NNS N
derive JJ N
greater JJR N
short-term JJ N
benefits NNS 1_o
of IN N
reduced JJ 1_o
pain NN 1_o
, , 1_o
shorter JJR 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
, , 1_o
and CC 1_o
earlier JJR 1_o
resumption NN 1_o
to TO 1_o
work VB 1_o
. . 1_o

Long-term JJ N
follow-up NN N
is VBZ N
necessary JJ N
to TO N
determine VB N
whether IN N
these DT N
initial JJ N
results NNS N
are VBP N
lasting VBG N
. . N

-DOCSTART- -X- O O

Does VBZ N
alliance VB 1_o
predict NN 1_o
symptoms NNS 1_o
throughout IN N
treatment NN N
, , N
or CC N
is VBZ N
it PRP N
the DT N
other JJ N
way NN N
around IN N
? . N
OBJECTIVE NNP N
Scholars NNP N
increasingly RB N
recognize VBP N
that IN N
therapeutic JJ 1_o
alliance NN 1_o
and CC 1_o
symptomatic JJ 1_o
change NN 1_o
are VBP N
associated VBN N
with IN N
one CD N
another DT N
. . N

A DT N
common JJ N
assumption NN N
is VBZ N
that IN N
alliance NN 1_o
predicts NNS 1_o
symptomatic JJ 1_o
change NN 1_o
. . 1_o

However RB N
, , N
the DT N
issue NN N
is VBZ N
far RB N
from IN N
settled VBN N
. . N

One CD N
challenge NN N
in IN N
determining VBG N
the DT N
causality NN N
is VBZ N
the DT N
establishment NN N
of IN N
temporal JJ N
precedence NN N
showing VBG N
that IN N
alliance NN N
, , N
as IN N
opposed VBN N
to TO N
previous JJ N
symptomatic JJ N
change NN N
, , N
drives VBZ N
subsequent JJ N
symptomatic JJ 1_o
reduction NN 1_o
. . 1_o

METHOD NNP N
To TO N
make VB N
further JJ N
advances NNS N
in IN N
untangling VBG N
this DT N
chicken-and-egg JJ N
question NN N
, , N
we PRP N
employed VBD N
autoregressive JJ N
cross-lagged JJ N
modeling NN N
over IN N
4 CD N
time NN N
points NNS N
in IN N
a DT N
sample NN N
of IN N
149 CD 1_p
depressive JJ 1_p
patients NNS 1_p
receiving VBG 1_p
supportive-expressive JJ 1_i
psychotherapy NN 1_i
or CC 1_i
clinical JJ 1_i
management NN 1_i
combined VBN 1_i
with IN 1_i
pharmacotherapy NN 1_i
or CC 1_i
clinical JJ 1_i
management NN 1_i
combined VBN 1_i
with IN 1_i
placebo NN 1_i
. . 1_i

RESULTS VB N
Using VBG N
this DT N
methodology NN N
, , N
we PRP N
found VBD N
that IN N
both DT N
alliance NN 1_o
and CC 1_o
symptoms NNS 1_o
across IN N
treatment NN N
made VBN N
significant JJ N
and CC N
unique JJ N
contributions NNS 1_o
in IN N
predicting VBG 1_o
subsequent JJ 1_o
symptomatic NN 1_o
levels NNS 1_o
throughout IN N
treatment NN N
. . N

Additionally RB N
, , N
alliance NN 1_o
, , N
but CC N
not RB N
symptoms NNS 1_o
, , N
predicted VBD N
subsequent JJ 1_o
alliance NN 1_o
levels NNS 1_o
. . 1_o

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
treatments NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
imply VBP N
that IN N
alliance NN 1_o
temporally RB N
precedes VBZ N
symptomatic JJ 1_o
levels NNS 1_o
throughout IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Cardiac JJ N
failure NN N
: : N
symptoms NNS N
and CC N
functional JJ N
status NN N
. . N

The DT N
associations NNS N
between IN N
exercise NN N
capacity NN N
, , N
symptoms NNS N
and CC N
specific JJ N
aspects NNS N
of IN N
quality NN N
of IN N
life NN N
were VBD N
examined VBN N
in IN N
subjects NNS 1_p
participating VBG 1_p
in IN 1_p
a DT 1_p
trial NN 1_p
of IN 1_p
the DT 1_p
treatment NN 1_i
of IN 1_i
heart NN 1_i
failure NN 1_i
. . 1_i

Patients NNS 1_i
were VBD 1_i
assessed VBN 1_i
on IN 1_p
entry NN 1_p
and CC 1_p
after IN 1_p
three CD 1_p
months NNS 1_p
treatment NN 1_i
. . 1_i

The DT N
principle NN N
symptoms NNS N
were VBD N
fatigue JJ 1_p
, , 1_p
breathlessness NN 1_p
and CC 1_p
chest NN 1_p
pain NN 1_p
. . 1_p

These DT N
limited VBD N
the DT N
extent NN N
and CC N
speed NN N
of IN N
physical JJ N
activities NNS N
, , N
restricted VBN N
social JJ N
, , N
leisure NN N
and CC N
family NN N
life NN N
and CC N
were VBD N
associated VBN N
with IN N
emotional JJ N
distress NN N
. . N

There EX N
were VBD N
associations NNS N
between IN N
baseline NN 1_o
exercise NN 1_o
capacity NN 1_o
and CC 1_o
measures NNS 1_o
of IN 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

Change NNP N
in IN N
exercise NN N
capacity NN N
during IN N
three CD N
months NNS N
treatment NN 1_i
was VBD N
correlated VBN N
with IN N
changes NNS N
in IN N
measures NNS 1_o
of IN 1_o
symptoms NNS 1_o
, , 1_o
limitation NN 1_o
of IN 1_o
activity NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

The DT N
findings NNS N
confirm VBP N
the DT N
value NN N
of IN N
change NN N
in IN N
exercise NN 1_o
capacity NN 1_o
as IN N
a DT N
measure NN N
of IN N
functional JJ N
status NN N
and CC N
suggest VBP N
that IN N
it PRP N
should MD N
be VB N
supported VBN N
by IN N
a DT N
limited JJ N
number NN N
of IN N
specific JJ N
measures NNS N
of IN N
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

-DOCSTART- -X- O O

A DT N
pilot JJ N
double-blind JJ N
placebo-controlled JJ 1_i
trial NN N
of IN N
pioglitazone NN 1_i
as IN N
adjunctive JJ N
treatment NN N
to TO N
risperidone VB N
: : N
Effects NNS N
on IN N
aberrant JJ N
behavior NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_o
. . 1_o

To TO N
assess VB N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
pioglitazone NN 1_i
added VBD 1_i
to TO 1_i
risperidone VB 1_i
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
autistic JJ 1_p
disorder NN 1_p
( ( 1_p
AD NNP 1_p
) ) 1_p
, , N
we PRP N
conducted VBD N
this DT N
study NN N
. . N

In IN N
a DT N
10-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ 1_i
clinical JJ N
trial NN N
, , N
44 CD 1_p
outpatients NNS 1_p
of IN 1_p
both DT 1_p
genders NNS 1_p
aged VBN 1_p
4-12 CD 1_p
years NNS 1_p
with IN 1_p
a DT 1_p
diagnosis NN 1_p
of IN 1_p
AD NNP 1_p
and CC 1_p
a DT 1_p
score NN 1_p
of IN 1_p
?12 NN 1_p
on IN 1_p
the DT 1_p
Aberrant NNP 1_p
Behavior NNP 1_p
Checklist-Community NNP 1_p
( ( 1_p
ABC-C NNP 1_p
) ) 1_p
irritability NN 1_p
subscale NN 1_p
were VBD 1_p
included VBN 1_o
. . 1_o

Mean NNP 1_o
change NN 1_o
of IN 1_o
ABC-C NNP 1_o
irritability NN 1_o
subscale NN 1_o
score NN 1_o
as IN 1_o
primary JJ N
outcome NN N
, , N
change NN N
in IN N
other JJ N
ABC-C JJ N
subscale NN N
scores NNS N
and CC N
partial JJ N
and CC N
complete JJ N
responses NNS N
were VBD N
compared VBN N
between IN N
two CD N
groups NNS 1_p
. . 1_p

Twenty CD 1_p
patients NNS 1_p
completed VBD 1_p
the DT N
trial NN N
in IN N
each DT N
group NN N
. . N

Level NNP N
of IN N
reduction NN N
and CC N
effect NN N
of IN N
time?treatment JJ N
interaction NN N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
significant JJ N
for IN N
irritability NN 1_o
( ( 1_o
P=0.03 NNP 1_o
) ) 1_o
, , 1_o
lethargy/social JJ 1_o
withdrawal NN 1_o
( ( 1_o
P=0.04 NNP 1_o
) ) N
and CC N
hyperactivity/non-compliance NN 1_o
( ( 1_o
P=0.03 NNP 1_o
) ) N
but CC N
not RB N
for IN N
stereotypic JJ N
behavior NN N
and CC N
inappropriate JJ N
speech NN N
subscales NNS N
compared VBN N
with IN N
the DT N
placebo NN N
group NN 1_o
. . 1_o

Vomiting NNP 1_o
and CC 1_o
headache NN 1_o
were VBD 1_o
the DT N
most RBS N
frequent JJ N
reported VBD N
side-effects NNS N
. . N

Results NNS N
of IN N
this DT N
preliminary JJ N
study NN N
indicate VBP N
positive JJ N
effects NNS N
of IN N
pioglitazone NN N
compared VBN N
with IN N
placebo NN N
in IN N
improving VBG N
the DT N
behavioral JJ 1_o
symptoms NNS 1_o
of IN 1_o
AD NNP 1_o
. . N

-DOCSTART- -X- O O

Corticosteroid-induced JJ N
osteopenia NN 1_o
and CC 1_o
vitamin NN 1_o
D NNP 1_o
metabolism NN 1_o
. . 1_o

Effect NNP N
of IN N
vitamin NN 1_i
D2 NNP 1_i
, , 1_i
calcium NN 1_i
phosphate NN 1_i
and CC N
sodium NN 1_i
fluoride JJ 1_i
administration NN N
. . N

Thirty-one CD 1_p
patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
long-term JJ 1_p
( ( 1_p
24 CD 1_p
weeks NNS 1_p
) ) 1_p
treatment NN 1_p
with IN 1_p
prednisone NN 1_i
in IN 1_p
comparatively RB 1_p
high JJ 1_p
doses NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
further JJ N
treatment NN N
groups NNS N
. . N

Group NNP 1_i
A NNP 1_i
received VBD 1_i
prednisone JJ 1_i
plus CC 1_i
'triple-treatment JJ 1_i
' '' 1_i
( ( 1_i
vitamin FW 1_i
D2 NNP 1_i
45000 CD 1_i
iu NN 1_i
twice RB 1_i
weekly RB 1_i
, , 1_i
sodium JJ 1_i
fluoride RB 1_i
50 CD 1_i
mg NNS 1_i
and CC 1_i
calcium NN 1_i
phosphate VBP 1_i
4.5 CD 1_i
g JJ 1_i
daily RB 1_i
) ) 1_i
, , 1_i
group NN 1_i
B NNP 1_i
received VBD 1_i
only RB 1_i
prednisone NN 1_i
. . 1_i

The DT N
study NN N
was VBD N
undertaken VBN N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prednisone- NN 1_i
and CC N
triple-treatment JJ 1_i
upon IN N
bone JJ 1_o
mineral NN 1_o
content NN 1_o
( ( 1_o
BMC NNP 1_o
) ) 1_o
and CC 1_o
vitamin $ 1_o
D NNP 1_o
metabolism NN 1_o
. . 1_o

The DT N
groups NNS N
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
and CC N
prednisone NN N
dose NN N
. . N

BMC NNP 1_o
fell VBD N
rapidly RB N
and CC N
similarly RB N
in IN N
both DT N
groups NNS N
, , N
demonstrating VBG N
that IN N
the DT N
triple-treatment NN N
has VBZ N
no DT N
preventive JJ N
effect NN N
on IN N
corticosteroid NN N
induced VBN N
osteopenia NN N
. . N

Serum NNP 1_o
concentrations NNS 1_o
of IN 1_o
25OHD2 CD 1_o
, , 1_o
25OHD3 CD 1_o
and CC 1_o
1,25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
2D CD 1_o
were VBD N
unchanged JJ N
in IN N
group NN N
B NNP N
( ( N
without IN N
triple-treatment NN N
) ) N
, , N
whereas RB N
in IN N
group NN N
A NNP N
25OHD2 CD 1_o
increased VBD N
enormously RB N
, , N
25OHD3 CD 1_o
was VBD N
suppressed VBN N
possibly RB N
by IN N
substrate NN N
competition NN N
for IN N
hydroxylation NN N
in IN N
the DT N
liver NN N
and CC N
1,25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
2D CD 1_o
was VBD N
halved VBN N
. . N

The DT N
suppression NN N
of IN N
1,25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
2D CD 1_o
may MD N
be VB N
an DT N
effect NN N
of IN N
raised VBD N
25OHD2 CD N
alone RB N
, , N
or CC N
in IN N
combination NN N
with IN N
corticosteroid JJ N
excess NN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN 1_i
carbasalate NN 1_i
plus CC 1_i
metoclopramide JJ 1_i
versus NN 1_i
ergotamine NN 1_i
tartrate NN 1_i
plus CC 1_i
caffeine NN 1_i
in IN N
the DT N
treatment NN N
of IN N
acute JJ 1_p
migraine NN 1_p
attacks NNS 1_p
. . 1_p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
multicenter NN 1_p
, , N
parallel-group JJ N
study NN N
aimed VBN N
at IN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN 1_i
carbasalate NN 1_i
( ( 1_i
equivalent JJ 1_i
to TO 1_i
900 CD 1_i
mg NNS 1_i
aspirin RB 1_i
) ) 1_i
plus CC 1_i
metoclopramide $ 1_i
10 CD 1_i
mg NN 1_i
( ( 1_i
CM NNP 1_i
) ) 1_i
with IN 1_i
ergotamine JJ 1_i
tartrate NN 1_i
1 CD 1_i
mg NN 1_i
plus CC 1_i
caffeine JJ 1_i
100 CD 1_i
mg NN 1_i
( ( 1_i
EC NNP 1_i
) ) 1_i
administered VBN N
in IN N
the DT N
treatment NN N
of IN N
2 CD N
acute JJ N
migraine NN N
attacks NNS N
. . N

A DT N
total NN N
of IN N
296 CD 1_p
patients NNS 1_p
fulfilling VBG 1_p
the DT 1_p
International NNP 1_p
Headache NNP 1_p
Society NNP 1_p
diagnostic JJ 1_p
criteria NNS 1_p
for IN 1_p
migraine NN 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

In IN N
total JJ N
, , N
one CD N
or CC N
two CD N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
in IN N
268 CD N
and CC N
235 CD N
patients NNS N
, , N
respectively RB N
. . N

The DT N
primary JJ N
endpoint NN N
for IN N
the DT N
first JJ N
treated VBD N
attack NN N
was VBD N
headache NN N
relief NN N
, , N
with IN N
intensity NN N
decreasing VBG N
from IN N
moderate JJ N
or CC N
severe JJ N
to TO N
mild VB N
or CC N
absent VB N
2 CD N
h NN N
after IN N
drug NN N
intake NN N
. . N

Usual JJ N
secondary JJ N
efficacy NN N
endpoints NNS N
were VBD N
assessed VBN N
. . N

A DT N
superiority NN N
of IN N
CM NNP 1_i
over IN N
EC NNP 1_i
was VBD N
observed VBN N
for IN N
both DT N
treated JJ N
attacks NNS N
for IN N
the DT N
main JJ N
endpoint NN N
: : N
success NN N
in IN N
54 CD N
versus NN N
36 CD N
% NN N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
the DT N
first JJ N
attack NN N
and CC N
60 CD N
versus NN N
44 CD N
% NN N
, , N
p NN N
= VBD N
0.02 CD N
for IN N
the DT N
second JJ N
attack NN N
. . N

CM NNP 1_o
was VBD 1_o
also RB 1_o
significantly RB 1_o
superior JJ 1_o
to TO 1_o
EC NNP 1_o
during IN 1_o
the DT 1_o
first JJ 1_o
attack NN 1_o
for IN 1_o
complete JJ 1_o
headache NN 1_o
relief NN 1_o
( ( 1_o
20 CD 1_o
vs. FW 1_o
8 CD 1_o
% NN 1_o
, , 1_o
p NN 1_o
= NNP 1_o
0.006 CD 1_o
) ) 1_o
, , 1_o
nausea NN 1_o
( ( 1_o
42 CD 1_o
vs. FW 1_o
63 CD 1_o
% NN 1_o
, , 1_o
p NN 1_o
= VBD 1_o
0 CD 1_o
. . 1_o

007 CD 1_o
) ) 1_o
and CC 1_o
willingness NN 1_o
to TO 1_o
take VB 1_o
the DT 1_o
drug NN 1_o
again RB 1_o
( ( 1_o
90 CD 1_o
vs. FW 1_o
80 CD 1_o
% NN 1_o
, , 1_o
p NN 1_o
= NNP 1_o
0.043 CD 1_o
) ) 1_o
. . 1_o

The DT 1_o
global JJ 1_o
efficacy NN 1_o
evaluation NN 1_o
, , 1_o
rated VBN 1_o
by IN 1_o
the DT 1_o
investigators NNS 1_o
, , 1_o
was VBD 1_o
significantly RB 1_o
more RBR 1_o
favorable JJ 1_o
to TO 1_o
CM NNP 1_o
for IN 1_o
both DT 1_o
attacks NNS 1_o
( ( 1_o
p VB 1_o
= $ 1_o
0.001 CD 1_o
for IN 1_o
the DT 1_o
first JJ 1_o
attack NN 1_o
and CC 1_o
p NN 1_o
= VBP 1_o
0.02 CD 1_o
for IN 1_o
the DT 1_o
second JJ 1_o
) ) 1_o
. . 1_o

The DT 1_o
patients NNS 1_o
' POS 1_o
evaluation NN 1_o
was VBD 1_o
significant JJ 1_o
for IN 1_o
the DT 1_o
first JJ 1_o
attack NN 1_o
( ( 1_o
p JJ 1_o
= NNP 1_o
0.002 CD 1_o
) ) 1_o
. . 1_o

The DT 1_o
global JJ 1_o
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
was VBD 1_o
45 CD 1_o
% NN 1_o
higher JJR 1_o
with IN 1_o
EC NNP 1_o
, , 1_o
though IN 1_o
not RB 1_o
significant JJ 1_o
( ( 1_o
32 CD 1_o
vs. FW 1_o
22 CD 1_o
% NN 1_o
, , 1_o
p NN 1_o
= NNP 1_o
0.075 CD 1_o
) ) 1_o
. . 1_o

They PRP 1_o
were VBD 1_o
most RBS 1_o
often RB 1_o
unspecific JJ 1_o
and CC 1_o
mild JJ 1_o
to TO 1_o
moderate VB 1_o
in IN 1_o
intensity NN 1_o
. . 1_o

Gastrointestinal JJ 1_o
side NN 1_o
effects NNS 1_o
were VBD 1_o
significantly RB 1_o
less RBR 1_o
frequent JJ 1_o
with IN 1_o
CM NNP 1_o
than IN 1_o
EC NNP 1_o
( ( 1_o
7 CD 1_o
vs. FW 1_o
21 CD 1_o
% NN 1_o
, , 1_o
p NN 1_o
= NNP 1_o
0.001 CD 1_o
) ) 1_o
. . 1_o

Thus RB 1_o
, , 1_o
CM NNP 1_o
is VBZ 1_o
more RBR 1_o
effective JJ 1_o
and CC 1_o
has VBZ 1_o
a DT 1_o
better JJR 1_o
gastrointestinal JJ 1_o
safety NN 1_o
than IN 1_o
EC NNP 1_o
in IN 1_o
the DT 1_o
acute JJ 1_o
treatment NN 1_o
of IN 1_o
migraine NN 1_o
attacks NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Effect NN N
of IN N
supplementary JJ 1_i
antioxidant JJ 1_i
vitamin NNS 1_i
intake VBP N
on IN N
carotid NNS 1_o
arterial JJ 1_o
wall JJ 1_o
intima-media JJ 1_o
thickness NN 1_o
in IN N
a DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
cholesterol NN N
lowering VBG N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
accumulating VBG N
experimental JJ N
, , N
epidemiological JJ N
, , N
and CC N
clinical JJ N
evidence NN N
of IN N
an DT N
association NN N
between IN N
anti-oxidant JJ 1_i
vitamin NNS 1_i
intake NN N
and CC N
reduced JJ N
risk NN N
of IN N
coronary JJ N
heart NN N
disease NN N
. . N

Using VBG N
data NNS N
from IN N
the DT N
Cholesterol NNP N
Lowering NNP N
Atherosclerosis NNP N
Study NNP N
( ( N
CLAS NNP N
) ) N
, , N
we PRP N
explored VBD N
the DT N
association NN N
of IN N
self-selected JJ N
supplementary JJ N
antioxidant NN 1_i
vitamin NNS 1_i
intake VBP N
on IN N
the DT N
rate NN N
of IN N
progression NN N
of IN N
early JJ 1_p
preintrusive JJ 1_p
atherosclerosis NN 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
CLAS NNP N
was VBD N
an DT N
arterial JJ N
imaging NN N
trial NN N
in IN N
which WDT N
nonsmoking VBG 1_p
40- JJ 1_p
to TO 1_p
59-year-old JJ 1_p
men NNS 1_p
with IN 1_p
previous JJ 1_p
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
graft NN 1_p
surgery NN 1_p
were VBD N
randomized VBN N
to TO N
colestipol/niacin VB 1_i
plus JJ 1_i
diet JJ 1_i
or CC N
placebo JJ 1_i
plus CC 1_i
diet JJ 1_i
. . 1_i

The DT N
rate NN 1_o
of IN 1_o
progression NN 1_o
of IN 1_o
early JJ 1_o
preintrusive JJ 1_o
atherosclerosis NN 1_o
was VBD N
determined VBN N
in IN N
146 CD 1_p
subjects NNS 1_p
using VBG N
high-resolution JJ N
B-mode NNP N
ultrasound JJ N
quantification NN N
of IN N
the DT N
distal JJ N
common JJ N
carotid NN N
artery NN N
far RB N
wall JJ N
intima-media JJ N
thickness NN N
( ( N
IMT NNP N
) ) N
. . N

From IN N
the DT N
nutritional JJ N
supplement NN N
database NN N
, , N
22 CD N
subjects NNS N
had VBD N
an DT N
on-trial JJ N
average JJ N
supplementary JJ N
vitamin NN 1_i
E NNP 1_i
intake NN N
of IN N
> NN N
or CC N
= $ N
100 CD N
IU NNP N
per IN N
day NN N
( ( N
high JJ N
users NNS N
) ) N
and CC N
29 CD N
subjects NNS N
had VBD N
an DT N
average JJ N
on-trial JJ N
supplementary JJ N
vitamin NN 1_i
C NNP 1_i
intake NN N
of IN N
> NN N
or CC N
= $ N
250 CD N
mg JJ N
per IN N
day NN N
( ( N
high JJ N
users NNS N
) ) N
. . N

Within IN N
the DT N
placebo NN 1_i
group NN N
, , N
less JJR 1_o
carotid JJ 1_o
IMT NNP 1_o
progression NN 1_o
was VBD N
found VBN N
for IN N
high JJ N
supplementary JJ N
vitamin NN 1_i
E NNP 1_i
users NNS N
when WRB N
compared VBN N
with IN N
low JJ N
vitamin NNS 1_i
E NN 1_i
users NNS N
( ( N
0.008 CD N
versus NN N
0.023 CD N
mm/y NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

No DT N
effect NN N
of IN N
vitamin NN 1_o
E NNP 1_i
within IN N
the DT N
drug NN N
group NN N
was VBD N
found VBN N
. . N

No DT N
effect NN N
of IN N
vitamin NN 1_i
C NNP 1_i
within IN N
the DT N
drug NN N
or CC N
placebo NN 1_i
group NN N
was VBD N
found VBN N
. . N

CONCLUSIONS NNP N
Supplementary NNP 1_i
vitamin NN 1_i
E NNP 1_i
intake NN N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG 1_o
the DT N
progression NN 1_o
of IN 1_o
atherosclerosis NN 1_o
in IN N
subjects NNS 1_p
not RB 1_p
treated VBN 1_p
with IN 1_p
lipid-lowering JJ 1_i
drugs NNS 1_i
while IN N
the DT N
process NN N
is VBZ N
still RB N
confined VBN N
to TO N
the DT N
arterial JJ N
wall NN N
( ( N
early JJ N
preintrusive JJ N
atherosclerosis NN N
) ) N
. . N

-DOCSTART- -X- O O

[ JJ 1_o
Acute NNP 1_o
cardiovascular NN 1_o
and CC 1_o
metabolic JJ 1_o
changes NNS 1_o
in IN N
interval NN N
and CC N
endurance NN 1_i
training NN 1_i
in IN N
selected VBN 1_p
patients NNS 1_p
following VBG 1_p
aortocoronary JJ 1_p
bypass NN 1_p
operation NN 1_p
] NNP 1_p
. . N

UNLABELLED VB N
This DT N
study NN N
compared VBN N
the DT N
acute NN 1_o
changes NNS 1_o
of IN 1_o
cardiovascular NN 1_o
and CC 1_o
metabolic JJ 1_o
reactions NNS 1_o
during IN N
interval NN 1_i
and CC 1_i
continuous JJ 1_i
training NN 1_i
after IN N
coronary JJ N
bypass NN N
surgery NN N
. . N

Two CD 1_p
groups NNS 1_p
of IN 1_p
9 CD 1_p
male JJ 1_p
patients NNS 1_p
( ( 1_p
age NN 1_p
: : 1_p
59 CD 1_p
+/- JJ 1_p
4 CD 1_p
and CC 1_p
56 CD 1_p
+/- JJ 1_p
6 CD 1_p
years NNS 1_p
, , 1_p
resp NN 1_p
. . 1_p

) ) 1_p
each DT 1_i
trained VBN 1_i
on IN 1_i
bicycle NN 1_i
ergometer JJ 1_i
start NN 1_i
on IN 1_i
post-operative JJ 1_i
days NNS 1_i
24 CD 1_i
and CC 1_i
26 CD 1_i
, , 1_i
resp NN 1_i
. . 1_i

In IN N
both DT N
training NN N
groups NNS N
training VBG 1_o
heart NN 1_o
rate NN 1_o
was VBD N
set VBN N
at IN N
86 CD N
% NN N
of IN N
individual JJ N
maximum JJ N
heart NN N
rate NN N
. . N

In IN 1_i
the DT 1_i
last JJ 1_i
week NN 1_i
of IN 1_i
training VBG 1_i
the DT 1_i
exercise NN 1_i
intensity NN 1_i
in IN 1_i
the DT 1_i
group NN 1_i
of IN 1_i
patients NNS 1_i
who WP 1_i
were VBD 1_i
trained VBN 1_i
by IN 1_i
the DT 1_i
continuous JJ 1_i
method NN 1_i
was VBD 1_i
at IN 1_i
83 CD 1_i
watts NN 1_i
, , 1_i
and CC 1_i
at IN 1_i
20:121 CD 1_i
watts NN 1_i
in IN 1_i
the DT 1_i
group NN 1_i
of IN 1_i
patients NNS 1_i
who WP 1_i
were VBD 1_i
trained VBN 1_i
by IN 1_i
interval JJ 1_i
method NN 1_i
( ( 1_i
rest NN 1_i
: : 1_i
work NN 1_i
each DT 1_i
1:1 CD 1_i
min NN 1_i
) ) 1_i
. . 1_i

At IN N
this DT N
exercise NN N
training NN N
that WDT N
lasted VBD N
for IN N
20 CD N
min PDT N
the DT N
acute JJ 1_o
response NN 1_o
of IN 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
rate-pressure JJ 1_o
product NN 1_o
, , 1_o
glucose JJ 1_o
, , 1_o
lactate JJ 1_o
and CC 1_o
catecholamines NNS 1_o
was VBD N
measured VBN N
. . N

RESULTS NNP N
In IN N
both DT N
methods NNS N
there EX N
were VBD N
no DT 1_o
significant JJ 1_o
differences NNS 1_o
in IN 1_o
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
pressure NN 1_o
, , 1_o
rate-pressure JJ 1_o
product NN 1_o
, , 1_o
in IN 1_o
glucose NN 1_o
or CC 1_o
catecholamine NN 1_o
levels NNS 1_o
. . 1_o

However RB N
, , N
there EX N
was VBD N
a DT N
significantly RB N
higher JJR N
rate NN 1_o
of IN 1_o
lactate NN 1_o
in IN N
the DT N
second JJ N
10 CD N
min NN N
of IN N
the DT N
interval JJ N
training NN N
. . N

And CC N
, , N
in IN N
spite NN N
of IN N
higher JJR N
peripheral JJ N
exercise NN N
intensity NN N
by IN N
interval JJ N
training NN N
, , N
there EX N
was VBD N
no DT N
higher JJR N
cardiac NN 1_o
work NN 1_o
than IN N
by IN N
the DT N
continuous JJ N
training NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
interval JJ N
training NN N
strains VBZ N
the DT N
oxidative JJ N
capacity NN N
of IN N
the DT N
trained JJ N
muscles NNS N
in IN N
a DT N
more RBR N
intensive JJ N
and CC N
direct JJ N
way NN N
than IN N
does VBZ N
continuous JJ N
training NN N
. . N

-DOCSTART- -X- O O

A DT N
clinical JJ N
evaluation NN N
of IN N
a DT N
blood NN 1_i
conservation NN 1_i
device NN 1_i
in IN N
medical JJ 1_p
intensive JJ 1_p
care NN 1_p
unit NN 1_p
patients NNS 1_p
. . 1_p

OBJECTIVES NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
a DT N
) ) N
document NN N
the DT N
efficacy NN N
of IN N
a DT N
device NN N
intended VBN N
to TO N
conserve VB N
blood NN N
in IN N
critically RB 1_p
ill JJ 1_p
patients NNS 1_p
; : 1_p
b NN N
) ) N
determine VBZ N
the DT N
effect NN N
of IN N
this DT N
blood NN N
conservation NN N
on IN N
hemoglobin JJ 1_o
concentration NN 1_o
and CC N
the DT N
need NN 1_o
for IN 1_o
blood NN 1_o
transfusions NNS 1_o
; : 1_o
c NNS N
) ) N
determine VBP N
if IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
interference NN N
with IN N
arterial JJ N
pressure NN N
waveforms NNS N
; : N
d NN N
) ) N
determine NN N
if IN N
use NN N
of IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
a DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
accidental JJ N
needle JJ N
punctures NNS N
suffered VBN N
by IN N
healthcare JJ N
workers NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
controlled VBD N
trial NN N
. . N

A DT N
clinical JJ N
trial NN N
using VBG N
prospective JJ N
, , N
random JJ N
allocation NN N
of IN N
consecutive JJ N
eligible JJ N
patients NNS N
. . N

SETTING VBG N
The DT 1_p
medical JJ 1_p
intensive JJ 1_p
care NN 1_p
unit NN 1_p
( ( 1_p
ICU NNP 1_p
) ) 1_p
of IN 1_p
a DT 1_p
university NN 1_p
hospital NN 1_p
located VBN 1_p
in IN 1_p
a DT 1_p
large JJ 1_p
metropolitan JJ 1_p
area NN 1_p
. . 1_p

PATIENTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
100 CD 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
admitted VBN 1_p
to TO 1_p
the DT 1_p
medical JJ 1_p
ICU NNP 1_p
, , 1_p
required VBD 1_p
arterial JJ 1_p
line NN 1_p
monitoring NN 1_p
for IN 1_p
clinical JJ 1_p
purposes NNS 1_p
, , 1_p
and CC 1_p
were VBD 1_p
managed VBN 1_p
by IN 1_p
the DT 1_p
ICU NNP 1_p
medical JJ 1_p
service NN 1_p
. . 1_p

Exclusion NNP 1_p
criteria NNS 1_p
included VBD 1_p
active JJ 1_p
bleeding NN 1_p
or CC 1_p
chronic JJ 1_p
renal JJ 1_p
failure NN 1_p
at IN 1_p
the DT 1_p
time NN 1_p
of IN 1_p
ICU NNP 1_p
admission NN 1_p
. . 1_p

INTERVENTIONS JJ N
Patients NNPS N
in IN N
the DT N
experimental JJ N
group NN N
had VBD N
a DT N
blood NN 1_i
conservation NN 1_i
device NN 1_i
incorporated VBN 1_i
into IN 1_i
the DT 1_i
arterial JJ 1_i
pressure NN 1_i
monitoring NN 1_i
system NN 1_i
, , N
while IN N
patients NNS N
in IN N
the DT N
control NN 1_i
group NN 1_i
received VBD 1_i
a DT 1_i
conventional JJ 1_i
arterial JJ 1_i
pressure NN 1_i
monitoring NN 1_i
system NN 1_i
. . 1_i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Data NNP N
gathered VBD N
included VBN N
: : N
age NN N
; : N
gender NN N
; : N
ICU NNP N
discharge NN N
status NN N
; : N
the DT N
duration NN 1_o
of IN 1_o
ICU NNP 1_o
stay NN 1_o
; : 1_o
time NN 1_o
in IN 1_o
the DT 1_o
study NN 1_o
; : 1_o
volume NN 1_o
of IN 1_o
all DT 1_o
blood NN 1_o
drawn NN 1_o
, , 1_o
discarded VBD 1_o
, , 1_o
or CC 1_o
lost VBN 1_o
due JJ 1_o
to TO 1_o
leakage VB 1_o
; : 1_o
hemoglobin JJ 1_o
concentrations NNS 1_o
; : 1_o
blood NN 1_o
transfusions NNS 1_o
; : 1_o
and CC 1_o
accidental JJ 1_o
needle JJ 1_o
injuries NNS 1_o
. . 1_o

Arterial JJ 1_o
pressure NN 1_o
waveforms NNS 1_o
were VBD N
recorded VBN N
and CC N
inspected VBN N
for IN N
dampening VBG N
or CC N
other JJ N
deformation NN N
. . N

Mean NNP 1_o
hemoglobin JJ 1_o
concentrations NNS 1_o
were VBD N
compared VBN N
on IN N
ICU NNP N
admission NN N
and CC N
at IN N
12-hr JJ N
intervals NNS N
. . N

Demographic NNP N
and CC N
clinical JJ N
characteristics NNS N
of IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
volume NN 1_o
of IN 1_o
blood NN 1_o
drawn NN 1_o
and CC 1_o
discarded VBD 1_o
from IN 1_o
arterial JJ 1_o
catheters NNS 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
( ( N
blood NN N
conservation NN N
device NN N
: : N
5.7 CD N
+/- JJ N
7.5 CD N
mL NN N
; : N
control NN N
: : N
96.4 CD N
+/- JJ N
88.5 CD N
mL NN N
; : N
p CC N
< NNP N
.0001 NNP N
) ) N
, , N
as IN N
was VBD N
the DT N
total JJ 1_o
volume NN 1_o
of IN 1_o
blood NN 1_o
discarded VBN 1_o
( ( N
blood NN N
conservation NN N
device NN N
: : N
19.4 CD N
+/- JJ N
47.4 CD N
mL NN N
; : N
control NN N
: : N
103.5 CD N
+/- JJ N
99.9 CD N
mL NN N
; : N
p CC N
< NNP N
.0001 NNP N
) ) N
. . N

Mean NNP 1_o
hemoglobin JJ 1_o
concentration NN 1_o
on IN N
admission NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
blood NN N
conservation NN N
device NN N
group NN N
: : N
11.8 CD N
+/- JJ N
2.5 CD N
g/dL NN N
; : N
control NN N
group NN N
: : N
12.6 CD N
+/- JJ N
2.3 CD N
g/dL NN N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
mean JJ 1_o
hemoglobin NN 1_o
concentration NN 1_o
declined VBD N
most JJS N
rapidly RB N
in IN N
the DT N
first JJ N
24 CD N
hrs NN N
of IN N
ICU NNP N
care NN N
and CC N
, , N
thereafter RB N
, , N
declined VBD N
more RBR N
slowly RB N
. . N

Although IN N
the DT N
mean JJ 1_o
hemoglobin NN 1_o
concentration NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
after IN N
6 CD N
days NNS N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
until IN N
9.5 CD N
days NNS N
of IN N
ICU NNP N
care NN N
. . N

The DT N
mean JJ 1_o
change NN 1_o
in IN 1_o
hemoglobin JJ 1_o
concentration NN 1_o
( ( N
overall JJ N
: : N
1.2 CD N
+/- JJ N
2.2 CD N
g/dL NN N
) ) N
during IN N
the DT N
study NN N
represents VBZ N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
decrease NN N
of IN N
9.7 CD N
% NN N
. . N

Hemoglobin NNP 1_o
concentration NN 1_o
during IN N
the DT N
study NN N
decreased VBN N
by IN N
1.4 CD N
+/- JJ N
2.2 CD N
g/dL NN N
in IN N
the DT N
control NN N
group NN N
and CC N
1.0 CD N
+/- JJ N
2.3 CD N
g/dL NN N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
( ( N
p JJ N
= NNP N
nonsignificant NN N
) ) N
. . N

Univariate NNP 1_o
and CC 1_o
multiple JJ 1_o
regression NN 1_o
analysis NN 1_o
demonstrated VBD N
discarded JJ N
blood NN 1_o
volume NN 1_o
to TO N
be VB N
a DT N
significant JJ N
and CC N
independent JJ N
predictor NN N
of IN N
the DT N
decline NN N
in IN N
hemoglobin JJ N
concentration NN N
. . N

Transfusion NN 1_o
requirements NNS 1_o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
blood NN 1_i
conservation NN 1_i
system NN 1_i
did VBD N
not RB N
alter VB N
or CC N
interfere VB N
with IN N
pressure NN 1_o
waveforms NNS 1_o
. . 1_o

There EX N
were VBD N
no DT N
accidental JJ 1_o
needle JJ 1_o
injuries NNS 1_o
noted VBD N
. . N

CONCLUSIONS VB N
The DT N
conservation NN N
of IN N
blood NN N
in IN N
critically RB 1_p
ill JJ 1_p
patients NNS 1_p
must MD N
be VB N
a DT N
high-priority JJ N
concern NN N
of IN N
all DT N
healthcare JJ N
workers NNS N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
blood NN N
conservation NN N
system NN N
eliminates VBZ N
a DT N
significant JJ N
factor NN N
in IN N
the DT N
decline NN N
in IN N
hemoglobin JJ 1_o
concentration NN 1_o
. . 1_o

With IN N
devices NNS N
as IN N
described NN N
here RB N
, , N
there EX N
is VBZ N
no DT N
reason NN N
to TO N
continue VB N
the DT N
practice NN N
of IN N
wasting VBG N
the DT N
blood NN N
of IN N
critically RB 1_p
ill JJ 1_p
patients NNS 1_p
in IN N
order NN N
to TO N
prevent VB N
preanalytic JJ N
error NN N
. . N

-DOCSTART- -X- O O

Early RB N
versus NN N
late JJ N
hCG NN 1_i
administration NN 1_i
to TO N
trigger VB N
ovulation NN N
in IN N
mild NN N
stimulated VBN N
IUI NNP N
cycles NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
verify VB N
non-inferiority NN N
of IN N
the DT N
clinical JJ N
pregnancy NN N
rate NN N
of IN N
Early NNP 1_i
hCG NN 1_i
administration NN 1_i
( ( N
leading VBG N
follicle NN N
sizes NNS N
within IN N
16.0-16.9 JJ N
mm NN N
in IN N
diameter NN N
) ) N
compared VBN N
to TO N
Late NNP 1_i
hCG NN 1_i
administration NN 1_i
( ( N
leading VBG N
follicle NN N
sizes NNS N
within IN N
18.0-18.9 JJ N
mm NN N
in IN N
diameter NN N
) ) N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
randomized VBD N
trial NN N
. . N

Six CD 1_p
hundred CD 1_p
and CC 1_p
twelve VB 1_p
infertile JJ 1_p
women NNS 1_p
candidates NNS 1_p
for IN 1_p
intrauterine JJ 1_p
insemination NN 1_p
( ( 1_p
IUI NNP 1_p
) ) 1_p
received VBD N
HP-hMG JJ 1_i
75 CD N
IU/day NNP N
SC NNP N
from IN N
cycle NN N
days NNS N
4 CD N
to TO N
8 CD N
and CC N
then RB N
as IN N
per IN N
ovarian JJ N
response NN N
. . N

Ovulation NN N
was VBD N
randomly RB N
triggered VBN N
( ( N
hCG JJ N
5000 CD N
IU NNP N
, , N
IM NNP N
) ) N
when WRB N
the DT N
leading VBG N
follicle NN N
diameter NN N
ranged VBD N
between IN N
either CC N
16.0 CD N
and CC N
16.9 CD N
mm NN N
( ( N
Early JJ N
hCG NN 1_i
group NN N
, , N
n=227 RB N
) ) N
or CC N
18.0 CD N
and CC N
18.9 CD N
mm NNS N
( ( N
Late JJ N
hCG NN N
group NN N
, , N
n=207 NN N
) ) N
and CC N
IUI NNP N
was VBD N
performed VBN N
approximately RB N
36 CD N
h NN N
later RB N
. . N

RESULTS NNP N
Whereas NNP N
population NN 1_o
and CC 1_o
sperm JJ 1_o
characteristics NNS 1_o
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
, , N
the DT N
number NN 1_o
of IN 1_o
follicles NNS 1_o
? . N
14 CD N
mm NN N
in IN N
diameter NN N
( ( N
P NNP N
< NNP N
0.007 CD N
) ) N
and CC 1_o
serum JJ 1_o
estradiol NN 1_o
levels NNS 1_o
( ( 1_o
P NNP N
< NNP N
0.001 CD N
) ) N
on IN N
the DT N
day NN N
of IN N
hCG NN 1_i
were VBD 1_i
lower JJR N
in IN N
the DT N
Early JJ N
versus NN N
the DT N
Late NNP 1_i
hCG NN 1_i
groups NNS 1_i
. . N

Clinical NNP N
( ( N
11.9 CD N
% NN N
versus IN N
12.1 CD N
% NN N
) ) N
and CC N
ongoing VBG N
( ( N
11.0 CD N
% NN N
versus IN N
8.6 CD 1_o
% NN 1_o
) ) 1_o
pregnancy NN 1_o
rates NNS 1_o
per IN 1_o
randomized VBN 1_p
women NNS 1_p
were VBD 1_p
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
and CC N
statistical JJ N
non-inferiority NN N
of IN N
clinical JJ 1_o
and CC 1_o
ongoing JJ 1_o
pregnancy NN 1_o
rates NNS 1_o
was VBD N
demonstrated VBN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN 1_i
hCG NN 1_i
administered VBD 1_i
when WRB N
the DT N
largest JJS N
follicle NN N
size NN N
reaches VBZ N
16.0-16.9 JJ N
mm NN N
leads VBZ N
to TO N
similar JJ N
clinical JJ N
and CC N
ongoing JJ N
pregnancy NN N
rates NNS N
as IN N
when WRB N
it PRP N
reaches VBZ N
18.0-18.9 JJ N
mm NN N
in IN N
IUI NNP N
cycles NNS N
. . N

-DOCSTART- -X- O O

The DT N
ADDITION-Cambridge NNP 1_p
trial NN 1_p
protocol NN 1_p
: : 1_p
a DT N
cluster NN N
-- : N
randomised VBD N
controlled JJ N
trial NN N
of IN N
screening VBG N
for IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
and CC 1_p
intensive JJ 1_p
treatment NN 1_p
for IN 1_p
screen-detected JJ 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
The DT N
increasing VBG N
prevalence NN N
of IN N
type NN N
2 CD N
diabetes VBZ N
poses NNS N
a DT N
major JJ N
public JJ N
health NN N
challenge NN N
. . N

Population-based JJ N
screening NN N
and CC N
early JJ N
treatment NN N
for IN N
type NN N
2 CD N
diabetes NNS N
could MD N
reduce VB N
this DT N
growing VBG N
burden NN N
. . N

However RB N
, , N
the DT N
benefits NNS N
of IN N
such JJ N
a DT N
strategy NN N
remain NN N
uncertain JJ N
. . N

METHODS NNP N
AND CC N
DESIGN NNP N
The DT N
ADDITION-Cambridge NNP N
study NN N
aims NNS N
to TO N
evaluate VB N
the DT N
effectiveness NN 1_o
and CC 1_o
cost-effectiveness NN 1_o
of IN N
( ( N
i NN N
) ) N
a DT N
stepwise NN 1_i
screening NN 1_i
strategy NN 1_i
for IN 1_i
type NN 1_i
2 CD 1_i
diabetes NNS 1_i
; : 1_i
and CC N
( ( N
ii NN N
) ) N
intensive JJ 1_i
multifactorial JJ 1_i
treatment NN 1_i
for IN 1_i
people NNS 1_i
with IN 1_i
screen-detected JJ 1_i
diabetes NNS 1_i
in IN 1_i
primary JJ 1_i
care NN 1_i
. . 1_i

63 CD 1_p
practices NNS 1_p
in IN 1_p
the DT 1_p
East NNP 1_p
Anglia NNP 1_p
region NN 1_p
participated VBD 1_p
. . 1_p

Three CD N
undertook IN N
the DT N
pilot NN N
study NN N
, , N
33 CD N
were VBD N
allocated VBN N
to TO N
three CD N
groups NNS N
: : N
no DT 1_i
screening NN 1_i
( ( 1_i
control NN 1_i
) ) 1_i
, , 1_i
screening VBG 1_i
followed VBN 1_i
by IN 1_i
intensive JJ 1_i
treatment NN 1_i
( ( 1_i
IT NNP 1_i
) ) 1_i
and CC 1_i
screening VBG 1_i
plus CC 1_i
routine JJ 1_i
care NN 1_i
( ( N
RC NNP N
) ) N
in IN N
an DT N
unbalanced JJ N
( ( N
1:3:3 CD N
) ) N
randomisation NN N
. . N

The DT N
remaining VBG N
27 CD N
practices NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
IT NNP N
and CC N
RC NNP N
. . N

A NNP N
risk NN N
score NN N
incorporating VBG N
routine JJ N
practice NN N
data NNS N
was VBD N
used VBN N
to TO N
identify VB N
people NNS 1_p
aged VBN 1_p
40-69 JJ 1_p
years NNS 1_p
at IN 1_p
high-risk NN 1_p
of IN 1_p
undiagnosed JJ 1_p
diabetes NNS 1_p
. . 1_p

In IN N
the DT N
screening NN N
practices NNS N
, , N
high-risk JJ N
individuals NNS N
were VBD N
invited VBN N
to TO N
take VB N
part NN N
in IN N
a DT N
stepwise NN N
screening VBG N
programme NN N
. . N

In IN N
the DT N
IT NNP N
group NN N
, , N
diabetes VBZ N
treatment NN N
is VBZ N
optimised VBN N
through IN N
guidelines NNS N
, , N
target-led JJ N
multifactorial JJ N
treatment NN N
, , N
audit NN N
, , N
feedback NN N
, , N
and CC N
academic JJ N
detailing NN N
for IN N
practice NN N
teams NNS N
, , N
alongside JJ N
provision NN N
of IN N
educational JJ N
materials NNS N
for IN N
newly RB N
diagnosed VBN N
participants NNS N
. . N

Primary JJ N
endpoints NNS N
are VBP N
modelled VBN 1_o
cardiovascular JJ 1_o
risk NN 1_o
at IN 1_o
one CD 1_o
year NN 1_o
, , 1_o
and CC 1_o
cardiovascular JJ 1_o
mortality NN 1_o
and CC 1_o
morbidity NN 1_o
at IN 1_o
five CD 1_o
years NNS 1_o
after IN N
diagnosis NN N
of IN N
diabetes NNS N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
all-cause JJ 1_o
mortality NN 1_o
, , 1_o
development NN 1_o
of IN 1_o
renal JJ 1_o
and CC 1_o
visual JJ 1_o
impairment NN 1_o
, , 1_o
peripheral JJ 1_o
neuropathy NN 1_o
, , 1_o
health NN 1_o
service NN 1_o
costs NNS 1_o
, , 1_o
self-reported JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
functional JJ 1_o
status NN 1_o
and CC 1_o
health NN 1_o
utility NN 1_o
. . 1_o

Impact NN N
of IN N
the DT N
screening NN N
programme NN N
at IN N
the DT N
population NN N
level NN N
is VBZ N
also RB N
assessed VBN N
through IN N
measures NNS N
of IN N
mortality NN 1_o
, , 1_o
cardiovascular JJ 1_o
morbidity NN 1_o
, , 1_o
health NN 1_o
status NN 1_o
and CC 1_o
health NN 1_o
service NN 1_o
use NN 1_o
among IN N
high-risk JJ N
individuals NNS N
. . N

DISCUSSION NNP N
ADDITION-Cambridge NNP N
is VBZ N
conducted VBN N
in IN N
a DT N
defined JJ N
high-risk JJ N
group NN N
accessible JJ N
through IN N
primary JJ N
care NN N
. . N

It PRP N
addresses VBZ N
the DT N
feasibility NN N
of IN N
population-based JJ N
screening NN N
for IN N
diabetes NNS N
, , N
as RB N
well RB N
as IN N
the DT N
benefits NNS N
and CC N
costs NNS N
of IN N
screening VBG N
and CC N
intensive JJ N
multifactorial JJ N
treatment NN N
early RB N
in IN N
the DT N
disease NN N
trajectory NN N
. . N

The DT N
intensive JJ N
treatment NN N
algorithm NN N
is VBZ N
based VBN N
on IN N
evidence NN N
from IN N
studies NNS N
including VBG N
individuals NNS 1_p
with IN 1_p
clinically RB 1_p
diagnosed VBN 1_p
diabetes NNS 1_p
and CC N
the DT N
education NN N
materials NNS N
are VBP N
informed VBN N
by IN N
psychological JJ N
theory NN N
. . N

ADDITION-Cambridge NNP N
will MD N
provide VB N
timely RB N
evidence NN N
concerning VBG N
the DT N
benefits NNS N
of IN N
early JJ N
intensive JJ N
treatment NN N
and CC N
will MD N
inform VB N
policy NN N
decisions NNS N
concerning VBG N
screening NN N
for IN N
type NN N
2 CD N
diabetes NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
trials NNS N
ISRCTN86769081 NNP N
. . N

-DOCSTART- -X- O O

Chromium NNP 1_i
Supplementation NNP 1_i
and CC N
the DT N
Effects NNS N
on IN N
Metabolic NNP 1_o
Status NNP 1_o
in IN N
Women NNP 1_p
with IN 1_p
Polycystic NNP 1_p
Ovary NNP 1_p
Syndrome NNP 1_p
: : 1_p
A DT N
Randomized NNP N
, , N
Double-Blind NNP N
, , N
Placebo-Controlled JJ N
Trial NNP N
. . N

BACKGROUND NNP N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
beneficial JJ N
effects NNS N
of IN N
chromium NN 1_i
intake NN N
on IN N
markers NNS N
of IN N
insulin NN 1_o
metabolism NN 1_o
and CC N
lipid JJ 1_o
profiles NNS 1_o
in IN N
women NNS 1_p
with IN 1_p
polycystic JJ 1_p
ovary JJ 1_p
syndrome NN 1_p
( ( 1_p
PCOS NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
, , N
64 CD 1_p
women NNS 1_p
with IN 1_p
PCOS NNP 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
receive VB N
200 CD 1_i
?g NNP 1_i
chromium NN 1_i
picolinate NN 1_i
supplements NNS 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
32 CD 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
( ( N
n JJ N
= NNP N
32 CD N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

Fasting VBG 1_o
blood NN 1_o
samples NNS 1_o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
8 CD N
weeks NNS N
after IN N
the DT N
intervention NN N
to TO N
quantify VB N
markers NNS N
of IN N
insulin NN N
metabolism NN N
and CC N
lipid JJ N
concentrations NNS N
. . N

RESULTS NNP 1_i
Chromium NNP 1_i
supplementation NN N
in IN N
women NNS N
with IN N
PCOS NNP N
resulted VBD N
in IN N
significant JJ N
decreases NNS N
in IN 1_o
serum JJ 1_o
insulin NN 1_o
levels NNS 1_o
( ( N
-3.6 VB N
? . N
7.4 CD N
vs. IN N
+3.6 NN N
? . N
6.2 CD N
?IU/ml NN N
, , N
p NN N
< NNP N
0.001 CD 1_o
) ) 1_o
, , 1_o
homeostasis JJ 1_o
model NN 1_o
of IN 1_o
assessment-insulin JJ 1_o
resistance NN 1_o
( ( 1_o
HOMA-IR NNP 1_o
; : N
-0.8 NNP N
? . N
1.6 CD N
vs. IN N
+0.9 NN N
? . N
1.5 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , 1_o
homeostatic JJ 1_o
model NN 1_o
assessment-beta NN 1_o
cell NN 1_o
function NN 1_o
( ( 1_o
HOMA-B NNP 1_o
; : N
-15.5 NNP N
? . N
32.3 CD N
vs. IN N
+13.6 NN N
? . N
23.1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
a DT N
significant JJ N
increase NN N
in IN 1_o
quantitative JJ 1_o
insulin NN 1_o
sensitivity NN 1_o
check NN 1_o
index NN 1_o
( ( 1_o
QUICKI NNP 1_o
) ) 1_o
score NN 1_o
( ( 1_o
+0.02 VB N
? . N
0.03 CD N
vs. IN N
-0.008 NN N
? . N
0.02 CD N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
compared VBN N
with IN 1_i
the DT 1_i
placebo NN 1_i
. . 1_i

In IN N
addition NN N
, , N
a DT N
trend NN N
toward IN N
a DT N
significant JJ N
effect NN N
of IN N
chromium NN 1_i
supplementation NN N
on IN N
decreasing VBG N
serum NN 1_o
triglycerides NNS 1_o
( ( 1_o
-12.4 VB 1_o
? . 1_o
74.4 CD N
vs. IN N
+15.2 NN N
? . N
32.4 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
very RB N
low-density JJ 1_o
lipoprotein-cholesterol NN 1_o
( ( 1_o
-2.5 VB 1_o
? . 1_o
14.9 CD 1_o
vs. IN N
+3.0 NN N
? . N
6.5 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
and CC N
cholesterol NN 1_o
concentrations NNS 1_o
( ( 1_o
-8.6 VB 1_o
? . 1_o
21.9 CD 1_o
vs. IN N
+0.7 NN N
? . N
22.4 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.09 CD N
) ) N
was VBD N
seen VBN N
. . N

CONCLUSIONS NNP N
Eight NNP 1_i
weeks NNS 1_i
of IN 1_i
chromium JJ 1_i
supplementation NN 1_i
among IN 1_p
PCOS NNP 1_p
women NNS 1_p
had VBD 1_p
favorable JJ N
effects NNS 1_o
on IN 1_o
markers NNS 1_o
of IN 1_o
insulin NN 1_o
metabolism NN 1_o
. . 1_o

-DOCSTART- -X- O O

Modest JJS N
visceral JJ N
fat NN 1_i
gain NN 1_i
causes VBZ N
endothelial JJ 1_p
dysfunction NN 1_p
in IN 1_p
healthy JJ 1_p
humans NNS 1_p
. . 1_p

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
fat JJ N
gain NN N
and CC N
its PRP$ N
distribution NN N
on IN N
endothelial JJ 1_o
function NN 1_o
in IN 1_p
lean JJ 1_p
healthy JJ 1_p
humans NNS 1_p
. . 1_p

BACKGROUND NNP N
Endothelial NNP 1_o
dysfunction NN 1_o
has VBZ N
been VBN N
identified VBN N
as IN N
an DT N
independent JJ N
predictor NN N
of IN N
cardiovascular JJ N
events NNS N
. . N

Whether NNP N
fat JJ 1_i
gain NN 1_i
impairs NNS N
endothelial JJ 1_o
function NN 1_o
is VBZ N
unknown JJ N
. . N

METHODS VB N
A DT N
randomized NN N
controlled VBD N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
fat JJ 1_i
gain NN 1_i
on IN N
endothelial JJ N
function NN N
. . N

Forty-three JJ 1_p
normal-weight JJ 1_p
healthy JJ 1_p
volunteers NNS 1_p
were VBD 1_p
recruited VBN 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
29 CD 1_p
years NNS 1_p
; : 1_p
18 CD 1_p
women NNS 1_p
) ) 1_p
. . 1_p

Subjects NNS 1_p
were VBD N
assigned VBN N
to TO N
gain VB 1_i
weight NN 1_i
( ( N
approximately RB N
4 CD N
kg NNS N
) ) N
( ( N
n=35 JJ N
) ) N
or CC N
to TO N
maintain VB 1_i
weight NN 1_i
( ( N
n=8 JJ N
) ) N
. . N

Endothelial JJ 1_o
function NN 1_o
( ( 1_o
brachial JJ 1_o
artery NN 1_o
flow-mediated JJ 1_o
dilation NN 1_o
[ NNP 1_o
FMD NNP 1_o
] NNP 1_o
) ) 1_o
was VBD N
measured VBN N
at IN N
baseline NN N
, , N
after IN N
fat JJ N
gain NN N
( ( N
8 CD N
weeks NNS N
) ) N
, , N
and CC N
after IN N
weight JJ N
loss NN N
( ( N
16 CD N
weeks NNS N
) ) N
for IN N
fat JJ N
gainers NNS N
and CC N
at IN N
baseline NN N
and CC N
follow-up NN N
( ( N
8 CD N
weeks NNS N
) ) N
for IN N
weight NN N
maintainers NNS N
. . N

Body NNP N
composition NN N
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
and CC N
abdominal JJ N
computed JJ N
tomographic JJ N
scans NNS N
. . N

RESULTS NNP N
After IN N
an DT N
average JJ N
weight JJ N
gain NN N
of IN N
4.1 CD N
kg NN N
, , N
fat JJ N
gainers NNS N
significantly RB N
increased VBD N
their PRP$ N
total JJ 1_o
, , 1_o
visceral JJ 1_o
, , 1_o
and CC 1_o
subcutaneous JJ 1_o
fat NN 1_o
. . 1_o

Blood NNP 1_o
pressure NN 1_o
and CC 1_o
overnight JJ 1_o
polysomnography NN 1_o
did VBD N
not RB N
change NN N
after IN N
fat JJ N
gain NN N
or CC N
loss NN N
. . N

FMD NNP 1_o
remained VBD N
unchanged JJ N
in IN N
weight JJ N
maintainers NNS N
. . N

FMD NNP 1_o
decreased VBD N
in IN N
fat JJ N
gainers NNS N
( ( N
9.1+/-3 CD N
% NN N
vs. FW N
7.8+/-3.2 CD N
% NN N
, , N
p=0.003 NN N
) ) N
but CC N
recovered VBD N
to TO N
baseline VB N
when WRB N
subjects NNS N
shed VBD N
the DT N
gained JJ N
weight NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
the DT N
decrease NN N
in IN N
FMD NNP 1_o
and CC N
the DT N
increase NN N
in IN N
visceral JJ 1_o
fat JJ 1_o
gain NN 1_o
( ( N
rho=-0.42 JJ N
, , N
p=0.004 NN N
) ) N
, , N
but CC N
not RB N
with IN N
subcutaneous JJ 1_o
fat JJ 1_o
gain NN 1_o
( ( N
rho=-0.22 JJ N
, , N
p=0.15 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
normal-weight JJ 1_p
healthy JJ 1_p
young JJ 1_p
subjects NNS 1_p
, , N
modest JJ N
fat JJ 1_i
gain NN 1_i
results NNS N
in IN N
impaired JJ N
endothelial JJ 1_o
function NN 1_o
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
changes NNS N
in IN N
blood NN 1_o
pressure NN 1_o
. . 1_o

Endothelial JJ 1_o
function NN 1_o
recovers NNS N
after IN N
weight JJ N
loss NN N
. . N

Increased VBN N
visceral JJ 1_o
rather RB 1_o
than IN 1_o
subcutaneous JJ 1_o
fat JJ 1_o
predicts NNS N
endothelial JJ 1_o
dysfunction NN 1_o
. . 1_o

( ( N
Fat JJ N
Gain NNP N
and CC N
Cardiovascular NNP N
Disease NNP N
Mechanisms NNP N
; : N
NCT00589498 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Intramuscular JJ 1_i
compared VBN 1_i
to TO 1_i
intravenous JJ 1_i
midazolam NN 1_i
for IN N
paediatric JJ N
sedation NN N
: : N
A DT N
study NN N
on IN N
cardiopulmonary JJ N
safety NN N
and CC N
effectiveness NN N
. . N

BACKGROUND NNP N
Sedation NNP N
in IN N
children NNS 1_p
remains VBZ N
a DT N
controversial JJ N
issue NN N
in IN N
emergency NN N
departments NNS N
( ( N
ED NNP N
) ) N
. . N

Midazolam NNP 1_i
, , N
as IN N
a DT N
benzodiazepine NN 1_i
is VBZ N
widely RB N
used VBN N
for IN N
procedural JJ N
sedation NN N
among IN N
paediatrics NNS N
. . N

We PRP N
compared VBN N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
two CD N
forms NNS N
of IN N
midazolam JJ 1_i
prescription NN 1_i
; : 1_i
intramuscular JJ 1_i
( ( 1_i
IM NNP 1_i
) ) 1_i
and CC 1_i
intravenous JJ 1_i
( ( 1_i
IV NNP 1_i
) ) 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
cohort NN N
study NN N
was VBD N
conducted VBN N
on IN N
two CD 1_p
matched JJ 1_p
groups NNS 1_p
of IN 1_p
30 CD 1_p
children NNS 1_p
referred VBD 1_p
to TO 1_p
our PRP$ 1_p
ED NNP 1_p
between IN 1_p
2010 CD 1_p
and CC 1_p
2011 CD 1_p
. . 1_p

The DT N
first JJ N
group NN N
received VBD N
IM NNP 1_i
midazolam NNP 1_i
( ( N
0.3 CD N
mg/kg NN N
) ) N
and CC N
the DT N
second JJ N
group NN N
received VBD N
IV NNP 1_i
midazolam NNP 1_i
( ( N
0.15 CD N
mg/kg NN N
) ) N
for IN N
sedation NN N
. . N

For IN N
evaluating VBG N
effectiveness NN 1_o
, , 1_o
sedation NN 1_o
, , 1_o
irritation NN 1_o
and CC 1_o
cooperation NN 1_o
score NN 1_o
were VBD N
followed VBN N
every DT N
15 CD N
min NN N
for IN N
60 CD N
min NNS N
and CC N
for IN N
safety NN 1_o
assessment NN 1_o
, , 1_o
vital JJ 1_o
signs NNS 1_o
and CC 1_o
O NNP 1_o
2 CD 1_o
saturation NN 1_o
were VBD N
observed VBN N
. . N

RESULTS JJ N
Mean JJ 1_p
age NN 1_p
was VBD 1_p
6.18 CD 1_p
? . 1_p
2.88 CD 1_p
years NNS 1_p
and CC 1_p
31 CD 1_p
patients NNS 1_p
( ( 1_p
51.7 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
male JJ 1_p
. . 1_p

All DT N
patients NNS N
were VBD 1_o
sedated VBN 1_o
completely RB N
after IN N
using VBG N
first RB N
dose RB N
. . N

There EX N
was VBD N
an DT 1_o
overall JJ 1_o
complication NN 1_o
rate NN 1_o
of IN N
68.3 CD N
% NN N
. . N

35 CD N
( ( N
58.3 CD N
% NN N
) ) N
patients NNS N
presented VBN 1_o
euphoria RB 1_o
as IN N
the DT N
most RBS N
common JJ N
complication NN N
, , N
but CC N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.396 CD N
) ) N
. . N

Cases NNPS N
who WP N
received VBD 1_i
IV NNP 1_i
midazolam NN 1_i
became VBD 1_o
sedated JJ 1_o
faster RBR N
than IN N
those DT N
received VBN 1_i
IM NNP 1_i
midazolam NN 1_i
( ( N
P NNP N
> NNP N
0.001 CD N
) ) N
. . N

The DT N
vital JJ N
signs NNS N
including VBG 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
respiratory NN 1_o
rate NN 1_o
, , 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
and CC 1_o
O NNP 1_o
2 CD 1_o
saturation NN 1_o
changed VBD N
significantly RB N
between IN N
and CC N
within IN N
groups NNS N
during IN N
the DT N
sedation NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Both DT N
forms NNS N
of IN 1_i
midazolam NN 1_i
, , 1_i
IM NNP 1_i
and CC 1_i
IV NNP 1_i
, , 1_i
are VBP 1_o
effective JJ 1_o
and CC 1_o
safe JJ 1_o
for IN N
paediatric JJ N
sedation NN N
in IN N
ED NNP N
. . N

Although IN N
the DT N
sedative JJ N
with IN N
IV NNP N
form NN N
might MD N
appear VB N
sooner NN N
, , N
IM NNP N
form NN N
of IN 1_i
midazolam NN 1_i
can MD N
be VB N
effectively RB N
used VBN N
in IN N
patient NN N
with IN N
limited JJ N
IV NNP N
access NN N
. . N

Patients NNS N
are VBP N
better JJR N
to TO N
observe VB N
closely RB N
for IN N
psychological JJ N
side-effects NNS N
. . N

-DOCSTART- -X- O O

Why WRB N
the DT N
prone NN 1_i
position NN 1_i
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
sudden JJ N
infant NN N
death NN N
syndrome NN N
. . N

INTRODUCTION NNP N
The DT N
laryngeal NN N
chemoreflex NN N
may MD N
explain VB N
why WRB N
prone NN N
sleeping NN N
increases VBZ N
the DT N
risk NN N
of IN N
sudden JJ N
infant NN N
death NN N
syndrome NN N
( ( N
SIDS NNP N
) ) N
. . N

Swallowing VBG N
and CC N
arousal NN N
are VBP N
crucial JJ N
to TO N
prevent VB N
laryngeal JJ N
chemoreflex JJ N
stimulation NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
examine VB N
these DT N
reflexes NNS 1_o
and CC 1_o
breathing VBG 1_o
responses NNS 1_o
in IN N
healthy JJ 1_p
neonates NNS 1_p
after IN N
pharyngeal JJ N
infusion NN N
of IN N
water NN N
in IN N
the DT N
supine NN N
versus IN N
the DT N
prone NN N
position NN N
, , N
controlling VBG N
for IN N
sleep JJ N
state NN N
. . N

METHODS CC N
A DT N
total NN N
of IN N
10 CD 1_p
term NN 1_p
infants NNS 1_p
were VBD N
recruited VBN N
after IN N
parental JJ N
consent NN N
and CC N
ethics NNS N
approval NN N
. . N

Polygraphic JJ N
recordings NNS N
included VBD N
sleep JJ 1_o
state NN 1_o
( ( 1_o
active JJ 1_o
and CC 1_o
quiet JJ 1_o
sleep NN 1_o
by IN 1_o
electroencephalogram NN 1_o
, , 1_o
eye NN 1_o
movements NNS 1_o
, , 1_o
breathing NN 1_o
, , 1_o
and CC 1_o
behavior NN 1_o
) ) 1_o
, , 1_o
cardiorespiratory JJ 1_o
measurements NNS 1_o
( ( 1_o
nasal JJ 1_o
airflow NN 1_o
, , 1_o
chest VBP 1_o
wall NN 1_o
movements NNS 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
oxygen PRP 1_o
saturation NN 1_o
) ) 1_o
, , 1_o
swallowing VBG 1_o
, , 1_o
and CC 1_o
esophageal JJ 1_o
activity NN 1_o
( ( 1_o
solid JJ 1_o
state NN 1_o
pressure NN 1_o
catheter NN 1_o
) ) 1_o
. . 1_o

Initial JJ 1_i
sleeping VBG 1_i
position NN 1_i
was VBD 1_i
assigned VBN 1_i
randomly RB 1_i
. . 1_i

Measurements NNS N
were VBD N
made VBN N
for IN N
1 CD 1_i
minute NN 1_i
before IN 1_i
and CC 1_i
after IN 1_i
0.4 CD 1_i
mL NN 1_i
of IN 1_i
water NN 1_i
was VBD 1_i
instilled VBN 1_i
into IN 1_i
the DT 1_i
oropharynx NN 1_i
. . 1_i

To TO N
detect VB N
a DT N
30 CD N
% NN N
decrease NN N
in IN N
swallowing NN 1_o
, , N
power NN N
analysis NN N
indicated VBD N
that IN N
> NNP N
/=10 NNP N
babies NNS N
were VBD N
required VBN N
. . N

Analysis NN N
, , N
blinded VBD N
to TO N
position NN N
, , N
was VBD N
made VBN N
using VBG N
nonparametric JJ N
statistics NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
164 CD N
infusions NNS N
, , N
the DT N
most RBS N
commonly RB N
evoked VBD N
airway RB N
protective JJ N
responses NNS N
to TO N
pharyngeal VB N
infusion NN N
were VBD N
swallowing VBG 1_o
( ( N
95 CD N
% NN N
) ) N
and CC N
arousal NN 1_o
( ( N
54 CD N
% NN N
) ) N
. . N

After IN N
infusion NN N
in IN N
active JJ N
sleep NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
swallowing VBG 1_o
and CC 1_o
breathing VBG 1_o
when WRB N
the DT N
prone NN N
position NN N
was VBD N
compared VBN N
with IN N
the DT N
supine JJ N
position NN N
( ( N
prone NN N
: : N
21.3 CD N
[ $ N
1.0 CD N
] NNP N
swallows/min NN 1_o
and CC N
-9.6 NNP N
[ NNP N
2.1 CD N
] NNP N
breaths/min NN 1_o
; : 1_o
and CC N
supine VB N
: : N
32 CD N
( ( N
2.2 CD N
) ) N
and CC N
-2 NNP N
. . N

9 CD N
( ( N
1.5 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
occurrence NN N
of IN N
arousal NN 1_o
after IN N
water NN N
infusion NN N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
airway NN N
protection NN N
is VBZ N
compromised VBN N
in IN N
the DT N
prone NN N
sleeping VBG N
position NN N
during IN N
active JJ N
sleep NN N
, , N
even RB N
in IN N
healthy JJ N
infants NNS N
exposed VBN N
to TO N
minute VB N
pharyngeal JJ N
fluid JJ N
volumes NNS N
of IN N
0.4 CD N
mL NN N
. . N

This DT N
is VBZ N
because IN N
swallowing VBG 1_o
rate NN 1_o
is VBZ N
reduced VBN N
significantly RB N
, , N
and CC N
there EX N
is VBZ N
no DT N
compensatory JJ N
increase NN N
in IN N
arousal NN 1_o
. . 1_o

The DT N
reduction NN N
in IN N
airway RB 1_o
protective JJ 1_o
reflexes NNS 1_o
when WRB N
in IN N
the DT N
prone NN N
position NN N
and CC N
in IN N
active JJ N
sleep NN N
may MD N
be VB N
the DT N
mechanism NN N
for IN N
the DT N
increased VBN N
risk NN N
of IN N
SIDS NNP N
in IN N
the DT N
prone NN N
position NN N
. . N

-DOCSTART- -X- O O

The DT N
cognitive NN 1_o
, , 1_o
subjective JJ 1_o
, , 1_o
and CC 1_o
physical JJ 1_o
effects NNS 1_o
of IN N
a DT N
ginkgo NN 1_i
biloba/panax NN 1_i
ginseng NN 1_i
combination NN 1_i
in IN N
healthy JJ 1_p
volunteers NNS 1_p
with IN 1_p
neurasthenic JJ 1_p
complaints NNS 1_p
. . 1_p

We PRP N
evaluated VBD N
the DT N
effects NNS 1_o
of IN N
a DT N
Ginkgo NNP 1_i
biloba/ginseng NN 1_i
combination NN 1_i
on IN N
cognitive JJ 1_o
function NN 1_o
in IN N
this DT N
90-day JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
parallel-group JJ N
study NN N
. . N

Sixty-four CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
( ( 1_p
aged VBN 1_p
40 CD 1_p
to TO 1_p
65 CD 1_p
years NNS 1_p
) ) 1_p
, , 1_p
selected VBN 1_p
on IN 1_p
the DT 1_p
basis NN 1_p
of IN 1_p
fulfilling VBG 1_p
the DT 1_p
ICD-10 NNP 1_p
F48.0 NNP 1_p
criteria NNS 1_p
for IN 1_p
neurasthenia NN 1_p
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
four CD N
equal JJ N
dosing NN N
groups NNS N
, , N
receiving VBG N
80 CD N
, , N
160 CD N
, , N
or CC N
320 CD N
mg NN N
of IN N
the DT N
combination NN N
b.i.d NN N
. . N

or CC N
placebo NN 1_i
. . 1_i

Assessments NNS N
were VBD N
performed VBN N
on IN N
the DT N
day NN N
before IN N
dosing NN N
, , N
and CC N
again RB N
at IN N
Days NNP N
1 CD N
, , N
30 CD N
, , N
and CC N
90 CD N
at IN N
1 CD N
hour NN N
after IN N
the DT N
morning NN N
dose NN N
and CC N
1 CD N
hour NN N
after IN N
the DT N
afternoon NN N
dose NN N
. . N

The DT N
assessments NNS N
included VBD N
the DT N
Cognitive NNP 1_o
Drug NNP 1_o
Research NNP 1_o
( ( 1_o
CDR NNP 1_o
) ) 1_o
computerized VBD 1_o
assessment NN 1_o
system NN 1_o
, , 1_o
the DT 1_o
Vienna NNP 1_o
Determination NNP 1_o
Unit NNP 1_o
, , 1_o
cycle NN 1_o
ergometry NN 1_o
, , 1_o
and CC 1_o
various JJ 1_o
questionnaires NNS 1_o
. . 1_o

The DT N
treatments NNS N
were VBD N
well RB 1_o
tolerated VBN 1_o
by IN N
all DT N
volunteers NNS N
. . N

On IN N
Day NNP N
90 CD N
at IN N
1 CD N
hour NN N
post NN N
morning NN N
dosing NN N
, , N
dose-related JJ 1_o
improvements NNS 1_o
were VBD N
seen VBN N
on IN N
the DT N
CDR NNP N
tests NNS N
, , N
the DT N
320 CD N
mg NN N
dose NN N
being VBG N
significantly RB N
superior JJ N
to TO N
placebo VB 1_i
. . 1_i

These DT N
effects NNS N
, , N
however RB N
, , N
were VBD N
reversed VBN N
1 CD N
hour NN N
after IN N
the DT N
afternoon NN N
dose NN N
, , N
possibly RB N
suggesting VBG N
that IN N
a DT N
longer JJR N
inter-dosing JJ N
interval NN N
would MD N
be VB N
preferable JJ N
. . N

The DT N
80-mg JJ N
dose NN N
produced VBD N
a DT N
significant JJ N
benefit NN N
on IN N
the DT N
ergometry NN 1_o
assessment NN 1_o
of IN 1_o
heart NN 1_o
rate NN 1_o
at IN N
maximum JJ N
load NN N
. . N

There EX N
were VBD N
also RB N
several JJ N
supporting VBG N
changes NNS N
from IN N
other JJ N
assessments NNS N
, , N
including VBG N
an DT N
advantage NN N
of IN N
320 CD N
mg NN N
over IN N
placebo NN 1_i
on IN N
the DT N
global JJ N
score NN N
from IN N
the DT N
Symptom NNP N
Checklist-90-revised JJ N
( ( N
SCL-90-R NNP N
) ) N
at IN N
Day NNP N
90 CD N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
intravenous JJ 1_i
fructose-1,6-diphosphate NN 1_i
on IN N
myocardial JJ 1_o
contractility NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
left JJ 1_p
ventricular JJ 1_p
dysfunction NN 1_p
. . 1_p

STUDY NNP N
OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
fructose-1,6-diphosphate NN 1_i
on IN N
myocardial JJ 1_o
performance NN 1_o
using VBG N
nuclear JJ N
scintigraphy NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
single-blind JJ N
, , N
parallel JJ N
study NN N
. . N

SETTING NNP N
Urban NNP 1_p
teaching VBG 1_p
hospital JJ 1_p
clinical JJ 1_p
research NN 1_p
center NN 1_p
. . 1_p

PATIENTS JJ N
Individuals NNS 1_p
with IN 1_p
New NNP 1_p
York NNP 1_p
Heart NNP 1_p
Association NNP 1_p
functional JJ 1_p
class NN 1_p
II-III NNP 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
) ) 1_p
. . 1_p

INTERVENTIONS JJ N
Subjects NNPS N
received VBD N
either DT N
intravenous JJ 1_i
fructose-1,6-diphosphate JJ 1_i
125 CD 1_i
mg/kg NN 1_i
or CC 1_i
normal JJ 1_i
saline JJ 1_i
1.3 CD N
ml/kg NN N
every DT N
12 CD N
hours NNS N
over IN N
10 CD N
minutes NNS N
for IN N
four CD N
consecutive JJ N
doses NNS N
. . N

Left NNP N
ventricular JJ N
performance NN N
was VBD N
assessed VBN N
by IN N
radionuclide NN 1_i
ventriculography NN 1_i
at IN N
baseline NN N
and CC N
within IN N
60 CD N
minutes NNS N
after IN N
the DT N
fourth JJ N
infusion NN N
. . N

Vital JJ N
signs NNS N
were VBD N
monitored VBN N
throughout IN N
the DT N
study NN N
period NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Fructose-1,6-diphosphate NNP 1_i
resulted VBD N
in IN N
a DT N
modest JJ N
7 CD N
% NN N
increase NN N
in IN N
left JJ 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Peak JJ 1_o
ejection NN 1_o
rate NN 1_o
and CC 1_o
peak VB 1_o
diastolic JJ 1_o
filling VBG 1_o
rate NN 1_o
did VBD N
not RB N
change VB N
significantly RB N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
blood NN 1_o
pressure NN 1_o
or CC 1_o
heart NN 1_o
rate NN 1_o
with IN N
either DT N
fructose-1,6-diphosphate JJ 1_i
or CC N
placebo NN 1_i
. . 1_i

CONCLUSIONS NNP N
Fructose-1,6-diphosphate NNP 1_i
produces VBZ N
a DT N
modest JJ N
but CC N
significant JJ N
increase NN N
in IN N
left JJ 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

-DOCSTART- -X- O O

Plasma NNP 1_o
kinetics NNS 1_o
of IN 1_o
zeaxanthin NN 1_o
and CC 1_o
3'-dehydro-lutein JJ 1_o
after IN N
multiple JJ N
oral JJ N
doses NNS N
of IN N
synthetic JJ 1_i
zeaxanthin NN 1_i
. . 1_i

BACKGROUND NNP N
Zeaxanthin NNP 1_i
is VBZ N
hypothesized VBN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
age-related JJ 1_p
macular JJ 1_p
degeneration NN 1_p
; : 1_p
however RB N
, , N
kinetic JJ N
information NN N
is VBZ N
limited VBN N
. . N

OBJECTIVES IN N
The DT N
objective NN N
was VBD N
to TO N
investigate VB N
the DT N
plasma NN 1_o
kinetics NNS 1_o
of IN 1_o
synthetic JJ 1_o
zeaxanthin NN 1_o
after IN N
repeated VBN N
oral JJ N
doses NNS N
and CC N
to TO N
assess VB N
the DT N
possible JJ N
influence NN N
of IN N
other JJ N
carotenoids NNS N
on IN N
plasma NN 1_o
zeaxanthin NN 1_o
concentrations NNS 1_o
. . 1_o

DESIGN NNP N
After IN N
a DT N
run-in NN N
of IN N
3 CD N
d NN N
, , N
20 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
assigned VBD N
to TO N
2 CD N
parallel NNS N
dose JJ N
groups NNS N
received VBD N
once RB N
daily JJ N
oral JJ N
doses NNS N
of IN N
either DT N
1 CD N
mg NN N
( ( N
1.76 CD N
micro RB N
mol NN N
) ) N
or CC N
10 CD N
mg NN N
( ( N
17.6 CD N
micro RB N
mol NN N
) ) N
zeaxanthin NN 1_i
for IN N
42 CD N
d. JJ N
Plasma NNP 1_o
concentration-time NN 1_o
profiles NNS 1_o
on IN N
days NNS N
1 CD N
and CC N
42 CD N
, , N
concentrations NNS N
immediately RB N
before IN N
zeaxanthin JJ 1_i
intake NN N
during IN N
the DT N
dosing JJ N
period NN N
, , N
and CC N
concentrations NNS N
after IN N
the DT N
last JJ N
dose JJ N
until IN N
day NN N
76 CD N
were VBD N
monitored VBN N
. . N

RESULTS NNP N
all-E-Zeaxanthin JJ 1_o
concentrations NNS 1_o
increased VBD N
from IN N
0.048 CD N
+/- JJ N
0.026 CD N
micro NN N
mol/L NN N
at IN N
baseline NN N
to TO N
0.20 CD N
+/- JJ N
0.07 CD N
and CC N
0.92 CD N
+/- JJ N
0.28 CD N
micro NN N
mol/L NN N
with IN N
1 CD N
and CC N
10 CD N
mg NN N
zeaxanthin NN 1_i
, , N
respectively RB N
. . N

The DT N
dose-normalized JJ 1_o
bioavailability NN 1_o
of IN 1_o
all-E-zeaxanthin JJ 1_o
after IN N
the10-mg JJ N
dose NN N
was VBD N
40 CD N
% NN N
lower JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
than IN N
after IN N
the DT N
1-mg JJ N
dose NN N
. . N

Other JJ N
kinetic JJ 1_o
parameters NNS 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
. . N

After IN N
17 CD N
d NN N
of IN N
dosing NN N
, , N
> VB N
90 CD N
% NN N
of IN N
steady JJ N
state NN N
concentrations NNS 1_o
were VBD N
reached VBN N
, , N
which WDT N
was VBD N
compatible JJ N
with IN N
an DT N
effective JJ N
half-life NN N
for IN N
accumulation NN N
of IN N
5 CD N
d. NN N
The DT N
terminal JJ 1_o
elimination NN 1_o
half-life NN 1_o
was VBD N
12 CD N
+/- JJ N
7 CD N
d NN N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

The DT N
time NN 1_o
course NN 1_o
of IN 1_o
plasma JJ 1_o
all-E-3-'dehydro-lutein JJ 1_o
concentrations NNS 1_o
resembled VBD N
that IN N
of IN N
all-E-zeaxanthin JJ 1_i
. . 1_i

The DT N
data NN N
provided VBD N
evidence NN N
that IN N
all-E-3-'dehydro-lutein NN 1_o
was VBD N
derived VBN N
from IN N
all-E-zeaxanthin JJ 1_o
. . 1_o

Concentrations NNS 1_o
of IN 1_o
other JJ 1_o
carotenoids NNS 1_o
were VBD N
not RB N
affected VBN N
. . N

Zeaxanthin NNP 1_i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSION NNP N
Long-term JJ N
oral JJ N
intake NN N
of IN N
1 CD N
and CC N
10 CD N
mg NN N
zeaxanthin NN 1_i
as IN N
beadlets NNS N
increases VBZ N
plasma NN 1_o
zeaxanthin JJ 1_o
concentrations NNS 1_o
approximately RB N
4- JJ N
and CC N
20-fold JJ N
, , N
respectively RB N
. . N

Evidence NN N
that IN N
all-E-3-dehydro-lutein NN 1_o
is VBZ N
formed VBN N
from IN N
zeaxanthin NN 1_i
was VBD N
strong JJ N
. . N

-DOCSTART- -X- O O

Atorvastatin NNP 1_i
and CC 1_i
quinapril JJ 1_i
inhibit NN N
blood NN N
coagulation NN N
in IN N
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
following VBG N
28 CD N
days NNS N
of IN N
therapy NN N
. . N

BACKGROUND IN N
We PRP N
evaluated VBD N
the DT N
antithrombotic JJ N
effects NNS N
of IN N
statins NNS 1_i
and CC N
angiotensin-converting JJ 1_i
enzyme NN 1_i
inhibitor NN 1_i
( ( 1_i
ACEI NNP 1_i
) ) 1_i
drugs NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
( ( 1_p
CAD NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
Blood NNP N
coagulation NN N
at IN N
the DT N
site NN N
of IN N
microvascular JJ N
injury NN N
was VBD N
assessed VBN N
in IN N
26 CD 1_p
males NNS 1_p
with IN 1_p
CAD NNP 1_p
before IN 1_p
and CC 1_p
after IN 1_p
treatment NN 1_p
with IN 1_p
quinapril NN 1_i
( ( 1_p
10 CD 1_p
mg RB 1_p
day-1 NN 1_p
; : 1_p
n=13 CC 1_p
) ) 1_p
or CC 1_p
atorvastatin NN 1_i
( ( 1_p
40 CD 1_p
mg RB 1_p
day-1 NN 1_p
; : 1_p
n=13 CC 1_p
) ) 1_p
for IN 1_p
4 CD 1_p
weeks NNS 1_p
and CC 1_p
an DT 1_p
additional JJ 1_p
4 CD 1_p
weeks NNS 1_p
of IN 1_p
combined JJ 1_p
therapy NN 1_p
( ( N
quinapril+atorvastatin NN N
) ) N
. . N

Rates NNS 1_o
of IN 1_o
prothrombin NN 1_o
and CC 1_o
factor NN 1_o
V NNP 1_o
activation NN 1_o
( ( 1_o
FVa NNP 1_o
) ) 1_o
, , 1_o
fibrinogen NN 1_o
( ( 1_o
Fbg NNP 1_o
) ) 1_o
cleavage NN 1_o
and CC 1_o
FVa NNP 1_o
inactivation NN 1_o
showed VBD N
that IN N
both DT N
quinapril NNS N
and CC N
atorvastatin NN N
decreased VBD N
the DT N
rates NNS N
of IN N
: : N
formation NN 1_o
of IN 1_o
thrombin JJ 1_o
B-chain NNP 1_o
( ( N
by IN N
30.6 CD N
% NN N
, , N
P=0.007 NNP N
; : N
and CC N
by IN N
34.3 CD N
% NN N
, , N
P=0.003 NNP N
) ) N
, , N
formation NN 1_o
of IN 1_o
thrombin-antithrombin NN 1_o
complexes NNS 1_o
( ( N
by IN N
30.4 CD N
% NN N
, , N
P=0.0002 NNP N
; : N
and CC N
by IN N
40 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
FV NNP 1_o
activation NN 1_o
( ( N
by IN N
19.1 CD N
% NN N
, , N
P=0.03 NNP N
; : N
and CC N
by IN N
21.8 CD N
% NN N
, , N
P=0.005 NNP N
) ) N
and CC N
Fbg NNP 1_o
depletion NN 1_o
( ( N
by IN N
29.2 CD N
% NN N
, , N
P=0.004 NNP N
; : N
and CC N
by IN N
32.7 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
. . N

Atorvastatin NNP N
alone RB N
accelerated VBD N
FVa NNP 1_o
inactivation NN 1_o
( ( N
P=0.005 NNP N
) ) N
. . N

A DT N
further JJ N
4 CD N
weeks NNS N
of IN N
combined JJ N
therapy NN N
enhanced VBD N
most RBS N
anticoagulant JJ 1_o
effects NNS 1_o
only RB N
when WRB N
atorvastatin NN N
was VBD N
added VBN N
to TO N
quinapril VB N
. . N

CONCLUSIONS NNP N
In IN N
CAD NNP 1_p
patients NNS 1_p
, , N
atorvastatin NN N
and CC N
quinapril NN N
slowed VBD N
blood NN N
clotting NN N
at IN N
the DT N
site NN N
of IN N
microvascular JJ N
injury NN N
after IN N
28 CD N
days NNS N
of IN N
therapy NN N
. . N

Addition NN N
of IN N
atorvastatin NN 1_i
to TO N
quinapril VB 1_i
, , N
but CC N
not RB N
quinapril VB 1_i
to TO N
the DT N
statin NN 1_i
, , N
enhanced VBD N
the DT N
anticoagulant JJ N
effects NNS N
. . N

Our PRP$ N
findings NNS N
might MD N
help VB N
explain VB N
the DT N
reduced JJ N
risk NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
stroke NN N
in IN N
patients NNS N
treated VBN N
with IN N
statins NNS 1_i
and/or VBP N
ACEIs NNP N
and CC N
the DT N
lack NN N
of IN N
clinical JJ N
benefits NNS N
from IN N
ACEI NNP N
added VBD N
to TO N
prior VB N
statin JJ N
therapy NN N
in IN N
patients NNS N
at IN N
cardiovascular JJ N
risk NN N
. . N

-DOCSTART- -X- O O

Ultrasonographic JJ 1_i
tissue NN 1_i
characterisation NN 1_i
of IN N
human JJ N
Achilles NNP N
tendons NNS N
: : N
quantification NN N
of IN N
tendon NN N
structure NN N
through IN N
a DT N
novel JJ N
non-invasive JJ N
approach NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
whether IN N
three-dimensional JJ 1_i
imaging NN 1_i
of IN 1_i
the DT 1_i
Achilles NNP 1_i
tendon NN 1_i
by IN 1_i
ultrasonographic JJ 1_i
tissue NN 1_i
characterisation NN 1_i
( ( 1_i
UTC NNP 1_i
) ) 1_i
can MD N
differentiate VB N
between IN N
symptomatic JJ N
and CC N
asymptomatic JJ N
tendons NNS N
. . N

DESIGN NNP N
Case-control NNP N
study NN N
. . N

SETTING NNP N
Sports NNP 1_p
Medical NNP 1_p
Department NNP 1_p
of IN 1_p
the DT 1_p
Hague NNP 1_p
Medical NNP 1_p
Centre NNP 1_p
. . 1_p

PATIENTS NNP N
Twenty-six JJ 1_p
tendons NNS 1_p
from IN 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
midportion NN 1_p
Achilles NNP 1_p
tendinopathy NN 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

The DT N
matched JJ N
control NN N
group NN N
consisted VBD N
of IN N
26 CD 1_p
asymptomatic JJ 1_p
tendons NNS 1_p
. . 1_p

INTERVENTIONS NNP N
Symptomatic NNP 1_i
and CC 1_i
asymptomatic JJ 1_i
tendons NNS 1_i
were VBD 1_i
scanned VBN 1_i
using VBG 1_i
the DT 1_i
UTC NNP 1_o
procedure NN 1_o
. . 1_o

One CD 1_i
researcher NN 1_i
performed VBD 1_i
the DT 1_i
ultrasonographic JJ 1_o
data NNS 1_i
collection NN 1_i
. . 1_i

These DT N
blinded VBN N
data NNS N
were VBD N
randomised VBN N
, , N
and CC N
outcome JJ N
measures NNS N
were VBD N
determined VBN N
by IN N
two CD N
independent JJ N
observers NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASUREMENTS NNP N
The DT N
raw JJ N
ultrasonographic JJ N
images NNS N
were VBD N
analysed VBN N
with IN N
a DT N
custom-designed JJ N
algorithm NN N
that WDT N
quantifies VBZ N
the DT N
three-dimensional JJ 1_o
stability NN 1_o
of IN 1_o
echo NN 1_o
patterns NNS 1_o
, , 1_o
qua JJ 1_o
intensity NN 1_o
and CC 1_o
distribution NN 1_o
over IN 1_o
contiguous JJ 1_o
transverse JJ 1_o
images NNS 1_o
. . 1_o

This DT N
three-dimensional JJ N
stability NN N
was VBD N
related VBN N
to TO N
tendon VB N
structure NN N
in IN N
previous JJ N
studies NNS N
. . N

UTC NNP N
categorises VBZ N
four CD N
different JJ N
echotypes NNS 1_o
that WDT N
represent VBP N
( ( N
I PRP N
) ) N
highly RB 1_o
stable JJ 1_o
; : 1_o
( ( N
II NNP N
) ) N
medium NN 1_o
stable JJ 1_o
; : 1_o
( ( N
III NNP N
) ) N
highly RB 1_o
variable JJ 1_o
and CC N
( ( N
IV NNP N
) ) N
constantly RB 1_o
low JJ 1_o
intensity NN N
and CC N
variable JJ N
distribution NN N
. . N

The DT N
percentages NNS N
of IN N
echo-types NNS 1_o
were VBD N
calculated VBN N
, , N
and CC N
the DT N
maximum JJ N
tendon NN 1_o
thickness NN 1_o
was VBD N
measured VBN N
. . N

Finally RB N
, , N
the DT N
inter-observer JJ N
reliability NN N
of IN N
UTC NNP 1_i
was VBD N
determined VBN N
. . N

RESULTS NNP N
Symptomatic JJ N
tendons NNS N
showed VBD N
less JJR N
pixels NNS N
in IN N
echo-types JJ N
I PRP N
and CC N
II NNP N
than IN N
asymptomatic JJ N
tendons NNS N
( ( N
51.5 CD N
% NN N
vs JJ N
76.6 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
thus RB N
less JJR N
three-dimensional JJ N
stability NN N
of IN N
the DT N
echo JJ 1_o
pattern NN 1_o
. . 1_o

The DT N
mean JJ N
maximum JJ N
tendon NN 1_o
thickness NN 1_o
was VBD N
9.2 CD N
mm NN N
in IN N
the DT N
symptomatic JJ N
group NN N
and CC N
6.8 CD N
mm NN N
in IN N
the DT N
asymptomatic JJ N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
Intraclass NNP 1_o
Correlation NNP 1_o
Coefficient NNP 1_o
( ( N
ICC NNP N
) ) N
for IN N
the DT N
interobserver JJ N
reliability NN N
of IN N
determining VBG N
the DT N
echo-types JJ N
I+II NNP N
was VBD N
0.95 CD N
. . N

The DT N
ICC NNP N
for IN N
tendon NN 1_o
thickness NN 1_o
was VBD N
0.84 CD N
. . N

CONCLUSION NNP N
UTC NNP N
can MD N
quantitatively RB N
evaluate VB N
tendon NN N
structure NN N
and CC N
thereby RB N
discriminate VB N
symptomatic JJ N
and CC N
asymptomatic JJ N
tendons NNS N
. . N

As IN N
such JJ N
, , N
UTC NNP 1_i
might MD N
be VB N
useful JJ N
to TO N
monitor VB N
treatment NN N
protocols NNS N
. . N

-DOCSTART- -X- O O

Visual JJ 1_i
Assessment NNP 1_i
of IN 1_i
Relative NNP 1_i
Apical NNP 1_i
Sparing NNP 1_i
Pattern NNP 1_i
Is VBZ N
More RBR N
Useful JJ N
Than NNP N
Quantitative NNP N
Assessment NNP N
for IN N
Diagnosing NNP N
Cardiac NNP N
Amyloidosis NNP N
in IN N
Borderline NNP 1_p
or CC 1_p
Mildly RB 1_p
Increased VBD 1_p
Left NNP 1_p
Ventricular NNP 1_p
Wall NNP 1_p
Thickness NNP 1_p
. . 1_p

BACKGROUND NNP N
Relative NNP 1_i
apical JJ 1_i
sparing VBG 1_i
pattern NN 1_i
of IN 1_i
longitudinal JJ 1_i
strain NN 1_i
( ( 1_i
RapSP-LS NNP 1_i
) ) 1_i
was VBD N
suggested VBN N
in IN N
advanced JJ N
cardiac JJ N
amyloidosis NN N
( ( N
CA NNP N
) ) N
. . N

It PRP N
is VBZ N
unclear JJ N
whether IN N
it PRP N
is VBZ N
present JJ N
in IN N
less RBR N
advanced JJ 1_p
CA NNP 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNP 1_p
with IN 1_p
presumptive JJ 1_p
diagnosis NN 1_p
of IN 1_p
CA NNP 1_p
and CC 1_p
mean VB 1_p
left JJR 1_p
ventricular NN 1_p
wall NN 1_p
thickness NN 1_p
( ( 1_p
LVWT NNP 1_p
) ) 1_p
?14 VBP 1_p
mm NNS 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

Apart RB N
from IN 1_i
RapSP-LS NNP 1_i
visually RB 1_i
identified VBD 1_i
, , 1_i
relative JJ 1_i
apical JJ 1_i
longitudinal NN 1_i
strain NN 1_i
index NN 1_i
( ( 1_i
RapLSI NNP 1_i
) ) 1_i
was VBD 1_i
defined VBN N
as IN N
[ JJ N
average JJ N
apical JJ N
LS/ NNP N
( ( N
average JJ N
basal NN N
LS+average NNP N
mid-ventricle NN N
LS NNP N
) ) 1_p
] NN 1_p
. . 1_p

Among IN 1_p
119 CD 1_p
patients NNS 1_p
included VBD 1_p
, , 1_p
47 CD 1_p
were VBD 1_p
finally RB 1_p
diagnosed VBN 1_p
with IN 1_p
CA NNP 1_p
. . 1_o

RapLSI NNP 1_o
was VBD 1_o
higher RBR N
in IN N
the DT N
CA NNP N
group NN N
compared VBN N
to TO N
other JJ N
causes NNS N
of IN N
increased JJ 1_o
mean NN 1_o
LVWT NNP 1_o
( ( 1_o
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
with IN N
a DT N
significant JJ N
range NN N
of IN N
overlap NN N
noted VBN N
. . N

In IN N
contrast NN 1_i
, , 1_i
RapSP-LS NNP 1_i
visually RB 1_i
assessed VBD N
was VBD N
noted VBN N
in IN N
most JJS N
CA JJ N
patients NNS N
( ( N
31/47 CD N
, , N
66.0 CD N
% NN N
) ) N
except IN N
in IN N
those DT N
with IN N
preserved JJ N
LV NNP N
ejection NN N
fraction NN N
, , N
normal JJ N
LVWT NNP N
, , N
and CC N
mildly RB N
decreased VBD N
global JJ N
LS NNP N
, , N
suggesting VBG N
least JJS N
advanced JJ N
CA NNP N
. . N

On IN N
multivariate JJ N
analysis NN N
of IN N
the DT N
added JJ N
diagnostic JJ N
role NN N
of IN N
RapSP-LS NNP 1_i
or CC 1_i
RapLSI NNP 1_i
on IN 1_i
top NN N
of IN N
clinical JJ N
, , N
electrocardiographic JJ N
, , N
and CC N
conventional JJ N
echocardiographic JJ N
parameters NNS N
, , N
addition NN N
of IN N
RapLSI NNP 1_i
produced VBD 1_i
only RB N
borderline JJ N
increase NN N
in IN N
area NN N
under IN N
the DT N
curve NN N
of IN N
the DT N
multivariate NN N
model NN N
( ( N
P=0.05 NNP N
) ) N
, , N
whereas JJ N
addition NN N
of IN N
RapSP-LS NNP 1_i
significantly RB 1_i
increased VBD N
it PRP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Visual NNP N
identification NN N
of IN N
RapSP-LS NNP 1_i
is VBZ 1_i
useful JJ N
in IN N
terms NNS N
of IN N
added VBN 1_o
diagnostic JJ 1_o
value NN 1_o
compared VBN 1_o
with IN N
quantitative JJ N
calculation NN N
of IN N
RapLSI NNP 1_i
. . 1_i

Its PRP$ N
clinical JJ N
application NN N
, , N
however RB N
, , N
should MD N
be VB N
used VBN N
with IN N
caution NN N
in IN N
patients NNS 1_p
with IN 1_p
less JJR 1_p
advanced JJ 1_p
CA NNP 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ N
Dose-effect NNP N
relationship NN N
of IN N
isosorbide NN 1_i
dinitrate NN 1_i
in IN N
the DT N
treatment NN N
of IN N
angina JJ N
pectoris NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

Fifteen JJ 1_p
males NNS 1_p
with IN 1_p
angiographic JJ 1_p
evidence NN 1_p
of IN 1_p
coronary JJ 1_p
heart NN 1_p
disease NN 1_p
and CC 1_p
stable JJ 1_p
, , 1_p
exercise-induced JJ 1_p
angina NN 1_p
pectoris NN 1_p
were VBD N
given VBN N
placebo NNS 1_i
or CC 1_i
isosorbide VB 1_i
dinitrate NN 1_i
( ( 1_i
ISDN NNP 1_i
) ) 1_i
in IN N
a DT N
dialy NN N
dose NN N
of IN N
30 CD N
mg NNS N
, , N
120 CD N
mg NN N
, , N
240 CD N
mg NN N
and CC N
480 CD N
mg NN N
in IN N
a DT N
randomized JJ N
single-blind JJ N
trial NN N
. . N

The DT N
daily JJ N
doses NNS N
were VBD N
given VBN N
as IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
5 CD N
mg NNS N
, , N
20 CD N
mg NN N
, , N
40 CD N
mg NN N
and CC N
80 CD N
mg JJ N
tablets NNS N
. . N

Each DT N
dose NN N
and CC N
placebo NN N
was VBD N
given VBN N
for IN N
seven CD N
days NNS N
. . N

On IN N
the DT N
seventh JJ N
day NN N
an DT N
exercise NN 1_o
ECG NNP 1_o
of IN N
standardized JJ N
level NN N
and CC N
duration NN 1_o
of IN 1_o
exercise NN 1_o
was VBD N
recorded VBN N
. . N

The DT N
ischaemia NN 1_o
response NN N
in IN N
the DT N
ECG NNP N
revealed VBD N
a DT N
dose-dependent JJ N
reduction NN 1_o
by IN N
28 CD N
% NN N
( ( N
5 CD N
mg RB N
ISDN NNP N
) ) N
, , N
43 CD N
% NN N
( ( N
20 CD N
mg NN N
) ) N
, , N
60 CD N
% NN N
( ( N
40 CD N
mg NN N
) ) N
and CC N
73 CD N
% NN N
( ( N
80 CD N
mg NN N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
anginal JJ 1_o
attacks NNS 1_o
similarly RB N
fell VBD N
parallel RB N
to TO N
dose VB N
. . N

Plasma NNP 1_o
level NN 1_o
of IN 1_o
ISDN NNP 1_o
and CC 1_o
the DT 1_o
mononitrates NNS 1_o
, , N
measured VBD N
one CD N
and CC N
four CD N
hours NNS N
after IN N
drug NN N
intake NN N
, , N
rose VBD N
almost RB N
linearly JJ N
in IN N
relation NN N
to TO N
dose VB N
. . N

Oral NNP N
ISDN NNP N
thus RB N
has VBZ N
a DT N
dose-dependent JJ N
effect NN N
on IN N
the DT N
frequency NN 1_o
of IN 1_o
angina NN 1_o
and CC 1_o
ischaemia NN 1_o
parameters NNS 1_o
during IN N
ergometric JJ N
exercise NN N
. . N

The DT N
protracted JJ N
anti-anginal JJ 1_o
effect NN 1_o
of IN N
ISDN NNP N
is VBZ N
largely RB N
due JJ N
to TO N
its PRP$ N
metabolites NNS N
. . N

At IN N
high JJ N
doses NNS N
there EX N
is VBZ N
presumably RB N
an DT N
added JJ N
effect NN N
of IN N
the DT N
high JJ N
blood NN N
level NN N
of IN N
the DT N
basic JJ N
substance.U NN N
-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
the DT N
recovery NN 1_o
times NNS 1_o
of IN N
desflurane NN 1_i
and CC N
isoflurane NN 1_i
in IN N
outpatient JJ 1_p
anesthesia NN 1_p
. . 1_p

The DT N
low JJ N
solubility NN N
of IN N
desflurane NN 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
contribute VB N
to TO N
faster VB N
awakening VBG N
from IN N
anesthesia NN N
when WRB N
compared VBN N
with IN N
other JJ N
anesthetics NNS N
in IN N
common JJ N
use NN N
. . N

However RB N
, , N
research NN N
has VBZ N
failed VBN N
to TO N
consistently RB N
demonstrate VB N
faster RBR N
discharge NN N
times NNS N
from IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
following VBG N
the DT N
use NN N
of IN N
desflurane NN 1_i
. . 1_i

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
recovery NN 1_o
and CC 1_o
discharge NN 1_o
times NNS 1_o
of IN N
outpatients NNS 1_p
undergoing VBG 1_p
procedures NNS 1_p
greater JJR 1_p
than IN 1_p
2 CD 1_p
hours NNS 1_p
in IN 1_p
length NN 1_p
. . 1_p

Thirty-three JJ 1_p
patients NNS 1_p
aged VBD 1_p
18 CD 1_p
to TO 1_p
70 CD 1_p
years NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
desflurane NN 1_i
or CC N
isoflurane NN 1_i
following VBG N
a DT N
standard JJ N
intravenous JJ N
induction NN N
with IN N
propofol NN 1_i
. . 1_i

Patients NNS 1_p
received VBD N
premedication NN N
and CC N
opioids NNS N
consistent JJ N
with IN N
institutional JJ N
practice NN N
, , N
and CC N
inhalation NN N
agents NNS N
were VBD N
titrated VBN N
to TO N
effect NN N
during IN N
anesthetic JJ N
maintenance NN N
. . N

Following VBG N
surgery NN N
, , N
patients NNS 1_p
were VBD N
evaluated VBN N
for IN N
time NN 1_o
to TO 1_o
emergence VB 1_o
and CC 1_o
time NN 1_o
to TO 1_o
meeting VBG 1_o
discharge JJ 1_o
criteria NNS 1_o
. . 1_o

The DT N
results NNS N
demonstrated VBD N
no DT N
differences NNS N
between IN N
the DT N
emergence NN N
or CC N
discharge NN N
times NNS N
following VBG N
desflurane NN 1_i
or CC N
isoflurane NN 1_i
. . 1_i

In IN N
addition NN N
, , N
measured VBD N
parameters NNS N
, , N
such JJ N
as IN N
intraoperative JJ 1_o
vital JJ 1_o
signs NNS 1_o
and CC 1_o
postoperative JJ 1_o
emesis NN 1_o
and CC 1_o
opioid NN 1_o
requirements NNS 1_o
, , N
were VBD N
not RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

The DT N
use NN N
of IN N
desflurane NN 1_i
as IN N
part NN N
of IN N
a DT N
balanced JJ N
anesthetic JJ N
technique NN N
did VBD N
not RB N
speed VB N
the DT N
emergence NN N
or CC N
discharge NN 1_o
time NN 1_o
when WRB N
compared VBN N
with IN N
isoflurane NN 1_i
. . 1_i

-DOCSTART- -X- O O

Endoscopic NNP 1_i
ligation NN 1_i
compared VBN N
with IN N
sclerotherapy NN 1_i
for IN N
bleeding VBG 1_o
esophageal JJ 1_o
varices NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
extrahepatic JJ 1_p
portal NN 1_p
venous JJ 1_p
obstruction NN 1_p
. . 1_p

Endoscopic NNP 1_i
sclerotherapy NN 1_i
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
bleeding VBG 1_o
esophageal JJ 1_o
varices NNS 1_o
, , N
but CC N
it PRP N
is VBZ N
associated VBN N
with IN N
significant JJ 1_o
complications NNS 1_o
. . 1_o

Endoscopic NNP 1_i
ligation NN 1_i
, , N
a DT N
new JJ N
form NN N
of IN N
endoscopic NN N
treatment NN N
for IN N
bleeding VBG 1_o
varices NNS 1_o
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
superior JJ N
to TO N
sclerotherapy VB N
in IN N
adult NN 1_p
patients NNS 1_p
with IN 1_p
cirrhosis NN 1_p
. . 1_p

To TO N
determine VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
endoscopic JJ N
sclerotherapy NN N
and CC N
ligation NN N
, , N
the DT N
2 CD N
methods NNS N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
control NN N
trial NN N
in IN N
49 CD 1_p
children NNS 1_p
with IN 1_p
extrahepatic JJ 1_p
portal NN 1_p
venous JJ 1_p
obstruction NN 1_p
who WP 1_p
had VBD 1_p
proven VBN 1_p
bleeding VBG 1_p
from IN 1_p
esophageal JJ 1_p
varices NNS 1_p
. . 1_p

Twenty-four CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
sclerotherapy NN 1_i
and CC 1_p
25 CD 1_p
with IN 1_p
band NN 1_i
ligation NN 1_i
. . 1_i

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
sclerotherapy NN N
and CC N
ligation NN N
groups NNS N
in IN N
arresting VBG 1_o
active JJ 1_o
index NN 1_o
bleeding NN 1_o
( ( N
100 CD N
% NN N
each DT N
) ) N
and CC N
achieving VBG 1_o
variceal JJ 1_o
eradication NN 1_o
( ( N
91.7 CD N
% NN N
vs. FW N
96 CD N
% NN N
, , N
P NNP N
=.61 NNP N
) ) N
. . N

Band NNP N
ligation NN N
eradicated VBD N
varices NNS 1_o
in IN N
fewer JJR N
endoscopic NN 1_o
sessions NNS 1_o
than IN N
did VBD N
sclerotherapy VB N
( ( N
3.9 CD N
+/- JJ N
1.1 CD N
vs. FW N
6.1 CD N
+/- JJ N
1.7 CD N
, , N
respectively RB N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

The DT N
rebleeding VBG 1_o
rate NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
sclerotherapy NN N
group NN N
( ( N
25 CD N
% NN N
vs. FW N
4 CD N
% NN N
, , N
P NNP N
=.049 NNP N
) ) N
, , N
as IN N
was VBD N
the DT N
rate NN 1_o
of IN 1_o
major JJ 1_o
complications NNS 1_o
( ( N
25 CD N
% NN N
vs. FW N
4 CD N
% NN N
, , N
P NNP N
=.049 NNP N
) ) N
. . N

After IN N
eradication NN N
, , N
esophageal JJ 1_o
variceal NN 1_o
recurrence NN 1_o
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
patients NNS N
treated VBN N
by IN N
ligation NN N
than IN N
by IN N
sclerotherapy NN N
( ( N
17.4 CD N
% NN N
vs. FW N
10 CD N
% NN N
, , N
P NNP N
=.67 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
variceal JJ 1_i
band NN 1_i
ligation NN 1_i
in IN N
children NNS 1_p
is VBZ N
a DT N
safe JJ 1_o
and CC 1_o
effective JJ 1_o
technique NN N
that WDT N
achieves VBZ N
variceal JJ 1_o
eradication NN 1_o
more RBR N
quickly RB N
, , N
with IN N
a DT N
lower JJR N
rebleeding NN 1_o
rate NN 1_o
and CC N
fewer JJR N
complications NNS 1_o
compared VBN N
with IN N
sclerotherapy NN N
. . N

-DOCSTART- -X- O O

Randomised VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
study NN N
of IN N
fluticasone NN 1_i
propionate NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
: : 1_p
the DT N
ISOLDE NNP N
trial NN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
long JJ N
term NN N
inhaled VBN N
corticosteroids NNS 1_i
on IN N
lung NN 1_o
function NN 1_o
, , 1_o
exacerbations NNS 1_o
, , 1_o
and CC 1_o
health NN 1_o
status NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
. . 1_p

DESIGN NNP N
Double NNP N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
study NN N
. . N

SETTING NNP N
Eighteen NNP 1_p
UK NNP 1_p
hospitals NNS 1_p
. . 1_p

PARTICIPANTS VB N
751 CD 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
aged VBD 1_p
between IN 1_p
40 CD 1_p
and CC 1_p
75 CD 1_p
years NNS 1_p
with IN 1_p
mean NN 1_p
forced JJ 1_p
expiratory NN 1_p
volume NN 1_p
in IN 1_p
one CD 1_p
second NN 1_p
( ( 1_p
FEV NNP 1_p
( ( 1_p
1 CD 1_p
) ) 1_p
) ) 1_p
50 CD 1_p
% NN 1_p
of IN 1_p
predicted VBN 1_p
normal JJ 1_p
. . 1_p

INTERVENTIONS NNP N
Inhaled VBD N
fluticasone NN 1_i
propionate NN 1_i
500 CD 1_i
microgram NN 1_i
twice RB 1_i
daily RB 1_i
from IN 1_i
a DT 1_i
metered VBN 1_i
dose JJ 1_i
inhaler NN 1_i
or CC 1_i
identical JJ 1_i
placebo NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP 1_o
measures NNS N
: : N
rate NN 1_o
of IN 1_o
decline NN 1_o
in IN 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
after IN 1_o
the DT 1_o
bronchodilator NN 1_o
and CC 1_o
in IN 1_o
health NN 1_o
status NN 1_o
, , 1_o
frequency NN 1_o
of IN 1_o
exacerbations NNS 1_o
, , 1_o
respiratory JJ 1_o
withdrawals NNS 1_o
. . 1_o

Safety NN N
measures NNS N
: : N
morning NN 1_o
serum NN 1_o
cortisol NN 1_o
concentration NN 1_o
, , 1_o
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
. . 1_o

RESULTS NNP N
There EX N
was VBD N
no DT 1_o
significant JJ 1_o
difference NN 1_o
in IN N
the DT N
annual JJ 1_o
rate NN 1_o
of IN 1_o
decline NN 1_o
in IN 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
( ( 1_o
P=0.16 NNP 1_o
) ) 1_o
. . N

Mean JJ 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
after IN N
bronchodilator NN N
remained VBD N
significantly RB 1_o
higher JJR 1_o
throughout IN N
the DT N
study NN N
with IN N
fluticasone NN 1_i
propionate NN 1_i
compared VBN N
with IN N
placebo NN 1_i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Median JJ 1_o
exacerbation NN 1_o
rate NN 1_o
was VBD N
reduced VBN 1_o
by IN N
25 CD N
% NN N
from IN N
1.32 CD N
a DT N
year NN N
on IN N
placebo NN 1_i
to TO N
0.99 CD N
a DT N
year NN N
on IN N
with IN N
fluticasone NN 1_i
propionate NN 1_i
( ( N
P=0.026 NNP N
) ) N
. . N

Health NNP 1_o
status NN 1_o
deteriorated VBN 1_o
by IN N
3.2 CD N
units NNS N
a DT N
year NN N
on IN N
placebo NN 1_i
and CC N
2.0 CD N
units NNS N
a DT N
year NN N
on IN N
fluticasone NN 1_i
propionate NN 1_i
( ( N
P=0.0043 NNP N
) ) N
. . N

Withdrawals NNS 1_o
because IN N
of IN N
respiratory NN N
disease NN N
not RB N
related VBN N
to TO N
malignancy NN N
were VBD N
higher JJR N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
25 CD N
% NN N
v JJ N
19 CD N
% NN N
, , N
P=0.034 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Fluticasone NNP 1_i
propionate NN 1_i
500 CD N
microgram NN N
twice RB N
daily RB N
did VBD N
not RB N
affect VB N
the DT N
rate NN 1_o
of IN 1_o
decline NN 1_o
in IN 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
but CC N
did VBD N
produce VB 1_o
a DT 1_o
small JJ 1_o
increase NN 1_o
in IN 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
. . 1_o

Patients NNS N
on IN N
fluticasone NN 1_i
propionate NN 1_i
had VBD N
fewer JJR N
exacerbations NNS 1_o
and CC N
a DT N
slower JJR 1_o
decline NN 1_o
in IN 1_o
health NN 1_o
status NN 1_o
. . 1_o

These DT N
improvements NNS N
in IN N
clinical JJ N
outcomes NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
. . 1_p

-DOCSTART- -X- O O

Anemia NNP N
and CC N
associated VBN N
clinical JJ N
outcomes NNS N
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
due JJ 1_p
to TO 1_p
reduced VB 1_p
left JJ 1_p
ventricular JJ 1_p
systolic JJ 1_p
function NN 1_p
. . 1_p

BACKGROUND NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
decreased JJ N
functional JJ N
capacity NN N
, , N
reduced VBD N
quality NN N
of IN N
life NN N
, , N
and CC N
worsened VBD N
outcomes NNS N
among IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
HF NNP 1_p
) ) 1_p
due JJ 1_p
to TO 1_p
reduced VB 1_p
left JJ 1_p
ventricular JJ 1_p
ejection NN 1_p
fraction NN 1_p
( ( 1_p
HFREF NNP 1_p
) ) 1_p
. . 1_p

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
independent JJ N
effect NN N
of IN N
anemia NN N
on IN N
clinical JJ N
outcomes NNS N
among IN N
those DT 1_p
with IN 1_p
HFREF NNP 1_p
. . 1_p

HYPOTHESIS NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
cardiovascular JJ N
events NNS N
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

METHODS PDT N
The DT N
HF-ACTION NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
exercise NN 1_i
therapy NN 1_i
vs NN 1_i
usual JJ 1_i
care NN 1_i
in IN N
2331 CD 1_p
patients NNS 1_p
with IN 1_p
HFREF NNP 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
New NNP 1_p
York NNP 1_p
Heart NNP 1_p
Association NNP 1_p
class NN 1_p
II NNP 1_p
to TO 1_p
IV NNP 1_p
HF NNP 1_p
and CC 1_p
left VBD 1_p
ventricular JJ 1_p
ejection NN 1_p
fractions NNS 1_p
of IN 1_p
? . 1_p
35 CD 1_p
% NN 1_p
were VBD 1_p
recruited VBN 1_o
. . 1_o

Hemoglobin NNP 1_o
( ( 1_o
Hb NNP 1_o
) ) 1_o
was VBD 1_o
measured VBN N
up RB N
to TO N
1 CD N
year NN N
prior RB N
to TO N
entry NN N
and CC N
was VBD N
stratified VBN N
by IN N
quintile NN 1_o
. . 1_o

Anemia NNP 1_o
was VBD 1_o
defined VBN N
as IN N
baseline NN 1_p
Hb NNP 1_p
< VBZ 1_p
13 CD 1_p
g/dL NN 1_p
and CC 1_p
< $ 1_p
12 CD 1_p
g/dL NN 1_p
in IN 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
, , 1_p
respectively RB 1_o
. . 1_o

Hemoglobin NNP 1_o
was VBD 1_o
assessed VBN N
in IN N
2 CD N
models NNS N
: : N
a DT N
global JJ N
prediction NN N
model NN N
that WDT N
had VBD N
been VBN N
previously RB N
developed VBN N
, , N
and CC N
a DT N
modified JJ N
model NN N
including VBG N
variables NNS N
associated VBN N
with IN N
anemia NN N
and CC N
the DT N
studied JJ N
outcomes NNS N
. . N

RESULTS NNP 1_o
Hemoglobin NNP 1_o
was VBD 1_o
available JJ N
at IN N
baseline NN N
in IN N
1763 CD 1_p
subjects NNS 1_p
( ( 1_p
76 CD 1_p
% NN 1_p
of IN 1_p
total JJ 1_p
study NN 1_p
population NN 1_p
) ) 1_p
; : 1_p
their PRP$ 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
59.0 CD 1_p
years NNS 1_p
, , 1_p
73 CD 1_p
% NN 1_p
were VBD 1_p
male JJ 1_p
, , 1_p
and CC 1_p
62 CD 1_p
% NN 1_p
were VBD 1_p
Caucasian JJ 1_p
. . 1_p

The DT N
prevalence NN N
of IN N
anemia NN N
was VBD N
515/1763 CD N
( ( N
29 CD N
% NN N
) ) N
. . N

Older JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
African JJ N
American NNP N
race NN N
, , N
diabetes VBZ N
, , N
hypertension NN N
, , N
and CC N
lower JJR N
estimated VBN N
glomerular JJ N
filtration NN N
rates NNS N
were VBD N
all DT N
more RBR N
frequent JJ N
in IN N
lower JJR N
Hb NNP N
quintiles NNS N
. . N

Over IN N
a DT N
median JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ 1_o
mortality NN 1_o
or CC 1_o
all-cause JJ 1_o
hospitalization NN 1_o
occurred VBD 1_o
in IN N
78 CD N
% NN N
of IN N
those DT N
with IN N
anemia NN N
and CC N
64 CD N
% NN N
in IN N
those DT N
without IN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
secondary JJ N
outcomes NNS N
of IN N
all-cause JJ 1_o
mortality NN 1_o
alone RB 1_o
, , 1_o
cardiovascular JJ 1_o
( ( 1_o
CV NNP 1_o
) ) 1_o
mortality NN 1_o
or CC 1_o
CV NNP 1_o
hospitalization NN 1_o
, , 1_o
and CC 1_o
CV NNP 1_o
mortality NN 1_o
or CC 1_o
HF NNP 1_o
hospitalization NN 1_o
occurred VBD 1_o
in IN N
23 CD N
% NN N
vs JJ N
15 CD N
% NN N
, , N
67 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
and CC N
44 CD N
vs NNS N
29 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD 1_o
) ) 1_o
. . 1_o

Heart NNP 1_o
failure NN 1_o
hospitalizations NNS 1_o
occurred VBD 1_o
in IN N
36 CD N
% NN N
vs JJ N
22 CD N
% NN N
, , N
and CC 1_o
urgent JJ 1_o
outpatient NN 1_o
visits NNS 1_o
for IN 1_o
HF NNP 1_o
exacerbations NNS 1_o
occurred VBD 1_o
in IN N
67 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
the DT N
global JJ N
model NN N
, , N
there EX N
was VBD N
an DT N
association NN N
observed VBD N
for IN N
anemia NN N
and CC 1_o
all-cause JJ 1_o
mortality NN 1_o
or CC 1_o
hospitalization NN 1_o
( ( 1_o
adjusted VBN N
hazard RB N
ratio JJ N
[ NNP N
HR NNP N
] NN N
: : N
1.15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.01-1.32 JJ N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
but CC N
other JJ N
outcomes NNS N
were VBD N
not RB N
significant JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

In IN N
the DT N
modified JJ N
model NN N
, , N
the DT N
adjusted JJ 1_o
HR NNP 1_o
for IN 1_o
anemia NN N
and CC N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ N
mortality NN N
or CC N
all-cause JJ N
hospitalization NN N
was VBD N
1.25 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.10-1.42 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
independent JJ N
associations NNS N
between IN 1_o
anemia NN 1_o
and CC 1_o
all-cause JJ 1_o
death NN 1_o
( ( 1_o
HR NNP N
: : N
1.11 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.87-1.42 JJ N
, , N
P NNP N
= NNP N
0.38 CD 1_o
) ) 1_o
, , 1_o
CV NNP 1_o
death NN 1_o
or CC 1_o
CV NNP 1_o
hospitalization NN 1_o
( ( 1_o
HR NNP N
: : N
1.16 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.33 JJ N
, , N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
and CC N
CV NNP N
death NN N
and CC 1_o
HF NNP 1_o
hospitalization NN 1_o
( ( 1_o
HR NNP N
: : N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.06-1.51 JJ N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSIONS NNP N
Anemia NNP N
modestly RB N
is VBZ N
associated VBN N
with IN N
increased JJ N
rates NNS N
of IN N
death NN N
, , N
hospitalization NN N
, , N
and CC N
HF NNP N
exacerbation NN N
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
HFREF NNP 1_p
. . 1_p

After IN N
adjusting VBG N
for IN N
other JJ N
important JJ N
covariates NNS N
, , N
anemia NN N
is VBZ N
independently RB N
associated VBN N
with IN N
an DT N
excess JJ N
hazard NN N
for IN N
all-cause JJ N
mortality NN N
and CC N
all-cause JJ N
hospitalization NN N
. . N

Anemia NNP N
is VBZ N
also RB N
associated VBN N
with IN N
combinations NNS N
of IN N
CV NNP N
death NN N
and CC N
CV/HF NNP N
hospitalizations NNS N
as IN N
composite JJ N
endpoints NNS N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
postprocedure NN N
cognitive JJ 1_o
function NN 1_o
using VBG N
3 CD N
distinct JJ N
standard JJ N
sedation NN 1_i
regimens NNS 1_i
for IN N
endoscopic NN N
procedures NNS N
. . N

The DT N
primary JJ N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
postprocedure NN 1_o
cognitive JJ 1_o
function NN 1_o
associated VBN N
with IN N
3 CD N
distinct JJ N
standard JJ 1_i
sedation NN 1_i
regimens NNS 1_i
used VBN N
for IN N
endoscopic NN 1_p
procedures NNS 1_p
. . 1_p

A DT N
secondary JJ N
aim NN N
was VBD N
to TO N
identify VB N
complications NNS N
requiring VBG N
provider NN N
interventions NNS N
. . N

Subjects NNS 1_p
scheduled VBN 1_p
for IN 1_p
colonoscopies NNS 1_p
were VBD N
approached VBN N
for IN N
enrollment NN N
the DT N
day NN N
of IN N
their PRP$ N
procedure NN N
. . N

A DT N
convenience NN 1_p
sample NN 1_p
of IN 1_p
96 CD 1_p
subjects NNS 1_p
was VBD N
randomly RB N
assigned VBN N
. . N

Cognitive JJ N
function NN N
was VBD N
recorded VBN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
using VBG N
the DT N
Mini-Mental JJ 1_i
State NNP 1_i
Examination NNP 1_i
( ( N
MMSE NNP N
) ) N
and CC N
24 CD N
and CC N
48 CD N
hours NNS N
postoperatively RB N
using VBG N
the DT N
Telephone NNP 1_o
Interview NNP 1_o
of IN 1_o
Cognitive NNP 1_o
Status NNP 1_o
( ( 1_o
TICS NNP 1_o
) ) 1_o
. . 1_o

The DT N
propofol JJ 1_i
plus CC 1_i
fentanyl JJ 1_i
group NN N
had VBD N
a DT N
mean JJ 1_o
TICS NNP 1_o
score NN 1_o
of IN N
34.53 CD N
at IN N
24 CD N
hours NNS N
compared VBN N
with IN N
34.96 CD N
at IN N
48 CD N
hours NNS N
( ( N
P NNP N
= NNP N
.017 NNP N
) ) N
. . N

The DT N
midazolam NN 1_i
plus CC 1_i
fentanyl JJ 1_i
group NN N
had VBD N
a DT N
mean JJ 1_o
TICS NNP 1_o
score NN 1_o
of IN N
34.76 CD N
at IN N
24 CD N
hours NNS N
compared VBN N
with IN N
36.26 CD N
at IN N
48 CD N
hours NNS N
( ( N
P NNP N
= NNP N
.004 NNP N
) ) N
. . N

The DT N
propofol-alone JJ 1_i
group NN N
had VBD N
a DT N
mean JJ 1_o
TICS NNP 1_o
score NN 1_o
of IN N
35.09 CD N
at IN N
24 CD N
hours NNS N
compared VBN N
with IN N
35.98 CD N
at IN N
48 CD N
hours NNS N
( ( N
P NNP N
= NNP N
.924 NNP N
) ) N
. . N

The DT N
results NNS N
of IN N
this DT N
investigation NN N
indicate VBP N
that IN N
the DT N
sedation NN N
regimen NNS N
of IN N
propofol NN 1_i
alone RB N
has VBZ N
the DT N
least JJS N
impact NN N
on IN N
postprocedure NN 1_o
cognitive JJ 1_o
function NN 1_o
. . 1_o

Additionally RB N
, , N
the DT N
number NN 1_o
of IN 1_o
jaw JJ 1_o
lift NN 1_o
interventions NNS 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
both DT N
groups NNS N
who WP N
received VBD N
fentanyl NN 1_i
. . 1_i

-DOCSTART- -X- O O

Treatment NN N
with IN N
the DT N
dipeptidyl JJ 1_i
peptidase-4 JJ 1_i
inhibitor NN 1_i
vildagliptin NN 1_i
improves VBZ N
fasting VBG N
islet-cell JJ N
function NN N
in IN N
subjects NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
. . 1_p

CONTEXT NNP N
Dipeptidyl NNP 1_i
peptidase NN 1_i
4 CD 1_i
( ( 1_i
DPP-4 NNP 1_i
) ) 1_i
inhibitors NNS 1_i
are VBP N
proposed VBN N
to TO N
lower VB N
blood NN N
glucose NN N
in IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
mellitus FW 1_p
( ( 1_p
T2DM NNP 1_p
) ) 1_p
by IN N
prolonging VBG N
the DT N
activity NN N
of IN N
the DT N
circulating NN N
incretins NNS N
, , N
glucose-dependent JJ N
insulinotropic NN N
polypeptide NN N
( ( N
GIP NNP N
) ) N
and CC N
glucagon-like JJ N
peptide NN N
1 CD N
( ( N
GLP-1 NNP N
) ) N
. . N

Consistent JJ N
with IN N
this DT N
mechanism NN N
of IN N
action NN N
, , N
DPP-4 NNP 1_i
inhibitors NNS 1_i
improve VBP N
glucose JJ N
tolerance NN N
after IN N
meals NNS N
by IN N
increasing VBG N
insulin NN N
and CC N
reducing VBG N
glucagon NN N
levels NNS N
in IN N
the DT N
plasma NN N
. . N

However RB N
, , N
DPP-4 NNP 1_i
inhibitors NNS 1_i
also RB N
reduce VB N
fasting VBG N
blood NN N
glucose NN N
, , N
an DT N
unexpected JJ N
effect NN N
because IN N
circulating VBG N
levels NNS N
of IN N
active JJ N
GIP NNP N
and CC N
GLP-1 NNP N
are VBP N
low JJ N
in IN N
the DT N
postabsorptive JJ N
state NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS 1_o
of IN 1_o
DPP-4 NNP 1_o
inhibition NN 1_o
on IN 1_o
fasting VBG 1_o
islet NN 1_o
function NN 1_o
. . 1_o

DESIGN NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

SETTING VB N
The DT N
study NN N
was VBD N
performed VBN N
in IN N
General NNP 1_p
Clinical NNP 1_p
Research NNP 1_p
Centers NNPS 1_p
at IN 1_p
two CD 1_p
University NNP 1_p
Hospitals NNP 1_p
. . 1_p

SUBJECTS NNP N
Forty-one JJ 1_p
subjects NNS 1_p
with IN 1_p
T2DM NNP 1_p
were VBD N
treated VBN N
with IN N
metformin NN 1_i
or CC N
diet NN 1_i
, , N
having VBG N
good JJ N
glycemic NNS N
control NN N
with IN N
glycosylated JJ N
hemoglobin NN N
values NNS N
of IN N
6.2-7.5 JJ N
% NN N
. . N

INTERVENTION JJ N
Subjects NNPS N
were VBD N
treated VBN N
with IN N
vildagliptin NN 1_i
( ( N
50 CD N
mg NN N
twice RB N
daily RB N
) ) N
or CC N
placebo NN 1_i
for IN N
3 CD N
months NNS N
, , N
followed VBN N
by IN N
a DT N
2-wk JJ N
washout NN N
. . N

Major JJ N
Outcome JJ N
Measure NN N
: : N
We PRP N
measured VBD N
insulin JJ 1_o
secretion NN 1_o
in IN 1_o
response NN 1_o
to TO 1_o
iv VB 1_o
glucose JJ 1_o
and CC 1_o
arginine JJ 1_o
before NN N
and CC N
after IN N
treatment NN N
and CC N
after IN N
drug NN N
washout NN N
. . N

RESULTS CC N
There EX N
were VBD N
small JJ N
and CC N
comparable JJ N
reductions NNS N
in IN N
glycosylated JJ 1_o
hemoglobin NN 1_o
in IN N
both DT N
groups NNS N
over IN N
3 CD N
months NNS N
. . N

Vildagliptin NNP N
increased VBD N
fasting VBG N
GLP-1 NNP 1_o
levels NNS N
in IN N
subjects NNS N
taking VBG N
metformin NN 1_i
, , N
but CC N
not RB N
those DT N
managed VBN N
with IN N
diet JJ 1_i
, , N
and CC N
raised VBD N
active JJ N
GIP NNP N
levels NNS N
slightly RB N
. . N

DPP-4 JJ 1_i
inhibitor NN 1_i
treatment NN N
improved VBD N
the DT N
acute JJ 1_o
insulin NN 1_o
and CC 1_o
C-peptide JJ 1_o
responses NNS 1_o
to TO N
glucose VB N
( ( N
50 CD N
and CC N
100 CD N
% NN N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
increased VBD N
the DT N
slope NN N
of IN N
the DT N
C-peptide NNP 1_o
response NN 1_o
to TO N
glucose VB N
( ( N
33 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

CONCLUSION NNP N
Vildagliptin NNP 1_i
improves VBZ N
islet JJ N
function NN N
in IN N
T2DM NNP N
under IN N
fasting VBG N
conditions NNS N
. . N

This DT N
suggests VBZ N
that IN N
DPP-4 NNP N
inhibition NN N
has VBZ N
metabolic JJ N
benefits NNS N
in IN N
addition NN N
to TO N
enhancing VBG N
meal-induced JJ N
GLP-1 NNP N
and CC N
GIP NNP N
activity NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
radiotherapy NN 1_i
on IN N
blood NN 1_o
lymphocyte JJ 1_o
population NN 1_o
in IN 1_p
mammary JJ 1_p
carcinoma NN 1_p
. . 1_p

-DOCSTART- -X- O O

Family-centred JJ 1_i
music NN 1_i
therapy NN 1_i
to TO N
promote VB N
social JJ 1_o
engagement NN 1_o
in IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
severe JJ 1_p
autism NN 1_p
spectrum JJ 1_p
disorder NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

BACKGROUND NNP N
Limited NNP N
capacity NN N
for IN N
social JJ N
engagement NN N
is VBZ N
a DT N
core NN N
feature NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
often RB N
evident JJ N
early JJ N
in IN N
the DT N
child NN N
's POS N
development NN N
. . N

While IN N
these DT N
skills NNS N
are VBP N
difficult JJ N
to TO N
train VB N
, , N
there EX N
is VBZ N
some DT N
evidence NN N
that IN N
active JJ N
involvement NN N
in IN N
music-making JJ N
provides VBZ N
unique JJ N
opportunities NNS N
for IN N
social JJ N
interaction NN N
between IN N
participants NNS N
. . N

Family-centred JJ 1_i
music NN 1_i
therapy NN 1_i
( ( 1_i
FCMT NNP 1_i
) ) 1_i
endeavours VBZ N
to TO N
support VB N
social JJ N
engagement NN N
between IN N
child NN N
and CC N
parent NN N
within IN N
active JJ N
music-making NN N
, , N
yet CC N
the DT N
extent NN N
of IN N
benefits NNS N
provided VBN N
is VBZ N
unknown JJ N
. . N

AIM VB N
This DT N
study NN N
investigated VBD N
the DT N
impacts NNS N
of IN N
FCMT NNP 1_i
on IN N
social JJ N
engagement NN N
abilities NNS N
. . N

METHODS NNP N
Twenty-three JJ 1_p
children NNS 1_p
( ( 1_p
36-60 JJ 1_p
months NNS 1_p
) ) 1_p
with IN 1_p
severe JJ 1_p
ASD NNP 1_p
received VBD 1_p
either RB 1_p
16 CD 1_i
weeks NNS 1_i
of IN 1_i
FCMT NNP 1_i
in IN 1_i
addition NN 1_i
to TO 1_i
their PRP$ 1_i
early JJ 1_i
intervention NN 1_i
programmes NNS 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
12 CD 1_i
) ) 1_i
, , 1_i
or CC 1_i
their PRP$ 1_i
early JJ 1_i
intervention NN 1_i
programme IN 1_i
only RB 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
11 CD 1_i
) ) 1_i
. . 1_i

Change NN N
in IN N
social JJ N
engagement NN N
was VBD N
measured VBN N
with IN N
standardized JJ 1_o
parent-report JJ 1_o
assessments NNS 1_o
, , 1_o
parent NN 1_o
interviews NNS 1_o
and CC 1_o
clinician JJ 1_o
observation NN 1_o
. . 1_o

RESULTS NNP N
Intention-to-treat JJ N
analysis NN N
for IN N
the DT N
Vineland NNP 1_o
Social NNP 1_o
Emotional NNP 1_o
Early NNP 1_o
Childhood NNP 1_o
Scale NNP 1_o
indicated VBD N
a DT N
significant JJ N
effect NN N
in IN N
favour NN N
of IN N
FCMT NNP 1_i
. . 1_i

Thematic NNP N
qualitative JJ N
analysis NN N
of IN N
the DT N
parent NN N
interviews NNS N
showed VBD N
that IN N
the DT N
parent-child JJ N
relationship NN N
grew VBD N
stronger JJR N
. . N

CONCLUSION NNP N
FCMT NNP 1_i
improves VBZ N
social JJ N
interactions NNS N
in IN N
the DT N
home NN N
and CC N
community NN N
and CC N
the DT N
parent-child JJ N
relationship NN N
, , N
but CC N
not RB N
language NN N
skills NNS N
or CC N
general JJ N
social JJ N
responsiveness NN N
. . N

This DT N
study NN N
provides VBZ N
preliminary JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
FCMT NNP 1_i
to TO N
promote VB N
social JJ N
engagement NN N
in IN N
children NNS 1_p
with IN 1_p
severe JJ 1_p
ASD NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Parenting VBG 1_o
stress NN 1_o
in IN 1_p
the DT 1_p
infant JJ 1_p
aphakia NN 1_p
treatment NN 1_p
study NN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
parenting VBG 1_p
stress NN 1_p
following VBG 1_p
infants NNS 1_p
' POS 1_p
cataract NN 1_i
extraction NN 1_i
surgery NN 1_i
, , N
and CC N
to TO N
determine VB N
if IN N
levels NNS N
of IN N
stress NN N
differ NN N
between IN N
2 CD N
treatments NNS N
for IN N
unilateral JJ 1_o
congenital JJ 1_o
cataract NN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
At IN N
surgery NN N
, , N
an DT N
intraocular JJ 1_i
lens NNS 1_i
( ( 1_i
IOL NNP 1_i
) ) 1_i
was VBD 1_i
implanted VBN 1_i
or CC N
children NNS N
were VBD N
left VBN 1_i
aphakic NN 1_i
, , 1_i
treated VBD 1_i
with IN 1_i
contact NN 1_i
lens NNS 1_i
( ( 1_i
CL NNP 1_i
) ) 1_i
. . 1_i

Stress JJ N
measures NNS N
were VBD N
administered VBN N
3 CD N
months NNS N
after IN N
surgery NN N
and CC N
at IN N
the DT N
first JJ N
visit NN N
after IN N
the DT N
visual JJ N
acuity NN N
( ( N
VA NNP N
) ) N
assessment NN N
done VBN N
at IN N
12 CD N
months NNS N
of IN N
age NN N
. . N

RESULTS NNP N
Caregivers NNPS 1_p
in IN N
the DT N
IOL NNP 1_i
group NN N
reported VBD N
higher JJR N
levels NNS N
of IN N
stress NN 1_o
than IN N
those DT N
in IN N
the DT N
CL NNP 1_i
group NN N
3 CD N
months NNS N
after IN N
surgery NN N
, , N
but CC N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
stress NN 1_o
scores NNS 1_o
at IN N
the DT N
post-VA JJ 1_o
assessment NN 1_o
. . 1_o

Stress NNP 1_o
scores NNS 1_o
did VBD N
not RB N
change VB N
differentially RB N
for IN N
participants NNS N
assigned VBN N
to TO N
IOL NNP 1_i
versus NN N
CL NNP 1_i
treatments NNS N
. . N

CONCLUSIONS NNP N
Treatment NNP N
assignment NN N
did VBD N
not RB N
have VB N
a DT N
significant JJ N
impact NN N
on IN N
caregiver NN 1_o
stress NN 1_o
during IN 1_p
infancy NN 1_p
or CC N
on IN N
the DT N
change NN N
in IN N
stress NN N
during IN N
the DT N
child NN N
's POS N
first JJ N
2 CD N
years NNS N
of IN N
life NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
peer NN 1_i
counseling VBG 1_i
on IN N
smoking VBG N
cessation NN 1_o
and CC N
reduction NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
a DT N
peer NN 1_i
counseling VBG 1_i
intervention NN 1_i
for IN N
pregnant JJ 1_p
smokers NNS 1_p
. . 1_p

METHODS NNP N
One CD 1_p
hundred VBD 1_p
forty-two NN 1_p
pregnant NN 1_p
, , 1_p
predominantly RB 1_p
Hispanic JJ 1_p
women NNS 1_p
were VBD N
assigned VBN N
to TO N
a DT N
peer-led JJ 1_i
smoking NN 1_i
cessation NN 1_i
program NN 1_i
or CC 1_i
to TO 1_i
usual JJ 1_i
care NN 1_i
. . 1_i

RESULTS NNP N
Compared VBD N
with IN N
usual JJ 1_i
care NN 1_i
, , 1_i
peer NN 1_i
counseling NN 1_i
reduced VBN N
smoking NN N
( ( N
-9.1 JJ N
versus NN N
-4.5 NNP N
cigarettes VBZ N
daily RB N
, , N
P NNP N
=.03 NNP N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
absolute JJ N
quit NN 1_o
rates NNS 1_o
( ( N
24 CD N
% NN N
versus IN N
21 CD N
% NN N
) ) N
at IN N
36 CD N
weeks NNS N
' POS N
gestation NN N
. . N

Infant NNP 1_o
birth NN 1_o
weight VBD 1_o
negatively RB N
correlated VBN N
with IN N
cigarettes NNS N
smoked VBN N
per IN N
day NN N
( ( N
r VB N
= NNP N
-0.29 NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
expired JJ N
carbon NN N
monoxide NN N
( ( N
r JJ N
= NNP N
-0.39 NN N
, , N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
delivery NN N
. . N

Birth NNP 1_o
weight VBD 1_o
for IN 1_o
infants NNS 1_o
born VBN 1_o
to TO 1_o
women NNS 1_o
who WP 1_o
quit VBP 1_o
smoking VBG 1_o
averaged VBD N
7.2 CD N
lb JJ N
versus NN N
6.8 CD N
and CC N
6.3 CD N
lb NN N
for IN N
mothers NNS N
smoking VBG N
one CD N
to TO N
six CD N
and CC N
more JJR N
than IN N
six CD N
cigarettes NNS N
per IN N
day NN N
at IN N
delivery NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSION NNP N
Peer NNP 1_o
counseling NN 1_o
reduced VBD N
the DT N
number NN 1_o
of IN 1_o
cigarettes NNS 1_o
smoked VBN 1_o
daily RB 1_o
but CC N
did VBD N
not RB N
increase VB N
cigarette NN 1_o
abstinence NN 1_o
rates NNS 1_o
. . 1_o

Infant NNP 1_o
birth NN 1_o
weight NN 1_o
increases NNS N
with IN N
both DT N
smoking VBG N
cessation NN N
and CC N
smoking NN N
reduction NN N
, , N
suggesting VBG N
that IN N
peer NN 1_i
counseling VBG 1_i
intervention NN 1_i
programs NNS 1_i
may MD N
improve VB N
newborn JJR 1_o
health NN 1_o
despite IN N
their PRP$ N
failure NN N
to TO N
affect VB N
smoking VBG N
cessation NN N
. . N

-DOCSTART- -X- O O

How WRB N
does VBZ N
Cash NNP 1_i
and CC 1_i
Counseling NNP 1_i
affect NN N
costs NNS N
? . N
OBJECTIVE NNP N
To TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
consumer-directed JJ N
model NN N
( ( 1_i
Cash NNP 1_i
and CC 1_i
Counseling NNP 1_i
) ) 1_i
of IN N
Medicaid NNP N
personal JJ 1_p
care NN 1_p
services NNS 1_p
( ( 1_p
PCS NNPS 1_p
) ) 1_p
or CC N
home- JJ N
and CC N
community-based JJ N
waiver NN N
services NNS N
( ( N
HCBS NNP N
) ) N
on IN N
the DT N
cost NN N
of IN N
Medicaid NNP N
services NNS N
. . N

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
Medicaid NNP N
claims NNS N
data NNS N
were VBD N
collected VBN N
for IN N
all DT 1_p
enrollees NNS 1_p
in IN 1_p
the DT 1_p
Cash NNP 1_p
and CC 1_p
Counseling NNP 1_p
demonstration NN 1_p
. . 1_p

Demonstration NNP 1_p
enrollees NNS 1_p
included VBD 1_p
those DT 1_p
eligible JJ 1_p
for IN 1_p
PCS NNP 1_p
( ( 1_p
in IN 1_p
Arkansas NNP 1_p
) ) 1_p
, , 1_p
those DT 1_p
assessed VBN 1_p
to TO 1_p
receive VB 1_p
such JJ 1_p
services NNS 1_p
( ( 1_p
in IN 1_p
New NNP 1_p
Jersey NNP 1_p
) ) 1_p
, , 1_p
and CC 1_p
recipients NNS 1_p
of IN 1_p
Medicaid NNP 1_p
HCBS NNP 1_p
( ( 1_p
in IN 1_p
Florida NNP 1_p
) ) 1_p
. . 1_p

Enrollment NN 1_p
occurred VBD 1_p
from IN 1_p
December NNP 1_p
1998 CD 1_p
through IN 1_p
April NNP 1_p
2001 CD 1_p
. . 1_p

The DT 1_p
follow-up JJ 1_p
period NN 1_p
covered VBD 1_p
up RB 1_p
to TO 1_p
24 CD 1_p
months NNS 1_p
after IN 1_p
enrollment NN 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
Demonstration NNP 1_p
volunteers NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
the DT N
option NN N
to TO N
participate VB N
in IN N
Cash NNP 1_i
and CC 1_i
Counseling NNP 1_i
( ( 1_p
the DT 1_p
treatment NN 1_p
group NN 1_p
) ) 1_p
, , 1_p
or CC 1_p
to TO 1_p
receive VB 1_p
Medicaid NNP 1_i
services NNS 1_i
as RB 1_i
usual JJ 1_i
from IN 1_i
an DT 1_i
agency NN 1_i
( ( N
the DT N
control NN N
group NN N
) ) N
. . N

Ordinary JJ N
least JJS N
squares NNS N
regressions NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
effect NN N
of IN N
the DT N
program NN N
on IN N
costs NNS 1_o
for IN 1_o
Medicaid NNP 1_o
PCS/waiver NNP 1_o
services NNS 1_o
and CC N
other JJ N
Medicaid NNP 1_o
services NNS 1_o
, , N
while IN N
controlling VBG N
for IN N
consumers NNS N
' POS N
preenrollment NN N
characteristics NNS N
and CC N
preenrollment NN N
Medicaid NNP N
spending NN N
. . N

Models NNS 1_p
were VBD 1_p
estimated VBN 1_p
separately RB 1_p
for IN 1_p
nonelderly RB 1_p
and CC 1_p
elderly JJ 1_p
adults NNS 1_p
in IN 1_p
each DT 1_p
state NN 1_p
and CC 1_p
for IN 1_p
children NNS 1_p
in IN 1_p
Florida NNP 1_p
. . 1_p

DATA NNP N
EXTRACTION NNP N
METHODS NNP N
Each DT N
state NN N
supplied VBD N
claims NNS N
data NNS N
for IN N
demonstration NN N
enrollees NNS N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Largely NNP N
because IN N
the DT N
program NN N
increased VBD N
consumers NNS N
' POS N
ability NN N
to TO N
get VB N
the DT N
authorized JJ N
amount NN N
of IN N
paid VBN N
care NN N
, , N
expenditures VBZ 1_o
for IN 1_o
personal JJ 1_o
care/waiver NN 1_o
services NNS 1_o
were VBD N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
in IN N
each DT N
state NN N
and CC N
age NN N
group NN N
, , N
except IN N
among IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
. . N

Higher JJR N
costs NNS 1_o
for IN 1_o
personal JJ 1_o
care/waiver NN 1_o
services NNS 1_o
were VBD N
partially RB N
offset VBN N
by IN N
savings NNS N
in IN N
other JJ N
Medicaid NNP N
services NNS N
, , N
particularly RB N
those DT N
related VBN N
to TO N
long-term JJ N
care NN N
. . N

During IN N
year NN N
1 CD N
, , N
total JJ 1_o
Medicaid NNP 1_o
costs NNS 1_o
were VBD N
generally RB N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
, , N
with IN N
treatment-control JJ N
cost NN N
differences NNS N
ranging VBG N
from IN N
1 CD N
percent NN N
( ( N
and CC N
statistically RB N
insignificant JJ N
) ) N
for IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
to TO N
17 CD N
percent NN N
for IN N
the DT N
elderly JJ N
in IN N
Arkansas NNP N
. . N

In IN N
year NN N
2 CD N
, , N
these DT N
cost NN 1_o
differences NNS 1_o
were VBD N
generally RB N
greater JJR N
than IN N
in IN N
year NN N
1 CD N
. . N

Only RB N
in IN N
Arkansas NNP N
did VBD N
the DT N
treatment-control NN N
difference NN N
in IN N
total JJ N
cost NN 1_o
shrink NN 1_o
over IN 1_o
time-to JJ 1_o
less JJR N
than IN N
5 CD N
percent NN N
( ( N
and CC N
statistically RB N
insignificant JJ N
) ) N
in IN N
year NN N
2 CD N
. . N

CONCLUSIONS NNP N
Medicaid NNP 1_o
costs NNS 1_o
were VBD N
generally RB N
higher JJR N
under IN N
Cash NNP 1_i
and CC 1_i
Counseling NNP 1_i
because IN N
those DT N
in IN N
the DT N
traditional JJ N
system NN N
did VBD N
not RB N
get VB N
the DT N
services NNS N
they PRP N
were VBD N
entitled VBN N
to TO N
. . N

Compared VBN N
with IN N
the DT N
treatment NN N
group NN N
, , N
( ( N
1 CD N
) ) N
control NN N
group NN N
members NNS N
were VBD N
less RBR N
likely JJ N
to TO N
receive VB 1_o
any DT 1_o
services NNS 1_o
at IN N
all DT N
( ( N
despite IN N
being VBG N
authorized VBN N
for IN N
them PRP N
) ) N
, , N
and CC N
( ( N
2 CD N
) ) N
service NN N
recipients NNS N
received VBD N
a DT N
lower JJR 1_o
proportion NN 1_o
of IN 1_o
the DT 1_o
amount NN 1_o
of IN 1_o
care NN 1_o
that WDT N
was VBD N
authorized VBN N
. . N

In IN N
addition NN N
, , N
a DT N
flaw NN N
in IN N
Florida NNP N
's POS N
reassessment NN N
procedures NNS N
led VBD N
to TO N
treatment NN N
group NN N
members NNS N
receiving VBG N
more RBR N
generous JJ N
benefit NN N
amounts NNS N
than IN N
control NN N
group NN N
members NNS N
. . N

To TO N
keep VB N
total JJ N
Medicaid NNP N
costs NNS N
per IN N
recipient NN N
at IN N
the DT N
level NN N
incurred VBN N
under IN N
the DT N
traditional JJ N
system NN N
, , N
consumer-directed JJ N
programs NNS N
need VBP N
to TO N
be VB N
carefully RB N
designed VBN N
and CC N
closely RB N
monitored VBN N
. . N

-DOCSTART- -X- O O

Phonophoresis NNP 1_i
versus NN N
topical JJ N
application NN N
of IN N
ketoprofen NN 1_i
: : 1_i
comparison NN N
between IN N
tissue NN N
and CC N
plasma NN N
levels NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Over IN N
the DT N
last JJ N
few JJ N
decades NNS N
, , N
application NN N
of IN N
ultrasound NN N
has VBZ N
been VBN N
attempted VBN N
to TO N
enhance VB N
transdermal JJ N
transport NN N
of IN N
several JJ N
drugs NNS N
, , N
a DT N
method NN N
referred VBD N
to TO N
as IN N
phonophoresis NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
the DT N
influence NN N
of IN N
ultrasound NN N
on IN N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
in IN N
humans NNS N
and CC N
to TO N
compare VB N
the DT N
concentrations NNS N
found VBD N
after IN N
continuous JJ N
and CC N
pulsed JJ N
application NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Twenty-six NNP 1_p
patients NNS 1_p
with IN 1_p
knee NN 1_p
disorders NNS 1_p
requiring VBG 1_p
arthroscopy NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

Just NNP N
before IN N
surgery NN N
, , N
phonophoresis NN 1_i
of IN 1_i
a DT 1_i
ketoprofen NN 1_i
gel NN 1_i
( ( N
Fastum NNP N
gel NN N
) ) N
was VBD N
given VBN N
to TO N
group NN N
A NNP N
using VBG N
continuous JJ 1_i
ultrasound NN 1_i
( ( N
1 CD N
MHz NNP N
, , N
1.5 CD N
W/cm2 NNP N
, , N
for IN N
5 CD N
minutes NNS N
) ) N
. . N

Group NNP N
B NNP N
received VBD N
the DT N
same JJ N
treatment NN N
but CC N
with IN N
pulsed JJ 1_i
ultrasound NN 1_i
( ( N
100 CD N
Hz NNP N
, , N
20 CD N
% NN N
duty NN N
cycle NN N
) ) N
. . N

Group NNP N
C NNP N
received VBD N
5 CD N
minutes NNS N
of IN N
sham NN 1_i
ultrasound NN 1_i
with IN 1_i
the DT 1_i
ketoprofen NN 1_i
gel NN 1_i
. . 1_i

The DT N
ultrasound JJ N
head NN N
was VBD N
moved VBN N
over IN N
a DT N
10-cm2 JJ N
area NN N
using VBG N
small JJ N
, , N
continuous JJ N
, , N
circular JJ N
movements NNS N
. . N

Biopsies NNS N
of IN N
adipose JJ N
tissue NN N
and CC N
synovial JJ N
tissue NN N
were VBD N
taken VBN N
during IN N
surgery NN N
to TO N
evaluate VB 1_o
the DT 1_o
local JJ 1_o
penetration NN 1_o
of IN 1_o
the DT 1_o
drug NN 1_o
. . 1_o

Blood NN N
samples NNS N
also RB N
were VBD N
collected VBN N
to TO N
determine VB 1_o
whether IN 1_o
ketoprofen NN 1_o
entered VBD 1_o
the DT 1_o
systemic JJ 1_o
circulation NN 1_o
. . 1_o

RESULTS VB N
The DT N
concentration NN 1_o
of IN 1_o
ketoprofen NN 1_o
in IN N
plasma NN N
was VBD N
negligible JJ N
in IN N
all DT N
3 CD N
groups NNS N
. . N

The DT N
concentration NN 1_o
of IN 1_o
ketoprofen NN 1_o
in IN N
synovial JJ N
tissue NN N
differed VBD N
from IN N
that IN N
in IN N
fat JJ N
tissue NN N
. . N

A DT N
difference NN N
in IN N
concentration NN 1_o
of IN 1_o
ketoprofen NN 1_o
in IN N
synovial JJ N
tissue NN N
was VBD N
found VBN N
between IN N
group NN N
C NNP N
and CC N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

The DT N
concentration NN 1_o
of IN 1_o
ketoprofen NN 1_o
in IN 1_o
fat JJ 1_o
tissue NN 1_o
and CC 1_o
synovial JJ 1_o
tissue NN 1_o
was VBD N
consistently RB N
higher JJR N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

DISCUSSION NNP N
AND CC N
CONCLUSION NNP N
This DT N
study NN N
confirms VBZ N
that IN N
phonophoresis NN N
of IN N
ketoprofen NN N
allows VBZ N
the DT N
attainment NN N
of IN N
higher JJR N
local JJ N
concentrations NNS N
, , N
whereas JJ N
systemic JJ N
exposure NN N
is VBZ N
lower JJR N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
, , N
in IN N
contrast NN N
to TO N
sham VB N
phonopheresis NN N
, , N
ultrasound NN N
can MD N
increase VB N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
. . N

-DOCSTART- -X- O O

[ RB N
Prophylactic NNP N
use NN N
of IN N
low JJ 1_i
molecular JJ 1_i
weight NN 1_i
heparin NN 1_i
in IN N
combination NN N
with IN N
graduated JJ 1_i
compression NN 1_i
stockings NNS 1_i
in IN N
post-operative JJ 1_p
patients NNS 1_p
with IN 1_p
gynecologic JJ 1_p
cancer NN 1_p
] NNP 1_p
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
low JJ 1_i
molecular JJ 1_i
weight NN 1_i
heparin NN 1_i
( ( 1_i
LMWH NNP 1_i
) ) 1_i
combined VBD 1_i
with IN 1_i
graduated JJ 1_i
compression NN 1_i
stockings NNS 1_i
( ( 1_i
GCS NNP 1_i
) ) 1_i
with IN N
GCS NNP 1_i
alone RB 1_i
as IN N
prophylactic JJ 1_o
measures NNS 1_o
for IN 1_o
venous JJ 1_o
thromboembolism NN 1_o
( ( 1_o
VTE NNP 1_o
) ) 1_o
in IN N
post-operative JJ 1_p
patients NNS 1_p
with IN 1_p
gynecologic JJ 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
Patients NNPS 1_p
diagnosed VBD 1_p
with IN 1_p
gynecologic JJ 1_p
cancer NN 1_p
undergoing VBG 1_p
primary JJ 1_p
major JJ 1_p
surgery NN 1_p
between IN 1_p
2010 CD 1_p
and CC 1_p
2011 CD 1_p
in IN 1_p
our PRP$ 1_p
institute NN 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
receive VB N
LMWH+GCS NNP 1_i
or CC N
GCS NNP 1_i
as IN N
VTE NNP N
prophylaxis IN N
post-operatively RB N
. . N

RESULTS NNP N
Altogether RB 1_p
247 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

The DT N
incidence NN 1_o
of IN 1_o
VTE NNP 1_o
in IN N
patients NNS N
treated VBN N
with IN N
LMWH NNP 1_i
+ NNP 1_i
GCS NNP 1_i
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
patients NNS N
using VBG N
GCS NNP 1_i
alone RB N
( ( N
0.8 CD N
% NN N
Vs. NNP N
8.1 CD N
% NN N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
severe JJ 1_o
bleeding VBG 1_o
complications NNS 1_o
in IN N
the DT N
patients NNS N
with IN N
prophylactic JJ N
use NN N
of IN N
LMWH NNP 1_i
and CC N
the DT N
occurrence NN 1_o
rate NN 1_o
of IN 1_o
wound NN 1_o
dehiscence NN 1_o
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Multivariable JJ N
logistic JJ N
regression NN N
analysis NN N
revealed VBD N
that IN N
age NN N
over IN N
60 CD N
years NNS N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
, , N
duration NN N
of IN N
operation NN N
over IN N
3 CD N
hours NNS N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
and CC N
without IN N
prophylactic JJ N
use NN N
of IN N
LMWH NNP 1_i
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
were VBD N
independent JJ N
risk NN N
factors NNS N
for IN N
VTE NNP N
. . N

CONCLUSIONS NNP N
Dual NNP N
prophylaxis NN N
with IN N
LMWH NNP 1_i
and CC 1_i
GCS NNP 1_i
should MD N
be VB N
recommended VBN N
for IN N
gynecologic JJ N
cancer NN N
patients NNS N
undergoing VBG N
major JJ N
surgery NN N
for IN N
its PRP$ N
better JJR N
efficacy NN 1_o
than IN N
GCS NNP 1_i
. . 1_i

Prophylactic NNP N
use NN N
of IN N
LMWH NNP 1_i
is VBZ N
safe JJ N
and CC N
convenient JJ N
. . N

Patients NNS N
with IN N
older JJR N
age NN N
and CC N
prolonged JJ N
operation NN N
time NN N
are VBP N
at IN N
highest JJS N
risk NN N
of IN N
developing VBG N
VTE NNP 1_o
post-operatively RB 1_o
. . 1_o

-DOCSTART- -X- O O

?-Smooth JJ 1_o
muscle NN 1_o
actin NN 1_o
expression NN 1_o
and CC 1_o
desmoplastic JJ 1_o
stromal JJ 1_o
reaction NN 1_o
in IN 1_p
pancreatic JJ 1_p
cancer NN 1_p
: : 1_p
results NNS N
from IN N
the DT N
CONKO-001 NNP N
study NN N
. . N

BACKGROUND NNP N
Previous JJ N
investigations NNS N
in IN N
pancreatic JJ N
cancer NN N
suggest VBP N
a DT N
prognostic JJ N
role NN N
for IN N
?-smooth JJ N
muscle NN N
actin NN N
( ( N
?-SMA JJ N
) ) N
expression NN N
and CC N
stromal JJ N
density NN N
in IN N
the DT N
peritumoural JJ N
stroma NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
further JJ N
validate VB N
the DT N
impact NN N
of IN N
?-SMA JJ N
expression NN N
and CC N
stromal JJ N
density NN N
in IN N
resectable JJ 1_p
pancreatic JJ 1_p
cancer NN 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
adjuvant JJ 1_i
gemcitabine NN 1_i
compared VBN 1_i
with IN 1_p
untreated JJ 1_p
patients NNS 1_p
. . 1_p

METHODS NNP 1_p
CONKO-001 NNP N
was VBD N
a DT N
prospective JJ N
randomised JJ N
phase NN N
III NNP N
study NN N
investigating VBG N
the DT N
role NN N
of IN 1_i
adjuvant JJ 1_i
gemcitabine NN 1_i
as IN 1_i
compared VBN N
with IN N
observation NN 1_p
. . 1_p

Tissue NNP 1_p
samples NNS 1_p
of IN 1_p
162 CD 1_p
patients NNS 1_p
were VBD 1_p
available JJ 1_p
for IN 1_p
immunohistochemistry NN N
on IN N
tissue NN N
microarrays NNS N
to TO N
evaluate VB N
the DT N
impact NN 1_o
of IN 1_o
?-SMA JJ 1_o
expression NN 1_o
and CC 1_o
stromal JJ 1_o
density NN 1_o
impact NN 1_o
on IN 1_o
patient JJ 1_o
outcome NN 1_o
. . 1_o

RESULTS NNP 1_o
High NNP 1_o
?-SMA JJ 1_o
expression NN 1_o
in IN 1_o
tumour JJ 1_o
stroma NN 1_o
was VBD 1_o
associated VBN 1_o
with IN 1_o
worse JJ 1_o
patient NN 1_o
outcome NN 1_o
( ( 1_o
DFS NNP 1_o
: : 1_o
P=0.05 NNP N
, , N
OS NNP N
: : N
P=0.047 NN 1_o
) ) 1_o
. . 1_o

A DT 1_o
dense JJ 1_o
stroma NN 1_o
reaction NN 1_o
was VBD 1_o
associated VBN 1_o
with IN N
improved JJ 1_o
disease-free JJ 1_o
survival NN 1_o
( ( 1_o
DFS NNP 1_o
) ) 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
in IN N
the DT N
overall JJ N
study NN N
population NN N
( ( N
DFS NNP N
: : N
P=0.001 NNP N
, , N
OS NNP N
: : N
P=0.001 NN N
) ) N
. . N

This DT N
positive JJ 1_o
prognostic JJ 1_o
impact NN 1_o
was VBD 1_o
restricted VBN 1_o
to TO N
patients NNS N
with IN N
no DT N
adjuvant JJ N
treatment NN N
( ( N
DFS NNP N
: : N
P NNP N
< VBZ N
0.001 CD N
, , N
OS NNP N
: : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
multivariable JJ N
analysis NN 1_o
, , 1_o
?-SMA JJ 1_o
and CC 1_o
stromal JJ 1_o
density NN 1_o
expression NN 1_o
were VBD 1_o
independently RB 1_o
predictive JJ N
factors NNS N
for IN 1_o
survival NN 1_o
. . 1_o

CONCLUSIONS VB 1_o
Our PRP$ N
data NNS N
confirm VBP N
the DT N
negative JJ 1_o
prognostic JJ 1_o
impact NN 1_o
of IN N
high JJ N
?-SMA JJ N
expression NN 1_p
in IN 1_p
pancreatic JJ 1_p
cancer NN 1_p
patients NNS 1_p
after IN 1_p
curatively RB 1_p
intended VBN N
resection NN N
. . N

In IN N
contrast NN N
to TO N
former JJ N
investigations NNS N
, , N
we PRP N
found VBD N
a DT N
positive JJ N
prognostic JJ 1_o
impact NN 1_o
for IN N
a DT N
dense NN N
stroma NN N
. . N

This DT N
significant JJ N
influence NN N
was VBD N
restricted VBN N
to TO N
patients NNS N
who WP N
received VBD N
no DT N
adjuvant JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

Trunk NNP 1_i
exercise NN 1_i
combined VBN 1_i
with IN 1_i
spinal JJ 1_i
manipulative NN 1_i
or CC 1_i
NSAID NNP 1_i
therapy NN 1_i
for IN N
chronic JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
: : 1_p
a DT N
randomized JJ N
, , N
observer-blinded JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
study VB N
the DT N
relative JJ N
efficacy NN N
of IN N
three CD N
different JJ N
treatment NN N
for IN N
chronic JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
( ( 1_p
CLBP NNP 1_p
) ) 1_p
. . 1_p

Two CD N
preplanned JJ N
comparisons NNS N
were VBD N
made VBN N
: : N
( ( N
a DT N
) ) N
Spinal NNP 1_i
manipulative JJ 1_i
therapy NN 1_i
( ( 1_i
SMT NNP 1_i
) ) 1_i
combined VBD 1_i
with IN 1_i
trunk NN 1_i
strengthening VBG 1_i
exercises NNS 1_i
( ( 1_i
TSE NNP 1_i
) ) 1_i
vs. FW 1_i
SMT NNP 1_i
combined VBD 1_i
with IN 1_i
trunk NN 1_i
stretching VBG 1_i
exercises NNS 1_i
, , 1_i
and CC 1_i
( ( N
b NN N
) ) N
SMT NNP 1_i
combined VBN 1_i
with IN 1_i
TSE NNP 1_i
vs. FW 1_i
nonsteroidal JJ 1_i
anti-inflammatory JJ 1_i
drug NN 1_i
( ( 1_i
NSAID NNP 1_i
) ) 1_i
therapy NN 1_i
combined VBN 1_i
with IN 1_i
TSE NNP 1_i
. . 1_i

STUDY NNP N
DESIGN NNP N
Interdisciplinary NNP N
, , N
prospective JJ N
, , N
observer-blinded JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
with IN N
a DT N
1-yr JJ N
follow-up JJ N
period NN N
. . N

The DT N
trial NN N
evaluated VBD N
therapies NNS N
in IN N
combination NN N
only RB N
and CC N
was VBD N
not RB N
designed VBN N
to TO N
test VB N
the DT N
individual JJ N
treatment NN N
components NNS N
. . N

SETTING NNP N
Primary NNP 1_p
contact NN 1_p
, , 1_p
college NN 1_p
out-patient JJ 1_p
clinic NN 1_p
. . 1_p

PATIENTS NNP N
In IN N
total JJ N
, , N
174 CD 1_p
patients NNS 1_p
aged VBN 1_p
20-60 JJ 1_p
yr NNS 1_p
were VBD N
admitted VBN N
to TO N
the DT N
study NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Patient-rated NNP 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
, , 1_o
disability NN 1_o
, , 1_o
and CC 1_o
functional JJ 1_o
health NN 1_o
status NN 1_o
at IN N
5 CD N
and CC N
11 CD N
wk NN N
. . N

INTERVENTIONS NNP N
Five NNP N
weeks NNS N
of IN N
SMT NNP 1_i
or CC 1_i
NSAID NNP 1_i
therapy NN 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
supervised JJ 1_i
trunk NN 1_i
exercise NN 1_i
, , N
followed VBN N
by IN N
and CC N
additional JJ N
6 CD N
wk NN N
of IN N
supervised JJ 1_i
exercise NN 1_i
alone RB 1_i
. . 1_i

RESULTS NNP N
Individual NNP N
group NN N
comparisons NNS N
after IN N
5 CD N
and CC N
11 CD N
wk NN N
of IN N
intervention NN N
on IN N
all DT N
three CD 1_o
main JJ 1_o
outcome NN 1_o
measures NNS 1_o
did VBD N
not RB N
reveal VB N
any DT N
clear JJ N
clinically RB N
important JJ N
or CC N
statistically RB N
significant JJ N
differences NNS N
. . N

There EX N
seemed VBD N
to TO N
be VB N
a DT N
sustained JJ N
reduction NN 1_o
in IN 1_o
medication NN 1_o
use NN 1_o
at IN 1_o
the DT 1_o
1-yr JJ 1_o
follow-up NN 1_o
. . 1_o

in IN N
the DT N
SMT/TSE NNP N
group NN N
. . N

Continuance NN N
of IN N
exercise NN N
during IN N
the DT N
follow-up JJ N
year NN N
, , N
regardless RB N
of IN N
type NN N
, , N
was VBD N
associated VBN N
with IN N
a DT N
better JJR N
outcome NN N
. . N

CONCLUSION NNP N
Each DT N
of IN N
the DT N
three CD N
therapeutic JJ N
regimens NNS N
was VBD N
associated VBN N
with IN N
similar JJ N
and CC N
clinically RB N
important JJ N
improvement NN N
over IN N
time NN N
that WDT N
was VBD N
considered VBN N
superior JJ N
to TO N
the DT N
expected JJ N
natural JJ N
history NN N
of IN N
long-standing JJ N
CLBP NNP N
. . N

For IN N
the DT N
management NN N
of IN N
CLBP NNP N
, , N
trunk NN N
exercise NN N
in IN N
combination NN N
with IN N
SMT NNP 1_i
or CC 1_i
NSAID NNP 1_i
therapy NN 1_i
seemed VBD N
to TO N
be VB N
beneficial JJ N
and CC N
worthwhile JJ N
. . N

The DT N
magnitude NN N
of IN N
nonspecific JJ N
therapeutic JJ N
( ( 1_i
placebo NN 1_i
) ) 1_i
effects NNS N
, , N
cost-effectiveness NN N
and CC N
relative JJ N
risks NNS N
of IN N
side NN N
effects NNS N
associated VBN N
with IN N
these DT N
types NNS N
of IN N
therapy NN N
need NN N
to TO N
be VB N
addressed VBN N
in IN N
future JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

Influence NN 1_o
of IN N
bony NN 1_p
defects NNS 1_p
on IN N
implant JJ N
stability NN N
. . N

INTRODUCTION NNP N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
evolution NN N
of IN N
implant JJ N
mechanical JJ N
stability NN N
in IN N
different JJ N
types/sizes NNS N
of IN N
bony NN 1_p
defects NNS 1_p
using VBG N
both DT N
Periotest NNP 1_i
and CC N
Osstell NNP 1_i
devices NNS N
as IN N
objective JJ N
tools NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-two NNP 1_p
implants NNS 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
to TO N
one CD N
of IN N
the DT N
four CD 1_p
types NNS 1_p
of IN 1_p
bone NN 1_p
defects NNS 1_p
: : 1_p
marginal JJ 1_p
bone NN 1_p
loss NN 1_p
, , 1_p
peri-apical JJ 1_p
bone NN 1_p
defect NN 1_p
, , 1_p
constant JJ 1_p
width NN 1_p
dehiscence NN 1_p
and CC 1_p
constant JJ 1_p
length NN 1_p
dehiscences NNS 1_p
. . 1_p

Periotest/Osstell NNP 1_o
measurements NNS 1_o
were VBD N
completed VBN N
before IN N
and CC N
during IN N
staged VBN N
bone NN N
removal NN N
( ( N
to TO N
enlarge VB N
defect JJ N
size NN N
) ) N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
initial JJ N
values NNS N
were VBD N
found VBN N
after IN N
a DT N
2 CD N
mm NN N
marginal JJ N
bone NN N
removal NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
peri-apical JJ 1_o
bone NN 1_o
lesion NN 1_o
, , N
after IN N
removal NN N
of IN N
5 CD N
mm NN N
( ( 1_i
Osstell NNP 1_i
) ) 1_i
or CC N
8 CD N
mm NN N
( ( 1_i
Periotest NNP 1_i
) ) 1_i
; : 1_i
for IN N
a DT N
6-mm-long JJ N
dehiscence NN N
, , N
after IN N
removal NN N
up RB N
to TO N
180 CD N
degrees NNS N
of IN N
the DT N
implant JJ N
perimeter NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
3-mm-wide JJ N
dehiscence NN N
, , N
after IN N
removal NN N
of IN N
10 CD N
mm NN N
( ( N
Osstell NNP N
) ) N
or CC N
6 CD N
mm NN N
( ( N
Periotest NNP N
) ) N
. . N

CONCLUSION NNP N
Periotest NNP 1_o
and CC N
Osstell NNP 1_o
are VBP N
in IN N
general JJ N
not RB N
very RB N
sensitive JJ N
in IN N
the DT N
identification NN N
of IN N
peri-implant JJ N
bone NN N
destruction NN N
, , N
except IN N
for IN N
marginal JJ N
bone NN N
loss NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
study NN N
of IN N
13-cis JJ 1_i
retinoic NN 1_i
acid NN 1_i
v NN N
placebo NN 1_i
in IN N
the DT N
myelodysplastic JJ 1_p
disorders NNS 1_p
. . 1_p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
trial NN N
of IN N
13-cis JJ 1_i
retinoic NN 1_i
acid NN 1_i
was VBD N
performed VBN N
to TO N
determine VB N
if IN N
the DT N
drug NN N
has VBZ N
a DT N
therapeutic JJ 1_o
effect NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
myelodysplastic JJ 1_p
syndromes NNS 1_p
( ( 1_p
MDS NNP 1_p
) ) 1_p
. . 1_p

Sixty-eight JJ 1_p
evaluable JJ 1_p
patients NNS 1_p
with IN 1_p
MDS NNP 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
receive VB N
a DT N
single JJ N
, , N
daily JJ N
oral JJ N
dose NN N
of IN N
either DT N
13-cis JJ 1_i
retinoic NN 1_i
acid NN 1_i
( ( 1_i
13-CRA JJ 1_i
, , N
100 CD N
mg/m2 NN N
) ) N
or CC N
matching VBG 1_i
placebo NN 1_i
. . 1_i

Treatment NN N
was VBD N
continued VBN N
, , N
when WRB N
possible JJ N
, , N
for IN N
a DT N
period NN N
of IN N
6 CD N
months NNS N
. . N

Determination NNP N
of IN N
response NN N
to TO N
treatment NN N
was VBD N
based VBN N
on IN N
clinical JJ 1_o
course NN 1_o
, , 1_o
repeat NN 1_o
bone NN 1_o
marrow NN 1_o
biopsies NNS 1_o
, , N
and CC N
aspirates NNS 1_o
and CC 1_o
blood NN 1_o
counts NNS 1_o
( ( 1_o
CBC NNP 1_o
) ) 1_o
with IN 1_o
WBC NNP 1_o
differential NN 1_o
, , 1_o
platelet NN 1_o
, , 1_o
and CC 1_o
reticulocyte JJ 1_o
numbers NNS 1_o
at IN 1_o
specified JJ 1_o
intervals NNS 1_o
. . 1_o

No DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
response NN N
to TO N
test VB N
drug NN N
( ( N
P NNP N
= NNP N
.66 NNP N
) ) N
. . N

One CD N
patient NN N
( ( N
3 CD N
% NN N
) ) N
in IN N
the DT N
13-CRA JJ 1_i
group NN N
and CC N
two CD N
patients NNS N
( ( N
6 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 1_i
group NN N
had VBD N
a DT N
minor JJ N
response NN 1_o
. . 1_o

Approximately RB N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
both DT N
groups NNS N
had VBD N
progression NN 1_o
of IN 1_o
their PRP$ 1_o
disease NN 1_o
, , N
and CC N
progression-free JJ 1_o
survival NN 1_o
was VBD N
nearly RB N
identical JJ N
. . N

Greater NNP N
than IN N
90 CD N
% NN N
of IN N
the DT N
patients NNS N
receiving VBG N
13-CRA JJ 1_i
developed JJ N
mild NN 1_o
or CC 1_o
moderate JJ 1_o
skin NN 1_o
toxicity NN 1_o
that WDT N
was VBD N
reversible JJ N
with IN N
decreasing VBG N
or CC N
discontinuing VBG N
the DT N
drug NN N
. . N

Our PRP$ N
study NN N
did VBD N
not RB N
find VB N
that IN N
13-CRA JJ 1_i
exerts NNS N
a DT N
beneficial JJ N
therapeutic JJ 1_o
effect NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
MDS NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Speech NN 1_i
following VBG 1_i
sign JJ 1_i
language NN 1_i
training NN 1_i
in IN N
autistic JJ 1_p
children NNS 1_p
with IN 1_p
minimal JJ 1_p
verbal JJ 1_p
language NN 1_p
. . 1_p

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
test VB N
the DT N
main JJ 1_o
and CC 1_o
interaction JJ 1_o
effects NNS 1_o
of IN N
training VBG N
condition NN N
and CC N
pretreatment-elicited JJ N
verbal JJ N
imitation NN N
ability NN N
when WRB N
predicting VBG N
spoken JJ N
language NN N
use NN N
during IN N
language NN 1_i
training NN 1_i
of IN N
60 CD 1_p
minimally RB 1_p
verbal JJ 1_p
autistic JJ 1_p
children NNS 1_p
. . 1_p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
Speech NNP 1_o
Alone NNP 1_o
, , 1_o
Sign NNP 1_o
Alone NNP 1_o
, , 1_o
Simultaneous NNP 1_o
Presentation NNP 1_o
of IN 1_o
Sign NNP 1_o
and CC 1_o
Speech NNP 1_o
, , 1_o
and CC 1_o
Alternating NNP 1_o
Presentation NNP 1_o
of IN 1_o
Sign NNP 1_o
and CC 1_o
Speech NNP 1_o
training NN 1_o
conditions NNS 1_o
. . 1_o

Speech NNP 1_o
Alone RB 1_o
, , 1_o
Simultaneous JJ 1_o
Presentation NNP 1_o
, , 1_o
and CC 1_o
Alternating NNP 1_o
Presentation NNP 1_o
condition NN 1_o
facilitated VBD N
more RBR N
child-initiated JJ N
speech NN N
during IN N
treatment NN N
than IN N
did VBD N
the DT N
Sign NNP 1_i
Alone NNP 1_i
condition NN N
. . N

Regardless NNP N
of IN N
training VBG N
condition NN N
, , N
pretreatment NN N
verbal JJ N
imitation NN N
ability NN N
positively RB N
predicted VBD N
the DT N
size NN 1_o
of IN 1_o
child-initiated JJ 1_o
spoken JJ 1_o
vocabulary JJ 1_o
observed VBD N
during IN N
training NN N
. . N

Exploratory JJ N
analyses NNS N
indicated VBD N
that IN N
, , N
in IN N
addition NN N
to TO N
verbal JJ N
imitation NN N
, , N
pretreatment JJ N
age NN N
and CC N
IQ NNP N
may MD N
also RB N
predict VB N
spoken JJ N
language NN N
developed VBD N
during IN N
training NN N
. . N

-DOCSTART- -X- O O

Genetic JJ 1_i
testing VBG 1_i
for IN 1_i
BRCA1 NNP N
: : N
effects NNS N
of IN N
a DT N
randomised JJ N
study NN N
of IN N
knowledge NN N
provision NN N
on IN N
interest NN N
in IN N
testing VBG N
and CC N
long JJ N
term NN N
test NN N
uptake NN N
; : N
implications NNS N
for IN N
the DT N
NICE NNP N
guidelines NNS N
. . N

INTRODUCTION JJ N
Interest NNP N
in IN N
searching VBG N
for IN N
mutations NNS N
in IN N
BRCA1 NNP N
and CC N
BRCA2 NNP N
is VBZ N
high JJ N
. . N

Knowledge NNP N
regarding VBG N
these DT N
genes NNS N
and CC N
the DT N
advantages NNS N
and CC N
limitations NNS N
of IN N
genetic JJ N
testing NN N
is VBZ N
limited VBN N
. . N

It PRP N
is VBZ N
unknown JJ N
whether IN N
increasing VBG N
knowledge NN N
about IN N
breast NN N
cancer NN N
genetic JJ N
testing VBG N
alters NNS N
interest NN N
in IN N
testing VBG N
. . N

METHODS NNP N
Three CD 1_p
hundred VBD 1_p
and CC 1_p
seventy JJ 1_p
nine CD 1_p
women NNS 1_p
( ( 1_p
260 CD 1_p
with IN 1_p
a DT 1_p
family NN 1_p
history NN 1_p
of IN 1_p
breast NN 1_p
cancer NN 1_p
; : 1_p
119 CD 1_p
with IN 1_p
breast NN 1_p
cancer NN 1_p
) ) 1_p
from IN 1_p
The DT 1_p
Royal NNP 1_p
Marsden NNP 1_p
NHS NNP 1_p
Foundation NNP 1_p
Trust NNP 1_p
were VBD N
randomised VBN N
to TO N
receive VB 1_i
or CC 1_i
not RB 1_i
receive JJ 1_i
written VBN 1_i
educational JJ 1_i
information NN 1_i
on IN N
cancer NN N
genetics NNS N
. . N

A DT N
questionnaire NN 1_i
was VBD N
completed VBN N
assessing VBG N
interest NN 1_o
in IN 1_o
BRCA1 NNP 1_o
testing VBG 1_o
and CC N
knowledge NN N
on IN N
breast NN N
cancer NN N
genetics NNS N
and CC N
screening VBG N
. . N

Actual JJ N
uptake NN N
of IN N
BRCA1 NNP 1_o
testing NN 1_o
is VBZ N
reported VBN N
with IN N
a DT N
six CD N
year NN N
follow-up RB N
. . N

RESULTS NNP N
Eighty NNP N
nine CD N
percent NN N
of IN N
women NNS N
at IN N
risk NN N
of IN N
breast NN N
cancer NN N
and CC N
76 CD N
% NN N
of IN N
women NNS N
with IN N
breast NN N
cancer NN N
were VBD N
interested JJ N
in IN N
BRCA1 NNP 1_o
testing NN 1_o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Provision NN N
of IN N
educational JJ N
information NN N
did VBD N
not RB N
affect VB N
level NN 1_o
of IN 1_o
interest NN 1_o
. . 1_o

Knowledge NNP 1_o
about IN 1_o
breast NN 1_o
cancer NN 1_o
susceptibility NN 1_o
genes NNS 1_o
was VBD N
poor JJ N
. . N

According VBG N
to TO N
the DT N
NICE NNP N
guidelines NNS N
regarding VBG N
eligibility NN N
for IN N
BRCA1 NNP N
and CC N
BRCA2 NNP N
testing NN N
, , N
the DT N
families NNS N
of IN N
66 CD N
% NN N
of IN N
the DT N
at IN N
risk NN N
group NN N
and CC N
13 CD N
% NN N
of IN N
the DT N
women NNS N
with IN N
breast NN N
cancer NN N
would MD N
be VB N
eligible JJ N
for IN N
testing VBG N
( ( N
probability NN N
of IN N
BRCA1 NNP N
mutation NN N
> NNP N
or=20 CD N
% NN N
) ) N
. . N

Within IN N
six CD N
years NNS N
of IN N
randomisation NN N
, , N
genetic JJ 1_o
testing NN 1_o
was VBD N
actually RB N
undertaken VBN N
on IN N
12 CD N
women NNS N
, , N
only RB N
10 CD N
of IN N
whom WP N
would MD N
now RB N
be VB N
eligible JJ N
, , N
on IN N
the DT N
NICE NNP N
guidelines NNS N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
strong JJ N
interest NN N
in IN N
BRCA1 NNP N
testing VBG N
. . N

Despite IN N
considerable JJ N
ignorance NN N
of IN N
factors NNS N
affecting VBG N
the DT N
inheritance NN N
of IN N
breast NN N
cancer NN N
, , N
education NN N
neither RB N
reduced VBN N
nor CC N
increased JJ N
interest NN 1_o
to TO 1_o
undergo VB 1_o
testing VBG 1_o
. . 1_o

The DT N
NICE NNP N
guidelines NNS N
successfully RB N
triage VBP N
those DT N
with IN N
a DT N
high JJ N
breast NN N
cancer NN N
risk NN N
to TO N
be VB N
managed VBN N
in IN N
cancer NN N
genetics NNS N
clinics NNS N
. . N

-DOCSTART- -X- O O

Family RB 1_i
economic JJ 1_i
empowerment NN 1_i
and CC N
mental JJ N
health NN N
among IN N
AIDS-affected JJ 1_p
children NNS 1_p
living VBG 1_p
in IN 1_p
AIDS-impacted JJ 1_p
communities NNS 1_p
: : 1_p
evidence NN N
from IN N
a DT N
randomised JJ N
evaluation NN N
in IN N
southwestern JJ 1_p
Uganda NNP 1_p
. . 1_p

OBJECTIVE CC N
The DT N
authors NNS N
examine VBP N
whether IN N
an DT N
innovative JJ N
family NN 1_i
economic JJ 1_i
empowerment NN 1_i
intervention NN N
addresses VBZ N
mental JJ N
health NN N
functioning NN N
of IN N
AIDS-affected JJ 1_p
children NNS 1_p
in IN 1_p
communities NNS 1_p
heavily RB 1_p
impacted VBN 1_p
by IN 1_p
HIV/AIDS NNP 1_p
in IN 1_p
Uganda NNP 1_p
. . 1_p

METHODS NNP N
A NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
consisting VBG N
of IN N
two CD N
study NN N
arms NNS N
, , N
a DT 1_p
treatment NN 1_i
condition NN 1_i
( ( 1_p
n=179 JJ 1_p
) ) 1_p
and CC 1_p
a DT 1_p
control NN 1_i
condition NN 1_i
( ( 1_p
n=118 JJ 1_p
) ) 1_p
, , N
was VBD N
used VBN N
to TO N
examine VB N
the DT N
impact NN N
of IN N
the DT N
family NN 1_i
economic JJ 1_i
empowerment NN 1_i
intervention NN 1_i
on IN N
children NNS N
's POS N
levels NNS N
of IN N
hopelessness NN N
and CC N
depression NN N
. . N

The DT N
intervention NN N
comprised VBD N
matched JJ 1_i
children NNS 1_i
savings NNS 1_i
accounts NNS 1_i
, , 1_i
financial JJ 1_i
management NN 1_i
workshops NNS 1_i
and CC 1_i
mentorship NN 1_i
. . 1_i

Data NNS N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
12 CD N
months NNS N
post-intervention NN N
. . N

RESULTS NNP N
Using VBG N
multivariate JJ N
analysis NN N
with IN N
several JJ N
socioeconomic JJ N
controls NNS N
, , N
the DT N
authors NNS N
find VBP N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
condition NN N
( ( N
receiving VBG N
the DT N
intervention NN N
) ) N
report NN N
significant JJ N
improvement NN N
in IN N
their PRP$ N
mental JJ 1_o
health NN 1_o
functioning NN 1_o
. . 1_o

Specifically RB N
, , N
the DT N
intervention NN N
reduces VBZ N
hopelessness NN 1_o
and CC 1_o
depression NN 1_o
levels NNS 1_o
. . 1_o

On IN N
the DT N
other JJ N
hand NN N
, , N
children NNS N
in IN N
the DT N
control NN 1_i
condition NN N
( ( N
not RB N
receiving VBG N
the DT N
intervention NN N
) ) N
report NN N
no DT N
changes NNS N
on IN N
both DT N
measures NNS N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
children NNS 1_p
with IN 1_p
poor JJ 1_p
mental JJ 1_p
health NN 1_p
functioning VBG 1_p
living NN 1_p
in IN 1_p
communities NNS 1_p
affected VBN 1_p
by IN 1_p
HIV/AIDS NNP 1_p
may MD N
benefit VB N
from IN N
innovative JJ N
family NN N
economic JJ N
empowerment NN N
interventions NNS N
. . N

As IN N
measures NNS N
of IN N
mental JJ N
health NN N
functioning NN N
, , N
both DT N
hopelessness NN 1_o
and CC 1_o
depression NN 1_o
have VBP N
long-term JJ N
negative JJ N
psychosocial NN N
and CC N
developmental JJ N
impacts NNS N
on IN N
children NNS N
. . N

These DT N
findings NNS N
have VBP N
implications NNS N
for IN N
public JJ N
health NN N
programmes NNS N
intended VBN N
for IN N
long-term JJ N
care NN N
and CC N
support NN N
of IN N
children NNS 1_p
living VBG 1_p
in IN 1_p
resource JJ 1_p
poor JJ 1_p
AIDS-impacted JJ 1_p
communities NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Best JJS N
evidence NN N
in IN N
critical JJ N
care NN N
medicine NN N
. . N

Steroids NNS 1_i
to TO N
prevent VB N
post-extubation NN 1_o
airway JJ 1_o
obstruction NN 1_o
in IN N
adult NN 1_p
critically RB 1_p
ill JJ 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
health-promotion NN 1_i
programme NN 1_i
and CC N
its PRP$ N
effect NN N
on IN N
ADL NNP 1_o
dependence NN N
and CC N
self-reported JJ 1_o
health NN 1_o
problems NNS 1_o
for IN N
the DT 1_p
elderly JJ 1_p
visually RB 1_p
impaired VBN 1_p
. . 1_p

BACKGROUND NNP N
Ageing VBG N
with IN N
visual JJ N
impairment NN N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
degree NN N
of IN N
disability NN N
whereby WRB N
age-related JJ N
macular JJ N
degeneration NN N
in IN N
particular JJ N
causes NNS N
dependence NN N
in IN N
activities NNS 1_o
of IN 1_o
daily JJ 1_o
living NN 1_o
( ( 1_o
ADL NNP 1_o
) ) 1_o
even RB N
at IN N
an DT N
early JJ N
stage NN N
. . N

AIMS NNP N
To TO N
compare VB N
an DT N
activity-based JJ N
, , N
health-promotion JJ 1_i
programme NN 1_i
with IN N
an DT N
individual JJ 1_i
programme NN 1_i
, , N
targeting VBG N
the DT 1_p
elderly JJ 1_p
with IN 1_p
age-related JJ 1_p
macular JJ 1_p
degeneration NN 1_p
concerning VBG N
the DT N
effect NN N
on IN N
the DT N
development NN N
of IN N
dependence NN N
in IN N
ADL NNP N
, , N
general JJ N
health NN N
, , N
and CC N
self-reported JJ N
health NN N
problems NNS N
. . N

METHODS VB N
A DT N
randomized NN N
controlled VBN N
study NN N
with IN N
a DT N
28-month JJ N
follow-up NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
229 CD 1_p
persons NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
the DT 1_p
study NN 1_p
and CC N
131 CD N
( ( N
57 CD N
% NN N
) ) N
were VBD N
followed VBN N
up RP N
( ( 1_i
individual JJ 1_i
intervention NN 1_i
n=69 NN N
, , N
health-promotion NN 1_i
programme NN 1_i
n=62 NN N
) ) N
at IN N
28-month JJ N
. . N

RESULTS VB N
The DT N
health-promotion NN 1_i
group NN 1_i
maintained VBD N
their PRP$ N
ADL NNP 1_o
level NN 1_o
despite IN N
a DT N
significant JJ N
decrease NN N
in IN N
visual JJ 1_o
acuity NN 1_o
, , N
while IN N
the DT N
individual JJ 1_i
intervention NN 1_i
group NN N
increased VBD N
its PRP$ N
dependence NN N
in IN N
ADL NNP 1_o
. . 1_o

General NNP 1_o
health NN 1_o
systematically RB N
dropped VBD N
to TO N
a DT N
lower JJR N
level NN N
in IN N
both DT N
groups NNS N
, , N
but CC N
participants NNS N
from IN N
the DT N
health-promotion NN 1_i
group NN 1_i
reported VBD N
fewer JJR 1_o
health NN 1_o
problems NNS 1_o
. . 1_o

There EX N
were VBD N
significantly RB N
fewer JJR 1_o
reports NNS 1_o
of IN 1_o
tiredness NN 1_o
and CC 1_o
dizziness NN 1_o
among IN N
the DT N
health-promotion NN 1_i
participants NNS N
. . N

CONCLUSION VB N
The DT N
health-promotion NN 1_i
programme NN 1_i
seems VBZ N
to TO N
have VB N
slowed VBN N
down RP N
the DT N
disablement JJ 1_o
process NN 1_o
among IN N
elderly JJ 1_p
with IN 1_p
decreased JJ 1_p
vision NN 1_p
by IN N
enabling VBG N
them PRP N
to TO N
maintain VB N
their PRP$ N
ADL NNP 1_o
level NN 1_o
and CC N
by IN N
reducing VBG 1_o
self-reported JJ 1_o
health NN 1_o
problems NNS 1_o
for IN N
at IN N
least JJS N
28 CD N
months NNS N
following VBG N
intervention NN N
. . N

-DOCSTART- -X- O O

Noninvasive JJ N
detection NN N
of IN N
candidate NN N
molecular JJ N
biomarkers NNS N
in IN 1_p
subjects NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
insulin NN 1_p
resistance NN 1_p
and CC 1_p
colorectal JJ 1_p
adenomas NN 1_p
. . 1_p

We PRP N
have VBP N
developed VBN N
novel JJ 1_i
molecular JJ 1_i
methods NNS 1_i
using VBG N
a DT N
stool NN N
sample NN N
, , N
which WDT N
contains VBZ N
intact JJ N
sloughed VBN N
colon NN N
cells NNS N
, , N
to TO N
quantify VB N
colonic JJ N
gene NN N
expression NN N
profiles NNS N
. . N

In IN N
this DT N
study NN N
, , N
our PRP$ N
goal NN N
was VBD N
to TO N
identify VB N
diagnostic JJ N
gene NN N
sets NNS N
( ( N
combinations NNS N
) ) N
for IN N
the DT N
noninvasive JJ N
classification NN N
of IN N
different JJ N
phenotypes NNS N
. . N

For IN N
this DT N
purpose NN N
, , N
the DT N
effects NNS N
of IN N
a DT N
legume-enriched JJ 1_i
, , 1_i
low JJ 1_i
glycemic JJ 1_i
index NN 1_i
, , 1_i
high JJ 1_i
fermentable JJ 1_i
fiber NN 1_i
diet NN 1_i
was VBD N
evaluated VBN N
in IN N
subjects NNS 1_p
with IN 1_p
four CD 1_p
possible JJ 1_p
combinations NNS 1_p
of IN 1_p
risk NN 1_p
factors NNS 1_p
, , 1_p
including VBG 1_p
insulin NN 1_p
resistance NN 1_p
and CC 1_p
a DT 1_p
history NN 1_p
of IN 1_p
adenomatous JJ 1_p
polyps NNS 1_p
. . 1_p

In IN N
a DT N
randomized JJ N
crossover NN N
design NN N
controlled VBD N
feeding NN N
study NN N
, , N
each DT N
participant NN N
( ( N
a DT N
total NN 1_p
of IN 1_p
23 CD 1_p
; : 1_p
5-12 JJ N
per IN N
group NN N
) ) N
consumed VBD N
the DT N
experimental JJ 1_i
diet NN 1_i
( ( 1_i
1.5 CD 1_i
cups NNS 1_i
of IN 1_i
cooked JJ 1_i
dry JJ 1_i
beans NNS 1_i
) ) 1_i
and CC 1_i
a DT 1_i
control NN 1_i
diet NN 1_i
( ( 1_i
isocaloric JJ 1_i
average JJ 1_i
American JJ 1_i
diet NN 1_i
) ) 1_i
for IN 1_i
4 CD 1_i
weeks NNS 1_i
with IN 1_i
a DT 1_i
3-week JJ 1_i
washout NN 1_i
period NN 1_i
between IN 1_i
diets NNS 1_i
. . 1_i

Using VBG N
prior JJ N
biological JJ N
knowledge NN N
, , N
the DT N
complexity NN N
of IN N
feature NN N
selection NN N
was VBD N
reduced VBN N
to TO N
perform VB N
an DT N
exhaustive JJ N
search NN N
on IN N
all DT N
allowable JJ N
feature NN N
( ( N
gene NN N
) ) N
sets NNS N
of IN N
size NN N
3 CD N
, , N
and CC N
among IN N
these DT N
, , N
27 CD N
had VBD N
( ( N
unbiased JJ N
) ) N
error NN N
estimates NNS N
of IN N
0.15 CD N
or CC N
less JJR N
. . N

Linear JJ N
discriminant JJ N
analysis NN N
was VBD N
successfully RB N
used VBN N
to TO N
identify VB N
the DT N
best JJS 1_o
single JJ 1_o
genes NNS 1_o
and CC 1_o
two- JJ 1_o
to TO 1_o
three-gene JJ 1_o
combinations NNS 1_o
for IN 1_o
distinguishing VBG 1_o
subjects NNS 1_o
with IN 1_o
insulin NN 1_o
resistance NN 1_o
, , 1_p
a DT 1_p
history NN 1_p
of IN 1_p
polyps NNS 1_p
, , 1_p
or CC 1_p
exposure NN 1_p
to TO 1_p
a DT 1_p
chemoprotective JJ 1_p
legume-rich JJ 1_p
diet NN 1_p
. . 1_p

These DT N
results NNS N
support VBD N
our PRP$ N
premise NN N
that IN N
gene NN N
products NNS N
( ( N
RNA NNP N
) ) N
isolated VBD N
from IN N
stool NN N
have VBP N
diagnostic JJ N
value NN N
in IN N
terms NNS N
of IN N
assessing VBG N
colon NN N
cancer NN N
risk NN N
. . N

-DOCSTART- -X- O O

Randomized NNP N
comparison NN N
of IN N
two CD 1_i
communication NN 1_i
interventions NNS 1_i
for IN N
preschoolers NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

This DT N
randomized JJ N
group NN N
experiment NN N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD 1_i
communication NN 1_i
interventions NNS 1_i
( ( 1_i
Responsive JJ 1_i
Education NN 1_i
and CC 1_i
Prelinguistic NNP 1_i
Milieu NNP 1_i
Teaching NNP 1_i
[ NNP 1_i
RPMT NNP 1_i
] NNP 1_i
and CC 1_i
the DT 1_i
Picture NNP 1_i
Exchange NNP 1_i
Communication NNP 1_i
System NNP 1_i
[ NNP 1_i
PECS NNP 1_i
] NNP 1_i
) ) 1_i
in IN N
36 CD 1_p
preschoolers NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

Each DT N
treatment NN N
was VBD N
delivered VBN N
3 CD N
times NNS N
per IN N
week NN N
, , N
in IN N
20-min JJ N
sessions NNS N
, , N
for IN N
6 CD N
months NNS N
. . N

The DT N
results NNS N
revealed VBD N
that IN N
the DT N
RPMT NNP 1_i
facilitated VBD N
the DT N
frequency NN 1_o
of IN 1_o
generalized JJ 1_o
turn NN 1_o
taking VBG 1_o
and CC 1_o
generalized VBN 1_o
initiating NN 1_o
joint JJ 1_o
attention NN 1_o
more RBR N
than IN N
did VBD N
the DT N
PECS NNP N
. . N

The DT N
latter JJ N
effect NN N
occurred VBD N
only RB N
for IN N
children NNS N
who WP N
began VBD N
treatment NN N
with IN N
at IN N
least JJS N
some DT N
initiating VBG 1_o
joint JJ 1_o
attention NN 1_o
. . 1_o

In IN N
contrast NN N
, , N
the DT N
PECS NNP 1_i
facilitated VBD N
generalized JJ 1_o
requests NNS 1_o
more RBR N
than IN N
the DT N
RPMT NNP N
in IN N
children NNS N
with IN N
very RB N
little JJ N
initiating VBG 1_o
joint JJ 1_o
attention NN 1_o
prior RB N
to TO N
treatment NN N
. . N

These DT N
effect NN 1_o
sizes NNS 1_o
were VBD N
large JJ 1_o
. . 1_o

-DOCSTART- -X- O O

Clinical JJ N
and CC N
prognostic JJ N
significance NN N
of IN N
serum NN N
magnesium NN N
concentration NN N
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
chronic JJ 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
: : 1_p
the DT N
PROMISE NNP N
Study NNP N
. . N

OBJECTIVES NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
prognostic JJ N
significance NN N
of IN N
alterations NNS N
in IN N
serum JJ N
magnesium NN N
in IN N
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

BACKGROUND NNP N
Reductions NNPS N
in IN N
serum NN N
magnesium NN N
have VBP N
been VBN N
postulated VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
promoting VBG N
arrhythmias NN N
and CC N
to TO N
have VB N
an DT N
adverse JJ N
impact NN N
on IN N
survival NN N
in IN N
congestive JJ N
heart NN N
failure NN N
, , N
although IN N
support NN N
for IN N
this DT N
postulate NN N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Serum NNP 1_o
magnesium NN 1_o
levels NNS 1_o
were VBD 1_o
measured VBN 1_o
in IN N
1,068 CD 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
survival NN 1_p
study NN 1_p
of IN 1_p
class NN 1_p
III NNP 1_p
or CC 1_p
IV NNP 1_p
heart NN 1_p
failure NN 1_p
at IN 1_p
the DT 1_p
time NN 1_p
of IN 1_p
double-blind JJ 1_p
randomization NN 1_p
to TO 1_p
milrinone VB 1_i
, , 1_i
a DT 1_i
phosphodiesterase NN 1_i
inhibitor NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

All DT N
patients NNS N
received VBD N
conventional JJ 1_i
therapy NN 1_i
with IN 1_i
digoxin NN 1_i
, , 1_i
diuretic JJ 1_i
drugs NNS 1_i
and CC 1_i
a DT 1_i
converting VBG 1_i
enzyme NN 1_i
inhibitor NN 1_i
throughout IN N
the DT N
trial NN N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
6.1 CD N
months NNS N
( ( N
range VB N
1 CD N
day NN N
to TO N
20 CD N
months NNS N
) ) N
. . N

RESULTS JJ N
Patients NNS N
with IN N
high JJ N
serum NN N
magnesium NN N
( ( N
defined VBN N
as IN N
> NN N
or CC N
= $ N
1.9 CD N
mEq/liter NN N
, , N
n JJ N
= NNP N
242 CD N
) ) N
were VBD N
less RBR N
likely JJ N
to TO N
survive VB 1_o
than IN N
were VBD N
patients NNS N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
( ( N
n JJ N
= NNP N
627 CD N
) ) N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
risk NN N
ratio NN N
= NNP N
1.41 CD N
) ) N
. . N

Patients NNS N
with IN N
a DT N
low JJ N
magnesium NN N
level NN N
( ( N
defined VBN N
as IN N
< NN N
or CC N
= $ N
1.5 CD N
mEq/liter NN N
, , N
n JJ N
= NNP N
199 CD N
) ) N
had VBD N
no DT N
difference NN N
in IN N
survival NN 1_o
compared VBN N
with IN N
the DT N
group NN N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
( ( N
p JJ N
= NNP N
NS NNP N
, , N
risk NN N
ratio NN N
= NNP N
0.89 CD N
) ) N
. . N

At IN N
baseline NN N
, , N
the DT N
patients NNS N
in IN N
the DT N
high JJ N
magnesium NN N
group NN N
were VBD N
older JJR N
and CC N
had VBD N
more RBR N
severe JJ N
functional JJ 1_o
and CC 1_o
renal JJ 1_o
impairment NN 1_o
. . 1_o

An DT N
analysis NN N
after IN N
adjustment NN N
for IN N
these DT N
variables NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
survival NN 1_o
comparing VBG N
the DT N
low JJ N
, , N
normal JJ N
and CC N
high JJ N
magnesium NN N
groups NNS N
. . N

Although IN N
the DT N
three CD N
groups NNS N
had VBD N
no DT N
difference NN N
in IN N
frequency NN N
of IN N
ventricular JJ 1_o
tachycardia NN 1_o
, , 1_o
length NN 1_o
of IN 1_o
longest JJS 1_o
run NN 1_o
or CC 1_o
frequency NN 1_o
of IN 1_o
ventricular JJ 1_o
premature NN 1_o
beats NNS 1_o
on IN N
baseline NN 1_o
Holter NNP 1_o
monitoring NN 1_o
, , N
the DT N
group NN N
with IN N
hypomagnesemia NN N
had VBD N
more RBR N
frequent JJ N
ventricular JJ N
couplets NNS N
. . N

CONCLUSIONS NNP N
Serum NNP N
magnesium NN N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
either DT N
sudden JJ 1_o
death NN 1_o
or CC 1_o
death NN 1_o
due JJ N
to TO N
all DT N
causes NNS N
in IN N
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
heart NN N
failure NN N
. . N

Hypomagnesemia NNP N
is VBZ N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
the DT N
frequency NN N
of IN N
certain JJ N
forms NNS N
of IN N
ventricular JJ 1_o
ectopic NN 1_o
activity NN 1_o
, , N
but CC N
this DT N
is VBZ N
not RB N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
clinical JJ N
events NNS N
. . N

The DT N
higher JJR N
mortality NN N
rate NN N
among IN N
the DT N
patients NNS N
with IN N
hypermagnesemia NN N
is VBZ N
attributable JJ N
to TO N
older JJR N
age NN N
, , N
more RBR N
advanced JJ N
heart NN N
failure NN N
and CC N
renal JJ N
insufficiency NN N
. . N

-DOCSTART- -X- O O

Aminocaproic NNP 1_i
acid VBZ 1_i
versus FW N
prednisone NN 1_i
for IN N
the DT N
treatment NN N
of IN N
traumatic JJ 1_p
hyphema NN 1_p
. . 1_p

A DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

One CD 1_p
hundred VBD 1_p
twelve NN 1_p
patients NNS 1_p
who WP 1_p
sustained VBD 1_p
hyphema NN 1_p
after IN 1_p
blunt NN 1_p
trauma NN 1_p
were VBD 1_p
enrolled VBN 1_p
in IN N
a DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
to TO N
determine VB N
the DT N
relative JJ N
efficacies NNS N
of IN N
aminocaproic JJ 1_i
acid NN 1_i
( ( 1_i
Amicar NNP 1_i
) ) 1_i
and CC N
systemic JJ 1_i
prednisone NN 1_i
for IN N
reducing VBG N
the DT N
rate NN 1_o
of IN 1_o
secondary JJ 1_o
hemorrhage NN 1_o
. . 1_o

Fifty-six JJ N
patients NNS N
received VBD N
an DT N
oral JJ 1_i
dosage NN 1_i
of IN 1_i
50 CD 1_i
mg/kg NN 1_i
of IN 1_i
aminocaproic JJ 1_i
acid NN 1_i
every DT N
4 CD N
hours NNS N
for IN N
5 CD N
days NNS N
, , N
up RB N
to TO N
a DT N
maximum NN N
of IN N
30 CD N
g JJ N
daily JJ N
, , N
and CC N
56 CD N
patients NNS N
received VBD N
an DT N
oral JJ 1_i
dosage NN 1_i
of IN 1_i
40 CD 1_i
mg NN 1_i
of IN 1_i
prednisone JJ 1_i
daily JJ 1_i
( ( N
adjusted VBN N
for IN N
weight NN N
) ) N
in IN N
two CD N
divided JJ N
doses NNS N
. . N

Placebo NNP 1_i
pills NNS N
and CC N
liquids NNS N
were VBD N
given VBN N
to TO N
each DT N
patient NN N
to TO N
mask VB N
the DT N
treatment NN N
schedules NNS N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
patient NN N
populations NNS N
for IN N
any DT N
demographic JJ N
or CC N
clinical JJ N
characteristic NN N
( ( N
e.g. JJ N
, , N
visual JJ 1_o
acuity NN 1_o
, , 1_o
intraocular JJ 1_o
pressure NN 1_o
[ NNP 1_o
IOP NNP 1_o
] NNP 1_o
, , 1_o
initial JJ 1_o
hyphema NN 1_o
size NN 1_o
) ) 1_o
measured VBN N
in IN N
the DT N
study NN N
. . N

Blacks NNS 1_p
comprised VBD 1_p
53 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
study NN 1_p
population NN 1_p
, , 1_p
and CC 1_p
the DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
was VBD 1_p
23.5 CD 1_p
years NNS 1_p
. . 1_p

Four CD N
patients NNS N
in IN N
each DT N
of IN N
the DT N
treatment NN N
groups NNS N
experienced VBD N
a DT N
secondary JJ 1_o
hemorrhage NN 1_o
; : 1_o
the DT N
rebleed NN 1_o
rate NN 1_o
was VBD N
7.1 CD N
% NN N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O

Causes NNS N
of IN N
variation NN N
in IN N
BCG NNP 1_i
vaccine NN 1_i
efficacy NN 1_o
: : 1_o
examining VBG N
evidence NN N
from IN N
the DT N
BCG NNP N
REVAC NNP N
cluster NN N
randomized VBD N
trial NN N
to TO N
explore VB N
the DT N
masking NN N
and CC N
the DT N
blocking NN N
hypotheses NNS N
. . N

BCG NNP N
protection NN N
varies NNS N
and CC N
in IN N
some DT N
places NNS N
( ( N
nearest JJS N
the DT N
equator NN N
) ) N
is VBZ N
low JJ N
or CC N
absent NN N
. . N

Understanding VBG N
this DT N
variation NN N
can MD N
inform VB N
the DT N
efforts NNS N
to TO N
develop VB N
new JJ N
vaccines NNS N
against IN N
tuberculosis NN N
. . N

Two CD N
main JJ N
hypotheses NNS N
are VBP N
used VBN N
to TO N
explain VB N
this DT N
variation NN N
: : N
under IN N
masking VBG N
, , N
new JJ N
vaccines NNS N
are VBP N
unlikely JJ N
to TO N
increase VB N
protection NN 1_o
; : 1_o
under IN N
blocking VBG N
new JJ N
vaccines NNS N
have VBP N
a DT N
greater JJR N
potential JJ N
to TO N
be VB N
effective JJ N
when WRB N
BCG NNP N
is VBZ N
not RB N
. . N

We PRP N
conducted VBD N
a DT N
cluster NN N
randomized VBN N
trial NN N
to TO N
explored VB N
the DT N
masking NN N
and CC N
blocking VBG N
hypotheses NNS N
by IN N
studying VBG N
BCG NNP 1_i
vaccine NN 1_i
efficacy NN N
of IN N
neonatal JJ N
vaccination NN N
and CC N
when WRB N
administered VBN N
for IN N
the DT N
first JJ N
or CC N
a DT N
second JJ N
( ( N
revaccination NN N
) ) N
time NN N
at IN N
school NN 1_p
age NN 1_p
in IN 1_p
two CD 1_p
sites NNS 1_p
( ( 1_p
Manaus NNP 1_p
close RB 1_p
and CC 1_p
Salvador NNP 1_p
further RB 1_p
south RB 1_p
from IN 1_p
the DT 1_p
equator NN 1_p
) ) 1_p
. . 1_p

Seven VBN 1_p
hundred CD 1_p
and CC 1_p
sixty VBD 1_p
three CD 1_p
state NN 1_p
schools NNS 1_p
were VBD 1_p
matched VBN 1_p
on IN 1_p
socio JJ 1_p
economic JJ 1_p
characteristics NNS 1_p
of IN 1_p
the DT 1_p
neighborhood NN 1_p
and CC 1_p
239,934 CD 1_p
children NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
vaccine VB N
( ( 1_i
BCG NNP 1_i
vaccination NN 1_i
at IN N
school NN N
age NN N
) ) N
or CC N
control VB 1_i
group NN 1_i
. . 1_i

Protection NN 1_o
by IN 1_o
first JJ 1_o
BCG NNP 1_o
vaccination NN 1_o
at IN N
school NN N
age NN N
was VBD N
high JJ N
in IN N
Salvador NNP 1_p
( ( N
34 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
7-53 CD N
% NN N
, , N
p=0.017 NN N
) ) N
but CC N
low JJ N
in IN N
Manaus NNP 1_p
( ( N
8 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
t0 VBZ N
39-40 CD N
% NN N
, , N
p=0.686 NN N
) ) N
. . N

For IN N
revaccination NN 1_o
at IN 1_o
school NN 1_o
age NN 1_o
, , N
protection NN N
was VBD N
modest JJ N
in IN N
Salvador NNP N
( ( N
19 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
3-33 CD N
% NN N
, , N
p=0.022 NN N
) ) N
and CC N
absent NN N
in IN N
Manaus NNP N
( ( N
1 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
to TO N
27-23 CD N
% NN N
, , N
p=0.932 NN N
) ) N
. . N

Vaccine NNP 1_o
efficacy NN 1_o
for IN N
neonatal JJ N
vaccination NN N
was VBD N
similar JJ N
in IN N
Salvador NNP N
( ( N
40 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
22-54 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
Manaus NNP N
( ( N
36 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
11-53 CD N
% NN N
, , N
p=0.008 NN N
) ) N
. . N

Variation NN 1_o
in IN 1_o
BCG NNP 1_o
efficacy NN 1_o
was VBD N
marked VBN N
when WRB N
vaccine NN N
was VBD N
given VBN N
at IN N
school NN N
age NN N
but CC N
absent NN N
at IN N
birth NN N
, , N
which WDT N
points VBZ N
towards NNS N
blocking VBG N
as IN N
the DT N
dominant JJ N
mechanism NN N
. . N

New NNP N
tuberculosis NN N
vaccines NNS N
that WDT N
overcome VBP N
or CC N
by IN N
pass NN N
this DT N
blocking VBG N
effect NN N
could MD N
confer VB N
protection NN N
in IN N
situations NNS N
where WRB N
BCG NNP N
is VBZ N
not RB N
protective JJ N
. . N

-DOCSTART- -X- O O

Prospective JJ N
randomized VBN N
trial NN N
of IN N
bispectral JJ N
index NN N
monitoring NN 1_i
of IN N
sedation NN N
depth NN N
during IN N
flexible JJ N
bronchoscopy NN N
. . N

BACKGROUND IN N
The DT N
clinical JJ N
benefits NNS N
associated VBN N
with IN N
the DT N
use NN N
of IN N
the DT N
bispectral JJ 1_i
index NN 1_i
( ( 1_i
BIS NNP 1_i
) ) 1_i
to TO N
monitor VB N
the DT N
depth NN 1_o
of IN 1_o
sedation NN 1_o
during IN N
flexible JJ N
fiberoptic JJ N
bronchoscopy NN N
( ( N
FFB NNP N
) ) N
are VBP N
questionable JJ N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
added JJ N
value NN N
in IN N
terms NNS N
of IN N
procedural JJ N
safety NN N
and CC N
patients NNS N
' POS N
awareness NN N
of IN N
monitoring VBG N
sedation NN N
depth NN N
using VBG N
the DT N
BIS NNP N
compared VBN N
to TO N
conventional JJ N
clinical JJ N
judgment NN N
alone RB N
in IN N
patients NNS N
undergoing VBG N
FFB NNP N
under IN N
propofol JJ N
sedation NN N
. . N

METHODS NNP N
The DT N
cohort NN N
included VBD N
81 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
diagnostic JJ 1_p
or CC 1_p
therapeutic JJ 1_p
bronchoscopy NN 1_p
under IN 1_p
propofol NN 1_i
sedation NN 1_i
that WDT N
were VBD N
prospectively RB 1_i
randomized VBN 1_i
to TO 1_i
guide VB 1_i
the DT 1_i
depth NN 1_o
of IN 1_o
sedation NN 1_o
by IN 1_i
BIS NNP 1_i
monitoring NN 1_i
( ( 1_i
BIS NNP 1_i
group NN 1_i
; : 1_i
n CC 1_i
= VB 1_i
40 CD 1_i
) ) 1_i
or CC 1_i
conventional JJ 1_i
monitoring NN 1_i
( ( 1_i
control JJ 1_i
group NN 1_i
; : 1_i
n CC 1_i
= VB 1_i
41 CD 1_i
) ) 1_i
. . 1_i

RESULTS VB N
The DT N
mean JJ N
durations NNS N
of IN N
the DT N
procedure NN N
were VBD N
18 CD N
and CC N
19 CD N
min NN N
in IN N
the DT N
BIS NNP N
and CC N
control NN N
groups NNS N
, , N
respectively RB N
. . N

No UH N
significant JJ N
difference NN N
was VBD N
noted VBN N
in IN N
the DT N
dosage NN 1_o
of IN 1_o
propofol NN 1_o
used VBN N
between IN N
the DT N
BIS NNP N
and CC N
control NN N
groups NNS N
( ( N
168.7 CD N
vs. FW N
167.3 CD N
mg NN N
, , N
respectively RB N
) ) N
. . N

Average JJ 1_o
sedation-related JJ 1_o
oxygen NN 1_o
saturation NN 1_o
drop NN N
and CC N
transcutaneous JJ 1_o
CO2 NNP 1_o
rise NN N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
that WDT N
required VBD N
either DT N
hemodynamic JJ N
support NN N
( ( N
5 CD N
vs. FW N
7.5 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
oxygen JJ N
supplementation NN N
by IN N
100 CD N
% NN N
O2 NNP N
mask NN N
( ( N
67.5 CD N
vs. FW N
82.5 CD N
% NN N
, , N
respectively RB N
) ) N
or CC N
Ambu NNP N
face VBP N
mask JJ N
manual JJ N
ventilation NN N
( ( N
2.5 CD N
vs. FW N
5 CD N
% NN N
, , N
respectively RB N
) ) N
between IN N
the DT N
groups NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
in IN N
terms NNS N
of IN N
patients NNS 1_o
' POS 1_o
awareness NN 1_o
during IN N
the DT N
procedure NN N
, , N
which WDT N
was VBD N
assessed VBN N
following VBG N
recovery NN N
by IN N
a DT N
structured JJ N
Brice NNP N
interview NN N
. . N

CONCLUSION NNP N
Using VBG N
BIS NNP N
to TO N
guide VB N
the DT N
depth NN N
of IN N
sedation NN N
during IN N
propofol JJ N
sedation NN N
in IN N
patients NNS 1_p
undergoing VBG 1_p
FFB NNP 1_p
of IN 1_p
relatively RB 1_p
short JJ 1_p
duration NN 1_p
offers VBZ N
no DT N
clinically RB N
significant JJ N
advantages NNS N
over IN N
conventional JJ N
monitoring NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
desonide NN 1_i
ointment NN 1_i
, , 1_i
0.05 CD 1_i
% NN 1_i
, , N
on IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
of IN N
children NNS 1_p
with IN 1_p
atopic NN 1_p
dermatitis NN 1_p
. . 1_p

Desonide NNP 1_i
ointment NN 1_i
has VBZ N
demonstrated VBN N
a DT N
good JJ N
safety NN N
and CC N
efficacy NN N
profile NN N
during IN N
the DT N
many JJ N
years NNS N
it PRP N
has VBZ N
been VBN N
used VBN N
in IN N
treating VBG N
dermatoses NNS N
. . N

However RB N
, , N
there EX N
have VBP N
been VBN N
no DT N
controlled JJ N
clinical JJ N
trials NNS N
to TO N
evaluate VB N
its PRP$ N
systemic JJ N
safety NN N
when WRB N
used VBN N
in IN N
treating VBG N
children NNS 1_p
. . 1_p

Suppression NN N
of IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
axis NN N
can MD N
occur VB N
after IN N
repeated JJ N
application NN N
of IN N
topical JJ N
corticosteroids NNS N
. . N

In IN N
general JJ N
, , N
the DT N
degree NN 1_o
of IN 1_o
suppression NN 1_o
of IN 1_o
the DT 1_o
HPA NNP 1_o
axis NN 1_o
function NN 1_o
is VBZ N
related VBN N
to TO N
the DT N
daily JJ N
dosage NN N
of IN N
steroid JJ N
given VBN N
, , N
the DT N
duration NN N
of IN N
its PRP$ N
administration NN N
, , N
the DT N
extent NN N
of IN N
body NN N
surface NN N
covered VBN N
, , N
and CC N
the DT N
potency NN N
of IN N
the DT N
corticosteroid NN N
. . N

This DT N
study NN N
sought VBD N
to TO N
determine VB N
the DT N
comparative JJ N
effects NNS N
of IN N
0.05 CD 1_i
percent NN 1_i
desonide NN 1_i
and CC 1_i
2.5 CD 1_i
percent NN 1_i
hydrocortisone NN 1_i
ointments NNS 1_i
on IN N
the DT N
HPA NNP N
axis NN N
of IN N
children NNS 1_p
with IN 1_p
atopic NN 1_p
dermatitis NN 1_p
. . 1_p

There EX N
was VBD N
no DT N
suppression NN 1_o
of IN 1_o
early JJ 1_o
morning NN 1_o
cortisol NN 1_o
in IN N
either DT N
treatment NN N
group NN N
. . N

The DT N
ACTH-stimulated JJ 1_o
mean NN 1_o
cortisol NN 1_o
values NNS 1_o
after IN N
four CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
baseline NN N
values VBZ N
for IN N
either DT N
treatment NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
neither CC N
0.05 CD 1_i
percent NN 1_i
desonide NN 1_i
ointment NN 1_i
nor CC N
2.5 CD 1_i
percent NN 1_i
hydrocortisone NN 1_i
ointment NN 1_i
compromised VBD N
the DT N
HPA NNP N
axis NN N
of IN N
children NNS 1_p
with IN 1_p
atopic NN 1_p
dermatitis NN 1_p
treated VBD N
topically RB N
for IN N
four CD N
weeks NNS N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
postdischarge NN N
outcomes NNS N
from IN N
information NN N
acquired VBN N
shortly RB N
after IN N
admission NN N
for IN N
acute JJ 1_p
heart NN 1_p
failure NN 1_p
: : 1_p
a DT N
report NN N
from IN N
the DT N
Placebo-Controlled NNP 1_i
Randomized NNP N
Study NNP N
of IN N
the DT N
Selective NNP 1_i
A1 NNP 1_i
Adenosine NNP 1_i
Receptor NNP 1_i
Antagonist NNP 1_i
Rolofylline NNP 1_i
for IN N
Patients NNP 1_p
Hospitalized NNP 1_p
With IN 1_p
Acute NNP 1_p
Decompensated NNP 1_p
Heart NNP 1_p
Failure NNP 1_p
and CC 1_p
Volume NN 1_p
Overload NNP 1_p
to TO N
Assess NNP N
Treatment NNP N
Effect NNP N
on IN N
Congestion NNP N
and CC N
Renal NNP N
Function NNP N
( ( N
PROTECT NNP N
) ) N
Study NNP N
. . N

BACKGROUND NNP N
Acute NNP 1_p
heart NN 1_p
failure NN 1_p
is VBZ N
a DT N
common JJ N
reason NN N
for IN N
admission NN N
, , N
and CC N
outcome NN N
is VBZ N
often RB N
poor JJ N
. . N

Improved VBN N
prognostic JJ N
risk NN N
stratification NN N
may MD N
assist VB N
in IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
and CC N
in IN N
patient JJ N
management NN N
. . N

Using VBG N
data NNS N
from IN N
a DT N
large JJ N
randomized JJ N
trial NN N
, , N
we PRP N
explored VBD N
the DT N
prognostic JJ N
value NN N
of IN N
clinical JJ N
variables NNS N
, , N
measured VBN N
at IN N
hospital JJ N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
, , N
to TO N
determine VB N
whether IN N
a DT N
few JJ N
selected VBN N
variables NNS N
were VBD N
inferior JJ N
to TO N
an DT N
extended VBN N
data NN N
set NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
prognostic JJ N
model NN N
included VBD N
37 CD N
clinical JJ N
characteristics NNS N
collected VBN N
at IN N
baseline NN N
in IN N
PROTECT NNP N
, , N
a DT N
study NN N
comparing VBG N
rolofylline NN 1_i
and CC 1_i
placebo NN 1_i
in IN N
2033 CD 1_p
patients NNS 1_p
admitted VBN 1_p
with IN 1_p
acute JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

Prespecified VBN N
outcomes NNS N
at IN N
30 CD N
days NNS N
were VBD N
death NN 1_o
or CC 1_o
rehospitalization NN 1_o
for IN 1_o
any DT 1_o
reason NN 1_o
; : 1_o
death NN 1_o
or CC 1_o
rehospitalization NN 1_o
for IN 1_o
cardiovascular NN 1_o
or CC 1_o
renal JJ 1_o
reasons NNS 1_o
; : 1_o
and CC N
, , N
at IN N
both DT N
30 CD N
and CC N
180 CD N
days NNS N
, , N
all-cause JJ N
mortality NN N
. . N

No DT N
variable JJ N
had VBD N
a DT N
c-index NN N
> NN N
0.70 CD N
, , N
and CC N
few JJ N
had VBD N
values NNS N
> $ N
0.60 CD N
; : N
c-indices NNS N
were VBD N
lower JJR N
for IN N
composite JJ N
outcomes NNS N
than IN N
for IN N
mortality NN N
. . N

Blood NNP 1_o
urea NN 1_o
was VBD N
generally RB N
the DT N
strongest JJS N
single JJ N
predictor NN N
. . N

Eighteen NNP N
variables NNS N
contributed VBD N
independent JJ N
prognostic JJ N
information NN N
, , N
but CC N
a DT N
reduced JJ N
model NN N
using VBG N
only RB N
8 CD N
items NNS N
( ( N
age NN N
, , N
previous JJ N
heart NN N
failure NN N
hospitalization NN N
, , N
peripheral JJ N
edema NN N
, , N
systolic JJ N
blood NN N
pressure NN N
, , N
serum NN N
sodium NN N
, , N
urea JJ N
, , N
creatinine NN N
, , N
and CC N
albumin NN N
) ) N
performed VBD N
similarly RB N
. . N

For IN N
prediction NN N
of IN N
all-cause JJ 1_o
mortality NN 1_o
at IN N
180 CD N
days NNS N
, , N
the DT N
model NN N
c-index NN N
using VBG N
all DT N
variables NNS N
was VBD N
0.72 CD N
and CC N
for IN N
the DT N
simplified JJ N
model NN N
, , N
also RB N
0.72 CD N
. . N

CONCLUSIONS VB N
A NNP N
few JJ N
simple JJ N
clinical JJ N
variables NNS N
measured VBN N
on IN N
admission NN N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
heart NN 1_p
failure NN 1_p
predict VBP N
a DT N
variety NN 1_o
of IN 1_o
adverse JJ 1_o
outcomes NNS 1_o
with IN N
accuracy NN 1_o
similar JJ N
to TO N
more RBR N
complex JJ N
models NNS N
. . N

However RB N
, , N
predictive JJ N
models NNS N
were VBD N
of IN N
only RB N
moderate JJ 1_o
accuracy NN 1_o
, , N
especially RB N
for IN N
outcomes NNS 1_o
that WDT 1_o
included VBD 1_o
nonfatal JJ 1_o
events NNS 1_o
. . 1_o

Better NNP N
methods NNS N
of IN N
risk NN N
stratification NN N
are VBP N
required VBN N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique JJ N
identifiers NNS N
: : N
NCT00328692 NNP N
and CC N
NCT00354458 NNP N
. . N

-DOCSTART- -X- O O

Advice NN N
or CC N
exercise NN N
for IN N
chronic JJ 1_p
whiplash NN 1_p
disorders NNS 1_p
? . N
Design NNP N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Whiplash-associated JJ 1_p
disorder NN 1_p
( ( N
or CC N
whiplash NN N
) ) N
is VBZ N
a DT N
common JJ N
condition NN N
incurring VBG N
considerable JJ N
expense NN N
in IN N
social JJ N
and CC N
economic JJ N
terms NNS N
. . N

A DT N
lack NN N
of IN N
research NN N
on IN N
effective JJ N
therapy NN N
for IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
whiplash NN 1_p
associated VBN 1_p
disorders NNS 1_p
prompted VBD N
the DT N
design NN N
of IN N
the DT N
current JJ N
study NN N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
randomised VBN N
controlled VBN N
trial NN N
is VBZ N
to TO N
determine VB N
the DT N
effects NNS 1_o
of IN 1_o
a DT 1_o
physical JJ 1_o
activity NN 1_o
program NN 1_o
for IN 1_o
people NNS 1_o
with IN 1_o
chronic JJ 1_o
( ( 1_o
symptoms NNS 1_o
of IN 1_o
> JJ 1_o
3 CD 1_o
months NNS 1_o
duration NN 1_o
) ) 1_o
whiplash NN 1_o
. . 1_o

A DT N
secondary JJ N
aim NN N
is VBZ N
to TO N
determine VB N
if IN N
pain JJ 1_o
severity NN 1_o
, , 1_o
level NN 1_o
of IN 1_o
disability NN 1_o
and CC 1_o
fear NN 1_o
of IN 1_o
movement/ NN 1_o
( ( 1_o
re NN 1_o
) ) 1_o
injury NN 1_o
predict VBP N
response NN 1_o
to TO N
a DT N
physical JJ N
activity NN N
program NN N
. . N

METHODS/DESIGN NNP N
This DT N
paper NN N
presents VBZ N
the DT N
rationale NN N
and CC N
design NN N
of IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
examining VBG N
the DT N
effects NNS 1_o
of IN 1_o
advice NN 1_o
and CC 1_o
individualized JJ 1_o
sub-maximal JJ 1_o
exercise NN 1_o
programs NNS 1_o
in IN N
the DT N
treatment NN N
of IN N
whiplash NN 1_p
associated VBN 1_p
disorders NNS 1_p
. . 1_p

DISCUSSION NNP N
This DT N
paper NN N
highlights VBZ N
the DT N
design NN N
, , N
methods NNS N
and CC N
operational JJ N
aspects NNS N
of IN N
a DT N
significant JJ N
clinical JJ N
trial NN N
in IN N
the DT N
area NN N
of IN N
whiplash NN 1_p
and CC 1_p
chronic JJ 1_p
pain NN 1_p
. . 1_p

-DOCSTART- -X- O O

Ventilatory JJ N
function NN N
during IN N
urography NN N
: : N
a DT N
comparison NN N
of IN N
iopamidol NN 1_i
and CC N
sodium NN 1_i
iothalamate NN 1_i
. . 1_i

The DT N
effects NNS N
on IN N
respiratory JJ N
function NN N
during IN N
intravenous JJ N
urography NN N
of IN N
the DT N
ionic JJ N
contrast NN N
medium NN N
sodium NN 1_i
iothalamate NN 1_i
and CC N
the DT N
non-ionic JJ 1_i
contrast NN 1_i
medium NN 1_i
iopamidol NN 1_i
were VBD N
compared VBN N
. . N

Forced NNP 1_o
expiratory JJ 1_o
volume NN 1_o
in IN 1_o
1 CD 1_o
s NN 1_o
( ( 1_o
FEV1 NNP 1_o
) ) 1_o
and CC N
forced VBN 1_o
vital JJ 1_o
capacity NN 1_o
( ( 1_o
FVC NNP 1_o
) ) 1_o
were VBD N
recorded VBN N
in IN N
37 CD 1_p
non-atopic JJ 1_p
patients NNS 1_p
referred VBD 1_p
for IN 1_p
intravenous JJ 1_p
urography NN 1_p
. . 1_p

Nineteen JJ 1_p
patients NNS 1_p
received VBD N
iopamidol JJ 1_i
and CC 1_i
18 CD 1_i
patients NNS 1_i
received VBD 1_i
sodium JJ 1_i
iothalamate NN 1_i
. . 1_i

Both CC N
the DT N
sodium NN 1_i
iothalamate NN 1_i
and CC N
the DT N
iopamidol NN 1_i
groups NNS N
showed VBD N
a DT N
significant JJ N
fall NN N
in IN N
FEV1 NNP 1_o
and CC 1_o
FVC NNP 1_o
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
reductions NNS N
in IN N
FEV1 NNP 1_o
and CC 1_o
FVC NNP 1_o
were VBD N
comparable JJ N
and CC N
were VBD N
not RB N
symptomatic JJ N
. . N

The DT N
differences NNS N
in IN N
the DT N
percentage NN N
changes NNS N
of IN N
the DT N
FEV1 NNP 1_o
and CC 1_o
FVC NNP 1_o
in IN N
the DT N
iopamidol NN 1_i
and CC N
the DT N
sodium NN 1_i
iothalamate NN 1_i
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
greater JJR N
than IN N
0.5 CD N
and CC N
P NNP N
greater JJR N
than IN N
0.1 CD N
respectively RB N
) ) N
. . N

No DT N
significant JJ N
change NN N
in IN N
the DT N
ratio NN 1_o
of IN 1_o
the DT 1_o
FEV1 NNP 1_o
and CC 1_o
the DT 1_o
FVC NNP 1_o
was VBD N
demonstrated VBN N
in IN N
either CC N
the DT N
iopamidol NN N
or CC N
the DT N
sodium NN N
iothalamate NN N
groups NNS N
. . N

Both CC N
the DT N
ionic NN N
and CC N
the DT N
non-ionic JJ N
contrast NN N
media NNS N
produced VBD N
a DT N
measurable JJ N
but CC N
asymptomatic JJ N
and CC N
biologically RB N
insignificant JJ N
fall NN N
in IN N
static JJ 1_o
ventilatory NN 1_o
function NN 1_o
. . 1_o

Bronchospasm NNP 1_o
does VBZ N
not RB N
appear VB N
to TO N
be VB N
an DT N
important JJ N
contrast-induced JJ N
effect NN N
in IN N
non-atopic JJ N
individuals NNS N
. . N

Iopamidol NNP 1_i
offers VBZ N
no DT N
advantage NN N
over IN N
sodium JJ 1_i
iothalamate NN 1_i
with IN N
respect NN N
to TO N
ventilatory JJ N
effects NNS N
in IN N
non-atopic JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
intravenous JJ 1_p
urography NN 1_p
. . 1_p

-DOCSTART- -X- O O

Effect NN N
of IN N
enalapril NN 1_i
on IN N
myocardial JJ N
infarction NN N
and CC N
unstable JJ N
angina NN N
in IN N
patients NNS 1_p
with IN 1_p
low JJ 1_p
ejection NN 1_p
fractions NNS 1_p
. . 1_p

An DT N
association NN N
between IN N
raised VBN N
renin NN N
levels NNS N
and CC N
myocardial JJ N
infarction NN N
has VBZ N
been VBN N
reported VBN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
enalapril NN 1_i
, , N
an DT N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitor NN N
, , N
on IN N
the DT N
development NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
unstable JJ N
angina NN N
in IN N
6797 CD 1_p
patients NNS 1_p
with IN 1_p
ejection NN 1_p
fractions NNS 1_p
< VBP 1_p
or CC 1_p
= VBP 1_p
0.35 CD 1_p
enrolled VBN 1_p
into IN 1_p
the DT 1_p
two CD 1_p
Studies NNS 1_p
of IN 1_p
Left NNP 1_p
Ventricular NNP 1_p
Dysfunction NNP 1_p
( ( 1_p
SOLVD NNP 1_p
) ) 1_p
trials NNS 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB 1_i
( ( N
n JJ N
= NN N
3401 CD N
) ) N
or CC N
enalapril $ 1_i
( ( N
n JJ N
= NN N
3396 CD N
) ) N
at IN N
doses NNS N
of IN N
2.5-20 JJ N
mg NNS N
per IN N
day NN N
in IN N
two CD N
concurrent JJ N
double-blind JJ N
trials NNS N
with IN N
the DT N
same JJ N
protocol NN N
. . N

Patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
entered VBD 1_p
the DT 1_p
treatment NN 1_p
trial NN 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
2569 CD 1_p
) ) 1_p
and CC 1_p
those DT 1_p
without IN 1_p
heart NN 1_p
failure NN 1_p
entered VBD 1_p
the DT 1_p
prevention NN 1_p
trial NN 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
4228 CD 1_p
) ) 1_p
. . 1_p

Follow-up NNP N
averaged VBD N
40 CD N
months NNS N
. . N

In IN N
each DT N
trial NN N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
developing VBG N
myocardial JJ N
infarction NN N
( ( N
treatment NN N
trial NN N
: : N
158 CD N
placebo NN 1_i
vs NN N
127 CD N
enalapril NN 1_i
, , N
p NN N
< VBD N
0.02 CD N
; : N
prevention NN N
trial NN N
: : N
204 CD N
vs NN N
161 CD N
p NN N
< NNP N
0.01 CD N
) ) N
or CC N
unstable JJ N
angina NN N
( ( N
240 CD N
vs RB N
187 CD N
p NN N
< NN N
0.001 CD N
; : N
355 CD N
vs NN N
312 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

Combined VBN N
, , N
there EX N
were VBD N
362 CD 1_p
placebo NNS 1_i
group NN 1_p
patients NNS N
with IN N
myocardial JJ N
infarction NN N
compared VBN N
with IN N
288 CD N
in IN N
the DT N
enalapril NN 1_i
group NN N
( ( N
risk NN N
reduction NN N
23 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
11-34 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

595 CD 1_p
placebo NN 1_i
group NN 1_p
patients NNS N
developed VBD N
unstable JJ 1_o
angina NNS 1_o
compared VBN N
with IN N
499 CD N
in IN N
the DT N
enalapril NN 1_i
group NN N
( ( N
risk NN N
reduction NN N
20 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
9-29 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
reduction NN 1_o
in IN 1_o
cardiac JJ 1_o
deaths NNS 1_o
( ( N
711 CD N
placebo NN 1_i
, , N
615 CD N
enalapril NN 1_i
; : 1_i
p CC N
< VB N
0.003 CD N
) ) N
, , N
so RB N
that IN N
the DT N
reduction NN N
in IN N
the DT N
combined JJ 1_o
endpoint NN 1_o
of IN 1_o
deaths NNS 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
and CC 1_o
unstable JJ 1_o
angina NN 1_o
was VBD N
highly RB N
significant JJ N
( ( N
20 CD N
% NN N
risk NN N
reduction NN N
, , N
95 CD N
% NN N
CI NNP N
14-26 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Enalapril NNP 1_i
treatment NN N
significantly RB N
reduced VBN N
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
unstable JJ 1_o
angina NN 1_o
, , 1_o
and CC 1_o
cardiac JJ 1_o
mortality NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
low JJ 1_p
ejection NN 1_p
fractions NNS 1_p
. . 1_p

-DOCSTART- -X- O O

B-vitamins NNS 1_i
reduce VB N
plasma NN 1_o
levels NNS 1_o
of IN N
beta NN N
amyloid NN N
. . N

Elevated VBN N
plasma JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
Alzheimer NNP N
's POS N
disease NN N
( ( N
AD NNP N
) ) N
, , N
and CC N
thus RB N
B NNP 1_i
vitamins NNS 1_i
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
tHcy JJ N
lowering NN N
vitamins NNS N
decrease VBP N
the DT N
circulating NN 1_o
levels NNS 1_o
of IN 1_o
A-beta NNP 1_o
protein NN 1_o
1-40 JJ 1_o
( ( 1_o
A NNP 1_o
beta RB 1_o
40 CD 1_o
) ) 1_o
. . 1_o

We PRP N
randomized VBD N
299 CD 1_p
older JJR 1_p
men NNS 1_p
to TO N
treatment NN N
with IN N
2mg CD 1_i
of IN 1_i
folate NN 1_i
, , 1_i
plus CC 1_i
25mg CD 1_i
of IN 1_i
B6 NNP 1_i
and CC 1_i
400 CD 1_i
microg NN 1_i
of IN 1_i
B12 NNP 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

After IN N
2 CD N
years NNS N
of IN N
treatment NN N
the DT N
mean NN 1_o
( ( 1_o
S.E NNP 1_o
. . 1_o

) ) 1_o
increase NN 1_o
of IN 1_o
A NNP 1_o
beta NN 1_o
40 CD 1_o
was VBD N
7.0 CD N
pg/ml NN N
( ( N
8.4 CD N
) ) N
in IN N
the DT N
vitamin NN N
group NN N
( ( N
4.9 CD N
% NN N
) ) N
, , N
and CC N
26.8 CD N
pg/ml NN N
( ( N
7.7 CD N
) ) N
( ( N
18.5 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
B NNP N
vitamins NNS N
may MD N
decrease VB N
the DT 1_o
plasma JJ 1_o
level NN 1_o
of IN 1_o
A NNP 1_o
beta NN 1_o
40 CD 1_o
and CC N
have VBP N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

-DOCSTART- -X- O O

How WRB N
to TO N
establish VB N
equivalence NN N
when WRB N
data NNS N
are VBP N
censored VBN N
: : N
a DT N
randomized JJ 1_p
trial NN 1_p
of IN 1_p
treatments NNS 1_p
for IN 1_p
B NNP 1_p
non-Hodgkin JJ 1_p
lymphoma NN 1_p
. . 1_p

Interest NN N
in IN N
equivalence NN N
trials NNS N
has VBZ N
been VBN N
increasing VBG N
for IN N
many JJ N
years NNS N
, , N
though IN N
the DT N
methodology NN N
which WDT N
has VBZ N
been VBN N
developed VBN N
for IN N
such JJ N
trials NNS N
is VBZ N
mainly RB N
for IN N
uncensored JJ N
data NNS N
. . N

In IN N
cancer NN N
research NN N
we PRP N
are VBP N
more RBR N
often RB N
concerned VBN N
with IN N
survival NN 1_o
. . 1_o

In IN N
an DT N
efficacy NN N
trial NN N
, , N
the DT N
null JJ N
hypothesis NN N
specifies NNS N
equality NN N
of IN N
the DT N
two CD N
survival JJ N
distributions NNS N
, , N
but CC N
in IN N
an DT N
equivalence NN N
trial NN N
, , N
a DT N
null JJ N
hypothesis NN N
of IN N
inequivalence NN N
H0 NNP N
has VBZ N
to TO N
be VB N
tested VBN N
. . N

The DT N
usual JJ N
logrank NN 1_i
test NN 1_i
has VBZ N
to TO N
be VB N
modified VBN N
to TO N
test VB N
whether IN N
the DT N
true JJ N
value NN N
r NN N
of IN N
the DT N
ratio NN N
of IN N
hazard NN N
rates NNS N
in IN N
two CD N
treatment NN N
groups NNS N
is VBZ N
at IN N
least JJS N
equal JJ N
to TO N
a DT N
limit NN N
value NN N
r0 NN N
. . N

If IN N
prognostic JJ N
factors NNS N
have VBP N
to TO N
be VB N
taken VBN N
into IN N
account NN N
, , N
the DT N
Cox NNP N
model NN N
provides VBZ N
tests NNS N
of IN N
Ho NNP N
, , N
and CC N
a DT N
useful JJ N
confidence NN N
interval NN N
for IN N
the DT N
adjusted JJ N
relative JJ N
derived VBN N
from IN N
the DT N
regression NN N
parameter NN N
for IN N
the DT N
treatment NN N
indicator NN N
. . N

An DT N
equivalence NN N
trial NN N
of IN N
maintenance NN 1_i
therapy NN 1_i
was VBD N
carried VBN N
out RP N
in IN N
children NNS 1_p
with IN 1_p
B NNP 1_p
non-Hodgkin JJ 1_p
lymphoma NN 1_p
, , N
and CC N
serves VBZ N
as IN N
an DT N
illustration NN N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
study NN N
of IN N
ofloxacin NN 1_i
and CC N
amoxycillin/clavulanate NN 1_i
in IN N
hospitalized JJ 1_p
patients NNS 1_p
with IN 1_p
lower JJR 1_o
respiratory NN 1_o
tract JJ 1_o
infections NNS 1_o
. . 1_o

We PRP N
conducted VBD N
an DT N
open JJ N
randomized VBN N
trial NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
parenteral JJ N
and CC N
oral JJ N
ofloxacin NN 1_i
with IN N
that DT N
of IN N
amoxycillin/clavulanate NN 1_i
. . 1_i

A DT N
total NN N
of IN N
121 CD 1_p
patients NNS 1_p
was VBD 1_p
studied VBN 1_p
; : 1_p
92 CD 1_p
were VBD 1_p
clinically RB 1_p
evaluable JJ 1_p
. . 1_p

Of IN N
these DT N
, , N
59 CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
ofloxacin NN 1_i
and CC 1_p
33 CD 1_p
with IN 1_p
the DT 1_p
comparator NN 1_p
drug NN 1_p
. . 1_p

Patients NNS N
were VBD N
given VBN N
the DT N
drugs NNS N
intravenously RB N
for IN N
a DT N
minimum NN N
of IN N
three CD N
days NNS N
followed VBN N
by IN N
oral JJ N
preparations NNS N
for IN N
the DT N
next JJ N
seven CD N
to TO N
ten VB N
days NNS N
. . N

Ofloxacin NNP 1_i
was VBD N
usually RB N
administered VBN N
as IN N
a DT N
200 CD N
mg NN N
dose NN N
bd NN N
. . N

In IN N
the DT N
ofloxacin NN 1_i
treated VBN N
group NN N
all DT N
patients NNS N
showed VBD N
clinical JJ 1_o
improvement NN 1_o
. . 1_o

In IN N
the DT N
comparator NN N
group NN N
94 CD N
% NN N
improved VBN N
clinically RB N
( ( N
either CC N
a DT N
complete JJ N
or CC N
partial JJ N
response NN N
) ) N
, , N
while IN N
6 CD N
% NN N
were VBD N
clinical JJ N
failures NNS N
. . N

Of IN N
the DT N
bacteriologically RB N
evaluable JJ N
patients NNS N
19 CD N
of IN N
20 CD N
showed VBD N
a DT N
satisfactory JJ 1_o
bacteriological JJ 1_o
response NN 1_o
in IN N
the DT N
ofloxacin NN N
treated VBD N
group NN N
, , N
while IN N
in IN N
the DT N
comparator NN N
group NN N
the DT N
bacteriological JJ N
response NN N
was VBD N
judged VBN N
satisfactory NN N
in IN N
14 CD N
of IN N
17 CD N
patients NNS N
. . N

A DT N
small JJ N
proportion NN N
of IN N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
treated VBD N
with IN N
ofloxacin NN 1_i
suffered VBD N
mild JJ 1_o
adverse JJ 1_o
effects NNS 1_o
( ( 1_o
nausea NN 1_o
, , 1_o
vomiting VBG 1_o
, , 1_o
headache NN 1_o
, , 1_o
hypotension NN 1_o
and CC 1_o
rash NN 1_o
) ) 1_o
. . 1_o

On IN N
the DT N
whole NN N
, , N
ofloxacin NN N
was VBD N
well RB N
tolerated VBN 1_o
by IN N
our PRP$ N
patients NNS N
. . N

The DT N
two CD N
deaths NNS 1_o
that IN N
occurred VBD N
were VBD N
in IN N
the DT N
comparator NN N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
ofloxacin NN 1_i
in IN N
both DT N
oral JJ N
and CC N
parenteral JJ N
forms NNS N
is VBZ N
an DT N
effective JJ 1_o
and CC 1_o
safe JJ 1_o
drug NN N
in IN N
the DT N
treatment NN N
of IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

-DOCSTART- -X- O O

A DT N
multi-center NN N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
parenteral JJ 1_i
nutrition NN 1_i
titrated VBD N
to TO N
resting VBG N
energy NN N
expenditure NN N
in IN N
children NNS 1_p
undergoing VBG 1_p
hematopoietic JJ 1_p
stem NN 1_p
cell NN 1_p
transplantation NN 1_p
( ( 1_p
PNTREE NNP 1_p
) ) 1_p
: : 1_p
rationale NN N
and CC N
design NN N
. . N

BACKGROUND NNP N
Children NNP 1_p
undergoing VBG 1_p
hematopoietic JJ 1_p
stem NN 1_p
cell NN 1_p
transplantation NN 1_p
( ( 1_p
HSCT NNP 1_p
) ) 1_p
frequently RB N
require VBP N
prolonged JJ N
courses NNS N
of IN N
parenteral JJ 1_i
nutrition NN 1_i
( ( 1_i
PN NNP 1_i
) ) 1_i
as IN N
a DT N
consequence NN N
of IN N
gastrointestinal JJ N
dysfunction NN N
related VBN N
to TO N
preparative JJ N
chemotherapy NN N
and CC N
radiation NN N
. . N

PN NNP N
has VBZ N
been VBN N
associated VBN N
with IN N
shorter JJR N
engraftment NN N
time NN N
and CC N
decreased JJ N
mortality NN N
during IN N
HSCT NNP N
, , N
however RB N
, , N
it PRP N
is VBZ N
also RB N
linked VBN N
with IN N
complications NNS N
, , N
including VBG N
infections NNS 1_o
, , 1_o
liver RB 1_o
disease NN 1_o
, , 1_o
and CC 1_o
metabolic JJ 1_o
disturbances NNS 1_o
. . 1_o

Some DT N
of IN N
these DT N
complications NNS N
may MD N
be VB N
a DT N
result NN N
of IN N
providing VBG N
PN NNP N
in IN N
excess NN N
of IN N
nutrient JJ N
requirements NNS N
. . N

We PRP N
previously RB N
described VBD N
significant JJ N
reductions NNS N
in IN N
resting VBG N
energy NN N
expenditure NN N
( ( N
REE NNP N
) ) N
, , N
as IN N
measured VBN N
by IN N
indirect JJ N
calorimetry NN N
, , N
over IN N
the DT N
course NN N
of IN N
HSCT NNP N
. . N

We PRP N
also RB N
documented VBD N
a DT N
decline NN N
in IN N
mid-arm JJ N
muscle NN N
area NN N
, , N
suggesting VBG N
depletion NN N
of IN N
muscle NN N
mass NN N
, , N
while IN N
triceps NNS N
skinfold RB N
, , N
a DT N
marker NN N
of IN N
fat JJ N
stores NNS N
, , N
was VBD N
unchanged JJ N
. . N

These DT N
results NNS N
suggested VBD N
the DT N
need NN N
for IN N
further JJ N
study NN N
of IN N
energy NN N
expenditure NN N
, , N
body NN N
composition NN N
and CC N
nutritional JJ N
intake NN N
in IN N
this DT N
group NN N
of IN N
high JJ N
risk NN N
patients NNS N
. . N

DESIGN NNP N
AND CC N
HYPOTHESIS NNP N
We PRP N
hypothesize VBP N
that IN N
changes NNS N
in IN N
body NN N
composition NN N
affect JJ N
REE NNP N
during IN N
HSCT NNP N
, , N
and CC N
that IN N
standard JJ N
nutritional JJ N
support NN N
may MD N
lead VB N
to TO N
overfeeding VBG N
. . N

We PRP N
are VBP N
performing VBG N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
parenteral JJ 1_i
nutrition NN 1_i
among IN N
children NNS 1_p
undergoing VBG 1_p
allogeneic NN 1_p
HSCT NNP 1_p
. . 1_p

Subjects NNS N
are VBP N
randomized VBN N
to TO N
receive VB 1_i
PN NNP 1_i
designed VBN 1_i
to TO 1_i
provide VB 1_i
100 CD 1_i
% NN 1_i
of IN 1_i
measured JJ 1_i
REE NNP 1_i
, , 1_i
or CC 1_i
standard JJ 1_i
PN NNP 1_i
, , 1_i
i.e. NN 1_i
, , N
140 CD 1_i
% NN 1_i
of IN 1_i
estimated VBN 1_i
energy NN 1_i
expenditure NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
variable NN N
is VBZ N
change VBN 1_o
in IN 1_o
percent NN 1_o
body NN 1_o
fat JJ 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
include VBP N
glycemic JJ 1_o
control NN 1_o
and CC 1_o
frequency NN 1_o
of IN 1_o
infections NNS 1_o
, , 1_o
changes NNS 1_o
in IN 1_o
REE NNP 1_o
and CC 1_o
body NN 1_o
composition NN 1_o
. . 1_o

CONCLUSION NNP N
This DT N
study NN N
will MD N
provide VB N
unique JJ N
and CC N
comprehensive JJ N
nutritional JJ N
data NNS N
and CC N
its PRP$ N
results NNS N
will MD N
guide VB N
nutritional JJ N
therapy NN N
for IN N
children NNS 1_p
undergoing VBG 1_p
HSCT NNP 1_p
and CC N
possibly RB N
other JJ N
catabolic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
glycemic JJ N
load NN N
on IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
during IN N
weight JJ N
loss NN N
. . N

High JJ N
eating JJ N
behavior JJ N
self-efficacy NN N
may MD N
contribute VB N
to TO N
successful JJ N
weight JJ N
loss NN N
. . N

Diet JJ 1_i
interventions NNS 1_i
that WDT N
maximize VBP N
eating VBG N
behavior JJ N
self-efficacy NN N
may MD N
therefore VB N
improve VB N
weight NN N
loss NN N
outcomes NNS N
. . N

However RB N
, , N
data NNS N
on IN N
the DT N
effect NN N
of IN N
diet JJ N
composition NN N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
are VBP N
sparse JJ N
. . N

To TO N
determine VB N
the DT N
effects NNS N
of IN N
dietary JJ N
glycemic JJ N
load NN N
( ( N
GL NNP N
) ) N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
during IN N
weight JJ N
loss NN N
, , N
body NN 1_o
weight NN 1_o
and CC N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
were VBD N
measured VBN N
every DT N
six CD N
months NNS N
in IN N
overweight JJ 1_p
adults NNS 1_p
participating VBG 1_p
in IN 1_p
a DT 1_p
12-mo JJ 1_p
randomized JJ 1_p
trial NN 1_p
testing VBG 1_i
energy-restricted JJ 1_i
diets NNS 1_i
differing VBG 1_i
in IN 1_i
GL NNP 1_i
. . 1_i

All DT N
food NN N
was VBD N
provided VBN N
during IN N
the DT N
first JJ N
six CD N
months NNS N
and CC N
self-selected JJ N
thereafter NN N
. . N

Total JJ 1_o
mean JJ 1_o
weight NN 1_o
loss NN 1_o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
, , N
and CC N
GL-level NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
. . 1_o

In IN N
the DT N
combined JJ N
cohort NN N
, , N
individuals NNS N
losing VBG N
the DT N
most RBS N
weight JJ N
reported VBD N
improvements NNS N
in IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
, , N
whereas IN N
those DT N
achieving VBG N
less JJR N
weight JJ 1_o
loss NN 1_o
reported VBD N
decrements NNS N
in IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
. . 1_o

Decrements NNS N
in IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
were VBD N
associated VBN N
with IN N
subsequent JJ N
weight NN 1_o
regain NN N
when WRB N
diets NNS N
were VBD N
self-selected JJ N
. . N

While IN N
GL NNP N
does VBZ N
not RB N
appear VB N
to TO N
influence VB N
eating VBG N
behavior JJ N
self-efficacy NN N
, , N
lesser JJR N
amounts NNS N
of IN N
weight JJ N
loss NN N
on IN N
provided-food JJ 1_i
energy NN 1_i
restricted VBN 1_i
diets NNS 1_i
may MD N
deter VB N
successful JJ N
maintenance NN N
of IN N
weight JJ N
loss NN N
by IN N
attenuating VBG N
improvements NNS N
in IN N
eating VBG N
behavior JJ N
self-efficacy NN N
. . N

-DOCSTART- -X- O O

Analysis NN 1_o
of IN 1_o
treatment NN 1_o
in IN N
childhood NN 1_p
leukaemia NN 1_p
. . 1_p

I. NNP N
Predisposition NNP N
to TO N
methotrexate-induced JJ N
neutropenia NN N
after IN 1_p
craniospinal JJ 1_p
irradiation NN 1_p
. . 1_p

Report NNP N
to TO N
the DT N
Medical NNP N
Research NNP N
Council NNP N
of IN N
the DT N
Working NNP N
Party NNP N
on IN N
Leukaemia NNP 1_p
in IN 1_p
Childhood NNP 1_p
. . 1_p

The DT N
degree NN N
of IN N
drug-induced JJ N
neutropenia NNS 1_o
resulting VBG N
from IN N
a DT N
controlled VBN N
trial NN N
( ( N
UKALL NNP N
I PRP N
) ) N
of IN N
treatment NN N
in IN N
acute JJ 1_p
lymphoblastic JJ 1_p
leukaemia NN 1_p
was VBD N
analysed VBN N
. . N

The DT N
main JJ N
agent NN N
associated VBN N
with IN N
severe JJ 1_o
neutropenia NN 1_o
was VBD N
methotrexate NN 1_i
, , N
and CC N
methotrexate-induced JJ 1_o
neutropenia NN 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS 1_p
who WP 1_p
had VBD 1_p
received VBN 1_p
craniospinal JJ 1_p
irradiation NN 1_p
. . 1_p

The DT N
synergistic JJ 1_o
toxic NN 1_o
effect NN 1_o
of IN 1_o
irradiation NN 1_o
followed VBN N
by IN N
methotrexate NN N
treatment NN N
seems VBZ N
to TO N
have VB N
contributed VBN N
to TO N
three CD N
of IN N
the DT N
five CD N
deaths NNS 1_o
which WDT N
occurred VBD N
in IN N
complete JJ N
remission NN 1_o
in IN N
this DT N
trial NN N
; : N
all DT N
deaths NNS N
in IN N
remission NN N
occurred VBD N
in IN N
patients NNS N
who WP N
had VBD N
received VBN N
central JJ N
nervous JJ N
system NN N
prophylaxis NN N
. . N

Analysis NN N
of IN N
patients NNS N
who WP N
subsequently RB N
relapsed VBD N
compared VBN N
with IN N
those DT N
still RB N
in IN N
remission NN N
after IN N
18 CD N
months NNS N
of IN N
treatment NN N
indicated VBD N
that IN N
the DT N
former JJ N
, , N
on IN N
average NN N
, , N
had VBD N
slightly RB N
lower JJR N
neutrophil NN 1_o
counts NNS 1_o
. . 1_o

This DT N
suggests VBZ N
that IN N
the DT N
children NNS 1_p
who WP N
relapsed VBD N
did VBD N
not RB N
receive VB N
any DT N
less RBR N
aggressive JJ N
treatment NN N
than IN N
those DT N
who WP N
remained VBD N
in IN N
remission NN N
. . N

-DOCSTART- -X- O O

The DT N
6 CD N
minute NN N
walk NN N
in IN N
idiopathic JJ N
pulmonary JJ N
fibrosis NN N
: : N
longitudinal JJ N
changes NNS N
and CC N
minimum JJ N
important JJ N
difference NN N
. . N

RATIONALE VB N
The DT N
response NN N
characteristics NNS N
of IN N
the DT N
6 CD 1_i
minute NN 1_i
walk NN 1_i
test NN 1_i
( ( 1_i
6MWT CD 1_i
) ) 1_i
in IN N
studies NNS N
of IN N
idiopathic JJ 1_p
pulmonary JJ 1_p
fibrosis NN 1_p
( ( 1_p
IPF NNP 1_p
) ) 1_p
are VBP N
only RB N
poorly RB N
understood JJ N
, , N
and CC N
the DT N
change NN N
in IN N
walk NN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
minimum JJ N
important JJ N
difference NN N
( ( N
MID NNP N
) ) N
over IN N
time NN N
is VBZ N
unknown JJ N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
changes NNS N
over IN N
time NN 1_o
in IN 1_o
distance NN 1_o
walked VBD 1_o
( ( N
ie NN N
, , N
6MWD CD N
) ) N
during IN N
the DT N
6MWT CD 1_i
and CC N
to TO N
estimate VB N
the DT N
change NN N
in IN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
MID NNP N
in IN N
patients NNS 1_p
with IN 1_p
IPF NNP 1_p
. . 1_p

METHODS NNP N
Data NNP N
from IN N
a DT N
recently RB N
completed VBN N
trial NN N
that WDT N
included VBD N
subjects NNS 1_p
with IN 1_p
IPF NNP 1_p
who WP 1_p
completed VBD 1_p
the DT 1_p
6MWT CD 1_i
, , 1_p
Saint NNP 1_p
George NNP 1_p
's POS 1_p
Respiratory NNP 1_p
Questionnaire NNP 1_p
( ( 1_p
SGRQ NNP 1_p
) ) 1_p
and CC 1_p
forced VBN 1_p
vital JJ 1_p
capacity NN 1_p
( ( 1_p
FVC NNP 1_p
) ) 1_p
at IN N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
used VBN N
to TO N
examine VB N
longitudinal JJ N
changes NNS N
in IN N
6MWD CD N
. . N

Both DT N
anchor- JJ N
and CC N
distribution-based JJ N
approaches NNS N
as RB N
well RB N
as IN N
linear JJ N
regression NN N
analyses NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
MID NNP N
for IN N
6MWD CD N
. . N

The DT N
SGRQ NNP 1_o
Total NNP 1_o
score NN 1_o
and CC 1_o
FVC NNP 1_o
were VBD N
used VBN N
as IN N
clinical JJ N
anchors NNS N
. . N

MAIN NNP N
RESULTS NNP N
Among IN N
123 CD 1_p
subjects NNS 1_p
alive JJ 1_p
and CC 1_p
able JJ 1_p
to TO 1_p
complete VB 1_p
the DT 1_p
6MWT CD 1_p
at IN 1_p
both DT 1_p
follow-up JJ 1_p
time NN 1_p
points NNS 1_p
, , N
6MWD CD 1_o
did VBD N
not RB N
change VB N
significantly RB N
over IN N
time NN N
( ( N
378.1 CD N
m NN N
at IN N
baseline NN N
vs NN N
376.8 CD N
m NN N
at IN N
6 CD N
months NNS N
vs RB N
361.3 CD N
m NN N
at IN N
12 CD N
months NNS N
, , N
p=0.5 NN N
) ) N
. . N

The DT N
point NN N
estimate NN N
for IN N
the DT N
6MWD CD 1_o
MID NNP 1_o
was VBD N
28 CD N
m NN N
with IN N
a DT N
range NN N
of IN N
10.8-58.5 JJ N
m. JJ N
CONCLUSION NNP N
In IN N
a DT N
group NN N
of IN N
patients NNS 1_p
with IN 1_p
IPF NNP 1_p
with IN 1_p
moderate JJ 1_p
physiological JJ 1_p
impairment NN 1_p
, , N
for IN N
those DT N
alive JJ N
and CC N
able JJ N
to TO N
complete VB N
a DT N
6MWT CD N
, , N
6MWD CD 1_o
does VBZ N
not RB N
change VB N
over IN N
12 CD N
months NNS N
. . N

At IN N
the DT N
population NN N
level NN N
, , N
the DT N
MID NNP N
for IN N
6MWD CD 1_o
appears VBZ N
to TO N
be VB N
approximately RB N
28 CD N
m. NNS N
Further NNP N
investigation NN N
using VBG N
other JJ N
anchors NNS N
and CC N
derivation NN N
methods NNS N
is VBZ N
required VBN N
to TO N
refine VB N
estimates NNS N
of IN N
the DT N
MID NNP N
for IN N
6MWD CD N
in IN N
this DT N
patient JJ 1_p
population NN 1_p
. . 1_p

-DOCSTART- -X- O O

Long-term JJ N
use NN N
of IN N
Viozan NNP 1_i
( ( 1_i
sibenadet JJ 1_i
HCl NNP 1_i
) ) 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
: : 1_p
results NNS N
of IN N
a DT N
1-year JJ N
study NN N
. . N

Viozan NNP 1_i
( ( 1_i
sibenadet JJ 1_i
HCl NNP 1_i
, , 1_i
AR-C68397AA NNP 1_i
) ) 1_i
is VBZ N
a DT N
novel JJ N
dual JJ N
D2 NNP N
dopamine NN N
receptor NN N
, , N
beta2-adrenoceptor JJ N
agonist NN N
that WDT N
has VBZ N
been VBN N
investigated VBN N
for IN N
efficacy NN N
in IN N
alleviating VBG N
the DT N
symptoms NNS N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
. . N

The DT N
slowly RB N
progressive JJ N
nature NN N
of IN N
this DT N
disease NN N
means VBZ N
that IN N
patients NNS N
will MD N
require VB N
ongoing JJ N
therapeutic JJ N
management NN N
for IN N
many JJ N
years NNS N
, , N
or CC N
even RB N
decades NNS N
. . N

With IN N
such JJ N
long-term JJ N
treatment NN N
, , N
the DT N
safety NN N
profile NN N
of IN N
new JJ N
agents NNS N
will MD N
be VB N
of IN N
paramount JJ N
importance NN N
. . N

As IN N
part NN N
of IN N
the DT N
large-scale JJ N
assessment NN N
of IN N
sibenadet NN 1_i
, , N
a DT N
12-month JJ N
safety NN N
study NN N
has VBZ N
been VBN N
conducted VBN N
. . N

Following VBG N
completion NN N
of IN N
a DT N
2-week JJ N
baseline NN N
period NN N
, , N
435 CD 1_p
adults NNS 1_p
with IN 1_p
stable JJ 1_p
, , 1_p
symptomatic JJ 1_p
, , 1_p
smoking-related JJ 1_p
COPD NNP 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
receive VB N
either RB N
500 CD 1_i
microg NN 1_i
sibenadet NN 1_i
or CC 1_i
placebo NN 1_i
delivered VBN N
via IN N
pressurized VBN N
metered VBD N
dose JJ N
inhaler NN N
( ( N
pMDI NN N
) ) N
, , N
three CD N
times NNS N
daily RB N
for IN N
52 CD N
weeks NNS N
. . N

Sibenadet NNP 1_i
therapy NN 1_i
was VBD N
generally RB N
well RB 1_o
tolerated VBN 1_o
, , N
with IN N
the DT N
only JJ N
notable JJ 1_o
differences NNS 1_o
seen VBN N
in IN N
the DT N
incidence NN 1_o
of IN 1_o
tremor NN 1_o
and CC 1_o
taste NN 1_o
of IN 1_o
treatment NN 1_o
( ( N
16.9 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
and CC N
14.5 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
in IN N
the DT N
sibenadet NN N
and CC N
placebo NN 1_i
groups NNS N
respectively RB N
) ) N
. . N

There EX N
were VBD N
a DT N
total NN N
of IN N
79 CD 1_p
patients NNS 1_p
with IN 1_p
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_p
SAEs NNP 1_p
) ) 1_p
, , 1_p
43 CD 1_p
( ( 1_p
14.8 CD 1_p
% NN 1_p
) ) 1_p
in IN 1_p
the DT 1_p
sibenadet NN 1_p
pMDI NN 1_p
group NN 1_p
and CC 1_p
36 CD 1_p
( ( 1_p
24.8 CD 1_p
% NN 1_p
) ) 1_p
in IN 1_p
the DT 1_p
placebo NN 1_i
group NN 1_i
. . 1_i

No DT N
clinically RB 1_o
significant JJ 1_o
abnormal JJ 1_o
laboratory NN 1_o
values NNS 1_o
or CC N
overall JJ 1_o
differences NNS 1_o
between IN N
treatment NN N
groups NNS N
were VBD N
noted VBN N
. . N

Similarly RB N
, , N
there EX N
were VBD N
no DT 1_o
clinically RB 1_o
significant JJ 1_o
differences NNS 1_o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
cardiac JJ 1_o
variables NNS 1_o
, , 1_o
or CC 1_o
in IN 1_o
vital JJ 1_o
signs NNS 1_o
. . 1_o

The DT N
secondary JJ 1_o
variables NNS 1_o
showed VBD N
no DT 1_o
notable JJ 1_o
differences NNS 1_o
with IN N
respect NN N
to TO N
lung NN 1_o
function NN 1_o
, , 1_o
exacerbations NNS 1_o
or CC 1_o
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

Due NNP N
to TO N
the DT N
effective JJ N
beta2-agonist NN N
properties NNS N
, , N
patients NNS N
in IN N
the DT N
sibenadet NN N
group NN N
did VBD N
, , N
however RB N
, , N
report NN N
reduced VBD 1_o
rescue JJ 1_o
medication NN 1_o
usage NN 1_o
at IN 1_o
all DT 1_o
timepoints NNS 1_o
. . 1_o

While IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
, , N
overall JJ N
, , N
sibenadet JJ N
therapy NN N
was VBD N
well RB 1_o
tolerated VBN 1_o
, , N
the DT N
lack NN 1_o
of IN 1_o
sustained JJ 1_o
benefit NN 1_o
reported VBD N
in IN N
large-scale JJ 1_o
clinical JJ 1_o
efficacy NN 1_o
studies NNS 1_o
means VBZ N
that IN N
sibenadet NN N
development NN N
will MD N
not RB N
be VB N
continued VBN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
parallel NN N
study NN N
to TO N
assess VB N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
two CD N
different JJ N
dosing VBG N
regimens NNS N
of IN N
5 CD N
% NN N
imiquimod NN 1_i
in IN N
the DT N
treatment NN N
of IN N
superficial JJ 1_p
basal NN 1_p
cell NN 1_p
carcinoma NN 1_p
. . 1_p

OBJECTIVES CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
two CD N
cycled VBD N
dosing VBG N
regimens NNS N
of IN N
imiquimod JJ 1_i
5 CD N
% NN N
cream NN N
for IN N
treatment NN N
of IN N
superficial JJ 1_p
basal NN 1_p
cell NN 1_p
carcinoma NN 1_p
( ( 1_p
sBCC NN 1_p
) ) 1_p
. . 1_p

METHODS JJ N
Patients NNPS 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
32 CD 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
two CD N
treatment NN N
regimens NNS N
: : N
8 CD 1_i
weeks NNS 1_i
of IN 1_i
treatment NN 1_i
with IN 1_i
once-daily JJ 1_i
dosing VBG 1_i
for IN 1_i
alternate JJ 1_i
weeks NNS 1_i
( ( 1_i
R1 NNP 1_i
) ) 1_i
and CC 1_i
5 CD 1_i
weeks NNS 1_i
of IN 1_i
once-daily JJ 1_i
dosing NN 1_i
with IN 1_i
a DT 1_i
1-week JJ 1_i
interval NN 1_i
in IN 1_i
the DT 1_i
middle NN 1_i
of IN 1_i
the DT 1_i
course NN 1_i
( ( N
R2 NNP N
) ) N
. . N

Efficacy NN N
measures NNS N
were VBD N
tumour JJ 1_o
clearance NN 1_o
at IN N
weeks NNS N
19 CD N
and CC N
52 CD N
and CC N
measures NNS 1_o
of IN 1_o
patients NNS 1_o
' POS 1_o
acceptability NN 1_o
. . 1_o

RESULTS NNP N
Data NNP N
from IN N
30 CD 1_p
patients NNS 1_p
( ( 1_p
13 CD 1_p
females NNS 1_p
) ) 1_p
, , 1_p
14 CD 1_p
on IN 1_p
R1 NNP 1_p
and CC 1_p
16 CD 1_p
on IN 1_p
R2 NNP 1_p
, , N
were VBD N
analysed VBN N
. . N

The DT N
results NNS N
revealed VBD N
an DT N
initial JJ N
clearance NN 1_o
rate NN 1_o
of IN N
64 CD N
% NN N
at IN N
week NN N
19 CD N
for IN N
R1 NNP N
and CC N
81 CD N
% NN N
for IN N
R2 NNP N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
: : N
-14 NN N
% NN N
to TO N
45 CD N
% NN N
, , N
p NN N
= NNP N
0.21 CD N
) ) N
. . N

However RB N
, , N
clearance NN 1_o
rates NNS 1_o
at IN N
week NN N
52 CD N
were VBD N
significantly RB N
different JJ N
: : N
43 CD N
% NN N
for IN N
R1 NNP N
and CC N
88 CD N
% NN N
for IN N
R2 NNP N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
: : N
11 CD N
% NN N
to TO N
68 CD N
% NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
acceptability NN 1_o
of IN 1_o
treatment NN 1_o
as IN N
measured VBN N
by IN N
composite JJ N
median JJ N
visual JJ N
analogue NN N
scores NNS N
at IN N
week NN N
8 CD N
. . N

CONCLUSION NNP N
Five NNP N
weeks NNS N
of IN N
5 CD N
% NN N
imiquimod JJ 1_i
cream NN N
once RB N
daily JJ N
with IN N
a DT N
1-week JJ N
interval NN N
was VBD N
more RBR N
effective JJ 1_o
but CC N
as RB N
well RB 1_o
tolerated VBN 1_o
as IN N
the DT N
8-week JJ N
alternate NN N
week NN N
regimen NNS N
for IN N
sBCC NN 1_p
. . 1_p

-DOCSTART- -X- O O

Topical JJ 1_i
anesthesia NN 1_i
during IN N
infant JJ N
eye NN N
examinations NNS N
: : N
does VBZ N
it PRP N
reduce VB N
stress NN N
? . N
We PRP N
studied VBD N
the DT N
effect NN N
of IN N
topical JJ 1_i
anesthesia NN 1_i
on IN N
infant JJ N
stress NN N
and CC N
corneal NN N
haze NN N
during IN N
the DT N
routine JJ N
eye NN N
examination NN N
for IN N
retinopathy NN N
of IN N
prematurity NN N
. . N

Using VBG N
a DT N
double-blind JJ N
protocol NN N
, , N
55 CD 1_p
premature NN 1_p
infants NNS 1_p
weighing VBG 1_p
less JJR 1_p
than IN 1_p
1501 CD 1_p
g NN 1_p
at IN 1_p
birth NN 1_p
were VBD 1_p
selected VBN 1_p
randomly RB 1_p
to TO N
receive VB N
normal JJ 1_i
saline NN 1_i
or CC 1_i
proparacaine NN 1_i
HCl NNP 1_i
0.5 CD 1_i
% NN 1_i
eye NN 1_i
drops VBZ 1_i
as IN N
a DT N
corneal NN N
wetting VBG N
agent NN N
at IN 1_p
their PRP$ 1_p
initial JJ 1_p
eye NN 1_p
examination NN 1_p
. . 1_p

Before IN N
, , N
during IN N
, , N
and CC N
after IN N
the DT N
procedure NN N
, , N
infant JJ N
stress NN N
was VBD N
evaluated VBN N
by IN N
heart NN 1_o
rate NN 1_o
, , 1_o
respiration NN 1_o
rate NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
transcutaneous JJ 1_o
oxygen NN 1_o
saturation NN 1_o
. . 1_o

Subjective JJ 1_o
assessment NN 1_o
of IN 1_o
the DT 1_o
infant NN 1_o
's POS 1_o
cry NN 1_o
intensity NN 1_o
and CC 1_o
corneal NN 1_o
haze NN 1_o
also RB N
were VBD N
recorded VBN N
. . N

Adequate NNP N
data NNS N
were VBD N
collected VBN N
on IN N
42 CD 1_p
patients NNS 1_p
. . 1_p

Using VBG N
analysis NN N
of IN N
variance NN N
and CC N
chi-square NN N
tests NNS N
, , N
we PRP N
found VBD N
no DT N
difference NN N
in IN N
any DT N
of IN N
these DT N
parameters NNS N
between IN N
the DT N
two CD N
patients NNS N
groups NNS N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
topical JJ N
anesthetic JJ 1_i
agents NNS N
offer VBP N
no DT N
advantage NN N
over IN N
normal JJ N
saline JJ N
eye NN N
drops NNS N
during IN N
the DT N
examination NN N
of IN N
premature JJ 1_p
infants NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Menstrual JJ 1_o
cycle NN 1_o
symptoms NNS 1_o
in IN N
infertile JJ 1_p
and CC 1_p
control JJ 1_p
subjects NNS 1_p
: : 1_p
a DT N
re-evaluation NN 1_i
of IN 1_i
the DT 1_i
evidence NN 1_i
for IN N
psychological JJ 1_o
changes NNS 1_o
. . 1_o

-DOCSTART- -X- O O

TEN NNP 1_i
versus VBZ N
TPN NNP 1_i
following VBG N
major JJ 1_p
abdominal JJ 1_p
trauma NN 1_p
-- : 1_p
reduced VBD 1_p
septic JJ 1_p
morbidity NN 1_p
. . 1_p

Recent NNP N
animal JJ N
models NNS N
suggest VBP N
that IN N
enteral JJ 1_i
feeding NN 1_i
( ( 1_i
TEN NNP 1_i
) ) 1_i
compared VBN N
to TO N
parenteral JJ 1_i
nutrition NN 1_i
( ( 1_i
TPN NNP 1_i
) ) 1_i
improves VBZ N
resistance NN N
to TO N
infection NN N
. . N

This DT N
prospective JJ N
clinical JJ N
trial NN N
examined VBD N
the DT N
impact NN N
of IN N
early JJ N
TEN NNP 1_i
vs. FW N
TPN NNP 1_i
in IN N
the DT 1_p
critically RB 1_p
injured VBN 1_p
. . 1_p

Seventy-five JJ 1_p
patients NNS 1_p
with IN 1_p
an DT 1_p
abdominal JJ 1_p
trauma NN 1_p
index NN 1_p
( ( 1_p
ATI NNP 1_p
) ) 1_p
greater JJR 1_p
than IN 1_p
15 CD 1_p
and CC 1_p
less JJR 1_p
than IN 1_p
40 CD 1_p
were VBD 1_p
randomized VBN 1_p
at IN 1_p
initial JJ 1_i
laparotomy NN 1_i
to TO 1_p
receive VB 1_i
either RB 1_i
TEN NNP 1_i
( ( 1_i
Vivonex NNP 1_i
TEN NNP 1_i
) ) 1_i
or CC 1_i
TPN NNP 1_i
( ( 1_i
Freamine NNP 1_i
HBC NNP 1_i
6.9 CD 1_i
% NN 1_i
and CC 1_i
Trophamine NNP 1_i
6 CD 1_i
% NN 1_i
) ) 1_i
; : 1_i
both DT 1_p
regimens NNS 1_p
contained VBD 1_p
2.5 CD 1_p
% NN 1_p
fat NN 1_p
, , 1_p
33 CD 1_p
% NN 1_p
branched VBD 1_p
chain NN 1_p
amino NN 1_p
acids NNS 1_p
, , 1_p
and CC 1_p
had VBD 1_p
a DT 1_p
calorie NN 1_p
to TO 1_p
nitrogen VB 1_p
ratio NN 1_p
of IN 1_p
150:1 CD 1_p
. . 1_p

TEN NN 1_i
was VBD N
delivered VBN N
via IN N
a DT N
needle JJ N
catheter NN N
jejunostomy NN N
. . N

Nutritional JJ N
support NN N
was VBD N
initiated VBN N
within IN N
12 CD N
hours NNS N
postoperatively RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
infused VBD N
at IN N
a DT N
rate NN N
sufficient NN N
to TO N
render VB N
the DT N
patients NNS N
in IN N
positive JJ N
nitrogen NN N
balance NN N
. . N

The DT N
study NN N
groups NNS N
( ( 1_i
TEN NNP 1_i
= VBZ N
29 CD N
vs NN N
TPN NNP 1_i
= NNP N
30 CD N
) ) N
were VBD N
comparable JJ N
in IN N
age NN N
, , N
injury NN N
severity NN N
and CC N
initial JJ N
metabolic JJ N
stress NN N
. . N

Jejunal NNP N
feeding NN N
was VBD N
tolerated VBN 1_o
unconditionally RB N
in IN N
25 CD N
( ( N
86 CD N
% NN N
) ) N
of IN N
the DT N
TEN NNP 1_i
group NN N
. . N

Nitrogen NNP 1_o
balance NN 1_o
remained VBD N
equivalent JJ N
throughout IN N
the DT N
study NN N
period NN N
, , N
at IN N
day NN N
5 CD N
TEN NNP 1_i
= NNP N
-0.3 NNP N
+/- JJ N
1.0 CD N
vs. FW N
TPN NNP 1_i
0.1 CD N
+/- JJ N
0.8 CD N
gm/day NN N
. . N

Traditional JJ N
nutritional JJ 1_o
protein NN 1_o
markers NNS 1_o
( ( 1_o
albumin NN 1_o
, , 1_o
transferrin NN 1_o
, , 1_o
and CC 1_o
retinol VB 1_o
binding VBG 1_o
protein NN 1_o
) ) 1_o
were VBD N
restored VBN N
better RBR N
in IN N
the DT N
TEN NNP 1_i
group NN N
. . N

Infections NNP 1_o
developed VBD N
in IN N
5 CD N
( ( N
17 CD N
% NN N
) ) N
of IN N
the DT N
TEN NNP 1_i
patients NNS N
compared VBN N
to TO N
11 CD N
( ( N
37 CD N
% NN N
) ) N
of IN N
the DT N
TPN NNP 1_i
group NN N
. . N

The DT N
incidence NN N
of IN N
major JJ 1_o
septic JJ 1_o
morbidity NN 1_o
was VBD N
3 CD N
% NN N
( ( N
1 CD N
= NNP N
abdominal JJ N
abscess NN N
) ) N
in IN N
the DT N
TEN NNP 1_i
group NN N
contrasted VBD N
to TO N
20 CD N
% NN N
( ( N
2 CD N
= NNP N
abdominal JJ N
abscess NN N
, , N
6 CD N
= NNP N
pneumonia NN N
) ) N
with IN N
TPN NNP 1_i
. . 1_i

This DT N
clinical JJ N
study NN N
demonstrates VBZ N
that IN N
TEN NNP 1_i
is VBZ N
well RB N
tolerated VBN N
in IN N
the DT N
severely RB 1_p
injured JJ 1_p
, , N
and CC N
that IN N
early JJ N
feeding NN N
via IN N
the DT N
gut NN N
reduces VBZ N
septic JJ N
complications NNS N
in IN N
the DT N
stressed JJ N
patient NN N
. . N

-DOCSTART- -X- O O

[ JJ 1_o
Photoplethysmographic NNP 1_o
evaluation NN 1_o
of IN N
the DT N
effect NN N
of IN N
a DT N
vascular JJ 1_i
tonic JJ 1_i
drug NN 1_i
] NN 1_i
. . N

-DOCSTART- -X- O O

Inhibition NN N
of IN N
PCSK9 NNP N
with IN N
evolocumab NN 1_i
in IN N
homozygous JJ 1_p
familial JJ 1_p
hypercholesterolaemia NN 1_p
( ( N
TESLA NNP N
Part NNP N
B NNP N
) ) N
: : N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

BACKGROUND NNP N
Homozygous NNP 1_p
familial JJ 1_p
hypercholesterolaemia NN 1_p
is VBZ N
a DT N
rare JJ N
, , N
serious JJ N
disorder NN N
caused VBN N
by IN N
very RB N
low JJ N
or CC N
absent JJ N
plasma JJ N
clearance NN N
of IN N
LDL NNP N
, , N
substantially RB N
raised VBN N
LDL NNP N
cholesterol NN N
, , N
and CC N
accelerated VBD 1_o
development NN 1_o
of IN 1_o
cardiovascular JJ 1_o
disease NN 1_o
. . 1_o

Conventional JJ N
lipid-lowering JJ N
treatments NNS N
are VBP N
modestly RB N
effective JJ N
. . N

Evolocumab NNP 1_i
, , N
a DT N
monoclonal JJ 1_i
antibody NN 1_i
to TO N
proprotein VB 1_i
convertase NN 1_i
subtilisin/kexin NN 1_i
type NN 1_i
9 CD 1_i
( ( N
PCSK9 NNP N
) ) N
, , N
reduced VBD N
LDL NNP 1_o
cholesterol NN 1_o
by IN N
16 CD N
% NN N
in IN N
a DT N
pilot NN N
study NN N
. . N

We PRP N
now RB N
report VBP N
results NNS N
with IN N
evolocumab NN 1_i
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
phase NN N
3 CD N
trial NN N
. . N

METHODS NNP N
This DT N
randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
phase NN N
3 CD N
trial NN N
was VBD N
undertaken VBN N
at IN N
17 CD N
sites NNS N
in IN N
ten JJ 1_p
countries NNS 1_p
in IN 1_p
North NNP 1_p
America NNP 1_p
, , 1_p
Europe NNP 1_p
, , 1_p
the DT 1_p
Middle NNP 1_p
East NNP 1_p
, , 1_p
and CC 1_p
South NNP 1_p
Africa NNP 1_p
. . 1_p

50 CD 1_p
eligible JJ 1_p
patients NNS 1_p
( ( 1_p
aged VBN 1_p
?12 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
homozygous JJ 1_p
familial JJ 1_p
hypercholesterolaemia NN 1_p
, , 1_p
on IN 1_p
stable JJ 1_i
lipid-regulating JJ 1_i
therapy NN 1_i
for IN 1_i
at IN 1_p
least JJS 1_p
4 CD 1_p
weeks NNS 1_p
, , 1_p
and CC 1_p
not RB 1_p
receiving VBG 1_p
lipoprotein JJ 1_p
apheresis NN 1_p
, , 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
by IN 1_p
a DT 1_p
computer-generated JJ 1_p
randomisation NN 1_p
sequence NN 1_p
in IN 1_p
a DT 1_p
2:1 CD 1_p
ratio NN 1_p
to TO 1_p
receive VB 1_i
subcutaneous JJ 1_i
evolocumab NNS 1_i
420 CD 1_i
mg NN 1_i
or CC 1_i
placebo NN 1_i
every DT 1_i
4 CD 1_p
weeks NNS 1_p
for IN 1_p
12 CD 1_p
weeks NNS 1_p
. . 1_p

Randomisation NN N
was VBD N
stratified VBN N
by IN N
LDL NNP N
cholesterol NN N
at IN N
screening VBG N
( ( N
< JJ N
11 CD N
mmol/L NN N
or CC N
?11 VB N
mmol/L NN N
) ) N
and CC N
implemented VBN N
by IN N
a DT N
computerised JJ 1_i
interactive JJ 1_i
voice-response NN 1_i
system NN 1_i
. . 1_i

Patients NNS 1_i
, , 1_p
study NN 1_p
personnel NNS 1_p
, , 1_p
and CC 1_p
the DT 1_p
funder NN 1_p
were VBD 1_p
masked VBN 1_p
to TO 1_p
treatment NN 1_p
and CC 1_p
to TO 1_p
the DT 1_p
efficacy NN 1_p
results NNS 1_p
by IN 1_p
the DT 1_p
central JJ 1_p
laboratory NN 1_p
not RB 1_p
returning VBG 1_p
LDL NNP 1_p
cholesterol NN 1_p
or CC 1_p
any DT 1_p
lipid JJ 1_p
results NNS 1_p
to TO 1_p
the DT 1_p
clinical JJ 1_p
sites NNS 1_p
after IN 1_p
the DT 1_p
baseline NN 1_p
visit NN 1_p
. . 1_p

The DT 1_p
primary JJ N
endpoint NN N
was VBD N
percentage NN N
change NN 1_o
in IN 1_o
ultracentrifugation NN 1_o
LDL NNP 1_o
cholesterol NN 1_o
from IN 1_o
baseline NN N
at IN N
week NN N
12 CD N
compared VBN N
with IN N
placebo NN N
, , N
analysed VBN N
by IN N
intention-to-treat NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01588496 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT N
50 CD 1_p
eligible JJ 1_p
patients NNS 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
the DT 1_p
two CD 1_p
treatment NN 1_p
groups NNS 1_p
, , 1_p
49 CD 1_p
actually RB 1_p
received VBD 1_p
the DT 1_p
study NN 1_p
drug NN 1_p
and CC 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
( ( 1_p
16 CD 1_p
in IN 1_p
the DT 1_p
placebo NN 1_i
group NN 1_i
and CC 1_p
33 CD 1_p
in IN 1_p
the DT 1_p
evolocumab NN 1_i
group NN 1_i
) ) 1_p
. . 1_p

Compared VBN 1_p
with IN N
placebo NN 1_i
, , 1_i
evolocumab VBP 1_i
significantly RB 1_i
reduced VBN 1_o
ultracentrifugation NN 1_o
LDL NNP 1_o
cholesterol NN 1_o
at IN 1_o
12 CD N
weeks NNS N
by IN N
30?9 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-43?9 NNP N
% NN N
to TO N
-18?0 CD N
% NN N
; : N
p CC N
< VB N
0?0001 CD 1_o
) ) 1_o
. . 1_o

Treatment-emergent JJ 1_o
adverse JJ 1_o
events NNS 1_o
occurred VBD N
in IN N
ten NN N
( ( N
63 CD N
% NN N
) ) N
of IN N
16 CD N
patients NNS N
in IN 1_i
the DT 1_i
placebo NN 1_i
group NN N
and CC N
12 CD N
( ( N
36 CD N
% NN N
) ) N
of IN N
33 CD N
in IN N
the DT 1_i
evolocumab NN 1_i
group NN 1_i
. . 1_i

No DT N
serious JJ N
clinical JJ N
or CC N
laboratory JJ N
adverse JJ N
events NNS N
occurred VBD N
, , N
and CC N
no DT N
anti-evolocumab JJ 1_o
antibody NN 1_o
development NN 1_o
was VBD 1_o
detected VBN 1_o
during IN N
the DT N
study NN N
. . N

INTERPRETATION NNP 1_p
In IN 1_p
patients NNS 1_p
with IN 1_p
homozygous JJ 1_p
familial JJ 1_p
hypercholesterolaemia NN 1_p
receiving VBG 1_p
stable JJ N
background IN N
lipid-lowering JJ N
treatment NN N
and CC N
not RB N
on IN N
apheresis NN 1_i
, , 1_i
evolocumab VBZ 1_i
420 CD 1_i
mg NN 1_i
administered VBN N
every DT N
4 CD N
weeks NNS N
was VBD N
well RB N
tolerated VBN 1_o
and CC 1_o
significantly RB 1_o
reduced VBN N
LDL NNP 1_o
cholesterol NN 1_o
compared VBN 1_o
with IN 1_i
placebo NN 1_i
. . N

FUNDING NNP N
Amgen NNP N
Inc NNP N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
cardiac JJ 1_o
muscle NN 1_o
mass NN 1_o
and CC N
function NN N
in IN N
hemodialysis NN 1_p
patients NNS 1_p
during IN 1_p
growth NN 1_i
hormone CD 1_i
treatment NN 1_i
. . 1_i

BACKGROUND NNP N
Adult NNP 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
renal JJ 1_p
failure NN 1_p
( ( 1_p
CRF NNP 1_p
) ) 1_p
often RB N
show VBP N
symptoms NNS N
as IN N
fatigue NN N
, , N
wasting NN N
, , N
and CC N
reduced VBD N
working VBG N
capacity NN N
with IN N
concomitant JJ N
findings NNS N
of IN N
reduced JJ N
cardiac JJ N
performance NN N
and CC N
muscle NN N
mass NN N
. . N

This DT N
state NN N
may MD N
in IN N
part NN N
be VB N
caused VBN N
by IN N
an DT N
imbalance NN N
in IN N
the DT N
somatostatin/somatomedine NN N
axis NN N
resulting VBG N
in IN N
increased JJ N
catabolism NN N
. . N

During IN N
an DT N
attempt NN N
to TO N
correct VB N
this DT N
catabolic JJ N
state NN N
by IN N
administration NN 1_i
of IN 1_i
exogenous JJ 1_i
growth NN 1_i
hormone NN 1_i
, , N
cardiac JJ N
muscle NN N
mass NN N
and CC N
performance NN N
were VBD N
studied VBN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
6-month JJ N
study NN N
comprising VBG N
20 CD 1_p
adult NN 1_p
enfeebled VBD 1_i
hemodialysis NN 1_i
patients NNS 1_i
, , N
9 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
single JJ N
daily JJ N
subcutaneous JJ N
injection NN N
of IN N
recombinant JJ 1_i
human JJ 1_i
growth NN 1_i
hormone NN 1_i
( ( 1_i
rhGH NN 1_i
) ) 1_i
4 CD N
IU/m2 NNP N
and CC N
11 CD N
with IN N
placebo JJ 1_i
injections NNS N
. . N

Left NNP 1_o
ventricular JJ 1_o
muscle NN 1_o
mass NN 1_o
( ( 1_o
LVM NNP 1_o
) ) 1_o
and CC N
ejection NN 1_o
fraction NN 1_o
( ( 1_o
EF NNP 1_o
) ) 1_o
were VBD N
evaluated VBN N
by IN N
echocardiography NN N
and CC N
the DT N
maximal JJ N
working NN N
capacity NN N
( ( N
MWC NNP N
) ) N
was VBD N
measured VBN N
by IN N
a DT N
bicycle NN 1_i
exercise NN 1_i
test NN 1_i
performed VBD N
before IN N
and CC N
after IN N
the DT N
treatment NN N
period NN N
. . N

Supplementary JJ N
electrocardiography NN 1_o
( ( 1_o
ECG NNP 1_o
) ) 1_o
was VBD N
performed VBN N
before IN N
and CC N
after IN N
6-month JJ N
treatment NN N
. . N

RESULTS NNP N
Median JJ 1_o
LVM NNP 1_o
increased VBD N
significantly RB N
from IN N
172 CD N
to TO N
220 CD N
g NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
in IN N
the DT N
rhGH-treated JJ N
group NN N
, , N
while IN N
an DT N
insignificant JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
the DT N
placebo NN N
group NN N
from IN N
281 CD N
to TO N
200 CD N
g NN N
( ( N
p JJ N
= NNP N
0.3 CD N
) ) N
. . N

The DT N
EF NNP 1_o
showed VBD N
no DT N
significant JJ N
changes NNS N
in IN N
the DT N
two CD N
groups NNS N
. . N

MWC NNP 1_o
showed VBD N
a DT N
slight NN N
, , N
insignificant JJ N
decrease NN N
in IN N
both DT N
groups NNS N
. . N

From IN N
ECG NNP N
no DT N
significant JJ N
ST NNP 1_o
deviations NNS 1_o
were VBD N
found VBN N
and CC N
no DT N
significant JJ N
changes NNS N
regarding VBG N
B-Hb NNP N
, , N
blood NN N
pressure NN N
or CC N
pulse NN N
were VBD N
observed VBN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Irregular JJ 1_o
heart NN 1_o
rhythm NN 1_o
aggravated VBD N
in IN N
one CD N
patient NN N
during IN N
the DT N
first JJ N
month NN N
of IN N
treatment NN N
with IN N
rhGH NN N
, , N
but CC N
was VBD N
overcome VBN N
by IN N
a DT N
-blocking JJ N
agent NN N
. . N

CONCLUSION VB N
The DT N
treatment NN N
with IN N
rhGH NN N
of IN N
adult NN N
chronic JJ N
hemodialysis NN N
patients NNS N
for IN N
6 CD N
months NNS N
increased VBD N
the DT 1_o
left NN 1_o
ventricular JJ 1_o
mass NN 1_o
significantly RB N
, , N
but CC N
without IN N
any DT N
effect NN N
on IN N
ejection NN N
fraction NN N
or CC N
maximal JJ N
working JJ N
capacity NN N
. . N

No DT N
electrocardiographic JJ N
signs NNS N
of IN N
ischemia NN N
were VBD N
associated VBN N
with IN N
the DT N
increasing VBG N
muscle NN N
mass NN N
and CC N
only RB N
one CD N
patient NN N
developed VBD N
symptoms NNS N
that WDT N
might MD N
relate VB N
to TO N
ischemia VB N
. . N

No DT N
changes NNS N
in IN N
B-Hb NNP 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
or CC N
pulse NN N
were VBD N
observed VBN N
during IN N
the DT N
treatment NN N
period NN N
. . N

-DOCSTART- -X- O O

Independent NNP N
prognostic JJ N
information NN N
provided VBN N
by IN N
sphygmomanometrically RB 1_i
determined VBN 1_i
pulse JJ 1_o
pressure NN 1_o
and CC 1_i
mean JJ 1_i
arterial JJ 1_o
pressure NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
left JJ 1_p
ventricular JJ 1_p
dysfunction NN 1_p
. . 1_p

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
relationship NN N
of IN N
baseline NN N
pulse JJ N
pressure NN N
and CC N
mean JJ N
arterial JJ N
pressure NN N
to TO N
mortality NN N
in IN N
patients NNS 1_p
with IN 1_p
left JJ 1_p
ventricular JJ 1_p
dysfunction NN 1_p
. . 1_p

BACKGROUND NNP N
Increased VBD N
conduit NN N
vessel NN N
stiffness NN N
increases VBZ N
pulse JJ N
pressure NN N
and CC N
pulsatile NN N
load NN N
, , N
potentially RB N
contributing VBG N
to TO N
adverse VB N
outcomes NNS N
in IN N
patients NNS 1_p
with IN 1_p
left JJ 1_p
ventricular JJ 1_p
dysfunction NN 1_p
. . 1_p

METHODS NNP N
Pulse NNP N
and CC N
mean VB N
arterial JJ N
pressure NN N
were VBD N
analyzed VBN N
for IN N
their PRP$ N
effect NN N
on IN N
mortality NN 1_o
, , N
adjusting VBG N
for IN N
other JJ N
modifiers NNS N
of IN N
risk NN N
, , N
using VBG N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
analysis NN N
of IN N
data NNS N
collected VBN N
from IN N
6,781 CD 1_p
patients NNS 1_p
randomized VBN 1_p
into IN 1_p
the DT 1_p
Studies NNPS 1_p
of IN 1_p
Left NNP 1_p
Ventricular NNP 1_p
Dysfunction NNP 1_p
trials NNS 1_p
. . 1_p

RESULTS NNP N
Pulse NNP 1_o
and CC 1_o
mean VB 1_o
arterial JJ 1_o
pressure NN 1_o
were VBD N
related VBN N
positively RB N
to TO N
each DT N
other JJ N
, , N
age NN N
, , N
ejection NN N
fraction NN N
and CC N
prevalence NN N
of IN N
diabetes NNS N
and CC N
hypertension NN N
and CC N
inversely RB N
to TO N
prior VB N
myocardial JJ N
infarction NN N
and CC N
beta-adrenergic JJ N
blocking NN N
agent NN N
use NN N
. . N

Higher JJR 1_o
pulse JJ 1_o
pressure NN 1_o
was VBD N
associated VBN N
with IN N
increased JJ N
prevalence NN N
of IN N
female JJ N
gender NN N
, , N
greater JJR N
calcium NN 1_i
channel NN 1_i
blocking VBG 1_i
agent NN 1_i
, , 1_i
digoxin NN 1_i
and CC N
diuretic JJ 1_i
use NN N
, , N
lower JJR N
heart NN N
rate NN N
and CC N
a DT N
higher JJR N
rate NN N
of IN N
reported VBN N
smoking NN N
history NN N
. . N

Higher JJR 1_o
mean JJ 1_o
arterial JJ 1_o
pressure NN 1_o
was VBD N
associated VBN N
with IN N
higher JJR N
heart NN N
rate NN N
, , N
lower JJR N
calcium NN 1_i
channel NN 1_i
blocker NN 1_i
and CC N
digoxin NN 1_i
use NN N
and CC N
lower JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
functional JJ N
class NN N
. . N

Over IN N
a DT N
61-month JJ N
follow-up JJ N
1,582 CD N
deaths NNS 1_o
( ( N
1,397 CD N
cardiovascular NN N
) ) N
occurred VBD N
. . N

In IN N
a DT N
multivariate NN N
analysis NN N
adjusting VBG N
for IN N
the DT N
above JJ N
covariates NNS N
and CC N
treatment NN N
assignment NN N
, , N
higher JJR N
pulse JJ 1_o
pressure NN 1_o
remained VBD N
an DT N
independent JJ N
predictor NN N
of IN N
total JJ 1_o
and CC 1_o
cardiovascular JJ 1_o
mortality NN 1_o
( ( N
total JJ N
mortality NN N
relative NN N
risk NN N
, , N
1.05 CD N
per IN N
10 CD N
mm NN N
Hg NNP N
increment NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.01 CD N
to TO N
1.10 CD N
; : N
p NN N
= VBZ N
0.02 CD N
) ) N
. . N

Mean JJ 1_o
arterial JJ 1_o
pressure NN 1_o
was VBD N
inversely RB N
related VBN N
to TO N
total JJ 1_o
and CC 1_o
cardiovascular JJ 1_o
mortality NN 1_o
( ( N
total JJ N
mortality NN N
relative NN N
risk NN N
, , N
0.89 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.85 CD N
to TO N
0.94 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
. . N

CONCLUSIONS NNP N
One CD N
noninvasive JJ 1_i
blood NN 1_i
pressure NN 1_i
measurement NN 1_i
provides VBZ N
two CD N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
survival NN 1_o
. . 1_o

Increased VBD 1_o
conduit NN 1_o
vessel NN 1_o
stiffness NN 1_o
, , N
as IN N
assessed VBN N
by IN N
pulse JJ N
pressure NN N
, , N
may MD N
contribute VB N
to TO N
increased VBN N
mortality NN 1_o
in IN N
patients NNS N
with IN N
left JJ N
ventricular JJ N
dysfunction NN N
, , N
independent JJ N
of IN N
mean JJ N
arterial JJ N
pressure NN N
. . N

-DOCSTART- -X- O O

Phase NNP N
II NNP N
trial NN N
of IN N
nab-paclitaxel JJ N
compared VBN N
with IN N
docetaxel NN 1_i
as IN N
first-line JJ N
chemotherapy NN N
in IN N
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
: : 1_p
final JJ N
analysis NN N
of IN N
overall JJ N
survival NN N
. . N

BACKGROUND VB N
A DT N
randomized JJ N
phase NN N
II NNP N
study NN N
in IN N
first-line JJ N
MBC NNP N
demonstrated VBD N
superior JJ N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
weekly JJ N
nab-paclitaxel NNS N
compared VBN N
with IN N
docetaxel NN 1_i
. . 1_i

Final NNP N
survival NN 1_o
analyses NNS 1_o
and CC N
updated JJ N
safety NN 1_o
results NNS N
are VBP N
reported VBN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Three NNP 1_p
hundred VBD 1_p
two CD 1_p
patients NNS 1_p
with IN 1_p
no DT 1_p
previous JJ 1_p
chemotherapy NN 1_p
for IN 1_p
MBC NNP 1_p
were VBD N
randomized VBN 1_i
to TO 1_i
receive VB 1_i
nab-paclitaxel JJ 1_i
300 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
q3w NN 1_i
, , 1_i
nab-paclitaxel JJ 1_i
100 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
or CC 1_i
150 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
the DT 1_i
first JJ 1_i
3 CD 1_i
of IN 1_i
4 CD 1_i
weeks NNS 1_i
( ( 1_i
qw VB 1_i
3/4 CD 1_i
) ) 1_i
, , 1_i
or CC 1_i
docetaxel VB 1_i
100 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
q3w NN 1_i
. . 1_i

The DT N
trial NN N
was VBD N
powered VBN N
for IN N
analyses NNS N
of IN N
antitumor NN 1_o
activity NN 1_o
and CC N
safety NN 1_o
. . 1_o

RESULTS NNP N
Treatment NNP N
with IN N
nab-paclitaxel JJ N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
resulted VBD N
in IN N
a DT N
median JJ N
overall JJ N
survival NN 1_o
( ( N
OS NNP N
) ) N
of IN N
33.8 CD N
months NNS N
compared VBN N
with IN N
22.2 CD N
, , N
27.7 CD N
, , N
and CC N
26.6 CD N
months NNS N
for IN N
nab-paclitaxel JJ N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
, , N
nab-paclitaxel JJ N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
q3w NN N
, , N
and CC N
docetaxel NN 1_i
, , N
respectively RB N
( ( N
overall JJ N
P NNP N
= NNP N
.047 NNP N
) ) N
. . N

Patients NNPS N
receiving VBG N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel NN N
had VBD N
prolonged VBN N
median JJ 1_o
OS NNP 1_o
compared VBN N
with IN N
those DT N
in IN N
the DT N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel JJ N
arm NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.575 CD N
; : N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

A DT N
trend NN N
toward IN N
a DT N
longer JJR N
OS NNP 1_o
was VBD N
noted VBN N
in IN N
the DT N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel JJ N
arm NN N
versus NN N
docetaxel NN 1_i
arm NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.688 CD N
) ) N
. . N

Grade $ 1_o
3 CD 1_o
or CC 1_o
4 CD 1_o
fatigue NN 1_o
, , 1_o
neutropenia NN 1_o
, , 1_o
and CC 1_o
febrile JJ 1_o
neutropenia NN 1_o
were VBD N
less JJR N
frequent JJ N
in IN N
all DT N
nab-paclitaxel JJ N
arms NNS N
compared VBN N
with IN N
docetaxel NN 1_i
. . 1_i

CONCLUSIONS NNP N
Consistent NNP N
with IN N
previously RB N
published VBN N
efficacy NN N
results NNS N
, , N
these DT N
data NNS N
suggest VBP N
that IN N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
may MD N
represent VB N
the DT N
most RBS N
clinically RB N
efficacious JJ N
nab-paclitaxel JJ N
dosing VBG N
regimen NNS N
for IN N
patients NNS 1_p
with IN 1_p
no DT 1_p
previous JJ 1_p
chemotherapy NN 1_p
for IN 1_p
MBC NNP 1_p
. . 1_p

A DT N
phase NN N
III NNP N
trial NN N
confirming VBG N
these DT N
results NNS N
would MD N
be VB N
necessary JJ N
and CC N
prudent JJ N
before RB N
widespread JJ N
adoption NN N
of IN N
the DT N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
dose NN N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

[ JJ 1_p
Complaints NNS 1_p
in IN 1_p
the DT 1_p
postoperative JJ 1_p
phase NN 1_p
related VBN 1_p
to TO 1_p
anesthetics NNS 1_p
] NNP 1_p
. . N

In IN N
two CD N
prospective JJ N
, , N
randomized JJ N
studies NNS N
the DT N
frequency NN 1_o
of IN 1_o
headache NN 1_o
, , 1_o
nausea NN 1_o
, , 1_o
vomiting NN 1_o
, , 1_o
and CC 1_o
analgesic JJ 1_o
requirement NN 1_o
during IN 1_p
the DT 1_p
first JJ 1_p
postoperative JJ 1_p
24 CD 1_p
h NN 1_p
was VBD N
observed VBN N
in IN N
order NN N
to TO N
study VB N
differences NNS N
between IN N
the DT N
sexes NNS N
and CC N
the DT N
inhalation NN N
anesthetics NNS 1_i
halothane NN 1_i
, , 1_i
enflurane NN 1_i
, , 1_i
isoflurane NN 1_i
, , 1_i
or CC 1_i
balanced VBD 1_i
anesthesia NNS 1_i
with IN 1_i
enflurane/alfentanil NN 1_i
. . 1_i

Nausea NN 1_o
and CC 1_o
vomiting NN 1_o
were VBD N
more RBR N
frequent JJ N
after IN N
enflurane NN 1_i
than IN N
after IN N
halothane NN 1_i
or CC N
isoflurane NN 1_i
. . 1_i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
anesthetics NNS N
and CC N
frequency NN 1_o
of IN 1_o
headache NN 1_o
, , N
but CC N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
postoperative JJ 1_o
analgesic NN 1_o
requirements NNS 1_o
which WDT N
were VBD N
highest JJS N
after IN N
halothane NN 1_i
and CC N
lowest JJS N
after IN N
isoflurane NN 1_i
. . 1_i

Postoperative JJ 1_o
complaints NNS 1_o
were VBD N
always RB N
significantly RB N
greater JJR N
among IN N
women NNS 1_p
than IN N
among IN N
men NNS 1_p
. . 1_p

The DT N
second JJ N
study NN N
indicated VBD N
that IN N
balanced VBD N
anesthesia NN N
did VBD N
not RB N
reduce VB N
the DT N
analgesic JJ 1_o
requirement NN 1_o
compared VBN N
to TO N
enflurane VB 1_i
without IN N
alfentanil NN 1_i
, , N
but CC N
lead VBP N
to TO N
a DT N
higher JJR N
incidence NN N
of IN N
vomiting VBG 1_o
. . 1_o

After IN N
premedication NN N
with IN N
flunitrazepam NN N
and CC N
atropine NN N
and CC N
combined VBN N
with IN N
70 CD N
% NN N
N2O/30 NNP N
% NN N
O2 NNP N
, , N
isoflurane NN 1_i
was VBD N
the DT N
most RBS N
favorable JJ N
anesthetic JJ N
agent NN N
with IN N
regard NN N
to TO N
the DT N
parameters NNS N
studied VBN N
. . N

Balanced NNP 1_i
anesthesia NN 1_i
with IN 1_i
enflurane/alfentanil NN 1_i
did VBD N
not RB N
show VB N
any DT N
advantages NNS N
for IN N
patients NNS 1_p
in IN 1_p
the DT 1_p
postoperative JJ 1_p
phase NN 1_p
under IN N
the DT N
given VBN N
conditions NNS N
. . N

-DOCSTART- -X- O O

Iron NNP 1_i
in IN N
relation NN N
to TO N
gastric JJ 1_p
cancer NN 1_p
in IN 1_p
the DT N
Alpha-tocopherol NNP N
, , N
Beta-carotene NNP N
Cancer NNP N
Prevention NNP N
Study NNP N
. . N

BACKGROUND NNP N
Iron NNP 1_i
is VBZ N
an DT N
essential JJ N
micronutrient NN N
that WDT N
can MD N
have VB N
carcinogenic JJ 1_o
effects NNS 1_o
when WRB N
at IN N
high JJ N
or CC N
low JJ N
concentrations NNS N
. . N

Previous JJ N
studies NNS N
of IN N
iron NN N
in IN N
relation NN N
to TO N
gastric JJ N
cancer NN N
have VBP N
not RB N
assessed VBN N
subtype-specific JJ N
relationships NNS N
. . N

We PRP N
used VBD N
the DT N
prospective JJ N
Alpha-Tocopherol NNP N
, , N
Beta-Carotene NNP N
( ( N
ATBC NNP N
) ) N
Cancer NNP N
Prevention NNP N
Study NNP N
to TO N
assess VB N
whether IN N
iron NN N
metrics NNS N
were VBD N
associated VBN N
with IN N
gastric JJ 1_o
cardia NN 1_o
cancer NN 1_o
( ( 1_o
GCC NNP 1_o
) ) 1_o
and CC 1_o
gastric JJ 1_o
noncardia NN 1_o
cancer NN 1_o
( ( 1_o
GNCC NNP 1_o
) ) 1_o
. . 1_o

METHODS NNP N
We PRP N
selected VBD N
341 CD 1_p
incident JJ 1_p
gastric JJ 1_p
cancer NN 1_p
cases NNS 1_p
( ( 1_p
86 CD 1_p
cardia NN 1_p
, , 1_p
172 CD 1_p
noncardia NN 1_p
, , 1_p
and CC 1_p
83 CD 1_p
nonspecified VBN 1_p
) ) 1_p
, , 1_p
accrued VBN 1_p
during IN 1_p
22 CD 1_p
years NNS 1_p
of IN 1_p
follow-up NN 1_p
, , 1_p
and CC 1_p
341 CD 1_p
individually RB 1_p
matched VBN 1_p
controls NNS 1_p
. . 1_p

We PRP N
measured VBD N
prediagnostic JJ N
serum NN N
iron NN N
, , N
ferritin NN N
, , N
unsaturated JJ N
iron NN N
binding NN N
capacity NN N
, , N
and CC N
C-reactive JJ N
protein NN N
. . N

Total JJ 1_o
iron-binding JJ 1_o
capacity NN 1_o
( ( 1_o
TIBC NNP 1_o
) ) 1_o
and CC N
transferrin JJ N
saturation NN N
were VBD N
estimated VBN N
from IN N
these DT N
metrics NNS N
. . N

Dietary NNP 1_i
iron NN 1_i
exposures NNS N
were VBD N
estimated VBN N
from IN N
a DT N
food NN N
frequency NN N
questionnaire NN N
. . N

Multivariable JJ N
logistic JJ N
regression NN N
was VBD N
used VBN N
for IN N
analysis NN N
. . N

RESULTS NNP N
Serum NNP 1_o
iron NN 1_o
metrics NNS 1_o
were VBD N
not RB N
associated VBN N
with IN N
GCC NNP 1_o
, , N
except IN N
for IN N
a DT N
potential JJ N
n NN N
-shaped VBD N
relationship NN N
with IN N
TIBC NNP N
( ( N
global JJ N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

GNCC NNP 1_o
was VBD N
inversely RB N
associated VBN N
with IN N
serum NN 1_o
ferritin NN 1_o
( ( N
global JJ N
P NNP N
= NNP N
0.024 CD N
) ) N
, , N
serum JJ 1_o
iron NN 1_o
( ( N
global JJ N
P NNP N
= NNP N
0.060 CD N
) ) N
and CC N
, , N
possibly RB N
, , N
transferrin JJ 1_o
saturation NN 1_o
. . 1_o

TIBC NNP 1_o
appeared VBD N
to TO N
share NN N
a DT N
u NN N
-shaped VBD N
relationship NN N
with IN N
GNCC NNP 1_o
( ( N
global JJ N
P NNP N
= NNP N
0.033 CD N
) ) N
. . N

Dietary NNP 1_o
iron NN 1_o
exposures NNS 1_o
were VBD N
not RB N
associated VBN N
with IN N
either DT N
subsite NN N
. . N

Adjustment NN N
for IN N
Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
atrophy NN N
had VBD N
little JJ N
effect NN N
on IN N
observed JJ N
associations NNS N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
little JJ N
evidence NN N
for IN N
the DT N
involvement NN N
of IN N
iron NN 1_i
exposure NN N
in IN N
the DT N
pathogenesis NN 1_o
of IN 1_o
GCC NNP 1_o
. . 1_o

GNCC NNP 1_o
was VBD N
associated VBN N
with IN N
an DT N
iron NN 1_i
profile NN N
similar JJ N
to TO N
that DT N
of IN N
iron NN N
deficiency NN N
. . N

IMPACT NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
inverse JJ N
associations NNS N
between IN N
iron NN N
metrics NNS N
and CC N
gastric JJ N
cancer NN N
are VBP N
driven VBN N
by IN N
associations NNS N
with IN N
GNCC NNP N
. . N

Further NNP N
elucidation NN N
of IN N
potential JJ N
mechanisms NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Anti-IgG JJ N
antibodies NNS N
during IN N
immunotherapy NN N
with IN N
purified JJ N
grass NN N
pollen NN N
extracts NNS N
. . N

In IN N
a DT N
double JJ N
blind NN N
study NN N
40 CD 1_p
patients NNS 1_p
were VBD 1_p
allocated VBN 1_p
specific JJ 1_i
immunotherapy NN 1_i
( ( 1_i
hyposensitization NN 1_i
) ) 1_i
with IN 1_i
partially RB 1_i
purified VBN 1_i
timothy JJ 1_i
extract NN 1_i
or CC 1_i
two CD 1_i
timothy JJ 1_i
major JJ 1_i
allergens NNS 1_i
19 CD 1_i
, , 1_i
25 CD 1_i
. . 1_i

All DT 1_p
patients NNS 1_p
had VBD 1_p
typical JJ 1_p
grass NN 1_p
pollen NN 1_p
hay NN 1_p
fever NN 1_p
, , 1_p
in IN 1_p
27 CD 1_p
% NN 1_p
associated VBN 1_p
with IN 1_p
grass NN 1_p
pollen NN 1_p
asthma NN 1_p
and CC 1_p
in IN 1_p
13 CD 1_p
% NN 1_p
with IN 1_p
birch NN 1_p
pollen NN 1_p
allergy NN 1_p
. . 1_p

Serum NNP 1_o
IgG NNP 1_o
anti-IgG JJ 1_o
antibodies NNS 1_o
were VBD N
determined VBN N
after IN N
dithiothreitol JJ 1_p
treatment NN 1_p
. . 1_p

Before IN N
hyposensitization NN N
, , N
IgG NNP 1_o
anti-IgG JJ 1_o
titres NNS 1_o
greater JJR 1_p
than IN 1_p
or CC 1_p
equal JJ 1_p
to TO 1_p
9 CD 1_p
were VBD 1_p
demonstrated VBN 1_p
in IN 1_p
45 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
. . 1_p

During IN N
hyposensitization NN N
IgG NNP 1_o
anti-IgG NN 1_o
titres NNS 1_o
showed VBD N
a DT N
slight JJ N
initial JJ N
increase NN N
followed VBN N
by IN N
a DT N
decrease NN N
below IN N
pretreatment JJ N
level NN N
. . N

Neither CC N
increase VB N
nor CC N
decrease VB N
was VBD N
statistically RB N
significant JJ N
. . N

Reactions NNS 1_o
to TO 1_o
rabbit VB 1_o
IgG NNP 1_o
F NNP 1_o
( ( 1_o
ab IN 1_o
' POS 1_o
) ) 1_o
2 CD 1_o
fractions NNS N
were VBD N
only RB N
obtained VBN N
during IN N
hyposensitization NN N
. . N

The DT N
occurrence NN N
of IN N
anti-IgG JJ 1_o
antibodies NNS 1_o
did VBD N
no DT N
correlate NN N
with IN N
symptoms NNS 1_o
, , 1_o
side NN 1_o
effects NNS 1_o
, , 1_o
or CC 1_o
the DT 1_o
level NN 1_o
of IN 1_o
allergen-specific JJ 1_o
IgG NNP 1_o
. . 1_o

In IN N
a DT N
previous JJ N
study NN N
it PRP N
was VBD N
demonstrated VBN N
that IN N
patients NNS N
with IN N
multiallergy JJ N
hyposensitized VBN N
with IN N
combined JJ N
allergen NN N
extracts NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
IgG NNP 1_o
anti-IgG JJ 1_o
titres NNS 1_o
during IN N
treatment NN N
. . N

The DT N
increase NN N
failed VBD N
to TO N
appear VB N
in IN N
the DT N
present JJ N
patients NNS N
allergic VBZ N
only RB N
to TO N
pollen VB N
and CC N
treated VBN N
with IN N
purified JJ N
allergen NN N
extracts NNS N
. . N

It PRP N
is VBZ N
therefore RB N
suggested VBN N
that IN N
a DT N
multiallergic JJ N
condition NN N
and CC N
the DT N
combination NN N
and/or JJ N
purification NN N
of IN N
allergen NN N
extracts NNS N
administered VBN N
during IN N
hyposensitization NN N
may MD N
influence VB N
the DT N
production NN N
of IN N
IgG NNP 1_o
anti- JJ 1_o
IgG NNP 1_o
antibodies NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Dynamic NNP N
surface NN 1_o
electromyographic JJ 1_o
responses NNS 1_o
in IN N
chronic JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
treated VBN N
by IN N
traditional JJ 1_i
bone NN 1_i
setting NN 1_i
and CC 1_i
conventional JJ 1_i
physical JJ 1_i
therapy NN 1_i
. . 1_i

OBJECTIVE CC N
This DT N
study NN N
compared VBN N
the DT N
dynamic JJ 1_o
surface NN 1_o
electromyographic JJ 1_o
( ( 1_o
EMG NNP 1_o
) ) 1_o
activities NNS 1_o
of IN N
back JJ N
muscles NNS N
and CC N
pain NN N
before IN N
and CC N
after IN N
traditional JJ 1_i
bone NN 1_i
setting NN 1_i
and CC 1_i
physical JJ 1_i
therapy NN 1_i
. . 1_i

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
clinical JJ N
trial NN N
that WDT N
compared VBN N
surface NN 1_o
EMG NNP 1_o
dynamic JJ 1_o
activities NNS 1_o
after IN N
traditional JJ 1_i
bone NN 1_i
setting NN 1_i
and CC 1_i
physical JJ 1_i
therapy NN 1_i
. . 1_i

Sixty-one CD 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
41 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
nonspecific JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
were VBD 1_p
randomized VBN 1_p
into IN N
two CD N
subgroups NNS N
by IN N
treatment NN N
. . N

The DT N
patients NNS N
underwent VBD N
a DT N
dynamic JJ 1_o
EMG NNP 1_o
evaluation NN 1_o
for IN N
which WDT N
they PRP N
were VBD N
asked VBN N
to TO N
stand VB N
and CC N
then RB N
bend VB N
forward RB N
as RB N
far RB N
as IN N
possible JJ N
, , N
stay VB N
fully RB N
flexed VBN N
, , N
and CC N
return NN N
to TO N
standing VBG N
. . N

A DT N
flexion-relaxation JJ 1_o
ratio NN 1_o
was VBD N
calculated VBN N
by IN N
comparing VBG N
maximal JJ 1_o
EMG NNP 1_o
activity NN 1_o
while IN N
flexing VBG N
with IN N
the DT N
average JJ N
EMG NNP N
activity NN N
in IN N
full JJ N
flexion NN N
. . N

Concentric NNP 1_o
( ( 1_o
maximal JJ 1_o
EMG NNP 1_o
activity NN 1_o
during IN 1_o
extension NN 1_o
) ) 1_o
and CC 1_o
eccentric JJ 1_o
( ( 1_o
maximal JJ 1_o
EMG NNP 1_o
activity NN 1_o
during IN 1_o
flexion NN 1_o
) ) 1_o
ratios NNS 1_o
were VBD N
also RB N
used VBN N
in IN N
the DT N
analyses NNS N
. . N

RESULTS NNP N
Disability NNP 1_o
, , 1_o
depression NN 1_o
, , 1_o
and CC 1_o
visual JJ 1_o
analog NN 1_o
scale NN 1_o
scores NNS 1_o
decreased VBN N
significantly RB N
after IN N
both DT N
treatments NNS N
. . N

The DT N
concentric JJ 1_o
ratio NN 1_o
increased VBD N
statistically RB N
in IN N
both DT N
groups NNS N
after IN N
the DT N
treatments NNS N
. . N

The DT N
study NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
association NN N
between IN N
experienced VBN N
back RB N
pain NN N
and CC N
EMG NNP 1_o
parameters NNS 1_o
. . 1_o

CONCLUSIONS NNP N
Both NNP N
treatments NNS N
seem VBP N
to TO N
have VB N
a DT N
positive JJ N
influence NN N
on IN N
back JJ N
muscle NN N
function NN N
by IN N
improving VBG N
muscle NN 1_o
symmetry NN 1_o
; : 1_o
however RB N
, , N
the DT N
treatments NNS N
had VBD N
no DT N
effect NN N
on IN N
the DT N
flexion-relaxation NN 1_o
phenomenon NN 1_o
after IN N
1 CD N
month NN N
. . N

Active NNP 1_i
back RB 1_i
exercise NN 1_i
at IN 1_i
home NN 1_i
together RB N
with IN N
rehabilitation NN N
treatments NNS 1_i
might MD N
be VB N
effective JJ N
and CC N
improve VB N
function NN N
for IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

-DOCSTART- -X- O O

The DT N
specific JJ N
role NN N
of IN N
isoflavones NNS 1_i
on IN N
estrogen NN N
metabolism NN N
in IN 1_p
premenopausal JJ 1_p
women NNS 1_p
. . 1_p

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
evidence NN N
that IN N
dietary JJ N
factors NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
production NN N
, , N
metabolism NN N
, , N
and CC N
bioavailability NN N
of IN N
sex NN N
hormones NNS N
and CC N
their PRP$ N
impact NN N
on IN N
target NN N
tissues NNS N
. . N

The DT N
specific JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
supplementing VBG N
a DT 1_p
group NN 1_p
of IN 1_p
premenopausal JJ 1_p
women NNS 1_p
who WP 1_p
were VBD 1_p
free JJ 1_p
of IN 1_p
breast NN 1_p
carcinoma NN 1_p
with IN N
a DT N
dietary JJ N
supplement NN N
of IN N
isoflavones NNS 1_i
( ( N
40 CD N
mg NNS N
per IN N
day NN N
) ) N
in IN N
producing VBG N
a DT N
change NN N
in IN N
steroid JJ N
hormones NNS N
and CC N
menstrual JJ N
cycle NN N
length NN N
. . N

METHODS NNP N
Sixty-eight NNP 1_p
consecutively RB 1_p
recruited VBD 1_p
, , 1_p
premenopausal NN 1_p
, , 1_p
omnivorous JJ 1_p
women NNS 1_p
of IN 1_p
all DT 1_p
races NNS 1_p
and CC 1_p
ethnicities NNS 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
25 CD 1_p
years NNS 1_p
and CC 1_p
55 CD 1_p
years NNS 1_p
were VBD 1_p
admitted VBN 1_p
to TO 1_p
the DT 1_p
study NN 1_p
and CC N
randomized VBN N
to TO N
an DT N
experimental JJ N
group NN N
supplemented VBD N
with IN N
soy NN 1_i
( ( 1_i
40 CD 1_i
mg NN N
genistein NNS N
per IN N
day NN N
) ) N
or CC N
to TO N
a DT N
control NN N
group NN N
that WDT N
consumed VBD N
a DT N
placebo NN 1_i
for IN N
a DT N
12-week JJ N
period NN N
. . N

Changes NNS N
in IN N
their PRP$ N
anthropometric NN 1_o
, , 1_o
nutritional JJ 1_o
, , 1_o
and CC 1_o
hormonal JJ 1_o
biomarkers NNS 1_o
from IN N
early JJ N
follicular JJ N
phase NN N
were VBD N
analyzed VBN N
at IN N
baseline NN N
and CC N
post-intervention NN N
. . N

RESULTS NNP N
Serum-free JJ 1_o
estradiol NN 1_o
and CC 1_o
estrone NN 1_o
levels NNS 1_o
decreased VBN N
moderately RB N
in IN N
the DT N
experimental JJ N
group NN N
. . N

Serum NNP 1_o
hormone-binding JJ 1_o
globulin NN 1_o
levels NNS 1_o
increased VBN N
in IN N
41.4 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
37.5 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

Free JJ 1_o
estradiol NN 1_o
decreased VBN N
in IN N
53.85 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
37.5 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

Estrone CD 1_o
decreased VBD N
in IN N
55.56 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
42.86 CD N
% NN N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

Those DT N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
who WP N
were VBD N
consuming VBG N
soy NN 1_i
had VBD N
their PRP$ N
mean JJ 1_o
menstrual JJ 1_o
cycle NN 1_o
length NN 1_o
increased VBN N
by IN N
3.52 CD N
days NNS N
compared VBN N
with IN N
a DT N
mean JJ N
decrease NN N
of IN N
0.06 CD N
days NNS N
for IN N
women NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
from IN N
baseline NN N
to TO N
the DT N
third JJ N
menstrual JJ N
cycle NN N
. . N

In IN N
addition NN N
, , N
women NNS N
who WP N
were VBD N
taking VBG N
soy NN 1_i
had VBD N
their PRP$ N
mean JJ 1_o
follicular JJ 1_o
phase NN 1_o
increase NN 1_o
by IN N
1.46 CD N
days NNS N
compared VBN N
with IN N
a DT N
mean JJ N
increase NN N
of IN N
0.14 CD N
days NNS N
for IN N
women NNS N
who WP N
were VBD N
taking VBG N
the DT N
placebo NN 1_i
( ( N
P NNP N
= NNP N
0.08 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
increased VBD N
isoflavone NN 1_i
intake NN N
affects NNS N
estrogen VBP N
metabolism NN N
by IN N
altering VBG N
the DT N
steroid NN N
hormone NN N
concentrations NNS N
and CC N
menstrual JJ N
cycle NN N
length NN N
, , N
thereby RB N
demonstrating VBG N
a DT N
potential JJ N
to TO N
reduce VB N
the DT N
risk NN N
for IN N
breast NN 1_p
carcinoma NN 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
Preoperative NNP 1_i
Oral NNP 1_i
Rehydration NNP 1_o
on IN N
Onset NNP N
Time NNP N
and CC N
Recovery NNP N
Time NNP N
of IN N
Rocuronium NNP N
] NNP N
. . N

BACKGROUND NNP N
Preoperative NNP N
oral JJ 1_i
rehydration NN 1_o
solution NN 1_i
( ( 1_i
ORS NNP 1_i
) ) 1_i
prevents VBZ N
hypovolemia NN 1_o
. . 1_o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
intubating VBG N
dose NN N
of IN N
rocuronium NN 1_i
in IN N
patients NNS 1_p
taking VBG 1_p
and CC 1_p
those DT 1_p
not RB 1_p
taking VBG 1_p
preoperative JJ 1_o
ORS NNP 1_o
. . 1_o

METHODS NNP N
Twenty NNP 1_p
patients NNS 1_p
, , 1_p
ASA NNP 1_p
I PRP 1_p
aged VBD 1_p
20-50 CD 1_p
years NNS 1_p
scheduled VBN 1_p
for IN 1_p
elective JJ 1_p
surgery NN 1_p
, , N
were VBD N
investigated VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
drinking NN N
1,500 CD N
ml NN N
ORS NNP 1_i
6 CD N
to TO N
2 CD N
hours NNS N
before IN N
anesthesia NN N
( ( 1_i
ORS NNP 1_i
group NN 1_i
) ) 1_i
and CC N
nothing NN 1_i
by IN 1_i
mouth NN 1_i
from IN N
6 CD N
hours NNS N
before IN N
anesthesia NN N
( ( 1_i
control VB 1_i
group NN 1_i
) ) 1_i
. . N

Anesthesia NNP N
was VBD N
maintained VBN N
with IN N
propofol NN 1_i
and CC N
remifentanil NN 1_o
, , N
and CC N
rocuronium NN 1_i
0.6 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
was VBD N
administrated VBN N
. . N

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
rocuronium NN N
, , N
acceleromyography NN 1_o
at IN N
the DT N
adductor NN N
pollicis NN N
was VBD N
performed VBN N
using VBG N
0.1 CD N
Hz NNP N
stimulation NN N
. . N

Cardiac NNP 1_o
index NN 1_o
( ( 1_o
CI NNP 1_o
) ) 1_o
and CC 1_o
stroke VBD 1_o
volume NN 1_o
variation NN 1_o
( ( 1_o
SVV NNP 1_o
) ) 1_o
from IN N
FloTra/Vigileo NNP N
, , N
times NNS N
to TO N
95 CD N
% NN N
twitch NN N
depression NN 1_o
as IN N
onset JJ 1_o
time NN 1_o
( ( 1_o
OT NNP 1_o
) ) 1_o
, , N
and CC N
times NNS N
to TO N
first JJ N
twitch VB 1_o
re-detection NN 1_o
( ( 1_o
TR NNP 1_o
) ) 1_o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
SVV NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
ORS NNP 1_o
group NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
CI NNP N
showed VBD N
no DT N
difference NN N
. . N

In IN N
ORS NNP 1_i
group NN N
, , N
TR NNP N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
of IN N
control NN N
group NN N
( ( N
P=0.002 NNP N
) ) N
, , N
and CC N
OT NNP N
tended VBD N
to TO N
be VB N
prolonged VBN N
( ( N
99.0 CD N
? . N
36.3 CD N
s NN N
vs. FW N
84.0 CD N
? . N
37.5 CD N
s NN N
) ) N
, , N
but CC N
not RB N
significantly RB N
. . N

CONCLUSIONS NNP N
Preoperative NNP N
oral JJ N
rehydration NN N
possibly RB N
increases VBZ N
circulating VBG N
blood NN N
volume NN N
, , N
and CC N
shortens VBZ N
the DT N
duration NN N
of IN N
rocuronium NN 1_o
effect NN 1_o
. . 1_o

-DOCSTART- -X- O O

Improving VBG N
maternal JJ 1_o
mental JJ 1_o
health NN 1_o
after IN 1_p
a DT 1_p
child NN 1_p
's POS 1_p
diagnosis NN 1_p
of IN 1_p
autism NN 1_p
spectrum JJ 1_p
disorder NN 1_p
: : 1_p
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE VBZ N
The DT N
prevalence NN N
of IN N
psychological JJ N
distress NN N
among IN N
mothers NNS 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
suggests VBZ N
a DT N
need NN N
for IN N
interventions NNS N
that WDT N
address VBP N
parental JJ 1_o
mental JJ 1_o
health NN 1_o
during IN N
the DT N
critical JJ N
period NN N
after IN N
the DT N
child NN N
's POS N
autism NN N
diagnosis NN N
when WRB N
parents NNS N
are VBP N
learning VBG N
to TO N
navigate VB N
the DT N
complex JJ N
system NN N
of IN N
autism NN N
services NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
whether IN N
a DT N
brief JJ N
cognitive JJ N
behavioral JJ N
intervention NN N
, , N
problem-solving JJ 1_i
education NN 1_i
( ( 1_i
PSE NNP 1_i
) ) 1_i
, , N
decreases VBZ N
parenting VBG 1_o
stress NN 1_o
and CC 1_o
maternal JJ 1_o
depressive NN 1_o
symptoms NNS 1_o
during IN N
the DT N
period NN N
immediately RB N
following VBG N
a DT N
child NN N
's POS N
diagnosis NN N
of IN N
ASD NNP N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
A NNP N
randomized VBD N
clinical JJ N
trial NN N
compared VBN N
6 CD N
sessions NNS N
of IN N
PSE NNP 1_i
with IN N
usual JJ 1_i
care NN 1_i
. . 1_i

Settings NNP N
included VBD N
an DT N
autism NN 1_p
clinic NN 1_p
and CC 1_p
6 CD 1_p
community-based JJ 1_p
early JJ 1_p
intervention NN 1_p
programs NNS 1_p
that WDT 1_p
primarily RB 1_p
serve VBP 1_p
low-income JJ 1_p
families NNS 1_p
. . 1_p

Participants NNS 1_p
were VBD 1_p
mothers NNS 1_p
of IN 1_p
122 CD 1_p
young JJ 1_p
children NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
34 CD 1_p
months NNS 1_p
) ) 1_p
who WP 1_p
recently RB 1_p
received VBD 1_p
a DT 1_p
diagnosis NN 1_p
of IN 1_p
ASD NNP 1_p
. . 1_p

Among IN N
mothers NNS N
assessed VBN N
for IN N
eligibility NN N
, , N
17.0 CD N
% NN N
declined VBD N
participation NN N
. . N

We PRP N
report VBP N
outcomes NNS N
after IN N
3 CD N
months NNS N
of IN N
follow-up NN N
( ( N
immediate JJ N
postdiagnosis NN N
period NN N
) ) N
. . N

INTERVENTIONS NNP N
Problem-solving JJ 1_i
education NN 1_i
is VBZ N
a DT N
brief JJ N
, , N
cognitive JJ N
intervention NN N
delivered VBN N
in IN N
six CD N
30-minute JJ 1_i
individualized VBN 1_i
sessions NNS 1_i
by IN 1_i
existing VBG 1_i
staff NN 1_i
( ( N
early JJ N
intervention NN N
programs NNS N
) ) N
or CC N
research NN 1_i
staff NN 1_i
without IN 1_i
formal JJ 1_i
mental JJ 1_i
health NN 1_i
training NN 1_i
( ( N
autism NN N
clinic NN N
) ) N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
were VBD N
parental JJ 1_o
stress NN 1_o
and CC 1_o
maternal JJ 1_o
depressive NN 1_o
symptoms NNS 1_o
. . 1_o

RESULTS NNP N
Fifty-nine JJ 1_p
mothers NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
PSE NNP 1_i
and CC N
63 CD N
to TO N
receive VB N
usual JJ 1_i
care NN 1_i
. . 1_i

The DT N
follow-up JJ N
rate NN N
was VBD N
91.0 CD N
% NN N
. . N

Most JJS N
intervention NN N
mothers NNS N
( ( N
78.0 CD N
% NN N
) ) N
received VBD N
the DT N
full JJ N
PSE NNP 1_i
course NN N
. . N

At IN N
the DT N
3-month JJ N
follow-up JJ N
assessment NN N
, , N
PSE NNP 1_i
mothers NNS N
were VBD N
significantly RB N
less RBR N
likely JJ N
than IN N
those DT N
serving VBG N
as RB N
controls NNS N
to TO N
have VB N
clinically RB N
significant JJ N
parental JJ 1_o
stress NN 1_o
( ( N
3.8 CD N
% NN N
vs JJ N
29.3 CD N
% NN N
; : N
adjusted VBN N
relative JJ N
risk NN N
[ NNP N
aRR NN N
] NNP N
, , N
0.17 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.04 CD N
to TO N
0.65 CD N
) ) N
. . N

For IN N
depressive JJ 1_o
symptoms NNS 1_o
, , N
the DT N
risk NN N
reduction NN N
in IN N
clinically RB N
significant JJ N
symptoms NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
( ( N
5.7 CD N
% NN N
vs JJ N
22.4 CD N
% NN N
; : N
aRR CC N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.10 CD N
to TO N
1.08 CD N
) ) N
; : N
however RB N
, , N
the DT N
reduction NN N
in IN N
mean JJ N
depressive NN 1_o
symptoms NNS 1_o
was VBD N
statistically RB N
significant JJ N
( ( N
Quick NNP N
Inventory NNP N
of IN N
Depressive NNP N
Symptomatology NNP N
score NN N
, , N
4.6 CD N
with IN N
PSE NNP N
vs FW N
6.9 CD N
with IN N
usual JJ N
care NN N
; : N
adjusted VBN N
mean NN N
difference NN N
, , N
-1.67 NNP N
; : N
95 CD N
% NN N
CI NNP N
, , N
-3.17 NNP N
to TO N
-0.18 VB N
) ) N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
The DT N
positive JJ N
effects NNS N
of IN N
PSE NNP 1_i
in IN N
reducing VBG N
parenting VBG 1_o
stress NN 1_o
and CC N
depressive JJ 1_o
symptoms NNS 1_o
during IN N
the DT N
critical JJ N
postdiagnosis NN N
period NN N
, , N
when WRB N
parents NNS N
are VBP N
asked VBN N
to TO N
navigate VB N
a DT N
complex JJ N
service NN N
delivery NN N
system NN N
, , N
suggest VBP N
that IN N
it PRP N
may MD N
have VB N
a DT N
place NN N
in IN N
clinical JJ N
practice NN N
. . N

Further NNP N
work NN N
will MD N
monitor VB N
these DT N
families NNS N
for IN N
a DT N
total NN N
of IN N
9 CD N
months NNS N
to TO N
determine VB N
the DT N
trajectory NN N
of IN N
outcomes NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01021384 NN N
. . N

-DOCSTART- -X- O O

Trace NNP 1_i
element NN 1_i
supplementation NN 1_i
after IN N
major JJ 1_p
burns NNS 1_p
modulates VBZ N
antioxidant JJ N
status NN N
and CC N
clinical JJ N
course NN N
by IN N
way NN N
of IN N
increased JJ N
tissue NN 1_o
trace NN 1_o
element NN 1_o
concentrations NNS 1_o
. . 1_o

BACKGROUND NNP N
After IN N
major JJ 1_p
burns NNS 1_p
, , 1_p
patients NNS 1_p
can MD N
develop VB N
nutritional JJ 1_p
deficiencies NNS 1_p
including VBG 1_p
trace NN 1_o
element NN 1_o
( ( 1_o
TE NNP 1_o
) ) 1_o
deficiencies NNS 1_p
. . 1_p

Various JJ N
complications NNS N
, , N
such JJ N
as IN N
infections NNS N
and CC N
delayed VBN N
wound NN N
healing NN N
, , N
influence VB N
the DT N
clinical JJ N
course NN N
of IN N
such JJ N
patients NNS N
. . N

OBJECTIVES IN N
We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
large JJ N
, , N
intravenous JJ N
doses NNS N
of IN N
TE NNP 1_i
supplements NNS 1_i
on IN N
circulating NN N
and CC N
cutaneous JJ N
TE NNP N
tissue NN N
concentrations NNS N
, , N
on IN N
antioxidant JJ 1_o
status NN 1_o
, , N
and CC N
on IN N
clinical JJ 1_o
outcome NN 1_o
after IN N
major JJ 1_p
burns NNS 1_p
. . 1_p

DESIGN NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
trial NN N
in IN N
21 CD 1_p
patients NNS 1_p
aged VBD 1_p
35 CD 1_p
+/- JJ 1_p
11 CD 1_p
y NN 1_p
( ( 1_p
x JJ 1_p
+/- NNP 1_p
SD NNP 1_p
) ) 1_p
with IN 1_p
burns NNS 1_p
on IN 1_p
45 CD 1_p
+/- JJ 1_p
21 CD 1_p
% NN 1_p
of IN 1_p
their PRP$ 1_p
body NN 1_p
surface NN 1_p
area NN 1_p
. . 1_p

Intravenous JJ 1_i
copper NN 1_i
, , 1_i
selenium NN 1_i
, , 1_i
and CC 1_i
zinc NN 1_i
( ( 1_i
TE NNP 1_i
group NN 1_i
) ) 1_i
or CC 1_i
vehicle NN 1_i
( ( N
V NNP N
group NN N
) ) N
was VBD N
given VBN N
with IN N
a DT N
saline JJ N
solution NN N
for IN N
14-21 JJ N
d. NN N
Blood NNP N
and CC N
urine JJ N
samples NNS N
were VBD N
collected VBN N
until IN N
day NN N
20 CD N
, , N
and CC N
skin FW N
biopsy NN N
specimens NNS N
were VBD N
collected VBN N
on IN N
days NNS N
3 CD N
, , N
10 CD N
, , N
and CC N
20 CD N
. . N

RESULTS VB N
The DT N
age NN N
of IN N
the DT N
patients NNS N
and CC N
the DT N
severity NN N
of IN N
their PRP$ N
burns NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
. . N

Plasma NNP 1_o
TE NNP 1_o
concentrations NNS 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
TE NNP N
group NN N
. . N

In IN N
burned JJ N
areas NNS N
, , N
skin JJ 1_o
contents NNS 1_o
of IN 1_o
both DT 1_o
selenium NN 1_o
( ( N
P=0.05 NNP N
) ) N
and CC N
zinc NN 1_o
( ( N
P=0.04 NNP N
) ) N
increased VBD N
significantly RB N
by IN N
day NN N
20 CD N
. . N

Plasma NNP 1_o
and CC 1_o
tissue NN 1_o
antioxidant NN 1_o
status NN 1_o
was VBD N
improved VBN N
by IN N
supplementation NN N
. . N

The DT N
number NN 1_o
of IN 1_o
infections NNS 1_o
in IN N
the DT N
first JJ N
30 CD N
d NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TE NNP N
group NN N
( ( N
P=0.015 NNP N
) ) N
, , N
with IN N
a DT N
median JJ N
number NN N
of IN N
2 CD N
versus NN N
4 CD N
infections NNS N
per IN N
patient NN N
in IN N
the DT N
TE NNP N
and CC N
V NNP N
groups NNS N
, , N
respectively RB N
, , N
as IN N
a DT N
result NN N
of IN N
a DT N
reduction NN N
in IN N
pulmonary JJ 1_o
infections NNS N
( ( N
P=0.03 NNP N
) ) N
. . N

Wound IN 1_o
healing NN 1_o
was VBD N
improved VBN N
in IN N
the DT N
TE NNP N
group NN N
, , N
with IN N
lower JJR N
requirements NNS 1_o
for IN 1_o
regrafting VBG 1_o
( ( N
P=0.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
TE NNP 1_i
supplementation NN N
was VBD N
associated VBN N
with IN N
higher JJR N
circulating NN 1_o
plasma NN 1_o
and CC 1_o
skin JJ 1_o
tissue NN 1_o
contents NNS 1_o
of IN 1_o
selenium NN 1_o
and CC 1_o
zinc NN 1_o
and CC N
improved VBN N
antioxidant JJ 1_o
status NN 1_o
. . 1_o

These DT N
changes NNS N
were VBD N
associated VBN N
with IN N
improved JJ N
clinical JJ 1_o
outcome NN 1_o
, , 1_o
including VBG 1_o
fewer JJR 1_o
pulmonary JJ 1_o
infections NNS 1_o
and CC 1_o
better JJR 1_o
wound NN 1_o
healing NN 1_o
. . 1_o

-DOCSTART- -X- O O

Clomipramine NNP 1_i
versus NN 1_i
haloperidol NN 1_i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ 1_p
disorder NN 1_p
: : 1_p
a DT N
double-blind NN N
, , N
placebo-controlled JJ 1_i
, , N
crossover NN N
study NN N
. . N

Clomipramine NNP 1_i
, , 1_i
haloperidol NN 1_i
, , 1_i
and CC 1_i
placebo NN 1_i
were VBD N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN 1_p
, , N
and CC N
overall JJ 1_o
outcome NN 1_o
, , 1_o
specific JJ 1_o
symptoms NNS 1_o
, , 1_o
and CC 1_o
side JJ 1_o
effects NNS 1_o
were VBD N
examined VBN N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
clomipramine NN 1_i
would MD N
be VB N
better RB N
tolerated VBN N
than IN N
haloperidol NN 1_i
and CC N
prove VB N
superior JJ N
on IN N
a DT N
measure NN N
of IN N
stereotypy NN N
. . N

Individuals NNS 1_p
with IN 1_p
a DT 1_p
DSM-IV JJ 1_p
diagnosis NN 1_p
of IN 1_p
autistic JJ 1_p
disorder NN 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
16.3 CD 1_p
years NNS 1_p
; : 1_p
range NN 1_p
, , 1_p
10-36 JJ 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
, , 1_p
by IN 1_p
using VBG 1_p
a DT 1_p
Latin NNP 1_p
square NN 1_p
design NN 1_p
, , 1_p
to TO 1_p
the DT 1_p
following JJ 1_p
7-week JJ 1_p
trials NNS 1_p
: : 1_p
placebo NN 1_i
, , 1_i
clomipramine NN 1_i
( ( 1_p
mean JJ 1_p
daily RB 1_p
dose RB 1_p
, , 1_p
128.4 CD 1_p
mg NN 1_p
; : 1_p
range NN 1_p
, , 1_p
100-150 JJ 1_p
mg NN 1_p
) ) 1_p
, , 1_p
or CC 1_p
haloperidol NN 1_i
( ( 1_p
mean JJ 1_p
daily RB 1_p
dose RB 1_p
, , 1_p
1.3 CD 1_p
mg NN 1_p
; : 1_p
range NN 1_p
, , 1_p
1-1.5 JJ 1_p
mg NN 1_p
) ) 1_p
. . 1_p

Data NNP 1_p
on IN 1_p
36 CD 1_p
subjects NNS 1_p
were VBD 1_p
analyzed VBN 1_p
and CC N
taken VBN N
together RB N
; : N
the DT N
results NNS N
favored VBD N
haloperidol NN 1_i
. . 1_i

In IN N
those DT N
patients NNS N
who WP N
were VBD N
able JJ N
to TO N
complete VB N
a DT N
full JJ N
therapeutic JJ N
trial NN N
, , N
clomipramine NN 1_i
proved VBD N
comparable JJ N
to TO N
haloperidol VB 1_i
in IN N
terms NNS N
of IN N
improvement NN 1_o
compared VBN N
with IN N
baseline NN N
. . N

However RB N
, , N
significantly RB N
fewer JJR N
individuals NNS N
receiving VBG N
clomipramine NN 1_i
versus NN N
haloperidol NN 1_i
were VBD N
able JJ N
to TO N
complete VB N
the DT N
trial NN N
( ( N
37.5 CD N
% NN N
vs. FW N
69.7 CD N
% NN N
, , N
respectively RB N
) ) N
for IN N
reasons NNS N
related VBN N
to TO N
both DT N
side NN 1_o
effects NNS 1_o
and CC 1_o
efficacy NN 1_o
or CC 1_o
behavior NN 1_o
problems NNS 1_o
. . 1_o

In IN N
the DT N
intent-to-treat JJ N
sample NN N
, , N
which WDT N
is VBZ N
perhaps RB N
more RBR N
clinically RB N
relevant JJ N
, , N
only RB N
haloperidol VBZ 1_i
proved VBN N
superior JJ N
to TO N
baseline VB N
on IN N
a DT N
global JJ N
measure NN N
of IN N
autistic JJ 1_o
symptom NN 1_o
severity NN 1_o
, , N
as RB N
well RB N
as IN N
specific JJ N
measures NNS N
for IN N
irritability NN 1_o
and CC 1_o
hyperactivity NN 1_o
. . 1_o

Clomipramine NNP 1_i
did VBD N
not RB N
seem VB N
more RBR N
effective JJ N
on IN N
a DT N
measure NN N
of IN N
stereotypy NN N
, , N
nor CC N
was VBD N
it PRP N
better RBR N
tolerated VBN N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
effect NN 1_o
of IN N
fuzheng NN 1_i
yiliu NN 1_i
granule NN 1_i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
effect NN 1_o
of IN N
Fuzheng NNP 1_i
Yiliu NNP 1_i
Granule NNP 1_i
( ( 1_i
FZYLG NNP 1_i
) ) 1_i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
( ( N
NF-kappa NNP N
B NNP N
) ) N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
. . N

METHODS NNP N
Seventy-six JJ 1_p
patients NNS 1_p
with IN 1_p
esophageal JJ 1_p
gastric JJ 1_p
carcinoma NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
FZYLG NNP 1_i
group NN 1_p
and CC N
the DT N
control NN 1_i
group NN 1_i
. . 1_i

FZYLG NNP 1_i
was VBD N
given VBN N
to TO N
the DT N
former JJ N
for IN N
15 CD N
days NNS N
. . N

The DT N
tumor NN N
tissue NN N
in IN N
both DT N
groups NNS N
was VBD N
resected VBN N
and CC N
cell JJ 1_o
cycle NN 1_o
and CC N
apoptosis NN 1_o
rate NN 1_o
as RB N
well RB N
as IN N
NF-kappa NNP N
B NNP N
were VBD N
determined VBN N
by IN N
flowcytometry NN N
. . N

RESULTS NNP N
Level NNP 1_o
of IN 1_o
NF-kappa NNP 1_o
B NNP 1_o
in IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
treated JJ N
group NN N
, , N
the DT N
percentage NN 1_o
of IN 1_o
G0/G1 NNP 1_o
stage NN 1_o
cells NNS 1_o
were VBD N
significantly RB N
increased VBN N
and CC N
that IN N
of IN N
S NNP 1_o
stage NN 1_o
significantly RB N
decreased VBN N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
same JJ N
time NN N
, , N
obvious JJ N
cell NN 1_o
apoptosis NN 1_o
was VBD N
found VBN N
in IN N
the DT N
treated JJ N
group NN N
, , N
the DT N
apoptosis NN 1_o
rate NN 1_o
of IN N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
FZYLG NNP 1_i
can MD N
increase VB N
the DT N
NF-kappa NNP N
B NNP N
expression NN N
, , N
block VB N
the DT N
proliferation NN N
to TO N
promote VB N
the DT N
apoptosis NN 1_o
of IN N
tumor NN N
cells NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
single-dose JJ N
oral JJ N
granisetron NN 1_i
versus NN N
intravenous JJ N
ondansetron NN 1_i
in IN N
the DT N
prevention NN N
of IN N
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
induced VBN 1_o
by IN 1_o
moderately RB 1_o
emetogenic JJ 1_o
chemotherapy NN 1_o
: : 1_o
a DT N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
parallel NN N
study NN N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effectiveness NN N
and CC N
safety NN N
of IN N
single-dose JJ N
oral JJ N
granisetron NN 1_i
were VBD N
compared VBN N
with IN N
intravenous JJ N
( ( N
I.V NNP N
. . N

) ) N
ondansetron NN 1_i
in IN N
chemotherapy-naive JJ 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
moderately RB 1_i
emetogenic JJ 1_i
chemotherapy NN 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
parallel-group NN 1_p
study NN 1_p
, , 1_p
patients NNS 1_p
naive VBP 1_p
to TO 1_p
emetogenic VB 1_i
chemotherapy NN 1_i
( ( 1_p
N NNP 1_p
= NNP 1_p
1,085 CD 1_p
) ) 1_p
who WP 1_p
were VBD 1_p
scheduled VBN 1_p
to TO 1_p
receive VB 1_p
cyclophosphamide- NN 1_i
( ( 1_i
500 CD 1_i
to TO 1_i
1,200 CD 1_i
mg/m2 NN 1_i
) ) 1_i
or CC 1_i
carboplatin NN 1_i
( ( 1_p
> CD 1_p
or CC 1_p
= VB 1_p
300 CD 1_p
mg/m2 NN 1_p
) ) 1_p
based VBN 1_p
chemotherapy NN 1_p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
granisetron NN 1_i
( ( N
n JJ N
= NNP N
542 CD N
) ) N
or CC N
I.V NNP N
. . N

ondansetron NN 1_i
( ( N
n JJ N
= NNP N
543 CD N
) ) N
. . N

Efficacy NN N
assessments NNS N
included VBD N
the DT N
proportion NN N
of IN N
patients NNS N
in IN N
each DT N
treatment NN 1_i
group NN 1_i
with IN N
total JJ N
control NN 1_i
over IN N
the DT N
24 CD N
and CC N
48 CD N
hours NNS N
following VBG N
chemotherapy NN 1_i
initiation NN N
, , N
as RB N
well RB N
as IN N
incidence NN N
and CC N
severity NN N
of IN N
nausea NN 1_o
and CC 1_o
emesis NN 1_o
and CC N
use NN N
of IN N
antiemetic JJ N
rescue NN N
medication NN N
. . N

Prophylactic JJ 1_i
corticosteroids NNS 1_i
were VBD 1_i
allowed VBN 1_i
. . 1_i

Safety NNP N
assessment NN N
was VBD N
based VBN N
on IN N
patients NNS N
' POS N
reports NNS N
of IN N
adverse JJ N
experiences NNS N
. . N

RESULTS NNP N
Approximately RB N
80 CD N
% NN N
of IN N
patients NNS N
received VBN N
prophylactic JJ 1_i
corticosteroids NNS 1_i
. . 1_i

Single-dose JJ N
oral JJ N
granisetron NN 1_i
( ( N
2 CD N
mg NN N
) ) N
and CC N
I.V NNP N
. . N

ondansetron NN 1_i
( ( N
32 CD N
mg NN N
) ) N
resulted VBD N
in IN N
equivalent JJ N
levels NNS N
of IN N
total JJ 1_o
emetic JJ 1_o
control NN 1_o
during IN N
the DT N
first JJ N
48 CD N
hours NNS N
after IN N
chemotherapy NN 1_i
. . 1_i

The DT N
proportion NN 1_o
of IN 1_o
nausea- JJ 1_o
and CC 1_o
emesis-free JJ 1_o
patients NNS 1_o
at IN N
24 CD N
and CC N
48 CD N
hours NNS N
were VBD N
also RB N
approximately RB N
equivalent JJ N
. . N

The DT N
most RBS N
commonly RB N
reported VBD N
adverse JJ N
experiences NNS N
were VBD N
headache NN 1_o
, , 1_o
asthenia NN 1_o
, , 1_o
and CC 1_o
constipation NN 1_o
. . 1_o

More JJR N
patients NNS N
who WP N
received VBD N
ondonsetron JJR 1_i
than IN N
granisetron NN 1_i
reported VBN N
dizziness NN 1_o
( ( N
9.6 CD N
% NN N
v JJ N
5.4 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.011 NNP N
) ) N
and CC N
abnormal JJ 1_o
vision NN 1_o
( ( N
4.2 CD N
% NN N
v JJ N
0.6 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
granisetron NN 1_i
( ( N
2 CD N
mg NN N
) ) N
resulted VBD N
in IN N
equivalent JJ N
levels NNS N
of IN N
antiemetic JJ 1_o
protection NN 1_o
as IN N
I.V NNP N
. . N

ondansetron NN 1_i
( ( N
32 CD N
mg NN N
) ) N
. . N

Both DT N
agents NNS N
were VBD N
well RB N
tolerated VBN N
, , N
although IN N
more JJR N
dizziness NN 1_o
and CC 1_o
abnormal JJ 1_o
vision NN 1_o
were VBD N
reported VBN N
with IN N
ondansetron NN 1_i
. . 1_i

Because IN N
the DT N
two CD N
antiemetic JJ N
regimens NNS N
exhibited VBD N
equivalent JJ N
efficacies NNS N
, , N
additional JJ N
factors NNS N
such JJ N
as IN N
convenience NN N
and CC N
cost NN N
of IN N
therapy NN N
should MD N
be VB N
considered VBN N
. . N

-DOCSTART- -X- O O

Limited JJ N
effects NNS N
of IN N
micronutrient JJ 1_i
supplementation NN 1_i
on IN N
strength NN 1_o
and CC 1_o
physical JJ 1_o
function NN 1_o
after IN N
abdominal JJ 1_o
aortic JJ 1_p
aneurysmectomy NN 1_p
. . 1_p

BACKGROUND NNP N
Tissue NNP N
injury NN N
following VBG N
ischemia-reperfusion NN N
is VBZ N
mediated VBN N
in IN N
part NN N
by IN N
free JJ N
oxygen NN N
radicals NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
perioperative JJ N
micronutrient NN 1_i
supplementation NN 1_i
would MD N
augment VB 1_o
antioxidant JJ 1_o
defenses NNS 1_o
, , 1_o
minimize VB 1_o
muscle NN 1_o
injury NN 1_o
, , 1_o
and CC 1_o
minimize VB 1_o
postoperative JJ 1_o
decreases NNS 1_o
in IN 1_o
muscle NN 1_o
strength NN 1_o
and CC 1_o
physical JJ 1_o
function NN 1_o
following VBG N
abdominal JJ N
aortic JJ N
aneurysmectomy NN N
. . N

SETTING VB N
A DT N
university-affiliated JJ 1_p
hospital NN 1_p
and CC 1_p
regional JJ 1_p
referral JJ 1_p
center NN 1_p
. . 1_p

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
of IN N
supplementation NN 1_i
with IN 1_i
beta-carotene NN 1_i
, , 1_i
vitamins VBZ 1_i
C NNP 1_i
and CC 1_i
E NNP 1_i
, , 1_i
zinc NN 1_i
, , 1_i
and CC 1_i
selenium NN 1_i
for IN N
a DT N
period NN N
of IN N
2-3 JJ N
weeks NNS N
prior RB N
to TO N
surgery NN N
and CC N
1 CD N
week NN N
thereafter RB N
. . N

STUDY NNP N
POPULATION NNP N
Patients NNP 1_p
undergoing VBG 1_p
elective JJ 1_p
abdominal JJ 1_i
aortic JJ 1_i
aneurysmectomy NN 1_i
( ( 1_p
n=18 JJ 1_p
per IN 1_p
group NN 1_p
) ) 1_p
. . 1_p

PRINCIPAL JJ N
MEASUREMENTS NNP N
Handgrip NNP 1_o
and CC 1_o
other JJ 1_o
measures NNS 1_o
of IN 1_o
strength NN 1_o
and CC 1_o
physical JJ 1_o
function NN 1_o
. . 1_o

RESULTS NNP N
Handgrip NNP 1_o
and CC 1_o
quadriceps JJ 1_o
strength NN 1_o
decreased VBD N
following VBG N
surgery NN N
, , N
but CC N
not RB N
to TO N
a DT N
significantly RB N
different JJ N
extent NN N
in IN N
the DT N
placebo NN N
and CC N
supplemented VBD N
groups NNS N
. . N

Self-rated JJ 1_o
physical JJ 1_o
function NN 1_o
decreased VBD N
following VBG N
surgery NN 1_i
in IN N
the DT N
placebo NN N
group NN N
and CC N
was VBD N
preserved VBN N
in IN N
the DT N
supplemented JJ N
group NN N
. . N

CONCLUSIONS NNP N
Perioperative NNP 1_i
supplementation NN 1_i
with IN 1_i
micronutrients NNS 1_i
with IN N
antioxidant JJ N
properties NNS N
has VBZ N
limited VBN N
effects NNS N
on IN N
strength NN 1_o
and CC 1_o
physical JJ 1_o
function NN 1_o
following VBG N
major JJ N
elective JJ N
surgery NN N
. . N

-DOCSTART- -X- O O

A DT N
Regulated JJ N
Trial NNP N
of IN N
Bicuspid NNP N
Aortic NNP N
Valve NNP N
Repair NNP N
Supported NNP N
by IN N
Geometric NNP 1_i
Ring NNP 1_i
Annuloplasty NNP 1_i
. . 1_i

BACKGROUND NNP N
Annular NNP N
stabilization NN N
is VBZ N
important JJ N
during IN N
bicuspid JJ N
aortic JJ N
valve NN N
( ( N
BAV NNP N
) ) N
repair NN N
to TO N
obtain VB N
the DT N
best JJS N
long-term JJ N
results NNS N
. . N

This DT N
report NN N
describes VBZ N
the DT N
early JJ N
outcomes NNS N
of IN N
a DT N
novel JJ N
bicuspid JJ N
annuloplasty NN N
ring NN N
for IN N
this DT N
purpose NN N
. . N

METHODS NNP N
Under IN N
regulatory JJ N
supervision NN N
( ( N
NCT02071849 NNP N
) ) N
, , N
a DT N
geometric JJ 1_i
bicuspid NN 1_i
annuloplasty JJ 1_i
ring NN 1_i
was VBD N
used VBN N
during IN 1_p
valve JJ 1_p
repair NN 1_p
in IN 1_p
16 CD 1_p
patients NNS 1_p
. . 1_p

Three CD 1_p
patients NNS 1_p
had VBD 1_p
Sievers NNP 1_p
type JJ 1_p
0 CD 1_p
valves NNS 1_p
, , 1_p
11 CD 1_p
had VBD 1_p
Sievers NNP 1_p
type JJ 1_p
1 CD 1_p
, , 1_p
and CC 1_p
2 CD 1_p
had VBD 1_p
Sievers NNP 1_p
type JJ 1_p
2 CD 1_p
. . 1_p

Thirteen JJ 1_p
patients NNS 1_p
had VBD 1_p
left-/right-coronary JJ 1_p
cusp NN 1_p
fusion NN 1_p
, , 1_p
1 CD 1_p
had VBD 1_p
right-/noncoronary JJ 1_p
cusp NN 1_p
fusion NN 1_p
, , 1_p
and CC 1_p
2 CD 1_p
had VBD 1_p
both DT 1_p
. . 1_p

Moderate NNP 1_p
to TO 1_p
severe VB 1_p
aortic JJ 1_p
insufficiency NN 1_p
( ( 1_p
AI NNP 1_p
) ) 1_p
was VBD 1_p
present JJ 1_p
in IN 1_p
13 CD 1_p
of IN 1_p
16 CD 1_p
patients NNS 1_p
, , 1_p
and CC 1_p
3 CD 1_p
had VBD 1_p
mild VBN 1_p
AI NNP 1_p
with IN 1_p
aortic JJ 1_p
aneurysms NNS 1_p
. . 1_p

Ascending NNP N
aortic JJ N
aneurysms NNS N
, , N
root NN N
aneurysms NNS N
, , N
or CC N
both DT N
were VBD N
replaced VBN N
in IN N
7 CD N
of IN N
16 CD N
patients NNS N
. . N

The DT N
Dacron-covered JJ 1_i
titanium NN 1_i
ring NN 1_i
had VBD N
circular JJ N
base NN N
geometry NN N
and CC N
two CD N
outwardly RB N
flaring JJ N
subcommissural JJ N
posts NNS N
positioned VBD N
opposite RB N
on IN N
the DT N
circumference NN N
. . N

The DT N
ring NN N
was VBD N
implanted VBN N
into IN N
the DT N
annulus JJ N
beneath NN N
the DT N
valve NN N
, , N
and CC N
then RB N
leaflet VB N
repair NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
Immediate NNP 1_o
postrepair NN 1_o
echocardiograms NN 1_o
showed VBD 1_o
grade JJ 1_o
0 CD 1_o
residual JJ 1_o
AI NNP N
in IN N
all DT N
patients NNS N
, , N
with IN N
good JJ N
cusp NN 1_o
mobility NN 1_o
and CC 1_o
effective JJ 1_o
height NN 1_o
, , 1_o
and CC 1_o
satisfactory JJ 1_o
gradients NNS 1_o
. . 1_o

There EX N
were VBD N
no DT 1_o
in-hospital JJ 1_o
or CC 1_o
late JJ 1_o
mortalities NNS 1_o
. . 1_o

Two CD N
patients NNS N
experienced VBD 1_o
leaflet JJ 1_o
tears NNS 1_o
from IN N
long JJ N
annular JJ N
suture NN N
tails NNS N
, , N
requiring VBG 1_o
late JJ 1_o
valve NN 1_o
replacement NN 1_o
. . 1_o

After IN N
implementation NN N
of IN N
a DT N
lateral JJ N
suture NN N
fixation NN N
technique NN N
, , N
no DT N
more JJR 1_o
failures NNS 1_o
occurred VBD N
. . N

At IN N
a DT N
mean JJ N
follow-up JJ N
time NN N
of IN N
9 CD N
months NNS N
, , N
the DT N
remaining VBG N
14 CD N
patients NNS N
were VBD N
in IN 1_o
New NNP 1_o
York NNP 1_o
Heart NNP 1_o
Association NNP 1_o
class NN 1_o
I PRP N
, , N
with IN N
predominant JJ 1_o
grade NN 1_o
0 CD 1_o
AI NNP 1_o
. . 1_o

CONCLUSIONS NNP N
As IN N
a DT N
technique NN N
for IN N
BAV NNP N
repair NN N
, , N
internal JJ N
ring NN N
annuloplasty NN N
produces VBZ N
major JJ 1_o
annular JJ 1_o
remodeling NN 1_o
and CC 1_o
stabilization NN 1_o
. . 1_o

Annular JJ N
reduction NN N
and CC N
reshaping VBG N
to TO N
a DT N
50/50 CD N
% NN N
symmetric JJ N
circular JJ N
geometry NN N
facilitates NNS 1_o
leaflet VBP 1_o
repair NN 1_o
and CC N
enhances NNS 1_o
cusp JJ 1_o
coaptation NN 1_o
. . 1_o

Geometric NNP N
ring VBG N
annuloplasty NN N
could MD N
have VB N
useful JJ N
applications NNS N
in IN N
BAV NNP N
repair NN N
. . N

-DOCSTART- -X- O O

Heart NNP N
rate NN N
variability NN N
characteristics NNS N
in IN 1_p
sedentary JJ 1_p
postmenopausal JJ 1_p
women NNS 1_p
following VBG N
six CD N
months NNS N
of IN N
exercise NN 1_i
training NN 1_i
: : 1_i
the DT N
DREW NNP N
study NN N
. . N

BACKGROUND NNP N
Decreased VBD N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
mortality NN N
. . N

Overall JJ N
, , N
postmenopausal JJ 1_p
women NNS 1_p
have VBP N
lower JJR N
levels NNS N
of IN N
HRV NNP N
than IN N
premenopausal JJ N
women NNS N
, , N
which WDT N
may MD N
be VB N
additionally RB N
complicated VBN N
by IN N
lifestyle JJ N
related JJ N
behaviors NNS N
such JJ N
as IN N
physical JJ N
inactivity NN N
and CC N
obesity NN N
. . N

Though IN N
cardiorespiratory JJ 1_i
exercise NN 1_i
training NN 1_i
increases NNS N
HRV NNP N
, , N
little JJ N
is VBZ N
known VBN N
regarding VBG N
the DT N
exercise NN N
dose NN N
necessary JJ N
to TO N
promote VB N
this DT N
improvement NN N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
Our PRP$ N
primary JJ N
aim NN N
was VBD N
to TO N
measure VB N
HRV NNP N
in IN N
post-menopausal JJ 1_p
women NNS 1_p
following VBG N
6-months JJ N
of IN N
exercise NN 1_i
training NN 1_i
. . 1_i

We PRP N
examined VBD N
supine JJ 1_p
resting VBG 1_p
HRV NNP 1_p
in IN 1_p
373 CD 1_p
post-menopausal JJ 1_p
women NNS 1_p
( ( 1_p
45-75 JJ 1_p
y NN 1_p
) ) 1_p
after IN 1_p
6-months CD 1_p
of IN 1_p
randomly NN 1_p
assigned VBN 1_p
and CC N
double-blinded JJ N
administered JJ N
exercise NN 1_i
training NN 1_i
exercise NN 1_i
training NN 1_i
at IN N
50 CD N
% NN N
, , N
100 CD N
% NN N
and CC N
150 CD N
% NN N
of IN N
the DT N
NIH NNP N
Consensus NNP N
Development NNP N
Panel NNP N
's POS N
recommended JJ N
minimal JJ N
physical JJ N
activity NN N
level NN N
. . N

This DT N
corresponded VBD N
to TO N
4 CD N
, , N
8 CD N
, , N
or CC N
12 CD N
kcal/kg NNS N
per IN N
week NN N
( ( N
KKW NNP N
) ) N
of IN N
energy NN N
expenditure NN N
. . N

At IN N
baseline NN N
, , N
we PRP N
observed VBD N
no DT N
significant JJ N
differences NNS N
in IN N
HRV NNP 1_o
or CC N
hormone NN 1_o
replacement NN N
use NN N
between IN N
treatment NN N
groups NNS N
. . N

However RB N
, , N
we PRP N
did VBD N
observe VB N
that DT N
Caucasian JJ N
women NNS N
and CC N
those DT N
taking VBG N
antidepressant JJ N
medications NNS N
had VBD N
lower JJR N
levels NNS N
of IN N
baseline NN 1_o
HRV NNP 1_o
. . 1_o

After IN N
6-months JJ N
of IN N
exercise NN 1_i
intervention NN 1_i
, , N
we PRP N
observed VBD N
a DT N
dose JJ N
dependent JJ N
increase NN N
in IN N
all DT N
parasympathetically RB N
derived VBN N
time NN 1_o
and CC 1_o
frequency NN 1_o
domain NN 1_o
measurements NNS 1_o
across IN N
exercise NN N
groups NNS N
after IN N
adjustment NN N
for IN N
age NN N
, , N
ethnicity NN N
, , N
antidepressants NNS 1_o
, , N
and CC N
baseline NN N
rMSSD NN N
( ( N
all DT N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
example NN N
, , N
the DT N
parasympathetic JJ 1_o
index NN 1_o
rMSSD NN 1_o
was VBD N
greater JJR N
than IN N
control NN N
( ( N
23.19+/-1.0 JJ N
) ) N
for IN N
the DT N
4-KKW JJ N
( ( N
25.98+/-0.8 JJ N
; : N
P NNP N
= NNP N
0.14 CD N
) ) N
, , N
8-KKW JJ N
( ( N
27.66+/-1.0 JJ N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
12-KKW JJ N
( ( N
27.40+/-0.0 JJ N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
groups NNS N
at IN N
follow-up JJ N
. . N

CONCLUSIONS/SIGNIFICANCE NNP N
Moderate NNP 1_i
intensity NN 1_i
exercise NN 1_i
training NN 1_i
exercise NN 1_i
is VBZ N
sufficient JJ N
to TO N
improve VB N
HRV NNP N
in IN N
previously RB N
sedentary JJ 1_p
postmenopausal NN 1_p
women NNS 1_p
in IN N
a DT N
dose-dependent JJ N
manner NN N
, , N
as IN N
4-KKW JJ N
is VBZ N
insufficient JJ N
to TO N
improve VB N
parasympathetic JJ N
indices NNS N
of IN N
HRV NNP N
, , N
while IN N
12-KKW JJ N
conferred VBD N
no DT N
greater JJR N
improvement NN N
than IN N
8-KKW JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
NCT NNP N
00011193 CD N
. . N

-DOCSTART- -X- O O

Resisting VBG N
good JJ N
news NN N
: : N
reactions NNS N
to TO N
breast VB 1_p
cancer NN 1_p
risk NN 1_p
communication NN N
. . N

Many JJ N
women NNS N
overestimate VBP N
their PRP$ N
percentage NN N
risk NN N
of IN N
breast NN N
cancer NN N
, , N
even RB N
after IN N
they PRP N
have VBP N
received VBN N
careful JJ 1_i
estimates NNS 1_i
from IN N
health NN N
professionals NNS N
. . N

In IN N
2 CD N
experiments NNS N
with IN N
134 CD 1_p
young JJ 1_p
adult NN 1_p
women NNS 1_p
, , 1_p
6 CD 1_p
variables NNS 1_p
were VBD N
explored VBN N
that IN N
might MD N
influence VB N
such JJ N
risk NN 1_o
perception NN 1_o
persistence NN N
. . N

In IN N
Study NNP N
1 CD N
, , N
each DT N
of IN N
the DT N
following JJ N
explanations NNS N
was VBD N
unrelated JJ N
to TO N
persistence VB 1_o
: : 1_o
public JJ 1_i
commitment NN 1_i
, , 1_i
self-consistency NN 1_i
, , N
and CC N
unique JJ 1_i
causal NN 1_i
risk NN 1_i
models NNS 1_i
. . 1_i

In IN N
Study NNP N
2 CD N
, , N
two CD N
individual JJ N
difference NN N
measures NNS N
, , N
pessimism NN N
and CC N
differences NNS N
in IN N
understanding JJ N
percentages NNS N
, , N
were VBD N
unrelated JJ N
to TO N
risk VB 1_o
perception NN 1_o
persistence NN 1_o
. . 1_o

However RB N
, , N
providing VBG N
a DT N
risk NN 1_i
anchor NN 1_i
based VBN 1_i
on IN 1_i
downward JJ 1_i
social JJ 1_i
comparison NN 1_i
processes NNS 1_i
resulted VBD N
in IN N
better JJR N
risk NN 1_o
acceptance NN 1_o
at IN N
posttest JJS N
that IN N
persisted VBD N
at IN N
a DT N
2-week JJ N
follow-up JJ N
assessment NN N
. . N

This DT N
article NN N
discusses VBZ N
why WRB N
comparison NN 1_i
anchors NNS 1_i
might MD N
be VB N
important JJ N
in IN N
risk NN N
feedback NN N
situations NNS N
and CC N
concludes NNS N
with IN N
recommendations NNS N
for IN N
professionals NNS N
who WP N
wish VBP N
to TO N
provide VB N
accurate NN N
risk NN N
information NN N
and CC N
have VBP N
patients NNS N
adopt VB N
that DT N
information NN N
. . N

-DOCSTART- -X- O O

Masticatory JJ N
performance NN N
and CC N
chewing VBG N
experience NN N
with IN N
implant-retained JJ 1_p
mandibular JJ 1_p
overdentures NNS 1_p
. . 1_p

The DT N
relationship NN N
between IN N
masticatory NN N
performance NN N
and CC N
chewing VBG N
experience NN N
has VBZ N
not RB N
yet RB N
been VBN N
explored VBN N
for IN N
patients NNS 1_p
with IN 1_p
implant-retained JJ 1_i
overdentures NNS 1_i
. . 1_i

Although IN N
many JJ N
relationships NNS N
have VBP N
been VBN N
found VBN N
between IN N
parameters NNS N
of IN N
objective JJ N
and CC N
subjective JJ N
oral JJ N
function NN N
, , N
the DT N
structure NN N
of IN N
these DT N
relationships NNS N
remain VBP N
unclear JJ N
. . N

Therefore RB N
, , N
we PRP N
studied VBD N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
the DT N
relationship NN N
between IN N
the DT N
comminution NN N
of IN N
an DT N
artificial JJ N
test NN N
food NN N
, , N
i.e NN 1_i
. . 1_i

masticatory JJ 1_o
performance NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
subjective JJ 1_o
chewing NN 1_o
experience NN 1_o
. . 1_o

The DT N
trial NN N
involved VBD N
a DT N
comparison NN N
between IN N
two CD N
groups NNS N
receiving VBG N
implant JJ 1_i
treatment NN 1_i
and CC 1_i
one CD 1_i
group NN 1_i
receiving VBG 1_i
conventional JJ 1_i
complete JJ 1_i
dentures NNS 1_i
( ( 1_i
CD NN 1_i
) ) 1_i
. . 1_i

The DT N
implant JJ N
treatment NN N
involved VBN N
either CC N
a DT N
mainly RB N
implant-supported JJ 1_i
mandibular JJ 1_i
overdenture NN 1_i
on IN N
a DT N
transmandibular JJ 1_i
implant NN 1_i
( ( 1_i
TMI NNP 1_i
) ) 1_i
or CC N
an DT N
implant-tissue-supported JJ 1_i
mandibular JJ 1_i
overdenture NN 1_i
on IN N
two CD N
IMZ JJ 1_i
implants NNS 1_i
( ( 1_i
IMZ NNP 1_i
) ) 1_i
. . 1_i

Masticatory JJ 1_o
performance NN 1_o
as RB 1_o
well RB 1_o
as IN 1_o
chewing VBG 1_o
experience NN 1_o
were VBD N
substantially RB N
better JJR N
for IN N
the DT N
implant-retained JJ N
overdentures NNS N
compared VBN N
with IN N
the DT N
complete JJ N
denture NN N
group NN N
. . N

No DT N
significant JJ N
differences NNS N
emerged VBD N
between IN N
the DT N
TMI NNP 1_i
and CC N
the DT N
IMZ NNP 1_i
group NN N
. . N

A DT N
multiple JJ N
regression NN N
analysis NN N
did VBD N
not RB N
provide VB N
any DT N
comprehensibility NN N
in IN N
the DT N
relationship NN N
between IN N
masticatory NN 1_o
performance NN 1_o
and CC 1_o
the DT 1_o
variables NNS 1_o
of IN 1_o
chewing VBG 1_o
experience NN 1_o
. . 1_o

In IN N
the DT N
linear JJ N
structural JJ N
relation NN N
analysis NN N
( ( N
LISREL NNP N
) ) N
no DT N
direct JJ N
relationship NN N
was VBD N
found VBN N
between IN N
masticatory JJ 1_o
performance NN 1_o
and CC 1_o
functional JJ 1_o
complaints NNS 1_o
mandibular JJ 1_o
denture NN 1_o
. . 1_o

The DT N
results NNS N
show VBP N
that IN N
an DT N
improvement NN N
in IN N
masticatory JJ N
performance NN N
does VBZ N
not RB N
imply VB N
the DT N
same JJ N
improvement NN N
in IN N
chewing VBG N
experience NN N
and CC N
vice NN N
versa NN N
. . N

-DOCSTART- -X- O O

Laparoscopic NNP 1_i
vs NN N
open JJ 1_i
appendectomy NN 1_i
in IN N
overweight JJ 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Laparoscopic NNP 1_i
appendectomy NN 1_i
( ( 1_i
LA NNP 1_i
) ) 1_i
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
faster JJ N
recovery NN N
and CC N
less RBR N
postoperative JJ N
pain NN N
than IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
few JJ N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
clinical JJ N
outcome NN N
of IN N
LA NNP 1_i
in IN N
overweight JJ 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
A NNP 1_p
group NN 1_p
of IN 1_p
106 CD 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
body NN 1_p
mass NN 1_p
index NN 1_p
( ( 1_p
BMI NNP 1_p
) ) 1_p
> VBD 1_p
26.4 CD 1_p
, , 1_p
representing VBG 1_p
the DT 1_p
upper JJ 1_p
quintile NN 1_p
of IN 1_p
500 CD 1_p
prospectively RB 1_p
randomized JJ 1_p
patients NNS 1_p
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

They PRP N
were VBD N
randomized VBN N
to TO N
undergo VB N
either DT N
laparoscopic NN 1_i
or CC 1_i
open JJ 1_i
appendectomy NN 1_i
( ( 1_i
OA NNP 1_i
) ) 1_i
. . 1_i

Operating NN 1_o
and CC 1_o
anesthesia NN 1_o
times NNS 1_o
, , 1_o
postoperative JJ 1_o
pain NN 1_o
, , 1_o
complications NNS 1_o
, , 1_o
hospital NN 1_o
stay NN 1_o
, , 1_o
functional JJ 1_o
index NN 1_o
( ( N
1 CD N
week NN N
postoperatively RB N
) ) N
, , N
sick JJ 1_o
leave VBP 1_o
, , 1_o
and CC 1_o
time NN 1_o
to TO 1_o
full JJ 1_o
recovery NN 1_o
were VBD N
documented VBN N
. . N

RESULTS NNP N
In IN N
OA NNP 1_i
, , N
the DT N
operating NN 1_o
time NN 1_o
for IN N
overweight JJ 1_o
patients NNS 1_p
was VBD N
significantly RB N
longer JJR N
than IN N
that DT N
for IN N
patients NNS N
in IN N
the DT N
normal JJ N
weight NN N
range NN N
( ( N
40 CD N
vs RB N
35 CD N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
LA NNP 1_i
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
operating NN 1_o
time NN 1_o
between IN N
the DT N
normal JJ N
and CC N
overweight JJ N
patients NNS N
. . N

Overweight JJ N
patients NNS N
who WP N
underwent JJ N
LA NNP 1_i
had VBD N
longer RBR N
operating NN 1_o
and CC 1_o
anesthesia NN 1_o
times NNS 1_o
than IN N
their PRP$ N
OA NNP 1_i
counterparts NNS N
( ( N
55 CD N
vs RB N
40 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
; : N
and CC N
125 CD N
vs NN N
100 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

Postoperative JJ 1_o
pain NN 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP 1_i
than IN N
in IN N
those DT N
treated VBN N
with IN N
the DT N
laparoscopic NN 1_i
technique NN 1_i
. . 1_i

Postoperative JJ 1_o
pain NN 1_o
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP 1_i
than IN N
in IN N
patients NNS N
of IN N
normal JJ N
weight NN N
after IN N
4 CD N
weeks NNS N
; : N
the DT N
clinical JJ N
significance NN N
may MD N
, , N
however RB N
, , N
be VB N
of IN N
less JJR N
importance NN N
since IN N
the DT N
values NNS N
are VBP N
low JJ N
( ( N
0.26 CD N
vs NN N
0.09 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
operating VBG N
techniques NNS N
in IN N
terms NNS N
of IN N
complications NNS N
. . N

Hospital NNP 1_o
stay NN 1_o
was VBD N
longer JJR N
for IN N
overweight NN N
patients NNS N
than IN N
for IN N
normal-weight JJ N
patients NNS N
undergoing VBG N
OA NNP 1_i
( ( N
3.0 CD N
vs NN N
2.0 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
functional JJ N
index NN N
did VBD N
not RB N
differ VB N
between IN N
any DT N
group NN N
of IN N
patients NNS N
. . N

Sick NNP 1_o
leave NN 1_o
was VBD N
longer JJR N
for IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP 1_i
than IN N
for IN N
normal-weight JJ N
patients NNS N
treated VBN N
with IN N
the DT N
same JJ N
technique NN N
( ( N
17 CD N
vs RB N
13 CD N
days NNS N
, , N
p VBP N
< RB N
0.01 CD N
) ) N
. . N

In IN N
the DT N
laparoscopic NN 1_i
group NN N
, , N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
overweight NN 1_p
and CC 1_p
normal-weight JJ 1_p
patients NNS 1_p
. . 1_p

Time NN 1_o
to TO 1_o
full JJ 1_o
recovery NN 1_o
was VBD N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP 1_i
than IN N
in IN N
the DT N
overweight JJ N
patients NNS N
in IN N
the DT N
LA NNP 1_i
group NN N
( ( N
22 CD N
vs RB N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
, , N
overweight JJ N
patients NNS N
who WP N
were VBD N
submitted VBN N
to TO N
LA NNP 1_i
had VBD N
less RBR N
postoperative JJ 1_o
pain NN 1_o
and CC N
a DT N
faster RBR N
postoperative JJ 1_o
recovery NN 1_o
than IN N
overweight JJ N
patients NNS N
who WP N
had VBD N
OA NNP 1_i
. . 1_i

LA NNP 1_i
also RB N
abolished VBD N
some DT N
of IN N
the DT N
negative JJ N
effects NNS N
that WDT N
overweight VBD N
had VBD N
on IN N
operating NN 1_o
time NN 1_o
, , 1_o
hospital NN 1_o
stay NN 1_o
, , 1_o
and CC 1_o
sick JJ 1_o
leave NN 1_o
with IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
anesthesia NN N
and CC N
operating NN N
times NNS N
were VBD N
significantly RB N
longer RBR N
in IN N
LA NNP 1_i
for IN N
both DT N
overweight JJ N
patients NNS N
and CC N
those DT N
with IN N
a DT N
normal JJ N
BMI NNP N
. . N

-DOCSTART- -X- O O

Effectiveness NN 1_o
of IN N
aromatherapy JJ 1_i
massage NN 1_i
in IN N
the DT N
management NN N
of IN N
anxiety NN 1_o
and CC 1_o
depression NN 1_o
in IN 1_p
patients NNS 1_p
with IN 1_p
cancer NN 1_p
: : 1_p
a DT N
multicenter NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
To TO N
test VB N
the DT N
effectiveness NN 1_o
of IN N
supplementing VBG N
usual JJ N
supportive JJ N
care NN N
with IN N
aromatherapy JJ 1_i
massage NN 1_i
in IN N
the DT N
management NN N
of IN N
anxiety NN 1_p
and CC 1_p
depression NN 1_p
in IN 1_p
cancer NN 1_p
patients NNS 1_p
through IN N
a DT N
pragmatic JJ N
two-arm NN N
randomized VBD N
controlled JJ N
trial NN N
in IN N
four CD N
United NNP 1_p
Kingdom NNP 1_p
cancer NN N
centers NNS N
and CC N
a DT N
hospice NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Two CD 1_p
hundred VBD 1_p
eighty-eight JJ 1_p
cancer NN 1_p
patients NNS 1_p
, , 1_p
referred VBD 1_p
to TO 1_p
complementary JJ 1_p
therapy NN 1_p
services NNS 1_p
with IN 1_p
clinical JJ 1_p
anxiety NN 1_p
and/or NN 1_p
depression NN 1_p
, , N
were VBD N
allocated VBN N
randomly RB N
to TO N
a DT N
course NN N
of IN N
aromatherapy JJ 1_i
massage NN 1_i
or CC 1_i
usual JJ 1_i
supportive JJ 1_i
care NN 1_i
alone RB 1_i
. . 1_i

RESULTS JJ N
Patients NNPS N
who WP N
received VBD N
aromatherapy JJ 1_i
massage NN 1_i
had VBD N
no DT N
significant JJ N
improvement NN N
in IN N
clinical JJ 1_o
anxiety NN 1_o
and/or NN 1_o
depression NN 1_o
compared VBN N
with IN N
those DT N
receiving VBG N
usual JJ N
care NN N
at IN N
10 CD N
weeks NNS N
postrandomization NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.3 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.9 CD N
to TO N
1.7 CD N
; : N
P NNP N
= NNP N
.1 NNP N
) ) N
, , N
but CC N
did VBD N
at IN N
6 CD N
weeks NNS N
postrandomization NN N
( ( N
OR NNP N
, , N
1.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.1 CD N
to TO N
1.9 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Patients NNS N
receiving VBG N
aromatherapy JJ 1_i
massage NN 1_i
also RB N
described VBD N
greater JJR N
improvement NN N
in IN N
self-reported JJ 1_o
anxiety NN 1_o
at IN N
both DT N
6 CD N
and CC N
10 CD N
weeks NNS N
postrandomization NN N
( ( N
OR NNP N
, , N
3.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.2 CD N
to TO N
6.7 CD N
; : N
P NNP N
= NNP N
.04 NNP N
and CC N
OR NNP N
, , N
3.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.2 CD N
to TO N
6.6 CD N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Aromatherapy NNP 1_i
massage NN 1_i
does VBZ N
not RB N
appear VB N
to TO N
confer VB N
benefit NN 1_o
on IN N
cancer NN 1_p
patients NNS 1_p
' POS 1_p
anxiety NN 1_o
and/or NN 1_o
depression NN 1_o
in IN N
the DT N
long-term JJ N
, , N
but CC N
is VBZ N
associated VBN N
with IN N
clinically RB N
important JJ N
benefit NN 1_o
up IN N
to TO N
2 CD N
weeks NNS N
after IN N
the DT N
intervention NN N
. . N

-DOCSTART- -X- O O

Altered NNP N
accuracy NN N
of IN N
saccadic JJ 1_i
eye NN 1_i
movements NNS 1_i
in IN N
children NNS 1_p
with IN 1_p
fetal JJ 1_p
alcohol NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

BACKGROUND NNP N
Prenatal NNP N
exposure NN N
to TO N
alcohol VB N
is VBZ N
a DT N
major JJ N
, , N
preventable JJ N
cause NN N
of IN N
neurobehavioral JJ N
dysfunction NN N
in IN N
children NNS N
worldwide RB N
. . N

The DT N
measurement NN N
and CC N
quantification NN N
of IN N
saccadic JJ N
eye NN N
movements NNS N
is VBZ N
a DT N
powerful JJ N
tool NN N
for IN N
assessing VBG N
sensory NN N
, , N
motor NN N
, , N
and CC N
cognitive JJ N
function NN N
. . N

The DT N
quality NN N
of IN N
the DT N
motor NN N
process NN N
of IN N
an DT N
eye NN N
movement NN N
is VBZ N
known VBN N
as IN N
saccade NN N
metrics NNS N
. . N

Saccade NNP N
accuracy NN N
is VBZ N
1 CD N
component NN N
of IN N
metrics NNS N
, , N
which WDT N
to TO N
function VB N
optimally RB N
requires VBZ N
several JJ N
cortical JJ N
brain NN N
structures NNS N
as RB N
well RB N
as IN N
an DT N
intact JJ N
cerebellum NN N
and CC N
brain-stem NN N
. . N

The DT N
cerebellum NN N
has VBZ N
frequently RB N
been VBN N
reported VBN N
to TO N
be VB N
damaged VBN N
by IN N
prenatal JJ N
alcohol NN N
exposure NN N
. . N

This DT N
study NN N
, , N
therefore RB N
, , N
tested VBD N
the DT N
hypothesis NN N
that WDT N
children NNS 1_p
with IN 1_p
fetal JJ 1_p
alcohol NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
FASD NNP 1_p
) ) 1_p
will MD N
exhibit VB N
deficits NNS N
in IN N
the DT N
accuracy NN N
of IN N
saccades NNS N
. . N

METHODS NNP N
A NNP 1_p
group NN 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
FASD NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
27 CD 1_p
) ) 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
8 CD 1_p
and CC 1_p
16 CD 1_p
and CC 1_p
typically RB 1_p
developing VBG 1_p
control NN 1_p
children NNS 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
27 CD 1_p
) ) 1_p
matched VBN 1_p
for IN 1_p
age NN 1_p
and CC 1_p
sex NN 1_p
, , N
completed VBD N
3 CD 1_i
saccadic JJ 1_i
eye NN 1_i
movement NN 1_i
tasks NNS 1_i
of IN 1_i
increasing VBG 1_i
difficulty NN 1_i
. . 1_i

Eye NNP N
movement NN N
performance NN N
during IN N
the DT N
tasks NNS N
was VBD N
captured VBN N
using VBG N
an DT N
infrared JJ N
eye NN N
tracker NN N
. . N

Saccade VB 1_o
metrics NNS 1_o
( ( 1_o
e.g. NN 1_o
, , N
velocity NN 1_o
, , 1_o
amplitude NN 1_o
, , 1_o
accuracy NN 1_o
) ) 1_o
were VBD N
quantified VBN N
and CC N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
for IN N
the DT N
3 CD N
different JJ N
tasks NNS N
. . N

RESULTS NNP N
Children NNP N
with IN N
FASD NNP N
were VBD N
more RBR N
variable JJ N
in IN N
saccade JJ 1_o
endpoint NN 1_o
accuracy NN 1_o
, , N
which WDT N
was VBD N
reflected VBN N
by IN N
statistically RB N
significant JJ N
increases NNS N
in IN N
the DT N
error NN N
of IN N
the DT N
initial JJ 1_o
saccade NN 1_o
endpoint NN 1_o
and CC N
the DT N
frequency NN N
of IN N
additional JJ N
, , N
corrective JJ 1_o
saccades NNS 1_o
required VBN N
to TO N
achieve VB N
final JJ N
fixation NN N
. . N

This DT N
increased JJ N
variability NN N
in IN N
accuracy NN 1_o
was VBD N
amplified VBN N
when WRB N
the DT N
cognitive JJ N
demand NN N
of IN N
the DT N
tasks NNS N
increased VBD N
. . N

Children NNP N
with IN N
FASD NNP N
also RB N
displayed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
response NN 1_o
inhibition NN 1_o
errors NNS 1_o
. . 1_o

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
children NNS N
with IN N
FASD NNP N
may MD N
have VB N
deficits NNS N
in IN N
eye NN N
movement NN N
control NN N
and CC N
sensory-motor JJ N
integration NN N
including VBG N
cerebellar JJ N
circuits NNS N
, , N
thereby RB N
impairing VBG N
saccade JJ N
accuracy NN N
. . N

-DOCSTART- -X- O O

Differences NNS N
in IN N
vision NN N
between IN N
clinic JJ N
and CC N
home NN N
and CC N
the DT N
effect NN N
of IN N
lighting VBG N
in IN N
older JJR 1_p
adults NNS 1_p
with IN 1_p
and CC 1_p
without IN 1_p
glaucoma NN 1_p
. . 1_p

IMPORTANCE JJ N
Patients NNS N
often RB N
report VBP N
greater JJR N
visual JJ N
difficulties NNS N
at IN N
home NN N
than IN N
expected VBN N
from IN N
vision NN N
testing VBG N
in IN N
the DT N
clinic NN N
. . N

Such JJ N
discordance NN N
may MD N
be VB N
owing VBG N
to TO N
worse VB N
vision NN N
in IN N
the DT N
home NN N
than IN N
measured VBN N
in IN N
clinic NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
vision NN 1_o
measured VBN N
between IN N
the DT N
clinic NN N
and CC N
home NN N
and CC N
evaluate JJ N
factors NNS N
, , N
including VBG N
lighting NN N
, , N
associated VBN N
with IN N
these DT N
differences NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
cross-sectional JJ N
study NN N
conducted VBN 1_p
from IN 1_p
2005-2009 CD 1_p
involved JJ 1_p
126 CD 1_p
patients NNS 1_p
with IN 1_p
glaucoma NN 1_p
and CC 1_p
49 CD 1_p
without IN 1_p
glaucoma NN 1_p
recruited VBN 1_p
from IN 1_p
the DT 1_p
Glaucoma NNP 1_p
and CC 1_p
Comprehensive NNP 1_p
Eye NNP 1_p
Clinics NNP 1_p
at IN 1_p
Washington NNP 1_p
University NNP 1_p
, , 1_p
St NNP 1_p
Louis NNP 1_p
, , 1_p
Missouri NNP 1_p
. . 1_p

Patients NNPS N
underwent JJ N
clinic JJ N
and CC N
home NN N
visits NNS N
, , N
were VBD N
aged VBN 1_p
55 CD 1_p
to TO 1_p
90 CD 1_p
years NNS 1_p
, , N
were VBD N
consecutively RB N
recruited VBN N
, , N
and CC N
met VBD N
inclusion NN N
criteria NNS N
for IN N
this DT N
study NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
166 CD 1_p
eligible JJ 1_p
patients NNS 1_p
refused VBD 1_p
participation NN 1_p
. . 1_p

EXPOSURE NNP N
Participants NNPS 1_i
underwent JJ 1_i
clinic NN 1_i
and CC 1_i
home NN 1_i
visits NNS 1_i
randomized VBN N
to TO N
order NN N
of IN N
completion NN N
. . N

At IN 1_i
each DT 1_i
visit NN 1_i
, , 1_i
masked VBN 1_i
and CC 1_i
certified VBN 1_i
examiners NNS 1_i
measured VBD 1_i
binocular JJ 1_o
distance NN 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
DVA NNP 1_o
) ) 1_o
with IN 1_o
a DT 1_o
nonbacklit JJ 1_o
chart NN 1_o
, , 1_o
near IN 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
NVA NNP 1_o
) ) 1_o
, , 1_o
contrast JJ 1_o
sensitivity NN 1_o
( ( 1_o
CS NNP 1_o
) ) 1_o
, , 1_o
CS NNP 1_o
with IN 1_o
glare NN 1_o
, , 1_o
and CC 1_o
lighting VBG 1_o
. . 1_o

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Differences NNP 1_o
in IN 1_o
vision NN 1_o
between IN 1_o
the DT 1_o
clinic NN 1_o
and CC 1_o
home NN 1_o
. . 1_o

RESULTS VB N
The DT N
mean JJ N
scores NNS N
for IN N
all DT 1_o
vision NN 1_o
tests NNS 1_o
were VBD 1_o
significantly RB 1_o
better RBR 1_o
in IN N
the DT N
clinic NN N
than IN N
home NN N
for IN N
participants NNS N
with IN N
and CC N
without IN N
glaucoma NN N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
matched-pair JJ N
t NN N
tests NNS N
) ) N
. . N

For IN N
DVA NNP N
, , N
29 CD N
% NN N
of IN N
participants NNS N
with IN N
glaucoma NN N
read VBP 1_o
2 CD 1_o
or CC 1_o
more JJR 1_o
lines NNS 1_o
better RBR 1_o
in IN N
the DT N
clinic NN N
than IN N
home NN N
and CC N
39 CD N
% NN N
with IN N
advanced JJ N
glaucoma NN N
read VBD N
3 CD N
or CC N
more JJR N
lines NNS N
better RBR N
. . N

For IN N
the DT N
entire JJ N
sample NN N
, , N
21 CD N
% NN N
of IN N
participants NNS N
read VBP 1_o
2 CD 1_o
or CC 1_o
more JJR 1_o
lines NNS 1_o
better RBR N
in IN N
the DT N
clinic NN N
than IN N
home NN N
for IN N
NVA NNP N
and CC N
49 CD N
% NN N
read JJ N
2 CD N
or CC N
more JJR N
triplets NNS N
better RBR N
in IN N
the DT N
clinic NN N
for IN N
CS NNP N
with IN N
glare NN N
. . N

Lighting NNP N
was VBD N
the DT N
most RBS N
significant JJ N
factor NN N
associated VBN N
with IN N
differences NNS N
in IN N
vision NN N
between IN N
the DT N
clinic NN N
and CC N
home NN N
for IN N
DVA NNP 1_o
, , 1_o
NVA NNP 1_o
, , 1_o
and CC 1_o
CS NNP 1_o
with IN N
glare NN N
testing VBG N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
multiple JJ N
regression NN N
model NN N
) ) N
. . N

Median JJ 1_o
home NN 1_o
lighting NN 1_o
was VBD N
4.3 CD N
times NNS N
and CC N
2.8 CD N
times NNS N
lower JJR N
than IN N
clinic JJ N
lighting NN N
in IN N
areas NNS N
tested VBN N
for IN N
DVA NNP N
and CC N
NVA NNP N
, , N
respectively RB N
. . N

Home NNP 1_o
lighting NN 1_o
was VBD N
below IN N
that DT N
recommended VBD N
in IN N
85 CD N
% NN N
or CC N
greater JJR N
of IN N
participants NNS N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
Vision NNP 1_o
measured VBD N
in IN N
the DT N
clinic NN N
is VBZ N
generally RB N
better JJR N
than IN N
vision NN N
measured VBN N
at IN N
home NN N
, , N
with IN N
differences NNS N
mainly RB N
owing VBG N
to TO N
poor JJ N
home NN N
lighting NN N
. . N

Knowledge NNP N
that IN N
vision NN N
discrepancies NNS N
between IN N
patient JJ N
report NN N
and CC N
clinical JJ N
testing NN N
may MD N
be VB N
owing VBG N
to TO N
home NN N
lighting NN N
may MD N
initiate VB N
clinician-patient JJ N
discussions NNS N
to TO N
optimize VB N
home NN N
lighting NN N
and CC N
improve VB N
the DT N
vision NN N
of IN N
older JJR 1_p
adults NNS 1_p
in IN N
their PRP$ N
homes NNS N
. . N

-DOCSTART- -X- O O

Subcutaneous JJ 1_o
versus NN 1_o
intravenous JJ 1_o
bortezomib NN 1_o
in IN N
two CD N
different JJ N
induction NN N
therapies NNS N
for IN N
newly RB N
diagnosed VBN N
multiple JJ N
myeloma NN N
: : N
an DT N
interim JJ N
analysis NN N
from IN N
the DT N
prospective JJ N
GMMG-MM5 NNP N
trial NN N
. . N

We PRP N
investigated VBD N
the DT N
impact NN N
of IN N
subcutaneous JJ 1_o
versus NN 1_i
intravenous JJ 1_o
bortezomib NN 1_o
in IN N
the DT N
MM5 NNP N
trial NN N
of IN N
the DT N
German-Speaking NNP N
Myeloma NNP N
Multicenter NNP N
Group NNP N
which WDT N
compared VBN N
bortezomib NN 1_i
, , 1_i
doxorubicin NN 1_i
, , 1_i
and CC 1_i
dexamethasone NN 1_i
with IN 1_i
bortezomib NN 1_i
, , 1_i
cyclophosphamide NN 1_i
, , 1_i
and CC 1_i
dexamethasone NN 1_i
induction NN N
therapy NN N
in IN N
newly RB 1_p
diagnosed VBN 1_p
multiple JJ 1_p
myeloma NN 1_p
. . 1_p

Based VBN N
on IN N
data NNS N
from IN N
relapsed VBN N
myeloma NN N
, , N
the DT N
route NN N
of IN N
administration NN N
for IN N
bortezomib NN N
was VBD N
changed VBN N
from IN N
intravenous JJ N
to TO N
subcutaneous JJ N
after IN N
314 CD 1_p
of IN 1_p
604 CD 1_p
patients NNS 1_p
had VBD 1_p
been VBN 1_p
enrolled VBN 1_p
. . 1_p

We PRP N
analyzed VBD N
598 CD 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
dose NN 1_p
of IN 1_p
trial NN 1_p
medication NN 1_p
. . 1_p

Adverse JJ 1_o
events NNS 1_o
were VBD N
reported VBN N
more RBR N
frequently RB N
in IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
intravenous JJ 1_p
bortezomib NNS 1_p
( ( N
intravenous=65 JJ N
% NN N
; : N
subcutaneous=56 CC N
% NN N
, , N
P=0.02 NNP N
) ) N
. . N

Rates NNS 1_o
of IN 1_o
grade JJ 1_o
2 CD 1_o
or CC 1_o
more JJR 1_o
peripheral JJ 1_o
neuropathy NNS 1_o
were VBD N
higher JJR N
in IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
intravenous JJ 1_p
bortezomib NN 1_p
during IN N
the DT N
third JJ N
cycle NN N
( ( N
intravenous=8 JJ N
% NN N
; : N
subcutaneous=2 CC N
% NN N
, , N
P=0.001 NNP N
) ) N
. . N

Overall JJ 1_o
response NN 1_o
rates NNS 1_o
were VBD N
similar JJ N
in IN N
patients NNS N
treated VBN N
intravenously RB N
or CC N
subcutaneously RB N
. . N

The DT N
presence NN N
of IN N
International NNP 1_o
Staging NNP 1_o
System NNP 1_o
stage NN 1_o
III NNP 1_o
disease NN 1_o
, , 1_o
renal JJ 1_o
impairment NN 1_o
or CC 1_o
adverse JJ 1_o
cytogenetic JJ 1_o
abnormalities NNS 1_o
did VBD N
not RB N
have VB N
a DT N
negative JJ N
impact NN N
on IN N
overall JJ N
response NN N
rates NNS N
in IN N
either DT N
group NN N
. . N

To TO N
our PRP$ N
knowledge NN N
this DT N
is VBZ N
the DT N
largest JJS N
study NN N
to TO N
present VB N
data NNS N
comparing VBG N
subcutaneous JJ N
with IN N
intravenous JJ N
bortezomib NNS N
in IN N
newly RB N
diagnosed VBN N
myeloma NN 1_o
. . 1_o

We PRP N
show VBP N
better JJR N
tolerance NN 1_o
and CC N
similar JJ N
overall JJ N
response NN 1_o
rates NNS N
for IN N
subcutaneous JJ N
compared VBN N
to TO N
intravenous JJ N
bortezomib NN N
. . N

The DT N
clinical JJ N
trial NN N
is VBZ N
registered VBN N
at IN N
eudract.ema.europa.eu NN N
as IN N
n. JJ N
2010-019173-16 JJ N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
physiotherapy JJ 1_i
management NN 1_i
of IN N
knee NN 1_p
joint JJ 1_p
osteoarthritis NN 1_p
: : 1_p
a DT N
randomised JJ N
, , N
double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
a DT N
multimodal JJ 1_i
physiotherapy NN 1_i
programme NN 1_i
including VBG 1_i
taping VBG 1_i
, , 1_i
exercises NNS 1_i
, , 1_i
and CC 1_i
massage NN 1_i
is VBZ N
effective JJ N
for IN N
knee NN 1_p
osteoarthritis NN 1_p
, , N
and CC N
if IN N
benefits NNS N
can MD N
be VB N
maintained VBN N
with IN N
self JJ N
management NN N
. . N

METHODS NNP N
Randomised VBD N
, , N
double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
trial NN N
; : N
140 CD 1_p
community NN 1_p
volunteers NNS 1_p
with IN 1_p
knee NN 1_p
osteoarthritis NN 1_p
participated VBD 1_p
and CC 1_p
119 CD 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
. . 1_p

Physiotherapy NNP 1_i
and CC 1_i
placebo JJ 1_i
interventions NNS N
were VBD N
applied VBN N
by IN N
10 CD N
physiotherapists NNS N
in IN N
private JJ N
practices NNS N
for IN N
12 CD N
weeks NNS N
. . N

Physiotherapy NNP 1_i
included VBD 1_i
exercise NN 1_i
, , 1_i
massage NN 1_i
, , 1_i
taping VBG 1_i
, , 1_i
and CC 1_i
mobilisation NN 1_i
, , 1_i
followed VBN 1_i
by IN 1_i
12 CD 1_i
weeks NNS 1_i
of IN 1_i
self JJ 1_i
management NN 1_i
. . 1_i

Placebo NNP 1_i
was VBD N
sham VBN 1_i
ultrasound JJ 1_i
and CC 1_i
light JJ 1_i
application NN 1_i
of IN 1_i
a DT 1_i
non-therapeutic JJ 1_i
gel NN 1_i
, , 1_i
followed VBN 1_i
by IN 1_i
no DT 1_i
treatment NN 1_i
. . 1_i

Primary JJ N
outcomes NNS N
were VBD N
pain RB 1_o
measured VBN 1_o
by IN 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
and CC 1_o
patient JJ 1_o
global JJ 1_o
change NN 1_o
. . 1_o

Secondary JJ N
measures NNS N
included VBD N
WOMAC NNP 1_o
, , 1_o
knee NN 1_o
pain NN 1_o
scale NN 1_o
, , 1_o
SF-36 NNP 1_o
, , 1_o
assessment NN 1_o
of IN 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
index NN 1_o
, , 1_o
quadriceps JJ 1_o
strength NN 1_o
, , 1_o
and CC 1_o
balance NN 1_o
test NN 1_o
. . 1_o

RESULTS NNP N
Using VBG N
an DT N
intention NN N
to TO N
treat VB N
analysis NN N
, , N
physiotherapy NN 1_p
and CC 1_p
placebo NN 1_p
groups NNS 1_p
showed VBD N
similar JJ N
pain NN 1_o
reductions NNS 1_o
at IN N
12 CD N
weeks NNS N
: : N
-2.2 NN N
cm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-2.6 NNP N
to TO N
-1.7 VB N
) ) N
and CC N
-2.0 $ N
cm NN N
( ( N
-2.5 UH N
to TO N
-1.5 VB N
) ) N
, , N
respectively RB N
. . N

At IN N
24 CD N
weeks NNS N
, , N
pain NN 1_o
remained VBD 1_o
reduced VBN 1_o
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
: : N
-2.1 NN N
( ( N
-2.6 UH N
to TO N
-1.6 VB N
) ) N
and CC N
-1.6 NNP N
( ( N
-2.2 UH N
to TO N
-1.0 VB N
) ) N
, , N
respectively RB N
. . N

Global JJ 1_o
improvement NN 1_o
was VBD N
reported VBN N
by IN N
70 CD N
% NN N
of IN N
physiotherapy NN N
participants NNS N
( ( N
51/73 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
59 CD N
% NN N
( ( N
43/73 CD N
) ) N
at IN N
24 CD N
weeks NNS N
. . N

Similarly RB N
, , N
global JJ 1_o
improvement NN 1_o
was VBD N
reported VBN N
by IN N
72 CD N
% NN N
of IN N
placebo NN N
participants NNS N
( ( N
48/67 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
49 CD N
% NN N
( ( N
33/67 CD N
) ) N
at IN N
24 CD N
weeks NNS N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
physiotherapy NN 1_i
programme NN 1_i
tested VBN N
in IN N
this DT N
trial NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
regular JJ N
contact NN N
with IN N
a DT N
therapist NN N
at IN N
reducing VBG N
pain NN N
and CC N
disability NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
ozone NN 1_i
application NN 1_i
on IN N
the DT N
resin-dentin JJ 1_o
microtensile NN 1_o
bond NN 1_o
strength NN 1_o
. . 1_o

When WRB N
ozone NN N
is VBZ N
used VBN N
during IN N
caries NNS N
treatment NN N
, , N
bond NN N
strength NN N
can MD N
be VB N
compromised VBN N
by IN N
the DT N
release NN N
of IN N
oxygen NN N
. . N

The DT N
use NN N
of IN N
antioxidant JJ N
agents NNS N
neutralizes VBZ N
the DT N
free JJ N
oxygen NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
ozone NN 1_i
and CC 1_i
sodium NN 1_i
ascorbate NN 1_i
on IN N
resin-dentin JJ 1_o
microtensile NN 1_o
bond NN 1_o
strength NN 1_o
( ( 1_o
?TBS NN 1_o
) ) 1_o
. . 1_o

Forty NNP 1_p
human JJ 1_p
third JJ 1_p
molars NNS 1_p
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
: : N
Group NNP N
1 CD N
, , N
not RB 1_i
treated VBN 1_i
with IN 1_i
ozone NN 1_i
; : 1_i
Group NNP N
2 CD N
, , N
ozone NN 1_i
application NN 1_i
followed VBN 1_i
by IN 1_i
acid NN 1_i
etching NN 1_i
; : 1_i
Group NNP N
3 CD N
, , N
acid NN 1_i
etching VBG 1_i
followed VBN 1_i
by IN 1_i
ozone NN 1_i
application NN 1_i
; : 1_i
and CC N
Group NNP N
4 CD N
, , N
ozone NN 1_i
and CC 1_i
application NN 1_i
of IN 1_i
sodium NN 1_i
ascorbate NN 1_i
. . 1_i

Bonded VBN N
beams NN N
( ( N
1.0 CD N
mm NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
tested VBN N
under IN N
tension NN N
( ( N
0.5 CD N
mm NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

The DT 1_o
?TBS JJ 1_o
values NNS 1_o
were VBD N
analyzed VBN N
using VBG N
one-way JJ N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
and CC N
the DT N
Tukey NNP N
test NN N
( ( N
p=0.05 NN N
) ) N
. . N

All DT N
beams NNS N
that WDT N
fractured VBD N
were VBD N
analyzed VBN N
under IN N
stereomicroscopy NN N
( ( N
40? CD N
) ) N
. . N

Group NNP N
1 CD N
had VBD N
significantly RB N
higher JJR 1_o
?TBS NN 1_o
values NNS 1_o
than IN 1_o
Group NNP N
2 CD N
or CC N
3 CD N
. . N

The DT N
?TBS JJ 1_o
values NNS 1_o
of IN 1_o
Groups NNP 1_o
1 CD N
and CC N
4 CD N
were VBD N
similar JJ N
and CC N
higher JJR N
than IN N
those DT N
of IN N
Group NNP N
2 CD N
. . N

The DT N
use NN N
of IN N
ozone NN N
in IN N
Group NNP N
2 CD N
resulted VBD N
in IN N
lower JJR N
values NNS 1_o
of IN 1_o
?TBS NN 1_o
in IN N
all DT N
conditions NNS N
evaluated VBN N
. . N

The DT N
predominant JJ 1_o
failure NN 1_o
mode NN 1_o
was VBD N
adhesive JJ N
. . N

The DT N
application NN N
of IN N
ozone NN N
decreased VBD 1_o
the DT 1_o
?TBS NN 1_o
of IN 1_o
the DT 1_o
dentin-composite JJ 1_o
resin NN 1_o
interface NN 1_o
. . 1_o

These DT 1_o
values NNS N
were VBD N
reversed VBN N
when WRB N
compared VBN N
with IN N
Groups NNP N
1 CD N
and CC N
2 CD N
when WRB N
sodium NN N
ascorbate NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O

Lipoprotein NNP N
( ( N
a DT N
) ) N
serum NN N
levels NNS N
in IN N
post-menopausal JJ 1_p
women NNS 1_p
treated VBN 1_p
with IN 1_p
oral JJ 1_i
estrogens NNS 1_i
administered VBN 1_p
at IN 1_p
different JJ 1_p
times NNS 1_p
. . 1_p

The DT N
different JJ N
effects NNS 1_o
on IN N
serum NN N
lipoprotein NN N
( ( N
a DT N
) ) N
[ NN N
Lp NNP N
( ( N
a DT N
) ) N
] NN N
levels NNS N
by IN N
administering VBG N
estrogens NNS 1_i
at IN 1_i
different JJ 1_i
times NNS 1_i
of IN 1_i
the DT 1_i
day NN 1_i
( ( N
8 CD N
a.m. RB N
and CC N
8 CD N
p.m. NN N
) ) N
were VBD N
evaluated VBN N
in IN N
twenty-four JJ 1_p
post-menopausal JJ 1_p
women NNS 1_p
. . 1_p

Patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
by IN N
random JJ N
sampling VBG N
numbers NNS N
. . N

Patients NNS N
of IN N
both DT N
groups NNS N
received VBD N
0.625 CD N
mg NNS N
conjugated VBN 1_i
equine JJ 1_i
estrogens NNS 1_i
daily JJ N
per IN N
os NN N
for IN N
21 CD N
days NNS N
. . N

Group NNP N
A NNP N
patients NNS N
( ( N
n JJ N
: : N
9 CD N
) ) N
received VBD N
the DT N
pill NN N
at IN N
8 CD N
a.m. NN N
, , N
and CC N
group NN N
B NNP N
patients NNS N
( ( N
n JJ N
: : N
12 CD N
) ) N
received VBD N
the DT N
pill NN N
at IN N
8 CD N
p.m NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
as IN N
regards NNS N
the DT N
anthropometric JJ 1_o
characteristics NNS 1_o
, , 1_o
the DT 1_o
basal NN 1_o
values NNS 1_o
of IN 1_o
the DT 1_o
Lp NNP 1_o
( ( 1_o
a DT 1_o
) ) 1_o
, , 1_o
the DT 1_o
sex NN 1_o
steroid NN 1_o
and CC 1_o
pituitary JJ 1_o
hormone NN 1_o
levels NNS 1_o
. . 1_o

Administration NN N
of IN N
conjugated JJ 1_i
equine NN 1_i
estrogens NNS 1_i
resulted VBD N
in IN N
decreased JJ N
levels NNS 1_o
of IN 1_o
Lp NNP 1_o
( ( 1_o
a DT 1_o
) ) 1_o
only RB N
in IN N
group NN N
B NNP N
after IN N
treatment NN N
. . N

The DT N
different JJ N
Lp NNP N
( ( N
a DT N
) ) N
behaviour NN N
in IN N
the DT N
two CD N
groups NNS N
and CC N
in IN N
the DT N
presence NN N
of IN N
the DT N
same JJ N
serum JJ N
hormonal NN N
levels NNS N
, , N
seems VBZ N
to TO N
be VB N
dependent JJ N
on IN N
the DT N
existence NN N
of IN N
a DT N
circadian JJ N
rhythm NN N
of IN N
the DT N
hepatic JJ N
responsiveness NN N
to TO N
estrogens VB N
, , N
whose WP$ N
expression NN N
is VBZ N
higher JJR N
during IN N
evening NN N
hours NNS N
. . N

-DOCSTART- -X- O O

[ RB N
Therapeutic NNP N
value NN N
of IN N
a DT N
combination NN N
of IN N
trimetazidine NN 1_i
with IN N
a DT N
calcium NN N
inhibitor NN N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ 1_p
coronary JJ 1_p
insufficiency NN 1_p
] NNP 1_p
. . N

This DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
sought VBD N
to TO N
examine VB N
the DT N
short-term JJ N
benefit NN N
of IN N
adding VBG N
60 CD N
mg NN N
of IN N
trimetazidine NN 1_i
to TO N
the DT N
daily JJ N
therapeutic JJ N
regimen NNS N
of IN N
29 CD 1_p
male JJ 1_p
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
insufficiency NN 1_p
who WP 1_p
had VBD 1_p
persistent JJ 1_p
ST NNP 1_p
depression NN 1_p
on IN 1_p
exercise NN 1_p
tolerance NN 1_p
test NN 1_p
( ( 1_p
greater JJR 1_p
than IN 1_p
or CC 1_p
equal JJ 1_p
to TO 1_p
1 CD 1_p
mm NN 1_p
) ) 1_p
, , 1_p
despite IN 1_p
treatment NN 1_p
with IN 1_p
nifedipine JJ 1_i
40 CD 1_p
mg JJ 1_p
per IN 1_p
day NN 1_p
. . 1_p

As IN 1_o
compared VBN 1_o
with IN 1_o
the DT 1_o
placebo NN 1_o
group NN 1_o
, , 1_o
after IN 1_o
only RB 1_o
14 CD 1_o
days NNS 1_o
, , 1_o
the DT 1_o
patients NNS 1_o
treated VBN 1_o
with IN 1_o
trimetazidine NN 1_o
showed VBN 1_o
statistically RB 1_o
significant JJ 1_o
increases NNS 1_o
in IN 1_o
the DT 1_o
maximum JJ 1_o
workload NN 1_o
level NN 1_o
attained VBD 1_o
before IN 1_o
ST NNP 1_o
depression NN 1_o
occurred VBD 1_o
( ( 1_o
31 CD 1_o
% NN 1_o
versus NN 1_o
- : 1_o
6 CD 1_o
% NN 1_o
; : 1_o
P NNP 1_o
= NNP 1_o
0.009 CD 1_o
) ) 1_o
, , 1_o
the DT 1_o
total JJ 1_o
work NN 1_o
performed VBD 1_o
( ( 1_o
31 CD 1_o
% NN 1_o
versus IN 1_o
2 CD 1_o
% NN 1_o
; : 1_o
P NNP 1_o
= NNP 1_o
0.024 CD 1_o
) ) 1_o
and CC 1_o
a DT 1_o
significant JJ 1_o
decrease NN 1_o
in IN 1_o
the DT 1_o
systolic JJ 1_o
tension NN 1_o
time NN 1_o
( ( 1_o
double JJ 1_o
product NN 1_o
) ) 1_o
/workload NN 1_o
ratio NN 1_o
( ( 1_o
-5 CD 1_o
% NN 1_o
versus IN 1_o
+11 CD 1_o
% NN 1_o
; : 1_o
P NNP 1_o
= NNP 1_o
0.005 CD 1_o
) ) 1_o
. . 1_o

Throughout IN N
the DT N
study NN N
the DT N
clinical JJ N
acceptability NN N
was VBD N
excellent JJ N
, , N
with IN N
no DT N
side NN N
effects NNS N
attributable JJ N
to TO N
trimetazidine VB N
being VBG N
recorded VBN N
. . N

This DT N
study NN N
shows VBZ N
that IN N
the DT N
addition NN N
of IN N
trimetazidine NN N
to TO N
a DT N
calcium NN N
antagonist NN N
brings VBZ N
a DT N
valuable JJ N
improvement NN N
in IN N
therapeutic JJ N
results NNS N
. . N

-DOCSTART- -X- O O

Plasma NNP N
Epstein-Barr NNP N
virus NN N
DNA NNP N
predicts VBZ N
outcome VBN N
in IN N
advanced JJ 1_p
Hodgkin NNP 1_p
lymphoma NN 1_p
: : 1_p
correlative JJ N
analysis NN N
from IN N
a DT N
large JJ 1_p
North JJ 1_p
American JJ 1_p
cooperative NN 1_p
group NN 1_p
trial NN 1_p
. . 1_p

Epstein-Barr JJ N
virus NN N
( ( N
EBV NNP N
) ) N
is VBZ N
associated VBN N
with IN N
Hodgkin NNP N
lymphoma NN N
( ( N
HL NNP N
) ) N
and CC N
can MD N
be VB N
detected VBN N
by IN N
in IN N
situ JJ N
hybridization NN N
( ( N
ISH NNP N
) ) N
of IN N
viral JJ N
nucleic JJ N
acid NN N
( ( N
EBER NNP N
) ) N
in IN N
tumor NN N
cells NNS N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
plasma JJ N
EBV-DNA NNP N
could MD N
serve VB N
as IN N
a DT N
surrogate NN N
for IN N
EBER-ISH NNP 1_o
and CC N
to TO N
explore VB N
its PRP$ N
prognostic JJ N
utility NN N
in IN N
HL NNP N
. . N

Specimens NNS 1_p
from IN 1_p
the DT 1_p
Cancer NNP 1_p
Cooperative NNP 1_p
Intergroup NNP 1_p
Trial NNP 1_p
E2496 NNP 1_p
were VBD N
used VBN N
to TO N
compare VB 1_i
pretreatment JJ 1_i
plasma JJ 1_i
EBV-DNA JJ 1_i
quantification NN 1_i
with IN 1_i
EBV NNP 1_i
tumor NN 1_o
status NN 1_o
by IN 1_i
EBER-ISH NNP 1_o
. . 1_o

A NNP N
cutoff NN N
of IN N
> $ N
60 CD N
viral JJ N
copies/100 NN N
?L NNP N
plasma NN N
yielded VBD N
96 CD N
% NN N
concordance NN N
with IN 1_o
EBER-ISH NNP 1_o
. . 1_o

Pretreatment NNP N
and CC N
month NN N
6 CD N
plasma NN 1_p
specimens NNS 1_p
were VBD N
designated VBN N
EBV NNP N
( ( N
- : N
) ) N
or CC N
EBV NNP N
( ( N
+ NNP N
) ) N
by IN N
this DT N
cutoff NN N
. . N

Patients NNS N
with IN N
pretreatment JJ N
EBV NNP N
( ( N
+ NNP N
) ) N
plasma NN N
( ( N
n JJ N
= NNP N
54 CD N
) ) N
had VBD 1_o
inferior JJ 1_o
failure-free JJ 1_o
survival NN 1_o
( ( 1_o
FFS NNP 1_o
) ) 1_o
compared VBN N
with IN N
those DT N
with IN N
pretreatment JJ N
EBV NNP N
( ( N
- : N
) ) N
plasma NN N
( ( N
n JJ N
= NNP N
274 CD N
) ) N
, , N
log-rank JJ N
P NNP N
= NNP N
.009 NNP N
. . N

By IN N
contrast NN N
, , N
no DT N
difference NN N
in IN 1_o
FFS NNP 1_o
was VBD N
observed VBN N
when WRB N
patients NNS N
were VBD N
stratified VBN N
by IN 1_o
EBER-ISH NNP 1_o
. . 1_o

Pretreatment NNP N
plasma NN N
EBV NNP N
positivity NN N
was VBD N
an DT N
independent JJ N
predictor NN N
of IN N
treatment NN N
failure NN N
on IN N
multivariate NN N
analyses NNS N
. . N

At IN N
month NN N
6 CD N
, , N
plasma NN 1_o
EBV NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
patients NNS N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
had VBD 1_o
inferior JJ 1_o
FFS NNP 1_o
compared VBN N
with IN 1_o
plasma NN 1_o
EBV NNP 1_o
( ( 1_o
- : 1_o
) ) 1_o
patients NNS N
( ( N
n JJ N
= NNP N
125 CD N
) ) N
, , N
log-rank JJ N
P NNP N
= NNP N
.007 NNP N
. . N

These DT N
results NNS N
confirm VBP N
that IN N
plasma JJ N
EBV-DNA NNP N
is VBZ N
highly RB N
concordant JJ N
with IN 1_o
EBER-ISH NNP 1_o
in IN N
HL NNP N
and CC N
suggest VBP N
that IN N
it PRP N
may MD N
have VB N
prognostic JJ N
utility NN N
both DT N
at IN N
baseline NN N
and CC N
after IN N
therapy NN N
. . N

This DT N
trial NN N
was VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00003389 NNP N
. . N

-DOCSTART- -X- O O

Low JJ N
body NN N
mass NN N
index NN N
and CC N
dyslipidemia NN N
in IN N
dialysis NN 1_i
patients NNS 1_p
linked VBN N
to TO N
elevated VBN N
plasma NN N
fibroblast NN N
growth NN N
factor NN N
23 CD N
. . N

BACKGROUND NNP N
Fibroblast NNP N
growth NN N
factor NN N
23 CD N
( ( N
FGF23 NNP N
) ) N
has VBZ N
been VBN N
associated VBN N
with IN N
death NN N
in IN N
dialysis NN 1_i
patients NNS 1_p
. . 1_p

Since IN N
FGF23 NNP N
shares NNS N
structural JJ N
features NNS N
with IN N
FGF19 NNP N
subfamily RB N
members NNS N
that IN N
exert JJ N
hormonal JJ N
control NN N
of IN N
fat JJ N
mass NN N
, , N
we PRP N
hypothesized VBD N
that DT N
high JJ N
circulating NN N
FGF23 NNP N
concentrations NNS N
would MD N
be VB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
a DT N
uremic JJ N
lipid NN N
profile NN N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
conducted VBN N
among IN N
654 CD 1_p
patients NNS 1_p
receiving VBG 1_p
chronic JJ 1_p
hemodialysis NN 1_i
. . 1_i

C-terminal JJ 1_o
FGF23 NNP 1_o
concentrations NNS 1_o
were VBD 1_i
measured VBN 1_i
in IN 1_i
stored JJ 1_i
plasma NN 1_i
samples NNS 1_i
. . 1_i

Linear JJ 1_i
regression NN 1_i
was VBD 1_i
used VBN 1_i
to TO 1_i
examine VB 1_i
the DT 1_i
cross-sectional JJ 1_i
associations NNS 1_i
of IN 1_i
plasma NN 1_o
FGF23 NNP 1_o
concentrations NNS 1_o
with IN 1_o
BMI NNP 1_o
, , 1_o
total JJ 1_o
cholesterol NN 1_o
( ( 1_o
TC NNP 1_o
) ) 1_o
, , 1_o
low-density JJ 1_o
lipoprotein-cholesterol NN 1_o
( ( 1_o
LDL-C NNP 1_o
) ) 1_o
, , 1_o
high-density JJ 1_o
lipoprotein-cholesterol NN 1_o
( ( 1_o
HDL-C NNP 1_o
) ) 1_o
and CC 1_o
triglycerides NNS 1_o
. . 1_o

Cox NNP N
proportional JJ N
hazard NN N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
association NN N
between IN N
FGF23 NNP N
concentrations NNS N
and CC N
all-cause JJ N
mortality NN N
. . N

RESULTS JJ N
Participants NNS 1_p
had VBD 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
60 CD 1_p
? . 1_p
11 CD 1_p
years NNS 1_p
and CC 1_p
a DT 1_p
median JJ 1_p
( ( 1_p
IQR NNP 1_p
) ) 1_p
FGF23 NNP 1_p
concentration NN 1_p
of IN 1_p
4,212 CD 1_p
( ( 1_p
1,411-13,816 JJ 1_p
) ) 1_p
RU/ml NNP 1_p
. . 1_p

An DT N
increase NN N
per IN N
SD NNP N
in IN N
log10 JJ N
FGF23 NNP N
was VBD N
associated VBN N
with IN N
lower JJR N
BMI NNP N
( ( N
? . N
= NNP N
-1.11 NNP N
; : N
p VBZ N
= $ N
0.008 CD N
) ) N
, , N
TC NNP N
( ( N
? . N
= NNP N
-6.46 NNP N
; : N
p VBZ N
= $ N
0.02 CD N
) ) N
, , N
LDL-C NNP N
( ( N
? . N
= NNP N
-4.73 NNP N
; : N
p VBZ N
= $ N
0.04 CD N
) ) N
and CC N
HDL-C NNP N
( ( N
? . N
= NNP N
-2.14 NNP N
; : N
p VBZ N
= $ N
0.03 CD N
) ) N
; : N
after IN N
adjusting VBG N
for IN N
age NN N
, , N
gender NN N
, , N
race NN N
, , N
cardiovascular JJ N
risk NN N
factors NNS N
, , N
serum NN N
albumin NN N
, , N
markers NNS N
of IN N
mineral JJ N
metabolism NN N
, , N
and CC N
use NN N
of IN N
lipid-lowering JJ N
drugs NNS N
. . N

The DT N
association NN N
of IN N
FGF23 NNP N
with IN N
death NN N
was VBD N
attenuated VBN N
after IN N
adjustment NN N
for IN N
HDL-C NNP N
( ( N
HR NNP N
of IN N
highest JJS N
quartile NN N
1.53 CD N
, , N
95 CD N
% NN N
CI NNP N
1.06-2.20 CD N
compared VBN N
to TO N
lowest VB N
quartile NN N
) ) N
. . N

CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
higher JJR N
plasma NN N
FGF23 NNP N
levels NNS N
are VBP N
associated VBN N
with IN N
lower JJR N
BMI NNP N
and CC N
dyslipidemia NN 1_i
in IN 1_i
dialysis NN 1_i
patients NNS 1_i
. . 1_p

The DT 1_p
association NN N
between IN N
FGF23 NNP N
and CC N
death NN N
may MD N
be VB N
mediated VBN N
through IN N
unexplored JJ N
metabolic JJ N
risk NN N
factors NNS N
unrelated VBD N
to TO N
mineral JJ N
metabolism NN N
. . N

-DOCSTART- -X- O O

Do NNP N
heavier JJR 1_p
women NNS 1_p
benefit VBP N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
leuprolide JJ 1_i
acetate NN 1_i
for IN N
suppression NN N
of IN N
serum NN N
estradiol NN N
? . N
OBJECTIVE UH N
To TO N
determine VB N
if IN N
heavier JJR 1_p
women NNS 1_p
benefit VBP N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
the DT N
gonadotropin-releasing JJ 1_i
hormone NN 1_i
analogue NN 1_i
leuprolide NN 1_i
acetate NN 1_i
( ( 1_i
LA NNP 1_i
) ) 1_i
depot NN N
in IN N
terms NNS N
of IN N
suppression NN N
of IN N
serum NN N
estradiol NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
retrospective JJ N
analysis NN N
of IN N
the DT N
effect NN N
of IN N
LA NNP 1_i
depot FW 1_i
3.75 CD N
mg NN N
and CC N
7.5 CD N
mg NN N
on IN N
serum NN 1_i
estradiol NN 1_i
from IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
12-week JJ N
study NN N
of IN N
women NNS 1_p
with IN 1_p
anemia NN 1_p
due JJ 1_p
to TO 1_p
bleeding VBG 1_p
from IN 1_p
uterine JJ 1_p
leiomyomata NN 1_p
. . 1_p

Serum NNP 1_o
estradiol NN 1_o
levels NNS 1_o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
12 CD N
. . N

Patients NNS 1_p
were VBD 1_p
divided VBN 1_p
into IN 1_p
weight NN 1_p
quartiles NNS 1_p
according VBG 1_p
to TO 1_p
their PRP$ 1_p
baseline NN 1_p
weight NN 1_p
in IN 1_p
kilograms NNS 1_p
: : 1_p
46- JJ 1_p
< NN 1_p
64 CD 1_p
, , 1_p
64- JJ 1_p
< NN 1_p
72 CD 1_p
, , 1_p
72- JJ 1_p
< NN 1_p
89 CD 1_p
, , 1_p
89-159 JJ 1_p
( ( 1_p
pounds-102- JJ 1_p
< NN 1_p
140 CD 1_p
, , 1_p
140- JJ 1_p
< NN 1_p
159 CD 1_p
, , 1_p
159- JJ 1_p
< NN 1_p
196 CD 1_p
, , 1_p
196-350 JJ 1_p
) ) 1_p
. . 1_p

RESULTS VBN N
At IN N
baseline NN N
there EX N
was VBD N
no DT 1_o
statistically RB 1_o
significant JJ 1_o
difference NN 1_o
in IN N
estradiol JJ 1_o
level NN 1_o
between IN N
groups NNS N
as IN N
a DT N
whole NN N
or CC N
within IN N
weight JJ N
quartiles NNS N
. . N

Within IN N
each DT N
group NN N
there EX N
was VBD N
no DT N
relationship NN N
between IN N
weight NN N
and CC N
baseline NN N
estradiol NN N
. . N

At IN N
week NN N
12 CD N
, , N
whereas NNS N
estradiol VBP 1_o
levels NNS 1_o
were VBD N
significantly RB 1_o
greater JJR 1_o
in IN N
the DT N
heavier JJR N
patients NNS N
in IN N
each DT N
of IN N
the DT N
groups NNS N
( ( N
LA NNP N
3.75 CD N
mg NN N
, , N
p NN N
= VBD N
0.044 CD N
; : N
LA NNP N
7.5 CD N
mg NN N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
, , N
there EX N
was VBD N
no DT 1_o
significant JJ 1_o
difference NN 1_o
in IN 1_o
estradiol NN 1_o
between IN N
groups NNS N
as IN N
a DT N
whole NN N
or CC N
within IN N
any DT N
of IN N
the DT N
weight NN N
quartiles NNS N
. . N

Moreover RB N
, , N
at IN N
week NN N
12 CD N
there EX N
was VBD N
no DT 1_o
significant JJ 1_o
difference NN 1_o
between IN N
groups NNS N
in IN N
the DT N
percentage NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
estradiol NNS 1_o
suppressed VBN 1_o
to TO 1_o
the DT 1_o
menopausal NN 1_o
range NN 1_o
. . 1_o

CONCLUSION NNP N
Heavier NNP 1_p
women NNS 1_p
do VBP N
not RB N
benefit VB N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
LA NNP 1_i
depot NNP N
( ( N
7.5 CD N
vs. FW N
3.75 CD N
mg NN N
) ) N
for IN N
suppression NN N
of IN N
serum NN N
levels NNS N
of IN N
estradiol NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
maternal JJ N
and CC N
dietary JJ 1_i
selenium NN 1_i
( ( 1_i
Se-enriched NNP 1_i
yeast NN 1_i
) ) 1_i
on IN N
the DT N
expression NN 1_p
of IN 1_p
p34 NN 1_p
( ( 1_p
cdc2 NN 1_p
) ) 1_p
and CC 1_p
CyclinB1 NNP 1_p
of IN 1_p
germ JJ 1_p
cells NNS 1_p
of IN 1_p
their PRP$ 1_p
offspring NN 1_p
in IN 1_p
goats NNS 1_p
. . 1_p

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
selenium NN 1_i
on IN N
the DT N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
( ( N
two CD N
components NNS N
of IN N
MPF NNP N
regulating VBG N
cell NN N
cycle NN N
) ) N
of IN N
germ JJ N
cells NNS N
of IN N
their PRP$ N
offspring NN N
in IN N
goats NNS 1_p
. . 1_p

A DT N
herd NN 1_p
of IN 1_p
119 CD 1_p
Taihang NNP 1_p
Black NNP 1_p
Goats NNP 1_p
, , N
which WDT N
was VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
treatments NNS N
, , N
received VBD N
experimental JJ 1_i
diet JJ 1_i
with IN 1_i
different JJ 1_i
Se NNP 1_i
levels NNS 1_i
( ( N
from IN N
Se-enriched NNP N
yeast NN N
) ) N
for IN N
174d CD N
. . N

The DT N
four CD N
treatments NNS N
, , N
fed VBN N
with IN N
a DT N
basal NN N
diet JJ N
, , N
were VBD N
supplemented VBN N
with IN N
0 CD N
( ( N
control NN N
) ) N
, , N
0.5 CD N
, , N
2 CD N
and CC N
4 CD N
mgkg?? NN N
DM NNP N
Se NNP N
. . N

Testis NN N
samples NNS N
were VBD N
collected VBN N
from IN N
the DT N
young JJ 1_p
male NN 1_p
goats NNS 1_p
of IN 1_p
each DT N
treatment NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
30d CD N
after IN N
weaning VBG N
) ) N
for IN N
mRNA NN N
expression NN N
using VBG N
real-time JJ 1_i
PCR NNP 1_i
and CC 1_i
for IN N
protein JJ N
expression NN N
by IN N
immunohistochemistry NN N
assay NN N
. . N

Results NNP N
show VBP N
that IN N
a DT N
significant JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
p34 NN 1_o
( ( 1_o
cdc2 NN 1_o
) ) 1_o
and CC 1_o
CyclinB1 NNP 1_o
in IN 1_o
the DT 1_o
testis NN 1_o
of IN 1_o
Se-deficient NNP 1_o
( ( 1_o
Group NNP 1_o
1 CD N
) ) N
and CC N
Se-excess NNP N
( ( N
Group NNP N
4 CD N
) ) N
animals NNS N
compared VBN N
with IN N
that DT N
in IN N
Groups NNP N
2 CD N
and CC N
3 CD N
. . N

However RB N
, , N
no DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
p34 NN 1_o
( ( 1_o
cdc2 NN 1_o
) ) 1_o
between IN 1_o
Se-deficient NNP N
( ( N
Group NNP N
1 CD N
) ) N
and CC N
Se-excess NNP N
( ( N
Group NNP N
4 CD N
) ) N
. . N

Also RB N
the DT N
immunohistochemistry NN N
assay NN N
detected VBD N
similar JJ N
results NNS N
of IN N
protein JJ 1_o
expression NN 1_o
of IN 1_o
these DT N
two CD N
genes NNS N
. . N

These DT N
results NNS N
suggest VBP N
, , N
that DT N
maternal JJ N
and CC N
dietary JJ N
Se-induced NNP N
oxidative JJ N
stress NN N
can MD N
modulate VB N
the DT N
mRNA NN 1_o
and CC 1_o
protein JJ 1_o
expression NN 1_o
of IN 1_o
the DT N
cell NN N
cycle NN N
related VBN N
genes NNS N
( ( N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
) ) N
in IN N
the DT N
testis NN N
of IN N
their PRP$ N
offspring NN N
. . N

In IN N
addition NN N
, , N
Se NNP N
deficiency NN N
and CC N
Se NNP N
excess NN N
could MD N
prevent VB N
the DT N
completion NN N
of IN N
the DT N
cell NN N
cycle NN N
. . N

-DOCSTART- -X- O O

Physical JJ N
health NN N
-- : N
a DT N
cluster NN 1_i
randomized VBN 1_i
controlled VBN 1_i
lifestyle JJ 1_i
intervention NN 1_i
among IN N
persons NNS 1_p
with IN 1_p
a DT 1_p
psychiatric JJ 1_p
disability NN 1_p
and CC 1_p
their PRP$ 1_p
staff NN 1_p
. . 1_p

The DT N
objective NN N
was VBD N
to TO N
explore VB N
the DT N
impact NN N
on IN N
physical JJ N
health NN N
of IN N
a DT N
lifestyle JJ 1_i
programme NN 1_i
among IN N
persons NNS 1_p
with IN 1_p
psychiatric JJ 1_p
disabilities NNS 1_p
, , 1_p
and CC 1_p
their PRP$ 1_p
caregivers NNS 1_p
. . 1_p

Their PRP$ N
satisfaction NN N
with IN N
the DT N
intervention NN N
was VBD N
also RB N
assessed VBN N
. . N

Somatic JJ N
comorbidity NN N
and CC N
an DT N
increased VBN N
mortality NN N
related VBN N
to TO N
the DT N
lifestyle NN N
among IN N
persons NNS 1_p
with IN 1_p
psychiatric JJ 1_p
disabilities NNS 1_p
are VBP N
well RB N
known VBN N
. . N

Few JJ N
randomized VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
aimed VBN N
specifically RB N
at IN N
lifestyle JJ N
issues NNS N
among IN N
persons NNS 1_p
with IN 1_p
a DT 1_p
psychiatric JJ 1_p
disability NN 1_p
. . 1_p

This DT N
trial NN N
includes VBZ N
clients NNS 1_p
with IN 1_p
psychiatric JJ 1_p
disabilities NNS 1_p
living VBG 1_p
in IN 1_p
supported JJ 1_p
housing NN 1_p
and CC 1_p
their PRP$ 1_p
staff NN 1_p
. . 1_p

Forty-one CD 1_p
persons NNS 1_p
with IN 1_p
a DT 1_p
DSM- NNP 1_p
? . 1_p
V NNP 1_p
diagnosis NN 1_p
of IN 1_p
severe JJ 1_p
mental JJ 1_p
illness NN 1_p
from IN 1_p
psychiatric JJ 1_p
disability NN 1_p
from IN 1_p
10 CD 1_p
supported VBD 1_p
housing NN 1_p
facilities NNS 1_p
and CC 1_p
41 CD 1_p
of IN 1_p
their PRP$ 1_p
caregivers NNS 1_p
participated VBN 1_p
in IN 1_p
this DT 1_p
12-month JJ 1_p
study NN 1_p
during IN 1_p
2005-2006 JJ 1_p
in IN 1_p
Sweden NNP 1_p
. . 1_p

The DT N
supported JJ N
housing NN N
facilities NNS N
with IN N
residents NNS N
and CC N
staff NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
a DT N
health NN 1_i
intervention NN 1_i
programme NN 1_i
or CC N
a DT N
control NN N
programme NN N
with IN N
an DT N
aesthetic JJ N
content NN N
. . N

The DT N
presence NN 1_o
of IN 1_o
metabolic JJ 1_o
syndrome NN 1_o
and CC 1_o
changes NNS 1_o
in IN 1_o
the DT 1_o
mean NN 1_o
of IN 1_o
physiological JJ 1_o
parameters NNS 1_o
such JJ 1_o
as IN 1_o
Hba1c NNP 1_o
, , 1_o
P-glucose NNP 1_o
, , 1_o
P-insulin NNP 1_o
, , 1_o
lipids NNS 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
physical JJ 1_o
working NN 1_o
capacity NN 1_o
, , 1_o
body NN 1_o
mass NN 1_o
index NN 1_o
, , 1_o
Heart NNP 1_o
Score NNP 1_o
were VBD 1_o
investigated VBN 1_o
and CC 1_o
participants NNS 1_o
' POS 1_o
satisfaction NN 1_o
assessed VBD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
mean NN 1_o
of IN 1_o
metabolic JJ 1_o
syndrome JJ 1_o
criteria NNS 1_o
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
at IN N
the DT N
follow-up NN N
. . N

The DT N
participants NNS N
expressed VBD N
satisfaction NN N
with IN N
the DT N
programme NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
health NN 1_i
interventions NNS 1_i
on IN N
lifestyle JJ N
issues NNS N
when WRB N
involving VBG N
carers NNS 1_p
are VBP N
appreciated VBN N
, , N
feasible JJ N
and CC N
could MD N
be VB N
successful JJ N
in IN N
reducing VBG N
some DT N
health-related JJ 1_o
risk NN 1_o
factors NNS 1_o
among IN N
persons NNS 1_p
with IN 1_p
psychiatric JJ 1_p
disabilities NNS 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ N
Application NNP N
of IN N
tacrolimus NN 1_i
and CC 1_i
cyclosporine VB 1_i
A NNP 1_i
in IN N
HBV-carrying NNP 1_p
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
] VBP 1_p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
long-term JJ N
effect NN N
and CC N
safety NN N
of IN N
tacrolimus NN 1_i
( ( 1_i
FK506 NNP 1_i
) ) 1_i
and CC 1_i
cyclosporine NN 1_i
( ( 1_i
CsA NNP 1_i
) ) 1_i
in IN N
kidney NN 1_p
transplant NN 1_p
( ( 1_p
KT NNP 1_p
) ) 1_p
recipients VBZ 1_p
carrying VBG 1_p
hepatitis NN 1_p
B NNP 1_p
Virus NNP 1_p
( ( 1_p
HBV NNP 1_p
) ) 1_p
. . 1_p

METHODS CC N
A DT N
total NN N
of IN N
109 CD 1_p
patients NNS 1_p
with IN 1_p
HBV NNP 1_p
were VBD N
randomized VBN N
into IN N
FK506 NNP 1_i
group NN N
( ( N
52 CD N
cases NNS N
) ) N
and CC N
CsA NNP 1_i
group NN N
( ( N
57 CD N
cases NNS N
) ) N
after IN N
KT NNP N
, , N
and CC N
a DT N
2-year-long JJ N
follow-up NN N
of IN N
the DT N
patients NNS N
was VBD N
conducted VBN N
to TO N
record VB N
the DT N
patient NN 1_o
and CC 1_o
graft NN 1_o
survival NN 1_o
, , 1_o
incidence NN 1_o
of IN 1_o
acute NN 1_o
graft NN 1_o
rejection NN 1_o
and CC N
postoperative JJ 1_o
liver NN 1_o
function NN 1_o
. . 1_o

RESULTS VB N
The DT N
2-year JJ 1_o
patient/graft NN 1_o
survival NN 1_o
was VBD N
86.0 CD N
% NN N
/73.7 CC N
% NN N
and CC N
94.2 CD N
% NN N
/90.3 CD N
% NN N
in IN N
CsA NNP N
and CC N
FK506 NNP N
groups NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
with IN N
incidence NN N
of IN N
acute JJ 1_o
rejection NN 1_o
of IN N
10.5 CD N
% NN N
and CC N
9.6 CD N
% NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
and CC N
rate NN N
of IN N
abnormal JJ 1_o
liver NN 1_o
function NN 1_o
of IN N
26.3 CD N
% NN N
and CC N
15.4 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Eight CD N
patients NNS N
( ( N
14.4 CD N
% NN N
) ) N
in IN N
CsA NNP N
group NN N
required VBD N
a DT N
drug NN N
conversion NN N
but CC N
none NN N
in IN N
FK506 NNP N
group NN N
. . N

The DT N
drug NN N
conversion NN N
resulted VBD N
in IN N
significant JJ N
reduction NN N
of IN N
ALT/AST NNP 1_o
level NN 1_o
from IN N
255.13+/-31.38/201.88+/-21.25 JJ N
U/L NNP N
to TO N
31.25+/-11.50/25.13+/-9.68 JJ N
U/L NNP N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
For IN N
HBV-carrying NNP 1_p
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
, , N
FK506 NNP 1_i
as IN N
the DT N
primary JJ N
choice NN N
of IN N
immunosuppressant NN N
can MD N
be VB N
more RBR N
effective JJ N
and CC N
safer JJR N
than IN N
CsA NNP N
. . N

-DOCSTART- -X- O O

A DT N
drug NN N
interaction NN N
study NN N
between IN N
ticlopidine NN 1_i
and CC N
cyclosporin NN 1_i
in IN N
heart NN 1_p
transplant NN 1_p
recipients NNS 1_p
. . 1_p

OBJECTIVES NNP N
Previous NNP N
uncontrolled JJ N
studies NNS N
have VBP N
suggested VBN N
an DT N
interaction NN N
between IN N
ticlopidine NN 1_i
, , N
a DT N
major JJ N
antiplatelet NN N
agent NN N
, , N
and CC N
cyclosporin NN 1_i
in IN N
heart- JJ N
and CC N
kidney-transplant JJ N
recipients NNS N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
fashion NN N
, , N
the DT N
possible JJ N
interaction NN N
between IN N
cyclosporin NN 1_i
A NNP 1_i
and CC 1_i
ticlopidine NN 1_i
( ( N
250 CD N
mg NNS N
per IN N
day NN N
) ) N
and CC N
the DT N
tolerability NN N
of IN N
this DT N
combination NN N
in IN N
heart-transplant JJ 1_p
recipients NNS 1_p
. . 1_p

METHODS NNP N
Twenty NNP 1_p
heart-transplant JJ 1_p
recipients NNS 1_p
were VBD 1_p
randomised VBN 1_p
into IN 1_p
either CC 1_p
a DT 1_p
treated JJ 1_p
or CC 1_p
a DT 1_p
placebo NN 1_i
group NN 1_p
. . 1_p

Blood NN N
samples NNS N
were VBD N
drawn VBN N
for IN N
time-course JJ N
evaluation NN N
of IN N
cyclosporin NN N
blood NN N
levels NNS N
over IN N
a DT N
period NN N
of IN N
12 CD N
h NNS N
, , N
following VBG N
the DT N
morning NN N
intake NN N
of IN N
cyclosporin NN 1_i
and CC N
, , N
for IN N
platelet NN N
aggregation NN N
studies NNS N
, , N
before IN N
and CC N
after IN N
14 CD N
days NNS N
of IN N
ticlopidine JJ 1_i
administration NN N
. . N

Twenty CD N
four-hour JJ N
urine JJ N
samples NNS N
were VBD N
collected VBN N
for IN N
6-beta-hydroxycortisol JJ N
measurements NNS N
, , N
before IN N
and CC N
after IN N
14 CD N
days NNS N
of IN N
ticlopidine NN N
. . N

RESULTS NNP N
Although IN N
given VBN N
at IN N
half PDT N
the DT N
recommended JJ N
daily JJ N
dosage NN N
, , N
ticlopidine NN N
significantly RB N
reduced VBN N
platelet NN 1_o
aggregation NN 1_o
. . 1_o

Pharmacokinetic JJ N
parameters NNS N
indicate VBP N
that IN N
the DT N
bioavailability NN 1_o
of IN 1_o
cyclosporin NN 1_o
A NNP 1_o
was VBD N
not RB N
significantly RB N
modified VBN N
by IN N
ticlopidine NN 1_i
. . 1_i

However RB N
, , N
one CD 1_p
patient NN 1_p
in IN 1_p
the DT 1_p
ticlopidine NN 1_p
group NN 1_p
was VBD 1_p
withdrawn VBN 1_p
because IN 1_p
of IN 1_p
a DT 1_p
major JJ 1_p
fall NN 1_o
in IN 1_o
cyclosporin JJ 1_o
blood NN 1_o
level NN 1_o
within IN 1_p
3 CD 1_p
days NNS 1_p
of IN 1_p
treatment NN 1_p
. . 1_p

Urinary JJ 1_o
excretion NN 1_o
of IN 1_o
6-beta-hydroxycortisol NNP 1_o
was VBD N
augmented VBN N
after IN N
treatment NN N
in IN N
the DT N
ticlopidine NN 1_i
group NN N
compared VBN N
with IN N
the DT N
placebo NN 1_i
group NN N
, , N
suggesting VBG N
that IN N
induction NN N
of IN N
drug NN N
metabolism NN N
might MD N
have VB N
occurred VBN N
. . N

Data NNP N
also RB N
show VBP N
quite RB N
a DT N
large JJ N
intra-individual JJ N
variability NN N
in IN N
cyclosporin JJ 1_o
bioavailability NN 1_o
in IN N
the DT N
placebo NN 1_i
group NN N
, , N
suggesting VBG N
that IN N
poor JJ N
absorption NN N
of IN N
the DT N
drug NN N
formulation NN N
and/or IN N
poor JJ N
compliance NN N
might MD N
have VB N
contributed VBN N
to TO N
the DT N
decreased VBN N
cyclosporin NN 1_o
blood NN 1_o
levels NNS 1_o
in IN N
the DT N
patient JJ N
withdrawn NN N
from IN N
this DT N
study NN N
and CC N
in IN N
previous JJ N
uncontrolled JJ N
studies NNS N
. . N

CONCLUSION NNP N
Cyclosporin NNP 1_o
bioavailability NN 1_o
was VBD N
not RB N
clearly RB N
modified VBN N
by IN N
a DT N
half JJ N
dosage NN N
of IN N
ticlopidine NN 1_i
in IN N
this DT N
study NN N
. . N

We PRP N
, , N
however RB N
, , N
recommend VBP N
closely RB N
monitoring JJ N
cyclosporin NNS N
blood NN N
levels NNS N
when WRB N
prescribing VBG N
ticlopidine NN 1_i
. . 1_i

Further JJ N
studies NNS N
will MD N
be VB N
needed VBN N
with IN N
new JJ N
formulations NNS N
of IN N
cyclosporin NN 1_i
or CC N
when WRB N
using VBG N
the DT N
full JJ N
dosage NN N
of IN N
ticlopidine NN 1_i
. . 1_i

-DOCSTART- -X- O O

Effectiveness NN 1_o
of IN N
N NNP N
, , N
N-dimethylglycine NNP N
in IN N
autism NN 1_p
and CC 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
. . 1_p

N NNP 1_i
, , 1_i
N-dimethylglycine NNP 1_i
, , N
a DT N
dietary JJ N
supplement NN N
, , N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
beneficial JJ N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
. . 1_p

We PRP N
examined VBD N
the DT N
effectiveness NN N
of IN N
dimethylglycine NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
pervasive JJ 1_p
developmental NN 1_p
disorder NN 1_p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Thirty-seven JJ 1_p
children NNS 1_p
between IN 1_p
3 CD 1_p
and CC 1_p
11 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
a DT 1_p
diagnosis NN 1_p
of IN 1_p
autism NN 1_p
and/or JJ 1_p
pervasive JJ 1_p
developmental NN 1_p
disorder NN 1_p
were VBD N
gender JJR N
and CC N
age NN N
matched VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
receive VB 1_i
either DT 1_i
placebo NN 1_i
or CC 1_i
dimethylglycine NN 1_i
for IN 1_i
4 CD 1_i
weeks NNS 1_i
. . 1_i

All DT N
children NNS N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
treatment NN N
on IN N
two CD 1_i
behavioral JJ 1_i
measures NNS 1_i
, , 1_i
the DT 1_i
Vineland NNP 1_o
Maladaptive NNP 1_o
Behavior NNP 1_o
Domain NNP 1_o
and CC 1_o
the DT 1_o
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
. . 1_o

Standardized NNP 1_o
neurologic JJ 1_o
examinations NNS 1_o
before IN 1_o
and CC 1_o
after IN 1_o
treatment NN 1_o
on IN N
33 CD N
children NNS N
showed VBD N
no DT N
change NN N
. . N

An DT N
overall JJ N
improvement NN N
on IN N
all DT 1_o
behavioral JJ 1_o
measures NNS 1_o
was VBD N
observed VBN N
for IN N
both DT N
the DT N
placebo NN N
and CC N
the DT N
dimethylglycine NN N
groups NNS N
. . N

However RB N
, , N
the DT N
improvement NN N
among IN N
the DT N
children NNS N
who WP N
received VBD N
dimethylglycine NN N
was VBD N
not RB N
statistically RB N
different JJ N
from IN N
the DT N
improvement NN N
observed VBD N
among IN N
the DT N
children NNS N
who WP N
received VBD N
the DT N
placebo NN N
. . N

The DT N
children NNS 1_p
who WP 1_p
participated VBD 1_p
in IN 1_p
this DT 1_p
study NN 1_p
were VBD 1_p
a DT 1_p
heterogeneous JJ 1_p
group NN 1_p
, , N
and CC N
their PRP$ N
apparent JJ N
responses NNS N
to TO N
the DT N
dimethylglycine NN N
varied VBN N
. . N

Some DT N
children NNS N
appeared VBD N
to TO N
respond VB N
positively RB N
to TO N
the DT N
dimethylglycine NN N
, , N
and CC N
there RB N
was VBD N
a DT N
smaller JJR N
proportion NN N
of IN N
negative JJ N
changes NNS N
in IN N
the DT N
dimethylglycine NN N
group NN N
, , N
but CC N
the DT N
quantitative JJ N
changes NNS N
in IN N
the DT N
dimethylglycine JJ N
behavioral JJ N
assessments NNS N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
what WP N
was VBD N
observed VBN N
among IN N
children NNS N
who WP N
received VBD N
placebo NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
of IN N
controlled JJ N
release NN N
melatonin NN 1_i
treatment NN 1_i
of IN N
delayed JJ 1_p
sleep JJ 1_p
phase NN 1_p
syndrome NN 1_p
and CC N
impaired JJ 1_p
sleep JJ 1_p
maintenance NN 1_p
in IN N
children NNS 1_p
with IN 1_p
neurodevelopmental JJ 1_p
disabilities NNS 1_p
. . 1_p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN 1_o
of IN N
controlled-release NN N
( ( N
CR NNP N
) ) N
melatonin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
delayed JJ 1_p
sleep JJ 1_p
phase NN 1_p
syndrome NN 1_p
and CC N
impaired JJ 1_p
sleep JJ 1_p
maintenance NN 1_p
of IN N
children NNS 1_p
with IN 1_p
neurodevelopmental JJ 1_p
disabilities NNS 1_p
including VBG 1_p
autistic JJ 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

A DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ 1_i
crossover NN N
trial NN N
of IN N
CR NNP 1_i
melatonin NN 1_i
( ( N
5 CD N
mg NN N
) ) N
followed VBN N
by IN N
a DT N
3-month JJ N
open-label NN N
study NN N
was VBD N
conducted VBN N
during IN N
which WDT N
the DT N
dose NN N
was VBD N
gradually RB N
increased VBN N
until IN N
the DT N
therapy NN N
showed VBD N
optimal JJ N
beneficial JJ N
effects NNS N
. . N

Sleep JJ 1_o
characteristics NNS 1_o
were VBD N
measured VBN N
by IN N
caregiver NN N
who WP N
completed VBD N
somnologs NNS N
and CC N
wrist JJ N
actigraphs NN N
. . N

Clinician JJ 1_o
rating NN 1_o
of IN N
severity NN N
of IN N
the DT N
sleep JJ N
disorder NN N
and CC N
improvement NN N
from IN N
baseline NN N
, , N
along IN N
with IN N
caregiver JJ 1_o
ratings NNS 1_o
of IN N
global JJ N
functioning NN N
and CC N
family NN N
stress NN N
were VBD N
also RB N
obtained VBN N
. . N

Fifty-one CD 1_p
children NNS 1_p
( ( 1_p
age NN 1_p
range NN 1_p
2-18 CD 1_p
years NNS 1_p
) ) 1_p
who WP 1_p
did VBD 1_p
not RB 1_p
respond VB 1_p
to TO 1_p
sleep VB 1_p
hygiene NN 1_p
intervention NN 1_p
were VBD N
enrolled VBN N
. . N

Fifty JJ N
patients NNS N
completed VBD N
the DT N
crossover NN N
trial NN N
and CC N
47 CD N
completed VBD N
the DT N
open-label JJ N
phase NN N
. . N

Recordings NNS N
of IN N
total JJ 1_o
night-time JJ 1_o
sleep NN 1_o
and CC N
sleep JJ 1_o
latency NN 1_o
showed VBD N
significant JJ N
improvement NN N
of IN N
approximately RB N
30 CD N
min NNS N
. . N

Similarly RB N
, , N
significant JJ 1_o
improvement NN 1_o
was VBD N
observed VBN N
in IN N
clinician JJ 1_o
and CC 1_o
parent JJ 1_o
ratings NNS 1_o
. . 1_o

There EX N
was VBD N
additional JJ N
improvement NN 1_o
in IN N
the DT N
open-label JJ 1_o
somnolog NN 1_o
measures NNS 1_o
of IN N
sleep JJ 1_o
efficiency NN 1_o
and CC N
the DT 1_o
longest JJS 1_o
sleep JJ 1_o
episode NN 1_o
in IN N
the DT N
open-label JJ N
phase NN N
. . N

Overall UH N
, , N
the DT N
therapy NN N
improved VBD 1_o
the DT 1_o
sleep NN 1_o
of IN N
47 CD N
children NNS N
and CC N
was VBD N
effective JJ 1_o
in IN 1_o
reducing VBG 1_o
family NN 1_o
stress NN 1_o
. . 1_o

Children NNP 1_p
with IN 1_p
neurodevelopmental JJ 1_p
disabilities NNS 1_p
, , N
who WP N
had VBD 1_p
treatment NN 1_o
resistant JJ 1_o
chronic JJ 1_o
delayed VBN 1_o
sleep JJ 1_o
phase NN 1_o
syndrome NN 1_o
and CC 1_p
impaired JJ 1_o
sleep JJ 1_o
maintenance NN 1_o
, , N
showed VBD N
improvement NN N
in IN N
melatonin NN 1_i
therapy NN 1_i
. . 1_i

-DOCSTART- -X- O O

Treatment NN N
of IN N
recurrent NN 1_p
chronic JJ 1_p
hyperplastic JJ 1_p
sinusitis NN 1_p
with IN 1_p
nasal JJ 1_p
polyposis NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
demonstrate VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
intranasal JJ N
furosemide NN 1_i
, , N
an DT N
inhibitor NN N
of IN N
the DT N
sodium NN N
chloride NN N
cotransporter NN N
channel NN N
at IN N
the DT N
basolateral JJ N
surface NN N
of IN N
the DT N
respiratory JJ N
epithelial JJ N
cell NN N
, , N
vs VBZ N
no DT 1_i
therapeutic JJ 1_i
intervention NN 1_i
vs NN N
intranasal NN N
mometasone NN 1_i
furoate NN 1_i
, , 1_i
a DT 1_i
corticosteroid NN 1_i
, , N
in IN N
preventing VBG N
relapses NNS N
of IN N
chronic JJ N
hyperplastic JJ N
sinusitis NN N
with IN N
nasal JJ N
polyposis NN N
. . N

DESIGN NNP N
Randomized NNP N
prospective NN N
controlled VBD N
study NN N
. . N

Patients NNS N
were VBD N
examined VBN N
every DT N
6 CD N
months NNS N
during IN N
follow-up NN N
( ( N
range NN N
, , N
1-9 JJ N
years NNS N
) ) N
. . N

PATIENTS VB N
One CD 1_p
hundred JJ 1_p
seventy NN 1_p
patients NNS 1_p
with IN 1_p
bilateral JJ 1_p
obstructive CD 1_p
or CC 1_p
minimally RB 1_p
obstructive JJ 1_p
chronic JJ 1_p
hyperplastic JJ 1_p
sinusitis NN 1_p
with IN 1_p
nasal JJ 1_p
polyposis NN 1_p
. . 1_p

INTERVENTION NNP N
All DT 1_p
patients NNS 1_p
were VBD 1_p
surgically RB 1_p
treated VBN 1_p
in IN 1_p
the DT 1_p
ENT NNP 1_p
Department NNP 1_p
, , 1_p
University NNP 1_p
of IN 1_p
Siena NNP 1_p
Medical NNP 1_p
School NNP 1_p
. . 1_p

One CD 1_p
month NN 1_p
after IN 1_p
surgery NN 1_p
, , N
group NN N
1 CD 1_p
patients NNS 1_p
( ( N
n JJ N
= NNP N
97 CD N
) ) N
started VBD N
treatment NN 1_i
with IN 1_i
intranasal JJ 1_i
furosemide NN 1_i
, , N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
received VBD 1_i
no DT 1_i
therapeutic JJ 1_i
treatment NN 1_i
, , N
and CC N
group NN N
3 CD N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
were VBD N
treated VBN 1_i
with IN 1_i
mometasone NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Clinical NNP 1_o
and CC 1_o
instrumental JJ 1_o
evaluation NN 1_o
of IN 1_o
postoperative JJ 1_o
outcomes NNS 1_o
. . 1_o

RESULTS NNP N
Seventeen NNP N
( ( N
17.5 CD N
% NN N
) ) N
of IN N
97 CD N
patients NNS N
in IN N
group NN N
1 CD N
, , N
12 CD N
( ( N
30.0 CD N
% NN N
) ) N
of IN N
40 CD N
patients NNS N
in IN N
group NN N
2 CD N
, , N
and CC N
8 CD N
( ( N
24.2 CD N
% NN N
) ) N
of IN N
33 CD N
patients NNS N
in IN N
group NN N
3 CD N
experienced VBD N
nasal JJ 1_o
polyposis NN 1_o
relapses NNS 1_o
. . 1_o

We PRP N
noted VBD N
a DT N
prevalence NN N
of IN N
early-stage JJ 1_o
relapse NN 1_o
in IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
furosemide NN 1_i
or CC 1_p
mometasone NN 1_i
, , N
whereas JJ N
patients NNS 1_p
who WP 1_p
did VBD 1_p
not RB 1_p
receive VB 1_p
any DT 1_p
treatment NN 1_p
experienced VBD N
more JJR N
severe JJ N
grades NNS 1_o
of IN 1_o
chronic JJ 1_o
hyperplastic JJ 1_o
sinusitis NN 1_o
with IN 1_o
nasal JJ 1_o
polyposis NN 1_o
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
intranasal NN N
furosemide JJ 1_i
represents VBZ N
a DT N
valid JJ N
therapeutic JJ N
treatment NN N
in IN N
the DT N
prevention NN N
of IN N
chronic JJ 1_p
hyperplastic JJ 1_p
sinusitis NN 1_p
with IN 1_p
nasal JJ 1_p
polyposis NN 1_p
. . 1_p

-DOCSTART- -X- O O

Lactobacillus NNP 1_i
plantarum NN 1_i
CECT7315 NNP 1_i
and CC 1_i
CECT7316 NNP 1_i
stimulate VBP N
immunoglobulin NN 1_o
production NN 1_o
after IN N
influenza JJ 1_i
vaccination NN 1_i
in IN 1_p
elderly JJ 1_p
. . 1_p

OBJECTIVE IN N
The DT N
effectiveness NN N
of IN N
influenza JJ 1_i
vaccination NN 1_i
in IN N
preventing VBG N
illness NN N
is VBZ N
lower RBR N
in IN N
the DT N
elderly JJ N
; : N
this DT N
is VBZ N
why WRB N
the DT N
ability NN N
of IN N
Lactobacillus NNP 1_i
plantarum NN 1_i
CECT NNP 1_i
7315/7316 CD 1_i
to TO N
stimulate VB 1_o
the DT 1_o
response NN 1_o
to TO 1_o
influenza VB 1_o
vaccination NN 1_o
in IN 1_p
elderly JJ 1_p
was VBD N
evaluated VBN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
human JJ N
trial NN N
including VBG N
60 CD 1_p
institutionalized JJ 1_p
volunteers NNS 1_p
aged VBN 1_p
65-85 CD 1_p
years NNS 1_p
was VBD N
performed VBN N
. . N

All PDT N
the DT N
volunteers NNS N
were VBD N
vaccinated VBN N
with IN N
a DT N
trivalent JJ 1_i
influenza NN 1_i
vaccine NN 1_i
( ( 1_i
A/Wisconsin/67/2005 NNP 1_i
NYMC NNP 1_i
X-161B NNP 1_i
( ( 1_i
H3N2 NNP 1_i
) ) 1_i
, , 1_i
A/Solomon NNP 1_i
Islands/3/2006 NNP 1_i
( ( 1_i
H1N1 NNP 1_i
) ) 1_i
and CC 1_i
B/Malaysia/2506/2004 NNP 1_i
) ) 1_i
for IN N
the DT N
Spanish JJ N
vaccine NN N
campaign NN N
2006/2007 CD N
. . N

The DT N
consumption NN N
of IN N
the DT N
probiotic JJ N
began VBD N
between IN N
three CD N
and CC N
four CD N
months NNS N
after IN N
the DT N
vaccination NN N
. . N

Volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
following VBG N
groups NNS N
: : N
group NN N
A NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
9 CD N
) ) N
cfu/day NN N
of IN N
L. NNP 1_i
plantarum NN 1_i
CECT NNP 1_i
7315/7316 CD 1_i
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
, , N
group NN N
B NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
8 CD N
) ) N
cfu/day NN N
of IN N
L. NNP 1_i
plantarum NN 1_i
CECT NNP 1_i
7315/7316 CD 1_i
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
and CC N
group NN N
C NNP N
or CC N
placebo NN 1_i
( ( N
20 CD N
g NN N
powered VBN 1_i
skim JJ 1_i
milk NN 1_i
) ) 1_i
. . 1_i

The DT N
participants NNS N
consumed VBD N
the DT N
probiotic JJ N
during IN N
3 CD N
months NNS N
. . N

RESULTS VB N
The DT N
consumption NN N
of IN N
L. NNP 1_i
plantarum NN 1_i
CECT NNP 1_i
7315/7316 CD 1_i
during IN N
3 CD N
months NNS N
after IN N
influenza JJ 1_i
vaccination NN 1_i
increased VBD N
the DT N
levels NNS 1_o
of IN 1_o
influenza-specific JJ 1_o
IgA NNP 1_o
and CC 1_o
IgG NNP 1_o
antibodies NNS 1_o
. . 1_o

Moreover RB N
, , N
a DT N
trend NN N
towards IN N
an DT N
increase NN N
in IN N
influenza-specific JJ 1_o
IgM NNP 1_o
antibodies NNS 1_o
was VBD N
also RB N
observed VBN N
. . N

CONCLUSION NNP N
L. NNP 1_i
plantarum NN 1_i
CECT7315/7316 NNP 1_i
has VBZ N
an DT N
immunostimulating JJ N
effect NN N
and CC N
could MD N
be VB N
used VBN N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB 1_i
vaccination NN 1_i
in IN N
elderly JJ N
. . N

-DOCSTART- -X- O O

Oral NNP N
ondansetron NN 1_i
in IN N
the DT N
prevention NN 1_o
of IN 1_o
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
. . 1_o

The DT N
effect NN N
of IN N
three CD N
times NNS N
daily JJ N
oral JJ N
ondansetron NN N
in IN N
preventing VBG N
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
was VBD N
investigated VBN N
in IN N
two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
multi-centre JJ N
studies NNS N
. . N

The DT N
first JJ N
study NN N
compared VBN N
ondansetron RB 1_i
1 CD 1_i
, , 1_i
8 CD 1_i
and CC 1_i
16 CD 1_i
mg NN 1_i
to TO N
placebo VB 1_i
, , N
and CC N
the DT N
second JJ N
study NN N
compared VBN N
8 CD 1_i
mg JJ 1_i
ondansetron NN 1_i
to TO 1_i
placebo VB 1_i
. . 1_i

Both DT N
studies NNS N
included VBD N
ASA NNP 1_p
Class NNP 1_p
I-III NNP 1_p
female JJ 1_p
patients NNS 1_p
about IN 1_p
to TO 1_p
undergo VB 1_p
major JJ 1_p
abdominal JJ 1_p
gynaecological JJ 1_p
surgery NN 1_p
or CC 1_p
vaginal JJ 1_p
hysterectomy NN 1_p
. . 1_p

In IN N
the DT N
first JJ N
study NN N
, , N
the DT N
8 CD 1_i
and CC 1_i
16 CD 1_i
mg NN 1_i
ondansetron NN 1_i
groups NNS 1_i
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN 1_o
of IN 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
in IN N
the DT N
0-24 JJ N
h JJ N
period NN N
following VBG N
recovery NN N
from IN N
anaesthesia NN N
than IN N
the DT N
placebo NN 1_i
group NN N
. . N

Ondansetron NNP 1_i
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
was VBD N
also RB N
significantly RB N
better JJR N
than IN N
placebo NN N
in IN N
the DT N
second JJ N
study NN N
. . N

Side-effects NNS 1_o
mainly RB N
consisted VBD N
of IN N
constipation NN 1_o
, , 1_o
headache NN 1_o
, , 1_o
and CC 1_o
asymptomatic JJ 1_o
elevation NN 1_o
of IN 1_o
liver NN 1_o
enzymes NNS 1_o
. . 1_o

The DT N
incidence NN N
of IN N
side-effects NNS 1_o
was VBD N
similar JJ N
in IN N
ondansetron- JJ N
and CC N
placebo-treated JJ N
patients NNS N
. . N

There EX N
appeared VBD N
to TO N
be VB N
no DT N
clinically RB 1_o
important JJ 1_o
benefit NN 1_o
of IN N
the DT N
16 CD N
mg NN N
three CD N
times NNS N
daily JJ N
ondansetron VBP 1_i
regimen NNS N
over IN N
the DT N
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
dose VBP N
, , N
therefore RB N
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
is VBZ N
recommended VBN N
as IN N
the DT N
optimal JJ 1_o
oral JJ 1_o
dose NN 1_o
in IN N
the DT N
prevention NN N
of IN N
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
. . 1_o

-DOCSTART- -X- O O

Lowering VBG N
of IN N
glucose NN N
in IN N
critical JJ N
care NN N
: : N
a DT N
randomized JJ N
pilot NN N
trial NN N
. . N

BACKGROUND NNP N
Similar NNP N
to TO N
cardiac VB N
surgery NN N
patients NNS N
, , N
medical-surgical JJ 1_p
critically RB 1_p
ill JJ 1_p
patients NNS 1_p
may MD N
benefit VB N
from IN N
intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
. . 1_i

The DT N
objectives NNS N
of IN N
this DT N
pilot NN N
trial NN N
were VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
with IN N
respect NN N
to TO N
( ( N
a DT N
) ) N
achieving VBG N
target NN N
glucose JJ N
values NNS N
in IN N
the DT N
2 CD N
ranges NNS N
of IN N
5 CD N
to TO N
7 CD N
and CC N
8 CD N
to TO N
10 CD N
mmol/L NNS N
and CC N
( ( N
b NN N
) ) N
uncovering VBG N
problems NNS N
with IN N
the DT N
protocol NN N
in IN N
anticipation NN N
of IN N
a DT N
larger JJR N
trial NN N
. . N

SETTING VB N
The DT N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
15-bed JJ 1_p
medical-surgical JJ 1_p
university-affiliated JJ 1_p
intensive JJ 1_p
care NN 1_p
unit NN 1_p
( ( 1_p
ICU NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
We PRP N
included VBD N
patients NNS 1_p
older JJR 1_p
than IN 1_p
18 CD 1_p
years NNS 1_p
, , 1_p
expected VBN 1_p
to TO 1_p
be VB 1_p
in IN 1_p
ICU NNP 1_p
for IN 1_p
more JJR 1_p
than IN 1_p
72 CD 1_p
hours NNS 1_p
, , 1_p
with IN 1_p
a DT 1_p
glucose JJ 1_p
value NN 1_p
of IN 1_p
more JJR 1_p
than IN 1_p
10 CD 1_p
mmol/L NNS 1_p
within IN 1_p
48 CD 1_p
hours NNS 1_p
of IN 1_p
ICU NNP 1_p
admission NN 1_p
. . 1_p

Exclusion NN 1_p
criteria NNS 1_p
were VBD 1_p
diabetic JJ 1_p
ketoacidosis NN 1_p
, , 1_p
severe JJ 1_p
hepatic JJ 1_p
failure NN 1_p
or CC 1_p
hepatic JJ 1_p
resection NN 1_p
, , 1_p
pancreatitis NN 1_p
, , 1_p
glucose NN 1_p
of IN 1_p
less JJR 1_p
than IN 1_p
2.2 CD 1_p
mmol/L NN 1_p
on IN 1_p
admission NN 1_p
to TO 1_p
hospital NN 1_p
, , 1_p
insulin JJ 1_p
infusion NN 1_p
on IN 1_p
admission NN 1_p
to TO 1_p
ICU NNP 1_p
, , 1_p
planned VBD 1_p
withdrawal NN 1_p
of IN 1_p
life NN 1_p
support NN 1_p
, , 1_p
and CC 1_p
inability NN 1_p
to TO 1_p
obtain VB 1_p
informed JJ 1_p
consent NN 1_p
. . 1_p

Patients NNS N
underwent JJ N
concealed JJ 1_i
random NN 1_i
allocation NN 1_i
to TO 1_i
a DT 1_i
target NN 1_i
glucose JJ 1_i
range NN 1_i
of IN 1_i
5 CD 1_i
to TO 1_i
7 CD 1_i
or CC 1_i
8 CD 1_i
to TO 1_i
10 CD 1_i
mmol/L NNS 1_i
using VBG 1_i
pretested JJ 1_i
algorithms NN 1_i
of IN 1_i
insulin NN 1_i
infusions NNS 1_i
. . 1_i

Dedicated VBN N
glucometer JJ N
measurement NN N
of IN N
arterial JJ N
glucose NN N
values NNS N
was VBD N
calibrated VBN N
daily RB N
to TO N
values NNS N
measured VBN N
in IN N
the DT N
laboratory NN N
. . N

RESULTS NNP N
We PRP 1_p
enrolled VBD 1_p
20 CD 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
mean NN 1_p
( ( 1_p
SD NNP 1_p
) ) 1_p
Acute NNP 1_o
Physiology NNP 1_o
and CC 1_o
Chronic NNP 1_o
Health NNP 1_o
Evaluation NNP 1_o
( ( 1_o
APACHE NNP 1_o
) ) 1_o
II NNP 1_o
score NN 1_o
of IN 1_p
32 CD 1_p
( ( 1_p
10.2 CD 1_p
) ) 1_p
; : 1_p
14 CD 1_p
were VBD 1_p
insulin-dependent JJ 1_p
pre-ICU JJ 1_p
, , 1_p
and CC 1_p
all DT 1_p
were VBD 1_p
medical JJ 1_p
admissions NNS 1_p
. . 1_p

Mean NNP 1_o
glucose JJ 1_o
values NNS 1_o
were VBD N
different JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
7.1 CD N
+/- JJ N
2.6 CD N
vs JJ N
9.4 CD N
+/- JJ N
2.1 CD N
mmol/L NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Although IN N
the DT N
intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
group NN N
had VBD N
more RBR N
glucose JJ 1_o
measurements NNS 1_o
performed VBN N
than IN N
the DT N
control NN N
group NN N
, , N
a DT N
similar JJ N
proportion NN N
of IN N
values NNS N
were VBD N
within IN N
the DT N
target NN N
range NN N
( ( N
682 CD N
[ RB N
42.4 CD N
% NN N
] NN N
of IN N
1607 CD N
values NNS N
in IN N
the DT N
5- JJ N
to TO N
7-mmol/L JJ N
range NN N
; : N
250 CD N
[ $ N
38.7 CD N
% NN N
] NN N
of IN N
660 CD N
values NNS N
in IN N
the DT N
8- JJ N
to TO N
10-mmol/L JJ N
range NN N
, , N
P NNP N
= NNP N
.35 NNP N
) ) N
. . N

Glucose NNP 1_o
values NNS 1_o
of IN N
less JJR N
than IN N
2.5 CD N
mmol/L NN N
developed VBD N
7 CD N
times NNS N
in IN N
5 CD N
patients NNS N
, , N
4 CD N
of IN N
whom WP N
were VBD N
in IN N
the DT N
intensive JJ N
insulin NN 1_i
therapy NN N
group NN N
; : N
however RB N
, , N
no DT N
adverse JJ N
consequences NNS N
were VBD N
documented VBN N
. . N

As IN N
expected VBN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
clinically RB N
important JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
pilot JJ N
trial NN N
of IN N
ICU NNP 1_p
patients NNS 1_p
with IN 1_p
high JJ 1_p
illness NN 1_p
severity NN 1_p
, , N
glucose JJ 1_o
values NNS 1_o
were VBD N
in IN N
the DT N
2 CD N
target NN N
ranges VBZ N
only RB N
40 CD N
% NN N
of IN N
the DT N
time NN N
, , N
using VBG N
well-accepted JJ N
initiation NN N
and CC N
maintenance NN N
insulin NN N
infusion NN N
algorithms NN N
. . N

A DT N
large JJ N
randomized JJ N
trial NN N
of IN N
glycemic JJ N
control NN N
is VBZ N
feasible JJ N
in IN N
this DT N
population NN N
to TO N
examine VB N
clinically RB N
important JJ N
outcomes NNS N
, , N
but CC N
will MD N
require VB N
refined JJ N
insulin NN 1_i
algorithms NN N
and CC N
more RBR N
comprehensive JJ N
behavior NN N
change NN N
strategies NNS N
to TO N
achieve VB N
target NN N
values NNS N
. . N

-DOCSTART- -X- O O

Interventional NNP N
study NN N
to TO N
strengthen VB N
the DT N
health NN N
promoting VBG N
behaviours NNS N
of IN N
pregnant JJ 1_p
women NNS 1_p
to TO N
prevent VB N
anaemia NN N
in IN N
southern JJ 1_p
India NNP 1_p
. . 1_p

OBJECTIVES NNP N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
health NN 1_i
information NN 1_i
package NN 1_i
in IN N
terms NNS N
of IN N
empowering VBG N
the DT N
pregnant JJ 1_p
women NNS 1_p
to TO N
modify VB N
their PRP$ N
health-care JJ N
behaviour NN N
and CC N
take VB N
appropriate JJ N
action NN N
to TO N
combat VB N
anaemia NN N
in IN N
pregnancy NN N
. . N

DESIGN VB N
the DT N
study NN N
was VBD N
conceptualized VBN N
based VBN N
on IN N
Rosenstock NNP N
and CC N
Becker NNP N
's POS N
health NN N
belief NN N
model NN N
. . N

A DT N
quasi-experimental JJ N
pretest-posttest JJ N
control NN N
group NN N
design NN N
was VBD N
used VBN N
. . N

The DT N
sample NN N
consists VBZ N
of IN N
225 CD 1_p
anaemic JJ 1_p
pregnant JJ 1_p
women NNS 1_p
randomly RB N
allocated VBN N
in IN N
experimental JJ 1_i
( ( N
n=75 JJ N
) ) N
, , N
control NN 1_i
group NN 1_i
A NNP 1_i
( ( N
n=75 NN N
) ) N
and CC N
control NN 1_i
group NN 1_i
B NNP 1_i
( ( N
n=75 NN N
) ) N
. . N

The DT N
health NN N
seeking VBG N
behaviour NN N
outcome NN N
measure NN N
included VBD N
knowledge NN N
regarding VBG N
anaemia NN N
, , N
food NN N
selection NN N
ability NN N
, , N
increase NN N
in IN N
haemoglobin JJ N
level NN N
and CC N
compliance NN N
to TO N
iron VB N
supplementation NN N
. . N

Intervention NN N
was VBD N
a DT N
validated JJ 1_i
planned JJ 1_i
educational JJ 1_i
programme NN 1_i
with IN 1_i
visual JJ 1_i
aids NNS 1_i
and CC 1_i
iron NN 1_i
supplementation NN 1_i
. . 1_i

FINDINGS IN N
the DT N
results NNS N
show VBP N
the DT N
mean JJ 1_o
gain NN 1_o
of IN 1_o
knowledge NN 1_o
scores NNS 1_o
of IN N
experimental JJ N
group NN N
was VBD N
comparatively RB N
higher JJR N
and CC N
control VB N
groups NNS N
A NNP N
and CC N
B NNP N
showed VBD N
that IN N
F NNP N
ratio NN N
was VBD N
( ( N
F NNP N
( ( N
2,190 CD N
) ) N
=11.910 NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
indicating NN N
that IN N
the DT N
pregnant JJ 1_p
women NNS 1_p
learned VBD N
more RBR N
about IN N
anaemia NN N
prevention NN N
than IN N
others NNS N
. . N

With IN N
regard NN N
to TO N
food NN N
selection NN N
ability NN N
scores NNS N
of IN N
experimental JJ N
, , N
control NN N
groups NNS N
A NNP N
and CC N
B NNP N
the DT N
F NNP N
ratio NN N
was VBD N
also RB N
significant JJ N
( ( N
F NNP N
( ( N
2,190 CD N
) ) N
=20.92 NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Nearly RB N
61.2 CD N
% NN N
of IN N
the DT N
subjects NNS N
in IN N
experimental JJ N
group NN N
became VBD N
non-anaemic JJ 1_o
after IN N
the DT N
intervention NN N
when WRB N
compared VBN N
to TO N
control VB N
group NN N
A NNP N
. . N

This DT N
indicated VBD N
that IN N
inspite NN N
of IN N
iron NN 1_i
supplementation NN 1_i
received VBN N
by IN N
the DT N
three CD N
groups NNS N
health NN N
education NN N
contributed VBD N
significantly RB N
in IN N
modifying VBG N
their PRP$ N
health NN N
seeking VBG N
behaviour NN N
and CC N
their PRP$ N
perception NN N
about IN N
significance NN N
of IN N
anaemia NN N
has VBZ N
a DT N
problem NN N
. . N

CONCLUSION NNP N
developing VBG N
countries NNS N
still RB N
face VBP N
the DT N
critical JJ N
problem NN N
of IN N
anaemia NN N
in IN N
pregnancy NN N
. . N

These DT N
are VBP N
the DT N
socio-cultural JJ N
priority NN N
problems NNS N
that WDT N
demand VBP N
immediate JJ N
attention NN N
by IN N
the DT N
policy NN N
makers NNS N
and CC N
health NN N
professionals NNS N
. . N

The DT N
national JJ N
anaemia NN N
control NN N
programme NN N
focuses VBZ N
on IN N
iron NN N
supplementation NN N
, , N
but CC N
nutritional JJ N
education NN N
and CC N
supervision NN N
of IN N
iron NN N
supplementation NN N
has VBZ N
failed VBN N
in IN N
different JJ N
regions NNS N
. . N

The DT N
study NN N
implies VBZ N
that IN N
economic JJ N
empowerment NN N
; : N
strengthening VBG N
health NN N
literacy NN N
through IN N
planned VBN N
educational JJ N
programs NNS N
will MD N
definitely RB N
improve VB N
the DT N
health NN N
behaviour NN N
of IN N
individual JJ N
and CC N
community NN N
at IN N
large JJ N
. . N

-DOCSTART- -X- O O

Bronchodilator NNP 1_i
treatment NN 1_i
in IN N
asthma NN 1_p
and CC 1_p
bronchitis NN 1_p
. . 1_p

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
an DT N
aqueous JJ 1_i
and CC N
a DT N
pressurized JJ 1_i
nasal NN 1_i
spray NN 1_i
of IN N
beclomethasone NN 1_i
dipropionate NN 1_i
in IN N
the DT N
management NN 1_o
of IN 1_o
seasonal JJ 1_o
rhinitis NN 1_o
. . 1_o

A DT N
multi-centre JJ N
, , N
double-blind JJ N
, , N
parallel JJ N
group NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
38 CD 1_p
patients NNS 1_p
with IN 1_p
seasonal JJ 1_p
rhinitis NN 1_p
to TO N
compare VB N
a DT N
new JJ N
aqueous JJ 1_i
nasal NN 1_i
spray NN 1_i
of IN 1_i
beclomethasone NN 1_i
dipropionate NN 1_i
with IN 1_i
the DT 1_i
conventional JJ 1_i
pressurized JJ 1_i
nasal NN 1_i
spray NN 1_i
. . 1_i

Beclomethasone NNP 1_i
dipropionate NN 1_i
( ( N
200 CD N
micrograms NNS N
) ) N
was VBD N
administered VBN N
twice RB N
daily RB N
for IN N
a DT N
treatment NN N
period NN N
of IN N
2 CD N
weeks NNS N
. . N

Both DT N
treatments NNS N
were VBD N
found VBN N
to TO N
be VB N
equally RB N
effective JJ 1_o
and CC 1_o
well RB 1_o
tolerated VBN 1_o
. . 1_o

It PRP N
is VBZ N
suggested VBN N
, , N
therefore RB N
, , N
that IN N
the DT N
new JJ N
aqueous JJ 1_i
nasal NN 1_i
spray NN 1_i
provides VBZ N
an DT N
alternative JJ N
method NN N
of IN N
intranasal JJ N
administration NN N
of IN N
the DT N
steroid NN N
for IN N
patients NNS N
who WP N
may MD N
prefer VB N
an DT N
aqueous JJ N
product NN N
. . N

-DOCSTART- -X- O O

Intravenous JJ N
pretreatment NN N
of IN N
hypertonic JJ 1_i
saline NN 1_i
can MD N
prevent VB N
systemic JJ 1_o
hypotension NN 1_o
induced VBN N
by IN N
spinal JJ N
anesthesia NN N
. . N

BACKGROUND NNP N
Hypertonic NNP N
saline NN N
improves VBZ N
organ JJ 1_o
perfusion NN 1_o
and CC N
patient JJ 1_o
survival NN 1_o
during IN N
hemorrhagic NN N
shock NN N
because IN N
it PRP N
expands VBZ N
plasma JJ N
volume NN N
and CC N
increases VBZ N
tissue NN N
oxygenation NN N
. . N

Its PRP$ N
beneficial JJ N
results NNS N
have VBP N
been VBN N
reported VBN N
in IN N
patients NNS N
suffering VBG N
from IN N
hypotension NN N
during IN N
spinal JJ N
anesthesia NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
influence NN N
between IN N
prehydration NN N
with IN N
3 CD N
% NN N
hypertonic JJ 1_i
saline NN 1_i
and CC 1_i
with IN 1_i
isotonic JJ 1_i
lactated VBN 1_i
Ringer NNP 1_i
's POS 1_i
solution NN 1_i
on IN N
the DT N
hemodynamic JJ N
changes NNS N
and CC N
serum NN N
electrolyte NN N
concentrations NNS N
in IN N
patients NNS 1_p
undergoing JJ 1_p
spinal JJ 1_p
anesthesia NN 1_p
. . 1_p

METHODS NNP N
Sixty NNP 1_p
ASA NNP 1_p
class NN 1_p
I PRP 1_p
patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
herniorrhapy NN 1_i
under IN 1_p
spinal JJ 1_p
anesthesia NN 1_p
were VBD N
assigned VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

Group NNP 1_p
1 CD 1_p
= NN 1_p
patients NNS 1_p
were VBD N
prehydrated VBN 1_i
with IN 1_i
isotonic JJ 1_i
lactated VBN 1_i
Ringer NNP 1_i
's POS 1_i
solution NN 1_i
at IN 1_i
7 CD 1_i
mg/kg NN 1_i
( ( N
n JJ N
= NNP N
30 CD N
) ) N
; : N
Group NNP 1_p
2 CD 1_p
= NN 1_p
patients NNS 1_p
were VBD N
given VBN N
prehydration NN 1_i
with IN 1_i
3 CD 1_i
% NN 1_i
hypertonic JJ 1_i
saline NN 1_i
at IN 1_i
7 CD 1_i
ml/kg NN 1_i
( ( N
n JJ N
= NNP N
30 CD N
) ) N
. . N

Following VBG N
prehydration NN N
, , N
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
were VBD N
recorded VBN N
and CC N
serum JJ 1_o
electrolyte NN 1_o
concentrations NNS 1_o
were VBD N
measured VBN N
. . N

RESULTS VB N
The DT N
incidence NN 1_o
of IN 1_o
hypotension NN 1_o
was VBD N
17/30 CD N
( ( N
57 CD N
% NN N
) ) N
in IN N
the DT N
isotonic JJ N
lactated VBD N
Ringer NNP N
's POS N
solution NN N
group NN N
as IN N
against IN N
7/30 CD N
( ( N
23 CD N
% NN N
) ) N
in IN N
the DT N
hypertonic JJ N
saline NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ 1_o
difference NN 1_o
between IN N
two CD N
groups NNS N
in IN N
relation NN N
to TO N
the DT N
level NN 1_o
of IN 1_o
anesthesia NN 1_o
or CC 1_o
maximal JJ 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
electrolyte JJ 1_o
imbalance NN 1_o
did VBD N
not RB N
occur VB N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
Prior NNP N
to TO N
spinal VB N
anesthesia NN N
, , N
hydration NN N
with IN N
small JJ N
amount NN N
of IN N
hypertonic JJ 1_i
saline NN 1_i
is VBZ N
effective JJ N
to TO N
minimize VB N
hypotension NN N
associated VBN N
with IN N
spinal JJ N
anesthesia NN N
. . N

If IN N
so RB N
administered VBN N
it PRP N
would MD N
not RB N
increase VB N
bodily RB N
sodium JJ N
load NN N
and CC N
unlike IN N
isotonic JJ N
crystalloid NN N
solution NN N
it PRP N
dose VBD N
not RB N
cause JJ N
accumulation NN N
of IN N
water NN N
in IN N
the DT N
body NN N
on IN N
equipollent JJ N
basis NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
angiotensin NN 1_i
II NNP 1_i
receptor NN 1_i
blocker NN 1_i
therapy NN 1_i
( ( 1_i
olmesartan JJ 1_i
or CC 1_i
valsartan NN 1_i
) ) 1_i
on IN N
coronary JJ N
atherosclerotic JJ N
plaque NN N
volume NN N
measured VBN N
by IN N
intravascular JJ N
ultrasound NN N
in IN N
patients NNS 1_p
with IN 1_p
stable JJ 1_p
angina JJ 1_p
pectoris NN 1_p
. . 1_p

Coronary JJ N
plaques NNS N
can MD N
be VB N
reduced VBN N
by IN N
some DT N
medications NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
2 CD N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
( ( 1_i
olmesartan NN 1_i
at IN N
20 CD N
mg/day NN N
or CC 1_i
valsartan NN 1_i
at IN N
80 CD N
mg/day NN N
) ) N
on IN N
coronary JJ N
plaque NN N
by IN N
coronary JJ N
intravascular JJ N
ultrasound NN N
. . N

One CD 1_p
hundred VBD 1_p
hypertensive JJ 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
angina NNS 1_p
pectoris NNS 1_p
who WP 1_p
underwent VBP 1_p
elective JJ 1_p
percutaneous JJ 1_p
coronary JJ 1_p
intervention NN 1_p
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
1 CD N
of IN N
the DT N
2 CD N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
after IN N
coronary JJ N
intervention NN N
. . N

Nontarget NNP 1_o
coronary JJ 1_o
lesions NNS 1_o
with IN 1_o
mild NN 1_o
to TO 1_o
moderate VB 1_o
stenosis NN 1_o
were VBD N
measured VBN N
by IN N
volumetric JJ N
intravascular JJ N
ultrasound NN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

After IN N
6 CD N
months NNS N
, , N
both CC N
the DT N
olmesartan NN 1_i
and CC N
the DT N
valsartan NN 1_i
groups NNS N
showed VBD N
significant JJ N
reduction NN N
of IN N
the DT N
examined JJ 1_o
coronary JJ 1_o
plaque NN 1_o
volume NN 1_o
( ( N
46.2 CD N
? . N
24.1 CD N
mm? NN N
at IN N
baseline NN N
vs NN N
41.6 CD N
? . N
21.1 CD N
mm? NN N
at IN N
6 CD N
months NNS N
: : N
4.7 CD N
% NN N
decrease NN N
, , N
p VBP N
= JJ N
0.0002 CD N
; : N
and CC N
47.2 CD N
? . N
32.7 CD N
mm? NN N
at IN N
baseline NN N
vs NN N
42.5 CD N
? . N
30.2 CD N
mm? NN N
at IN N
6 CD N
months NNS N
: : N
4.8 CD N
% NN N
decrease NN N
, , N
p VBP N
= JJ N
0.002 CD N
, , N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN 1_o
of IN 1_o
plaque JJ 1_o
regression NN 1_o
between IN 1_o
the DT N
2 CD N
groups NNS N
( ( N
p JJ N
= NNP N
0.96 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
from IN N
baseline NN N
in IN 1_o
the DT 1_o
coronary JJ 1_o
plaque NN 1_o
volume NN 1_o
in IN 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
angina NNS 1_p
pectoris NN 1_p
who WP 1_p
received VBD 1_p
olmesartan PRP 1_i
or CC 1_i
valsartan VB 1_i
for IN 1_i
6 CD 1_i
months NNS 1_i
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
reduction NN 1_o
of IN 1_o
plaque NN 1_o
volume NN 1_o
achieved VBN N
by IN N
these DT N
2 CD N
medications NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
treatment NN N
with IN N
interleukin-1 JJ 1_i
receptor NN 1_i
antagonist NN 1_i
on IN N
the DT N
inflamed JJ N
synovial JJ N
membrane NN N
in IN N
rheumatoid JJ 1_p
arthritis NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
interleukin-1 JJ 1_i
receptor NN 1_i
antagonist NN 1_i
( ( 1_i
IL-1Ra NNP 1_i
) ) 1_i
on IN N
synovial JJ N
tissue NN N
in IN N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS NNP N
Twelve NNP 1_p
patients NNS 1_p
with IN 1_p
RA NNP 1_p
entering VBG 1_p
a DT 1_p
randomized JJ 1_p
clinical JJ 1_p
trial NN 1_p
of IN 1_p
human JJ 1_i
recombinant JJ 1_i
IL-1Ra NNP 1_i
underwent NN N
synovial JJ 1_i
biopsies NNS 1_i
before IN N
and CC N
after IN N
treatment NN N
. . N

Cellular JJ 1_o
infiltration NN 1_o
and CC 1_o
adhesion NN 1_o
molecule NN 1_o
expression NN 1_o
were VBD N
evaluated VBN N
after IN N
immunohistochemical JJ N
staining NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
notable JJ N
reduction NN 1_o
in IN 1_o
intimal JJ 1_o
layer NN 1_o
macrophages NNS 1_o
and CC 1_o
subintimal JJ 1_o
macrophages NNS 1_o
and CC 1_o
lymphocytes NNS 1_o
after IN N
treatment NN N
with IN N
IL-1Ra NNP 1_i
at IN N
150 CD N
mg/day NN N
( ( N
n=3 JJ N
) ) N
. . N

Increased VBN N
cellular JJ 1_o
infiltration NN 1_o
was VBD N
observed VBN N
in IN N
all DT N
patients NNS N
receiving VBG N
placebo NN 1_i
( ( N
n=3 JJ N
) ) N
; : N
variable JJ N
changes NNS N
were VBD N
observed VBN N
after IN N
IL-1Ra NNP 1_i
30 CD N
mg/day NN N
( ( N
n=6 JJ N
) ) N
. . N

In IN N
a DT N
limited JJ N
study NN N
of IN N
adhesion NN N
molecule NN N
expression NN N
, , N
down-regulation NN 1_o
of IN 1_o
E-selectin NNP 1_o
and CC 1_o
vascular JJ 1_o
cell NN 1_o
adhesion NN 1_o
molecule-1 NN 1_o
was VBD N
observed VBN N
after IN N
treatment NN N
with IN N
IL-1Ra NNP 1_i
150 CD N
mg/day NN N
, , N
but CC N
not RB N
after IN N
IL-1Ra NNP 1_i
30 CD N
mg/day NN N
or CC N
placebo NN 1_i
. . 1_i

The DT N
apparent JJ N
arrest NN 1_o
of IN 1_o
progressive JJ 1_o
joint JJ 1_o
damage NN 1_o
seen VBN N
in IN N
four CD N
patients NNS N
after IN N
treatment NN N
with IN N
IL-1Ra NNP 1_i
was VBD N
associated VBN N
with IN N
reduced JJ N
intimal JJ N
layer NN N
macrophage NN N
accumulation NN N
in IN N
all DT N
patients NNS N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
RA NNP N
with IN N
IL-1Ra NNP 1_i
resulted VBD N
in IN N
reduced JJ N
mononuclear NN N
cell NN N
infiltration NN N
of IN N
synovial JJ N
membrane NN N
, , N
which WDT N
may MD N
represent VB N
the DT N
in IN N
vivo JJ N
inhibition NN N
of IN N
biologically RB N
relevant JJ N
IL-1ss-mediated JJ N
pathogenic JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Gene NNP 1_i
expression NN 1_i
of IN 1_i
endothelin-1 JJ 1_i
and CC 1_i
its PRP$ 1_i
receptors NNS 1_i
in IN N
the DT N
heart NN 1_p
of IN 1_p
broiler NN 1_p
chickens NNS 1_p
with IN 1_p
T NNP 1_p
( ( 1_p
3 CD 1_p
) ) 1_p
-induced VBD 1_p
pulmonary JJ 1_p
hypertension NN 1_p
. . 1_p

To TO N
investigate VB N
the DT N
effect NN N
of IN N
T NNP N
( ( N
3 CD N
) ) N
-induced VBD N
pulmonary JJ N
hypertension NN N
on IN N
endothelin NN N
( ( N
ET NNP N
) ) N
production NN N
and CC N
genes NNS 1_o
expression NN 1_o
of IN 1_o
ET-1 NNP 1_o
, , 1_o
ET NNP 1_o
( ( 1_o
A NNP 1_o
) ) 1_o
and CC 1_o
ET NNP 1_o
( ( 1_o
B NNP 1_o
) ) 1_o
receptors NNS 1_o
( ( 1_o
ET NNP 1_o
( ( 1_o
A NNP 1_o
) ) 1_o
R NNP 1_o
and CC 1_o
ET NNP 1_o
( ( 1_o
B NNP 1_o
) ) 1_o
R NNP 1_o
) ) 1_o
during IN N
rearing NN N
, , N
semiquantitative JJ 1_i
RT-PCR NNP 1_i
and CC 1_i
enzyme VB 1_i
immunometric JJ 1_i
assay NN 1_i
were VBD N
performed VBN N
in IN N
the DT N
heart NN N
ventricles NNS N
and CC N
serum NN N
, , N
respectively RB N
. . N

The DT N
ET-1 JJ 1_o
and CC 1_o
its PRP$ 1_o
receptor NN 1_o
genes NNS 1_o
were VBD N
expressed VBN N
in IN N
the DT N
right NN N
and CC N
left VBD N
ventricles NNS N
of IN N
control NN N
and CC N
T NNP N
( ( N
3 CD N
) ) N
-treated VBD N
broilers NNS N
at IN N
12 CD N
, , N
28 CD N
and CC N
49 CD N
days NNS N
of IN N
age NN N
. . N

There EX N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
reductions NNS 1_o
of IN 1_o
the DT 1_o
relative JJ 1_o
amounts NNS 1_o
of IN 1_o
ET-1 NNP 1_o
( ( 1_o
in IN 1_o
both DT 1_o
ventricles NNS 1_o
) ) 1_o
and CC 1_o
ET NNP 1_o
( ( 1_o
A NNP 1_o
) ) 1_o
R NNP 1_o
( ( 1_o
in IN 1_o
the DT 1_o
right JJ 1_o
ventricle NN 1_o
) ) 1_o
mRNAs NN 1_o
at IN N
28 CD N
and CC N
49 CD N
days NNS N
of IN N
age NN N
, , N
in IN N
T NNP N
( ( N
3 CD N
) ) N
-treated VBD N
broilers NNS N
compared VBN N
to TO N
controls NNS N
. . N

The DT N
relative JJ 1_o
amounts NNS 1_o
of IN 1_o
ET NNP 1_o
( ( 1_o
B NNP 1_o
) ) 1_o
R NNP 1_o
mRNA NN 1_o
in IN N
the DT N
right NN N
and CC N
left VBD N
ventricles NNS N
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
control NN N
and CC N
T NNP N
( ( N
3 CD N
) ) N
-treated VBD N
broilers NNS N
at IN N
any DT N
age NN N
. . N

The DT N
serum JJ 1_o
level NN 1_o
of IN 1_o
ET NNP 1_o
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
increased VBN N
in IN N
T NNP N
( ( N
3 CD N
) ) N
-treated VBD N
chickens NNS N
at IN N
28 CD N
and CC N
49 CD N
days NNS N
of IN N
age NN N
when WRB N
compared VBN N
with IN N
that DT N
of IN N
the DT N
control NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
ET-1 NNP 1_o
, , 1_o
ET NNP 1_o
( ( 1_o
A NNP 1_o
) ) 1_o
R NNP 1_o
and CC 1_o
ET NNP 1_o
( ( 1_o
B NNP 1_o
) ) 1_o
R NNP 1_o
genes NNS 1_o
are VBP N
normally RB N
expressed VBN N
in IN N
the DT N
heart NN N
ventricles NNS N
of IN N
broilers NNS N
. . N

It PRP N
is VBZ N
likely JJ N
that IN N
increased VBD N
serum JJ 1_o
level NN 1_o
of IN 1_o
ET NNP 1_o
and CC 1_o
decreased VBN 1_o
ET-1/ET NNP 1_o
( ( 1_o
A NNP 1_o
) ) 1_o
R NNP 1_o
genes NNS 1_o
expression NN 1_o
in IN N
the DT N
ventricles NNS N
are VBP N
involved VBN N
in IN N
the DT N
heart NN N
dysfunction NN N
of IN N
broiler NN 1_p
chickens NNS 1_p
with IN 1_p
developmental JJ 1_p
pulmonary JJ 1_p
hypertension NN 1_p
. . 1_p

-DOCSTART- -X- O O

Three-Arm NNP N
Randomized NNP N
Phase NNP N
III NNP N
Trial NNP N
: : N
Quality NN N
Aloe NNP 1_i
and CC 1_i
Placebo NNP 1_i
Cream NNP N
Versus NNP N
Powder NNP 1_i
as IN N
Skin NNP N
Treatment NNP N
During IN N
Breast NNP 1_p
Cancer NNP 1_p
Radiation NNP 1_p
Therapy NNP 1_p
. . 1_p

BACKGROUND NNP N
The DT N
efficacy NN N
of IN N
aloe JJ 1_i
extract NN 1_i
in IN N
reducing VBG N
radiation-induced JJ 1_o
skin JJ 1_o
injury NN 1_o
is VBZ N
controversial JJ N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
3-arm JJ N
randomized VBN N
trial NN N
was VBD N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
quality-tested JJ N
aloe NN N
extract NN N
in IN N
reducing VBG N
the DT N
severity NN N
of IN N
radiation-induced JJ N
skin JJ N
injury NN N
and CC N
, , N
secondarily RB N
, , N
to TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
moist NN 1_i
cream NN 1_i
versus IN N
a DT N
dry JJ 1_i
powder NN 1_i
skin NN 1_i
care NN 1_i
regimen NNS 1_i
. . 1_i

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
248 CD 1_p
patients NNS 1_p
with IN 1_p
breast JJ 1_p
cancer NN 1_p
were VBD N
randomized VBN N
to TO N
powder VB 1_i
, , 1_i
aloe VB 1_i
cream NN 1_i
, , N
or CC N
placebo NN 1_i
cream NN 1_i
. . 1_i

Acute NNP 1_o
skin JJ 1_o
toxicity NN 1_o
was VBD N
scored VBN N
weekly JJ N
and CC N
after IN N
treatment NN N
at IN N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
4 CD N
using VBG N
a DT N
modified VBN N
10-point JJ N
Catterall NNP N
scale NN N
. . N

The DT N
patients NNS N
scored VBD N
their PRP$ N
symptom JJ N
severity NN N
using VBG N
a DT N
6-point JJ N
Likert NNP N
scale NN N
and CC N
kept VBD N
an DT N
acute JJ N
phase NN N
diary NN N
. . N

RESULTS VB N
The DT N
aloe JJ N
formulation NN N
did VBD N
not RB N
reduce VB 1_o
acute JJ 1_o
skin NN 1_o
toxicity NN 1_o
or CC 1_o
symptom JJ 1_o
severity NN 1_o
. . 1_o

Patients NNS 1_p
with IN N
a DT N
greater JJR N
body NN N
mass NN N
index NN N
were VBD N
more RBR N
likely JJ N
to TO N
develop VB 1_o
acute JJ 1_o
skin NN 1_o
toxicity NN 1_o
. . 1_o

A DT N
similar JJ N
pattern NN N
of IN N
increased VBN N
skin NN 1_o
reaction NN 1_o
toxicity NN 1_o
occurred VBD N
with IN N
both DT N
study NN N
creams NNS N
compared VBN N
with IN N
the DT N
dry JJ N
powder NN N
regimen NNS N
. . N

CONCLUSION NNP N
No NNP N
evidence NN N
was VBD N
found VBN N
to TO N
support VB N
prophylactic JJ N
application NN N
of IN N
quality NN N
aloe VBP 1_i
extract NN 1_i
or CC N
cream NN N
to TO N
improve VB N
the DT N
symptoms NNS N
or CC N
reduce VB N
the DT N
skin NN 1_o
reaction NN 1_o
severity NN 1_o
. . 1_o

Our PRP$ N
results NNS N
support VB N
a DT N
dry JJ N
skin NN N
care NN N
regimen NNS N
of IN N
powder NN N
during IN N
radiation NN N
therapy NN N
. . N

-DOCSTART- -X- O O

Scent NN N
and CC N
mood NN N
state NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
water NN 1_i
, , 1_i
lavender NN 1_i
, , 1_i
or CC 1_i
rosemary JJ 1_i
scent NN 1_i
on IN N
physiology NN 1_o
and CC 1_o
mood NN 1_o
state NN 1_o
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT 1_p
nonsmoking JJ 1_p
participants NNS 1_p
, , 1_p
ages VBZ 1_p
18-30 CD 1_p
years NNS 1_p
, , 1_p
included VBD 1_p
42 CD 1_p
women NNS 1_p
and CC 1_p
31 CD 1_p
men NNS 1_p
who WP 1_p
reported VBD 1_p
demographic JJ 1_p
information NN 1_p
and CC 1_p
measures NNS 1_p
of IN 1_p
external JJ 1_p
temperature NN 1_p
and CC 1_p
heart NN 1_p
rate NN 1_p
were VBD 1_p
taken VBN 1_p
prior RB 1_p
to TO 1_p
introduction NN 1_p
of IN 1_p
an DT 1_p
anxiety-eliciting JJ 1_i
task NN 1_i
and CC 1_p
exposure NN 1_p
to TO 1_p
lavender VB 1_i
, , 1_i
rosemary JJ 1_i
, , 1_i
or CC 1_i
water NN 1_i
scents NNS 1_i
. . 1_i

Following VBG N
the DT N
task NN N
, , N
participants NNS N
completed VBD N
the DT N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
to TO N
assess VB N
mood NN 1_o
, , 1_o
and CC 1_o
temperature NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
were VBD N
reassessed VBN N
. . N

Participants NNS N
rated VBD N
the DT N
pleasantness NN N
of IN N
the DT N
scent NN N
received VBD N
. . N

When WRB N
pleasantness JJ N
ratings NNS N
of IN N
scent NN N
were VBD N
covaried VBN N
, , N
physiological JJ 1_o
changes NNS 1_o
in IN 1_o
temperature NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
did VBD N
not RB N
differ VB N
based VBN N
on IN N
scent NN N
exposure NN N
, , N
but CC N
mood VBD 1_o
ratings NNS 1_o
differed VBN N
by IN N
scent JJ N
condition NN N
. . N

Participants NNS N
in IN N
the DT N
rosemary JJ N
condition NN N
scored VBD N
higher JJR N
on IN N
measures NNS N
of IN N
tension-anxiety NN 1_o
and CC 1_o
confusion-bewilderment JJ 1_o
relative NN N
to TO N
the DT N
lavender NN N
and CC N
control NN N
conditions NNS N
. . N

The DT N
lavender NN N
and CC N
control NN N
conditions NNS N
showed VBD N
higher JJR N
mean JJ 1_o
vigor-activity NN 1_o
ratings NNS 1_o
relative VBP N
to TO N
the DT N
rosemary JJ N
group NN N
, , N
while IN N
both DT N
rosemary JJ N
and CC N
lavender JJ N
scents NNS N
were VBD N
associated VBN N
with IN N
lower JJR N
mean NN 1_o
ratings NNS 1_o
on IN 1_o
the DT 1_o
fatigue-inertia JJ 1_o
subscale NN 1_o
, , N
relative JJ N
to TO N
the DT N
control NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
, , N
when WRB N
individual JJ N
perception NN N
of IN N
scent JJ N
pleasantness NN N
is VBZ N
controlled VBN N
, , N
scent NN N
has VBZ N
the DT N
potential JJ N
to TO N
moderate VB N
different JJ N
aspects NNS N
of IN N
mood NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

-DOCSTART- -X- O O

Early JJ N
immunisation NN N
with IN N
hepatitis NN 1_i
B NNP 1_i
vaccine NN 1_i
: : 1_i
a DT N
five-year JJ N
study NN N
. . N

We PRP N
evaluated VBD N
the DT N
response NN N
to TO N
the DT N
recombinant NN 1_i
Hepatitis NNP 1_i
B NNP 1_i
vaccine NN 1_i
using VBG N
an DT N
accelerated JJ N
schedule NN N
versus IN N
the DT N
traditional JJ N
schedule NN N
by IN N
studying VBG N
the DT N
immunologic JJ N
memory NN N
induced VBN N
in IN N
200 CD 1_p
children NNS 1_p
with IN 1_p
HBs-Ag NNP 1_p
negative JJ 1_p
mothers NNS 1_p
. . 1_p

At IN N
seroconversion NN N
, , N
the DT N
traditional JJ N
schedule NN N
presented VBD N
a DT N
higher JJR N
percentage NN N
of IN N
children NNS 1_p
with IN 1_p
serum JJ 1_p
HBs-Ag JJ 1_p
concentrations NNS 1_p
over IN 1_p
100 CD 1_p
mIU/ml NNS 1_p
than IN 1_p
the DT 1_p
accelerated JJ 1_p
schedule NN 1_p
. . 1_p

After IN N
five CD N
years NNS N
this DT N
difference NN N
was VBD N
no RB N
longer RBR N
statistically RB N
significant JJ N
and CC N
children NNS 1_p
who WP 1_p
presented VBD 1_p
anti-HBsAg JJ 1_o
concentrations NNS 1_o
below IN 1_o
10 CD 1_o
mUI/ml NN 1_o
received VBD N
an DT N
additional JJ N
booster NN N
dose NN N
which WDT N
stimulated VBD N
the DT N
antibody NN 1_o
concentration NN 1_o
to TO 1_o
exceed VB 1_o
100 CD 1_o
mIU/ml NNS 1_o
in IN 1_o
all DT N
cases NNS N
. . N

Recombinant JJ 1_i
HBV NNP 1_i
vaccine NN 1_i
induced VBD N
better JJR N
long JJ N
term NN N
immunologic JJ 1_o
memory NN 1_o
when WRB N
it PRP N
was VBD N
administered VBN N
earlier RBR N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
Aloe NNP 1_i
arborescens NNS 1_i
Mill NNP 1_i
. . 1_i

extract NN 1_i
on IN N
selected VBN N
parameters NNS 1_o
of IN N
pro-oxidant-antioxidant JJ 1_o
equilibrium NN 1_o
and CC N
cytokine JJ 1_o
synthesis NN 1_o
in IN N
rowers NNS 1_p
. . 1_p

This DT N
investigation NN N
examined VBD N
the DT N
effect NN N
of IN N
supplementation NN 1_i
with IN 1_i
Biostimine NNP 1_i
, , 1_i
extract NN 1_i
from IN 1_i
Aloe NNP 1_i
arborescens NNS 1_i
Mill NNP 1_i
. . 1_i

leaves NNS 1_i
, , N
on IN N
the DT N
levels NNS N
of IN N
pro-oxidant-antioxidant JJ 1_o
equilibrium NN 1_o
markers NNS 1_o
and CC N
anti- JJ N
and CC N
proinflammatory JJ 1_o
cytokines NNS 1_o
in IN N
rowers NNS 1_p
subjected VBN 1_p
to TO 1_p
exhaustive VB 1_p
exercise NN 1_p
. . 1_p

This DT N
double-blind NN N
study NN 1_p
included VBD 1_p
18 CD 1_p
members NNS 1_p
of IN 1_p
the DT 1_p
Polish JJ 1_p
Rowing NNP 1_p
Team NNP 1_p
. . 1_p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
supplemented VBN N
group NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
, , N
which WDT N
received VBD N
one CD N
ampoule NN N
of IN N
Biostimine NNP 1_i
once RB N
daily RB N
for IN N
4 CD N
weeks NNS N
, , N
or CC N
to TO N
the DT N
placebo NN 1_i
group NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
. . N

Subjects NNS N
performed VBD N
a DT N
2,000-meter-maximum JJ N
test NN N
on IN N
a DT N
rowing NN N
ergometer NN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
preparatory NN N
camp NN N
. . N

Blood NN N
samples NNS N
were VBD N
obtained VBN N
from IN N
the DT N
antecubital JJ N
vein NN N
before IN N
each DT N
exercise NN N
test NN N
, , N
1 CD N
min NN N
after IN N
completing VBG N
the DT N
test NN N
and CC N
after IN N
a DT N
24-hr JJ N
recovery NN N
period NN N
. . N

Superoxide NNP 1_o
dismutase NN 1_o
and CC 1_o
glutathione NN 1_o
peroxidase NN 1_o
activity NN 1_o
as RB N
well RB N
as IN N
the DT 1_o
concentration NN 1_o
of IN 1_o
thiobarbituric JJ 1_o
acid NN 1_o
reactive JJ 1_o
substances NNS 1_o
( ( 1_o
TBARS NNP 1_o
) ) 1_o
were VBD N
assessed VBN N
in IN N
erythrocytes NNS N
. . N

In IN N
addition NN N
, , N
total JJ 1_o
antioxidant JJ 1_o
capacity NN 1_o
( ( 1_o
TAC NNP 1_o
) ) 1_o
and CC 1_o
creatine JJ 1_o
kinase NN 1_o
activity NN 1_o
were VBD N
measured VBN N
in IN N
plasma NN N
samples NNS N
, , N
and CC N
cytokine NN 1_o
( ( 1_o
IL-6 NNP 1_o
, , 1_o
IL-10 NNP 1_o
) ) 1_o
concentrations NNS 1_o
were VBD N
determined VBN N
in IN N
the DT N
serum NN N
. . N

Before IN N
and CC N
after IN N
Biostimine NNP 1_i
supplementation NN 1_i
, , N
exercise VBP N
significantly RB N
increased VBN N
the DT N
values NNS 1_o
of IN 1_o
SOD NNP 1_o
, , 1_o
IL-6 NNP 1_o
, , 1_o
IL-10 NNP 1_o
, , 1_o
and CC 1_o
TBARS NNP 1_o
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
postexercise NN N
and CC N
recovery NN N
levels NNS N
of IN N
TBARS NNP 1_o
were VBD N
significantly RB N
lower JJR N
in IN N
athletes NNS N
receiving VBG N
Biostimine NNP 1_i
than IN N
in IN N
controls NNS N
. . N

After IN N
supplementation NN N
, , N
TAC NNP 1_o
was VBD N
the DT N
only JJ N
variable NN N
with IN N
the DT N
level NN N
being VBG N
significantly RB N
higher RBR N
in IN N
the DT N
supplemented JJ N
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

Consequently RB N
, , N
we PRP N
can MD N
conclude VB N
that DT N
Biostimine NNP 1_i
supplementation NN 1_i
reduces VBZ N
the DT N
postexercise NN N
level NN N
of IN N
TBARS NNP 1_o
by IN N
increasing VBG N
the DT N
antioxidant JJ 1_o
activity NN 1_o
of IN 1_o
plasma NN 1_o
but CC N
has VBZ N
no DT N
effect NN N
on IN N
inflammatory NN 1_o
markers NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Combined VBN 1_i
chemotherapy NN 1_i
and CC 1_i
radiotherapy NN 1_i
compared VBN N
with IN N
radiotherapy NN 1_i
alone RB 1_i
in IN N
patients NNS 1_p
with IN 1_p
cancer NN 1_p
of IN 1_p
the DT 1_p
esophagus NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
conventional JJ N
treatment NN N
with IN N
surgery NN N
and CC N
radiation NN N
for IN N
cancer NN N
of IN N
the DT N
esophagus NN N
is VBZ N
limited VBN N
. . N

The DT N
median JJ N
survival NN N
is VBZ N
less JJR N
than IN N
10 CD N
months NNS N
, , N
and CC N
less JJR N
than IN N
10 CD N
percent NN N
of IN N
patients NNS N
survive VBP N
for IN N
5 CD N
years NNS N
. . N

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
combined JJ 1_i
chemotherapy NN 1_i
and CC 1_i
radiation NN 1_i
therapy NN 1_i
may MD N
result VB N
in IN N
improved JJ N
survival NN N
. . N

METHODS NNP N
This DT N
phase NN N
III NNP N
prospective NN N
, , N
randomized VBN N
, , N
and CC N
stratified VBD N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
four CD N
courses NNS N
of IN N
combined JJ N
fluorouracil NN 1_i
( ( 1_i
1000 CD 1_i
mg NN 1_i
per IN 1_i
square JJ 1_i
meter NN 1_i
of IN 1_i
body-surface JJ 1_i
area NN 1_i
daily RB 1_i
for IN 1_i
four CD 1_i
days NNS 1_i
) ) 1_i
and CC 1_i
cisplatin NN 1_i
( ( 1_i
75 CD 1_i
mg NN 1_i
per IN 1_i
square JJ 1_i
meter NN 1_i
on IN 1_i
the DT 1_i
first JJ 1_i
day NN 1_i
) ) 1_i
plus CC 1_i
5000 CD 1_i
cGy NN 1_i
of IN 1_i
radiation NN 1_i
therapy NN 1_i
, , N
as IN N
compared VBN N
with IN N
6400 CD 1_i
cGy NN 1_i
of IN 1_i
radiation NN 1_i
therapy NN 1_i
alone RB N
, , N
in IN N
patients NNS N
with IN N
squamous-cell JJ N
carcinoma NN N
or CC N
adenocarcinoma NN N
of IN N
the DT N
thoracic NN N
esophagus NN N
. . N

The DT N
trial NN N
was VBD N
stopped VBN N
after IN N
the DT N
accumulated JJ N
results NNS N
in IN N
121 CD 1_p
patients NNS 1_p
demonstrated VBD 1_p
a DT 1_p
significant JJ 1_p
advantage NN 1_p
for IN 1_p
survival NN 1_p
in IN 1_p
the DT 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
chemotherapy NN 1_i
and CC 1_i
radiation NN 1_i
therapy NN 1_i
. . 1_i

RESULTS VB N
The DT N
median JJ 1_o
survival NN 1_o
was VBD N
8.9 CD N
months NNS N
in IN N
the DT N
radiation-treated JJ N
patients NNS N
, , N
as IN N
compared VBN N
with IN N
12.5 CD N
months NNS N
in IN N
the DT N
patients NNS N
treated VBN N
with IN N
chemotherapy NN 1_i
and CC 1_i
radiation NN 1_i
therapy NN 1_i
. . 1_i

In IN N
the DT N
former JJ N
group NN N
, , N
the DT N
survival NN 1_o
rates NNS 1_o
at IN N
12 CD N
and CC N
24 CD N
months NNS N
were VBD N
33 CD N
percent NN N
and CC N
10 CD N
percent NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
50 CD N
percent NN N
and CC N
38 CD N
percent NN N
in IN N
the DT N
patients NNS N
receiving VBG N
combined VBN 1_i
therapy NN 1_i
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Seven JJ 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
radiotherapy NN 1_i
group NN 1_p
and CC 1_p
25 CD 1_p
in IN 1_p
the DT 1_p
combined-therapy JJ 1_i
group NN 1_p
were VBD N
alive JJ 1_o
at IN N
the DT N
time NN N
of IN N
the DT N
analysis NN N
. . N

The DT N
patients NNS N
who WP N
received VBD N
combined JJ N
treatment NN N
had VBD N
fewer JJR N
local JJ 1_o
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
fewer JJR N
distant NN 1_o
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
recurrences NNS 1_o
. . 1_o

Severe NNP 1_o
and CC 1_o
life-threatening JJ 1_o
side NN 1_o
effects NNS 1_o
occurred VBD N
in IN N
44 CD N
percent NN N
and CC N
20 CD N
percent NN N
, , N
respectively RB N
, , N
of IN N
the DT N
patients NNS N
who WP N
received VBD N
combined JJ N
therapy NN N
, , N
as IN N
compared VBN N
with IN N
25 CD N
percent NN N
and CC N
3 CD N
percent NN N
of IN N
those DT N
treated VBN N
with IN N
radiation NN N
alone RB N
. . N

CONCLUSIONS NNP N
Concurrent NNP 1_i
therapy NN 1_i
with IN 1_i
cisplatin NN 1_i
and CC 1_i
fluorouracil NN 1_i
and CC 1_i
radiation NN 1_i
is VBZ N
superior JJ N
to TO N
radiation VB 1_i
therapy NN 1_i
alone RB N
in IN N
patients NNS N
with IN N
localized JJ N
carcinoma NN N
of IN N
the DT N
esophagus NN N
, , N
as IN N
measured VBN N
by IN N
control NN N
of IN N
local JJ N
tumors NNS N
, , N
distant JJ N
metastases NNS N
, , N
and CC N
survival NN N
, , N
but CC N
at IN N
the DT N
cost NN N
of IN N
increased JJ N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

Safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
chimpanzee JJ 1_i
adenovirus-vectored JJ 1_i
Ebola NNP 1_i
vaccine NN 1_i
in IN N
healthy JJ 1_p
adults NNS 1_p
: : 1_p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
dose-finding JJ N
, , N
phase VB N
1/2a CD N
study NN N
. . N

BACKGROUND NNP N
The DT N
ongoing JJ N
Ebola NNP N
outbreak NN N
led VBD N
to TO N
accelerated VBN N
efforts NNS N
to TO N
test VB N
vaccine NN N
candidates NNS N
. . N

On IN N
the DT N
basis NN N
of IN N
a DT N
request NN N
by IN N
WHO NNP N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
monovalent NN 1_i
, , 1_i
recombinant NN 1_i
, , 1_i
chimpanzee JJ 1_i
adenovirus JJ 1_i
type-3 JJ 1_i
vector-based JJ 1_i
Ebola NNP 1_i
Zaire NNP 1_i
vaccine NN 1_i
( ( 1_i
ChAd3-EBO-Z NNP 1_i
) ) 1_i
. . 1_i

METHODS NNP N
We PRP N
did VBD N
this DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
dose-finding JJ N
, , N
phase VB N
1/2a CD N
trial NN N
at IN N
the DT N
Centre NNP 1_p
Hospitalier NNP 1_p
Universitaire NNP 1_p
Vaudois NNP 1_p
, , 1_p
Lausanne NNP 1_p
, , 1_p
Switzerland NNP 1_p
. . 1_p

Participants NNS 1_p
( ( 1_p
aged VBN 1_p
18-65 CD 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
( ( N
2:2:1 CD N
) ) N
, , N
via IN N
two CD N
computer-generated JJ N
randomisation NN N
lists NNS N
for IN N
individuals NNS 1_p
potentially RB 1_p
deployed VBN 1_p
in IN 1_p
endemic JJ 1_p
areas NNS 1_p
and CC 1_p
those DT 1_p
not RB 1_p
deployed VBN 1_p
, , N
to TO N
receive VB N
a DT N
single JJ N
intramuscular NN N
dose NN N
of IN N
high-dose JJ 1_i
vaccine NN 1_i
( ( N
5 CD N
? . N
10 CD N
( ( N
10 CD N
) ) N
viral JJ N
particles NNS 1_i
) ) 1_i
, , 1_i
low-dose JJ 1_i
vaccine NN 1_i
( ( 1_i
2?5 CD 1_i
? . N
10 CD N
( ( N
10 CD N
) ) N
viral JJ N
particles NNS N
) ) N
, , N
or CC 1_i
placebo NN 1_i
. . N

Deployed VBN N
participants NNS N
were VBD N
allocated VBN N
to TO N
only RB N
the DT N
vaccine NN N
groups NNS N
. . N

Group NNP N
allocation NN N
was VBD N
concealed VBN N
from IN N
non-deployed JJ N
participants NNS N
, , N
investigators NNS N
, , N
and CC N
outcome JJ N
assessors NNS N
. . N

The DT N
safety NN N
evaluation NN N
was VBD N
not RB N
masked VBN N
for IN N
potentially RB N
deployed JJ N
participants NNS N
, , N
who WP N
were VBD N
therefore RB N
not RB N
included VBN N
in IN N
the DT N
safety NN N
analysis NN N
for IN N
comparison NN N
between IN N
the DT N
vaccine NN N
doses NNS N
and CC N
placebo NN N
, , N
but CC N
were VBD N
pooled VBN N
with IN N
the DT N
non-deployed JJ N
group NN N
to TO N
compare VB N
immunogenicity NN N
. . N

The DT N
main JJ N
objectives NNS N
were VBD N
safety NN N
and CC N
immunogenicity NN N
of IN N
ChAd3-EBO-Z NNP N
. . N

We PRP N
did VBD N
analysis NN N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT02289027 NNP N
. . 1_p

FINDINGS NNP 1_p
Between NNP 1_p
Oct NNP 1_p
24 CD 1_p
, , 1_p
2014 CD 1_p
, , 1_p
and CC 1_p
June NNP 1_p
22 CD 1_p
, , 1_p
2015 CD 1_p
, , 1_p
we PRP 1_p
randomly VBP 1_p
assigned VBN 1_p
120 CD 1_p
participants NNS 1_p
, , 1_p
of IN 1_p
whom WP 1_p
18 CD 1_p
( ( 1_p
15 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
potentially RB 1_p
deployed VBN 1_p
and CC 1_p
102 CD 1_p
( ( 1_p
85 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
non-deployed JJ 1_p
, , 1_p
to TO 1_p
receive VB 1_p
high-dose JJ 1_p
vaccine NN 1_p
( ( 1_p
n=49 JJ 1_p
) ) 1_p
, , 1_p
low-dose JJ 1_p
vaccine NN 1_p
( ( 1_p
n=51 JJ 1_p
) ) 1_p
, , 1_p
or CC 1_p
placebo NN 1_p
( ( 1_p
n=20 JJ 1_p
) ) 1_p
. . 1_p

Participants NNS 1_p
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

No DT N
vaccine-related JJ 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD 1_o
reported VBN N
. . N

We PRP N
recorded VBD N
local JJ 1_o
adverse JJ 1_o
events NNS 1_o
in IN 1_o
30 CD N
( ( N
75 CD N
% NN N
) ) N
of IN N
40 CD N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
33 CD N
( ( N
79 CD N
% NN N
) ) N
of IN N
42 CD N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
five CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
20 CD N
participants NNS N
in IN N
the DT N
placebo NN N
group NN 1_o
. . 1_o

Fatigue NNP 1_o
or CC 1_o
malaise NN 1_o
was VBD N
the DT N
most RBS N
common JJ N
systemic JJ N
adverse JJ N
event NN N
, , N
reported VBD N
in IN N
25 CD N
( ( N
62 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
25 CD N
( ( N
60 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
five CD N
( ( N
25 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
placebo NN N
group NN N
, , N
followed VBN N
by IN N
headache NN N
, , N
reported VBD N
in IN N
23 CD N
( ( N
57 CD N
% NN N
) ) N
, , N
25 CD N
( ( N
60 CD N
% NN N
) ) N
, , N
and CC N
three CD N
( ( N
15 CD N
% NN N
) ) N
participants NNS N
, , N
respectively RB 1_o
. . 1_o

Fever NNP 1_o
occurred VBD 1_o
24 CD N
h NN N
after IN N
injection NN N
in IN N
12 CD N
( ( N
30 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
and CC N
11 CD N
( ( N
26 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
versus IN N
one CD N
( ( N
5 CD N
% NN N
) ) N
participant NN N
in IN N
the DT N
placebo NN N
group NN 1_o
. . 1_o

Geometric NNP 1_o
mean JJ 1_o
concentrations NNS 1_o
of IN 1_o
IgG NNP 1_o
antibodies NNS 1_o
against IN 1_o
Ebola NNP 1_o
glycoprotein NN 1_o
peaked VBD 1_o
on IN 1_o
day NN N
28 CD N
at IN N
51 CD N
?g/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
41?1-63?3 CD N
) ) N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
44?9 CD N
?g/mL NN N
( ( N
25?8-56?3 JJ N
) ) N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
5?2 CD N
?g/mL NN N
( ( N
3?5-7?6 JJ N
) ) N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
respective JJ N
response NN N
rates NNS N
of IN N
96 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
85?7-99?5 CD N
) ) N
, , N
96 CD N
% NN N
( ( N
86?5-99?5 JJ N
) ) N
, , N
and CC N
5 CD N
% NN N
( ( N
0?1-24?9 JJ 1_o
) ) 1_o
. . 1_o

Geometric JJ 1_o
mean JJ 1_o
concentrations NNS 1_o
decreased VBN 1_o
by IN N
day NN N
180 CD N
to TO N
25?5 CD N
?g/mL NNS N
( ( N
95 CD N
% NN N
CI NNP N
20?6-31?5 CD N
) ) N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
22?1 CD N
?g/mL NN N
( ( N
19?3-28?6 JJ N
) ) N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
3?2 CD N
?g/mL NN N
( ( N
2?4-4?9 JJ N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

28 CD N
( ( N
57 CD N
% NN N
) ) N
participants NNS N
given VBN N
high-dose JJ N
vaccine NN N
and CC N
31 CD N
( ( N
61 CD N
% NN N
) ) N
participants NNS N
given VBN N
low-dose JJ N
vaccine NN N
developed VBD 1_o
glycoprotein-specific JJ 1_o
CD4 NNP 1_o
cell NN 1_o
responses NNS 1_o
, , 1_o
and CC 1_o
33 CD 1_o
( ( 1_o
67 CD 1_o
% NN 1_o
) ) 1_o
and CC 1_o
35 CD 1_o
( ( N
69 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
developed VBD N
CD8 NNP N
responses NNS N
. . N

INTERPRETATION NNP N
ChAd3-EBO-Z NNP N
was VBD 1_o
safe JJ 1_o
and CC 1_o
well RB 1_o
tolerated VBN 1_o
, , N
although IN N
mild NN N
to TO N
moderate VB N
systemic JJ N
adverse JJ N
events NNS N
were VBD N
common JJ N
. . N

A DT N
single JJ N
dose NN N
was VBD N
immunogenic JJ N
in IN N
almost RB N
all DT N
vaccine NN N
recipients NNS N
. . N

Antibody NN N
responses NNS N
were VBD N
still RB N
significantly RB N
present JJ N
at IN N
6 CD N
months NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
doses NNS N
for IN N
safety NN N
and CC N
immunogenicity NN N
outcomes RB N
. . N

This DT N
acceptable JJ N
safety NN N
profile NN N
provides VBZ N
a DT N
reliable JJ N
basis NN N
to TO N
proceed VB N
with IN N
phase NN N
2 CD N
and CC N
phase VB N
3 CD N
efficacy NN N
trials NNS N
in IN N
Africa NNP N
. . N

FUNDING NN N
Swiss JJ N
State NNP N
Secretariat NNP N
for IN N
Education NNP N
, , N
Research NNP N
and CC N
Innovation NNP N
( ( N
SERI NNP N
) ) N
, , N
through IN N
the DT N
EU NNP N
Horizon NNP N
2020 CD N
Research NNP N
and CC N
Innovation NNP N
Programme NNP N
. . N

-DOCSTART- -X- O O

Protective JJ N
effect NN N
of IN N
1-adamantanamine JJ 1_i
hydrochloride NN 1_i
on IN N
influenza NN 1_p
A2 NNP 1_p
infections NNS 1_o
in IN 1_p
the DT 1_p
family NN 1_p
environment NN 1_p
: : 1_p
a DT N
controlled VBN N
double-blind NN N
study NN N
. . N

-DOCSTART- -X- O O

Early RB N
clinical JJ N
outcomes NNS N
and CC N
toxicity NN N
of IN N
intensity NN N
modulated VBN N
versus IN N
conventional JJ N
pelvic JJ N
radiation NN N
therapy NN N
for IN N
locally RB 1_p
advanced JJ 1_p
cervix NN 1_p
carcinoma NN 1_p
: : 1_p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
toxicity NN 1_o
and CC 1_o
clinical JJ 1_o
outcome NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
locally RB 1_p
advanced JJ 1_p
cervical JJ 1_p
cancer NN 1_p
( ( 1_p
LACC NNP 1_p
) ) 1_p
treated VBD N
with IN N
whole JJ 1_i
pelvic JJ 1_i
conventional JJ 1_i
radiation NN 1_i
therapy NN 1_i
( ( N
WP-CRT NNP N
) ) N
versus NN N
intensity NN 1_i
modulated VBN 1_i
radiation NN 1_i
therapy NN 1_i
( ( N
WP-IMRT NNP N
) ) N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP 1_p
January NNP 1_p
2010 CD 1_p
and CC 1_p
January NNP 1_p
2012 CD 1_p
, , 1_p
44 CD 1_p
patients NNS 1_p
with IN 1_p
International NNP 1_p
Federation NNP 1_p
of IN 1_p
Gynecology NNP 1_p
and CC 1_p
Obstetrics NNP 1_p
( ( 1_p
FIGO NNP 1_p
2009 CD 1_p
) ) 1_p
stage NN 1_p
IIB-IIIB NNP 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
cervix NN 1_p
were VBD 1_p
randomized VBN 1_i
to TO 1_i
receive VB 1_i
50.4 CD 1_i
Gy NNP 1_i
in IN 1_i
28 CD 1_i
fractions NNS 1_i
delivered VBN 1_i
via IN 1_i
either DT 1_i
WP-CRT JJ 1_i
or CC 1_i
WP-IMRT JJ 1_i
with IN 1_i
concurrent JJ 1_i
weekly JJ 1_i
cisplatin NN 1_i
40 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
. . 1_i

Acute NNP 1_o
toxicity NN 1_o
was VBD 1_i
graded VBN 1_i
according VBG 1_i
to TO 1_i
the DT 1_i
Common NNP 1_o
Terminology NNP 1_o
Criteria NNP 1_o
for IN 1_o
Adverse NNP 1_o
Events NNP 1_o
, , 1_o
version NN 1_o
3.0 CD 1_o
, , 1_o
and CC 1_o
late JJ 1_o
toxicity NN 1_o
was VBD 1_o
graded VBN 1_o
according VBG 1_o
to TO 1_o
the DT 1_o
Radiation NNP 1_o
Therapy NNP 1_o
Oncology NNP 1_o
Group NNP 1_o
system NN 1_o
. . 1_o

The DT N
primary JJ N
and CC N
secondary JJ N
endpoints NNS N
were VBD N
acute JJ 1_o
gastrointestinal JJ 1_o
toxicity NN 1_o
and CC N
disease-free JJ 1_o
survival NN 1_o
, , N
respectively RB N
. . N

RESULTS NNP N
Of IN N
44 CD N
patients NNS N
, , N
22 CD N
patients NNS N
received VBD N
WP-CRT NNP 1_i
and CC N
22 CD N
received VBD N
WP-IMRT NNP 1_i
. . 1_i

In IN N
the DT N
WP-CRT JJ 1_i
arm NN N
, , N
13 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
9 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
; : N
in IN N
the DT N
IMRT NNP 1_i
arm NN N
, , N
12 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
10 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
. . N

The DT N
median JJ N
follow-up JJ N
time NN N
in IN N
the DT N
WP-CRT JJ N
arm NN N
was VBD N
21.7 CD N
months NNS N
( ( N
range NN N
, , N
10.7-37.4 JJ N
months NNS N
) ) N
, , N
and CC N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
it PRP N
was VBD N
21.6 CD N
months NNS N
( ( N
range NN N
, , N
7.7-34.4 JJ N
months NNS N
) ) N
. . N

At IN N
27 CD N
months NNS N
, , N
disease-free JJ 1_o
survival NN 1_o
was VBD N
79.4 CD N
% NN N
in IN N
the DT N
WP-CRT NNP 1_i
group NN N
versus VBD N
60 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP 1_i
group NN N
( ( N
P=.651 NNP N
) ) N
, , N
and CC N
overall JJ 1_o
survival NN 1_o
was VBD N
76 CD N
% NN N
in IN N
the DT N
WP-CRT NNP N
group NN N
versus VBD N
85.7 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP N
group NN N
( ( N
P=.645 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
experienced VBD N
significantly RB N
fewer JJR N
grade NN 1_o
?2 NNP 1_o
acute VBZ 1_o
gastrointestinal JJ 1_o
toxicities NNS 1_o
( ( 1_o
31.8 CD N
% NN N
vs JJ N
63.6 CD N
% NN N
, , N
P=.034 NNP N
) ) N
and CC N
grade JJ N
?3 NNP N
gastrointestinal JJ 1_o
toxicities NNS 1_o
( ( 1_o
4.5 CD 1_o
% NN N
vs JJ N
27.3 CD N
% NN N
, , N
P=.047 NNP N
) ) N
than IN N
did VBD N
patients NNS N
receiving VBG N
WP-CRT NNP N
and CC N
had VBD N
less JJR N
chronic JJ 1_o
gastrointestinal JJ 1_o
toxicity NN 1_o
( ( 1_o
13.6 CD 1_o
% NN N
vs JJ N
50 CD N
% NN N
, , N
P=.011 NNP N
) ) N
. . N

CONCLUSION NNP 1_i
WP-IMRT NNP 1_i
is VBZ 1_i
associated VBN N
with IN N
significantly RB 1_o
less JJR 1_o
toxicity NN 1_o
compared VBN 1_o
with IN N
WP-CRT NNP 1_i
and CC 1_i
has VBZ N
a DT N
comparable JJ 1_o
clinical JJ 1_o
outcome NN 1_o
. . 1_o

Further JJ 1_o
studies NNS N
with IN N
larger JJR N
sample NN N
sizes NNS N
and CC N
longer JJR N
follow-up JJ N
times NNS N
are VBP N
warranted VBN N
to TO N
justify VB N
its PRP$ N
use NN N
in IN N
routine JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Errors NNS N
during IN N
the DT N
preparation NN N
of IN N
drug NN N
infusions NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
We PRP N
investigated VBD N
the DT N
extent NN N
and CC N
frequency NN N
of IN N
dose JJ N
errors NNS N
and CC N
treatment NN N
delays NNS N
made VBN N
as IN N
a DT N
consequence NN N
of IN N
preparing VBG N
drug NN 1_i
infusions NNS 1_i
at IN 1_i
the DT 1_i
bedside NN 1_i
, , N
rather RB N
than IN N
using VBG N
pre-filled JJ 1_i
syringes NNS 1_i
. . 1_i

METHODS NNP N
Forty-eight JJ 1_p
nurses NNS 1_p
with IN 1_p
critical JJ 1_p
care NN 1_p
experience NN 1_p
volunteered VBD 1_p
to TO 1_p
take VB 1_p
part NN 1_p
in IN 1_p
this DT 1_p
randomized VBN 1_p
, , 1_p
blinded VBD 1_p
, , 1_p
controlled VBD 1_p
study NN 1_p
conducted VBN 1_p
in IN 1_p
the DT 1_p
simulation NN 1_p
centre NN 1_p
of IN 1_p
an DT 1_p
urban JJ 1_p
hospital NN 1_p
. . 1_p

They PRP N
assisted VBD N
in IN N
the DT N
management NN N
of IN N
a DT N
simulated JJ 1_p
patient NN 1_p
with IN 1_p
septic JJ 1_p
shock NN 1_p
. . 1_p

Vasopressor NNP 1_i
infusions NNS 1_i
were VBD N
prepared VBN N
either RB N
by IN N
diluting VBG 1_i
concentrated VBN 1_i
drugs NNS 1_i
from IN 1_i
ampoules NNS 1_i
or CC N
were VBD N
provided VBN N
in IN N
syringes NNS 1_i
pre-filled JJ 1_i
beforehand NN N
by IN N
an DT N
intensive JJ N
care NN N
unit NN N
resident NN N
. . N

RESULTS VB N
The DT N
time NN N
taken VBN N
for IN N
the DT N
infusion NN N
to TO N
be VB N
started VBN N
and CC N
the DT N
final JJ 1_o
concentration NN 1_o
of IN 1_o
the DT 1_o
drugs NNS 1_o
were VBD 1_o
measured VBN 1_o
. . 1_o

We PRP N
also RB N
measured VBD N
the DT N
concentration NN 1_o
of IN 1_o
infusions NNS 1_o
prepared VBN N
by IN N
a DT N
pharmacist NN N
and CC N
a DT N
pharmaceutical JJ N
company NN N
. . N

Nurses NNS N
took VBD N
156 CD N
s NN N
to TO N
start VB N
infusions NNS N
when WRB N
using VBG N
pre-filled JJ 1_i
syringes NNS 1_i
compared VBN N
with IN N
276 CD N
s NNS N
when WRB N
preparing VBG N
them PRP N
de FW N
novo FW N
, , N
a DT N
mean JJ N
delay NN N
of IN N
106 CD N
s NNS N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
73-140 CD N
s NN N
, , N
P NNP N
< VBZ N
0.0001 CD N
] NN N
. . N

One CD N
infusion NN N
prepared VBN N
from IN N
ampoules NNS N
contained VBN N
one-fifth CD N
of IN N
the DT N
expected JJ N
concentration NN N
of IN N
epinephrine NN 1_i
; : 1_i
another DT N
contained VBD N
none NN N
at IN N
all DT N
. . N

Medication NNP 1_o
errors NNS 1_o
were VBD N
17.0 CD N
times NNS N
less RBR N
likely JJ N
when WRB N
pre-filled JJ 1_i
syringes NNS 1_i
were VBD N
used VBN N
( ( N
95 CD N
% NN N
CI NNP N
5.2-55.5 CD N
) ) N
, , N
and CC N
infusions NNS 1_i
prepared VBN N
by IN N
pharmacy NN N
and CC N
industry NN N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
contain VB N
the DT N
expected JJ N
concentration NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
for IN N
norepinephrine NN 1_i
and CC N
P=0.001 NNP N
for IN N
epinephrine NN 1_i
) ) 1_i
. . N

CONCLUSIONS NNP N
Providing VBG N
drug NN 1_i
infusions NNS 1_i
in IN N
syringes NNS N
pre-filled VBN 1_i
by IN N
pharmacists NNS N
or CC N
pharmaceutical JJ N
companies NNS N
would MD N
reduce VB N
medication NN 1_o
errors NNS 1_o
and CC 1_o
treatment NN 1_o
delays NNS 1_o
, , N
and CC N
improve VB N
patient NN 1_o
safety NN 1_o
. . 1_o

However RB N
, , N
this DT N
approach NN N
would MD N
have VB N
substantial JJ N
financial JJ N
implications NNS N
for IN N
healthcare NN N
providers NNS N
, , N
especially RB N
in IN N
less JJR N
developed JJ N
countries NNS N
. . N

-DOCSTART- -X- O O

Two-year JJ N
prospective JJ N
clinical JJ N
comparison NN N
of IN N
immediate JJ 1_i
replacement NN 1_i
vs. FW 1_i
immediate JJ 1_i
restoration NN 1_i
of IN 1_i
single JJ 1_i
tooth NN 1_i
in IN 1_p
the DT 1_p
esthetic JJ 1_p
zone NN 1_p
. . 1_p

AIM NNP N
To TO N
compare VB N
the DT N
immediate JJ N
restoration NN N
of IN N
single JJ 1_i
implants NNS 1_i
in IN N
the DT N
esthetic JJ N
zones NNS N
performed VBN N
on IN N
implants NNS N
placed VBN N
immediately RB N
after IN N
tooth JJ N
extraction NN N
or CC N
8 CD N
weeks NNS N
later RB N
( ( N
immediate JJ N
replacement NN 1_i
vs. FW N
immediate JJ N
restoration NN 1_i
) ) 1_i
. . N

METHODS NNP N
Sixteen JJ 1_p
patients NNS 1_p
( ( 1_p
10 CD 1_p
women NNS 1_p
and CC 1_p
6 CD 1_p
men NNS 1_p
) ) 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
35 CD 1_p
years NNS 1_p
( ( 1_p
ranging VBG 1_p
from IN 1_p
21 CD 1_p
to TO 1_p
49 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
were VBD 1_p
treated VBN 1_p
from IN 1_p
2004 CD 1_p
to TO 1_p
2005 CD 1_p
for IN 1_p
single-tooth JJ 1_p
replacement NN 1_p
in IN 1_p
the DT 1_p
upper JJ 1_p
arch NN 1_p
. . 1_p

The DT 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN N
two CD N
groups NNS N
: : N
in IN N
the DT N
test NN N
group NN N
patients NNS N
received VBD N
implants NNS 1_i
placed VBN 1_i
and CC 1_i
restored VBN 1_i
( ( N
non-occlusal JJ N
loading NN N
) ) N
at IN N
the DT N
time NN N
of IN N
tooth JJ N
extraction NN N
; : N
in IN N
the DT N
control NN N
group NN N
implants NNS 1_i
were VBD 1_i
placed VBN 1_i
8 CD N
weeks NNS N
after IN 1_i
tooth DT 1_i
extraction NN 1_i
and CC 1_i
immediately RB 1_i
restored VBN 1_i
. . 1_i

All PDT 1_p
the DT 1_p
patients NNS 1_p
received VBD 1_p
tapered JJ 1_i
effect NN 1_i
( ( 1_i
TE NNP 1_i
) ) 1_i
implants NNS 1_i
from IN 1_p
the DT 1_p
Straumann NNP 1_p
Dental NNP 1_p
Implant NNP 1_p
System NNP 1_p
. . 1_p

The DT N
following JJ N
parameters NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
moment NN N
of IN N
provisional JJ N
restoration NN N
( ( N
within IN N
48 CD N
h NN N
after IN N
implant JJ N
placement NN N
) ) N
and CC N
at IN N
the DT N
2 CD N
years NNS N
follow-up JJ N
visit NN N
: : N
marginal JJ 1_o
bone NN 1_o
resorption NN 1_o
, , 1_o
papilla NN 1_o
index NN 1_o
, , 1_o
position NN 1_o
of IN 1_o
the DT 1_o
mucosal NN 1_o
margin NN 1_o
. . 1_o

The DT N
implant JJ 1_o
stability NN 1_o
quotient NN 1_o
was VBD N
measured VBN N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
and CC N
at IN N
the DT N
moment NN N
of IN N
the DT N
delivery NN N
of IN N
the DT N
definitive JJ N
restoration NN N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
studied JJ N
parameters NNS N
between IN N
the DT N
test NN N
and CC N
the DT N
control NN N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
implant JJ 1_o
stability NN 1_o
quotient NN 1_o
values NNS 1_o
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
but CC N
were VBD N
no DT N
more RBR N
significant JJ N
at IN N
the DT N
loading NN N
of IN N
the DT N
definitive JJ N
restoration NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
suggest VBP N
that IN N
immediate JJ N
replacement NN N
without IN N
functional JJ N
loading NN N
may MD N
be VB N
considered VBN N
a DT N
valuable JJ N
therapeutic JJ N
option NN N
for IN N
selected VBN N
cases NNS N
of IN N
single-tooth JJ 1_i
replacement NN 1_i
in IN N
the DT N
esthetic JJ N
area NN N
when WRB N
TE NNP N
implants NNS N
are VBP N
used VBN N
. . N

Implant JJ 1_o
stability NN 1_o
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
is VBZ N
slightly RB N
inferior JJ N
in IN N
the DT N
immediate JJ N
replacement NN N
group NN N
, , N
but CC N
it PRP N
does VBZ N
not RB N
affect VB N
the DT N
treatment NN N
result NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
ibuprofen NN 1_i
on IN N
cyclooxygenase NN 1_o
and CC 1_o
nitric JJ 1_o
oxide JJ 1_o
synthase NN 1_o
of IN 1_o
gastric JJ 1_o
mucosa NN 1_o
: : 1_o
correlation NN N
with IN N
endoscopic JJ 1_o
lesions NNS 1_o
and CC 1_o
adverse JJ 1_o
reactions NNS 1_o
. . 1_o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ibuprofen NN 1_i
on IN N
gastric JJ 1_o
mucosa NN 1_o
and CC 1_o
enzymes NNS 1_o
involved VBN 1_o
in IN 1_o
gastroprotection NN 1_o
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

Twenty-four JJ 1_p
Helicobacter NNP 1_p
pylori-negative JJ 1_p
subjects NNS 1_p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
ibuprofen NN 1_i
or CC 1_i
ibuprofen-arginate NN 1_i
( ( N
each DT N
600 CD N
mg/6 NN N
hr NN N
during IN N
3 CD N
days NNS N
) ) N
. . N

Endoscopies NNS 1_i
were VBD N
performed VBN N
1 CD N
week NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Biopsies NNS N
were VBD N
taken VBN N
from IN N
the DT N
gastric JJ N
antrum NN N
and CC N
corpus NN N
for IN N
determination NN N
of IN N
prostaglandin NN N
E2 NNP N
( ( N
PGE2 NNP N
) ) N
by IN N
ELISA NNP 1_i
and CC N
cyclooxygenase NN N
( ( N
COX-1 JJ N
and CC N
COX-2 NNP N
) ) N
and CC N
nitric JJ N
oxide NN N
synthase NN N
( ( N
eNOS JJ N
and CC N
iNOS NN N
) ) N
by IN N
western JJ N
blot NN N
. . N

All DT N
subjects NNS N
had VBD N
at IN N
least JJS N
one CD N
gastric JJ N
lesion NN N
except IN N
for IN N
two CD N
individuals NNS N
taking VBG N
ibuprofen-arginate NN N
. . N

Ibuprofen-arginate NNP N
caused VBD N
a DT N
lower JJR N
rate NN N
of IN N
clinical JJ 1_o
adverse JJ 1_o
reactions NNS 1_o
than IN N
ibuprofen NN N
. . N

Subjects NNS N
with IN N
gastric JJ 1_o
lesions NNS 1_o
or CC N
adverse JJ N
reactions NNS N
had VBD N
lower JJR N
PGE2 NNP N
levels NNS N
. . N

COX-1 NNP 1_o
, , 1_o
COX-2 NNP 1_o
, , 1_o
eNOS NN 1_o
, , 1_o
and CC 1_o
iNOS NNS 1_o
were VBD N
detectable JJ N
in IN N
all DT N
subjects NNS N
. . N

The DT N
constitutive JJ N
enzymes NNS N
( ( N
COX-1 NNP N
and CC N
eNOS NN N
) ) N
did VBD N
not RB N
change VB N
after IN N
treatment NN N
. . N

COX-2 NNP N
was VBD N
higher RBR N
in IN N
corpus NN N
than IN N
antrum NN N
and CC N
it PRP N
increased VBD N
after IN N
ibuprofen JJ N
treatment NN N
. . N

iNOS NN N
tended VBD N
to TO N
increase VB N
mildly RB N
in IN N
the DT N
corpus NN N
in IN N
subjects NNS N
with IN N
adverse JJ N
reactions NNS N
or CC N
endoscopic JJ N
lesions NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
ibuprofen NN N
and CC N
ibuprofen-arginate NN N
in IN N
PGE2 NNP N
, , N
or CC N
enzymes NNS N
. . N

-DOCSTART- -X- O O

Myocardial JJ N
extracellular JJ N
volume NN N
by IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
in IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
anthracycline-based JJ 1_p
chemotherapy NN 1_p
. . 1_p

We PRP N
aimed VBD N
to TO N
determine VB N
whether IN N
the DT N
myocardial JJ 1_o
extracellular JJ 1_o
volume NN 1_o
( ( 1_o
ECV NNP 1_o
) ) 1_o
, , N
measured VBN N
using VBG N
T1 NNP 1_o
measurements NNS 1_o
obtained VBD N
during IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
were VBD N
increased VBN N
in IN N
patients NNS 1_i
treated VBN 1_i
with IN 1_i
anthracyclines NNS 1_i
. . 1_i

We PRP N
performed VBD N
cardiac JJ 1_i
magnetic JJ 1_i
resonance NN 1_i
imaging NN 1_i
and CC 1_i
echocardiography NN 1_i
and CC 1_i
measured VBD 1_i
the DT 1_i
ECV NNP 1_o
in IN N
42 CD 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
anthracyclines NNS 1_i
. . 1_i

The DT N
data NN N
from IN N
the DT N
cardiac JJ N
magnetic JJ N
resonance NN N
study NN N
were VBD N
compared VBN N
to TO N
those DT N
from IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

The DT N
anthracycline-treated JJ N
cohort NN N
consisted VBD N
of IN N
21 CD 1_p
men NNS 1_p
and CC 1_p
21 CD 1_p
women NNS 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
55 CD 1_p
? . 1_p
17 CD 1_p
years NNS 1_p
, , 1_p
who WP 1_p
presented VBD 1_p
a DT 1_p
median NN 1_p
of IN 1_p
84 CD 1_p
months NNS 1_p
after IN 1_p
chemotherapy NN 1_p
with IN 1_p
a DT 1_p
cumulative JJ 1_p
anthracycline NN 1_p
exposure NN 1_p
of IN 1_p
282 CD 1_p
? . 1_p
65 CD 1_p
mg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
and CC 1_p
a DT 1_p
mean NN 1_o
left VBD 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
of IN 1_o
52 CD 1_p
? . 1_p
12 CD 1_p
% NN 1_p
. . 1_p

The DT 1_p
ECV NNP 1_o
was VBD 1_o
elevated VBN N
in IN N
the DT N
anthracycline-treated JJ N
patients NNS N
compared VBN N
to TO N
the DT N
age- JJ N
and CC N
gender-matched JJ N
controls NNS N
( ( N
0.36 CD N
? . N
0.03 CD N
vs NN N
0.28 CD N
? . N
0.02 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

A NNP N
positive JJ N
association NN N
was VBD N
found VBN N
between IN 1_o
the DT 1_o
ECV NNP 1_o
and CC N
left VBD N
atrial JJ N
volume NN 1_o
( ( 1_o
ECV NNP 1_o
vs RB 1_o
indexed VBD 1_o
left JJ 1_o
atrial JJ 1_o
volume NN 1_o
, , 1_o
r NN 1_o
= VBD 1_o
0.65 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
negative JJ N
association NN N
was VBD N
found VBN N
between IN N
the DT N
ECV NNP N
and CC 1_o
diastolic JJ 1_o
function NN 1_o
( ( 1_o
E NNP 1_o
' POS 1_o
lateral NN N
, , N
r NN N
= NNP N
-0.64 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
myocardial JJ 1_o
ECV NNP 1_o
is VBZ N
elevated VBN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
previous JJ 1_p
anthracycline NN 1_p
treatment NN 1_p
and CC 1_p
is VBZ N
associated VBN N
with IN N
the DT N
diastolic JJ N
function NN N
and CC N
increased VBD N
atrial JJ N
volumes NNS N
. . N

-DOCSTART- -X- O O

Combination NNP N
hydrocodone NN 1_i
and CC 1_i
ibuprofen JJ 1_i
versus NN N
combination NN N
codeine NN 1_i
and CC 1_i
acetaminophen NN 1_i
for IN N
the DT N
treatment NN 1_p
of IN 1_p
chronic JJ 1_p
pain NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
combination NN N
hydrocodone NN 1_i
7.5 CD N
mg NN N
and CC N
ibuprofen $ 1_i
200 CD N
mg NN N
with IN N
that DT N
of IN N
combination NN N
codeine NN 1_i
30 CD N
mg NN N
and CC N
acetaminophen $ 1_i
300 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
pain NN N
. . N

BACKGROUND NNP N
Hydrocodone NNP 1_i
7.5 CD N
mg NN N
with IN N
ibuprofen JJ 1_i
200 CD N
mg NN N
is VBZ N
the DT N
only JJ N
approved VBD N
fixed-dose JJ N
combination NN N
analgesic IN N
containing VBG N
an DT N
opioid NN N
and CC N
ibuprofen NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
repeated-dose JJ N
, , N
active-comparator JJ N
, , N
4-week JJ N
, , N
multicenter NN N
study NN N
, , N
469 CD 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
1-tablet JJ N
( ( N
n JJ N
= NNP N
156 CD N
) ) N
or CC N
2-tablet JJ N
( ( N
n JJ N
= NNP N
153 CD N
) ) N
dose NN N
of IN N
combination NN 1_i
hydrocodone NN 1_i
7.5 CD 1_i
mg NN 1_i
and CC 1_i
ibuprofen $ 1_i
200 CD 1_i
mg NN 1_i
( ( N
HI1 NNP N
and CC N
HI2 NNP N
, , N
respectively RB N
) ) N
or CC N
a DT N
2-tablet JJ 1_i
dose NN 1_i
of IN N
combination NN N
codeine NN 1_i
30 CD 1_i
mg NN 1_i
and CC 1_i
acetaminophen $ 1_i
300 CD 1_i
mg NN 1_i
( ( N
CA NNP N
, , N
n RB N
= VBZ N
160 CD N
) ) N
, , N
the DT N
active JJ N
comparator NN N
, , N
every DT N
6 CD N
to TO N
8 CD N
hours NNS N
as IN N
needed VBN N
for IN N
pain NN N
. . N

Efficacy NN N
was VBD N
measured VBN N
through IN N
pain NN 1_o
relief NN 1_o
scores NNS 1_o
, , 1_o
number NN 1_o
of IN 1_o
daily JJ 1_o
doses NNS 1_o
of IN 1_o
study NN 1_o
medication NN 1_o
, , 1_o
number NN 1_o
of IN 1_o
daily JJ 1_o
doses NNS 1_o
of IN 1_o
supplemental JJ 1_o
analgesics NNS 1_o
, , 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
discontinued VBD 1_o
therapy NN 1_o
due JJ 1_o
to TO 1_o
an DT 1_o
unsatisfactory JJ 1_o
analgesic JJ 1_o
response NN 1_o
, , N
and CC N
global JJ N
assessment NN N
scores NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
469 CD 1_p
patients NNS 1_p
, , 1_p
255 CD 1_p
( ( 1_p
54.4 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
female JJ 1_p
and CC 1_p
214 CD 1_p
( ( 1_p
45.6 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
male JJ 1_p
. . 1_p

The DT N
mean JJ 1_p
age NN 1_p
was VBD 1_p
51.1 CD 1_p
years NNS 1_p
. . 1_p

Types NNS 1_p
of IN 1_p
chronic NN 1_p
pain NN 1_p
included VBD 1_p
back RB 1_p
( ( 1_p
214 CD 1_p
; : 1_p
45.6 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
arthritic JJ 1_p
( ( 1_p
145 CD 1_p
; : 1_p
30.9 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
other JJ 1_p
musculoskeletal NN 1_p
( ( 1_p
65 CD 1_p
; : 1_p
13.9 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
cancer NN 1_p
( ( 1_p
6 CD 1_p
; : 1_p
1.3 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
diabetic JJ 1_p
neuropathic NN 1_p
( ( 1_p
3 CD 1_p
; : 1_p
0.6 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
postherpetic JJ 1_p
neuralgic NN 1_p
( ( 1_p
5 CD 1_p
; : 1_p
1.1 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
other JJ 1_p
neurologic NN 1_p
( ( 1_p
21 CD 1_p
; : 1_p
4.5 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
other JJ 1_p
unclassified JJ 1_p
chronic JJ 1_p
pain NN 1_p
( ( 1_p
10 CD 1_p
; : 1_p
2.1 CD 1_p
% NN 1_p
) ) 1_p
. . N

During IN N
the DT N
48 CD N
hours NNS N
prior RB N
to TO N
the DT N
study NN N
, , N
351 CD N
( ( N
74.8 CD N
% NN N
) ) N
patients NNS N
had VBD N
been VBN N
treated VBN N
with IN N
opioid JJ N
or CC N
opioid-nonopioid JJ N
combination NN N
analgesics NNS N
. . N

The DT N
overall JJ 1_o
mean JJ 1_o
daily JJ 1_o
pain NN 1_o
relief NN 1_o
score NN 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.25+/-0.89 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
1.98+/-0.87 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
1.85+/-0.96 JJ N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
overall JJ 1_o
mean JJ 1_o
number NN 1_o
of IN 1_o
daily JJ 1_o
doses NNS 1_o
of IN 1_o
study NN 1_o
medication NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.94+/-0.99 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
3.23+/-0.76 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
3.26+/-0.75 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

The DT N
overall JJ 1_o
mean JJ 1_o
number NN 1_o
of IN 1_o
daily JJ 1_o
doses NNS 1_o
of IN 1_o
supplemental JJ 1_o
analgesics NNS 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
0.24+/-0.49 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
0.34+/-0.58 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
or CC N
CA NNP N
group NN N
( ( N
0.49+/-0.85 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
discontinued VBD 1_o
treatment NN 1_o
due JJ 1_o
to TO 1_o
an DT 1_o
unsatisfactory JJ 1_o
analgesic JJ 1_o
response NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2 CD N
; : N
1.3 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
CA NNP N
group NN N
( ( N
12 CD N
; : N
7.5 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

HI2 NNP N
was VBD N
more RBR N
effective JJ N
than IN N
HI1 NNP N
and CC N
CA NNP N
as IN N
measured VBN N
by IN N
pain NN 1_o
relief NN 1_o
scores NNS 1_o
for IN N
week NN N
1 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
and CC N
week NN N
3 CD N
( ( N
P NNP N
= VBZ N
0.008 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ 1_o
doses NNS 1_o
of IN 1_o
study NN 1_o
medication NN 1_o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.019 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.011 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ 1_o
doses NNS 1_o
of IN 1_o
supplemental JJ 1_o
analgesics NNS 1_o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.010 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
; : N
and CC N
global JJ 1_o
assessment NN 1_o
scores NNS 1_o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.018 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
= VBZ N
0.005 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
and CC N
week NN N
4 CD N
( ( N
P NNP N
= VBZ N
0.013 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.023 CD N
vs NN N
CA NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
HI1 NNP 1_i
and CC N
CA NNP 1_i
in IN N
any DT N
efficacy NN 1_o
variable JJ N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
experiencing VBG 1_o
adverse JJ 1_o
events NNS 1_o
in IN N
the DT N
HI2 NNP N
( ( N
127 CD N
; : N
83 CD N
% NN N
) ) N
, , N
HI1 NNP 1_i
( ( N
124 CD N
; : N
79.5 CD N
% NN N
) ) N
, , N
and CC N
CA NNP 1_i
( ( N
129 CD N
; : N
80.6 CD N
% NN N
) ) N
groups NNS N
. . N

However RB N
, , N
the DT N
mean JJ 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
discontinued VBD 1_o
treatment NN 1_o
due JJ 1_o
to TO 1_o
adverse JJ 1_o
events NNS 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP 1_i
group NN N
( ( N
40 CD N
; : N
26.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
HI1 NNP 1_i
group NN N
( ( N
23 CD N
; : N
14.7 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
hydrocodone NN 1_i
7.5 CD N
mg NN N
and CC 1_i
ibuprofen $ 1_i
200 CD N
mg NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
1-tablet JJ N
doses NNS N
of IN N
this DT N
combination NN N
or CC N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN 1_i
30 CD N
mg NN N
and CC 1_i
acetaminophen $ 1_i
300 CD N
mg NN N
. . N

Moreover RB N
, , N
1-tablet JJ N
doses NNS N
of IN N
combination NN 1_i
hydrocodone NN 1_i
7.5 CD 1_i
mg NN 1_i
and CC 1_i
ibuprofen $ 1_i
200 CD N
mg NN N
may MD N
be VB N
as RB N
effective JJ N
as IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN 1_i
30 CD N
mg NN N
and CC 1_i
acetaminophen $ 1_i
300 CD N
mg NN N
. . N

-DOCSTART- -X- O O

Diverting VBG 1_o
stoma NN 1_o
after IN N
low JJ N
anterior JJ N
resection NN N
: : N
more JJR N
arguments NNS N
in IN N
favor NN N
. . N

PURPOSE VB N
The DT N
necessity NN N
of IN N
a DT N
protective JJ 1_i
stoma NN 1_i
in IN N
patients NNS 1_p
undergoing VBG 1_p
low JJ 1_i
anterior JJ 1_i
resection NN 1_i
with IN 1_p
total JJ 1_p
mesorectal JJ 1_p
excision NN 1_p
for IN 1_p
primary JJ 1_p
rectal JJ 1_p
cancer NN 1_p
is VBZ N
discussed VBN N
controversially RB N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
, , N
pilot-study NN N
to TO N
evaluate VB N
the DT N
need NN N
for IN N
diverting VBG 1_o
ileostomy NN 1_o
in IN N
patients NNS 1_p
undergoing VBG 1_p
low JJ 1_p
anterior JJ 1_p
resection NN 1_p
[ NNP N
NCT00457327 NNP N
] NNP N
. . N

METHODS NNP N
Forty NNP 1_p
patients NNS 1_p
after IN 1_p
elective JJ 1_p
sphincter-saving JJ 1_p
low JJ 1_p
anterior JJ 1_p
resection NN 1_p
were VBD N
eligible JJ N
for IN N
intraoperative JJ N
randomization NN N
. . N

The DT N
primary JJ N
objective NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
demonstrate VB N
similar JJ 1_o
risks NNS 1_o
after IN N
the DT N
resection NN N
with IN N
both DT N
techniques NNS N
. . N

A DT N
priori JJ N
stopping NN N
rules NNS N
were VBD N
defined VBN N
for IN N
early JJ N
termination NN N
of IN N
the DT N
trial NN N
. . N

RESULTS NNP N
Between NNP N
July NNP N
4 CD N
, , N
2006 CD N
and CC N
March NNP N
12 CD N
, , N
2007 CD N
, , N
a DT 1_p
total NN 1_p
of IN 1_p
41 CD 1_p
patients NNS 1_p
were VBD 1_p
screened VBN 1_p
and CC 1_p
34 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
. . 1_p

Eighteen JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
the DT 1_p
stoma NN 1_i
group NN 1_i
and CC 1_p
16 CD 1_p
patients NNS 1_p
to TO 1_p
the DT 1_p
nonstoma NN 1_i
group NN 1_i
The DT 1_o
symptomatic JJ 1_o
anastomotic JJ 1_o
leakage NN 1_o
rate NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
nonstoma NN N
group NN N
( ( N
37.5 CD N
percent NN N
) ) N
than IN N
in IN N
the DT N
stoma NN N
group NN N
( ( N
5.5 CD N
percent NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

In IN N
all DT N
six CD N
cases NNS N
in IN N
the DT N
nonstoma NN N
group NN N
, , N
reoperations NNS 1_o
were VBD N
necessary JJ N
. . N

The DT N
study NN N
was VBD N
stopped VBN N
after IN N
34 CD N
patients NNS N
were VBD N
included VBN N
. . N

A DT N
meta-analysis NN N
of IN N
the DT N
available JJ N
data NNS N
confirmed VBD N
the DT N
value NN N
of IN N
a DT N
protective JJ N
ostomy NN N
for IN N
patients NNS 1_p
undergoing VBG 1_p
low JJ 1_p
anterior JJ 1_p
resection NN 1_p
. . 1_p

CONCLUSIONS VB N
The DT N
data NN N
demonstrate NN N
a DT N
high JJ N
risk NN N
for IN N
patients NNS 1_p
undergoing VBG 1_p
low JJ 1_p
anterior JJ 1_p
resection NN 1_p
without IN N
diverting VBG N
ileostomy NN N
. . N

-DOCSTART- -X- O O

Amoxicillin/metronidazole/omeprazole/clarithromycin NN N
: : N
a DT N
new JJ N
, , N
short JJ N
quadruple NN N
therapy NN 1_p
for IN 1_p
Helicobacter NNP 1_o
pylori JJ 1_o
eradication NN 1_o
. . 1_o

BACKGROUND NNP N
Triple NNP N
therapy NN N
regimens VBZ N
including VBG N
two CD N
antibiotics NNS N
plus CC N
acid JJ N
suppression NN N
have VBP N
become VBN N
the DT N
new JJ N
standard NN N
therapy NN N
in IN N
Helicobacter NNP N
pylori FW N
eradication NN N
because IN N
of IN N
success NN N
rates NNS N
of IN N
about RB N
90 CD N
% NN N
. . N

However RB N
, , N
these DT N
regimens NNS N
are VBP N
still RB N
costly JJ N
, , N
duration NN N
is VBZ N
about IN N
one CD N
week NN N
or CC N
less JJR N
, , N
and CC N
side-effects NNS N
are VBP N
not RB N
negligible JJ N
. . N

We PRP N
therefore RB N
evaluated VBD N
a DT N
new JJ N
quadruple NN N
therapy NN N
, , N
because IN N
theoretically RB N
a DT N
shorter JJR N
duration NN N
of IN N
treatment NN N
may MD N
result VB N
in IN N
reduced JJ N
costs NNS N
, , N
fewer JJR N
side-effects NNS N
, , N
and CC N
possibly RB N
in IN N
a DT N
lower JJR N
potential NN N
for IN N
antibiotic JJ N
resistances NNS N
. . N

METHODS NNP N
Controlled NNP N
, , N
prospective JJ N
pilot NN N
study NN N
including VBG N
H. NNP 1_p
pylori-positive JJ 1_p
patients NNS 1_p
with IN 1_p
gastric JJ 1_p
or CC 1_p
duodenal JJ 1_p
ulcers NNS 1_p
or CC 1_p
erosive JJ 1_p
gastritis NN 1_p
, , 1_p
treated VBN 1_p
after IN 1_p
failure NN 1_p
of IN 1_p
dual JJ 1_p
therapy NN 1_p
( ( 1_p
proton-pump-inhibitors NNS 1_p
or CC 1_p
ranitidine VB 1_p
plus CC 1_p
amoxicillin VB 1_p
) ) 1_p
or CC 1_p
for IN 1_p
the DT 1_p
first JJ 1_p
time NN 1_p
. . 1_p

They PRP N
were VBD N
assigned VBN N
to TO N
a DT N
one CD 1_i
week NN 1_i
triple JJ 1_i
standard NN 1_i
therapy NN 1_i
, , 1_i
consisting VBG 1_i
of IN 1_i
metronidazole JJ 1_i
400 CD 1_i
mg JJ 1_i
bid NN 1_i
+ NNP 1_i
omeprazole VBZ 1_i
20 CD 1_i
mg NN 1_i
bid NN 1_i
+ NNP 1_i
clarithromycin VBZ 1_i
250 CD 1_i
mg NN 1_i
bid NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
newly RB 1_i
created VBN 1_i
quadruple-regimen NNS 1_i
, , 1_i
which WDT 1_i
adds VBZ 1_i
amoxicillin NN 1_i
( ( 1_i
1 CD 1_i
g RB 1_i
bid NN 1_i
) ) 1_i
to TO 1_i
the DT 1_i
above JJ 1_i
triple NN 1_i
regimen NNS 1_i
. . 1_i

Each DT N
of IN N
the DT N
four CD N
drugs NNS N
was VBD N
given VBN N
for IN N
5 CD N
days NNS N
. . N

H. NNP N
pylori NN N
status NN N
was VBD N
checked VBN N
by IN N
13C CD 1_o
urea JJ 1_o
breath NN 1_o
test NN 1_o
before IN N
and CC N
after IN N
four CD N
weeks NNS N
of IN N
therapy NN N
. . N

RESULTS VB N
A DT N
total NN 1_p
of IN 1_p
71 CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
by IN 1_p
quadruple JJ 1_p
therapy NN 1_p
, , 1_p
and CC 1_p
42 CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
by IN 1_p
triple JJ 1_p
therapy NN 1_p
. . 1_p

The DT N
eradication NN 1_o
rate NN 1_o
of IN N
H. NNP N
pylori NN N
for IN N
patients NNS N
under IN N
quadruple JJ N
treatment NN N
, , N
without IN N
vs. FW N
with IN N
previous JJ N
dual JJ N
therapy NN N
, , N
were VBD N
96 CD N
% NN N
vs. FW N
92 CD N
% NN N
( ( N
42/44 CD N
vs. FW N
22/24 CD N
) ) N
by IN N
per IN N
protocol NN N
and CC N
91 CD N
% NN N
vs. FW N
88 CD N
% NN N
( ( N
42/46 CD N
vs. FW N
22/25 CD N
) ) N
by IN N
intention NN N
to TO N
treat VB N
analysis NN N
( ( N
comparisons NNS N
not RB N
significant JJ N
) ) N
. . N

No DT N
major JJ N
side-effects NNS N
were VBD N
reported VBN N
. . N

CONCLUSIONS NNP N
Five-day JJ N
quadruple NN N
therapy NN N
( ( N
with IN N
omeprazole NN N
, , N
metronidazole NN N
, , N
clarithromycin NN N
and CC N
amoxicillin NN N
) ) N
represents VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
new JJ N
regimen NNS N
for IN N
H. NNP N
pylori JJ N
eradication NN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
the DT N
ophthalmic JJ 1_i
insert NN 1_i
Mydriasert NNP 1_i
in IN N
patients NNS 1_p
undergoing JJ 1_p
retinal JJ 1_p
angiography NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
verify VB N
the DT N
efficacy NN N
to TO N
obtain VB N
mydriasis NN N
and CC N
cardiovascular JJ N
safety NN N
of IN N
Mydriasert NNP 1_i
( ( 1_i
ophthalmic JJ 1_i
insert NN 1_i
containing VBG 1_i
tropicamide NN 1_i
and CC 1_i
phenylephrine NN 1_i
) ) 1_i
in IN N
diabetic JJ 1_p
and CC 1_p
nondiabetic JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
retinal JJ 1_p
angiography NN 1_p
by IN 1_p
comparing VBG 1_p
it PRP 1_p
with IN 1_p
usually RB 1_p
administered VBN 1_p
eyedrops NNS 1_p
( ( 1_i
tropicamide VB 1_i
1 CD 1_i
% NN 1_i
and CC 1_i
phenylephrine VB 1_i
10 CD 1_i
% NN 1_i
) ) 1_i
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

A DT N
total NN 1_p
of IN 1_p
154 CD 1_p
eyes NNS 1_p
of IN 1_p
77 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
2 CD 1_p
groups NNS 1_p
: : 1_p
group NN N
1 CD N
consisted VBD N
of IN N
78 CD N
eyes NNS N
, , N
group NN N
2 CD N
consisted VBD N
of IN N
76 CD N
eyes NNS N
, , N
and CC N
the DT N
patients NNS N
were VBD N
monitored VBN N
for IN N
pupillary JJ N
dilation NN N
, , N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
and CC N
possible JJ N
adverse JJ N
effects NNS N
at IN N
0 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
minutes NNS N
. . N

RESULTS NNP N
No NNP N
severe JJ 1_o
adverse JJ 1_o
effects NNS 1_o
were VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

In IN N
the DT N
entire JJ N
sample NN N
studied VBD N
, , N
the DT N
mean JJ 1_o
pupillary JJ 1_o
diameter NN 1_o
was VBD N
greater JJR N
in IN N
the DT N
eyedrops NNS N
group NN N
after IN N
20 CD N
and CC N
40 CD N
minutes NNS N
, , N
while IN N
mydriasis NN 1_o
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
after IN N
60 CD N
minutes NNS N
. . N

The DT N
diabetic JJ 1_p
patients NNS 1_p
treated VBN N
with IN N
Mydriasert NNP 1_i
had VBD N
less JJR N
mydriasis NN 1_o
than IN N
those DT N
treated VBN N
with IN N
eyedrops NNS N
after IN N
20 CD N
and CC N
40 CD N
minutes NNS N
, , N
and CC N
diabetic JJ N
patients NNS N
showed VBD N
less JJR N
mydriasis NN N
than IN N
the DT N
nondiabetic JJ N
patients NNS N
after IN N
60 CD N
and CC N
90 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
between-group JJ N
difference NN N
in IN N
mean JJ 1_o
heart NN 1_o
rate NN 1_o
or CC 1_o
systolic NN 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
at IN N
any DT N
of IN N
the DT N
time NN N
points NNS N
. . N

CONCLUSIONS NNP N
Mydriasert NNP 1_i
assures VBZ N
an DT N
adequate JJ N
degree NN N
of IN N
mydriasis NN N
for IN N
retinal JJ N
angiography NN N
in IN N
both DT N
diabetic JJ 1_p
and CC 1_p
nondiabetic JJ 1_p
patients NNS 1_p
. . 1_p

There EX N
are VBP N
no DT N
differences NNS N
in IN N
efficacy NN N
or CC N
safety NN N
between IN N
the DT N
insert NN N
and CC N
the DT N
usually RB N
administered VBN N
eyedrops NNS N
, , N
but CC N
the DT N
low JJ N
total JJ N
drug NN N
dose NN N
administered VBN N
with IN N
the DT N
insert NN N
reduces VBZ N
the DT N
risk NN N
of IN N
cardiovascular JJ N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

Validation NN N
of IN N
an DT N
FFQ NNP N
for IN N
evaluation NN N
of IN N
EPA NNP 1_o
and CC 1_o
DHA NNP 1_o
intake VBP 1_o
. . 1_o

OBJECTIVE NNP N
To TO N
validate VB N
an DT N
FFQ NNP N
for IN N
the DT N
assessment NN N
of IN N
dietary JJ N
EPA NNP 1_o
and CC 1_o
DHA NNP 1_o
against IN N
their PRP$ N
relative JJ 1_o
concentrations NNS 1_o
in IN 1_o
red JJ 1_o
blood NN 1_o
cells NNS 1_o
( ( 1_o
RBC NNP 1_o
) ) 1_o
. . 1_o

DESIGN NNP N
Cross-sectional JJ N
analysis NN N
of IN N
baseline NN N
data NNS N
. . N

Intakes NNS N
of IN N
marine NN 1_i
food NN 1_i
products NNS 1_i
and CC N
EPA NNP 1_i
and CC N
DHA NNP 1_i
were VBD N
estimated VBN N
by IN N
FFQ NNP N
on IN N
the DT N
basis NN N
of IN N
consumption NN N
of IN N
marine NN 1_i
food NN 1_i
products NNS 1_i
in IN N
the DT N
last JJ N
month NN N
. . N

Fatty NNP N
acid JJ N
composition NN N
of IN N
RBC NNP N
membranes NNS N
was VBD N
quantified VBN N
by IN N
GC NNP N
. . N

SETTING NNP N
Saint-Fran?ois JJ 1_p
d'Assise NN 1_p
Hospital NNP 1_p
, , 1_p
Qu?bec NNP 1_p
, , 1_p
Canada NNP 1_p
. . 1_p

SUBJECTS NNP N
A NNP N
total NN N
of IN N
sixty-five JJ 1_p
middle-aged JJ 1_p
women NNS 1_p
who WP 1_p
participated VBD 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
clinical JJ 1_p
trial NN 1_p
. . 1_p

RESULTS NNP N
Spearman NNP N
's POS N
correlation NN N
coefficient NN N
between IN 1_o
intake NN 1_o
of IN 1_o
EPA NNP 1_o
, , 1_o
DHA NNP 1_o
and CC 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
and CC 1_o
their PRP$ N
corresponding JJ 1_o
concentration NN 1_o
in IN 1_o
RBC NNP 1_o
was VBD 1_o
0.46 CD N
, , N
0.40 CD N
and CC N
0.42 CD N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
of IN N
EPA+DHA NNP 1_o
intake NN 1_o
and CC 1_o
RBC NNP 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
concentration NN 1_o
indicated VBD 1_o
positive JJ N
and CC N
significant JJ N
correlations NNS N
for IN N
oily RB N
fish JJ N
( ( N
beta JJ N
= NN N
0.44 CD N
, , N
95 CD N
% NN N
CI NNP N
0.16 CD N
, , N
0.72 CD N
, , N
P NNP N
= NNP N
0.0027 CD N
) ) N
, , N
total JJ N
fish NN N
( ( N
beta JJ N
= NN N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.19 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0005 CD N
) ) N
and CC 1_i
marine VB 1_i
food NN 1_i
products NNS 1_i
( ( 1_i
beta NN N
= RB N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.20 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

No UH N
other JJ N
marine VB N
food NN N
products NNS N
significantly RB N
predicted VBD 1_o
RBC NNP 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
concentration NN 1_o
. . 1_o

CONCLUSIONS NNP N
Although IN N
the DT N
present JJ N
validation NN N
study NN N
was VBD N
undertaken VBN N
among IN 1_p
middle-aged JJ 1_p
women NNS 1_p
with IN 1_p
low JJ 1_p
consumption NN 1_p
of IN 1_p
marine NN 1_p
food NN 1_p
products NNS 1_p
( ( 1_p
< $ 1_p
3 CD 1_p
servings/week NN 1_p
) ) 1_p
, , 1_p
our PRP$ N
FFQ NNP N
provided VBD N
estimates NNS N
of IN N
EPA NNP 1_o
and CC 1_o
DHA NNP 1_o
intakes NNS 1_o
that WDT 1_o
correlated VBD N
fairly RB N
well RB N
with IN N
their PRP$ 1_o
RBC NNP 1_o
concentrations NNS 1_o
. . 1_o

However RB N
, , N
the DT N
absence NN N
of IN N
correlations NNS N
between IN 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
intakes NNS 1_o
from IN 1_o
different JJ N
marine NN N
species NNS N
suggests VBZ N
that IN N
a DT N
minimum JJ 1_i
EPA NNP 1_i
+ NNP 1_i
DHA NNP 1_i
intake NN 1_i
is VBZ N
necessary JJ N
to TO N
observe VB N
a DT N
relationship NN N
with IN 1_o
RBC NNP 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
concentrations NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Interferon NNP 1_i
alfa NN 1_i
in IN N
acute JJ 1_p
posttransfusion NN 1_p
hepatitis NN 1_p
C NNP 1_p
: : 1_p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

-DOCSTART- -X- O O

The DT N
use NN N
of IN N
transvaginal JJ 1_i
synthetic JJ 1_i
mesh NN 1_i
for IN N
anterior JJ 1_p
vaginal JJ 1_p
wall NN 1_p
prolapse NN 1_p
repair NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

INTRODUCTION NNP N
AND CC N
HYPOTHESIS NNP N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
transvaginal JJ 1_i
trocar-guided JJ 1_i
polypropylene NN 1_i
mesh JJ 1_i
insertion NN 1_i
with IN 1_i
traditional JJ 1_i
colporrhaphy NN 1_i
for IN N
treatment NN N
of IN N
anterior JJ 1_p
vaginal JJ 1_p
wall NN 1_p
prolapse NN 1_p
. . 1_p

METHODS NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
in IN N
which WDT N
women NNS 1_p
with IN 1_p
advanced JJ 1_p
anterior JJ 1_p
vaginal NN 1_p
wall NN 1_p
prolapse NN 1_p
, , 1_p
at IN 1_p
least JJS 1_p
stage NN 1_p
II NNP 1_p
with IN 1_p
Ba NNP 1_p
? . 1_p
+1 NN 1_p
cm NN 1_p
according VBG 1_p
to TO 1_p
the DT 1_p
Pelvic NNP 1_p
Organ NNP 1_p
Prolapse NNP 1_p
Quantification NNP 1_p
( ( 1_p
POP-Q NNP 1_p
) ) 1_p
classification NN 1_p
, , 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
either DT 1_i
anterior JJ 1_i
colporrhaphy NN 1_i
( ( 1_i
n JJ N
= NNP N
39 CD N
) ) N
or CC N
repair NN 1_i
using VBG 1_i
trocar-guided JJ 1_i
transvaginal JJ 1_i
mesh NN 1_i
( ( 1_i
n JJ N
= NNP N
40 CD N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD 1_o
objective JJ 1_o
cure NN 1_o
rate NN 1_o
of IN 1_o
the DT 1_o
anterior JJ 1_o
compartment NN 1_o
( ( 1_o
point NN 1_o
Ba NNP 1_o
) ) 1_o
assessed VBD 1_o
at IN N
the DT N
12-month JJ N
follow-up JJ N
visit NN N
, , N
with IN N
stages NNS N
0 CD N
and CC N
I PRP N
defined VBD N
as IN N
anatomical JJ N
success NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD 1_o
quantification NN 1_o
of IN 1_o
other JJ 1_o
vaginal JJ 1_o
compartments NNS 1_o
( ( 1_o
POP-Q NNP 1_o
points NNS 1_o
) ) 1_o
, , 1_o
comparison NN 1_o
of IN 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
by IN 1_o
the DT 1_o
prolapse NN 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
P-QOL NNP 1_o
) ) 1_o
questionnaire NN 1_o
, , 1_o
and CC 1_o
complication NN 1_o
rate NN 1_o
between IN 1_o
the DT N
groups NNS N
after IN N
1 CD N
year NN N
. . N

Study NNP N
power NN N
was VBD N
fixed VBN N
as IN N
80 CD N
% NN N
with IN N
5 CD N
% NN N
cutoff NN N
point NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
statistical JJ N
significance NN N
. . N

RESULTS VB N
The DT N
groups NNS N
were VBD N
similar JJ N
regarding VBG N
demographic JJ N
and CC N
clinical JJ N
preoperative NN N
parameters NNS 1_o
. . 1_o

Anatomical JJ 1_o
success NN 1_o
rates NNS 1_o
for IN 1_o
colporrhaphy NN 1_o
and CC 1_o
repair NN 1_o
with IN 1_o
mesh JJ 1_i
placement NN 1_i
groups NNS 1_i
were VBD N
56.4 CD N
vs JJ N
82.5 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
0.068-0.54 NN N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
difference NN N
between IN N
the DT N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.018 CD N
) ) N
. . N

Similar JJ 1_o
total JJ 1_o
complication NN 1_o
rates NNS 1_o
were VBD 1_o
observed VBN N
in IN N
both DT N
groups NNS N
, , N
with IN N
tape NN N
exposure NN N
observed VBN N
in IN N
5 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
all DT 1_o
P-QOL NNP 1_o
domains NNS 1_o
as IN 1_o
a DT N
result NN N
of IN N
both DT N
procedures NNS N
( ( N
p VB N
< RB N
0.001 CD N
) ) N
, , N
but CC N
they PRP N
were VBD N
not RB N
distinct JJ N
between IN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP 1_i
Trocar-guided JJ 1_i
transvaginal JJ 1_i
synthetic JJ 1_i
mesh NN 1_i
for IN 1_i
advanced JJ N
anterior JJ N
POP NNP N
repair NN N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR 1_o
anatomical JJ 1_o
success NN 1_o
rate NN 1_o
for IN 1_o
the DT N
anterior JJ N
compartment NN N
compared VBN N
with IN N
traditional JJ 1_i
colporrhaphy NN 1_o
. . 1_o

Quality NN 1_o
of IN 1_o
life NN 1_o
equally RB 1_o
improved VBN 1_o
after IN N
both DT N
techniques NNS N
. . N

However RB N
, , N
the DT N
trial NN N
failed VBD N
to TO N
detect VB N
differences NNS N
in IN N
P-QOL NNP 1_o
scores NNS 1_o
and CC 1_o
complication NN 1_o
rates NNS 1_o
between IN 1_o
the DT N
groups NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
magnesium NN 1_i
sulfate NN 1_i
and CC 1_i
nimodipine NN 1_i
for IN N
the DT N
prevention NN 1_o
of IN 1_o
eclampsia NN 1_o
. . 1_o

-DOCSTART- -X- O O

Immunological JJ 1_o
changes NNS 1_o
after IN N
minimally RB 1_i
invasive JJ 1_i
or CC 1_i
conventional JJ 1_i
esophageal JJ 1_i
resection NN 1_i
for IN N
cancer NN 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
This DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
substudy NN N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
conventional JJ 1_i
open JJ 1_i
esophagectomy NN 1_i
[ NNP N
open JJ N
surgical JJ N
technique NN N
( ( N
OE NNP N
) ) N
] NN N
by IN N
thoracotomy NN 1_i
and CC 1_i
laparotomy NN 1_i
with IN N
minimally RB 1_i
invasive JJ 1_i
esophagectomy NN 1_i
[ NNP 1_i
minimally RB 1_i
invasive JJ 1_i
procedure NN 1_i
( ( 1_i
MIE NNP 1_i
) ) 1_i
] NN 1_i
by IN 1_i
thoracoscopy NN 1_i
and CC 1_i
laparoscopy NN 1_i
. . 1_i

This DT N
additional JJ N
analysis NN N
focuses VBZ N
on IN N
the DT N
immunological JJ 1_o
changes NNS 1_o
and CC N
surgical JJ 1_o
stress NN 1_o
response NN 1_o
in IN N
these DT N
two CD N
randomized VBD N
groups NNS N
of IN N
a DT N
single JJ N
center NN N
. . N

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
a DT 1_p
resectable JJ 1_p
esophageal NN 1_p
cancer NN 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
OE NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
13 CD 1_p
) ) 1_p
or CC 1_p
MIE NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
14 CD 1_p
) ) 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
received VBD 1_p
neoadjuvant JJ 1_i
chemoradiotherapy NN 1_i
. . 1_i

The DT N
immunological JJ 1_o
response NN 1_o
was VBD N
measured VBN N
by IN N
means NNS N
of IN N
leukocyte NN 1_o
counts NNS 1_o
, , 1_o
HLA-DR NNP 1_o
expression NN 1_o
on IN 1_o
monocytes NNS 1_o
, , 1_o
the DT 1_o
acute-phase JJ 1_o
response NN 1_o
by IN 1_o
means NNS 1_o
of IN 1_o
C-reactive JJ 1_o
protein NN 1_o
( ( 1_o
CRP NNP 1_o
) ) 1_o
, , 1_o
interleukin-6 JJ 1_o
( ( 1_o
IL-6 NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
interleukin-8 JJ 1_o
( ( 1_o
IL-8 NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
the DT 1_o
stress NN 1_o
response NN 1_o
was VBD 1_o
measured VBN 1_o
by IN 1_o
cortisol NN 1_o
, , 1_o
growth NN 1_o
hormone NN 1_o
, , 1_o
and CC 1_o
prolactin NN 1_o
. . 1_o

All DT N
parameters NNS N
were VBD N
determined VBN N
at IN N
baseline NN N
( ( N
preoperatively RB N
) ) N
and CC N
24 CD N
, , N
72 CD N
, , N
96 CD N
, , N
and CC N
168 CD N
h NN N
postoperatively RB N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
MIE NNP N
group NN N
with IN N
regard NN N
to TO N
leukocyte VB 1_o
counts NNS 1_o
, , 1_o
IL-8 NNP 1_o
, , 1_o
and CC 1_o
prolactin NN 1_o
at IN N
168 CD N
h NN N
( ( N
1 CD N
week NN N
) ) N
postoperatively RB N
. . N

For IN N
HLA-DR NNP 1_o
expression NN 1_o
, , 1_o
IL-6 NNP 1_o
, , 1_o
and CC 1_o
CRP NNP 1_o
levels NNS 1_o
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
, , N
although IN N
there EX N
was VBD N
a DT N
clear JJ N
rise NN N
in IN N
levels NNS N
upon IN N
operation NN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
substudy NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
minimally RB N
invasive JJ N
and CC N
conventional JJ N
open JJ N
esophagectomies NNS N
for IN N
cancer NN N
, , N
significantly RB N
better RBR N
preserved VBN N
leukocyte JJ 1_o
counts NNS 1_o
and CC 1_o
IL-8 JJ 1_o
levels NNS 1_o
were VBD N
observed VBN N
in IN N
the DT N
MIE NNP N
group NN N
compared VBN N
to TO N
the DT N
open JJ N
group NN N
. . N

Both DT N
findings NNS N
can MD N
be VB N
related VBN N
to TO N
fewer JJR 1_o
respiratory NN 1_o
infections NNS 1_o
found VBD N
postoperatively RB N
in IN N
the DT N
MIE NNP N
group NN N
. . N

Moreover RB N
, , N
significant JJ N
differences NNS N
in IN N
the DT N
prolactin NN 1_o
levels NNS 1_o
at IN N
168 CD N
h NN N
after IN N
surgery NN N
imply NN N
that IN N
the DT N
stress NN 1_o
response NN 1_o
is VBZ N
better RBR N
preserved VBN N
in IN N
the DT N
MIE NNP 1_i
group NN N
. . N

These DT N
findings NNS N
indicate VBP N
that IN N
less JJR N
surgical JJ N
trauma NN N
could MD N
lead VB N
to TO N
better JJR N
preserved VBN N
acute-phase NN N
and CC N
stress NN N
responses NNS N
and CC N
fewer JJR N
clinical JJ N
manifestations NNS N
of IN N
respiratory JJ N
infections NNS N
. . N

-DOCSTART- -X- O O

Modeling VBG 1_p
hippocampal NN 1_i
and CC 1_i
neocortical JJ 1_i
contributions NNS 1_p
to TO 1_p
recognition VB 1_o
memory NN 1_p
: : 1_p
a DT 1_p
complementary-learning-systems JJ 1_p
approach NN 1_p
. . 1_p

The DT N
authors NNS N
present VBP N
a DT N
computational JJ 1_p
neural-network JJ 1_p
model NN 1_p
of IN N
how WRB N
the DT N
hippocampus NN N
and CC N
medial JJ N
temporal JJ N
lobe NN N
cortex NN N
( ( N
MTLC NNP N
) ) N
contribute NN N
to TO N
recognition VB 1_o
memory NN 1_o
. . 1_o

The DT N
hippocampal JJ 1_i
component NN N
contributes NNS N
by IN N
recalling VBG N
studied VBN N
details NNS N
. . N

The DT N
MTLC NNP N
component NN N
can MD N
not RB N
support VB N
recall NN N
, , N
but CC N
one CD N
can MD N
extract VB N
a DT N
scalar JJ N
familiarity NN N
signal NN N
from IN N
MTLC NNP N
that WDT N
tracks VBZ N
how WRB N
well RB N
a DT N
test NN N
item NN N
matches NNS N
studied VBN N
items NNS N
. . N

The DT N
authors NNS N
present JJ N
simulations NNS 1_i
that IN N
establish VB N
key JJ N
differences NNS N
in IN N
the DT N
operating NN N
characteristics NNS N
of IN N
the DT N
hippocampal-recall JJ 1_o
and CC N
MTLC-familiarity JJ 1_o
signals NNS 1_o
and CC N
identify VB N
several JJ N
manipulations NNS N
( ( N
e.g. NN N
, , N
target-lure JJ N
similarity NN N
, , N
interference NN N
) ) N
that WDT N
differentially RB N
affect VBP N
the DT N
2 CD N
signals NNS N
. . N

They PRP N
also RB N
use VBP N
the DT N
model NN N
to TO N
address VB N
the DT N
stochastic JJ N
relationship NN N
between IN N
recall NN N
and CC N
familiarity NN N
and CC N
the DT N
effects NNS N
of IN N
partial JJ N
versus NN N
complete JJ N
hippocampal JJ N
lesions NNS N
on IN N
recognition NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
Effects NNPS N
of IN N
Valsartan NNP 1_i
and CC N
Amlodipine NNP 1_i
on IN N
the DT N
Levels NNP N
of IN N
Irisin NNP 1_i
, , 1_i
Adropin NNP 1_i
, , 1_i
and CC 1_i
Perilipin NNP 1_i
. . 1_i

BACKGROUND NNP N
Hypertension NNP 1_p
and CC 1_p
obesity NN 1_p
are VBP N
two CD N
major JJ N
threats NNS N
for IN N
public JJ N
health NN N
. . N

Up IN N
to TO N
the DT N
present JJ N
, , N
antihypertensive JJ N
medications NNS N
have VBP N
been VBN N
used VBN N
to TO N
lower VB N
blood NN N
pressure NN N
, , N
which WDT N
seem VBP N
to TO N
provide VB N
a DT N
better JJR N
life NN N
with IN N
lower JJR N
morbidity NN N
and CC N
mortality NN N
rates NNS N
. . N

Their PRP$ N
effect NN N
on IN N
etiopathogenesis NN N
of IN N
hypertension NN N
is VBZ N
now RB N
an DT N
area NN N
of IN N
developing VBG N
research NN N
. . N

The DT N
association NN N
between IN N
hypertension NN N
and CC N
obesity NN N
also RB N
suggests VBZ N
the DT N
link NN N
between IN N
antihypertensive JJ N
agents NNS N
and CC N
energy NN N
hemostasis NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
antihypertensive JJ N
treatment NN N
on IN N
the DT N
irisin NN N
, , N
adropin NN N
, , N
and CC N
perilipin NN N
levels NNS N
in IN N
patients NNS 1_p
with IN 1_p
essential JJ 1_p
hypertension NN 1_p
and CC N
to TO N
compare VB N
them PRP N
with IN N
healthy JJ 1_p
volunteers NNS 1_p
in IN N
terms NNS N
of IN N
their PRP$ N
effect NN N
on IN N
energy NN N
hemostasis NN N
. . N

METHODS NNP N
In IN N
total JJ N
, , N
85 CD 1_p
newly RB 1_p
diagnosed VBN 1_p
patients NNS 1_p
with IN 1_p
untreated JJ 1_p
essential JJ 1_p
hypertension NN 1_p
were VBD 1_p
admitted VBN 1_p
to TO 1_p
the DT 1_p
outpatient NN 1_p
clinic NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
treatment NN N
protocols NNS N
: : N
amlodipine NN 1_i
or CC 1_i
valsartan NN 1_i
for IN N
a DT N
12 CD N
week NN N
period NN N
. . N

42 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
into IN 1_p
the DT 1_p
valsartan NN 1_i
group NN 1_p
and CC 1_p
43 CD 1_p
patients NNS 1_p
into IN 1_p
the DT 1_p
amlodipine NN 1_i
group NN 1_p
. . 1_p

Serum NNP 1_o
perilipin NN 1_o
, , 1_o
irisin NN 1_o
, , 1_o
and CC 1_o
adropin NN 1_o
levels NNS 1_o
were VBD N
measured VBN N
before IN N
and CC N
after IN N
drug NN N
treatment NN N
by IN N
ELISA NNP 1_i
kits NNS 1_i
. . 1_i

RESULTS NNP N
We PRP N
discovered VBD N
that IN N
the DT N
hypertensive JJ N
patients NNS N
have VBP N
lower JJR N
levels NNS 1_o
of IN 1_o
perilipin NN 1_o
and CC N
higher JJR N
levels NNS 1_o
of IN 1_o
adropin NN 1_o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Both DT N
amlodipine JJ 1_i
and CC N
valsartan NN 1_i
increased VBD N
the DT N
levels NNS 1_o
of IN 1_o
perilipin NN 1_o
, , 1_o
irisin NN 1_o
, , 1_o
and CC 1_o
adropin RB 1_o
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
conclusion NN N
, , N
in IN N
regulating VBG N
energy NN N
balance NN N
, , N
perilipin NN N
, , N
irisin NN N
, , N
and CC N
adropin NN N
, , N
could MD N
be VB N
of IN N
pathogenic JJ N
importance NN N
in IN N
obesity-induced JJ 1_p
hypertension NN 1_p
. . 1_p

Hence NNP N
, , N
ongoing VBG N
trials NNS N
need VBP N
to TO N
elucidate VB N
this DT N
mechanism NN N
. . N

-DOCSTART- -X- O O

Humoral NNP 1_p
immunity NN 1_p
after IN 1_p
kidney NN 1_p
transplantation NN 1_p
: : 1_p
impact NN N
of IN N
two CD N
randomized JJ N
immunosuppressive JJ N
protocols NNS N
. . N

BACKGROUND NNP N
Controlling NNP N
alloimmune JJ N
humoral JJ N
response NN N
is VBZ N
a DT N
challenge NN N
in IN N
transplantation NN N
. . N

Few JJ N
studies NNS N
have VBP N
evaluated VBN N
the DT N
impact NN N
of IN N
maintenance NN N
immunosuppression NN N
on IN N
blood NN N
humoral JJ N
parameters NNS N
. . N

MATERIAL/METHODS NNP N
We PRP N
performed VBD N
a DT N
post-hoc JJ N
analysis NN N
on IN N
307 CD 1_p
kidney NN 1_p
transplant NN 1_p
recipients NNS 1_p
included VBD 1_p
in IN 1_p
a DT 1_p
prospective JJ 1_p
randomized VBN 1_p
trial NN 1_p
comparing VBG 1_p
tacrolimus/mycophenolate NN 1_i
mofetil NN 1_i
( ( 1_i
Tac/MMF NNP 1_i
) ) 1_i
vs. FW 1_i
cyclosporine/azathioprine NN 1_i
( ( 1_i
CsA/AZA NNP 1_i
) ) 1_i
, , N
both DT N
used VBN N
with IN N
antithymocyte JJ 1_i
globulin NN 1_i
induction NN 1_i
and CC N
steroids NNS 1_i
. . 1_i

Humoral JJ N
parameters NNS N
were VBD N
analyzed VBN N
at IN N
D0 NNP N
, , N
D15 NNP N
, , N
and CC N
M12 NNP N
. . N

RESULTS NNP N
IgG NNP 1_o
, , 1_o
IgA NNP 1_o
, , 1_o
and CC 1_o
IgM NNP 1_o
levels NNS 1_o
decreased VBN N
significantly RB N
as RB N
soon RB N
as IN N
D15 NNP N
in IN N
both DT N
groups NNS N
( ( N
?35 CD N
% NN N
, , N
?26 CD N
% NN N
, , N
and CC N
?35 CD N
% NN N
respectively RB N
, , N
vs. FW N
D0 NNP N
) ) N
. . N

At IN N
M12 NNP N
, , N
although IN 1_o
peripheral JJ 1_o
B-cell NNP 1_o
counts NNS 1_o
did VBD 1_o
not RB 1_o
differ VB N
between IN N
the DT N
groups NNS N
, , N
Tac/MMF NNP N
regimen NN N
was VBD N
associated VBN N
with IN N
lower JJR N
IgG NNP N
, , N
IgA NNP N
, , N
and CC N
IgM NNP N
levels NNS N
than IN N
CsA/AZA NNP N
( ( N
?5.9 CD N
% NN N
, , N
?14.6 CD N
% NN N
, , N
and CC N
?34 NNP N
% NN N
, , N
respectively RB N
) ) 1_o
. . 1_o

Hypogammaglobulinemia NNP 1_o
at IN 1_o
D15 NNP 1_o
was VBD 1_o
not RB N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN 1_o
of IN 1_o
infections NNS 1_o
during IN N
the DT N
first JJ N
year NN N
. . N

The DT 1_o
proportion NN 1_o
of IN 1_o
HLA-sensitized JJ 1_o
patients NNS 1_o
decreased VBN 1_o
in IN N
the DT N
Tac/MMF NNP N
group NN N
( ( N
15.9 CD N
% NN N
at IN N
D0 NNP N
and CC N
6.7 CD N
% NN N
at IN N
M12 NNP N
, , N
p=0.02 NN N
) ) N
and CC N
remained VBD N
stable JJ N
in IN N
the DT N
CsA/AZA NNP N
group NN N
( ( N
10.3 CD N
% NN N
at IN N
D0 NNP N
and CC N
8.9 CD N
% NN N
at IN N
M12 NNP N
, , N
p=0.5 NN N
) ) N
. . N

More JJR N
patients NNS N
sensitized VBN N
at IN N
baseline NN N
became VBD N
non-sensitized JJ N
at IN N
M12 NNP N
with IN N
Tac/MMF NNP N
than IN N
with IN N
CsA/AZA NNP N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
humoral JJ N
immunosuppression NN N
is VBZ N
better RBR N
with IN N
Tac/MMF NNP N
than IN N
with IN N
CsA/AZA NNP N
during IN N
the DT N
first JJ N
year NN N
of IN N
kidney NN N
transplantation NN N
. . N

-DOCSTART- -X- O O

Contingency NNP 1_i
management NN 1_i
for IN N
the DT N
treatment NN N
of IN N
antipsychotic-induced JJ N
weight JJ 1_o
gain NN 1_o
: : 1_o
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
Weight NNP N
gain NN N
is VBZ N
common JJ N
for IN N
individuals NNS 1_p
with IN 1_p
serious JJ 1_p
mental JJ 1_p
illness NN 1_p
( ( 1_p
SMI NNP 1_p
) ) 1_p
receiving VBG 1_p
antipsychotic JJ 1_p
drug NN 1_p
therapy NN 1_p
. . 1_p

Contingency NNP 1_i
management NN 1_i
( ( 1_i
CM NNP 1_i
) ) 1_i
is VBZ N
a DT N
behavioral JJ N
intervention NN N
that IN N
rewards NNS N
positive JJ N
performance NN N
and CC N
has VBZ N
demonstrated VBN N
effectiveness NN N
in IN N
reducing VBG N
drug NN N
use NN N
in IN N
SMI NNP N
populations NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
feasibility NN N
of IN N
using VBG N
CM NNP 1_i
to TO N
promote VB N
weight JJ N
loss NN N
in IN N
individuals NNS 1_p
with IN 1_p
SMI NNP 1_p
over IN 1_p
8 CD 1_p
weeks NNS 1_p
. . 1_p

METHOD NNP N
30 CD 1_p
individuals NNS 1_p
( ( 1_p
BMI NNP 1_p
? . 1_p
28 CD 1_p
kg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
) ) 1_p
were VBD 1_p
randomized VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
i NN N
) ) N
The DT 1_i
combination NN 1_i
of IN 1_i
a DT 1_i
standardized JJ 1_i
lifestyle NN 1_i
modification NN 1_i
( ( 1_i
LM NNP 1_i
) ) 1_i
program NN 1_i
for IN 1_i
individuals NNS 1_i
with IN 1_i
SMI NNP 1_i
and CC 1_i
payment NN 1_i
for IN 1_i
group NN 1_i
attendance NN 1_i
( ( 1_i
CM NNP 1_i
( ( 1_i
attendance NN 1_i
) ) 1_i
) ) 1_i
, , 1_i
ii NN 1_i
) ) 1_i
The DT 1_i
combination NN 1_i
of IN 1_i
LM NNP 1_i
and CC 1_i
payment NN 1_i
for IN 1_i
weight JJ 1_i
loss NN 1_i
( ( 1_i
CM NNP 1_i
( ( 1_i
weight NN 1_i
) ) 1_i
) ) 1_i
, , 1_i
and CC 1_i
iii NN 1_i
) ) 1_i
waitlist NN 1_i
control NN 1_i
( ( 1_i
CON NNP 1_i
) ) 1_i
. . 1_i

After IN N
the DT N
waitlist JJ N
period NN N
, , N
those DT N
participants NNS N
joined VBD N
a DT N
LM NNP 1_i
group NN 1_i
and CC 1_i
received VBD 1_i
payment NN 1_i
for IN 1_i
behavioral JJ 1_i
change NN 1_i
( ( 1_i
CM NNP 1_i
( ( 1_i
behavior NN 1_i
) ) 1_i
) ) 1_i
. . 1_i

RESULTS JJ N
Subjects NNPS N
in IN N
the DT N
CM NNP N
( ( N
attendance NN N
) ) N
and CC N
in IN N
the DT N
CM NNP N
( ( N
weight NN N
) ) N
group NN N
lost VBD N
a DT N
mean NN 1_o
of IN 1_o
1.16 CD N
kg NNS N
and CC N
1.23 CD N
kg NN N
, , N
respectively RB N
, , N
while IN N
subjects NNS N
in IN N
the DT N
CON NNP 1_o
gained VBD 1_o
a DT 1_o
mean NN N
of IN N
0.68 CD N
kg NNS N
. . N

Subjects NNS N
receiving VBG N
CM NNP N
( ( N
behavior NN N
) ) N
, , N
lost VBD N
a DT N
mean NN N
of IN N
2.54 CD N
kg NNS N
, , N
which WDT N
was VBD N
a DT N
significant JJ 1_o
weight NN 1_o
loss NN 1_o
compared VBN 1_o
to TO N
the DT N
control NN N
period NN N
. . N

CONCLUSION NNP 1_i
LM NNP 1_i
supplemented VBD 1_i
with IN 1_i
CM NNP 1_i
may MD 1_i
facilitate VB 1_o
weight NN 1_o
loss NN 1_o
in IN 1_o
patients NNS 1_p
taking VBG 1_p
antipsychotic JJ 1_p
medications NNS 1_p
; : 1_p
financial JJ 1_p
reimbursement NN N
for IN N
behavioral JJ N
change NN N
may MD N
be VB N
particularly RB N
effective JJ N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Studies NNS N
on IN N
leptin NN 1_o
and CC 1_o
leptin NN 1_o
receptor NN 1_o
gene NN 1_o
expression NN 1_o
in IN N
myometrium NN 1_p
and CC 1_p
uterine JJ 1_p
myomas NN 1_p
of IN 1_p
gnRH JJ 1_i
analogue-treated JJ 1_i
women NNS 1_p
. . 1_p

AIM NNP N
To TO N
test VB N
if IN N
treatment NN N
with IN N
GnRH NNP 1_i
analogue NN 1_i
, , N
which WDT N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
myoma NN 1_o
volume NN 1_o
, , 1_o
changes NNS 1_o
expression NN 1_o
of IN 1_o
leptin NN 1_o
genes NNS 1_o
and CC 1_o
gene NN 1_o
coding VBG 1_o
leptin JJ 1_o
receptor NN 1_o
isoforms NNS 1_o
in IN N
uterine JJ N
myomas NN N
and CC N
in IN N
the DT N
surrounding NN N
unaltered JJ N
myometrium NN N
. . N

METHODS NNP N
Using VBG N
RT-PCR NNP N
, , N
expression NN N
of IN N
leptin NN N
genes NNS N
and CC N
leptin NN N
receptor NN N
genes NNS N
was VBD N
studied VBN N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
in IN N
women NNS 1_p
with IN 1_p
uterine JJ 1_p
myomas NN 1_p
, , 1_p
untreated VBD 1_p
or CC 1_p
treated VBN 1_p
with IN 1_p
GnRH NNP 1_i
analogue NN 1_i
. . 1_i

In IN N
the DT N
randomly RB N
selected VBN N
cases NNS N
presence NN N
of IN N
leptin NN N
protein NN N
and CC N
of IN N
leptin JJ N
receptor NN N
proteins NNS N
was VBD N
examined VBN N
also RB N
by IN N
Western JJ N
blotting NN N
. . N

RESULTS NNP N
Expression NNP 1_o
of IN 1_o
leptin NN 1_o
genes NNS 1_o
was VBD N
demonstrated VBN N
both DT N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
, , N
and CC N
a DT N
similar JJ N
pattern NN N
of IN N
expression NN N
was VBD N
found VBN N
for IN N
leptin JJ N
receptor NN N
isoforms NNS N
. . N

The DT N
results NNS N
of IN N
RT-PCR NNP N
were VBD N
confirmed VBN N
by IN N
Western JJ N
blotting NN N
, , N
which WDT N
documented VBD N
the DT N
identical JJ N
distribution NN N
of IN N
leptin NN 1_o
proteins NNS 1_o
and CC 1_o
leptin JJ 1_o
receptor NN 1_o
proteins NNS 1_o
in IN N
studied JJ N
tissues NNS N
. . N

Treatment NN N
with IN N
GnRH NNP 1_i
analogue NN 1_i
had VBD N
no DT N
effect NN 1_o
on IN N
the DT N
expression NN 1_o
pattern NN 1_o
of IN N
studied VBN N
genes NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
on IN N
the DT N
administration NN N
of IN N
GnRH NNP 1_i
analogue NN 1_i
to TO N
females NNS 1_p
with IN 1_p
myomas NN 1_p
suggest VBP N
that IN N
no DT N
direct JJ N
or CC N
immediate JJ N
inter-relationship JJ N
exists NNS N
between IN N
expression NN N
of IN N
leptin NN 1_o
genes NNS 1_o
in IN N
uterine JJ N
myomas NN N
on IN N
one CD N
hand NN N
and CC N
estrogen NN N
, , N
progesterone NN N
and CC N
leptin NN N
levels NNS N
in IN N
the DT N
blood NN N
on IN N
the DT N
other JJ N
. . N

Expression NN N
seems VBZ N
to TO N
be VB N
of IN N
a DT N
more RBR N
durable JJ N
nature NN N
but CC N
factors NNS N
that WDT N
induce VBP N
such JJ N
expression NN N
remain VBP N
unknown JJ N
. . N

-DOCSTART- -X- O O

Improved VBN 1_o
intraoperative JJ 1_o
management NN 1_o
of IN N
anastomotic JJ 1_o
bleeding NN 1_o
during IN 1_p
aortic JJ 1_p
reconstruction NN 1_p
: : 1_p
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
the DT N
effectiveness NN 1_o
of IN N
a DT N
polymeric JJ 1_i
surgical JJ 1_i
sealant NN 1_i
( ( 1_i
CoSeal NNP 1_i
) ) 1_i
was VBD N
compared VBN 1_i
to TO 1_i
Gelfoam/thrombin NNP 1_i
for IN 1_i
managing VBG 1_i
anastomotic JJ 1_o
bleeding NN 1_o
after IN 1_i
implantation NN 1_i
of IN 1_i
Dacron NNP 1_i
grafts NNS 1_i
during IN 1_i
aortic JJ 1_i
reconstruction NN 1_i
for IN 1_i
nonruptured JJ 1_i
aneurysms NNS 1_i
. . 1_i

Each DT 1_i
treatment NN 1_i
was VBD 1_i
directly RB 1_i
applied VBN 1_i
to TO 1_i
the DT 1_i
suture NN 1_i
line NN 1_i
after IN 1_i
confirmation NN 1_i
of IN 1_i
anastomotic JJ 1_i
bleeding NN 1_i
. . 1_i

The DT N
proportion NN N
of IN N
suture NN N
line NN N
sites VBZ N
that IN N
achieved VBD N
immediate JJ 1_o
sealing NN 1_o
and CC N
the DT N
proportion NN N
sealed VBD N
within IN N
5 CD N
minutes NNS N
were VBD N
determined VBN N
among IN N
37 CD 1_p
experimental JJ 1_p
( ( 1_p
59 CD 1_p
sites NNS 1_p
) ) 1_p
and CC 1_p
17 CD 1_p
control NN 1_p
subjects NNS 1_p
( ( 1_p
27 CD 1_p
sites NNS 1_p
) ) 1_p
. . 1_p

A DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
bleeding VBG N
suture NN N
line NN N
sites NNS N
treated VBD N
with IN N
the DT N
polymeric JJ 1_i
sealant NN 1_i
achieved VBN N
immediate JJ 1_o
sealing NN 1_o
following VBG N
reestablishment NN N
of IN N
blood NN N
flow NN N
compared VBN N
with IN N
control-treated JJ N
sites NNS N
[ VBP N
48 CD N
of IN N
59 CD N
( ( N
81 CD N
% NN N
) ) N
vs VBZ N
10 CD N
of IN N
27 CD N
( ( N
37 CD N
% NN N
) ) N
; : N
P NNP N
= VBD N
0.002 CD N
] NN N
. . N

The DT N
difference NN N
between IN N
treatment NN N
groups NNS N
was VBD N
maintained VBN N
after IN N
5 CD N
minutes NNS N
with IN N
approximately RB N
85 CD N
per IN N
cent NN N
( ( N
50 CD N
of IN N
59 CD N
) ) N
of IN N
CoSeal NNP 1_i
sites NNS N
compared VBN N
to TO N
just RB N
over IN N
one-half JJ N
( ( N
14 CD N
of IN N
27 CD N
) ) N
of IN N
control NN N
sites VBZ N
demonstrating VBG N
ultimate JJ 1_o
sealing NN 1_o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
adverse JJ N
events NNS N
related VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
polymeric JJ 1_i
sealant NN 1_i
in IN N
this DT N
study NN N
. . N

These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
novel JJ N
sealant NN N
for IN N
the DT N
intraoperative JJ 1_p
management NN 1_p
of IN 1_p
anastomotic JJ 1_p
bleeding NN 1_p
during IN 1_p
aortic JJ 1_p
reconstruction NN 1_p
procedures NNS 1_p
. . 1_p

-DOCSTART- -X- O O

The DT N
EUROSCAN NNP 1_i
Study NNP 1_p
. . 1_p

EUROSCAN NNP 1_i
Steering NNP 1_p
Committee NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Comparison NNP 1_p
of IN 1_p
some DT 1_p
pharmacokinetic JJ 1_o
parameters NNS 1_o
of IN 1_p
( ( 1_o
+ NNP 1_o
) ) 1_o
-cyanidanol-3 NN 1_o
obtained VBN 1_p
with IN 1_p
specific JJ 1_p
and CC 1_p
non-specific JJ 1_p
analytical JJ 1_p
methods NNS 1_p
. . 1_p

-DOCSTART- -X- O O

The DT N
acute JJ N
effects NNS N
of IN N
fluid JJ N
intake NN N
on IN N
urine JJ N
specific JJ N
gravity NN N
and CC N
fluid JJ N
retention NN N
in IN N
a DT 1_p
mildly RB 1_p
dehydrated JJ 1_p
state NN 1_p
. . 1_p

Many JJ N
athletes NNS 1_p
arrive VBP N
at IN N
training NN N
sessions NNS N
and CC N
competitions NNS N
in IN N
a DT N
mildly RB 1_p
hypohydrated VBN 1_p
( ( 1_p
HYPO NNP 1_p
) ) 1_p
state NN 1_p
and CC N
are VBP N
instructed VBN N
to TO N
drink VB N
fluids NNS N
before IN N
exercise NN N
to TO N
reach VB N
a DT N
euhydrated JJ N
( ( N
HYD NNP N
) ) N
state NN N
. . N

Ten CD 1_p
recreational JJ 1_p
athletes NNS 1_p
( ( 1_p
6 CD 1_p
women NNS 1_p
, , 1_p
4 CD 1_p
men NNS 1_p
; : 1_p
71.9 CD 1_p
? . 1_p
4.6 CD 1_p
kg NN 1_p
, , 1_p
25.2 CD 1_p
? . 1_p
0.9 CD 1_p
years NNS 1_p
) ) 1_p
participated VBD 1_p
in IN 1_p
the DT N
studies NNS N
to TO N
examine VB N
( ( N
a DT N
) ) N
the DT N
day-to-day JJ N
variability NN N
of IN N
morning NN N
urine NN N
specific JJ N
gravity NN N
( ( N
USG NNP N
) ) N
, , N
( ( N
b NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG 1_i
600 CD 1_i
ml NN 1_i
of IN 1_i
water NN 1_i
on IN 1_i
the DT N
hydration NN N
status NN N
of IN N
HYD NNP N
and CC N
HYPO NNP N
( ( N
USG NNP N
> NNP N
1.020 CD N
) ) N
subjects NNS N
, , N
and CC N
( ( N
c NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG 1_i
water NN 1_i
( ( 1_i
W NNP 1_i
) ) 1_i
, , 1_i
salt-water JJ 1_i
( ( 1_i
SW NNP N
, , N
40 CD N
mM NN N
Na NNP N
) ) N
, , N
a DT N
carbohydrate-electrolyte JJ 1_i
solution NN 1_i
with IN 1_i
3 CD 1_i
% NN 1_i
or CC 1_i
light JJ 1_i
carbohydrate NN 1_i
( ( 1_i
CES-L NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
or CC N
a DT N
CES NN 1_i
with IN 1_i
6 CD 1_i
% NN 1_i
carbohydrate NN 1_i
( ( 1_i
CES NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYPO NNP N
subjects NNS N
. . N

The DT N
hydration NN N
status NN N
was VBD N
assessed VBN N
with IN N
USG NNP N
and CC N
body NN N
mass NN N
measures NNS N
and CC N
urine JJ N
volume NN N
collections NNS N
. . N

The DT N
day-to-day JJ N
variability NN N
in IN N
morning NN N
USG NNP N
( ( N
coefficient NN N
of IN N
variation NN N
= FW N
0.2 CD N
? . N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
and CC N
the DT N
responses NNS N
to TO N
600 CD N
ml NN N
of IN N
W NNP N
ingestion NN N
were VBD N
repeatable JJ 1_o
. . 1_o

Pretrial JJ 1_o
USG NNP 1_o
was VBD 1_o
1.022 CD N
? . N
0.001 CD N
in IN N
the DT N
HYPO NNP N
trial NN N
and CC N
decreased VBD N
< NNS N
1.020 CD N
by IN N
45 CD N
minutes NNS N
( ( N
1.013 CD N
? . N
0.003 CD N
) ) N
. . N

In IN N
the DT N
CES NNP N
study NN N
, , N
HYPO NNP N
subjects VBZ N
reached VBN N
HYD NNP N
status NN N
at IN N
45 CD N
minutes NNS N
in IN N
all DT N
conditions NNS N
( ( N
W NNP N
1.013 CD N
? . N
0.003 CD N
, , N
SW NNP N
1.013 CD N
? . N
0.003 CD N
, , N
CES-L NNP N
1.011 CD N
? . N
0.003 CD N
, , N
CES NNP N
1.017 CD N
? . N
0.004 CD N
) ) N
because IN N
salt NN N
or CC N
CES NNP N
ingestion NN N
did VBD N
not RB N
affect VB 1_o
fluid NN 1_o
retention NN 1_o
( ( 1_o
W NNP 1_o
68 CD 1_o
% NN 1_o
, , 1_o
SW NNP N
72 CD N
% NN N
, , N
CES-L JJ N
68 CD N
% NN N
, , N
CES NNP N
76 CD N
% NN N
) ) N
. . N

This DT N
study NN N
demonstrated VBD 1_p
that IN 1_p
mildly RB 1_p
HYPO NNP 1_p
subjects NNS 1_p
could MD N
reach VB N
euhydration NN N
within IN N
45 CD N
minutes NNS N
of IN N
the DT N
ingestion NN N
of IN N
600 CD N
ml NN N
of IN N
W NNP 1_i
or CC N
a DT N
combination NN N
of IN N
salt NN N
and CC N
CES NNP 1_i
solutions NNS N
. . N

Following VBG N
this DT N
practice NN N
will MD N
minimize VB N
the DT N
incidence NN N
of IN N
starting VBG N
a DT N
practice NN N
or CC N
competition NN N
hypohydrated VBN N
. . N

-DOCSTART- -X- O O

A DT N
trial NN N
of IN N
D-cycloserine NNP 1_i
to TO N
treat VB N
stereotypies NNS N
in IN N
older JJR 1_p
adolescents NNS 1_p
and CC 1_p
young JJ 1_p
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

OBJECTIVES CC N
Autism NNP N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
have VBP N
core VBN N
impairments NNS N
in IN N
social JJ N
communication NN N
as RB N
well RB N
as IN N
the DT N
presence NN N
of IN N
repetitive JJ N
, , N
stereotypic JJ N
behaviors NNS N
and CC N
restricted JJ N
interests NNS N
. . N

Older JJR N
adolescents NNS N
and CC N
young JJ N
adults NNS N
are VBP N
particularly RB N
impacted VBN N
by IN N
these DT N
deficits NNS N
. . N

Preclinical NNP N
data NN N
implicate NN N
glutamatergic JJ N
dysfunction NN N
in IN N
the DT N
pathophysiology NN N
of IN N
ASDs NNP N
. . N

D-Cycloserine NNP 1_i
( ( 1_i
DCS NNP 1_i
) ) 1_i
, , N
a DT N
partial JJ N
glycineB NN N
agonist NN N
at IN N
the DT N
N-methyl-D-aspartic JJ N
acid NN N
receptor NN N
site NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
sociability NN N
in IN N
mouse NN N
models NNS N
and CC N
a DT N
small JJ N
human NN N
study NN N
. . N

The DT N
sensitivity NN N
of IN N
the DT N
obligatory JJ N
glycineB JJ N
co-agonist NN N
binding VBG N
site NN N
may MD N
change VB N
with IN N
daily JJ N
administration NN N
of IN N
DCS NNP N
as IN N
a DT N
result NN N
of IN N
agonist-induced JJ N
desensitization NN N
. . N

The DT N
efficacy NN 1_o
of IN N
a DT N
pulsed JJ N
once-weekly JJ N
administration NN N
versus IN N
daily JJ N
administration NN N
of IN N
DCS NNP N
was VBD N
compared VBN N
. . N

METHODS NNP N
Males NNP 1_p
and CC 1_p
females NNS 1_p
, , 1_p
ages VBZ 1_p
14 CD 1_p
to TO 1_p
25 CD 1_p
years NNS 1_p
, , 1_p
with IN 1_p
a DT 1_p
Diagnostic NNP 1_p
and CC 1_p
Statistical NNP 1_p
Manual NNP 1_p
of IN 1_p
Mental NNP 1_p
Disorders NNP 1_p
, , 1_p
Fourth NNP 1_p
Edition NNP 1_p
Text NNP 1_p
Revision NNP 1_p
diagnosis NN 1_p
of IN 1_p
an DT 1_p
ASD NNP 1_p
were VBD 1_p
enrolled VBN 1_p
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
10-week JJ N
trial NN N
consisting NN N
of IN N
8 CD N
weeks NNS N
of IN N
active JJ N
drug NN N
with IN N
either DT N
weekly JJ N
or CC N
daily JJ N
administration NN N
of IN N
50 CD N
mg NN N
of IN N
DCS NNP 1_i
followed VBN N
by IN N
a DT N
2-week JJ N
follow-up JJ N
visit NN N
. . N

RESULTS NNP N
For IN N
the DT N
purposes NNS N
of IN N
this DT N
study NN N
, , N
no DT N
statistical JJ N
or CC N
clinical JJ N
differences NNS 1_o
existed VBD N
between IN N
the DT N
2 CD N
dosage NN N
groups NNS N
on IN N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
subscale NN 1_o
3 CD 1_o
, , 1_o
which WDT 1_o
measures VBZ 1_o
stereotypies/repetitive JJ 1_o
movements NNS 1_o
. . 1_o

When WRB N
combining VBG N
groups NNS N
, , N
a DT N
statistically RB N
significant JJ N
decrease NN N
of IN N
37 CD N
% NN N
was VBD N
found VBN N
from IN N
baseline NN N
to TO N
week NN N
8 CD N
when WRB N
study NN N
drug NN N
was VBD N
completed VBN N
using VBG N
a DT N
linear JJ N
mixed JJ N
effects NNS N
model FW N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSIONS NNP N
D-Cycloserine NNP 1_i
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
improving VBG N
stereotypic NN 1_o
symptoms NNS 1_o
in IN N
older JJR N
adolescents NNS N
and CC N
young JJ N
adults NNS N
with IN N
ASDs NNP N
measured VBN N
by IN N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
subscale VBD 1_o
3 CD 1_o
. . 1_o

In IN N
addition NN N
, , N
DCS NNP 1_i
was VBD N
safe JJ 1_o
and CC 1_o
well RB 1_o
tolerated VBN 1_o
. . 1_o

-DOCSTART- -X- O O

Effects NNS N
of IN N
skin-to-skin JJ 1_i
contact NN 1_i
on IN N
autonomic JJ 1_o
pain NN 1_o
responses NNS 1_o
in IN N
preterm JJ 1_p
infants NNS 1_p
. . 1_p

UNLABELLED IN N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
crossover NN N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
on IN N
autonomic JJ N
responses NNS N
in IN N
preterm JJ 1_p
infants NNS 1_p
of IN 1_p
longer JJR 1_p
Kangaroo NNP 1_i
Care NNP 1_i
( ( 1_p
30 CD 1_p
minutes NNS 1_p
, , 1_p
KC30 NNP 1_i
) ) 1_i
and CC 1_p
shorter JJR 1_p
KC NNP 1_i
( ( 1_p
15 CD 1_p
minutes NNS 1_p
, , 1_p
KC15 NNP 1_i
) ) 1_i
before IN 1_p
and CC 1_p
throughout IN 1_p
heel NN 1_p
stick NNS 1_p
compared VBN 1_p
with IN 1_p
incubator NN 1_i
care NN 1_i
( ( 1_i
IC NNP 1_i
) ) 1_i
. . 1_p

Beat-to-beat JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
and CC N
spectral JJ N
power NN N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
, , N
low JJ N
frequency NN N
power NN N
( ( N
LF NNP N
) ) N
, , N
high JJ N
frequency NN N
power NN N
( ( N
HF NNP N
) ) N
, , N
and CC N
LF/HF NNP N
ratio NN N
were VBD N
measured VBN N
in IN N
26 CD 1_p
infants NNS 1_p
. . 1_p

HR NNP 1_o
changes NNS N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
were VBD N
significantly RB N
less RBR N
in IN N
KC30 NNP N
and CC N
KC15 NNP N
than IN N
in IN N
IC NNP N
, , N
and CC N
more JJR N
infants NNS N
had VBD N
HR NNP 1_o
decrease NN N
in IN N
IC NNP N
than IN N
in IN N
2 CD N
KC NNP N
conditions NNS N
. . N

In IN N
IC NNP N
, , N
LF NNP 1_o
and CC 1_o
HF NNP 1_o
significantly RB N
increased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
dropped VBD N
from IN N
Heel NNP N
Stick NNP N
to TO N
Recovery NNP N
; : N
in IN N
2 CD N
KC NNP N
conditions NNS N
, , N
no DT N
changes NNS N
across IN N
study NN N
phases NNS N
were VBD N
found VBN N
. . N

During IN N
Heel NNP N
Stick NNP N
, , N
LF NNP 1_o
and CC N
HF NNP 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
IC NNP N
than IN N
in IN N
KC30 NNP 1_i
. . 1_i

In IN N
all DT N
3 CD N
conditions NNS N
, , N
LF/HF NNP 1_o
ratio NN 1_o
decreased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
increased VBD N
to TO N
Recovery NNP N
; : N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
IC NNP 1_i
and CC N
two CD N
KC NNP 1_i
conditions NNS N
. . N

Both NNP N
longer JJR N
and CC N
shorter JJR N
KC NNP 1_i
before IN N
and CC N
throughout IN N
heel NN N
stick NN N
can MD N
stabilize VB N
HR NNP 1_o
response NN 1_o
in IN N
preterm JJ N
infants NNS N
, , N
and CC N
longer JJR N
KC NNP 1_i
significantly RB N
affected VBD N
infants NNS N
' POS N
sympathetic JJ N
and CC N
parasympathetic JJ N
responses NNS N
during IN N
heel NN N
stick NNS N
compared VBN N
with IN N
incubator NN 1_i
care NN 1_i
. . 1_i

PERSPECTIVE VB N
This DT N
study NN N
showed VBD N
that IN N
KC NNP 1_i
has VBZ N
a DT N
significant JJ N
effect NN N
on IN N
reducing VBG N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ 1_p
infants NNS 1_p
. . 1_p

The DT N
findings NNS N
support NN N
that IN N
KC NNP 1_i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pain NN N
intervention NN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
activated JJ N
charcoal NN N
in IN N
a DT N
simulated JJ N
poisoning NN 1_p
with IN 1_p
acetaminophen NN 1_p
: : 1_p
a DT N
new JJ N
loading NN N
dose NN N
for IN N
N-acetylcysteine NNP 1_i
? . N
STUDY NNP N
OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
ability NN N
of IN N
a DT N
supranormal JJ N
dose NN N
of IN N
N-acetylcysteine NNP 1_i
to TO N
overcome VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
N-acetylcysteine NNP N
bioavailability NN N
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
serum NN N
acetaminophen NN N
levels NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Ten NNP 1_p
healthy JJ 1_p
adult NN 1_p
volunteers NNS 1_p
participated VBD N
in IN N
a DT N
controlled JJ N
cross-over JJ N
experiment NN N
. . N

During IN N
phase NN N
I PRP N
( ( N
control NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD 1_i
g NN 1_i
acetaminophen NN 1_i
, , N
followed VBD N
one CD 1_i
hour NN 1_i
later RB 1_i
by IN 1_i
the DT 1_i
normal JJ 1_i
loading VBG 1_i
dose NN 1_i
of IN 1_i
N-acetylcysteine NNP 1_i
( ( N
140 CD N
mg/kg NN N
) ) N
. . N

During IN N
phase NN N
II NNP N
( ( N
charcoal NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD 1_i
g NN 1_i
acetaminophen NN 1_i
, , N
followed VBD N
one CD N
hour NN N
later RB N
by IN N
60 CD 1_i
g NNS 1_i
activated VBN 1_i
charcoal NN 1_i
and CC 1_i
a DT 1_i
supranormal JJ 1_i
loading NN 1_i
dose NN 1_i
of IN 1_i
N-acetylcysteine NNP 1_i
( ( N
235 CD N
mg/kg NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Serum NNP 1_o
levels NNS 1_o
of IN 1_o
N-acetylcysteine NNP 1_o
were VBD N
measured VBN N
every DT N
30 CD N
minutes NNS N
for IN N
six CD N
hours NNS N
. . N

A DT N
serum NN 1_o
acetaminophen NN 1_o
level NN 1_o
was VBD N
measured VBN N
at IN N
four CD N
hours NNS N
. . N

RESULTS VB N
The DT N
area NN 1_o
under IN 1_o
the DT 1_o
curve NN 1_o
for IN 1_o
N-acetylcysteine NNP 1_o
was VBD N
significantly RB N
higher JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
. . N

Peak VB 1_o
N-acetylcysteine JJ 1_o
and CC 1_o
time NN 1_o
to TO 1_o
peak VB 1_o
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
four-hour JJ 1_o
serum NN 1_o
acetaminophen NN 1_o
level NN 1_o
was VBD N
significantly RB N
lower JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
. . N

Diarrhea NNP 1_o
occurred VBD N
during IN N
both DT N
phases NNS N
, , N
but CC N
N-acetylcysteine NNP 1_i
was VBD N
otherwise RB N
well RB N
tolerated VBN 1_o
. . 1_o

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
activated JJ N
charcoal NN N
can MD N
be VB N
used VBN N
safely RB N
for IN N
victims NNS 1_p
of IN 1_p
acetaminophen NN 1_p
overdose NN 1_p
. . 1_p

A DT N
beneficial JJ N
effect NN N
in IN N
preventing VBG N
acetaminophen JJ N
absorption NN N
can MD N
be VB N
expected VBN N
if IN N
it PRP N
is VBZ N
given VBN N
within IN N
one CD N
hour NN N
after IN N
ingestion NN N
. . N

If IN N
N-acetylcysteine NNP 1_i
is VBZ N
needed VBN N
because IN N
of IN N
a DT N
toxic JJ N
serum NN N
acetaminophen NN N
level NN N
, , N
bioavailability NN N
can MD N
be VB N
ensured VBN N
by IN N
increasing VBG N
the DT N
N-acetylcysteine JJ 1_i
loading NN N
dose NN N
from IN N
140 CD N
mg/kg NNS N
to TO N
235 CD N
mg/kg NNS N
. . N

-DOCSTART- -X- O O

Long JJ N
term NN N
response NN N
to TO N
therapy NN N
of IN N
chronic JJ 1_p
anti-HBe-positive JJ 1_p
hepatitis NN 1_p
B NNP 1_p
is VBZ N
poor JJ N
independent JJ N
of IN N
type NN N
and CC N
schedule NN N
of IN N
interferon NN N
. . N

OBJECTIVE CC N
The DT N
response NN 1_o
rate NN 1_o
to TO 1_o
alpha VB 1_o
interferon NN 1_o
( ( 1_o
IFN NNP 1_o
) ) 1_o
of IN N
chronic JJ N
anti-HBe-positive JJ N
hepatitis NN N
B NNP N
is VBZ N
variable JJ N
. . N

We PRP N
studied VBD N
whether IN N
type NN N
, , N
dose NN N
, , N
and CC N
schedule NN N
of IN N
IFN NNP 1_i
, , N
and CC N
type NN N
and CC N
frequency NN N
of IN N
posttreatment NN N
monitoring NN N
, , N
influence VB N
the DT N
response NN N
rate NN N
. . N

METHODS NNP N
Seventy-two JJ 1_p
consecutive JJ 1_p
anti-HBe-positive JJ 1_p
chronic NN 1_p
hepatitis NN 1_p
B NNP 1_p
patients NNS 1_p
( ( 1_p
59 CD 1_p
male NN 1_p
and CC 1_p
13 CD 1_p
female NN 1_p
, , 1_p
median JJ 1_p
age NN 1_p
41 CD 1_p
yr NN 1_p
) ) 1_p
stratified VBN 1_p
by IN 1_p
sex NN 1_p
and CC 1_p
histology NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
arms NNS N
. . N

Twenty-seven JJ N
patients NNS N
( ( N
A DT N
) ) N
received VBD N
10 CD N
million CD N
units NNS N
alpha-N1 JJ 1_i
IFN NNP 1_i
i.m NN 1_i
. . 1_i

t.w NN N
. . N

for IN N
24 CD N
wk NN N
( ( N
total JJ N
dose NN N
: : N
720 CD N
million CD N
units NNS N
) ) N
; : N
21 CD N
( ( N
B NNP N
) ) N
received VBD N
9 CD N
million CD N
units NNS N
alpha-2a JJ 1_i
IFN NNP 1_i
i.m NN 1_i
. . 1_i

t.w NN N
. . N

for IN N
4 CD N
wk NN N
, , N
followed VBN N
by IN N
18 CD N
million CD N
units NNS N
for IN N
12 CD N
wk NN N
and CC N
9 CD N
million CD N
units NNS N
for IN N
8 CD N
wk NN N
( ( N
972 CD N
million CD N
units NNS N
) ) N
; : N
24 CD N
( ( N
C NNP N
) ) N
received VBD N
2 CD 1_i
alpha-2a JJ 1_i
IFN NNP 1_i
courses NNS 1_i
( ( N
9 CD N
million CD N
units NNS N
i.m RB N
. . N

t.w NN N
. . N

for IN N
16 CD N
and CC N
12 CD N
wk NN N
separated VBN N
by IN N
a DT N
6-month JJ N
interval NN N
[ $ N
756 CD N
million CD N
units NNS N
] NNP N
) ) N
. . N

Primary JJ N
response NN N
was VBD N
defined VBN N
by IN N
normal JJ 1_o
ALT NNP 1_o
and CC 1_o
serum VB 1_o
HBV-DNA NNP 1_o
levels NNS 1_o
below IN N
10 CD N
pg/ml NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBN N
response NN N
by IN N
normal JJ 1_o
ALT NNP 1_o
( ( N
tested VBN N
monthly RB N
) ) N
, , N
undetectable JJ 1_o
HBV-DNA NN 1_o
and CC N
IgM NNP N
anti-HBc NN N
( ( N
< JJ N
7 CD N
I.U NNP N
. . N

Paul NNP N
Ehrlich NNP N
Institute NNP N
) ) N
( ( N
tested VBN N
every DT N
3 CD N
months NNS N
) ) N
during IN N
the DT N
posttreatment JJ N
follow-up NN N
. . N

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
12 CD N
, , N
8 CD N
, , N
and CC N
13 CD N
patients NNS N
from IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
, , N
respectively RB N
, , N
were VBD N
responders NNS N
. . N

At IN N
the DT N
18-month JJ N
follow-up JJ N
, , N
two CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
only RB N
one CD N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
maintained VBD N
the DT N
response NN 1_o
. . 1_o

Overall NNP N
, , N
after IN N
34 CD N
months NNS N
( ( N
median JJ N
posttreatment NN N
follow-up NN N
) ) N
, , N
three CD N
patients NNS N
were VBD N
long JJ N
term NN N
responders NNS N
, , N
whereas NNS N
three CD N
showed VBD N
a DT N
sustained VBN N
remission NN 1_o
after IN N
relapse NN N
. . N

CONCLUSIONS VB N
The DT N
rate NN 1_o
of IN 1_o
long JJ 1_o
term NN 1_o
response NN 1_o
to TO N
interferon VB N
of IN N
anti-HBe-positive JJ N
chronic JJ N
hepatitis NN N
B NNP N
is VBZ N
poor JJ N
, , N
independent JJ N
of IN N
IFN NNP N
type NN N
, , N
dose VB N
, , N
or CC N
schedule NN N
; : N
the DT N
more RBR N
stringent JJ N
the DT N
monitoring NN N
, , N
the DT N
higher JJR N
the DT N
relapse NN N
rate NN N
. . N

-DOCSTART- -X- O O

Standardized NNP N
preoperative JJ N
corticosteroid NN 1_i
treatment NN N
in IN N
neonates NNS 1_p
undergoing VBG 1_p
cardiac JJ 1_p
surgery NN 1_p
: : 1_p
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE CC N
A DT N
heightened JJ N
inflammatory NN N
response NN N
occurs VBZ N
after IN N
cardiac JJ N
surgery NN N
. . N

The DT N
perioperative JJ N
use NN N
of IN N
glucocorticoids NNS N
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
method NN N
to TO N
improve VB N
postoperative JJ N
outcomes NNS N
. . N

Randomized VBN N
prospective JJ N
studies NNS N
to TO N
quantify VB N
the DT N
effect NN N
of IN N
methylprednisolone NN 1_i
on IN N
perioperative JJ N
outcomes NNS N
in IN N
neonatal JJ 1_p
cardiac NN 1_p
surgery NN 1_p
have VBP N
not RB N
been VBN N
performed VBN N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
preoperative JJ N
methylprednisolone NN N
would MD N
improve VB N
postoperative JJ N
recovery NN N
in IN N
neonates NNS N
requiring VBG N
cardiac JJ N
surgery NN N
. . N

METHODS NNP N
Neonates NNP 1_p
scheduled VBD 1_p
for IN 1_p
cardiac JJ 1_p
surgery NN 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
receive VB 1_p
either DT N
2-dose JJ N
( ( N
8 CD N
hours NNS N
preoperatively RB N
and CC N
operatively RB N
, , N
n JJ 1_p
= NNP 1_p
39 CD 1_p
) ) 1_p
or CC 1_p
single-dose JJ N
( ( N
operatively RB 1_p
, , 1_p
n JJ 1_p
= NNP 1_i
37 CD 1_i
) ) 1_i
methylprednisolone NN 1_i
( ( 1_i
30 CD 1_i
mg/kg NN N
per IN N
dose NN N
) ) N
in IN N
a DT N
prospective JJ N
double-blind JJ N
trial NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
incidence NN 1_o
of IN 1_o
low JJ 1_o
cardiac JJ 1_o
output NN 1_o
syndrome NN 1_o
( ( 1_o
standardized VBN 1_o
score NN N
) ) N
or CC N
death NN N
36 CD N
hours NNS N
postoperatively RB N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
death NN 1_o
at IN 1_o
30 CD 1_o
days NNS 1_o
, , 1_o
interleukin-6 JJ 1_o
levels NNS 1_o
, , 1_o
inotropic NN 1_o
score NN 1_o
, , 1_o
fluid NN 1_o
balance NN 1_o
, , 1_o
serum JJ 1_o
creatinine NN 1_o
, , 1_o
and CC 1_o
intensive JJ 1_o
care NN 1_o
unit NN 1_o
and CC 1_o
hospital NN 1_o
stay NN 1_o
. . 1_o

RESULTS NNP 1_o
Preoperative NNP 1_o
plasma NN 1_o
levels NNS 1_o
of IN 1_o
the DT N
inflammatory JJ 1_o
cytokine JJ 1_o
interleukin-6 NN 1_o
were VBD 1_o
reduced VBN N
by IN N
2-fold JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
2-dose JJ N
methylprednisolone NN N
group NN N
, , N
consistent NN N
with IN N
the DT N
anti-inflammatory JJ N
effects NNS N
of IN N
methylprednisolone NN N
. . N

However RB N
, , N
the DT N
incidence NN 1_o
of IN 1_o
low JJ 1_o
cardiac JJ 1_o
output NN 1_o
syndrome NN 1_o
was VBD 1_o
46 CD 1_o
% NN N
( ( N
17/37 CD N
) ) N
in IN N
the DT N
single-dose JJ N
and CC N
38 CD N
% NN N
( ( N
15/39 CD N
) ) N
in IN N
the DT N
2-dose JJ N
methylprednisolone NN N
groups NNS N
( ( N
P NNP N
= NNP N
.51 NNP N
) ) N
. . N

Two-dose JJ N
methylprednisolone NN N
was VBD N
associated VBN 1_o
with IN 1_o
a DT 1_o
higher JJR 1_o
serum NN 1_o
creatinine NN 1_o
( ( 1_o
0.61 CD 1_o
? . 1_o
0.18 CD N
mg/dL NN N
vs NN N
0.53 CD N
? . N
0.12 CD N
mg/dL NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC 1_o
poorer $ 1_o
postoperative JJ 1_o
diuresis NN 1_o
( ( 1_o
-96 VB 1_o
? . N
49 CD N
mL NN N
, , N
P NNP N
= NNP N
.05 NNP N
) ) N
. . N

Inotropic NNP 1_o
requirement NN 1_o
, , 1_o
duration NN 1_o
of IN 1_o
mechanical JJ 1_o
ventilation NN 1_o
, , 1_o
intensive JJ 1_o
care NN 1_o
unit NN 1_o
, , 1_o
and CC 1_o
hospital JJ 1_o
stay NN 1_o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Combined NNP N
preoperative NN N
and CC N
intraoperative JJ N
use NN N
of IN N
glucocorticoids NNS N
in IN N
neonatal JJ N
cardiac JJ N
surgery NN N
does VBZ N
not RB N
favorably RB N
affect VBP N
early JJ N
clinical JJ N
outcomes NNS N
and CC N
may MD N
exacerbate VB N
perioperative JJ N
renal JJ N
dysfunction NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
clinical JJ N
context NN N
on IN N
simulator-based JJ N
assessment NN N
of IN N
blood NN 1_o
pressure NN 1_o
taking VBG 1_p
- : N
a DT N
pilot NN N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Blood NNP N
pressure NN N
measurement NN N
is VBZ N
an DT N
essential JJ N
clinical JJ N
skill NN N
that WDT N
can MD N
readily RB N
be VB N
assessed VBN N
in IN N
objective JJ N
structured JJ N
clinical JJ N
examination NN N
( ( N
OSCE NNP N
) ) N
. . N

While IN N
the DT N
use NN N
of IN N
simulators NNS 1_i
can MD N
enhance VB N
test NN N
validity NN N
and CC N
reliability NN N
, , N
the DT N
given VBN N
clinical JJ N
context NN N
may MD N
also RB N
affect VB N
student NN N
performance NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
variations NNS N
in IN N
clinical JJ N
context NN N
on IN N
blood NN N
pressure NN N
measurement NN N
in IN N
a DT N
simulator-based JJ 1_i
OSCE NNP 1_i
. . 1_i

METHOD NNP N
We PRP N
randomized VBD 1_p
162 CD 1_p
first-year JJ 1_p
medical JJ 1_p
students NNS 1_p
into IN 1_p
four CD 1_p
groups NNS 1_p
that WDT 1_p
received VBD 1_p
different JJ 1_p
lead-in JJ 1_p
statements NNS 1_p
before IN 1_p
measuring VBG 1_p
blood NN 1_o
pressure NN 1_o
on IN 1_p
a DT 1_p
manikin JJ 1_i
simulator NN 1_i
. . 1_i

These DT N
statements NNS N
described VBD N
hypothetical JJ N
patients NNS N
with IN N
different JJ N
likelihoods NNS N
of IN N
having VBG N
systemic JJ 1_o
hypertension NN 1_o
. . 1_o

RESULTS VB N
The DT N
lead-in JJ N
that WDT N
described VBD N
the DT N
highest JJS N
likelihood NN 1_o
of IN 1_o
hypertension NN 1_o
was VBD N
associated VBN N
with IN N
significantly RB N
higher JJR N
reported VBD 1_o
readings NNS 1_o
and CC 1_o
lower JJR 1_o
accuracy NN 1_o
. . 1_o

The DT N
lead-in NN N
that WDT N
suggested VBD N
normality NN N
yielded VBN N
the DT N
best JJS N
performance NN N
. . N

CONCLUSION NNP N
Student NNP 1_p
performance NN N
in IN N
simulator-based JJ 1_i
OSCE NNP 1_i
may MD N
be VB N
affected VBN N
by IN N
the DT N
clinical JJ N
context NN N
provided VBN N
. . N

However RB N
, , N
we PRP N
argue VBP N
that IN N
construct NN N
validity NN N
should MD N
be VB N
viewed VBN N
in IN N
light NN N
of IN N
the DT N
application NN N
of IN N
a DT N
test NN N
, , N
in IN N
that DT N
patients NNS N
may MD N
also RB N
present VB N
with IN N
different JJ N
cues NNS N
and CC N
likelihoods NNS N
of IN N
having VBG N
hypertension NN N
. . N

Variations NNS N
in IN N
construct NN N
design NN N
should MD N
be VB N
further RB N
explored VBN N
to TO N
enhance VB N
the DT N
training NN N
and CC N
assessment NN N
of IN N
clinical JJ N
competence NN N
that WDT N
reflects VBZ N
the DT N
unpredictability NN N
encountered VBN N
in IN N
daily JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Aspirin-associated JJ 1_p
iron NN 1_p
loss NN 1_p
as IN 1_p
an DT 1_p
anticancer NN 1_p
mechanism NN 1_p
. . 1_p

A DT N
consensus NN N
view NN N
has VBZ N
emerged VBN N
favoring VBG N
an DT N
anticancer JJ N
effect NN N
of IN N
long-term JJ N
aspirin NN N
use NN N
. . N

Aspirin-induced JJ 1_i
loss NN N
of IN N
stored VBN N
iron NN N
from IN N
chronic JJ N
gastrointestinal JJ N
bleeding NN N
is VBZ N
proposed VBN N
as IN N
a DT N
mechanism NN N
underlying VBG N
this DT N
beneficial JJ N
effect NN N
. . N

In IN N
iron NN N
depletion NN N
, , N
less JJR N
iron NN N
may MD N
be VB N
available JJ N
for IN N
carcinogenesis NN N
through IN N
free-radical JJ N
mediated VBN N
mechanisms NNS N
and CC N
for IN N
promotion NN N
of IN N
tumor NN N
growth NN N
. . N

Low-dose JJ 1_i
aspirin NN 1_i
increases NNS N
gastrointestinal JJ 1_o
losses NNS 1_o
of IN N
transfused VBN 1_o
radiolabeled VBN 1_o
autologous JJ 1_o
red JJ 1_o
cells NNS 1_o
. . 1_o

Observational JJ N
studies NNS N
report VBP N
lower JJR N
serum NN N
ferritin NN N
values NNS N
with IN N
regular JJ N
aspirin NN N
use NN N
. . N

A DT N
protective JJ N
effect NN N
of IN N
induced JJ N
iron NN N
reduction NN N
against IN N
cancer NN N
mortality NN N
has VBZ N
been VBN N
confirmed VBN N
in IN N
a DT N
recent JJ N
trial NN N
( ( N
FeAST NNP N
) ) N
with IN N
subjects NNS 1_p
randomized VBN 1_p
to TO 1_p
iron VB 1_p
reduction NN 1_p
or CC 1_p
observation NN 1_p
. . 1_p

Serum NNP 1_o
ferritin JJ 1_o
reductions NNS 1_o
in IN N
the DT N
FeAST NNP N
trial NN N
were VBD N
within IN N
conventionally RB N
normal JJ N
reference NN N
ranges NNS N
and CC N
were VBD N
quantitatively RB N
similar JJ N
to TO N
ferritin VB N
reductions NNS N
in IN N
observational JJ N
studies NNS N
in IN N
regular JJ 1_p
aspirin NN 1_p
users NNS 1_p
. . 1_p

Delayed NNP N
anticancer NN N
effects NNS N
of IN N
aspirin NN N
are VBP N
compatible JJ N
with IN N
the DT N
proposed VBN N
mechanism NN N
, , N
as IN N
continual JJ N
microbleeding NN 1_o
has VBZ N
a DT N
gradual JJ N
cumulative JJ N
effect NN N
on IN N
stored VBN N
iron NN N
. . N

-DOCSTART- -X- O O

Impacts NNS N
of IN N
a DT N
disease JJ 1_i
management NN 1_i
program NN 1_i
for IN N
dually RB 1_p
eligible JJ 1_p
beneficiaries NNS 1_p
. . 1_p

The DT N
LifeMasters NNPS 1_i
Supported NNP 1_i
SelfCare NNP 1_i
demonstration NN 1_i
program NN 1_i
provides VBZ N
disease JJ 1_i
management NN 1_i
( ( 1_i
DM NNP 1_i
) ) 1_i
services NNS 1_i
to TO N
Florida NNP 1_p
Medicare NNP 1_p
beneficiaries NNS 1_p
who WP 1_p
are VBP 1_p
also RB 1_p
enrolled VBN 1_p
in IN 1_p
Medicaid NNP 1_p
and CC 1_p
have VBP 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
CHF NNP 1_p
) ) 1_p
, , 1_p
diabetes VBZ 1_p
, , 1_p
or CC 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
( ( 1_p
CAD NNP 1_p
) ) 1_p
. . 1_p

The DT N
population-based JJ N
program NN N
provides VBZ N
primarily RB 1_i
telephonic JJ 1_i
patient JJ 1_i
education NN 1_i
and CC 1_i
monitoring NN 1_i
services NNS 1_i
. . 1_i

Findings NNS N
from IN N
the DT N
randomized VBN N
, , N
intent-to-treat JJ N
design NN N
over IN N
the DT N
first JJ N
18 CD N
months NNS N
of IN N
operations NNS N
show VBP N
virtually RB N
no DT N
overall JJ N
impacts NNS 1_o
on IN 1_o
hospital NN 1_o
or CC 1_o
emergency NN 1_o
room NN 1_o
( ( 1_o
ER NNP 1_o
) ) 1_o
use NN 1_o
, , 1_o
Medicare NNP 1_o
expenditures VBZ 1_o
, , 1_o
quality NN 1_o
of IN 1_o
care NN 1_o
, , 1_o
or CC 1_o
prescription NN 1_o
drug NN 1_o
use NN 1_o
for IN N
the DT N
33,000 CD 1_p
enrollees NNS 1_p
. . 1_p

However RB N
, , N
for IN N
beneficiaries NNS 1_p
with IN 1_p
CHF NNP 1_p
who WP 1_p
resided VBD 1_p
in IN 1_p
high-cost NN 1_p
South NNP 1_p
Florida NNP 1_p
counties NNS 1_p
, , N
the DT N
program NN N
reduced VBN N
Medicare NNP 1_o
expenditures NNS 1_o
by IN N
9.6 CD N
percent NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
tailored JJ N
skin NN N
cancer NN N
prevention NN N
messages NNS N
for IN N
adults NNS 1_p
: : 1_p
Project NN N
SCAPE NNP N
. . N

OBJECTIVES NNP N
We PRP N
evaluated VBD N
the DT N
impact NN N
of IN N
a DT N
mailed VBN 1_i
, , 1_i
tailored VBN 1_i
intervention NN 1_i
on IN N
skin JJ 1_o
cancer NN 1_o
prevention NN N
and CC N
skin JJ 1_o
self-examination NN 1_o
behaviors NNS 1_o
of IN N
adults NNS 1_p
at IN 1_p
moderate JJ 1_p
and CC 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
skin JJ 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
Adults NNP 1_p
at IN 1_p
moderate NNP 1_p
and CC 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
skin JJ 1_p
cancer NN 1_p
were VBD 1_p
recruited VBN 1_p
in IN 1_p
primary JJ 1_p
health NN 1_p
care NN 1_p
settings NNS 1_p
in IN 1_p
Honolulu NNP 1_p
, , 1_p
HI NNP 1_p
, , 1_p
and CC 1_p
Long NNP 1_p
Island NNP 1_p
, , 1_p
NY NNP 1_p
. . 1_p

After IN N
completing VBG N
a DT N
baseline NN N
survey NN N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
. . N

The DT N
treatment NN N
group NN N
received VBD N
tailored JJ 1_i
materials NNS 1_i
, , 1_i
including VBG 1_i
personalized VBN 1_i
risk NN 1_i
feedback NN 1_i
, , N
and CC N
the DT N
control NN 1_i
group NN N
received VBD N
general JJ 1_i
educational JJ 1_i
materials NNS 1_i
. . 1_i

Multivariate NNP N
analyses NNS N
compared VBN N
sun JJ 1_o
protection NN 1_o
and CC N
skin VB 1_o
self-examination NN 1_o
between IN N
groups NNS N
, , N
controlling VBG N
for IN N
location NN N
, , N
risk NN N
level NN N
, , N
gender NN N
, , N
and CC N
age NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
596 CD 1_p
adults NNS 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
. . 1_p

The DT N
tailored JJ N
materials NNS N
had VBD N
a DT N
significant JJ N
effect NN N
on IN N
overall JJ 1_o
sun-protection NN 1_o
habits NNS 1_o
, , 1_o
the DT 1_o
use NN 1_o
of IN 1_o
hats NNS 1_o
, , 1_o
the DT 1_o
use NN 1_o
of IN 1_o
sunglasses NNS 1_o
, , 1_o
and CC 1_o
the DT 1_o
recency NN 1_o
of IN 1_o
skin JJ 1_o
self-examination NN 1_o
. . 1_o

Some DT N
effects NNS N
were VBD N
moderated VBN N
by IN N
location NN N
and CC N
risk NN N
level NN N
. . N

CONCLUSIONS NNP N
Tailored NNP 1_i
communications NNS 1_i
including VBG N
personalized VBN N
risk NN N
feedback NN N
can MD N
improve VB N
sun-protection NN 1_o
behaviors NNS 1_o
and CC 1_o
skin JJ 1_o
self-examination NN 1_o
among IN N
adults NNS 1_p
at IN 1_p
increased VBN 1_p
risk NN 1_p
for IN 1_p
skin JJ 1_p
cancer NN 1_p
. . 1_p

These DT N
convenient NN N
, , N
low-cost JJ N
interventions NNS N
can MD N
be VB N
implemented VBN N
in IN N
a DT N
variety NN N
of IN N
settings NNS N
and CC N
should MD N
be VB N
tested VBN N
further JJ N
to TO N
assess VB N
their PRP$ N
long-term JJ N
effectiveness NN N
. . N

-DOCSTART- -X- O O

Comparing VBG N
two CD N
web-based JJ 1_p
smoking VBG 1_o
cessation NN 1_o
programs NNS 1_p
: : 1_p
randomized VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Smoking NNP 1_o
cessation NN 1_o
remains VBZ N
a DT N
significant JJ N
public JJ N
health NN N
problem NN N
. . N

Innovative JJ N
interventions NNS N
that WDT N
use VBP N
the DT N
Internet NNP N
have VBP N
begun VBN N
to TO N
emerge VB N
that DT N
offer NN N
great JJ N
promise NN N
in IN N
reaching VBG N
large JJ N
numbers NNS N
of IN N
participants NNS N
and CC N
encouraging VBG N
widespread JJ N
behavior NN N
change NN N
. . N

To TO N
date NN N
, , N
the DT N
relatively RB N
few JJ N
controlled JJ N
trials NNS N
of IN N
Web-based JJ N
smoking NN 1_o
cessation NN 1_o
programs NNS N
have VBP N
been VBN N
limited VBN N
by IN N
short JJ N
follow-up JJ N
intervals NNS N
. . N

OBJECTIVE IN N
We PRP N
describe VBP N
the DT N
6-month JJ N
follow-up JJ N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
in IN N
which WDT N
participants NNS 1_p
recruited VBD 1_p
online NN 1_p
were VBD N
randomly RB 1_i
assigned VBN 1_i
to TO 1_i
either VB 1_i
a DT 1_i
Web-based JJ 1_i
smoking NN 1_o
cessation NN 1_o
program NN 1_i
( ( 1_i
Quit NNP 1_i
Smoking NNP 1_i
Network NNP 1_i
; : 1_i
QSN NNP 1_i
) ) 1_i
or CC 1_i
a DT 1_i
Web-based JJ 1_i
exercise NN 1_i
enhancement NN 1_i
program NN 1_i
( ( 1_i
Active NNP 1_i
Lives VBZ 1_i
) ) 1_i
adapted VBD 1_i
somewhat RB 1_i
to TO 1_i
encourage VB 1_i
smoking VBG 1_i
cessation NN 1_i
. . 1_i

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
two-arm JJ N
randomized NN N
controlled VBD N
trial NN N
that IN N
compared VBN N
two CD 1_i
Web-based JJ 1_i
smoking VBG 1_o
cessation NN 1_o
programs NNS 1_i
: : 1_i
( ( 1_i
1 CD 1_i
) ) 1_i
the DT 1_i
QSN NNP 1_i
intervention NN 1_i
condition NN 1_i
presented VBD 1_i
cognitive-behavioral JJ 1_i
strategies NNS 1_i
, , 1_i
and CC 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
the DT 1_i
Active NNP 1_i
Lives VBZ 1_i
control VB 1_i
condition NN 1_i
provided VBD 1_i
participants NNS 1_i
with IN 1_i
guidance NN 1_i
in IN 1_i
developing VBG 1_i
a DT 1_i
physical JJ 1_i
activity NN 1_i
program NN 1_i
to TO 1_i
assist VB 1_i
them PRP 1_i
with IN 1_i
quitting VBG 1_i
. . 1_i

The DT 1_i
QSN NNP 1_i
condition NN 1_i
provided VBD 1_i
smoking VBG 1_i
cessation NN 1_i
information NN 1_i
and CC 1_i
behavior NN 1_i
change NN 1_i
strategies NNS 1_i
while IN 1_i
the DT 1_i
Active NNP 1_i
Lives VBZ 1_i
condition NN 1_i
provided VBD 1_i
participants NNS 1_i
with IN 1_i
physical JJ 1_i
activity NN 1_i
recommendations NNS 1_i
and CC 1_i
goal NN 1_i
setting NN 1_i
. . 1_i

The DT 1_i
QSN NNP 1_i
condition NN 1_i
was VBD 1_i
designed VBN 1_i
to TO 1_i
be VB 1_i
more JJR 1_i
engaging NN 1_i
( ( 1_i
eg UH 1_i
, , 1_i
it PRP 1_i
included VBD 1_i
multimedia JJ 1_i
components NNS 1_i
) ) 1_i
and CC 1_i
to TO 1_i
present VB 1_i
much RB 1_i
greater JJR 1_i
content NN 1_i
than IN 1_i
is VBZ 1_i
typically RB 1_i
found VBN 1_i
in IN 1_i
smoking VBG 1_i
cessation NN 1_i
programs NNS 1_i
. . 1_i

RESULTS NNP N
Contrary NNP N
to TO N
our PRP$ N
hypotheses NNS N
, , N
no DT N
between-condition NN N
differences NNS N
in IN N
smoking VBG 1_o
abstinence NN 1_o
were VBD N
found VBN N
at IN N
3- JJ N
and CC N
6-month JJ N
follow-up JJ N
assessments NNS N
. . N

While IN N
participants NNS N
in IN N
the DT N
QSN NNP N
intervention NN N
condition NN N
spent VBD N
more JJR N
time NN N
than IN N
controls NNS N
visiting VBG N
the DT N
online JJ N
program NN N
, , N
the DT N
median JJ N
number NN N
of IN N
1.0 CD N
visit NN N
in IN N
each DT N
condition NN N
and CC N
the DT N
substantial JJ N
attrition NN N
( ( N
60.8 CD N
% NN N
at IN N
the DT N
6-month JJ N
follow-up NN N
) ) N
indicate VBP N
that IN N
participants NNS N
were VBD N
not RB N
as RB N
engaged VBN N
as IN N
we PRP N
had VBD N
expected VBN N
. . N

CONCLUSIONS NNP N
Contrary NNP N
to TO N
our PRP$ N
hypothesis NN N
, , N
our PRP$ N
test NN N
of IN N
two CD N
Web-based JJ N
smoking VBG 1_o
cessation NN 1_o
conditions NNS N
, , N
an DT N
intervention NN N
and CC N
an DT N
attention NN N
placebo NN N
control NN N
, , N
failed VBD N
to TO N
show VB N
differences NNS N
at IN N
3- JJ N
and CC N
6-month JJ N
assessments NNS N
. . N

We PRP N
explored VBD N
possible JJ N
reasons NNS N
for IN N
this DT N
finding NN N
, , N
including VBG N
limited JJ N
engagement NN N
of IN N
participants NNS N
and CC N
simplifying VBG N
program NN N
content NN N
and CC N
architecture NN N
. . N

Future JJ N
research NN N
needs VBZ N
to TO N
address VB N
methods NNS N
to TO N
improve VB N
participant JJ N
engagement NN N
in IN N
online JJ N
smoking NN N
cessation NN N
programs NNS N
. . N

Possible JJ N
approaches NNS N
in IN N
this DT N
regard NN N
can MD N
include VB N
new JJ N
informed JJ N
consent NN N
procedures NNS N
that WDT N
better VBP N
explain VB N
the DT N
roles NNS N
and CC N
responsibilities NNS N
of IN N
being VBG N
a DT N
research NN N
participant NN N
, , N
new JJ N
program NN N
designs NNS N
that WDT N
add VBP N
more JJR N
vitality NN N
( ( N
changing VBG N
content NN N
from IN N
visit NN N
to TO N
visit VB N
) ) N
, , N
and CC N
new JJ N
types NNS N
of IN N
reminders NNS N
pushed VBN N
out RP N
to TO N
participants NNS N
to TO N
encourage VB N
return VB N
visits NNS N
. . N

Simplifying VBG N
program NN N
content NN N
through IN N
a DT N
combination NN N
of IN N
enhanced JJ N
tailoring NN N
and CC N
information NN N
architecture NN N
also RB N
merits VBZ N
further JJ N
research NN N
attention NN N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
adult NN 1_i
intervention NN 1_i
on IN N
infants NNS 1_o
' POS 1_o
level NN 1_o
of IN 1_o
attention NN 1_o
. . 1_o

The DT N
effects NNS N
of IN N
adult NN 1_i
intervention NN 1_i
on IN N
infants NNS N
' POS N
level NN 1_o
of IN 1_o
attention NN 1_o
to TO N
objects NNS N
were VBD N
studied VBN N
with IN N
10-month-old JJ 1_p
infants NNS 1_p
. . 1_p

After IN N
a DT N
baseline JJ N
measure NN N
of IN N
spontaneous JJ N
attention NN N
was VBD N
obtained VBN N
, , N
infants NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
( ( 1_i
low JJ 1_i
, , 1_i
medium NN 1_i
, , 1_i
high JJ 1_i
intervention NN 1_i
, , 1_i
or CC 1_i
no-intervention JJ 1_i
control NN 1_i
) ) 1_i
. . N

Level NN N
of IN N
intervention NN N
was VBD N
controlled VBN N
by IN N
systematically RB 1_i
varying VBG 1_i
the DT 1_i
manner NN 1_i
and CC 1_i
frequency NN 1_i
with IN 1_i
which WDT 1_i
objects NNS 1_i
were VBD 1_i
presented VBN 1_i
, , 1_i
the DT 1_i
extent NN 1_i
to TO 1_i
which WDT 1_i
the DT 1_i
experimenter NN 1_i
talked VBD 1_i
to TO 1_i
the DT 1_i
infant NN 1_i
, , 1_i
and CC 1_i
physical JJ 1_i
proximity NN 1_i
. . 1_i

Infant JJ N
attention NN N
was VBD N
defined VBN N
as IN N
duration NN 1_o
of IN 1_o
time NN 1_o
spent VBN 1_o
examining VBG 1_o
objects NNS 1_o
. . 1_o

The DT N
overall JJ 1_o
duration NN 1_o
of IN 1_o
infant JJ 1_o
attention NN 1_o
increased VBD N
during IN N
medium NN N
intervention NN N
when WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Baseline NNP N
attention NN N
was VBD N
then RB N
used VBN N
to TO N
separate VB N
low JJ N
and CC N
high JJ N
attenders NNS N
. . N

Low JJ N
attending VBG N
infants NNS N
attended VBD 1_o
more RBR N
in IN N
medium NN N
and CC N
high JJ N
intervention NN N
than IN N
in IN N
the DT N
low JJ N
condition NN N
, , N
while IN N
high JJ N
attending VBG N
infants NNS N
were VBD N
unaffected VBN N
by IN N
intervention NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
level NN N
of IN N
intervention NN 1_i
interacts NNS N
with IN N
the DT N
child NN 1_o
's POS 1_o
spontaneous JJ 1_o
tendency NN 1_o
to TO 1_o
focus VB 1_o
attention NN 1_o
on IN N
objects NNS N
. . N

-DOCSTART- -X- O O

Increased VBN 1_o
concentration NN 1_o
of IN 1_o
corticosteroid-binding JJ 1_o
globulin NN 1_o
due JJ N
to TO N
antidepressant VB 1_p
treatment NN 1_p
with IN 1_p
amitritpyline NN 1_i
, , N
but CC N
not RB N
paroxetine VB 1_i
. . 1_i

-DOCSTART- -X- O O

Visual JJ N
field NN N
progression NN N
in IN N
the DT N
Collaborative NNP 1_p
Initial NNP 1_p
Glaucoma NNP 1_p
Treatment NNP 1_p
Study NNP 1_p
the DT N
impact NN N
of IN N
treatment NN N
and CC N
other JJ N
baseline NN N
factors NNS N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
factors NNS N
associated VBN N
with IN N
visual JJ 1_o
field NN 1_o
( ( 1_o
VF NNP 1_o
) ) 1_o
progression NN 1_o
, , N
using VBG N
all DT N
available JJ N
follow-up NNS N
through IN N
9 CD N
years NNS N
after IN N
treatment NN N
initiation NN N
, , N
in IN N
the DT N
Collaborative NNP N
Initial NNP N
Glaucoma NNP N
Treatment NNP N
Study NNP N
( ( N
CIGTS NNP N
) ) N
. . N

DESIGN NNP N
Longitudinal NNP N
follow-up NN N
of IN N
participants NNS N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

PARTICIPANTS NNP N
Six NNP 1_p
hundred VBD 1_p
seven CD 1_p
newly RB 1_p
diagnosed VBN 1_p
glaucoma NN 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
607 CD 1_p
subjects NNS 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
open-angle JJ 1_p
glaucoma NN 1_p
initially RB N
were VBD N
treated VBN 1_i
with IN 1_i
either DT 1_i
medication NN 1_i
or CC 1_i
trabeculectomy NN 1_i
. . 1_i

After IN N
treatment NN N
initiation NN N
and CC N
early JJ N
follow-up NN N
, , N
subjects NNS N
were VBD N
evaluated VBN N
clinically RB N
at IN N
6-month JJ N
intervals NNS N
. . N

Study NNP N
participants NNS N
in IN N
both DT N
arms NNS N
of IN N
the DT N
CIGTS NNP N
were VBD N
treated VBN 1_i
aggressively RB 1_i
in IN 1_i
an DT 1_i
effort NN 1_i
to TO 1_i
reduce VB 1_o
intraocular JJ 1_o
pressure NN 1_o
( ( 1_o
IOP NNP 1_o
) ) 1_o
to TO 1_i
a DT 1_i
level NN 1_i
at IN 1_i
or CC 1_i
below IN 1_i
a DT 1_i
predetermined JJ 1_i
, , 1_i
eye-specific JJ 1_i
target NN 1_i
pressure NN 1_i
. . 1_i

Visual JJ 1_i
field NN 1_i
progression NN 1_i
was VBD 1_i
analyzed VBN 1_i
using VBG 1_i
repeated JJ 1_i
measures NNS 1_i
models NNS 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Visual NNP 1_o
field NN 1_o
progression NN 1_o
, , 1_o
measured VBN 1_o
by IN 1_o
Humphrey NNP 1_o
24-2 JJ 1_o
full-threshold JJ 1_o
testing NN 1_o
and CC 1_o
assessed VBN 1_o
by IN 1_o
the DT 1_o
change NN 1_o
in IN 1_o
the DT 1_o
mean JJ 1_o
deviation NN 1_o
( ( 1_o
MD NNP 1_o
) ) 1_o
, , N
and CC N
an DT 1_o
indicator NN 1_o
of IN 1_o
substantial JJ 1_o
worsening NN 1_o
of IN 1_o
the DT 1_o
VF NNP 1_o
( ( N
MD NNP N
decrease NN N
of IN N
> NN N
or CC N
=3 JJ N
dB NN N
from IN N
baseline NN N
) ) N
, , N
assessed VBN N
at IN N
each DT N
follow-up JJ N
visit NN N
. . N

RESULTS NNP N
Follow-up NNP N
indicated VBD N
minimal JJ N
change NN N
from IN N
baseline NN N
in IN N
each DT N
initial JJ N
treatment NN N
group NN N
's POS N
average JJ N
MD NNP 1_o
. . 1_o

However RB N
, , N
at IN N
the DT N
8-year JJ N
follow-up JJ N
examination NN N
, , N
substantial JJ N
worsening NN 1_o
( ( 1_o
> CD 1_o
or CC 1_o
=3 VB 1_o
dB NN 1_o
) ) 1_o
of IN 1_o
MD NNP 1_o
from IN 1_o
baseline NN 1_o
was VBD N
found VBN N
in IN N
21.3 CD N
% NN N
and CC N
25.5 CD N
% NN N
of IN N
the DT N
initial JJ N
surgery NN N
and CC N
initial JJ N
medicine NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
effect NN N
of IN N
initial JJ N
treatment NN N
on IN N
subsequent JJ N
VF NNP 1_o
loss NN 1_o
was VBD N
modified VBN N
by IN N
time NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
baseline JJ N
MD NNP N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
diabetes NNS N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

Initial JJ 1_i
surgery NN 1_i
led VBD N
to TO N
less RBR N
VF NNP 1_o
progression NN 1_o
than IN N
initial JJ 1_i
medicine NN 1_i
in IN N
subjects NNS 1_p
with IN 1_p
advanced JJ 1_p
VF NNP 1_p
loss NN 1_p
at IN 1_p
baseline NN 1_p
, , N
whereas JJ N
subjects NNS 1_p
with IN 1_p
diabetes NNS 1_p
had VBD N
more RBR N
VF JJ 1_o
loss NN 1_o
over IN N
time NN N
if IN N
treated VBN N
initially RB N
with IN N
surgery NN N
. . N

CONCLUSIONS VB N
The DT N
CIGTS NNP N
intervention NN N
protocol NN N
led VBD N
to TO N
a DT N
lowering NN 1_o
of IN 1_o
IOP NNP 1_o
that WDT N
persisted VBD N
over IN N
time NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Progression NN N
in IN N
VF NNP N
loss NN N
was VBD N
seen VBN N
in IN N
a DT N
subset NN N
, , N
increasing VBG N
to TO N
more JJR N
than IN N
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
. . N

The DT N
findings NNS N
regarding VBG N
initial JJ N
surgery NN N
being VBG N
beneficial JJ N
for IN N
subjects NNS 1_p
with IN 1_p
more RBR 1_p
advanced JJ 1_p
VF NNP 1_o
loss NN 1_o
at IN 1_p
presentation NN 1_p
, , N
but CC N
detrimental JJ N
for IN N
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
, , N
are VBP N
noteworthy JJ N
and CC N
warrant JJ N
independent JJ N
confirmation NN N
. . N

FINANCIAL NNP N
DISCLOSURE NNP N
( ( N
S NNP N
) ) N
The DT N
author NN N
( ( N
s PRP N
) ) N
have VBP N
no DT N
proprietary JJ N
or CC N
commercial JJ N
interest NN N
in IN N
any DT N
materials NNS N
discussed VBN N
in IN N
this DT N
article NN N
. . N

-DOCSTART- -X- O O

Intermittent NNP 1_i
recombinant JJ 1_i
growth NN 1_i
hormone NN 1_i
treatment NN 1_i
in IN N
short JJ 1_p
children NNS 1_p
born VBP 1_p
small JJ 1_p
for IN 1_p
gestational JJ 1_p
age NN 1_p
: : 1_p
four-year JJ N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
different JJ N
treatment NN N
regimens NNS N
. . N

BACKGROUND NNP N
Treatment NNP N
of IN N
short JJ 1_p
children NNS 1_p
born VBP 1_p
small JJ 1_p
for IN 1_p
gestational JJ 1_p
age NN 1_p
SGA NNP 1_p
with IN N
recombinant JJ 1_i
human JJ 1_i
growth NN 1_i
hormone VBD 1_i
r-hGH JJ 1_i
increases NNS N
growth NN 1_o
velocity NN 1_o
during IN N
childhood NN N
. . N

As IN N
in IN N
other JJ N
indications NNS N
, , N
the DT N
growth NN 1_o
velocity NN 1_o
in IN N
these DT N
patients NNS N
is VBZ N
more JJR N
marked JJ N
during IN N
the DT N
first JJ N
year NN N
of IN N
treatment NN N
and CC N
then RB N
decreases VBZ N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
different JJ N
r-hGH JJ 1_i
treatment NN 1_i
schedules NNS N
( ( N
67 CD N
microg/kg/day NN N
in IN N
a DT N
discontinuous JJ N
or CC N
continuous JJ N
regimen NNS N
) ) N
during IN N
the DT N
second JJ N
year NN N
of IN N
r-hGH JJ N
treatment NN N
by IN N
comparing VBG N
height JJ 1_o
velocity NN 1_o
changes NNS N
and CC N
total JJ 1_o
gain NN 1_o
of IN 1_o
height NN 1_o
over IN N
a DT N
4-year JJ N
period NN N
. . N

METHODS $ N
58 CD 1_p
growth-retarded JJ 1_p
SGA NNP 1_p
children NNS 1_p
aged VBN 1_p
2-5 CD 1_p
years NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
a DT N
TOTO NNP 1_i
regimen NN 1_i
( ( N
4 CD N
years NNS N
alternating VBG N
treatment NN N
( ( N
T NNP N
) ) N
and CC N
observation NN N
( ( N
O NNP N
) ) N
, , N
n JJ N
= NNP N
30 CD N
) ) N
or CC N
a DT N
TTOO JJ N
regimen NN N
( ( N
2 CD N
years NNS N
' POS N
treatment NN N
, , N
followed VBN N
by IN N
2 CD N
years NNS N
' POS N
observation NN N
, , N
n JJ N
= NNP N
28 CD N
) ) N
. . N

Height NNP 1_o
velocity NN 1_o
HV NNP 1_o
and CC 1_o
total JJ 1_o
height NN 1_o
gain NN 1_o
were VBD N
assessed VBN N
during IN N
the DT N
4-year JJ N
study NN N
. . N

RESULTS NNP N
In IN N
both DT N
groups NNS N
, , N
HV NNP 1_o
and CC 1_o
HV NNP 1_o
standard JJ 1_o
deviation NN 1_o
score VBD 1_o
HV-SDSCA NNP 1_o
increased VBD N
during IN N
treatment NN N
and CC N
decreased VBD N
during IN N
observation NN N
periods NNS N
. . N

Interruption NN N
of IN N
treatment NN N
in IN N
the DT N
TOTO NNP N
group NN N
did VBD N
not RB N
result VB N
in IN N
a DT N
better JJR N
gain NN 1_o
in IN 1_o
height JJ 1_o
standard NN 1_o
deviation NN 1_o
score VBD 1_o
H-SDSCA NNP 1_o
when WRB N
compared VBN N
with IN N
the DT N
TTOO NNP N
group NN N
. . N

After IN N
4 CD N
years NNS N
of IN N
study NN N
, , N
the DT N
gain NN 1_o
in IN 1_o
H-SDSCA NNP 1_o
was VBD N
1.4 CD N
+ NN N
or CC N
- : N
01 CD N
in IN N
the DT N
TOTO NNP N
group NN N
and CC N
1.6 CD N
+ NN N
or CC N
- : N
0.2 CD N
in IN N
the DT N
TTOO NNP N
group NN N
leading VBG N
to TO N
a DT N
mean JJ N
height NN 1_o
of IN N
-2.0 NNP N
+ NNP N
or CC N
- : N
1.0 CD N
SDS NNP N
and CC N
-2.0 NNP N
+ NNP N
or CC N
- : N
0.8 CD N
SDS NNP N
, , N
respectively RB N
. . N

The DT N
rate NN 1_o
of IN 1_o
bone NN 1_o
maturation NN 1_o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
short JJ N
SGA NNP N
children NNS N
, , N
TOTO NNP 1_i
and CC N
TTOO NNP 1_i
regimens NNS N
produced VBD N
significant JJ N
improvements NNS N
in IN N
growth NN 1_o
during IN N
r-hGH JJ 1_i
treatment NN 1_i
. . N

However RB N
, , N
treatment NN N
interruption NN N
after IN N
1 CD N
year NN N
did VBD N
not RB N
influence VB N
the DT N
overall JJ 1_o
gain NN 1_o
in IN 1_o
height NN 1_o
SDS NNP 1_o
when WRB N
compared VBN N
with IN N
2 CD N
years NNS N
' POS N
continuous JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

The DT N
Finnish JJ 1_p
Diabetes NNP 1_p
Prevention NNP N
Study NNP N
. . N

The DT N
aim NN N
of IN N
the DT N
Finnish NNP 1_p
Diabetes NNP 1_p
Prevention NNP N
Study NNP N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN 1_o
of IN N
an DT N
intensive JJ 1_i
diet-exercise NN 1_i
programme NN 1_i
in IN N
preventing VBG N
or CC N
delaying VBG N
type JJ 1_o
2 CD 1_o
diabetes NNS 1_o
in IN 1_p
individuals NNS 1_p
with IN 1_p
impaired JJ 1_p
glucose JJ 1_p
tolerance NN 1_p
( ( 1_p
IGT NNP 1_p
) ) 1_p
and CC N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
programme NN N
on IN N
the DT N
risk NN N
factors NNS N
of IN N
atherosclerotic JJ N
vascular NN N
diseases NNS N
and CC N
the DT N
incidence NN N
of IN N
cardiovascular JJ N
events NNS N
. . N

In IN N
this DT N
ongoing JJ N
study NN N
, , N
a DT 1_p
total NN 1_p
of IN 1_p
523 CD 1_p
overweight JJ 1_p
subjects NNS 1_p
with IN 1_p
IGT NNP 1_p
based VBN 1_p
on IN 1_p
two CD 1_p
oral JJ 1_p
glucose JJ 1_p
tolerance NN 1_p
tests NNS 1_p
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
intervention NN 1_p
group NN 1_p
or CC N
a DT N
control NN 1_p
group NN 1_p
. . 1_p

The DT N
main JJ N
measure NN N
in IN N
the DT N
intervention NN N
group NN N
is VBZ N
individual JJ 1_o
dietary JJ 1_o
advice NN 1_o
aimed VBN N
at IN N
reducing VBG 1_i
weight NN 1_i
and CC 1_i
intake NN 1_i
of IN 1_i
saturated JJ 1_i
fat NN 1_i
and CC 1_i
increasing VBG 1_i
intake NN 1_i
of IN 1_i
dietary JJ 1_i
fibre NN 1_i
. . 1_i

The DT N
intervention NN N
subjects NNS N
are VBP N
individually RB N
guided VBN N
to TO N
increase VB 1_o
their PRP$ 1_o
level NN 1_o
of IN 1_o
physical JJ 1_o
activity NN 1_o
. . 1_o

The DT N
control NN 1_i
group NN 1_i
receives VBZ 1_i
general JJ 1_i
information NN 1_i
about IN 1_i
the DT 1_i
benefits NNS 1_i
of IN 1_i
weight NN 1_i
reduction NN 1_i
, , 1_i
physical JJ 1_i
activity NN 1_i
and CC 1_i
healthy JJ 1_i
diet NN 1_i
in IN 1_i
the DT 1_i
prevention NN 1_i
of IN 1_i
diabetes NNS 1_i
. . 1_i

A DT N
pilot NN N
study NN N
began VBD N
in IN N
1993 CD N
, , N
and CC N
recruitment NN N
ended VBN N
in IN N
1998 CD N
. . N

By IN N
the DT N
end NN N
of IN N
April NNP N
1999 CD N
there EX N
were VBD N
65 CD N
new JJ N
cases NNS N
of IN N
diabetes NNS N
, , N
34 CD N
drop-outs NNS N
and CC N
one CD N
death NN 1_o
. . 1_o

The DT N
weight NN 1_o
reduction NN 1_o
was VBD N
greater JJR N
( ( N
-4.6 NNP N
kg NN N
) ) N
at IN N
1 CD N
year NN N
in IN N
the DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
152 CD N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NN N
143 CD N
, , N
-0.9 NNP N
kg NNP N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
this DT N
difference NN N
was VBD N
sustained VBN N
in IN N
the DT N
second JJ N
year NN N
of IN N
follow-up NN N
. . N

At IN N
1 CD N
year NN N
43.4 CD N
% NN N
and CC N
at IN N
2 CD N
years NNS N
41.8 CD N
% NN N
of IN N
the DT N
intervention NN N
subjects NNS N
had VBD N
achieved VBN N
a DT N
weight JJ 1_o
reduction NN 1_o
of IN N
at IN N
least JJS N
5 CD N
kg NNS N
, , N
while IN N
the DT N
corresponding JJ N
figures NNS N
for IN N
the DT N
control NN N
subjects VBZ N
were VBD N
14.0 CD N
and CC N
12.0 CD N
% NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
between IN N
the DT N
groups NNS N
) ) N
. . N

At IN N
1 CD N
year NN N
the DT N
intervention NN N
group NN N
showed VBD N
significantly RB N
greater JJR 1_o
reductions NNS 1_o
in IN N
2 CD 1_o
h NN 1_o
glucose NN 1_o
, , 1_o
fasting VBG 1_o
and CC 1_o
2 CD 1_o
h NN 1_o
insulin NN 1_o
, , 1_o
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
serum NN 1_o
triglycerides NNS 1_o
. . 1_o

Most JJS N
of IN N
the DT N
beneficial JJ N
changes NNS N
in IN N
cardiovascular JJ 1_o
risk NN 1_o
factors NNS 1_o
were VBD N
sustained VBN N
for IN N
2 CD N
years NNS N
. . N

These DT N
interim JJ N
results NNS N
of IN N
the DT N
ongoing JJ N
Finnish JJ N
Diabetes NNP N
Prevention NNP N
Study NNP N
demonstrate VB N
the DT N
efficacy NN 1_o
and CC 1_o
feasibility NN 1_o
of IN N
the DT N
lifestyle JJ N
intervention NN N
programme NN N
. . N

-DOCSTART- -X- O O

Dacarbazine NNP 1_i
versus NN 1_i
dacarbazine-vindesine NN 1_i
in IN N
disseminated JJ N
malignant JJ N
melanoma NN N
: : N
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
. . N

In IN N
a DT N
phase NN N
II NNP N
study NN N
119 CD 1_p
patients NNS 1_p
with IN 1_p
disseminated JJ 1_p
malignant JJ 1_p
melanoma NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
treatment NN N
with IN N
dacarbazine JJ 1_i
alone NN N
or CC N
in IN N
combination NN N
with IN N
vindesine NN N
. . N

The DT N
study NN N
was VBD N
designed VBN N
to TO N
reveal VB N
an DT N
additive JJ N
response NN N
rate NN N
when WRB N
the DT N
drugs NNS N
were VBD N
combined VBN N
. . N

Dacarbazine NNP 1_i
was VBD 1_i
given VBN 1_i
i.v NN 1_i
. . 1_i

at IN 1_i
250 CD 1_i
mg JJ 1_i
m-2 JJ 1_i
per IN 1_i
day NN 1_i
X NNP 1_i
V NNP 1_i
every DT 1_i
4 CD 1_i
weeks NNS 1_i
. . 1_i

In IN N
the DT N
combination NN N
regimen NNS N
vindesine VB 1_i
given VBN N
at IN N
3 CD N
mg JJ N
m-2 JJ N
per IN N
week NN N
was VBD N
included VBN N
. . N

One CD 1_p
hundred CD 1_p
and CC 1_p
ten JJ 1_p
patients NNS 1_p
were VBD 1_p
available JJ 1_p
for IN 1_p
evaluation NN 1_p
of IN 1_p
response NN 1_p
. . 1_p

With IN N
dacarbazine JJ 1_i
4/51 CD N
patients NNS N
obtained VBD N
a DT N
complete JJ 1_o
remission NN 1_o
( ( N
8 CD N
% NN N
) ) N
and CC N
5/51 CD N
patients NNS N
a DT N
partial JJ 1_o
remission NN 1_o
( ( N
10 CD N
% NN N
) ) N
. . N

Overall JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
18 CD N
% NN N
. . N

With IN N
dacarbazine-vindesine JJ 1_i
8/59 CD N
patients NNS N
obtained VBD N
a DT N
complete JJ 1_o
remission NN 1_o
( ( N
13 CD N
% NN N
) ) N
and CC N
7/59 CD N
patients NNS N
a DT N
partial JJ 1_o
remission NN 1_o
( ( N
12 CD N
% NN N
) ) N
. . N

Overall JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
25 CD N
% NN N
. . N

The DT N
difference NN N
in IN N
response NN 1_o
rates NNS 1_o
observed VBD N
between IN N
the DT N
treatment NN N
arms NNS N
is VBZ N
not RB N
statistically RB N
significant JJ N
. . N

Median JJ N
response NN N
duration NN N
was VBD N
123 CD N
days NNS N
for IN N
dacarbazine JJ N
patients NNS N
and CC N
171 CD N
days NNS N
for IN N
patients NNS N
receiving VBG N
dacarbazine-vindesine NN N
( ( N
difference NN N
not RB N
statistically RB N
significant JJ N
) ) N
. . N

-DOCSTART- -X- O O

A DT N
Randomized NNP N
, , N
Placebo-Controlled JJ 1_i
Trial NNP N
Evaluating NNP N
Safety NNP N
and CC N
Immunogenicity NNP N
of IN N
the DT N
Killed NNP N
, , N
Bivalent NNP N
, , N
Whole-Cell NNP 1_i
Oral NNP 1_i
Cholera NNP 1_i
Vaccine NNP 1_i
in IN 1_p
Ethiopia NNP 1_p
. . 1_p

Killed VBN 1_i
whole-cell JJ 1_i
oral JJ 1_i
cholera NN 1_i
vaccine NN 1_i
( ( 1_i
OCV NNP 1_i
) ) 1_i
has VBZ N
been VBN N
a DT N
key JJ N
component NN N
of IN N
a DT N
comprehensive JJ N
package NN N
including VBG N
water NN N
and CC N
sanitation NN N
measures NNS N
for IN N
recent JJ N
cholera NN N
epidemics NNS N
. . N

The DT N
vaccine NN 1_i
, , N
given VBN N
in IN N
a DT N
two-dose JJ N
regimen NN N
, , N
has VBZ N
been VBN N
evaluated VBN N
in IN N
a DT 1_p
large JJ 1_p
number NN 1_p
of IN 1_p
human JJ 1_p
volunteers NNS 1_p
in IN 1_p
India NNP 1_p
, , 1_p
Vietnam NNP 1_p
, , 1_p
and CC 1_p
Bangladesh NNP 1_p
, , N
where WRB N
it PRP N
has VBZ N
demonstrated VBN N
safety NN N
, , N
immunogenicity NN N
, , N
and CC N
clinical JJ N
efficacy NN N
. . N

We PRP N
conducted VBD N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ 1_i
trial NN N
in IN 1_p
Ethiopia NNP 1_p
, , N
where WRB N
we PRP N
evaluated VBD 1_p
the DT 1_p
safety NN 1_o
and CC 1_o
immunogenicity NN 1_o
of IN 1_p
the DT 1_p
vaccine NN 1_i
in IN 1_p
216 CD 1_p
healthy JJ 1_p
adults NNS 1_p
and CC 1_p
children NNS 1_p
. . 1_p

OCV NNP 1_i
was VBD N
found VBN N
to TO N
be VB N
safe JJ 1_o
and CC 1_o
elicited VBD 1_o
a DT 1_o
robust JJ 1_o
immunological JJ 1_o
response NN 1_o
against IN 1_o
Vibrio NNP 1_o
cholerae NN 1_o
O1 NNP 1_o
, , N
with IN N
81 CD N
% NN N
adults NNS N
and CC N
77 CD N
% NN N
children NNS N
demonstrating VBG N
seroconversion NN 1_o
14 CD N
days NNS N
after IN N
the DT N
second JJ N
dose NN N
of IN N
vaccine NN N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
evaluate VB N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
vaccine NN 1_i
in IN N
a DT N
population NN 1_p
outside IN 1_p
Asia NNP 1_p
using VBG N
a DT N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
, , N
randomized JJ N
study NN N
design NN N
. . N

-DOCSTART- -X- O O

Complex NNP 1_i
decongestive JJ 1_i
therapy NN 1_i
and CC 1_i
taping VBG 1_i
for IN N
patients NNS 1_p
with IN 1_p
postmastectomy JJ 1_p
lymphedema NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
Kinesio NNP 1_i
Taping NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
Application NN 1_i
with IN 1_i
Complex NNP 1_i
Decongestive NNP 1_i
Therapy NNP 1_i
( ( 1_i
CDT NNP 1_i
) ) 1_i
in IN 1_p
patients NNS 1_p
with IN 1_p
lymphedema NN 1_p
. . 1_p

MATERIALS NNP N
AND NNP N
METHODS NNP 1_p
45 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
3 CD 1_p
groups NNS 1_p
( ( N
CDT NNP 1_i
including VBG 1_i
Bandage NNP 1_i
, , 1_i
CDT NNP 1_i
including VBG 1_i
Bandage NNP 1_i
+ NNP 1_i
Kinesio NNP 1_i
Tape NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
, , 1_i
CDT NNP 1_i
including VBG 1_i
Kinesio NNP 1_i
Tape NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
without IN 1_i
bandage NN 1_i
) ) 1_i
. . 1_i

Assessments NNS 1_i
included VBD N
the DT N
severity NN 1_o
of IN 1_o
the DT 1_o
symptoms NNS 1_o
such JJ 1_o
as IN 1_o
pain NN 1_o
, , 1_o
discomfort NN 1_o
, , 1_o
heaviness NN 1_o
, , 1_o
tension NN 1_o
, , 1_o
stiffness NN 1_o
and CC 1_o
weakness NN 1_o
. . 1_o

Bilateral JJ 1_o
circumference NN 1_o
measurements NNS 1_o
were VBD N
done VBN N
for IN N
evaluation NN N
of IN N
the DT N
edema NN N
. . N

RESULTS NNP N
Symptoms NNP N
were VBD N
decreased VBN N
in IN N
all DT N
three CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CDT NNP N
was VBD N
found VBN N
effective JJ N
only RB N
during IN N
treatment NN N
in IN N
arm NN 1_o
volume NN 1_o
( ( 1_o
p JJ 1_o
< NNP N
0.05 CD 1_i
) ) 1_i
. . 1_i

Kinesio NNP 1_i
Taping NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
applied VBD 1_i
with IN N
CDT NNP 1_i
had VBD N
effect NN N
of IN N
decreasing VBG 1_o
edema NN 1_o
after IN 1_o
10 CD N
days NNS N
of IN N
treatment NN N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
for IN N
control NN N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Only RB N
the DT N
application NN 1_i
of IN 1_i
Kinesio NNP 1_i
Taping NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
group NN 1_i
also RB N
had VBD N
significant JJ N
decrease NN 1_o
at IN 1_o
edema NN 1_o
( ( 1_o
p JJ 1_o
< NNP 1_o
0.05 CD N
) ) N
. . N

CONCLUSION NNP 1_i
Kinesio NNP 1_i
Taping NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
Application NN 1_i
along IN N
with IN 1_i
CDT NNP 1_i
may MD 1_i
have VB N
a DT N
better JJR N
effect NN N
on IN N
decreasing VBG 1_o
lymphedema NN 1_o
which WDT 1_o
can MD N
stimulate VB N
the DT N
reduction NN 1_o
of IN 1_o
edema NN 1_o
for IN N
long JJ N
term NN N
effects NNS N
. . N

-DOCSTART- -X- O O

The DT N
incidence NN N
of IN N
first-dose JJ N
hypotension NN N
with IN N
quinapril NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
hypertension NN 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
2242 CD 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
hypertension NN 1_p
( ( 1_p
diastolic JJ 1_p
pressure NN 1_p
95-120 CD 1_p
mmHg NN 1_p
) ) 1_p
were VBD N
randomised VBN N
on IN N
a DT N
double-blind JJ N
basis NN N
to TO N
receive VB N
a DT N
single JJ N
dose NN N
of IN N
placebo NN 1_i
, , 1_i
5 CD 1_i
mg NN 1_i
quinapril NN 1_i
or CC 1_i
10 CD 1_i
mg JJ 1_i
quinapril NN 1_i
. . 1_i

Patients NNS 1_p
were VBD 1_p
identified VBN 1_p
who WP 1_p
: : 1_p
( ( 1_p
a DT 1_p
) ) 1_p
met VBD 1_p
the DT 1_p
blood NN 1_o
pressure NN 1_o
( ( 1_p
BP NNP 1_p
) ) 1_p
criteria NNS 1_p
for IN 1_p
first-dose JJ 1_p
hypotension NN 1_p
( ( 1_p
sitting VBG 1_p
or CC 1_p
standing VBG 1_p
systolic JJ 1_p
BP NNP 1_p
< NNP 1_p
100 CD 1_p
mmHg NN 1_p
, , 1_p
or CC 1_p
a DT 1_p
fall NN 1_p
in IN 1_p
systolic JJ 1_p
BP NNP 1_p
> NN 1_p
or CC 1_p
= $ 1_p
20 CD 1_p
mmHg NN 1_p
on IN 1_p
standing VBG 1_p
) ) 1_p
; : 1_p
( ( 1_p
b NN 1_p
) ) 1_p
had VBD 1_p
symptoms NNS 1_p
suggestive JJ 1_p
of IN 1_p
hypotension NN 1_p
; : 1_p
and CC 1_p
( ( 1_p
c NN 1_p
) ) 1_p
met VBD 1_p
the DT 1_p
BP NNP 1_p
criteria NNS 1_p
and CC 1_p
had VBD 1_p
symptoms NNS 1_p
. . 1_p

In IN N
all DT N
three CD N
classifications NNS N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
incidences NNS N
in IN N
placebo NN N
and CC N
combined VBD N
active JJ N
treatment NN N
groups NNS N
, , N
or CC N
between IN N
those DT N
in IN N
the DT N
two CD N
quinapril NN N
groups NNS N
. . N

No RB N
associated JJ 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
reported VBN N
. . N

In IN N
the DT N
low-risk JJ 1_p
population NN 1_p
studied VBD N
, , N
it PRP N
would MD N
appear VB N
that IN N
the DT N
incidence NN N
of IN N
first-dose JJ N
hypotension NN N
with IN N
quinapril NN N
is VBZ N
similar JJ N
to TO N
placebo VB N
and CC N
is VBZ N
not RB N
dose-related JJ N
. . N

-DOCSTART- -X- O O

Argon NNP 1_i
laser NN 1_i
trabeculoplasty NN 1_i
in IN N
primary JJ 1_p
open-angle JJ 1_p
glaucoma NN 1_p
-- : 1_p
results NNS 1_p
in IN N
black JJ 1_p
Jamaican JJ 1_p
population NN 1_p
. . 1_p

A DT N
controlled JJ N
, , N
randomised VBD N
, , N
prospective JJ N
trial NN N
of IN N
Argon NNP 1_i
laser NN 1_i
trabeculoplasty NN 1_i
( ( 1_i
ALT NNP 1_i
) ) 1_i
was VBD N
carried VBN N
out RP N
on IN N
48 CD 1_p
eyes NNS 1_p
of IN 1_p
30 CD 1_p
black JJ 1_p
Jamaican JJ 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
open-angle JJ 1_p
glaucoma NN 1_p
. . 1_p

All DT 1_p
eyes NNS 1_p
had VBD 1_p
uncontrolled VBN 1_p
intra-ocular JJ 1_o
pressures NNS 1_o
( ( 1_p
greater JJR 1_p
than IN 1_p
or CC 1_p
equal JJ 1_p
to TO 1_p
22 CD 1_p
mm NNS 1_p
Hg NNP 1_p
) ) 1_p
despite IN 1_p
medical JJ 1_p
therapy NN 1_p
. . 1_p

Treatment NN N
was VBD N
successful JJ N
in IN N
controlling VBG 1_o
intraocular JJ 1_o
pressure NN 1_o
in IN N
68 CD N
% NN N
of IN N
eyes NNS N
after IN N
12 CD N
months NNS N
follow-up JJ N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
average JJ N
drop NN 1_o
in IN 1_o
intraocular JJ 1_o
pressure NN 1_o
attributable JJ N
to TO N
ALT NNP 1_i
was VBD N
6.6 CD N
mmHg NN N
. . N

Argon NNP 1_i
laser NN 1_i
trabeculoplasty NN 1_i
is VBZ N
an DT N
effective JJ N
adjunct NN N
in IN N
managing VBG N
to TO N
control VB N
intraocular JJ 1_o
pressure NN 1_o
in IN N
black JJ N
Jamaican NNP 1_p
glaucoma NN 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Primary JJ 1_i
vitrectomy NN 1_i
for IN N
combined VBN 1_p
rhegmatogenous JJ 1_p
retinal JJ 1_p
detachment NN 1_p
and CC 1_p
choroidal JJ 1_p
detachment NN 1_p
with IN 1_i
or CC 1_i
without IN 1_i
oral JJ 1_i
corticosteroids NNS 1_i
: : 1_i
a DT N
pilot NN N
study NN N
. . N

PURPOSE VB N
The DT N
occurrence NN N
of IN N
choroidal JJ 1_p
detachment NN 1_p
( ( 1_p
CD NN 1_p
) ) 1_p
in IN 1_p
eyes NNS 1_p
with IN 1_p
primary JJ 1_p
rhegmatogenous JJ 1_p
retinal JJ 1_p
detachment NN 1_p
( ( 1_p
RRD NNP 1_p
) ) 1_p
is VBZ N
relatively RB N
uncommon JJ N
( ( N
2 CD N
% NN N
-4.5 NNP N
% NN N
) ) N
. . N

Recent JJ N
reports NNS N
suggest VBP N
that IN N
primary JJ N
vitrectomy NN N
yields NNS N
better RBR N
anatomic JJ N
success NN N
than IN N
scleral JJ N
buckling NN N
. . N

However RB N
, , N
for IN N
these DT N
inflamed JJ 1_p
eyes NNS 1_p
with IN 1_p
low JJ 1_p
intraocular JJ 1_p
pressure NN 1_p
, , N
the DT N
influence NN N
of IN N
preoperative JJ N
oral JJ N
steroids NNS N
on IN N
reattachment NN N
rates NNS N
has VBZ N
not RB N
been VBN N
elucidated VBN N
yet RB N
. . N

METHODS NNP N
Twenty NNP 1_p
eyes NNS 1_p
with IN 1_p
combined JJ 1_p
RRD NNP 1_p
and CC 1_p
CD NNP 1_p
that WDT 1_p
underwent JJ 1_i
primary JJ 1_i
vitrectomy NN 1_i
were VBD N
randomized VBN N
to TO N
receive VB 1_i
oral JJ 1_i
steroids NNS 1_i
( ( 1_i
for IN 1_i
1 CD 1_i
week NN 1_i
) ) 1_i
or CC 1_i
no DT 1_i
oral JJ 1_i
steroids NNS 1_i
before IN 1_i
surgery NN 1_i
. . 1_i

RESULTS NNP N
Preoperative NNP N
clinical JJ N
data NNS N
such JJ N
as IN N
mean JJ N
age NN N
, , N
lens VBZ N
status NN N
, , N
Snellen NNP N
visual JJ N
acuity NN N
, , N
duration NN N
of IN N
macular JJ N
detachment NN N
, , N
CD NNP N
( ( N
size NN N
and CC N
extent NN N
) ) N
, , N
and CC N
retinal JJ N
detachment NN N
characteristics NNS N
( ( N
e.g. NN N
, , N
extent NN N
, , N
number NN N
of IN N
retinal JJ N
breaks NNS N
, , N
atrophic JJ N
or CC N
tractional JJ N
retinal JJ N
break NN N
, , N
size NN N
of IN N
retinal JJ N
break NN N
, , N
and CC N
location NN N
of IN N
retinal JJ N
break NN N
) ) N
were VBD N
similarly RB N
distributed VBN N
in IN N
both DT N
groups NNS N
. . N

Single-operation NNP 1_o
anatomic JJ 1_o
success NN 1_o
was VBD N
81.8 CD N
% NN N
( ( N
9/11 CD N
) ) N
among IN N
those DT N
patients NNS N
who WP N
received VBD N
preoperative JJ N
oral JJ N
steroids NNS 1_i
and CC N
was VBD N
66.7 CD N
% NN N
( ( N
6/9 CD N
) ) N
among IN N
those DT N
who WP N
did VBD N
not RB N
receive VB N
preoperative JJ N
oral JJ N
steroids NNS 1_i
. . 1_i

After IN N
reoperation NN N
, , N
anatomic JJ 1_o
success NN 1_o
was VBD N
100 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean JJ N
follow-up NN N
was VBD N
20.1 CD N
months NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
administration NN N
of IN N
oral JJ N
steroids NNS 1_i
before IN N
primary JJ N
vitrectomy NN N
in IN N
eyes NNS N
with IN N
combined JJ 1_p
RRD NNP 1_p
and CC 1_p
CD NNP 1_p
improves VBZ 1_p
reattachment JJ N
rates NNS N
. . N

-DOCSTART- -X- O O

Prophylaxis NN N
with IN N
meropenem NN 1_i
of IN N
septic JJ 1_o
complications NNS 1_o
in IN N
acute JJ N
pancreatitis NN N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
versus NN N
imipenem NN 1_i
. . 1_i

OBJECTIVES NNP N
Prophylactic JJ N
antibiotics NNS N
are VBP N
helpful JJ N
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
septic JJ 1_o
complications NNS 1_o
in IN N
acute JJ N
pancreatitis NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
meropenem NN 1_i
, , N
a DT N
new JJ 1_i
carbapenem NN 1_i
antibiotic JJ 1_i
, , N
with IN N
that DT N
of IN N
imipenem NN 1_i
, , N
which WDT N
is VBZ N
the DT N
standard JJ N
prophylactic JJ 1_i
treatment NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
acute NN 1_p
pancreatitis NN 1_p
. . 1_p

METHODS NNP N
One CD 1_p
hundred VBD 1_p
seventy-six JJ 1_p
patients NNS 1_p
with IN 1_p
necrotizing JJ 1_p
pancreatitis NN 1_p
were VBD N
prospectively RB N
randomized VBN N
to TO N
prophylactic JJ 1_i
treatment NN 1_i
with IN N
0.5 CD 1_i
g NNS 1_i
meropenem JJ 1_i
t.i.d NN 1_i
. . 1_i

intravenously RB 1_i
or CC 1_i
0.5 CD 1_i
g NNS 1_i
imipenem JJ 1_i
q.i.d NN 1_i
. . 1_i

intravenously RB 1_i
. . 1_i

The DT N
occurrence NN 1_o
of IN 1_o
infection NN 1_o
of IN 1_o
pancreatic JJ 1_o
necrosis NN 1_o
, , 1_o
rate NN 1_o
of IN 1_o
extrapancreatic JJ 1_o
infections NNS 1_o
, , 1_o
systemic JJ 1_o
and CC 1_o
local JJ 1_o
complications NNS 1_o
, , 1_o
need VBP 1_o
for IN 1_o
surgery NN 1_o
, , 1_o
mortality NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
length NN 1_o
of IN 1_o
hospitalization NN 1_o
were VBD N
recorded VBN N
for IN N
each DT N
group NN N
. . N

When WRB N
a DT N
septic JJ 1_o
complication NN 1_o
of IN N
pancreatic JJ N
necrosis NN N
was VBD N
suspected VBN N
, , N
fine JJ N
needle JJ N
aspiration NN N
with IN N
cultures NNS N
of IN N
the DT N
sample NN N
was VBD N
performed VBN N
. . N

Surgery NN N
was VBD N
performed VBN N
in IN N
cases NNS N
of IN N
verified JJ N
infected JJ N
necrosis NN N
. . N

CONCLUSION NNP N
No NNP N
difference NN N
was VBD N
observed VBN N
between IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
meropenem NN 1_i
and CC 1_p
those DT 1_p
treated VBN 1_p
with IN 1_p
imipenem NN 1_i
in IN 1_p
terms NNS 1_p
of IN 1_p
incidence NN 1_o
of IN 1_o
pancreatic JJ 1_o
infection NN 1_o
( ( 1_p
11.4 CD 1_p
% NN 1_p
versus IN 1_p
13.6 CD 1_p
% NN 1_p
) ) 1_p
and CC 1_p
extrapancreatic JJ 1_o
infections NNS 1_o
( ( 1_p
21.6 CD 1_p
% NN 1_p
versus IN 1_p
23.9 CD 1_p
% NN 1_p
) ) 1_p
and CC 1_p
clinical JJ 1_o
outcome NN 1_o
. . 1_o

Meropenem NNP 1_i
is VBZ N
as RB N
effective JJ N
as IN N
imipenem NN 1_i
in IN N
preventing VBG N
septic JJ 1_o
complications NNS 1_o
of IN N
patients NNS N
with IN N
severe JJ N
acute NN N
pancreatitis NN N
. . N

-DOCSTART- -X- O O

The DT N
UKEP NNP N
study NN N
: : N
multicentre JJ N
clinical JJ N
trial NN N
on IN N
two CD N
local JJ N
regimens NNS N
of IN N
urokinase NN 1_i
in IN N
massive JJ N
pulmonary JJ N
embolism NN N
. . N

The DT N
UKEP NNP N
Study NNP N
Research NNP N
Group NNP N
. . N

A NNP 1_i
multicentre JJ 1_i
trial NN 1_i
( ( 1_i
10 CD 1_i
centres NNS 1_i
) ) 1_i
of IN 1_i
urokinase NN 1_i
( ( 1_i
UK NNP 1_i
) ) 1_i
was VBD N
performed VBN N
in IN N
patients NNS 1_p
with IN 1_p
acute NN 1_p
severe JJ 1_p
pulmonary JJ 1_p
embolism NN 1_p
( ( 1_p
PE NNP 1_p
) ) 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
, , N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
two CD 1_i
doses NNS 1_i
of IN 1_i
UK NNP 1_i
administered VBD 1_i
via IN 1_i
a DT 1_i
catheter NN 1_i
in IN 1_i
the DT 1_i
pulmonary JJ 1_i
artery NN 1_i
: : 1_i
2000 CD 1_i
IU NNP 1_i
kg-1 JJ 1_i
h-1 NN 1_i
for IN 1_i
24 CD 1_i
hours NNS 1_i
( ( 1_i
UK IN 1_i
2000 CD 1_i
) ) 1_i
in IN 1_i
conjunction NN 1_i
with IN 1_i
heparin NN 1_i
versus NN 1_i
4400 CD 1_i
IU NNP 1_i
kg-1 JJ 1_i
h-1 JJ 1_i
UK NNP 1_i
alone RB 1_i
for IN 1_i
12 CD 1_i
hours NNS 1_i
( ( 1_i
UK IN 1_i
4400 CD 1_i
) ) 1_i
followed VBN 1_i
by IN 1_i
heparin NN 1_i
. . 1_i

PE NNP 1_p
was VBD 1_p
less JJR 1_p
than IN 1_p
5 CD 1_p
days NNS 1_p
old JJ 1_p
and CC N
the DT N
clinical JJ N
diagnosis NN N
was VBD N
confirmed VBN N
by IN N
pulmonary JJ N
angiograms NNS N
demonstrating VBG N
a DT N
vascular JJ N
obstruction NN N
of IN N
more JJR N
than IN N
30 CD N
% NN N
( ( N
Miller NNP N
's POS N
index NN N
greater JJR N
than IN N
11 CD N
) ) N
. . N

The DT N
efficacy NN N
of IN N
treatment NN N
was VBD N
evaluated VBN N
by IN N
the DT N
degree NN 1_o
of IN 1_o
early JJ 1_o
revascularization NN 1_o
( ( N
pulmonary JJ N
angiograms NNS N
were VBD N
performed VBN N
30 CD N
to TO N
48 CD N
hours NNS N
after IN N
initiation NN N
of IN N
thrombolytic JJ 1_i
treatment NN 1_i
and CC N
analysed VBN N
blindly RB N
by IN N
four CD N
independent JJ N
vascular JJ N
radiologists NNS N
) ) N
. . N

133 CD 1_p
patients NNS 1_p
were VBD N
included VBN N
in IN N
this DT N
trial NN N
: : N
two CD 1_p
patients NNS 1_p
died VBD 1_o
before IN 1_p
treatment NN 1_p
and CC 1_p
two CD 1_p
were VBD 1_p
excluded VBN 1_p
retrospectively RB 1_p
, , 1_p
leaving VBG 1_p
129 CD 1_p
patients NNS 1_p
for IN 1_p
final JJ 1_p
analysis NN 1_p
( ( N
67 CD N
: : N
UK NN N
2000 CD N
+ NNP N
heparin NN N
; : N
62 CD N
: : N
UK JJ N
4400 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
had VBD N
similar JJ N
pretreatment NN N
clinical JJ N
, , N
haemodynamic JJ N
and CC N
angiographic JJ N
characteristics NNS N
: : N
the DT N
Miller NNP 1_o
angiographic JJ 1_o
index NN 1_o
of IN N
severity NN N
averaged VBD N
22.6 CD N
+/- JJ N
3.7 CD N
for IN N
patients NNS N
in IN N
the DT N
UK NNP N
2000 CD N
group NN N
, , N
and CC N
22.6 CD N
+/- JJ N
3.4 CD N
for IN N
patients NNS N
in IN N
the DT N
UK NNP N
4400 CD N
group NN N
( ( N
average JJ N
filling VBG N
defect NN N
of IN N
66 CD N
% NN N
on IN N
pulmonary JJ N
angiograms NNS N
) ) N
. . N

There EX N
was VBD N
a DT N
similar JJ N
and CC N
significant JJ 1_o
degree NN 1_o
of IN 1_o
resolution NN 1_o
in IN N
the DT N
two CD N
groups NNS N
: : N
26 CD N
% NN N
and CC N
20 CD N
% NN N
, , N
respectively RB N
. . N

Minor NNP 1_o
and CC 1_o
major JJ 1_o
bleeding NN 1_o
problems NNS 1_o
were VBD N
observed VBN N
with IN N
equal JJ N
frequency NN N
in IN N
the DT N
two CD 1_p
groups NNS 1_p
( ( N
24 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

These DT N
bleeding VBG N
complications NNS N
were VBD N
severe RB N
in IN N
only RB N
4.5 CD N
% NN N
and CC N
3 CD N
% NN N
, , N
respectively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
diclofenac NN 1_i
and CC N
ketorolac NN N
after IN N
refractive JJ 1_p
surgery NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN 1_o
of IN N
diclofenac NN 1_i
and CC 1_i
ketorolac NN 1_i
in IN N
relieving VBG 1_o
corneal NN 1_o
pain NN 1_o
after IN 1_p
refractive JJ 1_p
surgery NN 1_p
, , N
and CC N
determine VB N
if IN N
there EX N
is VBZ N
a DT N
difference NN N
in IN N
stinging VBG N
on IN N
instillation NN N
. . N

METHODS NNP N
Thirty NNP 1_p
patients NNS 1_p
were VBD N
randomized VBN N
prospectively RB N
to TO N
postoperative VB 1_i
diclofenac NN 1_i
in IN 1_i
one CD 1_i
eye NN 1_i
and CC 1_i
ketorolac NN 1_i
in IN 1_i
the DT 1_i
other JJ 1_i
. . 1_i

Patients NNS N
and CC N
surgeon NN N
did VBD N
not RB N
know VB N
which WDT N
medications NNS N
were VBD N
used VBN N
. . N

Ocular JJ 1_o
postoperative JJ 1_o
pain NN 1_o
and CC 1_o
discomfort NN 1_o
on IN 1_o
instillation NN 1_o
of IN 1_o
medication NN 1_o
were VBD N
measured VBN N
after IN N
radial JJ N
keratotomy NN N
with IN N
a DT N
visual JJ 1_o
analog NN 1_o
scale NN 1_o
and CC 1_o
a DT 1_o
questionnaire NN 1_o
. . 1_o

RESULTS NNP N
Both NNP N
medications NNS N
were VBD N
highly RB N
effective JJ 1_o
in IN 1_o
relieving VBG 1_o
pain NN 1_o
. . 1_o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN 1_o
relief NN 1_o
, , N
or CC N
stinging VBG 1_o
on IN 1_o
instillation NN 1_o
( ( N
P NNP N
= NNP N
.29 NNP N
) ) N
. . N

CONCLUSION NNP N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
effectiveness NN N
of IN N
the DT N
medications NNS N
on IN N
pain NN 1_o
relief NN 1_o
, , N
or CC N
in IN N
stinging VBG 1_o
on IN 1_o
instillation NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
prophylactic JJ 1_i
calcium NN 1_i
and CC 1_i
magnesium NN 1_i
infusions NNS 1_i
on IN N
the DT N
incidence NN N
of IN N
neurotoxicity NN N
and CC N
clinical JJ N
outcome NN N
of IN N
oxaliplatin-based JJ N
systemic JJ N
treatment NN N
in IN N
advanced JJ 1_p
colorectal JJ 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Peripheral NNP N
sensory JJ N
neurotoxicity NN N
is VBZ N
a DT N
frequent JJ N
and CC N
potentially RB N
debilitating JJ N
side NN N
effect NN N
of IN N
oxaliplatin NN N
treatment NN N
. . N

Calcium NN N
and CC N
magnesium NN N
( ( N
Ca/Mg NNP N
) ) N
infusions NNS N
are VBP N
frequently RB N
used VBN N
to TO N
prevent VB N
this DT N
toxicity NN N
. . N

However RB N
, , N
concerns NNS N
about IN N
a DT N
negative JJ N
impact NN N
of IN N
Ca/Mg NNP N
infusions NNS N
on IN N
outcome NN N
have VBP N
been VBN N
raised VBN N
. . N

We PRP N
retrospectively RB N
assessed VBD N
the DT N
effect NN N
of IN N
Ca/Mg NNP N
infusions NNS N
on IN N
the DT N
incidence NN 1_o
of IN 1_o
neurotoxicity NN 1_o
and CC N
on IN N
clinical JJ 1_o
outcome NN 1_o
in IN N
advanced JJ 1_p
colorectal JJ 1_p
cancer NN 1_p
( ( 1_p
ACC NNP 1_p
) ) 1_p
patients NNS 1_p
treated VBN 1_p
in IN 1_p
the DT 1_p
phase NN 1_p
III NNP 1_p
CAIRO2 NNP 1_p
study NN 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
Seven NNP 1_p
hundred VBD 1_p
and CC 1_p
fifty JJ 1_p
five CD 1_p
previously RB 1_p
untreated JJ 1_p
ACC NNP 1_p
patients NNS 1_p
were VBD N
randomised VBN N
between IN N
treatment NN 1_i
with IN 1_i
capecitabine NN 1_i
, , 1_i
oxaliplatin NN 1_i
and CC 1_i
bevacizumab NN 1_i
or CC 1_i
the DT 1_i
same JJ 1_i
combination NN 1_i
with IN 1_i
the DT 1_i
addition NN 1_i
of IN 1_i
cetuximab NN 1_i
. . 1_i

Patients NNS N
were VBD N
retrospectively RB N
divided VBN N
into IN N
two CD 1_i
groups NNS 1_i
: : 1_i
patients NNS 1_i
in IN 1_i
the DT 1_i
Ca/Mg NNP 1_i
( ( 1_i
+ NNP 1_i
) ) 1_i
group NN 1_i
received VBD 1_i
Ca/Mg NNP 1_i
at IN 1_i
least JJS 1_i
during IN 1_i
their PRP$ 1_i
first JJ 1_i
treatment NN 1_i
cycle NN 1_i
, , 1_i
and CC 1_i
patients NNS 1_i
in IN 1_i
the DT 1_i
Ca/Mg NNP 1_i
( ( 1_i
- : 1_i
) ) 1_i
group NN 1_i
did VBD 1_i
not RB 1_i
. . 1_i

RESULTS VB N
Seven NNP 1_p
hundred CD 1_p
and CC 1_p
thirty VB 1_p
two CD 1_p
patients NNS 1_p
were VBD 1_p
evaluable JJ 1_p
for IN N
this DT N
analysis NN N
. . N

The DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
group NN N
consisted VBD N
of IN N
551 CD N
patients NNS N
, , N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
consisted VBD N
of IN N
181 CD N
patients NNS N
. . N

The DT N
incidence NN N
of IN N
all DT 1_o
grade JJ 1_o
neurotoxicity NN 1_o
in IN N
the DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
group NN N
and CC N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
was VBD N
85 CD N
% NN N
and CC N
92 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
the DT N
incidence NN N
of IN N
grade NN N
? . N
2 CD N
neurotoxicity NN 1_o
was VBD 1_o
40 CD N
% NN N
and CC N
45 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.22 CD N
) ) N
. . N

The DT 1_o
median JJ 1_o
PFS NNP 1_o
in IN 1_o
the DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
versus NN N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
was VBD N
10.1 CD N
versus NN N
10.7 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.92 CD N
) ) N
, , N
the DT N
median JJ N
OS NNP N
was VBD N
19.8 CD N
versus NN N
20.7 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
, , N
and CC N
the DT N
response NN N
rate NN N
was VBD N
43.1 CD N
% NN N
versus IN N
50 CD N
% NN N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
largest JJS N
retrospective JJ N
analysis NN N
to TO N
date NN N
we PRP N
observed VBD N
that IN N
Ca/Mg NNP N
infusions NNS N
significantly RB N
reduced VBD N
all DT N
grade JJ N
oxaliplatin-related JJ N
neurotoxicity NN 1_i
. . 1_i

Ca/Mg NNP 1_i
infusions NNS 1_i
did VBD 1_i
not RB N
affect VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Mask NNP 1_i
ventilation NN 1_i
with IN N
two CD N
different JJ N
face NN N
masks NNS N
in IN N
the DT N
delivery NN N
room NN N
for IN N
preterm JJ 1_p
infants NNS 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
If IN N
an DT N
infant NN 1_p
fails VBZ 1_p
to TO 1_p
initiate VB 1_p
spontaneous JJ 1_p
breathing NN 1_p
after IN 1_p
birth NN 1_p
, , N
international JJ N
guidelines NNS N
recommend VBP N
a DT N
positive JJ N
pressure NN N
ventilation NN N
( ( N
PPV NNP N
) ) N
. . N

However RB N
, , N
PPV NNP N
by IN N
face NN 1_i
mask NN 1_i
is VBZ N
frequently RB N
inadequate JJ N
because IN N
of IN N
leak NN N
between IN N
the DT N
face NN N
and CC N
mask NN N
. . N

Despite IN N
a DT N
variety NN N
of IN N
available JJ N
face NN N
masks NNS N
, , N
none NN N
have VBP N
been VBN N
prospectively RB N
compared VBN N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
and CC N
compare VB N
leak NN 1_o
between IN 1_o
two CD 1_o
commercially RB 1_o
available JJ 1_o
round NN 1_o
face NN 1_o
masks NNS 1_o
( ( 1_i
Fisher NNP 1_i
& CC 1_i
Paykel NNP 1_i
( ( 1_i
F NNP 1_i
& CC 1_i
P NNP 1_i
) ) 1_i
and CC 1_i
Laerdal NNP 1_i
) ) 1_i
in IN N
preterm NN 1_p
infants NNS 1_p
< VBP 1_p
33 CD 1_p
weeks NNS 1_p
gestational JJ 1_p
age NN 1_p
in IN 1_p
the DT 1_p
delivery NN 1_p
room NN 1_p
. . 1_p

METHODS NNP N
Infants NNPS 1_p
born VBN 1_p
at IN 1_p
the DT 1_p
Royal NNP 1_p
Alexandra NNP 1_p
Hospital NNP 1_p
from IN 1_p
April NNP 1_p
to TO 1_p
September NNP 1_p
2013 CD 1_p
at IN 1_p
< $ 1_p
33 CD 1_p
weeks NNS 1_p
gestational JJ 1_p
age NN 1_p
who WP 1_p
received VBD 1_p
mask NN 1_i
PPV NNP 1_i
in IN 1_p
the DT 1_p
delivery NN 1_p
room NN 1_p
routinely RB N
had VBD N
a DT N
flow NN N
sensor NN N
placed VBD N
between IN N
the DT N
mask NN N
and CC N
T-piece NNP N
resuscitator NN N
. . N

Infants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
PPV NNP 1_i
with IN 1_i
either CC 1_i
a DT 1_i
F NNP 1_i
& CC 1_i
P NNP 1_i
or CC 1_i
Laerdal NNP 1_i
face NN 1_i
mask NN 1_i
. . 1_i

All DT N
resuscitators NNS N
were VBD N
trained VBN N
in IN N
the DT N
use NN N
of IN N
both DT N
face NN N
masks NNS N
. . N

We PRP N
compared VBN N
mask NN 1_o
leak NN 1_o
, , 1_o
airway NN 1_o
pressures NNS 1_o
, , 1_o
tidal JJ 1_o
volume NN 1_o
and CC 1_o
ventilation NN 1_o
rate NN 1_o
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Fifty-six JJ 1_p
preterm JJ 1_p
infants NNS 1_p
( ( 1_p
n=28 NN 1_p
in IN 1_p
each DT 1_p
group NN 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
; : 1_p
mean?s.d NN 1_p
. . 1_p

gestational JJ 1_p
age NN 1_p
28?3 CD 1_p
weeks NNS 1_p
; : 1_p
birth NN 1_p
weight VBD 1_p
1210?448 CD 1_p
g NN 1_p
; : 1_p
and CC 1_p
30 CD 1_p
( ( 1_p
52 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
male JJ 1_p
. . 1_p

Apgar JJ 1_p
scores NNS N
at IN N
1 CD N
and CC N
5 CD N
min NNS N
were VBD N
5?3 CD N
and CC N
7?2 CD N
, , N
respectively RB N
. . N

Infants NNS N
randomized VBD 1_i
to TO 1_i
the DT 1_i
F NNP 1_i
& CC 1_i
P NNP 1_i
face NN 1_i
mask NN 1_i
and CC 1_i
Laerdal NNP 1_i
face NN 1_i
mask NN 1_i
had VBD 1_i
similar JJ 1_o
mask NN 1_o
leak NN 1_o
( ( 1_o
30 CD 1_o
( ( N
25-38 JJ N
) ) N
versus NN N
35 CD N
( ( N
24-46 JJ N
) ) N
% NN N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
, , N
respectively RB N
, , N
P=0.40 NNP N
) ) N
and CC 1_o
tidal JJ 1_o
volume NN 1_o
( ( 1_o
7.1 CD N
( ( N
4.9-8.9 JJ N
) ) N
versus NN N
6.6 CD N
( ( N
5.2-8.9 JJ N
) ) N
ml NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
P=0.69 NNP N
) ) N
during IN N
PPV NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN 1_o
ventilation NN 1_o
rate NN 1_o
, , 1_o
inflation NN 1_o
time NN 1_o
or CC 1_o
airway NN 1_o
pressures NNS 1_o
between IN 1_o
groups NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
either DT N
face NN N
mask NN N
during IN N
PPV NNP N
in IN N
the DT N
delivery NN N
room NN N
yields NNS N
similar JJ 1_o
mask NN 1_o
leak NN 1_o
in IN 1_o
preterm JJ 1_p
infants NNS 1_p
< VBP 1_p
33 CD 1_p
weeks NNS 1_p
gestational JJ 1_p
age NN 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
effect NN N
of IN N
transcatheter NN 1_i
arterial JJ 1_i
chemoembolization NN 1_i
combined VBN N
with IN N
high JJ 1_i
intensity NN 1_i
focused VBD 1_i
ultrasound JJ 1_i
ablation NN 1_i
in IN N
treatment NN N
of IN N
large JJ 1_p
hepatocellular JJ 1_p
carcinoma NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
clinical JJ N
effect NN N
of IN N
transcatheter NN 1_i
arterial JJ 1_i
chemoembolization NN 1_i
( ( 1_i
TACE NNP 1_i
) ) 1_i
combined VBN N
with IN N
high JJ 1_i
intensity NN 1_i
focused VBN 1_i
ultrasound NN 1_i
( ( 1_i
HIFU NNP 1_i
) ) 1_i
ablation NN N
in IN N
treatment NN N
of IN N
large JJ N
hepatocellular JJ 1_p
carcinoma NN 1_p
( ( 1_p
HCC NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Sixty-eight JJ 1_p
patients NNS 1_p
with IN 1_p
unresectable JJ 1_p
HCC NNP 1_p
were VBD N
randomized VBN N
into IN N
2 CD 1_i
age NN 1_i
, , 1_i
tumor NN 1_i
size NN 1_i
, , 1_i
TNM NNP 1_i
stages VBZ 1_i
, , 1_i
and CC 1_i
liver JJ 1_i
function NN 1_i
grade-matched JJ 1_i
groups NNS 1_i
: : 1_i
TACE NNP 1_i
group NN 1_i
( ( 1_i
n=30 RB 1_i
) ) 1_i
undergoing VBG 1_i
TACE NNP 1_i
and CC 1_i
TACE+HIFU NNP 1_i
group NN 1_i
( ( 1_i
n=38 RB 1_i
) ) 1_i
undergoing VBG 1_i
2-3 JJ 1_i
weeks NNS 1_i
after IN 1_i
TACE NNP 1_i
. . 1_i

A NNP N
total NN N
of IN N
88 CD N
tumors NNS N
( ( N
9.3+/-3.2 CD N
) ) N
( ( N
5.0-14.5 JJ N
) ) N
cm NN N
in IN N
diameter NN N
were VBD N
detected VBN N
, , N
and CC N
the DT N
largest JJS N
tumor NN N
in IN N
a DT N
specific JJ N
patients NNS 1_p
with IN 1_p
multiple JJ 1_p
lesions NNS 1_p
was VBD N
selected VBN N
for IN N
observation NN N
. . N

Follow-up NNP N
was VBD N
conducted VBN N
for IN N
( ( N
13+/-7 JJ N
) ) N
( ( N
3-24 JJ N
) ) N
months NNS N
to TO N
observe VB N
the DT N
necrosis NN 1_o
of IN 1_o
tumor NN 1_o
, , 1_o
size NN 1_o
of IN 1_o
tumor NN 1_o
, , 1_o
local JJ 1_o
recurrence NN 1_o
, , N
and CC N
survival NN 1_o
of IN 1_o
patient NN 1_o
. . 1_o

RESULTS VB N
The DT N
clinical JJ 1_o
symptom JJ 1_o
remission NN 1_o
rate NN 1_o
was VBD N
90.6 CD N
% NN N
( ( N
29/32 CD N
) ) N
in IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
and CC N
70.8 CD N
% NN N
( ( N
28/38 CD N
) ) N
in IN N
the DT N
TACE NNP N
group NN N
. . N

The DT N
tumor NN 1_o
necrosis NN 1_o
and CC 1_o
minification NN 1_o
rates NNS 1_o
of IN N
the DT N
TACE+HIFU NNP 1_i
and CC N
TACE NNP 1_i
groups NNS N
were VBD N
73.7 CD N
% NN N
and CC N
68.4 CD N
% NN N
respectively RB N
, , N
both DT N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
TACE NNP 1_i
group NN N
( ( N
26.7 CD N
% NN N
and CC N
33.3 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
tumor NN 1_o
local JJ 1_o
recurrence NN 1_o
rate NN 1_o
of IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
was VBD N
21.1 CD N
% NN N
, , N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
the DT N
TACE NNP 1_i
group NN N
( ( N
33.3 CD N
% NN N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
median JJ 1_o
survival NN 1_o
duration NN 1_o
of IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
was VBD N
18 CD N
months NNS N
, , N
significantly RB N
longer JJR N
than IN N
that DT N
of IN N
the DT N
TACE NNP 1_i
group NN N
( ( N
10 CD N
months NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
the DT N
TACE NNP 1_i
therapy NN N
alone RB N
, , N
the DT N
combination NN N
therapy NN N
improves VBZ N
the DT N
tumor NN 1_o
necrosis NN 1_o
rate NN 1_o
and CC N
prolongs VBZ N
the DT N
patients NNS 1_o
' POS 1_o
survival JJ 1_o
duration NN 1_o
. . 1_o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
esmolol NN 1_i
, , N
a DT N
short-acting JJ N
beta NN N
blocker NN N
, , N
with IN N
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
supraventricular JJ 1_p
tachyarrhythmias NN 1_p
. . 1_p

The DT N
Esmolol NNP 1_i
vs NN 1_i
Placebo NNP 1_i
Multicenter NNP N
Study NNP N
Group NNP N
. . N

The DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
esmolol NN 1_i
, , N
a DT N
short-acting JJ N
intravenous JJ N
beta-adrenergic-blocking JJ N
agent NN N
, , N
and CC N
placebo NN 1_i
were VBD N
compared VBN N
in IN N
patients NNS 1_p
with IN 1_p
supraventricular JJ 1_p
tachyarrhythmias NN 1_p
( ( 1_p
heart NN 1_p
rate NN 1_p
greater JJR 1_p
than IN 1_p
120 CD 1_p
bpm NN 1_p
) ) 1_p
in IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
partial-crossover JJ N
study NN N
. . N

Seventy-one CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
esmolol NN 1_i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
as IN N
initial JJ N
treatment NN N
. . N

Therapeutic JJ N
failures NNS N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
other JJ N
study NN N
medication NN N
. . N

Therapeutic JJ 1_o
response NN 1_o
was VBD N
defined VBN N
as IN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
20 CD N
% NN N
reduction NN N
in IN N
heart NN 1_o
rate NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
less JJR 1_o
than IN 1_o
100 CD 1_o
bpm NN 1_o
, , 1_o
or CC 1_o
conversion NN 1_o
to TO 1_o
normal JJ 1_o
sinus NN 1_o
rhythm NN 1_o
. . 1_o

The DT 1_o
therapeutic JJ 1_o
response NN 1_o
to TO N
esmolol VB 1_i
during IN N
the DT N
initial JJ N
treatment NN N
period NN N
( ( N
72 CD N
% NN N
) ) N
was VBD N
similar JJ N
to TO N
that DT N
obtained VBN N
when WRB N
esmolol NN N
was VBD N
given VBN N
as IN N
a DT N
second JJ N
agent NN N
. . N

The DT N
average JJ N
esmolol JJ N
dosage NN N
producing VBG N
a DT N
therapeutic JJ N
response NN N
was VBD N
97.5 CD N
micrograms/kg/min NN N
. . N

Four CD N
patients NNS N
( ( N
6 CD N
% NN N
) ) N
converted VBD N
to TO N
normal JJ 1_o
sinus JJ 1_o
rhythm NN 1_o
during IN N
esmolol JJ N
infusion NN N
. . N

In IN N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
, , N
therapeutic JJ 1_o
response NN 1_o
was VBD N
lost VBN N
within IN N
30 CD N
minutes NNS N
following VBG N
discontinuation NN N
of IN N
esmolol JJ 1_i
infusion NN N
, , N
a DT N
finding JJ N
indicative NN N
of IN N
rapid JJ N
reversal NN N
of IN N
beta-adrenoceptor NN N
blockade NN N
. . N

The DT N
most RBS N
prevalent JJ N
adverse JJ 1_o
effect NN 1_o
during IN N
esmolol JJ 1_i
infusion NN N
was VBD N
hypotension NN 1_o
which WDT N
occurred VBD N
in IN N
eight CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
. . N

Hypotension NN 1_o
and CC 1_o
associated VBN 1_o
symptoms NNS 1_o
resolved VBD N
within IN N
30 CD N
minutes NNS N
after IN N
discontinuation NN N
of IN N
esmolol JJ 1_i
infusion NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
short JJ N
duration NN N
of IN N
action NN N
of IN N
esmolol NN 1_i
( ( N
elimination JJ N
half-life NN N
of IN N
9.2 CD N
minutes NNS N
) ) N
. . N

-DOCSTART- -X- O O

Parenteral JJ N
nutrition NN N
and CC N
protein NN N
sparing NN N
after IN N
surgery NN 1_i
: : 1_i
do VBP N
we PRP N
need VB N
glucose RB 1_i
? . N
Although IN N
capable JJ N
of IN N
inducing VBG N
an DT N
anabolic JJ N
state NN N
after IN N
surgery NN N
, , N
parenteral JJ 1_i
nutrition NN 1_i
, , N
including VBG N
glucose NN 1_i
, , N
leads VBZ N
to TO N
hyperglycemia VB N
. . N

Even RB N
moderate JJ N
increases NNS N
in IN N
blood NN N
glucose NN N
are VBP N
associated VBN N
with IN N
poor JJ N
surgical JJ N
outcome NN N
. . N

We PRP N
examined VBD N
the DT N
hypothesis NN N
that WDT N
amino NN 1_i
acids NNS 1_i
, , N
in IN N
the DT N
absence NN N
of IN N
glucose JJ 1_i
supply NN N
, , N
spare JJ N
protein NN N
while IN N
preventing VBG N
hyperglycemia NN N
. . N

In IN N
this DT N
prospective JJ N
study NN N
, , N
14 CD 1_p
patients NNS 1_p
with IN 1_p
colonic JJ 1_p
cancer NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
a DT N
6-hour JJ N
stable JJ N
isotope NN 1_i
infusion NN 1_i
study NN N
( ( N
3 CD N
hours NNS N
of IN N
fasting VBG 1_i
followed VBN N
by IN N
3-hour JJ N
infusions NNS N
of IN N
amino NN 1_i
acids NNS 1_i
, , 1_i
Travasol NNP 1_i
[ NNP N
Baxter NNP N
, , N
Montreal NNP N
, , N
Canada NNP N
] VBD N
10 CD N
% NN N
at IN N
0.02 CD N
mL.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
, , N
with IN 1_i
or CC 1_i
without IN 1_i
glucose JJ 1_i
at IN N
4 CD N
mg.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
) ) N
on IN N
the DT N
second JJ N
day NN N
after IN N
colorectal JJ N
surgery NN N
. . N

Protein NNP 1_o
breakdown NN 1_o
, , 1_o
protein JJ 1_o
oxidation NN 1_o
, , 1_o
protein JJ 1_o
balance NN 1_o
, , 1_o
and CC 1_o
glucose JJ 1_o
production NN 1_o
were VBD N
assessed VBN N
by IN N
stable JJ N
isotope NN N
tracer NN N
kinetics NNS N
using VBG N
l- JJ N
[ JJ N
1- JJ N
( ( N
13 CD N
) ) N
C NNP N
] NNP N
leucine NN N
and CC N
[ JJ N
6,6- JJ N
( ( N
2 CD N
) ) N
H2 NNP N
] NNP N
glucose NN N
. . N

Circulating VBG 1_o
concentrations NNS 1_o
of IN 1_o
glucose NN 1_o
, , 1_o
cortisol NN 1_o
, , 1_o
insulin NN 1_o
, , 1_o
and CC 1_o
glucagon NN 1_o
were VBD N
determined VBN N
. . N

The DT N
administration NN N
of IN N
amino JJ 1_i
acids NNS 1_i
increased VBD N
protein JJ 1_o
balance NN 1_o
from IN N
-16+/-4 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
in IN N
the DT N
fasted JJ N
state NN N
to TO N
16+/-3 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
. . N

Combined VBN N
infusion NN N
of IN N
amino JJ 1_i
acids NNS 1_i
and CC 1_i
glucose VB 1_i
increased JJ N
protein NN 1_o
balance NN 1_o
from IN N
-17+/-7 JJ N
to TO N
7+/-5 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
. . N

The DT N
increase NN N
in IN N
protein JJ 1_o
balance NN 1_o
during IN N
nutrition NN N
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
P=.07 NNP N
) ) N
. . N

Combined VBN N
administration NN N
of IN N
amino JJ 1_i
acids NNS 1_i
and CC 1_i
glucose VB 1_i
decreased VBN N
endogenous JJ 1_o
glucose JJ 1_o
production NN 1_o
( ( N
P=.001 NNP N
) ) N
and CC N
stimulated VBN N
insulin NN 1_o
secretion NN 1_o
( ( N
P=.001 NNP N
) ) N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
the DT N
administration NN N
of IN N
amino JJ 1_i
acids NNS 1_i
alone RB N
. . N

Hyperglycemia NNP 1_o
( ( N
blood NN N
glucose NN N
, , N
10.1+/-1.9 JJ N
micromol/L NN N
) ) N
occurred VBD N
only RB N
in IN N
the DT N
presence NN N
of IN N
glucose JJ 1_i
infusion NN N
. . N

In IN N
summary JJ N
, , N
excluding VBG N
glucose NN 1_i
from IN N
a DT N
short-term JJ N
feeding NN N
protocol NN N
does VBZ N
not RB N
diminish VB N
the DT N
protein-sparing JJ 1_o
effect NN 1_o
of IN N
amino NN 1_i
acids NNS 1_i
and CC N
avoids NNS N
hyperglycemia NN 1_o
. . 1_o

-DOCSTART- -X- O O

Antihypertensive JJ N
and CC N
volume-depleting JJ N
effects NNS N
of IN N
mild JJ 1_i
exercise NN 1_i
on IN N
essential JJ N
hypertension NN N
. . N

After IN N
a DT N
general JJ N
clinical JJ N
observation NN N
period NN N
of IN N
over IN N
4 CD N
weeks NNS N
, , N
20 CD 1_p
essential JJ 1_p
hypertensive JJ 1_p
subjects NNS 1_p
( ( 1_p
Japanese JJ 1_p
) ) 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

One CD 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= VBZ 1_p
10 CD 1_p
; : 1_p
4 CD 1_p
men NNS 1_p
and CC 1_p
6 CD 1_p
women NNS 1_p
; : 1_p
51.4 CD 1_p
+/- JJ 1_p
2.8 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
agreed VBD N
to TO N
physical JJ 1_i
training NN 1_i
using VBG 1_i
bicycle NN 1_i
ergometer NN 1_i
exercise NN 1_i
with IN 1_i
the DT 1_i
intensity NN 1_i
at IN 1_i
blood NN 1_i
lactate NN 1_i
threshold NN 1_i
for IN 1_i
60 CD 1_i
minutes NNS 1_i
three CD 1_i
times NNS 1_i
a DT 1_i
week NN 1_i
for IN 1_i
10 CD 1_i
weeks NNS 1_i
, , N
while IN N
the DT 1_p
other JJ 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= VBZ 1_p
10 CD 1_p
; : 1_p
4 CD 1_p
men NNS 1_p
and CC 1_p
6 CD 1_p
women NNS 1_p
; : 1_p
51.0 CD 1_p
+/- JJ 1_p
2.9 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
did VBD N
no DT 1_i
particular JJ 1_i
physical JJ 1_i
training NN 1_i
and CC N
was VBD N
followed VBN N
once RB N
a DT N
week NN N
as IN N
the DT N
control NN N
. . N

Changes NNS N
in IN N
blood NN 1_o
pressure NN 1_o
, , 1_o
hemodynamics NNS 1_o
, , 1_o
and CC 1_o
humoral JJ 1_o
factors NNS 1_o
of IN N
the DT N
exercised VBN N
group NN N
were VBD N
compared VBN N
with IN N
values NNS N
in IN N
the DT N
controls NNS N
. . N

The DT N
following JJ N
significant JJ N
changes NNS N
were VBD N
found VBN N
only RB N
in IN N
the DT N
exercised JJ N
group NN N
. . N

Blood NNP 1_o
pressure NN 1_o
was VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
reduced VBN N
. . N

Whole JJ 1_o
blood NN 1_o
and CC 1_o
plasma NN 1_o
volume NN 1_o
indices NNS 1_o
were VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
, , N
p NN N
less JJR N
than IN N
0.01 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
change NN N
in IN N
ratio NN 1_o
of IN 1_o
serum NN 1_o
sodium NN 1_o
to TO 1_o
potassium VB 1_o
positively RB N
correlated VBN N
with IN N
the DT N
change NN N
in IN N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( N
r JJ N
= NN N
0.76 CD N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

Plasma NNP 1_o
norepinephrine JJ 1_o
concentrations NNS 1_o
both DT N
at IN N
rest NN N
and CC N
at IN N
the DT N
workload NN N
of IN N
blood NN N
lactate NN N
threshold NN N
during IN N
graded JJ N
exercise NN N
tests NNS N
were VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
respectively RB N
) ) N
after IN N
10 CD N
weeks NNS N
of IN N
exercise NN 1_i
training NN 1_i
. . 1_i

The DT N
change NN N
in IN N
the DT N
resting VBG 1_o
level NN 1_o
of IN 1_o
plasma JJ 1_o
norepinephrine NN 1_o
positively RB N
correlated VBN N
with IN N
that DT N
in IN N
the DT N
mean JJ 1_o
blood NN 1_o
pressure NN 1_o
. . 1_o

No DT N
such JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
both DT N
groups NNS N
, , N
body NN N
weight NN N
and CC N
urinary JJ N
sodium NN N
excretion NN N
showed VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

The DT N
patient JJ 1_p
experience NN 1_p
of IN N
community NN 1_i
hospital NN 1_i
-- : 1_i
the DT 1_i
process NN 1_i
of IN 1_i
care NN 1_i
as IN N
a DT N
determinant NN N
of IN N
satisfaction NN N
. . N

AIMS NNP N
AND CC N
OBJECTIVES NNP N
We PRP N
report VBP N
findings NNS N
from IN N
a DT N
qualitative JJ N
study NN N
to TO N
identify VB N
patient JJ 1_p
views NNS 1_p
of IN 1_p
community NN 1_i
hospital NN 1_i
care NN 1_i
. . 1_i

We PRP N
consider VBP N
how WRB N
far RB N
these DT N
were VBD N
in IN N
accord NN N
with IN N
the DT N
hospital NN N
staffs NNS N
' POS N
views NNS N
. . N

This DT N
constituted JJ N
part NN N
of IN N
a DT N
wider NN N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

The DT N
methodological JJ N
challenges NNS N
in IN N
seeking VBG N
to TO N
identify VB N
patient JJ N
satisfaction NN 1_o
and CC N
in IN N
linking VBG N
qualitative JJ 1_o
findings NNS 1_o
with IN N
trial NN N
results NNS N
are VBP N
explored JJ N
. . N

DESIGN VB N
A DT 1_p
sample NN 1_p
of IN 1_p
13 CD 1_p
patients NNS 1_p
randomized VBN 1_p
to TO 1_p
the DT 1_p
community NN 1_p
hospital NN 1_p
arm NN 1_p
of IN 1_p
the DT 1_p
RCT NNP 1_p
joined VBD 1_p
the DT 1_p
qualitative JJ 1_i
study NN 1_i
. . 1_i

Official JJ N
documentation NN N
from IN N
the DT N
hospital NN N
were VBD N
accessed VBN N
and CC N
six CD N
staff NN N
interviewed VBN N
to TO N
identify VB N
assumptions NNS N
underlying VBG N
practice NN N
. . N

RESULTS NNP N
Analysis NNP N
of IN N
interviews NNS 1_i
identified VBN N
a DT N
complex JJ N
picture NN N
concerning VBG N
expectations NNS N
These DT N
could MD N
be VB N
classified VBN N
as IN N
ideal NN N
, , N
realistic JJ N
, , N
normative JJ N
and CC N
unformed JJ N
. . N

The DT N
hospital NN N
philosophy NN N
and CC N
staff NN 1_o
views NNS 1_o
about IN N
service NN N
delivery NN N
were VBD N
closely RB N
in IN N
harmony NN N
, , N
they PRP N
delivered VBD N
rehabilitation NN N
in IN N
a DT N
home-based JJ N
atmosphere NN N
. . N

The DT N
formal JJ 1_o
, , 1_o
or CC 1_o
'hard POS 1_o
' '' 1_o
, , 1_o
process NN 1_o
of IN 1_o
rehabilitation NN 1_o
was VBD N
not RB N
well RB N
understood JJ N
by IN N
patients NNS N
. . N

They PRP N
were VBD N
primarily RB N
concerned VBN N
with IN N
'soft NNP N
' POS N
or CC N
process NN N
issues NNS N
-- : N
where WRB N
and CC N
how WRB N
care NN N
was VBD N
delivered VBN N
. . N

CONCLUSIONS NNP N
We PRP N
identify VBP N
a DT N
model NN N
of IN N
community NN N
hospital NN N
care NN N
that WDT N
incorporates VBZ N
technical JJ N
aspects NNS N
of IN N
rehabilitation NN N
within IN N
a DT N
human JJ N
approach NN N
that WDT N
is VBZ N
welcomed VBN N
by IN N
patients NNS 1_p
. . 1_p

If IN N
patients NNS 1_p
are VBP N
to TO N
be VB N
able JJ N
to TO N
participate VB N
in IN N
making VBG N
informed JJ N
decisions NNS N
about IN N
care NN N
, , N
the DT N
rationale NN N
for IN N
the DT N
activities NNS N
of IN N
staff NN N
need NN N
to TO N
be VB N
more JJR N
clearly RB N
explained VBN N
. . N

Recommendations NNS N
are VBP N
made VBN N
about IN N
the DT N
appropriate JJ N
scope NN N
of IN N
qualitative JJ N
findings NNS N
in IN N
the DT N
context NN N
of IN N
trials NNS N
and CC N
about RB N
techniques NNS N
to TO N
access NN N
patient JJ 1_p
views NNS N
in IN N
areas NNS N
where WRB N
they PRP N
have VBP N
difficulty NN N
in IN N
expressing VBG N
critical JJ N
impressions NNS N
. . N

-DOCSTART- -X- O O

Mandibular JJ 1_i
advancement NN 1_i
splint NN 1_i
improves VBZ N
indices NNS N
of IN N
obstructive JJ 1_p
sleep NN 1_p
apnoea NN 1_p
and CC 1_p
snoring VBG 1_p
but CC N
side JJ N
effects NNS N
are VBP N
common JJ N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
mandibular JJ 1_i
advancement NN 1_i
splint NN 1_i
( ( 1_i
MAS NNP 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
obstructive JJ 1_o
sleep JJ 1_o
apnoea NN 1_o
syndrome NN 1_o
( ( 1_o
OSAS NNP 1_o
) ) 1_o
. . 1_o

METHODS NNP N
Nineteen NNP 1_p
patients NNS 1_p
using VBG 1_p
a DT 1_p
MAS NNP 1_i
for IN 1_p
symptomatic JJ 1_p
OSAS NNP 1_p
underwent NN 1_p
polysomnography NN 1_i
, , 1_p
with IN 1_p
MAS NNP 1_i
use NN 1_p
randomised VBD 1_p
to TO 1_p
one CD 1_p
half NN 1_p
of IN 1_p
the DT 1_p
night NN 1_p
. . 1_p

Indices NNS 1_o
of IN 1_o
snoring VBG 1_o
and CC 1_o
OSAS NNP 1_o
were VBD N
compared VBN N
. . N

Side NNP 1_o
effects NNS 1_o
, , 1_o
compliance NN 1_o
and CC 1_o
treatment NN 1_o
response NN 1_o
were VBD N
evaluated VBN N
by IN N
questionnaire NN N
. . N

RESULTS NNP N
Use NNP N
of IN N
the DT N
MAS NNP 1_i
improved VBD N
total JJ 1_o
respiratory NN 1_o
disturbance NN 1_o
index NN 1_o
( ( 1_o
RDI NNP 1_o
) ) 1_o
from IN N
22.2 CD N
+/- JJ N
19.8 CD N
( ( N
SD NNP N
) ) N
events NNS 1_o
per IN 1_o
hour NN 1_o
to TO N
16.5 CD N
+/- JJ N
21.4/hr CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
, , N
supine JJ 1_o
RDI NNP 1_o
( ( N
30.8 CD N
+/- JJ N
23.8/hr CD N
to TO N
18.8 CD N
+/- JJ N
22.1/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
arousal JJ 1_o
index NN 1_o
( ( N
25.2 CD N
+/- JJ N
18.9/hr CD N
to TO N
19.3 CD N
+/- JJ N
14.2/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
and CC N
snoring VBG 1_o
intensity NN 1_o
( ( N
52.7 CD N
+/- JJ N
4.1 CD N
to TO N
50.7 CD N
+/- JJ N
2.7 CD N
dB NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
but CC N
not RB N
total JJ 1_o
snore NN 1_o
frequency NN 1_o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Using VBG N
polysomnographic JJ N
criteria NNS N
, , N
MAS NNP 1_i
treatment NN N
was VBD N
completely RB 1_o
successful JJ 1_o
in IN N
four CD N
( ( N
21 CD N
% NN N
) ) N
patients NNS N
, , N
partially RB 1_o
successful JJ 1_o
in IN N
ten NN N
( ( N
52.6 CD N
% NN N
) ) N
and CC N
a DT N
failure NN 1_o
in IN N
five CD N
( ( N
26.3 CD N
% NN N
) ) N
. . N

Treatment NN N
over IN N
a DT N
median NN N
of IN N
6.5 CD N
weeks NNS N
( ( N
range VB N
2-48 CD N
) ) N
was VBD N
perceived VBN N
as IN N
beneficial JJ N
by IN N
ten NN N
of IN N
eleven JJ N
partners NNS N
. . N

Fifteen JJ 1_p
patients NNS 1_p
( ( 1_p
79 CD 1_p
% NN 1_p
) ) 1_p
reported VBD N
side JJ 1_o
effects NNS 1_o
, , N
9 CD N
( ( N
46 CD N
% NN N
) ) N
did VBD N
not RB N
use VB N
the DT N
device NN N
every DT N
night NN N
and CC N
four CD N
( ( N
21 CD N
% NN N
) ) N
used VBD N
the DT N
device NN N
less JJR N
than IN N
three CD N
nights NNS N
per IN N
week NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
the DT N
MAS NNP 1_i
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
indices NNS N
of IN N
OSAS NNP 1_o
and CC 1_o
snoring VBG 1_o
. . 1_o

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
patients NNS N
had VBD N
difficulty NN N
tolerating NN N
and CC N
regularly RB N
using VBG N
the DT N
device NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Observation NNP N
on IN N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN 1_i
on IN N
early JJ 1_p
peripheral JJ 1_p
facial JJ 1_p
paralysis NN 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effects NNS N
of IN N
acupuncture NN 1_i
at IN N
different JJ N
opportunities NNS N
on IN N
peripheral JJ 1_p
facial JJ 1_p
paralysis NN 1_p
. . 1_p

METHODS NNP N
Fifty-two JJ 1_p
cases NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
treatment NN N
group NN N
( ( N
n=28 CC N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
n=24 RB N
) ) N
. . N

The DT N
treatment NN N
group NN N
at IN N
the DT N
acute JJ N
stage NN N
( ( N
1-10 JJ N
days NNS N
) ) N
were VBD N
treated VBN N
with IN N
acupuncture NN 1_i
at IN 1_i
Dicang NNP 1_i
( ( 1_i
ST NNP 1_i
4 CD 1_i
) ) 1_i
, , 1_i
Jiache NNP 1_i
( ( 1_i
ST NNP 1_i
6 CD 1_i
) ) 1_i
, , 1_i
Yangbai NNP 1_i
( ( 1_i
GB NNP 1_i
14 CD 1_i
) ) 1_i
, , 1_i
etc. FW 1_i
, , N
with IN 1_i
less JJR 1_i
than IN 1_i
4 CD 1_i
points NNS 1_i
selected VBN 1_i
on IN 1_i
the DT 1_i
face NN 1_i
and CC 1_i
with IN 1_i
shallow JJ 1_i
puncture NN 1_i
, , 1_i
and CC 1_i
10 CD 1_i
days NNS 1_i
later RB 1_i
electroacupuncture VBP 1_i
were VBD 1_i
added VBN 1_i
at IN 1_i
acupoints NNS 1_i
selected VBN 1_i
routinely RB 1_i
; : 1_i
the DT 1_i
control NN 1_i
group NN 1_i
were VBD 1_i
treated VBN 1_i
with IN 1_i
the DT 1_i
same JJ 1_i
methods NNS 1_i
as IN 1_i
the DT 1_i
treatment NN 1_i
group NN 1_i
but CC 1_i
acupuncture NN 1_i
was VBD 1_i
not RB 1_i
given VBN 1_i
at IN 1_i
the DT 1_i
acute JJ 1_i
stage NN 1_i
. . 1_i

RESULTS VB N
The DT N
cured JJ 1_o
rate NN 1_o
of IN N
78.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
50.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Early JJ N
acupuncture NN 1_i
is VBZ N
a DT N
key NN N
for IN N
achieving VBG N
the DT N
best JJS N
therapeutic JJ N
effect NN N
on IN N
facial JJ 1_p
paralysis NN 1_p
. . 1_p

-DOCSTART- -X- O O

Anecortave NNP 1_i
acetate NN 1_i
treatment NN 1_i
for IN N
retinal JJ 1_p
angiomatous JJ 1_p
proliferation NN 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
anecortave JJ 1_i
acetate JJ 1_i
treatment NN 1_i
of IN N
retinal JJ 1_p
angiomatous JJ 1_p
proliferation NN 1_p
( ( 1_p
RAP NNP 1_p
) ) 1_p
, , N
a DT N
neovascular JJ N
form NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
, , N
with IN N
specific JJ N
regard NN N
to TO N
inhibition NN 1_o
of IN 1_o
neovascularization NN 1_o
and CC 1_o
maintenance NN 1_o
of IN 1_o
vision NN 1_o
. . 1_o

METHODS NNP N
Thirty-four JJ 1_p
patients NNS 1_p
with IN 1_p
RAP NNP 1_p
with IN 1_p
any DT 1_p
stage NN 1_p
of IN 1_p
neovascularization NN 1_p
were VBD N
randomized VBN N
1:1:1 CD N
for IN N
treatment NN N
with IN N
three CD N
different JJ N
quantities NNS N
( ( N
30 CD N
mg NN N
, , N
15 CD N
mg NN N
, , N
3 CD N
mg NN N
) ) N
of IN N
anecortave NN 1_i
acetate NN 1_i
sterile JJ 1_i
suspension NN 1_i
for IN 1_i
juxtascleral JJ 1_i
administration NN 1_i
. . 1_i

Best-corrected JJ 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
Early JJ 1_o
Treatment NNP 1_o
Diabetic NNP 1_o
Retinopathy NNP 1_o
Study NNP 1_o
chart NN 1_o
) ) 1_o
, , 1_o
intraocular JJ 1_o
pressure NN 1_o
measurement NN 1_o
, , 1_o
biomicroscopy NN 1_o
, , 1_o
funduscopy NN 1_o
, , 1_o
digital JJ 1_o
fluorescein NN 1_o
, , 1_o
and CC 1_o
indocyanine NN 1_o
green JJ 1_o
angiography NN 1_o
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
3 CD N
months NNS N
. . N

A DT N
6-month JJ N
retreatment NN N
interval NN N
was VBD N
established VBN N
for IN N
this DT N
study NN N
with IN N
a DT N
follow-up NN N
of IN N
12 CD N
months NNS N
. . N

In IN N
selected JJ N
patients NNS N
optical JJ N
coherence NN N
tomography NN N
was VBD N
performed VBN N
. . N

The DT N
outcomes NNS N
were VBD N
mean JJ 1_o
changes NNS 1_o
in IN 1_o
visual JJ 1_o
acuity NN 1_o
and CC 1_o
lesion NN 1_o
size NN 1_o
at IN 1_o
1 CD 1_o
year NN 1_o
. . 1_o

RESULTS VB N
The DT N
detachment NN 1_o
of IN 1_o
the DT 1_o
neurosensory JJ 1_o
retina NN 1_o
and CC 1_o
retinal JJ 1_o
pigment NN 1_o
epithelium NN 1_o
improved VBN N
in IN N
all DT N
eyes NNS N
, , N
but CC N
all DT N
neovascular JJ 1_o
lesions NNS 1_o
increased VBD 1_o
in IN 1_o
size NN 1_o
. . 1_o

Vision NNP 1_o
loss NN 1_o
occurred VBD N
in IN N
the DT N
majority NN N
of IN N
study NN N
eyes NNS N
( ( N
22 CD N
out IN N
of IN N
34 CD N
eyes NNS N
, , N
64.7 CD N
% NN N
) ) N
independent JJ N
of IN N
the DT N
concentration NN N
administered VBD N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
a DT N
posterior JJ N
juxtascleral JJ N
injection NN N
of IN N
anecortave JJ 1_i
acetate NN 1_i
reduces NNS N
capillary JJ 1_o
permeability NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
RAP NNP 1_p
. . 1_p

However RB N
, , N
in IN N
spite NN N
of IN N
improvement NN N
of IN N
the DT N
exudation NN N
there EX N
is VBZ N
a DT N
progression NN N
of IN N
neovascularization NN 1_o
and CC N
a DT N
significant JJ 1_o
loss NN 1_o
of IN 1_o
vision NN 1_o
in IN N
all PDT N
these DT N
patients NNS N
. . N

Like IN N
other JJ N
monotherapeutic JJ N
methods NNS N
used VBN N
to TO N
treat VB N
this DT N
variant NN N
of IN N
neovascular JJ N
age-related JJ N
macular JJ N
degeneration NN N
, , N
anecortave VBP 1_i
acetate JJ 1_i
alone RB N
does VBZ N
not RB N
appear VB N
to TO N
benefit VB N
these DT N
patients NNS N
. . N

Future JJ N
studies NNS N
should MD N
investigate VB N
a DT N
combination NN N
form NN N
of IN N
therapy NN N
. . N

-DOCSTART- -X- O O

End-expiratory JJ 1_p
lung NN 1_p
volume NN 1_p
recovers NNS N
more RBR N
slowly RB N
after IN N
closed JJ 1_i
endotracheal NN 1_o
suctioning VBG 1_i
than IN N
after IN N
open JJ 1_i
suctioning NN 1_i
: : 1_i
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

PURPOSE NNP N
Endotracheal NNP N
suctioning VBG N
causes NNS N
significant JJ N
lung JJ N
derecruitment NN N
. . N

Closed VBN 1_i
suction NN 1_o
( ( 1_i
CS NNP 1_i
) ) 1_i
minimizes VBZ N
lung JJ N
volume NN N
loss NN N
during IN N
suction NN N
, , N
and CC N
therefore RB N
, , N
volumes NNS N
are VBP N
presumed VBN N
to TO N
recover VB N
more RBR N
quickly RB N
postsuctioning VBG N
. . N

Conflicting VBG N
evidence NN N
exists VBZ N
regarding VBG N
this DT N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
open JJ 1_i
suction NN 1_i
( ( 1_i
OS NNP 1_i
) ) 1_i
and CC 1_i
CS NNP 1_i
on IN N
lung NN 1_o
volume NN 1_o
loss NN N
during IN N
suctioning NN 1_o
, , N
and CC N
recovery NN N
of IN N
end-expiratory JJ 1_o
lung NN 1_o
volume NN 1_o
( ( 1_o
EELV NNP 1_o
) ) 1_o
up RB N
to TO N
30 CD N
minutes NNS N
postsuction NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Randomized NNP N
crossover NN N
study NN N
examining VBG N
20 CD 1_p
patients NNS 1_p
postcardiac JJ 1_o
surgery NN 1_p
. . 1_p

CS NNP 1_o
and CC N
OS NNP 1_o
were VBD N
performed VBN N
in IN N
random JJ N
order NN N
, , N
30 CD N
minutes NNS N
apart RB N
. . N

Lung NNP 1_o
impedance NN 1_o
was VBD N
measured VBN N
during IN N
suction NN N
, , N
and CC N
end-expiratory JJ N
lung NN N
impedance NN N
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
postsuctioning VBG N
using VBG N
electrical JJ N
impedance NN N
tomography NN N
. . N

Oximetry NNP 1_o
, , 1_o
partial JJ 1_o
pressure NN 1_o
of IN 1_o
oxygen NN 1_o
in IN 1_o
the DT 1_o
alveoli/fraction NN 1_o
of IN 1_o
inspired JJ 1_o
oxygen NN 1_o
ratio NN 1_o
and CC 1_o
compliance NN 1_o
were VBD N
collected VBN N
. . N

RESULTS JJ N
Reductions NNPS N
in IN N
lung NN N
impedance NN 1_o
during IN N
suctioning VBG N
were VBD N
less JJR N
for IN N
CS NNP 1_i
than IN N
for IN N
OS NNP 1_i
( ( N
mean JJ N
difference NN N
, , N
-905 JJ N
impedance NN N
units NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
-1234 NNP N
to TO N
-587 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

However RB N
, , N
at IN N
all DT N
points NNS N
postsuctioning VBG N
, , N
EELV NNP 1_o
recovered VBD N
more RBR N
slowly RB N
after IN N
CS NNP 1_i
than IN N
after IN N
OS NNP 1_i
. . 1_i

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
other JJ N
respiratory NN N
parameters NNS N
. . N

CONCLUSIONS NNP N
Closed VBD 1_i
suctioning VBG 1_i
minimized VBN N
lung NN N
volume NN N
loss NN N
during IN N
suctioning VBG N
but CC N
, , N
counterintuitively RB N
, , N
resulted VBD N
in IN N
slower JJR N
recovery NN N
of IN N
EELV NNP N
postsuction NN N
compared VBN N
with IN N
OS NNP 1_i
. . 1_i

Therefore NNP N
, , N
the DT N
use NN N
of IN N
CS NNP 1_i
can MD N
not RB N
be VB N
assumed VBN N
to TO N
be VB N
protective JJ N
of IN N
lung NN N
volumes NNS N
postsuctioning VBG 1_o
. . 1_o

Consideration NN N
should MD N
be VB N
given VBN N
to TO N
restoring VBG N
EELV NNP N
after IN N
either DT N
suction NN N
method NN N
via IN N
a DT N
recruitment JJ N
maneuver NN N
. . N

-DOCSTART- -X- O O

The DT N
relationship NN N
of IN N
alexithymia NN N
to TO N
emotional JJ N
dysregulation NN N
within IN N
an DT N
alcohol NN 1_p
dependent JJ 1_p
treatment NN 1_p
sample NN 1_p
. . 1_p

Difficulties NNS N
regulating VBG N
emotions NNS N
have VBP N
implications NNS N
for IN N
the DT N
development NN N
, , N
maintenance NN N
, , N
and CC N
recovery NN N
from IN N
alcohol NN 1_p
problems NNS 1_p
. . 1_p

One CD N
construct NN N
thought NN N
to TO N
impede VB N
the DT N
regulation NN N
of IN N
emotion NN N
is VBZ N
alexithymia JJ N
. . N

Alexithymia NNP N
is VBZ N
characterized VBN N
by IN N
difficulties NNS N
identifying VBG N
, , N
differentiating VBG N
and CC N
expressing VBG N
feelings NNS N
, , N
a DT N
limited JJ N
imagination NN N
and CC N
fantasy JJ N
life NN N
, , N
and CC N
an DT N
externally-oriented JJ N
thinking NN N
style NN N
( ( N
e.g. UH N
, , N
prefer VBP N
talking VBG N
about IN N
daily JJ N
activities NNS N
rather RB N
than IN N
feelings NNS N
) ) N
. . N

Given VBN N
that IN N
poor JJ N
emotion NN N
regulation NN N
skills NNS N
have VBP N
been VBN N
found VBN N
to TO N
predict VB N
posttreatment NN 1_p
levels NNS 1_p
of IN 1_p
alcohol NN 1_p
use NN 1_p
, , N
and CC N
that IN N
several JJ N
defining VBG N
characteristics NNS N
of IN N
alexithymia JJ N
bear JJ N
similarity NN N
to TO N
deficits NNS N
in IN N
emotion NN N
regulation NN N
skills NNS N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
alexithymia NN N
may MD N
predict VB N
poorer JJR N
alcohol NN N
treatment NN N
outcomes NNS N
. . N

Thus RB N
, , N
the DT N
present JJ N
study NN N
first RB N
examined VBD N
the DT N
relationship NN N
of IN N
alexithymia NN 1_i
to TO N
several JJ N
other JJ N
emotion NN 1_o
regulation NN 1_o
measures NNS 1_o
and CC N
then RB N
investigated VBD N
the DT N
impact NN N
of IN N
alexithymia NN 1_i
on IN N
attrition NN N
and CC N
alcohol NN N
treatment NN N
outcomes NNS N
in IN N
men NNS 1_p
and CC 1_p
women NNS 1_p
( ( 1_p
N=77 NNP 1_p
) ) 1_p
enrolled VBD 1_p
in IN 1_p
a DT 1_p
12-week JJ 1_i
cognitive-behavioral JJ 1_i
intervention NN 1_i
for IN 1_i
alcohol NN 1_i
dependence NN 1_i
. . 1_i

At IN N
baseline NN N
, , N
higher JJR N
scores NNS N
on IN N
alexithymia NN N
were VBD N
associated VBN N
poorer JJR 1_o
emotion NN 1_o
regulation NN 1_o
skills NNS 1_o
, , 1_o
fewer JJR 1_o
percent NN 1_o
days NNS 1_o
abstinent NN 1_o
, , 1_o
greater JJR 1_o
alcohol NN 1_o
dependence NN 1_o
severity NN 1_o
, , 1_o
and CC 1_o
several JJ 1_o
high-risk JJ 1_o
drinking NN 1_o
situations NNS 1_o
. . 1_o

Alexithymia NNP N
was VBD N
unrelated JJ N
to TO N
attrition NN N
and CC N
to TO N
level NN N
of IN N
alcohol NN N
consumption NN N
at IN N
posttreatment NN N
. . N

Overall UH N
, , N
the DT N
construct NN N
of IN N
alexithymia NN N
is VBZ N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
several JJ N
theoretically-related JJ N
constructs NNS N
( ( N
e.g. NN N
, , N
emotion NN N
regulation NN N
, , N
mindfulness NN N
) ) N
but CC N
demonstrated VBD N
a DT N
limited JJ N
relationship NN N
to TO N
drinking VBG N
outcomes NNS N
in IN N
those DT 1_p
seeking VBG 1_p
treatment NN 1_p
for IN 1_p
alcohol NN 1_p
dependence NN 1_p
. . 1_p

-DOCSTART- -X- O O

A DT N
preliminary JJ N
trial NN N
of IN N
ascorbic JJ 1_i
acid NN 1_i
as IN N
supplemental JJ N
therapy NN N
for IN N
autism NN 1_p
. . 1_p

1 CD N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
30-week JJ N
double-blind NN N
, , N
placebo-controlled JJ 1_i
trial NN N
exploring VBG N
the DT N
effectiveness NN N
of IN N
ascorbic JJ 1_i
acid NN 1_i
( ( N
8g/70kg/day CD N
) ) N
as IN N
a DT N
supplemental JJ N
pharmacological JJ N
treatment NN N
for IN N
autistic JJ 1_p
children NNS 1_p
in IN 1_p
residential JJ 1_p
treatment NN 1_p
. . 1_p

2 CD N
. . N

Residential JJ 1_p
school NN 1_p
children NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
18 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
ascorbate-ascorbate-placebo JJ 1_i
treatment NN 1_i
order NN 1_i
group NN 1_i
or CC 1_i
ascorbate-placebo-ascorbate JJ 1_i
treatment NN 1_i
order NN 1_i
group NN N
. . N

Each DT N
treatment NN N
phase NN N
lasted VBD N
10 CD N
weeks NNS N
and CC N
behaviors NNS N
were VBD N
rated VBN N
weekly JJ N
using VBG N
the DT N
Ritvo-Freeman NNP N
scale NN N
. . N

3 CD N
. . N

Significant JJ N
group NN N
by IN N
phase NN N
interactions NNS N
were VBD N
found VBN N
for IN N
total JJ 1_o
scores NNS 1_o
and CC N
also RB N
sensory JJ 1_o
motor NN 1_o
scores NNS 1_o
indicating VBG N
a DT N
reduction NN N
in IN N
symptom JJ 1_o
severity NN 1_o
associated VBN N
with IN N
the DT N
ascorbic JJ 1_i
acid NN 1_i
treatment NN 1_i
. . 1_i

4 CD N
. . N

These DT N
results NNS N
were VBD N
consistent JJ N
with IN N
a DT N
hypothesized VBN N
dopaminergic NN N
mechanism NN N
of IN N
action NN N
of IN N
ascorbic JJ 1_i
acid NN 1_i
. . 1_i

-DOCSTART- -X- O O

Effects NNS 1_o
of IN 1_o
surfactant NN 1_o
on IN N
biofilm NN N
formation NN N
on IN N
silicone NN 1_i
nasal NN 1_i
splints NNS 1_i
. . 1_i

Biofilms NNS 1_i
are VBP N
sessile JJ N
communities NNS N
of IN N
bacteria NNS N
embedded VBN N
in IN N
self-produced JJ N
extracellular JJ N
polysaccharide NN N
matrix NN N
and CC N
are VBP N
considered VBN N
to TO N
be VB N
responsible JJ N
for IN N
bacterial JJ N
infections NNS N
in IN N
humans NNS 1_p
. . 1_p

Topical NNP N
surfactant NN N
use NN N
on IN N
silicone NN N
nasal JJ N
splints NNS N
may MD N
have VB N
a DT N
preventive JJ N
effect NN N
on IN N
biofilm NN 1_o
formation NN 1_o
. . 1_o

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
surfactant-containing JJ N
nasal JJ N
solutions NNS N
on IN N
biofilm NN 1_o
formation NN 1_o
over IN N
the DT N
surface NN N
of IN N
silicone NN 1_o
nasal JJ 1_o
splints NNS 1_o
. . 1_o

Forty CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
after IN 1_p
septoplasty NN 1_i
to TO N
receive VB N
surfactant-containing JJ 1_i
saline JJ 1_i
solution NN 1_i
( ( 1_i
group NN 1_i
1 CD N
) ) N
or CC N
saline VB 1_i
without IN 1_i
surfactant JJ 1_i
( ( N
group NN N
2 CD N
) ) N
. . N

At IN N
the DT N
postoperative JJ N
48th CD N
, , N
72th CD N
and CC N
96th CD N
hours NNS N
, , N
pieces NNS N
of IN N
splint NN N
samples NNS N
were VBD N
taken VBN N
and CC N
prepared VBN N
for IN N
scanning VBG 1_o
electron NN 1_o
microscopic NN 1_o
evaluation NN 1_o
. . 1_o

Biofilm NNP 1_o
formation NN 1_o
was VBD N
observed VBN N
in IN N
3 CD N
, , N
6 CD N
and CC N
14 CD N
of IN N
20 CD N
samples NNS N
in IN N
group NN N
1 CD N
( ( N
surfactant NN N
used VBN N
) ) N
and CC N
3 CD N
, , N
14 CD N
and CC N
20 CD N
of IN N
20 CD N
samples NNS N
in IN N
group NN N
2 CD N
( ( N
control NN N
) ) N
at IN N
48th CD N
, , N
72th CD N
and CC N
96th CD N
hours NNS N
, , N
respectively RB N
. . N

Biofilm NNP 1_o
formation NN 1_o
incidences NNS N
of IN N
groups NNS N
at IN N
48th CD N
hour NN N
were VBD N
similar JJ N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
, , N
whereas IN N
it PRP N
was VBD N
significantly RB N
lower JJR N
at IN N
group NN N
1 CD N
regarding VBG N
72th CD N
and CC N
96th CD N
hours NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Surfactant-containing JJ 1_i
nasal JJ 1_i
solutions NNS 1_i
have VBP N
an DT N
inhibitory JJ N
effect NN N
on IN N
biofilm NN 1_o
formation NN 1_o
over IN N
the DT N
surface NN N
of IN N
silicone NN N
nasal JJ N
splints NNS N
especially RB N
after IN N
48 CD N
h. JJ N
Surfactant-containing JJ 1_i
nasal JJ 1_i
solutions NNS 1_i
may MD N
have VB N
an DT N
important JJ N
role NN N
in IN N
nasal JJ 1_o
septal JJ 1_o
dressing NN 1_o
in IN N
the DT N
future NN N
. . N

-DOCSTART- -X- O O

Penetration NN N
of IN N
ofloxacin NN 1_i
and CC 1_i
ciprofloxacin NN 1_i
into IN N
the DT N
aqueous JJ N
humor NN N
of IN N
eyes NNS 1_p
with IN 1_p
functioning VBG 1_p
filtering VBG 1_p
blebs NN 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
concentrations NNS N
of IN N
ofloxacin NN N
and CC N
ciprofloxacin NN N
hydrochloride NN N
in IN N
aqueous JJ N
humor NN N
after IN N
topical JJ N
or CC N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
in IN N
eyes NNS 1_p
with IN 1_p
filtering VBG 1_p
blebs NN 1_p
. . 1_p

DESIGN VB N
A DT N
prospective JJ N
, , N
investigator-masked JJ N
, , N
randomized VBN N
, , N
controlled VBD N
comparative JJ N
study NN N
involving VBG N
36 CD 1_p
eyes NNS 1_p
of IN 1_p
34 CD 1_p
patients NNS 1_p
with IN 1_p
functioning VBG 1_p
filtering VBG 1_p
blebs NNS 1_p
who WP 1_p
were VBD 1_p
to TO 1_p
undergo VB 1_p
cataract NN 1_p
surgery NN 1_p
. . 1_p

Treatment NN N
groups NNS N
received VBD N
either RB N
topical JJ 1_i
ofloxacin NN 1_i
or CC 1_i
topical JJ 1_i
ciprofloxacin NN 1_i
( ( N
instillation NN N
of IN N
0.3 CD N
% NN N
ophthalmic JJ N
solution NN N
every DT N
30 CD N
minutes NNS N
for IN N
4 CD N
hours NNS N
before IN N
surgery NN 1_i
) ) 1_i
, , N
or CC N
a DT N
combined JJ N
topical JJ N
plus CC N
oral JJ N
regimen NNS N
( ( 1_i
ciprofloxacin JJ 1_i
hydrochloride NN 1_i
, , 1_i
four CD 1_i
100-mg JJ 1_i
tablets NNS 1_i
, , 1_i
or CC 1_i
ofloxacin RB 1_i
, , 1_i
one CD 1_i
400-mg JJ 1_i
tablet NN 1_i
, , N
administered VBN N
24-26 JJ N
, , N
12-14 JJ N
, , N
and CC N
2 CD N
hours NNS N
preceding VBG N
surgery NN 1_i
) ) 1_i
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
antibiotic JJ 1_o
concentration NN 1_o
measured VBN N
by IN N
chromatographic JJ N
separation NN N
and CC N
mass NN N
spectrometry NN N
of IN N
aqueous JJ N
samples NNS N
obtained VBN N
during IN N
surgery NN N
. . N

RESULTS NNP N
Topical NNP N
antibiotic JJ N
treatment NN N
yielded VBN N
mean JJ N
concentrations NNS 1_o
of IN 1_o
ofloxacin NN 1_o
, , N
0.75 CD N
microg/mL NN N
, , N
and CC N
ciprofloxacin NN 1_i
, , N
0.21 CD N
microg/mL NN N
, , N
in IN N
aqueous JJ N
. . N

With IN N
combined JJ N
topical JJ N
and CC N
oral JJ N
therapy NN N
, , N
significantly RB N
more JJR N
ofloxacin NN N
was VBD N
measured VBN N
than IN N
ciprofloxacin NN N
( ( N
3.84 CD N
microg/mL NN N
vs NN N
0.35 CD N
microg/mL NN N
[ NNP N
P NNP N
< NNP N
.001 NNP N
] NNP N
) ) N
. . N

The DT N
combination NN N
regimen NNS N
produced VBD N
significantly RB N
greater JJR 1_o
ofloxacin NN 1_o
levels NNS 1_o
than IN N
did VBD N
topical JJ N
therapy NN N
alone RB N
( ( N
P NNP N
=.007 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Ofloxacin NNP N
penetrates VBZ N
better JJR N
than IN N
ciprofloxacin NN 1_o
into IN N
the DT N
aqueous JJ N
of IN N
eyes NNS N
with IN N
filtering VBG N
blebs NNS N
, , N
particularly RB N
after IN N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
, , N
by IN N
which WDT N
ofloxacin NN N
reaches VBZ N
more JJR N
than IN N
a DT N
10-fold JJ N
greater JJR N
concentration NN N
than IN N
does VBZ N
ciprofloxacin VB N
. . N

Combined VBN N
topical JJ 1_i
and CC 1_i
oral JJ 1_i
therapy NN 1_i
with IN 1_i
ofloxacin NN 1_i
may MD N
be VB N
beneficial JJ N
in IN N
the DT N
treatment NN N
of IN N
bleb-associated JJ N
infections NNS N
. . N

-DOCSTART- -X- O O

Risperidone NNP 1_i
treatment NN N
of IN N
autistic JJ N
disorder NN N
: : N
longer-term JJ N
benefits NNS N
and CC N
blinded VBD N
discontinuation NN N
after IN N
6 CD N
months NNS N
. . N

OBJECTIVE NNP N
Risperidone NNP 1_i
is VBZ N
effective JJ N
for IN N
short-term JJ N
treatment NN N
of IN N
aggression NN N
, , N
temper JJ N
outbursts NNS N
, , N
and CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Because IN N
these DT N
behaviors NNS N
may MD N
be VB N
chronic JJ N
, , N
there EX N
is VBZ N
a DT N
need NN N
to TO N
establish VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
longer-term JJ N
treatment NN N
with IN N
this DT N
agent NN N
. . N

METHOD NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
multisite NN N
, , N
two-part JJ N
study NN N
of IN N
risperidone NN 1_i
in IN 1_p
children NNS 1_p
ages NNS 1_p
5 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
with IN 1_p
autism NN 1_p
accompanied VBN 1_p
by IN 1_p
severe JJ 1_p
tantrums NNS 1_p
, , 1_p
aggression NN 1_p
, , 1_p
and/or JJ 1_p
self-injurious JJ 1_p
behavior NN 1_p
who WP 1_p
showed VBD 1_p
a DT 1_p
positive JJ 1_p
response NN 1_p
in IN 1_p
an DT 1_p
earlier JJR 1_p
8-week JJ 1_p
trial NN 1_p
. . 1_p

Part NN N
I PRP N
consisted VBD N
of IN N
4-month JJ N
open-label JJ N
treatment NN N
with IN N
risperidone NN 1_i
, , N
starting VBG N
at IN N
the DT N
established VBN N
optimal JJ N
dose NN N
; : N
part NN N
II NNP N
was VBD N
an DT N
8-week JJ N
randomized NN N
, , N
double-blind JJ N
, , N
placebo-substitution JJ 1_i
study NN N
of IN N
risperidone NN 1_i
withdrawal NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
irritability NN 1_o
subscale NN 1_o
and CC 1_o
the DT 1_o
Clinical NNP 1_o
Global NNP 1_o
Impression NNP 1_o
improvement NN 1_o
scale NN 1_o
. . 1_o

RESULTS NNP N
Part NNP 1_p
I PRP 1_p
included VBD 1_p
63 CD 1_p
children NNS 1_p
. . 1_p

The DT N
mean JJ N
risperidone NN 1_i
dose NN N
was VBD N
1.96 CD N
mg/day NN N
at IN N
entry NN N
and CC N
remained VBD N
stable JJ N
over IN N
16 CD N
weeks NNS N
of IN N
open JJ N
treatment NN N
. . N

The DT N
change NN N
on IN N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
irritability NN 1_o
subscale NN 1_o
was VBD N
small JJ N
and CC N
clinically JJ N
insignificant NN N
. . N

Reasons NNS N
for IN N
discontinuation NN N
of IN N
part NN N
I PRP N
included VBD N
loss NN 1_o
of IN 1_o
efficacy NN 1_o
( ( N
N=5 NNP N
) ) N
and CC N
adverse JJ 1_o
effects NNS 1_o
( ( N
N=1 NNP N
) ) N
. . N

The DT N
subjects NNS N
gained VBD N
an DT N
average NN N
of IN N
5.1 CD N
kg NNS N
. . N

Part NNP 1_p
II NNP 1_p
included VBD 1_p
32 CD 1_p
patients NNS 1_p
. . 1_p

The DT N
relapse NN 1_o
rates NNS 1_o
were VBD N
62.5 CD N
% NN N
for IN N
gradual JJ N
placebo NN N
substitution NN N
and CC N
12.5 CD N
% NN N
for IN N
continued JJ N
risperidone NN 1_i
; : 1_i
this DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

CONCLUSIONS NNP N
Risperidone NNP 1_i
showed VBD N
persistent JJ N
efficacy NN 1_o
and CC N
good JJ N
tolerability NN 1_o
for IN N
intermediate-length JJ N
treatment NN N
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
characterized VBN 1_p
by IN 1_p
tantrums NNS 1_p
, , 1_p
aggression NN 1_p
, , 1_p
and/or JJ 1_p
self-injurious JJ 1_p
behavior NN 1_p
. . 1_p

Discontinuation NN N
after IN N
6 CD N
months NNS N
was VBD N
associated VBN N
with IN N
a DT N
rapid JJ N
return NN N
of IN N
disruptive JJ N
and CC N
aggressive JJ N
behavior NN N
in IN N
most JJS N
subjects NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
guided JJ 1_i
imagery NN 1_i
on IN N
length NN 1_o
of IN 1_o
stay NN 1_o
, , 1_o
pain NN 1_o
and CC 1_o
anxiety NN 1_o
in IN N
cardiac JJ 1_p
surgery NN 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Changes NNS N
in IN N
calcanean JJ N
bone NN N
mineral NN N
occurring VBG N
spontaneously RB N
and CC N
during IN N
hormone JJ 1_i
replacement NN 1_i
therapy NN 1_i
in IN N
early JJ 1_p
post-menopausal JJ 1_p
women NNS 1_p
. . 1_p

The DT N
spontaneous JJ 1_p
calcanean JJ 1_p
bone NN 1_p
loss NN 1_p
occurring VBG 1_p
in IN 1_p
healthy JJ 1_p
early JJ 1_p
post-menopausal JJ 1_p
women NNS 1_p
and CC N
the DT N
effect NN N
of IN N
two CD 1_i
hormone NN 1_i
replacement NN 1_i
therapies NNS 1_i
( ( 1_i
HRT NNP 1_i
's POS 1_i
) ) 1_i
were VBD N
investigated VBN N
in IN N
a DT N
longitudinal JJ N
study NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
right NN N
and CC N
left VBD N
calcanean JJ N
BMC NNP N
or CC N
BMD NNP N
( ( N
p JJ N
> NNP N
0.15 CD N
) ) N
. . N

The DT N
spontaneous JJ N
bone NN N
loss NN N
was VBD N
similar JJ N
at IN N
all PDT N
the DT N
skeletal JJ N
sites NNS N
measured VBD N
, , N
with IN N
a DT N
mean JJ N
spontaneous JJ N
loss NN N
in IN N
calcanean JJ N
BMD NNP N
of IN N
1.6 CD N
% NN N
over IN N
one CD N
year NN N
. . N

Both DT N
HRT NNP N
's POS N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
prevented VBD N
the DT N
bone NN 1_o
loss NN 1_o
from IN N
all DT N
skeletal JJ N
sites NNS N
irrespective VBP N
of IN N
the DT N
weight-bearing NN N
or CC N
content NN N
of IN N
trabecular JJ N
bone NN N
, , N
and CC N
( ( N
for IN N
the DT N
weight-bearing JJ N
bones NNS N
) ) N
there EX N
was VBD N
even RB N
a DT N
gain NN N
in IN N
calcanean JJ 1_o
BMC NNP 1_o
and CC 1_o
BMD NNP 1_o
and CC 1_o
spinal JJ 1_o
BMD NNP 1_o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Bone NNP N
mineral NN N
of IN N
the DT N
calcaneus NN N
and CC N
the DT N
spine NN N
correlated VBN N
equally RB N
to TO N
body NN N
weight NN N
( ( N
r VB N
approximately RB N
0.4 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
whereas WP N
bone RB N
mineral NN N
in IN N
the DT N
forearm NN N
was VBD N
not RB N
correlated VBN N
to TO N
body VB N
weight NN N
. . N

The DT N
correlations NNS N
between IN N
the DT N
changes NNS N
in IN N
bone NN N
mineral NN N
at IN N
the DT N
sites NNS N
measured VBN N
were VBD N
all DT N
significant JJ N
( ( N
r VB N
approximately RB N
0.2-0.4 JJ N
) ) N
. . N

-DOCSTART- -X- O O

The DT N
interobserver JJ N
variability NN N
of IN N
digital JJ 1_i
rectal JJ 1_i
examination NN 1_i
in IN N
a DT N
large JJ N
randomized JJ N
trial NN N
for IN N
the DT N
screening NN N
of IN N
prostate NN N
cancer NN N
. . N

BACKGROUND NNP N
To TO N
analyze VB N
to TO N
what WP N
extent VB N
the DT N
percentage NN N
of IN N
suspicious JJ N
digital JJ 1_i
rectal JJ 1_i
examination NN 1_i
( ( 1_i
DRE NNP 1_i
) ) 1_i
findings NNS N
vary VBP N
between IN N
examiners NNS N
and CC N
to TO 1_p
what WP 1_p
extent VB 1_p
the DT 1_p
percentage NN 1_p
of IN 1_p
prostate NN 1_p
cancers NNS 1_p
( ( 1_p
PCs NNS 1_p
) ) 1_p
detected VBN 1_p
in IN 1_p
men NNS 1_p
with IN 1_p
these DT 1_p
suspicious JJ 1_p
findings NNS 1_p
varies NNS 1_p
between IN 1_p
examiners NNS 1_p
. . 1_p

METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
of IN N
the DT N
European NNP N
Randomized NNP N
study NN N
of IN N
Screening VBG N
for IN N
PC NN N
( ( N
ERSPC NNP N
) ) N
Rotterdam NNP N
, , N
7,280 CD 1_p
men NNS 1_p
underwent VBD 1_p
a DT 1_p
PSA-determination NN 1_i
and CC 1_i
DRE NNP 1_i
of IN 1_i
whom WP 1_i
2,102 CD 1_i
underwent JJ 1_i
prostate NN 1_i
biopsy NN 1_i
( ( 1_p
biopsy JJ 1_p
indication NN 1_p
PSA NNP 1_p
> NNP 1_p
or CC 1_p
= $ 1_p
4.0 CD 1_p
ng/ml JJ 1_p
and/or RB 1_p
suspicious JJ 1_p
DRE NNP 1_p
and/or NN 1_p
TRUS NNP 1_p
) ) 1_p
. . 1_p

Descriptive JJ 1_o
statistics NNS 1_o
of IN 1_o
DRE-outcome NNP 1_o
per IN 1_o
PSA-range NNP 1_o
were VBD N
used VBN N
to TO N
determine VB N
the DT N
observer JJ N
variability NN N
of IN N
six CD N
examiners NNS N
. . N

Because IN N
this DT N
analysis NN N
did VBD N
not RB N
correct VB N
properly RB N
for IN N
other JJ N
predictors NNS N
of IN N
a DT N
suspicious JJ 1_o
DRE NNP 1_o
( ( 1_o
PSA-level NNP 1_o
, , 1_o
biopsy NN 1_o
indication NN 1_o
, , 1_o
TRUS-outcome NNP 1_o
, , 1_o
prostate NN 1_o
volume NN 1_o
and CC 1_o
age NN 1_o
) ) 1_o
, , N
a DT N
logistic JJ N
regression NN N
analysis NN N
controlling VBG N
for IN N
these DT N
explanatory JJ N
variables NNS N
was VBD N
performed VBN N
as RB N
well RB N
. . N

RESULTS NNP N
In IN N
2,102 CD 1_p
men NNS 1_p
biopsied VBD 1_p
, , 1_p
443 CD 1_p
PCs NNS 1_p
were VBD 1_p
detected VBN 1_p
( ( 1_p
PPV NNP 1_p
= RB 1_p
21 CD 1_p
% NN 1_p
) ) 1_p
. . N

For IN N
all DT N
PSA NNP 1_o
levels NNS 1_o
the DT N
percentage NN 1_o
suspicious JJ 1_o
DRE NNP 1_o
varied VBD N
between IN N
examiners NNS N
from IN N
4 CD N
% NN N
to TO N
28 CD N
% NN N
and CC N
percentage NN 1_o
PC NN 1_o
detected VBN N
in IN N
men NNS 1_p
with IN 1_p
a DT 1_p
suspicious JJ 1_p
DRE NNP 1_p
varied VBD N
from IN N
18 CD N
% NN N
to TO N
36 CD N
% NN N
. . N

Logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
three CD N
of IN N
six CD N
examiners NNS N
considered VBN N
DRE NNP 1_o
significantly RB N
more RBR N
often RB N
abnormal JJ N
than IN N
others NNS N
( ( N
ORs NNP N
3.48 CD N
, , N
2.80 CD N
, , N
2.47 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
all DT N
examiners NNS N
the DT N
odds NNS N
to TO N
have VB N
PC NN 1_o
was VBD N
statistically RB N
significantly RB N
higher JJR N
in IN N
case NN N
of IN N
a DT N
suspicious JJ 1_o
DRE NNP 1_o
( ( N
ORs NNP N
2.21-5.96 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
increased VBD N
chance NN N
to TO N
find VB N
PC NN 1_o
was VBD N
not RB N
significantly RB N
observer-dependent JJ N
. . N

CONCLUSIONS NNP N
Three CD N
of IN N
six CD N
examiners NNS N
considered VBN N
DRE NNP 1_o
significantly RB N
more RBR N
often RB N
suspicious JJ N
than IN N
the DT N
others NNS N
. . N

However RB N
, , N
under IN N
equal JJ N
circumstances NNS N
a DT N
suspicious JJ N
DRE NNP 1_o
executed VBN N
by IN N
each DT N
examiner NN N
increased VBD N
the DT N
chance NN N
of IN N
the DT N
presence NN N
of IN N
PC NNP 1_o
similarly RB N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
long-term JJ 1_i
vitamin NN 1_i
E NNP 1_i
supplementation NN 1_i
on IN N
cardiovascular JJ 1_o
events NNS 1_o
and CC 1_o
cancer NN 1_o
: : 1_o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Experimental NNP N
and CC N
epidemiological JJ N
data NNS N
suggest VBP N
that IN N
vitamin NN 1_i
E NNP 1_i
supplementation NN 1_i
may MD N
prevent VB N
cancer NN 1_p
and CC 1_p
cardiovascular JJ 1_p
events NNS 1_p
. . 1_p

Clinical JJ N
trials NNS N
have VBP N
generally RB N
failed VBN N
to TO N
confirm VB N
benefits NNS N
, , N
possibly RB N
due JJ N
to TO N
their PRP$ N
relatively RB N
short JJ N
duration NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
long-term JJ 1_i
supplementation NN 1_i
with IN 1_i
vitamin JJ 1_i
E NN 1_i
decreases VBZ N
the DT N
risk NN 1_o
of IN 1_o
cancer NN 1_o
, , 1_o
cancer NN 1_o
death NN 1_o
, , 1_o
and CC 1_o
major JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
. . 1_o

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
international JJ 1_p
trial NN N
( ( N
the DT N
initial JJ N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
[ NNP N
HOPE NNP N
] NNP N
trial NN N
conducted VBD N
between IN N
December NNP N
21 CD N
, , N
1993 CD N
, , N
and CC N
April NNP N
15 CD N
, , N
1999 CD N
) ) N
of IN N
patients NNS 1_p
at IN 1_p
least JJS 1_p
55 CD 1_p
years NNS 1_p
old JJ 1_p
with IN 1_p
vascular JJ 1_p
disease NN 1_p
or CC 1_p
diabetes VBZ 1_p
mellitus NN 1_p
was VBD 1_p
extended VBN 1_p
( ( 1_p
HOPE-The NNP 1_p
Ongoing NNP 1_p
Outcomes NNP 1_p
[ NNP 1_p
HOPE-TOO NNP 1_p
] NNP 1_p
) ) 1_p
between IN 1_p
April NNP 1_p
16 CD 1_p
, , 1_p
1999 CD 1_p
, , 1_p
and CC 1_p
May NNP 1_p
26 CD 1_p
, , 1_p
2003 CD 1_p
. . 1_p

Of IN N
the DT N
initial JJ N
267 CD 1_p
HOPE NNP 1_p
centers NNS 1_p
that WDT 1_p
had VBD 1_p
enrolled VBN 1_p
9541 CD 1_p
patients NNS 1_p
, , 1_p
174 CD 1_p
centers NNS 1_p
participated VBN 1_p
in IN 1_p
the DT 1_p
HOPE-TOO NNP 1_p
trial NN 1_p
. . 1_p

Of IN N
7030 CD 1_p
patients NNS 1_p
enrolled VBN 1_p
at IN 1_p
these DT 1_p
centers NNS 1_p
, , 1_p
916 CD 1_p
were VBD 1_p
deceased VBN 1_p
at IN 1_p
the DT 1_p
beginning NN 1_p
of IN 1_p
the DT 1_p
extension NN 1_p
, , 1_p
1382 CD 1_p
refused VBD 1_p
participation NN 1_p
, , 1_p
3994 CD 1_p
continued VBD 1_p
to TO 1_p
take VB 1_p
the DT 1_p
study NN 1_p
intervention NN 1_p
, , 1_p
and CC 1_p
738 CD 1_p
agreed VBD 1_p
to TO 1_p
passive VB 1_p
follow-up NN 1_p
. . 1_p

Median JJ N
duration NN N
of IN N
follow-up NN N
was VBD N
7.0 CD N
years NNS N
. . N

INTERVENTION NNP N
Daily NNP 1_i
dose NN 1_i
of IN 1_i
natural JJ 1_i
source NN 1_i
vitamin NN 1_i
E NNP 1_i
( ( 1_i
400 CD 1_i
IU NNP 1_i
) ) 1_i
or CC 1_i
matching VBG 1_i
placebo NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
included VBD N
cancer NN 1_o
incidence NN 1_o
, , 1_o
cancer NN 1_o
deaths NNS 1_o
, , 1_o
and CC 1_o
major JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
( ( 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
stroke NN 1_o
, , 1_o
and CC 1_o
cardiovascular JJ 1_o
death NN 1_o
) ) 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
included VBD N
heart NN 1_o
failure NN 1_o
, , 1_o
unstable JJ 1_o
angina NN 1_o
, , 1_o
and CC 1_o
revascularizations NNS 1_o
. . 1_o

RESULTS NNP N
Among IN N
all DT N
HOPE NNP N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
primary JJ N
analysis NN N
: : N
for IN N
cancer NN 1_o
incidence NN 1_o
, , N
there EX N
were VBD N
552 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
vitamin NN 1_i
E NNP 1_i
group NN N
vs VBD N
586 CD N
( ( N
12.3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.94 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.84-1.06 NNP N
; : N
P NNP N
= NNP N
.30 NNP N
) ) N
; : N
for IN N
cancer NN 1_o
deaths NNS 1_o
, , N
156 CD N
( ( N
3.3 CD N
% NN N
) ) N
vs NN N
178 CD N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.09 NNP N
; : N
P NNP N
= NNP N
.24 NNP N
) ) N
; : N
and CC N
for IN N
major JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
, , N
1022 CD N
( ( N
21.5 CD N
% NN N
) ) N
vs NN N
985 CD N
( ( N
20.6 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
1.04 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96-1.14 NNP N
; : N
P NNP N
= NNP N
.34 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
vitamin NN 1_i
E NNP 1_i
group NN N
had VBD N
a DT N
higher JJR N
risk NN 1_o
of IN 1_o
heart NN 1_o
failure NN 1_o
( ( N
RR NNP N
, , N
1.13 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.26 JJ N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
hospitalization NN 1_o
for IN 1_o
heart NN 1_o
failure NN 1_o
( ( N
RR NNP N
, , N
1.21 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.00-1.47 JJ N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

Similarly RB N
, , N
among IN N
patients NNS N
enrolled VBN N
at IN N
the DT N
centers NNS N
participating VBG N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
cancer NN 1_o
incidence NN 1_o
, , 1_o
cancer NN 1_o
deaths NNS 1_o
, , 1_o
and CC 1_o
major JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
, , N
but CC N
higher JJR N
rates NNS 1_o
of IN 1_o
heart NN 1_o
failure NN 1_o
and CC 1_o
hospitalizations NNS 1_o
for IN 1_o
heart NN 1_o
failure NN 1_o
. . 1_o

CONCLUSION NNP N
In IN N
patients NNS 1_p
with IN 1_p
vascular JJ 1_p
disease NN 1_p
or CC 1_p
diabetes VBZ 1_p
mellitus NNS 1_p
, , N
long-term JJ 1_i
vitamin NN 1_i
E NNP 1_i
supplementation NN 1_i
does VBZ N
not RB N
prevent VB N
cancer NN 1_o
or CC 1_o
major JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
and CC N
may MD N
increase VB N
the DT N
risk NN 1_o
for IN 1_o
heart NN 1_o
failure NN 1_o
. . 1_o

-DOCSTART- -X- O O

Pharmacokinetic- JJ N
pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
role NN N
of IN N
CYP2C19 NNP N
genotypes NNS N
in IN N
short-term JJ N
rabeprazole-based JJ 1_i
triple JJ 1_i
therapy NN 1_i
against IN N
Helicobacter NNP N
pylori NN N
. . N

AIMS IN N
The DT N
aim NN N
was VBD N
to TO N
explore VB N
the DT N
role NN N
of IN N
CYP2C19 NNP N
polymorphism NN N
in IN N
short-term JJ N
rabeprazole-based JJ 1_i
triple JJ 1_i
therapy NN 1_i
against IN N
Helicobacter NNP 1_p
pylori JJ 1_p
infection NN 1_p
. . 1_p

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
H. NNP 1_p
pylori FW 1_p
infection NN 1_p
were VBD N
tested VBN N
for IN N
CYP2C19 NNP N
genotype NN N
as IN N
poor JJ N
metabolizers NNS N
( ( N
PMs NNP N
) ) N
or CC N
extensive JJ N
metabolizers NNS N
( ( N
EMs NNP N
, , N
homozygous JJ N
EM NNP N
or CC N
heterozygous JJ N
EM NNP N
) ) N
and CC N
given VBN N
rabeprazole NN 1_i
for IN N
7 CD N
days NNS N
. . N

Antibiotics NNS 1_i
( ( 1_i
clarithromycin NN 1_i
and CC 1_i
amoxicillin NN 1_i
) ) 1_i
were VBD N
given VBN N
on IN N
days NNS N
1-4 CD N
, , N
days NNS N
4-7 CD N
, , N
or CC N
days NNS N
1-7 RB N
. . N

A DT N
direct JJ N
link NN N
model NN N
with IN N
an DT N
effect NN N
compartment NN N
was VBD N
used VBN N
in IN N
the DT N
population NN N
pharmacokinetic-pharmacodynamic JJ N
analysis NN N
. . N

The DT N
status NN N
of IN N
H. NNP 1_o
pylori FW 1_o
infection NN 1_o
was VBD N
evaluated VBN N
. . N

RESULTS NNP N
Rabeprazole NNP 1_o
clearance NN 1_o
was VBD N
lower JJR N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
( ( N
with IN N
average NN N
values NNS N
of IN N
10.7 CD N
vs. FW N
16.8 CD N
l NN N
h NN N
( ( N
-1 NNP N
) ) N
in IN N
PMs NNP N
and CC N
EMs NNP N
, , N
respectively RB N
) ) N
, , N
resulting VBG N
in IN N
higher JJR N
plasma NN N
levels NNS N
in IN N
the DT N
former JJ N
group NN N
. . N

The DT N
values NNS 1_o
of IN 1_o
EC NNP 1_o
( ( 1_o
50 CD 1_o
) ) 1_o
and CC 1_o
k $ 1_o
( ( 1_o
eo NN 1_o
) ) 1_o
of IN 1_o
gastrin JJ 1_o
response NN 1_o
increased VBD N
with IN N
multiple JJ N
doses NNS N
of IN N
rabeprazole NN 1_i
. . 1_i

The DT N
k NN 1_o
( ( 1_o
eo NN 1_o
) ) 1_o
values NNS 1_o
were VBD N
lower JJR N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
on IN N
day NN N
1 CD N
( ( N
0.012 CD N
vs. FW N
0.017 CD N
x $ N
10 CD N
( ( N
-4 NN N
) ) N
l NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
and CC N
higher JJR N
than IN N
in IN N
EMs NNP N
on IN N
day NN N
4 CD N
( ( N
0.804 CD N
vs. FW N
0.169 CD N
x $ N
10 CD N
( ( N
-4 NN N
) ) N
l NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
of IN N
rabeprazole NN 1_i
treatment NN N
. . N

The DT N
predicted JJ 1_o
gastrin-time NN 1_o
profile NN 1_o
showed VBD N
a DT N
higher JJR N
response NN N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
on IN N
days NNS N
4 CD N
and CC N
7 CD N
. . N

Helicobacter NNP 1_o
pylori NN 1_o
was VBD 1_o
eradicated VBN 1_o
in IN N
all DT N
CYP2C19 NNP N
PMs NNP N
except IN N
in IN N
one CD N
patient NN N
infected VBN N
by IN N
a DT N
resistant JJ N
strain NN N
. . N

In IN N
contrast NN N
, , N
in IN N
CYP2C19 NNP N
EMs NNP N
the DT N
eradication NN 1_o
rates NNS 1_o
ranged VBD N
from IN N
58 CD N
to TO N
85 CD N
% NN N
. . N

CONCLUSIONS NNP N
CYP2C19 NNP N
genotypes VBZ N
play VB N
a DT N
role NN N
in IN N
H. NNP N
pylori FW N
eradication NN N
therapy NN N
. . N

Rabeprazole-based JJ 1_i
short-term JJ 1_i
triple JJ 1_i
therapy NN 1_i
may MD N
be VB N
applicable JJ N
in IN N
CYP2C19 NNP N
PMs NNP N
for IN N
H. NNP N
pylori JJ N
eradication NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
comparing VBG N
standard NN 1_i
wound NN 1_i
care NN 1_i
with IN N
adjunctive JJ 1_i
hyperbaric JJ 1_i
oxygen NN 1_i
therapy NN 1_i
( ( 1_i
HBOT NNP 1_i
) ) 1_i
to TO N
standard VB N
wound NN N
care NN N
only RB N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ 1_o
, , 1_o
non-healing JJ 1_o
ulcers NNS 1_o
of IN 1_p
the DT 1_p
lower JJR 1_p
limb NN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
mellitus NNS 1_p
: : 1_p
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
adjunctive JJ 1_i
hyperbaric JJ 1_i
oxygen NN 1_i
therapy NN 1_i
improves VBZ N
the DT N
healing NN N
of IN N
diabetic JJ 1_o
foot NN 1_o
ulcers NNS 1_o
, , N
and CC N
decreases VBZ N
the DT N
risk NN N
of IN N
lower JJR 1_o
extremity NN 1_o
amputations NNS 1_o
. . 1_o

A DT N
limited JJ N
number NN N
of IN N
studies NNS N
have VBP N
used VBN N
a DT N
double JJ N
blind NN N
approach NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ 1_i
oxygen NN 1_i
therapy NN 1_i
in IN N
the DT N
treatment NN N
of IN N
diabetic JJ 1_p
ulcers NNS 1_p
. . 1_p

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ 1_i
oxygen NN 1_i
therapy NN 1_i
plus CC 1_i
standard NN 1_i
wound NN 1_i
care NN 1_i
compared VBN N
with IN N
standard NN 1_i
wound NN 1_i
care NN 1_i
alone RB N
in IN N
preventing VBG N
the DT N
need NN N
for IN N
major JJ 1_o
amputation NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
mellitus NNS 1_p
and CC 1_p
chronic JJ 1_p
ulcers NNS 1_p
of IN 1_p
the DT 1_p
lower JJR 1_p
limb NN 1_p
. . 1_p

METHODS/DESIGN NNP N
One CD 1_p
hundred CD 1_p
and CC 1_p
eighteen JJ 1_p
( ( 1_p
59 CD 1_p
patients NNS 1_p
per IN 1_p
arm NN 1_p
) ) 1_p
patients NNS 1_p
with IN 1_p
non-healing JJ 1_p
diabetic JJ 1_p
ulcers NNS 1_p
of IN 1_p
the DT 1_p
lower JJR 1_p
limb NN 1_p
, , 1_p
referred VBD 1_p
to TO 1_p
the DT 1_p
Judy NNP 1_p
Dan NNP 1_p
Research NNP 1_p
and CC 1_p
Treatment NNP 1_p
Centre NNP 1_p
are VBP 1_p
being VBG 1_p
recruited VBN 1_p
if IN 1_p
they PRP 1_p
are VBP 1_p
at IN 1_p
least JJS 1_p
18 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , 1_p
have VBP 1_p
either DT 1_p
Type NNP 1_p
1 CD 1_p
or CC 1_p
2 CD 1_p
diabetes NNS 1_p
with IN 1_p
a DT 1_p
Wagner NNP 1_p
grading NN 1_p
of IN 1_p
foot NN 1_p
lesions NNS 1_p
2 CD 1_p
, , 1_p
3 CD 1_p
or CC 1_p
4 CD 1_p
on IN 1_p
lower JJR 1_p
limb NN 1_p
not RB 1_p
healing VBG 1_p
for IN 1_p
at IN 1_p
least JJS 1_p
4 CD 1_p
weeks NNS 1_p
. . 1_p

Patients NNS N
receive JJ N
hyperbaric JJ 1_i
oxygen NN 1_i
therapy NN 1_i
every DT N
day NN N
for IN N
6 CD N
weeks NNS N
during IN N
the DT N
treatment NN N
phase NN N
and CC N
are VBP N
provided VBN N
ongoing VBG 1_i
wound NN 1_i
care NN 1_i
and CC N
weekly JJ N
assessments NNS N
. . N

Patients NNS N
are VBP N
required VBN N
to TO N
return VB N
to TO N
the DT N
study NN N
centre NN N
every DT N
week NN N
for IN N
an DT N
additional JJ N
6 CD N
weeks NNS N
of IN N
follow-up NN N
for IN N
wound JJ N
evaluation NN N
and CC N
management NN N
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
freedom RB 1_o
from IN 1_o
having VBG 1_o
, , 1_o
or CC 1_o
meeting VBG 1_o
the DT 1_o
criteria NN 1_o
for IN 1_o
, , 1_o
a DT 1_o
major JJ 1_o
amputation NN 1_o
( ( 1_o
below IN 1_o
knee NN 1_o
amputation NN 1_o
, , 1_o
or CC 1_o
metatarsal VB 1_o
level NN 1_o
) ) 1_o
up RB N
to TO N
12 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
decision NN N
to TO N
amputate VB N
is VBZ N
made VBN N
by IN N
a DT N
vascular JJ N
surgeon NN N
. . N

Other JJ N
outcomes NNS N
include VBP N
wound IN 1_o
healing NN 1_o
, , 1_o
effectiveness NN 1_o
, , 1_o
safety NN 1_o
, , 1_o
healthcare JJ 1_o
resource NN 1_o
utilization NN 1_o
, , 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
and CC 1_o
cost-effectiveness NN 1_o
. . 1_o

The DT N
study NN N
will MD N
run VB N
for IN N
a DT N
total NN N
of IN N
about IN N
3 CD N
years NNS N
. . N

DISCUSSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
will MD N
provide VB N
detailed JJ N
information NN N
on IN N
the DT N
efficacy NN N
of IN N
hyperbaric JJ 1_i
oxygen NN 1_i
therapy NN 1_i
for IN N
the DT N
treatment NN N
of IN N
non-healing JJ 1_p
ulcers NNS 1_p
of IN 1_p
the DT 1_p
lower JJR 1_p
limb NN 1_p
. . 1_p

This DT N
will MD N
be VB N
the DT N
first JJ N
double-blind JJ N
randomized VBN N
controlled JJ N
trial NN N
for IN N
this DT N
health NN N
technology NN N
which WDT N
evaluates VBZ N
the DT N
efficacy NN N
of IN N
hyperbaric JJ 1_i
oxygen NN 1_i
therapy NN 1_i
in IN N
prevention NN N
of IN N
amputations NNS 1_o
in IN N
diabetic JJ 1_p
patients NNS 1_p
. . 1_p

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
: : N
NCT00621608 NN N
. . N

-DOCSTART- -X- O O

Induction NNP 1_i
versus NN N
noninduction NN 1_i
in IN N
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
with IN 1_p
tacrolimus-based JJ 1_p
immunosuppression NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
induction NN N
treatment NN N
with IN N
antithymocyte NN 1_i
globulins NNS 1_i
( ( 1_i
ATG NNP 1_i
) ) 1_i
followed VBN N
by IN N
tacrolimus JJ 1_i
therapy NN N
with IN N
immediate JJ N
tacrolimus NNS N
therapy NN N
in IN N
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
. . 1_p

METHODS NNP N
This DT N
12-month JJ N
, , N
open JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
in IN N
15 CD 1_p
centers NNS 1_p
in IN 1_p
France NNP 1_p
and CC 1_p
1 CD 1_p
center NN 1_p
in IN 1_p
Belgium NNP 1_p
; : 1_p
309 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
receive VB 1_p
either DT 1_p
induction NN 1_i
therapy NN 1_i
with IN 1_i
ATG NNP 1_i
( ( 1_p
n=151 NN 1_p
) ) 1_p
followed VBN 1_p
by IN 1_p
initiation NN 1_p
of IN 1_p
tacrolimus NN 1_i
on IN 1_p
day NN 1_p
9 CD 1_p
or CC 1_p
immediate JJ 1_p
tacrolimus-based JJ 1_i
triple NN 1_i
therapy NN 1_i
( ( 1_p
n=158 JJ 1_p
) ) 1_p
. . 1_p

In IN N
both DT N
study NN N
arms NNS N
, , N
the DT N
initial JJ N
daily JJ N
tacrolimus NN 1_i
dose NN N
was VBD N
0.2 CD N
mg/kg NN N
. . N

Steroid JJ 1_i
boluses NNS 1_i
were VBD N
given VBN N
in IN N
the DT N
first JJ N
2 CD N
days NNS N
and CC N
tapered JJ N
thereafter NN N
from IN N
20 CD N
mg/day NN N
to TO N
5 CD N
mg/day NN N
. . N

Azathioprine NNP 1_i
was VBD N
administered VBN N
at IN N
1-2 JJ N
mg/kg NNS N
per IN N
day NN N
. . N

RESULTS NNP N
At IN N
month NN N
12 CD N
, , N
biopsy-confirmed JJ 1_o
acute NN 1_o
rejections NNS 1_o
were VBD N
reported VBN N
for IN N
15.2 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
30.4 CD N
% NN N
( ( N
noninduction NN N
) ) N
of IN N
patients NNS N
( ( N
P=0.001 NNP N
) ) N
. . N

The DT N
incidence NN 1_o
of IN 1_o
steroid-sensitive JJ 1_o
acute JJ 1_o
rejections NNS 1_o
was VBD N
7.9 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
22.2 CD N
% NN N
( ( N
noninduction NN N
) ) N
( ( N
P=0.001 NNP N
) ) N
. . N

Steroid-resistant JJ 1_o
acute JJ 1_o
rejections NNS 1_o
were VBD N
reported VBN N
for IN N
8.6 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
8.9 CD N
% NN N
( ( N
noninduction NN N
) ) N
of IN N
patients NNS N
. . N

A DT N
total NN N
of IN N
nine CD N
patients NNS N
died VBD 1_o
. . 1_o

Patient NNP 1_o
survival NN 1_o
and CC 1_o
graft NN 1_o
survival NN 1_o
at IN N
month NN N
12 CD N
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
( ( N
97.4 CD N
% NN N
vs. FW N
96.8 CD N
% NN N
and CC N
92.1 CD N
% NN N
vs. FW N
91.1 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Statistically NNP N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
found VBN N
for IN N
cytomegalovirus NN 1_o
( ( 1_o
CMV NNP 1_o
) ) 1_o
infection NN 1_o
( ( N
induction NN N
, , N
32.5 CD N
% NN N
vs. FW N
noninduction NN N
, , N
19.0 CD N
% NN N
, , N
P=0.009 NNP N
) ) N
, , N
leukopenia NN 1_o
( ( N
37.3 CD N
% NN N
vs. FW N
9.5 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
fever RB 1_o
( ( N
25.2 CD N
% NN N
vs. FW N
10.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
herpes VBZ 1_o
simplex JJ 1_o
( ( N
17.9 CD N
% NN N
vs. FW N
5.7 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
thrombocytopenia NN 1_o
( ( N
11.3 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
, , N
P=0.007 NNP N
) ) N
. . N

In IN N
the DT N
induction NN N
group NN N
, , N
serum NN 1_o
sickness NN 1_o
was VBD N
observed VBN N
in IN N
10.6 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
incidence NN N
of IN N
new JJ 1_o
onset NN 1_o
diabetes NNS 1_o
mellitus NN 1_o
was VBD N
3.4 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
4.5 CD N
% NN N
( ( N
noninduction NN N
) ) N
. . N

CONCLUSION NNP N
Low NNP N
incidences NNS N
of IN N
acute JJ 1_o
rejection NN 1_o
were VBD N
found VBN N
in IN N
both DT N
treatment NN N
arms NNS N
. . N

Induction NNP N
treatment NN N
with IN N
ATG NNP 1_i
has VBZ N
the DT N
advantage NN N
of IN N
a DT N
lower JJR N
incidence NN N
of IN N
acute JJ N
rejection NN N
, , N
but CC N
it PRP N
significantly RB N
increases VBZ N
adverse JJ 1_o
events NNS 1_o
, , N
particularly RB N
CMV NNP 1_o
infection NN 1_o
. . 1_o

-DOCSTART- -X- O O

Prospective JJ N
study NN N
of IN N
C-reactive NNP 1_o
protein NN 1_o
, , 1_o
homocysteine NN 1_o
, , 1_o
and CC 1_o
plasma VB 1_o
lipid JJ 1_o
levels NNS 1_o
as IN N
predictors NNS N
of IN N
sudden JJ N
cardiac JJ N
death NN N
. . N

BACKGROUND NNP N
Sudden NNP 1_o
cardiac JJ 1_o
death NN 1_o
( ( 1_o
SCD NNP 1_o
) ) 1_o
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
mortality NN N
even RB N
among IN N
apparently RB N
healthy JJ N
populations NNS N
. . N

However RB N
, , N
our PRP$ N
ability NN N
to TO N
identify VB N
those DT N
at IN N
risk NN N
for IN N
SCD NNP N
in IN N
the DT N
general JJ N
population NN N
is VBZ N
poor JJ N
, , N
and CC N
more RBR N
specific JJ N
markers NNS N
are VBP N
needed VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
To TO N
compare VB N
and CC N
contrast VB N
the DT N
relative JJ N
importance NN N
of IN N
C-reactive JJ 1_o
protein NN 1_o
( ( 1_o
CRP NNP 1_o
) ) 1_o
, , 1_o
homocysteine NN 1_o
, , 1_o
and CC 1_o
lipids NNS 1_o
as IN N
long-term JJ N
predictors NNS N
of IN N
SCD NNP N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
nested JJ N
, , N
case-control JJ N
analysis NN N
involving VBG N
97 CD 1_p
cases NNS 1_p
of IN 1_p
SCD NNP 1_p
among IN 1_p
apparently RB 1_p
healthy JJ 1_p
men NNS 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
Physician NNP 1_p
's POS 1_p
Health NNP 1_p
Study NNP 1_p
. . 1_p

Of IN N
these DT N
plasma JJ N
markers NNS N
measured VBD N
, , N
only RB N
baseline JJ N
CRP NNP 1_o
levels NNS 1_o
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
SCD NNP N
over IN N
the DT N
ensuing VBG N
17 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P NNP N
for IN N
trend=0.001 NN N
) ) N
. . N

The DT N
increase NN N
in IN N
risk NN N
associated VBN N
with IN N
CRP NNP 1_o
levels NNS 1_o
was VBD N
primarily RB N
seen VBN N
among IN N
men NNS N
in IN N
the DT N
highest JJS N
quartile NN N
, , N
who WP N
were VBD N
at IN N
a DT N
2.78-fold JJ N
increased JJ N
risk NN N
of IN N
SCD NNP 1_o
( ( N
95 CD N
% NN N
CI NNP N
1.35 CD N
to TO N
5.72 CD N
) ) N
compared VBN N
with IN N
men NNS N
in IN N
the DT N
lowest JJS N
quartile NN N
. . N

These DT N
results NNS N
were VBD N
not RB N
significantly RB N
altered VBN N
in IN N
analyses NNS N
that WDT N
( ( N
in IN N
addition NN N
to TO N
the DT N
matching JJ N
variables NNS N
of IN N
age NN N
and CC N
smoking NN N
status NN N
) ) N
controlled VBD N
for IN N
lipid JJ 1_o
parameters NNS 1_o
, , 1_o
homocysteine NN 1_o
, , 1_o
and CC 1_o
multiple JJ 1_o
cardiac JJ 1_o
risk NN 1_o
factors NNS 1_o
( ( N
relative JJ N
risk NN N
for IN N
highest JJS N
versus NN N
lowest JJS N
quartile NN N
2.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.79 CD N
to TO N
8.83 CD N
; : N
P NNP N
for IN N
trend=0.03 NN N
) ) N
. . N

In IN N
contrast NN N
to TO N
the DT N
positive JJ N
relationship NN N
observed VBD N
for IN N
CRP NNP 1_i
, , N
neither DT N
homocysteine NN N
nor CC N
lipid JJ N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
risk NN N
of IN N
SCD NNP 1_o
. . 1_o

CONCLUSIONS NNP N
These DT N
prospective JJ N
data NNS N
suggest VBP N
that IN N
CRP NNP N
levels NNS N
may MD N
be VB N
useful JJ N
in IN N
identifying VBG N
apparently RB 1_p
healthy JJ 1_p
men NNS 1_p
who WP 1_p
are VBP 1_p
at IN 1_p
an DT 1_p
increased VBN 1_p
long-term JJ 1_o
risk NN 1_o
of IN 1_o
SCD NNP 1_o
. . 1_o

-DOCSTART- -X- O O

Mass NNP N
inoculation NN N
in IN N
a DT N
community NN N
: : N
the DT N
effect NN N
of IN N
primary JJ N
prevention NN N
of IN N
stress JJ 1_o
reactions NNS 1_o
. . 1_o

This DT N
study NN N
assessed VBD N
the DT N
effectiveness NN N
of IN N
a DT N
brief JJ N
, , N
situation-specific JJ N
, , N
group-administered JJ N
preparatory NN N
intervention NN N
in IN N
a DT N
nonclient JJ 1_p
school NN 1_p
population NN 1_p
undergoing VBG 1_p
mass NN 1_i
inoculation NN 1_i
against IN 1_i
rubella NN 1_i
. . 1_i

Fifty-one CD 1_p
girls NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
practice NN 1_i
, , 1_i
no-practice JJ 1_i
, , 1_i
or CC 1_i
control NN 1_i
groups NNS 1_i
. . 1_i

Both CC N
the DT N
practice NN N
and CC N
the DT N
no-practice JJ N
groups NNS N
received VBD N
information NN N
that IN N
described VBD N
the DT N
inoculation NN N
procedure NN N
and CC N
how WRB N
to TO N
cope VB N
with IN N
it PRP N
by IN N
using VBG N
cognitive-behavioral JJ N
coping NN N
skills NNS N
. . N

The DT N
practice NN N
group NN N
was VBD N
encouraged VBN N
to TO N
perform VB N
coping VBG N
techniques NNS N
of IN N
this DT N
type NN N
, , N
whereas IN N
the DT N
no-practice JJ N
group NN N
was VBD N
told VBN N
only RB N
that IN N
the DT N
intervention NN N
would MD N
help VB N
them PRP N
during IN N
the DT N
inoculation NN N
. . N

Subjects NNS N
in IN N
both DT N
practice NN N
and CC N
no-practice JJ N
groups NNS N
reported VBD N
less JJR N
anxiety NN 1_o
and CC 1_o
exhibited VBD 1_o
more RBR 1_o
cooperative JJ 1_o
behavior NN 1_o
during IN N
inoculation NN N
than IN N
subjects NNS N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
those DT N
who WP N
were VBD N
guided VBN N
and CC N
prompted VBN N
to TO N
actively RB N
practice NN N
derived VBD N
greater JJR N
benefit NN 1_o
. . 1_o

-DOCSTART- -X- O O

Comments NNS N
on IN N
Secretin NNP 1_o
and CC N
autism NN 1_o
: : 1_o
a DT N
two-part JJ N
clinical JJ N
investigation NN N
by IN N
M.G NNP N
. . N

Chez NNP N
et CC N
al NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
two CD N
combined JJ N
hormonal JJ 1_i
contraceptives NNS 1_i
with IN N
the DT N
same JJ N
composition NN N
and CC N
different JJ N
doses NNS N
on IN N
female JJ 1_p
sexual JJ N
function NN N
and CC N
plasma NN N
androgen NN N
levels NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
two CD N
contraceptive JJ 1_i
pills NNS 1_i
with IN N
different JJ N
doses NNS N
of IN N
the DT N
same JJ N
components NNS N
, , N
on IN N
plasma JJ 1_o
androgen NN 1_o
levels NNS 1_o
and CC N
female JJ 1_o
sexual JJ 1_o
function NN 1_o
among IN 1_o
women NNS 1_o
without IN 1_o
previous JJ 1_o
sexual JJ 1_o
dysfunction NN 1_o
. . 1_o

STUDY NNP N
DESIGN NNP N
The DT N
participants NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
to TO N
receive VB N
pills NNS N
containing VBG N
ethynylestradiol NN 1_i
( ( 1_i
EE NNP 1_i
) ) 1_i
30 CD 1_i
mcg NN 1_i
and CC 1_i
levonorgestrel NN 1_i
( ( 1_i
LNG NNP 1_i
) ) 1_i
150 CD 1_i
mcg NN 1_i
or CC 1_i
EE NNP 1_i
20 CD 1_i
mcg NN 1_i
and CC 1_i
LNG NNP 1_i
100 CD 1_i
mcg NN 1_i
, , N
for IN N
six CD N
cycles NNS N
. . N

Sexual JJ 1_o
function NN 1_o
was VBD N
assessed VBN N
using VBG N
a DT N
standardized JJ N
questionnaire NN N
[ NNP N
Female NNP N
Sexual NNP N
Function NNP N
Index NNP N
( ( N
FSFI NNP N
) ) N
] NN N
. . N

Hormone NNP 1_o
assays NNS 1_o
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
sixth JJ N
cycle NN N
. . N

RESULTS NNP N
Forty-nine JJ 1_p
women NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
EE30/LNG150 NNP 1_i
group NN 1_p
and CC 1_p
48 CD 1_p
in IN 1_p
the DT 1_p
EE20/LNG100 NNP 1_i
group NN 1_p
. . 1_p

EE30/LNG150 NNP 1_i
group NN N
presented VBD N
54 CD N
% NN N
and CC N
67 CD N
% NN N
decreases NNS N
of IN N
total JJ 1_o
testosterone NN 1_o
and CC 1_o
free JJ 1_o
androgen NN 1_o
index NN 1_o
, , N
respectively RB N
, , N
with IN N
statistical JJ N
significance NN N
. . N

EE20/LNG100 NNP 1_i
presented VBD N
reductions NNS N
of IN N
20 CD N
% NN N
and CC N
42 CD N
% NN N
, , N
respectively RB N
, , N
but CC N
without IN N
statistical JJ N
significance NN N
. . N

Both DT N
groups NNS N
showed VBD N
improvements NNS N
in IN N
the DT N
FSFI NNP 1_o
desire NN 1_o
score NN 1_o
, , N
but CC N
with IN N
statistical JJ N
significance NN N
only RB N
for IN N
EE20/LNG100 NNP 1_i
group NN N
. . N

CONCLUSIONS NNP N
EE30/LNG150 NNP 1_i
decreased VBD N
plasma JJ N
androgen NN N
levels NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
impairment NN N
in IN N
sexual JJ N
desire NN N
, , N
on IN N
the DT N
other JJ N
hand NN N
, , N
sexual JJ N
desire NN N
score NN N
increased VBD N
with IN N
EE20/LNG100 NNP 1_i
formulation NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
once RB N
and CC N
twice RB N
daily JJ N
atenolol NN 1_i
for IN N
angina JJ 1_p
pectoris NN 1_p
. . 1_p

We PRP N
have VBP N
studied VBN N
the DT N
effects NNS N
of IN N
four CD N
doses NNS N
of IN N
atenolol NN 1_i
in IN N
11 CD 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
angina NNS 1_p
pectoris VBP 1_p
using VBG N
a DT N
symptom-limited JJ N
exercise NN N
test NN N
and CC N
angina NN N
diaries NNS N
. . N

The DT N
doses NNS N
100 CD N
mg JJ N
twice RB N
daily RB N
and CC N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
and CC N
200 CD N
mg NN N
once RB N
daily JJ N
were VBD N
given VBN N
double-blind NNS N
and CC N
randomised VBD N
within IN N
patients NNS N
following VBG N
run-in NN N
on IN N
placebo NN 1_i
. . 1_i

Measurements NNS N
were VBD N
made VBN N
12 CD N
hours NNS N
after IN N
the DT N
last JJ N
twice JJ N
daily RB N
dose JJ N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
last JJ N
once JJ N
daily JJ N
dose NN N
. . N

Exercise NN 1_o
tolerance NN 1_o
was VBD N
improved VBN N
by IN N
40-74 JJ N
% NN N
and CC N
exercise NN 1_o
duration NN 1_o
before IN 1_o
the DT 1_o
onset NN 1_o
of IN 1_o
angina NN 1_o
by IN N
61-94 JJ N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Maximal JJ 1_o
heart NN 1_o
rate NN 1_o
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
, , N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
. . N

The DT N
largest JJS N
increase NN N
in IN N
exercise NN 1_o
tolerance NN 1_o
was VBD N
obtained VBN N
during IN N
treatment NN N
with IN N
50 CD N
mg NNS N
once RB N
daily RB N
. . N

Atenolol NNP 1_i
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
. . N

-DOCSTART- -X- O O

Oral NNP N
health NN N
impacts NNS N
on IN N
daily JJ N
living NN N
related VBN N
to TO N
four CD N
different JJ N
treatment NN N
protocols NNS N
for IN N
chronic JJ 1_p
periodontitis NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
oral JJ N
health NN N
impacts NNS N
perceived VBN N
by IN N
patients NNS 1_p
submitted VBN 1_p
to TO 1_p
different JJ 1_p
treatments NNS 1_p
of IN 1_p
chronic JJ 1_p
periodontitis NN 1_p
and CC 1_p
their PRP$ 1_p
association NN 1_p
with IN 1_p
clinical JJ 1_p
parameters NNS 1_p
. . 1_p

METHODS NNP N
Sixty NNP 1_p
patients NNS 1_p
were VBD 1_p
assigned VBN 1_p
to TO N
one CD N
of IN N
the DT N
following JJ N
therapeutic JJ N
groups NNS N
: : N
control NN 1_i
, , 1_i
treated VBN 1_i
with IN 1_i
full-mouth JJ 1_i
scaling NN 1_i
and CC 1_i
root NN 1_i
planing NN 1_i
( ( 1_i
SRP NNP 1_i
) ) 1_i
; : 1_i
test $ N
1 CD N
, , N
treated VBN 1_i
with IN 1_i
SRP NNP 1_i
and CC 1_i
400 CD 1_i
mg NNS 1_i
systemically RB 1_i
administered VBN 1_i
metronidazole NN 1_i
( ( 1_i
MET NNP 1_i
) ) 1_i
three CD N
times NNS N
per IN N
day NN N
for IN N
10 CD N
days NNS N
; : N
test JJS N
2 CD N
, , N
treated VBN 1_i
with IN 1_i
SRP NNP 1_i
and CC 1_i
professional JJ 1_i
supragingival NN 1_i
plaque NN 1_i
removal NN 1_i
( ( 1_i
PP NNP 1_i
) ) 1_i
every DT N
week NN N
for IN N
3 CD N
months NNS N
; : N
and CC N
test VB N
3 CD N
, , N
treated VBN N
with IN N
SRP NNP 1_i
and CC 1_i
MET NNP 1_i
plus CC 1_i
PP NNP 1_i
. . 1_i

Clinical NNP N
periodontal JJ N
measurements NNS N
and CC N
data NNS N
regarding VBG N
patients NNS N
' POS N
oral JJ 1_o
health NN 1_o
impacts NNS 1_o
( ( 1_o
perceived VBN 1_o
impacts NNS 1_o
on IN 1_o
bleeding VBG 1_o
gums NNS 1_o
, , 1_o
gingival JJ 1_o
recession NN 1_o
, , 1_o
sensitivity NN 1_o
to TO 1_o
cold VB 1_o
, , 1_o
packing VBG 1_o
foods NNS 1_o
, , 1_o
aesthetics NNS 1_o
, , 1_o
bad JJ 1_o
breath NN 1_o
, , 1_o
and CC 1_o
tooth DT 1_o
mobility NN 1_o
) ) 1_o
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
3 CD N
months NNS N
after IN N
therapy NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
presented VBD N
significant JJ N
improvement NN N
in IN N
oral JJ 1_o
health NN 1_o
perceived VBD 1_o
impacts NNS 1_o
. . 1_o

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
of IN N
oral JJ 1_o
health NN 1_o
impacts NNS 1_o
among IN N
groups NNS N
subjected VBN N
to TO N
different JJ N
treatments NNS N
. . N

The DT N
clinical JJ N
data NNS N
of IN N
percentage NN N
of IN N
deep JJ 1_o
probing VBG 1_o
depth NN 1_o
, , 1_o
deep JJ 1_o
clinical JJ 1_o
attachment NN 1_o
level NN 1_o
, , 1_o
and CC 1_o
bleeding VBG 1_o
on IN 1_o
probing VBG 1_o
were VBD N
found VBN N
to TO N
be VB N
correlated VBN N
significantly RB N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

CONCLUSIONS NNP N
Periodontal NNP 1_i
treatment NN 1_i
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
of IN N
self-perceived JJ 1_o
impacts NNS 1_o
regardless RB N
of IN N
the DT N
non-surgical JJ N
treatment NN N
protocol NN N
employed VBN N
. . N

Most JJS N
of IN N
the DT N
clinical JJ N
data NNS N
were VBD N
associated VBN N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

-DOCSTART- -X- O O

Tactile NNP 1_o
feedback NN 1_o
is VBZ N
present JJ N
during IN N
minimally RB 1_i
invasive JJ 1_i
surgery NN 1_i
. . 1_i

BACKGROUND IN N
The DT N
applications NNS N
of IN N
minimally RB 1_i
invasive JJ 1_i
surgery NN 1_i
( ( 1_i
MIS NNP 1_i
) ) 1_i
and CC N
laparoscopy $ 1_i
are VBP N
rapidly RB N
expanding VBG N
. . N

Despite IN N
this DT N
expansion NN N
, , N
our PRP$ N
understanding NN N
of IN N
the DT N
importance NN N
of IN N
haptic JJ N
feedback NN N
during IN N
laparoscopic NN 1_i
surgery NN 1_i
is VBZ N
incomplete JJ N
. . N

Although IN N
many JJ N
surgeons NNS N
believe VBP N
that IN N
the DT N
use NN N
of IN N
minimally RB 1_i
invasive JJ 1_i
techniques NNS 1_i
eliminates VBZ N
force VBP 1_o
feedback NN 1_o
and CC 1_o
tactile JJ 1_o
sensation NN 1_o
( ( 1_o
haptics NNS 1_o
) ) 1_o
, , N
the DT N
importance NN N
of IN N
haptics NNS N
in IN N
MIS NNP N
has VBZ N
not RB N
been VBN N
fully RB N
evaluated VBN N
. . N

There EX N
is VBZ N
considerable JJ N
interest NN N
in IN N
the DT N
development NN N
of IN N
simulators NNS N
for IN N
MIS NNP N
even RB N
though IN N
the DT N
importance NN N
of IN N
force NN 1_o
feedback NN 1_o
remains VBZ N
poorly RB N
understood JJ N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
ability NN N
of IN N
experienced JJ 1_p
surgeons NNS 1_p
to TO N
interpret VB N
haptic JJ 1_o
feedback NN 1_o
with IN N
respect NN N
to TO N
texture NN 1_o
, , 1_o
shape NN 1_o
, , 1_o
and CC 1_o
consistency NN 1_o
of IN 1_o
an DT 1_o
object NN 1_o
. . 1_o

STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
single-blinded JJ N
study NN N
was VBD N
designed VBN N
. . N

Twenty CD 1_p
surgeons NNS 1_p
were VBD 1_p
presented VBN 1_p
objects NNS 1_p
in IN 1_p
a DT 1_p
random NN 1_p
order NN 1_p
, , 1_p
with IN 1_p
participants NNS 1_p
blinded VBN 1_p
as IN 1_p
to TO 1_p
their PRP$ 1_p
identity NN 1_p
. . 1_p

Inspection NN 1_o
by IN 1_o
direct JJ 1_o
palpation NN 1_o
, , 1_o
conventional JJ 1_o
instruments NNS 1_o
, , 1_o
and CC 1_o
laparoscopic JJ 1_o
instruments NNS 1_o
was VBD N
performed VBN N
on IN N
all DT N
objects NNS N
. . N

Statistic JJ N
analysis NN N
of IN N
the DT N
data NN N
was VBD N
performed VBN N
using VBG N
chi-square JJ N
analysis NN N
and CC N
, , N
when WRB N
appropriate NN N
, , N
a DT N
Fischer NNP N
exact JJ N
probability NN N
test NN N
. . N

RESULTS NNP N
Direct NNP 1_o
palpation NN 1_o
was VBD N
associated VBN N
with IN N
the DT N
highest JJS N
accuracy NN N
for IN N
shape NN N
identification NN N
and CC N
was VBD N
superior VBN N
to TO N
both DT N
conventional JJ N
instruments NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
laparoscopic JJ N
instruments NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Fine JJ N
texture NN N
analysis NN N
with IN N
either CC N
a DT N
conventional JJ 1_i
instrument NN 1_i
or CC N
a DT N
laparoscopic JJ 1_i
instrument NN 1_i
was VBD N
superior JJ N
to TO N
direct JJ N
palpation NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Finally RB N
, , N
the DT N
three CD N
methods NNS N
of IN N
analysis NN N
were VBD N
comparable JJ N
for IN N
consistency NN N
analysis NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
laparoscopic NN N
instruments NNS N
do VBP N
, , N
in IN N
fact NN N
, , N
provide VB N
surgeons NNS 1_p
with IN N
haptic JJ 1_o
feedback NN 1_o
. . 1_o

Interpretation NN N
of IN N
the DT N
texture NN N
, , N
shape NN N
, , N
and CC N
consistency NN N
of IN N
objects NNS N
can MD N
be VB N
performed VBN N
. . N

In IN N
some DT N
situations NNS N
, , N
laparoscopic JJ 1_i
instruments NNS 1_i
appear VBP N
to TO N
amplify VB N
the DT N
haptic JJ N
information NN N
available JJ N
. . N

Our PRP$ N
ongoing JJ N
work NN N
is VBZ N
directed VBN N
at IN N
further JJ N
defining VBG N
force NN N
interactions NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
amantadine NN 1_i
and CC N
pemoline NN 1_i
on IN N
cognitive JJ 1_p
functioning NN 1_p
in IN N
multiple JJ N
sclerosis NN N
. . N

BACKGROUND NNP N
Amantadine NNP 1_i
hydrochloride NN 1_i
and CC N
pemoline NN 1_i
, , N
both DT N
frequently RB N
used VBN N
to TO N
treat VB N
the DT N
fatigue NN N
of IN N
multiple JJ N
sclerosis NN N
( ( N
MS NNP N
) ) N
, , N
may MD N
also RB N
improve VB N
attention NN N
and CC N
other JJ N
cognitive JJ N
functions NNS N
in IN N
MS. NNP N
To TO N
our PRP$ N
knowledge NN N
, , N
these DT N
agents NNS N
have VBP N
never RB N
been VBN N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS 1_p
with IN 1_p
MS NNP 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amantadine NN 1_i
and CC 1_i
pemoline NN 1_i
on IN N
cognitive JJ N
functioning NN N
in IN N
MS. NNP N
METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
45 CD 1_p
ambulatory JJ 1_p
patients NNS 1_p
with IN 1_p
MS NNP 1_p
and CC 1_p
severe JJ 1_p
fatigue NN 1_p
were VBD N
treated VBN N
for IN N
6 CD N
weeks NNS N
with IN N
amantadine NN 1_i
, , 1_i
pemoline NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
using VBG N
a DT N
parallel JJ N
group NN N
design NN N
. . N

They PRP N
underwent VBD N
comprehensive JJ N
neuropsychological JJ N
testing NN N
to TO N
determine VB N
treatment NN N
effects NNS N
on IN N
cognitive JJ N
functioning NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
tests NNS N
of IN N
attention NN N
( ( 1_o
Digit NNP 1_o
Span NNP 1_o
, , 1_o
Trail NNP 1_o
Making NNP 1_o
Test NNP 1_o
, , 1_o
and CC 1_o
Symbol NNP 1_o
Digit NNP 1_o
Modalities NNP 1_o
Test NNP 1_o
) ) 1_o
, , 1_o
verbal JJ 1_o
memory NN 1_o
( ( 1_o
Selective JJ 1_o
Reminding NNP 1_o
Test NNP 1_o
) ) 1_o
, , 1_o
nonverbal JJ 1_o
memory NN 1_o
( ( 1_o
Benton NNP 1_o
Visual NNP 1_o
Retention NNP 1_o
Test NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
motor NN 1_o
speed NN 1_o
( ( 1_o
Finger NNP 1_o
Tapping NNP 1_o
Test NNP 1_o
) ) 1_o
. . N

RESULTS NNP N
Fatigue NNP 1_o
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
any DT N
of IN N
the DT N
neuropsychological JJ N
outcome NN N
measures NNS N
at IN N
baseline NN N
or CC N
after IN N
treatment NN N
. . N

All DT N
three CD N
treatment NN N
groups NNS N
improved VBN N
on IN N
tests NNS 1_o
of IN 1_o
attention NN 1_o
( ( N
P NNP N
< NNP N
.003 NNP N
) ) N
, , N
verbal JJ 1_o
memory NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
motor NN 1_o
speed NN 1_o
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
amantadine NN N
, , N
pemoline NN N
, , N
and CC N
placebo NN N
. . N

CONCLUSIONS NNP N
Cognitive NNP N
functioning NN N
in IN N
MS NNP N
is VBZ N
independent JJ N
of IN N
fatigue NN N
. . N

Neither CC N
amantadine JJ 1_i
nor CC N
pemoline JJ 1_i
enhances NNS N
cognitive JJ N
performance NN N
in IN N
MS NNP N
compared VBN N
with IN N
placebo NN 1_i
. . 1_i

-DOCSTART- -X- O O

FloSeal NNP 1_i
hemostatic JJ 1_i
matrix NN 1_i
in IN N
persistent JJ 1_p
epistaxis NN 1_p
: : 1_p
prospective JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
Although IN N
most JJS N
cases NNS N
of IN N
epistaxis NN N
are VBP N
managed VBN N
conservatively RB N
, , N
occasionally RB N
they PRP N
can MD N
progress VB N
to TO N
significant JJ N
hemorrhage NN N
requiring VBG N
more JJR N
involved JJ N
management NN N
or CC N
surgery NN N
. . N

Endoscopic NNP N
ligation NN N
surgery NN N
is VBZ N
the DT N
current JJ N
institutional JJ N
standard NN N
of IN N
care NN N
for IN N
patients NNS N
who WP N
fail VBP N
conservative JJ N
management NN N
. . N

However RB N
, , N
surgical JJ N
ligation NN N
requires VBZ N
availability NN N
of IN N
surgical JJ N
resources NNS N
and CC N
patients NNS N
who WP N
are VBP N
able JJ N
to TO N
withstand VB N
an DT N
anesthetic JJ N
. . N

This DT N
study NN N
's POS N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
FloSeal NNP 1_i
hemostatic JJ 1_i
matrix NN 1_i
( ( N
Baxter NNP N
Healthcare NNP N
Corporation NNP N
, , N
Hayward NNP N
, , N
CA NNP N
) ) N
in IN N
epistaxis JJ N
refractory NN N
to TO N
nasal VB N
packing VBG N
. . N

METHODS NNP N
A NNP N
prospective JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
epistaxis NN 1_p
patients NNS 1_p
whose WP$ 1_p
nasal JJ 1_p
hemorrhage NN 1_p
persisted VBD 1_p
despite IN 1_p
adequate JJ 1_p
nasal NNS 1_p
packing VBG 1_p
by IN 1_p
the DT 1_p
otolaryngology-head JJ 1_p
and CC 1_p
neck NN 1_p
surgery NN 1_p
team NN 1_p
. . 1_p

Once RB N
enrolled JJ N
, , N
patients NNS 1_p
are VBP N
given VBN N
a DT N
trial NN N
of IN N
intranasal JJ N
FloSeal NNP 1_i
hemostatic JJ 1_i
matrix NN 1_i
to TO N
abort VB N
the DT N
epistaxis NN N
. . N

Should MD N
this DT N
fail NN N
, , N
patients NNS N
then RB N
proceed VBP N
with IN N
surgical JJ N
clipping NN N
. . N

RESULTS VB N
Our PRP$ N
prospective JJ N
cohort NN N
demonstrated VBD N
significant JJ N
success NN N
in IN N
80 CD 1_p
% NN 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
persistent JJ 1_p
epistaxis NN 1_p
, , N
who WP N
would MD N
have VB N
otherwise RB N
been VBN N
taken VBN N
to TO N
the DT N
operating NN N
theatre NN N
, , N
avoiding VBG N
the DT N
need NN N
for IN N
further JJ N
surgical JJ 1_o
intervention NN 1_o
. . 1_o

The DT N
majority NN N
of IN N
enrolled JJ N
patients NNS 1_p
with IN 1_p
persistent JJ 1_p
nasal JJ 1_p
hemorrhage NN 1_p
were VBD N
adequately RB N
managed VBN N
with IN N
the DT N
hemostatic JJ N
matrix NN N
alone RB N
and CC N
were VBD N
discharged VBN 1_o
from IN 1_o
hospital NN 1_o
in IN N
a DT N
timeframe NN N
comparable JJ N
to TO N
that DT N
of IN N
surgical JJ N
managment NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
revealed VBD N
a DT N
highly RB N
effective JJ N
tool NN N
in IN N
the DT N
otolaryngologist NN N
's POS N
management NN N
of IN N
persistent JJ 1_p
epistaxis NN 1_p
. . 1_p

Given VBN N
the DT N
ease NN N
of IN N
use NN N
, , N
decreased VBN N
morbidity NN N
to TO N
the DT N
patient NN N
, , N
and CC N
cost-effectiveness NN N
, , N
FloSeal NNP 1_i
hemostatic JJ 1_i
matrix NN 1_i
could MD N
change VB N
clinical JJ N
practice NN N
in IN N
managing VBG N
this DT N
common JJ N
condition NN N
. . N

-DOCSTART- -X- O O

Direct JJ 1_i
renin NN 1_i
inhibition NN 1_i
improves VBZ N
parasympathetic JJ N
function NN N
in IN N
diabetes NNS 1_p
. . 1_p

AIM VB N
The DT N
renin-angiotensin-aldosterone NN N
system NN N
( ( N
RAAS NNP N
) ) N
and CC N
autonomic JJ N
nervous JJ N
system NN N
regulate VB N
the DT N
cardiovascular JJ N
system NN N
. . N

Blockade NN N
of IN N
the DT N
RAAS NNP N
may MD N
slow VB N
the DT N
progression NN N
of IN N
end-organ JJ N
damage NN N
. . N

Direct JJ 1_i
renin NN 1_i
inhibition NN 1_i
offers VBZ N
a DT N
means NN N
for IN N
blocking VBG N
the DT N
RAAS NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
direct JJ 1_i
renin NN 1_i
inhibition NN 1_i
on IN N
cardiovascular JJ N
autonomic JJ N
function NN N
. . N

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ 1_i
trial NN N
, , N
60 CD 1_p
individuals NNS 1_p
with IN 1_p
diabetes NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
300 CD N
mg NN N
of IN N
aliskiren NN 1_i
or CC 1_i
placebo NN 1_i
once RB N
daily JJ N
for IN N
6 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
a DT N
change NN 1_o
in IN 1_o
tests NNS 1_o
of IN 1_o
cardiovascular JJ 1_o
autonomic JJ 1_o
function NN 1_o
. . 1_o

Autonomic NNP 1_o
function NN 1_o
was VBD N
assessed VBN N
by IN N
power NN N
spectral JJ N
analysis NN N
and CC N
RR-variation NNP N
during IN N
deep JJ N
breathing NN N
[ JJ N
i.e NN N
. . N

mean VB N
circular JJ N
resultant NN N
( ( N
MCR NNP N
) ) N
, , N
expiration/inspiration NN N
( ( N
E/I NNP N
) ) N
ratio NN N
] NN N
. . N

The DT N
MCR NNP N
and CC N
E/I NNP N
ratio NN N
assess NN N
parasympathetic JJ N
function NN N
. . N

Secondary JJ N
measures NNS N
included VBD N
change NN 1_o
in IN 1_o
biochemical JJ 1_o
parameters NNS 1_o
[ VBP 1_o
e.g NN 1_o
. . 1_o

plasma JJ 1_o
renin NN 1_o
activity NN 1_o
, , 1_o
leptin NN 1_o
and CC 1_o
interleukin-6 JJ 1_o
] NN 1_o
. . 1_o

Change NN 1_o
in IN 1_o
cardiovascular JJ 1_o
autonomic JJ 1_o
function NN 1_o
and CC 1_o
blood NN 1_o
analytes NNS 1_o
were VBD N
analysed VBN N
by IN N
a DT N
mixed JJ N
effects NNS N
model NN N
for IN N
repeated JJ N
measures NNS N
. . N

RESULTS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
similar JJ N
between IN N
treatment NN N
groups NNS N
. . N

In IN N
response NN N
to TO N
aliskiren NNS 1_i
compared VBN N
with IN N
placebo NN 1_i
, , N
blood NN 1_o
pressure NN 1_o
was VBD N
reduced VBN N
as RB N
well RB N
as IN N
plasma JJ N
renin NN N
activity NN N
[ VBP N
from IN N
2.4 CD N
? . N
3.8 CD N
( ( N
mean VB N
? . N
standard JJ N
deviation NN N
) ) N
to TO N
0.5 CD N
? . N
0.4 CD N
?g/l/h NN N
, , N
p NN N
< VBD N
0.001 CD N
] NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
interaction NN 1_i
( ( 1_i
aliskiren VB 1_i
? . 1_i
visit NN 1_i
) ) N
for IN N
MCR NNP N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
E/I NNP N
ratio NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
indicating VBG N
improvement NN N
in IN N
MCR NNP N
and CC N
E/I NNP N
ratio NN N
for IN N
those DT N
on IN 1_i
aliskiren NNS 1_i
. . 1_i

MCR NNP 1_i
means VBZ N
, , N
baseline VB N
vs. IN N
follow-up JJ N
, , N
were VBD N
41.8 CD N
? . N
19.7 CD N
vs. IN N
50.8 CD N
? . N
26.1 CD N
( ( 1_i
aliskiren NN 1_i
) ) 1_i
and CC 1_i
38.2 CD 1_i
? . N
23.6 CD N
vs. IN N
37.5 CD N
? . N
24.1 CD N
( ( N
placebo NN 1_i
) ) N
. . N

CONCLUSIONS NNP N
Parasympathetic NNP N
function NN N
( ( N
i.e JJ N
. . N

MCR NNP N
and CC N
E/I NNP N
ratio NN N
) ) N
was VBD N
enhanced VBN N
by IN N
downregulation NN N
of IN N
the DT N
RAAS NNP N
. . N

-DOCSTART- -X- O O

[ IN N
The DT N
efficacy NN N
of IN N
psychotherapy NN 1_i
with IN 1_i
biofeedback NN 1_i
in IN N
the DT N
rehabilitation NN N
of IN N
hypertension NN 1_p
patients NNS 1_p
] VBP 1_p
. . N

85 CD 1_p
females NNS 1_p
with IN 1_p
borderline JJ 1_p
mental JJ 1_p
disorders NNS 1_p
in IN 1_p
essential JJ 1_p
hypertension NN 1_p
were VBD N
followed VBN N
up RP N
for IN N
a DT N
month NN N
and CC N
6 CD N
months NNS N
after IN N
the DT N
treatment NN N
( ( 1_i
hypotensive JJ 1_i
drugs NNS 1_i
+ VBP 1_i
psychotherapy NN 1_i
with IN 1_i
biofeedback NN 1_i
or CC 1_i
hypotensive JJ 1_i
drugs NNS 1_i
only RB 1_i
-- : 1_i
45 CD 1_i
patients NNS N
and CC N
40 CD N
controls NNS 1_i
, , N
respectively RB N
) ) N
. . N

The DT N
addition NN 1_o
of IN 1_o
psychotherapy NN 1_o
to TO 1_o
hypotensive VB 1_o
drugs NNS 1_o
contributed VBD 1_o
to TO 1_o
a DT 1_o
higher JJR 1_o
hypotensive JJ 1_o
effect NN 1_o
, , 1_o
long-term JJ 1_o
improvement NN 1_o
of IN 1_o
psychic JJ 1_o
condition NN 1_o
, , 1_o
more RBR 1_o
active JJ 1_o
attitude NN 1_o
to TO 1_o
the DT 1_o
treatment NN 1_o
process NN 1_o
and CC 1_o
psychic JJ 1_o
adaptation NN 1_o
. . 1_o

Better NNP 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
was VBD 1_o
achieved VBN 1_o
. . 1_o

-DOCSTART- -X- O O

Beneficial JJ N
effect NN N
of IN N
etidronate NN 1_i
therapy NN 1_i
in IN N
chronically RB 1_p
hospitalized VBN 1_p
, , 1_p
disabled JJ 1_p
patients NNS 1_p
with IN 1_p
stroke NN 1_p
. . 1_p

Incidence NN N
of IN N
hip NN N
fractures NNS N
is VBZ N
high JJ N
in IN N
chronically RB 1_p
hospitalized VBN 1_p
, , 1_p
disabled VBD 1_p
, , 1_p
elderly JJ 1_p
patients NNS 1_p
after IN 1_p
stroke NN 1_p
. . 1_p

Duration NN 1_p
of IN 1_p
hospitalization NN 1_p
was VBD 1_p
more JJR 1_p
than IN 1_p
1 CD 1_p
year NN 1_p
because IN 1_p
of IN 1_p
insufficiency NN 1_p
of IN 1_p
nursing NN 1_p
homes NNS 1_p
. . 1_p

Our PRP$ N
study NN N
showed VBD N
that IN N
immobilization-induced JJ N
hypercalcemia NN N
and CC N
25-hydroxyvitamin JJ N
D NNP N
deficiency NN N
contribute NN N
to TO N
reduced VB N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
address VB N
the DT N
possibility NN N
that WDT N
treatment NN N
with IN N
etidronate NN 1_i
may MD N
reduce VB N
the DT N
bone NN N
resorption NN N
and CC N
lower JJR N
the DT N
incidence NN N
of IN N
fractures NNS N
in IN N
elderly JJ 1_p
patients NNS 1_p
who WP 1_p
are VBP 1_p
chronically RB 1_p
hospitalized VBN 1_p
and CC 1_p
disabled VBN 1_p
as IN 1_p
a DT 1_p
result NN 1_p
of IN 1_p
hemiparesis NN 1_p
after IN 1_p
stroke NN 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
stroke NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
daily VB N
treatment NN N
with IN N
400 CD N
mg NNS N
of IN N
etidronate NN 1_i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
or CC N
a DT N
placebo NN 1_i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
, , N
and CC N
followed VBD N
up RB N
for IN N
2 CD N
years NNS N
. . N

At IN N
baseline NN N
, , N
both DT N
groups NNS N
had VBD N
low JJ N
BMD NNP 1_o
with IN N
high JJ 1_o
levels NNS 1_o
of IN 1_o
serum NN 1_o
ionized VBN 1_o
calcium NN 1_o
and CC 1_o
urinary JJ 1_o
deoxypyridinoline NN 1_o
. . 1_o

In IN N
the DT N
etidronate NN 1_i
group NN N
, , N
serum NN 1_o
calcium NN 1_o
and CC 1_o
urinary JJ 1_o
deoxypyridinoline NN 1_o
levels NNS 1_o
decreased VBN N
significantly RB N
during IN N
the DT N
study NN N
period NN N
, , N
whereas IN N
the DT N
levels NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
were VBD N
increased VBN N
. . N

BMD NNP 1_o
on IN 1_o
the DT 1_o
hemiplegic JJ 1_o
side NN 1_o
increased VBN N
by IN N
1.4 CD N
% NN N
in IN N
the DT N
etidronate NN N
group NN N
and CC N
decreased VBN N
by IN N
2.2 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Two CD N
patients NNS N
sustained VBD N
hip JJ 1_o
fractures NNS 1_o
in IN N
the DT N
placebo NN 1_i
group NN N
, , N
and CC N
no DT N
hip NN 1_o
fracture NN 1_o
occurred VBD N
in IN N
the DT N
etidronate NN 1_i
group NN N
. . N

Treatment NN N
with IN N
etidronate NN 1_i
increases NNS N
BMD NNP 1_o
in IN N
chronically RB 1_p
hospitalized VBN 1_p
patients NNS 1_p
poststroke VBD 1_p
, , N
and CC N
may MD N
prevent VB N
hip NN N
fracture NN N
. . N

-DOCSTART- -X- O O

Clinical JJ 1_i
hypnosis NN 1_i
versus NN 1_i
cognitive JJ 1_i
behavioral JJ 1_i
training NN 1_i
for IN N
pain NN 1_o
management NN 1_o
with IN N
pediatric JJ 1_p
cancer NN 1_p
patients NNS 1_p
undergoing VBG 1_p
bone NN 1_p
marrow NN 1_p
aspirations NNS 1_p
. . 1_p

A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
clinical JJ 1_i
hypnosis NN 1_i
versus NN 1_i
cognitive JJ 1_i
behavioral NN 1_i
( ( 1_i
CB NNP 1_i
) ) 1_i
coping VBG 1_i
skills NNS 1_i
training VBG 1_i
in IN N
alleviating VBG N
the DT N
pain NN 1_o
and CC 1_o
distress NN 1_o
of IN N
30 CD 1_p
pediatric JJ 1_p
cancer NN 1_p
patients NNS 1_p
( ( 1_p
age NN 1_p
5 CD 1_p
to TO 1_p
15 CD 1_p
years NNS 1_p
) ) 1_p
undergoing VBG 1_p
bone NN 1_p
marrow NN 1_p
aspirations NNS 1_p
. . 1_p

Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
hypnosis NN 1_i
, , 1_i
a DT 1_i
package NN 1_i
of IN 1_i
CB NNP 1_i
coping VBG 1_i
skills NNS 1_i
, , 1_i
and CC 1_i
no DT 1_i
intervention NN 1_i
. . 1_i

Patients NNS N
who WP N
received VBD N
either CC N
hypnosis NN N
or CC N
CB NNP N
reported VBD N
less JJR N
pain NN 1_o
and CC 1_o
pain-related JJ 1_o
anxiety NN 1_o
than IN N
did VBD N
control VB N
patients NNS N
and CC N
less JJR N
pain NN 1_o
and CC 1_o
anxiety NN 1_o
than IN N
at IN N
their PRP$ N
own JJ N
baseline NN N
. . N

Hypnosis NNP N
and CC N
CB NNP N
were VBD N
similarly RB N
effective JJ N
in IN N
the DT N
relief NN 1_o
of IN 1_o
pain NN 1_o
. . 1_o

Results NNP N
also RB N
indicated VBD N
that IN N
children NNS N
reported VBD N
more RBR N
anxiety NN 1_o
and CC N
exhibited VBD N
more RBR N
behavioral JJ 1_o
distress NN 1_o
in IN N
the DT N
CB NNP N
group NN N
than IN N
in IN N
the DT N
hypnosis NN N
group NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
hypnosis NN N
and CC N
CB NNP N
coping VBG N
skills NNS N
are VBP N
effective JJ 1_o
in IN N
preparing VBG 1_o
pediatric JJ 1_p
oncology NN 1_p
patients NNS 1_p
for IN N
bone NN N
marrow NN N
aspiration NN N
. . N

-DOCSTART- -X- O O

Sulfadoxine/pyrimethamine NNP 1_i
alone RB 1_i
or CC 1_i
with IN 1_i
amodiaquine JJ 1_i
or CC 1_i
artesunate NN 1_i
for IN N
treatment NN N
of IN N
uncomplicated JJ 1_o
malaria NNS 1_o
: : 1_o
a DT N
longitudinal JJ N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
New NNP N
antimalarial JJ N
treatments NNS N
are VBP N
urgently RB N
needed VBN N
in IN N
sub-Saharan JJ 1_p
Africa NNP 1_p
. . 1_p

Improved NNP N
therapies NNS N
should MD N
decrease VB N
failure NN 1_o
rates NNS 1_o
in IN N
the DT N
short JJ N
term NN N
, , N
but CC N
their PRP$ N
effect NN N
on IN N
incidence NN N
of IN N
subsequent JJ N
episodes NNS N
of IN N
malaria NN N
is VBZ N
little JJ N
studied JJ N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
short-term JJ N
and CC N
long-term JJ N
effectiveness NN N
of IN N
three CD N
antimalarial JJ N
regimens NNS N
in IN N
children NNS 1_p
from IN 1_p
Kampala NNP 1_p
, , 1_p
Uganda NNP 1_p
. . 1_p

METHODS NNP N
We PRP N
randomly RB N
allocated VBD N
healthy JJ 1_p
children NNS 1_p
aged VBD 1_p
6 CD 1_p
months NNS 1_p
to TO 1_p
5 CD 1_p
years NNS 1_p
to TO N
receive VB N
25 CD 1_i
mg/kg JJ 1_i
sulfadoxine NN 1_i
and CC 1_i
1.25 CD 1_i
mg/kg NN 1_i
pyrimethamine NN 1_i
plus CC 1_i
either DT 1_i
placebo NN 1_i
, , 1_i
25 CD 1_i
mg/kg NN 1_i
amodiaquine NN 1_i
, , 1_i
or CC 1_i
12 CD 1_i
mg/kg JJ 1_i
artesunate NN 1_i
. . 1_i

Participants NNS N
were VBD N
followed VBN N
up RP N
for IN N
1 CD N
year NN N
and CC N
received VBD N
the DT N
same JJ N
preassigned JJ N
treatment NN N
for IN N
every DT N
new JJ N
episode NN N
of IN N
uncomplicated JJ N
malaria NNS N
diagnosed VBN N
during IN N
follow-up JJ N
. . N

Recrudescent NNP N
and CC N
new JJ N
infections NNS N
were VBD N
distinguished VBN N
by IN N
comparison NN N
of IN N
polymorphisms NNS N
in IN N
merozoite JJ N
surface NN N
protein NN N
2 CD N
( ( N
MSP2 NNP N
) ) N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
the DT N
total JJ 1_o
number NN 1_o
of IN 1_o
treatments NNS 1_o
for IN 1_o
malaria NNS 1_o
per IN N
time NN N
at IN N
risk NN N
. . N

Analyses NNS N
were VBD N
done VBN N
per IN N
protocol NN N
. . N

FINDINGS $ N
183 CD N
( ( N
61 CD N
% NN N
) ) N
of IN N
316 CD 1_p
participants NNS 1_p
were VBD N
diagnosed VBN N
with IN N
at IN N
least JJS N
one CD N
episode NN N
of IN N
uncomplicated JJ N
malaria NN N
. . N

A DT N
total NN N
of IN N
577 CD N
episodes NNS N
of IN N
uncomplicated JJ N
Plasmodium NNP N
falciparum NN N
malaria NNS N
were VBD N
treated VBN N
with IN N
study NN N
drugs NNS N
; : N
all DT N
regimens NNS N
were VBD N
safe JJ 1_o
and CC N
well RB N
tolerated VBN 1_o
. . 1_o

Clinical JJ 1_o
treatment NN 1_o
failure NN 1_o
after IN N
14 CD N
days NNS N
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
the DT N
sulfadoxine/pyrimethamine NN N
group NN N
( ( N
38 CD N
of IN N
215 CD N
, , N
18 CD N
% NN N
) ) N
compared VBN N
with IN N
either CC N
the DT N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine JJ N
group NN N
( ( N
two CD N
of IN N
164 CD N
, , N
1 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
or CC N
sulfadoxine/pyrimethamine JJ N
plus CC N
artesunate JJ N
group NN N
( ( N
one CD N
of IN N
198 CD N
, , N
1 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

After IN N
28 CD N
and CC N
42 CD N
days NNS N
, , N
patients NNS N
in IN N
the DT N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine JJ N
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
develop VB N
malaria NNS 1_o
than IN N
were VBD N
those DT N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Overall NNP N
, , N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine NN N
reduced VBD N
the DT N
rate NN 1_o
of IN 1_o
subsequent JJ 1_o
treatments NNS 1_o
for IN 1_o
malaria NN 1_o
by IN N
54 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
36-66 CD N
, , N
p VBZ N
< NNP N
0.0001 CD N
) ) N
compared VBN N
with IN N
sulfadoxine/ JJ N
pyrimethamine NN N
alone RB N
and CC N
by IN N
37 CD N
% NN N
( ( N
12-54 JJ N
, , N
p=0.007 NN N
) ) N
compared VBN N
with IN N
sulfadoxine/pyrimethamine JJ N
plus JJ N
artesunate NN N
. . N

INTERPRETATION NNP N
Sulfadoxine/pyrimethamine NNP N
plus CC N
amodiaquine NN N
could MD N
be VB N
used VBN N
as IN N
an DT N
inexpensive JJ N
regimen NNS N
to TO N
decrease VB 1_o
the DT 1_o
rate NN 1_o
of IN 1_o
subsequent JJ 1_o
episodes NNS 1_o
of IN 1_o
malaria NN 1_o
. . 1_o

-DOCSTART- -X- O O

0.1 CD N
% NN N
bupivacaine NN 1_i
does VBZ N
not RB N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
infusion NN N
after IN 1_p
major JJ 1_p
abdominal JJ 1_p
surgery NN 1_p
. . 1_p

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Although IN N
local JJ N
anesthesia NN N
has VBZ N
been VBN N
demonstrated VBN N
to TO N
potentiate VB N
spinal JJ N
morphine NN N
analgesia NN N
in IN N
animal JJ N
studies NNS N
, , N
results NNS N
comparing VBG N
epidural JJ N
local JJ N
anesthesia/opioid NN N
mixtures NNS N
with IN N
opioid JJ N
alone NN N
are VBP N
contradictory JJ N
in IN N
clinical JJ N
studies NNS N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
, , N
although IN N
the DT N
concentration NN N
of IN N
bupivacaine NN 1_i
( ( N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
to TO N
minimize VB N
its PRP$ N
adverse JJ N
effects NNS N
, , N
if IN N
the DT N
infusion NN N
rate NN N
of IN N
a DT N
fentanyl/bupivacaine JJ 1_i
solution NN N
was VBD N
closely RB N
adjusted VBN N
according VBG N
to TO N
need NN N
, , N
the DT N
presence NN N
bupivacaine NN N
would MD N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
. . N

METHODS NNP N
Forty NNP 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN 1_i
to TO 1_i
receive VB 1_i
either DT 1_i
fentanyl NN 1_i
( ( 1_i
10 CD 1_i
micrograms/mL NN 1_i
) ) 1_i
or CC 1_i
a DT 1_i
fentanyl/bupivacaine NN 1_i
( ( 1_i
0.1 CD 1_i
% NN 1_i
) ) 1_i
mixture NN 1_i
epidurally RB 1_i
corresponding VBG 1_i
to TO 1_i
the DT 1_i
dermatome NN 1_i
of IN 1_i
the DT 1_i
surgical JJ 1_i
incision NN 1_i
in IN 1_i
a DT 1_i
double-blind JJ 1_i
fashion NN 1_i
for IN 1_i
the DT 1_i
first JJ 1_i
18 CD 1_i
hours NNS 1_i
after IN 1_i
major JJ 1_i
abdominal JJ 1_i
surgery NN 1_i
. . 1_i

The DT 1_i
infusion NN 1_i
was VBD 1_i
titrated VBN 1_i
for IN 1_i
each DT 1_i
patient NN 1_i
to TO 1_i
the DT 1_i
rate NN 1_i
required VBN 1_i
for IN 1_i
pain NN 1_i
relief NN 1_i
during IN 1_i
forced VBN 1_i
inspiration NN 1_i
( ( 1_i
pain NN 1_i
score NN 1_i
< NN 1_i
or CC 1_i
= $ 1_i
2 CD 1_i
, , 1_i
maximum JJ 1_i
10 CD 1_i
) ) 1_i
. . 1_i

Pain NN N
scores NNS N
, , N
the DT N
fentanyl JJ N
doses NNS N
required VBN N
, , N
plasma JJ N
concentrations NNS N
of IN N
fentanyl NN N
at IN N
18 CD N
hours NNS N
, , N
and CC N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ 1_o
effects NNS 1_o
were VBD N
recorded VBN N
. . N

RESULTS JJ N
Patients NNPS N
reported VBD N
similar JJ N
median JJ 1_o
pain NN 1_o
scores NNS 1_o
and CC N
were VBD N
equally RB N
satisfied VBN N
with IN N
pain NN 1_o
relief NN 1_o
in IN N
both DT N
groups NNS N
. . N

The DT N
mean NN 1_o
required VBN 1_o
post-operative JJ 1_o
fentanyl JJ 1_o
infusion NN 1_o
rate NN 1_o
( ( N
57.7 CD N
+/- JJ N
19.5 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN 1_o
concentrations NNS 1_o
( ( N
0.84 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl NN N
group NN N
were VBD N
comparable JJ N
to TO N
the DT N
infusion NN 1_o
rate NN 1_o
( ( N
54.4 CD N
+/- JJ N
19.2 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN 1_o
concentrations NNS 1_o
( ( N
0.86 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl/bupivacaine NN N
group NN N
. . N

Respiratory NNP 1_o
and CC 1_o
cardiovascular JJ 1_o
functions NNS 1_o
were VBD N
preserved VBN N
, , N
and CC N
the DT N
incidence NN 1_o
of IN 1_o
nausea NN 1_o
, , 1_o
pruritus NN 1_o
, , 1_o
and CC 1_o
periods NNS 1_o
of IN 1_o
drowsiness NN 1_o
or CC 1_o
sleep NN 1_o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
low JJ N
concentrations NNS N
( ( N
0.1 CD N
% NN N
) ) N
, , N
bupivacaine NN 1_i
did VBD N
not RB N
reduce VB N
the DT N
titrated JJ N
dose NN N
of IN N
epidural JJ N
fentanyl NN N
required VBN N
for IN N
adequate JJ N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
also RB N
comparable JJ N
whether IN N
or CC N
not RB N
low-dose JJ N
bupivacaine NN 1_i
infusion NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O

Efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
10 CD N
% NN N
HES NNP 1_i
130/0.4 CD N
versus NN N
10 CD N
% NN N
HES NNP 1_i
200/0.5 CD N
for IN N
plasma NN N
volume NN N
expansion NN N
in IN N
cardiac JJ 1_p
surgery NN 1_p
patients NNS 1_p
. . 1_p

AIM NNP N
Hydroxyethyl NNP 1_i
starch NN 1_i
( ( N
HES NNP N
) ) N
solutions NNS N
are VBP N
frequently RB N
used VBN N
for IN N
perioperative JJ N
volume NN N
replacement NN N
. . N

Whereas NNP N
older JJR N
HES NNP N
specimen NNS N
tended VBD N
to TO N
accumulate VB N
in IN N
the DT N
plasma NN N
and CC N
to TO N
cause VB N
negative JJ N
effects NNS N
on IN N
hemostasis NN N
, , N
more RBR N
recent JJ N
products NNS N
, , N
e.g. NN N
, , N
HES NNP N
130/0.4 CD N
, , N
are VBP N
characterised VBN N
by IN N
improved JJ N
pharmacological JJ N
properties NNS N
. . N

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
and CC N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
. . N

METHODS NN N
In IN N
this DT N
post-hoc JJ N
analysis NN N
of IN N
a DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
, , N
multi-center JJ N
therapeutic JJ N
equivalence NN N
trial NN N
, , N
76 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
elective JJ 1_p
on-pump JJ 1_p
cardiac NN 1_p
surgery NN 1_p
received VBD N
perioperative JJ 1_i
volume NN 1_i
replacement NN 1_i
using VBG 1_i
either CC 1_i
10 CD 1_i
% NN 1_i
HES NNP 1_i
130/0.4 CD 1_i
( ( 1_i
N.=37 NNP 1_i
) ) 1_i
or CC 1_i
10 CD 1_i
% NN 1_i
HES NNP 1_i
200/0.5 CD 1_i
( ( 1_i
N.=39 NNP 1_i
) ) 1_i
up RB 1_i
to TO 1_i
a DT 1_i
maximum JJ 1_i
dose NN 1_i
of IN 1_i
20 CD 1_i
mL JJ 1_i
kg-1 NN 1_i
. . 1_i

RESULTS NNP N
Equivalent NNP 1_o
volumes NNS 1_o
of IN 1_o
investigational JJ 1_o
medication NN 1_o
were VBD N
infused VBN N
until IN N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
( ( N
1577 CD N
vs. IN N
1540 CD N
mL NN N
; : N
treatment NN N
difference NN N
37 CD N
[ JJ N
-150 NN N
; : N
223 CD N
] NNP N
mL NN N
; : N
P NNP N
< VBZ N
0.0001 CD N
for IN N
equivalence NN N
) ) N
. . N

Whereas NNP N
standard JJ 1_o
laboratory NN 1_o
tests NNS 1_o
of IN 1_o
coagulation NN 1_o
were VBD N
comparable JJ N
between IN N
groups NNS N
, , N
von FW 1_o
Willebrand NNP 1_o
factor NN 1_o
activity NN 1_o
on IN N
the DT N
first JJ N
postoperative JJ N
morning NN N
tended VBD N
to TO N
be VB N
higher JJR N
following VBG N
treatment NN N
with IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
( ( N
P=0.025 NNP N
) ) N
with IN N
this DT N
difference NN N
being VBG N
statistically RB N
significant JJ N
only RB N
in IN N
the DT N
per-protocol JJ N
analysis NN N
( ( N
P=0.02 NNP N
) ) N
. . N

Treatment JJ N
groups NNS N
were VBD N
comparable JJ N
concerning VBG N
other JJ N
safety NN 1_o
parameters NNS 1_o
and CC 1_o
the DT 1_o
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
drug NN 1_o
reactions NNS 1_o
. . 1_o

In IN N
particular JJ N
, , N
renal JJ 1_o
function NN 1_o
was VBD N
well RB N
preserved VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Ten CD N
percent NN N
HES NNP N
130/0.4 CD N
was VBD N
equally RB N
effective JJ N
and CC N
safe JJ N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
for IN N
volume NN N
therapy NN N
in IN N
patients NNS 1_p
undergoing VBG 1_p
cardiovascular JJ 1_p
surgery NN 1_p
. . 1_p

Postoperative JJ 1_o
coagulation NN 1_o
and CC 1_o
renal JJ 1_o
function NN 1_o
, , N
as IN N
measured VBN N
by IN N
standard JJ N
laboratory NN N
tests NNS N
, , N
were VBD N
similar JJ N
among IN N
groups NNS N
. . N

-DOCSTART- -X- O O

Short-term JJ N
effect NN N
of IN N
pitavastatin NN 1_i
on IN N
the DT N
reactive JJ 1_o
hyperemic JJ 1_o
index NN 1_o
in IN N
post-menopausal JJ 1_p
women NNS 1_p
with IN 1_p
high JJ 1_p
levels NNS 1_p
in IN 1_p
serum JJ 1_p
LDL-cholesterol NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Activation NN N
of IN N
the DT N
carotid NN N
chemoreflex JJ N
secondary JJ N
to TO N
muscle VB 1_o
metaboreflex JJ 1_o
stimulation NN 1_o
in IN N
men NNS 1_p
. . 1_p

Recent JJ N
work NN N
has VBZ N
shown VBN N
that IN N
the DT N
carotid NN N
chemoreceptor NN N
( ( N
CC NNP N
) ) N
contributes VBZ N
to TO N
sympathetic VB N
control NN N
of IN N
cardiovascular JJ N
function NN N
during IN N
exercise NN N
, , N
despite IN N
no DT N
evidence NN N
of IN N
increased JJ N
circulating VBG N
CC NNP N
stimuli NN N
, , N
suggesting VBG N
enhanced VBN N
CC NNP N
activity/sensitivity NN N
. . N

As IN N
interactions NNS N
between IN N
metaboreceptors NNS N
and CC N
chemoreceptors NNS N
have VBP N
been VBN N
previously RB N
observed VBN N
, , N
the DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
isolate VB N
the DT N
metaboreflex NN N
while IN N
acutely RB N
stimulating VBG N
or CC N
inhibiting VBG N
the DT N
CC NNP N
to TO N
determine VB N
whether IN N
the DT N
metaboreflex NN N
increased VBD N
CC NNP N
activity/sensitivity NN N
. . N

Fourteen NNP 1_p
young JJ 1_p
healthy JJ 1_p
men NNS 1_p
( ( 1_p
height NN 1_p
: : 1_p
177.0 CD 1_p
? . 1_p
2.1 CD 1_p
cm NN 1_p
, , 1_p
weight NN 1_p
: : 1_p
85.8 CD 1_p
? . 1_p
5.5 CD 1_p
kg NN 1_p
, , 1_p
age NN 1_p
: : 1_p
24.6 CD 1_p
? . 1_p
1.1 CD 1_p
yr NN 1_p
) ) 1_p
performed VBD 1_p
three CD N
trials NNS N
of IN N
40 CD 1_i
% NN 1_i
maximal JJ 1_i
voluntary JJ 1_i
contraction NN 1_i
handgrip NN 1_i
for IN 1_i
2 CD N
min NN N
, , N
followed VBN N
by IN N
3 CD 1_i
min NN 1_i
of IN 1_i
postexercise NN 1_i
circulatory NN 1_i
occlusion NN 1_i
( ( 1_i
PECO NNP 1_i
) ) 1_i
to TO 1_i
stimulate VB N
the DT N
metaboreflex NN N
. . N

In IN N
random JJ N
order NN N
, , N
subjects VBZ N
either CC N
breathed JJ 1_i
room NN 1_i
air NN 1_i
, , 1_o
hypoxia NN 1_o
( ( 1_o
target VB 1_o
SPo2 NNP N
= NNP N
85 CD N
% NN N
) ) N
, , N
or CC N
hyperoxia NN 1_o
( ( 1_o
FiO2 NNP 1_o
= NNP N
1.0 CD N
) ) N
during IN N
the DT N
PECO NNP N
to TO N
modulate VB N
the DT N
chemoreflex NN N
. . N

After IN N
these DT N
trials NNS N
, , N
a DT N
resting VBG N
hypoxia JJ N
trial NN N
was VBD N
conducted VBN N
without IN N
handgrip NN N
or CC N
PECO NNP 1_o
. . 1_o

Ventilation NNP 1_o
( ( 1_o
Ve NNP 1_o
) ) 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
muscle NN 1_o
sympathetic JJ 1_o
nervous JJ 1_o
activity NN 1_o
( ( 1_o
MSNA NNP 1_o
) ) 1_o
data NNS 1_o
were VBD 1_o
continuously RB N
obtained VBN N
. . N

Relative JJ N
to TO N
normoxic JJ N
PECO NNP N
, , N
inhibition NN N
of IN N
the DT N
CC NNP N
during IN N
hyperoxic JJ N
PECO NNP N
resulted VBD N
in IN N
lower JJR 1_o
MSNA NNP 1_o
( ( 1_o
P NNP 1_o
= NNP N
0.038 CD N
) ) N
and CC N
HR NNP N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
. . N

Relative JJ N
to TO N
normoxic JJ N
PECO NNP N
, , N
stimulation NN N
of IN N
the DT N
CC NNP N
during IN N
hypoxic JJ N
PECO NNP N
resulted VBD N
in IN N
higher JJR 1_o
HR NNP 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
Ve NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
ventilatory NN 1_o
and CC 1_o
MSNA NNP 1_o
responses NNS 1_o
to TO N
hypoxic VB 1_o
PECO NNP 1_o
were VBD 1_o
not RB N
greater JJR N
than IN N
the DT N
sum NN N
of IN N
the DT N
responses NNS N
to TO N
hypoxia VB N
and CC N
PECO NNP N
individually RB N
, , N
indicating VBG N
that IN N
the DT N
CC NNP 1_o
are VBP 1_o
not RB 1_o
sensitized VBN 1_o
during IN 1_o
metaboreflex JJ N
activation NN N
. . N

These DT N
results NNS N
demonstrate VBP N
that IN 1_o
stimulation NN 1_o
of IN 1_o
the DT 1_o
metaboreflex NN 1_o
activates VBZ 1_o
, , 1_o
but CC 1_o
does VBZ N
not RB N
sensitize VB N
the DT N
CC NNP 1_o
, , N
and CC N
help NN N
explain VB N
the DT N
enhanced JJ N
CC NNP N
activity NN N
with IN N
exercise NN N
. . N

-DOCSTART- -X- O O

Combined VBN N
therapy NN N
for IN N
obese JJ 1_o
type NN 1_o
2 CD 1_o
diabetes NNS 1_o
: : 1_o
suppertime NN 1_i
mixed JJ 1_i
insulin NN 1_i
with IN 1_i
daytime JJ 1_i
sulfonylurea NN 1_i
. . 1_i

Combined VBN 1_i
insulin NN 1_i
and CC 1_i
sulfonylurea JJ 1_i
therapy NN 1_i
for IN N
type NN 1_o
2 CD 1_o
diabetes NNS 1_o
may MD N
improve VB N
the DT N
effectiveness NN 1_o
of IN N
a DT N
single JJ N
injection NN 1_i
of IN 1_i
insulin NN 1_i
, , N
thereby RB N
postponing VBG N
the DT N
need NN N
for IN N
multiple JJ N
injections NNS N
. . N

This DT N
concept NN N
was VBD N
tested VBN N
in IN N
21 CD 1_p
obese JJ 1_p
subjects NNS 1_p
imperfectly RB 1_p
controlled VBN 1_p
by IN 1_p
20 CD 1_i
mg NNS 1_i
of IN 1_i
glyburide JJ 1_i
daily JJ 1_i
in IN 1_i
a DT N
double JJ N
masked VBN N
, , N
placebo-controlled JJ 1_i
, , N
parallel JJ N
design NN N
, , N
16-week JJ N
protocol NN N
. . N

Premixed CC 1_i
70 CD 1_i
% NN 1_i
NPH/30 NNP 1_i
% NN 1_i
Regular NNP 1_i
insulin NN 1_i
was VBD 1_i
taken VBN 1_i
before RB 1_i
supper JJ 1_i
, , 1_i
and CC 1_i
the DT 1_i
dosage NN 1_i
was VBD 1_i
adjusted VBN 1_i
weekly RB 1_i
by IN 1_i
an DT 1_i
algorithm NN 1_i
seeking VBG 1_i
nearly RB 1_i
normal JJ 1_i
fasting VBG 1_i
glycemia NN 1_i
. . 1_i

Eleven JJ 1_p
subjects NNS 1_p
using VBG 1_p
insulin NN 1_i
plus CC 1_i
10 CD 1_p
mg NNS 1_p
glyburide NN 1_i
before IN N
breakfast NN N
had VBD N
lower JJR N
mean NN N
fasting VBG N
glucose NN N
at IN N
10-16 JJ N
weeks NNS N
than IN N
10 CD N
subjects NNS N
using VBG N
insulin NN N
with IN N
placebo NN 1_i
( ( N
mean JJ N
+/- JJ N
SEM NNP N
; : N
5.9 CD N
+/- JJ N
0.3 CD N
versus NN N
7.5 CD N
+/- JJ N
0.7 CD N
mmol/L NN N
; : N
p CC N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
had VBD N
a DT N
greater JJR N
decrement NN N
of IN N
glycosylated JJ 1_o
hemoglobin NN 1_o
from IN N
baseline NN N
values NNS N
( ( N
1.3 CD N
+/- JJ N
0.1 CD N
versus NN N
0.8 CD N
+/- JJ N
0.2 CD N
% NN N
A1 NNP N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

After IN N
16 CD N
weeks NNS N
the DT N
combined JJ N
therapy NN N
group NN N
used VBD 1_o
half NN N
as IN N
much JJ N
insulin NN 1_o
as IN N
the DT N
insulin-only JJ N
group NN N
( ( N
50 CD N
+/- JJ N
5 CD N
versus NN N
101 CD N
+/- JJ N
13 CD N
units/d NN N
; : N
p CC N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Fasting VBG 1_o
serum JJ 1_o
free JJ 1_o
insulin NN 1_o
values NNS 1_o
increased VBD N
58 CD N
% NN N
from IN N
baseline NN N
after IN N
insulin NN N
therapy NN N
in IN N
the DT N
insulin-only JJ N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
but CC N
did VBD N
not RB N
increase VB N
with IN N
combined JJ N
therapy NN N
. . N

Weight NNP 1_o
gain NN 1_o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

These DT N
data NNS N
support NN N
this DT N
form NN N
of IN N
combined JJ N
therapy NN N
as IN N
one CD N
option NN N
for IN N
treating VBG N
obese JJ 1_p
persons NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes VBZ 1_p
no RB N
longer RBR N
responsive VB N
to TO N
oral JJ N
therapy NN N
alone RB N
. . N

-DOCSTART- -X- O O

Pharmacodynamic JJ N
analysis NN N
of IN N
intravenous JJ 1_i
recombinant JJ 1_i
urate JJ 1_i
oxidase NN 1_i
using VBG N
an DT N
indirect JJ 1_p
pharmacological JJ 1_p
response NN 1_p
model NN 1_p
in IN 1_p
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

AIM NNP N
Pharmacodynamic NNP N
analysis NN N
of IN N
intravenous JJ 1_i
recombinant JJ 1_i
urate JJ 1_i
oxidase NN 1_i
produced VBN N
by IN N
Escherichia NNP N
coli NN N
was VBD N
performed VBN N
in IN 1_p
healthy JJ 1_p
subjects NNS 1_p
using VBG 1_p
a DT 1_p
pharmacokinetic/pharmacodynamic JJ 1_p
( ( 1_p
PK/PD NNP 1_p
) ) 1_p
model NN 1_p
. . 1_p

METHODS CC N
A DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
was VBD N
performed VBN N
in IN 1_p
40 CD 1_p
healthy JJ 1_p
Chinese JJ 1_p
subjects NNS 1_p
( ( 1_p
4 CD 1_p
groups NNS 1_p
of IN 1_p
10 CD 1_p
subjects NNS 1_p
each DT 1_p
, , 1_p
placebo VBZ 1_p
4:1 CD 1_p
ratio NN 1_p
) ) 1_p
who WP 1_p
received VBD 1_p
infusions NNS 1_p
of IN 1_p
uricase NN 1_i
( ( 1_p
single JJ 1_p
doses NNS 1_p
of IN 1_p
0.1 CD 1_p
, , 1_p
0.2 CD 1_p
, , 1_p
and CC 1_p
0.3 CD 1_p
mg/kg NN 1_p
; : 1_p
multiple JJ 1_p
doses NNS 1_p
of IN 1_p
0.2 CD 1_p
mg?kg NN 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
?d NN 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
for IN 1_p
7 CD 1_p
d NN 1_p
) ) 1_p
. . 1_p

PK JJ N
profiles NNS N
were VBD N
determined VBN N
through IN 1_o
plasma JJ 1_o
uricase JJ 1_o
activity NN 1_o
, , 1_o
and CC N
PD NNP N
profiles NNS N
were VBD N
established VBN N
using VBG 1_o
uric JJ 1_o
acid NN 1_o
levels NNS 1_o
in IN 1_o
plasma NN 1_o
and CC 1_o
urine NN 1_o
. . 1_o

The DT N
plasma NN N
PD NNP N
parameter NN N
was VBD N
estimated VBN N
as IN N
changes NNS N
in IN N
plasma NN 1_o
uric JJ 1_o
acid NN 1_o
levels NNS 1_o
as IN 1_o
the DT N
effect NN N
in IN N
the DT N
indirect JJ N
response NN N
model NN 1_o
. . 1_o

Adverse JJ 1_o
events NNS 1_o
were VBD 1_o
also RB N
monitored VBN N
. . N

RESULTS VB N
A DT N
two-compartment JJ N
PK NNP N
model NN N
with IN N
constant JJ N
iv NN N
input NN N
and CC N
first-order NN N
output NN N
was VBD N
used VBN N
to TO N
describe VB N
the DT N
kinetic JJ N
process NN N
of IN N
plasma JJ N
uricase NN N
. . N

The DT N
low JJ N
value NN N
( ( N
2.8 CD N
U/L NNP N
) ) N
of IN N
drug NN N
concentration NN N
that WDT N
achieved VBD N
50 CD N
% NN N
of IN N
maximum JJ N
effect NN N
( ( N
EC50 NNP N
) ) N
indicated VBD N
that IN N
low JJ N
plasma NN N
uricase NN N
concentrations NNS N
were VBD N
sufficient JJ N
to TO N
produce VB 1_o
pharmacological JJ 1_o
effects NNS 1_o
. . 1_o

A DT N
strong JJ N
relationship NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
=0.9991 NN N
) ) N
between IN N
the DT 1_o
mean JJ 1_o
uric JJ 1_o
acid NN 1_o
concentration NN 1_o
in IN 1_o
blood NN 1_o
and CC 1_o
the DT 1_o
mean JJ 1_o
uric JJ 1_o
acid JJ 1_o
excretion NN 1_o
rate NN 1_o
in IN 1_o
urine NN 1_o
in IN 1_o
the DT N
range NN N
of IN N
11 CD N
to TO N
30 CD N
h NN N
after IN N
single JJ N
dosing NN N
was VBD N
found VBN N
. . N

Infusions NNS 1_p
of IN 1_p
uricase NN 1_i
were VBD 1_i
well RB 1_p
tolerated VBN 1_p
in IN 1_p
all DT 1_p
subjects NNS 1_p
. . 1_p

CONCLUSION VB N
The DT N
PK/PD NNP N
model NN N
predicted VBD N
the DT 1_p
effective JJ 1_p
dose NN 1_p
to TO 1_p
be VB 1_p
0.1 CD 1_p
mg/kg NN 1_p
in IN 1_p
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

The DT N
excretion NN N
rate NN N
of IN N
uric JJ N
acid NN N
in IN N
urine NN N
may MD N
be VB N
used VBN N
as IN N
a DT N
new JJ N
index NN N
for IN N
pharmacological JJ N
effects NNS N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

Learning VBG N
curve NN N
in IN N
multidetector NN 1_i
CT NNP 1_i
coronary JJ 1_i
angiography NN 1_i
( ( N
MDCT-CA NNP N
) ) N
. . N

PURPOSE NNP N
Coronary NNP 1_i
angiography NN 1_i
using VBG 1_i
multidetector NN 1_i
computed VBD 1_i
tomography NN 1_i
( ( 1_i
MDCT-CA NNP 1_i
) ) 1_i
is VBZ N
a DT N
recent JJ N
technique NN N
for IN N
the DT N
nonivasive JJ N
study NN N
of IN N
coronary JJ N
arteries NNS N
. . N

This DT N
study NN N
assessed VBD N
the DT N
diagnostic JJ 1_o
accuracy NN 1_o
of IN 1_o
coronary JJ 1_o
artery NN 1_o
stenosis NN 1_o
evaluation NN 1_o
obtained VBN N
by IN N
three CD 1_p
readers NNS 1_p
at IN 1_p
different JJ 1_p
levels NNS 1_p
of IN 1_p
training NN 1_p
or CC 1_p
at IN 1_p
different JJ 1_p
points NNS 1_p
of IN 1_p
the DT 1_p
learning VBG 1_p
curve NN 1_p
proposed VBN 1_p
by IN 1_p
the DT 1_p
international JJ 1_p
guidelines NNS 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
Three NNP 1_p
radiologists VBZ 1_p
in IN 1_p
training VBG 1_p
with IN 1_p
different JJ 1_p
levels NNS 1_p
of IN 1_p
experience NN 1_p
in IN 1_p
MDCT-CA NNP 1_p
scored VBD N
50 CD N
cases NNS N
at IN N
various JJ N
time NN N
points NNS N
of IN N
the DT N
learning VBG N
curve NN N
: : N
baseline NN N
, , N
4 CD N
weeks NNS N
, , N
8 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
. . N

The DT 1_p
trainee NN 1_p
radiologists VBZ 1_p
evaluated VBD N
the DT N
degree NN 1_o
of IN 1_o
stenosis NN 1_o
on IN 1_o
each DT 1_o
coronary JJ 1_o
segment NN 1_o
, , N
and CC N
overall JJ 1_o
accuracy NN 1_o
was VBD N
calculated VBN N
on IN N
a DT N
per-segment JJ N
, , N
pervessel JJ N
and CC N
per-patient JJ N
basis NN N
. . N

RESULTS NNP N
All NNP N
readers NNS N
improved VBD 1_o
analysis NN 1_o
accuracy NN 1_o
per IN 1_o
segment NN 1_o
( ( N
range NN N
, , N
73-90 CD N
% NN N
) ) N
; : N
sensitivity NN 1_o
reached VBD N
45 CD N
% NN N
per IN N
segment NN N
, , N
84 CD N
% NN N
per IN N
vessel NN N
and CC N
93 CD N
% NN N
per IN N
patient NN N
; : N
specificity NN 1_o
was VBD N
99 CD N
% NN N
per IN N
segment NN N
and CC N
vessel NN N
and CC N
98 CD N
% NN N
per IN N
patient NN N
. . N

Positive JJ 1_o
and CC 1_o
negative JJ 1_o
predictive JJ 1_o
values NNS 1_o
increased VBD 1_o
to TO N
94 CD N
% NN N
and CC N
92 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Although IN N
all DT N
readers NNS N
improved VBN N
in IN N
diagnostic JJ 1_o
performance NN 1_o
with IN N
growing VBG N
experience NN N
with IN N
MDCT-CA NNP N
, , N
a DT N
longer RBR 1_i
training JJ 1_i
period NN 1_i
may MD N
be VB N
necessary JJ N
to TO N
achieve VB N
adequate JJ N
levels NNS N
of IN N
expertise NN N
in IN N
MDCT-CA NNP N
to TO N
be VB N
able JJ N
to TO N
perform VB N
as IN N
independent JJ N
readers NNS N
. . N

-DOCSTART- -X- O O

Information NNP 1_i
source NN 1_i
affects VBZ N
peers NNS N
' POS N
initial JJ N
attitudes NNS N
toward IN N
autism NN 1_o
. . 1_o

Authors NNS N
examined VBD N
the DT N
effects NNS N
of IN N
information NN N
source NN N
on IN N
peers NNS N
' POS N
cognitive NN 1_o
and CC 1_o
behavioral JJ 1_o
attitudes NNS 1_o
toward IN N
an DT N
unfamiliar JJ 1_p
child NN 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Children NNP 1_p
( ( 1_p
N=296 NNP 1_p
; : 1_p
M NNP 1_p
age=10.21 IN 1_p
years NNS 1_p
) ) 1_p
received VBD N
information NN N
about IN N
an DT N
unfamiliar JJ 1_p
child NN 1_p
with IN 1_p
autism NN 1_p
from IN N
one CD N
of IN N
the DT N
following JJ N
sources NNS N
: : N
( ( N
a DT N
) ) N
videotape NN 1_i
, , N
( ( N
b NN N
) ) N
teacher NN 1_i
, , N
( ( N
c NN N
) ) N
hypothetical JJ 1_i
mother NN 1_i
, , N
( ( N
d NN N
) ) N
hypothetical JJ 1_i
father NN 1_i
, , N
or CC N
( ( N
e NN N
) ) N
hypothetical JJ 1_i
doctor NN 1_i
. . 1_i

Interactive JJ N
effects NNS N
between IN N
source NN N
, , N
and CC N
sex NN N
and CC N
grade NN N
were VBD N
found VBN N
for IN N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
. . N

Fifth-graders NNS 1_p
reported VBD N
more RBR N
favorable JJ N
cognitive JJ 1_o
and CC 1_o
behavioral JJ 1_o
attitudes NNS 1_o
when WRB N
information NN N
was VBD N
provided VBN N
by IN N
extra-familial JJ N
sources NNS N
( ( N
i.e. NN N
, , N
doctor NN N
) ) N
versus NN N
parent NN N
sources NNS N
. . N

Mother NNP N
yielded VBD N
more RBR 1_o
persuasive JJ 1_o
effects NNS 1_o
on IN 1_o
behavioral JJ 1_o
attitudes NNS 1_o
for IN N
third-graders NNS N
versus JJ N
fifth-graders NNS N
. . N

Attitudes NNS N
toward IN N
autism NN N
differ VBP N
depending VBG N
on IN N
who WP N
provides VBZ N
information NN N
about IN N
the DT N
disability NN N
. . N

Persuasion NNP N
theory NN N
appears VBZ N
useful JJ N
to TO N
guide VB N
evaluation NN N
of IN N
educational JJ N
interventions NNS N
to TO N
improve VB N
attitudes NNS 1_o
towards IN 1_o
autism NN 1_o
. . 1_o

Implications NNS N
of IN N
the DT N
findings NNS N
, , N
study NN N
limitations NNS N
, , N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS 1_o
of IN N
prophylactic JJ 1_i
management NN 1_i
and CC 1_i
therapeutics NNS 1_i
on IN N
hypertensive JJ 1_o
disease NN 1_o
in IN 1_p
pregnancy NN 1_p
: : 1_p
preliminary JJ N
studies NNS N
. . N

A DT N
controlled JJ N
prospective JJ N
evaluation NN N
of IN N
pregnancy NN N
complicated VBN N
by IN N
chronic JJ N
hypertension NN N
is VBZ N
proposed VBN N
and CC N
preliminary JJ N
data NNS N
on IN N
population NN 1_o
selection NN 1_o
and CC 1_o
pregnancy NN 1_o
outcome NN 1_o
are VBP N
presented VBN N
. . N

Sixty-three JJ 1_p
women NNS 1_p
with IN 1_p
evidence NN 1_p
of IN 1_p
underlying VBG 1_p
hypertensive JJ 1_p
disease NN 1_p
were VBD 1_p
followed VBN 1_p
prospectively RB N
throughout IN N
pregnancy NN N
. . N

Twenty-three JJ N
patients NNS N
were VBD N
followed VBN N
in IN N
a DT N
protocol NN N
of IN N
intensified JJ N
prenatal JJ N
care NN N
and CC N
randomized JJ N
assignment NN N
of IN N
antihypertensive JJ 1_i
agents NNS 1_i
: : 1_i
placebo NN 1_i
, , 1_i
hydralazine NN 1_i
, , 1_i
or CC 1_i
methyldopa NN 1_i
. . 1_i

Forty CD 1_p
patients NNS 1_p
were VBD 1_p
followed VBN 1_p
in IN 1_p
the DT 1_p
high-risk JJ 1_p
pregnancy NN 1_p
clinics NNS 1_p
at IN 1_p
Duke NNP 1_p
University NNP 1_p
. . 1_p

The DT N
incidence NN 1_o
of IN 1_o
preeclampsia NN 1_o
in IN N
the DT N
randomized JJ N
prophylactic JJ N
antihypertensive JJ N
group NN N
was VBD N
statistically RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
nonrandomized JJ N
group NN N
( ( N
8.7 CD N
versus RB N
32.5 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
other JJ N
statistically RB N
significant JJ N
differences NNS 1_o
between IN N
the DT N
groups NNS N
. . N

The DT N
63 CD 1_p
hypertensive JJ 1_p
women NNS 1_p
had VBD N
a DT N
high JJ N
incidence NN N
of IN N
diabetes NNS 1_o
mellitus NNS 1_o
diagnosed VBD N
during IN N
pregnancy NN N
( ( N
49.2 CD N
% NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
authors NNS N
' POS N
general JJ N
obstetric JJ N
population NN N
( ( N
8.1 CD N
% NN N
) ) N
. . N

-DOCSTART- -X- O O

A DT N
program NN N
of IN N
screening VBG N
and CC N
prompting VBG N
improves NNS N
short-term JJ N
physician JJ N
counseling NN N
of IN N
dependent NN 1_p
and CC 1_p
nondependent JJ 1_p
harmful JJ 1_p
drinkers NNS 1_p
. . 1_p

BACKGROUND NNP N
Physicians NNPS N
in IN N
the DT N
general JJ N
medical JJ N
setting VBG N
commonly RB N
encounter RB N
but CC N
rarely RB N
counsel NN N
patients NNS 1_p
with IN 1_p
dependent JJ 1_p
or CC 1_p
harmful JJ 1_p
drinking NN 1_p
behaviors NNS 1_p
. . 1_p

We PRP N
tested VBD N
whether IN N
providing VBG N
physicians NNS N
with IN N
their PRP$ N
patients NNS N
' POS N
results NNS N
on IN N
the DT N
alcohol NN N
module NN N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
would MD N
prompt VB N
them PRP N
to TO N
counsel NN N
these DT N
patients NNS N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBN N
83 CD 1_p
first- JJ 1_p
, , 1_p
second- JJ 1_p
, , 1_p
and CC 1_p
third-year JJ 1_p
medical JJ 1_p
residents NNS 1_p
to TO 1_p
receive VB 1_i
or CC 1_i
not RB 1_i
to TO 1_i
receive VB 1_i
diagnostic JJ 1_i
information NN 1_i
and CC 1_i
counseling VBG 1_i
directives NNS 1_i
on IN 1_i
214 CD 1_p
patients NNS 1_p
who WP 1_p
reported VBD 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
symptom NN 1_p
of IN 1_p
alcohol NN 1_p
impairment NN 1_p
as IN 1_p
defined VBN 1_p
in IN 1_p
the DT 1_p
Diagnostic NNP 1_p
and CC 1_p
Statistical NNP 1_p
Manual NNP 1_p
of IN 1_p
Mental NNP 1_p
Disorders NNP 1_p
, , 1_p
Third NNP 1_p
Edition NNP 1_p
. . 1_p

Using VBG N
binary JJ 1_i
logistic JJ 1_i
regression NN 1_i
, , N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
specific JJ N
covariables NNS N
on IN N
rates NNS N
of IN N
physician JJ N
counseling NN N
. . N

These DT N
variables NNS N
included VBD N
physician JJ N
information NN N
status NN N
, , N
patient JJ N
gender NN N
, , N
and CC N
drinking VBG N
disorder NN N
severity NN N
and CC N
recency NN N
. . N

We PRP N
also RB N
examined VBD N
the DT N
effect NN N
of IN N
physician JJ N
prompting VBG N
on IN N
counseling NN N
of IN N
female JJ 1_p
patients NNS 1_p
, , 1_p
patients NNS 1_p
with IN 1_p
inactive JJ 1_p
disorders NNS 1_p
, , 1_p
and CC 1_p
nondependent NN 1_p
but CC 1_p
harmful JJ 1_p
drinkers NNS 1_p
. . 1_p

We PRP N
determined VBD N
counseling VBG N
by IN N
post-visit JJ N
patient JJ N
interviews NNS N
. . N

RESULTS NNP N
Physician JJ 1_o
prompting NN 1_o
, , 1_o
dependent JJ 1_o
drinking NN 1_o
, , 1_o
and CC 1_o
recent JJ 1_o
disorder NN 1_o
activity NN 1_o
were VBD N
significant JJ N
correlates NNS N
of IN N
physician JJ N
counseling NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
while IN N
male JJ N
gender NN N
was VBD N
a DT N
marginally RB N
significant JJ N
correlate NN N
( ( N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

Informed VBN N
physicians NNS N
counseled VBD N
female JJ N
patients NNS N
, , N
harmful JJ N
but CC N
nondependent JJ N
drinkers NNS N
, , N
and CC N
patients NNS N
with IN N
inactive JJ N
disorders NNS N
more RBR N
often RB N
than IN N
their PRP$ N
uninformed JJ N
colleagues NNS N
, , N
although IN N
only RB N
the DT N
last JJ N
variable JJ N
achieved VBD N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Providing VBG N
physicians NNS N
with IN N
the DT N
results NNS N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
resulted VBD N
in IN N
short-term JJ N
improvement NN N
in IN N
their PRP$ N
rates NNS N
of IN N
counseling VBG N
patients NNS N
with IN N
a DT N
history NN N
of IN N
dependent NN N
or CC N
nondependent NN N
but CC N
harmful JJ N
drinking NN N
. . N

Further NNP N
research NN N
is VBZ N
necessary JJ N
to TO N
determine VB N
long-term JJ N
gains NNS N
in IN N
rates NNS N
of IN N
physician JJ 1_i
counseling NN 1_i
and CC 1_i
improvements NNS 1_i
in IN N
the DT N
course NN N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Translucency NN N
of IN N
zirconia NN 1_p
copings NNS 1_p
made VBN N
with IN N
different JJ N
CAD/CAM NNP N
systems NNS N
. . N

STATEMENT NNP N
OF IN N
PROBLEM NNP N
Zirconia NNP 1_p
cores NNS 1_p
are VBP N
reported VBN N
to TO N
be VB N
less RBR N
translucent JJ N
than IN N
glass NN N
, , N
lithium NN N
disilicate NN N
, , N
or CC N
alumina JJ N
cores NNS N
. . N

This DT N
could MD N
affect VB N
the DT N
esthetic JJ N
appearance NN N
and CC N
the DT N
clinical JJ N
choices NNS N
made VBD N
when WRB N
using VBG N
zirconia-based JJ N
restorations NNS N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
in IN N
vitro NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
translucency NN 1_o
of IN N
zirconia NN 1_i
copings NNS 1_i
for IN N
single JJ 1_p
crowns NNS 1_p
fabricated VBN N
using VBG N
different JJ N
CAD/CAM NNP N
systems NNS N
, , N
using VBG N
lithium NN 1_i
disilicate NN 1_i
glass NN 1_i
ceramic NN 1_i
as IN N
a DT N
control NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Using NNP N
impressions NNS N
made VBD N
from IN N
a DT N
stainless JJ N
steel NN N
complete-crown JJ N
master NN N
die NN N
, , N
9 CD 1_p
stone NN 1_p
cast NN 1_p
replicas NN 1_p
were VBD 1_p
fabricated VBN 1_p
, , 1_p
numbered VBN 1_p
, , 1_p
and CC 1_p
distributed VBD 1_p
into IN 1_p
8 CD 1_p
ceramic JJ 1_p
ZrO NNP 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
CAD/CAM NNP 1_p
system NN 1_p
groups NNS 1_p
( ( 1_p
Lava NNP 1_p
Frame NNP 1_p
0.3 CD 1_p
and CC 1_p
0.5 CD 1_p
, , 1_p
IPS NNP 1_p
e.max VBZ 1_p
ZirCAD NNP 1_p
, , 1_p
VITA NNP 1_p
YZ NNP 1_p
, , 1_p
Procera NNP 1_p
AllZircon NNP 1_p
, , 1_p
Digizon NNP 1_p
, , 1_p
DC NNP 1_p
Zircon NNP 1_p
, , 1_p
and CC 1_p
Cercon NNP 1_p
Base NNP 1_p
) ) 1_p
and CC 1_p
to TO 1_p
a DT 1_p
lithium NN 1_p
disilicate JJ 1_p
glass-ceramic JJ 1_p
control NN 1_p
group NN 1_p
( ( 1_p
IPS NNP 1_p
e.max RB 1_p
Press NNP 1_p
) ) 1_p
using VBG 1_p
a DT 1_p
simple JJ 1_p
computer-generated JJ 1_p
randomization NN 1_p
method NN 1_p
. . 1_p

From IN N
each DT N
die NN N
, , N
the DT N
manufacturer NN N
's POS N
authorized JJ N
milling NN N
centers NNS N
supplied VBD N
5 CD N
copings NNS N
per IN N
group NN N
without IN N
applying VBG N
any DT N
dying VBG N
technique NN N
to TO N
the DT N
ceramic JJ N
base NN N
material NN N
. . N

The DT N
copings NNS N
were VBD N
prepared VBN N
to TO N
allow VB N
for IN N
a DT N
40-mum JJ N
cement NN N
layer NN N
and CC N
were VBD N
of IN N
different JJ N
thicknesses NNS N
according VBG N
to TO N
system NN N
specifications NNS N
. . N

Translucency NN 1_o
was VBD N
measured VBN N
by IN N
the DT N
direct JJ N
transmission NN N
method NN N
with IN N
a DT N
digital JJ N
photoradiometer NN N
mounted VBN N
in IN N
a DT N
dark JJ N
chamber NN N
. . N

The DT N
light JJ N
source NN N
was VBD N
a DT N
150-W JJ N
halogen NN N
lamp NN N
beam NN N
. . N

Measurements NNS N
were VBD N
repeated VBN N
3 CD N
times NNS N
for IN N
each DT N
specimen NNS N
. . N

Data NNS N
obtained VBN N
were VBD N
analyzed VBN N
using VBG N
1-way JJ N
ANOVA NNP N
and CC N
the DT N
Bonferroni NNP N
multiple NN N
comparison NN N
test NN N
( ( N
alpha=.05 NN N
) ) N
. . N

RESULTS NNP N
Among IN N
ZrO NNP N
( ( N
2 CD N
) ) N
copings NNS N
, , N
Lava NNP N
( ( N
0.3 CD N
mm NN N
and CC N
0.5 CD N
mm NNS N
thick NN N
) ) N
showed VBD N
the DT N
highest JJS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
values NNS 1_o
of IN 1_o
translucency NN 1_o
measured VBN N
as IN N
light JJ N
flow JJ N
units NNS N
( ( N
3.572 CD N
+ NN N
or CC N
- : N
018 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
and CC N
3.181 CD N
+ NN N
or CC N
- : N
0.13 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
, , N
respectively RB N
) ) N
. . N

These DT N
values NNS N
represent VBP N
71.7 CD N
% NN N
and CC N
63.9 CD N
% NN N
, , N
respectively RB N
, , N
of IN N
the DT N
glass-ceramic JJ N
control NN N
group NN N
( ( N
4.98 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
) ) N
. . N

CONCLUSIONS NNP N
All NNP N
ZrO NNP 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
copings NNS 1_p
demonstrated VBN N
different JJ N
levels NNS N
of IN N
light JJ N
transmission NN N
, , N
with IN N
the DT N
2 CD N
Lava NNP N
specimens NNS N
showing VBG N
the DT N
highest JJS N
values NNS N
. . N

Translucency NN 1_o
of IN N
zirconia NN 1_p
copings NNS 1_p
was VBD N
significantly RB N
lower JJR N
( ( N
P=.001 NNP N
) ) N
than IN N
that DT N
of IN N
the DT N
lithium NN N
disilicate JJ N
glass-ceramic JJ N
control NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
intranasal NN 1_i
oxytocin NN 1_i
on IN N
the DT N
neural JJ N
basis NN N
of IN N
face NN N
processing NN N
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

BACKGROUND NNP N
Autism NNP 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
is VBZ N
associated VBN N
with IN N
altered JJ N
face NN N
processing NN N
and CC N
decreased JJ N
activity NN N
in IN N
brain NN N
regions NNS N
involved VBN N
in IN N
face NN N
processing NN N
. . N

The DT N
neuropeptide JJ 1_i
oxytocin NN 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
promote VB N
face NN N
processing NN N
and CC N
modulate NN N
brain NN N
activity NN N
in IN N
healthy JJ 1_p
adults NNS 1_p
. . 1_p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
oxytocin NN 1_i
on IN N
the DT N
neural JJ N
basis NN N
of IN N
face NN N
processing NN N
in IN N
adults NNS 1_p
with IN 1_p
Asperger NNP 1_p
syndrome NN 1_p
( ( 1_p
AS IN 1_p
) ) 1_p
. . 1_p

METHODS NNP N
A NNP N
group NN N
of IN N
14 CD 1_p
individuals NNS 1_p
with IN 1_p
AS NNP 1_p
and CC 1_p
a DT 1_p
group NN 1_p
of IN 1_p
14 CD 1_p
neurotypical JJ 1_p
control NN 1_p
participants NNS 1_p
performed VBD N
a DT N
face-matching JJ N
and CC N
a DT N
house-matching JJ N
task NN N
during IN N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
24 CD N
IU NNP N
intranasally RB N
administered VBD N
oxytocin NNS 1_i
were VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
, , N
within-subject JJ N
, , N
cross-over JJ N
design NN N
. . N

RESULTS NNP N
Under IN N
placebo NN 1_i
, , N
the DT N
AS NNP N
group NN N
showed VBD N
decreased JJ N
activity NN 1_o
in IN 1_o
the DT 1_o
right JJ 1_o
amygdala NN 1_o
, , 1_o
fusiform NN 1_o
gyrus NN 1_o
, , 1_o
and CC 1_o
inferior JJ 1_o
occipital JJ 1_o
gyrus NN 1_o
compared VBN N
with IN N
the DT N
control NN N
group NN N
during IN N
face NN N
processing NN N
. . N

After IN N
oxytocin JJ N
treatment NN N
, , N
right JJ 1_o
amygdala NN 1_o
activity NN 1_o
to TO 1_o
facial JJ 1_o
stimuli NNS 1_o
increased VBN N
in IN N
the DT N
AS NNP N
group NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
oxytocin NN N
increases VBZ N
the DT N
saliency NN N
of IN N
social JJ N
stimuli NNS N
and CC N
in IN N
ASD NNP 1_p
and CC N
suggest VBP N
that IN N
oxytocin NN 1_i
might MD N
promote VB N
face NN N
processing NN N
and CC N
eye NN N
contact NN N
in IN N
individuals NNS N
with IN N
ASD NNP 1_p
as IN N
prerequisites NNS N
for IN N
neurotypical JJ N
social JJ N
interaction NN N
. . N

-DOCSTART- -X- O O

Oscillatory NN 1_p
potentials NNS 1_p
, , 1_p
retinopathy NN 1_p
, , 1_p
and CC 1_p
long-term JJ 1_p
glucose NN 1_p
control NN 1_p
in IN 1_p
insulin-dependent JJ 1_p
diabetes NNS 1_p
. . 1_p

The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess JJ N
effects NNS N
of IN N
long-term JJ 1_i
lowering NN 1_i
of IN 1_i
glucosylated JJ 1_o
hemoglobin NN 1_o
( ( 1_i
HbA1 NNP 1_i
% NN 1_i
) ) 1_i
on IN N
neurosensory JJ N
function NN N
in IN N
insulin-dependent JJ 1_p
diabetes NNS 1_p
. . 1_p

Individual NNP 1_i
( ( 1_i
OP-1 NNP 1_i
, , 1_i
OP-2 NNP 1_i
, , 1_i
OP-3 NNP 1_i
) ) 1_i
and CC 1_i
summed VBN 1_i
( ( 1_i
OP-sum NNP 1_i
) ) 1_i
amplitudes NNS 1_i
of IN 1_i
oscillatory JJ 1_i
potentials NNS 1_i
( ( 1_i
OPs NNP 1_i
) ) 1_i
of IN 1_i
electroretinography NN 1_i
were VBD 1_i
recorded VBN 1_i
at IN N
study JJ N
start NN N
and CC N
7-years NNS N
later RB N
in IN N
45 CD 1_p
patients NNS 1_p
( ( N
the DT N
Oslo NNP 1_p
study NN N
) ) N
. . N

As IN N
an DT N
overall JJ N
7-year JJ N
change NN N
, , N
amplitudes NNS 1_o
of IN 1_o
OP-2 NNP 1_o
, , 1_o
OP-3 NNP 1_o
and CC 1_o
OP-sum NNP 1_o
were VBD 1_o
reduced VBN 1_o
( ( N
p JJ N
< NNP N
0.0001-0.01 NN N
) ) N
, , N
retinopathy JJ 1_o
worsened VBD 1_o
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
intraocular JJ 1_o
pressure NN 1_o
decreased VBN 1_o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
increased VBD 1_o
( ( N
p JJ N
< NNP N
0.0002 CD N
) ) N
, , N
and CC N
glycemic JJ 1_o
control NN 1_o
improved VBN N
from IN N
HbA1 NNP N
of IN N
11.2 CD N
+/- JJ N
2.2 CD N
% NN N
at IN N
study JJ N
start NN N
to TO N
a DT N
7-year JJ N
cumulative JJ N
mean NN N
of IN N
9.5 CD N
+/- JJ N
1.5 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
did VBD N
not RB N
identify VB N
any DT N
independent JJ N
relations NNS N
between IN N
change NN N
in IN N
OP-1 NNP 1_o
, , 1_o
OP-2 NNP 1_o
, , 1_o
OP-3 NNP 1_o
, , 1_o
OP-sum NNP 1_o
and CC N
change NN 1_o
in IN 1_o
glycemic JJ 1_o
control NN 1_o
or CC 1_o
background NN 1_o
variables NNS 1_o
, , N
including VBG N
change NN N
in IN N
age NN N
and CC N
duration NN N
of IN N
diabetes NNS N
. . N

However RB N
, , N
cross-sectional JJ N
observations NNS N
at IN N
7 CD N
years NNS N
showed VBD N
negative JJ N
correlations NNS N
between IN N
all DT N
OPs NNP 1_o
and CC N
age NN N
( ( N
p JJ N
< NNP N
0.0001-0.003 NN N
) ) N
, , N
and CC N
between IN N
OP-3 NNP 1_o
and CC 1_o
duration NN 1_o
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
counts NNS 1_o
of IN 1_o
microaneurysms NNS 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
various JJ N
clinical JJ N
background NN N
variables NNS N
may MD N
influence VB N
individual JJ N
and CC N
summed VBD N
amplitudes NNS N
of IN N
OPs NNP N
differently RB N
. . N

Reduced NNP 1_o
neurosensory JJ 1_o
retinal JJ 1_o
function NN 1_o
( ( 1_o
OPs NNP 1_o
) ) 1_o
seemed VBD N
to TO N
appear VB N
after IN N
7-years NNS N
, , N
independently RB N
of IN N
vascular JJ 1_o
defects NNS 1_o
of IN 1_o
retinopathy JJ 1_o
and CC N
long-term JJ 1_o
improvement NN 1_o
in IN 1_o
glucose JJ 1_o
control NN 1_o
. . 1_o

-DOCSTART- -X- O O

The DT N
use NN N
of IN N
adrenocorticotrophic JJ 1_i
hormone NN 1_i
( ( 1_i
4-9 JJ 1_i
) ) 1_i
analog NN 1_i
ORG NNP 1_i
2766 CD 1_i
in IN N
autistic JJ 1_p
children NNS 1_p
: : 1_p
effects NNS N
on IN N
the DT N
organization NN N
of IN N
behavior NN N
. . N

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
trial NN N
, , N
14 CD 1_p
autistic JJ 1_p
children NNS 1_p
were VBD N
treated VBN N
with IN N
the DT N
neuropeptide NN 1_i
ORG NNP 1_i
2766 CD 1_i
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
adrenocorticotrophic JJ N
hormone NN N
( ( N
ACTH NNP N
) ) N
( ( N
4-9 JJ N
) ) N
. . N

ORG JJ 1_i
2766 CD 1_i
treatment NN 1_i
( ( N
20 CD N
mg NNS N
per IN N
day NN N
during IN N
4 CD N
weeks NNS N
) ) N
was VBD N
associated VBN N
with IN N
an DT N
increased JJ N
amount NN N
and CC N
an DT N
improved JJ N
quality NN N
of IN N
the DT N
social JJ N
interaction NN N
of IN N
the DT N
autistic JJ 1_p
children NNS 1_p
with IN N
a DT N
familiar JJ N
experimenter NN N
. . N

These DT N
changes NNS N
in IN N
interaction NN N
were VBD N
clinically RB N
relevant JJ N
. . N

Following VBG N
treatment NN N
with IN N
ORG NNP 1_i
2766 CD 1_i
gaze NN 1_o
and CC 1_o
smile JJ 1_o
behaviors NNS 1_o
of IN N
child NN N
and CC N
experimenter NN N
showed VBD N
stronger JJR 1_o
temporal JJ 1_o
contingencies NNS 1_o
. . 1_o

Further NNP N
, , N
after IN N
ORG NNP 1_i
2766 CD 1_i
, , N
stereotypies NNS N
were VBD N
temporally RB N
disconnected VBN N
from IN N
verbal JJ 1_o
initiatives NNS 1_o
. . 1_o

The DT N
data NN N
supported VBD N
the DT N
notion NN N
of IN N
a DT N
stimulating JJ N
effect NN N
of IN N
ORG NNP 1_i
2766 CD 1_i
on IN N
social JJ N
interaction NN N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
for IN N
the DT N
endogenous JJ N
opioid JJ N
theory NN N
of IN N
autism NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Carbon NNP 1_i
dioxide NN 1_i
insufflation NN 1_i
in IN N
open-chamber JJ N
cardiac JJ N
surgery NN N
: : N
a DT N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
neurocognitive JJ N
effects NNS N
. . N

OBJECTIVE IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
first RB N
to TO N
analyze VB N
neurocognitive JJ 1_o
outcomes NNS 1_o
of IN N
patients NNS 1_p
after IN 1_p
open-chamber JJ 1_p
cardiac JJ 1_p
surgery NN 1_p
to TO N
determine VB N
whether IN N
carbon NN 1_i
dioxide NN 1_i
pericardial JJ 1_i
insufflation NN 1_i
reduces NNS N
incidence NN N
of IN N
neurocognitive JJ 1_o
decline NN 1_o
( ( N
primary JJ N
end NN N
point NN N
) ) N
as IN N
measured VBN N
6 CD N
weeks NNS N
postoperatively RB N
and CC N
second JJ N
to TO N
assess VB N
the DT N
utility NN N
of IN N
carbon NN 1_i
dioxide NN 1_i
insufflation NN 1_i
in IN N
cardiac JJ N
chamber NN N
deairing NN N
as IN N
assessed VBN N
by IN N
transesophageal JJ N
echocardiography NN N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
compared VBN N
neurocognitive JJ N
outcomes NNS N
in IN N
patients NNS 1_p
undergoing VBG 1_p
open-chamber JJ 1_p
( ( 1_p
left-sided JJ 1_p
) ) 1_p
cardiac NN 1_p
surgery NN 1_p
who WP 1_p
were VBD 1_p
assigned VBN 1_p
carbon NN 1_i
dioxide NN 1_i
insufflation NN 1_i
or CC 1_i
placebo NN 1_i
( ( 1_p
control VB 1_p
group NN 1_p
) ) 1_p
in IN 1_p
addition NN 1_p
to TO 1_p
standardized VB 1_p
mechanical JJ 1_p
deairing VBG 1_p
maneuvers NNS 1_p
. . 1_p

RESULTS NNP N
One CD 1_p
hundred VBD 1_p
twenty-five JJ 1_p
patients NNS 1_p
underwent JJ 1_p
surgery NN 1_p
and CC N
were VBD N
randomly RB N
allocated VBN N
. . N

Neurocognitive JJ N
testing NN N
showed VBD N
no DT N
clinically RB N
significant JJ N
differences NNS N
in IN N
z NN 1_o
scores NNS 1_o
between IN N
preoperative JJ N
and CC N
postoperative JJ N
testing NN N
. . N

Linear JJ N
regression NN N
was VBD N
used VBN N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
neurocognitive JJ N
decline NN N
. . N

Factors NNS 1_p
most RBS 1_p
strongly RB 1_p
associated VBN 1_p
with IN 1_p
neurocognitive JJ 1_p
decline NN 1_p
were VBD 1_p
hypercholesterolemia JJ 1_o
, , 1_o
aortic JJ 1_o
atheroma NN 1_o
grade NN 1_o
, , 1_o
and CC 1_o
coronary JJ 1_o
artery NN 1_o
disease NN 1_o
. . 1_o

There EX N
was VBD N
significantly RB N
more JJR N
intracardiac JJ 1_o
gas NN 1_o
noted VBD N
on IN N
intraoperative JJ N
transesophageal NN N
echocardiography NN N
in IN N
all DT N
cardiac JJ N
chambers NNS N
( ( N
left JJ N
atrium NN N
, , N
left VBD N
ventricle NN N
, , N
and CC N
aorta NN N
) ) N
at IN N
all DT N
measured VBN N
times NNS N
( ( N
after IN N
crossclamp NN N
removal NN N
, , N
during IN N
weaning VBG N
from IN N
cardiopulmonary JJ N
bypass NN N
, , N
and CC N
at IN N
declaration NN N
of IN N
adequate JJ N
deairing NN N
by IN N
the DT N
anesthetist NN N
) ) N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
carbon NN N
dioxide NN N
group NN N
( ( N
P NNP N
< NNP N
.04 NNP N
) ) N
. . N

Deairing VBG 1_o
time NN 1_o
was VBD N
also RB N
significantly RB N
longer RBR N
in IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
minutes NNS N
[ VBP N
interquartile JJ N
range NN N
, , N
9-18 CD N
] NNP N
versus NN N
9 CD N
minutes NNS N
[ VBP N
interquartile JJ N
range NN N
, , N
7-14 JJ N
minutes NNS N
] VBP N
; : N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Carbon NNP 1_i
dioxide IN 1_i
pericardial JJ N
insufflation NN N
in IN N
open-chamber JJ N
cardiac JJ N
surgery NN N
does VBZ N
not RB N
affect VB N
postoperative JJ N
neurocognitive JJ 1_o
decline NN 1_o
. . 1_o

The DT 1_p
most RBS 1_p
important JJ 1_p
factor NN 1_p
is VBZ 1_p
atheromatous JJ 1_p
vascular JJ 1_p
disease NN 1_p
. . 1_p

-DOCSTART- -X- O O

Fluorouracil NNP 1_i
as IN N
an DT N
adjuvant NN N
to TO N
surgery VB 1_i
in IN N
carcinoma NN 1_p
of IN 1_p
the DT 1_p
colon NN 1_p
. . 1_p

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
comparing VBG N
intravesical JJ 1_i
instillations NNS 1_i
of IN N
mitoxantrone NN 1_i
and CC 1_i
doxorubicin NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
superficial JJ 1_p
bladder NN 1_p
cancer NN 1_p
. . 1_p

BACKGROUND NNP N
This DT N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN 1_o
and CC N
side JJ 1_o
effects NNS 1_o
of IN N
intravesical JJ 1_i
mitoxantrone NN 1_i
instillation NN 1_i
with IN N
those DT N
of IN N
doxorubicin NN 1_i
in IN N
superficial JJ 1_p
bladder NN 1_p
cancer NN 1_p
following VBG 1_p
transurethral JJ 1_p
resection NN 1_p
. . 1_p

METHODS NNP N
Sixty-three JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
into IN N
mitoxantrone NN 1_i
and CC 1_i
doxorubicin NN 1_i
groups NNS N
. . N

Most JJS N
of IN N
the DT N
patients NNS 1_p
enrolled VBN 1_p
were VBD 1_p
elderly JJ 1_p
people NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
71 CD 1_p
years NNS 1_p
) ) 1_p
. . 1_p

The DT N
instilled JJ N
doses NNS N
of IN N
doxorubicin NN 1_i
and CC 1_i
mitoxantrone NN 1_i
were VBD N
30 CD N
and CC N
14 CD N
mg NN N
, , N
respectively RB N
. . N

Disease NNP 1_o
recurrence NN 1_o
and CC 1_o
side NN 1_o
effects NNS 1_o
were VBD N
compared VBN N
using VBG N
Fisher NNP N
's POS N
exact JJ N
test NN N
. . N

The DT N
interval NN 1_o
to TO 1_o
recurrence NN 1_o
was VBD N
shown VBN N
by IN N
Kaplan-Meier NNP N
survivorship NN N
curves NNS N
, , N
and CC N
the DT N
log-rank JJ N
test NN N
was VBD N
used VBN N
to TO N
compare VB N
the DT N
time NN 1_o
to TO 1_o
recurrence VB 1_o
. . 1_o

RESULTS VB N
The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
36 CD N
months NNS N
. . N

Thirty-three JJ N
patients NNS N
received VBD N
mitoxantrone NN 1_i
, , N
whereas JJ N
30 CD N
patients NNS N
used VBN N
doxorubicin NN 1_i
. . 1_i

The DT N
recurrence NN 1_o
rate NN 1_o
in IN N
the DT N
doxorubicin NN 1_i
group NN N
was VBD N
30 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
19.8 CD N
% NN N
-38.8 NNP N
% NN N
) ) N
, , N
while IN N
it PRP N
was VBD N
27.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
17.5 CD N
% NN N
-36.8 NNP N
% NN N
) ) N
in IN N
the DT N
mitoxantrone NN 1_i
group NN N
. . N

The DT N
median JJ 1_o
recurrence-free JJ 1_o
survival NN 1_o
in IN N
the DT N
mitoxantrone NN 1_i
group NN N
and CC N
in IN N
the DT N
doxorubicin NN 1_i
group NN N
was VBD N
22 CD N
and CC N
20 CD N
months NNS N
, , N
respectively RB N
( ( N
p=0.580 NN N
) ) N
. . N

Higher JJR N
recurrence NN 1_o
rates NNS 1_o
were VBD N
found VBN N
for IN N
Grade NNP N
III NNP N
and CC N
multiple JJ N
primary JJ N
tumors NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
response NN 1_o
rates NNS 1_o
( ( N
p=0.784 NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
side NN 1_o
effects NNS 1_o
was VBD N
20 CD N
% NN N
in IN N
the DT N
doxorubicin NN 1_i
group NN N
and CC N
21.2 CD N
% NN N
in IN N
the DT N
mitoxantrone NN 1_i
group NN N
. . N

However RB N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
( ( N
p JJ N
> NNP N
0.99 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
revealed VBD N
that IN N
the DT N
efficacy NN 1_o
and CC 1_o
side JJ 1_o
effects NNS 1_o
of IN N
mitoxantrone NN 1_i
were VBD N
similar JJ N
to TO N
those DT N
of IN N
doxorubicin NN 1_i
. . 1_i

Especially RB N
for IN N
patients NNS 1_p
with IN 1_p
pulmonary JJ 1_p
tuberculosis NN 1_p
or CC 1_p
aged VBN 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
bladder NN 1_p
tumors NNS 1_p
, , N
mitoxantrone NN 1_i
and CC N
doxorubicin NN 1_i
may MD N
be VB N
the DT N
tolerable JJ N
and CC N
effective JJ N
intravesical JJ N
agents NNS N
. . N

-DOCSTART- -X- O O

Microbial JJ N
protein NN N
synthesis NN N
, , N
nitrogen JJ N
capture NN N
efficiency NN N
and CC N
nutrient JJ N
utilisation NN N
in IN N
sheep JJ 1_p
fed NN 1_p
on IN 1_p
finger NN 1_i
millet NN 1_i
straw NN 1_i
( ( 1_i
Eleucine NNP 1_i
coracana NN 1_i
) ) 1_i
-based VBD 1_i
diet JJ 1_p
with IN N
different JJ N
rumen-degradable JJ N
nitrogen NN N
levels NNS N
. . N

BACKGROUND NNP N
Microbial NNP N
protein NN N
synthesised VBD N
in IN N
the DT N
rumen NNS N
is VBZ N
a DT N
very RB N
important JJ N
protein NN N
source NN N
for IN N
ruminants NNS N
. . N

It PRP N
is VBZ N
essential JJ N
to TO N
provide VB N
an DT N
adequate JJ N
amount NN N
of IN N
rumen-degradable JJ N
nitrogen NN N
( ( N
RDN NNP N
) ) N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
in IN N
the DT N
rumen NNS N
on IN N
straw-based JJ N
diets NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
RDN NNP N
requirement NN N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
( ( N
MPS NNP N
) ) N
, , N
nitrogen JJ N
capture NN N
efficiency NN N
( ( N
NCE NNP N
) ) N
and CC N
nutrient JJ N
utilisation NN N
in IN N
Nellore NNP 1_p
rams NNS 1_p
fed VBP 1_p
on IN 1_p
a DT 1_p
finger NN 1_i
millet NN 1_i
straw NN 1_i
( ( 1_i
FMS NNP 1_i
) ) 1_i
-based VBD 1_i
diet JJ 1_i
. . 1_i

RESULTS VB N
Thirty-six JJ 1_p
Nellore NNP 1_p
sheep NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
of IN N
nine CD N
animals NNS N
each DT N
using VBG N
a DT N
balanced VBN N
, , N
completely RB N
randomised JJ N
design NN N
. . N

The DT N
animals NNS N
in IN N
group NN N
1 CD N
( ( N
RDN0 NNP N
) ) N
were VBD N
fed VBN N
with IN N
ad NN 1_i
libitum NN 1_i
FMS NNP 1_i
. . 1_i

Those DT N
in IN N
groups NNS N
2 CD N
, , N
3 CD N
and CC N
4 CD N
( ( N
RDN1 NNP N
, , N
RDN2 NNP N
and CC N
RDN3 NNP N
) ) N
were VBD N
supplemented VBN N
with IN N
groundnut NNS 1_i
cake VBP 1_i
to TO N
provide VB N
RDN NNP 1_o
levels NNS 1_o
of IN N
14 CD N
, , N
18 CD N
and CC N
23 CD N
g NN N
RDN NNP N
kg?? NNP N
digestible JJ N
organic JJ N
matter NN N
intake NN N
( ( N
DOMI NNP N
) ) N
or CC N
21 CD N
, , N
27 CD N
and CC N
35 CD N
g NN N
RDN NNP N
kg?? NNP N
digestible JJ N
organic JJ N
matter NN N
apparently RB N
digested VBN N
in IN N
the DT N
rumen NNS N
( ( N
DOMR NNP N
) ) N
respectively RB N
along IN N
with IN 1_i
FMS NNP 1_o
. . 1_o

The DT 1_o
digestibility NN 1_o
coefficients NNS 1_o
of IN 1_o
all DT 1_o
nutrients NNS 1_o
and CC 1_o
MPS NNP 1_o
increased VBD 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
0.05 CD N
) ) N
quadratically RB N
with IN N
increasing VBG 1_o
level NN 1_o
of IN 1_o
RDN NNP 1_o
supplementation NN 1_o
. . 1_o

NCE NNP 1_o
decreased VBD 1_o
linearly RB 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
the DT N
level NN N
of IN 1_o
RDN NNP 1_o
increased VBD 1_o
. . 1_o

CONCLUSION NNP 1_o
The DT N
results NNS N
suggest VBP N
that IN N
12 CD N
g NNS N
RDN NNP N
kg?? VBP N
DOMI NNP N
or CC N
19 CD N
g NNS N
RDN NNP N
kg?? VBD N
DOMR NNP N
may MD N
be VB N
adequate JJ N
for IN N
optimum JJ N
MPS NNP N
, , N
NCE NNP N
and CC N
digestibility NN N
of IN N
nutrients NNS N
in IN N
sheep JJ 1_p
fed NN 1_p
on IN 1_p
an DT 1_i
FMS-based JJ 1_i
diet NN 1_i
. . 1_i

-DOCSTART- -X- O O

Effects NNS N
of IN N
misoprostol NN 1_o
on IN N
human JJ 1_p
circulation NN 1_p
. . 1_p

Prostaglandins NNP N
( ( N
PGs NNP N
) ) N
of IN N
the DT N
E-type NNP N
are VBP N
potent JJ N
vasodilators NNS N
in IN N
most JJS N
species NNS N
and CC N
in IN N
most JJS N
vascular JJ N
beds NNS N
. . N

However RB N
, , N
vasoconstrictor JJ N
effects NNS N
of IN N
PGEs NNP N
have VBP N
also RB N
been VBN N
noted VBN N
at IN N
selected VBN N
sites NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
misoprostol NN 1_o
, , N
a DT N
PGE1 NNP N
analog NN N
with IN N
antiulcer NN N
activity NN N
, , N
on IN N
the DT N
human JJ N
cardiovascular NN N
system NN N
. . N

Twenty NNP 1_p
healthy JJ 1_p
subjects NNS 1_p
participated VBN 1_p
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

Following VBG N
a DT N
12 CD N
hour NN N
fast NN N
, , N
heart NN N
rate NN N
, , N
arterial JJ N
blood NN N
pressure NN N
, , N
light JJ N
reflex JJ N
plethysmography NN N
of IN N
the DT N
finger NN N
, , N
resting VBG N
blood NN N
flow NN N
volume NN N
in IN N
the DT N
lower JJR N
arm NN N
and CC N
leg NN N
and CC N
peripheral JJ 1_o
vascular JJ 1_o
resistance NN 1_o
were VBD N
measured VBN N
at IN N
10 CD N
min NN N
. . N

intervals NNS N
for IN N
1 CD N
hour NN N
prior RB N
to TO N
drug NN N
administration NN N
, , N
to TO N
permit VB N
calculating VBG N
baseline NN N
values NNS N
. . N

Misoprostol NNP 1_i
( ( 1_i
400 CD 1_i
mcg NN 1_i
) ) 1_i
or CC 1_i
its PRP$ 1_i
matching JJ 1_i
placebo NN 1_i
were VBD N
administered VBN N
orally RB N
, , N
and CC N
the DT N
measurements NNS N
were VBD N
repeated VBN N
at IN N
10 CD N
min NN N
. . N

intervals NNS N
over IN N
the DT N
next JJ N
2 CD N
hours NNS N
. . N

A DT N
decrease NN N
in IN N
leg NN 1_o
blood NN 1_o
flow NN 1_o
volume NN 1_o
and CC 1_o
a DT 1_o
corresponding JJ 1_o
increase NN 1_o
in IN 1_o
leg JJ 1_o
peripheral JJ 1_o
vascular JJ 1_o
resistance NN 1_o
were VBD N
noted VBN N
in IN N
the DT N
misoprostol NN 1_i
group NN N
. . N

A DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
heart NN 1_o
rate NN 1_o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
was VBD N
also RB N
noted VBN N
. . N

These DT N
small JJ N
changes NNS N
were VBD N
not RB N
considered VBN N
to TO N
be VB N
of IN N
clinical JJ N
importance NN N
. . N

No DT N
adverse JJ 1_o
experiences NNS 1_o
were VBD N
reported VBN N
. . N

In IN N
conclusion NN N
, , N
a DT N
single JJ N
dose NN N
of IN N
misoprostol NN 1_i
( ( N
400 CD N
mcg NN N
) ) N
has VBZ N
no DT N
clinically RB N
significant JJ N
vasoconstrictive JJ 1_o
or CC 1_o
vasodilative JJ 1_o
properties NNS N
in IN N
man NN N
. . N

-DOCSTART- -X- O O

Comparative NNP N
study NN N
for IN N
the DT N
effect NN N
of IN N
photodynamic JJ 1_i
therapy NN 1_i
, , 1_i
imiquimod JJ 1_i
immunotherapy NN 1_i
and CC 1_i
combination NN 1_i
of IN 1_i
both DT 1_i
therapies NNS 1_i
on IN N
40 CD 1_p
lesions NNS 1_p
of IN 1_p
actinic JJ 1_p
keratosis NN 1_p
in IN 1_p
Japanese JJ 1_p
patients NNS 1_p
. . 1_p

We PRP N
treated VBD N
12 CD 1_p
, , 1_p
15 CD 1_p
and CC 1_p
13 CD 1_p
Japanese JJ 1_p
actinic JJ 1_p
keratosis NN 1_p
( ( 1_p
AK NNP 1_p
) ) 1_p
lesions NNS 1_p
with IN N
5-aminolevulinic JJ 1_i
acid JJ 1_i
photodynamic JJ 1_i
therapy NN 1_i
( ( 1_i
PDT NNP 1_i
) ) 1_i
, , 1_i
5 CD 1_i
% NN 1_i
imiquimod JJ 1_i
cream NN 1_i
and CC 1_i
combination NN 1_i
of IN 1_i
both DT 1_i
therapies NNS 1_i
, , N
respectively RB N
, , N
and CC N
compared VBN N
the DT N
effects NNS N
. . N

Patients NNS N
underwent VBD N
the DT N
second JJ N
course NN N
, , N
when WRB N
AK NNP N
lesions NNS N
remained VBD N
after IN N
the DT N
first JJ N
course NN N
. . N

Efficacy NNP 1_o
was VBD N
evaluated VBN N
1 CD N
month NN N
after IN N
each DT N
treatment NN N
. . N

Combination NNP 1_i
therapy NN 1_i
cleared VBD N
all DT N
AK NNP N
lesions NNS N
only RB N
after IN N
the DT N
first JJ N
course NN N
, , N
while IN 1_i
PDT NNP 1_i
and CC 1_i
imiquimod JJ 1_i
therapy NN 1_i
cleared VBD N
41.7 CD N
% NN N
and CC N
66.7 CD N
% NN N
of IN N
AK NNP N
lesions NNS N
after IN N
the DT N
first JJ N
course NN N
, , N
respectively RB N
. . N

All DT N
residual JJ N
AK NNP N
lesions NNS N
after IN N
the DT N
first JJ N
course NN N
were VBD 1_o
cleared VBN 1_o
by IN N
the DT N
second JJ N
courses NNS N
of IN 1_i
PDT NNP 1_i
or CC 1_i
imiquimod JJ 1_i
therapy NN 1_i
. . 1_i

During IN N
the DT N
course NN N
, , N
erosion NN 1_o
and CC 1_o
crust NN 1_o
developed VBD N
significantly RB N
more RBR N
frequently RB N
in IN N
combination NN N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Most JJS 1_p
Japanese JJ 1_p
AK NNP 1_p
lesions NNS 1_p
can MD 1_p
be VB N
satisfactorily RB N
treated VBN N
with IN N
either DT 1_i
PDT NNP 1_i
or CC 1_i
imiquimod JJ 1_i
monotherapy NN 1_i
. . 1_i

However RB 1_i
, , N
only RB N
severe JJ N
cases NNS N
may MD N
better RB N
be VB N
treated VBN N
with IN 1_i
combination NN 1_i
therapy NN 1_i
, , 1_i
which WDT 1_i
show VBP N
higher JJR N
efficacy NN N
even RB N
though IN N
adverse JJ N
events NNS N
occur VBP N
frequently RB N
. . N

-DOCSTART- -X- O O

Long-term JJ N
exposure NN N
to TO N
belatacept VB N
in IN N
recipients NNS 1_p
of IN 1_p
extended JJ 1_p
criteria NNS 1_p
donor JJ 1_p
kidneys NNS 1_p
. . 1_p

Patients NNS 1_p
in IN 1_p
the DT 1_p
BENEFIT-EXT NNP 1_p
study NN 1_p
received VBD 1_p
extended JJ 1_p
criteria NNS 1_p
donor JJ 1_p
kidneys NNS 1_p
and CC N
a DT N
more RBR 1_i
intensive JJ 1_i
( ( 1_i
MI NNP 1_i
) ) 1_i
or CC 1_i
less RBR 1_i
intensive JJ 1_i
( ( 1_i
LI NNP 1_i
) ) 1_i
belatacept IN 1_i
immunosuppression NN 1_i
regimen NNS 1_i
, , 1_i
or CC 1_i
cyclosporine VB 1_i
A NNP 1_i
( ( 1_i
CsA NNP 1_i
) ) 1_i
. . 1_i

Patients NNS 1_p
who WP 1_p
remained VBD 1_p
on IN 1_p
assigned JJ 1_p
therapy NN 1_p
through IN 1_p
year NN 1_p
3 CD 1_p
were VBD 1_p
eligible JJ 1_p
to TO 1_p
enter VB 1_p
a DT 1_p
long-term JJ 1_p
extension NN 1_p
( ( 1_p
LTE NNP 1_p
) ) 1_p
study NN 1_p
. . 1_p

Three CD 1_p
hundred VBD 1_p
four CD 1_p
patients NNS 1_p
entered VBD 1_p
the DT 1_p
LTE NNP 1_p
( ( 1_p
n JJ 1_p
= $ 1_p
104 CD 1_p
MI NNP 1_p
; : 1_p
n CC 1_p
= $ 1_p
113 CD 1_p
LI NNP 1_p
; : 1_p
n CC 1_p
= $ 1_p
87 CD 1_p
CsA NNP 1_p
) ) 1_p
, , 1_p
and CC 1_p
260 CD 1_p
continued VBD 1_p
treatment NN 1_p
through IN 1_p
year NN 1_p
5 CD 1_p
( ( 1_p
n JJ 1_p
= $ 1_p
91 CD N
MI NNP N
; : N
n CC N
= $ N
100 CD N
LI NNP N
; : N
n CC N
= $ N
69 CD 1_p
CsA NNP 1_p
) ) 1_p
. . 1_p

Twenty CD 1_p
patients NNS 1_o
died VBD 1_o
during IN 1_o
the DT N
LTE NNP N
( ( N
n JJ N
= $ N
5 CD N
MI NNP N
; : N
n CC N
= $ N
9 CD N
LI NNP N
; : N
n CC N
= $ N
6 CD N
CsA NNP N
) ) N
, , N
and CC N
eight CD N
experienced VBD 1_o
graft NN 1_o
loss NN 1_o
( ( 1_o
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
; : N
n CC N
= $ N
5 CD N
CsA NNP N
) ) N
. . N

Three CD N
patients NNS N
experienced VBD N
an DT 1_o
acute JJ 1_o
rejection NN 1_o
episode NN 1_o
( ( N
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
) ) N
. . N

The DT N
incidence NN N
rate NN N
of IN 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
, , 1_o
viral JJ 1_o
infections NNS 1_o
and CC 1_o
fungal JJ 1_o
infections NNS 1_o
was VBD N
similar JJ N
across IN N
groups NNS N
during IN N
the DT N
LTE NNP N
. . N

There EX N
were VBD N
four CD N
cases NNS 1_o
of IN 1_o
posttransplant JJ 1_o
lymphoproliferative JJ 1_o
disorder NN 1_o
( ( 1_o
PTLD NNP 1_o
) ) N
from IN N
the DT N
beginning NN N
of IN N
the DT N
LTE NNP N
to TO N
year NN N
5 CD N
( ( N
n JJ N
= $ N
3 CD N
LI NNP N
; : N
n CC N
= $ N
1 CD N
CsA NNP N
) ) N
; : N
two CD N
of IN N
three CD N
PTLD NNP N
cases NNS N
in IN N
the DT N
LI NNP N
group NN N
were VBD N
in IN N
patients NNS 1_p
who WP 1_p
were VBD 1_p
seronegative JJ 1_p
for IN 1_p
Epstein-Barr NNP 1_p
virus NN 1_p
( ( 1_p
EBV NNP 1_p
( ( 1_p
- : 1_p
) ) 1_p
) ) 1_p
at IN 1_p
transplantation NN 1_p
. . N

Mean NNP N
? . N
SD NNP N
calculated VBD 1_o
GFR NNP 1_o
at IN 1_o
year NN N
5 CD N
was VBD N
55.9 CD N
? . N
17.5 CD N
( ( N
MI NNP N
) ) N
, , N
59.0 CD N
? . N
29.1 CD N
( ( N
LI NNP N
) ) N
and CC N
44.6 CD N
? . N
16.4 CD N
( ( N
CsA NNP N
) ) N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
. . N

Continued VBN N
treatment NN N
with IN N
belatacept NN N
was VBD N
associated VBN N
with IN N
a DT N
consistent JJ N
safety NN N
profile NN N
and CC N
sustained VBD N
improvement NN N
in IN N
renal JJ N
function NN N
versus NN N
CsA NNP N
over IN N
time NN N
. . N

-DOCSTART- -X- O O

Loss NNP N
of IN N
bone JJ 1_o
mineral JJ 1_o
density NN 1_o
after IN N
antiretroviral JJ 1_i
therapy NN 1_i
initiation NN 1_i
, , N
independent JJ N
of IN N
antiretroviral JJ N
regimen NNS N
. . N

BACKGROUND NNP N
Decreased VBD N
bone JJ 1_o
mineral JJ 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
has VBZ N
been VBN N
described VBN N
in IN N
HIV-infected JJ 1_p
patients NNS 1_p
initiating VBG 1_p
antiretroviral JJ 1_p
therapy NN 1_p
( ( 1_p
ART NNP 1_p
) ) 1_p
, , N
but CC N
the DT N
contributions NNS N
of IN N
ART NNP N
and CC N
immunologic JJ N
and/or NN N
virologic JJ N
factors NNS N
remain VBP N
unclear JJ N
. . N

METHODS NNP N
We PRP N
compared VBN N
total JJ N
BMD NNP 1_o
changes NNS N
over IN N
96 CD N
weeks NNS N
in IN N
106 CD 1_p
ART-naive JJ 1_p
HIV-infected JJ 1_p
subjects NNS 1_p
who WP 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
receive VB 1_p
efavirenz NN 1_i
( ( 1_i
EFV NNP 1_i
) ) 1_i
+ FW 1_i
zidovudine/lamivudine NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
32 CD 1_i
) ) 1_i
or CC 1_i
lopinavir/ritonavir NN 1_i
( ( 1_i
LPV/r NNP 1_i
) ) 1_i
+ VBP 1_i
zidovudine/lamivudine JJ 1_i
induction NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
74 CD 1_p
) ) 1_p
for IN 1_p
24-48 JJ 1_p
weeks NNS 1_p
followed VBN 1_p
by IN 1_p
LPV/r NNP 1_i
monotherapy NN 1_i
. . 1_i

We PRP N
also RB N
sought VBD N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
BMD NNP N
loss NN N
, , N
including VBG N
markers NNS N
of IN N
systemic JJ N
inflammation NN N
[ NNP N
soluble JJ N
tumor NN N
necrosis NN N
factor-alpha JJ N
receptors NNS N
( ( N
sTNFR NN N
I PRP N
and CC N
II NNP N
) ) N
] NN N
. . N

RESULTS NNP N
After IN N
96 CD N
weeks NNS N
, , N
the DT N
mean JJ N
percent NN 1_o
change NN 1_o
from IN 1_o
baseline NN 1_o
in IN 1_o
total JJ 1_o
BMD NNP 1_o
was VBD N
-2.5 VBN N
% NN N
( ( N
LPV/r NNP N
) ) N
and CC N
-2.3 $ N
% NN N
( ( N
EFV NNP N
) ) N
( ( N
P NNP N
< VBZ N
0.01 CD N
for IN N
within-group JJ N
changes NNS N
in IN N
either DT N
arm NN N
; : N
P NNP N
= VBZ N
0.86 CD N
for IN N
between-group JJ N
differences NNS N
) ) N
. . N

No DT N
alteration NN N
in IN N
the DT N
rate NN 1_o
of IN 1_o
BMD NNP 1_o
change NN 1_o
was VBD N
observed VBN N
upon IN N
simplification NN N
to TO N
LPV/r NNP N
monotherapy NN N
. . N

Although IN N
soluble JJ N
tumor NN N
necrosis NN N
factor-alpha JJ N
receptor NN N
II NNP N
concentrations NNS N
at IN N
baseline NN N
and CC N
24 CD N
weeks NNS N
were VBD N
at IN N
least JJS N
marginally RB N
associated VBN N
with IN N
subsequent JJ N
changes NNS N
in IN N
BMD NNP 1_o
( ( N
P NNP N
= NNP N
0.06 CD N
and CC N
P NNP N
= NNP N
0.028 CD N
, , N
respectively RB N
) ) N
, , N
these DT N
associations NNS N
were VBD N
no RB N
longer RBR N
significant JJ N
after IN N
adjustment NN N
for IN N
CD4 NNP N
T NNP N
cell NN N
count NN N
. . N

Subjects NNS 1_p
with IN 1_p
lower JJR 1_p
baseline NN 1_p
CD4 NNP 1_p
T NNP 1_p
cell NN 1_p
count NN 1_p
, , 1_p
non-black JJ 1_p
race NN 1_p
, , 1_p
and CC 1_p
higher JJR 1_p
baseline NN 1_p
glucose NN 1_p
demonstrated VBD N
a DT N
higher JJR N
risk NN N
for IN N
> JJ N
5 CD N
% NN N
decrease NN N
in IN N
BMD NNP 1_o
. . 1_o

CONCLUSIONS NNP N
Similar JJ N
decreases NNS N
in IN N
BMD NNP 1_o
over IN N
96 CD N
weeks NNS N
occurred VBD N
in IN N
ART-naive JJ 1_p
subjects NNS 1_p
receiving VBG N
either CC N
EFV-based JJ N
regimen NNS N
or CC N
LPV/r-based JJ N
regimen NNS N
, , N
which WDT N
was VBD N
not RB N
altered VBN N
by IN N
simplification NN N
to TO N
LPV/r NNP N
monotherapy NN N
and CC N
was VBD N
unrelated VBN N
to TO N
markers NNS N
of IN N
tumor NN N
necrosis JJ N
factor-alpha JJ N
activity NN N
. . N

-DOCSTART- -X- O O

5 CD N
FU NNP N
infusion NN N
with IN N
mitomycin-C JJ 1_i
vs. FW 1_i
5 CD 1_i
FU NNP 1_i
infusion NN 1_i
with IN 1_i
methyl-CCNU NN 1_i
in IN N
the DT N
treatment NN N
of IN N
advanced JJ 1_p
upper JJ 1_p
gastrointestinal JJ 1_p
cancer NN 1_p
: : 1_p
a DT N
Southwest NNP N
Oncology NNP N
Group NNP N
Study NNP N
. . N

A NNP N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
by IN N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
( ( N
SWOG NNP N
) ) N
in IN N
advanced JJ 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
stomach NN 1_p
and CC 1_p
pancreas NNS 1_p
. . 1_p

Patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
monthly JJ N
5-fluorouracil JJ 1_i
96-hour CD 1_i
continuous JJ 1_i
infusions NNS 1_i
with IN N
either DT N
bolus JJ 1_i
mitomycin-C NN 1_i
or CC 1_i
oral JJ 1_i
methyl-CCNU JJ 1_i
. . 1_i

Mitomycin-C JJ 1_i
and CC 1_i
methyl-CCNU JJ 1_i
were VBD N
administered VBN N
every DT N
eight CD N
weeks NNS N
. . N

The DT N
5 CD 1_i
FU-mitomycin JJ 1_i
combination NN 1_i
produced VBD N
a DT N
14 CD N
% NN N
and CC N
22 CD N
% NN N
response NN 1_o
rate NN 1_o
in IN N
disseminated VBN N
stomach NN N
and CC N
pancreatic JJ N
carcinoma NN N
, , N
respectively RB N
. . N

The DT N
combination NN 1_i
of IN 1_i
infusion NN 1_i
5 CD 1_i
FU NNP 1_i
and CC 1_i
methyl-CCNU JJ 1_i
achieved JJ N
responses NNS 1_o
in IN N
9 CD N
% NN N
and CC N
5 CD N
% NN N
of IN N
stomach NN N
and CC N
pancreatic JJ N
tumors NNS N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN 1_o
in IN 1_o
survival NN 1_o
between IN N
limbs NNS N
for IN N
either DT N
tumor NN N
. . N

Median JJ 1_o
survival NN 1_o
in IN N
gastric JJ N
carcinoma NN N
on IN N
the DT N
5 CD 1_i
FU-mitomycin JJ 1_i
regimen NNS N
was VBD N
25 CD N
weeks NNS N
vs. RB N
18 CD N
weeks NNS N
on IN N
the DT N
5 CD 1_i
FU-METHYL-CCNU JJ 1_i
arm NN N
. . N

In IN N
pancreatic JJ 1_o
carcinoma NN 1_o
median JJ 1_o
survival NN 1_o
on IN N
the DT N
mitomycin NN N
limb NN N
was VBD N
19 CD N
weeks NNS N
as RB N
compared VBN N
to TO N
17 CD N
weeks NNS N
on IN N
the DT N
methyl-CCNU JJ 1_i
program NN N
. . N

Leukopenia NNP 1_o
was VBD N
greater JJR N
for IN N
the DT N
first JJ N
course NN N
on IN N
the DT N
mitomycin NN 1_i
limb NN N
. . N

Regression NNP N
analysis NN N
demonstrated VBD N
that IN N
performance NN 1_o
status NN 1_o
was VBD N
the DT N
most RBS N
important JJ N
pretreatment NN N
characteristic NN N
for IN N
predicting VBG N
survival NN 1_o
in IN N
both DT N
tumors NNS N
. . N

Neither CC N
5 CD 1_i
FU NNP 1_i
infusion NN 1_i
combination NN N
appears VBZ N
to TO N
significantly RB N
alter VB 1_o
the DT 1_o
dismal JJ 1_o
prognosis NN 1_o
of IN N
advanced JJ N
upper JJ N
gastrointestinal JJ N
neoplasms NNS N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
psoriasis NN 1_p
vulgaris NN 1_p
by IN N
oral JJ N
administration NN N
of IN N
yin JJ 1_i
xie NNP 1_i
ping NN 1_i
granules NNS 1_i
-- : 1_i
a DT 1_i
clinical JJ 1_p
report NN 1_p
of IN 1_p
60 CD 1_p
cases NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Nonnucleoside NNP 1_i
reverse JJ 1_i
transcriptase NN 1_i
inhibitor-containing JJ 1_i
regimens NNS 1_i
are VBP N
associated VBN 1_p
with IN 1_p
increased JJ 1_p
satisfaction NN 1_o
with IN 1_o
sexual JJ 1_o
life NN 1_o
. . 1_o

-DOCSTART- -X- O O

Cost NNP N
effectiveness NN N
of IN N
training VBG N
incontinent JJ 1_p
elderly RB 1_p
in IN 1_p
nursing VBG 1_p
homes NNS 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
with IN N
133 CD 1_p
incontinent JJ 1_p
elderly RB 1_p
in IN 1_p
seven CD 1_p
nursing NN 1_p
homes NNS 1_p
to TO N
evaluate VB N
the DT N
effectiveness NN 1_o
of IN N
a DT N
behavioral JJ 1_i
training NN 1_i
therapy NN 1_i
and CC N
its PRP$ N
cost NN N
implications NNS N
. . N

The DT N
training NN N
program NN N
lasted VBD N
three CD N
months NNS N
, , N
and CC N
a DT N
22-week JJ N
follow-up JJ N
period NN N
examined VBD N
the DT N
durability NN N
of IN N
the DT N
treatment NN N
effect NN N
. . N

The DT N
therapy NN N
became VBD N
effective JJ N
after IN N
six CD N
weeks NNS N
of IN N
training NN N
. . N

By IN N
the DT N
final JJ N
months NNS N
of IN N
training NN N
, , N
the DT N
treatment NN N
participants NNS N
' POS N
wet NN 1_o
episodes NNS 1_o
had VBD N
been VBN N
reduced VBN N
by IN N
0.6 CD N
episode NNS N
per IN N
day NN N
, , N
or CC N
a DT N
26 CD N
percent NN N
reduction NN N
over IN N
baseline NN N
, , N
and CC N
improvement NN N
was VBD N
maintained VBN N
during IN N
the DT N
follow-up JJ N
period NN N
. . N

Trainees NNS 1_p
with IN 1_p
a DT 1_p
high JJ 1_p
frequency NN 1_p
of IN 1_p
incontinence NN 1_p
during IN 1_p
baseline NN 1_p
, , 1_p
relatively RB 1_p
more RBR 1_p
cognitive JJ 1_p
residents NNS 1_p
, , 1_p
and CC 1_p
residents NNS 1_p
with IN 1_p
a DT 1_p
normal JJ 1_p
bladder NN 1_p
capacity NN 1_p
responded VBD N
better JJR N
to TO N
this DT N
behavioral JJ 1_i
program NN 1_i
. . 1_i

The DT N
cost NN 1_o
of IN 1_o
training NN 1_o
was VBD N
the DT N
equivalent NN N
of IN N
about IN N
one CD N
hour NN N
of IN N
nursing VBG N
aide JJ N
time NN N
per IN N
patient JJ N
day NN N
. . N

The DT N
reduction NN N
in IN N
incontinence NN 1_o
during IN N
the DT N
follow-up JJ N
period NN N
resulted VBD N
in IN N
some DT N
small JJ 1_o
savings NNS 1_o
in IN 1_o
laundry NN 1_o
costs NNS 1_o
and CC 1_o
supplies NNS 1_o
used VBN 1_o
, , N
and CC N
some DT N
quantitatively RB N
unmeasurable JJ N
but CC N
detectable JJ N
improvement NN 1_o
in IN 1_o
psychosocial JJ 1_o
well-being NN 1_o
among IN N
the DT N
trainees NNS N
. . N

Since IN N
the DT N
central JJ N
figure NN N
in IN N
implementing VBG N
this DT N
training NN N
protocol NN N
is VBZ N
the DT N
nursing NN N
aide NN N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
find VB N
an DT N
organizational JJ N
management NN N
scheme NN N
that WDT N
will MD N
stimulate VB N
nursing NN N
aides NNS N
to TO N
reduce VB N
incontinence NN N
among IN N
nursing JJ 1_p
home NN 1_p
residents NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Measuring VBG N
and CC N
supporting VBG N
language NN 1_p
function NN 1_p
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
evidence NN N
from IN N
a DT N
randomized VBN N
control NN N
trial NN N
of IN N
a DT N
social-interaction-based JJ 1_i
therapy NN 1_i
. . 1_i

In IN N
a DT N
report NN N
of IN N
the DT N
effectiveness NN 1_o
of IN N
MEHRIT NNP 1_i
, , 1_i
a DT 1_i
social-interaction-based JJ 1_i
intervention NN 1_i
for IN N
autism NN N
, , N
Casenhiser NNP N
et CC N
al NN N
. . N

( ( 1_p
Autism $ 1_p
17 CD 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
:220-241 NN 1_p
, , 1_p
2013 CD 1_p
) ) 1_p
failed VBD N
to TO N
find VB N
a DT N
significant JJ N
advantage NN N
for IN N
language NN N
development NN N
in IN N
the DT N
treatment NN N
group NN N
using VBG N
standardized JJ N
language NN N
assessments NNS N
. . N

We PRP N
present VBD N
the DT N
results NNS N
from IN N
a DT N
re-analysis NN N
of IN N
their PRP$ N
results NNS N
to TO N
illustrate VB N
the DT N
importance NN N
of IN N
measuring VBG N
communicative JJ 1_o
language NN 1_o
acts NNS 1_o
( ( N
formally RB N
called VBN N
speech NN N
acts NNS N
) ) N
. . N

Reanalysis NN N
confirmed VBD N
that IN N
children NNS N
in IN N
the DT N
MEHRIT NNP 1_i
group NN N
outperformed VBD 1_o
the DT N
community NN N
treatment NN N
group NN N
on IN N
measures NNS N
of IN N
MLUm NNP 1_o
, , 1_o
number NN 1_o
of IN 1_o
utterances NNS 1_o
produced VBN 1_o
, , 1_o
and CC 1_o
various JJ 1_o
speech NN 1_o
act NN 1_o
categories NNS 1_o
. . 1_o

The DT N
study NN N
underscores VBZ N
the DT N
importance NN N
of IN N
functional JJ 1_o
language NN 1_o
measures NNS 1_o
in IN N
guiding VBG N
and CC N
evaluating VBG N
treatment NN N
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
, , N
and CC N
suggests VBZ N
that DT N
MEHRIT NNP N
is VBZ N
effective JJ N
in IN N
improving VBG N
children NNS 1_o
's POS 1_o
use NN 1_o
of IN 1_o
language NN 1_o
during IN 1_o
parent-child JJ 1_o
interactions NNS 1_o
. . 1_o

-DOCSTART- -X- O O

[ NN 1_p
Use NNP 1_p
of IN 1_p
Tachocomb NNP 1_i
for IN 1_p
prevention NN 1_p
of IN 1_p
postoperative JJ 1_p
lymphatic JJ 1_o
leaks NNS 1_o
in IN 1_p
the DT 1_p
abdomen NNS 1_p
] VBP 1_p
. . N

-DOCSTART- -X- O O

Delayed VBN 1_o
alloimmunization NN 1_o
using VBG N
random JJ 1_i
single JJ 1_i
donor NN 1_i
platelet NN 1_i
transfusions NNS 1_i
: : 1_i
a DT N
prospective JJ N
study NN N
in IN N
thrombocytopenic JJ 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
leukemia NN 1_p
. . 1_p

A DT N
randomized JJ N
study NN N
was VBD N
performed VBN N
in IN N
54 CD 1_p
thrombocytopenic JJ 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
leukemia NN 1_p
. . 1_p

Alloimmunization NN N
of IN N
recipients NNS N
of IN N
random JJ N
multiple-donor JJ 1_i
platelet NN 1_i
concentrates NNS 1_i
( ( N
MD NNP N
group NN N
) ) N
was VBD N
compared VBN N
to TO N
that DT N
of IN N
patients NNS N
receiving VBG N
random JJ 1_i
single-donor JJ 1_i
platelets NNS 1_i
( ( N
SD NNP N
group NN N
) ) N
. . N

In IN N
the DT N
SD NNP N
patients NNS N
, , N
formation NN 1_o
of IN 1_o
alloantibodies NNS 1_o
( ( 1_o
mostly RB 1_o
anti-HLA RB 1_o
) ) 1_o
occurred VBD N
less RBR N
frequently RB N
( ( N
p NN N
less JJR N
than IN N
0.002 CD N
) ) N
, , N
after IN N
a DT N
longer JJR N
time NN N
period NN N
( ( N
p NN N
less JJR N
than IN N
0.002 CD N
) ) N
, , N
and CC N
after IN N
a DT N
higher JJR N
number NN N
of IN N
transfusions NNS N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
as IN N
compared VBN N
to TO N
MD NNP N
patients NNS N
. . N

SD NNP N
patients NNS N
also RB N
became VBD N
refractory JJ N
to TO N
random VB N
platelets NNS N
less RBR N
frequently RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
, , N
after IN N
a DT N
longer JJR N
time NN N
period NN N
, , N
and CC N
after IN N
a DT N
higher JJR 1_o
number NN 1_o
of IN 1_o
transfusions NNS 1_o
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

In IN N
SD NNP N
patients NNS N
, , N
the DT N
increments NNS 1_o
after IN N
the DT N
first JJ 1_o
and CC 1_o
the DT 1_o
last JJ 1_o
transfusion NN 1_o
were VBD N
in IN N
the DT N
same JJ N
range NN N
, , N
whereas NNS N
in IN N
MD NNP N
patients NNS N
, , N
the DT N
1-hr JJ N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
the DT N
24-hr JJ N
( ( N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
increments NNS 1_o
decreased VBN N
from IN N
the DT N
first JJ N
to TO N
the DT N
last JJ N
transfusion NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
random NN 1_i
SD NNP 1_i
platelet NN 1_i
transfusions NNS 1_i
postponed VBD N
alloimmunization NN N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
postoperative JJ N
hypocalcemia NN N
with IN N
routine JJ N
oral JJ N
calcium NN 1_i
and CC N
vitamin NN 1_i
D NNP 1_i
supplements NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
differentiated JJ 1_p
papillary JJ 1_p
thyroid NN 1_p
carcinoma NN 1_p
undergoing JJ 1_p
total JJ 1_p
thyroidectomy NN 1_p
plus CC 1_p
central JJ 1_p
neck NN 1_p
dissection NN 1_p
. . 1_p

BACKGROUND NNP N
Routine NNP N
oral JJ 1_i
calcium NN 1_i
and CC 1_i
vitamin NN 1_i
D NNP 1_i
supplementation NN 1_i
may MD N
prevent VB N
hypocalcemic JJ N
crisis NN N
, , N
but CC N
its PRP$ N
efficacy NN N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
patients NNS 1_p
undergoing VBG 1_p
thyroidectomy JJ 1_p
plus JJ 1_p
central JJ 1_p
neck NN 1_p
dissection NN 1_p
( ( 1_p
CND NNP 1_p
) ) 1_p
. . 1_p

The DT N
authors NNS N
therefore VBP N
prospectively RB N
evaluated VBN N
the DT N
clinical JJ N
usefulness NN N
of IN N
routine JJ N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplementation NN N
for IN N
prevention NN N
of IN N
hypocalcemia NN N
after IN N
total JJ N
thyroidectomy NN N
and CC N
CND NNP N
. . N

METHODS NNP N
Of IN N
197 CD 1_p
patients NNS 1_p
with IN 1_p
differentiated JJ 1_p
papillary JJ 1_p
thyroid NN 1_p
carcinoma NN 1_p
, , N
49 CD N
underwent JJ N
total JJ N
thyroidectomy NN N
alone RB N
, , N
and CC N
148 CD N
underwent JJ N
total JJ 1_i
thyroidectomy NN 1_i
plus CC 1_i
CND NNP 1_i
. . 1_i

The DT N
latter JJ N
were VBD N
randomized VBN N
to TO N
oral JJ 1_i
calcium NN 1_i
( ( N
3 CD N
g/day NN N
) ) N
plus CC N
vitamin JJ 1_i
D NNP 1_i
( ( N
1 CD N
mg/day NN N
) ) N
( ( N
Group NNP N
A NNP N
, , N
n=49 NN N
) ) N
, , N
calcium NN 1_i
alone RB 1_i
( ( N
Group NNP N
B NNP N
, , N
n=49 NN N
) ) N
, , N
or CC N
no DT 1_i
supplements NNS 1_i
( ( N
Group NNP N
C NNP N
, , N
n=50 RB N
) ) N
. . N

Hypocalcemic NNP 1_o
symptoms NNS 1_o
, , 1_o
serum JJ 1_o
calcium NN 1_o
, , 1_o
and CC 1_o
parathyroid VB 1_o
hormone NN 1_o
( ( 1_o
PTH NNP 1_o
) ) 1_o
levels NNS 1_o
were VBD N
compared VBN N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
Group NNP N
C NNP N
had VBD N
significantly RB N
higher JJR N
incidences NNS N
of IN N
symptomatic JJ N
( ( N
26.0 CD N
% NN N
vs JJ N
6.1 CD N
% NN N
; : N
P NNP N
< NNP N
.015 NNP N
) ) N
and CC N
laboratory NN N
( ( N
44.0 CD N
% NN N
vs JJ N
14.3 CD N
% NN N
; : N
P NNP N
< NNP N
.015 NNP N
) ) N
hypocalcemia NN 1_o
than IN N
the DT N
group NN N
without IN N
CND NNP N
. . N

The DT N
incidences NNS N
of IN N
symptomatic JJ 1_o
and CC 1_o
laboratory JJ 1_o
hypocalcemia NN 1_o
were VBD N
significantly RB N
decreased VBN N
in IN N
Groups NNP N
A NNP N
( ( N
2.0 CD N
% NN N
and CC N
8.2 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
B NNP N
( ( N
12.2 CD N
% NN N
and CC N
24.5 CD N
% NN N
, , N
respectively RB N
) ) N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Serum NNP 1_o
calcium NN 1_o
levels NNS 1_o
decreased VBN N
in IN N
most JJS N
patients NNS N
after IN N
surgery NN N
, , N
but CC N
recovered VBD N
earliest JJS N
in IN N
Group NNP N
A. NNP N
Hypercalcemia NNP N
and CC N
PTH NNP N
inhibition NN N
did VBD N
not RB N
occur VB N
in IN N
gs NN N
A NNP N
and CC N
B NNP N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
total JJ N
thyroidectomy NN N
alone RB N
, , N
CND NNP N
significantly RB N
increases VBZ N
the DT N
rate NN N
of IN N
postoperative JJ 1_o
hypocalcemia NN 1_o
, , N
which WDT N
can MD N
be VB N
prevented VBN N
by IN N
routine JJ N
postoperative JJ N
supplementation NN N
with IN N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
. . N

-DOCSTART- -X- O O

Cimetidine NNP 1_i
is VBZ N
not RB N
more RBR N
effective JJ 1_o
than IN N
placebo NN 1_i
in IN N
acute JJ 1_p
infectious JJ 1_p
mononucleosis NN 1_p
. . 1_p

-DOCSTART- -X- O O

Effect NN N
of IN N
addition NN N
of IN N
single JJ N
dose NN N
of IN N
oral JJ N
montelukast NN 1_i
to TO N
standard VB N
treatment NN N
in IN N
acute JJ 1_p
moderate NN 1_p
to TO 1_p
severe VB 1_p
asthma NN 1_p
in IN 1_p
children NNS 1_p
between IN 1_p
5 CD 1_p
and CC 1_p
15 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
: : 1_p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
the DT N
addition NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
oral JJ 1_i
montelukast NN 1_i
to TO N
standard VB 1_i
therapy NN 1_i
in IN N
acute JJ 1_p
moderate NN 1_p
to TO 1_p
severe VB 1_p
asthma NN 1_p
. . 1_p

DESIGN NNP N
Double-blind NNP N
randomised VBD N
controlled VBN N
trial NN N
. . N

Setting VBG N
Emergency NNP 1_p
room/outpatient NN 1_p
paediatric NN 1_p
services NNS 1_p
of IN 1_p
a DT 1_p
tertiary JJ 1_p
care NN 1_p
hospital NN 1_p
. . 1_p

PATIENTS NNP N
Children NNP 1_p
aged VBD 1_p
5-15 CD 1_p
years NNS 1_p
( ( 1_p
without IN 1_p
prior RB 1_p
use NN 1_p
of IN 1_p
montelukast NN 1_i
) ) 1_i
with IN 1_p
acute JJ 1_p
moderate NN 1_p
to TO 1_p
severe VB 1_p
asthma JJ 1_p
exacerbation NN 1_p
, , 1_p
as IN 1_p
defined VBN 1_p
using VBG 1_p
Modified NNP 1_o
Pulmonary NNP 1_o
Index NNP 1_o
Score NNP 1_o
( ( 1_o
MPIS NNP 1_o
) ) 1_o
> VBD 1_p
or CC 1_p
=9 NNS 1_p
, , 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

INTERVENTION NNP N
Children NNP N
received VBD N
montelukast NN 1_i
( ( N
5-12 JJ N
years NNS N
: : N
5 CD N
mg NN N
and CC N
> $ N
12 CD N
years NNS N
: : N
10 CD N
mg NN N
) ) N
or CC N
placebo VBN 1_i
orally RB N
in IN N
addition NN N
to TO N
the DT N
standard JJ N
therapy NN N
. . N

MPIS NNP 1_o
and CC 1_o
forced VBD 1_o
expiratory JJ 1_o
volume NN 1_o
in IN 1_o
1 CD 1_o
second JJ 1_o
( ( 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
) ) 1_o
were VBD N
recorded VBN N
before IN N
administering VBG N
study NN N
medication NN N
and CC N
thereafter RB N
, , N
hourly RB N
for IN N
4 CD N
hours NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
was VBD N
decrease NN 1_o
in IN 1_o
MPIS NNP 1_o
to TO N
less JJR N
than IN N
9 CD N
at IN N
the DT N
end NN N
of IN N
4 CD N
hours NNS N
. . N

RESULTS VB N
117 CD 1_p
children NNS 1_p
( ( 1_p
60 CD 1_p
in IN 1_p
montelukast NN 1_i
group NN 1_p
and CC 1_p
57 CD 1_p
in IN 1_p
placebo NN 1_i
group NN 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
number NN N
of IN N
children NNS N
with IN N
decrease NN 1_o
in IN 1_o
MPIS NNP 1_o
to TO N
less JJR N
than IN N
9 CD N
at IN N
4 CD N
hours NNS N
was VBD N
33 CD N
( ( N
55 CD N
% NN N
) ) N
in IN N
the DT N
montelukast NN 1_i
group NN N
and CC N
36 CD N
( ( N
63.2 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
p=0.37 NN N
) ) N
. . N

There EX N
was VBD N
significant JJ N
improvement NN 1_o
in IN 1_o
MPIS NNP 1_o
and CC 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
within IN N
both CC N
the DT N
groups NNS N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
4 CD N
hours NNS N
. . N

No DT N
differences NNS N
in IN N
side NN 1_o
effects NNS 1_o
and CC 1_o
hospitalisation NN 1_o
rates NNS 1_o
were VBD N
noticed VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Single NNP N
dose JJ N
oral JJ 1_i
montelukast NN 1_i
added VBD N
to TO N
standard JJ 1_i
therapy NN 1_i
of IN 1_i
inhaled JJ 1_i
bronchodilators NNS 1_i
and CC 1_i
systemic JJ 1_i
glucocorticoids NNS 1_i
did VBD N
not RB N
provide VB N
additional JJ N
clinical JJ N
benefit NN N
in IN N
children NNS 1_p
with IN 1_p
acute JJ 1_p
moderate NN 1_p
to TO 1_p
severe VB 1_p
asthma NN 1_p
. . 1_p

Trial JJ N
registration NN N
number NN N
The DT N
trial NN N
was VBD N
registered VBN N
at IN N
the DT N
http NN N
: : N
//clinicaltrials.gov JJ N
site NN N
( ( N
trial NN N
ID NNP N
: : N
NCT00565955 NN N
) ) N
. . N

-DOCSTART- -X- O O

Clinical JJ N
outcome NN N
of IN N
postoperative JJ N
adjuvant JJ N
immunochemotherapy NN N
with IN N
sizofiran NN 1_i
for IN N
patients NNS 1_p
with IN 1_p
resectable JJ 1_p
gastric JJ 1_p
cancer NN 1_p
: : 1_p
a DT N
randomised VBN N
controlled VBN N
study NN N
. . N

Adjuvant NNP 1_i
immunochemotherapy NN 1_i
using VBG 1_i
the DT 1_i
antitumour JJ 1_i
polysaccharide NN 1_i
sizofiran NN 1_i
( ( 1_i
SPG NNP 1_i
) ) 1_i
, , N
an DT N
extract NN N
from IN N
the DT N
culture NN N
broth NN N
of IN N
Schizophyllum NNP N
commune NN N
Fries NNS N
, , N
was VBD N
prescribed VBN N
randomly RB N
for IN N
386 CD 1_p
Japanese JJ 1_p
patients NNS 1_p
with IN 1_p
resectable JJ 1_p
gastric JJ 1_p
cancer NN 1_p
. . 1_p

Although IN N
the DT N
overall JJ 1_o
survival NN 1_o
probability NN 1_o
for IN N
5 CD N
years NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
SPG NNP N
and CC N
control NN N
groups NNS N
, , N
in IN N
264 CD 1_p
patients NNS 1_p
with IN 1_p
curatively RB 1_p
resected VBN 1_p
cancer NN 1_p
, , N
the DT N
probability NN N
to TO N
5 CD N
year NN N
survival NN N
and CC N
to TO N
recurrence VB 1_o
in IN N
the DT N
sizofiran-administered JJ N
patients NNS N
was VBD N
better JJR N
than IN N
in IN N
the DT N
controls NNS N
. . N

In IN N
the DT N
multivariate NN 1_o
analysis NN 1_o
, , N
four CD N
of IN N
six CD N
prognostic JJ N
factors NNS N
correlated VBD N
with IN N
the DT N
prognosis NN N
of IN N
the DT N
264 CD 1_p
patients NNS 1_p
who WP N
underwent VBP N
curative JJ N
surgery NN N
, , N
that WDT N
is VBZ N
, , N
nodal JJ 1_o
involvement NN 1_o
( ( N
chi JJ N
2 CD N
= JJ N
21.426 CD N
, , N
P NNP N
= NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
, , N
age NN 1_o
distribution NN 1_o
( ( N
chi JJ N
2 CD N
= JJ N
9.262 CD N
, , N
P NNP N
= NNP N
0.010 CD N
) ) N
, , N
sizofiran JJ 1_o
administration NN 1_o
( ( N
chi JJ N
2 CD N
= JJ N
6.507 CD N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
, , N
and CC N
primary JJ 1_o
tumour NN 1_o
size NN 1_o
( ( N
chi JJ N
2 CD N
= JJ N
9.345 CD N
, , N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

Thus RB N
, , N
patients NNS 1_p
with IN 1_p
a DT 1_p
curatively RB 1_p
resected VBN 1_p
gastric JJ 1_p
cancer NN 1_p
had VBD N
a DT N
better JJR N
prognosis NN N
when WRB N
sizofiran NN 1_i
was VBD N
prescribed VBN N
in IN N
combination NN N
with IN N
antitumour JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
efficacy NN N
of IN N
fluoxetine NN 1_i
alone RB 1_i
vs. FW 1_i
fluoxetine JJ 1_i
plus CC 1_i
local JJ 1_i
lidocaine NN 1_i
ointment NN 1_i
in IN N
the DT N
treatment NN N
of IN N
premature JJ 1_p
ejaculation NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
present JJ N
study NN N
compares VBZ N
the DT N
efficacy NN N
and CC N
side JJ N
effects NNS N
of IN N
fluoxetine NN 1_i
alone RB 1_i
vs. FW 1_i
fluoxetine JJ 1_i
plus CC 1_i
local JJ 1_i
lidocaine NN 1_i
ointment NN 1_i
in IN N
the DT N
treatment NN N
of IN N
premature JJ 1_p
ejaculation NN 1_p
. . 1_p

METHODS NNP N
Forty-three JJ 1_p
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
premature JJ 1_p
ejaculation NN 1_p
were VBD N
studied VBN N
. . N

The DT 1_p
exclusion NN 1_p
criteria NNS 1_p
were VBD 1_p
erectile JJ 1_p
dysfunction NN 1_p
, , 1_p
loss NN 1_p
of IN 1_p
libido NN 1_p
, , 1_p
alcohol NN 1_p
and CC 1_p
substance NN 1_p
abuse NN 1_p
, , 1_p
mental JJ 1_p
retardation NN 1_p
, , 1_p
diabetes VBZ 1_p
mellitus NN 1_p
, , 1_p
thyroid JJ 1_p
disease NN 1_p
, , 1_p
hypotension NN 1_p
, , 1_p
previous JJ 1_p
use NN 1_p
of IN 1_p
these DT 1_p
drugs NNS 1_p
and CC 1_p
urogenital JJ 1_p
infections NNS 1_p
. . 1_p

The DT 1_p
patients NNS 1_p
' POS 1_p
ages NNS 1_p
ranged VBD 1_p
from IN 1_p
19 CD 1_p
to TO 1_p
48 CD 1_p
years NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
28 CD 1_p
+/- JJ 1_p
1.6 CD 1_p
) ) 1_p
. . 1_p

They PRP 1_p
had VBD 1_p
regular JJ 1_p
sexual JJ 1_p
lives NNS 1_p
. . 1_p

They PRP 1_p
had VBD 1_p
normal JJ 1_p
psychiatric JJ 1_p
consultation NN 1_p
and CC 1_p
the DT 1_p
Glombock NNP 1_o
Rast NNP 1_o
Sexual NNP 1_o
Satisfactory NNP 1_o
Test NNP 1_o
( ( 1_o
GRISS NNP 1_o
) ) 1_o
psychiatric JJ 1_o
test NN 1_o
were VBD 1_p
in IN 1_p
accordance NN 1_p
with IN 1_p
premature JJ 1_p
ejaculation NN 1_p
. . 1_p

RESULTS VB N
The DT N
patients NNS N
were VBD N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

Twenty-six JJ N
patients NNS N
, , N
aged VBD N
21 CD N
to TO N
36 CD N
years NNS N
( ( N
mean JJ N
age NN N
27 CD N
) ) N
, , N
received VBD N
only RB N
fluoxetine JJ 1_i
20 CD N
mg/day NN N
( ( N
1 CD N
capsule NN N
) ) N
for IN N
a DT N
week NN N
which WDT N
was VBD N
later RBR N
increased VBN N
to TO N
40 CD N
mg/day NN N
( ( N
2 CD N
capsules NNS N
) ) N
. . N

Seventeen JJ N
patients NNS N
, , N
aged VBD N
19 CD N
to TO N
48 CD N
years NNS N
( ( N
mean JJ N
age NN N
31 CD N
) ) N
, , N
were VBD N
given VBN N
fluoxetine JJ 1_i
20 CD N
mg/day JJ N
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ 1_i
ointment NN 1_i
. . 1_i

The DT N
patients NNS N
and CC N
partners NNS N
were VBD N
re-evaluated JJ N
8 CD N
weeks NNS N
after IN N
the DT N
treatment NN N
. . N

The DT N
results NNS N
were VBD N
classified VBN N
as IN N
unsuccessful JJ 1_o
, , 1_o
improvement NN 1_o
and CC 1_o
cure NN 1_o
. . 1_o

The DT N
chi-square JJ 1_o
test NN 1_o
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

In IN N
the DT N
fluoxetine NN N
group NN N
, , N
8 CD N
( ( N
30.8 CD N
% NN N
) ) N
patients NNS N
cured VBD 1_o
, , N
11 CD N
( ( N
42.2 CD N
% NN N
) ) N
showed VBD N
improvement NN 1_o
and CC N
there EX N
were VBD N
7 CD N
failures NNS 1_o
( ( N
26.9 CD N
% NN N
) ) N
. . N

In IN N
the DT N
combination NN N
treatment NN N
group NN N
, , N
9 CD N
( ( N
52.9 CD N
% NN N
) ) N
patients NNS N
cured VBN N
, , N
improvement NN 1_o
was VBD N
observed VBN N
in IN N
5 CD N
( ( N
29.4 CD N
% NN N
) ) N
and CC N
failure NN N
in IN N
3 CD N
( ( N
17.6 CD N
% NN N
) ) N
. . N

Side JJ N
effects NNS N
in IN N
group NN N
I PRP N
were VBD N
observed VBN N
in IN N
6 CD N
patients NNS N
( ( N
23 CD N
% NN N
) ) N
and CC N
in IN N
5 CD N
( ( N
29.4 CD N
% NN N
) ) N
in IN N
group NN N
II NNP N
. . N

There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
according VBG N
to TO N
the DT N
side NN N
effects NNS N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

No UH 1_p
patients NNS 1_p
were VBD 1_p
excluded VBN 1_p
from IN 1_p
the DT 1_p
study NN 1_p
due JJ 1_p
to TO 1_p
side VB 1_p
effects NNS 1_p
. . 1_p

CONCLUSION VB N
The DT N
combination NN N
of IN N
fluoxetine JJ 1_i
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ 1_i
ointment NN N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
fluoxetine VB 1_i
alone RB N
in IN N
the DT N
treatment NN N
of IN N
premature JJ 1_p
ejaculation NN 1_p
. . 1_p

However RB N
, , N
the DT N
results NNS N
should MD N
be VB N
confirmed VBN N
in IN N
further JJ N
studies NNS N
with IN N
a DT N
placebo NN N
group NN N
to TO N
rule VB N
out IN N
the DT N
placebo NN N
effect NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN 1_i
treatment NN 1_p
on IN 1_p
prolactin NN 1_o
levels NNS 1_o
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN 1_i
treatment NN N
on IN N
serum NN N
prolactin NN N
were VBD N
assessed VBN N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
autism NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
101 CD 1_p
, , 1_p
5-17 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
an DT N
8-week JJ N
trial NN N
of IN N
risperidone NN 1_i
or CC 1_i
placebo NN 1_i
and CC N
63 CD 1_p
then RB 1_p
took VBD 1_p
part NN 1_p
in IN 1_p
a DT 1_p
4-month JJ 1_p
open-label JJ 1_p
follow-up JJ 1_p
phase NN 1_p
. . 1_p

Serum NNP N
samples NNS N
were VBD N
obtained VBN N
at IN N
Baseline NNP N
and CC N
Week-8 NNP N
( ( N
N NNP N
= NNP N
78 CD N
) ) N
, , N
and CC N
at IN N
6-month JJ N
( ( N
N NNP N
= NNP N
43 CD N
) ) N
and CC N
22-month JJ N
( ( N
N NNP N
= NNP N
30 CD N
) ) N
follow-up NN N
. . N

Serum NNP N
prolactin NN N
was VBD N
determined VBN N
by IN N
immunoradiometric JJ N
assay NN N
; : N
dopamine JJ 1_o
type-2 JJ 1_o
receptor NN 1_o
( ( 1_o
DRD2 NNP 1_o
) ) 1_o
polymorphisms NNS 1_o
were VBD 1_o
genotyped VBN 1_o
. . 1_o

RESULTS NNP N
Baseline NNP 1_o
prolactin NN 1_o
levels NNS 1_o
were VBD N
similar JJ N
in IN N
the DT N
risperidone NN 1_i
( ( N
N NNP N
= NNP N
42 CD N
) ) N
and CC N
placebo NN 1_i
( ( N
N NNP N
= NNP N
36 CD N
) ) N
groups NNS N
( ( N
9.3 CD N
+/- JJ N
7.5 CD N
and CC N
9.3 CD N
+/- JJ N
7.6 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
risperidone NN 1_i
, , N
prolactin NN 1_o
increased VBD N
to TO N
39.0 CD N
+/- JJ N
19.2 CD N
ng/ml NN N
, , N
compared VBN N
with IN N
10.1 CD N
+/- JJ N
8.8 CD N
ng/ml NN N
for IN N
placebo NN N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN 1_o
levels NNS 1_o
were VBD N
also RB N
significantly RB N
increased VBN N
at IN N
6 CD N
months NNS N
( ( N
32.4 CD N
+/- JJ N
17.8 CD N
ng/ml NN N
; : N
N NNP N
= VBZ N
43 CD N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
and CC N
at IN N
22 CD N
months NNS N
( ( N
N NNP N
= NNP N
30 CD N
, , N
25.3 CD N
+/- JJ N
15.6 CD N
ng/ml NN N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN 1_o
levels NNS 1_o
were VBD N
not RB N
associated VBN N
with IN N
adverse JJ N
effects NNS N
and CC N
DRD2 NNP N
alleles NNS N
( ( N
Taq1A NNP N
, , N
-141C NNP N
Ins/Del NNP N
, , N
C957T NNP N
) ) N
did VBD N
not RB N
significantly RB N
influence VB N
baseline NN N
levels NNS N
or CC N
risperidone-induced JJ N
increases NNS N
in IN N
prolactin NN N
. . N

CONCLUSIONS NNP N
Risperidone NNP 1_i
treatment NN N
was VBD N
associated VBN N
with IN N
two- JJ N
to TO N
four-fold JJ N
mean NN N
increases NNS N
in IN N
serum NN N
prolactin NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Although IN N
risperidone-induced JJ N
increases NNS N
tended VBD N
to TO N
diminish VB N
with IN N
time NN N
, , N
further JJ N
research NN N
on IN N
the DT N
consequences NNS N
of IN N
long-term JJ N
prolactin NN N
elevations NNS N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

Development NNP N
of IN N
the DT N
Therapist NNP 1_p
Empathy NNP N
Scale NNP N
. . N

BACKGROUND NNP N
Few JJ N
measures NNS N
exist VBP N
to TO N
examine VB N
therapist NN 1_p
empathy NN N
as IN N
it PRP N
occurs VBZ N
in IN N
session NN N
. . N

AIMS VB N
A DT N
9-item JJ N
observer NN N
rating NN N
scale NN N
, , N
called VBD N
the DT N
Therapist NNP 1_i
Empathy NNP 1_i
Scale NNP 1_i
( ( N
TES NNP N
) ) N
, , N
was VBD N
developed VBN N
based VBN N
on IN N
Watson NNP N
's POS N
( ( N
1999 CD N
) ) N
work NN N
to TO N
assess VB N
affective JJ N
, , N
cognitive JJ N
, , N
attitudinal JJ N
, , N
and CC N
attunement JJ N
aspects NNS N
of IN N
therapist NN N
empathy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
inter-rater JJ N
reliability NN N
, , N
internal JJ N
consistency NN N
, , N
and CC N
construct NN N
and CC N
criterion NN N
validity NN N
of IN N
the DT N
TES NNP N
. . N

METHOD NNP N
Raters NNPS N
evaluated VBD N
therapist JJ 1_p
empathy NN N
in IN N
315 CD 1_p
client NN 1_i
sessions NNS 1_i
conducted VBN 1_p
by IN 1_p
91 CD 1_p
therapists NNS 1_p
, , 1_p
using VBG 1_p
data NNS 1_p
from IN 1_p
a DT 1_p
multi-site JJ 1_p
therapist NN 1_p
training NN 1_p
trial NN 1_p
( ( 1_p
Martino NNP 1_p
et RB 1_p
al. RB 1_p
, , N
2010 CD 1_p
) ) 1_p
in IN 1_p
Motivational NNP 1_i
Interviewing NNP 1_i
( ( 1_i
MI NNP 1_i
) ) 1_i
. . 1_i

RESULTS JJ N
Inter-rater JJ 1_o
reliability NN 1_o
( ( N
ICC NNP N
= NNP N
.87 NNP N
to TO N
.91 VB N
) ) N
and CC N
internal JJ 1_o
consistency NN 1_o
( ( N
Cronbach NNP N
's POS N
alpha NN N
= NNP N
.94 NNP N
) ) N
were VBD N
high JJ N
. . N

Confirmatory NNP N
factor NN 1_o
analyses NNS 1_o
indicated VBD N
some DT N
support NN N
for IN N
single-factor JJ N
fit NN N
. . N

Convergent NNP 1_o
validity NN 1_o
was VBD N
supported VBN N
by IN N
correlations NNS N
between IN N
TES NNP 1_o
scores NNS 1_o
and CC 1_o
MI NNP 1_o
fundamental JJ 1_o
adherence NN 1_o
( ( N
r JJ N
range NN N
.50 NN N
to TO N
.67 VB N
) ) N
and CC N
competence NN 1_o
scores NNS 1_o
( ( N
r NN N
range NN N
.56 NN N
to TO N
.69 VB N
) ) N
. . N

Discriminant JJ 1_o
validity NN 1_o
was VBD N
indicated VBN N
by IN N
negative JJ N
or CC N
nonsignificant JJ N
correlations NNS N
between IN N
TES NNP N
and CC N
MI-inconsistent NNP N
behavior NN N
( ( N
r JJ N
range NN N
.05 NN N
to TO N
-.33 VB N
) ) N
. . N

CONCLUSIONS VB N
The DT N
TES NNP N
demonstrates VBZ N
excellent JJ N
inter-rater JJ N
reliability NN N
and CC N
internal JJ N
consistency NN N
. . N

RESULTS NNP N
indicate VBP N
some DT N
support NN N
for IN N
a DT N
single-factor JJ N
solution NN N
and CC N
convergent NN N
and CC N
discriminant JJ N
validity NN N
. . N

Future JJ N
studies NNS N
should MD N
examine VB N
the DT N
use NN N
of IN N
the DT N
TES NNP N
to TO N
evaluate VB N
therapist NN 1_p
empathy NN N
in IN N
different JJ N
psychotherapy NN N
approaches NNS N
and CC N
to TO N
determine VB N
the DT N
impact NN N
of IN N
therapist NN N
empathy NN N
on IN N
client NN N
outcome NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
regimens NNS N
of IN N
amphotericin NN 1_i
B NNP 1_i
deoxycholate NN 1_i
in IN N
kala-azar NN 1_p
. . 1_p

A DT N
total NN N
of IN N
288 CD 1_p
parasitologically RB 1_p
proved JJ 1_p
patients NNS 1_p
of IN 1_p
kala-azar NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
groups NNS N
. . N

Patients NNS N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
received VBD N
amphotericin JJ 1_i
B NNP 1_i
( ( 1_i
AMB NNP 1_i
) ) 1_i
in IN N
a DT N
dose NN N
of IN N
1 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
bw NN N
) ) N
/day NN N
, , N
0.75 CD N
mg/kg NN N
bw/day NN N
and CC N
0.5 CD N
mg/kg NNS N
bw/day NN N
for IN N
20 CD N
days NNS N
respectively RB N
. . N

Apparent JJ 1_o
cure NN 1_o
( ( N
afebrile NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
) ) N
occurred VBD N
in IN N
all DT N
patients NNS N
and CC N
parasitological JJ 1_o
cure NN 1_o
in IN N
96 CD N
( ( N
100 CD N
% NN N
) ) N
, , N
92 CD N
( ( N
96 CD N
% NN N
) ) N
and CC N
84 CD N
( ( N
88 CD N
% NN N
) ) N
patients NNS N
respectively RB N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C. NNP N
Ultimate NNP 1_o
cure NN 1_o
( ( N
no DT N
relapse NN N
in IN N
six CD N
months NNS N
of IN N
follow VBP N
up RP N
) ) N
occurred VBD N
in IN N
95 CD N
( ( N
99 CD N
% NN N
) ) N
, , N
87 CD N
( ( N
91 CD N
% NN N
) ) N
and CC N
79 CD N
( ( N
82 CD N
% NN N
) ) N
patients NNS N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
respectively RB N
. . N

The DT N
difference NN N
between IN N
the DT N
ultimate JJ 1_o
cure NN 1_o
in IN N
the DT N
three CD N
groups NNS N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
adverse JJ 1_o
events NNS 1_o
( ( 1_o
rise NN 1_o
in IN 1_o
serum JJ 1_o
creatinine NN 1_o
and CC 1_o
fall NN 1_o
in IN 1_o
serum JJ 1_o
potassium NN 1_o
, , 1_o
loss NN 1_o
of IN 1_o
appetite NN 1_o
and CC 1_o
shivering NN 1_o
, , 1_o
rigor NN 1_o
and CC 1_o
fever NN 1_o
during IN 1_o
infusion NN 1_o
indicative NN 1_o
of IN 1_o
renal JJ 1_o
, , 1_o
GIT NNP 1_o
and CC 1_o
infusion NN 1_o
related JJ 1_o
toxicities NNS 1_o
respectively RB 1_o
) ) 1_o
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

This DT N
study NN N
showed VBD N
that IN N
amphotericin NN 1_i
B NNP 1_i
should MD N
be VB N
given VBN N
at IN N
a DT N
dosage NN N
of IN N
1 CD N
mg/kg NNS N
bw/day NN N
for IN N
20 CD N
days NNS N
for IN N
Indian JJ 1_p
kala-azar JJ 1_p
patients NNS 1_p
to TO N
minimise VB N
relapses NNS 1_o
and CC N
prevent NN N
development NN 1_o
of IN N
drug NN 1_o
unresponsiveness NN 1_o
. . 1_o

-DOCSTART- -X- O O

Low-dose JJ N
mifepristone NN 1_i
for IN N
uterine JJ N
leiomyomata NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
5 CD N
and CC N
10 CD N
mg NN N
of IN N
mifepristone NN 1_i
on IN N
uterine JJ 1_o
leiomyoma NN 1_o
size NN 1_o
and CC 1_o
symptoms NNS 1_o
, , N
and CC N
to TO N
measure VB N
side JJ N
effects NNS N
. . N

METHODS NNP N
Forty NNP 1_p
premenopausal JJ 1_p
women NNS 1_p
with IN 1_p
large JJ 1_p
, , 1_p
symptomatic JJ 1_p
leiomyomata NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB 1_i
either RB 1_i
5 CD 1_i
or CC 1_i
10 CD 1_i
mg NN 1_i
of IN 1_i
mifepristone JJ 1_i
daily JJ 1_i
for IN 1_i
6 CD 1_i
months NNS 1_i
in IN 1_i
an DT 1_i
open-label JJ 1_i
study NN 1_i
. . 1_i

Uterine NNP N
volume NN N
was VBD N
measured VBN N
at IN N
bimonthly JJ N
intervals NNS N
by IN N
sonography NN N
. . N

Serum NNP N
concentrations NNS N
of IN N
hemoglobin NN N
levels NNS N
, , N
follicle-stimulating JJ N
hormone NN N
, , N
and CC N
liver RB N
enzymes NNS N
were VBD N
obtained VBN N
, , N
and CC N
endometrial JJ N
samples NNS N
, , N
symptoms NNS N
, , N
and CC N
menstrual JJ N
bleeding NN N
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
Nineteen NNP 1_p
of IN 1_p
20 CD 1_p
subjects NNS 1_p
taking VBG N
5 CD N
mg NN N
and CC N
all DT N
20 CD N
subjects NNS N
taking VBG N
10 CD N
mg NN N
completed VBD N
all DT N
6 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

Mean NNP 1_o
uterine JJ 1_o
volume NN 1_o
shrank NN 1_o
by IN N
48 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
5-mg JJ N
group NN N
and CC N
49 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
10-mg JJ N
group NN N
, , N
a DT N
nonsignificant JJ N
difference NN N
. . N

Leiomyoma-related JJ 1_o
symptoms NNS 1_o
were VBD N
comparably RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

Amenorrhea NNP 1_o
occurred VBD N
in IN N
60-65 CD N
% NN N
of IN N
both DT N
groups NNS N
. . N

Hemoglobin NNP 1_o
levels NNS 1_o
increased VBN N
by IN N
2.5 CD N
g/dL NNS N
in IN N
anemic JJ N
subjects NNS N
. . N

The DT N
incidence NN N
of IN N
hot JJ 1_o
flashes NNS 1_o
increased VBD N
significantly RB N
over IN N
baseline NN N
in IN N
the DT N
10-mg JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
5-mg JJ N
group NN N
. . N

Simple NNP 1_o
endometrial JJ 1_o
hyperplasia NN 1_o
occurred VBD N
in IN N
28 CD N
% NN N
of IN N
all DT N
subjects NNS N
, , N
with IN N
no DT N
difference NN N
between IN N
groups NNS N
. . N

No DT N
atypical JJ 1_o
hyperplasia NN 1_o
was VBD N
noted VBN N
. . N

CONCLUSION NNP N
Mifepristone NNP 1_i
in IN N
doses NNS N
of IN N
5 CD N
mg NNS N
or CC N
10 CD N
mg JJ N
results NNS N
in IN N
comparable JJ N
leiomyoma NN 1_o
regression NN 1_o
, , 1_o
improvement NN 1_o
in IN 1_o
symptoms NNS 1_o
, , 1_o
and CC 1_o
few JJ 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

Further NNP N
study NN N
is VBZ N
needed VBN N
to TO N
assess VB N
the DT N
long-term JJ N
safety NN N
and CC N
efficacy NN N
of IN N
low-dose JJ N
mifepristone NN 1_i
. . 1_i

-DOCSTART- -X- O O

Improvement NN N
of IN N
pain NN N
related VBN N
self JJ N
management NN N
for IN N
oncologic JJ 1_p
patients NNS 1_p
through IN N
a DT N
trans JJ N
institutional JJ N
modular JJ N
nursing NN N
intervention NN N
: : N
protocol NN N
of IN N
a DT N
cluster NN N
randomized VBN N
multicenter RB N
trial NN N
. . N

BACKGROUND NNP N
Pain NNP N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
frequent JJ N
and CC N
distressing VBG N
symptoms NNS N
in IN N
cancer NN 1_p
patients NNS 1_p
. . 1_p

For IN N
the DT N
majority NN N
of IN N
the DT N
patients NNS N
, , N
sufficient JJ N
pain NN N
relief NN N
can MD N
be VB N
obtained VBN N
if IN N
adequate JJ N
treatment NN N
is VBZ N
provided VBN N
. . N

However RB N
, , N
pain NN N
remains NNS N
often RB N
undertreated VBD N
due JJ N
to TO N
institutional JJ N
, , N
health NN N
care NN N
professional JJ N
and CC N
patient JJ N
related JJ N
barriers NNS N
. . N

Patients NNS N
self JJ N
management NN N
skills NNS N
are VBP N
affected VBN N
by IN N
the DT N
patients NNS N
' POS N
knowledge NN N
, , N
activities NNS N
and CC N
attitude NN N
to TO N
pain VB N
management NN N
. . N

This DT N
trial NN N
protocol NN N
is VBZ N
aimed VBN N
to TO N
test VB N
the DT N
SCION-PAIN JJ N
program NN N
, , N
a DT N
multi NN N
modular NN N
structured VBD N
intervention NN N
to TO N
improve VB N
self NN N
management NN N
in IN N
cancer NN 1_p
patients NNS 1_p
with IN 1_p
pain NN 1_p
. . 1_p

METHODS NNP N
240 CD 1_p
patients NNS 1_p
with IN 1_p
diagnosed JJ 1_p
malignancy NN 1_p
and CC 1_p
pain NN 1_p
> VBP 1_p
3 CD 1_p
days NNS 1_p
and CC 1_p
average JJ 1_p
pain NN 1_p
> JJ 1_p
or= NN 1_p
3/10 CD 1_p
will MD 1_p
participate VB 1_p
in IN 1_p
a DT 1_p
cluster NN 1_p
randomized VBN 1_p
trial NN 1_p
on IN 1_p
18 CD 1_p
wards NNS 1_p
in IN 1_p
2 CD 1_p
German JJ 1_p
university NN 1_p
hospitals NNS 1_p
. . 1_p

Patients NNS N
from IN N
the DT N
intervention NN N
wards NNS N
will MD N
receive VB N
, , N
additionally RB N
to TO N
standard VB 1_i
pain NN 1_i
treatment NN 1_i
, , 1_i
the DT 1_i
SCION-PAIN JJ 1_i
program NN 1_i
consisting NN 1_i
of IN 1_i
3 CD 1_i
modules NNS 1_i
: : 1_i
pharmacologic NN 1_i
pain NN 1_i
management NN 1_i
, , 1_i
nonpharmacologic RB 1_i
pain JJ 1_i
management NN 1_i
and CC 1_i
discharge NN 1_i
management NN 1_i
. . 1_i

The DT N
intervention NN N
will MD N
be VB N
conducted VBN N
by IN N
specially RB N
trained JJ N
oncology NN N
nurses NNS N
and CC N
includes VBZ N
components NNS N
of IN N
patient JJ 1_i
education NN 1_i
, , 1_i
skills NNS 1_i
training NN 1_i
and CC 1_i
counseling NN 1_i
to TO 1_i
improve VB 1_i
self PRP 1_i
care VB 1_i
regarding VBG 1_i
pain JJ 1_i
management NN 1_i
beginning VBG 1_i
with IN 1_i
admission NN 1_i
followed VBN 1_i
by IN 1_i
booster NN 1_i
session NN 1_i
every DT 1_i
3rd CD 1_i
day NN 1_i
and CC 1_i
one CD 1_i
follow VBP 1_i
up RP 1_i
telephone NN 1_i
counseling NN 1_i
within IN 1_i
2 CD 1_i
to TO 1_i
3 CD 1_i
days NNS 1_i
after IN 1_i
discharge NN 1_i
. . 1_i

Patients NNS N
in IN N
the DT N
control NN N
group NN N
will MD N
receive VB N
standard NN N
care NN N
. . N

Primary JJ N
endpoint NN N
is VBZ N
the DT N
group NN 1_o
difference NN 1_o
in IN 1_o
patient NN 1_o
related JJ 1_o
barriers NNS 1_o
to TO 1_o
management NN 1_o
of IN 1_o
cancer NN 1_o
pain NN 1_o
( ( N
BQII NNP N
) ) N
, , N
7 CD N
days NNS N
after IN N
discharge NN N
. . N

Secondary JJ N
endpoints NNS N
are VBP N
: : N
pain NN 1_o
intensity NN 1_o
& CC 1_o
interference NN 1_o
, , 1_o
adherence NN 1_o
, , 1_o
coping VBG 1_o
and CC 1_o
HRQoL NNP 1_o
. . 1_o

DISCUSSION NNP N
The DT N
study NN N
will MD N
determine VB N
if IN N
the DT N
acquired VBN N
self NN N
management NN N
skills NNS N
of IN N
the DT N
patients NNS N
continue VBP N
to TO N
be VB N
used VBN N
after IN N
discharge NN N
from IN N
hospital NN N
. . N

It PRP N
is VBZ N
hypothesized VBN N
that IN N
patients NNS N
who WP N
receive VBP N
the DT N
multi NN N
modular NN N
structured VBN N
intervention NN N
will MD N
have VB N
less RBR N
patient JJ N
related JJ N
barriers NNS N
and CC N
a DT N
better JJR N
self JJ N
management NN N
of IN N
cancer NN 1_o
pain NN 1_o
. . 1_o

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials NNP N
NCT00779597 NNP N
. . N

-DOCSTART- -X- O O

Stress NNP N
reduction NN N
and CC N
analgesia NN N
in IN N
patients NNS 1_p
exposed VBN N
to TO N
calming VBG N
music NN N
postoperatively RB N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
, , N
first RB N
, , N
whether IN N
intra- JJ N
or CC N
postoperative JJ N
music NN N
therapy NN N
could MD N
influence VB N
stress NN 1_o
and CC N
immune JJ 1_o
response NN 1_o
during IN N
and CC N
after IN N
general JJ N
anaesthesia NN N
and CC N
second JJ N
, , N
if IN N
there EX N
was VBD N
a DT N
different JJ N
response NN N
between IN N
patients NNS N
exposed VBN N
to TO N
music NN N
intra- NN N
or CC N
postoperatively RB N
. . N

METHOD NNP N
Seventy-five JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
open JJ 1_p
hernia NN 1_p
repair NN 1_p
as IN 1_p
day NN 1_p
care NN 1_p
surgery NN 1_p
were VBD N
randomly RB 1_i
allocated VBN 1_i
to TO 1_i
three CD 1_i
groups NNS 1_i
: : 1_i
intraoperative JJ 1_i
music NN 1_i
, , 1_i
postoperative JJ 1_i
music NN 1_i
and CC 1_i
silence NN 1_i
( ( 1_i
control VB 1_i
group NN 1_i
) ) 1_i
. . 1_i

Anaesthesia NNP 1_i
and CC 1_i
postoperative JJ 1_i
analgesia NN 1_i
were VBD 1_i
standardized VBN 1_i
and CC 1_i
the DT 1_i
same JJ 1_i
surgeon NN 1_i
performed VBD 1_i
all PDT 1_i
the DT 1_i
operations NNS 1_i
. . 1_i

Stress NNP 1_o
response NN 1_o
was VBD 1_i
assessed VBN 1_i
during IN 1_i
and CC 1_i
after IN 1_i
surgery NN 1_i
by IN 1_i
determining VBG 1_i
the DT 1_i
plasma NN 1_o
cortisol NN 1_o
and CC 1_o
blood NN 1_o
glucose NN 1_o
levels NNS 1_o
. . 1_o

Immune NNP 1_o
function NN 1_o
was VBD 1_i
evaluated VBN 1_i
by IN 1_i
studying VBG 1_i
immunoglobulin NN 1_o
A NNP 1_o
( ( 1_o
IgA NNP 1_o
) ) 1_o
levels NNS 1_o
. . 1_o

Patients NNS 1_o
' POS 1_o
postoperative JJ 1_o
pain NN 1_o
, , 1_o
anxiety NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
and CC 1_o
oxygen JJ 1_o
saturation NN 1_o
were VBD 1_o
also RB 1_o
studied VBN 1_o
as IN 1_o
stress NN 1_o
markers NNS 1_o
. . 1_o

RESULTS NNP N
There EX N
was VBD N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
level NN 1_o
of IN 1_o
cortisol NN 1_o
in IN N
the DT N
postoperative JJ N
music NN N
group NN N
vs. IN N
the DT N
control NN N
group NN N
( ( N
206 CD N
and CC N
72 CD N
mmol NN N
L NNP N
( ( N
-1 NNP N
) ) N
decreases VBZ N
, , N
respectively RB N
) ) N
after IN N
2 CD N
h NN N
in IN N
the DT N
post NN N
anaesthesia NN N
care NN N
unit NN N
. . N

The DT N
postoperative JJ N
music NN N
group NN N
had VBD N
less JJR N
anxiety NN 1_o
and CC 1_o
pain NN 1_o
and CC N
required VBD N
less JJR N
morphine NN 1_o
after IN N
1 CD N
h NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
postoperative JJ N
music NN N
group NN N
the DT N
total JJ N
requirement NN N
of IN N
morphine NN 1_o
was VBD N
significantly RB N
lower JJR N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
intraoperative JJ N
music NN N
group NN N
reported VBD N
less JJR N
pain NN 1_o
after IN N
1 CD N
h NN N
in IN N
the DT N
post NN N
anaesthesia NN N
care NN N
unit NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
IgA NNP 1_o
, , 1_o
blood NN 1_o
glucose NN 1_o
, , 1_o
BP NNP 1_o
, , 1_o
HR NNP 1_o
and CC 1_o
oxygen NN 1_o
saturation NN 1_o
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
study NN N
suggests VBZ N
that IN N
intraoperative JJ N
music NN N
may MD N
decrease VB N
postoperative JJ N
pain NN N
, , N
and CC N
that IN N
postoperative JJ N
music NN N
therapy NN N
may MD N
reduce VB N
anxiety NN 1_o
, , 1_o
pain NN 1_o
and CC N
morphine NN 1_o
consumption NN 1_o
. . 1_o

-DOCSTART- -X- O O

Clinical JJ N
pathway NN N
for IN N
fractured JJ 1_p
neck NN 1_p
of IN 1_p
femur NN 1_p
: : 1_p
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
outcomes NNS N
of IN N
using VBG N
a DT N
clinical JJ N
pathway NN N
for IN N
managing VBG N
patients NNS 1_p
with IN 1_p
fractured JJ 1_p
neck NN 1_p
of IN 1_p
femur NN 1_p
. . 1_p

DESIGN NNP N
Prospective NNP N
, , N
pseudorandomised VBD N
, , N
controlled VBD N
trial NN N
. . N

SETTING NN N
St NNP 1_p
Vincent NNP 1_p
's POS 1_p
Hospital NNP 1_p
, , 1_p
Melbourne NNP 1_p
, , 1_p
Victoria NNP 1_p
( ( 1_p
a DT 1_p
tertiary JJ 1_p
referral NN 1_p
, , 1_p
university NN 1_p
teaching VBG 1_p
hospital NN 1_p
) ) 1_p
, , 1_p
1 CD 1_p
October NNP 1_p
1997 CD 1_p
to TO 1_p
30 CD 1_p
November NNP 1_p
1998 CD 1_p
. . 1_p

PARTICIPANTS VB N
111 CD 1_p
patients NNS 1_p
( ( 1_p
80 CD 1_p
women NNS 1_p
and CC 1_p
31 CD 1_p
men NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
81 CD 1_p
years NNS 1_p
) ) 1_p
admitted VBD 1_p
via IN 1_p
the DT 1_p
emergency NN 1_p
department NN 1_p
with IN 1_p
a DT 1_p
primary JJ 1_p
diagnosis NN 1_p
of IN 1_p
fractured JJ 1_p
neck NN 1_p
of IN 1_p
femur NN 1_p
. . 1_p

INTERVENTIONS NNP N
Management NNP 1_i
guided VBN 1_i
by IN 1_i
a DT 1_i
clinical JJ 1_i
pathway NN 1_i
( ( 1_i
55 CD 1_i
patients NNS 1_i
) ) 1_i
or CC 1_i
established VBN 1_i
standard NN 1_i
of IN 1_i
care NN 1_i
( ( N
control NN N
group NN N
, , N
56 CD N
patients NNS N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Timing NNP 1_o
of IN 1_o
referrals NNS 1_o
and CC 1_o
discharge NN 1_o
planning NN 1_o
; : 1_o
total JJ 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
; : 1_o
and CC 1_o
complication NN 1_o
and CC 1_o
readmission NN 1_o
rates NNS 1_o
within IN 1_o
28 CD 1_o
days NNS 1_o
of IN 1_o
discharge NN 1_o
. . 1_o

RESULTS JJ N
Patients NNS N
managed VBD N
according VBG N
to TO N
the DT N
clinical JJ N
pathway NN N
had VBD N
a DT N
shorter NN N
total JJ 1_o
stay NN 1_o
( ( N
6.6 CD N
versus NN N
8.0 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
even RB N
if IN N
assessment NN N
for IN N
placement NN N
by IN N
the DT N
Aged NNP N
Care NNP N
Assessment NNP N
Service NNP N
was VBD N
required VBN N
( ( N
9.5 CD N
versus NN N
13.6 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
complication NN 1_o
and CC 1_o
readmission NN 1_o
rates NNS 1_o
between IN N
pathway NN N
and CC N
control NN 1_p
patients NNS 1_p
( ( N
complication NN N
rates NNS N
, , N
24 CD N
% NN N
versus IN N
36 CD N
% NN N
; : N
P NNP N
= VBZ N
0.40 CD N
; : N
readmission NN N
rates NNS N
, , N
4 CD N
% NN N
versus IN N
11 CD N
% NN N
; : N
P NNP N
= NNP N
0.28 CD N
) ) N
. . N

CONCLUSION NNP N
Coordinated VBD N
multidisciplinary JJ N
care NN N
of IN N
patients NNS 1_p
with IN 1_p
fractured JJ 1_p
neck NN 1_p
of IN 1_p
femur NN 1_p
reduces NNS N
length NN 1_o
of IN 1_o
stay NN 1_o
without IN N
increasing VBG N
complications NNS N
. . N

-DOCSTART- -X- O O

An DT N
intervention NN N
for IN N
sensory JJ N
difficulties NNS N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
a DT N
manualized VBN 1_i
intervention NN 1_i
for IN 1_i
sensory JJ 1_i
difficulties NNS 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
, , 1_p
ages VBZ 1_p
4-8 CD 1_p
years NNS 1_p
, , N
using VBG N
a DT N
randomized JJ N
trial NN N
design NN N
. . N

Diagnosis NN N
of IN N
autism NN N
was VBD N
confirmed VBN N
using VBG N
gold JJ N
standard NN N
measures NNS N
. . N

Results NNP N
show VBP N
that IN N
the DT N
children NNS 1_p
in IN 1_p
the DT 1_p
treatment NN 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
17 CD 1_p
) ) 1_p
who WP N
received VBD N
30 CD 1_i
sessions NNS 1_i
of IN 1_i
the DT 1_i
occupational JJ 1_i
therapy NN 1_i
intervention NN 1_i
scored VBD N
significantly RB N
higher JJR N
( ( N
p JJ N
= NN N
0.003 CD N
, , N
d NN N
= NNP N
1.2 CD N
) ) N
on IN N
Goal NNP 1_o
Attainment NNP 1_o
Scales NNP 1_o
( ( 1_o
primary JJ 1_o
outcome NN 1_o
) ) 1_o
, , N
and CC N
also RB N
scored VBD N
significantly RB N
better RBR N
on IN N
measures NNS N
of IN N
caregiver NN 1_o
assistance NN 1_o
in IN 1_o
self-care NN 1_o
( ( N
p JJ N
= $ N
0.008 CD N
d NN N
= NNP N
0.9 CD N
) ) N
and CC N
socialization NN 1_o
( ( N
p JJ N
= NN N
0.04 CD N
, , N
d NN N
= NNP N
0.7 CD N
) ) N
than IN N
the DT N
Usual NNP 1_i
Care NNP 1_i
control NN 1_i
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
15 CD 1_p
) ) 1_p
. . 1_p

The DT N
study NN N
shows VBZ N
high JJ N
rigor NN N
in IN N
its PRP$ N
measurement NN N
of IN N
treatment NN N
fidelity NN N
and CC N
use NN N
of IN N
a DT N
manualized VBN N
protocol NN N
, , N
and CC N
provides VBZ N
support NN N
for IN N
the DT N
use NN N
of IN N
this DT N
intervention NN N
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Findings NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
their PRP$ N
implications NNS N
for IN N
practice NN N
and CC N
future JJ N
research NN N
. . N

-DOCSTART- -X- O O

Perispinal JJ N
analgesia NN N
for IN N
labour NN 1_p
followed VBN N
by IN N
patient-controlled JJ N
infusion NN N
with IN N
bupivacaine NN 1_i
and CC N
sufentanil NN 1_i
: : 1_i
combined VBN 1_i
spinal-epidural JJ 1_i
vs. FW 1_i
epidural JJ 1_i
analgesia NN N
alone RB N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Combined NNP N
spinal-epidural JJ N
is VBZ N
an DT N
alternative JJ N
technique NN N
to TO N
epidural JJ N
analgesia NN N
for IN N
labour NN N
, , N
but CC N
its PRP$ N
benefits NNS N
are VBP N
not RB N
clearly RB N
identified VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
, , N
blinded VBD N
, , N
randomized VBD N
study NN N
was VBD N
undertaken JJ N
involving VBG N
113 CD 1_p
women NNS 1_p
attending VBG 1_p
a DT 1_p
university NN 1_p
hospital NN 1_p
obstetric JJ 1_p
department NN 1_p
. . 1_p

Analgesia NNP N
was VBD N
initiated VBN 1_i
with IN 1_i
intrathecal JJ 1_i
bupivacaine NN 1_i
0.25 CD 1_i
% NN 1_i
1 CD 1_i
mL NN 1_i
+ NNP 1_i
sufentanil VBD 1_i
5 CD 1_i
microg NN 1_i
in IN 1_i
the DT 1_i
combined JJ 1_i
spinal-epidural JJ 1_i
group NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
54 CD 1_i
) ) 1_i
, , 1_i
and CC 1_i
with IN 1_i
bupivacaine JJ 1_i
0.125 CD 1_i
% NN 1_i
+ JJ 1_i
epinephrine NN 1_i
2.5 CD 1_i
microg NN 1_i
mL NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
+ VBD 1_i
sufentanil $ 1_i
7.5 CD 1_i
microg NN 1_i
in IN 1_i
the DT 1_i
epidural JJ 1_i
group NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
59 CD 1_i
) ) 1_i
. . 1_i

In IN 1_i
both DT 1_i
cases NNS 1_i
this DT 1_i
was VBD 1_i
followed VBN 1_i
by IN 1_i
patient-controlled JJ 1_i
epidural JJ 1_i
analgesia NN 1_i
with IN 1_i
bupivacaine JJ 1_i
0.125 CD 1_i
% NN 1_i
( ( 1_i
+ JJ 1_i
sufentanil NN 1_i
0.25 CD 1_i
microg NN 1_i
mL NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
) ) 1_i
. . 1_i

Duration NN N
of IN N
labour NN N
, , N
quality NN 1_o
of IN 1_o
analgesia NN 1_o
and CC 1_o
side-effects NNS 1_o
were VBD N
compared VBN N
between IN N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
the DT N
onset NN 1_o
of IN 1_o
analgesia NN 1_o
was VBD 1_o
faster RBR 1_o
( ( N
5 CD N
vs. FW N
15 CD N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
consumption NN 1_o
of IN 1_o
bupivacaine NN 1_o
was VBD 1_o
lower JJR 1_o
( ( N
7.5 CD N
vs. FW N
11.3 CD N
mg NN N
h NN N
( ( N
-1 NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
there EX N
was VBD N
less JJR 1_o
unilateral JJ 1_o
analgesia NN 1_o
( ( N
14.8 CD N
% NN N
vs. FW N
40.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
than IN N
in IN N
the DT N
epidural JJ N
group NN N
. . N

The DT 1_p
characteristics NNS 1_o
of IN 1_o
labour NN 1_o
were VBD 1_p
similar JJ 1_p
in IN 1_p
both DT 1_p
groups NNS 1_p
. . 1_p

However RB N
, , N
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
there EX N
was VBD N
a DT N
higher JJR 1_o
incidence NN 1_o
of IN 1_o
posterior JJ 1_o
presentation NN 1_o
( ( N
25.9 CD N
% NN N
vs. FW N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
pruritus NN 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
hypotension NN 1_o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
somnolence NN 1_o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
nausea NN 1_o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
one CD N
case NN N
of IN N
meningitis NN 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
combined JJ N
spinal-epidural JJ N
technique NN N
provided VBD N
more RBR N
effective JJ N
analgesia NN N
during IN 1_p
labour JJR 1_p
than IN N
epidural JJ N
analgesia NN N
alone RB N
but CC N
offered VBN N
no DT N
other JJ N
advantage NN N
. . N

It PRP N
induced VBD N
more RBR N
adverse JJ N
effects NNS N
and CC N
this DT N
should MD N
be VB N
considered VBN N
before IN N
routinely RB N
using VBG N
the DT N
combined JJ N
spinal-epidural JJ N
technique NN N
. . N

-DOCSTART- -X- O O

Caudal NNP 1_i
epidural JJ 1_i
analgesia NN 1_i
using VBG N
lidocaine JJ 1_i
alone RB 1_i
or CC N
in IN N
combination NN 1_i
with IN 1_i
ketamine NN 1_i
in IN N
dromedary JJ 1_p
camels NNS 1_p
Camelus NNP 1_p
dromedarius NN 1_p
. . 1_p

This DT N
study NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
analgesic JJ 1_o
effect NN 1_o
of IN N
lidocaine NN 1_i
and CC 1_i
a DT 1_i
combination NN 1_i
of IN 1_i
lidocaine NN 1_i
and CC 1_i
ketamine NN 1_i
following VBG N
epidural JJ N
administration NN N
in IN N
dromedary JJ 1_p
camels NNS 1_p
. . 1_p

Ten CD 1_p
12-18-month-old JJ 1_p
camels NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
equal JJ N
groups NNS N
. . N

In IN N
group NN N
L NNP N
, , N
the DT N
animals NNS N
received VBD N
2 CD N
% NN N
lidocaine NN 1_i
( ( N
0.22 CD N
mg/kg NN N
) ) N
and CC N
in IN N
group NN N
LK NNP N
the DT N
animals NNS N
received VBD N
a DT N
mixture NN N
of IN N
10 CD N
% NN N
ketamine NN 1_i
( ( N
1 CD N
mg/kg NN N
) ) N
and CC N
2 CD N
% NN N
lidocaine NN 1_i
( ( N
0.22 CD N
mg/kg NN N
) ) N
administered VBD N
into IN N
the DT N
first JJ N
intercoccygeal NN N
( ( N
Co1-Co2 NNP N
) ) N
epidural JJ N
space NN N
while IN N
standing VBG N
. . N

Onset NNP 1_o
time NN 1_o
and CC 1_o
duration NN 1_o
of IN 1_o
caudal JJ 1_o
analgesia NN 1_o
, , 1_o
sedation NN 1_o
level NN 1_o
and CC 1_o
ataxia NN 1_o
were VBD N
recorded VBN N
after IN N
drug NN N
administration NN N
. . N

Data NNS N
were VBD N
analysed VBN N
by IN N
U NNP N
Mann-Whitney NNP N
tests NNS N
and CC N
significance NN N
was VBD N
taken VBN N
as IN N
p NN N
& CC N
lt NN N
; : N
0.05 CD N
. . N

The DT N
results NNS N
showed VBD N
that IN N
epidural JJ 1_i
lidocaine NN 1_i
and CC N
co-administration NN N
of IN N
lidocaine NN 1_i
and CC 1_i
ketamine VB 1_i
produced VBN N
complete JJ 1_o
analgesia NN 1_o
in IN 1_o
the DT 1_o
tail NN 1_o
, , 1_o
anus NN 1_o
and CC 1_o
perineum NN 1_o
. . 1_o

Epidural JJ N
administration NN N
of IN N
the DT N
lidocaine-ketamine JJ 1_i
mixture NN 1_i
resulted VBD N
in IN N
mild NN 1_o
to TO 1_o
moderate VB 1_o
sedation NN 1_o
, , N
whilst VBP N
the DT N
animals NNS N
that WDT N
received VBD N
epidural JJ 1_i
lidocaine NN 1_i
alone RB N
were VBD N
alert JJ 1_o
and CC 1_o
nervous JJ 1_o
during IN N
the DT N
study NN N
. . N

Ataxia NNP 1_o
was VBD N
observed VBN N
in IN N
all DT N
test NN N
subjects NNS N
and CC N
was VBD N
slightly RB N
more JJR N
severe JJ N
in IN N
camels NNS N
that WDT N
received VBD N
the DT N
lidocaine-ketamine JJ 1_i
mixture NN 1_i
. . 1_i

It PRP N
was VBD N
concluded VBN N
that IN N
epidural JJ N
administration NN N
of IN N
lidocaine JJ 1_i
plus CC 1_i
ketamine JJ 1_i
resulted VBN N
in IN N
longer JJR N
caudal NN N
analgesia NN 1_o
in IN N
standing VBG 1_p
conscious JJ 1_p
dromedary JJ 1_p
camels NNS 1_p
compared VBN N
with IN N
the DT N
effect NN N
of IN N
administering VBG N
lidocaine JJ 1_i
alone RB N
. . N

-DOCSTART- -X- O O

Monitoring VBG N
tumour NN N
cells NNS N
in IN N
the DT N
peripheral JJ N
blood NN N
of IN N
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Flow NNP 1_i
cytometry NN 1_i
was VBD N
used VBN N
to TO N
enumerate VB N
tumour JJ N
cells NNS N
in IN N
longitudinal JJ N
studies NNS N
of IN N
peripheral JJ N
blood NN N
from IN N
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
( ( 1_p
SCLC NNP 1_p
) ) 1_p
patients NNS 1_p
, , N
together RB N
with IN N
magnetic JJ N
bead NN N
selection NN N
to TO N
isolate VB N
and CC N
identify VB N
these DT N
cells NNS N
. . N

As IN N
part NN N
of IN N
a DT N
trial NN N
, , N
11 CD 1_p
patients NNS 1_p
received VBD 1_p
either RB 1_p
standard JJ 1_p
( ( 1_p
four CD 1_p
weekly RB 1_p
) ) 1_p
chemotherapy NN 1_i
with IN 1_i
ifosfamide NN 1_i
, , 1_i
carboplatin NN 1_i
, , 1_i
and CC 1_i
etoposide RB 1_i
( ( 1_i
ICE NNP 1_i
) ) 1_i
or CC 1_i
accelerated VBN 1_i
( ( 1_i
two CD 1_i
weekly RB 1_i
) ) 1_i
ICE NNP 1_i
with IN 1_i
filgrastim NN 1_i
( ( 1_i
granulocyte JJ 1_i
colony-stimulating NN 1_i
factor NN 1_i
[ IN 1_i
G-CSF NNP 1_i
] NNP 1_i
) ) 1_i
and CC 1_i
autologous JJ 1_i
stem NN 1_i
cell NN 1_i
support NN 1_i
. . 1_i

METHODS NNP N
Fresh NNP N
venous JJ N
blood NN N
was VBD N
taken VBN N
throughout IN N
treatment NN N
and CC N
follow-up NN N
. . N

Aliquots NNS N
were VBD N
stained VBN N
with IN N
a DT N
tumour-specific JJ N
antibody NN N
against IN N
epithelial JJ N
tissue NN N
( ( N
Ber NNP N
EP4 NNP N
) ) N
, , N
verified VBD N
as IN N
a DT N
good JJ N
marker NN N
of IN N
SCLC NNP N
cells NNS N
by IN N
immunohistochemistry NN N
. . N

Matched NNP N
samples NNS N
labelled VBD N
with IN N
Ber NNP N
EP4 NNP N
were VBD N
separated VBN N
magnetically RB N
by IN N
adding VBG N
a DT N
secondary JJ N
bead-antibody NN N
conjugate NN N
for IN N
confirmation NN N
of IN N
tumour NN N
cell NN N
identity NN N
. . N

RESULTS NNP N
Circulating NNP 1_o
tumour JJ 1_o
cells NNS 1_o
were VBD N
detected VBN N
and CC N
monitored VBN N
throughout IN N
treatment NN N
periods NNS N
. . N

An DT N
initial JJ 1_o
rise NN 1_o
in IN 1_o
circulating VBG 1_o
cells NNS 1_o
after IN 1_o
the DT 1_o
first JJ 1_o
cycle NN 1_o
was VBD N
followed VBN N
by IN N
a DT N
fall NN N
in IN N
both DT N
treatment NN N
arms NNS N
to TO N
baseline NN N
levels NNS N
set VBN N
by IN N
normal JJ N
controls NNS N
. . N

This DT N
was VBD N
achieved VBN N
by IN N
week NN N
12 CD N
in IN N
the DT N
accelerated JJ N
treatment NN N
arm NN N
and CC N
by IN N
week NN N
24 CD N
in IN N
the DT N
standard JJ N
arm NN N
. . N

CONCLUSIONS NNP N
Flow NNP N
cytometry NN N
and CC N
magnetic JJ N
bead NN N
isolation NN N
can MD N
be VB N
used VBN N
to TO N
identify VB N
changes NNS N
in IN N
numbers NNS N
of IN N
circulating VBG N
tumour JJ N
cells NNS N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN 1_i
for IN N
SCLC NNP N
and CC N
thereafter RB N
during IN N
follow-up JJ N
periods NNS N
. . N

Absence NN N
of IN N
tumour JJ N
cells NNS N
may MD N
indicate VB N
a DT N
more RBR N
favourable JJ N
patient NN N
group NN N
who WP N
would MD N
benefit VB N
from IN N
a DT N
more RBR N
intense JJ N
course NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Neurophysiological JJ N
double-blind JJ N
trial NN N
of IN N
a DT N
botulinum NN 1_i
neurotoxin NN 1_i
type IN 1_i
a DT 1_i
free JJ N
of IN N
complexing VBG N
proteins NNS N
. . N

OBJECTIVE NNP N
Safety NNP 1_o
and CC 1_o
efficacy NN 1_o
of IN N
botulinum NN 1_i
neurotoxin NN 1_i
type NN 1_i
A DT 1_i
preparation NN 1_i
NT NNP 1_i
201 CD 1_i
( ( N
Xeomin NNP N
, , N
Merz NNP N
Pharmaceuticals NNP N
GmbH NNP N
, , N
Frankfurt NNP N
am VBP N
Main NNP N
, , N
Germany NNP N
) ) N
were VBD N
investigated VBN N
over IN N
52 CD N
weeks NNS N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN 1_p
trial NN 1_p
with IN 1_p
32 CD 1_p
male JJ 1_p
volunteers NNS 1_p
. . 1_p

METHODS NNP N
Electroneurographic JJ 1_o
assessments NNS 1_o
with IN 1_o
surface NN 1_o
electrodes NNS 1_o
were VBD N
performed VBN N
after IN N
single JJ 1_i
injections NNS 1_i
of IN 1_i
NT NNP 1_i
201 CD 1_i
( ( N
2 CD N
, , N
4 CD N
, , N
16 CD N
, , N
or CC N
32 CD N
units NNS N
) ) N
into IN N
the DT N
extensor NN 1_i
digitorum NN 1_i
brevis NN 1_i
( ( N
EDB NNP N
) ) N
muscle NN N
and CC N
the DT N
same JJ 1_i
dose NN 1_i
( ( N
Botox NNP N
; : N
Allergan NNP N
Pharmaceuticals NNP N
( ( N
Ireland NNP N
) ) N
Ltd. NNP N
Westport NNP N
, , N
Ireland NNP N
) ) N
into IN 1_i
the DT 1_i
contralateral JJ 1_i
EDB NNP 1_i
. . 1_i

RESULTS NNP N
All NNP N
NT NNP 1_i
201 CD 1_i
and CC 1_i
BTXCo NNP 1_i
doses VBZ N
achieved VBD N
a DT N
statistically RB N
significant JJ N
reduction NN 1_o
of IN 1_o
the DT 1_o
compound NN 1_o
muscle NN 1_o
action NN 1_o
potential JJ 1_o
M-wave NNP 1_o
amplitude NN 1_o
in IN N
the DT 1_o
EDB NNP 1_o
muscle NN 1_o
. . 1_o

At IN N
week NN N
4 CD N
, , N
the DT N
highest JJS N
dose NN N
was VBD N
statistically RB N
significantly RB N
more RBR N
effective JJ 1_o
than IN N
the DT N
lowest JJS N
dose NN N
( ( N
NT NNP N
201 CD N
, , N
P NNP N
= NNP N
0.019 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.195-1.370 JJ N
; : N
and CC N
BTXCo NNP N
, , N
P NNP N
= NNP N
0.002 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.309-1.167 JJ N
) ) N
. . N

Duration NN 1_o
of IN 1_o
effect NN 1_o
was VBD N
dose JJ N
dependent NN N
. . N

The DT N
mean JJ 1_o
values NNS 1_o
of IN 1_o
compound NN 1_o
muscle NN 1_o
action NN 1_o
potential JJ 1_o
M-wave NNP 1_o
amplitudes NNS 1_o
in IN 1_o
the DT 1_o
adjacent JJ 1_o
muscles NNS 1_o
( ( N
abductor NN N
digiti NN N
quinti NN N
and CC N
abductor NN N
hallucis NN N
) ) N
were VBD N
above IN N
the DT N
predefined JJ N
threshold NN N
of IN N
effect NN N
, , N
indicating VBG N
that IN N
there EX N
was VBD N
no DT N
relevant JJ N
diffusion-induced JJ N
reduction NN N
of IN N
muscle NN 1_o
activity NN 1_o
. . 1_o

NT CC 1_i
201 CD 1_i
and CC N
BTXCo NNP 1_i
were VBD N
well RB N
tolerated VBN 1_o
. . 1_o

CONCLUSIONS NNP N
NT NNP 1_i
201 CD 1_i
is VBZ N
effective JJ N
and CC N
safe JJ N
in IN N
inducing VBG N
the DT N
desired VBN N
paretic JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Oxidative JJ N
DNA NNP N
damage NN N
measured VBD N
in IN N
human JJ N
lymphocytes NNS N
: : N
large JJ N
differences NNS N
between IN N
sexes NNS N
and CC N
between IN N
countries NNS N
, , N
and CC N
correlations NNS N
with IN N
heart NN N
disease NN N
mortality NN N
rates NNS N
. . N

The DT N
'antioxidant JJ N
hypothesis NN N
' POS N
proposes NNS N
that IN N
vitamin NN 1_i
C NNP 1_i
, , 1_i
vitamin NN 1_i
E NNP 1_i
, , 1_i
carotenoids NNS 1_i
, , N
and CC N
other JJ N
antioxidants NNS 1_i
occurring VBG N
in IN N
fruit NN N
and CC N
vegetables NNS N
afford VBP N
protection NN N
against IN N
heart NN N
disease NN N
and CC N
cancer NN N
by IN N
preventing VBG N
oxidative JJ N
damage NN N
to TO N
lipids NNS N
and CC N
to TO N
DNA NNP N
, , N
respectively RB N
. . N

To TO N
test VB N
elements NNS N
of IN N
this DT N
hypothesis NN N
, , N
we PRP N
have VBP N
measured VBN 1_i
blood NN 1_i
levels NNS 1_i
of IN N
dietary JJ N
antioxidants NNS N
, , N
and CC N
8-oxodeoxyguanosine JJ 1_i
( ( N
8-oxo-dG JJ N
) ) N
concentrations NNS N
in IN N
lymphocyte NN 1_i
DNA NN 1_i
, , N
in IN N
healthy JJ 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
from IN 1_p
five CD 1_p
European JJ 1_p
countries NNS 1_p
: : 1_p
France NNP 1_p
, , 1_p
Ireland NNP 1_p
, , 1_p
The DT 1_p
Netherlands NNP 1_p
, , 1_p
Spain NNP 1_p
, , 1_p
and CC 1_p
the DT 1_p
U.K NNP 1_p
. . 1_p

Volunteers NNS 1_p
, , 1_p
aged VBD 1_p
25 CD 1_p
45 CD 1_p
, , 1_p
all DT 1_p
nonsmokers NNS 1_p
, , N
gave VBD N
blood NN N
samples NNS N
before IN N
and CC N
after IN N
a DT N
12-wk JJ 1_i
carotenoid NN 1_i
supplementation NN 1_i
regime NN 1_i
. . 1_i

Vitamin NNP N
C NNP N
was VBD N
measured VBN N
in IN N
plasma NN N
and CC N
vitamin NN N
E NNP N
and CC N
carotenoids NNS N
were VBD N
measured VBN N
in IN N
serum NN N
by IN N
high-performance NN N
liquid NN 1_i
chromatography NN 1_i
( ( N
HPLC NNP N
) ) N
. . N

8-oxo-dG CD N
was VBD N
assayed VBN N
by IN N
HPLC NNP N
( ( N
with IN N
coulometric JJ N
detection NN N
) ) N
in IN N
DNA NNP N
isolated VBD N
from IN N
lymphocytes NNS N
from IN N
the DT N
same JJ N
blood NN N
samples NNS N
. . N

Mean JJ N
values NNS N
were VBD N
calculated VBN N
for IN N
groups NNS N
of IN N
volunteers NNS N
at IN N
each DT N
sampling NN N
time NN N
according VBG N
to TO N
country NN N
, , N
sex NN N
, , N
and CC N
supplementation NN N
( ( N
between IN N
9 CD N
and CC N
24 CD N
individual JJ N
samples NNS N
contributing VBG N
to TO N
each DT N
mean NN N
) ) N
. . N

We PRP N
found VBD N
that IN N
8-oxo-dG JJ 1_o
levels NNS 1_o
in IN 1_o
lymphocyte NN 1_o
DNA NNP 1_o
vary NN N
significantly RB N
according VBG N
to TO N
sex NN N
and CC N
country NN N
. . N

A DT N
low JJ N
mean JJ 1_o
8-oxo-dG JJ 1_o
concentration NN 1_o
is VBZ N
seen VBN N
in IN N
DNA NNP N
of IN N
women NNS N
from IN N
all DT N
five CD N
countries NNS N
, , N
and CC N
of IN N
men NNS N
from IN N
France NNP N
and CC N
Spain NNP N
. . N

8-oxo-dG NN 1_o
is VBZ N
significantly RB N
higher JJR N
( ( N
up IN N
to TO N
about IN N
threefold NN N
) ) N
in IN N
lymphocyte NN N
DNA NN N
from IN N
men NNS N
in IN N
Ireland NNP N
and CC N
the DT N
U.K. NNP N
Oxidative NNP 1_o
DNA NNP 1_o
damage NN 1_o
is VBZ N
not RB N
significantly RB N
affected VBN N
by IN N
carotenoid JJ N
supplementation NN N
; : N
nor CC N
is VBZ N
there EX N
any DT N
association NN N
with IN N
mean JJ 1_o
baseline NN 1_o
levels NNS 1_o
of IN 1_o
antioxidants NNS 1_o
, , N
which WDT N
are VBP N
generally RB N
similar JJ N
in IN N
the DT N
five CD N
countries NNS N
. . N

The DT N
five CD N
countries NNS N
sampled VBN N
lie NN N
on IN N
an DT N
axis NN N
from IN N
northern JJ N
to TO N
southern JJ N
Europe NNP N
with IN N
a DT N
steep JJ N
gradient NN N
in IN N
terms NNS N
of IN N
premature JJ N
heart NN N
disease NN N
. . N

There EX N
is VBZ N
a DT N
strong JJ N
association NN N
between IN N
premature NN 1_o
coronary JJ 1_o
heart NN 1_o
disease NN 1_o
mortality NN 1_o
in IN N
men NNS N
and CC N
the DT N
mean JJ N
levels NNS N
of IN N
8-oxo-dG NN N
for IN N
the DT N
five CD N
countries NNS N
( ( N
r NN N
= VBZ N
0.95 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Women NNS N
have VBP N
low JJ N
coronary JJ 1_o
heart NN 1_o
disease NN 1_o
mortality NN 1_o
rates NNS 1_o
, , N
which WDT N
do VBP N
not RB N
correlate VB N
with IN N
8-oxo-dG JJ N
. . N

In IN N
terms NNS N
of IN N
cancer NN N
deaths NNS N
, , N
only RB N
colorectal JJ N
cancer NN N
in IN N
men NNS N
shows VBZ N
a DT N
significant JJ 1_o
positive JJ 1_o
correlation NN 1_o
( ( N
r JJ N
= NN N
0.91 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
stomach NN 1_o
cancer NN 1_o
in IN N
women NNS N
is VBZ N
negatively RB N
correlated VBN N
with IN N
DNA NNP N
oxidation NN N
( ( N
r JJ N
= NNP N
-0.92 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

-DOCSTART- -X- O O

Pharmacokinetics NNS 1_o
and CC 1_o
relative JJ 1_o
bioavailability NN 1_o
of IN N
prajmalium NN 1_i
bitartrate NN 1_i
after IN N
single JJ N
oral JJ N
dosing NN N
. . N

Pharmacokinetics NNS 1_o
and CC 1_o
relative JJ 1_o
bioavailability NN 1_o
of IN N
the DT N
marketed JJ N
prajmalium NN 1_i
bitartrate NN 1_i
tablet NN 1_i
( ( 1_i
Neo-Gilurytmal JJ 1_i
, , 1_i
CAS NNP 1_i
2589-47-1 CD 1_i
) ) 1_i
compared VBN 1_i
to TO 1_i
an DT 1_i
oral JJ 1_i
solution NN 1_i
were VBD N
investigated VBN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
, , N
single-dose JJ N
two-fold JJ N
crossover NN N
study NN N
in IN N
20 CD 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
. . 1_p

One CD 1_p
subject NN 1_p
was VBD 1_p
identified VBN 1_p
to TO 1_p
be VB 1_p
a DT 1_p
poor JJ 1_o
metabolizer NN 1_o
. . 1_o

In IN N
the DT N
study NN N
population NN N
with IN N
normal JJ N
metabolic JJ N
status NN N
the DT N
two CD N
oral JJ N
formulations NNS N
proved VBD N
to TO N
be VB N
bioequivalent JJ N
with IN N
regard NN N
to TO N
the DT N
pharmacokinetic JJ 1_o
parameters NNS 1_o
Cmax NNP 1_o
, , 1_o
AUC NNP 1_o
( ( 1_o
0-Tlast NN 1_o
) ) 1_o
, , 1_o
AUC NNP 1_o
( ( 1_o
0-infinity NN 1_o
) ) 1_o
and CC 1_o
Ae NNP 1_o
( ( 1_o
24h CD 1_o
) ) 1_o
. . 1_o

tmax NN 1_o
was VBD N
prolonged VBN N
after IN N
administration NN N
of IN N
the DT N
tablets NNS N
. . N

The DT N
relative JJ 1_o
bioavailability NN 1_o
of IN N
prajmalium NN N
bitartrate NN N
from IN N
the DT N
tablet NN N
amounted VBD N
to TO N
112 CD N
% NN N
. . N

The DT N
poor JJ N
metabolizer NN N
demonstrated VBN N
in IN N
both DT N
oral JJ N
formulations NNS N
high JJ 1_o
plasma NN 1_o
concentrations NNS 1_o
, , 1_o
increased VBD 1_o
AUCs NNP 1_o
and CC 1_o
prolonged VBD 1_o
terminal JJ 1_o
half-lives NNS 1_o
as RB 1_o
well RB 1_o
as IN 1_o
increased VBN 1_o
renal JJ 1_o
excretion NN 1_o
of IN 1_o
prajmalium NN 1_o
bitartrate NN 1_o
. . 1_o

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
an DT N
inference NN 1_i
generation NN 1_i
strategy NN 1_i
intervention NN 1_i
for IN N
adults NNS 1_p
with IN 1_p
high-functioning JJ 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

PURPOSE VB N
The DT N
present JJ N
intervention NN N
study NN N
investigated VBD N
the DT N
efficacy NN N
of IN N
the DT N
ACT NNP 1_i
& CC 1_i
Check NNP 1_i
Strategy NNP 1_i
intervention NN 1_i
to TO N
improve VB N
inference NN 1_o
generation NN 1_o
when WRB 1_o
reading NN 1_o
, , 1_o
metacognitive JJ 1_o
ability NN 1_o
, , 1_o
general JJ 1_o
reading NN 1_o
comprehension NN 1_o
, , 1_o
and CC 1_o
social JJ 1_o
inference NN 1_o
ability NN 1_o
in IN N
adults NNS 1_p
with IN 1_p
high-functioning JJ 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
HF-ASD NNP 1_p
) ) 1_p
. . 1_p

METHOD NNP N
Twenty-five JJ 1_p
adults NNS 1_p
with IN 1_p
HF-ASD NNP 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
treatment NN N
or CC N
a DT N
control NN 1_i
group NN 1_i
. . 1_i

Treatment JJ N
sessions NNS N
were VBD N
conducted VBN N
in IN N
1-hr JJ N
sessions NNS N
, , N
twice RB N
a DT N
week NN N
, , N
for IN N
a DT N
total NN N
of IN N
6 CD N
weeks NNS N
. . N

Treatment NNP N
focused VBD N
on IN N
explicit JJ 1_i
instruction NN 1_i
of IN 1_i
components NNS 1_i
of IN 1_i
inference NN 1_i
generation NN 1_i
, , 1_i
categories NNS 1_i
of IN 1_i
inferences NNS 1_i
, , 1_i
and CC 1_i
increasingly RB 1_i
independent JJ 1_i
strategy NN 1_i
use NN 1_i
. . 1_i

RESULTS VB N
The DT N
treatment NN N
group NN N
demonstrated VBD N
significantly RB N
superior JJ 1_o
performance NN 1_o
on IN 1_o
1 CD 1_o
of IN 1_o
2 CD 1_o
measures NNS 1_o
of IN 1_o
inference NN 1_o
generation NN 1_o
in IN 1_o
reading NN 1_o
and CC 1_o
1 CD 1_o
measure NN 1_o
of IN 1_o
metacognitive JJ 1_o
ability NN 1_o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Significant JJ N
differences NNS N
between IN N
groups NNS N
were VBD N
not RB N
found VBN N
on IN N
measures NNS 1_o
of IN 1_o
reading VBG 1_o
comprehension NN 1_o
or CC 1_o
social JJ 1_o
inference NN 1_o
ability NN 1_o
. . 1_o

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
ACT NNP 1_i
& CC 1_i
Check NNP 1_i
Strategy NNP 1_i
was VBD N
effective JJ N
in IN N
improving VBG N
participants NNS 1_o
' POS 1_o
ability NN 1_o
to TO 1_o
generate VB 1_o
inferences NNS 1_o
in IN 1_o
reading NN 1_o
and CC 1_o
certain JJ 1_o
metacognitive JJ 1_o
abilities NNS 1_o
, , N
but CC N
the DT N
skills NNS N
do VBP N
not RB N
appear VB N
to TO N
generalize VB N
to TO N
other JJ N
social JJ N
communication NN N
contexts NNS N
, , N
such JJ N
as IN N
social JJ 1_o
inference NN 1_o
generation NN 1_o
. . 1_o

This DT N
research NN N
provides VBZ N
a DT N
measure NN N
of IN N
support NN N
for IN N
explicitly RB N
teaching VBG N
inference NN N
generation NN N
to TO N
address VB N
a DT N
reading NN 1_o
inference NN 1_o
deficit NN 1_o
in IN N
adults NNS 1_p
with IN 1_p
HF-ASD NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Amiprilose NNP 1_i
hydrochloride NN 1_i
for IN N
rheumatoid JJ 1_p
arthritis NN 1_p
. . 1_p

STUDY NNP N
OBJECTIVE NNP N
To TO N
assess VB N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
amiprilose JJ 1_i
hydrochloride NN 1_i
( ( 1_i
HCl NNP 1_i
) ) 1_i
, , N
a DT N
novel JJ N
synthetic JJ N
carbohydrate NN N
with IN N
anti-inflammatory JJ N
and CC N
immunomodulatory JJ N
properties NNS N
, , N
in IN N
patients NNS 1_p
with IN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
. . 1_p

DESIGN NNP N
Prospective NNP N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
, , N
double-blind JJ N
placebo-controlled JJ 1_i
12-week JJ N
trial NN N
. . N

PATIENTS VB N
Two CD 1_p
hundred CD 1_p
and CC 1_p
one CD 1_p
functional JJ 1_p
class NN 1_p
I PRP 1_p
and CC 1_p
II NNP 1_p
patients NNS 1_p
with IN 1_p
definite JJ 1_p
or CC 1_p
classic JJ 1_p
rheumatoid NN 1_p
arthritis NN 1_p
, , 1_p
previously RB 1_p
untreated VBN 1_p
with IN 1_p
disease NN 1_p
modifying VBG 1_p
antirheumatic JJ 1_p
drugs NNS 1_p
. . 1_p

INTERVENTIONS NN N
Patients NNPS N
were VBD N
withdrawn VBN N
from IN N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
therapy NN N
. . N

Those DT N
who WP N
flared VBD N
were VBD N
randomly RB N
assigned VBN N
to TO N
amiprilose VB 1_i
HCl NNP 1_i
, , 1_i
6 CD 1_i
g/d NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
for IN N
12 CD N
weeks NNS N
. . N

No DT N
concomitant JJ N
anti-inflammatory NN N
or CC N
antirheumatic JJ N
drug NN N
therapy NN N
was VBD N
permitted VBN N
during IN N
the DT N
study NN N
. . N

Combination NNP N
acetaminophen NN N
and CC N
propoxyphene NN N
napsylate NN N
was VBD N
the DT N
only JJ N
supplemental JJ N
analgesic JJ N
medication NN N
allowed VBN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
number NN 1_o
of IN 1_o
painful JJ 1_o
joints NNS 1_o
and CC 1_o
swollen JJ 1_o
joints NNS 1_o
, , 1_o
joint JJ 1_o
pain NN 1_o
and CC 1_o
joint JJ 1_o
swelling NN 1_o
indices NNS 1_o
, , 1_o
left VBD 1_o
and CC 1_o
right JJ 1_o
grip NN 1_o
strength NN 1_o
, , 1_o
investigator NN 1_o
global JJ 1_o
assessment NN 1_o
, , 1_o
and CC 1_o
patient JJ 1_o
global JJ 1_o
assessment NN 1_o
returned VBD N
to TO N
baseline VB N
for IN N
the DT N
amiprilose JJ 1_i
group NN N
and CC N
showed VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
differences NNS N
from IN N
the DT N
placebo NN 1_i
group NN N
within IN N
4 CD N
to TO N
6 CD N
weeks NNS N
. . N

The DT N
protocol NN N
criteria NNS N
for IN N
overall JJ 1_o
therapeutic JJ 1_o
response NN 1_o
were VBD N
satisfied VBN N
by IN N
41 CD N
% NN N
of IN N
the DT N
amiprilose JJ 1_i
patients NNS N
, , N
compared VBN N
with IN N
21 CD N
% NN N
of IN N
the DT N
placebo NN 1_i
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

Approximately RB N
0.5 CD N
tablet NNS N
per IN N
day NN N
less CC N
analgesic JJ 1_o
medication NN 1_o
was VBD N
taken VBN N
by IN N
the DT N
amiprilose JJ N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
at IN N
weeks NNS N
6 CD N
and CC N
12 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
morning NN 1_o
stiffness NN 1_o
, , 1_o
walking VBG 1_o
time NN 1_o
, , 1_o
erythrocyte JJ 1_o
sedimentation NN 1_o
rate NN 1_o
, , 1_o
C-reactive JJ 1_o
protein NN 1_o
, , 1_o
or CC 1_o
rheumatoid VB 1_o
factor NN 1_o
between IN N
the DT N
groups NNS N
. . N

A DT N
similar JJ N
number NN N
of IN N
adverse JJ 1_o
experiences NNS 1_o
were VBD N
reported VBN N
by IN N
the DT N
patients NNS N
on IN N
amiprilose JJ 1_i
( ( N
67 CD N
% NN N
) ) N
and CC N
on IN N
placebo NN 1_i
( ( N
63 CD N
% NN N
) ) N
. . N

One CD N
patient NN N
on IN N
amiprilose NN 1_i
developed VBN N
thrombocytopenia NN 1_o
of IN N
unknown JJ N
cause NN N
; : N
no DT N
other JJ N
reported VBD N
adverse JJ 1_o
effects NNS 1_o
were VBD N
serious JJ N
. . N

CONCLUSIONS NNP N
Amiprilose NNP 1_i
HCl NNP 1_i
has VBZ N
significant JJ N
anti-inflammatory JJ 1_o
activity NN 1_o
and CC N
a DT N
favorable JJ 1_o
safety NN 1_o
profile NN 1_o
when WRB N
used VBN N
as IN N
the DT N
sole JJ N
antirheumatic JJ N
therapy NN N
in IN N
patients NNS 1_p
with IN 1_p
active JJ 1_p
rheumatoid NN 1_p
arthritis NN 1_p
. . 1_p

Synthetic JJ N
carbohydrates NNS N
may MD N
represent VB N
an DT N
important JJ N
new JJ N
class NN N
of IN N
drugs NNS N
for IN N
the DT N
treatment NN N
of IN N
inflammatory NN N
, , N
autoimmune JJ N
diseases NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
a DT N
stage-of-change NN 1_i
oriented VBN 1_i
smoking VBG 1_i
cessation NN 1_i
intervention NN 1_i
in IN N
infertile NN 1_p
and CC 1_p
pregnant JJ 1_p
women NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
assess VB N
a DT N
stage-of-change NN 1_i
oriented VBN 1_i
smoking VBG 1_i
cessation NN 1_i
intervention NN 1_i
for IN N
infertile NN 1_p
and CC 1_p
pregnant JJ 1_p
women NNS 1_p
, , N
compared VBN N
with IN N
standard NN N
of IN N
care NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Three CD 1_p
university NN 1_p
teaching VBG 1_p
hospitals NNS 1_p
in IN 1_p
Hamilton NNP 1_p
, , 1_p
Ontario NNP 1_p
, , 1_p
Canada NNP 1_p
. . 1_p

PATIENT NNP N
( ( N
S NNP N
) ) N
Infertile NNP 1_p
women NNS 1_p
at IN 1_p
their PRP$ 1_p
first JJ 1_p
visit NN 1_p
to TO 1_p
a DT 1_p
tertiary JJ 1_p
referral JJ 1_p
infertility NN 1_p
clinic NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
94 CD 1_p
) ) 1_p
and CC 1_p
new JJ 1_p
patients NNS 1_p
seeking VBG 1_p
pre-natal JJ 1_p
care NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
110 CD 1_p
) ) 1_p
who WP 1_p
had VBD 1_p
smoked VBN 1_p
> NNP 1_p
/= $ 1_p
3 CD 1_p
cigarettes NNS 1_p
in IN 1_p
the DT 1_p
past JJ 1_p
six CD 1_p
months NNS 1_p
. . 1_p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
A NNP N
three CD 1_i
to TO 1_i
five CD 1_i
minute NN 1_i
scripted VBN 1_i
intervention NN 1_i
and CC 1_i
booklet NN 1_i
specific NN 1_i
to TO 1_i
the DT 1_i
woman NN 1_i
's POS 1_i
stage-of-change NN 1_i
in IN 1_i
the DT 1_i
smoking NN 1_i
continuum NN 1_i
, , 1_i
versus JJ 1_i
standard NN 1_i
of IN 1_i
care NN 1_i
. . 1_i

Exhaled VBN 1_i
carbon-monoxide NN 1_i
( ( 1_i
CO NNP 1_i
) ) 1_i
monitoring NN 1_i
was VBD N
used VBN N
to TO N
validate VB N
exposure NN N
in IN N
both DT N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Delta NNP 1_o
stage-of-change NN 1_o
and CC 1_o
rate NN 1_o
of IN 1_o
maintained VBN 1_o
cessation NN 1_o
at IN N
12 CD N
months NNS N
post VBN N
follow-up JJ N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Intervention NNP N
and CC N
control NN N
were VBD N
similarly RB N
effective JJ N
for IN N
infertile JJ N
women NNS N
: : N
the DT N
rate NN 1_o
of IN 1_o
maintained VBN 1_o
cessation NN 1_o
rose VBD N
significantly RB N
from IN N
4 CD N
% NN N
to TO N
24 CD N
% NN N
over IN N
twelve JJ N
months NNS N
, , N
with IN N
a DT N
mean JJ 1_o
delta NN 1_o
stage-of-change NN 1_o
0.28 CD N
. . N

In IN N
prenatal JJ N
women NNS N
, , N
neither CC N
approach NN N
was VBD N
effective JJ N
. . N

Maintained VBN 1_o
cessation NN 1_o
did VBD N
not RB N
significantly RB N
change VBP N
from IN N
0 CD N
to TO N
12 CD N
months NNS N
( ( N
19 CD N
% NN N
to TO N
18 CD N
% NN N
) ) N
. . N

Mean JJ 1_o
delta JJ 1_o
stage-of-change NN 1_o
declined VBN N
by IN N
-0.62 NNP N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
For IN N
infertile JJ N
women NNS N
, , N
basic JJ N
information NN N
describing VBG N
the DT N
impact NN N
of IN N
smoking VBG N
on IN N
fertility NN N
, , N
along IN N
with IN N
exhaled JJ N
CO NNP N
monitoring NN N
and CC N
a DT N
more RBR N
intensive JJ N
intervention NN N
were VBD N
both DT N
highly RB N
effective JJ N
. . N

In IN N
pregnant JJ N
women NNS N
neither CC N
approach NN N
was VBD N
beneficial JJ N
, , N
with IN N
some DT N
evidence NN N
of IN N
post-partum JJ N
relapse NN N
. . N

-DOCSTART- -X- O O

Cost NNP 1_o
effectiveness NN 1_o
of IN 1_o
treatment NN 1_o
with IN 1_o
percutaneous JJ 1_o
Kirschner NNP 1_o
wires VBZ 1_o
versus IN 1_i
volar JJ 1_i
locking VBG 1_i
plate NN 1_i
for IN N
adult NN 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
dorsally RB 1_p
displaced JJ 1_p
fracture NN 1_p
of IN 1_p
the DT 1_p
distal JJ 1_p
radius NN 1_p
: : 1_p
analysis NN N
from IN N
the DT N
DRAFFT NNP N
trial NN N
. . N

We PRP N
present VBD N
an DT N
economic JJ N
evaluation NN N
using VBG N
data NNS N
from IN N
the DT N
Distal NNP N
Radius NNP N
Acute NNP N
Fracture NNP N
Fixation NNP N
Trial NNP N
( ( N
DRAFFT NNP N
) ) N
to TO N
compare VB N
the DT N
relative JJ N
cost NN N
effectiveness NN N
of IN N
percutaneous JJ 1_i
Kirschner NNP 1_i
wire NN 1_i
( ( 1_i
K-wire NNP 1_i
) ) 1_i
fixation NN 1_i
and CC 1_i
volar JJ 1_i
locking-plate JJ 1_i
fixation NN 1_i
for IN N
patients NNS 1_p
with IN 1_p
dorsally-displaced JJ 1_p
fractures NNS 1_p
of IN 1_p
the DT 1_p
distal JJ 1_p
radius NN 1_p
. . 1_p

The DT N
cost NN N
effectiveness NN N
analysis NN N
( ( 1_o
cost NN 1_o
per IN 1_o
quality-adjusted JJ 1_o
life NN 1_o
year NN 1_o
; : 1_o
QALY NNP 1_o
) ) 1_o
was VBD N
derived VBN N
from IN N
a DT N
multi-centre JJ N
, , N
two-arm JJ N
, , N
parallel JJ N
group NN N
, , N
assessor-blind NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
which WDT N
took VBD N
place NN N
in IN N
18 CD 1_p
trauma NN 1_p
centres NNS 1_p
in IN 1_p
the DT 1_p
United NNP 1_p
Kingdom NNP 1_p
. . 1_p

Data NNP 1_p
from IN 1_p
460 CD 1_p
patients NNS 1_p
were VBD 1_p
available JJ 1_p
for IN 1_p
analysis NN 1_p
, , N
which WDT N
includes VBZ N
both CC N
a DT N
National NNP N
Health NNP N
Service NNP N
cost NN N
perspective NN N
including VBG N
costs NNS 1_o
of IN 1_o
surgery NN 1_o
, , 1_o
implants NNS 1_o
and CC N
healthcare NN 1_o
resource NN 1_o
use NN 1_o
over IN N
a DT N
12-month JJ N
period NN N
after IN N
surgery NN N
, , N
and CC N
a DT N
societal JJ N
perspective NN N
, , N
which WDT N
includes VBZ N
the DT N
cost NN 1_o
of IN 1_o
time NN 1_o
off IN 1_o
work NN 1_o
and CC N
the DT N
need NN N
for IN N
additional JJ 1_o
private JJ 1_o
care NN 1_o
. . 1_o

There EX N
was VBD N
only RB N
a DT N
small JJ N
difference NN N
in IN N
QALYs NNP 1_o
gained VBD N
for IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
locking-plate JJ 1_i
fixation NN 1_i
over IN 1_p
those DT 1_p
treated VBN 1_p
with IN 1_p
K-wires NNP 1_i
. . 1_i

At IN N
a DT N
mean JJ N
additional JJ N
cost NN N
of IN N
?714 NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
588 CD N
to TO N
865 CD N
) ) N
per IN N
patient NN N
, , N
locking-plate JJ N
fixation NN N
presented VBD N
an DT 1_o
incremental JJ 1_o
cost NN 1_o
effectiveness NN 1_o
ratio NN 1_o
( ( 1_o
ICER NNP 1_o
) ) 1_o
of IN N
?89,322 NN N
per IN N
QALY NNP N
within IN N
the DT N
first JJ N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

Sensitivity NN N
analyses NNS N
were VBD N
undertaken VBN N
to TO N
assess VB N
the DT 1_o
ICER NNP 1_o
of IN 1_o
locking-plate JJ 1_i
fixation NN 1_i
compared VBN 1_i
with IN 1_i
K-wires NNP 1_i
. . 1_i

These DT N
were VBD N
greater JJR N
than IN N
?30,000 NN N
. . N

Compared VBN N
with IN 1_i
locking-plate JJ 1_i
fixation NN 1_i
, , 1_i
K-wire NNP 1_i
fixation NN 1_i
is VBZ N
a DT N
'cost JJ N
saving NN N
' '' N
intervention NN N
, , N
with IN N
similar JJ N
health NN N
benefits NNS N
. . N

-DOCSTART- -X- O O

Biventricular JJ N
pacing VBG N
improves NNS N
cardiac JJ 1_o
function NN 1_o
and CC N
prevents NNS N
further RBR N
left VBD 1_o
atrial JJ 1_o
remodeling NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
symptomatic JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
after IN 1_p
atrioventricular JJ 1_p
node JJ 1_p
ablation NN 1_p
. . 1_p

BACKGROUND NNP N
Randomized NNP N
trials NNS N
have VBP N
demonstrated VBN N
benefits NNS N
of IN N
biventricular NN 1_i
( ( 1_i
BiV NNP 1_i
) ) 1_i
pacing NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
heart NN 1_p
failure NN 1_p
, , 1_p
intraventricular JJ 1_p
conduction NN 1_p
delay NN 1_p
, , 1_p
and CC 1_p
atrial JJ 1_p
fibrillation NN 1_p
( ( 1_p
AF NNP 1_p
) ) 1_p
post-atrioventricular NN 1_p
( ( 1_p
AV NNP 1_p
) ) 1_p
node NN 1_p
ablation NN 1_p
. . 1_p

The DT N
AV NNP N
Node NNP N
Ablation NNP N
with IN N
CLS NNP N
and CC N
CRT NNP N
Pacing NNP N
Therapies NNP N
for IN N
Treatment NNP N
of IN N
AF NNP N
trial NN N
( ( N
AVAIL NNP N
CLS/CRT NNP N
) ) N
was VBD N
designed VBN N
to TO N
demonstrate VB N
superiority NN N
of IN N
BiV NNP N
pacing VBG N
in IN N
patients NNS N
with IN N
AF NNP N
after IN N
AV NNP N
node JJ N
ablation NN N
, , N
to TO N
evaluate VB N
its PRP$ N
effects NNS N
on IN N
cardiac JJ N
structure NN N
and CC N
function NN N
, , N
and CC N
to TO N
investigate VB N
additional JJ N
benefits NNS N
of IN N
Closed JJ N
Loop NNP N
Stimulation NNP N
( ( N
CLS NNP N
) ) N
( ( N
BIOTRONIK NNP N
, , N
Berlin NNP N
, , N
Germany NNP N
) ) N
. . N

METHODS JJ N
Patients NNS 1_p
with IN 1_p
refractory JJ 1_p
AF NNP 1_p
underwent NN 1_p
AV NNP 1_p
node CC 1_p
ablation NN 1_p
and CC N
were VBD N
randomized VBN N
( ( N
2:2:1 CD N
) ) N
to TO N
BiV NNP 1_i
pacing VBG 1_i
with IN 1_i
CLS NNP 1_i
, , 1_i
BiV NNP 1_i
pacing VBG 1_i
with IN 1_i
accelerometer NN 1_i
, , 1_i
or CC 1_i
right JJ 1_i
ventricular NN 1_i
( ( 1_i
RV NNP 1_i
) ) 1_i
pacing NN 1_i
. . 1_i

Echocardiography NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
, , N
with IN N
paired VBN N
data NNS N
available JJ N
for IN N
108 CD 1_p
patients NNS 1_p
. . 1_p

RESULTS VB N
The DT N
RV NNP N
pacing NN N
contributed VBD N
to TO N
significant JJ N
increase NN N
in IN N
left JJ 1_o
atrial JJ 1_o
volume NN 1_o
, , 1_o
left VBD 1_o
ventricular JJ 1_o
( ( 1_o
LV NNP 1_o
) ) 1_o
end-systolic JJ 1_o
volume NN 1_o
, , 1_o
and CC 1_o
LV NNP 1_o
mass NN 1_o
compared VBN N
to TO N
BiV NNP N
pacing NN N
. . N

Ejection NNP 1_o
fraction NN 1_o
decreased VBD N
insignificantly RB N
with IN N
RV NNP N
pacing VBG N
compared VBN N
to TO N
significant JJ N
increase NN N
with IN N
BiV NNP N
pacing VBG N
. . N

Interventricular JJ 1_o
dyssynchrony NN 1_o
significantly RB N
decreased VBN N
with IN N
BiV NNP N
compared VBN N
with IN N
RV NNP N
pacing VBG N
. . N

Closed VBN N
Loop NNP N
Stimulation NNP N
did VBD N
not RB N
result VB N
in IN N
additional JJ N
echocardiographic JJ 1_o
changes NNS 1_o
; : 1_o
heart NN 1_o
rate NN 1_o
distribution NN 1_o
was VBD N
significantly RB N
wider JJR N
with IN N
CLS NNP N
. . N

All DT N
groups NNS N
showed VBD N
significant JJ N
improvement NN N
in IN N
6-minute JJ 1_o
walk NN 1_o
distance NN 1_o
, , 1_o
quality-of-life JJ 1_o
score NN 1_o
, , 1_o
and CC 1_o
New NNP 1_o
York NNP 1_o
Heart NNP 1_o
Association NNP 1_o
class NN 1_o
. . 1_o

CONCLUSION NNP N
In IN N
conclusion NN N
, , N
RV NNP N
pacing VBG N
results NNS N
in IN N
significant JJ N
increase NN N
in IN N
left JJ 1_o
atrial JJ 1_o
volume NN 1_o
, , 1_o
LV NNP 1_o
mass NN 1_o
, , N
and CC N
worsening NN 1_o
of IN 1_o
LV NNP 1_o
contractility NN 1_o
compared VBN N
to TO N
patients NNS N
receiving VBG N
BiV NNP N
pacing VBG N
post-AV JJ N
node JJ N
ablation NN N
for IN N
refractory NN N
AF NNP N
. . N

Closed VBD N
Loop NNP N
Stimulation NNP N
was VBD N
not RB N
associated VBN N
with IN N
additional JJ N
structural JJ 1_o
changes NNS 1_o
but CC N
resulted VBD N
in IN N
significantly RB N
wider JJR 1_o
heart NN 1_o
rate NN 1_o
distribution NN 1_o
. . 1_o

-DOCSTART- -X- O O

Ketorolac NNP 1_i
versus NN 1_i
fentanyl NN 1_i
for IN N
gynaecological JJ 1_p
day-case NN 1_p
surgery NN 1_p
. . 1_p

The DT N
effectiveness NN N
of IN N
fentanyl NN 1_i
and CC N
ketorolac NN 1_i
in IN N
providing VBG N
analgesia NN N
for IN N
day-case JJ 1_p
gynaecological JJ 1_p
procedures NNS 1_p
was VBD 1_p
evaluated VBN 1_p
in IN 1_p
55 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
in IN 1_p
a DT 1_p
single JJ 1_p
blinded JJ 1_p
fashion NN 1_p
. . 1_p

Fentanyl NNP 1_i
( ( N
1 CD N
mcg/kg RB N
iv NN N
) ) N
and CC N
ketorolac NN 1_i
( ( N
30 CD N
mg RB N
im NN N
) ) N
were VBD N
administered VBN N
immediately RB N
following VBG N
induction NN N
of IN N
anaesthesia NN N
. . N

Anaesthesia NNP N
was VBD N
standardized VBN N
with IN N
propofol NN 1_i
, , 1_i
nitrous JJ 1_i
oxide NN 1_i
and CC 1_i
enflurane NN 1_i
. . 1_i

Outcome NNP N
variables NNS N
assessed VBN N
were VBD N
pain RB 1_o
, , 1_o
additional JJ 1_o
analgesic NN 1_o
requirements NNS 1_o
, , 1_o
and CC 1_o
incidence NN 1_o
of IN 1_o
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
. . 1_o

All DT N
variables NNS N
were VBD N
recorded VBN N
at IN N
15 CD N
minutes NNS N
, , N
2 CD N
hours NNS N
and CC N
24 CD N
hours NNS N
postoperatively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
with IN N
respect NN N
to TO N
any DT N
of IN N
the DT N
measured JJ N
variables NNS N
. . N

Both DT N
drugs NNS N
were VBD N
ineffective JJ 1_o
as IN N
sole JJ 1_o
analgesic JJ 1_o
agents NNS 1_o
in IN N
half NN N
of IN N
their PRP$ N
respective JJ N
groups NNS N
. . N

It PRP N
may MD N
be VB N
that IN N
a DT N
combination NN N
of IN N
these DT N
drugs NNS N
, , N
providing VBG N
a DT N
multireceptor NN N
approach NN N
to TO N
analgesia VB N
, , N
will MD N
prove VB N
to TO N
be VB N
more RBR N
effective JJ N
. . N

-DOCSTART- -X- O O

Short-term JJ N
pulmonary JJ N
effects NNS N
of IN N
total JJ 1_i
parenteral JJ 1_i
nutrition NN 1_i
in IN N
children NNS 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
. . 1_p

Indices NNS N
of IN N
respiratory JJ N
muscle NN N
strength NN N
, , N
pulmonary JJ N
function NN N
, , N
and CC N
pulmonary JJ N
diffusing NN N
capacity NN N
were VBD N
measured VBN N
in IN N
11 CD 1_p
malnourished JJ 1_p
children NNS 1_p
( ( 1_p
age NN 1_p
10 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
, , 1_p
before IN 1_p
and CC 1_p
after IN 1_p
improvement NN 1_p
of IN 1_p
nutritional JJ 1_p
status NN 1_p
with IN 1_p
supplemental JJ 1_i
parenteral JJ 1_i
nutrients NNS 1_i
for IN 1_p
1 CD 1_p
month NN 1_p
. . 1_p

During IN N
this DT N
time NN N
, , N
the DT N
children NNS N
received VBD N
120 CD N
% NN N
of IN N
estimated VBN N
energy NN N
requirements NNS N
( ( N
either CC N
3.75 CD N
% NN N
or CC N
22.5 CD N
% NN N
as IN N
lipid NN 1_i
) ) 1_i
and CC N
amino JJ 1_i
acids NNS 1_i
2.5 CD N
gm/120 JJ N
kcal JJ N
by IN N
central JJ N
venous JJ N
catheter NN N
, , N
plus CC N
as IN N
much JJ N
of IN N
their PRP$ N
usual JJ N
diet NN N
as IN N
desired VBN N
. . N

With IN N
nutritional JJ 1_o
supplementation NN 1_o
, , 1_o
body NN 1_o
weight NN 1_o
, , 1_o
triceps NNS 1_o
skinfold VBD 1_o
thickness NN 1_o
, , 1_o
and CC 1_o
mid-arm JJ 1_o
muscle NN 1_o
circumference NN 1_o
increased VBD N
( ( N
mean JJ N
15 CD N
% NN N
, , N
62 CD N
% NN N
, , N
and CC N
95 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Maximum JJ 1_o
inspiratory JJ 1_o
airway NN 1_o
pressure NN 1_o
also RB N
increased VBD N
( ( N
mean JJ N
29 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
suggesting VBG N
improvement NN N
in IN N
respiratory JJ 1_o
muscle NN 1_o
strength NN 1_o
. . 1_o

However RB N
, , N
none NN N
of IN N
the DT N
indices NNS 1_o
of IN 1_o
pulmonary JJ 1_o
function NN 1_o
improved VBN N
. . N

Pulmonary JJ 1_o
diffusing VBG 1_o
capacity NN 1_o
did VBD N
not RB N
change VB N
during IN N
parenteral JJ N
nutrition NN N
regardless NN N
of IN N
the DT N
amount NN N
of IN N
parenteral JJ 1_o
energy NN 1_o
intake NN 1_o
supplied VBN N
by IN N
lipid JJ N
, , N
but CC N
arterial JJ 1_o
oxygen NN 1_o
saturation NN 1_o
decreased VBN N
( ( N
mean NN N
of IN N
93.5 CD N
% NN N
to TO N
91.5 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
0.005 CD N
) ) N
. . N

During IN N
the DT N
month NN N
following VBG N
parenteral JJ N
nutrition NN N
, , N
weight NN N
, , N
skinfold JJ N
thickness NN N
, , N
and CC N
mid-arm JJ N
muscle NN N
circumference NN N
, , N
but CC N
not RB N
MIP NNP N
, , N
decreased VBD N
and CC N
arterial JJ N
oxygen NN N
saturation NN N
returned VBD N
to TO N
the DT N
initial JJ N
value NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

-DOCSTART- -X- O O

Acute NNP 1_o
and CC 1_o
late JJ 1_o
toxicity NN 1_o
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
conventional JJ 1_i
versus NN N
hypofractionated VBD 1_i
three-dimensional JJ 1_i
conformal JJ 1_i
radiotherapy NN 1_i
for IN N
prostate NN 1_p
cancer NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
compare VB N
the DT N
toxicity NN N
between IN N
hypofractionation NN 1_i
vs. FW 1_i
conventional JJ 1_i
fractionation NN 1_i
schedules NNS N
in IN N
patients NNS 1_p
with IN 1_p
high-risk JJ 1_p
prostate NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP 1_p
January NNP 1_p
2003 CD 1_p
and CC 1_p
December NNP 1_p
2007 CD 1_p
, , 1_p
168 CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
hypofractionated VBN 1_i
( ( N
62 CD N
Gy NNP N
in IN N
20 CD N
fractions NNS N
within IN N
5 CD N
weeks NNS N
, , N
4 CD N
fractions/wk NN N
) ) N
or CC 1_i
conventionally RB 1_i
fractionated VBN 1_i
( ( N
80 CD N
Gy NNP N
in IN N
40 CD N
fractions NNS N
within IN N
8 CD N
weeks NNS N
) ) N
three-dimensional JJ 1_i
conformal JJ 1_i
radiotherapy NN 1_i
to TO N
the DT N
prostate NN N
and CC N
seminal JJ N
vesicles NNS N
. . N

All DT 1_p
patients NNS 1_p
had VBD 1_p
undergone RP 1_p
a DT 1_p
9-month JJ 1_p
course NN 1_p
of IN 1_p
total JJ 1_p
androgen NN 1_p
deprivation NN 1_p
, , 1_p
with IN 1_p
radiotherapy NN 1_p
starting VBG 1_p
2 CD 1_p
months NNS 1_p
after IN 1_p
initiation NN 1_p
of IN 1_p
the DT 1_p
total JJ 1_p
androgen NN 1_p
deprivation NN 1_p
. . 1_p

RESULTS VB N
The DT N
median JJ N
follow-up NN N
was VBD N
32 CD N
and CC N
35 CD N
months NNS N
in IN N
the DT N
hypofractionation NN N
and CC N
conventional JJ N
fractionation NN N
arms NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
patients NNS N
developing VBG N
acute JJ N
toxicity NN N
, , N
no DT N
difference NN N
between IN N
the DT N
two CD N
fractionation NN N
groups NNS N
was VBD N
found VBN N
in IN N
either DT N
severity NN 1_o
or CC 1_o
duration NN 1_o
of IN 1_o
gastrointestinal JJ 1_o
or CC 1_o
genitourinary JJ 1_o
toxicity NN 1_o
. . 1_o

Also RB N
, , N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
incidence NN N
and CC N
severity NN 1_o
of IN 1_o
late JJ 1_o
gastrointestinal NN 1_o
and CC 1_o
genitourinary JJ 1_o
toxicity NN 1_o
between IN N
the DT N
two CD N
treatment NN N
schedules NNS N
, , N
with IN N
a DT N
3-year JJ N
rate NN N
of IN N
Grade NNP N
2 CD N
or CC N
greater JJR N
toxicity NN N
of IN N
17 CD N
% NN N
and CC N
16 CD N
% NN N
for IN N
the DT N
hypofractionation NN N
arm NN N
and CC N
14 CD N
% NN N
and CC N
11 CD N
% NN N
for IN N
the DT N
conventional JJ N
fractionation NN N
arm NN N
, , N
respectively RB N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
acute NN 1_o
and CC 1_o
late JJ 1_o
gastrointestinal JJ 1_o
toxicity NN 1_o
was VBD N
found VBN N
only RB N
in IN N
the DT N
conventional JJ N
fractionation NN N
group NN N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
the DT N
hypofractionation NN 1_i
regimen NNS N
used VBN N
in IN N
our PRP$ N
study NN N
is VBZ N
safe JJ N
, , N
with IN N
only RB N
a DT N
slight NN N
, , N
nonsignificant JJ N
increase NN N
in IN N
tolerable JJ 1_o
and CC 1_o
temporary JJ 1_o
acute NN 1_o
toxicity NN 1_o
compared VBN N
with IN N
the DT N
conventional JJ N
fractionation NN N
schedule NN N
. . N

The DT N
severity NN N
and CC N
frequency NN N
of IN N
late JJ N
complications NNS N
was VBD N
equivalent JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

-DOCSTART- -X- O O

Differential JJ 1_o
effects NNS 1_o
of IN N
two CD N
dihydropyridine JJ 1_i
calcium NN 1_i
antagonists NNS 1_i
in IN N
humans NNS N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
after IN N
single JJ N
doses NNS N
of IN N
niguldipine NN 1_i
( ( N
0.3 CD N
, , N
0.6 CD N
, , N
and CC N
0.9 CD N
mg NN N
intravenously RB N
; : N
8 CD N
and CC N
16 CD N
mg NNS N
orally RB N
) ) N
and CC N
nifedipine JJ 1_i
( ( N
2 CD N
mg NN N
intravenously RB N
; : N
20 CD N
mg NNS N
orally RB N
) ) N
in IN N
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
in IN N
randomized JJ N
placebo-controlled JJ 1_i
experiments NNS N
. . N

Total JJ 1_o
peripheral JJ 1_o
resistance NN 1_o
( ( 1_o
TPR NNP 1_o
) ) 1_o
, , 1_o
heart NN 1_o
rate-corrected JJ 1_o
electromechanical JJ 1_o
systole NN 1_o
( ( 1_o
QS2c NNP 1_o
) ) 1_o
, , N
and CC N
preejection NN 1_o
period NN 1_o
( ( 1_o
PEPc NNP 1_o
) ) 1_o
were VBD N
assessed VBN N
noninvasively RB N
. . N

Both DT N
drugs NNS N
induced VBD N
a DT N
similar JJ N
pronounced NN N
decreased VBD N
in IN N
TRP NNP 1_o
, , N
indicating VBG N
peripheral JJ N
vasodilation NN N
, , N
followed VBN N
by IN N
increasing VBG N
heart NN 1_o
rate NN 1_o
and CC N
cardiac JJ 1_o
output NN 1_o
, , N
a DT N
decrease NN N
in IN N
diastolic JJ N
blood NN N
pressure NN N
, , N
and CC N
a DT N
shortening NN N
of IN N
the DT N
PEPc NNP N
. . N

QS2c NNP 1_o
was VBD N
unchanged JJ N
after IN N
niguldipine NN N
. . N

The DT N
prolongation NN 1_o
of IN 1_o
QS2c NNP 1_o
after IN N
oral JJ N
nifedipine NN 1_i
is VBZ N
suggestive JJ N
of IN N
a DT N
negative JJ 1_o
inotropic NN 1_o
effect NN 1_o
. . 1_o

We PRP N
conclude VBP N
that IN N
the DT N
vasodilatory JJ 1_o
effects NNS 1_o
of IN N
dihydropyridines NNS 1_i
may MD N
( ( N
as IN N
for IN N
nifedipine NN 1_i
) ) 1_i
or CC N
may MD N
not RB N
( ( N
as IN N
for IN N
niguldipine NN 1_i
) ) 1_i
be VB N
associated VBN N
with IN N
changes NNS N
that WDT N
are VBP N
suggestive JJ N
of IN N
negative JJ 1_o
inotropic NN 1_o
effects NNS 1_o
, , N
and CC N
that IN N
this DT N
difference NN N
is VBZ N
detectable JJ N
by IN N
noninvasive JJ N
methods NNS N
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Bioavailability NN 1_o
of IN N
omega-3 JJ 1_i
essential JJ 1_i
fatty JJ 1_i
acids NNS 1_i
from IN 1_p
perilla NN 1_i
seed NN 1_i
oil NN 1_i
. . 1_i

Increased VBD N
dietary JJ N
intake NN N
of IN N
fish JJ 1_i
oil NN 1_i
omega-3 JJ 1_i
fatty NN 1_i
acids NNS 1_i
, , N
eicosapentanoic JJ N
acid NN N
and CC N
docosohexanoic NN N
acid NN N
, , N
and CC N
their PRP$ N
precursor NN N
, , N
alpha-linolenic JJ 1_i
acid NN 1_i
( ( N
ALA NNP N
) ) N
, , N
is VBZ N
associated VBN N
with IN N
various JJ N
health NN N
benefits NNS N
. . N

Enteric-coating NNP N
( ( N
Entrox NNP N
) ) N
, , N
which WDT N
improves VBZ N
stability NN N
of IN N
omega-3 JJ N
capsules NNS N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
facilitate VB N
fish JJ N
oil NN N
absorption NN N
after IN N
chronic JJ N
treatment NN N
. . N

To TO N
assess VB N
the DT N
effect NN N
of IN N
Entrox NNP N
coating VBG N
on IN N
the DT N
short-term JJ N
bioavailability NN N
of IN N
ALA NNP 1_i
administered VBD N
in IN N
the DT N
form NN N
of IN N
ALA-rich NNP N
Perilla NNP N
seed NN N
oil NN N
, , N
12 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
( ( 1_p
6 CD 1_p
males NNS 1_p
and CC 1_p
6 CD 1_p
females NNS 1_p
) ) 1_p
received VBN N
in IN N
a DT N
random JJ N
order NN N
Entrox-coated JJ 1_i
and CC 1_i
non-coated JJ 1_i
ALA NNP 1_i
formulations NNS 1_i
, , N
each DT N
as IN N
a DT N
single JJ N
6g CD N
dose NN N
separated VBN N
by IN N
a DT N
3-week JJ N
washout NN N
period NN N
. . N

Measurements NNS N
of IN N
plasma NN 1_o
ALA NNP 1_o
concentrations NNS 1_o
from IN N
0 CD N
to TO N
24h CD N
showed VBD N
no DT N
difference NN N
in IN N
ALA NNP N
pharmacokinetics NNS N
between IN N
the DT N
two CD N
formulations NNS N
. . N

However RB N
, , N
significantly RB N
greater JJR N
increases NNS N
in IN N
plasma JJ 1_o
ALA NNP 1_o
levels NNS 1_o
from IN N
baseline NN N
to TO N
24h CD N
were VBD N
observed VBN N
after IN N
ingestion NN N
of IN N
Entrox NNP N
vs. IN N
non-coated JJ N
product NN N
, , N
suggesting VBG N
a DT N
possible JJ N
benefit NN N
of IN N
Entrox NNP N
with IN N
long-term JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
a DT N
family NN 1_i
practice-based JJ 1_i
lifestyle JJ 1_i
intervention NN 1_i
program NN 1_i
to TO N
increase VB N
physical JJ 1_o
activity NN 1_o
and CC N
reduce VB N
clinical JJ N
and CC N
physiological JJ N
markers NNS N
of IN N
vascular JJ N
health NN N
in IN N
patients NNS 1_p
with IN 1_p
high JJ 1_p
normal JJ 1_p
blood NN 1_p
pressure NN 1_p
and/or RB 1_p
high JJ 1_p
normal JJ 1_p
blood NN 1_p
glucose NN 1_p
( ( 1_p
SNAC NNP 1_p
) ) 1_p
: : 1_p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous JJ N
interventions NNS N
to TO N
increase VB N
physical JJ 1_o
activity NN 1_o
and CC N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
have VBP N
been VBN N
targeted VBN N
at IN N
individuals NNS N
with IN N
established VBN N
disease NN N
; : N
less CC N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
intervention VB N
among IN N
individuals NNS 1_p
with IN 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
disease NN 1_p
nor CC N
has VBZ N
there RB N
been VBN N
determination NN N
of IN N
the DT N
influence NN N
of IN N
setting VBG N
in IN N
which WDT N
the DT N
intervention NN N
is VBZ N
provided VBN N
. . N

In IN N
particular JJ N
, , N
family NN N
practice NN N
represents VBZ N
an DT N
ideal JJ N
setting NN N
for IN N
the DT N
provision NN N
and CC N
long-term JJ N
maintenance NN N
of IN N
lifestyle JJ N
interventions NNS N
for IN N
patients NNS 1_p
at IN 1_p
risk NN 1_p
( ( 1_p
ie JJ 1_p
high-normal JJ 1_p
blood NN 1_p
pressure NN 1_p
or CC 1_p
impaired JJ 1_p
glucose JJ 1_p
tolerance NN 1_p
) ) 1_p
. . 1_p

METHODS/DESIGN PDT N
The DT N
Staged NNP 1_p
Nutrition NNP 1_p
and CC 1_p
Activity NNP 1_p
Counseling NNP 1_p
( ( 1_p
SNAC NNP 1_p
) ) 1_p
study NN 1_p
is VBZ N
a DT N
randomized JJ N
clustered JJ N
design NN N
clinical JJ N
trial NN N
that WDT N
will MD N
investigate VB N
the DT N
effectiveness NN N
and CC N
efficacy NN N
of IN N
a DT N
multi-component JJ 1_i
lifestyle JJ 1_i
intervention NN 1_i
on IN N
cardiovascular JJ 1_p
disease NN 1_p
risk NN 1_p
factors NNS 1_p
and CC 1_p
vascular JJ 1_p
function NN 1_p
in IN 1_p
patients NNS 1_p
at IN 1_p
risk NN 1_p
in IN 1_p
primary JJ 1_p
care NN 1_p
. . 1_p

Patients NNS N
will MD N
be VB N
randomized VBN N
by IN N
practice NN N
to TO N
either VB N
a DT N
standard NN 1_i
of IN 1_i
care NN 1_i
lifestyle JJ 1_i
intervention NN 1_i
or CC N
a DT N
behaviourally-based JJ 1_i
, , 1_i
matched VBD 1_i
prescriptive JJ 1_i
physical JJ 1_i
activity NN 1_i
and CC 1_i
diet JJ 1_i
change NN 1_i
program NN 1_i
. . 1_i

The DT N
primary JJ N
goal NN N
is VBZ N
to TO N
increase VB N
physical JJ 1_o
activity NN 1_o
and CC N
improve VB N
dietary JJ 1_o
intake NN 1_o
according VBG N
to TO N
Canada NNP 1_o
's POS 1_o
Guides NNP 1_o
to TO 1_o
Physical NNP 1_o
Activity NNP 1_o
Healthy NNP 1_o
Eating NNP 1_o
over IN N
24 CD N
months NNS N
. . N

The DT N
primary JJ N
intention NN N
to TO N
treat VB N
analysis NN N
will MD N
compare VB N
behavioral JJ N
, , N
physiological JJ N
and CC N
metabolic JJ N
outcomes NNS N
at IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
post-randomization JJ N
including VBG N
estimation NN N
of IN N
incident JJ N
hypertension NN 1_o
and/or NN N
diabetes VBZ 1_o
. . 1_o

DISCUSSION VB N
The DT N
design NN N
features NNS N
of IN N
our PRP$ N
trial NN N
, , N
and CC N
the DT N
practical JJ N
problems NNS N
( ( N
and CC N
solutions NNS N
) ) N
associated VBN N
with IN N
implementing VBG N
these DT N
design NN N
features NNS N
, , N
particularly RB N
those DT N
that IN N
result NN N
in IN N
potential JJ N
delay NN N
between IN N
recruitment NN N
, , N
baseline NN N
data NNS N
collection NN N
, , N
randomization NN N
, , N
intervention NN N
, , N
and CC N
assessment NN N
will MD N
be VB N
discussed VBN N
. . N

Results NNS N
of IN N
the DT N
SNAC NNP N
trial NN N
will MD N
provide VB N
scientific JJ N
rationale NN N
for IN N
the DT N
implementation NN N
of IN N
this DT N
lifestyle JJ N
intervention NN N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
: : N
ISRCTN:42921300 NNP N
. . N

-DOCSTART- -X- O O

Safety NN 1_o
and CC 1_o
immunogenicity NN 1_o
of IN N
IMVAMUNE NNP 1_i
, , N
a DT N
promising JJ N
candidate NN N
as IN N
a DT N
third JJ N
generation NN N
smallpox NN N
vaccine NN N
. . N

A DT N
Phase NN N
I PRP N
trial NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
safety NN 1_o
and CC 1_o
immunogenicity NN 1_o
of IN N
the DT N
third JJ 1_i
generation NN 1_i
smallpox VBD 1_i
vaccine JJ 1_i
MVA-BN NNP 1_i
( ( 1_i
IMVAMUNE NNP 1_i
) ) 1_i
, , N
a DT N
highly RB N
attenuated VBN N
clone NN N
derived VBN N
from IN N
the DT N
Modified NNP N
Vaccinia NNP N
Virus NNP N
Ankara NNP N
strain NN N
571 CD N
, , N
in IN 1_p
naive JJ 1_p
and CC 1_p
pre-immunized JJ 1_p
subjects NNS 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
86 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
received VBD N
the DT N
vaccine NN 1_i
in IN N
five CD N
groups NNS N
using VBG N
different JJ N
doses NNS N
and CC N
routes NNS N
of IN N
administration NN N
. . N

All DT N
38 CD N
subjects NNS N
seroconverted VBN N
in IN N
the DT N
groups NNS N
receiving VBG N
the DT N
highest JJS N
dose NN N
( ( N
10 CD N
( ( N
8 CD N
) ) N
TCID50 NN N
) ) N
. . N

All DT N
vaccinations NNS N
were VBD N
well RB 1_o
tolerated VBN 1_o
with IN N
mainly RB N
mild NN 1_o
or CC 1_o
moderate JJ 1_o
pain NN 1_o
at IN 1_o
the DT 1_o
injection NN 1_o
site NN 1_o
being VBG N
the DT N
most RBS N
frequent JJ N
symptom NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
MVA-BN NNP N
has VBZ N
the DT N
potential JJ N
to TO N
be VB N
developed VBN N
as IN N
an DT N
efficient NN 1_o
and CC 1_o
safe JJ 1_o
alternative NN N
to TO N
the DT N
conventional JJ N
smallpox JJ N
vaccines NNS N
such JJ N
as IN N
Lister-Elstree NNP 1_i
or CC 1_i
Dryvax NNP 1_i
. . 1_i

Unique NNP N
attributes VBZ N
render VBP N
it PRP N
a DT N
promising JJ N
candidate NN N
for IN N
prophylactic JJ N
mass NN N
immunization NN N
, , N
even RB N
in IN N
subjects NNS N
for IN N
whom WP N
conventional JJ N
smallpox NN N
vaccines NNS N
are VBP N
contraindicated VBN N
. . N

-DOCSTART- -X- O O

Take VB N
a DT N
walk NN N
in IN N
the DT N
park NN N
? . N
A DT N
cross-over NN N
pilot NN N
trial NN N
comparing VBG N
brisk JJ 1_i
walking VBG 1_i
in IN 1_i
two CD 1_i
different JJ 1_i
environments NNS 1_i
: : 1_i
park NN N
and CC N
urban JJ N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
differences NNS N
exist VBP N
between IN N
a DT N
30 CD 1_i
minute NN 1_i
brisk NN 1_i
walk VBP 1_i
taken VBN N
in IN N
two CD N
different JJ N
environments NNS N
in IN N
order NN N
to TO N
determine VB N
which WDT N
environment NN N
best JJS N
facilitates NNS N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
: : N
park NN N
or CC N
urban JJ N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
cross-over NN N
pilot NN N
study NN N
, , N
participants NNS 1_p
performed VBD 1_p
a DT 1_p
self-timed JJ 1_i
30 CD 1_i
minute NN 1_i
brisk NN 1_i
walk VBP 1_i
in IN 1_i
two CD 1_i
different JJ 1_i
environments NNS 1_i
, , 1_i
park NN 1_i
and CC 1_i
urban JJ 1_i
, , N
in IN N
Glasgow NNP N
, , N
Scotland NNP N
( ( N
October NNP N
2009 CD N
to TO N
January NNP N
2010 CD N
) ) N
. . N

Cadence NN 1_o
, , N
recorded VBD N
using VBG N
the DT N
activPAL? NN N
activity NN N
monitor NN N
, , N
was VBD N
used VBN N
to TO N
measure VB N
intensity NN N
. . N

Outcome CC N
measures NNS N
were VBD 1_o
: : 1_o
mean JJ 1_o
cadence NN 1_o
; : 1_o
moderate-to-vigorous JJ 1_o
physical JJ 1_o
activity NN 1_o
time NN 1_o
accumulated VBN 1_o
in IN 1_o
bouts NNS 1_o
lasting VBG 1_o
? . 1_o
10 CD 1_o
min NN 1_o
; : 1_o
number NN 1_o
of IN 1_o
walking VBG 1_o
breaks NNS 1_o
; : 1_o
and CC 1_o
duration NN 1_o
. . 1_o

RESULTS VB 1_o
A DT N
convenience NN N
sample NN 1_p
of IN 1_p
40 CD 1_p
healthy JJ 1_p
adults NNS 1_p
was VBD 1_p
recruited VBN 1_p
: : 1_p
16 CD 1_p
males NNS 1_p
, , 1_p
24 CD 1_p
females NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
22.9 CD 1_p
( ( 1_p
5.5 CD 1_p
) ) 1_p
years NNS 1_p
. . 1_p

The DT 1_p
mean JJ 1_o
cadence NN 1_o
for IN 1_o
the DT 1_o
whole JJ 1_o
walk NN 1_o
was VBD 1_o
higher RBR N
in IN N
the DT N
park NN N
: : N
119.3 CD N
( ( N
8.3 CD N
) ) N
vs. FW N
110.9 CD N
( ( N
8.9 CD N
) ) N
steps/min NN 1_p
. . 1_p

Participants NNS 1_p
accumulated VBD 1_p
more RBR N
moderate-to-vigorous JJ 1_o
physical JJ 1_o
activity NN 1_o
in IN 1_o
? . 1_o
10 CD 1_o
minute NN 1_o
bouts NNS 1_o
during IN N
park JJ N
walks NNS N
: : N
25.5 CD N
( ( N
9.6 CD N
) ) N
[ NN N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
] VBZ N
vs. FW N
14.0 CD N
( ( N
20.3 CD N
) ) N
min NN N
. . N

There EX N
was VBD N
no DT N
difference NN 1_o
in IN 1_o
self-timed JJ 1_o
duration NN 1_o
between IN 1_o
locations NNS N
. . N

CONCLUSION NNP N
Participants NNPS N
accumulated VBD 1_o
more RBR 1_o
moderate-to-vigorous JJ 1_o
physical JJ 1_o
activity NN 1_o
in IN 1_o
bouts NNS 1_o
? . N
10 CD N
min NN N
in IN N
duration NN N
on IN N
park NN N
walks NNS N
due JJ N
to TO N
the DT N
lack NN N
of IN N
interruptions NNS N
in IN N
walking VBG N
. . N

Hence NNP N
the DT N
park NN N
environment NN N
better RBR N
facilitated VBD N
the DT N
achievement NN N
of IN N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
. . N

Further JJ N
research NN N
involving VBG N
a DT N
larger JJR N
, , N
more RBR N
heterogeneous JJ N
sample NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
neurocognitive JJ 1_o
functioning NN 1_o
in IN N
children NNS 1_p
previously RB 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
intrathecal JJ 1_i
methotrexate NN 1_i
compared VBN N
with IN N
triple JJ 1_i
intrathecal JJ 1_i
therapy NN 1_i
for IN N
the DT N
treatment NN N
of IN N
childhood NN 1_p
acute NN 1_p
lymphoblastic JJ 1_p
leukemia NN 1_p
. . 1_p

PURPOSE NNP N
For IN N
the DT N
majority NN N
of IN N
children NNS 1_p
with IN 1_p
acute JJ 1_p
lymphoblastic JJ 1_p
leukemia NN 1_p
( ( 1_p
ALL NNP 1_p
) ) 1_p
, , 1_p
CNS NNP 1_p
prophylaxis NN 1_p
consists VBZ 1_p
of IN 1_p
either DT 1_p
intrathecal JJ 1_i
( ( 1_i
IT NNP 1_i
) ) 1_i
methotrexate NN 1_i
or CC 1_i
triple VB 1_i
IT NNP 1_i
therapy NN 1_i
( ( 1_i
ie JJ 1_i
, , 1_i
methotrexate NN 1_i
with IN 1_i
both DT 1_i
cytarabine NN 1_i
and CC 1_i
hydrocortisone NN 1_i
) ) 1_i
. . 1_i

The DT N
long-term JJ N
neurotoxicities NNS N
of IN N
these DT N
two CD N
IT NNP N
strategies NNS N
have VBP N
not RB N
yet RB N
been VBN N
directly RB N
compared VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
multisite NN N
study NN N
, , N
171 CD 1_p
children NNS 1_p
with IN 1_p
standard-risk JJ 1_p
ALL NNP 1_p
, , 1_p
age NN 1_p
1 CD 1_p
to TO 1_p
9.99 CD 1_p
years NNS 1_p
at IN 1_p
diagnosis NN 1_p
, , 1_p
previously RB 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
IT NNP 1_i
methotrexate NNP 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
82 CD 1_p
) ) 1_p
or CC 1_p
to TO 1_p
triple VB 1_i
IT NNP 1_i
therapy NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
89 CD 1_p
) ) 1_p
on IN 1_p
CCG NNP 1_p
1952 CD 1_p
, , 1_p
underwent JJ 1_p
neurocognitive JJ 1_p
evaluation NN 1_p
by IN 1_p
a DT 1_p
licensed JJ 1_p
psychologist NN 1_p
at IN 1_p
a DT 1_p
mean NN 1_p
of IN 1_p
5.9 CD 1_p
years NNS 1_p
after IN 1_p
random JJ 1_p
assignment NN 1_p
. . 1_p

RESULTS JJ N
Patients NNPS 1_p
who WP 1_p
received VBD 1_p
IT NNP 1_i
methotrexate NNP 1_i
had VBD N
a DT N
mean JJ 1_o
Processing NNP 1_o
Speed NNP 1_o
Index NNP 1_o
that WDT N
was VBD N
3.6 CD N
points NNS N
lower JJR N
, , N
about IN N
one CD N
fourth JJ N
of IN N
a DT N
standard JJ N
deviation NN N
, , N
than IN N
those DT N
who WP N
received VBD N
triple JJ 1_i
IT NNP 1_i
therapy NN 1_i
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
after IN N
analysis NN N
was VBD N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
and CC N
time NN N
since IN N
diagnosis NN N
. . N

Likewise NNP N
, , N
19.5 CD 1_p
% NN 1_p
of IN 1_p
children NNS 1_p
in IN 1_p
the DT 1_p
IT NNP 1_i
methotrexate NNP 1_i
group NN 1_p
had VBD N
a DT N
Processing NNP 1_o
Speed NNP 1_o
Index NNP 1_o
score NN 1_o
in IN N
the DT N
below-average NN N
range NN N
compared VBN N
with IN N
6.9 CD N
% NN N
in IN N
the DT N
triple NN 1_i
IT NNP 1_i
therapy NN 1_i
group NN 1_i
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Otherwise UH N
, , N
the DT N
groups NNS N
performed VBD N
similarly RB N
on IN N
tests NNS 1_o
of IN 1_o
full-scale JJ 1_o
intelligence NN 1_o
quotient NN 1_o
, , 1_o
academic JJ 1_o
achievement NN 1_o
, , 1_o
attention/concentration NN 1_o
, , 1_o
memory NN 1_o
, , 1_o
and CC 1_o
visual JJ 1_o
motor NN 1_o
integration NN 1_o
. . 1_o

The DT N
association NN N
of IN N
treatment NN N
with IN N
measures NNS 1_o
of IN 1_o
cognitive JJ 1_o
functioning NN 1_o
was VBD N
not RB N
modified VBN N
by IN N
sex NN 1_p
or CC 1_p
age NN 1_p
at IN 1_p
diagnosis NN 1_p
. . 1_p

In IN N
the DT N
post-therapy JJ N
period NN N
, , N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
special JJ 1_o
education NN 1_o
services NNS 1_o
, , 1_o
neurologic JJ 1_o
events NNS 1_o
, , 1_o
or CC 1_o
use NN 1_o
of IN 1_o
psychotropic NN 1_o
medications NNS 1_o
. . 1_o

CONCLUSION NNP N
This DT N
study NN N
did VBD N
not RB N
show VB N
any DT N
clinically RB N
meaningful JJ N
differences NNS N
in IN N
neurocognitive JJ 1_o
functioning NN 1_o
between IN N
patients NNS N
previously RB N
randomly RB N
assigned VBN N
to TO N
IT NNP 1_i
methotrexate NN 1_i
or CC N
triple VB 1_i
IT NNP 1_i
therapy NN 1_i
except IN N
for IN N
a DT N
small JJ N
difference NN N
in IN N
processing VBG 1_o
speed NN 1_o
in IN N
the DT N
IT NNP 1_i
methotrexate NNP 1_i
group NN 1_i
. . 1_i

-DOCSTART- -X- O O

Comparison NNP N
of IN N
neodymium-doped JJ 1_i
yttrium NN 1_i
aluminum NN 1_i
garnet NN 1_i
laser NN 1_i
treatment NN 1_i
with IN N
cold JJ 1_i
knife NN 1_i
endoscopic NN 1_i
incision NN 1_i
of IN N
urethral JJ N
strictures NNS N
in IN N
male JJ 1_p
patients NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN 1_o
of IN N
visual JJ 1_i
laser NN 1_i
ablation NN 1_i
treatment NN 1_i
with IN 1_i
neodymium-doped JJ 1_i
yttrium NN 1_i
aluminum NN 1_i
garnet NN 1_i
( ( 1_i
Nd NNP 1_i
: : 1_i
YAG NN 1_i
) ) 1_i
laser NN N
in IN 1_p
male JJ 1_p
patients NNS 1_p
with IN 1_p
urethral JJ 1_p
strictures NNS 1_p
and CC N
to TO N
compare VB N
the DT N
effects NNS N
with IN N
those DT N
obtained VBN N
in IN N
patients NNS N
treated VBN N
with IN N
Sachse NNP N
's POS N
optical JJ N
urethrotomy NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty NNP 1_p
patients NNS 1_p
aged VBD 1_p
22 CD 1_p
to TO 1_p
83 CD 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
61.8 CD 1_p
) ) 1_p
with IN 1_p
primary JJ 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
26 CD 1_p
, , 1_p
52 CD 1_p
% NN 1_p
) ) 1_p
and CC 1_p
recurrent NN 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
24 CD 1_p
, , 1_p
48 CD 1_p
% NN 1_p
) ) 1_p
urethral JJ 1_p
strictures VBZ 1_p
0.3 CD 1_p
to TO 1_p
2.4 CD 1_p
cm NNS 1_p
long RB 1_p
qualified VBD 1_p
for IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
30 CD N
men NNS N
treated VBD N
using VBG N
visual JJ 1_i
laser NN 1_i
ablation NN 1_i
of IN 1_i
urethral JJ 1_i
strictures NNS 1_i
( ( 1_i
VLASU NNP 1_i
) ) 1_i
with IN 1_i
Nd NNP 1_i
: : 1_i
YAGlaser NN 1_i
and CC N
20 CD N
men NNS N
treated VBN N
by IN N
correction NN 1_i
of IN 1_i
urethral JJ 1_i
strictures NNS 1_i
using VBG 1_i
Sachse NNP 1_i
's POS 1_i
optical JJ 1_i
urethrotomy NN 1_i
. . 1_i

RESULTS VB N
At IN N
12-month JJ N
follow-up NN N
, , N
seven CD N
( ( N
35 CD N
% NN N
) ) N
patients NNS N
who WP N
underwent JJ N
optical JJ 1_i
urethrotomy NN 1_i
and CC N
21 CD N
( ( N
70 CD N
% NN N
) ) N
in IN N
the DT N
VLASU NNP 1_i
group NN N
did VBD N
not RB N
require VB N
repetition NN 1_o
of IN 1_o
the DT 1_o
procedure NN 1_o
. . 1_o

The DT N
choice NN N
of IN N
VLASU NNP 1_i
as IN N
a DT N
method NN N
of IN N
treatment NN N
significantly RB N
decreased VBD 1_o
the DT 1_o
probability NN 1_o
of IN 1_o
therapeutic JJ 1_o
failure NN 1_o
and CC 1_o
recurrence NN 1_o
of IN 1_o
urethral JJ 1_o
strictures NNS 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSION NNP N
VLASU NNP 1_i
can MD N
be VB N
used VBN N
as IN N
a DT N
method NN N
of IN N
treatment NN N
of IN N
this DT N
disorder NN N
. . N

It PRP N
is VBZ N
an DT N
effective JJ N
, , N
modern JJ N
, , N
low-invasive JJ N
, , N
and CC N
repeatable JJ N
technique NN N
and CC N
is VBZ N
technically RB N
simple JJ N
and CC N
easy JJ N
to TO N
master NN N
. . N

It PRP N
can MD N
be VB N
used VBN N
in IN N
cases NNS N
in IN N
which WDT N
introduction NN N
of IN N
a DT N
22 CD N
Char NNP N
optical JJ N
urethrotome NN N
into IN N
the DT N
stricture NN N
site NN N
is VBZ N
impossible JJ N
, , N
as RB N
well RB N
as IN N
for IN N
treatment NN N
of IN N
multiple JJ N
strictures NNS N
during IN N
one CD N
procedure NN N
. . N

-DOCSTART- -X- O O

[ RB N
Preoperative NNP N
chemotherapy NN 1_i
of IN N
esophageal JJ N
cancer NN N
] NNP N
. . N

A NNP 1_p
series NN 1_p
of IN 1_p
25 CD 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
esophageal NN 1_p
cancer NN 1_p
treated VBN 1_p
from IN 1_p
Mar NNP 1_p
. . 1_p

1981 CD 1_p
to TO 1_p
Sep. VB 1_p
1982 CD 1_p
by IN 1_p
preoperative JJ 1_i
chemotherapy NN 1_i
plus CC 1_i
surgery NN 1_i
is VBZ N
reported VBN N
. . N

All PDT N
the DT N
patients NNS 1_p
came VBD 1_p
from IN 1_p
the DT 1_p
hospitals NNS 1_p
of IN 1_p
the DT 1_p
cooperative JJ 1_p
research NN 1_p
group NN 1_p
and CC N
were VBD N
randomized VBN N
into IN N
chemotherapy NN 1_i
and CC N
control NN 1_i
groups NNS N
. . N

They PRP N
were VBD N
proved VBN N
by IN N
X-ray NNP N
, , N
cytology NN N
and CC N
histopathology NN N
prior RB N
to TO N
treatment NN N
. . N

By IN 1_p
histology NN 1_p
, , 1_p
22 CD 1_p
cases NNS 1_p
were VBD 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
, , 1_p
1 CD 1_p
adenocarcinoma NN 1_p
and CC 1_p
2 CD 1_p
squamous JJ 1_p
adenocarcinoma NN 1_p
. . 1_p

The DT N
COF NNP N
chemotherapy NN 1_i
consisted VBD N
of IN N
Vincristine NNP 1_i
1 CD 1_i
mg NN 1_i
, , 1_i
cyclophosphamide RB 1_i
600 CD 1_i
mg NNS 1_i
and CC 1_i
5-fluorouracil JJ 1_i
500 CD 1_i
mg NN 1_i
IV NNP 1_i
on IN N
days NNS N
1 CD N
and CC N
8 CD N
with IN N
or CC N
without IN N
the DT N
addition NN N
of IN N
Pingyangmycin NNP 1_i
, , N
a DT N
drug NN N
equivalent NN N
to TO N
Bleomycin NNP 1_i
A5 NNP 1_i
, , N
at IN N
the DT N
dose NN N
of IN N
10 CD N
mg NNS N
IM NNP N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
6 CD N
and CC N
8 CD N
. . N

The DT N
interval NN N
between IN N
the DT N
ending VBG N
of IN N
chemotherapy NN 1_i
and CC N
the DT N
surgical JJ 1_i
resection NN 1_i
was VBD N
5-6 JJ N
days NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
preoperative JJ N
chemotherapy NN N
caused VBD N
no DT 1_o
myelosuppression NN 1_o
, , N
but CC N
merely RB N
mild JJ 1_o
gastrointestinal JJ 1_o
symptoms NNS 1_o
. . 1_o

All DT N
patients NNS N
were VBD N
operated VBN N
and CC N
resected VBN N
without IN N
difficulty NN N
. . N

The DT N
subjective JJ N
improvement NN N
in IN N
various JJ N
degrees NNS N
and CC N
the DT N
shrinkage NN 1_o
of IN 1_o
tumor NN 1_o
in IN 1_o
the DT 1_o
X-ray JJ 1_o
films NNS 1_o
were VBD N
present JJ N
in IN N
5/25 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ N
chemotherapy NN 1_i
. . 1_i

The DT N
histopathological JJ 1_o
changes NNS 1_o
in IN N
the DT N
chemotherapy NN N
and CC N
control NN N
groups NNS N
( ( N
16 CD N
specimens NNS N
) ) N
were VBD N
different JJ N
. . N

In IN N
the DT N
chemotherapy NN 1_i
group NN N
, , N
excessive JJ 1_o
keratinization NN 1_o
in IN 1_o
the DT 1_o
squamous JJ 1_o
component NN 1_o
of IN 1_o
the DT 1_o
esophageal NN 1_o
cancerous JJ 1_o
tissue NN 1_o
appeared VBD N
in IN N
the DT N
resected JJ N
specimens NNS N
. . N

The DT N
incidence NN 1_o
of IN 1_o
degeneration NN 1_o
and CC 1_o
necrosis NN 1_o
in IN 1_o
the DT 1_o
squamous JJ 1_o
epithelium NN 1_o
adjacent NN 1_o
to TO 1_o
carcinoma VB 1_o
was VBD N
higher RBR N
in IN N
the DT N
chemotherapy NN 1_i
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
results NNS N
suggested VBD N
that IN N
such JJ N
combined JJ N
modality NN N
is VBZ N
worth IN N
further JJ N
study NN N
. . N

-DOCSTART- -X- O O

Literacy NNP N
skills NNS N
in IN N
primary JJ 1_p
school-aged JJ 1_p
children NNS 1_p
with IN 1_p
pragmatic JJ 1_p
language NN 1_p
impairment NN 1_p
: : 1_p
a DT N
comparison NN N
with IN N
children NNS 1_p
with IN 1_p
specific JJ 1_p
language NN 1_p
impairment NN 1_p
. . 1_p

BACKGROUND NNP N
Children NNP 1_p
with IN 1_p
pragmatic JJ 1_p
language NN 1_p
impairment NN 1_p
( ( 1_p
CwPLI NNP 1_p
) ) 1_p
are VBP N
characterized VBN N
by IN N
difficulties NNS N
with IN N
the DT N
interpersonal JJ N
use NN N
of IN N
language NN N
in IN N
social JJ N
contexts NN N
and CC N
they PRP N
possess VBP N
a DT N
range NN N
of IN N
language NN N
difficulties NNS N
that WDT N
affect VBP N
their PRP$ N
educational JJ N
attainment NN N
. . N

Since IN N
literacy NN N
skills NNS N
are VBP N
central JJ N
to TO N
this DT N
attainment NN N
, , N
one CD N
way NN N
of IN N
identifying VBG N
appropriate JJ N
support NN N
needs NNS N
for IN N
CwPLI NNP 1_p
would MD N
be VB N
to TO N
profile VB N
their PRP$ N
reading NN N
and CC N
writing VBG N
skills NNS N
as IN N
a DT N
group NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
word NN 1_o
reading NN 1_o
, , 1_o
non-word JJ 1_o
reading NN 1_o
, , 1_o
reading VBG 1_o
comprehension NN 1_o
, , 1_o
and CC 1_o
written VBN 1_o
expression NN 1_o
skills NNS 1_o
of IN N
CwPLI NNP N
and CC N
a DT N
comparison NN N
group NN N
of IN N
children NNS 1_p
with IN 1_p
specific JJ 1_p
language NN 1_p
impairment NN 1_p
( ( 1_p
CwSLI NNP 1_p
) ) 1_p
. . 1_p

CwSLI NNP N
were VBD N
recruited VBN N
in IN N
order NN N
to TO N
examine VB N
any DT N
overlaps NNS N
in IN N
literacy NN N
impairments NNS N
for IN N
the DT N
two CD N
groups NNS N
. . N

METHODS NNP N
& CC N
PROCEDURES NNP N
Primary NNP 1_p
school-aged JJ 1_p
CwPLI NNP 1_p
( ( 1_p
n= JJ 1_p
59 CD 1_p
) ) 1_p
and CC 1_p
CwSLI NNP 1_p
( ( 1_p
n= JJ 1_p
12 CD 1_p
) ) 1_p
were VBD 1_p
recruited VBN 1_p
from IN 1_p
speech NN 1_p
and CC 1_p
language NN 1_p
therapists NNS 1_p
. . 1_p

Children NNP N
completed VBD N
standardized JJ 1_i
assessments NNS 1_i
of IN N
literacy NN N
skills NNS N
. . N

The DT N
level NN N
of IN N
impairment NN N
for IN N
each DT N
component NN N
literacy NN N
skill NN N
was VBD N
examined VBN N
for IN N
CwPLI NNP N
and CC N
CwSLI NNP N
. . N

OUTCOMES NNP N
& CC N
RESULTS NNP N
For IN N
the DT N
CwPLI NNP N
, , N
group NN N
mean JJ N
scores NNS N
on IN N
each DT N
of IN N
the DT N
literacy NN 1_o
skills NNS 1_o
were VBD N
at IN N
the DT N
lower JJR N
end NN N
of IN N
the DT N
normal JJ N
range NN N
compared VBN N
with IN N
population NN N
norms NNS N
. . N

The DT N
range NN N
of IN N
individual JJ 1_o
scores NNS 1_o
was VBD N
large JJ N
, , N
with IN N
some DT N
children NNS N
scoring VBG N
near IN N
floor NN N
level NN N
and CC N
others NNS N
scoring VBG N
up RB N
to TO N
2 CD N
SDs NNP N
( ( N
standard JJ N
deviations NNS N
) ) N
above IN N
the DT N
mean NN N
, , N
illustrating VBG N
the DT N
heterogeneity NN N
of IN N
literacy NN N
skills NNS N
within IN N
the DT N
group NN N
. . N

For IN N
the DT N
CwSLI NNP N
, , N
group NN N
mean JJ 1_o
scores NNS 1_o
on IN 1_o
each DT 1_o
of IN 1_o
the DT 1_o
literacy NN 1_o
skills NNS 1_o
were VBD N
between IN N
1 CD N
SD NNP N
and CC N
2 CD N
SDs NNP N
below IN N
the DT N
population NN N
mean NN N
. . N

CwSLI NNP N
were VBD N
significantly RB N
more JJR N
impaired JJ N
on IN N
all DT N
of IN N
the DT N
literacy NN 1_o
measures NNS 1_o
compared VBN N
with IN N
CwPLI NNP N
. . N

This DT N
difference NN N
remained VBD N
even RB N
when WRB N
receptive JJ N
language NN 1_o
ability NN 1_o
and CC N
non-verbal JJ 1_o
intelligence NN 1_o
were VBD N
controlled VBN N
for IN N
. . N

CONCLUSIONS NNP N
& CC N
IMPLICATIONS NNP N
The DT N
results NNS N
demonstrate VBP N
that IN N
there EX N
is VBZ N
a DT N
high JJ N
level NN 1_o
of IN 1_o
literacy NN 1_o
impairment NN 1_o
within IN N
CwPLI NNP 1_p
and CC 1_p
CwSLI NNP 1_p
, , N
providing VBG N
evidence NN N
that IN N
individualized JJ N
literacy NN N
skill NN N
intervention NN N
is VBZ N
important JJ N
for IN N
the DT N
long-term JJ N
academic JJ N
outcome NN N
of IN N
these DT N
children NNS N
. . N

-DOCSTART- -X- O O

Spironolactone NN 1_i
for IN N
heart NN N
failure NN N
with IN N
preserved JJ N
ejection NN 1_o
fraction NN 1_o
. . 1_o

BACKGROUND NNP N
Mineralocorticoid-receptor NNP N
antagonists NNS N
improve VBP N
the DT N
prognosis NN N
for IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
and CC N
a DT N
reduced JJ N
left NN N
ventricular JJ N
ejection NN N
fraction NN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS 1_o
of IN N
spironolactone NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
and CC 1_p
a DT 1_p
preserved JJ 1_p
left NN 1_p
ventricular JJ 1_p
ejection NN 1_p
fraction NN 1_p
. . 1_p

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
, , N
we PRP N
assigned VBD N
3445 CD 1_p
patients NNS 1_p
with IN 1_p
symptomatic JJ 1_p
heart NN 1_p
failure NN 1_p
and CC 1_p
a DT 1_p
left JJ 1_p
ventricular JJ 1_p
ejection NN 1_p
fraction NN 1_p
of IN 1_p
45 CD 1_p
% NN 1_p
or CC 1_p
more JJR 1_p
to TO N
receive VB 1_i
either DT 1_i
spironolactone NN 1_i
( ( 1_i
15 CD 1_i
to TO 1_i
45 CD 1_i
mg NNS 1_i
daily RB 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
composite JJ 1_o
of IN 1_o
death NN 1_o
from IN 1_o
cardiovascular JJ 1_o
causes NNS 1_o
, , 1_o
aborted VBD 1_o
cardiac JJ 1_o
arrest NN 1_o
, , 1_o
or CC 1_o
hospitalization NN 1_o
for IN 1_o
the DT 1_o
management NN 1_o
of IN 1_o
heart NN 1_o
failure NN 1_o
. . 1_o

RESULTS NN N
With IN N
a DT N
mean JJ N
follow-up NN N
of IN N
3.3 CD N
years NNS N
, , N
the DT N
primary JJ N
outcome NN N
occurred VBD N
in IN N
320 CD N
of IN N
1722 CD N
patients NNS N
in IN N
the DT N
spironolactone NN 1_i
group NN N
( ( N
18.6 CD N
% NN N
) ) N
and CC N
351 CD N
of IN N
1723 CD N
patients NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
20.4 CD N
% NN N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
0.89 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.77 CD N
to TO N
1.04 CD N
; : N
P=0.14 NNP N
) ) N
. . N

Of IN N
the DT N
components NNS N
of IN N
the DT N
primary JJ N
outcome NN N
, , N
only RB N
hospitalization NN 1_o
for IN 1_o
heart NN 1_o
failure NN 1_o
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN N
in IN N
the DT N
spironolactone NN 1_i
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
206 CD N
patients NNS N
[ JJ N
12.0 CD N
% NN N
] NNP N
vs. IN N
245 CD N
patients NNS N
[ JJ N
14.2 CD N
% NN N
] NN N
; : N
hazard CC N
ratio NN N
, , N
0.83 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.69 CD N
to TO N
0.99 CD N
, , N
P=0.04 NNP N
) ) N
. . N

Neither CC N
total JJ 1_o
deaths NNS 1_o
nor CC N
hospitalizations NNS 1_o
for IN N
any DT N
reason NN N
were VBD N
significantly RB N
reduced VBN N
by IN N
spironolactone NN 1_i
. . 1_i

Treatment NN N
with IN N
spironolactone NN 1_i
was VBD N
associated VBN N
with IN N
increased JJ N
serum NN 1_o
creatinine NN 1_o
levels NNS 1_o
and CC N
a DT N
doubling NN N
of IN N
the DT N
rate NN 1_o
of IN 1_o
hyperkalemia NN 1_o
( ( N
18.7 CD N
% NN N
, , N
vs. FW N
9.1 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
) ) N
but CC N
reduced JJ N
hypokalemia NN N
. . N

With IN N
frequent JJ N
monitoring NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
, , N
a DT N
serum JJ 1_o
creatinine NN 1_o
level NN 1_o
of IN N
3.0 CD N
mg NNS N
per IN N
deciliter NN N
( ( N
265 CD N
?mol NN N
per IN N
liter NN N
) ) N
or CC N
higher JJR N
, , N
or CC N
dialysis NN N
. . N

CONCLUSIONS NNP N
In IN 1_p
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
and CC 1_p
a DT 1_p
preserved JJ 1_p
ejection NN 1_p
fraction NN 1_p
, , 1_p
treatment NN N
with IN 1_i
spironolactone NN 1_i
did VBD N
not RB N
significantly RB N
reduce VB N
the DT 1_o
incidence NN 1_o
of IN 1_o
the DT 1_o
primary JJ 1_o
composite JJ 1_o
outcome NN 1_o
of IN 1_o
death NN 1_o
from IN 1_o
cardiovascular JJ 1_o
causes NNS 1_o
, , 1_o
aborted VBD 1_o
cardiac JJ 1_o
arrest NN 1_o
, , 1_o
or CC 1_o
hospitalization NN 1_o
for IN 1_o
the DT 1_o
management NN 1_o
of IN 1_o
heart NN 1_o
failure NN 1_o
. . 1_o

( ( N
Funded VBN N
by IN N
the DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
; : N
TOPCAT NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00094302 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
TENS NNP N
on IN N
pain NN 1_o
, , 1_o
medications NNS 1_o
, , 1_o
and CC 1_o
pulmonary JJ 1_o
function NN 1_o
following VBG 1_p
coronary JJ 1_p
artery JJ 1_p
bypass NN 1_p
graft NN 1_p
surgery NN 1_p
. . 1_p

The DT N
efficacy NN N
of IN N
transcutaneous JJ 1_i
electrical JJ 1_i
nerve NN 1_i
stimulation NN 1_i
( ( 1_i
TENS NNP 1_i
) ) 1_i
as IN N
an DT N
adjunct NN N
to TO N
narcotic JJ N
medications NNS N
for IN N
the DT N
management NN N
of IN N
postoperative JJ 1_o
pain NN 1_o
was VBD N
assessed VBN N
in IN N
a DT N
prospective JJ 1_p
, , 1_p
randomized VBN 1_p
, , 1_p
controlled VBD 1_p
study NN 1_p
of IN 1_p
patients NNS 1_p
following VBG 1_p
coronary JJ 1_p
artery JJ 1_p
bypass NN 1_p
graft NN 1_p
( ( 1_p
CABG NNP 1_p
) ) 1_p
surgery NN 1_p
with IN 1_p
the DT 1_p
right NN 1_p
or CC 1_p
left VBD 1_p
internal JJ 1_p
thoracic NN 1_p
artery NN 1_p
( ( 1_p
ITA NNP 1_p
) ) 1_p
. . 1_p

Forty-five JJ 1_p
male JJ 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
57 CD 1_p
+/- JJ 1_p
6 CD 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
( ( N
1 CD N
) ) N
TENS NN 1_i
, , N
( ( N
2 CD N
) ) N
placebo NN 1_i
TENS NNP 1_i
, , 1_i
or CC 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
control NN 1_i
treatments NNS 1_i
( ( N
n JJ N
= RB N
15 CD N
each DT N
) ) N
, , N
following VBG N
extubation NN N
and CC N
during IN N
the DT N
24- JJ N
to TO N
72-h JJ N
postoperative JJ N
period NN N
. . N

Two-way JJ N
analysis NN N
of IN N
variance NN N
tests NNS N
indicated VBD N
no DT N
significant JJ N
differences NNS N
among IN N
treatment NN N
groups NNS N
for IN N
( ( 1_o
1 CD 1_o
) ) 1_o
pain NN 1_o
with IN 1_o
cough NN 1_o
, , 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
narcotic JJ 1_o
medication NN 1_o
intake NN 1_o
, , 1_o
( ( 1_o
3 CD 1_o
) ) 1_o
FVC NNP 1_o
, , 1_o
( ( 1_o
4 CD 1_o
) ) 1_o
FEV1 NNP 1_o
, , 1_o
and CC 1_o
( ( 1_o
5 CD 1_o
) ) 1_o
PEFR NNP 1_o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
pain VBP 1_o
at IN 1_o
rest NN 1_o
reported VBN N
by IN N
the DT N
TENS NNP 1_p
group NN 1_p
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
reported VBN N
by IN N
the DT N
control NN N
group NN N
( ( N
treatment NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.04 CD N
) ) N
, , N
although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
TENS NNP N
and CC N
placebo NN N
or CC N
between IN N
the DT N
placebo NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

All DT N
six CD N
criterion NN N
measures NNS N
were VBD N
characterized VBN N
by IN N
significant JJ N
changes NNS N
over IN N
time NN N
for IN N
the DT N
entire JJ N
group NN N
( ( N
n JJ N
= VBZ N
45 CD N
; : N
time NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
, , N
as IN N
follows VBZ N
: : N
pain NN 1_o
and CC 1_o
medication NN 1_o
intake NN 1_o
were VBD N
similar JJ N
on IN N
days NNS N
1 CD N
and CC N
2 CD N
, , N
but CC N
were VBD N
significantly RB N
less JJR N
on IN N
day NN N
3 CD N
, , N
and CC N
pulmonary JJ 1_o
functions NNS 1_o
were VBD N
significantly RB N
lower JJR N
than IN N
preoperatively RB N
on IN N
day NN N
1 CD N
, , N
decreased VBD N
further RBR N
on IN N
day NN N
2 CD N
, , N
and CC N
despite IN N
an DT N
improvement NN N
on IN N
day NN N
3 CD N
, , N
remained VBD N
significantly RB N
lower JJR N
than IN N
preoperative JJ N
values NNS N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
suggests VBZ N
that IN N
the DT N
addition NN N
of IN N
TENS NNP 1_i
, , N
applied VBD N
continuously RB N
during IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
following VBG N
CABG NNP N
with IN N
ITA NNP N
, , N
may MD N
not RB N
be VB N
advantageous JJ N
in IN N
pain NN 1_o
management NN 1_o
or CC N
the DT N
prevention NN N
of IN N
pulmonary JJ 1_o
dysfunction NN 1_o
. . 1_o

-DOCSTART- -X- O O

Is VBZ N
anti-Pseudomonas JJ N
therapy NN N
warranted VBN N
in IN N
acute JJ N
respiratory NN 1_o
exacerbations NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
? . N
A DT N
controlled JJ N
study NN N
was VBD N
designed VBN N
to TO N
clarify VB N
the DT N
indications NNS N
for IN N
antibiotic JJ N
therapy NN N
in IN N
children NNS 1_p
with IN 1_p
advanced JJ 1_p
cystic JJ 1_p
fibrosis NN 1_p
hospitalized VBN 1_p
with IN 1_p
respiratory JJ 1_p
exacerbations NNS 1_p
. . 1_p

Twenty-two JJ 1_p
children NNS 1_p
with IN 1_p
severe JJ 1_p
CF NNP 1_p
and CC 1_p
signs NNS 1_p
of IN 1_p
acute NN 1_p
lower JJR 1_p
respiratory NN 1_p
infection NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
cloxacillin NN 1_i
or CC 1_i
carbenicillin NN 1_i
plus CC 1_i
gentamicin NN 1_i
administered VBD N
intravenously RB N
for IN N
ten JJ N
days NNS N
. . N

Other JJ N
aspects NNS N
of IN N
therapy NN N
were VBD N
constant JJ N
. . N

The DT N
groups NNS N
were VBD N
comparable JJ N
in IN N
all DT N
respects NNS N
and CC N
Pseudomonas NNP 1_p
aeruginosa NN 1_p
was VBD 1_p
the DT 1_p
predominant JJ 1_p
sputum NN 1_p
pathogen NN 1_p
in IN 1_p
most JJS 1_p
patients NNS 1_p
. . 1_p

Clinical JJ 1_o
improvement NN 1_o
, , 1_o
chest VBP 1_o
radiograph NN 1_o
changes NNS 1_o
, , 1_o
evidence NN 1_o
of IN 1_o
airway JJ 1_o
obstruction NN 1_o
, , 1_o
and CC 1_o
bacteriologic JJ 1_o
flora NNS 1_o
of IN 1_o
sputum NN 1_o
were VBD N
no DT N
different JJ N
regardless NN N
of IN N
the DT N
regimen NNS N
used VBN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
anti-Pseudomonas JJ N
medication NN N
in IN N
these DT N
children NNS N
may MD N
not RB N
always RB N
be VB N
necessary JJ N
. . N

These DT N
observations NNS N
need VBP N
to TO N
be VB N
confirmed VBN N
by IN N
blind-controlled JJ N
studies NNS N
in IN N
larger JJR N
numbers NNS N
of IN N
patients NNS N
with IN N
mild JJ N
as RB N
well RB N
as IN N
severe JJ N
respiratory NN N
involvement NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
zero-balanced JJ 1_i
ultrafiltration NN 1_i
and CC 1_i
modified VBN 1_i
ultrafiltration NN 1_i
on IN N
pulmonary JJ N
function NN N
after IN 1_p
cardiac JJ 1_p
surgery NN 1_p
in IN 1_p
infants NNS 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
determine VB N
the DT N
protective JJ N
effect NN N
of IN N
zero-balanced JJ 1_i
ultrafiltration NN 1_i
and CC 1_i
modified VBN 1_i
ultrafiltration NN 1_i
on IN N
infants NNS 1_p
' POS 1_p
pulmonary JJ 1_p
function NN 1_p
after IN 1_p
cardiac JJ 1_p
surgery NN 1_p
. . 1_p

METHODS NNP N
Sixty NNP 1_p
infants NNS 1_p
with IN 1_p
congenital JJ 1_p
heart NN 1_p
diseases NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD 1_i
groups NNS 1_i
: : 1_i
a DT 1_i
zero-balanced JJ 1_i
ultrafiltration NN 1_i
group NN 1_i
( ( 1_i
Z NNP 1_i
group NN 1_i
) ) 1_i
, , 1_i
a DT 1_i
modified JJ 1_i
ultrafiltration NN 1_i
group NN 1_i
( ( 1_i
M NNP 1_i
group NN 1_i
) ) 1_i
and CC 1_i
a DT 1_i
zero-balanced JJ 1_i
ultrafiltration NN 1_i
with IN 1_i
modified JJ 1_i
ultrafiltration NN 1_i
group NN 1_i
( ( 1_i
Z+M NNP 1_i
group NN 1_i
) ) 1_i
. . N

Oxygenation NNP 1_o
index NN 1_o
( ( 1_o
OI NNP 1_o
) ) 1_o
, , 1_o
difference NN 1_o
of IN 1_o
alveoli-arterial JJ 1_o
oxygen NN 1_o
pressure NN 1_o
( ( 1_o
P NNP 1_o
( ( 1_o
A-? NNP 1_o
) ) 1_o
O2 NNP 1_o
) ) 1_o
, , 1_o
static JJ 1_o
lung NN 1_o
compliance NN 1_o
( ( 1_o
Cstat NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
airway RB 1_o
resistance NN 1_o
( ( 1_o
Raw NNP 1_o
) ) 1_o
were VBD 1_o
measured VBN 1_o
before IN 1_i
caridopulmonary JJ 1_i
bypass NN 1_i
( ( 1_i
CPB NNP 1_i
, , 1_i
T1 NNP 1_i
) ) 1_i
, , 1_i
20 CD 1_i
minutes NNS 1_i
after IN 1_i
the DT 1_i
CPB NNP 1_i
( ( 1_i
T2 NNP 1_i
) ) 1_i
, , 1_i
2 CD 1_i
h NN 1_i
after IN 1_i
the DT 1_i
operation NN 1_i
( ( 1_i
T3 NNP 1_i
) ) 1_i
, , 1_i
6 CD 1_i
h NN 1_i
after IN 1_i
the DT 1_i
operation NN 1_i
( ( 1_i
T4 NNP 1_i
) ) 1_i
and CC 1_i
12 CD 1_i
h NN 1_i
after IN 1_i
the DT 1_i
operation NN 1_i
( ( 1_i
T5 NNP 1_i
) ) 1_i
. . 1_i

The DT 1_o
time NN 1_o
of IN 1_o
mechanical JJ 1_o
ventilation NN 1_o
was VBD N
also RB N
monitored VBN N
. . N

RESULTS NNP N
After IN N
the DT 1_o
CPB NNP 1_o
, , 1_o
OI NNP 1_o
and CC 1_o
Cstat NNP 1_o
in IN N
all DT N
groups NNS N
decreased VBD N
significantly RB N
, , N
while IN 1_o
Raw NNP 1_o
and CC 1_o
P NNP 1_o
( ( 1_o
A-? NNP 1_o
) ) 1_o
O2 NNP 1_o
increased VBD 1_o
significantly RB N
. . N

At IN N
T3 NNP 1_o
, , 1_o
T4 NNP 1_o
and CC 1_o
T5 NNP 1_o
, , 1_o
OI NNP 1_o
and CC 1_o
Cstat NNP 1_o
in IN 1_o
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP 1_o
0.05 CD 1_o
) ) 1_o
, , 1_o
Raw NNP 1_o
and CC 1_o
P NNP 1_o
( ( 1_o
A-? NNP 1_o
) ) 1_o
O2 NNP 1_o
in IN 1_o
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ventilation NN 1_o
time NN 1_o
in IN 1_o
the DT N
Z+M NNP N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP 1_i
Zero-balanced JJ 1_i
ultrafiltration NN 1_i
and CC 1_i
modified JJ 1_i
ultrafiltration NN 1_i
can MD 1_i
effectively RB N
promote VB N
the DT N
pulmonary JJ N
function NN N
after IN N
cardiac JJ N
surgery NN N
in IN N
infants NNS N
. . N

-DOCSTART- -X- O O

Weight-adjusted JJ N
dalteparin NN 1_i
for IN N
prevention NN N
of IN N
vascular JJ 1_o
thromboembolism NN 1_o
in IN N
advanced JJ 1_p
pancreatic JJ 1_p
cancer NN 1_p
patients NNS 1_p
decreases VBZ N
serum JJ 1_o
tissue NN 1_o
factor NN 1_o
and CC 1_o
serum-mediated JJ 1_o
induction NN 1_o
of IN 1_o
cancer NN 1_o
cell NN 1_o
invasion NN 1_o
. . 1_o

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
role NN N
of IN N
tissue NN N
factor NN N
and CC N
serum-induced JJ N
cell NN N
invasion NN N
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_o
pancreatic JJ 1_o
cancer NN 1_o
( ( 1_p
APC NNP 1_p
) ) 1_p
. . 1_p

A DT N
cohort NN 1_p
of IN 1_p
39 CD 1_p
patients NNS 1_p
with IN 1_p
APC NNP 1_p
, , 1_p
without IN 1_p
thrombosis NN 1_p
, , 1_p
receiving VBG 1_p
chemotherapy NN 1_i
, , N
were VBD N
entered VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
ISRCTN NNP N
= NNP N
76464767 CD N
) ) N
of IN N
thromboprevention NN 1_i
with IN 1_i
weight-adjusted JJ 1_i
dalteparin NN 1_i
( ( N
WAD NNP N
) ) N
. . N

A DT N
total NN N
of IN N
19 CD N
patients NNS N
received VBD N
WAD NNP 1_i
, , N
the DT N
remaining VBG N
20 CD N
acting VBG N
as IN N
a DT N
control NN 1_i
group NN 1_i
. . 1_i

Serum NNP N
from IN N
baseline NN N
and CC N
week NN N
8 CD N
was VBD N
analysed VBN N
for IN N
circulating-tissue JJ N
factor NN N
antigen NN N
using VBG N
ELISA NNP N
. . N

Circulating-tissue NNP 1_o
factor NN 1_o
antigen NN 1_o
rose VBD N
from IN N
324 CD N
pg/ml NN N
, , N
[ NNP N
interquartile NN N
range NN N
( ( N
IQR NNP N
) ) N
282-347 CD N
pg/ml NN N
] NN N
to TO N
356 CD N
pg/ml NN N
, , N
( ( N
IQR NNP N
319-431 NNP N
pg/ml NN N
) ) N
in IN N
controls NNS N
( ( N
C NNP N
) ) N
, , N
and CC N
decreased VBN N
in IN N
the DT N
dalteparin-treated JJ N
group NN N
( ( N
D NNP N
) ) N
from IN N
336 CD N
pg/ml NN N
( ( N
IQR NNP N
281-346 CD N
pg/ml NN N
) ) N
to TO N
303 CD N
pg/ml NN N
( ( N
IQR NNP N
274-339 CD N
pg/ml NN N
) ) N
. . N

The DT N
difference NN N
in IN N
median JJ N
percentage NN N
change NN N
between IN N
D NNP N
and CC N
C NNP N
was VBD N
statistically RB N
significant JJ N
[ JJ N
-4.0 NN N
( ( N
D NNP N
) ) N
vs. FW N
4.7 CD N
( ( N
C NNP N
) ) N
; : N
P NNP N
= VBZ N
0.005 CD N
, , N
n RB N
= VBZ N
39 CD N
] NN N
. . N

Serum-induced JJ 1_o
cellular JJ 1_o
invasion NN 1_o
of IN 1_o
MIA-Paca-2 NNP 1_o
cells NNS 1_o
in IN N
response NN N
to TO N
patient VB N
serum NN N
was VBD N
studied VBN N
using VBG N
a DT N
Boyden NNP N
chamber NN N
assay NN N
in IN N
30 CD N
patients NNS N
( ( N
14 CD N
WAD NNP N
and CC N
16 CD N
C NNP N
) ) N
. . N

The DT N
median JJ 1_o
percentage NN 1_o
change NN 1_o
between IN N
C NNP N
and CC N
D NNP N
was VBD N
significant JJ N
[ JJ N
+54.9 NN N
( ( N
C NNP N
) ) N
vs. FW N
-21.9 FW N
( ( N
D NNP N
) ) N
P NNP N
= $ N
0.025 CD N
, , N
n RB N
= VBZ N
30 CD N
] NN N
. . N

There EX N
was VBD N
a DT N
weak JJ N
correlation NN N
between IN N
BB-tissue NNP N
factor NN N
reduction NN N
and CC N
cellular JJ N
invasion NN N
reduction NN N
( ( N
Spearman NNP N
) ) N
[ VBZ N
0.384 CD N
( ( N
P NNP N
= NNP N
0.037 CD N
, , N
n RB N
= VBZ N
30 CD N
) ) N
] NN N
. . N

APC NNP 1_p
patients NNS 1_p
treated VBD 1_p
with IN N
WAD NNP N
have VBP N
lower JJR 1_o
tissue NN 1_o
factor NN 1_o
antigen NN 1_o
levels NNS 1_o
and CC 1_o
attenuated JJ 1_o
induction NN 1_o
of IN 1_o
cellular JJ 1_o
invasion NN 1_o
in IN 1_o
their PRP$ 1_o
blood NN 1_o
. . 1_o

These DT N
assays NNS N
may MD N
provide VB N
useful JJ N
markers NNS N
to TO N
guide VB N
appropriate JJ N
dalteparin NN N
( ( N
and CC N
other JJ N
low-molecular JJ N
weight NN N
heparin NN N
) ) N
dosing VBG N
schedules NNS N
to TO N
optimize VB N
anticancer JJ 1_o
effects NNS 1_o
of IN N
dalteparin NN N
in IN N
APC NNP N
. . N

-DOCSTART- -X- O O

[ JJ 1_i
Prophylactic NNP 1_i
intraaortic JJ 1_i
balloon NN 1_i
pumping VBG 1_i
in IN N
high-risk JJ 1_p
cardiac JJ 1_p
surgery NN 1_p
patients NNS 1_p
] VBP 1_p
. . N

BACKGROUND NNP N
We PRP N
examined VBD N
the DT N
impact NN N
of IN N
prophylactic JJ 1_i
IABP NNP 1_i
insertion NN 1_i
in IN N
EuroSCORE-stratified JJ 1_p
high-risk JJ 1_p
cardiac NN 1_p
surgery NN 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
score NN 1_p
?8 NN 1_p
. . 1_p

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP N
randomized JJ N
trial NN N
with IN 1_p
104 CD 1_p
patients NNS 1_p
either CC 1_i
without IN 1_i
prophylactic JJ 1_i
IABP NNP 1_i
insertion NN 1_i
( ( 1_i
group NN 1_i
A NNP 1_p
, , 1_p
n=52 NN 1_p
) ) 1_p
or CC 1_p
with IN 1_p
IABP NNP 1_i
( ( 1_i
group NN 1_i
B NNP 1_p
, , 1_p
n=52 NN 1_p
) ) 1_p
was VBD 1_p
conducted VBN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
30-day JJ 1_o
mortality NN 1_o
. . 1_o

RESULTS VB 1_o
The DT 1_p
median JJ 1_p
age NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
was VBD 1_p
74 CD 1_p
years NNS 1_p
and CC 1_p
43 CD 1_p
% NN 1_p
of IN 1_p
participants NNS 1_p
were VBD 1_p
females NNS 1_o
. . 1_o

The DT 1_o
30-day JJ 1_o
mortality NN 1_o
did VBD 1_o
not RB 1_o
differ VB N
between IN N
group NN N
A NNP N
( ( N
17.3 CD N
% NN N
) ) N
and CC N
group NN N
B NNP N
( ( N
13.4 CD N
% NN N
; : N
p=0.78 NN N
) ) N
. . N

The DT 1_o
median JJ 1_o
hospital NN 1_o
stay NN 1_o
was VBD 1_o
14 CD N
days NNS N
in IN N
both DT N
groups NNS N
. . N

Intra- NNP N
and CC N
postoperative JJ 1_i
IABP NNP 1_i
support NN 1_i
was VBD N
required VBN N
by IN N
13 CD N
patients NNS N
( ( N
21 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
. . N

The DT 1_o
median JJ 1_o
ventilation NN 1_o
time NN 1_o
( ( 1_o
14 CD 1_o
hours NNS N
versus VBD N
13 CD N
hours NNS N
) ) N
, , N
median JJ 1_o
catecholamine NN 1_o
dose NN 1_o
, , 1_o
frequency NN 1_o
of IN 1_o
dialysis-dependent JJ 1_o
acute JJ 1_o
renal JJ 1_o
failure NN 1_o
( ( 1_o
28 CD 1_o
% NN N
versus IN N
18 CD N
% NN N
) ) N
, , N
cardiac JJ 1_o
indices NNS 1_o
, , 1_o
and CC 1_o
frequency NN 1_o
of IN 1_o
a DT 1_o
low JJ 1_o
cardiac JJ 1_o
output NN 1_o
syndrome NN 1_o
( ( 1_o
26 CD 1_o
% NN N
versus IN N
25 CD N
% NN N
) ) N
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
Prophylactic NNP 1_i
preoperative JJ 1_i
IABP NNP 1_i
insertion NN 1_i
in IN 1_i
EuroSCORE-stratified JJ 1_p
high-risk JJ 1_p
patients NNS 1_p
is VBZ 1_p
not RB N
associated VBN N
with IN N
decreased JJ N
30-day JJ N
mortality NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
beta-alanine NN 1_i
, , N
with IN N
and CC N
without IN N
sodium NN 1_i
bicarbonate NN 1_i
, , N
on IN N
2000-m JJ 1_o
rowing NN 1_o
performance NN 1_o
. . 1_o

PURPOSE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
beta-alanine NN N
only RB N
and CC N
beta-alanine JJ 1_i
with IN 1_i
sodium NN 1_i
bicarbonate NN 1_i
supplementation NN 1_i
on IN N
2,000-m JJ 1_o
rowing NN 1_o
performance NN 1_o
. . 1_o

METHODS NNP N
Twenty NNP 1_p
well-trained JJ 1_p
rowers NNS 1_p
( ( 1_p
age NN 1_p
23 CD 1_p
? . 1_p
4 CD 1_p
y NN 1_p
; : 1_p
height VBD 1_p
1.85 CD 1_p
? . 1_p
0.08 CD 1_p
m NN 1_p
; : 1_p
body NN 1_p
mass NN 1_p
82.5 CD 1_p
? . 1_p
8.9 CD 1_p
kg NN 1_p
) ) 1_p
were VBD 1_p
assigned VBN N
to TO N
either VB 1_i
a DT 1_i
placebo NN 1_i
or CC 1_i
beta-alanine NN 1_i
( ( 1_i
6.4 CD 1_i
g NN N
? . N
d NN N
( ( N
-1 NNP N
) ) N
for IN N
4 CD N
weeks NNS N
) ) N
group NN 1_o
. . 1_o

A DT 1_o
2,000-m JJ 1_o
rowing NN 1_o
time NN 1_o
trial NN 1_o
( ( 1_o
TT NNP 1_o
) ) 1_o
was VBD 1_o
performed VBN N
before IN 1_i
supplementation NN 1_i
( ( 1_i
Baseline NNP 1_i
) ) N
and CC N
after IN N
28 CD N
and CC N
30 CD N
days NNS N
of IN 1_i
supplementation NN 1_i
. . 1_i

The DT 1_i
post NN N
supplementation NN N
trials NNS N
involved VBN N
supplementation NN N
with IN N
either DT N
maltodextrin NN N
or CC N
sodium NN N
bicarbonate NN N
in IN N
a DT N
double-blind NN N
, , N
crossover NN N
design NN N
, , N
creating VBG N
four CD N
study NN N
conditions NNS 1_i
( ( 1_i
placebo NN 1_i
with IN 1_i
maltodextrin NN 1_i
; : 1_i
placebo NN 1_i
with IN 1_i
sodium JJ 1_i
bicarbonate NN 1_i
; : 1_i
beta-alanine JJ 1_i
with IN 1_i
maltodextrin NN 1_i
; : 1_i
beta-alanine JJ 1_i
with IN 1_i
sodium JJ 1_i
bicarbonate NN 1_o
) ) 1_o
. . 1_o

Blood NNP 1_o
lactate NN 1_o
, , 1_o
pH NN 1_o
, , 1_o
bicarbonate NN 1_o
, , 1_o
and CC 1_o
base NN 1_o
excess NN 1_o
were VBD 1_o
measured VBN N
pre-TT JJ N
, , N
immediately RB N
post-TT JJ N
and CC N
at IN N
TT+5 NNP N
min NN N
. . N

Performance NNP 1_o
data NNS 1_o
were VBD 1_o
analyzed VBN N
using VBG 1_o
magnitude NN 1_o
based VBN 1_o
inferences NNS 1_o
. . 1_o

RESULTS NNP 1_o
Beta-alanine JJ 1_i
supplementation NN 1_i
was VBD 1_i
very RB N
likely JJ N
to TO N
be VB N
beneficial JJ 1_o
to TO 1_o
2,000-m JJ 1_o
rowing NN 1_o
performance NN 1_o
( ( 1_o
6.4 CD 1_o
? . N
8.1 CD N
s JJ N
effect NN N
compared VBN N
with IN N
placebo NN N
) ) N
, , N
with IN N
the DT N
effect NN N
of IN N
sodium NN N
bicarbonate NN N
having VBG N
a DT N
likely JJ N
benefit NN N
( ( N
3.2 CD N
? . N
8.8 CD N
s NN N
) ) N
. . N

There EX N
was VBD N
a DT N
small JJ N
( ( N
1.1 CD N
? . N
5.6 CD N
s NN N
) ) N
but CC N
possibly RB N
beneficial JJ 1_o
additional JJ 1_o
effect NN 1_o
when WRB N
combining VBG N
chronic JJ N
beta-alanine JJ N
supplementation NN N
with IN N
acute JJ N
sodium NN N
bicarbonate NN N
supplementation NN N
compared VBN N
with IN N
chronic JJ N
beta-alanine JJ N
supplementation NN N
alone RB N
. . N

Sodium JJ N
bicarbonate NN N
ingestion NN N
led VBD N
to TO N
increases NNS 1_o
in IN 1_o
plasma NN 1_o
pH NN 1_o
, , 1_o
base NN 1_o
excess NN 1_o
, , 1_o
bicarbonate NN 1_o
, , 1_o
and CC 1_o
lactate JJ 1_o
concentrations NNS 1_o
. . 1_o

CONCLUSIONS NNP 1_o
Both NNP 1_i
chronic JJ 1_i
beta-alanine NN 1_i
and CC 1_i
acute JJ 1_i
sodium NN 1_i
bicarbonate NN 1_i
supplementation NN 1_i
alone RB 1_i
had VBD N
positive JJ N
effects NNS N
on IN 1_o
2,000-m JJ 1_o
rowing NN 1_o
performance NN 1_o
. . 1_o

The DT 1_o
addition NN 1_o
of IN 1_i
acute JJ 1_i
sodium NN 1_i
bicarbonate NN 1_i
to TO 1_i
chronic VB 1_i
beta-alanine JJ 1_i
supplementation NN 1_i
may MD 1_i
further VB 1_i
enhance NN N
rowing VBG 1_o
performance NN 1_o
. . 1_o

-DOCSTART- -X- O O

Multi-institutional JJ N
phase NN N
2 CD N
clinical JJ N
and CC N
pharmacogenomic JJ N
trial NN N
of IN N
tipifarnib JJ 1_i
plus CC 1_i
etoposide JJ 1_i
for IN N
elderly JJ 1_p
adults NNS 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
acute RB 1_p
myelogenous JJ 1_p
leukemia NN 1_p
. . 1_p

Tipifarnib NNP N
( ( N
T NNP N
) ) N
exhibits VBZ N
modest JJ N
activity NN N
in IN N
elderly JJ 1_p
adults NNS 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
acute RB 1_p
myelogenous JJ 1_p
leukemia NN 1_p
( ( 1_p
AML NNP 1_p
) ) 1_p
. . 1_p

Based VBN N
on IN N
preclinical JJ N
synergy NN N
, , N
a DT N
phase NN N
1 CD N
trial NN N
of IN N
T NNP N
plus CC N
etoposide NN N
( ( N
E NNP N
) ) N
yielded VBD N
25 CD N
% NN N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
. . N

We PRP N
selected VBD N
2 CD N
comparable JJ N
dose NN N
levels NNS N
for IN N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
in IN N
84 CD 1_p
adults NNS 1_p
( ( 1_p
age NN 1_p
range NN 1_p
, , 1_p
70-90 JJ 1_p
years NNS 1_p
; : 1_p
median JJ 1_p
, , 1_p
76 CD 1_p
years NNS 1_p
) ) 1_p
who WP 1_p
were VBD 1_p
not RB 1_p
candidates NNS 1_p
for IN 1_p
conventional JJ 1_p
chemotherapy NN 1_p
. . 1_p

Arm VB N
A NNP N
( ( N
T NNP N
600 CD N
mg NN N
twice RB N
a DT N
day NN N
? . N
14 CD N
days NNS N
, , N
E NNP N
100 CD N
mg NN N
days NNS N
1-3 CD N
and CC N
8-10 JJ N
) ) N
and CC N
arm NN N
B NNP N
( ( N
T NNP N
400 CD N
mg NN N
twice RB N
a DT N
day NN N
? . N
14 CD N
days NNS N
, , N
E NNP N
200 CD N
mg NN N
days NNS N
1-3 CD N
and CC N
8-10 CD N
) ) N
yielded VBD N
similar JJ N
CR NNP N
, , N
but CC N
arm NN N
B NNP N
had VBD N
greater JJR N
toxicity NN 1_o
. . 1_o

Total JJ 1_o
CR NNP 1_o
was VBD 1_o
25 CD N
% NN N
, , N
day NN N
30 CD N
death NN N
rate NN N
7 CD N
% NN N
. . N

A DT N
2-gene JJ N
signature NN N
of IN N
high JJ N
RASGRP1 NNP N
and CC N
low JJ N
aprataxin NN N
( ( N
APTX NNP N
) ) N
expression NN N
previously RB N
predicted VBN N
for IN N
T NNP N
response NN 1_o
. . 1_o

Assays NNS N
using VBG N
blasts NNS N
from IN N
a DT N
subset NN N
of IN N
40 CD 1_p
patients NNS 1_p
treated VBN 1_p
with IN N
T NNP N
plus CC N
E NNP N
on IN N
this DT N
study NN N
showed VBD N
that IN 1_o
AMLs NNP 1_o
with IN 1_o
a DT 1_o
RASGRP1/APTX NNP 1_o
ratio NN 1_o
of IN 1_o
more JJR N
than IN N
5.2 CD N
had VBD N
a DT N
78 CD N
% NN N
CR NNP N
rate NN N
and CC N
negative JJ N
predictive JJ N
value NN N
87 CD N
% NN N
. . N

This DT N
ratio NN N
did VBD N
not RB N
correlate VB N
with IN N
outcome NN N
in IN N
41 CD N
patients NNS N
treated VBN N
with IN N
conventional JJ N
chemotherapies NNS N
. . N

The DT N
next JJ N
T-based JJ N
clinical JJ N
trials NNS N
will MD N
test VB N
the DT N
ability NN N
of IN N
the DT N
2-gene JJ N
signature NN N
to TO N
enrich VB N
for IN N
T NNP N
responders NNS N
prospectively RB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00602771 NNP N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
recombinant JJ N
human JJ N
thyrotropin NN N
and CC N
thyroid VB N
hormone NN N
withdrawal NN N
for IN N
the DT N
detection NN N
of IN N
thyroid JJ N
remnant NN N
or CC N
cancer NN N
. . N

Recombinant NNP 1_i
human JJ 1_i
TSH NNP 1_i
has VBZ N
been VBN N
developed VBN N
to TO N
facilitate VB N
monitoring NN N
for IN N
thyroid JJ N
carcinoma NN N
recurrence NN N
or CC N
persistence NN N
without IN N
the DT N
attendant JJ N
morbidity NN N
of IN N
hypothyroidism NN N
seen VBN N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
administered VBN 1_i
recombinant JJ 1_i
human JJ 1_i
TSH NN 1_i
with IN N
thyroid JJ N
hormone NN N
withdrawal NN N
on IN N
the DT N
results NNS N
of IN N
radioiodine JJ N
whole JJ N
body NN N
scanning VBG N
( ( N
WBS NNP N
) ) N
and CC N
serum JJ N
thyroglobulin NN N
( ( N
Tg NNP N
) ) N
levels NNS N
. . N

Two CD 1_p
hundred CD 1_p
and CC 1_p
twenty-nine JJ 1_p
adult NN 1_p
patients NNS 1_p
with IN 1_p
differentiated JJ 1_p
thyroid NN 1_p
cancer NN 1_p
requiring VBG 1_p
radioiodine NN 1_p
WBS NNP 1_p
were VBD 1_p
studied VBN 1_p
. . 1_p

Radioiodine NNP 1_i
WBS NNP 1_i
and CC N
serum VB N
Tg NNP N
measurements NNS N
were VBD N
performed VBN N
after IN N
administration NN N
of IN N
recombinant JJ 1_i
human JJ 1_i
TSH NNP 1_i
and CC N
again RB N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
in IN N
each DT N
patient NN N
. . N

Radioiodine NNP N
whole JJ N
body NN N
scans NNS N
were VBD N
concordant JJ N
between IN N
the DT N
recombinant JJ 1_o
TSH-stimulated JJ 1_o
and CC 1_o
thyroid JJ 1_o
hormone NN 1_o
withdrawal NN 1_o
phases NNS 1_o
in IN N
195 CD N
of IN N
220 CD N
( ( N
89 CD N
% NN N
) ) N
patients NNS N
. . N

Of IN N
the DT N
discordant NN N
scans NNS N
, , N
8 CD N
( ( N
4 CD N
% NN N
) ) N
had VBD N
superior JJ N
scans NNS N
after IN N
recombinant JJ 1_i
human JJ 1_i
TSH NNP 1_i
administration NN 1_i
, , N
and CC N
17 CD N
( ( N
8 CD N
% NN N
) ) N
had VBD N
superior JJ N
scans NNS N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
( ( N
P NNP N
= NNP N
0.108 CD N
) ) N
. . N

Based VBN N
on IN N
a DT N
serum NN 1_o
Tg NNP 1_o
level NN 1_o
of IN N
2 CD N
ng/mL NNS N
or CC N
more JJR N
, , N
thyroid JJ N
tissue NN N
or CC N
cancer NN N
was VBD N
detected VBN N
during IN N
thyroid JJ 1_i
hormone NN 1_i
therapy NN 1_i
in IN N
22 CD N
% NN N
, , N
after IN N
recombinant JJ 1_i
human JJ 1_i
TSH NNP 1_i
stimulation NN N
in IN N
52 CD N
% NN N
, , N
and CC N
after IN N
thyroid JJ 1_i
hormone NN 1_i
withdrawal NN 1_i
in IN N
56 CD N
% NN N
of IN N
patients NNS 1_p
with IN 1_p
disease NN 1_p
or CC 1_p
tissue NN 1_p
limited VBN 1_p
to TO 1_p
the DT 1_p
thyroid NN 1_p
bed NN 1_p
and CC N
in IN N
80 CD N
% NN N
, , N
100 CD N
% NN N
, , N
and CC N
100 CD 1_p
% NN 1_p
of IN 1_p
patients NNS 1_p
, , 1_p
respectively RB 1_p
, , 1_p
with IN 1_p
metastatic JJ 1_p
disease NN 1_p
. . 1_p

A DT N
combination NN N
of IN N
radioiodine NN N
WBS NNP N
and CC N
serum NN N
Tg NNP N
after IN N
recombinant JJ N
human JJ N
TSH NNP N
stimulation NN N
detected VBD N
thyroid JJ 1_o
tissue NN 1_o
or CC 1_o
cancer NN 1_o
in IN N
93 CD N
% NN N
of IN N
patients NNS 1_p
with IN 1_p
disease NN 1_p
or CC 1_p
tissue NN 1_p
limited VBN 1_p
to TO 1_p
the DT 1_p
thyroid NN 1_p
bed NN 1_p
and CC N
100 CD N
% NN N
of IN N
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
disease NN 1_p
. . 1_p

In IN N
conclusion NN N
, , N
recombinant JJ 1_i
human JJ 1_i
TSH NNP 1_i
administration NN 1_i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
means NNS N
of IN N
stimulating VBG N
radioiodine JJ N
uptake NN N
and CC N
serum NN N
Tg NNP N
levels NNS N
in IN N
patients NNS 1_p
undergoing JJ 1_p
evaluation NN 1_p
for IN 1_p
thyroid JJ 1_p
cancer NN 1_p
persistence NN 1_p
and CC 1_p
recurrence NN 1_p
. . 1_p

-DOCSTART- -X- O O

Oral NNP N
amoxicillin NN 1_i
vs. FW N
oral JJ N
erythromycin NN 1_i
in IN N
the DT N
treatment NN 1_o
of IN 1_o
pyoderma NN 1_o
in IN 1_p
Bamako NNP 1_p
, , 1_p
Mali NNP 1_p
: : 1_p
an DT N
open JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Pyoderma NNP 1_p
( ( 1_p
bacterial JJ 1_p
superficial NN 1_p
skin NN 1_p
infection NN 1_p
) ) 1_p
is VBZ N
an DT N
extremely RB N
common JJ N
disorder NN N
in IN N
tropical JJ 1_p
developing VBG 1_p
countries NNS 1_p
. . 1_p

In IN N
these DT N
settings NNS N
, , N
Streptococcus NNP N
pyogenes NNS N
is VBZ N
considered VBN N
to TO N
be VB N
the DT N
main JJ N
etiological JJ N
agent NN N
. . N

Apart RB N
from IN N
epidemics NNS N
of IN N
poststreptococcal JJ N
glomerulonephritis NN N
where WRB N
mass NN N
treatment NN N
with IN N
intramuscular JJ N
benzathine-penicillin NN 1_i
is VBZ N
recommended VBN N
, , N
no DT N
recommendation NN N
exists VBZ N
for IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
this DT N
setting NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
oral JJ N
amoxicillin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
Mali NNP N
, , N
by IN N
comparison NN N
with IN N
oral JJ N
erythromycin NN 1_i
. . 1_i

METHODS NNP N
In IN 1_p
Bamako NNP 1_p
, , 1_p
132 CD 1_p
patients NNS 1_p
with IN 1_p
pyoderma NN 1_p
, , 1_p
diagnosed VBN 1_p
and CC 1_p
graded VBN 1_p
as IN 1_p
severe JJ 1_p
on IN 1_p
clinical JJ 1_p
grounds NNS 1_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
oral JJ N
treatment NN N
by IN N
either DT N
amoxicillin NN 1_i
( ( N
50 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
or CC N
erythromycin $ 1_i
; : 1_i
infections NNS N
of IN N
the DT N
follicular JJ N
appendage NN N
were VBD N
excluded VBN N
. . N

Both DT N
drugs NNS N
were VBD N
associated VBN N
with IN N
the DT N
topical JJ N
application NN N
of IN N
povidone NN N
iodine NN N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
openly RB N
at IN N
the DT N
seventh JJ N
day NN N
of IN N
treatment NN N
for IN N
cure NN N
or CC N
marked JJ N
improvement NN N
of IN N
the DT N
clinical JJ 1_o
features NNS 1_o
, , N
indicating VBG N
successful JJ 1_o
treatment NN 1_o
. . 1_o

RESULTS NNP N
Three CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up JJ N
. . N

Treatment NN 1_o
was VBD 1_o
successful JJ 1_o
in IN N
57 CD N
of IN N
64 CD N
patients NNS N
treated VBN N
with IN N
amoxicillin NN N
vs. FW N
58 CD N
of IN N
65 CD N
patients NNS N
treated VBN N
with IN N
erythromycin NN N
( ( N
P NNP N
= NNP N
0.00 CD N
) ) N
. . N

CONCLUSIONS NNP N
Amoxicillin NNP 1_o
was VBD 1_o
as RB 1_o
efficacious JJ 1_o
as IN N
erythromycin NN N
in IN N
the DT N
treatment NN 1_o
of IN 1_o
severe JJ 1_o
pyoderma NN 1_o
in IN 1_p
Mali NNP 1_p
. . 1_p

Owing VBG N
to TO N
its PRP$ N
efficacy NN N
, , N
added VBD N
to TO N
high JJ N
availability NN N
and CC N
low JJ N
cost NN N
, , N
this DT N
compound NN N
should MD N
be VB N
considered VBN N
a DT N
first-line JJ N
treatment NN N
of IN N
this DT N
disorder NN N
in IN N
this DT N
country NN N
, , N
and CC N
perhaps RB N
in IN N
other JJ N
countries NNS N
where WRB N
this DT N
condition NN N
presents VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

-DOCSTART- -X- O O

Low-dose JJ 1_i
prednisolone NN 1_i
treatment NN 1_i
of IN N
early JJ 1_p
rheumatoid NN 1_p
arthritis NN 1_p
and CC N
late JJ 1_o
cardiovascular JJ 1_o
outcome NN 1_o
and CC 1_o
survival NN 1_o
: : 1_o
10-year JJ N
follow-up NN N
of IN N
a DT N
2-year JJ N
randomised JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
long-term JJ 1_o
effects NNS 1_o
of IN N
early JJ N
low-dose JJ N
prednisolone NN 1_i
use NN N
in IN N
patients NNS 1_p
with IN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
( ( 1_p
RA NNP 1_p
) ) 1_p
on IN 1_p
cardiovascular NN 1_o
( ( 1_o
CV NNP 1_o
) ) 1_o
morbidity NN 1_o
and CC 1_o
mortality NN 1_o
. . 1_o

DESIGN NNP N
Retrieval NNP N
of IN N
data NNS N
from IN N
a DT N
2-year JJ N
open JJ N
randomised VBN N
trial NN N
comparing VBG N
prednisolone NN 1_i
7.5 CD N
mg/day NN N
in IN N
addition NN N
to TO N
disease-modifying JJ 1_i
antirheumatic JJ 1_i
drugs NNS 1_i
( ( 1_i
DMARDs NNP 1_i
) ) 1_i
with IN 1_i
DMARD NNP 1_i
therapy NN 1_i
alone RB N
. . N

Participants NNS N
were VBD N
followed VBN N
for IN N
10 CD N
years NNS N
since IN N
inclusion NN N
into IN N
the DT N
original JJ N
prednisolone NN 1_i
trial NN N
or CC N
until IN N
occurrence NN N
of IN N
the DT N
studied JJ N
outcomes NNS N
. . N

SETTING NN N
Secondary JJ N
level NN N
of IN N
care NN N
; : N
six CD 1_p
participating VBG 1_p
centres NNS 1_p
from IN 1_p
southern JJ 1_p
Sweden NNP 1_p
; : 1_p
both DT 1_p
urban JJ 1_p
and CC 1_p
rural JJ 1_p
populations NNS 1_p
. . 1_p

PARTICIPANTS NNP N
Overall NNP N
, , N
223 CD 1_p
patients NNS 1_p
with IN 1_p
early JJ 1_p
RA NNP 1_p
were VBD N
included VBN N
. . N

The DT N
participants NNS 1_p
had VBD 1_p
no DT 1_p
history NN 1_p
of IN 1_p
CV NNP 1_o
events NNS 1_o
at IN 1_p
baseline NN 1_p
and CC N
incident JJ N
cases NNS N
were VBD N
identified VBN N
via IN N
the DT N
Swedish JJ N
Hospital NNP N
Discharge NNP N
and CC N
Cause NNP N
of IN N
Death NNP N
Registries NNP N
. . N

OUTCOMES NNP N
Composite NNP 1_o
CV NNP 1_o
events NNS 1_o
, , 1_o
that DT 1_o
is VBZ 1_o
, , 1_o
ischaemic JJ 1_o
coronary NN 1_o
and CC 1_o
cerebrovascular JJ 1_o
events NNS 1_o
, , 1_o
components NNS 1_o
of IN 1_o
the DT 1_o
composite JJ 1_o
CV NNP 1_o
outcome NN 1_o
, , 1_o
and CC 1_o
death NN 1_o
. . 1_o

Relative JJ 1_o
HRs NNP 1_o
from IN 1_o
Cox NNP 1_o
proportional-hazards NNS 1_o
regression NN 1_o
models NNS 1_o
were VBD N
calculated VBN N
. . N

RESULTS NNP N
Within IN N
2041 CD N
person-years NNS N
, , N
17 CD N
incident NN N
composite JJ 1_o
CV NNP 1_o
events NNS 1_o
occurred VBD N
in IN N
112 CD N
patients NNS N
( ( N
15 CD N
% NN N
) ) N
randomised VBD N
to TO N
prednisolone VB 1_i
, , N
and CC N
15 CD N
events NNS N
of IN N
111 CD N
patients NNS N
( ( N
14 CD N
% NN N
) ) N
who WP N
were VBD N
assigned VBN N
not RB N
to TO N
receive VB N
prednisolone NN 1_i
. . 1_i

There EX N
were VBD N
nine CD N
deaths NNS 1_o
( ( N
8 CD N
% NN N
) ) N
in IN N
each DT N
group NN N
. . N

The DT N
age-adjusted JJ 1_o
relative JJ 1_o
hazards NNS 1_o
( ( N
HRs NNP N
; : N
95 CD N
% NN N
CI NNP N
) ) N
for IN N
the DT N
first JJ N
composite JJ 1_o
CV NNP 1_o
event NN 1_o
, , 1_o
first RB 1_o
coronary JJ 1_o
event NN 1_o
and CC 1_o
death NN 1_o
in IN N
the DT N
prednisolone NN 1_i
group NN N
versus IN N
the DT N
group NN N
not RB N
treated VBN N
with IN N
prednisolone NN 1_i
were VBD N
1.8 CD N
( ( N
0.9 CD N
to TO N
3.6 CD N
) ) N
, , N
0.98 CD N
( ( N
0.4 CD N
to TO N
2.6 CD N
) ) N
and CC N
1.6 CD N
( ( N
0.6 CD N
to TO N
4.1 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
risk NN 1_o
for IN 1_o
the DT 1_o
first JJ 1_o
cerebrovascular JJ 1_o
event NN 1_o
showed VBD N
a DT N
3.7-fold JJ N
increased JJ N
relative JJ N
hazard NN N
( ( N
95 CD N
% NN N
CI NNP N
1.2 CD N
to TO N
11.4 CD N
) ) N
among IN N
prednisolone NN 1_i
treated VBD N
patients NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
inception NN N
cohort NN N
study NN N
of IN N
low-dose JJ N
prednisolone NN 1_i
use NN N
during IN N
the DT N
first JJ N
2 CD N
years NNS N
of IN N
RA NNP N
disease NN N
, , N
the DT N
incidence NN 1_o
of IN 1_o
ischaemic JJ 1_o
coronary JJ 1_o
artery NN 1_o
events NNS 1_o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
, , N
whereas IN N
the DT N
long-term JJ 1_o
risk NN 1_o
of IN 1_o
ischaemic JJ 1_o
cerebrovascular JJ 1_o
events NNS 1_o
was VBD N
higher RBR N
in IN N
the DT N
prednisolone NN 1_i
group NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
towards NN N
reduced VBD 1_o
survival NN 1_o
in IN N
the DT N
prednisolone NN 1_i
group NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN20612367 NNP N
. . N

-DOCSTART- -X- O O

Fondaparinux NNP 1_i
combined VBD 1_i
with IN 1_i
intermittent JJ 1_i
pneumatic JJ 1_i
compression NN 1_i
vs. FW N
intermittent JJ 1_i
pneumatic JJ 1_i
compression NN 1_i
alone RB 1_i
for IN N
prevention NN N
of IN N
venous JJ 1_o
thromboembolism NN 1_o
after IN 1_p
abdominal JJ 1_p
surgery NN 1_p
: : 1_p
a DT N
randomized JJ N
, , N
double-blind JJ N
comparison NN N
. . N

BACKGROUND VB N
The DT N
benefit NN N
of IN N
combined JJ N
mechanical JJ N
and CC N
pharmacologic JJ N
methods NNS N
for IN N
venous JJ 1_o
thromboembolism NN 1_o
prevention NN N
after IN 1_p
abdominal JJ 1_p
surgery NN 1_p
has VBZ N
not RB N
been VBN N
clearly RB N
established VBN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
fondaparinux NN 1_i
in IN 1_i
conjunction NN 1_i
with IN 1_i
intermittent JJ 1_i
pneumatic JJ 1_i
compression NN 1_i
vs. FW N
intermittent JJ 1_i
pneumatic JJ 1_i
compression NN 1_i
alone RB 1_i
in IN N
this DT N
context NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
superiority NN N
trial NN N
. . N

Patients NNS 1_p
aged VBN 1_p
at IN 1_p
least JJS 1_p
40 CD 1_p
years NNS 1_p
undergoing JJ 1_p
abdominal JJ 1_p
surgery NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
fondaparinux JJ 1_i
2.5 CD N
mg NN N
or CC N
placebo NN 1_i
s.c. NN N
for IN N
5-9 JJ N
days NNS N
, , N
starting VBG N
6-8 JJ N
h NN N
postoperatively RB N
. . N

All DT N
patients NNS N
received VBD N
intermittent JJ 1_i
pneumatic JJ 1_i
compression NN 1_i
. . 1_i

The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
venous JJ 1_o
thromboembolism NN 1_o
up RB 1_o
to TO 1_o
day NN 1_o
10 CD 1_o
. . 1_o

The DT N
main JJ N
safety NN N
outcomes NNS N
were VBD N
major JJ 1_o
bleeding NN 1_o
and CC 1_o
all-cause JJ 1_o
mortality NN 1_o
. . 1_o

Follow-up NNP N
lasted VBD N
32 CD N
days NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
1309 CD 1_p
patients NNS 1_p
randomized VBN N
, , N
842 CD N
( ( N
64.3 CD N
% NN N
) ) N
were VBD N
evaluable JJ N
for IN N
efficacy NN N
. . N

The DT N
venous JJ 1_o
thromboembolism NN 1_o
rate NN 1_o
was VBD N
1.7 CD N
% NN N
( ( N
7/424 CD N
) ) N
in IN N
the DT N
fondaparinux-treated JJ 1_i
patients NNS 1_p
and CC N
5.3 CD N
% NN N
( ( N
22/418 CD N
) ) N
in IN N
the DT N
placebo-treated JJ 1_i
patients NNS 1_p
( ( N
odds NNS N
ratio VBP N
reduction NN N
69.8 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
27.9-87.3 JJ N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

Fondaparinux NNP 1_i
significantly RB N
reduced VBD N
the DT N
proximal JJ 1_o
deep JJ 1_o
vein NN 1_o
thrombosis NN 1_o
rate NN 1_o
from IN N
1.7 CD N
% NN N
( ( N
7/417 CD N
) ) N
to TO N
0.2 CD N
% NN N
( ( N
1/424 CD N
; : N
P NNP N
= NNP N
0.037 CD N
) ) N
. . N

Major JJ 1_o
bleeds NNS 1_o
occurred VBD N
in IN N
1.6 CD N
% NN N
( ( N
10/635 CD N
) ) N
and CC N
0.2 CD N
% NN N
( ( N
1/650 CD N
) ) N
of IN N
fondaparinux-treated JJ 1_i
and CC N
placebo-treated JJ 1_i
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
none NN N
being VBG N
fatal JJ N
or CC N
involving VBG N
a DT N
critical JJ N
organ NN N
. . N

By IN N
day NN N
32 CD N
, , N
eight CD N
patients NNS N
( ( N
1.3 CD N
% NN N
) ) N
receiving NN N
fondaparinux NN 1_i
and CC N
five CD N
( ( N
0.8 CD N
% NN N
) ) N
receiving NN N
placebo NN 1_i
had VBD N
died VBN 1_o
. . 1_o

CONCLUSIONS NNP N
In IN N
patients NNS 1_p
undergoing JJ 1_p
abdominal JJ 1_p
surgery NN 1_p
and CC 1_p
receiving VBG 1_p
intermittent JJ 1_i
pneumatic JJ 1_i
compression NN 1_i
, , 1_i
fondaparinux VBP 1_i
2.5 CD N
mg NN N
reduced VBD N
the DT N
venous JJ 1_o
thromboembolism NN 1_o
rate NN 1_o
by IN N
69.8 CD N
% NN N
as IN N
compared VBN N
to TO N
pneumatic JJ 1_i
compression NN 1_i
alone RB 1_i
, , N
with IN N
a DT N
low JJ 1_o
bleeding NN 1_o
risk NN 1_o
as IN N
compared VBN N
to TO N
placebo VB 1_i
. . 1_i

-DOCSTART- -X- O O

Impact NN N
of IN N
isotonic JJ 1_i
and CC 1_i
hypertonic JJ 1_i
saline NN 1_i
solutions NNS 1_i
on IN N
mucociliary JJ N
activity NN N
in IN N
various JJ 1_p
nasal JJ 1_p
pathologies NNS 1_p
: : 1_p
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
nasal JJ N
irrigation NN N
with IN N
isotonic JJ 1_i
or CC 1_i
hypertonic JJ 1_i
sodium NN 1_i
chloride JJ 1_i
solution NN 1_i
on IN N
mucociliary JJ N
clearance NN N
time NN N
in IN N
patients NNS 1_p
with IN 1_p
allergic JJ 1_p
rhinitis NN 1_p
, , 1_p
acute JJ 1_p
sinusitis NN 1_p
and CC 1_p
chronic JJ 1_p
sinusitis NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Mucociliary NNP N
clearance NN N
time NN N
was VBD N
measured VBN N
using VBG N
the DT N
saccharine JJ N
clearance NN N
test NN N
on IN N
132 CD 1_p
adults NNS 1_p
before IN N
and CC N
after IN N
10 CD N
days NNS N
' POS N
application NN 1_i
of IN 1_i
intranasal NN 1_i
isotonic NN 1_i
or CC 1_i
hypertonic JJ 1_i
saline NN 1_i
. . 1_i

Patient JJ 1_p
numbers NNS 1_p
were VBD 1_p
as IN 1_p
follows VBZ 1_p
: : 1_p
controls NNS 1_p
, , 1_p
45 CD 1_p
; : 1_p
allergic JJ 1_p
rhinitis NN 1_p
, , 1_p
21 CD 1_p
; : 1_p
acute JJ 1_p
sinusitis NN 1_p
, , 1_p
24 CD 1_p
; : 1_p
and CC 1_p
chronic JJ 1_p
sinusitis NN 1_p
, , 1_p
42 CD 1_p
. . 1_p

The DT N
results NNS N
before IN N
and CC N
after IN N
irrigation NN N
were VBD N
compared VBN N
using VBG N
the DT N
Wilcoxon NNP N
t-test NN N
. . N

RESULTS NNP N
Before IN N
application NN N
of IN N
saline JJ 1_i
solutions NNS 1_i
, , N
mucociliary JJ 1_o
clearance NN 1_o
times NNS 1_o
in IN N
the DT N
three CD N
patient NN N
treatment NN N
groups NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
delayed VBN N
, , N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Irrigation NN N
with IN N
hypertonic JJ 1_i
saline NN 1_i
restored VBN 1_o
impaired JJ 1_o
mucociliary JJ 1_o
clearance NN 1_o
in IN 1_o
chronic JJ 1_o
sinusitis NN 1_o
patients NNS 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
while IN N
isotonic JJ 1_i
saline NN 1_i
improved VBD 1_o
mucociliary JJ 1_o
clearance NN 1_o
times NNS 1_o
significantly RB 1_o
in IN N
allergic JJ N
rhinitis NN N
and CC N
acute JJ N
sinusitis NN N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Nasal NNP N
irrigation NN N
with IN N
isotonic JJ 1_i
or CC 1_i
hypertonic JJ 1_i
saline NN 1_i
can MD N
improve VB N
mucociliary JJ 1_o
clearance NN 1_o
time NN 1_o
in IN N
various JJ N
nasal JJ N
pathologies NNS N
. . N

However RB N
, , N
these DT N
solutions NNS N
should MD N
be VB N
selectively RB N
prescribed IN N
rather RB N
than IN N
used VBN N
based VBN N
on IN N
anecdotal JJ N
evidence NN N
. . N

Further JJ N
studies NNS N
should MD N
be VB N
conducted VBN N
to TO N
develop VB N
a DT N
protocol NN N
for IN N
standardised VBN N
use NN N
of IN N
saline JJ 1_i
solution NN 1_i
irrigation NN 1_i
in IN N
various JJ N
nasal JJ N
pathologies NNS N
. . N

-DOCSTART- -X- O O

Treatment NN N
with IN N
metformin NN 1_i
of IN N
non-diabetic JJ 1_p
men NNS 1_p
with IN 1_p
hypertension NN 1_p
, , 1_p
hypertriglyceridaemia NN 1_p
and CC 1_p
central JJ 1_p
fat JJ 1_p
distribution NN 1_p
: : 1_p
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
. . N

BACKGROUND NNP N
In IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
, , N
one CD N
year NN N
of IN N
treatment NN N
with IN N
metformin NN 1_i
in IN N
non-diabetic JJ 1_p
obese JJ 1_p
subjects NNS 1_p
with IN 1_p
a DT 1_p
central JJ 1_p
fat JJ 1_p
distribution NN 1_p
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
fasting VBG N
plasma JJ N
triglyceride JJ N
concentration NN N
or CC N
on IN N
blood NN N
pressure NN N
despite IN N
a DT N
decrease NN N
in IN N
weight NN N
, , N
fasting VBG N
plasma JJ N
insulin NN N
and CC N
glucose JJ N
concentrations NNS N
. . N

To TO N
re-evaluate VB N
the DT N
effect NN N
of IN N
metformin NN 1_i
on IN N
fasting VBG N
triglyceride JJ N
concentration NN N
and CC N
on IN N
blood NN N
pressure NN N
, , N
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
included VBD N
non-diabetic JJ 1_p
men NNS 1_p
( ( 1_p
n=168 NN 1_p
) ) 1_p
with IN 1_p
a DT 1_p
fasting VBG 1_p
plasma NN 1_p
triglyceride JJ 1_p
concentration NN 1_p
> NN 1_p
or CC 1_p
=1.7 NN 1_p
and CC 1_p
< NN 1_p
or CC 1_p
=6.5 NN 1_p
mmol/l NN 1_p
, , 1_p
high JJ 1_p
blood NN 1_p
pressure NN 1_p
( ( 1_p
systolic JJ 1_p
> NN 1_p
or CC 1_p
=140 NN 1_p
and CC 1_p
< NN 1_p
or CC 1_p
=180 VB 1_p
and/or JJ 1_p
diastolic JJ 1_p
> NN 1_p
or CC 1_p
=90 NN 1_p
and CC 1_p
< NN 1_p
or CC 1_p
=105 NN 1_p
mmHg NN 1_p
, , 1_p
or CC 1_p
treatment NN 1_p
for IN 1_p
hypertension NN 1_p
) ) 1_p
and CC 1_p
a DT 1_p
waist-to-hip JJ 1_p
ratio NN 1_p
> NN 1_p
or CC 1_p
=0.95 NN 1_p
. . 1_p

METHODS NNP N
A DT N
randomised JJ N
double-blind JJ N
trial NN N
comparing VBG N
metformin NN 1_i
treatment NN 1_i
( ( 1_i
850 CD 1_i
mg RB 1_i
bid NN 1_i
) ) 1_i
with IN 1_i
placebo NN 1_i
. . 1_i

RESULTS NNP N
Metformin NNP 1_i
had VBD N
no DT N
significant JJ N
effect NN N
either DT N
on IN N
blood NN 1_o
pressure NN 1_o
or CC 1_o
plasma NN 1_o
triglyceride JJ 1_o
concentration NN 1_o
. . 1_o

In IN N
comparison NN N
with IN N
the DT N
placebo NN 1_i
group NN N
, , N
fasting VBG 1_o
plasma JJ 1_o
insulin NN 1_o
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
, , N
total JJ 1_o
cholesterol NN 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
Apo NNP 1_o
B NNP 1_o
( ( N
p JJ N
< NNP N
0.008 CD N
) ) N
concentrations NNS 1_o
decreased VBD N
more RBR N
in IN N
the DT N
metformin NN N
group NN N
in IN N
the DT N
BIGPRO NNP N
1 CD N
. . N

2 CD N
trial NN N
, , N
confirming VBG N
most JJS N
of IN N
the DT N
previous JJ N
results NNS N
of IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
. . N

Tissue NNP 1_o
plasminogen NN 1_o
activator NN 1_o
antigen NN 1_o
concentration NN 1_o
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
only RB N
in IN N
the DT N
metformin NN 1_i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
placebo NN 1_i
group NN N
( ( N
p JJ N
< NNP N
0.12 CD N
) ) N
; : N
further RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
plasminogen NN N
activator NN N
inhibitor NN N
1 CD N
. . N

CONCLUSIONS VB N
The DT N
consistency NN N
of IN N
the DT N
two CD N
BIGPRO NNP N
trials NNS N
supports VBZ N
the DT N
conclusion NN N
that IN N
metformin VBZ 1_i
affects NNS N
several JJ N
cardiovascular JJ N
risk NN N
factors NNS N
favourably RB N
in IN N
non-diabetic JJ 1_p
subjects NNS 1_p
with IN 1_p
a DT 1_p
central JJ 1_p
fat JJ 1_p
distribution NN 1_p
. . 1_p

-DOCSTART- -X- O O

A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
clear JJ N
liquids NNS N
versus IN N
low-fat JJ N
solid JJ N
diet NN N
as IN N
the DT N
initial JJ N
meal NN N
in IN N
mild JJ 1_p
acute JJ 1_p
pancreatitis NN 1_p
. . 1_p

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS 1_p
recovering VBG 1_p
from IN 1_p
mild JJ 1_p
acute JJ 1_p
pancreatitis NN 1_p
typically RB N
receive VBP N
a DT N
clear JJ 1_i
liquid NN 1_i
diet NN 1_i
( ( 1_i
CLD NNP 1_i
) ) 1_i
when WRB N
ready JJ N
to TO N
initiate VB N
oral JJ N
nutrition NN N
. . N

Patient NNP N
discharge NN N
then RB N
depends VBZ N
on IN N
their PRP$ N
successful JJ N
advancement NN N
to TO N
solid VB N
food NN N
. . N

We PRP N
hypothesized VBD N
that IN N
initiating VBG N
oral JJ 1_i
nutrition NN 1_i
with IN 1_i
a DT 1_i
low-fat JJ 1_i
solid JJ 1_i
diet NN 1_i
( ( 1_i
LFSD NNP 1_i
) ) 1_i
after IN N
mild JJ N
pancreatitis NN N
would MD N
be VB N
well RB N
tolerated VBN N
and CC N
would MD N
result VB N
in IN N
a DT N
shorter JJR N
length NN 1_o
of IN 1_o
hospitalization NN 1_o
( ( N
LOH NNP N
) ) N
. . N

METHODS JJ N
Patients NNS 1_p
with IN 1_p
mild JJ 1_p
pancreatitis NNS 1_p
were VBD N
randomized VBN N
to TO N
a DT N
CLD NNP 1_i
or CC 1_i
LFSD NNP 1_i
when WRB N
they PRP N
were VBD N
ready JJ N
to TO N
resume VB N
oral JJ N
nutrition NN N
. . N

Decisions NNS N
about IN N
diet JJ N
advancement NN N
and CC N
hospital NN N
discharge NN N
were VBD N
at IN N
the DT N
discretion NN N
of IN N
the DT N
medical JJ N
team NN N
, , N
without IN N
input NN N
from IN N
study NN N
team NN N
members NNS N
. . N

Patients NNS N
were VBD N
monitored VBN N
daily RB N
for IN N
recurrence NN N
of IN N
pain NN 1_o
, , 1_o
need VBP 1_o
to TO 1_o
stop VB 1_o
feeding NN 1_o
, , 1_o
post-refeeding JJ 1_o
LOH NNP 1_o
( ( N
primary JJ N
end NN N
point NN N
) ) N
, , N
and CC N
for IN N
28 CD N
days NNS N
post-refeeding JJ N
to TO N
capture VB N
re-admission NN 1_o
rates NNS 1_o
. . 1_o

RESULTS NNP N
We PRP N
randomized VBD N
121 CD 1_p
patients NNS 1_p
: : 1_p
66 CD 1_p
to TO 1_p
CLD NNP 1_p
and CC 1_p
55 CD 1_p
to TO 1_p
LFSD NNP 1_p
. . 1_p

The DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
requiring VBG 1_o
cessation NN 1_o
of IN 1_o
feeding VBG 1_o
because IN 1_o
of IN 1_o
pain NN 1_o
or CC 1_o
nausea NN 1_o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
6 CD N
% NN N
for IN N
CLD NNP N
, , N
11 CD N
% NN N
for IN N
LFSD NNP N
; : N
P NNP N
= NNP N
.51 NNP N
) ) N
. . N

The DT N
median JJ 1_o
LOH NNP 1_o
after IN 1_o
refeeding VBG 1_o
was VBD N
identical JJ N
in IN N
both DT N
groups NNS N
( ( N
1-day JJ N
interquartile NN N
range NN N
, , N
1-2 JJ N
; : N
P NNP N
= NNP N
.77 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
LFSD NNP N
arm NN N
consumed VBD N
significantly RB N
more JJR N
calories NNS 1_o
and CC 1_o
grams NNS 1_o
of IN 1_o
fat NN 1_o
than IN N
those DT N
in IN N
the DT N
CLD NNP N
arm NN N
during IN N
their PRP$ N
first JJ N
meal NN N
and CC N
on IN N
study NN N
day NN N
1 CD N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
28-day JJ 1_o
re-admission NN 1_o
rates NNS 1_o
between IN N
the DT N
2 CD N
arms NNS N
. . N

CONCLUSIONS NNP N
Initiating NNP N
oral JJ N
nutrition NN N
after IN N
mild JJ 1_o
acute JJ 1_o
pancreatitis NN 1_o
with IN N
an DT N
LFSD NNP 1_o
appeared VBD N
safe JJ N
and CC N
provided VBD N
more JJR N
calories NNS N
than IN N
a DT N
CLD NNP N
, , N
but CC N
did VBD N
not RB N
result VB N
in IN N
a DT N
shorter NN N
LOH NNP 1_o
. . 1_o

-DOCSTART- -X- O O

Randomised VBN N
clinical JJ N
trial NN N
of IN N
physiotherapy NN 1_i
after IN N
open JJ N
abdominal JJ N
surgery NN N
in IN N
high JJ 1_p
risk NN 1_p
patients NNS 1_p
. . 1_p

Postoperative NNP 1_i
physiotherapy NN 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB 1_o
the DT 1_o
incidence NN 1_o
of IN N
postoperative JJ N
pulmonary JJ N
complications NNS N
after IN N
open JJ N
abdominal JJ N
surgery NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
if IN N
the DT N
addition NN N
of IN N
deep JJ 1_i
breathing NN 1_i
exercises NNS 1_i
and CC N
secretion NN 1_i
clearing NN 1_i
techniques NNS 1_i
to TO N
a DT N
standardised JJ 1_i
physiotherapist-directed JJ 1_i
program NN 1_i
of IN N
early JJ N
mobilisation NN N
improved VBD N
clinical JJ N
outcomes NNS N
in IN N
patients NNS 1_p
undergoing VBG 1_p
open JJ 1_p
abdominal JJ 1_p
surgery NN 1_p
. . 1_p

Fifty-six JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
open JJ 1_i
abdominal JJ 1_i
surgery NN 1_i
, , 1_p
at IN 1_p
high JJ 1_p
risk NN 1_p
of IN 1_p
developing VBG 1_p
postoperative JJ 1_p
pulmonary JJ 1_p
complications NNS 1_p
, , N
were VBD N
randomised VBN 1_i
before IN 1_i
operation NN 1_i
to TO 1_i
an DT 1_i
early JJ 1_i
mobilisation-only JJ 1_i
group NN 1_i
or CC 1_i
an DT 1_i
early JJ 1_i
mobilisation-plus-deep JJ 1_i
breathing NN 1_i
and CC 1_i
coughing VBG 1_i
group NN 1_i
. . 1_i

Mobility NNP 1_o
duration NN 1_o
, , 1_o
frequency NN 1_o
and CC 1_o
intensity NN 1_o
of IN 1_o
breathing VBG 1_o
interventions NNS 1_o
were VBD 1_i
quantified VBN 1_i
for IN 1_i
both DT 1_i
groups NNS 1_i
. . 1_i

All DT 1_i
outcomes NNS 1_i
were VBD 1_i
assessed VBN 1_i
by IN 1_i
a DT 1_i
blinded JJ 1_i
outcomes NN 1_i
researcher NN 1_i
using VBG 1_i
a DT 1_i
standardised JJ 1_i
outcomes NNS 1_i
measurement JJ 1_i
tool NN 1_i
developed VBD 1_i
specifically RB 1_i
for IN 1_i
this DT 1_i
population NN 1_i
. . 1_i

Outcomes CC 1_o
included VBD 1_o
incidence NN 1_o
of IN 1_o
clinically RB 1_o
significant JJ 1_o
postoperative JJ 1_o
pulmonary JJ 1_o
complications NNS 1_o
, , 1_o
fever RB 1_o
, , 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
, , 1_o
and CC 1_o
restoration NN 1_o
of IN 1_o
mobility NN 1_o
. . 1_o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
mean JJ 1_o
age NN 1_o
, , 1_o
anaesthetic JJ 1_o
time NN 1_o
, , 1_o
perioperative JJ 1_o
morbidity NN 1_o
, , 1_o
or CC 1_o
postoperative JJ 1_o
mobility NN 1_o
. . 1_o

Outcome NNP N
data NNS N
were VBD N
available JJ N
for IN N
89 CD N
% NN N
of IN N
enrolled JJ N
subjects NNS N
. . N

Overall JJ N
incidence NN N
of IN N
postoperative JJ 1_o
pulmonary JJ 1_o
complications NNS 1_o
was VBD N
16 CD N
% NN N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ 1_o
pulmonary JJ 1_o
complications NNS 1_o
in IN N
the DT N
non-deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
14 CD N
% NN N
, , N
and CC N
the DT N
incidence NN N
of IN N
postoperative JJ 1_o
pulmonary JJ 1_o
complications NNS 1_o
in IN N
the DT N
deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
17 CD N
% NN N
, , N
( ( N
absolute JJ N
risk NN N
reduction NN N
-3 NNP N
% NN N
, , N
95 CD N
% NN N
C1 NNP N
-22 NNP N
to TO N
19 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
incidence NN N
of IN N
fever NN 1_o
, , 1_o
physiotherapist JJ 1_o
time NN 1_o
, , 1_o
or CC 1_o
the DT 1_o
number NN 1_o
of IN 1_o
treatments NNS 1_o
. . 1_o

This DT N
study NN N
suggests VBZ N
that IN N
, , N
in IN N
this DT N
clinical JJ N
setting NN N
, , N
the DT N
addition NN N
of IN N
deep JJ 1_i
breathing NN 1_i
and CC 1_i
coughing NN 1_i
exercises NNS 1_i
to TO N
a DT N
physiotherapist-directed JJ N
program NN N
of IN N
early JJ N
mobilisation NN N
does VBZ N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
significant JJ N
postoperative JJ N
pulmonary JJ N
complications NNS N
in IN N
high JJ 1_p
risk NN 1_p
open JJ 1_p
abdominal JJ 1_p
surgery NN 1_p
subjects NNS 1_p
. . 1_p

-DOCSTART- -X- O O

The DT N
FLT3ITD NNP 1_i
mRNA NN 1_i
level NN 1_i
has VBZ N
a DT N
high JJ N
prognostic JJ N
impact NN N
in IN N
NPM1 NNP 1_p
mutated VBD 1_p
, , 1_p
but CC 1_p
not RB 1_p
in IN 1_p
NPM1 NNP 1_p
unmutated VBD 1_p
, , 1_p
AML NNP 1_p
with IN 1_p
a DT 1_p
normal JJ 1_p
karyotype NN 1_p
. . 1_p

The DT N
impact NN N
of IN N
a DT N
FLT3-internal JJ N
tandem NN N
duplication NN N
( ( N
FLT3ITD NNP N
) ) N
on IN N
prognosis NN N
of IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
( ( 1_p
AML NNP 1_p
) ) 1_p
is VBZ N
dependent JJ N
on IN N
the DT N
ratio NN N
of IN N
mutated VBN N
to TO N
wild-type JJ N
allele NN N
. . N

In IN N
648 CD 1_p
normal JJ 1_p
karyotype NN 1_p
( ( 1_p
NK NNP 1_p
) ) 1_p
AML NNP 1_p
patients NNS 1_p
, , N
we PRP N
found VBD N
a DT N
significant JJ N
independent JJ N
effect NN N
of IN N
the DT N
quantitative JJ 1_o
FLT3ITD NNP 1_o
mRNA NN 1_o
level NN 1_o
-- : 1_o
measured VBN 1_o
as IN N
( ( 1_i
FLT3ITD/wtFLT3 NNP 1_i
) ) 1_i
/ NN 1_i
( ( 1_i
FLT3ITD/wtFLT3+1 NNP 1_i
) ) 1_i
-- : 1_i
on IN 1_i
outcome NN N
. . N

Moreover RB N
, , N
this DT N
effect NN N
was VBD N
clearly RB N
seen VBN N
in IN N
329 CD 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
mutated VBN 1_p
NPM1 NNP 1_p
gene NN 1_p
( ( 1_p
NPM1+ NNP 1_p
) ) 1_p
, , N
but CC N
not RB N
in IN N
319 CD 1_p
patients NNS 1_p
without IN 1_p
a DT 1_p
NPM1 NNP 1_p
mutation NN 1_p
( ( 1_p
wtNPM1 NN 1_p
) ) 1_p
. . 1_p

In IN N
a DT N
multivariate NN N
Cox NNP N
regression NN N
model NN N
, , N
the DT N
quantitative JJ N
FLT3ITD NNP 1_i
mRNA NN N
level NN N
showed VBD N
an DT N
independent JJ N
prognostic JJ N
impact NN N
on IN N
overall JJ 1_o
survival NN 1_o
( ( N
OS NNP N
) ) N
and CC N
relapse-free JJ 1_o
survival NN 1_o
( ( N
RFS NNP N
) ) N
only RB N
in IN N
the DT N
NPM1+ NNP 1_p
subgroup NN 1_p
( ( N
OS NNP N
: : N
hazard NN N
ratio NN N
, , N
5.9 CD N
; : N
[ CC N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
3.1-11.2 JJ N
] NN N
; : N
RFS NNP N
: : N
hazard NN N
ratio NN N
, , N
7.5 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
3.4-16.5 JJ N
] NN N
) ) N
. . N

The DT N
FLT3ITD NNP 1_i
mRNA MD N
level VB N
contributes NNS N
to TO N
relapse VB N
risk NN N
stratification NN N
and CC N
might MD N
help VB N
to TO N
guide VB N
postremission NN N
therapy NN N
in IN N
NPM1-mutated JJ 1_p
AML NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Qingre NNP N
quyu NN N
granule NN N
stabilizes VBZ N
plaques NNS N
through IN N
inhibiting VBG N
the DT N
expression NN N
of IN N
tenascin-C NN N
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
carotid NN 1_p
stenosis NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
therapeutic JJ 1_o
effects NNS 1_o
of IN N
Qingre NNP 1_i
Quyu NNP 1_i
Granule NNP 1_i
( ( 1_i
QQG NNP 1_i
) ) 1_i
on IN N
the DT N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
carotid NN 1_p
stenosis NN 1_p
, , N
and CC N
to TO N
explore VB N
the DT N
mechanism NN N
of IN N
it PRP N
. . N

METHODS NNP N
Ninety-six JJ 1_p
patients NNS 1_p
with IN 1_p
severe JJ 1_p
carotid NN 1_p
stenosis NN 1_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
were VBD N
classified VBN N
into IN N
a DT N
QQG NNP 1_i
group NN N
( ( N
n=48 CC N
) ) N
and CC N
a DT N
control NN 1_i
group NN 1_i
( ( N
n=48 RB N
) ) N
randomly RB N
using VBG N
consecutively RB N
numbered JJ N
envelopes NNS N
. . N

The DT N
patients NNS N
in IN N
the DT N
QQG NNP 1_i
group NN N
were VBD N
given VBN N
QQG NNP 1_i
and CC N
Western NNP 1_i
medicine NN 1_i
, , N
those DT N
in IN N
the DT N
control NN N
group NN N
were VBD N
given VBN N
Western JJ 1_i
medicine NN 1_i
merely RB N
, , N
the DT N
course NN N
of IN N
treatment NN N
was VBD N
16 CD N
weeks NNS N
. . N

All DT N
patients NNS N
went VBD N
through IN N
endarterectomy NN N
after IN N
treatment NN N
. . N

Plaques NNS N
were VBD N
subjected VBN N
to TO N
the DT N
analysis NN N
of IN N
CD3 NNP N
, , N
CD68 NNP N
, , N
soluble JJ N
intercellular JJ N
adhesion NN N
molecule NN N
1 CD N
( ( N
ICAM-1 NNP N
) ) N
, , N
matrix JJ N
metalloprotease-9 NN N
( ( N
MMP-9 NNP N
) ) N
, , N
CD40L NNP N
, , N
tenascin-C NN N
, , N
and CC N
collagen NN N
content NN N
lipid JJ N
content NN N
by IN N
immunohistochemistry NN N
or CC N
polarized VBN N
light JJ N
analysis NN N
. . N

RESULTS VBN N
By IN N
the DT N
end NN N
of IN N
experiment NN N
, , N
the DT N
expressions NNS 1_o
of IN 1_o
CD3 NNP 1_o
, , 1_o
CD68 NNP 1_o
, , 1_o
ICAM-1 NNP 1_o
, , 1_o
MMP9 NNP 1_o
, , 1_o
CD40L NNP 1_o
and CC 1_o
tenascin-C NN 1_o
on IN N
the DT N
plaques NNS N
were VBD N
statistically RB N
significant JJ N
lower JJR N
in IN N
the DT N
QQG NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
lipid JJ 1_o
content NN 1_o
of IN 1_o
the DT 1_o
plaque NN 1_o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
QQG NNP 1_i
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
interstitial JJ N
collagen NN N
in IN N
the DT N
tissue NN N
sections NNS N
of IN N
the DT N
plaques NNS N
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
QQG NNP 1_i
group NN N
in IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
QQG NNP 1_i
could MD N
stabilize VB N
carotid JJ N
artery NN N
plaques NNS N
through IN N
inhibiting VBG N
pro-inflammation NN N
factors NNS N
and CC N
restraining VBG N
the DT N
tenascin-C NN N
and CC N
MMP9 NNP N
pathway NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
cuffed NN 1_i
and CC 1_i
uncuffed JJ 1_i
endotracheal NN 1_i
tubes NNS 1_i
in IN N
young JJ 1_p
children NNS 1_p
during IN 1_p
general JJ 1_p
anesthesia NN 1_p
. . 1_p

BACKGROUND NNP N
Uncuffed NNP 1_i
endotracheal NN 1_i
tubes NNS 1_i
are VBP N
routinely RB N
used VBN N
in IN N
young JJ 1_p
children NNS 1_p
. . 1_p

This DT N
study NN N
tests VBZ N
a DT N
formula NN N
for IN N
selecting VBG N
appropriately RB N
sized VBN N
cuffed NN N
endotracheal NN N
tubes NNS N
and CC N
compares VBZ N
the DT N
use NN N
of IN N
cuffed NN 1_i
versus NN 1_i
uncuffed JJ 1_i
endotracheal NN 1_i
tubes NNS 1_i
for IN N
patients NNS 1_p
whose WP$ N
lungs NNS N
are VBP N
mechanically RB N
ventilated VBN N
during IN N
anesthesia NN N
. . N

METHODS NNP N
Full-term NNP 1_p
newborns NNS 1_p
and CC 1_p
children NNS 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
488 CD 1_p
) ) 1_p
through IN 1_p
8 CD 1_p
yr NN 1_p
of IN 1_p
age NN 1_p
who WP 1_p
required VBD 1_p
general JJ 1_p
anesthesia NN 1_p
and CC 1_p
tracheal JJ 1_p
intubation NN 1_p
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
either CC N
a DT N
cuffed NN 1_i
tube NN 1_i
sized VBN 1_i
by IN 1_i
a DT 1_i
new JJ 1_i
formula NN 1_i
[ NN N
size NN N
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
3 CD N
] NN N
, , N
or CC N
an DT N
uncuffed JJ 1_i
tube NN 1_i
sized VBN 1_i
by IN 1_i
the DT 1_i
modified JJ 1_i
Cole NNP 1_i
's POS 1_i
formula NN 1_i
[ NN N
size NN N
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
4 CD N
] NN N
. . N

The DT N
number NN 1_o
of IN 1_o
intubations NNS 1_o
required VBN 1_o
to TO 1_o
achieve VB 1_o
an DT 1_o
appropriately RB 1_o
sized JJ 1_o
tube NN 1_o
, , N
the DT N
need NN 1_o
to TO 1_o
use VB 1_o
more JJR 1_o
than IN 1_o
21.min-1 JJ 1_o
fresh JJ 1_o
gas NN 1_o
flow NN 1_o
, , N
the DT N
concentration NN 1_o
of IN 1_o
nitrous JJ 1_o
oxide NN 1_o
in IN 1_o
the DT 1_o
operating NN 1_o
room NN 1_o
, , N
and CC N
the DT N
incidence NN 1_o
of IN 1_o
croup NN 1_o
were VBD N
compared VBN N
. . N

RESULTS NNP N
Cuffed NNP 1_i
tubes RB 1_i
selected VBN N
by IN N
our PRP$ N
formula NN N
were VBD N
appropriate JJ 1_o
for IN N
99 CD N
% NN N
of IN N
patients NNS N
. . N

Uncuffed NNP 1_i
tubes RB 1_i
selected VBN N
by IN N
Cole NNP N
's POS N
formula NN N
were VBD N
appropriate JJ 1_o
for IN N
77 CD N
% NN N
of IN N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
lungs NNS 1_o
of IN 1_o
patients NNS 1_o
with IN N
cuffed JJ N
tubes NNS N
were VBD N
adequately RB 1_o
ventilated VBN 1_o
with IN N
2 CD N
1.min-1 JJ N
fresh JJ N
gas NN N
flow NN N
, , N
whereas RB N
11 CD N
% NN N
of IN N
those DT N
with IN N
uncuffed JJ N
tubes NNS N
needed VBN N
greater JJR N
fresh JJ N
gas NN N
flow NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Ambient NNP 1_o
nitrous JJ 1_o
oxide IN 1_o
concentration NN 1_o
exceeded VBD N
25 CD N
parts NNS N
per IN N
million CD N
in IN N
37 CD N
% NN N
of IN N
cases NNS N
with IN N
uncuffed JJ N
tubes NNS N
and CC N
in IN N
0 CD N
% NN N
of IN N
cases NNS N
with IN N
cuffed JJ N
tubes NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Three CD N
patients NNS N
in IN N
each DT N
group NN N
were VBD N
treated VBN N
for IN N
croup NN 1_o
symptoms NNS 1_o
( ( N
1.2 CD N
% NN N
cuffed NN N
; : N
1.3 CD N
% NN N
uncuffed NN N
) ) N
. . N

CONCLUSIONS VB N
Our PRP$ N
formula NN N
for IN N
cuffed NN N
tube NN N
selection NN N
is VBZ N
appropriate JJ 1_o
for IN N
young JJ 1_o
children NNS 1_o
. . 1_o

Advantages NNS 1_o
of IN N
cuffed JJ 1_i
endotracheal JJ 1_i
tubes NNS 1_i
include VBP N
avoidance NN 1_o
of IN 1_o
repeated VBN 1_o
laryngoscopy NN 1_o
, , 1_o
use NN 1_o
of IN 1_o
low JJ 1_o
fresh JJ 1_o
gas NN 1_o
flow NN 1_o
, , N
and CC N
reduction NN 1_o
of IN 1_o
the DT 1_o
concentration NN 1_o
of IN 1_o
anesthetics NNS 1_o
detectable JJ 1_o
in IN 1_o
the DT 1_o
operating NN 1_o
room NN 1_o
. . 1_o

We PRP N
conclude VBP N
that IN N
cuffed NN 1_i
endotracheal VBP 1_i
tubes NNS 1_i
may MD N
be VB N
used VBN N
routinely RB N
during IN N
controlled VBN N
ventilation NN N
in IN N
full-term JJ 1_p
newborns NNS 1_p
and CC 1_p
children NNS 1_p
during IN 1_p
anesthesia NN 1_p
. . 1_p

-DOCSTART- -X- O O

[ IN 1_p
The DT 1_p
use NN 1_p
of IN 1_p
cephalosporins NNS 1_i
in IN 1_p
hospital NN 1_p
practice NN 1_p
] NN 1_p
. . N

-DOCSTART- -X- O O

Efficacy NN 1_o
and CC N
safety NN 1_o
relative VBP N
to TO N
placebo VB 1_i
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN 1_i
and CC N
sustained-release JJ N
pseudoephedrine NN 1_i
in IN N
the DT N
management NN 1_o
of IN 1_o
nasal JJ 1_o
congestion NN 1_o
. . 1_o

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
clinical JJ 1_o
efficacy NN 1_o
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN 1_i
5 CD N
mg NN N
with IN N
sustained-release JJ N
pseudoephedrine NN 1_i
( ( N
PSE NNP N
) ) N
120 CD N
mg JJ N
relative NN N
to TO N
placebo VB 1_i
in IN N
patients NNS 1_p
with IN 1_p
nasal JJ 1_o
congestion NN 1_o
. . 1_o

METHODS NNP N
Twenty-four JJ 1_p
patients NNS 1_p
with IN 1_p
perennial JJ 1_p
rhinitis NN 1_p
due JJ 1_p
to TO 1_p
house-dust-mite JJ 1_p
( ( 1_p
HDM NNP 1_p
) ) 1_p
allergy NN 1_p
were VBD 1_p
recruited VBN 1_p
in IN N
this DT N
crossover NN N
study NN N
. . N

A DT N
treatment NN N
period NN N
of IN N
1 CD N
week NN N
, , N
in IN N
which WDT N
cetirizine/PSE NN 1_i
was VBD N
administered VBN N
twice RB N
daily RB N
, , N
was VBD N
followed VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
2 CD N
weeks NNS N
and CC N
a DT N
further JJ N
period NN N
of IN N
1 CD N
week NN N
in IN N
which WDT N
the DT N
alternative NN N
treatment NN N
was VBD N
given VBN N
to TO N
each DT N
patient NN N
. . N

Immediately RB N
after IN N
the DT N
first JJ N
dose NN N
of IN N
each DT N
medication NN N
( ( N
day NN N
1 CD N
) ) N
, , N
nasal JJ 1_o
congestion NN 1_o
and CC N
related VBN 1_o
symptoms NNS 1_o
were VBD N
assessed VBN N
during IN N
a DT N
7-h JJ N
challenge NN N
with IN N
HDM NNP N
feces NNS N
, , N
with IN N
the DT N
Vienna NNP N
Challenge NNP N
Chamber NNP N
( ( N
VCC NNP N
) ) N
, , N
to TO N
investigate VB N
onset NN N
of IN N
action NN N
of IN N
the DT N
preparation NN N
. . N

A DT N
second JJ N
challenge NN N
of IN N
3-h JJ N
duration NN N
, , N
carried VBD N
out RP N
at IN N
least JJS N
12 CD N
h NN N
after IN N
the DT N
final JJ N
dose NN N
, , N
was VBD N
undertaken VBN N
after IN N
1 CD N
week NN N
( ( N
mean JJ N
) ) N
of IN N
twice-daily JJ N
treatment NN N
to TO N
assess VB N
residual JJ N
effects NNS 1_o
of IN N
the DT N
formulation NN N
after IN N
achievement NN N
of IN N
steady JJ N
state NN N
. . N

RESULTS VB N
The DT N
oral JJ N
formulation NN N
of IN N
cetirizine/PSE NN 1_i
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
superior NN N
to TO N
placebo VB 1_i
in IN N
improving VBG N
nasal JJ 1_o
obstruction NN 1_o
during IN N
both DT N
challenges NNS N
. . N

The DT N
improvement NN 1_o
in IN 1_o
nasal JJ 1_o
airflow NN 1_o
and CC 1_o
nasal JJ 1_o
patency NN 1_o
was VBD N
significantly RB N
greater JJR N
with IN N
cetirizine/PSE NN 1_i
than IN N
with IN N
placebo NN 1_i
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

In IN N
addition NN N
, , N
subjective JJ N
assessment NN N
of IN N
nasal NN 1_o
symptoms NNS 1_o
showed VBD N
that IN N
cetirizine/PSE NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB 1_i
in IN N
both DT N
challenges NNS N
for IN N
the DT N
sum NN 1_o
of IN 1_o
nasal JJ 1_o
obstruction NN 1_o
scores NNS 1_o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Both DT N
medications NNS N
were VBD N
well RB N
tolerated VBN 1_o
, , N
and CC N
no DT N
serious JJ N
adverse JJ 1_o
events NNS 1_o
occurred VBD N
during IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
cetirizine/PSE NN 1_i
relieved VBD N
nasal JJ 1_o
congestion NN 1_o
and CC N
other JJ N
objective JJ N
and CC N
subjective JJ N
symptoms NNS 1_o
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
than IN N
placebo NN N
. . N

No DT N
serious JJ N
adverse JJ 1_o
events NNS 1_o
occurred VBD N
, , N
and CC N
both DT N
regimens NNS N
were VBD N
equally RB N
well RB N
tolerated VBN 1_o
. . 1_o

-DOCSTART- -X- O O

Physiologic NNP N
modeling NN N
of IN N
the DT N
intravenous JJ 1_o
glucose JJ 1_o
tolerance NN 1_o
test NN 1_o
in IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
: : 1_p
a DT N
new JJ N
approach NN N
to TO N
the DT N
insulin NN N
compartment NN N
. . N

The DT N
minimal JJ N
model NN N
of IN N
Bergman NNP N
et FW N
al NN N
has VBZ N
been VBN N
used VBN N
to TO N
yield VB N
estimates NNS N
of IN N
insulin NN 1_o
sensitivity NN 1_o
( ( 1_o
Si NNP 1_o
) ) 1_o
and CC 1_o
glucose JJ 1_o
effectiveness NN 1_o
( ( 1_o
Sg NNP 1_o
) ) 1_o
in IN N
type NN N
2 CD N
diabetes NNS N
by IN N
incorporating VBG N
exogenous JJ 1_i
insulin NN 1_i
protocols NNS 1_i
into IN N
the DT N
regular JJ N
intravenous JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
IVGTT NNP N
) ) N
. . N

These DT N
estimates NNS N
, , N
however RB N
, , N
are VBP N
influenced VBN N
by IN N
the DT N
degree NN N
to TO N
which WDT N
the DT N
dose NN N
of IN N
exogenous JJ 1_i
insulin NN 1_i
is VBZ N
greater JJR N
than IN N
the DT N
physiologic JJ N
response NN N
to TO N
a DT N
glucose JJ N
load NN N
. . N

Moreover RB N
, , N
most JJS N
studies NNS N
have VBP N
related VBN N
to TO N
type VB 1_p
2 CD 1_p
diabetes NNS 1_p
subjects NNS 1_p
whose WP$ N
diabetes NNS N
was VBD N
relatively RB N
mild JJ N
in IN N
terms NNS N
of IN N
therapeutic JJ N
requirements NNS N
. . N

To TO N
develop VB N
a DT N
minimal JJ N
disturbance NN N
approach NN N
in IN N
estimating VBG N
Si NNP 1_o
and CC 1_o
Sg NNP 1_o
in IN N
type NN N
2 CD N
diabetes NNS N
, , N
we PRP N
have VBP N
used VBN N
a DT N
reduced JJ 1_i
glucose JJ 1_i
load NN 1_i
( ( N
200 CD N
mg/kg NN N
) ) N
and CC 1_i
a DT 1_i
physiologic JJ 1_i
insulin NN 1_i
infusion NN 1_i
throughout IN N
the DT N
IVGTT NNP N
in IN N
a DT N
series NN N
of IN N
8 CD 1_p
patients NNS 1_p
, , 1_p
5 CD 1_p
of IN 1_p
whom WP 1_p
were VBD 1_p
insulin-requiring JJ 1_p
. . 1_p

Data NNS N
from IN N
this DT N
approach NN N
were VBD N
analyzed VBN N
using VBG N
the DT N
modelling VBG N
program NN N
CONSAM NNP N
to TO N
apply VB N
the DT N
Bergman NNP N
model NN N
, , N
either RB N
unmodified JJ N
( ( N
BMM NNP N
) ) N
, , N
or CC N
incorporating VBG N
an DT N
additional JJ N
delay NN N
element NN N
between IN N
the DT N
plasma NN N
and CC N
remote JJ N
insulin NN N
compartments NNS N
( ( N
MMD NNP N
) ) N
. . N

Application NN N
of IN N
the DT N
MMD NNP N
and CC N
extension NN N
of IN N
the DT N
IVGTT NNP N
from IN N
3 CD N
to TO N
5 CD N
hours NNS N
improved VBN N
successful JJ N
resolution NN 1_o
of IN 1_o
Si NNP 1_o
and CC 1_o
Sg NNP 1_o
from IN N
37.5 CD N
% NN N
( ( N
BMM NNP N
, , N
3-hour JJ N
IVGTT NNP N
) ) N
to TO N
100 CD N
% NN N
( ( N
MMD NNP N
, , N
5-hour JJ N
IVGTT NNP N
) ) N
. . N

Si NNP 1_o
was VBD N
reduced VBN N
in IN N
these DT N
type NN N
2 CD N
diabetes VBZ N
patients NNS N
compared VBN N
with IN N
normal JJ N
subjects NNS N
( ( N
1.86 CD N
+/- JJ N
0.60 CD N
v. JJ N
8.65 CD N
+/- JJ N
2.27 CD N
min NN N
( ( N
-1 NNP N
) ) N
x VBP N
microU NN N
( ( N
-1 NNP N
) ) N
x VBP N
mL JJ N
x $ N
10 CD N
( ( N
4 CD N
) ) N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
results NNS N
were VBD N
validated VBN N
in IN N
the DT N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
group NN 1_p
using VBG N
a DT N
2-stage JJ N
euglycemic JJ N
clamp NN N
( ( N
( ( N
Si NNP N
) ) N
CLAMP NNP N
= $ N
2.02 CD N
+/- JJ N
0.42 CD N
min NN N
( ( N
-1 NNP N
) ) N
x VBP N
microU NN N
( ( N
-1 NNP N
) ) N
x VBP N
mL JJ N
x $ N
10 CD N
( ( N
4 CD N
) ) N
P NNP N
> NNP N
.4 NNP N
) ) N
. . N

Sg NNP 1_o
was VBD N
not RB N
significantly RB N
reduced VBN N
( ( N
2.00 CD N
+/- JJ N
0.25 CD N
type NN N
2 CD N
diabetes NNS N
v. JJ N
1.55 CD N
+/- JJ N
0.26 CD N
normal JJ N
min NN N
( ( N
-1 NNP N
) ) N
x VBZ N
10 CD N
( ( N
2 CD N
) ) N
) ) N
. . N

Data NNS N
from IN N
a DT N
group NN N
of IN N
normal JJ 1_p
nondiabetic JJ 1_p
subjects NNS 1_p
was VBD N
then RB N
analyzed VBN N
using VBG N
the DT N
MMD NNP N
, , N
but CC N
this DT N
approach NN N
did VBD N
not RB N
enhance VB N
the DT N
fit NN N
of IN N
the DT N
model NN N
compared VBN N
with IN N
the DT N
BMM NNP N
. . N

This DT N
result NN N
indicates VBZ N
that IN N
the DT N
delay NN N
in IN N
insulin JJ N
action NN N
in IN N
type NN N
2 CD N
diabetes VBZ N
represents VBZ N
an DT N
abnormality NN N
whereby WRB N
the DT N
onset NN N
of IN N
insulin JJ N
action NN N
can MD N
not RB N
be VB N
described VBN N
as IN N
a DT N
single JJ N
phase NN N
in IN N
the DT N
transfer NN N
of IN N
insulin NN N
from IN N
plasma NN N
to TO N
the DT N
remote JJ N
compartment NN N
. . N

It PRP N
is VBZ N
postulated VBN N
that IN N
the DT N
physiologic JJ N
basis NN N
for IN N
this DT N
delayed JJ N
action NN N
may MD N
relate VB N
to TO N
transcapillary JJ N
endothelial JJ N
transfer NN N
of IN N
insulin NN N
, , N
this DT N
process NN N
limiting VBG N
the DT N
rate NN N
of IN N
onset NN N
of IN N
insulin JJ N
action NN N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
sequential JJ N
annual JJ N
vaccination NN 1_i
and CC 1_i
of IN 1_i
DHEA NNP 1_i
administration NN 1_i
on IN N
the DT N
efficacy NN N
of IN N
the DT N
immune JJ N
response NN N
to TO N
influenza VB 1_p
vaccine NN 1_p
in IN 1_p
the DT 1_p
elderly JJ 1_p
. . 1_p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
repeated VBN N
vaccination NN 1_i
and CC N
of IN N
dehydroepiandrosterone NN 1_i
( ( 1_i
DHEA NNP 1_i
) ) 1_i
treatment NN N
on IN N
the DT N
immune JJ N
response NN N
to TO N
influenza VB 1_i
vaccine NN 1_i
in IN 1_p
elderly JJ 1_p
subjects NNS 1_p
. . 1_p

Seventy-one CD 1_p
elderly JJ 1_p
volunteers NNS 1_p
, , 1_p
aged VBN 1_p
61-89 CD 1_p
years NNS 1_p
, , N
enrolled VBD N
in IN N
a DT N
prospective JJ N
randomized VBN N
, , N
double-blind JJ N
study NN N
to TO N
receive VB N
either DT N
DHEA NNP 1_i
( ( N
50 CD N
mg NN N
qd NN N
p.o NN N
. . N

for IN N
4 CD N
consecutive JJ N
days NNS N
starting VBG N
2 CD N
days NNS N
before IN N
immunization NN N
) ) N
or CC N
placebo NN 1_i
. . 1_i

Antibody NNP N
response NN N
against IN N
the DT N
three CD N
strains NNS N
of IN N
vaccine NN N
was VBD N
measured VBN N
before IN N
and CC N
28 CD N
days NNS N
after IN N
vaccination NN N
, , N
and CC N
compared VBN N
between IN N
previously RB N
vaccinated VBN N
and CC N
non-vaccinated JJ N
subjects NNS N
. . N

DHEA NNP 1_i
treatment NN 1_i
did VBD N
not RB N
enhance VB N
established VBN 1_o
immunity NN 1_o
. . 1_o

A DT N
significant JJ N
decrease NN N
in IN N
attainment NN N
of IN N
protective JJ 1_o
antibody NN 1_o
titer NN 1_o
( ( N
titer NN N
of IN N
1:40 CD N
or CC N
greater JJR N
) ) N
against IN N
A/Texas NNP N
in IN N
subjects NNS N
with IN N
non-protective JJ N
baseline NN N
antibody NN N
titer NN N
was VBD N
recorded VBN N
following VBG N
DHEA NNP 1_i
treatment NN 1_i
compared VBN N
to TO N
placebo VB N
( ( N
52 CD N
vs. FW N
84 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Post-immunization NN 1_o
titers NNS 1_o
against IN N
influenza VBP N
A DT N
strains NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
those DT N
subjects NNS N
who WP N
were VBD N
never RB N
immunized VBN N
before RB N
. . N

Additionally RB N
, , N
post-vaccination JJ 1_o
protective JJ 1_o
titers NNS 1_o
against IN N
the DT N
A/Johannesburg NNP N
strain NN N
were VBD N
more RBR N
prevalent JJ N
in IN N
those DT N
subjects NNS N
who WP N
were VBD N
never RB N
vaccinated VBN N
before RB N
. . N

The DT N
results NNS N
were VBD N
not RB N
the DT N
same JJ N
for IN N
anti-B/Harbin JJ N
antibodies-repeated JJ N
vaccination NN N
caused VBD N
a DT N
non-significant JJ N
increase NN N
in IN N
HI NNP N
titer NN N
in IN N
previously RB N
vaccinated VBN N
subjects NNS N
. . N

-DOCSTART- -X- O O

Assessment NN N
of IN N
paravalvular JJ N
aortic JJ N
regurgitation NN N
after IN N
transcatheter NN 1_i
aortic JJ 1_i
valve NN 1_i
replacement NN 1_i
: : 1_i
intra-core JJ N
laboratory NN N
variability NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
significant JJ N
disparity NN N
in IN N
the DT N
reported JJ N
incidence NN N
of IN N
moderate JJ 1_p
and CC 1_p
severe JJ 1_p
paravalvular JJ 1_o
aortic JJ 1_o
regurgitation NN 1_o
( ( 1_o
PAR NNP 1_o
) ) 1_o
between IN N
the DT N
Placement NNP 1_p
of IN 1_p
Aortic NNP 1_p
Transcatheter NNP 1_p
Valves NNP 1_p
( ( 1_p
PARTNER NNP 1_p
) ) 1_p
I PRP 1_p
and CC 1_p
PARTNER NNP 1_p
II NNP 1_p
trials NNS 1_p
, , N
which WDT N
may MD N
be VB N
related VBN N
to TO N
the DT N
echocardiographic JJ N
methodologies NNS N
used VBN N
by IN N
separate JJ N
core NN N
laboratories NNS N
. . N

To TO N
further RBR N
explore VB N
the DT N
variability NN N
in IN N
echocardiographic JJ N
interpretation NN N
of IN N
PAR NNP N
, , N
agreement NN N
between IN N
the DT N
grading NN N
of IN N
PAR NNP N
by IN N
the DT N
core NN N
laboratory NN N
of IN N
PARTNER NNP N
IIB NNP N
was VBD N
compared VBN N
with IN N
that DT N
by IN N
a DT N
consortium NN N
of IN N
echocardiography NN N
core NN N
laboratory NN N
directors NNS N
. . N

METHODS NNP N
The DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
reevaluated VBD N
patients NNS N
using VBG N
primarily RB N
the DT N
circumferential JJ N
extent NN N
of IN N
the DT N
regurgitant NN N
jet NN N
for IN N
PAR NNP 1_o
. . 1_o

A NNP N
consortium NN 1_p
of IN 1_p
echocardiography NN 1_p
core NN 1_p
laboratory NN 1_p
directors NNS 1_p
was VBD N
formed VBN N
to TO N
evaluate VB N
the DT N
echocardiographic JJ 1_i
images NNS 1_i
and CC N
to TO N
grade VB N
PAR NNP 1_o
and CC N
central JJ N
and CC N
total JJ N
aortic JJ N
regurgitation NN N
in IN N
a DT N
randomly JJ 1_p
chosen NN 1_p
subset NN 1_p
of IN 1_p
the DT 1_p
randomized JJ 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
PARTNER NNP 1_p
IIB NNP 1_p
trial NN 1_p
using VBG 1_p
a DT 1_p
multiwindow NN 1_p
, , 1_p
multiparametric JJ 1_p
approach NN 1_p
. . 1_p

Both CC N
a DT N
four-class JJ N
scale NN N
( ( N
none NN N
or CC N
trace NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
and CC N
severe RB N
) ) N
and CC N
a DT N
seven-class NN N
( ( N
none NN N
, , N
trace NN N
, , N
mild NN N
, , N
mild NN N
to TO N
moderate VB N
, , N
moderate VB N
, , N
moderate VB N
to TO N
severe VB N
, , N
and CC N
severe RB N
) ) N
scale NN N
were VBD N
used VBN N
. . N

Levels NNP N
of IN N
grading VBG N
agreement NN N
between IN N
the DT N
consortium NN N
and CC N
original JJ N
core NN N
laboratory NN N
in IN N
both DT N
scales NNS N
were VBD N
determined VBN N
using VBG N
weighted VBN N
? . N
statistics NNS N
. . N

RESULTS NNP 1_p
Only RB 1_p
87 CD 1_p
patients NNS 1_p
assessed VBN 1_p
for IN 1_o
PAR NNP 1_o
by IN 1_p
the DT 1_p
consortium NN 1_p
could MD 1_p
be VB 1_p
paired VBN 1_p
with IN 1_p
readings NNS 1_p
by IN 1_p
the DT 1_p
PARTNER NNP 1_p
IIB NNP 1_p
core NN 1_p
laboratory NN 1_p
. . 1_p

Using VBG N
the DT N
four-class NN N
grading VBG N
scheme NN N
the DT 1_o
weighted VBN 1_o
? . 1_o
statistic JJ 1_o
for IN 1_o
PAR NNP 1_o
was VBD 1_o
0.481 CD N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
, , N
0.367 CD N
, , N
0.595 CD N
) ) N
. . N

Using VBG N
the DT N
seven-class JJ N
scale NN N
, , N
the DT 1_o
weighted VBN 1_o
? . 1_o
statistic JJ 1_o
for IN 1_o
PAR NNP 1_o
was VBD 1_o
0.517 CD N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
, , N
0.431 CD N
, , N
0.607 CD N
) ) N
. . N

For IN N
either DT N
grading VBG N
scheme NN N
, , N
15.9 CD N
% NN N
of IN N
patients NNS N
graded VBN N
by IN N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
as IN N
having VBG N
moderate JJ 1_o
PAR NNP 1_o
would MD 1_o
have VB N
been VBN N
graded VBN N
as IN N
having VBG N
mild JJ 1_o
PAR NNP 1_o
using VBG 1_o
the DT N
multiparametric JJ N
approach NN N
. . N

Similar JJ N
results NNS N
were VBD N
seen VBN N
for IN N
central JJ 1_o
and CC 1_o
total JJ 1_o
aortic JJ 1_o
regurgitation NN 1_o
assessments NNS 1_o
. . N

CONCLUSIONS NNP N
Using NNP N
primarily RB N
the DT N
circumferential JJ N
extent NN N
criteria NNS N
, , N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
overestimated VBD N
the DT N
severity NN N
of IN N
PAR NNP 1_o
compared VBN 1_o
to TO N
the DT N
consortium NN N
using VBG N
a DT N
multi-parametric JJ N
approach NN N
. . N

Although IN N
a DT N
more RBR N
granular JJ N
classification NN N
scheme NN N
for IN N
PAR NNP N
may MD N
slightly RB N
improve VB N
concordance NN N
between IN N
core NN N
laboratories NNS N
, , N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
moderate JJ N
or CC N
severe JJ 1_o
PAR NN 1_o
are VBP 1_o
likely JJ N
related VBN N
to TO N
differences NNS N
in IN N
grading VBG N
methodology NN N
. . N

A DT N
multiparametric JJ N
approach NN N
is VBZ N
advocated VBN N
, , N
and CC N
other JJ N
echocardiographic JJ N
methods NNS N
for IN N
assessing VBG N
PAR NNP N
deserve VB N
further RB N
study NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
on IN N
parental JJ 1_o
mental JJ 1_o
health NN 1_o
of IN N
an DT N
education NN 1_i
and CC 1_i
skills NNS 1_i
training VBG 1_i
program NN 1_i
for IN N
parents NNS 1_p
of IN 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
impact NN N
of IN N
a DT N
parent NN 1_i
education NN 1_i
and CC 1_i
behavior JJ 1_i
management NN 1_i
intervention NN 1_i
( ( 1_i
PEBM NNP 1_i
) ) 1_i
on IN N
the DT N
mental JJ N
health NN N
and CC N
adjustment NN N
of IN N
parents NNS 1_p
with IN 1_p
preschool JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

METHOD NNP N
A NNP N
randomized JJ N
, , N
group-comparison JJ N
design NN N
involving VBG N
a DT N
parent NN 1_i
education NN 1_i
and CC 1_i
counseling VBG 1_i
intervention NN 1_i
to TO N
control VB N
for IN N
nonspecific JJ N
therapist NN N
effects NNS N
and CC N
a DT N
control NN N
sample NN N
was VBD N
used VBN N
. . N

Two CD 1_p
metropolitan JJ 1_p
and CC 1_p
two CD 1_p
rural JJ 1_p
regions NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
intervention NN N
groups NNS N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
or CC N
control NN N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

The DT 1_p
parents NNS 1_p
of IN 1_p
consecutive JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
( ( 1_p
2 CD 1_p
( ( 1_p
1/2 CD 1_p
) ) 1_p
-5 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
from IN 1_p
the DT 1_p
autism NN 1_p
assessment NN 1_p
services NNS 1_p
for IN 1_p
the DT 1_p
intervention NN 1_p
regions NNS 1_p
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
20-week JJ 1_i
manual-based JJ 1_i
parent NN 1_i
education NN 1_i
and CC 1_i
behavior JJ 1_i
management NN 1_i
intervention NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
35 CD 1_i
) ) 1_i
or CC 1_i
a DT 1_i
manual-based JJ 1_i
parent NN 1_i
education NN 1_i
and CC 1_i
counseling VBG 1_i
intervention NN 1_i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

The DT N
main JJ N
outcome JJ N
measure NN N
of IN N
parental JJ 1_o
mental JJ 1_o
health NN 1_o
was VBD N
the DT N
General NNP 1_o
Health NNP 1_o
Questionnaire NNP 1_o
used VBD N
pre- NN N
and CC N
postintervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Both NNP N
treatments NNS N
resulted VBD N
in IN N
significant JJ 1_o
and CC 1_o
progressive JJ 1_o
improvement NN 1_o
in IN 1_o
overall JJ 1_o
mental JJ 1_o
health NN 1_o
at IN N
follow-up NN N
( ( N
F NNP N
= NNP N
2 CD N
, , N
97 CD N
, , N
p FW N
=.007 NN N
) ) N
and CC N
mental JJ 1_o
health NN 1_o
significantly RB 1_o
improved VBN 1_o
over RP 1_o
time NN 1_o
in IN N
the DT N
54 CD N
% NN N
of IN N
principal JJ N
caregivers NNS N
who WP N
had VBD N
the DT N
highest JJS N
levels NNS N
of IN N
mental JJ N
health NN N
problems NNS N
. . N

The DT N
parent NN 1_o
education NN 1_o
and CC 1_o
behavior JJ 1_o
management NN 1_o
intervention NN N
was VBD N
effective JJ N
in IN N
alleviating VBG 1_o
a DT 1_o
greater JJR 1_o
percentage NN 1_o
of IN 1_o
anxiety NN 1_o
, , 1_o
insomnia NN 1_o
, , 1_o
and CC 1_o
somatic JJ 1_o
symptoms NNS 1_o
and CC 1_o
family NN 1_o
dysfunction NN 1_o
than IN N
parent NN N
education NN N
and CC N
counseling VBG N
at IN N
6-month JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
A DT N
20-week JJ N
parent NN 1_i
education NN 1_i
and CC 1_i
skills NNS 1_i
training VBG 1_i
program NN 1_i
for IN N
parents NNS 1_p
of IN 1_p
young JJ 1_p
children NNS 1_p
newly RB 1_p
diagnosed VBN 1_p
with IN 1_p
autism NN 1_p
provides VBZ N
significant JJ N
improvements NNS N
in IN N
parental JJ 1_o
mental JJ 1_o
health NN 1_o
and CC 1_o
adjustment NN 1_o
, , N
justifying VBG N
its PRP$ N
addition NN N
to TO N
early JJ N
intervention NN N
programs NNS N
at IN N
least JJS N
for IN N
parents NNS 1_p
with IN 1_p
mental JJ 1_p
health NN 1_p
problems NNS 1_p
. . 1_p

-DOCSTART- -X- O O

[ JJ N
Pharmacokinetics NNS N
of IN N
theophylline NN N
in IN N
sustained-release JJ N
formulation NN N
in IN N
young JJ 1_p
asthmatics NNS 1_p
] VBP 1_p
. . N

Pharmacokinetics NNS N
of IN N
two CD 1_i
theophylline NN 1_i
( ( 1_i
CAS NNP 1_i
58-55-9 NNP 1_i
) ) 1_i
sustained VBD 1_i
release NN 1_i
preparations NNS 1_i
( ( 1_i
T NNP 1_i
: : 1_i
Bronchoretard NNP 1_i
Capsules/R NNP 1_i
: : 1_i
Capsule JJ 1_i
formulation NN 1_i
from IN 1_i
the DT 1_i
US NNP 1_i
market NN 1_i
) ) 1_i
were VBD N
investigated VBN N
in IN N
an DT N
open JJ N
randomised VBD N
two-way RB N
crossover JJ N
design NN N
. . N

The DT N
capsules NNS N
of IN N
the DT N
test NN N
formulation NN N
were VBD N
opened VBN N
and CC N
administered VBN N
on IN N
a DT N
tablespoonful NN N
of IN N
apple NN N
sauce NN N
. . N

Nineteen JJ 1_p
asthmatics NNS 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
12 CD 1_p
years NNS 1_p
participated VBN N
in IN N
this DT N
study NN N
. . N

Following VBG 1_i
individual JJ 1_i
dosing NN 1_i
of IN 1_i
100-300 JJ 1_i
mg NNS 1_i
theophylline VB 1_i
twice RB 1_i
a DT 1_i
day NN 1_i
, , 1_i
a DT 1_i
pharmacokinetic JJ 1_i
profile NN 1_i
for IN 1_i
24 CD 1_i
h NN 1_i
was VBD 1_i
derived VBN 1_i
after IN 1_i
seven CD 1_i
days NNS 1_i
of IN 1_i
multiple JJ 1_i
dosing NN 1_i
. . 1_i

All DT 1_i
relevant JJ 1_o
parameters NNS 1_o
for IN 1_o
rate NN 1_o
( ( 1_o
Cmax NNP 1_o
ss NN 1_o
, , 1_o
Cmin NNP 1_o
ss NN 1_o
, , 1_o
Cav NNP 1_o
ss NN 1_o
, , 1_o
plateau NN 1_o
time NN 1_o
, , 1_o
peak-trough JJ 1_o
fluctuation NN 1_o
, , 1_o
nocturnal JJ 1_o
excess NN 1_o
, , 1_o
tmax VB 1_o
ss NN 1_o
) ) 1_o
and CC 1_i
extent NN 1_o
of IN 1_o
absorption NN 1_o
( ( 1_o
AUCss NNP 1_o
) ) 1_o
were VBD 1_i
calculated VBN 1_i
for IN 1_i
both DT 1_i
formulations NNS 1_i
. . 1_i

With IN N
long JJ N
plateau NN 1_o
times NNS 1_o
( ( N
T NNP N
: : N
17.3 CD N
h NN N
) ) N
and CC N
small JJ 1_o
peak-trough JJ 1_o
fluctuations NNS 1_o
( ( N
T NNP N
: : N
49.0 CD N
% NN N
) ) N
, , N
established VBN N
quality NN N
criteria NNS N
for IN N
high JJ N
quality NN N
theophylline NN N
preparations NNS N
were VBD N
fulfilled VBN N
by IN N
the DT N
test NN N
formulation NN N
. . N

Furthermore NNP N
, , N
symmetrical JJ 1_o
peaks NNS 1_o
resulted VBD N
after IN N
morning NN N
and CC N
evening VBG N
administration NN N
of IN N
the DT N
test NN N
formulation NN N
. . N

In IN N
conclusion NN N
, , N
smooth JJ N
and CC N
predictable JJ N
concentration/time NN 1_o
profiles NNS 1_o
were VBD N
achieved VBN N
, , N
enabling VBG N
an DT N
efficacious JJ N
and CC N
safe JJ N
therapy NN N
of IN N
asthma NN N
. . N

This DT N
individual JJ N
mode NN N
of IN N
administration NN N
allows VBZ N
not RB N
only RB N
a DT N
perfect JJ N
dose JJ N
titration NN N
in IN N
young JJ 1_p
asthmatics NNS 1_p
, , N
but CC N
is VBZ N
also RB N
helpful JJ N
to TO N
patients NNS 1_p
who WP 1_p
have VBP 1_p
difficulty NN 1_p
in IN 1_p
swallowing VBG 1_p
large JJ 1_p
dosage NN 1_p
forms NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Enoxaparin NNP 1_i
in IN N
the DT N
prevention NN N
of IN N
deep JJ N
venous JJ 1_o
thrombosis NN 1_o
after IN N
major JJ 1_p
surgery NN 1_p
: : 1_p
multicentric NN N
study NN N
. . N

The DT N
Italian JJ 1_p
Study NNP 1_p
Group NNP 1_p
. . 1_p

DVT NNP 1_o
is VBZ N
a DT N
very RB N
frequent JJ N
complication NN N
of IN N
general JJ N
surgery NN N
. . N

Heparin NNP N
and CC N
, , N
more RBR N
recently RB N
, , N
LMWHs NNP 1_i
can MD N
successfully RB N
prevent VB N
post NN 1_o
surgical JJ 1_o
thromboembolism NN 1_o
. . 1_o

One CD 1_p
thousand CD 1_p
one CD 1_p
hundred CD 1_p
and CC 1_p
twenty-two JJ 1_p
patients NNS 1_p
( ( 1_p
533 CD 1_p
males NNS 1_p
and CC 1_p
589 CD 1_p
females NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
62.2 CD 1_p
+/- JJ 1_p
11.4 CD 1_p
yrs NN 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
multicentre NN 1_p
controlled VBN 1_p
study NN 1_p
, , N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
enoxaparin NN 1_i
in IN N
comparison NN N
to TO N
calcium VB 1_i
heparin NN 1_i
in IN N
the DT N
prevention NN N
of IN N
deep JJ 1_o
venous JJ 1_o
thrombosis NN 1_o
( ( 1_o
DVT NNP 1_o
) ) 1_o
following VBG N
general JJ N
surgery NN N
. . N

Patients NNS N
assigned VBD N
to TO N
the DT N
enoxaparin NN 1_i
and CC N
the DT N
calcium NN 1_i
heparin NN 1_i
groups NNS N
received VBD N
1 CD N
daily JJ N
dose NN N
of IN N
20 CD N
mg NN N
( ( N
2000 CD N
I.U NNP N
. . N

) ) N
and CC N
2 CD N
daily JJ N
doses NNS N
of IN N
0.2 CD N
ml NN N
( ( N
5000 CD N
I.U NNP N
. . N

) ) N
, , N
respectively RB N
starting VBG N
2 CD N
hours NNS N
before IN N
the DT N
operation NN N
. . N

Both DT N
drugs NNS N
were VBD N
given VBN N
by IN N
subcutaneous JJ N
route NN N
. . N

A DT N
Doppler NNP N
or CC N
Duplex NNP N
Scan NNP N
diagnosis NN N
of IN N
DVT NNP 1_o
was VBD N
made VBN N
in IN N
3 CD N
( ( N
0.5 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
enoxaparin NN 1_i
group NN N
( ( N
2 CD N
cases NNS N
during IN N
treatment NN N
and CC N
1 CD N
patient NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
and CC N
in IN N
6 CD N
( ( N
1.1 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
calcium NN 1_i
heparin NN 1_i
group NN N
( ( N
5 CD N
cases NNS N
during IN N
treatment NN N
and CC N
1 CD N
, , N
bilateral NN N
, , N
after IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
. . N

Pulmonary JJ 1_o
embolism NN 1_o
( ( 1_o
PE NNP 1_o
) ) 1_o
was VBD N
ascertained VBN N
by IN N
angiography NN N
in IN N
1 CD N
patient NN N
( ( N
0.18 CD N
% NN N
) ) N
in IN N
the DT N
enoxaparin NN 1_i
group NN N
and CC N
in IN N
2 CD N
patients NNS N
( ( N
0.36 CD N
% NN N
) ) N
in IN N
the DT N
calcium NN 1_i
heparin NN 1_i
one CD N
. . N

Hemorrhagic NNP 1_o
complications NNS 1_o
occurred VBD N
in IN N
29 CD N
patients NNS N
( ( N
5.2 CD N
% NN N
) ) N
in IN N
the DT N
enoxaparin NN 1_i
group NN N
and CC N
in IN N
34 CD N
( ( N
6.1 CD N
% NN N
) ) N
in IN N
the DT N
calcium NN 1_i
heparin NN 1_i
group NN N
. . N

Haematomas NNP 1_o
located VBN N
in IN N
the DT N
injection NN N
site NN N
were VBD N
reported VBN N
in IN N
16.1 CD N
% NN N
and CC N
25.3 CD N
% NN N
in IN N
the DT N
enoxaparin NN 1_i
and CC N
calcium NN 1_i
heparin NN 1_i
groups NNS N
respectively RB N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

Local JJ N
pain NN N
in IN N
the DT N
injection NN N
site NN N
at IN N
the DT N
5th JJ N
day NN N
of IN N
treatment NN N
was VBD N
reported VBN N
in IN N
8.4 CD N
% NN N
and CC N
16.6 CD N
% NN N
in IN N
the DT N
enoxaparin NN N
and CC N
calcium NN N
heparin NN N
groups NNS N
respectively RB N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Study NNP N
protocol NN N
: : N
Rehabilitation NN 1_i
including VBG 1_i
Social NNP 1_i
and CC 1_i
Physical NNP 1_i
activity NN 1_i
and CC 1_i
Education NN 1_i
in IN N
Children NNP 1_p
and CC 1_p
Teenagers NNP 1_p
with IN 1_p
Cancer NNP 1_p
( ( N
RESPECT NNP N
) ) N
. . N

BACKGROUND NNP N
During IN N
cancer NN N
treatment NN N
children NNS 1_p
have VBP 1_p
reduced VBN 1_p
contact NN 1_p
with IN 1_p
their PRP$ 1_p
social JJ 1_p
network NN 1_p
of IN 1_p
friends NNS 1_p
, , 1_p
and CC 1_p
have VBP 1_p
limited VBN 1_p
participation NN 1_p
in IN 1_p
education NN 1_p
, , 1_p
sports NNS 1_p
, , 1_p
and CC 1_p
leisure NN 1_p
activities NNS 1_p
. . 1_p

During IN N
and CC N
following VBG N
cancer NN N
treatment NN N
, , N
children NNS 1_p
describe VBP N
school NN N
related VBN N
problems NNS N
, , N
reduced VBD N
physical JJ N
fitness NN N
, , N
and CC N
problems NNS N
related VBN N
to TO N
interaction NN N
with IN N
peers NNS N
. . N

METHODS/DESIGN NNP N
The DT N
RESPECT NNP N
study NN N
is VBZ N
a DT N
nationwide JJ 1_p
population-based JJ N
prospective NN N
, , N
controlled VBN N
, , N
mixed-methods NNS N
intervention NN N
study NN N
looking VBG N
at IN N
children NNS 1_p
aged VBN 1_p
6-18 CD 1_p
years NNS 1_p
newly RB 1_p
diagnosed VBN 1_p
with IN 1_p
cancer NN 1_p
in IN 1_p
eastern JJ 1_p
Denmark NNP 1_p
( ( 1_p
n=120 NN 1_p
) ) 1_p
and CC 1_p
a DT 1_p
matched JJ 1_p
control NN 1_p
group NN 1_p
in IN 1_p
western JJ 1_p
Denmark NNP 1_p
( ( 1_p
n=120 NN 1_p
) ) 1_p
. . 1_p

RESPECT NNP N
includes VBZ 1_p
Danish-speaking NNP 1_p
children NNS 1_p
diagnosed VBD 1_p
with IN 1_p
cancer NN 1_p
and CC 1_p
treated VBN 1_p
at IN 1_p
pediatric JJ 1_p
oncology NN 1_p
units NNS 1_p
in IN 1_p
Denmark NNP 1_p
. . 1_p

Primary JJ N
endpoints NNS N
are VBP N
the DT N
level NN 1_o
of IN 1_o
educational JJ 1_o
achievement NN 1_o
one CD 1_o
year NN 1_o
after IN 1_o
the DT 1_o
cessation NN 1_o
of IN 1_o
first-line JJ 1_o
cancer NN 1_o
therapy NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
value NN 1_o
of IN 1_o
VO2max NNP 1_o
one CD 1_o
year NN 1_o
after IN 1_o
the DT 1_o
cessation NN 1_o
of IN 1_o
first-line JJ 1_o
cancer NN 1_o
therapy NN 1_o
. . 1_o

Secondary JJ N
endpoints NNS N
are VBP N
quality NN 1_o
of IN 1_o
life NN 1_o
measured VBN 1_o
by IN 1_o
validated JJ 1_o
questionnaires NNS 1_o
and CC 1_o
interviews NNS 1_o
, , 1_o
and CC 1_o
physical JJ 1_o
performance NN 1_o
. . 1_o

RESPECT NNP N
includes VBZ N
a DT N
multimodal JJ 1_i
intervention NN 1_i
program NN 1_i
, , 1_i
including VBG 1_i
ambassador-facilitated JJ 1_i
educational JJ 1_i
, , 1_i
physical JJ 1_i
, , 1_i
and CC 1_i
social JJ 1_i
interventions NNS 1_i
. . 1_i

The DT N
educational JJ 1_i
intervention NN 1_i
includes VBZ N
an DT N
educational JJ 1_i
program NN 1_i
aimed VBN N
at IN N
the DT N
child NN 1_p
with IN 1_p
cancer NN 1_p
, , N
the DT N
child NN N
's POS N
schoolteachers NNS N
and CC N
classmates NNS N
, , N
and CC N
the DT N
child NN N
's POS N
parents NNS N
. . N

Children NNP 1_p
with IN 1_p
cancer NN 1_p
will MD N
each DT N
have VB N
two CD N
ambassadors NNS N
assigned VBD N
from IN N
their PRP$ N
class NN N
. . N

The DT N
ambassadors NNS N
visit VBP 1_i
the DT 1_i
child NN 1_i
with IN 1_i
cancer NN 1_i
at IN N
the DT N
hospital NN N
at IN N
alternating VBG N
2-week JJ N
intervals NNS N
and CC 1_i
participate VB 1_i
in IN 1_i
the DT 1_i
intervention NN 1_i
program NN 1_i
. . 1_i

The DT N
physical JJ 1_i
and CC 1_i
social JJ 1_i
intervention NN 1_i
examines VBZ N
the DT N
effect NN N
of IN N
early JJ N
, , N
structured VBN N
, , N
individualized VBN N
, , N
and CC N
continuous JJ N
physical JJ N
activity NN N
from IN N
diagnosis NN N
throughout IN N
the DT N
treatment NN N
period NN N
. . N

The DT N
patients NNS 1_p
are VBP N
tested VBN N
at IN N
diagnosis NN N
, , N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
diagnosis NN N
, , N
and CC N
one CD N
year NN N
after IN N
the DT N
cessation NN N
of IN N
treatment NN N
. . N

The DT N
study NN N
is VBZ N
powered VBN N
to TO N
quantify VB N
the DT N
impact NN N
of IN N
the DT N
combined JJ N
educational JJ 1_i
, , 1_i
physical JJ 1_i
, , 1_i
and CC 1_i
social JJ 1_i
intervention NN 1_i
programs NNS 1_i
. . 1_i

DISCUSSION NNP N
RESPECT NNP N
is VBZ N
the DT N
first JJ N
population-based JJ N
study NN N
to TO N
examine VB N
the DT N
effect NN N
of IN N
early JJ N
rehabilitation NN N
for IN N
children NNS N
with IN N
cancer NN N
, , N
and CC N
to TO N
use VB N
healthy JJ N
classmates NNS 1_i
as IN 1_i
ambassadors NNS 1_i
to TO N
facilitate VB N
the DT N
normalization NN N
of IN N
social JJ N
life NN N
in IN N
the DT N
hospital NN N
. . N

For IN N
children NNS 1_p
with IN 1_p
cancer NN 1_p
, , N
RESPECT NNP N
contributes VBZ N
to TO N
expanding VBG N
knowledge NN N
on IN N
rehabilitation NN N
that WDT N
can MD N
also RB N
facilitate VB N
rehabilitation NN N
of IN N
other JJ N
children NNS N
undergoing VBG N
hospitalization NN N
for IN N
long-term JJ N
illness NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials.gov NNP N
: : N
file NN N
. . N

NCT01772849 NNP N
and CC N
NCT01772862 NNP N
. . N

-DOCSTART- -X- O O

Hepatectomy NNP 1_i
Versus NNP 1_i
Hepatectomy NNP 1_i
With IN 1_i
Lymphadenectomy NNP 1_i
in IN N
Hepatocellular NNP N
Carcinoma NNP N
: : N
A DT N
Prospective NNP N
, , N
Randomized NNP N
Controlled NNP N
Clinical NNP N
Trial NNP N
. . N

GOALS NNP N
AND CC N
BACKGROUND NNP N
The DT N
role NN N
of IN N
preventive JJ N
lymphadenectomy NN N
has VBZ N
not RB N
yet RB N
been VBN N
determined VBN N
for IN N
hepatocellular JJ 1_p
carcinoma NN 1_p
( ( 1_p
HCC NNP 1_p
) ) 1_p
patients NNS 1_p
. . 1_p

We PRP N
designed VBD N
a DT N
study NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
hepatectomy NN 1_i
combined VBN 1_i
with IN 1_i
preventive JJ 1_i
lymphadenectomy NN 1_i
on IN N
HCC NNP 1_p
patients NNS 1_p
. . 1_p

STUDY NNP N
Patients NNPS N
were VBD N
randomly RB N
divided VBN N
into IN N
group NN N
A NNP N
( ( 1_i
treated VBN 1_i
with IN 1_i
hepatectomy JJ 1_i
alone RB 1_i
) ) 1_i
and CC N
group NN N
B NNP N
( ( 1_i
underwent JJ 1_i
hepatectomy NN 1_i
combined VBN 1_i
with IN 1_i
lymphadenectomy NN 1_i
) ) 1_i
. . N

The DT N
postoperative JJ N
complications NNS N
and CC N
oncologic JJ 1_o
prognoses NNS 1_o
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
85 CD 1_p
patients NNS 1_p
enrolled VBD 1_p
into IN 1_p
this DT 1_p
study NN 1_p
, , 1_p
79 CD 1_p
cases NNS 1_p
( ( 1_p
38 CD 1_p
in IN 1_p
group NN 1_p
A NNP 1_p
and CC 1_p
41 CD 1_p
in IN 1_p
group NN 1_p
B NNP 1_p
) ) 1_p
were VBD N
pathologically RB 1_p
confirmed VBN 1_p
to TO 1_p
have VB 1_p
HCC NNP 1_p
and CC N
received VBD N
curative JJ N
resection NN N
. . N

One CD N
hundred CD N
and CC N
sixteen JJ N
lymph NN N
nodes NNS N
were VBD N
dissected VBN N
and CC N
evaluated VBN N
as IN N
negative JJ N
by IN N
the DT N
pathologist NN N
. . N

The DT N
12- JJ N
, , N
36- JJ N
, , N
and CC N
60-month JJ N
disease-free JJ 1_o
survival NN 1_o
rates NNS 1_o
of IN N
group NN N
A NNP N
were VBD N
81.6 CD N
% NN N
, , N
68.4 CD N
% NN N
, , N
and CC N
63.2 CD N
% NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
78.0 CD N
% NN N
, , N
65.9 CD N
% NN N
, , N
and CC N
63.4 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
group NN N
B NNP N
. . N

The DT N
12- JJ N
, , N
36- JJ N
, , N
and CC N
60-month JJ N
overall JJ 1_o
survival NN 1_o
rates NNS 1_o
in IN N
group NN N
A NNP N
were VBD N
94.7 CD N
% NN N
, , N
78.9 CD N
% NN N
, , N
and CC N
65.8 CD N
% NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
87.8 CD N
% NN N
, , N
78.0 CD N
% NN N
, , N
and CC N
70.7 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
group NN N
B NNP N
. . N

The DT N
differences NNS N
in IN N
the DT N
disease-free JJ 1_o
survival NN 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
according VBG N
to TO N
the DT N
log-rank JJ N
test NN N
( ( N
P=0.811 NNP N
and CC N
P=0.881 NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
difference NN N
in IN N
the DT N
surgical JJ 1_o
complication NN 1_o
rate NN 1_o
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
47.4 CD N
% NN N
vs. FW N
36.6 CD N
% NN N
, , N
P=0.332 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
hepatectomy NN 1_i
combined VBN 1_i
with IN 1_i
regional JJ 1_i
lymphadenectomy NN 1_i
is VBZ N
a DT N
safe JJ N
procedure NN N
, , N
preventive JJ N
lymphadenectomy NN N
may MD N
not RB N
decrease VB N
the DT N
rate NN N
of IN N
tumor NN N
recurrence NN 1_o
nor CC N
improve VB N
the DT N
prognosis NN 1_o
in IN N
early-stage JJ 1_p
HCC NNP 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Treatment NN N
of IN N
bulimia NN 1_o
nervosa NN 1_o
with IN N
lithium JJ 1_i
carbonate NN 1_i
. . 1_i

A DT N
controlled JJ N
study NN N
. . N

Ninety-one CD 1_p
female JJ 1_p
bulimic JJ 1_p
outpatients NNS 1_p
received VBD N
lithium JJ 1_i
carbonate NN 1_i
or CC 1_i
placebo NN 1_i
on IN N
a DT N
random JJ N
basis NN N
, , N
after IN N
being VBG N
separated VBN N
into IN N
depressed JJ 1_p
and CC 1_p
nondepressed JJ 1_p
subgroups NNS N
, , N
in IN N
an DT N
8-week JJ N
double-blind JJ N
trial NN N
. . N

Sixty-eight JJ 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
experienced VBD N
a DT N
significant JJ N
decrease NN N
in IN N
bulimic JJ 1_o
episodes NNS 1_o
after IN N
the DT N
8 CD N
weeks NNS N
. . N

Lithium NNP 1_i
, , N
in IN N
a DT N
dosage NN N
yielding VBG N
relatively RB 1_o
low JJ 1_o
plasma NN 1_o
levels NNS 1_o
, , N
was VBD N
not RB N
more RBR N
effective JJ N
than IN N
placebo NN 1_i
. . 1_i

However RB N
, , N
depression NN 1_o
and CC 1_o
other JJ 1_o
psychopathologies NNS 1_o
decreased VBN N
with IN N
improvement NN N
in IN N
bulimic JJ 1_o
behavior NN 1_o
. . 1_o

-DOCSTART- -X- O O

Children NNP 1_p
with IN 1_p
autism NN 1_p
's POS 1_p
response NN 1_o
to TO 1_o
novel VB 1_o
stimuli NNS 1_o
while IN N
participating VBG N
in IN N
interventions NNS N
targeting VBG N
joint JJ 1_i
attention NN 1_i
or CC N
symbolic JJ 1_i
play NN 1_i
skills NNS N
. . N

Thirty-five JJ 1_p
children NNS 1_p
diagnosed VBN 1_p
with IN 1_p
autism NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
joint JJ 1_i
attention NN 1_i
or CC 1_i
a DT 1_i
symbolic JJ 1_i
play NN 1_i
intervention NN 1_i
. . 1_i

During IN N
the DT N
5-8 JJ N
week NN N
treatment NN N
, , N
three CD N
novel NN N
probes NNS N
were VBD N
administered VBN N
to TO N
determine VB N
mastery NN 1_o
of IN 1_o
joint JJ 1_o
attention NN 1_o
skills NNS 1_o
. . 1_o

The DT N
probes NNS N
consisted VBD N
of IN N
auditory NN N
and CC N
visual JJ N
stimuli NN N
, , N
such JJ N
as IN N
a DT N
loud JJ N
spider NN N
crawling NN N
or CC N
a DT N
musical JJ N
ball NN N
bouncing NN N
. . N

The DT N
current JJ N
study NN N
examined VBD N
affect JJ 1_o
, , 1_o
gaze JJ 1_o
, , 1_o
joint JJ 1_o
attention NN 1_o
behaviors NNS 1_o
, , N
and CC N
verbalizations NNS 1_o
at IN N
three CD N
different JJ N
time NN N
points NNS N
of IN N
intervention NN N
. . N

Results NNS N
revealed VBD N
that IN N
children NNS N
randomized VBN N
to TO N
the DT N
joint JJ 1_i
attention NN 1_i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
acknowledge VB 1_o
the DT 1_o
probe NN 1_o
and CC 1_o
engage NN 1_o
in IN 1_o
shared VBN 1_o
interactions NNS 1_o
between IN N
intervener NN N
and CC N
probe NN N
upon IN N
termination NN N
of IN N
intervention NN N
. . N

Additionally RB N
, , N
the DT N
joint JJ N
attention NN N
group NN N
improved VBD N
in IN N
the DT N
proportion NN 1_o
of IN 1_o
time NN 1_o
spent VBN 1_o
sharing VBG 1_o
coordinated VBN 1_o
joint JJ 1_o
looks NNS 1_o
between IN N
intervener NN N
and CC N
probe NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
generalization NN N
of IN N
joint JJ N
attention NN N
skills NNS N
to TO N
a DT N
novel JJ N
probe NN N
did VBD N
occur VB N
for IN N
the DT N
group NN N
targeting VBG N
joint JJ N
attention NN N
and CC N
provides VBZ N
further JJ N
evidence NN N
of IN N
the DT N
effectiveness NN N
of IN N
the DT N
joint JJ N
attention NN N
intervention NN N
. . N

-DOCSTART- -X- O O

Can MD N
a DT N
questionnaire NN 1_i
predict NN N
vitamin NN N
D NNP 1_o
status NN 1_o
in IN N
postmenopausal NN 1_p
women NNS 1_p
? . N
OBJECTIVE NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
questionnaire NN 1_i
can MD N
identify VB N
individuals NNS N
with IN N
vitamin NN 1_o
D NNP 1_o
insufficiency NN 1_o
( ( 1_p
VDI NNP 1_p
) ) 1_p
. . 1_p

DESIGN NNP N
Women NNP N
completed VBD N
the DT N
Vitamin NNP 1_i
D NNP 1_i
& CC 1_i
Sun NNP 1_i
( ( 1_i
VIDSUN NNP 1_i
) ) 1_i
questionnaire NN 1_i
and CC N
we PRP N
measured VBD 1_i
their PRP$ 1_i
serum JJ 1_o
25-hydrocyvitamin JJ 1_o
D NNP 1_o
( ( 1_o
25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
D NNP 1_o
) ) 1_o
levels NNS 1_o
. . 1_o

We PRP N
assessed VBD N
the DT N
sensitivity NN 1_o
and CC 1_o
specificity NN 1_o
of IN N
the DT N
questionnaire NN N
to TO N
identify VB 1_o
VDI NNP 1_o
( ( 1_o
25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
D NNP 1_o
level NN 1_o
< VBD N
50 CD N
nmol/l NN N
) ) N
. . N

SETTING NNP N
Clinical JJ N
Research NNP N
Unit NNP N
, , N
University NNP N
of IN N
Wisconsin-Madison NNP N
. . N

SUBJECTS NNP N
Postmenopausal NNP 1_p
women NNS 1_p
. . 1_p

RESULTS NNP N
We PRP N
recruited VBD N
609 CD 1_p
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
61 CD 1_p
( ( 1_p
sd JJ 1_p
6 CD 1_p
years NNS 1_p
) ) 1_p
, , 1_p
of IN 1_p
whom WP 1_p
113 CD 1_p
( ( 1_p
19 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
VDI NNP 1_p
. . 1_p

Women NNP N
with IN N
VDI NNP 1_o
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
black JJ 1_o
( ( N
17 CD N
% NN N
v. JJ N
2 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
heavier JJR N
( ( 1_o
BMI NNP 1_o
33.0 CD N
( ( N
sd VB N
7 CD N
) ) N
kg/m2 NN N
v. $ N
29.0 CD N
( ( N
sd VB N
7 CD N
) ) N
kg/m2 NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
less RBR N
likely JJ 1_o
to TO 1_o
tan VB 1_o
in IN 1_o
the DT 1_o
past JJ 1_o
year NN 1_o
( ( N
49 CD N
% NN N
v. JJ N
72 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
use VBP N
sunscreen JJ 1_o
( ( N
57 CD N
% NN N
v. JJ N
72 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
or CC N
report VB 1_o
sun NN 1_o
exposure NN 1_o
in IN 1_o
the DT 1_o
last JJ 1_o
3 CD 1_o
months NNS 1_o
. . 1_o

They PRP N
consumed VBD N
less JJR N
vitamin JJ 1_o
D NNP 1_o
from IN 1_o
supplements NNS 1_o
( ( N
2.15 CD N
( ( N
sd VB N
5.24 CD N
) ) N
?g/d NN N
( ( N
86 CD N
( ( N
sd VB N
210 CD N
) ) N
IU/d NNP N
) ) N
v. VBZ N
4.55 CD N
( ( N
sd VB N
8.48 CD N
) ) N
?g/d NN N
( ( N
188 CD N
( ( N
sd VB N
344 CD N
) ) N
IU/d NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

In IN N
logistic JJ N
regression NN N
models NNS 1_o
, , 1_o
black JJ 1_o
race NN 1_o
, , 1_o
BMI NNP 1_o
, , 1_o
suntan NN 1_o
within IN 1_o
the DT 1_o
past JJ 1_o
year NN 1_o
, , 1_o
sun NN 1_o
exposure NN 1_o
in IN 1_o
the DT 1_o
past JJ 1_o
3 CD 1_o
months NNS 1_o
, , 1_o
sunscreen JJ 1_o
use NN 1_o
and CC 1_o
supplemental JJ 1_o
vitamin NN 1_o
D NNP 1_o
intake NN 1_o
were VBD 1_o
the DT N
most RBS N
useful JJ N
questions NNS N
to TO N
identify VB N
VDI NNP N
. . N

From IN N
these DT N
six CD N
items NNS N
, , N
a DT N
composite JJ N
score NN N
of IN N
? . N
2.25 CD N
demonstrated VBD N
?89 CD N
% NN N
sensitivity NN 1_o
but CC 1_o
?35 CD 1_o
% NN 1_o
specificity NN 1_o
for IN 1_o
VDI NNP 1_o
. . N

CONCLUSIONS NNP N
The DT N
VIDSUN NNP N
questionnaire NN N
provides VBZ N
an DT N
initial JJ N
tool NN N
to TO N
identify VB N
postmenopausal JJ N
women NNS N
at IN N
high JJ N
or CC N
low JJ N
risk NN N
of IN N
VDI NNP 1_o
. . 1_o

Existing VBG N
studies NNS N
suggest VBP N
that IN N
inclusion NN N
of IN N
physical JJ N
activity NN N
and CC N
TAG NNP N
levels NNS N
might MD N
improve VB N
the DT N
performance NN N
of IN N
the DT N
VIDSUN NNP N
questionnaire NN N
. . N

-DOCSTART- -X- O O

Ovulation NN N
and CC N
follicular JJ N
development NN N
associated VBN N
with IN N
three CD N
low-dose JJ 1_i
oral JJ 1_i
contraceptives NNS 1_i
: : 1_i
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
address VB N
the DT N
hypothesis NN N
that WDT N
multiphasic JJ 1_i
oral JJ 1_i
contraceptives NNS 1_i
( ( 1_i
OCs NNP 1_i
) ) 1_i
increase NN N
rather RB N
than IN N
decrease VB N
the DT N
risk NN 1_o
of IN 1_o
functional JJ 1_o
ovarian JJ 1_o
cysts NNS 1_o
. . 1_o

METHODS NNP N
In IN N
this DT N
single-center NN N
, , N
randomized VBN N
controlled VBD N
study NN N
, , N
women NNS 1_p
were VBD N
assigned VBN N
to TO N
a DT N
multiphasic JJ 1_i
pill NN 1_i
, , 1_i
a DT 1_i
lower-dose JJ 1_i
monophasic NN 1_i
pill NN 1_i
, , 1_i
a DT 1_i
higher-dose JJ 1_i
monophasic NN 1_i
pill NN 1_i
, , 1_i
or CC 1_i
nonsteroidal JJ 1_i
contraception NN 1_i
. . 1_i

Forty JJ 1_p
volunteers NNS 1_p
were VBD 1_p
randomized VBN 1_p
( ( 1_p
ten VB 1_p
each DT 1_p
) ) 1_p
to TO 1_p
three CD 1_i
different JJ 1_i
pill NN 1_i
regimens VBZ 1_i
or CC 1_p
to TO 1_p
nonsteroidal DT 1_i
contraception NN 1_i
. . 1_i

During IN N
6 CD N
months NNS N
of IN N
treatment NN N
, , N
follicular JJ 1_o
development NN 1_o
was VBD N
measured VBN N
by IN N
vaginal JJ N
ultrasonography NN N
and CC N
ovulation NN 1_o
was VBD N
indicated VBN N
by IN N
serum NN N
progesterone NN N
levels NNS N
. . N

RESULTS VB N
The DT N
relative JJ 1_o
risk NN 1_o
( ( 1_o
RR NNP 1_o
) ) 1_o
of IN 1_o
developing VBG 1_o
a DT 1_o
follicular JJ 1_o
structure NN 1_o
greater JJR 1_o
than IN 1_o
30 CD 1_o
mm NN 1_o
in IN 1_o
diameter NN 1_o
during IN N
a DT N
cycle NN N
with IN N
the DT N
higher-dose JJ N
monophasic NN 1_i
pill NN 1_i
was VBD N
0.5 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
0.1-1.9 NN N
; : N
P NNP N
= NNP N
.49 NNP N
) ) N
compared VBN N
with IN N
the DT N
multiphasic NN N
pill NN N
. . N

The DT N
risk NN 1_o
with IN 1_o
the DT 1_o
lower-dose JJ 1_o
monophasic NN 1_o
pill NN 1_o
was VBD N
comparable JJ N
to TO N
that DT N
with IN N
the DT N
multiphasic NN 1_i
pill NN 1_i
( ( N
RR NNP N
1.3 CD N
, , N
95 CD N
% NN N
CI NNP N
0.5-3.6 CD N
; : N
P NNP N
= NNP N
.56 NNP N
) ) N
. . N

With IN N
the DT N
multiphasic NN 1_i
pill NN 1_i
, , N
the DT N
maximum JJ 1_o
ovulation NN 1_o
rate NN 1_o
over IN N
60 CD N
cycles NNS N
was VBD N
1.7 CD N
per IN N
100 CD N
cycles NNS N
( ( N
95 CD N
% NN N
CI NNP N
0.0-8.9 NN N
) ) N
. . N

CONCLUSION VB N
This DT N
multiphasic JJ 1_i
pill NN 1_i
more RBR N
closely RB N
resembled VBN N
the DT N
lower-dose JJ N
monophasic NN 1_i
pill NN 1_i
than IN N
the DT N
higher-dose JJ N
monophasic NN 1_i
pill NN 1_i
in IN N
its PRP$ N
suppression NN 1_o
of IN 1_o
follicular JJ 1_o
development NN 1_o
. . 1_o

-DOCSTART- -X- O O

Evaluation NN N
of IN N
asthma NN N
knowledge NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
Hungarian JJ 1_p
asthmatics NNS 1_p
. . 1_p

BACKGROUND IN N
The DT N
objective NN N
was VBD N
to TO N
develop VB N
an DT N
educational JJ 1_i
instrument NN 1_i
, , N
to TO N
assess VB N
its PRP$ N
impact NN N
as IN N
an DT N
intervention NN 1_i
instrument NN N
and CC N
to TO N
examine VB N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
. . N

METHODS $ N
119 CD 1_p
asthmatics NNS 1_p
were VBD 1_p
randomized VBN 1_p
( ( N
64 CD N
in IN N
the DT N
intervention NN 1_i
and CC N
55 CD N
in IN N
the DT N
reference NN 1_i
group NN N
) ) N
. . N

The DT N
education NN 1_i
instrument NN 1_i
was VBD N
developed VBN N
based VBN N
on IN N
the DT N
EuroPharm-Forum NNP N
Guidelines NNP N
and CC N
its PRP$ N
impact NN N
assessed VBN N
by IN N
a DT N
self-developed JJ N
questionnaire NN N
. . N

Patients NNS N
' POS N
QoL NNP N
, , N
asthma NN N
knowledge NN N
was VBD N
assessed VBN N
twice RB N
, , N
once RB N
before IN N
and CC N
after IN N
the DT N
education NN 1_i
seminar NN 1_i
, , N
education NN N
was VBD N
only RB N
provided VBN N
for IN N
the DT N
intervention NN N
group NN N
. . N

QoL NNP 1_o
was VBD N
measured VBN N
with IN N
the DT N
St NNP 1_o
George NNP 1_o
's POS 1_o
Respiratory NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
SGRQ NNP 1_o
) ) 1_o
and CC N
a DT N
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
. . N

RESULTS NNP N
We PRP N
found VBD N
significant JJ N
differences NNS N
in IN N
answers NNS N
to TO N
the DT N
asthma JJ N
questions NNS N
, , N
by IN N
40 CD N
% NN N
improvement NN N
, , N
but CC N
no DT N
changes NNS N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
inhaler-use NN N
technique NN N
, , N
we PRP N
could MD N
not RB N
find VB N
significant JJ N
changes NNS N
neither CC N
in IN N
the DT N
intervention NN N
nor CC N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
results NNS N
of IN N
the DT N
two CD N
visits NNS N
neither CC N
with IN N
the DT N
VAS NNP 1_o
nor CC N
with IN N
the DT N
SGRQ NNP 1_o
on IN N
the DT N
QoL NNP 1_o
data NN 1_o
. . 1_o

CONCLUSION NNP N
The DT N
results NNS N
indicate VBP N
that IN N
asthmatics NNS N
experience VB N
lower JJR N
QoL NNP 1_o
. . 1_o

As IN N
the DT 1_p
subjects NNS 1_p
were VBD 1_p
regularly RB 1_p
controlled VBN 1_p
asthmatics NNS 1_p
they PRP N
had VBD N
better RBR N
general JJ N
knowledge NN N
and CC N
inhaler-use NN N
technique NN N
was VBD N
expected VBN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
regularly VB N
refresh JJ N
asthma NN N
knowledge NN N
, , N
to TO N
assess VB N
patients NNS N
' POS N
self-management JJ N
plans NNS N
to TO N
achieve VB N
long-term JJ N
effectiveness NN N
of IN N
asthma JJ N
management NN N
. . N

-DOCSTART- -X- O O

Tacrolimus/sirolimus NNP 1_i
vs NN 1_i
tacrolimus/methotrexate NN 1_i
as IN N
GVHD NNP N
prophylaxis NN N
after IN 1_p
matched VBN 1_p
, , N
related VBN N
donor NN 1_p
allogeneic NN 1_p
HCT NNP 1_p
. . 1_p

Grades NNP N
2-4 JJ N
acute JJ N
graft-versus-host JJ N
disease NN N
( ( N
GVHD NNP N
) ) N
occurs VBZ N
in IN N
approximately RB N
35 CD N
% NN N
of IN N
matched VBN 1_p
, , 1_p
related VBN 1_p
donor NN 1_p
( ( 1_p
MRD NNP 1_p
) ) 1_p
allogeneic VBZ 1_p
hematopoietic JJ 1_p
cell NN 1_p
transplantation NN 1_p
( ( 1_p
HCT NNP 1_p
) ) 1_p
recipients NNS 1_p
. . 1_p

We PRP N
sought VBD N
to TO N
determine VB N
if IN N
the DT N
combination NN N
of IN N
tacrolimus NN 1_i
and CC 1_i
sirolimus NN 1_i
( ( 1_i
Tac/Sir NNP 1_i
) ) 1_i
was VBD N
more RBR N
effective JJ N
than IN N
tacrolimus NN 1_i
and CC 1_i
methotrexate NN 1_i
( ( 1_i
Tac/Mtx NNP 1_i
) ) 1_i
in IN N
preventing VBG N
acute JJ N
GVHD NNP N
and CC N
early JJ N
mortality NN N
after IN N
allogeneic JJ N
MRD NNP N
HCT NNP N
in IN N
a DT N
phase NN N
3 CD N
, , N
multicenter JJR N
trial NN N
. . N

The DT N
primary JJ 1_o
end NN 1_o
point NN 1_o
of IN N
the DT N
trial NN N
was VBD N
to TO N
compare VB N
114-day JJ 1_o
grades NNS 1_o
2-4 JJ 1_o
acute JJ 1_o
GVHD-free NNP 1_o
survival NN 1_o
using VBG N
an DT N
intention-to-treat JJ N
analysis NN N
of IN N
304 CD 1_p
randomized JJ 1_p
subjects NNS 1_p
. . 1_p

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
probability NN N
of IN N
day NN N
114 CD N
grades NNS N
2-4 JJ N
acute JJ N
GVHD-free JJ N
survival NN N
( ( N
67 CD N
% NN N
vs JJ N
62 CD N
% NN N
, , N
P NNP N
= NNP N
.38 NNP N
) ) N
. . N

Grades NNP 1_o
2-4 JJ 1_o
GVHD NNP 1_o
was VBD N
similar JJ N
in IN N
the DT N
Tac/Sir NNP N
and CC N
Tac/Mtx NNP N
arms NNS N
( ( N
26 CD N
% NN N
vs JJ N
34 CD N
% NN N
, , N
P NNP N
= NNP N
.48 NNP N
) ) N
. . N

Neutrophil NNP 1_o
and CC 1_o
platelet VB 1_o
engraftment NN 1_o
were VBD N
more RBR N
rapid JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
14 CD N
vs RB N
16 CD N
days NNS N
, , N
P NNP N
< NNP N
.001 NNP N
; : N
16 CD N
vs IN N
19 CD N
days NNS N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Oropharyngeal NNP 1_o
mucositis NN 1_o
was VBD N
less RBR N
severe JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
peak JJ N
Oral NNP 1_o
Mucositis NNP 1_o
Assessment NNP 1_o
Scale NNP 1_o
score VBD 1_o
0.70 CD N
vs NN N
0.96 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
but CC N
otherwise RB N
toxicity NN 1_o
was VBD N
similar JJ N
. . N

Chronic NNP 1_o
GVHD NNP 1_o
, , 1_o
relapse-free JJ 1_o
survival NN 1_o
, , 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
at IN 1_o
2 CD 1_o
years NNS 1_o
were VBD N
no DT N
different JJ N
between IN N
study NN N
arms NNS N
( ( N
53 CD N
% NN N
vs JJ N
45 CD N
% NN N
, , N
P NNP N
= NNP N
.06 NNP N
; : N
53 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
P NNP N
= NNP N
.77 NNP N
; : N
and CC N
59 CD N
% NN N
vs JJ N
63 CD N
% NN N
, , N
P NNP N
= NNP N
.36 NNP N
) ) N
. . N

Based VBN N
on IN N
similar JJ N
long-term JJ N
outcomes NNS N
, , N
more RBR N
rapid JJ N
engraftment NN N
, , N
and CC N
less JJR N
oropharyngeal JJ N
mucositis NN N
, , N
the DT N
combination NN N
of IN N
Tac/Sir NNP N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
to TO N
Tac/Mtx NNP N
after IN 1_p
MRD NNP 1_p
HCT NNP 1_p
. . 1_p

This DT N
study NN N
was VBD N
funded VBN N
by IN N
the DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
and CC N
the DT N
National NNP N
Cancer NNP N
Institute NNP N
; : N
and CC N
the DT N
trial NN N
was VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00406393 NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
selumetinib NN 1_i
vs NN N
chemotherapy NN 1_i
on IN N
progression-free JJ N
survival NN N
in IN N
uveal JJ 1_p
melanoma NN 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Uveal NNP N
melanoma NN N
is VBZ N
characterized VBN N
by IN N
mutations NNS N
in IN N
GNAQ NNP N
and CC N
GNA11 NNP N
, , N
resulting VBG N
in IN N
mitogen-activated JJ N
protein NN N
kinase VB N
pathway JJ N
activation NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
selumetinib NN 1_i
, , N
a DT N
selective JJ N
, , N
non-adenosine JJ N
triphosphate NN N
competitive JJ N
inhibitor NN N
of IN N
MEK1 NNP N
and CC N
MEK2 NNP N
, , N
in IN N
uveal JJ 1_p
melanoma NN 1_p
. . 1_p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Randomized NNP N
, , N
open-label NN N
, , N
phase NN N
2 CD N
clinical JJ N
trial NN N
comparing VBG N
selumetinib JJ 1_i
vs NN N
chemotherapy NN 1_i
conducted VBN N
from IN 1_p
August NNP 1_p
2010 CD 1_p
through IN 1_p
December NNP 1_p
2013 CD 1_p
among IN 1_p
120 CD 1_p
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
uveal JJ 1_p
melanoma NN 1_p
at IN 1_p
15 CD 1_p
academic JJ 1_p
oncology NN 1_p
centers NNS 1_p
in IN 1_p
the DT 1_p
United NNP 1_p
States NNPS 1_p
and CC 1_p
Canada NNP 1_p
. . 1_p

INTERVENTIONS NNP N
One CD 1_p
hundred VBD 1_p
one CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
in IN 1_p
a DT 1_p
1:1 CD 1_p
ratio NN 1_p
to TO N
receive VB N
selumetinib NN 1_i
, , N
75 CD N
mg NN N
orally RB N
twice RB N
daily RB N
on IN N
a DT N
continual JJ N
basis NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
, , N
or CC N
chemotherapy NN 1_i
( ( 1_i
temozolomide JJ 1_i
, , 1_i
150 CD 1_i
mg/m2 NNS N
orally RB N
daily RB N
for IN N
5 CD N
of IN N
every DT N
28 CD N
days NNS N
, , N
or CC N
dacarbazine NN 1_i
, , 1_i
1000 CD 1_i
mg/m2 NN N
intravenously RB N
every DT N
21 CD N
days NNS N
[ NNP N
investigator NN N
choice NN N
] NNP N
; : N
n CC N
= VB N
51 CD N
) ) N
until IN N
disease NN N
progression NN N
, , N
death NN N
, , N
intolerable JJ N
adverse JJ N
effects NNS N
, , N
or CC N
withdrawal NN N
of IN N
consent NN N
. . N

After IN N
primary JJ N
outcome NN N
analysis NN N
, , 1_p
19 CD 1_p
patients NNS 1_p
were VBD 1_p
registered VBN 1_p
and CC 1_p
18 CD 1_p
treated VBN 1_p
with IN 1_p
selumetinib NN 1_p
without IN 1_p
randomization NN 1_p
to TO 1_p
complete VB 1_p
the DT 1_p
planned VBN 1_p
120-patient JJ 1_p
enrollment NN 1_p
. . 1_p

Patients NNS 1_p
in IN 1_i
the DT 1_i
chemotherapy NN 1_i
group NN 1_i
could MD 1_i
receive VB N
selumetinib NN 1_i
at IN 1_i
the DT 1_i
time NN N
of IN N
radiographic JJ N
progression NN N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Progression-free NNP 1_o
survival NN 1_o
, , 1_o
the DT 1_o
primary JJ 1_o
end NN N
point NN N
, , N
was VBD N
assessed VBN N
as IN N
of IN N
April NNP N
22 CD N
, , N
2013 CD N
. . N

Additional JJ N
end NN N
points NNS N
, , N
including VBG 1_o
overall JJ 1_o
survival NN 1_o
, , 1_o
response NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
safety/toxicity NN 1_o
, , 1_o
were VBD 1_o
assessed VBN 1_o
as IN N
of IN N
December NNP N
31 CD N
, , N
2013 CD N
. . N

RESULTS VB N
Median JJ N
progression-free JJ N
survival NN N
among IN N
patients NNS N
randomized VBN 1_i
to TO 1_i
chemotherapy VB 1_i
was VBD 1_i
7 CD 1_i
weeks NNS 1_i
( ( N
95 CD N
% NN N
CI NNP N
, , N
4.3-8.4 JJ N
weeks NNS N
; : N
median JJ N
treatment NN N
duration NN N
, , N
8 CD N
weeks NNS N
; : N
interquartile JJ N
range NN N
[ NNP N
IQR NNP N
] NNP N
, , N
4.3-16 JJ N
weeks NNS N
) ) N
and CC N
among IN N
those DT N
randomized VBN 1_i
to TO 1_i
selumetinib VB 1_i
was VBD 1_i
15.9 CD 1_i
weeks NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
8.4-21.1 JJ N
weeks NNS N
; : N
median JJ N
treatment NN N
duration NN N
, , N
16.1 CD N
weeks NNS N
; : N
IQR NNP N
, , N
8.1-25.3 JJ N
weeks NNS N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.30-0.71 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) 1_o
. . 1_o

Median JJ 1_o
overall JJ 1_o
survival NN 1_o
time NN 1_o
was VBD 1_o
9.1 CD 1_o
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
6.1-11.1 JJ N
months NNS N
) ) N
with IN N
chemotherapy NN N
and CC N
11.8 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
9.8-15.7 JJ N
months NNS N
) ) N
with IN N
selumetinib NN 1_i
( ( N
hazard JJ N
ratio NN N
, , N
0.66 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.41-1.06 NNP N
; : N
P NNP N
= NNP N
.09 NNP N
) ) N
. . N

No DT N
objective JJ N
responses NNS N
were VBD N
observed VBN N
with IN 1_i
chemotherapy NN 1_i
. . 1_i

Forty-nine JJ 1_i
percent NN N
of IN N
patients NNS N
treated VBN N
with IN 1_i
selumetinib NN 1_i
achieved VBN 1_o
tumor NN 1_o
regression NN 1_o
, , 1_o
with IN 1_o
14 CD N
% NN N
achieving VBG N
an DT N
objective JJ N
radiographic JJ N
response NN N
to TO N
therapy VB N
. . N

Treatment-related JJ N
adverse JJ N
events NNS N
were VBD N
observed VBN N
in IN N
97 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
selumetinib NN N
, , N
with IN N
37 CD N
% NN N
requiring VBG N
at IN N
least JJS N
1 CD N
dose JJ N
reduction NN N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
In IN N
this DT N
hypothesis-generating JJ 1_p
study NN 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
uveal JJ 1_p
melanoma NN 1_p
, , 1_p
selumetinib NN N
compared VBN 1_i
with IN 1_i
chemotherapy NN 1_i
resulted VBN 1_i
in IN N
a DT N
modestly RB N
improved VBN N
progression-free JJ N
survival NN N
and CC N
response NN N
rate NN N
; : N
however RB N
, , N
no DT N
improvement NN N
in IN N
overall JJ N
survival NN N
was VBD N
observed VBN N
. . N

Improvement NN N
in IN N
clinical JJ N
outcomes NNS N
was VBD N
accompanied VBN N
by IN N
a DT N
high JJ N
rate NN N
of IN N
adverse JJ N
events NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01143402 NN N
. . N

-DOCSTART- -X- O O

Laser NNP 1_i
therapy NN 1_i
combined VBN 1_i
with IN 1_i
brachytherapy NN 1_i
for IN N
the DT N
palliation NN N
of IN N
malignant JJ 1_p
dysphagia NN 1_p
. . 1_p

BACKGROUND/AIM NNP N
OF IN N
STUDY NNP N
Laser NNP 1_i
therapy NN 1_i
is VBZ N
effective JJ N
in IN N
relieving VBG N
malignant JJ 1_o
dysphagia NN 1_o
, , N
but CC N
repeated VBD N
treatments NNS N
at IN N
4 CD N
to TO N
6 CD N
week NN N
intervals NNS N
are VBP N
usually RB N
required VBN N
. . N

This DT N
prospective JJ N
randomised VBN N
trial NN N
is VBZ N
designed VBN N
to TO N
determine VB N
if IN N
addition NN N
of IN N
brachytherapy NN N
offers NNS N
any DT N
advantages NNS N
over IN N
laser JJR 1_i
therapy NN 1_i
alone RB N
. . N

METHODS JJ N
Patients NNS 1_p
with IN 1_p
inoperable JJ 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
oesophagus NN 1_p
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
endoscopic NN 1_i
Nd NN 1_i
: : 1_i
YAG NNP 1_i
laser NN 1_i
therapy NN 1_i
alone RB N
, , N
or CC N
laser NN 1_i
followed VBN N
by IN N
brachytherapy NN 1_i
. . 1_i

Patients NNS N
who WP N
developed VBD N
worsening VBG N
dysphagia NN N
during IN N
follow-up JJ N
were VBD N
offered VBN N
further RB N
treatment NN N
as IN N
appropriate JJ N
. . N

RESULTS NNP N
Fourteen JJ 1_p
patients NNS 1_p
were VBD 1_p
randomised VBN 1_p
to TO 1_p
receive VB 1_p
laser NN 1_i
only RB 1_i
, , 1_p
and CC 1_p
12 CD 1_p
to TO 1_p
receive VB 1_p
laser NN 1_p
followed VBN 1_p
by IN 1_p
brachytherapy NN 1_i
. . 1_i

Of IN N
these DT N
12 CD N
, , N
one CD N
was VBD N
lost VBN N
to TO N
follow-up JJ N
and CC N
four CD N
did VBD N
not RB N
receive VB N
brachytherapy NN 1_i
because IN N
they PRP N
were VBD N
unfit JJ N
, , N
had VBD N
extension NN N
into IN N
the DT N
cardia NN N
or CC N
had VBD N
mainly RB N
extrinsic JJ N
compression NN N
. . N

These DT N
4 CD N
are VBP N
included VBN N
on IN N
an DT N
'intention-to-treat JJ N
' POS N
basis NN N
. . N

The DT N
mean JJ 1_o
therapeutic JJ 1_o
interval NN 1_o
for IN N
the DT N
brachytherapy NN N
group NN N
was VBD N
significantly RB N
longer JJR N
, , N
83 CD N
days NNS N
compared VBN N
to TO N
36 CD N
days NNS N
for IN N
the DT N
laser NN N
group NN N
( ( N
p JJ N
= NNP N
0.026 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
degree NN 1_o
of IN 1_o
dysphagia NN 1_o
relief NN 1_o
, , 1_o
number NN 1_o
of IN 1_o
endoscopic JJ 1_o
procedures NNS 1_o
or CC 1_o
survival JJ 1_o
times NNS 1_o
. . 1_o

CONCLUSION VB N
The DT N
preliminary JJ N
results NNS N
of IN N
this DT N
trial NN N
suggest VBP N
that IN N
brachytherapy NN 1_i
in IN N
addition NN N
to TO N
laser VB N
therapy NN N
prolongs IN N
the DT N
first JJ N
therapeutic JJ 1_o
interval NN 1_o
. . 1_o

However RB N
, , N
no DT N
long-term JJ N
advantages NNS N
have VBP N
been VBN N
shown VBN N
. . N

-DOCSTART- -X- O O

Continuous JJ N
glucose JJ N
monitoring NN N
in IN N
acute JJ 1_p
coronary JJ 1_p
syndrome NN 1_p
. . 1_p

BACKGROUND NNP N
Diabetes NNP 1_p
mellitus NN 1_p
is VBZ N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ 1_p
disease NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN 1_o
of IN 1_o
devices NNS 1_o
for IN N
continuous JJ N
glucose JJ N
monitoring NN N
and CC N
capillary JJ N
glucose NN N
monitoring NN N
in IN N
hospitalized JJ 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
coronary JJ 1_p
syndrome NN 1_p
using VBG N
the DT N
following JJ N
parameters NNS N
: : N
time NN 1_o
to TO 1_o
achieve VB 1_o
normoglycemia NN 1_o
, , 1_o
period NN 1_o
of IN 1_o
time NN 1_o
in IN 1_o
normoglycemia NN 1_o
, , 1_o
and CC 1_o
episodes NNS 1_o
of IN 1_o
hypoglycemia NN 1_o
. . 1_o

METHODS NNP N
We PRP N
performed VBD N
a DT N
pilot NN N
, , N
non-randomized JJ N
, , N
unblinded JJ N
clinical JJ N
trial NN N
that WDT N
included VBD N
16 CD 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
coronary JJ 1_p
artery NN 1_p
syndrome NN 1_p
, , 1_p
a DT 1_p
capillary JJ 1_p
or CC 1_p
venous JJ 1_p
blood NN 1_p
glucose NN 1_p
? . 1_p
140 CD 1_p
mg/dl NN 1_p
, , 1_p
and CC 1_p
treatment NN 1_p
with IN 1_p
a DT 1_p
continuous JJ 1_p
infusion NN 1_p
of IN 1_p
fast JJ 1_p
acting VBG 1_p
human JJ 1_i
insulin NN 1_i
. . 1_i

These DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT N
conventional JJ N
group NN N
, , N
in IN N
which WDT 1_i
capillary JJ 1_i
measurement NN 1_i
and CC 1_i
recording NN 1_i
as RB 1_i
well RB 1_i
as IN 1_i
insulin NN 1_i
adjustment NN 1_i
were VBD 1_i
made VBN N
every DT N
4h CD N
, , N
and CC N
an DT N
intervention NN N
group NN N
, , N
in IN N
which WDT 1_i
measurement NN 1_i
and CC 1_i
recording NN 1_i
as RB 1_i
well RB 1_i
as IN 1_i
insulin NN 1_i
adjustment NN 1_i
were VBD 1_i
made VBN 1_i
every DT 1_i
hour NN 1_i
with IN 1_i
a DT 1_i
subcutaneous JJ 1_i
continuous JJ 1_i
monitoring NN 1_i
system NN 1_o
. . 1_o

Student NN 1_o
's POS 1_o
t-test NN 1_o
was VBD 1_o
applied VBN N
for IN N
mean JJ N
differences NNS N
and CC N
the DT 1_o
X NNP 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
test NN 1_o
for IN 1_o
qualitative JJ N
variables NNS N
. . N

RESULTS NNP N
We PRP N
observed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT 1_o
mean JJ 1_o
time NN 1_o
for IN 1_o
achieving VBG 1_o
normoglycemia NN 1_o
, , 1_o
favoring VBG N
the DT N
conventional JJ N
group NN N
with IN N
a DT N
P NNP N
= NN N
0.02 CD N
. . N

CONCLUSION NNP N
Continuous NNP N
monitoring VBG N
systems NNS N
are VBP N
as RB N
useful JJ N
as IN N
capillary JJ N
monitoring NN N
for IN N
achieving VBG N
normoglycemia NN N
. . N

-DOCSTART- -X- O O

Successful JJ N
production NN 1_o
of IN N
piglets NNS 1_p
derived VBN N
from IN N
expanded JJ N
blastocysts NNS N
vitrified VBD N
using VBG N
a DT N
micro NN 1_i
volume NN 1_i
air NN 1_i
cooling VBG 1_i
method NN 1_i
without IN N
direct JJ N
exposure NN N
to TO N
liquid VB N
nitrogen NN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
clarify VB N
the DT N
feasibility NN N
of IN N
newly RB N
developed VBN N
vitrification NN N
techniques NNS N
for IN N
porcine NN 1_p
embryos NN 1_p
using VBG N
the DT N
micro NN 1_i
volume NN 1_i
air NN 1_i
cooling VBG 1_i
( ( 1_i
MVAC NNP 1_i
) ) 1_i
method NN N
without IN N
direct JJ N
contact NN N
with IN N
liquid JJ N
nitrogen NN N
( ( N
LN? NNP N
) ) N
. . N

Expanded VBN N
blastocysts NNS N
were VBD N
vitrified VBN N
in IN N
a DT N
solution NN N
containing VBG 1_i
6 CD 1_i
M NNP 1_i
ethylene NN 1_i
glycol NN 1_i
, , 1_i
0.6 CD 1_i
M NNP 1_i
trehalose NN 1_i
and CC 1_i
2 CD 1_i
% NN 1_i
( ( 1_i
wt/vol NN 1_i
) ) 1_i
polyethylene NN 1_i
glycol NN 1_i
in IN 1_i
10 CD 1_i
% NN 1_i
HEPES-buffered JJ 1_i
PZM-5 NNP 1_i
. . 1_i

The DT N
blastocysts NNS N
were VBD N
collected VBN N
from IN N
gilts NNS N
and CC N
vitrified VBD N
using VBG N
the DT 1_i
new JJ 1_i
device NN 1_i
( ( 1_i
MVAC NNP 1_i
) ) 1_i
or CC 1_i
a DT 1_i
Cryotop NNP 1_i
( ( 1_i
CT NNP 1_i
) ) 1_i
. . 1_i

Blastocysts NNS N
were VBD N
stored VBN N
in IN N
LN? NNP N
for IN N
at IN N
least JJS N
1 CD N
month NN N
. . N

After IN N
warming VBG N
, , N
cryoprotective JJ N
agents NNS N
were VBD N
removed VBN N
using VBG N
a DT N
single JJ N
step NN N
. . 1_o

Survival NN 1_o
of IN 1_o
the DT 1_o
embryos NN 1_o
was VBD 1_o
assessed VBN N
by IN N
in IN N
vitro JJ N
culture NN N
( ( N
Experiment NNP N
1 CD N
) ) N
and CC N
by IN N
embryo NN N
transfer NN N
to TO N
recipients NNS N
( ( N
Experiment NNP N
2 CD N
) ) N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
the DT N
embryos NN N
vitrified VBN N
by IN N
the DT N
MVAC NNP 1_i
or CC 1_i
CT NNP 1_i
and CC N
fresh JJ N
embryos NN N
without IN N
vitrification NN N
( ( N
Control NNP N
) ) N
were VBD N
used VBN N
. . N

The DT N
survival JJ 1_o
rates NNS 1_o
of IN 1_o
embryos NN 1_o
in IN 1_o
the DT N
MVAC NNP 1_i
, , 1_i
CT NNP 1_i
and CC N
Control NNP N
groups NNS N
were VBD N
88.9 CD N
% NN N
( ( N
32/36 CD N
) ) N
, , N
91.7 CD N
% NN N
( ( N
33/36 CD N
) ) N
and CC N
100 CD N
% NN N
( ( N
34/34 CD N
) ) N
, , N
respectively RB N
, , N
after IN N
48 CD N
h JJ N
culture NN N
, , N
and CC N
the DT N
hatching VBG 1_o
rates NNS 1_o
of IN 1_o
embryos NN 1_o
after IN 1_o
48 CD 1_o
h JJ 1_o
incubation NN 1_o
were VBD 1_o
69.4 CD N
% NN N
( ( N
25/36 CD N
) ) N
, , N
63.9 CD N
% NN N
( ( N
23/36 CD N
) ) N
and CC N
94.1 CD N
% NN N
( ( N
32/34 CD N
) ) N
, , N
respectively RB N
. . N

In IN N
Experiment JJ 1_p
2 CD 1_p
, , 1_p
64 CD 1_p
vitrified VBD 1_p
embryos NN 1_p
were VBD 1_p
transferred VBN N
to TO N
5 CD N
recipient NN N
gilts NNS N
, , N
and CC N
8 CD 1_o
healthy JJ 1_o
piglets NNS 1_o
were VBD 1_o
produced VBN N
from IN N
3 CD N
recipients NNS N
in IN N
the DT N
MVAC NNP 1_i
group NN 1_i
. . N

Similarly RB 1_p
, , 1_p
66 CD 1_p
vitrified VBD 1_p
embryos NN 1_p
were VBD 1_p
transferred VBN N
to TO N
5 CD N
recipient NN N
gilts NNS N
, , N
and CC N
9 CD 1_o
healthy JJ 1_o
piglets NNS 1_o
were VBD 1_o
produced VBN N
from IN N
2 CD N
recipients NNS N
in IN N
the DT N
CT NNP 1_i
group NN N
. . N

These DT N
results NNS N
indicated VBD N
that IN N
porcine NN 1_p
expanded VBN 1_p
blastocysts NNS 1_p
can MD 1_p
be VB N
cryopreserved VBN N
using VBG N
the DT N
MVAC NNP 1_i
method NN 1_i
without IN N
potential JJ N
pathogen NN N
contamination NN N
from IN N
LN? NNP N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
prior JJ N
pharmacotherapy NN 1_i
on IN N
remission NN 1_o
of IN 1_o
psychotic JJ 1_o
depression NN 1_o
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Having VBG N
failed VBN N
to TO N
respond VB N
to TO N
an DT N
adequate JJ N
antidepressant JJ N
treatment NN N
course NN N
predicts VBZ N
poorer JJR N
treatment NN 1_o
outcomes NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
major JJ 1_p
depression NN 1_p
. . 1_p

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
impact NN N
of IN N
prior JJ N
treatment NN N
on IN N
the DT N
outcome NN 1_o
of IN N
major JJ 1_p
depression NN 1_p
with IN 1_p
psychotic JJ 1_p
features NNS 1_p
( ( 1_p
MDpsy NNP 1_p
) ) 1_p
. . 1_p

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
prior JJ N
treatment NN N
history NN N
on IN N
the DT N
outcome NN 1_o
of IN 1_o
pharmacotherapy NN 1_o
of IN N
MDpsy NNP 1_p
in IN 1_p
patients NNS 1_p
who WP 1_p
participated VBD 1_p
in IN 1_p
the DT 1_p
STOPD-PD NNP 1_p
study NN 1_p
, , 1_p
a DT 1_p
randomized VBN 1_p
, , 1_p
double-blind JJ 1_p
, , 1_p
clinical JJ 1_p
trial NN 1_p
comparing VBG 1_p
a DT 1_p
combination NN N
of IN N
olanzapine JJ 1_i
plus CC 1_i
sertraline JJ 1_i
vs. FW 1_i
olanzapine JJ 1_i
plus CC 1_i
placebo NN 1_i
. . 1_i

The DT N
strength NN N
of IN N
treatment NN N
courses NNS N
received VBD N
prior RB N
to TO N
randomization NN N
was VBD N
classified VBN N
using VBG N
a DT N
validated JJ N
method NN N
. . N

A DT N
hierarchy NN N
of IN N
outcomes NNS 1_o
was VBD N
hypothesized VBN N
based VBN N
on IN N
treatments NNS N
received VBN N
prior RB N
to TO N
randomization NN N
and CC N
randomized JJ N
treatment NN N
. . N

A DT N
high JJ 1_o
remission NN 1_o
rate NN 1_o
was VBD N
observed VBN N
in IN N
subjects NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
no DT 1_p
prior JJ 1_p
treatment NN 1_p
or CC 1_p
inadequate JJ 1_p
treatment NN 1_p
who WP 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
a DT 1_p
combination NN 1_p
of IN 1_p
olanzapine NN 1_i
and CC 1_p
sertraline NN 1_i
. . 1_i

A DT N
low JJ 1_o
remission NN 1_o
rate NN 1_o
was VBD N
observed VBN N
in IN N
subjects NNS 1_p
who WP 1_p
had VBD 1_p
previously RB 1_p
failed VBN 1_p
to TO 1_p
respond VB 1_p
to TO 1_p
an DT 1_p
antidepressant JJ 1_p
alone NN 1_p
and CC 1_p
who WP 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
olanzapine JJ 1_i
monotherapy NN 1_p
. . 1_p

A DT N
low JJ 1_o
remission NN 1_o
rate NN 1_o
was VBD N
also RB N
observed VBN N
in IN N
subjects NNS 1_p
who WP 1_p
had VBD 1_p
previously RB 1_p
failed VBN 1_p
to TO 1_p
respond VB 1_p
to TO 1_p
a DT 1_p
combination NN 1_p
of IN 1_p
an DT 1_p
antipsychotic JJ 1_p
and CC 1_p
an DT 1_p
antidepressant NN 1_p
. . 1_p

Similar JJ N
to TO N
patients NNS N
with IN N
major JJ N
depression NN N
, , N
these DT N
results NNS N
emphasize VBP N
the DT N
impact NN 1_o
of IN 1_o
prior JJ 1_o
pharmacotherapy NN 1_o
on IN N
treatment NN 1_o
outcomes NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
MDpsy NNP 1_p
. . 1_p

-DOCSTART- -X- O O

Specific JJ 1_i
exercises VBZ 1_i
to TO N
treat VB N
pregnancy-related JJ N
low JJ N
back RB N
pain NN N
in IN N
a DT N
South JJ 1_p
African JJ 1_p
population NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
an DT N
exercise NN 1_i
program NN 1_i
, , 1_i
including VBG 1_i
specific JJ 1_i
stabilizing NN 1_i
exercises NNS 1_i
, , N
on IN N
pain NN N
intensity NN N
and CC N
functional JJ N
ability NN N
in IN N
women NNS 1_p
with IN 1_p
pregnancy-related JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

METHODS NNP N
Fifty NNP 1_p
women NNS 1_p
between IN 1_p
16 CD 1_p
and CC 1_p
24 CD 1_p
weeks NNS 1_p
of IN 1_p
pregnancy NN 1_p
were VBD 1_p
recruited VBN 1_p
at IN 1_p
Tygerberg NNP 1_p
and CC 1_p
Paarl NNP 1_p
Hospitals NNP 1_p
, , 1_p
Western NNP 1_p
Cape NNP 1_p
, , 1_p
South NNP 1_p
Africa NNP 1_p
. . 1_p

Twenty-six JJ 1_p
women NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
a DT 1_p
10-week JJ 1_i
exercise NN 1_i
program NN 1_i
and CC 1_i
24 CD 1_p
were VBD 1_p
randomized VBN 1_p
as IN 1_p
controls NNS 1_i
. . 1_i

RESULTS NNP N
Overall NNP N
, , N
the DT N
most RBS N
frequent JJ N
type NN N
of IN N
back RB N
pain NN N
experienced VBD N
was VBD N
lumbar JJ 1_o
pain NN 1_o
( ( N
36 CD N
[ RB N
72.0 CD N
% NN N
] NN N
) ) N
. . N

Pain NNP 1_o
intensity NN 1_o
( ( N
P=0.76 NNP N
) ) N
and CC N
functional JJ 1_o
ability NN 1_o
( ( N
P=0.29 NNP N
) ) N
were VBD N
comparable JJ N
between IN N
the DT N
groups NNS N
on IN N
study NN N
entry NN N
. . N

In IN N
the DT N
study NN N
group NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
pain NN 1_o
intensity NN 1_o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
an DT N
improvement NN N
in IN N
functional JJ 1_o
ability NN 1_o
( ( N
P=0.06 NNP N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
pain NN 1_o
intensity NN 1_o
( ( N
P=0.89 NNP N
) ) N
or CC N
functional JJ 1_o
ability NN 1_o
( ( N
P=0.70 NNP N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

CONCLUSION VB N
A DT N
specific JJ 1_i
exercise NN 1_i
program NN 1_i
decreased VBN N
back RB N
pain JJ N
intensity NN N
and CC N
increased VBD N
functional JJ N
ability NN N
during IN N
pregnancy NN 1_p
in IN 1_p
South JJ 1_p
African JJ 1_p
women NNS 1_p
with IN 1_p
lumbar NN 1_p
and CC 1_p
pelvic JJ 1_p
girdle NN 1_p
pain NN 1_p
. . 1_p

-DOCSTART- -X- O O

Estradiol NNP 1_i
and CC 1_i
the DT 1_i
addition NN 1_i
of IN 1_i
progesterone NN 1_i
increase NN N
the DT N
sensitivity NN N
to TO N
a DT N
neurosteroid NN N
in IN N
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacodynamic JJ N
response NN N
to TO N
a DT N
neuroactive JJ 1_i
steroid NN 1_i
, , 1_i
pregnanolone NN 1_i
, , N
before IN N
and CC N
during IN N
different JJ N
hormonal JJ N
settings NNS N
of IN N
postmenopausal NN 1_i
hormone NN 1_i
replacement NN 1_i
therapy NN 1_i
( ( 1_i
HRT NNP 1_i
) ) 1_i
, , N
using VBG N
natural JJ 1_i
progesterone NN 1_i
. . 1_i

A DT N
second JJ N
aim NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
response NN N
to TO N
pregnanolone NN 1_i
was VBD N
associated VBN N
with IN N
cyclicity NN N
in IN N
negative JJ 1_o
mood NN 1_o
symptoms NNS 1_o
during IN N
treatment NN N
. . N

Twenty NNP 1_p
six CD 1_p
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
climacteric JJ 1_p
symptoms NNS 1_p
were VBD 1_p
administered VBN N
HRT NNP 1_i
in IN N
a DT N
randomized JJ N
, , N
double JJ N
blinded VBN N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

The DT N
women NNS N
received VBD N
2 CD N
mg JJ N
oral JJ 1_i
estradiol NN 1_i
( ( 1_i
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
) ) 1_i
continuously RB N
during IN N
two CD N
28-day JJ N
cycles NNS N
and CC N
800 CD N
mg NN N
of IN N
vaginal JJ 1_i
progesterone NN 1_i
or CC 1_i
placebo NN 1_i
sequentially RB N
for IN N
the DT N
last JJ N
14 CD N
days NNS N
of IN N
each DT N
treatment NN N
cycle NN N
. . N

Pharmacodynamic NNP 1_o
response NN 1_o
to TO N
pregnanolone NN 1_i
was VBD N
assessed VBN N
before IN N
treatment NN N
, , N
and CC N
during IN N
the DT N
last JJ N
week NN N
of IN N
each DT N
treatment NN N
cycle NN N
, , N
by IN N
comparing VBG N
the DT N
effects NNS N
of IN N
intravenous JJ N
pregnanolone NN 1_i
( ( 1_i
3alpha-hydroxy-5beta-pregnan-20-one CD 1_i
) ) 1_i
on IN N
saccadic JJ 1_o
eye NN 1_o
velocity NN 1_o
( ( 1_o
SEV NNP 1_o
) ) 1_o
, , 1_o
saccade JJ 1_o
acceleration NN 1_o
, , 1_o
saccade JJ 1_o
latency NN 1_o
and CC 1_o
self-rated JJ 1_o
sedation NN 1_o
. . 1_o

Throughout IN N
the DT N
study NN N
daily JJ 1_o
symptom NN 1_o
rating NN 1_o
scales NNS 1_o
were VBD N
kept VBN N
. . N

According VBG N
to TO N
the DT N
daily JJ 1_o
symptom NN 1_o
rating NN 1_o
scales NNS 1_o
, , N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD 1_p
groups NNS 1_p
; : 1_p
one CD 1_p
group NN 1_p
who WP 1_p
displayed VBD 1_p
a DT 1_p
significant JJ 1_p
variance NN 1_p
in IN 1_p
negative JJ 1_o
mood NN 1_o
symptoms NNS 1_o
during IN 1_p
HRT NNP 1_i
( ( 1_p
cyclicity NN 1_p
) ) 1_p
and CC 1_p
one CD 1_p
group NN 1_p
with IN 1_p
no DT 1_p
cyclical JJ 1_p
changes NNS 1_p
in IN 1_p
negative JJ 1_o
mood NN 1_o
symptoms NNS 1_o
during IN 1_p
treatment NN 1_p
. . 1_p

During IN N
treatment NN N
with IN N
either DT N
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
alone RB 1_i
or CC 1_i
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
+progesterone CD 1_i
the DT N
response NN N
in IN N
saccadic JJ 1_o
eye NN 1_o
movement NN 1_o
parameters NNS 1_o
and CC N
in IN N
self-rated JJ 1_o
sedation NN 1_o
to TO N
pregnanolone NN N
was VBD N
enhanced VBN N
compared VBN N
to TO N
pretreatment VB N
values NNS N
. . N

The DT N
SEV NNP N
, , N
saccade JJ 1_o
acceleration NN 1_o
and CC 1_o
sedation NN 1_o
responses NNS 1_o
to TO N
pregnanolone NN 1_i
was VBD N
also RB N
increased VBN N
in IN N
women NNS N
expressing VBG N
cyclicity NN N
in IN N
negative JJ 1_o
mood NN 1_o
symptoms NNS 1_o
compared VBN N
to TO N
women NNS N
with IN N
no DT N
cyclical JJ N
changes NNS N
in IN N
negative JJ N
mood NN N
during IN N
HRT NNP 1_i
. . 1_i

In IN N
conclusion NN N
, , N
during IN N
treatment NN N
with IN N
either DT N
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
alone RB 1_i
, , 1_i
or CC 1_i
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
+progesterone NN 1_i
, , 1_i
pregnanolone NN 1_o
sensitivity NN 1_o
was VBD N
increased VBN N
. . N

Women NNP 1_p
expressing VBG 1_p
cyclicity NN 1_p
in IN 1_p
negative JJ 1_p
mood NN 1_p
symptoms NNS 1_p
were VBD N
more RBR N
sensitive JJ N
to TO N
pregnanolone VB 1_i
than IN N
women NNS N
without IN N
symptom JJ N
cyclicity NN N
during IN N
HRT NNP 1_i
. . 1_i

-DOCSTART- -X- O O

Rifampicin NNP 1_i
plus CC 1_i
isoniazid NN 1_i
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN 1_p
in IN 1_p
an DT 1_p
immigrant JJ 1_p
population NN 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
tolerance NN N
, , N
adherence NN N
and CC N
effectiveness NN N
of IN N
two CD N
approaches NNS N
for IN N
the DT N
treatment NN N
of IN N
latent JJ N
tuberculosis NN N
infection NN N
( ( N
LTBI NNP N
) ) N
: : N
6 CD N
months NNS N
of IN N
isoniazid NN 1_i
( ( 1_i
6H CD 1_i
) ) 1_i
vs. FW N
3 CD N
months NNS N
of IN N
isoniazid JJ 1_i
plus CC 1_i
rifampicin JJ 1_i
( ( 1_i
3RH CD 1_i
) ) 1_i
. . 1_i

POPULATION JJ N
Immigrants NNS 1_p
with IN 1_p
LTBI NNP 1_p
. . 1_p

METHODS NNP N
Participants NNPS N
were VBD N
enrolled VBN N
in IN N
a DT N
controlled VBN N
, , N
randomised VBD N
clinical JJ N
trial NN N
in IN 1_p
Barcelona NNP 1_p
, , 1_p
Spain NNP 1_p
, , 1_p
from IN 1_p
April NNP 1_p
2001 CD 1_p
to TO 1_p
April NNP 1_p
2005 CD 1_p
. . 1_p

Monthly JJ N
follow-up NN N
was VBD N
done VBN N
to TO N
assess VB N
tolerance NN N
, , N
side NN N
effects NNS N
and CC N
adherence NN N
. . N

Effectiveness NNP N
was VBD N
evaluated VBN N
at IN N
5 CD N
years NNS N
. . N

RESULTS NN N
In IN N
the DT N
590 CD 1_p
subjects NNS 1_p
enrolled VBN 1_p
, , N
the DT N
rate NN 1_o
of IN 1_o
adherence NN 1_o
was VBD N
greater JJR N
in IN N
the DT N
3RH CD N
than IN N
in IN N
the DT N
6H CD N
arm NN N
( ( N
72 CD N
% NN N
vs. FW N
52.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
study NN N
arms NNS N
were VBD N
observed VBN N
with IN N
respect NN N
to TO N
hepatotoxicity NN 1_o
or CC 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

Variables NNS N
associated VBN N
with IN N
non-adherence NN N
were VBD N
diagnosis VBN N
by IN N
screening VBG 1_o
( ( N
OR CC N
1.88 CD N
, , N
95 CD N
% NN N
CI NNP N
1.26-2.82 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
illegal JJ 1_o
immigration NN 1_o
status NN 1_o
( ( N
OR CC N
1.48 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01-2.15 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
unemployment NN 1_o
( ( N
OR CC N
1.91 CD N
, , N
95 CD N
% NN N
CI NNP N
1.28-2.85 CD N
, , N
P NNP N
= NNP N
0.0008 CD N
) ) N
, , N
illiteracy NN 1_o
( ( N
OR CC N
1.73 CD N
, , N
95 CD N
% NN N
CI NNP N
1.04-2.88 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
lack NN 1_o
of IN 1_o
family NN 1_o
support NN 1_o
( ( N
OR NNP N
3.7 CD N
, , N
95 CD N
% NN N
CI NNP N
2.54-5.4 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
the DT N
6-month JJ 1_o
treatment NN 1_o
regimen NNS 1_o
( ( N
OR NNP N
2.45 CD N
, , N
95 CD N
% NN N
CI NNP N
1.68-3.57 CD N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
who WP N
completed VBD N
either CC N
treatment NN N
developed VBD N
tuberculosis NN 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
3RH CD 1_i
regimen NNS 1_i
facilitates VBZ N
adherence NN N
to TO N
LTBI NNP N
treatment NN N
and CC N
offers VBZ N
a DT N
safe JJ N
, , N
well-tolerated JJ N
and CC N
effective JJ N
alternative NN N
. . N

-DOCSTART- -X- O O

Over IN N
time NN N
relationships NNS N
between IN N
early JJ 1_p
adolescent NN 1_p
and CC 1_p
peer NN 1_o
substance NN 1_o
use NN N
. . N

Peer NNP N
and CC N
adolescent JJ N
substance NN N
use NN N
are VBP N
highly RB N
correlated VBN N
, , N
but CC N
this DT N
relationship NN N
is VBZ N
not RB N
fully RB N
understood JJ N
. . N

In IN N
particular JJ N
, , N
the DT N
relative JJ N
contributions NNS N
of IN N
selection NN N
and CC N
socialization NN N
to TO N
substance VB N
use NN N
progression NN N
have VBP N
not RB N
been VBN N
established VBN N
. . N

Students NNS 1_p
( ( 1_p
n=2453 NN 1_p
) ) 1_p
in IN 1_p
the DT 1_p
seven CD 1_p
middle JJ 1_p
schools NNS 1_p
in IN 1_p
one CD 1_p
school NN 1_p
district NN 1_p
were VBD 1_p
assessed VBN 1_p
at IN 1_p
school NN 1_p
at IN 1_p
the DT 1_p
beginning NN 1_p
and CC 1_p
end NN 1_p
of IN 1_p
the DT 1_p
sixth JJ 1_p
, , 1_p
seventh JJ 1_p
, , 1_p
eighth JJ 1_p
grade NN 1_p
and CC 1_p
beginning NN 1_p
of IN 1_p
the DT 1_p
9th CD 1_p
grade NN 1_p
. . 1_p

Self-reported JJ 1_o
smoking NN 1_o
and CC 1_o
drinking NN 1_o
and CC 1_p
the DT 1_p
number NN 1_p
of IN 1_p
substance NN 1_p
using VBG 1_p
friends NNS 1_p
were VBD 1_p
assessed VBN 1_p
5 CD 1_p
times NNS 1_p
over IN 1_p
3 CD 1_p
years NNS 1_p
. . 1_p

The DT N
relationship NN 1_i
between IN 1_i
peer NN 1_o
and CC 1_o
adolescent NN 1_o
substance NN 1_o
use NN 1_o
were VBD 1_i
assessed VBN 1_i
in IN 1_i
parallel JJ 1_i
processes NNS 1_i
as IN 1_i
part NN 1_i
of IN 1_i
an DT 1_i
autoregressive JJ 1_i
latent NN 1_i
trajectory NN 1_i
model NN 1_i
. . 1_i

Substance NNP 1_o
use NN 1_o
and CC N
the DT 1_o
number NN 1_o
of IN 1_o
substance NN 1_o
using VBG N
friends NNS N
increased VBN N
in IN N
linear JJ N
fashion NN N
from IN N
T1 NNP N
to TO N
T5 NNP N
. . N

Initial NNP N
substance NN N
use NN N
predicted VBD N
an DT N
increase NN N
in IN N
the DT N
number NN 1_o
of IN 1_o
substance NN 1_o
using VBG 1_o
friends NNS 1_o
over IN 1_o
time NN 1_o
, , N
indicating VBG N
an DT N
effect NN N
of IN N
selection NN N
, , N
and CC N
the DT N
initial JJ N
number NN N
of IN N
substance NN N
using VBG N
friends NNS N
predicted VBD N
substance NN 1_o
use NN 1_o
progression NN N
, , N
providing VBG N
evidence NN N
of IN N
socialization NN N
. . N

The DT N
magnitudes NNS N
of IN N
these DT N
relationships NNS N
were VBD N
similar JJ N
. . N

Bivariate NNP N
, , N
lagged VBD N
autoregressive JJ N
analyses NNS N
of IN N
the DT N
successive JJ N
relationships NNS N
from IN N
one CD N
assessment NN N
to TO N
the DT N
next JJ N
showed JJ N
consistent NN N
, , N
significant JJ N
associations NNS N
from IN N
peer NN 1_o
use NN 1_o
to TO 1_o
adolescent VB 1_o
substance NN 1_o
use NN 1_o
. . 1_o

The DT N
association NN N
from IN N
adolescent NN 1_o
to TO 1_o
peer VB 1_o
use NN 1_o
was VBD N
significant JJ N
only RB N
from IN N
7th CD N
to TO N
8th CD N
grade NN N
. . N

The DT N
findings NNS N
provide VBP N
evidence NN N
of IN N
reciprocal JJ N
influences NNS N
, , N
but CC N
socialization NN N
was VBD N
a DT N
more RBR N
consistent JJ N
influence NN N
than IN N
selection NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
treatment NN N
of IN N
urinary JJ 1_p
incontinence NN 1_p
in IN N
general JJ N
practice NN N
. . N

A DT N
total NN 1_p
of IN 1_p
110 CD 1_p
women NNS 1_p
who WP 1_p
had VBD 1_p
reported VBN 1_p
urinary JJ 1_p
incontinence NN 1_p
to TO 1_p
their PRP$ 1_p
general JJ 1_p
practitioners NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
treatment NN N
or CC N
control NN N
group NN N
. . N

Treatment NNP N
consisted VBD N
of IN N
pelvic JJ 1_i
floor NN 1_i
exercises NNS 1_i
in IN N
the DT N
case NN N
of IN N
stress NN N
incontinence NN N
and CC N
bladder NN 1_i
training NN 1_i
in IN N
the DT N
case NN N
of IN N
urge JJ N
incontinence NN N
. . N

The DT N
results NNS N
were VBD N
measured VBN N
after IN N
3 CD N
and CC N
12 CD N
months NNS N
by IN N
a DT N
research NN N
assistant NN N
on IN N
the DT N
basis NN N
of IN N
a DT N
constructed JJ N
severity NN N
scale NN N
, , N
an DT N
incontinence NN N
diary NN N
, , N
and CC N
a DT N
comparison NN N
by IN N
the DT N
patients NNS N
themselves PRP N
of IN N
their PRP$ N
previous JJ N
and CC N
current JJ N
conditions NNS N
. . N

After IN N
3 CD N
months NNS N
the DT N
control NN N
group NN N
were VBD N
given VBN N
the DT N
same JJ N
treatment NN N
. . N

After IN N
a DT N
further JJ N
3 CD N
and CC N
12 CD N
months NNS N
, , N
they PRP N
were VBD N
assessed VBN N
in IN N
exactly RB N
the DT N
same JJ N
way NN N
as IN N
the DT N
treatment NN N
group NN N
. . N

After IN N
3 CD N
months NNS N
about IN N
60 CD N
% NN N
of IN N
the DT N
patients NNS N
were VBD N
either RB N
dry JJ 1_o
or CC 1_o
only RB 1_o
mildly RB 1_o
incontinent JJ 1_o
; : 1_o
the DT N
mean JJ 1_o
number NN 1_o
of IN 1_o
wet JJ 1_o
episodes NNS 1_o
had VBD N
gone VBN N
down RB N
from IN N
20 CD N
to TO N
7 CD N
, , N
and CC N
74 CD N
% NN N
of IN N
the DT N
women NNS N
felt VBD N
improved JJ 1_o
or CC 1_o
cured VBN 1_o
. . 1_o

These DT N
results NNS N
were VBD N
later RB N
corroborated VBN N
by IN N
the DT N
control NN N
group NN N
. . N

After IN N
12 CD N
months NNS N
this DT N
successful JJ N
outcome NN N
was VBD N
improved VBN N
slightly RB N
further RBR N
. . N

It PRP N
may MD N
be VB N
concluded VBN N
that IN N
the DT N
majority NN N
of IN N
women NNS 1_p
with IN 1_p
incontinence NN 1_p
can MD N
be VB N
successfully RB N
treated VBN 1_o
by IN N
the DT N
general JJ N
practitioner NN N
. . N

The DT N
effect NN N
of IN N
this DT N
treatment NN N
continues VBZ N
after IN N
one CD N
year NN N
. . N

-DOCSTART- -X- O O

[ IN N
The DT N
analgetic JJ 1_o
effect NN 1_o
of IN N
intramuscular JJ N
pethidine NN 1_i
compared VBN N
with IN N
epidural JJ 1_i
morphine NN 1_i
in IN N
upper JJ 1_p
abdominal JJ 1_p
laparotomies NNS 1_p
] VBP 1_p
. . N

-DOCSTART- -X- O O

Randomised VBN N
trial NN N
comparing VBG N
the DT N
recording VBG N
ability NN N
of IN N
a DT N
novel NN 1_i
, , 1_i
electronic JJ 1_i
emergency NN 1_i
documentation NN 1_i
system NN 1_i
with IN N
the DT N
AHA NNP 1_i
paper NN 1_i
cardiac NN 1_i
arrest NN 1_i
record NN 1_i
. . 1_i

OBJECTIVE UH N
To TO N
evaluate VB 1_o
the DT 1_o
ability NN 1_o
of IN N
an DT N
electronic JJ 1_i
system NN 1_i
created VBD N
at IN N
the DT N
University NNP N
of IN N
Washington NNP N
to TO N
accurately RB N
document VB N
prerecorded JJ N
VF NNP N
and CC N
pulseless JJ N
electrical JJ N
activity NN N
( ( N
PEA NNP N
) ) N
cardiac VBP N
arrest JJS N
scenarios NNS N
compared VBN N
with IN N
the DT N
American NNP N
Heart NNP N
Association NNP N
paper NN N
cardiac NN N
arrest NN N
record NN N
. . N

METHODS NNP N
16 CD 1_p
anaesthesiology NN 1_p
residents NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB N
one CD N
of IN N
two CD N
prerecorded VBD N
, , N
simulated VBD 1_i
VF NNP 1_i
and CC 1_i
PEA NNP 1_i
scenarios NNS 1_i
and CC N
asked VBD N
to TO N
document VB N
the DT N
event NN N
with IN N
either CC N
the DT N
paper NN 1_i
or CC 1_i
electronic JJ 1_i
system NN 1_i
. . 1_i

Each DT N
subject NN N
then RB N
repeated VBD N
the DT N
process NN N
with IN N
the DT N
other JJ N
video NN N
and CC N
documentation NN N
method NN N
. . N

Five CD N
types NNS N
of IN N
documentation NN N
errors NNS N
were VBD N
defined VBN N
: : N
( ( 1_o
1 CD 1_o
) ) 1_o
omission NN 1_o
, , 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
specification NN 1_o
, , 1_o
( ( 1_o
3 CD 1_o
) ) 1_o
timing NN 1_o
, , 1_o
( ( 1_o
4 CD 1_o
) ) 1_o
commission NN 1_o
and CC 1_o
( ( 1_o
5 CD 1_o
) ) 1_o
noise NN 1_o
. . 1_o

The DT N
mean JJ N
difference NN N
in IN N
errors NNS N
between IN N
the DT N
paper NN 1_o
and CC 1_o
electronic JJ 1_o
methods NNS 1_o
was VBD 1_o
analysed VBN 1_o
using VBG N
a DT N
single JJ N
factor NN N
repeated VBD 1_o
measures NNS 1_o
ANOVA NNP 1_o
model NN 1_o
. . N

RESULTS NNP N
Compared VBD N
with IN N
paper NN N
records NNS N
, , N
the DT N
electronic JJ N
system NN N
omitted VBD N
6.3 CD N
fewer JJR N
events NNS N
( ( N
95 CD N
% NN N
CI NNP N
-10.1 NNP N
to TO N
-2.5 VB N
, , N
p=0.003 NN N
) ) N
, , N
which WDT N
represents VBZ N
a DT N
28 CD N
% NN N
reduction NN N
in IN N
omission NN N
errors NNS N
. . N

Users NNS N
recorded VBD N
2.9 CD N
fewer JJR N
noise NN N
items NNS N
( ( N
95 CD N
% NN N
CI NNP N
-5.3 NNP N
to TO N
-0.6 VB N
, , N
p=0.003 NN N
) ) N
when WRB N
compared VBN N
with IN N
paper NN 1_i
, , N
representing VBG N
a DT N
36 CD N
% NN N
decrease NN N
in IN N
redundant NN N
or CC N
irrelevant JJ N
information NN N
. . N

The DT N
rate NN 1_o
of IN 1_o
timing NN 1_o
( ( N
?=-3.2 JJ N
, , N
95 CD N
% NN N
CI NNP N
-9.3 NNP N
to TO N
3.0 CD N
, , N
p=0.286 NN N
) ) N
and CC 1_o
commission NN 1_o
( ( N
?=-4.4 JJ N
, , N
95 CD N
% NN N
CI NNP N
-9.4 NNP N
to TO N
0.5 CD N
, , N
p=0.075 NN N
) ) N
errors NNS N
were VBD N
similar JJ N
between IN N
the DT 1_i
electronic JJ 1_i
system NN 1_i
and CC 1_i
paper NN 1_i
, , 1_i
while IN N
the DT N
rate NN N
of IN N
specification NN N
errors NNS N
were VBD N
about IN N
a DT N
third JJ N
lower JJR N
for IN N
the DT N
electronic JJ N
system NN N
when WRB N
compared VBN N
with IN N
the DT N
paper NN N
record NN N
( ( N
?=-3.2 JJ N
, , N
95 CD N
% NN N
CI NNP N
-6.3 NNP N
to TO N
-0.2 VB N
, , N
p=0.037 NN N
) ) N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN 1_i
paper NN 1_i
documentation NN 1_i
, , 1_i
documentation NN 1_i
with IN 1_i
the DT 1_i
electronic JJ 1_i
system NN 1_i
captured VBD 1_i
24 CD N
% NN N
more JJR N
critical JJ N
information NN N
during IN N
a DT N
simulated JJ N
medical JJ N
emergency NN N
without IN N
loss NN N
in IN N
data NNS N
quality NN N
. . N

-DOCSTART- -X- O O

An DT N
in IN N
vitro NN N
comparative JJ N
analysis NN N
: : N
scanning NN N
electron NN N
microscopy NN N
of IN N
dentin/restoration NN N
interfaces NNS N
. . N

One CD 1_p
hundred VBD 1_p
maxillary JJ 1_p
premolar JJ 1_p
teeth NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
ten VB 1_p
groups NNS 1_p
. . 1_p

Each DT 1_p
group NN 1_p
was VBD N
restored VBN N
with IN N
one CD N
of IN N
ten JJ 1_i
different JJ 1_i
restorative NN 1_i
techniques NNS 1_i
. . 1_i

The DT N
teeth NNS N
were VBD N
stored VBN N
in IN N
deionized JJ 1_i
water NN 1_i
for IN 1_i
7d CD 1_i
prior JJ 1_i
to TO 1_i
longitudinal JJ 1_i
sectioning NN 1_i
in IN 1_i
a DT 1_i
mesio-distal JJ 1_i
plane NN 1_i
. . 1_i

Following VBG N
sectioning NN N
, , N
ten JJ N
specimens NNS N
from IN N
each DT N
group NN N
were VBD N
chosen VBN N
at IN N
random NN N
from IN N
the DT N
20 CD N
available JJ N
sections NNS N
. . N

The DT N
sectioned JJ N
surfaces NNS N
were VBD N
polished VBN 1_i
using VBG 1_i
600-grit JJ 1_i
SiC NNP 1_i
abrasive JJ 1_i
paper NN 1_i
and CC 1_i
etched VBD 1_i
for IN 1_i
10 CD 1_i
s NN 1_i
with IN 1_i
50 CD 1_i
% NN 1_i
phosphoric JJ 1_i
acid NN 1_i
to TO N
remove VB N
the DT N
smear JJ N
layer NN N
produced VBN N
by IN N
sectioning VBG N
. . N

Five CD N
tooth JJ N
sections NNS N
from IN N
the DT N
dentin NN N
bonding VBG N
resin NN N
groups NNS N
were VBD N
allowed VBN N
to TO N
dry VB N
at IN N
20 CD N
degrees NNS N
C NNP N
for IN N
24h CD N
. . N

The DT N
glass NN N
ionomer-based JJ N
groups NNS N
were VBD N
reimmersed VBN N
in IN N
deionized JJ N
water NN N
during IN N
this DT N
period NN N
. . N

The DT N
remaining VBG N
five CD N
sections NNS N
from IN N
each DT N
group NN N
were VBD N
replicated VBN N
using VBG N
an DT N
addition-cure JJ 1_i
vinyl NN 1_i
polysiloxane NN 1_i
impression NN 1_i
material NN 1_i
and CC 1_i
an DT 1_i
epoxy JJ 1_i
resin NN 1_i
. . 1_i

A DT N
comparison NN N
was VBD N
made VBN N
of IN N
the DT N
sections NNS N
and CC N
the DT N
replicas NN N
. . N

All DT N
tooth JJ N
specimens NNS N
were VBD N
sputter-coated JJ 1_i
with IN 1_i
gold NN 1_i
for IN N
4 CD N
min NNS N
and CC N
examined VBD N
using VBG N
a DT N
scanning VBG N
electron NN N
microscope NN N
. . N

Replicas NNPS N
were VBD N
gold-coated JJ N
for IN N
3 CD N
min NN N
. . N

Different JJ N
tooth/restoration NN N
interfaces NNS N
, , N
associated VBN N
with IN N
different JJ N
materials NNS N
, , N
were VBD N
observed VBN N
. . N

A DT N
marked JJ N
difference NN 1_o
between IN N
the DT N
replicas NN N
and CC N
tooth JJ N
sections NNS N
was VBD N
observed VBN N
for IN N
glass NN 1_i
ionomer-based JJ 1_i
restorations NNS 1_i
but CC N
not RB N
for IN N
resin-based JJ 1_i
bonding NN 1_i
systems NNS N
. . N

Representative JJ N
samples NNS N
of IN N
replicas NN N
and CC N
specimens NNS N
are VBP N
shown VBN N
, , N
and CC N
the DT N
significance NN N
of IN N
the DT N
observed JJ N
differences NNS N
is VBZ N
discussed VBN N
. . N

-DOCSTART- -X- O O

Playing VBG N
on IN N
the DT N
typewriter NN N
, , N
typing VBG N
on IN N
the DT N
piano NN N
: : N
manipulation NN N
knowledge NN N
of IN N
objects NNS N
. . N

Two CD N
experiments NNS N
investigated VBD N
sensory/motor-based JJ 1_o
functional JJ 1_o
knowledge NN 1_o
of IN 1_p
man-made JJ 1_p
objects NNS 1_p
: : 1_p
manipulation NN N
features NNS N
associated VBN N
with IN N
the DT N
actual JJ N
usage NN N
of IN N
objects NNS N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
a DT N
series NN N
of IN N
prime-target JJ N
pairs NNS N
was VBD N
presented VBN N
auditorily RB N
, , N
and CC N
participants NNS 1_p
were VBD N
asked VBN N
to TO N
make VB N
a DT N
lexical JJ 1_i
decision NN 1_i
on IN N
the DT N
target NN N
word NN N
. . N

Participants NNS 1_p
made VBD N
a DT N
significantly RB N
faster JJR N
decision NN 1_o
about IN N
the DT N
target NN 1_i
word NN 1_i
( ( N
e.g NN N
. . N

'typewriter CC N
' POS N
) ) N
following VBG N
a DT N
related JJ N
prime NN N
that WDT N
shared VBD N
manipulation NN N
features NNS N
with IN N
the DT N
target NN N
( ( N
e.g JJ N
. . N

'piano CC N
' POS N
) ) N
than IN N
an DT N
unrelated JJ N
prime NN N
( ( N
e.g NN N
. . N

'blanket CC N
' POS N
) ) N
. . N

In IN N
Experiment JJ N
2 CD N
, , N
participants NNS 1_p
' POS 1_p
eye NN N
movements NNS N
were VBD N
monitored VBN N
when WRB N
they PRP N
viewed VBD N
a DT N
visual JJ 1_i
display NN 1_i
on IN 1_i
a DT 1_i
computer NN 1_i
screen NN 1_i
while IN 1_i
listening VBG 1_i
to TO 1_i
a DT 1_i
concurrent JJ 1_i
auditory NN 1_i
input NN 1_i
. . 1_i

Participants NNS 1_p
were VBD N
instructed VBN N
to TO N
simply RB N
identify VB N
the DT N
auditory NN N
input NN N
and CC N
touch VB N
the DT N
corresponding JJ N
object NN N
on IN N
the DT N
computer NN N
display NN N
. . N

Participants NNS 1_p
fixated VBD 1_o
an DT N
object JJ N
picture NN N
( ( N
e.g JJ N
. . N

typewriter NN N
) ) N
related VBN N
to TO N
a DT N
target NN N
word NN N
( ( N
e.g NN N
. . N

'piano CC N
' POS N
) ) N
significantly RB N
more RBR N
often RB N
than IN N
an DT N
unrelated JJ N
object JJ N
picture NN N
( ( N
e.g JJ N
. . N

bucket NN N
) ) N
as RB N
well RB N
as IN N
a DT N
visually RB N
matched VBN N
control NN N
( ( N
e.g JJ N
. . N

couch NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
two CD N
experiments NNS N
suggest VBP N
that IN N
manipulation NN 1_o
knowledge NN 1_o
of IN 1_o
words NNS 1_o
is VBZ N
retrieved VBN N
without IN N
conscious JJ N
effort NN N
and CC N
that DT N
manipulation NN 1_o
knowledge NN 1_o
constitutes VBZ N
a DT N
part NN N
of IN N
the DT N
lexical-semantic JJ N
representation NN N
of IN N
objects NNS N
. . N

-DOCSTART- -X- O O

Inhibition NN N
of IN N
histamine-induced JJ 1_i
skin NN N
wheal NN N
and CC N
flare NN N
after IN N
5 CD N
days NNS N
of IN N
mizolastine NN 1_i
. . 1_i

Mizolastine NNP 1_i
is VBZ N
a DT N
new JJ N
, , N
nonsedating JJ N
antihistamine NN N
providing VBG N
satisfactory JJ N
symptomatic JJ N
relief NN 1_o
in IN 1_o
allergic JJ 1_o
rhinitis NN 1_o
and CC 1_o
urticaria NN 1_o
. . 1_o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
inhibition NN N
of IN N
wheal NN N
and CC N
flare NN N
formation NN N
after IN N
2-mu JJ N
g NN N
intradermal JJ N
histamine NN N
injections NNS N
as IN N
a DT N
measure NN N
of IN N
the DT N
antihistamine JJ N
effect NN N
of IN N
repeated JJ N
doses NNS N
of IN N
mizolastine NN N
. . N

Eight CD 1_p
volunteers NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN N
this DT N
four-arm JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
randomized VBN N
study NN N
. . N

Three CD N
dose JJ N
levels NNS N
of IN N
once-daily JJ 1_i
mizolastine NN 1_i
( ( N
5 CD N
mg NN N
, , N
10 CD N
mg NN N
, , N
and CC N
15 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
placebo NN 1_i
during IN N
5-day JJ N
dose JJ N
periods NNS N
. . N

Histamine NN 1_i
tests NNS 1_i
were VBD N
performed VBN N
before IN N
drug NN N
intake NN N
on IN N
days NNS N
1 CD N
and CC N
5 CD N
, , N
and CC N
then RB N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
, , N
10 CD N
, , N
12 CD N
, , N
14 CD N
, , N
and CC N
24 CD N
hours NNS N
after IN N
drug NN N
intake NN N
on IN N
day NN N
5 CD N
. . N

All DT N
3 CD N
doses NNS N
of IN N
mizolastine NN 1_i
were VBD N
more RBR 1_o
effective JJ 1_o
than IN N
placebo NN 1_i
in IN N
suppressing VBG N
wheal NN 1_o
and CC 1_o
flare NN 1_o
reactions NNS 1_o
, , N
and CC N
the DT N
antihistamine NN 1_o
activity NN 1_o
was VBD N
highest JJS N
at IN N
both DT N
the DT N
10- JJ N
and CC N
15-mg JJ N
dose NN N
levels NNS N
. . N

The DT N
effect NN 1_o
on IN 1_o
the DT 1_o
flare JJ 1_o
reaction NN 1_o
appeared VBD N
within IN N
1 CD N
hour NN N
, , N
reached VBD N
a DT N
maximum JJ N
effect NN N
4 CD N
hours NNS N
after IN N
administration NN N
, , N
and CC N
persisted VBD N
for IN N
as RB N
long RB N
as IN N
24 CD N
hours NNS N
. . N

The DT N
relative JJ N
changes NNS 1_o
in IN N
wheal NN N
and CC N
flare JJ N
areas NNS N
were VBD N
correlated VBN N
with IN N
mizolastine NN 1_i
trough IN N
plasma NN N
levels NNS N
on IN N
day NN N
5 CD N
. . N

Safety NN 1_o
was VBD N
satisfactory JJ N
in IN N
all DT N
groups NNS N
. . N

This DT N
study NN N
confirms VBZ N
that IN N
mizolastine NN 1_i
is VBZ N
a DT N
rapid JJ N
and CC N
potent JJ N
antihistamine NN 1_o
; : 1_o
and CC N
its PRP$ N
long-lasting JJ N
effectiveness NN N
indicates VBZ N
that IN N
a DT N
once-daily JJ N
regimen NN N
is VBZ N
acceptable JJ N
for IN N
clinical JJ N
use NN N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
study NN N
of IN N
clarithromycin NN 1_i
, , 1_i
roxithromycin NN 1_i
and CC 1_i
erythromycin JJ 1_i
stearate NN 1_i
in IN N
mild JJ 1_p
pneumonia NN 1_p
. . 1_p

The DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
clarithromycin NN 1_i
, , 1_i
roxithromycin NN 1_i
and CC 1_i
erythromycin JJ 1_i
stearate NN 1_i
in IN N
mild JJ N
pneumonia NN N
were VBD N
compared VBN N
in IN N
an DT N
open JJ N
randomized VBN N
trial NN N
. . N

Eighty-six JJ 1_p
male JJ 1_p
patients NNS 1_p
, , 1_p
doing VBG 1_p
their PRP$ 1_p
obligatory JJ 1_p
military JJ 1_p
service NN 1_p
, , 1_p
ranging VBG 1_p
between IN 1_p
19 CD 1_p
and CC 1_p
24 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
( ( 1_p
mean JJ 1_p
20 CD 1_p
) ) 1_p
, , N
were VBD N
randomly RB N
treated VBN N
: : N
29 CD N
with IN N
clarithromycin NN 1_i
500 CD 1_i
mg NN 1_i
12-hourly RB 1_i
, , 1_i
30 CD 1_i
with IN 1_i
roxithromycin NN 1_i
150 CD 1_i
mg NN 1_i
12-hourly JJ 1_i
, , 1_i
and CC 1_i
27 CD 1_i
with IN 1_i
erythromycin JJ 1_i
stearate NN 1_i
500 CD N
mg NN N
6-hourly RB N
, , N
each DT N
course NN N
being VBG N
administered VBN N
for IN N
10 CD N
days NNS N
. . N

Seventy-eight JJ 1_p
patients NNS 1_p
were VBD 1_p
able JJ 1_p
to TO 1_p
be VB 1_p
evaluated VBN 1_p
for IN 1_p
efficacy NN 1_o
, , N
28 CD N
receiving VBG N
clarithromycin NN 1_i
, , N
28 CD N
roxithromycin NN 1_i
, , N
and CC N
22 CD N
erythromycin JJ 1_i
stearate NN 1_i
. . 1_i

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
the DT N
groups NNS N
in IN N
terms NNS 1_o
of IN 1_o
clinical JJ 1_o
success NN 1_o
rates NNS 1_o
( ( N
clinical JJ N
cure NN N
or CC N
improvement NN N
: : N
89 CD N
% NN N
for IN N
clarithromycin NN 1_i
, , N
82 CD N
% NN N
for IN N
roxithromycin NN 1_i
, , N
and CC N
73 CD N
% NN N
for IN N
erythromycin JJ 1_i
stearate NN 1_i
, , N
p NN N
= NNP N
0.32 CD N
) ) N
. . N

However RB N
, , N
we PRP N
found VBD N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
among IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
clinical JJ 1_o
cure NN 1_o
rates NNS 1_o
( ( N
75 CD N
% NN N
for IN N
clarithromycin NN 1_i
, , N
64 CD N
% NN N
for IN N
roxithromycin NN 1_i
, , N
and CC N
41 CD N
% NN N
for IN N
erythromycin JJ 1_i
stearate NN 1_i
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Adverse JJ 1_o
events NNS 1_o
, , 1_o
mostly RB 1_o
gastrointestinal JJ 1_o
, , N
caused JJ N
discontinuation NN N
of IN N
treatment NN N
in IN N
3.4 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
clarithromycin NN 1_i
group NN N
, , N
in IN N
6.6 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
roxithromycin NN 1_i
group NN N
, , N
and CC N
in IN N
18.5 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
erythromycin JJ 1_i
stearate NN 1_i
group NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
among IN N
the DT N
three CD N
treatment NN N
groups NNS N
in IN N
terms NNS N
of IN N
clinical JJ N
success NN N
rates NNS N
, , N
but CC N
that IN N
clarithromycin NN 1_i
and CC N
roxithromycin NN 1_i
were VBD N
better RB N
tolerated VBN 1_o
. . 1_o

-DOCSTART- -X- O O

Ten-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
prognosis NN N
after IN N
infarction NN N
. . N

Department NNP N
of IN N
Veterans NNP N
Affairs NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

BACKGROUND NNP N
The DT N
10-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
( ( N
fatal JJ N
and CC N
nonfatal JJ N
) ) N
and CC N
the DT N
prognosis NN N
after IN N
infarction NN N
were VBD N
evaluated VBN N
in IN N
686 CD 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
angina NNS 1_p
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
medical JJ 1_i
or CC 1_i
surgical JJ 1_i
treatment NN 1_i
in IN N
the DT N
Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Myocardial NNP N
infarction NN N
was VBD N
defined VBN N
by IN N
either DT N
new JJ N
Q NNP N
wave VBP N
findings NNS N
or CC N
clinical JJ N
symptoms NNS N
compatible JJ N
with IN N
myocardial JJ 1_p
infarction NN 1_p
accompanied VBN 1_p
by IN 1_p
serum NN 1_p
enzyme NN 1_p
elevations NNS 1_p
with IN 1_p
or CC 1_p
without IN 1_p
electrocardiographic JJ 1_p
findings NNS N
. . N

Treatment JJ N
comparisons NNS N
were VBD N
made VBN N
according VBG N
to TO N
original JJ N
treatment NN N
assignment NN N
; : N
35 CD N
% NN N
of IN N
the DT N
medical JJ N
cohort NN N
had VBD N
bypass NN 1_i
surgery NN 1_i
during IN N
the DT N
10-year JJ N
follow-up JJ N
period NN N
. . N

The DT N
overall JJ 1_o
cumulative JJ 1_o
infarction NN 1_o
rate NN 1_o
was VBD N
somewhat RB N
higher JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
surgery VB 1_i
( ( N
36 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
31 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
due JJ N
to TO N
perioperative JJ N
infarctions NNS N
( ( N
13 CD N
% NN N
) ) N
and CC N
an DT N
accelerated JJ 1_o
infarction NN 1_o
rate NN 1_o
after IN N
the DT N
fifth JJ N
year NN N
of IN N
follow-up NN N
( ( N
average JJ N
, , N
2.4 CD N
% NN N
/yr NN N
in IN N
the DT N
surgical JJ N
group NN N
versus VBD N
1.4 CD N
% NN N
/yr NN N
in IN N
the DT N
medical JJ N
group NN N
) ) N
. . N

The DT N
10-year JJ 1_o
cumulative JJ 1_o
incidence NN 1_o
of IN 1_o
death NN 1_o
or CC 1_o
myocardial JJ 1_o
infarction NN 1_o
was VBD N
also RB N
higher JJR N
in IN N
surgical JJ N
( ( N
54 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
( ( N
p JJ N
= NNP N
0.20 CD N
) ) N
. . N

According VBG N
to TO N
the DT N
Cox NNP N
model NN N
, , N
the DT N
estimated VBN 1_o
risk NN 1_o
of IN 1_o
death NN 1_o
after IN 1_o
infarction NN 1_o
was VBD N
59 CD N
% NN N
lower JJR N
in IN N
surgical JJ N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
reduction NN 1_o
in IN N
postinfarction NN 1_o
mortality NN 1_o
with IN N
surgery NN N
was VBD N
most RBS N
striking JJ N
in IN N
the DT N
first JJ N
month NN N
after IN N
the DT N
event NN N
: : N
99 CD N
% NN N
in IN N
the DT N
first JJ N
month NN N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
and CC N
49 CD N
% NN N
subsequently RB N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
estimated VBN N
risk NN 1_o
of IN 1_o
death NN 1_o
in IN 1_o
the DT 1_o
absence NN 1_o
of IN 1_o
infarction NN 1_o
was VBD N
nearly RB N
identical JJ N
regardless NN N
of IN N
treatment NN N
( ( N
p JJ N
= NNP N
0.75 CD N
) ) N
. . N

Exclusion NN N
of IN N
perioperative JJ N
infarctions NNS N
did VBD N
not RB N
alter VB N
the DT N
findings NNS N
. . N

CONCLUSIONS NNP N
Although IN N
surgery NN N
does VBZ N
not RB N
reduce VB N
the DT N
incidence NN N
of IN N
myocardial JJ 1_o
infarction NN 1_o
overall RB N
, , N
it PRP N
does VBZ N
reduce VB N
the DT N
risk NN N
of IN N
mortality NN 1_o
after IN N
infarction NN N
, , N
particularly RB N
in IN N
the DT N
first JJ N
30 CD N
days NNS N
after IN N
the DT N
event NN N
( ( N
fatal JJ N
infarctions NNS N
) ) N
. . N

-DOCSTART- -X- O O

Once-daily RB N
MMX NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
mesalamine NN 1_i
for IN N
endoscopic JJ N
maintenance NN N
of IN N
remission NN N
of IN 1_p
ulcerative JJ 1_p
colitis NN 1_p
. . 1_p

OBJECTIVES NNP N
Treatment NNP N
with IN 1_i
mesalamine NN 1_i
to TO N
maintain VB N
endoscopic JJ N
remission NN N
( ( N
mucosal JJ N
healing VBG N
) ) N
of IN N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
relapse NN N
and CC N
is VBZ N
the DT N
recommended JJ N
first-line JJ N
maintenance NN N
therapy NN N
. . N

To TO N
improve VB N
treatment NN N
adherence NN N
, , N
a DT N
mesalamine NN N
formulation NN N
that WDT N
can MD N
be VB N
administered VBN N
once-daily RB N
, , N
MMX NNP 1_i
( ( 1_i
? . 1_i
) ) 1_i
mesalamine NN 1_i
( ( 1_i
Lialda NNP 1_i
; : 1_i
Shire NNP 1_i
Pharmaceuticals NNP 1_i
LLC NNP 1_i
, , 1_i
Wayne NNP 1_i
, , 1_i
PA NNP 1_i
) ) 1_i
, , 1_i
was VBD N
developed VBN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ 1_i
MMX NNP 1_i
mesalamine NN 1_i
compared VBN 1_i
with IN N
twice-daily JJ 1_i
delayed-release JJ 1_i
mesalamine NN 1_i
( ( 1_i
Asacol NNP 1_i
; : 1_i
Warner NNP 1_i
Chilcott NNP 1_i
, , 1_i
Dublin NNP 1_i
, , 1_i
Ireland NNP 1_i
) ) 1_i
for IN 1_i
maintaining VBG N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ 1_i
MMX NNP 1_i
mesalamine NN 1_i
2.4 CD 1_i
g/day NN N
compared VBN N
with IN 1_i
twice-daily JJ 1_i
delayed-release JJ 1_i
mesalamine NN 1_i
at IN 1_i
a DT 1_i
total JJ 1_i
daily JJ 1_i
dose NN 1_i
of IN 1_i
1.6 CD 1_i
g/day NN 1_i
in IN 1_i
patients NNS N
with IN N
UC NNP N
in IN N
endoscopic JJ N
remission NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD 1_o
maintenance NN 1_o
of IN 1_o
endoscopic JJ 1_o
remission NN 1_o
at IN 1_o
month NN 1_o
6 CD 1_o
in IN 1_o
the DT 1_o
per-protocol NN 1_o
( ( 1_o
PP NNP 1_o
) ) 1_o
population NN 1_o
. . 1_o

RESULTS NNP N
Overall NNP 1_p
, , 1_p
826 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
and CC 1_p
dosed VBN 1_p
. . 1_p

The DT N
primary JJ N
objective JJ N
( ( N
non-inferiority NN N
) ) N
was VBD N
met VBN N
. . N

At IN N
month NN N
6 CD N
, , N
83.7 CD N
and CC N
77.8 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
in IN N
the DT N
PP NNP N
and CC N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
populations NNS N
, , N
respectively RB N
, , N
had VBD N
maintained VBN 1_o
endoscopic JJ 1_o
remission NN 1_o
compared VBN 1_o
with IN N
81.5 CD N
% NN N
( ( N
PP NNP N
) ) N
and CC N
76.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
of IN N
patients NNS N
receiving VBG N
delayed-release JJ N
mesalamine NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
difference NN N
: : N
-3.9 CD N
% NN N
, , N
8.1 CD N
% NN N
( ( N
PP NNP N
) ) N
; : N
-5.0 CD N
% NN N
, , N
6.9 CD N
% NN N
( ( N
ITT NNP 1_o
) ) 1_o
) ) 1_o
. . 1_o

Time NN 1_o
to TO 1_o
relapse VB 1_o
was VBD 1_o
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
( ( N
log-rank JJ N
test NN N
, , N
P=0.5116 NNP N
( ( N
PP NNP N
) ) N
; : N
P=0.5455 NNP N
( ( N
ITT NNP N
) ) N
) ) N
. . N

The DT 1_o
proportion NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
adverse JJ 1_o
events NNS 1_o
was VBD 1_o
37.1 CD N
and CC N
36.0 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
and CC N
delayed-release JJ N
mesalamine NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Once-daily JJ N
dosing NN N
of IN N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
was VBD N
shown VBN N
to TO N
be VB N
well RB N
tolerated VBN N
and CC N
non-inferior JJ N
to TO N
twice-daily JJ N
dosing VBG N
with IN N
delayed-release JJ N
mesalamine NN N
1.6 CD N
g/day NN N
for IN N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

-DOCSTART- -X- O O

1H CD N
Magnetic JJ N
Resonance NNP N
Spectroscopy NNP N
Predicts NNP N
Hepatocellular NNP N
Carcinoma NNP N
in IN N
a DT N
Subset NNP N
of IN N
Patients NNPS 1_p
With IN 1_p
Liver NNP 1_p
Cirrhosis NNP 1_p
: : 1_p
A DT N
Randomized NNP N
Trial NNP N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
utility NN N
of IN N
H NNP 1_i
magnetic JJ 1_i
resonance NN 1_i
spectroscopy NN 1_i
( ( 1_i
H-MRS NNP 1_i
) ) 1_i
to TO N
quantify VB N
the DT N
differences NNS N
in IN N
liver NN N
metabolites NNS N
. . N

Magnetic JJ N
resonance NN N
spectroscopy NN N
was VBD N
used VBN N
as IN N
a DT N
means NN N
of IN N
predicting VBG N
the DT N
probability NN N
of IN N
developing VBG N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
liver JJ 1_p
cirrhosis NN 1_p
secondary JJ 1_p
to TO 1_p
chronic VB 1_p
hepatitis NN 1_p
B.This NNP 1_p
study NN 1_p
included VBD 1_p
20 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
, , 1_p
20 CD 1_p
patients NNS 1_p
with IN 1_p
liver JJ 1_p
cirrhosis NN 1_p
secondary JJ 1_p
to TO 1_p
chronic VB 1_p
hepatitis NN 1_p
B NNP 1_p
( ( 1_p
cirrhosis NN 1_p
group NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
20 CD 1_p
patients NNS 1_p
with IN 1_p
small JJ 1_p
HCC NNP 1_p
secondary JJ 1_p
to TO 1_p
cirrhosis VB 1_p
liver RB 1_p
parenchyma NN 1_p
( ( 1_p
HCC NNP 1_p
group NN 1_p
) ) 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
underwent JJ 1_p
routine JJ 1_i
MRI NNP 1_i
and CC 1_i
H-MRS NNP 1_i
scanning NN 1_i
. . 1_i

LCModel NNP N
software NN N
was VBD N
used VBN N
to TO N
quantify VB 1_o
Cho NNP 1_o
( ( 1_o
Choline NNP 1_o
) ) 1_o
, , 1_o
Lip NNP 1_o
( ( 1_o
lipid JJ 1_o
) ) 1_o
, , 1_o
and CC 1_o
Cho/Lip NNP 1_o
in IN N
the DT N
3 CD N
groups NNS N
, , N
and CC N
a DT N
one-way JJ N
ANOVA NNP 1_o
was VBD N
used VBN N
to TO N
compare VB N
the DT N
differences NNS N
in IN N
these DT N
metabolites NNS N
between IN N
groups.Choline NN N
levels NNS N
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
control NN N
and CC N
HCC NNP N
group NN N
and CC N
between IN N
the DT N
cirrhosis NN N
group NN N
and CC N
the DT N
HCC NNP N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
significant JJ 1_o
difference NN 1_o
in IN 1_o
Lip NNP 1_o
levels NNS 1_o
between IN 1_o
the DT N
control NN N
and CC N
cirrhosis NN N
group NN N
and CC N
the DT N
control NN N
and CC N
HCC NNP N
groups NNS N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
also RB N
differences NNS 1_o
in IN 1_o
Cho/Lip NNP 1_o
between IN N
the DT N
control NN N
and CC N
cirrhosis NN N
groups NNS N
, , N
the DT N
control NN N
and CC N
HCC NNP N
groups NNS N
, , N
and CC N
the DT N
cirrhosis NN N
and CC N
HCC NNP N
groups NNS N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
.H-MRS NN N
followed VBN N
by IN N
the DT N
analysis NN N
with IN N
LCModel NNP N
can MD N
be VB N
used VBN N
to TO N
measure VB N
changes NNS 1_o
in IN 1_o
hepatic JJ 1_o
metabolite NN 1_o
levels NNS 1_o
in IN 1_o
patients NNS 1_o
with IN N
liver JJ N
cirrhosis NN N
secondary JJ N
to TO N
chronic VB N
hepatitis NN N
B NNP N
and CC N
HCC NNP N
. . N

Thus NNP N
, , N
H-MRS NNP N
may MD N
be VB N
helpful JJ N
in IN N
monitoring VBG N
HCC NNP N
and CC N
liver RB N
cirrhosis NN N
development NN N
. . N

-DOCSTART- -X- O O

Hyperinsulinemia NNP N
fails VBZ N
to TO N
augment VB N
ET-1 JJ N
action NN N
in IN N
the DT N
skeletal JJ N
muscle NN N
vascular JJ N
bed NN N
in IN N
vivo NN 1_p
in IN 1_p
humans NNS 1_p
. . 1_p

Endogenous JJ N
endothelin JJ N
action NN N
is VBZ N
augmented VBN N
in IN N
human JJ N
obesity NN N
and CC N
type NN N
2 CD N
diabetes NNS N
and CC N
contributes NNS N
to TO N
endothelial JJ N
dysfunction NN N
and CC N
impairs VB N
insulin-mediated JJ N
vasodilation NN N
in IN N
humans NNS 1_p
. . 1_p

We PRP N
hypothesized VBD N
that IN N
insulin JJ N
resistance-associated JJ N
hyperinsulinemia NN N
could MD N
preferentially RB N
drive VB N
endothelin-mediated JJ 1_o
vasoconstriction NN 1_o
. . 1_o

We PRP N
applied VBD N
hyperinsulinemic-euglycemic JJ 1_i
clamps NNS 1_i
with IN N
higher JJR 1_p
insulin NN 1_i
dosing VBG 1_p
in IN 1_p
obese JJ 1_p
subjects NNS 1_p
than IN 1_p
lean JJ 1_p
subjects NNS 1_p
( ( 1_p
30 CD 1_p
vs. FW 1_p
10 CD 1_p
mU.m NN 1_p
( ( 1_p
-2 NNP 1_p
) ) 1_p
.min NNP 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
, , 1_p
respectively RB 1_p
) ) 1_p
, , N
with IN N
the DT N
goal NN N
of IN N
matching VBG N
insulin NN N
's POS N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
-mediated VBD N
vascular JJ N
effects NNS N
. . N

We PRP N
predicted VBD N
that IN N
, , N
under IN N
these DT N
circumstances NNS N
, , N
insulin-stimulated JJ N
endothelin-1 JJ N
( ( N
ET-1 NNP N
) ) N
action NN N
( ( N
assessed VBN N
with IN N
the DT N
type NN N
A NNP N
endothelin NN N
receptor NN N
antagonist IN N
BQ-123 NNP N
) ) N
would MD N
be VB N
augmented VBN N
in IN N
proportion NN N
to TO N
hyperinsulinemia VB N
. . N

NO DT 1_o
bioactivity NN 1_o
was VBD N
assessed VBN N
using VBG N
the DT N
nitric JJ N
oxide JJ N
synthase NN N
inhibitor NN N
N NNP N
( ( N
G NNP N
) ) N
-monomethyl-l-arginine NN N
. . N

Insulin-mediated JJ 1_o
vasodilation NN 1_o
and CC 1_o
insulin-stimulated JJ 1_o
NO NNP 1_o
bioavailability NN 1_o
were VBD N
well RB N
matched VBN N
across IN N
groups NNS N
by IN N
this DT N
approach NN N
. . N

As IN N
expected VBN N
, , N
steady-state JJ 1_o
insulin NN 1_o
levels NNS 1_o
were VBD N
approximately RB N
threefold JJ N
higher JJR N
in IN N
obese JJ N
than IN N
lean JJ N
subjects NNS N
( ( N
109.2 CD N
+/- JJ N
10.2 CD N
pmol/l NN N
vs. FW N
518.4 CD N
+/- JJ N
84.0 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Despite IN N
this DT N
, , N
the DT N
augmentation NN N
of IN N
insulin-mediated JJ 1_o
vasodilation NN 1_o
by IN N
BQ-123 NNP N
was VBD N
not RB N
different JJ N
between IN N
groups NNS N
. . N

ET-1 JJ 1_o
flux NN 1_o
across IN N
the DT N
leg NN N
was VBD N
not RB N
augmented VBN N
by IN N
insulin NN N
alone RB N
but CC N
was VBD N
increased VBN N
with IN N
the DT N
addition NN N
of IN N
BQ-123 NNP N
to TO N
insulin VB N
( ( N
P NNP N
= VBZ N
0.01 CD N
BQ-123 JJ N
effect NN N
, , N
P NNP N
= NNP N
not RB N
significant JJ N
comparing VBG N
groups NNS N
) ) N
. . N

Endothelin NNP N
antagonism NN N
augmented VBD N
insulin-stimulated JJ 1_o
NO NNP 1_o
bioavailability NN 1_o
and CC 1_o
NOx NNP 1_o
flux NN 1_o
, , N
but CC N
not RB N
differently RB N
between IN N
groups NNS N
and CC N
not RB N
proportional JJ N
to TO N
hyperinsulinemia VB N
. . N

These DT N
findings NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
insulin VBZ N
resistance-associated JJ N
hyperinsulinemia NN N
preferentially RB N
drives VBZ N
endothelin-mediated JJ 1_o
vasoconstriction NN 1_o
. . 1_o

-DOCSTART- -X- O O

[ JJ 1_i
Propofol NNP 1_i
infusion NN N
for IN N
the DT N
maintenance NN N
of IN N
short-term JJ 1_p
anesthesia NN 1_o
] NN 1_o
. . N

The DT N
administration NN N
of IN N
propofol NN 1_i
by IN N
infusion NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
has VBZ N
attracted VBN N
much JJ N
attention NN N
recently RB N
. . N

We PRP N
investigated VBD N
the DT N
necessary JJ N
infusion NN N
rate NN N
of IN N
propofol NN 1_i
to TO N
maintain VB N
anesthesia NN N
for IN N
short JJ N
surgical JJ N
procedures NNS N
without IN N
loss NN N
of IN N
the DT N
evident JJ N
advantages NNS N
of IN N
this DT N
substance NN N
. . N

Forty NNP 1_p
unpremedicated JJ 1_p
female NN 1_p
patients NNS 1_p
aged VBN 1_p
18-59 JJ 1_p
, , 1_p
scheduled VBN 1_p
for IN 1_p
minor JJ 1_p
gynecological JJ 1_p
procedures NNS 1_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
. . N

Anesthesia NNP N
was VBD N
induced VBN N
with IN N
2.0 CD 1_i
mg/kg NNS 1_i
propofol JJ 1_i
i.v NN 1_i
. . 1_i

and CC N
simultaneously RB N
an DT N
infusion NN N
of IN N
0.05 CD N
, , N
0.10 CD N
, , N
0.15 CD N
, , N
or CC N
0.20 CD N
mg NNS N
propofol/kg JJ 1_i
per IN N
minute NN N
was VBD N
started VBN N
. . N

The DT N
patients NNS 1_p
were VBD N
breathing VBG N
N2O/O2 NNP 1_i
with IN 1_i
FIO2 NNP 1_i
33 CD N
% NN N
. . N

Additional NNP N
propofol NN 1_i
was VBD N
administered VBN N
as IN N
a DT N
bolus NN N
of IN N
10 CD N
to TO N
20 CD N
mg NN N
when WRB N
the DT N
patients NNS N
moved VBD N
. . N

With IN N
0.05 CD N
mg NNS N
propofol/kg JJ 1_i
per IN N
minute NN N
all DT N
patients NNS N
required VBN N
additional JJ N
bolus NN N
injections NNS N
of IN N
propofol NN 1_i
; : 1_i
with IN N
0.10 CD N
mg NNS N
8 CD N
patients NNS N
, , N
with IN N
0.15 CD N
mg NNS N
5 CD N
patients NNS N
, , N
and CC N
with IN N
0.20 CD N
mg NNS N
1 CD N
patient NN N
required VBN N
bolus JJ N
injection NN N
. . N

Therefore NNP N
, , N
0.15 CD N
mg/kg NN N
per IN N
minute NN N
can MD N
be VB N
considered VBN N
as IN N
an DT N
approximate JJ N
ED50 NNP N
value NN N
. . N

The DT N
total JJ 1_o
propofol NN 1_o
consumption NN 1_o
( ( N
infusion NN N
+ NNP N
bolus NN N
) ) N
increased VBD N
from IN N
0.102 CD N
+/- JJ N
0.028 CD N
( ( N
+/- JJ N
SD NNP N
) ) N
with IN N
the DT N
lowest JJS N
infusion NN 1_o
rate NN 1_o
to TO N
0.202 CD N
+/- JJ N
0.006 CD N
mg/kg NNS N
per IN N
minute NN N
with IN N
the DT N
highest JJS N
infusion NN 1_o
rate NN 1_o
and CC 1_o
recovery NN 1_o
time NN 1_o
from IN N
5.2 CD N
+/- JJ N
1.4 CD N
to TO N
9.9 CD N
+/- JJ N
2.6 CD N
min NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
propofol JJ 1_o
consumption NN 1_o
and CC 1_o
recovery NN 1_o
time NN 1_o
. . 1_o

After IN N
induction NN N
, , N
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
decreased VBN N
by IN N
systolic/diastolic JJ N
20/10-15 JJ N
mmHg NN N
. . N

With IN N
the DT N
low JJ N
infusion NN N
rate NN N
, , N
arterial JJ 1_o
pressure NN 1_o
increased VBD N
to TO N
its PRP$ N
control NN N
value NN N
during IN N
operation NN N
; : N
it PRP N
remained VBD N
at IN N
the DT N
postinduction NN N
value NN N
with IN N
high JJ N
infusion NN N
rates NNS N
. . N

Side-effects NNS N
: : N
10 CD N
patients NNS N
had VBD N
salivation NN N
that IN N
in IN N
some DT N
instances NNS N
lead VBP N
to TO N
coughing VBG N
, , N
9 CD N
reported VBD N
pain NN N
at IN N
the DT N
injection NN N
site NN N
during IN N
induction NN N
, , N
and CC N
9 CD N
reported VBD N
dreams NNS N
of IN N
a DT N
pleasant JJ N
nature NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Erythrocyte NNP 1_o
deformability NN 1_o
, , 1_o
endothelin NN 1_o
levels NNS 1_o
, , 1_o
and CC 1_o
renal JJ 1_o
function NN 1_o
in IN N
cyclosporin-treated JJ 1_i
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
: : 1_p
effects NNS N
of IN N
intervention NN N
with IN N
fish JJ 1_i
oil NN 1_i
and CC N
corn NN 1_i
oil NN 1_i
. . 1_i

Twenty NNP 1_p
nine CD 1_p
stable JJ 1_p
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
, , 1_p
10 CD 1_p
receiving VBG 1_p
cyclosporin NN 1_i
, , 1_i
10 CD 1_i
cyclosporin-prednisolone NN 1_i
and CC 1_i
nine CD 1_i
azathioprine-prednisolone NN 1_i
were VBD N
supplemented VBN N
in IN N
a DT N
double JJ N
blind JJ N
randomization NN N
cross-over NN N
study NN N
with IN N
fish JJ 1_i
oil NN 1_i
and CC N
corn NN 1_i
oil NN 1_i
for IN N
a DT N
period NN N
of IN N
4 CD N
months NNS N
each DT N
. . N

Erythrocyte NNP 1_o
deformability NN 1_o
was VBD N
reduced VBN N
in IN N
the DT N
cyclosporin-treated JJ 1_i
patients NNS N
and CC N
returned VBN N
to TO N
normal JJ N
values NNS N
after IN N
supplementation NN N
of IN N
either DT N
oil NN 1_i
. . 1_i

The DT N
oil NN N
supplementation NN N
resulted VBD N
in IN N
an DT N
increased VBN N
polyunsaturated JJ 1_o
fatty JJ 1_o
acid NN 1_o
content NN 1_o
in IN N
the DT N
plasma NN N
phospholipids NNS N
. . N

An DT N
increased JJ N
erythrocyte NN N
membrane NN N
polyunsaturated VBD N
fatty JJ N
acid JJ N
content NN N
might MD N
correct VB N
the DT N
lower JJR N
erythrocyte NN N
deformability NN N
in IN N
cyclosporin NN 1_i
treated VBD N
patients NNS N
. . N

Therefore RB N
, , N
it PRP N
is VBZ N
probable JJ N
that IN N
these DT N
changes NNS N
are VBP N
membrane-related JJ N
. . N

The DT N
oil NN 1_i
supplementation NN N
had VBD N
no DT N
effect NN N
on IN N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
, , 1_o
effective JJ 1_o
renal JJ 1_o
plasma NN 1_o
flow NN 1_o
, , 1_o
filtration NN 1_o
fraction NN 1_o
or CC 1_o
blood NN 1_o
pressure NN 1_o
, , N
which WDT N
does VBZ N
not RB N
exclude VB N
effects NNS N
of IN N
the DT N
cyclosporin-induced JJ N
rigidified JJ N
erythrocytes NNS N
in IN N
the DT N
acute JJ N
phase NN N
of IN N
renal JJ N
transplantation NN N
. . N

Decreased VBN N
erythrocyte JJ 1_o
deformability NN 1_o
could MD N
play VB N
a DT N
role NN N
in IN N
the DT N
cyclosporin-induced JJ 1_i
deterioration NN N
of IN N
renal JJ N
haemodynamics NNS N
. . N

This DT N
may MD N
enhance VB N
the DT N
effects NNS N
of IN N
endothelin NN N
, , N
as IN N
these DT N
patients NNS N
also RB N
had VBD N
elevated VBN N
endothelin NN N
levels NNS N
. . N

-DOCSTART- -X- O O

Fentanyl NNP 1_i
supplementation NN N
to TO N
inhalation NN 1_p
anaesthesia NN 1_p
. . 1_p

In IN N
eight CD 1_p
out IN 1_p
of IN 1_p
15 CD 1_p
healthy JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
body NN 1_p
surface NN 1_p
surgery NN 1_p
, , N
the DT N
effect NN N
of IN N
a DT N
fentanyl JJ 1_i
infusion NN 1_i
on IN N
a DT N
conventional JJ N
thiopentone NN 1_i
, , 1_i
nitrous JJ 1_i
oxide NN 1_i
, , 1_i
oxygen NN 1_i
and CC N
halothane NN 1_i
anaesthetic NN 1_i
was VBD N
studied VBN N
. . N

The DT N
fentanyl JJ 1_i
infusion NN 1_i
( ( N
2 CD N
micrograms/kg/hour NN N
) ) N
reduced VBD N
the DT N
induction NN 1_o
dose NN 1_o
of IN 1_o
thiopentone NN 1_o
and CC N
caused VBD N
marked JJ 1_o
respiratory JJ 1_o
depression NN 1_o
with IN N
a DT N
reduction NN N
in IN N
the DT N
patients NNS N
' POS N
response NN N
to TO N
surgery NN N
. . N

The DT N
mean JJ 1_o
arterial JJ 1_o
pressures NNS 1_o
and CC 1_o
pulse JJ 1_o
rates NNS 1_o
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
each DT N
group NN N
throughout IN N
the DT N
course NN N
of IN N
the DT N
operation NN N
. . N

The DT N
fentanyl NN 1_i
made VBD N
no DT N
difference NN N
to TO N
the DT N
patients NNS N
' POS N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
to TO N
their PRP$ N
recovery NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
. . N

-DOCSTART- -X- O O

Pre-treatment JJ N
proliferation NN N
and CC N
the DT N
outcome NN N
of IN N
conventional JJ 1_i
and CC 1_i
accelerated JJ 1_i
radiotherapy NN 1_i
. . 1_i

This DT N
study NN N
investigated VBD N
the DT N
influence NN N
of IN N
pre-treatment JJ N
proliferation NN N
characteristics NNS N
, , N
assessed VBN 1_i
by IN 1_i
Ki-67 NNP 1_i
staining NN 1_i
, , N
in IN N
patients NNS 1_p
treated VBN 1_p
in IN 1_p
the DT 1_p
CHART NNP 1_p
trial NN 1_p
of IN 1_p
accelerated JJ 1_i
radiotherapy NN 1_i
in IN 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
. . 1_p

Histological JJ N
material NN N
from IN N
402 CD 1_p
patients NNS 1_p
was VBD N
collected VBN N
and CC N
stained VBN N
for IN N
the DT N
presence NN N
and CC N
pattern NN N
of IN N
Ki-67 NNP N
staining NN N
. . N

Locoregional NNP 1_o
control NN 1_o
and CC N
overall JJ N
survival NN N
were VBD N
the DT N
main JJ N
clinical JJ N
endpoints NNS N
. . N

Increasing VBG N
Ki-67 NNP N
positivity NN N
was VBD N
associated VBN N
with IN N
decreasing VBG N
differentiation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
increasing VBG N
N-stage NN N
( ( N
P NNP N
< NNP N
0.004 CD N
) ) N
. . N

Increasing VBG N
N-stage NN N
was VBD N
also RB N
associated VBN N
with IN N
the DT N
progression NN N
of IN N
proliferation NN N
pattern NN N
from IN N
marginal JJ N
to TO N
random VB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Using VBG N
a DT N
multivariate NN N
model NN N
, , N
a DT N
trend NN N
was VBD N
seen VBN N
towards NNS N
a DT N
greater JJR N
benefit NN N
from IN N
CHART NNP N
in IN N
the DT N
lower JJR N
Ki-67 NNP N
tumours NNS N
( ( N
P NNP N
= NNP N
0.08 CD N
) ) N
; : N
this DT N
became VBD N
significant JJ N
by IN N
pooling VBG N
the DT N
low JJ N
and CC N
intermediate JJ N
Ki-67 NNP N
groups NNS N
in IN N
comparison NN N
with IN N
the DT N
high JJ N
Ki-67 NNP N
group NN N
( ( N
P NNP N
= NNP N
0.032 CD N
) ) N
. . N

Tumours $ N
with IN N
marginal JJ N
proliferation NN N
pattern NN N
showed VBD N
a DT N
lower JJR N
hazard NN N
ratio NN N
with IN N
CHART NNP N
versus VBP N
conventional JJ N
for IN N
locoregional JJ N
control NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

The DT N
data NN N
presented VBN N
in IN N
this DT N
study NN N
do VBP N
not RB N
support VB N
that IN N
a DT N
high JJ N
pre-treatment JJ N
Ki-67 NNP N
is VBZ N
associated VBN N
with IN N
a DT N
therapeutic JJ 1_o
benefit NN 1_o
from IN N
accelerated VBN 1_i
radiotherapy NN 1_i
. . 1_i

-DOCSTART- -X- O O

Detection NN 1_p
and CC 1_p
quantification NN 1_p
of IN 1_p
the DT 1_p
solid JJ 1_p
component NN 1_p
in IN 1_p
pulmonary JJ 1_p
subsolid JJ 1_p
nodules NNS 1_p
by IN 1_p
semiautomatic JJ 1_i
segmentation NN 1_i
. . 1_i

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
semiautomatic JJ 1_i
volumetric NNS 1_i
software NN 1_i
can MD N
differentiate VB N
part-solid JJ N
from IN N
nonsolid JJ N
pulmonary JJ N
nodules NNS N
and CC N
aid JJ N
quantification NN N
of IN N
the DT N
solid JJ N
component NN N
. . N

METHODS NNP N
As IN N
per IN N
reference NN N
standard NN N
, , N
115 CD 1_p
nodules NNS 1_p
were VBD N
differentiated VBN N
into IN N
nonsolid JJ N
and CC N
part-solid JJ N
by IN N
two CD N
radiologists NNS N
; : N
disagreements NNS N
were VBD N
adjudicated VBN N
by IN N
a DT N
third JJ N
radiologist NN N
. . N

The DT N
diameters NNS N
of IN N
solid JJ N
components NNS N
were VBD N
measured VBN N
manually RB N
. . N

Semiautomatic JJ N
volumetric JJ N
measurements NNS N
were VBD N
used VBN N
to TO N
identify VB N
and CC N
quantify VB N
a DT N
possible JJ N
solid JJ N
component NN N
, , N
using VBG N
different JJ N
Hounsfield NNP N
unit NN N
( ( N
HU NNP N
) ) N
thresholds NNS N
. . N

The DT N
measurements NNS N
were VBD N
compared VBN N
with IN N
the DT N
reference NN N
standard NN N
and CC N
manual JJ N
measurements NNS N
. . N

RESULTS VB N
The DT N
reference NN N
standard NN N
detected VBD N
a DT N
solid JJ N
component NN N
in IN N
86 CD N
nodules NNS N
. . N

Diagnosis NN N
of IN N
a DT N
solid JJ N
component NN N
by IN N
semiautomatic JJ N
software NN N
depended VBN N
on IN N
the DT N
threshold JJ N
chosen NN N
. . N

A DT N
threshold NN N
of IN N
-300 NNP N
HU NNP N
resulted VBD N
in IN N
the DT N
detection NN 1_o
of IN 1_o
a DT 1_o
solid JJ 1_o
component NN 1_o
in IN N
75 CD N
nodules NNS N
with IN N
good JJ N
sensitivity NN N
( ( N
90 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
88 CD N
% NN N
) ) N
. . N

At IN N
a DT N
threshold NN N
of IN N
-130 NNP N
HU NNP N
, , N
semiautomatic JJ N
measurements NNS N
of IN N
the DT N
diameter NN N
of IN N
the DT N
solid JJ 1_o
component NN 1_o
( ( N
mean JJ N
2.4 CD N
mm NN N
, , N
SD NNP N
2.7 CD N
mm NN N
) ) N
were VBD N
comparable JJ N
to TO N
manual JJ N
measurements NNS N
at IN N
the DT N
mediastinal JJ N
window NN N
setting NN N
( ( N
mean JJ N
2.3 CD N
mm NN N
, , N
SD NNP N
2.5 CD N
mm NN N
[ NNP N
p NN N
= VBD N
0.63 CD N
] NN N
) ) N
. . N

CONCLUSION NNP N
Semiautomatic NNP N
segmentation NN N
of IN N
subsolid JJ N
nodules NNS N
could MD N
diagnose VB N
part-solid JJ N
nodules NNS N
and CC N
quantify VB N
the DT N
solid JJ N
component NN N
similar JJ N
to TO N
human JJ N
observers NNS N
. . N

Performance NNP N
depends VBZ N
on IN N
the DT N
attenuation NN N
segmentation NN N
thresholds NNS N
. . N

This DT N
method NN N
may MD N
prove VB N
useful JJ N
in IN N
managing VBG N
subsolid JJ N
nodules NNS N
. . N

KEY NNP N
POINTS NNP N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
accurately RB N
differentiate VB N
nonsolid JJ N
from IN N
part-solid JJ N
pulmonary JJ N
nodules NNS N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
quantify VB N
the DT N
solid JJ N
component NN N
similar JJ N
to TO N
manual JJ N
measurements NNS N
? . N
Semiautomatic JJ N
segmentation NN N
may MD N
aid VB N
management NN N
of IN N
subsolid JJ N
nodules NNS N
following VBG N
Fleischner NNP N
Society NNP N
recommendations NNS N
? . N
Performance NN N
for IN N
the DT N
segmentation NN N
of IN N
subsolid JJ N
nodules NNS N
depends VBZ N
on IN N
the DT N
chosen VBN N
attenuation NN N
thresholds NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
fenoterol NN 1_i
on IN N
inspiratory JJ N
effort NN N
sensation NN N
and CC N
fatigue NN N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
fenoterol NN 1_i
on IN N
the DT N
relationship NN N
between IN N
inspiratory NN N
effort NN N
sensation NN N
( ( N
IES NNP N
) ) N
and CC N
inspiratory JJ N
muscle NN N
fatigue NN N
induced VBN N
by IN N
inspiratory NN N
threshold NN N
loading NN N
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

The DT N
magnitude NN N
of IN N
the DT N
threshold NN N
was VBD N
60 CD N
% NN N
of IN N
maximal JJ N
static JJ N
inspiratory NN N
mouth NN N
pressure NN N
( ( N
PI NNP N
, , N
mmax NN N
) ) N
at IN N
functional JJ N
residual JJ N
capacity NN N
, , N
and CC N
the DT N
duty NN N
cycle NN N
was VBD N
0.5 CD N
. . N

Subjects NNS 1_p
continued VBD N
the DT N
threshold NN N
loaded VBD N
breathing NN N
until IN N
the DT N
target NN N
mouth NN N
pressure NN N
could MD N
no RB N
longer RB N
be VB N
maintained VBN N
( ( N
endurance JJ N
time NN N
) ) N
. . N

The DT N
intensity NN N
of IN N
the DT N
IES NNP N
was VBD N
scored VBN N
with IN N
a DT N
modified JJ N
Borg NNP N
scale NN N
. . N

Either CC N
fenoterol NN 1_i
( ( 1_i
5 CD 1_i
mg NN 1_i
) ) 1_i
or CC 1_i
a DT 1_i
placebo NN 1_i
was VBD N
given VBN N
orally RB N
2 CD N
h NN N
before IN N
loading VBG N
in IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
protocol NN N
. . N

The DT N
endurance NN 1_o
time NN 1_o
with IN N
fenoterol NN N
( ( N
34.4 CD N
+/- JJ N
8.6 CD N
min NN N
) ) N
was VBD N
longer JJR N
than IN N
that DT N
with IN N
the DT N
placebo NN N
( ( N
22.2 CD N
+/- JJ N
7.1 CD N
min NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ratio NN 1_o
of IN 1_o
high- JJ 1_o
to TO 1_o
low-frequency JJ 1_o
power NN 1_o
of IN 1_o
the DT 1_o
diaphragmatic JJ 1_o
electromyogram NN 1_o
( ( 1_o
EMGdi NNP 1_o
) ) 1_o
decreased VBD N
during IN N
loading NN N
; : N
the DT N
decrease NN N
was VBD N
less RBR N
with IN N
fenoterol NN 1_i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
EMGdi NNP 1_o
also RB N
decreased VBD N
with IN N
loading NN N
; : N
the DT N
decrease NN N
was VBD N
greater JJR N
on IN N
fenoterol NN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
PI NNP 1_o
, , 1_o
mmax NN 1_o
and CC 1_o
maximal JJ 1_o
transdiaphragmatic JJ 1_o
pressure NN 1_o
( ( 1_o
Pdi NNP 1_o
) ) 1_o
were VBD N
similarly RB N
decreased VBN N
after IN N
loading VBG N
on IN N
either DT N
treatment NN N
. . N

The DT N
intensity NN 1_o
of IN 1_o
the DT 1_o
IES NNP 1_o
rose VBD 1_o
with IN 1_o
time NN 1_o
during IN N
loading VBG N
in IN N
both DT N
groups NNS N
but CC N
was VBD N
lower JJR N
with IN N
fenoterol NN 1_i
than IN N
with IN N
the DT N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ratio NN 1_o
of IN 1_o
Pdi NNP 1_o
to TO N
integrated JJ N
activity NN N
of IN N
the DT N
EMGdi NNP N
increased VBD N
with IN N
fenoterol NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Fenoterol NNP N
treatment NN N
increased VBD N
both DT N
superimposed VBN 1_o
Pdi NNP 1_o
twitch NN 1_o
and CC 1_o
Pdi NNP 1_o
twitch NN 1_o
of IN 1_o
relaxed JJ 1_o
diaphragm NN 1_o
and CC N
decreased VBD N
the DT N
value NN 1_o
of IN 1_o
( ( 1_o
1-superimposed JJ 1_o
Pdi NNP 1_o
twitch/Pdi NN 1_o
twitch NN 1_o
of IN 1_o
relaxed JJ 1_o
diaphragm NN 1_o
) ) 1_o
. . 1_o

Thus IN N
we PRP N
conclude VBP N
that IN N
in IN N
normal JJ 1_p
subjects NNS 1_p
fenoterol JJ N
reduces NNS N
diaphragmatic JJ N
fatigue NN N
and CC N
decreases VBZ N
the DT N
motor NN N
command NN N
to TO N
the DT N
diaphragm NN N
, , N
resulting VBG N
in IN N
a DT N
decrease NN N
in IN N
IES NNP N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
and CC N
a DT N
prolongation NN N
of IN N
endurance NN N
. . N

-DOCSTART- -X- O O

Unstable JJ 1_p
angina NN 1_p
. . 1_p

Quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
of IN N
pentoxifylline NN 1_i
for IN N
the DT N
treatment NN N
of IN N
recurrent NN 1_p
aphthous JJ 1_p
stomatitis NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
pentoxifylline NN 1_i
for IN N
the DT N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
. . N

DESIGN VB N
A DT N
60-day JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
with IN N
a DT N
60-day JJ N
no DT N
treatment NN N
follow-up RB N
. . N

SETTING VBG N
An DT N
oral JJ N
medicine NN N
specialist NN N
referral JJ N
center NN N
in IN N
Manchester NNP N
. . N

PARTICIPANTS NNP N
Forty-nine JJ 1_p
volunteers NNS 1_p
who WP 1_p
passed VBD 1_p
the DT 1_p
initial JJ 1_p
assessment NN 1_p
for IN 1_p
recurrent NN 1_p
aphthous JJ 1_p
stomatitis NN 1_p
entered VBD 1_p
a DT 1_p
pretrial JJ 1_p
phase NN 1_p
in IN 1_p
which WDT 1_p
their PRP$ 1_p
eligibility NN 1_p
for IN 1_p
the DT 1_p
trial NN 1_p
phase NN 1_p
of IN 1_p
the DT 1_p
study NN 1_p
was VBD 1_p
assessed VBN 1_p
. . 1_p

Sixteen JJ 1_p
subjects NNS 1_p
were VBD 1_p
deemed VBN 1_p
ineligible JJ 1_p
, , N
and CC N
7 CD N
failed VBD N
to TO N
attend VB N
or CC N
withdrew VB N
. . N

The DT N
remaining VBG N
26 CD 1_p
subjects NNS 1_p
were VBD N
randomized VBN N
to TO N
placebo VB N
or CC N
treatment NN N
. . N

Six NNP N
subjects VBZ N
withdrew JJ N
because IN N
of IN N
adverse JJ N
effects NNS N
, , N
and CC N
1 CD N
was VBD N
unavailable JJ N
for IN N
follow-up NN N
. . N

INTERVENTION NNP N
Pentoxifylline NNP 1_i
( ( N
also RB N
called VBN N
oxpentifylline NN N
) ) N
, , N
400 CD N
mg NN N
3 CD N
times NNS N
daily RB N
, , N
or CC N
matching VBG N
placebo NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
A NNP N
reduction NN N
in IN N
the DT N
median JJ 1_o
pain NN 1_o
score NN 1_o
, , 1_o
ulcer JJ 1_o
size NN 1_o
, , 1_o
number NN 1_o
of IN 1_o
ulcers NNS 1_o
, , 1_o
or CC 1_o
total JJ 1_o
number NN 1_o
of IN 1_o
ulcer JJ 1_o
episodes NNS 1_o
. . 1_o

RESULTS JJ N
Patients NNPS N
taking VBG N
pentoxifylline NN 1_i
had VBD N
less JJR 1_o
pain NN 1_o
and CC N
reported VBD N
smaller JJR 1_o
and CC 1_o
fewer JJR 1_o
ulcers NNS 1_o
compared VBN N
with IN N
baseline NN N
. . N

Patients NNS N
taking VBG N
placebo NN 1_i
reported VBD N
no DT 1_o
improvement NN 1_o
in IN N
these DT N
variables NNS N
. . N

Patients NNS N
taking VBG N
pentoxifylline NN 1_i
also RB N
reported VBD N
more RBR 1_o
ulcer-free JJ 1_o
days NNS 1_o
than IN N
those DT N
taking VBG N
placebo NN 1_i
. . 1_i

However RB N
, , N
the DT N
differences NNS 1_o
were VBD 1_o
small JJ 1_o
and CC N
, , N
with IN N
the DT N
exception NN 1_o
of IN 1_o
median JJ 1_o
ulcer NN 1_o
size NN 1_o
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
, , N
did VBD 1_o
not RB 1_o
reach VB 1_o
statistical JJ 1_o
significance NN 1_o
. . 1_o

Adverse JJ 1_o
effects NNS 1_o
were VBD N
common JJ N
with IN N
pentoxifylline NN 1_i
, , N
but CC N
not RB 1_o
significantly RB 1_o
different JJ 1_o
from IN N
those DT N
experienced VBN N
by IN N
patients NNS N
taking VBG N
placebo NN 1_i
. . 1_i

CONCLUSIONS NNP N
Although IN N
pentoxifylline NN 1_i
may MD N
have VB N
some DT N
benefit NN N
in IN N
the DT N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
, , N
the DT N
benefit NN N
is VBZ N
limited VBN N
. . N

It PRP N
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
unresponsive JJ N
to TO N
other JJ N
treatments NNS N
, , N
but CC N
can MD N
not RB N
yet RB N
be VB N
recommended VBN N
as IN N
a DT N
first-line JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
values NNS N
affirmation VBP N
on IN N
race-discordant JJ 1_p
patient-provider JJ 1_p
communication NN N
. . N

BACKGROUND NNP N
Communication NNP N
between IN N
African JJ 1_p
American JJ 1_p
patients NNS 1_p
and CC 1_p
white JJ 1_p
health NN 1_p
care NN 1_p
providers NNS 1_p
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
of IN N
poorer JJR N
quality NN N
when WRB N
compared VBN N
with IN N
race-concordant JJ N
patient-provider JJ N
communication NN N
. . N

Fear NN N
on IN N
the DT N
part NN N
of IN N
patients NNS N
that WDT N
providers NNS N
stereotype VBP N
them PRP N
negatively RB N
might MD N
be VB N
one CD N
cause NN N
of IN N
this DT N
poorer JJR N
communication NN N
. . N

This DT N
stereotype JJ N
threat NN N
may MD N
be VB N
lessened VBN N
by IN N
a DT N
values-affirmation NN N
intervention NN N
. . N

METHODS NNP N
In IN N
a DT N
blinded JJ N
experiment NN N
, , N
we PRP N
randomized VBD N
99 CD 1_p
African JJ 1_p
American JJ 1_p
patients NNS 1_p
with IN 1_p
hypertension NN 1_p
to TO N
perform VB N
a DT N
values-affirmation NN 1_i
exercise NN 1_i
or CC 1_i
a DT 1_i
control NN 1_i
exercise NN 1_i
before IN N
a DT N
visit NN N
with IN N
their PRP$ N
primary JJ N
care NN N
provider NN N
. . N

We PRP N
compared VBN N
patient-provider JJ N
communication NN N
for IN N
the DT N
2 CD N
groups NNS N
using VBG N
audio JJ N
recordings NNS N
of IN N
the DT N
visit NN N
analyzed VBN N
with IN N
the DT N
Roter NNP N
Interaction NNP N
Analysis NNP N
System NNP N
. . N

We PRP N
also RB N
evaluated VBD N
visit JJ N
satisfaction NN N
, , N
trust NN N
, , N
stress NN N
, , N
and CC N
mood NN N
after IN N
the DT N
visit NN N
by IN N
means NNS N
of IN N
a DT N
questionnaire NN N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
intervention NN N
group NN N
requested VBD N
and CC N
provided VBD N
more JJR N
information NN 1_o
about IN N
their PRP$ N
medical JJ 1_o
condition NN 1_o
( ( N
mean JJ N
[ NNP N
SE NNP N
] NNP N
number NN N
of IN N
utterances NNS N
, , N
66.3 CD N
[ NN N
6.8 CD N
] NN N
in IN N
the DT N
values-affirmation NN N
group NN N
vs VBD N
48.1 CD N
[ JJ N
5.9 CD N
] NN N
in IN N
the DT N
control NN N
group NN N
[ NNP N
P NNP N
= NNP N
.03 NNP N
] NNP N
) ) N
. . N

Patient-provider JJ N
communication NN N
in IN N
the DT N
intervention NN N
group NN N
was VBD N
characterized VBN N
as IN N
being VBG N
more RBR N
interested JJ 1_o
, , 1_o
friendly JJ 1_o
, , 1_o
responsive JJ 1_o
, , 1_o
interactive JJ 1_o
, , 1_o
and CC 1_o
respectful JJ 1_o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
less JJR N
depressed JJ 1_o
and CC 1_o
distressed JJ 1_o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Patient JJ N
questionnaires NNS N
did VBD N
not RB N
detect VB N
differences NNS N
in IN N
visit NN 1_o
satisfaction NN 1_o
, , 1_o
trust NN 1_o
, , 1_o
stress NN 1_o
, , 1_o
or CC 1_o
mood NN 1_o
. . 1_o

Mean NNP 1_o
visit NN 1_o
duration NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
19.2 CD N
minutes NNS N
in IN N
the DT N
control NN N
group NN N
vs VBD N
20.5 CD N
minutes NNS N
in IN N
the DT N
intervention NN N
group NN N
[ NNP N
P NNP N
= NNP N
.29 NNP N
] NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
values-affirmation NN 1_i
exercise NN 1_i
improves VBZ N
aspects NNS N
of IN N
patient-provider JJ N
communication NN N
in IN N
race-discordant JJ N
primary JJ N
care NN N
visits NNS N
. . N

The DT N
clinical JJ N
impact NN N
of IN N
the DT N
intervention NN N
must MD N
be VB N
defined VBN N
before IN N
widespread JJ N
implementation NN N
can MD N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Inclusion NN N
of IN N
anti-phospholipase JJ 1_i
A2 NNP 1_i
antibody NN 1_i
to TO N
backgrounding VBG N
diets NNS N
on IN N
performance NN 1_o
, , 1_o
feed NN 1_o
efficiency NN 1_o
, , 1_o
in IN 1_o
vitro JJ 1_o
fermentation NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
acute-phase JJ 1_o
response NN 1_o
of IN 1_o
growing VBG 1_o
beef NN 1_o
calves NNS 1_o
. . 1_o

In IN N
Exp NNP N
. . N

1 CD N
, , N
individual JJ N
performance NN N
and CC N
daily JJ N
DMI NNP N
was VBD N
measured VBN N
on IN N
70 CD 1_p
crossbred JJ 1_p
weaned VBD 1_p
calves NNS 1_p
during IN 1_p
a DT 1_p
70-d JJ 1_p
period NN 1_p
using VBG 1_p
a DT 1_p
GrowSafe NNP 1_p
system NN 1_p
( ( 1_p
GrowSafe NNP 1_p
Systems NNPS 1_p
Ltd. NNP 1_p
, , N
Airdrie NNP 1_p
, , 1_p
AB NNP 1_p
, , 1_p
Canada NNP 1_p
) ) 1_p
at IN 1_p
the DT 1_p
University NNP 1_p
of IN 1_p
Florida NNP 1_p
North NNP 1_p
Florida NNP 1_p
Research NNP 1_p
and CC 1_p
Education NNP 1_p
Center NNP 1_p
Feed NNP 1_p
Efficiency NNP 1_p
Facility NNP 1_p
( ( 1_p
FEF NNP 1_p
) ) 1_p
. . 1_p

Calves NNS 1_p
were VBD N
fed VBN N
a DT N
low-concentrate NN 1_i
( ( 1_i
LC NNP 1_i
) ) 1_i
growing VBG 1_i
diet JJ 1_i
, , N
blocked VBN N
by IN N
weight NN N
and CC N
sex NN N
, , N
and CC N
then RB N
randomly RB N
assigned VBN N
to TO N
pens NNS N
to TO N
receive VB N
either RB 1_i
no DT 1_i
additional JJ 1_i
supplement NN 1_i
( ( N
CON NNP N
; : N
n CC N
= VB N
35 CD N
) ) N
or CC 1_i
receive VB 1_i
a DT 1_i
supplement NN 1_i
of IN 1_i
anti-phospholipase JJ 1_i
A2 NNP 1_i
antibody NN 1_i
( ( 1_i
aPLA2 NN 1_i
) ) 1_i
at IN N
an DT N
inclusion NN N
rate NN N
of IN N
0.6 CD N
% NN N
of IN N
the DT N
diet JJ N
DM NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

After IN N
the DT N
70-d JJ N
feed NN N
efficiency NN N
( ( N
FE NNP N
) ) N
trial NN N
( ( N
Phase NNP N
1 CD N
) ) N
, , N
calves NNS N
were VBD N
loaded VBN N
into IN N
a DT N
commercial JJ N
livestock NN N
trailer NN N
and CC N
were VBD N
driven VBN N
for IN N
approximately RB N
1,600 CD N
km NNS N
during IN N
24 CD N
h. NNS N
Upon NNP N
return NN N
to TO N
the DT N
FEF NNP N
( ( N
Phase NNP N
2 CD N
) ) N
, , N
calves NNS N
were VBD N
relocated VBN N
to TO N
the DT N
same JJ N
pens NNS N
and CC N
groups NNS N
and CC N
received VBD N
the DT N
same JJ N
diets NNS N
and CC N
treatments NNS N
for IN N
28 CD N
d. NNS N
Blood NNP N
samples NNS N
from IN N
each DT N
calf NN N
were VBD N
collected VBN N
on IN N
d NN N
0 CD N
, , N
1 CD N
, , N
3 CD N
, , N
5 CD N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
, , N
and CC N
28 CD N
relative NN N
to TO N
initiation NN N
of IN N
transportation NN N
and CC N
were VBD N
analyzed VBN N
for IN N
determination NN N
of IN N
concentrations NNS 1_o
of IN 1_o
plasma NN 1_o
ceruloplasmin NN 1_o
and CC 1_o
haptoglobin NN 1_o
. . 1_o

In IN N
Phase NNP N
1 CD N
, , N
initial JJ N
BW NNP 1_o
( ( N
242.0 CD N
? . N
3.7 CD N
kg NN N
; : N
P NNP N
= NNP N
0.92 CD N
) ) N
, , N
BW NNP 1_o
at IN N
d NN N
70 CD N
( ( N
313.0 CD N
? . N
4.1 CD N
kg NN N
; : N
P NNP N
= NNP N
0.79 CD N
) ) N
, , N
and CC 1_o
ADG NNP 1_o
( ( 1_o
1.01 CD N
? . N
0.02 CD N
kg NN N
; : N
P NNP N
= NNP N
0.95 CD N
) ) N
were VBD N
similar JJ N
between IN N
treatments NNS N
. . N

However RB 1_o
, , 1_o
daily JJ 1_o
DMI NNP 1_o
was VBD 1_o
greater JJR N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
for IN N
CON NNP N
( ( N
9.18 CD N
? . N
0.15 CD N
kg NN N
) ) N
than IN N
aPLA2 NN N
( ( N
8.53 CD N
? . N
0.15 CD N
kg NN N
) ) N
. . N

In IN N
addition NN 1_o
, , 1_o
residual JJ 1_o
feed NN 1_o
intake NN 1_o
was VBD 1_o
greater JJR N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
for IN N
CON NNP N
( ( N
0.389 CD N
? . N
0.110 CD N
kg/d NN N
) ) N
than IN N
aPLA2 NN N
calves NNS N
( ( N
-0.272 VB N
? . N
0.110 CD N
kg/d NN N
) ) N
. . N

In IN N
Phase NNP N
2 CD N
, , N
after IN N
transportation NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
treatments NNS 1_o
on IN 1_o
BW NNP 1_o
loss NN 1_o
due JJ 1_o
to TO 1_o
transportation NN 1_o
shrink VB 1_o
( ( N
26.0 CD N
? . N
0.6 CD N
kg NN N
; : N
P NNP N
= NNP N
0.86 CD N
) ) N
, , N
BW NNP N
at IN N
d NN N
28 CD N
( ( N
339.0 CD N
? . N
4.1 CD N
kg NN N
; : N
P NNP N
= NNP N
0.72 CD N
) ) N
, , N
ADG NNP N
( ( N
1.28 CD N
? . N
0.03 CD N
kg/d NN N
; : N
P NNP N
= NNP N
0.72 CD N
) ) N
, , N
G NNP N
: : N
F NNP N
( ( N
0.164 CD N
? . N
0.004 CD N
; : N
P NNP N
= NNP N
0.83 CD N
) ) N
, , N
and CC N
concentrations NNS N
of IN N
plasma NN N
haptoglobin NN N
( ( N
0.08 CD N
? . N
0.02 CD N
mg/mL NN N
; : N
P NNP N
= NNP N
0.41 CD N
) ) N
. . N

However RB 1_o
, , 1_o
concentrations NNS 1_o
of IN 1_o
plasma NN 1_o
ceruloplasmin NN 1_o
were VBD 1_o
greater JJR 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
CON NNP N
calves NNS N
( ( N
14.3 CD N
? . N
0.3 CD N
mg/dL NN N
) ) N
compared VBN N
to TO N
aPLA2 VB N
calves NNS N
( ( N
13.0 CD N
? . N
0.3 CD N
mg/dL NN N
) ) N
. . N

In IN N
Exp NNP N
. . N

2 CD N
, , N
the DT N
effects NNS N
of IN N
aPLA2 JJ 1_o
inclusion NN 1_o
on IN 1_o
LC NNP 1_o
and CC 1_o
high-concentrate NN 1_o
( ( 1_o
HC NNP 1_o
) ) 1_o
substrates VBZ 1_o
on IN 1_o
in IN 1_o
vitro JJ 1_o
fermentation NN 1_o
parameters NNS 1_o
were VBD 1_o
assessed VBN N
. . N

Addition NN N
of IN N
aPLA2 NN N
had VBD N
no DT N
effects NNS N
on IN N
in IN 1_o
vitro JJ 1_o
fermentation NN 1_o
parameters NNS 1_o
of IN 1_o
LC NNP 1_o
and CC 1_o
HC NNP 1_o
substrates NNS 1_o
. . N

In IN N
conclusion NN N
, , N
supplementation NN 1_i
of IN 1_i
aPLA2 NN 1_i
improved VBN 1_i
FE NNP 1_o
of IN 1_o
growing VBG N
beef NN N
calves NNS N
when WRB N
fed VBN N
LC NNP N
diets NNS N
in IN N
Phase NNP N
1 CD N
and CC N
addition NN N
of IN N
aPLA2 NN N
had VBD N
no DT N
effect NN N
on IN 1_o
fermentation NN 1_o
parameters NNS 1_o
of IN 1_o
LC NNP 1_o
and CC 1_o
HC NNP 1_o
substrates NNS 1_o
. . N

In IN N
addition NN N
, , N
calves NNS N
supplemented VBD N
with IN N
aPLA2 NN N
had VBD N
reduced VBN 1_o
concentrations NNS 1_o
of IN 1_o
plasma NN 1_o
ceruloplasmin NN 1_o
after IN N
24 CD N
h NN N
of IN N
transportation NN N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
asimadoline NN 1_i
, , N
a DT N
new JJ N
kappa-opioid JJ N
receptor NN N
agonist NN N
, , N
on IN N
tubular JJ N
water NN N
absorption NN N
and CC N
vasopressin NN 1_p
secretion NN 1_p
in IN 1_p
man NN 1_p
. . 1_p

AIMS VBZ N
The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS 1_o
of IN N
asimadoline NN 1_i
, , N
a DT N
new JJ N
kappa-opioid JJ N
agonist NN N
, , N
on IN N
renal JJ N
function NN N
and CC N
on IN N
hormones NNS N
related VBN N
to TO N
body NN N
fluid JJ N
balance NN N
as RB N
well RB N
as IN N
its PRP$ N
tolerability NN N
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
placebo-controlled JJ 1_i
, , N
randomised JJ N
, , N
double-blind JJ N
crossover NN N
design NN N
we PRP N
studied VBD N
the DT N
effects NNS N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
1 CD 1_i
, , 1_i
5 CD 1_i
, , 1_i
and CC 1_i
10 CD 1_i
mg NN 1_i
of IN 1_i
asimadoline NN 1_i
, , N
in IN N
24 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

Two CD N
hour NN N
control NN N
urine JJ N
collections NNS N
were VBD N
followed VBN N
by IN N
2 CD N
h NNS N
postdose JJ N
urine JJ N
collections NNS N
and CC N
subsequently RB N
2.5 CD 1_i
% NN 1_i
saline NN 1_i
was VBD N
given VBN N
i.v NN N
. . N

at IN N
a DT N
rate NN N
of IN N
0.3 CD N
ml NNS N
min NN N
( ( N
-1 NNP N
) ) N
kg NN N
( ( N
-1 JJ N
) ) N
during IN N
another DT N
2 CD N
h NN N
urine JJ N
collection NN N
. . N

Blood NNP N
was VBD N
obtained VBN N
hourly RB N
. . N

Arginine-vasopressin NNP 1_o
( ( 1_o
AVP NNP 1_o
) ) 1_o
, , 1_o
atrial JJ 1_o
natriuretic JJ 1_o
peptide NN 1_o
( ( 1_o
alpha-hANP JJ 1_o
) ) 1_o
, , 1_o
endothelin FW 1_o
( ( 1_o
ET-1 NNP 1_o
) ) 1_o
and CC 1_o
cAMP NN 1_o
were VBD N
determined VBN N
by IN N
r.i.a NN N
. . N

or CC N
ELISA NNP N
. . N

RESULTS NNP N
GC-MS JJ N
measurements NNS N
revealed VBD N
Cmax NNP 1_o
values NNS 1_o
of IN 1_o
asimadoline NN 1_o
in IN 1_o
plasma NN 1_o
ranging VBG N
from IN N
18 CD N
ng JJ N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
1 CD N
mg NN N
dose NN N
, , N
91 CD N
ng NN N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
5 CD N
mg NN N
dose NN N
, , N
to TO N
214 CD N
ng NNS N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
10 CD N
mg NN N
dose NN N
after IN N
an DT N
average NN N
of IN N
1.1-1.4 JJ N
h. NN N
Without NNP N
effects NNS N
on IN N
blood NN 1_o
pressure NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
GFR NNP 1_o
or CC 1_o
urine JJ 1_o
electrolyte JJ 1_o
excretion NN 1_o
, , 1_o
urine JJ 1_o
volume NN 1_o
increased VBD N
after IN N
1-2 JJ N
h NN N
after IN N
administration NN N
of IN N
5 CD N
and CC N
10 CD N
mg NNS N
asimadoline VBP N
from IN N
3.3+/-1.3 JJ N
to TO N
5.6+/-1.4 JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
from IN N
3.2 CD N
+/-1.6 JJ N
to TO N
5.5+/-2.2 JJ N
ml NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
respectively RB N
. . N

CH2O NNP 1_o
rose VBD N
from IN N
0.2+/-1.5 JJ N
to TO N
2.0+/-1.6 JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
from IN N
0.6+/-1.6 JJ N
to TO N
3.0+/-1.6 JJ N
ml NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Urinary JJ 1_o
excretion NN 1_o
of IN N
AVP NNP N
was VBD N
suppressed VBN N
only RB N
with IN N
the DT N
10 CD N
mg NNS N
dose RB N
from IN N
46+/-23 JJ N
to TO N
25+/-15 JJ N
fmol NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
without IN N
and CC N
from IN N
410+/-206 JJ N
to TO N
181+/-125 JJ N
fmol NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
stimulation NN N
by IN N
2.5 CD N
% NN N
saline NN N
. . N

Plasma NNP 1_o
AVP NNP 1_o
was VBD N
suppressed VBN N
only RB N
by IN N
the DT N
10 CD N
mg NN N
dose NN N
of IN N
asimadoline NN N
in IN N
six CD N
of IN N
eight CD N
subjects NNS N
during IN N
the DT N
2.5 CD N
% NN N
saline JJ N
infusion NN N
. . N

Changes NNS N
in IN N
the DT N
alpha-hANP JJ N
or CC N
ET-1 JJ N
systems NNS N
were VBD N
not RB N
affected VBN N
by IN N
asimadoline NN N
. . N

CONCLUSIONS NNP N
Asimadoline NNP 1_i
is VBZ N
diuretic JJ N
in IN N
man NN N
after IN N
single JJ N
doses NNS N
of IN N
5 CD N
or CC N
10 CD N
mg NN N
probably RB N
through IN N
a DT N
direct JJ N
effect NN N
at IN N
the DT N
renal JJ N
tubular JJ N
level NN N
. . N

Suppression NN N
of IN N
AVP NNP N
secretion NN N
was VBD N
observed VBN N
only RB N
at IN N
the DT N
highest JJS N
dose JJ N
level NN N
of IN N
10 CD N
mg NN N
of IN N
asimadoline NN N
. . N

-DOCSTART- -X- O O

The DT N
maximal JJ 1_i
double JJ 1_i
step NN 1_i
length RB 1_i
test NN 1_i
can MD N
evaluate VB N
more RBR N
adequately RB N
the DT N
decrease NN N
of IN N
physical JJ N
function NN N
with IN N
age NN N
, , N
than IN N
the DT N
maximal JJ N
single JJ N
step NN N
length JJ N
test NN N
. . N

The DT N
maximal JJ 1_i
double JJ 1_i
step NN 1_i
length NN 1_i
( ( N
MDSL NNP N
) ) N
test NN N
is VBZ N
a DT N
modified JJ N
version NN N
of IN N
the DT N
maximal JJ 1_i
step NN 1_i
length NN 1_i
( ( 1_i
MSL NNP 1_i
) ) 1_i
test NN 1_i
used VBN N
to TO N
evaluate VB N
the DT N
dynamic JJ N
balance NN N
related VBN N
to TO N
falls NNS N
in IN N
the DT N
elderly JJ N
. . N

Although IN N
this DT N
test NN N
can MD N
evaluate VB N
their PRP$ N
physical JJ N
function NN N
using VBG N
movements NNS N
similar JJ N
to TO N
daily JJ N
activities NNS N
as IN N
compared VBN N
to TO N
MSL NNP 1_i
, , N
it PRP N
has VBZ N
not RB N
been VBN N
clarified VBN N
whether IN N
it PRP N
can MD N
adequately RB N
evaluate VB N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
( ( N
ADL NNP N
) ) N
abilities NNS N
of IN N
the DT N
elderly JJ N
, , N
as IN N
they PRP N
decrease VBP N
with IN N
age NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
both DT N
MSL NNP 1_i
and CC N
MDSL NNP 1_i
on IN N
age NN N
and CC N
ADL NNP N
in IN 1_p
elderly JJ 1_p
subjects NNS 1_p
. . 1_p

Fifty-seven CD 1_p
elderly JJ 1_p
females NNS 1_p
who WP 1_p
live VBP 1_p
independently RB 1_p
( ( 1_p
age NN 1_p
74.8?5.6 CD 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

MSL NNP 1_i
and CC 1_i
MDSL NNP 1_i
were VBD N
conducted VBN N
twice RB N
after IN N
completing VBG N
an DT N
ADL NNP N
questionnaire NN N
. . N

Intra-class JJ 1_o
correlation NN 1_o
coefficients NNS 1_o
( ( 1_o
ICCs NNP 1_o
) ) 1_o
of IN N
both DT N
tests NNS N
were VBD N
high JJ N
( ( N
for IN 1_i
MSL NNP 1_i
: : 1_i
ICC=0.95 NNP N
, , N
for IN 1_i
MDSL NNP 1_i
: : 1_i
ICC=0.81-0.82 NN N
) ) N
. . N

Age NNP N
and CC N
ADL NNP N
significantly RB N
correlated VBD N
to TO 1_o
MDSL NNP 1_o
( ( N
age NN N
: : N
r=-0.32-0.41 NN N
, , N
ADL NNP N
: : N
r=0.28-0.48 NN N
) ) N
, , N
but CC N
not RB N
to TO N
MSL NNP N
( ( N
age NN N
: : N
r=-0.19 NN N
, , N
ADL NNP N
: : N
r=0.15 NN N
) ) N
. . N

MDSL NNP 1_i
has VBZ N
high JJ N
reliability NN N
as IN N
it PRP N
relates VBZ N
to TO N
age NN N
and CC N
ADL NNP N
. . N

It PRP N
may MD N
be VB N
more JJR N
useful JJ N
to TO N
evaluate VB N
ADL NNP N
required VBN N
for IN N
independent JJ N
living NN N
and CC N
prevent NN N
falls NNS N
in IN N
the DT N
elderly JJ N
better JJR N
than IN 1_i
MSL NNP 1_i
. . 1_i

-DOCSTART- -X- O O

Short-term JJ N
metformin NN 1_i
treatment NN N
for IN N
clomiphene JJ 1_p
citrate-resistant JJ 1_p
women NNS 1_p
with IN 1_p
polycystic JJ 1_p
ovary JJ 1_p
syndrome NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
short-course JJ N
pretreatment NN N
with IN N
metformin NN 1_i
on IN N
hyperandrogenism NN 1_o
, , 1_o
insulin NN 1_o
resistance NN 1_o
, , 1_o
cervical JJ 1_o
scores NNS 1_o
, , 1_o
and CC 1_o
pregnancy NN 1_o
rates NNS 1_o
in IN N
women NNS 1_p
with IN 1_p
clomiphene JJ 1_i
citrate NN 1_i
( ( 1_p
CC NNP 1_p
) ) 1_p
-resistant VBP 1_p
polycystic JJ 1_p
ovary JJ 1_p
syndrome NN 1_p
( ( 1_p
PCOS NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Thirty-seven JJ 1_p
women NNS 1_p
with IN 1_p
CC-resistant JJ 1_p
PCOS NNP 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
be VB N
pretreated VBN N
with IN N
500 CD N
mg NNS N
of IN N
metformin NN 1_i
or CC 1_i
placebo NN 1_i
3 CD N
times NNS N
per IN N
day NN N
for IN N
2 CD N
cycles NNS N
, , N
and CC N
100 CD N
mg NN N
of IN N
CC NNP 1_i
was VBD N
given VBN N
on IN N
days NNS N
5 CD N
through IN N
9 CD N
of IN N
the DT N
second JJ N
cycle NN N
in IN N
both DT N
groups NNS N
. . N

Luteinizing VBG 1_o
hormone NN 1_o
( ( 1_o
LH NNP 1_o
) ) 1_o
, , 1_o
follicle NN 1_o
stimulating VBG 1_o
hormone NN 1_o
( ( 1_o
FSH NNP 1_o
) ) 1_o
, , 1_o
dehydroepiandrostendione JJ 1_o
sulfate NN 1_o
( ( 1_o
DHEAS NNP 1_o
) ) 1_o
, , 1_o
total JJ 1_o
testosterone NN 1_o
( ( 1_o
T NNP 1_o
) ) 1_o
, , 1_o
glucose JJ 1_o
, , 1_o
and CC 1_o
insulin NN 1_o
levels NNS 1_o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
first JJ N
cycle NN N
, , N
as RB N
well RB N
as IN N
body NN 1_o
mass NN 1_o
index NN 1_o
( ( 1_o
BMI NNP 1_o
) ) 1_o
, , 1_o
cervical JJ 1_o
score NN 1_o
, , 1_o
and CC 1_o
pregnancy NN 1_o
rate NN 1_o
. . 1_o

RESULTS NNP N
After IN N
1 CD N
cycle NN N
, , N
BMI NNP 1_o
, , 1_o
total JJ 1_o
T NNP 1_o
level NN 1_o
, , 1_o
and CC 1_o
percentage NN 1_o
of IN 1_o
participants NNS 1_o
with IN 1_o
insulin NN 1_o
resistance NN 1_o
were VBD N
significantly RB N
decreased VBN N
in IN N
the DT N
metformin NN 1_i
group NN N
, , N
without IN N
any DT N
significant JJ N
decrease NN N
in IN N
LH NNP 1_o
, , 1_o
FSH NNP 1_o
, , 1_o
and CC 1_o
DHEAS NNP 1_o
levels NNS 1_o
; : 1_o
and CC N
in IN N
the DT N
second JJ N
cycle NN N
, , N
CC NNP 1_i
treatment NN N
resulted VBD N
in IN N
a DT N
higher JJR N
ovulation NN 1_o
rate NN 1_o
and CC 1_o
a DT 1_o
thicker NN 1_o
endometrium NN 1_o
in IN N
the DT N
metformin NN 1_i
group NN N
. . N

The DT N
pregnancy NN 1_o
rate NN 1_o
and CC 1_o
cervical JJ 1_o
scores NNS 1_o
were VBD N
also RB N
higher JJR N
in IN N
that DT N
group NN N
. . N

CONCLUSION VB N
The DT N
short-course JJ N
pretreatment NN N
with IN N
metformin NNS 1_i
decreased VBN N
hyperandrogenism NN 1_o
and CC 1_o
insulin NN 1_o
resistance NN 1_o
and CC N
improved JJ N
cervical JJ 1_o
sores NNS 1_o
, , 1_o
ovulation NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
pregnancy NN 1_o
rate NN 1_o
among IN N
women NNS 1_p
with IN 1_p
CC-resistant JJ 1_p
PCOS NNP 1_p
. . 1_p

-DOCSTART- -X- O O

The DT N
Beyond NNP N
Ageing NNP N
Project NNP N
Phase NNP N
2 CD N
-- : N
a DT N
double-blind JJ N
, , N
selective JJ N
prevention NN N
, , N
randomised VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
omega-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
and CC 1_i
sertraline NN 1_i
in IN N
an DT 1_p
older JJR 1_p
age NN 1_p
cohort NN 1_p
at IN 1_p
risk NN 1_p
for IN 1_p
depression NN 1_p
: : 1_p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Late-life JJ 1_p
depression NN 1_p
is VBZ N
associated VBN N
with IN N
high JJ 1_o
rates NNS 1_o
of IN 1_o
morbidity NN 1_o
, , 1_o
premature NN 1_o
mortality NN 1_o
, , 1_o
disability NN 1_o
, , 1_o
functional JJ 1_o
decline NN 1_o
, , 1_o
caregiver NN 1_o
burden NN 1_o
and CC 1_o
increased VBD 1_o
health NN 1_o
care NN 1_o
costs NNS 1_o
. . 1_o

While IN N
clinical JJ N
and CC N
public JJ N
health NN N
approaches NNS N
are VBP N
focused VBN N
on IN N
prevention NN N
or CC N
early JJ N
intervention NN N
strategies NNS N
, , N
the DT N
ideal JJ N
method NN N
of IN N
intervention NN N
remains VBZ N
unclear JJ N
. . N

No DT N
study NN N
has VBZ N
set VBN N
out RP N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
neurobiological JJ N
agents NNS N
in IN N
preventing VBG N
depressive JJ N
symptoms NNS N
in IN N
older JJR N
populations NNS N
at IN N
risk NN N
of IN N
depression NN N
. . N

METHODS/DESIGN NNP N
Subjects VBZ 1_p
with IN 1_p
previously RB 1_p
reported VBN 1_p
sub-threshold JJ 1_p
depressive NN 1_p
symptoms NNS 1_p
, , 1_p
aged VBD 1_p
60 CD 1_p
to TO 1_p
74 CD 1_p
years NNS 1_p
, , N
will MD N
be VB N
screened VBN N
to TO N
participate VB N
in IN N
a DT N
single-centre JJ N
, , N
double-blind JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN 1_i
three CD 1_i
parallel JJ 1_i
groups NNS 1_i
involving VBG 1_i
omega-3 JJ 1_i
fatty JJ 1_i
acid JJ 1_i
supplementation NN 1_i
or CC 1_i
sertraline NN 1_i
hydrochloride NN 1_i
, , 1_i
compared VBN 1_i
with IN 1_i
matching VBG 1_i
placebo NN 1_i
. . 1_i

Subjects NNS 1_p
will MD 1_p
be VB 1_p
excluded VBN 1_p
if IN 1_p
they PRP 1_p
have VBP 1_p
current JJ 1_p
depression NN 1_p
or CC 1_p
suicide JJ 1_p
ideation NN 1_p
; : 1_p
are VBP 1_p
taking VBG 1_p
antidepressants NNS 1_p
or CC 1_p
any DT 1_p
supplement JJ 1_p
containing VBG 1_p
omega-3 JJ 1_p
fatty JJ 1_p
acid NN 1_p
; : 1_p
or CC 1_p
have VBP 1_p
a DT 1_p
prior JJ 1_p
history NN 1_p
of IN 1_p
stroke NN 1_p
or CC 1_p
other JJ 1_p
serious JJ 1_p
cerebrovascular NN 1_p
or CC 1_p
cardiovascular JJ 1_p
disease NN 1_p
, , 1_p
neurological JJ 1_p
disease NN 1_p
, , 1_p
significant JJ 1_p
psychiatric JJ 1_p
disease NN 1_p
( ( 1_p
other JJ 1_p
than IN 1_p
depression NN 1_p
) ) 1_p
or CC 1_p
neurodegenerative JJ 1_p
disease NN 1_p
. . 1_p

The DT N
trial NN N
will MD N
consist VB N
of IN N
a DT N
12 CD N
month NN N
treatment NN N
phase NN N
with IN N
follow-up NN N
at IN N
three CD N
months NNS N
and CC N
12 CD N
months NNS N
to TO N
assess VB N
outcome JJ N
events NNS N
. . N

At IN 1_i
three CD 1_i
months NNS 1_i
, , 1_i
subjects NNS 1_i
will MD 1_i
undergo VB 1_i
structural JJ 1_o
neuroimaging VBG 1_o
to TO 1_i
assess VB 1_i
whether IN 1_i
treatment NN 1_i
effects NNS 1_i
on IN 1_i
depressive JJ 1_i
symptoms NNS 1_i
correlate VBP 1_i
with IN 1_i
brain NN 1_i
changes NNS 1_i
. . 1_i

Additionally RB N
, , N
proton NN 1_o
spectroscopy NN 1_o
techniques NNS N
will MD N
be VB N
used VBN N
to TO N
capture VB N
brain-imaging JJ 1_o
markers NNS 1_o
of IN N
the DT N
biological JJ N
effects NNS N
of IN N
the DT N
interventions NNS N
. . N

The DT N
trial NN N
will MD N
be VB N
conducted VBN N
in IN N
urban JJ 1_p
New NNP 1_p
South NNP 1_p
Wales NNP 1_p
, , 1_p
Australia NNP 1_p
, , N
and CC N
will MD N
recruit VB N
a DT N
community-based JJ 1_p
sample NN 1_p
of IN 1_p
450 CD 1_p
adults NNS 1_p
. . 1_p

Using VBG N
intention-to-treat JJ N
methods NNS N
, , N
the DT N
primary JJ N
endpoint NN N
is VBZ N
an DT N
absence NN N
of IN N
clinically RB N
relevant JJ N
depression NN N
scores NNS N
at IN N
12 CD N
months NNS N
between IN N
the DT N
omega-3 JJ N
fatty JJ N
acid NN N
and CC N
sertraline JJ N
interventions NNS N
and CC N
the DT N
placebo NN N
condition NN N
. . N

DISCUSSION VB N
The DT N
current JJ N
health NN 1_o
, , 1_o
social JJ 1_o
and CC 1_o
economic JJ 1_o
costs NNS 1_o
of IN N
late-life JJ N
depression NN N
make VBP N
prevention NN N
imperative NN N
from IN N
a DT N
public JJ N
health NN N
perspective NN N
. . N

This DT N
innovative JJ N
trial NN N
aims NNS N
to TO N
address VB N
the DT N
long-neglected JJ N
area NN N
of IN N
prevention NN N
of IN N
depression NN N
in IN N
older JJR N
adults NNS N
. . N

The DT N
interventions NNS N
are VBP N
targeted VBN N
to TO N
the DT N
pathophysiology NN N
of IN N
disease NN N
, , N
and CC N
regardless RB N
of IN N
the DT N
effect NN N
size NN N
of IN N
treatment NN N
, , N
the DT N
outcomes NNS N
will MD N
offer VB N
major JJ N
scientific JJ N
advances NNS N
regarding VBG N
the DT N
neurobiological JJ N
action NN N
of IN N
these DT N
agents NNS N
. . N

The DT N
main JJ N
results NNS N
are VBP N
expected VBN N
to TO N
be VB N
available JJ N
in IN N
2017 CD N
. . N

TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
and CC N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
ACTRN12610000032055 NNP N
( ( N
12 CD N
January NNP N
2010 CD N
) ) N
. . N

-DOCSTART- -X- O O

The DT N
limit NN N
to TO N
exercise VB N
tolerance NN N
in IN N
humans NNS 1_p
: : 1_p
mind NN N
over IN N
muscle NN N
? . N
In IN N
exercise NN N
physiology NN N
, , N
it PRP N
has VBZ N
been VBN N
traditionally RB N
assumed VBN N
that IN N
high-intensity NN 1_i
aerobic JJ 1_i
exercise NN 1_i
stops NNS N
at IN N
the DT N
point NN N
commonly RB N
called VBD N
exhaustion NN N
because IN N
fatigued VBN N
subjects NNS N
are VBP N
no RB N
longer RBR N
able JJ N
to TO N
generate VB N
the DT N
power NN N
output NN N
required VBN N
by IN N
the DT N
task NN N
despite IN N
their PRP$ N
maximal JJ N
voluntary JJ N
effort NN N
. . N

We PRP N
tested VBD N
the DT N
validity NN N
of IN N
this DT N
assumption NN N
by IN N
measuring VBG N
maximal JJ 1_o
voluntary JJ 1_o
cycling VBG 1_o
power NN 1_o
before IN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
1,075 CD N
+/- JJ N
214 CD N
W NNP N
) ) N
and CC N
immediately RB N
after IN N
( ( N
731 CD N
+/- JJ N
206 CD N
W NNP N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
exhaustive VBP 1_i
cycling VBG 1_i
exercise NN 1_i
at IN N
242 CD N
+/- JJ N
24 CD N
W NNP N
( ( N
80 CD N
% NN N
of IN N
peak NN N
aerobic JJ N
power NN N
measured VBN N
during IN N
a DT N
preliminary JJ N
incremental NN N
exercise NN N
test NN N
) ) N
in IN N
ten JJ 1_p
fit JJ 1_p
male NN 1_p
human JJ 1_p
subjects NNS 1_p
. . 1_p

Perceived NNP 1_o
exertion NN 1_o
during IN N
exhaustive JJ 1_i
cycling NN 1_i
exercise NN 1_i
was VBD N
strongly RB N
correlated VBN N
( ( N
r JJ N
= NNP N
-0.82 NNP N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
with IN N
time NN 1_o
to TO 1_o
exhaustion NN 1_o
( ( N
10.5 CD N
+/- JJ N
2.1 CD N
min NN N
) ) N
. . N

These DT N
results NNS N
challenge VBP N
the DT N
long-standing JJ N
assumption NN N
that IN N
muscle NN N
fatigue NN N
causes VBZ N
exhaustion NN N
during IN N
high-intensity NN N
aerobic JJ N
exercise NN N
, , N
and CC N
suggest VBP N
that IN N
exercise NN N
tolerance NN N
in IN N
highly RB N
motivated JJ N
subjects NNS N
is VBZ N
ultimately RB N
limited VBN N
by IN N
perception NN N
of IN N
effort NN N
. . N

-DOCSTART- -X- O O

Folate NNP N
and CC N
arsenic JJ N
metabolism NN N
: : N
a DT N
double-blind NN N
, , N
placebo-controlled JJ 1_i
folic JJ 1_i
acid-supplementation NN 1_i
trial NN 1_p
in IN 1_p
Bangladesh NNP 1_p
. . 1_p

BACKGROUND NNP N
Populations NNPS 1_p
in IN 1_p
South NNP 1_p
and CC 1_p
East NNP 1_p
Asia NNP 1_p
and CC 1_p
many JJ 1_p
other JJ 1_p
regions NNS 1_p
of IN 1_p
the DT 1_p
world NN 1_p
are VBP 1_p
chronically RB 1_p
exposed VBN 1_p
to TO 1_p
arsenic-contaminated JJ 1_p
drinking NN 1_p
water NN 1_p
. . 1_p

To TO N
various JJ N
degrees NNS N
, , N
ingested VBN N
inorganic JJ N
arsenic NN N
( ( N
InAs NNP N
) ) N
is VBZ N
methylated VBN N
to TO N
monomethylarsonic JJ N
acid NN N
( ( N
MMA NNP N
) ) N
and CC N
dimethylarsinic JJ N
acid NN N
( ( N
DMA NNP N
) ) N
via IN N
folate-dependent JJ N
one-carbon JJ N
metabolism NN N
; : N
impaired JJ N
methylation NN N
is VBZ N
associated VBN N
with IN N
adverse JJ N
health NN N
outcomes NNS N
. . N

Consequently RB N
, , N
folate JJ N
nutritional JJ N
status NN N
may MD N
influence VB N
arsenic JJ 1_o
methylation NN 1_o
and CC N
toxicity NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
folic JJ 1_i
acid DT 1_i
supplementation NN 1_i
of IN N
arsenic-exposed JJ 1_p
adults NNS 1_p
would MD N
increase VB N
arsenic JJ N
methylation NN N
. . N

DESIGN NNP N
Two CD 1_p
hundred VBD 1_p
adults NNS 1_p
in IN 1_p
a DT 1_p
rural JJ 1_p
region NN 1_p
of IN 1_p
Bangladesh NNP 1_p
, , 1_p
previously RB 1_p
found VBN 1_p
to TO 1_p
have VB 1_p
low JJ 1_p
plasma JJ 1_p
concentrations NNS 1_p
of IN 1_p
folate NN 1_p
( ( 1_p
< JJ 1_p
/=9 NNP 1_p
nmol/L NN 1_p
) ) 1_p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
folic JJ 1_i
acid-supplementation NN 1_i
trial NN N
. . N

Plasma NNP 1_o
concentrations NNS 1_o
of IN 1_o
folate NN 1_o
and CC 1_o
homocysteine NN 1_o
and CC 1_o
urinary JJ 1_o
concentrations NNS 1_o
of IN 1_o
arsenic JJ 1_o
metabolites NNS 1_o
were VBD N
analyzed VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
wk NN N
of IN N
supplementation NN 1_i
with IN 1_i
folic JJ 1_i
acid NN 1_i
at IN N
a DT N
dose NN N
of IN N
400 CD N
microg/d NN N
or CC 1_i
placebo NN 1_i
. . 1_i

RESULTS VB N
The DT N
increase NN N
in IN N
the DT N
proportion NN 1_o
of IN 1_o
total JJ 1_o
urinary JJ 1_o
arsenic NN 1_o
excreted VBD N
as IN N
DMA NNP N
in IN N
the DT N
folic JJ N
acid NN N
group NN N
( ( N
72 CD N
% NN N
before IN N
and CC N
79 CD N
% NN N
after IN N
supplementation NN N
) ) N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN 1_i
group NN N
, , N
as IN N
was VBD N
the DT N
reduction NN N
in IN N
the DT N
proportions NNS N
of IN N
total JJ 1_o
urinary JJ 1_o
arsenic NN 1_o
excreted VBD 1_o
as IN N
MMA NNP N
( ( N
13 CD N
% NN N
and CC N
10 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
as IN N
InAs NNP N
( ( N
15 CD N
% NN N
and CC N
11 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
folic JJ 1_i
acid JJ 1_i
supplementation NN N
to TO N
participants NNS 1_p
with IN 1_p
low JJ 1_p
plasma NN 1_p
folate NN 1_p
enhances NNS N
arsenic JJ N
methylation NN N
. . N

Because IN N
persons NNS N
whose WP$ N
urine JJ N
contains NNS N
low JJ N
proportions NNS N
of IN N
DMA NNP N
and CC N
high JJ N
proportions NNS N
of IN N
MMA NNP N
and CC N
InAs NNP N
have VBP N
been VBN N
reported VBN N
to TO N
be VB N
at IN N
greater JJR N
risk NN N
of IN N
skin NN N
and CC N
bladder NN N
cancers NNS N
and CC N
peripheral JJ N
vascular JJ N
disease NN N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
folic JJ 1_i
acid DT 1_i
supplementation NN N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
arsenic-related JJ N
health NN N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Total JJ 1_i
parenteral JJ 1_i
nutrition NN 1_i
with IN 1_i
glutamine JJ 1_i
dipeptide NN 1_i
shortened VBD N
hospital JJ 1_o
stays NNS 1_o
and CC N
improved VBN N
immune JJ 1_o
status NN 1_o
and CC 1_o
nitrogen NN 1_o
economy NN 1_o
after IN 1_p
major JJ 1_p
abdominal JJ 1_p
surgery NN 1_p
. . 1_p

-DOCSTART- -X- O O

Effects NNS 1_o
of IN N
three CD N
oral JJ N
analgesics NNS 1_i
on IN N
postoperative JJ N
pain NN N
following VBG N
root JJ N
canal JJ N
preparation NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
three CD N
oral JJ N
medications NNS N
on IN N
postoperative JJ N
pain NN 1_o
following VBG N
instrumentation NN N
of IN N
root NN N
canals NNS N
in IN N
teeth NN N
with IN N
irreversible JJ N
pulpitis NN N
. . N

METHODOLOGY NNP N
In IN N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
, , N
100 CD 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
anterior CC 1_p
or CC 1_p
premolar JJ 1_p
teeth NNS 1_p
with IN 1_p
irreversible JJ 1_p
pulpitis NN 1_p
without IN 1_p
any DT 1_p
signs NNS 1_p
and CC 1_p
symptoms NNS 1_p
of IN 1_p
acute NN 1_p
or CC 1_p
chronic JJ 1_p
apical JJ 1_p
periodontitis NN 1_p
and CC 1_p
moderate VB 1_p
to TO 1_p
severe VB 1_p
pain NN 1_p
were VBD N
divided VBN N
by IN N
balanced JJ N
block NN N
random NN N
allocation NN N
into IN N
four CD N
groups NNS N
of IN N
25 CD N
each DT N
, , N
a DT N
control NN 1_i
group NN 1_i
receiving VBG 1_i
a DT 1_i
placebo NN 1_i
medication NN 1_i
, , 1_i
and CC 1_i
three CD 1_i
experimental JJ 1_i
groups NNS 1_i
receiving VBG 1_i
a DT 1_i
single JJ 1_i
dose NN 1_i
of IN 1_i
either DT 1_i
Tramadol NNP 1_i
( ( 1_i
100 CD 1_i
mg NN 1_i
) ) 1_i
, , 1_i
Novafen NNP 1_i
( ( 1_i
325 CD 1_i
mg NN 1_i
of IN 1_i
paracetamol NN 1_i
, , 1_i
200 CD 1_i
mg NN 1_i
ibuprofen NN 1_i
and CC 1_i
40 CD 1_i
mg NNS 1_i
caffeine VBP 1_i
anhydrous JJ 1_i
) ) 1_i
or CC 1_i
Naproxen NNP 1_i
( ( 1_i
500 CD 1_i
mg NN 1_i
) ) 1_i
immediately RB 1_i
after IN 1_i
the DT 1_i
first JJ 1_i
appointment NN 1_i
where WRB 1_i
the DT 1_i
pulp NN 1_i
was VBD 1_i
removed VBN 1_i
, , 1_i
and CC 1_i
the DT 1_i
canals NNS 1_i
were VBD 1_i
fully RB 1_i
prepared VBN 1_i
. . 1_i

The DT 1_o
intensity NN 1_o
of IN 1_o
pain NN 1_o
was VBD 1_o
scored VBN 1_o
based VBN 1_o
on IN 1_o
10-point JJ 1_o
VAS NNP 1_o
before IN 1_o
and CC 1_o
after IN 1_o
treatment NN 1_o
for IN 1_o
up IN 1_o
to TO 1_o
24 CD 1_o
h NN 1_o
postoperatively RB 1_o
. . 1_o

Data NNS 1_o
were VBD 1_o
submitted VBN 1_o
to TO 1_o
repeated VBN 1_o
analysis NN 1_o
of IN 1_o
variance NN 1_o
. . N

RESULTS NNP N
At IN N
the DT N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NNS N
postoperative JJ N
intervals NNS N
after IN N
drug NN N
administration NN N
, , 1_o
the DT 1_o
intensity NN 1_o
of IN 1_o
pain NN 1_o
was VBD 1_o
significantly RB 1_o
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT 1_i
placebo NN 1_i
group NN 1_i
( ( N
P NNP N
< NNP N
0.01 CD 1_i
) ) 1_i
. . 1_i

Tramadol NNP 1_i
was VBD 1_i
significantly RB 1_i
less RBR N
effective JJ N
( ( N
P NNP N
< NNP N
0.05 CD 1_i
) ) 1_i
than IN 1_i
Naproxen NNP 1_i
, , 1_i
and CC 1_i
Novafen NNP 1_i
that WDT N
were VBD N
similar JJ N
to TO N
each DT N
other JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN 1_i
of IN 1_i
Naproxen NNP 1_i
, , 1_i
Novafen NNP 1_i
and CC 1_i
Tramadol NNP 1_i
taken VBN 1_i
immediately RB N
after IN N
treatment NN N
reduced VBD N
postoperative JJ N
pain NN N
following VBG N
pulpectomy NN N
and CC N
root JJ N
canal JJ N
preparation NN N
of IN N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
. . N

-DOCSTART- -X- O O

Fibrin NNP 1_i
application NN 1_i
for IN N
preventing VBG N
lymphocysts NNS N
after IN N
retroperitoneal JJ N
lymphadenectomy NN N
in IN N
patients NNS 1_p
with IN 1_p
gynecologic JJ 1_p
malignancies NNS 1_p
. . 1_p

OBJECTIVE IN N
We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
prospective JJ N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
fibrin JJ 1_i
glue NN 1_i
on IN N
the DT N
incidence NN N
of IN N
lymphocysts NNS N
after IN N
systematic JJ N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
in IN N
patients NNS 1_p
with IN 1_p
gynecologic JJ 1_p
malignancies NNS 1_p
. . 1_p

METHODS NNP N
Ninety-three JJ 1_p
consecutive JJ 1_p
patients NNS 1_p
with IN 1_p
gynecologic JJ 1_p
pelvic JJ 1_p
malignancies NNS 1_p
who WP 1_p
underwent VBP 1_p
surgery NN 1_p
including VBG 1_p
pelvic NN 1_p
or CC 1_p
pelvic NN 1_p
and CC 1_p
paraaortic JJ 1_p
lymphadenectomy NN 1_p
were VBD N
randomized VBN N
during IN N
surgery NN N
to TO N
be VB N
treated VBN 1_i
with IN 1_i
fibrin JJ 1_i
glue NN 1_i
or CC 1_i
not RB 1_i
. . 1_i

Serial JJ 1_i
computed JJ 1_i
tomography NN 1_i
( ( 1_i
CT NNP 1_i
) ) 1_i
scans NNS 1_i
were VBD N
performed VBN N
during IN N
follow-up JJ N
. . N

CT NNP N
findings NNS N
of IN N
a DT N
smooth JJ N
and CC N
thin-walled JJ N
cavity NN N
filled VBN N
with IN N
a DT N
water-equivalent JJ N
fluid NN N
, , N
sharply RB N
demarcated VBN N
from IN N
its PRP$ N
surroundings NNS N
and CC N
without IN N
signs NNS N
of IN N
infiltration NN N
were VBD N
interpreted VBN N
as IN N
lymphocysts NNS 1_o
. . 1_o

RESULTS NNP N
Forty-seven JJ N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
were VBD N
treated VBN N
with IN N
fibrin JJ 1_i
glue NN 1_i
and CC N
46 CD N
( ( N
49 CD N
% NN N
) ) N
were VBD N
not RB N
. . N

All DT N
93 CD 1_p
patients NNS 1_p
underwent JJ N
pelvic JJ N
lymphadenectomy NN N
; : N
15 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
of IN N
the DT N
fibrin NN N
group NN N
and CC N
12 CD N
( ( N
26 CD N
% NN N
) ) N
of IN N
the DT N
controls NNS N
also RB N
underwent JJ N
paraaortic JJ N
lymphadenectomy NN N
. . N

We PRP N
found VBD N
no DT 1_o
significant JJ 1_o
differences NNS 1_o
between IN N
patients NNS N
who WP N
received VBD N
fibrin JJ 1_o
glue NN 1_o
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

CONCLUSION NNP N
Intraoperative NNP N
application NN N
of IN N
fibrin JJ N
glue NN N
did VBD 1_o
not RB 1_o
reduce VB 1_o
the DT 1_o
rate NN 1_o
of IN 1_o
postoperative JJ 1_o
lymphocysts NNS 1_o
after IN N
lymphadenectomy NN N
and CC N
had VBD N
no DT 1_o
impact NN 1_o
on IN N
any DT N
follow-up JJ 1_o
parameter NN 1_o
. . 1_o

Its PRP$ N
use NN N
seems VBZ N
not RB N
to TO N
be VB N
indicated VBN N
in IN N
systematic JJ N
gynecologic NN N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
. . N

-DOCSTART- -X- O O

Competitive JJ N
employment NN N
for IN N
youth NN 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
early JJ N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

For IN N
most JJS N
youth NN 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
, , N
employment NN N
upon IN N
graduation NN N
from IN N
high JJ N
school NN N
or CC N
college NN N
is VBZ N
elusive JJ N
. . N

Employment JJ N
rates NNS N
are VBP N
reported VBN N
in IN N
many JJ N
studies NNS N
to TO N
be VB N
very RB N
low JJ N
despite IN N
many JJ N
years NNS N
of IN N
intensive JJ N
special JJ N
education NN N
services NNS N
. . N

This DT N
paper NN N
presented VBD N
the DT N
preliminary JJ N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
Project NNP 1_i
SEARCH NNP 1_i
plus CC 1_i
ASD NNP 1_i
Supports NNP 1_i
on IN N
the DT N
employment NN N
outcomes NNS N
for IN N
youth NN 1_p
with IN 1_p
ASD NNP 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
18-21 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

This DT 1_o
model NN 1_o
provides VBZ 1_o
very RB 1_o
promising JJ 1_o
results NNS 1_o
in IN 1_o
that DT 1_o
the DT 1_o
employment NN 1_o
outcomes NNS 1_o
for IN 1_o
youth NN 1_o
in IN 1_o
the DT 1_o
treatment NN 1_o
group NN 1_o
were VBD 1_o
much RB 1_o
higher JJR 1_o
in IN 1_o
non-traditional JJ 1_o
jobs NNS 1_o
with IN 1_o
higher JJR 1_o
than IN 1_o
minimum JJ 1_o
wage NN 1_o
incomes NNS 1_o
than IN 1_o
for IN 1_o
youth NN 1_o
in IN 1_o
the DT 1_o
control NN 1_o
condition NN 1_o
. . 1_o

Specifically RB 1_o
, , 1_o
21 CD 1_o
out IN 1_o
of IN 1_o
24 CD 1_o
( ( 1_o
87.5 CD 1_o
% NN 1_o
) ) 1_o
treatment NN 1_o
group NN 1_o
participants NNS 1_o
acquired VBD 1_o
employment NN 1_o
while IN 1_o
1 CD 1_o
of IN 1_o
16 CD 1_o
( ( 1_o
6.25 CD 1_o
% NN 1_o
) ) 1_o
of IN 1_o
control NN 1_o
group NN 1_o
participants NNS 1_o
acquired VBD 1_o
employment NN 1_o
. . 1_o

-DOCSTART- -X- O O

Delineation NN N
of IN N
cryptogenic JJ N
Lennox-Gastaut NNP N
syndrome NN N
and CC N
myoclonic JJ N
astatic JJ N
epilepsy NN N
using VBG N
multiple JJ 1_i
correspondence NN 1_i
analysis NN 1_i
. . 1_i

PURPOSE NNP N
To TO N
distinguish VB N
various JJ N
types NNS N
of IN N
childhood NN 1_p
severe JJ 1_p
cryptogenic/idiopathic NN 1_p
generalised VBD 1_p
epilepsy NN 1_p
on IN N
the DT N
basis NN N
of IN N
reproducible JJ N
diagnostic JJ N
criteria NNS N
, , N
using VBG N
multiple JJ 1_i
correspondence NN 1_i
analysis NN 1_i
( ( 1_i
MCA NNP 1_i
) ) 1_i
. . 1_i

METHODS NNP N
We PRP N
applied VBD N
MCA NNP N
to TO N
a DT N
series NN N
of IN N
72 CD 1_p
children NNS 1_p
with IN 1_p
no DT 1_p
evidence NN 1_p
of IN 1_p
brain NN 1_p
damage NN 1_p
, , 1_p
starting VBG 1_p
epilepsy NN 1_p
between IN 1_p
1 CD 1_p
and CC 1_p
10 CD 1_p
years NNS 1_p
, , 1_p
with IN 1_p
two CD 1_p
or CC 1_p
more JJR 1_p
types NNS 1_p
of IN 1_p
generalised JJ 1_p
seizures NNS 1_p
. . 1_p

We PRP N
excluded VBD 1_p
patients NNS 1_p
with IN 1_p
infantile JJ 1_p
spasms NNS 1_p
or CC 1_p
typical JJ 1_p
absences NNS 1_p
. . 1_p

MCA NNP 1_i
was VBD N
performed VBN N
on IN N
all DT N
clinical JJ N
and CC N
EEG NNP N
parameters NNS N
, , N
first RB N
throughout IN N
follow-up NN N
, , N
then RB N
restricted VBD N
to TO N
the DT N
first JJ N
year NN N
of IN N
the DT N
disease NN N
. . N

RESULTS VB N
When WRB N
including VBG N
all DT N
follow-up JJ N
variables NNS N
, , N
there EX N
were VBD N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
Thirty-seven CD N
children NNS N
with IN N
male JJ N
predominance NN N
, , N
familial JJ N
history NN N
of IN N
epilepsy NN N
, , N
simple JJ N
febrile JJ N
convulsions NNS N
, , N
massive JJ N
myoclonus NN N
, , N
tonic-clonic JJ N
fits NNS N
. . N

Outcome NNP N
was VBD N
favourable JJ N
, , N
with IN N
no DT 1_o
seizures NNS 1_o
and CC 1_o
mildly RB 1_o
affected VBD 1_o
cognitive JJ 1_o
functions NNS 1_o
. . 1_o

Interictal NNP N
EEG NNP 1_i
showed VBD N
short JJ 1_o
sequences NNS 1_o
of IN 1_o
irregular JJ 1_o
3-Hz JJ 1_o
spike-waves NNS 1_o
. . 1_o

( ( N
2 CD N
) ) N
In IN N
18 CD N
children NNS N
, , N
clinical JJ 1_o
characteristics NNS 1_o
were VBD N
similar JJ N
to TO N
those DT N
of IN N
the DT N
first JJ N
group NN N
at IN N
the DT N
early JJ N
stage NN N
, , N
but CC N
95 CD N
% NN N
exhibited VBD N
myoclonic JJ 1_o
status NN 1_o
and CC 1_o
vibratory NN 1_o
tonic JJ 1_o
seizures NNS 1_o
, , 1_o
with IN 1_o
persisting VBG 1_o
seizures NNS 1_o
on IN N
follow-up NN N
. . N

EEG NNP N
showed VBD N
long JJ 1_o
sequences NNS 1_o
of IN 1_o
generalised JJ 1_o
irregular JJ 1_o
spike NN 1_o
and CC 1_o
slow JJ 1_o
waves NNS 1_o
. . 1_o

Those DT N
two CD N
groups NNS N
meet VBD N
the DT N
characteristics NNS N
of IN N
childhood NN N
onset VBN N
myoclonic-astatic JJ N
epilepsy NN N
( ( N
MAE NNP N
) ) N
with IN N
respectively RB N
, , N
favourable JJ N
and CC N
unfavourable JJ N
outcome NN N
. . N

( ( N
3 CD N
) ) N
Eleven NNP N
children NNS N
had VBD N
later RBR N
onset VBN N
, , N
atypical JJ 1_o
absences NNS 1_o
, , 1_o
tonic JJ 1_o
and CC 1_o
partial JJ 1_o
seizures NNS 1_o
, , N
and CC N
no DT N
myoclonus NN N
, , N
or CC N
vibratory NN N
tonic JJ N
seizures NNS N
. . N

All DT N
had VBD N
mental JJ 1_o
retardation NN 1_o
and CC 1_o
persisting NN 1_o
seizures NNS 1_o
. . 1_o

EEG NNP N
showed VBD N
long JJ 1_o
sequences NNS 1_o
of IN 1_o
slow JJ 1_o
spike-wave JJ 1_o
activity NN 1_o
and CC 1_o
half PDT 1_o
the DT 1_o
patients NNS 1_o
had VBD 1_o
spike VBN 1_o
and CC 1_o
slow JJ 1_o
wave NN 1_o
foci NN 1_o
. . 1_o

These DT N
patients NNS N
met VBD N
the DT N
major JJ N
characteristics NNS N
of IN N
Lennox-Gastaut NNP N
syndrome NN N
. . N

Initial JJ N
parameters NNS N
failed VBD N
to TO N
distinguish VB N
the DT N
first JJ N
two CD N
groups NNS N
, , N
but CC N
Lennox-Gastaut NNP N
syndrome NN N
( ( N
the DT N
third JJ N
group NN N
) ) N
was VBD N
distinct VBN N
from IN N
both DT N
groups NNS N
of IN N
myoclonic JJ N
astatic JJ N
epilepsy NN N
from IN N
the DT N
onset NN N
. . N

Within IN N
MAE NNP N
groups NNS N
combined VBD N
, , N
clinical JJ N
and CC N
EEG NNP N
risk NN N
factors NNS N
for IN N
mental JJ N
retardation NN N
could MD N
be VB N
identified VBN N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
possible JJ N
to TO N
validate VB N
statistically RB N
the DT N
distinction NN N
between IN N
discrete JJ N
epileptic JJ N
syndromes NNS N
. . N

Myoclonic NNP N
astatic JJ N
epilepsy NN N
is VBZ N
therefore RB N
distinct JJ N
from IN N
Lennox-Gastaut NNP N
syndrome NN N
, , N
and CC N
the DT N
distinction NN N
appears VBZ N
from IN N
the DT N
first JJ N
year NN N
of IN N
the DT N
disorder NN N
. . N

-DOCSTART- -X- O O

Low JJ 1_i
intensity NN 1_i
physical JJ 1_i
training NN 1_i
in IN N
older JJR 1_p
subjects NNS 1_p
. . 1_p

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
low JJ 1_i
intensity NN 1_i
general JJ 1_i
training NN 1_i
program NN 1_i
( ( N
< JJ N
50 CD N
% NN N
of IN N
heart NN N
rate NN N
reserve NN N
) ) N
on IN N
physical JJ N
fitness NN N
of IN N
healthy JJ 1_p
older JJR 1_p
subjects NNS 1_p
, , N
by IN N
comparing VBG N
maximal JJ N
and CC N
submaximal JJ N
indices NNS N
of IN N
training NN N
response NN N
. . N

METHODS NNP N
Twenty-two JJ 1_p
volunteers NNS 1_p
over IN 1_p
60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
participated VBN N
in IN N
the DT N
present JJ N
study NN N
. . N

The DT N
sample NN N
was VBD N
randomly RB N
divided VBN N
in IN N
an DT 1_p
experimental JJ 1_p
group NN 1_p
of IN 1_p
13 CD 1_p
older JJR 1_p
subjects NNS 1_p
( ( 1_p
3 CD 1_p
men NNS 1_p
and CC 1_p
10 CD 1_p
women NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
63.5 CD 1_p
+/- JJ 1_p
3 CD 1_p
years NNS 1_p
) ) 1_p
while IN 1_p
the DT 1_p
remaining VBG 1_p
9 CD 1_p
subjects NNS 1_p
( ( 1_p
3 CD 1_p
men NNS 1_p
and CC 1_p
6 CD 1_p
women NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
64.2 CD 1_p
+/- JJ 1_p
4 CD 1_p
years NNS 1_p
) ) 1_p
served VBD 1_p
as IN 1_p
inactive JJ 1_i
control NN 1_i
group NN 1_i
. . 1_i

After IN N
medical JJ N
screening VBG N
all DT N
participants NNS N
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
12 CD N
weeks NNS N
in IN N
which WDT N
the DT N
experimental JJ N
subjects NNS N
underwent VBD N
a DT N
low JJ 1_i
intensity NN 1_i
training NN 1_i
. . 1_i

Each DT N
subjects-either JJ N
inactive JJ N
or CC N
active-performed JJ N
two CD 1_i
treadmill NN 1_i
tests NNS 1_i
at IN N
two-days JJ N
interval NN N
, , N
to TO N
measure VB N
maximal JJ N
and CC N
submaximal JJ N
responses NNS N
to TO N
exercise VB N
, , N
respectively RB N
. . N

Heart NNP N
rate NN N
( ( N
HR NNP N
) ) N
, , N
oxygen JJ 1_o
uptake NN 1_o
( ( 1_o
VO2 NNP 1_o
) ) 1_o
and CC N
pulmonary JJ 1_o
ventilation NN 1_o
( ( 1_o
VE NNP 1_o
) ) 1_o
were VBD N
measured VBN N
using VBG N
a DT N
telemetric JJ N
apparatus NN N
. . N

RESULTS VB N
The DT N
major JJ N
finding NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
significant JJ N
improvement NN N
in IN N
submaximal JJ 1_o
response NN 1_o
to TO 1_o
exercise NN 1_o
of IN 1_o
experimental JJ 1_o
subjects NNS 1_o
, , N
expressed VBN N
by IN N
the DT N
reduction NN N
in IN N
HR NNP 1_o
, , 1_o
VO2 NNP 1_o
VE NNP 1_o
while IN 1_o
VO2 NNP 1_o
max NN 1_o
did VBD N
not RB N
change NN N
. . N

CONCLUSIONS NNP N
Thus NNP N
, , N
it PRP N
appears VBZ N
that IN N
a DT N
low JJ N
intensity NN N
general JJ N
training NN N
similar JJ N
to TO N
that DT N
followed VBN N
in IN N
the DT N
present JJ N
study NN N
may MD N
represent VB N
a DT N
good JJ N
means NN N
to TO N
improve VB N
physical JJ 1_o
fitness NN 1_o
in IN N
healthy JJ 1_p
elderly JJ 1_p
people NNS 1_p
. . 1_p

Similarly RB N
, , N
this DT N
study NN N
supports VBZ N
the DT N
effectiveness NN N
of IN N
evaluation NN N
tests NNS N
based VBN N
on IN N
submaximal JJ 1_o
responses NNS 1_o
to TO N
exercise VB N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Ultrasonography-guided JJ 1_i
bilateral JJ 1_i
rectus NN 1_i
sheath NN 1_i
block NN 1_i
vs NN 1_i
local JJ 1_i
anesthetic JJ 1_i
infiltration NN 1_i
after IN N
pediatric JJ N
umbilical JJ N
hernia NN N
repair NN N
: : N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Regional NNP 1_i
anesthetic JJ 1_i
techniques NNS 1_i
can MD N
be VB N
used VBN N
to TO N
alleviate VB N
postoperative JJ N
pain NN N
in IN N
children NNS N
undergoing VBG N
pediatric JJ N
surgical JJ N
procedures NNS N
. . N

Use NNP N
of IN N
ultrasonographic JJ N
guidance NN N
for IN N
bilateral JJ N
rectus NN N
sheath NN N
block NN N
( ( N
BRSB NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
immediate JJ N
pain NN N
scores NNS N
and CC N
reduce VB N
use NN N
of IN N
postoperative JJ N
analgesia NN N
in IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
( ( N
PACU NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
efficacy NN N
of IN N
ultrasonography-guided JJ N
BRSB NNP N
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
( ( N
LAI NNP N
) ) N
in IN N
providing VBG N
postoperative JJ N
analgesia NN N
after IN 1_p
pediatric JJ 1_p
umbilical JJ 1_p
hernia NN 1_p
repair NN 1_p
. . 1_p

DESIGN NNP N
Prospective NNP N
, , N
observer-blinded JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

SETTING CC N
Tertiary-referral JJ 1_p
urban JJ 1_p
children NNS 1_p
's POS 1_p
hospital NN 1_p
. . 1_p

PARTICIPANTS NNP N
Eligible JJ 1_p
children NNS 1_p
3 CD 1_p
to TO 1_p
12 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
undergoing JJ 1_p
elective JJ 1_p
umbilical JJ 1_p
hernia NN 1_p
repair NN 1_p
from IN 1_p
November NNP 1_p
16 CD 1_p
, , 1_p
2009 CD 1_p
, , 1_p
through IN 1_p
May NNP 1_p
31 CD 1_p
, , 1_p
2011 CD 1_p
. . 1_p

INTERVENTIONS NNP N
Ropivacaine NNP 1_i
hydrochloride NN 1_i
administered VBD 1_i
at IN 1_i
the DT 1_i
conclusion NN 1_i
of IN 1_i
surgery NN 1_i
as IN 1_i
LAI NNP 1_i
by IN 1_i
the DT 1_i
surgeon NN 1_i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
as IN 1_i
ultrasonography-guided JJ 1_i
BRSB NNP 1_i
by IN 1_i
the DT 1_i
anesthesiologist NN 1_i
( ( 1_i
n JJ 1_i
= NNP N
27 CD N
) ) N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Scores NNP 1_o
on IN 1_o
the DT 1_o
FACES NNP 1_o
Pain NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
measured VBD 1_o
at IN 1_o
10-minute JJ 1_o
intervals NNS 1_o
and CC 1_o
all DT 1_o
use NN 1_o
of IN 1_o
analgesic JJ 1_o
medications NNS 1_o
in IN 1_o
the DT 1_o
PACU NNP 1_o
. . 1_o

RESULTS NNP 1_o
Median JJ 1_o
FACES NNP 1_o
scores NNS 1_o
in IN N
the DT N
PACU NNP N
were VBD N
lower JJR N
in IN N
the DT N
BRSB NNP N
group NN N
compared VBN N
with IN N
the DT N
LAI NNP N
group NN N
at IN N
10 CD N
minutes NNS N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
, , N
30 CD N
minutes NNS N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
and CC N
40 CD N
minutes NNS N
or CC N
later RB N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Fewer JJR N
doses NNS 1_o
of IN 1_o
opioid NN 1_o
and CC 1_o
nonopioid JJ 1_o
medications NNS 1_o
were VBD 1_o
given VBN 1_o
to TO N
the DT N
BRSB NNP N
group NN N
compared VBN N
with IN N
the DT N
LAI NNP N
group NN N
( ( N
5 CD N
vs RB N
11 CD N
doses NNS N
for IN N
opioids NNS N
; : N
5 CD N
vs NN N
10 CD N
for IN N
nonopioids NNS N
) ) N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
In IN N
the DT N
PACU NNP N
, , N
ultrasonography-guided JJ N
BRSB NNP N
after IN N
umbilical JJ N
hernia NN N
repair NN N
in IN N
children NNS N
is VBZ N
associated VBN N
with IN N
lower JJR N
median JJ N
FACES NNP N
scores NNS N
and CC N
decreased VBN N
use NN N
of IN N
opioid NN N
and CC N
nonopioid JJ N
medications NNS N
compared VBN N
with IN N
LAI NNP N
. . N

Future NNP N
studies NNS N
could MD N
examine VB N
the DT N
use NN N
of IN N
longer-acting JJ N
anesthetic JJ N
agents NNS N
with IN N
ultrasonography-guided JJ N
BRSB NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01015053 NN N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
, , N
placebo-controlled JJ 1_i
, , N
dose-ranging JJ N
study NN N
of IN N
new JJ N
recombinant JJ 1_i
hypoallergenic JJ 1_i
Bet NNP 1_i
v NN 1_i
1 CD 1_i
in IN N
an DT N
environmental JJ N
exposure NN N
chamber NN N
. . N

BACKGROUND NNP N
Recombinant NNP N
allergens VBZ N
offer VBP N
a DT N
tool NN N
for IN N
improving VBG N
specific JJ N
immunotherapy NN N
( ( N
SIT NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
find VB N
the DT N
optimal JJ N
dose NN N
of IN N
a DT N
new JJ N
hypoallergenic JJ N
folding NN N
variant NN N
of IN N
recombinant JJ 1_i
Bet NNP 1_i
v NN 1_i
1 CD 1_i
( ( 1_i
rBet JJ 1_i
v IN 1_i
1-FV JJ 1_i
) ) 1_i
as IN N
SIT NNP N
for IN N
patients NNS 1_p
with IN 1_p
birch NN 1_p
pollen NN 1_p
allergy NN 1_p
. . 1_p

METHODS NNP N
Before IN N
SIT NNP N
, , N
thirty-seven JJ 1_p
adult NN 1_p
patients NNS 1_p
were VBD 1_p
exposed VBN 1_p
for IN 1_p
eight CD 1_p
hours NNS 1_p
in IN 1_p
an DT 1_p
environmental JJ 1_i
exposure NN 1_i
chamber NN 1_i
( ( 1_p
EEC NNP 1_p
) ) 1_p
to TO 1_p
birch VB 1_p
pollen NN 1_p
at IN 1_p
an DT 1_p
average JJ 1_p
concentration NN 1_p
of IN 1_p
3500 CD 1_p
? . 1_p
500 CD 1_p
grains/m NN 1_p
( ( 1_p
3 CD 1_p
) ) 1_p
, , N
then RB N
randomized VBD N
to TO N
four CD N
maintenance NN N
dose NN N
groups NNS N
of IN 1_i
rBet JJ 1_i
v JJ 1_i
1-FV JJ 1_i
and CC N
one CD 1_i
placebo NN 1_i
group NN N
: : N
20 CD N
?g NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
80 CD N
?g NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
, , N
160 CD N
?g NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
320 CD N
?g NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
, , N
and CC N
placebo NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
7 CD N
) ) N
. . N

Patients NNS N
were VBD N
treated VBN N
for IN N
10 CD N
weeks NNS N
with IN N
weekly JJ N
injections NNS N
and CC N
then RB N
re-exposed JJ N
in IN N
the DT N
EEC NNP N
. . N

The DT N
optimal JJ N
dose NN N
for IN N
SIT NNP N
was VBD N
assessed VBN N
using VBG N
efficacy NN 1_o
results NNS 1_o
from IN 1_o
the DT 1_o
EEC NNP 1_o
, , 1_o
IgG NNP 1_o
responses VBZ 1_o
, , 1_o
and CC 1_o
tolerability NN 1_o
. . 1_o

RESULTS NNP 1_o
Thirty-six JJ 1_p
patients NNS 1_p
were VBD 1_p
evaluable JJ N
for IN N
efficacy NN N
assessment NN N
. . N

The DT N
total JJ 1_o
symptom NN 1_o
score NN 1_o
significantly RB 1_o
decreased VBN N
in IN N
all DT N
active JJ N
groups NNS N
compared VBN N
with IN N
placebo NN 1_i
( ( 1_i
-18.8 CD 1_i
% NN N
for IN N
placebo NN N
patients NNS N
; : N
-71.9 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0022 CD N
for IN N
20 CD N
?g NN N
; : N
-75.6 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0007 CD N
for IN N
80 CD N
?g NN N
; : N
-81.8 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0009 CD N
for IN N
160 CD N
?g NN N
; : N
-78.3 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0003 CD N
for IN N
320 CD N
?g NN N
) ) N
. . N

IgG1 NNP 1_o
increased VBD 1_o
significantly RB N
in IN N
all DT N
active JJ N
groups NNS N
compared VBN N
to TO N
placebo VB N
. . N

All DT N
four CD N
active JJ N
doses NNS N
were VBD N
well RB N
tolerated VBN 1_o
, , 1_o
no DT 1_o
serious JJ 1_o
adverse JJ 1_o
event NN 1_o
occurred VBD 1_o
; : N
two CD 1_o
Grade NNP 1_o
II NNP 1_o
reactions NNS 1_o
, , 1_o
according VBG 1_o
to TO N
EAACI NNP N
classification NN N
, , N
were VBD N
observed VBN N
, , N
one CD N
in IN N
each DT N
of IN N
the DT N
160- JJ N
and CC N
320-?g JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Considering NNP N
efficacy NN N
, , N
immunological JJ N
response NN N
, , N
and CC N
tolerability NN N
, , N
a DT N
maintenance NN N
dose NN N
of IN N
80 CD N
?g NN N
of IN 1_i
rBet JJ 1_i
v JJ 1_i
1-FV JJ 1_i
appears VBZ 1_i
to TO N
be VB N
the DT N
ideal NN N
dose NN N
for IN N
allergen NN N
immunotherapy NN 1_p
in IN 1_p
birch NN 1_p
pollen NN 1_p
allergic JJ 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Evaluation NN N
of IN N
a DT N
preventive JJ 1_i
intervention NN 1_i
for IN N
child JJ 1_p
anxiety NN 1_p
in IN N
two CD N
randomized JJ N
attention-control JJ N
school NN N
trials NNS N
. . N

The DT N
present JJ N
research NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive-behavioral JJ 1_o
therapy NN 1_o
( ( 1_i
CBT NNP 1_i
) ) 1_i
based VBN 1_i
intervention NN 1_i
program NN 1_i
, , 1_i
FRIENDS NNP 1_i
, , N
for IN 1_p
children NNS 1_p
from IN 1_p
grades NNS 1_p
4 CD 1_p
to TO 1_p
6 CD 1_p
, , 1_p
using VBG 1_p
random JJ 1_p
assignment NN 1_p
at IN 1_p
the DT 1_p
school-level NN 1_p
and CC N
an DT N
attention-control JJ N
design NN N
in IN N
two CD N
longitudinal JJ N
studies NNS N
. . N

The DT N
first JJ N
study NN N
targeted VBD N
children NNS 1_p
with IN 1_p
anxiety NN 1_o
symptoms NNS 1_o
( ( 1_p
N=191 NNP 1_p
, , 1_p
mean JJ 1_p
age=10.1 NN 1_p
) ) 1_p
as IN 1_p
screened VBN 1_p
with IN 1_p
self NN 1_p
, , 1_p
parent NN 1_p
, , 1_p
and CC 1_p
teacher-reports NNS 1_p
; : 1_p
the DT 1_p
second JJ 1_p
study NN 1_p
took VBD 1_p
a DT 1_p
universal JJ 1_p
approach NN 1_p
with IN 1_p
full JJ 1_p
classrooms NNS 1_p
of IN 1_p
children NNS 1_p
participating VBG 1_p
( ( 1_p
N=253 NNP 1_p
, , 1_p
mean JJ 1_p
age=9.8 NN 1_p
) ) 1_p
. . 1_p

The DT N
results NNS N
showed VBD N
no DT N
intervention NN N
effect NN N
in IN N
both DT N
studies NNS N
, , N
with IN 1_o
children NNS 1_o
's POS 1_o
anxiety NN 1_o
symptoms NNS 1_o
decreasing VBG N
over IN N
time NN N
regardless NN N
of IN N
whether IN N
they PRP N
were VBD N
in IN N
the DT 1_i
story-reading NN 1_i
( ( N
attention NN N
control NN N
) ) N
or CC 1_i
FRIENDS JJ 1_i
condition NN N
. . N

The DT N
findings NNS N
also RB N
indicated VBD N
that IN N
girls NNS N
reported VBD N
a DT N
higher JJR 1_o
level NN 1_o
of IN 1_o
anxiety NN 1_o
than IN N
boys NNS N
and CC N
children NNS N
in IN N
higher JJR N
grades NNS N
reported VBD N
lower JJR 1_o
anxiety NN 1_o
relative NN N
to TO N
younger JJR N
children NNS N
in IN N
both DT N
studies NNS N
. . N

In IN N
addition NN N
, , N
similar JJ N
patterns NNS N
were VBD N
found VBN N
using VBG N
a DT N
subgroup NN N
of IN 1_p
children NNS 1_p
with IN 1_o
high-anxiety NN 1_o
symptoms NNS 1_o
from IN N
both DT N
studies NNS N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
the DT N
video NN 1_i
game NN 1_i
Mindlight NNP 1_i
on IN N
anxiety NN 1_o
symptoms NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
an DT 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorder NNP 1_p
. . 1_p

BACKGROUND NNP N
In IN N
the DT N
clinical JJ N
setting NN N
, , N
a DT N
large JJ N
proportion NN N
of IN N
children NNS 1_p
with IN 1_p
an DT 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
experience NN 1_p
anxiety NN 1_o
symptoms NNS 1_o
. . 1_o

Because IN N
anxiety NN N
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
impairment NN N
for IN N
children NNS 1_p
with IN 1_p
an DT 1_p
ASD NNP 1_p
, , N
it PRP N
is VBZ N
necessary JJ N
that IN N
effective JJ N
anxiety NN N
interventions NNS N
are VBP N
implemented VBN N
for IN N
these DT N
children NNS N
. . N

Recently RB N
, , N
a DT N
serious JJ N
game NN 1_i
called VBN 1_i
Mindlight NNP 1_i
has VBZ N
been VBN N
developed VBN N
that DT N
is VBZ N
focused VBN N
on IN N
decreasing VBG N
anxiety NN N
in IN N
children NNS N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
recent JJ N
research NN N
suggesting VBG N
that IN N
video JJ 1_i
games NNS 1_i
might MD N
be VB N
suitable JJ N
as IN N
an DT N
intervention NN N
vehicle NN N
to TO N
enhance VB N
mental JJ N
health NN N
in IN N
children NNS N
. . N

In IN N
the DT N
present JJ N
study NN N
it PRP N
will MD N
be VB N
investigated VBN N
whether IN N
Mindlight NNP 1_i
is VBZ N
effective JJ N
in IN N
decreasing VBG N
( ( N
sub NN N
) ) N
clinical JJ 1_o
anxiety NN 1_o
symptoms NNS 1_o
in IN N
children NNS 1_p
who WP 1_p
are VBP 1_p
diagnosed VBN 1_p
with IN 1_p
an DT 1_p
ASD NNP 1_p
. . 1_p

METHODS/DESIGN NNP N
The DT N
present JJ N
study NN N
involves VBZ N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
with IN N
two CD N
conditions NNS N
( ( N
experimental JJ N
versus NN N
control NN N
) ) N
, , N
in IN N
which WDT N
it PRP N
is VBZ N
investigated VBN N
whether IN N
Mindlight NNP 1_i
is VBZ N
effective JJ N
in IN N
decreasing VBG N
( ( N
sub NN N
) ) N
clinical JJ N
anxiety NN 1_o
symptoms NNS 1_o
in IN N
children NNS N
with IN N
an DT N
ASD NNP N
. . N

For IN N
this DT N
study NN N
, , N
children NNS 1_p
of IN 1_p
8-16 CD 1_p
years NNS 1_p
old JJ 1_p
with IN 1_p
a DT 1_p
diagnosis NN 1_p
of IN 1_p
an DT 1_p
ASD NNP 1_p
and CC 1_p
( ( 1_p
sub NN 1_p
) ) 1_p
clinical JJ 1_p
anxiety NN 1_o
symptoms NNS 1_o
will MD 1_p
be VB 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
the DT 1_p
experimental NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
60 CD 1_p
) ) 1_p
or CC 1_p
the DT 1_p
control NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
60 CD 1_p
) ) 1_p
condition NN 1_p
. . 1_p

Children NNP N
in IN N
the DT N
experimental JJ N
condition NN N
will MD N
play VB 1_i
Mindlight NNP 1_i
for IN N
one CD N
hour NN N
per IN N
week NN N
, , N
for IN N
six CD N
consecutive JJ N
weeks NNS N
. . N

Children NNP N
in IN N
the DT N
control NN N
condition NN N
will MD N
play VB N
the DT N
puzzle NN 1_i
game NN 1_i
Triple NNP 1_i
Town NNP 1_i
, , N
also RB N
for IN N
one CD N
hour NN N
per IN N
week NN N
and CC N
for IN N
six CD N
consecutive JJ N
weeks NNS N
. . N

All DT N
children NNS N
will MD N
complete VB N
assessments NNS N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
3-months JJ N
follow-up NN N
. . N

Furthermore NNP N
, , N
parents NNS N
and CC N
teachers NNS N
will MD N
also RB N
complete JJ N
assessments NNS N
at IN N
the DT N
same JJ N
time NN N
points NNS N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
child JJ 1_o
report NN 1_o
of IN 1_o
anxiety NN 1_o
symptoms NNS 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
will MD N
be VB N
parent JJ 1_o
report NN 1_o
of IN 1_o
child JJ 1_o
anxiety NN 1_o
, , 1_o
child/parent JJ 1_o
report NN 1_o
of IN 1_o
depressive JJ 1_o
symptoms NNS 1_o
, , 1_o
and CC 1_o
parent/teacher JJ 1_o
report NN 1_o
of IN 1_o
social JJ 1_o
functioning NN 1_o
and CC 1_o
behavior NN 1_o
problems NNS 1_o
. . 1_o

DISCUSSION NNP N
This DT N
paper NN N
aims VBZ N
to TO N
describe VB N
a DT N
study NN N
that WDT N
will MD N
examine VB N
the DT N
effect NN N
of IN N
the DT N
serious JJ N
game NN N
Mindlight NNP N
on IN N
( ( N
sub NN N
) ) N
clinical JJ N
anxiety NN N
symptoms NNS N
of IN N
children NNS N
with IN N
an DT N
ASD NNP 1_o
in IN 1_o
the DT 1_o
age NN 1_o
of IN 1_o
8-16 CD 1_o
years NNS 1_o
old JJ 1_o
. . 1_o

It PRP N
is VBZ N
expected VBN N
that IN N
children NNS N
in IN N
the DT N
experimental JJ N
condition NN N
will MD N
show VB N
lower JJR N
levels NNS N
of IN N
anxiety NN 1_o
symptoms NNS 1_o
at IN N
3-months JJ N
follow-up NN N
, , N
compared VBN N
to TO N
children NNS N
in IN N
the DT N
control NN N
condition NN N
. . N

If IN N
Mindlight NNP 1_i
turns VBZ N
out RP N
to TO N
be VB N
effective JJ N
, , N
it PRP N
could MD N
be VB N
an DT N
important JJ N
contribution NN N
to TO N
the DT N
already RB N
existing JJ N
interventions NNS N
for IN N
anxiety NN N
in IN N
children NNS N
with IN N
an DT N
ASD NNP N
. . N

Mindlight NNP 1_i
could MD N
then RB N
be VB N
implemented VBN N
as IN N
an DT N
evidence-based JJ N
treatment NN N
for IN N
anxiety NN 1_o
symptoms NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
an DT 1_p
ASD NNP 1_p
in IN N
mental JJ N
health NN N
institutes NNS N
and CC N
special JJ N
education NN N
schools NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
NTR5069 NNP N
. . N

Registered VBD N
20 CD N
April NNP N
2015 CD N
. . N

-DOCSTART- -X- O O

Synthetic JJ 1_i
serum NN 1_i
substitute NN 1_i
( ( 1_i
SSS NNP 1_i
) ) 1_i
: : 1_i
a DT N
globulin-enriched JJ N
protein NN N
supplement NN N
for IN N
human JJ 1_p
embryo JJ 1_p
culture NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
an DT N
IVF NNP N
protein NN N
supplement NN N
prepared VBN N
from IN N
human JJ N
serum NN N
albumin NN N
( ( N
HSA NNP N
) ) N
and CC N
human JJ N
globulins NNS N
would MD N
retain VB N
performance NN 1_o
characteristics NNS 1_o
equivalent JJ N
to TO N
those DT N
reported VBN N
for IN N
the DT N
commercial JJ N
plasma NN N
expanders NNS N
, , N
Plasmatein NNP 1_i
( ( N
Alpha NNP N
Therapeutics NNP N
, , N
Los NNP N
Angeles NNP N
, , N
California NNP N
) ) N
and CC N
Plasmanate NNP 1_i
( ( N
Cutter NNP N
Biological NNP N
, , N
Miles NNP N
Inc. NNP N
, , N
Elkhart NNP N
, , N
Indiana NNP N
) ) N
. . N

METHODS NNP N
Pronuclear-stage JJ 1_p
human JJ 1_p
embryos NN 1_p
were VBD N
randomly RB N
divided VBN 1_i
and CC 1_i
cultured VBN 1_i
in IN 1_i
human JJ 1_i
tubal JJ 1_i
fluid NN 1_i
medium NN 1_i
( ( 1_i
HTF NNP 1_i
) ) 1_i
supplemented VBD 1_i
with IN 1_i
either DT 1_i
HSA NNP 1_i
( ( 1_i
5 CD 1_i
mg/mL NN 1_i
) ) 1_i
or CC 1_i
Plasmatein NNP 1_i
( ( 1_i
10 CD 1_i
% NN 1_i
, , 1_i
v/v NN 1_i
; : 1_i
5 CD 1_i
mg/ml NN 1_i
) ) 1_i
as IN 1_i
a DT 1_i
means NN 1_i
of IN 1_i
indirectly RB 1_i
assessing VBG 1_i
the DT 1_i
effect NN 1_i
alpha- JJ 1_i
and CC 1_i
beta-globulins NNS 1_i
have VBP 1_i
on IN 1_i
embryonic JJ 1_i
development NN 1_i
. . 1_i

Those DT N
results NNS N
coupled VBD N
with IN N
the DT N
known VBN N
composition NN N
characteristics NNS N
of IN N
Plasmatein NNP 1_i
were VBD N
used VBN N
as IN N
the DT N
starting VBG N
basis NN N
to TO N
formulate VB N
test JJ N
lots NNS N
of IN N
synthetic JJ N
serum NN N
substitute NN N
( ( N
SSS NNP N
) ) N
. . N

RESULTS NNP N
Significantly NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
more JJR N
of IN N
the DT N
human JJ N
embryos NN N
cultured VBN N
in IN N
Plasmatein NNP 1_i
supplemented VBD N
medium NN N
reached VBD N
the DT N
four-cell NN 1_o
or CC 1_o
greater JJR 1_o
stage NN 1_o
by IN N
40 CD N
hr NNS N
postinsemination NN N
than IN N
a DT N
comparable JJ N
group NN N
cultured VBD N
in IN N
HSA NNP 1_i
alone RB N
. . N

Lot NNP N
1 CD N
of IN N
SSS NNP N
, , N
formulated VBD N
with IN N
HSA NNP N
( ( N
84 CD N
% NN N
of IN N
total JJ N
protein NN N
) ) N
and CC N
human JJ N
globulins NNS N
( ( N
16 CD N
% NN N
of IN N
total JJ N
protein NN N
) ) N
and CC N
an DT N
aqueous JJ N
lipoprotein NN N
fraction NN N
derived VBN N
from IN N
human JJ N
plasma NN N
( ( N
Excyte NNP N
IV NNP N
; : N
Miles NNP N
Diagnostics NNPS N
, , N
Kankakee NNP N
, , N
Illinois NNP N
) ) N
, , N
produced VBD N
accelerated VBN N
early JJ 1_o
embryonic JJ 1_o
growth NN 1_o
relative JJ N
to TO N
control VB N
murine JJ N
embryos NNS N
grown VBN N
in IN N
the DT N
presence NN N
of IN N
Plasmatein NNP N
, , N
however RB N
, , N
the DT N
percentage NN N
of IN N
the DT N
embryos NN N
reaching VBG N
the DT N
hatched JJ N
blastocyst NN N
stage NN N
was VBD N
decreased VBN N
( ( N
45 CD N
vs RB N
100 CD N
% NN N
) ) N
. . N

Human JJ 1_p
embryos NN 1_p
from IN 1_p
seven CD 1_p
patients NNS 1_p
, , N
randomized VBN N
to TO N
HTF NNP N
medium NN N
supplemented VBD N
with IN N
Plasmatein NNP 1_i
or CC N
lot NN N
1 CD N
of IN N
SSS NNP 1_i
, , N
showed VBD N
equivalent JJ N
growth NN 1_o
at IN N
36-40 JJ N
hr NN N
postinsemination NN N
. . N

A DT N
microprecipitate NN N
developed VBN N
in IN N
media NNS N
supplemented VBN N
with IN N
lot NN N
1 CD N
after IN N
several JJ N
days NNS N
of IN N
culture NN N
. . N

The DT N
Excyte NNP 1_o
IV NNP 1_o
concentration NN 1_o
was VBD N
reduced VBN N
and CC N
, , N
ultimately RB N
, , N
eliminated VBN N
from IN N
the DT N
subsequent JJ N
and CC N
final JJ N
prototype NN N
lots NNS N
of IN N
SSS NNP N
. . N

Murine NNP 1_p
embryos JJ 1_p
grown VBN N
in IN N
the DT N
presence NN N
of IN N
lipoprotein JJ N
free JJ N
SSS NNP 1_i
showed VBD N
significantly RB N
accelerated VBN 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
0.01 CD 1_o
) ) 1_o
growth NN 1_o
at IN N
17 CD N
hr NN N
postthaw NN N
compared VBN N
to TO N
Plasmatein NNP 1_i
and CC N
all DT N
embryos NNS N
progressed VBN N
to TO N
hatching VBG 1_o
by IN N
41 CD N
hr NN N
. . N

Human NNP 1_p
embryos NN 1_p
, , N
randomized VBN N
to TO N
either DT N
Plasmatein NNP 1_i
or CC N
lot NN N
3 CD N
of IN N
SSS NNP 1_i
, , N
showed VBD N
significantly RB N
accelerated VBN 1_o
growth NN 1_o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
when WRB N
scored VBN N
at IN N
38 CD N
hr NN N
following VBG N
insemination NN N
. . N

CONCLUSION NNP N
Synthetic NNP 1_i
serum NN 1_i
substitute NN 1_i
provides VBZ N
a DT N
convient NN N
, , N
standardized JJ N
means NNS N
of IN N
adding VBG N
protein NN N
to TO N
media NNS N
used VBN N
in IN N
assisted JJ N
reproductive JJ N
technology NN N
( ( N
ART NNP N
) ) N
procedures NNS N
. . N

-DOCSTART- -X- O O

Cyclosporine NNP 1_i
inhibition NN N
of IN N
P-glycoprotein NNP N
in IN N
chronic JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
blast NN 1_p
phase NN 1_p
. . 1_p

Chronic NNP N
myeloid NN N
leukemia NN N
blast NN N
phase NN N
( ( N
CML-BP NNP N
) ) N
cells NNS N
commonly RB N
express VBP N
the DT N
multidrug NN N
transporter NN N
, , N
P-glycoprotein NNP N
( ( N
Pgp NNP N
) ) N
. . N

To TO N
determine VB N
whether IN N
Pgp NNP N
inhibition NN N
improves VBZ N
treatment NN N
outcome NN N
in IN N
CML-BP NNP N
, , N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
performed VBD N
a DT N
randomized VBN 1_i
, , 1_i
controlled VBN 1_i
trial NN 1_i
testing VBG 1_i
the DT 1_i
benefit NN 1_i
of IN 1_i
the DT 1_i
Pgp NNP 1_i
modulator NN 1_i
, , 1_i
cyclosporin VB 1_i
A NNP 1_i
( ( 1_i
CsA NNP 1_i
) ) 1_i
. . 1_i

Seventy-three JJ 1_p
eligible JJ 1_p
patients NNS 1_p
were VBD N
assigned VBN 1_i
to TO 1_i
treatment NN 1_i
with IN 1_i
cytarabine NN 1_i
and CC 1_i
infusional JJ 1_i
daunorubicin NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
intravenous JJ 1_i
CsA NNP 1_i
. . 1_i

Treatment NN N
with IN N
CsA NNP N
yielded VBD N
no DT 1_o
improvement NN 1_o
in IN N
treatment NN N
outcome NN N
as IN N
measured VBN N
by IN N
the DT N
frequency NN 1_o
of IN 1_o
induction NN 1_o
resistance NN 1_o
( ( N
68 CD N
% NN N
vs JJ N
53 CD N
% NN N
) ) N
, , N
rate NN 1_o
of IN 1_o
complete JJ 1_o
remission NN 1_o
or CC 1_o
restored VBN 1_o
chronic JJ 1_o
phase NN 1_o
( ( N
CR/CP NNP N
, , N
8 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
, , N
and CC N
survival NN 1_o
( ( N
3 CD N
vs RB N
5 CD N
months NNS N
) ) N
. . N

Blast NNP 1_o
expression NN 1_o
of IN 1_o
Pgp NNP 1_o
( ( N
63 CD N
% NN N
) ) N
and CC N
LRP NNP 1_o
( ( N
71 CD N
% NN N
) ) N
was VBD N
common JJ N
, , N
whereas IN N
only RB N
Pgp NNP N
adversely RB N
impacted VBD N
the DT N
rate NN 1_o
of IN 1_o
CR/CP NNP 1_o
( ( N
P NNP N
=.025 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
Pgp NNP N
has VBZ N
prognostic JJ N
relevance NN N
in IN N
CML-BP NNP N
but CC N
that IN N
the DT N
modulation NN N
of IN N
Pgp NNP N
function NN N
with IN N
CsA NNP N
as IN N
applied VBN N
in IN N
this DT N
trial NN N
is VBZ N
ineffective JJ N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
ranolazine NN 1_i
on IN N
A1C NNP N
and CC N
glucose JJ N
levels NNS N
in IN N
hyperglycemic JJ 1_p
patients NNS 1_p
with IN 1_p
non-ST JJ 1_p
elevation NN 1_p
acute NN 1_p
coronary JJ 1_p
syndrome NN 1_p
. . 1_p

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
relationships NNS N
between IN N
glycemia NN N
at IN N
randomization NN N
, , N
concurrent JJ 1_i
antidiabetic JJ 1_i
therapy NN 1_i
, , N
and CC N
change NN N
in IN N
A1C NNP N
and CC N
fasting VBG N
plasma NN N
glucose NN N
( ( N
FPG NNP N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
receiving VBG 1_p
standard JJ 1_p
treatment NN 1_p
for IN 1_p
diabetes NNS 1_p
and CC 1_p
randomized VBN 1_p
to TO 1_p
ranolazine VB 1_i
or CC 1_i
placebo VB 1_i
within IN 1_p
the DT 1_p
MERLIN-TIMI-36 NNP 1_p
( ( 1_p
MERLIN NNP 1_p
) ) 1_p
study NN 1_p
. . 1_p

Ranolazine NNP 1_i
is VBZ N
a DT N
novel JJ N
first-in-class JJ N
drug NN N
approved VBD N
for IN N
treating VBG N
angina JJ N
pectoris NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Randomization NNP N
and CC N
4-month JJ N
glycemic NN 1_i
and CC 1_i
antidiabetes VBZ 1_i
drug NN 1_i
usage NN 1_i
data NNS 1_i
from IN N
MERLIN NNP N
were VBD N
analyzed VBN N
using VBG N
Spotfire NNP N
and CC N
SAS NNP N
version NN N
9.1 CD N
software NN N
. . N

RESULTS NNP N
In IN N
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
and CC 1_p
A1C NNP 1_p
of IN 1_p
> NNP 1_p
or=8-10 JJ 1_p
% NN 1_p
at IN 1_p
randomization NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
171 CD 1_p
) ) 1_p
, , N
there EX N
was VBD N
an DT N
absolute JJ N
A1C NNP 1_o
reduction NN 1_o
in IN N
the DT N
ranolazine NN 1_i
group NN N
of IN N
1.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.4 NNP N
to TO N
-1.0 VB N
) ) N
, , N
and CC N
the DT N
placebo-adjusted JJ 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
182 CD 1_p
) ) 1_p
decrease NN N
in IN N
A1C NNP 1_o
by IN N
ranolazine NN N
was VBD N
0.59 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-0.99 NNP N
to TO N
-0.20 VB N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS 1_p
with IN 1_p
FPG NNP 1_p
of IN 1_p
150-400 JJ 1_p
mg/dl NN 1_p
at IN 1_p
randomization NN 1_p
, , 1_p
ranolazine NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
131 CD 1_p
) ) 1_p
compared VBN N
with IN N
placebo NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
147 CD 1_p
) ) 1_p
reduced VBN N
FPG NNP N
by IN N
25.7 CD N
mg/dl NNS N
( ( N
95 CD N
% NN N
CI NNP N
-43.3 NNP N
to TO N
-8.1 VB N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

When WRB N
changes NNS N
in IN N
either DT N
A1C NNP 1_o
or CC 1_o
FPG NNP 1_o
were VBD N
correlated VBN N
to TO N
A1C NNP 1_o
or CC 1_o
FPG NNP 1_o
at IN N
randomization NN N
, , N
the DT N
slopes NNS N
were VBD N
significantly RB N
steeper JJR N
for IN N
ranolazine NN 1_i
than IN N
placebo NN 1_i
( ( N
A1C NNP N
, , N
P NNP N
= NNP N
0.046 CD N
; : N
FPG NNP N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
indicating VBG N
that IN N
lowering VBG N
of IN N
A1C NNP 1_o
and CC 1_o
FPG NNP 1_o
by IN N
ranolazine NN 1_i
is VBZ N
related VBN N
to TO N
hyperglycemia VB N
at IN N
randomization NN N
. . N

Ranolazine NNP N
, , N
compared VBN N
with IN N
placebo NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
serious JJ 1_o
hypoglycemic JJ 1_o
events NNS 1_o
, , N
associated VBN N
with IN N
significant JJ N
changes NNS N
in IN N
concurrent JJ 1_o
antidiabetic JJ 1_o
therapy NN 1_o
, , N
or CC N
dependent NN N
on IN N
a DT N
history NN 1_o
of IN 1_o
angina NN 1_o
. . 1_o

CONCLUSIONS NNP N
Ranolazine NNP 1_i
, , N
when WRB N
added VBN N
to TO N
concurrent VB N
antidiabetes NNS N
treatment NN N
, , N
lowers NNS N
FPG NNP 1_o
and CC 1_o
A1C NNP 1_o
in IN N
patients NNS 1_p
with IN 1_p
cardiovascular JJ 1_p
disease NN 1_p
and CC 1_p
poorly RB 1_p
controlled VBN 1_p
diabetes NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Motion NNP 1_i
style NN 1_i
acupuncture NN 1_i
treatment NN 1_i
( ( 1_i
MSAT NNP 1_i
) ) 1_i
for IN N
acute NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
with IN 1_p
severe JJ 1_p
disability NN 1_p
: : 1_p
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
protocol NN N
. . N

BACKGROUND NNP N
Acupuncture NNP N
is VBZ N
widely-used JJ N
to TO N
treat VB N
patients NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
, , N
despite IN N
insufficient JJ N
evidence NN N
of IN N
the DT N
technique NN N
's POS N
efficacy NN N
for IN N
acute NN N
back RB N
pain NN N
. . N

Motion NNP 1_i
style NN 1_i
acupuncture NN 1_i
treatment NN 1_i
( ( 1_i
MSAT NNP 1_i
) ) 1_i
is VBZ N
a DT N
non-traditional JJ N
acupuncture NN N
treatment NN N
requiring VBG N
a DT N
patient NN N
to TO N
exercise VB N
while IN N
receiving VBG N
acupuncture NN N
. . N

In IN 1_p
Korea NNP 1_p
, , N
MSAT NNP N
is VBZ N
used VBN N
to TO N
reduce VB N
musculoskeletal JJ N
pain NN N
and CC N
improve VB N
functional JJ N
status NN N
. . N

The DT N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
MSAT NNP N
on IN N
acute NN N
low JJ N
back RB N
pain NN N
with IN N
severe JJ N
disability NN N
. . N

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
active-controlled JJ N
trial NN N
with IN N
two CD N
parallel JJ N
arms NNS N
. . N

Participants NNS 1_p
with IN 1_p
acute NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
and CC 1_p
severe JJ 1_p
functional JJ 1_p
disability NN 1_p
, , 1_p
defined VBD 1_p
as IN 1_p
an DT 1_p
Oswestry NNP 1_p
Disability NNP 1_p
Index NNP 1_p
( ( 1_p
ODI NNP 1_p
) ) 1_p
value NN 1_p
> $ 1_p
60 CD 1_p
% NN 1_p
, , N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
the DT N
acupuncture NN 1_i
group NN 1_i
and CC 1_i
the DT 1_i
nonsteroidal JJ 1_i
anti-inflammatory JJ 1_i
drug NN 1_i
( ( 1_i
NSAID NNP 1_i
) ) 1_i
injection NN 1_i
group NN 1_i
. . 1_i

The DT N
acupuncture NN N
group NN N
will MD N
receive VB N
MSAT NNP 1_i
and CC 1_i
the DT 1_i
NSAID NNP 1_i
injection NN 1_i
group NN 1_i
will MD N
receive VB N
an DT N
intramuscular JJ N
injection NN N
of IN N
diclofenac NN 1_i
. . 1_i

All DT N
procedures NNS N
will MD N
be VB N
limited VBN N
to TO N
one CD N
session NN N
and CC N
the DT N
symptoms NNS N
before IN N
and CC N
after IN N
treatment NN N
will MD N
be VB N
measured VBN N
by IN N
assessors NNS N
blinded VBD N
to TO N
treatment NN N
allocation NN N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
numerical JJ 1_o
rating NN 1_o
scale NN 1_o
( ( 1_o
NRS NNP 1_o
) ) 1_o
of IN 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
while IN 1_o
the DT 1_o
patient NN 1_o
is VBZ 1_o
moving VBG 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
NRS NNP 1_o
of IN 1_o
leg NN 1_o
pain NN 1_o
, , 1_o
ODI NNP 1_o
, , 1_o
patient NN 1_o
global JJ 1_o
impression NN 1_o
of IN 1_o
change NN 1_o
, , 1_o
range NN 1_o
of IN 1_o
motion NN 1_o
( ( 1_o
ROM NNP 1_o
) ) 1_o
of IN 1_o
the DT 1_o
lumbar NN 1_o
spine NN 1_o
, , 1_o
and CC 1_o
degrees NNS 1_o
of IN 1_o
straight JJ 1_o
leg NN 1_o
raising VBG 1_o
( ( 1_o
SLR NNP 1_o
) ) 1_o
. . 1_o

Post-treatment JJ N
follow-up NN N
will MD N
be VB N
performed VBN N
to TO N
measure VB N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
with IN N
the DT N
exception NN N
of IN N
ROM NNP 1_o
and CC 1_o
SLR NNP 1_o
at IN N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
. . N

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
trial NN N
will MD N
be VB N
discussed VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
NCT01315561 NNP N
. . N

-DOCSTART- -X- O O

The DT N
nature NN N
of IN N
placebo NN 1_i
response NN N
in IN N
clinical JJ N
studies NNS N
of IN N
major JJ 1_p
depressive JJ 1_p
disorder NN 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
review VB N
factors NNS N
influencing VBG N
placebo NN 1_i
response NN N
and CC N
clinical JJ N
trial NN N
outcome NN N
in IN N
depression NN 1_p
, , N
and CC N
suggest VBP N
ways NNS N
to TO N
optimize VB N
trial NN N
success NN N
in IN N
mood NN N
disorders NNS N
. . N

DATA NNP N
SOURCES NNP N
PubMed NNP N
searches NNS N
were VBD N
conducted VBN N
by IN N
cross-referencing VBG N
the DT N
terms NNS N
depression NN N
, , N
depressive JJ N
with IN N
placebo NN 1_i
, , N
clinical JJ N
trial NN N
, , N
and CC N
clinical JJ N
trials NNS N
for IN N
studies NNS 1_p
published VBN 1_p
in IN 1_p
English NNP 1_p
between IN 1_p
1970 CD 1_p
and CC 1_p
September NNP 1_p
2013 CD 1_p
. . 1_p

STUDY NNP N
SELECTION NNP N
Relevant NNP N
abstracts NNS N
were VBD N
identified VBN N
in IN N
PubMed NNP N
, , N
including VBG N
clinical JJ N
trials NNS N
, , N
quantitative JJ N
studies NNS N
, , N
and CC N
qualitative JJ N
research NN N
. . N

We PRP N
obtained VBD N
and CC N
reviewed VBD N
relevant JJ N
articles NNS N
and CC N
utilized VBD N
their PRP$ N
information NN N
to TO N
synthesize VB N
the DT N
present JJ N
review NN N
. . N

DATA NNP N
EXTRACTION NNP N
Included VBD N
articles NNS N
were VBD N
grouped VBN N
in IN N
the DT N
following JJ N
areas NNS N
of IN N
relevance NN N
: : N
( ( N
1 CD N
) ) N
biological JJ N
validity NN N
of IN N
illness NN N
, , N
( ( N
2 CD N
) ) N
baseline NN N
severity NN N
of IN N
illness NN N
, , N
( ( N
3 CD N
) ) N
chronicity NN N
of IN N
the DT N
index NN N
episode NN N
of IN N
depression NN N
, , N
( ( N
4 CD N
) ) N
age NN N
of IN N
participants NNS N
, , N
( ( N
5 CD N
) ) N
medical JJ N
and CC N
psychiatric JJ N
comorbidity NN N
, , N
( ( N
6 CD N
) ) N
probability NN N
of IN N
receiving VBG 1_i
placebo NN 1_i
, , N
( ( N
7 CD N
) ) N
use NN N
of IN N
prospective JJ N
treatment NN N
phases NNS N
( ( N
lead-in NN N
) ) N
( ( N
8 CD N
) ) N
dosing NN N
schedule NN N
, , N
( ( N
9 CD N
) ) N
trial NN N
duration NN N
, , N
( ( N
10 CD N
) ) N
frequency NN N
of IN N
follow-up JJ N
assessments NNS N
, , N
and CC N
( ( N
11 CD N
) ) N
study NN N
outcome JJ N
measure NN N
. . N

RESULTS NNP N
Several JJ N
key JJ N
elements NNS N
emerge VBP N
as RB N
critical JJ N
to TO N
the DT N
ultimate JJ N
success NN N
of IN N
a DT N
clinical JJ N
trial NN N
, , N
including VBG N
the DT N
probability NN 1_o
of IN 1_o
receiving VBG 1_o
placebo NN 1_o
, , 1_o
study NN 1_o
duration NN 1_o
, , 1_o
dosing VBG 1_o
schedule NN 1_o
, , 1_o
visit NN 1_o
frequency NN 1_o
, , 1_o
the DT 1_o
use NN 1_o
of IN 1_o
blinded JJ 1_o
lead-in JJ 1_o
phases NNS 1_o
, , 1_o
the DT 1_o
use NN 1_o
of IN 1_o
centralized JJ 1_o
raters NNS 1_o
, , 1_o
illness JJ 1_o
severity NN 1_o
and CC 1_o
duration NN 1_o
, , 1_o
and CC 1_o
comorbid NN 1_o
anxiety NN 1_o
. . 1_o

CONCLUSIONS NNP N
Our PRP$ N
increasing VBG N
understanding NN N
of IN N
the DT N
placebo NN 1_i
response NN 1_p
in IN 1_p
clinical JJ 1_p
trials NNS 1_p
of IN N
major JJ 1_p
depressive JJ 1_p
disorder NN 1_p
lends VBZ N
to TO N
a DT N
, , N
gradually RB N
, , N
more RBR N
predictable JJ N
phenomenon NN N
and CC N
, , N
hopefully RB N
, , N
to TO N
one CD N
that WDT N
becomes VBZ N
lesser JJR N
in IN N
magnitude NN N
and CC N
variability NN N
. . N

Several JJ N
elements NNS N
have VBP N
emerged VBN N
that WDT N
seem VBP N
to TO N
play VB N
a DT N
critical JJ N
role NN N
in IN N
trial NN N
success NN N
, , N
gradually RB N
reshaping VBG N
the DT N
design NN N
of IN N
clinical JJ N
, , N
translational JJ N
, , N
as RB N
well RB N
as IN N
mechanistic JJ N
studies NNS N
in IN N
depression NN N
. . N

-DOCSTART- -X- O O

Influenza NNP N
and CC N
pneumococcal JJ N
vaccination NN 1_i
as IN N
a DT N
model NN N
to TO N
assess VB N
C-reactive JJ N
protein NN N
response NN N
to TO N
mild VB 1_p
inflammation NN 1_p
. . 1_p

This DT N
study NN N
was VBD N
set VBN N
up RP N
to TO N
examine VB N
whether IN N
an DT N
influenza JJ 1_i
vaccine NN 1_i
or CC 1_i
an DT 1_i
influenza JJ 1_i
vaccine NN 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
pneumococcal JJ 1_i
vaccine NN 1_i
can MD N
be VB N
used VBN N
as IN N
a DT N
model NN N
to TO N
study VB N
responses NNS N
to TO N
mild VB N
stimulation NN N
of IN N
the DT N
inflammatory NN N
system NN N
. . N

In IN N
this DT N
study NN N
, , N
19 CD 1_p
subjects NNS 1_p
received VBD 1_p
the DT 1_p
influenza JJ 1_i
vaccine NN 1_i
, , 1_p
20 CD 1_p
subjects NNS 1_p
the DT 1_p
combination NN 1_p
of IN 1_p
influenza NN 1_i
and CC 1_i
pneumococcal JJ 1_i
vaccine NN 1_i
. . 1_i

CRP NNP 1_o
and CC 1_o
prothrombin VB 1_o
fragment JJ 1_o
1 CD 1_o
and CC 1_o
2 CD 1_o
( ( 1_o
F1+2 NNP 1_o
) ) 1_o
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
and CC N
two CD N
times NNS N
after IN N
vaccination NN N
. . N

Influenza NNP 1_i
vaccination NN 1_i
increased VBD N
CRP NNP 1_o
by IN N
0.20 CD N
mg/L NNS N
, , N
and CC N
influenza NN N
in IN N
combination NN N
with IN N
pneumococcal JJ 1_i
vaccine NN 1_i
increased VBN N
CRP NNP 1_o
by IN N
0.60 CD N
mg/L NN N
. . N

F1+2 NNP 1_o
increased VBD N
0.15 CD N
nmol/L NN N
after IN N
the DT N
combined JJ N
vaccination NN N
; : N
an DT N
increase NN N
in IN N
response NN 1_o
to TO 1_o
the DT 1_o
influenza JJ 1_o
vaccination NN 1_o
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Our PRP$ N
findings NNS N
show VBP N
that IN N
the DT N
influenza JJ 1_i
vaccine NN 1_i
alone RB N
as RB N
well RB N
as IN N
the DT N
combination NN N
of IN N
the DT N
influenza NN 1_i
and CC 1_i
pneumococcal JJ 1_i
vaccine NN 1_i
increases VBZ N
CRP-levels NNP 1_o
with IN N
a DT N
peak JJ N
2 CD N
days NNS N
after IN N
vaccination NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Opiate NNP N
hypothesis NN N
in IN N
infantile JJ 1_p
autism NN 1_p
? . N
Therapeutic JJ N
trials NNS N
with IN N
naltrexone JJ 1_i
] NN 1_i
. . N

The DT N
opioid JJ N
hypothesis NN N
suggests VBZ N
that IN N
childhood NN N
autism NN N
may MD N
result VB N
from IN N
excessive JJ N
brain NN N
opioid JJ N
activity NN N
during IN N
neonatal JJ N
period NN N
which WDT N
may MD N
constitutionally RB N
inhibit VB N
social JJ N
motivation NN N
, , N
yielding VBG N
autistic JJ N
isolation NN N
and CC N
aloofness NN N
( ( N
Panksepp NNP N
, , N
1979 CD N
) ) N
. . N

This DT N
hypothesis NN N
has VBZ N
now RB N
received VBN N
strong JJ N
support NN N
and CC N
is VBZ N
currently RB N
based VBN N
on IN N
three CD N
types NNS N
of IN N
arguments NNS N
: : N
( ( N
1 CD N
) ) N
similarity NN N
between IN N
autistic JJ N
symptomatology NN N
and CC N
abnormal JJ N
behaviors NNS N
induced VBD N
in IN N
young JJ N
animals NNS N
by IN N
injections NNS N
of IN N
exogenous JJ N
opioids NNS N
, , N
such JJ N
as IN N
increasing VBG N
social JJ N
aloofness NN N
and CC N
decreasing VBG N
social JJ N
vocalization NN N
; : N
( ( N
2 CD N
) ) N
direct JJ N
biochemical JJ N
evidence NN N
of IN N
abnormalities NNS N
of IN N
peripheral JJ N
endogenous JJ N
opioids NNS N
being VBG N
reported VBN N
in IN N
autism NN N
and CC N
( ( N
3 CD N
) ) N
therapeutic JJ N
effects NNS N
of IN N
the DT N
long JJ N
lasting NN N
opioid JJ N
receptor NN N
blocking VBG N
agent NN N
naltrexone NN N
in IN N
autism NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
give VBP N
description NN N
of IN N
open JJ N
and CC N
double-blind JJ N
studies NNS N
of IN N
naltrexone NN 1_i
in IN N
autism NN N
. . N

Naltrexone NN 1_i
has VBZ N
been VBN N
tested VBN N
in IN N
several JJ N
open JJ N
studies NNS N
. . N

We PRP N
performed VBD N
an DT N
open JJ N
trial NN N
with IN N
naltrexone NN 1_i
in IN N
2 CD 1_p
autistic JJ 1_p
girls NNS 1_p
, , 1_p
displaying VBG 1_p
serious JJ 1_p
self-injurious JJ 1_p
behavior NN 1_p
, , 1_p
reduced VBD 1_p
crying NN 1_p
and CC 1_p
a DT 1_p
marked JJ 1_p
preference NN 1_p
for IN 1_p
salty NN 1_p
and CC 1_p
spicy NN 1_p
foods NNS 1_p
, , 1_p
symptoms NNS 1_p
that WDT 1_p
could MD 1_p
be VB 1_p
related VBN 1_p
to TO 1_p
a DT 1_p
dysfunction NN 1_p
of IN 1_p
the DT 1_p
opioid JJ 1_p
system NN 1_p
. . 1_p

With IN N
dosages NNS N
of IN N
1 CD N
mg/kg/day NN N
, , N
we PRP N
observed VBD N
an DT N
immediate JJ N
reduction NN 1_o
of IN 1_o
hyperactivity NN 1_o
, , 1_o
self-injurious JJ 1_o
behavior NN 1_o
and CC 1_o
aggressiveness NN 1_o
, , 1_o
while IN 1_o
attention NN 1_o
improved VBN 1_o
. . 1_o

In IN N
addition NN N
, , N
social JJ 1_o
behaviors NNS 1_o
, , 1_o
smiling VBG 1_o
, , 1_o
social JJ 1_o
seeking VBG 1_o
behaviors NNS 1_o
and CC 1_o
play VB 1_o
interactions NNS 1_o
increased VBN N
( ( N
Leboyer NNP N
, , N
Bouvard NNP N
et VBZ N
Dugas NNP N
, , N
1988 CD N
) ) N
. . N

Campbell NNP N
et CC N
al NN N
. . N

( ( N
1988 CD N
) ) N
has VBZ N
also RB N
reported VBN N
a DT N
tranquilizing NN 1_o
and CC 1_o
a DT 1_o
stimulating JJ 1_o
effect NN 1_o
in IN N
6 CD N
out IN N
of IN N
8 CD N
children NNS N
with IN N
autism NN N
. . N

We PRP N
did VBD N
confirm VB N
these DT N
preliminary JJ N
results NNS N
in IN N
a DT N
double-blind NN N
study NN N
performed VBD N
on IN N
4 CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

In IN N
a DT N
cross-over JJ N
double-blind NN N
study NN N
, , N
three CD N
dosages NNS N
of IN N
naltrexone NN N
( ( N
0.5 CD N
, , N
1 CD N
and CC N
2 CD N
mg/kg/day NN N
) ) N
and CC N
placebo NN N
were VBD N
compared VBN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Letter NN N
by IN N
Begg NNP N
et CC N
al NN N
regarding VBG N
article NN N
, , N
The DT N
effects NNS N
of IN N
vitamin NN 1_i
d NN 1_i
supplementation NN 1_i
on IN N
physical JJ 1_o
function NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
in IN N
older JJR 1_p
heart NN 1_p
failure NN 1_p
patients NNS 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -X- O O

Event-related JJ N
potentials NNS N
and CC N
monoamines NNS N
in IN N
autistic JJ 1_p
children NNS 1_p
on IN N
a DT N
clinical JJ N
trial NN N
of IN N
fenfluramine NN 1_i
. . 1_i

In IN N
a DT N
double JJ N
blind NN N
, , N
crossover NN N
study NN N
of IN N
the DT N
response NN N
of IN N
autistic JJ 1_p
subjects NNS 1_p
to TO N
fenfluramine VB 1_i
, , 1_i
event-related JJ 1_i
potentials NNS 1_i
( ( 1_i
ERPs NNP 1_i
) ) 1_i
were VBD N
recorded VBN N
from IN N
7 CD 1_p
subjects NNS 1_p
on IN N
an DT N
attention-demanding JJ N
auditory NN N
choice NN N
reaction NN N
time NN N
task NN N
( ( N
ACRT NNP N
) ) N
. . N

ACRT NNP N
, , N
IQ NNP N
and CC N
biochemical JJ N
measures NNS N
were VBD N
taken VBN N
after IN N
5 CD N
months NNS N
placebo NN 1_i
and CC N
5 CD N
months NNS N
fenfluramine JJ 1_i
treatment NN 1_i
. . 1_i

After IN N
fenfluramine JJ N
treatment NN N
blood NN N
serotonin NN N
levels NNS N
fell VBD N
, , N
urinary JJ N
catecholamine NN N
levels NNS N
fell VBD N
and CC N
the DT N
HVA/DA NNP N
ratio NN N
rose VBD N
. . N

IQ NNP 1_o
and CC 1_o
ACRT NNP 1_o
performance NN 1_o
improved VBD N
. . N

On IN N
the DT N
ACRT NNP 1_o
subjects NNS N
were VBD N
asked VBN N
to TO N
press VB N
a DT N
button NN N
to TO N
a DT N
rare JJ N
target NN N
( ( N
500 CD N
Hz NNP N
, , N
P NNP N
= NNP N
0.14 CD N
) ) N
and CC N
to TO N
ignore VB N
higher JJR N
pitched VBN N
rare JJ N
( ( N
2,000 CD N
Hz NNP N
, , N
P NNP N
= NNP N
0.14 CD N
) ) N
and CC N
frequent JJ N
non-targets NNS N
( ( N
1,000 CD N
Hz NNP N
) ) N
. . N

After IN N
fenfluramine JJ 1_i
treatment NN N
N1 NNP 1_o
latencies NNS 1_o
increased VBD N
. . N

The DT N
scalp JJ 1_o
distribution NN 1_o
of IN 1_o
ERP NNP 1_o
maxima NNP N
changes NNS N
slightly RB N
with IN N
treatment NN N
. . N

P3 NNP 1_o
maxima NN 1_o
elicited VBN N
by IN N
rare JJ N
non-targets NNS N
were VBD N
recorded VBN N
more RBR N
rostrally RB N
after IN N
fenfluramine JJ 1_i
treatment NN N
. . N

After IN N
rare JJ N
non-targets NNS N
N1 NNP 1_o
amplitudes NNS 1_o
at IN 1_o
Fz NNP 1_o
decreased VBD N
but CC N
P3 NNP 1_o
amplitudes NNS 1_o
at IN 1_o
Pz NNP 1_o
increased VBD N
. . N

Early JJ N
negativity NN N
after IN N
the DT N
rare JJ N
non-target JJ N
( ( N
particularly RB N
on IN N
the DT N
right JJ N
side NN N
) ) N
was VBD N
negatively RB N
correlated VBN N
with IN N
the DT N
HVA/DA NNP N
ratio NN N
. . N

Subtraction NN N
of IN N
the DT N
P3 NNP N
component NN N
elicited VBN N
in IN N
a DT N
passive JJ N
condition NN N
where WRB N
no DT N
response NN N
was VBD N
required VBN N
from IN N
the DT N
active JJ N
condition NN N
showed VBD N
that IN N
P3 NNP 1_o
positivity NN 1_o
to TO N
targets NNS N
was VBD N
halved VBN N
with IN N
treatment NN N
. . N

( ( N
In IN N
contrast NN N
Nd NNP N
increased VBD N
on IN N
fenfluramine JJ N
treatment NN N
) ) N
. . N

Overall JJ N
, , N
N1 NNP N
and CC N
P3 NNP N
components NNS N
showed VBD N
greatest JJS N
responsiveness NN N
to TO N
rare VB N
non-targets NNS N
on IN N
fenfluramine NN N
. . N

N1 NNP N
but CC N
not RB N
P3 NNP N
changes NNS N
may MD N
represent VB N
slight JJ N
improvement NN N
of IN N
attention-related JJ N
function NN N
with IN N
treatment NN N
. . N

Small JJ N
changes NNS N
in IN N
ERP NNP 1_o
latency NN 1_o
and CC 1_o
distribution NN 1_o
, , N
associated VBN N
with IN N
the DT N
neuroleptic JJ N
action NN N
of IN N
fenfluramine NN 1_i
may MD N
be VB N
partly RB N
responsible JJ N
for IN N
a DT N
mild JJ N
improvement NN N
of IN N
IQ NNP N
and CC N
ACRT NNP N
performance NN N
on IN N
medication NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
trials NNS N
of IN N
intrasplenic JJ N
arterial JJ N
infusion NN N
of IN N
interleukin-2 NN 1_i
( ( 1_i
IS-IL-2 NNP 1_i
) ) 1_i
to TO N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
cancer NN 1_p
. . 1_p

We PRP N
tried VBD N
a DT N
infusion NN N
of IN N
interleukin-2 NN N
( ( N
IL-2 NNP N
) ) N
of IN N
a DT N
relatively RB N
low JJ N
dose NN N
via IN N
an DT N
intrasplenic JJ N
arterial JJ N
catheter NN N
connected VBN N
to TO N
a DT N
chronometric JJ N
infusion NN N
( ( N
IS-IL-2 NNP N
) ) N
. . N

Eighteen JJ 1_p
patients NNS 1_p
of IN 1_p
colorectal JJ 1_p
cancer NN 1_p
with IN 1_p
metastases NNS 1_p
to TO 1_p
the DT 1_p
liver NN 1_p
or CC 1_p
lung NN 1_p
or CC 1_p
of IN 1_p
unresectable JJ 1_p
hepatoma NN 1_p
received VBD N
a DT N
24 CD N
hour NN N
continuous JJ 1_i
infusion NN 1_i
with IN 1_i
low JJ 1_i
dose JJ 1_i
recombinant NN 1_i
of IN 1_i
IL-2 NNP 1_i
( ( N
mainly RB N
8 CD N
x JJ N
10 CD N
( ( N
5 CD N
) ) N
JRU/day NN N
) ) N
for IN N
25-40 JJ N
days NNS N
. . N

All DT N
patients NNS N
tolerated VBD 1_o
this DT N
protocol NN N
of IN N
the DT N
therapy NN N
and CC N
the DT N
main JJ 1_o
toxic NN 1_o
effects NNS 1_o
were VBD 1_o
fever RB 1_o
and CC 1_o
general JJ 1_o
fatigue NN 1_o
. . 1_o

Such JJ N
serious JJ N
toxicity NN 1_o
as IN N
previously RB N
reported VBN N
by IN N
high JJ N
dose JJ N
IL-2 NNP N
therapy NN N
was VBD N
not RB N
observed VBN N
. . N

Data NNP N
of IN N
hepatic JJ 1_o
and CC 1_o
renal JJ 1_o
functions NNS 1_o
were VBD N
normal JJ N
. . N

IS-IL-2 JJ N
therapy NN N
induced VBD N
a DT N
high JJ N
incidence NN N
of IN N
eosinophilia NN 1_o
( ( 1_o
12/18 CD 1_o
) ) 1_o
and CC 1_o
thrombocythemia NN 1_o
( ( N
12/18 CD N
) ) N
. . N

Peripheral JJ 1_o
natural JJ 1_o
killer NN 1_o
( ( 1_o
NK NNP 1_o
) ) 1_o
and CC 1_o
LAK NNP 1_o
activities NNS 1_o
were VBD N
augmented VBN N
in IN N
all DT N
patients NNS N
and CC N
total JJ 1_o
white JJ 1_o
blood NN 1_o
cell NN 1_o
counts NNS 1_o
were VBD N
increased VBN N
during IN N
IS-IL-2 NNP N
therapy NN N
. . N

An DT N
increase NN N
in IN N
IL-2 NNP 1_o
receptor NN 1_o
expression NN 1_o
of IN 1_o
peripheral JJ 1_o
blood NN 1_o
mononuclear NN 1_o
cells NNS 1_o
and CC 1_o
significant JJ 1_o
rises NNS 1_o
in IN 1_o
numbers NNS 1_o
of IN 1_o
Leu11 NNP 1_o
( ( 1_o
CD16 NNP 1_o
) ) 1_o
+ NN 1_o
, , 1_o
OKM1 NNP 1_o
( ( 1_o
CD11 NNP 1_o
) ) 1_o
+ NN 1_o
and CC 1_o
OKIa1 NNP 1_o
( ( 1_o
HLA-DR NNP 1_o
) ) 1_o
+ NN 1_o
were VBD N
observed VBN N
. . N

Of IN 1_p
18 CD 1_p
patients NNS 1_p
12 CD 1_p
were VBD 1_p
evaluable JJ 1_p
for IN 1_p
their PRP$ 1_p
response NN 1_p
to TO 1_p
therapy NN 1_p
. . 1_p

Partial JJ N
response NN N
( ( N
PR NNP N
) ) N
was VBD N
observed VBN N
in IN N
one CD N
unresectable JJ 1_o
hepatoma NN 1_o
and CC N
11 CD N
demonstrated VBD N
no DT 1_o
change NN 1_o
( ( 1_o
NC NNP 1_o
) ) 1_o
or CC 1_o
progressive JJ 1_o
disease NN 1_o
( ( 1_o
PD NNP 1_o
) ) 1_o
. . 1_o

Six CD N
patients NNS N
were VBD N
not RB N
evaluable JJ N
because IN N
of IN N
additional JJ N
therapy NN N
( ( N
3 CD N
cases NNS N
) ) N
or CC N
decreasing VBG N
tumor NN N
cell NN N
markers NNS N
having VBG N
no DT N
measurable JJ N
lesions NNS N
( ( N
3 CD N
cases NNS N
) ) N
. . N

Three CD N
patients NNS N
of IN N
colorectal JJ N
cancer NN N
from IN N
an DT N
unresectable JJ N
group NN N
were VBD N
presumed VBN N
to TO N
have VB N
micrometastases NNS N
to TO N
the DT N
liver NN N
as IN N
suggested VBN N
by IN N
an DT N
elevated JJ N
serum NN N
CEA NNP N
level NN N
. . N

After IN N
receiving VBG N
IS-IL-2 JJ N
therapy NN N
they PRP N
demonstrated VBD N
a DT N
decrease NN N
in IN N
the DT N
serum NN N
CEA NNP N
level NN N
for IN N
more JJR N
than IN N
3 CD N
years NNS N
after IN N
treatment NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Short-term NNP 1_i
intravenous JJ 1_i
antibiotic JJ 1_i
treatment NN 1_i
of IN N
acute JJ 1_p
hematogenous JJ 1_p
bone NN 1_p
and CC 1_p
joint JJ 1_p
infection NN 1_p
in IN 1_p
children NNS 1_p
: : 1_p
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

Thirty-three JJ 1_p
cases NNS 1_p
of IN 1_p
acute JJ 1_p
hematogenous JJ 1_p
bone NN 1_p
or CC 1_p
joint JJ 1_p
infection NN 1_p
in IN 1_p
children NNS 1_p
were VBD N
randomly RB N
treated VBN N
with IN N
short-term JJ 1_i
( ( N
7 CD N
days NNS N
for IN N
joint JJ N
infection NN N
, , N
10 CD N
days NNS N
for IN N
bone JJ N
infection NN N
) ) N
or CC N
long-term JJ 1_i
( ( N
14 CD N
days NNS N
and CC N
21 CD N
days NNS N
, , N
respectively RB N
) ) N
intravenous JJ 1_i
antibiotics NNS 1_i
after IN N
surgical JJ 1_i
drainage NN 1_i
. . 1_i

The DT N
treatment NN N
outcome NN N
was VBD N
measured VBN N
through IN N
a DT N
detailed JJ 1_o
scoring NN 1_o
system NN 1_o
that WDT 1_o
included VBD 1_o
the DT 1_o
ability NN 1_o
to TO 1_o
eradicate VB 1_o
infection NN 1_o
, , 1_o
the DT 1_o
functional JJ 1_o
status NN 1_o
of IN 1_o
the DT 1_o
limb NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
radiographic JJ 1_o
appearance NN 1_o
of IN 1_o
the DT 1_o
bone NN 1_o
and CC 1_o
joint NN 1_o
. . 1_o

The DT N
results NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
showing VBG N
the DT N
added JJ N
benefit NN N
of IN N
a DT N
shorter JJR N
hospital NN N
stay NN N
for IN N
children NNS 1_p
with IN 1_p
blood-borne JJ 1_p
musculoskeletal JJ 1_p
infection NN 1_p
. . 1_p

The DT N
use NN N
of IN N
this DT N
scoring VBG N
system NN N
in IN N
choosing VBG N
the DT N
route NN N
of IN N
antibiotic JJ 1_i
administration NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- O O

Pharmacokinetics NNS N
of IN N
pregabalin JJ 1_i
controlled-release NN N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
: : 1_p
effect NN N
of IN N
food NN N
in IN N
five CD N
single-dose JJ N
, , N
randomized VBN N
, , N
clinical JJ N
pharmacology NN N
studies NNS N
. . N

BACKGROUND IN N
The DT N
pharmacokinetic JJ N
properties NNS N
of IN N
the DT N
immediate-release NN N
( ( N
IR NNP N
) ) N
and CC N
the DT N
recently RB N
developed VBN N
controlled-release NN N
( ( N
CR NNP N
) ) N
formulation NN N
of IN N
pregabalin NN 1_i
are VBP N
dose JJ N
proportional JJ N
. . N

Pregabalin NNP 1_i
IR NNP 1_i
can MD N
be VB N
taken VBN N
with IN N
or CC N
without IN N
food NN N
. . N

OBJECTIVES CC N
This DT N
analysis NN N
characterizes VBZ N
the DT N
effect NN N
of IN N
food NN N
on IN N
pregabalin NN 1_i
CR NNP 1_i
. . 1_i

The DT N
objectives NNS N
of IN N
this DT N
analysis NN N
were VBD N
: : N
( ( N
1 CD N
) ) N
to TO N
evaluate VB N
the DT N
effect NN 1_o
of IN 1_o
administration NN 1_o
time NN 1_o
and CC 1_o
fat NN 1_o
or CC 1_o
caloric JJ 1_o
content NN 1_o
of IN N
an DT N
accompanying VBG N
meal NN N
on IN N
the DT N
pharmacokinetic JJ N
properties NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
pregabalin NN 1_i
CR NNP 1_i
( ( N
330 CD N
mg NN N
) ) N
relative NN N
to TO N
a DT N
single JJ 1_i
dose NN 1_i
of IN 1_i
pregabalin NN 1_i
IR NNP 1_i
( ( N
300 CD N
mg NN N
) ) N
; : N
( ( N
2 CD N
) ) N
to TO N
evaluate VB N
the DT 1_o
pharmacokinetic JJ 1_o
properties NNS 1_o
of IN 1_o
a DT N
single JJ N
dose NN N
of IN N
pregabalin NN 1_i
CR NNP 1_i
administered VBD 1_i
fasted JJ N
relative NN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
pregabalin NN 1_i
CR NNP 1_i
administered VBD 1_i
immediately RB N
after IN N
food NN N
; : N
and CC N
( ( N
3 CD N
) ) N
to TO N
determine VB N
the DT 1_o
safety NN 1_o
and CC 1_o
tolerability NN 1_o
of IN 1_o
single-dose JJ N
administration NN N
of IN N
pregabalin JJ 1_i
CR NNP 1_i
and CC 1_i
IR NNP 1_i
with IN 1_i
and CC N
without IN N
food NN N
. . N

METHODS NNP N
The DT N
effect NN N
of IN N
food NN N
on IN N
the DT 1_o
pharmacokinetic JJ 1_o
properties NNS 1_o
of IN 1_o
pregabalin NN 1_o
CR NNP 1_o
was VBD 1_o
determined VBN N
in IN N
five CD N
phase NN N
I PRP N
, , N
open-label JJ N
, , N
single-dose JJ N
, , N
crossover JJ N
studies NNS 1_p
( ( 1_p
24-28 JJ 1_p
participants/study NN 1_p
) ) 1_p
. . 1_p

Caloric NNP N
and CC N
fat JJ N
content NN N
of IN N
meals NNS N
were VBD N
varied VBN N
and CC N
treatments NNS N
were VBD N
administered VBN N
in IN N
the DT N
morning NN N
, , N
at IN N
midday NN N
, , N
or CC N
in IN N
the DT N
evening NN 1_o
. . 1_o

Blood NN 1_o
samples NNS 1_o
were VBD 1_o
collected VBN N
up RB N
to TO N
48 CD N
h JJ N
post-dose JJ 1_o
. . 1_o

Pharmacokinetic JJ 1_o
parameters NNS 1_o
were VBD 1_o
estimated VBN N
from IN 1_o
plasma JJ 1_o
concentration-time JJ 1_o
data NNS 1_o
using VBG 1_o
standard JJ N
noncompartmental JJ N
methods NNS N
. . N

Adverse JJ N
events NNS N
were VBD N
monitored VBN N
throughout IN N
all DT N
studies NNS N
. . N

RESULTS VB 1_p
One CD 1_p
hundred CD 1_p
and CC 1_p
twenty-eight JJ 1_p
healthy JJ 1_p
participants NNS 1_p
( ( 1_p
19-54 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
received VBD 1_i
pregabalin NN 1_o
. . 1_o

Peak NNP 1_o
plasma JJ 1_o
concentrations NNS 1_o
( ( 1_o
C NNP 1_o
max NN 1_o
) ) 1_o
were VBD 1_o
lower JJR N
for IN N
CR NNP N
than IN N
the DT N
respective JJ N
pregabalin NN 1_i
IR NNP 1_i
doses VBZ N
, , N
and CC N
time NN N
to TO N
C NNP N
max NN N
occurred VBD N
later RB N
. . N

When WRB N
pregabalin NN 1_i
CR NNP 1_i
was VBD N
administered VBN N
with IN N
food NN N
at IN N
midday NN N
or CC N
in IN N
the DT N
evening NN 1_o
, , 1_o
total JJ 1_o
exposures NNS 1_o
[ VBP 1_o
area NN 1_o
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
from IN N
time NN N
zero CD N
extrapolated VBN N
to TO N
infinite VB N
time NN N
( ( N
AUC? NNP N
) ) N
] WDT N
were VBD N
equivalent JJ N
for IN N
pregabalin NN N
CR NNP N
and CC N
IR NNP N
formulations NNS N
regardless RB N
of IN N
fat NN N
or CC N
caloric JJ N
content NN N
. . N

When WRB N
pregabalin NN 1_i
CR NNP 1_i
was VBD 1_i
administered VBN N
with IN N
an DT N
800-1,000 JJ N
calorie NN N
medium-fat JJ N
breakfast NN 1_o
, , 1_o
AUC? NNP 1_o
was VBD N
equivalent JJ N
for IN N
pregabalin NN N
CR NNP N
and CC N
IR NNP N
. . 1_o

Bioequivalence NNP 1_o
criteria NNS 1_o
for IN N
comparison NN N
of IN N
pregabalin NN N
CR NNP N
after IN N
a DT N
low- JJ N
or CC N
medium-calorie JJ N
breakfast NN N
relative NN N
to TO 1_i
pregabalin VB 1_i
IR NNP 1_i
were VBD 1_i
not RB N
met VBN N
; : N
however RB N
, , N
bioavailability NN 1_i
of IN 1_i
the DT 1_i
pregabalin NN 1_i
CR NNP 1_i
vs. IN 1_i
IR NNP 1_i
formulation NN N
was VBD N
relatively RB N
high JJ N
( ( N
75-86 CD N
% NN N
) ) N
. . 1_i

When WRB 1_i
pregabalin NN 1_i
CR NNP 1_i
was VBD 1_i
administered VBN 1_i
fasted VBN N
, , N
the DT 1_o
AUC? NNP 1_o
was VBD N
70-78 JJ N
% NN N
of IN N
the DT N
AUC? NNP N
of IN N
pregabalin NN N
CR NNP N
administered VBD N
with IN N
food NN N
and CC N
bioequivalence NN N
criteria NNS N
were VBD N
not RB N
met VBN N
. . N

Additionally RB N
, , N
the DT 1_o
AUC? NNP 1_o
of IN 1_o
the DT 1_o
pregabalin NN N
CR NNP N
formulation NN N
administered VBD N
fasted VBN N
was VBD N
62-69 JJ N
% NN N
of IN N
that DT N
of IN 1_i
pregabalin NN 1_i
IR NNP 1_i
administered VBD N
fasted VBN N
and CC N
bioequivalence NN N
criteria NNS N
were VBD N
not RB N
met VBN N
. . N

Single-dose JJ 1_i
pregabalin NN 1_i
CR NNP 1_i
and CC 1_i
IR NNP 1_o
were VBD 1_o
well RB 1_o
tolerated VBN 1_o
in IN 1_o
all DT N
studies NNS N
, , N
with IN N
no DT 1_o
serious JJ 1_o
or CC 1_o
severe JJ 1_o
adverse JJ 1_o
events NNS 1_o
reported VBN 1_o
. . N

CONCLUSION NNP N
Time NNP N
of IN N
day NN N
of IN N
administration NN N
and CC N
the DT N
fat NN N
and CC N
caloric JJ N
content NN N
of IN N
the DT N
accompanying VBG N
meal NN N
had VBD 1_o
minimal JJ 1_o
overall JJ 1_o
effect NN 1_o
on IN 1_o
the DT N
pharmacokinetic JJ N
properties NNS N
and CC N
bioavailability NN N
of IN N
the DT 1_i
pregabalin NN 1_i
CR NNP N
formulation NN N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
smoking VBG 1_p
cessation NN 1_p
among IN 1_p
cancer NN 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
smoking NN 1_i
cessation NN 1_i
program NN 1_p
. . 1_p

UNLABELLED NNP N
Many JJ N
cancer NN 1_p
patients NNS 1_p
continue VBP N
to TO N
smoke VB N
postdiagnosis NN N
, , N
which WDT N
is VBZ N
associated VBN N
with IN N
poorer JJR N
clinical JJ N
outcomes NNS N
. . N

Identifying VBG N
prospective JJ N
predictors NNS N
of IN N
smoking VBG N
cessation NN N
among IN N
patients NNS N
currently RB N
receiving VBG N
smoking VBG 1_i
cessation NN 1_i
treatment NN N
can MD N
help VB N
guide VB N
the DT N
development NN N
and CC N
implementation NN N
of IN N
smoking VBG 1_i
cessation NN 1_i
programs NNS 1_i
with IN N
this DT N
population NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
Data NNP 1_p
from IN 1_p
246 CD 1_p
cancer NN 1_p
patients NNS 1_p
participating VBG 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
placebo-controlled JJ 1_i
smoking NN 1_p
cessation NN 1_p
clinical JJ 1_p
trial NN 1_p
were VBD N
used VBN N
to TO N
examine VB N
baseline JJ N
predictors NNS N
of IN N
end-of-treatment JJ N
and CC N
six-month JJ N
postbaseline NN N
smoking NN 1_i
cessation NN 1_i
outcomes RB N
. . N

Baseline NNP N
demographic JJ N
, , N
smoking-related JJ N
, , N
disease-related JJ N
, , N
and CC N
psychological JJ N
variables NNS N
were VBD N
examined VBN N
as IN N
predictors NNS N
of IN N
biochemically-confirmed JJ N
point-prevalence NN N
abstinence NN N
. . N

RESULTS NNP N
Multivariate NNP 1_o
analysis NN N
indicated VBD N
that IN N
, , N
for IN N
end-of-treatment JJ 1_o
abstinence NN 1_o
, , N
patients NNS N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
have VB N
quit NN 1_o
smoking VBG 1_o
if IN N
they PRP N
were VBD N
older JJR N
( ( N
OR NNP N
= VBZ N
1.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.03-1.10 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
were VBD N
diagnosed VBN N
with IN N
a DT N
non-tobacco JJ N
related JJ N
cancer NN N
( ( N
OR NNP N
= VBZ N
2.54 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.24-5.20 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Likewise NNP N
, , N
for IN N
six-month JJ 1_o
abstinence NN 1_o
, , N
patients NNS N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
have VB N
quit NN 1_o
smoking VBG 1_o
if IN N
they PRP N
were VBD N
older JJR N
( ( N
OR NNP N
= VBZ N
1.04 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.08 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
have VB N
quit NN N
smoking VBG N
if IN N
they PRP N
were VBD N
female JJ N
( ( N
OR NNP N
= VBZ N
0.47 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.22-0.97 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNS 1_p
with IN 1_p
tobacco-related JJ 1_p
cancers NNS 1_p
and CC 1_p
female JJ 1_p
patients NNS 1_p
reported VBD N
significantly RB N
higher JJR N
levels NNS 1_o
of IN 1_o
depression NN 1_o
symptoms NNS 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
which WDT N
proved VBD N
predictive NN 1_o
of IN 1_o
smoking VBG 1_o
relapse NN 1_o
. . 1_o

CONCLUSIONS NNP N
Patient NNP N
age NN N
, , N
gender NN N
, , N
and CC N
cancer-type NN N
may MD N
be VB N
important JJ N
factors NNS N
to TO N
consider VB N
when WRB N
developing VBG N
and CC N
implementing VBG N
smoking VBG 1_i
cessation NN 1_i
interventions NNS 1_i
for IN N
cancer NN 1_p
patients NNS 1_p
. . 1_p

-DOCSTART- -X- O O

Treatment NN N
of IN N
acute JJ N
asthma NN N
. . N

Lack NNP N
of IN N
therapeutic JJ 1_o
benefit NN 1_o
and CC 1_o
increase NN 1_o
of IN 1_o
the DT 1_o
toxicity NN 1_o
from IN N
aminophylline JJ 1_i
given VBN N
in IN N
addition NN N
to TO N
high JJ N
doses NNS N
of IN N
salbutamol NN 1_i
delivered VBN N
by IN N
metered-dose JJ N
inhaler NN N
with IN N
a DT N
spacer NN N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
to TO N
determine VB N
if IN N
intravenous JJ N
aminophylline NN 1_i
adds VBZ N
any DT N
benefit NN 1_o
to TO N
high JJ N
doses NNS N
of IN N
inhaled JJ N
salbutamol NN 1_i
in IN N
patients NNS 1_p
who WP 1_p
presented VBD 1_p
for IN 1_p
treatment NN 1_p
of IN 1_p
acute JJ 1_p
asthma NN 1_p
. . 1_p

We PRP N
studied VBD N
94 CD 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
35.6 CD 1_p
+/- JJ 1_p
11.2 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
acute JJ 1_p
asthma NN 1_p
. . 1_p

All DT N
patients NNS N
received VBD N
therapy NN N
with IN N
salbutamol NN 1_i
delivered VBN N
with IN N
metered-dose JJ 1_i
inhaler NN 1_i
( ( 1_i
MDI NNP 1_i
) ) 1_i
into IN 1_i
a DT 1_i
spacer NN 1_i
device NN 1_i
( ( N
Volumatic NNP N
) ) N
in IN N
four CD N
puffs NNS N
( ( N
400 CD N
micrograms NNS N
) ) N
at IN N
10-min JJ N
interval NN N
, , N
and CC N
intravenous JJ 1_i
hydrocortisone NN 1_i
( ( N
500 CD N
mg NN N
) ) N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
loading NN N
dose NN N
of IN N
intravenous JJ N
aminophylline NN 1_i
followed VBN N
by IN N
a DT N
routine JJ N
infusion NN N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
or CC N
an DT N
equal JJ N
volume NN N
of IN N
placebo NN 1_i
as IN N
a DT N
loading NN N
dose NN N
and CC N
infusion NN N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
showed VBD N
no DT N
differences NNS N
in IN N
measurements NNS N
of IN N
peak JJ 1_o
expiratory NN 1_o
flow NN 1_o
, , 1_o
FEV1 NNP 1_o
, , 1_o
and CC 1_o
FVC NNP 1_o
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

However RB N
, , N
the DT N
patients NNS N
treated VBN N
with IN N
aminophylline NN 1_i
had VBD N
significantly RB N
more RBR N
adverse JJ 1_o
effects NNS 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
final JJ N
mean NN N
dose NN N
of IN N
salbutamol NN N
( ( N
6.3 CD N
+/- JJ N
44.5 CD N
mg NN N
for IN N
the DT N
placebo NN 1_i
group NN N
and CC N
5.8 CD N
+/- JJ N
4.2 CD N
mg NN N
for IN N
the DT N
aminophylline NN N
group NN N
) ) N
, , N
hospital JJ N
admission NN N
rate NN N
( ( N
10.2 CD N
percent NN N
for IN N
the DT N
placebo NN N
group NN N
and CC N
9.0 CD N
percent NN N
for IN N
the DT N
aminophylline NN 1_i
group NN N
) ) N
, , N
and CC N
mean JJ N
duration NN N
of IN N
Emergency NNP N
Department NNP N
treatment NN N
( ( N
2.5 CD N
+/- JJ N
1.83 CD N
h NN N
for IN N
the DT N
placebo NN 1_i
group NN N
and CC N
2.37 CD N
+/- JJ N
1.75 CD N
h NN N
for IN N
the DT N
aminophylline NN 1_i
group NN N
) ) N
. . N

The DT N
results NNS N
were VBD N
similar JJ N
when WRB N
the DT N
patients NNS N
were VBD N
divided VBN N
in IN N
accord NN N
with IN N
the DT N
degree NN N
of IN N
respiratory NN 1_o
obstruction NN 1_o
( ( N
baseline JJ N
FEV1 NNP N
< NNP N
30 CD N
percent NN N
of IN N
predicted VBN N
) ) N
and CC N
theophylline JJ 1_o
level NN 1_o
at IN N
30 CD N
min NN N
of IN N
treatment NN N
( ( N
placebo JJ N
group NN N
patients NNS N
with IN N
theophylline JJ 1_i
level NN N
< VBD N
10 CD N
mg/L NN N
vs NN N
aminophylline NN 1_i
group NN N
patients NNS N
with IN N
theophylline JJ N
level NN N
> NN N
or CC N
= $ N
10 CD N
mg/L NN N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
intravenous JJ N
aminophylline NN N
adds VBZ N
to TO N
the DT N
toxicity NN 1_o
but CC N
not RB N
the DT N
efficacy NN 1_o
of IN N
inhaled JJ N
salbutamol NN 1_i
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
exacerbations NNS N
of IN N
asthma NN N
. . N

-DOCSTART- -X- O O

Identifying VBG N
the DT N
indications NNS N
for IN N
laparoscopically RB 1_i
assisted VBN 1_i
vaginal JJ 1_i
hysterectomy NN 1_i
: : 1_i
a DT N
prospective JJ N
, , N
randomised VBD N
comparison NN N
with IN N
abdominal JJ 1_i
hysterectomy NN 1_i
in IN 1_p
patients NNS 1_p
with IN 1_p
symptomatic JJ 1_p
uterine JJ 1_p
fibroids NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
compare VB N
laparoscopically RB 1_i
assisted VBN 1_i
vaginal JJ 1_i
hysterectomy NN 1_i
( ( 1_i
LAVH NNP 1_i
) ) 1_i
and CC 1_i
total JJ 1_i
abdominal JJ 1_i
hysterectomy NN 1_i
( ( 1_i
TAH NNP 1_i
) ) 1_i
in IN N
patients NNS 1_p
with IN 1_p
uterine JJ 1_p
fibroids NNS 1_p
. . 1_p

DESIGN VB N
A DT N
prospective JJ N
randomised VBN N
study NN N
. . N

SETTING CC N
The DT 1_p
San NNP 1_p
Paolo NNP 1_p
Hospital NNP 1_p
, , 1_p
Milan NNP 1_p
. . 1_p

POPULATION NNP N
Sixty-two JJ 1_p
patients NNS 1_p
, , 1_p
who WP 1_p
were VBD 1_p
not RB 1_p
suitable JJ 1_p
for IN 1_p
a DT 1_p
vaginal JJ 1_p
hysterectomy NN 1_p
, , 1_p
requiring VBG 1_p
treatment NN 1_p
for IN 1_p
uterine JJ 1_p
fibroids NNS 1_p
. . 1_p

METHODS NNP N
Randomisation NNP N
between IN N
LAVH NNP 1_i
and CC 1_i
TAH NNP 1_i
. . 1_i

Comparison NNP N
of IN N
outcomes NNS N
on IN N
the DT N
whole JJ N
series NN N
, , N
patients NNS N
with IN N
uteri JJ N
< NN N
or CC N
= $ N
500 CD N
g NN N
( ( N
Group NNP N
1 CD N
) ) N
and CC N
patients NNS N
with IN N
uteri JJ N
> $ N
500 CD N
g NN N
( ( N
Group NNP N
2 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
To TO N
establish VB N
operating NN 1_o
time NN 1_o
, , 1_o
blood NN 1_o
loss NN 1_o
, , 1_o
complications NNS 1_o
, , 1_o
febrile JJ 1_o
morbidity NN 1_o
, , 1_o
analgesics NNS 1_o
administration NN 1_o
and CC 1_o
hospital JJ 1_o
stay NN 1_o
for IN N
both DT N
treatment NN N
approaches NNS N
. . N

RESULTS NNP N
Median JJ 1_o
uterine JJ 1_o
weight NN 1_o
was VBD N
400 CD N
g NN N
in IN N
both DT N
LAVH NNP 1_i
and CC N
TAH NNP 1_i
group NN N
. . N

Median JJ 1_o
operating NN 1_o
time NN 1_o
was VBD N
longer RBR N
for IN N
LAVH NNP 1_i
( ( N
135 CD N
min NNS N
compared VBN N
with IN N
120 CD N
min NNS N
for IN N
TAH NNP 1_i
; : 1_i
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
but CC N
patients NNS N
undergoing JJ N
LAVH NNP 1_i
had VBD N
less RBR N
analgesics JJ 1_o
administration NN 1_o
( ( N
23 CD N
% NN N
compared VBN N
with IN N
77 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
shorter NN N
median JJ 1_o
hospital NN 1_o
stay NN 1_o
( ( N
3.8 CD N
compared VBN N
with IN N
5.8 CD N
days NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

LAVH NNP 1_i
, , N
when WRB N
compared VBN N
with IN N
TAH NNP 1_i
in IN N
the DT N
two CD N
weight NN N
subgroups NNS N
, , N
required VBD N
a DT N
significantly RB N
longer RBR N
operating VBG 1_o
time NN 1_o
only RB N
in IN N
Group NNP N
2 CD N
, , N
significantly RB N
reduced VBN N
analgesics NNS 1_o
administration NN 1_o
only RB N
in IN N
Group NNP N
1 CD N
, , N
and CC N
significantly RB N
reduced VBN N
hospital NN 1_o
stay NN 1_o
in IN N
both DT N
groups NNS N
. . N

Conversions NNS N
of IN N
LAVH NNP N
to TO N
laparotomy VB N
were VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
Group NNP N
2 CD N
( ( N
3/11 CD N
) ) N
than IN N
in IN N
Group NNP N
1 CD N
( ( N
0/20 CD N
) ) N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
TAH NNP 1_i
, , 1_i
LAVH NNP 1_i
has VBZ N
advantages NNS 1_o
in IN N
removing VBG N
uteri JJ N
weighing VBG N
< NN N
or CC N
= $ N
500 CD N
g NN N
, , N
with IN N
comparable JJ N
operating NN 1_o
time NN 1_o
, , N
less JJR N
post-operative JJ 1_o
pain NN 1_o
and CC N
shorter JJR N
recovery NN 1_o
. . 1_o

Among IN N
uteri JJ N
weighing VBG N
> JJ N
500 CD N
g NN N
LAVH NNP 1_i
showed VBD N
a DT N
shorter NN N
recovery NN N
, , N
but CC N
longer JJR N
operating NN N
time NN N
than IN N
TAH NNP 1_i
and CC N
a DT N
27 CD N
% NN N
rate NN N
of IN N
conversion NN 1_o
to TO 1_o
laparotomy VB 1_o
. . 1_o

-DOCSTART- -X- O O

Direct JJ 1_i
trocar NN 1_i
insertion NN 1_i
vs. FW 1_i
Verres NNP 1_i
needle FW 1_i
use NN 1_i
for IN N
laparoscopic JJ 1_p
sterilization NN 1_p
. . 1_p

A DT N
randomized JJ 1_p
, , 1_p
prospective JJ 1_p
trial NN 1_p
was VBD 1_p
designed VBN 1_p
to TO 1_p
compare VB 1_p
direct JJ 1_i
trocar NN 1_i
insertion NN 1_i
with IN 1_i
prior JJ 1_i
peritoneal JJ 1_i
insufflation NN 1_i
with IN 1_i
a DT 1_i
Verres NNP 1_i
needle NN 1_i
for IN 1_i
laparoscopic NN 1_i
tubal JJ 1_i
sterilization NN 1_i
. . 1_i

Direct JJ 1_i
trocar NN 1_i
insertion NN 1_i
resulted VBD N
in IN N
fewer JJR N
instrument NN 1_o
insertions NNS 1_o
( ( N
21.8 CD N
% NN N
vs. FW N
7.8 CD N
% NN N
) ) N
and CC N
use NN N
of IN N
smaller JJR 1_o
volumes NNS 1_o
of IN 1_o
CO2 NNP 1_o
( ( N
2.67 CD N
vs. FW N
2.32 CD N
L NNP N
) ) N
. . N

Direct JJ 1_i
trocar NN 1_i
use NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
operating NN 1_o
time NN 1_o
from IN N
9 CD N
minutes NNS N
, , N
40 CD N
seconds NNS N
in IN N
the DT N
needle JJ 1_p
group NN 1_p
to TO N
7 CD N
minutes NNS N
, , N
30 CD N
seconds NNS N
in IN N
the DT N
trocar NN 1_p
group NN 1_p
. . 1_p

Minor NNP 1_o
omental JJ 1_o
injuries NNS 1_o
occurred VBD N
in IN N
a DT N
small JJ N
percentage NN N
of IN N
each DT N
group NN N
, , N
while IN N
serious JJ N
complications NNS N
occurred VBD N
once RB N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O

PDE5 NNP 1_i
inhibition NN 1_i
with IN N
sildenafil JJ 1_i
improves NNS N
left VBD N
ventricular JJ N
diastolic JJ N
function NN N
, , N
cardiac JJ N
geometry NN N
, , N
and CC N
clinical JJ N
status NN N
in IN N
patients NNS 1_p
with IN 1_p
stable JJ 1_p
systolic JJ 1_p
heart NN 1_p
failure NN 1_p
: : 1_p
results NNS N
of IN N
a DT N
1-year JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
study NN N
. . N

BACKGROUND NNP N
In IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
, , N
a DT N
defective JJ N
nitric JJ N
oxide IN N
signaling VBG N
is VBZ N
involved VBN N
in IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
diastolic NN N
abnormalities NNS N
and CC N
remodeling VBG N
. . N

PDE5 NNP N
inhibition NN N
, , N
by IN N
blocking VBG N
degradation NN N
of IN N
nitric JJ N
oxide IN N
second-messenger JJ N
cyclic JJ N
guanosine NN N
monophosphate NN N
, , N
might MD N
be VB N
beneficial JJ N
. . N

In IN N
a DT N
cohort NN N
of IN N
systolic JJ 1_p
HF NNP 1_p
patients NNS 1_p
, , N
we PRP N
tested VBD N
the DT N
effects NNS N
of IN N
PDE5 NNP N
inhibition NN N
( ( 1_i
sildenafil NN 1_i
) ) 1_i
on IN N
LV NNP N
ejection NN N
fraction NN N
, , N
diastolic JJ N
function NN N
, , N
cardiac JJ N
geometry NN N
, , N
and CC N
clinical JJ N
status NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Forty-five JJ 1_p
HF NNP 1_p
patients NNS 1_p
( ( 1_p
New NNP 1_p
York NNP 1_p
Heart NNP 1_p
Association NNP 1_p
class NN 1_p
II-III NNP 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB 1_i
or CC 1_i
sildenafil VB 1_i
( ( N
50 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
) ) N
for IN N
1 CD N
year NN N
, , N
with IN N
assessment NN N
( ( N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
) ) N
of IN N
LV NNP 1_o
ejection NN 1_o
fraction NN 1_o
, , 1_o
diastolic JJ 1_o
function NN 1_o
, , 1_o
geometry NN 1_o
, , 1_o
cardiopulmonary JJ 1_o
exercise NN 1_o
performance NN 1_o
, , 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

In IN N
the DT N
sildenafil NN N
group NN N
only RB N
, , N
at IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
, , N
LV NNP 1_o
ejection NN 1_o
fraction NN 1_o
, , 1_o
early JJ 1_o
diastolic JJ 1_o
tissue NN 1_o
Doppler NNP 1_o
velocities NNS 1_o
( ( 1_o
E NNP 1_o
' POS 1_o
) ) 1_o
at IN 1_o
the DT 1_o
mitral JJ 1_o
lateral JJ 1_o
( ( N
from IN N
4.62 CD N
to TO N
5.20 CD N
and CC N
5.19 CD N
m/s NN N
) ) N
and CC N
septal JJ 1_o
( ( N
from IN N
4.71 CD N
to TO N
5.23 CD N
and CC N
5.24 CD N
m/s NN N
) ) N
annuli VBZ 1_o
significantly RB 1_o
increased VBN N
, , N
whereas IN N
the DT N
ratio NN N
of IN N
early JJ N
transmitral NN N
( ( N
E NNP N
) ) N
to TO N
E NNP N
' POS N
lateral JJ N
decreased VBN N
( ( N
from IN N
13.1 CD N
to TO N
9.8 CD N
to TO N
9.4 CD N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Changes NNS N
were VBD N
accompanied VBN N
by IN N
a DT N
reverse NN 1_o
remodeling NN 1_o
of IN 1_o
left JJ 1_o
atrial JJ 1_o
volume NN 1_o
index NN 1_o
( ( N
from IN N
32.0 CD N
to TO N
29.0 CD N
and CC N
29.1 CD N
mL/m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
LV NNP 1_o
mass NNP 1_o
index NN 1_o
( ( N
from IN N
148.0 CD N
to TO N
130.0 CD N
and CC N
128.0 CD N
g/m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Furthermore UH N
, , N
sildenafil JJ 1_i
improved VBN N
exercise NN 1_o
performance NN 1_o
( ( 1_o
peak JJ 1_o
Vo NNP 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
) ) 1_o
, , 1_o
ventilation NN 1_o
efficiency NN 1_o
( ( 1_o
ventilation NN 1_o
to TO 1_o
CO NNP 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
production NN 1_o
slope NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Minor JJ N
adverse JJ N
effects NNS N
were VBD N
noted VBN N
: : N
flushing NN 1_o
in IN N
4 CD N
and CC N
headache NN 1_o
in IN N
2 CD N
treated JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Findings NNP N
confirm NN N
that IN N
in IN N
HF NNP N
, , N
sildenafil NN 1_i
improves VBZ N
functional JJ 1_o
capacity NN 1_o
and CC 1_o
clinical JJ 1_o
status NN 1_o
and CC N
provide VB N
the DT N
first JJ N
human JJ N
evidence NN N
that IN N
LV NNP 1_o
diastolic JJ 1_o
function NN 1_o
and CC N
cardiac JJ 1_o
geometry NN 1_o
are VBP N
additional JJ N
targets NNS N
of IN N
benefits NNS N
related VBN N
to TO N
chronic JJ N
PDE5 NNP N
inhibition NN N
. . N

-DOCSTART- -X- O O

Timing NN N
of IN N
antibiotic JJ 1_i
administration NN 1_i
in IN N
knee JJ 1_p
replacement NN 1_p
under IN 1_p
tourniquet NN 1_p
. . 1_p

Cephamandole NNP 1_o
levels NNS 1_o
in IN 1_o
serum NN 1_o
and CC 1_o
drain NN 1_o
fluid NN 1_o
were VBD N
measured VBN N
in IN N
32 CD 1_p
knee JJ 1_p
replacement NN 1_p
operations NNS 1_p
to TO N
determine VB N
the DT N
benefit NN N
of IN N
an DT N
intravenous JJ N
dose NN N
of IN N
antibiotic JJ N
at IN N
the DT N
time NN N
of IN N
tourniquet JJ N
deflation NN N
. . N

Concentrations NNS N
of IN N
cephamandole NN 1_o
in IN 1_o
drain NN 1_o
fluid NN 1_o
were VBD N
directly RB N
proportional JJ N
to TO N
the DT N
serum NN N
concentration NN N
at IN N
the DT N
time NN N
of IN N
tourniquet JJ N
release NN N
. . N

A DT N
'tourniquet-release JJ 1_i
' POS 1_i
dose NN 1_i
of IN 1_i
antibiotic JJ 1_i
increased VBD N
drain NN 1_o
fluid NN 1_o
concentration NN 1_o
threefold NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
intravenous JJ N
and CC N
intra-arterial JJ N
urokinase JJ N
thrombolysis NN N
for IN N
acute JJ 1_p
ischaemic JJ 1_p
stroke NN 1_p
. . 1_p

Intravenous JJ 1_i
fibrinolysis NN 1_i
( ( 1_i
IVF NNP 1_i
) ) 1_i
with IN 1_i
rt-PA NN 1_i
( ( 1_i
alteplase NN 1_i
) ) 1_i
provides VBZ N
significant JJ N
benefits NNS N
in IN N
acute JJ N
ischaemic JJ N
stroke NN N
when WRB N
it PRP N
is VBZ N
given VBN N
within IN N
the DT N
first JJ N
three CD N
hours NNS N
following VBG N
stroke NN N
onset VBN N
. . N

Intra-arterial JJ 1_i
fibrinolysis NN 1_i
( ( 1_i
IAF NNP 1_i
) ) 1_i
with IN 1_i
pro-urokinase NN 1_i
in IN N
PROACT NNP N
II NNP N
study NN N
provides VBZ N
quite RB N
the DT N
same JJ N
benefit NN N
in IN N
the DT N
first JJ N
6 CD N
hours NNS N
. . N

IVF NNP 1_i
and CC N
IAF NNP 1_i
have VBP N
never RB N
been VBN N
compared VBN N
. . N

To TO N
compare VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
IVF NNP 1_i
and CC N
IAF NNP 1_i
with IN N
urokinase JJ N
given VBN N
within IN 1_p
the DT 1_p
first JJ 1_p
6 CD 1_p
hours NNS 1_p
of IN 1_p
acute JJ 1_p
ischaemic JJ 1_p
stroke NN 1_p
. . 1_p

Patients NNS 1_p
fulfilling VBG 1_p
the DT 1_p
selection NN 1_p
criteria NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
urokinase JJ 1_i
900,000 CD N
units NNS N
via IN N
intravenous JJ N
or CC N
intra-arterial JJ N
routes NNS N
. . N

This DT N
randomised VBD N
monocentre NN N
study NN N
was VBD N
done VBN N
between IN N
December NNP N
1995 CD N
and CC N
August NNP N
1997 CD N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
the DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
a DT 1_o
modified JJ 1_o
Rankin NNP 1_o
score NN 1_o
of IN 1_o
2 CD 1_o
or CC 1_o
less JJR 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
included VBD N
mortality NN 1_o
, , 1_o
frequency NN 1_o
of IN 1_o
symptomatic JJ 1_o
intracranial JJ 1_o
haemorrhage NN 1_o
( ( 1_o
SIH NNP 1_o
) ) 1_o
, , 1_o
neurological JJ 1_o
and CC 1_o
functional JJ 1_o
scores NNS 1_o
. . 1_o

Fourteen CD 1_p
patients NNS 1_p
were VBD 1_p
given VBN 1_p
IVF NNP 1_i
and CC 1_p
13 CD 1_p
IAF NNP 1_i
. . 1_i

The DT N
study NN N
was VBD N
terminated VBN N
by IN N
the DT N
National NNP N
Health NNP N
Authorities NNP N
when WRB N
27 CD 1_p
patients NNS 1_p
had VBD 1_p
been VBN 1_p
included VBN 1_p
because IN 1_p
of IN 1_p
the DT 1_p
mortality NN 1_p
rate NN 1_p
. . 1_p

Seven CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
died VBD N
, , N
4 CD N
in IN N
the DT N
IV NNP N
group NN N
( ( N
oedematous JJ N
infarct NN N
in IN N
3 CD N
and CC N
recurrence NN N
in IN N
1 CD N
) ) N
, , N
3 CD N
in IN N
the DT N
IA NNP N
group NN N
( ( N
SIH NNP N
in IN N
2 CD N
, , N
and CC N
oedematous JJ N
infarct NN N
in IN N
1 CD N
) ) N
. . N

Patients NNS N
given VBN N
IVF NNP 1_i
were VBD N
treated VBN N
significantly RB N
earlier RBR N
( ( N
4:16 CD N
h NN N
vs NN N
5:24 CD N
h NN N
; : N
p=.007 NN N
) ) N
. . N

Although IN N
IA NNP N
patients NNS N
showed VBD N
greater JJR N
and CC N
earlier RBR N
improvement NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
. . N

Because IN N
of IN N
premature NN N
termination NN N
, , N
the DT N
trial NN N
was VBD N
too RB N
small JJ N
to TO N
provide VB N
any DT N
reliable JJ N
and CC N
conclusive JJ N
results NNS N
. . N

Intra-arterial JJ N
fibrinolysis NN N
began VBD N
significantly RB N
later RBR N
than IN N
IV NNP N
fibrinolysis NN N
but CC N
it PRP N
gave VBD N
non-significantly RB N
better JJ N
results NNS N
in IN N
this DT N
prematurely RB N
terminated VBN N
study NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
combination NN N
chemotherapy NN 1_i
in IN N
hormone-resistant JJ 1_p
metastatic JJ 1_p
prostate NN 1_p
carcinoma NN 1_p
. . 1_p

A DT N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
in IN N
51 CD 1_p
patients NNS 1_p
with IN 1_p
stage JJ 1_p
D NNP 1_p
hormone-resistant JJ 1_p
prostatic JJ 1_p
carcinoma NN 1_p
, , N
comparing VBG N
a DT N
combination NN N
of IN N
doxorubicin NN 1_i
and CC 1_i
lomustine NN 1_i
( ( N
DC NNP N
) ) N
with IN N
cyclophosphamide NN 1_i
and CC 1_i
5-FU JJ 1_i
( ( 1_i
CF NNP 1_i
) ) 1_i
. . 1_i

Patients NNS N
were VBD N
assessed VBN N
objectively RB N
( ( N
employing VBG N
National NNP N
Prostate NNP N
Cancer NNP N
Project NNP N
criteria NNS N
) ) N
and CC N
subjectively RB N
( ( N
using VBG N
a DT N
numerical JJ N
scoring NN N
scheme NN N
) ) N
. . N

Each DT N
regimen NN N
was VBD N
well RB N
tolerated VBN 1_o
with IN N
acceptable JJ N
levels NNS 1_o
of IN 1_o
myelosuppression NN 1_o
. . 1_o

The DT N
objective JJ 1_o
partial JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
57 CD N
% NN N
for IN N
DC NNP N
and CC N
8 CD N
% NN N
for IN N
CF NNP N
. . N

Objective NNP 1_o
stabilization NN 1_o
occurred VBD N
, , N
respectively RB N
, , N
in IN N
14 CD N
% NN N
and CC N
44 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

Similarly RB N
, , N
DC NNP N
demonstrated VBD N
a DT N
significantly RB N
superior JJ N
subjective JJ 1_o
response NN 1_o
rate NN 1_o
( ( 1_o
partial JJ 1_o
plus CC 1_o
complete JJ 1_o
) ) 1_o
of IN N
82 CD N
% NN N
, , N
compared VBN N
to TO N
48 CD N
% NN N
for IN N
CF NNP 1_i
. . 1_i

Patients NNS N
with IN N
poor JJ 1_p
initial JJ 1_p
performance NN 1_p
status NN 1_p
or CC 1_p
liver VB 1_p
involvement NN 1_p
had VBD N
significantly RB N
lower JJR N
response NN 1_o
rates NNS 1_o
and CC N
reduced JJ N
survival NN 1_o
. . 1_o

Overall JJ N
, , N
there EX 1_o
was VBD 1_o
no DT 1_o
significant JJ 1_o
difference NN 1_o
in IN 1_o
survival NN 1_o
between IN 1_o
the DT 1_o
two CD 1_o
arms NNS 1_o
, , 1_o
reflecting VBG 1_o
the DT 1_o
similarity NN 1_o
between IN 1_o
DC NNP 1_o
and CC 1_o
CF NNP 1_o
in IN 1_o
total JJ 1_o
objective JJ 1_o
response NN 1_o
rate NN 1_o
( ( 1_o
partial JJ 1_o
response NN 1_o
plus CC 1_o
stable JJ 1_o
disease NN 1_o
) ) 1_o
. . 1_o

DC NNP 1_i
provided VBD N
superior JJ N
palliation NN 1_o
and CC N
was VBD N
well RB N
tolerated VBN 1_o
by IN N
an DT N
essentially RB 1_p
geriatric JJ 1_p
population NN 1_p
. . 1_p

-DOCSTART- -X- O O

Pethidine NNP 1_i
versus NN 1_i
tramadol NN 1_i
for IN N
pain NN 1_o
relief NN 1_o
during IN 1_p
labor NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
and CC N
compare VB N
the DT N
analgesic JJ 1_o
efficacy NN 1_o
and CC N
adverse JJ 1_o
effects NNS 1_o
of IN N
tramadol NN 1_i
and CC N
pethidine NN 1_i
in IN N
labor NN N
. . N

METHOD NNP N
Fifty-nine NNP 1_p
full JJ 1_p
term NN 1_p
parturients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
one CD 1_p
of IN 1_p
two CD 1_p
groups NNS 1_p
in IN 1_p
active JJ 1_p
labor NN 1_p
. . 1_p

Group NNP N
1 CD N
received VBD N
100 CD N
mg NNS N
pethidine VBP 1_i
; : 1_i
group NN N
2 CD N
, , N
100 CD N
mg NN N
tramadol NN 1_i
, , N
intramuscularly RB N
. . N

Analgesic JJ 1_o
efficacy NN 1_o
, , 1_o
maternal JJ 1_o
side NN 1_o
effects NNS 1_o
, , 1_o
changes NNS 1_o
in IN 1_o
the DT 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
duration NN 1_o
of IN 1_o
labor NN 1_o
were VBD N
assessed VBN N
. . N

RESULT NNP N
At IN N
30 CD N
and CC N
60 CD N
min NNS N
after IN N
drug NN N
administration NN N
, , N
pain VBP 1_o
relief NN 1_o
was VBD N
greater JJR N
in IN N
the DT N
pethidine NN 1_i
group NN N
than IN N
in IN N
tramadol JJ 1_i
group NN N
. . N

The DT N
incidence NN N
of IN N
nausea NN 1_o
and CC 1_o
fatigue NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
tramadol NN 1_i
group NN N
. . N

Following VBG N
drug NN N
administration NN N
the DT N
decrease NN 1_o
in IN 1_o
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
and CC N
the DT N
increase NN 1_o
in IN 1_o
heart NN 1_o
rate NN 1_o
were VBD N
statistically RB N
significant JJ N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
groups NNS N
when WRB N
compared VBN N
for IN N
duration NN 1_o
of IN 1_o
labor NN 1_o
and CC 1_o
Apgar NNP 1_o
scores NNS 1_o
. . 1_o

None NN N
of IN N
the DT N
neonates NNS N
developed VBD N
respiratory JJ 1_o
depression NN 1_o
. . 1_o

CONCLUSION NNP N
Pethidine NNP 1_i
seems VBZ N
to TO N
be VB N
a DT N
better RBR N
alternative JJ N
than IN N
tramadol NN 1_i
in IN N
obstetric JJ N
analgesia NN N
because IN N
of IN N
its PRP$ N
superiority NN N
in IN N
analgesic JJ 1_o
efficacy NN 1_o
and CC N
low JJ N
incidence NN N
of IN N
maternal JJ 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

-DOCSTART- -X- O O

Effectiveness NN 1_o
and CC 1_o
Safety NNP 1_o
of IN N
Tapentadol NNP 1_i
Prolonged NNP N
Release NNP N
( ( N
PR NNP N
) ) N
Versus NNP N
a DT N
Combination NNP 1_i
of IN 1_i
Tapentadol NNP 1_i
PR NNP 1_i
and CC 1_i
Pregabalin NNP 1_i
for IN N
the DT N
Management NNP N
of IN N
Severe NNP 1_p
, , 1_p
Chronic NNP 1_p
Low NNP 1_p
Back NNP 1_p
Pain NNP 1_p
With IN 1_p
a DT 1_p
Neuropathic JJ 1_p
Component NN 1_p
: : 1_p
A DT N
Randomized NNP N
, , N
Double-blind NNP N
, , N
Phase NNP N
3b CD N
Study NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
tapentadol NN 1_i
PR NNP 1_i
monotherapy NN N
versus NN N
tapentadol NN 1_i
PR/pregabalin NNP 1_i
combination NN N
therapy NN N
for IN N
severe JJ 1_p
, , 1_p
chronic JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
with IN 1_p
a DT 1_p
neuropathic JJ 1_p
component NN 1_p
. . 1_p

METHODS NNP N
Eligible JJ 1_p
patients NNS 1_p
had VBD 1_p
painDETECT VBN 1_p
unclear JJ 1_p
or CC 1_p
positive JJ 1_p
ratings NNS 1_p
and CC 1_p
average JJ 1_p
pain NN 1_p
intensity NN 1_p
? . 1_p
6 CD 1_p
( ( 1_p
11-point JJ 1_p
NRS-3 NNP 1_p
[ NNP 1_p
average JJ 1_p
3-day JJ 1_p
pain NN 1_p
intensity NN 1_p
] NN 1_p
) ) 1_p
at IN 1_p
baseline NN 1_i
. . 1_i

Patients NNS 1_i
were VBD 1_i
titrated VBN 1_i
to TO 1_i
tapentadol VB 1_i
PR NNP 1_i
300 CD 1_i
mg/day NN 1_i
over IN 1_i
3 CD 1_i
weeks NNS 1_i
. . 1_i

Patients NNS 1_i
with IN N
? . N
1-point JJ N
decrease NN N
in IN 1_o
pain NN 1_o
intensity NN 1_o
and CC 1_o
average JJ 1_o
pain NN 1_o
intensity NN 1_o
? . 1_o
4 CD 1_o
were VBD 1_o
randomized VBN N
to TO 1_i
tapentadol VB 1_i
PR NNP 1_i
( ( 1_i
500 CD 1_i
mg/day NN 1_i
) ) 1_i
or CC 1_i
tapentadol JJ 1_i
PR NNP 1_i
( ( 1_i
300 CD 1_i
mg/day NN 1_i
) ) 1_i
/pregabalin NN 1_i
( ( 1_i
300 CD 1_i
mg/day NN 1_i
) ) 1_i
during IN N
an DT N
8-week JJ N
comparative JJ N
period NN N
. . N

RESULTS NNP N
In IN N
the DT N
per-protocol JJ N
population NN N
( ( N
n JJ N
= NNP N
288 CD N
) ) N
, , N
the DT N
effectiveness NN 1_o
of IN 1_o
tapentadol NN 1_i
PR NNP 1_i
was VBD 1_i
clinically RB N
and CC N
statistically RB N
comparable JJ 1_i
to TO 1_i
tapentadol VB 1_i
PR/pregabalin NNP 1_i
based VBN 1_i
on IN N
the DT N
change NN N
in IN N
pain NN 1_o
intensity NN 1_o
from IN N
randomization NN N
to TO N
final JJ N
evaluation NN N
( ( N
LOCF NNP N
; : N
LSMD NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
, , N
-0.066 NNP N
[ NNP N
-0.57 NNP N
, , N
0.43 CD N
] NN N
; : N
P NNP N
< VBZ N
0.0001 CD N
for IN N
noninferiority NN N
) ) 1_o
. . 1_o

Neuropathic JJ 1_o
pain NN 1_o
and CC 1_o
quality-of-life JJ 1_o
measures NNS 1_o
improved VBN 1_o
significantly RB N
in IN N
both DT 1_o
groups NNS 1_o
. . 1_o

Tolerability NNP 1_o
was VBD 1_o
good JJ N
in IN N
both DT N
groups NNS N
, , N
in IN N
line NN N
with IN N
prior JJ N
trials NNS N
in IN N
the DT N
high JJ N
dose NN N
range NN N
of IN N
500 CD N
mg/day NN N
for IN N
tapentadol NN 1_i
PR NNP 1_i
monotherapy NN N
, , N
and CC N
favorable JJ N
compared VBN N
with IN N
historical JJ N
combination NN N
trials NNS N
of IN N
strong JJ N
opioids NNS N
and CC N
anticonvulsants NNS N
for IN N
combination NN N
therapy NN N
. . N

The DT N
incidence NN N
of IN N
the DT N
composite NN N
of IN N
dizziness NN 1_o
and/or NN 1_o
somnolence NN 1_o
was VBD N
significantly RB N
lower JJR N
with IN 1_i
tapentadol JJ 1_i
PR NNP 1_i
( ( N
16.9 CD N
% NN 1_i
) ) 1_i
than IN 1_i
tapentadol NN 1_i
PR/pregabalin NNP 1_i
( ( 1_i
27.0 CD 1_i
% NN N
; : N
P NNP N
= NNP N
0.0302 CD N
) ) N
. . N

CONCLUSIONS NNP 1_i
Tapentadol NNP 1_i
PR NNP 1_i
500 CD 1_i
mg NN 1_i
is VBZ N
associated VBN N
with IN N
comparable JJ 1_o
improvements NNS 1_o
in IN 1_o
pain NN 1_o
intensity NN 1_o
and CC 1_o
quality-of-life JJ 1_o
measures NNS 1_o
to TO 1_o
tapentadol VB 1_o
PR NNP 1_i
300 CD 1_i
mg/pregabalin NN N
300 CD N
mg NN 1_o
, , 1_o
with IN 1_o
improved JJ 1_o
central JJ 1_o
nervous JJ 1_o
system NN 1_o
tolerability NN 1_o
, , 1_o
suggesting VBG 1_o
that IN N
tapentadol NN N
PR NNP N
monotherapy NN N
may MD N
offer VB N
a DT N
favorable JJ N
treatment NN N
option NN 1_p
for IN 1_p
severe JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
with IN 1_p
a DT 1_p
neuropathic JJ 1_p
component NN 1_p
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
radiation NN 1_i
therapy NN 1_i
compared VBN N
to TO N
split VB 1_i
course NN 1_i
radiation NN 1_i
therapy NN 1_i
combined VBN 1_i
with IN 1_i
mitomycin JJ 1_i
C NNP 1_i
and CC 1_i
5 CD 1_i
fluorouracil NN 1_i
as IN N
initial JJ N
treatment NN N
for IN N
advanced JJ 1_p
laryngeal NN 1_p
and CC 1_p
hypopharyngeal NN 1_p
squamous JJ 1_p
carcinoma NN 1_p
. . 1_p

Two CD 1_p
hundred VBD 1_p
and CC 1_p
twelve JJ 1_p
patients NNS 1_p
with IN 1_p
previously RB 1_p
untreated VBN 1_p
advanced JJ 1_p
squamous JJ 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
larynx NN 1_p
or CC 1_p
hypopharynx NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
initial JJ N
treatment NN N
with IN N
radiotherapy NN 1_i
, , 1_i
50 CD 1_i
Gy NNP 1_i
in IN 1_i
20 CD 1_i
fractions NNS 1_i
in IN 1_i
28 CD 1_i
days NNS 1_i
or CC N
split JJ 1_i
course NN 1_i
radiotherapy NN 1_i
and CC 1_i
concurrent NN 1_i
chemotherapy NN 1_i
, , 1_i
25 CD 1_i
Gy NNP 1_i
in IN 1_i
10 CD 1_i
fractions NNS 1_i
in IN 1_i
14 CD 1_i
days NNS 1_i
followed VBN 1_i
by IN 1_i
a DT 1_i
4 CD 1_i
week NN 1_i
rest NN 1_i
and CC 1_i
a DT 1_i
further JJ 1_i
25 CD 1_i
Gy NNP 1_i
in IN 1_i
10 CD 1_i
fractions NNS 1_i
in IN 1_i
14 CD 1_i
days NNS 1_i
starting VBG 1_i
on IN 1_i
day NN 1_i
43 CD 1_i
; : 1_i
Mitomycin NNP 1_i
C NNP 1_i
was VBD 1_i
given VBN 1_i
on IN 1_i
day NN 1_i
1 CD 1_i
and CC 1_i
day NN 1_i
43 CD 1_i
and CC 1_i
5FU CD 1_i
continuous JJ 1_i
infusions NNS 1_i
on IN 1_i
days NNS 1_i
1 CD 1_i
-- : 1_i
4 CD 1_i
and CC 1_i
days NNS 1_i
43 CD 1_i
-- : 1_i
46 CD 1_i
. . 1_i

Surgery NN N
was VBD N
reserved VBN N
for IN N
persistent NN N
or CC N
recurrent JJ N
disease NN N
. . N

Two CD 1_p
hundred VBD 1_p
and CC 1_p
nine CD 1_p
of IN 1_p
the DT 1_p
212 CD 1_p
patients NNS 1_p
randomized VBN 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
analyses NNS 1_p
. . 1_p

Outcome NN N
analyses NNS N
were VBD N
performed VBN N
at IN N
a DT N
median JJ N
follow-up JJ N
interval NN N
of IN N
4.4 CD N
years NNS N
. . N

No DT N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
arms NNS N
for IN N
the DT N
end NN N
points NNS N
of IN N
local JJ 1_o
relapse-free JJ 1_o
rate NN 1_o
( ( N
p JJ N
= NNP N
0.91 CD N
) ) N
, , N
regional JJ 1_o
relapse-free JJ 1_o
rate NN 1_o
( ( N
p JJ N
= NN N
0.17 CD N
, , N
adjusted VBN N
) ) N
or CC N
overall JJ 1_o
survival NN 1_o
( ( N
p JJ N
= NNP N
0.86 CD N
) ) N
. . N

Eight-eight JJ N
patients NNS N
had VBD N
attempted VBN N
surgical JJ 1_o
resection NN 1_o
following VBG 1_o
radiotherapy JJ 1_o
failure NN 1_o
. . 1_o

The DT N
contribution NN N
of IN N
salvage NN N
surgery NN N
to TO N
overall JJ 1_o
survival NN 1_o
was VBD 1_o
similar JJ N
for IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
as IN N
was VBD N
the DT N
surgical JJ 1_o
complication NN 1_o
rate NN 1_o
. . 1_o

Serious JJ 1_o
late JJ 1_o
radiation NN 1_o
toxicity NN 1_o
was VBD N
minimal JJ N
( ( N
3 CD N
% NN N
in IN N
the DT N
RT NNP N
group NN N
, , N
0 CD N
% NN N
in IN N
the DT N
radiation NN N
therapy NN N
plus CC N
chemotherapy NN N
group NN N
) ) N
. . N

The DT N
result NN N
of IN N
the DT N
trial NN N
shows VBZ N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
local JJ N
control NN N
or CC N
survival NN N
for IN N
the DT N
experimental JJ N
treatment NN N
arm NN N
of IN N
split NN N
course NN N
radiotherapy NN 1_i
and CC N
concurrent JJ 1_i
chemotherapy NN 1_i
with IN 1_i
Mitomycin NNP 1_i
C NNP 1_i
and CC 1_i
5 CD 1_i
Fluorouracil NNP 1_i
compared VBN N
to TO N
radiotherapy VB N
alone RB N
. . N

-DOCSTART- -X- O O

Protein NNP 1_i
ingestion NN 1_i
further RBR N
augments NNS N
S6K1 NNP N
phosphorylation NN N
in IN N
skeletal JJ N
muscle NN N
following VBG N
resistance NN 1_p
type NN 1_p
exercise NN 1_p
in IN 1_p
males NNS 1_p
. . 1_p

Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
carbohydrate NN 1_i
and/or NN 1_i
protein NN 1_i
ingestion NN 1_i
before IN N
and CC N
after IN N
exercise NN 1_i
on IN N
ribosomal JJ N
protein NN N
S6 NNP N
kinase NN N
( ( N
S6K1 NNP N
) ) N
and CC N
S6 NNP N
phosphorylation NN N
status NN N
in IN N
human JJ 1_p
skeletal JJ N
muscle NN N
tissue NN N
. . N

Seven NNP 1_p
healthy JJ 1_p
, , 1_p
untrained JJ 1_p
men NNS 1_p
( ( 1_p
22.5 CD 1_p
+/- JJ 1_p
0.9 CD 1_p
y NN 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
2 CD N
cross-over JJ N
experiments NNS N
. . N

Before IN N
, , N
immediately RB N
after IN N
, , N
and CC N
1 CD N
h NN N
after IN N
a DT N
single JJ N
bout NN N
of IN N
resistance NN 1_i
exercise NN 1_i
, , N
subjects NNS N
consumed VBD N
0.3 CD N
g NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
carbohydrate NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
0.3 CD 1_i
g NN 1_i
x NN 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
protein NN 1_i
hydrolysate NN 1_i
( ( 1_i
CHO+PRO NNP 1_i
and CC 1_i
CHO NNP 1_i
, , 1_i
respectively RB 1_i
) ) 1_i
. . 1_i

Muscle NN 1_i
biopsies NNS 1_i
were VBD N
taken VBN N
before RB N
and CC N
immediately RB N
after IN N
exercise NN N
and CC N
after IN N
1 CD N
and CC N
4 CD N
h NN N
of IN N
postexercise NN N
recovery NN N
to TO N
determine VB N
4E-BP1 JJ N
, , N
S6K1 NNP N
( ( N
both DT N
T NNP N
( ( N
421 CD N
) ) N
/S NN N
( ( N
424 CD N
) ) N
and CC N
T NNP N
( ( N
389 CD N
) ) N
) ) N
, , N
and CC N
S6 NNP N
phosphorylation NN N
status NN N
. . N

Following VBG 1_o
resistance NN 1_o
exercise NN 1_o
, , 1_o
4E-BP1 JJ 1_o
phosphorylation NN 1_o
was VBD 1_o
reduced VBN 1_o
to TO 1_o
a DT 1_o
greater JJR 1_o
extent NN 1_o
in IN 1_o
the DT 1_o
CHO NNP 1_o
treatment NN 1_o
( ( 1_o
-48 JJ 1_o
+/- JJ 1_o
7 CD 1_o
% NN 1_o
) ) 1_o
than IN 1_o
in IN 1_o
the DT 1_o
CHO+PRO NNP 1_o
treatment NN 1_o
( ( 1_o
-15 JJ 1_o
+/- JJ 1_o
14 CD 1_o
% NN 1_o
, , 1_o
P NNP 1_o
< NNP 1_o
0.01 CD 1_o
) ) 1_o
. . 1_o

During IN 1_o
recovery NN 1_o
, , 1_o
4E-BP1 JJ 1_o
phosphorylation NN 1_o
increased VBN 1_o
in IN 1_o
both DT 1_o
experiments NNS 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
0.01 CD 1_o
) ) 1_o
, , 1_o
and CC 1_o
tended VBD 1_o
to TO 1_o
be VB 1_o
higher JJR 1_o
in IN 1_o
the DT 1_o
CHO+PRO NNP 1_o
test NN 1_o
( ( 1_o
P NNP 1_o
= NNP 1_o
0.08 CD 1_o
) ) 1_o
. . 1_o

S6K1 JJ 1_o
phosphorylation NN 1_o
at IN 1_o
T NNP 1_o
( ( 1_o
421 CD 1_o
) ) 1_o
/S NN 1_o
( ( 1_o
424 CD 1_o
) ) 1_o
substantially RB 1_o
increased VBD 1_o
following VBG 1_o
exercise NN 1_o
and CC 1_o
remained VBD 1_o
elevated VBN 1_o
during IN 1_o
recovery NN 1_o
with IN 1_o
no DT 1_o
differences NNS 1_o
between IN 1_o
treatments NNS 1_o
. . 1_o

In IN 1_o
contrast NN 1_o
to TO 1_o
the DT 1_o
CHO NNP 1_o
treatment NN 1_o
( ( 1_o
-4 JJ 1_o
+/- JJ 1_o
2 CD 1_o
% NN 1_o
) ) 1_o
, , 1_o
S6K1 NNP 1_o
phosphorylation NN 1_o
at IN 1_o
T NNP 1_o
( ( 1_o
389 CD 1_o
) ) 1_o
was VBD 1_o
higher JJR 1_o
following VBG 1_o
exercise NN 1_o
in IN 1_o
the DT 1_o
CHO+PRO NNP 1_o
treatment NN 1_o
only RB 1_o
( ( 1_o
+78 JJ 1_o
+/- JJ 1_o
2 CD 1_o
% NN 1_o
, , 1_o
P NNP 1_o
< NNP 1_o
0.01 CD 1_o
) ) 1_o
. . 1_o

During IN 1_o
recovery NN 1_o
, , 1_o
S6K1 NNP 1_o
phosphorylation NN 1_o
at IN 1_o
T NNP 1_o
( ( 1_o
389 CD 1_o
) ) 1_o
remained VBD 1_o
higher RBR 1_o
in IN 1_o
CHO+PRO NNP 1_o
than IN 1_o
in IN 1_o
CHO NNP 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
0.05 CD 1_o
) ) 1_o
. . 1_o

S6 NNP 1_o
phosphorylation NN 1_o
was VBD 1_o
substantially RB 1_o
higher JJR 1_o
following VBG 1_o
exercise NN 1_o
in IN 1_o
the DT 1_o
CHO+PRO NNP 1_o
( ( 1_o
1.69 CD 1_o
+/- JJ 1_o
0.35 CD 1_o
) ) 1_o
than IN 1_o
in IN 1_o
the DT 1_o
CHO NNP 1_o
experiment NN 1_o
( ( 1_o
0.45 CD 1_o
+/- JJ 1_o
0.07 CD 1_o
, , 1_o
P NNP 1_o
< NNP 1_o
0.01 CD 1_o
) ) 1_o
and CC 1_o
remained VBD 1_o
elevated VBN 1_o
during IN 1_o
recovery NN 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
0.05 CD 1_o
) ) 1_o
. . 1_o

We PRP N
conclude VBP N
that IN N
the DT N
availability NN N
of IN N
dietary JJ N
protein NN N
further RBR N
enhances NNS N
phosphorylation NN N
of IN N
S6K1 NNP N
during IN N
recovery NN N
from IN N
resistance NN N
type NN N
exercise NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
placebo-controlled JJ 1_i
, , N
crossover NN N
study NN N
of IN N
methylphenidate NN 1_i
for IN N
attention-deficit/hyperactivity NN N
disorder NN N
symptoms NNS N
in IN 1_p
preschoolers NNS 1_p
with IN 1_p
developmental JJ 1_p
disorders NNS 1_p
. . 1_p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
efficacy NN 1_o
and CC N
safety NN N
of IN N
methylphenidate NN 1_i
( ( 1_i
MPH NNP 1_i
) ) 1_i
to TO N
treat VB N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
symptoms NNS N
in IN N
an DT N
understudied JJ 1_p
population NN 1_p
of IN 1_p
preschoolers NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
( ( 1_p
PDD NNP 1_p
) ) 1_p
or CC 1_p
intellectual JJ 1_p
disability NN 1_p
( ( 1_p
ID NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Fourteen NNP 1_p
preschoolers NNS 1_p
with IN 1_p
developmental JJ 1_p
disorders NNS 1_p
( ( 1_p
DD NNP 1_p
, , 1_p
n JJ 1_p
= VBP 1_p
14 CD 1_p
; : 1_p
PDD NNP 1_p
, , 1_p
n JJ 1_p
= VBP 1_p
12 CD 1_p
; : 1_p
ID NNP 1_p
, , 1_p
n JJ 1_p
= NNP 1_p
2 CD 1_p
) ) 1_p
underwent NN N
MPH NNP 1_i
titration NN 1_i
in IN N
a DT N
single-blind JJ N
manner NN N
followed VBN N
by IN N
a DT N
4-week JJ N
double-blind NN N
crossover NN N
phase NN N
. . N

Each DT N
child NN N
was VBD N
administered VBN N
placebo NN 1_i
for IN N
2 CD N
weeks NNS N
and CC N
optimal JJ 1_i
dose NN 1_i
for IN N
2 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Diagnostic NNP 1_o
and CC 1_o
Statistical NNP 1_o
Manual NNP 1_o
of IN 1_o
Mental NNP 1_o
Disorders NNP 1_o
, , 1_o
4 CD 1_o
( ( 1_o
th NN 1_o
) ) 1_o
edition NN 1_o
( ( 1_o
DSM-IV NNP 1_o
) ) 1_o
ADHD NNP 1_o
subscale NN 1_o
of IN 1_o
the DT 1_o
Conners NNP 1_o
' POS 1_o
Parent NN 1_o
Rating VBG 1_o
Scale-Revised JJ 1_o
( ( N
CPRS-R-DSM-IV-ADHD NNP N
) ) N
. . N

RESULTS NNP N
MPH NNP 1_i
improved VBD N
parent-rated JJ 1_o
ADHD NNP 1_o
symptoms NNS 1_o
of IN N
the DT N
preschoolers NNS N
; : N
50 CD N
% NN N
were VBD N
rated VBN N
as IN N
responders NNS N
. . N

The DT N
CPRS-R-DSM-IV-ADHD JJ 1_o
subscale NN 1_o
was VBD N
significant JJ N
for IN N
the DT N
PDD NNP 1_p
subgroup NN 1_p
( ( N
p JJ N
= NN N
0.005 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.97 CD N
) ) N
and CC N
marginally RB N
significant JJ N
for IN N
the DT N
entire JJ N
DD NNP N
sample NN N
( ( N
p JJ N
= NN N
0.08 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.50 CD N
) ) N
. . N

Half NN N
of IN N
the DT N
preschoolers NNS 1_p
experienced VBD N
side JJ 1_o
effects NNS 1_o
with IN N
MPH NNP 1_i
, , N
including VBG N
reports NNS N
of IN N
increased VBN N
stereotypic NN 1_o
behavior NN 1_o
, , 1_o
upset JJ 1_o
stomach NN 1_o
, , 1_o
sleep-related JJ 1_o
difficulties NNS 1_o
, , 1_o
and CC 1_o
emotional JJ 1_o
lability NN 1_o
. . 1_o

One CD N
child NN N
discontinued VBN N
during IN N
titration NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

CONCLUSION VB N
The DT N
predominant JJ N
direction NN N
of IN N
response NN N
in IN N
these DT N
preschoolers NNS 1_p
with IN 1_p
both DT 1_p
ADHD NNP 1_p
and CC 1_p
PDD/ID NNP 1_p
favored VBD N
MPH NNP 1_i
, , N
even RB N
though IN N
the DT N
response NN N
was VBD N
more RBR N
subtle JJ N
and CC N
variable JJ N
than IN N
in IN N
older JJR N
and CC N
typically RB N
developing VBG N
children NNS N
. . N

Due NNP N
to TO N
high JJ N
rates NNS N
of IN N
adverse JJ N
effects NNS N
, , N
preschoolers NNS N
should MD N
be VB N
monitored VBN N
closely RB N
. . N

-DOCSTART- -X- O O

Improved VBN N
fibrinolysis NN N
after IN N
1-year JJ N
treatment NN N
with IN N
HMG NNP 1_i
CoA NNP 1_i
reductase NN 1_i
inhibitors NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
heart NN 1_p
disease NN 1_p
. . 1_p

The DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
statins NNS 1_i
on IN N
the DT N
levels NNS N
of IN N
haemostatic JJ N
variables NNS N
reflecting VBG N
procoagulant NN N
and CC N
fibrinolytic JJ N
activity NN N
in IN N
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
heart NN 1_p
disease NN 1_p
( ( 1_p
CHD NNP 1_p
) ) 1_p
, , N
with IN N
the DT N
hypothesis NN N
that WDT N
statins VBZ 1_i
might MD N
beneficially RB N
modify VB N
these DT N
levels NNS N
. . N

Fifty-eight JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
atorvastatin NN 1_i
( ( N
n=28 JJ N
) ) N
or CC N
simvastatin NN 1_i
( ( N
n=30 JJ N
) ) N
for IN N
1 CD N
year NN N
. . N

The DT N
starting VBG N
dose NN N
in IN N
both DT N
groups NNS N
was VBD N
20 CD N
mg/day NN N
. . N

Fasting VBG 1_o
blood NN 1_o
samples NNS 1_o
were VBD N
collected VBN N
before IN N
and CC N
after IN N
12-month JJ N
treatment NN N
for IN N
determinations NNS N
of IN N
fibrinogen NN 1_o
, , 1_o
prothrombin JJ 1_o
fragment NN 1_o
1+2 CD 1_o
( ( 1_o
F1+2 NNP 1_o
) ) 1_o
, , 1_o
plasma JJ 1_o
D-dimer NNP 1_o
, , 1_o
soluble JJ 1_o
tissue NN 1_o
factor NN 1_o
, , 1_o
tissue NN 1_o
plasminogen NN 1_o
activator NN 1_o
( ( 1_o
tPA NN 1_o
) ) 1_o
antigen NN 1_o
, , 1_o
tPA NN 1_o
activity NN 1_o
, , 1_o
plasminogen NN 1_o
activator NN 1_o
inhibitor JJ 1_o
type-1 JJ 1_o
activity NN 1_o
( ( 1_o
PAI-1 NNP 1_o
activity NN 1_o
) ) 1_o
and CC 1_o
serum JJ 1_o
D-dimer NNP 1_o
as IN 1_o
a DT 1_o
global JJ 1_o
test NN 1_o
of IN 1_o
fibrinolytic JJ 1_o
activity NN 1_o
. . 1_o

In IN N
the DT N
total JJ N
population NN N
, , N
improved VBN 1_o
fibrinolytic JJ 1_o
activity NN 1_o
was VBD N
observed VBN N
after IN N
1 CD N
year NN N
with IN N
increased JJ 1_o
levels NNS 1_o
of IN N
serum NN 1_o
D-dimer NNP 1_o
( ( N
P=.001 NNP N
) ) N
and CC N
tPA JJ 1_o
activity NN 1_o
( ( N
P=.024 NNP N
) ) N
and CC N
a DT N
reduction NN 1_o
in IN 1_o
tPA NN 1_o
antigen NN 1_o
( ( N
P=.048 NNP N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
measured JJ N
coagulation NN N
variables NNS N
. . N

Separately RB N
examined VBD N
, , N
an DT N
improved JJ N
fibrinolytic JJ N
profile NN N
was VBD N
seen VBN N
in IN N
the DT N
atorvastatin NN 1_i
group NN N
with IN N
a DT N
significant JJ 1_o
increase NN 1_o
in IN 1_o
serum JJ 1_o
D-dimer NNP 1_o
( ( N
P=.005 NNP N
) ) N
, , N
a DT N
borderline JJ 1_o
increase NN 1_o
in IN 1_o
tPA JJ 1_o
activity NN 1_o
( ( N
P=.083 NNP N
) ) N
and CC N
a DT N
borderline NN 1_o
reduction NN 1_o
in IN 1_o
tPA NN 1_o
antigen NN 1_o
( ( N
P=.069 NNP N
) ) N
. . N

Within IN N
the DT N
simvastatin NN 1_i
group NN N
, , N
a DT N
reduction NN 1_o
in IN 1_o
prothrombin NN 1_o
F1+2 NNP 1_o
was VBD N
observed VBN N
( ( N
P=.038 NNP N
) ) N
. . N

The DT N
differences NNS N
in IN N
changes NNS N
between IN N
the DT N
groups NNS N
were VBD N
statistically RB N
significant JJ N
only RB N
for IN N
global JJ 1_o
fibrinolysis NN 1_o
( ( N
serum JJ N
D-dimer NNP N
, , N
P=.046 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
an DT N
improved JJ N
fibrinolytic JJ 1_o
profile NN 1_o
was VBD N
observed VBN N
after IN N
statin NN 1_i
treatment NN N
, , N
most RBS N
pronounced JJ N
with IN N
atorvastatin NN 1_i
. . 1_i

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
drugs NNS N
promote VBP N
a DT N
profibrinolytic JJ N
profile NN N
, , N
and CC N
may MD N
in IN N
part NN N
explain VBP N
the DT N
benefit NN N
of IN N
statin NN 1_i
treatment NN N
rendered VBN N
in IN N
the DT N
prevention NN N
of IN N
CHD NNP N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
two-month JJ 1_i
vocal JJ 1_i
exercising NN 1_i
with IN N
and CC N
without IN N
spectral JJ 1_i
biofeedback NN 1_i
on IN N
student NN 1_p
actors NNS 1_p
' POS 1_p
speaking NN N
voice NN N
. . N

Twelve NNP 1_p
student NN 1_p
actors NNS 1_p
( ( 1_p
6 CD 1_p
males NNS 1_p
, , 1_p
6 CD 1_p
females NNS 1_p
) ) 1_p
were VBD N
given VBN N
voice NN 1_i
training VBG 1_i
for IN N
two CD N
months NNS N
. . N

Randomly NNP N
selected VBD N
, , N
half NN N
of IN N
the DT N
students NNS 1_p
( ( 1_p
3 CD 1_p
males NNS 1_p
, , 1_p
3 CD 1_p
females NNS 1_p
) ) 1_p
was VBD N
trained VBN N
in IN N
the DT N
traditional JJ 1_i
way NN 1_i
, , N
while IN N
the DT N
other JJ N
half NN N
was VBD N
given VBN N
biofeedback RP N
with IN N
real-time JJ N
spectrum NN N
analysis NN N
. . N

The DT N
aim NN N
was VBD N
a DT N
ringing JJ 1_o
voice NN 1_o
quality NN 1_o
with IN 1_o
strong JJ 1_o
overtones NNS 1_o
at IN 1_o
3-5 JJ 1_o
kHz NN 1_o
. . 1_o

Text NNP N
samples VBZ N
read VBP N
at IN N
different JJ N
loudness NN N
levels NNS N
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
training NN N
. . N

Fundamental JJ 1_o
frequency NN 1_o
( ( 1_o
F0 NNP 1_o
) ) 1_o
, , 1_o
sound JJ 1_o
pressure NN 1_o
level NN 1_o
( ( 1_o
SPL NNP 1_o
) ) 1_o
and CC 1_o
long-term-average JJ 1_o
spectrum NN 1_o
( ( 1_o
LTAS NNP 1_o
) ) 1_o
analyses NNS 1_o
were VBD N
made VBN N
. . N

Voice NNP 1_o
quality NN 1_o
was VBD N
evaluated VBN N
by IN N
two CD N
voice NN N
trainers NNS N
. . N

Sound NNP 1_o
energy NN 1_o
at IN 1_o
3-5 JJ 1_o
kHz NNS 1_o
increased VBN 1_o
by IN 1_o
3-4 JJ 1_o
dB NN 1_o
( ( N
1.5-14.5 JJ N
dB NN N
) ) N
across IN N
groups NNS N
after IN N
training VBG N
. . N

This DT N
change NN N
, , N
which WDT N
was VBD N
slightly RB N
larger JJR N
for IN N
the DT N
biofeedback NN N
( ( N
BF NNP N
) ) N
group NN N
, , N
did VBD N
not RB N
correlate VB N
with IN N
SPL NNP 1_o
. . 1_o

F0 NNP 1_o
increased VBD 1_o
slightly RB 1_o
in IN N
the DT N
BF NNP N
group NN N
and CC N
decreased VBN 1_o
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
relative JJ 1_o
dB NN 1_o
level NN 1_o
of IN 1_o
fundamental JJ 1_o
decreased VBN N
significantly RB N
more RBR N
in IN N
the DT N
BF NNP N
group NN N
probably RB N
suggesting VBG N
a DT N
tighter JJR N
adduction NN N
. . N

Voice NNP 1_o
quality NN 1_o
improved VBN N
in IN N
both DT N
groups NNS N
. . N

Visual JJ N
feedback NN N
seems VBZ N
to TO N
add VB N
some DT N
efficacy NN 1_o
in IN N
voice NN N
training NN N
. . N

However RB N
, , N
there EX N
is VBZ N
a DT N
danger NN N
of IN N
hyperfunctional JJ N
voice NN N
production NN N
if IN N
other JJ N
sensory JJ N
feedback NN N
is VBZ N
neglected VBN N
. . N

-DOCSTART- -X- O O

Rationale NNP N
and CC N
design NN N
of IN N
the DT N
Clinical NNP N
Evaluation NNP N
of IN N
Magnetic NNP 1_i
Resonance NNP 1_i
Imaging NNP 1_i
in IN N
Coronary NNP N
heart NN N
disease NN N
2 CD N
trial NN N
( ( N
CE-MARC NNP N
2 CD N
) ) N
: : N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
randomized VBN N
trial NN N
of IN N
diagnostic JJ N
strategies NNS N
in IN N
suspected JJ 1_p
coronary JJ 1_p
heart NN 1_p
disease NN 1_p
. . 1_p

BACKGROUND VB N
A DT N
number NN N
of IN N
investigative JJ N
strategies NNS N
exist VBP N
for IN N
the DT N
diagnosis NN N
of IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
. . N

Despite IN N
the DT N
widespread JJ N
availability NN N
of IN N
noninvasive JJ N
imaging NN N
, , N
invasive JJ 1_i
angiography NN 1_i
is VBZ N
commonly RB N
used VBN N
early RB N
in IN N
the DT N
diagnostic JJ N
pathway NN N
. . N

Consequently RB N
, , N
approximately RB N
60 CD N
% NN N
of IN N
angiograms JJ N
reveal VBP N
no DT N
evidence NN N
of IN N
obstructive JJ N
coronary JJ N
disease NN N
. . N

Reducing VBG N
unnecessary JJ N
angiography NN N
has VBZ N
potential JJ N
financial JJ N
savings NNS N
and CC N
avoids NNS N
exposing VBG N
the DT N
patient NN N
to TO N
unnecessary JJ N
risk NN N
. . N

There EX N
are VBP N
no DT N
large-scale JJ N
comparative JJ N
effectiveness NN N
trials NNS N
of IN N
the DT N
different JJ N
diagnostic JJ N
strategies NNS N
recommended VBD N
in IN N
international JJ N
guidelines NNS N
and CC N
none NN N
that WDT N
have VBP N
evaluated VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
cardiovascular JJ N
magnetic JJ N
resonance NN N
. . N

TRIAL NNP N
DESIGN NNP N
CE-MARC NNP N
2 CD N
is VBZ N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
3-arm JJ N
parallel NN N
group NN N
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
patients NNS 1_p
with IN 1_p
suspected JJ 1_p
CHD NNP 1_p
( ( 1_p
pretest JJS 1_p
likelihood RB 1_p
10 CD 1_p
% NN 1_p
-90 NNP 1_p
% NN 1_p
) ) 1_p
requiring VBG 1_p
further JJ 1_p
investigation NN 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
1,200 CD 1_p
patients NNS 1_p
will MD 1_p
be VB 1_p
randomized VBN 1_p
on IN N
a DT N
2:2:1 JJ N
basis NN N
to TO N
receive VB N
3.0-T JJ 1_i
cardiovascular JJ 1_i
magnetic JJ 1_i
resonance-guided JJ 1_i
care NN 1_i
, , 1_i
single-photon JJ 1_i
emission NN 1_i
computed VBD 1_i
tomography-guided JJ 1_i
care NN 1_i
( ( N
according VBG N
to TO N
American NNP N
College NNP N
of IN N
Cardiology/American NNP N
Heart NNP N
Association NNP N
appropriate-use IN N
criteria NNS N
) ) N
, , N
or CC 1_i
National NNP 1_i
Institute NNP 1_i
for IN 1_i
Health NNP 1_i
and CC 1_i
Care NNP 1_i
Excellence NNP 1_i
guidelines-based JJ 1_i
management NN 1_i
. . 1_i

The DT N
primary JJ N
( ( N
efficacy NN N
) ) N
end NN N
point NN N
is VBZ N
the DT N
occurrence NN 1_o
of IN 1_o
unnecessary JJ 1_o
angiography NN 1_o
as IN N
defined VBN N
by IN N
a DT N
normal JJ N
( ( N
> JJ N
0.8 CD N
) ) N
invasive JJ 1_o
fractional JJ 1_o
flow NN 1_o
reserve NN 1_o
. . 1_o

Safety NN 1_o
of IN N
each DT N
strategy NN N
will MD N
be VB N
assessed VBN N
by IN N
3-year JJ N
major JJ N
adverse JJ N
cardiovascular JJ N
event NN N
rates NNS N
. . N

Cost-effectiveness JJ 1_o
and CC 1_o
health-related JJ 1_o
quality-of-life JJ 1_o
measures NNS 1_o
will MD N
be VB N
performed VBN N
. . N

CONCLUSIONS VB N
The DT N
CE-MARC NNP N
2 CD N
trial NN N
will MD N
provide VB N
comparative JJ N
efficacy NN N
and CC N
safety NN N
evidence NN N
for IN N
3 CD N
different JJ N
strategies NNS N
of IN N
investigating VBG N
patients NNS 1_p
with IN 1_p
suspected JJ 1_p
CHD NNP 1_p
, , N
with IN N
the DT N
intension NN N
of IN N
reducing VBG N
unnecessary JJ N
invasive JJ N
angiography NN N
rates NNS N
. . N

Evaluation NN N
of IN N
these DT N
management NN N
strategies NNS N
has VBZ N
the DT N
potential NN N
to TO N
improve VB N
patient NN N
care NN N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
the DT N
cost-effectiveness NN N
of IN N
CHD NNP N
investigation NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
in IN N
performing VBG N
eye-hand JJ N
integration NN N
tasks NNS N
: : N
four CD N
preliminary JJ N
studies NNS N
with IN N
children NNS 1_p
showing VBG 1_p
low-functioning JJ 1_p
autism NN 1_p
. . 1_p

This DT N
report NN N
, , N
based VBN N
on IN N
four CD N
studies NNS N
with IN N
children NNS 1_p
with IN 1_p
low-functioning JJ 1_p
autism NN 1_p
, , N
aimed VBN N
at IN N
evaluating VBG N
the DT N
effects NNS N
of IN N
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
delivered VBN N
on IN N
the DT N
left NN N
and CC N
right JJ N
premotor NN N
cortices NNS N
on IN N
eye-hand JJ N
integration NN N
tasks NNS N
; : N
defining VBG N
the DT N
long-lasting JJ N
effects NNS N
of IN N
high-frequency NN 1_i
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
; : 1_i
and CC N
investigating VBG N
the DT N
real JJ N
efficacy NN N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
by IN N
comparing VBG N
three CD N
kinds NNS N
of IN N
treatments NNS N
( ( N
high-frequency JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
, , N
a DT N
traditional JJ N
eye-hand JJ N
integration NN N
training NN N
, , N
and CC N
both DT N
treatments NNS N
combined VBN N
) ) N
. . N

Results $ N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
eye-hand JJ 1_o
performances NNS 1_o
only RB N
when WRB N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
was VBD N
delivered VBN N
on IN N
the DT N
left JJ N
premotor NN N
cortex NN N
; : N
a DT N
persistent NN N
improvement NN N
up IN N
to TO N
1 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
the DT N
stimulation NN N
; : N
better JJR N
outcomes NNS N
in IN N
the DT N
treatment NN N
combining VBG N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
and CC N
eye-hand JJ N
integration NN N
training NN N
. . N

Based VBN N
on IN N
these DT N
preliminary JJ N
findings NNS N
, , N
further JJ N
evaluations NNS N
on IN N
the DT N
usefulness NN N
of IN N
high-frequency NN 1_i
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
in IN N
rehabilitation NN N
of IN N
children NNS 1_o
with IN 1_o
autism NN 1_o
are VBP N
strongly RB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
rapid JJ 1_i
radiation NN 1_i
treatment NN 1_i
schedules NNS N
utilizing VBG N
two CD N
treatment NN N
sessions NNS N
per IN N
day NN N
. . N

The DT N
authors NNS N
studied VBD N
normal JJ 1_p
human JJ 1_p
skin NN 1_p
reactions NNS 1_p
to TO 1_p
two CD 1_p
different JJ 1_p
rapid JJ 1_i
radiotherapy NN 1_i
schedules NNS 1_i
of IN 1_p
2 CD 1_p
sessions NNS 1_p
per IN 1_p
day NN 1_p
and CC 1_p
evaluated VBD 1_p
their PRP$ 1_p
effectiveness NN 1_p
in IN 1_p
relief NN 1_p
of IN 1_p
pain NN 1_p
and CC 1_p
local JJ 1_p
tumor NN 1_p
control NN 1_p
. . 1_p

Patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
three CD 1_p
treatment NN 1_p
groups NNS 1_p
: : 1_p
SCHEDULE VB 1_i
A NNP 1_i
( ( 1_i
control NN 1_i
) ) 1_i
: : 1_i
conventional JJ 1_i
one CD 1_i
treatment NN 1_i
per IN 1_i
day NN 1_i
regimen NNS 1_i
totalling VBG 1_p
3,760 CD 1_p
rads NNS 1_i
in IN 1_p
22-23 JJ 1_p
days NNS 1_p
; : 1_p
SCHEDULE NNP 1_p
B NNP 1_p
: : 1_p
2 CD 1_i
sessions NNS 1_i
per IN 1_i
day NN 1_i
totalling VBG 1_p
3,440 CD 1_p
rads NNS 1_i
in IN 1_p
10-11 JJ 1_p
days NNS 1_p
; : 1_p
and CC 1_p
SCHEDULE NNP 1_p
C NNP 1_p
: : 1_p
2 CD 1_p
sessions NNS 1_p
per IN 1_p
day NN 1_p
totalling VBG 1_p
3,568 CD 1_p
rads NNS 1_p
in IN 1_p
10-11 JJ 1_p
days NNS 1_p
. . 1_p

The DT N
pattern NN N
and CC N
magnitude NN N
of IN N
skin JJ 1_o
reactions NNS 1_o
in IN N
the DT N
three CD N
schedules NNS N
are VBP N
nearly RB N
identical JJ N
but CC N
tumor JJ 1_o
regression NN 1_o
and CC 1_o
pain NN 1_o
relief NN 1_o
were VBD N
achieved VBN N
faster RBR N
in IN N
the DT N
rapid JJ N
fractionation NN N
schedules NNS N
. . N

-DOCSTART- -X- O O

Single-use NNP N
plaque NN N
removal NN N
efficacy NN 1_o
of IN N
three CD 1_p
power NN 1_i
toothbrushes NNS 1_i
. . 1_i

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
safety NN 1_o
and CC 1_o
plaque NN 1_o
removal NN 1_o
efficacy NN 1_o
of IN N
two CD 1_i
oscillating/rotating/pulsating VBG 1_i
toothbrushes NNS 1_i
( ( 1_i
Oral-B NNP 1_i
ProfessionalCare NNP 1_i
7000 CD 1_i
[ NNP 1_i
PC NN 1_i
7000 CD 1_i
] NN 1_i
and CC 1_i
Oral-B JJ 1_i
3D CD 1_i
Excel NNP 1_i
[ VBD 1_i
3DE CD 1_i
] NN 1_i
) ) 1_i
and CC 1_i
a DT 1_i
high-frequency NN 1_i
toothbrush NN 1_i
( ( 1_i
Sonicare NNP 1_i
Advance NNP 1_i
, , 1_i
Philips NNP 1_i
Oral NNP 1_i
Healthcare NNP 1_i
; : 1_i
SA NNP 1_i
) ) 1_i
in IN N
a DT N
single-use NN N
, , N
examiner-blind NN N
, , N
three CD N
period NN N
crossover NN N
study NN N
. . N

METHODS NNP N
After IN 1_p
refraining VBG 1_p
from IN 1_p
all DT 1_p
oral JJ 1_p
hygiene NN 1_p
procedures NNS 1_p
for IN 1_p
23-25 JJ 1_p
hours NNS 1_p
, , 1_p
subjects NNS 1_p
received VBD 1_p
an DT 1_p
oral JJ 1_p
tissue NN 1_p
examination NN 1_p
and CC N
those DT N
with IN N
pre-brushing JJ N
whole JJ N
mouth NN N
mean JJ N
plaque NN N
scores NNS N
> VBP N
or CC N
= VBP N
0.6 CD N
based VBN N
on IN N
the DT N
Rustogi NNP N
et CC N
al NN N
. . N

Modified NNP N
Navy NNP N
Plaque NNP N
Index NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
sequence NN N
. . N

After IN N
brushing VBG N
with IN N
the DT N
assigned JJ N
toothbrush NN N
and CC N
a DT N
commercially RB N
available JJ N
dentifrice NN N
for IN N
2 CD N
minutes NNS N
, , N
oral JJ 1_o
tissues NNS 1_o
were VBD 1_o
then RB 1_o
re-examined JJ 1_o
and CC 1_o
post-brushing JJ 1_o
plaque NN 1_o
scores NNS 1_o
recorded VBN 1_o
. . 1_o

Following VBG N
a DT N
brief JJ N
washout JJ N
period NN N
between IN N
two CD N
additional JJ N
visits NNS N
, , N
the DT N
above NN N
procedures NNS N
were VBD N
repeated VBN N
with IN N
the DT N
two CD N
alternate NN N
toothbrushes NNS N
. . N

One CD N
examiner NN N
, , N
blinded VBD N
to TO N
the DT N
treatment NN N
sequence NN N
, , N
performed VBD N
all DT N
clinical JJ N
measurements NNS N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
79 CD 1_p
subjects NNS 1_p
( ( 1_p
28 CD 1_p
males NNS 1_p
and CC 1_p
51 CD 1_p
females NNS 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
and CC 1_p
completed VBN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Each DT N
toothbrush NN N
was VBD N
found VBN N
to TO N
be VB N
safe JJ 1_o
and CC N
significantly RB N
reduced VBN N
plaque NN 1_o
levels NNS 1_o
after IN N
a DT N
single JJ N
brushing NN N
. . N

The DT N
PC NN N
7000 CD N
and CC N
3DE CD N
were VBD N
equally RB N
more RBR N
effective JJ N
in IN N
plaque NN 1_o
removal NN 1_o
than IN N
the DT N
SA NNP N
, , N
at IN N
all DT N
tooth DT N
areas NNS N
, , N
reducing VBG N
plaque NN 1_o
by IN N
59.0 CD N
% NN N
, , N
59.7 CD N
% NN N
and CC N
51.8 CD N
% NN N
, , N
respectively RB N
on IN N
whole JJ N
mouth NN N
surfaces NNS N
, , N
and CC N
by IN N
67.5 CD N
% NN N
, , N
67.8 CD N
% NN N
and CC N
59.4 CD N
% NN N
, , N
respectively RB N
on IN N
approximal JJ N
surfaces NNS N
. . N

CONCLUSIONS VB N
The DT N
action NN N
of IN N
the DT N
oscillating/rotating/pulsating NN N
toothbrushes NNS N
( ( N
Oral-B NNP N
ProfessionalCare NNP N
7000 CD N
and CC N
Oral-B NNP N
3D CD N
Excel NNP N
) ) N
was VBD N
more RBR N
effective JJ N
in IN N
plaque NN N
removal NN N
than IN N
the DT N
high-frequency NN N
toothbrush NN N
( ( N
Sonicare NNP N
Advance NNP N
) ) N
. . N

-DOCSTART- -X- O O

[ VB N
A DT N
clinical JJ N
trial NN N
of IN N
ultrasound-guided JJ 1_i
facet NNS 1_i
joint JJ 1_i
block NN 1_i
in IN N
the DT N
lumbar NN N
spine NN N
to TO N
treat VB N
facet JJ 1_p
joint NN 1_p
related VBD 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
feasibility NN N
and CC N
clinical JJ N
efficacy NN N
of IN N
ultrasound-guided JJ 1_i
facet NNS 1_i
joint JJ 1_i
injection NN 1_i
and CC N
nerve NN 1_i
block NN 1_i
in IN 1_i
lumbar NN 1_i
facet NN 1_i
joint NN 1_i
for IN N
the DT N
treatment NN N
of IN N
facet-joint NN 1_p
related VBN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

METHODS NNP N
20 CD 1_p
patients NNS 1_p
with IN 1_p
facet-joint JJ 1_p
pain NN 1_p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
received VBD N
block RB 1_i
blindly RB 1_i
( ( 1_i
B NNP 1_i
group NN 1_i
) ) 1_i
or CC 1_i
guided VBN 1_i
by IN 1_i
ultrasound NN 1_i
( ( 1_i
US NNP 1_i
group NN 1_i
) ) 1_i
respectively RB 1_i
. . 1_i

The DT N
location NN N
of IN N
needle JJ N
tip NN N
was VBD N
confirmed VBN N
by IN N
CT NNP N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
accuracy NN N
was VBD N
computed VBN N
afterwards NNS N
. . N

VAS NNP 1_o
score NN 1_o
, , 1_o
puncture NN 1_o
time NN 1_o
and CC 1_o
one-time JJ 1_o
puncture NN 1_o
success NN 1_o
rate NN 1_o
( ( N
% NN N
) ) N
were VBD N
recorded VBN N
. . N

VAS NNP 1_o
scores NNS 1_o
and CC 1_o
pain VB 1_o
remission NN 1_o
rates NNS 1_o
in IN N
both DT N
groups NNS N
were VBD N
recorded VBN N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
, , N
6 CD N
weeks NNS N
after IN N
the DT N
block NN N
. . N

RESULTS VB N
The DT N
VAS NNP 1_o
scores NNS 1_o
were VBD N
3.3 CD N
+/- JJ N
0.4 CD N
in IN N
US NNP N
group NN N
and CC N
1.2 CD N
+/- JJ N
0.3 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
puncture NN 1_o
time NN 1_o
was VBD N
( ( N
206 CD N
+/- JJ N
27 CD N
) ) N
s NN N
in IN N
US NNP N
group NN N
while IN N
( ( N
397 CD N
+/- JJ N
31 CD N
) ) N
s NN N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
37 CD N
facet JJ 1_i
joint NN 1_i
blocks NNS 1_i
guided VBN 1_i
by IN 1_i
ultrasound NN 1_i
, , N
in IN N
which WDT N
32 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
. . N

The DT N
success NN 1_o
rate NN 1_o
is VBZ N
86.5 CD N
% NN N
. . N

There EX N
were VBD N
35 CD N
facet JJ 1_i
joint NN 1_i
blocks NNS 1_i
blindly RB 1_i
, , N
in IN N
which WDT N
11 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
. . N

The DT N
success NN 1_o
rate NN 1_o
is VBZ N
31.4 CD N
% NN N
. . N

The DT N
difference NN N
of IN N
one-time JJ 1_o
puncture NN 1_o
success NN 1_o
rate NN 1_o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
significant JJ 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Differences NNS N
of IN N
VAS NNP 1_o
and CC 1_o
pain VB 1_o
remission NN 1_o
rate NN 1_o
at IN N
half PDT N
an DT N
hour NN N
after IN N
facet JJ N
joint JJ N
injection NN N
between IN N
B NNP N
group NN N
and CC N
US NNP N
group NN N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
8 CD N
, , N
9 CD N
, , N
9 CD N
, , N
and CC N
9 CD N
patients NNS N
in IN N
US NNP N
group NN N
obtaining VBG N
a DT N
reduction NN 1_o
in IN N
VAS NNP 1_o
scores NNS 1_o
> VBP N
or CC N
= VBP N
3 CD N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
and CC N
6 CD N
weeks NNS N
after IN N
the DT N
procedure NN N
respectively RB N
, , N
while IN N
the DT N
numbers NNS N
of IN N
such JJ N
patients NNS N
were VBD N
5 CD N
, , N
6 CD N
, , N
5 CD N
, , N
5 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

After IN N
6 CD N
weeks NNS N
of IN N
follow-up NN N
, , N
the DT N
overall JJ 1_o
remission NN 1_o
rates NNS 1_o
were VBD N
( ( N
72.3 CD N
+/- JJ N
14.0 CD N
) ) N
% NN N
in IN N
US NNP N
group NN N
, , N
and CC N
( ( N
56.7 CD N
+/- JJ N
11.0 CD N
) ) N
% NN N
in IN N
B NNP N
group NN N
, , N
there EX N
was VBD N
no DT 1_o
significant JJ 1_o
difference NN 1_o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
ultrasound-guided JJ 1_i
lumbar NN 1_i
facet NN 1_i
joint JJ 1_i
injection NN 1_i
technique NN 1_i
had VBD N
a DT N
high JJ N
feasibility NN N
and CC N
accuracy NN N
, , N
and CC N
had VBD N
better RBR N
clinical JJ N
efficacy NN N
than IN N
block NN 1_i
blindly RB 1_i
. . 1_i

-DOCSTART- -X- O O

A DT N
cost-benefit JJ 1_o
comparison NN N
of IN N
intensive JJ 1_i
diabetes NNS 1_i
management NN 1_i
with IN 1_i
implantable JJ 1_i
pumps NNS 1_i
versus IN N
multiple JJ 1_i
subcutaneous JJ 1_i
injections NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
type NN 1_p
I PRP 1_p
diabetes VBZ 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
investigate VB N
if IN N
intraperitoneal JJ 1_i
( ( 1_i
IP NNP 1_i
) ) 1_i
insulin NN 1_i
infusion NN 1_i
via IN 1_i
programmable JJ 1_i
implantable JJ 1_i
pumps NNS 1_i
is VBZ N
a DT N
potential JJ N
alternative NN N
to TO N
subcutaneous JJ 1_i
( ( 1_i
SC NNP 1_i
) ) 1_i
insulin NN 1_i
via IN 1_i
multiple JJ 1_i
injections NNS 1_i
. . 1_i

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
compared VBN N
the DT N
cost-benefits NNS 1_o
of IN N
the DT N
two CD N
methods NNS N
using VBG N
a DT N
randomized VBN N
, , N
prospective JJ N
, , N
6-month JJ N
, , N
crossover JJ N
design NN N
in IN N
10 CD 1_p
adult NN 1_p
type NN 1_p
I PRP 1_p
diabetic JJ 1_p
patients NNS 1_p
. . 1_p

RESULTS NNP N
When WRB N
judged VBN N
on IN N
the DT N
last JJ N
month NN N
of IN N
IP NNP N
versus NN N
SC NNP N
periods NNS N
in IN N
the DT N
nine CD N
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
, , N
metabolic JJ 1_o
data NN 1_o
showed VBD N
better JJR N
glycemic JJ 1_o
control NN 1_o
( ( N
HbA1c NNP N
: : N
7.2 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs. FW N
8.5 CD N
+/- JJ N
0.7 CD N
% NN N
SC NNP N
, , N
mean JJ N
+/- JJ N
SE NNP N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
reduced VBN 1_o
glycemic JJ 1_o
fluctuations NNS 1_o
( ( N
SD NNP N
of IN N
capillary JJ N
glucose JJ N
values NNS N
: : N
3.4 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs. FW N
4.6 CD N
+/- JJ N
0.2 CD N
mM NN N
SC NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
fewer JJR N
mild JJ 1_o
hypoglycemic JJ 1_o
events NNS 1_o
( ( N
5.7 CD N
+/- JJ N
2.0 CD N
IP NNP N
vs. FW N
10.0 CD N
+/- JJ N
3.1 CD N
events/month JJ N
SC NNP N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
judged VBN 1_o
by IN 1_o
Diabetes NNP 1_o
Control NNP 1_o
and CC 1_o
Complications NNP 1_o
Trial NNP 1_o
questionnaires NNS 1_o
, , N
was VBD N
unaffected VBN N
by IN N
pump NN 1_i
therapy NN N
. . N

Direct JJ 1_o
costs NNS 1_o
, , 1_o
including VBG 1_o
pump JJ 1_o
acquisition NN 1_o
, , 1_o
implantation NN 1_o
, , 1_o
and CC 1_o
follow-up NN 1_o
, , N
were VBD N
2.6-fold JJ N
higher JJR N
with IN N
IP NNP N
than IN N
with IN N
SC NNP N
delivery NN N
. . N

CONCLUSIONS VB N
The DT N
implantable JJ 1_i
pump NN 1_i
is VBZ N
more RBR 1_o
effective JJ 1_o
in IN N
the DT N
short JJ N
term NN N
, , N
equally RB N
accepted VBN 1_o
, , N
but CC N
more RBR N
costly JJ 1_o
than IN N
multiple JJ 1_i
injections NNS 1_i
and CC N
should MD N
be VB N
limited VBN N
to TO N
patients NNS N
with IN N
unsatisfactory JJ N
glycemic JJ 1_o
control NN 1_o
despite IN N
intensive JJ N
diabetes NNS N
management NN N
with IN N
SC NNP N
insulin NN N
. . N

In IN N
addition NN N
, , N
longer-term JJ N
, , N
larger-scale JJ N
, , N
and CC N
comparative JJ N
evaluation NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
fasting VBG 1_i
and CC 1_i
treatment NN 1_i
omission NN 1_i
on IN N
susceptibility NN 1_o
to TO 1_o
hypoglycaemia VB 1_o
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
GH NNP 1_p
and CC 1_p
cortisol JJ 1_p
insufficiency NN 1_p
. . 1_p

OBJECTIVE NNP N
Hypoglycaemia NNP N
may MD N
be VB N
a DT N
frequent JJ N
occurrence NN N
in IN N
young JJ 1_p
GH NNP 1_p
deficient NN 1_p
patients NNS 1_p
and CC N
so RB N
we PRP N
studied VBD N
the DT N
response NN N
to TO N
fasting VBG N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
GH NNP 1_p
and/or VBP 1_p
cortisol JJ 1_p
deficiency NN 1_p
. . 1_p

METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
20 CD 1_p
patients NNS 1_p
( ( 1_p
2-18 CD 1_p
years NNS 1_p
) ) 1_p
fasted VBD 1_i
for IN 1_p
14 CD 1_p
h NN 1_p
( ( 1_p
22.00-12.00 JJ 1_p
h NN 1_p
) ) 1_p
on IN 1_p
two CD 1_p
occasions NNS 1_p
as IN N
part NN N
of IN N
a DT N
randomized JJ N
cross-over NN N
study NN N
. . N

Fourteen NNP 1_p
had VBD 1_p
pituitary JJ 1_p
hormone NN 1_p
deficiency NN 1_p
( ( 1_p
PHD NNP 1_p
) ) 1_p
including VBG 1_p
GH NNP 1_p
deficiency NN 1_p
( ( 1_p
GHD NNP 1_p
) ) 1_p
. . 1_p

Of IN 1_p
the DT 1_p
14 CD 1_p
patients NNS 1_p
, , 1_p
seven CD 1_p
were VBD 1_p
ACTH NNP 1_p
sufficient NN 1_p
( ( 1_p
PHDC+ NNP 1_p
) ) 1_p
and CC 1_p
seven CD 1_p
ACTH NNP 1_p
deficient NN 1_p
( ( 1_p
PHDC- NNP 1_p
) ) 1_p
. . 1_p

Six NNP 1_p
had VBD 1_p
primary JJ 1_p
adrenal JJ 1_p
failure NN 1_p
( ( 1_p
PAF NNP 1_p
) ) 1_p
. . 1_p

Subjects NNPS N
administered VBD N
or CC N
omitted VBD 1_i
their PRP$ N
normal JJ 1_i
dose NN 1_i
of IN 1_i
evening VBG 1_i
GH NNP 1_i
and/or NN 1_i
morning NN 1_i
hydrocortisone NN 1_i
. . 1_i

Glucose NNP 1_o
, , 1_o
insulin NN 1_o
, , 1_o
GH NNP 1_o
, , 1_o
cortisol NN 1_o
, , 1_o
ketones NNS 1_o
and CC 1_o
catecholamines NNS 1_o
were VBD N
measured VBN N
at IN N
04.00 CD N
h NN N
and CC N
regularly RB N
from IN N
07.00 CD N
to TO N
12.00 CD N
h. NNS N
Insulin NNP 1_o
sensitivity NN 1_o
was VBD N
assessed VBN N
by IN N
HOMA NNP 1_o
and CC N
hypoglycaemia NN 1_o
defined VBN N
as IN N
a DT N
blood NN 1_o
glucose NN 1_o
( ( N
BG NNP N
) ) N
< VBD N
/= $ N
3.3 CD N
mmol/l NN N
. . N

RESULTS NNP N
BG NNP N
was VBD N
related VBN N
to TO N
age NN 1_o
and CC 1_o
body NN 1_o
mass NN 1_o
index NN 1_o
on IN N
treatment NN N
but CC N
no DT N
subject NN N
became VBD N
hypoglycaemic JJ N
on IN N
or CC N
off IN N
therapy NN N
prior RB N
to TO N
07.00 CD N
h. NN N
Five CD N
children NNS N
( ( N
aged VBN N
3 CD N
, , N
4 CD N
, , N
7 CD N
, , N
8 CD N
and CC N
11 CD N
years NNS N
) ) N
were VBD N
hypoglycaemic JJ 1_o
between IN N
07.00 CD N
and CC N
12.00 CD N
h NNS N
off IN N
treatment NN N
. . N

There EX N
was VBD N
a DT N
positive JJ N
relationship NN N
between IN N
GH NNP 1_o
AUC NNP 1_o
and CC 1_o
minimum JJ 1_o
BG NNP 1_o
in IN N
patients NNS N
with IN N
PHD NNP N
on IN N
treatment NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
= NN N
0.45 CD N
, , N
P NNP N
= NNP N
0.012 CD N
) ) N
with IN N
increased VBN N
insulin NN 1_o
sensitivity NN 1_o
off IN N
treatment NN N
. . N

Increased VBN 1_o
cortisol NN 1_o
levels NNS 1_o
were VBD N
seen VBN N
in IN N
PHDC+ NNP N
patients NNS N
off RP N
GH NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
negative JJ N
relationship NN N
was VBD N
observed VBN N
between IN N
minimum JJ N
BG NNP 1_o
and CC 1_o
adrenaline NN 1_o
( ( N
r NN N
( ( N
2 CD N
) ) N
= NN N
0.37 CD N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
ketone JJ 1_o
bodies NNS 1_o
( ( N
r NN N
( ( N
2 CD N
) ) N
= NN N
-0.20 NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
NEFA NNP 1_o
( ( N
r NN N
( ( N
2 CD N
) ) N
= NN N
-0.35 NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Noradrenaline JJ 1_o
levels NNS 1_o
were VBD N
reduced VBN N
in IN N
patients NNS 1_p
with IN 1_p
PHDC- NNP 1_p
. . 1_p

Low NNP N
BMI NNP 1_o
( ( N
on IN N
treatment NN N
) ) N
and CC N
young JJ N
age NN N
( ( N
off IN N
treatment NN N
) ) N
were VBD N
determinants NNS N
of IN N
low JJ 1_o
BG NNP 1_o
levels NNS 1_o
in IN N
a DT N
multiple JJ N
regression NN N
model NN N
. . N

CONCLUSIONS NNP N
Unrecognized NNP N
overnight VBD N
hypoglycaemia NN N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
on IN N
pituitary JJ N
hormone NN N
replacement NN N
is VBZ N
uncommon JJ N
but CC N
BG NNP 1_o
levels NNS 1_o
quickly RB N
become VBP N
abnormal JJ N
when WRB N
treatment NN N
and CC N
meals NNS N
are VBP N
omitted VBN 1_i
. . 1_i

The DT N
insulin NN 1_o
antagonistic JJ 1_o
actions NNS 1_o
of IN 1_o
GH NNP 1_o
are VBP N
important JJ N
in IN N
preventing VBG N
hypoglycaemia NN N
. . N

Patients NNS 1_p
with IN 1_p
PHD NNP 1_p
have VBP N
altered VBN N
sympathetic JJ 1_o
nerve NN 1_o
activity NN 1_o
. . 1_o

-DOCSTART- -X- O O

Households NNS 1_p
with IN 1_p
young JJ 1_p
children NNS 1_p
and CC 1_p
use NN 1_p
of IN 1_p
freely RB 1_p
distributed VBN 1_p
bednets NNS 1_i
in IN 1_p
rural JJ 1_p
Madagascar NNP 1_p
. . 1_p

BACKGROUND NNP N
Malaria NNP N
infections NNS N
are VBP N
the DT N
leading VBG N
cause NN N
of IN N
death NN N
for IN N
children NNS 1_p
in IN 1_p
Madagascar NNP 1_p
. . 1_p

Insecticide-treated JJ 1_i
bednets NNS 1_i
offer VBP N
effective JJ N
prevention NN N
, , N
but CC N
it PRP N
is VBZ N
unclear JJ N
how WRB N
well RB N
free JJ 1_i
bednet NN 1_i
distribution NN 1_i
programs NNS 1_i
reach VBP N
young JJ 1_p
children NNS 1_p
. . 1_p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
secondary JJ N
analysis NN N
of IN N
a DT N
free JJ 1_i
bednet NN 1_i
distribution NN 1_i
program NN 1_i
in IN 1_p
Madagascar NNP 1_p
from IN 1_p
2007-2008 JJ 1_p
. . 1_p

Interviews NNS 1_i
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

Principal JJ N
components NNS N
analysis NN N
was VBD N
used VBN N
to TO N
construct VB N
a DT N
wealth NN N
and CC N
malaria NNS N
knowledge VBP N
index NN N
. . N

Coverage NNP N
efficiency NN N
was VBD N
calculated VBN N
as IN N
coverage NN 1_i
of IN 1_i
children NNS 1_i
per IN 1_i
bednet NN 1_i
owned VBN 1_i
. . 1_i

Univariable JJ N
and CC N
multivariable JJ N
regressions NNS N
were VBD N
used VBN N
to TO N
determine VB N
predictors NNS N
of IN N
bednet NN 1_i
use NN N
. . N

RESULTS NNP N
Bednet NNP 1_o
use NN 1_o
, , N
among IN N
the DT N
560 CD 1_p
households NNS 1_p
in IN 1_p
the DT 1_p
study NN 1_p
, , N
increased VBD N
from IN N
6 CD N
to TO N
91 CD N
% NN N
after IN N
6 CD N
months NNS N
. . N

Coverage NNP 1_o
efficiency NN 1_o
increased VBD N
from IN N
1.29 CD N
to TO N
1.56 CD N
children NNS N
covered VBN N
per IN N
bednet NN N
owned VBN N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
having VBG N
a DT N
child NN 1_p
under IN 1_p
5 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
was VBD N
the DT N
only JJ N
variable NN N
associated VBN N
with IN N
bednet NN N
use NN N
( ( N
OR CC N
9.10 CD N
; : N
p=0.001 NN N
) ) N
, , N
yielding VBG N
a DT N
99 CD N
% NN N
likelihood NN N
of IN N
using VBG N
a DT N
bednet NN N
( ( N
95 CD N
% NN N
CI NNP N
96.4 CD N
to TO N
99.9 CD N
% NN N
) ) N
versus VBZ N
82 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
72.2 CD N
to TO N
88.4 CD N
% NN N
) ) N
in IN N
households NNS N
without IN N
young JJ N
children NNS N
. . N

CONCLUSION VB N
This DT N
free JJ 1_i
bednet NN 1_i
distribution NN 1_i
program NN 1_i
achieved VBN N
high JJ N
levels NNS N
of IN N
adherence NN N
after IN N
6 CD N
months NNS N
. . N

Household NNP N
presence NN N
of IN N
children NNS 1_p
was VBD N
associated VBN N
with IN N
bednet NN N
use NN N
, , N
but CC N
not RB N
household JJ N
income NN N
or CC N
education NN N
, , N
suggesting VBG N
that IN N
distribution NN N
to TO N
priority NN N
groups NNS N
may MD N
help VB N
overcome VB N
traditional JJ N
barriers NNS N
to TO N
adoption NN N
in IN N
some DT N
settings NNS N
. . N

